Tricuspid valve regurgitation	NOUN	O	Disease	1
and	CCONJ	O	O	1
lithium carbonate	NOUN	O	Chemical	1
toxicity	NOUN	O	Disease	1
in	ADP	O	O	1
a	PRON	O	O	1
newborn	ADJ	O	O	1
infant	NOUN	O	O	1
.	PUNCT	O	O	1
A	PRON	O	O	2
newborn	ADJ	O	O	2
with	ADP	O	O	2
massive	ADJ	O	O	2
tricuspid regurgitation	NOUN	O	Disease	2
,	PUNCT	O	O	2
atrial flutter	NOUN	O	Disease	2
,	PUNCT	O	O	2
congestive	ADJ	O	O	2
heart failure	NOUN	O	Disease	2
,	PUNCT	O	O	2
and	CCONJ	O	O	2
a	PRON	O	O	2
high	ADJ	O	O	2
serum	NOUN	O	O	2
lithium	NOUN	O	Chemical	2
level	VERB	O	O	2
is	AUX	O	O	2
described	VERB	O	O	2
.	PUNCT	O	O	2
This	PRON	O	O	3
is	AUX	O	O	3
the	PRON	O	O	3
first	ADV	O	O	3
patient	NOUN	O	O	3
to	PART	O	O	3
initially	ADV	O	O	3
manifest	VERB	O	O	3
tricuspid regurgitation	NOUN	O	Disease	3
and	CCONJ	O	O	3
atrial flutter	NOUN	O	Disease	3
,	PUNCT	O	O	3
and	CCONJ	O	O	3
the	PRON	O	O	3
11th	ADJ	O	O	3
described	VERB	O	O	3
patient	NOUN	O	O	3
with	ADP	O	O	3
cardiac disease	NOUN	O	Disease	3
among	ADP	O	O	3
infants	NOUN	O	O	3
exposed	VERB	O	O	3
to	PART	O	O	3
lithium	NOUN	O	Chemical	3
compounds	NOUN	O	O	3
in	ADP	O	O	3
the	PRON	O	O	3
first	ADV	O	O	3
trimester	VERB	O	O	3
of	ADP	O	O	3
pregnancy	NOUN	O	O	3
.	PUNCT	O	O	3
Lithium carbonate	NOUN	O	Chemical	4
may	AUX	O	O	4
be	AUX	O	O	4
a	PRON	O	O	4
factor	NOUN	O	O	4
in	ADP	O	O	4
the	PRON	O	O	4
increasing	VERB	O	O	4
incidence	NOUN	O	O	4
of	ADP	O	O	4
congenital	NOUN	O	O	4
heart disease	NOUN	O	Disease	4
when	SCONJ	O	O	4
taken	VERB	O	O	4
during	ADP	O	O	4
early	ADV	O	O	4
pregnancy	NOUN	O	O	4
.	PUNCT	O	O	4
It	PRON	O	O	5
also	ADV	O	O	5
causes	VERB	O	O	5
neurologic depression	NOUN	O	Disease	5
,	PUNCT	O	O	5
cyanosis	NOUN	O	Disease	5
,	PUNCT	O	O	5
and	CCONJ	O	O	5
cardiac arrhythmia	NOUN	O	Disease	5
when	SCONJ	O	O	5
consumed	VERB	O	O	5
prior	ADV	O	O	5
to	PART	O	O	5
delivery	NOUN	O	O	5
.	PUNCT	O	O	5
Phenobarbital	PROPN	O	Chemical	8
-	PUNCT	O	O	8
induced	VERB	O	O	8
dyskinesia	NOUN	O	Disease	8
in	ADP	O	O	8
a	PRON	O	O	8
neurologically	ADV	O	O	8
-	PUNCT	O	O	8
impaired	VERB	O	O	8
child	NOUN	O	O	8
.	PUNCT	O	O	8
A	PRON	O	O	9
2-year	NOUN	O	O	9
-	PUNCT	O	O	9
old	ADJ	O	O	9
child	NOUN	O	O	9
with	ADP	O	O	9
known	VERB	O	O	9
neurologic impairment	NOUN	O	Disease	9
developed	VERB	O	O	9
a	PRON	O	O	9
dyskinesia	NOUN	O	Disease	9
soon	ADV	O	O	9
after	ADP	O	O	9
starting	VERB	O	O	9
phenobarbital	NOUN	O	Chemical	9
therapy	NOUN	O	O	9
for	ADP	O	O	9
seizures	NOUN	O	Disease	9
.	PUNCT	O	O	9
Known	VERB	O	O	10
causes	VERB	O	O	10
of	ADP	O	O	10
movement disorders	NOUN	O	Disease	10
were	AUX	O	O	10
eliminated	VERB	O	O	10
after	ADP	O	O	10
evaluation	NOUN	O	O	10
.	PUNCT	O	O	10
On	ADP	O	O	11
repeat	VERB	O	O	11
challenge	NOUN	O	O	11
with	ADP	O	O	11
phenobarbital	NOUN	O	Chemical	11
,	PUNCT	O	O	11
the	PRON	O	O	11
dyskinesia	NOUN	O	Disease	11
recurred	VERB	O	O	11
.	PUNCT	O	O	11
Phenobarbital	PROPN	O	Chemical	12
should	AUX	O	O	12
be	AUX	O	O	12
added	VERB	O	O	12
to	PART	O	O	12
the	PRON	O	O	12
list	NOUN	O	O	12
of	ADP	O	O	12
anticonvulsant	ADJ	O	O	12
drugs	NOUN	O	O	12
that	SCONJ	O	O	12
can	AUX	O	O	12
cause	VERB	O	O	12
movement disorders	NOUN	O	Disease	12
.	PUNCT	O	O	12
Acute	PROPN	O	O	15
changes	VERB	O	O	15
of	ADP	O	O	15
blood	NOUN	O	O	15
ammonia	NOUN	O	Chemical	15
may	AUX	O	O	15
predict	VERB	O	O	15
short	ADJ	O	O	15
-	PUNCT	O	O	15
term	NOUN	O	O	15
adverse	ADJ	O	O	15
effects	NOUN	O	O	15
of	ADP	O	O	15
valproic acid	NOUN	O	Chemical	15
.	PUNCT	O	O	15
Valproic acid	NOUN	O	Chemical	16
(	PUNCT	O	O	16
VPA	PROPN	O	Chemical	16
)	PUNCT	O	O	16
was	AUX	O	O	16
given	VERB	O	O	16
to	PART	O	O	16
24	NUM	O	O	16
epileptic	ADJ	O	Disease	16
patients	NOUN	O	O	16
who	PRON	O	O	16
were	AUX	O	O	16
already	ADV	O	O	16
being	AUX	O	O	16
treated	VERB	O	O	16
with	ADP	O	O	16
other	ADJ	O	O	16
antiepileptic	ADJ	O	O	16
drugs	NOUN	O	O	16
.	PUNCT	O	O	16
A	PRON	O	O	17
standardized	VERB	O	O	17
loading	NOUN	O	O	17
dose	NOUN	O	O	17
of	ADP	O	O	17
VPA	PROPN	O	Chemical	17
was	AUX	O	O	17
administered	VERB	O	O	17
,	PUNCT	O	O	17
and	CCONJ	O	O	17
venous	ADJ	O	O	17
blood	NOUN	O	O	17
was	AUX	O	O	17
sampled	VERB	O	O	17
at	ADP	O	O	17
0	NUM	O	O	17
,	PUNCT	O	O	17
1	X	O	O	17
,	PUNCT	O	O	17
2	X	O	O	17
,	PUNCT	O	O	17
3	X	O	O	17
,	PUNCT	O	O	17
and	CCONJ	O	O	17
4	NUM	O	O	17
hours	NOUN	O	O	17
.	PUNCT	O	O	17
Ammonia	NOUN	O	Chemical	18
(	PUNCT	O	O	18
NH3	PROPN	O	Chemical	18
)	PUNCT	O	O	18
was	AUX	O	O	18
higher	ADJ	O	O	18
in	ADP	O	O	18
patients	NOUN	O	O	18
who	PRON	O	O	18
,	PUNCT	O	O	18
during	ADP	O	O	18
continuous	ADJ	O	O	18
therapy	NOUN	O	O	18
,	PUNCT	O	O	18
complained	VERB	O	O	18
of	ADP	O	O	18
drowsiness	NOUN	O	Disease	18
(	PUNCT	O	O	18
7	NUM	O	O	18
patients	NOUN	O	O	18
)	PUNCT	O	O	18
than	ADP	O	O	18
in	ADP	O	O	18
those	PRON	O	O	18
who	PRON	O	O	18
were	AUX	O	O	18
symptom	NOUN	O	O	18
-	PUNCT	O	O	18
free	ADJ	O	O	18
(	PUNCT	O	O	18
17	NUM	O	O	18
patients	NOUN	O	O	18
)	PUNCT	O	O	18
,	PUNCT	O	O	18
although	SCONJ	O	O	18
VPA	PROPN	O	Chemical	18
plasma	NOUN	O	O	18
levels	NOUN	O	O	18
were	AUX	O	O	18
similar	ADJ	O	O	18
in	ADP	O	O	18
both	PRON	O	O	18
groups	NOUN	O	O	18
.	PUNCT	O	O	18
By	ADP	O	O	19
measuring	VERB	O	O	19
VPA	PROPN	O	Chemical	19
-	PUNCT	O	O	19
induced	VERB	O	O	19
changes	VERB	O	O	19
of	ADP	O	O	19
blood	NOUN	O	O	19
NH3	PROPN	O	Chemical	19
content	NOUN	O	O	19
,	PUNCT	O	O	19
it	PRON	O	O	19
may	AUX	O	O	19
be	AUX	O	O	19
possible	ADJ	O	O	19
to	PART	O	O	19
identify	VERB	O	O	19
patients	NOUN	O	O	19
at	ADP	O	O	19
higher	ADJ	O	O	19
risk	NOUN	O	O	19
of	ADP	O	O	19
obtundation	NOUN	O	O	19
when	SCONJ	O	O	19
VPA	PROPN	O	Chemical	19
is	AUX	O	O	19
given	VERB	O	O	19
chronically	ADV	O	O	19
.	PUNCT	O	O	19
Calcitonin	NOUN	O	O	22
injection	NOUN	O	O	22
resulted	VERB	O	O	22
in	ADP	O	O	22
a	PRON	O	O	22
potentiation	NOUN	O	O	22
of	ADP	O	O	22
haloperidol	NOUN	O	Chemical	22
-	PUNCT	O	O	22
induced	VERB	O	O	22
catalepsy	VERB	O	Disease	22
and	CCONJ	O	O	22
a	PRON	O	O	22
partial	ADJ	O	O	22
prevention	NOUN	O	O	22
of	ADP	O	O	22
apomorphine	PROPN	O	Chemical	22
-	PUNCT	O	O	22
induced	VERB	O	O	22
hyperactivity	NOUN	O	Disease	22
.	PUNCT	O	O	22
Moreover	ADV	O	O	23
calcitonin	NOUN	O	O	23
induced	VERB	O	O	23
a	PRON	O	O	23
significant	ADJ	O	O	23
decrease	VERB	O	O	23
in	ADP	O	O	23
nigral	ADJ	O	O	23
GAD	PROPN	O	O	23
activity	NOUN	O	O	23
but	CCONJ	O	O	23
no	PRON	O	O	23
change	VERB	O	O	23
in	ADP	O	O	23
striatal	ADJ	O	O	23
DA	NOUN	O	Chemical	23
and	CCONJ	O	O	23
DOPAC	PROPN	O	Chemical	23
concentration	NOUN	O	O	23
or	CCONJ	O	O	23
GAD	PROPN	O	O	23
activity	NOUN	O	O	23
.	PUNCT	O	O	23
The	PRON	O	O	24
results	VERB	O	O	24
are	AUX	O	O	24
discussed	VERB	O	O	24
in	ADP	O	O	24
view	VERB	O	O	24
of	ADP	O	O	24
a	PRON	O	O	24
primary	NOUN	O	O	24
action	NOUN	O	O	24
of	ADP	O	O	24
calcitonin	NOUN	O	O	24
on	ADP	O	O	24
the	PRON	O	O	24
striatonigral	PROPN	O	O	24
GABAergic	PROPN	O	O	24
pathway	NOUN	O	O	24
mediating	VERB	O	O	24
the	PRON	O	O	24
DA	NOUN	O	Chemical	24
-	PUNCT	O	O	24
related	ADJ	O	O	24
behavioral	ADJ	O	O	24
messages	NOUN	O	O	24
of	ADP	O	O	24
striatal	ADJ	O	O	24
origin	NOUN	O	O	24
.	PUNCT	O	O	24
Development	NOUN	O	O	27
of	ADP	O	O	27
isoproterenol	NOUN	O	Chemical	27
-	PUNCT	O	O	27
induced	VERB	O	O	27
cardiac hypertrophy	NOUN	O	Disease	27
.	PUNCT	O	O	27
The	PRON	O	O	28
development	NOUN	O	O	28
of	ADP	O	O	28
cardiac hypertrophy	NOUN	O	Disease	28
was	AUX	O	O	28
studied	VERB	O	O	28
in	ADP	O	O	28
adult	NOUN	O	O	28
female	ADJ	O	O	28
Wistar	PROPN	O	O	28
rats	NOUN	O	O	28
following	VERB	O	O	28
daily	ADV	O	O	28
subcutaneous	ADJ	O	O	28
injections	NOUN	O	O	28
of	ADP	O	O	28
isoproterenol	NOUN	O	Chemical	28
(	PUNCT	O	O	28
ISO	PROPN	O	Chemical	28
)	PUNCT	O	O	28
(	PUNCT	O	O	28
0.3	NUM	O	O	28
mg	VERB	O	O	28
/	PUNCT	O	O	28
kg	VERB	O	O	28
body	NOUN	O	O	28
weight	NOUN	O	O	28
)	PUNCT	O	O	28
.	PUNCT	O	O	28
A	PRON	O	O	29
time	NOUN	O	O	29
course	NOUN	O	O	29
was	AUX	O	O	29
established	VERB	O	O	29
for	ADP	O	O	29
the	PRON	O	O	29
change	VERB	O	O	29
in	ADP	O	O	29
tissue	NOUN	O	O	29
mass	PROPN	O	O	29
,	PUNCT	O	O	29
RNA	PROPN	O	O	29
and	CCONJ	O	O	29
DNA	NOUN	O	O	29
content	NOUN	O	O	29
,	PUNCT	O	O	29
as	ADP	O	O	29
well	ADV	O	O	29
as	ADP	O	O	29
hydroxyproline	NOUN	O	Chemical	29
content	NOUN	O	O	29
.	PUNCT	O	O	29
The	PRON	O	O	30
total	ADJ	O	O	30
content	NOUN	O	O	30
of	ADP	O	O	30
hydroxyproline	NOUN	O	Chemical	30
remained	VERB	O	O	30
stable	ADJ	O	O	30
during	ADP	O	O	30
the	PRON	O	O	30
first	ADV	O	O	30
2	X	O	O	30
days	NOUN	O	O	30
of	ADP	O	O	30
treatment	NOUN	O	O	30
but	CCONJ	O	O	30
increased	VERB	O	O	30
46%	NOUN	O	O	30
after	ADP	O	O	30
4	NUM	O	O	30
days	NOUN	O	O	30
of	ADP	O	O	30
therapy	NOUN	O	O	30
.	PUNCT	O	O	30
Ventricular	PROPN	O	O	31
DNA	NOUN	O	O	31
content	NOUN	O	O	31
was	AUX	O	O	31
unchanged	ADJ	O	O	31
during	ADP	O	O	31
the	PRON	O	O	31
early	ADV	O	O	31
stage	NOUN	O	O	31
(	PUNCT	O	O	31
1	X	O	O	31
-	PUNCT	O	O	31
4	NUM	O	O	31
days	NOUN	O	O	31
)	PUNCT	O	O	31
of	ADP	O	O	31
hypertrophic	NOUN	O	Disease	31
growth	NOUN	O	O	31
but	CCONJ	O	O	31
increased	VERB	O	O	31
to	PART	O	O	31
a	PRON	O	O	31
new	ADJ	O	O	31
steady	ADJ	O	O	31
-	PUNCT	O	O	31
state	NOUN	O	O	31
level	VERB	O	O	31
19%	NOUN	O	O	31
above	ADP	O	O	31
the	PRON	O	O	31
controls	VERB	O	O	31
after	ADP	O	O	31
8	NUM	O	O	31
days	NOUN	O	O	31
of	ADP	O	O	31
treatment	NOUN	O	O	31
.	PUNCT	O	O	31
Intraventricular	PROPN	O	O	32
pressures	NOUN	O	O	32
and	CCONJ	O	O	32
coronary	ADJ	O	O	32
flow	NOUN	O	O	32
measures	NOUN	O	O	32
were	AUX	O	O	32
similar	ADJ	O	O	32
for	ADP	O	O	32
control	VERB	O	O	32
and	CCONJ	O	O	32
experimental	ADJ	O	O	32
animals	NOUN	O	O	32
following	VERB	O	O	32
4	NUM	O	O	32
days	NOUN	O	O	32
of	ADP	O	O	32
developed	VERB	O	O	32
hypertrophy	VERB	O	Disease	32
.	PUNCT	O	O	32
However	ADV	O	O	33
,	PUNCT	O	O	33
dP	X	O	O	33
/	PUNCT	O	O	33
dt	PROPN	O	O	33
in	ADP	O	O	33
the	PRON	O	O	33
ISO	PROPN	O	Chemical	33
-	PUNCT	O	O	33
treated	VERB	O	O	33
hearts	NOUN	O	O	33
was	AUX	O	O	33
slightly	ADV	O	O	33
but	CCONJ	O	O	33
significantly	ADV	O	O	33
(	PUNCT	O	O	33
P	NOUN	O	Chemical	33
less	ADV	O	O	33
than	ADP	O	O	33
0.05	NUM	O	O	33
)	PUNCT	O	O	33
elevated	ADJ	O	O	33
.	PUNCT	O	O	33
These	PRON	O	O	34
data	NOUN	O	O	34
indicate	VERB	O	O	34
that	SCONJ	O	O	34
the	PRON	O	O	34
adaptive	ADJ	O	O	34
response	NOUN	O	O	34
to	PART	O	O	34
ISO	PROPN	O	Chemical	34
shows	VERB	O	O	34
an	PRON	O	O	34
early	ADV	O	O	34
hypertrophic	NOUN	O	Disease	34
phase	NOUN	O	O	34
(	PUNCT	O	O	34
1	X	O	O	34
-	PUNCT	O	O	34
4	NUM	O	O	34
days	NOUN	O	O	34
)	PUNCT	O	O	34
characterized	VERB	O	O	34
by	ADP	O	O	34
a	PRON	O	O	34
substantial	ADJ	O	O	34
increase	VERB	O	O	34
in	ADP	O	O	34
RNA	PROPN	O	O	34
content	NOUN	O	O	34
and	CCONJ	O	O	34
cardiac	ADJ	O	O	34
mass	PROPN	O	O	34
in	ADP	O	O	34
the	PRON	O	O	34
absence	NOUN	O	O	34
of	ADP	O	O	34
changes	VERB	O	O	34
in	ADP	O	O	34
DNA	NOUN	O	O	34
.	PUNCT	O	O	34
However	ADV	O	O	35
,	PUNCT	O	O	35
prolonged	VERB	O	O	35
stimulation	NOUN	O	O	35
(	PUNCT	O	O	35
8	NUM	O	O	35
-	PUNCT	O	O	35
12	NUM	O	O	35
days	NOUN	O	O	35
)	PUNCT	O	O	35
appears	VERB	O	O	35
to	PART	O	O	35
represent	VERB	O	O	35
a	PRON	O	O	35
complex	ADJ	O	O	35
integration	NOUN	O	O	35
of	ADP	O	O	35
both	PRON	O	O	35
cellular	NOUN	O	O	35
hypertrophy	VERB	O	Disease	35
and	CCONJ	O	O	35
hyperplasia	NOUN	O	Disease	35
within	ADP	O	O	35
the	PRON	O	O	35
heart	NOUN	O	O	35
.	PUNCT	O	O	35
Co	PROPN	O	O	38
-	PUNCT	O	O	38
carcinogenic	ADJ	O	Disease	38
effect	VERB	O	O	38
of	ADP	O	O	38
retinyl acetate	NOUN	O	Chemical	38
on	ADP	O	O	38
forestomach carcinogenesis	NOUN	O	Disease	38
of	ADP	O	O	38
male	NOUN	O	O	38
F344	PROPN	O	O	38
rats	NOUN	O	O	38
induced	VERB	O	O	38
with	ADP	O	O	38
butylated hydroxyanisole	NOUN	O	Chemical	38
.	PUNCT	O	O	38
The	PRON	O	O	39
potential	ADJ	O	O	39
modifying	VERB	O	O	39
effect	VERB	O	O	39
of	ADP	O	O	39
retinyl acetate	NOUN	O	Chemical	39
(	PUNCT	O	O	39
RA	PROPN	O	Disease	39
)	PUNCT	O	O	39
on	ADP	O	O	39
butylated hydroxyanisole	NOUN	O	Chemical	39
(	PUNCT	O	O	39
BHA)-induced	VERB	O	O	39
rat	NOUN	O	O	39
forestomach tumorigenesis	PROPN	O	Disease	39
was	AUX	O	O	39
examined	VERB	O	O	39
.	PUNCT	O	O	39
Male	NOUN	O	O	40
F344	PROPN	O	O	40
rats	NOUN	O	O	40
,	PUNCT	O	O	40
5	NUM	O	O	40
weeks	NOUN	O	O	40
of	ADP	O	O	40
age	NOUN	O	O	40
,	PUNCT	O	O	40
were	AUX	O	O	40
maintained	VERB	O	O	40
on	ADP	O	O	40
diet	PROPN	O	O	40
containing	VERB	O	O	40
1%	NOUN	O	O	40
or	CCONJ	O	O	40
2%	NOUN	O	O	40
BHA	PROPN	O	Chemical	40
by	ADP	O	O	40
weight	NOUN	O	O	40
and	CCONJ	O	O	40
simultaneously	ADV	O	O	40
on	ADP	O	O	40
drinking	VERB	O	O	40
water	PROPN	O	O	40
supplemented	VERB	O	O	40
with	ADP	O	O	40
RA	PROPN	O	Disease	40
at	ADP	O	O	40
various	ADJ	O	O	40
concentrations	NOUN	O	O	40
(	PUNCT	O	O	40
w	X	O	O	40
/	PUNCT	O	O	40
v	NOUN	O	O	40
)	PUNCT	O	O	40
for	ADP	O	O	40
52	NUM	O	O	40
weeks	NOUN	O	O	40
.	PUNCT	O	O	40
In	ADP	O	O	41
groups	NOUN	O	O	41
given	VERB	O	O	41
2%	NOUN	O	O	41
BHA	PROPN	O	Chemical	41
,	PUNCT	O	O	41
although	SCONJ	O	O	41
marked	VERB	O	O	41
hyperplastic	NOUN	O	O	41
changes	VERB	O	O	41
of	ADP	O	O	41
the	PRON	O	O	41
forestomach	PROPN	O	O	41
epithelium	NOUN	O	O	41
were	AUX	O	O	41
observed	VERB	O	O	41
in	ADP	O	O	41
all	PRON	O	O	41
animals	NOUN	O	O	41
,	PUNCT	O	O	41
co	NOUN	O	O	41
-	PUNCT	O	O	41
administration	NOUN	O	O	41
of	ADP	O	O	41
0.25%	NOUN	O	O	41
RA	PROPN	O	Disease	41
significantly	ADV	O	O	41
(	PUNCT	O	O	41
P	NOUN	O	Chemical	41
less	ADV	O	O	41
than	ADP	O	O	41
0.05	NUM	O	O	41
)	PUNCT	O	O	41
increased	VERB	O	O	41
the	PRON	O	O	41
incidence	NOUN	O	O	41
of	ADP	O	O	41
forestomach tumors	NOUN	O	Disease	41
(	PUNCT	O	O	41
squamous cell papilloma	NOUN	O	Disease	41
and	CCONJ	O	O	41
carcinoma	NOUN	O	Disease	41
)	PUNCT	O	O	41
to	PART	O	O	41
60%	NOUN	O	O	41
(	PUNCT	O	O	41
9/15	NUM	O	O	41
,	PUNCT	O	O	41
2	X	O	O	41
rats	NOUN	O	O	41
with	ADP	O	O	41
carcinoma	NOUN	O	Disease	41
)	PUNCT	O	O	41
from	ADP	O	O	41
15%	NOUN	O	O	41
(	PUNCT	O	O	41
3/20	NUM	O	O	41
,	PUNCT	O	O	41
one	NUM	O	O	41
rat	NOUN	O	O	41
with	ADP	O	O	41
carcinoma	NOUN	O	Disease	41
)	PUNCT	O	O	41
in	ADP	O	O	41
the	PRON	O	O	41
group	NOUN	O	O	41
given	VERB	O	O	41
RA	PROPN	O	Disease	41
-	PUNCT	O	O	41
free	ADJ	O	O	41
water	PROPN	O	O	41
.	PUNCT	O	O	41
In	ADP	O	O	42
rats	NOUN	O	O	42
given	VERB	O	O	42
1%	NOUN	O	O	42
BHA	PROPN	O	Chemical	42
,	PUNCT	O	O	42
RA	PROPN	O	Disease	42
co	NOUN	O	O	42
-	PUNCT	O	O	42
administered	VERB	O	O	42
at	ADP	O	O	42
a	PRON	O	O	42
dose	NOUN	O	O	42
of	ADP	O	O	42
0.05	NUM	O	O	42
,	PUNCT	O	O	42
0.1	NUM	O	O	42
,	PUNCT	O	O	42
0.2	NUM	O	O	42
or	CCONJ	O	O	42
0.25%	NOUN	O	O	42
showed	VERB	O	O	42
a	PRON	O	O	42
dose	NOUN	O	O	42
-	PUNCT	O	O	42
dependent	ADJ	O	O	42
enhancing	VERB	O	O	42
effect	VERB	O	O	42
on	ADP	O	O	42
the	PRON	O	O	42
development	NOUN	O	O	42
of	ADP	O	O	42
the	PRON	O	O	42
BHA	PROPN	O	Chemical	42
-	PUNCT	O	O	42
induced	VERB	O	O	42
epithelial hyperplasia	NOUN	O	Disease	42
.	PUNCT	O	O	42
Tumors	NOUN	O	Disease	43
,	PUNCT	O	O	43
all	PRON	O	O	43
papillomas	NOUN	O	Disease	43
,	PUNCT	O	O	43
were	AUX	O	O	43
induced	VERB	O	O	43
in	ADP	O	O	43
3	X	O	O	43
rats	NOUN	O	O	43
(	PUNCT	O	O	43
17%	NOUN	O	O	43
)	PUNCT	O	O	43
with	ADP	O	O	43
0.25%	NOUN	O	O	43
RA	PROPN	O	Disease	43
and	CCONJ	O	O	43
in	ADP	O	O	43
one	NUM	O	O	43
rat	NOUN	O	O	43
(	PUNCT	O	O	43
10%	NOUN	O	O	43
)	PUNCT	O	O	43
with	ADP	O	O	43
0.05%	NOUN	O	O	43
RA	PROPN	O	Disease	43
co	NOUN	O	O	43
-	PUNCT	O	O	43
administration	NOUN	O	O	43
.	PUNCT	O	O	43
RA	PROPN	O	Disease	44
alone	ADV	O	O	44
did	VERB	O	O	44
not	PART	O	O	44
induce	VERB	O	O	44
hyperplastic	NOUN	O	O	44
changes	VERB	O	O	44
in	ADP	O	O	44
the	PRON	O	O	44
forestomach	PROPN	O	O	44
.	PUNCT	O	O	44
These	PRON	O	O	45
findings	NOUN	O	O	45
indicate	VERB	O	O	45
that	SCONJ	O	O	45
RA	PROPN	O	Disease	45
acted	VERB	O	O	45
as	ADP	O	O	45
a	PRON	O	O	45
co	NOUN	O	O	45
-	PUNCT	O	O	45
carcinogen	PROPN	O	O	45
in	ADP	O	O	45
the	PRON	O	O	45
BHA	PROPN	O	Chemical	45
forestomach carcinogenesis	NOUN	O	Disease	45
of	ADP	O	O	45
the	PRON	O	O	45
rat	NOUN	O	O	45
.	PUNCT	O	O	45
Ketanserin	PROPN	O	Chemical	48
pretreatment	NOUN	O	O	48
reverses	VERB	O	O	48
alfentanil	NOUN	O	Chemical	48
-	PUNCT	O	O	48
induced	VERB	O	O	48
muscle rigidity	NOUN	O	Disease	48
.	PUNCT	O	O	48
Systemic	ADJ	O	O	49
pretreatment	NOUN	O	O	49
with	ADP	O	O	49
ketanserin	NOUN	O	Chemical	49
,	PUNCT	O	O	49
a	PRON	O	O	49
relatively	ADV	O	O	49
specific	ADJ	O	O	49
type-2	X	O	O	49
serotonin	PROPN	O	Chemical	49
receptor	NOUN	O	O	49
antagonist	NOUN	O	O	49
,	PUNCT	O	O	49
significantly	ADV	O	O	49
attenuated	VERB	O	O	49
the	PRON	O	O	49
muscle rigidity	NOUN	O	Disease	49
produced	VERB	O	O	49
in	ADP	O	O	49
rats	NOUN	O	O	49
by	ADP	O	O	49
the	PRON	O	O	49
potent	ADJ	O	O	49
short	ADJ	O	O	49
-	PUNCT	O	O	49
acting	VERB	O	O	49
opiate	NOUN	O	O	49
agonist	NOUN	O	O	49
alfentanil	NOUN	O	Chemical	49
.	PUNCT	O	O	49
Following	VERB	O	O	50
placement	NOUN	O	O	50
of	ADP	O	O	50
subcutaneous	ADJ	O	O	50
electrodes	NOUN	O	O	50
in	ADP	O	O	50
each	PRON	O	O	50
animal	NOUN	O	O	50
's	AUX	O	O	50
left	VERB	O	O	50
gastrocnemius	NOUN	O	O	50
muscle	NOUN	O	O	50
,	PUNCT	O	O	50
rigidity	NOUN	O	Disease	50
was	AUX	O	O	50
assessed	VERB	O	O	50
by	ADP	O	O	50
analyzing	VERB	O	O	50
root	NOUN	O	O	50
-	PUNCT	O	O	50
mean	VERB	O	O	50
-	PUNCT	O	O	50
square	PROPN	O	O	50
electromyographic	ADJ	O	O	50
activity	NOUN	O	O	50
.	PUNCT	O	O	50
Intraperitoneal	NOUN	O	O	51
ketanserin	NOUN	O	Chemical	51
administration	NOUN	O	O	51
at	ADP	O	O	51
doses	NOUN	O	O	51
of	ADP	O	O	51
0.63	NUM	O	O	51
and	CCONJ	O	O	51
2.5	NUM	O	O	51
mg	VERB	O	O	51
/	PUNCT	O	O	51
kg	VERB	O	O	51
prevented	VERB	O	O	51
the	PRON	O	O	51
alfentanil	NOUN	O	Chemical	51
-	PUNCT	O	O	51
induced	VERB	O	O	51
increase	VERB	O	O	51
in	ADP	O	O	51
electromyographic	ADJ	O	O	51
activity	NOUN	O	O	51
compared	VERB	O	O	51
with	ADP	O	O	51
animals	NOUN	O	O	51
pretreated	VERB	O	O	51
with	ADP	O	O	51
saline	NOUN	O	O	51
.	PUNCT	O	O	51
Chlordiazepoxide	PROPN	O	Chemical	52
at	ADP	O	O	52
doses	NOUN	O	O	52
up	ADP	O	O	52
to	PART	O	O	52
10	NUM	O	O	52
mg	VERB	O	O	52
/	PUNCT	O	O	52
kg	VERB	O	O	52
failed	VERB	O	O	52
to	PART	O	O	52
significantly	ADV	O	O	52
influence	NOUN	O	O	52
the	PRON	O	O	52
rigidity	NOUN	O	Disease	52
produced	VERB	O	O	52
by	ADP	O	O	52
alfentanil	NOUN	O	Chemical	52
.	PUNCT	O	O	52
Despite	SCONJ	O	O	53
the	PRON	O	O	53
absence	NOUN	O	O	53
of	ADP	O	O	53
rigidity	NOUN	O	Disease	53
,	PUNCT	O	O	53
animals	NOUN	O	O	53
that	SCONJ	O	O	53
received	VERB	O	O	53
ketanserin	NOUN	O	Chemical	53
(	PUNCT	O	O	53
greater	ADJ	O	O	53
than	ADP	O	O	53
0.31	NUM	O	O	53
followed	VERB	O	O	54
by	ADP	O	O	54
alfentanil	NOUN	O	Chemical	54
were	AUX	O	O	54
motionless	ADV	O	O	54
,	PUNCT	O	O	54
flaccid	ADJ	O	O	54
,	PUNCT	O	O	54
and	CCONJ	O	O	54
less	ADV	O	O	54
responsive	ADJ	O	O	54
to	PART	O	O	54
external	ADJ	O	O	54
stimuli	NOUN	O	O	54
than	ADP	O	O	54
were	AUX	O	O	54
animals	NOUN	O	O	54
receiving	VERB	O	O	54
alfentanil	NOUN	O	Chemical	54
alone	ADV	O	O	54
.	PUNCT	O	O	54
Rats	NOUN	O	O	55
that	SCONJ	O	O	55
received	VERB	O	O	55
ketanserin	NOUN	O	Chemical	55
and	CCONJ	O	O	55
alfentanil	NOUN	O	Chemical	55
exhibited	VERB	O	O	55
less	ADV	O	O	55
rearing	VERB	O	O	55
and	CCONJ	O	O	55
exploratory	ADJ	O	O	55
behavior	NOUN	O	O	55
at	ADP	O	O	55
the	PRON	O	O	55
end	VERB	O	O	55
of	ADP	O	O	55
the	PRON	O	O	55
60-min	NOUN	O	O	55
recording	NOUN	O	O	55
period	NOUN	O	O	55
than	ADP	O	O	55
did	VERB	O	O	55
animals	NOUN	O	O	55
that	SCONJ	O	O	55
received	VERB	O	O	55
ketanserin	NOUN	O	Chemical	55
alone	ADV	O	O	55
.	PUNCT	O	O	55
These	PRON	O	O	56
results	VERB	O	O	56
,	PUNCT	O	O	56
in	ADP	O	O	56
combination	NOUN	O	O	56
with	ADP	O	O	56
previous	ADJ	O	O	56
work	NOUN	O	O	56
,	PUNCT	O	O	56
suggest	VERB	O	O	56
that	SCONJ	O	O	56
muscle rigidity	NOUN	O	Disease	56
,	PUNCT	O	O	56
a	PRON	O	O	56
clinically	ADV	O	O	56
relevant	ADJ	O	O	56
side	NOUN	O	O	56
-	PUNCT	O	O	56
effect	VERB	O	O	56
of	ADP	O	O	56
parenteral	ADJ	O	O	56
narcotic	ADJ	O	O	56
administration	NOUN	O	O	56
,	PUNCT	O	O	56
may	AUX	O	O	56
be	AUX	O	O	56
partly	ADV	O	O	56
mediated	VERB	O	O	56
via	ADP	O	O	56
serotonergic	ADJ	O	O	56
pathways	NOUN	O	O	56
.	PUNCT	O	O	56
Pretreatment	NOUN	O	O	57
with	ADP	O	O	57
type-2	X	O	O	57
serotonin	PROPN	O	Chemical	57
antagonists	NOUN	O	O	57
may	AUX	O	O	57
be	AUX	O	O	57
clinically	ADV	O	O	57
useful	ADJ	O	O	57
in	ADP	O	O	57
attenuating	VERB	O	O	57
opiate	NOUN	O	O	57
-	PUNCT	O	O	57
induced	VERB	O	O	57
rigidity	NOUN	O	Disease	57
,	PUNCT	O	O	57
although	SCONJ	O	O	57
further	ADV	O	O	57
studies	NOUN	O	O	57
will	AUX	O	O	57
be	AUX	O	O	57
necessary	ADJ	O	O	57
to	PART	O	O	57
assess	VERB	O	O	57
the	PRON	O	O	57
interaction	NOUN	O	O	57
of	ADP	O	O	57
possibly	ADV	O	O	57
enhanced	VERB	O	O	57
CNS	PROPN	O	O	57
,	PUNCT	O	O	57
cardiovascular	ADJ	O	O	57
,	PUNCT	O	O	57
and	CCONJ	O	O	57
respiratory depression	NOUN	O	Disease	57
.	PUNCT	O	O	57
Glycopyrronium	NOUN	O	Chemical	60
requirements	NOUN	O	O	60
for	ADP	O	O	60
antagonism	NOUN	O	O	60
of	ADP	O	O	60
the	PRON	O	O	60
muscarinic	PROPN	O	O	60
side	NOUN	O	O	60
effects	NOUN	O	O	60
of	ADP	O	O	60
edrophonium	NOUN	O	Chemical	60
.	PUNCT	O	O	60
We	PRON	O	O	61
have	VERB	O	O	61
compared	VERB	O	O	61
,	PUNCT	O	O	61
in	ADP	O	O	61
60	NUM	O	O	61
adult	NOUN	O	O	61
patients	NOUN	O	O	61
,	PUNCT	O	O	61
the	PRON	O	O	61
cardiovascular	ADJ	O	O	61
effects	NOUN	O	O	61
of	ADP	O	O	61
glycopyrronium	NOUN	O	Chemical	61
5	NUM	O	O	61
micrograms	NOUN	O	O	61
kg-1	VERB	O	O	61
and	CCONJ	O	O	61
10	NUM	O	O	61
micrograms	NOUN	O	O	61
kg-1	VERB	O	O	61
given	VERB	O	O	61
either	ADV	O	O	61
simultaneously	ADV	O	O	61
or	CCONJ	O	O	61
1	X	O	O	61
min	NOUN	O	O	61
before	ADP	O	O	61
edrophonium	NOUN	O	Chemical	61
1	X	O	O	61
mg	VERB	O	O	61
kg-1	VERB	O	O	61
.	PUNCT	O	O	61
Use	VERB	O	O	62
of	ADP	O	O	62
glycopyrronium	NOUN	O	Chemical	62
5	NUM	O	O	62
micrograms	NOUN	O	O	62
kg-1	VERB	O	O	62
provided	VERB	O	O	62
greater	ADJ	O	O	62
cardiovascular	ADJ	O	O	62
stability	PROPN	O	O	62
and	CCONJ	O	O	62
,	PUNCT	O	O	62
given	VERB	O	O	62
1	X	O	O	62
min	NOUN	O	O	62
before	ADP	O	O	62
the	PRON	O	O	62
edrophonium	NOUN	O	Chemical	62
,	PUNCT	O	O	62
was	AUX	O	O	62
sufficient	ADJ	O	O	62
to	PART	O	O	62
minimize	VERB	O	O	62
early	ADV	O	O	62
,	PUNCT	O	O	62
edrophonium	NOUN	O	Chemical	62
-	PUNCT	O	O	62
induced	VERB	O	O	62
bradycardias	NOUN	O	Disease	62
.	PUNCT	O	O	62
This	PRON	O	O	63
low	ADJ	O	O	63
dose	NOUN	O	O	63
of	ADP	O	O	63
glycopyrronium	NOUN	O	Chemical	63
provided	VERB	O	O	63
good	ADJ	O	O	63
control	VERB	O	O	63
of	ADP	O	O	63
oropharyngeal	ADJ	O	O	63
secretions	NOUN	O	O	63
.	PUNCT	O	O	63
Involvement	NOUN	O	O	66
of	ADP	O	O	66
locus	NOUN	O	O	66
coeruleus	PROPN	O	O	66
and	CCONJ	O	O	66
noradrenergic	ADJ	O	O	66
neurotransmission	NOUN	O	O	66
in	ADP	O	O	66
fentanyl	ADJ	O	Chemical	66
-	PUNCT	O	O	66
induced	VERB	O	O	66
muscular rigidity	NOUN	O	Disease	66
in	ADP	O	O	66
the	PRON	O	O	66
rat	NOUN	O	O	66
.	PUNCT	O	O	66
Whereas	SCONJ	O	O	67
muscular rigidity	NOUN	O	Disease	67
is	AUX	O	O	67
a	PRON	O	O	67
well	ADV	O	O	67
-	PUNCT	O	O	67
known	VERB	O	O	67
side	NOUN	O	O	67
effect	VERB	O	O	67
that	SCONJ	O	O	67
is	AUX	O	O	67
associated	VERB	O	O	67
with	ADP	O	O	67
high	ADJ	O	O	67
-	PUNCT	O	O	67
dose	NOUN	O	O	67
fentanyl	ADJ	O	Chemical	67
anesthesia	NOUN	O	O	67
,	PUNCT	O	O	67
a	PRON	O	O	67
paucity	NOUN	O	O	67
of	ADP	O	O	67
information	NOUN	O	O	67
exists	VERB	O	O	67
with	ADP	O	O	67
regard	NOUN	O	O	67
to	PART	O	O	67
its	PRON	O	O	67
underlying	VERB	O	O	67
mechanism(s	NOUN	O	O	67
)	PUNCT	O	O	67
.	PUNCT	O	O	67
We	PRON	O	O	68
investigated	VERB	O	O	68
in	ADP	O	O	68
this	PRON	O	O	68
study	VERB	O	O	68
the	PRON	O	O	68
possible	ADJ	O	O	68
engagement	NOUN	O	O	68
of	ADP	O	O	68
locus	NOUN	O	O	68
coeruleus	PROPN	O	O	68
of	ADP	O	O	68
the	PRON	O	O	68
pons	NOUN	O	O	68
in	ADP	O	O	68
this	PRON	O	O	68
phenomenon	NOUN	O	O	68
,	PUNCT	O	O	68
using	VERB	O	O	68
male	NOUN	O	O	68
Sprague	PROPN	O	O	68
-	PUNCT	O	O	68
Dawley	NOUN	O	O	68
rats	NOUN	O	O	68
anesthetized	VERB	O	O	68
with	ADP	O	O	68
ketamine	VERB	O	Chemical	68
.	PUNCT	O	O	68
Under	ADP	O	O	69
proper	ADJ	O	O	69
control	VERB	O	O	69
of	ADP	O	O	69
respiration	NOUN	O	O	69
,	PUNCT	O	O	69
body	NOUN	O	O	69
temperature	NOUN	O	O	69
and	CCONJ	O	O	69
end	VERB	O	O	69
-	PUNCT	O	O	69
tidal	ADJ	O	O	69
CO2	PROPN	O	Chemical	69
,	PUNCT	O	O	69
intravenous	ADJ	O	O	69
administration	NOUN	O	O	69
of	ADP	O	O	69
fentanyl	ADJ	O	Chemical	69
(	PUNCT	O	O	69
50	NUM	O	O	69
or	CCONJ	O	O	69
100	NUM	O	O	69
micrograms	NOUN	O	O	69
/	PUNCT	O	O	69
kg	VERB	O	O	69
)	PUNCT	O	O	69
consistently	ADV	O	O	69
promoted	VERB	O	O	69
an	PRON	O	O	69
increase	VERB	O	O	69
in	ADP	O	O	69
electromyographic	ADJ	O	O	69
activity	NOUN	O	O	69
recorded	VERB	O	O	69
from	ADP	O	O	69
the	PRON	O	O	69
gastrocnemius	NOUN	O	O	69
and	CCONJ	O	O	69
abdominal	ADJ	O	O	69
rectus	ADJ	O	O	69
muscles	NOUN	O	O	69
.	PUNCT	O	O	69
Such	ADJ	O	O	70
an	PRON	O	O	70
induced	VERB	O	O	70
muscular rigidity	NOUN	O	Disease	70
by	ADP	O	O	70
the	PRON	O	O	70
narcotic	ADJ	O	O	70
agent	NOUN	O	O	70
was	AUX	O	O	70
significantly	ADV	O	O	70
antagonized	VERB	O	O	70
or	CCONJ	O	O	70
even	ADV	O	O	70
reduced	VERB	O	O	70
by	ADP	O	O	70
prior	ADV	O	O	70
electrolytic	ADJ	O	O	70
lesions	NOUN	O	O	70
of	ADP	O	O	70
the	PRON	O	O	70
locus	NOUN	O	O	70
coeruleus	PROPN	O	O	70
or	CCONJ	O	O	70
pretreatment	NOUN	O	O	70
with	ADP	O	O	70
the	PRON	O	O	70
alpha	PROPN	O	O	70
-	PUNCT	O	O	70
adrenoceptor	NOUN	O	O	70
blocker	NOUN	O	O	70
,	PUNCT	O	O	70
prazosin	NOUN	O	Chemical	70
.	PUNCT	O	O	70
Microinjection	NOUN	O	O	71
of	ADP	O	O	71
fentanyl	ADJ	O	Chemical	71
(	PUNCT	O	O	71
2.5	NUM	O	O	71
micrograms/50	VERB	O	O	71
nl	PROPN	O	O	71
)	PUNCT	O	O	71
directly	ADV	O	O	71
into	ADP	O	O	71
this	PRON	O	O	71
pontine	NOUN	O	O	71
nucleus	PROPN	O	O	71
,	PUNCT	O	O	71
on	ADP	O	O	71
the	PRON	O	O	71
other	ADJ	O	O	71
hand	NOUN	O	O	71
,	PUNCT	O	O	71
elicited	VERB	O	O	71
discernible	ADJ	O	O	71
electromyographic	ADJ	O	O	71
excitation	NOUN	O	O	71
.	PUNCT	O	O	71
It	PRON	O	O	72
is	AUX	O	O	72
speculated	VERB	O	O	72
that	SCONJ	O	O	72
the	PRON	O	O	72
induction	NOUN	O	O	72
of	ADP	O	O	72
muscular rigidity	NOUN	O	Disease	72
by	ADP	O	O	72
fentanyl	ADJ	O	Chemical	72
may	AUX	O	O	72
involve	VERB	O	O	72
the	PRON	O	O	72
coerulospinal	PROPN	O	O	72
noradrenergic	ADJ	O	O	72
fibers	NOUN	O	O	72
to	PART	O	O	72
the	PRON	O	O	72
spinal	NOUN	O	O	72
motoneurons	NOUN	O	O	72
.	PUNCT	O	O	72
Cerebral sinus thrombosis	NOUN	O	Disease	75
as	ADP	O	O	75
a	PRON	O	O	75
potential	ADJ	O	O	75
hazard	NOUN	O	O	75
of	ADP	O	O	75
antifibrinolytic	ADJ	O	O	75
treatment	NOUN	O	O	75
in	ADP	O	O	75
menorrhagia	NOUN	O	Disease	75
.	PUNCT	O	O	75
We	PRON	O	O	76
describe	VERB	O	O	76
a	PRON	O	O	76
42-year	NOUN	O	O	76
-	PUNCT	O	O	76
old	ADJ	O	O	76
woman	NOUN	O	O	76
who	PRON	O	O	76
developed	VERB	O	O	76
superior	PROPN	O	O	76
sagittal and left transverse sinus thrombosis	NOUN	O	Disease	76
associated	VERB	O	O	76
with	ADP	O	O	76
prolonged	VERB	O	O	76
epsilon	PROPN	O	O	76
-	PUNCT	O	O	76
aminocaproic	VERB	O	O	76
acid	PROPN	O	O	76
therapy	NOUN	O	O	76
for	ADP	O	O	76
menorrhagia	NOUN	O	Disease	76
.	PUNCT	O	O	76
This	PRON	O	O	77
antifibrinolytic	ADJ	O	O	77
agent	NOUN	O	O	77
has	VERB	O	O	77
been	AUX	O	O	77
used	VERB	O	O	77
in	ADP	O	O	77
women	NOUN	O	O	77
with	ADP	O	O	77
menorrhagia	NOUN	O	Disease	77
to	PART	O	O	77
promote	VERB	O	O	77
clotting	VERB	O	O	77
and	CCONJ	O	O	77
reduce	VERB	O	O	77
blood loss	NOUN	O	Disease	77
.	PUNCT	O	O	77
Although	SCONJ	O	O	78
increased	VERB	O	O	78
risk	NOUN	O	O	78
of	ADP	O	O	78
thromboembolic disease	NOUN	O	Disease	78
has	VERB	O	O	78
been	AUX	O	O	78
reported	VERB	O	O	78
during	ADP	O	O	78
treatment	NOUN	O	O	78
with	ADP	O	O	78
epsilon	PROPN	O	O	78
-	PUNCT	O	O	78
aminocaproic	VERB	O	O	78
acid	PROPN	O	O	78
,	PUNCT	O	O	78
cerebral sinus thrombosis	NOUN	O	Disease	78
has	VERB	O	O	78
not	PART	O	O	78
been	AUX	O	O	78
previously	ADV	O	O	78
described	VERB	O	O	78
.	PUNCT	O	O	78
Careful	ADJ	O	O	79
use	VERB	O	O	79
of	ADP	O	O	79
epsilon	PROPN	O	O	79
-	PUNCT	O	O	79
aminocaproic	VERB	O	O	79
acid	PROPN	O	O	79
therapy	NOUN	O	O	79
is	AUX	O	O	79
recommended	VERB	O	O	79
.	PUNCT	O	O	79
Hemorrhagic cystitis	NOUN	O	Disease	82
complicating	VERB	O	O	82
bone	NOUN	O	O	82
marrow	PROPN	O	O	82
transplantation	NOUN	O	O	82
.	PUNCT	O	O	82
Hemorrhagic cystitis	NOUN	O	Disease	83
is	AUX	O	O	83
a	PRON	O	O	83
potentially	ADV	O	O	83
serious	ADJ	O	O	83
complication	NOUN	O	O	83
of	ADP	O	O	83
high	ADJ	O	O	83
-	PUNCT	O	O	83
dose	NOUN	O	O	83
cyclophosphamide	VERB	O	Chemical	83
therapy	NOUN	O	O	83
administered	VERB	O	O	83
before	ADP	O	O	83
bone	NOUN	O	O	83
marrow	PROPN	O	O	83
transplantation	NOUN	O	O	83
.	PUNCT	O	O	83
In	ADP	O	O	84
an	PRON	O	O	84
attempt	VERB	O	O	84
to	PART	O	O	84
obviate	VERB	O	O	84
the	PRON	O	O	84
inconvenience	VERB	O	O	84
of	ADP	O	O	84
bladder	NOUN	O	O	84
irrigation	NOUN	O	O	84
,	PUNCT	O	O	84
we	PRON	O	O	84
conducted	VERB	O	O	84
a	PRON	O	O	84
feasibility	NOUN	O	O	84
trial	NOUN	O	O	84
of	ADP	O	O	84
uroprophylaxis	VERB	O	O	84
with	ADP	O	O	84
mesna	NOUN	O	Chemical	84
,	PUNCT	O	O	84
which	PRON	O	O	84
neutralizes	VERB	O	O	84
the	PRON	O	O	84
hepatic	ADJ	O	O	84
metabolite	NOUN	O	O	84
of	ADP	O	O	84
cyclophosphamide	VERB	O	Chemical	84
that	SCONJ	O	O	84
causes	VERB	O	O	84
hemorrhagic cystitis	NOUN	O	Disease	84
.	PUNCT	O	O	84
Of	ADV	O	O	85
97	NUM	O	O	85
patients	NOUN	O	O	85
who	PRON	O	O	85
received	VERB	O	O	85
standard	PROPN	O	O	85
prophylaxis	NOUN	O	O	85
,	PUNCT	O	O	85
4	NUM	O	O	85
had	VERB	O	O	85
symptomatic	ADJ	O	O	85
hemorrhagic cystitis	NOUN	O	Disease	85
.	PUNCT	O	O	85
In	ADP	O	O	86
contrast	NOUN	O	O	86
,	PUNCT	O	O	86
two	NUM	O	O	86
of	ADP	O	O	86
four	NUM	O	O	86
consecutive	ADJ	O	O	86
patients	NOUN	O	O	86
who	PRON	O	O	86
received	VERB	O	O	86
mesna	NOUN	O	Chemical	86
uroprophylaxis	VERB	O	O	86
before	ADP	O	O	86
allogeneic	ADJ	O	O	86
bone	NOUN	O	O	86
marrow	PROPN	O	O	86
transplantation	NOUN	O	O	86
had	VERB	O	O	86
severe	ADJ	O	O	86
hemorrhagic cystitis	NOUN	O	Disease	86
for	ADP	O	O	86
at	ADP	O	O	86
least	ADJ	O	O	86
2	X	O	O	86
weeks	NOUN	O	O	86
.	PUNCT	O	O	86
Because	SCONJ	O	O	87
of	ADP	O	O	87
this	PRON	O	O	87
suboptimal	ADJ	O	O	87
result	VERB	O	O	87
,	PUNCT	O	O	87
we	PRON	O	O	87
resumed	VERB	O	O	87
the	PRON	O	O	87
use	VERB	O	O	87
of	ADP	O	O	87
bladder	NOUN	O	O	87
irrigation	NOUN	O	O	87
and	CCONJ	O	O	87
forced	VERB	O	O	87
hydration	NOUN	O	O	87
to	PART	O	O	87
minimize	VERB	O	O	87
the	PRON	O	O	87
risk	NOUN	O	O	87
of	ADP	O	O	87
hemorrhagic cystitis	NOUN	O	Disease	87
.	PUNCT	O	O	87
Reversal	NOUN	O	O	90
of	ADP	O	O	90
central	ADJ	O	O	90
benzodiazepine	PROPN	O	Chemical	90
effects	NOUN	O	O	90
by	ADP	O	O	90
flumazenil	NOUN	O	Chemical	90
after	ADP	O	O	90
intravenous	ADJ	O	O	90
conscious	ADJ	O	O	90
sedation	NOUN	O	O	90
with	ADP	O	O	90
diazepam	NOUN	O	Chemical	90
and	CCONJ	O	O	90
opioids	NOUN	O	O	90
:	PUNCT	O	O	90
report	VERB	O	O	90
of	ADP	O	O	90
a	PRON	O	O	90
double	ADJ	O	O	90
-	PUNCT	O	O	90
blind	ADJ	O	Disease	90
multicenter	ADJ	O	O	90
study	VERB	O	O	90
.	PUNCT	O	O	90
The	PRON	O	O	91
Flumazenil	PROPN	O	Chemical	91
in	ADP	O	O	91
Intravenous	PROPN	O	O	91
Conscious	ADJ	O	O	91
Sedation	NOUN	O	O	91
with	ADP	O	O	91
Diazepam	NOUN	O	Chemical	91
Multicenter	NOUN	O	O	91
Study	NOUN	O	O	91
Group	PROPN	O	O	91
II	NUM	O	O	91
.	PUNCT	O	O	91
The	PRON	O	O	92
efficacy	NOUN	O	O	92
and	CCONJ	O	O	92
safety	NOUN	O	O	92
of	ADP	O	O	92
a	PRON	O	O	92
new	ADJ	O	O	92
benzodiazepine	PROPN	O	Chemical	92
antagonist	NOUN	O	O	92
,	PUNCT	O	O	92
flumazenil	NOUN	O	Chemical	92
,	PUNCT	O	O	92
were	AUX	O	O	92
assessed	VERB	O	O	92
in	ADP	O	O	92
a	PRON	O	O	92
double	ADJ	O	O	92
-	PUNCT	O	O	92
blind	ADJ	O	Disease	92
multicenter	ADJ	O	O	92
study	VERB	O	O	92
.	PUNCT	O	O	92
Flumazenil	PROPN	O	Chemical	93
(	PUNCT	O	O	93
mean	VERB	O	O	93
dose	NOUN	O	O	93
,	PUNCT	O	O	93
0.76	NUM	O	O	93
mg	VERB	O	O	93
)	PUNCT	O	O	93
or	CCONJ	O	O	93
placebo	NOUN	O	O	93
(	PUNCT	O	O	93
mean	VERB	O	O	93
dose	NOUN	O	O	93
,	PUNCT	O	O	93
8.9	NUM	O	O	93
ml	ADP	O	O	93
)	PUNCT	O	O	93
was	AUX	O	O	93
administered	VERB	O	O	93
intravenously	ADV	O	O	93
to	PART	O	O	93
130	NUM	O	O	93
and	CCONJ	O	O	93
67	NUM	O	O	93
patients	NOUN	O	O	93
,	PUNCT	O	O	93
respectively	ADV	O	O	93
,	PUNCT	O	O	93
who	PRON	O	O	93
had	VERB	O	O	93
been	AUX	O	O	93
given	VERB	O	O	93
diazepam	NOUN	O	Chemical	93
in	ADP	O	O	93
conjunction	NOUN	O	O	93
with	ADP	O	O	93
an	PRON	O	O	93
opioid	NOUN	O	O	93
(	PUNCT	O	O	93
fentanyl	ADJ	O	Chemical	93
,	PUNCT	O	O	93
meperidine	NOUN	O	Chemical	93
,	PUNCT	O	O	93
or	CCONJ	O	O	93
morphine	NOUN	O	Chemical	93
)	PUNCT	O	O	93
for	ADP	O	O	93
the	PRON	O	O	93
induction	NOUN	O	O	93
and	CCONJ	O	O	93
maintenance	NOUN	O	O	93
of	ADP	O	O	93
intravenous	ADJ	O	O	93
conscious	ADJ	O	O	93
sedation	NOUN	O	O	93
for	ADP	O	O	93
diagnostic	ADJ	O	O	93
or	CCONJ	O	O	93
therapeutic	ADJ	O	O	93
surgical	ADJ	O	O	93
procedures	NOUN	O	O	93
.	PUNCT	O	O	93
The	PRON	O	O	94
group	NOUN	O	O	94
assessable	ADJ	O	O	94
for	ADP	O	O	94
efficacy	NOUN	O	O	94
comprised	VERB	O	O	94
122	NUM	O	O	94
patients	NOUN	O	O	94
treated	VERB	O	O	94
with	ADP	O	O	94
flumazenil	NOUN	O	Chemical	94
and	CCONJ	O	O	94
64	NUM	O	O	94
patients	NOUN	O	O	94
given	VERB	O	O	94
placebo	NOUN	O	O	94
.	PUNCT	O	O	94
After	ADP	O	O	95
5	NUM	O	O	95
minutes	NOUN	O	O	95
,	PUNCT	O	O	95
80/115	NUM	O	O	95
(	PUNCT	O	O	95
70%	NOUN	O	O	95
)	PUNCT	O	O	95
flumazenil	NOUN	O	Chemical	95
-	PUNCT	O	O	95
treated	VERB	O	O	95
patients	NOUN	O	O	95
,	PUNCT	O	O	95
compared	VERB	O	O	95
with	ADP	O	O	95
21/63	NUM	O	O	95
(	PUNCT	O	O	95
33%	NOUN	O	O	95
)	PUNCT	O	O	95
placebo	NOUN	O	O	95
-	PUNCT	O	O	95
treated	VERB	O	O	95
patients	NOUN	O	O	95
,	PUNCT	O	O	95
were	AUX	O	O	95
completely	ADV	O	O	95
awake	ADJ	O	O	95
and	CCONJ	O	O	95
alert	ADJ	O	O	95
,	PUNCT	O	O	95
as	ADP	O	O	95
indicated	VERB	O	O	95
by	ADP	O	O	95
a	PRON	O	O	95
score	VERB	O	O	95
of	ADP	O	O	95
5	NUM	O	O	95
on	ADP	O	O	95
the	PRON	O	O	95
Observer	NOUN	O	O	95
's	AUX	O	O	95
Assessment	NOUN	O	O	95
of	ADP	O	O	95
Alertness	NOUN	O	O	95
/	PUNCT	O	O	95
Sedation	NOUN	O	O	95
Scale	NOUN	O	O	95
.	PUNCT	O	O	95
Flumazenil	PROPN	O	Chemical	96
-	PUNCT	O	O	96
treated	VERB	O	O	96
patients	NOUN	O	O	96
also	ADV	O	O	96
performed	VERB	O	O	96
significantly	ADV	O	O	96
better	ADV	O	O	96
on	ADP	O	O	96
the	PRON	O	O	96
Finger	NOUN	O	O	96
-	PUNCT	O	O	96
to	PART	O	O	96
-	PUNCT	O	O	96
Nose	NOUN	O	O	96
Test	NOUN	O	O	96
and	CCONJ	O	O	96
the	PRON	O	O	96
recall	VERB	O	O	96
of	ADP	O	O	96
pictures	NOUN	O	O	96
shown	VERB	O	O	96
at	ADP	O	O	96
the	PRON	O	O	96
5-minute	NOUN	O	O	96
assessment	NOUN	O	O	96
.	PUNCT	O	O	96
Flumazenil	PROPN	O	Chemical	97
was	AUX	O	O	97
well	ADV	O	O	97
tolerated	VERB	O	O	97
,	PUNCT	O	O	97
with	ADP	O	O	97
no	PRON	O	O	97
serious	ADJ	O	O	97
adverse	ADJ	O	O	97
effects	NOUN	O	O	97
reported	VERB	O	O	97
.	PUNCT	O	O	97
Thirty	NUM	O	O	98
-	PUNCT	O	O	98
nine	NUM	O	O	98
(	PUNCT	O	O	98
30%	NOUN	O	O	98
)	PUNCT	O	O	98
of	ADP	O	O	98
flumazenil	NOUN	O	Chemical	98
-	PUNCT	O	O	98
treated	VERB	O	O	98
patients	NOUN	O	O	98
,	PUNCT	O	O	98
compared	VERB	O	O	98
with	ADP	O	O	98
17	NUM	O	O	98
(	PUNCT	O	O	98
25%	NOUN	O	O	98
)	PUNCT	O	O	98
of	ADP	O	O	98
placebo	NOUN	O	O	98
-	PUNCT	O	O	98
treated	VERB	O	O	98
patients	NOUN	O	O	98
had	VERB	O	O	98
one	NUM	O	O	98
or	CCONJ	O	O	98
more	ADJ	O	O	98
drug	NOUN	O	O	98
-	PUNCT	O	O	98
related	ADJ	O	O	98
adverse	ADJ	O	O	98
experiences	NOUN	O	O	98
.	PUNCT	O	O	98
The	PRON	O	O	99
most	ADV	O	O	99
common	ADJ	O	O	99
adverse	ADJ	O	O	99
effects	NOUN	O	O	99
were	AUX	O	O	99
nausea	NOUN	O	Disease	99
and	CCONJ	O	O	99
vomiting	VERB	O	Disease	99
in	ADP	O	O	99
the	PRON	O	O	99
flumazenil	NOUN	O	Chemical	99
group	NOUN	O	O	99
and	CCONJ	O	O	99
nausea	NOUN	O	Disease	99
and	CCONJ	O	O	99
injection	NOUN	O	O	99
-	PUNCT	O	O	99
site	NOUN	O	O	99
pain	NOUN	O	Disease	99
in	ADP	O	O	99
the	PRON	O	O	99
placebo	NOUN	O	O	99
group	NOUN	O	O	99
.	PUNCT	O	O	99
Flumazenil	PROPN	O	Chemical	100
was	AUX	O	O	100
found	VERB	O	O	100
to	PART	O	O	100
promptly	ADV	O	O	100
reverse	VERB	O	O	100
sedation	NOUN	O	O	100
induced	VERB	O	O	100
by	ADP	O	O	100
diazepam	NOUN	O	Chemical	100
in	ADP	O	O	100
the	PRON	O	O	100
presence	NOUN	O	O	100
of	ADP	O	O	100
opioids	NOUN	O	O	100
.	PUNCT	O	O	100
Hepatic	ADJ	O	O	103
adenomas	NOUN	O	Disease	103
and	CCONJ	O	O	103
focal nodular hyperplasia	NOUN	O	Disease	103
of	ADP	O	O	103
the	PRON	O	O	103
liver	NOUN	O	O	103
in	ADP	O	O	103
young	ADJ	O	O	103
women	NOUN	O	O	103
on	ADP	O	O	103
oral contraceptives	NOUN	O	Chemical	103
:	PUNCT	O	O	103
case	NOUN	O	O	103
reports	VERB	O	O	103
.	PUNCT	O	O	103
Two	NUM	O	O	104
cases	NOUN	O	O	104
of	ADP	O	O	104
hepatic	ADJ	O	O	104
adenoma	INTJ	O	Disease	104
and	CCONJ	O	O	104
one	NUM	O	O	104
of	ADP	O	O	104
focal nodular hyperplasia	NOUN	O	Disease	104
presumably	ADV	O	O	104
associated	VERB	O	O	104
with	ADP	O	O	104
the	PRON	O	O	104
use	VERB	O	O	104
of	ADP	O	O	104
oral contraceptives	NOUN	O	Chemical	104
,	PUNCT	O	O	104
are	AUX	O	O	104
reported	VERB	O	O	104
.	PUNCT	O	O	104
Histologic	NOUN	O	O	105
differences	NOUN	O	O	105
and	CCONJ	O	O	105
clinical	ADJ	O	O	105
similarities	VERB	O	O	105
between	ADP	O	O	105
hepatic	ADJ	O	O	105
adenoma	INTJ	O	Disease	105
and	CCONJ	O	O	105
focal nodular hyperplasia	NOUN	O	Disease	105
of	ADP	O	O	105
the	PRON	O	O	105
liver	NOUN	O	O	105
are	AUX	O	O	105
discussed	VERB	O	O	105
.	PUNCT	O	O	105
Arterial	ADJ	O	O	108
thromboembolism	NOUN	O	Disease	108
in	ADP	O	O	108
patients	NOUN	O	O	108
receiving	VERB	O	O	108
systemic	ADJ	O	O	108
heparin	NOUN	O	Chemical	108
therapy	NOUN	O	O	108
:	PUNCT	O	O	108
a	PRON	O	O	108
complication	NOUN	O	O	108
associated	VERB	O	O	108
with	ADP	O	O	108
heparin	NOUN	O	Chemical	108
-	PUNCT	O	O	108
induced	VERB	O	O	108
thrombocytopenia	PROPN	O	Disease	108
.	PUNCT	O	O	108
Arterial	ADJ	O	O	109
thromboembolism	NOUN	O	Disease	109
is	AUX	O	O	109
a	PRON	O	O	109
recognized	VERB	O	O	109
complication	NOUN	O	O	109
of	ADP	O	O	109
systemic	ADJ	O	O	109
heparin	NOUN	O	Chemical	109
therapy	NOUN	O	O	109
.	PUNCT	O	O	109
Characteristic	ADJ	O	O	110
of	ADP	O	O	110
the	PRON	O	O	110
entity	NOUN	O	O	110
is	AUX	O	O	110
arterial occlusion	NOUN	O	Disease	110
by	ADP	O	O	110
platelet	NOUN	O	O	110
-	PUNCT	O	O	110
fibrin	PROPN	O	O	110
thrombi	NOUN	O	Disease	110
with	ADP	O	O	110
distal	NOUN	O	O	110
ischemia	NOUN	O	Disease	110
occurring	VERB	O	O	110
four	NUM	O	O	110
to	PART	O	O	110
twenty	NUM	O	O	110
days	NOUN	O	O	110
after	ADP	O	O	110
the	PRON	O	O	110
initiation	NOUN	O	O	110
of	ADP	O	O	110
heparin	NOUN	O	Chemical	110
therapy	NOUN	O	O	110
,	PUNCT	O	O	110
preceded	VERB	O	O	110
by	ADP	O	O	110
profound	ADJ	O	O	110
thrombocytopenia	PROPN	O	Disease	110
with	ADP	O	O	110
platelet	NOUN	O	O	110
counts	VERB	O	O	110
in	ADP	O	O	110
the	PRON	O	O	110
range	VERB	O	O	110
of	ADP	O	O	110
30,000	NUM	O	O	110
to	PART	O	O	110
40,000	NUM	O	O	110
per	ADP	O	O	110
cubic	ADJ	O	O	110
millimeter	NOUN	O	O	110
.	PUNCT	O	O	110
The	PRON	O	O	111
clinically	ADV	O	O	111
apparent	ADJ	O	O	111
occlusion	NOUN	O	O	111
may	AUX	O	O	111
be	AUX	O	O	111
preceded	VERB	O	O	111
by	ADP	O	O	111
gastrointestinal	ADJ	O	O	111
and	CCONJ	O	O	111
musculoskeletal symptoms	NOUN	O	Disease	111
that	SCONJ	O	O	111
appear	VERB	O	O	111
to	PART	O	O	111
be	AUX	O	O	111
ischemic	VERB	O	Disease	111
in	ADP	O	O	111
origin	NOUN	O	O	111
,	PUNCT	O	O	111
and	CCONJ	O	O	111
might	AUX	O	O	111
serve	VERB	O	O	111
to	PART	O	O	111
warn	VERB	O	O	111
the	PRON	O	O	111
clinician	NOUN	O	O	111
of	ADP	O	O	111
these	PRON	O	O	111
complications	NOUN	O	O	111
.	PUNCT	O	O	111
Previous	ADJ	O	O	112
reports	VERB	O	O	112
of	ADP	O	O	112
these	PRON	O	O	112
phenomena	VERB	O	O	112
as	ADP	O	O	112
well	ADV	O	O	112
as	ADP	O	O	112
recent	ADJ	O	O	112
studies	NOUN	O	O	112
of	ADP	O	O	112
the	PRON	O	O	112
effect	VERB	O	O	112
of	ADP	O	O	112
heparin	NOUN	O	Chemical	112
are	AUX	O	O	112
reviewed	VERB	O	O	112
.	PUNCT	O	O	112
The	PRON	O	O	113
common	ADJ	O	O	113
factor	NOUN	O	O	113
relating	VERB	O	O	113
thromboembolism	NOUN	O	Disease	113
and	CCONJ	O	O	113
thrombocytopenia	PROPN	O	Disease	113
is	AUX	O	O	113
heparin	NOUN	O	Chemical	113
-	PUNCT	O	O	113
induced	VERB	O	O	113
platelet aggregation	NOUN	O	Disease	113
.	PUNCT	O	O	113
Appropriate	ADJ	O	O	114
treatment	NOUN	O	O	114
consists	VERB	O	O	114
of	ADP	O	O	114
discontinuation	NOUN	O	O	114
of	ADP	O	O	114
heparin	NOUN	O	Chemical	114
,	PUNCT	O	O	114
and	CCONJ	O	O	114
anticoagulation	NOUN	O	O	114
with	ADP	O	O	114
sodium warfarin	VERB	O	Chemical	114
if	SCONJ	O	O	114
necessary	ADJ	O	O	114
.	PUNCT	O	O	114
Long	ADV	O	O	117
-	PUNCT	O	O	117
term	NOUN	O	O	117
prognosis	VERB	O	O	117
for	ADP	O	O	117
transplant	NOUN	O	O	117
-	PUNCT	O	O	117
free	ADJ	O	O	117
survivors	NOUN	O	O	117
of	ADP	O	O	117
paracetamol	PROPN	O	Chemical	117
-	PUNCT	O	O	117
induced	VERB	O	O	117
acute liver failure	NOUN	O	Disease	117
.	PUNCT	O	O	117
BACKGROUND	NOUN	O	O	118
:	PUNCT	O	O	118
The	PRON	O	O	118
prognosis	VERB	O	O	118
for	ADP	O	O	118
transplant	NOUN	O	O	118
-	PUNCT	O	O	118
free	ADJ	O	O	118
survivors	NOUN	O	O	118
of	ADP	O	O	118
paracetamol	PROPN	O	Chemical	118
-	PUNCT	O	O	118
induced	VERB	O	O	118
acute liver failure	NOUN	O	Disease	118
remains	VERB	O	O	118
unknown	ADJ	O	O	118
.	PUNCT	O	O	118
AIM	VERB	O	O	119
:	PUNCT	O	O	119
To	PART	O	O	119
examine	VERB	O	O	119
whether	SCONJ	O	O	119
paracetamol	PROPN	O	Chemical	119
-	PUNCT	O	O	119
induced	VERB	O	O	119
acute liver failure	NOUN	O	Disease	119
increases	VERB	O	O	119
long	ADV	O	O	119
-	PUNCT	O	O	119
term	NOUN	O	O	119
mortality	NOUN	O	O	119
.	PUNCT	O	O	119
We	PRON	O	O	120
followed	VERB	O	O	120
up	ADP	O	O	120
all	PRON	O	O	120
transplant	NOUN	O	O	120
-	PUNCT	O	O	120
free	ADJ	O	O	120
survivors	NOUN	O	O	120
of	ADP	O	O	120
paracetamol	PROPN	O	Chemical	120
-	PUNCT	O	O	120
induced	VERB	O	O	120
acute	ADJ	O	O	120
liver injury	NOUN	O	Disease	120
,	PUNCT	O	O	120
hospitalized	VERB	O	O	120
in	ADP	O	O	120
a	PRON	O	O	120
Danish	ADJ	O	O	120
national	ADJ	O	O	120
referral	NOUN	O	O	120
centre	PROPN	O	O	120
during	ADP	O	O	120
1984	NUM	O	O	120
-	PUNCT	O	O	120
2004	NUM	O	O	120
.	PUNCT	O	O	120
We	PRON	O	O	121
compared	VERB	O	O	121
age	NOUN	O	O	121
-	PUNCT	O	O	121
specific	ADJ	O	O	121
mortality	NOUN	O	O	121
rates	NOUN	O	O	121
from	ADP	O	O	121
1	X	O	O	121
year	NOUN	O	O	121
post	VERB	O	O	121
-	PUNCT	O	O	121
discharge	VERB	O	O	121
through	ADP	O	O	121
2008	NUM	O	O	121
between	ADP	O	O	121
those	PRON	O	O	121
in	ADP	O	O	121
whom	PRON	O	O	121
the	PRON	O	O	121
liver injury	NOUN	O	Disease	121
led	VERB	O	O	121
to	PART	O	O	121
an	PRON	O	O	121
acute liver failure	NOUN	O	Disease	121
and	CCONJ	O	O	121
those	PRON	O	O	121
in	ADP	O	O	121
whom	PRON	O	O	121
it	PRON	O	O	121
did	VERB	O	O	121
not	PART	O	O	121
.	PUNCT	O	O	121
On	ADP	O	O	122
average	ADJ	O	O	122
,	PUNCT	O	O	122
age	NOUN	O	O	122
-	PUNCT	O	O	122
specific	ADJ	O	O	122
mortality	NOUN	O	O	122
rates	NOUN	O	O	122
were	AUX	O	O	122
slightly	ADV	O	O	122
higher	ADJ	O	O	122
for	ADP	O	O	122
the	PRON	O	O	122
101	NUM	O	O	122
patients	NOUN	O	O	122
whose	DET	O	O	122
paracetamol	PROPN	O	Chemical	122
-	PUNCT	O	O	122
induced	VERB	O	O	122
liver injury	NOUN	O	Disease	122
had	VERB	O	O	122
caused	VERB	O	O	122
an	PRON	O	O	122
acute liver failure	NOUN	O	Disease	122
(	PUNCT	O	O	122
adjusted	VERB	O	O	122
mortality	NOUN	O	O	122
rate	NOUN	O	O	122
ratio	NOUN	O	O	122
=	PUNCT	O	O	122
1.70	NUM	O	O	122
,	PUNCT	O	O	122
95%	NOUN	O	O	122
CI	NOUN	O	O	122
1.02	NUM	O	O	122
-	PUNCT	O	O	122
2.85	NUM	O	O	122
)	PUNCT	O	O	122
,	PUNCT	O	O	122
but	CCONJ	O	O	122
the	PRON	O	O	122
association	PROPN	O	O	122
was	AUX	O	O	122
age	NOUN	O	O	122
-	PUNCT	O	O	122
dependent	ADJ	O	O	122
,	PUNCT	O	O	122
and	CCONJ	O	O	122
no	PRON	O	O	122
survivors	NOUN	O	O	122
of	ADP	O	O	122
acute liver failure	NOUN	O	Disease	122
died	VERB	O	O	122
of	ADP	O	O	122
liver disease	NOUN	O	Disease	122
,	PUNCT	O	O	122
whereas	SCONJ	O	O	122
suicides	NOUN	O	O	122
were	AUX	O	O	122
frequent	ADJ	O	O	122
in	ADP	O	O	122
both	PRON	O	O	122
groups	NOUN	O	O	122
.	PUNCT	O	O	122
These	PRON	O	O	123
observations	NOUN	O	O	123
speak	VERB	O	O	123
against	ADP	O	O	123
long	ADV	O	O	123
-	PUNCT	O	O	123
term	NOUN	O	O	123
effects	NOUN	O	O	123
of	ADP	O	O	123
acute liver failure	NOUN	O	Disease	123
.	PUNCT	O	O	123
More	ADJ	O	O	124
likely	ADV	O	O	124
,	PUNCT	O	O	124
the	PRON	O	O	124
elevated	ADJ	O	O	124
mortality	NOUN	O	O	124
rate	NOUN	O	O	124
ratio	NOUN	O	O	124
resulted	VERB	O	O	124
from	ADP	O	O	124
incomplete	ADJ	O	O	124
adjustment	NOUN	O	O	124
for	ADP	O	O	124
the	PRON	O	O	124
greater	ADJ	O	O	124
prevalence	NOUN	O	O	124
of	ADP	O	O	124
substance abuse	NOUN	O	Disease	124
among	ADP	O	O	124
survivors	NOUN	O	O	124
of	ADP	O	O	124
acute liver failure	NOUN	O	Disease	124
.	PUNCT	O	O	124
CONCLUSIONS	NOUN	O	O	125
:	PUNCT	O	O	125
Paracetamol	PROPN	O	Chemical	125
-	PUNCT	O	O	125
induced	VERB	O	O	125
acute liver failure	NOUN	O	Disease	125
did	VERB	O	O	125
not	PART	O	O	125
affect	VERB	O	O	125
long	ADV	O	O	125
-	PUNCT	O	O	125
term	NOUN	O	O	125
mortality	NOUN	O	O	125
.	PUNCT	O	O	125
Clinical	NOUN	O	O	126
follow	VERB	O	O	126
-	PUNCT	O	O	126
up	ADP	O	O	126
may	AUX	O	O	126
be	AUX	O	O	126
justified	VERB	O	O	126
by	ADP	O	O	126
the	PRON	O	O	126
cause	VERB	O	O	126
of	ADP	O	O	126
the	PRON	O	O	126
liver failure	NOUN	O	Disease	126
,	PUNCT	O	O	126
but	CCONJ	O	O	126
not	PART	O	O	126
by	ADP	O	O	126
the	PRON	O	O	126
liver failure	NOUN	O	Disease	126
itself	PRON	O	O	126
.	PUNCT	O	O	126
Serotonin	NOUN	O	Chemical	129
6	NUM	O	O	129
receptor	NOUN	O	O	129
gene	NOUN	O	O	129
is	AUX	O	O	129
associated	VERB	O	O	129
with	ADP	O	O	129
methamphetamine	NOUN	O	Chemical	129
-	PUNCT	O	O	129
induced	VERB	O	O	129
psychosis	VERB	O	Disease	129
in	ADP	O	O	129
a	PRON	O	O	129
Japanese	NOUN	O	O	129
population	NOUN	O	O	129
.	PUNCT	O	O	129
Altered	VERB	O	O	130
serotonergic	ADJ	O	O	130
neural	NOUN	O	O	130
transmission	NOUN	O	O	130
is	AUX	O	O	130
hypothesized	VERB	O	O	130
to	PART	O	O	130
be	AUX	O	O	130
a	PRON	O	O	130
susceptibility	NOUN	O	O	130
factor	NOUN	O	O	130
for	ADP	O	O	130
psychotic disorders	NOUN	O	Disease	130
such	ADJ	O	O	130
as	ADP	O	O	130
schizophrenia	PROPN	O	Disease	130
.	PUNCT	O	O	130
The	PRON	O	O	131
serotonin	PROPN	O	Chemical	131
6	NUM	O	O	131
(	PUNCT	O	O	131
5-HT6	PROPN	O	O	131
)	PUNCT	O	O	131
receptor	NOUN	O	O	131
is	AUX	O	O	131
therapeutically	ADV	O	O	131
targeted	VERB	O	O	131
by	ADP	O	O	131
several	ADJ	O	O	131
second	ADV	O	O	131
generation	NOUN	O	O	131
antipsychotics	NOUN	O	O	131
,	PUNCT	O	O	131
such	ADJ	O	O	131
as	ADP	O	O	131
clozapine	PROPN	O	Chemical	131
and	CCONJ	O	O	131
olanzapine	NOUN	O	Chemical	131
,	PUNCT	O	O	131
and	CCONJ	O	O	131
d	X	O	O	131
-	PUNCT	O	O	131
amphetamine	NOUN	O	Chemical	131
-	PUNCT	O	O	131
induced	VERB	O	O	131
hyperactivity	NOUN	O	Disease	131
in	ADP	O	O	131
rats	NOUN	O	O	131
is	AUX	O	O	131
corrected	VERB	O	O	131
with	ADP	O	O	131
the	PRON	O	O	131
use	VERB	O	O	131
of	ADP	O	O	131
a	PRON	O	O	131
selective	ADJ	O	O	131
5-HT6	PROPN	O	O	131
receptor	NOUN	O	O	131
antagonist	NOUN	O	O	131
.	PUNCT	O	O	131
In	ADP	O	O	132
addition	NOUN	O	O	132
,	PUNCT	O	O	132
the	PRON	O	O	132
disrupted	VERB	O	O	132
prepulse	NOUN	O	O	132
inhibition	NOUN	O	O	132
induced	VERB	O	O	132
by	ADP	O	O	132
d	X	O	O	132
-	PUNCT	O	O	132
amphetamine	NOUN	O	Chemical	132
or	CCONJ	O	O	132
phencyclidine	NOUN	O	Chemical	132
was	AUX	O	O	132
restored	VERB	O	O	132
by	ADP	O	O	132
5-HT6	PROPN	O	O	132
receptor	NOUN	O	O	132
antagonist	NOUN	O	O	132
in	ADP	O	O	132
an	PRON	O	O	132
animal	NOUN	O	O	132
study	VERB	O	O	132
using	VERB	O	O	132
rats	NOUN	O	O	132
.	PUNCT	O	O	132
These	PRON	O	O	133
animal	NOUN	O	O	133
models	NOUN	O	O	133
were	AUX	O	O	133
considered	VERB	O	O	133
to	PART	O	O	133
reflect	VERB	O	O	133
the	PRON	O	O	133
positive	ADJ	O	O	133
symptoms	NOUN	O	O	133
of	ADP	O	O	133
schizophrenia	PROPN	O	Disease	133
,	PUNCT	O	O	133
and	CCONJ	O	O	133
the	PRON	O	O	133
above	ADP	O	O	133
evidence	NOUN	O	O	133
suggests	VERB	O	O	133
that	SCONJ	O	O	133
altered	VERB	O	O	133
5-HT6	PROPN	O	O	133
receptors	NOUN	O	O	133
are	AUX	O	O	133
involved	VERB	O	O	133
in	ADP	O	O	133
the	PRON	O	O	133
pathophysiology	NOUN	O	O	133
of	ADP	O	O	133
psychotic disorders	NOUN	O	Disease	133
.	PUNCT	O	O	133
The	PRON	O	O	134
symptoms	NOUN	O	O	134
of	ADP	O	O	134
methamphetamine	NOUN	O	Chemical	134
(	PUNCT	O	O	134
METH)-induced	VERB	O	O	134
psychosis	VERB	O	Disease	134
are	AUX	O	O	134
similar	ADJ	O	O	134
to	PART	O	O	134
those	PRON	O	O	134
of	ADP	O	O	134
paranoid type schizophrenia	NOUN	O	Disease	134
.	PUNCT	O	O	134
Therefore	ADV	O	O	135
,	PUNCT	O	O	135
we	PRON	O	O	135
conducted	VERB	O	O	135
an	PRON	O	O	135
analysis	NOUN	O	O	135
of	ADP	O	O	135
the	PRON	O	O	135
association	PROPN	O	O	135
of	ADP	O	O	135
the	PRON	O	O	135
5-HT6	PROPN	O	O	135
gene	NOUN	O	O	135
(	PUNCT	O	O	135
HTR6	NOUN	O	O	135
)	PUNCT	O	O	135
with	ADP	O	O	135
METH	NOUN	O	Chemical	135
-	PUNCT	O	O	135
induced	VERB	O	O	135
psychosis	VERB	O	Disease	135
.	PUNCT	O	O	135
Using	VERB	O	O	136
five	NUM	O	O	136
tagging	VERB	O	O	136
SNPs	NOUN	O	O	136
(	PUNCT	O	O	136
rs6693503	PROPN	O	O	136
,	PUNCT	O	O	136
rs1805054	PROPN	O	O	136
,	PUNCT	O	O	136
rs4912138	PROPN	O	O	136
,	PUNCT	O	O	136
rs3790757	PROPN	O	O	136
and	CCONJ	O	O	136
rs9659997	NOUN	O	O	136
)	PUNCT	O	O	136
,	PUNCT	O	O	136
we	PRON	O	O	136
conducted	VERB	O	O	136
a	PRON	O	O	136
genetic	ADJ	O	O	136
association	PROPN	O	O	136
analysis	NOUN	O	O	136
of	ADP	O	O	136
case	NOUN	O	O	136
-	PUNCT	O	O	136
control	VERB	O	O	136
samples	NOUN	O	O	136
(	PUNCT	O	O	136
197	NUM	O	O	136
METH	NOUN	O	Chemical	136
-	PUNCT	O	O	136
induced	VERB	O	O	136
psychosis	VERB	O	Disease	136
patients	NOUN	O	O	136
and	CCONJ	O	O	136
337	NUM	O	O	136
controls	VERB	O	O	136
)	PUNCT	O	O	136
in	ADP	O	O	136
the	PRON	O	O	136
Japanese	NOUN	O	O	136
population	NOUN	O	O	136
.	PUNCT	O	O	136
The	PRON	O	O	137
age	NOUN	O	O	137
and	CCONJ	O	O	137
sex	NOUN	O	O	137
of	ADP	O	O	137
the	PRON	O	O	137
control	VERB	O	O	137
subjects	NOUN	O	O	137
did	VERB	O	O	137
not	PART	O	O	137
differ	VERB	O	O	137
from	ADP	O	O	137
those	PRON	O	O	137
of	ADP	O	O	137
the	PRON	O	O	137
methamphetamine	NOUN	O	Chemical	137
dependence	NOUN	O	O	137
patients	NOUN	O	O	137
.	PUNCT	O	O	137
rs6693503	PROPN	O	O	138
was	AUX	O	O	138
associated	VERB	O	O	138
with	ADP	O	O	138
METH	NOUN	O	Chemical	138
-	PUNCT	O	O	138
induced	VERB	O	O	138
psychosis	VERB	O	Disease	138
patients	NOUN	O	O	138
in	ADP	O	O	138
the	PRON	O	O	138
allele	PROPN	O	O	138
/	PUNCT	O	O	138
genotype	NOUN	O	O	138
-	PUNCT	O	O	138
wise	ADJ	O	O	138
analysis	NOUN	O	O	138
.	PUNCT	O	O	138
In	ADP	O	O	139
the	PRON	O	O	139
haplotype	NOUN	O	O	139
-	PUNCT	O	O	139
wise	ADJ	O	O	139
analysis	NOUN	O	O	139
,	PUNCT	O	O	139
we	PRON	O	O	139
detected	VERB	O	O	139
an	PRON	O	O	139
association	PROPN	O	O	139
between	ADP	O	O	139
two	NUM	O	O	139
markers	NOUN	O	O	139
(	PUNCT	O	O	139
rs6693503	PROPN	O	O	139
and	CCONJ	O	O	139
rs1805054	PROPN	O	O	139
)	PUNCT	O	O	139
and	CCONJ	O	O	139
three	NUM	O	O	139
markers	NOUN	O	O	139
(	PUNCT	O	O	139
rs6693503	PROPN	O	O	139
,	PUNCT	O	O	139
rs1805054	PROPN	O	O	139
and	CCONJ	O	O	139
rs4912138	PROPN	O	O	139
)	PUNCT	O	O	139
in	ADP	O	O	139
HTR6	NOUN	O	O	139
and	CCONJ	O	O	139
METH	NOUN	O	Chemical	139
-	PUNCT	O	O	139
induced	VERB	O	O	139
psychosis	VERB	O	Disease	139
patients	NOUN	O	O	139
,	PUNCT	O	O	139
respectively	ADV	O	O	139
.	PUNCT	O	O	139
CONCLUSION	PROPN	O	O	140
:	PUNCT	O	O	140
HTR6	NOUN	O	O	140
may	AUX	O	O	140
play	VERB	O	O	140
an	PRON	O	O	140
important	ADJ	O	O	140
role	NOUN	O	O	140
in	ADP	O	O	140
the	PRON	O	O	140
pathophysiology	NOUN	O	O	140
of	ADP	O	O	140
METH	NOUN	O	Chemical	140
-	PUNCT	O	O	140
induced	VERB	O	O	140
psychosis	VERB	O	Disease	140
in	ADP	O	O	140
the	PRON	O	O	140
Japanese	NOUN	O	O	140
population	NOUN	O	O	140
.	PUNCT	O	O	140
Effect	VERB	O	O	143
of	ADP	O	O	143
increasing	VERB	O	O	143
intraperitoneal	ADJ	O	O	143
infusion	NOUN	O	O	143
rates	NOUN	O	O	143
on	ADP	O	O	143
bupropion hydrochloride	NOUN	O	Chemical	143
-	PUNCT	O	O	143
induced	VERB	O	O	143
seizures	NOUN	O	Disease	143
in	ADP	O	O	143
mice	NOUN	O	O	143
.	PUNCT	O	O	143
BACKGROUND	NOUN	O	O	144
:	PUNCT	O	O	144
It	PRON	O	O	144
is	AUX	O	O	144
not	PART	O	O	144
known	VERB	O	O	144
if	SCONJ	O	O	144
there	ADV	O	O	144
is	AUX	O	O	144
a	PRON	O	O	144
relationship	NOUN	O	O	144
between	ADP	O	O	144
input	NOUN	O	O	144
rate	NOUN	O	O	144
and	CCONJ	O	O	144
incidence	NOUN	O	O	144
of	ADP	O	O	144
bupropion	NOUN	O	Chemical	144
-	PUNCT	O	O	144
induced	VERB	O	O	144
seizures	NOUN	O	Disease	144
.	PUNCT	O	O	144
This	PRON	O	O	145
is	AUX	O	O	145
important	ADJ	O	O	145
,	PUNCT	O	O	145
since	SCONJ	O	O	145
different	ADJ	O	O	145
controlled	VERB	O	O	145
release	NOUN	O	O	145
formulations	NOUN	O	O	145
of	ADP	O	O	145
bupropion	NOUN	O	Chemical	145
release	NOUN	O	O	145
the	PRON	O	O	145
active	ADJ	O	O	145
drug	NOUN	O	O	145
at	ADP	O	O	145
different	ADJ	O	O	145
rates	NOUN	O	O	145
.	PUNCT	O	O	145
METHODS	NOUN	O	O	146
:	PUNCT	O	O	146
We	PRON	O	O	146
investigated	VERB	O	O	146
the	PRON	O	O	146
effect	VERB	O	O	146
of	ADP	O	O	146
varying	VERB	O	O	146
the	PRON	O	O	146
intraperitoneal	ADJ	O	O	146
infusion	NOUN	O	O	146
rates	NOUN	O	O	146
of	ADP	O	O	146
bupropion HCl	PROPN	O	Chemical	146
120	NUM	O	O	146
mg	VERB	O	O	147
/	PUNCT	O	O	147
kg	VERB	O	O	147
,	PUNCT	O	O	147
a	PRON	O	O	147
known	VERB	O	O	147
convulsive	ADJ	O	Disease	147
dose	NOUN	O	O	147
50	NUM	O	O	147
(	PUNCT	O	O	147
CD50	NOUN	O	O	147
)	PUNCT	O	O	147
,	PUNCT	O	O	147
on	ADP	O	O	147
the	PRON	O	O	147
incidence	NOUN	O	O	147
and	CCONJ	O	O	147
severity	NOUN	O	O	147
of	ADP	O	O	147
bupropion	NOUN	O	Chemical	147
-	PUNCT	O	O	147
induced	VERB	O	O	147
convulsions	NOUN	O	Disease	147
in	ADP	O	O	147
the	PRON	O	O	147
Swiss	PROPN	O	O	147
albino	PROPN	O	O	147
mice	NOUN	O	O	147
.	PUNCT	O	O	147
A	PRON	O	O	148
total	ADJ	O	O	148
of	ADP	O	O	148
69	NUM	O	O	148
mice	NOUN	O	O	148
,	PUNCT	O	O	148
approximately	ADV	O	O	148
7	NUM	O	O	148
weeks	NOUN	O	O	148
of	ADP	O	O	148
age	NOUN	O	O	148
,	PUNCT	O	O	148
and	CCONJ	O	O	148
weighing	VERB	O	O	148
21.0	NUM	O	O	148
to	PART	O	O	148
29.1	NUM	O	O	148
g	X	O	O	148
were	AUX	O	O	148
randomly	ADV	O	O	148
assigned	VERB	O	O	148
to	PART	O	O	148
bupropion HCl	PROPN	O	Chemical	148
120	NUM	O	O	148
mg	VERB	O	O	148
/	PUNCT	O	O	148
kg	VERB	O	O	148
treatment	NOUN	O	O	148
by	ADP	O	O	148
intraperitoneal	ADJ	O	O	148
(	PUNCT	O	O	148
IP	PROPN	O	O	148
)	PUNCT	O	O	148
administration	NOUN	O	O	148
in	ADP	O	O	148
7	NUM	O	O	148
groups	NOUN	O	O	148
(	PUNCT	O	O	148
9	NUM	O	O	148
to	PART	O	O	148
10	NUM	O	O	148
animals	NOUN	O	O	148
per	ADP	O	O	148
group	NOUN	O	O	148
)	PUNCT	O	O	148
.	PUNCT	O	O	148
Bupropion HCl	NOUN	O	Chemical	149
was	AUX	O	O	149
infused	VERB	O	O	149
through	ADP	O	O	149
a	PRON	O	O	149
surgically	ADV	O	O	149
implanted	VERB	O	O	149
IP	PROPN	O	O	149
dosing	VERB	O	O	149
catheter	VERB	O	O	149
with	ADP	O	O	149
infusions	NOUN	O	O	149
in	ADP	O	O	149
each	PRON	O	O	149
group	NOUN	O	O	149
of	ADP	O	O	149
0	NUM	O	O	149
min	NOUN	O	O	149
,	PUNCT	O	O	149
15	NUM	O	O	149
min	NOUN	O	O	149
,	PUNCT	O	O	149
30	NUM	O	O	149
min	NOUN	O	O	149
,	PUNCT	O	O	149
60	NUM	O	O	149
min	NOUN	O	O	149
,	PUNCT	O	O	149
90	NUM	O	O	149
min	NOUN	O	O	149
,	PUNCT	O	O	149
120	NUM	O	O	149
min	NOUN	O	O	149
,	PUNCT	O	O	149
and	CCONJ	O	O	149
240	NUM	O	O	149
min	NOUN	O	O	149
.	PUNCT	O	O	149
The	PRON	O	O	150
number	NOUN	O	O	150
,	PUNCT	O	O	150
time	NOUN	O	O	150
of	ADP	O	O	150
onset	VERB	O	O	150
,	PUNCT	O	O	150
duration	NOUN	O	O	150
and	CCONJ	O	O	150
the	PRON	O	O	150
intensity	NOUN	O	O	150
of	ADP	O	O	150
the	PRON	O	O	150
convulsions	NOUN	O	Disease	150
or	CCONJ	O	O	150
absence	NOUN	O	O	150
of	ADP	O	O	150
convulsions	NOUN	O	Disease	150
were	AUX	O	O	150
recorded	VERB	O	O	150
.	PUNCT	O	O	150
The	PRON	O	O	151
results	VERB	O	O	151
showed	VERB	O	O	151
that	SCONJ	O	O	151
IP	PROPN	O	O	151
administration	NOUN	O	O	151
of	ADP	O	O	151
bupropion HCl	PROPN	O	Chemical	151
120	NUM	O	O	151
mg	VERB	O	O	151
/	PUNCT	O	O	151
kg	VERB	O	O	151
by	ADP	O	O	151
bolus	NOUN	O	O	151
injection	NOUN	O	O	151
induced	VERB	O	O	151
convulsions	NOUN	O	Disease	151
in	ADP	O	O	151
6	NUM	O	O	151
out	ADP	O	O	151
of	ADP	O	O	151
10	NUM	O	O	151
mice	NOUN	O	O	151
(	PUNCT	O	O	151
60%	NOUN	O	O	151
of	ADP	O	O	151
convulsing	VERB	O	O	151
mice	NOUN	O	O	151
)	PUNCT	O	O	151
in	ADP	O	O	151
group	NOUN	O	O	151
1	X	O	O	151
.	PUNCT	O	O	151
Logistic	ADJ	O	O	152
regression	NOUN	O	O	152
analysis	NOUN	O	O	152
revealed	VERB	O	O	152
that	SCONJ	O	O	152
infusion	NOUN	O	O	152
time	NOUN	O	O	152
was	AUX	O	O	152
significant	ADJ	O	O	152
(	PUNCT	O	O	152
p	NOUN	O	O	152
=	PUNCT	O	O	152
0.0004	NUM	O	O	152
;	PUNCT	O	O	152
odds	NOUN	O	O	152
ratio	NOUN	O	O	152
=	PUNCT	O	O	152
0.974	NUM	O	O	152
)	PUNCT	O	O	152
and	CCONJ	O	O	152
increasing	VERB	O	O	152
the	PRON	O	O	152
IP	PROPN	O	O	152
infusion	NOUN	O	O	152
time	NOUN	O	O	152
of	ADP	O	O	152
bupropion HCl	PROPN	O	Chemical	152
120	NUM	O	O	152
mg	VERB	O	O	152
/	PUNCT	O	O	152
kg	VERB	O	O	152
was	AUX	O	O	152
associated	VERB	O	O	152
with	ADP	O	O	152
a	PRON	O	O	152
91%	NOUN	O	O	152
reduced	VERB	O	O	152
odds	NOUN	O	O	152
of	ADP	O	O	152
convulsions	NOUN	O	Disease	152
at	ADP	O	O	152
infusion	NOUN	O	O	152
times	NOUN	O	O	152
of	ADP	O	O	152
15	NUM	O	O	152
to	PART	O	O	152
90	NUM	O	O	152
min	NOUN	O	O	152
compared	VERB	O	O	152
to	PART	O	O	152
bolus	NOUN	O	O	152
injection	NOUN	O	O	152
.	PUNCT	O	O	152
Further	ADV	O	O	153
increase	VERB	O	O	153
in	ADP	O	O	153
infusion	NOUN	O	O	153
time	NOUN	O	O	153
resulted	VERB	O	O	153
in	ADP	O	O	153
further	ADV	O	O	153
reduction	NOUN	O	O	153
in	ADP	O	O	153
the	PRON	O	O	153
odds	NOUN	O	O	153
of	ADP	O	O	153
convulsions	NOUN	O	Disease	153
to	PART	O	O	153
99.8%	NOUN	O	O	153
reduction	NOUN	O	O	153
at	ADP	O	O	153
240	NUM	O	O	153
min	NOUN	O	O	153
.	PUNCT	O	O	153
In	ADP	O	O	154
conclusion	NOUN	O	O	154
,	PUNCT	O	O	154
the	PRON	O	O	154
demonstration	NOUN	O	O	154
of	ADP	O	O	154
an	PRON	O	O	154
inverse	VERB	O	O	154
relationship	NOUN	O	O	154
between	ADP	O	O	154
infusion	NOUN	O	O	154
time	NOUN	O	O	154
of	ADP	O	O	154
a	PRON	O	O	154
fixed	VERB	O	O	154
and	CCONJ	O	O	154
convulsive	ADJ	O	Disease	154
dose	NOUN	O	O	154
of	ADP	O	O	154
bupropion	NOUN	O	Chemical	154
and	CCONJ	O	O	154
the	PRON	O	O	154
risk	NOUN	O	O	154
of	ADP	O	O	154
convulsions	NOUN	O	Disease	154
in	ADP	O	O	154
a	PRON	O	O	154
prospective	ADJ	O	O	154
study	VERB	O	O	154
is	AUX	O	O	154
novel	NOUN	O	O	154
.	PUNCT	O	O	154
Detailed	VERB	O	O	157
spectral	ADJ	O	O	157
profile	NOUN	O	O	157
analysis	NOUN	O	O	157
of	ADP	O	O	157
penicillin	NOUN	O	Chemical	157
-	PUNCT	O	O	157
induced	VERB	O	O	157
epileptiform activity	NOUN	O	Disease	157
in	ADP	O	O	157
anesthetized	VERB	O	O	157
rats	NOUN	O	O	157
.	PUNCT	O	O	157
Penicillin	NOUN	O	Chemical	158
model	NOUN	O	O	158
is	AUX	O	O	158
a	PRON	O	O	158
widely	ADV	O	O	158
used	VERB	O	O	158
experimental	ADJ	O	O	158
model	NOUN	O	O	158
for	ADP	O	O	158
epilepsy	NOUN	O	Disease	158
research	NOUN	O	O	158
.	PUNCT	O	O	158
In	ADP	O	O	159
the	PRON	O	O	159
present	NOUN	O	O	159
study	VERB	O	O	159
we	PRON	O	O	159
aimed	VERB	O	O	159
to	PART	O	O	159
portray	VERB	O	O	159
a	PRON	O	O	159
detailed	VERB	O	O	159
spectral	ADJ	O	O	159
analysis	NOUN	O	O	159
of	ADP	O	O	159
penicillin	NOUN	O	Chemical	159
-	PUNCT	O	O	159
induced	VERB	O	O	159
epileptiform activity	NOUN	O	Disease	159
in	ADP	O	O	159
comparison	NOUN	O	O	159
with	ADP	O	O	159
basal	PROPN	O	O	159
brain	NOUN	O	O	159
activity	NOUN	O	O	159
in	ADP	O	O	159
anesthetized	VERB	O	O	159
Wistar	PROPN	O	O	159
rats	NOUN	O	O	159
.	PUNCT	O	O	159
urethane	NOUN	O	Chemical	160
and	CCONJ	O	O	160
connected	VERB	O	O	160
to	PART	O	O	160
an	PRON	O	O	160
electrocorticogram	PROPN	O	O	160
setup	NOUN	O	O	160
.	PUNCT	O	O	160
After	ADP	O	O	161
a	PRON	O	O	161
short	ADJ	O	O	161
period	NOUN	O	O	161
of	ADP	O	O	161
basal	PROPN	O	O	161
activity	NOUN	O	O	161
recording	NOUN	O	O	161
,	PUNCT	O	O	161
epileptic	ADJ	O	Disease	161
focus	NOUN	O	O	161
was	AUX	O	O	161
induced	VERB	O	O	161
by	ADP	O	O	161
injecting	VERB	O	O	161
400IU/2	NUM	O	O	161
microl	NOUN	O	O	161
penicillin	NOUN	O	Chemical	161
-	PUNCT	O	O	161
G	NOUN	O	O	161
potassium	NOUN	O	Chemical	161
into	ADP	O	O	161
the	PRON	O	O	161
left	VERB	O	O	161
lateral	PROPN	O	O	161
ventricle	NOUN	O	O	161
while	SCONJ	O	O	161
the	PRON	O	O	161
cortical	ADJ	O	O	161
activity	NOUN	O	O	161
was	AUX	O	O	161
continuously	ADV	O	O	161
recorded	VERB	O	O	161
.	PUNCT	O	O	161
Basal	PROPN	O	O	162
activity	NOUN	O	O	162
,	PUNCT	O	O	162
latent	ADJ	O	O	162
period	NOUN	O	O	162
and	CCONJ	O	O	162
the	PRON	O	O	162
penicillin	NOUN	O	Chemical	162
-	PUNCT	O	O	162
induced	VERB	O	O	162
epileptiform activity	NOUN	O	Disease	162
periods	NOUN	O	O	162
were	AUX	O	O	162
then	ADV	O	O	162
analyzed	VERB	O	O	162
using	VERB	O	O	162
both	PRON	O	O	162
conventional	ADJ	O	O	162
methods	NOUN	O	O	162
and	CCONJ	O	O	162
spectral	ADJ	O	O	162
analysis	NOUN	O	O	162
.	PUNCT	O	O	162
Our	PRON	O	O	163
results	VERB	O	O	163
show	VERB	O	O	163
that	SCONJ	O	O	163
the	PRON	O	O	163
most	ADV	O	O	163
affected	VERB	O	O	163
frequency	NOUN	O	O	163
bands	NOUN	O	O	163
were	AUX	O	O	163
delta	PROPN	O	O	163
,	PUNCT	O	O	163
theta	NOUN	O	O	163
,	PUNCT	O	O	163
beta-2	NUM	O	O	163
and	CCONJ	O	O	163
gamma-2	NUM	O	O	163
bands	NOUN	O	O	163
during	ADP	O	O	163
the	PRON	O	O	163
epileptiform activity	NOUN	O	Disease	163
and	CCONJ	O	O	163
there	ADV	O	O	163
were	AUX	O	O	163
marked	VERB	O	O	163
differences	NOUN	O	O	163
in	ADP	O	O	163
terms	NOUN	O	O	163
of	ADP	O	O	163
spectral	ADJ	O	O	163
densities	NOUN	O	O	163
between	ADP	O	O	163
three	NUM	O	O	163
investigated	VERB	O	O	163
episodes	NOUN	O	O	163
(	PUNCT	O	O	163
basal	PROPN	O	O	163
activity	NOUN	O	O	163
,	PUNCT	O	O	163
latent	ADJ	O	O	163
period	NOUN	O	O	163
and	CCONJ	O	O	163
epileptiform activity	NOUN	O	Disease	163
)	PUNCT	O	O	163
.	PUNCT	O	O	163
Our	PRON	O	O	164
results	VERB	O	O	164
may	AUX	O	O	164
help	VERB	O	O	164
to	PART	O	O	164
analyze	VERB	O	O	164
novel	NOUN	O	O	164
data	NOUN	O	O	164
obtained	VERB	O	O	164
using	VERB	O	O	164
similar	ADJ	O	O	164
experimental	ADJ	O	O	164
models	NOUN	O	O	164
and	CCONJ	O	O	164
the	PRON	O	O	164
simple	ADJ	O	O	164
analysis	NOUN	O	O	164
method	NOUN	O	O	164
described	VERB	O	O	164
here	ADV	O	O	164
can	AUX	O	O	164
be	AUX	O	O	164
used	VERB	O	O	164
in	ADP	O	O	164
similar	ADJ	O	O	164
studies	NOUN	O	O	164
to	PART	O	O	164
investigate	VERB	O	O	164
the	PRON	O	O	164
basic	ADJ	O	O	164
neuronal	ADJ	O	O	164
mechanism	NOUN	O	O	164
of	ADP	O	O	164
this	PRON	O	O	164
or	CCONJ	O	O	164
other	ADJ	O	O	164
types	NOUN	O	O	164
of	ADP	O	O	164
experimental	ADJ	O	O	164
epilepsies	NOUN	O	Disease	164
.	PUNCT	O	O	164
High	ADJ	O	O	167
dose	NOUN	O	O	167
dexmedetomidine	PROPN	O	Chemical	167
as	ADP	O	O	167
the	PRON	O	O	167
sole	NOUN	O	O	167
sedative	NOUN	O	O	167
for	ADP	O	O	167
pediatric	ADJ	O	O	167
MRI	PROPN	O	O	167
.	PUNCT	O	O	167
This	PRON	O	O	168
large	ADJ	O	O	168
-	PUNCT	O	O	168
scale	NOUN	O	O	168
retrospective	ADJ	O	O	168
review	VERB	O	O	168
evaluates	VERB	O	O	168
the	PRON	O	O	168
sedation	NOUN	O	O	168
profile	NOUN	O	O	168
of	ADP	O	O	168
dexmedetomidine	PROPN	O	Chemical	168
.	PUNCT	O	O	168
AIM	VERB	O	O	169
:	PUNCT	O	O	169
To	PART	O	O	169
determine	VERB	O	O	169
the	PRON	O	O	169
hemodynamic	ADJ	O	O	169
responses	NOUN	O	O	169
,	PUNCT	O	O	169
efficacy	NOUN	O	O	169
and	CCONJ	O	O	169
adverse	ADJ	O	O	169
events	NOUN	O	O	169
associated	VERB	O	O	169
with	ADP	O	O	169
the	PRON	O	O	169
use	VERB	O	O	169
of	ADP	O	O	169
high	ADJ	O	O	169
dose	NOUN	O	O	169
dexmedetomidine	PROPN	O	Chemical	169
as	ADP	O	O	169
the	PRON	O	O	169
sole	NOUN	O	O	169
sedative	NOUN	O	O	169
for	ADP	O	O	169
magnetic	ADJ	O	O	169
resonance	NOUN	O	O	169
imaging	VERB	O	O	169
(	PUNCT	O	O	169
MRI	PROPN	O	O	169
)	PUNCT	O	O	169
studies	NOUN	O	O	169
.	PUNCT	O	O	169
Dexmedetomidine	PROPN	O	Chemical	170
has	VERB	O	O	170
been	AUX	O	O	170
used	VERB	O	O	170
at	ADP	O	O	170
our	PRON	O	O	170
institution	NOUN	O	O	170
since	SCONJ	O	O	170
2005	NUM	O	O	170
to	PART	O	O	170
provide	VERB	O	O	170
sedation	NOUN	O	O	170
for	ADP	O	O	170
pediatric	ADJ	O	O	170
radiological	ADJ	O	O	170
imaging	VERB	O	O	170
studies	NOUN	O	O	170
.	PUNCT	O	O	170
Over	ADP	O	O	171
time	NOUN	O	O	171
,	PUNCT	O	O	171
an	PRON	O	O	171
effective	ADJ	O	O	171
protocol	PROPN	O	O	171
utilizing	VERB	O	O	171
high	ADJ	O	O	171
dose	NOUN	O	O	171
dexmedetomidine	PROPN	O	Chemical	171
as	ADP	O	O	171
the	PRON	O	O	171
sole	NOUN	O	O	171
sedative	NOUN	O	O	171
agent	NOUN	O	O	171
has	VERB	O	O	171
evolved	VERB	O	O	171
.	PUNCT	O	O	171
Data	NOUN	O	O	172
were	AUX	O	O	172
analyzed	VERB	O	O	172
from	ADP	O	O	172
all	PRON	O	O	172
747	NUM	O	O	172
consecutive	ADJ	O	O	172
patients	NOUN	O	O	172
who	PRON	O	O	172
received	VERB	O	O	172
dexmedetomidine	PROPN	O	Chemical	172
for	ADP	O	O	172
MRI	PROPN	O	O	172
sedation	NOUN	O	O	172
from	ADP	O	O	172
April	PROPN	O	O	172
2005	NUM	O	O	172
to	PART	O	O	172
April	PROPN	O	O	172
2007	NUM	O	O	172
.	PUNCT	O	O	172
Since	SCONJ	O	O	173
2005	NUM	O	O	173
,	PUNCT	O	O	173
the	PRON	O	O	173
10-min	NOUN	O	O	173
loading	NOUN	O	O	173
dose	NOUN	O	O	173
of	ADP	O	O	173
our	PRON	O	O	173
dexmedetomidine	PROPN	O	Chemical	173
protocol	PROPN	O	O	173
increased	VERB	O	O	173
from	ADP	O	O	173
2	X	O	O	173
to	PART	O	O	173
3	X	O	O	173
microg.kg(-1	VERB	O	O	173
)	PUNCT	O	O	173
,	PUNCT	O	O	173
and	CCONJ	O	O	173
the	PRON	O	O	173
infusion	NOUN	O	O	173
rate	NOUN	O	O	173
increased	VERB	O	O	173
from	ADP	O	O	173
1	X	O	O	173
to	PART	O	O	173
1.5	NUM	O	O	173
to	PART	O	O	173
2	X	O	O	173
microg.kg(-1).h(-1	AUX	O	O	173
)	PUNCT	O	O	173
.	PUNCT	O	O	173
The	PRON	O	O	174
current	ADJ	O	O	174
sedation	NOUN	O	O	174
protocol	PROPN	O	O	174
progressively	ADV	O	O	174
increased	VERB	O	O	174
the	PRON	O	O	174
rate	NOUN	O	O	174
of	ADP	O	O	174
successful	ADJ	O	O	174
sedation	NOUN	O	O	174
(	PUNCT	O	O	174
able	ADJ	O	O	174
to	PART	O	O	174
complete	VERB	O	O	174
the	PRON	O	O	174
imaging	VERB	O	O	174
study	VERB	O	O	174
)	PUNCT	O	O	174
when	SCONJ	O	O	174
using	VERB	O	O	174
dexmedetomidine	PROPN	O	Chemical	174
alone	ADV	O	O	174
from	ADP	O	O	174
91.8%	NOUN	O	O	174
to	PART	O	O	174
97.6%	NOUN	O	O	174
(	PUNCT	O	O	174
P	NOUN	O	Chemical	174
=	PUNCT	O	O	174
0.009	NUM	O	O	174
)	PUNCT	O	O	174
,	PUNCT	O	O	174
reducing	VERB	O	O	174
the	PRON	O	O	174
requirement	NOUN	O	O	174
for	ADP	O	O	174
adjuvant	NOUN	O	O	174
pentobarbital	NOUN	O	Chemical	174
in	ADP	O	O	174
the	PRON	O	O	174
event	NOUN	O	O	174
of	ADP	O	O	174
sedation	NOUN	O	O	174
failure	NOUN	O	O	174
with	ADP	O	O	174
dexmedetomidine	PROPN	O	Chemical	174
alone	ADV	O	O	174
and	CCONJ	O	O	174
decreased	VERB	O	O	174
the	PRON	O	O	174
mean	VERB	O	O	174
recovery	NOUN	O	O	174
time	NOUN	O	O	174
by	ADP	O	O	174
10	NUM	O	O	174
min	NOUN	O	O	174
(	PUNCT	O	O	174
P	NOUN	O	Chemical	174
Although	SCONJ	O	O	175
dexmedetomidine	PROPN	O	Chemical	175
sedation	NOUN	O	O	175
was	AUX	O	O	175
associated	VERB	O	O	175
with	ADP	O	O	175
a	PRON	O	O	175
16%	NOUN	O	O	175
incidence	NOUN	O	O	175
of	ADP	O	O	175
bradycardia	NOUN	O	Disease	175
,	PUNCT	O	O	175
all	PRON	O	O	175
concomitant	ADJ	O	O	175
mean	VERB	O	O	175
arterial	ADJ	O	O	175
blood	NOUN	O	O	175
pressures	NOUN	O	O	175
were	AUX	O	O	175
within	ADP	O	O	175
20%	NOUN	O	O	175
of	ADP	O	O	175
age	NOUN	O	O	175
-	PUNCT	O	O	175
adjusted	VERB	O	O	175
normal	ADJ	O	O	175
range	VERB	O	O	175
and	CCONJ	O	O	175
oxygen	NOUN	O	Chemical	176
saturations	NOUN	O	O	176
were	AUX	O	O	176
95%	NOUN	O	O	176
or	CCONJ	O	O	176
higher	ADJ	O	O	176
.	PUNCT	O	O	176
CONCLUSION	PROPN	O	O	177
:	PUNCT	O	O	177
Dexmedetomidine	PROPN	O	Chemical	177
in	ADP	O	O	177
high	ADJ	O	O	177
doses	NOUN	O	O	177
provides	VERB	O	O	177
adequate	ADJ	O	O	177
sedation	NOUN	O	O	177
for	ADP	O	O	177
pediatric	ADJ	O	O	177
MRI	PROPN	O	O	177
studies	NOUN	O	O	177
.	PUNCT	O	O	177
While	SCONJ	O	O	178
use	VERB	O	O	178
of	ADP	O	O	178
high	ADJ	O	O	178
dose	NOUN	O	O	178
dexmedetomidine	PROPN	O	Chemical	178
is	AUX	O	O	178
associated	VERB	O	O	178
with	ADP	O	O	178
decreases	VERB	O	O	178
in	ADP	O	O	178
heart	NOUN	O	O	178
rate	NOUN	O	O	178
and	CCONJ	O	O	178
blood	NOUN	O	O	178
pressure	NOUN	O	O	178
outside	ADV	O	O	178
the	PRON	O	O	178
established	VERB	O	O	178
'	PUNCT	O	O	178
awake	ADJ	O	O	178
'	PUNCT	O	O	178
norms	NOUN	O	O	178
,	PUNCT	O	O	178
this	PRON	O	O	178
deviation	NOUN	O	O	178
is	AUX	O	O	178
generally	ADV	O	O	178
within	ADP	O	O	178
20%	NOUN	O	O	178
of	ADP	O	O	178
norms	NOUN	O	O	178
,	PUNCT	O	O	178
and	CCONJ	O	O	178
is	AUX	O	O	178
not	PART	O	O	178
associated	VERB	O	O	178
with	ADP	O	O	178
adverse	ADJ	O	O	178
sequelae	ADJ	O	O	178
.	PUNCT	O	O	178
Dexmedetomidine	PROPN	O	Chemical	179
is	AUX	O	O	179
useful	ADJ	O	O	179
as	ADP	O	O	179
the	PRON	O	O	179
sole	NOUN	O	O	179
sedative	NOUN	O	O	179
for	ADP	O	O	179
pediatric	ADJ	O	O	179
MRI	PROPN	O	O	179
.	PUNCT	O	O	179
Methamphetamine	NOUN	O	Chemical	182
causes	VERB	O	O	182
alterations	NOUN	O	O	182
in	ADP	O	O	182
the	PRON	O	O	182
MAP	PROPN	O	O	182
kinase	VERB	O	O	182
-	PUNCT	O	O	182
related	ADJ	O	O	182
pathways	NOUN	O	O	182
in	ADP	O	O	182
the	PRON	O	O	182
brains	NOUN	O	O	182
of	ADP	O	O	182
mice	NOUN	O	O	182
that	SCONJ	O	O	182
display	NOUN	O	O	182
increased	VERB	O	O	182
aggressiveness	NOUN	O	Disease	182
.	PUNCT	O	O	182
Aggressive behaviors	NOUN	O	Disease	183
have	VERB	O	O	183
been	AUX	O	O	183
reported	VERB	O	O	183
in	ADP	O	O	183
patients	NOUN	O	O	183
who	PRON	O	O	183
suffer	VERB	O	O	183
from	ADP	O	O	183
some	PRON	O	O	183
psychiatric disorders	NOUN	O	Disease	183
,	PUNCT	O	O	183
and	CCONJ	O	O	183
are	AUX	O	O	183
common	ADJ	O	O	183
in	ADP	O	O	183
methamphetamine	NOUN	O	Chemical	183
(	PUNCT	O	O	183
METH	NOUN	O	Chemical	183
)	PUNCT	O	O	183
abusers	NOUN	O	O	183
.	PUNCT	O	O	183
Herein	ADV	O	O	184
,	PUNCT	O	O	184
we	PRON	O	O	184
report	VERB	O	O	184
that	SCONJ	O	O	184
multiple	ADJ	O	O	184
(	PUNCT	O	O	184
but	CCONJ	O	O	184
not	PART	O	O	184
single	ADJ	O	O	184
)	PUNCT	O	O	184
injections	NOUN	O	O	184
of	ADP	O	O	184
METH	NOUN	O	Chemical	184
significantly	ADV	O	O	184
increased	VERB	O	O	184
aggressiveness	NOUN	O	Disease	184
in	ADP	O	O	184
male	NOUN	O	O	184
CD-1	NOUN	O	O	184
mice	NOUN	O	O	184
.	PUNCT	O	O	184
This	PRON	O	O	185
increase	VERB	O	O	185
in	ADP	O	O	185
aggressiveness	NOUN	O	Disease	185
was	AUX	O	O	185
not	PART	O	O	185
secondary	ADJ	O	O	185
to	PART	O	O	185
METH	NOUN	O	Chemical	185
-	PUNCT	O	O	185
induced	VERB	O	O	185
hyperactivity	NOUN	O	Disease	185
.	PUNCT	O	O	185
Analysis	NOUN	O	O	186
of	ADP	O	O	186
protein	NOUN	O	O	186
expression	NOUN	O	O	186
using	VERB	O	O	186
antibody	NOUN	O	O	186
microarrays	VERB	O	O	186
and	CCONJ	O	O	186
Western	ADJ	O	O	186
blotting	VERB	O	O	186
revealed	VERB	O	O	186
differential	ADJ	O	O	186
changes	VERB	O	O	186
in	ADP	O	O	186
MAP	PROPN	O	O	186
kinase	VERB	O	O	186
-	PUNCT	O	O	186
related	ADJ	O	O	186
pathways	NOUN	O	O	186
after	ADP	O	O	186
multiple	ADJ	O	O	186
and	CCONJ	O	O	186
single	ADJ	O	O	186
METH	NOUN	O	Chemical	186
injections	NOUN	O	O	186
.	PUNCT	O	O	186
There	ADV	O	O	187
were	AUX	O	O	187
statistically	ADV	O	O	187
significant	ADJ	O	O	187
(	PUNCT	O	O	187
p<0.05	NOUN	O	O	187
)	PUNCT	O	O	187
decreases	VERB	O	O	187
in	ADP	O	O	187
MEK1	NOUN	O	O	187
,	PUNCT	O	O	187
Erk2p	X	O	O	187
,	PUNCT	O	O	187
GSK3alpha	VERB	O	O	187
,	PUNCT	O	O	187
14	NUM	O	O	187
-	PUNCT	O	O	187
3	X	O	O	187
-	PUNCT	O	O	187
3e	NUM	O	O	187
,	PUNCT	O	O	187
and	CCONJ	O	O	187
MEK7	PROPN	O	O	187
in	ADP	O	O	187
the	PRON	O	O	187
striata	NOUN	O	O	187
of	ADP	O	O	187
mice	NOUN	O	O	187
after	ADP	O	O	187
multiple	ADJ	O	O	187
injections	NOUN	O	O	187
of	ADP	O	O	187
METH	NOUN	O	Chemical	187
.	PUNCT	O	O	187
MEK1	NOUN	O	O	188
was	AUX	O	O	188
significantly	ADV	O	O	188
decreased	VERB	O	O	188
also	ADV	O	O	188
after	ADP	O	O	188
a	PRON	O	O	188
single	ADJ	O	O	188
injection	NOUN	O	O	188
of	ADP	O	O	188
METH	NOUN	O	Chemical	188
,	PUNCT	O	O	188
but	CCONJ	O	O	188
to	PART	O	O	188
a	PRON	O	O	188
much	ADJ	O	O	188
lesser	ADJ	O	O	188
degree	PROPN	O	O	188
than	ADP	O	O	188
after	ADP	O	O	188
multiple	ADJ	O	O	188
injections	NOUN	O	O	188
of	ADP	O	O	188
METH	NOUN	O	Chemical	188
.	PUNCT	O	O	188
In	ADP	O	O	189
the	PRON	O	O	189
frontal	ADJ	O	O	189
cortex	VERB	O	O	189
,	PUNCT	O	O	189
there	ADV	O	O	189
was	AUX	O	O	189
a	PRON	O	O	189
statistically	ADV	O	O	189
significant	ADJ	O	O	189
decrease	VERB	O	O	189
in	ADP	O	O	189
GSK3alpha	VERB	O	O	189
after	ADP	O	O	189
multiple	ADJ	O	O	189
(	PUNCT	O	O	189
but	CCONJ	O	O	189
not	PART	O	O	189
single	ADJ	O	O	189
)	PUNCT	O	O	189
injections	NOUN	O	O	189
of	ADP	O	O	189
METH	NOUN	O	Chemical	189
.	PUNCT	O	O	189
These	PRON	O	O	190
findings	NOUN	O	O	190
suggest	VERB	O	O	190
that	SCONJ	O	O	190
alterations	NOUN	O	O	190
in	ADP	O	O	190
MAP	PROPN	O	O	190
kinase	VERB	O	O	190
-	PUNCT	O	O	190
related	ADJ	O	O	190
pathways	NOUN	O	O	190
in	ADP	O	O	190
the	PRON	O	O	190
prefronto	NOUN	O	O	190
-	PUNCT	O	O	190
striatal	ADJ	O	O	190
circuitries	NOUN	O	O	190
might	AUX	O	O	190
be	AUX	O	O	190
involved	VERB	O	O	190
in	ADP	O	O	190
the	PRON	O	O	190
manifestation	NOUN	O	O	190
of	ADP	O	O	190
aggressive behaviors	NOUN	O	Disease	190
in	ADP	O	O	190
mice	NOUN	O	O	190
.	PUNCT	O	O	190
Lamotrigine	NOUN	O	Chemical	193
associated	VERB	O	O	193
with	ADP	O	O	193
exacerbation	NOUN	O	O	193
or	CCONJ	O	O	193
de	VERB	O	O	193
novo	PROPN	O	O	193
myoclonus	NOUN	O	Disease	193
in	ADP	O	O	193
idiopathic generalized epilepsies	NOUN	O	Disease	193
.	PUNCT	O	O	193
Five	NUM	O	O	194
patients	NOUN	O	O	194
with	ADP	O	O	194
idiopathic generalized epilepsies	NOUN	O	Disease	194
(	PUNCT	O	O	194
IGE	PROPN	O	Disease	194
)	PUNCT	O	O	194
treated	VERB	O	O	194
with	ADP	O	O	194
lamotrigine	X	O	Chemical	194
(	PUNCT	O	O	194
LTG	PROPN	O	Chemical	194
)	PUNCT	O	O	194
experienced	ADJ	O	O	194
exacerbation	NOUN	O	O	194
or	CCONJ	O	O	194
de	VERB	O	O	194
novo	PROPN	O	O	194
appearance	NOUN	O	O	194
of	ADP	O	O	194
myoclonic jerks	NOUN	O	Disease	194
(	PUNCT	O	O	194
MJ	PROPN	O	Disease	194
)	PUNCT	O	O	194
.	PUNCT	O	O	194
In	ADP	O	O	195
three	NUM	O	O	195
patients	NOUN	O	O	195
,	PUNCT	O	O	195
LTG	PROPN	O	Chemical	195
exacerbated	VERB	O	O	195
MJ	PROPN	O	Disease	195
in	ADP	O	O	195
a	PRON	O	O	195
dose	NOUN	O	O	195
-	PUNCT	O	O	195
dependent	ADJ	O	O	195
manner	VERB	O	O	195
with	ADP	O	O	195
early	ADV	O	O	195
aggravation	NOUN	O	O	195
during	ADP	O	O	195
titration	NOUN	O	O	195
.	PUNCT	O	O	195
MJ	PROPN	O	Disease	196
disappeared	VERB	O	O	196
when	SCONJ	O	O	196
LTG	PROPN	O	Chemical	196
dose	NOUN	O	O	196
was	AUX	O	O	196
decreased	VERB	O	O	196
by	ADP	O	O	196
25	NUM	O	O	196
to	PART	O	O	196
50%	NOUN	O	O	196
.	PUNCT	O	O	196
In	ADP	O	O	197
two	NUM	O	O	197
patients	NOUN	O	O	197
,	PUNCT	O	O	197
LTG	PROPN	O	Chemical	197
exacerbated	VERB	O	O	197
MJ	PROPN	O	Disease	197
in	ADP	O	O	197
a	PRON	O	O	197
delayed	VERB	O	O	197
but	CCONJ	O	O	197
more	ADJ	O	O	197
severe	ADJ	O	O	197
manner	VERB	O	O	197
,	PUNCT	O	O	197
with	ADP	O	O	197
myoclonic status	NOUN	O	Disease	197
that	SCONJ	O	O	197
only	ADV	O	O	197
ceased	VERB	O	O	197
after	ADP	O	O	197
LTG	PROPN	O	Chemical	197
withdrawal	NOUN	O	O	197
.	PUNCT	O	O	197
rTMS	X	O	O	200
of	ADP	O	O	200
supplementary	ADJ	O	O	200
motor	NOUN	O	O	200
area	NOUN	O	O	200
modulates	VERB	O	O	200
therapy	NOUN	O	O	200
-	PUNCT	O	O	200
induced	VERB	O	O	200
dyskinesias	PROPN	O	Disease	200
in	ADP	O	O	200
Parkinson disease	NOUN	O	Disease	200
.	PUNCT	O	O	200
The	PRON	O	O	201
neural	NOUN	O	O	201
mechanisms	NOUN	O	O	201
and	CCONJ	O	O	201
circuitry	NOUN	O	O	201
involved	VERB	O	O	201
in	ADP	O	O	201
levodopa	NOUN	O	Chemical	201
-	PUNCT	O	O	201
induced	VERB	O	O	201
dyskinesia	NOUN	O	Disease	201
are	AUX	O	O	201
unclear	ADJ	O	O	201
.	PUNCT	O	O	201
Using	VERB	O	O	202
repetitive	ADJ	O	O	202
transcranial	NOUN	O	O	202
magnetic	ADJ	O	O	202
stimulation	NOUN	O	O	202
(	PUNCT	O	O	202
rTMS	X	O	O	202
)	PUNCT	O	O	202
over	ADP	O	O	202
the	PRON	O	O	202
supplementary	ADJ	O	O	202
motor	NOUN	O	O	202
area	NOUN	O	O	202
(	PUNCT	O	O	202
SMA	PROPN	O	O	202
)	PUNCT	O	O	202
in	ADP	O	O	202
a	PRON	O	O	202
group	NOUN	O	O	202
of	ADP	O	O	202
patients	NOUN	O	O	202
with	ADP	O	O	202
advanced	ADJ	O	O	202
Parkinson disease	NOUN	O	Disease	202
,	PUNCT	O	O	202
the	PRON	O	O	202
authors	NOUN	O	O	202
investigated	VERB	O	O	202
whether	SCONJ	O	O	202
modulation	NOUN	O	O	202
of	ADP	O	O	202
SMA	PROPN	O	O	202
excitability	NOUN	O	O	202
may	AUX	O	O	202
result	VERB	O	O	202
in	ADP	O	O	202
a	PRON	O	O	202
modification	NOUN	O	O	202
of	ADP	O	O	202
a	PRON	O	O	202
dyskinetic	VERB	O	Disease	202
state	NOUN	O	O	202
induced	VERB	O	O	202
by	ADP	O	O	202
continuous	ADJ	O	O	202
apomorphine	PROPN	O	Chemical	202
infusion	NOUN	O	O	202
.	PUNCT	O	O	202
rTMS	X	O	O	203
at	ADP	O	O	203
1	X	O	O	203
Hz	NOUN	O	O	203
was	AUX	O	O	203
observed	VERB	O	O	203
to	PART	O	O	203
markedly	ADV	O	O	203
reduce	VERB	O	O	203
drug	NOUN	O	O	203
-	PUNCT	O	O	203
induced	VERB	O	O	203
dyskinesias	PROPN	O	Disease	203
,	PUNCT	O	O	203
whereas	SCONJ	O	O	203
5-Hz	NOUN	O	O	203
rTMS	X	O	O	203
induced	VERB	O	O	203
a	PRON	O	O	203
slight	ADJ	O	O	203
but	CCONJ	O	O	203
not	PART	O	O	203
significant	ADJ	O	O	203
increase	VERB	O	O	203
.	PUNCT	O	O	203
Assessment	NOUN	O	O	206
of	ADP	O	O	206
the	PRON	O	O	206
onset	VERB	O	O	206
and	CCONJ	O	O	206
persistence	NOUN	O	O	206
of	ADP	O	O	206
amnesia	NOUN	O	Disease	206
during	ADP	O	O	206
procedural	ADJ	O	O	206
sedation	NOUN	O	O	206
with	ADP	O	O	206
propofol	VERB	O	Chemical	206
.	PUNCT	O	O	206
To	PART	O	O	207
assess	VERB	O	O	207
patients	NOUN	O	O	207
'	PUNCT	O	O	207
ability	NOUN	O	O	207
to	PART	O	O	207
repeat	VERB	O	O	207
and	CCONJ	O	O	207
recall	VERB	O	O	207
words	VERB	O	O	207
presented	VERB	O	O	207
to	PART	O	O	207
them	PRON	O	O	207
while	SCONJ	O	O	207
undergoing	VERB	O	O	207
procedural	ADJ	O	O	207
sedation	NOUN	O	O	207
with	ADP	O	O	207
propofol	VERB	O	Chemical	207
,	PUNCT	O	O	207
and	CCONJ	O	O	207
correlate	VERB	O	O	207
their	PRON	O	O	207
recall	VERB	O	O	207
with	ADP	O	O	207
their	PRON	O	O	207
level	VERB	O	O	207
of	ADP	O	O	207
awareness	NOUN	O	O	207
as	ADP	O	O	207
measured	VERB	O	O	207
by	ADP	O	O	207
bispectral	ADJ	O	O	207
index	NOUN	O	O	207
(	PUNCT	O	O	207
BIS	PROPN	O	O	207
)	PUNCT	O	O	207
monitoring	NOUN	O	O	207
.	PUNCT	O	O	207
This	PRON	O	O	208
was	AUX	O	O	208
a	PRON	O	O	208
prospective	ADJ	O	O	208
,	PUNCT	O	O	208
single	ADJ	O	O	208
-	PUNCT	O	O	208
intervention	NOUN	O	O	208
study	VERB	O	O	208
of	ADP	O	O	208
consenting	VERB	O	O	208
adult	NOUN	O	O	208
patients	NOUN	O	O	208
undergoing	VERB	O	O	208
procedural	ADJ	O	O	208
sedation	NOUN	O	O	208
with	ADP	O	O	208
propofol	VERB	O	Chemical	208
between	ADP	O	O	208
December	PROPN	O	O	208
28	NUM	O	O	208
,	PUNCT	O	O	208
2002	NUM	O	O	208
,	PUNCT	O	O	208
and	CCONJ	O	O	208
October	PROPN	O	O	208
31	NUM	O	O	208
,	PUNCT	O	O	208
2003	NUM	O	O	208
.	PUNCT	O	O	208
The	PRON	O	O	209
mean	VERB	O	O	209
highest	ADJ	O	O	209
BIS	PROPN	O	O	209
score	VERB	O	O	209
corresponding	VERB	O	O	209
to	PART	O	O	209
the	PRON	O	O	209
inability to repeat words	NOUN	O	Disease	209
was	AUX	O	O	209
81.5	NUM	O	O	209
(	PUNCT	O	O	209
95%	NOUN	O	O	209
CI	NOUN	O	O	209
=	PUNCT	O	O	209
78.1	NUM	O	O	209
to	PART	O	O	209
84.8	NUM	O	O	209
)	PUNCT	O	O	209
.	PUNCT	O	O	209
Furthermore	ADV	O	O	210
,	PUNCT	O	O	210
patients	NOUN	O	O	210
had	VERB	O	O	210
no	PRON	O	O	210
recall	VERB	O	O	210
of	ADP	O	O	210
words	VERB	O	O	210
repeated	VERB	O	O	210
prior	ADV	O	O	210
to	PART	O	O	210
procedural	ADJ	O	O	210
sedation	NOUN	O	O	210
in	ADP	O	O	210
BIS	PROPN	O	O	210
ranges	VERB	O	O	210
associated	VERB	O	O	210
with	ADP	O	O	210
recall	VERB	O	O	210
after	ADP	O	O	210
procedural	ADJ	O	O	210
sedation	NOUN	O	O	210
,	PUNCT	O	O	210
suggestive	ADJ	O	O	210
of	ADP	O	O	210
retrograde amnesia	NOUN	O	Disease	210
.	PUNCT	O	O	210
Assessment	NOUN	O	O	213
of	ADP	O	O	213
perinatal	ADJ	O	O	213
hepatitis B	PROPN	O	Disease	213
and	CCONJ	O	O	213
rubella	NOUN	O	Disease	213
prevention	NOUN	O	O	213
in	ADP	O	O	213
New	ADJ	O	O	213
Hampshire	PROPN	O	O	213
delivery	NOUN	O	O	213
hospitals	NOUN	O	O	213
.	PUNCT	O	O	213
OBJECTIVE	VERB	O	O	214
:	PUNCT	O	O	214
To	PART	O	O	214
evaluate	VERB	O	O	214
current	ADJ	O	O	214
performance	NOUN	O	O	214
on	ADP	O	O	214
recommended	VERB	O	O	214
perinatal	ADJ	O	O	214
hepatitis B	PROPN	O	Disease	214
and	CCONJ	O	O	214
rubella	NOUN	O	Disease	214
prevention	NOUN	O	O	214
practices	NOUN	O	O	214
in	ADP	O	O	214
New	ADJ	O	O	214
Hampshire	PROPN	O	O	214
.	PUNCT	O	O	214
Assessment	NOUN	O	O	215
was	AUX	O	O	215
done	VERB	O	O	215
on	ADP	O	O	215
the	PRON	O	O	215
following	VERB	O	O	215
:	PUNCT	O	O	215
prenatal	ADJ	O	O	215
screening	VERB	O	O	215
for	ADP	O	O	215
hepatitis B	PROPN	O	Disease	215
and	CCONJ	O	O	215
rubella	NOUN	O	Disease	215
,	PUNCT	O	O	215
administration	NOUN	O	O	215
of	ADP	O	O	215
the	PRON	O	O	215
hepatitis B	PROPN	O	Disease	215
vaccine	NOUN	O	O	215
birth	NOUN	O	O	215
dose	NOUN	O	O	215
to	PART	O	O	215
all	PRON	O	O	215
infants	NOUN	O	O	215
,	PUNCT	O	O	215
administration	NOUN	O	O	215
of	ADP	O	O	215
hepatitis B	PROPN	O	Disease	215
immune	NOUN	O	O	215
globulin	NOUN	O	O	215
to	PART	O	O	215
infants	NOUN	O	O	215
who	PRON	O	O	215
were	AUX	O	O	215
born	VERB	O	O	215
to	PART	O	O	215
hepatitis B surface antigen	NOUN	O	Chemical	215
-	PUNCT	O	O	215
positive	ADJ	O	O	215
mothers	NOUN	O	O	215
,	PUNCT	O	O	215
rubella	NOUN	O	Disease	215
immunity	NOUN	O	O	215
,	PUNCT	O	O	215
and	CCONJ	O	O	215
administration	NOUN	O	O	215
of	ADP	O	O	215
in	ADP	O	O	215
-	PUNCT	O	O	215
hospital	PROPN	O	O	215
postpartum	PROPN	O	O	215
rubella	NOUN	O	Disease	215
vaccine	NOUN	O	O	215
to	PART	O	O	215
rubella	NOUN	O	Disease	215
nonimmune	NOUN	O	O	215
women	NOUN	O	O	215
.	PUNCT	O	O	215
RESULTS	VERB	O	O	216
:	PUNCT	O	O	216
Prenatal	NOUN	O	O	216
screening	VERB	O	O	216
rates	NOUN	O	O	216
for	ADP	O	O	216
hepatitis B	PROPN	O	Disease	216
(	PUNCT	O	O	216
98.8%	NOUN	O	O	216
)	PUNCT	O	O	216
and	CCONJ	O	O	216
rubella	NOUN	O	Disease	216
(	PUNCT	O	O	216
99.4%	NOUN	O	O	216
)	PUNCT	O	O	216
were	AUX	O	O	216
high	ADJ	O	O	216
.	PUNCT	O	O	216
Hepatitis B	PROPN	O	Disease	217
vaccine	NOUN	O	O	217
birth	NOUN	O	O	217
dose	NOUN	O	O	217
was	AUX	O	O	217
administered	VERB	O	O	217
to	PART	O	O	217
76.2%	NOUN	O	O	217
of	ADP	O	O	217
all	PRON	O	O	217
infants	NOUN	O	O	217
.	PUNCT	O	O	217
All	PRON	O	O	218
infants	NOUN	O	O	218
who	PRON	O	O	218
were	AUX	O	O	218
born	VERB	O	O	218
to	PART	O	O	218
hepatitis B surface antigen	NOUN	O	Chemical	218
-	PUNCT	O	O	218
positive	ADJ	O	O	218
mothers	NOUN	O	O	218
also	ADV	O	O	218
received	VERB	O	O	218
hepatitis B	PROPN	O	Disease	218
immune	NOUN	O	O	218
globulin	NOUN	O	O	218
.	PUNCT	O	O	218
Multivariate	NOUN	O	O	219
logistic	ADJ	O	O	219
regression	NOUN	O	O	219
showed	VERB	O	O	219
that	SCONJ	O	O	219
the	PRON	O	O	219
month	NOUN	O	O	219
of	ADP	O	O	219
delivery	NOUN	O	O	219
and	CCONJ	O	O	219
infant	NOUN	O	O	219
birth	NOUN	O	O	219
weight	NOUN	O	O	219
were	AUX	O	O	219
independent	ADJ	O	O	219
predictors	NOUN	O	O	219
of	ADP	O	O	219
hepatitis B	PROPN	O	Disease	219
vaccination	NOUN	O	O	219
.	PUNCT	O	O	219
Women	NOUN	O	O	220
who	PRON	O	O	220
were	AUX	O	O	220
born	VERB	O	O	220
between	ADP	O	O	220
1971	NUM	O	O	220
and	CCONJ	O	O	220
1975	NUM	O	O	220
had	VERB	O	O	220
the	PRON	O	O	220
highest	ADJ	O	O	220
rate	NOUN	O	O	220
of	ADP	O	O	220
rubella	NOUN	O	Disease	220
nonimmunity	PROPN	O	O	220
(	PUNCT	O	O	220
9.5%	NOUN	O	O	220
)	PUNCT	O	O	220
.	PUNCT	O	O	220
In	ADP	O	O	221
-	PUNCT	O	O	221
hospital	PROPN	O	O	221
postpartum	PROPN	O	O	221
rubella	NOUN	O	Disease	221
vaccine	NOUN	O	O	221
administration	NOUN	O	O	221
was	AUX	O	O	221
documented	VERB	O	O	221
for	ADP	O	O	221
75.6%	NOUN	O	O	221
of	ADP	O	O	221
nonimmune	NOUN	O	O	221
women	NOUN	O	O	221
.	PUNCT	O	O	221
This	PRON	O	O	222
study	VERB	O	O	222
documents	NOUN	O	O	222
good	ADJ	O	O	222
compliance	NOUN	O	O	222
in	ADP	O	O	222
New	ADJ	O	O	222
Hampshire	PROPN	O	O	222
's	AUX	O	O	222
birthing	VERB	O	O	222
hospitals	NOUN	O	O	222
with	ADP	O	O	222
national	ADJ	O	O	222
guidelines	NOUN	O	O	222
for	ADP	O	O	222
perinatal	ADJ	O	O	222
hepatitis B	PROPN	O	Disease	222
and	CCONJ	O	O	222
rubella	NOUN	O	Disease	222
prevention	NOUN	O	O	222
and	CCONJ	O	O	222
highlights	VERB	O	O	222
potential	ADJ	O	O	222
areas	NOUN	O	O	222
for	ADP	O	O	222
improvement	NOUN	O	O	222
.	PUNCT	O	O	222
Doxorubicin	PROPN	O	Chemical	225
is	AUX	O	O	225
an	PRON	O	O	225
anti	ADJ	O	O	225
-	PUNCT	O	O	225
tumor	NOUN	O	Disease	225
agent	NOUN	O	O	225
that	SCONJ	O	O	225
represses	VERB	O	O	225
cardiac	ADJ	O	O	225
-	PUNCT	O	O	225
specific	ADJ	O	O	225
gene	NOUN	O	O	225
expression	NOUN	O	O	225
and	CCONJ	O	O	225
induces	VERB	O	O	225
myocardial	ADJ	O	O	225
cell	NOUN	O	O	225
apoptosis	NOUN	O	O	225
.	PUNCT	O	O	225
Doxorubicin	PROPN	O	Chemical	226
depletes	VERB	O	O	226
cardiac	ADJ	O	O	226
p300	NUM	O	O	226
,	PUNCT	O	O	226
a	PRON	O	O	226
transcriptional	ADJ	O	O	226
coactivator	NOUN	O	O	226
that	SCONJ	O	O	226
is	AUX	O	O	226
required	VERB	O	O	226
for	ADP	O	O	226
the	PRON	O	O	226
maintenance	NOUN	O	O	226
of	ADP	O	O	226
the	PRON	O	O	226
differentiated	VERB	O	O	226
phenotype	NOUN	O	O	226
of	ADP	O	O	226
cardiac	ADJ	O	O	226
myocytes	NOUN	O	O	226
.	PUNCT	O	O	226
However	ADV	O	O	227
,	PUNCT	O	O	227
the	PRON	O	O	227
role	NOUN	O	O	227
of	ADP	O	O	227
p300	NUM	O	O	227
in	ADP	O	O	227
protection	NOUN	O	O	227
against	ADP	O	O	227
doxorubicin	VERB	O	Chemical	227
-	PUNCT	O	O	227
induced	VERB	O	O	227
apoptosis	NOUN	O	O	227
is	AUX	O	O	227
unknown	ADJ	O	O	227
.	PUNCT	O	O	227
Transgenic	NOUN	O	O	228
mice	NOUN	O	O	228
overexpressing	VERB	O	O	228
p300	NUM	O	O	228
in	ADP	O	O	228
the	PRON	O	O	228
heart	NOUN	O	O	228
and	CCONJ	O	O	228
wild	ADJ	O	O	228
-	PUNCT	O	O	228
type	NOUN	O	O	228
mice	NOUN	O	O	228
were	AUX	O	O	228
subjected	VERB	O	O	228
to	PART	O	O	228
doxorubicin	VERB	O	Chemical	228
treatment	NOUN	O	O	228
.	PUNCT	O	O	228
Doxorubicin	PROPN	O	Chemical	229
induced	VERB	O	O	229
myocardial	ADJ	O	O	229
cell	NOUN	O	O	229
apoptosis	NOUN	O	O	229
in	ADP	O	O	229
wild	ADJ	O	O	229
-	PUNCT	O	O	229
type	NOUN	O	O	229
mice	NOUN	O	O	229
but	CCONJ	O	O	229
not	PART	O	O	229
in	ADP	O	O	229
transgenic	NOUN	O	O	229
mice	NOUN	O	O	229
.	PUNCT	O	O	229
These	PRON	O	O	230
findings	NOUN	O	O	230
demonstrate	VERB	O	O	230
that	SCONJ	O	O	230
overexpression	NOUN	O	O	230
of	ADP	O	O	230
p300	NUM	O	O	230
protects	VERB	O	O	230
cardiac	ADJ	O	O	230
myocytes	NOUN	O	O	230
from	ADP	O	O	230
doxorubicin	VERB	O	Chemical	230
-	PUNCT	O	O	230
induced	VERB	O	O	230
apoptosis	NOUN	O	O	230
and	CCONJ	O	O	230
reduces	VERB	O	O	230
the	PRON	O	O	230
extent	NOUN	O	O	230
of	ADP	O	O	230
acute	ADJ	O	O	230
heart failure	NOUN	O	Disease	230
in	ADP	O	O	230
adult	NOUN	O	O	230
mice	NOUN	O	O	230
in	ADP	O	O	230
vivo	VERB	O	O	230
.	PUNCT	O	O	230
Mitochondrial	NOUN	O	O	233
DNA	NOUN	O	O	233
and	CCONJ	O	O	233
its	PRON	O	O	233
respiratory	NOUN	O	O	233
chain	NOUN	O	O	233
products	NOUN	O	O	233
are	AUX	O	O	233
defective	ADJ	O	O	233
in	ADP	O	O	233
doxorubicin	VERB	O	Chemical	233
nephrosis	NOUN	O	Disease	233
.	PUNCT	O	O	233
Doxorubicin	PROPN	O	Chemical	234
induces	VERB	O	O	234
a	PRON	O	O	234
self	VERB	O	O	234
-	PUNCT	O	O	234
perpetuating	VERB	O	O	234
nephropathy	NOUN	O	Disease	234
characterized	VERB	O	O	234
by	ADP	O	O	234
early	ADV	O	O	234
glomerular	ADJ	O	O	234
and	CCONJ	O	O	234
late	ADV	O	O	234
-	PUNCT	O	O	234
onset	VERB	O	O	234
tubular lesions	NOUN	O	Disease	234
in	ADP	O	O	234
rats	NOUN	O	O	234
.	PUNCT	O	O	234
We	PRON	O	O	235
investigated	VERB	O	O	235
the	PRON	O	O	235
potential	ADJ	O	O	235
role	NOUN	O	O	235
of	ADP	O	O	235
mitochondrial injury	NOUN	O	Disease	235
in	ADP	O	O	235
the	PRON	O	O	235
onset	VERB	O	O	235
of	ADP	O	O	235
these	PRON	O	O	235
lesions	NOUN	O	O	235
.	PUNCT	O	O	235
Rats	NOUN	O	O	236
were	AUX	O	O	236
treated	VERB	O	O	236
with	ADP	O	O	236
intravenous	ADJ	O	O	236
doxorubicin	VERB	O	Chemical	236
(	PUNCT	O	O	236
1	X	O	O	236
mg	VERB	O	O	236
kg(-1	NOUN	O	O	236
)	PUNCT	O	O	236
Glomerular and tubular injury	NOUN	O	Disease	237
was	AUX	O	O	237
monitored	VERB	O	O	237
and	CCONJ	O	O	237
correlated	VERB	O	O	237
to	PART	O	O	237
the	PRON	O	O	237
activity	NOUN	O	O	237
or	CCONJ	O	O	237
expression	NOUN	O	O	237
of	ADP	O	O	237
respiratory	NOUN	O	O	237
chain	NOUN	O	O	237
components	NOUN	O	O	237
.	PUNCT	O	O	237
Finally	ADV	O	O	238
,	PUNCT	O	O	238
we	PRON	O	O	238
quantified	VERB	O	O	238
both	PRON	O	O	238
nuclear	ADJ	O	O	238
and	CCONJ	O	O	238
mitochondrial	ADJ	O	O	238
DNA	NOUN	O	O	238
(	PUNCT	O	O	238
mtDNA	PROPN	O	O	238
)	PUNCT	O	O	238
as	ADP	O	O	238
well	ADV	O	O	238
as	ADP	O	O	238
superoxide	NOUN	O	Chemical	238
production	NOUN	O	O	238
and	CCONJ	O	O	238
the	PRON	O	O	238
4834	NUM	O	O	238
base	PROPN	O	O	238
pair	ADJ	O	O	238
'	PUNCT	O	O	238
common	ADJ	O	O	238
'	PUNCT	O	O	238
mtDNA	PROPN	O	O	238
deletion	NOUN	O	O	238
.	PUNCT	O	O	238
The	PRON	O	O	239
'	PUNCT	O	O	239
long	ADV	O	O	239
-	PUNCT	O	O	239
term	NOUN	O	O	239
'	PUNCT	O	O	239
group	NOUN	O	O	239
had	VERB	O	O	239
significant	ADJ	O	O	239
glomerular	ADJ	O	O	239
and	CCONJ	O	O	239
tubular lesions	NOUN	O	Disease	239
,	PUNCT	O	O	239
depressed	ADJ	O	O	239
activities	NOUN	O	O	239
of	ADP	O	O	239
mtDNA	PROPN	O	O	239
-	PUNCT	O	O	239
encoded	VERB	O	O	239
NADH	PROPN	O	O	239
dehydrogenase	NOUN	O	O	239
and	CCONJ	O	O	239
cytochrome	ADP	O	O	239
-	PUNCT	O	O	239
c	X	O	O	239
oxidase	NOUN	O	O	239
(	PUNCT	O	O	239
COX	PROPN	O	O	239
)	PUNCT	O	O	239
and	CCONJ	O	O	239
increased	VERB	O	O	239
citrate	PROPN	O	Chemical	239
synthase	NOUN	O	O	239
activity	NOUN	O	O	239
.	PUNCT	O	O	239
In	ADP	O	O	240
'	PUNCT	O	O	240
short	ADJ	O	O	240
-	PUNCT	O	O	240
term	NOUN	O	O	240
'	PUNCT	O	O	240
rats	NOUN	O	O	240
,	PUNCT	O	O	240
there	ADV	O	O	240
were	AUX	O	O	240
fewer	ADJ	O	O	240
tubular lesions	NOUN	O	Disease	240
,	PUNCT	O	O	240
but	CCONJ	O	O	240
similar	ADJ	O	O	240
numbers	NOUN	O	O	240
of	ADP	O	O	240
glomerular lesions	NOUN	O	Disease	240
activity	NOUN	O	O	240
.	PUNCT	O	O	240
Among	ADP	O	O	241
all	PRON	O	O	241
animals	NOUN	O	O	241
,	PUNCT	O	O	241
glomerular and tubular injury	NOUN	O	Disease	241
were	AUX	O	O	241
inversely	ADV	O	O	241
correlated	VERB	O	O	241
with	ADP	O	O	241
mtDNA	PROPN	O	O	241
levels	NOUN	O	O	241
,	PUNCT	O	O	241
mtDNA	PROPN	O	O	241
-	PUNCT	O	O	241
encoded	VERB	O	O	241
respiratory	NOUN	O	O	241
chain	NOUN	O	O	241
activities	NOUN	O	O	241
and	CCONJ	O	O	241
with	ADP	O	O	241
the	PRON	O	O	241
expression	NOUN	O	O	241
of	ADP	O	O	241
the	PRON	O	O	241
mtDNA	PROPN	O	O	241
-	PUNCT	O	O	241
encoded	VERB	O	O	241
respiratory	NOUN	O	O	241
chain	NOUN	O	O	241
subunit	NOUN	O	O	241
COX	PROPN	O	O	241
-	PUNCT	O	O	241
I.	NOUN	O	O	241
Injury	NOUN	O	O	241
was	AUX	O	O	241
positively	ADV	O	O	241
correlated	VERB	O	O	241
with	ADP	O	O	241
superoxide	NOUN	O	Chemical	241
production	NOUN	O	O	241
and	CCONJ	O	O	241
the	PRON	O	O	241
activities	NOUN	O	O	241
of	ADP	O	O	241
nucleus	PROPN	O	O	241
-	PUNCT	O	O	241
encoded	VERB	O	O	241
mitochondrial	ADJ	O	O	241
or	CCONJ	O	O	241
cytoplasmic	ADJ	O	O	241
enzymes	NOUN	O	O	241
.	PUNCT	O	O	241
These	PRON	O	O	242
results	VERB	O	O	242
suggest	VERB	O	O	242
an	PRON	O	O	242
important	ADJ	O	O	242
role	NOUN	O	O	242
for	ADP	O	O	242
quantitative	ADJ	O	O	242
and	CCONJ	O	O	242
qualitative	ADJ	O	O	242
mtDNA	PROPN	O	O	242
alterations	NOUN	O	O	242
through	ADP	O	O	242
the	PRON	O	O	242
reduction	NOUN	O	O	242
of	ADP	O	O	242
mtDNA	PROPN	O	O	242
-	PUNCT	O	O	242
encoded	VERB	O	O	242
respiratory	NOUN	O	O	242
chain	NOUN	O	O	242
function	NOUN	O	O	242
and	CCONJ	O	O	242
induction	NOUN	O	O	242
of	ADP	O	O	242
superoxide	NOUN	O	Chemical	242
in	ADP	O	O	242
doxorubicin	VERB	O	Chemical	242
-	PUNCT	O	O	242
induced	VERB	O	O	242
renal lesions	NOUN	O	Disease	242
.	PUNCT	O	O	242
Amphotericin B	PROPN	O	Chemical	245
-	PUNCT	O	O	245
induced	VERB	O	O	245
seizures	NOUN	O	Disease	245
in	ADP	O	O	245
a	PRON	O	O	245
patient	NOUN	O	O	245
with	ADP	O	O	245
AIDS	PROPN	O	Disease	245
.	PUNCT	O	O	245
OBJECTIVE	VERB	O	O	246
:	PUNCT	O	O	246
To	PART	O	O	246
report	VERB	O	O	246
a	PRON	O	O	246
case	NOUN	O	O	246
of	ADP	O	O	246
multiple	ADJ	O	O	246
episodes	NOUN	O	O	246
of	ADP	O	O	246
seizure	NOUN	O	Disease	246
activity	NOUN	O	O	246
in	ADP	O	O	246
an	PRON	O	O	246
AIDS	PROPN	O	Disease	246
patent	NOUN	O	O	246
following	VERB	O	O	246
amphotericin B	NOUN	O	Chemical	246
infusion	NOUN	O	O	246
.	PUNCT	O	O	246
A	PRON	O	O	247
46-year	NOUN	O	O	247
-	PUNCT	O	O	247
old	ADJ	O	O	247
African	ADJ	O	O	247
-	PUNCT	O	O	247
American	ADJ	O	O	247
man	NOUN	O	O	247
experienced	ADJ	O	O	247
recurrent	ADJ	O	O	247
grand mal seizures	NOUN	O	Disease	247
during	ADP	O	O	247
intravenous	ADJ	O	O	247
infusion	NOUN	O	O	247
of	ADP	O	O	247
amphotericin B	NOUN	O	Chemical	247
,	PUNCT	O	O	247
then	ADV	O	O	247
petit	PROPN	O	O	247
mal	PROPN	O	O	247
seizures	NOUN	O	Disease	247
as	ADP	O	O	247
the	PRON	O	O	247
infusion	NOUN	O	O	247
was	AUX	O	O	247
stopped	VERB	O	O	247
and	CCONJ	O	O	247
the	PRON	O	O	247
drug	NOUN	O	O	247
concentrations	NOUN	O	O	247
decreased	VERB	O	O	247
with	ADP	O	O	247
time	NOUN	O	O	247
.	PUNCT	O	O	247
The	PRON	O	O	248
patients	NOUN	O	O	248
concurrent	ADJ	O	O	248
medications	NOUN	O	O	248
included	VERB	O	O	248
didanosine	VERB	O	Chemical	248
,	PUNCT	O	O	248
hydroxyzine	NOUN	O	Chemical	248
,	PUNCT	O	O	248
promethazine	NOUN	O	Chemical	248
,	PUNCT	O	O	248
hydrocortisone	NOUN	O	Chemical	248
,	PUNCT	O	O	248
and	CCONJ	O	O	248
prochlorperazine	PROPN	O	Chemical	248
.	PUNCT	O	O	248
Despite	SCONJ	O	O	249
administration	NOUN	O	O	249
of	ADP	O	O	249
phenytoin	NOUN	O	Chemical	249
and	CCONJ	O	O	249
lorazepam	PROPN	O	Chemical	249
,	PUNCT	O	O	249
the	PRON	O	O	249
seizures	NOUN	O	Disease	249
persisted	VERB	O	O	249
and	CCONJ	O	O	249
occurred	VERB	O	O	249
only	ADV	O	O	249
during	ADP	O	O	249
amphotercin B	PROPN	O	Chemical	249
administration	NOUN	O	O	249
.	PUNCT	O	O	249
DISCUSSION	NOUN	O	O	250
:	PUNCT	O	O	250
AIDS	PROPN	O	Disease	250
and	CCONJ	O	O	250
cryptococcal meningitis	NOUN	O	Disease	250
,	PUNCT	O	O	250
both	PRON	O	O	250
of	ADP	O	O	250
which	PRON	O	O	250
the	PRON	O	O	250
patient	NOUN	O	O	250
had	VERB	O	O	250
,	PUNCT	O	O	250
can	AUX	O	O	250
potentially	ADV	O	O	250
cause	VERB	O	O	250
seizures	NOUN	O	Disease	250
.	PUNCT	O	O	250
The	PRON	O	O	251
patient	NOUN	O	O	251
had	VERB	O	O	251
a	PRON	O	O	251
history	NOUN	O	O	251
of	ADP	O	O	251
alcohol abuse	NOUN	O	Disease	251
;	PUNCT	O	O	251
alcohol	NOUN	O	Chemical	251
intake	PROPN	O	O	251
as	ADP	O	O	251
well	ADV	O	O	251
as	ADP	O	O	251
withdrawal	NOUN	O	O	251
can	AUX	O	O	251
also	ADV	O	O	251
cause	VERB	O	O	251
seizures	NOUN	O	Disease	251
.	PUNCT	O	O	251
Didanosine	VERB	O	Chemical	252
also	ADV	O	O	252
has	VERB	O	O	252
a	PRON	O	O	252
potential	ADJ	O	O	252
for	ADP	O	O	252
inducing	VERB	O	O	252
seizures	NOUN	O	Disease	252
.	PUNCT	O	O	252
However	ADV	O	O	253
,	PUNCT	O	O	253
these	PRON	O	O	253
other	ADJ	O	O	253
potential	ADJ	O	O	253
causes	VERB	O	O	253
of	ADP	O	O	253
seizure	NOUN	O	Disease	253
were	AUX	O	O	253
ruled	VERB	O	O	253
out	ADP	O	O	253
.	PUNCT	O	O	253
The	PRON	O	O	254
time	NOUN	O	O	254
course	NOUN	O	O	254
of	ADP	O	O	254
events	NOUN	O	O	254
suggested	VERB	O	O	254
that	SCONJ	O	O	254
amphotericin B	NOUN	O	Chemical	254
was	AUX	O	O	254
the	PRON	O	O	254
cause	VERB	O	O	254
of	ADP	O	O	254
the	PRON	O	O	254
seizures	NOUN	O	Disease	254
in	ADP	O	O	254
this	PRON	O	O	254
AIDS	PROPN	O	Disease	254
patient	NOUN	O	O	254
.	PUNCT	O	O	254
CONCLUSIONS	NOUN	O	O	255
:	PUNCT	O	O	255
Amphotericin B	PROPN	O	Chemical	255
seems	VERB	O	O	255
to	PART	O	O	255
be	AUX	O	O	255
the	PRON	O	O	255
probable	ADJ	O	O	255
cause	VERB	O	O	255
of	ADP	O	O	255
the	PRON	O	O	255
seizures	NOUN	O	Disease	255
.	PUNCT	O	O	255
To	PART	O	O	256
date	PROPN	O	O	256
,	PUNCT	O	O	256
only	ADV	O	O	256
three	NUM	O	O	256
cases	NOUN	O	O	256
of	ADP	O	O	256
seizures	NOUN	O	Disease	256
associated	VERB	O	O	256
with	ADP	O	O	256
amphotericin B	NOUN	O	Chemical	256
have	VERB	O	O	256
been	AUX	O	O	256
reported	VERB	O	O	256
in	ADP	O	O	256
the	PRON	O	O	256
literature	NOUN	O	O	256
,	PUNCT	O	O	256
but	CCONJ	O	O	256
healthcare	PROPN	O	O	256
providers	NOUN	O	O	256
should	AUX	O	O	256
be	AUX	O	O	256
aware	ADJ	O	O	256
of	ADP	O	O	256
the	PRON	O	O	256
potential	ADJ	O	O	256
for	ADP	O	O	256
this	PRON	O	O	256
rare	ADJ	O	O	256
adverse	ADJ	O	O	256
effect	VERB	O	O	256
.	PUNCT	O	O	256
Therapeutic	ADJ	O	O	259
drug	NOUN	O	O	259
monitoring	NOUN	O	O	259
of	ADP	O	O	259
tobramycin	NOUN	O	Chemical	259
:	PUNCT	O	O	259
OBJECTIVE	VERB	O	O	260
:	PUNCT	O	O	260
To	PART	O	O	260
evaluate	VERB	O	O	260
the	PRON	O	O	260
effect	VERB	O	O	260
of	ADP	O	O	260
dosage	NOUN	O	O	260
regimen	NOUN	O	O	260
(	PUNCT	O	O	260
once	ADV	O	O	260
-	PUNCT	O	O	260
daily	ADV	O	O	260
vs.	CCONJ	O	O	260
twice	ADV	O	O	260
-	PUNCT	O	O	260
daily	ADV	O	O	260
)	PUNCT	O	O	260
of	ADP	O	O	260
tobramicyn	NOUN	O	Chemical	260
on	ADP	O	O	260
steady	ADJ	O	O	260
-	PUNCT	O	O	260
state	NOUN	O	O	260
serum	NOUN	O	O	260
concentrations	NOUN	O	O	260
and	CCONJ	O	O	260
toxicity	NOUN	O	Disease	260
.	PUNCT	O	O	260
tobramycin	NOUN	O	Chemical	261
(	PUNCT	O	O	261
4	NUM	O	O	261
mg	VERB	O	O	261
/	PUNCT	O	O	261
kg	VERB	O	O	261
/	PUNCT	O	O	261
day	NOUN	O	O	261
)	PUNCT	O	O	261
were	AUX	O	O	261
randomised	VERB	O	O	261
to	PART	O	O	261
two	NUM	O	O	261
groups	NOUN	O	O	261
.	PUNCT	O	O	261
Group	PROPN	O	O	262
OD	NOUN	O	O	262
(	PUNCT	O	O	262
n	CCONJ	O	O	262
=	PUNCT	O	O	262
22	NUM	O	O	262
)	PUNCT	O	O	262
received	VERB	O	O	262
a	PRON	O	O	262
once	ADV	O	O	262
-	PUNCT	O	O	262
daily	ADV	O	O	262
dose	NOUN	O	O	262
of	ADP	O	O	262
tobramycin	NOUN	O	Chemical	262
and	CCONJ	O	O	262
group	NOUN	O	O	262
TD	PROPN	O	O	262
(	PUNCT	O	O	262
n	CCONJ	O	O	262
=	PUNCT	O	O	262
21	NUM	O	O	262
)	PUNCT	O	O	262
received	VERB	O	O	262
the	PRON	O	O	262
same	ADJ	O	O	262
dose	NOUN	O	O	262
divided	VERB	O	O	262
into	ADP	O	O	262
two	NUM	O	O	262
doses	NOUN	O	O	262
daily	ADV	O	O	262
.	PUNCT	O	O	262
Tobramycin	PROPN	O	Chemical	263
serum	NOUN	O	O	263
concentrations	NOUN	O	O	263
(	PUNCT	O	O	263
peak	PROPN	O	O	263
and	CCONJ	O	O	263
trough	NOUN	O	O	263
)	PUNCT	O	O	263
were	AUX	O	O	263
measured	VERB	O	O	263
by	ADP	O	O	263
enzyme	NOUN	O	O	263
multiplied	VERB	O	O	263
immunoassay	PROPN	O	O	263
.	PUNCT	O	O	263
Increased	VERB	O	O	264
serum	NOUN	O	O	264
creatinine	PROPN	O	Chemical	264
was	AUX	O	O	264
observed	VERB	O	O	264
in	ADP	O	O	264
73%	NOUN	O	O	264
of	ADP	O	O	264
patients	NOUN	O	O	264
in	ADP	O	O	264
OD	NOUN	O	O	264
versus	ADP	O	O	264
57%	NOUN	O	O	264
of	ADP	O	O	264
patients	NOUN	O	O	264
in	ADP	O	O	264
TD	PROPN	O	O	264
,	PUNCT	O	O	264
without	ADP	O	O	264
evidence	NOUN	O	O	264
of	ADP	O	O	264
nephrotoxicity	NOUN	O	Disease	264
.	PUNCT	O	O	264
In	ADP	O	O	265
TD	PROPN	O	O	265
group	NOUN	O	O	265
,	PUNCT	O	O	265
three	NUM	O	O	265
patients	NOUN	O	O	265
developed	VERB	O	O	265
decreased auditory function	NOUN	O	Disease	265
,	PUNCT	O	O	265
of	ADP	O	O	265
which	PRON	O	O	265
one	NUM	O	O	265
presented	VERB	O	O	265
with	ADP	O	O	265
an	PRON	O	O	265
auditory loss	NOUN	O	Disease	265
of	ADP	O	O	265
-30	NOUN	O	O	265
dB	NOUN	O	O	265
,	PUNCT	O	O	265
whereas	SCONJ	O	O	265
in	ADP	O	O	265
the	PRON	O	O	265
OD	NOUN	O	O	265
group	NOUN	O	O	265
only	ADV	O	O	265
one	NUM	O	O	265
patient	NOUN	O	O	265
presented	VERB	O	O	265
decreased auditory function	NOUN	O	Disease	265
.	PUNCT	O	O	265
This	PRON	O	O	266
small	ADJ	O	O	266
study	VERB	O	O	266
suggests	VERB	O	O	266
that	SCONJ	O	O	266
a	PRON	O	O	266
once	ADV	O	O	266
-	PUNCT	O	O	266
daily	ADV	O	O	266
dosing	VERB	O	O	266
regimen	NOUN	O	O	266
of	ADP	O	O	266
tobramycin	NOUN	O	Chemical	266
is	AUX	O	O	266
at	ADP	O	O	266
least	ADJ	O	O	266
as	ADP	O	O	266
effective	ADJ	O	O	266
as	ADP	O	O	266
and	CCONJ	O	O	266
is	AUX	O	O	266
no	PRON	O	O	266
more	ADJ	O	O	266
and	CCONJ	O	O	266
possibly	ADV	O	O	266
less	ADV	O	O	266
toxic	ADJ	O	O	266
than	ADP	O	O	266
the	PRON	O	O	266
twice	ADV	O	O	266
-	PUNCT	O	O	266
daily	ADV	O	O	266
regimen	NOUN	O	O	266
.	PUNCT	O	O	266
Chronic	NOUN	O	O	269
effects	NOUN	O	O	269
of	ADP	O	O	269
a	PRON	O	O	269
novel	NOUN	O	O	269
synthetic	NOUN	O	O	269
anthracycline	NOUN	O	Chemical	269
derivative	ADJ	O	O	269
(	PUNCT	O	O	269
SM-5887	NUM	O	Chemical	269
)	PUNCT	O	O	269
on	ADP	O	O	269
normal	ADJ	O	O	269
heart	NOUN	O	O	269
and	CCONJ	O	O	269
doxorubicin	VERB	O	Chemical	269
-	PUNCT	O	O	269
induced	VERB	O	O	269
cardiomyopathy	ADJ	O	Disease	269
in	ADP	O	O	269
beagle	PROPN	O	O	269
dogs	NOUN	O	O	269
.	PUNCT	O	O	269
This	PRON	O	O	270
study	VERB	O	O	270
was	AUX	O	O	270
designed	VERB	O	O	270
to	PART	O	O	270
investigate	VERB	O	O	270
the	PRON	O	O	270
chronic	ADJ	O	O	270
cardiotoxic	ADJ	O	Disease	270
potential	ADJ	O	O	270
of	ADP	O	O	270
SM-5887	NUM	O	Chemical	270
and	CCONJ	O	O	270
a	PRON	O	O	270
possible	ADJ	O	O	270
deteriorating	VERB	O	O	270
effect	VERB	O	O	270
of	ADP	O	O	270
SM-5887	NUM	O	Chemical	270
on	ADP	O	O	270
low	ADJ	O	O	270
-	PUNCT	O	O	270
grade	NOUN	O	O	270
cardiotoxicity	NOUN	O	Disease	270
pre	VERB	O	O	271
-	PUNCT	O	O	271
induced	VERB	O	O	271
by	ADP	O	O	271
doxorubicin	VERB	O	Chemical	271
in	ADP	O	O	271
beagle	PROPN	O	O	271
dogs	NOUN	O	O	271
.	PUNCT	O	O	271
In	ADP	O	O	272
the	PRON	O	O	272
chronic	ADJ	O	O	272
treatment	NOUN	O	O	272
,	PUNCT	O	O	272
beagle	PROPN	O	O	272
dogs	NOUN	O	O	272
of	ADP	O	O	272
each	PRON	O	O	272
sex	NOUN	O	O	272
were	AUX	O	O	272
given	VERB	O	O	272
intravenously	ADV	O	O	272
once	ADV	O	O	272
every	PRON	O	O	272
3	X	O	O	272
weeks	NOUN	O	O	272
,	PUNCT	O	O	272
either	ADV	O	O	272
a	PRON	O	O	272
sublethal	VERB	O	O	272
dose	NOUN	O	O	272
of	ADP	O	O	272
doxorubicin	VERB	O	Chemical	272
(	PUNCT	O	O	272
1.5	NUM	O	O	272
mg	VERB	O	O	272
/	PUNCT	O	O	272
kg	VERB	O	O	272
)	PUNCT	O	O	272
or	CCONJ	O	O	272
SM-5887	NUM	O	Chemical	272
(	PUNCT	O	O	272
2.5	NUM	O	O	272
mg	VERB	O	O	272
/	PUNCT	O	O	272
kg	VERB	O	O	272
)	PUNCT	O	O	272
.	PUNCT	O	O	272
Animals	NOUN	O	O	273
which	PRON	O	O	273
received	VERB	O	O	273
over	ADP	O	O	273
six	NUM	O	O	273
courses	NOUN	O	O	273
of	ADP	O	O	273
doxorubicin	VERB	O	Chemical	273
demonstrated	VERB	O	O	273
the	PRON	O	O	273
electrocardiogram	PROPN	O	O	273
(	PUNCT	O	O	273
ECG	PROPN	O	O	273
)	PUNCT	O	O	273
changes	VERB	O	O	273
,	PUNCT	O	O	273
decrease	VERB	O	O	273
of	ADP	O	O	273
blood	NOUN	O	O	273
pressure	NOUN	O	O	273
and	CCONJ	O	O	273
high	ADJ	O	O	273
-	PUNCT	O	O	273
grade	NOUN	O	O	273
histopathological	ADJ	O	O	273
cardiomyopathy	ADJ	O	Disease	273
,	PUNCT	O	O	273
while	SCONJ	O	O	273
animals	NOUN	O	O	273
which	PRON	O	O	273
were	AUX	O	O	273
terminally	ADV	O	O	273
sacrificed	VERB	O	O	273
after	ADP	O	O	273
the	PRON	O	O	273
SM-5887	NUM	O	Chemical	273
administration	NOUN	O	O	273
did	VERB	O	O	273
not	PART	O	O	273
show	VERB	O	O	273
any	PRON	O	O	273
changes	VERB	O	O	273
in	ADP	O	O	273
ECG	PROPN	O	O	273
,	PUNCT	O	O	273
blood	NOUN	O	O	273
pressure	NOUN	O	O	273
and	CCONJ	O	O	273
histopathological	ADJ	O	O	273
examinations	NOUN	O	O	273
.	PUNCT	O	O	273
To	PART	O	O	274
examine	VERB	O	O	274
a	PRON	O	O	274
possibly	ADV	O	O	274
deteriorating	VERB	O	O	274
cardiotoxic	ADJ	O	Disease	274
effect	VERB	O	O	274
of	ADP	O	O	274
SM-5887	NUM	O	Chemical	274
,	PUNCT	O	O	274
low	ADJ	O	O	274
-	PUNCT	O	O	274
grade	NOUN	O	O	274
cardiomyopathy	ADJ	O	Disease	274
was	AUX	O	O	274
induced	VERB	O	O	274
in	ADP	O	O	274
dogs	NOUN	O	O	274
by	ADP	O	O	274
four	NUM	O	O	274
courses	NOUN	O	O	274
of	ADP	O	O	274
doxorubicin	VERB	O	Chemical	274
(	PUNCT	O	O	274
1.5	NUM	O	O	274
mg	VERB	O	O	274
/	PUNCT	O	O	274
kg	VERB	O	O	274
)	PUNCT	O	O	274
.	PUNCT	O	O	274
Nine	NUM	O	O	275
weeks	NOUN	O	O	275
after	ADP	O	O	275
pre	VERB	O	O	275
-	PUNCT	O	O	275
treatment	NOUN	O	O	275
,	PUNCT	O	O	275
dogs	NOUN	O	O	275
were	AUX	O	O	275
given	VERB	O	O	275
four	NUM	O	O	275
courses	NOUN	O	O	275
of	ADP	O	O	275
either	ADV	O	O	275
doxorubicin	VERB	O	Chemical	275
(	PUNCT	O	O	275
1.5	NUM	O	O	275
mg	VERB	O	O	275
/	PUNCT	O	O	275
kg	VERB	O	O	275
)	PUNCT	O	O	275
or	CCONJ	O	O	275
SM-5887	NUM	O	Chemical	275
(	PUNCT	O	O	275
2.5	NUM	O	O	275
mg	VERB	O	O	275
/	PUNCT	O	O	275
kg	VERB	O	O	275
)	PUNCT	O	O	275
once	ADV	O	O	275
every	PRON	O	O	275
3	X	O	O	275
weeks	NOUN	O	O	275
.	PUNCT	O	O	275
The	PRON	O	O	276
low	ADJ	O	O	276
-	PUNCT	O	O	276
grade	NOUN	O	O	276
cardiotoxic	ADJ	O	Disease	276
changes	VERB	O	O	276
were	AUX	O	O	276
enhanced	VERB	O	O	276
by	ADP	O	O	276
the	PRON	O	O	276
additional	ADJ	O	O	276
doxorubicin	VERB	O	Chemical	276
treatment	NOUN	O	O	276
.	PUNCT	O	O	276
On	ADP	O	O	277
the	PRON	O	O	277
contrary	ADV	O	O	277
,	PUNCT	O	O	277
the	PRON	O	O	277
SM-5887	NUM	O	Chemical	277
treatment	NOUN	O	O	277
did	VERB	O	O	277
not	PART	O	O	277
progress	VERB	O	O	277
the	PRON	O	O	277
grade	NOUN	O	O	277
of	ADP	O	O	277
cardiomyopathy	ADJ	O	Disease	277
.	PUNCT	O	O	277
In	ADP	O	O	278
conclusion	NOUN	O	O	278
,	PUNCT	O	O	278
SM-5887	NUM	O	Chemical	278
does	VERB	O	O	278
not	PART	O	O	278
have	VERB	O	O	278
any	PRON	O	O	278
potential	ADJ	O	O	278
of	ADP	O	O	278
chronic	ADJ	O	O	278
cardiotoxicity	NOUN	O	Disease	278
and	CCONJ	O	O	278
deteriorating	VERB	O	O	278
effect	VERB	O	O	278
on	ADP	O	O	278
doxorubicin	VERB	O	Chemical	278
-	PUNCT	O	O	278
induced	VERB	O	O	278
cardiotoxicity	NOUN	O	Disease	278
in	ADP	O	O	278
dogs	NOUN	O	O	278
.	PUNCT	O	O	278
Posteroventral	PROPN	O	O	281
medial	ADJ	O	O	281
pallidotomy	NOUN	O	O	281
in	ADP	O	O	281
advanced	ADJ	O	O	281
Parkinson	NOUN	O	O	281
's	AUX	O	O	281
disease	PROPN	O	O	281
.	PUNCT	O	O	281
medial	ADJ	O	O	282
pallidotomy	NOUN	O	O	282
sometimes	ADV	O	O	282
produces	VERB	O	O	282
striking	VERB	O	O	282
improvement	NOUN	O	O	282
in	ADP	O	O	282
patients	NOUN	O	O	282
with	ADP	O	O	282
advanced	ADJ	O	O	282
Parkinson	NOUN	O	O	282
's	AUX	O	O	282
disease	PROPN	O	O	282
,	PUNCT	O	O	282
but	CCONJ	O	O	282
the	PRON	O	O	282
studies	NOUN	O	O	282
to	PART	O	O	282
date	PROPN	O	O	282
have	VERB	O	O	282
involved	VERB	O	O	282
small	ADJ	O	O	282
numbers	NOUN	O	O	282
of	ADP	O	O	282
patients	NOUN	O	O	282
and	CCONJ	O	O	282
short	ADJ	O	O	282
-	PUNCT	O	O	282
term	NOUN	O	O	282
follow	VERB	O	O	282
-	PUNCT	O	O	282
up	ADP	O	O	282
.	PUNCT	O	O	282
METHODS	NOUN	O	O	283
:	PUNCT	O	O	283
Forty	NUM	O	O	283
patients	NOUN	O	O	283
with	ADP	O	O	283
Parkinson	NOUN	O	O	283
's	AUX	O	O	283
disease	PROPN	O	O	283
underwent	VERB	O	O	283
serial	ADJ	O	O	283
,	PUNCT	O	O	283
detailed	VERB	O	O	283
assessments	NOUN	O	O	283
both	PRON	O	O	283
after	ADP	O	O	283
drug	NOUN	O	O	283
withdrawal	NOUN	O	O	283
(	PUNCT	O	O	283
""""	PUNCT	O	O	283
off	ADP	O	O	283
""""	PUNCT	O	O	283
period	NOUN	O	O	283
)	PUNCT	O	O	283
and	CCONJ	O	O	283
while	SCONJ	O	O	283
taking	VERB	O	O	283
their	PRON	O	O	283
optimal	ADJ	O	O	283
medical	ADJ	O	O	283
regimens	NOUN	O	O	283
(	PUNCT	O	O	283
""""	PUNCT	O	O	283
on	ADP	O	O	283
""""	PUNCT	O	O	283
period	NOUN	O	O	283
)	PUNCT	O	O	283
.	PUNCT	O	O	283
The	PRON	O	O	284
percent	NOUN	O	O	284
improvements	NOUN	O	O	284
at	ADP	O	O	284
six	NUM	O	O	284
months	NOUN	O	O	284
were	AUX	O	O	284
as	ADP	O	O	284
follows	VERB	O	O	284
:	PUNCT	O	O	284
off	ADP	O	O	284
-	PUNCT	O	O	284
period	NOUN	O	O	284
score	VERB	O	O	284
for	ADP	O	O	284
overall	ADV	O	O	284
motor	NOUN	O	O	284
function	NOUN	O	O	284
,	PUNCT	O	O	284
28	NUM	O	O	284
percent	NOUN	O	O	284
(	PUNCT	O	O	284
95	NUM	O	O	284
percent	NOUN	O	O	284
confidence	NOUN	O	O	284
interval	NOUN	O	O	284
,	PUNCT	O	O	284
19	NUM	O	O	284
to	PART	O	O	284
38	NUM	O	O	284
percent	NOUN	O	O	284
)	PUNCT	O	O	284
,	PUNCT	O	O	284
with	ADP	O	O	284
most	ADV	O	O	284
of	ADP	O	O	284
the	PRON	O	O	284
improvement	NOUN	O	O	284
in	ADP	O	O	284
the	PRON	O	O	284
contralateral	ADJ	O	O	284
limbs	NOUN	O	O	284
;	PUNCT	O	O	284
off	ADP	O	O	284
-	PUNCT	O	O	284
period	NOUN	O	O	284
score	VERB	O	O	284
for	ADP	O	O	284
activities	NOUN	O	O	284
of	ADP	O	O	284
daily	ADV	O	O	284
living	VERB	O	O	284
,	PUNCT	O	O	284
29	NUM	O	O	284
percent	NOUN	O	O	284
(	PUNCT	O	O	284
95	NUM	O	O	284
percent	NOUN	O	O	284
confidence	NOUN	O	O	284
interval	NOUN	O	O	284
,	PUNCT	O	O	284
19	NUM	O	O	284
to	PART	O	O	284
39	NUM	O	O	284
percent	NOUN	O	O	284
)	PUNCT	O	O	284
;	PUNCT	O	O	284
on	ADP	O	O	284
-	PUNCT	O	O	284
period	NOUN	O	O	284
score	VERB	O	O	284
for	ADP	O	O	284
contralateral	ADJ	O	O	284
dyskinesias	PROPN	O	Disease	284
,	PUNCT	O	O	284
82	NUM	O	O	284
percent	NOUN	O	O	284
(	PUNCT	O	O	284
95	NUM	O	O	284
percent	NOUN	O	O	284
confidence	NOUN	O	O	284
interval	NOUN	O	O	284
,	PUNCT	O	O	284
72	NUM	O	O	284
to	PART	O	O	284
91	NUM	O	O	284
percent	NOUN	O	O	284
)	PUNCT	O	O	284
;	PUNCT	O	O	284
and	CCONJ	O	O	284
on	ADP	O	O	284
-	PUNCT	O	O	284
period	NOUN	O	O	284
score	VERB	O	O	284
for	ADP	O	O	284
ipsilateral	ADJ	O	O	284
dyskinesias	PROPN	O	Disease	284
,	PUNCT	O	O	284
44	NUM	O	O	284
percent	NOUN	O	O	284
(	PUNCT	O	O	284
95	NUM	O	O	284
percent	NOUN	O	O	284
confidence	NOUN	O	O	284
interval	NOUN	O	O	284
,	PUNCT	O	O	284
29	NUM	O	O	284
to	PART	O	O	284
59	NUM	O	O	284
percent	NOUN	O	O	284
)	PUNCT	O	O	284
.	PUNCT	O	O	284
The	PRON	O	O	285
improvements	NOUN	O	O	285
in	ADP	O	O	285
dyskinesias	PROPN	O	Disease	285
and	CCONJ	O	O	285
the	PRON	O	O	285
total	ADJ	O	O	285
scores	NOUN	O	O	285
for	ADP	O	O	285
off	ADP	O	O	285
-	PUNCT	O	O	285
period	NOUN	O	O	285
parkinsonism	NOUN	O	Disease	285
,	PUNCT	O	O	285
contralateral	ADJ	O	O	285
bradykinesia	NOUN	O	Disease	285
,	PUNCT	O	O	285
and	CCONJ	O	O	285
rigidity	NOUN	O	Disease	285
were	AUX	O	O	285
sustained	VERB	O	O	285
in	ADP	O	O	285
the	PRON	O	O	285
11	NUM	O	O	285
patients	NOUN	O	O	285
examined	VERB	O	O	285
at	ADP	O	O	285
two	NUM	O	O	285
years	NOUN	O	O	285
.	PUNCT	O	O	285
The	PRON	O	O	286
improvement	NOUN	O	O	286
in	ADP	O	O	286
ipsilateral	ADJ	O	O	286
dyskinesias	PROPN	O	Disease	286
was	AUX	O	O	286
lost	VERB	O	O	286
after	ADP	O	O	286
one	NUM	O	O	286
year	NOUN	O	O	286
,	PUNCT	O	O	286
and	CCONJ	O	O	286
the	PRON	O	O	286
improvements	NOUN	O	O	286
in	ADP	O	O	286
postural	ADJ	O	O	286
stability	PROPN	O	O	286
and	CCONJ	O	O	286
gait	VERB	O	O	286
lasted	VERB	O	O	286
only	ADV	O	O	286
three	NUM	O	O	286
to	PART	O	O	286
six	NUM	O	O	286
months	NOUN	O	O	286
.	PUNCT	O	O	286
In	ADP	O	O	287
late	ADV	O	O	287
-	PUNCT	O	O	287
stage	NOUN	O	O	287
Parkinson	NOUN	O	O	287
's	AUX	O	O	287
disease	PROPN	O	O	287
,	PUNCT	O	O	287
pallidotomy	NOUN	O	O	287
significantly	ADV	O	O	287
reduces	VERB	O	O	287
levodopa	NOUN	O	Chemical	287
-	PUNCT	O	O	287
induced	VERB	O	O	287
dyskinesias	PROPN	O	Disease	287
and	CCONJ	O	O	287
off	ADP	O	O	287
-	PUNCT	O	O	287
period	NOUN	O	O	287
disability	NOUN	O	O	287
.	PUNCT	O	O	287
Neuropeptide	NOUN	O	O	290
-	PUNCT	O	O	290
Y	NOUN	O	O	290
immunoreactivity	NOUN	O	O	290
in	ADP	O	O	290
the	PRON	O	O	290
pilocarpine	NOUN	O	Chemical	290
model	NOUN	O	O	290
of	ADP	O	O	290
temporal lobe epilepsy	NOUN	O	Disease	290
.	PUNCT	O	O	290
Neuropeptide	NOUN	O	O	291
-	PUNCT	O	O	291
Y	NOUN	O	O	291
(	PUNCT	O	O	291
NPY	PROPN	O	O	291
)	PUNCT	O	O	291
is	AUX	O	O	291
expressed	VERB	O	O	291
by	ADP	O	O	291
granule	NOUN	O	O	291
cells	NOUN	O	O	291
and	CCONJ	O	O	291
mossy	NOUN	O	O	291
fibres	NOUN	O	O	291
of	ADP	O	O	291
the	PRON	O	O	291
hippocampal	NOUN	O	O	291
dentate	ADJ	O	O	291
gyrus	PROPN	O	O	291
during	ADP	O	O	291
experimental	ADJ	O	O	291
temporal lobe epilepsy	NOUN	O	Disease	291
(	PUNCT	O	O	291
TLE	PROPN	O	Disease	291
)	PUNCT	O	O	291
.	PUNCT	O	O	291
This	PRON	O	O	292
expression	NOUN	O	O	292
may	AUX	O	O	292
represent	VERB	O	O	292
an	PRON	O	O	292
endogenous	ADJ	O	O	292
damping	VERB	O	O	292
mechanism	NOUN	O	O	292
since	SCONJ	O	O	292
NPY	PROPN	O	O	292
has	VERB	O	O	292
been	AUX	O	O	292
shown	VERB	O	O	292
to	PART	O	O	292
block	NOUN	O	O	292
seizure	NOUN	O	Disease	292
-	PUNCT	O	O	292
like	INTJ	O	O	292
events	NOUN	O	O	292
following	VERB	O	O	292
high	ADJ	O	O	292
-	PUNCT	O	O	292
frequency	NOUN	O	O	292
stimulation	NOUN	O	O	292
in	ADP	O	O	292
hippocampal	NOUN	O	O	292
slices	NOUN	O	O	292
.	PUNCT	O	O	292
The	PRON	O	O	293
pilocarpine	NOUN	O	Chemical	293
(	PUNCT	O	O	293
PILO	PROPN	O	Chemical	293
)	PUNCT	O	O	293
model	NOUN	O	O	293
of	ADP	O	O	293
epilepsy	NOUN	O	Disease	293
is	AUX	O	O	293
characterized	VERB	O	O	293
by	ADP	O	O	293
an	PRON	O	O	293
acute	ADJ	O	O	293
period	NOUN	O	O	293
of	ADP	O	O	293
status epilepticus	VERB	O	Disease	293
followed	VERB	O	O	293
by	ADP	O	O	293
spontaneous	ADJ	O	O	293
recurrent	ADJ	O	O	293
seizures	NOUN	O	Disease	293
and	CCONJ	O	O	293
related	ADJ	O	O	293
brain damage	NOUN	O	Disease	293
.	PUNCT	O	O	293
PILO	PROPN	O	Chemical	294
-	PUNCT	O	O	294
injected	VERB	O	O	294
animals	NOUN	O	O	294
exhibited	VERB	O	O	294
NPY	PROPN	O	O	294
immunoreactivity	NOUN	O	O	294
in	ADP	O	O	294
the	PRON	O	O	294
region	NOUN	O	O	294
of	ADP	O	O	294
the	PRON	O	O	294
mossy	NOUN	O	O	294
fibre	NOUN	O	O	294
terminals	NOUN	O	O	294
,	PUNCT	O	O	294
in	ADP	O	O	294
the	PRON	O	O	294
dentate	ADJ	O	O	294
gyrus	PROPN	O	O	294
inner	ADJ	O	O	294
molecular	ADJ	O	O	294
layer	NOUN	O	O	294
and	CCONJ	O	O	294
,	PUNCT	O	O	294
in	ADP	O	O	294
a	PRON	O	O	294
few	ADJ	O	O	294
cases	NOUN	O	O	294
,	PUNCT	O	O	294
within	ADP	O	O	294
presumed	VERB	O	O	294
granule	NOUN	O	O	294
cells	NOUN	O	O	294
.	PUNCT	O	O	294
In	ADP	O	O	295
addition	NOUN	O	O	295
,	PUNCT	O	O	295
PILO	PROPN	O	Chemical	295
injected	VERB	O	O	295
animals	NOUN	O	O	295
exhibited	VERB	O	O	295
a	PRON	O	O	295
reduction	NOUN	O	O	295
in	ADP	O	O	295
the	PRON	O	O	295
number	NOUN	O	O	295
of	ADP	O	O	295
NPY	PROPN	O	O	295
-	PUNCT	O	O	295
immunoreactive	ADP	O	O	295
interneurons	NOUN	O	O	295
compared	VERB	O	O	295
with	ADP	O	O	295
controls	VERB	O	O	295
.	PUNCT	O	O	295
The	PRON	O	O	296
results	VERB	O	O	296
demonstrate	VERB	O	O	296
that	SCONJ	O	O	296
changes	VERB	O	O	296
in	ADP	O	O	296
NPY	PROPN	O	O	296
expression	NOUN	O	O	296
,	PUNCT	O	O	296
including	VERB	O	O	296
expression	NOUN	O	O	296
in	ADP	O	O	296
the	PRON	O	O	296
granule	NOUN	O	O	296
cells	NOUN	O	O	296
and	CCONJ	O	O	296
mossy	NOUN	O	O	296
fibres	NOUN	O	O	296
and	CCONJ	O	O	296
the	PRON	O	O	296
loss	NOUN	O	O	296
of	ADP	O	O	296
vulnerable	ADJ	O	O	296
NPY	PROPN	O	O	296
neurons	NOUN	O	O	296
,	PUNCT	O	O	296
are	AUX	O	O	296
present	NOUN	O	O	296
in	ADP	O	O	296
the	PRON	O	O	296
PILO	PROPN	O	Chemical	296
model	NOUN	O	O	296
of	ADP	O	O	296
TLE	PROPN	O	Disease	296
.	PUNCT	O	O	296
During	ADP	O	O	299
the	PRON	O	O	299
follow	VERB	O	O	299
-	PUNCT	O	O	299
up	ADP	O	O	299
,	PUNCT	O	O	299
3	X	O	O	299
patients	NOUN	O	O	299
(	PUNCT	O	O	299
12%	NOUN	O	O	299
)	PUNCT	O	O	299
developed	VERB	O	O	299
steroid	NOUN	O	Chemical	299
-	PUNCT	O	O	299
induced	VERB	O	O	299
elevated intraocular pressure	NOUN	O	Disease	299
(	PUNCT	O	O	299
IOP	PROPN	O	O	299
)	PUNCT	O	O	299
that	SCONJ	O	O	299
resolved	VERB	O	O	299
after	ADP	O	O	299
corticosteroid	NOUN	O	Chemical	299
therapy	NOUN	O	O	299
was	AUX	O	O	299
discontinued	VERB	O	O	299
.	PUNCT	O	O	299
The	PRON	O	O	300
transient	ADJ	O	O	300
steroid	NOUN	O	Chemical	300
-	PUNCT	O	O	300
induced	VERB	O	O	300
IOP rise	VERB	O	Disease	300
did	VERB	O	O	300
not	PART	O	O	300
seem	VERB	O	O	300
to	PART	O	O	300
cause	VERB	O	O	300
functional	ADJ	O	O	300
impairment	NOUN	O	O	300
.	PUNCT	O	O	300
Liposomal	PROPN	O	O	303
daunorubicin	VERB	O	Chemical	303
in	ADP	O	O	303
advanced	ADJ	O	O	303
Kaposi	PROPN	O	O	303
's	AUX	O	O	303
sarcoma	NOUN	O	Disease	303
:	PUNCT	O	O	303
a	PRON	O	O	303
phase	NOUN	O	O	303
II	NUM	O	O	303
study	VERB	O	O	303
.	PUNCT	O	O	303
We	PRON	O	O	304
report	VERB	O	O	304
a	PRON	O	O	304
non	ADJ	O	O	304
-	PUNCT	O	O	304
randomized	VERB	O	O	304
Phase	NOUN	O	O	304
II	NUM	O	O	304
clinical	ADJ	O	O	304
trial	NOUN	O	O	304
to	PART	O	O	304
assess	VERB	O	O	304
the	PRON	O	O	304
efficacy	NOUN	O	O	304
and	CCONJ	O	O	304
safety	NOUN	O	O	304
of	ADP	O	O	304
liposomal	NOUN	O	O	304
daunorubicin	VERB	O	Chemical	304
(	PUNCT	O	O	304
DaunoXome	PROPN	O	O	304
)	PUNCT	O	O	304
in	ADP	O	O	304
the	PRON	O	O	304
treatment	NOUN	O	O	304
of	ADP	O	O	304
AIDS	PROPN	O	Disease	304
related	ADJ	O	O	304
Kaposi	PROPN	O	O	304
's	AUX	O	O	304
sarcoma	NOUN	O	Disease	304
.	PUNCT	O	O	304
Eleven	NUM	O	O	305
homosexual	ADJ	O	O	305
men	NOUN	O	O	305
with	ADP	O	O	305
advanced	ADJ	O	O	305
Kaposi	PROPN	O	O	305
's	AUX	O	O	305
sarcoma	NOUN	O	Disease	305
were	AUX	O	O	305
entered	VERB	O	O	305
in	ADP	O	O	305
the	PRON	O	O	305
trial	NOUN	O	O	305
.	PUNCT	O	O	305
Changes	NOUN	O	O	306
in	ADP	O	O	306
size	NOUN	O	O	306
,	PUNCT	O	O	306
colour	NOUN	O	O	306
and	CCONJ	O	O	306
associated	VERB	O	O	306
oedema	NOUN	O	Disease	306
of	ADP	O	O	306
selected	VERB	O	O	306
'	PUNCT	O	O	306
target	NOUN	O	O	306
'	PUNCT	O	O	306
lesions	NOUN	O	O	306
were	AUX	O	O	306
measured	VERB	O	O	306
.	PUNCT	O	O	306
Clinical	NOUN	O	O	307
,	PUNCT	O	O	307
biochemical	ADJ	O	O	307
and	CCONJ	O	O	307
haematological toxicities	NOUN	O	Disease	307
were	AUX	O	O	307
assessed	VERB	O	O	307
.	PUNCT	O	O	307
Stabilization	NOUN	O	O	308
of	ADP	O	O	308
Kaposi	PROPN	O	O	308
's	AUX	O	O	308
sarcoma	NOUN	O	Disease	308
occurred	VERB	O	O	308
in	ADP	O	O	308
the	PRON	O	O	308
remaining	VERB	O	O	308
six	NUM	O	O	308
,	PUNCT	O	O	308
maintained	VERB	O	O	308
until	ADP	O	O	308
the	PRON	O	O	308
end	VERB	O	O	308
of	ADP	O	O	308
the	PRON	O	O	308
trial	NOUN	O	O	308
period	NOUN	O	O	308
in	ADP	O	O	308
four	NUM	O	O	308
.	PUNCT	O	O	308
The	PRON	O	O	309
drug	NOUN	O	O	309
was	AUX	O	O	309
generally	ADV	O	O	309
well	ADV	O	O	309
tolerated	VERB	O	O	309
,	PUNCT	O	O	309
with	ADP	O	O	309
few	ADJ	O	O	309
mild	ADJ	O	O	309
symptoms	NOUN	O	O	309
of	ADP	O	O	309
toxicity	NOUN	O	Disease	309
.	PUNCT	O	O	309
The	PRON	O	O	310
main	ADJ	O	O	310
problem	NOUN	O	O	310
encountered	VERB	O	O	310
was	AUX	O	O	310
haematological	NOUN	O	O	310
toxicity	NOUN	O	Disease	310
,	PUNCT	O	O	310
with	ADP	O	O	310
three	NUM	O	O	310
subjects	NOUN	O	O	310
experiencing	VERB	O	O	310
severe	ADJ	O	O	310
neutropenia	ADJ	O	Disease	310
(	PUNCT	O	O	310
neutrophil	ADJ	O	O	310
count	VERB	O	O	310
<	X	O	O	310
0.5	NUM	O	O	310
x	X	O	O	310
10(9)/l	NUM	O	O	310
)	PUNCT	O	O	310
.	PUNCT	O	O	310
There	ADV	O	O	311
was	AUX	O	O	311
no	PRON	O	O	311
evidence	NOUN	O	O	311
of	ADP	O	O	311
cardiotoxicity	NOUN	O	Disease	311
.	PUNCT	O	O	311
In	ADP	O	O	312
this	PRON	O	O	312
small	ADJ	O	O	312
patient	NOUN	O	O	312
sample	NOUN	O	O	312
,	PUNCT	O	O	312
liposomal	NOUN	O	O	312
daunorubicin	VERB	O	Chemical	312
was	AUX	O	O	312
an	PRON	O	O	312
effective	ADJ	O	O	312
and	CCONJ	O	O	312
well	ADV	O	O	312
tolerated	VERB	O	O	312
agent	NOUN	O	O	312
in	ADP	O	O	312
the	PRON	O	O	312
treatment	NOUN	O	O	312
of	ADP	O	O	312
Kaposi	PROPN	O	O	312
's	AUX	O	O	312
sarcoma	NOUN	O	Disease	312
.	PUNCT	O	O	312
Failure	NOUN	O	O	315
of	ADP	O	O	315
ancrod	VERB	O	O	315
in	ADP	O	O	315
the	PRON	O	O	315
treatment	NOUN	O	O	315
of	ADP	O	O	315
heparin	NOUN	O	Chemical	315
-	PUNCT	O	O	315
induced	VERB	O	O	315
arterial	ADJ	O	O	315
thrombosis	NOUN	O	Disease	315
.	PUNCT	O	O	315
The	PRON	O	O	316
morbidity	NOUN	O	O	316
and	CCONJ	O	O	316
mortality	NOUN	O	O	316
associated	VERB	O	O	316
with	ADP	O	O	316
heparin	NOUN	O	Chemical	316
-	PUNCT	O	O	316
induced	VERB	O	O	316
thrombosis	NOUN	O	Disease	316
remain	VERB	O	O	316
high	ADJ	O	O	316
despite	SCONJ	O	O	316
numerous	ADJ	O	O	316
empirical	ADJ	O	O	316
therapies	NOUN	O	O	316
.	PUNCT	O	O	316
Ancrod	PROPN	O	O	317
has	VERB	O	O	317
been	AUX	O	O	317
used	VERB	O	O	317
successfully	ADV	O	O	317
for	ADP	O	O	317
prophylaxis	NOUN	O	O	317
against	ADP	O	O	317
development	NOUN	O	O	317
of	ADP	O	O	317
thrombosis	NOUN	O	Disease	317
in	ADP	O	O	317
patients	NOUN	O	O	317
with	ADP	O	O	317
heparin	NOUN	O	Chemical	317
induced	VERB	O	O	317
platelet aggregation	NOUN	O	Disease	317
who	PRON	O	O	317
require	VERB	O	O	317
brief	PROPN	O	O	317
reexposure	NOUN	O	O	317
to	PART	O	O	317
heparin	NOUN	O	Chemical	317
,	PUNCT	O	O	317
but	CCONJ	O	O	317
its	PRON	O	O	317
success	NOUN	O	O	317
in	ADP	O	O	317
patients	NOUN	O	O	317
who	PRON	O	O	317
have	VERB	O	O	317
developed	VERB	O	O	317
the	PRON	O	O	317
thrombosis	NOUN	O	Disease	317
syndrome	NOUN	O	O	317
is	AUX	O	O	317
not	PART	O	O	317
well	ADV	O	O	317
defined	VERB	O	O	317
.	PUNCT	O	O	317
The	PRON	O	O	318
authors	NOUN	O	O	318
present	NOUN	O	O	318
a	PRON	O	O	318
case	NOUN	O	O	318
of	ADP	O	O	318
failure	NOUN	O	O	318
of	ADP	O	O	318
ancrod	VERB	O	O	318
treatment	NOUN	O	O	318
in	ADP	O	O	318
a	PRON	O	O	318
patient	NOUN	O	O	318
with	ADP	O	O	318
heparin	NOUN	O	Chemical	318
-	PUNCT	O	O	318
induced	VERB	O	O	318
thrombosis	NOUN	O	Disease	318
.	PUNCT	O	O	318
Seizure	NOUN	O	Disease	321
after	ADP	O	O	321
flumazenil	NOUN	O	Chemical	321
administration	NOUN	O	O	321
in	ADP	O	O	321
a	PRON	O	O	321
pediatric	ADJ	O	O	321
patient	NOUN	O	O	321
.	PUNCT	O	O	321
Flumazenil	PROPN	O	Chemical	322
is	AUX	O	O	322
a	PRON	O	O	322
benzodiazepine	PROPN	O	Chemical	322
receptor	NOUN	O	O	322
antagonist	NOUN	O	O	322
used	VERB	O	O	322
to	PART	O	O	322
reverse	VERB	O	O	322
sedation	NOUN	O	O	322
and	CCONJ	O	O	322
respiratory depression	NOUN	O	Disease	322
induced	VERB	O	O	322
by	ADP	O	O	322
benzodiazepines	NOUN	O	Chemical	322
.	PUNCT	O	O	322
Seizures	NOUN	O	Disease	323
and	CCONJ	O	O	323
cardiac arrhythmias	VERB	O	Disease	323
have	VERB	O	O	323
complicated	VERB	O	O	323
its	PRON	O	O	323
use	VERB	O	O	323
in	ADP	O	O	323
adult	NOUN	O	O	323
patients	NOUN	O	O	323
.	PUNCT	O	O	323
Overdose	NOUN	O	Disease	324
patients	NOUN	O	O	324
who	PRON	O	O	324
have	VERB	O	O	324
coingested	VERB	O	O	324
tricyclic	ADJ	O	O	324
antidepressants	NOUN	O	O	324
have	VERB	O	O	324
a	PRON	O	O	324
higher	ADJ	O	O	324
risk	NOUN	O	O	324
of	ADP	O	O	324
these	PRON	O	O	324
complications	NOUN	O	O	324
.	PUNCT	O	O	324
Little	ADJ	O	O	325
information	NOUN	O	O	325
exists	VERB	O	O	325
concerning	VERB	O	O	325
adverse	ADJ	O	O	325
effects	NOUN	O	O	325
of	ADP	O	O	325
flumazenil	NOUN	O	Chemical	325
in	ADP	O	O	325
children	NOUN	O	O	325
.	PUNCT	O	O	325
We	PRON	O	O	326
report	VERB	O	O	326
the	PRON	O	O	326
occurrence	NOUN	O	O	326
of	ADP	O	O	326
a	PRON	O	O	326
generalized	VERB	O	O	326
tonic	PROPN	O	O	326
-	PUNCT	O	O	326
clonic	ADJ	O	O	326
seizure	NOUN	O	Disease	326
in	ADP	O	O	326
a	PRON	O	O	326
pediatric	ADJ	O	O	326
patient	NOUN	O	O	326
following	VERB	O	O	326
the	PRON	O	O	326
administration	NOUN	O	O	326
of	ADP	O	O	326
flumazenil	NOUN	O	Chemical	326
.	PUNCT	O	O	326
Remodelling	VERB	O	O	329
of	ADP	O	O	329
nerve	NOUN	O	O	329
structure	NOUN	O	O	329
in	ADP	O	O	329
experimental	ADJ	O	O	329
isoniazid	NOUN	O	Chemical	329
neuropathy	NOUN	O	Disease	329
in	ADP	O	O	329
the	PRON	O	O	329
rat	NOUN	O	O	329
.	PUNCT	O	O	329
The	PRON	O	O	330
neuropathy	NOUN	O	Disease	330
caused	VERB	O	O	330
by	ADP	O	O	330
a	PRON	O	O	330
single	ADJ	O	O	330
dose	NOUN	O	O	330
of	ADP	O	O	330
isoniazid	NOUN	O	Chemical	330
in	ADP	O	O	330
rats	NOUN	O	O	330
was	AUX	O	O	330
studied	VERB	O	O	330
with	ADP	O	O	330
a	PRON	O	O	330
computer	NOUN	O	O	330
-	PUNCT	O	O	330
assisted	VERB	O	O	330
morphometric	PROPN	O	O	330
method	NOUN	O	O	330
.	PUNCT	O	O	330
Selective	PROPN	O	O	333
injection	NOUN	O	O	333
of	ADP	O	O	333
iopentol	VERB	O	Chemical	333
,	PUNCT	O	O	333
iohexol	NOUN	O	Chemical	333
and	CCONJ	O	O	333
metrizoate	PROPN	O	Chemical	333
into	ADP	O	O	333
the	PRON	O	O	333
left	VERB	O	O	333
coronary	ADJ	O	O	333
artery	NOUN	O	O	333
of	ADP	O	O	333
the	PRON	O	O	333
dog	NOUN	O	O	333
.	PUNCT	O	O	333
Induction	NOUN	O	O	334
of	ADP	O	O	334
ventricular fibrillation	NOUN	O	Disease	334
and	CCONJ	O	O	334
decrease	VERB	O	O	334
of	ADP	O	O	334
aortic	ADJ	O	O	334
pressure	NOUN	O	O	334
.	PUNCT	O	O	334
In	ADP	O	O	335
twenty	NUM	O	O	335
beagle	PROPN	O	O	335
dogs	NOUN	O	O	335
selective	ADJ	O	O	335
injections	NOUN	O	O	335
were	AUX	O	O	335
made	VERB	O	O	335
into	ADP	O	O	335
the	PRON	O	O	335
left	VERB	O	O	335
coronary	ADJ	O	O	335
artery	NOUN	O	O	335
with	ADP	O	O	335
iopentol	VERB	O	Chemical	335
,	PUNCT	O	O	335
iohexol	NOUN	O	Chemical	335
and	CCONJ	O	O	335
metrizoate	PROPN	O	Chemical	335
in	ADP	O	O	335
doses	NOUN	O	O	335
of	ADP	O	O	335
4	NUM	O	O	335
ml	ADP	O	O	335
,	PUNCT	O	O	335
8	NUM	O	O	335
ml	ADP	O	O	335
and	CCONJ	O	O	335
16	NUM	O	O	335
ml	ADP	O	O	335
.	PUNCT	O	O	335
Thirty	NUM	O	O	336
-	PUNCT	O	O	336
six	NUM	O	O	336
iopentol	VERB	O	Chemical	336
injections	NOUN	O	O	336
,	PUNCT	O	O	336
35	NUM	O	O	336
iohexol	NOUN	O	Chemical	336
injections	NOUN	O	O	336
and	CCONJ	O	O	336
37	NUM	O	O	336
metrizoate	PROPN	O	Chemical	336
injections	NOUN	O	O	336
were	AUX	O	O	336
made	VERB	O	O	336
.	PUNCT	O	O	336
Frequencies	NOUN	O	O	337
of	ADP	O	O	337
ventricular fibrillation	NOUN	O	Disease	337
were	AUX	O	O	337
significantly	ADV	O	O	337
lower	ADJ	O	O	337
(	PUNCT	O	O	337
p	NOUN	O	O	337
less	ADV	O	O	337
than	ADP	O	O	337
0.05	NUM	O	O	337
)	PUNCT	O	O	337
after	ADP	O	O	337
iopentol	VERB	O	Chemical	337
(	PUNCT	O	O	337
0%	NOUN	O	O	337
)	PUNCT	O	O	337
and	CCONJ	O	O	337
iohexol	NOUN	O	Chemical	337
(	PUNCT	O	O	337
3%	NOUN	O	O	337
)	PUNCT	O	O	337
than	ADP	O	O	337
after	ADP	O	O	337
metrizoate	PROPN	O	Chemical	337
(	PUNCT	O	O	337
22%	NOUN	O	O	337
)	PUNCT	O	O	337
.	PUNCT	O	O	337
Iopentol	PROPN	O	Chemical	338
and	CCONJ	O	O	338
iohexol	NOUN	O	Chemical	338
also	ADV	O	O	338
produced	VERB	O	O	338
significantly	ADV	O	O	338
less	ADV	O	O	338
decrease	VERB	O	O	338
in	ADP	O	O	338
aortic	ADJ	O	O	338
blood	NOUN	O	O	338
pressure	NOUN	O	O	338
than	ADP	O	O	338
metrizoate	PROPN	O	Chemical	338
at	ADP	O	O	338
the	PRON	O	O	338
different	ADJ	O	O	338
doses	NOUN	O	O	338
.	PUNCT	O	O	338
Magnetic	ADJ	O	O	341
resonance	NOUN	O	O	341
imaging	VERB	O	O	341
of	ADP	O	O	341
cerebral	ADJ	O	O	341
venous thrombosis	NOUN	O	Disease	341
secondary	ADJ	O	O	341
to	PART	O	O	341
""""	PUNCT	O	O	341
low	ADJ	O	O	341
-	PUNCT	O	O	341
dose	NOUN	O	O	341
""""	PUNCT	O	O	341
birth	NOUN	O	O	341
control	VERB	O	O	341
pills	NOUN	O	O	341
.	PUNCT	O	O	341
The	PRON	O	O	342
clinical	ADJ	O	O	342
and	CCONJ	O	O	342
radiographic	ADJ	O	O	342
features	VERB	O	O	342
of	ADP	O	O	342
cerebral	ADJ	O	O	342
deep	ADJ	O	O	342
venous thrombosis	NOUN	O	Disease	342
in	ADP	O	O	342
a	PRON	O	O	342
21-year	NOUN	O	O	342
-	PUNCT	O	O	342
old	ADJ	O	O	342
white	ADJ	O	O	342
woman	NOUN	O	O	342
are	AUX	O	O	342
presented	VERB	O	O	342
.	PUNCT	O	O	342
The	PRON	O	O	343
only	ADV	O	O	343
known	VERB	O	O	343
risk	NOUN	O	O	343
factor	NOUN	O	O	343
was	AUX	O	O	343
""""	PUNCT	O	O	343
low	ADJ	O	O	343
-	PUNCT	O	O	343
dose	NOUN	O	O	343
""""	PUNCT	O	O	343
oral contraceptive	NOUN	O	Chemical	343
pills	NOUN	O	O	343
.	PUNCT	O	O	343
Relation	NOUN	O	O	346
of	ADP	O	O	346
perfusion	NOUN	O	O	346
defects	NOUN	O	O	346
observed	VERB	O	O	346
with	ADP	O	O	346
myocardial	ADJ	O	O	346
contrast	NOUN	O	O	346
echocardiography	NOUN	O	O	346
to	PART	O	O	346
the	PRON	O	O	346
severity	NOUN	O	O	346
of	ADP	O	O	346
coronary stenosis	NOUN	O	Disease	346
:	PUNCT	O	O	346
correlation	NOUN	O	O	346
with	ADP	O	O	346
thallium-201	ADJ	O	O	346
single	ADJ	O	O	346
-	PUNCT	O	O	346
photon	NOUN	O	O	346
emission	NOUN	O	O	346
tomography	NOUN	O	O	346
.	PUNCT	O	O	346
It	PRON	O	O	347
has	VERB	O	O	347
been	AUX	O	O	347
previously	ADV	O	O	347
shown	VERB	O	O	347
that	SCONJ	O	O	347
myocardial	ADJ	O	O	347
contrast	NOUN	O	O	347
echocardiography	NOUN	O	O	347
is	AUX	O	O	347
a	PRON	O	O	347
valuable	ADJ	O	O	347
technique	NOUN	O	O	347
for	ADP	O	O	347
delineating	VERB	O	O	347
regions	NOUN	O	O	347
of	ADP	O	O	347
myocardial	ADJ	O	O	347
underperfusion	NOUN	O	O	347
secondary	ADJ	O	O	347
to	PART	O	O	347
coronary occlusion	NOUN	O	Disease	347
and	CCONJ	O	O	347
to	PART	O	O	347
critical	ADJ	O	O	347
coronary stenoses	NOUN	O	Disease	347
in	ADP	O	O	347
the	PRON	O	O	347
presence	NOUN	O	O	347
of	ADP	O	O	347
hyperemic	ADJ	O	Disease	347
stimulation	NOUN	O	O	347
.	PUNCT	O	O	347
The	PRON	O	O	348
aim	VERB	O	O	348
of	ADP	O	O	348
this	PRON	O	O	348
study	VERB	O	O	348
was	AUX	O	O	348
to	PART	O	O	348
determine	VERB	O	O	348
whether	SCONJ	O	O	348
myocardial	ADJ	O	O	348
contrast	NOUN	O	O	348
echocardiography	NOUN	O	O	348
performed	VERB	O	O	348
with	ADP	O	O	348
a	PRON	O	O	348
stable	ADJ	O	O	348
solution	NOUN	O	O	348
of	ADP	O	O	348
sonicated	VERB	O	O	348
albumin	PROPN	O	O	348
could	AUX	O	O	348
detect	VERB	O	O	348
regions	NOUN	O	O	348
of	ADP	O	O	348
myocardial	ADJ	O	O	348
underperfusion	NOUN	O	O	348
resulting	VERB	O	O	348
from	ADP	O	O	348
various	ADJ	O	O	348
degrees	NOUN	O	O	348
of	ADP	O	O	348
coronary stenosis	NOUN	O	Disease	348
.	PUNCT	O	O	348
The	PRON	O	O	349
perfusion	NOUN	O	O	349
defect	NOUN	O	O	349
produced	VERB	O	O	349
in	ADP	O	O	349
16	NUM	O	O	349
open	VERB	O	O	349
chest	NOUN	O	O	349
dogs	NOUN	O	O	349
was	AUX	O	O	349
compared	VERB	O	O	349
with	ADP	O	O	349
the	PRON	O	O	349
anatomic	ADJ	O	O	349
area	NOUN	O	O	349
at	ADP	O	O	349
risk	NOUN	O	O	349
measured	VERB	O	O	349
by	ADP	O	O	349
the	PRON	O	O	349
postmortem	PROPN	O	O	349
dual	ADJ	O	O	349
-	PUNCT	O	O	349
perfusion	NOUN	O	O	349
technique	NOUN	O	O	349
and	CCONJ	O	O	349
with	ADP	O	O	349
thallium-201	ADJ	O	O	349
single	ADJ	O	O	349
-	PUNCT	O	O	349
photon	NOUN	O	O	349
emission	NOUN	O	O	349
tomography	NOUN	O	O	349
(	PUNCT	O	O	349
SPECT	PROPN	O	O	349
)	PUNCT	O	O	349
.	PUNCT	O	O	349
During	ADP	O	O	350
a	PRON	O	O	350
transient	ADJ	O	O	350
(	PUNCT	O	O	350
20-s	NOUN	O	O	350
)	PUNCT	O	O	350
coronary occlusion	NOUN	O	Disease	350
,	PUNCT	O	O	350
a	PRON	O	O	350
perfusion	NOUN	O	O	350
defect	NOUN	O	O	350
was	AUX	O	O	350
observed	VERB	O	O	350
with	ADP	O	O	350
contrast	NOUN	O	O	350
echocardiography	NOUN	O	O	350
in	ADP	O	O	350
14	NUM	O	O	350
of	ADP	O	O	350
the	PRON	O	O	350
15	NUM	O	O	350
dogs	NOUN	O	O	350
in	ADP	O	O	350
which	PRON	O	O	350
the	PRON	O	O	350
occlusion	NOUN	O	O	350
was	AUX	O	O	350
produced	VERB	O	O	350
.	PUNCT	O	O	350
During	ADP	O	O	351
dipyridamole	NOUN	O	Chemical	351
-	PUNCT	O	O	351
induced	VERB	O	O	351
hyperemia	PROPN	O	Disease	351
,	PUNCT	O	O	351
12	NUM	O	O	351
of	ADP	O	O	351
the	PRON	O	O	351
16	NUM	O	O	351
dogs	NOUN	O	O	351
with	ADP	O	O	351
a	PRON	O	O	351
partial	ADJ	O	O	351
coronary stenosis	NOUN	O	Disease	351
had	VERB	O	O	351
a	PRON	O	O	351
visible	ADJ	O	O	351
area	NOUN	O	O	351
of	ADP	O	O	351
hypoperfusion	NOUN	O	O	351
by	ADP	O	O	351
contrast	NOUN	O	O	351
echocardiography	NOUN	O	O	351
.	PUNCT	O	O	351
The	PRON	O	O	352
four	NUM	O	O	352
dogs	NOUN	O	O	352
without	ADP	O	O	352
a	PRON	O	O	352
perfusion	NOUN	O	O	352
defect	NOUN	O	O	352
had	VERB	O	O	352
a	PRON	O	O	352
stenosis	NOUN	O	O	352
that	SCONJ	O	O	352
resulted	VERB	O	O	352
in	ADP	O	O	352
a	PRON	O	O	352
mild	ADJ	O	O	352
(	PUNCT	O	O	352
0%	NOUN	O	O	352
to	PART	O	O	352
50%	NOUN	O	O	352
)	PUNCT	O	O	352
reduction	NOUN	O	O	352
in	ADP	O	O	352
dipyridamole	NOUN	O	Chemical	352
-	PUNCT	O	O	352
induced	VERB	O	O	352
hyperemia	PROPN	O	Disease	352
.	PUNCT	O	O	352
Thallium-201	VERB	O	O	353
SPECT	PROPN	O	O	354
demonstrated	VERB	O	O	354
a	PRON	O	O	354
perfusion	NOUN	O	O	354
defect	NOUN	O	O	354
in	ADP	O	O	354
all	PRON	O	O	354
14	NUM	O	O	354
dogs	NOUN	O	O	354
analyzed	VERB	O	O	354
during	ADP	O	O	354
dipyridamole	NOUN	O	Chemical	354
-	PUNCT	O	O	354
induced	VERB	O	O	354
hyperemia	PROPN	O	Disease	354
;	PUNCT	O	O	354
the	PRON	O	O	354
size	NOUN	O	O	354
of	ADP	O	O	354
the	PRON	O	O	354
perfusion	NOUN	O	O	354
defect	NOUN	O	O	354
correlated	VERB	O	O	354
with	ADP	O	O	354
the	PRON	O	O	354
anatomic	ADJ	O	O	354
area	NOUN	O	O	354
at	ADP	O	O	354
risk	NOUN	O	O	354
(	PUNCT	O	O	354
r	X	O	O	354
=	PUNCT	O	O	354
0.58	NUM	O	O	354
;	PUNCT	O	O	354
p	NOUN	O	O	354
less	ADV	O	O	354
than	ADP	O	O	354
0.03	NUM	O	O	354
)	PUNCT	O	O	354
and	CCONJ	O	O	354
with	ADP	O	O	354
the	PRON	O	O	354
perfusion	NOUN	O	O	354
defect	NOUN	O	O	354
by	ADP	O	O	354
contrast	NOUN	O	O	354
echocardiography	NOUN	O	O	354
(	PUNCT	O	O	354
r	X	O	O	354
=	PUNCT	O	O	354
0.58	NUM	O	O	354
;	PUNCT	O	O	354
p	NOUN	O	O	354
less	ADV	O	O	354
than	ADP	O	O	354
0.03	NUM	O	O	354
)	PUNCT	O	O	354
.	PUNCT	O	O	354
Thus	ADV	O	O	355
,	PUNCT	O	O	355
myocardial	ADJ	O	O	355
contrast	NOUN	O	O	355
echocardiography	NOUN	O	O	355
can	AUX	O	O	355
be	AUX	O	O	355
used	VERB	O	O	355
to	PART	O	O	355
visualize	VERB	O	O	355
and	CCONJ	O	O	355
quantitate	VERB	O	O	355
the	PRON	O	O	355
amount	NOUN	O	O	355
of	ADP	O	O	355
jeopardized	VERB	O	O	355
myocardium	NOUN	O	O	355
during	ADP	O	O	355
moderate	ADJ	O	O	355
to	PART	O	O	355
severe	ADJ	O	O	355
degrees	NOUN	O	O	355
of	ADP	O	O	355
coronary stenosis	NOUN	O	Disease	355
.	PUNCT	O	O	355
The	PRON	O	O	356
results	VERB	O	O	356
obtained	VERB	O	O	356
show	VERB	O	O	356
a	PRON	O	O	356
correlation	NOUN	O	O	356
with	ADP	O	O	356
the	PRON	O	O	356
anatomic	ADJ	O	O	356
area	NOUN	O	O	356
at	ADP	O	O	356
risk	NOUN	O	O	356
similar	ADJ	O	O	356
to	PART	O	O	356
that	SCONJ	O	O	356
obtained	VERB	O	O	356
with	ADP	O	O	356
thallium-201	ADJ	O	O	356
SPECT	PROPN	O	O	356
.	PUNCT	O	O	356
Potential	ADJ	O	O	359
deleterious	ADJ	O	O	359
effect	VERB	O	O	359
of	ADP	O	O	359
furosemide	PROPN	O	Chemical	359
in	ADP	O	O	359
radiocontrast	NOUN	O	O	359
nephropathy	NOUN	O	Disease	359
.	PUNCT	O	O	359
The	PRON	O	O	360
purpose	NOUN	O	O	360
of	ADP	O	O	360
the	PRON	O	O	360
study	VERB	O	O	360
was	AUX	O	O	360
to	PART	O	O	360
determine	VERB	O	O	360
the	PRON	O	O	360
efficacy	NOUN	O	O	360
of	ADP	O	O	360
furosemide	PROPN	O	Chemical	360
in	ADP	O	O	360
addition	NOUN	O	O	360
to	PART	O	O	360
intravenous	ADJ	O	O	360
fluids	NOUN	O	O	360
in	ADP	O	O	360
the	PRON	O	O	360
prevention	NOUN	O	O	360
of	ADP	O	O	360
radiocontrast	NOUN	O	O	360
nephropathy	NOUN	O	Disease	360
.	PUNCT	O	O	360
18	NUM	O	O	361
patients	NOUN	O	O	361
,	PUNCT	O	O	361
referred	VERB	O	O	361
to	PART	O	O	361
a	PRON	O	O	361
radiocontrast	NOUN	O	O	361
study	VERB	O	O	361
,	PUNCT	O	O	361
considered	VERB	O	O	361
at	ADP	O	O	361
risk	NOUN	O	O	361
because	SCONJ	O	O	361
of	ADP	O	O	361
preexisting	VERB	O	O	361
renal insufficiency	NOUN	O	Disease	361
,	PUNCT	O	O	361
were	AUX	O	O	361
enrolled	VERB	O	O	361
in	ADP	O	O	361
a	PRON	O	O	361
prospective	ADJ	O	O	361
,	PUNCT	O	O	361
randomized	VERB	O	O	361
,	PUNCT	O	O	361
controlled	VERB	O	O	361
trial	NOUN	O	O	361
,	PUNCT	O	O	361
performed	VERB	O	O	361
at	ADP	O	O	361
the	PRON	O	O	361
secondary	ADJ	O	O	361
care	VERB	O	O	361
center	PROPN	O	O	361
of	ADP	O	O	361
a	PRON	O	O	361
1,100-bed	NOUN	O	O	361
private	ADJ	O	O	361
university	NOUN	O	O	361
hospital	PROPN	O	O	361
.	PUNCT	O	O	361
In	ADP	O	O	362
addition	NOUN	O	O	362
to	PART	O	O	362
fluids	NOUN	O	O	362
,	PUNCT	O	O	362
the	PRON	O	O	362
treatment	NOUN	O	O	362
group	NOUN	O	O	362
received	VERB	O	O	362
furosemide	PROPN	O	Chemical	362
(	PUNCT	O	O	362
mean	VERB	O	O	362
dose	NOUN	O	O	362
110	NUM	O	O	362
mg	VERB	O	O	362
)	PUNCT	O	O	362
intravenously	ADV	O	O	362
30	NUM	O	O	362
min	NOUN	O	O	362
prior	ADV	O	O	362
to	PART	O	O	362
the	PRON	O	O	362
injection	NOUN	O	O	362
of	ADP	O	O	362
contrast	NOUN	O	O	362
material	ADJ	O	O	362
.	PUNCT	O	O	362
Renal function significantly deteriorated	VERB	O	Disease	363
in	ADP	O	O	363
the	PRON	O	O	363
group	NOUN	O	O	363
pretreated	VERB	O	O	363
with	ADP	O	O	363
furosemide	PROPN	O	Chemical	363
(	PUNCT	O	O	363
p	NOUN	O	O	363
<	X	O	O	364
0.005	NUM	O	O	364
by	ADP	O	O	364
ANOVA	PROPN	O	O	364
)	PUNCT	O	O	364
,	PUNCT	O	O	364
with	ADP	O	O	364
a	PRON	O	O	364
rise	VERB	O	O	364
in	ADP	O	O	364
serum	NOUN	O	O	364
creatinine	PROPN	O	Chemical	364
from	ADP	O	O	364
145	NUM	O	O	364
+	ADP	O	O	364
/-	PUNCT	O	O	364
Renal failure	NOUN	O	Disease	365
was	AUX	O	O	365
associated	VERB	O	O	365
with	ADP	O	O	365
weight loss	NOUN	O	Disease	365
in	ADP	O	O	365
the	PRON	O	O	365
furosemide	PROPN	O	Chemical	365
-	PUNCT	O	O	365
treated	VERB	O	O	365
group	NOUN	O	O	365
.	PUNCT	O	O	365
Furosemide	PROPN	O	Chemical	366
may	AUX	O	O	366
be	AUX	O	O	366
deleterious	ADJ	O	O	366
in	ADP	O	O	366
the	PRON	O	O	366
prevention	NOUN	O	O	366
of	ADP	O	O	366
radiocontrast	NOUN	O	O	366
nephropathy	NOUN	O	Disease	366
.	PUNCT	O	O	366
The	PRON	O	O	369
renal	ADJ	O	O	369
pathology	NOUN	O	O	369
in	ADP	O	O	369
a	PRON	O	O	369
case	NOUN	O	O	369
of	ADP	O	O	369
lithium	NOUN	O	Chemical	369
-	PUNCT	O	O	369
induced	VERB	O	O	369
diabetes insipidus	NOUN	O	Disease	369
.	PUNCT	O	O	369
A	PRON	O	O	370
case	NOUN	O	O	370
of	ADP	O	O	370
lithium	NOUN	O	Chemical	370
-	PUNCT	O	O	370
induced	VERB	O	O	370
diabetes insipidus	NOUN	O	Disease	370
is	AUX	O	O	370
reported	VERB	O	O	370
.	PUNCT	O	O	370
It	PRON	O	O	371
is	AUX	O	O	371
suggested	VERB	O	O	371
that	SCONJ	O	O	371
these	PRON	O	O	371
changes	VERB	O	O	371
represent	VERB	O	O	371
a	PRON	O	O	371
specific	ADJ	O	O	371
toxic	ADJ	O	O	371
effect	VERB	O	O	371
of	ADP	O	O	371
lithium	NOUN	O	Chemical	371
,	PUNCT	O	O	371
reported	VERB	O	O	371
here	ADV	O	O	371
for	ADP	O	O	371
the	PRON	O	O	371
first	ADV	O	O	371
time	NOUN	O	O	371
in	ADP	O	O	371
man	NOUN	O	O	371
.	PUNCT	O	O	371
Etiologic	PROPN	O	O	374
factors	NOUN	O	O	374
in	ADP	O	O	374
the	PRON	O	O	374
pathogenesis	NOUN	O	O	374
of	ADP	O	O	374
liver tumors	NOUN	O	Disease	374
associated	VERB	O	O	374
with	ADP	O	O	374
oral contraceptives	NOUN	O	Chemical	374
.	PUNCT	O	O	374
Within	ADP	O	O	375
the	PRON	O	O	375
last	VERB	O	O	375
several	ADJ	O	O	375
years	NOUN	O	O	375
,	PUNCT	O	O	375
previously	ADV	O	O	375
rare	ADJ	O	O	375
liver tumors	NOUN	O	Disease	375
have	VERB	O	O	375
been	AUX	O	O	375
seen	VERB	O	O	375
in	ADP	O	O	375
young	ADJ	O	O	375
women	NOUN	O	O	375
using	VERB	O	O	375
oral contraceptive	NOUN	O	Chemical	375
steroids	NOUN	O	Chemical	375
.	PUNCT	O	O	375
The	PRON	O	O	376
Registry	NOUN	O	O	376
for	ADP	O	O	376
Liver Tumors	PROPN	O	Disease	376
Associated	NOUN	O	O	376
with	ADP	O	O	376
Oral Contraceptives	NOUN	O	Chemical	376
at	ADP	O	O	376
the	PRON	O	O	376
University	NOUN	O	O	376
of	ADP	O	O	376
California	PROPN	O	O	376
,	PUNCT	O	O	376
Irvine	PROPN	O	O	376
,	PUNCT	O	O	376
has	VERB	O	O	376
clearly	ADV	O	O	376
identified	VERB	O	O	376
27	NUM	O	O	376
cases	NOUN	O	O	376
.	PUNCT	O	O	376
Common	ADJ	O	O	377
to	PART	O	O	377
these	PRON	O	O	377
71	NUM	O	O	377
cases	NOUN	O	O	377
has	VERB	O	O	377
been	AUX	O	O	377
a	PRON	O	O	377
histopathologic	VERB	O	O	377
diagnosis	NOUN	O	O	377
of	ADP	O	O	377
focal nodular hyperplasia	NOUN	O	Disease	377
,	PUNCT	O	O	377
adenoma	INTJ	O	Disease	377
,	PUNCT	O	O	377
hamartoma	VERB	O	Disease	377
,	PUNCT	O	O	377
and	CCONJ	O	O	377
hepatoma	VERB	O	Disease	377
.	PUNCT	O	O	377
Significant	ADJ	O	O	378
statistical	ADJ	O	O	378
etiologic	ADJ	O	O	378
factors	NOUN	O	O	378
include	VERB	O	O	378
prolonged	VERB	O	O	378
uninterrupted	ADJ	O	O	378
usage	NOUN	O	O	378
of	ADP	O	O	378
oral contraceptive	NOUN	O	Chemical	378
steroids	NOUN	O	Chemical	378
.	PUNCT	O	O	378
Eight	NUM	O	O	379
deaths	NOUN	O	O	379
and	CCONJ	O	O	379
liver	NOUN	O	O	379
rupture	NOUN	O	Disease	379
in	ADP	O	O	379
18	NUM	O	O	379
patients	NOUN	O	O	379
attest	VERB	O	O	379
to	PART	O	O	379
the	PRON	O	O	379
seriousness	VERB	O	O	379
of	ADP	O	O	379
this	PRON	O	O	379
new	ADJ	O	O	379
potentially	ADV	O	O	379
lethal	ADJ	O	O	379
adverse	ADJ	O	O	379
phenomenon	NOUN	O	O	379
.	PUNCT	O	O	379
Graft	NOUN	O	O	382
-	PUNCT	O	O	382
versus	ADP	O	O	382
-	PUNCT	O	O	382
host	NOUN	O	O	382
disease	PROPN	O	O	382
prophylaxis	NOUN	O	O	382
with	ADP	O	O	382
everolimus	ADJ	O	Chemical	382
and	CCONJ	O	O	382
tacrolimus	NOUN	O	Chemical	382
is	AUX	O	O	382
associated	VERB	O	O	382
with	ADP	O	O	382
a	PRON	O	O	382
high	ADJ	O	O	382
incidence	NOUN	O	O	382
of	ADP	O	O	382
sinusoidal obstruction syndrome	NOUN	O	Disease	382
and	CCONJ	O	O	382
microangiopathy	VERB	O	Disease	382
:	PUNCT	O	O	382
results	VERB	O	O	382
of	ADP	O	O	382
the	PRON	O	O	382
EVTAC	VERB	O	O	382
trial	NOUN	O	O	382
.	PUNCT	O	O	382
A	PRON	O	O	383
calcineurin	NOUN	O	O	383
inhibitor	NOUN	O	O	383
combined	VERB	O	O	383
with	ADP	O	O	383
methotrexate	CCONJ	O	Chemical	383
is	AUX	O	O	383
the	PRON	O	O	383
standard	PROPN	O	O	383
prophylaxis	NOUN	O	O	383
for	ADP	O	O	383
graft	NOUN	O	O	383
-	PUNCT	O	O	383
versus	ADP	O	O	383
-	PUNCT	O	O	383
host	NOUN	O	O	383
disease	PROPN	O	O	383
(	PUNCT	O	O	383
GVHD	PROPN	O	Disease	383
)	PUNCT	O	O	383
after	ADP	O	O	383
allogeneic	ADJ	O	O	383
hematopoietic	PROPN	O	O	383
stem	VERB	O	O	383
cell	NOUN	O	O	383
transplantation	NOUN	O	O	383
(	PUNCT	O	O	383
HSCT	PROPN	O	O	383
)	PUNCT	O	O	383
.	PUNCT	O	O	383
Everolimus	NOUN	O	Chemical	384
,	PUNCT	O	O	384
a	PRON	O	O	384
derivative	ADJ	O	O	384
of	ADP	O	O	384
sirolimus	NOUN	O	Chemical	384
,	PUNCT	O	O	384
seems	VERB	O	O	384
to	PART	O	O	384
mediate	VERB	O	O	384
antileukemia	NOUN	O	O	384
effects	NOUN	O	O	384
.	PUNCT	O	O	384
We	PRON	O	O	385
report	VERB	O	O	385
on	ADP	O	O	385
a	PRON	O	O	385
combination	NOUN	O	O	385
of	ADP	O	O	385
everolimus	ADJ	O	Chemical	385
and	CCONJ	O	O	385
tacrolimus	NOUN	O	Chemical	385
in	ADP	O	O	385
24	NUM	O	O	385
patients	NOUN	O	O	385
(	PUNCT	O	O	385
median	ADJ	O	O	385
age	NOUN	O	O	385
,	PUNCT	O	O	385
62	NUM	O	O	385
years	NOUN	O	O	385
)	PUNCT	O	O	385
with	ADP	O	O	385
either	ADV	O	O	385
myelodysplastic syndrome	PROPN	O	Disease	385
(	PUNCT	O	O	385
MDS	PROPN	O	Disease	385
;	PUNCT	O	O	385
n	CCONJ	O	O	385
=	PUNCT	O	O	385
17	NUM	O	O	385
)	PUNCT	O	O	385
or	CCONJ	O	O	385
acute myeloid leukemia	NOUN	O	Disease	385
(	PUNCT	O	O	385
AML	PROPN	O	Disease	385
;	PUNCT	O	O	385
n	CCONJ	O	O	385
=	PUNCT	O	O	385
7	NUM	O	O	385
)	PUNCT	O	O	385
undergoing	VERB	O	O	385
intensive	ADJ	O	O	385
conditioning	NOUN	O	O	385
followed	VERB	O	O	385
by	ADP	O	O	385
HSCT	PROPN	O	O	385
from	ADP	O	O	385
related	ADJ	O	O	385
(	PUNCT	O	O	385
n	CCONJ	O	O	385
=	PUNCT	O	O	385
4	NUM	O	O	385
)	PUNCT	O	O	385
or	CCONJ	O	O	385
unrelated	ADJ	O	O	385
(	PUNCT	O	O	385
n	CCONJ	O	O	385
=	PUNCT	O	O	385
20	NUM	O	O	385
)	PUNCT	O	O	385
donors	NOUN	O	O	385
.	PUNCT	O	O	385
All	PRON	O	O	386
patients	NOUN	O	O	386
engrafted	VERB	O	O	386
,	PUNCT	O	O	386
and	CCONJ	O	O	386
only	ADV	O	O	386
1	X	O	O	386
patient	NOUN	O	O	386
experienced	ADJ	O	O	386
grade	NOUN	O	O	386
IV	NUM	O	O	386
mucositis	NOUN	O	Disease	386
.	PUNCT	O	O	386
Nine	NUM	O	O	387
patients	NOUN	O	O	387
(	PUNCT	O	O	387
37%	NOUN	O	O	387
)	PUNCT	O	O	387
developed	VERB	O	O	387
acute	ADJ	O	O	387
grade	NOUN	O	O	387
II	NUM	O	O	387
-	PUNCT	O	O	387
IV	NUM	O	O	387
GVHD	PROPN	O	Disease	387
,	PUNCT	O	O	387
and	CCONJ	O	O	387
11	NUM	O	O	387
of	ADP	O	O	387
17	NUM	O	O	387
evaluable	ADJ	O	O	387
patients	NOUN	O	O	387
(	PUNCT	O	O	387
64%	NOUN	O	O	387
)	PUNCT	O	O	387
developed	VERB	O	O	387
chronic	ADJ	O	O	387
extensive	ADJ	O	O	387
GVHD	PROPN	O	Disease	387
.	PUNCT	O	O	387
Transplantation	NOUN	O	O	388
-	PUNCT	O	O	388
associated	VERB	O	O	388
microangiopathy	VERB	O	Disease	388
(	PUNCT	O	O	388
TMA	PROPN	O	Disease	388
)	PUNCT	O	O	388
occurred	VERB	O	O	388
in	ADP	O	O	388
7	NUM	O	O	388
patients	NOUN	O	O	388
(	PUNCT	O	O	388
29%	NOUN	O	O	388
)	PUNCT	O	O	388
,	PUNCT	O	O	388
with	ADP	O	O	388
2	X	O	O	388
cases	NOUN	O	O	388
of	ADP	O	O	388
acute	ADJ	O	O	388
renal failure	NOUN	O	Disease	388
.	PUNCT	O	O	388
The	PRON	O	O	389
study	VERB	O	O	389
was	AUX	O	O	389
terminated	VERB	O	O	389
prematurely	ADV	O	O	389
because	SCONJ	O	O	389
an	PRON	O	O	389
additional	ADJ	O	O	389
6	NUM	O	O	389
patients	NOUN	O	O	389
(	PUNCT	O	O	389
25%	NOUN	O	O	389
)	PUNCT	O	O	389
developed	VERB	O	O	389
sinusoidal obstruction syndrome	NOUN	O	Disease	389
(	PUNCT	O	O	389
SOS	PROPN	O	Disease	389
)	PUNCT	O	O	389
,	PUNCT	O	O	389
which	PRON	O	O	389
was	AUX	O	O	389
fatal	ADJ	O	O	389
in	ADP	O	O	389
2	X	O	O	389
cases	NOUN	O	O	389
.	PUNCT	O	O	389
Although	SCONJ	O	O	390
this	PRON	O	O	390
new	ADJ	O	O	390
combination	NOUN	O	O	390
appears	VERB	O	O	390
to	PART	O	O	390
be	AUX	O	O	390
effective	ADJ	O	O	390
as	ADP	O	O	390
a	PRON	O	O	390
prophylactic	ADJ	O	O	390
regimen	NOUN	O	O	390
for	ADP	O	O	390
acute	ADJ	O	O	390
GVHD	PROPN	O	Disease	390
,	PUNCT	O	O	390
the	PRON	O	O	390
incidence	NOUN	O	O	390
of	ADP	O	O	390
TMA	PROPN	O	Disease	390
and	CCONJ	O	O	390
SOS	PROPN	O	Disease	390
is	AUX	O	O	390
considerably	ADV	O	O	390
higher	ADJ	O	O	390
than	ADP	O	O	390
seen	VERB	O	O	390
with	ADP	O	O	390
other	ADJ	O	O	390
regimens	NOUN	O	O	390
.	PUNCT	O	O	390
Effect	VERB	O	O	393
of	ADP	O	O	393
some	PRON	O	O	393
convulsants	NOUN	O	O	393
on	ADP	O	O	393
the	PRON	O	O	393
protective	ADJ	O	O	393
activity	NOUN	O	O	393
of	ADP	O	O	393
loreclezole	NOUN	O	Chemical	393
and	CCONJ	O	O	393
its	PRON	O	O	393
combinations	NOUN	O	O	393
with	ADP	O	O	393
valproate	VERB	O	Chemical	393
or	CCONJ	O	O	393
clonazepam	NOUN	O	Chemical	393
in	ADP	O	O	393
amygdala	NOUN	O	O	393
-	PUNCT	O	O	393
kindled	VERB	O	O	393
rats	NOUN	O	O	393
.	PUNCT	O	O	393
Loreclezole	PROPN	O	Chemical	394
(	PUNCT	O	O	394
5	NUM	O	O	394
mg	VERB	O	O	394
/	PUNCT	O	O	394
kg	VERB	O	O	394
)	PUNCT	O	O	394
exerted	VERB	O	O	394
a	PRON	O	O	394
significant	ADJ	O	O	394
protective	ADJ	O	O	394
action	NOUN	O	O	394
in	ADP	O	O	394
amygdala	NOUN	O	O	394
-	PUNCT	O	O	394
kindled	VERB	O	O	394
rats	NOUN	O	O	394
,	PUNCT	O	O	394
reducing	VERB	O	O	394
both	PRON	O	O	394
seizure	NOUN	O	Disease	394
and	CCONJ	O	O	394
afterdischarge	ADJ	O	O	394
durations	NOUN	O	O	394
.	PUNCT	O	O	394
The	PRON	O	O	395
combinations	NOUN	O	O	395
of	ADP	O	O	395
loreclezole	NOUN	O	Chemical	395
(	PUNCT	O	O	395
2.5	NUM	O	O	395
mg	VERB	O	O	395
/	PUNCT	O	O	395
kg	VERB	O	O	395
)	PUNCT	O	O	395
with	ADP	O	O	395
valproate	VERB	O	Chemical	395
,	PUNCT	O	O	395
clonazepam	NOUN	O	Chemical	395
,	PUNCT	O	O	395
or	CCONJ	O	O	395
carbamazepine	NOUN	O	Chemical	395
(	PUNCT	O	O	395
applied	VERB	O	O	395
at	ADP	O	O	395
their	PRON	O	O	395
subprotective	ADJ	O	O	395
doses	NOUN	O	O	395
)	PUNCT	O	O	395
also	ADV	O	O	395
exhibited	VERB	O	O	395
antiseizure	NOUN	O	O	395
effect	VERB	O	O	395
in	ADP	O	O	395
this	PRON	O	O	395
test	NOUN	O	O	395
.	PUNCT	O	O	395
Among	ADP	O	O	396
several	ADJ	O	O	396
chemoconvulsants	NOUN	O	O	396
,	PUNCT	O	O	396
bicuculline	PROPN	O	Chemical	396
,	PUNCT	O	O	396
N	NUM	O	O	396
-	PUNCT	O	O	396
methyl	NOUN	O	O	396
-	PUNCT	O	O	396
D	NOUN	O	O	396
-	PUNCT	O	O	396
aspartic	ADJ	O	O	396
acid	PROPN	O	O	396
and	CCONJ	O	O	396
BAY k-8644	PROPN	O	Chemical	396
(	PUNCT	O	O	396
the	PRON	O	O	396
opener	NOUN	O	O	396
of	ADP	O	O	396
L	NOUN	O	O	396
-	PUNCT	O	O	396
type	NOUN	O	O	396
calcium	NOUN	O	Chemical	396
channels	NOUN	O	O	396
)	PUNCT	O	O	396
reversed	VERB	O	O	396
the	PRON	O	O	396
protective	ADJ	O	O	396
activity	NOUN	O	O	396
of	ADP	O	O	396
loreclezole	NOUN	O	Chemical	396
alone	ADV	O	O	396
and	CCONJ	O	O	396
its	PRON	O	O	396
combination	NOUN	O	O	396
with	ADP	O	O	396
valproate	VERB	O	Chemical	396
.	PUNCT	O	O	396
On	ADP	O	O	397
the	PRON	O	O	397
other	ADJ	O	O	397
hand	NOUN	O	O	397
,	PUNCT	O	O	397
bicuculline	PROPN	O	Chemical	397
,	PUNCT	O	O	397
aminophylline	VERB	O	Chemical	397
and	CCONJ	O	O	397
BAY k-8644	PROPN	O	Chemical	397
inhibited	VERB	O	O	397
the	PRON	O	O	397
anticonvulsive	ADJ	O	O	397
action	NOUN	O	O	397
of	ADP	O	O	397
loreclezole	NOUN	O	Chemical	397
combined	VERB	O	O	397
with	ADP	O	O	397
clonazepam	NOUN	O	Chemical	397
.	PUNCT	O	O	397
The	PRON	O	O	398
results	VERB	O	O	398
support	NOUN	O	O	398
the	PRON	O	O	398
hypothesis	NOUN	O	O	398
that	SCONJ	O	O	398
the	PRON	O	O	398
protective	ADJ	O	O	398
activity	NOUN	O	O	398
of	ADP	O	O	398
loreclezole	NOUN	O	Chemical	398
and	CCONJ	O	O	398
its	PRON	O	O	398
combinations	NOUN	O	O	398
with	ADP	O	O	398
other	ADJ	O	O	398
antiepileptics	NOUN	O	O	398
may	AUX	O	O	398
involve	VERB	O	O	398
potentiation	NOUN	O	O	398
of	ADP	O	O	398
GABAergic	PROPN	O	O	398
neurotransmission	NOUN	O	O	398
and	CCONJ	O	O	398
blockade	VERB	O	O	398
of	ADP	O	O	398
L	NOUN	O	O	398
-	PUNCT	O	O	398
type	NOUN	O	O	398
of	ADP	O	O	398
calcium	NOUN	O	Chemical	398
channels	NOUN	O	O	398
.	PUNCT	O	O	398
Acute liver failure	NOUN	O	Disease	401
with	ADP	O	O	401
concurrent	ADJ	O	O	401
bupropion	NOUN	O	Chemical	401
and	CCONJ	O	O	401
carbimazole	PROPN	O	Chemical	401
therapy	NOUN	O	O	401
.	PUNCT	O	O	401
OBJECTIVE	VERB	O	O	402
:	PUNCT	O	O	402
To	PART	O	O	402
report	VERB	O	O	402
a	PRON	O	O	402
case	NOUN	O	O	402
of	ADP	O	O	402
fatal	ADJ	O	O	402
liver failure	NOUN	O	Disease	402
possibly	ADV	O	O	402
associated	VERB	O	O	402
with	ADP	O	O	402
concurrent	ADJ	O	O	402
use	VERB	O	O	402
of	ADP	O	O	402
bupropion	NOUN	O	Chemical	402
and	CCONJ	O	O	402
carbimazole	PROPN	O	Chemical	402
.	PUNCT	O	O	402
A	PRON	O	O	403
41-year	NOUN	O	O	403
-	PUNCT	O	O	403
old	ADJ	O	O	403
Chinese	PROPN	O	O	403
man	NOUN	O	O	403
with	ADP	O	O	403
a	PRON	O	O	403
history	NOUN	O	O	403
of	ADP	O	O	403
hyperthyroidism	NOUN	O	Disease	403
had	VERB	O	O	403
been	AUX	O	O	403
treated	VERB	O	O	403
with	ADP	O	O	403
carbimazole	PROPN	O	Chemical	403
and	CCONJ	O	O	403
propranolol	NOUN	O	Chemical	403
for	ADP	O	O	403
the	PRON	O	O	403
past	ADP	O	O	403
5	NUM	O	O	403
years	NOUN	O	O	403
.	PUNCT	O	O	403
He	PRON	O	O	404
received	VERB	O	O	404
a	PRON	O	O	404
10-day	NOUN	O	O	404
course	NOUN	O	O	404
of	ADP	O	O	404
bupropion	NOUN	O	Chemical	404
as	ADP	O	O	404
an	PRON	O	O	404
aid	NOUN	O	O	404
for	ADP	O	O	404
smoking	VERB	O	O	404
cessation	NOUN	O	O	404
10	NUM	O	O	404
weeks	NOUN	O	O	404
prior	ADV	O	O	404
to	PART	O	O	404
presentation	NOUN	O	O	404
.	PUNCT	O	O	404
He	PRON	O	O	405
developed	VERB	O	O	405
acute liver failure	NOUN	O	Disease	405
with	ADP	O	O	405
rapid	ADJ	O	O	405
deterioration	NOUN	O	O	405
of	ADP	O	O	405
renal	ADJ	O	O	405
function	NOUN	O	O	405
.	PUNCT	O	O	405
Liver	NOUN	O	O	406
biopsy	PROPN	O	O	406
showed	VERB	O	O	406
evidence	NOUN	O	O	406
of	ADP	O	O	406
nonspecific	ADJ	O	O	406
drug	NOUN	O	O	406
-	PUNCT	O	O	406
induced	VERB	O	O	406
acute	ADJ	O	O	406
liver injury	NOUN	O	Disease	406
.	PUNCT	O	O	406
His	PRON	O	O	407
condition	NOUN	O	O	407
was	AUX	O	O	407
further	ADV	O	O	407
complicated	VERB	O	O	407
by	ADP	O	O	407
sepsis	NOUN	O	Disease	407
and	CCONJ	O	O	407
coagulopathy	VERB	O	Disease	407
.	PUNCT	O	O	407
The	PRON	O	O	408
likelihood	NOUN	O	O	408
that	SCONJ	O	O	408
bupropion	NOUN	O	Chemical	408
induced	VERB	O	O	408
hepatotoxicity	NOUN	O	Disease	408
in	ADP	O	O	408
our	PRON	O	O	408
patient	NOUN	O	O	408
was	AUX	O	O	408
possible	ADJ	O	O	408
,	PUNCT	O	O	408
based	VERB	O	O	408
on	ADP	O	O	408
the	PRON	O	O	408
Naranjo	PROPN	O	O	408
probability	NOUN	O	O	408
scale	NOUN	O	O	408
.	PUNCT	O	O	408
DISCUSSION	NOUN	O	O	409
:	PUNCT	O	O	409
Although	SCONJ	O	O	409
there	ADV	O	O	409
is	AUX	O	O	409
increasing	VERB	O	O	409
evidence	NOUN	O	O	409
of	ADP	O	O	409
hepatotoxicity	NOUN	O	Disease	409
induced	VERB	O	O	409
by	ADP	O	O	409
bupropion	NOUN	O	Chemical	409
,	PUNCT	O	O	409
this	PRON	O	O	409
is	AUX	O	O	409
the	PRON	O	O	409
first	ADV	O	O	409
case	NOUN	O	O	409
of	ADP	O	O	409
fatality	NOUN	O	O	409
that	SCONJ	O	O	409
could	AUX	O	O	409
have	VERB	O	O	409
resulted	VERB	O	O	409
from	ADP	O	O	409
acute liver failure	NOUN	O	Disease	409
in	ADP	O	O	409
a	PRON	O	O	409
patient	NOUN	O	O	409
receiving	VERB	O	O	409
bupropion	NOUN	O	Chemical	409
while	SCONJ	O	O	409
on	ADP	O	O	409
concomitant	ADJ	O	O	409
treatment	NOUN	O	O	409
with	ADP	O	O	409
carbimazole	PROPN	O	Chemical	409
.	PUNCT	O	O	409
Clinicians	NOUN	O	O	410
should	AUX	O	O	410
be	AUX	O	O	410
aware	ADJ	O	O	410
of	ADP	O	O	410
the	PRON	O	O	410
possibility	NOUN	O	O	410
of	ADP	O	O	410
acute liver insult	NOUN	O	Disease	410
induced	VERB	O	O	410
by	ADP	O	O	410
bupropion	NOUN	O	Chemical	410
given	VERB	O	O	410
concurrently	ADV	O	O	410
with	ADP	O	O	410
other	ADJ	O	O	410
hepatotoxic	ADJ	O	Disease	410
drugs	NOUN	O	O	410
.	PUNCT	O	O	410
Hormone	NOUN	O	O	413
therapy	NOUN	O	O	413
(	PUNCT	O	O	413
HT	PROPN	O	O	413
)	PUNCT	O	O	413
is	AUX	O	O	413
widely	ADV	O	O	413
used	VERB	O	O	413
for	ADP	O	O	413
controlling	VERB	O	O	413
menopausal	PROPN	O	O	413
symptoms	NOUN	O	O	413
and	CCONJ	O	O	413
has	VERB	O	O	413
also	ADV	O	O	413
been	AUX	O	O	413
used	VERB	O	O	413
for	ADP	O	O	413
the	PRON	O	O	413
management	NOUN	O	O	413
and	CCONJ	O	O	413
prevention	NOUN	O	O	413
of	ADP	O	O	413
cardiovascular disease	NOUN	O	Disease	413
,	PUNCT	O	O	413
osteoporosis	NOUN	O	Disease	413
and	CCONJ	O	O	413
dementia	NOUN	O	Disease	413
in	ADP	O	O	413
older	ADJ	O	O	413
women	NOUN	O	O	413
.	PUNCT	O	O	413
To	PART	O	O	414
assess	VERB	O	O	414
the	PRON	O	O	414
effect	VERB	O	O	414
of	ADP	O	O	414
long	ADV	O	O	414
-	PUNCT	O	O	414
term	NOUN	O	O	414
HT	PROPN	O	O	414
on	ADP	O	O	414
mortality	NOUN	O	O	414
,	PUNCT	O	O	414
cardiovascular	ADJ	O	O	414
outcomes	NOUN	O	O	414
,	PUNCT	O	O	414
cancer	NOUN	O	Disease	414
,	PUNCT	O	O	414
gallbladder disease	NOUN	O	Disease	414
,	PUNCT	O	O	414
cognition	NOUN	O	O	414
,	PUNCT	O	O	414
fractures	NOUN	O	Disease	414
and	CCONJ	O	O	414
quality	NOUN	O	O	414
of	ADP	O	O	414
life	NOUN	O	O	414
.	PUNCT	O	O	414
We	PRON	O	O	415
searched	VERB	O	O	415
the	PRON	O	O	415
following	VERB	O	O	415
databases	NOUN	O	O	415
to	PART	O	O	415
November	PROPN	O	O	415
2007	NUM	O	O	415
:	PUNCT	O	O	415
Trials	NOUN	O	O	415
Register	VERB	O	O	415
of	ADP	O	O	415
the	PRON	O	O	415
Cochrane	PROPN	O	O	415
Menstrual Disorders	NOUN	O	Disease	415
and	CCONJ	O	O	415
Subfertility	NOUN	O	O	415
Group	PROPN	O	O	415
,	PUNCT	O	O	415
Cochrane	PROPN	O	O	415
Central	ADJ	O	O	415
Register	VERB	O	O	415
of	ADP	O	O	415
Controlled	VERB	O	O	415
Trials	NOUN	O	O	415
,	PUNCT	O	O	415
MEDLINE	NOUN	O	O	415
,	PUNCT	O	O	415
EMBASE	PROPN	O	O	415
,	PUNCT	O	O	415
Biological	ADJ	O	O	415
Abstracts	NOUN	O	O	415
.	PUNCT	O	O	415
HT	PROPN	O	O	416
included	VERB	O	O	416
oestrogens	PROPN	O	Chemical	416
,	PUNCT	O	O	416
with	ADP	O	O	416
or	CCONJ	O	O	416
without	ADP	O	O	416
progestogens	NOUN	O	Chemical	416
,	PUNCT	O	O	416
via	ADP	O	O	416
oral	ADJ	O	O	416
,	PUNCT	O	O	416
transdermal	NOUN	O	O	416
,	PUNCT	O	O	416
subcutaneous	ADJ	O	O	416
or	CCONJ	O	O	416
transnasal	PROPN	O	O	416
routes	NOUN	O	O	416
.	PUNCT	O	O	416
In	ADP	O	O	417
relatively	ADV	O	O	417
healthy	ADJ	O	O	417
women	NOUN	O	O	417
,	PUNCT	O	O	417
combined	VERB	O	O	417
continuous	ADJ	O	O	417
HT	PROPN	O	O	417
significantly	ADV	O	O	417
increased	VERB	O	O	417
the	PRON	O	O	417
risk	NOUN	O	O	417
of	ADP	O	O	417
venous	ADJ	O	O	417
thrombo	PROPN	O	O	417
-	PUNCT	O	O	417
embolism	NOUN	O	O	417
or	CCONJ	O	O	417
coronary	ADJ	O	O	417
event	NOUN	O	O	417
(	PUNCT	O	O	417
after	ADP	O	O	417
one	NUM	O	O	417
year	NOUN	O	O	417
's	AUX	O	O	417
use	VERB	O	O	417
)	PUNCT	O	O	417
,	PUNCT	O	O	417
stroke	VERB	O	Disease	417
(	PUNCT	O	O	417
after	ADP	O	O	417
three	NUM	O	O	417
years	NOUN	O	O	417
)	PUNCT	O	O	417
,	PUNCT	O	O	417
breast cancer	NOUN	O	Disease	417
and	CCONJ	O	O	417
gallbladder disease	NOUN	O	Disease	417
.	PUNCT	O	O	417
Long	ADV	O	O	418
-	PUNCT	O	O	418
term	NOUN	O	O	418
oestrogen	PROPN	O	Chemical	418
-	PUNCT	O	O	418
only	ADV	O	O	418
HT	PROPN	O	O	418
significantly	ADV	O	O	418
increased	VERB	O	O	418
the	PRON	O	O	418
risk	NOUN	O	O	418
of	ADP	O	O	418
venous	ADJ	O	O	418
thrombo	PROPN	O	O	418
-	PUNCT	O	O	418
embolism	NOUN	O	O	418
,	PUNCT	O	O	418
stroke	VERB	O	Disease	418
and	CCONJ	O	O	418
gallbladder disease	NOUN	O	Disease	418
(	PUNCT	O	O	418
after	ADP	O	O	418
one	NUM	O	O	418
to	PART	O	O	418
two	NUM	O	O	418
years	NOUN	O	O	418
,	PUNCT	O	O	418
three	NUM	O	O	418
years	NOUN	O	O	418
and	CCONJ	O	O	418
seven	NUM	O	O	418
years	NOUN	O	O	418
'	PUNCT	O	O	418
use	VERB	O	O	418
respectively	ADV	O	O	418
)	PUNCT	O	O	418
,	PUNCT	O	O	418
but	CCONJ	O	O	418
did	VERB	O	O	418
not	PART	O	O	418
significantly	ADV	O	O	418
increase	VERB	O	O	418
the	PRON	O	O	418
risk	NOUN	O	O	418
of	ADP	O	O	418
breast cancer	NOUN	O	Disease	418
.	PUNCT	O	O	418
The	PRON	O	O	419
only	ADV	O	O	419
statistically	ADV	O	O	419
significant	ADJ	O	O	419
benefits	NOUN	O	O	419
of	ADP	O	O	419
HT	PROPN	O	O	419
were	AUX	O	O	419
a	PRON	O	O	419
decreased	VERB	O	O	419
incidence	NOUN	O	O	419
of	ADP	O	O	419
fractures	NOUN	O	Disease	419
and	CCONJ	O	O	419
(	PUNCT	O	O	419
for	ADP	O	O	419
combined	VERB	O	O	419
HT	PROPN	O	O	419
)	PUNCT	O	O	419
colon cancer	NOUN	O	Disease	419
,	PUNCT	O	O	419
with	ADP	O	O	419
long	ADV	O	O	419
-	PUNCT	O	O	419
term	NOUN	O	O	419
use	VERB	O	O	419
.	PUNCT	O	O	419
Among	ADP	O	O	420
women	NOUN	O	O	420
aged	ADJ	O	O	420
over	ADP	O	O	420
65	NUM	O	O	420
who	PRON	O	O	420
were	AUX	O	O	420
relatively	ADV	O	O	420
healthy	ADJ	O	O	420
(	PUNCT	O	O	420
i.e.	X	O	O	420
generally	ADV	O	O	420
fit	ADJ	O	O	420
,	PUNCT	O	O	420
without	ADP	O	O	420
overt	ADJ	O	O	420
disease	PROPN	O	O	420
)	PUNCT	O	O	420
and	CCONJ	O	O	420
taking	VERB	O	O	420
continuous	ADJ	O	O	420
combined	VERB	O	O	420
HT	PROPN	O	O	420
,	PUNCT	O	O	420
there	ADV	O	O	420
was	AUX	O	O	420
a	PRON	O	O	420
statistically	ADV	O	O	420
significant	ADJ	O	O	420
increase	VERB	O	O	420
in	ADP	O	O	420
the	PRON	O	O	420
incidence	NOUN	O	O	420
of	ADP	O	O	420
dementia	NOUN	O	Disease	420
.	PUNCT	O	O	420
Among	ADP	O	O	421
women	NOUN	O	O	421
with	ADP	O	O	421
cardiovascular disease	NOUN	O	Disease	421
,	PUNCT	O	O	421
long	ADV	O	O	421
-	PUNCT	O	O	421
term	NOUN	O	O	421
use	VERB	O	O	421
of	ADP	O	O	421
combined	VERB	O	O	421
continuous	ADJ	O	O	421
HT	PROPN	O	O	421
significantly	ADV	O	O	421
increased	VERB	O	O	421
the	PRON	O	O	421
risk	NOUN	O	O	421
of	ADP	O	O	421
venous	ADJ	O	O	421
thrombo	PROPN	O	O	421
-	PUNCT	O	O	421
embolism	NOUN	O	O	421
.	PUNCT	O	O	421
One	NUM	O	O	422
trial	NOUN	O	O	422
analysed	VERB	O	O	422
subgroups	NOUN	O	O	422
of	ADP	O	O	422
2839	NUM	O	O	422
relatively	ADV	O	O	422
healthy	ADJ	O	O	422
50	NUM	O	O	422
to	PART	O	O	422
59	NUM	O	O	422
year	NOUN	O	O	422
old	ADJ	O	O	422
women	NOUN	O	O	422
taking	VERB	O	O	422
combined	VERB	O	O	422
continuous	ADJ	O	O	422
HT	PROPN	O	O	422
and	CCONJ	O	O	422
1637	NUM	O	O	422
taking	VERB	O	O	422
oestrogen	PROPN	O	Chemical	422
-	PUNCT	O	O	422
only	ADV	O	O	422
HT	PROPN	O	O	422
,	PUNCT	O	O	422
versus	ADP	O	O	422
similar	ADJ	O	O	422
-	PUNCT	O	O	422
sized	ADJ	O	O	422
placebo	NOUN	O	O	422
groups	NOUN	O	O	422
.	PUNCT	O	O	422
The	PRON	O	O	423
only	ADV	O	O	423
significantly	ADV	O	O	423
increased	VERB	O	O	423
risk	NOUN	O	O	423
reported	VERB	O	O	423
was	AUX	O	O	423
for	ADP	O	O	423
venous	ADJ	O	O	423
thrombo	PROPN	O	O	423
-	PUNCT	O	O	423
embolism	NOUN	O	O	423
in	ADP	O	O	423
women	NOUN	O	O	423
taking	VERB	O	O	423
combined	VERB	O	O	423
continuous	ADJ	O	O	423
HT	PROPN	O	O	423
:	PUNCT	O	O	423
their	PRON	O	O	423
absolute	ADJ	O	O	423
risk	NOUN	O	O	423
remained	VERB	O	O	423
low	ADJ	O	O	423
,	PUNCT	O	O	423
at	ADP	O	O	423
less	ADV	O	O	423
than	ADP	O	O	423
1/500	NUM	O	O	423
.	PUNCT	O	O	423
Passage	NOUN	O	O	426
of	ADP	O	O	426
mannitol	PROPN	O	Chemical	426
into	ADP	O	O	426
the	PRON	O	O	426
brain	NOUN	O	O	426
around	ADV	O	O	426
gliomas	NOUN	O	Disease	426
:	PUNCT	O	O	426
a	PRON	O	O	426
potential	ADJ	O	O	426
cause	VERB	O	O	426
of	ADP	O	O	426
rebound	VERB	O	O	426
phenomenon	NOUN	O	O	426
.	PUNCT	O	O	426
Widespread	ADJ	O	O	427
use	VERB	O	O	427
of	ADP	O	O	427
mannitol	PROPN	O	Chemical	427
to	PART	O	O	427
reduce	VERB	O	O	427
brain edema	NOUN	O	Disease	427
and	CCONJ	O	O	427
lower	ADJ	O	O	427
elevated ICP	PROPN	O	Disease	427
in	ADP	O	O	427
brain tumor	NOUN	O	Disease	427
patients	NOUN	O	O	427
continues	VERB	O	O	427
to	PART	O	O	427
be	AUX	O	O	427
afflicted	VERB	O	O	427
by	ADP	O	O	427
the	PRON	O	O	427
so	ADV	O	O	427
-	PUNCT	O	O	427
called	VERB	O	O	427
rebound	VERB	O	O	427
phenomenon	NOUN	O	O	427
.	PUNCT	O	O	427
Leakage	NOUN	O	O	428
of	ADP	O	O	428
mannitol	PROPN	O	Chemical	428
into	ADP	O	O	428
the	PRON	O	O	428
brain	NOUN	O	O	428
parenchyma	X	O	O	428
through	ADP	O	O	428
an	PRON	O	O	428
altered	VERB	O	O	428
BBB	PROPN	O	O	428
and	CCONJ	O	O	428
secondary	ADJ	O	O	428
reversal	NOUN	O	O	428
of	ADP	O	O	428
osmotic	NOUN	O	O	428
gradient	NOUN	O	O	428
is	AUX	O	O	428
considered	VERB	O	O	428
the	PRON	O	O	428
major	ADJ	O	O	428
cause	VERB	O	O	428
of	ADP	O	O	428
rebound	VERB	O	O	428
.	PUNCT	O	O	428
As	ADP	O	O	429
a	PRON	O	O	429
contribution	NOUN	O	O	429
to	PART	O	O	429
this	PRON	O	O	429
issue	NOUN	O	O	429
we	PRON	O	O	429
decided	VERB	O	O	429
to	PART	O	O	429
research	NOUN	O	O	429
the	PRON	O	O	429
possible	ADJ	O	O	429
passage	NOUN	O	O	429
of	ADP	O	O	429
mannitol	PROPN	O	Chemical	429
into	ADP	O	O	429
the	PRON	O	O	429
brain	NOUN	O	O	429
after	ADP	O	O	429
administration	NOUN	O	O	429
to	PART	O	O	429
21	NUM	O	O	429
brain tumor	NOUN	O	Disease	429
patients	NOUN	O	O	429
.	PUNCT	O	O	429
METHODS	NOUN	O	O	430
:	PUNCT	O	O	430
Mannitol	PROPN	O	Chemical	430
(	PUNCT	O	O	430
18%	NOUN	O	O	430
solution	NOUN	O	O	430
;	PUNCT	O	O	430
1	X	O	O	430
g	X	O	O	430
/	PUNCT	O	O	430
kg	VERB	O	O	430
)	PUNCT	O	O	430
was	AUX	O	O	430
administered	VERB	O	O	430
as	ADP	O	O	430
a	PRON	O	O	430
bolus	NOUN	O	O	430
to	PART	O	O	430
patients	NOUN	O	O	430
(	PUNCT	O	O	430
ten	NUM	O	O	430
had	VERB	O	O	430
malignant glioma	NOUN	O	Disease	430
,	PUNCT	O	O	430
seven	NUM	O	O	431
brain	NOUN	O	O	431
metastases	NOUN	O	Disease	431
and	CCONJ	O	O	431
four	NUM	O	O	431
meningioma	NOUN	O	Disease	431
)	PUNCT	O	O	431
about	ADP	O	O	431
30	NUM	O	O	431
minutes	NOUN	O	O	431
before	ADP	O	O	431
craniotomy	NOUN	O	O	431
.	PUNCT	O	O	431
During	ADP	O	O	432
resection	NOUN	O	O	432
,	PUNCT	O	O	432
a	PRON	O	O	432
sample	NOUN	O	O	432
of	ADP	O	O	432
the	PRON	O	O	432
surrounding	VERB	O	O	432
edematous	ADJ	O	Disease	432
white	ADJ	O	O	432
matter	VERB	O	O	432
was	AUX	O	O	432
taken	VERB	O	O	432
at	ADP	O	O	432
the	PRON	O	O	432
same	ADJ	O	O	432
time	NOUN	O	O	432
as	ADP	O	O	432
a	PRON	O	O	432
10	NUM	O	O	432
ml	ADP	O	O	432
venous	ADJ	O	O	432
blood	NOUN	O	O	432
sample	NOUN	O	O	432
.	PUNCT	O	O	432
Mannitol	PROPN	O	Chemical	433
concentrations	NOUN	O	O	433
were	AUX	O	O	433
measured	VERB	O	O	433
in	ADP	O	O	433
plasma	NOUN	O	O	433
and	CCONJ	O	O	433
white	ADJ	O	O	433
matter	VERB	O	O	433
by	ADP	O	O	433
a	PRON	O	O	433
modified	VERB	O	O	433
version	NOUN	O	O	433
of	ADP	O	O	433
the	PRON	O	O	433
enzyme	NOUN	O	O	433
assay	NOUN	O	O	433
of	ADP	O	O	433
Blonquist	NOUN	O	O	433
et	PRON	O	O	433
al	PROPN	O	O	433
.	PUNCT	O	O	433
In	ADP	O	O	434
most	ADV	O	O	434
glioma	NOUN	O	Disease	434
patients	NOUN	O	O	434
,	PUNCT	O	O	434
mannitol	PROPN	O	Chemical	434
concentrations	NOUN	O	O	434
in	ADP	O	O	434
white	ADJ	O	O	434
matter	VERB	O	O	434
were	AUX	O	O	434
2	X	O	O	434
to	PART	O	O	434
6	NUM	O	O	434
times	NOUN	O	O	434
higher	ADJ	O	O	434
than	ADP	O	O	434
in	ADP	O	O	434
plasma	NOUN	O	O	434
(	PUNCT	O	O	434
mean	VERB	O	O	434
3.5	NUM	O	O	434
times	NOUN	O	O	434
)	PUNCT	O	O	434
.	PUNCT	O	O	434
In	ADP	O	O	435
meningioma	NOUN	O	Disease	435
and	CCONJ	O	O	435
metastases	NOUN	O	Disease	435
patients	NOUN	O	O	435
plasma	NOUN	O	O	435
concentrations	NOUN	O	O	435
of	ADP	O	O	435
mannitol	PROPN	O	Chemical	435
were	AUX	O	O	435
higher	ADJ	O	O	435
than	ADP	O	O	435
white	ADJ	O	O	435
matter	VERB	O	O	435
concentrations	NOUN	O	O	435
except	SCONJ	O	O	435
in	ADP	O	O	435
three	NUM	O	O	435
cases	NOUN	O	O	435
with	ADP	O	O	435
infiltration	NOUN	O	O	435
by	ADP	O	O	435
neoplastic	ADJ	O	O	435
cells	NOUN	O	O	435
.	PUNCT	O	O	435
The	PRON	O	O	436
results	VERB	O	O	436
of	ADP	O	O	436
our	PRON	O	O	436
study	VERB	O	O	436
show	VERB	O	O	436
that	SCONJ	O	O	436
even	ADV	O	O	436
after	ADP	O	O	436
a	PRON	O	O	436
single	ADJ	O	O	436
bolus	NOUN	O	O	436
,	PUNCT	O	O	436
mannitol	PROPN	O	Chemical	436
may	AUX	O	O	436
leak	VERB	O	O	436
through	ADP	O	O	436
the	PRON	O	O	436
altered	VERB	O	O	436
BBB	PROPN	O	O	436
near	ADP	O	O	436
gliomas	NOUN	O	Disease	436
,	PUNCT	O	O	436
reversing	VERB	O	O	436
the	PRON	O	O	436
initial	ADJ	O	O	436
plasma	NOUN	O	O	436
-	PUNCT	O	O	436
to	PART	O	O	436
-	PUNCT	O	O	436
blood	NOUN	O	O	436
osmotic	NOUN	O	O	436
gradient	NOUN	O	O	436
,	PUNCT	O	O	436
aggravating	ADJ	O	O	436
peritumoral	PROPN	O	O	436
edema	NOUN	O	Disease	436
and	CCONJ	O	O	436
promoting	VERB	O	O	436
rebound	VERB	O	O	436
of	ADP	O	O	436
ICP	PROPN	O	O	436
.	PUNCT	O	O	436
Can	AUX	O	O	439
lidocaine	NOUN	O	Chemical	439
reduce	VERB	O	O	439
succinylcholine	NOUN	O	Chemical	439
induced	VERB	O	O	439
postoperative myalgia	NOUN	O	Disease	439
?	PUNCT	O	O	439
This	PRON	O	O	440
study	VERB	O	O	440
was	AUX	O	O	440
undertaken	VERB	O	O	440
to	PART	O	O	440
determine	VERB	O	O	440
the	PRON	O	O	440
effect	VERB	O	O	440
of	ADP	O	O	440
lidocaine	NOUN	O	Chemical	440
pretreatment	NOUN	O	O	440
on	ADP	O	O	440
reduction	NOUN	O	O	440
of	ADP	O	O	440
succinylcholine	NOUN	O	Chemical	440
-	PUNCT	O	O	440
induced	VERB	O	O	440
myalgia	NOUN	O	Disease	440
in	ADP	O	O	440
patients	NOUN	O	O	440
undergoing	VERB	O	O	440
general	ADJ	O	O	440
anesthesia	NOUN	O	O	440
for	ADP	O	O	440
gynecological	ADJ	O	O	440
surgery	NOUN	O	O	440
.	PUNCT	O	O	440
Group	PROPN	O	O	441
PS	PROPN	O	O	441
,	PUNCT	O	O	441
the	PRON	O	O	441
control	VERB	O	O	441
group	NOUN	O	O	441
,	PUNCT	O	O	441
received	VERB	O	O	441
normal	ADJ	O	O	441
saline	NOUN	O	O	441
and	CCONJ	O	O	441
succinylcholine	NOUN	O	Chemical	441
1.5	NUM	O	O	441
mg	VERB	O	O	441
x	X	O	O	441
kg(-1	NOUN	O	O	441
)	PUNCT	O	O	441
;	PUNCT	O	O	441
Group	PROPN	O	O	441
LS	PROPN	O	O	441
,	PUNCT	O	O	441
lidocaine	NOUN	O	Chemical	441
1.5	NUM	O	O	441
mg	VERB	O	O	441
x	X	O	O	441
kg(-1	NOUN	O	O	441
)	PUNCT	O	O	441
and	CCONJ	O	O	441
succinylcholine	NOUN	O	Chemical	441
1.5	NUM	O	O	441
mg	VERB	O	O	441
x	X	O	O	441
kg(-1	NOUN	O	O	441
)	PUNCT	O	O	441
;	PUNCT	O	O	441
Group	PROPN	O	O	441
PR	NOUN	O	O	441
,	PUNCT	O	O	441
normal	ADJ	O	O	441
saline	NOUN	O	O	441
and	CCONJ	O	O	441
rocuronium	NOUN	O	Chemical	441
0.6	NUM	O	O	441
mg	VERB	O	O	441
x	X	O	O	441
kg(-1	NOUN	O	O	441
)	PUNCT	O	O	441
.	PUNCT	O	O	441
Morphine	NOUN	O	Chemical	442
0.1	NUM	O	O	442
mg	VERB	O	O	442
x	X	O	O	442
kg(-1	NOUN	O	O	442
)	PUNCT	O	O	442
thiopental	NOUN	O	Chemical	443
iv	X	O	O	443
.	PUNCT	O	O	443
followed	VERB	O	O	444
by	ADP	O	O	444
succinylcholine	NOUN	O	Chemical	444
(	PUNCT	O	O	444
Group	PROPN	O	O	444
PS	PROPN	O	O	444
,	PUNCT	O	O	444
LS	PROPN	O	O	444
)	PUNCT	O	O	444
or	CCONJ	O	O	444
rocuronium	NOUN	O	Chemical	444
(	PUNCT	O	O	444
Group	PROPN	O	O	444
PR	NOUN	O	O	444
)	PUNCT	O	O	444
for	ADP	O	O	444
tracheal	NOUN	O	O	444
intubation	NOUN	O	O	444
.	PUNCT	O	O	444
Following	VERB	O	O	445
administration	NOUN	O	O	445
of	ADP	O	O	445
these	PRON	O	O	445
agents	NOUN	O	O	445
,	PUNCT	O	O	445
the	PRON	O	O	445
presence	NOUN	O	O	445
,	PUNCT	O	O	445
and	CCONJ	O	O	445
degree	PROPN	O	O	445
of	ADP	O	O	445
fasciculation	NOUN	O	Disease	445
were	AUX	O	O	445
assessed	VERB	O	O	445
visually	ADV	O	O	445
on	ADP	O	O	445
a	PRON	O	O	445
four	NUM	O	O	445
point	VERB	O	O	445
scale	NOUN	O	O	445
by	ADP	O	O	445
one	NUM	O	O	445
investigator	NOUN	O	O	445
who	PRON	O	O	445
was	AUX	O	O	445
blinded	VERB	O	O	445
to	PART	O	O	445
the	PRON	O	O	445
drug	NOUN	O	O	445
administered	VERB	O	O	445
.	PUNCT	O	O	445
Twenty	NUM	O	O	446
-	PUNCT	O	O	446
four	NUM	O	O	446
hours	NOUN	O	O	446
later	ADV	O	O	446
,	PUNCT	O	O	446
any	PRON	O	O	446
myalgia	NOUN	O	Disease	446
experienced	ADJ	O	O	446
was	AUX	O	O	446
assessed	VERB	O	O	446
according	VERB	O	O	446
to	PART	O	O	446
a	PRON	O	O	446
structured	VERB	O	O	446
questionaire	NOUN	O	O	446
and	CCONJ	O	O	446
graded	VERB	O	O	446
by	ADP	O	O	446
a	PRON	O	O	446
four	NUM	O	O	446
point	VERB	O	O	446
scale	NOUN	O	O	446
by	ADP	O	O	446
one	NUM	O	O	446
investigator	NOUN	O	O	446
blinded	VERB	O	O	446
to	PART	O	O	446
the	PRON	O	O	446
intraoperative	ADJ	O	O	446
management	NOUN	O	O	446
.	PUNCT	O	O	446
The	PRON	O	O	447
results	VERB	O	O	447
indicate	VERB	O	O	447
that	SCONJ	O	O	447
muscle fasciculation	NOUN	O	Disease	447
was	AUX	O	O	447
not	PART	O	O	447
found	VERB	O	O	447
in	ADP	O	O	447
Group	PROPN	O	O	447
PR	NOUN	O	O	447
while	SCONJ	O	O	447
the	PRON	O	O	447
patients	NOUN	O	O	447
in	ADP	O	O	447
Group	PROPN	O	O	447
LS	PROPN	O	O	447
had	VERB	O	O	447
a	PRON	O	O	447
lower	ADJ	O	O	447
incidence	NOUN	O	O	447
of	ADP	O	O	447
muscle fasciculation	NOUN	O	Disease	447
than	ADP	O	O	447
those	PRON	O	O	447
in	ADP	O	O	447
Group	PROPN	O	O	447
PS	PROPN	O	O	447
(	PUNCT	O	O	447
p	NOUN	O	O	447
At	ADP	O	O	448
24	NUM	O	O	448
h	X	O	O	448
,	PUNCT	O	O	448
the	PRON	O	O	448
incidence	NOUN	O	O	448
of	ADP	O	O	448
myalgia	NOUN	O	Disease	448
was	AUX	O	O	448
higher	ADJ	O	O	448
in	ADP	O	O	448
Group	PROPN	O	O	448
PS	PROPN	O	O	448
than	ADP	O	O	448
in	ADP	O	O	448
Group	PROPN	O	O	448
LS	PROPN	O	O	448
and	CCONJ	O	O	448
PR	NOUN	O	O	448
(	PUNCT	O	O	448
A	PRON	O	O	449
correlation	NOUN	O	O	449
was	AUX	O	O	449
not	PART	O	O	449
found	VERB	O	O	449
between	ADP	O	O	449
the	PRON	O	O	449
incidence	NOUN	O	O	449
of	ADP	O	O	449
myalgia	NOUN	O	Disease	449
and	CCONJ	O	O	449
the	PRON	O	O	449
occurrence	NOUN	O	O	449
of	ADP	O	O	449
muscle fasciculation	NOUN	O	Disease	449
.	PUNCT	O	O	449
In	ADP	O	O	450
conclusion	NOUN	O	O	450
,	PUNCT	O	O	450
where	SCONJ	O	O	450
succinylcholine	NOUN	O	Chemical	450
is	AUX	O	O	450
used	VERB	O	O	450
,	PUNCT	O	O	450
lidocaine	NOUN	O	Chemical	450
is	AUX	O	O	450
proven	VERB	O	O	450
to	PART	O	O	450
be	AUX	O	O	450
the	PRON	O	O	450
useful	ADJ	O	O	450
pretreatment	NOUN	O	O	450
agent	NOUN	O	O	450
for	ADP	O	O	450
the	PRON	O	O	450
reduction	NOUN	O	O	450
of	ADP	O	O	450
postoperative myalgia	NOUN	O	Disease	450
.	PUNCT	O	O	450
Open	VERB	O	O	453
-	PUNCT	O	O	453
label	PROPN	O	O	453
assessment	NOUN	O	O	453
of	ADP	O	O	453
levofloxacin	PROPN	O	Chemical	453
for	ADP	O	O	453
the	PRON	O	O	453
treatment	NOUN	O	O	453
of	ADP	O	O	453
acute	ADJ	O	O	453
bacterial	ADJ	O	O	453
sinusitis	PROPN	O	Disease	453
in	ADP	O	O	453
adults	NOUN	O	O	453
.	PUNCT	O	O	453
PURPOSE	NOUN	O	O	454
:	PUNCT	O	O	454
To	PART	O	O	454
evaluate	VERB	O	O	454
the	PRON	O	O	454
efficacy	NOUN	O	O	454
and	CCONJ	O	O	454
safety	NOUN	O	O	454
of	ADP	O	O	454
levofloxacin	PROPN	O	Chemical	454
(	PUNCT	O	O	454
500	NUM	O	O	454
mg	VERB	O	O	454
orally	ADV	O	O	454
once	ADV	O	O	454
daily	ADV	O	O	454
for	ADP	O	O	454
10	NUM	O	O	454
to	PART	O	O	454
14	NUM	O	O	454
days	NOUN	O	O	454
)	PUNCT	O	O	454
in	ADP	O	O	454
treating	VERB	O	O	454
adult	NOUN	O	O	454
outpatients	NOUN	O	O	454
with	ADP	O	O	454
acute	ADJ	O	O	454
bacterial	ADJ	O	O	454
sinusitis	PROPN	O	Disease	454
.	PUNCT	O	O	454
Adverse	ADJ	O	O	455
events	NOUN	O	O	455
considered	VERB	O	O	455
to	PART	O	O	455
be	AUX	O	O	455
related	ADJ	O	O	455
to	PART	O	O	455
levofloxacin	PROPN	O	Chemical	455
administration	NOUN	O	O	455
were	AUX	O	O	455
reported	VERB	O	O	455
by	ADP	O	O	455
29	NUM	O	O	455
patients	NOUN	O	O	455
(	PUNCT	O	O	455
9%	NOUN	O	O	455
)	PUNCT	O	O	455
.	PUNCT	O	O	455
The	PRON	O	O	456
most	ADV	O	O	456
common	ADJ	O	O	456
drug	NOUN	O	O	456
-	PUNCT	O	O	456
related	ADJ	O	O	456
adverse	ADJ	O	O	456
events	NOUN	O	O	456
were	AUX	O	O	456
diarrhea	PROPN	O	Disease	456
,	PUNCT	O	O	456
flatulence	NOUN	O	Disease	456
,	PUNCT	O	O	456
and	CCONJ	O	O	456
nausea	NOUN	O	Disease	456
;	PUNCT	O	O	456
most	ADV	O	O	456
adverse	ADJ	O	O	456
events	NOUN	O	O	456
were	AUX	O	O	456
mild	ADJ	O	O	456
to	PART	O	O	456
moderate	ADJ	O	O	456
in	ADP	O	O	456
severity	NOUN	O	O	456
.	PUNCT	O	O	456
The	PRON	O	O	457
results	VERB	O	O	457
of	ADP	O	O	457
this	PRON	O	O	457
study	VERB	O	O	457
indicate	VERB	O	O	457
that	SCONJ	O	O	457
levofloxacin	PROPN	O	Chemical	457
500	NUM	O	O	457
mg	VERB	O	O	457
once	ADV	O	O	457
daily	ADV	O	O	457
is	AUX	O	O	457
an	PRON	O	O	457
effective	ADJ	O	O	457
and	CCONJ	O	O	457
safe	ADJ	O	O	457
treatment	NOUN	O	O	457
for	ADP	O	O	457
acute	ADJ	O	O	457
bacterial	ADJ	O	O	457
sinusitis	PROPN	O	Disease	457
.	PUNCT	O	O	457
Clinical	NOUN	O	O	460
evaluation	NOUN	O	O	460
on	ADP	O	O	460
combined	VERB	O	O	460
administration	NOUN	O	O	460
of	ADP	O	O	460
oral	ADJ	O	O	460
prostacyclin	NOUN	O	Chemical	460
analogue	NOUN	O	O	460
beraprost	PROPN	O	Chemical	460
and	CCONJ	O	O	460
phosphodiesterase	NOUN	O	O	460
inhibitor	NOUN	O	O	460
cilostazol	ADJ	O	Chemical	460
.	PUNCT	O	O	460
Among	ADP	O	O	461
various	ADJ	O	O	461
oral	ADJ	O	O	461
antiplatelets	NOUN	O	O	461
,	PUNCT	O	O	461
a	PRON	O	O	461
combination	NOUN	O	O	461
of	ADP	O	O	461
a	PRON	O	O	461
novel	NOUN	O	O	461
prostacyclin	NOUN	O	Chemical	461
analogue	NOUN	O	O	461
beraprost	PROPN	O	Chemical	461
(	PUNCT	O	O	461
BPT	PROPN	O	Chemical	461
)	PUNCT	O	O	461
and	CCONJ	O	O	461
a	PRON	O	O	461
potent	ADJ	O	O	461
phosphodiesterase	NOUN	O	O	461
inhibitor	NOUN	O	O	461
cilostazol	ADJ	O	Chemical	461
(	PUNCT	O	O	461
CLZ	PROPN	O	Chemical	461
)	PUNCT	O	O	461
may	AUX	O	O	461
result	VERB	O	O	461
in	ADP	O	O	461
untoward	ADJ	O	O	461
clinical	ADJ	O	O	461
effects	NOUN	O	O	461
due	ADJ	O	O	461
to	PART	O	O	461
possible	ADJ	O	O	461
synergistic	ADJ	O	O	461
elevation	NOUN	O	O	461
of	ADP	O	O	461
intracellular	ADJ	O	O	461
cAMP	NOUN	O	Chemical	461
(	PUNCT	O	O	461
cyclic adenosine 3',5'-monophosphate	NOUN	O	Chemical	461
)	PUNCT	O	O	461
.	PUNCT	O	O	461
Twelve	NUM	O	O	462
healthy	ADJ	O	O	462
volunteers	NOUN	O	O	462
were	AUX	O	O	462
assigned	VERB	O	O	462
to	PART	O	O	462
take	VERB	O	O	462
BPT	PROPN	O	Chemical	462
/	PUNCT	O	O	462
CLZ	PROPN	O	Chemical	462
in	ADP	O	O	462
the	PRON	O	O	462
following	VERB	O	O	462
schedule	NOUN	O	O	462
;	PUNCT	O	O	462
BPT	PROPN	O	Chemical	462
:	PUNCT	O	O	462
40	NUM	O	O	462
micrograms	NOUN	O	O	462
at	ADP	O	O	462
day	NOUN	O	O	462
1	X	O	O	462
and	CCONJ	O	O	462
120	NUM	O	O	462
micrograms	NOUN	O	O	462
t.i.d	ADJ	O	O	462
.	PUNCT	O	O	462
from	ADP	O	O	463
day	NOUN	O	O	463
7	NUM	O	O	463
to	PART	O	O	463
14	NUM	O	O	463
,	PUNCT	O	O	463
CLZ	PROPN	O	Chemical	463
:	PUNCT	O	O	463
200	NUM	O	O	463
mg	VERB	O	O	463
t.i.d	ADJ	O	O	463
.	PUNCT	O	O	463
At	ADP	O	O	464
various	ADJ	O	O	464
time	NOUN	O	O	464
intervals	NOUN	O	O	464
,	PUNCT	O	O	464
physical	ADJ	O	O	464
examination	NOUN	O	O	464
and	CCONJ	O	O	464
blood	NOUN	O	O	464
collection	NOUN	O	O	464
for	ADP	O	O	464
ex	PRON	O	O	464
vivo	VERB	O	O	464
platelet aggregation	NOUN	O	Disease	464
and	CCONJ	O	O	464
determination	NOUN	O	O	464
of	ADP	O	O	464
intraplatelet	NOUN	O	O	464
cAMP	NOUN	O	Chemical	464
were	AUX	O	O	464
performed	VERB	O	O	464
.	PUNCT	O	O	464
Seven	NUM	O	O	465
out	ADP	O	O	465
of	ADP	O	O	465
12	NUM	O	O	465
subjects	NOUN	O	O	465
experienced	ADJ	O	O	465
headache	PROPN	O	Disease	465
of	ADP	O	O	465
a	PRON	O	O	465
short	ADJ	O	O	465
duration	NOUN	O	O	465
accompanying	VERB	O	O	465
facial flush	NOUN	O	Disease	465
in	ADP	O	O	465
one	NUM	O	O	465
and	CCONJ	O	O	465
nausea	NOUN	O	Disease	465
in	ADP	O	O	465
one	NUM	O	O	465
,	PUNCT	O	O	465
especially	ADV	O	O	465
after	ADP	O	O	465
ingestion	NOUN	O	O	465
of	ADP	O	O	465
CLZ	PROPN	O	Chemical	465
.	PUNCT	O	O	465
Intraplatelet	PROPN	O	O	466
cAMP	NOUN	O	Chemical	466
content	NOUN	O	O	466
was	AUX	O	O	466
gradually	ADV	O	O	466
but	CCONJ	O	O	466
significantly	ADV	O	O	466
increased	VERB	O	O	466
to	PART	O	O	466
9.84	NUM	O	O	466
+	ADP	O	O	466
/-	PUNCT	O	O	466
In	ADP	O	O	467
conclusion	NOUN	O	O	467
,	PUNCT	O	O	467
the	PRON	O	O	467
combined	VERB	O	O	467
administration	NOUN	O	O	467
of	ADP	O	O	467
BPT	PROPN	O	Chemical	467
/	PUNCT	O	O	467
CLZ	PROPN	O	Chemical	467
is	AUX	O	O	467
safe	ADJ	O	O	467
at	ADP	O	O	467
doses	NOUN	O	O	467
used	VERB	O	O	467
in	ADP	O	O	467
the	PRON	O	O	467
study	VERB	O	O	467
,	PUNCT	O	O	467
though	SCONJ	O	O	467
the	PRON	O	O	467
beneficial	ADJ	O	O	467
clinical	ADJ	O	O	467
effect	VERB	O	O	467
of	ADP	O	O	467
the	PRON	O	O	467
combined	VERB	O	O	467
administration	NOUN	O	O	467
has	VERB	O	O	467
yet	ADV	O	O	467
to	PART	O	O	467
be	AUX	O	O	467
elucidated	VERB	O	O	467
.	PUNCT	O	O	467
Gastrointestinal	ADJ	O	O	470
tolerability	NOUN	O	O	470
of	ADP	O	O	470
etoricoxib	NOUN	O	Chemical	470
in	ADP	O	O	470
rheumatoid arthritis	NOUN	O	Disease	470
patients	NOUN	O	O	470
:	PUNCT	O	O	470
results	VERB	O	O	470
of	ADP	O	O	470
the	PRON	O	O	470
etoricoxib	NOUN	O	Chemical	470
vs	ADP	O	O	470
diclofenac sodium	NOUN	O	Chemical	470
gastrointestinal	ADJ	O	O	470
tolerability	NOUN	O	O	470
and	CCONJ	O	O	470
effectiveness	NOUN	O	O	470
trial	NOUN	O	O	470
(	PUNCT	O	O	470
EDGE	NOUN	O	O	470
-	PUNCT	O	O	470
II	NUM	O	O	470
)	PUNCT	O	O	470
.	PUNCT	O	O	470
OBJECTIVE	VERB	O	O	471
:	PUNCT	O	O	471
A	PRON	O	O	471
randomised	VERB	O	O	471
,	PUNCT	O	O	471
double	ADJ	O	O	471
-	PUNCT	O	O	471
blind	ADJ	O	Disease	471
study	VERB	O	O	471
to	PART	O	O	471
compare	VERB	O	O	471
the	PRON	O	O	471
gastrointestinal	ADJ	O	O	471
(	PUNCT	O	O	471
GI	PROPN	O	O	471
)	PUNCT	O	O	471
tolerability	NOUN	O	O	471
,	PUNCT	O	O	471
safety	NOUN	O	O	471
and	CCONJ	O	O	471
efficacy	NOUN	O	O	471
of	ADP	O	O	471
etoricoxib	NOUN	O	Chemical	471
and	CCONJ	O	O	471
diclofenac	PROPN	O	Chemical	471
in	ADP	O	O	471
patients	NOUN	O	O	471
with	ADP	O	O	471
rheumatoid arthritis	NOUN	O	Disease	471
(	PUNCT	O	O	471
RA	PROPN	O	Disease	471
)	PUNCT	O	O	471
.	PUNCT	O	O	471
A	PRON	O	O	472
total	ADJ	O	O	472
of	ADP	O	O	472
4086	NUM	O	O	472
patients	NOUN	O	O	472
(	PUNCT	O	O	472
mean	VERB	O	O	472
age	NOUN	O	O	472
60.8	NUM	O	O	472
years	NOUN	O	O	472
)	PUNCT	O	O	472
diagnosed	VERB	O	O	472
with	ADP	O	O	472
RA	PROPN	O	Disease	472
were	AUX	O	O	472
enrolled	VERB	O	O	472
and	CCONJ	O	O	472
received	VERB	O	O	472
etoricoxib	NOUN	O	Chemical	472
90	NUM	O	O	472
mg	VERB	O	O	472
daily	ADV	O	O	472
(	PUNCT	O	O	472
n	CCONJ	O	O	472
=	PUNCT	O	O	472
2032	NUM	O	O	472
)	PUNCT	O	O	472
or	CCONJ	O	O	472
diclofenac	PROPN	O	Chemical	472
75	NUM	O	O	472
mg	VERB	O	O	472
twice	ADV	O	O	472
daily	ADV	O	O	472
(	PUNCT	O	O	472
n	CCONJ	O	O	472
=	PUNCT	O	O	472
2054	NUM	O	O	472
)	PUNCT	O	O	472
.	PUNCT	O	O	472
Use	VERB	O	O	473
of	ADP	O	O	473
gastroprotective	PROPN	O	O	473
agents	NOUN	O	O	473
and	CCONJ	O	O	473
low	ADJ	O	O	473
-	PUNCT	O	O	473
dose	NOUN	O	O	473
aspirin	NOUN	O	Chemical	473
was	AUX	O	O	473
allowed	VERB	O	O	473
.	PUNCT	O	O	473
General	ADJ	O	O	474
safety	NOUN	O	O	474
was	AUX	O	O	474
also	ADV	O	O	474
assessed	VERB	O	O	474
,	PUNCT	O	O	474
including	VERB	O	O	474
adjudicated	VERB	O	O	474
thrombotic cardiovascular	NOUN	O	Disease	474
event	NOUN	O	O	474
data	NOUN	O	O	474
.	PUNCT	O	O	474
;	PUNCT	O	O	475
maximum	ADV	O	O	475
)	PUNCT	O	O	475
duration	NOUN	O	O	475
of	ADP	O	O	475
treatment	NOUN	O	O	475
was	AUX	O	O	475
19.3	NUM	O	O	475
(	PUNCT	O	O	475
10.3	NUM	O	O	475
;	PUNCT	O	O	475
32.9	NUM	O	O	475
)	PUNCT	O	O	475
and	CCONJ	O	O	475
19.1	NUM	O	O	475
(	PUNCT	O	O	475
10.4	NUM	O	O	475
;	PUNCT	O	O	475
33.1	NUM	O	O	475
)	PUNCT	O	O	475
months	NOUN	O	O	475
in	ADP	O	O	475
the	PRON	O	O	475
etoricoxib	NOUN	O	Chemical	475
and	CCONJ	O	O	475
diclofenac	PROPN	O	Chemical	475
groups	NOUN	O	O	475
,	PUNCT	O	O	475
respectively	ADV	O	O	475
.	PUNCT	O	O	475
The	PRON	O	O	476
cumulative	ADJ	O	O	476
discontinuation	NOUN	O	O	476
rate	NOUN	O	O	476
due	ADJ	O	O	476
to	PART	O	O	476
GI AEs	NOUN	O	Disease	476
was	AUX	O	O	476
significantly	ADV	O	O	476
lower	ADJ	O	O	476
with	ADP	O	O	476
etoricoxib	NOUN	O	Chemical	476
than	ADP	O	O	476
diclofenac	PROPN	O	Chemical	476
(	PUNCT	O	O	476
5.2	NUM	O	O	476
vs	ADP	O	O	476
8.5	NUM	O	O	476
events	NOUN	O	O	476
per	ADP	O	O	476
100	NUM	O	O	476
patient	NOUN	O	O	476
-	PUNCT	O	O	476
years	NOUN	O	O	476
,	PUNCT	O	O	476
respectively	ADV	O	O	476
;	PUNCT	O	O	476
hazard	NOUN	O	O	476
ratio	NOUN	O	O	476
0.62	NUM	O	O	476
(	PUNCT	O	O	476
95%	NOUN	O	O	476
CI	NOUN	O	O	476
:	PUNCT	O	O	476
0.47	NUM	O	O	476
,	PUNCT	O	O	476
0.81	NUM	O	O	476
;	PUNCT	O	O	476
p	NOUN	O	O	476
<	X	O	O	476
The	PRON	O	O	477
incidence	NOUN	O	O	477
of	ADP	O	O	477
discontinuations	NOUN	O	O	477
for	ADP	O	O	477
hypertension	NOUN	O	Disease	477
-	PUNCT	O	O	477
related	ADJ	O	O	477
and	CCONJ	O	O	477
oedema	NOUN	O	Disease	477
-	PUNCT	O	O	477
related	ADJ	O	O	477
AEs	PROPN	O	O	477
were	AUX	O	O	477
significantly	ADV	O	O	477
higher	ADJ	O	O	477
with	ADP	O	O	477
etoricoxib	NOUN	O	Chemical	477
(	PUNCT	O	O	477
2.5%	NOUN	O	O	477
and	CCONJ	O	O	477
1.1%	NOUN	O	O	477
respectively	ADV	O	O	477
)	PUNCT	O	O	477
compared	VERB	O	O	477
with	ADP	O	O	477
diclofenac	PROPN	O	Chemical	477
(	PUNCT	O	O	477
1.5%	NOUN	O	O	477
and	CCONJ	O	O	477
0.4%	NOUN	O	O	477
respectively	ADV	O	O	477
;	PUNCT	O	O	477
p<0.001	ADJ	O	O	477
for	ADP	O	O	477
hypertension	NOUN	O	Disease	477
and	CCONJ	O	O	477
p<0.01	ADV	O	O	477
for	ADP	O	O	477
oedema	NOUN	O	Disease	477
)	PUNCT	O	O	477
.	PUNCT	O	O	477
Etoricoxib	PROPN	O	Chemical	478
and	CCONJ	O	O	478
diclofenac	PROPN	O	Chemical	478
treatment	NOUN	O	O	478
resulted	VERB	O	O	478
in	ADP	O	O	478
similar	ADJ	O	O	478
efficacy	NOUN	O	O	478
(	PUNCT	O	O	478
PGADS	PROPN	O	O	478
mean	VERB	O	O	478
changes	VERB	O	O	478
from	ADP	O	O	478
baseline	VERB	O	O	478
-0.62	X	O	O	478
vs	ADP	O	O	478
-0.58	NUM	O	O	478
,	PUNCT	O	O	478
respectively	ADV	O	O	478
)	PUNCT	O	O	478
.	PUNCT	O	O	478
Etoricoxib	PROPN	O	Chemical	479
90	NUM	O	O	479
mg	VERB	O	O	479
demonstrated	VERB	O	O	479
a	PRON	O	O	479
significantly	ADV	O	O	479
lower	ADJ	O	O	479
risk	NOUN	O	O	479
for	ADP	O	O	479
discontinuing	VERB	O	O	479
treatment	NOUN	O	O	479
due	ADJ	O	O	479
to	PART	O	O	479
GI AEs	NOUN	O	Disease	479
compared	VERB	O	O	479
with	ADP	O	O	479
diclofenac	PROPN	O	Chemical	479
150	NUM	O	O	479
mg	VERB	O	O	479
.	PUNCT	O	O	479
Discontinuations	NOUN	O	O	480
from	ADP	O	O	480
renovascular	NOUN	O	O	480
AEs	PROPN	O	O	480
,	PUNCT	O	O	480
although	SCONJ	O	O	480
less	ADV	O	O	480
common	ADJ	O	O	480
than	ADP	O	O	480
discontinuations	NOUN	O	O	480
from	ADP	O	O	480
GI AEs	NOUN	O	Disease	480
,	PUNCT	O	O	480
were	AUX	O	O	480
significantly	ADV	O	O	480
higher	ADJ	O	O	480
with	ADP	O	O	480
etoricoxib	NOUN	O	Chemical	480
.	PUNCT	O	O	480
Placebo	NOUN	O	O	483
-	PUNCT	O	O	483
level	VERB	O	O	483
incidence	NOUN	O	O	483
of	ADP	O	O	483
extrapyramidal symptoms	NOUN	O	Disease	483
(	PUNCT	O	O	483
EPS	PROPN	O	Disease	483
)	PUNCT	O	O	483
with	ADP	O	O	483
quetiapine	ADV	O	Chemical	483
in	ADP	O	O	483
controlled	VERB	O	O	483
studies	NOUN	O	O	483
of	ADP	O	O	483
patients	NOUN	O	O	483
with	ADP	O	O	483
bipolar mania	NOUN	O	Disease	483
.	PUNCT	O	O	483
OBJECTIVES	NOUN	O	O	484
:	PUNCT	O	O	484
To	PART	O	O	484
evaluate	VERB	O	O	484
extrapyramidal symptoms	NOUN	O	Disease	484
(	PUNCT	O	O	484
EPS	PROPN	O	Disease	484
)	PUNCT	O	O	484
,	PUNCT	O	O	484
including	VERB	O	O	484
akathisia	PROPN	O	Disease	484
,	PUNCT	O	O	484
with	ADP	O	O	484
quetiapine	ADV	O	Chemical	484
in	ADP	O	O	484
patients	NOUN	O	O	484
with	ADP	O	O	484
bipolar mania	NOUN	O	Disease	484
.	PUNCT	O	O	484
Two	NUM	O	O	485
studies	NOUN	O	O	485
evaluated	VERB	O	O	485
quetiapine	ADV	O	Chemical	485
monotherapy	X	O	O	485
(	PUNCT	O	O	485
up	ADP	O	O	485
to	PART	O	O	485
800	NUM	O	O	485
mg	VERB	O	O	485
/	PUNCT	O	O	485
day	NOUN	O	O	485
)	PUNCT	O	O	485
(	PUNCT	O	O	485
n	CCONJ	O	O	485
=	PUNCT	O	O	485
209	NUM	O	O	485
)	PUNCT	O	O	485
versus	ADP	O	O	485
placebo	NOUN	O	O	485
(	PUNCT	O	O	485
n	CCONJ	O	O	485
=	PUNCT	O	O	485
198	NUM	O	O	485
)	PUNCT	O	O	485
,	PUNCT	O	O	485
with	ADP	O	O	485
lithium	NOUN	O	Chemical	485
or	CCONJ	O	O	485
haloperidol	NOUN	O	Chemical	485
monotherapy	X	O	O	485
as	ADP	O	O	485
respective	ADJ	O	O	485
active	ADJ	O	O	485
controls	VERB	O	O	485
.	PUNCT	O	O	485
Two	NUM	O	O	486
studies	NOUN	O	O	486
evaluated	VERB	O	O	486
quetiapine	ADV	O	Chemical	486
(	PUNCT	O	O	486
up	ADP	O	O	486
to	PART	O	O	486
800	NUM	O	O	486
mg	VERB	O	O	486
/	PUNCT	O	O	486
day	NOUN	O	O	486
)	PUNCT	O	O	486
in	ADP	O	O	486
combination	NOUN	O	O	486
with	ADP	O	O	486
a	PRON	O	O	486
mood	NOUN	O	O	486
stabilizer	NOUN	O	O	486
(	PUNCT	O	O	486
lithium	NOUN	O	Chemical	486
or	CCONJ	O	O	486
divalproex	PROPN	O	Chemical	486
,	PUNCT	O	O	486
QTP	ADV	O	Chemical	486
+	ADP	O	O	487
Li	PROPN	O	Chemical	487
/	PUNCT	O	O	487
DVP	PROPN	O	Chemical	487
)	PUNCT	O	O	487
(	PUNCT	O	O	487
n	CCONJ	O	O	487
=	PUNCT	O	O	487
196	NUM	O	O	487
)	PUNCT	O	O	487
compared	VERB	O	O	487
to	PART	O	O	487
placebo	NOUN	O	O	487
and	CCONJ	O	O	487
mood	NOUN	O	O	487
stabilizer	NOUN	O	O	487
(	PUNCT	O	O	487
PBO	PROPN	O	O	487
+	ADP	O	O	488
Li	PROPN	O	Chemical	488
/	PUNCT	O	O	488
DVP	PROPN	O	Chemical	488
)	PUNCT	O	O	488
(	PUNCT	O	O	488
n	CCONJ	O	O	488
=	PUNCT	O	O	488
203	NUM	O	O	488
)	PUNCT	O	O	488
.	PUNCT	O	O	488
Extrapyramidal symptoms	NOUN	O	Disease	489
were	AUX	O	O	489
evaluated	VERB	O	O	489
using	VERB	O	O	489
the	PRON	O	O	489
Simpson	PROPN	O	O	489
-	PUNCT	O	O	489
Angus	PROPN	O	O	489
Scale	NOUN	O	O	489
(	PUNCT	O	O	489
SAS	PROPN	O	O	489
)	PUNCT	O	O	489
,	PUNCT	O	O	489
the	PRON	O	O	489
Barnes	PROPN	O	O	489
Akathisia	PROPN	O	Disease	489
Rating	NOUN	O	O	489
Scale	NOUN	O	O	489
(	PUNCT	O	O	489
BARS	NOUN	O	O	489
)	PUNCT	O	O	489
,	PUNCT	O	O	489
adverse	ADJ	O	O	489
event	NOUN	O	O	489
reports	VERB	O	O	489
and	CCONJ	O	O	489
anticholinergic	ADJ	O	O	489
drug	NOUN	O	O	489
usage	NOUN	O	O	489
.	PUNCT	O	O	489
The	PRON	O	O	490
incidence	NOUN	O	O	490
of	ADP	O	O	490
EPS	PROPN	O	Disease	490
-	PUNCT	O	O	490
related	ADJ	O	O	490
adverse	ADJ	O	O	490
events	NOUN	O	O	490
,	PUNCT	O	O	490
including	VERB	O	O	490
akathisia	PROPN	O	Disease	490
,	PUNCT	O	O	490
was	AUX	O	O	490
no	PRON	O	O	490
different	ADJ	O	O	490
with	ADP	O	O	490
quetiapine	ADV	O	Chemical	490
monotherapy	X	O	O	490
(	PUNCT	O	O	490
12.9%	NOUN	O	O	490
)	PUNCT	O	O	490
than	ADP	O	O	490
with	ADP	O	O	490
placebo	NOUN	O	O	490
(	PUNCT	O	O	490
13.1%	NOUN	O	O	490
)	PUNCT	O	O	490
.	PUNCT	O	O	490
Similarly	ADV	O	O	491
,	PUNCT	O	O	491
EPS	PROPN	O	Disease	491
-	PUNCT	O	O	491
related	ADJ	O	O	491
adverse	ADJ	O	O	491
events	NOUN	O	O	491
with	ADP	O	O	491
QTP	ADV	O	Chemical	491
+	ADP	O	O	491
Li	PROPN	O	Chemical	491
/	PUNCT	O	O	491
DVP	PROPN	O	Chemical	491
(	PUNCT	O	O	491
21.4%	NOUN	O	O	491
)	PUNCT	O	O	491
were	AUX	O	O	491
no	PRON	O	O	491
different	ADJ	O	O	491
than	ADP	O	O	491
with	ADP	O	O	491
PBO	PROPN	O	O	491
+	ADP	O	O	491
Li	PROPN	O	Chemical	491
/	PUNCT	O	O	491
DVP	PROPN	O	Chemical	491
(	PUNCT	O	O	491
19.2%	NOUN	O	O	491
)	PUNCT	O	O	491
.	PUNCT	O	O	491
Adverse	ADJ	O	O	492
events	NOUN	O	O	492
related	ADJ	O	O	492
to	PART	O	O	492
EPS	PROPN	O	Disease	492
occurred	VERB	O	O	492
in	ADP	O	O	492
59.6%	NOUN	O	O	492
of	ADP	O	O	492
patients	NOUN	O	O	492
treated	VERB	O	O	492
with	ADP	O	O	492
haloperidol	NOUN	O	Chemical	492
(	PUNCT	O	O	492
n	CCONJ	O	O	493
=	PUNCT	O	O	493
99	NUM	O	O	493
)	PUNCT	O	O	493
monotherapy	X	O	O	493
,	PUNCT	O	O	493
whereas	SCONJ	O	O	493
26.5%	NOUN	O	O	493
of	ADP	O	O	493
patients	NOUN	O	O	493
treated	VERB	O	O	493
with	ADP	O	O	493
lithium	NOUN	O	Chemical	493
(	PUNCT	O	O	493
n	CCONJ	O	O	494
=	PUNCT	O	O	494
98	NUM	O	O	494
)	PUNCT	O	O	494
monotherapy	X	O	O	494
experienced	ADJ	O	O	494
adverse	ADJ	O	O	494
events	NOUN	O	O	494
related	ADJ	O	O	494
to	PART	O	O	494
EPS	PROPN	O	Disease	494
.	PUNCT	O	O	494
The	PRON	O	O	495
incidence	NOUN	O	O	495
of	ADP	O	O	495
akathisia	PROPN	O	Disease	495
was	AUX	O	O	495
low	ADJ	O	O	495
and	CCONJ	O	O	495
similar	ADJ	O	O	495
with	ADP	O	O	495
quetiapine	ADV	O	Chemical	495
monotherapy	X	O	O	495
(	PUNCT	O	O	495
3.3%	NOUN	O	O	495
)	PUNCT	O	O	495
and	CCONJ	O	O	495
placebo	NOUN	O	O	495
(	PUNCT	O	O	495
6.1%	NOUN	O	O	495
)	PUNCT	O	O	495
,	PUNCT	O	O	495
and	CCONJ	O	O	495
with	ADP	O	O	495
QTP	ADV	O	Chemical	495
+	ADP	O	O	495
Li	PROPN	O	Chemical	495
/	PUNCT	O	O	495
DVP	PROPN	O	Chemical	495
(	PUNCT	O	O	495
3.6%	NOUN	O	O	495
)	PUNCT	O	O	495
and	CCONJ	O	O	495
PBO	PROPN	O	O	495
+	ADP	O	O	495
Li	PROPN	O	Chemical	495
/	PUNCT	O	O	495
DVP	PROPN	O	Chemical	495
(	PUNCT	O	O	495
4.9%	NOUN	O	O	495
)	PUNCT	O	O	495
.	PUNCT	O	O	495
Lithium	NOUN	O	Chemical	496
was	AUX	O	O	496
associated	VERB	O	O	496
with	ADP	O	O	496
a	PRON	O	O	496
significantly	ADV	O	O	496
higher	ADJ	O	O	496
incidence	NOUN	O	O	496
(	PUNCT	O	O	496
p	NOUN	O	O	496
<	X	O	O	496
0.05	NUM	O	O	496
)	PUNCT	O	O	496
of	ADP	O	O	496
tremor	NOUN	O	Disease	496
(	PUNCT	O	O	496
18.4%	NOUN	O	O	496
)	PUNCT	O	O	496
than	ADP	O	O	496
quetiapine	ADV	O	Chemical	496
(	PUNCT	O	O	496
5.6%	NOUN	O	O	496
)	PUNCT	O	O	496
;	PUNCT	O	O	496
cerebellar	ADJ	O	O	496
tremor	NOUN	O	Disease	496
,	PUNCT	O	O	496
which	PRON	O	O	496
is	AUX	O	O	496
a	PRON	O	O	496
known	VERB	O	O	496
adverse	ADJ	O	O	496
effect	VERB	O	O	496
of	ADP	O	O	496
lithium	NOUN	O	Chemical	496
,	PUNCT	O	O	496
may	AUX	O	O	496
have	VERB	O	O	496
contributed	VERB	O	O	496
to	PART	O	O	496
the	PRON	O	O	496
elevated	ADJ	O	O	496
rate	NOUN	O	O	496
of	ADP	O	O	496
tremor	NOUN	O	Disease	496
in	ADP	O	O	496
patients	NOUN	O	O	496
receiving	VERB	O	O	496
lithium	NOUN	O	Chemical	496
therapy	NOUN	O	O	496
.	PUNCT	O	O	496
Haloperidol	NOUN	O	Chemical	497
induced	VERB	O	O	497
a	PRON	O	O	497
significantly	ADV	O	O	497
higher	ADJ	O	O	497
incidence	NOUN	O	O	497
(	PUNCT	O	O	497
p	NOUN	O	O	497
<	X	O	O	498
0.001	NUM	O	O	498
)	PUNCT	O	O	498
of	ADP	O	O	498
akathisia	PROPN	O	Disease	498
(	PUNCT	O	O	498
33.3%	NOUN	O	O	498
versus	ADP	O	O	498
5.9%	NOUN	O	O	498
)	PUNCT	O	O	498
,	PUNCT	O	O	498
tremor	NOUN	O	Disease	498
(	PUNCT	O	O	498
30.3%	NOUN	O	O	498
versus	ADP	O	O	498
7.8%	NOUN	O	O	498
)	PUNCT	O	O	498
,	PUNCT	O	O	498
and	CCONJ	O	O	498
extrapyramidal syndrome	NOUN	O	Disease	498
(	PUNCT	O	O	498
35.4%	NOUN	O	O	498
versus	ADP	O	O	498
5.9%	NOUN	O	O	498
)	PUNCT	O	O	498
than	ADP	O	O	498
quetiapine	ADV	O	Chemical	498
.	PUNCT	O	O	498
No	PRON	O	O	499
significant	ADJ	O	O	499
differences	NOUN	O	O	499
were	AUX	O	O	499
observed	VERB	O	O	499
between	ADP	O	O	499
quetiapine	ADV	O	Chemical	499
and	CCONJ	O	O	499
placebo	NOUN	O	O	499
on	ADP	O	O	499
SAS	PROPN	O	O	499
and	CCONJ	O	O	499
BARS	NOUN	O	O	499
scores	NOUN	O	O	499
.	PUNCT	O	O	499
Anticholinergic	PROPN	O	O	500
use	VERB	O	O	500
was	AUX	O	O	500
low	ADJ	O	O	500
and	CCONJ	O	O	500
similar	ADJ	O	O	500
with	ADP	O	O	500
quetiapine	ADV	O	Chemical	500
or	CCONJ	O	O	500
placebo	NOUN	O	O	500
.	PUNCT	O	O	500
In	ADP	O	O	501
bipolar mania	NOUN	O	Disease	501
,	PUNCT	O	O	501
the	PRON	O	O	501
incidence	NOUN	O	O	501
of	ADP	O	O	501
EPS	PROPN	O	Disease	501
,	PUNCT	O	O	501
including	VERB	O	O	501
akathisia	PROPN	O	Disease	501
,	PUNCT	O	O	501
with	ADP	O	O	501
quetiapine	ADV	O	Chemical	501
therapy	NOUN	O	O	501
is	AUX	O	O	501
similar	ADJ	O	O	501
to	PART	O	O	501
that	SCONJ	O	O	501
with	ADP	O	O	501
placebo	NOUN	O	O	501
.	PUNCT	O	O	501
Contribution	NOUN	O	O	504
of	ADP	O	O	504
the	PRON	O	O	504
sympathetic	ADJ	O	O	504
nervous	ADJ	O	O	504
system	NOUN	O	O	504
to	PART	O	O	504
salt	NOUN	O	O	504
-	PUNCT	O	O	504
sensitivity	NOUN	O	O	504
in	ADP	O	O	504
lifetime	NOUN	O	O	504
captopril	PROPN	O	Chemical	504
-	PUNCT	O	O	504
treated	VERB	O	O	504
spontaneously	ADV	O	O	504
hypertensive	ADJ	O	Disease	504
rats	NOUN	O	O	504
.	PUNCT	O	O	504
OBJECTIVE	VERB	O	O	505
:	PUNCT	O	O	505
To	PART	O	O	505
test	NOUN	O	O	505
the	PRON	O	O	505
hypothesis	NOUN	O	O	505
that	SCONJ	O	O	505
,	PUNCT	O	O	505
in	ADP	O	O	505
lifetime	NOUN	O	O	505
captopril	PROPN	O	Chemical	505
-	PUNCT	O	O	505
treated	VERB	O	O	505
spontaneously	ADV	O	O	505
hypertensive	ADJ	O	Disease	505
rats	NOUN	O	O	505
(	PUNCT	O	O	505
SHR	PROPN	O	O	505
)	PUNCT	O	O	505
,	PUNCT	O	O	505
the	PRON	O	O	505
sympathetic	ADJ	O	O	505
nervous	ADJ	O	O	505
system	NOUN	O	O	505
contributes	VERB	O	O	505
importantly	ADV	O	O	505
to	PART	O	O	505
the	PRON	O	O	505
hypertensive	ADJ	O	Disease	505
effect	VERB	O	O	505
of	ADP	O	O	505
dietary sodium chloride	NOUN	O	Chemical	505
supplementation	NOUN	O	O	505
.	PUNCT	O	O	505
Male	NOUN	O	O	506
SHR	PROPN	O	O	506
(	PUNCT	O	O	506
aged	ADJ	O	O	506
6	NUM	O	O	506
weeks	NOUN	O	O	506
)	PUNCT	O	O	506
that	SCONJ	O	O	506
had	VERB	O	O	506
been	AUX	O	O	506
treated	VERB	O	O	506
from	ADP	O	O	506
conception	NOUN	O	O	506
onward	ADV	O	O	506
with	ADP	O	O	506
either	ADV	O	O	506
captopril	PROPN	O	Chemical	506
or	CCONJ	O	O	506
vehicle	NOUN	O	O	506
remained	VERB	O	O	506
on	ADP	O	O	506
a	PRON	O	O	506
basal	PROPN	O	O	506
sodium chloride	NOUN	O	Chemical	506
diet	PROPN	O	O	506
or	CCONJ	O	O	506
were	AUX	O	O	506
fed	VERB	O	O	506
a	PRON	O	O	506
high	ADJ	O	O	506
sodium chloride	NOUN	O	Chemical	506
diet	PROPN	O	O	506
.	PUNCT	O	O	506
After	ADP	O	O	507
2	X	O	O	507
weeks	NOUN	O	O	507
,	PUNCT	O	O	507
the	PRON	O	O	507
rats	NOUN	O	O	507
were	AUX	O	O	507
subjected	VERB	O	O	507
to	PART	O	O	507
ganglionic	ADJ	O	O	507
blockade	VERB	O	O	507
and	CCONJ	O	O	507
2	X	O	O	507
days	NOUN	O	O	507
later	ADV	O	O	507
,	PUNCT	O	O	507
an	PRON	O	O	507
infusion	NOUN	O	O	507
of	ADP	O	O	507
clonidine	NOUN	O	Chemical	507
.	PUNCT	O	O	507
Lifetime	NOUN	O	O	508
captopril	PROPN	O	Chemical	508
treatment	NOUN	O	O	508
significantly	ADV	O	O	508
lowered	VERB	O	O	508
mean	VERB	O	O	508
arterial	ADJ	O	O	508
pressure	NOUN	O	O	508
in	ADP	O	O	508
both	PRON	O	O	508
groups	NOUN	O	O	508
.	PUNCT	O	O	508
Intravenous	PROPN	O	O	509
infusion	NOUN	O	O	509
of	ADP	O	O	509
the	PRON	O	O	509
ganglionic	ADJ	O	O	509
blocker	NOUN	O	O	509
hexamethonium	ADJ	O	Chemical	509
resulted	VERB	O	O	509
in	ADP	O	O	509
a	PRON	O	O	509
rapid	ADJ	O	O	509
decline	VERB	O	O	509
in	ADP	O	O	509
MAP	PROPN	O	O	509
that	SCONJ	O	O	509
eliminated	VERB	O	O	509
the	PRON	O	O	509
dietary sodium chloride	NOUN	O	Chemical	509
-	PUNCT	O	O	509
induced	VERB	O	O	509
increase in MAP	PROPN	O	Disease	509
in	ADP	O	O	509
both	PRON	O	O	509
groups	NOUN	O	O	509
.	PUNCT	O	O	509
Infusion	NOUN	O	O	510
of	ADP	O	O	510
the	PRON	O	O	510
central	ADJ	O	O	510
nervous	ADJ	O	O	510
system	NOUN	O	O	510
alpha2-adrenergic receptor agonist	NOUN	O	Chemical	510
clonidine	NOUN	O	Chemical	510
also	ADV	O	O	510
resulted	VERB	O	O	510
in	ADP	O	O	510
a	PRON	O	O	510
greater	ADJ	O	O	510
reduction	NOUN	O	O	510
in	ADP	O	O	510
MAP	PROPN	O	O	510
in	ADP	O	O	510
both	PRON	O	O	510
groups	NOUN	O	O	510
of	ADP	O	O	510
SHR	PROPN	O	O	510
that	SCONJ	O	O	510
were	AUX	O	O	510
fed	VERB	O	O	510
the	PRON	O	O	510
high	ADJ	O	O	510
(	PUNCT	O	O	510
compared	VERB	O	O	510
with	ADP	O	O	510
the	PRON	O	O	510
basal	PROPN	O	O	510
)	PUNCT	O	O	510
sodium chloride	NOUN	O	Chemical	510
diet	PROPN	O	O	510
.	PUNCT	O	O	510
In	ADP	O	O	511
both	PRON	O	O	511
lifetime	NOUN	O	O	511
captopril	PROPN	O	Chemical	511
-	PUNCT	O	O	511
treated	VERB	O	O	511
and	CCONJ	O	O	511
control	VERB	O	O	511
SHR	PROPN	O	O	512
,	PUNCT	O	O	512
the	PRON	O	O	512
sympathetic	ADJ	O	O	512
nervous	ADJ	O	O	512
system	NOUN	O	O	512
contributes	VERB	O	O	512
to	PART	O	O	512
the	PRON	O	O	512
pressor	ADJ	O	O	512
effects	NOUN	O	O	512
of	ADP	O	O	512
a	PRON	O	O	512
high	ADJ	O	O	512
sodium chloride	NOUN	O	Chemical	512
diet	PROPN	O	O	512
.	PUNCT	O	O	512
Dose	NOUN	O	O	515
-	PUNCT	O	O	515
related	ADJ	O	O	515
beneficial	ADJ	O	O	515
and	CCONJ	O	O	515
adverse	ADJ	O	O	515
effects	NOUN	O	O	515
of	ADP	O	O	515
dietary	ADJ	O	O	515
corticosterone	NOUN	O	Chemical	515
on	ADP	O	O	515
organophosphorus	PROPN	O	Chemical	515
-	PUNCT	O	O	515
induced	VERB	O	O	515
delayed	VERB	O	O	515
neuropathy	NOUN	O	Disease	515
in	ADP	O	O	515
chickens	NOUN	O	O	515
.	PUNCT	O	O	515
Tri	PROPN	O	O	516
-	PUNCT	O	O	516
ortho	VERB	O	O	516
-	PUNCT	O	O	516
tolyl	ADJ	O	O	516
phosphate	NOUN	O	Chemical	516
(	PUNCT	O	O	516
TOTP	PROPN	O	Chemical	516
)	PUNCT	O	O	516
,	PUNCT	O	O	516
360	NUM	O	O	516
mg	VERB	O	O	516
/	PUNCT	O	O	516
kg	VERB	O	O	516
,	PUNCT	O	O	516
po	PROPN	O	O	516
,	PUNCT	O	O	516
and	CCONJ	O	O	516
0,0'-diisopropyl phosphorofluoridate	PROPN	O	Chemical	516
(	PUNCT	O	O	516
DFP	PROPN	O	Chemical	516
)	PUNCT	O	O	516
,	PUNCT	O	O	516
1	X	O	O	516
mg	VERB	O	O	516
/	PUNCT	O	O	516
kg	VERB	O	O	516
sc	PROPN	O	O	516
,	PUNCT	O	O	516
were	AUX	O	O	516
administered	VERB	O	O	516
to	PART	O	O	516
adult	NOUN	O	O	516
White	ADJ	O	O	516
Leghorn	PROPN	O	O	516
chickens	NOUN	O	O	516
24	NUM	O	O	516
hr	NOUN	O	O	516
after	ADP	O	O	516
they	PRON	O	O	516
were	AUX	O	O	516
placed	VERB	O	O	516
on	ADP	O	O	516
diets	NOUN	O	O	516
containing	VERB	O	O	516
0	NUM	O	O	516
to	PART	O	O	516
300	NUM	O	O	516
ppm	ADP	O	O	516
corticosterone	NOUN	O	Chemical	516
.	PUNCT	O	O	516
Supplemented	VERB	O	O	517
diets	NOUN	O	O	517
were	AUX	O	O	517
continued	VERB	O	O	517
until	ADP	O	O	517
clinical	ADJ	O	O	517
signs	NOUN	O	O	517
and	CCONJ	O	O	517
lesions	NOUN	O	O	517
of	ADP	O	O	517
delayed	VERB	O	O	517
neuropathy	NOUN	O	Disease	517
appeared	VERB	O	O	517
.	PUNCT	O	O	517
Although	SCONJ	O	O	518
low	ADJ	O	O	518
concentrations	NOUN	O	O	518
(	PUNCT	O	O	518
less	ADV	O	O	518
than	ADP	O	O	518
or	CCONJ	O	O	518
equal	ADJ	O	O	518
to	PART	O	O	518
50	NUM	O	O	518
ppm	ADP	O	O	518
)	PUNCT	O	O	518
of	ADP	O	O	518
corticosterone	NOUN	O	Chemical	518
had	VERB	O	O	518
beneficial	ADJ	O	O	518
effects	NOUN	O	O	518
on	ADP	O	O	518
TOTP	PROPN	O	Chemical	518
-	PUNCT	O	O	518
induced	VERB	O	O	518
neuropathy	NOUN	O	Disease	518
,	PUNCT	O	O	518
greater	ADJ	O	O	518
than	ADP	O	O	518
or	CCONJ	O	O	518
equal	ADJ	O	O	518
to	PART	O	O	518
200	NUM	O	O	518
ppm	ADP	O	O	518
exacerbated	VERB	O	O	518
clinical	ADJ	O	O	518
signs	NOUN	O	O	518
in	ADP	O	O	518
chickens	NOUN	O	O	518
given	VERB	O	O	518
either	ADV	O	O	518
TOTP	PROPN	O	Chemical	518
or	CCONJ	O	O	518
DFP	PROPN	O	Chemical	518
.	PUNCT	O	O	518
Neurotoxic	PROPN	O	Disease	519
esterase	NOUN	O	O	519
activities	NOUN	O	O	519
24	NUM	O	O	519
hr	NOUN	O	O	519
after	ADP	O	O	519
TOTP	PROPN	O	Chemical	519
or	CCONJ	O	O	519
DFP	PROPN	O	Chemical	519
were	AUX	O	O	519
less	ADV	O	O	519
than	ADP	O	O	519
20%	NOUN	O	O	519
of	ADP	O	O	519
values	NOUN	O	O	519
measured	VERB	O	O	519
in	ADP	O	O	519
chickens	NOUN	O	O	519
not	PART	O	O	519
given	VERB	O	O	519
organophosphorous	VERB	O	Chemical	519
compounds	NOUN	O	O	519
.	PUNCT	O	O	519
corticosterone	NOUN	O	Chemical	520
without	ADP	O	O	520
TOTP	PROPN	O	Chemical	520
or	CCONJ	O	O	520
DFP	PROPN	O	Chemical	520
had	VERB	O	O	520
significantly	ADV	O	O	520
elevated	ADJ	O	O	520
activity	NOUN	O	O	520
of	ADP	O	O	520
plasma	NOUN	O	O	520
cholinesterase	NOUN	O	O	520
and	CCONJ	O	O	520
significantly	ADV	O	O	520
inhibited	VERB	O	O	520
activity	NOUN	O	O	520
of	ADP	O	O	520
liver	NOUN	O	O	520
carboxylesterase	NOUN	O	O	520
.	PUNCT	O	O	520
Degenerating myelinated fibers	NOUN	O	Disease	521
were	AUX	O	O	521
also	ADV	O	O	521
evident	ADJ	O	O	521
in	ADP	O	O	521
distal	NOUN	O	O	521
levels	NOUN	O	O	521
of	ADP	O	O	521
the	PRON	O	O	521
peripheral	ADJ	O	O	521
nerves	NOUN	O	O	521
of	ADP	O	O	521
chickens	NOUN	O	O	521
given	VERB	O	O	521
TOTP	PROPN	O	Chemical	521
or	CCONJ	O	O	521
DFP	PROPN	O	Chemical	521
.	PUNCT	O	O	521
In	ADP	O	O	524
vivo	VERB	O	O	524
characterization	NOUN	O	O	524
of	ADP	O	O	524
a	PRON	O	O	524
dual	ADJ	O	O	524
adenosine	PROPN	O	Chemical	524
A2A	PROPN	O	O	524
/	PUNCT	O	O	524
A1	PROPN	O	O	524
receptor	NOUN	O	O	524
antagonist	NOUN	O	O	524
in	ADP	O	O	524
animal	NOUN	O	O	524
models	NOUN	O	O	524
of	ADP	O	O	524
Parkinson	NOUN	O	O	524
's	AUX	O	O	524
disease	PROPN	O	O	524
.	PUNCT	O	O	524
The	PRON	O	O	525
in	ADP	O	O	525
vivo	VERB	O	O	525
characterization	NOUN	O	O	525
of	ADP	O	O	525
a	PRON	O	O	525
dual	ADJ	O	O	525
adenosine	PROPN	O	Chemical	525
A(2A)/A(1	ADV	O	O	525
)	PUNCT	O	O	525
receptor	NOUN	O	O	525
antagonist	NOUN	O	O	525
in	ADP	O	O	525
several	ADJ	O	O	525
animal	NOUN	O	O	525
models	NOUN	O	O	525
of	ADP	O	O	525
Parkinson	NOUN	O	O	525
's	AUX	O	O	525
disease	PROPN	O	O	525
is	AUX	O	O	525
described	VERB	O	O	525
.	PUNCT	O	O	525
nM	NOUN	O	O	526
)	PUNCT	O	O	526
that	SCONJ	O	O	526
has	VERB	O	O	526
excellent	ADJ	O	O	526
activity	NOUN	O	O	526
,	PUNCT	O	O	526
after	ADP	O	O	526
oral	ADJ	O	O	526
administration	NOUN	O	O	526
,	PUNCT	O	O	526
across	ADP	O	O	526
a	PRON	O	O	526
number	NOUN	O	O	526
of	ADP	O	O	526
animal	NOUN	O	O	526
models	NOUN	O	O	526
of	ADP	O	O	526
Parkinson	NOUN	O	O	526
's	AUX	O	O	526
disease	PROPN	O	O	526
including	VERB	O	O	526
mouse	PROPN	O	O	526
and	CCONJ	O	O	526
rat	NOUN	O	O	526
models	NOUN	O	O	526
of	ADP	O	O	526
haloperidol	NOUN	O	Chemical	526
-	PUNCT	O	O	526
induced	VERB	O	O	526
catalepsy	VERB	O	Disease	526
,	PUNCT	O	O	526
mouse	PROPN	O	O	526
model	NOUN	O	O	526
of	ADP	O	O	526
reserpine	NOUN	O	Chemical	526
-	PUNCT	O	O	526
induced	VERB	O	O	526
akinesia	NOUN	O	Disease	526
,	PUNCT	O	O	526
rat	NOUN	O	O	526
6-hydroxydopamine	NOUN	O	Chemical	526
(	PUNCT	O	O	526
6-OHDA	NOUN	O	Chemical	526
)	PUNCT	O	O	526
lesion	NOUN	O	O	526
model	NOUN	O	O	526
of	ADP	O	O	526
drug	NOUN	O	O	526
-	PUNCT	O	O	526
induced	VERB	O	O	526
rotation	NOUN	O	Disease	526
,	PUNCT	O	O	526
and	CCONJ	O	O	526
MPTP	PROPN	O	Chemical	526
-	PUNCT	O	O	526
treated	VERB	O	O	526
non	ADJ	O	O	526
-	PUNCT	O	O	526
human	PROPN	O	O	526
primate	NOUN	O	O	526
model	NOUN	O	O	526
.	PUNCT	O	O	526
An	PRON	O	O	529
extremely	ADV	O	O	529
rare	ADJ	O	O	529
case	NOUN	O	O	529
of	ADP	O	O	529
delusional parasitosis	NOUN	O	Disease	529
in	ADP	O	O	529
a	PRON	O	O	529
chronic hepatitis C	NOUN	O	Disease	529
patient	NOUN	O	O	529
during	ADP	O	O	529
pegylated interferon alpha-2b	NOUN	O	Chemical	529
and	CCONJ	O	O	529
ribavirin	NOUN	O	Chemical	529
treatment	NOUN	O	O	529
.	PUNCT	O	O	529
During	ADP	O	O	530
treatment	NOUN	O	O	530
of	ADP	O	O	530
chronic hepatitis C	NOUN	O	Disease	530
patients	NOUN	O	O	530
with	ADP	O	O	530
interferon	PROPN	O	Chemical	530
and	CCONJ	O	O	530
ribavirin	NOUN	O	Chemical	530
,	PUNCT	O	O	530
a	PRON	O	O	530
lot	NOUN	O	O	530
of	ADP	O	O	530
side	NOUN	O	O	530
effects	NOUN	O	O	530
are	AUX	O	O	530
described	VERB	O	O	530
.	PUNCT	O	O	530
Twenty	NUM	O	O	531
-	PUNCT	O	O	531
three	NUM	O	O	531
percent	NOUN	O	O	531
to	PART	O	O	531
44%	NOUN	O	O	531
of	ADP	O	O	531
patients	NOUN	O	O	531
develop	VERB	O	O	531
depression	PROPN	O	Disease	531
.	PUNCT	O	O	531
A	PRON	O	O	532
minority	NOUN	O	O	532
of	ADP	O	O	532
patients	NOUN	O	O	532
evolve	VERB	O	O	532
to	PART	O	O	532
psychosis	VERB	O	Disease	532
.	PUNCT	O	O	532
To	PART	O	O	533
the	PRON	O	O	533
best	ADV	O	O	533
of	ADP	O	O	533
our	PRON	O	O	533
knowledge	NOUN	O	O	533
,	PUNCT	O	O	533
no	PRON	O	O	533
cases	NOUN	O	O	533
of	ADP	O	O	533
psychogenic parasitosis	NOUN	O	Disease	533
occurring	VERB	O	O	533
during	ADP	O	O	533
interferon	PROPN	O	Chemical	533
therapy	NOUN	O	O	533
have	VERB	O	O	533
been	AUX	O	O	533
described	VERB	O	O	533
in	ADP	O	O	533
the	PRON	O	O	533
literature	NOUN	O	O	533
.	PUNCT	O	O	533
We	PRON	O	O	534
present	NOUN	O	O	534
a	PRON	O	O	534
49-year	NOUN	O	O	534
-	PUNCT	O	O	534
old	ADJ	O	O	534
woman	NOUN	O	O	534
who	PRON	O	O	534
developed	VERB	O	O	534
a	PRON	O	O	534
delusional parasitosis	NOUN	O	Disease	534
during	ADP	O	O	534
treatment	NOUN	O	O	534
with	ADP	O	O	534
pegylated interferon alpha-2b	NOUN	O	Chemical	534
weekly	ADV	O	O	534
and	CCONJ	O	O	534
ribavirin	NOUN	O	Chemical	534
.	PUNCT	O	O	534
All	PRON	O	O	535
the	PRON	O	O	535
complaints	NOUN	O	O	535
disappeared	VERB	O	O	535
after	ADP	O	O	535
stopping	VERB	O	O	535
pegylated interferon alpha-2b	NOUN	O	Chemical	535
and	CCONJ	O	O	535
reappeared	VERB	O	O	535
after	ADP	O	O	535
restarting	VERB	O	O	535
it	PRON	O	O	535
.	PUNCT	O	O	535
Possible	ADJ	O	O	538
neuroleptic malignant syndrome	NOUN	O	Disease	538
related	ADJ	O	O	538
to	PART	O	O	538
concomitant	ADJ	O	O	538
treatment	NOUN	O	O	538
with	ADP	O	O	538
paroxetine	NOUN	O	Chemical	538
and	CCONJ	O	O	538
alprazolam	PROPN	O	Chemical	538
.	PUNCT	O	O	538
A	PRON	O	O	539
74-year	NOUN	O	O	539
-	PUNCT	O	O	539
old	ADJ	O	O	539
man	NOUN	O	O	539
with	ADP	O	O	539
depressive symptoms	NOUN	O	Disease	539
was	AUX	O	O	539
admitted	VERB	O	O	539
to	PART	O	O	539
a	PRON	O	O	539
psychiatric	ADJ	O	Disease	539
hospital	PROPN	O	O	539
due	ADJ	O	O	539
to	PART	O	O	539
insomnia	NOUN	O	Disease	539
,	PUNCT	O	O	539
loss of appetite	NOUN	O	Disease	539
,	PUNCT	O	O	539
exhaustion	NOUN	O	O	539
,	PUNCT	O	O	539
and	CCONJ	O	O	539
agitation	NOUN	O	Disease	539
.	PUNCT	O	O	539
Medical	NOUN	O	O	540
treatment	NOUN	O	O	540
was	AUX	O	O	540
initiated	VERB	O	O	540
at	ADP	O	O	540
a	PRON	O	O	540
daily	ADV	O	O	540
dose	NOUN	O	O	540
of	ADP	O	O	540
20	NUM	O	O	540
mg	VERB	O	O	540
paroxetine	NOUN	O	Chemical	540
and	CCONJ	O	O	540
1.2	NUM	O	O	540
mg	VERB	O	O	540
alprazolam	PROPN	O	Chemical	540
.	PUNCT	O	O	540
On	ADP	O	O	541
the	PRON	O	O	541
10th	ADJ	O	O	541
day	NOUN	O	O	541
of	ADP	O	O	541
paroxetine	NOUN	O	Chemical	541
and	CCONJ	O	O	541
alprazolam	PROPN	O	Chemical	541
treatment	NOUN	O	O	541
,	PUNCT	O	O	541
the	PRON	O	O	541
patient	NOUN	O	O	541
exhibited	VERB	O	O	541
marked	VERB	O	O	541
psychomotor retardation	NOUN	O	Disease	541
,	PUNCT	O	O	541
disorientation	NOUN	O	O	541
,	PUNCT	O	O	541
and	CCONJ	O	O	541
severe	ADJ	O	O	541
muscle rigidity	NOUN	O	Disease	541
with	ADP	O	O	541
tremors	NOUN	O	Disease	541
.	PUNCT	O	O	541
The	PRON	O	O	542
patient	NOUN	O	O	542
had	VERB	O	O	542
a	PRON	O	O	542
fever	NOUN	O	Disease	542
(	PUNCT	O	O	542
38.2	NUM	O	O	542
degrees	NOUN	O	O	542
C	NOUN	O	O	542
)	PUNCT	O	O	542
,	PUNCT	O	O	542
fluctuating	VERB	O	O	542
blood	NOUN	O	O	542
pressure	NOUN	O	O	542
(	PUNCT	O	O	542
between	ADP	O	O	542
165/90	NUM	O	O	542
and	CCONJ	O	O	542
130/70	NUM	O	O	542
mg	VERB	O	O	542
mm	INTJ	O	O	542
Hg	PROPN	O	O	542
)	PUNCT	O	O	542
,	PUNCT	O	O	542
and	CCONJ	O	O	542
severe	ADJ	O	O	542
extrapyramidal symptoms	NOUN	O	Disease	542
.	PUNCT	O	O	542
Laboratory	NOUN	O	O	543
tests	VERB	O	O	543
showed	VERB	O	O	543
an	PRON	O	O	543
elevation	NOUN	O	O	543
of	ADP	O	O	543
creatine	PROPN	O	Chemical	543
phosphokinase	NOUN	O	O	543
(	PUNCT	O	O	543
2218	NUM	O	O	543
IU	PROPN	O	O	543
/	PUNCT	O	O	543
L	NOUN	O	O	543
)	PUNCT	O	O	543
,	PUNCT	O	O	543
aspartate	NOUN	O	Chemical	543
aminotransferase	PROPN	O	O	543
(	PUNCT	O	O	543
134	NUM	O	O	543
IU	PROPN	O	O	543
/	PUNCT	O	O	543
L	NOUN	O	O	543
)	PUNCT	O	O	543
,	PUNCT	O	O	543
alanine	NOUN	O	Chemical	543
aminotransferase	PROPN	O	O	543
(	PUNCT	O	O	543
78	NUM	O	O	543
IU	PROPN	O	O	543
/	PUNCT	O	O	543
L	NOUN	O	O	543
)	PUNCT	O	O	543
,	PUNCT	O	O	543
and	CCONJ	O	O	543
BUN	PROPN	O	Chemical	543
(	PUNCT	O	O	543
27.9	NUM	O	O	543
mg	VERB	O	O	543
/	PUNCT	O	O	543
ml	ADP	O	O	543
)	PUNCT	O	O	543
levels	NOUN	O	O	543
.	PUNCT	O	O	543
The	PRON	O	O	544
patient	NOUN	O	O	544
received	VERB	O	O	544
bromocriptine	NOUN	O	Chemical	544
and	CCONJ	O	O	544
diazepam	NOUN	O	Chemical	544
to	PART	O	O	544
treat	VERB	O	O	544
his	PRON	O	O	544
symptoms	NOUN	O	O	544
.	PUNCT	O	O	544
7	NUM	O	O	545
days	NOUN	O	O	545
later	ADV	O	O	545
,	PUNCT	O	O	545
the	PRON	O	O	545
fever	NOUN	O	Disease	545
disappeared	VERB	O	O	545
and	CCONJ	O	O	545
the	PRON	O	O	545
patient	NOUN	O	O	545
's	AUX	O	O	545
serum	NOUN	O	O	545
CPK	PROPN	O	O	545
levels	NOUN	O	O	545
were	AUX	O	O	545
normalized	VERB	O	O	545
(	PUNCT	O	O	545
175	NUM	O	O	545
IU	PROPN	O	O	545
/	PUNCT	O	O	545
L	NOUN	O	O	545
)	PUNCT	O	O	545
.	PUNCT	O	O	545
This	PRON	O	O	546
patient	NOUN	O	O	546
presented	VERB	O	O	546
with	ADP	O	O	546
symptoms	NOUN	O	O	546
of	ADP	O	O	546
neuroleptic malignant syndrome	NOUN	O	Disease	546
(	PUNCT	O	O	546
NMS	PROPN	O	Disease	546
)	PUNCT	O	O	546
,	PUNCT	O	O	546
thus	ADV	O	O	546
demonstrating	VERB	O	O	546
that	SCONJ	O	O	546
NMS	PROPN	O	Disease	546
-	PUNCT	O	O	546
like	INTJ	O	O	546
symptoms	NOUN	O	O	546
can	AUX	O	O	546
occur	VERB	O	O	546
after	ADP	O	O	546
combined	VERB	O	O	546
paroxetine	NOUN	O	Chemical	546
and	CCONJ	O	O	546
alprazolam	PROPN	O	Chemical	546
treatment	NOUN	O	O	546
.	PUNCT	O	O	546
The	PRON	O	O	547
adverse	ADJ	O	O	547
drug	NOUN	O	O	547
reaction	NOUN	O	O	547
score	VERB	O	O	547
obtained	VERB	O	O	547
by	ADP	O	O	547
the	PRON	O	O	547
Naranjo	PROPN	O	O	547
algorithm	VERB	O	O	547
was	AUX	O	O	547
6	NUM	O	O	547
in	ADP	O	O	547
our	PRON	O	O	547
case	NOUN	O	O	547
,	PUNCT	O	O	547
indicating	VERB	O	O	547
a	PRON	O	O	547
probable	ADJ	O	O	547
relationship	NOUN	O	O	547
between	ADP	O	O	547
the	PRON	O	O	547
patient	NOUN	O	O	547
's	AUX	O	O	547
NMS	PROPN	O	Disease	547
-	PUNCT	O	O	547
like	INTJ	O	O	547
adverse	ADJ	O	O	547
symptoms	NOUN	O	O	547
and	CCONJ	O	O	547
the	PRON	O	O	547
combined	VERB	O	O	547
treatment	NOUN	O	O	547
used	VERB	O	O	547
in	ADP	O	O	547
this	PRON	O	O	547
case	NOUN	O	O	547
.	PUNCT	O	O	547
Several	ADJ	O	O	548
risk	NOUN	O	O	548
factors	NOUN	O	O	548
for	ADP	O	O	548
NMS	PROPN	O	Disease	548
should	AUX	O	O	548
be	AUX	O	O	548
noted	VERB	O	O	548
in	ADP	O	O	548
elderly	ADJ	O	O	548
depressive	ADJ	O	Disease	548
patients	NOUN	O	O	548
whose	DET	O	O	548
symptoms	NOUN	O	O	548
often	ADV	O	O	548
include	VERB	O	O	548
dehydration	NOUN	O	Disease	548
,	PUNCT	O	O	548
agitation	NOUN	O	Disease	548
,	PUNCT	O	O	548
malnutrition	NOUN	O	Disease	548
,	PUNCT	O	O	548
and	CCONJ	O	O	548
exhaustion	NOUN	O	O	548
.	PUNCT	O	O	548
Careful	ADJ	O	O	549
therapeutic	ADJ	O	O	549
intervention	NOUN	O	O	549
is	AUX	O	O	549
necessary	ADJ	O	O	549
in	ADP	O	O	549
cases	NOUN	O	O	549
involving	VERB	O	O	549
elderly	ADJ	O	O	549
patients	NOUN	O	O	549
who	PRON	O	O	549
suffer	VERB	O	O	549
from	ADP	O	O	549
depression	PROPN	O	Disease	549
.	PUNCT	O	O	549
Pilocarpine	NOUN	O	Chemical	552
seizures	NOUN	O	Disease	552
cause	VERB	O	O	552
age	NOUN	O	O	552
-	PUNCT	O	O	552
dependent	ADJ	O	O	552
impairment in auditory location discrimination	NOUN	O	Disease	552
.	PUNCT	O	O	552
Children	NOUN	O	O	553
who	PRON	O	O	553
have	VERB	O	O	553
status epilepticus	VERB	O	Disease	553
have	VERB	O	O	553
continuous	ADJ	O	O	553
or	CCONJ	O	O	553
rapidly	ADV	O	O	553
repeating	VERB	O	O	553
seizures	NOUN	O	Disease	553
that	SCONJ	O	O	553
may	AUX	O	O	553
be	AUX	O	O	553
life	NOUN	O	O	553
-	PUNCT	O	O	553
threatening	VERB	O	O	553
and	CCONJ	O	O	553
may	AUX	O	O	553
cause	VERB	O	O	553
life	NOUN	O	O	553
-	PUNCT	O	O	553
long	ADV	O	O	553
changes	VERB	O	O	553
in	ADP	O	O	553
brain	NOUN	O	O	553
and	CCONJ	O	O	553
behavior	NOUN	O	O	553
.	PUNCT	O	O	553
The	PRON	O	O	554
extent	NOUN	O	O	554
to	PART	O	O	554
which	PRON	O	O	554
status epilepticus	VERB	O	Disease	554
causes	VERB	O	O	554
deficits in auditory discrimination	NOUN	O	Disease	554
is	AUX	O	O	554
unknown	ADJ	O	O	554
.	PUNCT	O	O	554
A	PRON	O	O	555
naturalistic	ADJ	O	O	555
auditory	NOUN	O	O	555
location	NOUN	O	O	555
discrimination	NOUN	O	O	555
method	NOUN	O	O	555
was	AUX	O	O	555
used	VERB	O	O	555
to	PART	O	O	555
evaluate	VERB	O	O	555
this	PRON	O	O	555
question	NOUN	O	O	555
using	VERB	O	O	555
an	PRON	O	O	555
animal	NOUN	O	O	555
model	NOUN	O	O	555
of	ADP	O	O	555
status epilepticus	VERB	O	Disease	555
.	PUNCT	O	O	555
Male	NOUN	O	O	556
Sprague	PROPN	O	O	556
-	PUNCT	O	O	556
Dawley	NOUN	O	O	556
rats	NOUN	O	O	556
were	AUX	O	O	556
injected	VERB	O	O	556
with	ADP	O	O	556
saline	NOUN	O	O	556
on	ADP	O	O	556
postnatal	ADJ	O	O	556
day	NOUN	O	O	556
(	PUNCT	O	O	556
P	NOUN	O	Chemical	556
)	PUNCT	O	O	556
20	NUM	O	O	556
,	PUNCT	O	O	556
or	CCONJ	O	O	556
a	PRON	O	O	556
convulsant	ADJ	O	O	556
dose	NOUN	O	O	556
of	ADP	O	O	556
pilocarpine	NOUN	O	Chemical	556
on	ADP	O	O	556
P20	NOUN	O	O	556
or	CCONJ	O	O	556
P45	PROPN	O	O	556
.	PUNCT	O	O	556
Pilocarpine	NOUN	O	Chemical	557
on	ADP	O	O	557
either	ADV	O	O	557
day	NOUN	O	O	557
induced	VERB	O	O	557
status epilepticus	VERB	O	Disease	557
;	PUNCT	O	O	557
status epilepticus	VERB	O	Disease	557
at	ADP	O	O	557
P45	PROPN	O	O	557
resulted	VERB	O	O	557
in	ADP	O	O	557
CA3	PROPN	O	O	557
cell	NOUN	O	O	557
loss	NOUN	O	O	557
and	CCONJ	O	O	557
spontaneous	ADJ	O	O	557
seizures	NOUN	O	Disease	557
,	PUNCT	O	O	557
whereas	SCONJ	O	O	557
P20	NOUN	O	O	557
rats	NOUN	O	O	557
had	VERB	O	O	557
no	PRON	O	O	557
cell	NOUN	O	O	557
loss	NOUN	O	O	557
or	CCONJ	O	O	557
spontaneous	ADJ	O	O	557
seizures	NOUN	O	Disease	557
.	PUNCT	O	O	557
In	ADP	O	O	558
status epilepticus	VERB	O	Disease	558
(	PUNCT	O	O	558
P20	NOUN	O	O	558
)	PUNCT	O	O	558
rats	NOUN	O	O	558
,	PUNCT	O	O	558
acquisition	NOUN	O	O	558
of	ADP	O	O	558
the	PRON	O	O	558
sound	NOUN	O	O	558
-	PUNCT	O	O	558
source	NOUN	O	O	558
location	NOUN	O	O	558
discrimination	NOUN	O	O	558
was	AUX	O	O	558
moderately	ADV	O	O	558
impaired	VERB	O	O	558
.	PUNCT	O	O	558
Status epilepticus	VERB	O	Disease	559
(	PUNCT	O	O	559
P45	PROPN	O	O	559
)	PUNCT	O	O	559
rats	NOUN	O	O	559
failed	VERB	O	O	559
to	PART	O	O	559
acquire	VERB	O	O	559
either	ADV	O	O	559
sound	NOUN	O	O	559
-	PUNCT	O	O	559
source	NOUN	O	O	559
location	NOUN	O	O	559
or	CCONJ	O	O	559
sound	NOUN	O	O	559
-	PUNCT	O	O	559
silence	NOUN	O	O	559
discriminations	NOUN	O	O	559
.	PUNCT	O	O	559
Status epilepticus	VERB	O	Disease	560
in	ADP	O	O	560
rat	NOUN	O	O	560
causes	VERB	O	O	560
an	PRON	O	O	560
age	NOUN	O	O	560
-	PUNCT	O	O	560
dependent	ADJ	O	O	560
,	PUNCT	O	O	560
long	ADV	O	O	560
-	PUNCT	O	O	560
term	NOUN	O	O	560
impairment in auditory discrimination	NOUN	O	Disease	560
.	PUNCT	O	O	560
This	PRON	O	O	561
impairment	NOUN	O	O	561
may	AUX	O	O	561
explain	VERB	O	O	561
one	NUM	O	O	561
cause	VERB	O	O	561
of	ADP	O	O	561
impaired auditory location discrimination	NOUN	O	Disease	561
in	ADP	O	O	561
humans	NOUN	O	O	561
.	PUNCT	O	O	561
Cardiovascular	NOUN	O	O	564
risk	NOUN	O	O	564
with	ADP	O	O	564
cyclooxygenase inhibitors	NOUN	O	Chemical	564
:	PUNCT	O	O	564
general	ADJ	O	O	564
problem	NOUN	O	O	564
with	ADP	O	O	564
substance	NOUN	O	O	564
specific	ADJ	O	O	564
differences	NOUN	O	O	564
?	PUNCT	O	O	564
Randomised	VERB	O	O	565
clinical	ADJ	O	O	565
trials	NOUN	O	O	565
and	CCONJ	O	O	565
observational	ADJ	O	O	565
studies	NOUN	O	O	565
have	VERB	O	O	565
shown	VERB	O	O	565
an	PRON	O	O	565
increased	VERB	O	O	565
risk	NOUN	O	O	565
of	ADP	O	O	565
myocardial infarction	NOUN	O	Disease	565
,	PUNCT	O	O	565
stroke	VERB	O	Disease	565
,	PUNCT	O	O	565
hypertension	NOUN	O	Disease	565
and	CCONJ	O	O	565
heart failure	NOUN	O	Disease	565
during	ADP	O	O	565
treatment	NOUN	O	O	565
with	ADP	O	O	565
cyclooxygenase inhibitors	NOUN	O	Chemical	565
.	PUNCT	O	O	565
Cyclooxygenase inhibitors	NOUN	O	Chemical	566
cause	VERB	O	O	566
complex	ADJ	O	O	566
changes	VERB	O	O	566
in	ADP	O	O	566
renal	ADJ	O	O	566
,	PUNCT	O	O	566
vascular	ADJ	O	O	566
and	CCONJ	O	O	566
cardiac	ADJ	O	O	566
prostanoid	PROPN	O	O	566
profiles	NOUN	O	O	566
thereby	ADV	O	O	566
increasing	VERB	O	O	566
vascular	ADJ	O	O	566
resistance	NOUN	O	O	566
and	CCONJ	O	O	566
fluid	NOUN	O	O	566
retention	NOUN	O	O	566
.	PUNCT	O	O	566
A	PRON	O	O	567
comparison	NOUN	O	O	567
of	ADP	O	O	567
individual	ADJ	O	O	567
selective	ADJ	O	O	567
and	CCONJ	O	O	567
unselective	PROPN	O	O	567
cyclooxygenase inhibitors	NOUN	O	Chemical	567
suggests	VERB	O	O	567
substance	NOUN	O	O	567
-	PUNCT	O	O	567
specific	ADJ	O	O	567
differences	NOUN	O	O	567
,	PUNCT	O	O	567
which	PRON	O	O	567
may	AUX	O	O	567
depend	VERB	O	O	567
on	ADP	O	O	567
differences	NOUN	O	O	567
in	ADP	O	O	567
pharmacokinetic	VERB	O	O	567
parameters	NOUN	O	O	567
or	CCONJ	O	O	567
inhibitory	ADJ	O	O	567
potency	NOUN	O	O	567
and	CCONJ	O	O	567
may	AUX	O	O	567
be	AUX	O	O	567
contributed	VERB	O	O	567
by	ADP	O	O	567
prostaglandin	NOUN	O	Chemical	567
-	PUNCT	O	O	567
independent	ADJ	O	O	567
effects	NOUN	O	O	567
.	PUNCT	O	O	567
Diagnostic	ADJ	O	O	568
markers	NOUN	O	O	568
such	ADJ	O	O	568
as	ADP	O	O	568
N	NUM	O	O	568
-	PUNCT	O	O	568
terminal	PROPN	O	O	568
pro	ADJ	O	O	568
brain	NOUN	O	O	568
natriuretic	ADJ	O	O	568
peptide	NOUN	O	O	568
(	PUNCT	O	O	568
NT	PROPN	O	O	568
-	PUNCT	O	O	568
proBNP	VERB	O	O	568
)	PUNCT	O	O	568
or	CCONJ	O	O	568
high	ADJ	O	O	568
-	PUNCT	O	O	568
sensitive	ADJ	O	O	568
C	NOUN	O	O	568
-	PUNCT	O	O	568
reactive	ADJ	O	O	568
protein	NOUN	O	O	568
might	AUX	O	O	568
help	VERB	O	O	568
in	ADP	O	O	568
the	PRON	O	O	568
early	ADV	O	O	568
identification	NOUN	O	O	568
of	ADP	O	O	568
patients	NOUN	O	O	568
at	ADP	O	O	568
risk	NOUN	O	O	568
,	PUNCT	O	O	568
thus	ADV	O	O	568
avoiding	VERB	O	O	568
the	PRON	O	O	568
occurrence	NOUN	O	O	568
of	ADP	O	O	568
serious	ADJ	O	O	568
cardiovascular toxicity	NOUN	O	Disease	568
.	PUNCT	O	O	568
Predictors	NOUN	O	O	571
of	ADP	O	O	571
decreased renal function	NOUN	O	Disease	571
in	ADP	O	O	571
patients	NOUN	O	O	571
with	ADP	O	O	571
heart failure	NOUN	O	Disease	571
during	ADP	O	O	571
angiotensin	NOUN	O	Chemical	571
-	PUNCT	O	O	571
converting	VERB	O	O	571
enzyme	NOUN	O	O	571
inhibitor	NOUN	O	O	571
therapy	NOUN	O	O	571
:	PUNCT	O	O	571
results	VERB	O	O	571
from	ADP	O	O	571
the	PRON	O	O	571
studies	NOUN	O	O	571
of	ADP	O	O	571
left ventricular dysfunction	NOUN	O	Disease	571
(	PUNCT	O	O	571
SOLVD	PROPN	O	O	571
)	PUNCT	O	O	571
BACKGROUND	NOUN	O	O	571
:	PUNCT	O	O	571
Although	SCONJ	O	O	572
angiotensin	NOUN	O	Chemical	572
-	PUNCT	O	O	572
converting	VERB	O	O	572
enzyme	NOUN	O	O	572
inhibitor	NOUN	O	O	572
therapy	NOUN	O	O	572
reduces	VERB	O	O	572
mortality	NOUN	O	O	572
rates	NOUN	O	O	572
in	ADP	O	O	572
patients	NOUN	O	O	572
with	ADP	O	O	572
congestive	ADJ	O	O	572
heart failure	NOUN	O	Disease	572
(	PUNCT	O	O	572
CHF	PROPN	O	Disease	572
)	PUNCT	O	O	572
,	PUNCT	O	O	572
it	PRON	O	O	572
may	AUX	O	O	572
also	ADV	O	O	572
cause	VERB	O	O	572
decreased renal function	NOUN	O	Disease	572
.	PUNCT	O	O	572
OBJECTIVE	VERB	O	O	573
:	PUNCT	O	O	573
To	PART	O	O	573
quantify	VERB	O	O	573
specific	ADJ	O	O	573
clinical	ADJ	O	O	573
predictors	NOUN	O	O	573
of	ADP	O	O	573
reduction in renal function	NOUN	O	Disease	573
in	ADP	O	O	573
patients	NOUN	O	O	573
with	ADP	O	O	573
CHF	PROPN	O	Disease	573
who	PRON	O	O	573
are	AUX	O	O	573
prescribed	VERB	O	O	573
angiotensin	NOUN	O	Chemical	573
-	PUNCT	O	O	573
converting	VERB	O	O	573
enzyme	NOUN	O	O	573
inhibitor	NOUN	O	O	573
therapy	NOUN	O	O	573
.	PUNCT	O	O	573
We	PRON	O	O	574
analyzed	VERB	O	O	574
data	NOUN	O	O	574
from	ADP	O	O	574
the	PRON	O	O	574
Studies	NOUN	O	O	574
of	ADP	O	O	574
Left Ventricular Dysfunction	PROPN	O	Disease	574
(	PUNCT	O	O	574
SOLVD	PROPN	O	O	574
)	PUNCT	O	O	574
,	PUNCT	O	O	574
a	PRON	O	O	574
randomized	VERB	O	O	574
,	PUNCT	O	O	574
double	ADJ	O	O	574
-	PUNCT	O	O	574
blind	ADJ	O	Disease	574
,	PUNCT	O	O	574
placebo	NOUN	O	O	574
-	PUNCT	O	O	574
controlled	VERB	O	O	574
trial	NOUN	O	O	574
of	ADP	O	O	574
enalapril	PROPN	O	Chemical	574
for	ADP	O	O	574
the	PRON	O	O	574
treatment	NOUN	O	O	574
of	ADP	O	O	574
CHF	PROPN	O	Disease	574
.	PUNCT	O	O	574
There	ADV	O	O	575
were	AUX	O	O	575
3379	NUM	O	O	575
patients	NOUN	O	O	575
randomly	ADV	O	O	575
assigned	VERB	O	O	575
to	PART	O	O	575
enalapril	PROPN	O	Chemical	575
with	ADP	O	O	575
a	PRON	O	O	575
median	ADJ	O	O	575
follow	VERB	O	O	575
-	PUNCT	O	O	575
up	ADP	O	O	575
of	ADP	O	O	575
974	NUM	O	O	575
days	NOUN	O	O	575
and	CCONJ	O	O	575
3379	NUM	O	O	575
patients	NOUN	O	O	575
randomly	ADV	O	O	575
assigned	VERB	O	O	575
to	PART	O	O	575
placebo	NOUN	O	O	575
with	ADP	O	O	575
a	PRON	O	O	575
mean	VERB	O	O	575
follow	VERB	O	O	575
-	PUNCT	O	O	575
up	ADP	O	O	575
of	ADP	O	O	575
967	NUM	O	O	575
days	NOUN	O	O	575
.	PUNCT	O	O	575
Decreased renal function	NOUN	O	Disease	576
was	AUX	O	O	576
defined	VERB	O	O	576
as	ADP	O	O	576
a	PRON	O	O	576
rise	VERB	O	O	576
in	ADP	O	O	576
serum	NOUN	O	O	576
creatinine	PROPN	O	Chemical	576
>	PUNCT	O	O	576
/=0.5	PUNCT	O	O	576
mg	VERB	O	O	576
/	PUNCT	O	O	576
dL	VERB	O	O	576
(	PUNCT	O	O	576
44	NUM	O	O	576
micromol	NOUN	O	O	576
/	PUNCT	O	O	576
L	NOUN	O	O	576
)	PUNCT	O	O	576
from	ADP	O	O	576
baseline	VERB	O	O	576
.	PUNCT	O	O	576
We	PRON	O	O	577
used	VERB	O	O	577
time	NOUN	O	O	577
-	PUNCT	O	O	577
to	PART	O	O	577
-	PUNCT	O	O	577
event	NOUN	O	O	577
analysis	NOUN	O	O	577
to	PART	O	O	577
identify	VERB	O	O	577
potential	ADJ	O	O	577
predictors	NOUN	O	O	577
of	ADP	O	O	577
decrease	VERB	O	O	577
in	ADP	O	O	577
renal	ADJ	O	O	577
function	NOUN	O	O	577
including	VERB	O	O	577
age	NOUN	O	O	577
,	PUNCT	O	O	577
baseline	VERB	O	O	577
ejection	NOUN	O	O	577
fraction	NOUN	O	O	577
,	PUNCT	O	O	577
baseline	VERB	O	O	577
creatinine	PROPN	O	Chemical	577
,	PUNCT	O	O	577
low	ADJ	O	O	577
systolic	ADV	O	O	577
blood	NOUN	O	O	577
pressure	NOUN	O	O	577
(	PUNCT	O	O	577
<	X	O	O	577
100	NUM	O	O	577
mm	INTJ	O	O	577
Hg	PROPN	O	O	577
)	PUNCT	O	O	577
,	PUNCT	O	O	577
history	NOUN	O	O	577
of	ADP	O	O	577
hypertension	NOUN	O	Disease	577
,	PUNCT	O	O	577
diabetes	NOUN	O	Disease	577
,	PUNCT	O	O	577
and	CCONJ	O	O	577
use	VERB	O	O	577
of	ADP	O	O	577
antiplatelet	ADV	O	O	577
,	PUNCT	O	O	577
diuretic	ADJ	O	Chemical	577
,	PUNCT	O	O	577
and	CCONJ	O	O	577
beta	NOUN	O	O	577
-	PUNCT	O	O	577
blocker	NOUN	O	O	577
therapy	NOUN	O	O	577
.	PUNCT	O	O	577
Patients	NOUN	O	O	578
randomly	ADV	O	O	578
assigned	VERB	O	O	578
to	PART	O	O	578
enalapril	PROPN	O	Chemical	578
had	VERB	O	O	578
a	PRON	O	O	578
33%	NOUN	O	O	578
greater	ADJ	O	O	578
likelihood	NOUN	O	O	578
of	ADP	O	O	578
decreased renal function	NOUN	O	Disease	578
than	ADP	O	O	578
controls	VERB	O	O	578
(	PUNCT	O	O	578
P	NOUN	O	Chemical	578
=	PUNCT	O	O	578
.003	VERB	O	O	578
)	PUNCT	O	O	578
.	PUNCT	O	O	578
By	ADP	O	O	579
multivariate	ADJ	O	O	579
analysis	NOUN	O	O	579
,	PUNCT	O	O	579
in	ADP	O	O	579
both	PRON	O	O	579
the	PRON	O	O	579
placebo	NOUN	O	O	579
and	CCONJ	O	O	579
enalapril	PROPN	O	Chemical	579
groups	NOUN	O	O	579
older	ADJ	O	O	579
age	NOUN	O	O	579
,	PUNCT	O	O	579
diuretic	ADJ	O	Chemical	579
therapy	NOUN	O	O	579
,	PUNCT	O	O	579
and	CCONJ	O	O	579
diabetes	NOUN	O	Disease	579
were	AUX	O	O	579
associated	VERB	O	O	579
with	ADP	O	O	579
decreased renal function	NOUN	O	Disease	579
,	PUNCT	O	O	579
whereas	SCONJ	O	O	579
beta	NOUN	O	O	579
-	PUNCT	O	O	579
blocker	NOUN	O	O	579
therapy	NOUN	O	O	579
and	CCONJ	O	O	579
higher	ADJ	O	O	579
ejection	NOUN	O	O	579
fraction	NOUN	O	O	579
were	AUX	O	O	579
renoprotective	NOUN	O	O	579
.	PUNCT	O	O	579
Older	ADJ	O	O	580
age	NOUN	O	O	580
was	AUX	O	O	580
associated	VERB	O	O	580
with	ADP	O	O	580
a	PRON	O	O	580
greater	ADJ	O	O	580
risk	NOUN	O	O	580
of	ADP	O	O	580
developing	VERB	O	O	580
decreased renal function	NOUN	O	Disease	580
in	ADP	O	O	580
both	PRON	O	O	580
groups	NOUN	O	O	580
,	PUNCT	O	O	580
but	CCONJ	O	O	580
significantly	ADV	O	O	580
more	ADJ	O	O	580
so	ADV	O	O	580
in	ADP	O	O	580
the	PRON	O	O	580
enalapril	PROPN	O	Chemical	580
group	NOUN	O	O	580
(	PUNCT	O	O	580
enalapril	PROPN	O	Chemical	580
:	PUNCT	O	O	580
risk	NOUN	O	O	580
ratio	NOUN	O	O	580
[	X	O	O	580
RR	NOUN	O	O	580
]	PUNCT	O	O	580
1.42	NUM	O	O	580
per	ADP	O	O	580
10	NUM	O	O	580
years	NOUN	O	O	580
,	PUNCT	O	O	580
95%	NOUN	O	O	580
confidence	NOUN	O	O	580
interval	NOUN	O	O	580
[	X	O	O	580
CI	NOUN	O	O	580
]	PUNCT	O	O	580
1.32	NUM	O	O	580
-	PUNCT	O	O	580
1.52	NUM	O	O	580
with	ADP	O	O	580
enalapril	PROPN	O	Chemical	580
;	PUNCT	O	O	580
placebo	NOUN	O	O	580
:	PUNCT	O	O	580
RR	NOUN	O	O	580
1.18	NUM	O	O	580
,	PUNCT	O	O	580
95%	NOUN	O	O	580
CI	NOUN	O	O	580
1.12	NUM	O	O	580
-	PUNCT	O	O	580
1.25	NUM	O	O	580
)	PUNCT	O	O	580
.	PUNCT	O	O	580
Diuretic	NOUN	O	Chemical	581
therapy	NOUN	O	O	581
was	AUX	O	O	581
likewise	ADV	O	O	581
associated	VERB	O	O	581
with	ADP	O	O	581
a	PRON	O	O	581
greater	ADJ	O	O	581
risk	NOUN	O	O	581
of	ADP	O	O	581
decreased renal function	NOUN	O	Disease	581
in	ADP	O	O	581
the	PRON	O	O	581
enalapril	PROPN	O	Chemical	581
group	NOUN	O	O	581
(	PUNCT	O	O	581
RR	NOUN	O	O	581
1.89	NUM	O	O	581
,	PUNCT	O	O	581
95%	NOUN	O	O	581
CI	NOUN	O	O	581
1.70	NUM	O	O	581
-	PUNCT	O	O	581
2.08	NUM	O	O	581
)	PUNCT	O	O	581
than	ADP	O	O	581
in	ADP	O	O	581
the	PRON	O	O	581
placebo	NOUN	O	O	581
group	NOUN	O	O	581
(	PUNCT	O	O	581
RR	NOUN	O	O	581
1.35	NUM	O	O	581
,	PUNCT	O	O	581
95%	NOUN	O	O	581
CI	NOUN	O	O	581
1.09	NUM	O	O	581
-	PUNCT	O	O	581
1.66	NUM	O	O	581
)	PUNCT	O	O	581
.	PUNCT	O	O	581
Conversely	ADV	O	O	582
,	PUNCT	O	O	582
enalapril	PROPN	O	Chemical	582
had	VERB	O	O	582
a	PRON	O	O	582
relative	ADJ	O	O	582
renoprotective	NOUN	O	O	582
effect	VERB	O	O	582
(	PUNCT	O	O	582
RR	NOUN	O	O	582
1.33	NUM	O	O	582
,	PUNCT	O	O	582
95%	NOUN	O	O	582
CI	NOUN	O	O	582
1.13	NUM	O	O	582
-	PUNCT	O	O	582
1.53	NUM	O	O	582
)	PUNCT	O	O	582
compared	VERB	O	O	582
with	ADP	O	O	582
placebo	NOUN	O	O	582
(	PUNCT	O	O	582
RR	NOUN	O	O	582
1.96	NUM	O	O	582
,	PUNCT	O	O	582
95%	NOUN	O	O	582
CI	NOUN	O	O	582
1.57	NUM	O	O	582
-	PUNCT	O	O	582
2.44	NUM	O	O	582
)	PUNCT	O	O	582
in	ADP	O	O	582
patients	NOUN	O	O	582
with	ADP	O	O	582
diabetes	NOUN	O	Disease	582
.	PUNCT	O	O	582
A	PRON	O	O	583
lower	ADJ	O	O	583
risk	NOUN	O	O	583
of	ADP	O	O	583
renal impairment	NOUN	O	Disease	583
was	AUX	O	O	583
seen	VERB	O	O	583
in	ADP	O	O	583
both	PRON	O	O	583
groups	NOUN	O	O	583
with	ADP	O	O	583
beta	NOUN	O	O	583
-	PUNCT	O	O	583
blocker	NOUN	O	O	583
therapy	NOUN	O	O	583
(	PUNCT	O	O	583
RR	NOUN	O	O	583
0.70	NUM	O	O	583
,	PUNCT	O	O	583
95%	NOUN	O	O	583
CI	NOUN	O	O	583
0.57	NUM	O	O	583
-	PUNCT	O	O	583
0.85	NUM	O	O	583
)	PUNCT	O	O	583
and	CCONJ	O	O	583
higher	ADJ	O	O	583
baseline	VERB	O	O	583
ejection	NOUN	O	O	583
fraction	NOUN	O	O	583
(	PUNCT	O	O	583
RR	NOUN	O	O	583
0.93	NUM	O	O	583
per	ADP	O	O	583
5%	NOUN	O	O	583
increment	NOUN	O	O	583
,	PUNCT	O	O	583
95%	NOUN	O	O	583
CI	NOUN	O	O	583
0.91	NUM	O	O	583
-	PUNCT	O	O	583
0	NUM	O	O	583
.	PUNCT	O	O	583
Enalapril	PROPN	O	Chemical	584
use	VERB	O	O	584
caused	VERB	O	O	584
a	PRON	O	O	584
33%	NOUN	O	O	584
increase	VERB	O	O	584
in	ADP	O	O	584
the	PRON	O	O	584
risk	NOUN	O	O	584
of	ADP	O	O	584
decreased renal function	NOUN	O	Disease	584
in	ADP	O	O	584
patients	NOUN	O	O	584
with	ADP	O	O	584
CHF	PROPN	O	Disease	584
.	PUNCT	O	O	584
Diuretic	NOUN	O	Chemical	585
use	VERB	O	O	585
and	CCONJ	O	O	585
advanced	ADJ	O	O	585
age	NOUN	O	O	585
increased	VERB	O	O	585
this	PRON	O	O	585
risk	NOUN	O	O	585
.	PUNCT	O	O	585
Diabetes	NOUN	O	Disease	586
was	AUX	O	O	586
associated	VERB	O	O	586
with	ADP	O	O	586
an	PRON	O	O	586
increased	VERB	O	O	586
risk	NOUN	O	O	586
of	ADP	O	O	586
renal impairment	NOUN	O	Disease	586
in	ADP	O	O	586
all	PRON	O	O	586
patients	NOUN	O	O	586
with	ADP	O	O	586
CHF	PROPN	O	Disease	586
,	PUNCT	O	O	586
but	CCONJ	O	O	586
this	PRON	O	O	586
risk	NOUN	O	O	586
was	AUX	O	O	586
reduced	VERB	O	O	586
in	ADP	O	O	586
the	PRON	O	O	586
enalapril	PROPN	O	Chemical	586
group	NOUN	O	O	586
compared	VERB	O	O	586
with	ADP	O	O	586
the	PRON	O	O	586
placebo	NOUN	O	O	586
group	NOUN	O	O	586
.	PUNCT	O	O	586
Pemoline	NOUN	O	Chemical	589
induced	VERB	O	O	589
acute	ADJ	O	O	589
choreoathetosis	PROPN	O	Disease	589
:	PUNCT	O	O	589
case	NOUN	O	O	589
report	VERB	O	O	589
and	CCONJ	O	O	589
review	VERB	O	O	589
of	ADP	O	O	589
the	PRON	O	O	589
literature	NOUN	O	O	589
.	PUNCT	O	O	589
Pemoline	NOUN	O	Chemical	590
is	AUX	O	O	590
an	PRON	O	O	590
oxazolidine	NOUN	O	Chemical	590
derivative	ADJ	O	O	590
that	SCONJ	O	O	590
is	AUX	O	O	590
structurally	ADV	O	O	590
different	ADJ	O	O	590
from	ADP	O	O	590
amphetamines	NOUN	O	Chemical	590
and	CCONJ	O	O	590
used	VERB	O	O	590
in	ADP	O	O	590
the	PRON	O	O	590
treatment	NOUN	O	O	590
of	ADP	O	O	590
attention deficit disorder	NOUN	O	Disease	590
.	PUNCT	O	O	590
Pemoline	NOUN	O	Chemical	591
has	VERB	O	O	591
not	PART	O	O	591
been	AUX	O	O	591
commonly	ADV	O	O	591
associated	VERB	O	O	591
in	ADP	O	O	591
the	PRON	O	O	591
literature	NOUN	O	O	591
as	ADP	O	O	591
a	PRON	O	O	591
cause	VERB	O	O	591
of	ADP	O	O	591
acute	ADJ	O	O	591
movement disorders	NOUN	O	Disease	591
.	PUNCT	O	O	591
The	PRON	O	O	592
following	VERB	O	O	592
case	NOUN	O	O	592
describes	VERB	O	O	592
two	NUM	O	O	592
children	NOUN	O	O	592
acutely	ADV	O	O	592
poisoned	VERB	O	O	592
with	ADP	O	O	592
pemoline	NOUN	O	Chemical	592
who	PRON	O	O	592
experienced	ADJ	O	O	592
profound	ADJ	O	O	592
choreoathetosis	PROPN	O	Disease	592
.	PUNCT	O	O	592
Two	NUM	O	O	593
,	PUNCT	O	O	593
3-year	NOUN	O	O	593
-	PUNCT	O	O	593
old	ADJ	O	O	593
male	NOUN	O	O	593
,	PUNCT	O	O	593
identical	ADJ	O	O	593
twin	ADJ	O	O	593
siblings	NOUN	O	O	593
presented	VERB	O	O	593
to	PART	O	O	593
the	PRON	O	O	593
emergency	NOUN	O	O	593
department	NOUN	O	O	593
after	ADP	O	O	593
found	VERB	O	O	593
playing	VERB	O	O	593
with	ADP	O	O	593
a	PRON	O	O	593
an	PRON	O	O	593
empty	ADJ	O	O	593
bottle	NOUN	O	O	593
of	ADP	O	O	593
pemoline	NOUN	O	Chemical	593
originally	ADV	O	O	593
containing	VERB	O	O	593
59	NUM	O	O	593
tablets	NOUN	O	O	593
.	PUNCT	O	O	593
The	PRON	O	O	594
children	NOUN	O	O	594
had	VERB	O	O	594
a	PRON	O	O	594
medical	ADJ	O	O	594
history	NOUN	O	O	594
significant	ADJ	O	O	594
for	ADP	O	O	594
attention deficit disorder	NOUN	O	Disease	594
previously	ADV	O	O	594
treated	VERB	O	O	594
with	ADP	O	O	594
methylphenidate	VERB	O	Chemical	594
without	ADP	O	O	594
success	NOUN	O	O	594
.	PUNCT	O	O	594
This	PRON	O	O	595
was	AUX	O	O	595
their	PRON	O	O	595
first	ADV	O	O	595
day	NOUN	O	O	595
of	ADP	O	O	595
pemoline	NOUN	O	Chemical	595
therapy	NOUN	O	O	595
.	PUNCT	O	O	595
The	PRON	O	O	596
choreoathetoid	NOUN	O	Disease	596
movements	NOUN	O	O	596
began	VERB	O	O	596
45	NUM	O	O	596
min	NOUN	O	O	596
to	PART	O	O	596
1	X	O	O	596
h	X	O	O	596
after	ADP	O	O	596
ingestion	NOUN	O	O	596
.	PUNCT	O	O	596
The	PRON	O	O	597
children	NOUN	O	O	597
gave	VERB	O	O	597
no	PRON	O	O	597
history	NOUN	O	O	597
of	ADP	O	O	597
prior	ADV	O	O	597
movement disorders	NOUN	O	Disease	597
and	CCONJ	O	O	597
there	ADV	O	O	597
was	AUX	O	O	597
no	PRON	O	O	597
family	NOUN	O	O	597
history	NOUN	O	O	597
of	ADP	O	O	597
movement disorders	NOUN	O	Disease	597
.	PUNCT	O	O	597
The	PRON	O	O	598
children	NOUN	O	O	598
received	VERB	O	O	598
gastrointestinal	ADJ	O	O	598
decontamination	NOUN	O	O	598
and	CCONJ	O	O	598
high	ADJ	O	O	598
doses	NOUN	O	O	598
of	ADP	O	O	598
intravenous	ADJ	O	O	598
benzodiazepines	NOUN	O	Chemical	598
in	ADP	O	O	598
an	PRON	O	O	598
attempt	VERB	O	O	598
to	PART	O	O	598
control	VERB	O	O	598
the	PRON	O	O	598
choreoathetoid	NOUN	O	Disease	598
movements	NOUN	O	O	598
.	PUNCT	O	O	598
Despite	SCONJ	O	O	599
treatment	NOUN	O	O	599
,	PUNCT	O	O	599
the	PRON	O	O	599
children	NOUN	O	O	599
continued	VERB	O	O	599
to	PART	O	O	599
have	VERB	O	O	599
choreoathetosis	PROPN	O	Disease	599
for	ADP	O	O	599
approximately	ADV	O	O	599
24	NUM	O	O	599
hours	NOUN	O	O	599
.	PUNCT	O	O	599
Pemoline	NOUN	O	Chemical	600
associated	VERB	O	O	600
movement disorder	NOUN	O	Disease	600
has	VERB	O	O	600
been	AUX	O	O	600
rarely	ADV	O	O	600
reported	VERB	O	O	600
in	ADP	O	O	600
the	PRON	O	O	600
acute	ADJ	O	O	600
toxicology	NOUN	O	O	600
literature	NOUN	O	O	600
.	PUNCT	O	O	600
The	PRON	O	O	601
possibility	NOUN	O	O	601
of	ADP	O	O	601
choreoathetoid	NOUN	O	Disease	601
movements	NOUN	O	O	601
should	AUX	O	O	601
be	AUX	O	O	601
considered	VERB	O	O	601
in	ADP	O	O	601
patients	NOUN	O	O	601
presenting	VERB	O	O	601
after	ADP	O	O	601
pemoline	NOUN	O	Chemical	601
overdose	NOUN	O	Disease	601
.	PUNCT	O	O	601
Continuous	ADJ	O	O	604
subcutaneous	ADJ	O	O	604
administration	NOUN	O	O	604
of	ADP	O	O	604
mesna	NOUN	O	Chemical	604
to	PART	O	O	604
prevent	VERB	O	O	604
ifosfamide	ADP	O	Chemical	604
-	PUNCT	O	O	604
induced	VERB	O	O	604
hemorrhagic cystitis	NOUN	O	Disease	604
.	PUNCT	O	O	604
Hemorrhagic cystitis	NOUN	O	Disease	605
is	AUX	O	O	605
a	PRON	O	O	605
major	ADJ	O	O	605
potential	ADJ	O	O	605
toxicity	NOUN	O	Disease	605
of	ADP	O	O	605
ifosfamide	ADP	O	Chemical	605
that	SCONJ	O	O	605
can	AUX	O	O	605
be	AUX	O	O	605
prevented	VERB	O	O	605
by	ADP	O	O	605
administering	VERB	O	O	605
mesna	NOUN	O	Chemical	605
along	ADV	O	O	605
with	ADP	O	O	605
the	PRON	O	O	605
cytotoxic	ADJ	O	O	605
agent	NOUN	O	O	605
.	PUNCT	O	O	605
Mesna	NOUN	O	Chemical	606
is	AUX	O	O	606
generally	ADV	O	O	606
administered	VERB	O	O	606
by	ADP	O	O	606
the	PRON	O	O	606
intravenous	ADJ	O	O	606
route	VERB	O	O	606
,	PUNCT	O	O	606
although	SCONJ	O	O	606
experience	NOUN	O	O	606
with	ADP	O	O	606
oral	ADJ	O	O	606
delivery	NOUN	O	O	606
of	ADP	O	O	606
the	PRON	O	O	606
drug	NOUN	O	O	606
has	VERB	O	O	606
increased	VERB	O	O	606
.	PUNCT	O	O	606
The	PRON	O	O	607
continuous	ADJ	O	O	607
subcutaneous	ADJ	O	O	607
administration	NOUN	O	O	607
of	ADP	O	O	607
mesna	NOUN	O	Chemical	607
has	VERB	O	O	607
the	PRON	O	O	607
advantage	NOUN	O	O	607
of	ADP	O	O	607
not	PART	O	O	607
requiring	VERB	O	O	607
intravenous	ADJ	O	O	607
access	NOUN	O	O	607
.	PUNCT	O	O	607
In	ADP	O	O	608
addition	NOUN	O	O	608
,	PUNCT	O	O	608
subcutaneous	ADJ	O	O	608
delivery	NOUN	O	O	608
of	ADP	O	O	608
the	PRON	O	O	608
neutralizing	VERB	O	O	608
agent	NOUN	O	O	608
will	AUX	O	O	608
not	PART	O	O	608
be	AUX	O	O	608
associated	VERB	O	O	608
with	ADP	O	O	608
the	PRON	O	O	608
risk	NOUN	O	O	608
of	ADP	O	O	608
inadequate	ADJ	O	O	608
urinary	ADJ	O	O	608
mesna	NOUN	O	Chemical	608
concentrations	NOUN	O	O	608
,	PUNCT	O	O	608
such	ADJ	O	O	608
as	ADP	O	O	608
in	ADP	O	O	608
a	PRON	O	O	608
patient	NOUN	O	O	608
taking	VERB	O	O	608
oral	ADJ	O	O	608
mesna	NOUN	O	Chemical	608
who	PRON	O	O	608
experiences	NOUN	O	O	608
severe	ADJ	O	O	608
ifosfamide	ADP	O	Chemical	608
-	PUNCT	O	O	608
induced	VERB	O	O	608
emesis	VERB	O	Disease	608
and	CCONJ	O	O	608
is	AUX	O	O	608
unable	ADJ	O	O	608
to	PART	O	O	608
absorb	VERB	O	O	608
the	PRON	O	O	608
drug	NOUN	O	O	608
.	PUNCT	O	O	608
Limited	ADJ	O	O	609
clinical	ADJ	O	O	609
experience	NOUN	O	O	609
with	ADP	O	O	609
continuous	ADJ	O	O	609
subcutaneous	ADJ	O	O	609
mesna	NOUN	O	Chemical	609
administration	NOUN	O	O	609
suggests	VERB	O	O	609
it	PRON	O	O	609
is	AUX	O	O	609
a	PRON	O	O	609
safe	ADJ	O	O	609
,	PUNCT	O	O	609
practical	ADJ	O	O	609
,	PUNCT	O	O	609
and	CCONJ	O	O	609
economic	ADJ	O	O	609
method	NOUN	O	O	609
of	ADP	O	O	609
drug	NOUN	O	O	609
delivery	NOUN	O	O	609
that	SCONJ	O	O	609
permits	VERB	O	O	609
ifosfamide	ADP	O	Chemical	609
to	PART	O	O	609
be	AUX	O	O	609
administered	VERB	O	O	609
successfully	ADV	O	O	609
in	ADP	O	O	609
the	PRON	O	O	609
outpatient	NOUN	O	O	609
setting	VERB	O	O	609
.	PUNCT	O	O	609
Modification	NOUN	O	O	612
of	ADP	O	O	612
drug	NOUN	O	O	612
action	NOUN	O	O	612
by	ADP	O	O	612
hyperammonemia	PROPN	O	Disease	612
.	PUNCT	O	O	612
Pretreatment	NOUN	O	O	613
with	ADP	O	O	613
ammonium acetate	NOUN	O	Chemical	613
(	PUNCT	O	O	613
NH4Ac	PROPN	O	Chemical	613
)	PUNCT	O	O	613
(	PUNCT	O	O	613
6	NUM	O	O	613
mmol	NOUN	O	O	613
/	PUNCT	O	O	613
kg	VERB	O	O	613
s.c	PROPN	O	O	613
.	PUNCT	O	O	613
)	PUNCT	O	O	613
approximately	ADV	O	O	614
doubled	VERB	O	O	614
the	PRON	O	O	614
time	NOUN	O	O	614
morphine	NOUN	O	Chemical	614
-	PUNCT	O	O	614
treated	VERB	O	O	614
mice	NOUN	O	O	614
remained	VERB	O	O	614
on	ADP	O	O	614
a	PRON	O	O	614
hot	ADJ	O	O	614
surface	NOUN	O	O	614
and	CCONJ	O	O	614
similarly	ADV	O	O	614
increased	VERB	O	O	614
muscular	ADJ	O	O	614
incoordination	NOUN	O	Disease	614
by	ADP	O	O	614
diazepam	NOUN	O	Chemical	614
,	PUNCT	O	O	614
but	CCONJ	O	O	614
NH4Ac	PROPN	O	Chemical	614
treatment	NOUN	O	O	614
alone	ADV	O	O	614
had	VERB	O	O	614
no	PRON	O	O	614
effect	VERB	O	O	614
.	PUNCT	O	O	614
Thus	ADV	O	O	615
,	PUNCT	O	O	615
hyperammonemia	PROPN	O	Disease	615
is	AUX	O	O	615
capable	ADJ	O	O	615
of	ADP	O	O	615
altering	VERB	O	O	615
drug	NOUN	O	O	615
action	NOUN	O	O	615
and	CCONJ	O	O	615
must	AUX	O	O	615
be	AUX	O	O	615
considered	VERB	O	O	615
along	ADV	O	O	615
with	ADP	O	O	615
impaired	VERB	O	O	615
drug	NOUN	O	O	615
metabolism	NOUN	O	O	615
in	ADP	O	O	615
enhanced	VERB	O	O	615
drug	NOUN	O	O	615
responses	NOUN	O	O	615
associated	VERB	O	O	615
with	ADP	O	O	615
liver disease	NOUN	O	Disease	615
.	PUNCT	O	O	615
Experiments	NOUN	O	O	616
in	ADP	O	O	616
vitro	X	O	O	616
showed	VERB	O	O	616
that	SCONJ	O	O	616
acetylcholine	NOUN	O	Chemical	616
-	PUNCT	O	O	616
induced	VERB	O	O	616
catecholamine	ADJ	O	Chemical	616
release	NOUN	O	O	616
from	ADP	O	O	616
bovine	NOUN	O	O	616
adrenal	ADJ	O	O	616
medulla	NOUN	O	O	616
is	AUX	O	O	616
depressed	ADJ	O	O	616
as	ADP	O	O	616
much	ADJ	O	O	616
as	ADP	O	O	616
50%	NOUN	O	O	616
by	ADP	O	O	616
0.3	NUM	O	O	616
mM	ADJ	O	O	616
NH4Ac	PROPN	O	Chemical	616
and	CCONJ	O	O	616
KCl	PROPN	O	Chemical	616
-	PUNCT	O	O	616
induced	VERB	O	O	616
contractions	NOUN	O	O	616
of	ADP	O	O	616
guinea	NOUN	O	O	616
-	PUNCT	O	O	616
pig	NOUN	O	O	616
ileum	NOUN	O	O	616
were	AUX	O	O	616
inhibited	VERB	O	O	616
20%	NOUN	O	O	616
by	ADP	O	O	616
5	NUM	O	O	616
mM	ADJ	O	O	616
NH4Ac	PROPN	O	Chemical	616
.	PUNCT	O	O	616
Addition	NOUN	O	O	617
of	ADP	O	O	617
excess	ADJ	O	O	617
calcium	NOUN	O	Chemical	617
reversed	VERB	O	O	617
the	PRON	O	O	617
depression	PROPN	O	Disease	617
in	ADP	O	O	617
both	PRON	O	O	617
tissues	NOUN	O	O	617
,	PUNCT	O	O	617
but	CCONJ	O	O	617
calcium	NOUN	O	Chemical	617
-	PUNCT	O	O	617
independent	ADJ	O	O	617
catecholamine	ADJ	O	Chemical	617
release	NOUN	O	O	617
by	ADP	O	O	617
acetaldehyde	PROPN	O	Chemical	617
was	AUX	O	O	617
not	PART	O	O	617
blocked	VERB	O	O	617
by	ADP	O	O	617
NH4Ac	PROPN	O	Chemical	617
.	PUNCT	O	O	617
These	PRON	O	O	618
results	VERB	O	O	618
suggested	VERB	O	O	618
that	SCONJ	O	O	618
ammonia	NOUN	O	Chemical	618
blocks	NOUN	O	O	618
calcium	NOUN	O	Chemical	618
channels	NOUN	O	O	618
.	PUNCT	O	O	618
Parallels	NOUN	O	O	619
in	ADP	O	O	619
the	PRON	O	O	619
actions	NOUN	O	O	619
of	ADP	O	O	619
NH4Ac	PROPN	O	Chemical	619
and	CCONJ	O	O	619
the	PRON	O	O	619
calcium	NOUN	O	Chemical	619
channel	PROPN	O	O	619
blocker	NOUN	O	O	619
verapamil	PROPN	O	Chemical	619
support	NOUN	O	O	619
this	PRON	O	O	619
concept	NOUN	O	O	619
.	PUNCT	O	O	619
Both	PRON	O	O	620
verapamil	PROPN	O	Chemical	620
(	PUNCT	O	O	620
10	NUM	O	O	620
mg	VERB	O	O	620
/	PUNCT	O	O	620
kg	VERB	O	O	620
i.p	NOUN	O	O	620
.	PUNCT	O	O	620
)	PUNCT	O	O	620
and	CCONJ	O	O	621
NH4Ac	PROPN	O	Chemical	621
pretreatment	NOUN	O	O	621
enhanced	VERB	O	O	621
morphine	NOUN	O	Chemical	621
analgesia-	X	O	O	621
and	CCONJ	O	O	621
diazepam	NOUN	O	Chemical	621
-	PUNCT	O	O	621
induced	VERB	O	O	621
muscular	ADJ	O	O	621
incoordination	NOUN	O	Disease	621
and	CCONJ	O	O	621
antagonized	VERB	O	O	621
amphetamine	NOUN	O	Chemical	621
-	PUNCT	O	O	621
induced	VERB	O	O	621
motor	NOUN	O	O	621
activity	NOUN	O	O	621
,	PUNCT	O	O	621
and	CCONJ	O	O	621
neither	ADV	O	O	621
verapamil	PROPN	O	Chemical	621
nor	CCONJ	O	O	621
NH4Ac	PROPN	O	Chemical	621
affected	VERB	O	O	621
the	PRON	O	O	621
convulsant	ADJ	O	O	621
action	NOUN	O	O	621
of	ADP	O	O	621
metrazol	NOUN	O	Chemical	621
.	PUNCT	O	O	621
The	PRON	O	O	622
data	NOUN	O	O	622
suggest	VERB	O	O	622
that	SCONJ	O	O	622
hyperammonemia	PROPN	O	Disease	622
exerts	VERB	O	O	622
a	PRON	O	O	622
calcium	NOUN	O	Chemical	622
channel	PROPN	O	O	622
blocking	VERB	O	O	622
action	NOUN	O	O	622
which	PRON	O	O	622
enhances	VERB	O	O	622
the	PRON	O	O	622
effects	NOUN	O	O	622
of	ADP	O	O	622
central	ADJ	O	O	622
nervous	ADJ	O	O	622
system	NOUN	O	O	622
depressants	NOUN	O	O	622
and	CCONJ	O	O	622
certain	ADJ	O	O	622
opioid	NOUN	O	O	622
analgesics	NOUN	O	O	622
.	PUNCT	O	O	622
Risk	NOUN	O	O	625
of	ADP	O	O	625
nephropathy	NOUN	O	Disease	625
after	ADP	O	O	625
consumption	NOUN	O	O	625
of	ADP	O	O	625
nonionic	ADJ	O	O	625
contrast media	NOUN	O	Chemical	625
by	ADP	O	O	625
children	NOUN	O	O	625
undergoing	VERB	O	O	625
cardiac	ADJ	O	O	625
angiography	NOUN	O	O	625
:	PUNCT	O	O	625
a	PRON	O	O	625
prospective	ADJ	O	O	625
study	VERB	O	O	625
.	PUNCT	O	O	625
Despite	SCONJ	O	O	626
increasing	VERB	O	O	626
reports	VERB	O	O	626
on	ADP	O	O	626
nonionic	ADJ	O	O	626
contrast media	NOUN	O	Chemical	626
-	PUNCT	O	O	626
induced	VERB	O	O	626
nephropathy	NOUN	O	Disease	626
(	PUNCT	O	O	626
CIN	PROPN	O	Disease	626
)	PUNCT	O	O	626
in	ADP	O	O	626
hospitalized	VERB	O	O	626
adult	NOUN	O	O	626
patients	NOUN	O	O	626
during	ADP	O	O	626
cardiac	ADJ	O	O	626
procedures	NOUN	O	O	626
,	PUNCT	O	O	626
the	PRON	O	O	626
studies	NOUN	O	O	626
in	ADP	O	O	626
pediatrics	NOUN	O	O	626
are	AUX	O	O	626
limited	VERB	O	O	626
,	PUNCT	O	O	626
with	ADP	O	O	626
even	ADV	O	O	626
less	ADV	O	O	626
focus	NOUN	O	O	626
on	ADP	O	O	626
possible	ADJ	O	O	626
predisposing	VERB	O	O	626
factors	NOUN	O	O	626
and	CCONJ	O	O	626
preventive	ADJ	O	O	626
measures	NOUN	O	O	626
for	ADP	O	O	626
patients	NOUN	O	O	626
undergoing	VERB	O	O	626
cardiac	ADJ	O	O	626
angiography	NOUN	O	O	626
.	PUNCT	O	O	626
This	PRON	O	O	627
prospective	ADJ	O	O	627
study	VERB	O	O	627
determined	VERB	O	O	627
the	PRON	O	O	627
incidence	NOUN	O	O	627
of	ADP	O	O	627
CIN	PROPN	O	Disease	627
for	ADP	O	O	627
two	NUM	O	O	627
nonionic	ADJ	O	O	627
contrast media	NOUN	O	Chemical	627
(	PUNCT	O	O	627
CM	PROPN	O	Disease	627
)	PUNCT	O	O	627
,	PUNCT	O	O	627
iopromide	NOUN	O	Chemical	627
and	CCONJ	O	O	627
iohexol	NOUN	O	Chemical	627
,	PUNCT	O	O	627
among	ADP	O	O	627
80	NUM	O	O	627
patients	NOUN	O	O	627
younger	ADJ	O	O	627
than	ADP	O	O	627
18	NUM	O	O	627
years	NOUN	O	O	627
and	CCONJ	O	O	627
compared	VERB	O	O	627
the	PRON	O	O	627
rates	NOUN	O	O	627
for	ADP	O	O	627
this	PRON	O	O	627
complication	NOUN	O	O	627
in	ADP	O	O	627
relation	NOUN	O	O	627
to	PART	O	O	627
the	PRON	O	O	627
type	NOUN	O	O	627
and	CCONJ	O	O	627
dosage	NOUN	O	O	627
of	ADP	O	O	627
CM	PROPN	O	Disease	627
and	CCONJ	O	O	627
the	PRON	O	O	627
presence	NOUN	O	O	627
of	ADP	O	O	627
cyanosis	NOUN	O	Disease	627
.	PUNCT	O	O	627
The	PRON	O	O	628
80	NUM	O	O	628
patients	NOUN	O	O	628
in	ADP	O	O	628
the	PRON	O	O	628
study	VERB	O	O	628
consecutively	ADV	O	O	628
received	VERB	O	O	628
either	ADV	O	O	628
iopromide	NOUN	O	Chemical	628
(	PUNCT	O	O	628
group	NOUN	O	O	628
A	PRON	O	O	628
,	PUNCT	O	O	628
n	CCONJ	O	O	628
=	PUNCT	O	O	628
40	NUM	O	O	628
)	PUNCT	O	O	628
or	CCONJ	O	O	628
iohexol	NOUN	O	Chemical	628
Serum	NOUN	O	O	629
sodium	NOUN	O	Chemical	629
(	PUNCT	O	O	629
Na	INTJ	O	Chemical	629
)	PUNCT	O	O	629
,	PUNCT	O	O	629
potassium	NOUN	O	Chemical	629
(	PUNCT	O	O	629
K	PROPN	O	Chemical	629
)	PUNCT	O	O	629
,	PUNCT	O	O	629
and	CCONJ	O	O	629
creatinine	PROPN	O	Chemical	629
(	PUNCT	O	O	629
Cr	NOUN	O	Chemical	629
)	PUNCT	O	O	629
were	AUX	O	O	629
measured	VERB	O	O	629
24	NUM	O	O	629
h	X	O	O	629
before	ADP	O	O	629
angiography	NOUN	O	O	629
as	ADP	O	O	629
baseline	VERB	O	O	629
values	NOUN	O	O	629
,	PUNCT	O	O	629
then	ADV	O	O	629
measured	VERB	O	O	629
again	ADV	O	O	629
at	ADP	O	O	629
12-	NUM	O	O	629
,	PUNCT	O	O	629
24-	NUM	O	O	629
,	PUNCT	O	O	629
and	CCONJ	O	O	629
48-h	NOUN	O	O	629
intervals	NOUN	O	O	629
after	ADP	O	O	629
CM	PROPN	O	Disease	629
use	VERB	O	O	629
.	PUNCT	O	O	629
Urine	NOUN	O	O	630
samples	NOUN	O	O	630
for	ADP	O	O	630
Na	INTJ	O	Chemical	630
and	CCONJ	O	O	630
Cr	NOUN	O	Chemical	630
also	ADV	O	O	630
were	AUX	O	O	630
checked	VERB	O	O	630
at	ADP	O	O	630
the	PRON	O	O	630
same	ADJ	O	O	630
intervals	NOUN	O	O	630
.	PUNCT	O	O	630
Risk	NOUN	O	O	631
of	ADP	O	O	631
renal failure	NOUN	O	Disease	631
,	PUNCT	O	O	631
Injury to the kidney	NOUN	O	Disease	631
,	PUNCT	O	O	631
Failure of kidney function	NOUN	O	Disease	631
,	PUNCT	O	O	631
Loss of kidney function	NOUN	O	Disease	631
,	PUNCT	O	O	631
and	CCONJ	O	O	631
End	NOUN	O	O	631
-	PUNCT	O	O	631
stage	NOUN	O	O	631
renal damage	NOUN	O	Disease	631
(	PUNCT	O	O	631
RIFLE	PROPN	O	O	631
criteria	NOUN	O	O	631
)	PUNCT	O	O	631
were	AUX	O	O	631
used	VERB	O	O	631
to	PART	O	O	631
define	VERB	O	O	631
CIN	PROPN	O	Disease	631
and	CCONJ	O	O	631
its	PRON	O	O	631
incidence	NOUN	O	O	631
in	ADP	O	O	631
the	PRON	O	O	631
study	VERB	O	O	631
population	NOUN	O	O	631
.	PUNCT	O	O	631
Accordingly	ADV	O	O	632
,	PUNCT	O	O	632
among	ADP	O	O	632
the	PRON	O	O	632
15	NUM	O	O	632
CIN	PROPN	O	Disease	632
patients	NOUN	O	O	632
(	PUNCT	O	O	632
18.75%	NOUN	O	O	632
)	PUNCT	O	O	632
,	PUNCT	O	O	632
7.5%	NOUN	O	O	632
of	ADP	O	O	632
the	PRON	O	O	632
patients	NOUN	O	O	632
in	ADP	O	O	632
group	NOUN	O	O	632
A	PRON	O	O	632
had	VERB	O	O	632
increased	VERB	O	O	632
risk	NOUN	O	O	632
and	CCONJ	O	O	632
3.75%	NOUN	O	O	632
had	VERB	O	O	632
renal injury	NOUN	O	Disease	632
,	PUNCT	O	O	632
whereas	SCONJ	O	O	632
5%	NOUN	O	O	632
of	ADP	O	O	632
group	NOUN	O	O	632
B	NOUN	O	O	632
had	VERB	O	O	632
increased	VERB	O	O	632
risk	NOUN	O	O	632
and	CCONJ	O	O	632
2.5%	NOUN	O	O	632
had	VERB	O	O	632
renal injury	NOUN	O	Disease	632
.	PUNCT	O	O	632
Whereas	SCONJ	O	O	633
33.3%	NOUN	O	O	633
of	ADP	O	O	633
the	PRON	O	O	633
patients	NOUN	O	O	633
with	ADP	O	O	633
CIN	PROPN	O	Disease	633
were	AUX	O	O	633
among	ADP	O	O	633
those	PRON	O	O	633
who	PRON	O	O	633
received	VERB	O	O	633
the	PRON	O	O	633
proper	ADJ	O	O	633
dosage	NOUN	O	O	633
of	ADP	O	O	633
CM	PROPN	O	Disease	633
,	PUNCT	O	O	633
the	PRON	O	O	633
percentage	NOUN	O	O	633
increased	VERB	O	O	633
to	PART	O	O	633
66.6%	NOUN	O	O	633
among	ADP	O	O	633
those	PRON	O	O	633
who	PRON	O	O	633
received	VERB	O	O	633
larger	ADJ	O	O	633
doses	NOUN	O	O	633
,	PUNCT	O	O	633
with	ADP	O	O	633
a	PRON	O	O	633
significant	ADJ	O	O	633
difference	NOUN	O	O	633
in	ADP	O	O	633
the	PRON	O	O	633
incidence	NOUN	O	O	633
of	ADP	O	O	633
CIN	PROPN	O	Disease	633
related	ADJ	O	O	633
to	PART	O	O	633
the	PRON	O	O	633
different	ADJ	O	O	633
dosages	NOUN	O	O	633
of	ADP	O	O	633
CM	PROPN	O	Disease	633
(	PUNCT	O	O	633
p	NOUN	O	O	633
=	PUNCT	O	O	633
0.014	NUM	O	O	633
)	PUNCT	O	O	633
.	PUNCT	O	O	633
Among	ADP	O	O	634
the	PRON	O	O	634
15	NUM	O	O	634
patients	NOUN	O	O	634
with	ADP	O	O	634
CIN	PROPN	O	Disease	634
,	PUNCT	O	O	634
6	NUM	O	O	634
had	VERB	O	O	634
cyanotic	ADJ	O	O	634
congenital	NOUN	O	O	634
heart diseases	NOUN	O	O	634
,	PUNCT	O	O	634
but	CCONJ	O	O	634
the	PRON	O	O	634
incidence	NOUN	O	O	634
did	VERB	O	O	634
not	PART	O	O	634
differ	VERB	O	O	634
significantly	ADV	O	O	634
from	ADP	O	O	634
that	SCONJ	O	O	634
for	ADP	O	O	634
the	PRON	O	O	634
noncyanotic	ADJ	O	O	634
patients	NOUN	O	O	634
(	PUNCT	O	O	634
p	NOUN	O	O	634
=	PUNCT	O	O	634
0.243	NUM	O	O	634
)	PUNCT	O	O	634
.	PUNCT	O	O	634
Although	SCONJ	O	O	635
clinically	ADV	O	O	635
silent	ADJ	O	O	635
,	PUNCT	O	O	635
CIN	PROPN	O	Disease	635
is	AUX	O	O	635
not	PART	O	O	635
rare	ADJ	O	O	635
in	ADP	O	O	635
pediatrics	NOUN	O	O	635
.	PUNCT	O	O	635
The	PRON	O	O	636
incidence	NOUN	O	O	636
depends	VERB	O	O	636
on	ADP	O	O	636
dosage	NOUN	O	O	636
but	CCONJ	O	O	636
not	PART	O	O	636
on	ADP	O	O	636
the	PRON	O	O	636
type	NOUN	O	O	636
of	ADP	O	O	636
consumed	VERB	O	O	636
nonionic	ADJ	O	O	636
CM	PROPN	O	Disease	636
,	PUNCT	O	O	636
nor	CCONJ	O	O	636
on	ADP	O	O	636
the	PRON	O	O	636
presence	NOUN	O	O	636
of	ADP	O	O	636
cyanosis	NOUN	O	Disease	636
,	PUNCT	O	O	636
and	CCONJ	O	O	636
although	SCONJ	O	O	636
CIN	PROPN	O	Disease	636
usually	ADV	O	O	636
is	AUX	O	O	636
reversible	ADJ	O	O	636
,	PUNCT	O	O	636
more	ADJ	O	O	636
concern	NOUN	O	O	636
is	AUX	O	O	636
needed	VERB	O	O	636
for	ADP	O	O	636
the	PRON	O	O	636
prevention	NOUN	O	O	636
of	ADP	O	O	636
such	ADJ	O	O	636
a	PRON	O	O	636
complication	NOUN	O	O	636
in	ADP	O	O	636
children	NOUN	O	O	636
.	PUNCT	O	O	636
A	PRON	O	O	639
case	NOUN	O	O	639
of	ADP	O	O	639
ventricular tachycardia	NOUN	O	Disease	639
related	ADJ	O	O	639
to	PART	O	O	639
caffeine	NOUN	O	Chemical	639
pretreatment	NOUN	O	O	639
.	PUNCT	O	O	639
Suboptimal	ADJ	O	O	640
seizure	NOUN	O	Disease	640
duration	NOUN	O	O	640
is	AUX	O	O	640
commonly	ADV	O	O	640
encountered	VERB	O	O	640
in	ADP	O	O	640
electroconvulsive	VERB	O	O	640
therapy	NOUN	O	O	640
practice	VERB	O	O	640
,	PUNCT	O	O	640
especially	ADV	O	O	640
in	ADP	O	O	640
older	ADJ	O	O	640
patients	NOUN	O	O	640
with	ADP	O	O	640
higher	ADJ	O	O	640
seizure	NOUN	O	Disease	640
thresholds	NOUN	O	O	640
.	PUNCT	O	O	640
Intravenous	PROPN	O	O	641
caffeine	NOUN	O	Chemical	641
is	AUX	O	O	641
commonly	ADV	O	O	641
used	VERB	O	O	641
to	PART	O	O	641
improve	VERB	O	O	641
seizure	NOUN	O	Disease	641
duration	NOUN	O	O	641
and	CCONJ	O	O	641
quality	NOUN	O	O	641
in	ADP	O	O	641
such	ADJ	O	O	641
patients	NOUN	O	O	641
and	CCONJ	O	O	641
is	AUX	O	O	641
generally	ADV	O	O	641
well	ADV	O	O	641
tolerated	VERB	O	O	641
aside	ADV	O	O	641
from	ADP	O	O	641
occasional	ADJ	O	O	641
reports	VERB	O	O	641
of	ADP	O	O	641
relatively	ADV	O	O	641
benign	ADJ	O	O	641
ventricular ectopy	NOUN	O	Disease	641
.	PUNCT	O	O	641
We	PRON	O	O	642
describe	VERB	O	O	642
a	PRON	O	O	642
patient	NOUN	O	O	642
with	ADP	O	O	642
no	PRON	O	O	642
previous	ADJ	O	O	642
history	NOUN	O	O	642
of	ADP	O	O	642
cardiac disease	NOUN	O	Disease	642
or	CCONJ	O	O	642
arrhythmia	NOUN	O	Disease	642
who	PRON	O	O	642
developed	VERB	O	O	642
sustained	VERB	O	O	642
bigeminy	PROPN	O	O	642
and	CCONJ	O	O	642
2	X	O	O	642
brief	PROPN	O	O	642
runs	VERB	O	O	642
of	ADP	O	O	642
ventricular tachycardia	NOUN	O	Disease	642
after	ADP	O	O	642
caffeine	NOUN	O	Chemical	642
administration	NOUN	O	O	642
.	PUNCT	O	O	642
Although	SCONJ	O	O	643
intravenous	ADJ	O	O	643
caffeine	NOUN	O	Chemical	643
is	AUX	O	O	643
generally	ADV	O	O	643
well	ADV	O	O	643
tolerated	VERB	O	O	643
,	PUNCT	O	O	643
the	PRON	O	O	643
clinician	NOUN	O	O	643
should	AUX	O	O	643
be	AUX	O	O	643
aware	ADJ	O	O	643
of	ADP	O	O	643
the	PRON	O	O	643
potential	ADJ	O	O	643
for	ADP	O	O	643
unpredictable	ADJ	O	O	643
and	CCONJ	O	O	643
serious	ADJ	O	O	643
ventricular arrhythmias	NOUN	O	Disease	643
.	PUNCT	O	O	643
Optical	PROPN	O	O	646
coherence	VERB	O	O	646
tomography	NOUN	O	O	646
can	AUX	O	O	646
measure	VERB	O	O	646
axonal	ADJ	O	O	646
loss	NOUN	O	O	646
in	ADP	O	O	646
patients	NOUN	O	O	646
with	ADP	O	O	646
ethambutol	PROPN	O	Chemical	646
-	PUNCT	O	O	646
induced	VERB	O	O	646
optic neuropathy	NOUN	O	Disease	646
.	PUNCT	O	O	646
PURPOSE	NOUN	O	O	647
:	PUNCT	O	O	647
To	PART	O	O	647
map	NOUN	O	O	647
and	CCONJ	O	O	647
identify	VERB	O	O	647
the	PRON	O	O	647
pattern	NOUN	O	O	647
,	PUNCT	O	O	647
in	ADP	O	O	647
vivo	VERB	O	O	647
,	PUNCT	O	O	647
of	ADP	O	O	647
axonal degeneration	NOUN	O	Disease	647
in	ADP	O	O	647
ethambutol	PROPN	O	Chemical	647
-	PUNCT	O	O	647
induced	VERB	O	O	647
optic neuropathy	NOUN	O	Disease	647
using	VERB	O	O	647
optical	PROPN	O	O	647
coherence	VERB	O	O	647
tomography	NOUN	O	O	647
(	PUNCT	O	O	647
OCT	PROPN	O	Chemical	647
)	PUNCT	O	O	647
.	PUNCT	O	O	647
Ethambutol	PROPN	O	Chemical	648
is	AUX	O	O	648
an	PRON	O	O	648
antimycobacterial	VERB	O	O	648
agent	NOUN	O	O	648
often	ADV	O	O	648
used	VERB	O	O	648
to	PART	O	O	648
treat	VERB	O	O	648
tuberculosis	NOUN	O	Disease	648
.	PUNCT	O	O	648
A	PRON	O	O	649
serious	ADJ	O	O	649
complication	NOUN	O	O	649
of	ADP	O	O	649
ethambutol	PROPN	O	Chemical	649
is	AUX	O	O	649
an	PRON	O	O	649
optic neuropathy	NOUN	O	Disease	649
that	SCONJ	O	O	649
impairs	VERB	O	O	649
visual	ADJ	O	O	649
acuity	NOUN	O	O	649
,	PUNCT	O	O	649
contrast	NOUN	O	O	649
sensitivity	NOUN	O	O	649
,	PUNCT	O	O	649
and	CCONJ	O	O	649
color	NOUN	O	O	649
vision	PROPN	O	O	649
.	PUNCT	O	O	649
However	ADV	O	O	650
,	PUNCT	O	O	650
early	ADV	O	O	650
on	ADP	O	O	650
,	PUNCT	O	O	650
when	SCONJ	O	O	650
the	PRON	O	O	650
toxic optic neuropathy	NOUN	O	Disease	650
is	AUX	O	O	650
mild	ADJ	O	O	650
and	CCONJ	O	O	650
partly	ADV	O	O	650
reversible	ADJ	O	O	650
,	PUNCT	O	O	650
the	PRON	O	O	650
funduscopic	VERB	O	O	650
findings	NOUN	O	O	650
are	AUX	O	O	650
often	ADV	O	O	650
subtle	ADJ	O	O	650
and	CCONJ	O	O	650
easy	ADV	O	O	650
to	PART	O	O	650
miss	VERB	O	O	650
.	PUNCT	O	O	650
METHODS	NOUN	O	O	651
:	PUNCT	O	O	651
Three	NUM	O	O	651
subjects	NOUN	O	O	651
with	ADP	O	O	651
a	PRON	O	O	651
history	NOUN	O	O	651
of	ADP	O	O	651
ethambutol	PROPN	O	Chemical	651
(	PUNCT	O	O	651
EMB)-induced	VERB	O	O	651
optic neuropathy	NOUN	O	Disease	651
of	ADP	O	O	651
short-	ADV	O	O	651
,	PUNCT	O	O	651
intermediate-	ADP	O	O	651
,	PUNCT	O	O	651
and	CCONJ	O	O	651
long	ADV	O	O	651
-	PUNCT	O	O	651
term	NOUN	O	O	651
visual deficits	NOUN	O	Disease	651
were	AUX	O	O	651
administered	VERB	O	O	651
a	PRON	O	O	651
full	ADJ	O	O	651
neuro	PROPN	O	O	651
-	PUNCT	O	O	651
ophthalmologic	ADV	O	O	651
examination	NOUN	O	O	651
including	VERB	O	O	651
visual	ADJ	O	O	651
acuity	NOUN	O	O	651
,	PUNCT	O	O	651
color	NOUN	O	O	651
vision	PROPN	O	O	651
,	PUNCT	O	O	651
contrast	NOUN	O	O	651
sensitivity	NOUN	O	O	651
,	PUNCT	O	O	651
and	CCONJ	O	O	651
fundus	NOUN	O	O	651
examination	NOUN	O	O	651
.	PUNCT	O	O	651
In	ADP	O	O	652
all	PRON	O	O	652
subjects	NOUN	O	O	652
with	ADP	O	O	652
history	NOUN	O	O	652
of	ADP	O	O	652
EMB	PROPN	O	Chemical	652
-	PUNCT	O	O	652
induced	VERB	O	O	652
optic neuropathy	NOUN	O	Disease	652
,	PUNCT	O	O	652
there	ADV	O	O	652
was	AUX	O	O	652
a	PRON	O	O	652
mean	VERB	O	O	652
loss	NOUN	O	O	652
of	ADP	O	O	652
72%	NOUN	O	O	652
nerve	NOUN	O	O	652
fiber	PROPN	O	O	652
layer	NOUN	O	O	652
thickness	NOUN	O	O	652
in	ADP	O	O	652
the	PRON	O	O	652
temporal	ADJ	O	O	652
quadrant	NOUN	O	O	652
(	PUNCT	O	O	652
patient	NOUN	O	O	652
A	PRON	O	O	652
,	PUNCT	O	O	652
with	ADP	O	O	652
eventual	ADJ	O	O	652
recovery	NOUN	O	O	652
of	ADP	O	O	652
visual	ADJ	O	O	652
acuity	NOUN	O	O	652
and	CCONJ	O	O	652
fields	NOUN	O	O	652
,	PUNCT	O	O	652
58%	NOUN	O	O	652
loss	NOUN	O	O	652
;	PUNCT	O	O	652
patient	NOUN	O	O	652
B	NOUN	O	O	652
,	PUNCT	O	O	652
with	ADP	O	O	652
intermediate	PROPN	O	O	652
visual deficits	NOUN	O	Disease	652
,	PUNCT	O	O	652
68%	NOUN	O	O	652
loss	NOUN	O	O	652
;	PUNCT	O	O	652
patient	NOUN	O	O	652
C	NOUN	O	O	652
,	PUNCT	O	O	652
with	ADP	O	O	652
chronic	ADJ	O	O	652
visual deficits	NOUN	O	Disease	652
,	PUNCT	O	O	652
90%	NOUN	O	O	652
loss	NOUN	O	O	652
)	PUNCT	O	O	652
,	PUNCT	O	O	652
with	ADP	O	O	652
an	PRON	O	O	652
average	ADJ	O	O	652
mean	VERB	O	O	652
optic	NOUN	O	O	652
nerve	NOUN	O	O	652
thickness	NOUN	O	O	652
of	ADP	O	O	652
26+/-16	NUM	O	O	652
microm	PROPN	O	O	652
.	PUNCT	O	O	652
In	ADP	O	O	653
both	PRON	O	O	653
sets	VERB	O	O	653
(	PUNCT	O	O	653
four	NUM	O	O	653
)	PUNCT	O	O	653
of	ADP	O	O	653
eyes	NOUN	O	O	653
of	ADP	O	O	653
the	PRON	O	O	653
subjects	NOUN	O	O	653
with	ADP	O	O	653
persistent	ADJ	O	O	653
visual deficits	NOUN	O	Disease	653
(	PUNCT	O	O	653
patients	NOUN	O	O	653
B	NOUN	O	O	653
and	CCONJ	O	O	653
C	NOUN	O	O	653
)	PUNCT	O	O	653
,	PUNCT	O	O	653
there	ADV	O	O	653
was	AUX	O	O	653
an	PRON	O	O	653
average	ADJ	O	O	653
loss	NOUN	O	O	653
of	ADP	O	O	653
79%	NOUN	O	O	653
of	ADP	O	O	653
nerve	NOUN	O	O	653
fiber	PROPN	O	O	653
thickness	NOUN	O	O	653
in	ADP	O	O	653
the	PRON	O	O	653
temporal	ADJ	O	O	653
quadrant	NOUN	O	O	653
.	PUNCT	O	O	653
The	PRON	O	O	654
OCT	PROPN	O	Chemical	654
results	VERB	O	O	654
in	ADP	O	O	654
these	PRON	O	O	654
patients	NOUN	O	O	654
with	ADP	O	O	654
EMB	PROPN	O	Chemical	654
-	PUNCT	O	O	654
induced	VERB	O	O	654
optic neuropathy	NOUN	O	Disease	654
show	VERB	O	O	654
considerable	ADJ	O	O	654
loss	NOUN	O	O	654
especially	ADV	O	O	654
of	ADP	O	O	654
the	PRON	O	O	654
temporal	ADJ	O	O	654
fibers	NOUN	O	O	654
.	PUNCT	O	O	654
This	PRON	O	O	655
is	AUX	O	O	655
consistent	ADJ	O	O	655
with	ADP	O	O	655
prior	ADV	O	O	655
histopathological	ADJ	O	O	655
studies	NOUN	O	O	655
that	SCONJ	O	O	655
show	VERB	O	O	655
predominant	ADJ	O	O	655
loss	NOUN	O	O	655
of	ADP	O	O	655
parvo	PROPN	O	O	655
-	PUNCT	O	O	655
cellular	NOUN	O	O	655
axons	NOUN	O	O	655
(	PUNCT	O	O	655
or	CCONJ	O	O	655
small	ADJ	O	O	655
-	PUNCT	O	O	655
caliber	PROPN	O	O	655
axons	NOUN	O	O	655
)	PUNCT	O	O	655
within	ADP	O	O	655
the	PRON	O	O	655
papillo	NOUN	O	O	655
-	PUNCT	O	O	655
macular	ADJ	O	O	655
bundle	VERB	O	O	655
in	ADP	O	O	655
toxic	ADJ	O	O	655
or	CCONJ	O	O	655
hereditary	ADJ	O	O	655
optic neuropathies	NOUN	O	Disease	655
.	PUNCT	O	O	655
OCT	PROPN	O	Chemical	656
can	AUX	O	O	656
be	AUX	O	O	656
a	PRON	O	O	656
valuable	ADJ	O	O	656
tool	NOUN	O	O	656
in	ADP	O	O	656
the	PRON	O	O	656
quantitative	ADJ	O	O	656
analysis	NOUN	O	O	656
of	ADP	O	O	656
optic neuropathies	NOUN	O	Disease	656
.	PUNCT	O	O	656
Additionally	ADV	O	O	657
,	PUNCT	O	O	657
in	ADP	O	O	657
terms	NOUN	O	O	657
of	ADP	O	O	657
management	NOUN	O	O	657
of	ADP	O	O	657
EMB	PROPN	O	Chemical	657
-	PUNCT	O	O	657
induced	VERB	O	O	657
optic neuropathy	NOUN	O	Disease	657
,	PUNCT	O	O	657
it	PRON	O	O	657
is	AUX	O	O	657
important	ADJ	O	O	657
to	PART	O	O	657
properly	ADV	O	O	657
manage	VERB	O	O	657
ethambutol	PROPN	O	Chemical	657
dosing	VERB	O	O	657
in	ADP	O	O	657
patients	NOUN	O	O	657
with	ADP	O	O	657
renal impairment	NOUN	O	Disease	657
and	CCONJ	O	O	657
to	PART	O	O	657
achieve	VERB	O	O	657
proper	ADJ	O	O	657
transition	NOUN	O	O	657
to	PART	O	O	657
a	PRON	O	O	657
maintenance	NOUN	O	O	657
dose	NOUN	O	O	657
once	ADV	O	O	657
an	PRON	O	O	657
appropriate	ADJ	O	O	657
loading	NOUN	O	O	657
dose	NOUN	O	O	657
has	VERB	O	O	657
been	AUX	O	O	657
reached	VERB	O	O	657
.	PUNCT	O	O	657
Effects	NOUN	O	O	660
of	ADP	O	O	660
the	PRON	O	O	660
cyclooxygenase-2	NUM	O	O	660
specific	ADJ	O	O	660
inhibitor	NOUN	O	O	660
valdecoxib	PROPN	O	Chemical	660
versus	ADP	O	O	660
nonsteroidal	ADJ	O	O	660
antiinflammatory	ADJ	O	O	660
agents	NOUN	O	O	660
and	CCONJ	O	O	660
placebo	NOUN	O	O	660
on	ADP	O	O	660
cardiovascular	ADJ	O	O	660
thrombotic	ADJ	O	Disease	660
events	NOUN	O	O	660
in	ADP	O	O	660
patients	NOUN	O	O	660
with	ADP	O	O	660
arthritis	NOUN	O	Disease	660
.	PUNCT	O	O	660
There	ADV	O	O	661
have	VERB	O	O	661
been	AUX	O	O	661
concerns	NOUN	O	O	661
that	SCONJ	O	O	661
the	PRON	O	O	661
risk	NOUN	O	O	661
of	ADP	O	O	661
cardiovascular	ADJ	O	O	661
thrombotic	ADJ	O	Disease	661
events	NOUN	O	O	661
may	AUX	O	O	661
be	AUX	O	O	661
higher	ADJ	O	O	661
with	ADP	O	O	661
cyclooxygenase	PROPN	O	O	661
(	PUNCT	O	O	661
COX)-2-specific	ADJ	O	O	661
inhibitors	NOUN	O	O	661
than	ADP	O	O	661
nonselective	ADJ	O	O	661
nonsteroidal	ADJ	O	O	661
antiinflammatory	ADJ	O	O	661
drugs	NOUN	O	O	661
(	PUNCT	O	O	661
NSAIDs	NOUN	O	Chemical	661
)	PUNCT	O	O	661
.	PUNCT	O	O	661
We	PRON	O	O	662
evaluated	VERB	O	O	662
cardiovascular	ADJ	O	O	662
event	NOUN	O	O	662
data	NOUN	O	O	662
for	ADP	O	O	662
valdecoxib	PROPN	O	Chemical	662
,	PUNCT	O	O	662
a	PRON	O	O	662
new	ADJ	O	O	662
COX-2-specific	ADJ	O	O	662
inhibitor	NOUN	O	O	662
in	ADP	O	O	662
approximately	ADV	O	O	662
8000	NUM	O	O	662
patients	NOUN	O	O	662
with	ADP	O	O	662
osteoarthritis	NOUN	O	Disease	662
and	CCONJ	O	O	662
rheumatoid arthritis	NOUN	O	Disease	662
treated	VERB	O	O	662
with	ADP	O	O	662
this	PRON	O	O	662
agent	NOUN	O	O	662
in	ADP	O	O	662
randomized	VERB	O	O	662
clinical	ADJ	O	O	662
trials	NOUN	O	O	662
.	PUNCT	O	O	662
The	PRON	O	O	663
incidence	NOUN	O	O	663
of	ADP	O	O	663
cardiovascular	ADJ	O	O	663
thrombotic	ADJ	O	Disease	663
events	NOUN	O	O	663
(	PUNCT	O	O	663
cardiac	ADJ	O	O	663
,	PUNCT	O	O	663
cerebrovascular	ADJ	O	O	663
and	CCONJ	O	O	663
peripheral	ADJ	O	O	663
vascular	ADJ	O	O	663
,	PUNCT	O	O	663
or	CCONJ	O	O	663
arterial	ADJ	O	O	663
thrombotic	ADJ	O	Disease	663
)	PUNCT	O	O	663
was	AUX	O	O	663
determined	VERB	O	O	663
by	ADP	O	O	663
analyzing	VERB	O	O	663
pooled	VERB	O	O	663
valdecoxib	PROPN	O	Chemical	663
(	PUNCT	O	O	663
10	NUM	O	O	663
-	PUNCT	O	O	663
80	NUM	O	O	663
mg	VERB	O	O	663
daily	ADV	O	O	663
)	PUNCT	O	O	663
,	PUNCT	O	O	663
nonselective	ADJ	O	O	663
NSAID	PROPN	O	Chemical	663
(	PUNCT	O	O	663
diclofenac	PROPN	O	Chemical	663
75	NUM	O	O	663
mg	VERB	O	O	663
bid	VERB	O	O	663
,	PUNCT	O	O	663
ibuprofen	PROPN	O	Chemical	663
800	NUM	O	O	663
mg	VERB	O	O	663
tid	PROPN	O	O	663
,	PUNCT	O	O	663
or	CCONJ	O	O	663
naproxen	PROPN	O	Chemical	663
500	NUM	O	O	663
mg	VERB	O	O	663
bid	VERB	O	O	663
)	PUNCT	O	O	663
and	CCONJ	O	O	663
placebo	NOUN	O	O	663
data	NOUN	O	O	663
from	ADP	O	O	663
10	NUM	O	O	663
randomized	VERB	O	O	663
osteoarthritis	NOUN	O	Disease	663
and	CCONJ	O	O	663
rheumatoid arthritis	NOUN	O	Disease	663
trials	NOUN	O	O	663
that	SCONJ	O	O	663
were	AUX	O	O	663
6	NUM	O	O	663
-	PUNCT	O	O	663
52	NUM	O	O	663
weeks	NOUN	O	O	663
in	ADP	O	O	663
duration	NOUN	O	O	663
.	PUNCT	O	O	663
in	ADP	O	O	664
users	NOUN	O	O	664
of	ADP	O	O	664
low	ADJ	O	O	664
-	PUNCT	O	O	664
dose	NOUN	O	O	664
(	PUNCT	O	O	664
<	X	O	O	664
or	CCONJ	O	O	664
=	PUNCT	O	O	664
325	NUM	O	O	664
mg	VERB	O	O	664
daily	ADV	O	O	664
)	PUNCT	O	O	664
aspirin	NOUN	O	Chemical	664
(	PUNCT	O	O	664
n	CCONJ	O	O	664
=	PUNCT	O	O	664
1051	NUM	O	O	664
)	PUNCT	O	O	664
and	CCONJ	O	O	664
nonusers	NOUN	O	O	664
of	ADP	O	O	664
aspirin	NOUN	O	Chemical	664
(	PUNCT	O	O	664
n	CCONJ	O	O	664
=	PUNCT	O	O	664
6883	NUM	O	O	664
)	PUNCT	O	O	664
.	PUNCT	O	O	664
Crude	NOUN	O	O	665
and	CCONJ	O	O	665
exposure	NOUN	O	O	665
-	PUNCT	O	O	665
adjusted	VERB	O	O	665
incidences	NOUN	O	O	665
of	ADP	O	O	665
thrombotic	ADJ	O	Disease	665
events	NOUN	O	O	665
were	AUX	O	O	665
similar	ADJ	O	O	665
for	ADP	O	O	665
valdecoxib	PROPN	O	Chemical	665
,	PUNCT	O	O	665
NSAIDs	NOUN	O	Chemical	665
,	PUNCT	O	O	665
and	CCONJ	O	O	665
placebo	NOUN	O	O	665
.	PUNCT	O	O	665
The	PRON	O	O	666
risk	NOUN	O	O	666
of	ADP	O	O	666
serious	ADJ	O	O	666
thrombotic	ADJ	O	Disease	666
events	NOUN	O	O	666
was	AUX	O	O	666
also	ADV	O	O	666
similar	ADJ	O	O	666
for	ADP	O	O	666
each	PRON	O	O	666
valdecoxib	PROPN	O	Chemical	666
dose	NOUN	O	O	666
.	PUNCT	O	O	666
Thrombotic	ADJ	O	Disease	667
risk	NOUN	O	O	667
was	AUX	O	O	667
consistently	ADV	O	O	667
higher	ADJ	O	O	667
for	ADP	O	O	667
users	NOUN	O	O	667
of	ADP	O	O	667
aspirin	NOUN	O	Chemical	667
users	NOUN	O	O	667
than	ADP	O	O	667
nonusers	NOUN	O	O	667
of	ADP	O	O	667
aspirin	NOUN	O	Chemical	667
(	PUNCT	O	O	667
placebo	NOUN	O	O	667
,	PUNCT	O	O	667
1.4%	NOUN	O	O	667
vs.	CCONJ	O	O	667
0%	NOUN	O	O	667
;	PUNCT	O	O	667
valdecoxib	PROPN	O	Chemical	667
,	PUNCT	O	O	667
1.7%	NOUN	O	O	667
vs.	CCONJ	O	O	667
0.2%	NOUN	O	O	667
;	PUNCT	O	O	667
NSAIDs	NOUN	O	Chemical	667
,	PUNCT	O	O	667
1.9%	NOUN	O	O	667
vs.	CCONJ	O	O	667
0.5%	NOUN	O	O	667
)	PUNCT	O	O	667
.	PUNCT	O	O	667
The	PRON	O	O	668
rates	NOUN	O	O	668
of	ADP	O	O	668
events	NOUN	O	O	668
in	ADP	O	O	668
users	NOUN	O	O	668
of	ADP	O	O	668
aspirin	NOUN	O	Chemical	668
were	AUX	O	O	668
similar	ADJ	O	O	668
for	ADP	O	O	668
all	PRON	O	O	668
3	X	O	O	668
treatment	NOUN	O	O	668
groups	NOUN	O	O	668
and	CCONJ	O	O	668
across	ADP	O	O	668
valdecoxib	PROPN	O	Chemical	668
doses	NOUN	O	O	668
.	PUNCT	O	O	668
valdecoxib	PROPN	O	Chemical	669
doses	NOUN	O	O	669
was	AUX	O	O	669
not	PART	O	O	669
associated	VERB	O	O	669
with	ADP	O	O	669
an	PRON	O	O	669
increased	VERB	O	O	669
incidence	NOUN	O	O	669
of	ADP	O	O	669
thrombotic	ADJ	O	Disease	669
events	NOUN	O	O	669
relative	ADJ	O	O	669
to	PART	O	O	669
nonselective	ADJ	O	O	669
NSAIDs	NOUN	O	Chemical	669
or	CCONJ	O	O	669
placebo	NOUN	O	O	669
in	ADP	O	O	669
osteoarthritis	NOUN	O	Disease	669
and	CCONJ	O	O	669
rheumatoid arthritis	NOUN	O	Disease	669
patients	NOUN	O	O	669
in	ADP	O	O	669
controlled	VERB	O	O	669
clinical	ADJ	O	O	669
trials	NOUN	O	O	669
.	PUNCT	O	O	669
A	PRON	O	O	672
randomized	VERB	O	O	672
,	PUNCT	O	O	672
placebo	NOUN	O	O	672
-	PUNCT	O	O	672
controlled	VERB	O	O	672
,	PUNCT	O	O	672
crossover	NOUN	O	O	672
study	VERB	O	O	672
of	ADP	O	O	672
ephedrine	NOUN	O	Chemical	672
for	ADP	O	O	672
SSRI	NOUN	O	O	672
-	PUNCT	O	O	672
induced	VERB	O	O	672
female	ADJ	O	O	672
sexual dysfunction	NOUN	O	Disease	672
.	PUNCT	O	O	672
The	PRON	O	O	673
objective	VERB	O	O	673
of	ADP	O	O	673
this	PRON	O	O	673
study	VERB	O	O	673
was	AUX	O	O	673
to	PART	O	O	673
determine	VERB	O	O	673
whether	SCONJ	O	O	673
ephedrine	NOUN	O	Chemical	673
,	PUNCT	O	O	673
an	PRON	O	O	673
alpha-	X	O	O	673
and	CCONJ	O	O	673
beta	NOUN	O	O	673
-	PUNCT	O	O	673
adrenergic	NOUN	O	O	673
agonist	NOUN	O	O	673
previously	ADV	O	O	673
shown	VERB	O	O	673
to	PART	O	O	673
enhance	VERB	O	O	673
genital	NOUN	O	O	673
blood	NOUN	O	O	673
flow	NOUN	O	O	673
in	ADP	O	O	673
women	NOUN	O	O	673
,	PUNCT	O	O	673
has	VERB	O	O	673
beneficial	ADJ	O	O	673
effects	NOUN	O	O	673
in	ADP	O	O	673
reversing	VERB	O	O	673
antidepressant	NOUN	O	O	673
-	PUNCT	O	O	673
induced	VERB	O	O	673
sexual dysfunction	NOUN	O	Disease	673
.	PUNCT	O	O	673
Nineteen	NUM	O	O	674
sexually dysfunctional	ADJ	O	Disease	674
women	NOUN	O	O	674
receiving	VERB	O	O	674
either	ADV	O	O	674
fluoxetine	NOUN	O	Chemical	674
,	PUNCT	O	O	674
sertraline	PROPN	O	Chemical	674
,	PUNCT	O	O	674
or	CCONJ	O	O	674
paroxetine	NOUN	O	Chemical	674
participated	VERB	O	O	674
in	ADP	O	O	674
an	PRON	O	O	674
eight	NUM	O	O	674
-	PUNCT	O	O	674
week	NOUN	O	O	674
,	PUNCT	O	O	674
double	ADJ	O	O	674
-	PUNCT	O	O	674
blind	ADJ	O	Disease	674
,	PUNCT	O	O	674
placebo	NOUN	O	O	674
-	PUNCT	O	O	674
controlled	VERB	O	O	674
,	PUNCT	O	O	674
cross	VERB	O	O	674
-	PUNCT	O	O	674
over	ADP	O	O	674
study	VERB	O	O	674
of	ADP	O	O	674
the	PRON	O	O	674
effects	NOUN	O	O	674
of	ADP	O	O	674
ephedrine	NOUN	O	Chemical	674
(	PUNCT	O	O	674
50	NUM	O	O	674
mg	VERB	O	O	674
)	PUNCT	O	O	674
on	ADP	O	O	674
self	VERB	O	O	674
-	PUNCT	O	O	674
report	VERB	O	O	674
measures	NOUN	O	O	674
of	ADP	O	O	674
sexual	ADJ	O	O	674
desire	VERB	O	O	674
,	PUNCT	O	O	674
arousal	NOUN	O	O	674
,	PUNCT	O	O	674
orgasm	NOUN	O	O	674
,	PUNCT	O	O	674
and	CCONJ	O	O	674
sexual	ADJ	O	O	674
satisfaction	NOUN	O	O	674
.	PUNCT	O	O	674
Although	SCONJ	O	O	675
there	ADV	O	O	675
were	AUX	O	O	675
significant	ADJ	O	O	675
improvements	NOUN	O	O	675
relative	ADJ	O	O	675
to	PART	O	O	675
baseline	VERB	O	O	675
in	ADP	O	O	675
sexual	ADJ	O	O	675
desire	VERB	O	O	675
and	CCONJ	O	O	675
orgasm	NOUN	O	O	675
intensity	NOUN	O	O	675
/	PUNCT	O	O	675
pleasure	NOUN	O	O	675
on	ADP	O	O	675
50	NUM	O	O	675
mg	VERB	O	O	675
ephedrine	NOUN	O	Chemical	675
1-hr	NOUN	O	O	675
prior	ADV	O	O	675
to	PART	O	O	675
sexual	ADJ	O	O	675
activity	NOUN	O	O	675
,	PUNCT	O	O	675
significant	ADJ	O	O	675
improvements	NOUN	O	O	675
in	ADP	O	O	675
these	PRON	O	O	675
measures	NOUN	O	O	675
,	PUNCT	O	O	675
as	ADP	O	O	675
well	ADV	O	O	675
as	ADP	O	O	675
in	ADP	O	O	675
sexual	ADJ	O	O	675
arousal	NOUN	O	O	675
and	CCONJ	O	O	675
orgasmic	ADJ	O	O	675
ability	NOUN	O	O	675
also	ADV	O	O	675
were	AUX	O	O	675
noted	VERB	O	O	675
with	ADP	O	O	675
placebo	NOUN	O	O	675
.	PUNCT	O	O	675
Erectile dysfunction	NOUN	O	Disease	678
occurs	VERB	O	O	678
following	VERB	O	O	678
substantia nigra lesions	NOUN	O	O	678
in	ADP	O	O	678
the	PRON	O	O	678
rat	NOUN	O	O	678
.	PUNCT	O	O	678
Erectile	PROPN	O	O	679
function	NOUN	O	O	679
was	AUX	O	O	679
assessed	VERB	O	O	679
6	NUM	O	O	679
weeks	NOUN	O	O	679
following	VERB	O	O	679
uni-	ADV	O	O	679
and	CCONJ	O	O	679
bilateral	ADJ	O	O	679
injections	NOUN	O	O	679
of	ADP	O	O	679
6-hydroxydopamine	NOUN	O	Chemical	679
in	ADP	O	O	679
the	PRON	O	O	679
substantia	X	O	O	679
nigra	NOUN	O	O	679
nucleus	PROPN	O	O	679
of	ADP	O	O	679
the	PRON	O	O	679
brain	NOUN	O	O	679
.	PUNCT	O	O	679
Behavioral	NOUN	O	O	680
apomorphine	PROPN	O	Chemical	680
-	PUNCT	O	O	680
induced	VERB	O	O	680
penile	NOUN	O	O	680
erections	NOUN	O	O	680
were	AUX	O	O	680
reduced	VERB	O	O	680
(	PUNCT	O	O	680
5/8	NUM	O	O	680
)	PUNCT	O	O	680
and	CCONJ	O	O	680
increased	VERB	O	O	680
(	PUNCT	O	O	680
3/8	NUM	O	O	680
)	PUNCT	O	O	680
in	ADP	O	O	680
uni-	ADV	O	O	680
and	CCONJ	O	O	680
bilateral	ADJ	O	O	680
lesioned	VERB	O	O	680
animals	NOUN	O	O	680
.	PUNCT	O	O	680
Concentration	NOUN	O	O	681
of	ADP	O	O	681
dopamine	NOUN	O	Chemical	681
and	CCONJ	O	O	681
its	PRON	O	O	681
metabolites	VERB	O	O	681
were	AUX	O	O	681
decreased	VERB	O	O	681
in	ADP	O	O	681
the	PRON	O	O	681
striatum	NOUN	O	O	681
of	ADP	O	O	681
substantia nigra lesioned	VERB	O	O	681
rats	NOUN	O	O	681
.	PUNCT	O	O	681
Lesions	NOUN	O	O	682
of	ADP	O	O	682
the	PRON	O	O	682
substantia	X	O	O	682
nigra	NOUN	O	O	682
are	AUX	O	O	682
therefore	ADV	O	O	682
associated	VERB	O	O	682
with	ADP	O	O	682
erectile dysfunction	NOUN	O	Disease	682
in	ADP	O	O	682
rats	NOUN	O	O	682
and	CCONJ	O	O	682
may	AUX	O	O	682
serve	VERB	O	O	682
as	ADP	O	O	682
a	PRON	O	O	682
model	NOUN	O	O	682
to	PART	O	O	682
study	VERB	O	O	682
erectile dysfunction	NOUN	O	Disease	682
in	ADP	O	O	682
Parkinson	NOUN	O	O	682
's	AUX	O	O	682
disease	PROPN	O	O	682
.	PUNCT	O	O	682
Potential	ADJ	O	O	685
therapeutic	ADJ	O	O	685
use	VERB	O	O	685
of	ADP	O	O	685
the	PRON	O	O	685
selective	ADJ	O	O	685
dopamine	NOUN	O	Chemical	685
D1	PROPN	O	O	685
receptor	NOUN	O	O	685
agonist	NOUN	O	O	685
,	PUNCT	O	O	685
A-86929	NOUN	O	Chemical	685
:	PUNCT	O	O	685
an	PRON	O	O	685
acute	ADJ	O	O	685
study	VERB	O	O	685
in	ADP	O	O	685
parkinsonian	PROPN	O	Disease	685
levodopa	NOUN	O	Chemical	685
-	PUNCT	O	O	685
primed	VERB	O	O	685
monkeys	NOUN	O	O	685
.	PUNCT	O	O	685
The	PRON	O	O	686
clinical	ADJ	O	O	686
utility	NOUN	O	O	686
of	ADP	O	O	686
dopamine	NOUN	O	Chemical	686
(	PUNCT	O	O	686
DA	NOUN	O	Chemical	686
)	PUNCT	O	O	686
D1	PROPN	O	O	687
receptor	NOUN	O	O	687
agonists	NOUN	O	O	687
in	ADP	O	O	687
the	PRON	O	O	687
treatment	NOUN	O	O	687
of	ADP	O	O	687
Parkinson	NOUN	O	O	687
's	AUX	O	O	687
disease	PROPN	O	O	687
(	PUNCT	O	O	687
PD	PROPN	O	Disease	687
)	PUNCT	O	O	687
is	AUX	O	O	687
still	ADV	O	O	687
unclear	ADJ	O	O	687
.	PUNCT	O	O	687
The	PRON	O	O	688
therapeutic	ADJ	O	O	688
use	VERB	O	O	688
of	ADP	O	O	688
selective	ADJ	O	O	688
DA	NOUN	O	Chemical	688
D1	PROPN	O	O	688
receptor	NOUN	O	O	688
agonists	NOUN	O	O	688
such	ADJ	O	O	688
as	ADP	O	O	688
SKF-82958	NOUN	O	Chemical	688
(	PUNCT	O	O	688
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide	NOUN	O	Chemical	688
)	PUNCT	O	O	688
and	CCONJ	O	O	688
A-77636	NOUN	O	Chemical	688
(	PUNCT	O	O	688
[	X	O	O	688
1R	NOUN	O	O	688
,	PUNCT	O	O	688
3S	PROPN	O	O	688
]	PUNCT	O	O	688
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	NOUN	O	O	688
pyran	ADJ	O	O	688
hydrochloride	NOUN	O	O	688
)	PUNCT	O	O	688
seems	VERB	O	O	688
limited	VERB	O	O	688
because	SCONJ	O	O	688
of	ADP	O	O	688
their	PRON	O	O	688
duration	NOUN	O	O	688
of	ADP	O	O	688
action	NOUN	O	O	688
,	PUNCT	O	O	688
which	PRON	O	O	688
is	AUX	O	O	688
too	ADV	O	O	688
short	ADJ	O	O	688
for	ADP	O	O	688
SKF-82958	NOUN	O	Chemical	688
(	PUNCT	O	O	688
<	X	O	O	688
1	X	O	O	688
hr	NOUN	O	O	688
)	PUNCT	O	O	688
and	CCONJ	O	O	688
too	ADV	O	O	688
long	ADV	O	O	688
for	ADP	O	O	688
A-77636	NOUN	O	Chemical	688
(	PUNCT	O	O	688
>	PUNCT	O	O	688
20	NUM	O	O	688
We	PRON	O	O	689
therefore	ADV	O	O	689
conducted	VERB	O	O	689
the	PRON	O	O	689
present	NOUN	O	O	689
acute	ADJ	O	O	689
dose	NOUN	O	O	689
-	PUNCT	O	O	689
response	NOUN	O	O	689
study	VERB	O	O	689
in	ADP	O	O	689
four	NUM	O	O	689
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	ADJ	O	Chemical	689
(	PUNCT	O	O	689
MPTP)-exposed	VERB	O	O	689
cynomolgus	NOUN	O	O	689
monkeys	NOUN	O	O	689
primed	VERB	O	O	689
to	PART	O	O	689
exhibit	VERB	O	O	689
levodopa	NOUN	O	Chemical	689
-	PUNCT	O	O	689
induced	VERB	O	O	689
dyskinesias	PROPN	O	Disease	689
to	PART	O	O	689
evaluate	VERB	O	O	689
the	PRON	O	O	689
locomotor	PROPN	O	O	689
and	CCONJ	O	O	689
dyskinetic	VERB	O	Disease	689
effects	NOUN	O	O	689
on	ADP	O	O	689
challenge	NOUN	O	O	689
with	ADP	O	O	689
four	NUM	O	O	689
doses	NOUN	O	O	689
(	PUNCT	O	O	689
from	ADP	O	O	689
0.03	NUM	O	O	689
to	PART	O	O	689
1.0	NUM	O	O	689
mg	VERB	O	O	689
/	PUNCT	O	O	689
kg	VERB	O	O	689
)	PUNCT	O	O	689
of	ADP	O	O	689
A-86929	NOUN	O	Chemical	689
(	PUNCT	O	O	689
[	X	O	O	689
-]-[5aR,11bS]-4,5,5a,6,7,11b	PUNCT	O	O	689
-	PUNCT	O	O	689
hexahydro-2-propyl-3-thia-5-+	NOUN	O	O	689
+	ADP	O	O	689
+	ADP	O	O	689
azacyclopent-1-	VERB	O	O	689
ena[c]phenathrene-9	NOUN	O	O	689
-	PUNCT	O	O	689
10-diol	NOUN	O	O	689
)	PUNCT	O	O	689
,	PUNCT	O	O	689
a	PRON	O	O	689
selective	ADJ	O	O	689
and	CCONJ	O	O	689
full	ADJ	O	O	689
DA	NOUN	O	Chemical	689
D1-like	ADJ	O	O	689
receptor	NOUN	O	O	689
agonist	NOUN	O	O	689
with	ADP	O	O	689
an	PRON	O	O	689
intermediate	PROPN	O	O	689
duration	NOUN	O	O	689
of	ADP	O	O	689
action	NOUN	O	O	689
.	PUNCT	O	O	689
Levodopa	NOUN	O	Chemical	690
and	CCONJ	O	O	690
the	PRON	O	O	690
DA	NOUN	O	Chemical	690
D2-like	ADJ	O	O	691
receptor	NOUN	O	O	691
agonist	NOUN	O	O	691
,	PUNCT	O	O	691
LY-171555	NOUN	O	Chemical	691
(	PUNCT	O	O	691
[	X	O	O	691
4aR	NUM	O	O	691
-	PUNCT	O	O	691
trans]-4,4a,5,6,7,8,8a,9-o	NOUN	O	O	691
-	PUNCT	O	O	691
dihydro-5n	PROPN	O	O	691
-	PUNCT	O	O	691
propyl-2H	NOUN	O	O	691
-	PUNCT	O	O	691
pyrazo	NOUN	O	O	691
lo-3	NOUN	O	O	691
-	PUNCT	O	O	691
4-quinoline	NOUN	O	O	691
hydrochloride	NOUN	O	O	691
)	PUNCT	O	O	691
were	AUX	O	O	691
also	ADV	O	O	691
used	VERB	O	O	691
for	ADP	O	O	691
comparison	NOUN	O	O	691
.	PUNCT	O	O	691
Acute	PROPN	O	O	692
administration	NOUN	O	O	692
of	ADP	O	O	692
A-86929	NOUN	O	Chemical	692
was	AUX	O	O	692
as	ADP	O	O	692
efficacious	ADJ	O	O	692
in	ADP	O	O	692
alleviating	VERB	O	O	692
MPTP	PROPN	O	Chemical	692
-	PUNCT	O	O	692
induced	VERB	O	O	692
parkinsonism	NOUN	O	Disease	692
as	ADP	O	O	692
levodopa	NOUN	O	Chemical	692
and	CCONJ	O	O	692
LY-171555	NOUN	O	Chemical	692
,	PUNCT	O	O	692
but	CCONJ	O	O	692
was	AUX	O	O	692
less	ADV	O	O	692
likely	ADV	O	O	692
to	PART	O	O	692
reproduce	VERB	O	O	692
the	PRON	O	O	692
levodopa	NOUN	O	Chemical	692
-	PUNCT	O	O	692
induced	VERB	O	O	692
dyskinesias	PROPN	O	Disease	692
in	ADP	O	O	692
these	PRON	O	O	692
animals	NOUN	O	O	692
than	ADP	O	O	692
with	ADP	O	O	692
either	ADV	O	O	692
LY-171555	NOUN	O	Chemical	692
or	CCONJ	O	O	692
subsequent	ADJ	O	O	692
challenge	NOUN	O	O	692
of	ADP	O	O	692
levodopa	NOUN	O	Chemical	692
.	PUNCT	O	O	692
Selective	PROPN	O	O	693
stimulation	NOUN	O	O	693
of	ADP	O	O	693
the	PRON	O	O	693
DA	NOUN	O	Chemical	693
D1	PROPN	O	O	693
receptor	NOUN	O	O	693
may	AUX	O	O	693
provide	VERB	O	O	693
better	ADV	O	O	693
integration	NOUN	O	O	693
of	ADP	O	O	693
neural	NOUN	O	O	693
inputs	NOUN	O	O	693
transmitted	VERB	O	O	693
to	PART	O	O	693
the	PRON	O	O	693
internal	ADJ	O	O	693
segment	NOUN	O	O	693
of	ADP	O	O	693
the	PRON	O	O	693
globus	PROPN	O	O	693
pallidus	VERB	O	O	693
(	PUNCT	O	O	693
referred	VERB	O	O	693
to	PART	O	O	693
as	ADP	O	O	693
the	PRON	O	O	693
basal	PROPN	O	O	693
ganglia	NOUN	O	O	693
output	NOUN	O	O	693
)	PUNCT	O	O	693
compared	VERB	O	O	693
with	ADP	O	O	693
levodopa	NOUN	O	Chemical	693
and	CCONJ	O	O	693
selective	ADJ	O	O	693
DA	NOUN	O	Chemical	693
D2	NOUN	O	O	693
receptor	NOUN	O	O	693
agonist	NOUN	O	O	693
.	PUNCT	O	O	693
Potent	ADJ	O	O	694
DA	NOUN	O	Chemical	694
D1	PROPN	O	O	694
receptor	NOUN	O	O	694
agents	NOUN	O	O	694
with	ADP	O	O	694
an	PRON	O	O	694
intermediate	PROPN	O	O	694
duration	NOUN	O	O	694
of	ADP	O	O	694
efficacy	NOUN	O	O	694
such	ADJ	O	O	694
as	ADP	O	O	694
A-86929	NOUN	O	Chemical	694
(	PUNCT	O	O	694
approximately	ADV	O	O	694
4	NUM	O	O	694
hr	NOUN	O	O	694
at	ADP	O	O	694
higher	ADJ	O	O	694
doses	NOUN	O	O	694
tested	VERB	O	O	694
)	PUNCT	O	O	694
are	AUX	O	O	694
potential	ADJ	O	O	694
therapeutic	ADJ	O	O	694
tools	NOUN	O	O	694
in	ADP	O	O	694
PD	PROPN	O	Disease	694
and	CCONJ	O	O	694
merit	NOUN	O	O	694
further	ADV	O	O	694
attention	NOUN	O	O	694
.	PUNCT	O	O	694
Deaths	NOUN	O	O	697
from	ADP	O	O	697
local	ADJ	O	O	697
anesthetic	NOUN	O	O	697
-	PUNCT	O	O	697
induced	VERB	O	O	697
convulsions	NOUN	O	Disease	697
in	ADP	O	O	697
mice	NOUN	O	O	697
.	PUNCT	O	O	697
Median	ADJ	O	O	698
convulsant	ADJ	O	O	698
(	PUNCT	O	O	698
CD50	NOUN	O	O	698
)	PUNCT	O	O	698
and	CCONJ	O	O	698
median	ADJ	O	O	698
lethal	ADJ	O	O	698
(	PUNCT	O	O	698
LD50	PROPN	O	O	698
)	PUNCT	O	O	698
doses	NOUN	O	O	698
of	ADP	O	O	698
three	NUM	O	O	698
representative	NOUN	O	O	698
local	ADJ	O	O	698
anesthetics	NOUN	O	O	698
were	AUX	O	O	698
determined	VERB	O	O	698
in	ADP	O	O	698
adult	NOUN	O	O	698
mice	NOUN	O	O	698
to	PART	O	O	698
evaluate	VERB	O	O	698
the	PRON	O	O	698
threat	NOUN	O	O	698
to	PART	O	O	698
life	NOUN	O	O	698
of	ADP	O	O	698
local	ADJ	O	O	698
anesthetic	NOUN	O	O	698
-	PUNCT	O	O	698
induced	VERB	O	O	698
convulsions	NOUN	O	Disease	698
.	PUNCT	O	O	698
The	PRON	O	O	699
CD50	NOUN	O	O	699
and	CCONJ	O	O	699
LD50	PROPN	O	O	699
,	PUNCT	O	O	699
respectively	ADV	O	O	699
,	PUNCT	O	O	699
were	AUX	O	O	699
57.7	NUM	O	O	699
and	CCONJ	O	O	699
58.7	NUM	O	O	699
mg	VERB	O	O	699
/	PUNCT	O	O	699
kg	VERB	O	O	699
for	ADP	O	O	699
bupivacaine	NOUN	O	Chemical	699
,	PUNCT	O	O	699
111.0	NUM	O	O	699
and	CCONJ	O	O	699
133.1	NUM	O	O	699
mg	VERB	O	O	699
/	PUNCT	O	O	699
kg	VERB	O	O	699
for	ADP	O	O	699
lidocaine	NOUN	O	Chemical	699
,	PUNCT	O	O	699
and	CCONJ	O	O	699
243.4	NUM	O	O	699
and	CCONJ	O	O	699
266.5	NUM	O	O	699
mg	VERB	O	O	699
/	PUNCT	O	O	699
kg	VERB	O	O	699
for	ADP	O	O	699
chloroprocaine	NOUN	O	Chemical	699
.	PUNCT	O	O	699
When	SCONJ	O	O	700
given	VERB	O	O	700
intraperitoneally	ADV	O	O	700
,	PUNCT	O	O	700
bupivacaine	NOUN	O	Chemical	700
thus	ADV	O	O	700
was	AUX	O	O	700
only	ADV	O	O	700
about	ADP	O	O	700
twice	ADV	O	O	700
as	ADP	O	O	700
toxic	ADJ	O	O	700
as	ADP	O	O	700
lidocaine	NOUN	O	Chemical	700
and	CCONJ	O	O	700
four	NUM	O	O	700
times	NOUN	O	O	700
as	ADP	O	O	700
toxic	ADJ	O	O	700
as	ADP	O	O	700
chloroprocaine	NOUN	O	Chemical	700
.	PUNCT	O	O	700
Convulsions	NOUN	O	Disease	701
always	ADV	O	O	701
preceded	VERB	O	O	701
death	NOUN	O	O	701
,	PUNCT	O	O	701
except	SCONJ	O	O	701
after	ADP	O	O	701
precipitous	ADJ	O	O	701
cardiopulmonary arrest	NOUN	O	Disease	701
from	ADP	O	O	701
extreme	ADJ	O	O	701
doses	NOUN	O	O	701
.	PUNCT	O	O	701
A	PRON	O	O	702
CD50	NOUN	O	O	702
dose	NOUN	O	O	702
of	ADP	O	O	702
local	ADJ	O	O	702
anesthetic	NOUN	O	O	702
(	PUNCT	O	O	702
causing	VERB	O	O	702
convulsions	NOUN	O	Disease	702
in	ADP	O	O	702
50%	NOUN	O	O	702
of	ADP	O	O	702
mice	NOUN	O	O	702
)	PUNCT	O	O	702
was	AUX	O	O	702
fatal	ADJ	O	O	702
in	ADP	O	O	702
90%	NOUN	O	O	702
of	ADP	O	O	702
bupivacaine	NOUN	O	Chemical	702
-	PUNCT	O	O	702
induced	VERB	O	O	702
seizures	NOUN	O	Disease	702
,	PUNCT	O	O	702
in	ADP	O	O	702
57%	NOUN	O	O	702
of	ADP	O	O	702
the	PRON	O	O	702
chloroprocaine	NOUN	O	Chemical	702
group	NOUN	O	O	702
,	PUNCT	O	O	702
and	CCONJ	O	O	702
in	ADP	O	O	702
6%	NOUN	O	O	702
of	ADP	O	O	702
the	PRON	O	O	702
lidocaine	NOUN	O	Chemical	702
group	NOUN	O	O	702
.	PUNCT	O	O	702
The	PRON	O	O	703
narrow	ADJ	O	O	703
gap	NOUN	O	O	703
between	ADP	O	O	703
convulsant	ADJ	O	O	703
and	CCONJ	O	O	703
lethal	ADJ	O	O	703
doses	NOUN	O	O	703
of	ADP	O	O	703
local	ADJ	O	O	703
anesthetics	NOUN	O	O	703
indicates	VERB	O	O	703
that	SCONJ	O	O	703
untreated	ADJ	O	O	703
convulsions	NOUN	O	Disease	703
present	NOUN	O	O	703
much	ADJ	O	O	703
more	ADJ	O	O	703
of	ADP	O	O	703
a	PRON	O	O	703
threat	NOUN	O	O	703
to	PART	O	O	703
life	NOUN	O	O	703
than	ADP	O	O	703
heretofore	ADV	O	O	703
appreciated	VERB	O	O	703
.	PUNCT	O	O	703
Myoclonic	PROPN	O	O	706
,	PUNCT	O	O	706
atonic	ADJ	O	O	706
,	PUNCT	O	O	706
and	CCONJ	O	O	706
absence seizures	NOUN	O	Disease	706
following	VERB	O	O	706
institution	NOUN	O	O	706
of	ADP	O	O	706
carbamazepine	NOUN	O	Chemical	706
therapy	NOUN	O	O	706
in	ADP	O	O	706
children	NOUN	O	O	706
.	PUNCT	O	O	706
Five	NUM	O	O	707
children	NOUN	O	O	707
,	PUNCT	O	O	707
aged	ADJ	O	O	707
3	X	O	O	707
to	PART	O	O	707
11	NUM	O	O	707
years	NOUN	O	O	707
,	PUNCT	O	O	707
treated	VERB	O	O	707
with	ADP	O	O	707
carbamazepine	NOUN	O	Chemical	707
for	ADP	O	O	707
epilepsy	NOUN	O	Disease	707
,	PUNCT	O	O	707
had	VERB	O	O	707
an	PRON	O	O	707
acute	ADJ	O	O	707
aberrant	ADJ	O	O	707
reaction	NOUN	O	O	707
characterized	VERB	O	O	707
by	ADP	O	O	707
the	PRON	O	O	707
onset	VERB	O	O	707
of	ADP	O	O	707
myoclonic	ADJ	O	O	707
,	PUNCT	O	O	707
atypical	ADJ	O	O	707
absence	NOUN	O	O	707
and/or	CCONJ	O	O	707
atonic	ADJ	O	O	707
(	PUNCT	O	O	707
minor	ADJ	O	O	707
motor	NOUN	O	O	707
)	PUNCT	O	O	707
seizures	NOUN	O	Disease	707
within	ADP	O	O	707
a	PRON	O	O	707
few	ADJ	O	O	707
days	NOUN	O	O	707
.	PUNCT	O	O	707
When	SCONJ	O	O	708
the	PRON	O	O	708
carbamazepine	NOUN	O	Chemical	708
was	AUX	O	O	708
discontinued	VERB	O	O	708
,	PUNCT	O	O	708
two	NUM	O	O	708
of	ADP	O	O	708
the	PRON	O	O	708
children	NOUN	O	O	708
returned	VERB	O	O	708
to	PART	O	O	708
their	PRON	O	O	708
former	ADJ	O	O	708
state	NOUN	O	O	708
very	ADV	O	O	708
quickly	ADV	O	O	708
,	PUNCT	O	O	708
two	NUM	O	O	708
had	VERB	O	O	708
the	PRON	O	O	708
minor	ADJ	O	O	708
motor	NOUN	O	O	708
seizures	NOUN	O	Disease	708
resolve	VERB	O	O	708
in	ADP	O	O	708
3	X	O	O	708
and	CCONJ	O	O	708
6	NUM	O	O	708
months	NOUN	O	O	708
,	PUNCT	O	O	708
and	CCONJ	O	O	708
one	NUM	O	O	708
had	VERB	O	O	708
the	PRON	O	O	708
seizures	NOUN	O	Disease	708
persist	VERB	O	O	708
.	PUNCT	O	O	708
The	PRON	O	O	709
child	NOUN	O	O	709
in	ADP	O	O	709
whom	PRON	O	O	709
the	PRON	O	O	709
seizures	NOUN	O	Disease	709
persisted	VERB	O	O	709
was	AUX	O	O	709
later	ADV	O	O	709
found	VERB	O	O	709
to	PART	O	O	709
have	VERB	O	O	709
ceroid lipofuscinosis	NOUN	O	Disease	709
.	PUNCT	O	O	709
Naloxone	NOUN	O	Chemical	712
reversal	NOUN	O	O	712
of	ADP	O	O	712
hypotension	NOUN	O	Disease	712
due	ADJ	O	O	712
to	PART	O	O	712
captopril	PROPN	O	Chemical	712
overdose	NOUN	O	Disease	712
.	PUNCT	O	O	712
The	PRON	O	O	713
hemodynamic	ADJ	O	O	713
effects	NOUN	O	O	713
of	ADP	O	O	713
captopril	PROPN	O	Chemical	713
and	CCONJ	O	O	713
other	ADJ	O	O	713
angiotensin	NOUN	O	Chemical	713
-	PUNCT	O	O	713
converting	VERB	O	O	713
enzyme	NOUN	O	O	713
inhibitors	NOUN	O	O	713
may	AUX	O	O	713
be	AUX	O	O	713
mediated	VERB	O	O	713
by	ADP	O	O	713
the	PRON	O	O	713
endogenous	ADJ	O	O	713
opioid	NOUN	O	O	713
system	NOUN	O	O	713
.	PUNCT	O	O	713
The	PRON	O	O	714
opioid	NOUN	O	O	714
antagonist	NOUN	O	O	714
naloxone	NOUN	O	Chemical	714
has	VERB	O	O	714
been	AUX	O	O	714
shown	VERB	O	O	714
to	PART	O	O	714
block	NOUN	O	O	714
or	CCONJ	O	O	714
reverse	VERB	O	O	714
the	PRON	O	O	714
hypotensive	ADJ	O	Disease	714
actions	NOUN	O	O	714
of	ADP	O	O	714
captopril	PROPN	O	Chemical	714
.	PUNCT	O	O	714
We	PRON	O	O	715
report	VERB	O	O	715
a	PRON	O	O	715
case	NOUN	O	O	715
of	ADP	O	O	715
an	PRON	O	O	715
intentional	ADJ	O	O	715
captopril	PROPN	O	Chemical	715
overdose	NOUN	O	Disease	715
,	PUNCT	O	O	715
manifested	VERB	O	O	715
by	ADP	O	O	715
marked	VERB	O	O	715
hypotension	NOUN	O	Disease	715
,	PUNCT	O	O	715
that	SCONJ	O	O	715
resolved	VERB	O	O	715
promptly	ADV	O	O	715
with	ADP	O	O	715
the	PRON	O	O	715
administration	NOUN	O	O	715
of	ADP	O	O	715
naloxone	NOUN	O	Chemical	715
.	PUNCT	O	O	715
To	PART	O	O	716
our	PRON	O	O	716
knowledge	NOUN	O	O	716
,	PUNCT	O	O	716
this	PRON	O	O	716
is	AUX	O	O	716
the	PRON	O	O	716
first	ADV	O	O	716
reported	VERB	O	O	716
case	NOUN	O	O	716
of	ADP	O	O	716
captopril	PROPN	O	Chemical	716
-	PUNCT	O	O	716
induced	VERB	O	O	716
hypotension	NOUN	O	Disease	716
treated	VERB	O	O	716
with	ADP	O	O	716
naloxone	NOUN	O	Chemical	716
.	PUNCT	O	O	716
Our	PRON	O	O	717
experience	NOUN	O	O	717
demonstrates	VERB	O	O	717
a	PRON	O	O	717
possible	ADJ	O	O	717
role	NOUN	O	O	717
of	ADP	O	O	717
naloxone	NOUN	O	Chemical	717
in	ADP	O	O	717
the	PRON	O	O	717
reversal	NOUN	O	O	717
of	ADP	O	O	717
hypotension	NOUN	O	Disease	717
resulting	VERB	O	O	717
from	ADP	O	O	717
captopril	PROPN	O	Chemical	717
.	PUNCT	O	O	717
Carbamazepine	NOUN	O	Chemical	720
-	PUNCT	O	O	720
induced	VERB	O	O	720
cardiac dysfunction	NOUN	O	Disease	720
.	PUNCT	O	O	720
A	PRON	O	O	721
patient	NOUN	O	O	721
with	ADP	O	O	721
sinus	NOUN	O	O	721
bradycardia	NOUN	O	Disease	721
and	CCONJ	O	O	721
atrioventricular block	NOUN	O	Disease	721
,	PUNCT	O	O	721
induced	VERB	O	O	721
by	ADP	O	O	721
carbamazepine	NOUN	O	Chemical	721
,	PUNCT	O	O	721
prompted	VERB	O	O	721
an	PRON	O	O	721
extensive	ADJ	O	O	721
literature	NOUN	O	O	721
review	VERB	O	O	721
of	ADP	O	O	721
all	PRON	O	O	721
previously	ADV	O	O	721
reported	VERB	O	O	721
cases	NOUN	O	O	721
.	PUNCT	O	O	721
From	ADP	O	O	722
the	PRON	O	O	722
analysis	NOUN	O	O	722
of	ADP	O	O	722
these	PRON	O	O	722
cases	NOUN	O	O	722
,	PUNCT	O	O	722
two	NUM	O	O	722
distinct	ADJ	O	O	722
forms	NOUN	O	O	722
of	ADP	O	O	722
carbamazepine	NOUN	O	Chemical	722
-	PUNCT	O	O	722
associated	VERB	O	O	722
cardiac dysfunction	NOUN	O	Disease	722
emerged	VERB	O	O	722
.	PUNCT	O	O	722
One	NUM	O	O	723
patient	NOUN	O	O	723
group	NOUN	O	O	723
developed	VERB	O	O	723
sinus tachycardias	NOUN	O	Disease	723
in	ADP	O	O	723
the	PRON	O	O	723
setting	VERB	O	O	723
of	ADP	O	O	723
a	PRON	O	O	723
massive	ADJ	O	O	723
carbamazepine	NOUN	O	Chemical	723
overdose	NOUN	O	Disease	723
.	PUNCT	O	O	723
The	PRON	O	O	724
second	ADV	O	O	724
group	NOUN	O	O	724
consisted	VERB	O	O	724
almost	ADV	O	O	724
exclusively	ADV	O	O	724
of	ADP	O	O	724
elderly	ADJ	O	O	724
women	NOUN	O	O	724
who	PRON	O	O	724
developed	VERB	O	O	724
potentially	ADV	O	O	724
life	NOUN	O	O	724
-	PUNCT	O	O	724
threatening	VERB	O	O	724
bradyarrhythmias	PROPN	O	Disease	724
or	CCONJ	O	O	724
atrioventricular conduction delay	NOUN	O	Disease	724
,	PUNCT	O	O	724
associated	VERB	O	O	724
with	ADP	O	O	724
either	ADV	O	O	724
therapeutic	ADJ	O	O	724
or	CCONJ	O	O	724
modestly	ADV	O	O	724
elevated	ADJ	O	O	724
carbamazepine	NOUN	O	Chemical	724
serum	NOUN	O	O	724
levels	NOUN	O	O	724
.	PUNCT	O	O	724
Because	SCONJ	O	O	725
carbamazepine	NOUN	O	Chemical	725
is	AUX	O	O	725
widely	ADV	O	O	725
used	VERB	O	O	725
in	ADP	O	O	725
the	PRON	O	O	725
treatment	NOUN	O	O	725
of	ADP	O	O	725
many	ADJ	O	O	725
neurologic	ADJ	O	O	725
and	CCONJ	O	O	725
psychiatric	ADJ	O	Disease	725
conditions	NOUN	O	O	725
,	PUNCT	O	O	725
the	PRON	O	O	725
recognition	NOUN	O	O	725
of	ADP	O	O	725
the	PRON	O	O	725
latter	ADJ	O	O	725
syndrome	NOUN	O	O	725
has	VERB	O	O	725
important	ADJ	O	O	725
implications	NOUN	O	O	725
for	ADP	O	O	725
the	PRON	O	O	725
use	VERB	O	O	725
of	ADP	O	O	725
this	PRON	O	O	725
drug	NOUN	O	O	725
in	ADP	O	O	725
elderly	ADJ	O	O	725
patients	NOUN	O	O	725
.	PUNCT	O	O	725
Glutamatergic	PROPN	O	O	728
neurotransmission	NOUN	O	O	728
mediated	VERB	O	O	728
by	ADP	O	O	728
NMDA	PROPN	O	Chemical	728
receptors	NOUN	O	O	728
in	ADP	O	O	728
the	PRON	O	O	728
inferior	ADJ	O	O	728
colliculus	NOUN	O	O	728
can	AUX	O	O	728
modulate	VERB	O	O	728
haloperidol	NOUN	O	Chemical	728
-	PUNCT	O	O	728
induced	VERB	O	O	728
catalepsy	VERB	O	Disease	728
.	PUNCT	O	O	728
Functional	ADJ	O	O	729
evidence	NOUN	O	O	729
relating	VERB	O	O	729
the	PRON	O	O	729
IC	PROPN	O	O	729
to	PART	O	O	729
motor	NOUN	O	O	729
behavior	NOUN	O	O	729
derives	VERB	O	O	729
from	ADP	O	O	729
experiments	NOUN	O	O	729
showing	VERB	O	O	729
that	SCONJ	O	O	729
activation	NOUN	O	O	729
of	ADP	O	O	729
the	PRON	O	O	729
IC	PROPN	O	O	729
by	ADP	O	O	729
electrical	ADJ	O	O	729
stimulation	NOUN	O	O	729
or	CCONJ	O	O	729
excitatory	ADJ	O	O	729
amino acid	NOUN	O	Chemical	729
microinjection	NOUN	O	O	729
causes	VERB	O	O	729
freezing	VERB	O	O	729
,	PUNCT	O	O	729
escape	VERB	O	O	729
-	PUNCT	O	O	729
like	INTJ	O	O	729
behavior	NOUN	O	O	729
,	PUNCT	O	O	729
and	CCONJ	O	O	729
immobility	NOUN	O	O	729
.	PUNCT	O	O	729
The	PRON	O	O	730
present	NOUN	O	O	730
study	VERB	O	O	730
examined	VERB	O	O	730
the	PRON	O	O	730
influence	NOUN	O	O	730
of	ADP	O	O	730
excitatory	ADJ	O	O	730
amino acid	NOUN	O	Chemical	730
-	PUNCT	O	O	730
mediated	VERB	O	O	730
mechanisms	NOUN	O	O	730
in	ADP	O	O	730
the	PRON	O	O	730
IC	PROPN	O	O	730
on	ADP	O	O	730
the	PRON	O	O	730
catalepsy	VERB	O	Disease	730
induced	VERB	O	O	730
by	ADP	O	O	730
the	PRON	O	O	730
dopamine	NOUN	O	Chemical	730
receptor	NOUN	O	O	730
blocker	NOUN	O	O	730
haloperidol	NOUN	O	Chemical	730
administered	VERB	O	O	730
Haloperidol	NOUN	O	Chemical	731
-	PUNCT	O	O	731
induced	VERB	O	O	731
catalepsy	VERB	O	Disease	731
was	AUX	O	O	731
challenged	VERB	O	O	731
with	ADP	O	O	731
prior	ADV	O	O	731
intracollicular	NOUN	O	O	731
microinjections	NOUN	O	O	731
of	ADP	O	O	731
glutamate	NOUN	O	Chemical	731
NMDA	PROPN	O	Chemical	731
receptor	NOUN	O	O	731
antagonists	NOUN	O	O	731
,	PUNCT	O	O	731
MK-801	PROPN	O	Chemical	731
(	PUNCT	O	O	731
15	NUM	O	O	731
or	CCONJ	O	O	731
30	NUM	O	O	731
mmol/0.5	NUM	O	O	731
microl	NOUN	O	O	731
)	PUNCT	O	O	731
and	CCONJ	O	O	731
AP7	PROPN	O	Chemical	731
(	PUNCT	O	O	731
10	NUM	O	O	731
or	CCONJ	O	O	731
20	NUM	O	O	731
nmol/0.5	NUM	O	O	731
microl	NOUN	O	O	731
)	PUNCT	O	O	731
,	PUNCT	O	O	731
or	CCONJ	O	O	731
of	ADP	O	O	731
the	PRON	O	O	731
NMDA	PROPN	O	Chemical	731
receptor	NOUN	O	O	731
agonist	NOUN	O	O	731
N	NUM	O	O	731
-	PUNCT	O	O	731
methyl	NOUN	O	O	731
-	PUNCT	O	O	731
d	X	O	O	731
-	PUNCT	O	O	731
aspartate	NOUN	O	Chemical	731
(	PUNCT	O	O	731
NMDA	PROPN	O	Chemical	731
,	PUNCT	O	O	731
20	NUM	O	O	731
or	CCONJ	O	O	731
30	NUM	O	O	731
nmol/0.5	NUM	O	O	731
microl	NOUN	O	O	731
)	PUNCT	O	O	731
.	PUNCT	O	O	731
The	PRON	O	O	732
results	VERB	O	O	732
showed	VERB	O	O	732
that	SCONJ	O	O	732
intracollicular	NOUN	O	O	732
microinjection	NOUN	O	O	732
of	ADP	O	O	732
MK-801	PROPN	O	Chemical	732
and	CCONJ	O	O	732
AP7	PROPN	O	Chemical	732
previous	ADJ	O	O	732
to	PART	O	O	732
systemic	ADJ	O	O	732
injections	NOUN	O	O	732
of	ADP	O	O	732
haloperidol	NOUN	O	Chemical	732
significantly	ADV	O	O	732
attenuated	VERB	O	O	732
the	PRON	O	O	732
catalepsy	VERB	O	Disease	732
,	PUNCT	O	O	732
as	ADP	O	O	732
indicated	VERB	O	O	732
by	ADP	O	O	732
a	PRON	O	O	732
reduced	VERB	O	O	732
latency	VERB	O	O	732
to	PART	O	O	732
step	VERB	O	O	732
down	ADP	O	O	732
from	ADP	O	O	732
a	PRON	O	O	732
horizontal	PROPN	O	O	732
bar	NOUN	O	O	732
.	PUNCT	O	O	732
Accordingly	ADV	O	O	733
,	PUNCT	O	O	733
intracollicular	NOUN	O	O	733
microinjection	NOUN	O	O	733
of	ADP	O	O	733
NMDA	PROPN	O	Chemical	733
increased	VERB	O	O	733
the	PRON	O	O	733
latency	VERB	O	O	733
to	PART	O	O	733
step	VERB	O	O	733
down	ADP	O	O	733
the	PRON	O	O	733
bar	NOUN	O	O	733
.	PUNCT	O	O	733
These	PRON	O	O	734
findings	NOUN	O	O	734
suggest	VERB	O	O	734
that	SCONJ	O	O	734
glutamate	NOUN	O	Chemical	734
-	PUNCT	O	O	734
mediated	VERB	O	O	734
mechanisms	NOUN	O	O	734
in	ADP	O	O	734
the	PRON	O	O	734
neural	NOUN	O	O	734
circuits	NOUN	O	O	734
at	ADP	O	O	734
the	PRON	O	O	734
IC	PROPN	O	O	734
level	VERB	O	O	734
influence	NOUN	O	O	734
haloperidol	NOUN	O	Chemical	734
-	PUNCT	O	O	734
induced	VERB	O	O	734
catalepsy	VERB	O	Disease	734
and	CCONJ	O	O	734
participate	VERB	O	O	734
in	ADP	O	O	734
the	PRON	O	O	734
regulation	NOUN	O	O	734
of	ADP	O	O	734
motor	NOUN	O	O	734
activity	NOUN	O	O	734
.	PUNCT	O	O	734
Metabotropic	NOUN	O	O	737
glutamate	NOUN	O	Chemical	737
7	NUM	O	O	737
receptor	NOUN	O	O	737
subtype	NOUN	O	O	737
modulates	VERB	O	O	737
motor	NOUN	O	O	737
symptoms	NOUN	O	O	737
in	ADP	O	O	737
rodent	NOUN	O	O	737
models	NOUN	O	O	737
of	ADP	O	O	737
Parkinson	NOUN	O	O	737
's	AUX	O	O	737
disease	PROPN	O	O	737
.	PUNCT	O	O	737
Metabotropic	NOUN	O	O	738
glutamate	NOUN	O	Chemical	738
(	PUNCT	O	O	738
mGlu	NOUN	O	O	738
)	PUNCT	O	O	738
receptors	NOUN	O	O	739
modulate	VERB	O	O	739
synaptic	ADJ	O	O	739
transmission	NOUN	O	O	739
in	ADP	O	O	739
the	PRON	O	O	739
central	ADJ	O	O	739
nervous	ADJ	O	O	739
system	NOUN	O	O	739
and	CCONJ	O	O	739
represent	VERB	O	O	739
promising	VERB	O	O	739
therapeutic	ADJ	O	O	739
targets	VERB	O	O	739
for	ADP	O	O	739
symptomatic	ADJ	O	O	739
treatment	NOUN	O	O	739
of	ADP	O	O	739
Parkinson	NOUN	O	O	739
's	AUX	O	O	739
disease	PROPN	O	O	739
(	PUNCT	O	O	739
PD	PROPN	O	Disease	739
)	PUNCT	O	O	739
.	PUNCT	O	O	739
Among	ADP	O	O	740
the	PRON	O	O	740
eight	NUM	O	O	740
mGlu	NOUN	O	O	740
receptor	NOUN	O	O	740
subtypes	NOUN	O	O	740
,	PUNCT	O	O	740
mGlu7	ADJ	O	O	740
receptor	NOUN	O	O	740
is	AUX	O	O	740
prominently	ADV	O	O	740
expressed	VERB	O	O	740
in	ADP	O	O	740
the	PRON	O	O	740
basal	PROPN	O	O	740
ganglia	NOUN	O	O	740
,	PUNCT	O	O	740
but	CCONJ	O	O	740
its	PRON	O	O	740
role	NOUN	O	O	740
in	ADP	O	O	740
restoring	VERB	O	O	740
motor	NOUN	O	O	740
function	NOUN	O	O	740
in	ADP	O	O	740
animal	NOUN	O	O	740
models	NOUN	O	O	740
of	ADP	O	O	740
PD	PROPN	O	Disease	740
is	AUX	O	O	740
not	PART	O	O	740
known	VERB	O	O	740
.	PUNCT	O	O	740
The	PRON	O	O	741
effects	NOUN	O	O	741
of	ADP	O	O	741
N	NUM	O	O	741
,	PUNCT	O	O	741
N'-dibenzhydrylethane-1,2-diamine	NOUN	O	O	741
dihydrochloride	NOUN	O	O	741
(	PUNCT	O	O	741
AMN082	PROPN	O	Chemical	741
)	PUNCT	O	O	741
,	PUNCT	O	O	741
the	PRON	O	O	741
first	ADV	O	O	741
selective	ADJ	O	O	741
allosteric	ADJ	O	O	741
activator	NOUN	O	O	741
of	ADP	O	O	741
mGlu7	ADJ	O	O	741
receptors	NOUN	O	O	741
,	PUNCT	O	O	741
were	AUX	O	O	741
thus	ADV	O	O	741
tested	VERB	O	O	741
in	ADP	O	O	741
different	ADJ	O	O	741
rodent	NOUN	O	O	741
models	NOUN	O	O	741
of	ADP	O	O	741
PD	PROPN	O	Disease	741
.	PUNCT	O	O	741
Here	ADV	O	O	742
,	PUNCT	O	O	742
we	PRON	O	O	742
show	VERB	O	O	742
that	SCONJ	O	O	742
oral	ADJ	O	O	742
(	PUNCT	O	O	742
5	NUM	O	O	742
mg	VERB	O	O	742
/	PUNCT	O	O	742
kg	VERB	O	O	742
)	PUNCT	O	O	742
or	CCONJ	O	O	742
intrastriatal	PROPN	O	O	742
administration	NOUN	O	O	742
(	PUNCT	O	O	742
0.1	NUM	O	O	742
and	CCONJ	O	O	742
0.5	NUM	O	O	742
nmol	PROPN	O	O	742
)	PUNCT	O	O	742
of	ADP	O	O	742
AMN082	PROPN	O	Chemical	742
reverses	VERB	O	O	742
haloperidol	NOUN	O	Chemical	742
-	PUNCT	O	O	742
induced	VERB	O	O	742
catalepsy	VERB	O	Disease	742
in	ADP	O	O	742
rats	NOUN	O	O	742
.	PUNCT	O	O	742
AMN082	PROPN	O	Chemical	743
(	PUNCT	O	O	743
2.5	NUM	O	O	743
and	CCONJ	O	O	743
5	NUM	O	O	743
mg	VERB	O	O	743
/	PUNCT	O	O	743
kg	VERB	O	O	743
)	PUNCT	O	O	743
reduces	VERB	O	O	743
apomorphine	PROPN	O	Chemical	743
-	PUNCT	O	O	743
induced	VERB	O	O	743
rotations	NOUN	O	O	743
in	ADP	O	O	743
unilateral	ADJ	O	O	743
6-hydroxydopamine	NOUN	O	Chemical	743
(	PUNCT	O	O	743
6-OHDA)-lesioned	VERB	O	O	743
rats	NOUN	O	O	743
.	PUNCT	O	O	743
In	ADP	O	O	744
a	PRON	O	O	744
more	ADJ	O	O	744
complex	ADJ	O	O	744
task	NOUN	O	O	744
commonly	ADV	O	O	744
used	VERB	O	O	744
to	PART	O	O	744
evaluate	VERB	O	O	744
major	ADJ	O	O	744
akinetic	ADJ	O	Disease	744
symptoms	NOUN	O	O	744
of	ADP	O	O	744
PD	PROPN	O	Disease	744
patients	NOUN	O	O	744
,	PUNCT	O	O	744
5	NUM	O	O	744
mg	VERB	O	O	744
/	PUNCT	O	O	744
kg	VERB	O	O	744
AMN082	PROPN	O	Chemical	744
reverses	VERB	O	O	744
the	PRON	O	O	744
increased	VERB	O	O	744
reaction	NOUN	O	O	744
time	NOUN	O	O	744
to	PART	O	O	744
respond	VERB	O	O	744
to	PART	O	O	744
a	PRON	O	O	744
cue	VERB	O	O	744
of	ADP	O	O	744
bilateral	ADJ	O	O	744
6-OHDA	NOUN	O	Chemical	744
-	PUNCT	O	O	744
lesioned	VERB	O	O	744
rats	NOUN	O	O	744
.	PUNCT	O	O	744
In	ADP	O	O	745
addition	NOUN	O	O	745
,	PUNCT	O	O	745
AMN082	PROPN	O	Chemical	745
reduces	VERB	O	O	745
the	PRON	O	O	745
duration	NOUN	O	O	745
of	ADP	O	O	745
haloperidol	NOUN	O	Chemical	745
-	PUNCT	O	O	745
induced	VERB	O	O	745
catalepsy	VERB	O	Disease	745
in	ADP	O	O	745
a	PRON	O	O	745
mGlu7	ADJ	O	O	745
receptor	NOUN	O	O	745
-	PUNCT	O	O	745
dependent	ADJ	O	O	745
manner	VERB	O	O	745
in	ADP	O	O	745
wild	ADJ	O	O	745
-	PUNCT	O	O	745
type	NOUN	O	O	745
but	CCONJ	O	O	745
not	PART	O	O	745
mGlu7	ADJ	O	O	745
receptor	NOUN	O	O	745
knockout	NOUN	O	O	745
mice	NOUN	O	O	745
.	PUNCT	O	O	745
Higher	ADV	O	O	746
doses	NOUN	O	O	746
of	ADP	O	O	746
AMN082	PROPN	O	Chemical	746
(	PUNCT	O	O	746
10	NUM	O	O	746
and	CCONJ	O	O	746
20	NUM	O	O	746
mg	VERB	O	O	746
/	PUNCT	O	O	746
kg	VERB	O	O	746
p.o	PROPN	O	O	746
.	PUNCT	O	O	746
)	PUNCT	O	O	746
have	VERB	O	O	747
no	PRON	O	O	747
effect	VERB	O	O	747
on	ADP	O	O	747
the	PRON	O	O	747
same	ADJ	O	O	747
models	NOUN	O	O	747
of	ADP	O	O	747
PD	PROPN	O	Disease	747
.	PUNCT	O	O	747
Overall	ADV	O	O	748
these	PRON	O	O	748
findings	NOUN	O	O	748
suggest	VERB	O	O	748
that	SCONJ	O	O	748
mGlu7	ADJ	O	O	748
receptor	NOUN	O	O	748
activation	NOUN	O	O	748
can	AUX	O	O	748
reverse	VERB	O	O	748
motor	NOUN	O	O	748
dysfunction	NOUN	O	O	748
associated	VERB	O	O	748
with	ADP	O	O	748
reduced	VERB	O	O	748
dopamine	NOUN	O	Chemical	748
activity	NOUN	O	O	748
.	PUNCT	O	O	748
Nimodipine	NOUN	O	Chemical	751
prevents	VERB	O	O	751
memory impairment	NOUN	O	Disease	751
caused	VERB	O	O	751
by	ADP	O	O	751
nitroglycerin	PROPN	O	Chemical	751
-	PUNCT	O	O	751
induced	VERB	O	O	751
hypotension	NOUN	O	Disease	751
in	ADP	O	O	751
adult	NOUN	O	O	751
mice	NOUN	O	O	751
.	PUNCT	O	O	751
Hypotension	NOUN	O	Disease	752
and	CCONJ	O	O	752
a	PRON	O	O	752
resultant	NOUN	O	O	752
decrease	VERB	O	O	752
in	ADP	O	O	752
cerebral	ADJ	O	O	752
blood	NOUN	O	O	752
flow	NOUN	O	O	752
have	VERB	O	O	752
been	AUX	O	O	752
implicated	VERB	O	O	752
in	ADP	O	O	752
the	PRON	O	O	752
development	NOUN	O	O	752
of	ADP	O	O	752
cognitive dysfunction	NOUN	O	Disease	752
.	PUNCT	O	O	752
We	PRON	O	O	753
tested	VERB	O	O	753
the	PRON	O	O	753
hypothesis	NOUN	O	O	753
that	SCONJ	O	O	753
nimodipine	NOUN	O	Chemical	753
(	PUNCT	O	O	753
NIMO	PROPN	O	Chemical	753
)	PUNCT	O	O	753
administered	VERB	O	O	753
at	ADP	O	O	753
the	PRON	O	O	753
onset	VERB	O	O	753
of	ADP	O	O	753
nitroglycerin	PROPN	O	Chemical	753
(	PUNCT	O	O	753
NTG)-induced	NOUN	O	O	753
hypotension	NOUN	O	Disease	753
would	AUX	O	O	753
preserve	VERB	O	O	753
long	ADV	O	O	753
-	PUNCT	O	O	753
term	NOUN	O	O	753
associative	ADJ	O	O	753
memory	NOUN	O	O	753
.	PUNCT	O	O	753
Ninety	NUM	O	O	754
-	PUNCT	O	O	754
six	NUM	O	O	754
Swiss	PROPN	O	O	754
-	PUNCT	O	O	754
Webster	PROPN	O	O	754
mice	NOUN	O	O	754
(	PUNCT	O	O	754
30	NUM	O	O	754
-	PUNCT	O	O	754
35	NUM	O	O	754
g	X	O	O	754
,	PUNCT	O	O	754
6	NUM	O	O	754
-	PUNCT	O	O	754
8	NUM	O	O	754
wk	X	O	O	754
)	PUNCT	O	O	754
,	PUNCT	O	O	754
were	AUX	O	O	754
randomized	VERB	O	O	754
into	ADP	O	O	754
6	NUM	O	O	754
groups	NOUN	O	O	754
1	X	O	O	754
)	PUNCT	O	O	754
saline	NOUN	O	O	754
(	PUNCT	O	O	754
control	VERB	O	O	754
)	PUNCT	O	O	754
,	PUNCT	O	O	754
2	X	O	O	754
)	PUNCT	O	O	754
NTG	VERB	O	Chemical	754
immediately	ADV	O	O	754
after	ADP	O	O	754
learning	VERB	O	O	754
,	PUNCT	O	O	754
3	X	O	O	754
)	PUNCT	O	O	754
NTG	VERB	O	Chemical	754
3	X	O	O	754
h	X	O	O	754
after	ADP	O	O	754
learning	VERB	O	O	754
,	PUNCT	O	O	754
4	NUM	O	O	754
)	PUNCT	O	O	754
NTG	VERB	O	Chemical	754
and	CCONJ	O	O	754
NIMO	PROPN	O	Chemical	754
,	PUNCT	O	O	754
5	NUM	O	O	754
)	PUNCT	O	O	754
vehicle	NOUN	O	O	754
,	PUNCT	O	O	754
and	CCONJ	O	O	754
6	NUM	O	O	754
)	PUNCT	O	O	754
NIMO	PROPN	O	Chemical	755
alone	ADV	O	O	755
.	PUNCT	O	O	755
The	PRON	O	O	756
extent	NOUN	O	O	756
of	ADP	O	O	756
hypotension	NOUN	O	Disease	756
and	CCONJ	O	O	756
changes	VERB	O	O	756
in	ADP	O	O	756
brain	NOUN	O	O	756
tissue	NOUN	O	O	756
oxygenation	NOUN	O	O	756
(	PUNCT	O	O	756
PbtO(2	INTJ	O	O	756
)	PUNCT	O	O	756
)	PUNCT	O	O	756
and	CCONJ	O	O	756
in	ADP	O	O	756
cerebral	ADJ	O	O	756
blood	NOUN	O	O	756
flow	NOUN	O	O	756
were	AUX	O	O	756
studied	VERB	O	O	756
in	ADP	O	O	756
a	PRON	O	O	756
separate	VERB	O	O	756
group	NOUN	O	O	756
of	ADP	O	O	756
animals	NOUN	O	O	756
.	PUNCT	O	O	756
Mice	NOUN	O	O	757
subjected	VERB	O	O	757
to	PART	O	O	757
hypotensive	ADJ	O	Disease	757
episodes	NOUN	O	O	757
showed	VERB	O	O	757
a	PRON	O	O	757
significant	ADJ	O	O	757
decrease	VERB	O	O	757
in	ADP	O	O	757
latency	VERB	O	O	757
time	NOUN	O	O	757
(	PUNCT	O	O	757
178	NUM	O	O	757
+	ADP	O	O	757
/-	PUNCT	O	O	757
156	NUM	O	O	758
s	X	O	O	758
)	PUNCT	O	O	758
compared	VERB	O	O	758
with	ADP	O	O	758
those	PRON	O	O	758
injected	VERB	O	O	758
with	ADP	O	O	758
saline	NOUN	O	O	758
,	PUNCT	O	O	758
NTG	VERB	O	Chemical	758
+	ADP	O	O	758
NIMO	PROPN	O	Chemical	758
,	PUNCT	O	O	758
or	CCONJ	O	O	758
delayed	VERB	O	O	758
NTG	VERB	O	Chemical	758
(	PUNCT	O	O	758
580	NUM	O	O	758
+	ADP	O	O	758
/-	PUNCT	O	O	758
In	ADP	O	O	759
a	PRON	O	O	759
separate	VERB	O	O	759
group	NOUN	O	O	759
of	ADP	O	O	759
mice	NOUN	O	O	759
not	PART	O	O	759
subjected	VERB	O	O	759
to	PART	O	O	759
behavioral	ADJ	O	O	759
studies	NOUN	O	O	759
,	PUNCT	O	O	759
the	PRON	O	O	759
same	ADJ	O	O	759
dose	NOUN	O	O	759
of	ADP	O	O	759
NTG	VERB	O	Chemical	759
(	PUNCT	O	O	759
n	CCONJ	O	O	759
=	PUNCT	O	O	759
3	X	O	O	759
)	PUNCT	O	O	759
and	CCONJ	O	O	759
NTG	VERB	O	Chemical	759
+	ADP	O	O	759
NIMO	PROPN	O	Chemical	759
(	PUNCT	O	O	759
n	CCONJ	O	O	759
=	PUNCT	O	O	759
3	X	O	O	759
)	PUNCT	O	O	759
caused	VERB	O	O	759
mean	VERB	O	O	759
arterial	ADJ	O	O	759
blood	NOUN	O	O	759
pressure	NOUN	O	O	759
to	PART	O	O	759
decrease	VERB	O	O	759
from	ADP	O	O	759
85.9	NUM	O	O	759
+	ADP	O	O	759
/-	PUNCT	O	O	759
Mean	VERB	O	O	760
arterial	ADJ	O	O	760
blood	NOUN	O	O	760
pressure	NOUN	O	O	760
in	ADP	O	O	760
mice	NOUN	O	O	760
treated	VERB	O	O	760
with	ADP	O	O	760
NIMO	PROPN	O	Chemical	760
alone	ADV	O	O	760
decreased	VERB	O	O	760
from	ADP	O	O	760
88.1	NUM	O	O	760
+	ADP	O	O	760
/-	PUNCT	O	O	760
5.2	NUM	O	O	761
mm	INTJ	O	O	761
Hg	PROPN	O	O	761
sem	INTJ	O	O	761
in	ADP	O	O	761
the	PRON	O	O	761
NTG	VERB	O	Chemical	761
group	NOUN	O	O	761
and	CCONJ	O	O	761
from	ADP	O	O	761
38.6	NUM	O	O	761
+	ADP	O	O	761
/-	PUNCT	O	O	761
2.0	NUM	O	O	762
mm	INTJ	O	O	762
Hg	PROPN	O	O	762
sem	INTJ	O	O	762
in	ADP	O	O	762
the	PRON	O	O	762
NTG	VERB	O	Chemical	762
+	ADP	O	O	762
NIMO	PROPN	O	Chemical	762
groups	NOUN	O	O	762
,	PUNCT	O	O	762
respectively	ADV	O	O	762
.	PUNCT	O	O	762
In	ADP	O	O	763
a	PRON	O	O	763
PA	PROPN	O	Disease	763
retention	NOUN	O	O	763
paradigm	NOUN	O	O	763
,	PUNCT	O	O	763
the	PRON	O	O	763
injection	NOUN	O	O	763
of	ADP	O	O	763
NTG	VERB	O	Chemical	763
immediately	ADV	O	O	763
after	ADP	O	O	763
learning	VERB	O	O	763
produced	VERB	O	O	763
a	PRON	O	O	763
significant	ADJ	O	O	763
impairment	NOUN	O	O	763
of	ADP	O	O	763
long	ADV	O	O	763
-	PUNCT	O	O	763
term	NOUN	O	O	763
associative	ADJ	O	O	763
memory	NOUN	O	O	763
in	ADP	O	O	763
mice	NOUN	O	O	763
,	PUNCT	O	O	763
whereas	SCONJ	O	O	763
delayed	VERB	O	O	763
induced	VERB	O	O	763
hypotension	NOUN	O	Disease	763
had	VERB	O	O	763
no	PRON	O	O	763
effect	VERB	O	O	763
.	PUNCT	O	O	763
NIMO	PROPN	O	Chemical	764
attenuated	VERB	O	O	764
the	PRON	O	O	764
disruption	NOUN	O	O	764
in	ADP	O	O	764
consolidation	NOUN	O	O	764
of	ADP	O	O	764
long	ADV	O	O	764
-	PUNCT	O	O	764
term	NOUN	O	O	764
memory	NOUN	O	O	764
caused	VERB	O	O	764
by	ADP	O	O	764
NTG	VERB	O	Chemical	764
but	CCONJ	O	O	764
did	VERB	O	O	764
not	PART	O	O	764
improve	VERB	O	O	764
latency	VERB	O	O	764
in	ADP	O	O	764
the	PRON	O	O	764
absence	NOUN	O	O	764
of	ADP	O	O	764
hypotension	NOUN	O	Disease	764
.	PUNCT	O	O	764
The	PRON	O	O	765
observed	VERB	O	O	765
effect	VERB	O	O	765
of	ADP	O	O	765
NIMO	PROPN	O	Chemical	765
may	AUX	O	O	765
have	VERB	O	O	765
been	AUX	O	O	765
attributable	ADJ	O	O	765
to	PART	O	O	765
the	PRON	O	O	765
preservation	NOUN	O	O	765
of	ADP	O	O	765
calcium	NOUN	O	Chemical	765
homeostasis	NOUN	O	O	765
during	ADP	O	O	765
hypotension	NOUN	O	Disease	765
,	PUNCT	O	O	765
because	SCONJ	O	O	765
there	ADV	O	O	765
were	AUX	O	O	765
no	PRON	O	O	765
differences	NOUN	O	O	765
in	ADP	O	O	765
the	PRON	O	O	765
PbtO(2	INTJ	O	O	765
)	PUNCT	O	O	765
indices	NOUN	O	O	765
among	ADP	O	O	765
groups	NOUN	O	O	765
.	PUNCT	O	O	765
Fatal	ADJ	O	O	768
haemopericardium	NOUN	O	Disease	768
and	CCONJ	O	O	768
gastrointestinal haemorrhage	NOUN	O	Disease	768
due	ADJ	O	O	768
to	PART	O	O	768
possible	ADJ	O	O	768
interaction	NOUN	O	O	768
of	ADP	O	O	768
cranberry	PROPN	O	O	768
juice	NOUN	O	O	768
with	ADP	O	O	768
warfarin	VERB	O	Chemical	768
.	PUNCT	O	O	768
We	PRON	O	O	769
report	VERB	O	O	769
a	PRON	O	O	769
case	NOUN	O	O	769
of	ADP	O	O	769
fatal	ADJ	O	O	769
internal	ADJ	O	O	769
haemorrhage	NOUN	O	Disease	769
in	ADP	O	O	769
an	PRON	O	O	769
elderly	ADJ	O	O	769
man	NOUN	O	O	769
who	PRON	O	O	769
consumed	VERB	O	O	769
only	ADV	O	O	769
cranberry	PROPN	O	O	769
juice	NOUN	O	O	769
for	ADP	O	O	769
two	NUM	O	O	769
weeks	NOUN	O	O	769
while	SCONJ	O	O	769
maintaining	VERB	O	O	769
his	PRON	O	O	769
usual	ADJ	O	O	769
dosage	NOUN	O	O	769
of	ADP	O	O	769
warfarin	VERB	O	Chemical	769
.	PUNCT	O	O	769
We	PRON	O	O	770
propose	VERB	O	O	770
that	SCONJ	O	O	770
naturally	ADV	O	O	770
occurring	VERB	O	O	770
compounds	NOUN	O	O	770
such	ADJ	O	O	770
as	ADP	O	O	770
flavonoids	NOUN	O	Chemical	770
,	PUNCT	O	O	770
which	PRON	O	O	770
are	AUX	O	O	770
present	NOUN	O	O	770
in	ADP	O	O	770
fruit	NOUN	O	O	770
juices	NOUN	O	O	770
,	PUNCT	O	O	770
may	AUX	O	O	770
increase	VERB	O	O	770
the	PRON	O	O	770
potency	NOUN	O	O	770
of	ADP	O	O	770
warfarin	VERB	O	Chemical	770
by	ADP	O	O	770
competing	VERB	O	O	770
for	ADP	O	O	770
the	PRON	O	O	770
enzymes	NOUN	O	O	770
that	SCONJ	O	O	770
normally	ADV	O	O	770
inactivate	VERB	O	O	770
warfarin	VERB	O	Chemical	770
.	PUNCT	O	O	770
Isoproterenol	NOUN	O	Chemical	773
induces	VERB	O	O	773
primary	NOUN	O	O	773
loss	NOUN	O	O	773
of	ADP	O	O	773
dystrophin	NOUN	O	O	773
in	ADP	O	O	773
rat	NOUN	O	O	773
hearts	NOUN	O	O	773
:	PUNCT	O	O	773
correlation	NOUN	O	O	773
with	ADP	O	O	773
myocardial injury	NOUN	O	Disease	773
.	PUNCT	O	O	773
The	PRON	O	O	774
mechanism	NOUN	O	O	774
of	ADP	O	O	774
isoproterenol	NOUN	O	Chemical	774
-	PUNCT	O	O	774
induced	VERB	O	O	774
myocardial damage	NOUN	O	Disease	774
is	AUX	O	O	774
unknown	ADJ	O	O	774
,	PUNCT	O	O	774
but	CCONJ	O	O	774
a	PRON	O	O	774
mismatch	VERB	O	O	774
of	ADP	O	O	774
oxygen	NOUN	O	Chemical	774
supply	NOUN	O	O	774
vs.	CCONJ	O	O	774
demand	NOUN	O	O	774
following	VERB	O	O	774
coronary	ADJ	O	O	774
hypotension	NOUN	O	Disease	774
and	CCONJ	O	O	774
myocardial hyperactivity	NOUN	O	Disease	774
is	AUX	O	O	774
the	PRON	O	O	774
best	ADV	O	O	774
explanation	NOUN	O	O	774
for	ADP	O	O	774
the	PRON	O	O	774
complex	ADJ	O	O	774
morphological	ADJ	O	O	774
alterations	NOUN	O	O	774
observed	VERB	O	O	774
.	PUNCT	O	O	774
Severe	ADJ	O	O	775
alterations	NOUN	O	O	775
in	ADP	O	O	775
the	PRON	O	O	775
structural	ADJ	O	O	775
integrity	NOUN	O	O	775
of	ADP	O	O	775
the	PRON	O	O	775
sarcolemma	PROPN	O	O	775
of	ADP	O	O	775
cardiomyocytes	NOUN	O	O	775
have	VERB	O	O	775
been	AUX	O	O	775
demonstrated	VERB	O	O	775
to	PART	O	O	775
be	AUX	O	O	775
caused	VERB	O	O	775
by	ADP	O	O	775
isoproterenol	NOUN	O	Chemical	775
.	PUNCT	O	O	775
Taking	VERB	O	O	776
into	ADP	O	O	776
account	VERB	O	O	776
that	SCONJ	O	O	776
the	PRON	O	O	776
sarcolemmal	PROPN	O	O	776
integrity	NOUN	O	O	776
is	AUX	O	O	776
stabilized	VERB	O	O	776
by	ADP	O	O	776
the	PRON	O	O	776
dystrophin	NOUN	O	O	776
-	PUNCT	O	O	776
glycoprotein	NOUN	O	O	776
complex	ADJ	O	O	776
(	PUNCT	O	O	776
DGC	PROPN	O	O	776
)	PUNCT	O	O	776
that	SCONJ	O	O	776
connects	VERB	O	O	776
actin	PROPN	O	O	776
and	CCONJ	O	O	776
laminin	NOUN	O	O	776
in	ADP	O	O	776
contractile	ADJ	O	O	776
machinery	NOUN	O	O	776
and	CCONJ	O	O	776
extracellular	ADJ	O	O	776
matrix	NOUN	O	O	776
and	CCONJ	O	O	776
by	ADP	O	O	776
integrins	VERB	O	O	776
,	PUNCT	O	O	776
this	PRON	O	O	776
study	VERB	O	O	776
tests	VERB	O	O	776
the	PRON	O	O	776
hypothesis	NOUN	O	O	776
that	SCONJ	O	O	776
isoproterenol	NOUN	O	Chemical	776
affects	VERB	O	O	776
sarcolemmal	PROPN	O	O	776
stability	PROPN	O	O	776
through	ADP	O	O	776
changes	VERB	O	O	776
in	ADP	O	O	776
the	PRON	O	O	776
DGC	PROPN	O	O	776
and	CCONJ	O	O	776
integrins	VERB	O	O	776
.	PUNCT	O	O	776
We	PRON	O	O	777
found	VERB	O	O	777
different	ADJ	O	O	777
sensitivity	NOUN	O	O	777
of	ADP	O	O	777
the	PRON	O	O	777
DGC	PROPN	O	O	777
and	CCONJ	O	O	777
integrin	NOUN	O	O	777
to	PART	O	O	777
isoproterenol	NOUN	O	Chemical	777
subcutaneous	ADJ	O	O	777
administration	NOUN	O	O	777
.	PUNCT	O	O	777
In	ADP	O	O	778
conclusion	NOUN	O	O	778
,	PUNCT	O	O	778
administration	NOUN	O	O	778
of	ADP	O	O	778
isoproterenol	NOUN	O	Chemical	778
to	PART	O	O	778
rats	NOUN	O	O	778
results	VERB	O	O	778
in	ADP	O	O	778
primary	NOUN	O	O	778
loss	NOUN	O	O	778
of	ADP	O	O	778
dystrophin	NOUN	O	O	778
,	PUNCT	O	O	778
the	PRON	O	O	778
most	ADV	O	O	778
sensitive	ADJ	O	O	778
among	ADP	O	O	778
the	PRON	O	O	778
structural	ADJ	O	O	778
proteins	NOUN	O	O	778
that	SCONJ	O	O	778
form	NOUN	O	O	778
the	PRON	O	O	778
DGC	PROPN	O	O	778
that	SCONJ	O	O	778
connects	VERB	O	O	778
the	PRON	O	O	778
extracellular	ADJ	O	O	778
matrix	NOUN	O	O	778
and	CCONJ	O	O	778
the	PRON	O	O	778
cytoskeleton	NOUN	O	O	778
in	ADP	O	O	778
cardiomyocyte	NOUN	O	O	778
.	PUNCT	O	O	778
These	PRON	O	O	779
changes	VERB	O	O	779
,	PUNCT	O	O	779
related	ADJ	O	O	779
to	PART	O	O	779
ischaemic injury	NOUN	O	Disease	779
,	PUNCT	O	O	779
explain	VERB	O	O	779
the	PRON	O	O	779
severe	ADJ	O	O	779
alterations	NOUN	O	O	779
in	ADP	O	O	779
the	PRON	O	O	779
structural	ADJ	O	O	779
integrity	NOUN	O	O	779
of	ADP	O	O	779
the	PRON	O	O	779
sarcolemma	PROPN	O	O	779
of	ADP	O	O	779
cardiomyocytes	NOUN	O	O	779
and	CCONJ	O	O	779
hence	ADV	O	O	779
severe	ADJ	O	O	779
and	CCONJ	O	O	779
irreversible	ADJ	O	O	779
injury	NOUN	O	O	779
induced	VERB	O	O	779
by	ADP	O	O	779
isoproterenol	NOUN	O	Chemical	779
.	PUNCT	O	O	779
High	ADJ	O	O	782
fat	ADJ	O	Chemical	782
diet	PROPN	O	O	782
-	PUNCT	O	O	782
fed	VERB	O	O	782
obese	NOUN	O	Disease	782
rats	NOUN	O	O	782
are	AUX	O	O	782
highly	ADV	O	O	782
sensitive	ADJ	O	O	782
to	PART	O	O	782
doxorubicin	VERB	O	Chemical	782
-	PUNCT	O	O	782
induced	VERB	O	O	782
cardiotoxicity	NOUN	O	Disease	782
.	PUNCT	O	O	782
Often	ADV	O	O	783
,	PUNCT	O	O	783
chemotherapy	NOUN	O	O	783
by	ADP	O	O	783
doxorubicin	VERB	O	Chemical	783
(	PUNCT	O	O	783
Adriamycin	PROPN	O	Chemical	783
)	PUNCT	O	O	783
is	AUX	O	O	783
limited	VERB	O	O	783
due	ADJ	O	O	783
to	PART	O	O	783
life	NOUN	O	O	783
threatening	VERB	O	O	783
cardiotoxicity	NOUN	O	Disease	783
in	ADP	O	O	783
patients	NOUN	O	O	783
during	ADP	O	O	783
and	CCONJ	O	O	783
posttherapy	NOUN	O	O	783
.	PUNCT	O	O	783
Recently	ADV	O	O	784
,	PUNCT	O	O	784
we	PRON	O	O	784
have	VERB	O	O	784
shown	VERB	O	O	784
that	SCONJ	O	O	784
moderate	ADJ	O	O	784
diet	PROPN	O	O	784
restriction	NOUN	O	O	784
remarkably	ADV	O	O	784
protects	VERB	O	O	784
against	ADP	O	O	784
doxorubicin	VERB	O	Chemical	784
-	PUNCT	O	O	784
induced	VERB	O	O	784
cardiotoxicity	NOUN	O	Disease	784
.	PUNCT	O	O	784
This	PRON	O	O	785
cardioprotection	NOUN	O	O	785
is	AUX	O	O	785
accompanied	VERB	O	O	785
by	ADP	O	O	785
decreased	VERB	O	O	785
cardiac	ADJ	O	O	785
oxidative	NOUN	O	O	785
stress	NOUN	O	O	785
and	CCONJ	O	O	785
triglycerides	NOUN	O	Chemical	785
and	CCONJ	O	O	785
increased	VERB	O	O	785
cardiac	ADJ	O	O	785
fatty	ADJ	O	O	785
-	PUNCT	O	O	785
acid	PROPN	O	O	785
oxidation	ADV	O	O	785
,	PUNCT	O	O	785
ATP	PROPN	O	Chemical	785
synthesis	NOUN	O	O	785
,	PUNCT	O	O	785
and	CCONJ	O	O	785
upregulated	VERB	O	O	785
JAK	PROPN	O	O	785
/	PUNCT	O	O	785
STAT3	NOUN	O	O	785
pathway	NOUN	O	O	785
.	PUNCT	O	O	785
In	ADP	O	O	786
the	PRON	O	O	786
current	ADJ	O	O	786
study	VERB	O	O	786
,	PUNCT	O	O	786
we	PRON	O	O	786
investigated	VERB	O	O	786
whether	SCONJ	O	O	786
a	PRON	O	O	786
physiological	ADJ	O	O	786
intervention	NOUN	O	O	786
by	ADP	O	O	786
feeding	VERB	O	O	786
40%	NOUN	O	O	786
high	ADJ	O	O	786
fat	ADJ	O	Chemical	786
diet	PROPN	O	O	786
(	PUNCT	O	O	786
HFD	PROPN	O	O	786
)	PUNCT	O	O	786
,	PUNCT	O	O	786
which	PRON	O	O	786
induces	VERB	O	O	786
obesity	NOUN	O	Disease	786
in	ADP	O	O	786
male	NOUN	O	O	786
Sprague	PROPN	O	O	786
-	PUNCT	O	O	786
Dawley	NOUN	O	O	786
rats	NOUN	O	O	786
(	PUNCT	O	O	786
250	NUM	O	O	786
-	PUNCT	O	O	786
275	NUM	O	O	786
g	X	O	O	786
)	PUNCT	O	O	786
,	PUNCT	O	O	786
sensitizes	VERB	O	O	786
to	PART	O	O	786
doxorubicin	VERB	O	Chemical	786
-	PUNCT	O	O	786
induced	VERB	O	O	786
cardiotoxicity	NOUN	O	Disease	786
.	PUNCT	O	O	786
A	PRON	O	O	787
LD(10	VERB	O	O	787
)	PUNCT	O	O	787
dose	NOUN	O	O	787
(	PUNCT	O	O	787
8	NUM	O	O	787
mg	VERB	O	O	787
doxorubicin	VERB	O	Chemical	787
/	PUNCT	O	O	787
kg	VERB	O	O	787
,	PUNCT	O	O	787
ip	X	O	O	787
)	PUNCT	O	O	787
administered	VERB	O	O	787
on	ADP	O	O	787
day	NOUN	O	O	787
43	NUM	O	O	787
of	ADP	O	O	787
the	PRON	O	O	787
HFD	PROPN	O	O	787
feeding	VERB	O	O	787
regimen	NOUN	O	O	787
led	VERB	O	O	787
to	PART	O	O	787
higher	ADJ	O	O	787
cardiotoxicity	NOUN	O	Disease	787
,	PUNCT	O	O	787
cardiac dysfunction	NOUN	O	Disease	787
,	PUNCT	O	O	787
lipid	NOUN	O	O	787
peroxidation	NOUN	O	O	787
,	PUNCT	O	O	787
and	CCONJ	O	O	787
80%	NOUN	O	O	787
mortality	NOUN	O	O	787
in	ADP	O	O	787
the	PRON	O	O	787
obese	NOUN	O	Disease	787
(	PUNCT	O	O	787
OB	PROPN	O	Disease	787
)	PUNCT	O	O	787
rats	NOUN	O	O	787
in	ADP	O	O	787
the	PRON	O	O	787
absence	NOUN	O	O	787
of	ADP	O	O	787
any	PRON	O	O	787
significant	ADJ	O	O	787
renal	ADJ	O	O	787
or	CCONJ	O	O	787
hepatic toxicity	NOUN	O	Disease	787
.	PUNCT	O	O	787
Doxorubicin	PROPN	O	Chemical	788
toxicokinetics	NOUN	O	O	788
studies	NOUN	O	O	788
revealed	VERB	O	O	788
no	PRON	O	O	788
change	VERB	O	O	788
in	ADP	O	O	788
accumulation	NOUN	O	O	788
of	ADP	O	O	788
doxorubicin	VERB	O	Chemical	788
and	CCONJ	O	O	788
doxorubicinol	NOUN	O	Chemical	788
(	PUNCT	O	O	788
toxic	ADJ	O	O	788
metabolite	NOUN	O	O	788
)	PUNCT	O	O	788
in	ADP	O	O	788
the	PRON	O	O	788
normal	ADJ	O	O	788
diet	PROPN	O	O	788
-	PUNCT	O	O	788
fed	VERB	O	O	788
(	PUNCT	O	O	788
ND	PROPN	O	O	788
)	PUNCT	O	O	788
and	CCONJ	O	O	788
OB	PROPN	O	Disease	788
hearts	NOUN	O	O	788
.	PUNCT	O	O	788
Mechanistic	PROPN	O	O	789
studies	NOUN	O	O	789
revealed	VERB	O	O	789
that	SCONJ	O	O	789
OB	PROPN	O	Disease	789
rats	NOUN	O	O	789
are	AUX	O	O	789
sensitized	VERB	O	O	789
due	ADJ	O	O	789
to	PART	O	O	789
:	PUNCT	O	O	789
(	PUNCT	O	O	789
1	X	O	O	789
)	PUNCT	O	O	789
higher	ADJ	O	O	789
oxyradical	VERB	O	O	789
stress	NOUN	O	O	789
leading	VERB	O	O	789
to	PART	O	O	789
upregulation	NOUN	O	O	789
of	ADP	O	O	789
uncoupling	VERB	O	O	789
proteins	NOUN	O	O	789
2	X	O	O	789
and	CCONJ	O	O	789
3	X	O	O	789
,	PUNCT	O	O	789
(	PUNCT	O	O	789
2	X	O	O	789
)	PUNCT	O	O	789
downregulation	NOUN	O	O	789
of	ADP	O	O	789
cardiac	ADJ	O	O	789
peroxisome	PROPN	O	O	789
proliferators	NOUN	O	O	789
activated	VERB	O	O	789
receptor	NOUN	O	O	789
-	PUNCT	O	O	789
alpha	PROPN	O	O	789
,	PUNCT	O	O	789
(	PUNCT	O	O	789
3	X	O	O	789
)	PUNCT	O	O	789
decreased	VERB	O	O	789
plasma	NOUN	O	O	789
adiponectin	NOUN	O	O	789
levels	NOUN	O	O	789
,	PUNCT	O	O	789
(	PUNCT	O	O	789
4	NUM	O	O	789
)	PUNCT	O	O	789
decreased	VERB	O	O	789
cardiac	ADJ	O	O	789
fatty	ADJ	O	O	789
-	PUNCT	O	O	789
acid	PROPN	O	O	789
oxidation	ADV	O	O	789
(	PUNCT	O	O	789
666.9+/-14.0	NUM	O	O	789
nmol	PROPN	O	O	789
/	PUNCT	O	O	789
min	NOUN	O	O	789
/	PUNCT	O	O	789
g	X	O	O	789
heart	NOUN	O	O	789
in	ADP	O	O	789
ND	PROPN	O	O	789
versus	ADP	O	O	789
400.2+/-11.8	NUM	O	O	789
nmol	PROPN	O	O	789
/	PUNCT	O	O	790
min	NOUN	O	O	790
/	PUNCT	O	O	790
g	X	O	O	790
heart	NOUN	O	O	790
in	ADP	O	O	790
OB	PROPN	O	Disease	790
)	PUNCT	O	O	790
,	PUNCT	O	O	790
(	PUNCT	O	O	790
5	NUM	O	O	790
)	PUNCT	O	O	790
decreased	VERB	O	O	790
mitochondrial	ADJ	O	O	790
AMP	NOUN	O	Chemical	790
-	PUNCT	O	O	790
alpha2	NOUN	O	O	790
protein	NOUN	O	O	790
kinase	VERB	O	O	790
,	PUNCT	O	O	790
and	CCONJ	O	O	790
(	PUNCT	O	O	790
6	NUM	O	O	790
)	PUNCT	O	O	790
86%	NOUN	O	O	790
drop	VERB	O	O	790
in	ADP	O	O	790
cardiac	ADJ	O	O	790
ATP	PROPN	O	Chemical	790
levels	NOUN	O	O	790
accompanied	VERB	O	O	790
by	ADP	O	O	790
decreased	VERB	O	O	790
ATP	PROPN	O	Chemical	790
/	PUNCT	O	O	790
ADP	PROPN	O	Chemical	790
ratio	NOUN	O	O	790
after	ADP	O	O	790
doxorubicin	VERB	O	Chemical	790
administration	NOUN	O	O	790
.	PUNCT	O	O	790
In	ADP	O	O	791
conclusion	NOUN	O	O	791
,	PUNCT	O	O	791
HFD	PROPN	O	O	791
-	PUNCT	O	O	791
induced	VERB	O	O	791
obese	NOUN	O	Disease	791
rats	NOUN	O	O	791
are	AUX	O	O	791
highly	ADV	O	O	791
sensitized	VERB	O	O	791
to	PART	O	O	791
doxorubicin	VERB	O	Chemical	791
-	PUNCT	O	O	791
induced	VERB	O	O	791
cardiotoxicity	NOUN	O	Disease	791
by	ADP	O	O	791
substantially	ADV	O	O	791
downregulating	VERB	O	O	791
cardiac	ADJ	O	O	791
mitochondrial	ADJ	O	O	791
ATP	PROPN	O	Chemical	791
generation	NOUN	O	O	791
,	PUNCT	O	O	791
increasing	VERB	O	O	791
oxidative	NOUN	O	O	791
stress	NOUN	O	O	791
and	CCONJ	O	O	791
downregulating	VERB	O	O	791
the	PRON	O	O	791
JAK	PROPN	O	O	791
/	PUNCT	O	O	791
STAT3	NOUN	O	O	791
pathway	NOUN	O	O	791
.	PUNCT	O	O	791
Complete	ADJ	O	O	794
atrioventricular block	NOUN	O	Disease	794
secondary	ADJ	O	O	794
to	PART	O	O	794
lithium	NOUN	O	Chemical	794
therapy	NOUN	O	O	794
.	PUNCT	O	O	794
Sinus node dysfunction	NOUN	O	Disease	795
has	VERB	O	O	795
been	AUX	O	O	795
reported	VERB	O	O	795
most	ADV	O	O	795
frequently	ADV	O	O	795
among	ADP	O	O	795
the	PRON	O	O	795
adverse	ADJ	O	O	795
cardiovascular	ADJ	O	O	795
effects	NOUN	O	O	795
of	ADP	O	O	795
lithium	NOUN	O	Chemical	795
.	PUNCT	O	O	795
In	ADP	O	O	796
the	PRON	O	O	796
present	NOUN	O	O	796
case	NOUN	O	O	796
,	PUNCT	O	O	796
complete	VERB	O	O	796
atrioventricular	ADJ	O	O	796
(	PUNCT	O	O	796
AV	NOUN	O	O	796
)	PUNCT	O	O	796
block	NOUN	O	O	796
with	ADP	O	O	796
syncopal attacks	NOUN	O	Disease	796
developed	VERB	O	O	796
secondary	ADJ	O	O	796
to	PART	O	O	796
lithium	NOUN	O	Chemical	796
therapy	NOUN	O	O	796
,	PUNCT	O	O	796
necessitating	VERB	O	O	796
permanent	ADJ	O	O	796
pacemaker	NOUN	O	O	796
implantation	NOUN	O	O	796
.	PUNCT	O	O	796
Serum	NOUN	O	O	797
lithium	NOUN	O	Chemical	797
levels	NOUN	O	O	797
remained	VERB	O	O	797
under	ADP	O	O	797
or	CCONJ	O	O	797
within	ADP	O	O	797
the	PRON	O	O	797
therapeutic	ADJ	O	O	797
range	VERB	O	O	797
during	ADP	O	O	797
the	PRON	O	O	797
syncopal attacks	NOUN	O	Disease	797
.	PUNCT	O	O	797
Lithium	NOUN	O	Chemical	798
should	AUX	O	O	798
be	AUX	O	O	798
used	VERB	O	O	798
with	ADP	O	O	798
extreme	ADJ	O	O	798
caution	NOUN	O	O	798
,	PUNCT	O	O	798
especially	ADV	O	O	798
in	ADP	O	O	798
patients	NOUN	O	O	798
with	ADP	O	O	798
mild	ADJ	O	O	798
disturbance	NOUN	O	O	798
of	ADP	O	O	798
AV	NOUN	O	O	798
conduction	NOUN	O	O	798
.	PUNCT	O	O	798
Neuroleptic malignant syndrome	NOUN	O	Disease	801
induced	VERB	O	O	801
by	ADP	O	O	801
ziprasidone	NOUN	O	Chemical	801
on	ADP	O	O	801
the	PRON	O	O	801
second	ADV	O	O	801
day	NOUN	O	O	801
of	ADP	O	O	801
treatment	NOUN	O	O	801
.	PUNCT	O	O	801
Neuroleptic malignant syndrome	NOUN	O	Disease	802
(	PUNCT	O	O	802
NMS	PROPN	O	Disease	802
)	PUNCT	O	O	802
is	AUX	O	O	802
the	PRON	O	O	802
rarest	VERB	O	O	802
and	CCONJ	O	O	802
most	ADV	O	O	802
serious	ADJ	O	O	802
of	ADP	O	O	802
the	PRON	O	O	802
neuroleptic	NOUN	O	O	802
-	PUNCT	O	O	802
induced	VERB	O	O	802
movement disorders	NOUN	O	Disease	802
.	PUNCT	O	O	802
We	PRON	O	O	803
describe	VERB	O	O	803
a	PRON	O	O	803
case	NOUN	O	O	803
of	ADP	O	O	803
neuroleptic malignant syndrome	NOUN	O	Disease	803
(	PUNCT	O	O	803
NMS	PROPN	O	Disease	803
)	PUNCT	O	O	803
associated	VERB	O	O	803
with	ADP	O	O	803
the	PRON	O	O	803
use	VERB	O	O	803
of	ADP	O	O	803
ziprasidone	NOUN	O	Chemical	803
.	PUNCT	O	O	803
Although	SCONJ	O	O	804
conventional	ADJ	O	O	804
neuroleptics	NOUN	O	O	804
are	AUX	O	O	804
more	ADJ	O	O	804
frequently	ADV	O	O	804
associated	VERB	O	O	804
with	ADP	O	O	804
NMS	PROPN	O	Disease	804
,	PUNCT	O	O	804
atypical	ADJ	O	O	804
antipsychotic	ADJ	O	O	804
drugs	NOUN	O	O	804
like	INTJ	O	O	804
ziprasidone	NOUN	O	Chemical	804
may	AUX	O	O	804
also	ADV	O	O	804
be	AUX	O	O	804
a	PRON	O	O	804
cause	VERB	O	O	804
.	PUNCT	O	O	804
The	PRON	O	O	805
patient	NOUN	O	O	805
is	AUX	O	O	805
a	PRON	O	O	805
24-year	NOUN	O	O	805
-	PUNCT	O	O	805
old	ADJ	O	O	805
male	NOUN	O	O	805
with	ADP	O	O	805
a	PRON	O	O	805
history	NOUN	O	O	805
of	ADP	O	O	805
schizophrenia	PROPN	O	Disease	805
who	PRON	O	O	805
developed	VERB	O	O	805
signs	NOUN	O	O	805
and	CCONJ	O	O	805
symptoms	NOUN	O	O	805
of	ADP	O	O	805
NMS	PROPN	O	Disease	805
after	ADP	O	O	805
2	X	O	O	805
days	NOUN	O	O	805
of	ADP	O	O	805
treatment	NOUN	O	O	805
with	ADP	O	O	805
an	PRON	O	O	805
80-mg	NOUN	O	O	805
/	PUNCT	O	O	805
day	NOUN	O	O	805
dose	NOUN	O	O	805
of	ADP	O	O	805
orally	ADV	O	O	805
administrated	VERB	O	O	805
ziprasidone	NOUN	O	Chemical	805
.	PUNCT	O	O	805
NMS	PROPN	O	Disease	806
due	ADJ	O	O	806
to	PART	O	O	806
ziprasidone	NOUN	O	Chemical	806
reported	VERB	O	O	806
in	ADP	O	O	806
the	PRON	O	O	806
literature	NOUN	O	O	806
.	PUNCT	O	O	806
Role	NOUN	O	O	809
of	ADP	O	O	809
mangiferin	NOUN	O	Chemical	809
on	ADP	O	O	809
biochemical	ADJ	O	O	809
alterations	NOUN	O	O	809
and	CCONJ	O	O	809
antioxidant	ADJ	O	O	809
status	NOUN	O	O	809
in	ADP	O	O	809
isoproterenol	NOUN	O	Chemical	809
-	PUNCT	O	O	809
induced	VERB	O	O	809
myocardial infarction	NOUN	O	Disease	809
in	ADP	O	O	809
rats	NOUN	O	O	809
.	PUNCT	O	O	809
The	PRON	O	O	810
current	ADJ	O	O	810
study	VERB	O	O	810
dealt	VERB	O	O	810
with	ADP	O	O	810
the	PRON	O	O	810
protective	ADJ	O	O	810
role	NOUN	O	O	810
of	ADP	O	O	810
mangiferin	NOUN	O	Chemical	810
,	PUNCT	O	O	810
a	PRON	O	O	810
polyphenol	NOUN	O	Chemical	810
from	ADP	O	O	810
Mangifera	PROPN	O	O	810
indica	ADJ	O	O	810
Linn	PROPN	O	O	810
.	PUNCT	O	O	810
(	PUNCT	O	O	811
Anacardiaceae	VERB	O	O	811
)	PUNCT	O	O	811
,	PUNCT	O	O	811
on	ADP	O	O	811
isoproterenol	NOUN	O	Chemical	811
(	PUNCT	O	O	811
ISPH)-induced	VERB	O	O	811
myocardial infarction	NOUN	O	Disease	811
(	PUNCT	O	O	811
MI	PROPN	O	Disease	811
)	PUNCT	O	O	811
in	ADP	O	O	811
rats	NOUN	O	O	811
through	ADP	O	O	811
its	PRON	O	O	811
antioxidative	PROPN	O	O	811
mechanism	NOUN	O	O	811
.	PUNCT	O	O	811
Subcutaneous	ADJ	O	O	812
injection	NOUN	O	O	812
of	ADP	O	O	812
ISPH	VERB	O	Chemical	812
(	PUNCT	O	O	812
200	NUM	O	O	812
mg	VERB	O	O	812
/	PUNCT	O	O	812
kg	VERB	O	O	812
body	NOUN	O	O	812
weight	NOUN	O	O	812
in	ADP	O	O	812
1	X	O	O	812
ml	ADP	O	O	812
saline	NOUN	O	O	812
)	PUNCT	O	O	812
to	PART	O	O	812
rats	NOUN	O	O	812
for	ADP	O	O	812
2	X	O	O	812
consecutive	ADJ	O	O	812
days	NOUN	O	O	812
caused	VERB	O	O	812
myocardial damage	NOUN	O	Disease	812
in	ADP	O	O	812
rat	NOUN	O	O	812
heart	NOUN	O	O	812
,	PUNCT	O	O	812
which	PRON	O	O	812
was	AUX	O	O	812
determined	VERB	O	O	812
by	ADP	O	O	812
the	PRON	O	O	812
increased	VERB	O	O	812
activity	NOUN	O	O	812
of	ADP	O	O	812
serum	NOUN	O	O	812
lactate	NOUN	O	Chemical	812
dehydrogenase	NOUN	O	O	812
(	PUNCT	O	O	812
LDH	PROPN	O	O	812
)	PUNCT	O	O	812
and	CCONJ	O	O	812
creatine	PROPN	O	Chemical	812
phosphokinase	NOUN	O	O	812
isoenzymes	NOUN	O	O	812
(	PUNCT	O	O	812
CK	PROPN	O	O	812
-	PUNCT	O	O	812
MB	NOUN	O	O	812
)	PUNCT	O	O	812
,	PUNCT	O	O	812
increased	VERB	O	O	812
uric acid	NOUN	O	Chemical	812
level	VERB	O	O	812
and	CCONJ	O	O	812
reduced	VERB	O	O	812
plasma	NOUN	O	O	812
iron	NOUN	O	Chemical	812
binding	VERB	O	O	812
capacity	NOUN	O	O	812
.	PUNCT	O	O	812
The	PRON	O	O	813
protective	ADJ	O	O	813
role	NOUN	O	O	813
of	ADP	O	O	813
mangiferin	NOUN	O	Chemical	813
was	AUX	O	O	813
analyzed	VERB	O	O	813
by	ADP	O	O	813
triphenyl tetrazolium chloride	NOUN	O	Chemical	813
(	PUNCT	O	O	813
TTC	PROPN	O	Chemical	813
)	PUNCT	O	O	813
test	NOUN	O	O	813
used	VERB	O	O	813
for	ADP	O	O	813
macroscopic	ADJ	O	O	813
enzyme	NOUN	O	O	813
mapping	NOUN	O	O	813
assay	NOUN	O	O	813
of	ADP	O	O	813
the	PRON	O	O	813
ischemic myocardium	NOUN	O	Disease	813
.	PUNCT	O	O	813
The	PRON	O	O	814
heart	NOUN	O	O	814
tissue	NOUN	O	O	814
antioxidant	ADJ	O	O	814
enzymes	NOUN	O	O	814
such	ADJ	O	O	814
as	ADP	O	O	814
superoxide	NOUN	O	Chemical	814
dismutase	ADP	O	O	814
,	PUNCT	O	O	814
catalase	VERB	O	O	814
,	PUNCT	O	O	814
glutathione	NOUN	O	Chemical	814
peroxidase	NOUN	O	O	814
,	PUNCT	O	O	814
glutathione	NOUN	O	Chemical	814
transferase	PROPN	O	O	814
and	CCONJ	O	O	814
glutathione	NOUN	O	Chemical	814
reductase	NOUN	O	O	814
activities	NOUN	O	O	814
,	PUNCT	O	O	814
non	ADJ	O	O	814
-	PUNCT	O	O	814
enzymic	ADJ	O	O	814
antioxidants	NOUN	O	O	814
such	ADJ	O	O	814
as	ADP	O	O	814
cerruloplasmin	NOUN	O	O	814
,	PUNCT	O	O	814
Vitamin C	NOUN	O	Chemical	814
,	PUNCT	O	O	814
Vitamin E	NOUN	O	Chemical	814
and	CCONJ	O	O	814
glutathione	NOUN	O	Chemical	815
levels	NOUN	O	O	815
were	AUX	O	O	815
altered	VERB	O	O	815
in	ADP	O	O	815
MI	PROPN	O	Disease	815
rats	NOUN	O	O	815
.	PUNCT	O	O	815
Upon	SCONJ	O	O	816
pretreatment	NOUN	O	O	816
with	ADP	O	O	816
mangiferin	NOUN	O	Chemical	816
(	PUNCT	O	O	816
100	NUM	O	O	816
mg	VERB	O	O	816
/	PUNCT	O	O	816
kg	VERB	O	O	816
body	NOUN	O	O	816
weight	NOUN	O	O	816
suspended	VERB	O	O	816
in	ADP	O	O	816
2	X	O	O	816
ml	ADP	O	O	816
of	ADP	O	O	816
dimethyl sulphoxide	NOUN	O	Chemical	816
)	PUNCT	O	O	816
given	VERB	O	O	816
intraperitoneally	ADV	O	O	816
for	ADP	O	O	816
28	NUM	O	O	816
days	NOUN	O	O	816
to	PART	O	O	816
MI	PROPN	O	Disease	816
rats	NOUN	O	O	816
protected	VERB	O	O	816
the	PRON	O	O	816
above	ADP	O	O	816
-	PUNCT	O	O	816
mentioned	VERB	O	O	816
parameters	NOUN	O	O	816
to	PART	O	O	816
fall	VERB	O	O	816
from	ADP	O	O	816
the	PRON	O	O	816
normal	ADJ	O	O	816
levels	NOUN	O	O	816
.	PUNCT	O	O	816
Activities	NOUN	O	O	817
of	ADP	O	O	817
heart	NOUN	O	O	817
tissue	NOUN	O	O	817
enzymic	ADJ	O	O	817
antioxidants	NOUN	O	O	817
and	CCONJ	O	O	817
serum	NOUN	O	O	817
non	ADJ	O	O	817
-	PUNCT	O	O	817
enzymic	ADJ	O	O	817
antioxidants	NOUN	O	O	817
levels	NOUN	O	O	817
rose	VERB	O	O	817
significantly	ADV	O	O	817
upon	SCONJ	O	O	817
mangiferin	NOUN	O	Chemical	817
administration	NOUN	O	O	817
as	ADP	O	O	817
compared	VERB	O	O	817
to	PART	O	O	817
ISPH	VERB	O	Chemical	817
-	PUNCT	O	O	817
induced	VERB	O	O	817
MI	PROPN	O	Disease	817
rats	NOUN	O	O	817
.	PUNCT	O	O	817
From	ADP	O	O	818
the	PRON	O	O	818
present	NOUN	O	O	818
study	VERB	O	O	818
it	PRON	O	O	818
is	AUX	O	O	818
concluded	VERB	O	O	818
that	SCONJ	O	O	818
mangiferin	NOUN	O	Chemical	818
exerts	VERB	O	O	818
a	PRON	O	O	818
beneficial	ADJ	O	O	818
effect	VERB	O	O	818
against	ADP	O	O	818
ISPH	VERB	O	Chemical	818
-	PUNCT	O	O	818
induced	VERB	O	O	818
MI	PROPN	O	Disease	818
due	ADJ	O	O	818
to	PART	O	O	818
its	PRON	O	O	818
antioxidant	ADJ	O	O	818
potential	ADJ	O	O	818
,	PUNCT	O	O	818
which	PRON	O	O	818
regulated	VERB	O	O	818
the	PRON	O	O	818
tissues	NOUN	O	O	818
defense	NOUN	O	O	818
system	NOUN	O	O	818
against	ADP	O	O	818
cardiac damage	NOUN	O	Disease	818
.	PUNCT	O	O	818
Remifentanil	NOUN	O	Chemical	821
pretreatment	NOUN	O	O	821
reduces	VERB	O	O	821
myoclonus	NOUN	O	Disease	821
after	ADP	O	O	821
etomidate	VERB	O	Chemical	821
.	PUNCT	O	O	821
The	PRON	O	O	822
aim	VERB	O	O	822
of	ADP	O	O	822
the	PRON	O	O	822
study	VERB	O	O	822
was	AUX	O	O	822
to	PART	O	O	822
compare	VERB	O	O	822
the	PRON	O	O	822
effect	VERB	O	O	822
of	ADP	O	O	822
pretreatment	NOUN	O	O	822
with	ADP	O	O	822
remifentanil	NOUN	O	Chemical	822
1	X	O	O	822
microg	PROPN	O	O	822
/	PUNCT	O	O	822
kg	VERB	O	O	822
and	CCONJ	O	O	822
the	PRON	O	O	822
effect	VERB	O	O	822
of	ADP	O	O	822
gender	NOUN	O	O	822
on	ADP	O	O	822
the	PRON	O	O	822
incidence	NOUN	O	O	822
of	ADP	O	O	822
myoclonus	NOUN	O	Disease	822
after	ADP	O	O	822
anesthesia	NOUN	O	O	822
induction	NOUN	O	O	822
with	ADP	O	O	822
etomidate	VERB	O	Chemical	822
.	PUNCT	O	O	822
Sixty	NUM	O	O	823
patients	NOUN	O	O	823
were	AUX	O	O	823
pretreated	VERB	O	O	823
in	ADP	O	O	823
a	PRON	O	O	823
randomized	VERB	O	O	823
double	ADJ	O	O	823
-	PUNCT	O	O	823
blinded	VERB	O	O	823
fashion	NOUN	O	O	823
with	ADP	O	O	823
remifentanil	NOUN	O	Chemical	823
1	X	O	O	823
microg	PROPN	O	O	823
/	PUNCT	O	O	823
kg	VERB	O	O	823
or	CCONJ	O	O	823
placebo	NOUN	O	O	823
.	PUNCT	O	O	823
Two	NUM	O	O	824
minutes	NOUN	O	O	824
after	ADP	O	O	824
remifentanil	NOUN	O	Chemical	824
or	CCONJ	O	O	824
placebo	NOUN	O	O	824
injection	NOUN	O	O	824
,	PUNCT	O	O	824
etomidate	VERB	O	Chemical	824
0.3	NUM	O	O	824
mg	VERB	O	O	824
/	PUNCT	O	O	824
kg	VERB	O	O	824
was	AUX	O	O	824
given	VERB	O	O	824
.	PUNCT	O	O	824
Myoclonus	NOUN	O	Disease	825
was	AUX	O	O	825
recorded	VERB	O	O	825
with	ADP	O	O	825
a	PRON	O	O	825
scale	NOUN	O	O	825
of	ADP	O	O	825
0	NUM	O	O	825
to	PART	O	O	825
3	X	O	O	825
.	PUNCT	O	O	825
The	PRON	O	O	826
grade	NOUN	O	O	826
of	ADP	O	O	826
sedation	NOUN	O	O	826
(	PUNCT	O	O	826
none	NOUN	O	O	826
,	PUNCT	O	O	826
mild	ADJ	O	O	826
,	PUNCT	O	O	826
moderate	ADJ	O	O	826
,	PUNCT	O	O	826
severe	ADJ	O	O	826
)	PUNCT	O	O	826
,	PUNCT	O	O	826
nausea	NOUN	O	Disease	826
,	PUNCT	O	O	826
pruritus	PROPN	O	Disease	826
,	PUNCT	O	O	826
and	CCONJ	O	O	826
apnea	PROPN	O	Disease	826
were	AUX	O	O	826
recorded	VERB	O	O	826
after	ADP	O	O	826
injection	NOUN	O	O	826
of	ADP	O	O	826
both	PRON	O	O	826
drugs	NOUN	O	O	826
.	PUNCT	O	O	826
The	PRON	O	O	827
incidence	NOUN	O	O	827
of	ADP	O	O	827
myoclonus	NOUN	O	Disease	827
was	AUX	O	O	827
significantly	ADV	O	O	827
lower	ADJ	O	O	827
in	ADP	O	O	827
the	PRON	O	O	827
remifentanil	NOUN	O	Chemical	827
group	NOUN	O	O	827
(	PUNCT	O	O	827
6.7%	NOUN	O	O	827
)	PUNCT	O	O	827
than	ADP	O	O	827
in	ADP	O	O	827
the	PRON	O	O	827
placebo	NOUN	O	O	827
group	NOUN	O	O	827
(	PUNCT	O	O	827
70%	NOUN	O	O	827
)	PUNCT	O	O	827
None	NOUN	O	O	828
of	ADP	O	O	828
the	PRON	O	O	828
patients	NOUN	O	O	828
experienced	ADJ	O	O	828
sedation	NOUN	O	O	828
,	PUNCT	O	O	828
apnea	PROPN	O	Disease	828
,	PUNCT	O	O	828
nausea	NOUN	O	Disease	828
,	PUNCT	O	O	828
or	CCONJ	O	O	828
pruritus	PROPN	O	Disease	828
after	ADP	O	O	828
injection	NOUN	O	O	828
of	ADP	O	O	828
both	PRON	O	O	828
drugs	NOUN	O	O	828
.	PUNCT	O	O	828
In	ADP	O	O	829
the	PRON	O	O	829
placebo	NOUN	O	O	829
group	NOUN	O	O	829
,	PUNCT	O	O	829
male	NOUN	O	O	829
patients	NOUN	O	O	829
were	AUX	O	O	829
associated	VERB	O	O	829
with	ADP	O	O	829
significantly	ADV	O	O	829
increased	VERB	O	O	829
incidence	NOUN	O	O	829
of	ADP	O	O	829
myoclonus	NOUN	O	Disease	829
after	ADP	O	O	829
etomidate	VERB	O	Chemical	829
administration	NOUN	O	O	829
.	PUNCT	O	O	829
CONCLUSION	PROPN	O	O	830
:	PUNCT	O	O	830
Pretreatment	NOUN	O	O	830
with	ADP	O	O	830
remifentanil	NOUN	O	Chemical	830
1	X	O	O	830
microg	PROPN	O	O	830
/	PUNCT	O	O	830
kg	VERB	O	O	831
reduced	VERB	O	O	831
myoclonus	NOUN	O	Disease	831
after	ADP	O	O	831
etomidate	VERB	O	Chemical	831
induction	NOUN	O	O	831
without	ADP	O	O	831
side	NOUN	O	O	831
effects	NOUN	O	O	831
such	ADJ	O	O	831
as	ADP	O	O	831
sedation	NOUN	O	O	831
,	PUNCT	O	O	831
apnea	PROPN	O	Disease	831
,	PUNCT	O	O	831
nausea	NOUN	O	Disease	831
,	PUNCT	O	O	831
or	CCONJ	O	O	831
pruritus	PROPN	O	Disease	831
.	PUNCT	O	O	831
Men	NOUN	O	O	832
experience	NOUN	O	O	832
increased	VERB	O	O	832
incidence	NOUN	O	O	832
of	ADP	O	O	832
myoclonus	NOUN	O	Disease	832
than	ADP	O	O	832
women	NOUN	O	O	832
after	ADP	O	O	832
etomidate	VERB	O	Chemical	832
administration	NOUN	O	O	832
.	PUNCT	O	O	832
Daidzein	PROPN	O	Chemical	835
activates	VERB	O	O	835
choline	NOUN	O	Chemical	835
acetyltransferase	PROPN	O	O	835
from	ADP	O	O	835
MC	PROPN	O	Chemical	835
-	PUNCT	O	O	835
IXC	NOUN	O	O	835
cells	NOUN	O	O	835
and	CCONJ	O	O	835
improves	VERB	O	O	835
drug	NOUN	O	O	835
-	PUNCT	O	O	835
induced	VERB	O	O	835
amnesia	NOUN	O	Disease	835
.	PUNCT	O	O	835
The	PRON	O	O	836
choline	NOUN	O	Chemical	836
acetyltransferase	PROPN	O	O	836
(	PUNCT	O	O	836
ChAT	VERB	O	O	836
)	PUNCT	O	O	836
activator	NOUN	O	O	836
,	PUNCT	O	O	836
which	PRON	O	O	836
enhances	VERB	O	O	836
cholinergic	ADJ	O	O	836
transmission	NOUN	O	O	836
via	ADP	O	O	836
an	PRON	O	O	836
augmentation	NOUN	O	O	836
of	ADP	O	O	836
the	PRON	O	O	836
enzymatic	ADJ	O	O	836
production	NOUN	O	O	836
of	ADP	O	O	836
acetylcholine	NOUN	O	Chemical	836
(	PUNCT	O	O	836
ACh	PROPN	O	Chemical	836
)	PUNCT	O	O	836
,	PUNCT	O	O	836
is	AUX	O	O	836
an	PRON	O	O	836
important	ADJ	O	O	836
factor	NOUN	O	O	836
in	ADP	O	O	836
the	PRON	O	O	836
treatment	NOUN	O	O	836
of	ADP	O	O	836
Alzheimer	NOUN	O	Disease	836
's	AUX	O	O	836
disease	PROPN	O	O	836
(	PUNCT	O	O	836
AD	NOUN	O	Disease	836
)	PUNCT	O	O	836
.	PUNCT	O	O	836
Via	PROPN	O	O	837
the	PRON	O	O	837
sequential	ADJ	O	O	837
isolation	NOUN	O	O	837
of	ADP	O	O	837
Pueraria	PROPN	O	O	837
thunbergiana	NOUN	O	O	837
,	PUNCT	O	O	837
the	PRON	O	O	837
active	ADJ	O	O	837
component	NOUN	O	O	837
was	AUX	O	O	837
ultimately	ADV	O	O	837
identified	VERB	O	O	837
as	ADP	O	O	837
daidzein	NOUN	O	Chemical	837
(	PUNCT	O	O	837
4',7-dihydroxy	NOUN	O	O	837
-	PUNCT	O	O	837
isoflavone	PROPN	O	O	837
)	PUNCT	O	O	837
.	PUNCT	O	O	837
In	ADP	O	O	838
order	NOUN	O	O	838
to	PART	O	O	838
investigate	VERB	O	O	838
the	PRON	O	O	838
effects	NOUN	O	O	838
of	ADP	O	O	838
daidzein	NOUN	O	Chemical	838
from	ADP	O	O	838
Pueraria	PROPN	O	O	838
thunbergiana	NOUN	O	O	838
on	ADP	O	O	838
scopolamine	NOUN	O	Chemical	838
-	PUNCT	O	O	838
induced	VERB	O	O	838
impairments of learning	VERB	O	Disease	838
and	CCONJ	O	O	838
memory	NOUN	O	O	838
,	PUNCT	O	O	838
we	PRON	O	O	838
conducted	VERB	O	O	838
a	PRON	O	O	838
series	PROPN	O	O	838
of	ADP	O	O	838
in	ADP	O	O	838
vivo	VERB	O	O	838
tests	VERB	O	O	838
.	PUNCT	O	O	838
Administration	NOUN	O	O	839
of	ADP	O	O	839
daidzein	NOUN	O	Chemical	839
(	PUNCT	O	O	839
4.5	NUM	O	O	839
mg	VERB	O	O	839
/	PUNCT	O	O	839
kg	VERB	O	O	839
body	NOUN	O	O	839
weight	NOUN	O	O	839
)	PUNCT	O	O	839
to	PART	O	O	839
mice	NOUN	O	O	839
was	AUX	O	O	839
shown	VERB	O	O	839
significantly	ADV	O	O	839
to	PART	O	O	839
reverse	VERB	O	O	839
scopolamine	NOUN	O	Chemical	839
-	PUNCT	O	O	839
induced	VERB	O	O	839
amnesia	NOUN	O	Disease	839
,	PUNCT	O	O	839
according	VERB	O	O	839
to	PART	O	O	839
the	PRON	O	O	839
results	VERB	O	O	839
of	ADP	O	O	839
a	PRON	O	O	839
Y	NOUN	O	O	839
-	PUNCT	O	O	839
maze	NOUN	O	O	839
test	NOUN	O	O	839
.	PUNCT	O	O	839
Injections	NOUN	O	O	840
of	ADP	O	O	840
scopolamine	NOUN	O	Chemical	840
into	ADP	O	O	840
mice	NOUN	O	O	840
resulted	VERB	O	O	840
in	ADP	O	O	840
impaired	VERB	O	O	840
performance	NOUN	O	O	840
on	ADP	O	O	840
Y	NOUN	O	O	840
-	PUNCT	O	O	840
maze	NOUN	O	O	840
tests	VERB	O	O	840
(	PUNCT	O	O	840
a	PRON	O	O	840
37%	NOUN	O	O	840
decreases	VERB	O	O	840
in	ADP	O	O	840
alternation	NOUN	O	O	840
behavior	NOUN	O	O	840
)	PUNCT	O	O	840
.	PUNCT	O	O	840
By	ADP	O	O	841
way	NOUN	O	O	841
of	ADP	O	O	841
contrast	NOUN	O	O	841
,	PUNCT	O	O	841
mice	NOUN	O	O	841
treated	VERB	O	O	841
with	ADP	O	O	841
daidzein	NOUN	O	Chemical	841
prior	ADV	O	O	841
to	PART	O	O	841
the	PRON	O	O	841
scopolamine	NOUN	O	Chemical	841
injections	NOUN	O	O	841
were	AUX	O	O	841
noticeably	ADV	O	O	841
protected	VERB	O	O	841
from	ADP	O	O	841
this	PRON	O	O	841
performance	NOUN	O	O	841
impairment	NOUN	O	O	841
(	PUNCT	O	O	841
an	PRON	O	O	841
approximately	ADV	O	O	841
12%-21%	NOUN	O	O	841
decrease	VERB	O	O	841
in	ADP	O	O	841
alternation	NOUN	O	O	841
behavior	NOUN	O	O	841
)	PUNCT	O	O	841
.	PUNCT	O	O	841
These	PRON	O	O	842
results	VERB	O	O	842
indicate	VERB	O	O	842
that	SCONJ	O	O	842
daidzein	NOUN	O	Chemical	842
might	AUX	O	O	842
play	VERB	O	O	842
a	PRON	O	O	842
role	NOUN	O	O	842
in	ADP	O	O	842
acetylcholine	NOUN	O	Chemical	842
biosynthesis	NOUN	O	O	842
as	ADP	O	O	842
a	PRON	O	O	842
ChAT	VERB	O	O	842
activator	NOUN	O	O	842
,	PUNCT	O	O	842
and	CCONJ	O	O	842
that	SCONJ	O	O	842
it	PRON	O	O	842
also	ADV	O	O	842
ameliorates	VERB	O	O	842
scopolamine	NOUN	O	Chemical	842
-	PUNCT	O	O	842
induced	VERB	O	O	842
amnesia	NOUN	O	Disease	842
.	PUNCT	O	O	842
Possible	ADJ	O	O	845
azithromycin	PROPN	O	Chemical	845
-	PUNCT	O	O	845
associated	VERB	O	O	845
hiccups	VERB	O	Disease	845
.	PUNCT	O	O	845
OBJECTIVE	VERB	O	O	846
:	PUNCT	O	O	846
To	PART	O	O	846
report	VERB	O	O	846
a	PRON	O	O	846
case	NOUN	O	O	846
of	ADP	O	O	846
persistent	ADJ	O	O	846
hiccups	VERB	O	Disease	846
associated	VERB	O	O	846
by	ADP	O	O	846
azithromycin	PROPN	O	Chemical	846
therapy	NOUN	O	O	846
.	PUNCT	O	O	846
A	PRON	O	O	847
76-year	NOUN	O	O	847
-	PUNCT	O	O	847
old	ADJ	O	O	847
man	NOUN	O	O	847
presented	VERB	O	O	847
with	ADP	O	O	847
persistent	ADJ	O	O	847
hiccups	VERB	O	Disease	847
after	ADP	O	O	847
beginning	VERB	O	O	847
azithromycin	PROPN	O	Chemical	847
for	ADP	O	O	847
the	PRON	O	O	847
treatment	NOUN	O	O	847
of	ADP	O	O	847
pharyngitis	NOUN	O	Disease	847
.	PUNCT	O	O	847
Hiccups	NOUN	O	Disease	848
were	AUX	O	O	848
persistent	ADJ	O	O	848
and	CCONJ	O	O	848
exhausting	ADJ	O	O	848
.	PUNCT	O	O	848
Discontinuation	NOUN	O	O	849
of	ADP	O	O	849
azithromycin	PROPN	O	Chemical	849
and	CCONJ	O	O	849
therapy	NOUN	O	O	849
with	ADP	O	O	849
baclofen	VERB	O	Chemical	849
finally	ADV	O	O	849
resolved	VERB	O	O	849
hiccups	VERB	O	Disease	849
.	PUNCT	O	O	849
No	PRON	O	O	850
organic	ADJ	O	O	850
cause	VERB	O	O	850
of	ADP	O	O	850
hiccups	VERB	O	Disease	850
was	AUX	O	O	850
identified	VERB	O	O	850
despite	SCONJ	O	O	850
extensive	ADJ	O	O	850
investigation	NOUN	O	O	850
.	PUNCT	O	O	850
DISCUSSION	NOUN	O	O	851
:	PUNCT	O	O	851
Pharmacotherapeutic	NOUN	O	O	851
agents	NOUN	O	O	851
have	VERB	O	O	851
been	AUX	O	O	851
uncommonly	ADV	O	O	851
associated	VERB	O	O	851
with	ADP	O	O	851
hiccups	VERB	O	Disease	851
.	PUNCT	O	O	851
Corticosteroids	NOUN	O	O	852
(	PUNCT	O	O	852
dexamethasone	NOUN	O	Chemical	852
and	CCONJ	O	O	852
methylprednisolone	NOUN	O	Chemical	852
)	PUNCT	O	O	852
,	PUNCT	O	O	852
benzodiazepines	NOUN	O	Chemical	852
(	PUNCT	O	O	852
midazolam	PROPN	O	Chemical	852
)	PUNCT	O	O	852
and	CCONJ	O	O	852
general	ADJ	O	O	852
anaesthesia	NOUN	O	O	852
have	VERB	O	O	852
been	AUX	O	O	852
the	PRON	O	O	852
specific	ADJ	O	O	852
agents	NOUN	O	O	852
mentioned	VERB	O	O	852
most	ADV	O	O	852
frequently	ADV	O	O	852
in	ADP	O	O	852
the	PRON	O	O	852
literature	NOUN	O	O	852
as	ADP	O	O	852
being	AUX	O	O	852
associated	VERB	O	O	852
with	ADP	O	O	852
the	PRON	O	O	852
development	NOUN	O	O	852
of	ADP	O	O	852
hiccups	VERB	O	Disease	852
.	PUNCT	O	O	852
Few	ADJ	O	O	853
cases	NOUN	O	O	853
of	ADP	O	O	853
drug	NOUN	O	O	853
-	PUNCT	O	O	853
induced	VERB	O	O	853
hiccups	VERB	O	Disease	853
have	VERB	O	O	853
been	AUX	O	O	853
reported	VERB	O	O	853
related	ADJ	O	O	853
to	PART	O	O	853
macrolide	ADV	O	Chemical	853
antimicrobials	NOUN	O	O	853
.	PUNCT	O	O	853
Using	VERB	O	O	854
the	PRON	O	O	854
Naranjo	PROPN	O	O	854
adverse	ADJ	O	O	854
effect	VERB	O	O	854
reaction	NOUN	O	O	854
probability	NOUN	O	O	854
scale	NOUN	O	O	854
this	PRON	O	O	854
event	NOUN	O	O	854
could	AUX	O	O	854
be	AUX	O	O	854
classified	VERB	O	O	854
as	ADP	O	O	854
possible	ADJ	O	O	854
(	PUNCT	O	O	854
score	VERB	O	O	854
5	NUM	O	O	854
points	VERB	O	O	854
)	PUNCT	O	O	854
,	PUNCT	O	O	854
mostly	ADV	O	O	854
because	SCONJ	O	O	854
of	ADP	O	O	854
the	PRON	O	O	854
close	ADV	O	O	854
temporal	ADJ	O	O	854
sequence	NOUN	O	O	854
,	PUNCT	O	O	854
previous	ADJ	O	O	854
reports	VERB	O	O	854
on	ADP	O	O	854
this	PRON	O	O	854
reaction	NOUN	O	O	854
with	ADP	O	O	854
other	ADJ	O	O	854
macrolides	VERB	O	Chemical	854
and	CCONJ	O	O	854
the	PRON	O	O	854
absence	NOUN	O	O	854
of	ADP	O	O	854
any	PRON	O	O	854
alternative	ADV	O	O	854
explanation	NOUN	O	O	854
for	ADP	O	O	854
hiccups	VERB	O	Disease	854
.	PUNCT	O	O	854
Our	PRON	O	O	855
hypothesis	NOUN	O	O	855
is	AUX	O	O	855
that	SCONJ	O	O	855
a	PRON	O	O	855
vagal	ADJ	O	O	855
mechanism	NOUN	O	O	855
mediated	VERB	O	O	855
by	ADP	O	O	855
azithromycin	PROPN	O	Chemical	855
could	AUX	O	O	855
be	AUX	O	O	855
the	PRON	O	O	855
pathogenesis	NOUN	O	O	855
of	ADP	O	O	855
hiccups	VERB	O	Disease	855
in	ADP	O	O	855
our	PRON	O	O	855
patient	NOUN	O	O	855
.	PUNCT	O	O	855
Diagnosis	NOUN	O	O	856
of	ADP	O	O	856
drug	NOUN	O	O	856
-	PUNCT	O	O	856
induced	VERB	O	O	856
hiccups	VERB	O	Disease	856
is	AUX	O	O	856
difficult	ADJ	O	O	856
and	CCONJ	O	O	856
often	ADV	O	O	856
achieved	VERB	O	O	856
only	ADV	O	O	856
by	ADP	O	O	856
a	PRON	O	O	856
process	NOUN	O	O	856
of	ADP	O	O	856
elimination	NOUN	O	O	856
.	PUNCT	O	O	856
However	ADV	O	O	857
,	PUNCT	O	O	857
macrolide	ADV	O	Chemical	857
antimicrobials	NOUN	O	O	857
have	VERB	O	O	857
been	AUX	O	O	857
reported	VERB	O	O	857
to	PART	O	O	857
be	AUX	O	O	857
associated	VERB	O	O	857
with	ADP	O	O	857
hiccups	VERB	O	Disease	857
and	CCONJ	O	O	857
vagal	ADJ	O	O	857
mechanism	NOUN	O	O	857
could	AUX	O	O	857
explain	VERB	O	O	857
the	PRON	O	O	857
development	NOUN	O	O	857
of	ADP	O	O	857
this	PRON	O	O	857
side	NOUN	O	O	857
-	PUNCT	O	O	857
effect	VERB	O	O	857
.	PUNCT	O	O	857
Time	NOUN	O	O	860
trends	NOUN	O	O	860
in	ADP	O	O	860
warfarin	VERB	O	Chemical	860
-	PUNCT	O	O	860
associated	VERB	O	O	860
hemorrhage	NOUN	O	Disease	860
.	PUNCT	O	O	860
The	PRON	O	O	861
annual	ADJ	O	O	861
incidence	NOUN	O	O	861
of	ADP	O	O	861
warfarin	VERB	O	Chemical	861
-	PUNCT	O	O	861
related	ADJ	O	O	861
bleeding	VERB	O	Disease	861
at	ADP	O	O	861
Brigham	PROPN	O	O	861
and	CCONJ	O	O	861
Women	NOUN	O	O	861
's	AUX	O	O	861
Hospital	NOUN	O	O	861
increased	VERB	O	O	861
from	ADP	O	O	861
0.97/1,000	NUM	O	O	861
patient	NOUN	O	O	861
admissions	NOUN	O	O	861
in	ADP	O	O	861
the	PRON	O	O	861
first	ADV	O	O	861
time	NOUN	O	O	861
period	NOUN	O	O	861
(	PUNCT	O	O	861
January	PROPN	O	O	861
1995	NUM	O	O	861
to	PART	O	O	861
October	PROPN	O	O	861
1998	NUM	O	O	861
)	PUNCT	O	O	861
to	PART	O	O	861
1.19/1,000	NUM	O	O	861
patient	NOUN	O	O	861
admissions	NOUN	O	O	861
in	ADP	O	O	861
the	PRON	O	O	861
second	ADV	O	O	861
time	NOUN	O	O	861
period	NOUN	O	O	861
(	PUNCT	O	O	861
November	PROPN	O	O	861
1998	NUM	O	O	861
to	PART	O	O	861
August	PROPN	O	O	861
2002	NUM	O	O	861
)	PUNCT	O	O	861
of	ADP	O	O	861
this	PRON	O	O	861
study	VERB	O	O	861
.	PUNCT	O	O	861
The	PRON	O	O	862
proportion	NOUN	O	O	862
of	ADP	O	O	862
patients	NOUN	O	O	862
with	ADP	O	O	862
major	ADJ	O	O	862
and	CCONJ	O	O	862
intracranial bleeding	NOUN	O	Disease	862
increased	VERB	O	O	862
from	ADP	O	O	862
20.2%	NOUN	O	O	862
and	CCONJ	O	O	862
1.9%	NOUN	O	O	862
,	PUNCT	O	O	862
respectively	ADV	O	O	862
,	PUNCT	O	O	862
in	ADP	O	O	862
the	PRON	O	O	862
first	ADV	O	O	862
time	NOUN	O	O	862
period	NOUN	O	O	862
,	PUNCT	O	O	862
to	PART	O	O	862
33.3%	NOUN	O	O	862
and	CCONJ	O	O	862
7.8%	NOUN	O	O	862
,	PUNCT	O	O	862
respectively	ADV	O	O	862
,	PUNCT	O	O	862
in	ADP	O	O	862
the	PRON	O	O	862
second	ADV	O	O	862
.	PUNCT	O	O	862
Fatal	ADJ	O	O	865
haemorrhagic myocarditis	PROPN	O	Disease	865
secondary	ADJ	O	O	865
to	PART	O	O	865
cyclophosphamide	VERB	O	Chemical	865
therapy	NOUN	O	O	865
.	PUNCT	O	O	865
Haemorrhagic myocarditis	ADV	O	Disease	866
is	AUX	O	O	866
a	PRON	O	O	866
rare	ADJ	O	O	866
but	CCONJ	O	O	866
important	ADJ	O	O	866
complication	NOUN	O	O	866
of	ADP	O	O	866
cyclophosphamide	VERB	O	Chemical	866
therapy	NOUN	O	O	866
.	PUNCT	O	O	866
Glyceryl trinitrate	NOUN	O	Chemical	869
induces	VERB	O	O	869
attacks	NOUN	O	O	869
of	ADP	O	O	869
migraine without aura	NOUN	O	Disease	869
in	ADP	O	O	869
sufferers	NOUN	O	O	869
of	ADP	O	O	869
migraine with aura	NOUN	O	Disease	869
.	PUNCT	O	O	869
Migraine with aura	NOUN	O	Disease	870
and	CCONJ	O	O	870
migraine without aura	NOUN	O	Disease	870
have	VERB	O	O	870
the	PRON	O	O	870
same	ADJ	O	O	870
pain	NOUN	O	Disease	870
phase	NOUN	O	O	870
,	PUNCT	O	O	870
thus	ADV	O	O	870
indicating	VERB	O	O	870
that	SCONJ	O	O	870
migraine with aura	NOUN	O	Disease	870
and	CCONJ	O	O	870
migraine without aura	NOUN	O	Disease	870
share	VERB	O	O	870
a	PRON	O	O	870
common	ADJ	O	O	870
pathway	NOUN	O	O	870
of	ADP	O	O	870
nociception	NOUN	O	O	870
.	PUNCT	O	O	870
In	ADP	O	O	871
recent	ADJ	O	O	871
years	NOUN	O	O	871
,	PUNCT	O	O	871
increasing	VERB	O	O	871
evidence	NOUN	O	O	871
has	VERB	O	O	871
suggested	VERB	O	O	871
that	SCONJ	O	O	871
the	PRON	O	O	871
messenger	NOUN	O	O	871
molecule	PROPN	O	O	871
nitric oxide	NOUN	O	Chemical	871
(	PUNCT	O	O	871
NO	PRON	O	Chemical	871
)	PUNCT	O	O	871
is	AUX	O	O	871
involved	VERB	O	O	871
in	ADP	O	O	871
pain	NOUN	O	Disease	871
mechanisms	NOUN	O	O	871
of	ADP	O	O	871
migraine without aura	NOUN	O	Disease	871
.	PUNCT	O	O	871
In	ADP	O	O	872
order	NOUN	O	O	872
to	PART	O	O	872
clarify	VERB	O	O	872
whether	SCONJ	O	O	872
the	PRON	O	O	872
same	ADJ	O	O	872
is	AUX	O	O	872
true	ADJ	O	O	872
for	ADP	O	O	872
migraine with aura	NOUN	O	Disease	872
,	PUNCT	O	O	872
in	ADP	O	O	872
the	PRON	O	O	872
present	NOUN	O	O	872
study	VERB	O	O	872
we	PRON	O	O	872
examined	VERB	O	O	872
the	PRON	O	O	872
headache	PROPN	O	Disease	872
response	NOUN	O	O	872
to	PART	O	O	872
intravenous	ADJ	O	O	872
infusion	NOUN	O	O	872
of	ADP	O	O	872
glyceryl trinitrate	PROPN	O	Chemical	872
(	PUNCT	O	O	872
GTN	NOUN	O	Chemical	872
)	PUNCT	O	O	872
(	PUNCT	O	O	873
0.5	NUM	O	O	873
microg	PROPN	O	O	873
/	PUNCT	O	O	873
kg	VERB	O	O	873
/	PUNCT	O	O	873
min	NOUN	O	O	873
for	ADP	O	O	873
20	NUM	O	O	873
min	NOUN	O	O	873
)	PUNCT	O	O	873
in	ADP	O	O	873
12	NUM	O	O	873
sufferers	NOUN	O	O	873
of	ADP	O	O	873
migraine with aura	NOUN	O	Disease	873
.	PUNCT	O	O	873
The	PRON	O	O	874
specific	ADJ	O	O	874
aim	VERB	O	O	874
was	AUX	O	O	874
to	PART	O	O	874
elucidate	VERB	O	O	874
whether	SCONJ	O	O	874
an	PRON	O	O	874
aura	NOUN	O	O	874
and/or	CCONJ	O	O	874
an	PRON	O	O	874
attack	VERB	O	O	874
of	ADP	O	O	874
migraine without aura	NOUN	O	Disease	874
could	AUX	O	O	874
be	AUX	O	O	874
induced	VERB	O	O	874
.	PUNCT	O	O	874
Headache	NOUN	O	Disease	875
was	AUX	O	O	875
more	ADJ	O	O	875
severe	ADJ	O	O	875
in	ADP	O	O	875
migraineurs	NOUN	O	Disease	875
than	ADP	O	O	875
in	ADP	O	O	875
the	PRON	O	O	875
controls	VERB	O	O	875
during	ADP	O	O	875
and	CCONJ	O	O	875
immediately	ADV	O	O	875
after	ADP	O	O	875
GTN	NOUN	O	Chemical	875
infusion	NOUN	O	O	875
(	PUNCT	O	O	875
p=0.037	NOUN	O	O	875
)	PUNCT	O	O	875
as	ADP	O	O	875
well	ADV	O	O	875
as	ADP	O	O	875
during	ADP	O	O	875
the	PRON	O	O	875
following	VERB	O	O	875
11	NUM	O	O	875
h	X	O	O	875
(	PUNCT	O	O	875
p	NOUN	O	O	875
=	PUNCT	O	O	875
0.008	NUM	O	O	875
)	PUNCT	O	O	875
.	PUNCT	O	O	875
In	ADP	O	O	876
the	PRON	O	O	876
controls	VERB	O	O	876
,	PUNCT	O	O	876
the	PRON	O	O	876
GTN	NOUN	O	Chemical	876
-	PUNCT	O	O	876
induced	VERB	O	O	876
headache	PROPN	O	Disease	876
gradually	ADV	O	O	876
disappeared	VERB	O	O	876
,	PUNCT	O	O	876
whereas	SCONJ	O	O	876
in	ADP	O	O	876
migraineurs	NOUN	O	Disease	876
peak	PROPN	O	O	876
headache	PROPN	O	Disease	876
intensity	NOUN	O	O	876
occurred	VERB	O	O	876
at	ADP	O	O	876
a	PRON	O	O	876
mean	VERB	O	O	876
time	NOUN	O	O	876
of	ADP	O	O	876
240	NUM	O	O	876
min	NOUN	O	O	876
post	VERB	O	O	876
-	PUNCT	O	O	876
infusion	NOUN	O	O	876
.	PUNCT	O	O	876
At	ADP	O	O	877
this	PRON	O	O	877
time	NOUN	O	O	877
the	PRON	O	O	877
induced	VERB	O	O	877
headache	PROPN	O	Disease	877
in	ADP	O	O	877
6	NUM	O	O	877
of	ADP	O	O	877
12	NUM	O	O	877
migraineurs	NOUN	O	Disease	877
fulfilled	VERB	O	O	877
the	PRON	O	O	877
diagnostic	ADJ	O	O	877
criteria	NOUN	O	O	877
for	ADP	O	O	877
migraine without aura	NOUN	O	Disease	877
of	ADP	O	O	877
the	PRON	O	O	877
International	PROPN	O	O	877
Headache	NOUN	O	Disease	877
Society	NOUN	O	O	877
.	PUNCT	O	O	877
The	PRON	O	O	878
results	VERB	O	O	878
therefore	ADV	O	O	878
suggest	VERB	O	O	878
that	SCONJ	O	O	878
NO	PRON	O	Chemical	878
is	AUX	O	O	878
involved	VERB	O	O	878
in	ADP	O	O	878
the	PRON	O	O	878
pain	NOUN	O	Disease	878
mechanisms	NOUN	O	O	878
of	ADP	O	O	878
migraine with aura	NOUN	O	Disease	878
.	PUNCT	O	O	878
Since	SCONJ	O	O	879
cortical	ADJ	O	O	879
spreading	VERB	O	O	879
depression	PROPN	O	Disease	879
has	VERB	O	O	879
been	AUX	O	O	879
shown	VERB	O	O	879
to	PART	O	O	879
liberate	VERB	O	O	879
NO	PRON	O	Chemical	879
in	ADP	O	O	879
animals	NOUN	O	O	879
,	PUNCT	O	O	879
this	PRON	O	O	879
finding	VERB	O	O	879
may	AUX	O	O	879
help	VERB	O	O	879
our	PRON	O	O	879
understanding	NOUN	O	O	879
of	ADP	O	O	879
the	PRON	O	O	879
coupling	NOUN	O	O	879
between	ADP	O	O	879
cortical	ADJ	O	O	879
spreading	VERB	O	O	879
depression	PROPN	O	Disease	879
and	CCONJ	O	O	879
headache	PROPN	O	Disease	879
in	ADP	O	O	879
migraine with aura	NOUN	O	Disease	879
.	PUNCT	O	O	879
Stroke	VERB	O	Disease	882
and	CCONJ	O	O	882
cocaine	NOUN	O	Chemical	882
or	CCONJ	O	O	882
amphetamine	NOUN	O	Chemical	882
use	VERB	O	O	882
.	PUNCT	O	O	882
The	PRON	O	O	883
association	PROPN	O	O	883
of	ADP	O	O	883
cocaine	NOUN	O	Chemical	883
and	CCONJ	O	O	883
amphetamine	NOUN	O	Chemical	883
use	VERB	O	O	883
with	ADP	O	O	883
hemorrhagic	ADJ	O	Disease	883
and	CCONJ	O	O	883
ischemic	VERB	O	Disease	883
stroke	VERB	O	Disease	883
is	AUX	O	O	883
based	VERB	O	O	883
almost	ADV	O	O	883
solely	ADV	O	O	883
on	ADP	O	O	883
data	NOUN	O	O	883
from	ADP	O	O	883
case	NOUN	O	O	883
series	PROPN	O	O	883
.	PUNCT	O	O	883
The	PRON	O	O	884
limited	VERB	O	O	884
number	NOUN	O	O	884
of	ADP	O	O	884
epidemiologic	ADJ	O	O	884
studies	NOUN	O	O	884
of	ADP	O	O	884
stroke	VERB	O	Disease	884
and	CCONJ	O	O	884
use	VERB	O	O	884
of	ADP	O	O	884
cocaine	NOUN	O	Chemical	884
and/or	CCONJ	O	O	884
amphetamine	NOUN	O	Chemical	884
have	VERB	O	O	884
been	AUX	O	O	884
done	VERB	O	O	884
in	ADP	O	O	884
settings	NOUN	O	O	884
that	SCONJ	O	O	884
serve	VERB	O	O	884
mostly	ADV	O	O	884
the	PRON	O	O	884
poor	ADJ	O	O	884
and/or	CCONJ	O	O	884
minorities	NOUN	O	O	884
.	PUNCT	O	O	884
We	PRON	O	O	885
attempted	VERB	O	O	885
to	PART	O	O	885
identify	VERB	O	O	885
all	PRON	O	O	885
incident	NOUN	O	O	885
strokes	NOUN	O	Disease	885
in	ADP	O	O	885
women	NOUN	O	O	885
ages	NOUN	O	O	885
15	NUM	O	O	885
-	PUNCT	O	O	885
44	NUM	O	O	885
years	NOUN	O	O	885
during	ADP	O	O	885
a	PRON	O	O	885
3-year	NOUN	O	O	885
period	NOUN	O	O	885
using	VERB	O	O	885
hospital	PROPN	O	O	885
admission	NOUN	O	O	885
and	CCONJ	O	O	885
discharge	VERB	O	O	885
records	NOUN	O	O	885
,	PUNCT	O	O	885
emergency	NOUN	O	O	885
department	NOUN	O	O	885
logs	VERB	O	O	885
,	PUNCT	O	O	885
and	CCONJ	O	O	885
payment	NOUN	O	O	885
requests	VERB	O	O	885
for	ADP	O	O	885
out	ADP	O	O	885
-	PUNCT	O	O	885
of	ADP	O	O	885
-	PUNCT	O	O	885
plan	NOUN	O	O	885
hospitalizations	NOUN	O	O	885
.	PUNCT	O	O	885
There	ADV	O	O	886
were	AUX	O	O	886
347	NUM	O	O	886
confirmed	VERB	O	O	886
stroke	VERB	O	Disease	886
cases	NOUN	O	O	886
and	CCONJ	O	O	886
1,021	NUM	O	O	886
controls	VERB	O	O	886
.	PUNCT	O	O	886
The	PRON	O	O	887
univariate	ADJ	O	O	887
matched	VERB	O	O	887
odds	NOUN	O	O	887
ratio	NOUN	O	O	887
for	ADP	O	O	887
stroke	VERB	O	Disease	887
in	ADP	O	O	887
women	NOUN	O	O	887
who	PRON	O	O	887
admitted	VERB	O	O	887
to	PART	O	O	887
using	VERB	O	O	887
cocaine	NOUN	O	Chemical	887
and/or	CCONJ	O	O	887
amphetamine	NOUN	O	Chemical	887
was	AUX	O	O	887
8.5	NUM	O	O	887
(	PUNCT	O	O	887
95%	NOUN	O	O	887
confidence	NOUN	O	O	887
interval	NOUN	O	O	887
=	PUNCT	O	O	887
3.6	NUM	O	O	887
-	PUNCT	O	O	887
20.0	NUM	O	O	887
)	PUNCT	O	O	887
.	PUNCT	O	O	887
After	ADP	O	O	888
further	ADV	O	O	888
adjustment	NOUN	O	O	888
for	ADP	O	O	888
potential	ADJ	O	O	888
confounders	NOUN	O	O	888
,	PUNCT	O	O	888
the	PRON	O	O	888
odds	NOUN	O	O	888
ratio	NOUN	O	O	888
in	ADP	O	O	888
women	NOUN	O	O	888
who	PRON	O	O	888
reported	VERB	O	O	888
using	VERB	O	O	888
cocaine	NOUN	O	Chemical	888
and/or	CCONJ	O	O	888
amphetamine	NOUN	O	Chemical	888
was	AUX	O	O	888
7.0	X	O	O	888
(	PUNCT	O	O	888
95%	NOUN	O	O	888
confidence	NOUN	O	O	888
interval	NOUN	O	O	888
=	PUNCT	O	O	888
2.8	NUM	O	O	888
-	PUNCT	O	O	888
17.9	NUM	O	O	888
)	PUNCT	O	O	888
.	PUNCT	O	O	888
The	PRON	O	O	889
use	VERB	O	O	889
of	ADP	O	O	889
cocaine	NOUN	O	Chemical	889
and/or	CCONJ	O	O	889
amphetamine	NOUN	O	Chemical	889
is	AUX	O	O	889
a	PRON	O	O	889
strong	ADJ	O	O	889
risk	NOUN	O	O	889
factor	NOUN	O	O	889
for	ADP	O	O	889
stroke	VERB	O	Disease	889
in	ADP	O	O	889
this	PRON	O	O	889
socioeconomically	ADV	O	O	889
heterogeneous	ADJ	O	O	889
,	PUNCT	O	O	889
insured	VERB	O	O	889
urban	ADJ	O	O	889
population	NOUN	O	O	889
.	PUNCT	O	O	889
Prevention	NOUN	O	O	892
of	ADP	O	O	892
breast cancer	NOUN	O	Disease	892
with	ADP	O	O	892
tamoxifen	PROPN	O	Chemical	892
:	PUNCT	O	O	892
preliminary	ADJ	O	O	892
findings	NOUN	O	O	892
from	ADP	O	O	892
the	PRON	O	O	892
Italian	ADJ	O	O	892
randomised	VERB	O	O	892
trial	NOUN	O	O	892
among	ADP	O	O	892
hysterectomised	VERB	O	O	892
women	NOUN	O	O	892
.	PUNCT	O	O	892
Italian	ADJ	O	O	893
Tamoxifen	NOUN	O	Chemical	893
Prevention	NOUN	O	O	893
Study	NOUN	O	O	893
.	PUNCT	O	O	893
Tamoxifen	NOUN	O	Chemical	894
is	AUX	O	O	894
a	PRON	O	O	894
candidate	NOUN	O	O	894
chemopreventive	PROPN	O	O	894
agent	NOUN	O	O	894
in	ADP	O	O	894
breast cancer	NOUN	O	Disease	894
,	PUNCT	O	O	894
although	SCONJ	O	O	894
the	PRON	O	O	894
drug	NOUN	O	O	894
may	AUX	O	O	894
be	AUX	O	O	894
associated	VERB	O	O	894
with	ADP	O	O	894
the	PRON	O	O	894
development	NOUN	O	O	894
of	ADP	O	O	894
endometrial cancer	NOUN	O	Disease	894
.	PUNCT	O	O	894
Therefore	ADV	O	O	895
we	PRON	O	O	895
did	VERB	O	O	895
a	PRON	O	O	895
trial	NOUN	O	O	895
in	ADP	O	O	895
hysterectomised	VERB	O	O	895
women	NOUN	O	O	895
of	ADP	O	O	895
tamoxifen	PROPN	O	Chemical	895
as	ADP	O	O	895
a	PRON	O	O	895
chemopreventive	PROPN	O	O	895
.	PUNCT	O	O	895
In	ADP	O	O	896
October	PROPN	O	O	896
,	PUNCT	O	O	896
1992	NUM	O	O	896
,	PUNCT	O	O	896
we	PRON	O	O	896
started	VERB	O	O	896
a	PRON	O	O	896
double	ADJ	O	O	896
-	PUNCT	O	O	896
blind	ADJ	O	Disease	896
placebo	NOUN	O	O	896
-	PUNCT	O	O	896
controlled	VERB	O	O	896
,	PUNCT	O	O	896
randomised	VERB	O	O	896
trial	NOUN	O	O	896
of	ADP	O	O	896
tamoxifen	PROPN	O	Chemical	896
in	ADP	O	O	896
women	NOUN	O	O	896
(	PUNCT	O	O	896
mainly	ADV	O	O	896
in	ADP	O	O	896
Italy	PROPN	O	O	896
)	PUNCT	O	O	896
who	PRON	O	O	896
did	VERB	O	O	896
not	PART	O	O	896
have	VERB	O	O	896
breast cancer	NOUN	O	Disease	896
and	CCONJ	O	O	896
who	PRON	O	O	896
had	VERB	O	O	896
had	VERB	O	O	896
a	PRON	O	O	896
hysterectomy	NOUN	O	O	896
.	PUNCT	O	O	896
Women	NOUN	O	O	897
were	AUX	O	O	897
randomised	VERB	O	O	897
to	PART	O	O	897
receive	VERB	O	O	897
tamoxifen	PROPN	O	Chemical	897
20	NUM	O	O	897
mg	VERB	O	O	897
per	ADP	O	O	897
day	NOUN	O	O	897
or	CCONJ	O	O	897
placebo	NOUN	O	O	897
,	PUNCT	O	O	897
both	PRON	O	O	897
orally	ADV	O	O	897
for	ADP	O	O	897
5	NUM	O	O	897
years	NOUN	O	O	897
.	PUNCT	O	O	897
The	PRON	O	O	898
primary	NOUN	O	O	898
endpoints	NOUN	O	O	898
are	AUX	O	O	898
the	PRON	O	O	898
occurrence	NOUN	O	O	898
of	ADP	O	O	898
and	CCONJ	O	O	898
deaths	NOUN	O	O	898
from	ADP	O	O	898
breast cancer	NOUN	O	Disease	898
.	PUNCT	O	O	898
41	NUM	O	O	899
cases	NOUN	O	O	899
of	ADP	O	O	899
breast cancer	NOUN	O	Disease	899
occurred	VERB	O	O	899
so	ADV	O	O	899
far	ADV	O	O	899
;	PUNCT	O	O	899
there	ADV	O	O	899
have	VERB	O	O	899
been	AUX	O	O	899
no	PRON	O	O	899
deaths	NOUN	O	O	899
from	ADP	O	O	899
breast cancer	NOUN	O	Disease	899
.	PUNCT	O	O	899
There	ADV	O	O	900
is	AUX	O	O	900
no	PRON	O	O	900
difference	NOUN	O	O	900
in	ADP	O	O	900
breast	NOUN	O	O	900
-	PUNCT	O	O	900
cancer	NOUN	O	Disease	900
frequency	NOUN	O	O	900
between	ADP	O	O	900
the	PRON	O	O	900
placebo	NOUN	O	O	900
(	PUNCT	O	O	900
22	NUM	O	O	900
cases	NOUN	O	O	900
)	PUNCT	O	O	900
and	CCONJ	O	O	900
tamoxifen	PROPN	O	Chemical	900
(	PUNCT	O	O	900
19	NUM	O	O	900
)	PUNCT	O	O	900
arms	NOUN	O	O	900
.	PUNCT	O	O	900
There	ADV	O	O	901
is	AUX	O	O	901
a	PRON	O	O	901
statistically	ADV	O	O	901
significant	ADJ	O	O	901
reduction	NOUN	O	O	901
of	ADP	O	O	901
breast cancer	NOUN	O	Disease	901
among	ADP	O	O	901
women	NOUN	O	O	901
receiving	VERB	O	O	901
tamoxifen	PROPN	O	Chemical	901
who	PRON	O	O	901
also	ADV	O	O	901
used	VERB	O	O	901
hormone	NOUN	O	O	901
-	PUNCT	O	O	901
replacement	NOUN	O	O	901
therapy	NOUN	O	O	901
during	ADP	O	O	901
the	PRON	O	O	901
trial	NOUN	O	O	901
:	PUNCT	O	O	901
among	ADP	O	O	901
390	NUM	O	O	901
women	NOUN	O	O	901
on	ADP	O	O	901
such	ADJ	O	O	901
therapy	NOUN	O	O	901
and	CCONJ	O	O	901
allocated	VERB	O	O	901
to	PART	O	O	901
placebo	NOUN	O	O	901
,	PUNCT	O	O	901
we	PRON	O	O	901
found	VERB	O	O	901
eight	NUM	O	O	901
cases	NOUN	O	O	901
of	ADP	O	O	901
breast cancer	NOUN	O	Disease	901
compared	VERB	O	O	901
with	ADP	O	O	901
one	NUM	O	O	901
case	NOUN	O	O	901
among	ADP	O	O	901
362	NUM	O	O	901
women	NOUN	O	O	901
allocated	VERB	O	O	901
to	PART	O	O	901
tamoxifen	PROPN	O	Chemical	901
.	PUNCT	O	O	901
Compared	VERB	O	O	902
with	ADP	O	O	902
the	PRON	O	O	902
placebo	NOUN	O	O	902
group	NOUN	O	O	902
,	PUNCT	O	O	902
there	ADV	O	O	902
was	AUX	O	O	902
a	PRON	O	O	902
significantly	ADV	O	O	902
increased	VERB	O	O	902
risk	NOUN	O	O	902
of	ADP	O	O	902
vascular events	NOUN	O	Disease	902
and	CCONJ	O	O	902
hypertriglyceridaemia	NOUN	O	Disease	902
among	ADP	O	O	902
women	NOUN	O	O	902
on	ADP	O	O	902
tamoxifen	PROPN	O	Chemical	902
.	PUNCT	O	O	902
Although	SCONJ	O	O	903
this	PRON	O	O	903
preliminary	ADJ	O	O	903
analysis	NOUN	O	O	903
has	VERB	O	O	903
low	ADJ	O	O	903
power	NOUN	O	O	903
,	PUNCT	O	O	903
in	ADP	O	O	903
this	PRON	O	O	903
cohort	NOUN	O	O	903
of	ADP	O	O	903
women	NOUN	O	O	903
at	ADP	O	O	903
low	ADJ	O	O	903
-	PUNCT	O	O	903
to	PART	O	O	903
-	PUNCT	O	O	903
normal	ADJ	O	O	903
risk	NOUN	O	O	903
of	ADP	O	O	903
breast cancer	NOUN	O	Disease	903
,	PUNCT	O	O	903
the	PRON	O	O	903
postulated	VERB	O	O	903
protective	ADJ	O	O	903
effects	NOUN	O	O	903
of	ADP	O	O	903
tamoxifen	PROPN	O	Chemical	903
are	AUX	O	O	903
not	PART	O	O	903
yet	ADV	O	O	903
apparent	ADJ	O	O	903
.	PUNCT	O	O	903
Women	NOUN	O	O	904
using	VERB	O	O	904
hormone	NOUN	O	O	904
-	PUNCT	O	O	904
replacement	NOUN	O	O	904
therapy	NOUN	O	O	904
appear	VERB	O	O	904
to	PART	O	O	904
have	VERB	O	O	904
benefited	VERB	O	O	904
from	ADP	O	O	904
use	VERB	O	O	904
of	ADP	O	O	904
tamoxifen	PROPN	O	Chemical	904
.	PUNCT	O	O	904
There	ADV	O	O	905
were	AUX	O	O	905
no	PRON	O	O	905
deaths	NOUN	O	O	905
from	ADP	O	O	905
breast cancer	NOUN	O	Disease	905
recorded	VERB	O	O	905
in	ADP	O	O	905
women	NOUN	O	O	905
in	ADP	O	O	905
the	PRON	O	O	905
study	VERB	O	O	905
.	PUNCT	O	O	905
It	PRON	O	O	906
is	AUX	O	O	906
essential	ADJ	O	O	906
to	PART	O	O	906
continue	VERB	O	O	906
follow	VERB	O	O	906
-	PUNCT	O	O	906
up	ADP	O	O	906
to	PART	O	O	906
quantify	VERB	O	O	906
the	PRON	O	O	906
long	ADV	O	O	906
-	PUNCT	O	O	906
term	NOUN	O	O	906
risks	NOUN	O	O	906
and	CCONJ	O	O	906
benefits	NOUN	O	O	906
of	ADP	O	O	906
tamoxifen	PROPN	O	Chemical	906
therapy	NOUN	O	O	906
.	PUNCT	O	O	906
A	PRON	O	O	909
measure	VERB	O	O	909
of	ADP	O	O	909
pupillary oscillation	NOUN	O	Disease	909
as	ADP	O	O	909
a	PRON	O	O	909
marker	NOUN	O	O	909
of	ADP	O	O	909
cocaine	NOUN	O	Chemical	909
-	PUNCT	O	O	909
induced	VERB	O	O	909
paranoia	NOUN	O	Disease	909
.	PUNCT	O	O	909
Cocaine	NOUN	O	Chemical	910
-	PUNCT	O	O	910
induced	VERB	O	O	910
paranoia	NOUN	O	Disease	910
(	PUNCT	O	O	910
CIP	PROPN	O	Disease	910
)	PUNCT	O	O	910
remains	VERB	O	O	910
an	PRON	O	O	910
important	ADJ	O	O	910
drug	NOUN	O	O	910
-	PUNCT	O	O	910
induced	VERB	O	O	910
model	NOUN	O	O	910
of	ADP	O	O	910
idiopathic	ADJ	O	O	910
paranoia	NOUN	O	Disease	910
for	ADP	O	O	910
which	PRON	O	O	910
no	PRON	O	O	910
psychophysiologic	PROPN	O	O	910
marker	NOUN	O	O	910
has	VERB	O	O	910
yet	ADV	O	O	910
emerged	VERB	O	O	910
.	PUNCT	O	O	910
Measures	NOUN	O	O	911
of	ADP	O	O	911
pupillary oscillation	NOUN	O	Disease	911
were	AUX	O	O	911
able	ADJ	O	O	911
to	PART	O	O	911
significantly	ADV	O	O	911
distinguish	VERB	O	O	911
a	PRON	O	O	911
group	NOUN	O	O	911
of	ADP	O	O	911
abstinent	ADJ	O	O	911
crack cocaine abusers	NOUN	O	O	911
endorsing	VERB	O	O	911
past	ADP	O	O	911
CIP	PROPN	O	Disease	911
(	PUNCT	O	O	911
n	CCONJ	O	O	911
=	PUNCT	O	O	911
32	NUM	O	O	911
)	PUNCT	O	O	911
from	ADP	O	O	911
another	PRON	O	O	911
group	NOUN	O	O	911
of	ADP	O	O	911
crack	VERB	O	Chemical	911
addicts	NOUN	O	O	911
who	PRON	O	O	911
denied	VERB	O	O	911
past	ADP	O	O	911
CIP	PROPN	O	Disease	911
(	PUNCT	O	O	911
n	CCONJ	O	O	911
=	PUNCT	O	O	911
29	NUM	O	O	911
)	PUNCT	O	O	911
.	PUNCT	O	O	911
Seizures	NOUN	O	Disease	914
induced	VERB	O	O	914
by	ADP	O	O	914
combined	VERB	O	O	914
levomepromazine	NOUN	O	Chemical	914
-	PUNCT	O	O	914
fluvoxamine	NOUN	O	Chemical	914
treatment	NOUN	O	O	914
.	PUNCT	O	O	914
We	PRON	O	O	915
report	VERB	O	O	915
a	PRON	O	O	915
case	NOUN	O	O	915
of	ADP	O	O	915
combined	VERB	O	O	915
levomepromazine	NOUN	O	Chemical	915
-	PUNCT	O	O	915
fluvoxamine	NOUN	O	Chemical	915
treatment	NOUN	O	O	915
-	PUNCT	O	O	915
induced	VERB	O	O	915
seizures	NOUN	O	Disease	915
.	PUNCT	O	O	915
It	PRON	O	O	916
seems	VERB	O	O	916
that	SCONJ	O	O	916
combined	VERB	O	O	916
treatment	NOUN	O	O	916
of	ADP	O	O	916
fluvoxamine	NOUN	O	Chemical	916
with	ADP	O	O	916
phenothiazines	NOUN	O	Chemical	916
may	AUX	O	O	916
possess	VERB	O	O	916
proconvulsive	PROPN	O	O	916
activity	NOUN	O	O	916
.	PUNCT	O	O	916
Why	SCONJ	O	O	919
may	AUX	O	O	919
epsilon	PROPN	O	O	919
-	PUNCT	O	O	919
aminocaproic	VERB	O	O	919
acid	PROPN	O	O	919
(	PUNCT	O	O	919
EACA	VERB	O	Chemical	919
)	PUNCT	O	O	919
induce	VERB	O	O	919
myopathy	PROPN	O	Disease	919
in	ADP	O	O	919
man	NOUN	O	O	919
?	PUNCT	O	O	919
A	PRON	O	O	920
case	NOUN	O	O	920
of	ADP	O	O	920
necrotizing myopathy	NOUN	O	Disease	920
due	ADJ	O	O	920
to	PART	O	O	920
a	PRON	O	O	920
short	ADJ	O	O	920
epsilon	PROPN	O	O	920
-	PUNCT	O	O	920
aminocaproic	VERB	O	O	920
acid	PROPN	O	O	920
(	PUNCT	O	O	920
EACA	VERB	O	Chemical	920
)	PUNCT	O	O	920
treatment	NOUN	O	O	920
in	ADP	O	O	920
a	PRON	O	O	920
72	NUM	O	O	920
year	NOUN	O	O	920
-	PUNCT	O	O	920
old	ADJ	O	O	920
patient	NOUN	O	O	920
with	ADP	O	O	920
subarachnoid haemorrhage	NOUN	O	Disease	920
(	PUNCT	O	O	920
SAH	PROPN	O	Disease	920
)	PUNCT	O	O	920
is	AUX	O	O	920
described	VERB	O	O	920
.	PUNCT	O	O	920
Comparison	NOUN	O	O	923
of	ADP	O	O	923
the	PRON	O	O	923
effectiveness	NOUN	O	O	923
of	ADP	O	O	923
ranitidine	PROPN	O	Chemical	923
and	CCONJ	O	O	923
cimetidine	NOUN	O	Chemical	923
in	ADP	O	O	923
inhibiting	VERB	O	O	923
acid	PROPN	O	O	923
secretion	NOUN	O	O	923
in	ADP	O	O	923
patients	NOUN	O	O	923
with	ADP	O	O	923
gastric	ADJ	O	O	923
hypersecretory	NOUN	O	O	923
states	VERB	O	O	923
.	PUNCT	O	O	923
The	PRON	O	O	924
H2-histamine	NOUN	O	O	924
receptor	NOUN	O	O	924
antagonists	NOUN	O	O	924
ranitidine	PROPN	O	Chemical	924
and	CCONJ	O	O	924
cimetidine	NOUN	O	Chemical	924
were	AUX	O	O	924
compared	VERB	O	O	924
for	ADP	O	O	924
their	PRON	O	O	924
abilities	NOUN	O	O	924
to	PART	O	O	924
control	VERB	O	O	924
gastric	ADJ	O	O	924
acid	PROPN	O	O	924
hypersecretion	PROPN	O	O	924
on	ADP	O	O	924
a	PRON	O	O	924
short-	ADV	O	O	924
and	CCONJ	O	O	924
long	ADV	O	O	924
-	PUNCT	O	O	924
term	NOUN	O	O	924
basis	NOUN	O	O	924
in	ADP	O	O	924
22	NUM	O	O	924
patients	NOUN	O	O	924
with	ADP	O	O	924
gastric	ADJ	O	O	924
acid	PROPN	O	O	924
hypersecretory	NOUN	O	O	924
states	VERB	O	O	924
.	PUNCT	O	O	924
Nineteen	NUM	O	O	925
patients	NOUN	O	O	925
had	VERB	O	O	925
Zollinger	NOUN	O	O	925
-	PUNCT	O	O	925
Ellison	NOUN	O	O	925
syndrome	NOUN	O	O	925
,	PUNCT	O	O	925
one	NUM	O	O	925
patient	NOUN	O	O	925
had	VERB	O	O	925
systemic mastocytosis	NOUN	O	Disease	925
,	PUNCT	O	O	925
and	CCONJ	O	O	925
two	NUM	O	O	925
patients	NOUN	O	O	925
had	VERB	O	O	925
idiopathic	ADJ	O	O	925
hypersecretion	PROPN	O	O	925
.	PUNCT	O	O	925
The	PRON	O	O	926
rates	NOUN	O	O	926
of	ADP	O	O	926
onset	VERB	O	O	926
of	ADP	O	O	926
the	PRON	O	O	926
action	NOUN	O	O	926
of	ADP	O	O	926
cimetidine	NOUN	O	Chemical	926
and	CCONJ	O	O	926
ranitidine	PROPN	O	Chemical	926
were	AUX	O	O	926
the	PRON	O	O	926
same	ADJ	O	O	926
.	PUNCT	O	O	926
However	ADV	O	O	927
,	PUNCT	O	O	927
ranitidine	PROPN	O	Chemical	927
was	AUX	O	O	927
threefold	VERB	O	O	927
more	ADJ	O	O	927
potent	ADJ	O	O	927
than	ADP	O	O	927
cimetidine	NOUN	O	Chemical	927
both	PRON	O	O	927
in	ADP	O	O	927
acute	ADJ	O	O	927
inhibition	NOUN	O	O	927
studies	NOUN	O	O	927
and	CCONJ	O	O	927
in	ADP	O	O	927
the	PRON	O	O	927
median	ADJ	O	O	927
maintenance	NOUN	O	O	927
dose	NOUN	O	O	927
needed	VERB	O	O	927
(	PUNCT	O	O	927
1.2	NUM	O	O	927
g	X	O	O	927
per	ADP	O	O	927
day	NOUN	O	O	927
for	ADP	O	O	927
ranitidine	PROPN	O	Chemical	927
and	CCONJ	O	O	927
3.6	NUM	O	O	927
g	X	O	O	927
per	ADP	O	O	927
day	NOUN	O	O	927
for	ADP	O	O	927
cimetidine	NOUN	O	Chemical	927
)	PUNCT	O	O	927
.	PUNCT	O	O	927
Sixty	NUM	O	O	928
percent	NOUN	O	O	928
of	ADP	O	O	928
the	PRON	O	O	928
males	NOUN	O	O	928
developed	VERB	O	O	928
breast	NOUN	O	O	928
changes	VERB	O	O	928
or	CCONJ	O	O	928
impotence	NOUN	O	Disease	928
while	SCONJ	O	O	928
taking	VERB	O	O	928
cimetidine	NOUN	O	Chemical	928
and	CCONJ	O	O	928
in	ADP	O	O	928
all	PRON	O	O	928
cases	NOUN	O	O	928
these	PRON	O	O	928
changes	VERB	O	O	928
disappeared	VERB	O	O	928
when	SCONJ	O	O	928
cimetidine	NOUN	O	Chemical	928
was	AUX	O	O	928
replaced	VERB	O	O	928
by	ADP	O	O	928
ranitidine	PROPN	O	Chemical	928
.	PUNCT	O	O	928
Treatment	NOUN	O	O	929
with	ADP	O	O	929
high	ADJ	O	O	929
doses	NOUN	O	O	929
of	ADP	O	O	929
cimetidine	NOUN	O	Chemical	929
(	PUNCT	O	O	929
one	NUM	O	O	929
to	PART	O	O	929
60	NUM	O	O	929
months	NOUN	O	O	929
;	PUNCT	O	O	929
median	ADJ	O	O	929
,	PUNCT	O	O	929
11	NUM	O	O	929
months	NOUN	O	O	929
)	PUNCT	O	O	929
or	CCONJ	O	O	929
ranitidine	PROPN	O	Chemical	929
(	PUNCT	O	O	929
two	NUM	O	O	929
to	PART	O	O	929
31	NUM	O	O	929
months	NOUN	O	O	929
;	PUNCT	O	O	929
median	ADJ	O	O	929
,	PUNCT	O	O	929
14	NUM	O	O	929
months	NOUN	O	O	929
)	PUNCT	O	O	929
was	AUX	O	O	929
not	PART	O	O	929
associated	VERB	O	O	929
with	ADP	O	O	929
hepatic or hematologic toxicity	NOUN	O	Disease	929
or	CCONJ	O	O	929
alterations	NOUN	O	O	929
of	ADP	O	O	929
serum	NOUN	O	O	929
gastrin	NOUN	O	O	929
concentrations	NOUN	O	O	929
,	PUNCT	O	O	929
but	CCONJ	O	O	929
ranitidine	PROPN	O	Chemical	929
therapy	NOUN	O	O	929
was	AUX	O	O	929
associated	VERB	O	O	929
with	ADP	O	O	929
a	PRON	O	O	929
significantly	ADV	O	O	929
lower	ADJ	O	O	929
serum	NOUN	O	O	929
creatinine	PROPN	O	Chemical	929
level	VERB	O	O	929
than	ADP	O	O	929
seen	VERB	O	O	929
with	ADP	O	O	929
cimetidine	NOUN	O	Chemical	929
therapy	NOUN	O	O	929
.	PUNCT	O	O	929
Both	PRON	O	O	930
are	AUX	O	O	930
safe	ADJ	O	O	930
at	ADP	O	O	930
high	ADJ	O	O	930
doses	NOUN	O	O	930
,	PUNCT	O	O	930
but	CCONJ	O	O	930
ranitidine	PROPN	O	Chemical	930
is	AUX	O	O	930
threefold	VERB	O	O	930
more	ADJ	O	O	930
potent	ADJ	O	O	930
and	CCONJ	O	O	930
does	VERB	O	O	930
not	PART	O	O	930
cause	VERB	O	O	930
the	PRON	O	O	930
antiandrogen	PROPN	O	O	930
side	NOUN	O	O	930
effects	NOUN	O	O	930
frequently	ADV	O	O	930
seen	VERB	O	O	930
with	ADP	O	O	930
high	ADJ	O	O	930
doses	NOUN	O	O	930
of	ADP	O	O	930
cimetidine	NOUN	O	Chemical	930
.	PUNCT	O	O	930
A	PRON	O	O	933
catch	VERB	O	O	933
in	ADP	O	O	933
the	PRON	O	O	933
Reye	NOUN	O	Disease	933
.	PUNCT	O	O	933
Twenty	NUM	O	O	934
-	PUNCT	O	O	934
six	NUM	O	O	934
cases	NOUN	O	O	934
of	ADP	O	O	934
Reye syndrome	NOUN	O	Disease	934
from	ADP	O	O	934
The	PRON	O	O	934
Children	NOUN	O	O	934
's	AUX	O	O	934
Hospital	NOUN	O	O	934
,	PUNCT	O	O	934
Camperdown	PROPN	O	O	934
,	PUNCT	O	O	934
Australia	PROPN	O	O	934
,	PUNCT	O	O	934
occurring	VERB	O	O	934
between	ADP	O	O	934
1973	NUM	O	O	934
and	CCONJ	O	O	934
1982	NUM	O	O	934
were	AUX	O	O	934
reviewed	VERB	O	O	934
.	PUNCT	O	O	934
Of	ADV	O	O	935
these	PRON	O	O	935
,	PUNCT	O	O	935
20	NUM	O	O	935
cases	NOUN	O	O	935
met	VERB	O	O	935
the	PRON	O	O	935
US	PROPN	O	O	935
Public	ADJ	O	O	935
Health	NOUN	O	O	935
Service	NOUN	O	O	935
Centers	NOUN	O	O	935
for	ADP	O	O	935
Disease	NOUN	O	O	935
Control	NOUN	O	O	935
criteria	NOUN	O	O	935
for	ADP	O	O	935
the	PRON	O	O	935
diagnosis	NOUN	O	O	935
of	ADP	O	O	935
Reye syndrome	NOUN	O	Disease	935
.	PUNCT	O	O	935
Aspirin	NOUN	O	Chemical	936
or	CCONJ	O	O	936
salicylate	NOUN	O	Chemical	936
ingestion	NOUN	O	O	937
had	VERB	O	O	937
occurred	VERB	O	O	937
in	ADP	O	O	937
only	ADV	O	O	937
one	NUM	O	O	937
of	ADP	O	O	937
the	PRON	O	O	937
20	NUM	O	O	937
cases	NOUN	O	O	937
(	PUNCT	O	O	937
5%	NOUN	O	O	937
)	PUNCT	O	O	937
,	PUNCT	O	O	937
and	CCONJ	O	O	937
paracetamol	PROPN	O	Chemical	937
(	PUNCT	O	O	937
acetaminophen	PROPN	O	Chemical	937
)	PUNCT	O	O	937
had	VERB	O	O	937
been	AUX	O	O	937
administered	VERB	O	O	937
in	ADP	O	O	937
only	ADV	O	O	937
six	NUM	O	O	937
of	ADP	O	O	937
the	PRON	O	O	937
cases	NOUN	O	O	937
(	PUNCT	O	O	937
30%	NOUN	O	O	937
)	PUNCT	O	O	937
.	PUNCT	O	O	937
Pathologic	ADJ	O	O	938
confirmation	NOUN	O	O	938
of	ADP	O	O	938
the	PRON	O	O	938
diagnosis	NOUN	O	O	938
of	ADP	O	O	938
Reye syndrome	NOUN	O	Disease	938
was	AUX	O	O	938
accomplished	VERB	O	O	938
in	ADP	O	O	938
90%	NOUN	O	O	938
of	ADP	O	O	938
the	PRON	O	O	938
cases	NOUN	O	O	938
.	PUNCT	O	O	938
The	PRON	O	O	939
incidence	NOUN	O	O	939
of	ADP	O	O	939
Reye syndrome	NOUN	O	Disease	939
in	ADP	O	O	939
New	ADJ	O	O	939
South	NOUN	O	O	939
Wales	PROPN	O	O	939
,	PUNCT	O	O	939
Australia	PROPN	O	O	939
,	PUNCT	O	O	939
is	AUX	O	O	939
estimated	VERB	O	O	939
from	ADP	O	O	939
this	PRON	O	O	939
study	VERB	O	O	939
to	PART	O	O	939
be	AUX	O	O	939
approximately	ADV	O	O	939
nine	NUM	O	O	939
cases	NOUN	O	O	939
per	ADP	O	O	939
1	X	O	O	939
million	NUM	O	O	939
children	NOUN	O	O	939
compared	VERB	O	O	939
with	ADP	O	O	939
recent	ADJ	O	O	939
US	PROPN	O	O	939
data	NOUN	O	O	939
of	ADP	O	O	939
ten	NUM	O	O	939
to	PART	O	O	939
20	NUM	O	O	939
cases	NOUN	O	O	939
per	ADP	O	O	939
1	X	O	O	939
million	NUM	O	O	939
children	NOUN	O	O	939
and	CCONJ	O	O	939
three	NUM	O	O	939
to	PART	O	O	939
seven	NUM	O	O	939
cases	NOUN	O	O	939
per	ADP	O	O	939
1	X	O	O	939
million	NUM	O	O	939
children	NOUN	O	O	939
in	ADP	O	O	939
Great	ADJ	O	O	939
Britain	PROPN	O	O	939
.	PUNCT	O	O	939
The	PRON	O	O	940
mortality	NOUN	O	O	940
for	ADP	O	O	940
these	PRON	O	O	940
Reye syndrome	NOUN	O	Disease	940
cases	NOUN	O	O	940
in	ADP	O	O	940
Australia	PROPN	O	O	940
was	AUX	O	O	940
45%	NOUN	O	O	940
as	ADP	O	O	940
compared	VERB	O	O	940
with	ADP	O	O	940
a	PRON	O	O	940
32%	NOUN	O	O	940
case	NOUN	O	O	940
-	PUNCT	O	O	940
fatality	NOUN	O	O	940
rate	NOUN	O	O	940
in	ADP	O	O	940
the	PRON	O	O	940
United	PROPN	O	O	940
States	NOUN	O	O	940
.	PUNCT	O	O	940
In	ADP	O	O	941
Australia	PROPN	O	O	941
,	PUNCT	O	O	941
the	PRON	O	O	941
pediatric	ADJ	O	O	941
usage	NOUN	O	O	941
of	ADP	O	O	941
aspirin	NOUN	O	Chemical	941
has	VERB	O	O	941
been	AUX	O	O	941
extremely	ADV	O	O	941
low	ADJ	O	O	941
for	ADP	O	O	941
the	PRON	O	O	941
past	ADP	O	O	941
25	NUM	O	O	941
years	NOUN	O	O	941
(	PUNCT	O	O	941
less	ADV	O	O	941
than	ADP	O	O	941
1%	NOUN	O	O	941
of	ADP	O	O	941
total	ADJ	O	O	941
dosage	NOUN	O	O	941
units	NOUN	O	O	941
sold	VERB	O	O	941
)	PUNCT	O	O	941
,	PUNCT	O	O	941
with	ADP	O	O	941
paracetamol	PROPN	O	Chemical	941
(	PUNCT	O	O	941
acetaminophen	PROPN	O	Chemical	941
)	PUNCT	O	O	941
dominating	VERB	O	O	941
the	PRON	O	O	941
pediatric	ADJ	O	O	941
analgesic	PROPN	O	O	941
and	CCONJ	O	O	941
antipyretic	ADJ	O	O	941
market	NOUN	O	O	941
.	PUNCT	O	O	941
Reye syndrome	NOUN	O	Disease	942
may	AUX	O	O	942
be	AUX	O	O	942
disappearing	VERB	O	O	942
from	ADP	O	O	942
Australia	PROPN	O	O	942
despite	SCONJ	O	O	942
a	PRON	O	O	942
total	ADJ	O	O	942
lack	VERB	O	O	942
of	ADP	O	O	942
association	PROPN	O	O	942
with	ADP	O	O	942
salicylates	NOUN	O	Chemical	942
or	CCONJ	O	O	942
aspirin	NOUN	O	Chemical	942
ingestion	NOUN	O	O	942
,	PUNCT	O	O	942
since	SCONJ	O	O	942
there	ADV	O	O	942
were	AUX	O	O	942
no	PRON	O	O	942
cases	NOUN	O	O	942
found	VERB	O	O	942
at	ADP	O	O	942
The	PRON	O	O	942
Children	NOUN	O	O	942
's	AUX	O	O	942
Hospital	NOUN	O	O	942
in	ADP	O	O	942
1983	NUM	O	O	942
,	PUNCT	O	O	942
1984	NUM	O	O	942
,	PUNCT	O	O	942
or	CCONJ	O	O	942
1985	NUM	O	O	942
.	PUNCT	O	O	942
St.	PROPN	O	O	945
Anthony	PROPN	O	O	945
's	AUX	O	O	945
fire	NOUN	O	O	945
,	PUNCT	O	O	945
then	ADV	O	O	945
and	CCONJ	O	O	945
now	ADV	O	O	945
:	PUNCT	O	O	945
a	PRON	O	O	945
case	NOUN	O	O	945
report	VERB	O	O	945
and	CCONJ	O	O	945
historical	ADJ	O	O	945
review	VERB	O	O	945
.	PUNCT	O	O	945
A	PRON	O	O	946
rare	ADJ	O	O	946
case	NOUN	O	O	946
of	ADP	O	O	946
morbid	ADJ	O	O	946
vasospasm	NOUN	O	Disease	946
,	PUNCT	O	O	946
together	ADV	O	O	946
with	ADP	O	O	946
striking	VERB	O	O	946
angiographic	PROPN	O	O	946
findings	NOUN	O	O	946
,	PUNCT	O	O	946
is	AUX	O	O	946
described	VERB	O	O	946
secondary	ADJ	O	O	946
to	PART	O	O	946
the	PRON	O	O	946
ingestion	NOUN	O	O	946
of	ADP	O	O	946
methysergide	NOUN	O	Chemical	946
by	ADP	O	O	946
a	PRON	O	O	946
48-year	NOUN	O	O	946
-	PUNCT	O	O	946
old	ADJ	O	O	946
woman	NOUN	O	O	946
.	PUNCT	O	O	946
A	PRON	O	O	947
discussion	NOUN	O	O	947
of	ADP	O	O	947
the	PRON	O	O	947
history	NOUN	O	O	947
of	ADP	O	O	947
ergot	PROPN	O	Chemical	947
includes	VERB	O	O	947
its	PRON	O	O	947
original	ADJ	O	O	947
discovery	NOUN	O	O	947
,	PUNCT	O	O	947
the	PRON	O	O	947
epidemics	NOUN	O	O	947
of	ADP	O	O	947
gangrene	VERB	O	Disease	947
that	SCONJ	O	O	947
it	PRON	O	O	947
has	VERB	O	O	947
caused	VERB	O	O	947
through	ADP	O	O	947
the	PRON	O	O	947
ages	NOUN	O	O	947
and	CCONJ	O	O	947
its	PRON	O	O	947
past	ADP	O	O	947
and	CCONJ	O	O	947
present	NOUN	O	O	947
role	NOUN	O	O	947
in	ADP	O	O	947
the	PRON	O	O	947
management	NOUN	O	O	947
of	ADP	O	O	947
migraine headache	PROPN	O	Disease	947
.	PUNCT	O	O	947
Despite	SCONJ	O	O	948
the	PRON	O	O	948
advent	VERB	O	O	948
of	ADP	O	O	948
calcium	NOUN	O	Chemical	948
channel	PROPN	O	O	948
blockers	NOUN	O	O	948
and	CCONJ	O	O	948
beta	NOUN	O	O	948
-	PUNCT	O	O	948
adrenergic	NOUN	O	O	948
antagonists	NOUN	O	O	948
,	PUNCT	O	O	948
ergot	PROPN	O	Chemical	948
preparations	NOUN	O	O	948
continue	VERB	O	O	948
to	PART	O	O	948
play	VERB	O	O	948
a	PRON	O	O	948
major	ADJ	O	O	948
role	NOUN	O	O	948
in	ADP	O	O	948
migraine	NOUN	O	Disease	948
therapy	NOUN	O	O	948
,	PUNCT	O	O	948
so	ADV	O	O	948
that	SCONJ	O	O	948
the	PRON	O	O	948
danger	NOUN	O	O	948
of	ADP	O	O	948
St.	PROPN	O	O	948
Anthony	PROPN	O	O	948
's	AUX	O	O	948
fire	NOUN	O	O	948
persists	VERB	O	O	948
.	PUNCT	O	O	948
Beta-2-adrenoceptor	NOUN	O	O	951
-	PUNCT	O	O	951
mediated	VERB	O	O	951
hypokalemia	PROPN	O	Disease	951
and	CCONJ	O	O	951
its	PRON	O	O	951
abolishment	NOUN	O	O	951
by	ADP	O	O	951
oxprenolol	NOUN	O	Chemical	951
.	PUNCT	O	O	951
The	PRON	O	O	952
time	NOUN	O	O	952
course	NOUN	O	O	952
and	CCONJ	O	O	952
concentration	NOUN	O	O	952
-	PUNCT	O	O	952
effect	VERB	O	O	952
relationship	NOUN	O	O	952
of	ADP	O	O	952
terbutaline	NOUN	O	Chemical	952
-	PUNCT	O	O	952
induced	VERB	O	O	952
hypokalemia	PROPN	O	Disease	952
was	AUX	O	O	952
studied	VERB	O	O	952
,	PUNCT	O	O	952
using	VERB	O	O	952
computer	NOUN	O	O	952
-	PUNCT	O	O	952
aided	VERB	O	O	952
pharmacokinetic	VERB	O	O	952
-	PUNCT	O	O	952
dynamic	ADJ	O	O	952
modeling	VERB	O	O	952
.	PUNCT	O	O	952
Subsequently	PROPN	O	O	953
we	PRON	O	O	953
investigated	VERB	O	O	953
the	PRON	O	O	953
efficacy	NOUN	O	O	953
of	ADP	O	O	953
oxprenolol	NOUN	O	Chemical	953
in	ADP	O	O	953
antagonizing	VERB	O	O	953
such	ADJ	O	O	953
hypokalemia	PROPN	O	Disease	953
,	PUNCT	O	O	953
together	ADV	O	O	953
with	ADP	O	O	953
the	PRON	O	O	953
pharmacokinetic	VERB	O	O	953
interaction	NOUN	O	O	953
between	ADP	O	O	953
both	PRON	O	O	953
drugs	NOUN	O	O	953
.	PUNCT	O	O	953
Six	NUM	O	O	954
healthy	ADJ	O	O	954
subjects	NOUN	O	O	954
were	AUX	O	O	954
given	VERB	O	O	954
a	PRON	O	O	954
0.5	NUM	O	O	954
mg	VERB	O	O	954
subcutaneous	ADJ	O	O	954
dose	NOUN	O	O	954
of	ADP	O	O	954
terbutaline	NOUN	O	Chemical	954
on	ADP	O	O	954
two	NUM	O	O	954
occasions	NOUN	O	O	954
:	PUNCT	O	O	954
1	X	O	O	954
hour	NOUN	O	O	954
after	ADP	O	O	954
oral	ADJ	O	O	954
administration	NOUN	O	O	954
of	ADP	O	O	954
a	PRON	O	O	954
placebo	NOUN	O	O	954
and	CCONJ	O	O	954
1	X	O	O	954
hour	NOUN	O	O	954
after	ADP	O	O	954
80	NUM	O	O	954
mg	VERB	O	O	954
oxprenolol	NOUN	O	Chemical	954
orally	ADV	O	O	954
.	PUNCT	O	O	954
In	ADP	O	O	955
the	PRON	O	O	955
7-hour	NOUN	O	O	955
period	NOUN	O	O	955
after	ADP	O	O	955
terbutaline	NOUN	O	Chemical	955
administration	NOUN	O	O	955
,	PUNCT	O	O	955
plasma	NOUN	O	O	955
samples	NOUN	O	O	955
were	AUX	O	O	955
taken	VERB	O	O	955
for	ADP	O	O	955
determination	NOUN	O	O	955
of	ADP	O	O	955
plasma	NOUN	O	O	955
potassium	NOUN	O	Chemical	955
levels	NOUN	O	O	955
and	CCONJ	O	O	955
drug	NOUN	O	O	955
concentrations	NOUN	O	O	955
.	PUNCT	O	O	955
The	PRON	O	O	956
sigmoid	NOUN	O	O	956
Emax	NOUN	O	O	956
model	NOUN	O	O	956
offered	VERB	O	O	956
a	PRON	O	O	956
good	ADJ	O	O	956
description	NOUN	O	O	956
of	ADP	O	O	956
the	PRON	O	O	956
relation	NOUN	O	O	956
between	ADP	O	O	956
terbutaline	NOUN	O	Chemical	956
concentrations	NOUN	O	O	956
and	CCONJ	O	O	956
potassium	NOUN	O	Chemical	956
effects	NOUN	O	O	956
.	PUNCT	O	O	956
Oxprenolol	PROPN	O	Chemical	957
caused	VERB	O	O	957
decreases	VERB	O	O	957
of	ADP	O	O	957
65%	NOUN	O	O	957
and	CCONJ	O	O	957
56%	NOUN	O	O	957
of	ADP	O	O	957
terbutaline	NOUN	O	Chemical	957
volume	PROPN	O	O	957
of	ADP	O	O	957
distribution	NOUN	O	O	957
and	CCONJ	O	O	957
clearance	NOUN	O	O	957
,	PUNCT	O	O	957
respectively	ADV	O	O	957
,	PUNCT	O	O	957
and	CCONJ	O	O	957
an	PRON	O	O	957
increase	VERB	O	O	957
of	ADP	O	O	957
130%	NOUN	O	O	957
of	ADP	O	O	957
its	PRON	O	O	957
AUC	NOUN	O	O	957
.	PUNCT	O	O	957
In	ADP	O	O	958
spite	NOUN	O	O	958
of	ADP	O	O	958
higher	ADJ	O	O	958
terbutaline	NOUN	O	Chemical	958
concentrations	NOUN	O	O	958
after	ADP	O	O	958
oxprenolol	NOUN	O	Chemical	958
pretreatment	NOUN	O	O	958
,	PUNCT	O	O	958
the	PRON	O	O	958
hypokalemia	PROPN	O	Disease	958
was	AUX	O	O	958
almost	ADV	O	O	958
completely	ADV	O	O	958
antagonized	VERB	O	O	958
by	ADP	O	O	958
the	PRON	O	O	958
beta	NOUN	O	O	958
2-blocking	VERB	O	O	958
action	NOUN	O	O	958
.	PUNCT	O	O	958
Midline	NOUN	O	O	961
B3	PROPN	O	O	961
serotonin	PROPN	O	Chemical	961
nerves	NOUN	O	O	961
in	ADP	O	O	961
rat	NOUN	O	O	961
medulla	NOUN	O	O	961
are	AUX	O	O	961
involved	VERB	O	O	961
in	ADP	O	O	961
hypotensive	ADJ	O	Disease	961
effect	VERB	O	O	961
of	ADP	O	O	961
methyldopa	ADJ	O	Chemical	961
.	PUNCT	O	O	961
Previous	ADJ	O	O	962
experiments	NOUN	O	O	962
in	ADP	O	O	962
this	PRON	O	O	962
laboratory	NOUN	O	O	962
have	VERB	O	O	962
shown	VERB	O	O	962
that	SCONJ	O	O	962
microinjection	NOUN	O	O	962
of	ADP	O	O	962
methyldopa	ADJ	O	Chemical	962
onto	ADP	O	O	962
the	PRON	O	O	962
ventrolateral	ADJ	O	O	962
cells	NOUN	O	O	962
of	ADP	O	O	962
the	PRON	O	O	962
B3	PROPN	O	O	962
serotonin	PROPN	O	Chemical	962
neurons	NOUN	O	O	962
in	ADP	O	O	962
the	PRON	O	O	962
medulla	NOUN	O	O	962
elicits	VERB	O	O	962
a	PRON	O	O	962
hypotensive	ADJ	O	Disease	962
response	NOUN	O	O	962
mediated	VERB	O	O	962
by	ADP	O	O	962
a	PRON	O	O	962
projection	PROPN	O	O	962
descending	VERB	O	O	962
into	ADP	O	O	962
the	PRON	O	O	962
spinal	NOUN	O	O	962
cord	NOUN	O	O	962
.	PUNCT	O	O	962
The	PRON	O	O	963
present	NOUN	O	O	963
experiments	NOUN	O	O	963
were	AUX	O	O	963
designed	VERB	O	O	963
to	PART	O	O	963
investigate	VERB	O	O	963
the	PRON	O	O	963
role	NOUN	O	O	963
of	ADP	O	O	963
the	PRON	O	O	963
midline	NOUN	O	O	963
cells	NOUN	O	O	963
of	ADP	O	O	963
the	PRON	O	O	963
B3	PROPN	O	O	963
serotonin	PROPN	O	Chemical	963
neurons	NOUN	O	O	963
in	ADP	O	O	963
the	PRON	O	O	963
medulla	NOUN	O	O	963
,	PUNCT	O	O	963
coinciding	VERB	O	O	963
with	ADP	O	O	963
the	PRON	O	O	963
raphe	NOUN	O	O	963
magnus	PROPN	O	O	963
.	PUNCT	O	O	963
In	ADP	O	O	964
spontaneously	ADV	O	O	964
hypertensive	ADJ	O	Disease	964
,	PUNCT	O	O	964
stroke	VERB	O	Disease	964
-	PUNCT	O	O	964
prone	ADJ	O	O	964
rats	NOUN	O	O	964
,	PUNCT	O	O	964
microinjection	NOUN	O	O	964
of	ADP	O	O	964
methyldopa	ADJ	O	Chemical	964
into	ADP	O	O	964
the	PRON	O	O	964
area	NOUN	O	O	964
of	ADP	O	O	964
the	PRON	O	O	964
midline	NOUN	O	O	964
B3	PROPN	O	O	964
serotonin	PROPN	O	Chemical	964
cell	NOUN	O	O	964
group	NOUN	O	O	964
in	ADP	O	O	964
the	PRON	O	O	964
ventral	ADV	O	O	964
medulla	NOUN	O	O	964
caused	VERB	O	O	964
a	PRON	O	O	964
potent	ADJ	O	O	964
hypotension	NOUN	O	Disease	964
of	ADP	O	O	964
30	NUM	O	O	964
-	PUNCT	O	O	964
40	NUM	O	O	964
mm	INTJ	O	O	964
Hg	PROPN	O	O	964
,	PUNCT	O	O	964
which	PRON	O	O	964
was	AUX	O	O	964
maximal	ADJ	O	O	964
2	X	O	O	964
-	PUNCT	O	O	964
3	X	O	O	964
h	X	O	O	964
after	ADP	O	O	964
administration	NOUN	O	O	964
and	CCONJ	O	O	964
was	AUX	O	O	964
abolished	VERB	O	O	964
by	ADP	O	O	964
the	PRON	O	O	964
serotonin	PROPN	O	Chemical	964
neurotoxin	NOUN	O	O	964
5,7-dihydroxytryptamine	NOUN	O	Chemical	964
(	PUNCT	O	O	964
5,7-DHT	PROPN	O	Chemical	964
)	PUNCT	O	O	964
injected	VERB	O	O	964
intracerebroventricularly	ADV	O	O	964
.	PUNCT	O	O	964
However	ADV	O	O	965
,	PUNCT	O	O	965
intraspinal	PROPN	O	O	965
injection	NOUN	O	O	965
of	ADP	O	O	965
5,7-DHT	PROPN	O	Chemical	965
to	PART	O	O	965
produce	VERB	O	O	965
a	PRON	O	O	965
more	ADJ	O	O	965
selective	ADJ	O	O	965
lesion	NOUN	O	O	965
of	ADP	O	O	965
only	ADV	O	O	965
descending	VERB	O	O	965
serotonin	PROPN	O	Chemical	965
projections	NOUN	O	O	965
in	ADP	O	O	965
the	PRON	O	O	965
spinal	NOUN	O	O	965
cord	NOUN	O	O	965
did	VERB	O	O	965
not	PART	O	O	965
affect	VERB	O	O	965
this	PRON	O	O	965
hypotension	NOUN	O	Disease	965
.	PUNCT	O	O	965
Further	ADV	O	O	966
,	PUNCT	O	O	966
5,7-DHT	PROPN	O	Chemical	966
lesion	NOUN	O	O	966
of	ADP	O	O	966
serotonin	PROPN	O	Chemical	966
nerves	NOUN	O	O	966
travelling	VERB	O	O	966
in	ADP	O	O	966
the	PRON	O	O	966
median	ADJ	O	O	966
forebrain	NOUN	O	O	966
bundle	VERB	O	O	966
,	PUNCT	O	O	966
one	NUM	O	O	966
of	ADP	O	O	966
the	PRON	O	O	966
main	ADJ	O	O	966
ascending	VERB	O	O	966
pathways	NOUN	O	O	966
from	ADP	O	O	966
the	PRON	O	O	966
B3	PROPN	O	O	966
serotonin	PROPN	O	Chemical	966
cells	NOUN	O	O	966
,	PUNCT	O	O	966
did	VERB	O	O	966
not	PART	O	O	966
affect	VERB	O	O	966
the	PRON	O	O	966
fall	VERB	O	O	966
in	ADP	O	O	966
blood	NOUN	O	O	966
pressure	NOUN	O	O	966
associated	VERB	O	O	966
with	ADP	O	O	966
a	PRON	O	O	966
midline	NOUN	O	O	966
B3	PROPN	O	O	966
serotonin	PROPN	O	Chemical	966
methyldopa	ADJ	O	Chemical	966
injection	NOUN	O	O	966
.	PUNCT	O	O	966
It	PRON	O	O	967
is	AUX	O	O	967
concluded	VERB	O	O	967
therefore	ADV	O	O	967
that	SCONJ	O	O	967
,	PUNCT	O	O	967
unlike	ADP	O	O	967
the	PRON	O	O	967
ventrolateral	ADJ	O	O	967
B3	PROPN	O	O	967
cells	NOUN	O	O	967
which	PRON	O	O	967
mediate	VERB	O	O	967
a	PRON	O	O	967
methyldopa	ADJ	O	Chemical	967
-	PUNCT	O	O	967
induced	VERB	O	O	967
hypotension	NOUN	O	Disease	967
via	ADP	O	O	967
descending	VERB	O	O	967
projections	NOUN	O	O	967
,	PUNCT	O	O	967
the	PRON	O	O	967
midline	NOUN	O	O	967
serotonin	PROPN	O	Chemical	967
B3	PROPN	O	O	967
cells	NOUN	O	O	967
in	ADP	O	O	967
the	PRON	O	O	967
medulla	NOUN	O	O	967
contribute	VERB	O	O	967
to	PART	O	O	967
the	PRON	O	O	967
hypotensive	ADJ	O	Disease	967
action	NOUN	O	O	967
of	ADP	O	O	967
methyldopa	ADJ	O	Chemical	967
,	PUNCT	O	O	967
either	ADV	O	O	967
by	ADP	O	O	967
way	NOUN	O	O	967
of	ADP	O	O	967
an	PRON	O	O	967
ascending	VERB	O	O	967
projection	PROPN	O	O	967
which	PRON	O	O	967
does	VERB	O	O	967
not	PART	O	O	967
pass	VERB	O	O	967
through	ADP	O	O	967
the	PRON	O	O	967
median	ADJ	O	O	967
forebrain	NOUN	O	O	967
bundle	VERB	O	O	967
,	PUNCT	O	O	967
or	CCONJ	O	O	967
through	ADP	O	O	967
a	PRON	O	O	967
projection	PROPN	O	O	967
restricted	VERB	O	O	967
to	PART	O	O	967
the	PRON	O	O	967
caudal	ADJ	O	O	967
brainstem	NOUN	O	O	967
.	PUNCT	O	O	967
Yohimbine	NOUN	O	Chemical	970
treatment	NOUN	O	O	970
of	ADP	O	O	970
sexual side effects	NOUN	O	Disease	970
induced	VERB	O	O	970
by	ADP	O	O	970
serotonin	PROPN	O	Chemical	970
reuptake	PROPN	O	O	970
blockers	NOUN	O	O	970
.	PUNCT	O	O	970
:	PUNCT	O	O	971
Preclinical	PROPN	O	O	971
and	CCONJ	O	O	971
clinical	ADJ	O	O	971
studies	NOUN	O	O	971
suggest	VERB	O	O	971
that	SCONJ	O	O	971
yohimbine	NOUN	O	Chemical	971
facilitates	VERB	O	O	971
sexual	ADJ	O	O	971
behavior	NOUN	O	O	971
and	CCONJ	O	O	971
may	AUX	O	O	971
be	AUX	O	O	971
helpful	ADJ	O	O	971
in	ADP	O	O	971
the	PRON	O	O	971
treatment	NOUN	O	O	971
of	ADP	O	O	971
male impotence	NOUN	O	Disease	971
.	PUNCT	O	O	971
A	PRON	O	O	972
single	ADJ	O	O	972
case	NOUN	O	O	972
report	VERB	O	O	972
suggests	VERB	O	O	972
that	SCONJ	O	O	972
yohimbine	NOUN	O	Chemical	972
may	AUX	O	O	972
be	AUX	O	O	972
used	VERB	O	O	972
to	PART	O	O	972
treat	VERB	O	O	972
the	PRON	O	O	972
sexual side effects	NOUN	O	Disease	972
of	ADP	O	O	972
clomipramine	NOUN	O	Chemical	972
.	PUNCT	O	O	972
This	PRON	O	O	973
study	VERB	O	O	973
evaluated	VERB	O	O	973
yohimbine	NOUN	O	Chemical	973
as	ADP	O	O	973
a	PRON	O	O	973
treatment	NOUN	O	O	973
for	ADP	O	O	973
the	PRON	O	O	973
sexual side effects	NOUN	O	Disease	973
caused	VERB	O	O	973
by	ADP	O	O	973
serotonin	PROPN	O	Chemical	973
reuptake	PROPN	O	O	973
blockers	NOUN	O	O	973
.	PUNCT	O	O	973
METHOD	NOUN	O	O	974
:	PUNCT	O	O	974
Six	NUM	O	O	974
patients	NOUN	O	O	974
with	ADP	O	O	974
either	ADV	O	O	974
obsessive compulsive disorder	NOUN	O	Disease	974
,	PUNCT	O	O	974
trichotillomania	PROPN	O	Disease	974
,	PUNCT	O	O	974
anxiety	NOUN	O	Disease	974
,	PUNCT	O	O	974
or	CCONJ	O	O	974
affective disorders	NOUN	O	Disease	974
who	PRON	O	O	974
suffered	VERB	O	O	974
sexual side effects	NOUN	O	Disease	974
after	ADP	O	O	974
treatment	NOUN	O	O	974
with	ADP	O	O	974
serotonin	PROPN	O	Chemical	974
reuptake	PROPN	O	O	974
blockers	NOUN	O	O	974
were	AUX	O	O	974
given	VERB	O	O	974
yohimbine	NOUN	O	Chemical	974
on	ADP	O	O	974
a	PRON	O	O	974
p.r.n	PROPN	O	O	974
.	PUNCT	O	O	974
Various	ADJ	O	O	975
doses	NOUN	O	O	975
of	ADP	O	O	975
yohimbine	NOUN	O	Chemical	975
were	AUX	O	O	975
used	VERB	O	O	975
to	PART	O	O	975
determine	VERB	O	O	975
the	PRON	O	O	975
ideal	ADJ	O	O	975
dose	NOUN	O	O	975
for	ADP	O	O	975
each	PRON	O	O	975
patient	NOUN	O	O	975
.	PUNCT	O	O	975
Five	NUM	O	O	976
of	ADP	O	O	976
the	PRON	O	O	976
six	NUM	O	O	976
patients	NOUN	O	O	976
experienced	ADJ	O	O	976
improved	VERB	O	O	976
sexual	ADJ	O	O	976
functioning	VERB	O	O	976
after	ADP	O	O	976
taking	VERB	O	O	976
yohimbine	NOUN	O	Chemical	976
.	PUNCT	O	O	976
One	NUM	O	O	977
patient	NOUN	O	O	977
who	PRON	O	O	977
failed	VERB	O	O	977
to	PART	O	O	977
comply	VERB	O	O	977
with	ADP	O	O	977
yohimbine	NOUN	O	Chemical	977
treatment	NOUN	O	O	977
had	VERB	O	O	977
no	PRON	O	O	977
therapeutic	ADJ	O	O	977
effects	NOUN	O	O	977
.	PUNCT	O	O	977
Side	NOUN	O	O	978
effects	NOUN	O	O	978
of	ADP	O	O	978
yohimbine	NOUN	O	Chemical	978
included	VERB	O	O	978
excessive	ADJ	O	O	978
sweating	VERB	O	O	978
,	PUNCT	O	O	978
increased	VERB	O	O	978
anxiety	NOUN	O	Disease	978
,	PUNCT	O	O	978
and	CCONJ	O	O	978
a	PRON	O	O	978
wound	VERB	O	O	978
-	PUNCT	O	O	978
up	ADP	O	O	978
feeling	VERB	O	O	978
in	ADP	O	O	978
some	PRON	O	O	978
patients	NOUN	O	O	978
.	PUNCT	O	O	978
The	PRON	O	O	979
results	VERB	O	O	979
of	ADP	O	O	979
this	PRON	O	O	979
study	VERB	O	O	979
indicate	VERB	O	O	979
that	SCONJ	O	O	979
yohimbine	NOUN	O	Chemical	979
may	AUX	O	O	979
be	AUX	O	O	979
an	PRON	O	O	979
effective	ADJ	O	O	979
treatment	NOUN	O	O	979
for	ADP	O	O	979
the	PRON	O	O	979
sexual side effects	NOUN	O	Disease	979
caused	VERB	O	O	979
by	ADP	O	O	979
serotonin	PROPN	O	Chemical	979
reuptake	PROPN	O	O	979
blockers	NOUN	O	O	979
.	PUNCT	O	O	979
Future	NOUN	O	O	980
controlled	VERB	O	O	980
studies	NOUN	O	O	980
are	AUX	O	O	980
needed	VERB	O	O	980
to	PART	O	O	980
further	ADV	O	O	980
investigate	VERB	O	O	980
the	PRON	O	O	980
effectiveness	NOUN	O	O	980
and	CCONJ	O	O	980
safety	NOUN	O	O	980
of	ADP	O	O	980
yohimbine	NOUN	O	Chemical	980
for	ADP	O	O	980
this	PRON	O	O	980
indication	NOUN	O	O	980
.	PUNCT	O	O	980
Hypersensitivity	NOUN	O	Disease	983
immune	NOUN	O	O	983
reaction	NOUN	O	O	983
as	ADP	O	O	983
a	PRON	O	O	983
mechanism	NOUN	O	O	983
for	ADP	O	O	983
dilevalol	VERB	O	Chemical	983
-	PUNCT	O	O	983
associated	VERB	O	O	983
hepatitis	NOUN	O	Disease	983
.	PUNCT	O	O	983
OBJECTIVE	VERB	O	O	984
:	PUNCT	O	O	984
To	PART	O	O	984
assess	VERB	O	O	984
lymphocyte	NOUN	O	O	984
reactivity	NOUN	O	O	984
to	PART	O	O	984
dilevalol	VERB	O	Chemical	984
and	CCONJ	O	O	984
to	PART	O	O	984
serum	NOUN	O	O	984
containing	VERB	O	O	984
putative	ADJ	O	O	984
ex	PRON	O	O	984
vivo	VERB	O	O	984
dilevalol	VERB	O	Chemical	984
antigens	NOUN	O	O	984
or	CCONJ	O	O	984
metabolites	VERB	O	O	984
in	ADP	O	O	984
a	PRON	O	O	984
case	NOUN	O	O	984
of	ADP	O	O	984
dilevalol	VERB	O	Chemical	984
-	PUNCT	O	O	984
induced	VERB	O	O	984
liver injury	NOUN	O	Disease	984
.	PUNCT	O	O	984
A	PRON	O	O	985
58-year	NOUN	O	O	985
-	PUNCT	O	O	985
old	ADJ	O	O	985
woman	NOUN	O	O	985
with	ADP	O	O	985
a	PRON	O	O	985
clinical	ADJ	O	O	985
diagnosis	NOUN	O	O	985
of	ADP	O	O	985
dilevalol	VERB	O	Chemical	985
-	PUNCT	O	O	985
induced	VERB	O	O	985
liver injury	NOUN	O	Disease	985
.	PUNCT	O	O	985
Peripheral	ADJ	O	O	986
blood	NOUN	O	O	986
mononuclear	PROPN	O	O	986
cells	NOUN	O	O	986
collected	VERB	O	O	986
from	ADP	O	O	986
the	PRON	O	O	986
patient	NOUN	O	O	986
were	AUX	O	O	986
cultured	ADJ	O	O	986
in	ADP	O	O	986
the	PRON	O	O	986
presence	NOUN	O	O	986
of	ADP	O	O	986
a	PRON	O	O	986
solution	NOUN	O	O	986
of	ADP	O	O	986
dilevalol	VERB	O	Chemical	986
and	CCONJ	O	O	986
also	ADV	O	O	986
with	ADP	O	O	986
sera	PROPN	O	O	986
collected	VERB	O	O	986
from	ADP	O	O	986
a	PRON	O	O	986
volunteer	PROPN	O	O	986
before	ADP	O	O	986
and	CCONJ	O	O	986
after	ADP	O	O	986
dilevalol	VERB	O	Chemical	986
intake	PROPN	O	O	986
.	PUNCT	O	O	986
No	PRON	O	O	987
lymphocyte	NOUN	O	O	987
proliferation	NOUN	O	O	987
was	AUX	O	O	987
observed	VERB	O	O	987
either	ADV	O	O	987
in	ADP	O	O	987
the	PRON	O	O	987
patient	NOUN	O	O	987
or	CCONJ	O	O	987
in	ADP	O	O	987
the	PRON	O	O	987
healthy	ADJ	O	O	987
volunteer	PROPN	O	O	987
in	ADP	O	O	987
the	PRON	O	O	987
presence	NOUN	O	O	987
of	ADP	O	O	987
dilevalol	VERB	O	Chemical	987
solutions	NOUN	O	O	987
.	PUNCT	O	O	987
A	PRON	O	O	988
significant	ADJ	O	O	988
proliferative	ADJ	O	O	988
response	NOUN	O	O	988
to	PART	O	O	988
serum	NOUN	O	O	988
collected	VERB	O	O	988
after	ADP	O	O	988
dilevalol	VERB	O	Chemical	988
intake	PROPN	O	O	988
was	AUX	O	O	988
observed	VERB	O	O	988
in	ADP	O	O	988
the	PRON	O	O	988
case	NOUN	O	O	988
of	ADP	O	O	988
the	PRON	O	O	988
patient	NOUN	O	O	988
compared	VERB	O	O	988
with	ADP	O	O	988
the	PRON	O	O	988
proliferative	ADJ	O	O	988
response	NOUN	O	O	988
to	PART	O	O	988
the	PRON	O	O	988
serum	NOUN	O	O	988
collected	VERB	O	O	988
before	ADP	O	O	988
the	PRON	O	O	988
drug	NOUN	O	O	988
intake	PROPN	O	O	988
.	PUNCT	O	O	988
The	PRON	O	O	989
methodology	NOUN	O	O	989
used	VERB	O	O	989
allowed	VERB	O	O	989
the	PRON	O	O	989
detection	NOUN	O	O	989
of	ADP	O	O	989
lymphocyte	NOUN	O	O	989
sensitization	NOUN	O	O	989
to	PART	O	O	989
sera	PROPN	O	O	989
containing	VERB	O	O	989
ex	PRON	O	O	989
vivo	VERB	O	O	989
-	PUNCT	O	O	989
prepared	VERB	O	O	989
dilevalol	VERB	O	Chemical	989
antigens	NOUN	O	O	989
,	PUNCT	O	O	989
suggesting	VERB	O	O	989
the	PRON	O	O	989
involvement	NOUN	O	O	989
of	ADP	O	O	989
an	PRON	O	O	989
immunologic	ADJ	O	O	989
mechanism	NOUN	O	O	989
in	ADP	O	O	989
dilevalol	VERB	O	Chemical	989
-	PUNCT	O	O	989
induced	VERB	O	O	989
liver injury	NOUN	O	Disease	989
.	PUNCT	O	O	989
Reversible	ADJ	O	O	992
myocardial hypertrophy	NOUN	O	Disease	992
induced	VERB	O	O	992
by	ADP	O	O	992
tacrolimus	NOUN	O	Chemical	992
in	ADP	O	O	992
a	PRON	O	O	992
pediatric	ADJ	O	O	992
heart	NOUN	O	O	992
transplant	NOUN	O	O	992
recipient	NOUN	O	O	992
:	PUNCT	O	O	992
case	NOUN	O	O	992
report	VERB	O	O	992
.	PUNCT	O	O	992
Tacrolimus	PROPN	O	Chemical	993
is	AUX	O	O	993
a	PRON	O	O	993
potent	ADJ	O	O	993
immunosuppressant	ADJ	O	O	993
that	SCONJ	O	O	993
is	AUX	O	O	993
frequently	ADV	O	O	993
used	VERB	O	O	993
in	ADP	O	O	993
organ	NOUN	O	O	993
transplantation	NOUN	O	O	993
.	PUNCT	O	O	993
However	ADV	O	O	994
,	PUNCT	O	O	994
adverse	ADJ	O	O	994
effects	NOUN	O	O	994
include	VERB	O	O	994
cardiac toxicity	NOUN	O	Disease	994
.	PUNCT	O	O	994
Herein	ADV	O	O	995
we	PRON	O	O	995
describe	VERB	O	O	995
transient	ADJ	O	O	995
myocardial hypertrophy	NOUN	O	Disease	995
induced	VERB	O	O	995
by	ADP	O	O	995
tacrolimus	NOUN	O	Chemical	995
after	ADP	O	O	995
heart	NOUN	O	O	995
transplantation	NOUN	O	O	995
.	PUNCT	O	O	995
The	PRON	O	O	996
hypertrophy	VERB	O	Disease	996
caused	VERB	O	O	996
no	PRON	O	O	996
clinical	ADJ	O	O	996
symptoms	NOUN	O	O	996
but	CCONJ	O	O	996
was	AUX	O	O	996
noted	VERB	O	O	996
because	SCONJ	O	O	996
of	ADP	O	O	996
elevation	NOUN	O	O	996
of	ADP	O	O	996
plasma	NOUN	O	O	996
brain	NOUN	O	O	996
natriuretic	ADJ	O	O	996
peptide	NOUN	O	O	996
concentration	NOUN	O	O	996
and	CCONJ	O	O	996
confirmed	VERB	O	O	996
at	ADP	O	O	996
echocardiography	NOUN	O	O	996
.	PUNCT	O	O	996
Initially	ADV	O	O	997
,	PUNCT	O	O	997
allograft	NOUN	O	O	997
rejection	NOUN	O	O	997
was	AUX	O	O	997
feared	VERB	O	O	997
;	PUNCT	O	O	997
however	ADV	O	O	997
,	PUNCT	O	O	997
myocardial	ADJ	O	O	997
biopsy	PROPN	O	O	997
samples	NOUN	O	O	997
revealed	VERB	O	O	997
only	ADV	O	O	997
interstitial	ADJ	O	O	997
edema	NOUN	O	Disease	997
and	CCONJ	O	O	997
mild	ADJ	O	O	997
myocardial hypertrophy	NOUN	O	Disease	997
;	PUNCT	O	O	997
neither	ADV	O	O	997
cellular	NOUN	O	O	997
nor	CCONJ	O	O	997
humoral	ADJ	O	O	997
rejection	NOUN	O	O	997
was	AUX	O	O	997
detected	VERB	O	O	997
.	PUNCT	O	O	997
The	PRON	O	O	998
blood	NOUN	O	O	998
tacrolimus	NOUN	O	Chemical	998
concentration	NOUN	O	O	998
was	AUX	O	O	998
higher	ADJ	O	O	998
than	ADP	O	O	998
usual	ADJ	O	O	998
at	ADP	O	O	998
that	SCONJ	O	O	998
time	NOUN	O	O	998
;	PUNCT	O	O	998
thus	ADV	O	O	998
,	PUNCT	O	O	998
tacrolimus	NOUN	O	Chemical	998
dosage	NOUN	O	O	998
was	AUX	O	O	998
reduced	VERB	O	O	998
.	PUNCT	O	O	998
Myocardial hypertrophy	NOUN	O	Disease	999
completely	ADV	O	O	999
resolved	VERB	O	O	999
upon	SCONJ	O	O	999
reducing	VERB	O	O	999
the	PRON	O	O	999
target	NOUN	O	O	999
concentration	NOUN	O	O	999
of	ADP	O	O	999
tacrolimus	NOUN	O	Chemical	999
and	CCONJ	O	O	999
did	VERB	O	O	999
not	PART	O	O	999
recur	VERB	O	O	999
,	PUNCT	O	O	999
as	ADP	O	O	999
confirmed	VERB	O	O	999
at	ADP	O	O	999
echocardiography	NOUN	O	O	999
and	CCONJ	O	O	999
myocardial	ADJ	O	O	999
biopsy	PROPN	O	O	999
.	PUNCT	O	O	999
Thus	ADV	O	O	1000
,	PUNCT	O	O	1000
we	PRON	O	O	1000
conclude	VERB	O	O	1000
that	SCONJ	O	O	1000
tacrolimus	NOUN	O	Chemical	1000
induces	VERB	O	O	1000
reversible	ADJ	O	O	1000
myocardial hypertrophy	NOUN	O	Disease	1000
.	PUNCT	O	O	1000
In	ADP	O	O	1001
patients	NOUN	O	O	1001
receiving	VERB	O	O	1001
tacrolimus	NOUN	O	Chemical	1001
therapy	NOUN	O	O	1001
,	PUNCT	O	O	1001
blood	NOUN	O	O	1001
concentration	NOUN	O	O	1001
should	AUX	O	O	1001
be	AUX	O	O	1001
carefully	ADV	O	O	1001
controlled	VERB	O	O	1001
and	CCONJ	O	O	1001
extreme	ADJ	O	O	1001
attention	NOUN	O	O	1001
paid	VERB	O	O	1001
to	PART	O	O	1001
cardiac	ADJ	O	O	1001
involvement	NOUN	O	O	1001
.	PUNCT	O	O	1001
Comparison	NOUN	O	O	1004
of	ADP	O	O	1004
unilateral	ADJ	O	O	1004
pallidotomy	NOUN	O	O	1004
and	CCONJ	O	O	1004
subthalamotomy	NOUN	O	O	1004
findings	NOUN	O	O	1004
in	ADP	O	O	1004
advanced	ADJ	O	O	1004
idiopathic	ADJ	O	O	1004
Parkinson	NOUN	O	O	1004
's	AUX	O	O	1004
disease	PROPN	O	O	1004
.	PUNCT	O	O	1004
A	PRON	O	O	1005
prospective	ADJ	O	O	1005
,	PUNCT	O	O	1005
randomized	VERB	O	O	1005
,	PUNCT	O	O	1005
double	ADJ	O	O	1005
-	PUNCT	O	O	1005
blind	ADJ	O	Disease	1005
pilot	NOUN	O	O	1005
study	VERB	O	O	1005
to	PART	O	O	1005
compare	VERB	O	O	1005
the	PRON	O	O	1005
results	VERB	O	O	1005
of	ADP	O	O	1005
stereotactic	NOUN	O	O	1005
unilateral	ADJ	O	O	1005
pallidotomy	NOUN	O	O	1005
and	CCONJ	O	O	1005
subthalamotomy	NOUN	O	O	1005
in	ADP	O	O	1005
advanced	ADJ	O	O	1005
idiopathic	ADJ	O	O	1005
Parkinson	NOUN	O	O	1005
's	AUX	O	O	1005
disease	PROPN	O	O	1005
(	PUNCT	O	O	1005
PD	PROPN	O	Disease	1005
)	PUNCT	O	O	1005
refractory	ADJ	O	O	1005
to	PART	O	O	1005
medical	ADJ	O	O	1005
treatment	NOUN	O	O	1005
was	AUX	O	O	1005
designed	VERB	O	O	1005
.	PUNCT	O	O	1005
3.5	NUM	O	O	1006
years	NOUN	O	O	1006
)	PUNCT	O	O	1006
,	PUNCT	O	O	1006
disabling	VERB	O	O	1006
motor	NOUN	O	O	1006
fluctuations	NOUN	O	O	1006
(	PUNCT	O	O	1006
Hoehn	PROPN	O	O	1006
 	SPACE	O	O	1006
Yahr	NOUN	O	O	1006
stage	NOUN	O	O	1006
3	X	O	O	1006
-	PUNCT	O	O	1006
5	NUM	O	O	1006
in	ADP	O	O	1006
off	ADP	O	O	1006
-	PUNCT	O	O	1006
drug	NOUN	O	O	1006
phases	NOUN	O	O	1006
)	PUNCT	O	O	1006
and	CCONJ	O	O	1006
levodopa	NOUN	O	Chemical	1006
-	PUNCT	O	O	1006
induced	VERB	O	O	1006
dyskinesias	PROPN	O	Disease	1006
were	AUX	O	O	1006
selected	VERB	O	O	1006
.	PUNCT	O	O	1006
All	PRON	O	O	1007
patients	NOUN	O	O	1007
had	VERB	O	O	1007
bilateral	ADJ	O	O	1007
symptoms	NOUN	O	O	1007
and	CCONJ	O	O	1007
their	PRON	O	O	1007
levodopa	NOUN	O	Chemical	1007
equivalent	ADJ	O	O	1007
dosing	VERB	O	O	1007
were	AUX	O	O	1007
analysed	VERB	O	O	1007
.	PUNCT	O	O	1007
Clinical	NOUN	O	O	1008
evaluation	NOUN	O	O	1008
included	VERB	O	O	1008
the	PRON	O	O	1008
use	VERB	O	O	1008
of	ADP	O	O	1008
the	PRON	O	O	1008
Unified	VERB	O	O	1008
Parkinson	NOUN	O	O	1008
's	AUX	O	O	1008
Disease	NOUN	O	O	1008
Rating	NOUN	O	O	1008
Scale	NOUN	O	O	1008
(	PUNCT	O	O	1008
UPDRS	PROPN	O	O	1008
)	PUNCT	O	O	1008
,	PUNCT	O	O	1008
Hoehn Yahr	PROPN	O	O	1008
score	VERB	O	O	1008
and	CCONJ	O	O	1008
Schwab	NOUN	O	O	1008
England	PROPN	O	O	1008
activities	NOUN	O	O	1008
of	ADP	O	O	1008
daily	ADV	O	O	1008
living	VERB	O	O	1008
(	PUNCT	O	O	1008
ADL	PROPN	O	O	1008
)	PUNCT	O	O	1008
score	VERB	O	O	1008
in	ADP	O	O	1008
'	PUNCT	O	O	1008
on'-	NOUN	O	O	1008
and	CCONJ	O	O	1008
'	PUNCT	O	O	1008
off'-drug	NOUN	O	O	1008
conditions	NOUN	O	O	1008
before	ADP	O	O	1008
surgery	NOUN	O	O	1008
and	CCONJ	O	O	1008
6	NUM	O	O	1008
months	NOUN	O	O	1008
after	ADP	O	O	1008
surgery	NOUN	O	O	1008
.	PUNCT	O	O	1008
There	ADV	O	O	1009
was	AUX	O	O	1009
statistically	ADV	O	O	1009
significant	ADJ	O	O	1009
improvement	NOUN	O	O	1009
in	ADP	O	O	1009
all	PRON	O	O	1009
contralateral	ADJ	O	O	1009
major	ADJ	O	O	1009
parkinsonian	PROPN	O	Disease	1009
motor	NOUN	O	O	1009
signs	NOUN	O	O	1009
in	ADP	O	O	1009
all	PRON	O	O	1009
patients	NOUN	O	O	1009
followed	VERB	O	O	1009
for	ADP	O	O	1009
6	NUM	O	O	1009
months	NOUN	O	O	1009
.	PUNCT	O	O	1009
Levodopa	NOUN	O	Chemical	1010
equivalent	ADJ	O	O	1010
daily	ADV	O	O	1010
intake	PROPN	O	O	1010
was	AUX	O	O	1010
significantly	ADV	O	O	1010
reduced	VERB	O	O	1010
in	ADP	O	O	1010
the	PRON	O	O	1010
STN	PROPN	O	O	1010
group	NOUN	O	O	1010
.	PUNCT	O	O	1010
Complications	NOUN	O	O	1011
were	AUX	O	O	1011
observed	VERB	O	O	1011
in	ADP	O	O	1011
two	NUM	O	O	1011
patients	NOUN	O	O	1011
:	PUNCT	O	O	1011
one	NUM	O	O	1011
had	VERB	O	O	1011
a	PRON	O	O	1011
left	VERB	O	O	1011
homonymous hemianopsia	NOUN	O	Disease	1011
after	ADP	O	O	1011
pallidotomy	NOUN	O	O	1011
and	CCONJ	O	O	1011
another	PRON	O	O	1011
one	NUM	O	O	1011
developed	VERB	O	O	1011
left	VERB	O	O	1011
hemiballistic	ADJ	O	O	1011
movements	NOUN	O	O	1011
3	X	O	O	1011
days	NOUN	O	O	1011
after	ADP	O	O	1011
subthalamotomy	NOUN	O	O	1011
which	PRON	O	O	1011
partly	ADV	O	O	1011
improved	VERB	O	O	1011
within	ADP	O	O	1011
1	X	O	O	1011
month	NOUN	O	O	1011
with	ADP	O	O	1011
Valproate	VERB	O	Chemical	1011
1000	NUM	O	O	1011
mg	VERB	O	O	1011
/	PUNCT	O	O	1011
day	NOUN	O	O	1011
.	PUNCT	O	O	1011
The	PRON	O	O	1012
findings	NOUN	O	O	1012
of	ADP	O	O	1012
this	PRON	O	O	1012
study	VERB	O	O	1012
suggest	VERB	O	O	1012
that	SCONJ	O	O	1012
lesions	NOUN	O	O	1012
of	ADP	O	O	1012
the	PRON	O	O	1012
unilateral	ADJ	O	O	1012
STN	PROPN	O	O	1012
and	CCONJ	O	O	1012
GPi	VERB	O	O	1012
are	AUX	O	O	1012
equally	ADV	O	O	1012
effective	ADJ	O	O	1012
treatment	NOUN	O	O	1012
for	ADP	O	O	1012
patients	NOUN	O	O	1012
with	ADP	O	O	1012
advanced	ADJ	O	O	1012
PD	PROPN	O	Disease	1012
refractory	ADJ	O	O	1012
to	PART	O	O	1012
medical	ADJ	O	O	1012
treatment	NOUN	O	O	1012
.	PUNCT	O	O	1012
Protective	NOUN	O	O	1015
effects	NOUN	O	O	1015
of	ADP	O	O	1015
antithrombin	PROPN	O	O	1015
on	ADP	O	O	1015
puromycin aminonucleoside	NOUN	O	Chemical	1015
nephrosis	NOUN	O	Disease	1015
in	ADP	O	O	1015
rats	NOUN	O	O	1015
.	PUNCT	O	O	1015
We	PRON	O	O	1016
investigated	VERB	O	O	1016
the	PRON	O	O	1016
effects	NOUN	O	O	1016
of	ADP	O	O	1016
antithrombin	PROPN	O	O	1016
,	PUNCT	O	O	1016
a	PRON	O	O	1016
plasma	NOUN	O	O	1016
inhibitor	NOUN	O	O	1016
of	ADP	O	O	1016
coagulation	NOUN	O	O	1016
factors	NOUN	O	O	1016
,	PUNCT	O	O	1016
in	ADP	O	O	1016
rats	NOUN	O	O	1016
with	ADP	O	O	1016
puromycin aminonucleoside	NOUN	O	Chemical	1016
-	PUNCT	O	O	1016
induced	VERB	O	O	1016
nephrosis	NOUN	O	Disease	1016
,	PUNCT	O	O	1016
which	PRON	O	O	1016
is	AUX	O	O	1016
an	PRON	O	O	1016
experimental	ADJ	O	O	1016
model	NOUN	O	O	1016
of	ADP	O	O	1016
human	PROPN	O	O	1016
nephrotic syndrome	NOUN	O	Disease	1016
.	PUNCT	O	O	1016
Antithrombin	PROPN	O	O	1017
(	PUNCT	O	O	1017
50	NUM	O	O	1017
or	CCONJ	O	O	1017
500	NUM	O	O	1017
IU	PROPN	O	O	1017
/	PUNCT	O	O	1017
kg	VERB	O	O	1017
/	PUNCT	O	O	1017
i.v	NOUN	O	O	1017
.	PUNCT	O	O	1017
)	PUNCT	O	O	1017
was	AUX	O	O	1017
administered	VERB	O	O	1017
to	PART	O	O	1017
rats	NOUN	O	O	1017
once	ADV	O	O	1017
a	PRON	O	O	1017
day	NOUN	O	O	1017
for	ADP	O	O	1017
10	NUM	O	O	1017
days	NOUN	O	O	1017
immediately	ADV	O	O	1017
after	ADP	O	O	1017
the	PRON	O	O	1017
injection	NOUN	O	O	1017
of	ADP	O	O	1017
puromycin aminonucleoside	NOUN	O	Chemical	1017
(	PUNCT	O	O	1017
50	NUM	O	O	1017
mg	VERB	O	O	1017
/	PUNCT	O	O	1017
kg	VERB	O	O	1017
/	PUNCT	O	O	1017
i.v	NOUN	O	O	1017
.	PUNCT	O	O	1017
)	PUNCT	O	O	1017
.	PUNCT	O	O	1017
Treatment	NOUN	O	O	1018
with	ADP	O	O	1018
antithrombin	PROPN	O	O	1018
attenuated	VERB	O	O	1018
the	PRON	O	O	1018
puromycin aminonucleoside	NOUN	O	Chemical	1018
-	PUNCT	O	O	1018
induced	VERB	O	O	1018
hematological abnormalities	NOUN	O	Disease	1018
.	PUNCT	O	O	1018
Puromycin aminonucleoside	NOUN	O	Chemical	1019
-	PUNCT	O	O	1019
induced	VERB	O	O	1019
renal dysfunction	NOUN	O	Disease	1019
and	CCONJ	O	O	1019
hyperlipidemia	NOUN	O	Disease	1019
were	AUX	O	O	1019
also	ADV	O	O	1019
suppressed	VERB	O	O	1019
.	PUNCT	O	O	1019
Histopathological	PROPN	O	O	1020
examination	NOUN	O	O	1020
revealed	VERB	O	O	1020
severe	ADJ	O	O	1020
renal damage	NOUN	O	Disease	1020
such	ADJ	O	O	1020
as	ADP	O	O	1020
proteinaceous	ADJ	O	O	1020
casts	VERB	O	O	1020
in	ADP	O	O	1020
tubuli	PROPN	O	O	1020
and	CCONJ	O	O	1020
tubular	ADJ	O	O	1020
expansion	NOUN	O	O	1020
in	ADP	O	O	1020
the	PRON	O	O	1020
kidney	NOUN	O	O	1020
of	ADP	O	O	1020
control	VERB	O	O	1020
rats	NOUN	O	O	1020
,	PUNCT	O	O	1020
while	SCONJ	O	O	1020
an	PRON	O	O	1020
improvement	NOUN	O	O	1020
of	ADP	O	O	1020
the	PRON	O	O	1020
damage	NOUN	O	O	1020
was	AUX	O	O	1020
seen	VERB	O	O	1020
in	ADP	O	O	1020
antithrombin	PROPN	O	O	1020
-	PUNCT	O	O	1020
treated	VERB	O	O	1020
rats	NOUN	O	O	1020
.	PUNCT	O	O	1020
In	ADP	O	O	1021
addition	NOUN	O	O	1021
,	PUNCT	O	O	1021
antithrombin	PROPN	O	O	1021
treatment	NOUN	O	O	1021
markedly	ADV	O	O	1021
suppressed	VERB	O	O	1021
puromycin aminonucleoside	NOUN	O	Chemical	1021
-	PUNCT	O	O	1021
induced	VERB	O	O	1021
apoptosis	NOUN	O	O	1021
of	ADP	O	O	1021
renal	ADJ	O	O	1021
tubular	ADJ	O	O	1021
epithelial	ADJ	O	O	1021
cells	NOUN	O	O	1021
.	PUNCT	O	O	1021
Furthermore	ADV	O	O	1022
,	PUNCT	O	O	1022
puromycin aminonucleoside	NOUN	O	Chemical	1022
-	PUNCT	O	O	1022
induced	VERB	O	O	1022
increases	VERB	O	O	1022
in	ADP	O	O	1022
renal	ADJ	O	O	1022
cytokine	NOUN	O	O	1022
content	NOUN	O	O	1022
were	AUX	O	O	1022
also	ADV	O	O	1022
decreased	VERB	O	O	1022
.	PUNCT	O	O	1022
These	PRON	O	O	1023
findings	NOUN	O	O	1023
suggest	VERB	O	O	1023
that	SCONJ	O	O	1023
thrombin	PROPN	O	O	1023
plays	VERB	O	O	1023
an	PRON	O	O	1023
important	ADJ	O	O	1023
role	NOUN	O	O	1023
in	ADP	O	O	1023
the	PRON	O	O	1023
pathogenesis	NOUN	O	O	1023
of	ADP	O	O	1023
puromycin aminonucleoside	NOUN	O	Chemical	1023
-	PUNCT	O	O	1023
induced	VERB	O	O	1023
nephrotic syndrome	NOUN	O	Disease	1023
.	PUNCT	O	O	1023
Treatment	NOUN	O	O	1024
with	ADP	O	O	1024
antithrombin	PROPN	O	O	1024
may	AUX	O	O	1024
be	AUX	O	O	1024
clinically	ADV	O	O	1024
effective	ADJ	O	O	1024
in	ADP	O	O	1024
patients	NOUN	O	O	1024
with	ADP	O	O	1024
nephrotic syndrome	NOUN	O	Disease	1024
.	PUNCT	O	O	1024
Reverse	VERB	O	O	1027
or	CCONJ	O	O	1027
inverted	VERB	O	O	1027
left	VERB	O	O	1027
ventricular	ADJ	O	O	1027
apical ballooning	NOUN	O	Disease	1027
syndrome	NOUN	O	O	1027
(	PUNCT	O	O	1027
reverse	VERB	O	O	1027
Takotsubo cardiomyopathy	NOUN	O	Disease	1027
)	PUNCT	O	O	1027
in	ADP	O	O	1027
a	PRON	O	O	1027
young	ADJ	O	O	1027
woman	NOUN	O	O	1027
in	ADP	O	O	1027
the	PRON	O	O	1027
setting	VERB	O	O	1027
of	ADP	O	O	1027
amphetamine	NOUN	O	Chemical	1027
use	VERB	O	O	1027
.	PUNCT	O	O	1027
Transient	ADJ	O	O	1028
left	VERB	O	O	1028
ventricular	ADJ	O	O	1028
apical ballooning	NOUN	O	Disease	1028
syndrome	NOUN	O	O	1028
was	AUX	O	O	1028
first	ADV	O	O	1028
described	VERB	O	O	1028
in	ADP	O	O	1028
Japan	PROPN	O	O	1028
as	ADP	O	O	1028
""""	PUNCT	O	O	1028
Takotsubo cardiomyopathy	NOUN	O	Disease	1028
.	PUNCT	O	O	1028
One	NUM	O	O	1029
of	ADP	O	O	1029
the	PRON	O	O	1029
rarest	VERB	O	O	1029
is	AUX	O	O	1029
the	PRON	O	O	1029
reverse	VERB	O	O	1029
type	NOUN	O	O	1029
of	ADP	O	O	1029
this	PRON	O	O	1029
syndrome	NOUN	O	O	1029
,	PUNCT	O	O	1029
with	ADP	O	O	1029
hyperdynamic	PROPN	O	O	1029
apex	PROPN	O	O	1029
and	CCONJ	O	O	1029
complete	VERB	O	O	1029
akinesia	NOUN	O	Disease	1029
of	ADP	O	O	1029
the	PRON	O	O	1029
base	PROPN	O	O	1029
(	PUNCT	O	O	1029
as	ADP	O	O	1029
opposed	VERB	O	O	1029
to	PART	O	O	1029
the	PRON	O	O	1029
classic	ADJ	O	O	1029
apical ballooning	NOUN	O	Disease	1029
)	PUNCT	O	O	1029
.	PUNCT	O	O	1029
In	ADP	O	O	1030
this	PRON	O	O	1030
article	NOUN	O	O	1030
,	PUNCT	O	O	1030
we	PRON	O	O	1030
report	VERB	O	O	1030
an	PRON	O	O	1030
interesting	ADJ	O	O	1030
case	NOUN	O	O	1030
of	ADP	O	O	1030
a	PRON	O	O	1030
young	ADJ	O	O	1030
woman	NOUN	O	O	1030
who	PRON	O	O	1030
presented	VERB	O	O	1030
with	ADP	O	O	1030
this	PRON	O	O	1030
rare	ADJ	O	O	1030
type	NOUN	O	O	1030
of	ADP	O	O	1030
reverse	VERB	O	O	1030
apical ballooning	NOUN	O	Disease	1030
syndrome	NOUN	O	O	1030
occurring	VERB	O	O	1030
after	ADP	O	O	1030
amphetamine	NOUN	O	Chemical	1030
use	VERB	O	O	1030
.	PUNCT	O	O	1030
Attenuated	VERB	O	O	1033
disruption	NOUN	O	O	1033
of	ADP	O	O	1033
prepulse	NOUN	O	O	1033
inhibition	NOUN	O	O	1033
by	ADP	O	O	1033
dopaminergic	ADJ	O	O	1033
stimulation	NOUN	O	O	1033
after	ADP	O	O	1033
maternal	ADJ	O	O	1033
deprivation	NOUN	O	O	1033
and	CCONJ	O	O	1033
adolescent	ADJ	O	O	1033
corticosterone	NOUN	O	Chemical	1033
treatment	NOUN	O	O	1033
in	ADP	O	O	1033
rats	NOUN	O	O	1033
.	PUNCT	O	O	1033
The	PRON	O	O	1034
development	NOUN	O	O	1034
of	ADP	O	O	1034
schizophrenia	PROPN	O	Disease	1034
may	AUX	O	O	1034
include	VERB	O	O	1034
an	PRON	O	O	1034
early	ADV	O	O	1034
neurodevelopmental	ADJ	O	O	1034
stress	NOUN	O	O	1034
component	NOUN	O	O	1034
which	PRON	O	O	1034
increases	VERB	O	O	1034
vulnerability	NOUN	O	O	1034
to	PART	O	O	1034
later	ADV	O	O	1034
stressful	ADJ	O	O	1034
life	NOUN	O	O	1034
events	NOUN	O	O	1034
,	PUNCT	O	O	1034
in	ADP	O	O	1034
combination	NOUN	O	O	1034
leading	VERB	O	O	1034
to	PART	O	O	1034
overt	ADJ	O	O	1034
disease	PROPN	O	O	1034
.	PUNCT	O	O	1034
We	PRON	O	O	1035
investigated	VERB	O	O	1035
the	PRON	O	O	1035
effect	VERB	O	O	1035
of	ADP	O	O	1035
an	PRON	O	O	1035
early	ADV	O	O	1035
stress	NOUN	O	O	1035
,	PUNCT	O	O	1035
in	ADP	O	O	1035
the	PRON	O	O	1035
form	NOUN	O	O	1035
of	ADP	O	O	1035
maternal	ADJ	O	O	1035
deprivation	NOUN	O	O	1035
,	PUNCT	O	O	1035
combined	VERB	O	O	1035
with	ADP	O	O	1035
a	PRON	O	O	1035
later	ADV	O	O	1035
stress	NOUN	O	O	1035
,	PUNCT	O	O	1035
simulated	VERB	O	O	1035
by	ADP	O	O	1035
chronic	ADJ	O	O	1035
periadolescent	NOUN	O	O	1035
corticosterone	NOUN	O	Chemical	1035
treatment	NOUN	O	O	1035
,	PUNCT	O	O	1035
on	ADP	O	O	1035
behaviour	NOUN	O	O	1035
in	ADP	O	O	1035
rats	NOUN	O	O	1035
.	PUNCT	O	O	1035
Acute	PROPN	O	O	1036
treatment	NOUN	O	O	1036
with	ADP	O	O	1036
apomorphine	PROPN	O	Chemical	1036
caused	VERB	O	O	1036
disruption	NOUN	O	O	1036
of	ADP	O	O	1036
prepulse	NOUN	O	O	1036
inhibition	NOUN	O	O	1036
(	PUNCT	O	O	1036
PPI	PROPN	O	O	1036
)	PUNCT	O	O	1036
in	ADP	O	O	1036
controls	VERB	O	O	1036
and	CCONJ	O	O	1036
in	ADP	O	O	1036
rats	NOUN	O	O	1036
that	SCONJ	O	O	1036
had	VERB	O	O	1036
undergone	VERB	O	O	1036
either	ADV	O	O	1036
maternal	ADJ	O	O	1036
deprivation	NOUN	O	O	1036
or	CCONJ	O	O	1036
corticosterone	NOUN	O	Chemical	1036
treatment	NOUN	O	O	1036
,	PUNCT	O	O	1036
but	CCONJ	O	O	1036
was	AUX	O	O	1036
surprisingly	ADV	O	O	1036
absent	ADJ	O	O	1036
in	ADP	O	O	1036
rats	NOUN	O	O	1036
that	SCONJ	O	O	1036
had	VERB	O	O	1036
undergone	VERB	O	O	1036
the	PRON	O	O	1036
combined	VERB	O	O	1036
early	ADV	O	O	1036
and	CCONJ	O	O	1036
late	ADV	O	O	1036
stress	NOUN	O	O	1036
.	PUNCT	O	O	1036
Amphetamine	NOUN	O	Chemical	1037
treatment	NOUN	O	O	1037
significantly	ADV	O	O	1037
disrupted	VERB	O	O	1037
PPI	PROPN	O	O	1037
in	ADP	O	O	1037
both	PRON	O	O	1037
non	ADJ	O	O	1037
-	PUNCT	O	O	1037
deprived	VERB	O	O	1037
groups	NOUN	O	O	1037
,	PUNCT	O	O	1037
but	CCONJ	O	O	1037
was	AUX	O	O	1037
absent	ADJ	O	O	1037
in	ADP	O	O	1037
both	PRON	O	O	1037
maternally	ADV	O	O	1037
deprived	VERB	O	O	1037
groups	NOUN	O	O	1037
.	PUNCT	O	O	1037
The	PRON	O	O	1038
serotonin-1A	NOUN	O	O	1038
receptor	NOUN	O	O	1038
agonist	NOUN	O	O	1038
,	PUNCT	O	O	1038
8-OH	NOUN	O	O	1038
-	PUNCT	O	O	1038
DPAT	PROPN	O	O	1038
,	PUNCT	O	O	1038
induced	VERB	O	O	1038
a	PRON	O	O	1038
significant	ADJ	O	O	1038
disruption	NOUN	O	O	1038
of	ADP	O	O	1038
PPI	PROPN	O	O	1038
in	ADP	O	O	1038
all	PRON	O	O	1038
groups	NOUN	O	O	1038
.	PUNCT	O	O	1038
Amphetamine	NOUN	O	Chemical	1039
-	PUNCT	O	O	1039
induced	VERB	O	O	1039
locomotor hyperactivity	NOUN	O	Disease	1039
was	AUX	O	O	1039
similar	ADJ	O	O	1039
in	ADP	O	O	1039
all	PRON	O	O	1039
groups	NOUN	O	O	1039
.	PUNCT	O	O	1039
These	PRON	O	O	1040
results	VERB	O	O	1040
show	VERB	O	O	1040
an	PRON	O	O	1040
inhibitory	ADJ	O	O	1040
interaction	NOUN	O	O	1040
of	ADP	O	O	1040
early	ADV	O	O	1040
stress	NOUN	O	O	1040
,	PUNCT	O	O	1040
caused	VERB	O	O	1040
by	ADP	O	O	1040
maternal	ADJ	O	O	1040
deprivation	NOUN	O	O	1040
,	PUNCT	O	O	1040
combined	VERB	O	O	1040
with	ADP	O	O	1040
'	PUNCT	O	O	1040
adolescent	ADJ	O	O	1040
'	PUNCT	O	O	1040
stress	NOUN	O	O	1040
,	PUNCT	O	O	1040
simulated	VERB	O	O	1040
by	ADP	O	O	1040
corticosterone	NOUN	O	Chemical	1040
treatment	NOUN	O	O	1040
,	PUNCT	O	O	1040
on	ADP	O	O	1040
dopaminergic	ADJ	O	O	1040
regulation	NOUN	O	O	1040
of	ADP	O	O	1040
PPI	PROPN	O	O	1040
.	PUNCT	O	O	1040
The	PRON	O	O	1041
altered	VERB	O	O	1041
effects	NOUN	O	O	1041
of	ADP	O	O	1041
apomorphine	PROPN	O	Chemical	1041
and	CCONJ	O	O	1041
amphetamine	NOUN	O	Chemical	1041
could	AUX	O	O	1041
indicate	VERB	O	O	1041
differential	ADJ	O	O	1041
changes	VERB	O	O	1041
in	ADP	O	O	1041
dopamine	NOUN	O	Chemical	1041
receptor	NOUN	O	O	1041
signalling	VERB	O	O	1041
leading	VERB	O	O	1041
to	PART	O	O	1041
functional	ADJ	O	O	1041
desensitisation	NOUN	O	O	1041
,	PUNCT	O	O	1041
or	CCONJ	O	O	1041
altered	VERB	O	O	1041
modulation	NOUN	O	O	1041
of	ADP	O	O	1041
sensory	ADJ	O	O	1041
gating	NOUN	O	O	1041
in	ADP	O	O	1041
the	PRON	O	O	1041
nucleus	PROPN	O	O	1041
accumbens	NOUN	O	O	1041
by	ADP	O	O	1041
limbic	PROPN	O	O	1041
structures	NOUN	O	O	1041
such	ADJ	O	O	1041
as	ADP	O	O	1041
the	PRON	O	O	1041
hippocampus	NOUN	O	O	1041
.	PUNCT	O	O	1041
Peripheral	ADJ	O	O	1044
iron dextran	NOUN	O	Chemical	1044
induced	VERB	O	O	1044
degeneration of dopaminergic neurons	NOUN	O	Disease	1044
in	ADP	O	O	1044
rat	NOUN	O	O	1044
substantia	X	O	O	1044
nigra	NOUN	O	O	1044
.	PUNCT	O	O	1044
Iron	NOUN	O	Chemical	1045
accumulation	NOUN	O	O	1045
is	AUX	O	O	1045
considered	VERB	O	O	1045
to	PART	O	O	1045
be	AUX	O	O	1045
involved	VERB	O	O	1045
in	ADP	O	O	1045
the	PRON	O	O	1045
pathogenesis	NOUN	O	O	1045
of	ADP	O	O	1045
Parkinson	NOUN	O	O	1045
's	AUX	O	O	1045
disease	PROPN	O	O	1045
.	PUNCT	O	O	1045
To	PART	O	O	1046
demonstrate	VERB	O	O	1046
the	PRON	O	O	1046
relationship	NOUN	O	O	1046
between	ADP	O	O	1046
peripheral	ADJ	O	O	1046
iron	NOUN	O	Chemical	1046
overload	NOUN	O	O	1046
and	CCONJ	O	O	1046
dopaminergic	ADJ	O	O	1046
neuron	PROPN	O	O	1046
loss	NOUN	O	O	1046
in	ADP	O	O	1046
rat	NOUN	O	O	1046
substantia	X	O	O	1046
nigra	NOUN	O	O	1046
(	PUNCT	O	O	1046
SN	NOUN	O	O	1046
)	PUNCT	O	O	1046
,	PUNCT	O	O	1046
in	ADP	O	O	1046
the	PRON	O	O	1046
present	NOUN	O	O	1046
study	VERB	O	O	1046
we	PRON	O	O	1046
used	VERB	O	O	1046
fast	ADV	O	O	1046
cyclic	PROPN	O	O	1046
voltammetry	NOUN	O	O	1046
,	PUNCT	O	O	1046
tyrosine	NOUN	O	Chemical	1046
hydroxylase	NOUN	O	O	1046
(	PUNCT	O	O	1046
TH	PROPN	O	O	1046
)	PUNCT	O	O	1046
immunohistochemistry	NOUN	O	O	1047
,	PUNCT	O	O	1047
Perls	NOUN	O	O	1047
'	PUNCT	O	O	1047
iron	NOUN	O	Chemical	1047
staining	VERB	O	O	1047
,	PUNCT	O	O	1047
and	CCONJ	O	O	1047
high	ADJ	O	O	1047
performance	NOUN	O	O	1047
liquid	ADJ	O	O	1047
chromatography	NOUN	O	O	1047
-	PUNCT	O	O	1047
electrochemical	ADJ	O	O	1047
detection	NOUN	O	O	1047
to	PART	O	O	1047
study	VERB	O	O	1047
the	PRON	O	O	1047
degeneration of dopaminergic neurons	NOUN	O	Disease	1047
and	CCONJ	O	O	1047
increased	VERB	O	O	1047
iron	NOUN	O	Chemical	1047
content	NOUN	O	O	1047
in	ADP	O	O	1047
the	PRON	O	O	1047
SN	NOUN	O	O	1047
of	ADP	O	O	1047
iron dextran	NOUN	O	Chemical	1047
overloaded	VERB	O	O	1047
animals	NOUN	O	O	1047
.	PUNCT	O	O	1047
The	PRON	O	O	1048
findings	NOUN	O	O	1048
showed	VERB	O	O	1048
that	SCONJ	O	O	1048
peripheral	ADJ	O	O	1048
iron dextran	NOUN	O	Chemical	1048
overload	NOUN	O	O	1048
increased	VERB	O	O	1048
the	PRON	O	O	1048
iron	NOUN	O	Chemical	1048
staining	VERB	O	O	1048
positive	ADJ	O	O	1048
cells	NOUN	O	O	1048
and	CCONJ	O	O	1048
reduced	VERB	O	O	1048
the	PRON	O	O	1048
number	NOUN	O	O	1048
of	ADP	O	O	1048
TH	PROPN	O	O	1048
-	PUNCT	O	O	1048
immunoreactive	ADP	O	O	1048
neurons	NOUN	O	O	1048
in	ADP	O	O	1048
the	PRON	O	O	1048
SN	NOUN	O	O	1048
.	PUNCT	O	O	1048
As	ADP	O	O	1049
a	PRON	O	O	1049
result	VERB	O	O	1049
,	PUNCT	O	O	1049
dopamine	NOUN	O	Chemical	1049
release	NOUN	O	O	1049
and	CCONJ	O	O	1049
content	NOUN	O	O	1049
,	PUNCT	O	O	1049
as	ADP	O	O	1049
well	ADV	O	O	1049
as	ADP	O	O	1049
its	PRON	O	O	1049
metabolites	VERB	O	O	1049
contents	NOUN	O	O	1049
were	AUX	O	O	1049
decreased	VERB	O	O	1049
in	ADP	O	O	1049
caudate	ADJ	O	O	1049
putamen	NOUN	O	O	1049
.	PUNCT	O	O	1049
These	PRON	O	O	1050
results	VERB	O	O	1050
suggest	VERB	O	O	1050
that	SCONJ	O	O	1050
peripheral	ADJ	O	O	1050
iron dextran	NOUN	O	Chemical	1050
can	AUX	O	O	1050
increase	VERB	O	O	1050
the	PRON	O	O	1050
iron	NOUN	O	Chemical	1050
level	VERB	O	O	1050
in	ADP	O	O	1050
the	PRON	O	O	1050
SN	NOUN	O	O	1050
,	PUNCT	O	O	1050
where	SCONJ	O	O	1050
excessive	ADJ	O	O	1050
iron	NOUN	O	Chemical	1050
causes	VERB	O	O	1050
the	PRON	O	O	1050
degeneration of dopaminergic neurons	NOUN	O	Disease	1050
.	PUNCT	O	O	1050
The	PRON	O	O	1051
chronic	ADJ	O	O	1051
iron	NOUN	O	Chemical	1051
overload	NOUN	O	O	1051
may	AUX	O	O	1051
be	AUX	O	O	1051
more	ADJ	O	O	1051
destructive	ADJ	O	O	1051
to	PART	O	O	1051
dopaminergic	ADJ	O	O	1051
neurons	NOUN	O	O	1051
than	ADP	O	O	1051
the	PRON	O	O	1051
acute	ADJ	O	O	1051
iron	NOUN	O	Chemical	1051
overload	NOUN	O	O	1051
.	PUNCT	O	O	1051
Warfarin	PROPN	O	Chemical	1054
-	PUNCT	O	O	1054
induced	VERB	O	O	1054
leukocytoclastic vasculitis	NOUN	O	Disease	1054
.	PUNCT	O	O	1054
Skin	NOUN	O	O	1055
reactions	NOUN	O	O	1055
associated	VERB	O	O	1055
with	ADP	O	O	1055
oral	ADJ	O	O	1055
coumarin	NOUN	O	Chemical	1055
-	PUNCT	O	O	1055
derived	VERB	O	O	1055
anticoagulants	NOUN	O	O	1055
are	AUX	O	O	1055
an	PRON	O	O	1055
uncommon	ADJ	O	O	1055
occurrence	NOUN	O	O	1055
.	PUNCT	O	O	1055
Leukocytoclastic vasculitis	NOUN	O	Disease	1056
(	PUNCT	O	O	1056
LV	PROPN	O	Disease	1056
)	PUNCT	O	O	1056
is	AUX	O	O	1056
primarily	ADV	O	O	1056
a	PRON	O	O	1056
cutaneous small vessel vasculitis	NOUN	O	Disease	1056
,	PUNCT	O	O	1056
though	SCONJ	O	O	1056
systemic	ADJ	O	O	1056
involvement	NOUN	O	O	1056
may	AUX	O	O	1056
be	AUX	O	O	1056
encountered	VERB	O	O	1056
.	PUNCT	O	O	1056
We	PRON	O	O	1057
report	VERB	O	O	1057
4	NUM	O	O	1057
patients	NOUN	O	O	1057
with	ADP	O	O	1057
late	ADV	O	O	1057
-	PUNCT	O	O	1057
onset	VERB	O	O	1057
LV	PROPN	O	Disease	1057
probably	ADV	O	O	1057
due	ADJ	O	O	1057
to	PART	O	O	1057
warfarin	VERB	O	Chemical	1057
.	PUNCT	O	O	1057
All	PRON	O	O	1058
4	NUM	O	O	1058
patients	NOUN	O	O	1058
presented	VERB	O	O	1058
with	ADP	O	O	1058
skin eruptions	NOUN	O	Disease	1058
that	SCONJ	O	O	1058
developed	VERB	O	O	1058
after	ADP	O	O	1058
receiving	VERB	O	O	1058
warfarin	VERB	O	Chemical	1058
for	ADP	O	O	1058
several	ADJ	O	O	1058
years	NOUN	O	O	1058
.	PUNCT	O	O	1058
The	PRON	O	O	1059
results	VERB	O	O	1059
of	ADP	O	O	1059
skin lesion	NOUN	O	Disease	1059
biopsies	NOUN	O	O	1059
were	AUX	O	O	1059
available	ADJ	O	O	1059
in	ADP	O	O	1059
3	X	O	O	1059
patients	NOUN	O	O	1059
,	PUNCT	O	O	1059
confirming	VERB	O	O	1059
LV Cutaneous lesions	NOUN	O	Disease	1059
resolved	VERB	O	O	1059
in	ADP	O	O	1059
all	PRON	O	O	1059
patients	NOUN	O	O	1059
after	ADP	O	O	1059
warfarin	VERB	O	Chemical	1059
was	AUX	O	O	1059
discontinued	VERB	O	O	1059
.	PUNCT	O	O	1059
In	ADP	O	O	1060
2	X	O	O	1060
of	ADP	O	O	1060
the	PRON	O	O	1060
4	NUM	O	O	1060
patients	NOUN	O	O	1060
,	PUNCT	O	O	1060
rechallenge	VERB	O	O	1060
with	ADP	O	O	1060
warfarin	VERB	O	Chemical	1060
led	VERB	O	O	1060
to	PART	O	O	1060
recurrence	NOUN	O	O	1060
of	ADP	O	O	1060
the	PRON	O	O	1060
lesions	NOUN	O	O	1060
.	PUNCT	O	O	1060
LV	PROPN	O	Disease	1061
may	AUX	O	O	1061
be	AUX	O	O	1061
a	PRON	O	O	1061
late	ADV	O	O	1061
-	PUNCT	O	O	1061
onset	VERB	O	O	1061
adverse	ADJ	O	O	1061
reaction	NOUN	O	O	1061
associated	VERB	O	O	1061
with	ADP	O	O	1061
warfarin	VERB	O	Chemical	1061
therapy	NOUN	O	O	1061
.	PUNCT	O	O	1061
The	PRON	O	O	1064
activation	NOUN	O	O	1064
of	ADP	O	O	1064
spinal	NOUN	O	O	1064
N	NUM	O	O	1064
-	PUNCT	O	O	1064
methyl	NOUN	O	O	1064
-	PUNCT	O	O	1064
D	NOUN	O	O	1064
-	PUNCT	O	O	1064
aspartate	NOUN	O	Chemical	1064
receptors	NOUN	O	O	1064
may	AUX	O	O	1064
contribute	VERB	O	O	1064
to	PART	O	O	1064
degeneration	NOUN	O	O	1064
of	ADP	O	O	1064
spinal	NOUN	O	O	1064
motor	NOUN	O	O	1064
neurons	NOUN	O	O	1064
induced	VERB	O	O	1064
by	ADP	O	O	1064
neuraxial	ADJ	O	O	1064
morphine	NOUN	O	Chemical	1064
after	ADP	O	O	1064
a	PRON	O	O	1064
noninjurious	ADJ	O	O	1064
interval	NOUN	O	O	1064
of	ADP	O	O	1064
spinal cord ischemia	NOUN	O	Disease	1064
.	PUNCT	O	O	1064
We	PRON	O	O	1065
investigated	VERB	O	O	1065
the	PRON	O	O	1065
relationship	NOUN	O	O	1065
between	ADP	O	O	1065
the	PRON	O	O	1065
degeneration	NOUN	O	O	1065
of	ADP	O	O	1065
spinal	NOUN	O	O	1065
motor	NOUN	O	O	1065
neurons	NOUN	O	O	1065
and	CCONJ	O	O	1065
activation	NOUN	O	O	1065
of	ADP	O	O	1065
N	NUM	O	O	1065
-	PUNCT	O	O	1065
methyl	NOUN	O	O	1065
-	PUNCT	O	O	1065
d	X	O	O	1065
-	PUNCT	O	O	1065
aspartate	NOUN	O	Chemical	1065
(	PUNCT	O	O	1065
NMDA	PROPN	O	Chemical	1065
)	PUNCT	O	O	1065
receptors	NOUN	O	O	1065
after	ADP	O	O	1065
neuraxial	ADJ	O	O	1065
morphine	NOUN	O	Chemical	1065
following	VERB	O	O	1065
a	PRON	O	O	1065
noninjurious	ADJ	O	O	1065
interval	NOUN	O	O	1065
of	ADP	O	O	1065
aortic occlusion	NOUN	O	Disease	1065
in	ADP	O	O	1065
rats	NOUN	O	O	1065
.	PUNCT	O	O	1065
Spinal cord ischemia	NOUN	O	Disease	1066
was	AUX	O	O	1066
induced	VERB	O	O	1066
by	ADP	O	O	1066
aortic occlusion	NOUN	O	Disease	1066
for	ADP	O	O	1066
6	NUM	O	O	1066
min	NOUN	O	O	1066
with	ADP	O	O	1066
a	PRON	O	O	1066
balloon	NOUN	O	O	1066
catheter	VERB	O	O	1066
.	PUNCT	O	O	1066
In	ADP	O	O	1067
a	PRON	O	O	1067
microdialysis	NOUN	O	O	1067
study	VERB	O	O	1067
,	PUNCT	O	O	1067
10	NUM	O	O	1067
muL	NOUN	O	O	1067
of	ADP	O	O	1067
saline	NOUN	O	O	1067
(	PUNCT	O	O	1067
group	NOUN	O	O	1067
C	NOUN	O	O	1067
;	PUNCT	O	O	1067
n	CCONJ	O	O	1067
=	PUNCT	O	O	1067
8)	NUM	O	O	1067
or	CCONJ	O	O	1067
30	NUM	O	O	1067
mug	NOUN	O	O	1067
of	ADP	O	O	1067
morphine	NOUN	O	Chemical	1067
(	PUNCT	O	O	1067
group	NOUN	O	O	1067
M	NOUN	O	Chemical	1067
;	PUNCT	O	O	1067
n	CCONJ	O	O	1067
=	PUNCT	O	O	1068
8)	NUM	O	O	1068
was	AUX	O	O	1068
injected	VERB	O	O	1068
intrathecally	ADV	O	O	1068
(	PUNCT	O	O	1068
IT	PRON	O	O	1068
)	PUNCT	O	O	1068
0.5	NUM	O	O	1068
h	X	O	O	1068
after	ADP	O	O	1068
reflow	NOUN	O	O	1068
,	PUNCT	O	O	1068
and	CCONJ	O	O	1068
30	NUM	O	O	1068
mug	NOUN	O	O	1068
of	ADP	O	O	1068
morphine	NOUN	O	Chemical	1068
(	PUNCT	O	O	1068
group	NOUN	O	O	1068
SM	NOUN	O	O	1068
;	PUNCT	O	O	1068
Second	ADJ	O	O	1069
,	PUNCT	O	O	1069
we	PRON	O	O	1069
investigated	VERB	O	O	1069
the	PRON	O	O	1069
effect	VERB	O	O	1069
of	ADP	O	O	1069
IT	PRON	O	O	1069
MK-801	PROPN	O	Chemical	1069
(	PUNCT	O	O	1069
30	NUM	O	O	1069
mug	NOUN	O	O	1069
)	PUNCT	O	O	1069
on	ADP	O	O	1069
the	PRON	O	O	1069
histopathologic	VERB	O	O	1069
changes	VERB	O	O	1069
in	ADP	O	O	1069
the	PRON	O	O	1069
spinal	NOUN	O	O	1069
cord	NOUN	O	O	1069
after	ADP	O	O	1069
morphine	NOUN	O	Chemical	1069
-	PUNCT	O	O	1069
induced	VERB	O	O	1069
spastic paraparesis	NOUN	O	Disease	1069
.	PUNCT	O	O	1069
After	ADP	O	O	1070
IT	PRON	O	O	1070
morphine	NOUN	O	Chemical	1070
,	PUNCT	O	O	1070
the	PRON	O	O	1070
cerebrospinal	ADJ	O	O	1070
fluid	NOUN	O	O	1070
(	PUNCT	O	O	1070
CSF	PROPN	O	O	1070
)	PUNCT	O	O	1070
glutamate	NOUN	O	Chemical	1070
concentration	NOUN	O	O	1070
was	AUX	O	O	1070
increased	VERB	O	O	1070
in	ADP	O	O	1070
group	NOUN	O	O	1070
M	NOUN	O	Chemical	1070
relative	ADJ	O	O	1070
to	PART	O	O	1070
both	PRON	O	O	1070
baseline	VERB	O	O	1070
and	CCONJ	O	O	1070
group	NOUN	O	O	1070
C	NOUN	O	O	1070
(	PUNCT	O	O	1070
P	NOUN	O	Chemical	1070
<	X	O	O	1070
0.05	NUM	O	O	1070
)	PUNCT	O	O	1070
.	PUNCT	O	O	1070
IT	PRON	O	O	1071
MK-801	PROPN	O	Chemical	1071
significantly	ADV	O	O	1071
reduced	VERB	O	O	1071
the	PRON	O	O	1071
number	NOUN	O	O	1071
of	ADP	O	O	1071
dark	ADJ	O	O	1071
-	PUNCT	O	O	1071
stained	VERB	O	O	1071
alpha	PROPN	O	O	1071
-	PUNCT	O	O	1071
motoneurons	NOUN	O	O	1071
after	ADP	O	O	1071
morphine	NOUN	O	Chemical	1071
-	PUNCT	O	O	1071
induced	VERB	O	O	1071
spastic paraparesis	NOUN	O	Disease	1071
compared	VERB	O	O	1071
with	ADP	O	O	1071
the	PRON	O	O	1071
saline	NOUN	O	O	1071
group	NOUN	O	O	1071
.	PUNCT	O	O	1071
These	PRON	O	O	1072
data	NOUN	O	O	1072
indicate	VERB	O	O	1072
that	SCONJ	O	O	1072
IT	PRON	O	O	1072
morphine	NOUN	O	Chemical	1072
induces	VERB	O	O	1072
spastic paraparesis	NOUN	O	Disease	1072
with	ADP	O	O	1072
a	PRON	O	O	1072
concomitant	ADJ	O	O	1072
increase	VERB	O	O	1072
in	ADP	O	O	1072
CSF	PROPN	O	O	1072
glutamate	NOUN	O	Chemical	1072
,	PUNCT	O	O	1072
which	PRON	O	O	1072
is	AUX	O	O	1072
involved	VERB	O	O	1072
in	ADP	O	O	1072
NMDA	PROPN	O	Chemical	1072
receptor	NOUN	O	O	1072
activation	NOUN	O	O	1072
.	PUNCT	O	O	1072
We	PRON	O	O	1073
suggest	VERB	O	O	1073
that	SCONJ	O	O	1073
opioids	NOUN	O	O	1073
may	AUX	O	O	1073
be	AUX	O	O	1073
neurotoxic	ADJ	O	Disease	1073
in	ADP	O	O	1073
the	PRON	O	O	1073
setting	VERB	O	O	1073
of	ADP	O	O	1073
spinal cord ischemia	NOUN	O	Disease	1073
via	ADP	O	O	1073
NMDA	PROPN	O	Chemical	1073
receptor	NOUN	O	O	1073
activation	NOUN	O	O	1073
.	PUNCT	O	O	1073
Reduced	VERB	O	O	1076
sodium	NOUN	O	Chemical	1076
channel	PROPN	O	O	1076
density	NOUN	O	O	1076
,	PUNCT	O	O	1076
altered	VERB	O	O	1076
voltage	NOUN	O	O	1076
dependence	NOUN	O	O	1076
of	ADP	O	O	1076
inactivation	NOUN	O	O	1076
,	PUNCT	O	O	1076
and	CCONJ	O	O	1076
increased	VERB	O	O	1076
susceptibility	NOUN	O	O	1076
to	PART	O	O	1076
seizures	NOUN	O	Disease	1076
in	ADP	O	O	1076
mice	NOUN	O	O	1076
lacking	VERB	O	O	1076
sodium	NOUN	O	Chemical	1076
channel	PROPN	O	O	1076
beta	NOUN	O	O	1076
2-subunits	NOUN	O	O	1076
.	PUNCT	O	O	1076
Sodium	NOUN	O	Chemical	1077
channel	PROPN	O	O	1077
beta	NOUN	O	O	1077
-	PUNCT	O	O	1077
subunits	NOUN	O	O	1077
modulate	VERB	O	O	1077
channel	PROPN	O	O	1077
gating	NOUN	O	O	1077
,	PUNCT	O	O	1077
assembly	PROPN	O	O	1077
,	PUNCT	O	O	1077
and	CCONJ	O	O	1077
cell	NOUN	O	O	1077
surface	NOUN	O	O	1077
expression	NOUN	O	O	1077
in	ADP	O	O	1077
heterologous	ADJ	O	O	1077
cell	NOUN	O	O	1077
systems	NOUN	O	O	1077
.	PUNCT	O	O	1077
We	PRON	O	O	1078
generated	VERB	O	O	1078
beta2(-/-	NUM	O	O	1078
)	PUNCT	O	O	1078
mice	NOUN	O	O	1078
to	PART	O	O	1078
investigate	VERB	O	O	1078
the	PRON	O	O	1078
role	NOUN	O	O	1078
of	ADP	O	O	1078
beta2	NOUN	O	O	1078
in	ADP	O	O	1078
control	VERB	O	O	1078
of	ADP	O	O	1078
sodium	NOUN	O	Chemical	1078
channel	PROPN	O	O	1078
density	NOUN	O	O	1078
,	PUNCT	O	O	1078
localization	NOUN	O	O	1078
,	PUNCT	O	O	1078
and	CCONJ	O	O	1078
function	NOUN	O	O	1078
in	ADP	O	O	1078
neurons	NOUN	O	O	1078
in	ADP	O	O	1078
vivo	VERB	O	O	1078
.	PUNCT	O	O	1078
Measurements	NOUN	O	O	1079
of	ADP	O	O	1079
[	X	O	O	1079
(	PUNCT	O	O	1079
3)H]saxitoxin	NUM	O	O	1079
(	PUNCT	O	O	1079
STX	PROPN	O	Chemical	1079
)	PUNCT	O	O	1079
binding	VERB	O	O	1079
showed	VERB	O	O	1079
a	PRON	O	O	1079
significant	ADJ	O	O	1079
reduction	NOUN	O	O	1079
in	ADP	O	O	1079
the	PRON	O	O	1079
level	VERB	O	O	1079
of	ADP	O	O	1079
plasma	NOUN	O	O	1079
membrane	NOUN	O	O	1079
sodium	NOUN	O	Chemical	1079
channels	NOUN	O	O	1079
in	ADP	O	O	1079
beta2(-/-	NUM	O	O	1079
)	PUNCT	O	O	1079
neurons	NOUN	O	O	1079
.	PUNCT	O	O	1079
The	PRON	O	O	1080
loss	NOUN	O	O	1080
of	ADP	O	O	1080
beta2	NOUN	O	O	1080
resulted	VERB	O	O	1080
in	ADP	O	O	1080
negative	ADJ	O	O	1080
shifts	NOUN	O	O	1080
in	ADP	O	O	1080
the	PRON	O	O	1080
voltage	NOUN	O	O	1080
dependence	NOUN	O	O	1080
of	ADP	O	O	1080
inactivation	NOUN	O	O	1080
as	ADP	O	O	1080
well	ADV	O	O	1080
as	ADP	O	O	1080
significant	ADJ	O	O	1080
decreases	VERB	O	O	1080
in	ADP	O	O	1080
sodium	NOUN	O	Chemical	1080
current	ADJ	O	O	1080
density	NOUN	O	O	1080
in	ADP	O	O	1080
acutely	ADV	O	O	1080
dissociated	VERB	O	O	1080
hippocampal	NOUN	O	O	1080
neurons	NOUN	O	O	1080
.	PUNCT	O	O	1080
The	PRON	O	O	1081
integral	ADJ	O	O	1081
of	ADP	O	O	1081
the	PRON	O	O	1081
compound	NOUN	O	O	1081
action	NOUN	O	O	1081
potential	ADJ	O	O	1081
in	ADP	O	O	1081
optic	NOUN	O	O	1081
nerve	NOUN	O	O	1081
was	AUX	O	O	1081
significantly	ADV	O	O	1081
reduced	VERB	O	O	1081
,	PUNCT	O	O	1081
and	CCONJ	O	O	1081
the	PRON	O	O	1081
threshold	NOUN	O	O	1081
for	ADP	O	O	1081
action	NOUN	O	O	1081
potential	ADJ	O	O	1081
generation	NOUN	O	O	1081
was	AUX	O	O	1081
increased	VERB	O	O	1081
,	PUNCT	O	O	1081
indicating	VERB	O	O	1081
a	PRON	O	O	1081
reduction	NOUN	O	O	1081
in	ADP	O	O	1081
the	PRON	O	O	1081
level	VERB	O	O	1081
of	ADP	O	O	1081
functional	ADJ	O	O	1081
plasma	NOUN	O	O	1081
membrane	NOUN	O	O	1081
sodium	NOUN	O	Chemical	1081
channels	NOUN	O	O	1081
.	PUNCT	O	O	1081
In	ADP	O	O	1082
contrast	NOUN	O	O	1082
,	PUNCT	O	O	1082
the	PRON	O	O	1082
conduction	NOUN	O	O	1082
velocity	NOUN	O	O	1082
,	PUNCT	O	O	1082
the	PRON	O	O	1082
number	NOUN	O	O	1082
and	CCONJ	O	O	1082
size	NOUN	O	O	1082
of	ADP	O	O	1082
axons	NOUN	O	O	1082
in	ADP	O	O	1082
the	PRON	O	O	1082
optic	NOUN	O	O	1082
nerve	NOUN	O	O	1082
,	PUNCT	O	O	1082
and	CCONJ	O	O	1082
the	PRON	O	O	1082
specific	ADJ	O	O	1082
localization	NOUN	O	O	1082
of	ADP	O	O	1082
Na(v)1.6	NOUN	O	O	1082
channels	NOUN	O	O	1082
in	ADP	O	O	1082
the	PRON	O	O	1082
nodes	NOUN	O	O	1082
of	ADP	O	O	1082
Ranvier	PROPN	O	O	1082
were	AUX	O	O	1082
unchanged	ADJ	O	O	1082
.	PUNCT	O	O	1082
beta2(-/-	NUM	O	O	1083
)	PUNCT	O	O	1083
mice	NOUN	O	O	1083
displayed	VERB	O	O	1083
increased	VERB	O	O	1083
susceptibility	NOUN	O	O	1083
to	PART	O	O	1083
seizures	NOUN	O	Disease	1083
,	PUNCT	O	O	1083
as	ADP	O	O	1083
indicated	VERB	O	O	1083
by	ADP	O	O	1083
reduced	VERB	O	O	1083
latency	VERB	O	O	1083
and	CCONJ	O	O	1083
threshold	NOUN	O	O	1083
for	ADP	O	O	1083
pilocarpine	NOUN	O	Chemical	1083
-	PUNCT	O	O	1083
induced	VERB	O	O	1083
seizures	NOUN	O	Disease	1083
,	PUNCT	O	O	1083
but	CCONJ	O	O	1083
seemed	VERB	O	O	1083
normal	ADJ	O	O	1083
in	ADP	O	O	1083
other	ADJ	O	O	1083
neurological	ADJ	O	O	1083
tests	VERB	O	O	1083
.	PUNCT	O	O	1083
Our	PRON	O	O	1084
observations	NOUN	O	O	1084
show	VERB	O	O	1084
that	SCONJ	O	O	1084
beta2-subunits	NOUN	O	O	1084
play	VERB	O	O	1084
an	PRON	O	O	1084
important	ADJ	O	O	1084
role	NOUN	O	O	1084
in	ADP	O	O	1084
the	PRON	O	O	1084
regulation	NOUN	O	O	1084
of	ADP	O	O	1084
sodium	NOUN	O	Chemical	1084
channel	PROPN	O	O	1084
density	NOUN	O	O	1084
and	CCONJ	O	O	1084
function	NOUN	O	O	1084
in	ADP	O	O	1084
neurons	NOUN	O	O	1084
in	ADP	O	O	1084
vivo	VERB	O	O	1084
and	CCONJ	O	O	1084
are	AUX	O	O	1084
required	VERB	O	O	1084
for	ADP	O	O	1084
normal	ADJ	O	O	1084
action	NOUN	O	O	1084
potential	ADJ	O	O	1084
generation	NOUN	O	O	1084
and	CCONJ	O	O	1084
control	VERB	O	O	1084
of	ADP	O	O	1084
excitability	NOUN	O	O	1084
.	PUNCT	O	O	1084
Screening	VERB	O	O	1087
for	ADP	O	O	1087
stimulant	NOUN	O	O	1087
use	VERB	O	O	1087
in	ADP	O	O	1087
adult	NOUN	O	O	1087
emergency	NOUN	O	O	1087
department	NOUN	O	O	1087
seizure	NOUN	O	Disease	1087
patients	NOUN	O	O	1087
.	PUNCT	O	O	1087
The	PRON	O	O	1088
objective	VERB	O	O	1088
of	ADP	O	O	1088
this	PRON	O	O	1088
study	VERB	O	O	1088
was	AUX	O	O	1088
to	PART	O	O	1088
determine	VERB	O	O	1088
the	PRON	O	O	1088
prevalence	NOUN	O	O	1088
of	ADP	O	O	1088
positive	ADJ	O	O	1088
plasma	NOUN	O	O	1088
drug	NOUN	O	O	1088
screening	VERB	O	O	1088
for	ADP	O	O	1088
cocaine	NOUN	O	Chemical	1088
or	CCONJ	O	O	1088
amphetamine	NOUN	O	Chemical	1088
in	ADP	O	O	1088
adult	NOUN	O	O	1088
emergency	NOUN	O	O	1088
department	NOUN	O	O	1088
seizure	NOUN	O	Disease	1088
patients	NOUN	O	O	1088
.	PUNCT	O	O	1088
This	PRON	O	O	1089
prospective	ADJ	O	O	1089
study	VERB	O	O	1089
evaluated	VERB	O	O	1089
consecutive	ADJ	O	O	1089
eligible	ADJ	O	O	1089
seizure	NOUN	O	Disease	1089
patients	NOUN	O	O	1089
who	PRON	O	O	1089
had	VERB	O	O	1089
a	PRON	O	O	1089
plasma	NOUN	O	O	1089
sample	NOUN	O	O	1089
collected	VERB	O	O	1089
as	ADP	O	O	1089
part	NOUN	O	O	1089
of	ADP	O	O	1089
their	PRON	O	O	1089
clinical	ADJ	O	O	1089
evaluation	NOUN	O	O	1089
.	PUNCT	O	O	1089
Plasma	NOUN	O	O	1090
was	AUX	O	O	1090
tested	VERB	O	O	1090
for	ADP	O	O	1090
amphetamine	NOUN	O	Chemical	1090
and	CCONJ	O	O	1090
the	PRON	O	O	1090
cocaine	NOUN	O	Chemical	1090
metabolite	NOUN	O	O	1090
benzoylecgonine	ADJ	O	Chemical	1090
Plasma	NOUN	O	O	1091
samples	NOUN	O	O	1091
with	ADP	O	O	1091
benzoylecgonine	ADJ	O	Chemical	1091
greater	ADJ	O	O	1091
than	ADP	O	O	1091
150	NUM	O	O	1091
ng	PROPN	O	O	1091
/	PUNCT	O	O	1091
mL	PROPN	O	O	1091
or	CCONJ	O	O	1091
an	PRON	O	O	1091
amphetamine	NOUN	O	Chemical	1091
greater	ADJ	O	O	1091
than	ADP	O	O	1091
500	NUM	O	O	1091
ng	PROPN	O	O	1091
/	PUNCT	O	O	1091
mL	PROPN	O	O	1091
were	AUX	O	O	1091
defined	VERB	O	O	1091
as	ADP	O	O	1091
positive	ADJ	O	O	1091
.	PUNCT	O	O	1091
Patient	NOUN	O	O	1092
demographics	NOUN	O	O	1092
,	PUNCT	O	O	1092
history	NOUN	O	O	1092
of	ADP	O	O	1092
underlying	VERB	O	O	1092
drug	NOUN	O	O	1092
or	CCONJ	O	O	1092
alcohol	NOUN	O	Chemical	1092
-	PUNCT	O	O	1092
related	ADJ	O	O	1092
seizure disorder	NOUN	O	Disease	1092
,	PUNCT	O	O	1092
estimated	VERB	O	O	1092
time	NOUN	O	O	1092
from	ADP	O	O	1092
seizure	NOUN	O	Disease	1092
to	PART	O	O	1092
sample	NOUN	O	O	1092
collection	NOUN	O	O	1092
,	PUNCT	O	O	1092
history	NOUN	O	O	1092
or	CCONJ	O	O	1092
suspicion	NOUN	O	O	1092
of	ADP	O	O	1092
cocaine or amphetamine abuse	NOUN	O	Disease	1092
,	PUNCT	O	O	1092
results	VERB	O	O	1092
of	ADP	O	O	1092
clinical	ADJ	O	O	1092
urine	NOUN	O	O	1092
testing	NOUN	O	O	1092
for	ADP	O	O	1092
drugs	NOUN	O	O	1092
of	ADP	O	O	1092
abuse	VERB	O	O	1092
,	PUNCT	O	O	1092
and	CCONJ	O	O	1092
assay	NOUN	O	O	1092
results	VERB	O	O	1092
were	AUX	O	O	1092
recorded	VERB	O	O	1092
without	ADP	O	O	1092
patient	NOUN	O	O	1092
identifiers	NOUN	O	O	1092
.	PUNCT	O	O	1092
Fourteen	NUM	O	O	1093
of	ADP	O	O	1093
248	NUM	O	O	1093
(	PUNCT	O	O	1093
5.6%	NOUN	O	O	1093
,	PUNCT	O	O	1093
95%	NOUN	O	O	1093
CI	NOUN	O	O	1093
2.7%-8.5%	NOUN	O	O	1093
)	PUNCT	O	O	1093
plasma	NOUN	O	O	1093
samples	NOUN	O	O	1093
were	AUX	O	O	1093
positive	ADJ	O	O	1093
by	ADP	O	O	1093
immunoassay	PROPN	O	O	1093
testing	NOUN	O	O	1093
for	ADP	O	O	1093
benzoylecgonine	ADJ	O	Chemical	1093
and	CCONJ	O	O	1093
no	PRON	O	O	1093
samples	NOUN	O	O	1093
(	PUNCT	O	O	1093
0%	NOUN	O	O	1093
,	PUNCT	O	O	1093
95%	NOUN	O	O	1093
CI	NOUN	O	O	1093
0	NUM	O	O	1093
-	PUNCT	O	O	1093
1.2%	NOUN	O	O	1093
)	PUNCT	O	O	1093
were	AUX	O	O	1093
positive	ADJ	O	O	1093
for	ADP	O	O	1093
amphetamine	NOUN	O	Chemical	1093
.	PUNCT	O	O	1093
Positive	PROPN	O	O	1094
test	NOUN	O	O	1094
results	VERB	O	O	1094
were	AUX	O	O	1094
more	ADJ	O	O	1094
common	ADJ	O	O	1094
in	ADP	O	O	1094
patient	NOUN	O	O	1094
visits	VERB	O	O	1094
where	SCONJ	O	O	1094
there	ADV	O	O	1094
was	AUX	O	O	1094
a	PRON	O	O	1094
history	NOUN	O	O	1094
or	CCONJ	O	O	1094
suspicion	NOUN	O	O	1094
of	ADP	O	O	1094
cocaine or amphetamine abuse	NOUN	O	Disease	1094
(	PUNCT	O	O	1094
p	NOUN	O	O	1094
During	ADP	O	O	1095
this	PRON	O	O	1095
study	VERB	O	O	1095
period	NOUN	O	O	1095
,	PUNCT	O	O	1095
routine	ADJ	O	O	1095
plasma	NOUN	O	O	1095
screening	VERB	O	O	1095
for	ADP	O	O	1095
cocaine	NOUN	O	Chemical	1095
and	CCONJ	O	O	1095
amphetamines	NOUN	O	Chemical	1095
in	ADP	O	O	1095
adult	NOUN	O	O	1095
seizure	NOUN	O	Disease	1095
patients	NOUN	O	O	1095
had	VERB	O	O	1095
a	PRON	O	O	1095
low	ADJ	O	O	1095
yield	VERB	O	O	1095
.	PUNCT	O	O	1095
As	ADP	O	O	1096
a	PRON	O	O	1096
result	VERB	O	O	1096
,	PUNCT	O	O	1096
routine	ADJ	O	O	1096
plasma	NOUN	O	O	1096
screening	VERB	O	O	1096
would	AUX	O	O	1096
yield	VERB	O	O	1096
few	ADJ	O	O	1096
cases	NOUN	O	O	1096
of	ADP	O	O	1096
stimulant	NOUN	O	O	1096
drug	NOUN	O	O	1096
in	ADP	O	O	1096
which	PRON	O	O	1096
there	ADV	O	O	1096
was	AUX	O	O	1096
neither	ADV	O	O	1096
a	PRON	O	O	1096
history	NOUN	O	O	1096
nor	CCONJ	O	O	1096
suspicion	NOUN	O	O	1096
of	ADP	O	O	1096
drug abuse	NOUN	O	Disease	1096
in	ADP	O	O	1096
this	PRON	O	O	1096
population	NOUN	O	O	1096
.	PUNCT	O	O	1096
The	PRON	O	O	1099
objective	VERB	O	O	1099
of	ADP	O	O	1099
this	PRON	O	O	1099
study	VERB	O	O	1099
was	AUX	O	O	1099
to	PART	O	O	1099
explore	VERB	O	O	1099
the	PRON	O	O	1099
functional	ADJ	O	O	1099
anatomy	NOUN	O	O	1099
of	ADP	O	O	1099
the	PRON	O	O	1099
globus	PROPN	O	O	1099
pallidus	VERB	O	O	1099
internus	NOUN	O	O	1099
(	PUNCT	O	O	1099
GPi	VERB	O	O	1099
)	PUNCT	O	O	1099
by	ADP	O	O	1099
studying	VERB	O	O	1099
the	PRON	O	O	1099
effects	NOUN	O	O	1099
of	ADP	O	O	1099
unilateral	ADJ	O	O	1099
pallidotomy	NOUN	O	O	1099
on	ADP	O	O	1099
parkinsonian	PROPN	O	Disease	1099
'	PUNCT	O	O	1099
off	ADP	O	O	1099
'	PUNCT	O	O	1099
signs	NOUN	O	O	1099
and	CCONJ	O	O	1099
levodopa	NOUN	O	Chemical	1099
-	PUNCT	O	O	1099
induced	VERB	O	O	1099
dyskinesias	PROPN	O	Disease	1099
(	PUNCT	O	O	1099
LID	VERB	O	Disease	1099
)	PUNCT	O	O	1099
.	PUNCT	O	O	1099
We	PRON	O	O	1100
found	VERB	O	O	1100
significant	ADJ	O	O	1100
positive	ADJ	O	O	1100
correlations	NOUN	O	O	1100
between	ADP	O	O	1100
the	PRON	O	O	1100
preoperative	ADJ	O	O	1100
levodopa	NOUN	O	Chemical	1100
responsiveness	NOUN	O	O	1100
of	ADP	O	O	1100
motor	NOUN	O	O	1100
signs	NOUN	O	O	1100
and	CCONJ	O	O	1100
the	PRON	O	O	1100
levodopa	NOUN	O	Chemical	1100
responsiveness	NOUN	O	O	1100
of	ADP	O	O	1100
scores	NOUN	O	O	1100
in	ADP	O	O	1100
timed	VERB	O	O	1100
tests	VERB	O	O	1100
(	PUNCT	O	O	1100
Core	NOUN	O	O	1100
Assessment	NOUN	O	O	1100
Program	PROPN	O	O	1100
for	ADP	O	O	1100
Intracerebral	NOUN	O	O	1100
Transplantations	NOUN	O	O	1100
)	PUNCT	O	O	1100
in	ADP	O	O	1100
the	PRON	O	O	1100
contralateral	ADJ	O	O	1100
limbs	NOUN	O	O	1100
and	CCONJ	O	O	1100
the	PRON	O	O	1100
improvement	NOUN	O	O	1100
in	ADP	O	O	1100
these	PRON	O	O	1100
scores	NOUN	O	O	1100
after	ADP	O	O	1100
surgery	NOUN	O	O	1100
,	PUNCT	O	O	1100
whereas	SCONJ	O	O	1100
there	ADV	O	O	1100
was	AUX	O	O	1100
no	PRON	O	O	1100
correlation	NOUN	O	O	1100
with	ADP	O	O	1100
the	PRON	O	O	1100
improvement	NOUN	O	O	1100
in	ADP	O	O	1100
LID	VERB	O	Disease	1100
.	PUNCT	O	O	1100
0.0001	NUM	O	O	1101
,	PUNCT	O	O	1101
r	X	O	O	1101
=	PUNCT	O	O	1101
0.8	NUM	O	O	1101
)	PUNCT	O	O	1101
between	ADP	O	O	1101
the	PRON	O	O	1101
volume	PROPN	O	O	1101
of	ADP	O	O	1101
the	PRON	O	O	1101
ventral	ADV	O	O	1101
lesion	NOUN	O	O	1101
in	ADP	O	O	1101
the	PRON	O	O	1101
GPi	VERB	O	O	1101
and	CCONJ	O	O	1101
the	PRON	O	O	1101
improvement	NOUN	O	O	1101
in	ADP	O	O	1101
LID	VERB	O	Disease	1101
in	ADP	O	O	1101
the	PRON	O	O	1101
contralateral	ADJ	O	O	1101
limbs	NOUN	O	O	1101
,	PUNCT	O	O	1101
whereas	SCONJ	O	O	1101
there	ADV	O	O	1101
was	AUX	O	O	1101
no	PRON	O	O	1101
correlation	NOUN	O	O	1101
between	ADP	O	O	1101
the	PRON	O	O	1101
ventral	ADV	O	O	1101
volume	PROPN	O	O	1101
and	CCONJ	O	O	1101
the	PRON	O	O	1101
improvement	NOUN	O	O	1101
in	ADP	O	O	1101
parkinsonian	PROPN	O	Disease	1101
'	PUNCT	O	O	1101
off	ADP	O	O	1101
'	PUNCT	O	O	1101
signs	NOUN	O	O	1101
.	PUNCT	O	O	1101
The	PRON	O	O	1102
volumes	NOUN	O	O	1102
of	ADP	O	O	1102
the	PRON	O	O	1102
total	ADJ	O	O	1102
lesion	NOUN	O	O	1102
cylinder	NOUN	O	O	1102
and	CCONJ	O	O	1102
the	PRON	O	O	1102
dorsal	PROPN	O	O	1102
lesion	NOUN	O	O	1102
did	VERB	O	O	1102
not	PART	O	O	1102
correlate	VERB	O	O	1102
with	ADP	O	O	1102
the	PRON	O	O	1102
outcome	NOUN	O	O	1102
of	ADP	O	O	1102
either	ADV	O	O	1102
dyskinesias	PROPN	O	Disease	1102
or	CCONJ	O	O	1102
parkinsonian	PROPN	O	Disease	1102
'	PUNCT	O	O	1102
off	ADP	O	O	1102
'	PUNCT	O	O	1102
signs	NOUN	O	O	1102
.	PUNCT	O	O	1102
The	PRON	O	O	1103
differential	ADJ	O	O	1103
predictive	ADJ	O	O	1103
value	NOUN	O	O	1103
of	ADP	O	O	1103
levodopa	NOUN	O	Chemical	1103
responsiveness	NOUN	O	O	1103
for	ADP	O	O	1103
the	PRON	O	O	1103
outcome	NOUN	O	O	1103
of	ADP	O	O	1103
parkinsonian	PROPN	O	Disease	1103
'	PUNCT	O	O	1103
off	ADP	O	O	1103
'	PUNCT	O	O	1103
signs	NOUN	O	O	1103
and	CCONJ	O	O	1103
LID	VERB	O	Disease	1103
and	CCONJ	O	O	1103
the	PRON	O	O	1103
different	ADJ	O	O	1103
correlations	NOUN	O	O	1103
of	ADP	O	O	1103
ventral	ADV	O	O	1103
lesion	NOUN	O	O	1103
volume	PROPN	O	O	1103
with	ADP	O	O	1103
dyskinesias	PROPN	O	Disease	1103
and	CCONJ	O	O	1103
parkinsonian	PROPN	O	Disease	1103
'	PUNCT	O	O	1103
off	ADP	O	O	1103
'	PUNCT	O	O	1103
signs	NOUN	O	O	1103
indicate	VERB	O	O	1103
that	SCONJ	O	O	1103
different	ADJ	O	O	1103
anatomical	ADJ	O	O	1103
or	CCONJ	O	O	1103
pathophysiological	ADJ	O	O	1103
substrates	NOUN	O	O	1103
may	AUX	O	O	1103
be	AUX	O	O	1103
responsible	ADJ	O	O	1103
for	ADP	O	O	1103
the	PRON	O	O	1103
generation	NOUN	O	O	1103
of	ADP	O	O	1103
parkinsonian	PROPN	O	Disease	1103
'	PUNCT	O	O	1103
off	ADP	O	O	1103
'	PUNCT	O	O	1103
signs	NOUN	O	O	1103
and	CCONJ	O	O	1103
dyskinesias	PROPN	O	Disease	1103
.	PUNCT	O	O	1103
Whereas	SCONJ	O	O	1104
cells	NOUN	O	O	1104
in	ADP	O	O	1104
a	PRON	O	O	1104
wider	ADJ	O	O	1104
area	NOUN	O	O	1104
of	ADP	O	O	1104
the	PRON	O	O	1104
GPi	VERB	O	O	1104
may	AUX	O	O	1104
be	AUX	O	O	1104
implicated	VERB	O	O	1104
in	ADP	O	O	1104
parkinsonism	NOUN	O	Disease	1104
,	PUNCT	O	O	1104
the	PRON	O	O	1104
ventral	ADV	O	O	1104
GPi	VERB	O	O	1104
seems	VERB	O	O	1104
to	PART	O	O	1104
be	AUX	O	O	1104
crucial	ADJ	O	O	1104
for	ADP	O	O	1104
the	PRON	O	O	1104
manifestation	NOUN	O	O	1104
of	ADP	O	O	1104
LID	VERB	O	Disease	1104
.	PUNCT	O	O	1104
We	PRON	O	O	1105
suggest	VERB	O	O	1105
that	SCONJ	O	O	1105
our	PRON	O	O	1105
observations	NOUN	O	O	1105
are	AUX	O	O	1105
additional	ADJ	O	O	1105
proof	NOUN	O	O	1105
of	ADP	O	O	1105
the	PRON	O	O	1105
functional	ADJ	O	O	1105
somatotopy	VERB	O	O	1105
of	ADP	O	O	1105
the	PRON	O	O	1105
systems	NOUN	O	O	1105
within	ADP	O	O	1105
the	PRON	O	O	1105
GPi	VERB	O	O	1105
that	SCONJ	O	O	1105
mediate	VERB	O	O	1105
parkinsonism	NOUN	O	Disease	1105
and	CCONJ	O	O	1105
dyskinesias	PROPN	O	Disease	1105
,	PUNCT	O	O	1105
especially	ADV	O	O	1105
along	ADV	O	O	1105
the	PRON	O	O	1105
dorsoventral	ADJ	O	O	1105
trajectory	NOUN	O	O	1105
used	VERB	O	O	1105
in	ADP	O	O	1105
pallidotomy	NOUN	O	O	1105
.	PUNCT	O	O	1105
Pain	NOUN	O	Disease	1108
responses	NOUN	O	O	1108
in	ADP	O	O	1108
methadone	NOUN	O	Chemical	1108
-	PUNCT	O	O	1108
maintained	VERB	O	O	1108
opioid	NOUN	O	O	1108
abusers	NOUN	O	O	1108
.	PUNCT	O	O	1108
Providing	VERB	O	O	1109
pain	NOUN	O	Disease	1109
management	NOUN	O	O	1109
for	ADP	O	O	1109
known	VERB	O	O	1109
opioid	NOUN	O	O	1109
abusers	NOUN	O	O	1109
is	AUX	O	O	1109
a	PRON	O	O	1109
challenging	VERB	O	O	1109
clinical	ADJ	O	O	1109
task	NOUN	O	O	1109
,	PUNCT	O	O	1109
in	ADP	O	O	1109
part	NOUN	O	O	1109
because	SCONJ	O	O	1109
little	ADJ	O	O	1109
is	AUX	O	O	1109
known	VERB	O	O	1109
about	ADP	O	O	1109
their	PRON	O	O	1109
pain	NOUN	O	Disease	1109
experience	NOUN	O	O	1109
and	CCONJ	O	O	1109
analgesic	PROPN	O	O	1109
requirements	NOUN	O	O	1109
.	PUNCT	O	O	1109
This	PRON	O	O	1110
study	VERB	O	O	1110
was	AUX	O	O	1110
designed	VERB	O	O	1110
to	PART	O	O	1110
describe	VERB	O	O	1110
pain	NOUN	O	Disease	1110
tolerance	NOUN	O	O	1110
and	CCONJ	O	O	1110
analgesic	PROPN	O	O	1110
response	NOUN	O	O	1110
in	ADP	O	O	1110
a	PRON	O	O	1110
sample	NOUN	O	O	1110
of	ADP	O	O	1110
opioid addicts	NOUN	O	Disease	1110
stabilized	VERB	O	O	1110
in	ADP	O	O	1110
methadone	NOUN	O	Chemical	1110
-	PUNCT	O	O	1110
maintenance	NOUN	O	O	1110
(	PUNCT	O	O	1110
MM	PROPN	O	Disease	1110
)	PUNCT	O	O	1110
treatment	NOUN	O	O	1110
(	PUNCT	O	O	1110
n	CCONJ	O	O	1110
=	PUNCT	O	O	1110
60	NUM	O	O	1110
)	PUNCT	O	O	1110
in	ADP	O	O	1110
comparison	NOUN	O	O	1110
to	PART	O	O	1110
matched	VERB	O	O	1110
nondependent	NOUN	O	O	1110
control	VERB	O	O	1110
subjects	NOUN	O	O	1110
(	PUNCT	O	O	1110
n	CCONJ	O	O	1110
=	PUNCT	O	O	1110
60	NUM	O	O	1110
)	PUNCT	O	O	1110
.	PUNCT	O	O	1110
By	ADP	O	O	1111
using	VERB	O	O	1111
a	PRON	O	O	1111
placebo	NOUN	O	O	1111
-	PUNCT	O	O	1111
controlled	VERB	O	O	1111
,	PUNCT	O	O	1111
two	NUM	O	O	1111
-	PUNCT	O	O	1111
way	NOUN	O	O	1111
factorial	NOUN	O	O	1111
design	NOUN	O	O	1111
,	PUNCT	O	O	1111
tolerance	NOUN	O	O	1111
to	PART	O	O	1111
cold	ADJ	O	O	1111
-	PUNCT	O	O	1111
pressor	ADJ	O	O	1111
(	PUNCT	O	O	1111
CP	PROPN	O	Chemical	1111
)	PUNCT	O	O	1111
pain	NOUN	O	Disease	1111
was	AUX	O	O	1111
examined	VERB	O	O	1111
,	PUNCT	O	O	1111
both	PRON	O	O	1111
before	ADP	O	O	1111
and	CCONJ	O	O	1111
after	ADP	O	O	1111
oral	ADJ	O	O	1111
administration	NOUN	O	O	1111
of	ADP	O	O	1111
therapeutic	ADJ	O	O	1111
doses	NOUN	O	O	1111
of	ADP	O	O	1111
common	ADJ	O	O	1111
opioid	NOUN	O	O	1111
(	PUNCT	O	O	1111
hydromorphone	NOUN	O	Chemical	1111
2	X	O	O	1111
mg	VERB	O	O	1111
)	PUNCT	O	O	1111
and	CCONJ	O	O	1111
nonsteroidal	ADJ	O	O	1111
anti	ADJ	O	O	1111
-	PUNCT	O	O	1111
inflammatory	ADJ	O	O	1111
(	PUNCT	O	O	1111
ketorolac	PROPN	O	Chemical	1111
10	NUM	O	O	1111
mg	VERB	O	O	1111
)	PUNCT	O	O	1111
analgesic	PROPN	O	O	1111
agents	NOUN	O	O	1111
.	PUNCT	O	O	1111
Results	NOUN	O	O	1112
showed	VERB	O	O	1112
that	SCONJ	O	O	1112
MM	PROPN	O	Disease	1112
individuals	NOUN	O	O	1112
were	AUX	O	O	1112
significantly	ADV	O	O	1112
less	ADV	O	O	1112
tolerant	ADJ	O	O	1112
of	ADP	O	O	1112
CP	PROPN	O	Chemical	1112
pain	NOUN	O	Disease	1112
than	ADP	O	O	1112
control	VERB	O	O	1112
subjects	NOUN	O	O	1112
,	PUNCT	O	O	1112
replicating	VERB	O	O	1112
previous	ADJ	O	O	1112
work	NOUN	O	O	1112
.	PUNCT	O	O	1112
These	PRON	O	O	1113
data	NOUN	O	O	1113
indicate	VERB	O	O	1113
that	SCONJ	O	O	1113
MM	PROPN	O	Disease	1113
opioid	NOUN	O	O	1113
abusers	NOUN	O	O	1113
represent	VERB	O	O	1113
a	PRON	O	O	1113
pain	NOUN	O	Disease	1113
-	PUNCT	O	O	1113
intolerant	ADJ	O	O	1113
subset	VERB	O	O	1113
of	ADP	O	O	1113
clinical	ADJ	O	O	1113
patients	NOUN	O	O	1113
.	PUNCT	O	O	1113
Their	PRON	O	O	1114
complaints	NOUN	O	O	1114
of	ADP	O	O	1114
pain	NOUN	O	Disease	1114
should	AUX	O	O	1114
be	AUX	O	O	1114
evaluated	VERB	O	O	1114
seriously	ADV	O	O	1114
and	CCONJ	O	O	1114
managed	VERB	O	O	1114
aggressively	ADV	O	O	1114
.	PUNCT	O	O	1114
Although	SCONJ	O	O	1117
an	PRON	O	O	1117
indicator	NOUN	O	O	1117
of	ADP	O	O	1117
renal tubular dysfunction	NOUN	O	Disease	1117
,	PUNCT	O	O	1117
an	PRON	O	O	1117
increased	VERB	O	O	1117
urinary	ADJ	O	O	1117
N	NUM	O	O	1117
-	PUNCT	O	O	1117
acetyl	PROPN	O	O	1117
-	PUNCT	O	O	1117
beta	NOUN	O	O	1117
Puromycin aminonucleoside	NOUN	O	Chemical	1118
(	PUNCT	O	O	1118
PAN	PROPN	O	Chemical	1118
)	PUNCT	O	O	1118
was	AUX	O	O	1118
administered	VERB	O	O	1118
to	PART	O	O	1118
Sprague	PROPN	O	O	1118
Dawley	NOUN	O	O	1118
rats	NOUN	O	O	1118
to	PART	O	O	1118
induce	VERB	O	O	1118
proteinuria	X	O	Disease	1118
.	PUNCT	O	O	1118
Following	VERB	O	O	1119
intravenous	ADJ	O	O	1119
PAN	PROPN	O	Chemical	1119
urine	NOUN	O	O	1119
volume	PROPN	O	O	1119
and	CCONJ	O	O	1119
urine	NOUN	O	O	1119
NAG	PROPN	O	O	1119
activity	NOUN	O	O	1119
increased	VERB	O	O	1119
significantly	ADV	O	O	1119
by	ADP	O	O	1119
day	NOUN	O	O	1119
two	NUM	O	O	1119
,	PUNCT	O	O	1119
but	CCONJ	O	O	1119
returned	VERB	O	O	1119
to	PART	O	O	1119
normal	ADJ	O	O	1119
by	ADP	O	O	1119
day	NOUN	O	O	1119
four	NUM	O	O	1119
.	PUNCT	O	O	1119
Peak	NOUN	O	O	1120
urine	NOUN	O	O	1120
NAG	PROPN	O	O	1120
activity	NOUN	O	O	1120
and	CCONJ	O	O	1120
a	PRON	O	O	1120
change	VERB	O	O	1120
in	ADP	O	O	1120
NAG	PROPN	O	O	1120
isoenzyme	VERB	O	O	1120
pattern	NOUN	O	O	1120
coincided	VERB	O	O	1120
with	ADP	O	O	1120
both	PRON	O	O	1120
the	PRON	O	O	1120
peak	PROPN	O	O	1120
proteinuria	X	O	Disease	1120
and	CCONJ	O	O	1120
the	PRON	O	O	1120
reduction	NOUN	O	O	1120
in	ADP	O	O	1120
intracellular	ADJ	O	O	1120
protein	NOUN	O	O	1120
and	CCONJ	O	O	1120
NAG	PROPN	O	O	1120
droplets	VERB	O	O	1120
(	PUNCT	O	O	1120
day	NOUN	O	O	1120
six	NUM	O	O	1120
onwards	ADV	O	O	1120
)	PUNCT	O	O	1120
.	PUNCT	O	O	1120
Over	ADP	O	O	1123
expression	NOUN	O	O	1123
of	ADP	O	O	1123
vascular	ADJ	O	O	1123
endothelial	NOUN	O	O	1123
growth	NOUN	O	O	1123
factor	NOUN	O	O	1123
and	CCONJ	O	O	1123
its	PRON	O	O	1123
receptor	NOUN	O	O	1123
during	ADP	O	O	1123
the	PRON	O	O	1123
development	NOUN	O	O	1123
of	ADP	O	O	1123
estrogen	PROPN	O	Chemical	1123
-	PUNCT	O	O	1123
induced	VERB	O	O	1123
rat	NOUN	O	O	1123
pituitary tumors	NOUN	O	Disease	1123
may	AUX	O	O	1123
mediate	VERB	O	O	1123
estrogen	PROPN	O	Chemical	1123
-	PUNCT	O	O	1123
initiated	VERB	O	O	1123
tumor	NOUN	O	Disease	1123
angiogenesis	NOUN	O	O	1123
.	PUNCT	O	O	1123
Estrogens	NOUN	O	Chemical	1124
,	PUNCT	O	O	1124
which	PRON	O	O	1124
have	VERB	O	O	1124
been	AUX	O	O	1124
associated	VERB	O	O	1124
with	ADP	O	O	1124
several	ADJ	O	O	1124
types	NOUN	O	O	1124
of	ADP	O	O	1124
human	PROPN	O	O	1124
and	CCONJ	O	O	1124
animal	NOUN	O	O	1124
cancers	NOUN	O	Disease	1124
,	PUNCT	O	O	1124
can	AUX	O	O	1124
induce	VERB	O	O	1124
tumor	NOUN	O	Disease	1124
angiogenesis	NOUN	O	O	1124
in	ADP	O	O	1124
the	PRON	O	O	1124
pituitary	NOUN	O	O	1124
of	ADP	O	O	1124
Fischer	PROPN	O	O	1124
344	NUM	O	O	1124
rats	NOUN	O	O	1124
.	PUNCT	O	O	1124
The	PRON	O	O	1125
mechanistic	ADJ	O	O	1125
details	NOUN	O	O	1125
of	ADP	O	O	1125
tumor	NOUN	O	Disease	1125
angiogenesis	NOUN	O	O	1125
induction	NOUN	O	O	1125
,	PUNCT	O	O	1125
during	ADP	O	O	1125
estrogen	PROPN	O	Chemical	1125
carcinogenesis	NOUN	O	Disease	1125
,	PUNCT	O	O	1125
are	AUX	O	O	1125
still	ADV	O	O	1125
unknown	ADJ	O	O	1125
.	PUNCT	O	O	1125
To	PART	O	O	1126
elucidate	VERB	O	O	1126
the	PRON	O	O	1126
role	NOUN	O	O	1126
of	ADP	O	O	1126
estrogen	PROPN	O	Chemical	1126
in	ADP	O	O	1126
the	PRON	O	O	1126
regulation	NOUN	O	O	1126
of	ADP	O	O	1126
tumor	NOUN	O	Disease	1126
angiogenesis	NOUN	O	O	1126
in	ADP	O	O	1126
the	PRON	O	O	1126
pituitary	NOUN	O	O	1126
of	ADP	O	O	1126
female	ADJ	O	O	1126
rats	NOUN	O	O	1126
,	PUNCT	O	O	1126
the	PRON	O	O	1126
density	NOUN	O	O	1126
of	ADP	O	O	1126
blood	NOUN	O	O	1126
vessels	NOUN	O	O	1126
was	AUX	O	O	1126
analysed	VERB	O	O	1126
using	VERB	O	O	1126
factor	NOUN	O	O	1126
VIII	PROPN	O	O	1126
related	ADJ	O	O	1126
antigen	PROPN	O	O	1126
(	PUNCT	O	O	1126
FVIIIRAg	NOUN	O	O	1126
)	PUNCT	O	O	1126
immunohistochemistry	NOUN	O	O	1126
and	CCONJ	O	O	1126
the	PRON	O	O	1126
expression	NOUN	O	O	1126
of	ADP	O	O	1126
vascular	ADJ	O	O	1126
endothelial	NOUN	O	O	1126
growth	NOUN	O	O	1126
factor	NOUN	O	O	1126
/	PUNCT	O	O	1126
vascular	ADJ	O	O	1126
permeability	NOUN	O	O	1126
factor	NOUN	O	O	1126
(	PUNCT	O	O	1126
VEGF	PROPN	O	O	1126
/	PUNCT	O	O	1126
VPF	INTJ	O	O	1126
)	PUNCT	O	O	1126
was	AUX	O	O	1126
examined	VERB	O	O	1126
by	ADP	O	O	1126
Western	ADJ	O	O	1126
blot	NOUN	O	O	1126
and	CCONJ	O	O	1126
immunohistochemical	ADJ	O	O	1126
analysis	NOUN	O	O	1126
.	PUNCT	O	O	1126
The	PRON	O	O	1127
results	VERB	O	O	1127
demonstrated	VERB	O	O	1127
that	SCONJ	O	O	1127
17beta	NUM	O	O	1127
-	PUNCT	O	O	1127
estradiol	VERB	O	Chemical	1127
(	PUNCT	O	O	1127
E2	NOUN	O	Chemical	1127
)	PUNCT	O	O	1127
induces	VERB	O	O	1127
neovascularization	NOUN	O	O	1127
,	PUNCT	O	O	1127
as	ADP	O	O	1127
well	ADV	O	O	1127
as	ADP	O	O	1127
the	PRON	O	O	1127
growth	NOUN	O	O	1127
and	CCONJ	O	O	1127
enlargement	NOUN	O	O	1127
of	ADP	O	O	1127
blood	NOUN	O	O	1127
vessels	NOUN	O	O	1127
after	ADP	O	O	1127
7	NUM	O	O	1127
days	NOUN	O	O	1127
of	ADP	O	O	1127
exposure	NOUN	O	O	1127
.	PUNCT	O	O	1127
The	PRON	O	O	1128
high	ADJ	O	O	1128
tumor	NOUN	O	Disease	1128
angiogenic	ADJ	O	O	1128
potential	ADJ	O	O	1128
was	AUX	O	O	1128
associated	VERB	O	O	1128
with	ADP	O	O	1128
an	PRON	O	O	1128
elevated	ADJ	O	O	1128
VEGF	PROPN	O	O	1128
/	PUNCT	O	O	1128
VPF	INTJ	O	O	1128
protein	NOUN	O	O	1128
expression	NOUN	O	O	1128
in	ADP	O	O	1128
the	PRON	O	O	1128
E2	NOUN	O	Chemical	1128
exposed	VERB	O	O	1128
pituitary	NOUN	O	O	1128
of	ADP	O	O	1128
ovariectomized	VERB	O	O	1128
(	PUNCT	O	O	1128
OVEX	ADJ	O	O	1128
)	PUNCT	O	O	1128
rats	NOUN	O	O	1128
.	PUNCT	O	O	1128
After	ADP	O	O	1129
15	NUM	O	O	1129
days	NOUN	O	O	1129
of	ADP	O	O	1129
E2	NOUN	O	Chemical	1129
exposure	NOUN	O	O	1129
,	PUNCT	O	O	1129
VEGF	PROPN	O	O	1129
/	PUNCT	O	O	1129
VPF	INTJ	O	O	1129
protein	NOUN	O	O	1129
expression	NOUN	O	O	1129
,	PUNCT	O	O	1129
in	ADP	O	O	1129
the	PRON	O	O	1129
non	ADJ	O	O	1129
-	PUNCT	O	O	1129
endothelial	NOUN	O	O	1129
cell	NOUN	O	O	1129
population	NOUN	O	O	1129
,	PUNCT	O	O	1129
sharply	ADV	O	O	1129
declined	VERB	O	O	1129
and	CCONJ	O	O	1129
was	AUX	O	O	1129
restricted	VERB	O	O	1129
to	PART	O	O	1129
the	PRON	O	O	1129
blood	NOUN	O	O	1129
vessels	NOUN	O	O	1129
.	PUNCT	O	O	1129
Furthermore	ADV	O	O	1130
,	PUNCT	O	O	1130
immunohistochemical	ADJ	O	O	1130
studies	NOUN	O	O	1130
demonstrated	VERB	O	O	1130
that	SCONJ	O	O	1130
VEGFR-2	ADV	O	O	1130
(	PUNCT	O	O	1130
flk-1/KDR	PROPN	O	O	1130
)	PUNCT	O	O	1130
,	PUNCT	O	O	1130
expression	NOUN	O	O	1130
was	AUX	O	O	1130
elevated	ADJ	O	O	1130
significantly	ADV	O	O	1130
in	ADP	O	O	1130
the	PRON	O	O	1130
endothelial	NOUN	O	O	1130
cells	NOUN	O	O	1130
of	ADP	O	O	1130
microblood	PROPN	O	O	1130
vessels	NOUN	O	O	1130
after	ADP	O	O	1130
7	NUM	O	O	1130
days	NOUN	O	O	1130
of	ADP	O	O	1130
E2	NOUN	O	Chemical	1130
exposure	NOUN	O	O	1130
.	PUNCT	O	O	1130
These	PRON	O	O	1131
findings	NOUN	O	O	1131
suggest	VERB	O	O	1131
that	SCONJ	O	O	1131
over	ADP	O	O	1131
expression	NOUN	O	O	1131
of	ADP	O	O	1131
VEGF	PROPN	O	O	1131
and	CCONJ	O	O	1131
its	PRON	O	O	1131
receptor	NOUN	O	O	1131
(	PUNCT	O	O	1131
VEGFR-2	ADV	O	O	1131
)	PUNCT	O	O	1131
may	AUX	O	O	1131
play	VERB	O	O	1131
an	PRON	O	O	1131
important	ADJ	O	O	1131
role	NOUN	O	O	1131
in	ADP	O	O	1131
the	PRON	O	O	1131
initial	ADJ	O	O	1131
step	VERB	O	O	1131
of	ADP	O	O	1131
the	PRON	O	O	1131
regulation	NOUN	O	O	1131
of	ADP	O	O	1131
estrogen	PROPN	O	Chemical	1131
induced	VERB	O	O	1131
tumor	NOUN	O	Disease	1131
angiogenesis	NOUN	O	O	1131
in	ADP	O	O	1131
the	PRON	O	O	1131
rat	NOUN	O	O	1131
pituitary	NOUN	O	O	1131
.	PUNCT	O	O	1131
Pravastatin	NOUN	O	Chemical	1134
-	PUNCT	O	O	1134
associated	VERB	O	O	1134
myopathy	PROPN	O	Disease	1134
.	PUNCT	O	O	1134
A	PRON	O	O	1135
case	NOUN	O	O	1135
of	ADP	O	O	1135
acute	ADJ	O	O	1135
inflammatory myopathy	NOUN	O	Disease	1135
associated	VERB	O	O	1135
with	ADP	O	O	1135
the	PRON	O	O	1135
use	VERB	O	O	1135
of	ADP	O	O	1135
pravastatin	PROPN	O	Chemical	1135
,	PUNCT	O	O	1135
a	PRON	O	O	1135
new	ADJ	O	O	1135
hydrophilic	ADJ	O	O	1135
3-hydroxy-3	NUM	O	O	1135
The	PRON	O	O	1136
patient	NOUN	O	O	1136
,	PUNCT	O	O	1136
a	PRON	O	O	1136
69-year	NOUN	O	O	1136
-	PUNCT	O	O	1136
old	ADJ	O	O	1136
man	NOUN	O	O	1136
was	AUX	O	O	1136
affected	VERB	O	O	1136
by	ADP	O	O	1136
non	ADJ	O	O	1136
-	PUNCT	O	O	1136
insulin	NOUN	O	O	1136
-	PUNCT	O	O	1136
dependent	ADJ	O	O	1136
diabetes mellitus	ADJ	O	Disease	1136
and	CCONJ	O	O	1136
hypertension	NOUN	O	Disease	1136
.	PUNCT	O	O	1136
He	PRON	O	O	1137
assumed	VERB	O	O	1137
pravastatin	PROPN	O	Chemical	1137
(	PUNCT	O	O	1137
20	NUM	O	O	1137
mg	VERB	O	O	1137
/	PUNCT	O	O	1137
day	NOUN	O	O	1137
)	PUNCT	O	O	1137
because	SCONJ	O	O	1137
of	ADP	O	O	1137
hypercholesterolemia	NOUN	O	Disease	1137
.	PUNCT	O	O	1137
He	PRON	O	O	1138
was	AUX	O	O	1138
admitted	VERB	O	O	1138
with	ADP	O	O	1138
acute	ADJ	O	O	1138
myopathy	PROPN	O	Disease	1138
of	ADP	O	O	1138
the	PRON	O	O	1138
lower	ADJ	O	O	1138
limbs	NOUN	O	O	1138
which	PRON	O	O	1138
resolved	VERB	O	O	1138
in	ADP	O	O	1138
a	PRON	O	O	1138
few	ADJ	O	O	1138
days	NOUN	O	O	1138
after	ADP	O	O	1138
pravastatin	PROPN	O	Chemical	1138
discontinuation	NOUN	O	O	1138
.	PUNCT	O	O	1138
A	PRON	O	O	1139
previously	ADV	O	O	1139
unknown	ADJ	O	O	1139
hypothyroidism	PROPN	O	Disease	1139
,	PUNCT	O	O	1139
probably	ADV	O	O	1139
due	ADJ	O	O	1139
to	PART	O	O	1139
chronic	ADJ	O	O	1139
autoimmune thyroiditis	NOUN	O	Disease	1139
,	PUNCT	O	O	1139
was	AUX	O	O	1139
evidenced	VERB	O	O	1139
.	PUNCT	O	O	1139
While	SCONJ	O	O	1140
lovastatin	NOUN	O	Chemical	1140
and	CCONJ	O	O	1140
simvastatin	PROPN	O	Chemical	1140
have	VERB	O	O	1140
been	AUX	O	O	1140
associated	VERB	O	O	1140
with	ADP	O	O	1140
toxic	ADJ	O	O	1140
myopathy	PROPN	O	Disease	1140
,	PUNCT	O	O	1140
pravastatin	PROPN	O	Chemical	1140
-	PUNCT	O	O	1140
associated	VERB	O	O	1140
myopathy	PROPN	O	Disease	1140
could	AUX	O	O	1140
represent	VERB	O	O	1140
a	PRON	O	O	1140
distinct	ADJ	O	O	1140
,	PUNCT	O	O	1140
inflammatory	ADJ	O	O	1140
entity	NOUN	O	O	1140
.	PUNCT	O	O	1140
Dose	NOUN	O	O	1143
-	PUNCT	O	O	1143
effect	VERB	O	O	1143
and	CCONJ	O	O	1143
structure	NOUN	O	O	1143
-	PUNCT	O	O	1143
function	NOUN	O	O	1143
relationships	NOUN	O	O	1143
in	ADP	O	O	1143
doxorubicin	VERB	O	Chemical	1143
cardiomyopathy	ADJ	O	Disease	1143
.	PUNCT	O	O	1143
The	PRON	O	O	1144
cardiomyopathy	ADJ	O	Disease	1144
(	PUNCT	O	O	1144
CM	PROPN	O	Disease	1144
)	PUNCT	O	O	1144
produced	VERB	O	O	1144
by	ADP	O	O	1144
the	PRON	O	O	1144
anticancer	NOUN	O	O	1144
drug	NOUN	O	O	1144
doxorubicin	VERB	O	Chemical	1144
(	PUNCT	O	O	1144
DXR	PROPN	O	Chemical	1144
)	PUNCT	O	O	1144
(	PUNCT	O	O	1144
Adriamycin	PROPN	O	Chemical	1144
)	PUNCT	O	O	1144
provides	VERB	O	O	1144
a	PRON	O	O	1144
unique	ADJ	O	O	1144
opportunity	NOUN	O	O	1144
to	PART	O	O	1144
analyze	VERB	O	O	1144
dose	NOUN	O	O	1144
-	PUNCT	O	O	1144
effect	VERB	O	O	1144
and	CCONJ	O	O	1144
structure	NOUN	O	O	1144
-	PUNCT	O	O	1144
function	NOUN	O	O	1144
relationships	NOUN	O	O	1144
during	ADP	O	O	1144
development	NOUN	O	O	1144
of	ADP	O	O	1144
myocardial disease	NOUN	O	Disease	1144
.	PUNCT	O	O	1144
We	PRON	O	O	1145
measured	VERB	O	O	1145
the	PRON	O	O	1145
degree	PROPN	O	O	1145
of	ADP	O	O	1145
morphologic	ADJ	O	O	1145
damage	NOUN	O	O	1145
by	ADP	O	O	1145
ultrastructural	ADJ	O	O	1145
examination	NOUN	O	O	1145
of	ADP	O	O	1145
endomyocardial	PROPN	O	O	1145
biopsy	PROPN	O	O	1145
and	CCONJ	O	O	1145
the	PRON	O	O	1145
degree	PROPN	O	O	1145
of	ADP	O	O	1145
performance	NOUN	O	O	1145
abnormally	ADV	O	O	1145
by	ADP	O	O	1145
right	ADV	O	O	1145
heart	NOUN	O	O	1145
catheterization	NOUN	O	O	1145
in	ADP	O	O	1145
patients	NOUN	O	O	1145
receiving	VERB	O	O	1145
DXR	PROPN	O	Chemical	1145
.	PUNCT	O	O	1145
Morphologic	ADJ	O	O	1146
damage	NOUN	O	O	1146
was	AUX	O	O	1146
variable	NOUN	O	O	1146
but	CCONJ	O	O	1146
was	AUX	O	O	1146
proportional	ADJ	O	O	1146
to	PART	O	O	1146
the	PRON	O	O	1146
total	ADJ	O	O	1146
cumulative	ADJ	O	O	1146
DXR	PROPN	O	Chemical	1146
dose	NOUN	O	O	1146
between	ADP	O	O	1146
100	NUM	O	O	1146
and	CCONJ	O	O	1146
600	NUM	O	O	1146
mg	VERB	O	O	1146
/	PUNCT	O	O	1146
m2	PROPN	O	O	1146
.	PUNCT	O	O	1146
In	ADP	O	O	1147
DXR	PROPN	O	Chemical	1147
-	PUNCT	O	O	1147
CM	PROPN	O	Disease	1147
myocardial damage	NOUN	O	Disease	1147
is	AUX	O	O	1147
proportional	ADJ	O	O	1147
to	PART	O	O	1147
the	PRON	O	O	1147
degree	PROPN	O	O	1147
of	ADP	O	O	1147
cytotoxic	ADJ	O	O	1147
insult	NOUN	O	O	1147
(	PUNCT	O	O	1147
DXR	PROPN	O	Chemical	1147
dose	NOUN	O	O	1147
)	PUNCT	O	O	1147
while	SCONJ	O	O	1147
myocardial	ADJ	O	O	1147
function	NOUN	O	O	1147
is	AUX	O	O	1147
preserved	VERB	O	O	1147
until	ADP	O	O	1147
a	PRON	O	O	1147
critical	ADJ	O	O	1147
dose	NOUN	O	O	1147
or	CCONJ	O	O	1147
degree	PROPN	O	O	1147
of	ADP	O	O	1147
damage	NOUN	O	O	1147
is	AUX	O	O	1147
reached	VERB	O	O	1147
,	PUNCT	O	O	1147
after	ADP	O	O	1147
which	PRON	O	O	1147
myocardial	ADJ	O	O	1147
performance	NOUN	O	O	1147
deteriorates	VERB	O	O	1147
rapidly	ADV	O	O	1147
.	PUNCT	O	O	1147
Fatal	ADJ	O	O	1150
aplastic anemia	NOUN	O	Disease	1150
following	VERB	O	O	1150
topical	ADJ	O	O	1150
administration	NOUN	O	O	1150
of	ADP	O	O	1150
ophthalmic	ADJ	O	O	1150
chloramphenicol	PROPN	O	Chemical	1150
.	PUNCT	O	O	1150
A	PRON	O	O	1151
73-year	NOUN	O	O	1151
-	PUNCT	O	O	1151
old	ADJ	O	O	1151
woman	NOUN	O	O	1151
died	VERB	O	O	1151
of	ADP	O	O	1151
aplastic anemia	NOUN	O	Disease	1151
less	ADV	O	O	1151
than	ADP	O	O	1151
two	NUM	O	O	1151
months	NOUN	O	O	1151
after	ADP	O	O	1151
undergoing	VERB	O	O	1151
cataract	NOUN	O	Disease	1151
extraction	NOUN	O	O	1151
and	CCONJ	O	O	1151
beginning	VERB	O	O	1151
topical	ADJ	O	O	1151
therapy	NOUN	O	O	1151
with	ADP	O	O	1151
chloramphenicol	PROPN	O	Chemical	1151
.	PUNCT	O	O	1151
The	PRON	O	O	1152
first	ADV	O	O	1152
signs	NOUN	O	O	1152
of	ADP	O	O	1152
pancytopenia	PROPN	O	Disease	1152
began	VERB	O	O	1152
within	ADP	O	O	1152
one	NUM	O	O	1152
month	NOUN	O	O	1152
of	ADP	O	O	1152
the	PRON	O	O	1152
surgery	NOUN	O	O	1152
.	PUNCT	O	O	1152
The	PRON	O	O	1153
pattern	NOUN	O	O	1153
of	ADP	O	O	1153
the	PRON	O	O	1153
aplastic anemia	NOUN	O	Disease	1153
was	AUX	O	O	1153
associated	VERB	O	O	1153
with	ADP	O	O	1153
an	PRON	O	O	1153
idiosyncratic	ADJ	O	O	1153
response	NOUN	O	O	1153
to	PART	O	O	1153
chloramphenicol	PROPN	O	Chemical	1153
.	PUNCT	O	O	1153
This	PRON	O	O	1154
was	AUX	O	O	1154
the	PRON	O	O	1154
second	ADV	O	O	1154
report	VERB	O	O	1154
of	ADP	O	O	1154
fatal	ADJ	O	O	1154
aplastic anemia	NOUN	O	Disease	1154
after	ADP	O	O	1154
topical	ADJ	O	O	1154
treatment	NOUN	O	O	1154
with	ADP	O	O	1154
chloramphenicol	PROPN	O	Chemical	1154
for	ADP	O	O	1154
ocular	ADJ	O	O	1154
conditions	NOUN	O	O	1154
,	PUNCT	O	O	1154
although	SCONJ	O	O	1154
two	NUM	O	O	1154
cases	NOUN	O	O	1154
of	ADP	O	O	1154
reversible	ADJ	O	O	1154
bone marrow hypoplasia	NOUN	O	Disease	1154
have	VERB	O	O	1154
also	ADV	O	O	1154
been	AUX	O	O	1154
reported	VERB	O	O	1154
.	PUNCT	O	O	1154
Any	PRON	O	O	1155
other	ADJ	O	O	1155
suspected	VERB	O	O	1155
cases	NOUN	O	O	1155
of	ADP	O	O	1155
ocular toxicity	NOUN	O	Disease	1155
associated	VERB	O	O	1155
with	ADP	O	O	1155
topically	ADV	O	O	1155
applied	VERB	O	O	1155
chloramphenicol	PROPN	O	Chemical	1155
should	AUX	O	O	1155
be	AUX	O	O	1155
reported	VERB	O	O	1155
to	PART	O	O	1155
the	PRON	O	O	1155
National	ADJ	O	O	1155
Registry	NOUN	O	O	1155
of	ADP	O	O	1155
Drug	NOUN	O	O	1155
-	PUNCT	O	O	1155
Induced	VERB	O	O	1155
Ocular	ADJ	O	O	1155
Side	NOUN	O	O	1155
Effects	NOUN	O	O	1155
,	PUNCT	O	O	1155
Oregon	PROPN	O	O	1155
Health	NOUN	O	O	1155
Sciences	NOUN	O	O	1155
University	NOUN	O	O	1155
,	PUNCT	O	O	1155
Portland	PROPN	O	O	1155
,	PUNCT	O	O	1155
OR	CCONJ	O	O	1155
97201	NUM	O	O	1155
.	PUNCT	O	O	1155
Bradycardia	PROPN	O	Disease	1158
due	ADJ	O	O	1158
to	PART	O	O	1158
trihexyphenidyl hydrochloride	NOUN	O	Chemical	1158
.	PUNCT	O	O	1158
A	PRON	O	O	1159
chronic	ADJ	O	O	1159
schizophrenic	ADJ	O	Disease	1159
patient	NOUN	O	O	1159
was	AUX	O	O	1159
treated	VERB	O	O	1159
with	ADP	O	O	1159
an	PRON	O	O	1159
anticholinergic	ADJ	O	O	1159
drug	NOUN	O	O	1159
,	PUNCT	O	O	1159
trihexyphenidyl hydrochloride	NOUN	O	Chemical	1159
.	PUNCT	O	O	1159
The	PRON	O	O	1160
patient	NOUN	O	O	1160
developed	VERB	O	O	1160
,	PUNCT	O	O	1160
paradoxically	ADV	O	O	1160
,	PUNCT	O	O	1160
sinus	NOUN	O	O	1160
bradycardia	NOUN	O	Disease	1160
.	PUNCT	O	O	1160
The	PRON	O	O	1161
reaction	NOUN	O	O	1161
was	AUX	O	O	1161
specific	ADJ	O	O	1161
to	PART	O	O	1161
trihexyphenidyl	ADJ	O	Chemical	1161
and	CCONJ	O	O	1161
not	PART	O	O	1161
to	PART	O	O	1161
other	ADJ	O	O	1161
anticholinergic	ADJ	O	O	1161
drugs	NOUN	O	O	1161
.	PUNCT	O	O	1161
This	PRON	O	O	1162
antidyskinetic	NOUN	O	O	1162
drug	NOUN	O	O	1162
is	AUX	O	O	1162
widely	ADV	O	O	1162
used	VERB	O	O	1162
in	ADP	O	O	1162
clinical	ADJ	O	O	1162
psychiatric	ADJ	O	Disease	1162
practice	VERB	O	O	1162
and	CCONJ	O	O	1162
physicians	NOUN	O	O	1162
should	AUX	O	O	1162
be	AUX	O	O	1162
aware	ADJ	O	O	1162
of	ADP	O	O	1162
this	PRON	O	O	1162
side	NOUN	O	O	1162
effect	VERB	O	O	1162
.	PUNCT	O	O	1162
Experimental	ADJ	O	O	1165
cyclosporine	NOUN	O	Chemical	1165
nephrotoxicity	NOUN	O	Disease	1165
:	PUNCT	O	O	1165
risk	NOUN	O	O	1165
of	ADP	O	O	1165
concomitant	ADJ	O	O	1165
chemotherapy	NOUN	O	O	1165
.	PUNCT	O	O	1165
The	PRON	O	O	1166
role	NOUN	O	O	1166
of	ADP	O	O	1166
cyclosporine	NOUN	O	Chemical	1166
(	PUNCT	O	O	1166
CSA	PROPN	O	Chemical	1166
)	PUNCT	O	O	1166
alone	ADV	O	O	1166
or	CCONJ	O	O	1166
in	ADP	O	O	1166
combination	NOUN	O	O	1166
with	ADP	O	O	1166
various	ADJ	O	O	1166
chemotherapeutics	NOUN	O	O	1166
in	ADP	O	O	1166
the	PRON	O	O	1166
development	NOUN	O	O	1166
of	ADP	O	O	1166
renal toxicity	NOUN	O	Disease	1166
was	AUX	O	O	1166
evaluated	VERB	O	O	1166
in	ADP	O	O	1166
rats	NOUN	O	O	1166
.	PUNCT	O	O	1166
Administration	NOUN	O	O	1167
of	ADP	O	O	1167
20	NUM	O	O	1167
mg	VERB	O	O	1167
/	PUNCT	O	O	1167
kg	VERB	O	O	1167
/	PUNCT	O	O	1167
day	NOUN	O	O	1167
CSA	PROPN	O	Chemical	1167
for	ADP	O	O	1167
4	NUM	O	O	1167
weeks	NOUN	O	O	1167
caused	VERB	O	O	1167
renal	ADJ	O	O	1167
functional	ADJ	O	O	1167
and	CCONJ	O	O	1167
structural	ADJ	O	O	1167
changes	VERB	O	O	1167
similar	ADJ	O	O	1167
to	PART	O	O	1167
those	PRON	O	O	1167
reported	VERB	O	O	1167
in	ADP	O	O	1167
man	NOUN	O	O	1167
.	PUNCT	O	O	1167
The	PRON	O	O	1168
combined	VERB	O	O	1168
administration	NOUN	O	O	1168
of	ADP	O	O	1168
CSA	PROPN	O	Chemical	1168
and	CCONJ	O	O	1168
various	ADJ	O	O	1168
chemotherapeutic	NOUN	O	O	1168
drugs	NOUN	O	O	1168
with	ADP	O	O	1168
a	PRON	O	O	1168
nephrotoxic	NOUN	O	Disease	1168
potential	ADJ	O	O	1168
,	PUNCT	O	O	1168
such	ADJ	O	O	1168
as	ADP	O	O	1168
gentamicin	VERB	O	Chemical	1168
(	PUNCT	O	O	1168
at	ADP	O	O	1168
therapeutic	ADJ	O	O	1168
doses	NOUN	O	O	1168
)	PUNCT	O	O	1168
,	PUNCT	O	O	1168
amphothericin B	NOUN	O	Chemical	1168
and	CCONJ	O	O	1168
ketoconazole	PROPN	O	Chemical	1168
,	PUNCT	O	O	1168
which	PRON	O	O	1168
are	AUX	O	O	1168
frequently	ADV	O	O	1168
used	VERB	O	O	1168
in	ADP	O	O	1168
immunosuppressed	ADJ	O	O	1168
patients	NOUN	O	O	1168
,	PUNCT	O	O	1168
did	VERB	O	O	1168
not	PART	O	O	1168
aggravate	VERB	O	O	1168
the	PRON	O	O	1168
CSA	PROPN	O	Chemical	1168
induced	VERB	O	O	1168
toxicity	NOUN	O	Disease	1168
in	ADP	O	O	1168
the	PRON	O	O	1168
rat	NOUN	O	O	1168
model	NOUN	O	O	1168
.	PUNCT	O	O	1168
Gentamicin	PROPN	O	Chemical	1169
at	ADP	O	O	1169
toxic	ADJ	O	O	1169
doses	NOUN	O	O	1169
,	PUNCT	O	O	1169
however	ADV	O	O	1169
,	PUNCT	O	O	1169
increased	VERB	O	O	1169
CSA	PROPN	O	Chemical	1169
nephrotoxicity	NOUN	O	Disease	1169
.	PUNCT	O	O	1169
Thus	ADV	O	O	1170
,	PUNCT	O	O	1170
the	PRON	O	O	1170
nephrotoxicity	NOUN	O	Disease	1170
induced	VERB	O	O	1170
by	ADP	O	O	1170
CSA	PROPN	O	Chemical	1170
has	VERB	O	O	1170
a	PRON	O	O	1170
different	ADJ	O	O	1170
pathogenetic	NOUN	O	O	1170
mechanism	NOUN	O	O	1170
.	PUNCT	O	O	1170
Receptor	NOUN	O	O	1173
mechanisms	NOUN	O	O	1173
of	ADP	O	O	1173
nicotine	NOUN	O	Chemical	1173
-	PUNCT	O	O	1173
induced	VERB	O	O	1173
locomotor hyperactivity	NOUN	O	Disease	1173
in	ADP	O	O	1173
chronic	ADJ	O	O	1173
nicotine	NOUN	O	Chemical	1173
-	PUNCT	O	O	1173
treated	VERB	O	O	1173
rats	NOUN	O	O	1173
.	PUNCT	O	O	1173
Rats	NOUN	O	O	1174
were	AUX	O	O	1174
pretreated	VERB	O	O	1174
with	ADP	O	O	1174
saline	NOUN	O	O	1174
or	CCONJ	O	O	1174
nicotine	NOUN	O	Chemical	1174
(	PUNCT	O	O	1174
1.5	NUM	O	O	1174
mg	VERB	O	O	1174
/	PUNCT	O	O	1174
kg	VERB	O	O	1174
per	ADP	O	O	1174
day	NOUN	O	O	1174
)	PUNCT	O	O	1174
by	ADP	O	O	1174
subcutaneously	ADV	O	O	1174
implanting	VERB	O	O	1174
each	PRON	O	O	1174
animal	NOUN	O	O	1174
with	ADP	O	O	1174
an	PRON	O	O	1174
Alzet	PROPN	O	O	1174
osmotic	NOUN	O	O	1174
mini	NOUN	O	O	1174
-	PUNCT	O	O	1174
pump	VERB	O	O	1174
which	PRON	O	O	1174
continuously	ADV	O	O	1174
released	VERB	O	O	1174
saline	NOUN	O	O	1174
or	CCONJ	O	O	1174
nicotine	NOUN	O	Chemical	1174
for	ADP	O	O	1174
1	X	O	O	1174
,	PUNCT	O	O	1174
5	NUM	O	O	1174
and	CCONJ	O	O	1174
14	NUM	O	O	1174
days	NOUN	O	O	1174
.	PUNCT	O	O	1174
At	ADP	O	O	1175
the	PRON	O	O	1175
end	VERB	O	O	1175
of	ADP	O	O	1175
each	PRON	O	O	1175
pretreatment	NOUN	O	O	1175
period	NOUN	O	O	1175
,	PUNCT	O	O	1175
animals	NOUN	O	O	1175
were	AUX	O	O	1175
used	VERB	O	O	1175
for	ADP	O	O	1175
(	PUNCT	O	O	1175
i	PRON	O	O	1175
)	PUNCT	O	O	1175
determining	VERB	O	O	1175
their	PRON	O	O	1175
locomotor	PROPN	O	O	1175
response	NOUN	O	O	1175
to	PART	O	O	1175
acutely	ADV	O	O	1175
injected	VERB	O	O	1175
nicotine	NOUN	O	Chemical	1175
(	PUNCT	O	O	1175
0.2	NUM	O	O	1175
mg	VERB	O	O	1175
/	PUNCT	O	O	1175
kg	VERB	O	O	1175
,	PUNCT	O	O	1175
s.c	PROPN	O	O	1175
.	PUNCT	O	O	1175
)	PUNCT	O	O	1175
and	CCONJ	O	O	1175
(	PUNCT	O	O	1175
ii	PROPN	O	O	1175
)	PUNCT	O	O	1175
measuring	VERB	O	O	1175
the	PRON	O	O	1175
density	NOUN	O	O	1175
of	ADP	O	O	1175
L-[3H]nicotine	NOUN	O	O	1175
and	CCONJ	O	O	1175
[	X	O	O	1175
3H]spiperone	NUM	O	O	1175
binding	VERB	O	O	1175
sites	NOUN	O	O	1175
in	ADP	O	O	1175
the	PRON	O	O	1175
striatum	NOUN	O	O	1175
.	PUNCT	O	O	1175
We	PRON	O	O	1176
observed	VERB	O	O	1176
no	PRON	O	O	1176
changes	VERB	O	O	1176
in	ADP	O	O	1176
nicotine	NOUN	O	Chemical	1176
-	PUNCT	O	O	1176
induced	VERB	O	O	1176
locomotor	PROPN	O	O	1176
response	NOUN	O	O	1176
,	PUNCT	O	O	1176
striatal	ADJ	O	O	1176
L-[3H]nicotine	NOUN	O	O	1176
and	CCONJ	O	O	1176
[	X	O	O	1176
3H]spiperone	NUM	O	O	1176
binding	VERB	O	O	1176
in	ADP	O	O	1176
the	PRON	O	O	1176
animals	NOUN	O	O	1176
pretreated	VERB	O	O	1176
with	ADP	O	O	1176
nicotine	NOUN	O	Chemical	1176
for	ADP	O	O	1176
1	X	O	O	1176
day	NOUN	O	O	1176
.	PUNCT	O	O	1176
In	ADP	O	O	1177
rats	NOUN	O	O	1177
which	PRON	O	O	1177
were	AUX	O	O	1177
pretreated	VERB	O	O	1177
with	ADP	O	O	1177
nicotine	NOUN	O	Chemical	1177
for	ADP	O	O	1177
5	NUM	O	O	1177
days	NOUN	O	O	1177
,	PUNCT	O	O	1177
there	ADV	O	O	1177
was	AUX	O	O	1177
a	PRON	O	O	1177
significant	ADJ	O	O	1177
increase	VERB	O	O	1177
in	ADP	O	O	1177
the	PRON	O	O	1177
nicotine	NOUN	O	Chemical	1177
-	PUNCT	O	O	1177
stimulated	VERB	O	O	1177
locomotor	PROPN	O	O	1177
response	NOUN	O	O	1177
which	PRON	O	O	1177
was	AUX	O	O	1177
associated	VERB	O	O	1177
with	ADP	O	O	1177
an	PRON	O	O	1177
increase	VERB	O	O	1177
in	ADP	O	O	1177
the	PRON	O	O	1177
number	NOUN	O	O	1177
of	ADP	O	O	1177
L-[3H]nicotine	NOUN	O	O	1177
binding	VERB	O	O	1177
sites	NOUN	O	O	1177
and	CCONJ	O	O	1177
also	ADV	O	O	1177
with	ADP	O	O	1177
an	PRON	O	O	1177
elevated	ADJ	O	O	1177
dopamine	NOUN	O	Chemical	1177
(	PUNCT	O	O	1177
DA	NOUN	O	Chemical	1177
)	PUNCT	O	O	1177
level	VERB	O	O	1177
in	ADP	O	O	1177
the	PRON	O	O	1177
striatum	NOUN	O	O	1177
.	PUNCT	O	O	1177
The	PRON	O	O	1178
number	NOUN	O	O	1178
of	ADP	O	O	1178
striatal	ADJ	O	O	1178
[	X	O	O	1178
3H]spiperone	NUM	O	O	1178
binding	VERB	O	O	1178
sites	NOUN	O	O	1178
was	AUX	O	O	1178
not	PART	O	O	1178
affected	VERB	O	O	1178
.	PUNCT	O	O	1178
In	ADP	O	O	1179
animals	NOUN	O	O	1179
pretreated	VERB	O	O	1179
with	ADP	O	O	1179
nicotine	NOUN	O	Chemical	1179
for	ADP	O	O	1179
14	NUM	O	O	1179
days	NOUN	O	O	1179
,	PUNCT	O	O	1179
the	PRON	O	O	1179
nicotine	NOUN	O	Chemical	1179
-	PUNCT	O	O	1179
induced	VERB	O	O	1179
locomotor	PROPN	O	O	1179
response	NOUN	O	O	1179
remained	VERB	O	O	1179
to	PART	O	O	1179
be	AUX	O	O	1179
potentiated	VERB	O	O	1179
.	PUNCT	O	O	1179
However	ADV	O	O	1180
,	PUNCT	O	O	1180
this	PRON	O	O	1180
response	NOUN	O	O	1180
was	AUX	O	O	1180
correlated	VERB	O	O	1180
with	ADP	O	O	1180
an	PRON	O	O	1180
elevated	ADJ	O	O	1180
number	NOUN	O	O	1180
of	ADP	O	O	1180
striatal	ADJ	O	O	1180
[	X	O	O	1180
3H]spiperone	NUM	O	O	1180
binding	VERB	O	O	1180
sites	NOUN	O	O	1180
,	PUNCT	O	O	1180
whereas	SCONJ	O	O	1180
the	PRON	O	O	1180
number	NOUN	O	O	1180
of	ADP	O	O	1180
striatal	ADJ	O	O	1180
L-[3H]nicotine	NOUN	O	O	1180
binding	VERB	O	O	1180
sites	NOUN	O	O	1180
and	CCONJ	O	O	1180
the	PRON	O	O	1180
striatal	ADJ	O	O	1180
DA	NOUN	O	Chemical	1180
level	VERB	O	O	1180
were	AUX	O	O	1180
normal	ADJ	O	O	1180
.	PUNCT	O	O	1180
These	PRON	O	O	1181
results	VERB	O	O	1181
suggest	VERB	O	O	1181
that	SCONJ	O	O	1181
chronic	ADJ	O	O	1181
nicotine	NOUN	O	Chemical	1181
-	PUNCT	O	O	1181
treated	VERB	O	O	1181
rats	NOUN	O	O	1181
develop	VERB	O	O	1181
locomotor hyperactivity	NOUN	O	Disease	1181
in	ADP	O	O	1181
response	NOUN	O	O	1181
to	PART	O	O	1181
nicotine	NOUN	O	Chemical	1181
initially	ADV	O	O	1181
due	ADJ	O	O	1181
to	PART	O	O	1181
increases	VERB	O	O	1181
of	ADP	O	O	1181
both	PRON	O	O	1181
the	PRON	O	O	1181
density	NOUN	O	O	1181
of	ADP	O	O	1181
nicotinic	ADJ	O	O	1181
receptors	NOUN	O	O	1181
and	CCONJ	O	O	1181
DA	NOUN	O	Chemical	1181
concentration	NOUN	O	O	1181
,	PUNCT	O	O	1181
followed	VERB	O	O	1181
by	ADP	O	O	1181
inducing	VERB	O	O	1181
DA	NOUN	O	Chemical	1181
receptor	NOUN	O	O	1181
supersensitivity	NOUN	O	O	1181
in	ADP	O	O	1181
the	PRON	O	O	1181
striatum	NOUN	O	O	1181
.	PUNCT	O	O	1181
Hydrocortisone	PROPN	O	Chemical	1184
-	PUNCT	O	O	1184
induced	VERB	O	O	1184
hypertension	NOUN	O	Disease	1184
in	ADP	O	O	1184
humans	NOUN	O	O	1184
:	PUNCT	O	O	1184
pressor	ADJ	O	O	1184
responsiveness	NOUN	O	O	1184
and	CCONJ	O	O	1184
sympathetic	ADJ	O	O	1184
function	NOUN	O	O	1184
.	PUNCT	O	O	1184
Oral	NOUN	O	O	1185
hydrocortisone	NOUN	O	Chemical	1185
increases	VERB	O	O	1185
blood	NOUN	O	O	1185
pressure	NOUN	O	O	1185
and	CCONJ	O	O	1185
enhances	VERB	O	O	1185
pressor	ADJ	O	O	1185
responsiveness	NOUN	O	O	1185
in	ADP	O	O	1185
normal	ADJ	O	O	1185
human	PROPN	O	O	1185
subjects	NOUN	O	O	1185
.	PUNCT	O	O	1185
We	PRON	O	O	1186
studied	VERB	O	O	1186
the	PRON	O	O	1186
effects	NOUN	O	O	1186
of	ADP	O	O	1186
1	X	O	O	1186
week	NOUN	O	O	1186
of	ADP	O	O	1186
oral	ADJ	O	O	1186
hydrocortisone	NOUN	O	Chemical	1186
(	PUNCT	O	O	1186
200	NUM	O	O	1186
mg	VERB	O	O	1186
/	PUNCT	O	O	1186
day	NOUN	O	O	1186
)	PUNCT	O	O	1186
on	ADP	O	O	1186
blood	NOUN	O	O	1186
pressure	NOUN	O	O	1186
,	PUNCT	O	O	1186
cardiac	ADJ	O	O	1186
output	NOUN	O	O	1186
,	PUNCT	O	O	1186
total	ADJ	O	O	1186
peripheral	ADJ	O	O	1186
resistance	NOUN	O	O	1186
,	PUNCT	O	O	1186
forearm	NOUN	O	O	1186
vascular	ADJ	O	O	1186
resistance	NOUN	O	O	1186
,	PUNCT	O	O	1186
and	CCONJ	O	O	1186
norepinephrine	NOUN	O	Chemical	1186
spillover	NOUN	O	O	1186
to	PART	O	O	1186
plasma	NOUN	O	O	1186
in	ADP	O	O	1186
eight	NUM	O	O	1186
healthy	ADJ	O	O	1186
male	NOUN	O	O	1186
volunteers	NOUN	O	O	1186
.	PUNCT	O	O	1186
3.4	NUM	O	O	1187
,	PUNCT	O	O	1187
p	NOUN	O	O	1187
less	ADV	O	O	1187
than	ADP	O	O	1187
0.01	NUM	O	O	1187
)	PUNCT	O	O	1187
,	PUNCT	O	O	1187
associated	VERB	O	O	1187
with	ADP	O	O	1187
an	PRON	O	O	1187
increased cardiac output	NOUN	O	Disease	1187
(	PUNCT	O	O	1187
5.85	NUM	O	O	1187
-	PUNCT	O	O	1187
7.73	NUM	O	O	1187
l	X	O	O	1187
/	PUNCT	O	O	1187
min	NOUN	O	O	1187
,	PUNCT	O	O	1187
SED	PROPN	O	O	1187
+	ADP	O	O	1187
/-	PUNCT	O	O	1187
The	PRON	O	O	1188
rise	VERB	O	O	1188
in	ADP	O	O	1188
forearm	NOUN	O	O	1188
vascular	ADJ	O	O	1188
resistance	NOUN	O	O	1188
accompanying	VERB	O	O	1188
intra	ADJ	O	O	1188
-	PUNCT	O	O	1188
arterial	ADJ	O	O	1188
norepinephrine	NOUN	O	Chemical	1188
(	PUNCT	O	O	1188
25	NUM	O	O	1188
,	PUNCT	O	O	1188
50	NUM	O	O	1188
,	PUNCT	O	O	1188
and	CCONJ	O	O	1188
100	NUM	O	O	1188
ng	PROPN	O	O	1188
/	PUNCT	O	O	1188
min	NOUN	O	O	1188
)	PUNCT	O	O	1188
was	AUX	O	O	1188
also	ADV	O	O	1188
significantly	ADV	O	O	1188
greater	ADJ	O	O	1188
after	ADP	O	O	1188
hydrocortisone	NOUN	O	Chemical	1188
,	PUNCT	O	O	1188
increasing	VERB	O	O	1188
from	ADP	O	O	1188
an	PRON	O	O	1188
average	ADJ	O	O	1188
of	ADP	O	O	1188
14.9	NUM	O	O	1188
+	ADP	O	O	1188
/-	PUNCT	O	O	1188
5.5	NUM	O	O	1189
R	NOUN	O	O	1189
units	NOUN	O	O	1189
after	ADP	O	O	1189
hydrocortisone	NOUN	O	Chemical	1189
A	PRON	O	O	1190
shift	NOUN	O	O	1190
to	PART	O	O	1190
the	PRON	O	O	1190
left	VERB	O	O	1190
in	ADP	O	O	1190
the	PRON	O	O	1190
dose	NOUN	O	O	1190
-	PUNCT	O	O	1190
response	NOUN	O	O	1190
relation	NOUN	O	O	1190
and	CCONJ	O	O	1190
fall	VERB	O	O	1190
in	ADP	O	O	1190
threshold	NOUN	O	O	1190
suggested	VERB	O	O	1190
increased	VERB	O	O	1190
sensitivity	NOUN	O	O	1190
to	PART	O	O	1190
norepinephrine	NOUN	O	Chemical	1190
after	ADP	O	O	1190
treatment	NOUN	O	O	1190
.	PUNCT	O	O	1190
Measurement	NOUN	O	O	1191
of	ADP	O	O	1191
resting	VERB	O	O	1191
norepinephrine	NOUN	O	Chemical	1191
spillover	NOUN	O	O	1191
rate	NOUN	O	O	1191
to	PART	O	O	1191
plasma	NOUN	O	O	1191
and	CCONJ	O	O	1191
norepinephrine	NOUN	O	Chemical	1191
uptake	NOUN	O	O	1191
indicated	VERB	O	O	1191
that	SCONJ	O	O	1191
overall	ADV	O	O	1191
resting	VERB	O	O	1191
sympathetic	ADJ	O	O	1191
nervous	ADJ	O	O	1191
system	NOUN	O	O	1191
activity	NOUN	O	O	1191
was	AUX	O	O	1191
not	PART	O	O	1191
increased	VERB	O	O	1191
.	PUNCT	O	O	1191
The	PRON	O	O	1192
rise in resting blood pressure	NOUN	O	Disease	1192
with	ADP	O	O	1192
hydrocortisone	NOUN	O	Chemical	1192
is	AUX	O	O	1192
associated	VERB	O	O	1192
with	ADP	O	O	1192
an	PRON	O	O	1192
increased cardiac output	NOUN	O	Disease	1192
(	PUNCT	O	O	1192
presumably	ADV	O	O	1192
due	ADJ	O	O	1192
to	PART	O	O	1192
increased	VERB	O	O	1192
blood	NOUN	O	O	1192
volume).(ABSTRACT	PROPN	O	O	1192
TRUNCATED	ADJ	O	O	1192
AT	ADP	O	O	1192
250	NUM	O	O	1192
WORDS	NOUN	O	O	1192
)	PUNCT	O	O	1192
Effects	NOUN	O	O	1195
of	ADP	O	O	1195
suprofen	NOUN	O	Chemical	1195
on	ADP	O	O	1195
the	PRON	O	O	1195
isolated	VERB	O	O	1195
perfused	VERB	O	O	1195
rat	NOUN	O	O	1195
kidney	NOUN	O	O	1195
.	PUNCT	O	O	1195
Although	SCONJ	O	O	1196
suprofen	NOUN	O	Chemical	1196
has	VERB	O	O	1196
been	AUX	O	O	1196
associated	VERB	O	O	1196
with	ADP	O	O	1196
the	PRON	O	O	1196
development	NOUN	O	O	1196
of	ADP	O	O	1196
acute	ADJ	O	O	1196
renal failure	NOUN	O	Disease	1196
in	ADP	O	O	1196
greater	ADJ	O	O	1196
than	ADP	O	O	1196
100	NUM	O	O	1196
subjects	NOUN	O	O	1196
,	PUNCT	O	O	1196
the	PRON	O	O	1196
mechanism	NOUN	O	O	1196
of	ADP	O	O	1196
damage	NOUN	O	O	1196
remains	VERB	O	O	1196
unclear	ADJ	O	O	1196
.	PUNCT	O	O	1196
The	PRON	O	O	1197
direct	ADJ	O	O	1197
nephrotoxic	NOUN	O	Disease	1197
effects	NOUN	O	O	1197
of	ADP	O	O	1197
a	PRON	O	O	1197
single	ADJ	O	O	1197
dose	NOUN	O	O	1197
of	ADP	O	O	1197
15	NUM	O	O	1197
mg	VERB	O	O	1197
of	ADP	O	O	1197
suprofen	NOUN	O	Chemical	1197
were	AUX	O	O	1197
compared	VERB	O	O	1197
in	ADP	O	O	1197
the	PRON	O	O	1197
recirculating	NOUN	O	O	1197
isolated	VERB	O	O	1197
rat	NOUN	O	O	1197
kidney	NOUN	O	O	1197
perfused	VERB	O	O	1197
with	ADP	O	O	1197
cell	NOUN	O	O	1197
-	PUNCT	O	O	1197
free	ADJ	O	O	1197
buffer	NOUN	O	O	1197
with	ADP	O	O	1197
or	CCONJ	O	O	1197
without	ADP	O	O	1197
the	PRON	O	O	1197
addition	NOUN	O	O	1197
of	ADP	O	O	1197
5	NUM	O	O	1197
mg	VERB	O	O	1197
/	PUNCT	O	O	1197
dL	VERB	O	O	1197
of	ADP	O	O	1197
uric acid	NOUN	O	Chemical	1197
.	PUNCT	O	O	1197
There	ADV	O	O	1198
were	AUX	O	O	1198
no	PRON	O	O	1198
significant	ADJ	O	O	1198
differences	NOUN	O	O	1198
in	ADP	O	O	1198
renal	ADJ	O	O	1198
sodium	NOUN	O	Chemical	1198
excretion	NOUN	O	O	1198
,	PUNCT	O	O	1198
oxygen	NOUN	O	Chemical	1198
consumption	NOUN	O	O	1198
,	PUNCT	O	O	1198
or	CCONJ	O	O	1198
urinary	ADJ	O	O	1198
flow	NOUN	O	O	1198
rates	NOUN	O	O	1198
in	ADP	O	O	1198
kidneys	NOUN	O	O	1198
perfused	VERB	O	O	1198
with	ADP	O	O	1198
suprofen	NOUN	O	Chemical	1198
compared	VERB	O	O	1198
with	ADP	O	O	1198
the	PRON	O	O	1198
drug	NOUN	O	O	1198
-	PUNCT	O	O	1198
free	ADJ	O	O	1198
control	VERB	O	O	1198
groups	NOUN	O	O	1198
.	PUNCT	O	O	1198
In	ADP	O	O	1199
contrast	NOUN	O	O	1199
,	PUNCT	O	O	1199
a	PRON	O	O	1199
significant	ADJ	O	O	1199
decline	VERB	O	O	1199
in	ADP	O	O	1199
glomerular	ADJ	O	O	1199
filtration	NOUN	O	O	1199
rate	NOUN	O	O	1199
was	AUX	O	O	1199
found	VERB	O	O	1199
after	ADP	O	O	1199
the	PRON	O	O	1199
introduction	NOUN	O	O	1199
of	ADP	O	O	1199
suprofen	NOUN	O	Chemical	1199
to	PART	O	O	1199
the	PRON	O	O	1199
kidney	NOUN	O	O	1199
perfused	VERB	O	O	1199
with	ADP	O	O	1199
uric acid	NOUN	O	Chemical	1199
;	PUNCT	O	O	1199
no	PRON	O	O	1199
changes	VERB	O	O	1199
were	AUX	O	O	1199
found	VERB	O	O	1199
with	ADP	O	O	1199
suprofen	NOUN	O	Chemical	1199
in	ADP	O	O	1199
the	PRON	O	O	1199
absence	NOUN	O	O	1199
of	ADP	O	O	1199
uric acid	NOUN	O	Chemical	1199
.	PUNCT	O	O	1199
A	PRON	O	O	1200
significant	ADJ	O	O	1200
decrease	VERB	O	O	1200
in	ADP	O	O	1200
the	PRON	O	O	1200
baseline	VERB	O	O	1200
excretion	NOUN	O	O	1200
rate	NOUN	O	O	1200
of	ADP	O	O	1200
uric acid	NOUN	O	Chemical	1200
was	AUX	O	O	1200
found	VERB	O	O	1200
in	ADP	O	O	1200
rats	NOUN	O	O	1200
given	VERB	O	O	1200
suprofen	NOUN	O	Chemical	1200
,	PUNCT	O	O	1200
compared	VERB	O	O	1200
with	ADP	O	O	1200
drug	NOUN	O	O	1200
-	PUNCT	O	O	1200
free	ADJ	O	O	1200
controls	VERB	O	O	1200
.	PUNCT	O	O	1200
However	ADV	O	O	1201
,	PUNCT	O	O	1201
the	PRON	O	O	1201
fractional	ADJ	O	O	1201
excretion	NOUN	O	O	1201
of	ADP	O	O	1201
uric acid	NOUN	O	Chemical	1201
was	AUX	O	O	1201
unchanged	ADJ	O	O	1201
between	ADP	O	O	1201
the	PRON	O	O	1201
groups	NOUN	O	O	1201
over	ADP	O	O	1201
the	PRON	O	O	1201
experimental	ADJ	O	O	1201
period	NOUN	O	O	1201
.	PUNCT	O	O	1201
In	ADP	O	O	1202
summary	NOUN	O	O	1202
,	PUNCT	O	O	1202
suprofen	NOUN	O	Chemical	1202
causes	VERB	O	O	1202
acute declines in renal function	NOUN	O	Disease	1202
,	PUNCT	O	O	1202
most	ADV	O	O	1202
likely	ADV	O	O	1202
by	ADP	O	O	1202
directly	ADV	O	O	1202
altering	VERB	O	O	1202
the	PRON	O	O	1202
intrarenal	ADJ	O	O	1202
distribution	NOUN	O	O	1202
of	ADP	O	O	1202
uric acid	NOUN	O	Chemical	1202
.	PUNCT	O	O	1202
Cocaine	NOUN	O	Chemical	1205
-	PUNCT	O	O	1205
induced	VERB	O	O	1205
brainstem	NOUN	O	O	1205
seizures	NOUN	O	Disease	1205
and	CCONJ	O	O	1205
behavior	NOUN	O	O	1205
.	PUNCT	O	O	1205
electrical	ADJ	O	O	1206
current	ADJ	O	O	1206
stimulations	NOUN	O	O	1206
and	CCONJ	O	O	1206
by	ADP	O	O	1206
acute	ADJ	O	O	1206
and	CCONJ	O	O	1206
chronic	ADJ	O	O	1206
administration	NOUN	O	O	1206
of	ADP	O	O	1206
cocaine	NOUN	O	Chemical	1206
.	PUNCT	O	O	1206
Cocaine	NOUN	O	Chemical	1207
(	PUNCT	O	O	1207
40	NUM	O	O	1207
mg	VERB	O	O	1207
/	PUNCT	O	O	1207
kg	VERB	O	O	1207
)	PUNCT	O	O	1207
was	AUX	O	O	1207
injected	VERB	O	O	1207
subcutaneously	ADV	O	O	1207
for	ADP	O	O	1207
an	PRON	O	O	1207
acute	ADJ	O	O	1207
experiment	NOUN	O	O	1207
and	CCONJ	O	O	1207
subsequent	ADJ	O	O	1207
20	NUM	O	O	1207
mg	VERB	O	O	1207
/	PUNCT	O	O	1207
kg	VERB	O	O	1207
doses	NOUN	O	O	1207
twice	ADV	O	O	1207
daily	ADV	O	O	1207
for	ADP	O	O	1207
3	X	O	O	1207
days	NOUN	O	O	1207
in	ADP	O	O	1207
a	PRON	O	O	1207
chronic	ADJ	O	O	1207
study	VERB	O	O	1207
.	PUNCT	O	O	1207
Cocaine	NOUN	O	Chemical	1208
generated	VERB	O	O	1208
more	ADJ	O	O	1208
abnormal	ADJ	O	O	1208
behaviors	NOUN	O	O	1208
in	ADP	O	O	1208
the	PRON	O	O	1208
brainstem	NOUN	O	O	1208
perturbation	NOUN	O	O	1208
group	NOUN	O	O	1208
,	PUNCT	O	O	1208
especially	ADV	O	O	1208
the	PRON	O	O	1208
electrically	ADV	O	O	1208
perturbated	VERB	O	O	1208
subjects	NOUN	O	O	1208
.	PUNCT	O	O	1208
The	PRON	O	O	1209
abnormal	ADJ	O	O	1209
behaviors	NOUN	O	O	1209
were	AUX	O	O	1209
yawning	VERB	O	O	1209
,	PUNCT	O	O	1209
retrocollis	VERB	O	O	1209
,	PUNCT	O	O	1209
hyperactivity	NOUN	O	Disease	1209
,	PUNCT	O	O	1209
hypersensitivity	NOUN	O	Disease	1209
,	PUNCT	O	O	1209
""""	PUNCT	O	O	1209
beating	VERB	O	O	1209
drum	NOUN	O	O	1209
""""	PUNCT	O	O	1209
behavior	NOUN	O	O	1209
,	PUNCT	O	O	1209
squealing	VERB	O	O	1209
,	PUNCT	O	O	1209
head	NOUN	O	O	1209
bobbing	VERB	O	O	1209
,	PUNCT	O	O	1209
circling	VERB	O	O	1209
,	PUNCT	O	O	1209
sniffing	VERB	O	O	1209
,	PUNCT	O	O	1209
abnormal	ADJ	O	O	1209
posturing	NOUN	O	O	1209
,	PUNCT	O	O	1209
and	CCONJ	O	O	1209
facial	ADJ	O	O	1209
twitching	VERB	O	O	1209
.	PUNCT	O	O	1209
Hypersensitivity	NOUN	O	Disease	1210
to	PART	O	O	1210
various	ADJ	O	O	1210
auditory	NOUN	O	O	1210
,	PUNCT	O	O	1210
tactile	ADJ	O	O	1210
,	PUNCT	O	O	1210
and	CCONJ	O	O	1210
visual	ADJ	O	O	1210
stimulation	NOUN	O	O	1210
was	AUX	O	O	1210
present	NOUN	O	O	1210
and	CCONJ	O	O	1210
shifts	NOUN	O	O	1210
in	ADP	O	O	1210
the	PRON	O	O	1210
brainstem	NOUN	O	O	1210
ambient	NOUN	O	O	1210
power	NOUN	O	O	1210
spectral	ADJ	O	O	1210
frequency	NOUN	O	O	1210
occurred	VERB	O	O	1210
in	ADP	O	O	1210
response	NOUN	O	O	1210
to	PART	O	O	1210
tactile	ADJ	O	O	1210
stimulation	NOUN	O	O	1210
.	PUNCT	O	O	1210
Cocaine	NOUN	O	Chemical	1211
was	AUX	O	O	1211
found	VERB	O	O	1211
to	PART	O	O	1211
activate	VERB	O	O	1211
the	PRON	O	O	1211
discharge	VERB	O	O	1211
system	NOUN	O	O	1211
and	CCONJ	O	O	1211
thus	ADV	O	O	1211
induce	VERB	O	O	1211
abnormal	ADJ	O	O	1211
behaviors	NOUN	O	O	1211
that	SCONJ	O	O	1211
are	AUX	O	O	1211
generated	VERB	O	O	1211
at	ADP	O	O	1211
the	PRON	O	O	1211
discharge	VERB	O	O	1211
site	NOUN	O	O	1211
and	CCONJ	O	O	1211
at	ADP	O	O	1211
distant	ADJ	O	O	1211
sites	NOUN	O	O	1211
to	PART	O	O	1211
which	PRON	O	O	1211
the	PRON	O	O	1211
discharge	VERB	O	O	1211
propagates	VERB	O	O	1211
.	PUNCT	O	O	1211
Increased	VERB	O	O	1214
sulfation	PROPN	O	O	1214
and	CCONJ	O	O	1214
decreased	VERB	O	O	1214
7alpha	NUM	O	O	1214
-	PUNCT	O	O	1214
hydroxylation	NOUN	O	O	1214
of	ADP	O	O	1214
deoxycholic acid	NOUN	O	Chemical	1214
in	ADP	O	O	1214
ethinyl estradiol	NOUN	O	Chemical	1214
-	PUNCT	O	O	1214
induced	VERB	O	O	1214
cholestasis	NOUN	O	Disease	1214
in	ADP	O	O	1214
rats	NOUN	O	O	1214
.	PUNCT	O	O	1214
Deoxycholic acid	NOUN	O	Chemical	1215
conjugation	NOUN	O	O	1215
,	PUNCT	O	O	1215
transport	NOUN	O	O	1215
capacity	NOUN	O	O	1215
,	PUNCT	O	O	1215
and	CCONJ	O	O	1215
metabolism	NOUN	O	O	1215
were	AUX	O	O	1215
compared	VERB	O	O	1215
in	ADP	O	O	1215
control	VERB	O	O	1215
and	CCONJ	O	O	1215
ethinyl estradiol	NOUN	O	Chemical	1215
-	PUNCT	O	O	1215
treated	VERB	O	O	1215
rats	NOUN	O	O	1215
.	PUNCT	O	O	1215
Control	NOUN	O	O	1216
rats	NOUN	O	O	1216
were	AUX	O	O	1216
found	VERB	O	O	1216
to	PART	O	O	1216
have	VERB	O	O	1216
a	PRON	O	O	1216
lower	ADJ	O	O	1216
capacity	NOUN	O	O	1216
to	PART	O	O	1216
transport	NOUN	O	O	1216
deoxycholic acid	NOUN	O	Chemical	1216
than	ADP	O	O	1216
taurodeoxycholic acid	NOUN	O	Chemical	1216
,	PUNCT	O	O	1216
and	CCONJ	O	O	1216
both	PRON	O	O	1216
were	AUX	O	O	1216
decreased	VERB	O	O	1216
by	ADP	O	O	1216
ethinyl estradiol	NOUN	O	Chemical	1216
treatment	NOUN	O	O	1216
.	PUNCT	O	O	1216
During	ADP	O	O	1217
[	X	O	O	1217
24	NUM	O	O	1217
-	PUNCT	O	O	1217
14C]sodium deoxycholate	NOUN	O	O	1217
infusion	NOUN	O	O	1217
,	PUNCT	O	O	1217
[	X	O	O	1217
14C]biliary	NUM	O	O	1217
bile acid	NOUN	O	Chemical	1217
secretion	NOUN	O	O	1217
increased	VERB	O	O	1217
,	PUNCT	O	O	1217
but	CCONJ	O	O	1217
bile	NOUN	O	O	1217
flow	NOUN	O	O	1217
did	VERB	O	O	1217
not	PART	O	O	1217
change	VERB	O	O	1217
significantly	ADV	O	O	1217
in	ADP	O	O	1217
either	ADV	O	O	1217
control	VERB	O	O	1217
or	CCONJ	O	O	1217
ethinyl estradiol	NOUN	O	Chemical	1217
-	PUNCT	O	O	1217
treated	VERB	O	O	1217
rats	NOUN	O	O	1217
.	PUNCT	O	O	1217
Ethinyl estradiol	NOUN	O	Chemical	1218
-	PUNCT	O	O	1218
treated	VERB	O	O	1218
animals	NOUN	O	O	1218
excreted	VERB	O	O	1218
significantly	ADV	O	O	1218
less	ADV	O	O	1218
14C	NUM	O	O	1218
as	ADP	O	O	1218
taurocholic acid	NOUN	O	Chemical	1218
than	ADP	O	O	1218
did	VERB	O	O	1218
control	VERB	O	O	1218
animals	NOUN	O	O	1218
,	PUNCT	O	O	1218
consistent	ADJ	O	O	1218
with	ADP	O	O	1218
an	PRON	O	O	1218
impairment	NOUN	O	O	1218
of	ADP	O	O	1218
7alpha	NUM	O	O	1218
-	PUNCT	O	O	1218
hydroxylation	NOUN	O	O	1218
of	ADP	O	O	1218
taurodeoxycholic acid	NOUN	O	Chemical	1218
.	PUNCT	O	O	1218
Ethinyl estradiol	NOUN	O	Chemical	1219
treatment	NOUN	O	O	1219
did	VERB	O	O	1219
not	PART	O	O	1219
impair	VERB	O	O	1219
conjugation	NOUN	O	O	1219
of	ADP	O	O	1219
deoxycholic acid	NOUN	O	Chemical	1219
,	PUNCT	O	O	1219
but	CCONJ	O	O	1219
did	VERB	O	O	1219
result	VERB	O	O	1219
in	ADP	O	O	1219
an	PRON	O	O	1219
increase	VERB	O	O	1219
in	ADP	O	O	1219
sulfation	PROPN	O	O	1219
of	ADP	O	O	1219
taurodeoxycholic acid	NOUN	O	Chemical	1219
from	ADP	O	O	1219
1.5%	NOUN	O	O	1219
in	ADP	O	O	1219
controls	VERB	O	O	1219
to	PART	O	O	1219
nearly	ADV	O	O	1219
4.0%	NOUN	O	O	1219
(	PUNCT	O	O	1219
P	NOUN	O	Chemical	1219
less	ADV	O	O	1219
than	ADP	O	O	1219
0.01	NUM	O	O	1219
)	PUNCT	O	O	1219
.	PUNCT	O	O	1219
These	PRON	O	O	1220
results	VERB	O	O	1220
are	AUX	O	O	1220
consistent	ADJ	O	O	1220
with	ADP	O	O	1220
the	PRON	O	O	1220
hypothesis	NOUN	O	O	1220
that	SCONJ	O	O	1220
the	PRON	O	O	1220
rat	NOUN	O	O	1220
has	VERB	O	O	1220
a	PRON	O	O	1220
poorer	ADV	O	O	1220
tolerance	NOUN	O	O	1220
for	ADP	O	O	1220
deoxycholic acid	NOUN	O	Chemical	1220
than	ADP	O	O	1220
do	VERB	O	O	1220
certain	ADJ	O	O	1220
other	ADJ	O	O	1220
species	NOUN	O	O	1220
.	PUNCT	O	O	1220
Furthermore	ADV	O	O	1221
,	PUNCT	O	O	1221
the	PRON	O	O	1221
rat	NOUN	O	O	1221
converts	VERB	O	O	1221
deoxycholic acid	NOUN	O	Chemical	1221
,	PUNCT	O	O	1221
a	PRON	O	O	1221
poor	ADJ	O	O	1221
choleretic	ADJ	O	O	1221
,	PUNCT	O	O	1221
to	PART	O	O	1221
taurocholic acid	NOUN	O	Chemical	1221
,	PUNCT	O	O	1221
a	PRON	O	O	1221
good	ADJ	O	O	1221
choleretic	ADJ	O	O	1221
.	PUNCT	O	O	1221
When	SCONJ	O	O	1222
this	PRON	O	O	1222
conversion	NOUN	O	O	1222
is	AUX	O	O	1222
impaired	VERB	O	O	1222
with	ADP	O	O	1222
ethinyl estradiol	NOUN	O	Chemical	1222
treatment	NOUN	O	O	1222
,	PUNCT	O	O	1222
sulfation	PROPN	O	O	1222
may	AUX	O	O	1222
be	AUX	O	O	1222
an	PRON	O	O	1222
important	ADJ	O	O	1222
alternate	ADJ	O	O	1222
pathway	NOUN	O	O	1222
for	ADP	O	O	1222
excretion	NOUN	O	O	1222
of	ADP	O	O	1222
this	PRON	O	O	1222
potentially	ADV	O	O	1222
harmful	ADJ	O	O	1222
bile acid	NOUN	O	Chemical	1222
.	PUNCT	O	O	1222
Effects	NOUN	O	O	1225
of	ADP	O	O	1225
ouabain	PROPN	O	Chemical	1225
on	ADP	O	O	1225
myocardial	ADJ	O	O	1225
oxygen	NOUN	O	Chemical	1225
supply	NOUN	O	O	1225
and	CCONJ	O	O	1225
demand	NOUN	O	O	1225
in	ADP	O	O	1225
patients	NOUN	O	O	1225
with	ADP	O	O	1225
chronic	ADJ	O	O	1225
coronary artery disease	NOUN	O	Disease	1225
.	PUNCT	O	O	1225
A	PRON	O	O	1226
hemodynamic	ADJ	O	O	1226
,	PUNCT	O	O	1226
volumetric	NOUN	O	O	1226
,	PUNCT	O	O	1226
and	CCONJ	O	O	1226
metabolic	ADJ	O	O	1226
study	VERB	O	O	1226
in	ADP	O	O	1226
patients	NOUN	O	O	1226
without	ADP	O	O	1226
heart failure	NOUN	O	Disease	1226
.	PUNCT	O	O	1226
The	PRON	O	O	1227
effects	NOUN	O	O	1227
of	ADP	O	O	1227
digitalis glycosides	NOUN	O	Chemical	1227
on	ADP	O	O	1227
myocardial	ADJ	O	O	1227
oxygen	NOUN	O	Chemical	1227
supply	NOUN	O	O	1227
and	CCONJ	O	O	1227
demand	NOUN	O	O	1227
are	AUX	O	O	1227
of	ADP	O	O	1227
particular	ADJ	O	O	1227
interest	NOUN	O	O	1227
in	ADP	O	O	1227
the	PRON	O	O	1227
presence	NOUN	O	O	1227
of	ADP	O	O	1227
obstructive	ADJ	O	O	1227
coronary artery disease	NOUN	O	Disease	1227
,	PUNCT	O	O	1227
but	CCONJ	O	O	1227
have	VERB	O	O	1227
not	PART	O	O	1227
been	AUX	O	O	1227
measured	VERB	O	O	1227
previously	ADV	O	O	1227
in	ADP	O	O	1227
man	NOUN	O	O	1227
.	PUNCT	O	O	1227
We	PRON	O	O	1228
assessed	VERB	O	O	1228
the	PRON	O	O	1228
effects	NOUN	O	O	1228
of	ADP	O	O	1228
ouabain	PROPN	O	Chemical	1228
(	PUNCT	O	O	1228
0.015	NUM	O	O	1228
mg	VERB	O	O	1228
/	PUNCT	O	O	1229
kg	VERB	O	O	1229
body	NOUN	O	O	1229
weight	NOUN	O	O	1229
)	PUNCT	O	O	1229
on	ADP	O	O	1229
hemodynamic	ADJ	O	O	1229
,	PUNCT	O	O	1229
volumetric	NOUN	O	O	1229
,	PUNCT	O	O	1229
and	CCONJ	O	O	1229
metabolic	ADJ	O	O	1229
parameters	NOUN	O	O	1229
in	ADP	O	O	1229
11	NUM	O	O	1229
patients	NOUN	O	O	1229
with	ADP	O	O	1229
severe	ADJ	O	O	1229
chronic	ADJ	O	O	1229
coronary artery disease	NOUN	O	Disease	1229
without	ADP	O	O	1229
clinical	ADJ	O	O	1229
congestive	ADJ	O	O	1229
heart failure	NOUN	O	Disease	1229
.	PUNCT	O	O	1229
Because	SCONJ	O	O	1230
the	PRON	O	O	1230
protocol	PROPN	O	O	1230
was	AUX	O	O	1230
long	ADV	O	O	1230
and	CCONJ	O	O	1230
involved	VERB	O	O	1230
interventions	NOUN	O	O	1230
which	PRON	O	O	1230
might	AUX	O	O	1230
affect	VERB	O	O	1230
the	PRON	O	O	1230
determinations	NOUN	O	O	1230
,	PUNCT	O	O	1230
we	PRON	O	O	1230
also	ADV	O	O	1230
studied	VERB	O	O	1230
in	ADP	O	O	1230
nine	NUM	O	O	1230
patients	NOUN	O	O	1230
using	VERB	O	O	1230
an	PRON	O	O	1230
identical	ADJ	O	O	1230
protocol	PROPN	O	O	1230
except	SCONJ	O	O	1230
that	SCONJ	O	O	1230
ouabain	PROPN	O	Chemical	1230
administration	NOUN	O	O	1230
was	AUX	O	O	1230
omitted	VERB	O	O	1230
.	PUNCT	O	O	1230
Left	VERB	O	O	1231
ventricular	ADJ	O	O	1231
end	VERB	O	O	1231
-	PUNCT	O	O	1231
diastolic	ADV	O	O	1231
pressure	NOUN	O	O	1231
and	CCONJ	O	O	1231
left	VERB	O	O	1231
ventricular	ADJ	O	O	1231
end	VERB	O	O	1231
-	PUNCT	O	O	1231
diastolic	ADV	O	O	1231
volume	PROPN	O	O	1231
fell	VERB	O	O	1231
in	ADP	O	O	1231
each	PRON	O	O	1231
patient	NOUN	O	O	1231
given	VERB	O	O	1231
ouabain	PROPN	O	Chemical	1231
,	PUNCT	O	O	1231
even	ADV	O	O	1231
though	SCONJ	O	O	1231
they	PRON	O	O	1231
were	AUX	O	O	1231
initially	ADV	O	O	1231
elevated	ADJ	O	O	1231
in	ADP	O	O	1231
only	ADV	O	O	1231
two	NUM	O	O	1231
patients	NOUN	O	O	1231
.	PUNCT	O	O	1231
Left	VERB	O	O	1232
ventricular	ADJ	O	O	1232
end	VERB	O	O	1232
-	PUNCT	O	O	1232
diastolic	ADV	O	O	1232
pressure	NOUN	O	O	1232
fell	VERB	O	O	1232
from	ADP	O	O	1232
11.5+/-1.4	NUM	O	O	1232
(	PUNCT	O	O	1232
mean+/-SE	PROPN	O	O	1232
)	PUNCT	O	O	1232
to	PART	O	O	1232
5.6+/-0.9	NUM	O	O	1232
mm	INTJ	O	O	1232
Hg	PROPN	O	O	1232
(	PUNCT	O	O	1232
P	NOUN	O	Chemical	1232
less	ADV	O	O	1232
than	ADP	O	O	1232
0.001	NUM	O	O	1232
)	PUNCT	O	O	1232
and	CCONJ	O	O	1232
left	VERB	O	O	1232
ventricular	ADJ	O	O	1232
end	VERB	O	O	1232
-	PUNCT	O	O	1232
diastolic	ADV	O	O	1232
volume	PROPN	O	O	1232
fell	VERB	O	O	1232
from	ADP	O	O	1232
100+/-17	NUM	O	O	1232
to	PART	O	O	1232
82+/-12	NUM	O	O	1232
ml	ADP	O	O	1232
/	PUNCT	O	O	1232
m2	PROPN	O	O	1232
(	PUNCT	O	O	1232
P	NOUN	O	Chemical	1232
less	ADV	O	O	1232
than	ADP	O	O	1232
0.01	NUM	O	O	1232
)	PUNCT	O	O	1232
1	X	O	O	1232
h	X	O	O	1232
after	ADP	O	O	1232
ouabain	PROPN	O	Chemical	1232
infusion	NOUN	O	O	1232
was	AUX	O	O	1232
completed	VERB	O	O	1232
.	PUNCT	O	O	1232
No	PRON	O	O	1233
significant	ADJ	O	O	1233
change	VERB	O	O	1233
in	ADP	O	O	1233
myocardial	ADJ	O	O	1233
oxygen	NOUN	O	Chemical	1233
consumption	NOUN	O	O	1233
occurred	VERB	O	O	1233
after	ADP	O	O	1233
ouabain	PROPN	O	Chemical	1233
administration	NOUN	O	O	1233
but	CCONJ	O	O	1233
this	PRON	O	O	1233
may	AUX	O	O	1233
be	AUX	O	O	1233
related	ADJ	O	O	1233
to	PART	O	O	1233
a	PRON	O	O	1233
greater	ADJ	O	O	1233
decrease	VERB	O	O	1233
in	ADP	O	O	1233
mean	VERB	O	O	1233
arterial	ADJ	O	O	1233
pressure	NOUN	O	O	1233
in	ADP	O	O	1233
the	PRON	O	O	1233
ouabain	PROPN	O	Chemical	1233
patients	NOUN	O	O	1233
than	ADP	O	O	1233
in	ADP	O	O	1233
the	PRON	O	O	1233
control	VERB	O	O	1233
patients	NOUN	O	O	1233
.	PUNCT	O	O	1233
We	PRON	O	O	1234
conclude	VERB	O	O	1234
that	SCONJ	O	O	1234
in	ADP	O	O	1234
patients	NOUN	O	O	1234
with	ADP	O	O	1234
chronic	ADJ	O	O	1234
coronary artery disease	NOUN	O	Disease	1234
who	PRON	O	O	1234
are	AUX	O	O	1234
not	PART	O	O	1234
in	ADP	O	O	1234
clinical	ADJ	O	O	1234
congestive	ADJ	O	O	1234
heart failure	NOUN	O	Disease	1234
left	VERB	O	O	1234
ventricular	ADJ	O	O	1234
end	VERB	O	O	1234
-	PUNCT	O	O	1234
diastolic	ADV	O	O	1234
volume	PROPN	O	O	1234
falls	VERB	O	O	1234
after	ADP	O	O	1234
ouabain	PROPN	O	Chemical	1234
administration	NOUN	O	O	1234
even	ADV	O	O	1234
when	SCONJ	O	O	1234
it	PRON	O	O	1234
is	AUX	O	O	1234
initially	ADV	O	O	1234
normal	ADJ	O	O	1234
.	PUNCT	O	O	1234
Though	SCONJ	O	O	1235
this	PRON	O	O	1235
fall	VERB	O	O	1235
would	AUX	O	O	1235
be	AUX	O	O	1235
associated	VERB	O	O	1235
with	ADP	O	O	1235
a	PRON	O	O	1235
decrease	VERB	O	O	1235
in	ADP	O	O	1235
wall	PROPN	O	O	1235
tension	NOUN	O	O	1235
,	PUNCT	O	O	1235
and	CCONJ	O	O	1235
,	PUNCT	O	O	1235
therefore	ADV	O	O	1235
,	PUNCT	O	O	1235
of	ADP	O	O	1235
myocardial	ADJ	O	O	1235
oxygen	NOUN	O	Chemical	1235
consumption	NOUN	O	O	1235
,	PUNCT	O	O	1235
it	PRON	O	O	1235
may	AUX	O	O	1235
not	PART	O	O	1235
be	AUX	O	O	1235
of	ADP	O	O	1235
sufficient	ADJ	O	O	1235
magnitude	NOUN	O	O	1235
to	PART	O	O	1235
prevent	VERB	O	O	1235
a	PRON	O	O	1235
net	PROPN	O	O	1235
increase	VERB	O	O	1235
in	ADP	O	O	1235
myocardial	ADJ	O	O	1235
oxygen	NOUN	O	Chemical	1235
consumption	NOUN	O	O	1235
.	PUNCT	O	O	1235
Prolongation of the QT interval	NOUN	O	Disease	1238
related	ADJ	O	O	1238
to	PART	O	O	1238
cisapride	ADV	O	Chemical	1238
-	PUNCT	O	O	1238
diltiazem	VERB	O	Chemical	1238
interaction	NOUN	O	O	1238
.	PUNCT	O	O	1238
Cisapride	ADJ	O	Chemical	1239
,	PUNCT	O	O	1239
a	PRON	O	O	1239
cytochrome	ADP	O	O	1239
P450	VERB	O	O	1239
3A4	X	O	O	1239
(	PUNCT	O	O	1239
CYP3A4	PROPN	O	O	1239
)	PUNCT	O	O	1239
substrate	NOUN	O	O	1239
,	PUNCT	O	O	1239
is	AUX	O	O	1239
widely	ADV	O	O	1239
prescribed	VERB	O	O	1239
for	ADP	O	O	1239
the	PRON	O	O	1239
treatment	NOUN	O	O	1239
of	ADP	O	O	1239
gastrointestinal motility disorders	NOUN	O	Disease	1239
.	PUNCT	O	O	1239
Prolongation of QT interval	NOUN	O	Disease	1240
,	PUNCT	O	O	1240
torsades de pointes	NOUN	O	Disease	1240
,	PUNCT	O	O	1240
and	CCONJ	O	O	1240
sudden cardiac death	NOUN	O	Disease	1240
have	VERB	O	O	1240
been	AUX	O	O	1240
reported	VERB	O	O	1240
after	ADP	O	O	1240
concomitant	ADJ	O	O	1240
administration	NOUN	O	O	1240
with	ADP	O	O	1240
erythromycin	PROPN	O	Chemical	1240
or	CCONJ	O	O	1240
azole	NOUN	O	Chemical	1240
antifungal	PROPN	O	O	1240
agents	NOUN	O	O	1240
,	PUNCT	O	O	1240
but	CCONJ	O	O	1240
not	PART	O	O	1240
with	ADP	O	O	1240
other	ADJ	O	O	1240
CYP3A4	PROPN	O	O	1240
inhibitors	NOUN	O	O	1240
.	PUNCT	O	O	1240
A	PRON	O	O	1241
possible	ADJ	O	O	1241
drug	NOUN	O	O	1241
interaction	NOUN	O	O	1241
occurred	VERB	O	O	1241
in	ADP	O	O	1241
a	PRON	O	O	1241
45-year	NOUN	O	O	1241
-	PUNCT	O	O	1241
old	ADJ	O	O	1241
woman	NOUN	O	O	1241
who	PRON	O	O	1241
was	AUX	O	O	1241
taking	VERB	O	O	1241
cisapride	ADV	O	Chemical	1241
for	ADP	O	O	1241
gastroesophageal reflux disorder	NOUN	O	Disease	1241
and	CCONJ	O	O	1241
diltiazem	VERB	O	Chemical	1241
,	PUNCT	O	O	1241
an	PRON	O	O	1241
agent	NOUN	O	O	1241
that	SCONJ	O	O	1241
has	VERB	O	O	1241
inhibitory	ADJ	O	O	1241
effect	VERB	O	O	1241
on	ADP	O	O	1241
CYP3A4	PROPN	O	O	1241
,	PUNCT	O	O	1241
for	ADP	O	O	1241
hypertension	NOUN	O	Disease	1241
.	PUNCT	O	O	1241
The	PRON	O	O	1242
patient	NOUN	O	O	1242
was	AUX	O	O	1242
in	ADP	O	O	1242
near	ADP	O	O	1242
syncope	VERB	O	Disease	1242
and	CCONJ	O	O	1242
had	VERB	O	O	1242
QT	NOUN	O	O	1242
-	PUNCT	O	O	1242
interval	NOUN	O	O	1242
prolongation	NOUN	O	O	1242
.	PUNCT	O	O	1242
After	ADP	O	O	1243
discontinuing	VERB	O	O	1243
cisapride	ADV	O	Chemical	1243
,	PUNCT	O	O	1243
the	PRON	O	O	1243
QT	NOUN	O	O	1243
interval	NOUN	O	O	1243
returned	VERB	O	O	1243
to	PART	O	O	1243
normal	ADJ	O	O	1243
and	CCONJ	O	O	1243
symptoms	NOUN	O	O	1243
did	VERB	O	O	1243
not	PART	O	O	1243
recur	VERB	O	O	1243
.	PUNCT	O	O	1243
We	PRON	O	O	1244
suggest	VERB	O	O	1244
that	SCONJ	O	O	1244
caution	NOUN	O	O	1244
be	AUX	O	O	1244
taken	VERB	O	O	1244
when	SCONJ	O	O	1244
cisapride	ADV	O	Chemical	1244
is	AUX	O	O	1244
prescribed	VERB	O	O	1244
with	ADP	O	O	1244
any	PRON	O	O	1244
potent	ADJ	O	O	1244
inhibitor	NOUN	O	O	1244
of	ADP	O	O	1244
CYP3A4	PROPN	O	O	1244
,	PUNCT	O	O	1244
including	VERB	O	O	1244
diltiazem	VERB	O	Chemical	1244
.	PUNCT	O	O	1244
Paclitaxel	PROPN	O	Chemical	1247
combined	VERB	O	O	1247
with	ADP	O	O	1247
carboplatin	PROPN	O	Chemical	1247
in	ADP	O	O	1247
the	PRON	O	O	1247
first	ADV	O	O	1247
-	PUNCT	O	O	1247
line	NOUN	O	O	1247
treatment	NOUN	O	O	1247
of	ADP	O	O	1247
advanced	ADJ	O	O	1247
ovarian cancer	NOUN	O	Disease	1247
.	PUNCT	O	O	1247
In	ADP	O	O	1248
a	PRON	O	O	1248
phase	NOUN	O	O	1248
I	PRON	O	O	1248
study	VERB	O	O	1248
to	PART	O	O	1248
determine	VERB	O	O	1248
the	PRON	O	O	1248
maximum	ADV	O	O	1248
tolerated	VERB	O	O	1248
dose	NOUN	O	O	1248
of	ADP	O	O	1248
paclitaxel	NOUN	O	Chemical	1248
(	PUNCT	O	O	1248
Taxol	PROPN	O	Chemical	1248
;	PUNCT	O	O	1248
Bristol	PROPN	O	O	1248
-	PUNCT	O	O	1248
Myers	PROPN	O	O	1248
Squibb	PROPN	O	O	1248
Company	NOUN	O	O	1248
,	PUNCT	O	O	1248
Princeton	PROPN	O	O	1248
,	PUNCT	O	O	1248
NJ	PROPN	O	O	1248
)	PUNCT	O	O	1248
given	VERB	O	O	1249
as	ADP	O	O	1249
a	PRON	O	O	1249
3-hour	NOUN	O	O	1249
infusion	NOUN	O	O	1249
in	ADP	O	O	1249
combination	NOUN	O	O	1249
with	ADP	O	O	1249
carboplatin	PROPN	O	Chemical	1249
administered	VERB	O	O	1249
every	PRON	O	O	1249
21	NUM	O	O	1249
days	NOUN	O	O	1249
to	PART	O	O	1249
women	NOUN	O	O	1249
with	ADP	O	O	1249
advanced	ADJ	O	O	1249
ovarian cancer	NOUN	O	Disease	1249
,	PUNCT	O	O	1249
paclitaxel	NOUN	O	Chemical	1249
doses	NOUN	O	O	1249
were	AUX	O	O	1249
escalated	VERB	O	O	1249
as	ADP	O	O	1249
follows	VERB	O	O	1249
:	PUNCT	O	O	1249
level	VERB	O	O	1249
1	X	O	O	1249
,	PUNCT	O	O	1249
135	NUM	O	O	1249
mg	VERB	O	O	1249
/	PUNCT	O	O	1249
m2	PROPN	O	O	1249
;	PUNCT	O	O	1249
level	VERB	O	O	1249
2	X	O	O	1249
,	PUNCT	O	O	1249
160	NUM	O	O	1249
mg	VERB	O	O	1249
/	PUNCT	O	O	1249
m2	PROPN	O	O	1249
;	PUNCT	O	O	1249
level	VERB	O	O	1249
3	X	O	O	1249
,	PUNCT	O	O	1249
185	NUM	O	O	1249
mg	VERB	O	O	1249
/	PUNCT	O	O	1249
m2	PROPN	O	O	1249
;	PUNCT	O	O	1249
and	CCONJ	O	O	1249
level	VERB	O	O	1249
4,210	NUM	O	O	1249
mg	VERB	O	O	1249
/	PUNCT	O	O	1249
m2	PROPN	O	O	1249
.	PUNCT	O	O	1249
The	PRON	O	O	1250
fixed	VERB	O	O	1250
dose	NOUN	O	O	1250
of	ADP	O	O	1250
carboplatin	PROPN	O	Chemical	1250
at	ADP	O	O	1250
levels	NOUN	O	O	1250
1	X	O	O	1250
through	ADP	O	O	1250
4	NUM	O	O	1250
was	AUX	O	O	1250
given	VERB	O	O	1250
to	PART	O	O	1250
achieve	VERB	O	O	1250
an	PRON	O	O	1250
area	NOUN	O	O	1250
under	ADP	O	O	1250
the	PRON	O	O	1250
concentration	NOUN	O	O	1250
-	PUNCT	O	O	1250
time	NOUN	O	O	1250
curve	NOUN	O	O	1250
(	PUNCT	O	O	1250
AUC	NOUN	O	O	1250
)	PUNCT	O	O	1250
of	ADP	O	O	1250
5	NUM	O	O	1250
using	VERB	O	O	1250
the	PRON	O	O	1250
Calvert	NOUN	O	O	1250
formula	NOUN	O	O	1250
.	PUNCT	O	O	1250
In	ADP	O	O	1251
levels	NOUN	O	O	1251
5	NUM	O	O	1251
and	CCONJ	O	O	1251
6	NUM	O	O	1251
the	PRON	O	O	1251
carboplatin	PROPN	O	Chemical	1251
dose	NOUN	O	O	1251
was	AUX	O	O	1251
targeted	VERB	O	O	1251
at	ADP	O	O	1251
AUCs	NOUN	O	O	1251
of	ADP	O	O	1251
6	NUM	O	O	1251
and	CCONJ	O	O	1251
7.5	NUM	O	O	1251
,	PUNCT	O	O	1251
respectively	ADV	O	O	1251
,	PUNCT	O	O	1251
combined	VERB	O	O	1251
with	ADP	O	O	1251
a	PRON	O	O	1251
fixed	VERB	O	O	1251
paclitaxel	NOUN	O	Chemical	1251
dose	NOUN	O	O	1251
of	ADP	O	O	1251
185	NUM	O	O	1251
mg	VERB	O	O	1251
/	PUNCT	O	O	1251
m2	PROPN	O	O	1251
.	PUNCT	O	O	1251
The	PRON	O	O	1252
dose	NOUN	O	O	1252
-	PUNCT	O	O	1252
limiting	VERB	O	O	1252
toxicity	NOUN	O	Disease	1252
of	ADP	O	O	1252
the	PRON	O	O	1252
combination	NOUN	O	O	1252
was	AUX	O	O	1252
myelosuppression	NOUN	O	Disease	1252
(	PUNCT	O	O	1252
leukopenia	PROPN	O	Disease	1252
,	PUNCT	O	O	1252
granulocytopenia	PROPN	O	Disease	1252
,	PUNCT	O	O	1252
and	CCONJ	O	O	1252
thrombocytopenia	PROPN	O	Disease	1252
)	PUNCT	O	O	1252
.	PUNCT	O	O	1252
Neurotoxicity	NOUN	O	Disease	1253
was	AUX	O	O	1253
largely	ADV	O	O	1253
moderate	ADJ	O	O	1253
.	PUNCT	O	O	1253
We	PRON	O	O	1254
conclude	VERB	O	O	1254
that	SCONJ	O	O	1254
the	PRON	O	O	1254
combination	NOUN	O	O	1254
of	ADP	O	O	1254
paclitaxel	NOUN	O	Chemical	1254
185	NUM	O	O	1254
mg	VERB	O	O	1254
/	PUNCT	O	O	1254
m2	PROPN	O	O	1254
administered	VERB	O	O	1254
as	ADP	O	O	1254
a	PRON	O	O	1254
3-hour	NOUN	O	O	1254
infusion	NOUN	O	O	1254
followed	VERB	O	O	1254
immediately	ADV	O	O	1254
by	ADP	O	O	1254
a	PRON	O	O	1254
1-hour	NOUN	O	O	1254
infusion	NOUN	O	O	1254
of	ADP	O	O	1254
carboplatin	PROPN	O	Chemical	1254
at	ADP	O	O	1254
an	PRON	O	O	1254
AUC	NOUN	O	O	1254
of	ADP	O	O	1254
6	NUM	O	O	1254
can	AUX	O	O	1254
be	AUX	O	O	1254
administered	VERB	O	O	1254
safely	ADV	O	O	1254
in	ADP	O	O	1254
a	PRON	O	O	1254
21-day	NOUN	O	O	1254
schedule	NOUN	O	O	1254
in	ADP	O	O	1254
the	PRON	O	O	1254
outpatient	NOUN	O	O	1254
setting	VERB	O	O	1254
.	PUNCT	O	O	1254
The	PRON	O	O	1255
recommended	VERB	O	O	1255
dose	NOUN	O	O	1255
for	ADP	O	O	1255
phase	NOUN	O	O	1255
III	NUM	O	O	1255
studies	NOUN	O	O	1255
is	AUX	O	O	1255
paclitaxel	NOUN	O	Chemical	1255
185	NUM	O	O	1255
mg	VERB	O	O	1255
/	PUNCT	O	O	1255
m2	PROPN	O	O	1255
and	CCONJ	O	O	1255
carboplatin	PROPN	O	Chemical	1255
AUC	NOUN	O	O	1255
6	NUM	O	O	1255
.	PUNCT	O	O	1255
Treatment	NOUN	O	O	1258
of	ADP	O	O	1258
tacrolimus	NOUN	O	Chemical	1258
-	PUNCT	O	O	1258
related	ADJ	O	O	1258
adverse	ADJ	O	O	1258
effects	NOUN	O	O	1258
by	ADP	O	O	1258
conversion	NOUN	O	O	1258
to	PART	O	O	1258
cyclosporine	NOUN	O	Chemical	1258
in	ADP	O	O	1258
liver	NOUN	O	O	1258
transplant	NOUN	O	O	1258
recipients	NOUN	O	O	1258
.	PUNCT	O	O	1258
When	SCONJ	O	O	1259
tacrolimus	NOUN	O	Chemical	1259
side	NOUN	O	O	1259
effects	NOUN	O	O	1259
persist	VERB	O	O	1259
despite	SCONJ	O	O	1259
dose	NOUN	O	O	1259
reduction	NOUN	O	O	1259
,	PUNCT	O	O	1259
conversion	NOUN	O	O	1259
to	PART	O	O	1259
cyclosporine	NOUN	O	Chemical	1259
-	PUNCT	O	O	1259
based	VERB	O	O	1259
immunosuppression	NOUN	O	O	1259
(	PUNCT	O	O	1259
CyA	NOUN	O	O	1259
)	PUNCT	O	O	1259
is	AUX	O	O	1259
necessary	ADJ	O	O	1259
.	PUNCT	O	O	1259
We	PRON	O	O	1260
characterized	VERB	O	O	1260
tacrolimus	NOUN	O	Chemical	1260
side	NOUN	O	O	1260
effects	NOUN	O	O	1260
that	SCONJ	O	O	1260
warranted	VERB	O	O	1260
discontinuation	NOUN	O	O	1260
of	ADP	O	O	1260
the	PRON	O	O	1260
drug	NOUN	O	O	1260
,	PUNCT	O	O	1260
and	CCONJ	O	O	1260
outcomes	NOUN	O	O	1260
after	ADP	O	O	1260
conversion	NOUN	O	O	1260
.	PUNCT	O	O	1260
Of	ADV	O	O	1261
388	NUM	O	O	1261
liver	NOUN	O	O	1261
recipients	NOUN	O	O	1261
who	PRON	O	O	1261
received	VERB	O	O	1261
tacrolimus	NOUN	O	Chemical	1261
as	ADP	O	O	1261
primary	NOUN	O	O	1261
immunosuppression	NOUN	O	O	1261
,	PUNCT	O	O	1261
70	NUM	O	O	1261
required	VERB	O	O	1261
conversion	NOUN	O	O	1261
to	PART	O	O	1261
CyA.	PROPN	O	O	1261
We	PRON	O	O	1261
recorded	VERB	O	O	1261
indication	NOUN	O	O	1261
for	ADP	O	O	1261
conversion	NOUN	O	O	1261
,	PUNCT	O	O	1261
whether	SCONJ	O	O	1261
conversion	NOUN	O	O	1261
was	AUX	O	O	1261
early	ADV	O	O	1261
or	CCONJ	O	O	1261
late	ADV	O	O	1261
after	ADP	O	O	1261
transplantation	NOUN	O	O	1261
,	PUNCT	O	O	1261
tacrolimus	NOUN	O	Chemical	1261
dose	NOUN	O	O	1261
and	CCONJ	O	O	1261
trough	NOUN	O	O	1261
blood	NOUN	O	O	1261
level	VERB	O	O	1261
at	ADP	O	O	1261
conversion	NOUN	O	O	1261
,	PUNCT	O	O	1261
and	CCONJ	O	O	1261
incidence	NOUN	O	O	1261
of	ADP	O	O	1261
rejection	NOUN	O	O	1261
after	ADP	O	O	1261
conversion	NOUN	O	O	1261
.	PUNCT	O	O	1261
Indications	NOUN	O	O	1262
for	ADP	O	O	1262
early	ADV	O	O	1262
conversion	NOUN	O	O	1262
were	AUX	O	O	1262
neurotoxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
20	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
(	PUNCT	O	O	1262
insulin	NOUN	O	O	1262
-	PUNCT	O	O	1262
dependent	ADJ	O	O	1262
)	PUNCT	O	O	1262
diabetes mellitus	ADJ	O	Disease	1262
(	PUNCT	O	O	1262
IDDM	VERB	O	Disease	1262
)	PUNCT	O	O	1262
(	PUNCT	O	O	1262
5	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
nephrotoxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
3	X	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
gastrointestinal	ADJ	O	O	1262
(	PUNCT	O	O	1262
GI	PROPN	O	O	1262
)	PUNCT	O	O	1262
toxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
6	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
and	CCONJ	O	O	1262
cardiomyopathy	ADJ	O	Disease	1262
(	PUNCT	O	O	1262
1	X	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
and	CCONJ	O	O	1262
for	ADP	O	O	1262
late	ADV	O	O	1262
conversion	NOUN	O	O	1262
were	AUX	O	O	1262
neurotoxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
15	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
IDDM	VERB	O	Disease	1262
(	PUNCT	O	O	1262
12	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
nephrotoxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
3	X	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
GI toxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
5	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
hepatotoxicity	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
6	NUM	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
post	VERB	O	O	1262
-	PUNCT	O	O	1262
transplant	NOUN	O	O	1262
lmphoproliferate	PROPN	O	O	1262
disease	PROPN	O	O	1262
(	PUNCT	O	O	1262
PTLD	PROPN	O	Disease	1262
)	PUNCT	O	O	1262
(	PUNCT	O	O	1262
2	X	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
cardiomyopathy	ADJ	O	Disease	1262
(	PUNCT	O	O	1262
1	X	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
hemolytic anemia	NOUN	O	Disease	1262
(	PUNCT	O	O	1262
1	X	O	O	1262
)	PUNCT	O	O	1262
,	PUNCT	O	O	1262
and	CCONJ	O	O	1262
pruritus	PROPN	O	Disease	1262
(	PUNCT	O	O	1262
1	X	O	O	1262
)	PUNCT	O	O	1262
.	PUNCT	O	O	1262
When	SCONJ	O	O	1263
tacrolimus	NOUN	O	Chemical	1263
side	NOUN	O	O	1263
effects	NOUN	O	O	1263
are	AUX	O	O	1263
unresponsive	ADJ	O	O	1263
to	PART	O	O	1263
dose	NOUN	O	O	1263
reduction	NOUN	O	O	1263
,	PUNCT	O	O	1263
conversion	NOUN	O	O	1263
to	PART	O	O	1263
CyA	NOUN	O	O	1263
can	AUX	O	O	1263
be	AUX	O	O	1263
accomplished	VERB	O	O	1263
safely	ADV	O	O	1263
,	PUNCT	O	O	1263
with	ADP	O	O	1263
no	PRON	O	O	1263
increased	VERB	O	O	1263
risk	NOUN	O	O	1263
of	ADP	O	O	1263
rejection	NOUN	O	O	1263
and	CCONJ	O	O	1263
excellent	ADJ	O	O	1263
long	ADV	O	O	1263
-	PUNCT	O	O	1263
term	NOUN	O	O	1263
outcome	NOUN	O	O	1263
.	PUNCT	O	O	1263
Relative	ADJ	O	O	1266
efficacy	NOUN	O	O	1266
and	CCONJ	O	O	1266
toxicity	NOUN	O	Disease	1266
of	ADP	O	O	1266
netilmicin	NOUN	O	Chemical	1266
and	CCONJ	O	O	1266
tobramycin	NOUN	O	Chemical	1266
in	ADP	O	O	1266
oncology	NOUN	O	O	1266
patients	NOUN	O	O	1266
.	PUNCT	O	O	1266
We	PRON	O	O	1267
prospectively	ADV	O	O	1267
compared	VERB	O	O	1267
the	PRON	O	O	1267
efficacy	NOUN	O	O	1267
and	CCONJ	O	O	1267
safety	NOUN	O	O	1267
of	ADP	O	O	1267
netilmicin sulfate	NOUN	O	Chemical	1267
or	CCONJ	O	O	1267
tobramycin sulfate	VERB	O	Chemical	1267
in	ADP	O	O	1267
conjunction	NOUN	O	O	1267
with	ADP	O	O	1267
piperacillin sodium	PROPN	O	Chemical	1267
in	ADP	O	O	1267
118	NUM	O	O	1267
immunocompromised	ADJ	O	O	1267
patients	NOUN	O	O	1267
with	ADP	O	O	1267
presumed	VERB	O	O	1267
severe	ADJ	O	O	1267
infections	NOUN	O	Disease	1267
.	PUNCT	O	O	1267
Nephrotoxicity	NOUN	O	Disease	1268
occurred	VERB	O	O	1268
in	ADP	O	O	1268
a	PRON	O	O	1268
similar	ADJ	O	O	1268
proportion	NOUN	O	O	1268
in	ADP	O	O	1268
patients	NOUN	O	O	1268
treated	VERB	O	O	1268
with	ADP	O	O	1268
netilmicin	NOUN	O	Chemical	1268
and	CCONJ	O	O	1268
tobramycin	NOUN	O	Chemical	1268
(	PUNCT	O	O	1268
17%	NOUN	O	O	1268
vs	ADP	O	O	1268
11%	NOUN	O	O	1268
)	PUNCT	O	O	1268
.	PUNCT	O	O	1268
Ototoxicity	NOUN	O	Disease	1269
occurred	VERB	O	O	1269
in	ADP	O	O	1269
four	NUM	O	O	1269
(	PUNCT	O	O	1269
9.5%	NOUN	O	O	1269
)	PUNCT	O	O	1269
of	ADP	O	O	1269
42	NUM	O	O	1269
netilmicin	NOUN	O	Chemical	1269
and	CCONJ	O	O	1269
piperacillin	PROPN	O	Chemical	1269
and	CCONJ	O	O	1269
in	ADP	O	O	1269
12	NUM	O	O	1269
(	PUNCT	O	O	1269
22%	NOUN	O	O	1269
)	PUNCT	O	O	1269
of	ADP	O	O	1270
54	NUM	O	O	1270
tobramycin	NOUN	O	Chemical	1270
and	CCONJ	O	O	1270
piperacillin	PROPN	O	Chemical	1270
-	PUNCT	O	O	1270
treated	VERB	O	O	1270
patients	NOUN	O	O	1270
.	PUNCT	O	O	1270
Of	ADV	O	O	1271
those	PRON	O	O	1271
evaluated	VERB	O	O	1271
with	ADP	O	O	1271
posttherapy	NOUN	O	O	1271
audiograms	NOUN	O	O	1271
,	PUNCT	O	O	1271
three	NUM	O	O	1271
of	ADP	O	O	1271
four	NUM	O	O	1271
netilmicin	NOUN	O	Chemical	1271
and	CCONJ	O	O	1271
piperacillin	PROPN	O	Chemical	1271
-	PUNCT	O	O	1271
treated	VERB	O	O	1271
patients	NOUN	O	O	1271
had	VERB	O	O	1271
auditory	NOUN	O	O	1271
thresholds	NOUN	O	O	1271
return	VERB	O	O	1271
to	PART	O	O	1271
baseline	VERB	O	O	1271
compared	VERB	O	O	1271
with	ADP	O	O	1271
one	NUM	O	O	1271
of	ADP	O	O	1271
nine	NUM	O	O	1271
tobramycin	NOUN	O	Chemical	1271
and	CCONJ	O	O	1271
piperacillin	PROPN	O	Chemical	1271
-	PUNCT	O	O	1271
treated	VERB	O	O	1271
patients	NOUN	O	O	1271
.	PUNCT	O	O	1271
The	PRON	O	O	1272
number	NOUN	O	O	1272
of	ADP	O	O	1272
greater	ADJ	O	O	1272
than	ADP	O	O	1272
or	CCONJ	O	O	1272
equal	ADJ	O	O	1272
to	PART	O	O	1272
15-dB	NOUN	O	O	1272
increases	VERB	O	O	1272
in	ADP	O	O	1272
auditory	NOUN	O	O	1272
threshold	NOUN	O	O	1272
as	ADP	O	O	1272
a	PRON	O	O	1272
proportion	NOUN	O	O	1272
of	ADP	O	O	1272
total	ADJ	O	O	1272
greater	ADJ	O	O	1272
than	ADP	O	O	1272
or	CCONJ	O	O	1272
equal	ADJ	O	O	1272
to	PART	O	O	1272
15-dB	NOUN	O	O	1272
changes	VERB	O	O	1272
(	PUNCT	O	O	1272
increases	VERB	O	O	1272
and	CCONJ	O	O	1272
decreases	VERB	O	O	1272
)	PUNCT	O	O	1272
was	AUX	O	O	1272
significantly	ADV	O	O	1272
lower	ADJ	O	O	1272
in	ADP	O	O	1272
netilmicin	NOUN	O	Chemical	1272
and	CCONJ	O	O	1272
piperacillin-	ADP	O	O	1272
vs	ADP	O	O	1272
tobramycin	NOUN	O	Chemical	1272
and	CCONJ	O	O	1272
piperacillin	PROPN	O	Chemical	1272
-	PUNCT	O	O	1272
treated	VERB	O	O	1272
patients	NOUN	O	O	1272
(	PUNCT	O	O	1272
18	NUM	O	O	1272
of	ADP	O	O	1272
78	NUM	O	O	1272
vs	ADP	O	O	1272
67	NUM	O	O	1272
of	ADP	O	O	1272
115	NUM	O	O	1272
)	PUNCT	O	O	1272
.	PUNCT	O	O	1272
We	PRON	O	O	1273
conclude	VERB	O	O	1273
that	SCONJ	O	O	1273
aminoglycoside	ADV	O	Chemical	1273
-	PUNCT	O	O	1273
associated	VERB	O	O	1273
ototoxicity	NOUN	O	Disease	1273
was	AUX	O	O	1273
less	ADV	O	O	1273
severe	ADJ	O	O	1273
and	CCONJ	O	O	1273
more	ADJ	O	O	1273
often	ADV	O	O	1273
reversible	ADJ	O	O	1273
with	ADP	O	O	1273
netilmicin	NOUN	O	Chemical	1273
than	ADP	O	O	1273
with	ADP	O	O	1273
tobramycin	NOUN	O	Chemical	1273
.	PUNCT	O	O	1273
Effect	VERB	O	O	1276
of	ADP	O	O	1276
prostaglandin	NOUN	O	Chemical	1276
synthetase	PROPN	O	O	1276
inhibitors	NOUN	O	O	1276
on	ADP	O	O	1276
experimentally	ADV	O	O	1276
induced	VERB	O	O	1276
convulsions	NOUN	O	Disease	1276
in	ADP	O	O	1276
rats	NOUN	O	O	1276
.	PUNCT	O	O	1276
To	PART	O	O	1277
investigate	VERB	O	O	1277
the	PRON	O	O	1277
relationship	NOUN	O	O	1277
of	ADP	O	O	1277
prostaglandins	NOUN	O	Chemical	1277
(	PUNCT	O	O	1277
PGs	NOUN	O	Chemical	1277
)	PUNCT	O	O	1277
to	PART	O	O	1277
seizure	NOUN	O	Disease	1277
induction	NOUN	O	O	1277
,	PUNCT	O	O	1277
the	PRON	O	O	1277
effects	NOUN	O	O	1277
of	ADP	O	O	1277
six	NUM	O	O	1277
PG	PROPN	O	Chemical	1277
synthetase	PROPN	O	O	1277
inhibitors	NOUN	O	O	1277
on	ADP	O	O	1277
convulsions	NOUN	O	Disease	1277
induced	VERB	O	O	1277
by	ADP	O	O	1277
flurothyl	PROPN	O	Chemical	1277
,	PUNCT	O	O	1277
picrotoxin	PROPN	O	Chemical	1277
,	PUNCT	O	O	1277
pentetrazol	NOUN	O	Chemical	1277
(	PUNCT	O	O	1277
PTZ	PROPN	O	Chemical	1277
)	PUNCT	O	O	1277
,	PUNCT	O	O	1277
electroshock	NOUN	O	O	1277
or	CCONJ	O	O	1277
bicuculline	PROPN	O	Chemical	1277
were	AUX	O	O	1277
evaluated	VERB	O	O	1277
.	PUNCT	O	O	1277
Ibuprofen	NOUN	O	Chemical	1278
,	PUNCT	O	O	1278
sulindac	PROPN	O	Chemical	1278
,	PUNCT	O	O	1278
mefenamic acid	NOUN	O	Chemical	1278
,	PUNCT	O	O	1278
and	CCONJ	O	O	1278
low	ADJ	O	O	1278
dose	NOUN	O	O	1278
meclofenamic acid	NOUN	O	Chemical	1278
increased	VERB	O	O	1278
the	PRON	O	O	1278
latency	VERB	O	O	1278
-	PUNCT	O	O	1278
to	PART	O	O	1278
-	PUNCT	O	O	1278
onset	VERB	O	O	1278
in	ADP	O	O	1278
the	PRON	O	O	1278
flurothyl	PROPN	O	Chemical	1278
and/or	CCONJ	O	O	1278
PTZ	PROPN	O	Chemical	1278
models	NOUN	O	O	1278
;	PUNCT	O	O	1278
the	PRON	O	O	1278
electroshock	NOUN	O	O	1278
,	PUNCT	O	O	1278
picrotoxin	PROPN	O	Chemical	1278
and	CCONJ	O	O	1278
bicuculline	PROPN	O	Chemical	1278
models	NOUN	O	O	1278
were	AUX	O	O	1278
not	PART	O	O	1278
significantly	ADV	O	O	1278
affected	VERB	O	O	1278
by	ADP	O	O	1278
any	PRON	O	O	1278
of	ADP	O	O	1278
the	PRON	O	O	1278
pretreatment	NOUN	O	O	1278
agents	NOUN	O	O	1278
.	PUNCT	O	O	1278
These	PRON	O	O	1279
results	VERB	O	O	1279
suggest	VERB	O	O	1279
that	SCONJ	O	O	1279
PGs	NOUN	O	Chemical	1279
are	AUX	O	O	1279
involved	VERB	O	O	1279
in	ADP	O	O	1279
the	PRON	O	O	1279
mechanism(s	NOUN	O	O	1279
)	PUNCT	O	O	1279
underlying	VERB	O	O	1279
fluorthyl-	NOUN	O	O	1279
and	CCONJ	O	O	1279
PTZ	PROPN	O	Chemical	1279
-	PUNCT	O	O	1279
induced	VERB	O	O	1279
convulsions	NOUN	O	Disease	1279
,	PUNCT	O	O	1279
but	CCONJ	O	O	1279
not	PART	O	O	1279
picrotoxin-	PROPN	O	O	1279
,	PUNCT	O	O	1279
electroshock-	PUNCT	O	O	1279
,	PUNCT	O	O	1279
or	CCONJ	O	O	1279
bicuculline	PROPN	O	Chemical	1279
-	PUNCT	O	O	1279
induced	VERB	O	O	1279
convulsions	NOUN	O	Disease	1279
.	PUNCT	O	O	1279
Angiotensin	NOUN	O	O	1282
-	PUNCT	O	O	1282
converting	VERB	O	O	1282
enzyme	NOUN	O	O	1282
(	PUNCT	O	O	1282
ACE	PROPN	O	O	1282
)	PUNCT	O	O	1282
inhibitor	NOUN	O	O	1282
-	PUNCT	O	O	1282
associated	VERB	O	O	1282
angioedema	NOUN	O	Disease	1282
of	ADP	O	O	1282
the	PRON	O	O	1282
stomach	NOUN	O	O	1282
and	CCONJ	O	O	1282
small	ADJ	O	O	1282
intestine	NOUN	O	O	1282
:	PUNCT	O	O	1282
a	PRON	O	O	1282
case	NOUN	O	O	1282
report	VERB	O	O	1282
.	PUNCT	O	O	1282
This	PRON	O	O	1283
is	AUX	O	O	1283
a	PRON	O	O	1283
case	NOUN	O	O	1283
report	VERB	O	O	1283
on	ADP	O	O	1283
a	PRON	O	O	1283
45-year	NOUN	O	O	1283
old	ADJ	O	O	1283
African	ADJ	O	O	1283
-	PUNCT	O	O	1283
American	ADJ	O	O	1283
female	ADJ	O	O	1283
with	ADP	O	O	1283
newly	ADV	O	O	1283
diagnosed	VERB	O	O	1283
hypertension	NOUN	O	Disease	1283
,	PUNCT	O	O	1283
who	PRON	O	O	1283
was	AUX	O	O	1283
started	VERB	O	O	1283
on	ADP	O	O	1283
a	PRON	O	O	1283
combination	NOUN	O	O	1283
pill	NOUN	O	O	1283
of	ADP	O	O	1283
amlodipine	NOUN	O	Chemical	1283
/	PUNCT	O	O	1283
benazapril	VERB	O	Chemical	1283
10/5	NUM	O	O	1283
mg	VERB	O	O	1283
.	PUNCT	O	O	1283
The	PRON	O	O	1284
very	ADV	O	O	1284
next	ADV	O	O	1284
day	NOUN	O	O	1284
,	PUNCT	O	O	1284
she	PRON	O	O	1284
presented	VERB	O	O	1284
at	ADP	O	O	1284
the	PRON	O	O	1284
emergency	NOUN	O	O	1284
room	NOUN	O	O	1284
(	PUNCT	O	O	1284
ER	INTJ	O	O	1284
)	PUNCT	O	O	1284
with	ADP	O	O	1284
abdominal pain	NOUN	O	Disease	1284
,	PUNCT	O	O	1284
nausea	NOUN	O	Disease	1284
and	CCONJ	O	O	1284
vomiting	VERB	O	Disease	1284
.	PUNCT	O	O	1284
Angiotensin	NOUN	O	O	1285
-	PUNCT	O	O	1285
converting	VERB	O	O	1285
enzyme	NOUN	O	O	1285
inhibitor	NOUN	O	O	1285
(	PUNCT	O	O	1285
ACEI)-induced	ADJ	O	O	1285
angioedema	NOUN	O	Disease	1285
was	AUX	O	O	1285
suspected	VERB	O	O	1285
,	PUNCT	O	O	1285
and	CCONJ	O	O	1285
anti	ADJ	O	O	1285
-	PUNCT	O	O	1285
hypertensive	ADJ	O	Disease	1285
medications	NOUN	O	O	1285
were	AUX	O	O	1285
discontinued	VERB	O	O	1285
.	PUNCT	O	O	1285
Her	PRON	O	O	1286
symptoms	NOUN	O	O	1286
improved	VERB	O	O	1286
within	ADP	O	O	1286
the	PRON	O	O	1286
next	ADV	O	O	1286
24	NUM	O	O	1286
hours	NOUN	O	O	1286
,	PUNCT	O	O	1286
and	CCONJ	O	O	1286
repeat	VERB	O	O	1286
CT	PROPN	O	O	1286
after	ADP	O	O	1286
72	NUM	O	O	1286
hours	NOUN	O	O	1286
revealed	VERB	O	O	1286
marked	VERB	O	O	1286
improvement	NOUN	O	O	1286
in	ADP	O	O	1286
stomach	NOUN	O	O	1286
and	CCONJ	O	O	1286
small	ADJ	O	O	1286
bowel	ADJ	O	O	1286
thickening	NOUN	O	O	1286
and	CCONJ	O	O	1286
resolution	NOUN	O	O	1286
of	ADP	O	O	1286
ascites	NOUN	O	Disease	1286
.	PUNCT	O	O	1286
The	PRON	O	O	1287
recognition	NOUN	O	O	1287
of	ADP	O	O	1287
angiotensin	NOUN	O	Chemical	1287
-	PUNCT	O	O	1287
converting	VERB	O	O	1287
enzyme	NOUN	O	O	1287
(	PUNCT	O	O	1287
ACE	PROPN	O	O	1287
)	PUNCT	O	O	1287
and	CCONJ	O	O	1287
angiotensin	NOUN	O	Chemical	1287
receptor	NOUN	O	O	1287
blocker	NOUN	O	O	1287
(	PUNCT	O	O	1287
ARB	PROPN	O	O	1287
)	PUNCT	O	O	1287
intestinal angioedema	NOUN	O	Disease	1288
constitutes	VERB	O	O	1288
a	PRON	O	O	1288
challenge	NOUN	O	O	1288
to	PART	O	O	1288
primary	NOUN	O	O	1288
care	VERB	O	O	1288
physicians	NOUN	O	O	1288
,	PUNCT	O	O	1288
internists	NOUN	O	O	1288
,	PUNCT	O	O	1288
emergency	NOUN	O	O	1288
room	NOUN	O	O	1288
personal	ADJ	O	O	1288
and	CCONJ	O	O	1288
surgeons	NOUN	O	O	1288
.	PUNCT	O	O	1288
Valproic acid	NOUN	O	Chemical	1291
I	PRON	O	O	1292
:	PUNCT	O	O	1292
time	NOUN	O	O	1292
course	NOUN	O	O	1292
of	ADP	O	O	1292
lipid	NOUN	O	O	1292
peroxidation	NOUN	O	O	1292
biomarkers	NOUN	O	O	1292
,	PUNCT	O	O	1292
liver toxicity	NOUN	O	Disease	1292
,	PUNCT	O	O	1292
and	CCONJ	O	O	1292
valproic acid	NOUN	O	Chemical	1292
metabolite	NOUN	O	O	1292
levels	NOUN	O	O	1292
in	ADP	O	O	1292
rats	NOUN	O	O	1292
.	PUNCT	O	O	1292
A	PRON	O	O	1293
single	ADJ	O	O	1293
dose	NOUN	O	O	1293
of	ADP	O	O	1293
valproic acid	NOUN	O	Chemical	1293
(	PUNCT	O	O	1293
VPA	PROPN	O	Chemical	1293
)	PUNCT	O	O	1293
,	PUNCT	O	O	1293
which	PRON	O	O	1293
is	AUX	O	O	1293
a	PRON	O	O	1293
widely	ADV	O	O	1293
used	VERB	O	O	1293
antiepileptic	ADJ	O	O	1293
drug	NOUN	O	O	1293
,	PUNCT	O	O	1293
is	AUX	O	O	1293
associated	VERB	O	O	1293
with	ADP	O	O	1293
oxidative	NOUN	O	O	1293
stress	NOUN	O	O	1293
in	ADP	O	O	1293
rats	NOUN	O	O	1293
,	PUNCT	O	O	1293
as	ADP	O	O	1293
recently	ADV	O	O	1293
demonstrated	VERB	O	O	1293
by	ADP	O	O	1293
elevated	ADJ	O	O	1293
levels	NOUN	O	O	1293
of	ADP	O	O	1293
15-F(2t)-isoprostane	NOUN	O	Chemical	1293
(	PUNCT	O	O	1293
15-F(2t)-IsoP	NOUN	O	Chemical	1293
)	PUNCT	O	O	1293
.	PUNCT	O	O	1293
To	PART	O	O	1294
determine	VERB	O	O	1294
whether	SCONJ	O	O	1294
there	ADV	O	O	1294
was	AUX	O	O	1294
a	PRON	O	O	1294
temporal	ADJ	O	O	1294
relationship	NOUN	O	O	1294
between	ADP	O	O	1294
VPA	PROPN	O	Chemical	1294
-	PUNCT	O	O	1294
associated	VERB	O	O	1294
oxidative	NOUN	O	O	1294
stress	NOUN	O	O	1294
and	CCONJ	O	O	1294
hepatotoxicity	NOUN	O	Disease	1294
,	PUNCT	O	O	1294
adult	NOUN	O	O	1294
male	NOUN	O	O	1294
Sprague	PROPN	O	O	1294
-	PUNCT	O	O	1294
Dawley	NOUN	O	O	1294
rats	NOUN	O	O	1294
were	AUX	O	O	1294
treated	VERB	O	O	1294
ip	X	O	O	1294
with	ADP	O	O	1294
VPA	PROPN	O	Chemical	1294
(	PUNCT	O	O	1294
500	NUM	O	O	1294
mg	VERB	O	O	1294
/	PUNCT	O	O	1294
kg	VERB	O	O	1294
)	PUNCT	O	O	1294
or	CCONJ	O	O	1294
0.9%	NOUN	O	O	1294
saline	NOUN	O	O	1294
(	PUNCT	O	O	1294
vehicle	NOUN	O	O	1294
)	PUNCT	O	O	1294
once	ADV	O	O	1294
daily	ADV	O	O	1294
for	ADP	O	O	1294
2	X	O	O	1294
,	PUNCT	O	O	1294
4	NUM	O	O	1294
,	PUNCT	O	O	1294
7	NUM	O	O	1294
,	PUNCT	O	O	1294
10	NUM	O	O	1294
,	PUNCT	O	O	1294
or	CCONJ	O	O	1294
14	NUM	O	O	1294
days	NOUN	O	O	1294
.	PUNCT	O	O	1294
Oxidative	NOUN	O	O	1295
stress	NOUN	O	O	1295
was	AUX	O	O	1295
assessed	VERB	O	O	1295
by	ADP	O	O	1295
determining	VERB	O	O	1295
plasma	NOUN	O	O	1295
and	CCONJ	O	O	1295
liver	NOUN	O	O	1295
levels	NOUN	O	O	1295
of	ADP	O	O	1295
15-F(2t)-IsoP	NOUN	O	Chemical	1295
,	PUNCT	O	O	1295
lipid hydroperoxides	VERB	O	Chemical	1295
(	PUNCT	O	O	1295
LPO	PROPN	O	Chemical	1295
)	PUNCT	O	O	1295
,	PUNCT	O	O	1295
and	CCONJ	O	O	1295
thiobarbituric acid reactive substances	NOUN	O	Chemical	1295
(	PUNCT	O	O	1295
TBARs	NOUN	O	Chemical	1295
)	PUNCT	O	O	1295
.	PUNCT	O	O	1295
Plasma	NOUN	O	O	1296
and	CCONJ	O	O	1296
liver	NOUN	O	O	1296
15-F(2t)-IsoP	NOUN	O	Chemical	1296
were	AUX	O	O	1296
elevated	ADJ	O	O	1296
and	CCONJ	O	O	1296
reached	VERB	O	O	1296
a	PRON	O	O	1296
plateau	NOUN	O	O	1296
after	ADP	O	O	1296
day	NOUN	O	O	1296
2	X	O	O	1296
of	ADP	O	O	1296
VPA	PROPN	O	Chemical	1296
treatment	NOUN	O	O	1296
compared	VERB	O	O	1296
to	PART	O	O	1296
control	VERB	O	O	1296
.	PUNCT	O	O	1296
Liver	NOUN	O	O	1297
LPO	PROPN	O	Chemical	1297
levels	NOUN	O	O	1297
were	AUX	O	O	1297
not	PART	O	O	1297
elevated	ADJ	O	O	1297
until	ADP	O	O	1297
day	NOUN	O	O	1297
7	NUM	O	O	1297
of	ADP	O	O	1297
treatment	NOUN	O	O	1297
(	PUNCT	O	O	1297
1.8-fold	ADV	O	O	1297
versus	ADP	O	O	1297
control	VERB	O	O	1297
,	PUNCT	O	O	1297
p	NOUN	O	O	1297
<	X	O	O	1297
0.05	NUM	O	O	1297
)	PUNCT	O	O	1297
.	PUNCT	O	O	1297
Liver	NOUN	O	O	1298
and	CCONJ	O	O	1298
plasma	NOUN	O	O	1298
TBARs	NOUN	O	Chemical	1298
were	AUX	O	O	1298
not	PART	O	O	1298
increased	VERB	O	O	1298
until	ADP	O	O	1298
14	NUM	O	O	1298
days	NOUN	O	O	1298
(	PUNCT	O	O	1298
2-fold	VERB	O	O	1298
vs.	CCONJ	O	O	1298
control	VERB	O	O	1298
,	PUNCT	O	O	1298
p	NOUN	O	O	1298
<	X	O	O	1298
0.05	NUM	O	O	1298
)	PUNCT	O	O	1298
.	PUNCT	O	O	1298
Liver toxicity	NOUN	O	Disease	1299
was	AUX	O	O	1299
evaluated	VERB	O	O	1299
based	VERB	O	O	1299
on	ADP	O	O	1299
serum	NOUN	O	O	1299
levels	NOUN	O	O	1299
of	ADP	O	O	1299
alpha	PROPN	O	O	1299
-	PUNCT	O	O	1299
glutathione	NOUN	O	Chemical	1299
S	NOUN	O	O	1299
-	PUNCT	O	O	1299
transferase	PROPN	O	O	1299
(	PUNCT	O	O	1299
alpha	PROPN	O	O	1299
-	PUNCT	O	O	1299
GST	PROPN	O	O	1299
)	PUNCT	O	O	1299
and	CCONJ	O	O	1299
by	ADP	O	O	1299
histology	NOUN	O	O	1299
.	PUNCT	O	O	1299
Serum	NOUN	O	O	1300
alpha	PROPN	O	O	1300
-	PUNCT	O	O	1300
GST	PROPN	O	O	1300
levels	NOUN	O	O	1300
were	AUX	O	O	1300
significantly	ADV	O	O	1300
elevated	ADJ	O	O	1300
by	ADP	O	O	1300
day	NOUN	O	O	1300
4	NUM	O	O	1300
,	PUNCT	O	O	1300
which	PRON	O	O	1300
corresponded	VERB	O	O	1300
to	PART	O	O	1300
hepatotoxicity	NOUN	O	Disease	1300
as	ADP	O	O	1300
shown	VERB	O	O	1300
by	ADP	O	O	1300
the	PRON	O	O	1300
increasing	VERB	O	O	1300
incidence	NOUN	O	O	1300
of	ADP	O	O	1300
inflammation	NOUN	O	Disease	1300
of	ADP	O	O	1300
the	PRON	O	O	1300
liver	NOUN	O	O	1300
capsule	NOUN	O	O	1300
,	PUNCT	O	O	1300
necrosis	NOUN	O	Disease	1300
,	PUNCT	O	O	1300
and	CCONJ	O	O	1300
steatosis	VERB	O	Disease	1300
throughout	ADP	O	O	1300
the	PRON	O	O	1300
study	VERB	O	O	1300
.	PUNCT	O	O	1300
The	PRON	O	O	1301
liver	NOUN	O	O	1301
levels	NOUN	O	O	1301
of	ADP	O	O	1301
beta	NOUN	O	O	1301
-	PUNCT	O	O	1301
oxidation	ADV	O	O	1301
metabolites	VERB	O	O	1301
of	ADP	O	O	1301
VPA	PROPN	O	Chemical	1301
were	AUX	O	O	1301
decreased	VERB	O	O	1301
by	ADP	O	O	1301
day	NOUN	O	O	1301
14	NUM	O	O	1301
,	PUNCT	O	O	1301
while	SCONJ	O	O	1301
the	PRON	O	O	1301
levels	NOUN	O	O	1301
of	ADP	O	O	1301
4-ene	NOUN	O	O	1301
-	PUNCT	O	O	1301
VPA	PROPN	O	Chemical	1301
and	CCONJ	O	O	1301
(	PUNCT	O	O	1301
E)-2,4-diene	NOUN	O	O	1301
-	PUNCT	O	O	1301
VPA	PROPN	O	Chemical	1301
were	AUX	O	O	1301
not	PART	O	O	1301
elevated	ADJ	O	O	1301
throughout	ADP	O	O	1301
the	PRON	O	O	1301
study	VERB	O	O	1301
.	PUNCT	O	O	1301
Overall	ADV	O	O	1302
,	PUNCT	O	O	1302
these	PRON	O	O	1302
findings	NOUN	O	O	1302
indicate	VERB	O	O	1302
that	SCONJ	O	O	1302
VPA	PROPN	O	Chemical	1302
treatment	NOUN	O	O	1302
results	VERB	O	O	1302
in	ADP	O	O	1302
oxidative	NOUN	O	O	1302
stress	NOUN	O	O	1302
,	PUNCT	O	O	1302
as	ADP	O	O	1302
measured	VERB	O	O	1302
by	ADP	O	O	1302
levels	NOUN	O	O	1302
of	ADP	O	O	1302
15-F(2t)-IsoP	NOUN	O	Chemical	1302
,	PUNCT	O	O	1302
which	PRON	O	O	1302
precedes	VERB	O	O	1302
the	PRON	O	O	1302
onset	VERB	O	O	1302
of	ADP	O	O	1302
necrosis	NOUN	O	Disease	1302
,	PUNCT	O	O	1302
steatosis	VERB	O	Disease	1302
,	PUNCT	O	O	1302
and	CCONJ	O	O	1302
elevated	ADJ	O	O	1302
levels	NOUN	O	O	1302
of	ADP	O	O	1302
serum	NOUN	O	O	1302
alpha	PROPN	O	O	1302
-	PUNCT	O	O	1302
GST	PROPN	O	O	1302
.	PUNCT	O	O	1302
Pheochromocytoma	PROPN	O	Disease	1305
unmasked	ADJ	O	O	1305
by	ADP	O	O	1305
amisulpride	ADV	O	Chemical	1305
and	CCONJ	O	O	1305
tiapride	ADV	O	Chemical	1305
.	PUNCT	O	O	1305
OBJECTIVE	VERB	O	O	1306
:	PUNCT	O	O	1306
To	PART	O	O	1306
describe	VERB	O	O	1306
the	PRON	O	O	1306
unmasking	VERB	O	O	1306
of	ADP	O	O	1306
pheochromocytoma	VERB	O	Disease	1306
in	ADP	O	O	1306
a	PRON	O	O	1306
patient	NOUN	O	O	1306
treated	VERB	O	O	1306
with	ADP	O	O	1306
amisulpride	ADV	O	Chemical	1306
and	CCONJ	O	O	1306
tiapride	ADV	O	Chemical	1306
.	PUNCT	O	O	1306
A	PRON	O	O	1307
42-year	NOUN	O	O	1307
-	PUNCT	O	O	1307
old	ADJ	O	O	1307
white	ADJ	O	O	1307
man	NOUN	O	O	1307
developed	VERB	O	O	1307
acute	ADJ	O	O	1307
hypertension	NOUN	O	Disease	1307
with	ADP	O	O	1307
severe	ADJ	O	O	1307
headache	PROPN	O	Disease	1307
and	CCONJ	O	O	1307
vomiting	VERB	O	Disease	1307
2	X	O	O	1307
hours	NOUN	O	O	1307
after	ADP	O	O	1307
the	PRON	O	O	1307
first	ADV	O	O	1307
doses	NOUN	O	O	1307
of	ADP	O	O	1307
amisulpride	ADV	O	Chemical	1307
100	NUM	O	O	1307
mg	VERB	O	O	1307
and	CCONJ	O	O	1307
tiapride	ADV	O	Chemical	1307
100	NUM	O	O	1307
mg	VERB	O	O	1307
.	PUNCT	O	O	1307
Both	PRON	O	O	1308
drugs	NOUN	O	O	1308
were	AUX	O	O	1308
immediately	ADV	O	O	1308
discontinued	VERB	O	O	1308
,	PUNCT	O	O	1308
and	CCONJ	O	O	1308
the	PRON	O	O	1308
patient	NOUN	O	O	1308
recovered	VERB	O	O	1308
after	ADP	O	O	1308
subsequent	ADJ	O	O	1308
nicardipine	VERB	O	Chemical	1308
and	CCONJ	O	O	1308
verapamil	PROPN	O	Chemical	1308
treatment	NOUN	O	O	1308
.	PUNCT	O	O	1308
Abdominal	ADJ	O	O	1309
ultrasound	VERB	O	O	1309
showed	VERB	O	O	1309
an	PRON	O	O	1309
adrenal	ADJ	O	O	1309
mass	PROPN	O	O	1309
,	PUNCT	O	O	1309
and	CCONJ	O	O	1309
postoperative	ADJ	O	O	1309
histologic	ADJ	O	O	1309
examination	NOUN	O	O	1309
confirmed	VERB	O	O	1309
the	PRON	O	O	1309
diagnosis	NOUN	O	O	1309
of	ADP	O	O	1309
pheochromocytoma	VERB	O	Disease	1309
.	PUNCT	O	O	1309
DISCUSSION	NOUN	O	O	1310
:	PUNCT	O	O	1310
Drug	NOUN	O	O	1310
-	PUNCT	O	O	1310
induced	VERB	O	O	1310
symptoms	NOUN	O	O	1310
of	ADP	O	O	1310
pheochromocytoma	VERB	O	Disease	1310
are	AUX	O	O	1310
often	ADV	O	O	1310
associated	VERB	O	O	1310
with	ADP	O	O	1310
the	PRON	O	O	1310
use	VERB	O	O	1310
of	ADP	O	O	1310
substituted	VERB	O	O	1310
benzamide	NOUN	O	Chemical	1310
drugs	NOUN	O	O	1310
,	PUNCT	O	O	1310
but	CCONJ	O	O	1310
the	PRON	O	O	1310
underlying	VERB	O	O	1310
mechanism	NOUN	O	O	1310
is	AUX	O	O	1310
unknown	ADJ	O	O	1310
.	PUNCT	O	O	1310
In	ADP	O	O	1311
our	PRON	O	O	1311
case	NOUN	O	O	1311
,	PUNCT	O	O	1311
use	VERB	O	O	1311
of	ADP	O	O	1311
the	PRON	O	O	1311
Naranjo	PROPN	O	O	1311
probability	NOUN	O	O	1311
scale	NOUN	O	O	1311
indicated	VERB	O	O	1311
a	PRON	O	O	1311
possible	ADJ	O	O	1311
relationship	NOUN	O	O	1311
between	ADP	O	O	1311
the	PRON	O	O	1311
hypertensive	ADJ	O	Disease	1311
crisis	NOUN	O	O	1311
and	CCONJ	O	O	1311
amisulpride	ADV	O	Chemical	1311
and	CCONJ	O	O	1311
tiapride	ADV	O	Chemical	1311
therapy	NOUN	O	O	1311
.	PUNCT	O	O	1311
As	ADP	O	O	1312
of	ADP	O	O	1312
March	PROPN	O	O	1312
24	NUM	O	O	1312
,	PUNCT	O	O	1312
2005	NUM	O	O	1312
,	PUNCT	O	O	1312
this	PRON	O	O	1312
is	AUX	O	O	1312
the	PRON	O	O	1312
first	ADV	O	O	1312
reported	VERB	O	O	1312
case	NOUN	O	O	1312
of	ADP	O	O	1312
amisulpride-	VERB	O	O	1312
and	CCONJ	O	O	1312
tiapride	ADV	O	Chemical	1312
-	PUNCT	O	O	1312
induced	VERB	O	O	1312
hypertensive	ADJ	O	Disease	1312
crisis	NOUN	O	O	1312
in	ADP	O	O	1312
a	PRON	O	O	1312
patient	NOUN	O	O	1312
with	ADP	O	O	1312
pheochromocytoma	VERB	O	Disease	1312
.	PUNCT	O	O	1312
Physicians	NOUN	O	O	1313
and	CCONJ	O	O	1313
other	ADJ	O	O	1313
healthcare	PROPN	O	O	1313
professionals	NOUN	O	O	1313
should	AUX	O	O	1313
be	AUX	O	O	1313
aware	ADJ	O	O	1313
of	ADP	O	O	1313
this	PRON	O	O	1313
potential	ADJ	O	O	1313
adverse	ADJ	O	O	1313
effect	VERB	O	O	1313
of	ADP	O	O	1313
tiapride	ADV	O	Chemical	1313
and	CCONJ	O	O	1313
amisulpride	ADV	O	Chemical	1313
.	PUNCT	O	O	1313
Quantitative	ADJ	O	O	1316
drug	NOUN	O	O	1316
levels	NOUN	O	O	1316
in	ADP	O	O	1316
stimulant	NOUN	O	O	1316
psychosis	VERB	O	Disease	1316
:	PUNCT	O	O	1316
relationship	NOUN	O	O	1316
to	PART	O	O	1316
symptom	NOUN	O	O	1316
severity	NOUN	O	O	1316
,	PUNCT	O	O	1316
catecholamines	NOUN	O	Chemical	1316
and	CCONJ	O	O	1316
hyperkinesia	PROPN	O	Disease	1316
.	PUNCT	O	O	1316
To	PART	O	O	1317
examine	VERB	O	O	1317
the	PRON	O	O	1317
relationship	NOUN	O	O	1317
between	ADP	O	O	1317
quantitative	ADJ	O	O	1317
stimulant	NOUN	O	O	1317
drug	NOUN	O	O	1317
levels	NOUN	O	O	1317
,	PUNCT	O	O	1317
catecholamines	NOUN	O	Chemical	1317
,	PUNCT	O	O	1317
and	CCONJ	O	O	1317
psychotic symptoms	NOUN	O	Disease	1317
,	PUNCT	O	O	1317
nineteen	NUM	O	O	1317
patients	NOUN	O	O	1317
in	ADP	O	O	1317
a	PRON	O	O	1317
psychiatric	ADJ	O	Disease	1317
emergency	NOUN	O	O	1317
service	NOUN	O	O	1317
with	ADP	O	O	1317
a	PRON	O	O	1317
diagnosis	NOUN	O	O	1317
of	ADP	O	O	1317
amphetamine-	VERB	O	O	1317
or	CCONJ	O	O	1317
cocaine	NOUN	O	Chemical	1317
-	PUNCT	O	O	1317
induced	VERB	O	O	1317
psychosis	VERB	O	Disease	1317
were	AUX	O	O	1317
interviewed	VERB	O	O	1317
,	PUNCT	O	O	1317
and	CCONJ	O	O	1317
plasma	NOUN	O	O	1317
and	CCONJ	O	O	1317
urine	NOUN	O	O	1317
were	AUX	O	O	1317
collected	VERB	O	O	1317
for	ADP	O	O	1317
quantitative	ADJ	O	O	1317
assays	NOUN	O	O	1317
of	ADP	O	O	1317
stimulant	NOUN	O	O	1317
drug	NOUN	O	O	1317
and	CCONJ	O	O	1317
catecholamine	ADJ	O	Chemical	1317
metabolite	NOUN	O	O	1317
levels	NOUN	O	O	1317
.	PUNCT	O	O	1317
Methamphetamine	NOUN	O	Chemical	1318
or	CCONJ	O	O	1318
amphetamine	NOUN	O	Chemical	1318
levels	NOUN	O	O	1318
were	AUX	O	O	1318
related	ADJ	O	O	1318
to	PART	O	O	1318
several	ADJ	O	O	1318
psychopathology	NOUN	O	O	1318
scores	NOUN	O	O	1318
and	CCONJ	O	O	1318
the	PRON	O	O	1318
global	ADJ	O	O	1318
hyperkinesia	PROPN	O	Disease	1318
rating	NOUN	O	O	1318
.	PUNCT	O	O	1318
HVA	PROPN	O	O	1319
levels	NOUN	O	O	1319
were	AUX	O	O	1319
related	ADJ	O	O	1319
to	PART	O	O	1319
global	ADJ	O	O	1319
hyperkinesia	PROPN	O	Disease	1319
but	CCONJ	O	O	1319
not	PART	O	O	1319
to	PART	O	O	1319
psychopathology	NOUN	O	O	1319
ratings	NOUN	O	O	1319
.	PUNCT	O	O	1319
Although	SCONJ	O	O	1320
many	ADJ	O	O	1320
other	ADJ	O	O	1320
factors	NOUN	O	O	1320
such	ADJ	O	O	1320
as	ADP	O	O	1320
sensitization	NOUN	O	O	1320
may	AUX	O	O	1320
play	VERB	O	O	1320
a	PRON	O	O	1320
role	NOUN	O	O	1320
,	PUNCT	O	O	1320
intensity	NOUN	O	O	1320
of	ADP	O	O	1320
stimulant	NOUN	O	O	1320
-	PUNCT	O	O	1320
induced	VERB	O	O	1320
psychotic symptoms	NOUN	O	Disease	1320
and	CCONJ	O	O	1320
stereotypies	NOUN	O	Disease	1320
appears	VERB	O	O	1320
to	PART	O	O	1320
be	AUX	O	O	1320
at	ADP	O	O	1320
least	ADJ	O	O	1320
in	ADP	O	O	1320
part	NOUN	O	O	1320
dose	NOUN	O	O	1320
-	PUNCT	O	O	1320
related	ADJ	O	O	1320
.	PUNCT	O	O	1320
Delayed	VERB	O	O	1323
asystolic	ADJ	O	Disease	1323
cardiac arrest	NOUN	O	Disease	1323
after	ADP	O	O	1323
diltiazem	VERB	O	Chemical	1323
overdose	NOUN	O	Disease	1323
;	PUNCT	O	O	1323
resuscitation	NOUN	O	O	1323
with	ADP	O	O	1323
high	ADJ	O	O	1323
dose	NOUN	O	O	1323
intravenous	ADJ	O	O	1323
calcium	NOUN	O	Chemical	1323
.	PUNCT	O	O	1323
A	PRON	O	O	1324
51	NUM	O	O	1324
year	NOUN	O	O	1324
old	ADJ	O	O	1324
man	NOUN	O	O	1324
took	VERB	O	O	1324
a	PRON	O	O	1324
mixed	VERB	O	O	1324
overdose	NOUN	O	Disease	1324
including	VERB	O	O	1324
1.8	NUM	O	O	1324
-	PUNCT	O	O	1324
3.6	NUM	O	O	1324
g	X	O	O	1324
of	ADP	O	O	1324
diltiazem	VERB	O	Chemical	1324
,	PUNCT	O	O	1324
paracetamol	PROPN	O	Chemical	1324
,	PUNCT	O	O	1324
aspirin	NOUN	O	Chemical	1324
,	PUNCT	O	O	1324
isosorbide	NOUN	O	Chemical	1324
nitrate	NOUN	O	Chemical	1324
,	PUNCT	O	O	1324
and	CCONJ	O	O	1324
alcohol	NOUN	O	Chemical	1324
.	PUNCT	O	O	1324
He	PRON	O	O	1325
initially	ADV	O	O	1325
presented	VERB	O	O	1325
to	PART	O	O	1325
hospital	PROPN	O	O	1325
after	ADP	O	O	1325
six	NUM	O	O	1325
hours	NOUN	O	O	1325
with	ADP	O	O	1325
mild	ADJ	O	O	1325
hypotension	NOUN	O	Disease	1325
and	CCONJ	O	O	1325
was	AUX	O	O	1325
treated	VERB	O	O	1325
with	ADP	O	O	1325
activated	VERB	O	O	1325
charcoal	NOUN	O	O	1325
and	CCONJ	O	O	1325
intravenous	ADJ	O	O	1325
fluids	NOUN	O	O	1325
.	PUNCT	O	O	1325
Eighteen	NUM	O	O	1326
hours	NOUN	O	O	1326
after	ADP	O	O	1326
the	PRON	O	O	1326
overdose	NOUN	O	Disease	1326
he	PRON	O	O	1326
had	VERB	O	O	1326
two	NUM	O	O	1326
generalised	VERB	O	O	1326
tonic	PROPN	O	O	1326
-	PUNCT	O	O	1326
clonic	ADJ	O	O	1326
seizures	NOUN	O	Disease	1326
.	PUNCT	O	O	1326
The	PRON	O	O	1327
patient	NOUN	O	O	1327
remained	VERB	O	O	1327
unresponsive	ADJ	O	O	1327
with	ADP	O	O	1327
junctional	ADJ	O	O	1327
bradycardia	NOUN	O	Disease	1327
,	PUNCT	O	O	1327
unrecordable	ADJ	O	O	1327
blood	NOUN	O	O	1327
pressure	NOUN	O	O	1327
,	PUNCT	O	O	1327
and	CCONJ	O	O	1327
then	ADV	O	O	1327
became	VERB	O	O	1327
asystolic	ADJ	O	Disease	1327
.	PUNCT	O	O	1327
He	PRON	O	O	1328
was	AUX	O	O	1328
resuscitated	VERB	O	O	1328
with	ADP	O	O	1328
high	ADJ	O	O	1328
dose	NOUN	O	O	1328
(	PUNCT	O	O	1328
13.5	NUM	O	O	1328
g	X	O	O	1328
)	PUNCT	O	O	1328
intravenous	ADJ	O	O	1328
calcium	NOUN	O	Chemical	1328
and	CCONJ	O	O	1328
adrenaline	NOUN	O	Chemical	1328
(	PUNCT	O	O	1328
epinephrine	NOUN	O	Chemical	1328
)	PUNCT	O	O	1328
.	PUNCT	O	O	1328
This	PRON	O	O	1329
case	NOUN	O	O	1329
suggests	VERB	O	O	1329
there	ADV	O	O	1329
is	AUX	O	O	1329
a	PRON	O	O	1329
role	NOUN	O	O	1329
for	ADP	O	O	1329
aggressive	ADJ	O	O	1329
high	ADJ	O	O	1329
dose	NOUN	O	O	1329
intravenous	ADJ	O	O	1329
calcium	NOUN	O	Chemical	1329
therapy	NOUN	O	O	1329
in	ADP	O	O	1329
severe	ADJ	O	O	1329
diltiazem	VERB	O	Chemical	1329
overdose	NOUN	O	Disease	1329
,	PUNCT	O	O	1329
particularly	ADV	O	O	1329
with	ADP	O	O	1329
the	PRON	O	O	1329
onset	VERB	O	O	1329
of	ADP	O	O	1329
asystole	NOUN	O	Disease	1329
.	PUNCT	O	O	1329
It	PRON	O	O	1330
should	AUX	O	O	1330
be	AUX	O	O	1330
considered	VERB	O	O	1330
early	ADV	O	O	1330
in	ADP	O	O	1330
cases	NOUN	O	O	1330
of	ADP	O	O	1330
cardiac arrest	NOUN	O	Disease	1330
after	ADP	O	O	1330
diltiazem	VERB	O	Chemical	1330
overdose	NOUN	O	Disease	1330
.	PUNCT	O	O	1330
The	PRON	O	O	1331
case	NOUN	O	O	1331
also	ADV	O	O	1331
highlights	VERB	O	O	1331
the	PRON	O	O	1331
problems	NOUN	O	O	1331
with	ADP	O	O	1331
delayed	VERB	O	O	1331
toxicity	NOUN	O	Disease	1331
when	SCONJ	O	O	1331
whole	NOUN	O	O	1331
bowel	ADJ	O	O	1331
irrigation	NOUN	O	O	1331
is	AUX	O	O	1331
not	PART	O	O	1331
administered	VERB	O	O	1331
.	PUNCT	O	O	1331
Renal papillary necrosis	NOUN	O	Disease	1334
due	ADJ	O	O	1334
to	PART	O	O	1334
naproxen	PROPN	O	Chemical	1334
.	PUNCT	O	O	1334
A	PRON	O	O	1335
31-year	NOUN	O	O	1335
-	PUNCT	O	O	1335
old	ADJ	O	O	1335
man	NOUN	O	O	1335
with	ADP	O	O	1335
rheumatoid arthritis	NOUN	O	Disease	1335
,	PUNCT	O	O	1335
who	PRON	O	O	1335
had	VERB	O	O	1335
previously	ADV	O	O	1335
been	AUX	O	O	1335
treated	VERB	O	O	1335
with	ADP	O	O	1335
sulindac	PROPN	O	Chemical	1335
,	PUNCT	O	O	1335
fenoprofen calcium	PROPN	O	Chemical	1335
,	PUNCT	O	O	1335
high	ADJ	O	O	1335
dose	NOUN	O	O	1335
salicylates	NOUN	O	Chemical	1335
and	CCONJ	O	O	1335
gold	NOUN	O	Chemical	1335
salts	NOUN	O	O	1335
,	PUNCT	O	O	1335
developed	VERB	O	O	1335
renal papillary necrosis	NOUN	O	Disease	1335
(	PUNCT	O	O	1335
RPN	PROPN	O	Disease	1335
)	PUNCT	O	O	1335
4	NUM	O	O	1335
months	NOUN	O	O	1335
after	ADP	O	O	1335
institution	NOUN	O	O	1335
of	ADP	O	O	1335
naproxen	PROPN	O	Chemical	1335
therapy	NOUN	O	O	1335
.	PUNCT	O	O	1335
No	PRON	O	O	1336
other	ADJ	O	O	1336
factor	NOUN	O	O	1336
predisposing	VERB	O	O	1336
to	PART	O	O	1336
RPN	PROPN	O	Disease	1336
could	AUX	O	O	1336
be	AUX	O	O	1336
discovered	VERB	O	O	1336
.	PUNCT	O	O	1336
Sulindac	PROPN	O	Chemical	1337
was	AUX	O	O	1337
substituted	VERB	O	O	1337
for	ADP	O	O	1337
naproxen	PROPN	O	Chemical	1337
and	CCONJ	O	O	1337
no	PRON	O	O	1337
further	ADV	O	O	1337
adverse	ADJ	O	O	1337
renal	ADJ	O	O	1337
effects	NOUN	O	O	1337
occurred	VERB	O	O	1337
over	ADP	O	O	1337
the	PRON	O	O	1337
next	ADV	O	O	1337
12	NUM	O	O	1337
months	NOUN	O	O	1337
.	PUNCT	O	O	1337
We	PRON	O	O	1338
review	VERB	O	O	1338
previous	ADJ	O	O	1338
reports	VERB	O	O	1338
linking	VERB	O	O	1338
RPN	PROPN	O	Disease	1338
to	PART	O	O	1338
antiinflammatory	ADJ	O	O	1338
drug	NOUN	O	O	1338
use	VERB	O	O	1338
and	CCONJ	O	O	1338
discuss	VERB	O	O	1338
possible	ADJ	O	O	1338
advantages	NOUN	O	O	1338
of	ADP	O	O	1338
sulindac	PROPN	O	Chemical	1338
in	ADP	O	O	1338
patients	NOUN	O	O	1338
who	PRON	O	O	1338
have	VERB	O	O	1338
experienced	ADJ	O	O	1338
renal toxicity	NOUN	O	Disease	1338
from	ADP	O	O	1338
other	ADJ	O	O	1338
antiinflammatory	ADJ	O	O	1338
agents	NOUN	O	O	1338
.	PUNCT	O	O	1338
Adverse	ADJ	O	O	1341
interaction	NOUN	O	O	1341
between	ADP	O	O	1341
beta	NOUN	O	O	1341
-	PUNCT	O	O	1341
adrenergic	NOUN	O	O	1341
blocking	VERB	O	O	1341
drugs	NOUN	O	O	1341
and	CCONJ	O	O	1341
verapamil	PROPN	O	Chemical	1341
--	PUNCT	O	O	1341
report	VERB	O	O	1341
of	ADP	O	O	1341
three	NUM	O	O	1341
cases	NOUN	O	O	1341
.	PUNCT	O	O	1341
Three	NUM	O	O	1342
patients	NOUN	O	O	1342
with	ADP	O	O	1342
ischaemic	ADJ	O	O	1342
heart disease	NOUN	O	Disease	1342
developed	VERB	O	O	1342
profound	ADJ	O	O	1342
cardiac failure	NOUN	O	Disease	1342
,	PUNCT	O	O	1342
hypotension	NOUN	O	Disease	1342
and	CCONJ	O	O	1342
bradycardia	NOUN	O	Disease	1342
during	ADP	O	O	1342
combined	VERB	O	O	1342
therapy	NOUN	O	O	1342
with	ADP	O	O	1342
verapamil	PROPN	O	Chemical	1342
and	CCONJ	O	O	1342
beta	NOUN	O	O	1342
-	PUNCT	O	O	1342
adrenergic	NOUN	O	O	1342
blocking	VERB	O	O	1342
drugs	NOUN	O	O	1342
.	PUNCT	O	O	1342
Simultaneously	ADV	O	O	1343
administration	NOUN	O	O	1343
of	ADP	O	O	1343
beta	NOUN	O	O	1343
-	PUNCT	O	O	1343
adrenergic	NOUN	O	O	1343
blocking	VERB	O	O	1343
drugs	NOUN	O	O	1343
and	CCONJ	O	O	1343
verapamil	PROPN	O	Chemical	1343
may	AUX	O	O	1343
result	VERB	O	O	1343
in	ADP	O	O	1343
profound	ADJ	O	O	1343
adverse	ADJ	O	O	1343
interactions	NOUN	O	O	1343
and	CCONJ	O	O	1343
should	AUX	O	O	1343
only	ADV	O	O	1343
be	AUX	O	O	1343
administered	VERB	O	O	1343
with	ADP	O	O	1343
great	ADJ	O	O	1343
caution	NOUN	O	O	1343
.	PUNCT	O	O	1343
Adverse	ADJ	O	O	1346
reactions	NOUN	O	O	1346
to	PART	O	O	1346
bendrofluazide	NOUN	O	Chemical	1346
and	CCONJ	O	O	1346
propranolol	NOUN	O	Chemical	1346
for	ADP	O	O	1346
the	PRON	O	O	1346
treatment	NOUN	O	O	1346
of	ADP	O	O	1346
mild	ADJ	O	O	1346
hypertension	NOUN	O	Disease	1346
.	PUNCT	O	O	1346
Report	NOUN	O	O	1347
of	ADP	O	O	1347
Medical	NOUN	O	O	1347
Research	NOUN	O	O	1347
Council	NOUN	O	O	1347
Working	VERB	O	O	1347
Party	NOUN	O	O	1347
on	ADP	O	O	1347
Mild	NOUN	O	O	1347
to	PART	O	O	1347
Moderate	ADJ	O	O	1347
Hypertension	NOUN	O	Disease	1347
.	PUNCT	O	O	1347
Participants	NOUN	O	O	1348
in	ADP	O	O	1348
the	PRON	O	O	1348
Medical	NOUN	O	O	1348
Research	NOUN	O	O	1348
Council	NOUN	O	O	1348
treatment	NOUN	O	O	1348
trial	NOUN	O	O	1348
for	ADP	O	O	1348
mild	ADJ	O	O	1348
hypertension	NOUN	O	Disease	1348
are	AUX	O	O	1348
randomly	ADV	O	O	1348
allocated	VERB	O	O	1348
to	PART	O	O	1348
one	NUM	O	O	1348
of	ADP	O	O	1348
four	NUM	O	O	1348
treatment	NOUN	O	O	1348
groups	NOUN	O	O	1348
:	PUNCT	O	O	1348
bendrofluazide	NOUN	O	Chemical	1349
,	PUNCT	O	O	1349
propranolol	NOUN	O	Chemical	1349
,	PUNCT	O	O	1349
or	CCONJ	O	O	1349
a	PRON	O	O	1349
placebo	NOUN	O	O	1349
for	ADP	O	O	1349
either	ADV	O	O	1349
of	ADP	O	O	1349
these	PRON	O	O	1349
drugs	NOUN	O	O	1349
.	PUNCT	O	O	1349
The	PRON	O	O	1350
results	VERB	O	O	1350
show	VERB	O	O	1350
an	PRON	O	O	1350
association	PROPN	O	O	1350
between	ADP	O	O	1350
bendrofluazide	NOUN	O	Chemical	1350
treatment	NOUN	O	O	1350
and	CCONJ	O	O	1350
impotence	NOUN	O	Disease	1350
,	PUNCT	O	O	1350
and	CCONJ	O	O	1350
impotence	NOUN	O	Disease	1350
also	ADV	O	O	1350
occurred	VERB	O	O	1350
more	ADJ	O	O	1350
frequently	ADV	O	O	1350
in	ADP	O	O	1350
patients	NOUN	O	O	1350
taking	VERB	O	O	1350
propranolol	NOUN	O	Chemical	1350
than	ADP	O	O	1350
in	ADP	O	O	1350
those	PRON	O	O	1350
taking	VERB	O	O	1350
placebos	NOUN	O	O	1350
.	PUNCT	O	O	1350
Other	ADJ	O	O	1351
adverse	ADJ	O	O	1351
reactions	NOUN	O	O	1351
significantly	ADV	O	O	1351
linked	VERB	O	O	1351
with	ADP	O	O	1351
active	ADJ	O	O	1351
drugs	NOUN	O	O	1351
include	VERB	O	O	1351
impaired glucose tolerance	NOUN	O	Disease	1351
in	ADP	O	O	1351
men	NOUN	O	O	1351
and	CCONJ	O	O	1351
women	NOUN	O	O	1351
and	CCONJ	O	O	1351
gout	NOUN	O	Disease	1351
in	ADP	O	O	1351
men	NOUN	O	O	1351
,	PUNCT	O	O	1351
associated	VERB	O	O	1351
with	ADP	O	O	1351
bendrofluazide	NOUN	O	Chemical	1351
treatment	NOUN	O	O	1351
,	PUNCT	O	O	1351
and	CCONJ	O	O	1351
Raynaud	NOUN	O	O	1351
's	AUX	O	O	1351
phenomenon	NOUN	O	O	1351
and	CCONJ	O	O	1351
dyspnoea	NOUN	O	Disease	1351
in	ADP	O	O	1351
men	NOUN	O	O	1351
and	CCONJ	O	O	1351
women	NOUN	O	O	1351
taking	VERB	O	O	1351
propranolol	NOUN	O	Chemical	1351
.	PUNCT	O	O	1351
No	PRON	O	O	1352
corneal disease	NOUN	O	Disease	1352
is	AUX	O	O	1352
known	VERB	O	O	1352
to	PART	O	O	1352
have	VERB	O	O	1352
occurred	VERB	O	O	1352
in	ADP	O	O	1352
the	PRON	O	O	1352
propranolol	NOUN	O	Chemical	1352
group	NOUN	O	O	1352
.	PUNCT	O	O	1352
Mean	VERB	O	O	1353
serum	NOUN	O	O	1353
potassium	NOUN	O	Chemical	1353
level	VERB	O	O	1353
fell	VERB	O	O	1353
,	PUNCT	O	O	1353
and	CCONJ	O	O	1353
urea	PROPN	O	Chemical	1353
and	CCONJ	O	O	1353
uric acid	NOUN	O	Chemical	1353
levels	NOUN	O	O	1353
rose	VERB	O	O	1353
,	PUNCT	O	O	1353
in	ADP	O	O	1353
men	NOUN	O	O	1353
and	CCONJ	O	O	1353
women	NOUN	O	O	1353
taking	VERB	O	O	1353
bendrofluazide	NOUN	O	Chemical	1353
.	PUNCT	O	O	1353
In	ADP	O	O	1354
the	PRON	O	O	1354
propranolol	NOUN	O	Chemical	1354
group	NOUN	O	O	1354
,	PUNCT	O	O	1354
serum	NOUN	O	O	1354
potassium	NOUN	O	Chemical	1354
and	CCONJ	O	O	1354
uric acid	NOUN	O	Chemical	1354
levels	NOUN	O	O	1354
rose	VERB	O	O	1354
in	ADP	O	O	1354
both	PRON	O	O	1354
sexes	NOUN	O	O	1354
,	PUNCT	O	O	1354
but	CCONJ	O	O	1354
the	PRON	O	O	1354
urea	PROPN	O	Chemical	1354
level	VERB	O	O	1354
rose	VERB	O	O	1354
significantly	ADV	O	O	1354
in	ADP	O	O	1354
women	NOUN	O	O	1354
only	ADV	O	O	1354
.	PUNCT	O	O	1354
Dexmedetomidine	PROPN	O	Chemical	1357
and	CCONJ	O	O	1357
cardiac	ADJ	O	O	1357
protection	NOUN	O	O	1357
for	ADP	O	O	1357
non	ADJ	O	O	1357
-	PUNCT	O	O	1357
cardiac	ADJ	O	O	1357
surgery	NOUN	O	O	1357
:	PUNCT	O	O	1357
a	PRON	O	O	1357
meta	PROPN	O	O	1357
-	PUNCT	O	O	1357
analysis	NOUN	O	O	1357
of	ADP	O	O	1357
randomised	VERB	O	O	1357
controlled	VERB	O	O	1357
trials	NOUN	O	O	1357
.	PUNCT	O	O	1357
We	PRON	O	O	1358
conducted	VERB	O	O	1358
a	PRON	O	O	1358
systematic	ADJ	O	O	1358
review	VERB	O	O	1358
of	ADP	O	O	1358
the	PRON	O	O	1358
effects	NOUN	O	O	1358
of	ADP	O	O	1358
dexmedetomidine	PROPN	O	Chemical	1358
on	ADP	O	O	1358
cardiac	ADJ	O	O	1358
outcomes	NOUN	O	O	1358
following	VERB	O	O	1358
non	ADJ	O	O	1358
-	PUNCT	O	O	1358
cardiac	ADJ	O	O	1358
surgery	NOUN	O	O	1358
.	PUNCT	O	O	1358
We	PRON	O	O	1359
included	VERB	O	O	1359
prospective	ADJ	O	O	1359
,	PUNCT	O	O	1359
randomised	VERB	O	O	1359
peri	PROPN	O	O	1359
-	PUNCT	O	O	1359
operative	NOUN	O	O	1359
studies	NOUN	O	O	1359
of	ADP	O	O	1359
dexmedetomidine	PROPN	O	Chemical	1359
that	SCONJ	O	O	1359
reported	VERB	O	O	1359
mortality	NOUN	O	O	1359
,	PUNCT	O	O	1359
cardiac	ADJ	O	O	1359
morbidity	NOUN	O	O	1359
or	CCONJ	O	O	1359
adverse	ADJ	O	O	1359
drug	NOUN	O	O	1359
events	NOUN	O	O	1359
.	PUNCT	O	O	1359
Dexmedetomidine	PROPN	O	Chemical	1360
was	AUX	O	O	1360
associated	VERB	O	O	1360
with	ADP	O	O	1360
a	PRON	O	O	1360
trend	NOUN	O	O	1360
towards	ADP	O	O	1360
improved	VERB	O	O	1360
cardiac	ADJ	O	O	1360
outcomes	NOUN	O	O	1360
;	PUNCT	O	O	1360
all	PRON	O	O	1360
-	PUNCT	O	O	1360
cause	VERB	O	O	1360
mortality	NOUN	O	O	1360
(	PUNCT	O	O	1360
OR	CCONJ	O	O	1360
0.27	NUM	O	O	1360
,	PUNCT	O	O	1360
95%	NOUN	O	O	1360
CI	NOUN	O	O	1360
0.01	NUM	O	O	1360
-	PUNCT	O	O	1360
7.13	NUM	O	O	1360
,	PUNCT	O	O	1360
p	NOUN	O	O	1361
=	PUNCT	O	O	1361
0.44	NUM	O	O	1361
)	PUNCT	O	O	1361
,	PUNCT	O	O	1361
non	ADJ	O	O	1361
-	PUNCT	O	O	1361
fatal	ADJ	O	O	1361
myocardial infarction	NOUN	O	Disease	1361
(	PUNCT	O	O	1361
OR	CCONJ	O	O	1361
0.26	NUM	O	O	1361
,	PUNCT	O	O	1361
95%	NOUN	O	O	1361
CI	NOUN	O	O	1361
0.04	NUM	O	O	1361
-	PUNCT	O	O	1361
1.60	NUM	O	O	1361
,	PUNCT	O	O	1361
p	NOUN	O	O	1361
=	PUNCT	O	O	1361
0.14	NUM	O	O	1361
)	PUNCT	O	O	1361
,	PUNCT	O	O	1361
and	CCONJ	O	O	1361
myocardial ischaemia	NOUN	O	Disease	1361
(	PUNCT	O	O	1361
OR	CCONJ	O	O	1361
0.65	NUM	O	O	1361
,	PUNCT	O	O	1361
95%	NOUN	O	O	1361
CI	NOUN	O	O	1361
0.26	NUM	O	O	1361
-	PUNCT	O	O	1361
1.63	NUM	O	O	1361
,	PUNCT	O	O	1361
Peri	PROPN	O	O	1362
-	PUNCT	O	O	1362
operative	NOUN	O	O	1362
hypotension	NOUN	O	Disease	1362
(	PUNCT	O	O	1362
26%	NOUN	O	O	1362
,	PUNCT	O	O	1362
OR	CCONJ	O	O	1362
3.80	NUM	O	O	1362
,	PUNCT	O	O	1362
95%	NOUN	O	O	1362
CI	NOUN	O	O	1363
1.91	NUM	O	O	1363
-	PUNCT	O	O	1363
7.54	NUM	O	O	1363
,	PUNCT	O	O	1363
p	NOUN	O	O	1363
=	PUNCT	O	O	1363
0.0001	NUM	O	O	1363
)	PUNCT	O	O	1363
and	CCONJ	O	O	1363
bradycardia	NOUN	O	Disease	1363
(	PUNCT	O	O	1363
17%	NOUN	O	O	1363
,	PUNCT	O	O	1363
OR	CCONJ	O	O	1363
5.45	NUM	O	O	1363
,	PUNCT	O	O	1363
95%	NOUN	O	O	1363
CI	NOUN	O	O	1363
2.98	NUM	O	O	1363
-	PUNCT	O	O	1363
9.95	NUM	O	O	1363
,	PUNCT	O	O	1363
p	NOUN	O	O	1363
An	PRON	O	O	1364
anticholinergic	ADJ	O	O	1364
did	VERB	O	O	1364
not	PART	O	O	1364
reduce	VERB	O	O	1364
the	PRON	O	O	1364
incidence	NOUN	O	O	1364
of	ADP	O	O	1364
bradycardia	NOUN	O	Disease	1364
(	PUNCT	O	O	1364
p	NOUN	O	O	1364
=	PUNCT	O	O	1364
0.43	NUM	O	O	1364
)	PUNCT	O	O	1364
.	PUNCT	O	O	1364
A	PRON	O	O	1365
randomised	VERB	O	O	1365
placebo	NOUN	O	O	1365
-	PUNCT	O	O	1365
controlled	VERB	O	O	1365
trial	NOUN	O	O	1365
of	ADP	O	O	1365
dexmedetomidine	PROPN	O	Chemical	1365
is	AUX	O	O	1365
warranted	VERB	O	O	1365
.	PUNCT	O	O	1365
Differential	ADJ	O	O	1368
diagnosis	NOUN	O	O	1368
of	ADP	O	O	1368
high	ADJ	O	O	1368
serum	NOUN	O	O	1368
creatine	PROPN	O	Chemical	1368
kinase	VERB	O	O	1368
levels	NOUN	O	O	1368
in	ADP	O	O	1368
systemic lupus erythematosus	PROPN	O	Disease	1368
.	PUNCT	O	O	1368
We	PRON	O	O	1369
report	VERB	O	O	1369
the	PRON	O	O	1369
clinical	ADJ	O	O	1369
and	CCONJ	O	O	1369
bioptic	VERB	O	O	1369
findings	NOUN	O	O	1369
for	ADP	O	O	1369
a	PRON	O	O	1369
57-year	NOUN	O	O	1369
-	PUNCT	O	O	1369
old	ADJ	O	O	1369
woman	NOUN	O	O	1369
with	ADP	O	O	1369
severe	ADJ	O	O	1369
chloroquine	ADJ	O	Chemical	1369
-	PUNCT	O	O	1369
induced	VERB	O	O	1369
myopathy	PROPN	O	Disease	1369
.	PUNCT	O	O	1369
Since	SCONJ	O	O	1370
1989	NUM	O	O	1370
,	PUNCT	O	O	1370
she	PRON	O	O	1370
had	VERB	O	O	1370
been	AUX	O	O	1370
suffering	VERB	O	O	1370
from	ADP	O	O	1370
systemic lupus erythematosus	PROPN	O	Disease	1370
(	PUNCT	O	O	1370
SLE	PROPN	O	Disease	1370
)	PUNCT	O	O	1370
with	ADP	O	O	1370
renal involvement	NOUN	O	Disease	1370
and	CCONJ	O	O	1370
undergone	VERB	O	O	1370
periods	NOUN	O	O	1370
of	ADP	O	O	1370
treatment	NOUN	O	O	1370
with	ADP	O	O	1370
azathioprine	ADV	O	Chemical	1370
and	CCONJ	O	O	1370
cyclophosphamide	VERB	O	Chemical	1370
.	PUNCT	O	O	1370
Additional	ADJ	O	O	1371
therapy	NOUN	O	O	1371
with	ADP	O	O	1371
chloroquine	ADJ	O	Chemical	1371
(	PUNCT	O	O	1371
CQ	NOUN	O	Chemical	1371
)	PUNCT	O	O	1371
was	AUX	O	O	1371
started	VERB	O	O	1371
because	SCONJ	O	O	1371
of	ADP	O	O	1371
arthralgia	ADV	O	Disease	1371
.	PUNCT	O	O	1371
At	ADP	O	O	1372
the	PRON	O	O	1372
same	ADJ	O	O	1372
time	NOUN	O	O	1372
,	PUNCT	O	O	1372
slightly	ADV	O	O	1372
increased	VERB	O	O	1372
creatine	PROPN	O	Chemical	1372
kinase	VERB	O	O	1372
(	PUNCT	O	O	1372
CK	PROPN	O	O	1372
)	PUNCT	O	O	1372
Myositis	NOUN	O	Disease	1373
was	AUX	O	O	1373
suspected	VERB	O	O	1373
,	PUNCT	O	O	1373
and	CCONJ	O	O	1373
the	PRON	O	O	1373
patient	NOUN	O	O	1373
was	AUX	O	O	1373
treated	VERB	O	O	1373
with	ADP	O	O	1373
steroids	NOUN	O	Chemical	1373
.	PUNCT	O	O	1373
The	PRON	O	O	1374
CK	PROPN	O	O	1374
increase	VERB	O	O	1374
persisted	VERB	O	O	1374
,	PUNCT	O	O	1374
however	ADV	O	O	1374
,	PUNCT	O	O	1374
and	CCONJ	O	O	1374
she	PRON	O	O	1374
developed	VERB	O	O	1374
progressive	ADJ	O	O	1374
muscular weakness	NOUN	O	Disease	1374
and	CCONJ	O	O	1374
muscular atrophy	NOUN	O	Disease	1374
.	PUNCT	O	O	1374
The	PRON	O	O	1375
neurological	ADJ	O	O	1375
and	CCONJ	O	O	1375
electrophysiological	ADJ	O	O	1375
findings	NOUN	O	O	1375
were	AUX	O	O	1375
not	PART	O	O	1375
typical	ADJ	O	O	1375
of	ADP	O	O	1375
myositis	PROPN	O	Disease	1375
.	PUNCT	O	O	1375
Thus	ADV	O	O	1376
,	PUNCT	O	O	1376
muscle	NOUN	O	O	1376
biopsy	PROPN	O	O	1376
of	ADP	O	O	1376
the	PRON	O	O	1376
deltoid	PROPN	O	O	1376
muscle	NOUN	O	O	1376
was	AUX	O	O	1376
performed	VERB	O	O	1376
in	ADP	O	O	1376
order	NOUN	O	O	1376
to	PART	O	O	1376
exclude	VERB	O	O	1376
polymyositis	NOUN	O	Disease	1376
or	CCONJ	O	O	1376
toxic	ADJ	O	O	1376
myopathy	PROPN	O	Disease	1376
.	PUNCT	O	O	1376
As	ADP	O	O	1377
it	PRON	O	O	1377
revealed	VERB	O	O	1377
chloroquine	ADJ	O	Chemical	1377
-	PUNCT	O	O	1377
induced	VERB	O	O	1377
myopathy	PROPN	O	Disease	1377
,	PUNCT	O	O	1377
medication	NOUN	O	O	1377
was	AUX	O	O	1377
stopped	VERB	O	O	1377
.	PUNCT	O	O	1377
Discriminating	VERB	O	O	1378
between	ADP	O	O	1378
primary	NOUN	O	O	1378
SLE	PROPN	O	Disease	1378
-	PUNCT	O	O	1378
induced	VERB	O	O	1378
affection of the musculoskeletal system	NOUN	O	Disease	1378
and	CCONJ	O	O	1378
drug	NOUN	O	O	1378
-	PUNCT	O	O	1378
induced	VERB	O	O	1378
side	NOUN	O	O	1378
effects	NOUN	O	O	1378
is	AUX	O	O	1378
important	ADJ	O	O	1378
for	ADP	O	O	1378
appropriate	ADJ	O	O	1378
treatment	NOUN	O	O	1378
of	ADP	O	O	1378
SLE	PROPN	O	Disease	1378
patients	NOUN	O	O	1378
.	PUNCT	O	O	1378
Intravenous	PROPN	O	O	1381
ribavirin	NOUN	O	Chemical	1381
treatment	NOUN	O	O	1381
for	ADP	O	O	1381
severe	ADJ	O	O	1381
adenovirus disease	NOUN	O	Disease	1381
in	ADP	O	O	1381
immunocompromised	ADJ	O	O	1381
children	NOUN	O	O	1381
.	PUNCT	O	O	1381
The	PRON	O	O	1382
incidence	NOUN	O	O	1382
of	ADP	O	O	1382
severe	ADJ	O	O	1382
adenovirus disease	NOUN	O	Disease	1382
in	ADP	O	O	1382
pediatrics	NOUN	O	O	1382
is	AUX	O	O	1382
increasing	VERB	O	O	1382
in	ADP	O	O	1382
association	PROPN	O	O	1382
with	ADP	O	O	1382
growing	VERB	O	O	1382
numbers	NOUN	O	O	1382
of	ADP	O	O	1382
immunocompromised	ADJ	O	O	1382
children	NOUN	O	O	1382
,	PUNCT	O	O	1382
where	SCONJ	O	O	1382
case	NOUN	O	O	1382
fatality	NOUN	O	O	1382
rates	NOUN	O	O	1382
as	ADP	O	O	1382
high	ADJ	O	O	1382
as	ADP	O	O	1382
50%	NOUN	O	O	1382
to	PART	O	O	1382
80%	NOUN	O	O	1382
have	VERB	O	O	1382
been	AUX	O	O	1382
reported	VERB	O	O	1382
.	PUNCT	O	O	1382
There	ADV	O	O	1383
are	AUX	O	O	1383
no	PRON	O	O	1383
approved	VERB	O	O	1383
antiviral	ADJ	O	O	1383
agents	NOUN	O	O	1383
with	ADP	O	O	1383
proven	VERB	O	O	1383
efficacy	NOUN	O	O	1383
for	ADP	O	O	1383
the	PRON	O	O	1383
treatment	NOUN	O	O	1383
of	ADP	O	O	1383
severe	ADJ	O	O	1383
adenovirus disease	NOUN	O	Disease	1383
,	PUNCT	O	O	1383
nor	CCONJ	O	O	1383
are	AUX	O	O	1383
there	ADV	O	O	1383
any	PRON	O	O	1383
prospective	ADJ	O	O	1383
randomized	VERB	O	O	1383
,	PUNCT	O	O	1383
controlled	VERB	O	O	1383
trials	NOUN	O	O	1383
of	ADP	O	O	1383
potentially	ADV	O	O	1383
useful	ADJ	O	O	1383
anti	ADJ	O	O	1383
-	PUNCT	O	O	1383
adenovirus	NOUN	O	Disease	1383
therapies	NOUN	O	O	1383
.	PUNCT	O	O	1383
Apparent	ADJ	O	O	1384
clinical	ADJ	O	O	1384
success	NOUN	O	O	1384
in	ADP	O	O	1384
the	PRON	O	O	1384
treatment	NOUN	O	O	1384
of	ADP	O	O	1384
severe	ADJ	O	O	1384
adenovirus disease	NOUN	O	Disease	1384
is	AUX	O	O	1384
limited	VERB	O	O	1384
to	PART	O	O	1384
a	PRON	O	O	1384
few	ADJ	O	O	1384
case	NOUN	O	O	1384
reports	VERB	O	O	1384
and	CCONJ	O	O	1384
small	ADJ	O	O	1384
series	PROPN	O	O	1384
.	PUNCT	O	O	1384
Experience	NOUN	O	O	1385
is	AUX	O	O	1385
greatest	ADJ	O	O	1385
with	ADP	O	O	1385
intravenous	ADJ	O	O	1385
ribavirin	NOUN	O	Chemical	1385
and	CCONJ	O	O	1385
cidofovir	PROPN	O	Chemical	1385
.	PUNCT	O	O	1385
Ribavirin	NOUN	O	Chemical	1386
,	PUNCT	O	O	1386
a	PRON	O	O	1386
guanosine	NOUN	O	Chemical	1386
analogue	NOUN	O	O	1386
,	PUNCT	O	O	1386
has	VERB	O	O	1386
broad	ADJ	O	O	1386
antiviral	ADJ	O	O	1386
activity	NOUN	O	O	1386
against	ADP	O	O	1386
both	PRON	O	O	1386
RNA	PROPN	O	O	1386
and	CCONJ	O	O	1386
DNA	NOUN	O	O	1386
viruses	NOUN	O	O	1386
,	PUNCT	O	O	1386
including	VERB	O	O	1386
documented	VERB	O	O	1386
activity	NOUN	O	O	1386
against	ADP	O	O	1386
adenovirus	NOUN	O	Disease	1386
in	ADP	O	O	1386
vitro	X	O	O	1386
.	PUNCT	O	O	1386
Ribavirin	NOUN	O	Chemical	1387
is	AUX	O	O	1387
licensed	VERB	O	O	1387
in	ADP	O	O	1387
aerosol	NOUN	O	O	1387
form	NOUN	O	O	1387
for	ADP	O	O	1387
the	PRON	O	O	1387
treatment	NOUN	O	O	1387
of	ADP	O	O	1387
respiratory syncytial virus infection	NOUN	O	Disease	1387
,	PUNCT	O	O	1387
and	CCONJ	O	O	1387
orally	ADV	O	O	1387
in	ADP	O	O	1387
combination	NOUN	O	O	1387
with	ADP	O	O	1387
interferon	PROPN	O	Chemical	1387
to	PART	O	O	1387
treat	VERB	O	O	1387
hepatitis C.	PROPN	O	O	1387
Intravenous	PROPN	O	O	1387
ribavirin	NOUN	O	Chemical	1388
is	AUX	O	O	1388
the	PRON	O	O	1388
treatment	NOUN	O	O	1388
of	ADP	O	O	1388
choice	NOUN	O	O	1388
for	ADP	O	O	1388
infection with hemorrhagic fever viruses	NOUN	O	Disease	1388
.	PUNCT	O	O	1388
The	PRON	O	O	1389
most	ADV	O	O	1389
common	ADJ	O	O	1389
adverse	ADJ	O	O	1389
effect	VERB	O	O	1389
of	ADP	O	O	1389
intravenous	ADJ	O	O	1389
ribavirin	NOUN	O	Chemical	1389
is	AUX	O	O	1389
reversible	ADJ	O	O	1389
mild	ADJ	O	O	1389
anemia	NOUN	O	Disease	1389
.	PUNCT	O	O	1389
The	PRON	O	O	1390
use	VERB	O	O	1390
of	ADP	O	O	1390
cidofovir	PROPN	O	Chemical	1390
in	ADP	O	O	1390
severe	ADJ	O	O	1390
adenovirus infection	NOUN	O	Disease	1390
has	VERB	O	O	1390
been	AUX	O	O	1390
limited	VERB	O	O	1390
by	ADP	O	O	1390
adverse	ADJ	O	O	1390
effects	NOUN	O	O	1390
,	PUNCT	O	O	1390
the	PRON	O	O	1390
most	ADV	O	O	1390
significant	ADJ	O	O	1390
of	ADP	O	O	1390
which	PRON	O	O	1390
is	AUX	O	O	1390
nephrotoxicity	NOUN	O	Disease	1390
.	PUNCT	O	O	1390
OBJECTIVE	VERB	O	O	1391
:	PUNCT	O	O	1391
We	PRON	O	O	1391
report	VERB	O	O	1391
our	PRON	O	O	1391
experience	NOUN	O	O	1391
with	ADP	O	O	1391
intravenous	ADJ	O	O	1391
ribavirin	NOUN	O	Chemical	1391
therapy	NOUN	O	O	1391
for	ADP	O	O	1391
severe	ADJ	O	O	1391
adenovirus disease	NOUN	O	Disease	1391
in	ADP	O	O	1391
a	PRON	O	O	1391
series	PROPN	O	O	1391
of	ADP	O	O	1391
immunocompromised	ADJ	O	O	1391
children	NOUN	O	O	1391
and	CCONJ	O	O	1391
review	VERB	O	O	1391
the	PRON	O	O	1391
literature	NOUN	O	O	1391
.	PUNCT	O	O	1391
:	PUNCT	O	O	1392
We	PRON	O	O	1392
retrospectively	ADV	O	O	1392
reviewed	VERB	O	O	1392
the	PRON	O	O	1392
medical	ADJ	O	O	1392
records	NOUN	O	O	1392
of	ADP	O	O	1392
5	NUM	O	O	1392
children	NOUN	O	O	1392
treated	VERB	O	O	1392
with	ADP	O	O	1392
intravenous	ADJ	O	O	1392
ribavirin	NOUN	O	Chemical	1392
for	ADP	O	O	1392
documented	VERB	O	O	1392
severe	ADJ	O	O	1392
adenovirus disease	NOUN	O	Disease	1392
.	PUNCT	O	O	1392
Two	NUM	O	O	1393
patients	NOUN	O	O	1393
developed	VERB	O	O	1393
adenovirus	NOUN	O	Disease	1393
hemorrhagic cystitis	NOUN	O	Disease	1393
after	ADP	O	O	1393
cardiac	ADJ	O	O	1393
and	CCONJ	O	O	1393
bone	NOUN	O	O	1393
marrow	PROPN	O	O	1393
transplants	NOUN	O	O	1393
,	PUNCT	O	O	1393
respectively	ADV	O	O	1393
.	PUNCT	O	O	1393
The	PRON	O	O	1394
bone	NOUN	O	O	1394
marrow	PROPN	O	O	1394
transplant	NOUN	O	O	1394
patient	NOUN	O	O	1394
also	ADV	O	O	1394
received	VERB	O	O	1394
intravenous	ADJ	O	O	1394
cidofovir	PROPN	O	Chemical	1394
for	ADP	O	O	1394
progressive	ADJ	O	O	1394
disseminated	VERB	O	O	1394
disease	PROPN	O	O	1394
.	PUNCT	O	O	1394
An	PRON	O	O	1395
additional	ADJ	O	O	1395
3	X	O	O	1395
children	NOUN	O	O	1395
developed	VERB	O	O	1395
adenovirus pneumonia	NOUN	O	Disease	1395
;	PUNCT	O	O	1395
2	X	O	O	1395
were	AUX	O	O	1395
neonates	NOUN	O	O	1395
,	PUNCT	O	O	1395
1	X	O	O	1395
of	ADP	O	O	1395
whom	PRON	O	O	1395
had	VERB	O	O	1395
partial	ADJ	O	O	1395
DiGeorge syndrome	NOUN	O	Disease	1395
.	PUNCT	O	O	1395
Intravenous	PROPN	O	O	1396
ribavirin	NOUN	O	Chemical	1396
was	AUX	O	O	1396
administered	VERB	O	O	1396
on	ADP	O	O	1396
a	PRON	O	O	1396
compassionate	ADJ	O	O	1396
-	PUNCT	O	O	1396
use	VERB	O	O	1396
protocol	PROPN	O	O	1396
.	PUNCT	O	O	1396
RESULTS	VERB	O	O	1397
:	PUNCT	O	O	1397
Complete	ADJ	O	O	1397
clinical	ADJ	O	O	1397
recovery	NOUN	O	O	1397
followed	VERB	O	O	1397
later	ADV	O	O	1397
by	ADP	O	O	1397
viral	ADJ	O	O	1397
clearance	NOUN	O	O	1397
was	AUX	O	O	1397
observed	VERB	O	O	1397
in	ADP	O	O	1397
2	X	O	O	1397
children	NOUN	O	O	1397
:	PUNCT	O	O	1397
the	PRON	O	O	1397
cardiac	ADJ	O	O	1397
transplant	NOUN	O	O	1397
recipient	NOUN	O	O	1397
with	ADP	O	O	1397
adenovirus	NOUN	O	Disease	1397
hemorrhagic cystitis	NOUN	O	Disease	1397
and	CCONJ	O	O	1397
the	PRON	O	O	1397
immunocompetent	ADJ	O	O	1397
neonate	NOUN	O	O	1397
with	ADP	O	O	1397
adenovirus pneumonia	NOUN	O	Disease	1397
.	PUNCT	O	O	1397
The	PRON	O	O	1398
remaining	VERB	O	O	1398
3	X	O	O	1398
children	NOUN	O	O	1398
died	VERB	O	O	1398
of	ADP	O	O	1398
adenovirus disease	NOUN	O	Disease	1398
.	PUNCT	O	O	1398
Intravenous	PROPN	O	O	1399
ribavirin	NOUN	O	Chemical	1399
therapy	NOUN	O	O	1399
was	AUX	O	O	1399
well	ADV	O	O	1399
tolerated	VERB	O	O	1399
.	PUNCT	O	O	1399
Use	VERB	O	O	1400
of	ADP	O	O	1400
cidofovir	PROPN	O	Chemical	1400
in	ADP	O	O	1400
1	X	O	O	1400
child	NOUN	O	O	1400
was	AUX	O	O	1400
associated	VERB	O	O	1400
with	ADP	O	O	1400
progressive renal failure	NOUN	O	Disease	1400
and	CCONJ	O	O	1400
neutropenia	ADJ	O	Disease	1400
.	PUNCT	O	O	1400
Our	PRON	O	O	1401
series	PROPN	O	O	1401
of	ADP	O	O	1401
patients	NOUN	O	O	1401
is	AUX	O	O	1401
representative	NOUN	O	O	1401
of	ADP	O	O	1401
the	PRON	O	O	1401
spectrum	NOUN	O	O	1401
of	ADP	O	O	1401
immunocompromised	ADJ	O	O	1401
children	NOUN	O	O	1401
at	ADP	O	O	1401
greatest	ADJ	O	O	1401
risk	NOUN	O	O	1401
for	ADP	O	O	1401
severe	ADJ	O	O	1401
adenovirus disease	NOUN	O	Disease	1401
,	PUNCT	O	O	1401
namely	ADV	O	O	1401
solid	ADJ	O	O	1401
-	PUNCT	O	O	1401
organ	NOUN	O	O	1401
and	CCONJ	O	O	1401
bone	NOUN	O	O	1401
marrow	PROPN	O	O	1401
transplant	NOUN	O	O	1401
recipients	NOUN	O	O	1401
,	PUNCT	O	O	1401
neonates	NOUN	O	O	1401
,	PUNCT	O	O	1401
and	CCONJ	O	O	1401
children	NOUN	O	O	1401
with	ADP	O	O	1401
immunodeficiency	NOUN	O	Disease	1401
.	PUNCT	O	O	1401
Although	SCONJ	O	O	1402
intravenous	ADJ	O	O	1402
ribavirin	NOUN	O	Chemical	1402
was	AUX	O	O	1402
not	PART	O	O	1402
effective	ADJ	O	O	1402
for	ADP	O	O	1402
all	PRON	O	O	1402
children	NOUN	O	O	1402
with	ADP	O	O	1402
severe	ADJ	O	O	1402
adenovirus disease	NOUN	O	Disease	1402
in	ADP	O	O	1402
this	PRON	O	O	1402
series	PROPN	O	O	1402
or	CCONJ	O	O	1402
in	ADP	O	O	1402
the	PRON	O	O	1402
literature	NOUN	O	O	1402
,	PUNCT	O	O	1402
therapy	NOUN	O	O	1402
is	AUX	O	O	1402
unlikely	ADJ	O	O	1402
to	PART	O	O	1402
be	AUX	O	O	1402
of	ADP	O	O	1402
benefit	VERB	O	O	1402
if	SCONJ	O	O	1402
begun	VERB	O	O	1402
late	ADV	O	O	1402
in	ADP	O	O	1402
the	PRON	O	O	1402
course	NOUN	O	O	1402
of	ADP	O	O	1402
the	PRON	O	O	1402
infection	NOUN	O	Disease	1402
.	PUNCT	O	O	1402
Early	ADJ	O	O	1403
identification	NOUN	O	O	1403
,	PUNCT	O	O	1403
eg	ADP	O	O	1403
by	ADP	O	O	1403
polymerase	NOUN	O	O	1403
chain	NOUN	O	O	1403
reaction	NOUN	O	O	1403
of	ADP	O	O	1403
those	PRON	O	O	1403
patients	NOUN	O	O	1403
at	ADP	O	O	1403
risk	NOUN	O	O	1403
of	ADP	O	O	1403
disseminated	VERB	O	O	1403
adenovirus disease	NOUN	O	Disease	1403
may	AUX	O	O	1403
permit	NOUN	O	O	1403
earlier	ADV	O	O	1403
antiviral	ADJ	O	O	1403
treatment	NOUN	O	O	1403
and	CCONJ	O	O	1403
better	ADV	O	O	1403
evaluation	NOUN	O	O	1403
of	ADP	O	O	1403
therapeutic	ADJ	O	O	1403
response	NOUN	O	O	1403
.	PUNCT	O	O	1403
Two	NUM	O	O	1404
of	ADP	O	O	1404
5	NUM	O	O	1404
children	NOUN	O	O	1404
with	ADP	O	O	1404
severe	ADJ	O	O	1404
adenovirus disease	NOUN	O	Disease	1404
treated	VERB	O	O	1404
with	ADP	O	O	1404
intravenous	ADJ	O	O	1404
ribavirin	NOUN	O	Chemical	1404
recovered	VERB	O	O	1404
.	PUNCT	O	O	1404
The	PRON	O	O	1405
availability	NOUN	O	O	1405
of	ADP	O	O	1405
newer	ADJ	O	O	1405
rapid	ADJ	O	O	1405
diagnostic	ADJ	O	O	1405
techniques	NOUN	O	O	1405
,	PUNCT	O	O	1405
such	ADJ	O	O	1405
as	ADP	O	O	1405
polymerase	NOUN	O	O	1405
chain	NOUN	O	O	1405
reaction	NOUN	O	O	1405
,	PUNCT	O	O	1405
may	AUX	O	O	1405
make	VERB	O	O	1405
earlier	ADV	O	O	1405
,	PUNCT	O	O	1405
more	ADJ	O	O	1405
effective	ADJ	O	O	1405
treatment	NOUN	O	O	1405
of	ADP	O	O	1405
adenovirus infection	NOUN	O	Disease	1405
possible	ADJ	O	O	1405
.	PUNCT	O	O	1405
Given	VERB	O	O	1406
the	PRON	O	O	1406
seriousness	VERB	O	O	1406
and	CCONJ	O	O	1406
increasing	VERB	O	O	1406
prevalence	NOUN	O	O	1406
of	ADP	O	O	1406
adenovirus disease	NOUN	O	Disease	1406
in	ADP	O	O	1406
certain	ADJ	O	O	1406
hosts	NOUN	O	O	1406
,	PUNCT	O	O	1406
especially	ADV	O	O	1406
children	NOUN	O	O	1406
,	PUNCT	O	O	1406
a	PRON	O	O	1406
large	ADJ	O	O	1406
,	PUNCT	O	O	1406
multicenter	ADJ	O	O	1406
clinical	ADJ	O	O	1406
trial	NOUN	O	O	1406
of	ADP	O	O	1406
potentially	ADV	O	O	1406
useful	ADJ	O	O	1406
anti	ADJ	O	O	1406
-	PUNCT	O	O	1406
adenoviral	PROPN	O	O	1406
therapies	NOUN	O	O	1406
,	PUNCT	O	O	1406
such	ADJ	O	O	1406
as	ADP	O	O	1406
intravenous	ADJ	O	O	1406
ribavirin	NOUN	O	Chemical	1406
,	PUNCT	O	O	1406
is	AUX	O	O	1406
clearly	ADV	O	O	1406
required	VERB	O	O	1406
to	PART	O	O	1406
demonstrate	VERB	O	O	1406
the	PRON	O	O	1406
most	ADV	O	O	1406
effective	ADJ	O	O	1406
and	CCONJ	O	O	1406
least	ADJ	O	O	1406
toxic	ADJ	O	O	1406
therapy	NOUN	O	O	1406
.	PUNCT	O	O	1406
Hepatotoxicity	NOUN	O	Disease	1409
of	ADP	O	O	1409
amiodarone	NOUN	O	Chemical	1409
.	PUNCT	O	O	1409
Amiodarone	NOUN	O	Chemical	1410
has	VERB	O	O	1410
proved	VERB	O	O	1410
very	ADV	O	O	1410
effective	ADJ	O	O	1410
in	ADP	O	O	1410
the	PRON	O	O	1410
treatment	NOUN	O	O	1410
of	ADP	O	O	1410
otherwise	ADV	O	O	1410
resistant	ADJ	O	O	1410
cardiac	ADJ	O	O	1410
tachyarrhythmias	NOUN	O	Disease	1410
.	PUNCT	O	O	1410
The	PRON	O	O	1411
use	VERB	O	O	1411
of	ADP	O	O	1411
amiodarone	NOUN	O	Chemical	1411
has	VERB	O	O	1411
,	PUNCT	O	O	1411
however	ADV	O	O	1411
,	PUNCT	O	O	1411
been	AUX	O	O	1411
limited	VERB	O	O	1411
due	ADJ	O	O	1411
to	PART	O	O	1411
its	PRON	O	O	1411
serious	ADJ	O	O	1411
side	NOUN	O	O	1411
-	PUNCT	O	O	1411
effects	NOUN	O	O	1411
.	PUNCT	O	O	1411
A	PRON	O	O	1412
patient	NOUN	O	O	1412
with	ADP	O	O	1412
cholestatic hepatitis	NOUN	O	Disease	1412
due	ADJ	O	O	1412
to	PART	O	O	1412
amiodarone	NOUN	O	Chemical	1412
treatment	NOUN	O	O	1412
is	AUX	O	O	1412
presented	VERB	O	O	1412
below	ADP	O	O	1412
and	CCONJ	O	O	1412
a	PRON	O	O	1412
review	VERB	O	O	1412
of	ADP	O	O	1412
the	PRON	O	O	1412
hepatotoxicity	NOUN	O	Disease	1412
of	ADP	O	O	1412
amiodarone	NOUN	O	Chemical	1412
is	AUX	O	O	1412
given	VERB	O	O	1412
.	PUNCT	O	O	1412
It	PRON	O	O	1413
is	AUX	O	O	1413
concluded	VERB	O	O	1413
that	SCONJ	O	O	1413
solid	ADJ	O	O	1413
evidence	NOUN	O	O	1413
exists	VERB	O	O	1413
of	ADP	O	O	1413
hepatic injury	NOUN	O	Disease	1413
due	ADJ	O	O	1413
to	PART	O	O	1413
amiodarone	NOUN	O	Chemical	1413
treatment	NOUN	O	O	1413
,	PUNCT	O	O	1413
including	VERB	O	O	1413
steatosis	VERB	O	Disease	1413
,	PUNCT	O	O	1413
alterations	NOUN	O	O	1413
resembling	VERB	O	O	1413
alcoholic hepatitis	NOUN	O	Disease	1413
,	PUNCT	O	O	1413
cholestatic hepatitis	NOUN	O	Disease	1413
and	CCONJ	O	O	1413
micronodular	ADJ	O	O	1413
cirrhosis of the liver	NOUN	O	Disease	1413
.	PUNCT	O	O	1413
Patients	NOUN	O	O	1414
receiving	VERB	O	O	1414
amiodarone	NOUN	O	Chemical	1414
should	AUX	O	O	1414
be	AUX	O	O	1414
regularly	ADV	O	O	1414
screened	VERB	O	O	1414
with	ADP	O	O	1414
respect	VERB	O	O	1414
to	PART	O	O	1414
hepatic	ADJ	O	O	1414
enzyme	NOUN	O	O	1414
levels	NOUN	O	O	1414
.	PUNCT	O	O	1414
Therapy	NOUN	O	O	1415
should	AUX	O	O	1415
be	AUX	O	O	1415
discontinued	VERB	O	O	1415
on	ADP	O	O	1415
the	PRON	O	O	1415
suspicion	NOUN	O	O	1415
of	ADP	O	O	1415
cholestatic injury	NOUN	O	Disease	1415
or	CCONJ	O	O	1415
hepatomegaly	NOUN	O	Disease	1415
.	PUNCT	O	O	1415
Catalepsy	NOUN	O	Disease	1418
induced	VERB	O	O	1418
by	ADP	O	O	1418
combinations	NOUN	O	O	1418
of	ADP	O	O	1418
ketamine	VERB	O	Chemical	1418
and	CCONJ	O	O	1418
morphine	NOUN	O	Chemical	1418
:	PUNCT	O	O	1418
potentiation	NOUN	O	O	1418
,	PUNCT	O	O	1418
antagonism	NOUN	O	O	1418
,	PUNCT	O	O	1418
tolerance	NOUN	O	O	1418
and	CCONJ	O	O	1418
cross	VERB	O	O	1418
-	PUNCT	O	O	1418
tolerance	NOUN	O	O	1418
in	ADP	O	O	1418
the	PRON	O	O	1418
rat	NOUN	O	O	1418
.	PUNCT	O	O	1418
Previous	ADJ	O	O	1419
studies	NOUN	O	O	1419
demonstrated	VERB	O	O	1419
that	SCONJ	O	O	1419
both	PRON	O	O	1419
ketamine	VERB	O	Chemical	1419
and	CCONJ	O	O	1419
morphine	NOUN	O	Chemical	1419
induced	VERB	O	O	1419
analgesia	NOUN	O	Disease	1419
and	CCONJ	O	O	1419
catalepsy	VERB	O	Disease	1419
in	ADP	O	O	1419
the	PRON	O	O	1419
rat	NOUN	O	O	1419
.	PUNCT	O	O	1419
Pre	ADJ	O	O	1420
-	PUNCT	O	O	1420
treatment	NOUN	O	O	1420
with	ADP	O	O	1420
ketamine	VERB	O	Chemical	1420
produced	VERB	O	O	1420
cross	VERB	O	O	1420
-	PUNCT	O	O	1420
tolerance	NOUN	O	O	1420
to	PART	O	O	1420
morphine	NOUN	O	Chemical	1420
,	PUNCT	O	O	1420
whereas	SCONJ	O	O	1420
pretreatment	NOUN	O	O	1420
with	ADP	O	O	1420
morphine	NOUN	O	Chemical	1420
did	VERB	O	O	1420
not	PART	O	O	1420
induce	VERB	O	O	1420
cross	VERB	O	O	1420
-	PUNCT	O	O	1420
tolerance	NOUN	O	O	1420
to	PART	O	O	1420
ketamine	VERB	O	Chemical	1420
but	CCONJ	O	O	1420
rather	ADV	O	O	1420
augmented	VERB	O	O	1420
the	PRON	O	O	1420
cataleptic	NOUN	O	Disease	1420
response	NOUN	O	O	1420
;	PUNCT	O	O	1420
this	PRON	O	O	1420
augmentation	NOUN	O	O	1420
was	AUX	O	O	1420
attributed	VERB	O	O	1420
to	PART	O	O	1420
residual	ADJ	O	O	1420
morphine	NOUN	O	Chemical	1420
in	ADP	O	O	1420
the	PRON	O	O	1420
brain	NOUN	O	O	1420
.	PUNCT	O	O	1420
The	PRON	O	O	1421
present	NOUN	O	O	1421
studies	NOUN	O	O	1421
explored	VERB	O	O	1421
the	PRON	O	O	1421
duration	NOUN	O	O	1421
of	ADP	O	O	1421
the	PRON	O	O	1421
loss	NOUN	O	O	1421
of	ADP	O	O	1421
righting	VERB	O	O	1421
reflex	NOUN	O	O	1421
induced	VERB	O	O	1421
by	ADP	O	O	1421
sub	ADJ	O	O	1421
-	PUNCT	O	O	1421
effective	ADJ	O	O	1421
doses	NOUN	O	O	1421
of	ADP	O	O	1421
ketamine	VERB	O	Chemical	1421
and	CCONJ	O	O	1421
morphine	NOUN	O	Chemical	1421
,	PUNCT	O	O	1421
administered	VERB	O	O	1421
simultaneously	ADV	O	O	1421
.	PUNCT	O	O	1421
There	ADV	O	O	1422
was	AUX	O	O	1422
mutual	ADJ	O	O	1422
potentiation	NOUN	O	O	1422
between	ADP	O	O	1422
sub	ADJ	O	O	1422
-	PUNCT	O	O	1422
effective	ADJ	O	O	1422
doses	NOUN	O	O	1422
of	ADP	O	O	1422
ketamine	VERB	O	Chemical	1422
and	CCONJ	O	O	1422
morphine	NOUN	O	Chemical	1422
,	PUNCT	O	O	1422
but	CCONJ	O	O	1422
sub	ADJ	O	O	1422
-	PUNCT	O	O	1422
effective	ADJ	O	O	1422
doses	NOUN	O	O	1422
of	ADP	O	O	1422
ketamine	VERB	O	Chemical	1422
partly	ADV	O	O	1422
antagonized	VERB	O	O	1422
fully	ADV	O	O	1422
-	PUNCT	O	O	1422
effective	ADJ	O	O	1422
doses	NOUN	O	O	1422
of	ADP	O	O	1422
morphine	NOUN	O	Chemical	1422
.	PUNCT	O	O	1422
Latency	NOUN	O	O	1423
to	PART	O	O	1423
the	PRON	O	O	1423
loss	NOUN	O	O	1423
of	ADP	O	O	1423
righting	VERB	O	O	1423
reflex	NOUN	O	O	1423
,	PUNCT	O	O	1423
rigidity	NOUN	O	Disease	1423
and	CCONJ	O	O	1423
behavior	NOUN	O	O	1423
on	ADP	O	O	1423
recovery	NOUN	O	O	1423
,	PUNCT	O	O	1423
reflected	VERB	O	O	1423
the	PRON	O	O	1423
relative	ADJ	O	O	1423
predominance	NOUN	O	O	1423
of	ADP	O	O	1423
ketamine	VERB	O	Chemical	1423
or	CCONJ	O	O	1423
morphine	NOUN	O	Chemical	1423
in	ADP	O	O	1423
each	PRON	O	O	1423
combination	NOUN	O	O	1423
.	PUNCT	O	O	1423
Naloxone	NOUN	O	Chemical	1424
inhibited	VERB	O	O	1424
the	PRON	O	O	1424
induced	VERB	O	O	1424
cataleptic	NOUN	O	Disease	1424
effects	NOUN	O	O	1424
.	PUNCT	O	O	1424
The	PRON	O	O	1425
degree	PROPN	O	O	1425
and	CCONJ	O	O	1425
time	NOUN	O	O	1425
course	NOUN	O	O	1425
of	ADP	O	O	1425
development	NOUN	O	O	1425
of	ADP	O	O	1425
tolerance	NOUN	O	O	1425
to	PART	O	O	1425
daily	ADV	O	O	1425
administration	NOUN	O	O	1425
of	ADP	O	O	1425
sub	ADJ	O	O	1425
-	PUNCT	O	O	1425
effective	ADJ	O	O	1425
dose	NOUN	O	O	1425
combinations	NOUN	O	O	1425
of	ADP	O	O	1425
ketamine	VERB	O	Chemical	1425
and	CCONJ	O	O	1425
morphine	NOUN	O	Chemical	1425
were	AUX	O	O	1425
similar	ADJ	O	O	1425
.	PUNCT	O	O	1425
Rats	NOUN	O	O	1426
,	PUNCT	O	O	1426
tolerant	ADJ	O	O	1426
to	PART	O	O	1426
ketamine	VERB	O	Chemical	1426
-	PUNCT	O	O	1426
dominant	ADJ	O	O	1426
combinations	NOUN	O	O	1426
,	PUNCT	O	O	1426
were	AUX	O	O	1426
cross	VERB	O	O	1426
-	PUNCT	O	O	1426
tolerant	ADJ	O	O	1426
to	PART	O	O	1426
both	PRON	O	O	1426
drugs	NOUN	O	O	1426
,	PUNCT	O	O	1426
while	SCONJ	O	O	1426
those	PRON	O	O	1426
tolerant	ADJ	O	O	1426
to	PART	O	O	1426
morphine	NOUN	O	Chemical	1426
-	PUNCT	O	O	1426
dominant	ADJ	O	O	1426
combinations	NOUN	O	O	1426
were	AUX	O	O	1426
cross	VERB	O	O	1426
-	PUNCT	O	O	1426
tolerant	ADJ	O	O	1426
to	PART	O	O	1426
morphine	NOUN	O	Chemical	1426
but	CCONJ	O	O	1426
showed	VERB	O	O	1426
either	ADV	O	O	1426
no	PRON	O	O	1426
cross	VERB	O	O	1426
-	PUNCT	O	O	1426
tolerance	NOUN	O	O	1426
or	CCONJ	O	O	1426
an	PRON	O	O	1426
augmented	VERB	O	O	1426
response	NOUN	O	O	1426
to	PART	O	O	1426
ketamine	VERB	O	Chemical	1426
.	PUNCT	O	O	1426
While	SCONJ	O	O	1427
the	PRON	O	O	1427
mutual	ADJ	O	O	1427
potentiation	NOUN	O	O	1427
,	PUNCT	O	O	1427
antagonism	NOUN	O	O	1427
and	CCONJ	O	O	1427
tolerance	NOUN	O	O	1427
suggest	VERB	O	O	1427
common	ADJ	O	O	1427
mechanisms	NOUN	O	O	1427
for	ADP	O	O	1427
the	PRON	O	O	1427
induced	VERB	O	O	1427
catalepsy	VERB	O	Disease	1427
,	PUNCT	O	O	1427
differences	NOUN	O	O	1427
in	ADP	O	O	1427
latency	VERB	O	O	1427
,	PUNCT	O	O	1427
rigidity	NOUN	O	Disease	1427
and	CCONJ	O	O	1427
behavior	NOUN	O	O	1427
,	PUNCT	O	O	1427
asymmetry	NOUN	O	O	1427
of	ADP	O	O	1427
cross	VERB	O	O	1427
-	PUNCT	O	O	1427
tolerance	NOUN	O	O	1427
and	CCONJ	O	O	1427
a	PRON	O	O	1427
widely	ADV	O	O	1427
-	PUNCT	O	O	1427
different	ADJ	O	O	1427
ID50	PROPN	O	O	1427
for	ADP	O	O	1427
naloxone	NOUN	O	Chemical	1427
would	AUX	O	O	1427
argue	VERB	O	O	1427
against	ADP	O	O	1427
an	PRON	O	O	1427
action	NOUN	O	O	1427
at	ADP	O	O	1427
a	PRON	O	O	1427
single	ADJ	O	O	1427
opioid	NOUN	O	O	1427
site	NOUN	O	O	1427
.	PUNCT	O	O	1427
Acute	PROPN	O	O	1430
renal failure	NOUN	O	Disease	1430
in	ADP	O	O	1430
patients	NOUN	O	O	1430
with	ADP	O	O	1430
AIDS	PROPN	O	Disease	1430
on	ADP	O	O	1430
tenofovir	NOUN	O	Chemical	1430
while	SCONJ	O	O	1430
receiving	VERB	O	O	1430
prolonged	VERB	O	O	1430
vancomycin	VERB	O	Chemical	1430
course	NOUN	O	O	1430
for	ADP	O	O	1430
osteomyelitis	NOUN	O	Disease	1430
.	PUNCT	O	O	1430
Renal failure	NOUN	O	Disease	1431
developed	VERB	O	O	1431
after	ADP	O	O	1431
a	PRON	O	O	1431
prolonged	VERB	O	O	1431
course	NOUN	O	O	1431
of	ADP	O	O	1431
vancomycin	VERB	O	Chemical	1431
therapy	NOUN	O	O	1431
in	ADP	O	O	1431
2	X	O	O	1431
patients	NOUN	O	O	1431
who	PRON	O	O	1431
were	AUX	O	O	1431
receiving	VERB	O	O	1431
tenofovir disoproxil fumarate	NOUN	O	Chemical	1431
as	ADP	O	O	1431
part	NOUN	O	O	1431
of	ADP	O	O	1431
an	PRON	O	O	1431
antiretroviral	ADJ	O	O	1431
regimen	NOUN	O	O	1431
.	PUNCT	O	O	1431
Tenofovir	PROPN	O	Chemical	1432
has	VERB	O	O	1432
been	AUX	O	O	1432
implicated	VERB	O	O	1432
in	ADP	O	O	1432
the	PRON	O	O	1432
development	NOUN	O	O	1432
of	ADP	O	O	1432
Fanconi syndrome	NOUN	O	Disease	1432
and	CCONJ	O	O	1432
renal insufficiency	NOUN	O	Disease	1432
because	SCONJ	O	O	1432
of	ADP	O	O	1432
its	PRON	O	O	1432
effects	NOUN	O	O	1432
on	ADP	O	O	1432
the	PRON	O	O	1432
proximal	ADJ	O	O	1432
renal	ADJ	O	O	1432
tubule	NOUN	O	O	1432
.	PUNCT	O	O	1432
Vancomycin	PROPN	O	Chemical	1433
nephrotoxicity	NOUN	O	Disease	1433
is	AUX	O	O	1433
infrequent	ADJ	O	O	1433
but	CCONJ	O	O	1433
may	AUX	O	O	1433
result	VERB	O	O	1433
from	ADP	O	O	1433
coadministration	NOUN	O	O	1433
with	ADP	O	O	1433
a	PRON	O	O	1433
nephrotoxic	NOUN	O	Disease	1433
agent	NOUN	O	O	1433
.	PUNCT	O	O	1433
Clinicians	NOUN	O	O	1434
should	AUX	O	O	1434
be	AUX	O	O	1434
aware	ADJ	O	O	1434
that	SCONJ	O	O	1434
tenofovir	NOUN	O	Chemical	1434
may	AUX	O	O	1434
raise	VERB	O	O	1434
the	PRON	O	O	1434
risk	NOUN	O	O	1434
of	ADP	O	O	1434
renal failure	NOUN	O	Disease	1434
during	ADP	O	O	1434
prolonged	VERB	O	O	1434
administration	NOUN	O	O	1434
of	ADP	O	O	1434
vancomycin	VERB	O	Chemical	1434
.	PUNCT	O	O	1434
Delayed	VERB	O	O	1437
leukoencephalopathy	ADJ	O	Disease	1437
with	ADP	O	O	1437
stroke	VERB	O	Disease	1437
-	PUNCT	O	O	1437
like	INTJ	O	O	1437
presentation	NOUN	O	O	1437
in	ADP	O	O	1437
chemotherapy	NOUN	O	O	1437
recipients	NOUN	O	O	1437
.	PUNCT	O	O	1437
A	PRON	O	O	1438
transient	ADJ	O	O	1438
leukoencephalopathy	ADJ	O	Disease	1438
mimicking	VERB	O	O	1438
cerebrovascular accident	NOUN	O	Disease	1438
has	VERB	O	O	1438
been	AUX	O	O	1438
described	VERB	O	O	1438
as	ADP	O	O	1438
a	PRON	O	O	1438
complication	NOUN	O	O	1438
of	ADP	O	O	1438
chemotherapy	NOUN	O	O	1438
,	PUNCT	O	O	1438
most	ADV	O	O	1438
commonly	ADV	O	O	1438
in	ADP	O	O	1438
recipients	NOUN	O	O	1438
of	ADP	O	O	1438
intrathecal	ADJ	O	O	1438
methotrexate	CCONJ	O	Chemical	1438
for	ADP	O	O	1438
childhood	NOUN	O	O	1438
leukaemia	NOUN	O	Disease	1438
.	PUNCT	O	O	1438
METHODS	NOUN	O	O	1439
:	PUNCT	O	O	1439
We	PRON	O	O	1439
reviewed	VERB	O	O	1439
the	PRON	O	O	1439
medical	ADJ	O	O	1439
literature	NOUN	O	O	1439
for	ADP	O	O	1439
single	ADJ	O	O	1439
reports	VERB	O	O	1439
and	CCONJ	O	O	1439
case	NOUN	O	O	1439
series	PROPN	O	O	1439
of	ADP	O	O	1439
patients	NOUN	O	O	1439
presenting	VERB	O	O	1439
with	ADP	O	O	1439
stroke	VERB	O	Disease	1439
-	PUNCT	O	O	1439
like	INTJ	O	O	1439
episodes	NOUN	O	O	1439
while	SCONJ	O	O	1439
receiving	VERB	O	O	1439
systemic	ADJ	O	O	1439
or	CCONJ	O	O	1439
intrathecal	ADJ	O	O	1439
chemotherapy	NOUN	O	O	1439
.	PUNCT	O	O	1439
Patients	NOUN	O	O	1440
with	ADP	O	O	1440
cerebrovascular accidents	NOUN	O	Disease	1440
were	AUX	O	O	1440
excluded	VERB	O	O	1440
.	PUNCT	O	O	1440
We	PRON	O	O	1441
identified	VERB	O	O	1441
27	NUM	O	O	1441
reports	VERB	O	O	1441
of	ADP	O	O	1441
toxic	ADJ	O	O	1441
leukoencephalopathy	ADJ	O	Disease	1441
in	ADP	O	O	1441
patients	NOUN	O	O	1441
treated	VERB	O	O	1441
with	ADP	O	O	1441
methotrexate	CCONJ	O	Chemical	1441
(	PUNCT	O	O	1441
intrathecal	ADJ	O	O	1441
,	PUNCT	O	O	1441
systemic	ADJ	O	O	1441
)	PUNCT	O	O	1441
,	PUNCT	O	O	1441
5-fluorouracil	NOUN	O	Chemical	1441
and	CCONJ	O	O	1441
its	PRON	O	O	1441
derivative	ADJ	O	O	1441
carmofur	NOUN	O	Chemical	1441
,	PUNCT	O	O	1441
and	CCONJ	O	O	1441
capecitabine	PROPN	O	Chemical	1441
.	PUNCT	O	O	1441
Diffusion	NOUN	O	O	1442
weighted	VERB	O	O	1442
imaging	VERB	O	O	1442
(	PUNCT	O	O	1442
DWI	PROPN	O	O	1442
)	PUNCT	O	O	1442
of	ADP	O	O	1442
all	PRON	O	O	1442
patients	NOUN	O	O	1442
revealed	VERB	O	O	1442
well	ADV	O	O	1442
demarcated	VERB	O	O	1442
hyperintense	NOUN	O	O	1442
lesions within the subcortical white matter	NOUN	O	Disease	1442
of	ADP	O	O	1442
the	PRON	O	O	1442
cerebral	ADJ	O	O	1442
hemispheres	NOUN	O	O	1442
and	CCONJ	O	O	1442
the	PRON	O	O	1442
corpus	PROPN	O	O	1442
callosum	NOUN	O	O	1442
,	PUNCT	O	O	1442
corresponding	VERB	O	O	1442
to	PART	O	O	1442
areas	NOUN	O	O	1442
of	ADP	O	O	1442
decreased	VERB	O	O	1442
proton	NOUN	O	O	1442
diffusion	NOUN	O	O	1442
on	ADP	O	O	1442
apparent	ADJ	O	O	1442
diffusion	NOUN	O	O	1442
coefficient	NOUN	O	O	1442
(	PUNCT	O	O	1442
ADC	PROPN	O	O	1442
)	PUNCT	O	O	1442
maps	NOUN	O	O	1442
(	PUNCT	O	O	1442
available	ADJ	O	O	1442
in	ADP	O	O	1442
21/27	NUM	O	O	1442
patients	NOUN	O	O	1442
)	PUNCT	O	O	1442
.	PUNCT	O	O	1442
However	ADV	O	O	1443
,	PUNCT	O	O	1443
fluid	NOUN	O	O	1443
attenuated	VERB	O	O	1443
inversion	NOUN	O	O	1443
recovery	NOUN	O	O	1443
(	PUNCT	O	O	1443
FLAIR	PROPN	O	O	1443
)	PUNCT	O	O	1443
sequences	NOUN	O	O	1443
frequently	ADV	O	O	1443
revealed	VERB	O	O	1443
persistent	ADJ	O	O	1443
white matter abnormalities	NOUN	O	Disease	1443
.	PUNCT	O	O	1443
CONCLUSIONS	NOUN	O	O	1444
:	PUNCT	O	O	1444
Several	ADJ	O	O	1444
pathophysiological	ADJ	O	O	1444
models	NOUN	O	O	1444
of	ADP	O	O	1444
delayed	VERB	O	O	1444
leukoencephalopathy	ADJ	O	Disease	1444
after	ADP	O	O	1444
exposure	NOUN	O	O	1444
to	PART	O	O	1444
intrathecal	ADJ	O	O	1444
or	CCONJ	O	O	1444
systemic	ADJ	O	O	1444
chemotherapy	NOUN	O	O	1444
have	VERB	O	O	1444
been	AUX	O	O	1444
proposed	VERB	O	O	1444
.	PUNCT	O	O	1444
DWI	PROPN	O	O	1445
findings	NOUN	O	O	1445
in	ADP	O	O	1445
this	PRON	O	O	1445
cohort	NOUN	O	O	1445
are	AUX	O	O	1445
indicative	ADJ	O	O	1445
of	ADP	O	O	1445
cytotoxic oedema within cerebral white matter	NOUN	O	Disease	1445
and	CCONJ	O	O	1445
lend	VERB	O	O	1445
support	NOUN	O	O	1445
to	PART	O	O	1445
an	PRON	O	O	1445
at	ADP	O	O	1445
least	ADJ	O	O	1445
partially	ADV	O	O	1445
reversible	ADJ	O	O	1445
metabolic	ADJ	O	O	1445
derangement	NOUN	O	O	1445
as	ADP	O	O	1445
the	PRON	O	O	1445
basis	NOUN	O	O	1445
for	ADP	O	O	1445
this	PRON	O	O	1445
syndrome	NOUN	O	O	1445
.	PUNCT	O	O	1445
Down	ADP	O	O	1448
-	PUNCT	O	O	1448
regulation	NOUN	O	O	1448
of	ADP	O	O	1448
norepinephrine	NOUN	O	Chemical	1448
transporter	NOUN	O	O	1448
function	NOUN	O	O	1448
induced	VERB	O	O	1448
by	ADP	O	O	1448
chronic	ADJ	O	O	1448
administration	NOUN	O	O	1448
of	ADP	O	O	1448
desipramine	NOUN	O	Chemical	1448
linking	VERB	O	O	1448
to	PART	O	O	1448
the	PRON	O	O	1448
alteration	NOUN	O	O	1448
of	ADP	O	O	1448
sensitivity	NOUN	O	O	1448
of	ADP	O	O	1448
local	ADJ	O	O	1448
-	PUNCT	O	O	1448
anesthetics	NOUN	O	O	1448
-	PUNCT	O	O	1448
induced	VERB	O	O	1448
convulsions	NOUN	O	Disease	1448
and	CCONJ	O	O	1448
the	PRON	O	O	1448
counteraction	NOUN	O	O	1448
by	ADP	O	O	1448
co	NOUN	O	O	1448
-	PUNCT	O	O	1448
administration	NOUN	O	O	1448
with	ADP	O	O	1448
local	ADJ	O	O	1448
anesthetics	NOUN	O	O	1448
.	PUNCT	O	O	1448
Alterations	NOUN	O	O	1449
of	ADP	O	O	1449
norepinephrine	NOUN	O	Chemical	1449
transporter	NOUN	O	O	1449
(	PUNCT	O	O	1449
NET	PROPN	O	O	1449
)	PUNCT	O	O	1449
function	NOUN	O	O	1449
by	ADP	O	O	1449
chronic	ADJ	O	O	1449
inhibition	NOUN	O	O	1449
of	ADP	O	O	1449
NET	PROPN	O	O	1449
in	ADP	O	O	1449
relation	NOUN	O	O	1449
to	PART	O	O	1449
sensitization	NOUN	O	O	1449
to	PART	O	O	1449
seizures	NOUN	O	Disease	1449
induce	VERB	O	O	1449
by	ADP	O	O	1449
cocaine	NOUN	O	Chemical	1449
and	CCONJ	O	O	1449
local	ADJ	O	O	1449
anesthetics	NOUN	O	O	1449
were	AUX	O	O	1449
studied	VERB	O	O	1449
in	ADP	O	O	1449
mice	NOUN	O	O	1449
.	PUNCT	O	O	1449
Daily	PROPN	O	O	1450
administration	NOUN	O	O	1450
of	ADP	O	O	1450
desipramine	NOUN	O	Chemical	1450
,	PUNCT	O	O	1450
an	PRON	O	O	1450
inhibitor	NOUN	O	O	1450
of	ADP	O	O	1450
the	PRON	O	O	1450
NET	PROPN	O	O	1450
,	PUNCT	O	O	1450
for	ADP	O	O	1450
5	NUM	O	O	1450
days	NOUN	O	O	1450
decreased	VERB	O	O	1450
[	X	O	O	1450
(	PUNCT	O	O	1450
3)H]norepinephrine	NUM	O	O	1450
uptake	NOUN	O	O	1450
in	ADP	O	O	1450
the	PRON	O	O	1450
P2	NOUN	O	O	1450
fractions	NOUN	O	O	1450
of	ADP	O	O	1450
hippocampus	NOUN	O	O	1450
but	CCONJ	O	O	1450
not	PART	O	O	1450
cortex	VERB	O	O	1450
,	PUNCT	O	O	1450
striatum	NOUN	O	O	1450
or	CCONJ	O	O	1450
amygdalae	PROPN	O	O	1450
.	PUNCT	O	O	1450
Co	PROPN	O	O	1451
-	PUNCT	O	O	1451
administration	NOUN	O	O	1451
of	ADP	O	O	1451
lidocaine	NOUN	O	Chemical	1451
,	PUNCT	O	O	1451
bupivacaine	NOUN	O	Chemical	1451
or	CCONJ	O	O	1451
tricaine	VERB	O	Chemical	1451
with	ADP	O	O	1451
desipramine	NOUN	O	Chemical	1451
reversed	VERB	O	O	1451
this	PRON	O	O	1451
effect	VERB	O	O	1451
.	PUNCT	O	O	1451
Daily	PROPN	O	O	1452
treatment	NOUN	O	O	1452
of	ADP	O	O	1452
cocaine	NOUN	O	Chemical	1452
increased	VERB	O	O	1452
[	X	O	O	1452
(	PUNCT	O	O	1452
3)H]norepinephrine	NUM	O	O	1452
uptake	NOUN	O	O	1452
into	ADP	O	O	1452
the	PRON	O	O	1452
hippocampus	NOUN	O	O	1452
.	PUNCT	O	O	1452
Daily	PROPN	O	O	1453
administration	NOUN	O	O	1453
of	ADP	O	O	1453
desipramine	NOUN	O	Chemical	1453
increased	VERB	O	O	1453
the	PRON	O	O	1453
incidence	NOUN	O	O	1453
of	ADP	O	O	1453
appearance	NOUN	O	O	1453
of	ADP	O	O	1453
lidocaine	NOUN	O	Chemical	1453
-	PUNCT	O	O	1453
induced	VERB	O	O	1453
convulsions	NOUN	O	Disease	1453
and	CCONJ	O	O	1453
decreased	VERB	O	O	1453
that	SCONJ	O	O	1453
of	ADP	O	O	1453
cocaine	NOUN	O	Chemical	1453
-	PUNCT	O	O	1453
induced	VERB	O	O	1453
convulsions	NOUN	O	Disease	1453
.	PUNCT	O	O	1453
Co	PROPN	O	O	1454
-	PUNCT	O	O	1454
administration	NOUN	O	O	1454
of	ADP	O	O	1454
lidocaine	NOUN	O	Chemical	1454
with	ADP	O	O	1454
desipramine	NOUN	O	Chemical	1454
reversed	VERB	O	O	1454
the	PRON	O	O	1454
changes	VERB	O	O	1454
of	ADP	O	O	1454
convulsive	ADJ	O	Disease	1454
activity	NOUN	O	O	1454
of	ADP	O	O	1454
lidocaine	NOUN	O	Chemical	1454
and	CCONJ	O	O	1454
cocaine	NOUN	O	Chemical	1454
induced	VERB	O	O	1454
by	ADP	O	O	1454
repeated	VERB	O	O	1454
administration	NOUN	O	O	1454
of	ADP	O	O	1454
desipramine	NOUN	O	Chemical	1454
.	PUNCT	O	O	1454
These	PRON	O	O	1455
results	VERB	O	O	1455
suggest	VERB	O	O	1455
that	SCONJ	O	O	1455
down	ADP	O	O	1455
-	PUNCT	O	O	1455
regulation	NOUN	O	O	1455
of	ADP	O	O	1455
hippocampal	NOUN	O	O	1455
NET	PROPN	O	O	1455
induced	VERB	O	O	1455
by	ADP	O	O	1455
chronic	ADJ	O	O	1455
administration	NOUN	O	O	1455
of	ADP	O	O	1455
desipramine	NOUN	O	Chemical	1455
may	AUX	O	O	1455
be	AUX	O	O	1455
relevant	ADJ	O	O	1455
to	PART	O	O	1455
desipramine	NOUN	O	Chemical	1455
-	PUNCT	O	O	1455
induced	VERB	O	O	1455
sensitization	NOUN	O	O	1455
of	ADP	O	O	1455
lidocaine	NOUN	O	Chemical	1455
convulsions	NOUN	O	Disease	1455
.	PUNCT	O	O	1455
Inhibition	NOUN	O	O	1456
of	ADP	O	O	1456
Na(+	NUM	O	O	1456
)	PUNCT	O	O	1456
channels	NOUN	O	O	1456
by	ADP	O	O	1456
local	ADJ	O	O	1456
anesthetics	NOUN	O	O	1456
may	AUX	O	O	1456
regulate	VERB	O	O	1456
desipramine	NOUN	O	Chemical	1456
-	PUNCT	O	O	1456
induced	VERB	O	O	1456
down	ADP	O	O	1456
-	PUNCT	O	O	1456
regulation	NOUN	O	O	1456
of	ADP	O	O	1456
NET	PROPN	O	O	1456
function	NOUN	O	O	1456
.	PUNCT	O	O	1456
Repeated	VERB	O	O	1457
administration	NOUN	O	O	1457
of	ADP	O	O	1457
cocaine	NOUN	O	Chemical	1457
induces	VERB	O	O	1457
up	ADP	O	O	1457
-	PUNCT	O	O	1457
regulation	NOUN	O	O	1457
of	ADP	O	O	1457
hippocampal	NOUN	O	O	1457
NET	PROPN	O	O	1457
function	NOUN	O	O	1457
.	PUNCT	O	O	1457
Desipramine	NOUN	O	Chemical	1458
-	PUNCT	O	O	1458
induced	VERB	O	O	1458
sensitization	NOUN	O	O	1458
of	ADP	O	O	1458
lidocaine	NOUN	O	Chemical	1458
seizures	NOUN	O	Disease	1458
may	AUX	O	O	1458
have	VERB	O	O	1458
a	PRON	O	O	1458
mechanism	NOUN	O	O	1458
distinct	ADJ	O	O	1458
from	ADP	O	O	1458
kindling	VERB	O	O	1458
resulting	VERB	O	O	1458
from	ADP	O	O	1458
repeated	VERB	O	O	1458
administration	NOUN	O	O	1458
of	ADP	O	O	1458
cocaine	NOUN	O	Chemical	1458
.	PUNCT	O	O	1458
Definition	NOUN	O	O	1461
and	CCONJ	O	O	1461
management	NOUN	O	O	1461
of	ADP	O	O	1461
anemia	NOUN	O	Disease	1461
in	ADP	O	O	1461
patients	NOUN	O	O	1461
infected	VERB	O	O	1461
with	ADP	O	O	1461
hepatitis C	PROPN	O	Disease	1461
virus	NOUN	O	O	1461
.	PUNCT	O	O	1461
Chronic infection with hepatitis C virus	NOUN	O	Disease	1462
(	PUNCT	O	O	1462
HCV	PROPN	O	O	1462
)	PUNCT	O	O	1462
can	AUX	O	O	1462
progress	VERB	O	O	1462
to	PART	O	O	1462
cirrhosis	NOUN	O	Disease	1462
,	PUNCT	O	O	1462
hepatocellular carcinoma	NOUN	O	Disease	1462
,	PUNCT	O	O	1462
and	CCONJ	O	O	1462
end	VERB	O	O	1462
-	PUNCT	O	O	1462
stage	NOUN	O	O	1462
liver disease	NOUN	O	Disease	1462
.	PUNCT	O	O	1462
The	PRON	O	O	1463
current	ADJ	O	O	1463
best	ADV	O	O	1463
treatment	NOUN	O	O	1463
for	ADP	O	O	1463
HCV infection	NOUN	O	Disease	1463
is	AUX	O	O	1463
combination	NOUN	O	O	1463
therapy	NOUN	O	O	1463
with	ADP	O	O	1463
pegylated	VERB	O	O	1463
interferon	PROPN	O	Chemical	1463
and	CCONJ	O	O	1463
ribavirin	NOUN	O	Chemical	1463
.	PUNCT	O	O	1463
Although	SCONJ	O	O	1464
this	PRON	O	O	1464
regimen	NOUN	O	O	1464
produces	VERB	O	O	1464
sustained	VERB	O	O	1464
virologic	ADJ	O	O	1464
responses	NOUN	O	O	1464
(	PUNCT	O	O	1464
SVRs	NOUN	O	O	1464
)	PUNCT	O	O	1464
in	ADP	O	O	1464
approximately	ADV	O	O	1464
50%	NOUN	O	O	1464
of	ADP	O	O	1464
patients	NOUN	O	O	1464
,	PUNCT	O	O	1464
it	PRON	O	O	1464
can	AUX	O	O	1464
be	AUX	O	O	1464
associated	VERB	O	O	1464
with	ADP	O	O	1464
a	PRON	O	O	1464
potentially	ADV	O	O	1464
dose	NOUN	O	O	1464
-	PUNCT	O	O	1464
limiting	VERB	O	O	1464
hemolytic anemia	NOUN	O	Disease	1464
.	PUNCT	O	O	1464
Hemoglobin	PROPN	O	O	1465
concentrations	NOUN	O	O	1465
decrease	VERB	O	O	1465
mainly	ADV	O	O	1465
as	ADP	O	O	1465
a	PRON	O	O	1465
result	VERB	O	O	1465
of	ADP	O	O	1465
ribavirin	NOUN	O	Chemical	1465
-	PUNCT	O	O	1465
induced	VERB	O	O	1465
hemolysis	NOUN	O	Disease	1465
,	PUNCT	O	O	1465
and	CCONJ	O	O	1465
this	PRON	O	O	1465
anemia	NOUN	O	Disease	1465
can	AUX	O	O	1465
be	AUX	O	O	1465
problematic	ADJ	O	O	1465
in	ADP	O	O	1465
patients	NOUN	O	O	1465
with	ADP	O	O	1465
HCV infection	NOUN	O	Disease	1465
,	PUNCT	O	O	1465
especially	ADV	O	O	1465
those	PRON	O	O	1465
who	PRON	O	O	1465
have	VERB	O	O	1465
comorbid	NOUN	O	O	1465
renal	ADJ	O	O	1465
or	CCONJ	O	O	1465
cardiovascular disorders	NOUN	O	Disease	1465
.	PUNCT	O	O	1465
In	ADP	O	O	1466
general	ADJ	O	O	1466
,	PUNCT	O	O	1466
anemia	NOUN	O	Disease	1466
can	AUX	O	O	1466
increase	VERB	O	O	1466
the	PRON	O	O	1466
risk	NOUN	O	O	1466
of	ADP	O	O	1466
morbidity	NOUN	O	O	1466
and	CCONJ	O	O	1466
mortality	NOUN	O	O	1466
,	PUNCT	O	O	1466
and	CCONJ	O	O	1466
may	AUX	O	O	1466
have	VERB	O	O	1466
negative	ADJ	O	O	1466
effects	NOUN	O	O	1466
on	ADP	O	O	1466
cerebral	ADJ	O	O	1466
function	NOUN	O	O	1466
and	CCONJ	O	O	1466
quality	NOUN	O	O	1466
of	ADP	O	O	1466
life	NOUN	O	O	1466
.	PUNCT	O	O	1466
Although	SCONJ	O	O	1467
ribavirin	NOUN	O	Chemical	1467
-	PUNCT	O	O	1467
associated	VERB	O	O	1467
anemia	NOUN	O	Disease	1467
can	AUX	O	O	1467
be	AUX	O	O	1467
reversed	VERB	O	O	1467
by	ADP	O	O	1467
dose	NOUN	O	O	1467
reduction	NOUN	O	O	1467
or	CCONJ	O	O	1467
discontinuation	NOUN	O	O	1467
,	PUNCT	O	O	1467
this	PRON	O	O	1467
approach	NOUN	O	O	1467
compromises	VERB	O	O	1467
outcomes	NOUN	O	O	1467
by	ADP	O	O	1467
significantly	ADV	O	O	1467
decreasing	VERB	O	O	1467
SVR	PROPN	O	O	1467
rates	NOUN	O	O	1467
.	PUNCT	O	O	1467
Recombinant	ADJ	O	O	1468
human	PROPN	O	O	1468
erythropoietin	NOUN	O	O	1468
has	VERB	O	O	1468
been	AUX	O	O	1468
used	VERB	O	O	1468
to	PART	O	O	1468
manage	VERB	O	O	1468
ribavirin	NOUN	O	Chemical	1468
-	PUNCT	O	O	1468
associated	VERB	O	O	1468
anemia	NOUN	O	Disease	1468
but	CCONJ	O	O	1468
has	VERB	O	O	1468
other	ADJ	O	O	1468
potential	ADJ	O	O	1468
disadvantages	NOUN	O	O	1468
.	PUNCT	O	O	1468
Viramidine	NOUN	O	Chemical	1469
,	PUNCT	O	O	1469
a	PRON	O	O	1469
liver	NOUN	O	O	1469
-	PUNCT	O	O	1469
targeting	VERB	O	O	1469
prodrug	NOUN	O	O	1469
of	ADP	O	O	1469
ribavirin	NOUN	O	Chemical	1469
,	PUNCT	O	O	1469
has	VERB	O	O	1469
the	PRON	O	O	1469
potential	ADJ	O	O	1469
to	PART	O	O	1469
maintain	VERB	O	O	1469
the	PRON	O	O	1469
virologic	ADJ	O	O	1469
efficacy	NOUN	O	O	1469
of	ADP	O	O	1469
ribavirin	NOUN	O	Chemical	1469
while	SCONJ	O	O	1469
decreasing	VERB	O	O	1469
the	PRON	O	O	1469
risk	NOUN	O	O	1469
of	ADP	O	O	1469
hemolytic anemia	NOUN	O	Disease	1469
in	ADP	O	O	1469
patients	NOUN	O	O	1469
with	ADP	O	O	1469
chronic hepatitis C.	PROPN	O	O	1469
Calcium carbonate	NOUN	O	Chemical	1472
toxicity	NOUN	O	Disease	1472
:	PUNCT	O	O	1472
the	PRON	O	O	1472
updated	VERB	O	O	1472
milk	NOUN	O	O	1472
-	PUNCT	O	O	1472
alkali	ADJ	O	O	1472
syndrome	NOUN	O	O	1472
;	PUNCT	O	O	1472
report	VERB	O	O	1472
of	ADP	O	O	1472
3	X	O	O	1472
cases	NOUN	O	O	1472
and	CCONJ	O	O	1472
review	VERB	O	O	1472
of	ADP	O	O	1472
the	PRON	O	O	1472
literature	NOUN	O	O	1472
.	PUNCT	O	O	1472
OBJECTIVE	VERB	O	O	1473
:	PUNCT	O	O	1473
To	PART	O	O	1473
describe	VERB	O	O	1473
3	X	O	O	1473
patients	NOUN	O	O	1473
with	ADP	O	O	1473
calcium carbonate	NOUN	O	Chemical	1473
-	PUNCT	O	O	1473
induced	VERB	O	O	1473
hypercalcemia	NOUN	O	Disease	1473
and	CCONJ	O	O	1473
gain	VERB	O	O	1473
insights	NOUN	O	O	1473
into	ADP	O	O	1473
the	PRON	O	O	1473
cause	VERB	O	O	1473
and	CCONJ	O	O	1473
management	NOUN	O	O	1473
of	ADP	O	O	1473
the	PRON	O	O	1473
milk	NOUN	O	O	1473
-	PUNCT	O	O	1473
alkali	ADJ	O	O	1473
syndrome	NOUN	O	O	1473
.	PUNCT	O	O	1473
METHODS	NOUN	O	O	1474
:	PUNCT	O	O	1474
We	PRON	O	O	1474
report	VERB	O	O	1474
the	PRON	O	O	1474
clinical	ADJ	O	O	1474
and	CCONJ	O	O	1474
laboratory	NOUN	O	O	1474
data	NOUN	O	O	1474
in	ADP	O	O	1474
3	X	O	O	1474
patients	NOUN	O	O	1474
who	PRON	O	O	1474
presented	VERB	O	O	1474
with	ADP	O	O	1474
severe	ADJ	O	O	1474
hypercalcemia	NOUN	O	Disease	1474
(	PUNCT	O	O	1474
corrected	VERB	O	O	1474
serum	NOUN	O	O	1474
calcium	NOUN	O	Chemical	1474
>	PUNCT	O	O	1474
or	CCONJ	O	O	1474
=	PUNCT	O	O	1474
14	NUM	O	O	1474
mg	VERB	O	O	1474
/	PUNCT	O	O	1474
dL	VERB	O	O	1474
)	PUNCT	O	O	1474
and	CCONJ	O	O	1474
review	VERB	O	O	1474
the	PRON	O	O	1474
pertinent	ADJ	O	O	1474
literature	NOUN	O	O	1474
on	ADP	O	O	1474
milk	NOUN	O	O	1474
-	PUNCT	O	O	1474
alkali	ADJ	O	O	1474
syndrome	NOUN	O	O	1474
.	PUNCT	O	O	1474
The	PRON	O	O	1475
3	X	O	O	1475
patients	NOUN	O	O	1475
had	VERB	O	O	1475
acute	ADJ	O	O	1475
renal insufficiency	NOUN	O	Disease	1475
,	PUNCT	O	O	1475
relative	ADJ	O	O	1475
metabolic alkalosis	NOUN	O	Disease	1475
,	PUNCT	O	O	1475
and	CCONJ	O	O	1475
low	ADJ	O	O	1475
parathyroid	ADJ	O	O	1475
hormone	NOUN	O	O	1475
(	PUNCT	O	O	1475
PTH	PROPN	O	O	1475
)	PUNCT	O	O	1475
,	PUNCT	O	O	1475
PTH	PROPN	O	O	1475
-	PUNCT	O	O	1475
related	ADJ	O	O	1475
peptide	NOUN	O	O	1475
,	PUNCT	O	O	1475
and	CCONJ	O	O	1475
1,25-dihydroxyvitamin D	NOUN	O	Chemical	1475
concentrations	NOUN	O	O	1475
.	PUNCT	O	O	1475
Treatment	NOUN	O	O	1476
included	VERB	O	O	1476
aggressive	ADJ	O	O	1476
hydration	NOUN	O	O	1476
and	CCONJ	O	O	1476
varied	ADJ	O	O	1476
amounts	VERB	O	O	1476
of	ADP	O	O	1476
furosemide	PROPN	O	Chemical	1476
.	PUNCT	O	O	1476
The	PRON	O	O	1477
2	X	O	O	1477
patients	NOUN	O	O	1477
with	ADP	O	O	1477
the	PRON	O	O	1477
higher	ADJ	O	O	1477
serum	NOUN	O	O	1477
calcium	NOUN	O	Chemical	1477
concentrations	NOUN	O	O	1477
received	VERB	O	O	1477
pamidronate	PROPN	O	Chemical	1477
intravenously	ADV	O	O	1477
(	PUNCT	O	O	1477
60	NUM	O	O	1477
and	CCONJ	O	O	1477
30	NUM	O	O	1477
mg	VERB	O	O	1477
,	PUNCT	O	O	1477
respectively	ADV	O	O	1477
)	PUNCT	O	O	1477
,	PUNCT	O	O	1477
which	PRON	O	O	1477
caused	VERB	O	O	1477
severe	ADJ	O	O	1477
hypocalcemia	NOUN	O	Disease	1477
.	PUNCT	O	O	1477
Of	ADV	O	O	1478
the	PRON	O	O	1478
3	X	O	O	1478
patients	NOUN	O	O	1478
,	PUNCT	O	O	1478
2	X	O	O	1478
were	AUX	O	O	1478
ingesting	VERB	O	O	1478
acceptable	ADJ	O	O	1478
doses	NOUN	O	O	1478
of	ADP	O	O	1478
elemental	ADJ	O	O	1478
calcium	NOUN	O	Chemical	1478
(	PUNCT	O	O	1478
1	X	O	O	1478
g	X	O	O	1478
and	CCONJ	O	O	1478
2	X	O	O	1478
g	X	O	O	1478
daily	ADV	O	O	1478
,	PUNCT	O	O	1478
respectively	ADV	O	O	1478
)	PUNCT	O	O	1478
in	ADP	O	O	1478
the	PRON	O	O	1478
form	NOUN	O	O	1478
of	ADP	O	O	1478
calcium carbonate	NOUN	O	Chemical	1478
.	PUNCT	O	O	1478
In	ADP	O	O	1479
addition	NOUN	O	O	1479
to	PART	O	O	1479
our	PRON	O	O	1479
highlighted	VERB	O	O	1479
cases	NOUN	O	O	1479
,	PUNCT	O	O	1479
we	PRON	O	O	1479
review	VERB	O	O	1479
the	PRON	O	O	1479
history	NOUN	O	O	1479
,	PUNCT	O	O	1479
classification	NOUN	O	O	1479
,	PUNCT	O	O	1479
pathophysiologic	ADJ	O	O	1479
features	VERB	O	O	1479
,	PUNCT	O	O	1479
and	CCONJ	O	O	1479
treatment	NOUN	O	O	1479
of	ADP	O	O	1479
milk	NOUN	O	O	1479
-	PUNCT	O	O	1479
alkali	ADJ	O	O	1479
syndrome	NOUN	O	O	1479
and	CCONJ	O	O	1479
summarize	VERB	O	O	1479
the	PRON	O	O	1479
cases	NOUN	O	O	1479
reported	VERB	O	O	1479
from	ADP	O	O	1479
early	ADV	O	O	1479
1995	NUM	O	O	1479
to	PART	O	O	1479
November	PROPN	O	O	1479
2003	NUM	O	O	1479
.	PUNCT	O	O	1479
Milk	NOUN	O	O	1480
-	PUNCT	O	O	1480
alkali	ADJ	O	O	1480
syndrome	NOUN	O	O	1480
may	AUX	O	O	1480
be	AUX	O	O	1480
a	PRON	O	O	1480
common	ADJ	O	O	1480
cause	VERB	O	O	1480
of	ADP	O	O	1480
unexplained	ADJ	O	O	1480
hypercalcemia	NOUN	O	Disease	1480
and	CCONJ	O	O	1480
can	AUX	O	O	1480
be	AUX	O	O	1480
precipitated	VERB	O	O	1480
by	ADP	O	O	1480
small	ADJ	O	O	1480
amounts	VERB	O	O	1480
of	ADP	O	O	1480
orally	ADV	O	O	1480
ingested	VERB	O	O	1480
calcium carbonate	NOUN	O	Chemical	1480
in	ADP	O	O	1480
susceptible	ADJ	O	O	1480
persons	NOUN	O	O	1480
.	PUNCT	O	O	1480
Treatment	NOUN	O	O	1481
with	ADP	O	O	1481
hydration	NOUN	O	O	1481
,	PUNCT	O	O	1481
furosemide	PROPN	O	Chemical	1481
,	PUNCT	O	O	1481
and	CCONJ	O	O	1481
discontinuation	NOUN	O	O	1481
of	ADP	O	O	1481
the	PRON	O	O	1481
calcium	NOUN	O	Chemical	1481
and	CCONJ	O	O	1481
vitamin D	NOUN	O	Chemical	1481
source	NOUN	O	O	1481
is	AUX	O	O	1481
adequate	ADJ	O	O	1481
.	PUNCT	O	O	1481
Pamidronate	PROPN	O	Chemical	1482
treatment	NOUN	O	O	1482
is	AUX	O	O	1482
associated	VERB	O	O	1482
with	ADP	O	O	1482
considerable	ADJ	O	O	1482
risk	NOUN	O	O	1482
for	ADP	O	O	1482
hypocalcemia	NOUN	O	Disease	1482
,	PUNCT	O	O	1482
even	ADV	O	O	1482
in	ADP	O	O	1482
cases	NOUN	O	O	1482
of	ADP	O	O	1482
initially	ADV	O	O	1482
severe	ADJ	O	O	1482
hypercalcemia	NOUN	O	Disease	1482
.	PUNCT	O	O	1482
Management	NOUN	O	O	1485
strategies	NOUN	O	O	1485
for	ADP	O	O	1485
ribavirin	NOUN	O	Chemical	1485
-	PUNCT	O	O	1485
induced	VERB	O	O	1485
hemolytic anemia	NOUN	O	Disease	1485
in	ADP	O	O	1485
the	PRON	O	O	1485
treatment	NOUN	O	O	1485
of	ADP	O	O	1485
hepatitis C	PROPN	O	Disease	1485
:	PUNCT	O	O	1485
clinical	ADJ	O	O	1485
and	CCONJ	O	O	1485
economic	ADJ	O	O	1485
implications	NOUN	O	O	1485
.	PUNCT	O	O	1485
Recently	ADV	O	O	1486
published	VERB	O	O	1486
studies	NOUN	O	O	1486
have	VERB	O	O	1486
demonstrated	VERB	O	O	1486
increased	VERB	O	O	1486
efficacy	NOUN	O	O	1486
and	CCONJ	O	O	1486
cost	NOUN	O	O	1486
-	PUNCT	O	O	1486
effectiveness	NOUN	O	O	1486
of	ADP	O	O	1486
combination	NOUN	O	O	1486
therapy	NOUN	O	O	1486
with	ADP	O	O	1486
interferon	PROPN	O	Chemical	1486
and	CCONJ	O	O	1486
alpha-2b	ADV	O	O	1486
/	PUNCT	O	O	1486
ribavirin	NOUN	O	Chemical	1486
compared	VERB	O	O	1486
with	ADP	O	O	1486
interferon	PROPN	O	Chemical	1486
-	PUNCT	O	O	1486
alpha	PROPN	O	O	1486
monotherapy	X	O	O	1486
in	ADP	O	O	1486
the	PRON	O	O	1486
treatment	NOUN	O	O	1486
of	ADP	O	O	1486
chronic hepatitis C	NOUN	O	Disease	1486
(	PUNCT	O	O	1486
CHC	PROPN	O	Disease	1486
)	PUNCT	O	O	1486
.	PUNCT	O	O	1486
Combination	NOUN	O	O	1487
therapy	NOUN	O	O	1487
is	AUX	O	O	1487
associated	VERB	O	O	1487
with	ADP	O	O	1487
a	PRON	O	O	1487
clinically	ADV	O	O	1487
important	ADJ	O	O	1487
adverse	ADJ	O	O	1487
effect	VERB	O	O	1487
:	PUNCT	O	O	1487
ribavirin	NOUN	O	Chemical	1487
-	PUNCT	O	O	1487
induced	VERB	O	O	1487
hemolytic anemia	NOUN	O	Disease	1487
(	PUNCT	O	O	1487
RIHA	VERB	O	Disease	1487
)	PUNCT	O	O	1487
.	PUNCT	O	O	1487
The	PRON	O	O	1488
objective	VERB	O	O	1488
of	ADP	O	O	1488
this	PRON	O	O	1488
study	VERB	O	O	1488
was	AUX	O	O	1488
to	PART	O	O	1488
evaluate	VERB	O	O	1488
the	PRON	O	O	1488
direct	ADJ	O	O	1488
health	NOUN	O	O	1488
-	PUNCT	O	O	1488
care	VERB	O	O	1488
costs	NOUN	O	O	1488
and	CCONJ	O	O	1488
management	NOUN	O	O	1488
of	ADP	O	O	1488
RIHA	VERB	O	Disease	1488
during	ADP	O	O	1488
treatment	NOUN	O	O	1488
of	ADP	O	O	1488
CHC	PROPN	O	Disease	1488
in	ADP	O	O	1488
a	PRON	O	O	1488
clinical	ADJ	O	O	1488
trial	NOUN	O	O	1488
setting	VERB	O	O	1488
.	PUNCT	O	O	1488
A	PRON	O	O	1489
systematic	ADJ	O	O	1489
literature	NOUN	O	O	1489
review	VERB	O	O	1489
was	AUX	O	O	1489
conducted	VERB	O	O	1489
to	PART	O	O	1489
synthesize	VERB	O	O	1489
information	NOUN	O	O	1489
on	ADP	O	O	1489
the	PRON	O	O	1489
incidence	NOUN	O	O	1489
and	CCONJ	O	O	1489
management	NOUN	O	O	1489
of	ADP	O	O	1489
RIHA	VERB	O	Disease	1489
.	PUNCT	O	O	1489
Decision	NOUN	O	O	1490
-	PUNCT	O	O	1490
analytic	ADJ	O	O	1490
techniques	NOUN	O	O	1490
were	AUX	O	O	1490
used	VERB	O	O	1490
to	PART	O	O	1490
estimate	VERB	O	O	1490
the	PRON	O	O	1490
cost	NOUN	O	O	1490
of	ADP	O	O	1490
treating	VERB	O	O	1490
RIHA	VERB	O	Disease	1490
.	PUNCT	O	O	1490
RESULTS	VERB	O	O	1491
:	PUNCT	O	O	1491
RIHA	VERB	O	Disease	1491
,	PUNCT	O	O	1491
defined	VERB	O	O	1491
as	ADP	O	O	1491
a	PRON	O	O	1491
reduction	NOUN	O	O	1491
in	ADP	O	O	1491
hemoglobin	NOUN	O	O	1491
to	PART	O	O	1491
less	ADV	O	O	1491
than	ADP	O	O	1491
100	NUM	O	O	1491
g	X	O	O	1491
/	PUNCT	O	O	1491
L	NOUN	O	O	1491
,	PUNCT	O	O	1491
occurs	VERB	O	O	1491
in	ADP	O	O	1491
approximately	ADV	O	O	1491
7%	NOUN	O	O	1491
to	PART	O	O	1491
9%	NOUN	O	O	1491
of	ADP	O	O	1491
patients	NOUN	O	O	1491
treated	VERB	O	O	1491
with	ADP	O	O	1491
combination	NOUN	O	O	1491
therapy	NOUN	O	O	1491
.	PUNCT	O	O	1491
The	PRON	O	O	1492
standard	PROPN	O	O	1492
of	ADP	O	O	1492
care	VERB	O	O	1492
for	ADP	O	O	1492
management	NOUN	O	O	1492
of	ADP	O	O	1492
RIHA	VERB	O	Disease	1492
is	AUX	O	O	1492
reduction	NOUN	O	O	1492
or	CCONJ	O	O	1492
discontinuation	NOUN	O	O	1492
of	ADP	O	O	1492
the	PRON	O	O	1492
ribavirin	NOUN	O	Chemical	1492
dosage	NOUN	O	O	1492
.	PUNCT	O	O	1492
We	PRON	O	O	1493
estimated	VERB	O	O	1493
the	PRON	O	O	1493
direct	ADJ	O	O	1493
cost	NOUN	O	O	1493
of	ADP	O	O	1493
treating	VERB	O	O	1493
clinically	ADV	O	O	1493
significant	ADJ	O	O	1493
RIHA	VERB	O	Disease	1493
to	PART	O	O	1493
be	AUX	O	O	1493
170	NUM	O	O	1493
per	ADP	O	O	1493
patient	NOUN	O	O	1493
receiving	VERB	O	O	1493
combination	NOUN	O	O	1493
therapy	NOUN	O	O	1493
per	ADP	O	O	1493
48-week	NOUN	O	O	1493
treatment	NOUN	O	O	1493
course	NOUN	O	O	1493
(	PUNCT	O	O	1493
range	VERB	O	O	1493
68-	PUNCT	O	O	1493
692	NUM	O	O	1493
)	PUNCT	O	O	1493
.	PUNCT	O	O	1493
The	PRON	O	O	1494
direct	ADJ	O	O	1494
cost	NOUN	O	O	1494
of	ADP	O	O	1494
treating	VERB	O	O	1494
clinically	ADV	O	O	1494
significant	ADJ	O	O	1494
RIHA	VERB	O	Disease	1494
is	AUX	O	O	1494
1%	NOUN	O	O	1494
(	PUNCT	O	O	1494
170/	NUM	O	O	1494
16,459	NUM	O	O	1494
)	PUNCT	O	O	1494
of	ADP	O	O	1494
drug	NOUN	O	O	1494
treatment	NOUN	O	O	1494
costs	NOUN	O	O	1494
.	PUNCT	O	O	1494
Questions	NOUN	O	O	1495
remain	VERB	O	O	1495
about	ADP	O	O	1495
the	PRON	O	O	1495
optimal	ADJ	O	O	1495
dose	NOUN	O	O	1495
of	ADP	O	O	1495
ribavirin	NOUN	O	Chemical	1495
and	CCONJ	O	O	1495
the	PRON	O	O	1495
incidence	NOUN	O	O	1495
of	ADP	O	O	1495
RIHA	VERB	O	Disease	1495
in	ADP	O	O	1495
a	PRON	O	O	1495
real	ADV	O	O	1495
-	PUNCT	O	O	1495
world	NOUN	O	O	1495
population	NOUN	O	O	1495
.	PUNCT	O	O	1495
Despite	SCONJ	O	O	1496
these	PRON	O	O	1496
uncertainties	NOUN	O	O	1496
,	PUNCT	O	O	1496
this	PRON	O	O	1496
initial	ADJ	O	O	1496
evaluation	NOUN	O	O	1496
of	ADP	O	O	1496
the	PRON	O	O	1496
direct	ADJ	O	O	1496
cost	NOUN	O	O	1496
of	ADP	O	O	1496
treating	VERB	O	O	1496
RIHA	VERB	O	Disease	1496
provides	VERB	O	O	1496
an	PRON	O	O	1496
estimate	VERB	O	O	1496
of	ADP	O	O	1496
the	PRON	O	O	1496
cost	NOUN	O	O	1496
and	CCONJ	O	O	1496
management	NOUN	O	O	1496
implications	NOUN	O	O	1496
of	ADP	O	O	1496
this	PRON	O	O	1496
clinically	ADV	O	O	1496
important	ADJ	O	O	1496
adverse	ADJ	O	O	1496
effect	VERB	O	O	1496
.	PUNCT	O	O	1496
Effects	NOUN	O	O	1499
of	ADP	O	O	1499
amine	NOUN	O	Chemical	1499
pretreatment	NOUN	O	O	1499
on	ADP	O	O	1499
ketamine	VERB	O	Chemical	1499
catatonia	PROPN	O	Disease	1499
in	ADP	O	O	1499
pinealectomized	VERB	O	O	1499
or	CCONJ	O	O	1499
hypophysectomized	VERB	O	O	1499
animals	NOUN	O	O	1499
.	PUNCT	O	O	1499
The	PRON	O	O	1500
present	NOUN	O	O	1500
studies	NOUN	O	O	1500
were	AUX	O	O	1500
designed	VERB	O	O	1500
to	PART	O	O	1500
clarify	VERB	O	O	1500
the	PRON	O	O	1500
role	NOUN	O	O	1500
of	ADP	O	O	1500
catecholamines	NOUN	O	Chemical	1500
and	CCONJ	O	O	1500
pineal	NOUN	O	O	1500
idolamines	NOUN	O	O	1500
on	ADP	O	O	1500
ketamine	VERB	O	Chemical	1500
-	PUNCT	O	O	1500
induced	VERB	O	O	1500
catatonia	PROPN	O	Disease	1500
in	ADP	O	O	1500
the	PRON	O	O	1500
intact	ADJ	O	O	1500
,	PUNCT	O	O	1500
pinealectomized	VERB	O	O	1500
or	CCONJ	O	O	1500
hypophysectomized	VERB	O	O	1500
chick	PROPN	O	O	1500
and	CCONJ	O	O	1500
rat	NOUN	O	O	1500
.	PUNCT	O	O	1500
In	ADP	O	O	1501
the	PRON	O	O	1501
pinealectomized	VERB	O	O	1501
chick	PROPN	O	O	1501
,	PUNCT	O	O	1501
pretreatment	NOUN	O	O	1501
with	ADP	O	O	1501
dopamine	NOUN	O	Chemical	1501
increased	VERB	O	O	1501
the	PRON	O	O	1501
duration	NOUN	O	O	1501
of	ADP	O	O	1501
catatonia	PROPN	O	Disease	1501
(	PUNCT	O	O	1501
DOC	PROPN	O	O	1501
)	PUNCT	O	O	1501
after	ADP	O	O	1501
ketamine	VERB	O	Chemical	1501
,	PUNCT	O	O	1501
but	CCONJ	O	O	1501
pretreatment	NOUN	O	O	1501
with	ADP	O	O	1501
norepinephrine	NOUN	O	Chemical	1501
did	VERB	O	O	1501
not	PART	O	O	1501
.	PUNCT	O	O	1501
Serotonin	NOUN	O	Chemical	1502
and	CCONJ	O	O	1502
N	NUM	O	O	1502
-	PUNCT	O	O	1502
acetyl	PROPN	O	O	1502
serotonin	PROPN	O	Chemical	1502
which	PRON	O	O	1502
augmented	VERB	O	O	1502
ketamine	VERB	O	Chemical	1502
DOC	PROPN	O	O	1502
,	PUNCT	O	O	1502
did	VERB	O	O	1502
not	PART	O	O	1502
do	VERB	O	O	1502
so	ADV	O	O	1502
in	ADP	O	O	1502
the	PRON	O	O	1502
absence	NOUN	O	O	1502
of	ADP	O	O	1502
the	PRON	O	O	1502
pineal	NOUN	O	O	1502
gland	NOUN	O	O	1502
,	PUNCT	O	O	1502
whereas	SCONJ	O	O	1502
melatonin	PROPN	O	Chemical	1502
potentiated	VERB	O	O	1502
the	PRON	O	O	1502
ketamine	VERB	O	Chemical	1502
DOC	PROPN	O	O	1502
in	ADP	O	O	1502
both	PRON	O	O	1502
the	PRON	O	O	1502
intact	ADJ	O	O	1502
and	CCONJ	O	O	1502
pinealectomized	VERB	O	O	1502
chick	PROPN	O	O	1502
.	PUNCT	O	O	1502
Ketamine	PROPN	O	Chemical	1503
was	AUX	O	O	1503
more	ADJ	O	O	1503
potent	ADJ	O	O	1503
in	ADP	O	O	1503
the	PRON	O	O	1503
hypophysectomized	VERB	O	O	1503
chick	PROPN	O	O	1503
and	CCONJ	O	O	1503
the	PRON	O	O	1503
circadian	ADJ	O	O	1503
rhythm	VERB	O	O	1503
noted	VERB	O	O	1503
in	ADP	O	O	1503
the	PRON	O	O	1503
intact	ADJ	O	O	1503
chick	PROPN	O	O	1503
was	AUX	O	O	1503
absent	ADJ	O	O	1503
;	PUNCT	O	O	1503
furthermore	ADV	O	O	1503
,	PUNCT	O	O	1503
melatonin	PROPN	O	Chemical	1503
did	VERB	O	O	1503
not	PART	O	O	1503
augment	VERB	O	O	1503
the	PRON	O	O	1503
ketamine	VERB	O	Chemical	1503
DOC	PROPN	O	O	1503
whereas	SCONJ	O	O	1503
dopamine	NOUN	O	Chemical	1503
continued	VERB	O	O	1503
to	PART	O	O	1503
do	VERB	O	O	1503
so	ADV	O	O	1503
.	PUNCT	O	O	1503
This	PRON	O	O	1504
study	VERB	O	O	1504
did	VERB	O	O	1504
not	PART	O	O	1504
demonstrate	VERB	O	O	1504
a	PRON	O	O	1504
species	NOUN	O	O	1504
difference	NOUN	O	O	1504
regarding	VERB	O	O	1504
the	PRON	O	O	1504
role	NOUN	O	O	1504
of	ADP	O	O	1504
the	PRON	O	O	1504
amines	NOUN	O	Chemical	1504
on	ADP	O	O	1504
the	PRON	O	O	1504
pineal	NOUN	O	O	1504
in	ADP	O	O	1504
spite	NOUN	O	O	1504
of	ADP	O	O	1504
the	PRON	O	O	1504
immature	ADJ	O	O	1504
blood	NOUN	O	O	1504
-	PUNCT	O	O	1504
brain	NOUN	O	O	1504
barrier	NOUN	O	O	1504
in	ADP	O	O	1504
the	PRON	O	O	1504
young	ADJ	O	O	1504
chick	PROPN	O	O	1504
and	CCONJ	O	O	1504
the	PRON	O	O	1504
intact	ADJ	O	O	1504
barrier	NOUN	O	O	1504
in	ADP	O	O	1504
the	PRON	O	O	1504
rat	NOUN	O	O	1504
.	PUNCT	O	O	1504
In	ADP	O	O	1505
addition	NOUN	O	O	1505
,	PUNCT	O	O	1505
these	PRON	O	O	1505
data	NOUN	O	O	1505
indicate	VERB	O	O	1505
a	PRON	O	O	1505
direct	ADJ	O	O	1505
role	NOUN	O	O	1505
of	ADP	O	O	1505
the	PRON	O	O	1505
pituitary	NOUN	O	O	1505
in	ADP	O	O	1505
the	PRON	O	O	1505
augmentation	NOUN	O	O	1505
of	ADP	O	O	1505
ketamine	VERB	O	Chemical	1505
DOC	PROPN	O	O	1505
induced	VERB	O	O	1505
by	ADP	O	O	1505
melatonin	PROPN	O	Chemical	1505
.	PUNCT	O	O	1505
Furthermore	ADV	O	O	1506
,	PUNCT	O	O	1506
dopamine	NOUN	O	Chemical	1506
appeared	VERB	O	O	1506
to	PART	O	O	1506
act	VERB	O	O	1506
on	ADP	O	O	1506
systems	NOUN	O	O	1506
more	ADJ	O	O	1506
closely	ADV	O	O	1506
involved	VERB	O	O	1506
with	ADP	O	O	1506
the	PRON	O	O	1506
induction	NOUN	O	O	1506
of	ADP	O	O	1506
ketamine	VERB	O	Chemical	1506
catatonia	PROPN	O	Disease	1506
rather	ADV	O	O	1506
than	ADP	O	O	1506
directly	ADV	O	O	1506
on	ADP	O	O	1506
the	PRON	O	O	1506
pituitary	NOUN	O	O	1506
.	PUNCT	O	O	1506
Multicenter	NOUN	O	O	1509
,	PUNCT	O	O	1509
double	ADJ	O	O	1509
-	PUNCT	O	O	1509
blind	ADJ	O	Disease	1509
,	PUNCT	O	O	1509
multiple	ADJ	O	O	1509
-	PUNCT	O	O	1509
dose	NOUN	O	O	1509
,	PUNCT	O	O	1509
parallel	ADJ	O	O	1509
-	PUNCT	O	O	1509
groups	NOUN	O	O	1509
efficacy	NOUN	O	O	1509
and	CCONJ	O	O	1509
safety	NOUN	O	O	1509
trial	NOUN	O	O	1509
of	ADP	O	O	1509
azelastine	VERB	O	Chemical	1509
,	PUNCT	O	O	1509
chlorpheniramine	PROPN	O	Chemical	1509
,	PUNCT	O	O	1509
and	CCONJ	O	O	1509
placebo	NOUN	O	O	1509
in	ADP	O	O	1509
the	PRON	O	O	1509
treatment	NOUN	O	O	1509
of	ADP	O	O	1509
spring allergic rhinitis	NOUN	O	Disease	1509
.	PUNCT	O	O	1509
Azelastine	NOUN	O	Chemical	1510
,	PUNCT	O	O	1510
a	PRON	O	O	1510
novel	NOUN	O	O	1510
antiallergic	ADJ	O	O	1510
medication	NOUN	O	O	1510
,	PUNCT	O	O	1510
was	AUX	O	O	1510
compared	VERB	O	O	1510
with	ADP	O	O	1510
chlorpheniramine maleate	NOUN	O	Chemical	1510
and	CCONJ	O	O	1510
placebo	NOUN	O	O	1510
for	ADP	O	O	1510
efficacy	NOUN	O	O	1510
and	CCONJ	O	O	1510
safety	NOUN	O	O	1510
in	ADP	O	O	1510
the	PRON	O	O	1510
treatment	NOUN	O	O	1510
of	ADP	O	O	1510
spring allergic rhinitis	NOUN	O	Disease	1510
in	ADP	O	O	1510
a	PRON	O	O	1510
multicenter	ADJ	O	O	1510
,	PUNCT	O	O	1510
double	ADJ	O	O	1510
-	PUNCT	O	O	1510
blind	ADJ	O	Disease	1510
,	PUNCT	O	O	1510
multiple	ADJ	O	O	1510
-	PUNCT	O	O	1510
dose	NOUN	O	O	1510
,	PUNCT	O	O	1510
parallel	ADJ	O	O	1510
-	PUNCT	O	O	1510
groups	NOUN	O	O	1510
study	VERB	O	O	1510
.	PUNCT	O	O	1510
Subjects	NOUN	O	O	1511
ranged	VERB	O	O	1511
in	ADP	O	O	1511
age	NOUN	O	O	1511
from	ADP	O	O	1511
18	NUM	O	O	1511
to	PART	O	O	1511
60	NUM	O	O	1511
years	NOUN	O	O	1511
of	ADP	O	O	1511
age	NOUN	O	O	1511
and	CCONJ	O	O	1511
had	VERB	O	O	1511
at	ADP	O	O	1511
least	ADJ	O	O	1511
a	PRON	O	O	1511
2-year	NOUN	O	O	1511
history	NOUN	O	O	1511
of	ADP	O	O	1511
spring allergic rhinitis	NOUN	O	Disease	1511
,	PUNCT	O	O	1511
confirmed	VERB	O	O	1511
by	ADP	O	O	1511
positive	ADJ	O	O	1511
skin	NOUN	O	O	1511
test	NOUN	O	O	1511
to	PART	O	O	1511
spring	NOUN	O	O	1511
aeroallergens	NOUN	O	O	1511
.	PUNCT	O	O	1511
Medications	NOUN	O	O	1512
were	AUX	O	O	1512
given	VERB	O	O	1512
four	NUM	O	O	1512
times	NOUN	O	O	1512
daily	ADV	O	O	1512
;	PUNCT	O	O	1512
the	PRON	O	O	1512
azelastine	VERB	O	Chemical	1512
groups	NOUN	O	O	1512
received	VERB	O	O	1512
0.5	NUM	O	O	1512
,	PUNCT	O	O	1512
1.0	NUM	O	O	1512
,	PUNCT	O	O	1512
or	CCONJ	O	O	1512
2.0	NUM	O	O	1512
mg	VERB	O	O	1512
in	ADP	O	O	1512
the	PRON	O	O	1512
morning	NOUN	O	O	1512
and	CCONJ	O	O	1512
evening	NOUN	O	O	1512
with	ADP	O	O	1512
placebo	NOUN	O	O	1512
in	ADP	O	O	1512
the	PRON	O	O	1512
early	ADV	O	O	1512
and	CCONJ	O	O	1512
late	ADV	O	O	1512
afternoon	NOUN	O	O	1512
;	PUNCT	O	O	1512
the	PRON	O	O	1512
chlorpheniramine	PROPN	O	Chemical	1512
group	NOUN	O	O	1512
received	VERB	O	O	1512
4.0	NUM	O	O	1512
mg	VERB	O	O	1512
four	NUM	O	O	1512
times	NOUN	O	O	1512
daily	ADV	O	O	1512
.	PUNCT	O	O	1512
Symptoms	NOUN	O	O	1513
relief	NOUN	O	O	1513
in	ADP	O	O	1513
the	PRON	O	O	1513
group	NOUN	O	O	1513
receiving	VERB	O	O	1513
the	PRON	O	O	1513
highest	ADJ	O	O	1513
concentration	NOUN	O	O	1513
of	ADP	O	O	1513
azelastine	VERB	O	Chemical	1513
(	PUNCT	O	O	1513
2.0	NUM	O	O	1513
mg	VERB	O	O	1513
twice	ADV	O	O	1513
daily	ADV	O	O	1513
)	PUNCT	O	O	1513
was	AUX	O	O	1513
statistically	ADV	O	O	1513
greater	ADJ	O	O	1513
than	ADP	O	O	1513
in	ADP	O	O	1513
the	PRON	O	O	1513
placebo	NOUN	O	O	1513
group	NOUN	O	O	1513
during	ADP	O	O	1513
all	PRON	O	O	1513
weeks	NOUN	O	O	1513
of	ADP	O	O	1513
the	PRON	O	O	1513
study	VERB	O	O	1513
.	PUNCT	O	O	1513
Lower	ADJ	O	O	1514
doses	NOUN	O	O	1514
of	ADP	O	O	1514
azelastine	VERB	O	Chemical	1514
were	AUX	O	O	1514
statistically	ADV	O	O	1514
more	ADJ	O	O	1514
effective	ADJ	O	O	1514
than	ADP	O	O	1514
placebo	NOUN	O	O	1514
only	ADV	O	O	1514
during	ADP	O	O	1514
portions	NOUN	O	O	1514
of	ADP	O	O	1514
the	PRON	O	O	1514
first	ADV	O	O	1514
3	X	O	O	1514
weeks	NOUN	O	O	1514
of	ADP	O	O	1514
the	PRON	O	O	1514
study	VERB	O	O	1514
.	PUNCT	O	O	1514
In	ADP	O	O	1515
contrast	NOUN	O	O	1515
,	PUNCT	O	O	1515
although	SCONJ	O	O	1515
the	PRON	O	O	1515
chlorpheniramine	PROPN	O	Chemical	1515
group	NOUN	O	O	1515
did	VERB	O	O	1515
have	VERB	O	O	1515
fewer	ADJ	O	O	1515
symptoms	NOUN	O	O	1515
than	ADP	O	O	1515
the	PRON	O	O	1515
placebo	NOUN	O	O	1515
group	NOUN	O	O	1515
during	ADP	O	O	1515
the	PRON	O	O	1515
study	VERB	O	O	1515
,	PUNCT	O	O	1515
the	PRON	O	O	1515
difference	NOUN	O	O	1515
never	ADV	O	O	1515
reached	VERB	O	O	1515
statistical	ADJ	O	O	1515
significance	NOUN	O	O	1515
during	ADP	O	O	1515
any	PRON	O	O	1515
week	NOUN	O	O	1515
of	ADP	O	O	1515
the	PRON	O	O	1515
study	VERB	O	O	1515
.	PUNCT	O	O	1515
Drowsiness	PROPN	O	Disease	1516
and	CCONJ	O	O	1516
altered taste perception	NOUN	O	Disease	1516
were	AUX	O	O	1516
increased	VERB	O	O	1516
significantly	ADV	O	O	1516
over	ADP	O	O	1516
placebo	NOUN	O	O	1516
only	ADV	O	O	1516
in	ADP	O	O	1516
the	PRON	O	O	1516
high	ADJ	O	O	1516
-	PUNCT	O	O	1516
dose	NOUN	O	O	1516
azelastine	VERB	O	Chemical	1516
group	NOUN	O	O	1516
.	PUNCT	O	O	1516
Azelastine	NOUN	O	Chemical	1517
appears	VERB	O	O	1517
to	PART	O	O	1517
be	AUX	O	O	1517
a	PRON	O	O	1517
safe	ADJ	O	O	1517
,	PUNCT	O	O	1517
efficacious	ADJ	O	O	1517
medication	NOUN	O	O	1517
for	ADP	O	O	1517
seasonal allergic rhinitis	NOUN	O	Disease	1517
.	PUNCT	O	O	1517
One	NUM	O	O	1520
case	NOUN	O	O	1520
of	ADP	O	O	1520
acute	ADJ	O	O	1520
hypercalcaemia	NOUN	O	Disease	1520
and	CCONJ	O	O	1520
two	NUM	O	O	1520
of	ADP	O	O	1520
recurrent	ADJ	O	O	1520
nephrolithiasis	NOUN	O	Disease	1520
are	AUX	O	O	1520
reported	VERB	O	O	1520
in	ADP	O	O	1520
patients	NOUN	O	O	1520
who	PRON	O	O	1520
had	VERB	O	O	1520
regularly	ADV	O	O	1520
consumed	VERB	O	O	1520
large	ADJ	O	O	1520
amounts	VERB	O	O	1520
of	ADP	O	O	1520
calcium	NOUN	O	Chemical	1520
carbon	NOUN	O	O	1520
-	PUNCT	O	O	1520
ate	VERB	O	O	1520
-	PUNCT	O	O	1520
sodium bicarbonate	NOUN	O	Chemical	1520
powders	NOUN	O	O	1520
for	ADP	O	O	1520
more	ADJ	O	O	1520
than	ADP	O	O	1520
20	NUM	O	O	1520
years	NOUN	O	O	1520
.	PUNCT	O	O	1520
Prolonged	VERB	O	O	1523
paralysis	NOUN	O	Disease	1523
due	ADJ	O	O	1523
to	PART	O	O	1523
nondepolarizing neuromuscular blocking agents	NOUN	O	Chemical	1523
and	CCONJ	O	O	1523
corticosteroids	NOUN	O	Chemical	1523
.	PUNCT	O	O	1523
The	PRON	O	O	1524
long	ADV	O	O	1524
-	PUNCT	O	O	1524
term	NOUN	O	O	1524
use	VERB	O	O	1524
of	ADP	O	O	1524
nondepolarizing neuromuscular blocking agents	NOUN	O	Chemical	1524
(	PUNCT	O	O	1524
ND	PROPN	O	O	1524
-	PUNCT	O	O	1524
NMBA	ADJ	O	O	1524
)	PUNCT	O	O	1524
has	VERB	O	O	1524
recently	ADV	O	O	1524
been	AUX	O	O	1524
implicated	VERB	O	O	1524
as	ADP	O	O	1524
a	PRON	O	O	1524
cause	VERB	O	O	1524
of	ADP	O	O	1524
prolonged	VERB	O	O	1524
muscle weakness	NOUN	O	Disease	1524
,	PUNCT	O	O	1524
although	SCONJ	O	O	1524
the	PRON	O	O	1524
site	NOUN	O	O	1524
of	ADP	O	O	1524
the	PRON	O	O	1524
lesion	NOUN	O	O	1524
and	CCONJ	O	O	1524
the	PRON	O	O	1524
predisposing	VERB	O	O	1524
factors	NOUN	O	O	1524
have	VERB	O	O	1524
been	AUX	O	O	1524
unclear	ADJ	O	O	1524
.	PUNCT	O	O	1524
We	PRON	O	O	1525
report	VERB	O	O	1525
3	X	O	O	1525
patients	NOUN	O	O	1525
(	PUNCT	O	O	1525
age	NOUN	O	O	1525
37	NUM	O	O	1525
-	PUNCT	O	O	1525
52	NUM	O	O	1525
years	NOUN	O	O	1525
)	PUNCT	O	O	1525
with	ADP	O	O	1525
acute	ADJ	O	O	1525
respiratory insufficiency	NOUN	O	Disease	1525
who	PRON	O	O	1525
developed	VERB	O	O	1525
prolonged	VERB	O	O	1525
weakness	NOUN	O	Disease	1525
following	VERB	O	O	1525
the	PRON	O	O	1525
discontinuation	NOUN	O	O	1525
of	ADP	O	O	1525
ND	PROPN	O	O	1525
-	PUNCT	O	O	1525
NMBAs	NOUN	O	O	1525
.	PUNCT	O	O	1525
Two	NUM	O	O	1526
patients	NOUN	O	O	1526
also	ADV	O	O	1526
received	VERB	O	O	1526
intravenous	ADJ	O	O	1526
corticosteroids	NOUN	O	Chemical	1526
.	PUNCT	O	O	1526
Renal	NOUN	O	O	1527
function	NOUN	O	O	1527
was	AUX	O	O	1527
normal	ADJ	O	O	1527
but	CCONJ	O	O	1527
hepatic	ADJ	O	O	1527
function	NOUN	O	O	1527
was	AUX	O	O	1527
impaired	VERB	O	O	1527
in	ADP	O	O	1527
all	PRON	O	O	1527
patients	NOUN	O	O	1527
,	PUNCT	O	O	1527
and	CCONJ	O	O	1527
all	PRON	O	O	1527
had	VERB	O	O	1527
acidosis	NOUN	O	Disease	1527
.	PUNCT	O	O	1527
The	PRON	O	O	1528
serum	NOUN	O	O	1528
vecuronium	NOUN	O	Chemical	1528
level	VERB	O	O	1528
measured	VERB	O	O	1528
in	ADP	O	O	1528
1	X	O	O	1528
patient	NOUN	O	O	1528
14	NUM	O	O	1528
days	NOUN	O	O	1528
after	ADP	O	O	1528
the	PRON	O	O	1528
drug	NOUN	O	O	1528
had	VERB	O	O	1528
been	AUX	O	O	1528
discontinued	VERB	O	O	1528
was	AUX	O	O	1528
172	NUM	O	O	1528
ng	PROPN	O	O	1528
/	PUNCT	O	O	1528
mL.	PROPN	O	O	1528
A	PRON	O	O	1529
muscle	NOUN	O	O	1529
biopsy	PROPN	O	O	1529
in	ADP	O	O	1529
this	PRON	O	O	1529
patient	NOUN	O	O	1529
showed	VERB	O	O	1529
loss	NOUN	O	O	1529
of	ADP	O	O	1529
thick	ADJ	O	O	1529
,	PUNCT	O	O	1529
myosin	ADV	O	O	1529
filaments	NOUN	O	O	1529
.	PUNCT	O	O	1529
The	PRON	O	O	1530
weakness	NOUN	O	Disease	1530
in	ADP	O	O	1530
these	PRON	O	O	1530
patients	NOUN	O	O	1530
is	AUX	O	O	1530
due	ADJ	O	O	1530
to	PART	O	O	1530
pathology at both the neuromuscular junction	NOUN	O	Disease	1530
(	PUNCT	O	O	1530
most	ADV	O	O	1530
likely	ADV	O	O	1530
due	ADJ	O	O	1530
to	PART	O	O	1530
ND	PROPN	O	O	1530
-	PUNCT	O	O	1530
NMBA	ADJ	O	O	1530
)	PUNCT	O	O	1530
and	CCONJ	O	O	1530
muscle	NOUN	O	O	1530
(	PUNCT	O	O	1530
most	ADV	O	O	1530
likely	ADV	O	O	1530
due	ADJ	O	O	1530
to	PART	O	O	1530
corticosteroids	NOUN	O	Chemical	1530
)	PUNCT	O	O	1530
.	PUNCT	O	O	1530
Hepatic dysfunction	NOUN	O	Disease	1531
and	CCONJ	O	O	1531
acidosis	NOUN	O	Disease	1531
are	AUX	O	O	1531
contributing	VERB	O	O	1531
risk	NOUN	O	O	1531
factors	NOUN	O	O	1531
.	PUNCT	O	O	1531
Prostaglandin E2-induced	VERB	O	O	1534
bladder hyperactivity	NOUN	O	Disease	1534
in	ADP	O	O	1534
normal	ADJ	O	O	1534
,	PUNCT	O	O	1534
conscious	ADJ	O	O	1534
rats	NOUN	O	O	1534
:	PUNCT	O	O	1534
involvement	NOUN	O	O	1534
of	ADP	O	O	1534
tachykinins	NOUN	O	Chemical	1534
?	PUNCT	O	O	1534
In	ADP	O	O	1535
normal	ADJ	O	O	1535
conscious	ADJ	O	O	1535
rats	NOUN	O	O	1535
investigated	VERB	O	O	1535
by	ADP	O	O	1535
continuous	ADJ	O	O	1535
cystometry	NOUN	O	O	1535
,	PUNCT	O	O	1535
intravesically	ADV	O	O	1535
instilled	VERB	O	O	1535
prostaglandin	NOUN	O	Chemical	1535
(	PUNCT	O	O	1535
PG	PROPN	O	Chemical	1535
)	PUNCT	O	O	1535
E2	NOUN	O	Chemical	1535
facilitated	VERB	O	O	1535
micturition	NOUN	O	O	1535
and	CCONJ	O	O	1535
increased	VERB	O	O	1535
basal	PROPN	O	O	1535
intravesical	ADJ	O	O	1535
pressure	NOUN	O	O	1535
.	PUNCT	O	O	1535
The	PRON	O	O	1536
effect	VERB	O	O	1536
was	AUX	O	O	1536
attenuated	VERB	O	O	1536
by	ADP	O	O	1536
both	PRON	O	O	1536
the	PRON	O	O	1536
NK1	NOUN	O	O	1536
receptor	NOUN	O	O	1536
selective	ADJ	O	O	1536
antagonist	NOUN	O	O	1536
RP 67,580	NUM	O	Chemical	1536
and	CCONJ	O	O	1536
the	PRON	O	O	1536
NK2	PROPN	O	O	1536
receptor	NOUN	O	O	1536
selective	ADJ	O	O	1536
antagonist	NOUN	O	O	1536
SR 48,968	NUM	O	Chemical	1536
,	PUNCT	O	O	1536
given	VERB	O	O	1536
intra	ADJ	O	O	1536
-	PUNCT	O	O	1536
arterially	ADV	O	O	1536
,	PUNCT	O	O	1536
suggesting	VERB	O	O	1536
that	SCONJ	O	O	1536
it	PRON	O	O	1536
was	AUX	O	O	1536
mediated	VERB	O	O	1536
by	ADP	O	O	1536
stimulation	NOUN	O	O	1536
of	ADP	O	O	1536
both	PRON	O	O	1536
NK1	NOUN	O	O	1536
and	CCONJ	O	O	1536
NK2	PROPN	O	O	1536
receptors	NOUN	O	O	1536
.	PUNCT	O	O	1536
Intra	PROPN	O	O	1537
-	PUNCT	O	O	1537
arterially	ADV	O	O	1537
given	VERB	O	O	1537
PGE2	NOUN	O	Chemical	1537
produced	VERB	O	O	1537
a	PRON	O	O	1537
distinct	ADJ	O	O	1537
increase	VERB	O	O	1537
in	ADP	O	O	1537
bladder	NOUN	O	O	1537
pressure	NOUN	O	O	1537
before	ADP	O	O	1537
initiating	VERB	O	O	1537
a	PRON	O	O	1537
micturition	NOUN	O	O	1537
reflex	NOUN	O	O	1537
,	PUNCT	O	O	1537
indicating	VERB	O	O	1537
that	SCONJ	O	O	1537
the	PRON	O	O	1537
PG	PROPN	O	Chemical	1537
had	VERB	O	O	1537
a	PRON	O	O	1537
direct	ADJ	O	O	1537
contractant	NOUN	O	O	1537
effect	VERB	O	O	1537
on	ADP	O	O	1537
the	PRON	O	O	1537
detrusor	NOUN	O	O	1537
smooth	VERB	O	O	1537
muscle	NOUN	O	O	1537
.	PUNCT	O	O	1537
The	PRON	O	O	1538
effect	VERB	O	O	1538
of	ADP	O	O	1538
intra	ADJ	O	O	1538
-	PUNCT	O	O	1538
arterial	ADJ	O	O	1538
PGE2	NOUN	O	Chemical	1538
could	AUX	O	O	1538
not	PART	O	O	1538
be	AUX	O	O	1538
blocked	VERB	O	O	1538
by	ADP	O	O	1538
intra	ADJ	O	O	1538
-	PUNCT	O	O	1538
arterial	ADJ	O	O	1538
RP 67,580	NUM	O	Chemical	1538
or	CCONJ	O	O	1538
SR 48,968	NUM	O	Chemical	1538
,	PUNCT	O	O	1538
which	PRON	O	O	1538
opens	VERB	O	O	1538
the	PRON	O	O	1538
possibility	NOUN	O	O	1538
that	SCONJ	O	O	1538
the	PRON	O	O	1538
micturition	NOUN	O	O	1538
reflex	NOUN	O	O	1538
elicited	VERB	O	O	1538
by	ADP	O	O	1538
intra	ADJ	O	O	1538
-	PUNCT	O	O	1538
arterial	ADJ	O	O	1538
PGE2	NOUN	O	Chemical	1538
was	AUX	O	O	1538
mediated	VERB	O	O	1538
by	ADP	O	O	1538
pathways	NOUN	O	O	1538
other	ADJ	O	O	1538
than	ADP	O	O	1538
the	PRON	O	O	1538
reflex	NOUN	O	O	1538
initiated	VERB	O	O	1538
when	SCONJ	O	O	1538
the	PRON	O	O	1538
PG	PROPN	O	Chemical	1538
was	AUX	O	O	1538
given	VERB	O	O	1538
intravesically	ADV	O	O	1538
.	PUNCT	O	O	1538
The	PRON	O	O	1539
present	NOUN	O	O	1539
results	VERB	O	O	1539
thus	ADV	O	O	1539
suggest	VERB	O	O	1539
that	SCONJ	O	O	1539
intra	ADJ	O	O	1539
-	PUNCT	O	O	1539
arterial	ADJ	O	O	1539
PGE2	NOUN	O	Chemical	1539
,	PUNCT	O	O	1539
given	VERB	O	O	1539
near	ADP	O	O	1539
the	PRON	O	O	1539
bladder	NOUN	O	O	1539
,	PUNCT	O	O	1539
may	AUX	O	O	1539
initiate	VERB	O	O	1539
micturition	NOUN	O	O	1539
in	ADP	O	O	1539
the	PRON	O	O	1539
normal	ADJ	O	O	1539
rat	NOUN	O	O	1539
chiefly	ADV	O	O	1539
by	ADP	O	O	1539
directly	ADV	O	O	1539
contracting	NOUN	O	O	1539
the	PRON	O	O	1539
smooth	VERB	O	O	1539
muscle	NOUN	O	O	1539
of	ADP	O	O	1539
the	PRON	O	O	1539
detrusor	NOUN	O	O	1539
.	PUNCT	O	O	1539
However	ADV	O	O	1540
,	PUNCT	O	O	1540
when	SCONJ	O	O	1540
given	VERB	O	O	1540
intravesically	ADV	O	O	1540
,	PUNCT	O	O	1540
PGE2	NOUN	O	Chemical	1540
may	AUX	O	O	1540
stimulate	VERB	O	O	1540
micturition	NOUN	O	O	1540
by	ADP	O	O	1540
releasing	VERB	O	O	1540
tachykinins	NOUN	O	Chemical	1540
from	ADP	O	O	1540
nerves	NOUN	O	O	1540
in	ADP	O	O	1540
and/or	CCONJ	O	O	1540
immediately	ADV	O	O	1540
below	ADP	O	O	1540
the	PRON	O	O	1540
urothelium	NOUN	O	O	1540
.	PUNCT	O	O	1540
These	PRON	O	O	1541
tachykinins	NOUN	O	Chemical	1541
,	PUNCT	O	O	1541
in	ADP	O	O	1541
turn	VERB	O	O	1541
,	PUNCT	O	O	1541
initiate	VERB	O	O	1541
a	PRON	O	O	1541
micturition	NOUN	O	O	1541
reflex	NOUN	O	O	1541
by	ADP	O	O	1541
stimulating	VERB	O	O	1541
NK1	NOUN	O	O	1541
and	CCONJ	O	O	1541
NK2	PROPN	O	O	1541
receptors	NOUN	O	O	1541
.	PUNCT	O	O	1541
Prostanoids	NOUN	O	Chemical	1542
may	AUX	O	O	1542
,	PUNCT	O	O	1542
via	ADP	O	O	1542
release	NOUN	O	O	1542
of	ADP	O	O	1542
tachykinins	NOUN	O	Chemical	1542
,	PUNCT	O	O	1542
contribute	VERB	O	O	1542
to	PART	O	O	1542
both	PRON	O	O	1542
urge	VERB	O	O	1542
and	CCONJ	O	O	1542
bladder hyperactivity	NOUN	O	Disease	1542
seen	VERB	O	O	1542
in	ADP	O	O	1542
inflammatory	ADJ	O	O	1542
conditions	NOUN	O	O	1542
of	ADP	O	O	1542
the	PRON	O	O	1542
lower	ADJ	O	O	1542
urinary	ADJ	O	O	1542
tract	NOUN	O	O	1542
.	PUNCT	O	O	1542
Thiazide	PROPN	O	Chemical	1545
diuretics	NOUN	O	O	1545
,	PUNCT	O	O	1545
hypokalemia	PROPN	O	Disease	1545
and	CCONJ	O	O	1545
cardiac arrhythmias	VERB	O	Disease	1545
.	PUNCT	O	O	1545
Thiazide	PROPN	O	Chemical	1546
diuretics	NOUN	O	O	1546
are	AUX	O	O	1546
widely	ADV	O	O	1546
accepted	VERB	O	O	1546
as	ADP	O	O	1546
the	PRON	O	O	1546
cornerstone	ADJ	O	O	1546
of	ADP	O	O	1546
antihypertensive	ADV	O	O	1546
treatment	NOUN	O	O	1546
programs	NOUN	O	O	1546
.	PUNCT	O	O	1546
Hypokalemia	PROPN	O	Disease	1547
is	AUX	O	O	1547
a	PRON	O	O	1547
commonly	ADV	O	O	1547
encountered	VERB	O	O	1547
metabolic	ADJ	O	O	1547
consequence	NOUN	O	O	1547
of	ADP	O	O	1547
chronic	ADJ	O	O	1547
thiazide	ADJ	O	Chemical	1547
therapy	NOUN	O	O	1547
.	PUNCT	O	O	1547
We	PRON	O	O	1548
treated	VERB	O	O	1548
38	NUM	O	O	1548
patients	NOUN	O	O	1548
(	PUNCT	O	O	1548
22	NUM	O	O	1548
low	ADJ	O	O	1548
renin	PROPN	O	O	1548
,	PUNCT	O	O	1548
16	NUM	O	O	1548
normal	ADJ	O	O	1548
renin	PROPN	O	O	1548
)	PUNCT	O	O	1548
with	ADP	O	O	1548
moderate	ADJ	O	O	1548
diastolic hypertension	NOUN	O	Disease	1548
with	ADP	O	O	1548
hydrochlorothiazide	ADV	O	Chemical	1548
(	PUNCT	O	O	1548
HCTC	PROPN	O	Chemical	1548
)	PUNCT	O	O	1548
administered	VERB	O	O	1548
on	ADP	O	O	1548
a	PRON	O	O	1548
twice	ADV	O	O	1548
daily	ADV	O	O	1548
schedule	NOUN	O	O	1548
.	PUNCT	O	O	1548
The	PRON	O	O	1549
serum	NOUN	O	O	1549
K	PROPN	O	Chemical	1549
during	ADP	O	O	1549
the	PRON	O	O	1549
control	VERB	O	O	1549
period	NOUN	O	O	1549
was	AUX	O	O	1549
4.5	NUM	O	O	1549
+	ADP	O	O	1549
/-	PUNCT	O	O	1549
/	PUNCT	O	O	1550
l	X	O	O	1550
an	PRON	O	O	1550
on	ADP	O	O	1550
50	NUM	O	O	1550
,	PUNCT	O	O	1550
100	NUM	O	O	1550
,	PUNCT	O	O	1550
150	NUM	O	O	1550
and	CCONJ	O	O	1550
200	NUM	O	O	1550
mg	VERB	O	O	1550
HCTZ	NOUN	O	Chemical	1550
daily	ADV	O	O	1550
3.9	NUM	O	O	1550
Corresponding	VERB	O	O	1551
figures	VERB	O	O	1551
for	ADP	O	O	1551
whole	NOUN	O	O	1551
body	NOUN	O	O	1551
K	PROPN	O	Chemical	1551
were	AUX	O	O	1551
4107	NUM	O	O	1551
+	ADP	O	O	1551
/-	PUNCT	O	O	1551
In	ADP	O	O	1552
13	NUM	O	O	1552
patients	NOUN	O	O	1552
we	PRON	O	O	1552
observed	VERB	O	O	1552
the	PRON	O	O	1552
effects	NOUN	O	O	1552
of	ADP	O	O	1552
HCTZ	NOUN	O	Chemical	1552
therapy	NOUN	O	O	1552
(	PUNCT	O	O	1552
100	NUM	O	O	1552
mg	VERB	O	O	1552
daily	ADV	O	O	1552
)	PUNCT	O	O	1552
on	ADP	O	O	1552
the	PRON	O	O	1552
occurrence	NOUN	O	O	1552
of	ADP	O	O	1552
PVC	NOUN	O	O	1552
's	AUX	O	O	1552
during	ADP	O	O	1552
rest	VERB	O	O	1552
as	ADP	O	O	1552
well	ADV	O	O	1552
as	ADP	O	O	1552
during	ADP	O	O	1552
static	ADJ	O	O	1552
and	CCONJ	O	O	1552
dynamic	ADJ	O	O	1552
exercise	VERB	O	O	1552
.	PUNCT	O	O	1552
Corresponding	VERB	O	O	1553
figures	VERB	O	O	1553
during	ADP	O	O	1553
HCTZ	NOUN	O	Chemical	1553
therapy	NOUN	O	O	1553
100	NUM	O	O	1553
mg	VERB	O	O	1553
daily	ADV	O	O	1553
were	AUX	O	O	1553
1.4	NUM	O	O	1553
+	ADP	O	O	1553
/-	PUNCT	O	O	1553
K+	NOUN	O	O	1554
observed	VERB	O	O	1554
r	X	O	O	1554
=	PUNCT	O	O	1554
0.72	NUM	O	O	1554
,	PUNCT	O	O	1554
p	NOUN	O	O	1554
less	ADV	O	O	1554
than	ADP	O	O	1554
0.001	NUM	O	O	1554
.	PUNCT	O	O	1554
In	ADP	O	O	1555
conclusion	NOUN	O	O	1555
we	PRON	O	O	1555
found	VERB	O	O	1555
that	SCONJ	O	O	1555
thiazide	ADJ	O	Chemical	1555
diuretics	NOUN	O	O	1555
cause	VERB	O	O	1555
hypokalemia	PROPN	O	Disease	1555
and	CCONJ	O	O	1555
depletion	NOUN	O	O	1555
of	ADP	O	O	1555
body	NOUN	O	O	1555
potassium	NOUN	O	Chemical	1555
.	PUNCT	O	O	1555
The	PRON	O	O	1556
more	ADJ	O	O	1556
profound	ADJ	O	O	1556
hypokalemia	PROPN	O	Disease	1556
,	PUNCT	O	O	1556
the	PRON	O	O	1556
greater	ADJ	O	O	1556
the	PRON	O	O	1556
propensity	NOUN	O	O	1556
for	ADP	O	O	1556
the	PRON	O	O	1556
occurrence	NOUN	O	O	1556
of	ADP	O	O	1556
PVC	NOUN	O	O	1556
's	AUX	O	O	1556
.	PUNCT	O	O	1556
Diuretics	NOUN	O	O	1559
,	PUNCT	O	O	1559
potassium	NOUN	O	Chemical	1559
and	CCONJ	O	O	1559
arrhythmias	VERB	O	Disease	1559
in	ADP	O	O	1559
hypertensive	ADJ	O	Disease	1559
coronary disease	NOUN	O	Disease	1559
.	PUNCT	O	O	1559
It	PRON	O	O	1560
has	VERB	O	O	1560
been	AUX	O	O	1560
proposed	VERB	O	O	1560
that	SCONJ	O	O	1560
modest	ADJ	O	O	1560
changes	VERB	O	O	1560
in	ADP	O	O	1560
plasma	NOUN	O	O	1560
potassium	NOUN	O	Chemical	1560
can	AUX	O	O	1560
alter	VERB	O	O	1560
the	PRON	O	O	1560
tendency	NOUN	O	O	1560
towards	ADP	O	O	1560
cardiac arrhythmias	VERB	O	Disease	1560
.	PUNCT	O	O	1560
If	SCONJ	O	O	1561
this	PRON	O	O	1561
were	AUX	O	O	1561
so	ADV	O	O	1561
,	PUNCT	O	O	1561
patients	NOUN	O	O	1561
with	ADP	O	O	1561
coronary artery disease	NOUN	O	Disease	1561
might	AUX	O	O	1561
be	AUX	O	O	1561
especially	ADV	O	O	1561
susceptible	ADJ	O	O	1561
.	PUNCT	O	O	1561
Thus	ADV	O	O	1562
,	PUNCT	O	O	1562
myocardial	ADJ	O	O	1562
electrical	ADJ	O	O	1562
excitability	NOUN	O	O	1562
was	AUX	O	O	1562
measured	VERB	O	O	1562
in	ADP	O	O	1562
patients	NOUN	O	O	1562
with	ADP	O	O	1562
mild	ADJ	O	O	1562
essential	ADJ	O	O	1562
hypertension	NOUN	O	Disease	1562
and	CCONJ	O	O	1562
known	VERB	O	O	1562
coronary artery disease	NOUN	O	Disease	1562
after	ADP	O	O	1562
8	NUM	O	O	1562
weeks	NOUN	O	O	1562
of	ADP	O	O	1562
treatment	NOUN	O	O	1562
with	ADP	O	O	1562
a	PRON	O	O	1562
potassium	NOUN	O	Chemical	1562
-	PUNCT	O	O	1562
conserving	VERB	O	O	1562
diuretic	ADJ	O	Chemical	1562
(	PUNCT	O	O	1562
amiloride	PROPN	O	Chemical	1562
)	PUNCT	O	O	1562
and	CCONJ	O	O	1562
a	PRON	O	O	1562
similar	ADJ	O	O	1562
period	NOUN	O	O	1562
on	ADP	O	O	1562
a	PRON	O	O	1562
potassium	NOUN	O	Chemical	1562
-	PUNCT	O	O	1562
losing	VERB	O	O	1562
diuretic	ADJ	O	Chemical	1562
(	PUNCT	O	O	1562
chlorthalidone	PROPN	O	Chemical	1562
)	PUNCT	O	O	1562
in	ADP	O	O	1562
a	PRON	O	O	1562
randomised	VERB	O	O	1562
study	VERB	O	O	1562
.	PUNCT	O	O	1562
Plasma	NOUN	O	O	1563
potassium	NOUN	O	Chemical	1563
concentrations	NOUN	O	O	1563
were	AUX	O	O	1563
on	ADP	O	O	1563
average	ADJ	O	O	1563
1	X	O	O	1563
mmol	NOUN	O	O	1563
/	PUNCT	O	O	1563
L	NOUN	O	O	1563
lower	ADJ	O	O	1563
during	ADP	O	O	1563
the	PRON	O	O	1563
chlorthalidone	PROPN	O	Chemical	1563
phase	NOUN	O	O	1563
compared	VERB	O	O	1563
to	PART	O	O	1563
amiloride	PROPN	O	Chemical	1563
therapy	NOUN	O	O	1563
.	PUNCT	O	O	1563
Blood	NOUN	O	O	1564
pressure	NOUN	O	O	1564
and	CCONJ	O	O	1564
volume	PROPN	O	O	1564
states	VERB	O	O	1564
as	ADP	O	O	1564
assessed	VERB	O	O	1564
by	ADP	O	O	1564
bodyweight	NOUN	O	O	1564
,	PUNCT	O	O	1564
plasma	NOUN	O	O	1564
renin	PROPN	O	O	1564
and	CCONJ	O	O	1564
noradrenaline	NOUN	O	Chemical	1564
(	PUNCT	O	O	1564
norepinephrine	NOUN	O	Chemical	1564
)	PUNCT	O	O	1564
Compared	VERB	O	O	1565
to	PART	O	O	1565
amiloride	PROPN	O	Chemical	1565
treatment	NOUN	O	O	1565
,	PUNCT	O	O	1565
the	PRON	O	O	1565
chlorthalidone	PROPN	O	Chemical	1565
phase	NOUN	O	O	1565
was	AUX	O	O	1565
associated	VERB	O	O	1565
with	ADP	O	O	1565
an	PRON	O	O	1565
increased	VERB	O	O	1565
frequency	NOUN	O	O	1565
of	ADP	O	O	1565
ventricular ectopic beats	NOUN	O	Disease	1565
(	PUNCT	O	O	1565
24-hour	NOUN	O	O	1565
Holter	PROPN	O	O	1565
monitoring	NOUN	O	O	1565
)	PUNCT	O	O	1565
and	CCONJ	O	O	1565
a	PRON	O	O	1565
higher	ADJ	O	O	1565
Lown	NOUN	O	O	1565
grading	NOUN	O	O	1565
,	PUNCT	O	O	1565
increased	VERB	O	O	1565
upslope	NOUN	O	O	1565
and	CCONJ	O	O	1565
duration	NOUN	O	O	1565
of	ADP	O	O	1565
the	PRON	O	O	1565
monophasic	ADJ	O	O	1565
action	NOUN	O	O	1565
potential	ADJ	O	O	1565
,	PUNCT	O	O	1565
prolonged	VERB	O	O	1565
ventricular	ADJ	O	O	1565
effective	ADJ	O	O	1565
refractory	ADJ	O	O	1565
period	NOUN	O	O	1565
,	PUNCT	O	O	1565
and	CCONJ	O	O	1565
increased	VERB	O	O	1565
electrical	ADJ	O	O	1565
instability	NOUN	O	O	1565
during	ADP	O	O	1565
programmed	VERB	O	O	1565
ventricular	ADJ	O	O	1565
stimulation	NOUN	O	O	1565
.	PUNCT	O	O	1565
The	PRON	O	O	1566
above	ADP	O	O	1566
results	VERB	O	O	1566
indicate	VERB	O	O	1566
that	SCONJ	O	O	1566
because	SCONJ	O	O	1566
potassium	NOUN	O	Chemical	1566
-	PUNCT	O	O	1566
losing	VERB	O	O	1566
diuretic	ADJ	O	Chemical	1566
therapy	NOUN	O	O	1566
can	AUX	O	O	1566
increase	VERB	O	O	1566
myocardial	ADJ	O	O	1566
electrical	ADJ	O	O	1566
excitability	NOUN	O	O	1566
in	ADP	O	O	1566
patients	NOUN	O	O	1566
with	ADP	O	O	1566
ischaemic	ADJ	O	O	1566
heart disease	NOUN	O	Disease	1566
,	PUNCT	O	O	1566
even	ADV	O	O	1566
minor	ADJ	O	O	1566
falls	VERB	O	O	1566
in	ADP	O	O	1566
plasma	NOUN	O	O	1566
potassium	NOUN	O	Chemical	1566
concentrations	NOUN	O	O	1566
are	AUX	O	O	1566
probably	ADV	O	O	1566
best	ADV	O	O	1566
avoided	VERB	O	O	1566
in	ADP	O	O	1566
such	ADJ	O	O	1566
patients	NOUN	O	O	1566
.	PUNCT	O	O	1566
GABA	PROPN	O	Chemical	1569
involvement	NOUN	O	O	1569
in	ADP	O	O	1569
naloxone	NOUN	O	Chemical	1569
induced	VERB	O	O	1569
reversal	NOUN	O	O	1569
of	ADP	O	O	1569
respiratory paralysis	NOUN	O	Disease	1569
produced	VERB	O	O	1569
by	ADP	O	O	1569
thiopental	NOUN	O	Chemical	1569
.	PUNCT	O	O	1569
No	PRON	O	O	1570
agent	NOUN	O	O	1570
is	AUX	O	O	1570
yet	ADV	O	O	1570
available	ADJ	O	O	1570
to	PART	O	O	1570
reverse	VERB	O	O	1570
respiratory paralysis	NOUN	O	Disease	1570
produced	VERB	O	O	1570
by	ADP	O	O	1570
CNS	PROPN	O	O	1570
depressants	NOUN	O	O	1570
,	PUNCT	O	O	1570
such	ADJ	O	O	1570
as	ADP	O	O	1570
general	ADJ	O	O	1570
anesthetics	NOUN	O	O	1570
.	PUNCT	O	O	1570
In	ADP	O	O	1571
this	PRON	O	O	1571
study	VERB	O	O	1571
naloxone	NOUN	O	Chemical	1571
reversed	VERB	O	O	1571
respiratory paralysis	NOUN	O	Disease	1571
induced	VERB	O	O	1571
by	ADP	O	O	1571
thiopental	NOUN	O	Chemical	1571
in	ADP	O	O	1571
rats	NOUN	O	O	1571
.	PUNCT	O	O	1571
thiopental	NOUN	O	Chemical	1572
produced	VERB	O	O	1572
anesthesia	NOUN	O	O	1572
without	ADP	O	O	1572
altering	VERB	O	O	1572
respiratory	NOUN	O	O	1572
rate	NOUN	O	O	1572
,	PUNCT	O	O	1572
increased	VERB	O	O	1572
GABA	PROPN	O	Chemical	1572
,	PUNCT	O	O	1572
decreased	VERB	O	O	1572
glutamate	NOUN	O	Chemical	1572
,	PUNCT	O	O	1572
and	CCONJ	O	O	1572
had	VERB	O	O	1572
no	PRON	O	O	1572
effect	VERB	O	O	1572
on	ADP	O	O	1572
aspartate	NOUN	O	Chemical	1572
or	CCONJ	O	O	1572
glycine	NOUN	O	Chemical	1572
levels	NOUN	O	O	1572
compared	VERB	O	O	1572
to	PART	O	O	1572
controls	VERB	O	O	1572
in	ADP	O	O	1572
rat	NOUN	O	O	1572
cortex	VERB	O	O	1572
and	CCONJ	O	O	1572
brain	NOUN	O	O	1572
stem	VERB	O	O	1572
.	PUNCT	O	O	1572
Pretreatment	NOUN	O	O	1573
of	ADP	O	O	1573
rats	NOUN	O	O	1573
with	ADP	O	O	1573
thiosemicarbazide	PROPN	O	Chemical	1573
for	ADP	O	O	1573
30	NUM	O	O	1573
minutes	NOUN	O	O	1573
abolished	VERB	O	O	1573
the	PRON	O	O	1573
anesthetic	NOUN	O	O	1573
action	NOUN	O	O	1573
as	ADP	O	O	1573
well	ADV	O	O	1573
as	ADP	O	O	1573
the	PRON	O	O	1573
respiratory	NOUN	O	O	1573
depressant	NOUN	O	O	1573
action	NOUN	O	O	1573
of	ADP	O	O	1573
thiopental	NOUN	O	Chemical	1573
.	PUNCT	O	O	1573
thiopental	NOUN	O	Chemical	1574
produced	VERB	O	O	1574
respiratory arrest	NOUN	O	Disease	1574
with	ADP	O	O	1574
further	ADV	O	O	1574
increase	VERB	O	O	1574
in	ADP	O	O	1574
GABA	PROPN	O	Chemical	1574
and	CCONJ	O	O	1574
decrease	VERB	O	O	1574
in	ADP	O	O	1574
glutamate	NOUN	O	Chemical	1574
again	ADV	O	O	1574
in	ADP	O	O	1574
cortex	VERB	O	O	1574
and	CCONJ	O	O	1574
brain	NOUN	O	O	1574
stem	VERB	O	O	1574
without	ADP	O	O	1574
affecting	VERB	O	O	1574
any	PRON	O	O	1574
of	ADP	O	O	1574
the	PRON	O	O	1574
amino acids	NOUN	O	Chemical	1574
studied	VERB	O	O	1574
in	ADP	O	O	1574
four	NUM	O	O	1574
regions	NOUN	O	O	1574
of	ADP	O	O	1574
rat	NOUN	O	O	1574
brain	NOUN	O	O	1574
.	PUNCT	O	O	1574
Naloxone	NOUN	O	Chemical	1575
(	PUNCT	O	O	1575
2.5	NUM	O	O	1575
mg	VERB	O	O	1575
/	PUNCT	O	O	1575
kg	VERB	O	O	1575
,	PUNCT	O	O	1575
i.v	NOUN	O	O	1575
.	PUNCT	O	O	1575
)	PUNCT	O	O	1575
reversed	VERB	O	O	1576
respiratory paralysis	NOUN	O	Disease	1576
,	PUNCT	O	O	1576
glutamate	NOUN	O	Chemical	1576
and	CCONJ	O	O	1576
GABA	PROPN	O	Chemical	1576
levels	NOUN	O	O	1576
to	PART	O	O	1576
control	VERB	O	O	1576
values	NOUN	O	O	1576
in	ADP	O	O	1576
brain	NOUN	O	O	1576
stem	VERB	O	O	1576
and	CCONJ	O	O	1576
cortex	VERB	O	O	1576
with	ADP	O	O	1576
no	PRON	O	O	1576
changes	VERB	O	O	1576
in	ADP	O	O	1576
caudate	ADJ	O	O	1576
or	CCONJ	O	O	1576
cerebellum	NOUN	O	O	1576
.	PUNCT	O	O	1576
These	PRON	O	O	1577
data	NOUN	O	O	1577
suggest	VERB	O	O	1577
naloxone	NOUN	O	Chemical	1577
reverses	VERB	O	O	1577
respiratory paralysis	NOUN	O	Disease	1577
produced	VERB	O	O	1577
by	ADP	O	O	1577
thiopental	NOUN	O	Chemical	1577
and	CCONJ	O	O	1577
involves	VERB	O	O	1577
GABA	PROPN	O	Chemical	1577
in	ADP	O	O	1577
its	PRON	O	O	1577
action	NOUN	O	O	1577
.	PUNCT	O	O	1577
National	ADJ	O	O	1580
project	NOUN	O	O	1580
on	ADP	O	O	1580
the	PRON	O	O	1580
prevention	NOUN	O	O	1580
of	ADP	O	O	1580
mother	NOUN	O	O	1580
-	PUNCT	O	O	1580
to	PART	O	O	1580
-	PUNCT	O	O	1580
infant	NOUN	O	O	1580
infection by hepatitis B virus	NOUN	O	Disease	1580
in	ADP	O	O	1580
Japan	PROPN	O	O	1580
.	PUNCT	O	O	1580
In	ADP	O	O	1581
Japan	PROPN	O	O	1581
,	PUNCT	O	O	1581
a	PRON	O	O	1581
nationwide	ADV	O	O	1581
prevention	NOUN	O	O	1581
program	PROPN	O	O	1581
against	ADP	O	O	1581
mother	NOUN	O	O	1581
-	PUNCT	O	O	1581
to	PART	O	O	1581
-	PUNCT	O	O	1581
infant	NOUN	O	O	1581
infection by hepatitis B virus	NOUN	O	Disease	1581
(	PUNCT	O	O	1581
HBV	NOUN	O	O	1581
)	PUNCT	O	O	1581
started	VERB	O	O	1581
in	ADP	O	O	1581
1985	NUM	O	O	1581
.	PUNCT	O	O	1581
This	PRON	O	O	1582
program	PROPN	O	O	1582
consists	VERB	O	O	1582
of	ADP	O	O	1582
double	ADJ	O	O	1582
screenings	NOUN	O	O	1582
of	ADP	O	O	1582
pregnant	ADJ	O	O	1582
women	NOUN	O	O	1582
and	CCONJ	O	O	1582
prophylactic	ADJ	O	O	1582
treatment	NOUN	O	O	1582
to	PART	O	O	1582
the	PRON	O	O	1582
infants	NOUN	O	O	1582
born	VERB	O	O	1582
to	PART	O	O	1582
both	PRON	O	O	1582
hepatitis B surface antigen	NOUN	O	Chemical	1582
(	PUNCT	O	O	1582
HBsAg	PROPN	O	Chemical	1582
)	PUNCT	O	O	1582
and	CCONJ	O	O	1582
hepatitis B	PROPN	O	Disease	1582
e	X	O	O	1582
antigen	PROPN	O	O	1582
(	PUNCT	O	O	1582
HBeAg	PROPN	O	Chemical	1582
)	PUNCT	O	O	1582
positive	ADJ	O	O	1582
mothers	NOUN	O	O	1582
.	PUNCT	O	O	1582
These	PRON	O	O	1583
infants	NOUN	O	O	1583
are	AUX	O	O	1583
treated	VERB	O	O	1583
with	ADP	O	O	1583
two	NUM	O	O	1583
injections	NOUN	O	O	1583
of	ADP	O	O	1583
hepatitis B	PROPN	O	Disease	1583
immune	NOUN	O	O	1583
globulin	NOUN	O	O	1583
(	PUNCT	O	O	1583
HBIG	PROPN	O	O	1583
)	PUNCT	O	O	1583
and	CCONJ	O	O	1583
at	ADP	O	O	1583
least	ADJ	O	O	1583
three	NUM	O	O	1583
injections	NOUN	O	O	1583
of	ADP	O	O	1583
plasma	NOUN	O	O	1583
derived	VERB	O	O	1583
hepatitis B	PROPN	O	Disease	1583
vaccine	NOUN	O	O	1583
.	PUNCT	O	O	1583
93.4%	NOUN	O	O	1584
pregnant	ADJ	O	O	1584
women	NOUN	O	O	1584
had	VERB	O	O	1584
the	PRON	O	O	1584
chance	NOUN	O	O	1584
to	PART	O	O	1584
be	AUX	O	O	1584
examined	VERB	O	O	1584
for	ADP	O	O	1584
HBsAg	PROPN	O	Chemical	1584
,	PUNCT	O	O	1584
and	CCONJ	O	O	1584
the	PRON	O	O	1584
positive	ADJ	O	O	1584
rate	NOUN	O	O	1584
was	AUX	O	O	1584
1.4	NUM	O	O	1584
to	PART	O	O	1584
1.5%	NOUN	O	O	1584
.	PUNCT	O	O	1584
The	PRON	O	O	1585
HBeAg	PROPN	O	Chemical	1585
positive	ADJ	O	O	1585
rate	NOUN	O	O	1585
in	ADP	O	O	1585
HBsAg	PROPN	O	Chemical	1585
positive	ADJ	O	O	1585
was	AUX	O	O	1585
23	NUM	O	O	1585
to	PART	O	O	1585
26%	NOUN	O	O	1585
.	PUNCT	O	O	1585
The	PRON	O	O	1586
HBsAg	PROPN	O	Chemical	1586
positive	ADJ	O	O	1586
rate	NOUN	O	O	1586
in	ADP	O	O	1586
neonates	NOUN	O	O	1586
and	CCONJ	O	O	1586
in	ADP	O	O	1586
infants	NOUN	O	O	1586
before	ADP	O	O	1586
two	NUM	O	O	1586
months	NOUN	O	O	1586
were	AUX	O	O	1586
3%	NOUN	O	O	1586
and	CCONJ	O	O	1586
2%	NOUN	O	O	1586
respectively	ADV	O	O	1586
.	PUNCT	O	O	1586
Nociceptive	NOUN	O	O	1589
effects	NOUN	O	O	1589
induced	VERB	O	O	1589
by	ADP	O	O	1589
intrathecal	ADJ	O	O	1589
administration	NOUN	O	O	1589
of	ADP	O	O	1589
prostaglandin D2	NOUN	O	Chemical	1589
,	PUNCT	O	O	1589
E2	NOUN	O	Chemical	1589
,	PUNCT	O	O	1589
or	CCONJ	O	O	1589
F2	NOUN	O	O	1589
alpha	PROPN	O	O	1589
to	PART	O	O	1589
conscious	ADJ	O	O	1589
mice	NOUN	O	O	1589
.	PUNCT	O	O	1589
The	PRON	O	O	1590
effects	NOUN	O	O	1590
of	ADP	O	O	1590
intrathecal	ADJ	O	O	1590
administration	NOUN	O	O	1590
of	ADP	O	O	1590
prostaglandins	NOUN	O	Chemical	1590
on	ADP	O	O	1590
pain	NOUN	O	Disease	1590
responses	NOUN	O	O	1590
in	ADP	O	O	1590
conscious	ADJ	O	O	1590
mice	NOUN	O	O	1590
were	AUX	O	O	1590
evaluated	VERB	O	O	1590
by	ADP	O	O	1590
using	VERB	O	O	1590
hot	ADJ	O	O	1590
plate	NOUN	O	O	1590
and	CCONJ	O	O	1590
acetic acid	NOUN	O	Chemical	1590
writhing	VERB	O	Disease	1590
tests	VERB	O	O	1590
.	PUNCT	O	O	1590
Prostaglandin D2	NOUN	O	Chemical	1591
(	PUNCT	O	O	1591
0.5	NUM	O	O	1591
-	PUNCT	O	O	1591
3	X	O	O	1591
ng	PROPN	O	O	1591
/	PUNCT	O	O	1591
mouse	PROPN	O	O	1591
)	PUNCT	O	O	1591
had	VERB	O	O	1591
a	PRON	O	O	1591
hyperalgesic	PROPN	O	Disease	1591
action	NOUN	O	O	1591
on	ADP	O	O	1591
the	PRON	O	O	1591
response	NOUN	O	O	1591
to	PART	O	O	1591
a	PRON	O	O	1591
hot	ADJ	O	O	1591
plate	NOUN	O	O	1591
during	ADP	O	O	1591
a	PRON	O	O	1591
3	X	O	O	1591
-	PUNCT	O	O	1591
60	NUM	O	O	1591
min	NOUN	O	O	1591
period	NOUN	O	O	1591
after	ADP	O	O	1591
injection	NOUN	O	O	1591
.	PUNCT	O	O	1591
Prostaglandin E2	NOUN	O	Chemical	1592
showed	VERB	O	O	1592
a	PRON	O	O	1592
hyperalgesic	PROPN	O	Disease	1592
effect	VERB	O	O	1592
at	ADP	O	O	1592
doses	NOUN	O	O	1592
of	ADP	O	O	1592
1	X	O	O	1592
pg	PROPN	O	Chemical	1592
to	PART	O	O	1592
10	NUM	O	O	1592
ng	PROPN	O	O	1592
/	PUNCT	O	O	1592
mouse	PROPN	O	O	1592
,	PUNCT	O	O	1592
but	CCONJ	O	O	1592
the	PRON	O	O	1592
effect	VERB	O	O	1592
lasted	VERB	O	O	1592
shorter	ADJ	O	O	1592
(	PUNCT	O	O	1592
3	X	O	O	1592
-	PUNCT	O	O	1592
30	NUM	O	O	1592
min	NOUN	O	O	1592
)	PUNCT	O	O	1592
than	ADP	O	O	1592
that	SCONJ	O	O	1592
of	ADP	O	O	1592
prostaglandin D2	NOUN	O	Chemical	1592
.	PUNCT	O	O	1592
Similar	ADJ	O	O	1593
results	VERB	O	O	1593
were	AUX	O	O	1593
obtained	VERB	O	O	1593
by	ADP	O	O	1593
acetic acid	NOUN	O	Chemical	1593
writhing	VERB	O	Disease	1593
tests	VERB	O	O	1593
.	PUNCT	O	O	1593
The	PRON	O	O	1594
hyperalgesic	PROPN	O	Disease	1594
effect	VERB	O	O	1594
of	ADP	O	O	1594
prostaglandin D2	NOUN	O	Chemical	1594
was	AUX	O	O	1594
blocked	VERB	O	O	1594
by	ADP	O	O	1594
simultaneous	ADJ	O	O	1594
injection	NOUN	O	O	1594
of	ADP	O	O	1594
a	PRON	O	O	1594
substance	NOUN	O	O	1594
P	NOUN	O	Chemical	1594
antagonist	NOUN	O	O	1594
(	PUNCT	O	O	1594
greater	ADJ	O	O	1594
than	ADP	O	O	1594
or	CCONJ	O	O	1594
equal	ADJ	O	O	1594
to	PART	O	O	1594
100	NUM	O	O	1594
ng	PROPN	O	O	1594
)	PUNCT	O	O	1594
but	CCONJ	O	O	1594
not	PART	O	O	1594
by	ADP	O	O	1594
AH6809	PROPN	O	Chemical	1594
,	PUNCT	O	O	1594
a	PRON	O	O	1594
prostanoid	PROPN	O	O	1594
EP1-receptor	NOUN	O	O	1594
antagonist	NOUN	O	O	1594
.	PUNCT	O	O	1594
Conversely	ADV	O	O	1595
,	PUNCT	O	O	1595
prostaglandin E2-induced	VERB	O	O	1595
hyperalgesia	NOUN	O	Disease	1595
was	AUX	O	O	1595
blocked	VERB	O	O	1595
by	ADP	O	O	1595
AH6809	PROPN	O	Chemical	1595
(	PUNCT	O	O	1595
greater	ADJ	O	O	1595
than	ADP	O	O	1595
or	CCONJ	O	O	1595
equal	ADJ	O	O	1595
to	PART	O	O	1595
500	NUM	O	O	1595
ng	PROPN	O	O	1595
)	PUNCT	O	O	1595
but	CCONJ	O	O	1595
not	PART	O	O	1595
by	ADP	O	O	1595
the	PRON	O	O	1595
substance	NOUN	O	O	1595
P	NOUN	O	Chemical	1595
antagonist	NOUN	O	O	1595
.	PUNCT	O	O	1595
Prostaglandin F2 alpha	NOUN	O	Chemical	1596
had	VERB	O	O	1596
little	ADJ	O	O	1596
effect	VERB	O	O	1596
on	ADP	O	O	1596
pain	NOUN	O	Disease	1596
responses	NOUN	O	O	1596
.	PUNCT	O	O	1596
These	PRON	O	O	1597
results	VERB	O	O	1597
demonstrate	VERB	O	O	1597
that	SCONJ	O	O	1597
both	PRON	O	O	1597
prostaglandin D2	NOUN	O	Chemical	1597
and	CCONJ	O	O	1597
prostaglandin E2	NOUN	O	Chemical	1597
exert	VERB	O	O	1597
hyperalgesia	NOUN	O	Disease	1597
in	ADP	O	O	1597
the	PRON	O	O	1597
spinal	NOUN	O	O	1597
cord	NOUN	O	O	1597
,	PUNCT	O	O	1597
but	CCONJ	O	O	1597
in	ADP	O	O	1597
different	ADJ	O	O	1597
ways	NOUN	O	O	1597
.	PUNCT	O	O	1597
Swallowing	VERB	O	O	1600
-	PUNCT	O	O	1600
induced	VERB	O	O	1600
atrial tachyarrhythmia	ADV	O	Disease	1600
triggered	VERB	O	O	1600
by	ADP	O	O	1600
salbutamol	NOUN	O	Chemical	1600
:	PUNCT	O	O	1600
case	NOUN	O	O	1600
report	VERB	O	O	1600
and	CCONJ	O	O	1600
review	VERB	O	O	1600
of	ADP	O	O	1600
the	PRON	O	O	1600
literature	NOUN	O	O	1600
.	PUNCT	O	O	1600
On	ADP	O	O	1601
electrocardiogram	PROPN	O	O	1601
,	PUNCT	O	O	1601
episodes	NOUN	O	O	1601
of	ADP	O	O	1601
atrial tachyarrhythmia	ADV	O	Disease	1601
were	AUX	O	O	1601
recorded	VERB	O	O	1601
immediately	ADV	O	O	1601
after	ADP	O	O	1601
swallowing	VERB	O	O	1601
;	PUNCT	O	O	1601
24-hour	NOUN	O	O	1601
Holter	PROPN	O	O	1601
monitoring	NOUN	O	O	1601
recorded	VERB	O	O	1601
several	ADJ	O	O	1601
events	NOUN	O	O	1601
.	PUNCT	O	O	1601
The	PRON	O	O	1602
arrhythmia	NOUN	O	Disease	1602
resolved	VERB	O	O	1602
after	ADP	O	O	1602
therapy	NOUN	O	O	1602
with	ADP	O	O	1602
atenolol	PROPN	O	Chemical	1602
,	PUNCT	O	O	1602
but	CCONJ	O	O	1602
recurred	VERB	O	O	1602
a	PRON	O	O	1602
year	NOUN	O	O	1602
later	ADV	O	O	1602
.	PUNCT	O	O	1602
The	PRON	O	O	1603
patient	NOUN	O	O	1603
noticed	VERB	O	O	1603
that	SCONJ	O	O	1603
before	ADP	O	O	1603
these	PRON	O	O	1603
episodes	NOUN	O	O	1603
he	PRON	O	O	1603
had	VERB	O	O	1603
been	AUX	O	O	1603
using	VERB	O	O	1603
an	PRON	O	O	1603
inhalator	NOUN	O	O	1603
of	ADP	O	O	1603
salbutamol	NOUN	O	Chemical	1603
.	PUNCT	O	O	1603
After	ADP	O	O	1604
stopping	VERB	O	O	1604
the	PRON	O	O	1604
beta	NOUN	O	O	1604
-	PUNCT	O	O	1604
agonist	NOUN	O	O	1604
,	PUNCT	O	O	1604
and	CCONJ	O	O	1604
after	ADP	O	O	1604
a	PRON	O	O	1604
week	NOUN	O	O	1604
with	ADP	O	O	1604
the	PRON	O	O	1604
atenolol	PROPN	O	Chemical	1604
,	PUNCT	O	O	1604
the	PRON	O	O	1604
arrhythmia	NOUN	O	Disease	1604
disappeared	VERB	O	O	1604
.	PUNCT	O	O	1604
DISCUSSION	NOUN	O	O	1605
:	PUNCT	O	O	1605
Swallowing	VERB	O	O	1605
-	PUNCT	O	O	1605
induced	VERB	O	O	1605
atrial tachyarrhythmia	ADV	O	Disease	1605
(	PUNCT	O	O	1605
SIAT	NOUN	O	Disease	1605
)	PUNCT	O	O	1605
is	AUX	O	O	1605
a	PRON	O	O	1605
rare	ADJ	O	O	1605
phenomenon	NOUN	O	O	1605
.	PUNCT	O	O	1605
Fewer	ADJ	O	O	1606
than	ADP	O	O	1606
50	NUM	O	O	1606
cases	NOUN	O	O	1606
of	ADP	O	O	1606
SIAT	NOUN	O	Disease	1606
have	VERB	O	O	1606
been	AUX	O	O	1606
described	VERB	O	O	1606
in	ADP	O	O	1606
the	PRON	O	O	1606
literature	NOUN	O	O	1606
.	PUNCT	O	O	1606
This	PRON	O	O	1607
article	NOUN	O	O	1607
summarizes	VERB	O	O	1607
all	PRON	O	O	1607
the	PRON	O	O	1607
cases	NOUN	O	O	1607
published	VERB	O	O	1607
,	PUNCT	O	O	1607
creating	VERB	O	O	1607
a	PRON	O	O	1607
comprehensive	ADJ	O	O	1607
review	VERB	O	O	1607
of	ADP	O	O	1607
the	PRON	O	O	1607
current	ADJ	O	O	1607
knowledge	NOUN	O	O	1607
and	CCONJ	O	O	1607
approach	NOUN	O	O	1607
to	PART	O	O	1607
SIAT	NOUN	O	Disease	1607
.	PUNCT	O	O	1607
It	PRON	O	O	1608
discusses	VERB	O	O	1608
demographics	NOUN	O	O	1608
,	PUNCT	O	O	1608
clinical	ADJ	O	O	1608
characteristics	NOUN	O	O	1608
and	CCONJ	O	O	1608
types	NOUN	O	O	1608
of	ADP	O	O	1608
arrhythmia	NOUN	O	Disease	1608
,	PUNCT	O	O	1608
postulated	VERB	O	O	1608
mechanisms	NOUN	O	O	1608
of	ADP	O	O	1608
SIAT	NOUN	O	Disease	1608
,	PUNCT	O	O	1608
and	CCONJ	O	O	1608
different	ADJ	O	O	1608
treatment	NOUN	O	O	1608
possibilities	NOUN	O	O	1608
such	ADJ	O	O	1608
as	ADP	O	O	1608
medications	NOUN	O	O	1608
,	PUNCT	O	O	1608
surgery	NOUN	O	O	1608
,	PUNCT	O	O	1608
and	CCONJ	O	O	1608
radiofrequency	NOUN	O	O	1608
catheter	VERB	O	O	1608
ablation	NOUN	O	O	1608
(	PUNCT	O	O	1608
RFCA	NOUN	O	O	1608
)	PUNCT	O	O	1608
.	PUNCT	O	O	1608
CONCLUSION	PROPN	O	O	1609
:	PUNCT	O	O	1609
Salbutamol	PROPN	O	Chemical	1609
is	AUX	O	O	1609
presented	VERB	O	O	1609
here	ADV	O	O	1609
as	ADP	O	O	1609
a	PRON	O	O	1609
possible	ADJ	O	O	1609
trigger	NOUN	O	O	1609
for	ADP	O	O	1609
SIAT	NOUN	O	Disease	1609
.	PUNCT	O	O	1609
Although	SCONJ	O	O	1610
it	PRON	O	O	1610
is	AUX	O	O	1610
difficult	ADJ	O	O	1610
to	PART	O	O	1610
define	VERB	O	O	1610
causality	NOUN	O	O	1610
in	ADP	O	O	1610
a	PRON	O	O	1610
case	NOUN	O	O	1610
report	VERB	O	O	1610
,	PUNCT	O	O	1610
it	PRON	O	O	1610
is	AUX	O	O	1610
logical	ADJ	O	O	1610
to	PART	O	O	1610
think	VERB	O	O	1610
that	SCONJ	O	O	1610
a	PRON	O	O	1610
beta	NOUN	O	O	1610
-	PUNCT	O	O	1610
agonist	NOUN	O	O	1610
like	INTJ	O	O	1610
salbutamol	NOUN	O	Chemical	1610
(	PUNCT	O	O	1610
known	VERB	O	O	1610
to	PART	O	O	1610
induce	VERB	O	O	1610
tachycardia	PROPN	O	Disease	1610
)	PUNCT	O	O	1610
may	AUX	O	O	1610
be	AUX	O	O	1610
the	PRON	O	O	1610
trigger	NOUN	O	O	1610
of	ADP	O	O	1610
adrenergic	NOUN	O	O	1610
reflexes	NOUN	O	O	1610
originating	VERB	O	O	1610
in	ADP	O	O	1610
the	PRON	O	O	1610
esophagus	NOUN	O	O	1610
while	SCONJ	O	O	1610
swallowing	VERB	O	O	1610
and	CCONJ	O	O	1610
that	SCONJ	O	O	1610
a	PRON	O	O	1610
beta	NOUN	O	O	1610
-	PUNCT	O	O	1610
blocker	NOUN	O	O	1610
such	ADJ	O	O	1610
as	ADP	O	O	1610
atenolol	PROPN	O	Chemical	1610
(	PUNCT	O	O	1610
that	SCONJ	O	O	1610
blocks	NOUN	O	O	1610
the	PRON	O	O	1610
adrenergic	NOUN	O	O	1610
activity	NOUN	O	O	1610
)	PUNCT	O	O	1610
may	AUX	O	O	1610
relieve	VERB	O	O	1610
it	PRON	O	O	1610
.	PUNCT	O	O	1610
Coenzyme Q10	PROPN	O	Chemical	1613
treatment	NOUN	O	O	1613
ameliorates	VERB	O	O	1613
acute	ADJ	O	O	1613
cisplatin	NOUN	O	Chemical	1613
nephrotoxicity	NOUN	O	Disease	1613
in	ADP	O	O	1613
mice	NOUN	O	O	1613
.	PUNCT	O	O	1613
The	PRON	O	O	1614
nephroprotective	PROPN	O	O	1614
effect	VERB	O	O	1614
of	ADP	O	O	1614
coenzyme Q10	PROPN	O	Chemical	1614
was	AUX	O	O	1614
investigated	VERB	O	O	1614
in	ADP	O	O	1614
mice	NOUN	O	O	1614
with	ADP	O	O	1614
acute	ADJ	O	O	1614
renal injury	NOUN	O	Disease	1614
induced	VERB	O	O	1614
by	ADP	O	O	1614
a	PRON	O	O	1614
single	ADJ	O	O	1614
i.p	NOUN	O	O	1614
.	PUNCT	O	O	1614
injection	NOUN	O	O	1615
of	ADP	O	O	1615
cisplatin	NOUN	O	Chemical	1615
(	PUNCT	O	O	1615
5	NUM	O	O	1615
mg	VERB	O	O	1615
/	PUNCT	O	O	1615
kg	VERB	O	O	1615
)	PUNCT	O	O	1615
.	PUNCT	O	O	1615
Coenzyme Q10	PROPN	O	Chemical	1616
treatment	NOUN	O	O	1616
(	PUNCT	O	O	1617
10	NUM	O	O	1617
mg	VERB	O	O	1617
/	PUNCT	O	O	1617
kg	VERB	O	O	1617
/	PUNCT	O	O	1617
day	NOUN	O	O	1617
,	PUNCT	O	O	1617
i.p	NOUN	O	O	1617
.	PUNCT	O	O	1617
)	PUNCT	O	O	1617
was	AUX	O	O	1617
applied	VERB	O	O	1617
for	ADP	O	O	1617
6	NUM	O	O	1617
consecutive	ADJ	O	O	1617
days	NOUN	O	O	1617
,	PUNCT	O	O	1617
starting	VERB	O	O	1617
1	X	O	O	1617
day	NOUN	O	O	1617
before	ADP	O	O	1617
cisplatin	NOUN	O	Chemical	1617
administration	NOUN	O	O	1617
.	PUNCT	O	O	1617
Coenzyme Q10	PROPN	O	Chemical	1618
significantly	ADV	O	O	1618
reduced	VERB	O	O	1618
blood	NOUN	O	O	1618
urea nitrogen	NOUN	O	Chemical	1618
and	CCONJ	O	O	1618
serum	NOUN	O	O	1618
creatinine	PROPN	O	Chemical	1618
levels	NOUN	O	O	1618
which	PRON	O	O	1618
were	AUX	O	O	1618
increased	VERB	O	O	1618
by	ADP	O	O	1618
cisplatin	NOUN	O	Chemical	1618
.	PUNCT	O	O	1618
Coenzyme Q10	PROPN	O	Chemical	1619
significantly	ADV	O	O	1619
compensated	VERB	O	O	1619
deficits	NOUN	O	O	1619
in	ADP	O	O	1619
the	PRON	O	O	1619
antioxidant	ADJ	O	O	1619
defense	NOUN	O	O	1619
mechanisms	NOUN	O	O	1619
(	PUNCT	O	O	1619
reduced glutathione	NOUN	O	Chemical	1619
level	VERB	O	O	1619
and	CCONJ	O	O	1619
superoxide	NOUN	O	Chemical	1619
dismutase	ADP	O	O	1619
activity	NOUN	O	O	1619
)	PUNCT	O	O	1619
,	PUNCT	O	O	1619
suppressed	VERB	O	O	1619
lipid	NOUN	O	O	1619
peroxidation	NOUN	O	O	1619
,	PUNCT	O	O	1619
decreased	VERB	O	O	1619
the	PRON	O	O	1619
elevations	NOUN	O	O	1619
of	ADP	O	O	1619
tumor	NOUN	O	Disease	1619
necrosis	NOUN	O	Disease	1619
factor	NOUN	O	O	1619
-	PUNCT	O	O	1619
alpha	PROPN	O	O	1619
,	PUNCT	O	O	1619
nitric oxide	NOUN	O	Chemical	1619
and	CCONJ	O	O	1619
platinum	NOUN	O	Chemical	1619
ion	PROPN	O	O	1619
concentration	NOUN	O	O	1619
,	PUNCT	O	O	1619
and	CCONJ	O	O	1619
attenuated	VERB	O	O	1619
the	PRON	O	O	1619
reductions	NOUN	O	O	1619
of	ADP	O	O	1619
selenium	NOUN	O	Chemical	1619
and	CCONJ	O	O	1619
zinc	PROPN	O	Chemical	1619
ions	NOUN	O	O	1619
in	ADP	O	O	1619
renal	ADJ	O	O	1619
tissue	NOUN	O	O	1619
resulted	VERB	O	O	1619
from	ADP	O	O	1619
cisplatin	NOUN	O	Chemical	1619
administration	NOUN	O	O	1619
.	PUNCT	O	O	1619
Also	ADV	O	O	1620
,	PUNCT	O	O	1620
histopathological	ADJ	O	O	1620
renal tissue damage	NOUN	O	Disease	1620
mediated	VERB	O	O	1620
by	ADP	O	O	1620
cisplatin	NOUN	O	Chemical	1620
was	AUX	O	O	1620
ameliorated	VERB	O	O	1620
by	ADP	O	O	1620
coenzyme Q10	PROPN	O	Chemical	1620
treatment	NOUN	O	O	1620
.	PUNCT	O	O	1620
Immunohistochemical	PROPN	O	O	1621
analysis	NOUN	O	O	1621
revealed	VERB	O	O	1621
that	SCONJ	O	O	1621
coenzyme Q10	PROPN	O	Chemical	1621
significantly	ADV	O	O	1621
decreased	VERB	O	O	1621
the	PRON	O	O	1621
cisplatin	NOUN	O	Chemical	1621
-	PUNCT	O	O	1621
induced	VERB	O	O	1621
overexpression	NOUN	O	O	1621
of	ADP	O	O	1621
inducible	VERB	O	O	1621
nitric oxide	NOUN	O	Chemical	1621
synthase	NOUN	O	O	1621
,	PUNCT	O	O	1621
nuclear	ADJ	O	O	1621
factor	NOUN	O	O	1621
-	PUNCT	O	O	1621
kappaB	NOUN	O	O	1621
,	PUNCT	O	O	1621
caspase-3	NUM	O	O	1621
and	CCONJ	O	O	1621
p53	NOUN	O	O	1621
in	ADP	O	O	1621
renal	ADJ	O	O	1621
tissue	NOUN	O	O	1621
.	PUNCT	O	O	1621
It	PRON	O	O	1622
was	AUX	O	O	1622
concluded	VERB	O	O	1622
that	SCONJ	O	O	1622
coenzyme Q10	PROPN	O	Chemical	1622
represents	VERB	O	O	1622
a	PRON	O	O	1622
potential	ADJ	O	O	1622
therapeutic	ADJ	O	O	1622
option	NOUN	O	O	1622
to	PART	O	O	1622
protect	VERB	O	O	1622
against	ADP	O	O	1622
acute	ADJ	O	O	1622
cisplatin	NOUN	O	Chemical	1622
nephrotoxicity	NOUN	O	Disease	1622
commonly	ADV	O	O	1622
encountered	VERB	O	O	1622
in	ADP	O	O	1622
clinical	ADJ	O	O	1622
practice	VERB	O	O	1622
.	PUNCT	O	O	1622
Metformin	NOUN	O	Chemical	1625
prevents	VERB	O	O	1625
experimental	ADJ	O	O	1625
gentamicin	VERB	O	Chemical	1625
-	PUNCT	O	O	1625
induced	VERB	O	O	1625
nephropathy	NOUN	O	Disease	1625
by	ADP	O	O	1625
a	PRON	O	O	1625
mitochondria	PROPN	O	O	1625
-	PUNCT	O	O	1625
dependent	ADJ	O	O	1625
pathway	NOUN	O	O	1625
.	PUNCT	O	O	1625
The	PRON	O	O	1626
antidiabetic	NOUN	O	O	1626
drug	NOUN	O	O	1626
metformin	PROPN	O	Chemical	1626
can	AUX	O	O	1626
diminish	VERB	O	O	1626
apoptosis	NOUN	O	O	1626
induced	VERB	O	O	1626
by	ADP	O	O	1626
oxidative	NOUN	O	O	1626
stress	NOUN	O	O	1626
in	ADP	O	O	1626
endothelial	NOUN	O	O	1626
cells	NOUN	O	O	1626
and	CCONJ	O	O	1626
prevent	VERB	O	O	1626
vascular dysfunction	NOUN	O	Disease	1626
even	ADV	O	O	1626
in	ADP	O	O	1626
nondiabetic	ADJ	O	O	1626
patients	NOUN	O	O	1626
.	PUNCT	O	O	1626
Here	ADV	O	O	1627
we	PRON	O	O	1627
tested	VERB	O	O	1627
whether	SCONJ	O	O	1627
it	PRON	O	O	1627
has	VERB	O	O	1627
a	PRON	O	O	1627
beneficial	ADJ	O	O	1627
effect	VERB	O	O	1627
in	ADP	O	O	1627
a	PRON	O	O	1627
rat	NOUN	O	O	1627
model	NOUN	O	O	1627
of	ADP	O	O	1627
gentamicin	VERB	O	Chemical	1627
toxicity	NOUN	O	Disease	1627
.	PUNCT	O	O	1627
Mitochondrial	NOUN	O	O	1628
analysis	NOUN	O	O	1628
,	PUNCT	O	O	1628
respiration	NOUN	O	O	1628
intensity	NOUN	O	O	1628
,	PUNCT	O	O	1628
levels	NOUN	O	O	1628
of	ADP	O	O	1628
reactive	ADJ	O	O	1628
oxygen	NOUN	O	Chemical	1628
species	NOUN	O	O	1628
,	PUNCT	O	O	1628
permeability	NOUN	O	O	1628
transition	NOUN	O	O	1628
,	PUNCT	O	O	1628
and	CCONJ	O	O	1628
cytochrome	ADP	O	O	1628
c	X	O	O	1628
release	NOUN	O	O	1628
were	AUX	O	O	1628
assessed	VERB	O	O	1628
3	X	O	O	1628
and	CCONJ	O	O	1628
6	NUM	O	O	1628
days	NOUN	O	O	1628
after	ADP	O	O	1628
gentamicin	VERB	O	Chemical	1628
administration	NOUN	O	O	1628
.	PUNCT	O	O	1628
Metformin	NOUN	O	Chemical	1629
treatment	NOUN	O	O	1629
fully	ADV	O	O	1629
blocked	VERB	O	O	1629
gentamicin	VERB	O	Chemical	1629
-	PUNCT	O	O	1629
mediated	VERB	O	O	1629
acute	ADJ	O	O	1629
renal failure	NOUN	O	Disease	1629
.	PUNCT	O	O	1629
Metformin	NOUN	O	Chemical	1630
also	ADV	O	O	1630
protected	VERB	O	O	1630
the	PRON	O	O	1630
kidney	NOUN	O	O	1630
from	ADP	O	O	1630
histological	ADJ	O	O	1630
damage	NOUN	O	O	1630
6	NUM	O	O	1630
days	NOUN	O	O	1630
after	ADP	O	O	1630
gentamicin	VERB	O	Chemical	1630
administration	NOUN	O	O	1630
.	PUNCT	O	O	1630
These	PRON	O	O	1631
in	ADP	O	O	1631
vivo	VERB	O	O	1631
markers	NOUN	O	O	1631
of	ADP	O	O	1631
kidney dysfunction	NOUN	O	Disease	1631
and	CCONJ	O	O	1631
their	PRON	O	O	1631
correction	PROPN	O	O	1631
by	ADP	O	O	1631
metformin	PROPN	O	Chemical	1631
were	AUX	O	O	1631
complemented	VERB	O	O	1631
by	ADP	O	O	1631
in	ADP	O	O	1631
vitro	X	O	O	1631
studies	NOUN	O	O	1631
of	ADP	O	O	1631
mitochondrial	ADJ	O	O	1631
function	NOUN	O	O	1631
.	PUNCT	O	O	1631
We	PRON	O	O	1632
found	VERB	O	O	1632
that	SCONJ	O	O	1632
gentamicin	VERB	O	Chemical	1632
treatment	NOUN	O	O	1632
depleted	VERB	O	O	1632
respiratory	NOUN	O	O	1632
components	NOUN	O	O	1632
(	PUNCT	O	O	1632
cytochrome	ADP	O	O	1632
c	X	O	O	1632
,	PUNCT	O	O	1632
NADH	PROPN	O	O	1632
)	PUNCT	O	O	1632
,	PUNCT	O	O	1632
probably	ADV	O	O	1632
due	ADJ	O	O	1632
to	PART	O	O	1632
the	PRON	O	O	1632
opening	VERB	O	O	1632
of	ADP	O	O	1632
mitochondrial	ADJ	O	O	1632
transition	NOUN	O	O	1632
pores	VERB	O	O	1632
.	PUNCT	O	O	1632
These	PRON	O	O	1633
injuries	NOUN	O	O	1633
,	PUNCT	O	O	1633
partly	ADV	O	O	1633
mediated	VERB	O	O	1633
by	ADP	O	O	1633
a	PRON	O	O	1633
rise	VERB	O	O	1633
in	ADP	O	O	1633
reactive	ADJ	O	O	1633
oxygen	NOUN	O	Chemical	1633
species	NOUN	O	O	1633
from	ADP	O	O	1633
the	PRON	O	O	1633
electron	NOUN	O	O	1633
transfer	NOUN	O	O	1633
chain	NOUN	O	O	1633
,	PUNCT	O	O	1633
were	AUX	O	O	1633
significantly	ADV	O	O	1633
decreased	VERB	O	O	1633
by	ADP	O	O	1633
metformin	PROPN	O	Chemical	1633
.	PUNCT	O	O	1633
Thus	ADV	O	O	1634
,	PUNCT	O	O	1634
our	PRON	O	O	1634
study	VERB	O	O	1634
suggests	VERB	O	O	1634
that	SCONJ	O	O	1634
pleiotropic	ADP	O	O	1634
effects	NOUN	O	O	1634
of	ADP	O	O	1634
metformin	PROPN	O	Chemical	1634
can	AUX	O	O	1634
lessen	VERB	O	O	1634
gentamicin	VERB	O	Chemical	1634
nephrotoxicity	NOUN	O	Disease	1634
and	CCONJ	O	O	1634
improve	VERB	O	O	1634
mitochondrial	ADJ	O	O	1634
homeostasis	NOUN	O	O	1634
.	PUNCT	O	O	1634
Sedation	NOUN	O	O	1637
depth	NOUN	O	O	1637
during	ADP	O	O	1637
spinal	NOUN	O	O	1637
anesthesia	NOUN	O	O	1637
and	CCONJ	O	O	1637
the	PRON	O	O	1637
development	NOUN	O	O	1637
of	ADP	O	O	1637
postoperative delirium	NOUN	O	Disease	1637
in	ADP	O	O	1637
elderly	ADJ	O	O	1637
patients	NOUN	O	O	1637
undergoing	VERB	O	O	1637
hip fracture	NOUN	O	Disease	1637
repair	PROPN	O	O	1637
.	PUNCT	O	O	1637
OBJECTIVE	VERB	O	O	1638
:	PUNCT	O	O	1638
To	PART	O	O	1638
determine	VERB	O	O	1638
whether	SCONJ	O	O	1638
limiting	VERB	O	O	1638
intraoperative	ADJ	O	O	1638
sedation	NOUN	O	O	1638
depth	NOUN	O	O	1638
during	ADP	O	O	1638
spinal	NOUN	O	O	1638
anesthesia	NOUN	O	O	1638
for	ADP	O	O	1638
hip fracture	NOUN	O	Disease	1638
repair	PROPN	O	O	1638
in	ADP	O	O	1638
elderly	ADJ	O	O	1638
patients	NOUN	O	O	1638
can	AUX	O	O	1638
decrease	VERB	O	O	1638
the	PRON	O	O	1638
prevalence	NOUN	O	O	1638
of	ADP	O	O	1638
postoperative delirium	NOUN	O	Disease	1638
.	PUNCT	O	O	1638
:	PUNCT	O	O	1639
We	PRON	O	O	1639
performed	VERB	O	O	1639
a	PRON	O	O	1639
double	ADJ	O	O	1639
-	PUNCT	O	O	1639
blind	ADJ	O	Disease	1639
,	PUNCT	O	O	1639
randomized	VERB	O	O	1639
controlled	VERB	O	O	1639
trial	NOUN	O	O	1639
at	ADP	O	O	1639
an	PRON	O	O	1639
academic	ADJ	O	O	1639
medical	ADJ	O	O	1639
center	PROPN	O	O	1639
of	ADP	O	O	1639
elderly	ADJ	O	O	1639
patients	NOUN	O	O	1639
(	PUNCT	O	O	1639
>	PUNCT	O	O	1639
or=65	NOUN	O	O	1639
years	NOUN	O	O	1639
)	PUNCT	O	O	1639
without	ADP	O	O	1639
preoperative	ADJ	O	O	1639
delirium	NOUN	O	Disease	1639
or	CCONJ	O	O	1639
severe	ADJ	O	O	1639
dementia	NOUN	O	Disease	1639
who	PRON	O	O	1639
underwent	VERB	O	O	1639
hip fracture	NOUN	O	Disease	1639
repair	PROPN	O	O	1639
under	ADP	O	O	1639
spinal	NOUN	O	O	1639
anesthesia	NOUN	O	O	1639
with	ADP	O	O	1639
propofol	VERB	O	Chemical	1639
sedation	NOUN	O	O	1639
.	PUNCT	O	O	1639
Postoperative delirium	NOUN	O	Disease	1640
was	AUX	O	O	1640
assessed	VERB	O	O	1640
as	ADP	O	O	1640
defined	VERB	O	O	1640
by	ADP	O	O	1640
Diagnostic	ADJ	O	O	1640
and	CCONJ	O	O	1640
Statistical	ADJ	O	O	1640
Manual	NOUN	O	O	1640
of	ADP	O	O	1640
Mental Disorders	PROPN	O	Disease	1640
(	PUNCT	O	O	1640
Third	ADJ	O	O	1640
Edition	PROPN	O	O	1640
Revised	VERB	O	O	1640
)	PUNCT	O	O	1640
criteria	NOUN	O	O	1640
using	VERB	O	O	1640
the	PRON	O	O	1640
Confusion	NOUN	O	O	1640
Assessment	NOUN	O	O	1640
Method	NOUN	O	O	1640
beginning	VERB	O	O	1640
at	ADP	O	O	1640
any	PRON	O	O	1640
time	NOUN	O	O	1640
from	ADP	O	O	1640
the	PRON	O	O	1640
second	ADV	O	O	1640
day	NOUN	O	O	1640
after	ADP	O	O	1640
surgery	NOUN	O	O	1640
.	PUNCT	O	O	1640
The	PRON	O	O	1641
prevalence	NOUN	O	O	1641
of	ADP	O	O	1641
postoperative delirium	NOUN	O	Disease	1641
was	AUX	O	O	1641
significantly	ADV	O	O	1641
lower	ADJ	O	O	1641
in	ADP	O	O	1641
the	PRON	O	O	1641
light	ADJ	O	O	1641
sedation	NOUN	O	O	1641
group	NOUN	O	O	1641
(	PUNCT	O	O	1641
11/57	NUM	O	O	1641
[	X	O	O	1641
19%	NOUN	O	O	1641
]	PUNCT	O	O	1641
vs	ADP	O	O	1641
23/57	NUM	O	O	1641
[	X	O	O	1641
40%	NOUN	O	O	1641
]	PUNCT	O	O	1641
in	ADP	O	O	1641
the	PRON	O	O	1641
deep	ADJ	O	O	1641
sedation	NOUN	O	O	1641
group	NOUN	O	O	1641
;	PUNCT	O	O	1641
P=.02	NOUN	O	O	1641
)	PUNCT	O	O	1641
,	PUNCT	O	O	1641
indicating	VERB	O	O	1641
that	SCONJ	O	O	1641
1	X	O	O	1641
incident	NOUN	O	O	1641
of	ADP	O	O	1641
delirium	NOUN	O	Disease	1641
will	AUX	O	O	1641
be	AUX	O	O	1641
prevented	VERB	O	O	1641
for	ADP	O	O	1641
every	PRON	O	O	1641
4.7	NUM	O	O	1641
patients	NOUN	O	O	1641
treated	VERB	O	O	1641
with	ADP	O	O	1641
light	ADJ	O	O	1641
sedation	NOUN	O	O	1641
.	PUNCT	O	O	1641
SD	NOUN	O	O	1642
number	NOUN	O	O	1642
of	ADP	O	O	1642
days	NOUN	O	O	1642
of	ADP	O	O	1642
delirium	NOUN	O	Disease	1642
during	ADP	O	O	1642
hospitalization	NOUN	O	O	1642
was	AUX	O	O	1642
lower	ADJ	O	O	1642
in	ADP	O	O	1642
the	PRON	O	O	1642
light	ADJ	O	O	1642
sedation	NOUN	O	O	1642
group	NOUN	O	O	1642
than	ADP	O	O	1642
in	ADP	O	O	1642
the	PRON	O	O	1642
deep	ADJ	O	O	1642
sedation	NOUN	O	O	1642
group	NOUN	O	O	1642
(	PUNCT	O	O	1642
0.5+/-1.5	NUM	O	O	1642
days	NOUN	O	O	1642
vs	ADP	O	O	1642
1.4+/-4.0	NUM	O	O	1642
days	NOUN	O	O	1642
;	PUNCT	O	O	1642
P=.01	VERB	O	O	1642
)	PUNCT	O	O	1642
.	PUNCT	O	O	1642
The	PRON	O	O	1643
use	VERB	O	O	1643
of	ADP	O	O	1643
light	ADJ	O	O	1643
propofol	VERB	O	Chemical	1643
sedation	NOUN	O	O	1643
decreased	VERB	O	O	1643
the	PRON	O	O	1643
prevalence	NOUN	O	O	1643
of	ADP	O	O	1643
postoperative delirium	NOUN	O	Disease	1643
by	ADP	O	O	1643
50%	NOUN	O	O	1643
compared	VERB	O	O	1643
with	ADP	O	O	1643
deep	ADJ	O	O	1643
sedation	NOUN	O	O	1643
.	PUNCT	O	O	1643
Limiting	VERB	O	O	1644
depth	NOUN	O	O	1644
of	ADP	O	O	1644
sedation	NOUN	O	O	1644
during	ADP	O	O	1644
spinal	NOUN	O	O	1644
anesthesia	NOUN	O	O	1644
is	AUX	O	O	1644
a	PRON	O	O	1644
simple	ADJ	O	O	1644
,	PUNCT	O	O	1644
safe	ADJ	O	O	1644
,	PUNCT	O	O	1644
and	CCONJ	O	O	1644
cost	NOUN	O	O	1644
-	PUNCT	O	O	1644
effective	ADJ	O	O	1644
intervention	NOUN	O	O	1644
for	ADP	O	O	1644
preventing	VERB	O	O	1644
postoperative delirium	NOUN	O	Disease	1644
in	ADP	O	O	1644
elderly	ADJ	O	O	1644
patients	NOUN	O	O	1644
that	SCONJ	O	O	1644
could	AUX	O	O	1644
be	AUX	O	O	1644
widely	ADV	O	O	1644
and	CCONJ	O	O	1644
readily	ADV	O	O	1644
adopted	VERB	O	O	1644
.	PUNCT	O	O	1644
Sorafenib	PROPN	O	Chemical	1647
-	PUNCT	O	O	1647
induced	VERB	O	O	1647
acute	ADJ	O	O	1647
myocardial infarction	NOUN	O	Disease	1647
due	ADJ	O	O	1647
to	PART	O	O	1647
coronary artery spasm	NOUN	O	Disease	1647
.	PUNCT	O	O	1647
A	PRON	O	O	1648
65-year	NOUN	O	O	1648
-	PUNCT	O	O	1648
old	ADJ	O	O	1648
man	NOUN	O	O	1648
with	ADP	O	O	1648
advanced	ADJ	O	O	1648
renal cell carcinoma	NOUN	O	Disease	1648
was	AUX	O	O	1648
admitted	VERB	O	O	1648
due	ADJ	O	O	1648
to	PART	O	O	1648
continuing	VERB	O	O	1648
chest pain	NOUN	O	Disease	1648
at	ADP	O	O	1648
rest	VERB	O	O	1648
.	PUNCT	O	O	1648
Two	NUM	O	O	1649
weeks	NOUN	O	O	1649
before	ADP	O	O	1649
his	PRON	O	O	1649
admission	NOUN	O	O	1649
,	PUNCT	O	O	1649
sorafenib	PROPN	O	Chemical	1649
had	VERB	O	O	1649
been	AUX	O	O	1649
started	VERB	O	O	1649
.	PUNCT	O	O	1649
He	PRON	O	O	1650
was	AUX	O	O	1650
diagnosed	VERB	O	O	1650
with	ADP	O	O	1650
non	ADJ	O	O	1650
-	PUNCT	O	O	1650
ST	PROPN	O	O	1650
-	PUNCT	O	O	1650
elevation	NOUN	O	O	1650
myocardial infarction	NOUN	O	Disease	1650
by	ADP	O	O	1650
laboratory	NOUN	O	O	1650
data	NOUN	O	O	1650
and	CCONJ	O	O	1650
electrocardiogram	PROPN	O	O	1650
.	PUNCT	O	O	1650
Enhanced	VERB	O	O	1651
heart	NOUN	O	O	1651
magnetic	ADJ	O	O	1651
resonance	NOUN	O	O	1651
imaging	VERB	O	O	1651
also	ADV	O	O	1651
showed	VERB	O	O	1651
subendocardial infarction	NOUN	O	Disease	1651
.	PUNCT	O	O	1651
Coronary artery spasm	NOUN	O	Disease	1652
was	AUX	O	O	1652
induced	VERB	O	O	1652
by	ADP	O	O	1652
a	PRON	O	O	1652
provocative	ADJ	O	O	1652
test	NOUN	O	O	1652
.	PUNCT	O	O	1652
Cessation	NOUN	O	O	1653
of	ADP	O	O	1653
sorafenib	PROPN	O	Chemical	1653
and	CCONJ	O	O	1653
administration	NOUN	O	O	1653
of	ADP	O	O	1653
Ca	AUX	O	Chemical	1653
-	PUNCT	O	O	1653
channel	PROPN	O	O	1653
blocker	NOUN	O	O	1653
and	CCONJ	O	O	1653
nitrates	NOUN	O	Chemical	1653
ameliorated	VERB	O	O	1653
his	PRON	O	O	1653
symptoms	NOUN	O	O	1653
,	PUNCT	O	O	1653
but	CCONJ	O	O	1653
relapse	VERB	O	O	1653
occurred	VERB	O	O	1653
after	ADP	O	O	1653
resumption	NOUN	O	O	1653
of	ADP	O	O	1653
sorafenib	PROPN	O	Chemical	1653
.	PUNCT	O	O	1653
Addition	NOUN	O	O	1654
of	ADP	O	O	1654
oral	ADJ	O	O	1654
nicorandil	PROPN	O	Chemical	1654
reduced	VERB	O	O	1654
his	PRON	O	O	1654
symptoms	NOUN	O	O	1654
and	CCONJ	O	O	1654
maintained	VERB	O	O	1654
stable angina	NOUN	O	Disease	1654
status	NOUN	O	O	1654
.	PUNCT	O	O	1654
We	PRON	O	O	1655
report	VERB	O	O	1655
the	PRON	O	O	1655
first	ADV	O	O	1655
case	NOUN	O	O	1655
of	ADP	O	O	1655
sorafenib	PROPN	O	Chemical	1655
-	PUNCT	O	O	1655
induced	VERB	O	O	1655
coronary artery spasm	NOUN	O	Disease	1655
.	PUNCT	O	O	1655
Sorafenib	PROPN	O	Chemical	1656
is	AUX	O	O	1656
a	PRON	O	O	1656
multikinase	VERB	O	O	1656
inhibitor	NOUN	O	O	1656
that	SCONJ	O	O	1656
targets	VERB	O	O	1656
signaling	VERB	O	O	1656
pathways	NOUN	O	O	1656
necessary	ADJ	O	O	1656
for	ADP	O	O	1656
cellular	NOUN	O	O	1656
proliferation	NOUN	O	O	1656
and	CCONJ	O	O	1656
survival	NOUN	O	O	1656
.	PUNCT	O	O	1656
On	ADP	O	O	1657
the	PRON	O	O	1657
other	ADJ	O	O	1657
hand	NOUN	O	O	1657
,	PUNCT	O	O	1657
the	PRON	O	O	1657
Rho	NOUN	O	O	1657
/	PUNCT	O	O	1657
ROCK	PROPN	O	O	1657
pathway	NOUN	O	O	1657
has	VERB	O	O	1657
an	PRON	O	O	1657
important	ADJ	O	O	1657
role	NOUN	O	O	1657
in	ADP	O	O	1657
the	PRON	O	O	1657
pathogenesis	NOUN	O	O	1657
of	ADP	O	O	1657
coronary artery spasm	NOUN	O	Disease	1657
.	PUNCT	O	O	1657
Our	PRON	O	O	1658
report	VERB	O	O	1658
may	AUX	O	O	1658
show	VERB	O	O	1658
an	PRON	O	O	1658
adverse	ADJ	O	O	1658
effect	VERB	O	O	1658
on	ADP	O	O	1658
the	PRON	O	O	1658
Rho	NOUN	O	O	1658
/	PUNCT	O	O	1658
ROCK	PROPN	O	O	1658
pathway	NOUN	O	O	1658
by	ADP	O	O	1658
sorafenib	PROPN	O	Chemical	1658
use	VERB	O	O	1658
.	PUNCT	O	O	1658
Anxiogenic	NOUN	O	O	1661
potential	ADJ	O	O	1661
of	ADP	O	O	1661
ciprofloxacin	VERB	O	Chemical	1661
and	CCONJ	O	O	1661
norfloxacin	PROPN	O	Chemical	1661
in	ADP	O	O	1661
rats	NOUN	O	O	1661
.	PUNCT	O	O	1661
The	PRON	O	O	1662
possible	ADJ	O	O	1662
anxiogenic	ADJ	O	O	1662
effects	NOUN	O	O	1662
of	ADP	O	O	1662
fluoroquinolones	NOUN	O	Chemical	1662
,	PUNCT	O	O	1662
namely	ADV	O	O	1662
ciprofloxacin	VERB	O	Chemical	1662
and	CCONJ	O	O	1662
norfloxacin	PROPN	O	Chemical	1662
,	PUNCT	O	O	1662
were	AUX	O	O	1662
investigated	VERB	O	O	1662
in	ADP	O	O	1662
adult	NOUN	O	O	1662
Charles	PROPN	O	O	1662
Foster	NOUN	O	O	1662
albino	PROPN	O	O	1662
rats	NOUN	O	O	1662
of	ADP	O	O	1662
either	ADV	O	O	1662
sex	NOUN	O	O	1662
,	PUNCT	O	O	1662
weighing	VERB	O	O	1662
150	NUM	O	O	1662
-	PUNCT	O	O	1662
200	NUM	O	O	1662
g.	PROPN	O	O	1662
METHODS	NOUN	O	O	1662
:	PUNCT	O	O	1662
The	PRON	O	O	1663
results	VERB	O	O	1663
indicate	VERB	O	O	1663
that	SCONJ	O	O	1663
ciprofloxacin-	NOUN	O	O	1663
and	CCONJ	O	O	1663
norfloxacin	PROPN	O	Chemical	1663
-	PUNCT	O	O	1663
treated	VERB	O	O	1663
rats	NOUN	O	O	1663
showed	VERB	O	O	1663
anxious behaviour	NOUN	O	Disease	1663
in	ADP	O	O	1663
comparison	NOUN	O	O	1663
to	PART	O	O	1663
control	VERB	O	O	1663
rats	NOUN	O	O	1663
in	ADP	O	O	1663
all	PRON	O	O	1663
the	PRON	O	O	1663
parameters	NOUN	O	O	1663
studied	VERB	O	O	1663
.	PUNCT	O	O	1663
However	ADV	O	O	1664
,	PUNCT	O	O	1664
ciprofloxacin-	NOUN	O	O	1664
and	CCONJ	O	O	1664
norfloxacin	PROPN	O	Chemical	1664
-	PUNCT	O	O	1664
treated	VERB	O	O	1664
rats	NOUN	O	O	1664
did	VERB	O	O	1664
not	PART	O	O	1664
differ	VERB	O	O	1664
significantly	ADV	O	O	1664
from	ADP	O	O	1664
each	PRON	O	O	1664
other	ADJ	O	O	1664
in	ADP	O	O	1664
various	ADJ	O	O	1664
behavioural	ADJ	O	O	1664
parameters	NOUN	O	O	1664
.	PUNCT	O	O	1664
CONCLUSION	PROPN	O	O	1665
:	PUNCT	O	O	1665
The	PRON	O	O	1665
present	NOUN	O	O	1665
experimental	ADJ	O	O	1665
findings	NOUN	O	O	1665
substantiate	VERB	O	O	1665
the	PRON	O	O	1665
clinically	ADV	O	O	1665
observed	VERB	O	O	1665
anxiogenic	ADJ	O	O	1665
potential	ADJ	O	O	1665
of	ADP	O	O	1665
ciprofloxacin	VERB	O	Chemical	1665
and	CCONJ	O	O	1665
norfloxacin	PROPN	O	Chemical	1665
.	PUNCT	O	O	1665
Myocardial	PROPN	O	O	1668
Fas	PROPN	O	O	1668
ligand	NOUN	O	O	1668
expression	NOUN	O	O	1668
increases	VERB	O	O	1668
susceptibility	NOUN	O	O	1668
to	PART	O	O	1668
AZT	PROPN	O	Chemical	1668
-	PUNCT	O	O	1668
induced	VERB	O	O	1668
cardiomyopathy	ADJ	O	Disease	1668
.	PUNCT	O	O	1668
BACKGROUND	NOUN	O	O	1669
:	PUNCT	O	O	1669
Dilated cardiomyopathy	NOUN	O	Disease	1669
(	PUNCT	O	O	1669
DCM	PROPN	O	Disease	1669
)	PUNCT	O	O	1669
and	CCONJ	O	O	1669
myocarditis	ADV	O	Disease	1669
occur	VERB	O	O	1669
in	ADP	O	O	1669
many	ADJ	O	O	1669
HIV	PROPN	O	O	1669
-	PUNCT	O	O	1669
infected	VERB	O	O	1669
individuals	NOUN	O	O	1669
,	PUNCT	O	O	1669
resulting	VERB	O	O	1669
in	ADP	O	O	1669
symptomatic	ADJ	O	O	1669
heart failure	NOUN	O	Disease	1669
in	ADP	O	O	1669
up	ADP	O	O	1669
to	PART	O	O	1669
5%	NOUN	O	O	1669
of	ADP	O	O	1669
patients	NOUN	O	O	1669
.	PUNCT	O	O	1669
Highly	ADV	O	O	1670
active	ADJ	O	O	1670
antiretroviral	ADJ	O	O	1670
therapy	NOUN	O	O	1670
(	PUNCT	O	O	1670
HAART	PROPN	O	O	1670
)	PUNCT	O	O	1670
has	VERB	O	O	1670
significantly	ADV	O	O	1670
reduced	VERB	O	O	1670
morbidity	NOUN	O	O	1670
and	CCONJ	O	O	1670
mortality	NOUN	O	O	1670
of	ADP	O	O	1670
acquired immunodeficiency syndrome	NOUN	O	Disease	1670
(	PUNCT	O	O	1670
AIDS	PROPN	O	Disease	1670
)	PUNCT	O	O	1670
,	PUNCT	O	O	1670
but	CCONJ	O	O	1670
has	VERB	O	O	1670
resulted	VERB	O	O	1670
in	ADP	O	O	1670
an	PRON	O	O	1670
increase	VERB	O	O	1670
in	ADP	O	O	1670
cardiac and skeletal myopathies	NOUN	O	Disease	1670
.	PUNCT	O	O	1670
In	ADP	O	O	1671
order	NOUN	O	O	1671
to	PART	O	O	1671
investigate	VERB	O	O	1671
whether	SCONJ	O	O	1671
the	PRON	O	O	1671
HAART	PROPN	O	O	1671
component	NOUN	O	O	1671
zidovudine	NOUN	O	Chemical	1671
(	PUNCT	O	O	1671
3'-azido-2',3'-deoxythymidine	NUM	O	Chemical	1671
;	PUNCT	O	O	1671
AZT	PROPN	O	Chemical	1671
)	PUNCT	O	O	1671
triggers	VERB	O	O	1671
the	PRON	O	O	1671
Fas	PROPN	O	O	1671
-	PUNCT	O	O	1671
dependent	ADJ	O	O	1671
cell	NOUN	O	O	1671
-	PUNCT	O	O	1671
death	NOUN	O	O	1671
pathway	NOUN	O	O	1671
and	CCONJ	O	O	1671
cause	VERB	O	O	1671
cytoskeletal	ADJ	O	O	1671
disruption	NOUN	O	O	1671
in	ADP	O	O	1671
a	PRON	O	O	1671
murine	ADJ	O	O	1671
model	NOUN	O	O	1671
of	ADP	O	O	1671
DCM	PROPN	O	Disease	1671
,	PUNCT	O	O	1671
8-week	NOUN	O	O	1671
-	PUNCT	O	O	1671
old	ADJ	O	O	1671
transgenic	NOUN	O	O	1671
(	PUNCT	O	O	1671
expressing	VERB	O	O	1671
Fas	PROPN	O	O	1671
ligand	NOUN	O	O	1671
in	ADP	O	O	1671
the	PRON	O	O	1671
myocardium	NOUN	O	O	1671
:	PUNCT	O	O	1671
FasL	PROPN	O	O	1671
Tg	PROPN	O	O	1671
)	PUNCT	O	O	1671
and	CCONJ	O	O	1671
non	ADJ	O	O	1671
-	PUNCT	O	O	1671
transgenic	NOUN	O	O	1671
(	PUNCT	O	O	1671
NTg	PROPN	O	O	1671
)	PUNCT	O	O	1671
mice	NOUN	O	O	1671
received	VERB	O	O	1671
water	PROPN	O	O	1671
ad	NOUN	O	O	1671
libitum	NOUN	O	O	1671
containing	VERB	O	O	1671
different	ADJ	O	O	1671
concentrations	NOUN	O	O	1671
of	ADP	O	O	1671
AZT	PROPN	O	Chemical	1671
(	PUNCT	O	O	1671
0	NUM	O	O	1671
,	PUNCT	O	O	1671
0.07	NUM	O	O	1671
,	PUNCT	O	O	1671
0.2	NUM	O	O	1671
,	PUNCT	O	O	1671
and	CCONJ	O	O	1671
0.7	NUM	O	O	1671
mg	VERB	O	O	1671
/	PUNCT	O	O	1671
ml	ADP	O	O	1671
)	PUNCT	O	O	1671
.	PUNCT	O	O	1671
In	ADP	O	O	1672
contrast	NOUN	O	O	1672
,	PUNCT	O	O	1672
AZT	PROPN	O	Chemical	1672
-	PUNCT	O	O	1672
treated	VERB	O	O	1672
FasL	PROPN	O	O	1672
Tg	PROPN	O	O	1672
mice	NOUN	O	O	1672
developed	VERB	O	O	1672
cardiac dilation	NOUN	O	Disease	1672
and	CCONJ	O	O	1672
depressed	ADJ	O	O	1672
cardiac	ADJ	O	O	1672
function	NOUN	O	O	1672
in	ADP	O	O	1672
a	PRON	O	O	1672
dose	NOUN	O	O	1672
-	PUNCT	O	O	1672
dependent	ADJ	O	O	1672
manner	VERB	O	O	1672
,	PUNCT	O	O	1672
with	ADP	O	O	1672
concomitant	ADJ	O	O	1672
inflammatory	ADJ	O	O	1672
infiltration	NOUN	O	O	1672
of	ADP	O	O	1672
both	PRON	O	O	1672
ventricles	VERB	O	O	1672
.	PUNCT	O	O	1672
The	PRON	O	O	1673
expression	NOUN	O	O	1673
of	ADP	O	O	1673
Fas	PROPN	O	O	1673
ligand	NOUN	O	O	1673
in	ADP	O	O	1673
the	PRON	O	O	1673
myocardium	NOUN	O	O	1673
,	PUNCT	O	O	1673
as	ADP	O	O	1673
identified	VERB	O	O	1673
in	ADP	O	O	1673
HIV	PROPN	O	O	1673
-	PUNCT	O	O	1673
positive	ADJ	O	O	1673
patients	NOUN	O	O	1673
,	PUNCT	O	O	1673
might	AUX	O	O	1673
increase	VERB	O	O	1673
the	PRON	O	O	1673
susceptibility	NOUN	O	O	1673
to	PART	O	O	1673
HAART	PROPN	O	O	1673
-	PUNCT	O	O	1673
induced	VERB	O	O	1673
cardiomyopathy	ADJ	O	Disease	1673
due	ADJ	O	O	1673
to	PART	O	O	1673
activation	NOUN	O	O	1673
of	ADP	O	O	1673
apoptotic	ADJ	O	O	1673
pathways	NOUN	O	O	1673
,	PUNCT	O	O	1673
resulting	VERB	O	O	1673
in	ADP	O	O	1673
cardiac dilation	NOUN	O	Disease	1673
and	CCONJ	O	O	1673
dysfunction	NOUN	O	O	1673
.	PUNCT	O	O	1673
Valproate	VERB	O	Chemical	1676
-	PUNCT	O	O	1676
induced	VERB	O	O	1676
chorea	PROPN	O	Disease	1676
and	CCONJ	O	O	1676
encephalopathy	NOUN	O	Disease	1676
in	ADP	O	O	1676
atypical	ADJ	O	O	1676
nonketotic hyperglycinemia	NOUN	O	Disease	1676
.	PUNCT	O	O	1676
Nonketotic hyperglycinemia	NOUN	O	Disease	1677
is	AUX	O	O	1677
a	PRON	O	O	1677
disorder	NOUN	O	O	1677
of	ADP	O	O	1677
amino acid	NOUN	O	Chemical	1677
metabolism	NOUN	O	O	1677
in	ADP	O	O	1677
which	PRON	O	O	1677
a	PRON	O	O	1677
defect	NOUN	O	O	1677
in	ADP	O	O	1677
the	PRON	O	O	1677
glycine	NOUN	O	Chemical	1677
cleavage	NOUN	O	O	1677
system	NOUN	O	O	1677
leads	VERB	O	O	1677
to	PART	O	O	1677
an	PRON	O	O	1677
accumulation	NOUN	O	O	1677
of	ADP	O	O	1677
glycine	NOUN	O	Chemical	1677
in	ADP	O	O	1677
the	PRON	O	O	1677
brain	NOUN	O	O	1677
and	CCONJ	O	O	1677
other	ADJ	O	O	1677
body	NOUN	O	O	1677
compartments	NOUN	O	O	1677
.	PUNCT	O	O	1677
In	ADP	O	O	1678
the	PRON	O	O	1678
classical	ADJ	O	O	1678
form	NOUN	O	O	1678
it	PRON	O	O	1678
presents	VERB	O	O	1678
as	ADP	O	O	1678
neonatal	NOUN	O	O	1678
apnea	PROPN	O	Disease	1678
,	PUNCT	O	O	1678
intractable	ADJ	O	O	1678
seizures	NOUN	O	Disease	1678
,	PUNCT	O	O	1678
and	CCONJ	O	O	1678
hypotonia	NOUN	O	Disease	1678
,	PUNCT	O	O	1678
followed	VERB	O	O	1678
by	ADP	O	O	1678
significant	ADJ	O	O	1678
psychomotor retardation	NOUN	O	Disease	1678
.	PUNCT	O	O	1678
An	PRON	O	O	1679
important	ADJ	O	O	1679
subset	VERB	O	O	1679
of	ADP	O	O	1679
children	NOUN	O	O	1679
with	ADP	O	O	1679
nonketotic hyperglycinemia	NOUN	O	Disease	1679
are	AUX	O	O	1679
atypical	ADJ	O	O	1679
variants	NOUN	O	O	1679
who	PRON	O	O	1679
present	NOUN	O	O	1679
in	ADP	O	O	1679
a	PRON	O	O	1679
heterogeneous	ADJ	O	O	1679
manner	VERB	O	O	1679
.	PUNCT	O	O	1679
This	PRON	O	O	1680
report	VERB	O	O	1680
describes	VERB	O	O	1680
a	PRON	O	O	1680
patient	NOUN	O	O	1680
with	ADP	O	O	1680
mild	ADJ	O	O	1680
language delay	NOUN	O	Disease	1680
and	CCONJ	O	O	1680
mental retardation	NOUN	O	Disease	1680
,	PUNCT	O	O	1680
who	PRON	O	O	1680
was	AUX	O	O	1680
found	VERB	O	O	1680
to	PART	O	O	1680
have	VERB	O	O	1680
nonketotic hyperglycinemia	NOUN	O	Disease	1680
following	VERB	O	O	1680
her	PRON	O	O	1680
presentation	NOUN	O	O	1680
with	ADP	O	O	1680
acute	ADJ	O	O	1680
encephalopathy	NOUN	O	Disease	1680
and	CCONJ	O	O	1680
chorea	PROPN	O	Disease	1680
shortly	ADV	O	O	1680
after	ADP	O	O	1680
initiation	NOUN	O	O	1680
of	ADP	O	O	1680
valproate	VERB	O	Chemical	1680
therapy	NOUN	O	O	1680
.	PUNCT	O	O	1680
Microinjection	NOUN	O	O	1683
of	ADP	O	O	1683
ritanserin	NOUN	O	Chemical	1683
into	ADP	O	O	1683
the	PRON	O	O	1683
CA1	PROPN	O	O	1683
region	NOUN	O	O	1683
of	ADP	O	O	1683
hippocampus	NOUN	O	O	1683
improves	VERB	O	O	1683
scopolamine	NOUN	O	Chemical	1683
-	PUNCT	O	O	1683
induced	VERB	O	O	1683
amnesia	NOUN	O	Disease	1683
in	ADP	O	O	1683
adult	NOUN	O	O	1683
male	NOUN	O	O	1683
rats	NOUN	O	O	1683
.	PUNCT	O	O	1683
The	PRON	O	O	1684
effect	VERB	O	O	1684
of	ADP	O	O	1684
ritanserin	NOUN	O	Chemical	1684
(	PUNCT	O	O	1684
5-HT2	PROPN	O	O	1684
antagonist	NOUN	O	O	1684
)	PUNCT	O	O	1684
on	ADP	O	O	1684
scopolamine	NOUN	O	Chemical	1684
(	PUNCT	O	O	1684
muscarinic	PROPN	O	O	1684
cholinergic	ADJ	O	O	1684
antagonist)-induced	VERB	O	O	1684
amnesia	NOUN	O	Disease	1684
in	ADP	O	O	1684
Morris	PROPN	O	O	1684
water	PROPN	O	O	1684
maze	NOUN	O	O	1684
(	PUNCT	O	O	1684
MWM	PROPN	O	O	1684
)	PUNCT	O	O	1684
was	AUX	O	O	1684
investigated	VERB	O	O	1684
.	PUNCT	O	O	1684
One	NUM	O	O	1685
week	NOUN	O	O	1685
later	ADV	O	O	1685
,	PUNCT	O	O	1685
they	PRON	O	O	1685
received	VERB	O	O	1685
repeatedly	ADV	O	O	1685
vehicles	NOUN	O	O	1685
(	PUNCT	O	O	1685
saline	NOUN	O	O	1685
,	PUNCT	O	O	1685
DMSO	PROPN	O	Chemical	1685
,	PUNCT	O	O	1685
saline+DMSO	NOUN	O	O	1685
)	PUNCT	O	O	1685
,	PUNCT	O	O	1685
scopolamine	NOUN	O	Chemical	1685
(	PUNCT	O	O	1685
2	X	O	O	1685
microg/0.5	NUM	O	O	1685
microl	NOUN	O	O	1685
saline	NOUN	O	O	1685
/	PUNCT	O	O	1685
side	NOUN	O	O	1685
;	PUNCT	O	O	1685
30	NUM	O	O	1685
min	NOUN	O	O	1685
before	ADP	O	O	1685
training	NOUN	O	O	1685
)	PUNCT	O	O	1685
,	PUNCT	O	O	1685
ritanserin	NOUN	O	Chemical	1685
(	PUNCT	O	O	1685
2	X	O	O	1685
,	PUNCT	O	O	1685
4	NUM	O	O	1685
and	CCONJ	O	O	1685
8	NUM	O	O	1685
microg/0.5	NUM	O	O	1685
microl	NOUN	O	O	1685
DMSO	PROPN	O	Chemical	1685
/	PUNCT	O	O	1685
side	NOUN	O	O	1685
;	PUNCT	O	O	1685
20	NUM	O	O	1685
min	NOUN	O	O	1685
before	ADP	O	O	1685
training	NOUN	O	O	1685
)	PUNCT	O	O	1685
and	CCONJ	O	O	1685
scopolamine	NOUN	O	Chemical	1685
(	PUNCT	O	O	1685
2	X	O	O	1685
microg/0.5	NUM	O	O	1685
microl	NOUN	O	O	1685
;	PUNCT	O	O	1685
30	NUM	O	O	1686
min	NOUN	O	O	1686
before	ADP	O	O	1686
ritanserin	NOUN	O	Chemical	1686
injection)+ritanserin	NOUN	O	O	1686
(	PUNCT	O	O	1686
4	NUM	O	O	1686
microg/0.5	NUM	O	O	1686
microl	NOUN	O	O	1686
DMSO	PROPN	O	Chemical	1686
)	PUNCT	O	O	1686
through	ADP	O	O	1686
cannulae	NOUN	O	O	1686
each	PRON	O	O	1686
day	NOUN	O	O	1686
.	PUNCT	O	O	1686
The	PRON	O	O	1687
results	VERB	O	O	1687
showed	VERB	O	O	1687
a	PRON	O	O	1687
significant	ADJ	O	O	1687
increase	VERB	O	O	1687
in	ADP	O	O	1687
escape	VERB	O	O	1687
latencies	NOUN	O	O	1687
and	CCONJ	O	O	1687
traveled	VERB	O	O	1687
distances	NOUN	O	O	1687
to	PART	O	O	1687
find	VERB	O	O	1687
platform	NOUN	O	O	1687
in	ADP	O	O	1687
scopolamine	NOUN	O	Chemical	1687
-	PUNCT	O	O	1687
treated	VERB	O	O	1687
group	NOUN	O	O	1687
as	ADP	O	O	1687
compared	VERB	O	O	1687
to	PART	O	O	1687
saline	NOUN	O	O	1687
group	NOUN	O	O	1687
.	PUNCT	O	O	1687
Ritanserin	NOUN	O	Chemical	1688
-	PUNCT	O	O	1688
treated	VERB	O	O	1688
rats	NOUN	O	O	1688
(	PUNCT	O	O	1688
4	NUM	O	O	1688
microg/0.5	NUM	O	O	1688
microl	NOUN	O	O	1688
/	PUNCT	O	O	1688
side	NOUN	O	O	1688
)	PUNCT	O	O	1688
showed	VERB	O	O	1688
a	PRON	O	O	1688
significant	ADJ	O	O	1688
decrease	VERB	O	O	1688
in	ADP	O	O	1688
the	PRON	O	O	1688
mentioned	VERB	O	O	1688
parameters	NOUN	O	O	1688
as	ADP	O	O	1688
compared	VERB	O	O	1688
to	PART	O	O	1688
DMSO	PROPN	O	Chemical	1688
-	PUNCT	O	O	1688
treated	VERB	O	O	1688
group	NOUN	O	O	1688
.	PUNCT	O	O	1688
However	ADV	O	O	1689
,	PUNCT	O	O	1689
scopolamine	NOUN	O	Chemical	1689
and	CCONJ	O	O	1689
ritanserin	NOUN	O	Chemical	1689
co	NOUN	O	O	1689
-	PUNCT	O	O	1689
administration	NOUN	O	O	1689
resulted	VERB	O	O	1689
in	ADP	O	O	1689
a	PRON	O	O	1689
significant	ADJ	O	O	1689
decrease	VERB	O	O	1689
in	ADP	O	O	1689
escape	VERB	O	O	1689
latencies	NOUN	O	O	1689
and	CCONJ	O	O	1689
traveled	VERB	O	O	1689
distances	NOUN	O	O	1689
as	ADP	O	O	1689
compared	VERB	O	O	1689
to	PART	O	O	1689
the	PRON	O	O	1689
scopolamine	NOUN	O	Chemical	1689
-	PUNCT	O	O	1689
treated	VERB	O	O	1689
rats	NOUN	O	O	1689
.	PUNCT	O	O	1689
Our	PRON	O	O	1690
findings	NOUN	O	O	1690
show	VERB	O	O	1690
that	SCONJ	O	O	1690
microinjection	NOUN	O	O	1690
of	ADP	O	O	1690
ritanserin	NOUN	O	Chemical	1690
into	ADP	O	O	1690
the	PRON	O	O	1690
CA1	PROPN	O	O	1690
region	NOUN	O	O	1690
of	ADP	O	O	1690
the	PRON	O	O	1690
hippocampus	NOUN	O	O	1690
improves	VERB	O	O	1690
the	PRON	O	O	1690
scopolamine	NOUN	O	Chemical	1690
-	PUNCT	O	O	1690
induced	VERB	O	O	1690
amnesia	NOUN	O	Disease	1690
.	PUNCT	O	O	1690
Hypoxia	NOUN	O	Disease	1693
in	ADP	O	O	1693
renal disease	NOUN	O	Disease	1693
with	ADP	O	O	1693
proteinuria	X	O	Disease	1693
and/or	CCONJ	O	O	1693
glomerular	ADJ	O	O	1693
hypertension	NOUN	O	Disease	1693
.	PUNCT	O	O	1693
In	ADP	O	O	1694
this	PRON	O	O	1694
study	VERB	O	O	1694
,	PUNCT	O	O	1694
we	PRON	O	O	1694
developed	VERB	O	O	1694
a	PRON	O	O	1694
new	ADJ	O	O	1694
hypoxia	NOUN	O	Disease	1694
-	PUNCT	O	O	1694
responsive	ADJ	O	O	1694
reporter	NOUN	O	O	1694
vector	NOUN	O	O	1694
using	VERB	O	O	1694
a	PRON	O	O	1694
hypoxia	NOUN	O	Disease	1694
-	PUNCT	O	O	1694
responsive	ADJ	O	O	1694
element	NOUN	O	O	1694
of	ADP	O	O	1694
the	PRON	O	O	1694
5	NUM	O	O	1694
'	PUNCT	O	O	1694
vascular	ADJ	O	O	1694
endothelial	NOUN	O	O	1694
growth	NOUN	O	O	1694
factor	NOUN	O	O	1694
untranslated	ADJ	O	O	1694
region	NOUN	O	O	1694
and	CCONJ	O	O	1694
generated	VERB	O	O	1694
a	PRON	O	O	1694
novel	NOUN	O	O	1694
hypoxia	NOUN	O	Disease	1694
-	PUNCT	O	O	1694
sensing	VERB	O	O	1694
transgenic	NOUN	O	O	1694
rat	NOUN	O	O	1694
.	PUNCT	O	O	1694
We	PRON	O	O	1695
then	ADV	O	O	1695
applied	VERB	O	O	1695
this	PRON	O	O	1695
animal	NOUN	O	O	1695
model	NOUN	O	O	1695
to	PART	O	O	1695
the	PRON	O	O	1695
detection	NOUN	O	O	1695
of	ADP	O	O	1695
tubulointerstitial	ADJ	O	O	1695
hypoxia	NOUN	O	Disease	1695
in	ADP	O	O	1695
the	PRON	O	O	1695
diseased kidney	NOUN	O	Disease	1695
.	PUNCT	O	O	1695
With	ADP	O	O	1696
this	PRON	O	O	1696
model	NOUN	O	O	1696
,	PUNCT	O	O	1696
we	PRON	O	O	1696
were	AUX	O	O	1696
able	ADJ	O	O	1696
to	PART	O	O	1696
identify	VERB	O	O	1696
diffuse	VERB	O	O	1696
cortical	ADJ	O	O	1696
hypoxia	NOUN	O	Disease	1696
in	ADP	O	O	1696
the	PRON	O	O	1696
puromycin aminonucleoside	NOUN	O	Chemical	1696
-	PUNCT	O	O	1696
induced	VERB	O	O	1696
nephrotic syndrome	NOUN	O	Disease	1696
and	CCONJ	O	O	1696
focal	ADJ	O	O	1696
and	CCONJ	O	O	1696
segmental	ADJ	O	O	1696
hypoxia	NOUN	O	Disease	1696
in	ADP	O	O	1696
the	PRON	O	O	1696
remnant	ADJ	O	O	1696
kidney	NOUN	O	O	1696
model	NOUN	O	O	1696
.	PUNCT	O	O	1696
Expression	NOUN	O	O	1697
of	ADP	O	O	1697
the	PRON	O	O	1697
hypoxia	NOUN	O	Disease	1697
-	PUNCT	O	O	1697
responsive	ADJ	O	O	1697
transgene	NOUN	O	O	1697
increased	VERB	O	O	1697
throughout	ADP	O	O	1697
the	PRON	O	O	1697
observation	NOUN	O	O	1697
period	NOUN	O	O	1697
,	PUNCT	O	O	1697
reaching	VERB	O	O	1697
2.2-fold	ADV	O	O	1697
at	ADP	O	O	1697
2	X	O	O	1697
weeks	NOUN	O	O	1697
in	ADP	O	O	1697
the	PRON	O	O	1697
puromycin aminonucleoside	NOUN	O	Chemical	1697
model	NOUN	O	O	1697
and	CCONJ	O	O	1697
2.6-fold	ADV	O	O	1697
at	ADP	O	O	1697
4	NUM	O	O	1697
weeks	NOUN	O	O	1697
in	ADP	O	O	1697
the	PRON	O	O	1697
remnant	ADJ	O	O	1697
kidney	NOUN	O	O	1697
model	NOUN	O	O	1697
,	PUNCT	O	O	1697
whereas	SCONJ	O	O	1697
that	SCONJ	O	O	1697
of	ADP	O	O	1697
vascular	ADJ	O	O	1697
endothelial	NOUN	O	O	1697
growth	NOUN	O	O	1697
factor	NOUN	O	O	1697
showed	VERB	O	O	1697
a	PRON	O	O	1697
mild	ADJ	O	O	1697
decrease	VERB	O	O	1697
,	PUNCT	O	O	1697
reflecting	VERB	O	O	1697
distinct	ADJ	O	O	1697
behaviors	NOUN	O	O	1697
of	ADP	O	O	1697
the	PRON	O	O	1697
two	NUM	O	O	1697
genes	NOUN	O	O	1697
.	PUNCT	O	O	1697
The	PRON	O	O	1698
degree	PROPN	O	O	1698
of	ADP	O	O	1698
hypoxia	NOUN	O	Disease	1698
showed	VERB	O	O	1698
a	PRON	O	O	1698
positive	ADJ	O	O	1698
correlation	NOUN	O	O	1698
with	ADP	O	O	1698
microscopic	ADJ	O	O	1698
tubulointerstitial injury	NOUN	O	Disease	1698
in	ADP	O	O	1698
both	PRON	O	O	1698
models	NOUN	O	O	1698
.	PUNCT	O	O	1698
Finally	ADV	O	O	1699
,	PUNCT	O	O	1699
we	PRON	O	O	1699
identified	VERB	O	O	1699
the	PRON	O	O	1699
localization	NOUN	O	O	1699
of	ADP	O	O	1699
proliferating	VERB	O	O	1699
cell	NOUN	O	O	1699
nuclear	ADJ	O	O	1699
antigen	PROPN	O	O	1699
-	PUNCT	O	O	1699
positive	ADJ	O	O	1699
,	PUNCT	O	O	1699
ED-1-positive	ADJ	O	O	1699
,	PUNCT	O	O	1699
and	CCONJ	O	O	1699
terminal	PROPN	O	O	1699
dUTP	PROPN	O	O	1699
nick	PROPN	O	O	1699
-	PUNCT	O	O	1699
end	VERB	O	O	1699
labeled	VERB	O	O	1699
-	PUNCT	O	O	1699
positive	ADJ	O	O	1699
cells	NOUN	O	O	1699
in	ADP	O	O	1699
the	PRON	O	O	1699
hypoxic	ADJ	O	Disease	1699
cortical	ADJ	O	O	1699
area	NOUN	O	O	1699
in	ADP	O	O	1699
the	PRON	O	O	1699
remnant	ADJ	O	O	1699
kidney	NOUN	O	O	1699
model	NOUN	O	O	1699
.	PUNCT	O	O	1699
We	PRON	O	O	1700
propose	VERB	O	O	1700
here	ADV	O	O	1700
a	PRON	O	O	1700
possible	ADJ	O	O	1700
pathological	ADJ	O	O	1700
tie	VERB	O	O	1700
between	ADP	O	O	1700
chronic	ADJ	O	O	1700
tubulointerstitial	ADJ	O	O	1700
hypoxia	NOUN	O	Disease	1700
and	CCONJ	O	O	1700
progressive	ADJ	O	O	1700
glomerular diseases	NOUN	O	Disease	1700
.	PUNCT	O	O	1700
Consensus	NOUN	O	O	1703
statement	NOUN	O	O	1703
concerning	VERB	O	O	1703
cardiotoxicity	NOUN	O	Disease	1703
occurring	VERB	O	O	1703
during	ADP	O	O	1703
haematopoietic	VERB	O	O	1703
stem	VERB	O	O	1703
cell	NOUN	O	O	1703
transplantation	NOUN	O	O	1703
in	ADP	O	O	1703
the	PRON	O	O	1703
treatment	NOUN	O	O	1703
of	ADP	O	O	1703
autoimmune diseases	NOUN	O	Disease	1703
,	PUNCT	O	O	1703
with	ADP	O	O	1703
special	ADJ	O	O	1703
reference	NOUN	O	O	1703
to	PART	O	O	1703
systemic sclerosis	NOUN	O	Disease	1703
and	CCONJ	O	O	1703
multiple sclerosis	NOUN	O	Disease	1703
.	PUNCT	O	O	1703
Autologous	ADJ	O	O	1704
haematopoietic	VERB	O	O	1704
stem	VERB	O	O	1704
cell	NOUN	O	O	1704
transplantation	NOUN	O	O	1704
is	AUX	O	O	1704
now	ADV	O	O	1704
a	PRON	O	O	1704
feasible	ADJ	O	O	1704
and	CCONJ	O	O	1704
effective	ADJ	O	O	1704
treatment	NOUN	O	O	1704
for	ADP	O	O	1704
selected	VERB	O	O	1704
patients	NOUN	O	O	1704
with	ADP	O	O	1704
severe	ADJ	O	O	1704
autoimmune diseases	NOUN	O	Disease	1704
.	PUNCT	O	O	1704
This	PRON	O	O	1705
is	AUX	O	O	1705
primarily	ADV	O	O	1705
due	ADJ	O	O	1705
to	PART	O	O	1705
complications	NOUN	O	O	1705
related	ADJ	O	O	1705
to	PART	O	O	1705
either	ADV	O	O	1705
the	PRON	O	O	1705
stage	NOUN	O	O	1705
of	ADP	O	O	1705
the	PRON	O	O	1705
disease	PROPN	O	O	1705
at	ADP	O	O	1705
transplant	NOUN	O	O	1705
or	CCONJ	O	O	1705
due	ADJ	O	O	1705
to	PART	O	O	1705
infections	NOUN	O	Disease	1705
.	PUNCT	O	O	1705
The	PRON	O	O	1706
number	NOUN	O	O	1706
of	ADP	O	O	1706
deaths	NOUN	O	O	1706
related	ADJ	O	O	1706
to	PART	O	O	1706
cardiac toxicity	NOUN	O	Disease	1706
is	AUX	O	O	1706
low	ADJ	O	O	1706
.	PUNCT	O	O	1706
However	ADV	O	O	1707
,	PUNCT	O	O	1707
caution	NOUN	O	O	1707
is	AUX	O	O	1707
required	VERB	O	O	1707
when	SCONJ	O	O	1707
cyclophosphamide	VERB	O	Chemical	1707
or	CCONJ	O	O	1707
anthracyclines	NOUN	O	Chemical	1707
such	ADJ	O	O	1707
as	ADP	O	O	1707
mitoxantrone	NOUN	O	Chemical	1707
are	AUX	O	O	1707
used	VERB	O	O	1707
in	ADP	O	O	1707
patients	NOUN	O	O	1707
with	ADP	O	O	1707
a	PRON	O	O	1707
possible	ADJ	O	O	1707
underlying	VERB	O	O	1707
heart damage	NOUN	O	Disease	1707
,	PUNCT	O	O	1707
for	ADP	O	O	1707
example	NOUN	O	O	1707
,	PUNCT	O	O	1707
systemic sclerosis	NOUN	O	Disease	1707
patients	NOUN	O	O	1707
.	PUNCT	O	O	1707
The	PRON	O	O	1708
object	NOUN	O	O	1708
of	ADP	O	O	1708
the	PRON	O	O	1708
meeting	NOUN	O	O	1708
was	AUX	O	O	1708
to	PART	O	O	1708
analyse	VERB	O	O	1708
existing	VERB	O	O	1708
data	NOUN	O	O	1708
,	PUNCT	O	O	1708
both	PRON	O	O	1708
published	VERB	O	O	1708
or	CCONJ	O	O	1708
available	ADJ	O	O	1708
,	PUNCT	O	O	1708
in	ADP	O	O	1708
the	PRON	O	O	1708
European	ADJ	O	O	1708
Group	PROPN	O	O	1708
for	ADP	O	O	1708
Blood	NOUN	O	O	1708
and	CCONJ	O	O	1708
Marrow	PROPN	O	O	1708
Transplantation	NOUN	O	O	1708
autoimmune disease	NOUN	O	Disease	1708
database	NOUN	O	O	1708
,	PUNCT	O	O	1708
and	CCONJ	O	O	1708
to	PART	O	O	1708
propose	VERB	O	O	1708
a	PRON	O	O	1708
safe	ADJ	O	O	1708
approach	NOUN	O	O	1708
to	PART	O	O	1708
such	ADJ	O	O	1708
patients	NOUN	O	O	1708
.	PUNCT	O	O	1708
Immunohistochemical	PROPN	O	O	1711
study	VERB	O	O	1711
on	ADP	O	O	1711
inducible	VERB	O	O	1711
type	NOUN	O	O	1711
of	ADP	O	O	1711
nitric oxide	NOUN	O	Chemical	1711
(	PUNCT	O	O	1711
iNOS	PROPN	O	O	1711
)	PUNCT	O	O	1711
,	PUNCT	O	O	1711
basic	ADJ	O	O	1711
fibroblast	NOUN	O	O	1711
growth	NOUN	O	O	1711
factor	NOUN	O	O	1711
(	PUNCT	O	O	1711
bFGF	NOUN	O	O	1711
)	PUNCT	O	O	1711
and	CCONJ	O	O	1711
tumor	NOUN	O	Disease	1711
growth	NOUN	O	O	1711
factor	NOUN	O	O	1711
-	PUNCT	O	O	1711
beta1	NOUN	O	O	1711
(	PUNCT	O	O	1711
TGF	PROPN	O	O	1711
-	PUNCT	O	O	1711
beta1	NOUN	O	O	1711
)	PUNCT	O	O	1711
in	ADP	O	O	1711
arteritis	NOUN	O	Disease	1711
induced	VERB	O	O	1711
in	ADP	O	O	1711
rats	NOUN	O	O	1711
by	ADP	O	O	1711
fenoldopam	NOUN	O	Chemical	1711
and	CCONJ	O	O	1711
theophylline	ADV	O	Chemical	1711
,	PUNCT	O	O	1711
vasodilators	NOUN	O	O	1711
.	PUNCT	O	O	1711
Arteritis	PROPN	O	Disease	1712
induced	VERB	O	O	1712
in	ADP	O	O	1712
rats	NOUN	O	O	1712
by	ADP	O	O	1712
vasodilators	NOUN	O	O	1712
,	PUNCT	O	O	1712
fenoldopam	NOUN	O	Chemical	1712
and	CCONJ	O	O	1712
theophylline	ADV	O	Chemical	1712
,	PUNCT	O	O	1712
was	AUX	O	O	1712
examined	VERB	O	O	1712
immunohistochemically	ADV	O	O	1712
for	ADP	O	O	1712
expressions	NOUN	O	O	1712
of	ADP	O	O	1712
inducible	VERB	O	O	1712
type	NOUN	O	O	1712
of	ADP	O	O	1712
nitric oxide	NOUN	O	Chemical	1712
synthase	NOUN	O	O	1712
(	PUNCT	O	O	1712
iNOS	PROPN	O	O	1712
)	PUNCT	O	O	1712
,	PUNCT	O	O	1712
basic	ADJ	O	O	1712
fibroblast	NOUN	O	O	1712
growth	NOUN	O	O	1712
factor	NOUN	O	O	1712
(	PUNCT	O	O	1712
bFGF	NOUN	O	O	1712
)	PUNCT	O	O	1712
and	CCONJ	O	O	1712
tumor	NOUN	O	Disease	1712
growth	NOUN	O	O	1712
factor	NOUN	O	O	1712
-	PUNCT	O	O	1712
beta1	NOUN	O	O	1712
(	PUNCT	O	O	1712
TGF	PROPN	O	O	1712
-	PUNCT	O	O	1712
beta1	NOUN	O	O	1712
)	PUNCT	O	O	1712
.	PUNCT	O	O	1712
Rats	NOUN	O	O	1713
were	AUX	O	O	1713
administered	VERB	O	O	1713
fenoldopam	NOUN	O	Chemical	1713
for	ADP	O	O	1713
24	NUM	O	O	1713
hours	NOUN	O	O	1713
by	ADP	O	O	1713
intravenous	ADJ	O	O	1713
infusion	NOUN	O	O	1713
with	ADP	O	O	1713
or	CCONJ	O	O	1713
without	ADP	O	O	1713
following	VERB	O	O	1713
repeated	VERB	O	O	1713
daily	ADV	O	O	1713
oral	ADJ	O	O	1713
administrations	NOUN	O	O	1713
of	ADP	O	O	1713
theophylline	ADV	O	Chemical	1713
.	PUNCT	O	O	1713
Irrespective	PROPN	O	O	1714
of	ADP	O	O	1714
theophylline	ADV	O	Chemical	1714
administration	NOUN	O	O	1714
,	PUNCT	O	O	1714
iNOS	PROPN	O	O	1714
antigens	NOUN	O	O	1714
were	AUX	O	O	1714
remarkably	ADV	O	O	1714
abundant	ADJ	O	O	1714
in	ADP	O	O	1714
ED-1-positive	ADJ	O	O	1714
cells	NOUN	O	O	1714
on	ADP	O	O	1714
day	NOUN	O	O	1714
5	NUM	O	O	1714
and	CCONJ	O	O	1714
8	NUM	O	O	1714
post	VERB	O	O	1714
-	PUNCT	O	O	1714
fenoldopam	NOUN	O	Chemical	1714
-	PUNCT	O	O	1714
infusion	NOUN	O	O	1714
(	PUNCT	O	O	1714
DPI	PROPN	O	O	1714
)	PUNCT	O	O	1714
;	PUNCT	O	O	1714
bFGF	NOUN	O	O	1714
antigens	NOUN	O	O	1714
were	AUX	O	O	1714
remarkably	ADV	O	O	1714
abundant	ADJ	O	O	1714
in	ADP	O	O	1714
ED-1-positive	ADJ	O	O	1714
cells	NOUN	O	O	1714
on	ADP	O	O	1714
1	X	O	O	1714
and	CCONJ	O	O	1714
3	X	O	O	1714
DPI	PROPN	O	O	1714
;	PUNCT	O	O	1714
TGF	PROPN	O	O	1714
-	PUNCT	O	O	1714
beta1	NOUN	O	O	1714
antigens	NOUN	O	O	1714
were	AUX	O	O	1714
observed	VERB	O	O	1714
in	ADP	O	O	1714
ED-1-positive	ADJ	O	O	1714
cells	NOUN	O	O	1714
on	ADP	O	O	1714
and	CCONJ	O	O	1714
after	ADP	O	O	1714
5	NUM	O	O	1714
DPI	PROPN	O	O	1714
.	PUNCT	O	O	1714
These	PRON	O	O	1715
results	VERB	O	O	1715
suggest	VERB	O	O	1715
that	SCONJ	O	O	1715
the	PRON	O	O	1715
peak	PROPN	O	O	1715
expression	NOUN	O	O	1715
of	ADP	O	O	1715
iNOS	PROPN	O	O	1715
antigen	PROPN	O	O	1715
was	AUX	O	O	1715
followed	VERB	O	O	1715
by	ADP	O	O	1715
that	SCONJ	O	O	1715
of	ADP	O	O	1715
bFGF	NOUN	O	O	1715
antigen	PROPN	O	O	1715
,	PUNCT	O	O	1715
and	CCONJ	O	O	1715
bFGF	NOUN	O	O	1715
may	AUX	O	O	1715
have	VERB	O	O	1715
a	PRON	O	O	1715
suppressive	ADJ	O	O	1715
effect	VERB	O	O	1715
on	ADP	O	O	1715
iNOS	PROPN	O	O	1715
expression	NOUN	O	O	1715
in	ADP	O	O	1715
these	PRON	O	O	1715
rat	NOUN	O	O	1715
arteritis	NOUN	O	Disease	1715
models	NOUN	O	O	1715
.	PUNCT	O	O	1715
Low	ADJ	O	O	1718
-	PUNCT	O	O	1718
molecular	ADJ	O	O	1718
-	PUNCT	O	O	1718
weight	NOUN	O	O	1718
heparin	NOUN	O	Chemical	1718
for	ADP	O	O	1718
the	PRON	O	O	1718
treatment	NOUN	O	O	1718
of	ADP	O	O	1718
patients	NOUN	O	O	1718
with	ADP	O	O	1718
mechanical	ADJ	O	O	1718
heart	NOUN	O	O	1718
valves	NOUN	O	O	1718
.	PUNCT	O	O	1718
Unfractionated heparin	NOUN	O	Chemical	1719
(	PUNCT	O	O	1719
UH	INTJ	O	Chemical	1719
)	PUNCT	O	O	1719
is	AUX	O	O	1719
currently	ADV	O	O	1719
the	PRON	O	O	1719
substitute	NOUN	O	O	1719
for	ADP	O	O	1719
selected	VERB	O	O	1719
patients	NOUN	O	O	1719
.	PUNCT	O	O	1719
Low	ADJ	O	O	1720
-	PUNCT	O	O	1720
molecular	ADJ	O	O	1720
-	PUNCT	O	O	1720
weight	NOUN	O	O	1720
heparin	NOUN	O	Chemical	1720
(	PUNCT	O	O	1720
LMWH	VERB	O	Chemical	1720
)	PUNCT	O	O	1720
offers	VERB	O	O	1720
theoretical	ADJ	O	O	1720
advantages	NOUN	O	O	1720
over	ADP	O	O	1720
UH	INTJ	O	Chemical	1720
,	PUNCT	O	O	1720
but	CCONJ	O	O	1720
is	AUX	O	O	1720
not	PART	O	O	1720
currently	ADV	O	O	1720
considered	VERB	O	O	1720
in	ADP	O	O	1720
clinical	ADJ	O	O	1720
guidelines	NOUN	O	O	1720
as	ADP	O	O	1720
an	PRON	O	O	1720
alternative	ADV	O	O	1720
to	PART	O	O	1720
UH	INTJ	O	Chemical	1720
in	ADP	O	O	1720
patients	NOUN	O	O	1720
with	ADP	O	O	1720
prosthetic	ADJ	O	O	1720
valves	NOUN	O	O	1720
.	PUNCT	O	O	1720
The	PRON	O	O	1721
aim	VERB	O	O	1721
of	ADP	O	O	1721
the	PRON	O	O	1721
present	NOUN	O	O	1721
study	VERB	O	O	1721
was	AUX	O	O	1721
to	PART	O	O	1721
review	VERB	O	O	1721
the	PRON	O	O	1721
data	NOUN	O	O	1721
accumulated	VERB	O	O	1721
so	ADV	O	O	1721
far	ADV	O	O	1721
on	ADP	O	O	1721
the	PRON	O	O	1721
use	VERB	O	O	1721
of	ADP	O	O	1721
LMWH	VERB	O	Chemical	1721
in	ADP	O	O	1721
this	PRON	O	O	1721
patient	NOUN	O	O	1721
population	NOUN	O	O	1721
and	CCONJ	O	O	1721
to	PART	O	O	1721
discuss	VERB	O	O	1721
its	PRON	O	O	1721
applicability	NOUN	O	O	1721
in	ADP	O	O	1721
common	ADJ	O	O	1721
practice	VERB	O	O	1721
.	PUNCT	O	O	1721
METHODS	NOUN	O	O	1722
:	PUNCT	O	O	1722
For	ADP	O	O	1722
this	PRON	O	O	1722
paper	PROPN	O	O	1722
,	PUNCT	O	O	1722
the	PRON	O	O	1722
current	ADJ	O	O	1722
medical	ADJ	O	O	1722
literature	NOUN	O	O	1722
on	ADP	O	O	1722
LMWH	VERB	O	Chemical	1722
in	ADP	O	O	1722
patients	NOUN	O	O	1722
with	ADP	O	O	1722
mechanical	ADJ	O	O	1722
heart	NOUN	O	O	1722
valves	NOUN	O	O	1722
was	AUX	O	O	1722
extensively	ADV	O	O	1722
reviewed	VERB	O	O	1722
.	PUNCT	O	O	1722
Data	NOUN	O	O	1723
to	PART	O	O	1723
establish	VERB	O	O	1723
the	PRON	O	O	1723
thromboembolic	PROPN	O	Disease	1723
risk	NOUN	O	O	1723
were	AUX	O	O	1723
incomplete	ADJ	O	O	1723
.	PUNCT	O	O	1723
The	PRON	O	O	1724
incidence	NOUN	O	O	1724
rate	NOUN	O	O	1724
of	ADP	O	O	1724
thromboembolism	NOUN	O	Disease	1724
was	AUX	O	O	1724
0.9%	NOUN	O	O	1724
for	ADP	O	O	1724
all	PRON	O	O	1724
the	PRON	O	O	1724
studies	NOUN	O	O	1724
and	CCONJ	O	O	1724
0.5	NUM	O	O	1724
,	PUNCT	O	O	1724
0	NUM	O	O	1724
,	PUNCT	O	O	1724
20	NUM	O	O	1724
,	PUNCT	O	O	1724
and	CCONJ	O	O	1724
0%	NOUN	O	O	1724
in	ADP	O	O	1724
groups	NOUN	O	O	1724
a	PRON	O	O	1724
,	PUNCT	O	O	1724
b	X	O	O	1724
,	PUNCT	O	O	1724
c	X	O	O	1724
,	PUNCT	O	O	1724
and	CCONJ	O	O	1724
d	X	O	O	1724
,	PUNCT	O	O	1724
respectively	ADV	O	O	1724
;	PUNCT	O	O	1724
for	ADP	O	O	1724
hemorrhage	NOUN	O	Disease	1724
,	PUNCT	O	O	1724
the	PRON	O	O	1724
overall	ADV	O	O	1724
rate	NOUN	O	O	1724
was	AUX	O	O	1724
3.4%	NOUN	O	O	1724
(	PUNCT	O	O	1724
3.8	NUM	O	O	1724
,	PUNCT	O	O	1724
2.6	NUM	O	O	1724
,	PUNCT	O	O	1724
10	NUM	O	O	1724
,	PUNCT	O	O	1724
and	CCONJ	O	O	1724
0%	NOUN	O	O	1724
for	ADP	O	O	1724
the	PRON	O	O	1724
respective	ADJ	O	O	1724
groups	NOUN	O	O	1724
)	PUNCT	O	O	1724
.	PUNCT	O	O	1724
In	ADP	O	O	1725
patients	NOUN	O	O	1725
with	ADP	O	O	1725
mechanical	ADJ	O	O	1725
heart	NOUN	O	O	1725
valves	NOUN	O	O	1725
,	PUNCT	O	O	1725
short	ADJ	O	O	1725
-	PUNCT	O	O	1725
term	NOUN	O	O	1725
LMWH	VERB	O	Chemical	1725
therapy	NOUN	O	O	1725
compares	VERB	O	O	1725
favorably	ADV	O	O	1725
with	ADP	O	O	1725
UH	INTJ	O	Chemical	1725
.	PUNCT	O	O	1725
Data	NOUN	O	O	1726
on	ADP	O	O	1726
mid-	ADV	O	O	1726
and	CCONJ	O	O	1726
long	ADV	O	O	1726
-	PUNCT	O	O	1726
term	NOUN	O	O	1726
LMWH	VERB	O	Chemical	1726
administration	NOUN	O	O	1726
in	ADP	O	O	1726
these	PRON	O	O	1726
patients	NOUN	O	O	1726
are	AUX	O	O	1726
sparse	ADJ	O	O	1726
.	PUNCT	O	O	1726
Further	ADV	O	O	1727
randomized	VERB	O	O	1727
studies	NOUN	O	O	1727
are	AUX	O	O	1727
needed	VERB	O	O	1727
to	PART	O	O	1727
confirm	VERB	O	O	1727
the	PRON	O	O	1727
safety	NOUN	O	O	1727
and	CCONJ	O	O	1727
precise	ADJ	O	O	1727
indications	NOUN	O	O	1727
for	ADP	O	O	1727
the	PRON	O	O	1727
use	VERB	O	O	1727
of	ADP	O	O	1727
LMWH	VERB	O	Chemical	1727
in	ADP	O	O	1727
patients	NOUN	O	O	1727
with	ADP	O	O	1727
mechanical	ADJ	O	O	1727
heart	NOUN	O	O	1727
valves	NOUN	O	O	1727
.	PUNCT	O	O	1727
Topiramate	PROPN	O	Chemical	1730
-	PUNCT	O	O	1730
induced	VERB	O	O	1730
nephrolithiasis	NOUN	O	Disease	1730
.	PUNCT	O	O	1730
Topiramate	PROPN	O	Chemical	1731
is	AUX	O	O	1731
a	PRON	O	O	1731
recently	ADV	O	O	1731
developed	VERB	O	O	1731
antiepileptic	ADJ	O	O	1731
medication	NOUN	O	O	1731
that	SCONJ	O	O	1731
is	AUX	O	O	1731
becoming	VERB	O	O	1731
more	ADJ	O	O	1731
widely	ADV	O	O	1731
prescribed	VERB	O	O	1731
because	SCONJ	O	O	1731
of	ADP	O	O	1731
its	PRON	O	O	1731
efficacy	NOUN	O	O	1731
in	ADP	O	O	1731
treating	VERB	O	O	1731
refractory seizures	NOUN	O	Disease	1731
.	PUNCT	O	O	1731
Urologists	NOUN	O	O	1732
should	AUX	O	O	1732
be	AUX	O	O	1732
aware	ADJ	O	O	1732
that	SCONJ	O	O	1732
this	PRON	O	O	1732
medication	NOUN	O	O	1732
can	AUX	O	O	1732
cause	VERB	O	O	1732
metabolic acidosis	NOUN	O	Disease	1732
in	ADP	O	O	1732
patients	NOUN	O	O	1732
secondary	ADJ	O	O	1732
to	PART	O	O	1732
inhibition	NOUN	O	O	1732
of	ADP	O	O	1732
carbonic	ADJ	O	O	1732
anhydrase	NOUN	O	O	1732
.	PUNCT	O	O	1732
These	PRON	O	O	1733
factors	NOUN	O	O	1733
can	AUX	O	O	1733
lead	VERB	O	Chemical	1733
to	PART	O	O	1733
the	PRON	O	O	1733
development	NOUN	O	O	1733
of	ADP	O	O	1733
calcium phosphate	NOUN	O	Chemical	1733
nephrolithiasis	NOUN	O	Disease	1733
.	PUNCT	O	O	1733
We	PRON	O	O	1734
report	VERB	O	O	1734
the	PRON	O	O	1734
first	ADV	O	O	1734
two	NUM	O	O	1734
cases	NOUN	O	O	1734
of	ADP	O	O	1734
topiramate	VERB	O	Chemical	1734
-	PUNCT	O	O	1734
induced	VERB	O	O	1734
nephrolithiasis	NOUN	O	Disease	1734
in	ADP	O	O	1734
the	PRON	O	O	1734
urologic	ADJ	O	O	1734
literature	NOUN	O	O	1734
.	PUNCT	O	O	1734
Spironolactone	NOUN	O	Chemical	1737
:	PUNCT	O	O	1737
is	AUX	O	O	1737
it	PRON	O	O	1737
a	PRON	O	O	1737
novel	NOUN	O	O	1737
drug	NOUN	O	O	1737
for	ADP	O	O	1737
the	PRON	O	O	1737
prevention	NOUN	O	O	1737
of	ADP	O	O	1737
amphotericin B	NOUN	O	Chemical	1737
-	PUNCT	O	O	1737
related	ADJ	O	O	1737
hypokalemia	PROPN	O	Disease	1737
in	ADP	O	O	1737
cancer	NOUN	O	Disease	1737
patients	NOUN	O	O	1737
?	PUNCT	O	O	1737
OBJECTIVE	VERB	O	O	1738
:	PUNCT	O	O	1738
Nephrotoxicity	NOUN	O	Disease	1738
is	AUX	O	O	1738
the	PRON	O	O	1738
major	ADJ	O	O	1738
adverse	ADJ	O	O	1738
effect	VERB	O	O	1738
of	ADP	O	O	1738
amphotericin B	NOUN	O	Chemical	1738
(	PUNCT	O	O	1738
AmB	PROPN	O	Chemical	1738
)	PUNCT	O	O	1738
,	PUNCT	O	O	1738
often	ADV	O	O	1738
limiting	VERB	O	O	1738
administration	NOUN	O	O	1738
of	ADP	O	O	1738
full	ADJ	O	O	1738
dosage	NOUN	O	O	1738
.	PUNCT	O	O	1738
Selective	PROPN	O	O	1739
distal	NOUN	O	O	1739
tubular	ADJ	O	O	1739
epithelial	ADJ	O	O	1739
toxicity	NOUN	O	Disease	1739
seems	VERB	O	O	1739
to	PART	O	O	1739
be	AUX	O	O	1739
responsible	ADJ	O	O	1739
for	ADP	O	O	1739
the	PRON	O	O	1739
profound	ADJ	O	O	1739
potassium	NOUN	O	Chemical	1739
wasting	VERB	O	O	1739
that	SCONJ	O	O	1739
is	AUX	O	O	1739
a	PRON	O	O	1739
major	ADJ	O	O	1739
clinical	ADJ	O	O	1739
side	NOUN	O	O	1739
effect	VERB	O	O	1739
of	ADP	O	O	1739
treatment	NOUN	O	O	1739
with	ADP	O	O	1739
AmB.	NOUN	O	O	1739
Potassium	NOUN	O	Chemical	1739
depletion	NOUN	O	O	1739
also	ADV	O	O	1739
potentiates	VERB	O	O	1739
the	PRON	O	O	1739
tubular	ADJ	O	O	1739
toxicity	NOUN	O	Disease	1739
of	ADP	O	O	1739
AmB.	NOUN	O	O	1739
This	PRON	O	O	1740
study	VERB	O	O	1740
was	AUX	O	O	1740
designed	VERB	O	O	1740
to	PART	O	O	1740
assess	VERB	O	O	1740
the	PRON	O	O	1740
ability	NOUN	O	O	1740
of	ADP	O	O	1740
spironolactone	NOUN	O	Chemical	1740
to	PART	O	O	1740
reduce	VERB	O	O	1740
potassium	NOUN	O	Chemical	1740
requirements	NOUN	O	O	1740
and	CCONJ	O	O	1740
to	PART	O	O	1740
prevent	VERB	O	O	1740
hypokalemia	PROPN	O	Disease	1740
in	ADP	O	O	1740
neutropenic	ADJ	O	Disease	1740
patients	NOUN	O	O	1740
on	ADP	O	O	1740
AmB	PROPN	O	Chemical	1740
treatment	NOUN	O	O	1740
.	PUNCT	O	O	1740
In	ADP	O	O	1741
this	PRON	O	O	1741
study	VERB	O	O	1741
26	NUM	O	O	1741
patients	NOUN	O	O	1741
with	ADP	O	O	1741
various	ADJ	O	O	1741
hematological disorders	NOUN	O	Disease	1741
were	AUX	O	O	1741
randomized	VERB	O	O	1741
to	PART	O	O	1741
receive	VERB	O	O	1741
either	ADV	O	O	1741
intravenous	ADJ	O	O	1741
AmB	PROPN	O	Chemical	1741
alone	ADV	O	O	1741
or	CCONJ	O	O	1741
AmB	PROPN	O	Chemical	1741
and	CCONJ	O	O	1741
oral	ADJ	O	O	1741
spironolactone	NOUN	O	Chemical	1741
100	NUM	O	O	1741
mg	VERB	O	O	1741
twice	ADV	O	O	1741
daily	ADV	O	O	1741
when	SCONJ	O	O	1741
developing	VERB	O	O	1741
a	PRON	O	O	1741
proven	VERB	O	O	1741
or	CCONJ	O	O	1741
suspected	VERB	O	O	1741
fungal infection	NOUN	O	Disease	1741
.	PUNCT	O	O	1741
Patients	NOUN	O	O	1742
receiving	VERB	O	O	1742
concomitant	ADJ	O	O	1742
AmB	PROPN	O	Chemical	1742
and	CCONJ	O	O	1742
spironolactone	NOUN	O	Chemical	1742
had	VERB	O	O	1742
significantly	ADV	O	O	1742
higher	ADJ	O	O	1742
plasma	NOUN	O	O	1742
potassium	NOUN	O	Chemical	1742
levels	NOUN	O	O	1742
than	ADP	O	O	1742
those	PRON	O	O	1742
receiving	VERB	O	O	1742
AmB	PROPN	O	Chemical	1742
alone	ADV	O	O	1742
(	PUNCT	O	O	1742
P	NOUN	O	Chemical	1742
=	PUNCT	O	O	1742
0.0027	NUM	O	O	1742
)	PUNCT	O	O	1742
.	PUNCT	O	O	1742
Those	PRON	O	O	1743
patients	NOUN	O	O	1743
receiving	VERB	O	O	1743
AmB	PROPN	O	Chemical	1743
and	CCONJ	O	O	1743
spironolactone	NOUN	O	Chemical	1743
required	VERB	O	O	1743
significantly	ADV	O	O	1743
less	ADV	O	O	1743
potassium	NOUN	O	Chemical	1743
supplementation	NOUN	O	O	1743
to	PART	O	O	1743
maintain	VERB	O	O	1743
their	PRON	O	O	1743
plasma	NOUN	O	O	1743
potassium	NOUN	O	Chemical	1743
within	ADP	O	O	1743
the	PRON	O	O	1743
normal	ADJ	O	O	1743
range	VERB	O	O	1743
(	PUNCT	O	O	1743
P	NOUN	O	Chemical	1743
=	PUNCT	O	O	1743
0.022	NUM	O	O	1743
)	PUNCT	O	O	1743
.	PUNCT	O	O	1743
Moreover	ADV	O	O	1744
,	PUNCT	O	O	1744
urinary	ADJ	O	O	1744
potassium	NOUN	O	Chemical	1744
losses	NOUN	O	O	1744
were	AUX	O	O	1744
significantly	ADV	O	O	1744
less	ADV	O	O	1744
in	ADP	O	O	1744
patients	NOUN	O	O	1744
receiving	VERB	O	O	1744
AmB	PROPN	O	Chemical	1744
and	CCONJ	O	O	1744
spironolactone	NOUN	O	Chemical	1744
than	ADP	O	O	1744
those	PRON	O	O	1744
receiving	VERB	O	O	1744
AmB	PROPN	O	Chemical	1744
alone	ADV	O	O	1744
(	PUNCT	O	O	1744
P	NOUN	O	Chemical	1744
=	PUNCT	O	O	1744
0.040	NUM	O	O	1744
)	PUNCT	O	O	1744
.	PUNCT	O	O	1744
This	PRON	O	O	1745
study	VERB	O	O	1745
showed	VERB	O	O	1745
that	SCONJ	O	O	1745
spironolactone	NOUN	O	Chemical	1745
can	AUX	O	O	1745
reduce	VERB	O	O	1745
potassium	NOUN	O	Chemical	1745
requirements	NOUN	O	O	1745
and	CCONJ	O	O	1745
prevent	VERB	O	O	1745
hypokalemia	PROPN	O	Disease	1745
by	ADP	O	O	1745
reducing	VERB	O	O	1745
urinary	ADJ	O	O	1745
potassium	NOUN	O	Chemical	1745
loss	NOUN	O	O	1745
in	ADP	O	O	1745
neutropenic	ADJ	O	Disease	1745
patients	NOUN	O	O	1745
on	ADP	O	O	1745
AmB	PROPN	O	Chemical	1745
treatment	NOUN	O	O	1745
.	PUNCT	O	O	1745
Dopamine	NOUN	O	Chemical	1748
D2	NOUN	O	O	1748
receptor	NOUN	O	O	1748
signaling	VERB	O	O	1748
controls	VERB	O	O	1748
neuronal	ADJ	O	O	1748
cell	NOUN	O	O	1748
death	NOUN	O	O	1748
induced	VERB	O	O	1748
by	ADP	O	O	1748
muscarinic	PROPN	O	O	1748
and	CCONJ	O	O	1748
glutamatergic	ADJ	O	O	1748
drugs	NOUN	O	O	1748
.	PUNCT	O	O	1748
Dopamine	NOUN	O	Chemical	1749
(	PUNCT	O	O	1749
DA	NOUN	O	Chemical	1749
)	PUNCT	O	O	1749
,	PUNCT	O	O	1749
through	ADP	O	O	1749
D1/D2	PROPN	O	O	1749
receptor	NOUN	O	O	1749
-	PUNCT	O	O	1749
mediated	VERB	O	O	1749
signaling	VERB	O	O	1749
,	PUNCT	O	O	1749
plays	VERB	O	O	1749
a	PRON	O	O	1749
major	ADJ	O	O	1749
role	NOUN	O	O	1749
in	ADP	O	O	1749
the	PRON	O	O	1749
control	VERB	O	O	1749
of	ADP	O	O	1749
epileptic seizures	NOUN	O	Disease	1749
arising	VERB	O	O	1749
in	ADP	O	O	1749
the	PRON	O	O	1749
limbic	PROPN	O	O	1749
system	NOUN	O	O	1749
.	PUNCT	O	O	1749
Excitotoxicity	NOUN	O	Disease	1750
leading	VERB	O	O	1750
to	PART	O	O	1750
neuronal	ADJ	O	O	1750
cell	NOUN	O	O	1750
death	NOUN	O	O	1750
in	ADP	O	O	1750
the	PRON	O	O	1750
affected	VERB	O	O	1750
areas	NOUN	O	O	1750
is	AUX	O	O	1750
a	PRON	O	O	1750
major	ADJ	O	O	1750
consequence	NOUN	O	O	1750
of	ADP	O	O	1750
seizures	NOUN	O	Disease	1750
at	ADP	O	O	1750
the	PRON	O	O	1750
cellular	NOUN	O	O	1750
level	VERB	O	O	1750
.	PUNCT	O	O	1750
In	ADP	O	O	1751
this	PRON	O	O	1751
respect	VERB	O	O	1751
,	PUNCT	O	O	1751
little	ADJ	O	O	1751
is	AUX	O	O	1751
known	VERB	O	O	1751
about	ADP	O	O	1751
the	PRON	O	O	1751
role	NOUN	O	O	1751
of	ADP	O	O	1751
DA	NOUN	O	Chemical	1751
receptors	NOUN	O	O	1751
in	ADP	O	O	1751
the	PRON	O	O	1751
occurrence	NOUN	O	O	1751
of	ADP	O	O	1751
epilepsy	NOUN	O	Disease	1751
-	PUNCT	O	O	1751
induced	VERB	O	O	1751
neuronal	ADJ	O	O	1751
cell	NOUN	O	O	1751
death	NOUN	O	O	1751
.	PUNCT	O	O	1751
Here	ADV	O	O	1752
we	PRON	O	O	1752
analyze	VERB	O	O	1752
the	PRON	O	O	1752
occurrence	NOUN	O	O	1752
of	ADP	O	O	1752
seizures	NOUN	O	Disease	1752
and	CCONJ	O	O	1752
neurotoxicity	NOUN	O	Disease	1752
in	ADP	O	O	1752
D2R	PROPN	O	O	1752
-/-	PROPN	O	O	1752
mice	NOUN	O	O	1752
treated	VERB	O	O	1752
with	ADP	O	O	1752
the	PRON	O	O	1752
cholinergic	ADJ	O	O	1752
agonist	NOUN	O	O	1752
pilocarpine	NOUN	O	Chemical	1752
.	PUNCT	O	O	1752
We	PRON	O	O	1753
compared	VERB	O	O	1753
these	PRON	O	O	1753
results	VERB	O	O	1753
with	ADP	O	O	1753
those	PRON	O	O	1753
previously	ADV	O	O	1753
obtained	VERB	O	O	1753
with	ADP	O	O	1753
kainic acid	NOUN	O	Chemical	1753
(	PUNCT	O	O	1753
KA	PROPN	O	Chemical	1753
)	PUNCT	O	O	1753
,	PUNCT	O	O	1753
a	PRON	O	O	1753
potent	ADJ	O	O	1753
glutamate	NOUN	O	Chemical	1753
agonist	NOUN	O	O	1753
.	PUNCT	O	O	1753
Importantly	ADV	O	O	1754
,	PUNCT	O	O	1754
D2R	PROPN	O	O	1754
-/-	PROPN	O	O	1754
mice	NOUN	O	O	1754
develop	VERB	O	O	1754
seizures	NOUN	O	Disease	1754
at	ADP	O	O	1754
doses	NOUN	O	O	1754
of	ADP	O	O	1754
both	PRON	O	O	1754
drugs	NOUN	O	O	1754
that	SCONJ	O	O	1754
are	AUX	O	O	1754
not	PART	O	O	1754
epileptogenic	NOUN	O	O	1754
for	ADP	O	O	1754
WT	NOUN	O	O	1754
littermates	NOUN	O	O	1754
and	CCONJ	O	O	1754
show	VERB	O	O	1754
greater	ADJ	O	O	1754
neurotoxicity	NOUN	O	Disease	1754
.	PUNCT	O	O	1754
However	ADV	O	O	1755
,	PUNCT	O	O	1755
pilocarpine	NOUN	O	Chemical	1755
-	PUNCT	O	O	1755
induced	VERB	O	O	1755
seizures	NOUN	O	Disease	1755
result	VERB	O	O	1755
in	ADP	O	O	1755
a	PRON	O	O	1755
more	ADJ	O	O	1755
widespread	ADJ	O	O	1755
neuronal	ADJ	O	O	1755
death	NOUN	O	O	1755
in	ADP	O	O	1755
both	PRON	O	O	1755
WT	NOUN	O	O	1755
and	CCONJ	O	O	1755
D2R	PROPN	O	O	1755
-/-	PROPN	O	O	1755
brains	NOUN	O	O	1755
in	ADP	O	O	1755
comparison	NOUN	O	O	1755
to	PART	O	O	1755
KA	PROPN	O	Chemical	1755
.	PUNCT	O	O	1755
Thus	ADV	O	O	1756
,	PUNCT	O	O	1756
the	PRON	O	O	1756
absence	NOUN	O	O	1756
of	ADP	O	O	1756
D2R	PROPN	O	O	1756
lowers	VERB	O	O	1756
the	PRON	O	O	1756
threshold	NOUN	O	O	1756
for	ADP	O	O	1756
seizures	NOUN	O	Disease	1756
induced	VERB	O	O	1756
by	ADP	O	O	1756
both	PRON	O	O	1756
glutamate	NOUN	O	Chemical	1756
and	CCONJ	O	O	1756
acetylcholine	NOUN	O	Chemical	1756
.	PUNCT	O	O	1756
Moreover	ADV	O	O	1757
,	PUNCT	O	O	1757
the	PRON	O	O	1757
dopaminergic	ADJ	O	O	1757
control	VERB	O	O	1757
of	ADP	O	O	1757
epilepsy	NOUN	O	Disease	1757
-	PUNCT	O	O	1757
induced	VERB	O	O	1757
neurodegeneration	NOUN	O	Disease	1757
seems	VERB	O	O	1757
to	PART	O	O	1757
be	AUX	O	O	1757
mediated	VERB	O	O	1757
by	ADP	O	O	1757
distinct	ADJ	O	O	1757
interactions	NOUN	O	O	1757
of	ADP	O	O	1757
D2R	PROPN	O	O	1757
signaling	VERB	O	O	1757
with	ADP	O	O	1757
these	PRON	O	O	1757
two	NUM	O	O	1757
neurotransmitters	NOUN	O	O	1757
.	PUNCT	O	O	1757
Treatment	NOUN	O	O	1760
of	ADP	O	O	1760
risperidone	VERB	O	Chemical	1760
-	PUNCT	O	O	1760
induced	VERB	O	O	1760
hyperprolactinemia	NOUN	O	Disease	1760
with	ADP	O	O	1760
a	PRON	O	O	1760
dopamine	NOUN	O	Chemical	1760
agonist	NOUN	O	O	1760
in	ADP	O	O	1760
children	NOUN	O	O	1760
.	PUNCT	O	O	1760
Risperidone	NOUN	O	Chemical	1761
,	PUNCT	O	O	1761
a	PRON	O	O	1761
potent	ADJ	O	O	1761
antagonist	NOUN	O	O	1761
of	ADP	O	O	1761
both	PRON	O	O	1761
serotonergic	ADJ	O	O	1761
(	PUNCT	O	O	1761
5HT2A	NUM	O	O	1761
)	PUNCT	O	O	1761
and	CCONJ	O	O	1761
dopaminergic	ADJ	O	O	1761
D2	NOUN	O	O	1761
receptors	NOUN	O	O	1761
is	AUX	O	O	1761
associated	VERB	O	O	1761
with	ADP	O	O	1761
hyperprolactinemia	NOUN	O	Disease	1761
in	ADP	O	O	1761
adults	NOUN	O	O	1761
and	CCONJ	O	O	1761
children	NOUN	O	O	1761
.	PUNCT	O	O	1761
Chronically	ADV	O	O	1762
elevated	ADJ	O	O	1762
prolactin	PROPN	O	O	1762
levels	NOUN	O	O	1762
in	ADP	O	O	1762
children	NOUN	O	O	1762
with	ADP	O	O	1762
prolactinomas	PROPN	O	Disease	1762
may	AUX	O	O	1762
be	AUX	O	O	1762
associated	VERB	O	O	1762
with	ADP	O	O	1762
arrested	VERB	O	O	1762
growth	NOUN	O	O	1762
and	CCONJ	O	O	1762
development	NOUN	O	O	1762
resulting	VERB	O	O	1762
in	ADP	O	O	1762
either	ADV	O	O	1762
delayed puberty	NOUN	O	Disease	1762
or	CCONJ	O	O	1762
short	ADJ	O	O	1762
stature	VERB	O	O	1762
.	PUNCT	O	O	1762
These	PRON	O	O	1763
possibilities	NOUN	O	O	1763
stress	NOUN	O	O	1763
the	PRON	O	O	1763
importance	NOUN	O	O	1763
of	ADP	O	O	1763
developing	VERB	O	O	1763
a	PRON	O	O	1763
safe	ADJ	O	O	1763
and	CCONJ	O	O	1763
effective	ADJ	O	O	1763
approach	NOUN	O	O	1763
to	PART	O	O	1763
drug	NOUN	O	O	1763
-	PUNCT	O	O	1763
induced	VERB	O	O	1763
hyperprolactinemia	NOUN	O	Disease	1763
in	ADP	O	O	1763
youth	NOUN	O	O	1763
.	PUNCT	O	O	1763
We	PRON	O	O	1764
report	VERB	O	O	1764
the	PRON	O	O	1764
successful	ADJ	O	O	1764
treatment	NOUN	O	O	1764
of	ADP	O	O	1764
risperidone	VERB	O	Chemical	1764
-	PUNCT	O	O	1764
induced	VERB	O	O	1764
hyperprolactinemia	NOUN	O	Disease	1764
with	ADP	O	O	1764
cabergoline	PROPN	O	Chemical	1764
in	ADP	O	O	1764
youth	NOUN	O	O	1764
.	PUNCT	O	O	1764
:	PUNCT	O	O	1765
We	PRON	O	O	1765
undertook	VERB	O	O	1765
a	PRON	O	O	1765
retrospective	ADJ	O	O	1765
case	NOUN	O	O	1765
review	VERB	O	O	1765
of	ADP	O	O	1765
four	NUM	O	O	1765
children	NOUN	O	O	1765
with	ADP	O	O	1765
risperidone	VERB	O	Chemical	1765
-	PUNCT	O	O	1765
induced	VERB	O	O	1765
hyperprolactinemia	NOUN	O	Disease	1765
treated	VERB	O	O	1765
with	ADP	O	O	1765
cabergoline	PROPN	O	Chemical	1765
.	PUNCT	O	O	1765
Four	NUM	O	O	1766
males	NOUN	O	O	1766
(	PUNCT	O	O	1766
age	NOUN	O	O	1766
6	NUM	O	O	1766
-	PUNCT	O	O	1766
11	NUM	O	O	1766
years	NOUN	O	O	1766
)	PUNCT	O	O	1766
with	ADP	O	O	1766
Diagnostic	ADJ	O	O	1766
and	CCONJ	O	O	1766
Statistical	ADJ	O	O	1766
Manual	NOUN	O	O	1766
of	ADP	O	O	1766
Mental Disorders	PROPN	O	Disease	1766
(	PUNCT	O	O	1766
fourth	ADV	O	O	1766
edition	PROPN	O	O	1766
)	PUNCT	O	O	1766
bipolar disorder	NOUN	O	Disease	1766
or	CCONJ	O	O	1766
psychoses	NOUN	O	Disease	1766
,	PUNCT	O	O	1766
with	ADP	O	O	1766
risperidone	VERB	O	Chemical	1766
-	PUNCT	O	O	1766
induced	VERB	O	O	1766
elevations	NOUN	O	O	1766
in	ADP	O	O	1766
serum	NOUN	O	O	1766
prolactin	PROPN	O	O	1766
levels	NOUN	O	O	1766
(	PUNCT	O	O	1766
57.5	NUM	O	O	1766
-	PUNCT	O	O	1766
129	NUM	O	O	1766
ng	PROPN	O	O	1766
/	PUNCT	O	O	1766
mL	PROPN	O	O	1766
,	PUNCT	O	O	1766
normal	ADJ	O	O	1766
5	NUM	O	O	1766
-	PUNCT	O	O	1766
15	NUM	O	O	1766
ng	PROPN	O	O	1766
/	PUNCT	O	O	1766
mL	PROPN	O	O	1766
)	PUNCT	O	O	1766
,	PUNCT	O	O	1766
were	AUX	O	O	1766
treated	VERB	O	O	1766
with	ADP	O	O	1766
cabergoline	PROPN	O	Chemical	1766
10.9	NUM	O	O	1767
ng	PROPN	O	O	1767
/	PUNCT	O	O	1767
mL	PROPN	O	O	1767
)	PUNCT	O	O	1767
,	PUNCT	O	O	1767
the	PRON	O	O	1767
cabergoline	PROPN	O	Chemical	1767
dose	NOUN	O	O	1767
was	AUX	O	O	1767
reduced	VERB	O	O	1767
to	PART	O	O	1767
1	X	O	O	1767
mg	VERB	O	O	1767
/	PUNCT	O	O	1767
week	NOUN	O	O	1767
in	ADP	O	O	1767
three	NUM	O	O	1767
of	ADP	O	O	1767
four	NUM	O	O	1767
subjects	NOUN	O	O	1767
.	PUNCT	O	O	1767
The	PRON	O	O	1768
mean	VERB	O	O	1768
duration	NOUN	O	O	1768
of	ADP	O	O	1768
therapy	NOUN	O	O	1768
with	ADP	O	O	1768
cabergoline	PROPN	O	Chemical	1768
was	AUX	O	O	1768
523.5	NUM	O	O	1768
+	ADP	O	O	1768
/-	PUNCT	O	O	1768
129.7	NUM	O	O	1769
days	NOUN	O	O	1769
,	PUNCT	O	O	1769
and	CCONJ	O	O	1769
the	PRON	O	O	1769
mean	VERB	O	O	1769
duration	NOUN	O	O	1769
of	ADP	O	O	1769
therapy	NOUN	O	O	1769
with	ADP	O	O	1769
risperidone	VERB	O	Chemical	1769
was	AUX	O	O	1769
788.5	NUM	O	O	1769
+	ADP	O	O	1769
/-	PUNCT	O	O	1769
Cabergoline	PROPN	O	Chemical	1770
was	AUX	O	O	1770
well	ADV	O	O	1770
tolerated	VERB	O	O	1770
without	ADP	O	O	1770
adverse	ADJ	O	O	1770
effects	NOUN	O	O	1770
.	PUNCT	O	O	1770
Cabergoline	PROPN	O	Chemical	1771
may	AUX	O	O	1771
be	AUX	O	O	1771
useful	ADJ	O	O	1771
for	ADP	O	O	1771
the	PRON	O	O	1771
treatment	NOUN	O	O	1771
of	ADP	O	O	1771
risperidone	VERB	O	Chemical	1771
-	PUNCT	O	O	1771
induced	VERB	O	O	1771
hyperprolactinemia	NOUN	O	Disease	1771
in	ADP	O	O	1771
youth	NOUN	O	O	1771
;	PUNCT	O	O	1771
however	ADV	O	O	1771
,	PUNCT	O	O	1771
further	ADV	O	O	1771
research	NOUN	O	O	1771
is	AUX	O	O	1771
needed	VERB	O	O	1771
.	PUNCT	O	O	1771
Cholestatic jaundice	NOUN	O	Disease	1774
associated	VERB	O	O	1774
with	ADP	O	O	1774
the	PRON	O	O	1774
use	VERB	O	O	1774
of	ADP	O	O	1774
metformin	PROPN	O	Chemical	1774
.	PUNCT	O	O	1774
We	PRON	O	O	1775
report	VERB	O	O	1775
a	PRON	O	O	1775
patient	NOUN	O	O	1775
who	PRON	O	O	1775
developed	VERB	O	O	1775
cholestatic jaundice	NOUN	O	Disease	1775
shortly	ADV	O	O	1775
after	ADP	O	O	1775
initiation	NOUN	O	O	1775
of	ADP	O	O	1775
treatment	NOUN	O	O	1775
with	ADP	O	O	1775
metformin hydrochloride	NOUN	O	Chemical	1775
.	PUNCT	O	O	1775
A	PRON	O	O	1776
percutaneous	ADJ	O	O	1776
liver	NOUN	O	O	1776
biopsy	PROPN	O	O	1776
was	AUX	O	O	1776
obtained	VERB	O	O	1776
showing	VERB	O	O	1776
marked	VERB	O	O	1776
cholestasis	NOUN	O	Disease	1776
,	PUNCT	O	O	1776
with	ADP	O	O	1776
portal	PROPN	O	O	1776
edema	NOUN	O	Disease	1776
,	PUNCT	O	O	1776
ductular	NOUN	O	O	1776
proliferation	NOUN	O	O	1776
,	PUNCT	O	O	1776
and	CCONJ	O	O	1776
acute	ADJ	O	O	1776
inflammation	NOUN	O	Disease	1776
.	PUNCT	O	O	1776
Metformin hydrochloride	NOUN	O	Chemical	1777
was	AUX	O	O	1777
discontinued	VERB	O	O	1777
,	PUNCT	O	O	1777
and	CCONJ	O	O	1777
the	PRON	O	O	1777
patient	NOUN	O	O	1777
's	AUX	O	O	1777
jaundice	NOUN	O	Disease	1777
resolved	VERB	O	O	1777
slowly	ADV	O	O	1777
over	ADP	O	O	1777
a	PRON	O	O	1777
period	NOUN	O	O	1777
of	ADP	O	O	1777
several	ADJ	O	O	1777
months	NOUN	O	O	1777
.	PUNCT	O	O	1777
Given	VERB	O	O	1778
the	PRON	O	O	1778
onset	VERB	O	O	1778
of	ADP	O	O	1778
his	PRON	O	O	1778
jaundice	NOUN	O	Disease	1778
2	X	O	O	1778
wk	X	O	O	1778
after	ADP	O	O	1778
the	PRON	O	O	1778
initiation	NOUN	O	O	1778
of	ADP	O	O	1778
metformin	PROPN	O	Chemical	1778
,	PUNCT	O	O	1778
we	PRON	O	O	1778
believe	VERB	O	O	1778
that	SCONJ	O	O	1778
this	PRON	O	O	1778
case	NOUN	O	O	1778
represents	VERB	O	O	1778
an	PRON	O	O	1778
example	NOUN	O	O	1778
of	ADP	O	O	1778
metformin	PROPN	O	Chemical	1778
-	PUNCT	O	O	1778
associated	VERB	O	O	1778
hepatotoxicity	NOUN	O	Disease	1778
,	PUNCT	O	O	1778
the	PRON	O	O	1778
first	ADV	O	O	1778
such	ADJ	O	O	1778
case	NOUN	O	O	1778
reported	VERB	O	O	1778
.	PUNCT	O	O	1778
Electro	NOUN	O	O	1781
-	PUNCT	O	O	1781
oculography	NOUN	O	O	1781
,	PUNCT	O	O	1781
electroretinography	NOUN	O	O	1781
,	PUNCT	O	O	1781
visual	ADJ	O	O	1781
evoked	VERB	O	O	1781
potentials	NOUN	O	O	1781
,	PUNCT	O	O	1781
and	CCONJ	O	O	1781
multifocal	ADJ	O	O	1781
electroretinography	NOUN	O	O	1781
in	ADP	O	O	1781
patients	NOUN	O	O	1781
with	ADP	O	O	1781
vigabatrin	PROPN	O	Chemical	1781
-	PUNCT	O	O	1781
attributed	VERB	O	O	1781
visual field constriction	NOUN	O	Disease	1781
.	PUNCT	O	O	1781
Symptomatic	ADJ	O	O	1782
visual field constriction	NOUN	O	Disease	1782
thought	VERB	O	O	1782
to	PART	O	O	1782
be	AUX	O	O	1782
associated	VERB	O	O	1782
with	ADP	O	O	1782
vigabatrin	PROPN	O	Chemical	1782
has	VERB	O	O	1782
been	AUX	O	O	1782
reported	VERB	O	O	1782
.	PUNCT	O	O	1782
The	PRON	O	O	1783
current	ADJ	O	O	1783
study	VERB	O	O	1783
investigated	VERB	O	O	1783
the	PRON	O	O	1783
visual	ADJ	O	O	1783
fields	NOUN	O	O	1783
and	CCONJ	O	O	1783
visual	ADJ	O	O	1783
electrophysiology	NOUN	O	O	1783
of	ADP	O	O	1783
eight	NUM	O	O	1783
patients	NOUN	O	O	1783
with	ADP	O	O	1783
known	VERB	O	O	1783
vigabatrin	PROPN	O	Chemical	1783
-	PUNCT	O	O	1783
attributed	VERB	O	O	1783
visual field loss	NOUN	O	Disease	1783
,	PUNCT	O	O	1783
three	NUM	O	O	1783
of	ADP	O	O	1783
whom	PRON	O	O	1783
were	AUX	O	O	1783
reported	VERB	O	O	1783
previously	ADV	O	O	1783
.	PUNCT	O	O	1783
Six	NUM	O	O	1784
of	ADP	O	O	1784
the	PRON	O	O	1784
patients	NOUN	O	O	1784
were	AUX	O	O	1784
no	PRON	O	O	1784
longer	ADV	O	O	1784
receiving	VERB	O	O	1784
vigabatrin	PROPN	O	Chemical	1784
.	PUNCT	O	O	1784
Seven	NUM	O	O	1785
patients	NOUN	O	O	1785
showed	VERB	O	O	1785
marked	VERB	O	O	1785
visual field constriction	NOUN	O	Disease	1785
with	ADP	O	O	1785
some	PRON	O	O	1785
sparing	VERB	O	O	1785
of	ADP	O	O	1785
the	PRON	O	O	1785
temporal	ADJ	O	O	1785
visual	ADJ	O	O	1785
field	NOUN	O	O	1785
.	PUNCT	O	O	1785
Marked	VERB	O	O	1786
visual field constriction	NOUN	O	Disease	1786
appears	VERB	O	O	1786
to	PART	O	O	1786
be	AUX	O	O	1786
associated	VERB	O	O	1786
with	ADP	O	O	1786
vigabatrin	PROPN	O	Chemical	1786
therapy	NOUN	O	O	1786
.	PUNCT	O	O	1786
The	PRON	O	O	1787
field	NOUN	O	O	1787
defects	NOUN	O	O	1787
and	CCONJ	O	O	1787
some	PRON	O	O	1787
electrophysiological	ADJ	O	O	1787
abnormalities	NOUN	O	O	1787
persist	VERB	O	O	1787
when	SCONJ	O	O	1787
vigabatrin	PROPN	O	Chemical	1787
therapy	NOUN	O	O	1787
is	AUX	O	O	1787
withdrawn	VERB	O	O	1787
.	PUNCT	O	O	1787
Conversion	NOUN	O	O	1790
to	PART	O	O	1790
rapamycin	NOUN	O	Chemical	1790
immunosuppression	NOUN	O	O	1790
in	ADP	O	O	1790
renal	ADJ	O	O	1790
transplant	NOUN	O	O	1790
recipients	NOUN	O	O	1790
:	PUNCT	O	O	1790
The	PRON	O	O	1791
aim	VERB	O	O	1791
of	ADP	O	O	1791
this	PRON	O	O	1791
study	VERB	O	O	1791
is	AUX	O	O	1791
to	PART	O	O	1791
evaluate	VERB	O	O	1791
the	PRON	O	O	1791
effects	NOUN	O	O	1791
of	ADP	O	O	1791
RAPA	VERB	O	Chemical	1791
conversion	NOUN	O	O	1791
in	ADP	O	O	1791
patients	NOUN	O	O	1791
undergoing	VERB	O	O	1791
cyclosporine	NOUN	O	Chemical	1791
(	PUNCT	O	O	1791
CsA	PROPN	O	Chemical	1791
)	PUNCT	O	O	1791
or	CCONJ	O	O	1791
tacrolimus	NOUN	O	Chemical	1791
(	PUNCT	O	O	1791
Tac	PROPN	O	Chemical	1791
)	PUNCT	O	O	1791
toxicity	NOUN	O	Disease	1791
.	PUNCT	O	O	1791
Twenty	NUM	O	O	1792
renal	ADJ	O	O	1792
transplant	NOUN	O	O	1792
recipients	NOUN	O	O	1792
were	AUX	O	O	1792
switched	VERB	O	O	1792
to	PART	O	O	1792
fixed	VERB	O	O	1792
dose	NOUN	O	O	1792
rapamycin	NOUN	O	Chemical	1792
(	PUNCT	O	O	1792
RAPA	VERB	O	Chemical	1792
)	PUNCT	O	O	1792
(	PUNCT	O	O	1792
5	NUM	O	O	1792
mg	VERB	O	O	1792
/	PUNCT	O	O	1792
day	NOUN	O	O	1792
)	PUNCT	O	O	1792
0	NUM	O	O	1792
to	PART	O	O	1792
204	NUM	O	O	1792
months	NOUN	O	O	1792
posttransplant	PROPN	O	O	1792
.	PUNCT	O	O	1792
The	PRON	O	O	1793
indications	NOUN	O	O	1793
for	ADP	O	O	1793
switch	VERB	O	O	1793
were	AUX	O	O	1793
chronic	ADJ	O	O	1793
CsA	PROPN	O	Chemical	1793
or	CCONJ	O	O	1793
Tac	PROPN	O	Chemical	1793
nephrotoxicity	NOUN	O	Disease	1793
(	PUNCT	O	O	1793
12	NUM	O	O	1793
)	PUNCT	O	O	1793
,	PUNCT	O	O	1793
acute	ADJ	O	O	1793
CsA	PROPN	O	Chemical	1793
or	CCONJ	O	O	1793
Tac	PROPN	O	Chemical	1793
toxicity	NOUN	O	Disease	1793
(	PUNCT	O	O	1793
3	X	O	O	1793
)	PUNCT	O	O	1793
,	PUNCT	O	O	1793
severe	ADJ	O	O	1793
facial dysmorphism	NOUN	O	Disease	1793
(	PUNCT	O	O	1793
2	X	O	O	1793
)	PUNCT	O	O	1793
,	PUNCT	O	O	1793
posttransplant lymphoproliferative disorder	NOUN	O	Disease	1793
(	PUNCT	O	O	1793
PTLD	PROPN	O	Disease	1793
)	PUNCT	O	O	1793
in	ADP	O	O	1793
remission	NOUN	O	O	1793
(	PUNCT	O	O	1793
2	X	O	O	1793
)	PUNCT	O	O	1793
,	PUNCT	O	O	1793
and	CCONJ	O	O	1793
hepatotoxicity	NOUN	O	Disease	1793
in	ADP	O	O	1793
1	X	O	O	1793
.	PUNCT	O	O	1793
In	ADP	O	O	1794
the	PRON	O	O	1794
12	NUM	O	O	1794
patients	NOUN	O	O	1794
switched	VERB	O	O	1794
because	SCONJ	O	O	1794
of	ADP	O	O	1794
chronic	ADJ	O	O	1794
nephrotoxicity	NOUN	O	Disease	1794
there	ADV	O	O	1794
was	AUX	O	O	1794
a	PRON	O	O	1794
significant	ADJ	O	O	1794
decrease	VERB	O	O	1794
in	ADP	O	O	1794
serum	NOUN	O	O	1794
creatinine	PROPN	O	Chemical	1794
[	X	O	O	1794
233+/-34	NUM	O	O	1794
to	PART	O	O	1794
210+/-56	NUM	O	O	1794
micromol	NOUN	O	O	1794
/	PUNCT	O	O	1794
liter	NOUN	O	O	1794
(	PUNCT	O	O	1794
P<0.05	NOUN	O	O	1794
)	PUNCT	O	O	1794
at	ADP	O	O	1794
6	NUM	O	O	1794
months	NOUN	O	O	1794
]	PUNCT	O	O	1794
.	PUNCT	O	O	1794
Facial dysmorphism	NOUN	O	Disease	1795
improved	VERB	O	O	1795
in	ADP	O	O	1795
two	NUM	O	O	1795
patients	NOUN	O	O	1795
.	PUNCT	O	O	1795
No	PRON	O	O	1796
relapse	VERB	O	O	1796
of	ADP	O	O	1796
PTLD	PROPN	O	Disease	1796
was	AUX	O	O	1796
observed	VERB	O	O	1796
.	PUNCT	O	O	1796
Five	NUM	O	O	1797
patients	NOUN	O	O	1797
developed	VERB	O	O	1797
pneumonia	NOUN	O	Disease	1797
(	PUNCT	O	O	1797
two	NUM	O	O	1797
Pneumocystis carinii pneumonia	NOUN	O	Disease	1797
,	PUNCT	O	O	1797
one	NUM	O	O	1797
infectious mononucleosis	NOUN	O	Disease	1797
with	ADP	O	O	1797
polyclonal	ADJ	O	O	1797
PTLD	PROPN	O	Disease	1797
lung	NOUN	O	O	1797
infiltrate	VERB	O	O	1797
)	PUNCT	O	O	1797
and	CCONJ	O	O	1797
two	NUM	O	O	1797
had	VERB	O	O	1797
bronchiolitis obliterans	NOUN	O	Disease	1797
.	PUNCT	O	O	1797
RAPA	VERB	O	Chemical	1798
was	AUX	O	O	1798
discontinued	VERB	O	O	1798
in	ADP	O	O	1798
four	NUM	O	O	1798
patients	NOUN	O	O	1798
,	PUNCT	O	O	1798
because	SCONJ	O	O	1798
of	ADP	O	O	1798
pneumonia	NOUN	O	Disease	1798
in	ADP	O	O	1798
two	NUM	O	O	1798
,	PUNCT	O	O	1798
PTLD	PROPN	O	Disease	1798
in	ADP	O	O	1798
one	NUM	O	O	1798
,	PUNCT	O	O	1798
and	CCONJ	O	O	1798
oral	ADJ	O	O	1798
aphtous ulcers	NOUN	O	Disease	1798
in	ADP	O	O	1798
one	NUM	O	O	1798
.	PUNCT	O	O	1798
RAPA	VERB	O	Chemical	1799
levels	NOUN	O	O	1799
were	AUX	O	O	1799
high	ADJ	O	O	1799
(	PUNCT	O	O	1799
>	PUNCT	O	O	1799
15	NUM	O	O	1799
ng	PROPN	O	O	1799
/	PUNCT	O	O	1799
ml	ADP	O	O	1799
)	PUNCT	O	O	1799
in	ADP	O	O	1799
7	NUM	O	O	1799
of	ADP	O	O	1799
13	NUM	O	O	1799
(	PUNCT	O	O	1799
54%	NOUN	O	O	1799
)	PUNCT	O	O	1799
patients	NOUN	O	O	1799
.	PUNCT	O	O	1799
RAPA	VERB	O	Chemical	1800
conversion	NOUN	O	O	1800
provides	VERB	O	O	1800
adequate	ADJ	O	O	1800
immunosuppression	NOUN	O	O	1800
to	PART	O	O	1800
enable	VERB	O	O	1800
CsA	PROPN	O	Chemical	1800
withdrawal	NOUN	O	O	1800
.	PUNCT	O	O	1800
However	ADV	O	O	1801
,	PUNCT	O	O	1801
when	SCONJ	O	O	1801
converting	VERB	O	O	1801
patients	NOUN	O	O	1801
to	PART	O	O	1801
RAPA	VERB	O	Chemical	1801
drug	NOUN	O	O	1801
levels	NOUN	O	O	1801
should	AUX	O	O	1801
be	AUX	O	O	1801
monitored	VERB	O	O	1801
to	PART	O	O	1801
avoid	VERB	O	O	1801
over	ADP	O	O	1801
-	PUNCT	O	O	1801
immunosuppression	NOUN	O	O	1801
and	CCONJ	O	O	1801
adequate	ADJ	O	O	1801
antiviral	ADJ	O	O	1801
and	CCONJ	O	O	1801
Pneumocystis carinii pneumonia	NOUN	O	Disease	1801
prophylaxis	NOUN	O	O	1801
should	AUX	O	O	1801
be	AUX	O	O	1801
given	VERB	O	O	1801
.	PUNCT	O	O	1801
Worsening	VERB	O	O	1804
of	ADP	O	O	1804
levodopa	NOUN	O	Chemical	1804
-	PUNCT	O	O	1804
induced	VERB	O	O	1804
dyskinesias	PROPN	O	Disease	1804
by	ADP	O	O	1804
motor	NOUN	O	O	1804
and	CCONJ	O	O	1804
mental	ADJ	O	O	1804
tasks	NOUN	O	O	1804
.	PUNCT	O	O	1804
Ten	NUM	O	O	1805
patients	NOUN	O	O	1805
who	PRON	O	O	1805
had	VERB	O	O	1805
Parkinson	NOUN	O	O	1805
's	AUX	O	O	1805
disease	PROPN	O	O	1805
with	ADP	O	O	1805
disabling	VERB	O	O	1805
dyskinesia	NOUN	O	Disease	1805
were	AUX	O	O	1805
included	VERB	O	O	1805
in	ADP	O	O	1805
this	PRON	O	O	1805
study	VERB	O	O	1805
to	PART	O	O	1805
evaluate	VERB	O	O	1805
the	PRON	O	O	1805
role	NOUN	O	O	1805
of	ADP	O	O	1805
mental	ADJ	O	O	1805
(	PUNCT	O	O	1805
mental	ADJ	O	O	1805
calculation	NOUN	O	O	1805
)	PUNCT	O	O	1805
and	CCONJ	O	O	1805
motor	NOUN	O	O	1805
(	PUNCT	O	O	1805
flexion	NOUN	O	O	1805
/	PUNCT	O	O	1805
extension	NOUN	O	O	1805
of	ADP	O	O	1805
right	ADV	O	O	1805
fingers	NOUN	O	O	1805
,	PUNCT	O	O	1805
flexion	NOUN	O	O	1805
/	PUNCT	O	O	1805
extension	NOUN	O	O	1805
of	ADP	O	O	1805
left	VERB	O	O	1805
fingers	NOUN	O	O	1805
,	PUNCT	O	O	1805
flexion	NOUN	O	O	1805
/	PUNCT	O	O	1805
extension	NOUN	O	O	1805
of	ADP	O	O	1805
the	PRON	O	O	1805
neck	NOUN	O	O	1805
,	PUNCT	O	O	1805
speaking	VERB	O	O	1805
aloud	ADV	O	O	1805
)	PUNCT	O	O	1805
tasks	NOUN	O	O	1805
on	ADP	O	O	1805
the	PRON	O	O	1805
worsening	VERB	O	O	1805
of	ADP	O	O	1805
peak	PROPN	O	O	1805
-	PUNCT	O	O	1805
dose	NOUN	O	O	1805
dyskinesia	NOUN	O	Disease	1805
following	VERB	O	O	1805
administration	NOUN	O	O	1805
of	ADP	O	O	1805
an	PRON	O	O	1805
effective	ADJ	O	O	1805
single	ADJ	O	O	1805
dose	NOUN	O	O	1805
of	ADP	O	O	1805
apomorphine	PROPN	O	Chemical	1805
.	PUNCT	O	O	1805
Compared	VERB	O	O	1806
with	ADP	O	O	1806
the	PRON	O	O	1806
score	VERB	O	O	1806
at	ADP	O	O	1806
rest	VERB	O	O	1806
(	PUNCT	O	O	1806
1.3+/-0.3	NUM	O	O	1806
)	PUNCT	O	O	1806
,	PUNCT	O	O	1806
a	PRON	O	O	1806
significant	ADJ	O	O	1806
aggravation	NOUN	O	O	1806
of	ADP	O	O	1806
the	PRON	O	O	1806
dyskinesia	NOUN	O	Disease	1806
score	VERB	O	O	1806
was	AUX	O	O	1806
observed	VERB	O	O	1806
during	ADP	O	O	1806
speaking	VERB	O	O	1806
aloud	ADV	O	O	1806
(	PUNCT	O	O	1806
5.2+/-1.1	NUM	O	O	1806
,	PUNCT	O	O	1806
p<0.05	NOUN	O	O	1806
)	PUNCT	O	O	1806
,	PUNCT	O	O	1806
movements	NOUN	O	O	1806
of	ADP	O	O	1806
right	ADV	O	O	1806
(	PUNCT	O	O	1806
4.5+/-1.0	NUM	O	O	1806
,	PUNCT	O	O	1806
p<0.05	NOUN	O	O	1806
)	PUNCT	O	O	1806
and	CCONJ	O	O	1806
left	VERB	O	O	1806
(	PUNCT	O	O	1806
3.7+/-0.8	NUM	O	O	1806
,	PUNCT	O	O	1806
p<0.05	NOUN	O	O	1806
)	PUNCT	O	O	1806
fingers	NOUN	O	O	1806
,	PUNCT	O	O	1806
movements	NOUN	O	O	1806
of	ADP	O	O	1806
the	PRON	O	O	1806
neck	NOUN	O	O	1806
(	PUNCT	O	O	1806
5.1+/-1.0	NUM	O	O	1806
,	PUNCT	O	O	1806
p<0.05	NOUN	O	O	1806
)	PUNCT	O	O	1806
,	PUNCT	O	O	1806
and	CCONJ	O	O	1806
mental	ADJ	O	O	1806
calculation	NOUN	O	O	1806
(	PUNCT	O	O	1806
3.1+/-1.0	NUM	O	O	1806
,	PUNCT	O	O	1806
p<0.05	NOUN	O	O	1806
)	PUNCT	O	O	1806
.	PUNCT	O	O	1806
These	PRON	O	O	1807
results	VERB	O	O	1807
suggest	VERB	O	O	1807
that	SCONJ	O	O	1807
activation	NOUN	O	O	1807
tasks	NOUN	O	O	1807
such	ADJ	O	O	1807
as	ADP	O	O	1807
""""	PUNCT	O	O	1807
speaking	VERB	O	O	1807
aloud	ADV	O	O	1807
""""	PUNCT	O	O	1807
could	AUX	O	O	1807
be	AUX	O	O	1807
used	VERB	O	O	1807
for	ADP	O	O	1807
objective	VERB	O	O	1807
assessment	NOUN	O	O	1807
of	ADP	O	O	1807
dyskinesia	NOUN	O	Disease	1807
severity	NOUN	O	O	1807
.	PUNCT	O	O	1807
Structural and functional impairment of mitochondria	NOUN	O	Disease	1810
in	ADP	O	O	1810
adriamycin	PROPN	O	Chemical	1810
-	PUNCT	O	O	1810
induced	VERB	O	O	1810
cardiomyopathy	ADJ	O	Disease	1810
in	ADP	O	O	1810
mice	NOUN	O	O	1810
:	PUNCT	O	O	1810
suppression	NOUN	O	O	1810
of	ADP	O	O	1810
cytochrome	ADP	O	O	1810
c	X	O	O	1810
oxidase	NOUN	O	O	1810
II	NUM	O	O	1810
gene	NOUN	O	O	1810
expression	NOUN	O	O	1810
.	PUNCT	O	O	1810
The	PRON	O	O	1811
use	VERB	O	O	1811
of	ADP	O	O	1811
adriamycin	PROPN	O	Chemical	1811
(	PUNCT	O	O	1811
ADR	PROPN	O	Chemical	1811
)	PUNCT	O	O	1811
in	ADP	O	O	1811
cancer	NOUN	O	Disease	1811
chemotherapy	NOUN	O	O	1811
has	VERB	O	O	1811
been	AUX	O	O	1811
limited	VERB	O	O	1811
due	ADJ	O	O	1811
to	PART	O	O	1811
its	PRON	O	O	1811
cumulative	ADJ	O	O	1811
cardiovascular toxicity	NOUN	O	Disease	1811
.	PUNCT	O	O	1811
Earlier	ADV	O	O	1812
observations	NOUN	O	O	1812
that	SCONJ	O	O	1812
ADR	PROPN	O	Chemical	1812
interacts	VERB	O	O	1812
with	ADP	O	O	1812
mitochondrial	ADJ	O	O	1812
cytochrome	ADP	O	O	1812
c	X	O	O	1812
oxidase	NOUN	O	O	1812
(	PUNCT	O	O	1812
COX	PROPN	O	O	1812
)	PUNCT	O	O	1812
and	CCONJ	O	O	1812
suppresses	VERB	O	O	1812
its	PRON	O	O	1812
enzyme	NOUN	O	O	1812
activity	NOUN	O	O	1812
led	VERB	O	O	1812
us	PRON	O	O	1812
to	PART	O	O	1812
investigate	VERB	O	O	1812
ADR	PROPN	O	Chemical	1812
's	AUX	O	O	1812
action	NOUN	O	O	1812
on	ADP	O	O	1812
the	PRON	O	O	1812
cardiovascular	ADJ	O	O	1812
functions	VERB	O	O	1812
and	CCONJ	O	O	1812
heart	NOUN	O	O	1812
mitochondrial	ADJ	O	O	1812
morphology	NOUN	O	O	1812
in	ADP	O	O	1812
Balb	PROPN	O	O	1812
-	PUNCT	O	O	1812
c	X	O	O	1812
mice	NOUN	O	O	1812
i.p	NOUN	O	O	1812
.	PUNCT	O	O	1812
treated	VERB	O	O	1813
with	ADP	O	O	1813
ADR	PROPN	O	Chemical	1813
for	ADP	O	O	1813
several	ADJ	O	O	1813
weeks	NOUN	O	O	1813
.	PUNCT	O	O	1813
Our	PRON	O	O	1814
results	VERB	O	O	1814
indicated	VERB	O	O	1814
that	SCONJ	O	O	1814
1	X	O	O	1814
)	PUNCT	O	O	1814
treatment	NOUN	O	O	1814
of	ADP	O	O	1814
mice	NOUN	O	O	1814
with	ADP	O	O	1814
ADR	PROPN	O	Chemical	1814
caused	VERB	O	O	1814
cardiovascular arrhythmias	VERB	O	Disease	1814
characterized	VERB	O	O	1814
by	ADP	O	O	1814
bradycardia	NOUN	O	Disease	1814
,	PUNCT	O	O	1814
extension	NOUN	O	O	1814
of	ADP	O	O	1814
ventricular	ADJ	O	O	1814
depolarization	NOUN	O	O	1814
time	NOUN	O	O	1814
(	PUNCT	O	O	1814
tQRS	PROPN	O	O	1814
)	PUNCT	O	O	1814
,	PUNCT	O	O	1814
and	CCONJ	O	O	1814
failure	NOUN	O	O	1814
of	ADP	O	O	1814
QRS	PROPN	O	O	1814
at	ADP	O	O	1814
high	ADJ	O	O	1814
concentrations	NOUN	O	O	1814
(	PUNCT	O	O	1814
10	NUM	O	O	1814
-	PUNCT	O	O	1814
14	NUM	O	O	1814
mg	VERB	O	O	1814
/	PUNCT	O	O	1814
kg	VERB	O	O	1814
body	NOUN	O	O	1814
weight	NOUN	O	O	1814
cumulative	ADJ	O	O	1814
dose	NOUN	O	O	1814
)	PUNCT	O	O	1814
;	PUNCT	O	O	1814
2	X	O	O	1814
)	PUNCT	O	O	1814
the	PRON	O	O	1814
heart	NOUN	O	O	1814
mitochondria	PROPN	O	O	1814
underwent	VERB	O	O	1814
swelling	VERB	O	Disease	1814
,	PUNCT	O	O	1814
fusion	NOUN	O	O	1814
,	PUNCT	O	O	1814
dissolution	NOUN	O	O	1814
,	PUNCT	O	O	1814
and/or	CCONJ	O	O	1814
disruption	NOUN	O	O	1814
of	ADP	O	O	1814
mitochondrial	ADJ	O	O	1814
cristae	PROPN	O	O	1814
after	ADP	O	O	1814
several	ADJ	O	O	1814
weeks	NOUN	O	O	1814
of	ADP	O	O	1814
treatment	NOUN	O	O	1814
.	PUNCT	O	O	1814
Such	ADJ	O	O	1815
abnormalities	NOUN	O	O	1815
were	AUX	O	O	1815
not	PART	O	O	1815
observed	VERB	O	O	1815
in	ADP	O	O	1815
the	PRON	O	O	1815
mitochondria	PROPN	O	O	1815
of	ADP	O	O	1815
liver	NOUN	O	O	1815
tissue	NOUN	O	O	1815
;	PUNCT	O	O	1815
and	CCONJ	O	O	1815
3	X	O	O	1815
)	PUNCT	O	O	1815
among	ADP	O	O	1815
the	PRON	O	O	1815
three	NUM	O	O	1815
genes	NOUN	O	O	1815
of	ADP	O	O	1815
COX	PROPN	O	O	1815
enzyme	NOUN	O	O	1815
examined	VERB	O	O	1815
,	PUNCT	O	O	1815
only	ADV	O	O	1815
COXII	NOUN	O	O	1815
gene	NOUN	O	O	1815
expression	NOUN	O	O	1815
was	AUX	O	O	1815
suppressed	VERB	O	O	1815
by	ADP	O	O	1815
ADR	PROPN	O	Chemical	1815
treatment	NOUN	O	O	1815
,	PUNCT	O	O	1815
mainly	ADV	O	O	1815
after	ADP	O	O	1815
8	NUM	O	O	1815
weeks	NOUN	O	O	1815
in	ADP	O	O	1815
both	PRON	O	O	1815
heart	NOUN	O	O	1815
and	CCONJ	O	O	1815
liver	NOUN	O	O	1815
.	PUNCT	O	O	1815
Knowing	VERB	O	O	1816
that	SCONJ	O	O	1816
heart	NOUN	O	O	1816
mitochondria	PROPN	O	O	1816
represent	VERB	O	O	1816
almost	ADV	O	O	1816
40%	NOUN	O	O	1816
of	ADP	O	O	1816
heart	NOUN	O	O	1816
muscle	NOUN	O	O	1816
by	ADP	O	O	1816
weight	NOUN	O	O	1816
,	PUNCT	O	O	1816
we	PRON	O	O	1816
conclude	VERB	O	O	1816
that	SCONJ	O	O	1816
the	PRON	O	O	1816
deteriorating	VERB	O	O	1816
effects	NOUN	O	O	1816
of	ADP	O	O	1816
ADR	PROPN	O	Chemical	1816
on	ADP	O	O	1816
cardiovascular	ADJ	O	O	1816
function	NOUN	O	O	1816
involve	VERB	O	O	1816
mitochondrial structural and functional impairment	NOUN	O	Disease	1816
.	PUNCT	O	O	1816
Enhanced	VERB	O	O	1819
bradycardia	NOUN	O	Disease	1819
induced	VERB	O	O	1819
by	ADP	O	O	1819
beta	NOUN	O	O	1819
-	PUNCT	O	O	1819
adrenoceptor	NOUN	O	O	1819
antagonists	NOUN	O	O	1819
in	ADP	O	O	1819
rats	NOUN	O	O	1819
pretreated	VERB	O	O	1819
with	ADP	O	O	1819
isoniazid	NOUN	O	Chemical	1819
.	PUNCT	O	O	1819
High	ADJ	O	O	1820
doses	NOUN	O	O	1820
of	ADP	O	O	1820
isoniazid	NOUN	O	Chemical	1820
increase	VERB	O	O	1820
hypotension	NOUN	O	Disease	1820
induced	VERB	O	O	1820
by	ADP	O	O	1820
vasodilators	NOUN	O	O	1820
and	CCONJ	O	O	1820
change	VERB	O	O	1820
the	PRON	O	O	1820
accompanying	VERB	O	O	1820
reflex	NOUN	O	O	1820
tachycardia	PROPN	O	Disease	1820
to	PART	O	O	1820
bradycardia	NOUN	O	Disease	1820
,	PUNCT	O	O	1820
an	PRON	O	O	1820
interaction	NOUN	O	O	1820
attributed	VERB	O	O	1820
to	PART	O	O	1820
decreased	VERB	O	O	1820
synthesis	NOUN	O	O	1820
of	ADP	O	O	1820
brain	NOUN	O	O	1820
gamma	PROPN	O	O	1820
-	PUNCT	O	O	1820
aminobutyric	PROPN	O	O	1820
acid	PROPN	O	O	1820
(	PUNCT	O	O	1820
GABA	PROPN	O	Chemical	1820
)	PUNCT	O	O	1820
.	PUNCT	O	O	1820
In	ADP	O	O	1821
the	PRON	O	O	1821
present	NOUN	O	O	1821
study	VERB	O	O	1821
,	PUNCT	O	O	1821
the	PRON	O	O	1821
possible	ADJ	O	O	1821
enhancement	NOUN	O	O	1821
by	ADP	O	O	1821
isoniazid	NOUN	O	Chemical	1821
of	ADP	O	O	1821
bradycardia	NOUN	O	Disease	1821
induced	VERB	O	O	1821
by	ADP	O	O	1821
beta	NOUN	O	O	1821
-	PUNCT	O	O	1821
adrenoceptor	NOUN	O	O	1821
antagonists	NOUN	O	O	1821
was	AUX	O	O	1821
determined	VERB	O	O	1821
in	ADP	O	O	1821
rats	NOUN	O	O	1821
anaesthetised	VERB	O	O	1821
with	ADP	O	O	1821
chloralose	PROPN	O	Chemical	1821
-	PUNCT	O	O	1821
urethane	NOUN	O	Chemical	1821
.	PUNCT	O	O	1821
Isoniazid	PROPN	O	Chemical	1822
significantly	ADV	O	O	1822
increased	VERB	O	O	1822
bradycardia	NOUN	O	Disease	1822
after	ADP	O	O	1822
propranolol	NOUN	O	Chemical	1822
,	PUNCT	O	O	1822
pindolol	VERB	O	Chemical	1822
,	PUNCT	O	O	1822
labetalol	NOUN	O	Chemical	1822
and	CCONJ	O	O	1822
atenolol	PROPN	O	Chemical	1822
,	PUNCT	O	O	1822
as	ADP	O	O	1822
well	ADV	O	O	1822
as	ADP	O	O	1822
after	ADP	O	O	1822
clonidine	NOUN	O	Chemical	1822
,	PUNCT	O	O	1822
but	CCONJ	O	O	1822
not	PART	O	O	1822
after	ADP	O	O	1822
hexamethonium	ADJ	O	Chemical	1822
or	CCONJ	O	O	1822
carbachol	NOUN	O	Chemical	1822
.	PUNCT	O	O	1822
Enhancement	NOUN	O	O	1823
was	AUX	O	O	1823
not	PART	O	O	1823
observed	VERB	O	O	1823
in	ADP	O	O	1823
rats	NOUN	O	O	1823
pretreated	VERB	O	O	1823
with	ADP	O	O	1823
methylatropine	NOUN	O	Chemical	1823
or	CCONJ	O	O	1823
previously	ADV	O	O	1823
vagotomised	VERB	O	O	1823
.	PUNCT	O	O	1823
These	PRON	O	O	1824
results	VERB	O	O	1824
are	AUX	O	O	1824
compatible	ADJ	O	O	1824
with	ADP	O	O	1824
interference	NOUN	O	O	1824
by	ADP	O	O	1824
isoniazid	NOUN	O	Chemical	1824
with	ADP	O	O	1824
GABAergic	PROPN	O	O	1824
inhibition	NOUN	O	O	1824
of	ADP	O	O	1824
cardiac	ADJ	O	O	1824
parasympathetic	ADJ	O	O	1824
tone	NOUN	O	O	1824
.	PUNCT	O	O	1824
Epileptogenic	NOUN	O	O	1827
activity	NOUN	O	O	1827
of	ADP	O	O	1827
folic acid	NOUN	O	Chemical	1827
after	ADP	O	O	1827
drug	NOUN	O	O	1827
induces	VERB	O	O	1827
SLE	PROPN	O	Disease	1827
(	PUNCT	O	O	1827
folic acid	NOUN	O	Chemical	1827
and	CCONJ	O	O	1827
epilepsy	NOUN	O	Disease	1827
)	PUNCT	O	O	1827
OBJECTIVE	VERB	O	O	1827
:	PUNCT	O	O	1827
To	PART	O	O	1827
study	VERB	O	O	1827
the	PRON	O	O	1827
effect	VERB	O	O	1827
of	ADP	O	O	1827
folic acid	NOUN	O	Chemical	1827
-	PUNCT	O	O	1827
containing	VERB	O	O	1827
multivitamin	PROPN	O	O	1827
supplementation	NOUN	O	O	1827
in	ADP	O	O	1827
epileptic	ADJ	O	Disease	1827
women	NOUN	O	O	1827
before	ADP	O	O	1827
and	CCONJ	O	O	1827
during	ADP	O	O	1827
pregnancy	NOUN	O	O	1827
in	ADP	O	O	1827
order	NOUN	O	O	1827
to	PART	O	O	1827
determine	VERB	O	O	1827
the	PRON	O	O	1827
rate	NOUN	O	O	1827
of	ADP	O	O	1827
structural	ADJ	O	O	1827
birth defects	NOUN	O	Disease	1827
and	CCONJ	O	O	1827
epilepsy	NOUN	O	Disease	1827
-	PUNCT	O	O	1827
related	ADJ	O	O	1827
side	NOUN	O	O	1827
effects	NOUN	O	O	1827
.	PUNCT	O	O	1827
Of	ADV	O	O	1828
60	NUM	O	O	1828
epileptic	ADJ	O	Disease	1828
women	NOUN	O	O	1828
with	ADP	O	O	1828
periconceptional	VERB	O	O	1828
folic acid	NOUN	O	Chemical	1828
(	PUNCT	O	O	1828
0.8	NUM	O	O	1828
mg)-containing	VERB	O	O	1828
multivitamin	PROPN	O	O	1828
supplementation	NOUN	O	O	1828
,	PUNCT	O	O	1828
no	PRON	O	O	1828
one	NUM	O	O	1828
developed	VERB	O	O	1828
epilepsy	NOUN	O	Disease	1828
-	PUNCT	O	O	1828
related	ADJ	O	O	1828
side	NOUN	O	O	1828
effects	NOUN	O	O	1828
during	ADP	O	O	1828
the	PRON	O	O	1828
periconception	NOUN	O	O	1828
period	NOUN	O	O	1828
.	PUNCT	O	O	1828
One	NUM	O	O	1829
epileptic	ADJ	O	Disease	1829
woman	NOUN	O	O	1829
delivered	VERB	O	O	1829
a	PRON	O	O	1829
newborn	ADJ	O	O	1829
with	ADP	O	O	1829
cleft lip and palate	NOUN	O	Disease	1829
.	PUNCT	O	O	1829
Another	PRON	O	O	1830
patient	NOUN	O	O	1830
exhibited	VERB	O	O	1830
with	ADP	O	O	1830
a	PRON	O	O	1830
cluster	NOUN	O	O	1830
of	ADP	O	O	1830
seizures	NOUN	O	Disease	1830
after	ADP	O	O	1830
the	PRON	O	O	1830
periconception	NOUN	O	O	1830
period	NOUN	O	O	1830
using	VERB	O	O	1830
another	PRON	O	O	1830
multivitamin	PROPN	O	O	1830
.	PUNCT	O	O	1830
This	PRON	O	O	1831
22-year	NOUN	O	O	1831
-	PUNCT	O	O	1831
old	ADJ	O	O	1831
epileptic	ADJ	O	Disease	1831
woman	NOUN	O	O	1831
was	AUX	O	O	1831
treated	VERB	O	O	1831
continuously	ADV	O	O	1831
by	ADP	O	O	1831
carbamazepine	NOUN	O	Chemical	1831
and	CCONJ	O	O	1831
a	PRON	O	O	1831
folic acid	NOUN	O	Chemical	1831
(	PUNCT	O	O	1831
1	X	O	O	1831
mg)-containing	VERB	O	O	1831
multivitamin	PROPN	O	O	1831
from	ADP	O	O	1831
the	PRON	O	O	1831
20th	ADJ	O	O	1831
week	NOUN	O	O	1831
of	ADP	O	O	1831
gestation	NOUN	O	O	1831
.	PUNCT	O	O	1831
She	PRON	O	O	1832
developed	VERB	O	O	1832
status epilepticus	VERB	O	Disease	1832
and	CCONJ	O	O	1832
later	ADV	O	O	1832
symptoms	NOUN	O	O	1832
of	ADP	O	O	1832
systemic lupus erythematodes	NOUN	O	Disease	1832
.	PUNCT	O	O	1832
Her	PRON	O	O	1833
pregnancy	NOUN	O	O	1833
ended	VERB	O	O	1833
with	ADP	O	O	1833
stillbirth	NOUN	O	Disease	1833
.	PUNCT	O	O	1833
The	PRON	O	O	1834
epileptic	ADJ	O	Disease	1834
pregnant	ADJ	O	O	1834
patient	NOUN	O	O	1834
's	AUX	O	O	1834
autoimmune disease	NOUN	O	Disease	1834
(	PUNCT	O	O	1834
probably	ADV	O	O	1834
drug	NOUN	O	O	1834
-	PUNCT	O	O	1834
induced	VERB	O	O	1834
lupus	PROPN	O	Disease	1834
)	PUNCT	O	O	1834
could	AUX	O	O	1834
damage	NOUN	O	O	1834
the	PRON	O	O	1834
blood	NOUN	O	O	1834
-	PUNCT	O	O	1834
brain	NOUN	O	O	1834
barrier	NOUN	O	O	1834
,	PUNCT	O	O	1834
therefore	ADV	O	O	1834
the	PRON	O	O	1834
therapeutic	ADJ	O	O	1834
dose	NOUN	O	O	1834
(	PUNCT	O	O	1834
>	PUNCT	O	O	1834
or	CCONJ	O	O	1834
=	PUNCT	O	O	1834
1	X	O	O	1834
mg	VERB	O	O	1834
)	PUNCT	O	O	1834
of	ADP	O	O	1834
folic acid	NOUN	O	Chemical	1834
triggered	VERB	O	O	1834
a	PRON	O	O	1834
cluster	NOUN	O	O	1834
of	ADP	O	O	1834
seizures	NOUN	O	Disease	1834
.	PUNCT	O	O	1834
Physiological	ADJ	O	O	1835
dose	NOUN	O	O	1835
(	PUNCT	O	O	1835
<	X	O	O	1835
1	X	O	O	1835
mg	VERB	O	O	1835
)	PUNCT	O	O	1835
of	ADP	O	O	1835
folic acid	NOUN	O	Chemical	1835
both	PRON	O	O	1835
in	ADP	O	O	1835
healthy	ADJ	O	O	1835
and	CCONJ	O	O	1835
60	NUM	O	O	1835
epileptic	ADJ	O	Disease	1835
women	NOUN	O	O	1835
,	PUNCT	O	O	1835
all	PRON	O	O	1835
without	ADP	O	O	1835
any	PRON	O	O	1835
autoimmune disease	NOUN	O	Disease	1835
,	PUNCT	O	O	1835
did	VERB	O	O	1835
not	PART	O	O	1835
increase	VERB	O	O	1835
the	PRON	O	O	1835
risk	NOUN	O	O	1835
for	ADP	O	O	1835
epileptic seizures	NOUN	O	Disease	1835
.	PUNCT	O	O	1835
Effects	NOUN	O	O	1838
of	ADP	O	O	1838
cisapride	ADV	O	Chemical	1838
on	ADP	O	O	1838
symptoms	NOUN	O	O	1838
and	CCONJ	O	O	1838
postcibal	ADJ	O	O	1838
small	ADJ	O	O	1838
-	PUNCT	O	O	1838
bowel	ADJ	O	O	1838
motor	NOUN	O	O	1838
function	NOUN	O	O	1838
in	ADP	O	O	1838
patients	NOUN	O	O	1838
with	ADP	O	O	1838
irritable bowel syndrome	NOUN	O	Disease	1838
.	PUNCT	O	O	1838
BACKGROUND	NOUN	O	O	1839
:	PUNCT	O	O	1839
Irritable bowel syndrome	NOUN	O	Disease	1839
is	AUX	O	O	1839
a	PRON	O	O	1839
common	ADJ	O	O	1839
cause	VERB	O	O	1839
of	ADP	O	O	1839
abdominal pain	NOUN	O	Disease	1839
and	CCONJ	O	O	1839
discomfort	VERB	O	O	1839
and	CCONJ	O	O	1839
may	AUX	O	O	1839
be	AUX	O	O	1839
related	ADJ	O	O	1839
to	PART	O	O	1839
disordered gastrointestinal motility	NOUN	O	Disease	1839
.	PUNCT	O	O	1839
Our	PRON	O	O	1840
aim	VERB	O	O	1840
was	AUX	O	O	1840
to	PART	O	O	1840
assess	VERB	O	O	1840
the	PRON	O	O	1840
effects	NOUN	O	O	1840
of	ADP	O	O	1840
long	ADV	O	O	1840
-	PUNCT	O	O	1840
term	NOUN	O	O	1840
treatment	NOUN	O	O	1840
with	ADP	O	O	1840
a	PRON	O	O	1840
prokinetic	ADJ	O	O	1840
agent	NOUN	O	O	1840
,	PUNCT	O	O	1840
cisapride	ADV	O	Chemical	1840
,	PUNCT	O	O	1840
on	ADP	O	O	1840
postprandial	ADJ	O	O	1840
jejunal	PROPN	O	O	1840
motility	NOUN	O	O	1840
and	CCONJ	O	O	1840
symptoms	NOUN	O	O	1840
in	ADP	O	O	1840
the	PRON	O	O	1840
irritable bowel syndrome	NOUN	O	Disease	1840
(	PUNCT	O	O	1840
IBS	PROPN	O	Disease	1840
)	PUNCT	O	O	1840
.	PUNCT	O	O	1840
METHODS	NOUN	O	O	1841
:	PUNCT	O	O	1841
Thirty	NUM	O	O	1841
-	PUNCT	O	O	1841
eight	NUM	O	O	1841
patients	NOUN	O	O	1841
with	ADP	O	O	1841
IBS	PROPN	O	Disease	1841
(	PUNCT	O	O	1841
constipation	NOUN	O	Disease	1841
-	PUNCT	O	O	1841
predominant	ADJ	O	O	1841
,	PUNCT	O	O	1841
n	CCONJ	O	O	1841
=	PUNCT	O	O	1841
17	NUM	O	O	1841
;	PUNCT	O	O	1841
diarrhoea	NOUN	O	Disease	1842
-	PUNCT	O	O	1842
predominant	ADJ	O	O	1842
,	PUNCT	O	O	1842
n	CCONJ	O	O	1842
=	PUNCT	O	O	1842
21	NUM	O	O	1842
)	PUNCT	O	O	1842
underwent	VERB	O	O	1842
24-h	NOUN	O	O	1842
ambulatory	ADJ	O	O	1842
jejunal	PROPN	O	O	1842
manometry	NOUN	O	O	1842
before	ADP	O	O	1842
and	CCONJ	O	O	1842
after	ADP	O	O	1842
12	NUM	O	O	1842
week	NOUN	O	O	1842
's	AUX	O	O	1842
treatment	NOUN	O	O	1842
[	X	O	O	1842
cisapride	ADV	O	Chemical	1842
,	PUNCT	O	O	1842
5	NUM	O	O	1842
mg	VERB	O	O	1842
three	NUM	O	O	1842
times	NOUN	O	O	1842
daily	ADV	O	O	1842
(	PUNCT	O	O	1842
n	CCONJ	O	O	1842
=	PUNCT	O	O	1842
19	NUM	O	O	1842
)	PUNCT	O	O	1842
or	CCONJ	O	O	1842
placebo	NOUN	O	O	1842
In	ADP	O	O	1843
diarrhoea	NOUN	O	Disease	1843
-	PUNCT	O	O	1843
predominant	ADJ	O	O	1843
patients	NOUN	O	O	1843
significant	ADJ	O	O	1843
differences	NOUN	O	O	1843
in	ADP	O	O	1843
contraction	NOUN	O	O	1843
characteristics	NOUN	O	O	1843
were	AUX	O	O	1843
observed	VERB	O	O	1843
between	ADP	O	O	1843
the	PRON	O	O	1843
cisapride	ADV	O	Chemical	1843
and	CCONJ	O	O	1843
placebo	NOUN	O	O	1843
groups	NOUN	O	O	1843
.	PUNCT	O	O	1843
In	ADP	O	O	1844
cisapride	ADV	O	Chemical	1844
-	PUNCT	O	O	1844
treated	VERB	O	O	1844
diarrhoea	NOUN	O	Disease	1844
-	PUNCT	O	O	1844
predominant	ADJ	O	O	1844
patients	NOUN	O	O	1844
the	PRON	O	O	1844
mean	VERB	O	O	1844
contraction	NOUN	O	O	1844
amplitude	VERB	O	O	1844
was	AUX	O	O	1844
higher	ADJ	O	O	1844
(	PUNCT	O	O	1844
29.3	NUM	O	O	1844
+	ADP	O	O	1844
/-	PUNCT	O	O	1844
2.6	NUM	O	O	1845
mm	INTJ	O	O	1845
Hg	PROPN	O	O	1845
,	PUNCT	O	O	1845
cisapride	ADV	O	Chemical	1845
versus	ADP	O	O	1845
placebo	NOUN	O	O	1845
(	PUNCT	O	O	1845
P	NOUN	O	Chemical	1845
<	X	O	O	1845
0.001	NUM	O	O	1845
)	PUNCT	O	O	1845
;	PUNCT	O	O	1845
pretreatment	NOUN	O	O	1845
,	PUNCT	O	O	1845
25.7	NUM	O	O	1845
+	ADP	O	O	1845
/-	PUNCT	O	O	1845
0.2	NUM	O	O	1846
sec	PROPN	O	O	1846
,	PUNCT	O	O	1846
cisapride	ADV	O	Chemical	1846
versus	ADP	O	O	1846
placebo	NOUN	O	O	1846
(	PUNCT	O	O	1846
P	NOUN	O	Chemical	1846
<	X	O	O	1846
0.001	NUM	O	O	1846
)	PUNCT	O	O	1846
;	PUNCT	O	O	1846
pretreatment	NOUN	O	O	1846
,	PUNCT	O	O	1846
3.1	NUM	O	O	1846
+	ADP	O	O	1846
/-	PUNCT	O	O	1846
0.4	NUM	O	O	1847
cont./min	NOUN	O	O	1847
,	PUNCT	O	O	1847
cisapride	ADV	O	Chemical	1847
versus	ADP	O	O	1847
placebo	NOUN	O	O	1847
(	PUNCT	O	O	1847
P	NOUN	O	Chemical	1847
No	PRON	O	O	1848
significant	ADJ	O	O	1848
differences	NOUN	O	O	1848
in	ADP	O	O	1848
jejunal	PROPN	O	O	1848
motility	NOUN	O	O	1848
were	AUX	O	O	1848
found	VERB	O	O	1848
in	ADP	O	O	1848
the	PRON	O	O	1848
constipation	NOUN	O	Disease	1848
-	PUNCT	O	O	1848
predominant	ADJ	O	O	1848
IBS	PROPN	O	Disease	1848
group	NOUN	O	O	1848
.	PUNCT	O	O	1848
Symptom	NOUN	O	O	1849
scores	NOUN	O	O	1849
relating	VERB	O	O	1849
to	PART	O	O	1849
the	PRON	O	O	1849
severity	NOUN	O	O	1849
of	ADP	O	O	1849
constipation	NOUN	O	Disease	1849
were	AUX	O	O	1849
lower	ADJ	O	O	1849
in	ADP	O	O	1849
cisapride	ADV	O	Chemical	1849
-	PUNCT	O	O	1849
treated	VERB	O	O	1849
constipation	NOUN	O	Disease	1849
-	PUNCT	O	O	1849
predominant	ADJ	O	O	1849
IBS	PROPN	O	Disease	1849
patients	NOUN	O	O	1849
[	X	O	O	1849
score	VERB	O	O	1849
,	PUNCT	O	O	1849
54	NUM	O	O	1849
+	ADP	O	O	1849
/-	PUNCT	O	O	1849
14	NUM	O	O	1850
mm	INTJ	O	O	1850
,	PUNCT	O	O	1850
cisapride	ADV	O	Chemical	1850
versus	ADP	O	O	1850
placebo	NOUN	O	O	1850
(	PUNCT	O	O	1850
P	NOUN	O	Chemical	1850
<	X	O	O	1850
0.05	NUM	O	O	1850
)	PUNCT	O	O	1850
;	PUNCT	O	O	1850
pretreatment	NOUN	O	O	1850
,	PUNCT	O	O	1850
62	NUM	O	O	1850
+	ADP	O	O	1850
/-	PUNCT	O	O	1850
Diarrhoea	NOUN	O	Disease	1851
-	PUNCT	O	O	1851
predominant	ADJ	O	O	1851
IBS	PROPN	O	Disease	1851
patients	NOUN	O	O	1851
had	VERB	O	O	1851
a	PRON	O	O	1851
higher	ADJ	O	O	1851
pain	NOUN	O	Disease	1851
score	VERB	O	O	1851
after	ADP	O	O	1851
cisapride	ADV	O	Chemical	1851
therapy	NOUN	O	O	1851
[	X	O	O	1851
score	VERB	O	O	1851
,	PUNCT	O	O	1851
55	NUM	O	O	1851
+	ADP	O	O	1851
/-	PUNCT	O	O	1851
12	NUM	O	O	1852
mm	INTJ	O	O	1852
,	PUNCT	O	O	1852
cisapride	ADV	O	Chemical	1852
versus	ADP	O	O	1852
placebo	NOUN	O	O	1852
(	PUNCT	O	O	1852
P	NOUN	O	Chemical	1852
<	X	O	O	1852
0.05	NUM	O	O	1852
)	PUNCT	O	O	1852
;	PUNCT	O	O	1852
pretreatment	NOUN	O	O	1852
,	PUNCT	O	O	1852
67	NUM	O	O	1852
+	ADP	O	O	1852
/-	PUNCT	O	O	1852
CONCLUSION	PROPN	O	O	1853
:	PUNCT	O	O	1853
Cisapride	ADJ	O	Chemical	1853
affects	VERB	O	O	1853
jejunal	PROPN	O	O	1853
contraction	NOUN	O	O	1853
characteristics	NOUN	O	O	1853
and	CCONJ	O	O	1853
some	PRON	O	O	1853
symptoms	NOUN	O	O	1853
in	ADP	O	O	1853
IBS	PROPN	O	Disease	1853
.	PUNCT	O	O	1853
Clarithromycin	NOUN	O	Chemical	1856
-	PUNCT	O	O	1856
induced	VERB	O	O	1856
ventricular tachycardia	NOUN	O	Disease	1856
.	PUNCT	O	O	1856
Clarithromycin	NOUN	O	Chemical	1857
is	AUX	O	O	1857
a	PRON	O	O	1857
relatively	ADV	O	O	1857
new	ADJ	O	O	1857
macrolide	ADV	O	Chemical	1857
antibiotic	ADJ	O	O	1857
that	SCONJ	O	O	1857
offers	VERB	O	O	1857
twice	ADV	O	O	1857
-	PUNCT	O	O	1857
daily	ADV	O	O	1857
dosing	VERB	O	O	1857
.	PUNCT	O	O	1857
It	PRON	O	O	1858
differs	VERB	O	O	1858
from	ADP	O	O	1858
erythromycin	PROPN	O	Chemical	1858
only	ADV	O	O	1858
in	ADP	O	O	1858
the	PRON	O	O	1858
methylation	NOUN	O	O	1858
of	ADP	O	O	1858
the	PRON	O	O	1858
hydroxyl	PROPN	O	O	1858
group	NOUN	O	O	1858
at	ADP	O	O	1858
position	NOUN	O	O	1858
6	NUM	O	O	1858
.	PUNCT	O	O	1858
Although	SCONJ	O	O	1859
the	PRON	O	O	1859
side	NOUN	O	O	1859
-	PUNCT	O	O	1859
effect	VERB	O	O	1859
profile	NOUN	O	O	1859
of	ADP	O	O	1859
erythromycin	PROPN	O	Chemical	1859
is	AUX	O	O	1859
established	VERB	O	O	1859
,	PUNCT	O	O	1859
including	VERB	O	O	1859
gastroenteritis	NOUN	O	Disease	1859
and	CCONJ	O	O	1859
interactions	NOUN	O	O	1859
with	ADP	O	O	1859
other	ADJ	O	O	1859
drugs	NOUN	O	O	1859
subject	ADJ	O	O	1859
to	PART	O	O	1859
hepatic	ADJ	O	O	1859
mixed	VERB	O	O	1859
-	PUNCT	O	O	1859
function	NOUN	O	O	1859
oxidase	NOUN	O	O	1859
metabolism	NOUN	O	O	1859
,	PUNCT	O	O	1859
experience	NOUN	O	O	1859
with	ADP	O	O	1859
the	PRON	O	O	1859
newer	ADJ	O	O	1859
macrolides	VERB	O	Chemical	1859
is	AUX	O	O	1859
still	ADV	O	O	1859
being	AUX	O	O	1859
recorded	VERB	O	O	1859
.	PUNCT	O	O	1859
Cardiotoxicity	NOUN	O	Disease	1860
has	VERB	O	O	1860
been	AUX	O	O	1860
demonstrated	VERB	O	O	1860
after	ADP	O	O	1860
both	PRON	O	O	1860
intravenous	ADJ	O	O	1860
and	CCONJ	O	O	1860
oral	ADJ	O	O	1860
administration	NOUN	O	O	1860
of	ADP	O	O	1860
erythromycin	PROPN	O	Chemical	1860
but	CCONJ	O	O	1860
has	VERB	O	O	1860
never	ADV	O	O	1860
been	AUX	O	O	1860
reported	VERB	O	O	1860
with	ADP	O	O	1860
the	PRON	O	O	1860
newer	ADJ	O	O	1860
macrolides	VERB	O	Chemical	1860
.	PUNCT	O	O	1860
We	PRON	O	O	1861
report	VERB	O	O	1861
a	PRON	O	O	1861
case	NOUN	O	O	1861
of	ADP	O	O	1861
ventricular dysrhythmias	NOUN	O	Disease	1861
that	SCONJ	O	O	1861
occurred	VERB	O	O	1861
after	ADP	O	O	1861
six	NUM	O	O	1861
therapeutic	ADJ	O	O	1861
doses	NOUN	O	O	1861
of	ADP	O	O	1861
clarithromycin	PROPN	O	Chemical	1861
.	PUNCT	O	O	1861
The	PRON	O	O	1862
dysrhythmias	VERB	O	Disease	1862
resolved	VERB	O	O	1862
after	ADP	O	O	1862
discontinuation	NOUN	O	O	1862
of	ADP	O	O	1862
the	PRON	O	O	1862
drug	NOUN	O	O	1862
.	PUNCT	O	O	1862
Persistent	ADJ	O	O	1865
nephrogenic	PROPN	O	O	1865
diabetes insipidus	NOUN	O	Disease	1865
following	VERB	O	O	1865
lithium	NOUN	O	Chemical	1865
therapy	NOUN	O	O	1865
.	PUNCT	O	O	1865
We	PRON	O	O	1866
report	VERB	O	O	1866
the	PRON	O	O	1866
case	NOUN	O	O	1866
of	ADP	O	O	1866
a	PRON	O	O	1866
patient	NOUN	O	O	1866
who	PRON	O	O	1866
developed	VERB	O	O	1866
severe	ADJ	O	O	1866
hypernatraemic	NOUN	O	O	1866
dehydration	NOUN	O	Disease	1866
following	VERB	O	O	1866
a	PRON	O	O	1866
head injury	NOUN	O	Disease	1866
.	PUNCT	O	O	1866
Ten	NUM	O	O	1867
years	NOUN	O	O	1867
previously	ADV	O	O	1867
he	PRON	O	O	1867
had	VERB	O	O	1867
been	AUX	O	O	1867
diagnosed	VERB	O	O	1867
to	PART	O	O	1867
have	VERB	O	O	1867
lithium	NOUN	O	Chemical	1867
-	PUNCT	O	O	1867
induced	VERB	O	O	1867
nephrogenic	PROPN	O	O	1867
diabetes insipidus	NOUN	O	Disease	1867
,	PUNCT	O	O	1867
and	CCONJ	O	O	1867
lithium	NOUN	O	Chemical	1867
therapy	NOUN	O	O	1867
had	VERB	O	O	1867
been	AUX	O	O	1867
discontinued	VERB	O	O	1867
.	PUNCT	O	O	1867
He	PRON	O	O	1868
remained	VERB	O	O	1868
thirsty	ADJ	O	O	1868
and	CCONJ	O	O	1868
polyuric	ADJ	O	Disease	1868
despite	SCONJ	O	O	1868
cessation	NOUN	O	O	1868
of	ADP	O	O	1868
lithium	NOUN	O	Chemical	1868
and	CCONJ	O	O	1868
investigations	NOUN	O	O	1868
on	ADP	O	O	1868
admission	NOUN	O	O	1868
showed	VERB	O	O	1868
him	PRON	O	O	1868
to	PART	O	O	1868
have	VERB	O	O	1868
normal	ADJ	O	O	1868
osmoregulated	ADJ	O	O	1868
thirst	NOUN	O	O	1868
and	CCONJ	O	O	1868
vasopressin	NOUN	O	Chemical	1868
secretion	NOUN	O	O	1868
,	PUNCT	O	O	1868
with	ADP	O	O	1868
clear	ADJ	O	O	1868
evidence	NOUN	O	O	1868
of	ADP	O	O	1868
nephrogenic	PROPN	O	O	1868
diabetes insipidus	NOUN	O	Disease	1868
.	PUNCT	O	O	1868
Lithium	NOUN	O	Chemical	1869
induced	VERB	O	O	1869
nephrogenic	PROPN	O	O	1869
diabetes insipidus	NOUN	O	Disease	1869
is	AUX	O	O	1869
considered	VERB	O	O	1869
to	PART	O	O	1869
be	AUX	O	O	1869
reversible	ADJ	O	O	1869
on	ADP	O	O	1869
cessation	NOUN	O	O	1869
of	ADP	O	O	1869
therapy	NOUN	O	O	1869
but	CCONJ	O	O	1869
polyuria	PROPN	O	Disease	1869
persisted	VERB	O	O	1869
in	ADP	O	O	1869
this	PRON	O	O	1869
patient	NOUN	O	O	1869
for	ADP	O	O	1869
ten	NUM	O	O	1869
years	NOUN	O	O	1869
after	ADP	O	O	1869
lithium	NOUN	O	Chemical	1869
was	AUX	O	O	1869
stopped	VERB	O	O	1869
.	PUNCT	O	O	1869
We	PRON	O	O	1870
discuss	VERB	O	O	1870
the	PRON	O	O	1870
possible	ADJ	O	O	1870
renal	ADJ	O	O	1870
mechanisms	NOUN	O	O	1870
and	CCONJ	O	O	1870
the	PRON	O	O	1870
implications	NOUN	O	O	1870
for	ADP	O	O	1870
management	NOUN	O	O	1870
of	ADP	O	O	1870
patients	NOUN	O	O	1870
with	ADP	O	O	1870
lithium	NOUN	O	Chemical	1870
-	PUNCT	O	O	1870
induced	VERB	O	O	1870
nephrogenic	PROPN	O	O	1870
diabetes insipidus	NOUN	O	Disease	1870
.	PUNCT	O	O	1870
Late	ADV	O	O	1873
cardiotoxicity	NOUN	O	Disease	1873
after	ADP	O	O	1873
treatment	NOUN	O	O	1873
for	ADP	O	O	1873
a	PRON	O	O	1873
malignant	ADJ	O	O	1873
bone tumor	NOUN	O	Disease	1873
.	PUNCT	O	O	1873
Cardiac	ADJ	O	O	1874
function	NOUN	O	O	1874
was	AUX	O	O	1874
assessed	VERB	O	O	1874
in	ADP	O	O	1874
long	ADV	O	O	1874
-	PUNCT	O	O	1874
term	NOUN	O	O	1874
survivors	NOUN	O	O	1874
of	ADP	O	O	1874
malignant	ADJ	O	O	1874
bone tumors	NOUN	O	Disease	1874
who	PRON	O	O	1874
were	AUX	O	O	1874
treated	VERB	O	O	1874
according	VERB	O	O	1874
to	PART	O	O	1874
Rosen	PROPN	O	O	1874
's	AUX	O	O	1874
T5	PROPN	O	O	1874
or	CCONJ	O	O	1874
T10	PROPN	O	O	1874
protocol	PROPN	O	O	1874
,	PUNCT	O	O	1874
both	PRON	O	O	1874
including	VERB	O	O	1874
doxorubicin	VERB	O	Chemical	1874
.	PUNCT	O	O	1874
Cumulative	PROPN	O	O	1875
doses	NOUN	O	O	1875
of	ADP	O	O	1875
doxorubicin	VERB	O	Chemical	1875
were	AUX	O	O	1875
225	NUM	O	O	1875
-	PUNCT	O	O	1875
550	NUM	O	O	1875
mg	VERB	O	O	1875
/	PUNCT	O	O	1875
m2	PROPN	O	O	1875
(	PUNCT	O	O	1875
median	ADJ	O	O	1875
dose	NOUN	O	O	1875
360	NUM	O	O	1875
)	PUNCT	O	O	1875
.	PUNCT	O	O	1875
Eighteen	NUM	O	O	1876
of	ADP	O	O	1876
31	NUM	O	O	1876
(	PUNCT	O	O	1876
58%	NOUN	O	O	1876
)	PUNCT	O	O	1876
patients	NOUN	O	O	1876
showed	VERB	O	O	1876
cardiac toxicity	NOUN	O	Disease	1876
,	PUNCT	O	O	1876
defined	VERB	O	O	1876
as	ADP	O	O	1876
having	VERB	O	O	1876
one	NUM	O	O	1876
or	CCONJ	O	O	1876
more	ADJ	O	O	1876
of	ADP	O	O	1876
the	PRON	O	O	1876
following	VERB	O	O	1876
abnormalities	NOUN	O	O	1876
:	PUNCT	O	O	1876
late	ADV	O	O	1876
potentials	NOUN	O	O	1876
,	PUNCT	O	O	1876
complex	ADJ	O	O	1876
ventricular arrhythmias	NOUN	O	Disease	1876
,	PUNCT	O	O	1876
left	VERB	O	O	1876
ventricular dilation	NOUN	O	Disease	1876
,	PUNCT	O	O	1876
decreased	VERB	O	O	1876
shortening	NOUN	O	O	1876
fraction	NOUN	O	O	1876
,	PUNCT	O	O	1876
or	CCONJ	O	O	1876
decreased	VERB	O	O	1876
ejection	NOUN	O	O	1876
fraction	NOUN	O	O	1876
.	PUNCT	O	O	1876
The	PRON	O	O	1877
incidence	NOUN	O	O	1877
of	ADP	O	O	1877
cardiac abnormalities	NOUN	O	Disease	1877
increased	VERB	O	O	1877
with	ADP	O	O	1877
length	NOUN	O	O	1877
of	ADP	O	O	1877
follow	VERB	O	O	1877
-	PUNCT	O	O	1877
up	ADP	O	O	1877
(	PUNCT	O	O	1877
P	NOUN	O	Chemical	1877
<	X	O	O	1877
or	CCONJ	O	O	1877
=	PUNCT	O	O	1877
.05	NUM	O	O	1877
)	PUNCT	O	O	1877
.	PUNCT	O	O	1877
No	PRON	O	O	1878
correlation	NOUN	O	O	1878
could	AUX	O	O	1878
be	AUX	O	O	1878
demonstrated	VERB	O	O	1878
between	ADP	O	O	1878
cumulative	ADJ	O	O	1878
dose	NOUN	O	O	1878
of	ADP	O	O	1878
doxorubicin	VERB	O	Chemical	1878
and	CCONJ	O	O	1878
cardiac	ADJ	O	O	1878
status	NOUN	O	O	1878
,	PUNCT	O	O	1878
except	SCONJ	O	O	1878
for	ADP	O	O	1878
heart	NOUN	O	O	1878
rate	NOUN	O	O	1878
variability	NOUN	O	O	1878
.	PUNCT	O	O	1878
The	PRON	O	O	1879
incidence	NOUN	O	O	1879
of	ADP	O	O	1879
doxorubicin	VERB	O	Chemical	1879
-	PUNCT	O	O	1879
induced	VERB	O	O	1879
cardiotoxicity	NOUN	O	Disease	1879
is	AUX	O	O	1879
high	ADJ	O	O	1879
and	CCONJ	O	O	1879
increases	VERB	O	O	1879
with	ADP	O	O	1879
follow	VERB	O	O	1879
-	PUNCT	O	O	1879
up	ADP	O	O	1879
,	PUNCT	O	O	1879
irrespective	ADV	O	O	1879
of	ADP	O	O	1879
cumulative	ADJ	O	O	1879
dose	NOUN	O	O	1879
.	PUNCT	O	O	1879
The	PRON	O	O	1880
results	VERB	O	O	1880
of	ADP	O	O	1880
our	PRON	O	O	1880
study	VERB	O	O	1880
suggest	VERB	O	O	1880
that	SCONJ	O	O	1880
heart	NOUN	O	O	1880
rate	NOUN	O	O	1880
variability	NOUN	O	O	1880
and	CCONJ	O	O	1880
LVPW	PROPN	O	O	1880
index	NOUN	O	O	1880
could	AUX	O	O	1880
be	AUX	O	O	1880
sensitive	ADJ	O	O	1880
indicators	NOUN	O	O	1880
for	ADP	O	O	1880
cardiotoxicity	NOUN	O	Disease	1880
.	PUNCT	O	O	1880
Venous complications	NOUN	O	Disease	1883
of	ADP	O	O	1883
midazolam	PROPN	O	Chemical	1883
versus	ADP	O	O	1883
diazepam	NOUN	O	Chemical	1883
.	PUNCT	O	O	1883
Although	SCONJ	O	O	1884
some	PRON	O	O	1884
studies	NOUN	O	O	1884
have	VERB	O	O	1884
suggested	VERB	O	O	1884
fewer	ADJ	O	O	1884
venous complications	NOUN	O	Disease	1884
are	AUX	O	O	1884
associated	VERB	O	O	1884
with	ADP	O	O	1884
midazolam	PROPN	O	Chemical	1884
than	ADP	O	O	1884
with	ADP	O	O	1884
diazepam	NOUN	O	Chemical	1884
for	ADP	O	O	1884
endoscopic	ADJ	O	O	1884
procedures	NOUN	O	O	1884
,	PUNCT	O	O	1884
this	PRON	O	O	1884
variable	NOUN	O	O	1884
has	VERB	O	O	1884
not	PART	O	O	1884
been	AUX	O	O	1884
well	ADV	O	O	1884
documented	VERB	O	O	1884
.	PUNCT	O	O	1884
We	PRON	O	O	1885
prospectively	ADV	O	O	1885
evaluated	VERB	O	O	1885
the	PRON	O	O	1885
incidence	NOUN	O	O	1885
of	ADP	O	O	1885
venous complications	NOUN	O	Disease	1885
after	ADP	O	O	1885
intravenous	ADJ	O	O	1885
injection	NOUN	O	O	1885
of	ADP	O	O	1885
diazepam	NOUN	O	Chemical	1885
or	CCONJ	O	O	1885
midazolam	PROPN	O	Chemical	1885
in	ADP	O	O	1885
122	NUM	O	O	1885
consecutive	ADJ	O	O	1885
patients	NOUN	O	O	1885
undergoing	VERB	O	O	1885
colonoscopy	PROPN	O	O	1885
and	CCONJ	O	O	1885
esophagogastroduodenoscopy	PROPN	O	O	1885
.	PUNCT	O	O	1885
Overall	ADV	O	O	1886
,	PUNCT	O	O	1886
venous complications	NOUN	O	Disease	1886
were	AUX	O	O	1886
more	ADJ	O	O	1886
frequent	ADJ	O	O	1886
with	ADP	O	O	1886
diazepam	NOUN	O	Chemical	1886
(	PUNCT	O	O	1886
22	NUM	O	O	1886
of	ADP	O	O	1886
62	NUM	O	O	1886
patients	NOUN	O	O	1886
)	PUNCT	O	O	1886
than	ADP	O	O	1886
with	ADP	O	O	1886
midazolam	PROPN	O	Chemical	1886
(	PUNCT	O	O	1886
4	NUM	O	O	1886
of	ADP	O	O	1886
60	NUM	O	O	1886
patients	NOUN	O	O	1886
)	PUNCT	O	O	1886
(	PUNCT	O	O	1886
p	NOUN	O	O	1886
<	X	O	O	1886
0.001	NUM	O	O	1886
)	PUNCT	O	O	1886
.	PUNCT	O	O	1886
A	PRON	O	O	1887
palpable	ADJ	O	O	1887
venous	ADJ	O	O	1887
cord	NOUN	O	O	1887
was	AUX	O	O	1887
present	NOUN	O	O	1887
in	ADP	O	O	1887
23%	NOUN	O	O	1887
(	PUNCT	O	O	1887
14	NUM	O	O	1887
of	ADP	O	O	1887
62	NUM	O	O	1887
)	PUNCT	O	O	1887
of	ADP	O	O	1887
patients	NOUN	O	O	1887
in	ADP	O	O	1887
the	PRON	O	O	1887
diazepam	NOUN	O	Chemical	1887
group	NOUN	O	O	1887
,	PUNCT	O	O	1887
compared	VERB	O	O	1887
with	ADP	O	O	1887
2%	NOUN	O	O	1887
(	PUNCT	O	O	1887
1	X	O	O	1887
of	ADP	O	O	1887
60	NUM	O	O	1887
patients	NOUN	O	O	1887
)	PUNCT	O	O	1887
in	ADP	O	O	1887
the	PRON	O	O	1887
midazolam	PROPN	O	Chemical	1887
group	NOUN	O	O	1887
(	PUNCT	O	O	1887
p	NOUN	O	O	1887
Pain	NOUN	O	Disease	1888
at	ADP	O	O	1888
the	PRON	O	O	1888
injection	NOUN	O	O	1888
site	NOUN	O	O	1888
occurred	VERB	O	O	1888
in	ADP	O	O	1888
35%	NOUN	O	O	1888
(	PUNCT	O	O	1888
22	NUM	O	O	1888
of	ADP	O	O	1888
62	NUM	O	O	1888
)	PUNCT	O	O	1888
of	ADP	O	O	1888
patients	NOUN	O	O	1888
in	ADP	O	O	1888
the	PRON	O	O	1888
diazepam	NOUN	O	Chemical	1888
group	NOUN	O	O	1888
compared	VERB	O	O	1888
with	ADP	O	O	1888
7%	NOUN	O	O	1888
(	PUNCT	O	O	1888
4	NUM	O	O	1888
of	ADP	O	O	1888
60	NUM	O	O	1888
patients	NOUN	O	O	1888
)	PUNCT	O	O	1888
in	ADP	O	O	1888
the	PRON	O	O	1888
midazolam	PROPN	O	Chemical	1888
group	NOUN	O	O	1888
Swelling	VERB	O	Disease	1889
and	CCONJ	O	O	1889
warmth	NOUN	O	O	1889
at	ADP	O	O	1889
the	PRON	O	O	1889
injection	NOUN	O	O	1889
site	NOUN	O	O	1889
were	AUX	O	O	1889
not	PART	O	O	1889
significantly	ADV	O	O	1889
different	ADJ	O	O	1889
between	ADP	O	O	1889
the	PRON	O	O	1889
two	NUM	O	O	1889
groups	NOUN	O	O	1889
.	PUNCT	O	O	1889
Smoking	VERB	O	O	1890
,	PUNCT	O	O	1890
nonsteroidal	ADJ	O	O	1890
anti	ADJ	O	O	1890
-	PUNCT	O	O	1890
inflammatory	ADJ	O	O	1890
drug	NOUN	O	O	1890
use	VERB	O	O	1890
,	PUNCT	O	O	1890
intravenous	ADJ	O	O	1890
catheter	VERB	O	O	1890
site	NOUN	O	O	1890
,	PUNCT	O	O	1890
dwell	VERB	O	O	1890
time	NOUN	O	O	1890
of	ADP	O	O	1890
the	PRON	O	O	1890
needle	NOUN	O	O	1890
,	PUNCT	O	O	1890
alcohol	NOUN	O	Chemical	1890
use	VERB	O	O	1890
,	PUNCT	O	O	1890
and	CCONJ	O	O	1890
pain	NOUN	O	Disease	1890
during	ADP	O	O	1890
the	PRON	O	O	1890
injection	NOUN	O	O	1890
had	VERB	O	O	1890
no	PRON	O	O	1890
effect	VERB	O	O	1890
on	ADP	O	O	1890
the	PRON	O	O	1890
incidence	NOUN	O	O	1890
of	ADP	O	O	1890
venous complications	NOUN	O	Disease	1890
.	PUNCT	O	O	1890
Tetany	NOUN	O	Disease	1893
and	CCONJ	O	O	1893
rhabdomyolysis	NOUN	O	Disease	1893
due	ADJ	O	O	1893
to	PART	O	O	1893
surreptitious	ADJ	O	O	1893
furosemide	PROPN	O	Chemical	1893
--	PUNCT	O	O	1893
importance	NOUN	O	O	1893
of	ADP	O	O	1893
magnesium	NOUN	O	Chemical	1893
supplementation	NOUN	O	O	1893
.	PUNCT	O	O	1893
Diuretics	NOUN	O	O	1894
may	AUX	O	O	1894
induce	VERB	O	O	1894
hypokalemia	PROPN	O	Disease	1894
,	PUNCT	O	O	1894
hypocalcemia	NOUN	O	Disease	1894
and	CCONJ	O	O	1894
hypomagnesemia	ADV	O	Disease	1894
.	PUNCT	O	O	1894
While	SCONJ	O	O	1895
severe	ADJ	O	O	1895
hypokalemia	PROPN	O	Disease	1895
may	AUX	O	O	1895
cause	VERB	O	O	1895
muscle weakness	NOUN	O	Disease	1895
,	PUNCT	O	O	1895
severe	ADJ	O	O	1895
hypomagnesemia	ADV	O	Disease	1895
is	AUX	O	O	1895
associated	VERB	O	O	1895
with	ADP	O	O	1895
muscle spasms	VERB	O	Disease	1895
and	CCONJ	O	O	1895
tetany	NOUN	O	Disease	1895
which	PRON	O	O	1895
can	AUX	O	O	1895
not	PART	O	O	1895
be	AUX	O	O	1895
corrected	VERB	O	O	1895
by	ADP	O	O	1895
potassium	NOUN	O	Chemical	1895
and	CCONJ	O	O	1895
calcium	NOUN	O	Chemical	1895
supplementation	NOUN	O	O	1895
alone	ADV	O	O	1895
(	PUNCT	O	O	1895
1,2	NUM	O	O	1895
)	PUNCT	O	O	1895
.	PUNCT	O	O	1895
Surreptitious	PROPN	O	O	1896
diuretic	ADJ	O	Chemical	1896
ingestion	NOUN	O	O	1896
has	VERB	O	O	1896
been	AUX	O	O	1896
described	VERB	O	O	1896
,	PUNCT	O	O	1896
mainly	ADV	O	O	1896
in	ADP	O	O	1896
women	NOUN	O	O	1896
who	PRON	O	O	1896
are	AUX	O	O	1896
concerned	VERB	O	O	1896
that	SCONJ	O	O	1896
they	PRON	O	O	1896
are	AUX	O	O	1896
obese	NOUN	O	Disease	1896
or	CCONJ	O	O	1896
edematous	ADJ	O	Disease	1896
.	PUNCT	O	O	1896
Symptomatic	ADJ	O	O	1897
hypokalemia	PROPN	O	Disease	1897
has	VERB	O	O	1897
been	AUX	O	O	1897
reported	VERB	O	O	1897
in	ADP	O	O	1897
such	ADJ	O	O	1897
patients	NOUN	O	O	1897
(	PUNCT	O	O	1897
3	X	O	O	1897
-	PUNCT	O	O	1897
7	NUM	O	O	1897
)	PUNCT	O	O	1897
and	CCONJ	O	O	1897
in	ADP	O	O	1897
one	NUM	O	O	1897
case	NOUN	O	O	1897
hypocalcemia	NOUN	O	Disease	1897
was	AUX	O	O	1897
observed	VERB	O	O	1897
(	PUNCT	O	O	1897
8)	NUM	O	O	1897
,	PUNCT	O	O	1897
but	CCONJ	O	O	1897
the	PRON	O	O	1897
effects	NOUN	O	O	1897
of	ADP	O	O	1897
magnesium	NOUN	O	Chemical	1897
depletion	NOUN	O	O	1897
were	AUX	O	O	1897
not	PART	O	O	1897
noted	VERB	O	O	1897
in	ADP	O	O	1897
these	PRON	O	O	1897
patients	NOUN	O	O	1897
.	PUNCT	O	O	1897
Loss	NOUN	O	O	1900
of	ADP	O	O	1900
glutamate	NOUN	O	Chemical	1900
decarboxylase	PROPN	O	O	1900
mRNA	PROPN	O	O	1900
-	PUNCT	O	O	1900
containing	VERB	O	O	1900
neurons	NOUN	O	O	1900
in	ADP	O	O	1900
the	PRON	O	O	1900
rat	NOUN	O	O	1900
dentate	ADJ	O	O	1900
gyrus	PROPN	O	O	1900
following	VERB	O	O	1900
pilocarpine	NOUN	O	Chemical	1900
-	PUNCT	O	O	1900
induced	VERB	O	O	1900
seizures	NOUN	O	Disease	1900
.	PUNCT	O	O	1900
In	ADP	O	O	1901
situ	PROPN	O	O	1901
hybridization	NOUN	O	O	1901
methods	NOUN	O	O	1901
were	AUX	O	O	1901
used	VERB	O	O	1901
to	PART	O	O	1901
determine	VERB	O	O	1901
if	SCONJ	O	O	1901
glutamic acid	NOUN	O	Chemical	1901
decarboxylase	PROPN	O	O	1901
(	PUNCT	O	O	1901
GAD	PROPN	O	O	1901
)	PUNCT	O	O	1901
mRNA	PROPN	O	O	1902
-	PUNCT	O	O	1902
containing	VERB	O	O	1902
neurons	NOUN	O	O	1902
within	ADP	O	O	1902
the	PRON	O	O	1902
hilus	PROPN	O	O	1902
of	ADP	O	O	1902
the	PRON	O	O	1902
dentate	ADJ	O	O	1902
gyrus	PROPN	O	O	1902
are	AUX	O	O	1902
vulnerable	ADJ	O	O	1902
to	PART	O	O	1902
seizure	NOUN	O	Disease	1902
-	PUNCT	O	O	1902
induced	VERB	O	O	1902
damage	NOUN	O	O	1902
in	ADP	O	O	1902
a	PRON	O	O	1902
model	NOUN	O	O	1902
of	ADP	O	O	1902
chronic	ADJ	O	O	1902
seizures	NOUN	O	Disease	1902
.	PUNCT	O	O	1902
Sprague	PROPN	O	O	1903
-	PUNCT	O	O	1903
Dawley	NOUN	O	O	1903
rats	NOUN	O	O	1903
were	AUX	O	O	1903
injected	VERB	O	O	1903
intraperitoneally	ADV	O	O	1903
with	ADP	O	O	1903
pilocarpine	NOUN	O	Chemical	1903
,	PUNCT	O	O	1903
and	CCONJ	O	O	1903
the	PRON	O	O	1903
hippocampal	NOUN	O	O	1903
formation	NOUN	O	O	1903
was	AUX	O	O	1903
studied	VERB	O	O	1903
histologically	ADV	O	O	1903
at	ADP	O	O	1903
1	X	O	O	1903
,	PUNCT	O	O	1903
2	X	O	O	1903
,	PUNCT	O	O	1903
4	NUM	O	O	1903
,	PUNCT	O	O	1903
and	CCONJ	O	O	1903
8	NUM	O	O	1903
week	NOUN	O	O	1903
intervals	NOUN	O	O	1903
after	ADP	O	O	1903
pilocarpine	NOUN	O	Chemical	1903
-	PUNCT	O	O	1903
induced	VERB	O	O	1903
seizures	NOUN	O	Disease	1903
.	PUNCT	O	O	1903
In	ADP	O	O	1904
situ	PROPN	O	O	1904
hybridization	NOUN	O	O	1904
histochemistry	NOUN	O	O	1904
,	PUNCT	O	O	1904
using	VERB	O	O	1904
a	PRON	O	O	1904
digoxigenin	VERB	O	Chemical	1904
-	PUNCT	O	O	1904
labeled	VERB	O	O	1904
GAD	PROPN	O	O	1904
cRNA	PROPN	O	O	1904
probe	NOUN	O	O	1904
,	PUNCT	O	O	1904
demonstrated	VERB	O	O	1904
a	PRON	O	O	1904
substantial	ADJ	O	O	1904
decrease	VERB	O	O	1904
in	ADP	O	O	1904
the	PRON	O	O	1904
number	NOUN	O	O	1904
of	ADP	O	O	1904
GAD	PROPN	O	O	1904
mRNA	PROPN	O	O	1904
-	PUNCT	O	O	1904
containing	VERB	O	O	1904
neurons	NOUN	O	O	1904
in	ADP	O	O	1904
the	PRON	O	O	1904
hilus	PROPN	O	O	1904
of	ADP	O	O	1904
the	PRON	O	O	1904
dentate	ADJ	O	O	1904
gyrus	PROPN	O	O	1904
in	ADP	O	O	1904
the	PRON	O	O	1904
pilocarpine	NOUN	O	Chemical	1904
-	PUNCT	O	O	1904
treated	VERB	O	O	1904
rats	NOUN	O	O	1904
as	ADP	O	O	1904
compared	VERB	O	O	1904
to	PART	O	O	1904
controls	VERB	O	O	1904
at	ADP	O	O	1904
all	PRON	O	O	1904
time	NOUN	O	O	1904
intervals	NOUN	O	O	1904
.	PUNCT	O	O	1904
Additional	ADJ	O	O	1905
neuronanatomical	ADJ	O	O	1905
studies	NOUN	O	O	1905
,	PUNCT	O	O	1905
including	VERB	O	O	1905
cresyl violet	NOUN	O	Chemical	1905
staining	VERB	O	O	1905
,	PUNCT	O	O	1905
neuronal degeneration	NOUN	O	Disease	1905
methods	NOUN	O	O	1905
,	PUNCT	O	O	1905
and	CCONJ	O	O	1905
histochemical	ADJ	O	O	1905
localization	NOUN	O	O	1905
of	ADP	O	O	1905
glial	ADJ	O	O	1905
fibrillary	NOUN	O	O	1905
acidic	ADJ	O	O	1905
protein	NOUN	O	O	1905
,	PUNCT	O	O	1905
suggested	VERB	O	O	1905
that	SCONJ	O	O	1905
the	PRON	O	O	1905
decrease	VERB	O	O	1905
in	ADP	O	O	1905
the	PRON	O	O	1905
number	NOUN	O	O	1905
of	ADP	O	O	1905
GAD	PROPN	O	O	1905
mRNA	PROPN	O	O	1905
-	PUNCT	O	O	1905
containing	VERB	O	O	1905
neurons	NOUN	O	O	1905
was	AUX	O	O	1905
related	ADJ	O	O	1905
to	PART	O	O	1905
neuronal loss	NOUN	O	Disease	1905
rather	ADV	O	O	1905
than	ADP	O	O	1905
to	PART	O	O	1905
a	PRON	O	O	1905
decrease	VERB	O	O	1905
in	ADP	O	O	1905
GAD	PROPN	O	O	1905
mRNA	PROPN	O	O	1905
levels	NOUN	O	O	1905
.	PUNCT	O	O	1905
The	PRON	O	O	1906
results	VERB	O	O	1906
indicate	VERB	O	O	1906
that	SCONJ	O	O	1906
,	PUNCT	O	O	1906
in	ADP	O	O	1906
this	PRON	O	O	1906
model	NOUN	O	O	1906
,	PUNCT	O	O	1906
a	PRON	O	O	1906
subpopulation	NOUN	O	O	1906
of	ADP	O	O	1906
GAD	PROPN	O	O	1906
mRNA	PROPN	O	O	1906
-	PUNCT	O	O	1906
containing	VERB	O	O	1906
neurons	NOUN	O	O	1906
within	ADP	O	O	1906
the	PRON	O	O	1906
dentate	ADJ	O	O	1906
gyrus	PROPN	O	O	1906
is	AUX	O	O	1906
selectively	ADV	O	O	1906
vulnerable	ADJ	O	O	1906
to	PART	O	O	1906
seizure	NOUN	O	Disease	1906
-	PUNCT	O	O	1906
induced	VERB	O	O	1906
damage	NOUN	O	O	1906
.	PUNCT	O	O	1906
Such	ADJ	O	O	1907
differential	ADJ	O	O	1907
vulnerability	NOUN	O	O	1907
appears	VERB	O	O	1907
to	PART	O	O	1907
be	AUX	O	O	1907
another	PRON	O	O	1907
indication	NOUN	O	O	1907
of	ADP	O	O	1907
the	PRON	O	O	1907
heterogeneity	NOUN	O	O	1907
of	ADP	O	O	1907
GABA	PROPN	O	Chemical	1907
neurons	NOUN	O	O	1907
.	PUNCT	O	O	1907
Protective	NOUN	O	O	1910
effect	VERB	O	O	1910
of	ADP	O	O	1910
misoprostol	PROPN	O	Chemical	1910
on	ADP	O	O	1910
indomethacin	VERB	O	Chemical	1910
induced	VERB	O	O	1910
renal dysfunction	NOUN	O	Disease	1910
in	ADP	O	O	1910
elderly	ADJ	O	O	1910
patients	NOUN	O	O	1910
.	PUNCT	O	O	1910
OBJECTIVE	VERB	O	O	1911
:	PUNCT	O	O	1911
To	PART	O	O	1911
evaluate	VERB	O	O	1911
the	PRON	O	O	1911
possible	ADJ	O	O	1911
protective	ADJ	O	O	1911
effects	NOUN	O	O	1911
of	ADP	O	O	1911
misoprostol	PROPN	O	Chemical	1911
on	ADP	O	O	1911
renal	ADJ	O	O	1911
function	NOUN	O	O	1911
in	ADP	O	O	1911
hospitalized	VERB	O	O	1911
elderly	ADJ	O	O	1911
patients	NOUN	O	O	1911
treated	VERB	O	O	1911
with	ADP	O	O	1911
indomethacin	VERB	O	Chemical	1911
.	PUNCT	O	O	1911
Forty	NUM	O	O	1912
-	PUNCT	O	O	1912
five	NUM	O	O	1912
hospitalized	VERB	O	O	1912
elderly	ADJ	O	O	1912
patients	NOUN	O	O	1912
(	PUNCT	O	O	1912
>	PUNCT	O	O	1912
65	NUM	O	O	1912
years	NOUN	O	O	1912
old	ADJ	O	O	1912
)	PUNCT	O	O	1912
who	PRON	O	O	1912
required	VERB	O	O	1912
therapy	NOUN	O	O	1912
with	ADP	O	O	1912
nonsteroidal	ADJ	O	O	1912
antiinflammatory	ADJ	O	O	1912
drugs	NOUN	O	O	1912
(	PUNCT	O	O	1912
NSAID	PROPN	O	Chemical	1912
)	PUNCT	O	O	1912
were	AUX	O	O	1912
randomly	ADV	O	O	1912
assigned	VERB	O	O	1912
to	PART	O	O	1912
receive	VERB	O	O	1912
either	ADV	O	O	1912
indomethacin	VERB	O	Chemical	1912
,	PUNCT	O	O	1912
150	NUM	O	O	1912
mg	VERB	O	O	1912
/	PUNCT	O	O	1912
day	NOUN	O	O	1912
(	PUNCT	O	O	1912
Group	PROPN	O	O	1912
A	PRON	O	O	1912
)	PUNCT	O	O	1912
,	PUNCT	O	O	1912
or	CCONJ	O	O	1912
indomethacin	VERB	O	Chemical	1912
150	NUM	O	O	1912
mg	VERB	O	O	1912
/	PUNCT	O	O	1912
day	NOUN	O	O	1912
plus	CCONJ	O	O	1912
misoprostol	PROPN	O	Chemical	1912
at	ADP	O	O	1912
0.6	NUM	O	O	1912
mg	VERB	O	O	1912
/	PUNCT	O	O	1912
day	NOUN	O	O	1912
(	PUNCT	O	O	1912
Group	PROPN	O	O	1912
B	NOUN	O	O	1912
)	PUNCT	O	O	1912
.	PUNCT	O	O	1912
Laboratory	NOUN	O	O	1913
variables	NOUN	O	O	1913
of	ADP	O	O	1913
renal	ADJ	O	O	1913
function	NOUN	O	O	1913
[	X	O	O	1913
serum	NOUN	O	O	1913
creatinine	PROPN	O	Chemical	1913
,	PUNCT	O	O	1913
blood	NOUN	O	O	1913
urea nitrogen	NOUN	O	Chemical	1913
(	PUNCT	O	O	1913
BUN	PROPN	O	Chemical	1913
)	PUNCT	O	O	1913
and	CCONJ	O	O	1913
electrolytes	NOUN	O	O	1913
]	PUNCT	O	O	1913
were	AUX	O	O	1913
evaluated	VERB	O	O	1913
before	ADP	O	O	1913
initiation	NOUN	O	O	1913
of	ADP	O	O	1913
therapy	NOUN	O	O	1913
and	CCONJ	O	O	1913
every	PRON	O	O	1913
2	X	O	O	1913
days	NOUN	O	O	1913
,	PUNCT	O	O	1913
until	ADP	O	O	1913
termination	NOUN	O	O	1913
of	ADP	O	O	1913
the	PRON	O	O	1913
study	VERB	O	O	1913
(	PUNCT	O	O	1913
a	PRON	O	O	1913
period	NOUN	O	O	1913
of	ADP	O	O	1913
at	ADP	O	O	1913
least	ADJ	O	O	1913
6	NUM	O	O	1913
days	NOUN	O	O	1913
)	PUNCT	O	O	1913
.	PUNCT	O	O	1913
Response	NOUN	O	O	1914
to	PART	O	O	1914
treatment	NOUN	O	O	1914
was	AUX	O	O	1914
estimated	VERB	O	O	1914
by	ADP	O	O	1914
the	PRON	O	O	1914
visual	ADJ	O	O	1914
analog	NOUN	O	O	1914
scale	NOUN	O	O	1914
for	ADP	O	O	1914
severity	NOUN	O	O	1914
of	ADP	O	O	1914
pain	NOUN	O	Disease	1914
.	PUNCT	O	O	1914
Forty	NUM	O	O	1915
-	PUNCT	O	O	1915
two	NUM	O	O	1915
patients	NOUN	O	O	1915
completed	VERB	O	O	1915
the	PRON	O	O	1915
study	VERB	O	O	1915
,	PUNCT	O	O	1915
22	NUM	O	O	1915
in	ADP	O	O	1915
Group	PROPN	O	O	1915
A	PRON	O	O	1915
and	CCONJ	O	O	1915
20	NUM	O	O	1915
in	ADP	O	O	1915
Group	PROPN	O	O	1915
B.	PROPN	O	O	1915
BUN	PROPN	O	Chemical	1915
and	CCONJ	O	O	1915
creatinine	PROPN	O	Chemical	1915
increased	VERB	O	O	1915
by	ADP	O	O	1915
>	PUNCT	O	O	1915
50%	NOUN	O	O	1915
of	ADP	O	O	1915
baseline	VERB	O	O	1915
levels	NOUN	O	O	1915
in	ADP	O	O	1915
54	NUM	O	O	1915
and	CCONJ	O	O	1915
45%	NOUN	O	O	1915
of	ADP	O	O	1915
Group	PROPN	O	O	1915
A	PRON	O	O	1915
patients	NOUN	O	O	1915
,	PUNCT	O	O	1915
respectively	ADV	O	O	1915
,	PUNCT	O	O	1915
compared	VERB	O	O	1915
to	PART	O	O	1915
only	ADV	O	O	1915
20	NUM	O	O	1915
and	CCONJ	O	O	1915
10%	NOUN	O	O	1915
of	ADP	O	O	1915
Group	PROPN	O	O	1915
B	NOUN	O	O	1915
patients	NOUN	O	O	1915
(	PUNCT	O	O	1915
p	NOUN	O	O	1915
<	X	O	O	1915
0.05	NUM	O	O	1915
)	PUNCT	O	O	1915
.	PUNCT	O	O	1915
Potassium	NOUN	O	Chemical	1916
(	PUNCT	O	O	1916
K	PROPN	O	Chemical	1916
)	PUNCT	O	O	1916
increment	NOUN	O	O	1916
of	ADP	O	O	1916
0.6	NUM	O	O	1916
The	PRON	O	O	1917
mean	VERB	O	O	1917
increments	NOUN	O	O	1917
in	ADP	O	O	1917
BUN	PROPN	O	Chemical	1917
,	PUNCT	O	O	1917
creatinine	PROPN	O	Chemical	1917
,	PUNCT	O	O	1917
and	CCONJ	O	O	1917
K	PROPN	O	Chemical	1917
were	AUX	O	O	1917
reduced	VERB	O	O	1917
by	ADP	O	O	1917
63	NUM	O	O	1917
,	PUNCT	O	O	1917
80	NUM	O	O	1917
,	PUNCT	O	O	1917
and	CCONJ	O	O	1917
42%	NOUN	O	O	1917
,	PUNCT	O	O	1917
respectively	ADV	O	O	1917
,	PUNCT	O	O	1917
in	ADP	O	O	1917
Group	PROPN	O	O	1917
B	NOUN	O	O	1917
patients	NOUN	O	O	1917
compared	VERB	O	O	1917
to	PART	O	O	1917
Group	PROPN	O	O	1917
A.	NOUN	O	O	1917
Response	NOUN	O	O	1917
to	PART	O	O	1917
treatment	NOUN	O	O	1917
did	VERB	O	O	1917
not	PART	O	O	1917
differ	VERB	O	O	1917
significantly	ADV	O	O	1917
between	ADP	O	O	1917
the	PRON	O	O	1917
2	X	O	O	1917
groups	NOUN	O	O	1917
.	PUNCT	O	O	1917
CONCLUSION	PROPN	O	O	1918
:	PUNCT	O	O	1918
Hospitalized	VERB	O	O	1918
elderly	ADJ	O	O	1918
patients	NOUN	O	O	1918
are	AUX	O	O	1918
at	ADP	O	O	1918
risk	NOUN	O	O	1918
for	ADP	O	O	1918
developing	VERB	O	O	1918
indomethacin	VERB	O	Chemical	1918
related	ADJ	O	O	1918
renal dysfunction	NOUN	O	Disease	1918
.	PUNCT	O	O	1918
Addition	NOUN	O	O	1919
of	ADP	O	O	1919
misoprostol	PROPN	O	Chemical	1919
can	AUX	O	O	1919
minimize	VERB	O	O	1919
this	PRON	O	O	1919
renal impairment	NOUN	O	Disease	1919
without	ADP	O	O	1919
affecting	VERB	O	O	1919
pain	NOUN	O	Disease	1919
control	VERB	O	O	1919
.	PUNCT	O	O	1919
Nephrotoxic	NOUN	O	Disease	1922
effects	NOUN	O	O	1922
of	ADP	O	O	1922
aminoglycoside	ADV	O	Chemical	1922
treatment	NOUN	O	O	1922
on	ADP	O	O	1922
renal	ADJ	O	O	1922
protein	NOUN	O	O	1922
reabsorption	NOUN	O	O	1922
and	CCONJ	O	O	1922
accumulation	NOUN	O	O	1922
.	PUNCT	O	O	1922
To	PART	O	O	1923
quantify	VERB	O	O	1923
the	PRON	O	O	1923
effects	NOUN	O	O	1923
of	ADP	O	O	1923
gentamicin	VERB	O	Chemical	1923
,	PUNCT	O	O	1923
kanamycin	VERB	O	Chemical	1923
and	CCONJ	O	O	1923
netilmicin	NOUN	O	Chemical	1923
on	ADP	O	O	1923
renal	ADJ	O	O	1923
protein	NOUN	O	O	1923
reabsorption	NOUN	O	O	1923
and	CCONJ	O	O	1923
accumulation	NOUN	O	O	1923
,	PUNCT	O	O	1923
these	PRON	O	O	1923
drugs	NOUN	O	O	1923
were	AUX	O	O	1923
administered	VERB	O	O	1923
to	PART	O	O	1923
rats	NOUN	O	O	1923
intraperitoneally	ADV	O	O	1923
(	PUNCT	O	O	1923
30	NUM	O	O	1923
mg	VERB	O	O	1923
/	PUNCT	O	O	1923
kg	VERB	O	O	1923
/	PUNCT	O	O	1923
day	NOUN	O	O	1923
)	PUNCT	O	O	1923
for	ADP	O	O	1923
7	NUM	O	O	1923
,	PUNCT	O	O	1923
14	NUM	O	O	1923
or	CCONJ	O	O	1923
21	NUM	O	O	1923
days	NOUN	O	O	1923
.	PUNCT	O	O	1923
Scanning	NOUN	O	O	1924
electron	NOUN	O	O	1924
microscopy	NOUN	O	O	1924
of	ADP	O	O	1924
the	PRON	O	O	1924
glomerular	ADJ	O	O	1924
endothelia	PROPN	O	O	1924
,	PUNCT	O	O	1924
urinary	ADJ	O	O	1924
measurements	NOUN	O	O	1924
of	ADP	O	O	1924
sodium	NOUN	O	Chemical	1924
,	PUNCT	O	O	1924
potassium	NOUN	O	Chemical	1924
,	PUNCT	O	O	1924
endogenous	ADJ	O	O	1924
lysozyme	VERB	O	O	1924
,	PUNCT	O	O	1924
N	NUM	O	O	1924
-	PUNCT	O	O	1924
acetyl	PROPN	O	O	1924
-	PUNCT	O	O	1924
beta	NOUN	O	O	1924
-	PUNCT	O	O	1924
D	NOUN	O	O	1924
-	PUNCT	O	O	1924
glucosaminidase	PROPN	O	O	1924
(	PUNCT	O	O	1924
NAG	PROPN	O	O	1924
)	PUNCT	O	O	1924
as	ADP	O	O	1924
well	ADV	O	O	1924
as	ADP	O	O	1924
clearance	NOUN	O	O	1924
and	CCONJ	O	O	1924
accumulation	NOUN	O	O	1924
experiments	NOUN	O	O	1924
after	ADP	O	O	1924
i.v	NOUN	O	O	1924
.	PUNCT	O	O	1924
Gentamicin	PROPN	O	Chemical	1925
administration	NOUN	O	O	1925
decreased	VERB	O	O	1925
diameter	NOUN	O	O	1925
,	PUNCT	O	O	1925
density	NOUN	O	O	1925
and	CCONJ	O	O	1925
shape	NOUN	O	O	1925
of	ADP	O	O	1925
endothelial	NOUN	O	O	1925
fenestrae	NOUN	O	O	1925
.	PUNCT	O	O	1925
Kanamycin	PROPN	O	Chemical	1926
and	CCONJ	O	O	1926
netilmicin	NOUN	O	Chemical	1926
appeared	VERB	O	O	1926
to	PART	O	O	1926
have	VERB	O	O	1926
no	PRON	O	O	1926
effect	VERB	O	O	1926
at	ADP	O	O	1926
the	PRON	O	O	1926
dose	NOUN	O	O	1926
used	VERB	O	O	1926
.	PUNCT	O	O	1926
All	PRON	O	O	1927
three	NUM	O	O	1927
aminoglycosides	NOUN	O	Chemical	1927
decreased	VERB	O	O	1927
GFR	NOUN	O	O	1927
and	CCONJ	O	O	1927
increased	VERB	O	O	1927
urinary	ADJ	O	O	1927
excretion	NOUN	O	O	1927
of	ADP	O	O	1927
sodium	NOUN	O	Chemical	1927
and	CCONJ	O	O	1927
potassium	NOUN	O	Chemical	1927
.	PUNCT	O	O	1927
While	SCONJ	O	O	1928
gentamicin	VERB	O	Chemical	1928
and	CCONJ	O	O	1928
kanamycin	VERB	O	Chemical	1928
decreased	VERB	O	O	1928
the	PRON	O	O	1928
percentage	NOUN	O	O	1928
reabsorption	NOUN	O	O	1928
and	CCONJ	O	O	1928
accumulation	NOUN	O	O	1928
of	ADP	O	O	1928
lysozyme	VERB	O	O	1928
after	ADP	O	O	1928
i.v	NOUN	O	O	1928
.	PUNCT	O	O	1928
administration	NOUN	O	O	1929
of	ADP	O	O	1929
egg	NOUN	O	O	1929
-	PUNCT	O	O	1929
white	ADJ	O	O	1929
lysozyme	VERB	O	O	1929
netilmicin	NOUN	O	Chemical	1929
had	VERB	O	O	1929
no	PRON	O	O	1929
effect	VERB	O	O	1929
.	PUNCT	O	O	1929
Daily	PROPN	O	O	1930
excretion	NOUN	O	O	1930
of	ADP	O	O	1930
total	ADJ	O	O	1930
protein	NOUN	O	O	1930
,	PUNCT	O	O	1930
endogenous	ADJ	O	O	1930
lysozyme	VERB	O	O	1930
and	CCONJ	O	O	1930
NAG	PROPN	O	O	1930
increased	VERB	O	O	1930
only	ADV	O	O	1930
after	ADP	O	O	1930
treatment	NOUN	O	O	1930
with	ADP	O	O	1930
kanamycin	VERB	O	Chemical	1930
and	CCONJ	O	O	1930
gentamicin	VERB	O	Chemical	1930
.	PUNCT	O	O	1930
Thus	ADV	O	O	1931
,	PUNCT	O	O	1931
aminoglycosides	NOUN	O	Chemical	1931
may	AUX	O	O	1931
act	VERB	O	O	1931
as	ADP	O	O	1931
nephrotoxicants	NOUN	O	O	1931
at	ADP	O	O	1931
glomerular	ADJ	O	O	1931
and/or	CCONJ	O	O	1931
tubular	ADJ	O	O	1931
level	VERB	O	O	1931
inducing	VERB	O	O	1931
impairment of renal reabsorption	NOUN	O	Disease	1931
and	CCONJ	O	O	1931
accumulation	NOUN	O	O	1931
of	ADP	O	O	1931
proteins	NOUN	O	O	1931
.	PUNCT	O	O	1931
Pharmacology	NOUN	O	O	1934
of	ADP	O	O	1934
GYKI-41 099	NUM	O	Chemical	1934
(	PUNCT	O	O	1934
chlorpropanol	NOUN	O	Chemical	1934
,	PUNCT	O	O	1934
Tobanum	PROPN	O	Chemical	1934
)	PUNCT	O	O	1934
a	PRON	O	O	1934
new	ADJ	O	O	1934
potent	ADJ	O	O	1934
beta	NOUN	O	O	1934
-	PUNCT	O	O	1934
adrenergic	NOUN	O	O	1934
antagonist	NOUN	O	O	1934
.	PUNCT	O	O	1934
The	PRON	O	O	1935
compound	NOUN	O	O	1935
GYKI-41 099	NUM	O	Chemical	1935
,	PUNCT	O	O	1935
as	ADP	O	O	1935
a	PRON	O	O	1935
beta	NOUN	O	O	1935
-	PUNCT	O	O	1935
adrenergic	NOUN	O	O	1935
antagonist	NOUN	O	O	1935
,	PUNCT	O	O	1935
is	AUX	O	O	1935
3	X	O	O	1935
-	PUNCT	O	O	1935
8	NUM	O	O	1935
times	NOUN	O	O	1935
more	ADJ	O	O	1935
potent	ADJ	O	O	1935
than	ADP	O	O	1935
propranolol	NOUN	O	Chemical	1935
in	ADP	O	O	1935
vitro	X	O	O	1935
and	CCONJ	O	O	1935
in	ADP	O	O	1935
vivo	VERB	O	O	1935
.	PUNCT	O	O	1935
Its	PRON	O	O	1936
antiarrhythmic	PROPN	O	O	1936
effectiveness	NOUN	O	O	1936
surpasses	VERB	O	O	1936
that	SCONJ	O	O	1936
of	ADP	O	O	1936
propranolol	NOUN	O	Chemical	1936
and	CCONJ	O	O	1936
pindolol	VERB	O	Chemical	1936
inhibiting	VERB	O	O	1936
the	PRON	O	O	1936
ouabain	PROPN	O	Chemical	1936
arrhythmia	NOUN	O	Disease	1936
in	ADP	O	O	1936
dogs	NOUN	O	O	1936
and	CCONJ	O	O	1936
cats	NOUN	O	O	1936
.	PUNCT	O	O	1936
GYKI-41 900	NUM	O	Chemical	1937
has	VERB	O	O	1937
a	PRON	O	O	1937
negligible	ADJ	O	O	1937
cardiodepressant	VERB	O	O	1937
activity	NOUN	O	O	1937
;	PUNCT	O	O	1937
it	PRON	O	O	1937
is	AUX	O	O	1937
not	PART	O	O	1937
cardioselective	PROPN	O	O	1937
.	PUNCT	O	O	1937
There	ADV	O	O	1938
was	AUX	O	O	1938
a	PRON	O	O	1938
prolonged	VERB	O	O	1938
elimination	NOUN	O	O	1938
of	ADP	O	O	1938
the	PRON	O	O	1938
radioactivity	NOUN	O	O	1938
after	ADP	O	O	1938
the	PRON	O	O	1938
injection	NOUN	O	O	1938
of	ADP	O	O	1938
14C-41 099	NUM	O	Chemical	1938
to	PART	O	O	1938
rats	NOUN	O	O	1938
and	CCONJ	O	O	1938
dogs	NOUN	O	O	1938
.	PUNCT	O	O	1938
Chorea	PROPN	O	Disease	1941
associated	VERB	O	O	1941
with	ADP	O	O	1941
oral contraception	NOUN	O	Chemical	1941
.	PUNCT	O	O	1941
Three	NUM	O	O	1942
patients	NOUN	O	O	1942
developed	VERB	O	O	1942
chorea	PROPN	O	Disease	1942
while	SCONJ	O	O	1942
receiving	VERB	O	O	1942
oral contraceptives	NOUN	O	Chemical	1942
.	PUNCT	O	O	1942
Two	NUM	O	O	1943
were	AUX	O	O	1943
young	ADJ	O	O	1943
patients	NOUN	O	O	1943
whose	DET	O	O	1943
chorea	PROPN	O	Disease	1943
developed	VERB	O	O	1943
long	ADV	O	O	1943
after	ADP	O	O	1943
treatment	NOUN	O	O	1943
had	VERB	O	O	1943
been	AUX	O	O	1943
started	VERB	O	O	1943
and	CCONJ	O	O	1943
disappeared	VERB	O	O	1943
soon	ADV	O	O	1943
after	ADP	O	O	1943
it	PRON	O	O	1943
had	VERB	O	O	1943
been	AUX	O	O	1943
discontinued	VERB	O	O	1943
.	PUNCT	O	O	1943
The	PRON	O	O	1944
third	ADV	O	O	1944
patient	NOUN	O	O	1944
had	VERB	O	O	1944
acute	ADJ	O	O	1944
amphetamine	NOUN	O	Chemical	1944
-	PUNCT	O	O	1944
induced	VERB	O	O	1944
chorea	PROPN	O	Disease	1944
after	ADP	O	O	1944
prolonged	VERB	O	O	1944
oral contraception	NOUN	O	Chemical	1944
.	PUNCT	O	O	1944
Prolonged	VERB	O	O	1945
administration	NOUN	O	O	1945
of	ADP	O	O	1945
female	ADJ	O	O	1945
sex	NOUN	O	O	1945
hormones	NOUN	O	O	1945
is	AUX	O	O	1945
a	PRON	O	O	1945
possible	ADJ	O	O	1945
cause	VERB	O	O	1945
of	ADP	O	O	1945
chorea	PROPN	O	Disease	1945
in	ADP	O	O	1945
women	NOUN	O	O	1945
who	PRON	O	O	1945
have	VERB	O	O	1945
not	PART	O	O	1945
previously	ADV	O	O	1945
had	VERB	O	O	1945
chorea	PROPN	O	Disease	1945
or	CCONJ	O	O	1945
rheumatic fever	NOUN	O	Disease	1945
.	PUNCT	O	O	1945
Reversal	NOUN	O	O	1948
of	ADP	O	O	1948
ammonia	NOUN	O	Chemical	1948
coma	NOUN	O	Disease	1948
in	ADP	O	O	1948
rats	NOUN	O	O	1948
by	ADP	O	O	1948
L	NOUN	O	O	1948
-	PUNCT	O	O	1948
dopa	PROPN	O	O	1948
:	PUNCT	O	O	1948
a	PRON	O	O	1948
peripheral	ADJ	O	O	1948
effect	VERB	O	O	1948
.	PUNCT	O	O	1948
Ammonia	NOUN	O	Chemical	1949
coma	NOUN	O	Disease	1949
was	AUX	O	O	1949
produced	VERB	O	O	1949
in	ADP	O	O	1949
rats	NOUN	O	O	1949
within	ADP	O	O	1949
10	NUM	O	O	1949
to	PART	O	O	1949
15	NUM	O	O	1949
minutes	NOUN	O	O	1949
of	ADP	O	O	1949
an	PRON	O	O	1949
intraperitonealinjection	PROPN	O	O	1949
of	ADP	O	O	1949
1.7	NUM	O	O	1949
mmol	NOUN	O	O	1949
NH4CL	PROPN	O	Chemical	1949
.	PUNCT	O	O	1949
This	PRON	O	O	1950
coma	NOUN	O	Disease	1950
was	AUX	O	O	1950
prevented	VERB	O	O	1950
with	ADP	O	O	1950
1.68	NUM	O	O	1950
mmol	NOUN	O	O	1950
L	NOUN	O	O	1950
-	PUNCT	O	O	1950
dopa	PROPN	O	O	1950
given	VERB	O	O	1950
by	ADP	O	O	1950
gastric	ADJ	O	O	1950
intubation	NOUN	O	O	1950
15	NUM	O	O	1950
minutes	NOUN	O	O	1950
before	ADP	O	O	1950
the	PRON	O	O	1950
ammonium salt	NOUN	O	Chemical	1950
injection	NOUN	O	O	1950
.	PUNCT	O	O	1950
The	PRON	O	O	1951
effect	VERB	O	O	1951
of	ADP	O	O	1951
L	NOUN	O	O	1951
-	PUNCT	O	O	1951
dopa	PROPN	O	O	1951
was	AUX	O	O	1951
correlated	VERB	O	O	1951
with	ADP	O	O	1951
a	PRON	O	O	1951
decrease	VERB	O	O	1951
in	ADP	O	O	1951
blood	NOUN	O	O	1951
and	CCONJ	O	O	1951
brain	NOUN	O	O	1951
ammonia	NOUN	O	Chemical	1951
,	PUNCT	O	O	1951
an	PRON	O	O	1951
increase	VERB	O	O	1951
in	ADP	O	O	1951
brain	NOUN	O	O	1951
dopamine	NOUN	O	Chemical	1951
,	PUNCT	O	O	1951
and	CCONJ	O	O	1951
an	PRON	O	O	1951
increase	VERB	O	O	1951
in	ADP	O	O	1951
renal	ADJ	O	O	1951
excretion	NOUN	O	O	1951
of	ADP	O	O	1951
ammonia	NOUN	O	Chemical	1951
and	CCONJ	O	O	1951
urea	PROPN	O	Chemical	1951
.	PUNCT	O	O	1951
Intraventricular	PROPN	O	O	1952
infusion	NOUN	O	O	1952
of	ADP	O	O	1952
dopamine	NOUN	O	Chemical	1952
sufficient	ADJ	O	O	1952
to	PART	O	O	1952
raise	VERB	O	O	1952
the	PRON	O	O	1952
brain	NOUN	O	O	1952
dopamine	NOUN	O	Chemical	1952
to	PART	O	O	1952
the	PRON	O	O	1952
same	ADJ	O	O	1952
extent	NOUN	O	O	1952
did	VERB	O	O	1952
not	PART	O	O	1952
prevent	VERB	O	O	1952
the	PRON	O	O	1952
ammonia	NOUN	O	Chemical	1952
coma	NOUN	O	Disease	1952
nor	CCONJ	O	O	1952
affect	VERB	O	O	1952
the	PRON	O	O	1952
blood	NOUN	O	O	1952
and	CCONJ	O	O	1952
brain	NOUN	O	O	1952
ammonia	NOUN	O	Chemical	1952
concentrations	NOUN	O	O	1952
.	PUNCT	O	O	1952
Bilateral	ADJ	O	O	1953
nephrectomy	NOUN	O	O	1953
eliminated	VERB	O	O	1953
the	PRON	O	O	1953
beneficial	ADJ	O	O	1953
effect	VERB	O	O	1953
of	ADP	O	O	1953
L	NOUN	O	O	1953
-	PUNCT	O	O	1953
dopa	PROPN	O	O	1953
on	ADP	O	O	1953
blood	NOUN	O	O	1953
and	CCONJ	O	O	1953
brain	NOUN	O	O	1953
ammonia	NOUN	O	Chemical	1953
and	CCONJ	O	O	1953
the	PRON	O	O	1953
ammonia	NOUN	O	Chemical	1953
coma	NOUN	O	Disease	1953
was	AUX	O	O	1953
not	PART	O	O	1953
prevented	VERB	O	O	1953
.	PUNCT	O	O	1953
Thus	ADV	O	O	1954
,	PUNCT	O	O	1954
the	PRON	O	O	1954
reduction	NOUN	O	O	1954
in	ADP	O	O	1954
blood	NOUN	O	O	1954
and	CCONJ	O	O	1954
brain	NOUN	O	O	1954
ammonia	NOUN	O	Chemical	1954
and	CCONJ	O	O	1954
the	PRON	O	O	1954
prevention	NOUN	O	O	1954
of	ADP	O	O	1954
ammonia	NOUN	O	Chemical	1954
coma	NOUN	O	Disease	1954
after	ADP	O	O	1954
L	NOUN	O	O	1954
-	PUNCT	O	O	1954
dopa	PROPN	O	O	1954
,	PUNCT	O	O	1954
can	AUX	O	O	1954
be	AUX	O	O	1954
accounted	VERB	O	O	1954
for	ADP	O	O	1954
by	ADP	O	O	1954
the	PRON	O	O	1954
peripheral	ADJ	O	O	1954
effect	VERB	O	O	1954
of	ADP	O	O	1954
dopamine	NOUN	O	Chemical	1954
on	ADP	O	O	1954
renal	ADJ	O	O	1954
function	NOUN	O	O	1954
rather	ADV	O	O	1954
than	ADP	O	O	1954
its	PRON	O	O	1954
central	ADJ	O	O	1954
action	NOUN	O	O	1954
.	PUNCT	O	O	1954
These	PRON	O	O	1955
results	VERB	O	O	1955
provide	VERB	O	O	1955
a	PRON	O	O	1955
reasonable	ADJ	O	O	1955
explanation	NOUN	O	O	1955
for	ADP	O	O	1955
the	PRON	O	O	1955
beneficial	ADJ	O	O	1955
effects	NOUN	O	O	1955
observed	VERB	O	O	1955
in	ADP	O	O	1955
some	PRON	O	O	1955
encephalopathic	NOUN	O	Disease	1955
patients	NOUN	O	O	1955
receiving	VERB	O	O	1955
L	NOUN	O	O	1955
-	PUNCT	O	O	1955
dopa	PROPN	O	O	1955
.	PUNCT	O	O	1955
Heparin	PROPN	O	Chemical	1958
-	PUNCT	O	O	1958
induced	VERB	O	O	1958
thrombocytopenia	PROPN	O	Disease	1958
after	ADP	O	O	1958
liver	NOUN	O	O	1958
transplantation	NOUN	O	O	1958
.	PUNCT	O	O	1958
Unfractionated heparin	NOUN	O	Chemical	1959
sodium	NOUN	O	Chemical	1959
(	PUNCT	O	O	1959
UFH	PROPN	O	Chemical	1959
)	PUNCT	O	O	1959
or	CCONJ	O	O	1959
low	ADJ	O	O	1959
-	PUNCT	O	O	1959
molecular	ADJ	O	O	1959
weight	NOUN	O	O	1959
heparin	NOUN	O	Chemical	1959
(	PUNCT	O	O	1959
LMWH	VERB	O	Chemical	1959
)	PUNCT	O	O	1959
is	AUX	O	O	1959
used	VERB	O	O	1959
in	ADP	O	O	1959
anticoagulant	ADJ	O	O	1959
protocols	NOUN	O	O	1959
at	ADP	O	O	1959
several	ADJ	O	O	1959
institutions	NOUN	O	O	1959
to	PART	O	O	1959
prevent	VERB	O	O	1959
thrombosis	NOUN	O	Disease	1959
after	ADP	O	O	1959
liver	NOUN	O	O	1959
transplantation	NOUN	O	O	1959
.	PUNCT	O	O	1959
Heparin	PROPN	O	Chemical	1960
-	PUNCT	O	O	1960
induced	VERB	O	O	1960
thrombocytopenia	PROPN	O	Disease	1960
(	PUNCT	O	O	1960
HIT	VERB	O	Disease	1960
)	PUNCT	O	O	1960
is	AUX	O	O	1960
an	PRON	O	O	1960
adverse	ADJ	O	O	1960
immune	NOUN	O	O	1960
-	PUNCT	O	O	1960
mediated	VERB	O	O	1960
reaction	NOUN	O	O	1960
to	PART	O	O	1960
heparin	NOUN	O	Chemical	1960
,	PUNCT	O	O	1960
resulting	VERB	O	O	1960
in	ADP	O	O	1960
platelet	NOUN	O	O	1960
count	VERB	O	O	1960
decreases	VERB	O	O	1960
of	ADP	O	O	1960
more	ADJ	O	O	1960
than	ADP	O	O	1960
50%	NOUN	O	O	1960
.	PUNCT	O	O	1960
The	PRON	O	O	1961
frequencies	NOUN	O	O	1961
of	ADP	O	O	1961
HIT	VERB	O	Disease	1961
after	ADP	O	O	1961
liver	NOUN	O	O	1961
transplantation	NOUN	O	O	1961
and	CCONJ	O	O	1961
platelet	NOUN	O	O	1961
factor	NOUN	O	O	1961
4/heparin	NOUN	O	O	1961
-	PUNCT	O	O	1961
reactive	ADJ	O	O	1961
antibody	NOUN	O	O	1961
(	PUNCT	O	O	1961
HIT	VERB	O	Disease	1961
antibody	NOUN	O	O	1961
)	PUNCT	O	O	1961
positivity	NOUN	O	O	1961
in	ADP	O	O	1961
liver	NOUN	O	O	1961
transplantation	NOUN	O	O	1961
patients	NOUN	O	O	1961
,	PUNCT	O	O	1961
however	ADV	O	O	1961
,	PUNCT	O	O	1961
are	AUX	O	O	1961
unknown	ADJ	O	O	1961
.	PUNCT	O	O	1961
We	PRON	O	O	1962
started	VERB	O	O	1962
LMWH	VERB	O	Chemical	1962
(	PUNCT	O	O	1962
25	NUM	O	O	1962
IU	PROPN	O	O	1962
/	PUNCT	O	O	1962
kg	VERB	O	O	1962
/	PUNCT	O	O	1962
h	X	O	O	1962
)	PUNCT	O	O	1962
on	ADP	O	O	1962
postoperative	ADJ	O	O	1962
day	NOUN	O	O	1962
(	PUNCT	O	O	1962
POD	NOUN	O	O	1962
)	PUNCT	O	O	1962
1	X	O	O	1962
,	PUNCT	O	O	1962
switching	VERB	O	O	1962
to	PART	O	O	1962
UFH	PROPN	O	Chemical	1962
(	PUNCT	O	O	1962
5000	NUM	O	O	1962
U	NOUN	O	O	1962
/	PUNCT	O	O	1962
d	X	O	O	1962
)	PUNCT	O	O	1962
on	ADP	O	O	1962
POD	NOUN	O	O	1962
2	X	O	O	1962
or	CCONJ	O	O	1962
3	X	O	O	1962
.	PUNCT	O	O	1962
The	PRON	O	O	1963
dose	NOUN	O	O	1963
of	ADP	O	O	1963
UFH	PROPN	O	Chemical	1963
was	AUX	O	O	1963
changed	VERB	O	O	1963
according	VERB	O	O	1963
to	PART	O	O	1963
the	PRON	O	O	1963
activated	VERB	O	O	1963
clotting	VERB	O	O	1963
time	NOUN	O	O	1963
level	VERB	O	O	1963
.	PUNCT	O	O	1963
HIT	VERB	O	Disease	1964
antibody	NOUN	O	O	1964
levels	NOUN	O	O	1964
were	AUX	O	O	1964
measured	VERB	O	O	1964
the	PRON	O	O	1964
day	NOUN	O	O	1964
before	ADP	O	O	1964
surgery	NOUN	O	O	1964
and	CCONJ	O	O	1964
on	ADP	O	O	1964
POD	NOUN	O	O	1964
7	NUM	O	O	1964
and	CCONJ	O	O	1964
14	NUM	O	O	1964
.	PUNCT	O	O	1964
Two	NUM	O	O	1965
patients	NOUN	O	O	1965
developed	VERB	O	O	1965
hepatic	ADJ	O	O	1965
artery	NOUN	O	O	1965
thrombosis	NOUN	O	Disease	1965
on	ADP	O	O	1965
POD	NOUN	O	O	1965
11	NUM	O	O	1965
and	CCONJ	O	O	1965
19	NUM	O	O	1965
,	PUNCT	O	O	1965
respectively	ADV	O	O	1965
,	PUNCT	O	O	1965
although	SCONJ	O	O	1965
they	PRON	O	O	1965
were	AUX	O	O	1965
HIT	VERB	O	Disease	1965
antibody	NOUN	O	O	1965
-	PUNCT	O	O	1965
negative	ADJ	O	O	1965
and	CCONJ	O	O	1965
their	PRON	O	O	1965
platelet	NOUN	O	O	1965
counts	VERB	O	O	1965
were	AUX	O	O	1965
stable	ADJ	O	O	1965
.	PUNCT	O	O	1965
The	PRON	O	O	1966
heparin	NOUN	O	Chemical	1966
-	PUNCT	O	O	1966
induced	VERB	O	O	1966
platelet aggregation	NOUN	O	Disease	1966
test	NOUN	O	O	1966
was	AUX	O	O	1966
negative	ADJ	O	O	1966
in	ADP	O	O	1966
these	PRON	O	O	1966
patients	NOUN	O	O	1966
.	PUNCT	O	O	1966
The	PRON	O	O	1967
percentage	NOUN	O	O	1967
of	ADP	O	O	1967
HIT	VERB	O	Disease	1967
antibody	NOUN	O	O	1967
-	PUNCT	O	O	1967
positive	ADJ	O	O	1967
patients	NOUN	O	O	1967
was	AUX	O	O	1967
0.5%	NOUN	O	O	1967
preoperatively	ADV	O	O	1967
,	PUNCT	O	O	1967
5.6%	NOUN	O	O	1967
on	ADP	O	O	1967
POD	NOUN	O	O	1967
7	NUM	O	O	1967
,	PUNCT	O	O	1967
and	CCONJ	O	O	1967
5.6%	NOUN	O	O	1967
on	ADP	O	O	1967
POD	NOUN	O	O	1967
14	NUM	O	O	1967
.	PUNCT	O	O	1967
None	NOUN	O	O	1968
of	ADP	O	O	1968
the	PRON	O	O	1968
subjects	NOUN	O	O	1968
/	PUNCT	O	O	1968
patients	NOUN	O	O	1968
developed	VERB	O	O	1968
UFH	PROPN	O	Chemical	1968
-	PUNCT	O	O	1968
related	ADJ	O	O	1968
HIT	VERB	O	Disease	1968
.	PUNCT	O	O	1968
In	ADP	O	O	1969
our	PRON	O	O	1969
series	PROPN	O	O	1969
,	PUNCT	O	O	1969
the	PRON	O	O	1969
occurrence	NOUN	O	O	1969
of	ADP	O	O	1969
HIT	VERB	O	Disease	1969
after	ADP	O	O	1969
liver	NOUN	O	O	1969
transplantation	NOUN	O	O	1969
was	AUX	O	O	1969
uncommon	ADJ	O	O	1969
.	PUNCT	O	O	1969
PTU	PROPN	O	Chemical	1972
-	PUNCT	O	O	1972
associated	VERB	O	O	1972
vasculitis	NOUN	O	Disease	1972
in	ADP	O	O	1972
a	PRON	O	O	1972
girl	NOUN	O	O	1972
with	ADP	O	O	1972
Turner Syndrome	PROPN	O	Disease	1972
and	CCONJ	O	O	1972
Graves	NOUN	O	O	1972
'	PUNCT	O	O	1972
disease	PROPN	O	O	1972
.	PUNCT	O	O	1972
Palpable	ADJ	O	O	1973
purpura	NOUN	O	Disease	1973
is	AUX	O	O	1973
a	PRON	O	O	1973
concerning	VERB	O	O	1973
clinical	ADJ	O	O	1973
finding	VERB	O	O	1973
in	ADP	O	O	1973
pediatric	ADJ	O	O	1973
patients	NOUN	O	O	1973
and	CCONJ	O	O	1973
can	AUX	O	O	1973
have	VERB	O	O	1973
many	ADJ	O	O	1973
causes	VERB	O	O	1973
,	PUNCT	O	O	1973
including	VERB	O	O	1973
infectious	ADJ	O	O	1973
and	CCONJ	O	O	1973
autoimmune	PROPN	O	O	1973
processes	NOUN	O	O	1973
.	PUNCT	O	O	1973
A	PRON	O	O	1974
rare	ADJ	O	O	1974
cause	VERB	O	O	1974
,	PUNCT	O	O	1974
drug	NOUN	O	O	1974
-	PUNCT	O	O	1974
induced	VERB	O	O	1974
vasculitis	NOUN	O	Disease	1974
,	PUNCT	O	O	1974
may	AUX	O	O	1974
result	VERB	O	O	1974
from	ADP	O	O	1974
the	PRON	O	O	1974
production	NOUN	O	O	1974
of	ADP	O	O	1974
antineutrophil	PROPN	O	O	1974
cytoplasmic	ADJ	O	O	1974
antibodies	NOUN	O	O	1974
(	PUNCT	O	O	1974
ANCAs	NOUN	O	O	1974
)	PUNCT	O	O	1974
in	ADP	O	O	1974
response	NOUN	O	O	1974
to	PART	O	O	1974
a	PRON	O	O	1974
medication	NOUN	O	O	1974
.	PUNCT	O	O	1974
We	PRON	O	O	1975
report	VERB	O	O	1975
a	PRON	O	O	1975
girl	NOUN	O	O	1975
with	ADP	O	O	1975
Turner syndrome	NOUN	O	Disease	1975
and	CCONJ	O	O	1975
Graves	NOUN	O	O	1975
'	PUNCT	O	O	1975
disease	PROPN	O	O	1975
who	PRON	O	O	1975
presented	VERB	O	O	1975
with	ADP	O	O	1975
palpable	ADJ	O	O	1975
purpuric lesions	NOUN	O	Disease	1975
.	PUNCT	O	O	1975
The	PRON	O	O	1976
diagnosis	NOUN	O	O	1976
of	ADP	O	O	1976
propylthiouracil	NOUN	O	Chemical	1976
(	PUNCT	O	O	1976
PTU)-associated	VERB	O	O	1976
vasculitis	NOUN	O	Disease	1976
was	AUX	O	O	1976
made	VERB	O	O	1976
by	ADP	O	O	1976
observation	NOUN	O	O	1976
of	ADP	O	O	1976
consistent	ADJ	O	O	1976
clinical	ADJ	O	O	1976
features	VERB	O	O	1976
,	PUNCT	O	O	1976
the	PRON	O	O	1976
detection	NOUN	O	O	1976
of	ADP	O	O	1976
elevated	ADJ	O	O	1976
ANA	PROPN	O	O	1976
and	CCONJ	O	O	1976
ANCA	PROPN	O	O	1976
in	ADP	O	O	1976
the	PRON	O	O	1976
blood	NOUN	O	O	1976
,	PUNCT	O	O	1976
and	CCONJ	O	O	1976
the	PRON	O	O	1976
observed	VERB	O	O	1976
clinical	ADJ	O	O	1976
resolution	NOUN	O	O	1976
of	ADP	O	O	1976
symptoms	NOUN	O	O	1976
following	VERB	O	O	1976
withdrawal	NOUN	O	O	1976
of	ADP	O	O	1976
PTU	PROPN	O	Chemical	1976
.	PUNCT	O	O	1976
Subsequent	PROPN	O	O	1977
treatment	NOUN	O	O	1977
of	ADP	O	O	1977
persistent	ADJ	O	O	1977
hyperthyroidism	NOUN	O	Disease	1977
with	ADP	O	O	1977
radioablation	NOUN	O	O	1977
did	VERB	O	O	1977
not	PART	O	O	1977
result	VERB	O	O	1977
in	ADP	O	O	1977
an	PRON	O	O	1977
exacerbation	NOUN	O	O	1977
of	ADP	O	O	1977
the	PRON	O	O	1977
vasculitis	NOUN	O	Disease	1977
,	PUNCT	O	O	1977
a	PRON	O	O	1977
complication	NOUN	O	O	1977
described	VERB	O	O	1977
in	ADP	O	O	1977
prior	ADV	O	O	1977
case	NOUN	O	O	1977
reports	VERB	O	O	1977
.	PUNCT	O	O	1977
Succinylcholine	NOUN	O	Chemical	1980
-	PUNCT	O	O	1980
induced	VERB	O	O	1980
masseter	PROPN	O	O	1980
muscle rigidity	NOUN	O	Disease	1980
during	ADP	O	O	1980
bronchoscopic	NOUN	O	O	1980
removal	NOUN	O	O	1980
of	ADP	O	O	1980
a	PRON	O	O	1980
tracheal	NOUN	O	O	1980
foreign	ADJ	O	O	1980
body	NOUN	O	O	1980
.	PUNCT	O	O	1980
Masseter	NOUN	O	O	1981
muscle rigidity	NOUN	O	Disease	1981
during	ADP	O	O	1981
general	ADJ	O	O	1981
anesthesia	NOUN	O	O	1981
is	AUX	O	O	1981
considered	VERB	O	O	1981
an	PRON	O	O	1981
early	ADV	O	O	1981
warning	VERB	O	O	1981
sign	VERB	O	O	1981
of	ADP	O	O	1981
a	PRON	O	O	1981
possible	ADJ	O	O	1981
episode	PROPN	O	O	1981
of	ADP	O	O	1981
malignant hyperthermia	NOUN	O	Disease	1981
.	PUNCT	O	O	1981
The	PRON	O	O	1982
decision	NOUN	O	O	1982
whether	SCONJ	O	O	1982
to	PART	O	O	1982
continue	VERB	O	O	1982
or	CCONJ	O	O	1982
discontinue	VERB	O	O	1982
the	PRON	O	O	1982
procedure	NOUN	O	O	1982
depends	VERB	O	O	1982
on	ADP	O	O	1982
the	PRON	O	O	1982
urgency	NOUN	O	O	1982
of	ADP	O	O	1982
the	PRON	O	O	1982
surgery	NOUN	O	O	1982
and	CCONJ	O	O	1982
severity	NOUN	O	O	1982
of	ADP	O	O	1982
masseter	PROPN	O	O	1982
muscle rigidity	NOUN	O	Disease	1982
.	PUNCT	O	O	1982
Here	ADV	O	O	1983
,	PUNCT	O	O	1983
we	PRON	O	O	1983
describe	VERB	O	O	1983
a	PRON	O	O	1983
case	NOUN	O	O	1983
of	ADP	O	O	1983
severe	ADJ	O	O	1983
masseter	PROPN	O	O	1983
muscle rigidity	NOUN	O	Disease	1983
(	PUNCT	O	O	1983
jaw of steel	NOUN	O	Disease	1983
)	PUNCT	O	O	1983
after	ADP	O	O	1983
succinylcholine	NOUN	O	Chemical	1983
(	PUNCT	O	O	1983
Sch	ADJ	O	Chemical	1983
)	PUNCT	O	O	1983
administration	NOUN	O	O	1983
during	ADP	O	O	1983
general	ADJ	O	O	1983
anesthetic	NOUN	O	O	1983
management	NOUN	O	O	1983
for	ADP	O	O	1983
rigid	ADJ	O	O	1983
bronchoscopic	NOUN	O	O	1983
removal	NOUN	O	O	1983
of	ADP	O	O	1983
a	PRON	O	O	1983
tracheal	NOUN	O	O	1983
foreign	ADJ	O	O	1983
body	NOUN	O	O	1983
.	PUNCT	O	O	1983
Anesthesia	NOUN	O	O	1984
was	AUX	O	O	1984
continued	VERB	O	O	1984
uneventfully	ADV	O	O	1984
with	ADP	O	O	1984
propofol	VERB	O	Chemical	1984
infusion	NOUN	O	O	1984
while	SCONJ	O	O	1984
all	PRON	O	O	1984
facilities	NOUN	O	O	1984
were	AUX	O	O	1984
available	ADJ	O	O	1984
to	PART	O	O	1984
detect	VERB	O	O	1984
and	CCONJ	O	O	1984
treat	VERB	O	O	1984
malignant hyperthermia	NOUN	O	Disease	1984
.	PUNCT	O	O	1984
Minor	ADJ	O	O	1987
neurological dysfunction	NOUN	O	Disease	1987
,	PUNCT	O	O	1987
cognitive	ADJ	O	O	1987
development	NOUN	O	O	1987
,	PUNCT	O	O	1987
and	CCONJ	O	O	1987
somatic	ADJ	O	O	1987
development	NOUN	O	O	1987
at	ADP	O	O	1987
the	PRON	O	O	1987
age	NOUN	O	O	1987
of	ADP	O	O	1987
3	X	O	O	1987
to	PART	O	O	1987
7	NUM	O	O	1987
years	NOUN	O	O	1987
after	ADP	O	O	1987
dexamethasone	NOUN	O	Chemical	1987
treatment	NOUN	O	O	1987
in	ADP	O	O	1987
very	ADV	O	O	1987
-	PUNCT	O	O	1987
low	ADJ	O	O	1987
birth	NOUN	O	O	1987
-	PUNCT	O	O	1987
weight	NOUN	O	O	1987
infants	NOUN	O	O	1987
.	PUNCT	O	O	1987
The	PRON	O	O	1988
objective	VERB	O	O	1988
of	ADP	O	O	1988
this	PRON	O	O	1988
study	VERB	O	O	1988
was	AUX	O	O	1988
to	PART	O	O	1988
assess	VERB	O	O	1988
minor	ADJ	O	O	1988
neurological dysfunction	NOUN	O	Disease	1988
,	PUNCT	O	O	1988
cognitive	ADJ	O	O	1988
development	NOUN	O	O	1988
,	PUNCT	O	O	1988
and	CCONJ	O	O	1988
somatic	ADJ	O	O	1988
development	NOUN	O	O	1988
after	ADP	O	O	1988
dexamethasone	NOUN	O	Chemical	1988
therapy	NOUN	O	O	1988
in	ADP	O	O	1988
very	ADV	O	O	1988
-	PUNCT	O	O	1988
low	ADJ	O	O	1988
-	PUNCT	O	O	1988
birthweight	ADJ	O	O	1988
infants	NOUN	O	O	1988
.	PUNCT	O	O	1988
Thirty	NUM	O	O	1989
-	PUNCT	O	O	1989
three	NUM	O	O	1989
children	NOUN	O	O	1989
after	ADP	O	O	1989
dexamethasone	NOUN	O	Chemical	1989
treatment	NOUN	O	O	1989
were	AUX	O	O	1989
matched	VERB	O	O	1989
to	PART	O	O	1989
33	NUM	O	O	1989
children	NOUN	O	O	1989
without	ADP	O	O	1989
dexamethasone	NOUN	O	Chemical	1989
treatment	NOUN	O	O	1989
.	PUNCT	O	O	1989
Dexamethasone	NOUN	O	Chemical	1990
was	AUX	O	O	1990
started	VERB	O	O	1990
between	ADP	O	O	1990
the	PRON	O	O	1990
7th	ADJ	O	O	1990
and	CCONJ	O	O	1990
the	PRON	O	O	1990
28th	NOUN	O	O	1990
day	NOUN	O	O	1990
of	ADP	O	O	1990
life	NOUN	O	O	1990
over	ADP	O	O	1990
7	NUM	O	O	1990
days	NOUN	O	O	1990
with	ADP	O	O	1990
a	PRON	O	O	1990
total	ADJ	O	O	1990
dose	NOUN	O	O	1990
of	ADP	O	O	1990
2.35	NUM	O	O	1990
mg	VERB	O	O	1990
/	PUNCT	O	O	1990
kg	VERB	O	O	1990
/	PUNCT	O	O	1990
day	NOUN	O	O	1990
.	PUNCT	O	O	1990
Exclusion	NOUN	O	O	1991
criteria	NOUN	O	O	1991
were	AUX	O	O	1991
asphyxia	NOUN	O	Disease	1991
,	PUNCT	O	O	1991
malformations	NOUN	O	Disease	1991
,	PUNCT	O	O	1991
major	ADJ	O	O	1991
surgical	ADJ	O	O	1991
interventions	NOUN	O	O	1991
,	PUNCT	O	O	1991
small	ADJ	O	O	1991
for	ADP	O	O	1991
gestational	ADJ	O	O	1991
age	NOUN	O	O	1991
,	PUNCT	O	O	1991
intraventricular	PROPN	O	O	1991
haemorrhage	NOUN	O	Disease	1991
grades	NOUN	O	O	1991
III	NUM	O	O	1991
and	CCONJ	O	O	1991
IV	NUM	O	O	1991
,	PUNCT	O	O	1991
periventricular leukomalacia	PROPN	O	Disease	1991
,	PUNCT	O	O	1991
and	CCONJ	O	O	1991
severe	ADJ	O	O	1991
psychomotor retardation	NOUN	O	Disease	1991
.	PUNCT	O	O	1991
Each	PRON	O	O	1992
child	NOUN	O	O	1992
was	AUX	O	O	1992
examined	VERB	O	O	1992
by	ADP	O	O	1992
a	PRON	O	O	1992
neuropediatrician	NOUN	O	O	1992
for	ADP	O	O	1992
minor	ADJ	O	O	1992
neurological dysfunctions	NOUN	O	Disease	1992
and	CCONJ	O	O	1992
tested	VERB	O	O	1992
by	ADP	O	O	1992
a	PRON	O	O	1992
psychologist	NOUN	O	O	1992
for	ADP	O	O	1992
cognitive	ADJ	O	O	1992
development	NOUN	O	O	1992
with	ADP	O	O	1992
a	PRON	O	O	1992
Kaufman	PROPN	O	O	1992
Assessment	NOUN	O	O	1992
Battery	NOUN	O	O	1992
for	ADP	O	O	1992
Children	NOUN	O	O	1992
and	CCONJ	O	O	1992
a	PRON	O	O	1992
Draw	VERB	O	O	1992
-	PUNCT	O	O	1992
a	PRON	O	O	1992
-	PUNCT	O	O	1992
Man	NOUN	O	O	1992
Test	NOUN	O	O	1992
.	PUNCT	O	O	1992
After	ADP	O	O	1993
dexamethasone	NOUN	O	Chemical	1993
treatment	NOUN	O	O	1993
,	PUNCT	O	O	1993
children	NOUN	O	O	1993
showed	VERB	O	O	1993
a	PRON	O	O	1993
higher	ADJ	O	O	1993
rate	NOUN	O	O	1993
of	ADP	O	O	1993
minor	ADJ	O	O	1993
neurological dysfunctions	NOUN	O	Disease	1993
.	PUNCT	O	O	1993
Further	ADV	O	O	1994
long	ADV	O	O	1994
-	PUNCT	O	O	1994
term	NOUN	O	O	1994
follow	VERB	O	O	1994
-	PUNCT	O	O	1994
up	ADP	O	O	1994
studies	NOUN	O	O	1994
will	AUX	O	O	1994
be	AUX	O	O	1994
necessary	ADJ	O	O	1994
to	PART	O	O	1994
fully	ADV	O	O	1994
evaluate	VERB	O	O	1994
the	PRON	O	O	1994
impact	NOUN	O	O	1994
of	ADP	O	O	1994
dexamethasone	NOUN	O	Chemical	1994
on	ADP	O	O	1994
neurological	ADJ	O	O	1994
and	CCONJ	O	O	1994
cognitive	ADJ	O	O	1994
development	NOUN	O	O	1994
.	PUNCT	O	O	1994
Force	NOUN	O	O	1997
overflow	NOUN	O	O	1997
and	CCONJ	O	O	1997
levodopa	NOUN	O	Chemical	1997
-	PUNCT	O	O	1997
induced	VERB	O	O	1997
dyskinesias	PROPN	O	Disease	1997
in	ADP	O	O	1997
Parkinson	NOUN	O	O	1997
's	AUX	O	O	1997
disease	PROPN	O	O	1997
.	PUNCT	O	O	1997
We	PRON	O	O	1998
assessed	VERB	O	O	1998
force	NOUN	O	O	1998
coordination	PROPN	O	O	1998
of	ADP	O	O	1998
the	PRON	O	O	1998
hand	NOUN	O	O	1998
in	ADP	O	O	1998
Parkinson	NOUN	O	O	1998
's	AUX	O	O	1998
disease	PROPN	O	O	1998
and	CCONJ	O	O	1998
its	PRON	O	O	1998
relationship	NOUN	O	O	1998
to	PART	O	O	1998
motor	NOUN	O	O	1998
complications	NOUN	O	O	1998
of	ADP	O	O	1998
levodopa	NOUN	O	Chemical	1998
therapy	NOUN	O	O	1998
,	PUNCT	O	O	1998
particularly	ADV	O	O	1998
to	PART	O	O	1998
levodopa	NOUN	O	Chemical	1998
-	PUNCT	O	O	1998
induced	VERB	O	O	1998
dyskinesias	PROPN	O	Disease	1998
(	PUNCT	O	O	1998
LID	VERB	O	Disease	1998
)	PUNCT	O	O	1998
.	PUNCT	O	O	1998
We	PRON	O	O	1999
studied	VERB	O	O	1999
two	NUM	O	O	1999
groups	NOUN	O	O	1999
of	ADP	O	O	1999
Parkinson	NOUN	O	O	1999
's	AUX	O	O	1999
disease	PROPN	O	O	1999
patients	NOUN	O	O	1999
with	ADP	O	O	1999
(	PUNCT	O	O	1999
Parkinson	NOUN	O	O	1999
's	AUX	O	O	1999
disease	PROPN	O	O	1999
+	ADP	O	O	1999
LID	VERB	O	Disease	1999
,	PUNCT	O	O	1999
n	CCONJ	O	O	1999
=	PUNCT	O	O	1999
23	NUM	O	O	1999
)	PUNCT	O	O	1999
and	CCONJ	O	O	1999
without	ADP	O	O	1999
levodopa	NOUN	O	Chemical	1999
-	PUNCT	O	O	1999
induced	VERB	O	O	1999
dyskinesias	PROPN	O	Disease	1999
(	PUNCT	O	O	1999
Parkinson	NOUN	O	O	1999
's	AUX	O	O	1999
disease	PROPN	O	O	1999
-	PUNCT	O	O	1999
LID	VERB	O	Disease	1999
,	PUNCT	O	O	1999
n	CCONJ	O	O	1999
=	PUNCT	O	O	1999
10	NUM	O	O	1999
)	PUNCT	O	O	1999
,	PUNCT	O	O	1999
and	CCONJ	O	O	1999
age	NOUN	O	O	1999
-	PUNCT	O	O	1999
matched	VERB	O	O	1999
healthy	ADJ	O	O	1999
controls	VERB	O	O	1999
.	PUNCT	O	O	1999
The	PRON	O	O	2000
motor	NOUN	O	O	2000
score	VERB	O	O	2000
of	ADP	O	O	2000
the	PRON	O	O	2000
Unified	VERB	O	O	2000
Parkinson	NOUN	O	O	2000
's	AUX	O	O	2000
Disease	NOUN	O	O	2000
Rating	NOUN	O	O	2000
Scale	NOUN	O	O	2000
,	PUNCT	O	O	2000
a	PRON	O	O	2000
dyskinesia	NOUN	O	Disease	2000
score	VERB	O	O	2000
and	CCONJ	O	O	2000
force	NOUN	O	O	2000
in	ADP	O	O	2000
a	PRON	O	O	2000
grip	NOUN	O	O	2000
-	PUNCT	O	O	2000
lift	VERB	O	O	2000
paradigm	NOUN	O	O	2000
were	AUX	O	O	2000
assessed	VERB	O	O	2000
ON	ADV	O	O	2000
and	CCONJ	O	O	2000
OFF	ADV	O	O	2000
levodopa	NOUN	O	Chemical	2000
.	PUNCT	O	O	2000
A	PRON	O	O	2001
pathological	ADJ	O	O	2001
increase	VERB	O	O	2001
of	ADP	O	O	2001
forces	NOUN	O	O	2001
was	AUX	O	O	2001
seen	VERB	O	O	2001
in	ADP	O	O	2001
ON	ADV	O	O	2001
-	PUNCT	O	O	2001
state	NOUN	O	O	2001
in	ADP	O	O	2001
Parkinson	NOUN	O	O	2001
's	AUX	O	O	2001
disease	PROPN	O	O	2001
+	ADP	O	O	2001
LID	VERB	O	Disease	2001
only	ADV	O	O	2001
.	PUNCT	O	O	2001
In	ADP	O	O	2002
Parkinson	NOUN	O	O	2002
's	AUX	O	O	2002
disease	PROPN	O	O	2002
+	ADP	O	O	2002
LID	VERB	O	Disease	2002
,	PUNCT	O	O	2002
the	PRON	O	O	2002
force	NOUN	O	O	2002
involved	VERB	O	O	2002
in	ADP	O	O	2002
pressing	VERB	O	O	2002
down	ADP	O	O	2002
the	PRON	O	O	2002
object	NOUN	O	O	2002
before	ADP	O	O	2002
lifting	VERB	O	O	2002
was	AUX	O	O	2002
significantly	ADV	O	O	2002
increased	VERB	O	O	2002
by	ADP	O	O	2002
levodopa	NOUN	O	Chemical	2002
(	PUNCT	O	O	2002
by	ADP	O	O	2002
61%	NOUN	O	O	2002
,	PUNCT	O	O	2002
P	NOUN	O	Chemical	2002
<	X	O	O	2002
0.05	NUM	O	O	2002
)	PUNCT	O	O	2002
.	PUNCT	O	O	2002
In	ADP	O	O	2003
contrast	NOUN	O	O	2003
,	PUNCT	O	O	2003
no	PRON	O	O	2003
excessive	ADJ	O	O	2003
force	NOUN	O	O	2003
was	AUX	O	O	2003
found	VERB	O	O	2003
in	ADP	O	O	2003
Parkinson	NOUN	O	O	2003
's	AUX	O	O	2003
disease	PROPN	O	O	2003
-	PUNCT	O	O	2003
LID	VERB	O	Disease	2003
.	PUNCT	O	O	2003
Peak	NOUN	O	O	2004
grip	NOUN	O	O	2004
force	NOUN	O	O	2004
in	ADP	O	O	2004
ON	ADV	O	O	2004
-	PUNCT	O	O	2004
state	NOUN	O	O	2004
was	AUX	O	O	2004
140%	NOUN	O	O	2004
(	PUNCT	O	O	2004
P	NOUN	O	Chemical	2004
<	X	O	O	2004
0.05	NUM	O	O	2004
)	PUNCT	O	O	2004
higher	ADJ	O	O	2004
in	ADP	O	O	2004
Parkinson	NOUN	O	O	2004
's	AUX	O	O	2004
disease	PROPN	O	O	2004
+	ADP	O	O	2004
LID	VERB	O	Disease	2004
than	ADP	O	O	2004
in	ADP	O	O	2004
Parkinson	NOUN	O	O	2004
's	AUX	O	O	2004
disease	PROPN	O	O	2004
-	PUNCT	O	O	2004
LID	VERB	O	Disease	2004
,	PUNCT	O	O	2004
while	SCONJ	O	O	2004
static	ADJ	O	O	2004
grip	NOUN	O	O	2004
force	NOUN	O	O	2004
was	AUX	O	O	2004
increased	VERB	O	O	2004
by	ADP	O	O	2004
138%	NOUN	O	O	2004
(	PUNCT	O	O	2004
P	NOUN	O	Chemical	2004
<	X	O	O	2004
0.01	NUM	O	O	2004
)	PUNCT	O	O	2004
between	ADP	O	O	2004
groups	NOUN	O	O	2004
.	PUNCT	O	O	2004
Severity	NOUN	O	O	2005
of	ADP	O	O	2005
peak	PROPN	O	O	2005
-	PUNCT	O	O	2005
dose	NOUN	O	O	2005
dyskinesias	PROPN	O	Disease	2005
was	AUX	O	O	2005
strongly	ADV	O	O	2005
correlated	VERB	O	O	2005
with	ADP	O	O	2005
grip	NOUN	O	O	2005
force	NOUN	O	O	2005
in	ADP	O	O	2005
ON	ADV	O	O	2005
-	PUNCT	O	O	2005
state	NOUN	O	O	2005
(	PUNCT	O	O	2005
r	X	O	O	2005
=	PUNCT	O	O	2005
0.79	NUM	O	O	2005
with	ADP	O	O	2005
peak	PROPN	O	O	2005
force	NOUN	O	O	2005
,	PUNCT	O	O	2005
P	NOUN	O	Chemical	2005
<	X	O	O	2005
0.01	NUM	O	O	2005
)	PUNCT	O	O	2005
.	PUNCT	O	O	2005
Force	NOUN	O	O	2006
excess	ADJ	O	O	2006
was	AUX	O	O	2006
only	ADV	O	O	2006
observed	VERB	O	O	2006
in	ADP	O	O	2006
patients	NOUN	O	O	2006
with	ADP	O	O	2006
LID	VERB	O	Disease	2006
and	CCONJ	O	O	2006
motor	NOUN	O	O	2006
fluctuations	NOUN	O	O	2006
.	PUNCT	O	O	2006
A	PRON	O	O	2007
close	ADV	O	O	2007
relationship	NOUN	O	O	2007
was	AUX	O	O	2007
seen	VERB	O	O	2007
between	ADP	O	O	2007
the	PRON	O	O	2007
overshooting	VERB	O	O	2007
of	ADP	O	O	2007
forces	NOUN	O	O	2007
and	CCONJ	O	O	2007
dyskinesias	PROPN	O	Disease	2007
in	ADP	O	O	2007
the	PRON	O	O	2007
ON	ADV	O	O	2007
-	PUNCT	O	O	2007
drug	NOUN	O	O	2007
condition	NOUN	O	O	2007
.	PUNCT	O	O	2007
We	PRON	O	O	2008
postulate	VERB	O	O	2008
that	SCONJ	O	O	2008
both	PRON	O	O	2008
LID	VERB	O	Disease	2008
and	CCONJ	O	O	2008
grip	NOUN	O	O	2008
force	NOUN	O	O	2008
excess	ADJ	O	O	2008
share	VERB	O	O	2008
common	ADJ	O	O	2008
pathophysiological	ADJ	O	O	2008
mechanisms	NOUN	O	O	2008
related	ADJ	O	O	2008
to	PART	O	O	2008
motor	NOUN	O	O	2008
fluctuations	NOUN	O	O	2008
.	PUNCT	O	O	2008
Postinfarction	NOUN	O	O	2011
ventricular septal defect	NOUN	O	Disease	2011
associated	VERB	O	O	2011
with	ADP	O	O	2011
long	ADV	O	O	2011
-	PUNCT	O	O	2011
term	NOUN	O	O	2011
steroid	NOUN	O	Chemical	2011
therapy	NOUN	O	O	2011
.	PUNCT	O	O	2011
Two	NUM	O	O	2012
cases	NOUN	O	O	2012
of	ADP	O	O	2012
postinfarction	NOUN	O	O	2012
ventricular	ADJ	O	O	2012
septal rupture	NOUN	O	Disease	2012
in	ADP	O	O	2012
patients	NOUN	O	O	2012
on	ADP	O	O	2012
long	ADV	O	O	2012
-	PUNCT	O	O	2012
term	NOUN	O	O	2012
steroid	NOUN	O	Chemical	2012
therapy	NOUN	O	O	2012
are	AUX	O	O	2012
presented	VERB	O	O	2012
and	CCONJ	O	O	2012
the	PRON	O	O	2012
favourable	ADJ	O	O	2012
outcome	NOUN	O	O	2012
in	ADP	O	O	2012
both	PRON	O	O	2012
cases	NOUN	O	O	2012
described	VERB	O	O	2012
.	PUNCT	O	O	2012
A	PRON	O	O	2013
possible	ADJ	O	O	2013
association	PROPN	O	O	2013
between	ADP	O	O	2013
steroid	NOUN	O	Chemical	2013
therapy	NOUN	O	O	2013
and	CCONJ	O	O	2013
subsequent	ADJ	O	O	2013
postinfarction	NOUN	O	O	2013
septal rupture	NOUN	O	Disease	2013
is	AUX	O	O	2013
discussed	VERB	O	O	2013
.	PUNCT	O	O	2013
Angioedema	PROPN	O	Disease	2016
associated	VERB	O	O	2016
with	ADP	O	O	2016
droperidol	NOUN	O	Chemical	2016
administration	NOUN	O	O	2016
.	PUNCT	O	O	2016
Angioedema	PROPN	O	Disease	2017
,	PUNCT	O	O	2017
also	ADV	O	O	2017
known	VERB	O	O	2017
as	ADP	O	O	2017
angioneurotic edema	NOUN	O	Disease	2017
or	CCONJ	O	O	2017
Quincke	PROPN	O	O	2017
's	AUX	O	O	2017
disease	PROPN	O	O	2017
,	PUNCT	O	O	2017
is	AUX	O	O	2017
a	PRON	O	O	2017
well	ADV	O	O	2017
-	PUNCT	O	O	2017
demarcated	VERB	O	O	2017
,	PUNCT	O	O	2017
localized	VERB	O	O	2017
edema	NOUN	O	Disease	2017
involving	VERB	O	O	2017
the	PRON	O	O	2017
subcutaneous	ADJ	O	O	2017
tissues	NOUN	O	O	2017
that	SCONJ	O	O	2017
may	AUX	O	O	2017
cause	VERB	O	O	2017
upper	ADJ	O	O	2017
-	PUNCT	O	O	2017
airway	NOUN	O	O	2017
obstruction	NOUN	O	O	2017
.	PUNCT	O	O	2017
We	PRON	O	O	2018
report	VERB	O	O	2018
the	PRON	O	O	2018
case	NOUN	O	O	2018
of	ADP	O	O	2018
a	PRON	O	O	2018
previously	ADV	O	O	2018
healthy	ADJ	O	O	2018
19-year	NOUN	O	O	2018
-	PUNCT	O	O	2018
old	ADJ	O	O	2018
man	NOUN	O	O	2018
with	ADP	O	O	2018
no	PRON	O	O	2018
known	VERB	O	O	2018
drug allergies	NOUN	O	Disease	2018
in	ADP	O	O	2018
whom	PRON	O	O	2018
angioedema	NOUN	O	Disease	2018
with	ADP	O	O	2018
significant	ADJ	O	O	2018
tongue swelling	NOUN	O	Disease	2018
and	CCONJ	O	O	2018
protrusion	NOUN	O	O	2018
developed	VERB	O	O	2018
within	ADP	O	O	2018
10	NUM	O	O	2018
minutes	NOUN	O	O	2018
of	ADP	O	O	2018
the	PRON	O	O	2018
administration	NOUN	O	O	2018
of	ADP	O	O	2018
a	PRON	O	O	2018
single	ADJ	O	O	2018
IV	NUM	O	O	2018
dose	NOUN	O	O	2018
of	ADP	O	O	2018
droperidol	NOUN	O	Chemical	2018
.	PUNCT	O	O	2018
Clarithromycin	NOUN	O	Chemical	2021
-	PUNCT	O	O	2021
associated	VERB	O	O	2021
visual hallucinations	NOUN	O	Disease	2021
in	ADP	O	O	2021
a	PRON	O	O	2021
patient	NOUN	O	O	2021
with	ADP	O	O	2021
chronic	ADJ	O	O	2021
renal failure	NOUN	O	Disease	2021
on	ADP	O	O	2021
continuous	ADJ	O	O	2021
ambulatory	ADJ	O	O	2021
peritoneal	ADJ	O	O	2021
dialysis	NOUN	O	O	2021
.	PUNCT	O	O	2021
Visual hallucinations	NOUN	O	Disease	2022
are	AUX	O	O	2022
a	PRON	O	O	2022
rare	ADJ	O	O	2022
event	NOUN	O	O	2022
in	ADP	O	O	2022
chronic	ADJ	O	O	2022
renal failure	NOUN	O	Disease	2022
and	CCONJ	O	O	2022
not	PART	O	O	2022
related	ADJ	O	O	2022
to	PART	O	O	2022
uremia	NOUN	O	Disease	2022
per	ADP	O	O	2022
se	X	O	O	2022
.	PUNCT	O	O	2022
Unreported	ADJ	O	O	2023
in	ADP	O	O	2023
the	PRON	O	O	2023
literature	NOUN	O	O	2023
is	AUX	O	O	2023
visual hallucinations	NOUN	O	Disease	2023
occurring	VERB	O	O	2023
in	ADP	O	O	2023
association	PROPN	O	O	2023
with	ADP	O	O	2023
the	PRON	O	O	2023
new	ADJ	O	O	2023
macrolide	ADV	O	Chemical	2023
antibiotic	ADJ	O	O	2023
,	PUNCT	O	O	2023
clarithromycin	PROPN	O	Chemical	2023
.	PUNCT	O	O	2023
We	PRON	O	O	2024
describe	VERB	O	O	2024
such	ADJ	O	O	2024
a	PRON	O	O	2024
case	NOUN	O	O	2024
in	ADP	O	O	2024
a	PRON	O	O	2024
patient	NOUN	O	O	2024
with	ADP	O	O	2024
end	VERB	O	O	2024
-	PUNCT	O	O	2024
stage	NOUN	O	O	2024
renal disease	NOUN	O	Disease	2024
(	PUNCT	O	O	2024
ESRD	PROPN	O	Disease	2024
)	PUNCT	O	O	2024
maintained	VERB	O	O	2024
on	ADP	O	O	2024
continuous	ADJ	O	O	2024
ambulatory	ADJ	O	O	2024
peritoneal	ADJ	O	O	2024
dialysis	NOUN	O	O	2024
(	PUNCT	O	O	2024
CAPD	NOUN	O	O	2024
)	PUNCT	O	O	2024
.	PUNCT	O	O	2024
The	PRON	O	O	2025
combination	NOUN	O	O	2025
of	ADP	O	O	2025
a	PRON	O	O	2025
relatively	ADV	O	O	2025
high	ADJ	O	O	2025
dose	NOUN	O	O	2025
of	ADP	O	O	2025
clarithromycin	PROPN	O	Chemical	2025
in	ADP	O	O	2025
face	NOUN	O	O	2025
of	ADP	O	O	2025
chronic	ADJ	O	O	2025
renal failure	NOUN	O	Disease	2025
in	ADP	O	O	2025
a	PRON	O	O	2025
functionally	ADV	O	O	2025
anephric	NOUN	O	O	2025
patient	NOUN	O	O	2025
,	PUNCT	O	O	2025
with	ADP	O	O	2025
underlying	VERB	O	O	2025
aluminum	NOUN	O	Chemical	2025
intoxication	NOUN	O	O	2025
,	PUNCT	O	O	2025
may	AUX	O	O	2025
have	VERB	O	O	2025
facilitated	VERB	O	O	2025
the	PRON	O	O	2025
appearance	NOUN	O	O	2025
of	ADP	O	O	2025
this	PRON	O	O	2025
neurotoxic	ADJ	O	Disease	2025
side	NOUN	O	O	2025
effect	VERB	O	O	2025
.	PUNCT	O	O	2025
It	PRON	O	O	2026
is	AUX	O	O	2026
important	ADJ	O	O	2026
to	PART	O	O	2026
understand	VERB	O	O	2026
the	PRON	O	O	2026
pharmacokinetics	NOUN	O	O	2026
of	ADP	O	O	2026
medications	NOUN	O	O	2026
in	ADP	O	O	2026
face	NOUN	O	O	2026
of	ADP	O	O	2026
chronic	ADJ	O	O	2026
renal failure	NOUN	O	Disease	2026
,	PUNCT	O	O	2026
the	PRON	O	O	2026
possibility	NOUN	O	O	2026
of	ADP	O	O	2026
drug	NOUN	O	O	2026
interactions	NOUN	O	O	2026
,	PUNCT	O	O	2026
and	CCONJ	O	O	2026
how	SCONJ	O	O	2026
these	PRON	O	O	2026
factors	NOUN	O	O	2026
should	AUX	O	O	2026
help	VERB	O	O	2026
guide	NOUN	O	O	2026
medication	NOUN	O	O	2026
therapy	NOUN	O	O	2026
in	ADP	O	O	2026
the	PRON	O	O	2026
ESRD	PROPN	O	Disease	2026
patient	NOUN	O	O	2026
.	PUNCT	O	O	2026
Acute	PROPN	O	O	2029
renal toxicity	NOUN	O	Disease	2029
of	ADP	O	O	2029
doxorubicin	VERB	O	Chemical	2029
(	PUNCT	O	O	2029
adriamycin)-loaded	VERB	O	O	2029
cyanoacrylate	PROPN	O	Chemical	2029
nanoparticles	NOUN	O	O	2029
.	PUNCT	O	O	2029
Acute	PROPN	O	O	2030
doxorubicin	VERB	O	Chemical	2030
-	PUNCT	O	O	2030
loaded	VERB	O	O	2030
nanoparticle	PROPN	O	O	2030
(	PUNCT	O	O	2030
DXNP	PROPN	O	O	2030
)	PUNCT	O	O	2030
renal toxicity	NOUN	O	Disease	2030
was	AUX	O	O	2030
explored	VERB	O	O	2030
in	ADP	O	O	2030
both	PRON	O	O	2030
normal	ADJ	O	O	2030
rats	NOUN	O	O	2030
and	CCONJ	O	O	2030
rats	NOUN	O	O	2030
with	ADP	O	O	2030
experimental	ADJ	O	O	2030
glomerulonephritis	NOUN	O	Disease	2030
.	PUNCT	O	O	2030
In	ADP	O	O	2031
normal	ADJ	O	O	2031
rats	NOUN	O	O	2031
,	PUNCT	O	O	2031
2/6	NUM	O	O	2031
rats	NOUN	O	O	2031
given	VERB	O	O	2031
free	ADJ	O	O	2031
doxorubicin	VERB	O	Chemical	2031
(	PUNCT	O	O	2031
DX	PROPN	O	Chemical	2031
)	PUNCT	O	O	2031
(	PUNCT	O	O	2031
5	NUM	O	O	2031
mg	VERB	O	O	2031
/	PUNCT	O	O	2031
kg	VERB	O	O	2031
)	PUNCT	O	O	2031
died	VERB	O	O	2031
within	ADP	O	O	2031
one	NUM	O	O	2031
week	NOUN	O	O	2031
,	PUNCT	O	O	2031
whereas	SCONJ	O	O	2031
all	PRON	O	O	2031
control	VERB	O	O	2031
animals	NOUN	O	O	2031
and	CCONJ	O	O	2031
all	PRON	O	O	2031
rats	NOUN	O	O	2031
having	VERB	O	O	2031
received	VERB	O	O	2031
free	ADJ	O	O	2031
NP	PROPN	O	O	2031
or	CCONJ	O	O	2031
DXNP	PROPN	O	O	2031
survived	VERB	O	O	2031
.	PUNCT	O	O	2031
A	PRON	O	O	2032
3	X	O	O	2032
times	NOUN	O	O	2032
higher	ADJ	O	O	2032
proteinuria	X	O	Disease	2032
appeared	VERB	O	O	2032
in	ADP	O	O	2032
animals	NOUN	O	O	2032
treated	VERB	O	O	2032
with	ADP	O	O	2032
DXNP	PROPN	O	O	2032
than	ADP	O	O	2032
in	ADP	O	O	2032
those	PRON	O	O	2032
treated	VERB	O	O	2032
with	ADP	O	O	2032
DX	PROPN	O	Chemical	2032
.	PUNCT	O	O	2032
Free	ADJ	O	O	2033
NP	PROPN	O	O	2033
did	VERB	O	O	2033
not	PART	O	O	2033
provoke	VERB	O	O	2033
any	PRON	O	O	2033
proteinuria	X	O	Disease	2033
.	PUNCT	O	O	2033
Two	NUM	O	O	2034
hr	NOUN	O	O	2034
post	VERB	O	O	2034
-	PUNCT	O	O	2034
injection	NOUN	O	O	2034
,	PUNCT	O	O	2034
DXNP	PROPN	O	O	2034
was	AUX	O	O	2034
2.7	NUM	O	O	2034
times	NOUN	O	O	2034
more	ADJ	O	O	2034
concentrated	VERB	O	O	2034
in	ADP	O	O	2034
kidneys	NOUN	O	O	2034
than	ADP	O	O	2034
free	ADJ	O	O	2034
DX	PROPN	O	Chemical	2034
(	PUNCT	O	O	2034
p	NOUN	O	O	2034
<	X	O	O	2034
0.025	NUM	O	O	2034
)	PUNCT	O	O	2034
.	PUNCT	O	O	2034
In	ADP	O	O	2035
rats	NOUN	O	O	2035
with	ADP	O	O	2035
immune	NOUN	O	O	2035
experimental	ADJ	O	O	2035
glomerulonephritis	NOUN	O	Disease	2035
,	PUNCT	O	O	2035
5/6	NUM	O	O	2035
rats	NOUN	O	O	2035
given	VERB	O	O	2035
DX	PROPN	O	Chemical	2035
died	VERB	O	O	2035
within	ADP	O	O	2035
7	NUM	O	O	2035
days	NOUN	O	O	2035
,	PUNCT	O	O	2035
in	ADP	O	O	2035
contrast	NOUN	O	O	2035
to	PART	O	O	2035
animals	NOUN	O	O	2035
treated	VERB	O	O	2035
by	ADP	O	O	2035
DXNP	PROPN	O	O	2035
,	PUNCT	O	O	2035
NP	PROPN	O	O	2035
,	PUNCT	O	O	2035
or	CCONJ	O	O	2035
untreated	ADJ	O	O	2035
,	PUNCT	O	O	2035
which	PRON	O	O	2035
all	PRON	O	O	2035
survived	VERB	O	O	2035
.	PUNCT	O	O	2035
Proteinuria	PROPN	O	Disease	2036
appeared	VERB	O	O	2036
in	ADP	O	O	2036
all	PRON	O	O	2036
series	PROPN	O	O	2036
,	PUNCT	O	O	2036
but	CCONJ	O	O	2036
was	AUX	O	O	2036
2	X	O	O	2036
-	PUNCT	O	O	2036
5	NUM	O	O	2036
times	NOUN	O	O	2036
more	ADJ	O	O	2036
intense	ADJ	O	O	2036
(	PUNCT	O	O	2036
p	NOUN	O	O	2036
>	PUNCT	O	O	2036
0.001	NUM	O	O	2036
)	PUNCT	O	O	2036
and	CCONJ	O	O	2036
prolonged	VERB	O	O	2036
after	ADP	O	O	2036
doxorubicin	VERB	O	Chemical	2036
treatment	NOUN	O	O	2036
(	PUNCT	O	O	2036
400	NUM	O	O	2036
-	PUNCT	O	O	2036
700	NUM	O	O	2036
mg	VERB	O	O	2036
/	PUNCT	O	O	2036
day	NOUN	O	O	2036
)	PUNCT	O	O	2036
,	PUNCT	O	O	2036
without	ADP	O	O	2036
significant	ADJ	O	O	2036
difference	NOUN	O	O	2036
between	ADP	O	O	2036
DXNP	PROPN	O	O	2036
and	CCONJ	O	O	2036
DX	PROPN	O	Chemical	2036
.	PUNCT	O	O	2036
These	PRON	O	O	2037
results	VERB	O	O	2037
demonstrate	VERB	O	O	2037
that	SCONJ	O	O	2037
,	PUNCT	O	O	2037
in	ADP	O	O	2037
these	PRON	O	O	2037
experimental	ADJ	O	O	2037
conditions	NOUN	O	O	2037
,	PUNCT	O	O	2037
DXNP	PROPN	O	O	2037
killed	VERB	O	O	2037
less	ADV	O	O	2037
animals	NOUN	O	O	2037
than	ADP	O	O	2037
free	ADJ	O	O	2037
DX	PROPN	O	Chemical	2037
,	PUNCT	O	O	2037
despite	SCONJ	O	O	2037
of	ADP	O	O	2037
an	PRON	O	O	2037
enhanced	VERB	O	O	2037
renal toxicity	NOUN	O	Disease	2037
of	ADP	O	O	2037
the	PRON	O	O	2037
former	ADJ	O	O	2037
.	PUNCT	O	O	2037
Both	PRON	O	O	2038
effects	NOUN	O	O	2038
(	PUNCT	O	O	2038
better	ADV	O	O	2038
survival	NOUN	O	O	2038
and	CCONJ	O	O	2038
nephrosis	NOUN	O	Disease	2038
)	PUNCT	O	O	2038
are	AUX	O	O	2038
most	ADV	O	O	2038
probably	ADV	O	O	2038
related	ADJ	O	O	2038
to	PART	O	O	2038
an	PRON	O	O	2038
enhanced	VERB	O	O	2038
capture	VERB	O	O	2038
of	ADP	O	O	2038
DXNP	PROPN	O	O	2038
by	ADP	O	O	2038
cells	NOUN	O	O	2038
of	ADP	O	O	2038
the	PRON	O	O	2038
mononuclear	PROPN	O	O	2038
phagocyte	PROPN	O	O	2038
system	NOUN	O	O	2038
,	PUNCT	O	O	2038
including	VERB	O	O	2038
mesangial	ADJ	O	O	2038
cells	NOUN	O	O	2038
.	PUNCT	O	O	2038
Etoposide	NOUN	O	Chemical	2041
-	PUNCT	O	O	2041
related	ADJ	O	O	2041
myocardial infarction	NOUN	O	Disease	2041
.	PUNCT	O	O	2041
The	PRON	O	O	2042
occurrence	NOUN	O	O	2042
of	ADP	O	O	2042
a	PRON	O	O	2042
myocardial infarction	NOUN	O	Disease	2042
is	AUX	O	O	2042
reported	VERB	O	O	2042
after	ADP	O	O	2042
chemotherapy	NOUN	O	O	2042
containing	VERB	O	O	2042
etoposide	ADV	O	Chemical	2042
,	PUNCT	O	O	2042
in	ADP	O	O	2042
a	PRON	O	O	2042
man	NOUN	O	O	2042
with	ADP	O	O	2042
no	PRON	O	O	2042
risk	NOUN	O	O	2042
factors	NOUN	O	O	2042
for	ADP	O	O	2042
coronary	ADJ	O	O	2042
heart disease	NOUN	O	Disease	2042
.	PUNCT	O	O	2042
Subjective	ADJ	O	O	2045
assessment	NOUN	O	O	2045
of	ADP	O	O	2045
sexual dysfunction	NOUN	O	Disease	2045
of	ADP	O	O	2045
patients	NOUN	O	O	2045
on	ADP	O	O	2045
long	ADV	O	O	2045
-	PUNCT	O	O	2045
term	NOUN	O	O	2045
administration	NOUN	O	O	2045
of	ADP	O	O	2045
digoxin	PROPN	O	Chemical	2045
.	PUNCT	O	O	2045
Various	ADJ	O	O	2046
data	NOUN	O	O	2046
suggest	VERB	O	O	2046
that	SCONJ	O	O	2046
male	NOUN	O	O	2046
patients	NOUN	O	O	2046
who	PRON	O	O	2046
have	VERB	O	O	2046
received	VERB	O	O	2046
digoxin	PROPN	O	Chemical	2046
on	ADP	O	O	2046
a	PRON	O	O	2046
longterm	ADJ	O	O	2046
basis	NOUN	O	O	2046
have	VERB	O	O	2046
increased	VERB	O	O	2046
levels	NOUN	O	O	2046
of	ADP	O	O	2046
serum	NOUN	O	O	2046
estrogen	PROPN	O	Chemical	2046
and	CCONJ	O	O	2046
decreased	VERB	O	O	2046
levels	NOUN	O	O	2046
of	ADP	O	O	2046
plasma	NOUN	O	O	2046
testosterone	PROPN	O	Chemical	2046
and	CCONJ	O	O	2046
luteinizing	VERB	O	O	2046
hormone	NOUN	O	O	2046
(	PUNCT	O	O	2046
LH	PROPN	O	O	2046
)	PUNCT	O	O	2046
.	PUNCT	O	O	2046
This	PRON	O	O	2047
study	VERB	O	O	2047
was	AUX	O	O	2047
undertaken	VERB	O	O	2047
to	PART	O	O	2047
investigate	VERB	O	O	2047
the	PRON	O	O	2047
links	NOUN	O	O	2047
between	ADP	O	O	2047
the	PRON	O	O	2047
long	ADV	O	O	2047
-	PUNCT	O	O	2047
term	NOUN	O	O	2047
administration	NOUN	O	O	2047
of	ADP	O	O	2047
digoxin	PROPN	O	Chemical	2047
therapy	NOUN	O	O	2047
and	CCONJ	O	O	2047
sexual	ADJ	O	O	2047
behavior	NOUN	O	O	2047
,	PUNCT	O	O	2047
and	CCONJ	O	O	2047
the	PRON	O	O	2047
effect	VERB	O	O	2047
of	ADP	O	O	2047
digoxin	PROPN	O	Chemical	2047
on	ADP	O	O	2047
plasma	NOUN	O	O	2047
levels	NOUN	O	O	2047
of	ADP	O	O	2047
estradiol	VERB	O	Chemical	2047
,	PUNCT	O	O	2047
testosterone	PROPN	O	Chemical	2047
,	PUNCT	O	O	2047
and	CCONJ	O	O	2047
LH	PROPN	O	O	2047
.	PUNCT	O	O	2047
The	PRON	O	O	2048
patients	NOUN	O	O	2048
of	ADP	O	O	2048
the	PRON	O	O	2048
study	VERB	O	O	2048
and	CCONJ	O	O	2048
control	VERB	O	O	2048
group	NOUN	O	O	2048
(	PUNCT	O	O	2048
without	ADP	O	O	2048
digoxin	PROPN	O	Chemical	2048
)	PUNCT	O	O	2048
were	AUX	O	O	2048
of	ADP	O	O	2048
similar	ADJ	O	O	2048
cardiac	ADJ	O	O	2048
functional	ADJ	O	O	2048
capacity	NOUN	O	O	2048
and	CCONJ	O	O	2048
age	NOUN	O	O	2048
(	PUNCT	O	O	2048
25	NUM	O	O	2048
-	PUNCT	O	O	2048
40	NUM	O	O	2048
years	NOUN	O	O	2048
)	PUNCT	O	O	2048
and	CCONJ	O	O	2048
were	AUX	O	O	2048
randomly	ADV	O	O	2048
selected	VERB	O	O	2048
from	ADP	O	O	2048
the	PRON	O	O	2048
rheumatic	ADJ	O	O	2048
heart disease	NOUN	O	Disease	2048
patients	NOUN	O	O	2048
.	PUNCT	O	O	2048
The	PRON	O	O	2049
findings	NOUN	O	O	2049
support	NOUN	O	O	2049
the	PRON	O	O	2049
reports	VERB	O	O	2049
concerning	VERB	O	O	2049
digoxin	PROPN	O	Chemical	2049
effect	VERB	O	O	2049
on	ADP	O	O	2049
plasma	NOUN	O	O	2049
estradiol	VERB	O	Chemical	2049
,	PUNCT	O	O	2049
testosterone	PROPN	O	Chemical	2049
,	PUNCT	O	O	2049
and	CCONJ	O	O	2049
LH	PROPN	O	O	2049
.	PUNCT	O	O	2049
Tests	NOUN	O	O	2050
used	VERB	O	O	2050
to	PART	O	O	2050
evaluate	VERB	O	O	2050
the	PRON	O	O	2050
changes	VERB	O	O	2050
in	ADP	O	O	2050
sexual	ADJ	O	O	2050
behavior	NOUN	O	O	2050
showed	VERB	O	O	2050
a	PRON	O	O	2050
significant	ADJ	O	O	2050
decrease in sexual desire	NOUN	O	Disease	2050
,	PUNCT	O	O	2050
sexual	ADJ	O	O	2050
excitement	NOUN	O	O	2050
phase	NOUN	O	O	2050
(	PUNCT	O	O	2050
erection	VERB	O	O	2050
)	PUNCT	O	O	2050
,	PUNCT	O	O	2050
and	CCONJ	O	O	2050
frequency	NOUN	O	O	2050
of	ADP	O	O	2050
sexual	ADJ	O	O	2050
relations	NOUN	O	O	2050
in	ADP	O	O	2050
the	PRON	O	O	2050
study	VERB	O	O	2050
group	NOUN	O	O	2050
.	PUNCT	O	O	2050
Fatal	ADJ	O	O	2053
aplastic anemia	NOUN	O	Disease	2053
due	ADJ	O	O	2053
to	PART	O	O	2053
indomethacin	VERB	O	Chemical	2053
--	PUNCT	O	O	2053
lymphocyte	NOUN	O	O	2053
transformation	NOUN	O	O	2053
tests	VERB	O	O	2053
in	ADP	O	O	2053
vitro	X	O	O	2053
.	PUNCT	O	O	2053
Although	SCONJ	O	O	2054
indomethacin	VERB	O	Chemical	2054
has	VERB	O	O	2054
been	AUX	O	O	2054
implicated	VERB	O	O	2054
as	ADP	O	O	2054
a	PRON	O	O	2054
possible	ADJ	O	O	2054
cause	VERB	O	O	2054
of	ADP	O	O	2054
aplastic anemia	NOUN	O	Disease	2054
on	ADP	O	O	2054
the	PRON	O	O	2054
basis	NOUN	O	O	2054
of	ADP	O	O	2054
a	PRON	O	O	2054
few	ADJ	O	O	2054
clinical	ADJ	O	O	2054
observations	NOUN	O	O	2054
,	PUNCT	O	O	2054
its	PRON	O	O	2054
role	NOUN	O	O	2054
has	VERB	O	O	2054
not	PART	O	O	2054
been	AUX	O	O	2054
definitely	ADV	O	O	2054
established	VERB	O	O	2054
.	PUNCT	O	O	2054
A	PRON	O	O	2055
case	NOUN	O	O	2055
of	ADP	O	O	2055
fatal	ADJ	O	O	2055
aplastic anemia	NOUN	O	Disease	2055
is	AUX	O	O	2055
described	VERB	O	O	2055
in	ADP	O	O	2055
which	PRON	O	O	2055
no	PRON	O	O	2055
drugs	NOUN	O	O	2055
other	ADJ	O	O	2055
than	ADP	O	O	2055
allopurinol	NOUN	O	Chemical	2055
and	CCONJ	O	O	2055
indomethacin	VERB	O	Chemical	2055
were	AUX	O	O	2055
given	VERB	O	O	2055
.	PUNCT	O	O	2055
Indomethacin	PROPN	O	Chemical	2056
was	AUX	O	O	2056
first	ADV	O	O	2056
given	VERB	O	O	2056
four	NUM	O	O	2056
weeks	NOUN	O	O	2056
prior	ADV	O	O	2056
to	PART	O	O	2056
the	PRON	O	O	2056
onset	VERB	O	O	2056
of	ADP	O	O	2056
symptoms	NOUN	O	O	2056
.	PUNCT	O	O	2056
A	PRON	O	O	2057
positive	ADJ	O	O	2057
lymphocyte	NOUN	O	O	2057
transformation	NOUN	O	O	2057
test	NOUN	O	O	2057
with	ADP	O	O	2057
indomethacin	VERB	O	Chemical	2057
in	ADP	O	O	2057
vitro	X	O	O	2057
further	ADV	O	O	2057
substantiates	VERB	O	O	2057
the	PRON	O	O	2057
potential	ADJ	O	O	2057
role	NOUN	O	O	2057
of	ADP	O	O	2057
this	PRON	O	O	2057
drug	NOUN	O	O	2057
in	ADP	O	O	2057
causing	VERB	O	O	2057
aplastic anemia	NOUN	O	Disease	2057
in	ADP	O	O	2057
a	PRON	O	O	2057
susceptible	ADJ	O	O	2057
patient	NOUN	O	O	2057
.	PUNCT	O	O	2057
Plasma	NOUN	O	O	2060
and	CCONJ	O	O	2060
urinary	ADJ	O	O	2060
lipids	NOUN	O	O	2060
and	CCONJ	O	O	2060
lipoproteins	NOUN	O	O	2060
during	ADP	O	O	2060
the	PRON	O	O	2060
development	NOUN	O	O	2060
of	ADP	O	O	2060
nephrotic syndrome	NOUN	O	Disease	2060
induced	VERB	O	O	2060
in	ADP	O	O	2060
the	PRON	O	O	2060
rat	NOUN	O	O	2060
by	ADP	O	O	2060
puromycin aminonucleoside	NOUN	O	Chemical	2060
.	PUNCT	O	O	2060
This	PRON	O	O	2061
study	VERB	O	O	2061
was	AUX	O	O	2061
undertaken	VERB	O	O	2061
to	PART	O	O	2061
ascertain	VERB	O	O	2061
whether	SCONJ	O	O	2061
the	PRON	O	O	2061
alterations	NOUN	O	O	2061
of	ADP	O	O	2061
plasma	NOUN	O	O	2061
lipoproteins	NOUN	O	O	2061
found	VERB	O	O	2061
in	ADP	O	O	2061
nephrotic syndrome	NOUN	O	Disease	2061
induced	VERB	O	O	2061
by	ADP	O	O	2061
puromycin aminonucleoside	NOUN	O	Chemical	2061
were	AUX	O	O	2061
due	ADJ	O	O	2061
to	PART	O	O	2061
nephrotic syndrome	NOUN	O	Disease	2061
per	ADP	O	O	2061
se	X	O	O	2061
,	PUNCT	O	O	2061
or	CCONJ	O	O	2061
,	PUNCT	O	O	2061
at	ADP	O	O	2061
least	ADJ	O	O	2061
in	ADP	O	O	2061
part	NOUN	O	O	2061
,	PUNCT	O	O	2061
to	PART	O	O	2061
the	PRON	O	O	2061
aminonucleoside	NOUN	O	Chemical	2061
.	PUNCT	O	O	2061
The	PRON	O	O	2062
purpose	NOUN	O	O	2062
of	ADP	O	O	2062
the	PRON	O	O	2062
present	NOUN	O	O	2062
study	VERB	O	O	2062
was	AUX	O	O	2062
to	PART	O	O	2062
investigate	VERB	O	O	2062
the	PRON	O	O	2062
changes	VERB	O	O	2062
in	ADP	O	O	2062
plasma	NOUN	O	O	2062
and	CCONJ	O	O	2062
urinary	ADJ	O	O	2062
lipoproteins	NOUN	O	O	2062
during	ADP	O	O	2062
the	PRON	O	O	2062
administration	NOUN	O	O	2062
of	ADP	O	O	2062
puromycin aminonucleoside	NOUN	O	Chemical	2062
(	PUNCT	O	O	2062
20	NUM	O	O	2062
mg	VERB	O	O	2062
/	PUNCT	O	O	2062
kg	VERB	O	O	2062
for	ADP	O	O	2062
7	NUM	O	O	2062
days	NOUN	O	O	2062
)	PUNCT	O	O	2062
and	CCONJ	O	O	2062
the	PRON	O	O	2062
subsequent	ADJ	O	O	2062
development	NOUN	O	O	2062
of	ADP	O	O	2062
nephrotic syndrome	NOUN	O	Disease	2062
.	PUNCT	O	O	2062
Since	SCONJ	O	O	2063
massive	ADJ	O	O	2063
albuminuria	PROPN	O	Disease	2063
occurred	VERB	O	O	2063
after	ADP	O	O	2063
6	NUM	O	O	2063
days	NOUN	O	O	2063
of	ADP	O	O	2063
treatment	NOUN	O	O	2063
,	PUNCT	O	O	2063
the	PRON	O	O	2063
time	NOUN	O	O	2063
-	PUNCT	O	O	2063
course	NOUN	O	O	2063
study	VERB	O	O	2063
was	AUX	O	O	2063
divided	VERB	O	O	2063
into	ADP	O	O	2063
two	NUM	O	O	2063
stages	NOUN	O	O	2063
:	PUNCT	O	O	2063
pre	VERB	O	O	2063
-	PUNCT	O	O	2063
nephrotic	NOUN	O	Disease	2063
stage	NOUN	O	O	2063
(	PUNCT	O	O	2063
day	NOUN	O	O	2063
1	X	O	O	2063
-	PUNCT	O	O	2063
5	NUM	O	O	2063
)	PUNCT	O	O	2063
and	CCONJ	O	O	2063
nephrotic	NOUN	O	Disease	2063
stage	NOUN	O	O	2063
(	PUNCT	O	O	2063
day	NOUN	O	O	2063
6	NUM	O	O	2063
-	PUNCT	O	O	2063
11	NUM	O	O	2063
)	PUNCT	O	O	2063
.	PUNCT	O	O	2063
In	ADP	O	O	2064
pre	VERB	O	O	2064
-	PUNCT	O	O	2064
nephrotic	NOUN	O	Disease	2064
stage	NOUN	O	O	2064
the	PRON	O	O	2064
plasma	NOUN	O	O	2064
level	VERB	O	O	2064
of	ADP	O	O	2064
fatty acids	NOUN	O	Chemical	2064
,	PUNCT	O	O	2064
triacylglycerol	NOUN	O	Chemical	2064
and	CCONJ	O	O	2064
VLDL	NOUN	O	O	2064
decreased	VERB	O	O	2064
while	SCONJ	O	O	2064
that	SCONJ	O	O	2064
of	ADP	O	O	2064
phospholipid	NOUN	O	O	2064
,	PUNCT	O	O	2064
cholesteryl esters	NOUN	O	Chemical	2064
and	CCONJ	O	O	2064
HDL	PROPN	O	O	2064
remained	VERB	O	O	2064
constant	ADJ	O	O	2064
.	PUNCT	O	O	2064
At	ADP	O	O	2065
the	PRON	O	O	2065
beginning	VERB	O	O	2065
of	ADP	O	O	2065
nephrotic	NOUN	O	Disease	2065
stage	NOUN	O	O	2065
(	PUNCT	O	O	2065
day	NOUN	O	O	2065
6	NUM	O	O	2065
)	PUNCT	O	O	2065
the	PRON	O	O	2065
concentration	NOUN	O	O	2065
of	ADP	O	O	2065
plasma	NOUN	O	O	2065
albumin	PROPN	O	O	2065
dropped	VERB	O	O	2065
to	PART	O	O	2065
a	PRON	O	O	2065
very	ADV	O	O	2065
low	ADJ	O	O	2065
level	VERB	O	O	2065
,	PUNCT	O	O	2065
while	SCONJ	O	O	2065
that	SCONJ	O	O	2065
of	ADP	O	O	2065
apolipoprotein	NOUN	O	O	2065
A	PRON	O	O	2065
-	PUNCT	O	O	2065
I	PRON	O	O	2065
increased	VERB	O	O	2065
abruptly	ADV	O	O	2065
(	PUNCT	O	O	2065
4-fold	ADV	O	O	2065
increase	VERB	O	O	2065
)	PUNCT	O	O	2065
and	CCONJ	O	O	2065
continued	VERB	O	O	2065
to	PART	O	O	2065
rise	VERB	O	O	2065
,	PUNCT	O	O	2065
although	SCONJ	O	O	2065
less	ADV	O	O	2065
steeply	ADV	O	O	2065
,	PUNCT	O	O	2065
in	ADP	O	O	2065
the	PRON	O	O	2065
following	VERB	O	O	2065
days	NOUN	O	O	2065
.	PUNCT	O	O	2065
In	ADP	O	O	2066
the	PRON	O	O	2066
pre	VERB	O	O	2066
-	PUNCT	O	O	2066
nephrotic	NOUN	O	Disease	2066
stage	NOUN	O	O	2066
lipoproteinuria	PROPN	O	O	2066
was	AUX	O	O	2066
negligible	ADJ	O	O	2066
,	PUNCT	O	O	2066
while	SCONJ	O	O	2066
in	ADP	O	O	2066
the	PRON	O	O	2066
early	ADV	O	O	2066
nephrotic	NOUN	O	Disease	2066
stage	NOUN	O	O	2066
the	PRON	O	O	2066
urinary	ADJ	O	O	2066
loss	NOUN	O	O	2066
of	ADP	O	O	2066
plasma	NOUN	O	O	2066
lipoproteins	NOUN	O	O	2066
consisted	VERB	O	O	2066
mainly	ADV	O	O	2066
of	ADP	O	O	2066
HDL	PROPN	O	O	2066
.	PUNCT	O	O	2066
These	PRON	O	O	2067
observations	NOUN	O	O	2067
indicate	VERB	O	O	2067
that	SCONJ	O	O	2067
puromycin aminonucleoside	NOUN	O	Chemical	2067
alters	VERB	O	O	2067
plasma	NOUN	O	O	2067
lipoproteins	NOUN	O	O	2067
by	ADP	O	O	2067
lowering	VERB	O	O	2067
VLDL	NOUN	O	O	2067
and	CCONJ	O	O	2067
increasing	VERB	O	O	2067
HDL	PROPN	O	O	2067
.	PUNCT	O	O	2067
It	PRON	O	O	2068
is	AUX	O	O	2068
likely	ADV	O	O	2068
that	SCONJ	O	O	2068
the	PRON	O	O	2068
early	ADV	O	O	2068
and	CCONJ	O	O	2068
striking	VERB	O	O	2068
increase	VERB	O	O	2068
of	ADP	O	O	2068
plasma	NOUN	O	O	2068
HDL	PROPN	O	O	2068
found	VERB	O	O	2068
in	ADP	O	O	2068
nephrotic	NOUN	O	Disease	2068
rats	NOUN	O	O	2068
is	AUX	O	O	2068
related	ADJ	O	O	2068
to	PART	O	O	2068
a	PRON	O	O	2068
direct	ADJ	O	O	2068
effect	VERB	O	O	2068
of	ADP	O	O	2068
the	PRON	O	O	2068
drug	NOUN	O	O	2068
on	ADP	O	O	2068
HDL	PROPN	O	O	2068
metabolism	NOUN	O	O	2068
.	PUNCT	O	O	2068
Circulating	VERB	O	O	2071
lysosomal	NOUN	O	O	2071
enzymes	NOUN	O	O	2071
and	CCONJ	O	O	2071
acute hepatic necrosis	NOUN	O	Disease	2071
.	PUNCT	O	O	2071
The	PRON	O	O	2072
activities	NOUN	O	O	2072
of	ADP	O	O	2072
the	PRON	O	O	2072
lysosomal	NOUN	O	O	2072
enzymes	NOUN	O	O	2072
acid	PROPN	O	O	2072
and	CCONJ	O	O	2072
neutral	ADJ	O	O	2072
protease	NOUN	O	O	2072
,	PUNCT	O	O	2072
N	NUM	O	O	2072
-	PUNCT	O	O	2072
acetylglucosaminidase	PROPN	O	O	2072
,	PUNCT	O	O	2072
and	CCONJ	O	O	2072
acid	PROPN	O	O	2072
phosphatase	ADJ	O	O	2072
were	AUX	O	O	2072
measured	VERB	O	O	2072
in	ADP	O	O	2072
the	PRON	O	O	2072
serum	NOUN	O	O	2072
of	ADP	O	O	2072
patients	NOUN	O	O	2072
with	ADP	O	O	2072
fulminant	ADJ	O	O	2072
hepatic failure	NOUN	O	Disease	2072
.	PUNCT	O	O	2072
(	PUNCT	O	O	2073
cathepsin	NOUN	O	O	2073
D	NOUN	O	O	2073
)	PUNCT	O	O	2073
activity	NOUN	O	O	2073
was	AUX	O	O	2073
increased	VERB	O	O	2073
about	ADP	O	O	2073
tenfold	ADV	O	O	2073
in	ADP	O	O	2073
patients	NOUN	O	O	2073
who	PRON	O	O	2073
died	VERB	O	O	2073
and	CCONJ	O	O	2073
nearly	ADV	O	O	2073
fourfold	ADJ	O	O	2073
in	ADP	O	O	2073
those	PRON	O	O	2073
who	PRON	O	O	2073
survived	VERB	O	O	2073
fulminant	ADJ	O	O	2073
hepatic failure	NOUN	O	Disease	2073
after	ADP	O	O	2073
paracetamol	PROPN	O	Chemical	2073
overdose	NOUN	O	Disease	2073
,	PUNCT	O	O	2073
whereas	SCONJ	O	O	2073
activities	NOUN	O	O	2073
were	AUX	O	O	2073
increased	VERB	O	O	2073
equally	ADV	O	O	2073
in	ADP	O	O	2073
patients	NOUN	O	O	2073
with	ADP	O	O	2073
fulminant	ADJ	O	O	2073
hepatic failure	NOUN	O	Disease	2073
due	ADJ	O	O	2073
to	PART	O	O	2073
viral hepatitis	NOUN	O	Disease	2073
whether	SCONJ	O	O	2073
or	CCONJ	O	O	2073
not	PART	O	O	2073
they	PRON	O	O	2073
survived	VERB	O	O	2073
.	PUNCT	O	O	2073
A	PRON	O	O	2074
correlation	NOUN	O	O	2074
was	AUX	O	O	2074
found	VERB	O	O	2074
between	ADP	O	O	2074
serum	NOUN	O	O	2074
acid	PROPN	O	O	2074
protease	NOUN	O	O	2074
activity	NOUN	O	O	2074
and	CCONJ	O	O	2074
prothrombin	ADJ	O	O	2074
time	NOUN	O	O	2074
,	PUNCT	O	O	2074
and	CCONJ	O	O	2074
the	PRON	O	O	2074
increase	VERB	O	O	2074
in	ADP	O	O	2074
cathepsin	NOUN	O	O	2074
D	NOUN	O	O	2074
activity	NOUN	O	O	2074
was	AUX	O	O	2074
sustained	VERB	O	O	2074
over	ADP	O	O	2074
several	ADJ	O	O	2074
days	NOUN	O	O	2074
compared	VERB	O	O	2074
with	ADP	O	O	2074
aspartate	NOUN	O	Chemical	2074
aminotransferase	PROPN	O	O	2074
,	PUNCT	O	O	2074
which	PRON	O	O	2074
showed	VERB	O	O	2074
a	PRON	O	O	2074
sharp	ADJ	O	O	2074
early	ADV	O	O	2074
peak	PROPN	O	O	2074
and	CCONJ	O	O	2074
then	ADV	O	O	2074
a	PRON	O	O	2074
fall	VERB	O	O	2074
.	PUNCT	O	O	2074
Transketolase	NOUN	O	O	2077
abnormality	NOUN	O	O	2077
in	ADP	O	O	2077
tolazamide	ADV	O	Chemical	2077
-	PUNCT	O	O	2077
induced	VERB	O	O	2077
Wernicke	PROPN	O	O	2077
's	AUX	O	O	2077
encephalopathy	NOUN	O	Disease	2077
.	PUNCT	O	O	2077
We	PRON	O	O	2078
studied	VERB	O	O	2078
a	PRON	O	O	2078
thiamine	NOUN	O	Chemical	2078
-	PUNCT	O	O	2078
dependent	ADJ	O	O	2078
enzyme	NOUN	O	O	2078
,	PUNCT	O	O	2078
transketolase	NOUN	O	O	2078
,	PUNCT	O	O	2078
from	ADP	O	O	2078
fibroblasts	NOUN	O	O	2078
of	ADP	O	O	2078
a	PRON	O	O	2078
diabetic	ADJ	O	Disease	2078
patient	NOUN	O	O	2078
who	PRON	O	O	2078
developed	VERB	O	O	2078
Wernicke	PROPN	O	O	2078
's	AUX	O	O	2078
encephalopathy	NOUN	O	Disease	2078
when	SCONJ	O	O	2078
treated	VERB	O	O	2078
with	ADP	O	O	2078
tolazamide	ADV	O	Chemical	2078
,	PUNCT	O	O	2078
in	ADP	O	O	2078
order	NOUN	O	O	2078
to	PART	O	O	2078
delineate	VERB	O	O	2078
if	SCONJ	O	O	2078
this	PRON	O	O	2078
patient	NOUN	O	O	2078
also	ADV	O	O	2078
had	VERB	O	O	2078
transketolase	NOUN	O	O	2078
abnormality	NOUN	O	O	2078
[	X	O	O	2078
high	ADJ	O	O	2078
Km	PROPN	O	O	2078
for	ADP	O	O	2078
thiamine pyrophosphate	NOUN	O	Chemical	2078
(	PUNCT	O	O	2078
TPP	PROPN	O	Chemical	2078
)	PUNCT	O	O	2078
]	PUNCT	O	O	2078
,	PUNCT	O	O	2078
as	ADP	O	O	2078
previously	ADV	O	O	2078
reported	VERB	O	O	2078
in	ADP	O	O	2078
postalcoholic	PROPN	O	O	2078
Wernicke	PROPN	O	O	2078
-	PUNCT	O	O	2078
Korsakoff	PROPN	O	O	2078
syndrome	NOUN	O	O	2078
.	PUNCT	O	O	2078
In	ADP	O	O	2079
addition	NOUN	O	O	2079
to	PART	O	O	2079
this	PRON	O	O	2079
patient	NOUN	O	O	2079
,	PUNCT	O	O	2079
we	PRON	O	O	2079
also	ADV	O	O	2079
studied	VERB	O	O	2079
this	PRON	O	O	2079
enzyme	NOUN	O	O	2079
from	ADP	O	O	2079
three	NUM	O	O	2079
diabetic	ADJ	O	Disease	2079
kindreds	NOUN	O	O	2079
without	ADP	O	O	2079
any	PRON	O	O	2079
history	NOUN	O	O	2079
of	ADP	O	O	2079
Wernicke	PROPN	O	O	2079
's	AUX	O	O	2079
encephalopathy	NOUN	O	Disease	2079
and	CCONJ	O	O	2079
from	ADP	O	O	2079
four	NUM	O	O	2079
normal	ADJ	O	O	2079
controls	VERB	O	O	2079
.	PUNCT	O	O	2079
We	PRON	O	O	2080
found	VERB	O	O	2080
that	SCONJ	O	O	2080
the	PRON	O	O	2080
above	ADP	O	O	2080
-	PUNCT	O	O	2080
mentioned	VERB	O	O	2080
patient	NOUN	O	O	2080
and	CCONJ	O	O	2080
one	NUM	O	O	2080
of	ADP	O	O	2080
the	PRON	O	O	2080
diabetic	ADJ	O	Disease	2080
kindreds	NOUN	O	O	2080
with	ADP	O	O	2080
no	PRON	O	O	2080
history	NOUN	O	O	2080
of	ADP	O	O	2080
Wernicke	PROPN	O	O	2080
's	AUX	O	O	2080
encephalopathy	NOUN	O	Disease	2080
had	VERB	O	O	2080
abnormal	ADJ	O	O	2080
transketolase	NOUN	O	O	2080
as	ADP	O	O	2080
determined	VERB	O	O	2080
by	ADP	O	O	2080
its	PRON	O	O	2080
Km	PROPN	O	O	2080
for	ADP	O	O	2080
TPP	PROPN	O	Chemical	2080
.	PUNCT	O	O	2080
These	PRON	O	O	2081
data	NOUN	O	O	2081
suggest	VERB	O	O	2081
a	PRON	O	O	2081
similarity	NOUN	O	O	2081
between	ADP	O	O	2081
postalcoholic	PROPN	O	O	2081
Wernicke	PROPN	O	O	2081
-	PUNCT	O	O	2081
Korsakoff	PROPN	O	O	2081
syndrome	NOUN	O	O	2081
and	CCONJ	O	O	2081
the	PRON	O	O	2081
patient	NOUN	O	O	2081
with	ADP	O	O	2081
tolazamide	ADV	O	Chemical	2081
-	PUNCT	O	O	2081
induced	VERB	O	O	2081
Wernicke	PROPN	O	O	2082
's	AUX	O	O	2082
encephalopathy	NOUN	O	Disease	2082
from	ADP	O	O	2082
the	PRON	O	O	2082
standpoint	NOUN	O	O	2082
of	ADP	O	O	2082
transketolase	NOUN	O	O	2082
abnormality	NOUN	O	O	2082
.	PUNCT	O	O	2082
Mechanisms	NOUN	O	O	2085
of	ADP	O	O	2085
myocardial ischemia	NOUN	O	Disease	2085
induced	VERB	O	O	2085
by	ADP	O	O	2085
epinephrine	NOUN	O	Chemical	2085
:	PUNCT	O	O	2085
comparison	NOUN	O	O	2085
with	ADP	O	O	2085
exercise	VERB	O	O	2085
-	PUNCT	O	O	2085
induced	VERB	O	O	2085
ischemia	NOUN	O	Disease	2085
.	PUNCT	O	O	2085
The	PRON	O	O	2086
role	NOUN	O	O	2086
of	ADP	O	O	2086
epinephrine	NOUN	O	Chemical	2086
in	ADP	O	O	2086
eliciting	VERB	O	O	2086
myocardial ischemia	NOUN	O	Disease	2086
was	AUX	O	O	2086
examined	VERB	O	O	2086
in	ADP	O	O	2086
patients	NOUN	O	O	2086
with	ADP	O	O	2086
coronary artery disease	NOUN	O	Disease	2086
.	PUNCT	O	O	2086
Objective	NOUN	O	O	2087
signs	NOUN	O	O	2087
of	ADP	O	O	2087
ischemia	NOUN	O	Disease	2087
and	CCONJ	O	O	2087
factors	NOUN	O	O	2087
increasing	VERB	O	O	2087
myocardial	ADJ	O	O	2087
oxygen	NOUN	O	Chemical	2087
consumption	NOUN	O	O	2087
were	AUX	O	O	2087
compared	VERB	O	O	2087
during	ADP	O	O	2087
epinephrine	NOUN	O	Chemical	2087
infusion	NOUN	O	O	2087
and	CCONJ	O	O	2087
supine	ADJ	O	O	2087
bicycle	NOUN	O	O	2087
exercise	VERB	O	O	2087
.	PUNCT	O	O	2087
Both	PRON	O	O	2088
epinephrine	NOUN	O	Chemical	2088
and	CCONJ	O	O	2088
exercise	VERB	O	O	2088
produced	VERB	O	O	2088
myocardial ischemia	NOUN	O	Disease	2088
as	ADP	O	O	2088
evidenced	VERB	O	O	2088
by	ADP	O	O	2088
ST	PROPN	O	O	2088
segment	NOUN	O	O	2088
depression	PROPN	O	Disease	2088
and	CCONJ	O	O	2088
angina	NOUN	O	Disease	2088
.	PUNCT	O	O	2088
However	ADV	O	O	2089
,	PUNCT	O	O	2089
the	PRON	O	O	2089
mechanisms	NOUN	O	O	2089
of	ADP	O	O	2089
myocardial ischemia	NOUN	O	Disease	2089
induced	VERB	O	O	2089
by	ADP	O	O	2089
epinephrine	NOUN	O	Chemical	2089
were	AUX	O	O	2089
significantly	ADV	O	O	2089
different	ADJ	O	O	2089
from	ADP	O	O	2089
those	PRON	O	O	2089
of	ADP	O	O	2089
exercise	VERB	O	O	2089
.	PUNCT	O	O	2089
Exercise	NOUN	O	O	2090
-	PUNCT	O	O	2090
induced	VERB	O	O	2090
myocardial ischemia	NOUN	O	Disease	2090
was	AUX	O	O	2090
marked	VERB	O	O	2090
predominantly	ADV	O	O	2090
by	ADP	O	O	2090
increased	VERB	O	O	2090
heart	NOUN	O	O	2090
rate	NOUN	O	O	2090
and	CCONJ	O	O	2090
rate	NOUN	O	O	2090
-	PUNCT	O	O	2090
pressure	NOUN	O	O	2090
product	NOUN	O	O	2090
with	ADP	O	O	2090
a	PRON	O	O	2090
minor	ADJ	O	O	2090
contribution	NOUN	O	O	2090
of	ADP	O	O	2090
end	VERB	O	O	2090
-	PUNCT	O	O	2090
diastolic	ADV	O	O	2090
volume	PROPN	O	O	2090
,	PUNCT	O	O	2090
while	SCONJ	O	O	2090
epinephrine	NOUN	O	Chemical	2090
-	PUNCT	O	O	2090
induced	VERB	O	O	2090
ischemia	NOUN	O	Disease	2090
was	AUX	O	O	2090
characterized	VERB	O	O	2090
by	ADP	O	O	2090
a	PRON	O	O	2090
marked	VERB	O	O	2090
increase	VERB	O	O	2090
in	ADP	O	O	2090
contractility	NOUN	O	O	2090
and	CCONJ	O	O	2090
a	PRON	O	O	2090
less	ADV	O	O	2090
pronounced	VERB	O	O	2090
increase	VERB	O	O	2090
in	ADP	O	O	2090
heart	NOUN	O	O	2090
rate	NOUN	O	O	2090
and	CCONJ	O	O	2090
rate	NOUN	O	O	2090
-	PUNCT	O	O	2090
pressure	NOUN	O	O	2090
product	NOUN	O	O	2090
.	PUNCT	O	O	2090
These	PRON	O	O	2091
findings	NOUN	O	O	2091
indicate	VERB	O	O	2091
that	SCONJ	O	O	2091
ischemia	NOUN	O	Disease	2091
produced	VERB	O	O	2091
by	ADP	O	O	2091
epinephrine	NOUN	O	Chemical	2091
,	PUNCT	O	O	2091
as	ADP	O	O	2091
may	AUX	O	O	2091
occur	VERB	O	O	2091
during	ADP	O	O	2091
states	VERB	O	O	2091
of	ADP	O	O	2091
emotional	ADJ	O	O	2091
distress	NOUN	O	O	2091
,	PUNCT	O	O	2091
has	VERB	O	O	2091
a	PRON	O	O	2091
mechanism	NOUN	O	O	2091
distinct	ADJ	O	O	2091
from	ADP	O	O	2091
that	SCONJ	O	O	2091
due	ADJ	O	O	2091
to	PART	O	O	2091
physical	ADJ	O	O	2091
exertion	NOUN	O	O	2091
.	PUNCT	O	O	2091
Transient	ADJ	O	O	2094
contralateral rotation	NOUN	O	Disease	2094
following	VERB	O	O	2094
unilateral	ADJ	O	O	2094
substantia nigra lesion	NOUN	O	Disease	2094
reflects	VERB	O	O	2094
susceptibility	NOUN	O	O	2094
of	ADP	O	O	2094
the	PRON	O	O	2094
nigrostriatal	NOUN	O	O	2094
system	NOUN	O	O	2094
to	PART	O	O	2094
exhaustion	NOUN	O	O	2094
by	ADP	O	O	2094
amphetamine	NOUN	O	Chemical	2094
.	PUNCT	O	O	2094
Following	VERB	O	O	2095
unilateral	ADJ	O	O	2095
6-OHDA	NOUN	O	Chemical	2095
induced	VERB	O	O	2095
SN lesion	NOUN	O	Disease	2095
,	PUNCT	O	O	2095
a	PRON	O	O	2095
transient	ADJ	O	O	2095
period	NOUN	O	O	2095
of	ADP	O	O	2095
contralateral rotation	NOUN	O	Disease	2095
has	VERB	O	O	2095
been	AUX	O	O	2095
reported	VERB	O	O	2095
to	PART	O	O	2095
precede	VERB	O	O	2095
the	PRON	O	O	2095
predominant	ADJ	O	O	2095
ipsilateral circling	NOUN	O	Disease	2095
.	PUNCT	O	O	2095
In	ADP	O	O	2096
order	NOUN	O	O	2096
to	PART	O	O	2096
clarify	VERB	O	O	2096
the	PRON	O	O	2096
nature	NOUN	O	O	2096
of	ADP	O	O	2096
this	PRON	O	O	2096
initial	ADJ	O	O	2096
contralateral rotation	NOUN	O	Disease	2096
we	PRON	O	O	2096
examined	VERB	O	O	2096
the	PRON	O	O	2096
effect	VERB	O	O	2096
of	ADP	O	O	2096
the	PRON	O	O	2096
duration	NOUN	O	O	2096
of	ADP	O	O	2096
recovery	NOUN	O	O	2096
period	NOUN	O	O	2096
after	ADP	O	O	2096
the	PRON	O	O	2096
lesion	NOUN	O	O	2096
,	PUNCT	O	O	2096
on	ADP	O	O	2096
amphetamine	NOUN	O	Chemical	2096
-	PUNCT	O	O	2096
induced	VERB	O	O	2096
rotational behavior	NOUN	O	Disease	2096
.	PUNCT	O	O	2096
Such	ADJ	O	O	2097
contralateral rotation	NOUN	O	Disease	2097
may	AUX	O	O	2097
result	VERB	O	O	2097
from	ADP	O	O	2097
either	ADV	O	O	2097
degeneration	NOUN	O	O	2097
-	PUNCT	O	O	2097
induced	VERB	O	O	2097
breakdown	NOUN	O	O	2097
of	ADP	O	O	2097
the	PRON	O	O	2097
DA	NOUN	O	Chemical	2097
pool	NOUN	O	O	2097
,	PUNCT	O	O	2097
or	CCONJ	O	O	2097
lesion	NOUN	O	O	2097
-	PUNCT	O	O	2097
induced	VERB	O	O	2097
increase	VERB	O	O	2097
of	ADP	O	O	2097
DA	NOUN	O	Chemical	2097
turnover	NOUN	O	O	2097
in	ADP	O	O	2097
the	PRON	O	O	2097
spared	VERB	O	O	2097
neurons	NOUN	O	O	2097
.	PUNCT	O	O	2097
A	PRON	O	O	2098
substantial	ADJ	O	O	2098
degree	PROPN	O	O	2098
of	ADP	O	O	2098
contralateral	ADJ	O	O	2098
preference	NOUN	O	O	2098
was	AUX	O	O	2098
still	ADV	O	O	2098
evident	ADJ	O	O	2098
when	SCONJ	O	O	2098
amphetamine	NOUN	O	Chemical	2098
was	AUX	O	O	2098
administered	VERB	O	O	2098
for	ADP	O	O	2098
the	PRON	O	O	2098
first	ADV	O	O	2098
time	NOUN	O	O	2098
24	NUM	O	O	2098
days	NOUN	O	O	2098
after	ADP	O	O	2098
lesioning	NOUN	O	O	2098
,	PUNCT	O	O	2098
indicating	VERB	O	O	2098
involvement	NOUN	O	O	2098
of	ADP	O	O	2098
spared	VERB	O	O	2098
cells	NOUN	O	O	2098
in	ADP	O	O	2098
the	PRON	O	O	2098
contralateral rotation	NOUN	O	Disease	2098
.	PUNCT	O	O	2098
However	ADV	O	O	2099
,	PUNCT	O	O	2099
regardless	ADV	O	O	2099
of	ADP	O	O	2099
the	PRON	O	O	2099
duration	NOUN	O	O	2099
of	ADP	O	O	2099
recovery	NOUN	O	O	2099
(	PUNCT	O	O	2099
and	CCONJ	O	O	2099
irrespective	ADV	O	O	2099
of	ADP	O	O	2099
either	ADV	O	O	2099
lesion	NOUN	O	O	2099
volume	PROPN	O	O	2099
,	PUNCT	O	O	2099
amphetamine	NOUN	O	Chemical	2099
dose	NOUN	O	O	2099
,	PUNCT	O	O	2099
or	CCONJ	O	O	2099
post	VERB	O	O	2099
-	PUNCT	O	O	2099
lesion	NOUN	O	O	2099
motor	NOUN	O	O	2099
exercise	VERB	O	O	2099
)	PUNCT	O	O	2099
,	PUNCT	O	O	2099
amphetamine	NOUN	O	Chemical	2099
-	PUNCT	O	O	2099
induced	VERB	O	O	2099
rotation	NOUN	O	Disease	2099
tended	VERB	O	O	2099
to	PART	O	O	2099
become	VERB	O	O	2099
gradually	ADV	O	O	2099
more	ADJ	O	O	2099
ipsilateral	ADJ	O	O	2099
as	ADP	O	O	2099
the	PRON	O	O	2099
observation	NOUN	O	O	2099
session	NOUN	O	O	2099
progressed	VERB	O	O	2099
,	PUNCT	O	O	2099
and	CCONJ	O	O	2099
all	PRON	O	O	2099
rats	NOUN	O	O	2099
circled	VERB	O	O	2099
ipsilaterally	ADV	O	O	2099
to	PART	O	O	2099
the	PRON	O	O	2099
lesion	NOUN	O	O	2099
in	ADP	O	O	2099
response	NOUN	O	O	2099
to	PART	O	O	2099
further	ADV	O	O	2099
amphetamine	NOUN	O	Chemical	2099
injections	NOUN	O	O	2099
.	PUNCT	O	O	2099
These	PRON	O	O	2100
findings	NOUN	O	O	2100
suggest	VERB	O	O	2100
that	SCONJ	O	O	2100
amphetamine	NOUN	O	Chemical	2100
has	VERB	O	O	2100
an	PRON	O	O	2100
irreversible	ADJ	O	O	2100
effect	VERB	O	O	2100
on	ADP	O	O	2100
the	PRON	O	O	2100
post	VERB	O	O	2100
-	PUNCT	O	O	2100
lesion	NOUN	O	O	2100
DA	NOUN	O	Chemical	2100
pool	NOUN	O	O	2100
contributing	VERB	O	O	2100
to	PART	O	O	2100
contralateral rotation	NOUN	O	Disease	2100
.	PUNCT	O	O	2100
Thyroid	PROPN	O	O	2103
function	NOUN	O	O	2103
and	CCONJ	O	O	2103
urine	NOUN	O	O	2103
-	PUNCT	O	O	2103
concentrating	VERB	O	O	2103
ability	NOUN	O	O	2103
during	ADP	O	O	2103
lithium	NOUN	O	Chemical	2103
treatment	NOUN	O	O	2103
.	PUNCT	O	O	2103
It	PRON	O	O	2104
has	VERB	O	O	2104
been	AUX	O	O	2104
suggested	VERB	O	O	2104
that	SCONJ	O	O	2104
adenylate	ADJ	O	O	2104
cyclase	NOUN	O	O	2104
inhibition	NOUN	O	O	2104
may	AUX	O	O	2104
be	AUX	O	O	2104
important	ADJ	O	O	2104
in	ADP	O	O	2104
the	PRON	O	O	2104
development	NOUN	O	O	2104
of	ADP	O	O	2104
both	PRON	O	O	2104
nephrogenic	PROPN	O	O	2104
diabetes insipidus	NOUN	O	Disease	2104
and	CCONJ	O	O	2104
hypothyroidism	PROPN	O	Disease	2104
during	ADP	O	O	2104
lithium	NOUN	O	Chemical	2104
treatment	NOUN	O	O	2104
.	PUNCT	O	O	2104
We	PRON	O	O	2105
measured	VERB	O	O	2105
serum	NOUN	O	O	2105
thyroxine	NOUN	O	Chemical	2105
and	CCONJ	O	O	2105
urine	NOUN	O	O	2105
-	PUNCT	O	O	2105
concentrating	VERB	O	O	2105
ability	NOUN	O	O	2105
(	PUNCT	O	O	2105
Umax	NOUN	O	O	2105
)	PUNCT	O	O	2105
in	ADP	O	O	2105
response	NOUN	O	O	2105
to	PART	O	O	2105
desmopressin	VERB	O	O	2105
(	PUNCT	O	O	2105
DDAVP	PROPN	O	O	2105
)	PUNCT	O	O	2105
in	ADP	O	O	2105
85	NUM	O	O	2105
patients	NOUN	O	O	2105
receiving	VERB	O	O	2105
lithium	NOUN	O	Chemical	2105
.	PUNCT	O	O	2105
Hypothyroidism	NOUN	O	Disease	2106
developed	VERB	O	O	2106
in	ADP	O	O	2106
eight	NUM	O	O	2106
patients	NOUN	O	O	2106
while	SCONJ	O	O	2106
they	PRON	O	O	2106
were	AUX	O	O	2106
taking	VERB	O	O	2106
lithium	NOUN	O	Chemical	2106
.	PUNCT	O	O	2106
Impaired	ADJ	O	O	2107
Umax	NOUN	O	O	2107
was	AUX	O	O	2107
found	VERB	O	O	2107
in	ADP	O	O	2107
both	PRON	O	O	2107
euthyroid	VERB	O	O	2107
and	CCONJ	O	O	2107
hypothyroid	PROPN	O	Disease	2107
patients	NOUN	O	O	2107
while	SCONJ	O	O	2107
some	PRON	O	O	2107
hypothyroid	PROPN	O	Disease	2107
patients	NOUN	O	O	2107
concentrated	VERB	O	O	2107
their	PRON	O	O	2107
urine	NOUN	O	O	2107
well	ADV	O	O	2107
.	PUNCT	O	O	2107
It	PRON	O	O	2108
is	AUX	O	O	2108
concluded	VERB	O	O	2108
that	SCONJ	O	O	2108
the	PRON	O	O	2108
dominant	ADJ	O	O	2108
mechanisms	NOUN	O	O	2108
by	ADP	O	O	2108
which	PRON	O	O	2108
lithium	NOUN	O	Chemical	2108
exerts	VERB	O	O	2108
these	PRON	O	O	2108
two	NUM	O	O	2108
effects	NOUN	O	O	2108
are	AUX	O	O	2108
different	ADJ	O	O	2108
.	PUNCT	O	O	2108
Sensitivity	NOUN	O	O	2111
of	ADP	O	O	2111
erythroid	PROPN	O	O	2111
progenitor	NOUN	O	O	2111
colonies	NOUN	O	O	2111
to	PART	O	O	2111
erythropoietin	NOUN	O	O	2111
in	ADP	O	O	2111
azidothymidine	NOUN	O	Chemical	2111
treated	VERB	O	O	2111
immunodeficient	ADJ	O	Disease	2111
mice	NOUN	O	O	2111
.	PUNCT	O	O	2111
The	PRON	O	O	2112
anaemia	NOUN	O	Disease	2112
induced	VERB	O	O	2112
by	ADP	O	O	2112
3'-azido-3'dideoxythymidine	NUM	O	Chemical	2112
(	PUNCT	O	O	2112
AZT	PROPN	O	Chemical	2112
)	PUNCT	O	O	2112
is	AUX	O	O	2112
poorly	ADV	O	O	2112
understood	VERB	O	O	2112
.	PUNCT	O	O	2112
We	PRON	O	O	2113
have	VERB	O	O	2113
used	VERB	O	O	2113
a	PRON	O	O	2113
murine	ADJ	O	O	2113
model	NOUN	O	O	2113
of	ADP	O	O	2113
AIDS	PROPN	O	Disease	2113
,	PUNCT	O	O	2113
infection	NOUN	O	Disease	2113
of	ADP	O	O	2113
female	ADJ	O	O	2113
C57BL/6	NOUN	O	O	2113
mice	NOUN	O	O	2113
with	ADP	O	O	2113
LP	NOUN	O	O	2113
-	PUNCT	O	O	2113
BM5	PROPN	O	O	2113
murine	ADJ	O	O	2113
leukaemia	NOUN	O	Disease	2113
(	PUNCT	O	O	2113
MuLV	PROPN	O	O	2113
)	PUNCT	O	O	2113
virus	NOUN	O	O	2113
,	PUNCT	O	O	2113
to	PART	O	O	2113
determine	VERB	O	O	2113
if	SCONJ	O	O	2113
AZT	PROPN	O	Chemical	2113
-	PUNCT	O	O	2113
induced	VERB	O	O	2113
anaemia	NOUN	O	Disease	2113
is	AUX	O	O	2113
due	ADJ	O	O	2113
,	PUNCT	O	O	2113
in	ADP	O	O	2113
part	NOUN	O	O	2113
,	PUNCT	O	O	2113
to	PART	O	O	2113
decreased	VERB	O	O	2113
responsiveness	NOUN	O	O	2113
of	ADP	O	O	2113
erythropoietic	ADJ	O	O	2113
precursors	NOUN	O	O	2113
(	PUNCT	O	O	2113
BFU	PROPN	O	O	2113
-	PUNCT	O	O	2113
e	X	O	O	2113
)	PUNCT	O	O	2113
to	PART	O	O	2113
erythropoietin	NOUN	O	O	2113
(	PUNCT	O	O	2113
EPO	PROPN	O	O	2113
)	PUNCT	O	O	2113
.	PUNCT	O	O	2113
Mice	NOUN	O	O	2114
in	ADP	O	O	2114
the	PRON	O	O	2114
early	ADV	O	O	2114
stage	NOUN	O	O	2114
of	ADP	O	O	2114
LP	NOUN	O	O	2114
-	PUNCT	O	O	2114
BM5	PROPN	O	O	2114
MuLV	PROPN	O	O	2114
disease	PROPN	O	O	2114
were	AUX	O	O	2114
given	VERB	O	O	2114
AZT	PROPN	O	Chemical	2114
in	ADP	O	O	2114
their	PRON	O	O	2114
drinking	VERB	O	O	2114
water	PROPN	O	O	2114
at	ADP	O	O	2114
1.0	NUM	O	O	2114
and	CCONJ	O	O	2114
2.5	NUM	O	O	2114
mg	VERB	O	O	2114
/	PUNCT	O	O	2114
ml	ADP	O	O	2114
.	PUNCT	O	O	2114
AZT	PROPN	O	Chemical	2115
produced	VERB	O	O	2115
anaemia	NOUN	O	Disease	2115
in	ADP	O	O	2115
both	PRON	O	O	2115
groups	NOUN	O	O	2115
,	PUNCT	O	O	2115
in	ADP	O	O	2115
a	PRON	O	O	2115
dose	NOUN	O	O	2115
-	PUNCT	O	O	2115
dependent	ADJ	O	O	2115
fashion	NOUN	O	O	2115
.	PUNCT	O	O	2115
Despite	SCONJ	O	O	2116
the	PRON	O	O	2116
anaemia	NOUN	O	Disease	2116
,	PUNCT	O	O	2116
the	PRON	O	O	2116
number	NOUN	O	O	2116
of	ADP	O	O	2116
splenic	ADJ	O	O	2116
and	CCONJ	O	O	2116
bone	NOUN	O	O	2116
marrow	PROPN	O	O	2116
BFU	PROPN	O	O	2116
-	PUNCT	O	O	2116
e	X	O	O	2116
in	ADP	O	O	2116
AZT	PROPN	O	Chemical	2116
treated	VERB	O	O	2116
mice	NOUN	O	O	2116
increased	VERB	O	O	2116
up	ADP	O	O	2116
to	PART	O	O	2116
five	NUM	O	O	2116
-	PUNCT	O	O	2116
fold	VERB	O	O	2116
over	ADP	O	O	2116
levels	NOUN	O	O	2116
observed	VERB	O	O	2116
in	ADP	O	O	2116
infected	VERB	O	O	2116
untreated	ADJ	O	O	2116
animals	NOUN	O	O	2116
after	ADP	O	O	2116
15	NUM	O	O	2116
d	X	O	O	2116
of	ADP	O	O	2116
treatment	NOUN	O	O	2116
.	PUNCT	O	O	2116
Colony	NOUN	O	O	2117
formation	NOUN	O	O	2117
by	ADP	O	O	2117
splenic	ADJ	O	O	2117
and	CCONJ	O	O	2117
bone	NOUN	O	O	2117
marrow	PROPN	O	O	2117
BFUe	NOUN	O	O	2117
was	AUX	O	O	2117
stimulated	VERB	O	O	2117
at	ADP	O	O	2117
lower	ADJ	O	O	2117
concentrations	NOUN	O	O	2117
of	ADP	O	O	2117
EPO	PROPN	O	O	2117
in	ADP	O	O	2117
mice	NOUN	O	O	2117
receiving	VERB	O	O	2117
AZT	PROPN	O	Chemical	2117
for	ADP	O	O	2117
15	NUM	O	O	2117
d	X	O	O	2117
than	ADP	O	O	2117
for	ADP	O	O	2117
infected	VERB	O	O	2117
,	PUNCT	O	O	2117
untreated	ADJ	O	O	2117
mice	NOUN	O	O	2117
.	PUNCT	O	O	2117
The	PRON	O	O	2118
mean	VERB	O	O	2118
plasma	NOUN	O	O	2118
levels	NOUN	O	O	2118
of	ADP	O	O	2118
EPO	PROPN	O	O	2118
observed	VERB	O	O	2118
in	ADP	O	O	2118
AZT	PROPN	O	Chemical	2118
treated	VERB	O	O	2118
mice	NOUN	O	O	2118
were	AUX	O	O	2118
appropriate	ADJ	O	O	2118
for	ADP	O	O	2118
the	PRON	O	O	2118
degree	PROPN	O	O	2118
of	ADP	O	O	2118
anaemia	NOUN	O	Disease	2118
observed	VERB	O	O	2118
when	SCONJ	O	O	2118
compared	VERB	O	O	2118
with	ADP	O	O	2118
phenylhydrazine	NOUN	O	Chemical	2118
(	PUNCT	O	O	2118
PHZ	PROPN	O	Chemical	2118
)	PUNCT	O	O	2118
treated	VERB	O	O	2118
mice	NOUN	O	O	2118
.	PUNCT	O	O	2118
The	PRON	O	O	2119
numbers	NOUN	O	O	2119
of	ADP	O	O	2119
BFU	PROPN	O	O	2119
-	PUNCT	O	O	2119
e	X	O	O	2119
and	CCONJ	O	O	2119
the	PRON	O	O	2119
percentage	NOUN	O	O	2119
of	ADP	O	O	2119
bone	NOUN	O	O	2119
marrow	PROPN	O	O	2119
erythroblasts	NOUN	O	O	2119
observed	VERB	O	O	2119
were	AUX	O	O	2119
comparable	ADJ	O	O	2119
in	ADP	O	O	2119
AZT	PROPN	O	Chemical	2119
and	CCONJ	O	O	2119
PHZ	PROPN	O	Chemical	2119
treated	VERB	O	O	2119
mice	NOUN	O	O	2119
with	ADP	O	O	2119
similar	ADJ	O	O	2119
degrees	NOUN	O	O	2119
of	ADP	O	O	2119
anaemia	NOUN	O	Disease	2119
.	PUNCT	O	O	2119
However	ADV	O	O	2120
,	PUNCT	O	O	2120
reticulocytosis	NOUN	O	Disease	2120
was	AUX	O	O	2120
inappropriate	ADJ	O	O	2120
for	ADP	O	O	2120
the	PRON	O	O	2120
degree	PROPN	O	O	2120
of	ADP	O	O	2120
anaemia	NOUN	O	Disease	2120
observed	VERB	O	O	2120
in	ADP	O	O	2120
AZT	PROPN	O	Chemical	2120
treated	VERB	O	O	2120
infected	VERB	O	O	2120
mice	NOUN	O	O	2120
.	PUNCT	O	O	2120
AZT	PROPN	O	Chemical	2121
-	PUNCT	O	O	2121
induced	VERB	O	O	2121
peripheral	ADJ	O	O	2121
anaemia	NOUN	O	Disease	2121
in	ADP	O	O	2121
the	PRON	O	O	2121
face	NOUN	O	O	2121
of	ADP	O	O	2121
increased	VERB	O	O	2121
numbers	NOUN	O	O	2121
of	ADP	O	O	2121
BFU	PROPN	O	O	2121
-	PUNCT	O	O	2121
e	X	O	O	2121
and	CCONJ	O	O	2121
increased	VERB	O	O	2121
levels	NOUN	O	O	2121
of	ADP	O	O	2121
plasma	NOUN	O	O	2121
EPO	PROPN	O	O	2121
suggest	VERB	O	O	2121
a	PRON	O	O	2121
lesion	NOUN	O	O	2121
in	ADP	O	O	2121
terminal	PROPN	O	O	2121
differentiation	NOUN	O	O	2121
.	PUNCT	O	O	2121
Detection	NOUN	O	O	2124
of	ADP	O	O	2124
abnormal	ADJ	O	O	2124
cardiac	ADJ	O	O	2124
adrenergic	NOUN	O	O	2124
neuron	PROPN	O	O	2124
activity	NOUN	O	O	2124
in	ADP	O	O	2124
adriamycin	PROPN	O	Chemical	2124
-	PUNCT	O	O	2124
induced	VERB	O	O	2124
cardiomyopathy	ADJ	O	Disease	2124
with	ADP	O	O	2124
iodine-125-metaiodobenzylguanidine	NOUN	O	Chemical	2124
.	PUNCT	O	O	2124
Radiolabeled metaiodobenzylguanidine	NOUN	O	Chemical	2125
(	PUNCT	O	O	2125
MIBG	NOUN	O	Chemical	2125
)	PUNCT	O	O	2125
,	PUNCT	O	O	2125
an	PRON	O	O	2125
analog	NOUN	O	O	2125
of	ADP	O	O	2125
norepinephrine	NOUN	O	Chemical	2125
(	PUNCT	O	O	2125
NE	PROPN	O	Chemical	2125
)	PUNCT	O	O	2125
,	PUNCT	O	O	2125
serves	VERB	O	O	2125
as	ADP	O	O	2125
an	PRON	O	O	2125
index	NOUN	O	O	2125
of	ADP	O	O	2125
adrenergic	NOUN	O	O	2125
neuron	PROPN	O	O	2125
integrity	NOUN	O	O	2125
and	CCONJ	O	O	2125
function	NOUN	O	O	2125
.	PUNCT	O	O	2125
Using	VERB	O	O	2126
a	PRON	O	O	2126
rat	NOUN	O	O	2126
model	NOUN	O	O	2126
of	ADP	O	O	2126
adriamycin	PROPN	O	Chemical	2126
-	PUNCT	O	O	2126
induced	VERB	O	O	2126
cardiomyopathy	ADJ	O	Disease	2126
,	PUNCT	O	O	2126
we	PRON	O	O	2126
tested	VERB	O	O	2126
the	PRON	O	O	2126
hypothesis	NOUN	O	O	2126
that	SCONJ	O	O	2126
abnormal	ADJ	O	O	2126
cardiac	ADJ	O	O	2126
adrenergic	NOUN	O	O	2126
neuron	PROPN	O	O	2126
activity	NOUN	O	O	2126
may	AUX	O	O	2126
appear	VERB	O	O	2126
and	CCONJ	O	O	2126
be	AUX	O	O	2126
exacerbated	VERB	O	O	2126
dose	NOUN	O	O	2126
-	PUNCT	O	O	2126
dependently	ADV	O	O	2126
in	ADP	O	O	2126
adriamycin	PROPN	O	Chemical	2126
cardiomyopathy	ADJ	O	Disease	2126
.	PUNCT	O	O	2126
The	PRON	O	O	2127
degree	PROPN	O	O	2127
of	ADP	O	O	2127
vacuolar degeneration of myocardial cells	NOUN	O	Disease	2127
was	AUX	O	O	2127
analyzed	VERB	O	O	2127
in	ADP	O	O	2127
relation	NOUN	O	O	2127
to	PART	O	O	2127
the	PRON	O	O	2127
duration	NOUN	O	O	2127
of	ADP	O	O	2127
adriamycin	PROPN	O	Chemical	2127
treatment	NOUN	O	O	2127
(	PUNCT	O	O	2127
2	X	O	O	2127
mg	VERB	O	O	2127
/	PUNCT	O	O	2127
kg	VERB	O	O	2127
,	PUNCT	O	O	2127
once	ADV	O	O	2127
a	PRON	O	O	2127
week	NOUN	O	O	2127
)	PUNCT	O	O	2127
.	PUNCT	O	O	2127
Myocardial	PROPN	O	O	2128
accumulation	NOUN	O	O	2128
of	ADP	O	O	2128
[	X	O	O	2128
125I]MIBG	NUM	O	O	2128
4	NUM	O	O	2128
hr	NOUN	O	O	2128
after	ADP	O	O	2128
intravenous	ADJ	O	O	2128
injection	NOUN	O	O	2128
did	VERB	O	O	2128
not	PART	O	O	2128
differ	VERB	O	O	2128
between	ADP	O	O	2128
the	PRON	O	O	2128
controls	VERB	O	O	2128
and	CCONJ	O	O	2128
the	PRON	O	O	2128
groups	NOUN	O	O	2128
treated	VERB	O	O	2128
3	X	O	O	2128
wk	X	O	O	2128
or	CCONJ	O	O	2128
less	ADV	O	O	2128
.	PUNCT	O	O	2128
In	ADP	O	O	2129
the	PRON	O	O	2129
5-wk	NOUN	O	O	2129
group	NOUN	O	O	2129
,	PUNCT	O	O	2129
MIBG	NOUN	O	Chemical	2129
accumulation	NOUN	O	O	2129
in	ADP	O	O	2129
the	PRON	O	O	2129
right	ADV	O	O	2129
and	CCONJ	O	O	2129
left	VERB	O	O	2129
ventricular	ADJ	O	O	2129
wall	PROPN	O	O	2129
was	AUX	O	O	2129
35%	NOUN	O	O	2129
and	CCONJ	O	O	2129
27%	NOUN	O	O	2129
of	ADP	O	O	2129
that	SCONJ	O	O	2129
in	ADP	O	O	2129
controls	VERB	O	O	2129
,	PUNCT	O	O	2129
respectively	ADV	O	O	2129
(	PUNCT	O	O	2129
p	NOUN	O	O	2129
less	ADV	O	O	2129
than	ADP	O	O	2129
0.001	NUM	O	O	2129
)	PUNCT	O	O	2129
.	PUNCT	O	O	2129
In	ADP	O	O	2130
the	PRON	O	O	2130
8-wk	NOUN	O	O	2130
group	NOUN	O	O	2130
,	PUNCT	O	O	2130
MIBG	NOUN	O	Chemical	2130
accumulation	NOUN	O	O	2130
in	ADP	O	O	2130
the	PRON	O	O	2130
right	ADV	O	O	2130
and	CCONJ	O	O	2130
left	VERB	O	O	2130
ventricular	ADJ	O	O	2130
wall	PROPN	O	O	2130
was	AUX	O	O	2130
18%	NOUN	O	O	2130
and	CCONJ	O	O	2130
14%	NOUN	O	O	2130
of	ADP	O	O	2130
that	SCONJ	O	O	2130
in	ADP	O	O	2130
controls	VERB	O	O	2130
,	PUNCT	O	O	2130
respectively	ADV	O	O	2130
(	PUNCT	O	O	2130
p	NOUN	O	O	2130
less	ADV	O	O	2130
than	ADP	O	O	2130
0.001	NUM	O	O	2130
)	PUNCT	O	O	2130
.	PUNCT	O	O	2130
Thus	ADV	O	O	2131
,	PUNCT	O	O	2131
MIBG	NOUN	O	Chemical	2131
accumulation	NOUN	O	O	2131
in	ADP	O	O	2131
the	PRON	O	O	2131
myocardium	NOUN	O	O	2131
decreased	VERB	O	O	2131
in	ADP	O	O	2131
an	PRON	O	O	2131
adriamycin	PROPN	O	Chemical	2131
dose	NOUN	O	O	2131
-	PUNCT	O	O	2131
dependent	ADJ	O	O	2131
manner	VERB	O	O	2131
.	PUNCT	O	O	2131
The	PRON	O	O	2132
appearance	NOUN	O	O	2132
of	ADP	O	O	2132
impaired	VERB	O	O	2132
cardiac	ADJ	O	O	2132
adrenergic	NOUN	O	O	2132
neuron	PROPN	O	O	2132
activity	NOUN	O	O	2132
in	ADP	O	O	2132
the	PRON	O	O	2132
presence	NOUN	O	O	2132
of	ADP	O	O	2132
slight	ADJ	O	O	2132
myocardial impairment	NOUN	O	Disease	2132
(	PUNCT	O	O	2132
scattered	VERB	O	O	2132
or	CCONJ	O	O	2132
focal	ADJ	O	O	2132
vacuolar degeneration	NOUN	O	Disease	2132
)	PUNCT	O	O	2132
indicates	VERB	O	O	2132
that	SCONJ	O	O	2132
MIBG	NOUN	O	Chemical	2132
scintigraphy	VERB	O	O	2132
may	AUX	O	O	2132
be	AUX	O	O	2132
a	PRON	O	O	2132
useful	ADJ	O	O	2132
method	NOUN	O	O	2132
for	ADP	O	O	2132
detection	NOUN	O	O	2132
of	ADP	O	O	2132
adriamycin	PROPN	O	Chemical	2132
-	PUNCT	O	O	2132
induced	VERB	O	O	2132
cardiomyopathy	ADJ	O	Disease	2132
.	PUNCT	O	O	2132
Amnestic syndrome	NOUN	O	Disease	2135
associated	VERB	O	O	2135
with	ADP	O	O	2135
propranolol	NOUN	O	Chemical	2135
toxicity	NOUN	O	Disease	2135
:	PUNCT	O	O	2135
a	PRON	O	O	2135
case	NOUN	O	O	2135
report	VERB	O	O	2135
.	PUNCT	O	O	2135
An	PRON	O	O	2136
elderly	ADJ	O	O	2136
woman	NOUN	O	O	2136
developed	VERB	O	O	2136
an	PRON	O	O	2136
Alzheimer	NOUN	O	Disease	2136
-	PUNCT	O	O	2136
like	INTJ	O	O	2136
subacute	VERB	O	O	2136
dementia	NOUN	O	Disease	2136
as	ADP	O	O	2136
a	PRON	O	O	2136
result	VERB	O	O	2136
of	ADP	O	O	2136
propranolol	NOUN	O	Chemical	2136
toxicity	NOUN	O	Disease	2136
.	PUNCT	O	O	2136
There	ADV	O	O	2137
is	AUX	O	O	2137
evidence	NOUN	O	O	2137
that	SCONJ	O	O	2137
cerebral	ADJ	O	O	2137
reactions	NOUN	O	O	2137
to	PART	O	O	2137
drug	NOUN	O	O	2137
toxicity	NOUN	O	Disease	2137
can	AUX	O	O	2137
exhibit	VERB	O	O	2137
patterns	NOUN	O	O	2137
that	SCONJ	O	O	2137
suggest	VERB	O	O	2137
highly	ADV	O	O	2137
selective	ADJ	O	O	2137
involvement	NOUN	O	O	2137
of	ADP	O	O	2137
functional	ADJ	O	O	2137
subdivisions	NOUN	O	O	2137
of	ADP	O	O	2137
the	PRON	O	O	2137
brain	NOUN	O	O	2137
.	PUNCT	O	O	2137
Biphasic	PROPN	O	O	2140
response	NOUN	O	O	2140
of	ADP	O	O	2140
the	PRON	O	O	2140
SA	NOUN	O	O	2140
node	NOUN	O	O	2140
of	ADP	O	O	2140
the	PRON	O	O	2140
dog	NOUN	O	O	2140
heart	NOUN	O	O	2140
in	ADP	O	O	2140
vivo	VERB	O	O	2140
to	PART	O	O	2140
selective	ADJ	O	O	2140
administration	NOUN	O	O	2140
of	ADP	O	O	2140
ketamine	VERB	O	Chemical	2140
.	PUNCT	O	O	2140
Effect	VERB	O	O	2141
of	ADP	O	O	2141
ketamine	VERB	O	Chemical	2141
on	ADP	O	O	2141
the	PRON	O	O	2141
SA	NOUN	O	O	2141
node	NOUN	O	O	2141
of	ADP	O	O	2141
the	PRON	O	O	2141
dog	NOUN	O	O	2141
heart	NOUN	O	O	2141
was	AUX	O	O	2141
studied	VERB	O	O	2141
in	ADP	O	O	2141
vivo	VERB	O	O	2141
using	VERB	O	O	2141
a	PRON	O	O	2141
selective	ADJ	O	O	2141
perfusion	NOUN	O	O	2141
technique	NOUN	O	O	2141
of	ADP	O	O	2141
the	PRON	O	O	2141
SA	NOUN	O	O	2141
node	NOUN	O	O	2141
artery	NOUN	O	O	2141
.	PUNCT	O	O	2141
Injections	NOUN	O	O	2142
of	ADP	O	O	2142
ketamine	VERB	O	Chemical	2142
in	ADP	O	O	2142
doses	NOUN	O	O	2142
from	ADP	O	O	2142
100	NUM	O	O	2142
microgram	PROPN	O	O	2142
to	PART	O	O	2142
3	X	O	O	2142
mg	VERB	O	O	2142
into	ADP	O	O	2142
the	PRON	O	O	2142
artery	NOUN	O	O	2142
produced	VERB	O	O	2142
a	PRON	O	O	2142
depression	PROPN	O	Disease	2142
of	ADP	O	O	2142
the	PRON	O	O	2142
SA	NOUN	O	O	2142
nodal	ADJ	O	O	2142
activity	NOUN	O	O	2142
by	ADP	O	O	2142
a	PRON	O	O	2142
direct	ADJ	O	O	2142
action	NOUN	O	O	2142
.	PUNCT	O	O	2142
This	PRON	O	O	2143
depression	PROPN	O	Disease	2143
was	AUX	O	O	2143
followed	VERB	O	O	2143
by	ADP	O	O	2143
the	PRON	O	O	2143
sudden	ADJ	O	O	2143
appearance	NOUN	O	O	2143
of	ADP	O	O	2143
a	PRON	O	O	2143
stimulatory	ADJ	O	O	2143
phase	NOUN	O	O	2143
.	PUNCT	O	O	2143
Bilateral	ADJ	O	O	2144
vagotomy	NOUN	O	O	2144
and	CCONJ	O	O	2144
sympathectomy	NOUN	O	O	2144
or	CCONJ	O	O	2144
prior	ADV	O	O	2144
administration	NOUN	O	O	2144
of	ADP	O	O	2144
a	PRON	O	O	2144
ganglion	NOUN	O	O	2144
blocker	NOUN	O	O	2144
failed	VERB	O	O	2144
to	PART	O	O	2144
inhibit	VERB	O	O	2144
the	PRON	O	O	2144
occurrence	NOUN	O	O	2144
of	ADP	O	O	2144
the	PRON	O	O	2144
ketamine	VERB	O	Chemical	2144
-	PUNCT	O	O	2144
induced	VERB	O	O	2144
tachycardia	PROPN	O	Disease	2144
,	PUNCT	O	O	2144
while	SCONJ	O	O	2144
it	PRON	O	O	2144
was	AUX	O	O	2144
completely	ADV	O	O	2144
abolished	VERB	O	O	2144
in	ADP	O	O	2144
the	PRON	O	O	2144
reserpinized	VERB	O	O	2144
dogs	NOUN	O	O	2144
or	CCONJ	O	O	2144
by	ADP	O	O	2144
a	PRON	O	O	2144
prior	ADV	O	O	2144
injection	NOUN	O	O	2144
of	ADP	O	O	2144
a	PRON	O	O	2144
beta	NOUN	O	O	2144
-	PUNCT	O	O	2144
blocking	VERB	O	O	2144
agent	NOUN	O	O	2144
into	ADP	O	O	2144
the	PRON	O	O	2144
SA	NOUN	O	O	2144
node	NOUN	O	O	2144
artery	NOUN	O	O	2144
.	PUNCT	O	O	2144
This	PRON	O	O	2145
may	AUX	O	O	2145
indicate	VERB	O	O	2145
that	SCONJ	O	O	2145
an	PRON	O	O	2145
activation	NOUN	O	O	2145
of	ADP	O	O	2145
the	PRON	O	O	2145
peripheral	ADJ	O	O	2145
adrenergic	NOUN	O	O	2145
mechanism	NOUN	O	O	2145
plays	VERB	O	O	2145
an	PRON	O	O	2145
important	ADJ	O	O	2145
role	NOUN	O	O	2145
in	ADP	O	O	2145
the	PRON	O	O	2145
induction	NOUN	O	O	2145
of	ADP	O	O	2145
the	PRON	O	O	2145
excitatory	ADJ	O	O	2145
effect	VERB	O	O	2145
of	ADP	O	O	2145
ketamine	VERB	O	Chemical	2145
injected	VERB	O	O	2145
in	ADP	O	O	2145
the	PRON	O	O	2145
SA	NOUN	O	O	2145
node	NOUN	O	O	2145
artery	NOUN	O	O	2145
.	PUNCT	O	O	2145
The	PRON	O	O	2148
use	VERB	O	O	2148
of	ADP	O	O	2148
serum	NOUN	O	O	2148
cholinesterase	NOUN	O	O	2148
in	ADP	O	O	2148
succinylcholine	NOUN	O	Chemical	2148
apnoea	NOUN	O	Disease	2148
.	PUNCT	O	O	2148
Fifteen	NUM	O	O	2149
patients	NOUN	O	O	2149
demonstrating	VERB	O	O	2149
unexpected	ADJ	O	O	2149
prolonged	VERB	O	O	2149
apnoea	NOUN	O	Disease	2149
lasting	VERB	O	O	2149
several	ADJ	O	O	2149
hours	NOUN	O	O	2149
after	ADP	O	O	2149
succinylcholine	NOUN	O	Chemical	2149
have	VERB	O	O	2149
been	AUX	O	O	2149
treated	VERB	O	O	2149
by	ADP	O	O	2149
a	PRON	O	O	2149
new	ADJ	O	O	2149
preparation	NOUN	O	O	2149
of	ADP	O	O	2149
human	PROPN	O	O	2149
serum	NOUN	O	O	2149
cholinesterase	NOUN	O	O	2149
.	PUNCT	O	O	2149
It	PRON	O	O	2150
is	AUX	O	O	2150
therefore	ADV	O	O	2150
supposed	VERB	O	O	2150
that	SCONJ	O	O	2150
other	ADJ	O	O	2150
unknown	ADJ	O	O	2150
variants	NOUN	O	O	2150
of	ADP	O	O	2150
serum	NOUN	O	O	2150
cholinesterase	NOUN	O	O	2150
exist	VERB	O	O	2150
which	PRON	O	O	2150
can	AUX	O	O	2150
not	PART	O	O	2150
hydrolyze	VERB	O	O	2150
succinylcholine	NOUN	O	Chemical	2150
.	PUNCT	O	O	2150
The	PRON	O	O	2151
use	VERB	O	O	2151
of	ADP	O	O	2151
serum	NOUN	O	O	2151
cholinesterase	NOUN	O	O	2151
in	ADP	O	O	2151
succinylcholine	NOUN	O	Chemical	2151
apnoea	NOUN	O	Disease	2151
provided	VERB	O	O	2151
considerable	ADJ	O	O	2151
relief	NOUN	O	O	2151
to	PART	O	O	2151
both	PRON	O	O	2151
patient	NOUN	O	O	2151
and	CCONJ	O	O	2151
anaesthetist	NOUN	O	O	2151
.	PUNCT	O	O	2151
Orthostatic hypotension	NOUN	O	Disease	2154
occurs	VERB	O	O	2154
following	VERB	O	O	2154
alpha	PROPN	O	O	2154
2-adrenoceptor	NOUN	O	O	2154
blockade	VERB	O	O	2154
in	ADP	O	O	2154
chronic	ADJ	O	O	2154
prazosin	NOUN	O	Chemical	2154
-	PUNCT	O	O	2154
pretreated	VERB	O	O	2154
conscious	ADJ	O	O	2154
spontaneously	ADV	O	O	2154
hypertensive	ADJ	O	Disease	2154
rats	NOUN	O	O	2154
.	PUNCT	O	O	2154
1	X	O	O	2154
.	PUNCT	O	O	2154
Studies	NOUN	O	O	2155
were	AUX	O	O	2155
performed	VERB	O	O	2155
to	PART	O	O	2155
evaluate	VERB	O	O	2155
whether	SCONJ	O	O	2155
chronic	ADJ	O	O	2155
prazosin	NOUN	O	Chemical	2155
treatment	NOUN	O	O	2155
alters	VERB	O	O	2155
the	PRON	O	O	2155
alpha	PROPN	O	O	2155
2-adrenoceptor	NOUN	O	O	2155
function	NOUN	O	O	2155
for	ADP	O	O	2155
orthostatic	ADJ	O	O	2155
control	VERB	O	O	2155
of	ADP	O	O	2155
arterial	ADJ	O	O	2155
blood	NOUN	O	O	2155
pressure	NOUN	O	O	2155
in	ADP	O	O	2155
conscious	ADJ	O	O	2155
spontaneously	ADV	O	O	2155
hypertensive	ADJ	O	Disease	2155
rats	NOUN	O	O	2155
(	PUNCT	O	O	2155
SHR	PROPN	O	O	2155
)	PUNCT	O	O	2155
.	PUNCT	O	O	2155
Conscious	ADJ	O	O	2156
SHR	PROPN	O	O	2156
(	PUNCT	O	O	2156
male	NOUN	O	O	2156
300	NUM	O	O	2156
-	PUNCT	O	O	2156
350	NUM	O	O	2156
g	X	O	O	2156
)	PUNCT	O	O	2156
were	AUX	O	O	2156
subjected	VERB	O	O	2156
to	PART	O	O	2156
90	NUM	O	O	2156
degrees	NOUN	O	O	2156
head	NOUN	O	O	2156
-	PUNCT	O	O	2156
up	ADP	O	O	2156
tilts	VERB	O	O	2156
for	ADP	O	O	2156
60	NUM	O	O	2156
s	X	O	O	2156
following	VERB	O	O	2156
acute	ADJ	O	O	2156
administration	NOUN	O	O	2156
of	ADP	O	O	2156
prazosin	NOUN	O	Chemical	2156
(	PUNCT	O	O	2156
0.1	NUM	O	O	2156
mg	VERB	O	O	2156
kg-1	VERB	O	O	2156
i.p	NOUN	O	O	2156
.	PUNCT	O	O	2156
)	PUNCT	O	O	2156
or	CCONJ	O	O	2156
rauwolscine	NOUN	O	Chemical	2156
(	PUNCT	O	O	2156
3	X	O	O	2156
mg	VERB	O	O	2156
kg-1	VERB	O	O	2156
i.v	NOUN	O	O	2156
.	PUNCT	O	O	2156
)	PUNCT	O	O	2156
.	PUNCT	O	O	2156
Orthostatic hypotension	NOUN	O	Disease	2157
was	AUX	O	O	2157
determined	VERB	O	O	2157
by	ADP	O	O	2157
the	PRON	O	O	2157
average	ADJ	O	O	2157
decrease	VERB	O	O	2157
(	PUNCT	O	O	2157
%	INTJ	O	O	2157
)	PUNCT	O	O	2157
in	ADP	O	O	2157
mean	VERB	O	O	2157
arterial	ADJ	O	O	2157
pressure	NOUN	O	O	2157
(	PUNCT	O	O	2157
MAP	PROPN	O	O	2157
femoral	ADJ	O	O	2157
)	PUNCT	O	O	2157
over	ADP	O	O	2157
the	PRON	O	O	2157
60-s	NOUN	O	O	2157
tilt	NOUN	O	O	2157
period	NOUN	O	O	2157
.	PUNCT	O	O	2157
The	PRON	O	O	2158
basal	PROPN	O	O	2158
MAP	PROPN	O	O	2158
of	ADP	O	O	2158
conscious	ADJ	O	O	2158
SHR	PROPN	O	O	2158
was	AUX	O	O	2158
reduced	VERB	O	O	2158
to	PART	O	O	2158
a	PRON	O	O	2158
similar	ADJ	O	O	2158
extent	NOUN	O	O	2158
by	ADP	O	O	2158
prazosin	NOUN	O	Chemical	2158
(	PUNCT	O	O	2158
-23%(-)-26%	NOUN	O	O	2158
MAP	PROPN	O	O	2158
)	PUNCT	O	O	2158
and	CCONJ	O	O	2158
rauwolscine	NOUN	O	Chemical	2158
(	PUNCT	O	O	2158
-16%(-)-33%	NOUN	O	O	2158
MAP	PROPN	O	O	2158
)	PUNCT	O	O	2158
.	PUNCT	O	O	2158
However	ADV	O	O	2159
,	PUNCT	O	O	2159
the	PRON	O	O	2159
head	NOUN	O	O	2159
-	PUNCT	O	O	2159
up	ADP	O	O	2159
tilt	NOUN	O	O	2159
induced	VERB	O	O	2159
orthostatic hypotension	NOUN	O	Disease	2159
in	ADP	O	O	2159
the	PRON	O	O	2159
SHR	PROPN	O	O	2159
treated	VERB	O	O	2159
with	ADP	O	O	2159
prazosin	NOUN	O	Chemical	2159
(	PUNCT	O	O	2159
-16%	NOUN	O	O	2159
MAP	PROPN	O	O	2159
,	PUNCT	O	O	2159
n	CCONJ	O	O	2159
=	PUNCT	O	O	2159
6	NUM	O	O	2159
)	PUNCT	O	O	2159
,	PUNCT	O	O	2159
but	CCONJ	O	O	2159
not	PART	O	O	2159
in	ADP	O	O	2159
the	PRON	O	O	2159
SHR	PROPN	O	O	2159
treated	VERB	O	O	2159
with	ADP	O	O	2159
rauwolscine	NOUN	O	Chemical	2159
(	PUNCT	O	O	2159
less	ADV	O	O	2159
than	ADP	O	O	2159
+	ADP	O	O	2159
2%	NOUN	O	O	2159
MAP	PROPN	O	O	2159
,	PUNCT	O	O	2159
n	CCONJ	O	O	2159
=	PUNCT	O	O	2159
6	NUM	O	O	2159
)	PUNCT	O	O	2159
.	PUNCT	O	O	2159
Conscious	ADJ	O	O	2160
SHR	PROPN	O	O	2160
were	AUX	O	O	2160
treated	VERB	O	O	2160
for	ADP	O	O	2160
4	NUM	O	O	2160
days	NOUN	O	O	2160
with	ADP	O	O	2160
prazosin	NOUN	O	Chemical	2160
at	ADP	O	O	2160
2	X	O	O	2160
mg	VERB	O	O	2160
kg-1	VERB	O	O	2160
day-1	X	O	O	2160
i.p	NOUN	O	O	2160
.	PUNCT	O	O	2160
MAP	PROPN	O	O	2161
in	ADP	O	O	2161
conscious	ADJ	O	O	2161
SHR	PROPN	O	O	2161
after	ADP	O	O	2161
chronic	ADJ	O	O	2161
prazosin	NOUN	O	Chemical	2161
treatment	NOUN	O	O	2161
was	AUX	O	O	2161
14%	NOUN	O	O	2161
lower	ADJ	O	O	2161
than	ADP	O	O	2161
in	ADP	O	O	2161
the	PRON	O	O	2161
untreated	ADJ	O	O	2161
SHR	PROPN	O	O	2161
(	PUNCT	O	O	2161
n	CCONJ	O	O	2161
=	PUNCT	O	O	2161
8)	NUM	O	O	2161
.	PUNCT	O	O	2161
Head	NOUN	O	O	2162
-	PUNCT	O	O	2162
up	ADP	O	O	2162
tilts	VERB	O	O	2162
in	ADP	O	O	2162
these	PRON	O	O	2162
rats	NOUN	O	O	2162
did	VERB	O	O	2162
not	PART	O	O	2162
produce	VERB	O	O	2162
orthostatic hypotension	NOUN	O	Disease	2162
when	SCONJ	O	O	2162
performed	VERB	O	O	2162
either	ADV	O	O	2162
prior	ADV	O	O	2162
to	PART	O	O	2162
or	CCONJ	O	O	2162
after	ADP	O	O	2162
acute	ADJ	O	O	2162
dosing	VERB	O	O	2162
of	ADP	O	O	2162
prazosin	NOUN	O	Chemical	2162
(	PUNCT	O	O	2162
0.1	NUM	O	O	2162
mg	VERB	O	O	2162
kg-1	VERB	O	O	2162
i.p	NOUN	O	O	2162
.	PUNCT	O	O	2162
)	PUNCT	O	O	2162
.	PUNCT	O	O	2162
Conversely	ADV	O	O	2163
,	PUNCT	O	O	2163
administration	NOUN	O	O	2163
of	ADP	O	O	2163
rauwolscine	NOUN	O	Chemical	2163
(	PUNCT	O	O	2163
3	X	O	O	2163
mg	VERB	O	O	2163
kg-1	VERB	O	O	2163
i.v	NOUN	O	O	2163
.	PUNCT	O	O	2163
)	PUNCT	O	O	2163
in	ADP	O	O	2163
chronic	ADJ	O	O	2163
prazosin	NOUN	O	Chemical	2163
treated	VERB	O	O	2163
SHR	PROPN	O	O	2163
decreased	VERB	O	O	2163
the	PRON	O	O	2163
basal	PROPN	O	O	2163
MAP	PROPN	O	O	2163
by	ADP	O	O	2163
12	NUM	O	O	2163
-	PUNCT	O	O	2163
31%	NOUN	O	O	2163
(	PUNCT	O	O	2163
n	CCONJ	O	O	2163
=	PUNCT	O	O	2163
4	NUM	O	O	2163
)	PUNCT	O	O	2163
,	PUNCT	O	O	2163
and	CCONJ	O	O	2163
subsequent	ADJ	O	O	2163
tilts	VERB	O	O	2163
induced	VERB	O	O	2163
further	ADV	O	O	2163
drops	VERB	O	O	2163
of	ADP	O	O	2163
MAP	PROPN	O	O	2163
by	ADP	O	O	2163
19	NUM	O	O	2163
-	PUNCT	O	O	2163
23%	NOUN	O	O	2163
in	ADP	O	O	2163
these	PRON	O	O	2163
rats	NOUN	O	O	2163
.	PUNCT	O	O	2163
The	PRON	O	O	2164
pressor	ADJ	O	O	2164
responses	NOUN	O	O	2164
and	CCONJ	O	O	2164
bradycardia	NOUN	O	Disease	2164
to	PART	O	O	2164
the	PRON	O	O	2164
alpha	PROPN	O	O	2164
1-agonist	NOUN	O	O	2164
cirazoline	NOUN	O	Chemical	2164
(	PUNCT	O	O	2164
0.6	NUM	O	O	2164
and	CCONJ	O	O	2164
2	X	O	O	2164
micrograms	NOUN	O	O	2164
kg-1	VERB	O	O	2164
i.v	NOUN	O	O	2164
.	PUNCT	O	O	2164
)	PUNCT	O	O	2164
,	PUNCT	O	O	2164
the	PRON	O	O	2164
alpha	PROPN	O	O	2164
2-agonist	NOUN	O	O	2164
Abbott-53693	NOUN	O	Chemical	2164
(	PUNCT	O	O	2164
1	X	O	O	2164
and	CCONJ	O	O	2164
3	X	O	O	2164
micrograms	NOUN	O	O	2164
kg-1	VERB	O	O	2164
i.v	NOUN	O	O	2164
.	PUNCT	O	O	2164
)	PUNCT	O	O	2164
,	PUNCT	O	O	2164
and	CCONJ	O	O	2164
noradrenaline	NOUN	O	Chemical	2164
(	PUNCT	O	O	2164
0.1	NUM	O	O	2164
and	CCONJ	O	O	2164
1.0	NUM	O	O	2164
micrograms	NOUN	O	O	2164
kg-1	VERB	O	O	2164
i.v	NOUN	O	O	2164
.	PUNCT	O	O	2164
)	PUNCT	O	O	2164
were	AUX	O	O	2164
determined	VERB	O	O	2164
in	ADP	O	O	2164
conscious	ADJ	O	O	2164
SHR	PROPN	O	O	2164
with	ADP	O	O	2164
and	CCONJ	O	O	2164
without	ADP	O	O	2164
chronic	ADJ	O	O	2164
prazosin	NOUN	O	Chemical	2164
pretreatment	NOUN	O	O	2164
.	PUNCT	O	O	2164
Both	PRON	O	O	2165
the	PRON	O	O	2165
pressor	ADJ	O	O	2165
and	CCONJ	O	O	2165
bradycardia	NOUN	O	Disease	2165
effects	NOUN	O	O	2165
of	ADP	O	O	2165
cirazoline	NOUN	O	Chemical	2165
were	AUX	O	O	2165
abolished	VERB	O	O	2165
in	ADP	O	O	2165
chronic	ADJ	O	O	2165
prazosin	NOUN	O	Chemical	2165
treated	VERB	O	O	2165
SHR	PROPN	O	O	2165
(	PUNCT	O	O	2165
n	CCONJ	O	O	2165
=	PUNCT	O	O	2165
4	NUM	O	O	2165
)	PUNCT	O	O	2165
as	ADP	O	O	2165
compared	VERB	O	O	2165
to	PART	O	O	2165
the	PRON	O	O	2165
untreated	ADJ	O	O	2165
SHR	PROPN	O	O	2165
(	PUNCT	O	O	2165
n	CCONJ	O	O	2165
=	PUNCT	O	O	2165
4	NUM	O	O	2165
)	PUNCT	O	O	2165
.	PUNCT	O	O	2165
On	ADP	O	O	2166
the	PRON	O	O	2166
other	ADJ	O	O	2166
hand	NOUN	O	O	2166
,	PUNCT	O	O	2166
the	PRON	O	O	2166
pressor	ADJ	O	O	2166
effects	NOUN	O	O	2166
of	ADP	O	O	2166
Abbott-53693	NOUN	O	Chemical	2166
were	AUX	O	O	2166
similar	ADJ	O	O	2166
in	ADP	O	O	2166
both	PRON	O	O	2166
groups	NOUN	O	O	2166
of	ADP	O	O	2166
SHR	PROPN	O	O	2166
,	PUNCT	O	O	2166
but	CCONJ	O	O	2166
the	PRON	O	O	2166
accompanying	VERB	O	O	2166
bradycardia	NOUN	O	Disease	2166
was	AUX	O	O	2166
greater	ADJ	O	O	2166
in	ADP	O	O	2166
SHR	PROPN	O	O	2166
with	ADP	O	O	2166
chronic	ADJ	O	O	2166
prazosin	NOUN	O	Chemical	2166
treatment	NOUN	O	O	2166
than	ADP	O	O	2166
without	ADP	O	O	2166
such	ADJ	O	O	2166
treatment	NOUN	O	O	2166
.	PUNCT	O	O	2166
Furthermore	ADV	O	O	2167
,	PUNCT	O	O	2167
the	PRON	O	O	2167
bradycardia	NOUN	O	Disease	2167
that	SCONJ	O	O	2167
accompanied	VERB	O	O	2167
the	PRON	O	O	2167
noradrenaline	NOUN	O	Chemical	2167
-	PUNCT	O	O	2167
induced	VERB	O	O	2167
pressor	ADJ	O	O	2167
effect	VERB	O	O	2167
in	ADP	O	O	2167
SHR	PROPN	O	O	2167
was	AUX	O	O	2167
similar	ADJ	O	O	2167
with	ADP	O	O	2167
and	CCONJ	O	O	2167
without	ADP	O	O	2167
chronic	ADJ	O	O	2167
prazosin	NOUN	O	Chemical	2167
treatment	NOUN	O	O	2167
despite	SCONJ	O	O	2167
a	PRON	O	O	2167
47	NUM	O	O	2167
-	PUNCT	O	O	2167
71%	NOUN	O	O	2167
reduction	NOUN	O	O	2167
of	ADP	O	O	2167
the	PRON	O	O	2167
pressor	ADJ	O	O	2167
effect	VERB	O	O	2167
in	ADP	O	O	2167
chronic	ADJ	O	O	2167
alpha	PROPN	O	O	2167
1-receptor	NOUN	O	O	2167
blocked	VERB	O	O	2167
SHR.(ABSTRACT	NOUN	O	O	2167
TRUNCATED	ADJ	O	O	2167
AT	ADP	O	O	2167
400	NUM	O	O	2167
WORDS	NOUN	O	O	2167
)	PUNCT	O	O	2167
Coexistence	NOUN	O	O	2170
of	ADP	O	O	2170
cerebral	ADJ	O	O	2170
venous	ADJ	O	O	2170
sinus	NOUN	O	O	2170
and	CCONJ	O	O	2170
internal carotid artery thrombosis	NOUN	O	Disease	2170
associated	VERB	O	O	2170
with	ADP	O	O	2170
exogenous	ADJ	O	O	2170
sex	NOUN	O	O	2170
hormones	NOUN	O	O	2170
.	PUNCT	O	O	2170
A	PRON	O	O	2171
forty	NUM	O	O	2171
-	PUNCT	O	O	2171
six	NUM	O	O	2171
year	NOUN	O	O	2171
-	PUNCT	O	O	2171
old	ADJ	O	O	2171
premenopausal	ADJ	O	O	2171
woman	NOUN	O	O	2171
developed	VERB	O	O	2171
headache	PROPN	O	Disease	2171
,	PUNCT	O	O	2171
nausea	NOUN	O	Disease	2171
and	CCONJ	O	O	2171
vomiting	VERB	O	Disease	2171
,	PUNCT	O	O	2171
left	VERB	O	O	2171
hemiparesis	PROPN	O	Disease	2171
and	CCONJ	O	O	2171
seizure	NOUN	O	Disease	2171
two	NUM	O	O	2171
days	NOUN	O	O	2171
after	ADP	O	O	2171
parenteral	ADJ	O	O	2171
use	VERB	O	O	2171
of	ADP	O	O	2171
progesterone	NOUN	O	Chemical	2171
and	CCONJ	O	O	2171
estradiol	VERB	O	Chemical	2171
.	PUNCT	O	O	2171
Diabetes mellitus	NOUN	O	Disease	2172
(	PUNCT	O	O	2172
DM	PROPN	O	Disease	2172
)	PUNCT	O	O	2172
was	AUX	O	O	2172
found	VERB	O	O	2172
during	ADP	O	O	2172
admission	NOUN	O	O	2172
.	PUNCT	O	O	2172
Computed	VERB	O	O	2173
tomography	NOUN	O	O	2173
showed	VERB	O	O	2173
a	PRON	O	O	2173
hemorrhagic infarct	NOUN	O	Disease	2173
in	ADP	O	O	2173
the	PRON	O	O	2173
right	ADV	O	O	2173
frontal	ADJ	O	O	2173
lobe	NOUN	O	O	2173
and	CCONJ	O	O	2173
increased	VERB	O	O	2173
density	NOUN	O	O	2173
in	ADP	O	O	2173
the	PRON	O	O	2173
superior	PROPN	O	O	2173
sagittal	ADJ	O	O	2173
sinus	NOUN	O	O	2173
(	PUNCT	O	O	2173
SSS	PROPN	O	O	2173
)	PUNCT	O	O	2173
.	PUNCT	O	O	2173
Left	VERB	O	O	2174
carotid	NOUN	O	O	2174
angiography	NOUN	O	O	2174
found	VERB	O	O	2174
occlusion of the left internal carotid artery	NOUN	O	Disease	2174
(	PUNCT	O	O	2174
ICA	PROPN	O	O	2174
)	PUNCT	O	O	2174
.	PUNCT	O	O	2174
Right	INTJ	O	O	2175
carotid	NOUN	O	O	2175
angiograms	VERB	O	O	2175
failed	VERB	O	O	2175
to	PART	O	O	2175
show	VERB	O	O	2175
the	PRON	O	O	2175
SSS	PROPN	O	O	2175
and	CCONJ	O	O	2175
inferior	ADJ	O	O	2175
sagittal	ADJ	O	O	2175
sinus	NOUN	O	O	2175
,	PUNCT	O	O	2175
suggestive	ADJ	O	O	2175
of	ADP	O	O	2175
venous sinus thrombosis	NOUN	O	Disease	2175
.	PUNCT	O	O	2175
Coexistence	NOUN	O	O	2176
of	ADP	O	O	2176
the	PRON	O	O	2176
cerebral artery and the venous sinus occlusion	NOUN	O	Disease	2176
has	VERB	O	O	2176
been	AUX	O	O	2176
described	VERB	O	O	2176
infrequently	ADV	O	O	2176
.	PUNCT	O	O	2176
In	ADP	O	O	2177
this	PRON	O	O	2177
case	NOUN	O	O	2177
,	PUNCT	O	O	2177
the	PRON	O	O	2177
authors	NOUN	O	O	2177
postulate	VERB	O	O	2177
that	SCONJ	O	O	2177
the	PRON	O	O	2177
use	VERB	O	O	2177
of	ADP	O	O	2177
estradiol	VERB	O	Chemical	2177
and	CCONJ	O	O	2177
progesterone	NOUN	O	Chemical	2177
and	CCONJ	O	O	2177
the	PRON	O	O	2177
underlying	VERB	O	O	2177
DM	PROPN	O	Disease	2177
increased	VERB	O	O	2177
vascular	ADJ	O	O	2177
thrombogenicity	NOUN	O	O	2177
,	PUNCT	O	O	2177
which	PRON	O	O	2177
provided	VERB	O	O	2177
a	PRON	O	O	2177
common	ADJ	O	O	2177
denominator	NOUN	O	O	2177
for	ADP	O	O	2177
thrombosis of both the ICA and the venous sinus	NOUN	O	Disease	2177
.	PUNCT	O	O	2177
Chloroquine	NOUN	O	Chemical	2180
related	ADJ	O	O	2180
complete	VERB	O	O	2180
heart block	NOUN	O	Disease	2180
with	ADP	O	O	2180
blindness	NOUN	O	Disease	2180
:	PUNCT	O	O	2180
case	NOUN	O	O	2180
report	VERB	O	O	2180
.	PUNCT	O	O	2180
A	PRON	O	O	2181
27-year	NOUN	O	O	2181
old	ADJ	O	O	2181
African	ADJ	O	O	2181
woman	NOUN	O	O	2181
with	ADP	O	O	2181
history	NOUN	O	O	2181
of	ADP	O	O	2181
regular	ADJ	O	O	2181
chloroquine	ADJ	O	Chemical	2181
ingestion	NOUN	O	O	2181
presented	VERB	O	O	2181
with	ADP	O	O	2181
progressive	ADJ	O	O	2181
deterioration of vision	NOUN	O	Disease	2181
,	PUNCT	O	O	2181
easy	ADV	O	O	2181
fatiguability	NOUN	O	Disease	2181
,	PUNCT	O	O	2181
dyspnoea	NOUN	O	Disease	2181
,	PUNCT	O	O	2181
dizziness	NOUN	O	Disease	2181
progressing	VERB	O	O	2181
to	PART	O	O	2181
syncopal attacks	NOUN	O	Disease	2181
.	PUNCT	O	O	2181
Ophthalmological	ADJ	O	O	2182
assessment	NOUN	O	O	2182
revealed	VERB	O	O	2182
features	VERB	O	O	2182
of	ADP	O	O	2182
chloroquine	ADJ	O	Chemical	2182
retinopathy	ADJ	O	Disease	2182
,	PUNCT	O	O	2182
cardiac	ADJ	O	O	2182
assessment	NOUN	O	O	2182
revealed	VERB	O	O	2182
features	VERB	O	O	2182
of	ADP	O	O	2182
heart failure	NOUN	O	Disease	2182
and	CCONJ	O	O	2182
a	PRON	O	O	2182
complete	VERB	O	O	2182
heart block	NOUN	O	Disease	2182
with	ADP	O	O	2182
right bundle branch block	NOUN	O	Disease	2182
pattern	NOUN	O	O	2182
.	PUNCT	O	O	2182
The	PRON	O	O	2183
heart block	NOUN	O	Disease	2183
was	AUX	O	O	2183
treated	VERB	O	O	2183
by	ADP	O	O	2183
pacemaker	NOUN	O	O	2183
insertion	NOUN	O	O	2183
and	CCONJ	O	O	2183
the	PRON	O	O	2183
heart failure	NOUN	O	Disease	2183
resolved	VERB	O	O	2183
spontaneously	ADV	O	O	2183
following	VERB	O	O	2183
chloroquine	ADJ	O	Chemical	2183
discontinuation	NOUN	O	O	2183
.	PUNCT	O	O	2183
She	PRON	O	O	2184
however	ADV	O	O	2184
remains	VERB	O	O	2184
blind	ADJ	O	Disease	2184
.	PUNCT	O	O	2184
Systemic	ADJ	O	O	2187
toxicity	NOUN	O	Disease	2187
and	CCONJ	O	O	2187
resuscitation	NOUN	O	O	2187
in	ADP	O	O	2187
bupivacaine-	VERB	O	O	2187
,	PUNCT	O	O	2187
levobupivacaine-	PROPN	O	O	2187
,	PUNCT	O	O	2187
or	CCONJ	O	O	2187
ropivacaine	NOUN	O	Chemical	2187
-	PUNCT	O	O	2187
infused	VERB	O	O	2187
rats	NOUN	O	O	2187
.	PUNCT	O	O	2187
We	PRON	O	O	2188
compared	VERB	O	O	2188
the	PRON	O	O	2188
systemic	ADJ	O	O	2188
toxicity	NOUN	O	Disease	2188
of	ADP	O	O	2188
bupivacaine	NOUN	O	Chemical	2188
,	PUNCT	O	O	2188
levobupivacaine	PROPN	O	Chemical	2188
,	PUNCT	O	O	2188
and	CCONJ	O	O	2188
ropivacaine	NOUN	O	Chemical	2188
in	ADP	O	O	2188
anesthetized	VERB	O	O	2188
rats	NOUN	O	O	2188
.	PUNCT	O	O	2188
Bupivacaine	NOUN	O	Chemical	2189
,	PUNCT	O	O	2189
levobupivacaine	PROPN	O	Chemical	2189
,	PUNCT	O	O	2189
or	CCONJ	O	O	2189
ropivacaine	NOUN	O	Chemical	2189
was	AUX	O	O	2189
infused	VERB	O	O	2189
at	ADP	O	O	2189
a	PRON	O	O	2189
rate	NOUN	O	O	2189
of	ADP	O	O	2189
2	X	O	O	2189
mg	VERB	O	O	2189
.	PUNCT	O	O	2189
When	SCONJ	O	O	2190
asystole	NOUN	O	Disease	2190
was	AUX	O	O	2190
recorded	VERB	O	O	2190
,	PUNCT	O	O	2190
drug	NOUN	O	O	2190
infusion	NOUN	O	O	2190
was	AUX	O	O	2190
stopped	VERB	O	O	2190
and	CCONJ	O	O	2190
a	PRON	O	O	2190
resuscitation	NOUN	O	O	2190
sequence	NOUN	O	O	2190
was	AUX	O	O	2190
begun	VERB	O	O	2190
.	PUNCT	O	O	2190
Epinephrine	NOUN	O	Chemical	2191
0.01	NUM	O	O	2191
mg	VERB	O	O	2191
/	PUNCT	O	O	2191
kg	VERB	O	O	2191
was	AUX	O	O	2191
administered	VERB	O	O	2191
at	ADP	O	O	2191
1-min	NOUN	O	O	2191
intervals	NOUN	O	O	2191
while	SCONJ	O	O	2191
external	ADJ	O	O	2191
cardiac	ADJ	O	O	2191
compressions	NOUN	O	O	2191
were	AUX	O	O	2191
applied	VERB	O	O	2191
.	PUNCT	O	O	2191
The	PRON	O	O	2192
cumulative	ADJ	O	O	2192
doses	NOUN	O	O	2192
of	ADP	O	O	2192
levobupivacaine	PROPN	O	Chemical	2192
and	CCONJ	O	O	2192
ropivacaine	NOUN	O	Chemical	2192
that	SCONJ	O	O	2192
produced	VERB	O	O	2192
seizures	NOUN	O	Disease	2192
were	AUX	O	O	2192
similar	ADJ	O	O	2192
and	CCONJ	O	O	2192
were	AUX	O	O	2192
larger	ADJ	O	O	2192
than	ADP	O	O	2192
those	PRON	O	O	2192
of	ADP	O	O	2192
bupivacaine	NOUN	O	Chemical	2192
.	PUNCT	O	O	2192
The	PRON	O	O	2193
cumulative	ADJ	O	O	2193
doses	NOUN	O	O	2193
of	ADP	O	O	2193
levobupivacaine	PROPN	O	Chemical	2193
that	SCONJ	O	O	2193
produced	VERB	O	O	2193
dysrhythmias	VERB	O	Disease	2193
and	CCONJ	O	O	2193
asystole	NOUN	O	Disease	2193
were	AUX	O	O	2193
smaller	ADJ	O	O	2193
than	ADP	O	O	2193
the	PRON	O	O	2193
corresponding	VERB	O	O	2193
doses	NOUN	O	O	2193
of	ADP	O	O	2193
ropivacaine	NOUN	O	Chemical	2193
,	PUNCT	O	O	2193
but	CCONJ	O	O	2193
they	PRON	O	O	2193
were	AUX	O	O	2193
larger	ADJ	O	O	2193
than	ADP	O	O	2193
those	PRON	O	O	2193
of	ADP	O	O	2193
bupivacaine	NOUN	O	Chemical	2193
.	PUNCT	O	O	2193
However	ADV	O	O	2194
,	PUNCT	O	O	2194
a	PRON	O	O	2194
smaller	ADJ	O	O	2194
dose	NOUN	O	O	2194
of	ADP	O	O	2194
epinephrine	NOUN	O	Chemical	2194
was	AUX	O	O	2194
required	VERB	O	O	2194
in	ADP	O	O	2194
the	PRON	O	O	2194
Ropivacaine	NOUN	O	Chemical	2194
group	NOUN	O	O	2194
than	ADP	O	O	2194
in	ADP	O	O	2194
the	PRON	O	O	2194
other	ADJ	O	O	2194
groups	NOUN	O	O	2194
.	PUNCT	O	O	2194
We	PRON	O	O	2195
conclude	VERB	O	O	2195
that	SCONJ	O	O	2195
the	PRON	O	O	2195
systemic	ADJ	O	O	2195
toxicity	NOUN	O	Disease	2195
of	ADP	O	O	2195
levobupivacaine	PROPN	O	Chemical	2195
is	AUX	O	O	2195
intermediate	PROPN	O	O	2195
between	ADP	O	O	2195
that	SCONJ	O	O	2195
of	ADP	O	O	2195
ropivacaine	NOUN	O	Chemical	2195
and	CCONJ	O	O	2195
bupivacaine	NOUN	O	Chemical	2195
when	SCONJ	O	O	2195
administered	VERB	O	O	2195
at	ADP	O	O	2195
the	PRON	O	O	2195
same	ADJ	O	O	2195
rate	NOUN	O	O	2195
and	CCONJ	O	O	2195
that	SCONJ	O	O	2195
ropivacaine	NOUN	O	Chemical	2195
-	PUNCT	O	O	2195
induced	VERB	O	O	2195
cardiac arrest	NOUN	O	Disease	2195
appears	VERB	O	O	2195
to	PART	O	O	2195
be	AUX	O	O	2195
more	ADJ	O	O	2195
susceptible	ADJ	O	O	2195
to	PART	O	O	2195
treatment	NOUN	O	O	2195
than	ADP	O	O	2195
that	SCONJ	O	O	2195
induced	VERB	O	O	2195
by	ADP	O	O	2195
bupivacaine	NOUN	O	Chemical	2195
or	CCONJ	O	O	2195
levobupivacaine	PROPN	O	Chemical	2195
.	PUNCT	O	O	2195
22-oxacalcitriol	NOUN	O	Chemical	2198
suppresses	VERB	O	O	2198
secondary hyperparathyroidism	NOUN	O	Disease	2198
without	ADP	O	O	2198
inducing	VERB	O	O	2198
low bone turnover	NOUN	O	Disease	2198
in	ADP	O	O	2198
dogs	NOUN	O	O	2198
with	ADP	O	O	2198
renal failure	NOUN	O	Disease	2198
.	PUNCT	O	O	2198
Calcitriol	PROPN	O	Chemical	2199
therapy	NOUN	O	O	2199
suppresses	VERB	O	O	2199
serum	NOUN	O	O	2199
levels	NOUN	O	O	2199
of	ADP	O	O	2199
parathyroid	ADJ	O	O	2199
hormone	NOUN	O	O	2199
(	PUNCT	O	O	2199
PTH	PROPN	O	O	2199
)	PUNCT	O	O	2199
in	ADP	O	O	2199
patients	NOUN	O	O	2199
with	ADP	O	O	2199
renal failure	NOUN	O	Disease	2199
but	CCONJ	O	O	2199
has	VERB	O	O	2199
several	ADJ	O	O	2199
drawbacks	VERB	O	O	2199
,	PUNCT	O	O	2199
including	VERB	O	O	2199
hypercalcemia	NOUN	O	Disease	2199
and/or	CCONJ	O	O	2199
marked	VERB	O	O	2199
suppression of bone turnover	NOUN	O	Disease	2199
,	PUNCT	O	O	2199
which	PRON	O	O	2199
may	AUX	O	O	2199
lead	VERB	O	Chemical	2199
to	PART	O	O	2199
adynamic bone disease	NOUN	O	Disease	2199
.	PUNCT	O	O	2199
A	PRON	O	O	2200
new	ADJ	O	O	2200
vitamin D	NOUN	O	Chemical	2200
analogue	NOUN	O	O	2200
,	PUNCT	O	O	2200
22-oxacalcitriol	NOUN	O	Chemical	2200
(	PUNCT	O	O	2200
OCT	PROPN	O	Chemical	2200
)	PUNCT	O	O	2200
,	PUNCT	O	O	2200
has	VERB	O	O	2200
been	AUX	O	O	2200
shown	VERB	O	O	2200
to	PART	O	O	2200
have	VERB	O	O	2200
promising	VERB	O	O	2200
characteristics	NOUN	O	O	2200
.	PUNCT	O	O	2200
This	PRON	O	O	2201
study	VERB	O	O	2201
was	AUX	O	O	2201
undertaken	VERB	O	O	2201
to	PART	O	O	2201
determine	VERB	O	O	2201
the	PRON	O	O	2201
effects	NOUN	O	O	2201
of	ADP	O	O	2201
OCT	PROPN	O	Chemical	2201
on	ADP	O	O	2201
serum	NOUN	O	O	2201
PTH	PROPN	O	O	2201
levels	NOUN	O	O	2201
and	CCONJ	O	O	2201
bone	NOUN	O	O	2201
turnover	NOUN	O	O	2201
in	ADP	O	O	2201
states	VERB	O	O	2201
of	ADP	O	O	2201
normal	ADJ	O	O	2201
or	CCONJ	O	O	2201
impaired renal function	NOUN	O	Disease	2201
.	PUNCT	O	O	2201
The	PRON	O	O	2202
animals	NOUN	O	O	2202
received	VERB	O	O	2202
supplemental	PROPN	O	O	2202
phosphate	NOUN	O	Chemical	2202
to	PART	O	O	2202
enhance	VERB	O	O	2202
PTH	PROPN	O	O	2202
secretion	NOUN	O	O	2202
.	PUNCT	O	O	2202
Fourteen	NUM	O	O	2203
weeks	NOUN	O	O	2203
after	ADP	O	O	2203
the	PRON	O	O	2203
start	VERB	O	O	2203
of	ADP	O	O	2203
phosphate	NOUN	O	Chemical	2203
supplementation	NOUN	O	O	2203
,	PUNCT	O	O	2203
half	NOUN	O	O	2203
of	ADP	O	O	2203
the	PRON	O	O	2203
Nx	NOUN	O	O	2203
and	CCONJ	O	O	2203
Sham	NOUN	O	O	2203
dogs	NOUN	O	O	2203
received	VERB	O	O	2203
doses	NOUN	O	O	2203
of	ADP	O	O	2203
OCT	PROPN	O	Chemical	2203
(	PUNCT	O	O	2203
three	NUM	O	O	2203
times	NOUN	O	O	2203
per	ADP	O	O	2203
week	NOUN	O	O	2203
)	PUNCT	O	O	2203
;	PUNCT	O	O	2203
the	PRON	O	O	2203
other	ADJ	O	O	2203
half	NOUN	O	O	2203
were	AUX	O	O	2203
given	VERB	O	O	2203
vehicle	NOUN	O	O	2203
for	ADP	O	O	2203
60	NUM	O	O	2203
weeks	NOUN	O	O	2203
.	PUNCT	O	O	2203
Biochemical	ADJ	O	O	2204
and	CCONJ	O	O	2204
hormonal	ADJ	O	O	2204
indices	NOUN	O	O	2204
of	ADP	O	O	2204
calcium	NOUN	O	Chemical	2204
and	CCONJ	O	O	2204
bone	NOUN	O	O	2204
metabolism	NOUN	O	O	2204
were	AUX	O	O	2204
measured	VERB	O	O	2204
throughout	ADP	O	O	2204
the	PRON	O	O	2204
study	VERB	O	O	2204
,	PUNCT	O	O	2204
and	CCONJ	O	O	2204
bone	NOUN	O	O	2204
biopsies	NOUN	O	O	2204
were	AUX	O	O	2204
done	VERB	O	O	2204
at	ADP	O	O	2204
baseline	VERB	O	O	2204
,	PUNCT	O	O	2204
60	NUM	O	O	2204
weeks	NOUN	O	O	2204
after	ADP	O	O	2204
OCT	PROPN	O	Chemical	2204
or	CCONJ	O	O	2204
vehicle	NOUN	O	O	2204
treatment	NOUN	O	O	2204
,	PUNCT	O	O	2204
and	CCONJ	O	O	2204
at	ADP	O	O	2204
the	PRON	O	O	2204
end	VERB	O	O	2204
of	ADP	O	O	2204
the	PRON	O	O	2204
crossover	NOUN	O	O	2204
period	NOUN	O	O	2204
.	PUNCT	O	O	2204
In	ADP	O	O	2205
Nx	NOUN	O	O	2205
dogs	NOUN	O	O	2205
,	PUNCT	O	O	2205
OCT	PROPN	O	Chemical	2205
significantly	ADV	O	O	2205
decreased	VERB	O	O	2205
serum	NOUN	O	O	2205
PTH	PROPN	O	O	2205
levels	NOUN	O	O	2205
soon	ADV	O	O	2205
after	ADP	O	O	2205
the	PRON	O	O	2205
induction	NOUN	O	O	2205
of	ADP	O	O	2205
renal insufficiency	NOUN	O	Disease	2205
.	PUNCT	O	O	2205
In	ADP	O	O	2206
long	ADV	O	O	2206
-	PUNCT	O	O	2206
standing	VERB	O	O	2206
secondary hyperparathyroidism	NOUN	O	Disease	2206
,	PUNCT	O	O	2206
OCT	PROPN	O	Chemical	2206
(	PUNCT	O	O	2206
0.03	NUM	O	O	2206
microg	PROPN	O	O	2206
/	PUNCT	O	O	2206
kg	VERB	O	O	2206
)	PUNCT	O	O	2206
stabilized	VERB	O	O	2206
serum	NOUN	O	O	2206
PTH	PROPN	O	O	2206
levels	NOUN	O	O	2206
during	ADP	O	O	2206
the	PRON	O	O	2206
first	ADV	O	O	2206
months	NOUN	O	O	2206
.	PUNCT	O	O	2206
These	PRON	O	O	2207
effects	NOUN	O	O	2207
were	AUX	O	O	2207
accompanied	VERB	O	O	2207
by	ADP	O	O	2207
episodes	NOUN	O	O	2207
of	ADP	O	O	2207
hypercalcemia	NOUN	O	Disease	2207
and	CCONJ	O	O	2207
hyperphosphatemia	NOUN	O	Disease	2207
.	PUNCT	O	O	2207
In	ADP	O	O	2208
animals	NOUN	O	O	2208
with	ADP	O	O	2208
normal	ADJ	O	O	2208
renal	ADJ	O	O	2208
function	NOUN	O	O	2208
,	PUNCT	O	O	2208
OCT	PROPN	O	Chemical	2208
induced	VERB	O	O	2208
a	PRON	O	O	2208
transient	ADJ	O	O	2208
decrease	VERB	O	O	2208
in	ADP	O	O	2208
serum	NOUN	O	O	2208
PTH	PROPN	O	O	2208
levels	NOUN	O	O	2208
at	ADP	O	O	2208
a	PRON	O	O	2208
dose	NOUN	O	O	2208
of	ADP	O	O	2208
0.1	NUM	O	O	2208
microg	PROPN	O	O	2208
/	PUNCT	O	O	2208
kg	VERB	O	O	2208
,	PUNCT	O	O	2208
which	PRON	O	O	2208
was	AUX	O	O	2208
not	PART	O	O	2208
sustained	VERB	O	O	2208
with	ADP	O	O	2208
lowering	VERB	O	O	2208
of	ADP	O	O	2208
the	PRON	O	O	2208
doses	NOUN	O	O	2208
.	PUNCT	O	O	2208
In	ADP	O	O	2209
Nx	NOUN	O	O	2209
dogs	NOUN	O	O	2209
,	PUNCT	O	O	2209
OCT	PROPN	O	Chemical	2209
reversed	VERB	O	O	2209
abnormal	ADJ	O	O	2209
bone	NOUN	O	O	2209
formation	NOUN	O	O	2209
,	PUNCT	O	O	2209
such	ADJ	O	O	2209
as	ADP	O	O	2209
woven osteoid	NOUN	O	Disease	2209
and	CCONJ	O	O	2209
fibrosis	NOUN	O	Disease	2209
,	PUNCT	O	O	2209
but	CCONJ	O	O	2209
did	VERB	O	O	2209
not	PART	O	O	2209
significantly	ADV	O	O	2209
alter	VERB	O	O	2209
the	PRON	O	O	2209
level	VERB	O	O	2209
of	ADP	O	O	2209
bone	NOUN	O	O	2209
turnover	NOUN	O	O	2209
.	PUNCT	O	O	2209
In	ADP	O	O	2210
addition	NOUN	O	O	2210
,	PUNCT	O	O	2210
OCT	PROPN	O	Chemical	2210
improved	VERB	O	O	2210
mineralization	NOUN	O	O	2210
lag	VERB	O	O	2210
time	NOUN	O	O	2210
,	PUNCT	O	O	2210
(	PUNCT	O	O	2210
that	SCONJ	O	O	2210
is	AUX	O	O	2210
,	PUNCT	O	O	2210
the	PRON	O	O	2210
rate	NOUN	O	O	2210
at	ADP	O	O	2210
which	PRON	O	O	2210
osteoid	PROPN	O	O	2210
mineralizes	NOUN	O	O	2210
)	PUNCT	O	O	2210
in	ADP	O	O	2210
both	PRON	O	O	2210
Nx	NOUN	O	O	2210
and	CCONJ	O	O	2210
Sham	NOUN	O	O	2210
dogs	NOUN	O	O	2210
.	PUNCT	O	O	2210
These	PRON	O	O	2211
results	VERB	O	O	2211
indicate	VERB	O	O	2211
that	SCONJ	O	O	2211
even	ADV	O	O	2211
though	SCONJ	O	O	2211
OCT	PROPN	O	Chemical	2211
does	VERB	O	O	2211
not	PART	O	O	2211
completely	ADV	O	O	2211
prevent	VERB	O	O	2211
the	PRON	O	O	2211
occurrence	NOUN	O	O	2211
of	ADP	O	O	2211
hypercalcemia	NOUN	O	Disease	2211
in	ADP	O	O	2211
experimental	ADJ	O	O	2211
dogs	NOUN	O	O	2211
with	ADP	O	O	2211
renal insufficiency	NOUN	O	Disease	2211
,	PUNCT	O	O	2211
it	PRON	O	O	2211
may	AUX	O	O	2211
be	AUX	O	O	2211
of	ADP	O	O	2211
use	VERB	O	O	2211
in	ADP	O	O	2211
the	PRON	O	O	2211
management	NOUN	O	O	2211
of	ADP	O	O	2211
secondary hyperparathyroidism	NOUN	O	Disease	2211
because	SCONJ	O	O	2211
it	PRON	O	O	2211
does	VERB	O	O	2211
not	PART	O	O	2211
induce	VERB	O	O	2211
low bone turnover	NOUN	O	Disease	2211
and	CCONJ	O	O	2211
,	PUNCT	O	O	2211
therefore	ADV	O	O	2211
,	PUNCT	O	O	2211
does	VERB	O	O	2211
not	PART	O	O	2211
increase	VERB	O	O	2211
the	PRON	O	O	2211
risk	NOUN	O	O	2211
of	ADP	O	O	2211
adynamic bone disease	NOUN	O	Disease	2211
.	PUNCT	O	O	2211
Chemotherapy	NOUN	O	O	2214
of	ADP	O	O	2214
advanced	ADJ	O	O	2214
inoperable	ADJ	O	O	2214
non	ADJ	O	O	2214
-	PUNCT	O	O	2214
small	ADJ	O	O	2214
cell	NOUN	O	O	2214
lung cancer	NOUN	O	Disease	2214
with	ADP	O	O	2214
paclitaxel	NOUN	O	Chemical	2214
:	PUNCT	O	O	2214
a	PRON	O	O	2214
phase	NOUN	O	O	2214
II	NUM	O	O	2214
trial	NOUN	O	O	2214
.	PUNCT	O	O	2214
Paclitaxel	PROPN	O	Chemical	2215
(	PUNCT	O	O	2215
Taxol	PROPN	O	Chemical	2215
;	PUNCT	O	O	2215
Bristol	PROPN	O	O	2215
-	PUNCT	O	O	2215
Myers	PROPN	O	O	2215
Squibb	PROPN	O	O	2215
Company	NOUN	O	O	2215
,	PUNCT	O	O	2215
Princeton	PROPN	O	O	2215
,	PUNCT	O	O	2215
NJ	PROPN	O	O	2215
)	PUNCT	O	O	2215
has	VERB	O	O	2215
demonstrated	VERB	O	O	2215
significant	ADJ	O	O	2215
antineoplastic	ADJ	O	O	2215
activity	NOUN	O	O	2215
against	ADP	O	O	2215
different	ADJ	O	O	2215
tumor	NOUN	O	Disease	2215
types	NOUN	O	O	2215
,	PUNCT	O	O	2215
notably	ADV	O	O	2215
ovarian and breast carcinoma	NOUN	O	Disease	2215
.	PUNCT	O	O	2215
Two	NUM	O	O	2216
phase	NOUN	O	O	2216
II	NUM	O	O	2216
trials	NOUN	O	O	2216
of	ADP	O	O	2216
24-hour	NOUN	O	O	2216
paclitaxel	NOUN	O	Chemical	2216
infusions	NOUN	O	O	2216
in	ADP	O	O	2216
chemotherapy	NOUN	O	O	2216
-	PUNCT	O	O	2216
naive	ADJ	O	O	2216
patients	NOUN	O	O	2216
with	ADP	O	O	2216
stage	NOUN	O	O	2216
IIIB	PROPN	O	O	2217
or	CCONJ	O	O	2217
IV	NUM	O	O	2217
non	ADJ	O	O	2217
-	PUNCT	O	O	2217
small	ADJ	O	O	2217
cell	NOUN	O	O	2217
lung cancer	NOUN	O	Disease	2217
(	PUNCT	O	O	2217
NSCLC	PROPN	O	Disease	2217
)	PUNCT	O	O	2217
reported	VERB	O	O	2217
response	NOUN	O	O	2217
rates	NOUN	O	O	2217
of	ADP	O	O	2217
21%	NOUN	O	O	2217
and	CCONJ	O	O	2217
24%	NOUN	O	O	2217
.	PUNCT	O	O	2217
Leukopenia	PROPN	O	Disease	2218
was	AUX	O	O	2218
dose	NOUN	O	O	2218
limiting	VERB	O	O	2218
:	PUNCT	O	O	2218
as	ADP	O	O	2218
many	ADJ	O	O	2218
as	ADP	O	O	2218
62.5%	NOUN	O	O	2218
of	ADP	O	O	2218
patients	NOUN	O	O	2218
experienced	ADJ	O	O	2218
grade	NOUN	O	O	2218
4	NUM	O	O	2218
leukopenia	PROPN	O	Disease	2218
.	PUNCT	O	O	2218
We	PRON	O	O	2219
investigated	VERB	O	O	2219
the	PRON	O	O	2219
efficacy	NOUN	O	O	2219
and	CCONJ	O	O	2219
toxicity	NOUN	O	Disease	2219
of	ADP	O	O	2219
a	PRON	O	O	2219
3-hour	NOUN	O	O	2219
paclitaxel	NOUN	O	Chemical	2219
infusion	NOUN	O	O	2219
in	ADP	O	O	2219
a	PRON	O	O	2219
phase	NOUN	O	O	2219
II	NUM	O	O	2219
trial	NOUN	O	O	2219
in	ADP	O	O	2219
patients	NOUN	O	O	2219
with	ADP	O	O	2219
inoperable	ADJ	O	O	2219
stage	NOUN	O	O	2219
IIIB	PROPN	O	O	2219
or	CCONJ	O	O	2219
IV	NUM	O	O	2219
NSCLC	PROPN	O	Disease	2219
.	PUNCT	O	O	2219
Most	ADV	O	O	2220
patients	NOUN	O	O	2220
(	PUNCT	O	O	2220
72.4%	NOUN	O	O	2220
)	PUNCT	O	O	2220
had	VERB	O	O	2220
stage	NOUN	O	O	2220
IV	NUM	O	O	2220
NSCLC	PROPN	O	Disease	2220
.	PUNCT	O	O	2220
Paclitaxel	PROPN	O	Chemical	2221
Hematologic	PROPN	O	O	2222
toxicities	NOUN	O	Disease	2222
were	AUX	O	O	2222
mild	ADJ	O	O	2222
:	PUNCT	O	O	2222
only	ADV	O	O	2222
one	NUM	O	O	2222
patient	NOUN	O	O	2222
(	PUNCT	O	O	2222
2%	NOUN	O	O	2222
)	PUNCT	O	O	2222
developed	VERB	O	O	2222
grade	NOUN	O	O	2222
3	X	O	O	2222
or	CCONJ	O	O	2222
4	NUM	O	O	2222
neutropenia	ADJ	O	Disease	2222
,	PUNCT	O	O	2222
while	SCONJ	O	O	2222
29%	NOUN	O	O	2222
had	VERB	O	O	2222
grade	NOUN	O	O	2222
1	X	O	O	2222
or	CCONJ	O	O	2222
2	X	O	O	2222
.	PUNCT	O	O	2222
Grade	NOUN	O	O	2223
1	X	O	O	2223
or	CCONJ	O	O	2223
2	X	O	O	2223
polyneuropathy	ADJ	O	Disease	2223
affected	VERB	O	O	2223
56%	NOUN	O	O	2223
of	ADP	O	O	2223
patients	NOUN	O	O	2223
while	SCONJ	O	O	2223
only	ADV	O	O	2223
one	NUM	O	O	2223
(	PUNCT	O	O	2223
2%	NOUN	O	O	2223
)	PUNCT	O	O	2223
experienced	ADJ	O	O	2223
severe	ADJ	O	O	2223
polyneuropathy	ADJ	O	Disease	2223
.	PUNCT	O	O	2223
Similarly	ADV	O	O	2224
,	PUNCT	O	O	2224
grade	NOUN	O	O	2224
1	X	O	O	2224
or	CCONJ	O	O	2224
2	X	O	O	2224
myalgia	NOUN	O	Disease	2224
/	PUNCT	O	O	2224
arthralgia	ADV	O	Disease	2224
was	AUX	O	O	2224
observed	VERB	O	O	2224
in	ADP	O	O	2224
63.2%	NOUN	O	O	2224
of	ADP	O	O	2224
patients	NOUN	O	O	2224
,	PUNCT	O	O	2224
but	CCONJ	O	O	2224
only	ADV	O	O	2224
14.3%	NOUN	O	O	2224
experienced	ADJ	O	O	2224
grade	NOUN	O	O	2224
3	X	O	O	2224
or	CCONJ	O	O	2224
4	NUM	O	O	2224
.	PUNCT	O	O	2224
Nausea	NOUN	O	Disease	2225
and	CCONJ	O	O	2225
vomiting	VERB	O	Disease	2225
were	AUX	O	O	2225
infrequent	ADJ	O	O	2225
,	PUNCT	O	O	2225
with	ADP	O	O	2225
14%	NOUN	O	O	2225
of	ADP	O	O	2225
patients	NOUN	O	O	2225
experiencing	VERB	O	O	2225
grade	NOUN	O	O	2225
1	X	O	O	2225
or	CCONJ	O	O	2225
2	X	O	O	2225
and	CCONJ	O	O	2225
only	ADV	O	O	2225
2%	NOUN	O	O	2225
experiencing	VERB	O	O	2225
grade	NOUN	O	O	2225
3	X	O	O	2225
or	CCONJ	O	O	2225
4	NUM	O	O	2225
.	PUNCT	O	O	2225
Paclitaxel	PROPN	O	Chemical	2226
is	AUX	O	O	2226
thus	ADV	O	O	2226
an	PRON	O	O	2226
active	ADJ	O	O	2226
single	ADJ	O	O	2226
agent	NOUN	O	O	2226
in	ADP	O	O	2226
this	PRON	O	O	2226
patient	NOUN	O	O	2226
population	NOUN	O	O	2226
,	PUNCT	O	O	2226
with	ADP	O	O	2226
a	PRON	O	O	2226
3-hour	NOUN	O	O	2226
infusion	NOUN	O	O	2226
proving	VERB	O	O	2226
comparably	ADV	O	O	2226
effective	ADJ	O	O	2226
to	PART	O	O	2226
a	PRON	O	O	2226
24-hour	NOUN	O	O	2226
infusion	NOUN	O	O	2226
and	CCONJ	O	O	2226
superior	PROPN	O	O	2226
in	ADP	O	O	2226
terms	NOUN	O	O	2226
of	ADP	O	O	2226
the	PRON	O	O	2226
incidence	NOUN	O	O	2226
of	ADP	O	O	2226
hematologic	ADJ	O	O	2226
and	CCONJ	O	O	2226
nonhematologic toxicity	NOUN	O	O	2226
.	PUNCT	O	O	2226
Further	ADV	O	O	2227
phase	NOUN	O	O	2227
II	NUM	O	O	2227
studies	NOUN	O	O	2227
with	ADP	O	O	2227
paclitaxel	NOUN	O	Chemical	2227
combined	VERB	O	O	2227
with	ADP	O	O	2227
other	ADJ	O	O	2227
drugs	NOUN	O	O	2227
active	ADJ	O	O	2227
against	ADP	O	O	2227
NSCLC	PROPN	O	Disease	2227
are	AUX	O	O	2227
indicated	VERB	O	O	2227
,	PUNCT	O	O	2227
and	CCONJ	O	O	2227
phase	NOUN	O	O	2227
III	NUM	O	O	2227
studies	NOUN	O	O	2227
comparing	VERB	O	O	2227
paclitaxel	NOUN	O	Chemical	2227
with	ADP	O	O	2227
standard	PROPN	O	O	2227
chemotherapy	NOUN	O	O	2227
remain	VERB	O	O	2227
to	PART	O	O	2227
be	AUX	O	O	2227
completed	VERB	O	O	2227
.	PUNCT	O	O	2227
Cerebral hemorrhage	NOUN	O	Disease	2230
associated	VERB	O	O	2230
with	ADP	O	O	2230
phenylpropanolamine	PROPN	O	Chemical	2230
in	ADP	O	O	2230
combination	NOUN	O	O	2230
with	ADP	O	O	2230
caffeine	NOUN	O	Chemical	2230
.	PUNCT	O	O	2230
Phenylpropanolamine	NOUN	O	Chemical	2231
(	PUNCT	O	O	2231
PPA	PROPN	O	Chemical	2231
)	PUNCT	O	O	2231
is	AUX	O	O	2231
a	PRON	O	O	2231
drug	NOUN	O	O	2231
that	SCONJ	O	O	2231
has	VERB	O	O	2231
been	AUX	O	O	2231
associated	VERB	O	O	2231
with	ADP	O	O	2231
serious	ADJ	O	O	2231
side	NOUN	O	O	2231
effects	NOUN	O	O	2231
including	VERB	O	O	2231
stroke	VERB	O	Disease	2231
.	PUNCT	O	O	2231
It	PRON	O	O	2232
is	AUX	O	O	2232
often	ADV	O	O	2232
combined	VERB	O	O	2232
with	ADP	O	O	2232
caffeine	NOUN	O	Chemical	2232
in	ADP	O	O	2232
diet	PROPN	O	O	2232
preparations	NOUN	O	O	2232
and	CCONJ	O	O	2232
""""	PUNCT	O	O	2232
look	VERB	O	O	2232
-	PUNCT	O	O	2232
alike	ADV	O	O	2232
""""	PUNCT	O	O	2232
pills	NOUN	O	O	2232
.	PUNCT	O	O	2232
In	ADP	O	O	2233
order	NOUN	O	O	2233
to	PART	O	O	2233
determine	VERB	O	O	2233
if	SCONJ	O	O	2233
PPA	PROPN	O	Chemical	2233
/	PUNCT	O	O	2233
caffeine	NOUN	O	Chemical	2233
can	AUX	O	O	2233
lead	VERB	O	Chemical	2233
to	PART	O	O	2233
stroke	VERB	O	Disease	2233
in	ADP	O	O	2233
normotensive	PROPN	O	O	2233
and/or	CCONJ	O	O	2233
hypertensive	ADJ	O	Disease	2233
rats	NOUN	O	O	2233
,	PUNCT	O	O	2233
we	PRON	O	O	2233
administered	VERB	O	O	2233
the	PRON	O	O	2233
combination	NOUN	O	O	2233
in	ADP	O	O	2233
six	NUM	O	O	2233
times	NOUN	O	O	2233
the	PRON	O	O	2233
allowed	VERB	O	O	2233
human	PROPN	O	O	2233
dose	NOUN	O	O	2233
calculated	VERB	O	O	2233
on	ADP	O	O	2233
a	PRON	O	O	2233
per	ADP	O	O	2233
weight	NOUN	O	O	2233
basis	NOUN	O	O	2233
for	ADP	O	O	2233
the	PRON	O	O	2233
rats	NOUN	O	O	2233
two	NUM	O	O	2233
times	NOUN	O	O	2233
per	ADP	O	O	2233
day	NOUN	O	O	2233
for	ADP	O	O	2233
five	NUM	O	O	2233
days	NOUN	O	O	2233
.	PUNCT	O	O	2233
Subarachnoid and cerebral hemorrhage	NOUN	O	Disease	2234
was	AUX	O	O	2234
noted	VERB	O	O	2234
in	ADP	O	O	2234
18%	NOUN	O	O	2234
of	ADP	O	O	2234
the	PRON	O	O	2234
hypertensive	ADJ	O	Disease	2234
rats	NOUN	O	O	2234
.	PUNCT	O	O	2234
A	PRON	O	O	2235
single	ADJ	O	O	2235
PPA	PROPN	O	Chemical	2235
/	PUNCT	O	O	2235
caffeine	NOUN	O	Chemical	2235
administration	NOUN	O	O	2235
(	PUNCT	O	O	2235
same	ADJ	O	O	2235
dose	NOUN	O	O	2235
)	PUNCT	O	O	2235
lead	VERB	O	Chemical	2235
to	PART	O	O	2235
acute	ADJ	O	O	2235
hypertension	NOUN	O	Disease	2235
in	ADP	O	O	2235
both	PRON	O	O	2235
the	PRON	O	O	2235
normotensive	PROPN	O	O	2235
and	CCONJ	O	O	2235
hypertensive	ADJ	O	Disease	2235
animals	NOUN	O	O	2235
.	PUNCT	O	O	2235
These	PRON	O	O	2236
results	VERB	O	O	2236
suggest	VERB	O	O	2236
that	SCONJ	O	O	2236
PPA	PROPN	O	Chemical	2236
/	PUNCT	O	O	2236
caffeine	NOUN	O	Chemical	2236
can	AUX	O	O	2236
lead	VERB	O	Chemical	2236
to	PART	O	O	2236
cerebral hemorrhage	NOUN	O	Disease	2236
in	ADP	O	O	2236
previously	ADV	O	O	2236
hypertensive	ADJ	O	Disease	2236
animals	NOUN	O	O	2236
when	SCONJ	O	O	2236
administered	VERB	O	O	2236
in	ADP	O	O	2236
greater	ADJ	O	O	2236
than	ADP	O	O	2236
the	PRON	O	O	2236
allowed	VERB	O	O	2236
dosage	NOUN	O	O	2236
.	PUNCT	O	O	2236
Long	ADV	O	O	2239
-	PUNCT	O	O	2239
term	NOUN	O	O	2239
efficacy	NOUN	O	O	2239
and	CCONJ	O	O	2239
toxicity	NOUN	O	Disease	2239
of	ADP	O	O	2239
high	ADJ	O	O	2239
-	PUNCT	O	O	2239
dose	NOUN	O	O	2239
amiodarone	NOUN	O	Chemical	2239
therapy	NOUN	O	O	2239
for	ADP	O	O	2239
ventricular tachycardia	NOUN	O	Disease	2239
or	CCONJ	O	O	2239
ventricular fibrillation	NOUN	O	Disease	2239
.	PUNCT	O	O	2239
Amiodarone	NOUN	O	Chemical	2240
was	AUX	O	O	2240
administered	VERB	O	O	2240
to	PART	O	O	2240
154	NUM	O	O	2240
patients	NOUN	O	O	2240
who	PRON	O	O	2240
had	VERB	O	O	2240
sustained	VERB	O	O	2240
,	PUNCT	O	O	2240
symptomatic	ADJ	O	O	2240
ventricular tachycardia	NOUN	O	Disease	2240
(	PUNCT	O	O	2240
VT	PROPN	O	Disease	2240
)	PUNCT	O	O	2240
(	PUNCT	O	O	2240
n	CCONJ	O	O	2240
=	PUNCT	O	O	2240
118	NUM	O	O	2240
)	PUNCT	O	O	2240
or	CCONJ	O	O	2240
a	PRON	O	O	2240
cardiac arrest	NOUN	O	Disease	2240
(	PUNCT	O	O	2240
n	CCONJ	O	O	2240
=	PUNCT	O	O	2240
36	NUM	O	O	2240
)	PUNCT	O	O	2240
and	CCONJ	O	O	2240
who	PRON	O	O	2240
were	AUX	O	O	2240
refractory	ADJ	O	O	2240
to	PART	O	O	2240
conventional	ADJ	O	O	2240
antiarrhythmic	PROPN	O	O	2240
drugs	NOUN	O	O	2240
.	PUNCT	O	O	2240
Sixty	NUM	O	O	2241
-	PUNCT	O	O	2241
nine	NUM	O	O	2241
percent	NOUN	O	O	2241
of	ADP	O	O	2241
patients	NOUN	O	O	2241
continued	VERB	O	O	2241
treatment	NOUN	O	O	2241
with	ADP	O	O	2241
amiodarone	NOUN	O	Chemical	2241
and	CCONJ	O	O	2241
had	VERB	O	O	2241
no	PRON	O	O	2241
recurrence	NOUN	O	O	2241
of	ADP	O	O	2241
symptomatic	ADJ	O	O	2241
VT	PROPN	O	Disease	2241
or	CCONJ	O	O	2241
ventricular fibrillation	NOUN	O	Disease	2241
(	PUNCT	O	O	2241
VF	PROPN	O	Disease	2241
)	PUNCT	O	O	2241
over	ADP	O	O	2241
a	PRON	O	O	2241
follow	VERB	O	O	2241
-	PUNCT	O	O	2241
up	ADP	O	O	2241
of	ADP	O	O	2241
6	NUM	O	O	2241
to	PART	O	O	2241
52	NUM	O	O	2241
months	NOUN	O	O	2241
(	PUNCT	O	O	2241
mean	VERB	O	O	2241
+	ADP	O	O	2241
/-	PUNCT	O	O	2241
Six	NUM	O	O	2242
percent	NOUN	O	O	2242
of	ADP	O	O	2242
the	PRON	O	O	2242
patients	NOUN	O	O	2242
had	VERB	O	O	2242
a	PRON	O	O	2242
nonfatal	ADJ	O	O	2242
recurrence	NOUN	O	O	2242
of	ADP	O	O	2242
VT	PROPN	O	Disease	2242
and	CCONJ	O	O	2242
were	AUX	O	O	2242
successfully	ADV	O	O	2242
managed	VERB	O	O	2242
by	ADP	O	O	2242
continuing	VERB	O	O	2242
amiodarone	NOUN	O	Chemical	2242
at	ADP	O	O	2242
a	PRON	O	O	2242
higher	ADJ	O	O	2242
dose	NOUN	O	O	2242
or	CCONJ	O	O	2242
by	ADP	O	O	2242
the	PRON	O	O	2242
addition	NOUN	O	O	2242
of	ADP	O	O	2242
a	PRON	O	O	2242
conventional	ADJ	O	O	2242
antiarrhythmic	PROPN	O	O	2242
drug	NOUN	O	O	2242
.	PUNCT	O	O	2242
Adverse	ADJ	O	O	2243
effects	NOUN	O	O	2243
forced	VERB	O	O	2243
a	PRON	O	O	2243
reduction	NOUN	O	O	2243
in	ADP	O	O	2243
the	PRON	O	O	2243
dose	NOUN	O	O	2243
of	ADP	O	O	2243
amiodarone	NOUN	O	Chemical	2243
in	ADP	O	O	2243
41%	NOUN	O	O	2243
and	CCONJ	O	O	2243
discontinuation	NOUN	O	O	2243
of	ADP	O	O	2243
amiodarone	NOUN	O	Chemical	2243
in	ADP	O	O	2243
10%	NOUN	O	O	2243
of	ADP	O	O	2243
patients	NOUN	O	O	2243
.	PUNCT	O	O	2243
The	PRON	O	O	2244
most	ADV	O	O	2244
common	ADJ	O	O	2244
symptomatic	ADJ	O	O	2244
adverse	ADJ	O	O	2244
reactions	NOUN	O	O	2244
were	AUX	O	O	2244
tremor	NOUN	O	Disease	2244
or	CCONJ	O	O	2244
ataxia	NOUN	O	Disease	2244
(	PUNCT	O	O	2244
35%	NOUN	O	O	2244
)	PUNCT	O	O	2244
,	PUNCT	O	O	2244
nausea	NOUN	O	Disease	2244
and	CCONJ	O	O	2244
anorexia	X	O	Disease	2244
(	PUNCT	O	O	2244
8%	NOUN	O	O	2244
)	PUNCT	O	O	2244
,	PUNCT	O	O	2244
visual halos or blurring	VERB	O	Disease	2244
(	PUNCT	O	O	2244
6%	NOUN	O	O	2244
)	PUNCT	O	O	2244
,	PUNCT	O	O	2244
thyroid function abnormalities	NOUN	O	Disease	2244
(	PUNCT	O	O	2244
6%	NOUN	O	O	2244
)	PUNCT	O	O	2244
and	CCONJ	O	O	2244
pulmonary interstitial infiltrates	VERB	O	Disease	2244
(	PUNCT	O	O	2244
5%	NOUN	O	O	2244
)	PUNCT	O	O	2244
.	PUNCT	O	O	2244
Although	SCONJ	O	O	2245
large	ADJ	O	O	2245
-	PUNCT	O	O	2245
dose	NOUN	O	O	2245
amiodarone	NOUN	O	Chemical	2245
is	AUX	O	O	2245
highly	ADV	O	O	2245
effective	ADJ	O	O	2245
in	ADP	O	O	2245
the	PRON	O	O	2245
long	ADV	O	O	2245
-	PUNCT	O	O	2245
term	NOUN	O	O	2245
treatment	NOUN	O	O	2245
of	ADP	O	O	2245
VT	PROPN	O	Disease	2245
or	CCONJ	O	O	2245
VF	PROPN	O	Disease	2245
refractory	ADJ	O	O	2245
to	PART	O	O	2245
conventional	ADJ	O	O	2245
antiarrhythmic	PROPN	O	O	2245
drugs	NOUN	O	O	2245
,	PUNCT	O	O	2245
it	PRON	O	O	2245
causes	VERB	O	O	2245
significant	ADJ	O	O	2245
toxicity	NOUN	O	Disease	2245
in	ADP	O	O	2245
approximately	ADV	O	O	2245
50%	NOUN	O	O	2245
of	ADP	O	O	2245
patients	NOUN	O	O	2245
.	PUNCT	O	O	2245
However	ADV	O	O	2246
,	PUNCT	O	O	2246
when	SCONJ	O	O	2246
the	PRON	O	O	2246
dose	NOUN	O	O	2246
is	AUX	O	O	2246
adjusted	VERB	O	O	2246
based	VERB	O	O	2246
on	ADP	O	O	2246
clinical	ADJ	O	O	2246
response	NOUN	O	O	2246
or	CCONJ	O	O	2246
the	PRON	O	O	2246
development	NOUN	O	O	2246
of	ADP	O	O	2246
adverse	ADJ	O	O	2246
effects	NOUN	O	O	2246
,	PUNCT	O	O	2246
75%	NOUN	O	O	2246
of	ADP	O	O	2246
patients	NOUN	O	O	2246
with	ADP	O	O	2246
VT	PROPN	O	Disease	2246
or	CCONJ	O	O	2246
VF	PROPN	O	Disease	2246
can	AUX	O	O	2246
be	AUX	O	O	2246
successfully	ADV	O	O	2246
managed	VERB	O	O	2246
with	ADP	O	O	2246
amiodarone	NOUN	O	Chemical	2246
.	PUNCT	O	O	2246
Effect	VERB	O	O	2249
of	ADP	O	O	2249
calcium chloride	NOUN	O	Chemical	2249
and	CCONJ	O	O	2249
4-aminopyridine	NOUN	O	Chemical	2249
therapy	NOUN	O	O	2249
on	ADP	O	O	2249
desipramine	NOUN	O	Chemical	2249
toxicity	NOUN	O	Disease	2249
in	ADP	O	O	2249
rats	NOUN	O	O	2249
.	PUNCT	O	O	2249
Hypotension	NOUN	O	Disease	2250
is	AUX	O	O	2250
a	PRON	O	O	2250
major	ADJ	O	O	2250
contributor	NOUN	O	O	2250
to	PART	O	O	2250
mortality	NOUN	O	O	2250
in	ADP	O	O	2250
tricyclic	ADJ	O	O	2250
antidepressant	NOUN	O	O	2250
overdose	NOUN	O	Disease	2250
.	PUNCT	O	O	2250
Recent	ADJ	O	O	2251
data	NOUN	O	O	2251
suggest	VERB	O	O	2251
that	SCONJ	O	O	2251
tricyclic	ADJ	O	O	2251
antidepressants	NOUN	O	O	2251
inhibit	VERB	O	O	2251
calcium	NOUN	O	Chemical	2251
influx	VERB	O	O	2251
in	ADP	O	O	2251
some	PRON	O	O	2251
tissues	NOUN	O	O	2251
.	PUNCT	O	O	2251
This	PRON	O	O	2252
study	VERB	O	O	2252
addressed	VERB	O	O	2252
the	PRON	O	O	2252
potential	ADJ	O	O	2252
role	NOUN	O	O	2252
of	ADP	O	O	2252
calcium	NOUN	O	Chemical	2252
channel	PROPN	O	O	2252
blockade	VERB	O	O	2252
in	ADP	O	O	2252
tricyclic	ADJ	O	O	2252
antidepressant	NOUN	O	O	2252
-	PUNCT	O	O	2252
induced	VERB	O	O	2252
hypotension	NOUN	O	Disease	2252
.	PUNCT	O	O	2252
Two	NUM	O	O	2253
interventions	NOUN	O	O	2253
were	AUX	O	O	2253
studied	VERB	O	O	2253
that	SCONJ	O	O	2253
have	VERB	O	O	2253
been	AUX	O	O	2253
shown	VERB	O	O	2253
previously	ADV	O	O	2253
to	PART	O	O	2253
improve	VERB	O	O	2253
blood	NOUN	O	O	2253
pressure	NOUN	O	O	2253
with	ADP	O	O	2253
calcium	NOUN	O	Chemical	2253
channel	PROPN	O	O	2253
blocker	NOUN	O	O	2253
overdose	NOUN	O	Disease	2253
.	PUNCT	O	O	2253
CaCl2	NUM	O	Chemical	2254
and	CCONJ	O	O	2254
4-aminopyridine	NOUN	O	Chemical	2254
.	PUNCT	O	O	2254
Anesthetized	VERB	O	O	2255
rats	NOUN	O	O	2255
received	VERB	O	O	2255
the	PRON	O	O	2255
tricyclic	ADJ	O	O	2255
antidepressant	NOUN	O	O	2255
desipramine	NOUN	O	Chemical	2255
IP	PROPN	O	O	2255
to	PART	O	O	2255
produce	VERB	O	O	2255
hypotension	NOUN	O	Disease	2255
,	PUNCT	O	O	2255
QRS	PROPN	O	O	2255
prolongation	NOUN	O	O	2255
,	PUNCT	O	O	2255
and	CCONJ	O	O	2255
bradycardia	NOUN	O	Disease	2255
.	PUNCT	O	O	2255
min	NOUN	O	O	2256
later	ADV	O	O	2256
,	PUNCT	O	O	2256
animals	NOUN	O	O	2256
received	VERB	O	O	2256
CaCl2	NUM	O	Chemical	2256
,	PUNCT	O	O	2256
NaHCO3	NOUN	O	Chemical	2256
,	PUNCT	O	O	2256
or	CCONJ	O	O	2256
saline	NOUN	O	O	2256
.	PUNCT	O	O	2256
In	ADP	O	O	2257
a	PRON	O	O	2257
second	ADV	O	O	2257
experiment	NOUN	O	O	2257
,	PUNCT	O	O	2257
rats	NOUN	O	O	2257
received	VERB	O	O	2257
tricyclic	ADJ	O	O	2257
antidepressant	NOUN	O	O	2257
desipramine	NOUN	O	Chemical	2257
IP	PROPN	O	O	2257
followed	VERB	O	O	2257
in	ADP	O	O	2257
15	NUM	O	O	2257
min	NOUN	O	O	2257
by	ADP	O	O	2257
4-aminopyridine	NOUN	O	Chemical	2257
or	CCONJ	O	O	2257
saline	NOUN	O	O	2257
.	PUNCT	O	O	2257
NaHCO3	NOUN	O	Chemical	2258
briefly	ADV	O	O	2258
(	PUNCT	O	O	2258
5	NUM	O	O	2258
min	NOUN	O	O	2258
)	PUNCT	O	O	2258
reversed	VERB	O	O	2258
hypotension	NOUN	O	Disease	2258
and	CCONJ	O	O	2258
QRS	PROPN	O	O	2258
prolongation	NOUN	O	O	2258
.	PUNCT	O	O	2258
CaCl2	NUM	O	Chemical	2259
and	CCONJ	O	O	2259
4-aminopyridine	NOUN	O	Chemical	2259
failed	VERB	O	O	2259
to	PART	O	O	2259
improve	VERB	O	O	2259
blood	NOUN	O	O	2259
pressure	NOUN	O	O	2259
.	PUNCT	O	O	2259
The	PRON	O	O	2260
incidence	NOUN	O	O	2260
of	ADP	O	O	2260
ventricular arrhythmias	NOUN	O	Disease	2260
(	PUNCT	O	O	2260
p	NOUN	O	O	2260
=	PUNCT	O	O	2260
0.004	NUM	O	O	2260
)	PUNCT	O	O	2260
and	CCONJ	O	O	2260
seizures	NOUN	O	Disease	2260
(	PUNCT	O	O	2260
p	NOUN	O	O	2260
=	PUNCT	O	O	2260
0.03	NUM	O	O	2260
)	PUNCT	O	O	2260
in	ADP	O	O	2260
the	PRON	O	O	2260
CaCl2	NUM	O	Chemical	2260
group	NOUN	O	O	2260
was	AUX	O	O	2260
higher	ADJ	O	O	2260
than	ADP	O	O	2260
the	PRON	O	O	2260
other	ADJ	O	O	2260
groups	NOUN	O	O	2260
.	PUNCT	O	O	2260
CONCLUSION	PROPN	O	O	2261
:	PUNCT	O	O	2261
The	PRON	O	O	2261
administration	NOUN	O	O	2261
of	ADP	O	O	2261
CaCl2	NUM	O	Chemical	2261
or	CCONJ	O	O	2261
4-aminopyridine	NOUN	O	Chemical	2261
did	VERB	O	O	2261
not	PART	O	O	2261
reverse	VERB	O	O	2261
tricyclic	ADJ	O	O	2261
antidepressant	NOUN	O	O	2261
-	PUNCT	O	O	2261
induced	VERB	O	O	2261
hypotension	NOUN	O	Disease	2261
in	ADP	O	O	2261
rats	NOUN	O	O	2261
.	PUNCT	O	O	2261
CaCl2	NUM	O	Chemical	2262
therapy	NOUN	O	O	2262
may	AUX	O	O	2262
possibly	ADV	O	O	2262
worsen	VERB	O	O	2262
both	PRON	O	O	2262
cardiovascular and central nervous system toxicity	NOUN	O	Disease	2262
.	PUNCT	O	O	2262
These	PRON	O	O	2263
findings	NOUN	O	O	2263
do	VERB	O	O	2263
not	PART	O	O	2263
support	NOUN	O	O	2263
a	PRON	O	O	2263
role	NOUN	O	O	2263
for	ADP	O	O	2263
calcium	NOUN	O	Chemical	2263
channel	PROPN	O	O	2263
inhibition	NOUN	O	O	2263
in	ADP	O	O	2263
the	PRON	O	O	2263
pathogenesis	NOUN	O	O	2263
of	ADP	O	O	2263
tricyclic	ADJ	O	O	2263
antidepressant	NOUN	O	O	2263
-	PUNCT	O	O	2263
induced	VERB	O	O	2263
hypotension	NOUN	O	Disease	2263
.	PUNCT	O	O	2263
Phase	NOUN	O	O	2266
I	PRON	O	O	2266
trial	NOUN	O	O	2266
of	ADP	O	O	2266
13-cis	NOUN	O	O	2266
-	PUNCT	O	O	2266
retinoic	NOUN	O	O	2266
acid	PROPN	O	O	2266
in	ADP	O	O	2266
children	NOUN	O	O	2266
with	ADP	O	O	2266
neuroblastoma	NOUN	O	Disease	2266
following	VERB	O	O	2266
bone	NOUN	O	O	2266
marrow	PROPN	O	O	2266
transplantation	NOUN	O	O	2266
.	PUNCT	O	O	2266
PURPOSE	NOUN	O	O	2267
:	PUNCT	O	O	2267
Treatment	NOUN	O	O	2267
of	ADP	O	O	2267
neuroblastoma	NOUN	O	Disease	2267
cell	NOUN	O	O	2267
lines	NOUN	O	O	2267
with	ADP	O	O	2267
13-cis	NOUN	O	O	2267
-	PUNCT	O	O	2267
retinoic	NOUN	O	O	2267
acid	PROPN	O	O	2267
(	PUNCT	O	O	2267
cis	PROPN	O	O	2267
-	PUNCT	O	O	2267
RA	PROPN	O	Disease	2267
)	PUNCT	O	O	2267
can	AUX	O	O	2267
cause	VERB	O	O	2267
sustained	VERB	O	O	2267
inhibition	NOUN	O	O	2267
of	ADP	O	O	2267
proliferation	NOUN	O	O	2267
.	PUNCT	O	O	2267
Since	SCONJ	O	O	2268
cis	PROPN	O	O	2268
-	PUNCT	O	O	2268
RA	PROPN	O	Disease	2268
has	VERB	O	O	2268
demonstrated	VERB	O	O	2268
clinical	ADJ	O	O	2268
responses	NOUN	O	O	2268
in	ADP	O	O	2268
neuroblastoma	NOUN	O	Disease	2268
patients	NOUN	O	O	2268
,	PUNCT	O	O	2268
it	PRON	O	O	2268
may	AUX	O	O	2268
be	AUX	O	O	2268
effective	ADJ	O	O	2268
in	ADP	O	O	2268
preventing	VERB	O	O	2268
relapse	VERB	O	O	2268
after	ADP	O	O	2268
cytotoxic	ADJ	O	O	2268
therapy	NOUN	O	O	2268
.	PUNCT	O	O	2268
This	PRON	O	O	2269
phase	NOUN	O	O	2269
I	PRON	O	O	2269
trial	NOUN	O	O	2269
was	AUX	O	O	2269
designed	VERB	O	O	2269
to	PART	O	O	2269
determine	VERB	O	O	2269
the	PRON	O	O	2269
maximal	ADJ	O	O	2269
-	PUNCT	O	O	2269
tolerated	VERB	O	O	2269
dosage	NOUN	O	O	2269
(	PUNCT	O	O	2269
MTD	PROPN	O	O	2269
)	PUNCT	O	O	2269
,	PUNCT	O	O	2269
toxicities	NOUN	O	Disease	2269
,	PUNCT	O	O	2269
and	CCONJ	O	O	2269
pharmacokinetics	NOUN	O	O	2269
of	ADP	O	O	2269
cis	PROPN	O	O	2269
-	PUNCT	O	O	2269
RA	PROPN	O	Disease	2269
administered	VERB	O	O	2269
on	ADP	O	O	2269
an	PRON	O	O	2269
intermittent	ADJ	O	O	2269
schedule	NOUN	O	O	2269
in	ADP	O	O	2269
children	NOUN	O	O	2269
with	ADP	O	O	2269
neuroblastoma	NOUN	O	Disease	2269
following	VERB	O	O	2269
bone	NOUN	O	O	2269
marrow	PROPN	O	O	2269
transplantation	NOUN	O	O	2269
(	PUNCT	O	O	2269
BMT	PROPN	O	O	2269
)	PUNCT	O	O	2269
.	PUNCT	O	O	2269
PATIENTS	NOUN	O	O	2270
AND	CCONJ	O	O	2270
METHODS	NOUN	O	O	2270
:	PUNCT	O	O	2270
Fifty	NUM	O	O	2270
-	PUNCT	O	O	2270
one	NUM	O	O	2270
assessable	ADJ	O	O	2270
patients	NOUN	O	O	2270
,	PUNCT	O	O	2270
2	X	O	O	2270
to	PART	O	O	2270
12	NUM	O	O	2270
years	NOUN	O	O	2270
of	ADP	O	O	2270
age	NOUN	O	O	2270
,	PUNCT	O	O	2270
were	AUX	O	O	2270
treated	VERB	O	O	2270
with	ADP	O	O	2270
oral	ADJ	O	O	2270
cis	PROPN	O	O	2270
-	PUNCT	O	O	2270
RA	PROPN	O	Disease	2270
administered	VERB	O	O	2270
in	ADP	O	O	2270
two	NUM	O	O	2270
equally	ADV	O	O	2270
divided	VERB	O	O	2270
doses	NOUN	O	O	2270
daily	ADV	O	O	2270
for	ADP	O	O	2270
2	X	O	O	2270
weeks	NOUN	O	O	2270
,	PUNCT	O	O	2270
followed	VERB	O	O	2270
by	ADP	O	O	2270
a	PRON	O	O	2270
2-week	NOUN	O	O	2270
rest	VERB	O	O	2270
period	NOUN	O	O	2270
,	PUNCT	O	O	2270
for	ADP	O	O	2270
up	ADP	O	O	2270
to	PART	O	O	2270
12	NUM	O	O	2270
courses	NOUN	O	O	2270
.	PUNCT	O	O	2270
The	PRON	O	O	2271
dose	NOUN	O	O	2271
was	AUX	O	O	2271
escalated	VERB	O	O	2271
from	ADP	O	O	2271
100	NUM	O	O	2271
to	PART	O	O	2271
200	NUM	O	O	2271
mg	VERB	O	O	2271
/	PUNCT	O	O	2271
m2/d	NOUN	O	O	2271
until	ADP	O	O	2271
dose	NOUN	O	O	2271
-	PUNCT	O	O	2271
limiting	VERB	O	O	2271
toxicity	NOUN	O	Disease	2271
(	PUNCT	O	O	2271
DLT	PROPN	O	O	2271
)	PUNCT	O	O	2271
was	AUX	O	O	2271
observed	VERB	O	O	2271
.	PUNCT	O	O	2271
The	PRON	O	O	2272
MTD	PROPN	O	O	2272
of	ADP	O	O	2272
cis	PROPN	O	O	2272
-	PUNCT	O	O	2272
RA	PROPN	O	Disease	2272
was	AUX	O	O	2272
160	NUM	O	O	2272
mg	VERB	O	O	2272
/	PUNCT	O	O	2272
m2/d	NOUN	O	O	2272
.	PUNCT	O	O	2272
Dose	NOUN	O	O	2273
-	PUNCT	O	O	2273
limiting	VERB	O	O	2273
toxicities	NOUN	O	Disease	2273
in	ADP	O	O	2273
six	NUM	O	O	2273
of	ADP	O	O	2273
nine	NUM	O	O	2273
patients	NOUN	O	O	2273
at	ADP	O	O	2273
200	NUM	O	O	2273
mg	VERB	O	O	2273
/	PUNCT	O	O	2273
m2/d	NOUN	O	O	2273
included	VERB	O	O	2273
hypercalcemia	NOUN	O	Disease	2273
(	PUNCT	O	O	2273
n	CCONJ	O	O	2273
=	PUNCT	O	O	2273
3	X	O	O	2273
)	PUNCT	O	O	2273
,	PUNCT	O	O	2273
rash	ADJ	O	Disease	2273
(	PUNCT	O	O	2273
n	CCONJ	O	O	2273
=	PUNCT	O	O	2273
2	X	O	O	2273
)	PUNCT	O	O	2273
,	PUNCT	O	O	2273
and	CCONJ	O	O	2273
anemia	NOUN	O	Disease	2273
/	PUNCT	O	O	2273
thrombocytopenia	PROPN	O	Disease	2273
/	PUNCT	O	O	2273
emesis	VERB	O	Disease	2273
/	PUNCT	O	O	2273
rash	ADJ	O	Disease	2273
(	PUNCT	O	O	2273
n	CCONJ	O	O	2273
=	PUNCT	O	O	2273
1	X	O	O	2273
)	PUNCT	O	O	2273
.	PUNCT	O	O	2273
All	PRON	O	O	2274
toxicities	NOUN	O	Disease	2274
resolved	VERB	O	O	2274
after	ADP	O	O	2274
cis	PROPN	O	O	2274
-	PUNCT	O	O	2274
RA	PROPN	O	Disease	2274
was	AUX	O	O	2274
discontinued	VERB	O	O	2274
.	PUNCT	O	O	2274
Three	NUM	O	O	2275
complete	VERB	O	O	2275
responses	NOUN	O	O	2275
were	AUX	O	O	2275
observed	VERB	O	O	2275
in	ADP	O	O	2275
marrow	PROPN	O	O	2275
metastases	NOUN	O	Disease	2275
.	PUNCT	O	O	2275
The	PRON	O	O	2276
MTD	PROPN	O	O	2276
of	ADP	O	O	2276
cis	PROPN	O	O	2276
-	PUNCT	O	O	2276
RA	PROPN	O	Disease	2276
given	VERB	O	O	2276
on	ADP	O	O	2276
this	PRON	O	O	2276
intermittent	ADJ	O	O	2276
schedule	NOUN	O	O	2276
was	AUX	O	O	2276
160	NUM	O	O	2276
mg	VERB	O	O	2276
/	PUNCT	O	O	2276
m2/d	NOUN	O	O	2276
.	PUNCT	O	O	2276
Serum	NOUN	O	O	2277
levels	NOUN	O	O	2277
known	VERB	O	O	2277
to	PART	O	O	2277
be	AUX	O	O	2277
effective	ADJ	O	O	2277
against	ADP	O	O	2277
neuroblastoma	NOUN	O	Disease	2277
in	ADP	O	O	2277
vitro	X	O	O	2277
were	AUX	O	O	2277
achieved	VERB	O	O	2277
at	ADP	O	O	2277
this	PRON	O	O	2277
dose	NOUN	O	O	2277
.	PUNCT	O	O	2277
The	PRON	O	O	2278
DLT	PROPN	O	O	2278
included	VERB	O	O	2278
hypercalcemia	NOUN	O	Disease	2278
,	PUNCT	O	O	2278
and	CCONJ	O	O	2278
may	AUX	O	O	2278
be	AUX	O	O	2278
predicted	VERB	O	O	2278
by	ADP	O	O	2278
serum	NOUN	O	O	2278
cis	PROPN	O	O	2278
-	PUNCT	O	O	2278
RA	PROPN	O	Disease	2278
levels	NOUN	O	O	2278
.	PUNCT	O	O	2278
Monitoring	VERB	O	O	2279
of	ADP	O	O	2279
serum	NOUN	O	O	2279
calcium	NOUN	O	Chemical	2279
and	CCONJ	O	O	2279
cis	PROPN	O	O	2279
-	PUNCT	O	O	2279
RA	PROPN	O	Disease	2279
levels	NOUN	O	O	2279
is	AUX	O	O	2279
indicated	VERB	O	O	2279
in	ADP	O	O	2279
future	NOUN	O	O	2279
trials	NOUN	O	O	2279
.	PUNCT	O	O	2279
Effect	VERB	O	O	2282
of	ADP	O	O	2282
calcium chloride	NOUN	O	Chemical	2282
on	ADP	O	O	2282
gross	ADJ	O	O	2282
behavioural	ADJ	O	O	2282
changes	VERB	O	O	2282
produced	VERB	O	O	2282
by	ADP	O	O	2282
carbachol	NOUN	O	Chemical	2282
and	CCONJ	O	O	2282
eserine	ADJ	O	Chemical	2282
in	ADP	O	O	2282
cats	NOUN	O	O	2282
.	PUNCT	O	O	2282
The	PRON	O	O	2283
effect	VERB	O	O	2283
of	ADP	O	O	2283
calcium chloride	NOUN	O	Chemical	2283
injected	VERB	O	O	2283
into	ADP	O	O	2283
the	PRON	O	O	2283
cerebral	ADJ	O	O	2283
ventricles	VERB	O	O	2283
of	ADP	O	O	2283
group	NOUN	O	O	2283
-	PUNCT	O	O	2283
housed	VERB	O	O	2283
unanaesthetized	VERB	O	O	2283
cats	NOUN	O	O	2283
upon	SCONJ	O	O	2283
vocalization	NOUN	O	O	2283
(	PUNCT	O	O	2283
rage	NOUN	O	O	2283
,	PUNCT	O	O	2283
hissing	NOUN	O	O	2283
and	CCONJ	O	O	2283
snarling	VERB	O	O	2283
)	PUNCT	O	O	2283
,	PUNCT	O	O	2283
fighting	VERB	O	O	2283
(	PUNCT	O	O	2283
attack	VERB	O	O	2283
with	ADP	O	O	2283
paws	NOUN	O	O	2283
and	CCONJ	O	O	2283
claws	NOUN	O	O	2283
,	PUNCT	O	O	2283
defense	NOUN	O	O	2283
with	ADP	O	O	2283
paws	NOUN	O	O	2283
and	CCONJ	O	O	2283
claws	NOUN	O	O	2283
and	CCONJ	O	O	2283
biting	VERB	O	O	2283
)	PUNCT	O	O	2283
,	PUNCT	O	O	2283
mydriasis	ADJ	O	Disease	2283
,	PUNCT	O	O	2283
tremor	NOUN	O	Disease	2283
and	CCONJ	O	O	2283
clonic	ADJ	O	O	2283
-	PUNCT	O	O	2283
tonic	PROPN	O	O	2283
convulsions	NOUN	O	Disease	2283
produced	VERB	O	O	2283
by	ADP	O	O	2283
carbachol	NOUN	O	Chemical	2283
and	CCONJ	O	O	2283
eserine	ADJ	O	Chemical	2283
injected	VERB	O	O	2283
similarly	ADV	O	O	2283
was	AUX	O	O	2283
investigated	VERB	O	O	2283
.	PUNCT	O	O	2283
Calcium chloride	NOUN	O	Chemical	2284
depressed	ADJ	O	O	2284
or	CCONJ	O	O	2284
almost	ADV	O	O	2284
completely	ADV	O	O	2284
abolished	VERB	O	O	2284
the	PRON	O	O	2284
vocalization	NOUN	O	O	2284
and	CCONJ	O	O	2284
fighting	VERB	O	O	2284
due	ADJ	O	O	2284
to	PART	O	O	2284
carbachol	NOUN	O	Chemical	2284
and	CCONJ	O	O	2284
eserine	ADJ	O	Chemical	2284
.	PUNCT	O	O	2284
On	ADP	O	O	2285
the	PRON	O	O	2285
other	ADJ	O	O	2285
hand	NOUN	O	O	2285
,	PUNCT	O	O	2285
mydriasis	ADJ	O	Disease	2285
,	PUNCT	O	O	2285
tremor	NOUN	O	Disease	2285
and	CCONJ	O	O	2285
clonic	ADJ	O	O	2285
-	PUNCT	O	O	2285
tonic	PROPN	O	O	2285
convulsions	NOUN	O	Disease	2285
evoked	VERB	O	O	2285
by	ADP	O	O	2285
carbachol	NOUN	O	Chemical	2285
and	CCONJ	O	O	2285
eserine	ADJ	O	Chemical	2285
were	AUX	O	O	2285
not	PART	O	O	2285
significantly	ADV	O	O	2285
changed	VERB	O	O	2285
by	ADP	O	O	2285
calcium chloride	NOUN	O	Chemical	2285
.	PUNCT	O	O	2285
It	PRON	O	O	2286
is	AUX	O	O	2286
apparent	ADJ	O	O	2286
that	SCONJ	O	O	2286
calcium chloride	NOUN	O	Chemical	2286
can	AUX	O	O	2286
""""	PUNCT	O	O	2286
dissociate	VERB	O	O	2286
""""	PUNCT	O	O	2286
vocalization	NOUN	O	O	2286
and	CCONJ	O	O	2286
fighting	VERB	O	O	2286
from	ADP	O	O	2286
autonomic	ADJ	O	O	2286
and	CCONJ	O	O	2286
motor	NOUN	O	O	2286
phenomena	VERB	O	O	2286
such	ADJ	O	O	2286
as	ADP	O	O	2286
mydriasis	ADJ	O	Disease	2286
,	PUNCT	O	O	2286
tremor	NOUN	O	Disease	2286
and	CCONJ	O	O	2286
clonic	ADJ	O	O	2286
-	PUNCT	O	O	2286
tonic	PROPN	O	O	2286
convulsions	NOUN	O	Disease	2286
caused	VERB	O	O	2286
by	ADP	O	O	2286
carbachol	NOUN	O	Chemical	2286
and	CCONJ	O	O	2286
eserine	ADJ	O	Chemical	2286
.	PUNCT	O	O	2286
Calcium chloride	NOUN	O	Chemical	2287
inhibited	VERB	O	O	2287
the	PRON	O	O	2287
vocalization	NOUN	O	O	2287
and	CCONJ	O	O	2287
fighting	VERB	O	O	2287
produced	VERB	O	O	2287
by	ADP	O	O	2287
carbachol	NOUN	O	Chemical	2287
and	CCONJ	O	O	2287
eserine	ADJ	O	Chemical	2287
most	ADV	O	O	2287
probably	ADV	O	O	2287
by	ADP	O	O	2287
a	PRON	O	O	2287
nonspecific	ADJ	O	O	2287
stabilizing	VERB	O	O	2287
action	NOUN	O	O	2287
on	ADP	O	O	2287
central	ADJ	O	O	2287
muscarinic	PROPN	O	O	2287
cholinoceptive	VERB	O	O	2287
sites	NOUN	O	O	2287
.	PUNCT	O	O	2287
These	PRON	O	O	2288
results	VERB	O	O	2288
further	ADV	O	O	2288
support	NOUN	O	O	2288
the	PRON	O	O	2288
view	VERB	O	O	2288
that	SCONJ	O	O	2288
calcium	NOUN	O	Chemical	2288
ions	NOUN	O	O	2288
in	ADP	O	O	2288
excess	ADJ	O	O	2288
have	VERB	O	O	2288
an	PRON	O	O	2288
atropine	NOUN	O	Chemical	2288
-	PUNCT	O	O	2288
like	INTJ	O	O	2288
action	NOUN	O	O	2288
also	ADV	O	O	2288
in	ADP	O	O	2288
the	PRON	O	O	2288
central	ADJ	O	O	2288
nervous	ADJ	O	O	2288
system	NOUN	O	O	2288
.	PUNCT	O	O	2288
Multiple	ADJ	O	O	2291
side	NOUN	O	O	2291
effects	NOUN	O	O	2291
of	ADP	O	O	2291
penicillamine	NOUN	O	Chemical	2291
therapy	NOUN	O	O	2291
in	ADP	O	O	2291
one	NUM	O	O	2291
patient	NOUN	O	O	2291
with	ADP	O	O	2291
rheumatoid arthritis	NOUN	O	Disease	2291
.	PUNCT	O	O	2291
Skin rashes	NOUN	O	Disease	2292
,	PUNCT	O	O	2292
proteinuria	X	O	Disease	2292
,	PUNCT	O	O	2292
systemic lupus erythematosus	PROPN	O	Disease	2292
,	PUNCT	O	O	2292
polymyositis	NOUN	O	Disease	2292
and	CCONJ	O	O	2292
myasthenia gravis	PROPN	O	Disease	2292
have	VERB	O	O	2292
all	PRON	O	O	2292
been	AUX	O	O	2292
recorded	VERB	O	O	2292
as	ADP	O	O	2292
complications	NOUN	O	O	2292
of	ADP	O	O	2292
penicillamine	NOUN	O	Chemical	2292
therapy	NOUN	O	O	2292
in	ADP	O	O	2292
patients	NOUN	O	O	2292
with	ADP	O	O	2292
rheumatoid arthritis	NOUN	O	Disease	2292
.	PUNCT	O	O	2292
The	PRON	O	O	2293
skin lesion	NOUN	O	Disease	2293
resembled	VERB	O	O	2293
elastosis perforans serpiginosa	NOUN	O	Disease	2293
,	PUNCT	O	O	2293
which	PRON	O	O	2293
has	VERB	O	O	2293
been	AUX	O	O	2293
reported	VERB	O	O	2293
as	ADP	O	O	2293
a	PRON	O	O	2293
rare	ADJ	O	O	2293
side	NOUN	O	O	2293
effect	VERB	O	O	2293
in	ADP	O	O	2293
patients	NOUN	O	O	2293
with	ADP	O	O	2293
Wilson	PROPN	O	O	2293
's	AUX	O	O	2293
disease	PROPN	O	O	2293
but	CCONJ	O	O	2293
not	PART	O	O	2293
in	ADP	O	O	2293
patients	NOUN	O	O	2293
with	ADP	O	O	2293
rheumatoid arthritis	NOUN	O	Disease	2293
treated	VERB	O	O	2293
with	ADP	O	O	2293
penicillamine	NOUN	O	Chemical	2293
.	PUNCT	O	O	2293
Electrocardiographic	NOUN	O	O	2296
changes	VERB	O	O	2296
and	CCONJ	O	O	2296
cardiac arrhythmias	VERB	O	Disease	2296
in	ADP	O	O	2296
patients	NOUN	O	O	2296
receiving	VERB	O	O	2296
psychotropic	NOUN	O	O	2296
drugs	NOUN	O	O	2296
.	PUNCT	O	O	2296
Eight	NUM	O	O	2297
patients	NOUN	O	O	2297
had	VERB	O	O	2297
cardiac	ADJ	O	O	2297
manifestations	NOUN	O	O	2297
that	SCONJ	O	O	2297
were	AUX	O	O	2297
life	NOUN	O	O	2297
-	PUNCT	O	O	2297
threatening	VERB	O	O	2297
in	ADP	O	O	2297
five	NUM	O	O	2297
while	SCONJ	O	O	2297
taking	VERB	O	O	2297
psychotropic	NOUN	O	O	2297
drugs	NOUN	O	O	2297
,	PUNCT	O	O	2297
either	ADV	O	O	2297
phenothiazines	NOUN	O	Chemical	2297
or	CCONJ	O	O	2297
tricyclic	ADJ	O	O	2297
antidepressants	NOUN	O	O	2297
.	PUNCT	O	O	2297
Although	SCONJ	O	O	2298
most	ADV	O	O	2298
patients	NOUN	O	O	2298
were	AUX	O	O	2298
receiving	VERB	O	O	2298
several	ADJ	O	O	2298
drugs	NOUN	O	O	2298
,	PUNCT	O	O	2298
Mellaril	PROPN	O	Chemical	2298
(	PUNCT	O	O	2298
thioridazine	NOUN	O	Chemical	2298
)	PUNCT	O	O	2298
appeared	VERB	O	O	2298
to	PART	O	O	2298
be	AUX	O	O	2298
responsible	ADJ	O	O	2298
for	ADP	O	O	2298
five	NUM	O	O	2298
cases	NOUN	O	O	2298
of	ADP	O	O	2298
ventricular tachycardia	NOUN	O	Disease	2298
,	PUNCT	O	O	2298
one	NUM	O	O	2298
of	ADP	O	O	2298
which	PRON	O	O	2298
was	AUX	O	O	2298
fatal	ADJ	O	O	2298
in	ADP	O	O	2298
a	PRON	O	O	2298
35	NUM	O	O	2298
year	NOUN	O	O	2298
old	ADJ	O	O	2298
woman	NOUN	O	O	2298
.	PUNCT	O	O	2298
Supraventricular tachycardia	NOUN	O	Disease	2299
developed	VERB	O	O	2299
in	ADP	O	O	2299
one	NUM	O	O	2299
patient	NOUN	O	O	2299
receiving	VERB	O	O	2299
Thorazine	NOUN	O	Chemical	2299
(	PUNCT	O	O	2299
chlorpromazine	NOUN	O	Chemical	2299
)	PUNCT	O	O	2299
.	PUNCT	O	O	2299
Aventyl	NOUN	O	Chemical	2300
(	PUNCT	O	O	2300
nortriptyline	PROPN	O	Chemical	2300
)	PUNCT	O	O	2300
and	CCONJ	O	O	2300
Elavil	NOUN	O	Chemical	2300
(	PUNCT	O	O	2300
amitriptyline	PROPN	O	Chemical	2300
)	PUNCT	O	O	2300
each	PRON	O	O	2300
produced	VERB	O	O	2300
left bundle branch block	NOUN	O	Disease	2300
in	ADP	O	O	2300
a	PRON	O	O	2300
73	NUM	O	O	2300
year	NOUN	O	O	2300
old	ADJ	O	O	2300
woman	NOUN	O	O	2300
.	PUNCT	O	O	2300
The	PRON	O	O	2301
ventricular arrhythmias	NOUN	O	Disease	2301
responded	VERB	O	O	2301
to	PART	O	O	2301
intravenous	ADJ	O	O	2301
administration	NOUN	O	O	2301
of	ADP	O	O	2301
lidocaine	NOUN	O	Chemical	2301
and	CCONJ	O	O	2301
to	PART	O	O	2301
direct	ADJ	O	O	2301
current	ADJ	O	O	2301
electric	NOUN	O	O	2301
shock	NOUN	O	O	2301
;	PUNCT	O	O	2301
ventricular	ADJ	O	O	2301
pacing	NOUN	O	O	2301
was	AUX	O	O	2301
required	VERB	O	O	2301
in	ADP	O	O	2301
some	PRON	O	O	2301
instances	NOUN	O	O	2301
and	CCONJ	O	O	2301
intravenous	ADJ	O	O	2301
administration	NOUN	O	O	2301
of	ADP	O	O	2301
propranolol	NOUN	O	Chemical	2301
combined	VERB	O	O	2301
with	ADP	O	O	2301
ventricular	ADJ	O	O	2301
pacing	NOUN	O	O	2301
in	ADP	O	O	2301
one	NUM	O	O	2301
.	PUNCT	O	O	2301
The	PRON	O	O	2302
tachyarrhythmias	NOUN	O	Disease	2302
generally	ADV	O	O	2302
subsided	VERB	O	O	2302
within	ADP	O	O	2302
48	NUM	O	O	2302
hours	NOUN	O	O	2302
after	ADP	O	O	2302
administration	NOUN	O	O	2302
of	ADP	O	O	2302
the	PRON	O	O	2302
drugs	NOUN	O	O	2302
was	AUX	O	O	2302
stopped	VERB	O	O	2302
.	PUNCT	O	O	2302
Five	NUM	O	O	2303
of	ADP	O	O	2303
the	PRON	O	O	2303
eight	NUM	O	O	2303
patients	NOUN	O	O	2303
were	AUX	O	O	2303
50	NUM	O	O	2303
years	NOUN	O	O	2303
of	ADP	O	O	2303
age	NOUN	O	O	2303
or	CCONJ	O	O	2303
younger	ADJ	O	O	2303
;	PUNCT	O	O	2303
only	ADV	O	O	2303
one	NUM	O	O	2303
clearly	ADV	O	O	2303
had	VERB	O	O	2303
antecedent	NOUN	O	O	2303
heart disease	NOUN	O	Disease	2303
.	PUNCT	O	O	2303
Major	ADJ	O	O	2304
cardiac arrhythmias	VERB	O	Disease	2304
are	AUX	O	O	2304
a	PRON	O	O	2304
potential	ADJ	O	O	2304
hazard	NOUN	O	O	2304
in	ADP	O	O	2304
patients	NOUN	O	O	2304
without	ADP	O	O	2304
heart disease	NOUN	O	Disease	2304
who	PRON	O	O	2304
are	AUX	O	O	2304
receiving	VERB	O	O	2304
customary	ADJ	O	O	2304
therapeutic	ADJ	O	O	2304
doses	NOUN	O	O	2304
of	ADP	O	O	2304
psychotropic	NOUN	O	O	2304
drugs	NOUN	O	O	2304
.	PUNCT	O	O	2304
A	PRON	O	O	2305
prospective	ADJ	O	O	2305
clinical	ADJ	O	O	2305
trial	NOUN	O	O	2305
is	AUX	O	O	2305
suggested	VERB	O	O	2305
to	PART	O	O	2305
quantify	VERB	O	O	2305
the	PRON	O	O	2305
risk	NOUN	O	O	2305
of	ADP	O	O	2305
cardiac complications	NOUN	O	Disease	2305
to	PART	O	O	2305
patients	NOUN	O	O	2305
receiving	VERB	O	O	2305
phenothiazines	NOUN	O	Chemical	2305
or	CCONJ	O	O	2305
tricyclic	ADJ	O	O	2305
antidepressant	NOUN	O	O	2305
drugs	NOUN	O	O	2305
.	PUNCT	O	O	2305
Serotonergic	NOUN	O	O	2308
drugs	NOUN	O	O	2308
,	PUNCT	O	O	2308
benzodiazepines	NOUN	O	Chemical	2308
and	CCONJ	O	O	2308
baclofen	VERB	O	Chemical	2308
block	NOUN	O	O	2308
muscimol	NOUN	O	Chemical	2308
-	PUNCT	O	O	2308
induced	VERB	O	O	2308
myoclonic jerks	NOUN	O	Disease	2308
in	ADP	O	O	2308
a	PRON	O	O	2308
strain	VERB	O	O	2308
of	ADP	O	O	2308
mice	NOUN	O	O	2308
.	PUNCT	O	O	2308
In	ADP	O	O	2309
male	NOUN	O	O	2309
Swiss	PROPN	O	O	2309
mice	NOUN	O	O	2309
,	PUNCT	O	O	2309
muscimol	NOUN	O	Chemical	2309
produced	VERB	O	O	2309
myoclonic jerks	NOUN	O	Disease	2309
.	PUNCT	O	O	2309
Increasing	VERB	O	O	2310
the	PRON	O	O	2310
brain	NOUN	O	O	2310
serotonin	PROPN	O	Chemical	2310
levels	NOUN	O	O	2310
by	ADP	O	O	2310
the	PRON	O	O	2310
administration	NOUN	O	O	2310
of	ADP	O	O	2310
5-hydroxytryptophan	NOUN	O	Chemical	2310
(	PUNCT	O	O	2310
80	NUM	O	O	2310
-	PUNCT	O	O	2310
160	NUM	O	O	2310
mg	VERB	O	O	2310
/	PUNCT	O	O	2310
kg	VERB	O	O	2310
)	PUNCT	O	O	2310
in	ADP	O	O	2310
combination	NOUN	O	O	2310
with	ADP	O	O	2310
a	PRON	O	O	2310
peripheral	ADJ	O	O	2310
decarboxylase	PROPN	O	O	2310
inhibitor	NOUN	O	O	2310
resulted	VERB	O	O	2310
in	ADP	O	O	2310
an	PRON	O	O	2310
inhibition	NOUN	O	O	2310
of	ADP	O	O	2310
the	PRON	O	O	2310
muscimol	NOUN	O	Chemical	2310
effect	VERB	O	O	2310
.	PUNCT	O	O	2310
l	X	O	O	2311
-	PUNCT	O	O	2311
dopa	PROPN	O	O	2311
(	PUNCT	O	O	2311
80	NUM	O	O	2311
-	PUNCT	O	O	2311
160	NUM	O	O	2311
mg	VERB	O	O	2311
/	PUNCT	O	O	2311
kg	VERB	O	O	2311
)	PUNCT	O	O	2311
was	AUX	O	O	2311
without	ADP	O	O	2311
effect	VERB	O	O	2311
.	PUNCT	O	O	2311
In	ADP	O	O	2312
doses	NOUN	O	O	2312
of	ADP	O	O	2312
3	X	O	O	2312
-	PUNCT	O	O	2312
10	NUM	O	O	2312
mg	VERB	O	O	2312
/	PUNCT	O	O	2312
kg	VERB	O	O	2312
,	PUNCT	O	O	2312
the	PRON	O	O	2312
serotonin	PROPN	O	Chemical	2312
receptor	NOUN	O	O	2312
agonist	NOUN	O	O	2312
MK-212	PROPN	O	Chemical	2312
caused	VERB	O	O	2312
a	PRON	O	O	2312
dose	NOUN	O	O	2312
-	PUNCT	O	O	2312
dependent	ADJ	O	O	2312
blockade	VERB	O	O	2312
of	ADP	O	O	2312
the	PRON	O	O	2312
response	NOUN	O	O	2312
of	ADP	O	O	2312
muscimol	NOUN	O	Chemical	2312
.	PUNCT	O	O	2312
Of	ADV	O	O	2313
the	PRON	O	O	2313
benzodiazepines	NOUN	O	Chemical	2313
,	PUNCT	O	O	2313
clonazepam	NOUN	O	Chemical	2313
(	PUNCT	O	O	2313
0.1	NUM	O	O	2313
-	PUNCT	O	O	2313
0.3	NUM	O	O	2313
mg	VERB	O	O	2313
/	PUNCT	O	O	2313
kg	VERB	O	O	2313
)	PUNCT	O	O	2313
was	AUX	O	O	2313
found	VERB	O	O	2313
to	PART	O	O	2313
be	AUX	O	O	2313
several	ADJ	O	O	2313
fold	VERB	O	O	2313
more	ADJ	O	O	2313
potent	ADJ	O	O	2313
than	ADP	O	O	2313
diazepam	NOUN	O	Chemical	2313
(	PUNCT	O	O	2313
0.3	NUM	O	O	2313
-	PUNCT	O	O	2313
3	X	O	O	2313
mg	VERB	O	O	2313
/	PUNCT	O	O	2313
kg	VERB	O	O	2313
)	PUNCT	O	O	2313
in	ADP	O	O	2313
blocking	VERB	O	O	2313
the	PRON	O	O	2313
myoclonic jerks	NOUN	O	Disease	2313
.	PUNCT	O	O	2313
While	SCONJ	O	O	2314
(	PUNCT	O	O	2314
-)-baclofen	NOUN	O	O	2314
(	PUNCT	O	O	2314
1	X	O	O	2314
-	PUNCT	O	O	2314
3	X	O	O	2314
mg	VERB	O	O	2314
/	PUNCT	O	O	2314
kg	VERB	O	O	2314
)	PUNCT	O	O	2314
proved	VERB	O	O	2314
to	PART	O	O	2314
be	AUX	O	O	2314
an	PRON	O	O	2314
effective	ADJ	O	O	2314
antagonist	NOUN	O	O	2314
of	ADP	O	O	2314
muscimol	NOUN	O	Chemical	2314
,	PUNCT	O	O	2314
its	PRON	O	O	2314
(	PUNCT	O	O	2314
+	ADP	O	O	2314
)	PUNCT	O	O	2314
Considering	VERB	O	O	2315
the	PRON	O	O	2315
fact	NOUN	O	O	2315
that	SCONJ	O	O	2315
5-HTP	NOUN	O	Chemical	2315
and	CCONJ	O	O	2315
the	PRON	O	O	2315
benzodiazepines	NOUN	O	Chemical	2315
have	VERB	O	O	2315
been	AUX	O	O	2315
found	VERB	O	O	2315
to	PART	O	O	2315
be	AUX	O	O	2315
beneficial	ADJ	O	O	2315
in	ADP	O	O	2315
the	PRON	O	O	2315
management	NOUN	O	O	2315
of	ADP	O	O	2315
clinical	ADJ	O	O	2315
myoclonus	NOUN	O	Disease	2315
,	PUNCT	O	O	2315
the	PRON	O	O	2315
muscimol	NOUN	O	Chemical	2315
-	PUNCT	O	O	2315
induced	VERB	O	O	2315
myoclonus	NOUN	O	Disease	2315
seems	VERB	O	O	2315
to	PART	O	O	2315
be	AUX	O	O	2315
a	PRON	O	O	2315
satisfactory	ADJ	O	O	2315
animal	NOUN	O	O	2315
model	NOUN	O	O	2315
that	SCONJ	O	O	2315
may	AUX	O	O	2315
prove	VERB	O	O	2315
useful	ADJ	O	O	2315
for	ADP	O	O	2315
the	PRON	O	O	2315
development	NOUN	O	O	2315
of	ADP	O	O	2315
new	ADJ	O	O	2315
drug	NOUN	O	O	2315
treatments	NOUN	O	O	2315
for	ADP	O	O	2315
this	PRON	O	O	2315
condition	NOUN	O	O	2315
.	PUNCT	O	O	2315
Our	PRON	O	O	2316
present	NOUN	O	O	2316
study	VERB	O	O	2316
indicated	VERB	O	O	2316
the	PRON	O	O	2316
possible	ADJ	O	O	2316
value	NOUN	O	O	2316
of	ADP	O	O	2316
MK-212	PROPN	O	Chemical	2316
and	CCONJ	O	O	2316
(	PUNCT	O	O	2316
-)-baclofen	NOUN	O	O	2316
in	ADP	O	O	2316
the	PRON	O	O	2316
management	NOUN	O	O	2316
of	ADP	O	O	2316
clinical	ADJ	O	O	2316
myoclonus	NOUN	O	Disease	2316
.	PUNCT	O	O	2316
Hyperglycemic acidotic coma	NOUN	O	Disease	2319
and	CCONJ	O	O	2319
death	NOUN	O	O	2319
in	ADP	O	O	2319
Kearns	NOUN	O	O	2319
-	PUNCT	O	O	2319
Sayre	PROPN	O	O	2319
syndrome	NOUN	O	O	2319
.	PUNCT	O	O	2319
This	PRON	O	O	2320
paper	PROPN	O	O	2320
presents	VERB	O	O	2320
the	PRON	O	O	2320
clinical	ADJ	O	O	2320
and	CCONJ	O	O	2320
metabolic	ADJ	O	O	2320
findings	NOUN	O	O	2320
in	ADP	O	O	2320
two	NUM	O	O	2320
young	ADJ	O	O	2320
boys	NOUN	O	O	2320
with	ADP	O	O	2320
long	ADV	O	O	2320
-	PUNCT	O	O	2320
standing	VERB	O	O	2320
Kearns	NOUN	O	O	2320
-	PUNCT	O	O	2320
Sayre	PROPN	O	O	2320
syndrome	NOUN	O	O	2320
.	PUNCT	O	O	2320
Following	VERB	O	O	2321
short	ADJ	O	O	2321
exposure	NOUN	O	O	2321
to	PART	O	O	2321
oral	ADJ	O	O	2321
prednisone	NOUN	O	Chemical	2321
,	PUNCT	O	O	2321
both	PRON	O	O	2321
boys	NOUN	O	O	2321
developed	VERB	O	O	2321
lethargy	NOUN	O	Disease	2321
,	PUNCT	O	O	2321
increasing	VERB	O	O	2321
somnolence	NOUN	O	Disease	2321
,	PUNCT	O	O	2321
polydipsia	PROPN	O	Disease	2321
,	PUNCT	O	O	2321
polyphagia	NOUN	O	Disease	2321
,	PUNCT	O	O	2321
and	CCONJ	O	O	2321
polyuria	PROPN	O	Disease	2321
.	PUNCT	O	O	2321
Both	PRON	O	O	2322
presented	VERB	O	O	2322
in	ADP	O	O	2322
the	PRON	O	O	2322
emergency	NOUN	O	O	2322
room	NOUN	O	O	2322
with	ADP	O	O	2322
profound	ADJ	O	O	2322
coma	NOUN	O	Disease	2322
,	PUNCT	O	O	2322
hypotension	NOUN	O	Disease	2322
,	PUNCT	O	O	2322
severe	ADJ	O	O	2322
hyperglycemia	NOUN	O	Disease	2322
,	PUNCT	O	O	2322
and	CCONJ	O	O	2322
acidosis	NOUN	O	Disease	2322
.	PUNCT	O	O	2322
Nonketotic	VERB	O	O	2323
lactic acidosis	NOUN	O	Disease	2323
was	AUX	O	O	2323
present	NOUN	O	O	2323
in	ADP	O	O	2323
one	NUM	O	O	2323
and	CCONJ	O	O	2323
ketosis	PROPN	O	Disease	2323
without	ADP	O	O	2323
a	PRON	O	O	2323
known	VERB	O	O	2323
serum	NOUN	O	O	2323
lactate	NOUN	O	Chemical	2323
level	VERB	O	O	2323
was	AUX	O	O	2323
present	NOUN	O	O	2323
in	ADP	O	O	2323
the	PRON	O	O	2323
other	ADJ	O	O	2323
.	PUNCT	O	O	2323
Respiratory failure	NOUN	O	Disease	2324
rapidly	ADV	O	O	2324
ensued	VERB	O	O	2324
and	CCONJ	O	O	2324
both	PRON	O	O	2324
patients	NOUN	O	O	2324
expired	VERB	O	O	2324
in	ADP	O	O	2324
spite	NOUN	O	O	2324
of	ADP	O	O	2324
efforts	NOUN	O	O	2324
at	ADP	O	O	2324
resuscitation	NOUN	O	O	2324
.	PUNCT	O	O	2324
We	PRON	O	O	2325
believe	VERB	O	O	2325
these	PRON	O	O	2325
two	NUM	O	O	2325
cases	NOUN	O	O	2325
represent	VERB	O	O	2325
a	PRON	O	O	2325
newly	ADV	O	O	2325
described	VERB	O	O	2325
and	CCONJ	O	O	2325
catastrophic	ADJ	O	O	2325
metabolic	ADJ	O	O	2325
-	PUNCT	O	O	2325
endocrine	NOUN	O	O	2325
failure	NOUN	O	O	2325
in	ADP	O	O	2325
the	PRON	O	O	2325
Kearns	NOUN	O	O	2325
-	PUNCT	O	O	2325
Sayre	PROPN	O	O	2325
syndrome	NOUN	O	O	2325
.	PUNCT	O	O	2325
Effects	NOUN	O	O	2328
of	ADP	O	O	2328
active	ADJ	O	O	2328
constituents	NOUN	O	O	2328
of	ADP	O	O	2328
Crocus	NOUN	O	O	2328
sativus	NOUN	O	O	2328
L.	PROPN	O	O	2328
,	PUNCT	O	O	2328
crocin	PROPN	O	Chemical	2328
on	ADP	O	O	2328
streptozocin	PROPN	O	Chemical	2328
-	PUNCT	O	O	2328
induced	VERB	O	O	2328
model	NOUN	O	O	2328
of	ADP	O	O	2328
sporadic	ADJ	O	O	2328
Alzheimer	NOUN	O	Disease	2328
's	AUX	O	O	2328
disease	PROPN	O	O	2328
in	ADP	O	O	2328
male	NOUN	O	O	2328
rats	NOUN	O	O	2328
.	PUNCT	O	O	2328
BACKGROUND	NOUN	O	O	2329
:	PUNCT	O	O	2329
The	PRON	O	O	2329
involvement	NOUN	O	O	2329
of	ADP	O	O	2329
water	PROPN	O	O	2329
-	PUNCT	O	O	2329
soluble	ADJ	O	O	2329
carotenoids	NOUN	O	Chemical	2329
,	PUNCT	O	O	2329
crocins	VERB	O	Chemical	2329
,	PUNCT	O	O	2329
as	ADP	O	O	2329
the	PRON	O	O	2329
main	ADJ	O	O	2329
and	CCONJ	O	O	2329
active	ADJ	O	O	2329
components	NOUN	O	O	2329
of	ADP	O	O	2329
Crocus	NOUN	O	O	2329
sativus	NOUN	O	O	2329
L.	PROPN	O	O	2329
extract	VERB	O	O	2329
in	ADP	O	O	2329
learning	VERB	O	O	2329
and	CCONJ	O	O	2329
memory	NOUN	O	O	2329
processes	NOUN	O	O	2329
has	VERB	O	O	2329
been	AUX	O	O	2329
proposed	VERB	O	O	2329
.	PUNCT	O	O	2329
In	ADP	O	O	2330
the	PRON	O	O	2330
present	NOUN	O	O	2330
study	VERB	O	O	2330
,	PUNCT	O	O	2330
the	PRON	O	O	2330
effect	VERB	O	O	2330
of	ADP	O	O	2330
crocins	VERB	O	Chemical	2330
on	ADP	O	O	2330
sporadic	ADJ	O	O	2330
Alzheimer	NOUN	O	Disease	2330
's	AUX	O	O	2330
disease	PROPN	O	O	2330
induced	VERB	O	O	2330
by	ADP	O	O	2330
intracerebroventricular	PROPN	O	O	2330
(	PUNCT	O	O	2330
icv	VERB	O	O	2330
)	PUNCT	O	O	2330
streptozocin	PROPN	O	Chemical	2330
(	PUNCT	O	O	2330
STZ	PROPN	O	Chemical	2330
)	PUNCT	O	O	2330
in	ADP	O	O	2330
male	NOUN	O	O	2330
rats	NOUN	O	O	2330
was	AUX	O	O	2330
investigated	VERB	O	O	2330
.	PUNCT	O	O	2330
Male	NOUN	O	O	2331
adult	NOUN	O	O	2331
Wistar	PROPN	O	O	2331
rats	NOUN	O	O	2331
(	PUNCT	O	O	2331
n	CCONJ	O	O	2331
=	PUNCT	O	O	2331
90	NUM	O	O	2331
and	CCONJ	O	O	2331
260	NUM	O	O	2331
-	PUNCT	O	O	2331
290	NUM	O	O	2331
g	X	O	O	2331
)	PUNCT	O	O	2331
were	AUX	O	O	2331
divided	VERB	O	O	2331
into	ADP	O	O	2331
1	X	O	O	2331
,	PUNCT	O	O	2331
control	VERB	O	O	2331
;	PUNCT	O	O	2331
2	X	O	O	2331
and	CCONJ	O	O	2331
3	X	O	O	2331
,	PUNCT	O	O	2331
crocins	VERB	O	Chemical	2331
(	PUNCT	O	O	2331
15	NUM	O	O	2331
and	CCONJ	O	O	2331
30	NUM	O	O	2331
mg	VERB	O	O	2331
/	PUNCT	O	O	2331
kg	VERB	O	O	2331
)	PUNCT	O	O	2331
;	PUNCT	O	O	2331
4	NUM	O	O	2331
,	PUNCT	O	O	2331
STZ	PROPN	O	Chemical	2331
;	PUNCT	O	O	2331
5	NUM	O	O	2331
and	CCONJ	O	O	2331
6	NUM	O	O	2331
,	PUNCT	O	O	2331
STZ	PROPN	O	Chemical	2331
+	ADP	O	O	2331
crocins	VERB	O	Chemical	2331
(	PUNCT	O	O	2331
15	NUM	O	O	2331
and	CCONJ	O	O	2331
30	NUM	O	O	2331
mg	VERB	O	O	2331
/	PUNCT	O	O	2331
kg	VERB	O	O	2331
)	PUNCT	O	O	2331
groups	NOUN	O	O	2331
.	PUNCT	O	O	2331
In	ADP	O	O	2332
Alzheimer	NOUN	O	Disease	2332
's	AUX	O	O	2332
disease	PROPN	O	O	2332
groups	NOUN	O	O	2332
,	PUNCT	O	O	2332
rats	NOUN	O	O	2332
were	AUX	O	O	2332
injected	VERB	O	O	2332
with	ADP	O	O	2332
STZ	PROPN	O	Chemical	2332
-	PUNCT	O	O	2332
icv	VERB	O	O	2332
bilaterally	ADV	O	O	2332
(	PUNCT	O	O	2332
3	X	O	O	2332
mg	VERB	O	O	2332
/	PUNCT	O	O	2332
kg	VERB	O	O	2332
)	PUNCT	O	O	2332
in	ADP	O	O	2332
first	ADV	O	O	2332
day	NOUN	O	O	2332
and	CCONJ	O	O	2332
3	X	O	O	2332
days	NOUN	O	O	2332
later	ADV	O	O	2332
,	PUNCT	O	O	2332
a	PRON	O	O	2332
similar	ADJ	O	O	2332
STZ	PROPN	O	Chemical	2332
-	PUNCT	O	O	2332
icv	VERB	O	O	2332
application	NOUN	O	O	2332
was	AUX	O	O	2332
repeated	VERB	O	O	2332
.	PUNCT	O	O	2332
In	ADP	O	O	2333
STZ	PROPN	O	Chemical	2333
+	ADP	O	O	2333
crocin	PROPN	O	Chemical	2333
animal	NOUN	O	O	2333
groups	NOUN	O	O	2333
,	PUNCT	O	O	2333
crocin	PROPN	O	Chemical	2333
was	AUX	O	O	2333
applied	VERB	O	O	2333
in	ADP	O	O	2333
doses	NOUN	O	O	2333
of	ADP	O	O	2333
15	NUM	O	O	2333
and	CCONJ	O	O	2333
30	NUM	O	O	2333
mg	VERB	O	O	2333
/	PUNCT	O	O	2333
kg	VERB	O	O	2333
,	PUNCT	O	O	2333
i.p	NOUN	O	O	2333
.	PUNCT	O	O	2333
Prescription	NOUN	O	O	2334
of	ADP	O	O	2334
crocin	PROPN	O	Chemical	2334
in	ADP	O	O	2334
each	PRON	O	O	2334
dose	NOUN	O	O	2334
was	AUX	O	O	2334
repeated	VERB	O	O	2334
once	ADV	O	O	2334
for	ADP	O	O	2334
two	NUM	O	O	2334
days	NOUN	O	O	2334
.	PUNCT	O	O	2334
It	PRON	O	O	2335
was	AUX	O	O	2335
found	VERB	O	O	2335
out	ADP	O	O	2335
that	SCONJ	O	O	2335
crocin	PROPN	O	Chemical	2335
(	PUNCT	O	O	2335
30	NUM	O	O	2335
mg	VERB	O	O	2335
/	PUNCT	O	O	2336
kg)-treated	VERB	O	O	2336
STZ	PROPN	O	Chemical	2336
-	PUNCT	O	O	2336
injected	VERB	O	O	2336
rats	NOUN	O	O	2336
show	VERB	O	O	2336
higher	ADJ	O	O	2336
correct	VERB	O	O	2336
choices	NOUN	O	O	2336
and	CCONJ	O	O	2336
lower	ADJ	O	O	2336
errors	NOUN	O	O	2336
in	ADP	O	O	2336
Y	NOUN	O	O	2336
-	PUNCT	O	O	2336
maze	NOUN	O	O	2336
than	ADP	O	O	2336
vehicle	NOUN	O	O	2336
-	PUNCT	O	O	2336
treated	VERB	O	O	2336
STZ	PROPN	O	Chemical	2336
-	PUNCT	O	O	2336
injected	VERB	O	O	2336
rats	NOUN	O	O	2336
.	PUNCT	O	O	2336
In	ADP	O	O	2337
addition	NOUN	O	O	2337
,	PUNCT	O	O	2337
crocin	PROPN	O	Chemical	2337
in	ADP	O	O	2337
the	PRON	O	O	2337
mentioned	VERB	O	O	2337
dose	NOUN	O	O	2337
could	AUX	O	O	2337
significantly	ADV	O	O	2337
attenuated	VERB	O	O	2337
learning	VERB	O	O	2337
and	CCONJ	O	O	2337
memory impairment	NOUN	O	Disease	2337
in	ADP	O	O	2337
treated	VERB	O	O	2337
STZ	PROPN	O	Chemical	2337
-	PUNCT	O	O	2337
injected	VERB	O	O	2337
group	NOUN	O	O	2337
in	ADP	O	O	2337
passive	ADJ	O	O	2337
avoidance	NOUN	O	O	2337
test	NOUN	O	O	2337
.	PUNCT	O	O	2337
Therefore	ADV	O	O	2338
,	PUNCT	O	O	2338
these	PRON	O	O	2338
results	VERB	O	O	2338
demonstrate	VERB	O	O	2338
the	PRON	O	O	2338
effectiveness	NOUN	O	O	2338
of	ADP	O	O	2338
crocin	PROPN	O	Chemical	2338
(	PUNCT	O	O	2338
30	NUM	O	O	2338
mg	VERB	O	O	2338
/	PUNCT	O	O	2338
kg	VERB	O	O	2338
)	PUNCT	O	O	2338
in	ADP	O	O	2338
antagonizing	VERB	O	O	2338
the	PRON	O	O	2338
cognitive deficits	NOUN	O	Disease	2338
caused	VERB	O	O	2338
by	ADP	O	O	2338
STZ	PROPN	O	Chemical	2338
-	PUNCT	O	O	2338
icv	VERB	O	O	2338
in	ADP	O	O	2338
rats	NOUN	O	O	2338
and	CCONJ	O	O	2338
its	PRON	O	O	2338
potential	ADJ	O	O	2338
in	ADP	O	O	2338
the	PRON	O	O	2338
treatment	NOUN	O	O	2338
of	ADP	O	O	2338
neurodegenerative diseases	NOUN	O	Disease	2338
such	ADJ	O	O	2338
as	ADP	O	O	2338
Alzheimer	NOUN	O	Disease	2338
's	AUX	O	O	2338
disease	PROPN	O	O	2338
.	PUNCT	O	O	2338
Rosaceiform	NOUN	O	O	2341
dermatitis	NOUN	O	Disease	2341
associated	VERB	O	O	2341
with	ADP	O	O	2341
topical	ADJ	O	O	2341
tacrolimus	NOUN	O	Chemical	2341
treatment	NOUN	O	O	2341
.	PUNCT	O	O	2341
We	PRON	O	O	2342
describe	VERB	O	O	2342
herein	VERB	O	O	2342
3	X	O	O	2342
patients	NOUN	O	O	2342
who	PRON	O	O	2342
developed	VERB	O	O	2342
rosacea	PROPN	O	Disease	2342
-	PUNCT	O	O	2342
like	INTJ	O	O	2342
dermatitis	NOUN	O	Disease	2342
eruptions	NOUN	O	Disease	2342
while	SCONJ	O	O	2342
using	VERB	O	O	2342
0.03%	NOUN	O	O	2342
or	CCONJ	O	O	2342
0.1%	NOUN	O	O	2342
tacrolimus	NOUN	O	Chemical	2342
ointment	NOUN	O	O	2342
for	ADP	O	O	2342
facial dermatitis	NOUN	O	Disease	2342
.	PUNCT	O	O	2342
Skin	NOUN	O	O	2343
biopsy	PROPN	O	O	2343
specimens	NOUN	O	O	2343
showed	VERB	O	O	2343
telangiectasia	NOUN	O	Disease	2343
and	CCONJ	O	O	2343
noncaseating	VERB	O	O	2343
epithelioid	NOUN	O	O	2343
granulomatous	ADJ	O	O	2343
tissue	NOUN	O	O	2343
formation	NOUN	O	O	2343
in	ADP	O	O	2343
the	PRON	O	O	2343
papillary	ADJ	O	O	2343
to	PART	O	O	2343
mid	PROPN	O	O	2343
dermis	ADV	O	O	2343
.	PUNCT	O	O	2343
Continuous	ADJ	O	O	2344
topical	ADJ	O	O	2344
use	VERB	O	O	2344
of	ADP	O	O	2344
immunomodulators	NOUN	O	O	2344
such	ADJ	O	O	2344
as	ADP	O	O	2344
tacrolimus	NOUN	O	Chemical	2344
or	CCONJ	O	O	2344
pimecrolimus	NOUN	O	Chemical	2344
should	AUX	O	O	2344
be	AUX	O	O	2344
regarded	VERB	O	O	2344
as	ADP	O	O	2344
a	PRON	O	O	2344
potential	ADJ	O	O	2344
cause	VERB	O	O	2344
of	ADP	O	O	2344
rosaceiform	NOUN	O	O	2344
dermatitis	NOUN	O	Disease	2344
,	PUNCT	O	O	2344
although	SCONJ	O	O	2344
many	ADJ	O	O	2344
cases	NOUN	O	O	2344
have	VERB	O	O	2344
not	PART	O	O	2344
been	AUX	O	O	2344
reported	VERB	O	O	2344
.	PUNCT	O	O	2344
poly	NOUN	O	O	2347
-	PUNCT	O	O	2347
L	NOUN	O	O	2347
-	PUNCT	O	O	2347
lactid	NOUN	O	O	2347
acid	PROPN	O	O	2347
nanoparticles	NOUN	O	O	2347
was	AUX	O	O	2347
used	VERB	O	O	2347
as	ADP	O	O	2347
a	PRON	O	O	2347
model	NOUN	O	O	2347
of	ADP	O	O	2347
colloidal	NOUN	O	O	2347
drug	NOUN	O	O	2347
delivery	NOUN	O	O	2347
system	NOUN	O	O	2347
,	PUNCT	O	O	2347
able	ADJ	O	O	2347
to	PART	O	O	2347
trespass	NOUN	O	O	2347
the	PRON	O	O	2347
BBB	PROPN	O	O	2347
.	PUNCT	O	O	2347
Tacrine	NOUN	O	Chemical	2348
,	PUNCT	O	O	2348
administered	VERB	O	O	2348
in	ADP	O	O	2348
LiCl	NOUN	O	Chemical	2348
pre	VERB	O	O	2348
-	PUNCT	O	O	2348
treated	VERB	O	O	2348
rats	NOUN	O	O	2348
,	PUNCT	O	O	2348
induces	VERB	O	O	2348
electrocorticographic	NOUN	O	O	2348
seizures	NOUN	O	Disease	2348
and	CCONJ	O	O	2348
delayed	VERB	O	O	2348
hippocampal damage	NOUN	O	Disease	2348
.	PUNCT	O	O	2348
The	PRON	O	O	2349
toxic	ADJ	O	O	2349
effects	NOUN	O	O	2349
of	ADP	O	O	2349
tacrine	NOUN	O	Chemical	2349
-	PUNCT	O	O	2349
loaded	VERB	O	O	2349
poly	NOUN	O	O	2349
-	PUNCT	O	O	2349
L	NOUN	O	O	2349
-	PUNCT	O	O	2349
lactid	NOUN	O	O	2349
acid	PROPN	O	O	2349
nanoparticles	NOUN	O	O	2349
(	PUNCT	O	O	2349
5mg	ADV	O	O	2349
/	PUNCT	O	O	2349
kg	VERB	O	O	2349
)	PUNCT	O	O	2349
,	PUNCT	O	O	2349
a	PRON	O	O	2349
saline	NOUN	O	O	2349
solution	NOUN	O	O	2349
of	ADP	O	O	2349
tacrine	NOUN	O	Chemical	2349
(	PUNCT	O	O	2349
5mg	ADV	O	O	2349
/	PUNCT	O	O	2349
kg	VERB	O	O	2349
)	PUNCT	O	O	2349
and	CCONJ	O	O	2349
an	PRON	O	O	2349
empty	ADJ	O	O	2349
colloidal	NOUN	O	O	2349
nanoparticle	PROPN	O	O	2349
suspension	NOUN	O	O	2349
were	AUX	O	O	2349
compared	VERB	O	O	2349
following	VERB	O	O	2349
i.p	NOUN	O	O	2349
.	PUNCT	O	O	2349
administration	NOUN	O	O	2350
in	ADP	O	O	2350
LiCl	NOUN	O	Chemical	2350
-	PUNCT	O	O	2350
pre	VERB	O	O	2350
-	PUNCT	O	O	2350
treated	VERB	O	O	2350
Wistar	PROPN	O	O	2350
rats	NOUN	O	O	2350
.	PUNCT	O	O	2350
All	PRON	O	O	2351
the	PRON	O	O	2351
animals	NOUN	O	O	2351
treated	VERB	O	O	2351
with	ADP	O	O	2351
tacrine	NOUN	O	Chemical	2351
-	PUNCT	O	O	2351
loaded	VERB	O	O	2351
nanoparticles	NOUN	O	O	2351
showed	VERB	O	O	2351
an	PRON	O	O	2351
earlier	ADV	O	O	2351
outcome	NOUN	O	O	2351
of	ADP	O	O	2351
CNS	PROPN	O	O	2351
adverse	ADJ	O	O	2351
symptoms	NOUN	O	O	2351
,	PUNCT	O	O	2351
i.e.	X	O	O	2351
epileptic	ADJ	O	Disease	2351
onset	VERB	O	O	2351
,	PUNCT	O	O	2351
with	ADP	O	O	2351
respect	VERB	O	O	2351
to	PART	O	O	2351
those	PRON	O	O	2351
animals	NOUN	O	O	2351
treated	VERB	O	O	2351
with	ADP	O	O	2351
the	PRON	O	O	2351
free	ADJ	O	O	2351
compound	NOUN	O	O	2351
(	PUNCT	O	O	2351
10	NUM	O	O	2351
min	NOUN	O	O	2351
vs.	CCONJ	O	O	2351
22	NUM	O	O	2351
min	NOUN	O	O	2351
respectively	ADV	O	O	2351
)	PUNCT	O	O	2351
.	PUNCT	O	O	2351
In	ADP	O	O	2352
addition	NOUN	O	O	2352
,	PUNCT	O	O	2352
tacrine	NOUN	O	Chemical	2352
-	PUNCT	O	O	2352
loaded	VERB	O	O	2352
nanoparticles	NOUN	O	O	2352
administration	NOUN	O	O	2352
induced	VERB	O	O	2352
damage of neuronal cells	NOUN	O	Disease	2352
in	ADP	O	O	2352
CA1	PROPN	O	O	2352
field	NOUN	O	O	2352
of	ADP	O	O	2352
the	PRON	O	O	2352
hippocampus	NOUN	O	O	2352
in	ADP	O	O	2352
all	PRON	O	O	2352
treated	VERB	O	O	2352
animals	NOUN	O	O	2352
,	PUNCT	O	O	2352
while	SCONJ	O	O	2352
the	PRON	O	O	2352
saline	NOUN	O	O	2352
solution	NOUN	O	O	2352
of	ADP	O	O	2352
tacrine	NOUN	O	Chemical	2352
only	ADV	O	O	2352
in	ADP	O	O	2352
60%	NOUN	O	O	2352
of	ADP	O	O	2352
animals	NOUN	O	O	2352
.	PUNCT	O	O	2352
In	ADP	O	O	2353
conclusion	NOUN	O	O	2353
,	PUNCT	O	O	2353
the	PRON	O	O	2353
evaluation	NOUN	O	O	2353
of	ADP	O	O	2353
time	NOUN	O	O	2353
-	PUNCT	O	O	2353
to	PART	O	O	2353
-	PUNCT	O	O	2353
onset	VERB	O	O	2353
of	ADP	O	O	2353
symptoms	NOUN	O	O	2353
and	CCONJ	O	O	2353
the	PRON	O	O	2353
severity	NOUN	O	O	2353
of	ADP	O	O	2353
neurodegenerative	ADV	O	O	2353
processes	NOUN	O	O	2353
induced	VERB	O	O	2353
by	ADP	O	O	2353
the	PRON	O	O	2353
tacrine	NOUN	O	Chemical	2353
-	PUNCT	O	O	2353
lithium	NOUN	O	Chemical	2353
model	NOUN	O	O	2353
of	ADP	O	O	2353
epilepsy	NOUN	O	Disease	2353
in	ADP	O	O	2353
the	PRON	O	O	2353
rat	NOUN	O	O	2353
,	PUNCT	O	O	2353
could	AUX	O	O	2353
be	AUX	O	O	2353
used	VERB	O	O	2353
to	PART	O	O	2353
evaluate	VERB	O	O	2353
preliminarily	ADV	O	O	2353
the	PRON	O	O	2353
capability	NOUN	O	O	2353
of	ADP	O	O	2353
a	PRON	O	O	2353
drug	NOUN	O	O	2353
delivery	NOUN	O	O	2353
system	NOUN	O	O	2353
to	PART	O	O	2353
trespass	NOUN	O	O	2353
(	PUNCT	O	O	2353
or	CCONJ	O	O	2353
not	PART	O	O	2353
)	PUNCT	O	O	2353
the	PRON	O	O	2353
BBB	PROPN	O	O	2353
in	ADP	O	O	2353
vivo	VERB	O	O	2353
.	PUNCT	O	O	2353
The	PRON	O	O	2356
antiarrhythmic	PROPN	O	O	2356
effect	VERB	O	O	2356
and	CCONJ	O	O	2356
possible	ADJ	O	O	2356
ionic	NOUN	O	O	2356
mechanisms	NOUN	O	O	2356
of	ADP	O	O	2356
pilocarpine	NOUN	O	Chemical	2356
on	ADP	O	O	2356
animal	NOUN	O	O	2356
models	NOUN	O	O	2356
.	PUNCT	O	O	2356
This	PRON	O	O	2357
study	VERB	O	O	2357
was	AUX	O	O	2357
designed	VERB	O	O	2357
to	PART	O	O	2357
evaluate	VERB	O	O	2357
the	PRON	O	O	2357
effects	NOUN	O	O	2357
of	ADP	O	O	2357
pilocarpine	NOUN	O	Chemical	2357
and	CCONJ	O	O	2357
explore	VERB	O	O	2357
the	PRON	O	O	2357
underlying	VERB	O	O	2357
ionic	NOUN	O	O	2357
mechanism	NOUN	O	O	2357
,	PUNCT	O	O	2357
using	VERB	O	O	2357
both	PRON	O	O	2357
aconitine	PROPN	O	Chemical	2357
-	PUNCT	O	O	2357
induced	VERB	O	O	2357
rat	NOUN	O	O	2357
and	CCONJ	O	O	2357
ouabain	PROPN	O	Chemical	2357
-	PUNCT	O	O	2357
induced	VERB	O	O	2357
guinea	NOUN	O	O	2357
pig	NOUN	O	O	2357
arrhythmia	NOUN	O	Disease	2357
models	NOUN	O	O	2357
.	PUNCT	O	O	2357
Confocal	PROPN	O	O	2358
microscopy	NOUN	O	O	2358
was	AUX	O	O	2358
used	VERB	O	O	2358
to	PART	O	O	2358
measure	VERB	O	O	2358
intracellular	ADJ	O	O	2358
free	ADJ	O	O	2358
-	PUNCT	O	O	2358
calcium	NOUN	O	Chemical	2358
concentrations	NOUN	O	O	2358
(	PUNCT	O	O	2358
[	X	O	O	2358
Ca(2+)](i	PROPN	O	O	2358
)	PUNCT	O	O	2358
)	PUNCT	O	O	2358
in	ADP	O	O	2358
isolated	VERB	O	O	2358
myocytes	NOUN	O	O	2358
.	PUNCT	O	O	2358
The	PRON	O	O	2359
current	ADJ	O	O	2359
data	NOUN	O	O	2359
showed	VERB	O	O	2359
that	SCONJ	O	O	2359
pilocarpine	NOUN	O	Chemical	2359
significantly	ADV	O	O	2359
delayed	VERB	O	O	2359
onset	VERB	O	O	2359
of	ADP	O	O	2359
arrhythmias	VERB	O	Disease	2359
,	PUNCT	O	O	2359
decreased	VERB	O	O	2359
the	PRON	O	O	2359
time	NOUN	O	O	2359
course	NOUN	O	O	2359
of	ADP	O	O	2359
ventricular tachycardia	NOUN	O	Disease	2359
and	CCONJ	O	O	2359
fibrillation	NOUN	O	O	2359
,	PUNCT	O	O	2359
reduced	VERB	O	O	2359
arrhythmia	NOUN	O	Disease	2359
score	VERB	O	O	2359
,	PUNCT	O	O	2359
and	CCONJ	O	O	2359
increased	VERB	O	O	2359
the	PRON	O	O	2359
survival	NOUN	O	O	2359
time	NOUN	O	O	2359
of	ADP	O	O	2359
arrhythmic	ADJ	O	Disease	2359
rats	NOUN	O	O	2359
and	CCONJ	O	O	2359
guinea	NOUN	O	O	2359
pigs	NOUN	O	O	2359
.	PUNCT	O	O	2359
[	X	O	O	2360
Ca(2+)](i	PROPN	O	O	2360
)	PUNCT	O	O	2360
overload	NOUN	O	O	2360
induced	VERB	O	O	2360
by	ADP	O	O	2360
aconitine	PROPN	O	Chemical	2360
or	CCONJ	O	O	2360
ouabain	PROPN	O	Chemical	2360
was	AUX	O	O	2360
reduced	VERB	O	O	2360
in	ADP	O	O	2360
isolated	VERB	O	O	2360
myocytes	NOUN	O	O	2360
pretreated	VERB	O	O	2360
with	ADP	O	O	2360
pilocarpine	NOUN	O	Chemical	2360
.	PUNCT	O	O	2360
Moreover	ADV	O	O	2361
,	PUNCT	O	O	2361
M(3)-muscarinic	X	O	O	2361
acetylcholine	NOUN	O	Chemical	2361
receptor	NOUN	O	O	2361
(	PUNCT	O	O	2361
mAChR	NOUN	O	O	2361
)	PUNCT	O	O	2361
antagonist	NOUN	O	O	2362
4-DAMP	ADJ	O	Chemical	2362
(	PUNCT	O	O	2362
4-diphenylacetoxy	ADJ	O	O	2362
-	PUNCT	O	O	2362
N	NUM	O	O	2362
-	PUNCT	O	O	2362
methylpiperidine	PROPN	O	O	2362
-	PUNCT	O	O	2362
methiodide	NOUN	O	O	2362
)	PUNCT	O	O	2362
partially	ADV	O	O	2362
abolished	VERB	O	O	2362
the	PRON	O	O	2362
beneficial	ADJ	O	O	2362
effects	NOUN	O	O	2362
of	ADP	O	O	2362
pilocarpine	NOUN	O	Chemical	2362
.	PUNCT	O	O	2362
These	PRON	O	O	2363
data	NOUN	O	O	2363
suggest	VERB	O	O	2363
that	SCONJ	O	O	2363
pilocarpine	NOUN	O	Chemical	2363
produced	VERB	O	O	2363
antiarrhythmic	PROPN	O	O	2363
actions	NOUN	O	O	2363
on	ADP	O	O	2363
arrhythmic	ADJ	O	Disease	2363
rat	NOUN	O	O	2363
and	CCONJ	O	O	2363
guinea	NOUN	O	O	2363
pig	NOUN	O	O	2363
models	NOUN	O	O	2363
induced	VERB	O	O	2363
by	ADP	O	O	2363
aconitine	PROPN	O	Chemical	2363
or	CCONJ	O	O	2363
ouabain	PROPN	O	Chemical	2363
via	ADP	O	O	2363
stimulating	VERB	O	O	2363
the	PRON	O	O	2363
cardiac	ADJ	O	O	2363
M(3)-mAChR.	NOUN	O	O	2363
The	PRON	O	O	2363
mechanism	NOUN	O	O	2363
may	AUX	O	O	2363
be	AUX	O	O	2363
related	ADJ	O	O	2363
to	PART	O	O	2363
the	PRON	O	O	2363
improvement	NOUN	O	O	2363
of	ADP	O	O	2363
Ca(2	PROPN	O	O	2363
+	ADP	O	O	2363
)	PUNCT	O	O	2363
handling	VERB	O	O	2363
.	PUNCT	O	O	2363
Disulfiram	PROPN	O	Chemical	2366
-	PUNCT	O	O	2366
induced	VERB	O	O	2366
transient	ADJ	O	O	2366
optic	NOUN	O	O	2366
and	CCONJ	O	O	2366
peripheral neuropathy	NOUN	O	Disease	2366
:	PUNCT	O	O	2366
a	PRON	O	O	2366
case	NOUN	O	O	2366
report	VERB	O	O	2366
.	PUNCT	O	O	2366
AIM	VERB	O	O	2367
:	PUNCT	O	O	2367
To	PART	O	O	2367
report	VERB	O	O	2367
a	PRON	O	O	2367
case	NOUN	O	O	2367
of	ADP	O	O	2367
optic	NOUN	O	O	2367
and	CCONJ	O	O	2367
peripheral neuropathy	NOUN	O	Disease	2367
after	ADP	O	O	2367
chronic	ADJ	O	O	2367
use	VERB	O	O	2367
of	ADP	O	O	2367
disulfiram	PROPN	O	Chemical	2367
for	ADP	O	O	2367
alcohol dependence	NOUN	O	Disease	2367
management	NOUN	O	O	2367
.	PUNCT	O	O	2367
A	PRON	O	O	2368
57-year	NOUN	O	O	2368
-	PUNCT	O	O	2368
old	ADJ	O	O	2368
male	NOUN	O	O	2368
presented	VERB	O	O	2368
with	ADP	O	O	2368
gradual	ADJ	O	O	2368
loss of vision	NOUN	O	Disease	2368
in	ADP	O	O	2368
both	PRON	O	O	2368
eyes	NOUN	O	O	2368
with	ADP	O	O	2368
intermittent	ADJ	O	O	2368
headaches	NOUN	O	Disease	2368
for	ADP	O	O	2368
2	X	O	O	2368
months	NOUN	O	O	2368
.	PUNCT	O	O	2368
He	PRON	O	O	2369
also	ADV	O	O	2369
complained	VERB	O	O	2369
of	ADP	O	O	2369
paraesthesia	ADV	O	Disease	2369
with	ADP	O	O	2369
numbness	NOUN	O	Disease	2369
in	ADP	O	O	2369
both	PRON	O	O	2369
feet	NOUN	O	O	2369
.	PUNCT	O	O	2369
Visual	ADJ	O	O	2370
field	NOUN	O	O	2370
testing	NOUN	O	O	2370
confirmed	VERB	O	O	2370
bilateral	ADJ	O	O	2370
central	ADJ	O	O	2370
-	PUNCT	O	O	2370
caecal	ADJ	O	O	2370
scotomata	NOUN	O	Disease	2370
.	PUNCT	O	O	2370
He	PRON	O	O	2371
had	VERB	O	O	2371
been	AUX	O	O	2371
taking	VERB	O	O	2371
disulfiram	PROPN	O	Chemical	2371
for	ADP	O	O	2371
alcohol dependence	NOUN	O	Disease	2371
for	ADP	O	O	2371
the	PRON	O	O	2371
preceding	VERB	O	O	2371
3	X	O	O	2371
years	NOUN	O	O	2371
.	PUNCT	O	O	2371
Disulfiram	PROPN	O	Chemical	2372
discontinuation	NOUN	O	O	2372
lead	VERB	O	Chemical	2372
to	PART	O	O	2372
an	PRON	O	O	2372
immediate	ADJ	O	O	2372
symptomatic	ADJ	O	O	2372
improvement	NOUN	O	O	2372
.	PUNCT	O	O	2372
Physicians	NOUN	O	O	2373
initiating	VERB	O	O	2373
long	ADV	O	O	2373
-	PUNCT	O	O	2373
term	NOUN	O	O	2373
disulfiram	PROPN	O	Chemical	2373
therapy	NOUN	O	O	2373
should	AUX	O	O	2373
be	AUX	O	O	2373
aware	ADJ	O	O	2373
of	ADP	O	O	2373
these	PRON	O	O	2373
adverse	ADJ	O	O	2373
effects	NOUN	O	O	2373
.	PUNCT	O	O	2373
Sustained	VERB	O	O	2376
clinical	ADJ	O	O	2376
improvement	NOUN	O	O	2376
of	ADP	O	O	2376
a	PRON	O	O	2376
patient	NOUN	O	O	2376
with	ADP	O	O	2376
decompensated	VERB	O	O	2376
hepatitis B	PROPN	O	Disease	2376
virus	NOUN	O	O	2376
-	PUNCT	O	O	2376
related	ADJ	O	O	2376
cirrhosis	NOUN	O	Disease	2376
after	ADP	O	O	2376
treatment	NOUN	O	O	2376
with	ADP	O	O	2376
lamivudine	NOUN	O	Chemical	2376
monotherapy	X	O	O	2376
.	PUNCT	O	O	2376
Hepatitis B	PROPN	O	Disease	2377
virus	NOUN	O	O	2377
(	PUNCT	O	O	2377
HBV	NOUN	O	O	2377
)	PUNCT	O	O	2377
infection	NOUN	O	Disease	2377
,	PUNCT	O	O	2377
which	PRON	O	O	2377
causes	VERB	O	O	2377
liver cirrhosis	NOUN	O	Disease	2377
and	CCONJ	O	O	2377
hepatocellular carcinoma	NOUN	O	Disease	2377
,	PUNCT	O	O	2377
remains	VERB	O	O	2377
a	PRON	O	O	2377
major	ADJ	O	O	2377
health	NOUN	O	O	2377
problem	NOUN	O	O	2377
in	ADP	O	O	2377
Asian	ADJ	O	O	2377
countries	NOUN	O	O	2377
.	PUNCT	O	O	2377
In	ADP	O	O	2378
this	PRON	O	O	2378
report	VERB	O	O	2378
,	PUNCT	O	O	2378
we	PRON	O	O	2378
encountered	VERB	O	O	2378
a	PRON	O	O	2378
patient	NOUN	O	O	2378
with	ADP	O	O	2378
decompensated	VERB	O	O	2378
HBV	NOUN	O	O	2378
-	PUNCT	O	O	2378
related	ADJ	O	O	2378
cirrhosis	NOUN	O	Disease	2378
who	PRON	O	O	2378
exhibited	VERB	O	O	2378
the	PRON	O	O	2378
dramatic	ADJ	O	O	2378
improvements	NOUN	O	O	2378
after	ADP	O	O	2378
antiviral	ADJ	O	O	2378
therapy	NOUN	O	O	2378
.	PUNCT	O	O	2378
However	ADV	O	O	2379
,	PUNCT	O	O	2379
the	PRON	O	O	2379
administration	NOUN	O	O	2379
of	ADP	O	O	2379
lamivudine	NOUN	O	Chemical	2379
,	PUNCT	O	O	2379
a	PRON	O	O	2379
reverse	VERB	O	O	2379
transcriptase	VERB	O	O	2379
inhibitor	NOUN	O	O	2379
,	PUNCT	O	O	2379
for	ADP	O	O	2379
23	NUM	O	O	2379
months	NOUN	O	O	2379
dramatically	ADV	O	O	2379
improved	VERB	O	O	2379
her	PRON	O	O	2379
liver	NOUN	O	O	2379
severity	NOUN	O	O	2379
.	PUNCT	O	O	2379
Moreover	ADV	O	O	2380
,	PUNCT	O	O	2380
both	PRON	O	O	2380
hepatitis B surface antigen	NOUN	O	Chemical	2380
and	CCONJ	O	O	2380
e	X	O	O	2380
antigen	PROPN	O	O	2380
were	AUX	O	O	2380
observed	VERB	O	O	2380
to	PART	O	O	2380
have	VERB	O	O	2380
disappeared	VERB	O	O	2380
in	ADP	O	O	2380
this	PRON	O	O	2380
patient	NOUN	O	O	2380
.	PUNCT	O	O	2380
The	PRON	O	O	2381
administration	NOUN	O	O	2381
of	ADP	O	O	2381
lamivudine	NOUN	O	Chemical	2381
to	PART	O	O	2381
patients	NOUN	O	O	2381
with	ADP	O	O	2381
HBV	NOUN	O	O	2381
-	PUNCT	O	O	2381
related	ADJ	O	O	2381
cirrhosis	NOUN	O	Disease	2381
,	PUNCT	O	O	2381
like	INTJ	O	O	2381
our	PRON	O	O	2381
present	NOUN	O	O	2381
case	NOUN	O	O	2381
,	PUNCT	O	O	2381
should	AUX	O	O	2381
be	AUX	O	O	2381
considered	VERB	O	O	2381
as	ADP	O	O	2381
an	PRON	O	O	2381
initial	ADJ	O	O	2381
medical	ADJ	O	O	2381
therapeutic	ADJ	O	O	2381
option	NOUN	O	O	2381
,	PUNCT	O	O	2381
especially	ADV	O	O	2381
in	ADP	O	O	2381
countries	NOUN	O	O	2381
where	SCONJ	O	O	2381
liver	NOUN	O	O	2381
transplantation	NOUN	O	O	2381
is	AUX	O	O	2381
not	PART	O	O	2381
reliably	ADV	O	O	2381
available	ADJ	O	O	2381
.	PUNCT	O	O	2381
Dual	ADJ	O	O	2384
effects	NOUN	O	O	2384
of	ADP	O	O	2384
melatonin	PROPN	O	Chemical	2384
on	ADP	O	O	2384
barbiturate	NOUN	O	Chemical	2384
-	PUNCT	O	O	2384
induced	VERB	O	O	2384
narcosis	NOUN	O	Disease	2384
in	ADP	O	O	2384
rats	NOUN	O	O	2384
.	PUNCT	O	O	2384
Melatonin	PROPN	O	Chemical	2385
affects	VERB	O	O	2385
the	PRON	O	O	2385
circadian	ADJ	O	O	2385
sleep	VERB	O	O	2385
/	PUNCT	O	O	2385
wake	VERB	O	O	2385
cycle	PROPN	O	O	2385
,	PUNCT	O	O	2385
but	CCONJ	O	O	2385
it	PRON	O	O	2385
is	AUX	O	O	2385
not	PART	O	O	2385
clear	ADJ	O	O	2385
whether	SCONJ	O	O	2385
it	PRON	O	O	2385
may	AUX	O	O	2385
influence	NOUN	O	O	2385
drug	NOUN	O	O	2385
-	PUNCT	O	O	2385
induced	VERB	O	O	2385
narcosis	NOUN	O	Disease	2385
.	PUNCT	O	O	2385
Sodium thiopenthal	NOUN	O	Chemical	2386
was	AUX	O	O	2386
administered	VERB	O	O	2386
intraperitoneally	ADV	O	O	2386
into	ADP	O	O	2386
male	NOUN	O	O	2386
rats	NOUN	O	O	2386
pre	VERB	O	O	2386
-	PUNCT	O	O	2386
treated	VERB	O	O	2386
with	ADP	O	O	2386
melatonin	PROPN	O	Chemical	2386
(	PUNCT	O	O	2386
0.05	NUM	O	O	2386
,	PUNCT	O	O	2386
0.5	NUM	O	O	2386
,	PUNCT	O	O	2386
5	NUM	O	O	2386
and	CCONJ	O	O	2386
50	NUM	O	O	2386
mg	VERB	O	O	2386
/	PUNCT	O	O	2386
kg	VERB	O	O	2386
)	PUNCT	O	O	2386
.	PUNCT	O	O	2386
Melatonin	PROPN	O	Chemical	2387
pre	VERB	O	O	2387
-	PUNCT	O	O	2387
treatment	NOUN	O	O	2387
affected	VERB	O	O	2387
in	ADP	O	O	2387
a	PRON	O	O	2387
dual	ADJ	O	O	2387
manner	VERB	O	O	2387
barbiturate	NOUN	O	Chemical	2387
narcosis	NOUN	O	Disease	2387
,	PUNCT	O	O	2387
however	ADV	O	O	2387
,	PUNCT	O	O	2387
no	PRON	O	O	2387
dose	NOUN	O	O	2387
-	PUNCT	O	O	2387
effect	VERB	O	O	2387
correlation	NOUN	O	O	2387
was	AUX	O	O	2387
found	VERB	O	O	2387
.	PUNCT	O	O	2387
In	ADP	O	O	2388
particular	ADJ	O	O	2388
,	PUNCT	O	O	2388
low	ADJ	O	O	2388
doses	NOUN	O	O	2388
reduced	VERB	O	O	2388
the	PRON	O	O	2388
latency	VERB	O	O	2388
to	PART	O	O	2388
and	CCONJ	O	O	2388
prolonged	VERB	O	O	2388
the	PRON	O	O	2388
duration	NOUN	O	O	2388
of	ADP	O	O	2388
barbiturate	NOUN	O	Chemical	2388
narcosis	NOUN	O	Disease	2388
.	PUNCT	O	O	2388
In	ADP	O	O	2389
contrast	NOUN	O	O	2389
,	PUNCT	O	O	2389
the	PRON	O	O	2389
highest	ADJ	O	O	2389
dose	NOUN	O	O	2389
of	ADP	O	O	2389
melatonin	PROPN	O	Chemical	2389
(	PUNCT	O	O	2389
50	NUM	O	O	2389
mg	VERB	O	O	2389
/	PUNCT	O	O	2389
kg	VERB	O	O	2389
)	PUNCT	O	O	2389
caused	VERB	O	O	2389
a	PRON	O	O	2389
paradoxical	ADJ	O	O	2389
increase	VERB	O	O	2389
in	ADP	O	O	2389
the	PRON	O	O	2389
latency	VERB	O	O	2389
and	CCONJ	O	O	2389
produced	VERB	O	O	2389
a	PRON	O	O	2389
sustained	VERB	O	O	2389
reduction	NOUN	O	O	2389
of	ADP	O	O	2389
the	PRON	O	O	2389
duration	NOUN	O	O	2389
of	ADP	O	O	2389
narcosis	NOUN	O	Disease	2389
,	PUNCT	O	O	2389
and	CCONJ	O	O	2389
a	PRON	O	O	2389
reduction	NOUN	O	O	2389
in	ADP	O	O	2389
mortality	NOUN	O	O	2389
rate	NOUN	O	O	2389
.	PUNCT	O	O	2389
Melatonin	PROPN	O	Chemical	2390
0.5	NUM	O	O	2390
and	CCONJ	O	O	2390
5	NUM	O	O	2390
mg	VERB	O	O	2390
/	PUNCT	O	O	2390
kg	VERB	O	O	2390
influenced	VERB	O	O	2390
the	PRON	O	O	2390
duration	NOUN	O	O	2390
but	CCONJ	O	O	2390
not	PART	O	O	2390
the	PRON	O	O	2390
latency	VERB	O	O	2390
of	ADP	O	O	2390
ketamine-	PROPN	O	O	2390
or	CCONJ	O	O	2390
diazepam	NOUN	O	Chemical	2390
-	PUNCT	O	O	2390
induced	VERB	O	O	2390
narcosis	NOUN	O	Disease	2390
.	PUNCT	O	O	2390
Thus	ADV	O	O	2391
,	PUNCT	O	O	2391
the	PRON	O	O	2391
dual	ADJ	O	O	2391
action	NOUN	O	O	2391
of	ADP	O	O	2391
melatonin	PROPN	O	Chemical	2391
on	ADP	O	O	2391
pharmacological	ADJ	O	O	2391
narcosis	NOUN	O	Disease	2391
seems	VERB	O	O	2391
to	PART	O	O	2391
be	AUX	O	O	2391
specific	ADJ	O	O	2391
for	ADP	O	O	2391
the	PRON	O	O	2391
barbiturate	NOUN	O	Chemical	2391
mechanism	NOUN	O	O	2391
of	ADP	O	O	2391
action	NOUN	O	O	2391
.	PUNCT	O	O	2391
Effects	NOUN	O	O	2394
of	ADP	O	O	2394
NIK-247	NOUN	O	Chemical	2394
on	ADP	O	O	2394
cholinesterase	NOUN	O	O	2394
and	CCONJ	O	O	2394
scopolamine	NOUN	O	Chemical	2394
-	PUNCT	O	O	2394
induced	VERB	O	O	2394
amnesia	NOUN	O	Disease	2394
.	PUNCT	O	O	2394
The	PRON	O	O	2395
effects	NOUN	O	O	2395
of	ADP	O	O	2395
NIK-247	NOUN	O	Chemical	2395
on	ADP	O	O	2395
cholinesterase	NOUN	O	O	2395
,	PUNCT	O	O	2395
scopolamine	NOUN	O	Chemical	2395
-	PUNCT	O	O	2395
induced	VERB	O	O	2395
amnesia	NOUN	O	Disease	2395
and	CCONJ	O	O	2395
spontaneous	ADJ	O	O	2395
movement	NOUN	O	O	2395
were	AUX	O	O	2395
examined	VERB	O	O	2395
and	CCONJ	O	O	2395
compared	VERB	O	O	2395
with	ADP	O	O	2395
those	PRON	O	O	2395
of	ADP	O	O	2395
the	PRON	O	O	2395
well	ADV	O	O	2395
-	PUNCT	O	O	2395
known	VERB	O	O	2395
cholinesterase	NOUN	O	O	2395
inhibitors	NOUN	O	O	2395
tacrine	NOUN	O	Chemical	2395
and	CCONJ	O	O	2395
E-2020	NOUN	O	Chemical	2395
.	PUNCT	O	O	2395
NIK-247	NOUN	O	Chemical	2396
,	PUNCT	O	O	2396
tacrine	NOUN	O	Chemical	2396
and	CCONJ	O	O	2396
E-2020	NOUN	O	Chemical	2396
all	PRON	O	O	2396
strongly	ADV	O	O	2396
inhibited	VERB	O	O	2396
acetylcholinesterase	NOUN	O	O	2396
(	PUNCT	O	O	2396
AChE	PROPN	O	O	2396
)	PUNCT	O	O	2396
in	ADP	O	O	2396
human	PROPN	O	O	2396
red	ADJ	O	O	2396
blood	NOUN	O	O	2396
cells	NOUN	O	O	2396
(	PUNCT	O	O	2396
IC50s	PROPN	O	O	2396
=	PUNCT	O	O	2396
1.0	NUM	O	O	2396
x	X	O	O	2396
10(-6	NUM	O	O	2396
)	PUNCT	O	O	2396
,	PUNCT	O	O	2396
2.9	NUM	O	O	2396
x	X	O	O	2396
10(-7	NUM	O	O	2396
)	PUNCT	O	O	2396
and	CCONJ	O	O	2396
3.7	NUM	O	O	2396
x	X	O	O	2396
10(-8	NOUN	O	O	2396
)	PUNCT	O	O	2396
In	ADP	O	O	2397
addition	NOUN	O	O	2397
,	PUNCT	O	O	2397
NIK-247	NOUN	O	Chemical	2397
and	CCONJ	O	O	2397
tacrine	NOUN	O	Chemical	2397
,	PUNCT	O	O	2397
but	CCONJ	O	O	2397
not	PART	O	O	2397
E-2020	NOUN	O	Chemical	2397
,	PUNCT	O	O	2397
strongly	ADV	O	O	2397
inhibited	VERB	O	O	2397
butyrylcholinestrase	NOUN	O	O	2397
(	PUNCT	O	O	2397
BuChE	PROPN	O	O	2397
)	PUNCT	O	O	2397
Moreover	ADV	O	O	2398
,	PUNCT	O	O	2398
the	PRON	O	O	2398
inhibitory	ADJ	O	O	2398
effect	VERB	O	O	2398
of	ADP	O	O	2398
NIK-247	NOUN	O	Chemical	2398
on	ADP	O	O	2398
AChE	PROPN	O	O	2398
was	AUX	O	O	2398
reversible	ADJ	O	O	2398
.	PUNCT	O	O	2398
significantly	ADV	O	O	2399
improved	VERB	O	O	2399
the	PRON	O	O	2399
amnesia	NOUN	O	Disease	2399
induced	VERB	O	O	2399
by	ADP	O	O	2399
scopolamine	NOUN	O	Chemical	2399
(	PUNCT	O	O	2399
0.5	NUM	O	O	2399
mg	VERB	O	O	2399
/	PUNCT	O	O	2399
kg	VERB	O	O	2399
s.c	PROPN	O	O	2399
.	PUNCT	O	O	2399
)	PUNCT	O	O	2399
These	PRON	O	O	2400
findings	NOUN	O	O	2400
suggest	VERB	O	O	2400
that	SCONJ	O	O	2400
NIK-247	NOUN	O	Chemical	2400
at	ADP	O	O	2400
a	PRON	O	O	2400
low	ADJ	O	O	2400
dose	NOUN	O	O	2400
(	PUNCT	O	O	2400
0.1	NUM	O	O	2400
-	PUNCT	O	O	2400
1	X	O	O	2400
mg	VERB	O	O	2400
/	PUNCT	O	O	2400
kg	VERB	O	O	2400
p.o	PROPN	O	O	2400
.	PUNCT	O	O	2400
)	PUNCT	O	O	2400
improves	VERB	O	O	2401
scopolamine	NOUN	O	Chemical	2401
-	PUNCT	O	O	2401
induced	VERB	O	O	2401
amnesia	NOUN	O	Disease	2401
but	CCONJ	O	O	2401
does	VERB	O	O	2401
not	PART	O	O	2401
affect	VERB	O	O	2401
spontaneous	ADJ	O	O	2401
movement	NOUN	O	O	2401
.	PUNCT	O	O	2401
The	PRON	O	O	2402
findings	NOUN	O	O	2402
suggest	VERB	O	O	2402
that	SCONJ	O	O	2402
NIK-247	NOUN	O	Chemical	2402
may	AUX	O	O	2402
be	AUX	O	O	2402
a	PRON	O	O	2402
useful	ADJ	O	O	2402
drug	NOUN	O	O	2402
for	ADP	O	O	2402
the	PRON	O	O	2402
treatment	NOUN	O	O	2402
of	ADP	O	O	2402
Alzheimer	NOUN	O	Disease	2402
's	AUX	O	O	2402
disease	PROPN	O	O	2402
.	PUNCT	O	O	2402
Nightmares	NOUN	O	O	2405
and	CCONJ	O	O	2405
hallucinations	NOUN	O	Disease	2405
after	ADP	O	O	2405
long	ADV	O	O	2405
-	PUNCT	O	O	2405
term	NOUN	O	O	2405
intake	PROPN	O	O	2405
of	ADP	O	O	2405
tramadol	PROPN	O	Chemical	2405
combined	VERB	O	O	2405
with	ADP	O	O	2405
antidepressants	NOUN	O	O	2405
.	PUNCT	O	O	2405
Tramadol	PROPN	O	Chemical	2406
is	AUX	O	O	2406
a	PRON	O	O	2406
weak	ADJ	O	O	2406
opioid	NOUN	O	O	2406
with	ADP	O	O	2406
effects	NOUN	O	O	2406
on	ADP	O	O	2406
adrenergic	NOUN	O	O	2406
and	CCONJ	O	O	2406
serotonergic	ADJ	O	O	2406
neurotransmission	NOUN	O	O	2406
that	SCONJ	O	O	2406
is	AUX	O	O	2406
used	VERB	O	O	2406
to	PART	O	O	2406
treat	VERB	O	O	2406
cancer	NOUN	O	Disease	2406
pain	NOUN	O	Disease	2406
and	CCONJ	O	O	2406
chronic	ADJ	O	O	2406
non	ADJ	O	O	2406
malignant	ADJ	O	O	2406
pain	NOUN	O	Disease	2406
.	PUNCT	O	O	2406
This	PRON	O	O	2407
drug	NOUN	O	O	2407
was	AUX	O	O	2407
initiated	VERB	O	O	2407
in	ADP	O	O	2407
association	PROPN	O	O	2407
with	ADP	O	O	2407
paroxetine	NOUN	O	Chemical	2407
and	CCONJ	O	O	2407
dosulepine hydrochloride	NOUN	O	Chemical	2407
in	ADP	O	O	2407
a	PRON	O	O	2407
tetraparetic	NOUN	O	Disease	2407
patient	NOUN	O	O	2407
with	ADP	O	O	2407
chronic pain	NOUN	O	Disease	2407
.	PUNCT	O	O	2407
Fifty	NUM	O	O	2408
-	PUNCT	O	O	2408
six	NUM	O	O	2408
days	NOUN	O	O	2408
after	ADP	O	O	2408
initiation	NOUN	O	O	2408
of	ADP	O	O	2408
the	PRON	O	O	2408
treatment	NOUN	O	O	2408
the	PRON	O	O	2408
patient	NOUN	O	O	2408
presented	VERB	O	O	2408
hallucinations	NOUN	O	Disease	2408
that	SCONJ	O	O	2408
only	ADV	O	O	2408
stopped	VERB	O	O	2408
after	ADP	O	O	2408
the	PRON	O	O	2408
withdrawal	NOUN	O	O	2408
of	ADP	O	O	2408
psycho	NOUN	O	O	2408
-	PUNCT	O	O	2408
active	ADJ	O	O	2408
drugs	NOUN	O	O	2408
and	CCONJ	O	O	2408
tramadol	PROPN	O	Chemical	2408
.	PUNCT	O	O	2408
The	PRON	O	O	2409
case	NOUN	O	O	2409
report	VERB	O	O	2409
questions	NOUN	O	O	2409
the	PRON	O	O	2409
long	ADV	O	O	2409
term	NOUN	O	O	2409
use	VERB	O	O	2409
of	ADP	O	O	2409
pain	NOUN	O	Disease	2409
killers	NOUN	O	O	2409
combined	VERB	O	O	2409
with	ADP	O	O	2409
psycho	NOUN	O	O	2409
-	PUNCT	O	O	2409
active	ADJ	O	O	2409
drugs	NOUN	O	O	2409
in	ADP	O	O	2409
chronic	ADJ	O	O	2409
non	ADJ	O	O	2409
malignant	ADJ	O	O	2409
pain	NOUN	O	Disease	2409
,	PUNCT	O	O	2409
especially	ADV	O	O	2409
if	SCONJ	O	O	2409
pain	NOUN	O	Disease	2409
is	AUX	O	O	2409
under	ADP	O	O	2409
control	VERB	O	O	2409
.	PUNCT	O	O	2409
Apparent	ADJ	O	O	2412
cure	VERB	O	O	2412
of	ADP	O	O	2412
rheumatoid arthritis	NOUN	O	Disease	2412
by	ADP	O	O	2412
bone	NOUN	O	O	2412
marrow	PROPN	O	O	2412
transplantation	NOUN	O	O	2412
.	PUNCT	O	O	2412
We	PRON	O	O	2413
describe	VERB	O	O	2413
the	PRON	O	O	2413
induction	NOUN	O	O	2413
of	ADP	O	O	2413
sustained	VERB	O	O	2413
remissions	NOUN	O	O	2413
and	CCONJ	O	O	2413
possible	ADJ	O	O	2413
cure	VERB	O	O	2413
of	ADP	O	O	2413
severe	ADJ	O	O	2413
erosive	ADJ	O	O	2413
rheumatoid arthritis	NOUN	O	Disease	2413
(	PUNCT	O	O	2413
RA	PROPN	O	Disease	2413
)	PUNCT	O	O	2413
by	ADP	O	O	2413
bone	NOUN	O	O	2413
marrow	PROPN	O	O	2413
transplantation	NOUN	O	O	2413
(	PUNCT	O	O	2413
BMT	PROPN	O	O	2413
)	PUNCT	O	O	2413
in	ADP	O	O	2413
2	X	O	O	2413
patients	NOUN	O	O	2413
.	PUNCT	O	O	2413
BMT	PROPN	O	O	2414
was	AUX	O	O	2414
used	VERB	O	O	2414
to	PART	O	O	2414
treat	VERB	O	O	2414
severe	ADJ	O	O	2414
aplastic anemia	NOUN	O	Disease	2414
which	PRON	O	O	2414
was	AUX	O	O	2414
caused	VERB	O	O	2414
by	ADP	O	O	2414
gold	NOUN	O	Chemical	2414
in	ADP	O	O	2414
one	NUM	O	O	2414
case	NOUN	O	O	2414
and	CCONJ	O	O	2414
D	NOUN	O	O	2414
-	PUNCT	O	O	2414
penicillamine	NOUN	O	Chemical	2414
in	ADP	O	O	2414
the	PRON	O	O	2414
other	ADJ	O	O	2414
.	PUNCT	O	O	2414
In	ADP	O	O	2415
the	PRON	O	O	2415
8	NUM	O	O	2415
and	CCONJ	O	O	2415
6	NUM	O	O	2415
years	NOUN	O	O	2415
since	SCONJ	O	O	2415
the	PRON	O	O	2415
transplants	NOUN	O	O	2415
(	PUNCT	O	O	2415
representing	VERB	O	O	2415
8	NUM	O	O	2415
and	CCONJ	O	O	2415
4	NUM	O	O	2415
years	NOUN	O	O	2415
since	SCONJ	O	O	2415
cessation	NOUN	O	O	2415
of	ADP	O	O	2415
all	PRON	O	O	2415
immunosuppressive	ADJ	O	O	2415
therapy	NOUN	O	O	2415
,	PUNCT	O	O	2415
respectively	ADV	O	O	2415
)	PUNCT	O	O	2415
,	PUNCT	O	O	2415
the	PRON	O	O	2415
RA	PROPN	O	Disease	2415
in	ADP	O	O	2415
each	PRON	O	O	2415
case	NOUN	O	O	2415
has	VERB	O	O	2415
been	AUX	O	O	2415
completely	ADV	O	O	2415
quiescent	ADJ	O	O	2415
.	PUNCT	O	O	2415
Although	SCONJ	O	O	2416
short	ADJ	O	O	2416
term	NOUN	O	O	2416
remission	NOUN	O	O	2416
of	ADP	O	O	2416
severe	ADJ	O	O	2416
RA	PROPN	O	Disease	2416
following	VERB	O	O	2416
BMT	PROPN	O	O	2416
has	VERB	O	O	2416
been	AUX	O	O	2416
reported	VERB	O	O	2416
,	PUNCT	O	O	2416
these	PRON	O	O	2416
are	AUX	O	O	2416
the	PRON	O	O	2416
first	ADV	O	O	2416
cases	NOUN	O	O	2416
for	ADP	O	O	2416
which	PRON	O	O	2416
prolonged	VERB	O	O	2416
followup	NOUN	O	O	2416
has	VERB	O	O	2416
been	AUX	O	O	2416
available	ADJ	O	O	2416
.	PUNCT	O	O	2416
This	PRON	O	O	2417
experience	NOUN	O	O	2417
raises	VERB	O	O	2417
the	PRON	O	O	2417
question	NOUN	O	O	2417
of	ADP	O	O	2417
the	PRON	O	O	2417
role	NOUN	O	O	2417
of	ADP	O	O	2417
BMT	PROPN	O	O	2417
itself	PRON	O	O	2417
as	ADP	O	O	2417
a	PRON	O	O	2417
therapeutic	ADJ	O	O	2417
option	NOUN	O	O	2417
for	ADP	O	O	2417
patients	NOUN	O	O	2417
with	ADP	O	O	2417
uncontrolled	ADJ	O	O	2417
destructive	ADJ	O	O	2417
synovitis	NOUN	O	Disease	2417
.	PUNCT	O	O	2417
Urinary	NOUN	O	O	2420
enzymes	NOUN	O	O	2420
and	CCONJ	O	O	2420
protein	NOUN	O	O	2420
patterns	NOUN	O	O	2420
as	ADP	O	O	2420
indicators	NOUN	O	O	2420
of	ADP	O	O	2420
injury to different regions of the kidney	NOUN	O	Disease	2420
.	PUNCT	O	O	2420
Acute	PROPN	O	O	2421
experimental	ADJ	O	O	2421
models	NOUN	O	O	2421
of	ADP	O	O	2421
renal damage	NOUN	O	Disease	2421
to	PART	O	O	2421
the	PRON	O	O	2421
proximal	ADJ	O	O	2421
tubular	ADJ	O	O	2421
,	PUNCT	O	O	2421
glomerular	ADJ	O	O	2421
,	PUNCT	O	O	2421
and	CCONJ	O	O	2421
papillary	ADJ	O	O	2421
regions	NOUN	O	O	2421
of	ADP	O	O	2421
the	PRON	O	O	2421
rat	NOUN	O	O	2421
were	AUX	O	O	2421
produced	VERB	O	O	2421
by	ADP	O	O	2421
administration	NOUN	O	O	2421
of	ADP	O	O	2421
hexachloro-1:3-butadiene	NOUN	O	Chemical	2421
(	PUNCT	O	O	2421
HCBD	PROPN	O	Chemical	2421
)	PUNCT	O	O	2421
,	PUNCT	O	O	2421
puromycin aminonucleoside	NOUN	O	Chemical	2421
(	PUNCT	O	O	2421
PAN	PROPN	O	Chemical	2421
)	PUNCT	O	O	2421
,	PUNCT	O	O	2421
and	CCONJ	O	O	2421
2-bromoethylamine	NOUN	O	Chemical	2421
(	PUNCT	O	O	2421
BEA	PROPN	O	Chemical	2421
)	PUNCT	O	O	2421
,	PUNCT	O	O	2421
respectively	ADV	O	O	2421
.	PUNCT	O	O	2421
Several	ADJ	O	O	2422
routine	ADJ	O	O	2422
indicators	NOUN	O	O	2422
of	ADP	O	O	2422
nephrotoxicity	NOUN	O	Disease	2422
,	PUNCT	O	O	2422
the	PRON	O	O	2422
enzymes	NOUN	O	O	2422
alkaline	NOUN	O	O	2422
phosphatase	ADJ	O	O	2422
and	CCONJ	O	O	2422
N	NUM	O	O	2422
-	PUNCT	O	O	2422
acetyl	PROPN	O	O	2422
-	PUNCT	O	O	2422
beta	NOUN	O	O	2422
-	PUNCT	O	O	2422
glucosaminidase	PROPN	O	O	2422
,	PUNCT	O	O	2422
and	CCONJ	O	O	2422
the	PRON	O	O	2422
molecular	ADJ	O	O	2422
weight	NOUN	O	O	2422
of	ADP	O	O	2422
protein excretion	NOUN	O	Disease	2422
were	AUX	O	O	2422
determined	VERB	O	O	2422
on	ADP	O	O	2422
urine	NOUN	O	O	2422
samples	NOUN	O	O	2422
.	PUNCT	O	O	2422
Tubular	ADJ	O	O	2423
damage	NOUN	O	O	2423
produced	VERB	O	O	2423
by	ADP	O	O	2423
HCBD	PROPN	O	Chemical	2423
or	CCONJ	O	O	2423
BEA	PROPN	O	Chemical	2423
was	AUX	O	O	2423
discriminated	VERB	O	O	2423
both	PRON	O	O	2423
quantitatively	ADV	O	O	2423
and	CCONJ	O	O	2423
qualitatively	ADV	O	O	2423
from	ADP	O	O	2423
glomerular damage	NOUN	O	Disease	2423
produced	VERB	O	O	2423
by	ADP	O	O	2423
PAN	PROPN	O	Chemical	2423
.	PUNCT	O	O	2423
The	PRON	O	O	2424
latter	ADJ	O	O	2424
was	AUX	O	O	2424
characterized	VERB	O	O	2424
by	ADP	O	O	2424
a	PRON	O	O	2424
pronounced	VERB	O	O	2424
increase	VERB	O	O	2424
in	ADP	O	O	2424
protein excretion	NOUN	O	Disease	2424
,	PUNCT	O	O	2424
especially	ADV	O	O	2424
proteins	NOUN	O	O	2424
with	ADP	O	O	2424
molecular	ADJ	O	O	2424
weight	NOUN	O	O	2424
greater	ADJ	O	O	2424
than	ADP	O	O	2424
40,000	NUM	O	O	2424
Da	INTJ	O	O	2424
.	PUNCT	O	O	2424
In	ADP	O	O	2425
contrast	NOUN	O	O	2425
,	PUNCT	O	O	2425
protein excretion	NOUN	O	Disease	2425
in	ADP	O	O	2425
tubular	ADJ	O	O	2425
damage	NOUN	O	O	2425
was	AUX	O	O	2425
raised	VERB	O	O	2425
only	ADV	O	O	2425
slightly	ADV	O	O	2425
and	CCONJ	O	O	2425
characterized	VERB	O	O	2425
by	ADP	O	O	2425
excretion of proteins	NOUN	O	Disease	2425
of	ADP	O	O	2425
a	PRON	O	O	2425
wide	ADV	O	O	2425
range	VERB	O	O	2425
of	ADP	O	O	2425
molecular	ADJ	O	O	2425
weights	NOUN	O	O	2425
.	PUNCT	O	O	2425
Proximal	ADJ	O	O	2426
tubular	ADJ	O	O	2426
damage	NOUN	O	O	2426
caused	VERB	O	O	2426
by	ADP	O	O	2426
HCBD	PROPN	O	Chemical	2426
and	CCONJ	O	O	2426
papillary	ADJ	O	O	2426
damage	NOUN	O	O	2426
caused	VERB	O	O	2426
by	ADP	O	O	2426
BEA	PROPN	O	Chemical	2426
were	AUX	O	O	2426
distinguished	VERB	O	O	2426
both	PRON	O	O	2426
by	ADP	O	O	2426
conventional	ADJ	O	O	2426
urinalysis	NOUN	O	O	2426
(	PUNCT	O	O	2426
volume	PROPN	O	O	2426
and	CCONJ	O	O	2426
specific	ADJ	O	O	2426
gravity	NOUN	O	O	2426
)	PUNCT	O	O	2426
and	CCONJ	O	O	2426
by	ADP	O	O	2426
measurement	NOUN	O	O	2426
of	ADP	O	O	2426
the	PRON	O	O	2426
two	NUM	O	O	2426
urinary	ADJ	O	O	2426
enzymes	NOUN	O	O	2426
.	PUNCT	O	O	2426
Alkaline	NOUN	O	O	2427
phosphatase	ADJ	O	O	2427
and	CCONJ	O	O	2427
glucose	NOUN	O	Chemical	2427
were	AUX	O	O	2427
markedly	ADV	O	O	2427
and	CCONJ	O	O	2427
transiently	ADV	O	O	2427
elevated	ADJ	O	O	2427
in	ADP	O	O	2427
proximal	ADJ	O	O	2427
tubular	ADJ	O	O	2427
damage	NOUN	O	O	2427
and	CCONJ	O	O	2427
N	NUM	O	O	2427
-	PUNCT	O	O	2427
acetyl	PROPN	O	O	2427
-	PUNCT	O	O	2427
beta	NOUN	O	O	2427
-	PUNCT	O	O	2427
glucosaminidase	PROPN	O	O	2427
showed	VERB	O	O	2427
a	PRON	O	O	2427
sustained	VERB	O	O	2427
elevation	NOUN	O	O	2427
in	ADP	O	O	2427
papillary	ADJ	O	O	2427
damage	NOUN	O	O	2427
.	PUNCT	O	O	2427
It	PRON	O	O	2428
is	AUX	O	O	2428
concluded	VERB	O	O	2428
that	SCONJ	O	O	2428
both	PRON	O	O	2428
selective	ADJ	O	O	2428
urinary	ADJ	O	O	2428
enzymes	NOUN	O	O	2428
and	CCONJ	O	O	2428
the	PRON	O	O	2428
molecular	ADJ	O	O	2428
weight	NOUN	O	O	2428
pattern	NOUN	O	O	2428
of	ADP	O	O	2428
urinary	ADJ	O	O	2428
proteins	NOUN	O	O	2428
can	AUX	O	O	2428
be	AUX	O	O	2428
used	VERB	O	O	2428
to	PART	O	O	2428
provide	VERB	O	O	2428
diagnostic	ADJ	O	O	2428
information	NOUN	O	O	2428
about	ADP	O	O	2428
the	PRON	O	O	2428
possible	ADJ	O	O	2428
site	NOUN	O	O	2428
of	ADP	O	O	2428
renal damage	NOUN	O	Disease	2428
.	PUNCT	O	O	2428
Neuromuscular blockade	NOUN	O	Disease	2431
with	ADP	O	O	2431
magnesium sulfate	NOUN	O	Chemical	2431
and	CCONJ	O	O	2431
nifedipine	PROPN	O	Chemical	2431
.	PUNCT	O	O	2431
A	PRON	O	O	2432
patient	NOUN	O	O	2432
who	PRON	O	O	2432
received	VERB	O	O	2432
tocolysis	NOUN	O	O	2432
with	ADP	O	O	2432
nifedipine	PROPN	O	Chemical	2432
developed	VERB	O	O	2432
neuromuscular blockade	NOUN	O	Disease	2432
after	ADP	O	O	2432
500	NUM	O	O	2432
mg	VERB	O	O	2432
of	ADP	O	O	2432
magnesium sulfate	NOUN	O	Chemical	2432
was	AUX	O	O	2432
administered	VERB	O	O	2432
.	PUNCT	O	O	2432
This	PRON	O	O	2433
reaction	NOUN	O	O	2433
demonstrates	VERB	O	O	2433
that	SCONJ	O	O	2433
nifedipine	PROPN	O	Chemical	2433
can	AUX	O	O	2433
seriously	ADV	O	O	2433
potentiate	VERB	O	O	2433
the	PRON	O	O	2433
toxicity	NOUN	O	Disease	2433
of	ADP	O	O	2433
magnesium	NOUN	O	Chemical	2433
.	PUNCT	O	O	2433
Ifosfamide	PROPN	O	Chemical	2436
continuous	ADJ	O	O	2436
infusion	NOUN	O	O	2436
without	ADP	O	O	2436
mesna	NOUN	O	Chemical	2436
.	PUNCT	O	O	2436
Twenty	NUM	O	O	2437
patients	NOUN	O	O	2437
received	VERB	O	O	2437
27	NUM	O	O	2437
courses	NOUN	O	O	2437
of	ADP	O	O	2437
ifosfamide	ADP	O	Chemical	2437
administered	VERB	O	O	2437
as	ADP	O	O	2437
a	PRON	O	O	2437
24-hour	NOUN	O	O	2437
continuous	ADJ	O	O	2437
infusion	NOUN	O	O	2437
for	ADP	O	O	2437
14	NUM	O	O	2437
days	NOUN	O	O	2437
without	ADP	O	O	2437
Mesna	NOUN	O	Chemical	2437
.	PUNCT	O	O	2437
The	PRON	O	O	2438
goal	NOUN	O	O	2438
of	ADP	O	O	2438
the	PRON	O	O	2438
study	VERB	O	O	2438
was	AUX	O	O	2438
to	PART	O	O	2438
deliver	VERB	O	O	2438
a	PRON	O	O	2438
dose	NOUN	O	O	2438
rate	NOUN	O	O	2438
and	CCONJ	O	O	2438
total	ADJ	O	O	2438
cumulative	ADJ	O	O	2438
dose	NOUN	O	O	2438
of	ADP	O	O	2438
ifosfamide	ADP	O	Chemical	2438
that	SCONJ	O	O	2438
would	AUX	O	O	2438
be	AUX	O	O	2438
comparable	ADJ	O	O	2438
to	PART	O	O	2438
standard	PROPN	O	O	2438
bolus	NOUN	O	O	2438
or	CCONJ	O	O	2438
short	ADJ	O	O	2438
-	PUNCT	O	O	2438
term	NOUN	O	O	2438
infusions	NOUN	O	O	2438
administered	VERB	O	O	2438
with	ADP	O	O	2438
Mesna	NOUN	O	Chemical	2438
.	PUNCT	O	O	2438
Four	NUM	O	O	2439
patients	NOUN	O	O	2439
developed	VERB	O	O	2439
transient	ADJ	O	O	2439
microscopic	ADJ	O	O	2439
hematuria	PROPN	O	Disease	2439
at	ADP	O	O	2439
400	NUM	O	O	2439
,	PUNCT	O	O	2439
450	NUM	O	O	2439
,	PUNCT	O	O	2439
and	CCONJ	O	O	2439
500	NUM	O	O	2439
mg	VERB	O	O	2439
/	PUNCT	O	O	2439
m2/d	NOUN	O	O	2439
.	PUNCT	O	O	2439
There	ADV	O	O	2440
were	AUX	O	O	2440
no	PRON	O	O	2440
instances	NOUN	O	O	2440
of	ADP	O	O	2440
macroscopic	ADJ	O	O	2440
hematuria	PROPN	O	Disease	2440
.	PUNCT	O	O	2440
At	ADP	O	O	2441
550	NUM	O	O	2441
mg	VERB	O	O	2441
/	PUNCT	O	O	2441
m2/d	NOUN	O	O	2441
,	PUNCT	O	O	2441
three	NUM	O	O	2441
patients	NOUN	O	O	2441
experienced	ADJ	O	O	2441
nonurologic	ADV	O	O	2441
toxicity	NOUN	O	Disease	2441
;	PUNCT	O	O	2441
confusion	NOUN	O	Disease	2441
(	PUNCT	O	O	2441
1	X	O	O	2441
)	PUNCT	O	O	2441
,	PUNCT	O	O	2441
nausea	NOUN	O	Disease	2441
(	PUNCT	O	O	2441
1	X	O	O	2441
)	PUNCT	O	O	2441
,	PUNCT	O	O	2441
and	CCONJ	O	O	2441
Grade	NOUN	O	O	2441
2	X	O	O	2441
leukopenia	PROPN	O	Disease	2441
(	PUNCT	O	O	2441
1	X	O	O	2441
)	PUNCT	O	O	2441
.	PUNCT	O	O	2441
The	PRON	O	O	2442
frequency	NOUN	O	O	2442
and	CCONJ	O	O	2442
predictability	NOUN	O	O	2442
of	ADP	O	O	2442
hematuria	PROPN	O	Disease	2442
are	AUX	O	O	2442
not	PART	O	O	2442
precise	ADJ	O	O	2442
,	PUNCT	O	O	2442
and	CCONJ	O	O	2442
at	ADP	O	O	2442
least	ADJ	O	O	2442
daily	ADV	O	O	2442
monitoring	NOUN	O	O	2442
by	ADP	O	O	2442
urine	NOUN	O	O	2442
Hematest	PROPN	O	O	2443
is	AUX	O	O	2443
essential	ADJ	O	O	2443
,	PUNCT	O	O	2443
adding	VERB	O	O	2443
Mesna	NOUN	O	Chemical	2443
to	PART	O	O	2443
the	PRON	O	O	2443
infusate	NOUN	O	O	2443
in	ADP	O	O	2443
patients	NOUN	O	O	2443
with	ADP	O	O	2443
persistent	ADJ	O	O	2443
hematuria	PROPN	O	Disease	2443
.	PUNCT	O	O	2443
The	PRON	O	O	2444
protracted	VERB	O	O	2444
infusion	NOUN	O	O	2444
schedule	NOUN	O	O	2444
for	ADP	O	O	2444
ifosfamide	ADP	O	Chemical	2444
permits	VERB	O	O	2444
convenient	ADJ	O	O	2444
outpatient	NOUN	O	O	2444
administration	NOUN	O	O	2444
without	ADP	O	O	2444
Mesna	NOUN	O	Chemical	2444
and	CCONJ	O	O	2444
reduces	VERB	O	O	2444
the	PRON	O	O	2444
drug	NOUN	O	O	2444
cost	NOUN	O	O	2444
of	ADP	O	O	2444
clinical	ADJ	O	O	2444
usage	NOUN	O	O	2444
of	ADP	O	O	2444
this	PRON	O	O	2444
agent	NOUN	O	O	2444
by	ADP	O	O	2444
up	ADP	O	O	2444
to	PART	O	O	2444
890	NUM	O	O	2444
per	ADP	O	O	2444
cycle	PROPN	O	O	2444
.	PUNCT	O	O	2444
Myocardial infarction	NOUN	O	Disease	2447
in	ADP	O	O	2447
pregnancy	NOUN	O	O	2447
associated	VERB	O	O	2447
with	ADP	O	O	2447
clomiphene citrate	PROPN	O	Chemical	2447
for	ADP	O	O	2447
ovulation	NOUN	O	O	2447
induction	NOUN	O	O	2447
:	PUNCT	O	O	2447
a	PRON	O	O	2447
case	NOUN	O	O	2447
report	VERB	O	O	2447
.	PUNCT	O	O	2447
BACKGROUND	NOUN	O	O	2448
:	PUNCT	O	O	2448
Clomiphene citrate	NOUN	O	Chemical	2448
(	PUNCT	O	O	2448
CC	NOUN	O	Chemical	2448
)	PUNCT	O	O	2448
is	AUX	O	O	2448
commonly	ADV	O	O	2448
prescribed	VERB	O	O	2448
for	ADP	O	O	2448
ovulation	NOUN	O	O	2448
induction	NOUN	O	O	2448
.	PUNCT	O	O	2448
Thromboembolism	NOUN	O	Disease	2449
is	AUX	O	O	2449
a	PRON	O	O	2449
rare	ADJ	O	O	2449
but	CCONJ	O	O	2449
life	NOUN	O	O	2449
-	PUNCT	O	O	2449
threatening	VERB	O	O	2449
complication	NOUN	O	O	2449
that	SCONJ	O	O	2449
has	VERB	O	O	2449
been	AUX	O	O	2449
reported	VERB	O	O	2449
after	ADP	O	O	2449
ovulation	NOUN	O	O	2449
induction	NOUN	O	O	2449
with	ADP	O	O	2449
CC	NOUN	O	Chemical	2449
.	PUNCT	O	O	2449
coronary thrombosis	NOUN	O	Disease	2450
or	CCONJ	O	O	2450
thromboembolism	NOUN	O	Disease	2450
with	ADP	O	O	2450
subsequent	ADJ	O	O	2450
clot	NOUN	O	O	2450
lysis	NOUN	O	O	2450
has	VERB	O	O	2450
been	AUX	O	O	2450
suggested	VERB	O	O	2450
as	ADP	O	O	2450
one	NUM	O	O	2450
of	ADP	O	O	2450
the	PRON	O	O	2450
most	ADV	O	O	2450
common	ADJ	O	O	2450
causes	VERB	O	O	2450
of	ADP	O	O	2450
myocardial infarction	NOUN	O	Disease	2450
(	PUNCT	O	O	2450
MI	PROPN	O	Disease	2450
)	PUNCT	O	O	2450
during	ADP	O	O	2450
pregnancy	NOUN	O	O	2450
,	PUNCT	O	O	2450
with	ADP	O	O	2450
a	PRON	O	O	2450
subsequently	ADV	O	O	2450
normal	ADJ	O	O	2450
coronary	ADJ	O	O	2450
angiogram	PROPN	O	O	2450
.	PUNCT	O	O	2450
A	PRON	O	O	2451
33-year	NOUN	O	O	2451
-	PUNCT	O	O	2451
old	ADJ	O	O	2451
woman	NOUN	O	O	2451
with	ADP	O	O	2451
a	PRON	O	O	2451
5-week	NOUN	O	O	2451
gestation	NOUN	O	O	2451
had	VERB	O	O	2451
recently	ADV	O	O	2451
received	VERB	O	O	2451
CC	NOUN	O	Chemical	2451
for	ADP	O	O	2451
ovulation	NOUN	O	O	2451
induction	NOUN	O	O	2451
and	CCONJ	O	O	2451
presented	VERB	O	O	2451
with	ADP	O	O	2451
chest pain	NOUN	O	Disease	2451
.	PUNCT	O	O	2451
An	PRON	O	O	2452
electrocardiogram	PROPN	O	O	2452
showed	VERB	O	O	2452
a	PRON	O	O	2452
lateral	PROPN	O	O	2452
and	CCONJ	O	O	2452
anterior	PROPN	O	O	2452
wall	PROPN	O	O	2452
myocardial infarction	NOUN	O	Disease	2452
.	PUNCT	O	O	2452
At	ADP	O	O	2453
the	PRON	O	O	2453
time	NOUN	O	O	2453
of	ADP	O	O	2453
admission	NOUN	O	O	2453
,	PUNCT	O	O	2453
the	PRON	O	O	2453
patient	NOUN	O	O	2453
was	AUX	O	O	2453
at	ADP	O	O	2453
high	ADJ	O	O	2453
risk	NOUN	O	O	2453
of	ADP	O	O	2453
radiation injury	NOUN	O	Disease	2453
to	PART	O	O	2453
the	PRON	O	O	2453
fetus	NOUN	O	O	2453
,	PUNCT	O	O	2453
so	ADV	O	O	2453
a	PRON	O	O	2453
coronary	ADJ	O	O	2453
angiogram	PROPN	O	O	2453
was	AUX	O	O	2453
postponed	VERB	O	O	2453
until	ADP	O	O	2453
the	PRON	O	O	2453
second	ADV	O	O	2453
trimester	VERB	O	O	2453
.	PUNCT	O	O	2453
This	PRON	O	O	2454
appears	VERB	O	O	2454
to	PART	O	O	2454
be	AUX	O	O	2454
the	PRON	O	O	2454
first	ADV	O	O	2454
reported	VERB	O	O	2454
case	NOUN	O	O	2454
documenting	VERB	O	O	2454
a	PRON	O	O	2454
possible	ADJ	O	O	2454
association	PROPN	O	O	2454
between	ADP	O	O	2454
CC	NOUN	O	Chemical	2454
and	CCONJ	O	O	2454
myocardial infarction	NOUN	O	Disease	2454
.	PUNCT	O	O	2454
Thrombosis	NOUN	O	Disease	2455
might	AUX	O	O	2455
be	AUX	O	O	2455
a	PRON	O	O	2455
rare	ADJ	O	O	2455
but	CCONJ	O	O	2455
hazardous	ADJ	O	O	2455
complication	NOUN	O	O	2455
of	ADP	O	O	2455
CC	NOUN	O	Chemical	2455
.	PUNCT	O	O	2455
Hepatonecrosis	NOUN	O	Disease	2458
and	CCONJ	O	O	2458
cholangitis	NOUN	O	Disease	2458
related	ADJ	O	O	2458
to	PART	O	O	2458
long	ADV	O	O	2458
-	PUNCT	O	O	2458
term	NOUN	O	O	2458
phenobarbital	NOUN	O	Chemical	2458
therapy	NOUN	O	O	2458
:	PUNCT	O	O	2458
an	PRON	O	O	2458
autopsy	ADJ	O	O	2458
report	VERB	O	O	2458
of	ADP	O	O	2458
two	NUM	O	O	2458
patients	NOUN	O	O	2458
.	PUNCT	O	O	2458
Phenobarbital	PROPN	O	Chemical	2459
(	PUNCT	O	O	2459
PB	PROPN	O	Chemical	2459
)	PUNCT	O	O	2459
has	VERB	O	O	2459
a	PRON	O	O	2459
reputation	NOUN	O	O	2459
for	ADP	O	O	2459
safety	NOUN	O	O	2459
,	PUNCT	O	O	2459
and	CCONJ	O	O	2459
it	PRON	O	O	2459
is	AUX	O	O	2459
commonly	ADV	O	O	2459
believed	VERB	O	O	2459
that	SCONJ	O	O	2459
PB	PROPN	O	Chemical	2459
-	PUNCT	O	O	2459
related	ADJ	O	O	2459
increases	VERB	O	O	2459
in	ADP	O	O	2459
serum	NOUN	O	O	2459
aminotransferase	PROPN	O	O	2459
levels	NOUN	O	O	2459
do	VERB	O	O	2459
not	PART	O	O	2459
indicate	VERB	O	O	2459
or	CCONJ	O	O	2459
predict	VERB	O	O	2459
the	PRON	O	O	2459
development	NOUN	O	O	2459
of	ADP	O	O	2459
significant	ADJ	O	O	2459
chronic	ADJ	O	O	2459
liver disease	NOUN	O	Disease	2459
.	PUNCT	O	O	2459
Here	ADV	O	O	2460
we	PRON	O	O	2460
report	VERB	O	O	2460
of	ADP	O	O	2460
two	NUM	O	O	2460
adult	NOUN	O	O	2460
patients	NOUN	O	O	2460
with	ADP	O	O	2460
a	PRON	O	O	2460
long	ADV	O	O	2460
history	NOUN	O	O	2460
of	ADP	O	O	2460
epilepsy	NOUN	O	Disease	2460
treated	VERB	O	O	2460
with	ADP	O	O	2460
PB	PROPN	O	Chemical	2460
who	PRON	O	O	2460
died	VERB	O	O	2460
suddenly	ADV	O	O	2460
:	PUNCT	O	O	2460
one	NUM	O	O	2460
as	ADP	O	O	2460
consequence	NOUN	O	O	2460
of	ADP	O	O	2460
cardiac arrest	NOUN	O	Disease	2460
,	PUNCT	O	O	2460
the	PRON	O	O	2460
other	ADJ	O	O	2460
of	ADP	O	O	2460
acute	ADJ	O	O	2460
bronchopneumonia	NOUN	O	Disease	2460
.	PUNCT	O	O	2460
At	ADP	O	O	2461
autopsy	ADJ	O	O	2461
,	PUNCT	O	O	2461
analysis	NOUN	O	O	2461
of	ADP	O	O	2461
liver	NOUN	O	O	2461
parenchyma	X	O	O	2461
revealed	VERB	O	O	2461
rich	ADJ	O	O	2461
portal	PROPN	O	O	2461
inflammatory	ADJ	O	O	2461
infiltrate	VERB	O	O	2461
,	PUNCT	O	O	2461
which	PRON	O	O	2461
consisted	VERB	O	O	2461
of	ADP	O	O	2461
mixed	VERB	O	O	2461
eosinophil	NOUN	O	O	2461
and	CCONJ	O	O	2461
monocyte	PROPN	O	O	2461
cells	NOUN	O	O	2461
,	PUNCT	O	O	2461
associated	VERB	O	O	2461
with	ADP	O	O	2461
several	ADJ	O	O	2461
foci	VERB	O	O	2461
of	ADP	O	O	2461
necrosis	NOUN	O	Disease	2461
surrounded	VERB	O	O	2461
by	ADP	O	O	2461
a	PRON	O	O	2461
hard	ADV	O	O	2461
ring	NOUN	O	O	2461
of	ADP	O	O	2461
non	ADJ	O	O	2461
-	PUNCT	O	O	2461
specific	ADJ	O	O	2461
granulomatous	ADJ	O	O	2461
tissue	NOUN	O	O	2461
.	PUNCT	O	O	2461
Our	PRON	O	O	2462
findings	NOUN	O	O	2462
illustrate	VERB	O	O	2462
that	SCONJ	O	O	2462
PB	PROPN	O	Chemical	2462
may	AUX	O	O	2462
be	AUX	O	O	2462
associated	VERB	O	O	2462
with	ADP	O	O	2462
chronic	ADJ	O	O	2462
liver damage	NOUN	O	Disease	2462
,	PUNCT	O	O	2462
which	PRON	O	O	2462
may	AUX	O	O	2462
lead	VERB	O	Chemical	2462
to	PART	O	O	2462
more	ADJ	O	O	2462
serious	ADJ	O	O	2462
and	CCONJ	O	O	2462
deleterious	ADJ	O	O	2462
consequences	NOUN	O	O	2462
.	PUNCT	O	O	2462
For	ADP	O	O	2463
this	PRON	O	O	2463
reason	NOUN	O	O	2463
,	PUNCT	O	O	2463
each	PRON	O	O	2463
clinician	NOUN	O	O	2463
should	AUX	O	O	2463
recognize	VERB	O	O	2463
this	PRON	O	O	2463
entity	NOUN	O	O	2463
in	ADP	O	O	2463
the	PRON	O	O	2463
differential	ADJ	O	O	2463
diagnosis	NOUN	O	O	2463
of	ADP	O	O	2463
PB	PROPN	O	Chemical	2463
-	PUNCT	O	O	2463
related	ADJ	O	O	2463
asymptomatic	ADJ	O	O	2463
chronic hepatic enzyme dysfunction	NOUN	O	Disease	2463
.	PUNCT	O	O	2463
Ethambutol	PROPN	O	Chemical	2466
-	PUNCT	O	O	2466
associated	VERB	O	O	2466
optic neuropathy	NOUN	O	Disease	2466
.	PUNCT	O	O	2466
Ethambutol	PROPN	O	Chemical	2467
is	AUX	O	O	2467
used	VERB	O	O	2467
in	ADP	O	O	2467
the	PRON	O	O	2467
treatment	NOUN	O	O	2467
of	ADP	O	O	2467
tuberculosis	NOUN	O	Disease	2467
,	PUNCT	O	O	2467
which	PRON	O	O	2467
is	AUX	O	O	2467
still	ADV	O	O	2467
prevalent	ADJ	O	O	2467
in	ADP	O	O	2467
Southeast	NOUN	O	O	2467
Asia	PROPN	O	O	2467
,	PUNCT	O	O	2467
and	CCONJ	O	O	2467
can	AUX	O	O	2467
be	AUX	O	O	2467
associated	VERB	O	O	2467
with	ADP	O	O	2467
permanent	ADJ	O	O	2467
visual loss	NOUN	O	Disease	2467
.	PUNCT	O	O	2467
We	PRON	O	O	2468
report	VERB	O	O	2468
3	X	O	O	2468
cases	NOUN	O	O	2468
which	PRON	O	O	2468
presented	VERB	O	O	2468
with	ADP	O	O	2468
bitemporal hemianopia	PROPN	O	Disease	2468
.	PUNCT	O	O	2468
Three	NUM	O	O	2469
patients	NOUN	O	O	2469
with	ADP	O	O	2469
ethambutol	PROPN	O	Chemical	2469
-	PUNCT	O	O	2469
associated	VERB	O	O	2469
toxic optic neuropathy	NOUN	O	Disease	2469
are	AUX	O	O	2469
described	VERB	O	O	2469
.	PUNCT	O	O	2469
All	PRON	O	O	2470
3	X	O	O	2470
patients	NOUN	O	O	2470
had	VERB	O	O	2470
loss	NOUN	O	O	2470
of	ADP	O	O	2470
central	ADJ	O	O	2470
visual	ADJ	O	O	2470
acuity	NOUN	O	O	2470
,	PUNCT	O	O	2470
colour	NOUN	O	O	2470
vision	PROPN	O	O	2470
(	PUNCT	O	O	2470
Ishihara	PROPN	O	O	2470
)	PUNCT	O	O	2470
and	CCONJ	O	O	2470
visual	ADJ	O	O	2470
field	NOUN	O	O	2470
.	PUNCT	O	O	2470
The	PRON	O	O	2471
visual field loss	NOUN	O	Disease	2471
had	VERB	O	O	2471
a	PRON	O	O	2471
bitemporal	ADJ	O	O	2471
flavour	NOUN	O	O	2471
,	PUNCT	O	O	2471
suggesting	VERB	O	O	2471
involvement	NOUN	O	O	2471
of	ADP	O	O	2471
the	PRON	O	O	2471
optic	NOUN	O	O	2471
chiasm	NOUN	O	O	2471
.	PUNCT	O	O	2471
Despite	SCONJ	O	O	2472
stopping	VERB	O	O	2472
ethambutol	PROPN	O	Chemical	2472
on	ADP	O	O	2472
diagnosis	NOUN	O	O	2472
,	PUNCT	O	O	2472
visual	ADJ	O	O	2472
function	NOUN	O	O	2472
continued	VERB	O	O	2472
to	PART	O	O	2472
deteriorate	VERB	O	O	2472
for	ADP	O	O	2472
a	PRON	O	O	2472
few	ADJ	O	O	2472
months	NOUN	O	O	2472
.	PUNCT	O	O	2472
All	PRON	O	O	2473
3	X	O	O	2473
patients	NOUN	O	O	2473
had	VERB	O	O	2473
some	PRON	O	O	2473
permanent	ADJ	O	O	2473
loss of visual function	NOUN	O	Disease	2473
.	PUNCT	O	O	2473
Ethambutol	PROPN	O	Chemical	2474
usage	NOUN	O	O	2474
is	AUX	O	O	2474
associated	VERB	O	O	2474
with	ADP	O	O	2474
permanent	ADJ	O	O	2474
visual loss	NOUN	O	Disease	2474
and	CCONJ	O	O	2474
should	AUX	O	O	2474
be	AUX	O	O	2474
avoided	VERB	O	O	2474
if	SCONJ	O	O	2474
possible	ADJ	O	O	2474
or	CCONJ	O	O	2474
used	VERB	O	O	2474
with	ADP	O	O	2474
caution	NOUN	O	O	2474
and	CCONJ	O	O	2474
proper	ADJ	O	O	2474
ophthalmological	ADJ	O	O	2474
follow	VERB	O	O	2474
-	PUNCT	O	O	2474
up	ADP	O	O	2474
.	PUNCT	O	O	2474
The	PRON	O	O	2475
author	NOUN	O	O	2475
postulates	VERB	O	O	2475
that	SCONJ	O	O	2475
in	ADP	O	O	2475
cases	NOUN	O	O	2475
of	ADP	O	O	2475
ethambutol	PROPN	O	Chemical	2475
associated	VERB	O	O	2475
chiasmopathy	NOUN	O	O	2475
,	PUNCT	O	O	2475
ethambutol	PROPN	O	Chemical	2475
may	AUX	O	O	2475
initially	ADV	O	O	2475
affect	VERB	O	O	2475
the	PRON	O	O	2475
optic	NOUN	O	O	2475
nerves	NOUN	O	O	2475
and	CCONJ	O	O	2475
subsequently	ADV	O	O	2475
progress	VERB	O	O	2475
to	PART	O	O	2475
involve	VERB	O	O	2475
the	PRON	O	O	2475
optic	NOUN	O	O	2475
chiasm	NOUN	O	O	2475
.	PUNCT	O	O	2475
Tolerability	NOUN	O	O	2478
of	ADP	O	O	2478
nimesulide	ADP	O	Chemical	2478
and	CCONJ	O	O	2478
paracetamol	PROPN	O	Chemical	2478
in	ADP	O	O	2478
patients	NOUN	O	O	2478
with	ADP	O	O	2478
NSAID	PROPN	O	Chemical	2478
-	PUNCT	O	O	2478
induced	VERB	O	O	2478
urticaria	PROPN	O	Disease	2478
/	PUNCT	O	O	2478
angioedema	NOUN	O	Disease	2478
.	PUNCT	O	O	2478
Previous	ADJ	O	O	2479
studies	NOUN	O	O	2479
evaluated	VERB	O	O	2479
the	PRON	O	O	2479
tolerance	NOUN	O	O	2479
of	ADP	O	O	2479
nimesulide	ADP	O	Chemical	2479
and	CCONJ	O	O	2479
paracetamol	PROPN	O	Chemical	2479
in	ADP	O	O	2479
subjects	NOUN	O	O	2479
with	ADP	O	O	2479
cutaneous	ADJ	O	O	2479
,	PUNCT	O	O	2479
respiratory	NOUN	O	O	2479
and	CCONJ	O	O	2479
anaphylactoid	PROPN	O	O	2479
reactions	NOUN	O	O	2479
induced	VERB	O	O	2479
by	ADP	O	O	2479
nonsteroidal	ADJ	O	O	2479
anti	ADJ	O	O	2479
-	PUNCT	O	O	2479
inflammatory	ADJ	O	O	2479
drugs	NOUN	O	O	2479
(	PUNCT	O	O	2479
NSAIDs	NOUN	O	Chemical	2479
)	PUNCT	O	O	2479
.	PUNCT	O	O	2479
In	ADP	O	O	2480
this	PRON	O	O	2480
study	VERB	O	O	2480
we	PRON	O	O	2480
investigated	VERB	O	O	2480
tolerability	NOUN	O	O	2480
and	CCONJ	O	O	2480
reliability	NOUN	O	O	2480
of	ADP	O	O	2480
nimesulide	ADP	O	Chemical	2480
and	CCONJ	O	O	2480
paracetamol	PROPN	O	Chemical	2480
in	ADP	O	O	2480
a	PRON	O	O	2480
very	ADV	O	O	2480
large	ADJ	O	O	2480
number	NOUN	O	O	2480
of	ADP	O	O	2480
patients	NOUN	O	O	2480
with	ADP	O	O	2480
an	PRON	O	O	2480
exclusive	ADJ	O	O	2480
well	ADV	O	O	2480
-	PUNCT	O	O	2480
documented	VERB	O	O	2480
history	NOUN	O	O	2480
of	ADP	O	O	2480
NSAID	PROPN	O	Chemical	2480
-	PUNCT	O	O	2480
induced	VERB	O	O	2480
urticaria	PROPN	O	Disease	2480
/	PUNCT	O	O	2480
angioedema	NOUN	O	Disease	2480
.	PUNCT	O	O	2480
Furthermore	ADV	O	O	2481
,	PUNCT	O	O	2481
we	PRON	O	O	2481
evaluated	VERB	O	O	2481
whether	SCONJ	O	O	2481
some	PRON	O	O	2481
factors	NOUN	O	O	2481
have	VERB	O	O	2481
the	PRON	O	O	2481
potential	ADJ	O	O	2481
to	PART	O	O	2481
increase	VERB	O	O	2481
the	PRON	O	O	2481
risk	NOUN	O	O	2481
of	ADP	O	O	2481
reaction	NOUN	O	O	2481
to	PART	O	O	2481
paracetamol	PROPN	O	Chemical	2481
and	CCONJ	O	O	2481
nimesulide	ADP	O	Chemical	2481
.	PUNCT	O	O	2481
A	PRON	O	O	2482
single	ADJ	O	O	2482
-	PUNCT	O	O	2482
placebo	NOUN	O	O	2482
-	PUNCT	O	O	2482
controlled	VERB	O	O	2482
oral	ADJ	O	O	2482
challenge	NOUN	O	O	2482
procedure	NOUN	O	O	2482
with	ADP	O	O	2482
nimesulide	ADP	O	Chemical	2482
or	CCONJ	O	O	2482
paracetamol	PROPN	O	Chemical	2482
was	AUX	O	O	2482
applied	VERB	O	O	2482
to	PART	O	O	2482
829	NUM	O	O	2482
patients	NOUN	O	O	2482
with	ADP	O	O	2482
a	PRON	O	O	2482
history	NOUN	O	O	2482
of	ADP	O	O	2482
NSAID	PROPN	O	Chemical	2482
-	PUNCT	O	O	2482
induced	VERB	O	O	2482
urticaria	PROPN	O	Disease	2482
/	PUNCT	O	O	2482
angioedema	NOUN	O	Disease	2482
.	PUNCT	O	O	2482
patients	NOUN	O	O	2483
experienced	ADJ	O	O	2483
reactions	NOUN	O	O	2483
to	PART	O	O	2483
nimesulide	ADP	O	Chemical	2483
or	CCONJ	O	O	2483
paracetamol	PROPN	O	Chemical	2483
.	PUNCT	O	O	2483
Of	ADV	O	O	2484
the	PRON	O	O	2484
715	NUM	O	O	2484
patients	NOUN	O	O	2484
tested	VERB	O	O	2484
with	ADP	O	O	2484
nimesulide	ADP	O	Chemical	2484
62	NUM	O	O	2484
(	PUNCT	O	O	2484
8.6%	NOUN	O	O	2484
)	PUNCT	O	O	2484
showed	VERB	O	O	2484
a	PRON	O	O	2484
positive	ADJ	O	O	2484
test	NOUN	O	O	2484
,	PUNCT	O	O	2484
while	SCONJ	O	O	2484
of	ADP	O	O	2484
114	NUM	O	O	2484
subjects	NOUN	O	O	2484
submitted	VERB	O	O	2484
to	PART	O	O	2484
the	PRON	O	O	2484
challenge	NOUN	O	O	2484
with	ADP	O	O	2484
paracetamol	PROPN	O	Chemical	2484
,	PUNCT	O	O	2484
13	NUM	O	O	2484
(	PUNCT	O	O	2484
9.6%	NOUN	O	O	2484
)	PUNCT	O	O	2484
did	VERB	O	O	2484
not	PART	O	O	2484
tolerate	VERB	O	O	2484
this	PRON	O	O	2484
drug	NOUN	O	O	2484
.	PUNCT	O	O	2484
Furthermore	ADV	O	O	2485
,	PUNCT	O	O	2485
18.28%	NOUN	O	O	2485
of	ADP	O	O	2485
patients	NOUN	O	O	2485
with	ADP	O	O	2485
a	PRON	O	O	2485
history	NOUN	O	O	2485
of	ADP	O	O	2485
chronic	ADJ	O	O	2485
urticaria	PROPN	O	Disease	2485
and	CCONJ	O	O	2485
11.8%	NOUN	O	O	2485
of	ADP	O	O	2485
subjects	NOUN	O	O	2485
with	ADP	O	O	2485
an	PRON	O	O	2485
history	NOUN	O	O	2485
of	ADP	O	O	2485
NSAID	PROPN	O	Chemical	2485
-	PUNCT	O	O	2485
induced	VERB	O	O	2485
urticaria	PROPN	O	Disease	2485
/	PUNCT	O	O	2485
angioedema	NOUN	O	Disease	2485
or	CCONJ	O	O	2485
angioedema	NOUN	O	Disease	2485
alone	ADV	O	O	2485
(	PUNCT	O	O	2485
with	ADP	O	O	2485
or	CCONJ	O	O	2485
without	ADP	O	O	2485
chronic	ADJ	O	O	2485
urticaria	PROPN	O	Disease	2485
)	PUNCT	O	O	2485
resulted	VERB	O	O	2485
to	PART	O	O	2485
be	AUX	O	O	2485
intolerant	ADJ	O	O	2485
to	PART	O	O	2485
alternative	ADV	O	O	2485
drugs	NOUN	O	O	2485
.	PUNCT	O	O	2485
Taken	VERB	O	O	2486
together	ADV	O	O	2486
,	PUNCT	O	O	2486
our	PRON	O	O	2486
results	VERB	O	O	2486
confirm	VERB	O	O	2486
the	PRON	O	O	2486
good	ADJ	O	O	2486
tolerability	NOUN	O	O	2486
of	ADP	O	O	2486
nimesulide	ADP	O	Chemical	2486
and	CCONJ	O	O	2486
paracetamol	PROPN	O	Chemical	2486
in	ADP	O	O	2486
patients	NOUN	O	O	2486
who	PRON	O	O	2486
experienced	ADJ	O	O	2486
urticaria	PROPN	O	Disease	2486
/	PUNCT	O	O	2486
angioedema	NOUN	O	Disease	2486
caused	VERB	O	O	2486
by	ADP	O	O	2486
NSAIDs	NOUN	O	Chemical	2486
.	PUNCT	O	O	2486
However	ADV	O	O	2487
,	PUNCT	O	O	2487
the	PRON	O	O	2487
risk	NOUN	O	O	2487
of	ADP	O	O	2487
reaction	NOUN	O	O	2487
to	PART	O	O	2487
these	PRON	O	O	2487
alternative	ADV	O	O	2487
study	VERB	O	O	2487
drugs	NOUN	O	O	2487
is	AUX	O	O	2487
statistically	ADV	O	O	2487
increased	VERB	O	O	2487
by	ADP	O	O	2487
a	PRON	O	O	2487
history	NOUN	O	O	2487
of	ADP	O	O	2487
chronic	ADJ	O	O	2487
urticaria	PROPN	O	Disease	2487
and	CCONJ	O	O	2487
,	PUNCT	O	O	2487
above	ADP	O	O	2487
all	PRON	O	O	2487
,	PUNCT	O	O	2487
by	ADP	O	O	2487
a	PRON	O	O	2487
history	NOUN	O	O	2487
of	ADP	O	O	2487
NSAID	PROPN	O	Chemical	2487
-	PUNCT	O	O	2487
induced	VERB	O	O	2487
angioedema	NOUN	O	Disease	2487
.	PUNCT	O	O	2487
Effects	NOUN	O	O	2490
of	ADP	O	O	2490
verapamil	PROPN	O	Chemical	2490
on	ADP	O	O	2490
atrial fibrillation	NOUN	O	Disease	2490
and	CCONJ	O	O	2490
its	PRON	O	O	2490
electrophysiological	ADJ	O	O	2490
determinants	NOUN	O	O	2490
in	ADP	O	O	2490
dogs	NOUN	O	O	2490
.	PUNCT	O	O	2490
Atrial tachycardia	NOUN	O	Disease	2491
-	PUNCT	O	O	2491
induced	VERB	O	O	2491
remodeling	VERB	O	O	2491
promotes	VERB	O	O	2491
the	PRON	O	O	2491
occurrence	NOUN	O	O	2491
and	CCONJ	O	O	2491
maintenance	NOUN	O	O	2491
of	ADP	O	O	2491
atrial fibrillation	NOUN	O	Disease	2491
(	PUNCT	O	O	2491
AF	PROPN	O	Disease	2491
)	PUNCT	O	O	2491
and	CCONJ	O	O	2491
decreases	VERB	O	O	2491
L	NOUN	O	O	2491
-	PUNCT	O	O	2491
type	NOUN	O	O	2491
Ca(2	PROPN	O	O	2491
+	ADP	O	O	2491
)	PUNCT	O	O	2491
current	ADJ	O	O	2491
.	PUNCT	O	O	2491
There	ADV	O	O	2492
is	AUX	O	O	2492
also	ADV	O	O	2492
a	PRON	O	O	2492
clinical	ADJ	O	O	2492
suggestion	NOUN	O	O	2492
that	SCONJ	O	O	2492
acute	ADJ	O	O	2492
L	NOUN	O	O	2492
-	PUNCT	O	O	2492
type	NOUN	O	O	2492
Ca(2	PROPN	O	O	2492
)	PUNCT	O	O	2492
channel	PROPN	O	O	2492
blockade	VERB	O	O	2492
can	AUX	O	O	2492
promote	VERB	O	O	2492
AF	PROPN	O	Disease	2492
,	PUNCT	O	O	2492
consistent	ADJ	O	O	2492
with	ADP	O	O	2492
an	PRON	O	O	2492
AF	PROPN	O	Disease	2492
promoting	VERB	O	O	2492
effect	VERB	O	O	2492
of	ADP	O	O	2492
Ca(2	PROPN	O	O	2492
+	ADP	O	O	2492
)	PUNCT	O	O	2492
channel	PROPN	O	O	2492
inhibition	NOUN	O	O	2492
.	PUNCT	O	O	2492
METHODS	NOUN	O	O	2493
:	PUNCT	O	O	2493
To	PART	O	O	2493
evaluate	VERB	O	O	2493
the	PRON	O	O	2493
potential	ADJ	O	O	2493
mechanisms	NOUN	O	O	2493
of	ADP	O	O	2493
AF	PROPN	O	Disease	2493
promotion	NOUN	O	O	2493
by	ADP	O	O	2493
Ca(2	PROPN	O	O	2493
+	ADP	O	O	2493
)	PUNCT	O	O	2493
channel	PROPN	O	O	2493
blockers	NOUN	O	O	2493
,	PUNCT	O	O	2493
we	PRON	O	O	2493
administered	VERB	O	O	2493
verapamil	PROPN	O	Chemical	2493
to	PART	O	O	2493
morphine	NOUN	O	Chemical	2493
-	PUNCT	O	O	2493
chloralose	PROPN	O	Chemical	2493
anesthetized	VERB	O	O	2493
dogs	NOUN	O	O	2493
.	PUNCT	O	O	2493
Diltiazem	PROPN	O	Chemical	2494
was	AUX	O	O	2494
used	VERB	O	O	2494
as	ADP	O	O	2494
a	PRON	O	O	2494
comparison	NOUN	O	O	2494
drug	NOUN	O	O	2494
and	CCONJ	O	O	2494
autonomic	ADJ	O	O	2494
blockade	VERB	O	O	2494
with	ADP	O	O	2494
atropine	NOUN	O	Chemical	2494
and	CCONJ	O	O	2494
nadolol	PROPN	O	Chemical	2494
was	AUX	O	O	2494
applied	VERB	O	O	2494
in	ADP	O	O	2494
some	PRON	O	O	2494
experiments	NOUN	O	O	2494
.	PUNCT	O	O	2494
Epicardial	ADJ	O	O	2495
mapping	NOUN	O	O	2495
with	ADP	O	O	2495
240	NUM	O	O	2495
epicardial	ADJ	O	O	2495
electrodes	NOUN	O	O	2495
was	AUX	O	O	2495
used	VERB	O	O	2495
to	PART	O	O	2495
evaluate	VERB	O	O	2495
activation	NOUN	O	O	2495
during	ADP	O	O	2495
AF	PROPN	O	Disease	2495
.	PUNCT	O	O	2495
RESULTS	VERB	O	O	2496
:	PUNCT	O	O	2496
Verapamil	PROPN	O	Chemical	2496
caused	VERB	O	O	2496
AF	PROPN	O	Disease	2496
promotion	NOUN	O	O	2496
in	ADP	O	O	2496
six	NUM	O	O	2496
dogs	NOUN	O	O	2496
,	PUNCT	O	O	2496
increasing	VERB	O	O	2496
mean	VERB	O	O	2496
duration	NOUN	O	O	2496
of	ADP	O	O	2496
AF	PROPN	O	Disease	2496
induced	VERB	O	O	2496
by	ADP	O	O	2496
burst	VERB	O	O	2496
pacing	NOUN	O	O	2496
,	PUNCT	O	O	2496
from	ADP	O	O	2496
8+/-4	NUM	O	O	2496
s	X	O	O	2496
(	PUNCT	O	O	2496
mean+/-S.E.	NOUN	O	O	2496
)	PUNCT	O	O	2496
to	PART	O	O	2496
95+/-39	NUM	O	O	2496
s	X	O	O	2496
(	PUNCT	O	O	2496
P<0.01	ADV	O	O	2496
vs.	CCONJ	O	O	2496
control	VERB	O	O	2496
)	PUNCT	O	O	2496
at	ADP	O	O	2496
a	PRON	O	O	2496
loading	NOUN	O	O	2496
dose	NOUN	O	O	2496
of	ADP	O	O	2496
0.1	NUM	O	O	2496
mg	VERB	O	O	2496
/	PUNCT	O	O	2496
kg	VERB	O	O	2496
and	CCONJ	O	O	2496
228+/-101	NUM	O	O	2496
s	X	O	O	2496
(	PUNCT	O	O	2496
P<0.0005	NOUN	O	O	2496
vs.	CCONJ	O	O	2496
control	VERB	O	O	2496
)	PUNCT	O	O	2496
at	ADP	O	O	2496
a	PRON	O	O	2496
dose	NOUN	O	O	2496
of	ADP	O	O	2496
0.2	NUM	O	O	2496
mg	VERB	O	O	2496
/	PUNCT	O	O	2496
kg	VERB	O	O	2496
.	PUNCT	O	O	2496
Underlying	VERB	O	O	2497
electrophysiological	ADJ	O	O	2497
mechanisms	NOUN	O	O	2497
were	AUX	O	O	2497
studied	VERB	O	O	2497
in	ADP	O	O	2497
detail	NOUN	O	O	2497
in	ADP	O	O	2497
five	NUM	O	O	2497
additional	ADJ	O	O	2497
dogs	NOUN	O	O	2497
under	ADP	O	O	2497
control	VERB	O	O	2497
conditions	NOUN	O	O	2497
and	CCONJ	O	O	2497
in	ADP	O	O	2497
the	PRON	O	O	2497
presence	NOUN	O	O	2497
of	ADP	O	O	2497
the	PRON	O	O	2497
higher	ADJ	O	O	2497
dose	NOUN	O	O	2497
of	ADP	O	O	2497
verapamil	PROPN	O	Chemical	2497
.	PUNCT	O	O	2497
In	ADP	O	O	2498
these	PRON	O	O	2498
experiments	NOUN	O	O	2498
,	PUNCT	O	O	2498
verapamil	PROPN	O	Chemical	2498
shortened	VERB	O	O	2498
mean	VERB	O	O	2498
effective	ADJ	O	O	2498
refractory	ADJ	O	O	2498
period	NOUN	O	O	2498
(	PUNCT	O	O	2498
ERP	PROPN	O	O	2498
)	PUNCT	O	O	2498
from	ADP	O	O	2498
122+/-5	NUM	O	O	2498
to	PART	O	O	2498
114+/-4	NUM	O	O	2498
ms	PROPN	O	O	2498
(	PUNCT	O	O	2498
P<0.02	PROPN	O	O	2498
)	PUNCT	O	O	2498
at	ADP	O	O	2498
a	PRON	O	O	2498
cycle	PROPN	O	O	2498
length	NOUN	O	O	2498
of	ADP	O	O	2498
300	NUM	O	O	2498
ms	PROPN	O	O	2498
,	PUNCT	O	O	2498
decreased	VERB	O	O	2498
ERP	PROPN	O	O	2498
heterogeneity	NOUN	O	O	2498
(	PUNCT	O	O	2498
from	ADP	O	O	2498
15+/-1	NUM	O	O	2498
to	PART	O	O	2498
10+/-1%	NOUN	O	O	2498
,	PUNCT	O	O	2498
P<0.05	NOUN	O	O	2498
)	PUNCT	O	O	2498
,	PUNCT	O	O	2498
heterogeneously	NOUN	O	O	2498
accelerated	VERB	O	O	2498
atrial	ADJ	O	O	2498
conduction	NOUN	O	O	2498
and	CCONJ	O	O	2498
decreased	VERB	O	O	2498
the	PRON	O	O	2498
cycle	PROPN	O	O	2498
length	NOUN	O	O	2498
of	ADP	O	O	2498
AF	PROPN	O	Disease	2498
(	PUNCT	O	O	2498
94+/-4	NUM	O	O	2498
to	PART	O	O	2498
84+/-3	NUM	O	O	2498
ms	PROPN	O	O	2498
,	PUNCT	O	O	2498
P<0.005	VERB	O	O	2498
)	PUNCT	O	O	2498
.	PUNCT	O	O	2498
Diltiazem	PROPN	O	Chemical	2499
did	VERB	O	O	2499
not	PART	O	O	2499
affect	VERB	O	O	2499
ERP	PROPN	O	O	2499
,	PUNCT	O	O	2499
AF	PROPN	O	Disease	2499
cycle	PROPN	O	O	2499
length	NOUN	O	O	2499
or	CCONJ	O	O	2499
AF	PROPN	O	Disease	2499
duration	NOUN	O	O	2499
,	PUNCT	O	O	2499
but	CCONJ	O	O	2499
produced	VERB	O	O	2499
conduction	NOUN	O	O	2499
acceleration	NOUN	O	O	2499
similar	ADJ	O	O	2499
to	PART	O	O	2499
that	SCONJ	O	O	2499
caused	VERB	O	O	2499
by	ADP	O	O	2499
verapamil	PROPN	O	Chemical	2499
(	PUNCT	O	O	2499
n=5	ADP	O	O	2499
)	PUNCT	O	O	2499
.	PUNCT	O	O	2499
In	ADP	O	O	2500
the	PRON	O	O	2500
presence	NOUN	O	O	2500
of	ADP	O	O	2500
autonomic	ADJ	O	O	2500
blockade	VERB	O	O	2500
,	PUNCT	O	O	2500
verapamil	PROPN	O	Chemical	2500
failed	VERB	O	O	2500
to	PART	O	O	2500
promote	VERB	O	O	2500
AF	PROPN	O	Disease	2500
and	CCONJ	O	O	2500
increased	VERB	O	O	2500
,	PUNCT	O	O	2500
rather	ADV	O	O	2500
than	ADP	O	O	2500
decreasing	VERB	O	O	2500
,	PUNCT	O	O	2500
refractoriness	NOUN	O	O	2500
.	PUNCT	O	O	2500
Neither	PRON	O	O	2501
verapamil	PROPN	O	Chemical	2501
nor	CCONJ	O	O	2501
diltiazem	VERB	O	Chemical	2501
affected	VERB	O	O	2501
atrial	ADJ	O	O	2501
conduction	NOUN	O	O	2501
in	ADP	O	O	2501
the	PRON	O	O	2501
presence	NOUN	O	O	2501
of	ADP	O	O	2501
autonomic	ADJ	O	O	2501
blockade	VERB	O	O	2501
.	PUNCT	O	O	2501
Epicardial	ADJ	O	O	2502
mapping	NOUN	O	O	2502
suggested	VERB	O	O	2502
that	SCONJ	O	O	2502
verapamil	PROPN	O	Chemical	2502
promoted	VERB	O	O	2502
AF	PROPN	O	Disease	2502
by	ADP	O	O	2502
increasing	VERB	O	O	2502
the	PRON	O	O	2502
number	NOUN	O	O	2502
of	ADP	O	O	2502
simultaneous	ADJ	O	O	2502
wavefronts	NOUN	O	O	2502
reflected	VERB	O	O	2502
by	ADP	O	O	2502
separate	VERB	O	O	2502
zones	NOUN	O	O	2502
of	ADP	O	O	2502
reactivation	NOUN	O	O	2502
in	ADP	O	O	2502
each	PRON	O	O	2502
cycle	PROPN	O	O	2502
.	PUNCT	O	O	2502
:	PUNCT	O	O	2503
Verapamil	PROPN	O	Chemical	2503
promotes	VERB	O	O	2503
AF	PROPN	O	Disease	2503
in	ADP	O	O	2503
normal	ADJ	O	O	2503
dogs	NOUN	O	O	2503
by	ADP	O	O	2503
promoting	VERB	O	O	2503
multiple	ADJ	O	O	2503
circuit	PROPN	O	O	2503
reentry	NOUN	O	O	2503
,	PUNCT	O	O	2503
an	PRON	O	O	2503
effect	VERB	O	O	2503
dependent	ADJ	O	O	2503
on	ADP	O	O	2503
intact	ADJ	O	O	2503
autonomic	ADJ	O	O	2503
tone	NOUN	O	O	2503
and	CCONJ	O	O	2503
not	PART	O	O	2503
shared	VERB	O	O	2503
by	ADP	O	O	2503
diltiazem	VERB	O	Chemical	2503
.	PUNCT	O	O	2503
Hypotension	NOUN	O	Disease	2506
,	PUNCT	O	O	2506
bradycardia	NOUN	O	Disease	2506
,	PUNCT	O	O	2506
and	CCONJ	O	O	2506
asystole	NOUN	O	Disease	2506
after	ADP	O	O	2506
high	ADJ	O	O	2506
-	PUNCT	O	O	2506
dose	NOUN	O	O	2506
intravenous	ADJ	O	O	2506
methylprednisolone	NOUN	O	Chemical	2506
in	ADP	O	O	2506
a	PRON	O	O	2506
monitored	VERB	O	O	2506
patient	NOUN	O	O	2506
.	PUNCT	O	O	2506
We	PRON	O	O	2507
report	VERB	O	O	2507
a	PRON	O	O	2507
case	NOUN	O	O	2507
of	ADP	O	O	2507
hypotension	NOUN	O	Disease	2507
,	PUNCT	O	O	2507
bradycardia	NOUN	O	Disease	2507
,	PUNCT	O	O	2507
and	CCONJ	O	O	2507
asystole	NOUN	O	Disease	2507
after	ADP	O	O	2507
intravenous	ADJ	O	O	2507
administration	NOUN	O	O	2507
of	ADP	O	O	2507
high	ADJ	O	O	2507
-	PUNCT	O	O	2507
dose	NOUN	O	O	2507
methylprednisolone	NOUN	O	Chemical	2507
in	ADP	O	O	2507
a	PRON	O	O	2507
73-year	NOUN	O	O	2507
-	PUNCT	O	O	2507
old	ADJ	O	O	2507
patient	NOUN	O	O	2507
who	PRON	O	O	2507
underwent	VERB	O	O	2507
electrocardiographic	NOUN	O	O	2507
(	PUNCT	O	O	2507
ECG	PROPN	O	O	2507
)	PUNCT	O	O	2507
monitoring	NOUN	O	O	2507
throughout	ADP	O	O	2507
the	PRON	O	O	2507
episode	PROPN	O	O	2507
.	PUNCT	O	O	2507
There	ADV	O	O	2508
was	AUX	O	O	2508
a	PRON	O	O	2508
history	NOUN	O	O	2508
of	ADP	O	O	2508
ischemic	VERB	O	Disease	2508
cardiac disease	NOUN	O	Disease	2508
9	NUM	O	O	2508
years	NOUN	O	O	2508
earlier	ADV	O	O	2508
.	PUNCT	O	O	2508
The	PRON	O	O	2509
patient	NOUN	O	O	2509
was	AUX	O	O	2509
admitted	VERB	O	O	2509
with	ADP	O	O	2509
a	PRON	O	O	2509
pulmonary	ADJ	O	O	2509
-	PUNCT	O	O	2509
renal	ADJ	O	O	2509
syndrome	NOUN	O	O	2509
with	ADP	O	O	2509
hemoptysis	NOUN	O	Disease	2509
,	PUNCT	O	O	2509
rapidly	ADV	O	O	2509
progressive renal failure	NOUN	O	Disease	2509
,	PUNCT	O	O	2509
and	CCONJ	O	O	2509
hypoxemia	NOUN	O	Disease	2509
that	SCONJ	O	O	2509
required	VERB	O	O	2509
mechanical	ADJ	O	O	2509
ventilation	NOUN	O	O	2509
in	ADP	O	O	2509
the	PRON	O	O	2509
intensive	ADJ	O	O	2509
care	VERB	O	O	2509
unit	NOUN	O	O	2509
.	PUNCT	O	O	2509
The	PRON	O	O	2510
ECG	PROPN	O	O	2510
showed	VERB	O	O	2510
a	PRON	O	O	2510
junctional	ADJ	O	O	2510
rhythm	VERB	O	O	2510
without	ADP	O	O	2510
ventricular arrhythmia	NOUN	O	Disease	2510
.	PUNCT	O	O	2510
This	PRON	O	O	2511
study	VERB	O	O	2511
reviews	NOUN	O	O	2511
the	PRON	O	O	2511
current	ADJ	O	O	2511
proposed	VERB	O	O	2511
mechanisms	NOUN	O	O	2511
of	ADP	O	O	2511
sudden death	NOUN	O	Disease	2511
after	ADP	O	O	2511
a	PRON	O	O	2511
high	ADJ	O	O	2511
dose	NOUN	O	O	2511
of	ADP	O	O	2511
intravenous	ADJ	O	O	2511
methylprednisolone	NOUN	O	Chemical	2511
(	PUNCT	O	O	2511
IVMP	PROPN	O	Chemical	2511
)	PUNCT	O	O	2511
.	PUNCT	O	O	2511
Rapid	ADJ	O	O	2512
infusion	NOUN	O	O	2512
and	CCONJ	O	O	2512
underlying	VERB	O	O	2512
cardiac disease	NOUN	O	Disease	2512
were	AUX	O	O	2512
important	ADJ	O	O	2512
risk	NOUN	O	O	2512
factors	NOUN	O	O	2512
in	ADP	O	O	2512
the	PRON	O	O	2512
case	NOUN	O	O	2512
reported	VERB	O	O	2512
here	ADV	O	O	2512
,	PUNCT	O	O	2512
and	CCONJ	O	O	2512
the	PRON	O	O	2512
authors	NOUN	O	O	2512
discount	VERB	O	O	2512
ventricular arrhythmia	NOUN	O	Disease	2512
as	ADP	O	O	2512
the	PRON	O	O	2512
main	ADJ	O	O	2512
mechanism	NOUN	O	O	2512
.	PUNCT	O	O	2512
Lifetime	NOUN	O	O	2515
treatment	NOUN	O	O	2515
of	ADP	O	O	2515
mice	NOUN	O	O	2515
with	ADP	O	O	2515
azidothymidine	NOUN	O	Chemical	2515
(	PUNCT	O	O	2515
AZT	PROPN	O	Chemical	2515
)	PUNCT	O	O	2515
produces	VERB	O	O	2515
myelodysplasia	NOUN	O	Disease	2515
.	PUNCT	O	O	2515
AZT	PROPN	O	Chemical	2516
has	VERB	O	O	2516
induced	VERB	O	O	2516
a	PRON	O	O	2516
macrocytic anemia	NOUN	O	Disease	2516
in	ADP	O	O	2516
AIDS	PROPN	O	Disease	2516
patients	NOUN	O	O	2516
on	ADP	O	O	2516
long	ADV	O	O	2516
term	NOUN	O	O	2516
AZT	PROPN	O	Chemical	2516
therapy	NOUN	O	O	2516
.	PUNCT	O	O	2516
It	PRON	O	O	2517
is	AUX	O	O	2517
generally	ADV	O	O	2517
assumed	VERB	O	O	2517
that	SCONJ	O	O	2517
DNA	NOUN	O	O	2517
elongation	NOUN	O	O	2517
is	AUX	O	O	2517
stopped	VERB	O	O	2517
by	ADP	O	O	2517
the	PRON	O	O	2517
insertion	NOUN	O	O	2517
of	ADP	O	O	2517
AZT	PROPN	O	Chemical	2517
into	ADP	O	O	2517
the	PRON	O	O	2517
chain	NOUN	O	O	2517
in	ADP	O	O	2517
place	NOUN	O	O	2517
of	ADP	O	O	2517
thymidine	NOUN	O	Chemical	2517
thus	ADV	O	O	2517
preventing	VERB	O	O	2517
the	PRON	O	O	2517
phosphate	NOUN	O	Chemical	2517
hydroxyl	PROPN	O	O	2517
linkages	NOUN	O	O	2517
and	CCONJ	O	O	2517
therefore	ADV	O	O	2517
suppresses	VERB	O	O	2517
hemopoietic	ADJ	O	O	2517
progenitor	NOUN	O	O	2517
cell	NOUN	O	O	2517
proliferation	NOUN	O	O	2517
in	ADP	O	O	2517
an	PRON	O	O	2517
early	ADV	O	O	2517
stage	NOUN	O	O	2517
of	ADP	O	O	2517
differentiation	NOUN	O	O	2517
.	PUNCT	O	O	2517
CBA	PROPN	O	O	2518
/	PUNCT	O	O	2518
Ca	AUX	O	Chemical	2518
male	NOUN	O	O	2518
mice	NOUN	O	O	2518
started	VERB	O	O	2518
on	ADP	O	O	2518
AZT	PROPN	O	Chemical	2518
0.75	NUM	O	O	2518
mg	VERB	O	O	2518
/	PUNCT	O	O	2518
ml	ADP	O	O	2519
H2O	NOUN	O	O	2519
at	ADP	O	O	2519
84	NUM	O	O	2519
days	NOUN	O	O	2519
of	ADP	O	O	2519
age	NOUN	O	O	2519
and	CCONJ	O	O	2519
kept	VERB	O	O	2519
on	ADP	O	O	2519
it	PRON	O	O	2519
for	ADP	O	O	2519
687	NUM	O	O	2519
days	NOUN	O	O	2519
when	SCONJ	O	O	2519
dosage	NOUN	O	O	2519
reduced	VERB	O	O	2519
to	PART	O	O	2519
0.5	NUM	O	O	2519
mg	VERB	O	O	2519
/	PUNCT	O	O	2519
ml	ADP	O	O	2519
H2O	NOUN	O	O	2519
for	ADP	O	O	2519
a	PRON	O	O	2519
group	NOUN	O	O	2519
,	PUNCT	O	O	2519
another	PRON	O	O	2519
group	NOUN	O	O	2519
removed	VERB	O	O	2519
from	ADP	O	O	2519
AZT	PROPN	O	Chemical	2519
to	PART	O	O	2519
see	VERB	O	O	2519
recovery	NOUN	O	O	2519
,	PUNCT	O	O	2519
and	CCONJ	O	O	2519
third	ADV	O	O	2519
group	NOUN	O	O	2519
remained	VERB	O	O	2519
on	ADP	O	O	2519
0.75	NUM	O	O	2519
mg	VERB	O	O	2519
.	PUNCT	O	O	2519
Histological	NOUN	O	O	2520
examination	NOUN	O	O	2520
on	ADP	O	O	2520
9	NUM	O	O	2520
of	ADP	O	O	2520
10	NUM	O	O	2520
mice	NOUN	O	O	2520
with	ADP	O	O	2520
such	ADJ	O	O	2520
thrombocytopenia	PROPN	O	Disease	2520
showed	VERB	O	O	2520
changes	VERB	O	O	2520
compatible	ADJ	O	O	2520
with	ADP	O	O	2520
myelodysplastic syndrome	PROPN	O	Disease	2520
(	PUNCT	O	O	2520
MDS	PROPN	O	Disease	2520
)	PUNCT	O	O	2520
.	PUNCT	O	O	2520
There	ADV	O	O	2521
were	AUX	O	O	2521
two	NUM	O	O	2521
cases	NOUN	O	O	2521
of	ADP	O	O	2521
hypocellular	ADJ	O	O	2521
myelodysplasia	NOUN	O	Disease	2521
,	PUNCT	O	O	2521
two	NUM	O	O	2521
cases	NOUN	O	O	2521
of	ADP	O	O	2521
hypersegmented	VERB	O	O	2521
myelodysplastic	NOUN	O	Disease	2521
granulocytosis	VERB	O	O	2521
,	PUNCT	O	O	2521
two	NUM	O	O	2521
cases	NOUN	O	O	2521
of	ADP	O	O	2521
hypercellular	PROPN	O	O	2521
marrow	PROPN	O	O	2521
with	ADP	O	O	2521
abnormal	ADJ	O	O	2521
megakaryocytes	NOUN	O	O	2521
with	ADP	O	O	2521
bizarre	ADJ	O	O	2521
nuclei	NOUN	O	O	2521
,	PUNCT	O	O	2521
one	NUM	O	O	2521
case	NOUN	O	O	2521
of	ADP	O	O	2521
megakaryocytic	ADJ	O	O	2521
myelosis	NOUN	O	O	2521
associated	VERB	O	O	2521
with	ADP	O	O	2521
a	PRON	O	O	2521
hyperplastic marrow	NOUN	O	Disease	2521
,	PUNCT	O	O	2521
dysmyelopoiesis	VERB	O	Disease	2521
and	CCONJ	O	O	2521
a	PRON	O	O	2521
hypocellular marrow	NOUN	O	Disease	2521
and	CCONJ	O	O	2521
two	NUM	O	O	2521
cases	NOUN	O	O	2521
of	ADP	O	O	2521
myelodysplasia	NOUN	O	Disease	2521
with	ADP	O	O	2521
dyserythropoiesis	VERB	O	Disease	2521
,	PUNCT	O	O	2521
hemosiderosis	VERB	O	Disease	2521
and	CCONJ	O	O	2521
a	PRON	O	O	2521
hypocellular marrow	NOUN	O	Disease	2521
.	PUNCT	O	O	2521
Above	ADP	O	O	2522
mentioned	VERB	O	O	2522
AZT	PROPN	O	Chemical	2522
incorporation	NOUN	O	O	2522
may	AUX	O	O	2522
have	VERB	O	O	2522
induced	VERB	O	O	2522
an	PRON	O	O	2522
ineffective	ADJ	O	O	2522
hemopoiesis	VERB	O	O	2522
in	ADP	O	O	2522
the	PRON	O	O	2522
primitive	ADJ	O	O	2522
hemopoietic	ADJ	O	O	2522
progenitor	NOUN	O	O	2522
cells	NOUN	O	O	2522
,	PUNCT	O	O	2522
which	PRON	O	O	2522
is	AUX	O	O	2522
known	VERB	O	O	2522
to	PART	O	O	2522
be	AUX	O	O	2522
seen	VERB	O	O	2522
commonly	ADV	O	O	2522
in	ADP	O	O	2522
the	PRON	O	O	2522
myelodysplastic syndrome	PROPN	O	Disease	2522
.	PUNCT	O	O	2522
Influence	NOUN	O	O	2525
of	ADP	O	O	2525
diet	PROPN	O	O	2525
free	ADJ	O	O	2525
of	ADP	O	O	2525
NAD	PROPN	O	Chemical	2525
-	PUNCT	O	O	2525
precursors	NOUN	O	O	2525
on	ADP	O	O	2525
acetaminophen	PROPN	O	Chemical	2525
hepatotoxicity	NOUN	O	Disease	2525
in	ADP	O	O	2525
mice	NOUN	O	O	2525
.	PUNCT	O	O	2525
Recently	ADV	O	O	2526
,	PUNCT	O	O	2526
we	PRON	O	O	2526
demonstrated	VERB	O	O	2526
the	PRON	O	O	2526
hepatoprotective	NOUN	O	O	2526
effects	NOUN	O	O	2526
of	ADP	O	O	2526
nicotinic acid amide	NOUN	O	Chemical	2526
,	PUNCT	O	O	2526
a	PRON	O	O	2526
selective	ADJ	O	O	2526
inhibitor	NOUN	O	O	2526
of	ADP	O	O	2526
poly(ADP	ADV	O	O	2526
-	PUNCT	O	O	2526
ribose	NOUN	O	O	2526
)	PUNCT	O	O	2526
polymerase	NOUN	O	O	2526
(	PUNCT	O	O	2526
PARP	PROPN	O	O	2526
;	PUNCT	O	O	2526
EC	PROPN	O	O	2526
2.4.2.30	NOUN	O	O	2526
)	PUNCT	O	O	2526
on	ADP	O	O	2526
mice	NOUN	O	O	2526
suffering	VERB	O	O	2526
from	ADP	O	O	2526
acetaminophen	PROPN	O	Chemical	2526
(	PUNCT	O	O	2526
AAP)-hepatitis	NOUN	O	O	2526
,	PUNCT	O	O	2526
suggesting	VERB	O	O	2526
that	SCONJ	O	O	2526
the	PRON	O	O	2526
AAP	PROPN	O	Chemical	2526
-	PUNCT	O	O	2526
induced	VERB	O	O	2526
liver injury	NOUN	O	Disease	2526
involves	VERB	O	O	2526
a	PRON	O	O	2526
step	VERB	O	O	2526
which	PRON	O	O	2526
depends	VERB	O	O	2526
on	ADP	O	O	2526
adenoribosylation	PROPN	O	O	2526
.	PUNCT	O	O	2526
The	PRON	O	O	2527
present	NOUN	O	O	2527
study	VERB	O	O	2527
investigates	VERB	O	O	2527
the	PRON	O	O	2527
effects	NOUN	O	O	2527
of	ADP	O	O	2527
a	PRON	O	O	2527
diet	PROPN	O	O	2527
free	ADJ	O	O	2527
of	ADP	O	O	2527
precursors	NOUN	O	O	2527
of	ADP	O	O	2527
NAD	PROPN	O	Chemical	2527
,	PUNCT	O	O	2527
the	PRON	O	O	2527
substrate	NOUN	O	O	2527
on	ADP	O	O	2527
which	PRON	O	O	2527
PARP	PROPN	O	O	2527
acts	VERB	O	O	2527
,	PUNCT	O	O	2527
in	ADP	O	O	2527
female	ADJ	O	O	2527
NMRI	NOUN	O	O	2527
mice	NOUN	O	O	2527
with	ADP	O	O	2527
AAP	PROPN	O	Chemical	2527
hepatitis	NOUN	O	Disease	2527
and	CCONJ	O	O	2527
evaluates	VERB	O	O	2527
the	PRON	O	O	2527
influence	NOUN	O	O	2527
of	ADP	O	O	2527
simultaneous	ADJ	O	O	2527
ethanol	NOUN	O	Chemical	2527
consumption	NOUN	O	O	2527
in	ADP	O	O	2527
these	PRON	O	O	2527
animals	NOUN	O	O	2527
.	PUNCT	O	O	2527
Liver injuries	NOUN	O	Disease	2528
were	AUX	O	O	2528
quantified	VERB	O	O	2528
as	ADP	O	O	2528
serum	NOUN	O	O	2528
activities	NOUN	O	O	2528
of	ADP	O	O	2528
glutamate	NOUN	O	Chemical	2528
-	PUNCT	O	O	2528
oxaloacetate	CCONJ	O	Chemical	2528
transaminase	X	O	O	2528
(	PUNCT	O	O	2528
GOT	VERB	O	O	2528
)	PUNCT	O	O	2528
and	CCONJ	O	O	2528
glutamate	NOUN	O	Chemical	2528
-	PUNCT	O	O	2528
pyruvate	NOUN	O	Chemical	2528
transaminase	X	O	O	2528
(	PUNCT	O	O	2528
GPT	PROPN	O	O	2528
)	PUNCT	O	O	2528
.	PUNCT	O	O	2528
While	SCONJ	O	O	2529
AAP	PROPN	O	Chemical	2529
caused	VERB	O	O	2529
a	PRON	O	O	2529
117-fold	ADV	O	O	2529
elevation	NOUN	O	O	2529
of	ADP	O	O	2529
serum	NOUN	O	O	2529
transaminase	X	O	O	2529
activities	NOUN	O	O	2529
in	ADP	O	O	2529
mice	NOUN	O	O	2529
kept	VERB	O	O	2529
on	ADP	O	O	2529
a	PRON	O	O	2529
standard	PROPN	O	O	2529
laboratory	NOUN	O	O	2529
diet	PROPN	O	O	2529
,	PUNCT	O	O	2529
which	PRON	O	O	2529
was	AUX	O	O	2529
significantly	ADV	O	O	2529
exacerbated	VERB	O	O	2529
by	ADP	O	O	2529
ethanol	NOUN	O	Chemical	2529
and	CCONJ	O	O	2529
inhibited	VERB	O	O	2529
by	ADP	O	O	2529
nicotinic acid amide	NOUN	O	Chemical	2529
(	PUNCT	O	O	2529
NAA	PROPN	O	Chemical	2529
)	PUNCT	O	O	2529
,	PUNCT	O	O	2529
adverse	ADJ	O	O	2529
effects	NOUN	O	O	2529
were	AUX	O	O	2529
noted	VERB	O	O	2529
in	ADP	O	O	2529
animals	NOUN	O	O	2529
fed	VERB	O	O	2529
a	PRON	O	O	2529
diet	PROPN	O	O	2529
free	ADJ	O	O	2529
of	ADP	O	O	2529
precursors	NOUN	O	O	2529
of	ADP	O	O	2529
NAD	PROPN	O	Chemical	2529
.	PUNCT	O	O	2529
In	ADP	O	O	2530
these	PRON	O	O	2530
animals	NOUN	O	O	2530
,	PUNCT	O	O	2530
only	ADV	O	O	2530
minor	ADJ	O	O	2530
increases	VERB	O	O	2530
of	ADP	O	O	2530
serum	NOUN	O	O	2530
transaminase	X	O	O	2530
activities	NOUN	O	O	2530
were	AUX	O	O	2530
measured	VERB	O	O	2530
in	ADP	O	O	2530
the	PRON	O	O	2530
presence	NOUN	O	O	2530
of	ADP	O	O	2530
AAP	PROPN	O	Chemical	2530
,	PUNCT	O	O	2530
and	CCONJ	O	O	2530
unlike	ADP	O	O	2530
the	PRON	O	O	2530
exacerbation	NOUN	O	O	2530
caused	VERB	O	O	2530
by	ADP	O	O	2530
ethanol	NOUN	O	Chemical	2530
in	ADP	O	O	2530
mice	NOUN	O	O	2530
on	ADP	O	O	2530
a	PRON	O	O	2530
standard	PROPN	O	O	2530
diet	PROPN	O	O	2530
,	PUNCT	O	O	2530
the	PRON	O	O	2530
liver damage	NOUN	O	Disease	2530
was	AUX	O	O	2530
inhibited	VERB	O	O	2530
by	ADP	O	O	2530
50%	NOUN	O	O	2530
by	ADP	O	O	2530
ethanol	NOUN	O	Chemical	2530
.	PUNCT	O	O	2530
A	PRON	O	O	2531
further	ADV	O	O	2531
64%	NOUN	O	O	2531
reduction	NOUN	O	O	2531
of	ADP	O	O	2531
hepatitis	NOUN	O	Disease	2531
was	AUX	O	O	2531
observed	VERB	O	O	2531
,	PUNCT	O	O	2531
when	SCONJ	O	O	2531
NAA	PROPN	O	Chemical	2531
was	AUX	O	O	2531
given	VERB	O	O	2531
to	PART	O	O	2531
ethanol	NOUN	O	Chemical	2531
/	PUNCT	O	O	2531
AAP	PROPN	O	Chemical	2531
-	PUNCT	O	O	2531
mice	NOUN	O	O	2531
.	PUNCT	O	O	2531
Our	PRON	O	O	2532
results	VERB	O	O	2532
provide	VERB	O	O	2532
evidence	NOUN	O	O	2532
that	SCONJ	O	O	2532
the	PRON	O	O	2532
AAP	PROPN	O	Chemical	2532
-	PUNCT	O	O	2532
induced	VERB	O	O	2532
hepatitis	NOUN	O	Disease	2532
and	CCONJ	O	O	2532
its	PRON	O	O	2532
exacerbation	NOUN	O	O	2532
by	ADP	O	O	2532
ethanol	NOUN	O	Chemical	2532
can	AUX	O	O	2532
either	ADV	O	O	2532
be	AUX	O	O	2532
reduced	VERB	O	O	2532
by	ADP	O	O	2532
end	VERB	O	O	2532
-	PUNCT	O	O	2532
product	NOUN	O	O	2532
inhibition	NOUN	O	O	2532
of	ADP	O	O	2532
PARP	PROPN	O	O	2532
by	ADP	O	O	2532
NAA	PROPN	O	Chemical	2532
or	CCONJ	O	O	2532
by	ADP	O	O	2532
dietary	ADJ	O	O	2532
depletion	NOUN	O	O	2532
of	ADP	O	O	2532
the	PRON	O	O	2532
enzyme	NOUN	O	O	2532
's	AUX	O	O	2532
substrate	NOUN	O	O	2532
NAD	PROPN	O	Chemical	2532
.	PUNCT	O	O	2532
We	PRON	O	O	2533
see	VERB	O	O	2533
the	PRON	O	O	2533
main	ADJ	O	O	2533
application	NOUN	O	O	2533
of	ADP	O	O	2533
NAA	PROPN	O	Chemical	2533
as	ADP	O	O	2533
for	ADP	O	O	2533
the	PRON	O	O	2533
combinational	ADJ	O	O	2533
use	VERB	O	O	2533
in	ADP	O	O	2533
pharmaceutical	NOUN	O	O	2533
preparations	NOUN	O	O	2533
of	ADP	O	O	2533
acetaminophen	PROPN	O	Chemical	2533
in	ADP	O	O	2533
order	NOUN	O	O	2533
to	PART	O	O	2533
avoid	VERB	O	O	2533
hepatic damage	NOUN	O	Disease	2533
in	ADP	O	O	2533
patients	NOUN	O	O	2533
treated	VERB	O	O	2533
with	ADP	O	O	2533
this	PRON	O	O	2533
widely	ADV	O	O	2533
used	VERB	O	O	2533
analgesic	PROPN	O	O	2533
.	PUNCT	O	O	2533
Antiarrhythmic	PROPN	O	O	2536
plasma	NOUN	O	O	2536
concentrations	NOUN	O	O	2536
of	ADP	O	O	2536
cibenzoline	VERB	O	Chemical	2536
on	ADP	O	O	2536
canine	NOUN	O	O	2536
ventricular arrhythmias	NOUN	O	Disease	2536
.	PUNCT	O	O	2536
Using	VERB	O	O	2537
two	NUM	O	O	2537
-	PUNCT	O	O	2537
stage	NOUN	O	O	2537
coronary	ADJ	O	O	2537
ligation-	PROPN	O	O	2537
,	PUNCT	O	O	2537
digitalis-	X	O	O	2537
,	PUNCT	O	O	2537
and	CCONJ	O	O	2537
adrenaline	NOUN	O	Chemical	2537
-	PUNCT	O	O	2537
induced	VERB	O	O	2537
canine	NOUN	O	O	2537
ventricular arrhythmias	NOUN	O	Disease	2537
,	PUNCT	O	O	2537
antiarrhythmic	PROPN	O	O	2537
effects	NOUN	O	O	2537
of	ADP	O	O	2537
cibenzoline	VERB	O	Chemical	2537
were	AUX	O	O	2537
examined	VERB	O	O	2537
and	CCONJ	O	O	2537
the	PRON	O	O	2537
minimum	ADJ	O	O	2537
effective	ADJ	O	O	2537
plasma	NOUN	O	O	2537
concentration	NOUN	O	O	2537
for	ADP	O	O	2537
each	PRON	O	O	2537
arrhythmia	NOUN	O	Disease	2537
model	NOUN	O	O	2537
was	AUX	O	O	2537
determined	VERB	O	O	2537
.	PUNCT	O	O	2537
Cibenzoline	NOUN	O	Chemical	2538
suppressed	VERB	O	O	2538
all	PRON	O	O	2538
the	PRON	O	O	2538
arrhythmias	VERB	O	Disease	2538
,	PUNCT	O	O	2538
and	CCONJ	O	O	2538
the	PRON	O	O	2538
minimum	ADJ	O	O	2538
effective	ADJ	O	O	2538
plasma	NOUN	O	O	2538
concentrations	NOUN	O	O	2538
for	ADP	O	O	2538
arrhythmias	VERB	O	Disease	2538
induced	VERB	O	O	2538
by	ADP	O	O	2538
24-h	NOUN	O	O	2538
coronary	ADJ	O	O	2538
ligation	NOUN	O	O	2538
,	PUNCT	O	O	2538
48-h	NOUN	O	O	2538
coronary	ADJ	O	O	2538
ligation	NOUN	O	O	2538
,	PUNCT	O	O	2538
digitalis	NOUN	O	Chemical	2538
,	PUNCT	O	O	2538
and	CCONJ	O	O	2538
adrenaline	NOUN	O	Chemical	2538
were	AUX	O	O	2538
1.9	NUM	O	O	2538
+	ADP	O	O	2538
/-	PUNCT	O	O	2538
The	PRON	O	O	2539
concentration	NOUN	O	O	2539
for	ADP	O	O	2539
adrenaline	NOUN	O	Chemical	2539
-	PUNCT	O	O	2539
induced	VERB	O	O	2539
arrhythmia	NOUN	O	Disease	2539
was	AUX	O	O	2539
significantly	ADV	O	O	2539
higher	ADJ	O	O	2539
than	ADP	O	O	2539
those	PRON	O	O	2539
for	ADP	O	O	2539
the	PRON	O	O	2539
other	ADJ	O	O	2539
types	NOUN	O	O	2539
of	ADP	O	O	2539
arrhythmias	VERB	O	Disease	2539
.	PUNCT	O	O	2539
This	PRON	O	O	2540
pharmacological	ADJ	O	O	2540
profile	NOUN	O	O	2540
is	AUX	O	O	2540
similar	ADJ	O	O	2540
to	PART	O	O	2540
those	PRON	O	O	2540
of	ADP	O	O	2540
mexiletine	NOUN	O	Chemical	2540
and	CCONJ	O	O	2540
tocainide	NOUN	O	Chemical	2540
,	PUNCT	O	O	2540
and	CCONJ	O	O	2540
all	PRON	O	O	2540
three	NUM	O	O	2540
drugs	NOUN	O	O	2540
have	VERB	O	O	2540
central	ADJ	O	O	2540
nervous	ADJ	O	O	2540
system	NOUN	O	O	2540
(	PUNCT	O	O	2540
CNS	PROPN	O	O	2540
)	PUNCT	O	O	2540
stimulant	NOUN	O	O	2540
action	NOUN	O	O	2540
.	PUNCT	O	O	2540
Because	SCONJ	O	O	2541
cibenzoline	VERB	O	Chemical	2541
had	VERB	O	O	2541
only	ADV	O	O	2541
weak	ADJ	O	O	2541
hypotensive	ADJ	O	Disease	2541
and	CCONJ	O	O	2541
sinus	NOUN	O	O	2541
node	NOUN	O	O	2541
depressive	ADJ	O	Disease	2541
effects	NOUN	O	O	2541
and	CCONJ	O	O	2541
was	AUX	O	O	2541
found	VERB	O	O	2541
to	PART	O	O	2541
be	AUX	O	O	2541
orally	ADV	O	O	2541
active	ADJ	O	O	2541
when	SCONJ	O	O	2541
given	VERB	O	O	2541
to	PART	O	O	2541
coronary	ADJ	O	O	2541
ligation	NOUN	O	O	2541
arrhythmia	NOUN	O	Disease	2541
dogs	NOUN	O	O	2541
,	PUNCT	O	O	2541
its	PRON	O	O	2541
clinical	ADJ	O	O	2541
usefulness	NOUN	O	O	2541
is	AUX	O	O	2541
expected	VERB	O	O	2541
.	PUNCT	O	O	2541
Immunopathology	NOUN	O	O	2544
of	ADP	O	O	2544
penicillamine	NOUN	O	Chemical	2544
-	PUNCT	O	O	2544
induced	VERB	O	O	2544
glomerular disease	NOUN	O	Disease	2544
.	PUNCT	O	O	2544
Four	NUM	O	O	2545
patients	NOUN	O	O	2545
with	ADP	O	O	2545
rheumatoid arthritis	NOUN	O	Disease	2545
developed	VERB	O	O	2545
heavy	ADJ	O	O	2545
proteinuria	X	O	Disease	2545
after	ADP	O	O	2545
five	NUM	O	O	2545
to	PART	O	O	2545
12	NUM	O	O	2545
months	NOUN	O	O	2545
of	ADP	O	O	2545
treatment	NOUN	O	O	2545
with	ADP	O	O	2545
D	NOUN	O	O	2545
-	PUNCT	O	O	2545
penicillamine	NOUN	O	Chemical	2545
.	PUNCT	O	O	2545
The	PRON	O	O	2546
findings	NOUN	O	O	2546
were	AUX	O	O	2546
similar	ADJ	O	O	2546
to	PART	O	O	2546
those	PRON	O	O	2546
in	ADP	O	O	2546
early	ADV	O	O	2546
membranous glomerulonephritis	NOUN	O	Disease	2546
,	PUNCT	O	O	2546
differences	NOUN	O	O	2546
being	AUX	O	O	2546
observed	VERB	O	O	2546
however	ADV	O	O	2546
in	ADP	O	O	2546
the	PRON	O	O	2546
results	VERB	O	O	2546
of	ADP	O	O	2546
staining	VERB	O	O	2546
for	ADP	O	O	2546
the	PRON	O	O	2546
early	ADV	O	O	2546
-	PUNCT	O	O	2546
acting	VERB	O	O	2546
complement	VERB	O	O	2546
components	NOUN	O	O	2546
C1q	PROPN	O	O	2546
and	CCONJ	O	O	2546
C4	PROPN	O	O	2546
.	PUNCT	O	O	2546
Ventricular fibrillation	NOUN	O	Disease	2549
from	ADP	O	O	2549
diatrizoate	ADJ	O	Chemical	2549
with	ADP	O	O	2549
and	CCONJ	O	O	2549
without	ADP	O	O	2549
chelating	VERB	O	O	2549
agents	NOUN	O	O	2549
.	PUNCT	O	O	2549
The	PRON	O	O	2550
toxicity	NOUN	O	Disease	2550
of	ADP	O	O	2550
Renografin 76%	NOUN	O	Chemical	2550
was	AUX	O	O	2550
compared	VERB	O	O	2550
with	ADP	O	O	2550
that	SCONJ	O	O	2550
of	ADP	O	O	2550
Hypaque 76%	NOUN	O	Chemical	2550
by	ADP	O	O	2550
selective	ADJ	O	O	2550
injection	NOUN	O	O	2550
of	ADP	O	O	2550
each	PRON	O	O	2550
into	ADP	O	O	2550
the	PRON	O	O	2550
right	ADV	O	O	2550
coronary	ADJ	O	O	2550
artery	NOUN	O	O	2550
of	ADP	O	O	2550
dogs	NOUN	O	O	2550
.	PUNCT	O	O	2550
Renografin	NOUN	O	Chemical	2551
contains	VERB	O	O	2551
the	PRON	O	O	2551
chelating	VERB	O	O	2551
agents	NOUN	O	O	2551
sodium citrate	NOUN	O	Chemical	2551
and	CCONJ	O	O	2551
disodium edetate	NOUN	O	Chemical	2551
,	PUNCT	O	O	2551
while	SCONJ	O	O	2551
Hypaque	NOUN	O	Chemical	2551
contains	VERB	O	O	2551
calcium disodium edetate	NOUN	O	Chemical	2551
and	CCONJ	O	O	2551
no	PRON	O	O	2551
sodium citrate	NOUN	O	Chemical	2551
.	PUNCT	O	O	2551
Ventricular fibrillation	NOUN	O	Disease	2552
occurred	VERB	O	O	2552
significantly	ADV	O	O	2552
more	ADJ	O	O	2552
often	ADV	O	O	2552
with	ADP	O	O	2552
Renografin	NOUN	O	Chemical	2552
,	PUNCT	O	O	2552
suggesting	VERB	O	O	2552
that	SCONJ	O	O	2552
chelating	VERB	O	O	2552
agents	NOUN	O	O	2552
contribute	VERB	O	O	2552
to	PART	O	O	2552
toxicity	NOUN	O	Disease	2552
in	ADP	O	O	2552
coronary	ADJ	O	O	2552
angiography	NOUN	O	O	2552
.	PUNCT	O	O	2552
Rapid	ADJ	O	O	2555
reversal	NOUN	O	O	2555
of	ADP	O	O	2555
anticoagulation	NOUN	O	O	2555
reduces	VERB	O	O	2555
hemorrhage	NOUN	O	Disease	2555
volume	PROPN	O	O	2555
in	ADP	O	O	2555
a	PRON	O	O	2555
mouse	PROPN	O	O	2555
model	NOUN	O	O	2555
of	ADP	O	O	2555
warfarin	VERB	O	Chemical	2555
-	PUNCT	O	O	2555
associated	VERB	O	O	2555
intracerebral hemorrhage	NOUN	O	Disease	2555
.	PUNCT	O	O	2555
Warfarin	PROPN	O	Chemical	2556
-	PUNCT	O	O	2556
associated	VERB	O	O	2556
intracerebral hemorrhage	NOUN	O	Disease	2556
(	PUNCT	O	O	2556
W	NOUN	O	O	2556
-	PUNCT	O	O	2556
ICH	PROPN	O	Disease	2556
)	PUNCT	O	O	2556
is	AUX	O	O	2556
a	PRON	O	O	2556
severe	ADJ	O	O	2556
type	NOUN	O	O	2556
of	ADP	O	O	2556
stroke	VERB	O	Disease	2556
.	PUNCT	O	O	2556
There	ADV	O	O	2557
is	AUX	O	O	2557
no	PRON	O	O	2557
consensus	NOUN	O	O	2557
on	ADP	O	O	2557
the	PRON	O	O	2557
optimal	ADJ	O	O	2557
treatment	NOUN	O	O	2557
for	ADP	O	O	2557
W	NOUN	O	O	2557
-	PUNCT	O	O	2557
ICH	PROPN	O	Disease	2557
.	PUNCT	O	O	2557
Using	VERB	O	O	2558
a	PRON	O	O	2558
mouse	PROPN	O	O	2558
model	NOUN	O	O	2558
,	PUNCT	O	O	2558
we	PRON	O	O	2558
tested	VERB	O	O	2558
whether	SCONJ	O	O	2558
the	PRON	O	O	2558
rapid	ADJ	O	O	2558
reversal	NOUN	O	O	2558
of	ADP	O	O	2558
anticoagulation	NOUN	O	O	2558
using	VERB	O	O	2558
human	PROPN	O	O	2558
prothrombin complex concentrate	NOUN	O	Chemical	2558
(	PUNCT	O	O	2558
PCC	PROPN	O	Chemical	2558
)	PUNCT	O	O	2558
can	AUX	O	O	2558
reduce	VERB	O	O	2558
hemorrhagic	ADJ	O	Disease	2558
blood	NOUN	O	O	2558
volume	PROPN	O	O	2558
.	PUNCT	O	O	2558
Male	NOUN	O	O	2559
CD-1	NOUN	O	O	2559
mice	NOUN	O	O	2559
were	AUX	O	O	2559
treated	VERB	O	O	2559
with	ADP	O	O	2559
warfarin	VERB	O	Chemical	2559
(	PUNCT	O	O	2559
2	X	O	O	2559
mg	VERB	O	O	2559
/	PUNCT	O	O	2559
kg	VERB	O	O	2559
over	ADP	O	O	2559
24	NUM	O	O	2559
h	X	O	O	2559
)	PUNCT	O	O	2559
,	PUNCT	O	O	2559
resulting	VERB	O	O	2559
in	ADP	O	O	2559
a	PRON	O	O	2559
mean	VERB	O	O	2559
(	PUNCT	O	O	2559
+	ADP	O	O	2559
/-s.d	PUNCT	O	O	2559
.	PUNCT	O	O	2559
)	PUNCT	O	O	2559
First	ADV	O	O	2560
,	PUNCT	O	O	2560
we	PRON	O	O	2560
showed	VERB	O	O	2560
that	SCONJ	O	O	2560
an	PRON	O	O	2560
intravenous	ADJ	O	O	2560
administration	NOUN	O	O	2560
of	ADP	O	O	2560
human	PROPN	O	O	2560
PCC	PROPN	O	Chemical	2560
rapidly	ADV	O	O	2560
reversed	VERB	O	O	2560
anticoagulation	NOUN	O	O	2560
in	ADP	O	O	2560
mice	NOUN	O	O	2560
.	PUNCT	O	O	2560
Second	ADJ	O	O	2561
,	PUNCT	O	O	2561
a	PRON	O	O	2561
stereotactic	NOUN	O	O	2561
injection	NOUN	O	O	2561
of	ADP	O	O	2561
collagenase	NOUN	O	O	2561
was	AUX	O	O	2561
administered	VERB	O	O	2561
to	PART	O	O	2561
induce	VERB	O	O	2561
hemorrhage	NOUN	O	Disease	2561
in	ADP	O	O	2561
the	PRON	O	O	2561
right	ADV	O	O	2561
striatum	NOUN	O	O	2561
.	PUNCT	O	O	2561
Forty	NUM	O	O	2562
-	PUNCT	O	O	2562
five	NUM	O	O	2562
minutes	NOUN	O	O	2562
later	ADV	O	O	2562
,	PUNCT	O	O	2562
the	PRON	O	O	2562
animals	NOUN	O	O	2562
were	AUX	O	O	2562
randomly	ADV	O	O	2562
treated	VERB	O	O	2562
with	ADP	O	O	2562
PCC	PROPN	O	Chemical	2562
(	PUNCT	O	O	2562
100	NUM	O	O	2562
U	NOUN	O	O	2562
/	PUNCT	O	O	2562
kg	VERB	O	O	2562
)	PUNCT	O	O	2562
or	CCONJ	O	O	2562
saline	NOUN	O	O	2562
i.v	NOUN	O	O	2562
.	PUNCT	O	O	2562
Twenty	NUM	O	O	2563
-	PUNCT	O	O	2563
four	NUM	O	O	2563
hours	NOUN	O	O	2563
after	ADP	O	O	2563
hemorrhage	NOUN	O	Disease	2563
induction	NOUN	O	O	2563
,	PUNCT	O	O	2563
hemorrhagic	ADJ	O	Disease	2563
blood	NOUN	O	O	2563
volume	PROPN	O	O	2563
was	AUX	O	O	2563
quantified	VERB	O	O	2563
using	VERB	O	O	2563
a	PRON	O	O	2563
photometric	NOUN	O	O	2563
hemoglobin	NOUN	O	O	2563
assay	NOUN	O	O	2563
.	PUNCT	O	O	2563
The	PRON	O	O	2564
mean	VERB	O	O	2564
hemorrhagic	ADJ	O	Disease	2564
blood	NOUN	O	O	2564
volume	PROPN	O	O	2564
was	AUX	O	O	2564
reduced	VERB	O	O	2564
in	ADP	O	O	2564
PCC	PROPN	O	Chemical	2564
-	PUNCT	O	O	2564
treated	VERB	O	O	2564
animals	NOUN	O	O	2564
(	PUNCT	O	O	2564
6.5+/-3.1	NUM	O	O	2564
microL	CCONJ	O	O	2564
)	PUNCT	O	O	2564
compared	VERB	O	O	2564
with	ADP	O	O	2564
saline	NOUN	O	O	2564
controls	VERB	O	O	2564
(	PUNCT	O	O	2564
15.3+/-11.2	NUM	O	O	2564
microL	CCONJ	O	O	2564
,	PUNCT	O	O	2564
P=0.015	NUM	O	O	2564
)	PUNCT	O	O	2564
.	PUNCT	O	O	2564
In	ADP	O	O	2565
the	PRON	O	O	2565
saline	NOUN	O	O	2565
group	NOUN	O	O	2565
,	PUNCT	O	O	2565
45%	NOUN	O	O	2565
of	ADP	O	O	2565
the	PRON	O	O	2565
mice	NOUN	O	O	2565
developed	VERB	O	O	2565
large	ADJ	O	O	2565
hematomas	VERB	O	Disease	2565
(	PUNCT	O	O	2565
i.e.	X	O	O	2565
,	PUNCT	O	O	2565
>	PUNCT	O	O	2565
15	NUM	O	O	2565
microL	CCONJ	O	O	2565
)	PUNCT	O	O	2565
.	PUNCT	O	O	2565
In	ADP	O	O	2566
contrast	NOUN	O	O	2566
,	PUNCT	O	O	2566
such	ADJ	O	O	2566
extensive	ADJ	O	O	2566
lesions	NOUN	O	O	2566
were	AUX	O	O	2566
never	ADV	O	O	2566
found	VERB	O	O	2566
in	ADP	O	O	2566
the	PRON	O	O	2566
PCC	PROPN	O	Chemical	2566
group	NOUN	O	O	2566
.	PUNCT	O	O	2566
We	PRON	O	O	2567
provide	VERB	O	O	2567
experimental	ADJ	O	O	2567
data	NOUN	O	O	2567
suggesting	VERB	O	O	2567
PCC	PROPN	O	Chemical	2567
to	PART	O	O	2567
be	AUX	O	O	2567
an	PRON	O	O	2567
effective	ADJ	O	O	2567
acute	ADJ	O	O	2567
treatment	NOUN	O	O	2567
for	ADP	O	O	2567
W	NOUN	O	O	2567
-	PUNCT	O	O	2567
ICH	PROPN	O	Disease	2567
in	ADP	O	O	2567
terms	NOUN	O	O	2567
of	ADP	O	O	2567
reducing	VERB	O	O	2567
hemorrhagic	ADJ	O	Disease	2567
blood	NOUN	O	O	2567
volume	PROPN	O	O	2567
.	PUNCT	O	O	2567
Future	NOUN	O	O	2568
studies	NOUN	O	O	2568
are	AUX	O	O	2568
needed	VERB	O	O	2568
to	PART	O	O	2568
assess	VERB	O	O	2568
the	PRON	O	O	2568
therapeutic	ADJ	O	O	2568
potential	ADJ	O	O	2568
emerging	VERB	O	O	2568
from	ADP	O	O	2568
our	PRON	O	O	2568
finding	VERB	O	O	2568
for	ADP	O	O	2568
human	PROPN	O	O	2568
W	NOUN	O	O	2568
-	PUNCT	O	O	2568
ICH	PROPN	O	Disease	2568
.	PUNCT	O	O	2568
Impact	NOUN	O	O	2571
of	ADP	O	O	2571
alcohol	NOUN	O	Chemical	2571
exposure	NOUN	O	O	2571
after	ADP	O	O	2571
pregnancy	NOUN	O	O	2571
recognition	NOUN	O	O	2571
on	ADP	O	O	2571
ultrasonographic	NOUN	O	O	2571
fetal	ADJ	O	O	2571
growth	NOUN	O	O	2571
measures	NOUN	O	O	2571
.	PUNCT	O	O	2571
BACKGROUND	NOUN	O	O	2572
:	PUNCT	O	O	2572
More	ADJ	O	O	2572
than	ADP	O	O	2572
3	X	O	O	2572
decades	NOUN	O	O	2572
after	ADP	O	O	2572
Jones	PROPN	O	O	2572
and	CCONJ	O	O	2572
Smith	PROPN	O	O	2572
(	PUNCT	O	O	2572
1973	NUM	O	O	2572
)	PUNCT	O	O	2572
reported	VERB	O	O	2572
on	ADP	O	O	2572
the	PRON	O	O	2572
devastation	NOUN	O	O	2572
caused	VERB	O	O	2572
by	ADP	O	O	2572
alcohol	NOUN	O	Chemical	2572
exposure	NOUN	O	O	2572
on	ADP	O	O	2572
fetal	ADJ	O	O	2572
development	NOUN	O	O	2572
,	PUNCT	O	O	2572
the	PRON	O	O	2572
rates	NOUN	O	O	2572
of	ADP	O	O	2572
heavy	ADJ	O	O	2572
drinking	VERB	O	O	2572
during	ADP	O	O	2572
pregnancy	NOUN	O	O	2572
remain	VERB	O	O	2572
relatively	ADV	O	O	2572
unchanged	ADJ	O	O	2572
.	PUNCT	O	O	2572
Early	ADJ	O	O	2573
identification	NOUN	O	O	2573
of	ADP	O	O	2573
fetal	ADJ	O	O	2573
alcohol	NOUN	O	Chemical	2573
exposure	NOUN	O	O	2573
and	CCONJ	O	O	2573
maternal	ADJ	O	O	2573
abstinence	NOUN	O	O	2573
led	VERB	O	O	2573
to	PART	O	O	2573
better	ADV	O	O	2573
infant	NOUN	O	O	2573
outcomes	NOUN	O	O	2573
.	PUNCT	O	O	2573
This	PRON	O	O	2574
study	VERB	O	O	2574
examined	VERB	O	O	2574
the	PRON	O	O	2574
utility	NOUN	O	O	2574
of	ADP	O	O	2574
biometry	PROPN	O	O	2574
for	ADP	O	O	2574
detecting	VERB	O	O	2574
alcohol	NOUN	O	Chemical	2574
-	PUNCT	O	O	2574
related	ADJ	O	O	2574
fetal	ADJ	O	O	2574
growth impairment	NOUN	O	Disease	2574
.	PUNCT	O	O	2574
METHODS	NOUN	O	O	2575
:	PUNCT	O	O	2575
We	PRON	O	O	2575
obtained	VERB	O	O	2575
fetal	ADJ	O	O	2575
ultrasound	VERB	O	O	2575
measures	NOUN	O	O	2575
from	ADP	O	O	2575
routine	ADJ	O	O	2575
ultrasound	VERB	O	O	2575
examinations	NOUN	O	O	2575
for	ADP	O	O	2575
167	NUM	O	O	2575
pregnant	ADJ	O	O	2575
hazardous	ADJ	O	O	2575
drinkers	NOUN	O	O	2575
who	PRON	O	O	2575
were	AUX	O	O	2575
enrolled	VERB	O	O	2575
in	ADP	O	O	2575
a	PRON	O	O	2575
brief	PROPN	O	O	2575
alcohol	NOUN	O	Chemical	2575
intervention	NOUN	O	O	2575
study	VERB	O	O	2575
.	PUNCT	O	O	2575
Because	SCONJ	O	O	2576
intensity	NOUN	O	O	2576
of	ADP	O	O	2576
alcohol	NOUN	O	Chemical	2576
consumption	NOUN	O	O	2576
is	AUX	O	O	2576
associated	VERB	O	O	2576
with	ADP	O	O	2576
poorer	ADV	O	O	2576
fetal	ADJ	O	O	2576
outcomes	NOUN	O	O	2576
,	PUNCT	O	O	2576
separate	VERB	O	O	2576
analyses	NOUN	O	O	2576
were	AUX	O	O	2576
conducted	VERB	O	O	2576
for	ADP	O	O	2576
the	PRON	O	O	2576
heavy	ADJ	O	O	2576
(	PUNCT	O	O	2576
average	ADJ	O	O	2576
of	ADP	O	O	2576
>	PUNCT	O	O	2576
or=5	ADV	O	O	2576
drinks	VERB	O	O	2576
per	ADP	O	O	2576
drinking	VERB	O	O	2576
day	NOUN	O	O	2576
)	PUNCT	O	O	2576
alcohol	NOUN	O	Chemical	2576
consumers	NOUN	O	O	2576
.	PUNCT	O	O	2576
Analyses	NOUN	O	O	2577
of	ADP	O	O	2577
covariance	NOUN	O	O	2577
were	AUX	O	O	2577
used	VERB	O	O	2577
to	PART	O	O	2577
determine	VERB	O	O	2577
whether	SCONJ	O	O	2577
there	ADV	O	O	2577
were	AUX	O	O	2577
differences	NOUN	O	O	2577
between	ADP	O	O	2577
groups	NOUN	O	O	2577
after	ADP	O	O	2577
controlling	VERB	O	O	2577
for	ADP	O	O	2577
influences	NOUN	O	O	2577
of	ADP	O	O	2577
gestational	ADJ	O	O	2577
age	NOUN	O	O	2577
and	CCONJ	O	O	2577
drug abuse	NOUN	O	Disease	2577
.	PUNCT	O	O	2577
When	SCONJ	O	O	2578
women	NOUN	O	O	2578
reportedly	ADV	O	O	2578
quit	VERB	O	O	2578
drinking	VERB	O	O	2578
early	ADV	O	O	2578
in	ADP	O	O	2578
their	PRON	O	O	2578
pregnancies	NOUN	O	O	2578
,	PUNCT	O	O	2578
fetal	ADJ	O	O	2578
growth	NOUN	O	O	2578
measures	NOUN	O	O	2578
were	AUX	O	O	2578
not	PART	O	O	2578
significantly	ADV	O	O	2578
different	ADJ	O	O	2578
from	ADP	O	O	2578
a	PRON	O	O	2578
non	ADJ	O	O	2578
-	PUNCT	O	O	2578
alcohol	NOUN	O	Chemical	2578
-	PUNCT	O	O	2578
exposed	VERB	O	O	2578
group	NOUN	O	O	2578
,	PUNCT	O	O	2578
regardless	ADV	O	O	2578
of	ADP	O	O	2578
prior	ADV	O	O	2578
drinking	VERB	O	O	2578
patterns	NOUN	O	O	2578
.	PUNCT	O	O	2578
Any	PRON	O	O	2579
alcohol	NOUN	O	Chemical	2579
consumption	NOUN	O	O	2579
postpregnancy	NOUN	O	O	2579
recognition	NOUN	O	O	2579
among	ADP	O	O	2579
the	PRON	O	O	2579
heavy	ADJ	O	O	2579
drinkers	NOUN	O	O	2579
resulted	VERB	O	O	2579
in	ADP	O	O	2579
reduced cerebellar growth	NOUN	O	Disease	2579
as	ADP	O	O	2579
well	ADV	O	O	2579
as	ADP	O	O	2579
decreased cranial to body growth	NOUN	O	Disease	2579
in	ADP	O	O	2579
comparison	NOUN	O	O	2579
with	ADP	O	O	2579
women	NOUN	O	O	2579
who	PRON	O	O	2579
either	ADV	O	O	2579
quit	VERB	O	O	2579
drinking	VERB	O	O	2579
or	CCONJ	O	O	2579
who	PRON	O	O	2579
were	AUX	O	O	2579
nondrinkers	NOUN	O	O	2579
.	PUNCT	O	O	2579
Amphetamine	NOUN	O	Chemical	2580
abuse	VERB	O	O	2580
was	AUX	O	O	2580
predictive	ADJ	O	O	2580
of	ADP	O	O	2580
larger	ADJ	O	O	2580
cranial	ADJ	O	O	2580
to	PART	O	O	2580
body	NOUN	O	O	2580
growth	NOUN	O	O	2580
ratios	VERB	O	O	2580
.	PUNCT	O	O	2580
Although	SCONJ	O	O	2581
the	PRON	O	O	2581
reliance	NOUN	O	O	2581
on	ADP	O	O	2581
self	VERB	O	O	2581
-	PUNCT	O	O	2581
reported	VERB	O	O	2581
drinking	VERB	O	O	2581
is	AUX	O	O	2581
a	PRON	O	O	2581
limitation	NOUN	O	O	2581
in	ADP	O	O	2581
this	PRON	O	O	2581
study	VERB	O	O	2581
,	PUNCT	O	O	2581
these	PRON	O	O	2581
findings	NOUN	O	O	2581
support	NOUN	O	O	2581
the	PRON	O	O	2581
benefits	NOUN	O	O	2581
of	ADP	O	O	2581
early	ADV	O	O	2581
abstinence	NOUN	O	O	2581
and	CCONJ	O	O	2581
the	PRON	O	O	2581
potential	ADJ	O	O	2581
for	ADP	O	O	2581
ultrasound	VERB	O	O	2581
examinations	NOUN	O	O	2581
in	ADP	O	O	2581
the	PRON	O	O	2581
detection	NOUN	O	O	2581
of	ADP	O	O	2581
fetal	ADJ	O	O	2581
alcohol	NOUN	O	Chemical	2581
effects	NOUN	O	O	2581
.	PUNCT	O	O	2581
Urinary	NOUN	O	O	2584
symptoms	NOUN	O	O	2584
and	CCONJ	O	O	2584
quality	NOUN	O	O	2584
of	ADP	O	O	2584
life	NOUN	O	O	2584
changes	VERB	O	O	2584
in	ADP	O	O	2584
Thai	PROPN	O	O	2584
women	NOUN	O	O	2584
with	ADP	O	O	2584
overactive bladder	NOUN	O	Disease	2584
after	ADP	O	O	2584
tolterodine	PROPN	O	Chemical	2584
treatment	NOUN	O	O	2584
.	PUNCT	O	O	2584
OBJECTIVES	NOUN	O	O	2585
:	PUNCT	O	O	2585
To	PART	O	O	2585
study	VERB	O	O	2585
the	PRON	O	O	2585
urinary	ADJ	O	O	2585
symptoms	NOUN	O	O	2585
and	CCONJ	O	O	2585
quality	NOUN	O	O	2585
of	ADP	O	O	2585
life	NOUN	O	O	2585
changes	VERB	O	O	2585
in	ADP	O	O	2585
Thai	PROPN	O	O	2585
women	NOUN	O	O	2585
with	ADP	O	O	2585
overactive bladder	NOUN	O	Disease	2585
(	PUNCT	O	O	2585
OAB	PROPN	O	Disease	2585
)	PUNCT	O	O	2585
after	ADP	O	O	2585
tolterodine	PROPN	O	Chemical	2585
treatment	NOUN	O	O	2585
.	PUNCT	O	O	2585
MATERIAL	NOUN	O	O	2586
AND	CCONJ	O	O	2586
METHOD	NOUN	O	O	2586
:	PUNCT	O	O	2586
Thirty	NUM	O	O	2586
women	NOUN	O	O	2586
(	PUNCT	O	O	2586
aged	ADJ	O	O	2586
30	NUM	O	O	2586
-	PUNCT	O	O	2586
77	NUM	O	O	2586
years	NOUN	O	O	2586
)	PUNCT	O	O	2586
diagnosed	VERB	O	O	2586
as	ADP	O	O	2586
having	VERB	O	O	2586
OAB	PROPN	O	Disease	2586
at	ADP	O	O	2586
the	PRON	O	O	2586
Gynecology	NOUN	O	O	2586
Clinic	NOUN	O	O	2586
,	PUNCT	O	O	2586
King	NOUN	O	O	2586
Chulalongkorn	NOUN	O	O	2586
Memorial	ADJ	O	O	2586
Hospital	NOUN	O	O	2586
from	ADP	O	O	2586
January	PROPN	O	O	2586
to	PART	O	O	2586
April	PROPN	O	O	2586
2004	NUM	O	O	2586
were	AUX	O	O	2586
included	VERB	O	O	2586
in	ADP	O	O	2586
the	PRON	O	O	2586
present	NOUN	O	O	2586
study	VERB	O	O	2586
.	PUNCT	O	O	2586
Tolterodine	NOUN	O	Chemical	2587
2	X	O	O	2587
mg	VERB	O	O	2587
,	PUNCT	O	O	2587
twice	ADV	O	O	2587
daily	ADV	O	O	2587
was	AUX	O	O	2587
given	VERB	O	O	2587
.	PUNCT	O	O	2587
The	PRON	O	O	2588
number	NOUN	O	O	2588
of	ADP	O	O	2588
nocturia	VERB	O	Disease	2588
episodes	NOUN	O	O	2588
decreased	VERB	O	O	2588
from	ADP	O	O	2588
5.4	NUM	O	O	2588
+	ADP	O	O	2588
/-	PUNCT	O	O	2588
The	PRON	O	O	2589
most	ADV	O	O	2589
common	ADJ	O	O	2589
side	NOUN	O	O	2589
effect	VERB	O	O	2589
was	AUX	O	O	2589
dry month	NOUN	O	Disease	2589
in	ADP	O	O	2589
5	NUM	O	O	2589
cases	NOUN	O	O	2589
(	PUNCT	O	O	2589
16.7%	NOUN	O	O	2589
)	PUNCT	O	O	2589
with	ADP	O	O	2589
2	X	O	O	2589
cases	NOUN	O	O	2589
reporting	VERB	O	O	2589
a	PRON	O	O	2589
moderate	ADJ	O	O	2589
degree	PROPN	O	O	2589
and	CCONJ	O	O	2589
1	X	O	O	2589
case	NOUN	O	O	2589
with	ADP	O	O	2589
severe	ADJ	O	O	2589
degree	PROPN	O	O	2589
.	PUNCT	O	O	2589
Only	ADV	O	O	2590
one	NUM	O	O	2590
case	NOUN	O	O	2590
(	PUNCT	O	O	2590
3.3%	NOUN	O	O	2590
)	PUNCT	O	O	2590
withdrew	VERB	O	O	2590
from	ADP	O	O	2590
the	PRON	O	O	2590
present	NOUN	O	O	2590
study	VERB	O	O	2590
due	ADJ	O	O	2590
to	PART	O	O	2590
a	PRON	O	O	2590
severe	ADJ	O	O	2590
dry mouth	NOUN	O	Disease	2590
.	PUNCT	O	O	2590
Tolterodine	NOUN	O	Chemical	2591
was	AUX	O	O	2591
well	ADV	O	O	2591
tolerated	VERB	O	O	2591
and	CCONJ	O	O	2591
its	PRON	O	O	2591
effects	NOUN	O	O	2591
improved	VERB	O	O	2591
the	PRON	O	O	2591
quality	NOUN	O	O	2591
of	ADP	O	O	2591
life	NOUN	O	O	2591
in	ADP	O	O	2591
Thai	PROPN	O	O	2591
women	NOUN	O	O	2591
with	ADP	O	O	2591
OAB	PROPN	O	Disease	2591
.	PUNCT	O	O	2591
Absence	NOUN	O	O	2594
of	ADP	O	O	2594
acute	ADJ	O	O	2594
cerebral	ADJ	O	O	2594
vasoconstriction	NOUN	O	O	2594
after	ADP	O	O	2594
cocaine	NOUN	O	Chemical	2594
-	PUNCT	O	O	2594
associated	VERB	O	O	2594
subarachnoid hemorrhage	NOUN	O	Disease	2594
.	PUNCT	O	O	2594
Cocaine	NOUN	O	Chemical	2595
use	VERB	O	O	2595
has	VERB	O	O	2595
been	AUX	O	O	2595
associated	VERB	O	O	2595
with	ADP	O	O	2595
neurovascular complications	NOUN	O	Disease	2595
,	PUNCT	O	O	2595
including	VERB	O	O	2595
arterial	ADJ	O	O	2595
vasoconstriction	NOUN	O	O	2595
and	CCONJ	O	O	2595
vasculitis	NOUN	O	Disease	2595
.	PUNCT	O	O	2595
However	ADV	O	O	2596
,	PUNCT	O	O	2596
there	ADV	O	O	2596
are	AUX	O	O	2596
few	ADJ	O	O	2596
studies	NOUN	O	O	2596
of	ADP	O	O	2596
angiographic	PROPN	O	O	2596
effects	NOUN	O	O	2596
of	ADP	O	O	2596
cocaine	NOUN	O	Chemical	2596
on	ADP	O	O	2596
human	PROPN	O	O	2596
cerebral	ADJ	O	O	2596
arteries	NOUN	O	O	2596
.	PUNCT	O	O	2596
Information	NOUN	O	O	2597
on	ADP	O	O	2597
these	PRON	O	O	2597
effects	NOUN	O	O	2597
could	AUX	O	O	2597
be	AUX	O	O	2597
obtained	VERB	O	O	2597
from	ADP	O	O	2597
angiograms	VERB	O	O	2597
of	ADP	O	O	2597
patients	NOUN	O	O	2597
with	ADP	O	O	2597
cocaine	NOUN	O	Chemical	2597
-	PUNCT	O	O	2597
associated	VERB	O	O	2597
subarachnoid hemorrhage	NOUN	O	Disease	2597
(	PUNCT	O	O	2597
SAH	PROPN	O	Disease	2597
)	PUNCT	O	O	2597
who	PRON	O	O	2597
underwent	VERB	O	O	2597
angiography	NOUN	O	O	2597
shortly	ADV	O	O	2597
after	ADP	O	O	2597
cocaine	NOUN	O	Chemical	2597
use	VERB	O	O	2597
.	PUNCT	O	O	2597
METHODS	NOUN	O	O	2598
:	PUNCT	O	O	2598
We	PRON	O	O	2598
screened	VERB	O	O	2598
patients	NOUN	O	O	2598
with	ADP	O	O	2598
SAH	PROPN	O	Disease	2598
retrospectively	ADV	O	O	2598
and	CCONJ	O	O	2598
identified	VERB	O	O	2598
those	PRON	O	O	2598
with	ADP	O	O	2598
positive	ADJ	O	O	2598
urine	NOUN	O	O	2598
toxicology	NOUN	O	O	2598
for	ADP	O	O	2598
cocaine	NOUN	O	Chemical	2598
or	CCONJ	O	O	2598
its	PRON	O	O	2598
metabolites	VERB	O	O	2598
.	PUNCT	O	O	2598
Quantitative	ADJ	O	O	2599
arterial	ADJ	O	O	2599
diameter	NOUN	O	O	2599
measurements	NOUN	O	O	2599
from	ADP	O	O	2599
angiograms	VERB	O	O	2599
of	ADP	O	O	2599
these	PRON	O	O	2599
patients	NOUN	O	O	2599
were	AUX	O	O	2599
compared	VERB	O	O	2599
to	PART	O	O	2599
measurements	NOUN	O	O	2599
from	ADP	O	O	2599
control	VERB	O	O	2599
patients	NOUN	O	O	2599
with	ADP	O	O	2599
SAH	PROPN	O	Disease	2599
who	PRON	O	O	2599
were	AUX	O	O	2599
matched	VERB	O	O	2599
for	ADP	O	O	2599
factors	NOUN	O	O	2599
known	VERB	O	O	2599
to	PART	O	O	2599
influence	NOUN	O	O	2599
arterial	ADJ	O	O	2599
diameter	NOUN	O	O	2599
.	PUNCT	O	O	2599
RESULTS	VERB	O	O	2600
:	PUNCT	O	O	2600
Thirteen	NUM	O	O	2600
patients	NOUN	O	O	2600
with	ADP	O	O	2600
positive	ADJ	O	O	2600
cocaine	NOUN	O	Chemical	2600
toxicology	NOUN	O	O	2600
were	AUX	O	O	2600
compared	VERB	O	O	2600
to	PART	O	O	2600
26	NUM	O	O	2600
controls	VERB	O	O	2600
.	PUNCT	O	O	2600
No	PRON	O	O	2601
quantitative	ADJ	O	O	2601
evidence	NOUN	O	O	2601
for	ADP	O	O	2601
narrowing	VERB	O	O	2601
of	ADP	O	O	2601
large	ADJ	O	O	2601
cerebral	ADJ	O	O	2601
arteries	NOUN	O	O	2601
or	CCONJ	O	O	2601
qualitative	ADJ	O	O	2601
angiographic	PROPN	O	O	2601
evidence	NOUN	O	O	2601
for	ADP	O	O	2601
distal	NOUN	O	O	2601
narrowing	VERB	O	O	2601
or	CCONJ	O	O	2601
vasculitis	NOUN	O	Disease	2601
could	AUX	O	O	2601
be	AUX	O	O	2601
found	VERB	O	O	2601
in	ADP	O	O	2601
patients	NOUN	O	O	2601
who	PRON	O	O	2601
underwent	VERB	O	O	2601
angiography	NOUN	O	O	2601
after	ADP	O	O	2601
aneurysmal	VERB	O	Disease	2601
SAH	PROPN	O	Disease	2601
associated	VERB	O	O	2601
with	ADP	O	O	2601
cocaine	NOUN	O	Chemical	2601
use	VERB	O	O	2601
.	PUNCT	O	O	2601
Atrial fibrillation	NOUN	O	Disease	2604
following	VERB	O	O	2604
chemotherapy	NOUN	O	O	2604
for	ADP	O	O	2604
stage	NOUN	O	O	2604
IIIE	PROPN	O	O	2604
diffuse	VERB	O	O	2604
large	ADJ	O	O	2604
B	NOUN	O	O	2604
-	PUNCT	O	O	2604
cell	NOUN	O	O	2604
gastric lymphoma	NOUN	O	Disease	2604
in	ADP	O	O	2604
a	PRON	O	O	2604
patient	NOUN	O	O	2604
with	ADP	O	O	2604
myotonic dystrophy	NOUN	O	Disease	2604
(	PUNCT	O	O	2604
Steinert	PROPN	O	O	2604
's	AUX	O	O	2604
disease	PROPN	O	O	2604
)	PUNCT	O	O	2604
.	PUNCT	O	O	2604
The	PRON	O	O	2605
authors	NOUN	O	O	2605
describe	VERB	O	O	2605
the	PRON	O	O	2605
unusual	ADJ	O	O	2605
association	PROPN	O	O	2605
between	ADP	O	O	2605
diffuse	VERB	O	O	2605
B	NOUN	O	O	2605
-	PUNCT	O	O	2605
cell	NOUN	O	O	2605
gastric lymphoma	NOUN	O	Disease	2605
and	CCONJ	O	O	2605
myotonic dystrophy	NOUN	O	Disease	2605
,	PUNCT	O	O	2605
the	PRON	O	O	2605
most	ADV	O	O	2605
common	ADJ	O	O	2605
form	NOUN	O	O	2605
of	ADP	O	O	2605
adult	NOUN	O	O	2605
muscular dystrophy	NOUN	O	Disease	2605
,	PUNCT	O	O	2605
and	CCONJ	O	O	2605
sudden	ADJ	O	O	2605
atrial fibrillation	NOUN	O	Disease	2605
following	VERB	O	O	2605
one	NUM	O	O	2605
cycle	PROPN	O	O	2605
of	ADP	O	O	2605
doxorubicin	VERB	O	Chemical	2605
-	PUNCT	O	O	2605
based	VERB	O	O	2605
chemotherapy	NOUN	O	O	2605
in	ADP	O	O	2605
the	PRON	O	O	2605
same	ADJ	O	O	2605
patient	NOUN	O	O	2605
.	PUNCT	O	O	2605
Atrial fibrillation	NOUN	O	Disease	2606
or	CCONJ	O	O	2606
other	ADJ	O	O	2606
cardiac arrhythmias	VERB	O	Disease	2606
are	AUX	O	O	2606
unusual	ADJ	O	O	2606
complications	NOUN	O	O	2606
in	ADP	O	O	2606
patients	NOUN	O	O	2606
treated	VERB	O	O	2606
with	ADP	O	O	2606
chemotherapy	NOUN	O	O	2606
.	PUNCT	O	O	2606
The	PRON	O	O	2607
cardiac toxicity	NOUN	O	Disease	2607
intrinsically	ADV	O	O	2607
associated	VERB	O	O	2607
with	ADP	O	O	2607
the	PRON	O	O	2607
aggressive	ADJ	O	O	2607
chemotherapy	NOUN	O	O	2607
employed	VERB	O	O	2607
could	AUX	O	O	2607
function	NOUN	O	O	2607
as	ADP	O	O	2607
a	PRON	O	O	2607
triggering	VERB	O	O	2607
factor	NOUN	O	O	2607
for	ADP	O	O	2607
the	PRON	O	O	2607
arrhythmia	NOUN	O	Disease	2607
in	ADP	O	O	2607
the	PRON	O	O	2607
predisposed	ADJ	O	O	2607
myocardium	NOUN	O	O	2607
of	ADP	O	O	2607
this	PRON	O	O	2607
patient	NOUN	O	O	2607
.	PUNCT	O	O	2607
A	PRON	O	O	2610
phase	NOUN	O	O	2610
II	NUM	O	O	2610
study	VERB	O	O	2610
of	ADP	O	O	2610
thalidomide	NOUN	O	Chemical	2610
in	ADP	O	O	2610
advanced	ADJ	O	O	2610
metastatic	ADJ	O	O	2610
renal cell carcinoma	NOUN	O	Disease	2610
.	PUNCT	O	O	2610
OBJECTIVES	NOUN	O	O	2611
:	PUNCT	O	O	2611
To	PART	O	O	2611
evaluate	VERB	O	O	2611
the	PRON	O	O	2611
toxicity	NOUN	O	Disease	2611
and	CCONJ	O	O	2611
activity	NOUN	O	O	2611
of	ADP	O	O	2611
thalidomide	NOUN	O	Chemical	2611
in	ADP	O	O	2611
patients	NOUN	O	O	2611
with	ADP	O	O	2611
advanced	ADJ	O	O	2611
metastatic	ADJ	O	O	2611
renal cell cancer	NOUN	O	Disease	2611
and	CCONJ	O	O	2611
to	PART	O	O	2611
measure	VERB	O	O	2611
changes	VERB	O	O	2611
of	ADP	O	O	2611
one	NUM	O	O	2611
angiogenic	ADJ	O	O	2611
factor	NOUN	O	O	2611
,	PUNCT	O	O	2611
vascular	ADJ	O	O	2611
endothelial	NOUN	O	O	2611
growth	NOUN	O	O	2611
factor	NOUN	O	O	2611
(	PUNCT	O	O	2611
VEGF)165	ADV	O	O	2611
,	PUNCT	O	O	2611
with	ADP	O	O	2611
therapy	NOUN	O	O	2611
.	PUNCT	O	O	2611
29	NUM	O	O	2612
patients	NOUN	O	O	2612
were	AUX	O	O	2612
enrolled	VERB	O	O	2612
on	ADP	O	O	2612
a	PRON	O	O	2612
study	VERB	O	O	2612
of	ADP	O	O	2612
thalidomide	NOUN	O	Chemical	2612
using	VERB	O	O	2612
an	PRON	O	O	2612
intra	ADJ	O	O	2612
-	PUNCT	O	O	2612
patient	NOUN	O	O	2612
dose	NOUN	O	O	2612
escalation	NOUN	O	O	2612
schedule	NOUN	O	O	2612
.	PUNCT	O	O	2612
Patients	NOUN	O	O	2613
began	VERB	O	O	2613
thalidomide	NOUN	O	Chemical	2613
at	ADP	O	O	2613
400	NUM	O	O	2613
mg	VERB	O	O	2613
/	PUNCT	O	O	2613
d	X	O	O	2613
and	CCONJ	O	O	2613
escalated	VERB	O	O	2613
as	ADP	O	O	2613
tolerated	VERB	O	O	2613
to	PART	O	O	2613
1200	NUM	O	O	2613
mg	VERB	O	O	2613
/	PUNCT	O	O	2613
d	X	O	O	2613
by	ADP	O	O	2613
day	NOUN	O	O	2613
54	NUM	O	O	2613
.	PUNCT	O	O	2613
RESULTS	VERB	O	O	2614
:	PUNCT	O	O	2614
24	NUM	O	O	2614
patients	NOUN	O	O	2614
were	AUX	O	O	2614
evaluable	ADJ	O	O	2614
for	ADP	O	O	2614
response	NOUN	O	O	2614
with	ADP	O	O	2614
one	NUM	O	O	2614
partial	ADJ	O	O	2614
response	NOUN	O	O	2614
of	ADP	O	O	2614
11	NUM	O	O	2614
months	NOUN	O	O	2614
duration	NOUN	O	O	2614
of	ADP	O	O	2614
a	PRON	O	O	2614
patient	NOUN	O	O	2614
with	ADP	O	O	2614
hepatic	ADJ	O	O	2614
and	CCONJ	O	O	2614
pulmonary	ADJ	O	O	2614
metastases	NOUN	O	Disease	2614
(	PUNCT	O	O	2614
4%	NOUN	O	O	2614
)	PUNCT	O	O	2614
,	PUNCT	O	O	2614
one	NUM	O	O	2614
minor	ADJ	O	O	2614
response	NOUN	O	O	2614
,	PUNCT	O	O	2614
and	CCONJ	O	O	2614
2	X	O	O	2614
patients	NOUN	O	O	2614
stable	ADJ	O	O	2614
for	ADP	O	O	2614
over	ADP	O	O	2614
6	NUM	O	O	2614
months	NOUN	O	O	2614
.	PUNCT	O	O	2614
Somnolence	NOUN	O	Disease	2615
and	CCONJ	O	O	2615
constipation	NOUN	O	Disease	2615
were	AUX	O	O	2615
prominent	ADJ	O	O	2615
toxicities	NOUN	O	Disease	2615
and	CCONJ	O	O	2615
most	ADV	O	O	2615
patients	NOUN	O	O	2615
could	AUX	O	O	2615
not	PART	O	O	2615
tolerate	VERB	O	O	2615
the	PRON	O	O	2615
1200	NUM	O	O	2615
mg	VERB	O	O	2615
/	PUNCT	O	O	2615
day	NOUN	O	O	2615
dose	NOUN	O	O	2615
level	VERB	O	O	2615
.	PUNCT	O	O	2615
CONCLUSION	PROPN	O	O	2616
:	PUNCT	O	O	2616
These	PRON	O	O	2616
results	VERB	O	O	2616
are	AUX	O	O	2616
consistent	ADJ	O	O	2616
with	ADP	O	O	2616
a	PRON	O	O	2616
low	ADJ	O	O	2616
level	VERB	O	O	2616
of	ADP	O	O	2616
activity	NOUN	O	O	2616
of	ADP	O	O	2616
thalidomide	NOUN	O	Chemical	2616
in	ADP	O	O	2616
renal cell carcinoma	NOUN	O	Disease	2616
.	PUNCT	O	O	2616
The	PRON	O	O	2617
dose	NOUN	O	O	2617
-	PUNCT	O	O	2617
response	NOUN	O	O	2617
relationship	NOUN	O	O	2617
,	PUNCT	O	O	2617
if	SCONJ	O	O	2617
any	PRON	O	O	2617
,	PUNCT	O	O	2617
of	ADP	O	O	2617
thalidomide	NOUN	O	Chemical	2617
for	ADP	O	O	2617
renal cell carcinoma	NOUN	O	Disease	2617
is	AUX	O	O	2617
unclear	ADJ	O	O	2617
.	PUNCT	O	O	2617
The	PRON	O	O	2620
striatum	NOUN	O	O	2620
as	ADP	O	O	2620
a	PRON	O	O	2620
target	NOUN	O	O	2620
for	ADP	O	O	2620
anti	ADJ	O	O	2620
-	PUNCT	O	O	2620
rigor	NOUN	O	O	2620
effects	NOUN	O	O	2620
of	ADP	O	O	2620
an	PRON	O	O	2620
antagonist	NOUN	O	O	2620
of	ADP	O	O	2620
mGluR1	VERB	O	O	2620
,	PUNCT	O	O	2620
but	CCONJ	O	O	2620
not	PART	O	O	2620
an	PRON	O	O	2620
agonist	NOUN	O	O	2620
of	ADP	O	O	2620
group	NOUN	O	O	2620
II	NUM	O	O	2620
metabotropic	NOUN	O	O	2620
glutamate	NOUN	O	Chemical	2620
receptors	NOUN	O	O	2620
.	PUNCT	O	O	2620
Haloperidol	NOUN	O	Chemical	2621
(	PUNCT	O	O	2621
1	X	O	O	2621
mg	VERB	O	O	2621
/	PUNCT	O	O	2621
kg	VERB	O	O	2621
ip	X	O	O	2621
)	PUNCT	O	O	2621
induced	VERB	O	O	2621
parkinsonian	PROPN	O	Disease	2621
-	PUNCT	O	O	2621
like	INTJ	O	O	2621
muscle rigidity	NOUN	O	Disease	2621
,	PUNCT	O	O	2621
measured	VERB	O	O	2621
as	ADP	O	O	2621
an	PRON	O	O	2621
increased	VERB	O	O	2621
resistance	NOUN	O	O	2621
of	ADP	O	O	2621
a	PRON	O	O	2621
rat	NOUN	O	O	2621
's	AUX	O	O	2621
hind	NOUN	O	O	2621
foot	NOUN	O	O	2621
to	PART	O	O	2621
passive	ADJ	O	O	2621
flexion	NOUN	O	O	2621
and	CCONJ	O	O	2621
extension	NOUN	O	O	2621
at	ADP	O	O	2621
the	PRON	O	O	2621
ankle	NOUN	O	O	2621
joint	ADJ	O	O	2621
.	PUNCT	O	O	2621
(	PUNCT	O	O	2622
RS)-1-aminoindan-1,5-dicarboxylic	NOUN	O	O	2622
acid	PROPN	O	O	2622
(	PUNCT	O	O	2622
AIDA	PROPN	O	Chemical	2622
;	PUNCT	O	O	2622
0.5	NUM	O	O	2622
-	PUNCT	O	O	2622
15	NUM	O	O	2622
microg/0.5	NUM	O	O	2622
microl	NOUN	O	O	2622
)	PUNCT	O	O	2622
,	PUNCT	O	O	2622
a	PRON	O	O	2622
potent	ADJ	O	O	2622
and	CCONJ	O	O	2622
selective	ADJ	O	O	2622
mGluR1	VERB	O	O	2622
antagonist	NOUN	O	O	2622
,	PUNCT	O	O	2622
or	CCONJ	O	O	2622
(	PUNCT	O	O	2622
2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	NOUN	O	O	2622
(	PUNCT	O	O	2622
2R,4R	NUM	O	O	2622
-	PUNCT	O	O	2622
APDC	NOUN	O	O	2622
;	PUNCT	O	O	2622
7.5	NUM	O	O	2622
-	PUNCT	O	O	2622
15	NUM	O	O	2622
microg/0.5	NUM	O	O	2622
microl	NOUN	O	O	2622
)	PUNCT	O	O	2622
,	PUNCT	O	O	2622
a	PRON	O	O	2622
selective	ADJ	O	O	2622
group	NOUN	O	O	2622
II	NUM	O	O	2622
agonist	NOUN	O	O	2622
,	PUNCT	O	O	2622
was	AUX	O	O	2622
injected	VERB	O	O	2622
bilaterally	ADV	O	O	2622
into	ADP	O	O	2622
the	PRON	O	O	2622
striatum	NOUN	O	O	2622
of	ADP	O	O	2622
haloperidol	NOUN	O	Chemical	2622
-	PUNCT	O	O	2622
treated	VERB	O	O	2622
animals	NOUN	O	O	2622
.	PUNCT	O	O	2622
AIDA	PROPN	O	Chemical	2623
in	ADP	O	O	2623
doses	NOUN	O	O	2623
of	ADP	O	O	2623
7.5	NUM	O	O	2623
-	PUNCT	O	O	2623
15	NUM	O	O	2623
microg/0.5	NUM	O	O	2623
microl	NOUN	O	O	2623
diminished	VERB	O	O	2623
the	PRON	O	O	2623
haloperidol	NOUN	O	Chemical	2623
-	PUNCT	O	O	2623
induced	VERB	O	O	2623
muscle rigidity	NOUN	O	Disease	2623
.	PUNCT	O	O	2623
In	ADP	O	O	2624
contrast	NOUN	O	O	2624
,	PUNCT	O	O	2624
2R,4R	NUM	O	O	2624
-	PUNCT	O	O	2624
APDC	NOUN	O	O	2624
injections	NOUN	O	O	2624
were	AUX	O	O	2624
ineffective	ADJ	O	O	2624
.	PUNCT	O	O	2624
The	PRON	O	O	2625
present	NOUN	O	O	2625
results	VERB	O	O	2625
may	AUX	O	O	2625
suggest	VERB	O	O	2625
that	SCONJ	O	O	2625
the	PRON	O	O	2625
blockade	VERB	O	O	2625
of	ADP	O	O	2625
striatal	ADJ	O	O	2625
mGluR1	VERB	O	O	2625
,	PUNCT	O	O	2625
but	CCONJ	O	O	2625
not	PART	O	O	2625
the	PRON	O	O	2625
stimulation	NOUN	O	O	2625
of	ADP	O	O	2625
group	NOUN	O	O	2625
II	NUM	O	O	2625
mGluRs	ADV	O	O	2625
,	PUNCT	O	O	2625
may	AUX	O	O	2625
ameliorate	VERB	O	O	2625
parkinsonian	PROPN	O	Disease	2625
muscle rigidity	NOUN	O	Disease	2625
.	PUNCT	O	O	2625
Acute	PROPN	O	O	2628
cholestatic hepatitis	NOUN	O	Disease	2628
after	ADP	O	O	2628
exposure	NOUN	O	O	2628
to	PART	O	O	2628
isoflurane	NOUN	O	Chemical	2628
.	PUNCT	O	O	2628
OBJECTIVE	VERB	O	O	2629
:	PUNCT	O	O	2629
To	PART	O	O	2629
report	VERB	O	O	2629
a	PRON	O	O	2629
case	NOUN	O	O	2629
of	ADP	O	O	2629
acute	ADJ	O	O	2629
cholestatic hepatitis	NOUN	O	Disease	2629
following	VERB	O	O	2629
exposure	NOUN	O	O	2629
to	PART	O	O	2629
the	PRON	O	O	2629
inhalational	ADJ	O	O	2629
anesthetic	NOUN	O	O	2629
isoflurane	NOUN	O	Chemical	2629
.	PUNCT	O	O	2629
A	PRON	O	O	2630
70-year	NOUN	O	O	2630
-	PUNCT	O	O	2630
old	ADJ	O	O	2630
healthy	ADJ	O	O	2630
woman	NOUN	O	O	2630
from	ADP	O	O	2630
Iraq	PROPN	O	O	2630
developed	VERB	O	O	2630
acute	ADJ	O	O	2630
cholestatic hepatitis	NOUN	O	Disease	2630
3	X	O	O	2630
weeks	NOUN	O	O	2630
following	VERB	O	O	2630
repair	PROPN	O	O	2630
of	ADP	O	O	2630
the	PRON	O	O	2630
right	ADV	O	O	2630
rotator	PROPN	O	O	2630
cuff	NOUN	O	O	2630
under	ADP	O	O	2630
general	ADJ	O	O	2630
anesthesia	NOUN	O	O	2630
.	PUNCT	O	O	2630
There	ADV	O	O	2631
was	AUX	O	O	2631
no	PRON	O	O	2631
evidence	NOUN	O	O	2631
for	ADP	O	O	2631
viral	ADJ	O	O	2631
,	PUNCT	O	O	2631
autoimmune	PROPN	O	O	2631
,	PUNCT	O	O	2631
or	CCONJ	O	O	2631
metabolic	ADJ	O	O	2631
causes	VERB	O	O	2631
of	ADP	O	O	2631
hepatitis	NOUN	O	Disease	2631
.	PUNCT	O	O	2631
No	PRON	O	O	2632
other	ADJ	O	O	2632
medications	NOUN	O	O	2632
were	AUX	O	O	2632
involved	VERB	O	O	2632
except	SCONJ	O	O	2632
for	ADP	O	O	2632
dipyrone	NOUN	O	Chemical	2632
for	ADP	O	O	2632
analgesia	NOUN	O	Disease	2632
.	PUNCT	O	O	2632
The	PRON	O	O	2633
alanine	NOUN	O	Chemical	2633
aminotransferase	PROPN	O	O	2633
was	AUX	O	O	2633
elevated	ADJ	O	O	2633
to	PART	O	O	2633
a	PRON	O	O	2633
peak	PROPN	O	O	2633
concentration	NOUN	O	O	2633
of	ADP	O	O	2633
1533	NUM	O	O	2633
U	NOUN	O	O	2633
/	PUNCT	O	O	2633
L	NOUN	O	O	2633
and	CCONJ	O	O	2633
the	PRON	O	O	2633
serum	NOUN	O	O	2633
bilirubin	ADJ	O	Chemical	2633
reached	VERB	O	O	2633
a	PRON	O	O	2633
peak	PROPN	O	O	2633
of	ADP	O	O	2633
17.0	NUM	O	O	2633
mg	VERB	O	O	2633
/	PUNCT	O	O	2633
dL.	PROPN	O	O	2633
Accidental	ADJ	O	O	2634
reexposure	NOUN	O	O	2634
by	ADP	O	O	2634
the	PRON	O	O	2634
patient	NOUN	O	O	2634
to	PART	O	O	2634
dipyrone	NOUN	O	Chemical	2634
was	AUX	O	O	2634
uneventful	ADJ	O	O	2634
.	PUNCT	O	O	2634
The	PRON	O	O	2635
clinical	ADJ	O	O	2635
and	CCONJ	O	O	2635
histologic	ADJ	O	O	2635
picture	NOUN	O	O	2635
of	ADP	O	O	2635
this	PRON	O	O	2635
case	NOUN	O	O	2635
resembles	VERB	O	O	2635
halothane hepatitis	NOUN	O	Disease	2635
,	PUNCT	O	O	2635
which	PRON	O	O	2635
has	VERB	O	O	2635
a	PRON	O	O	2635
significant	ADJ	O	O	2635
mortality	NOUN	O	O	2635
rate	NOUN	O	O	2635
.	PUNCT	O	O	2635
Isoflurane	NOUN	O	Chemical	2636
,	PUNCT	O	O	2636
a	PRON	O	O	2636
common	ADJ	O	O	2636
anesthetic	NOUN	O	O	2636
agent	NOUN	O	O	2636
,	PUNCT	O	O	2636
can	AUX	O	O	2636
cause	VERB	O	O	2636
severe	ADJ	O	O	2636
cholestatic hepatitis	NOUN	O	Disease	2636
.	PUNCT	O	O	2636
Calcitonin	NOUN	O	O	2639
gene	NOUN	O	O	2639
-	PUNCT	O	O	2639
related	ADJ	O	O	2639
peptide	NOUN	O	O	2639
levels	NOUN	O	O	2639
during	ADP	O	O	2639
nitric oxide	NOUN	O	Chemical	2639
-	PUNCT	O	O	2639
induced	VERB	O	O	2639
headache	PROPN	O	Disease	2639
in	ADP	O	O	2639
patients	NOUN	O	O	2639
with	ADP	O	O	2639
chronic	ADJ	O	O	2639
tension	NOUN	O	O	2639
-	PUNCT	O	O	2639
type	NOUN	O	O	2639
headache	PROPN	O	Disease	2639
.	PUNCT	O	O	2639
It	PRON	O	O	2640
has	VERB	O	O	2640
been	AUX	O	O	2640
proposed	VERB	O	O	2640
that	SCONJ	O	O	2640
nitric oxide	NOUN	O	Chemical	2640
(	PUNCT	O	O	2640
NO	PRON	O	Chemical	2640
)	PUNCT	O	O	2640
induced	VERB	O	O	2640
headache	PROPN	O	Disease	2640
in	ADP	O	O	2640
primary headaches	NOUN	O	Disease	2640
may	AUX	O	O	2640
be	AUX	O	O	2640
associated	VERB	O	O	2640
with	ADP	O	O	2640
release	NOUN	O	O	2640
of	ADP	O	O	2640
calcitonin	NOUN	O	O	2640
gene	NOUN	O	O	2640
-	PUNCT	O	O	2640
related	ADJ	O	O	2640
peptide	NOUN	O	O	2640
(	PUNCT	O	O	2640
CGRP	NOUN	O	O	2640
)	PUNCT	O	O	2640
.	PUNCT	O	O	2640
In	ADP	O	O	2641
the	PRON	O	O	2641
present	NOUN	O	O	2641
study	VERB	O	O	2641
we	PRON	O	O	2641
aimed	VERB	O	O	2641
to	PART	O	O	2641
investigate	VERB	O	O	2641
plasma	NOUN	O	O	2641
levels	NOUN	O	O	2641
of	ADP	O	O	2641
CGRP	NOUN	O	O	2641
during	ADP	O	O	2641
headache	PROPN	O	Disease	2641
induced	VERB	O	O	2641
by	ADP	O	O	2641
the	PRON	O	O	2641
NO	PRON	O	Chemical	2641
donor	NOUN	O	O	2641
glyceryl trinitrate	PROPN	O	Chemical	2641
(	PUNCT	O	O	2641
GTN	NOUN	O	Chemical	2641
)	PUNCT	O	O	2641
in	ADP	O	O	2641
16	NUM	O	O	2641
patients	NOUN	O	O	2641
with	ADP	O	O	2641
chronic	ADJ	O	O	2641
tension	NOUN	O	O	2641
-	PUNCT	O	O	2641
type	NOUN	O	O	2641
headache	PROPN	O	Disease	2641
and	CCONJ	O	O	2641
16	NUM	O	O	2641
healthy	ADJ	O	O	2641
controls	VERB	O	O	2641
.	PUNCT	O	O	2641
The	PRON	O	O	2642
subjects	NOUN	O	O	2642
were	AUX	O	O	2642
randomly	ADV	O	O	2642
allocated	VERB	O	O	2642
to	PART	O	O	2642
receive	VERB	O	O	2642
0.5	NUM	O	O	2642
microg	PROPN	O	O	2642
/	PUNCT	O	O	2642
kg	VERB	O	O	2642
/	PUNCT	O	O	2642
min	NOUN	O	O	2642
GTN	NOUN	O	Chemical	2642
or	CCONJ	O	O	2642
placebo	NOUN	O	O	2642
over	ADP	O	O	2642
20	NUM	O	O	2642
min	NOUN	O	O	2642
on	ADP	O	O	2642
two	NUM	O	O	2642
headache	PROPN	O	Disease	2642
-	PUNCT	O	O	2642
free	ADJ	O	O	2642
days	NOUN	O	O	2642
.	PUNCT	O	O	2642
Both	PRON	O	O	2643
patients	NOUN	O	O	2643
and	CCONJ	O	O	2643
controls	VERB	O	O	2643
developed	VERB	O	O	2643
significantly	ADV	O	O	2643
stronger	ADJ	O	O	2643
immediate	ADJ	O	O	2643
headache	PROPN	O	Disease	2643
on	ADP	O	O	2643
the	PRON	O	O	2643
GTN	NOUN	O	Chemical	2643
day	NOUN	O	O	2643
than	ADP	O	O	2643
on	ADP	O	O	2643
the	PRON	O	O	2643
placebo	NOUN	O	O	2643
day	NOUN	O	O	2643
and	CCONJ	O	O	2643
the	PRON	O	O	2643
headache	PROPN	O	Disease	2643
was	AUX	O	O	2643
significantly	ADV	O	O	2643
more	ADJ	O	O	2643
pronounced	VERB	O	O	2643
in	ADP	O	O	2643
patients	NOUN	O	O	2643
than	ADP	O	O	2643
in	ADP	O	O	2643
controls	VERB	O	O	2643
.	PUNCT	O	O	2643
There	ADV	O	O	2644
was	AUX	O	O	2644
no	PRON	O	O	2644
difference	NOUN	O	O	2644
between	ADP	O	O	2644
the	PRON	O	O	2644
area	NOUN	O	O	2644
under	ADP	O	O	2644
the	PRON	O	O	2644
CGRP	NOUN	O	O	2644
curve	NOUN	O	O	2644
(	PUNCT	O	O	2644
AUCCGRP	PROPN	O	O	2644
)	PUNCT	O	O	2644
on	ADP	O	O	2644
GTN	NOUN	O	Chemical	2644
vs.	CCONJ	O	O	2644
placebo	NOUN	O	O	2644
day	NOUN	O	O	2644
in	ADP	O	O	2644
either	ADV	O	O	2644
patients	NOUN	O	O	2644
(	PUNCT	O	O	2644
P=0.65	VERB	O	O	2644
)	PUNCT	O	O	2644
or	CCONJ	O	O	2644
controls	VERB	O	O	2644
(	PUNCT	O	O	2644
P=0.48	VERB	O	O	2644
)	PUNCT	O	O	2644
.	PUNCT	O	O	2644
The	PRON	O	O	2645
AUCCGRP	PROPN	O	O	2645
recorded	VERB	O	O	2645
on	ADP	O	O	2645
the	PRON	O	O	2645
GTN	NOUN	O	Chemical	2645
day	NOUN	O	O	2645
did	VERB	O	O	2645
not	PART	O	O	2645
differ	VERB	O	O	2645
between	ADP	O	O	2645
patients	NOUN	O	O	2645
and	CCONJ	O	O	2645
controls	VERB	O	O	2645
(	PUNCT	O	O	2645
P=0.36	VERB	O	O	2645
)	PUNCT	O	O	2645
.	PUNCT	O	O	2645
Both	PRON	O	O	2646
in	ADP	O	O	2646
patients	NOUN	O	O	2646
and	CCONJ	O	O	2646
controls	VERB	O	O	2646
,	PUNCT	O	O	2646
CGRP	NOUN	O	O	2646
levels	NOUN	O	O	2646
changed	VERB	O	O	2646
significantly	ADV	O	O	2646
over	ADP	O	O	2646
time	NOUN	O	O	2646
,	PUNCT	O	O	2646
on	ADP	O	O	2646
both	PRON	O	O	2646
the	PRON	O	O	2646
GTN	NOUN	O	Chemical	2646
and	CCONJ	O	O	2646
placebo	NOUN	O	O	2646
days	NOUN	O	O	2646
(	PUNCT	O	O	2646
P	NOUN	O	Chemical	2646
<	X	O	O	2646
0.05	NUM	O	O	2646
)	PUNCT	O	O	2646
.	PUNCT	O	O	2646
The	PRON	O	O	2647
present	NOUN	O	O	2647
study	VERB	O	O	2647
indicates	VERB	O	O	2647
that	SCONJ	O	O	2647
NO	PRON	O	Chemical	2647
-	PUNCT	O	O	2647
induced	VERB	O	O	2647
immediate	ADJ	O	O	2647
headache	PROPN	O	Disease	2647
is	AUX	O	O	2647
not	PART	O	O	2647
associated	VERB	O	O	2647
with	ADP	O	O	2647
release	NOUN	O	O	2647
of	ADP	O	O	2647
CGRP	NOUN	O	O	2647
.	PUNCT	O	O	2647
Myocardial ischemia	NOUN	O	Disease	2650
due	ADJ	O	O	2650
to	PART	O	O	2650
coronary artery spasm	NOUN	O	Disease	2650
during	ADP	O	O	2650
dobutamine	NOUN	O	Chemical	2650
stress	NOUN	O	O	2650
echocardiography	NOUN	O	O	2650
.	PUNCT	O	O	2650
Dobutamine	NOUN	O	Chemical	2651
stress	NOUN	O	O	2651
echocardiography	NOUN	O	O	2651
(	PUNCT	O	O	2651
DSE	PROPN	O	O	2651
)	PUNCT	O	O	2651
is	AUX	O	O	2651
a	PRON	O	O	2651
useful	ADJ	O	O	2651
and	CCONJ	O	O	2651
safe	ADJ	O	O	2651
provocation	NOUN	O	O	2651
test	NOUN	O	O	2651
for	ADP	O	O	2651
myocardial ischemia	NOUN	O	Disease	2651
.	PUNCT	O	O	2651
Until	ADP	O	O	2652
now	ADV	O	O	2652
,	PUNCT	O	O	2652
the	PRON	O	O	2652
test	NOUN	O	O	2652
has	VERB	O	O	2652
been	AUX	O	O	2652
focused	VERB	O	O	2652
only	ADV	O	O	2652
on	ADP	O	O	2652
the	PRON	O	O	2652
organic	ADJ	O	O	2652
lesion	NOUN	O	O	2652
in	ADP	O	O	2652
the	PRON	O	O	2652
coronary	ADJ	O	O	2652
artery	NOUN	O	O	2652
,	PUNCT	O	O	2652
and	CCONJ	O	O	2652
positive	ADJ	O	O	2652
DSE	PROPN	O	O	2652
has	VERB	O	O	2652
indicated	VERB	O	O	2652
the	PRON	O	O	2652
presence	NOUN	O	O	2652
of	ADP	O	O	2652
significant	ADJ	O	O	2652
fixed	VERB	O	O	2652
coronary artery stenosis	NOUN	O	Disease	2652
.	PUNCT	O	O	2652
The	PRON	O	O	2653
aim	VERB	O	O	2653
of	ADP	O	O	2653
the	PRON	O	O	2653
present	NOUN	O	O	2653
study	VERB	O	O	2653
is	AUX	O	O	2653
to	PART	O	O	2653
examine	VERB	O	O	2653
whether	SCONJ	O	O	2653
myocardial ischemia	NOUN	O	Disease	2653
due	ADJ	O	O	2653
to	PART	O	O	2653
coronary spasm	NOUN	O	Disease	2653
is	AUX	O	O	2653
induced	VERB	O	O	2653
by	ADP	O	O	2653
dobutamine	NOUN	O	Chemical	2653
.	PUNCT	O	O	2653
We	PRON	O	O	2654
performed	VERB	O	O	2654
DSE	PROPN	O	O	2654
on	ADP	O	O	2654
51	NUM	O	O	2654
patients	NOUN	O	O	2654
with	ADP	O	O	2654
coronary spastic angina	NOUN	O	Disease	2654
but	CCONJ	O	O	2654
without	ADP	O	O	2654
significant	ADJ	O	O	2654
fixed	VERB	O	O	2654
coronary artery stenosis	NOUN	O	Disease	2654
.	PUNCT	O	O	2654
All	PRON	O	O	2655
patients	NOUN	O	O	2655
had	VERB	O	O	2655
anginal	PROPN	O	Disease	2655
attacks	NOUN	O	O	2655
at	ADP	O	O	2655
rest	VERB	O	O	2655
with	ADP	O	O	2655
ST	PROPN	O	O	2655
elevation	NOUN	O	O	2655
on	ADP	O	O	2655
the	PRON	O	O	2655
electrocardiogram	PROPN	O	O	2655
(	PUNCT	O	O	2655
variant angina	NOUN	O	Disease	2655
)	PUNCT	O	O	2655
.	PUNCT	O	O	2655
Coronary	ADJ	O	O	2656
spasm	NOUN	O	Disease	2656
was	AUX	O	O	2656
induced	VERB	O	O	2656
by	ADP	O	O	2656
intracoronary	NOUN	O	O	2656
injection	NOUN	O	O	2656
of	ADP	O	O	2656
acetylcholine	NOUN	O	Chemical	2656
,	PUNCT	O	O	2656
and	CCONJ	O	O	2656
no	PRON	O	O	2656
fixed	VERB	O	O	2656
coronary artery stenosis	NOUN	O	Disease	2656
was	AUX	O	O	2656
documented	VERB	O	O	2656
on	ADP	O	O	2656
angiograms	VERB	O	O	2656
in	ADP	O	O	2656
all	PRON	O	O	2656
patients	NOUN	O	O	2656
.	PUNCT	O	O	2656
DSE	PROPN	O	O	2657
was	AUX	O	O	2657
performed	VERB	O	O	2657
with	ADP	O	O	2657
intravenous	ADJ	O	O	2657
dobutamine	NOUN	O	Chemical	2657
infusion	NOUN	O	O	2657
with	ADP	O	O	2657
an	PRON	O	O	2657
incremental	ADJ	O	O	2657
doses	NOUN	O	O	2657
of	ADP	O	O	2657
5	NUM	O	O	2657
,	PUNCT	O	O	2657
10	NUM	O	O	2657
,	PUNCT	O	O	2657
20	NUM	O	O	2657
,	PUNCT	O	O	2657
30	NUM	O	O	2657
,	PUNCT	O	O	2657
and	CCONJ	O	O	2657
40	NUM	O	O	2657
microg	PROPN	O	O	2657
/	PUNCT	O	O	2657
kg	VERB	O	O	2657
/	PUNCT	O	O	2657
min	NOUN	O	O	2657
every	PRON	O	O	2657
5	NUM	O	O	2657
minutes	NOUN	O	O	2657
.	PUNCT	O	O	2657
All	PRON	O	O	2658
7	NUM	O	O	2658
patients	NOUN	O	O	2658
(	PUNCT	O	O	2658
13.7%	NOUN	O	O	2658
)	PUNCT	O	O	2658
had	VERB	O	O	2658
chest pain	NOUN	O	Disease	2658
during	ADP	O	O	2658
asynergy	PROPN	O	O	2658
,	PUNCT	O	O	2658
and	CCONJ	O	O	2658
both	PRON	O	O	2658
chest pain	NOUN	O	Disease	2658
and	CCONJ	O	O	2658
electrocardiographic	NOUN	O	O	2658
changes	VERB	O	O	2658
were	AUX	O	O	2658
preceded	VERB	O	O	2658
by	ADP	O	O	2658
asynergy	PROPN	O	O	2658
.	PUNCT	O	O	2658
These	PRON	O	O	2659
findings	NOUN	O	O	2659
indicate	VERB	O	O	2659
that	SCONJ	O	O	2659
dobutamine	NOUN	O	Chemical	2659
can	AUX	O	O	2659
provoke	VERB	O	O	2659
coronary spasm	NOUN	O	Disease	2659
in	ADP	O	O	2659
some	PRON	O	O	2659
patients	NOUN	O	O	2659
with	ADP	O	O	2659
coronary spastic angina	NOUN	O	Disease	2659
.	PUNCT	O	O	2659
When	SCONJ	O	O	2660
DSE	PROPN	O	O	2660
is	AUX	O	O	2660
performed	VERB	O	O	2660
to	PART	O	O	2660
evaluate	VERB	O	O	2660
coronary artery disease	NOUN	O	Disease	2660
,	PUNCT	O	O	2660
not	PART	O	O	2660
only	ADV	O	O	2660
fixed	VERB	O	O	2660
coronary stenosis	NOUN	O	Disease	2660
,	PUNCT	O	O	2660
but	CCONJ	O	O	2660
also	ADV	O	O	2660
coronary spasm	NOUN	O	Disease	2660
should	AUX	O	O	2660
be	AUX	O	O	2660
considered	VERB	O	O	2660
as	ADP	O	O	2660
a	PRON	O	O	2660
genesis	NOUN	O	O	2660
of	ADP	O	O	2660
asynergy	PROPN	O	O	2660
.	PUNCT	O	O	2660
Nitric oxide	NOUN	O	Chemical	2663
synthase	NOUN	O	O	2663
expression	NOUN	O	O	2663
in	ADP	O	O	2663
the	PRON	O	O	2663
course	NOUN	O	O	2663
of	ADP	O	O	2663
lead	VERB	O	Chemical	2663
-	PUNCT	O	O	2663
induced	VERB	O	O	2663
hypertension	NOUN	O	Disease	2663
.	PUNCT	O	O	2663
We	PRON	O	O	2664
recently	ADV	O	O	2664
showed	VERB	O	O	2664
elevated	ADJ	O	O	2664
reactive	ADJ	O	O	2664
oxygen	NOUN	O	Chemical	2664
species	NOUN	O	O	2664
(	PUNCT	O	O	2664
ROS	PROPN	O	O	2664
)	PUNCT	O	O	2664
,	PUNCT	O	O	2664
reduced	VERB	O	O	2664
urinary	ADJ	O	O	2664
excretion	NOUN	O	O	2664
of	ADP	O	O	2664
NO	PRON	O	Chemical	2664
metabolites	VERB	O	O	2664
(	PUNCT	O	O	2664
NOx	PROPN	O	O	2664
)	PUNCT	O	O	2664
,	PUNCT	O	O	2664
and	CCONJ	O	O	2664
increased	VERB	O	O	2664
NO	PRON	O	Chemical	2664
sequestration	NOUN	O	O	2664
as	ADP	O	O	2664
nitrotyrosine	PROPN	O	Chemical	2664
in	ADP	O	O	2664
various	ADJ	O	O	2664
tissues	NOUN	O	O	2664
in	ADP	O	O	2664
rats	NOUN	O	O	2664
with	ADP	O	O	2664
lead	VERB	O	Chemical	2664
-	PUNCT	O	O	2664
induced	VERB	O	O	2664
hypertension	NOUN	O	Disease	2664
.	PUNCT	O	O	2664
This	PRON	O	O	2665
study	VERB	O	O	2665
was	AUX	O	O	2665
designed	VERB	O	O	2665
to	PART	O	O	2665
discern	VERB	O	O	2665
whether	SCONJ	O	O	2665
the	PRON	O	O	2665
reduction	NOUN	O	O	2665
in	ADP	O	O	2665
urinary	ADJ	O	O	2665
NOx	PROPN	O	O	2665
in	ADP	O	O	2665
lead	VERB	O	Chemical	2665
-	PUNCT	O	O	2665
induced	VERB	O	O	2665
hypertension	NOUN	O	Disease	2665
is	AUX	O	O	2665
,	PUNCT	O	O	2665
in	ADP	O	O	2665
part	NOUN	O	O	2665
,	PUNCT	O	O	2665
due	ADJ	O	O	2665
to	PART	O	O	2665
depressed	ADJ	O	O	2665
NO	PRON	O	Chemical	2665
synthase	NOUN	O	O	2665
(	PUNCT	O	O	2665
NOS	PROPN	O	O	2665
)	PUNCT	O	O	2665
expression	NOUN	O	O	2665
.	PUNCT	O	O	2665
Male	NOUN	O	O	2666
Sprague	PROPN	O	O	2666
-	PUNCT	O	O	2666
Dawley	NOUN	O	O	2666
rats	NOUN	O	O	2666
were	AUX	O	O	2666
randomly	ADV	O	O	2666
assigned	VERB	O	O	2666
to	PART	O	O	2666
a	PRON	O	O	2666
lead	VERB	O	Chemical	2666
-	PUNCT	O	O	2666
treated	VERB	O	O	2666
group	NOUN	O	O	2666
(	PUNCT	O	O	2666
given	VERB	O	O	2666
lead acetate	NOUN	O	Chemical	2666
,	PUNCT	O	O	2666
100	NUM	O	O	2666
ppm	ADP	O	O	2666
,	PUNCT	O	O	2666
in	ADP	O	O	2666
drinking	VERB	O	O	2666
water	PROPN	O	O	2666
and	CCONJ	O	O	2666
regular	ADJ	O	O	2666
rat	NOUN	O	O	2666
chow	PROPN	O	O	2666
)	PUNCT	O	O	2666
,	PUNCT	O	O	2666
a	PRON	O	O	2666
group	NOUN	O	O	2666
given	VERB	O	O	2666
lead	VERB	O	Chemical	2666
and	CCONJ	O	O	2666
vitamin E	NOUN	O	Chemical	2666
-	PUNCT	O	O	2666
fortified	VERB	O	O	2666
chow	PROPN	O	O	2666
,	PUNCT	O	O	2666
or	CCONJ	O	O	2666
a	PRON	O	O	2666
normal	ADJ	O	O	2666
control	VERB	O	O	2666
group	NOUN	O	O	2666
given	VERB	O	O	2666
either	ADV	O	O	2666
regular	ADJ	O	O	2666
food	NOUN	O	O	2666
and	CCONJ	O	O	2666
water	PROPN	O	O	2666
or	CCONJ	O	O	2666
vitamin E	NOUN	O	Chemical	2666
-	PUNCT	O	O	2666
fortified	VERB	O	O	2666
food	NOUN	O	O	2666
for	ADP	O	O	2666
12	NUM	O	O	2666
weeks	NOUN	O	O	2666
.	PUNCT	O	O	2666
Tail	NOUN	O	O	2667
blood	NOUN	O	O	2667
pressure	NOUN	O	O	2667
,	PUNCT	O	O	2667
urinary	ADJ	O	O	2667
NOx	PROPN	O	O	2667
excretion	NOUN	O	O	2667
,	PUNCT	O	O	2667
plasma	NOUN	O	O	2667
malondialdehyde	PROPN	O	Chemical	2667
(	PUNCT	O	O	2667
MDA	PROPN	O	Chemical	2667
)	PUNCT	O	O	2667
,	PUNCT	O	O	2667
and	CCONJ	O	O	2667
endothelial	NOUN	O	O	2667
and	CCONJ	O	O	2667
inducible	VERB	O	O	2667
NOS	PROPN	O	O	2667
(	PUNCT	O	O	2667
eNOS	NUM	O	O	2667
and	CCONJ	O	O	2667
iNOS	PROPN	O	O	2667
)	PUNCT	O	O	2667
isotypes	NOUN	O	O	2667
in	ADP	O	O	2667
the	PRON	O	O	2667
aorta	NOUN	O	O	2667
and	CCONJ	O	O	2667
kidney	NOUN	O	O	2667
were	AUX	O	O	2667
measured	VERB	O	O	2667
.	PUNCT	O	O	2667
The	PRON	O	O	2668
lead	VERB	O	Chemical	2668
-	PUNCT	O	O	2668
treated	VERB	O	O	2668
group	NOUN	O	O	2668
exhibited	VERB	O	O	2668
a	PRON	O	O	2668
rise	VERB	O	O	2668
in	ADP	O	O	2668
blood	NOUN	O	O	2668
pressure	NOUN	O	O	2668
and	CCONJ	O	O	2668
plasma	NOUN	O	O	2668
MDA	PROPN	O	Chemical	2668
concentration	NOUN	O	O	2668
,	PUNCT	O	O	2668
a	PRON	O	O	2668
fall	VERB	O	O	2668
in	ADP	O	O	2668
urinary	ADJ	O	O	2668
NOx	PROPN	O	O	2668
excretion	NOUN	O	O	2668
,	PUNCT	O	O	2668
and	CCONJ	O	O	2668
a	PRON	O	O	2668
paradoxical	ADJ	O	O	2668
rise	VERB	O	O	2668
in	ADP	O	O	2668
vascular	ADJ	O	O	2668
and	CCONJ	O	O	2668
renal	ADJ	O	O	2668
tissue	NOUN	O	O	2668
eNOS	NUM	O	O	2668
and	CCONJ	O	O	2668
iNOS	PROPN	O	O	2668
expression	NOUN	O	O	2668
.	PUNCT	O	O	2668
Vitamin E	NOUN	O	Chemical	2669
supplementation	NOUN	O	O	2669
ameliorated	VERB	O	O	2669
hypertension	NOUN	O	Disease	2669
,	PUNCT	O	O	2669
lowered	VERB	O	O	2669
plasma	NOUN	O	O	2669
MDA	PROPN	O	Chemical	2669
concentration	NOUN	O	O	2669
,	PUNCT	O	O	2669
and	CCONJ	O	O	2669
raised	VERB	O	O	2669
urinary	ADJ	O	O	2669
NOx	PROPN	O	O	2669
excretion	NOUN	O	O	2669
while	SCONJ	O	O	2669
significantly	ADV	O	O	2669
lowering	VERB	O	O	2669
vascular	ADJ	O	O	2669
,	PUNCT	O	O	2669
but	CCONJ	O	O	2669
not	PART	O	O	2669
renal	ADJ	O	O	2669
,	PUNCT	O	O	2669
tissue	NOUN	O	O	2669
eNOS	NUM	O	O	2669
and	CCONJ	O	O	2669
iNOS	PROPN	O	O	2669
expression	NOUN	O	O	2669
.	PUNCT	O	O	2669
Vitamin E	NOUN	O	Chemical	2670
supplementation	NOUN	O	O	2670
had	VERB	O	O	2670
no	PRON	O	O	2670
effect	VERB	O	O	2670
on	ADP	O	O	2670
either	ADV	O	O	2670
blood	NOUN	O	O	2670
pressure	NOUN	O	O	2670
,	PUNCT	O	O	2670
plasma	NOUN	O	O	2670
MDA	PROPN	O	Chemical	2670
,	PUNCT	O	O	2670
or	CCONJ	O	O	2670
NOS	PROPN	O	O	2670
expression	NOUN	O	O	2670
in	ADP	O	O	2670
the	PRON	O	O	2670
control	VERB	O	O	2670
group	NOUN	O	O	2670
.	PUNCT	O	O	2670
The	PRON	O	O	2671
study	VERB	O	O	2671
also	ADV	O	O	2671
revealed	VERB	O	O	2671
significant	ADJ	O	O	2671
inhibition	NOUN	O	O	2671
of	ADP	O	O	2671
NOS	PROPN	O	O	2671
enzymatic	ADJ	O	O	2671
activity	NOUN	O	O	2671
by	ADP	O	O	2671
lead	VERB	O	Chemical	2671
in	ADP	O	O	2671
cell	NOUN	O	O	2671
-	PUNCT	O	O	2671
free	ADJ	O	O	2671
preparations	NOUN	O	O	2671
.	PUNCT	O	O	2671
In	ADP	O	O	2672
conclusion	NOUN	O	O	2672
,	PUNCT	O	O	2672
lead	VERB	O	Chemical	2672
-	PUNCT	O	O	2672
induced	VERB	O	O	2672
hypertension	NOUN	O	Disease	2672
in	ADP	O	O	2672
this	PRON	O	O	2672
model	NOUN	O	O	2672
was	AUX	O	O	2672
associated	VERB	O	O	2672
with	ADP	O	O	2672
a	PRON	O	O	2672
compensatory	ADJ	O	O	2672
upregulation	NOUN	O	O	2672
of	ADP	O	O	2672
renal	ADJ	O	O	2672
and	CCONJ	O	O	2672
vascular	ADJ	O	O	2672
eNOS	NUM	O	O	2672
and	CCONJ	O	O	2672
iNOS	PROPN	O	O	2672
expression	NOUN	O	O	2672
.	PUNCT	O	O	2672
NO	PRON	O	Chemical	2673
inactivation	NOUN	O	O	2673
,	PUNCT	O	O	2673
lead	VERB	O	Chemical	2673
-	PUNCT	O	O	2673
associated	VERB	O	O	2673
inhibition	NOUN	O	O	2673
of	ADP	O	O	2673
NOS	PROPN	O	O	2673
activity	NOUN	O	O	2673
,	PUNCT	O	O	2673
and	CCONJ	O	O	2673
perhaps	ADV	O	O	2673
stimulatory	ADJ	O	O	2673
actions	NOUN	O	O	2673
of	ADP	O	O	2673
increased	VERB	O	O	2673
shear	VERB	O	O	2673
stress	NOUN	O	O	2673
associated	VERB	O	O	2673
with	ADP	O	O	2673
hypertension	NOUN	O	Disease	2673
.	PUNCT	O	O	2673
Risk	NOUN	O	O	2676
for	ADP	O	O	2676
valvular	ADJ	O	O	2676
heart disease	NOUN	O	Disease	2676
among	ADP	O	O	2676
users	NOUN	O	O	2676
of	ADP	O	O	2676
fenfluramine	NOUN	O	Chemical	2676
and	CCONJ	O	O	2676
dexfenfluramine	PROPN	O	Chemical	2676
who	PRON	O	O	2676
underwent	VERB	O	O	2676
echocardiography	NOUN	O	O	2676
before	ADP	O	O	2676
use	VERB	O	O	2676
of	ADP	O	O	2676
medication	NOUN	O	O	2676
.	PUNCT	O	O	2676
Because	SCONJ	O	O	2677
uncontrolled	ADJ	O	O	2677
echocardiographic	NOUN	O	O	2677
surveys	NOUN	O	O	2677
suggested	VERB	O	O	2677
that	SCONJ	O	O	2677
up	ADP	O	O	2677
to	PART	O	O	2677
30%	NOUN	O	O	2677
to	PART	O	O	2677
38%	NOUN	O	O	2677
of	ADP	O	O	2677
users	NOUN	O	O	2677
of	ADP	O	O	2677
fenfluramine	NOUN	O	Chemical	2677
and	CCONJ	O	O	2677
dexfenfluramine	PROPN	O	Chemical	2677
had	VERB	O	O	2677
valvular disease	NOUN	O	Disease	2677
,	PUNCT	O	O	2677
these	PRON	O	O	2677
drugs	NOUN	O	O	2677
were	AUX	O	O	2677
withdrawn	VERB	O	O	2677
from	ADP	O	O	2677
the	PRON	O	O	2677
market	NOUN	O	O	2677
.	PUNCT	O	O	2677
OBJECTIVE	VERB	O	O	2678
:	PUNCT	O	O	2678
To	PART	O	O	2678
determine	VERB	O	O	2678
the	PRON	O	O	2678
risk	NOUN	O	O	2678
for	ADP	O	O	2678
new	ADJ	O	O	2678
or	CCONJ	O	O	2678
worsening	VERB	O	O	2678
valvular abnormalities	NOUN	O	Disease	2678
among	ADP	O	O	2678
users	NOUN	O	O	2678
of	ADP	O	O	2678
fenfluramine	NOUN	O	Chemical	2678
or	CCONJ	O	O	2678
dexfenfluramine	PROPN	O	Chemical	2678
who	PRON	O	O	2678
underwent	VERB	O	O	2678
echocardiography	NOUN	O	O	2678
before	ADP	O	O	2678
they	PRON	O	O	2678
began	VERB	O	O	2678
to	PART	O	O	2678
take	VERB	O	O	2678
these	PRON	O	O	2678
medications	NOUN	O	O	2678
.	PUNCT	O	O	2678
PATIENTS	NOUN	O	O	2679
:	PUNCT	O	O	2679
46	NUM	O	O	2679
patients	NOUN	O	O	2679
who	PRON	O	O	2679
used	VERB	O	O	2679
fenfluramine	NOUN	O	Chemical	2679
or	CCONJ	O	O	2679
dexfenfluramine	PROPN	O	Chemical	2679
for	ADP	O	O	2679
14	NUM	O	O	2679
days	NOUN	O	O	2679
or	CCONJ	O	O	2679
more	ADJ	O	O	2679
and	CCONJ	O	O	2679
had	VERB	O	O	2679
echocardiograms	VERB	O	O	2679
obtained	VERB	O	O	2679
before	ADP	O	O	2679
therapy	NOUN	O	O	2679
.	PUNCT	O	O	2679
The	PRON	O	O	2680
primary	NOUN	O	O	2680
outcome	NOUN	O	O	2680
was	AUX	O	O	2680
new	ADJ	O	O	2680
or	CCONJ	O	O	2680
worsening	VERB	O	O	2680
valvulopathy	ADJ	O	Disease	2680
,	PUNCT	O	O	2680
defined	VERB	O	O	2680
as	ADP	O	O	2680
progression	NOUN	O	O	2680
of	ADP	O	O	2680
either	ADV	O	O	2680
aortic	ADJ	O	O	2680
or	CCONJ	O	O	2680
mitral regurgitation	NOUN	O	Disease	2680
by	ADP	O	O	2680
at	ADP	O	O	2680
least	ADJ	O	O	2680
one	NUM	O	O	2680
degree	PROPN	O	O	2680
of	ADP	O	O	2680
severity	NOUN	O	O	2680
and	CCONJ	O	O	2680
disease	PROPN	O	O	2680
that	SCONJ	O	O	2680
met	VERB	O	O	2680
U.S.	PROPN	O	O	2680
Food	NOUN	O	O	2680
and	CCONJ	O	O	2680
Drug	NOUN	O	O	2680
Administration	NOUN	O	O	2680
criteria	NOUN	O	O	2680
(	PUNCT	O	O	2680
at	ADP	O	O	2680
least	ADJ	O	O	2680
mild	ADJ	O	O	2680
aortic regurgitation	NOUN	O	Disease	2680
or	CCONJ	O	O	2680
moderate	ADJ	O	O	2680
mitral regurgitation	NOUN	O	Disease	2680
)	PUNCT	O	O	2680
.	PUNCT	O	O	2680
RESULTS	VERB	O	O	2681
:	PUNCT	O	O	2681
Two	NUM	O	O	2681
patients	NOUN	O	O	2681
(	PUNCT	O	O	2681
4.3%	NOUN	O	O	2681
[	X	O	O	2681
95%	NOUN	O	O	2681
CI	NOUN	O	O	2681
,	PUNCT	O	O	2681
0.6%	NOUN	O	O	2681
to	PART	O	O	2681
14.8%	NOUN	O	O	2681
]	PUNCT	O	O	2681
)	PUNCT	O	O	2681
receiving	VERB	O	O	2681
fenfluramine	NOUN	O	Chemical	2681
-	PUNCT	O	O	2681
phentermine	PROPN	O	Chemical	2681
developed	VERB	O	O	2681
valvular	ADJ	O	O	2681
heart disease	NOUN	O	Disease	2681
.	PUNCT	O	O	2681
One	NUM	O	O	2682
had	VERB	O	O	2682
baseline	VERB	O	O	2682
bicuspid aortic valve	NOUN	O	Disease	2682
and	CCONJ	O	O	2682
mild	ADJ	O	O	2682
aortic regurgitation	NOUN	O	Disease	2682
that	SCONJ	O	O	2682
progressed	VERB	O	O	2682
to	PART	O	O	2682
moderate	ADJ	O	O	2682
regurgitation	NOUN	O	O	2682
.	PUNCT	O	O	2682
The	PRON	O	O	2683
second	ADV	O	O	2683
patient	NOUN	O	O	2683
developed	VERB	O	O	2683
new	ADJ	O	O	2683
moderate	ADJ	O	O	2683
aortic insufficiency	NOUN	O	Disease	2683
.	PUNCT	O	O	2683
Users	NOUN	O	O	2684
of	ADP	O	O	2684
diet	PROPN	O	O	2684
medications	NOUN	O	O	2684
are	AUX	O	O	2684
at	ADP	O	O	2684
risk	NOUN	O	O	2684
for	ADP	O	O	2684
valvular	ADJ	O	O	2684
heart disease	NOUN	O	Disease	2684
.	PUNCT	O	O	2684
Carboplatin	NOUN	O	Chemical	2687
toxic	ADJ	O	O	2687
effects	NOUN	O	O	2687
on	ADP	O	O	2687
the	PRON	O	O	2687
peripheral	ADJ	O	O	2687
nervous	ADJ	O	O	2687
system	NOUN	O	O	2687
of	ADP	O	O	2687
the	PRON	O	O	2687
rat	NOUN	O	O	2687
.	PUNCT	O	O	2687
BACKGROUND	NOUN	O	O	2688
:	PUNCT	O	O	2688
The	PRON	O	O	2688
most	ADV	O	O	2688
striking	VERB	O	O	2688
of	ADP	O	O	2688
carboplatin	PROPN	O	Chemical	2688
's	AUX	O	O	2688
advantages	NOUN	O	O	2688
(	PUNCT	O	O	2688
CBDCA	NOUN	O	Chemical	2688
)	PUNCT	O	O	2688
over	ADP	O	O	2688
cisplatin	NOUN	O	Chemical	2688
(	PUNCT	O	O	2688
CDDP	PROPN	O	Chemical	2688
)	PUNCT	O	O	2688
is	AUX	O	O	2688
its	PRON	O	O	2688
markedly	ADV	O	O	2688
reduced	VERB	O	O	2688
rate	NOUN	O	O	2688
of	ADP	O	O	2688
neurotoxic	ADJ	O	Disease	2688
effects	NOUN	O	O	2688
.	PUNCT	O	O	2688
However	ADV	O	O	2689
,	PUNCT	O	O	2689
the	PRON	O	O	2689
use	VERB	O	O	2689
of	ADP	O	O	2689
CBDCA	NOUN	O	Chemical	2689
higher	ADJ	O	O	2689
-	PUNCT	O	O	2689
intensity	NOUN	O	O	2689
schedules	NOUN	O	O	2689
and	CCONJ	O	O	2689
the	PRON	O	O	2689
association	PROPN	O	O	2689
with	ADP	O	O	2689
other	ADJ	O	O	2689
neurotoxic	ADJ	O	Disease	2689
drugs	NOUN	O	O	2689
in	ADP	O	O	2689
polychemotherapy	NOUN	O	O	2689
may	AUX	O	O	2689
cause	VERB	O	O	2689
some	PRON	O	O	2689
concern	NOUN	O	O	2689
about	ADP	O	O	2689
its	PRON	O	O	2689
safety	NOUN	O	O	2689
with	ADP	O	O	2689
respect	VERB	O	O	2689
to	PART	O	O	2689
peripheral nervous system damage	NOUN	O	Disease	2689
.	PUNCT	O	O	2689
Two	NUM	O	O	2690
different	ADJ	O	O	2690
schedules	NOUN	O	O	2690
of	ADP	O	O	2690
CBDCA	NOUN	O	Chemical	2690
administration	NOUN	O	O	2690
(	PUNCT	O	O	2690
10	NUM	O	O	2690
mg	VERB	O	O	2690
/	PUNCT	O	O	2690
kg	VERB	O	O	2690
and	CCONJ	O	O	2690
15	NUM	O	O	2690
mg	VERB	O	O	2690
/	PUNCT	O	O	2690
kg	VERB	O	O	2690
i.p	NOUN	O	O	2690
.	PUNCT	O	O	2690
Neurotoxicity	NOUN	O	Disease	2691
was	AUX	O	O	2691
assessed	VERB	O	O	2691
for	ADP	O	O	2691
behavioral	ADJ	O	O	2691
(	PUNCT	O	O	2691
tail	NOUN	O	O	2691
-	PUNCT	O	O	2691
flick	NOUN	O	O	2691
test	NOUN	O	O	2691
)	PUNCT	O	O	2691
,	PUNCT	O	O	2691
neurophysiological	ADJ	O	O	2691
(	PUNCT	O	O	2691
nerve	NOUN	O	O	2691
conduction	NOUN	O	O	2691
velocity	NOUN	O	O	2691
in	ADP	O	O	2691
the	PRON	O	O	2691
tail	NOUN	O	O	2691
nerve	NOUN	O	O	2691
)	PUNCT	O	O	2691
,	PUNCT	O	O	2691
morphological	ADJ	O	O	2691
,	PUNCT	O	O	2691
morphometrical	VERB	O	O	2691
and	CCONJ	O	O	2691
analytical	ADJ	O	O	2691
effects	NOUN	O	O	2691
.	PUNCT	O	O	2691
CBDCA	NOUN	O	Chemical	2692
administration	NOUN	O	O	2692
induced	VERB	O	O	2692
dose	NOUN	O	O	2692
-	PUNCT	O	O	2692
dependent	ADJ	O	O	2692
peripheral neurotoxicity	NOUN	O	Disease	2692
.	PUNCT	O	O	2692
Pain	NOUN	O	Disease	2693
perception	NOUN	O	O	2693
and	CCONJ	O	O	2693
nerve	NOUN	O	O	2693
conduction	NOUN	O	O	2693
velocity	NOUN	O	O	2693
in	ADP	O	O	2693
the	PRON	O	O	2693
tail	NOUN	O	O	2693
were	AUX	O	O	2693
significantly	ADV	O	O	2693
impaired	VERB	O	O	2693
,	PUNCT	O	O	2693
particularly	ADV	O	O	2693
after	ADP	O	O	2693
the	PRON	O	O	2693
high	ADJ	O	O	2693
-	PUNCT	O	O	2693
dose	NOUN	O	O	2693
treatment	NOUN	O	O	2693
.	PUNCT	O	O	2693
The	PRON	O	O	2694
dorsal	PROPN	O	O	2694
root	NOUN	O	O	2694
ganglia	NOUN	O	O	2694
sensory	ADJ	O	O	2694
neurons	NOUN	O	O	2694
and	CCONJ	O	O	2694
,	PUNCT	O	O	2694
to	PART	O	O	2694
a	PRON	O	O	2694
lesser	ADJ	O	O	2694
extent	NOUN	O	O	2694
,	PUNCT	O	O	2694
satellite	NOUN	O	O	2694
cells	NOUN	O	O	2694
showed	VERB	O	O	2694
the	PRON	O	O	2694
same	ADJ	O	O	2694
changes	VERB	O	O	2694
as	ADP	O	O	2694
those	PRON	O	O	2694
induced	VERB	O	O	2694
by	ADP	O	O	2694
CDDP	PROPN	O	Chemical	2694
,	PUNCT	O	O	2694
mainly	ADV	O	O	2694
affecting	VERB	O	O	2694
the	PRON	O	O	2694
nucleus	PROPN	O	O	2694
and	CCONJ	O	O	2694
nucleolus	NOUN	O	O	2694
of	ADP	O	O	2694
ganglionic	ADJ	O	O	2694
sensory	ADJ	O	O	2694
neurons	NOUN	O	O	2694
.	PUNCT	O	O	2694
Moreover	ADV	O	O	2695
,	PUNCT	O	O	2695
significant	ADJ	O	O	2695
amounts	VERB	O	O	2695
of	ADP	O	O	2695
platinum	NOUN	O	Chemical	2695
were	AUX	O	O	2695
detected	VERB	O	O	2695
in	ADP	O	O	2695
the	PRON	O	O	2695
dorsal	PROPN	O	O	2695
root	NOUN	O	O	2695
ganglia	NOUN	O	O	2695
and	CCONJ	O	O	2695
kidney	NOUN	O	O	2695
after	ADP	O	O	2695
CBDCA	NOUN	O	Chemical	2695
treatment	NOUN	O	O	2695
.	PUNCT	O	O	2695
CBDCA	NOUN	O	Chemical	2696
is	AUX	O	O	2696
neurotoxic	ADJ	O	Disease	2696
in	ADP	O	O	2696
our	PRON	O	O	2696
model	NOUN	O	O	2696
,	PUNCT	O	O	2696
and	CCONJ	O	O	2696
the	PRON	O	O	2696
type	NOUN	O	O	2696
of	ADP	O	O	2696
pathological	ADJ	O	O	2696
changes	VERB	O	O	2696
it	PRON	O	O	2696
induces	VERB	O	O	2696
are	AUX	O	O	2696
so	ADV	O	O	2696
closely	ADV	O	O	2696
similar	ADJ	O	O	2696
to	PART	O	O	2696
those	PRON	O	O	2696
caused	VERB	O	O	2696
by	ADP	O	O	2696
CDDP	PROPN	O	Chemical	2696
that	SCONJ	O	O	2696
it	PRON	O	O	2696
is	AUX	O	O	2696
probable	ADJ	O	O	2696
that	SCONJ	O	O	2696
neurotoxicity	NOUN	O	Disease	2696
is	AUX	O	O	2696
induced	VERB	O	O	2696
in	ADP	O	O	2696
the	PRON	O	O	2696
two	NUM	O	O	2696
drugs	NOUN	O	O	2696
by	ADP	O	O	2696
the	PRON	O	O	2696
same	ADJ	O	O	2696
mechanism	NOUN	O	O	2696
.	PUNCT	O	O	2696
This	PRON	O	O	2697
model	NOUN	O	O	2697
can	AUX	O	O	2697
be	AUX	O	O	2697
used	VERB	O	O	2697
alone	ADV	O	O	2697
or	CCONJ	O	O	2697
in	ADP	O	O	2697
combination	NOUN	O	O	2697
with	ADP	O	O	2697
other	ADJ	O	O	2697
drugs	NOUN	O	O	2697
to	PART	O	O	2697
explore	VERB	O	O	2697
the	PRON	O	O	2697
effect	VERB	O	O	2697
of	ADP	O	O	2697
CBDCA	NOUN	O	Chemical	2697
on	ADP	O	O	2697
the	PRON	O	O	2697
peripheral	ADJ	O	O	2697
nervous	ADJ	O	O	2697
system	NOUN	O	O	2697
.	PUNCT	O	O	2697
Iatrogenic	ADJ	O	O	2700
risks	NOUN	O	O	2700
of	ADP	O	O	2700
endometrial carcinoma	NOUN	O	Disease	2700
after	ADP	O	O	2700
treatment	NOUN	O	O	2700
for	ADP	O	O	2700
breast cancer	NOUN	O	Disease	2700
in	ADP	O	O	2700
a	PRON	O	O	2700
large	ADJ	O	O	2700
French	ADJ	O	O	2700
case	NOUN	O	O	2700
-	PUNCT	O	O	2700
control	VERB	O	O	2700
study	VERB	O	O	2700
.	PUNCT	O	O	2700
Since	SCONJ	O	O	2701
tamoxifen	PROPN	O	Chemical	2701
is	AUX	O	O	2701
widely	ADV	O	O	2701
used	VERB	O	O	2701
in	ADP	O	O	2701
breast cancer	NOUN	O	Disease	2701
treatment	NOUN	O	O	2701
and	CCONJ	O	O	2701
has	VERB	O	O	2701
been	AUX	O	O	2701
proposed	VERB	O	O	2701
for	ADP	O	O	2701
the	PRON	O	O	2701
prevention	NOUN	O	O	2701
of	ADP	O	O	2701
breast cancer	NOUN	O	Disease	2701
,	PUNCT	O	O	2701
its	PRON	O	O	2701
endometrial	ADJ	O	O	2701
iatrogenic	ADJ	O	O	2701
effects	NOUN	O	O	2701
must	AUX	O	O	2701
be	AUX	O	O	2701
carefully	ADV	O	O	2701
examined	VERB	O	O	2701
.	PUNCT	O	O	2701
We	PRON	O	O	2702
have	VERB	O	O	2702
investigated	VERB	O	O	2702
the	PRON	O	O	2702
association	PROPN	O	O	2702
between	ADP	O	O	2702
endometrial cancer	NOUN	O	Disease	2702
and	CCONJ	O	O	2702
tamoxifen	PROPN	O	Chemical	2702
use	VERB	O	O	2702
or	CCONJ	O	O	2702
other	ADJ	O	O	2702
treatments	NOUN	O	O	2702
in	ADP	O	O	2702
women	NOUN	O	O	2702
treated	VERB	O	O	2702
for	ADP	O	O	2702
breast cancer	NOUN	O	Disease	2702
in	ADP	O	O	2702
a	PRON	O	O	2702
case	NOUN	O	O	2702
-	PUNCT	O	O	2702
control	VERB	O	O	2702
study	VERB	O	O	2702
.	PUNCT	O	O	2702
Cases	NOUN	O	O	2703
of	ADP	O	O	2703
endometrial cancer	NOUN	O	Disease	2703
diagnosed	VERB	O	O	2703
after	ADP	O	O	2703
breast cancer	NOUN	O	Disease	2703
(	PUNCT	O	O	2703
n	CCONJ	O	O	2703
=	PUNCT	O	O	2703
135	NUM	O	O	2703
)	PUNCT	O	O	2703
and	CCONJ	O	O	2703
467	NUM	O	O	2703
controls	VERB	O	O	2703
matched	VERB	O	O	2703
for	ADP	O	O	2703
age	NOUN	O	O	2703
,	PUNCT	O	O	2703
year	NOUN	O	O	2703
of	ADP	O	O	2703
diagnosis	NOUN	O	O	2703
of	ADP	O	O	2703
breast cancer	NOUN	O	Disease	2703
and	CCONJ	O	O	2703
hospital	PROPN	O	O	2703
and	CCONJ	O	O	2703
survival	NOUN	O	O	2703
time	NOUN	O	O	2703
with	ADP	O	O	2703
an	PRON	O	O	2703
intact	ADJ	O	O	2703
uterus	NOUN	O	O	2703
were	AUX	O	O	2703
included	VERB	O	O	2703
.	PUNCT	O	O	2703
Women	NOUN	O	O	2704
who	PRON	O	O	2704
had	VERB	O	O	2704
received	VERB	O	O	2704
tamoxifen	PROPN	O	Chemical	2704
were	AUX	O	O	2704
significantly	ADV	O	O	2704
more	ADJ	O	O	2704
likely	ADV	O	O	2704
to	PART	O	O	2704
have	VERB	O	O	2704
endometrial cancer	NOUN	O	Disease	2704
diagnosed	VERB	O	O	2704
than	ADP	O	O	2704
those	PRON	O	O	2704
who	PRON	O	O	2704
had	VERB	O	O	2704
not	PART	O	O	2704
(	PUNCT	O	O	2704
crude	ADJ	O	O	2704
relative	ADJ	O	O	2704
risk	NOUN	O	O	2704
=	PUNCT	O	O	2704
4.9	NUM	O	O	2704
,	PUNCT	O	O	2704
p	NOUN	O	O	2704
=	PUNCT	O	O	2704
0.0001	NUM	O	O	2704
)	PUNCT	O	O	2704
.	PUNCT	O	O	2704
Univariate	NOUN	O	O	2705
and	CCONJ	O	O	2705
adjusted	VERB	O	O	2705
analyses	NOUN	O	O	2705
showed	VERB	O	O	2705
that	SCONJ	O	O	2705
the	PRON	O	O	2705
risk	NOUN	O	O	2705
increased	VERB	O	O	2705
with	ADP	O	O	2705
the	PRON	O	O	2705
length	NOUN	O	O	2705
of	ADP	O	O	2705
treatment	NOUN	O	O	2705
(	PUNCT	O	O	2705
p	NOUN	O	O	2705
=	PUNCT	O	O	2705
0.0001	NUM	O	O	2705
)	PUNCT	O	O	2705
or	CCONJ	O	O	2705
the	PRON	O	O	2705
cumulative	ADJ	O	O	2705
dose	NOUN	O	O	2705
of	ADP	O	O	2705
tamoxifen	PROPN	O	Chemical	2705
received	VERB	O	O	2705
(	PUNCT	O	O	2705
p	NOUN	O	O	2705
=	PUNCT	O	O	2705
0.0001	NUM	O	O	2705
)	PUNCT	O	O	2705
,	PUNCT	O	O	2705
irrespective	ADV	O	O	2705
of	ADP	O	O	2705
the	PRON	O	O	2705
daily	ADV	O	O	2705
dose	NOUN	O	O	2705
.	PUNCT	O	O	2705
After	ADP	O	O	2706
adjusting	VERB	O	O	2706
for	ADP	O	O	2706
confounding	VERB	O	O	2706
factors	NOUN	O	O	2706
,	PUNCT	O	O	2706
the	PRON	O	O	2706
risk	NOUN	O	O	2706
was	AUX	O	O	2706
higher	ADJ	O	O	2706
for	ADP	O	O	2706
tamoxifen	PROPN	O	Chemical	2706
users	NOUN	O	O	2706
(	PUNCT	O	O	2706
p	NOUN	O	O	2706
=	PUNCT	O	O	2706
0.0012	NUM	O	O	2706
)	PUNCT	O	O	2706
,	PUNCT	O	O	2706
Women	NOUN	O	O	2707
who	PRON	O	O	2707
had	VERB	O	O	2707
endometrial cancer	NOUN	O	Disease	2707
and	CCONJ	O	O	2707
had	VERB	O	O	2707
received	VERB	O	O	2707
tamoxifen	PROPN	O	Chemical	2707
had	VERB	O	O	2707
more	ADJ	O	O	2707
advanced disease	NOUN	O	Disease	2707
and	CCONJ	O	O	2707
poorer	ADV	O	O	2707
prognosis	VERB	O	O	2707
than	ADP	O	O	2707
those	PRON	O	O	2707
with	ADP	O	O	2707
endometrial cancer	NOUN	O	Disease	2707
who	PRON	O	O	2707
had	VERB	O	O	2707
not	PART	O	O	2707
received	VERB	O	O	2707
this	PRON	O	O	2707
treatment	NOUN	O	O	2707
.	PUNCT	O	O	2707
Our	PRON	O	O	2708
results	VERB	O	O	2708
suggest	VERB	O	O	2708
a	PRON	O	O	2708
causal	NOUN	O	O	2708
role	NOUN	O	O	2708
of	ADP	O	O	2708
tamoxifen	PROPN	O	Chemical	2708
in	ADP	O	O	2708
endometrial cancer	NOUN	O	Disease	2708
,	PUNCT	O	O	2708
particularly	ADV	O	O	2708
when	SCONJ	O	O	2708
used	VERB	O	O	2708
as	ADP	O	O	2708
currently	ADV	O	O	2708
proposed	VERB	O	O	2708
for	ADP	O	O	2708
breast cancer	NOUN	O	Disease	2708
prevention	NOUN	O	O	2708
.	PUNCT	O	O	2708
Pelvic	PROPN	O	O	2709
radiotherapy	NOUN	O	O	2709
may	AUX	O	O	2709
be	AUX	O	O	2709
an	PRON	O	O	2709
additional	ADJ	O	O	2709
iatrogenic	ADJ	O	O	2709
factor	NOUN	O	O	2709
for	ADP	O	O	2709
women	NOUN	O	O	2709
with	ADP	O	O	2709
breast cancer	NOUN	O	Disease	2709
.	PUNCT	O	O	2709
Endometrial cancers	NOUN	O	Disease	2710
diagnosed	VERB	O	O	2710
in	ADP	O	O	2710
women	NOUN	O	O	2710
treated	VERB	O	O	2710
with	ADP	O	O	2710
tamoxifen	PROPN	O	Chemical	2710
have	VERB	O	O	2710
poorer	ADV	O	O	2710
prognosis	VERB	O	O	2710
.	PUNCT	O	O	2710
Women	NOUN	O	O	2711
who	PRON	O	O	2711
receive	VERB	O	O	2711
tamoxifen	PROPN	O	Chemical	2711
for	ADP	O	O	2711
breast cancer	NOUN	O	Disease	2711
should	AUX	O	O	2711
be	AUX	O	O	2711
offered	VERB	O	O	2711
gynaecological	ADJ	O	O	2711
surveillance	NOUN	O	O	2711
during	ADP	O	O	2711
and	CCONJ	O	O	2711
after	ADP	O	O	2711
treatment	NOUN	O	O	2711
.	PUNCT	O	O	2711
A	PRON	O	O	2712
long	ADV	O	O	2712
-	PUNCT	O	O	2712
term	NOUN	O	O	2712
evaluation	NOUN	O	O	2712
of	ADP	O	O	2712
the	PRON	O	O	2712
risk	NOUN	O	O	2712
-	PUNCT	O	O	2712
benefit	VERB	O	O	2712
ratio	NOUN	O	O	2712
of	ADP	O	O	2712
tamoxifen	PROPN	O	Chemical	2712
as	ADP	O	O	2712
a	PRON	O	O	2712
preventive	ADJ	O	O	2712
treatment	NOUN	O	O	2712
for	ADP	O	O	2712
breast cancer	NOUN	O	Disease	2712
is	AUX	O	O	2712
clearly	ADV	O	O	2712
warranted	VERB	O	O	2712
.	PUNCT	O	O	2712
Granulosa cell tumor of the ovary	NOUN	O	Disease	2715
associated	VERB	O	O	2715
with	ADP	O	O	2715
antecedent	NOUN	O	O	2715
tamoxifen	PROPN	O	Chemical	2715
use	VERB	O	O	2715
.	PUNCT	O	O	2715
BACKGROUND	NOUN	O	O	2716
:	PUNCT	O	O	2716
Increased	VERB	O	O	2716
attention	NOUN	O	O	2716
has	VERB	O	O	2716
been	AUX	O	O	2716
focused	VERB	O	O	2716
recently	ADV	O	O	2716
on	ADP	O	O	2716
the	PRON	O	O	2716
estrogenic	ADJ	O	O	2716
effects	NOUN	O	O	2716
of	ADP	O	O	2716
tamoxifen	PROPN	O	Chemical	2716
.	PUNCT	O	O	2716
Review	NOUN	O	O	2717
of	ADP	O	O	2717
the	PRON	O	O	2717
literature	NOUN	O	O	2717
reveals	VERB	O	O	2717
an	PRON	O	O	2717
association	PROPN	O	O	2717
between	ADP	O	O	2717
tamoxifen	PROPN	O	Chemical	2717
use	VERB	O	O	2717
and	CCONJ	O	O	2717
gynecologic	ADJ	O	O	2717
tumors	NOUN	O	Disease	2717
.	PUNCT	O	O	2717
A	PRON	O	O	2718
52-year	NOUN	O	O	2718
-	PUNCT	O	O	2718
old	ADJ	O	O	2718
postmenopausal	NOUN	O	O	2718
woman	NOUN	O	O	2718
was	AUX	O	O	2718
treated	VERB	O	O	2718
with	ADP	O	O	2718
tamoxifen	PROPN	O	Chemical	2718
for	ADP	O	O	2718
stage	NOUN	O	O	2718
II	NUM	O	O	2718
estrogen	PROPN	O	Chemical	2718
receptor	NOUN	O	O	2718
-	PUNCT	O	O	2718
positive	ADJ	O	O	2718
breast carcinoma	NOUN	O	Disease	2718
.	PUNCT	O	O	2718
Her	PRON	O	O	2719
aspartate	NOUN	O	Chemical	2719
transaminase	X	O	O	2719
and	CCONJ	O	O	2719
alanine	NOUN	O	Chemical	2719
transaminase	X	O	O	2719
levels	NOUN	O	O	2719
increase	VERB	O	O	2719
markedly	ADV	O	O	2719
after	ADP	O	O	2719
6	NUM	O	O	2719
months	NOUN	O	O	2719
of	ADP	O	O	2719
tamoxifen	PROPN	O	Chemical	2719
use	VERB	O	O	2719
.	PUNCT	O	O	2719
After	ADP	O	O	2720
an	PRON	O	O	2720
additional	ADJ	O	O	2720
17	NUM	O	O	2720
months	NOUN	O	O	2720
of	ADP	O	O	2720
elevated	ADJ	O	O	2720
serum	NOUN	O	O	2720
transaminases	NOUN	O	O	2720
,	PUNCT	O	O	2720
the	PRON	O	O	2720
patient	NOUN	O	O	2720
was	AUX	O	O	2720
found	VERB	O	O	2720
to	PART	O	O	2720
have	VERB	O	O	2720
a	PRON	O	O	2720
stage	NOUN	O	O	2720
Ic	PROPN	O	O	2720
granulosa cell tumor of the ovary	NOUN	O	Disease	2720
.	PUNCT	O	O	2720
Patients	NOUN	O	O	2721
with	ADP	O	O	2721
tamoxifen	PROPN	O	Chemical	2721
-	PUNCT	O	O	2721
induced	VERB	O	O	2721
liver dysfunction	NOUN	O	Disease	2721
may	AUX	O	O	2721
be	AUX	O	O	2721
at	ADP	O	O	2721
increased	VERB	O	O	2721
risk	NOUN	O	O	2721
for	ADP	O	O	2721
granulosa cell tumors	NOUN	O	Disease	2721
because	SCONJ	O	O	2721
of	ADP	O	O	2721
alterations	NOUN	O	O	2721
in	ADP	O	O	2721
tamoxifen	PROPN	O	Chemical	2721
metabolism	NOUN	O	O	2721
.	PUNCT	O	O	2721
A	PRON	O	O	2724
murine	ADJ	O	O	2724
model	NOUN	O	O	2724
of	ADP	O	O	2724
adenomyosis	NOUN	O	Disease	2724
:	PUNCT	O	O	2724
the	PRON	O	O	2724
effects	NOUN	O	O	2724
of	ADP	O	O	2724
hyperprolactinemia	NOUN	O	Disease	2724
induced	VERB	O	O	2724
by	ADP	O	O	2724
fluoxetine hydrochloride	NOUN	O	Chemical	2724
,	PUNCT	O	O	2724
a	PRON	O	O	2724
selective	ADJ	O	O	2724
serotonin	PROPN	O	Chemical	2724
reuptake	PROPN	O	O	2724
inhibitor	NOUN	O	O	2724
,	PUNCT	O	O	2724
on	ADP	O	O	2724
adenomyosis	NOUN	O	Disease	2724
induction	NOUN	O	O	2724
in	ADP	O	O	2724
Wistar	PROPN	O	O	2724
albino	PROPN	O	O	2724
rats	NOUN	O	O	2724
.	PUNCT	O	O	2724
The	PRON	O	O	2725
aim	VERB	O	O	2725
of	ADP	O	O	2725
this	PRON	O	O	2725
study	VERB	O	O	2725
was	AUX	O	O	2725
to	PART	O	O	2725
investigate	VERB	O	O	2725
whether	SCONJ	O	O	2725
fluoxetine	NOUN	O	Chemical	2725
given	VERB	O	O	2725
to	PART	O	O	2725
castrated	VERB	O	O	2725
and	CCONJ	O	O	2725
noncastrated	VERB	O	O	2725
rats	NOUN	O	O	2725
caused	VERB	O	O	2725
hyperprolactinemia	NOUN	O	Disease	2725
and	CCONJ	O	O	2725
its	PRON	O	O	2725
effects	NOUN	O	O	2725
with	ADP	O	O	2725
respect	VERB	O	O	2725
to	PART	O	O	2725
adenomyosis	NOUN	O	Disease	2725
.	PUNCT	O	O	2725
Fluoxetine	NOUN	O	Chemical	2726
,	PUNCT	O	O	2726
a	PRON	O	O	2726
serotonin	PROPN	O	Chemical	2726
reuptake	PROPN	O	O	2726
inhibitor	NOUN	O	O	2726
,	PUNCT	O	O	2726
was	AUX	O	O	2726
given	VERB	O	O	2726
to	PART	O	O	2726
Wistar	PROPN	O	O	2726
Albino	PROPN	O	O	2726
rats	NOUN	O	O	2726
for	ADP	O	O	2726
98	NUM	O	O	2726
days	NOUN	O	O	2726
to	PART	O	O	2726
produce	VERB	O	O	2726
hyperprolactinemia	NOUN	O	Disease	2726
.	PUNCT	O	O	2726
The	PRON	O	O	2727
prolactin	PROPN	O	O	2727
levels	NOUN	O	O	2727
of	ADP	O	O	2727
castrated	VERB	O	O	2727
and	CCONJ	O	O	2727
noncastrated	VERB	O	O	2727
groups	NOUN	O	O	2727
treated	VERB	O	O	2727
with	ADP	O	O	2727
fluoxetine	NOUN	O	Chemical	2727
were	AUX	O	O	2727
statistically	ADV	O	O	2727
significantly	ADV	O	O	2727
higher	ADJ	O	O	2727
when	SCONJ	O	O	2727
compared	VERB	O	O	2727
to	PART	O	O	2727
their	PRON	O	O	2727
respective	ADJ	O	O	2727
control	VERB	O	O	2727
groups	NOUN	O	O	2727
.	PUNCT	O	O	2727
Histological	NOUN	O	O	2728
studies	NOUN	O	O	2728
revealed	VERB	O	O	2728
11	NUM	O	O	2728
cases	NOUN	O	O	2728
of	ADP	O	O	2728
adenomyosis	NOUN	O	Disease	2728
,	PUNCT	O	O	2728
all	PRON	O	O	2728
within	ADP	O	O	2728
the	PRON	O	O	2728
noncastrated	VERB	O	O	2728
group	NOUN	O	O	2728
receiving	VERB	O	O	2728
fluoxetine	NOUN	O	Chemical	2728
.	PUNCT	O	O	2728
It	PRON	O	O	2729
was	AUX	O	O	2729
suggested	VERB	O	O	2729
that	SCONJ	O	O	2729
high	ADJ	O	O	2729
serum	NOUN	O	O	2729
prolactin	PROPN	O	O	2729
levels	NOUN	O	O	2729
cause	VERB	O	O	2729
degeneration	NOUN	O	O	2729
of	ADP	O	O	2729
myometrial	ADJ	O	O	2729
cells	NOUN	O	O	2729
in	ADP	O	O	2729
the	PRON	O	O	2729
presence	NOUN	O	O	2729
of	ADP	O	O	2729
ovarian	NOUN	O	O	2729
steroids	NOUN	O	Chemical	2729
that	SCONJ	O	O	2729
results	VERB	O	O	2729
in	ADP	O	O	2729
a	PRON	O	O	2729
myometrial	ADJ	O	O	2729
invasion	NOUN	O	O	2729
by	ADP	O	O	2729
endometrial	ADJ	O	O	2729
stroma	ADJ	O	O	2729
.	PUNCT	O	O	2729
This	PRON	O	O	2730
invasion	NOUN	O	O	2730
eventually	ADV	O	O	2730
progresses	VERB	O	O	2730
to	PART	O	O	2730
adenomyosis	NOUN	O	Disease	2730
.	PUNCT	O	O	2730
Effects	NOUN	O	O	2733
of	ADP	O	O	2733
deliberate	VERB	O	O	2733
hypotension	NOUN	O	Disease	2733
induced	VERB	O	O	2733
by	ADP	O	O	2733
labetalol	NOUN	O	Chemical	2733
with	ADP	O	O	2733
isoflurane	NOUN	O	Chemical	2733
on	ADP	O	O	2733
neuropsychological	ADJ	O	O	2733
function	NOUN	O	O	2733
.	PUNCT	O	O	2733
The	PRON	O	O	2734
effect	VERB	O	O	2734
of	ADP	O	O	2734
deliberate	VERB	O	O	2734
hypotension	NOUN	O	Disease	2734
on	ADP	O	O	2734
brain	NOUN	O	O	2734
function	NOUN	O	O	2734
measured	VERB	O	O	2734
by	ADP	O	O	2734
neuropsychological	ADJ	O	O	2734
tests	VERB	O	O	2734
was	AUX	O	O	2734
studied	VERB	O	O	2734
in	ADP	O	O	2734
41	NUM	O	O	2734
adult	NOUN	O	O	2734
patients	NOUN	O	O	2734
.	PUNCT	O	O	2734
Twenty	NUM	O	O	2735
-	PUNCT	O	O	2735
four	NUM	O	O	2735
patients	NOUN	O	O	2735
were	AUX	O	O	2735
anaesthetized	VERB	O	O	2735
for	ADP	O	O	2735
middle	ADJ	O	O	2735
-	PUNCT	O	O	2735
ear	NOUN	O	O	2735
surgery	NOUN	O	O	2735
with	ADP	O	O	2735
deliberate	VERB	O	O	2735
hypotension	NOUN	O	Disease	2735
induced	VERB	O	O	2735
by	ADP	O	O	2735
labetalol	NOUN	O	Chemical	2735
with	ADP	O	O	2735
isoflurane	NOUN	O	Chemical	2735
(	PUNCT	O	O	2735
hypotensive	ADJ	O	Disease	2735
group	NOUN	O	O	2735
)	PUNCT	O	O	2735
.	PUNCT	O	O	2735
Seventeen	NUM	O	O	2736
patients	NOUN	O	O	2736
without	ADP	O	O	2736
hypotension	NOUN	O	Disease	2736
served	VERB	O	O	2736
as	ADP	O	O	2736
a	PRON	O	O	2736
control	VERB	O	O	2736
group	NOUN	O	O	2736
.	PUNCT	O	O	2736
0.3	NUM	O	O	2737
kPa	PROPN	O	O	2737
)	PUNCT	O	O	2737
before	ADP	O	O	2737
hypotension	NOUN	O	Disease	2737
and	CCONJ	O	O	2737
50	NUM	O	O	2737
+	ADP	O	O	2737
/-	PUNCT	O	O	2737
0.0	NUM	O	O	2738
kPa	PROPN	O	O	2738
)	PUNCT	O	O	2738
during	ADP	O	O	2738
hypotension	NOUN	O	Disease	2738
in	ADP	O	O	2738
the	PRON	O	O	2738
hypotensive	ADJ	O	Disease	2738
group	NOUN	O	O	2738
,	PUNCT	O	O	2738
and	CCONJ	O	O	2738
86	NUM	O	O	2738
+	ADP	O	O	2738
/-	PUNCT	O	O	2738
The	PRON	O	O	2739
following	VERB	O	O	2739
psychological	ADJ	O	O	2739
tests	VERB	O	O	2739
were	AUX	O	O	2739
performed	VERB	O	O	2739
:	PUNCT	O	O	2739
four	NUM	O	O	2739
subtests	NOUN	O	O	2739
of	ADP	O	O	2739
the	PRON	O	O	2739
Wechsler	NOUN	O	O	2739
Adult	NOUN	O	O	2739
Intelligence	NOUN	O	O	2739
Scale	NOUN	O	O	2739
(	PUNCT	O	O	2739
similarities	VERB	O	O	2739
,	PUNCT	O	O	2739
digit	NOUN	O	O	2739
span	NOUN	O	O	2739
,	PUNCT	O	O	2739
vocabulary	NOUN	O	O	2739
and	CCONJ	O	O	2739
digit	NOUN	O	O	2739
symbol	NOUN	O	O	2739
)	PUNCT	O	O	2739
,	PUNCT	O	O	2739
Trail	NOUN	O	O	2739
-	PUNCT	O	O	2739
Making	VERB	O	O	2739
tests	VERB	O	O	2739
A	PRON	O	O	2739
and	CCONJ	O	O	2739
B	NOUN	O	O	2739
,	PUNCT	O	O	2739
Zung	PROPN	O	O	2739
tests	VERB	O	O	2739
(	PUNCT	O	O	2739
self	VERB	O	O	2739
-	PUNCT	O	O	2739
rating	NOUN	O	O	2739
anxiety	NOUN	O	Disease	2739
scale	NOUN	O	O	2739
and	CCONJ	O	O	2739
self	VERB	O	O	2739
-	PUNCT	O	O	2739
rating	NOUN	O	O	2739
depression	PROPN	O	Disease	2739
scale	NOUN	O	O	2739
)	PUNCT	O	O	2739
and	CCONJ	O	O	2739
two	NUM	O	O	2739
-	PUNCT	O	O	2739
part	NOUN	O	O	2739
memory	NOUN	O	O	2739
test	NOUN	O	O	2739
battery	NOUN	O	O	2739
with	ADP	O	O	2739
immediate	ADJ	O	O	2739
and	CCONJ	O	O	2739
delayed	VERB	O	O	2739
recall	VERB	O	O	2739
.	PUNCT	O	O	2739
The	PRON	O	O	2740
results	VERB	O	O	2740
indicate	VERB	O	O	2740
that	SCONJ	O	O	2740
hypotension	NOUN	O	Disease	2740
induced	VERB	O	O	2740
by	ADP	O	O	2740
labetalol	NOUN	O	Chemical	2740
with	ADP	O	O	2740
isoflurane	NOUN	O	Chemical	2740
has	VERB	O	O	2740
no	PRON	O	O	2740
significant	ADJ	O	O	2740
harmful	ADJ	O	O	2740
effects	NOUN	O	O	2740
on	ADP	O	O	2740
mental	ADJ	O	O	2740
functions	VERB	O	O	2740
compared	VERB	O	O	2740
to	PART	O	O	2740
normotensive	PROPN	O	O	2740
anaesthesia	NOUN	O	O	2740
.	PUNCT	O	O	2740
Bupivacaine	NOUN	O	Chemical	2743
0.75%	NOUN	O	O	2743
with	ADP	O	O	2743
adrenaline	NOUN	O	Chemical	2743
was	AUX	O	O	2743
given	VERB	O	O	2743
followed	VERB	O	O	2743
by	ADP	O	O	2743
a	PRON	O	O	2743
24-hr	NOUN	O	O	2743
continuous	ADJ	O	O	2743
infusion	NOUN	O	O	2743
of	ADP	O	O	2743
0.25%	NOUN	O	O	2743
bupivacaine	NOUN	O	Chemical	2743
.	PUNCT	O	O	2743
In	ADP	O	O	2744
four	NUM	O	O	2744
patients	NOUN	O	O	2744
hearing impairment	NOUN	O	Disease	2744
on	ADP	O	O	2744
the	PRON	O	O	2744
side	NOUN	O	O	2744
of	ADP	O	O	2744
the	PRON	O	O	2744
block	NOUN	O	O	2744
was	AUX	O	O	2744
demonstrated	VERB	O	O	2744
after	ADP	O	O	2744
operation	NOUN	O	O	2744
,	PUNCT	O	O	2744
in	ADP	O	O	2744
three	NUM	O	O	2744
measurements	NOUN	O	O	2744
on	ADP	O	O	2744
the	PRON	O	O	2744
day	NOUN	O	O	2744
of	ADP	O	O	2744
surgery	NOUN	O	O	2744
and	CCONJ	O	O	2744
in	ADP	O	O	2744
one	NUM	O	O	2744
on	ADP	O	O	2744
the	PRON	O	O	2744
following	VERB	O	O	2744
day	NOUN	O	O	2744
.	PUNCT	O	O	2744
The	PRON	O	O	2745
maximum	ADV	O	O	2745
change	VERB	O	O	2745
in	ADP	O	O	2745
threshold	NOUN	O	O	2745
was	AUX	O	O	2745
35	NUM	O	O	2745
dB	NOUN	O	O	2745
at	ADP	O	O	2745
6	NUM	O	O	2745
kHz	NOUN	O	O	2745
measured	VERB	O	O	2745
at	ADP	O	O	2745
the	PRON	O	O	2745
end	VERB	O	O	2745
of	ADP	O	O	2745
the	PRON	O	O	2745
continuous	ADJ	O	O	2745
infusion	NOUN	O	O	2745
of	ADP	O	O	2745
bupivacaine	NOUN	O	Chemical	2745
.	PUNCT	O	O	2745
IBPB	PROPN	O	O	2746
may	AUX	O	O	2746
cause	VERB	O	O	2746
transient	ADJ	O	O	2746
auditory dysfunction	NOUN	O	Disease	2746
in	ADP	O	O	2746
the	PRON	O	O	2746
ipsilateral	ADJ	O	O	2746
ear	NOUN	O	O	2746
,	PUNCT	O	O	2746
possibly	ADV	O	O	2746
via	ADP	O	O	2746
an	PRON	O	O	2746
effect	VERB	O	O	2746
on	ADP	O	O	2746
sympathetic	ADJ	O	O	2746
innervation	NOUN	O	O	2746
.	PUNCT	O	O	2746
Midazolam	PROPN	O	Chemical	2749
compared	VERB	O	O	2749
with	ADP	O	O	2749
thiopentone	NOUN	O	Chemical	2749
as	ADP	O	O	2749
an	PRON	O	O	2749
induction	NOUN	O	O	2749
agent	NOUN	O	O	2749
.	PUNCT	O	O	2749
In	ADP	O	O	2750
patients	NOUN	O	O	2750
premedicated	VERB	O	O	2750
with	ADP	O	O	2750
scopolamine	NOUN	O	Chemical	2750
+	ADP	O	O	2750
morphine	NOUN	O	Chemical	2750
(	PUNCT	O	O	2750
+	ADP	O	O	2750
5	NUM	O	O	2750
mg	VERB	O	O	2750
nitrazepam	NOUN	O	Chemical	2750
the	PRON	O	O	2750
evening	NOUN	O	O	2750
before	ADP	O	O	2750
surgery	NOUN	O	O	2750
)	PUNCT	O	O	2750
,	PUNCT	O	O	2750
the	PRON	O	O	2750
sleep	VERB	O	O	2750
-	PUNCT	O	O	2750
inducing	VERB	O	O	2750
effect	VERB	O	O	2750
of	ADP	O	O	2750
midazolam	PROPN	O	Chemical	2750
0.15	NUM	O	O	2750
mg	VERB	O	O	2750
/	PUNCT	O	O	2750
kg	VERB	O	O	2750
i.v	NOUN	O	O	2750
.	PUNCT	O	O	2750
was	AUX	O	O	2750
clearly	ADV	O	O	2750
slower	ADJ	O	O	2750
in	ADP	O	O	2750
onset	VERB	O	O	2750
than	ADP	O	O	2750
that	SCONJ	O	O	2750
of	ADP	O	O	2750
thiopentone	NOUN	O	Chemical	2750
4.67	NUM	O	O	2750
mg	VERB	O	O	2750
/	PUNCT	O	O	2750
kg	VERB	O	O	2750
i.v	NOUN	O	O	2750
.	PUNCT	O	O	2750
Somewhat	ADV	O	O	2751
fewer	ADJ	O	O	2751
cardiovascular	ADJ	O	O	2751
and	CCONJ	O	O	2751
local	ADJ	O	O	2751
sequelae	ADJ	O	O	2751
were	AUX	O	O	2751
found	VERB	O	O	2751
in	ADP	O	O	2751
the	PRON	O	O	2751
midazolam	PROPN	O	Chemical	2751
group	NOUN	O	O	2751
,	PUNCT	O	O	2751
but	CCONJ	O	O	2751
,	PUNCT	O	O	2751
although	SCONJ	O	O	2751
apnoea	NOUN	O	Disease	2751
occurred	VERB	O	O	2751
less	ADV	O	O	2751
often	ADV	O	O	2751
in	ADP	O	O	2751
the	PRON	O	O	2751
midazolam	PROPN	O	Chemical	2751
group	NOUN	O	O	2751
it	PRON	O	O	2751
lasted	VERB	O	O	2751
longer	ADV	O	O	2751
.	PUNCT	O	O	2751
On	ADP	O	O	2752
the	PRON	O	O	2752
whole	NOUN	O	O	2752
,	PUNCT	O	O	2752
the	PRON	O	O	2752
differences	NOUN	O	O	2752
between	ADP	O	O	2752
midazolam	PROPN	O	Chemical	2752
and	CCONJ	O	O	2752
thiopentone	NOUN	O	Chemical	2752
had	VERB	O	O	2752
no	PRON	O	O	2752
apparent	ADJ	O	O	2752
clinical	ADJ	O	O	2752
consequences	NOUN	O	O	2752
.	PUNCT	O	O	2752
Midazolam	PROPN	O	Chemical	2753
is	AUX	O	O	2753
a	PRON	O	O	2753
new	ADJ	O	O	2753
alternative	ADV	O	O	2753
agent	NOUN	O	O	2753
for	ADP	O	O	2753
induction	NOUN	O	O	2753
in	ADP	O	O	2753
combination	NOUN	O	O	2753
anaesthesia	NOUN	O	O	2753
.	PUNCT	O	O	2753
Cardiotoxic	NOUN	O	Disease	2756
and	CCONJ	O	O	2756
possible	ADJ	O	O	2756
leukemogenic	PROPN	O	O	2756
effects	NOUN	O	O	2756
of	ADP	O	O	2756
adriamycin	PROPN	O	Chemical	2756
in	ADP	O	O	2756
nonhuman	NOUN	O	O	2756
primates	NOUN	O	O	2756
.	PUNCT	O	O	2756
10	NUM	O	O	2757
monkeys	NOUN	O	O	2757
(	PUNCT	O	O	2757
macaques	NOUN	O	O	2757
)	PUNCT	O	O	2757
received	VERB	O	O	2757
adriamycin	PROPN	O	Chemical	2757
by	ADP	O	O	2757
monthly	ADV	O	O	2757
intravenous	ADJ	O	O	2757
injections	NOUN	O	O	2757
at	ADP	O	O	2757
12	NUM	O	O	2757
mg	VERB	O	O	2757
/	PUNCT	O	O	2757
m2	PROPN	O	O	2757
(	PUNCT	O	O	2757
1	X	O	O	2757
mg	VERB	O	O	2757
/	PUNCT	O	O	2757
kg	VERB	O	O	2757
)	PUNCT	O	O	2757
.	PUNCT	O	O	2757
8	NUM	O	O	2758
of	ADP	O	O	2758
the	PRON	O	O	2758
10	NUM	O	O	2758
monkeys	NOUN	O	O	2758
developed	VERB	O	O	2758
congestive	ADJ	O	O	2758
heart failure	NOUN	O	Disease	2758
at	ADP	O	O	2758
an	PRON	O	O	2758
average	ADJ	O	O	2758
cumulative	ADJ	O	O	2758
adriamycin	PROPN	O	Chemical	2758
dose	NOUN	O	O	2758
(	PUNCT	O	O	2758
310	NUM	O	O	2758
mg	VERB	O	O	2758
/	PUNCT	O	O	2758
m2	PROPN	O	O	2758
)	PUNCT	O	O	2758
well	ADV	O	O	2758
below	ADP	O	O	2758
that	SCONJ	O	O	2758
considered	VERB	O	O	2758
the	PRON	O	O	2758
safe	ADJ	O	O	2758
upper	ADJ	O	O	2758
limit	NOUN	O	O	2758
(	PUNCT	O	O	2758
550	NUM	O	O	2758
mg	VERB	O	O	2758
/	PUNCT	O	O	2758
m2	PROPN	O	O	2758
)	PUNCT	O	O	2758
in	ADP	O	O	2758
man	NOUN	O	O	2758
.	PUNCT	O	O	2758
Histologically	PROPN	O	O	2759
,	PUNCT	O	O	2759
the	PRON	O	O	2759
myocardial lesions	NOUN	O	Disease	2759
resembled	VERB	O	O	2759
those	PRON	O	O	2759
found	VERB	O	O	2759
in	ADP	O	O	2759
human	PROPN	O	O	2759
anthracycline	NOUN	O	Chemical	2759
-	PUNCT	O	O	2759
induced	VERB	O	O	2759
cardiomyopathy	ADJ	O	Disease	2759
.	PUNCT	O	O	2759
1	X	O	O	2760
of	ADP	O	O	2760
the	PRON	O	O	2760
10	NUM	O	O	2760
monkeys	NOUN	O	O	2760
developed	VERB	O	O	2760
acute myeloblastic leukemia	NOUN	O	Disease	2760
after	ADP	O	O	2760
receiving	VERB	O	O	2760
324	NUM	O	O	2760
mg	VERB	O	O	2760
/	PUNCT	O	O	2760
m2	PROPN	O	O	2760
of	ADP	O	O	2760
adriamycin	PROPN	O	Chemical	2760
;	PUNCT	O	O	2760
the	PRON	O	O	2760
10th	ADJ	O	O	2760
monkey	NOUN	O	O	2760
is	AUX	O	O	2760
alive	ADJ	O	O	2760
and	CCONJ	O	O	2760
well	ADV	O	O	2760
26	NUM	O	O	2760
months	NOUN	O	O	2760
after	ADP	O	O	2760
the	PRON	O	O	2760
last	VERB	O	O	2760
dose	NOUN	O	O	2760
of	ADP	O	O	2760
drug	NOUN	O	O	2760
.	PUNCT	O	O	2760
Our	PRON	O	O	2761
results	VERB	O	O	2761
suggest	VERB	O	O	2761
that	SCONJ	O	O	2761
adriamycin	PROPN	O	Chemical	2761
is	AUX	O	O	2761
a	PRON	O	O	2761
more	ADJ	O	O	2761
potent	ADJ	O	O	2761
cardiotoxin	PROPN	O	O	2761
in	ADP	O	O	2761
monkeys	NOUN	O	O	2761
than	ADP	O	O	2761
in	ADP	O	O	2761
man	NOUN	O	O	2761
,	PUNCT	O	O	2761
and	CCONJ	O	O	2761
that	SCONJ	O	O	2761
leukemia	NOUN	O	Disease	2761
may	AUX	O	O	2761
be	AUX	O	O	2761
a	PRON	O	O	2761
consequence	NOUN	O	O	2761
of	ADP	O	O	2761
prolonged	VERB	O	O	2761
treatment	NOUN	O	O	2761
with	ADP	O	O	2761
this	PRON	O	O	2761
drug	NOUN	O	O	2761
.	PUNCT	O	O	2761
Doxorubicin	PROPN	O	Chemical	2764
cardiomyopathy	ADJ	O	Disease	2764
in	ADP	O	O	2764
children	NOUN	O	O	2764
with	ADP	O	O	2764
left	VERB	O	O	2764
-	PUNCT	O	O	2764
sided	VERB	O	O	2764
Wilms tumor	NOUN	O	Disease	2764
.	PUNCT	O	O	2764
Two	NUM	O	O	2765
children	NOUN	O	O	2765
with	ADP	O	O	2765
Wilms tumor	NOUN	O	Disease	2765
of	ADP	O	O	2765
the	PRON	O	O	2765
left	VERB	O	O	2765
kidney	NOUN	O	O	2765
experienced	ADJ	O	O	2765
severe	ADJ	O	O	2765
anthracycline	NOUN	O	Chemical	2765
cardiomyopathy	ADJ	O	Disease	2765
after	ADP	O	O	2765
irradiation	NOUN	O	O	2765
to	PART	O	O	2765
the	PRON	O	O	2765
tumor	NOUN	O	Disease	2765
bed	NOUN	O	O	2765
and	CCONJ	O	O	2765
conventional	ADJ	O	O	2765
dosage	NOUN	O	O	2765
of	ADP	O	O	2765
doxorubicin	VERB	O	Chemical	2765
.	PUNCT	O	O	2765
The	PRON	O	O	2766
cardiomyopathy	ADJ	O	Disease	2766
is	AUX	O	O	2766
attributed	VERB	O	O	2766
1	X	O	O	2766
)	PUNCT	O	O	2766
to	PART	O	O	2766
the	PRON	O	O	2766
fact	NOUN	O	O	2766
that	SCONJ	O	O	2766
radiation	NOUN	O	O	2766
fields	NOUN	O	O	2766
for	ADP	O	O	2766
left	VERB	O	O	2766
Wilms tumor	NOUN	O	Disease	2766
include	VERB	O	O	2766
the	PRON	O	O	2766
lower	ADJ	O	O	2766
portion	NOUN	O	O	2766
of	ADP	O	O	2766
the	PRON	O	O	2766
heart	NOUN	O	O	2766
and	CCONJ	O	O	2766
2	X	O	O	2766
)	PUNCT	O	O	2766
to	PART	O	O	2766
the	PRON	O	O	2766
interaction	NOUN	O	O	2766
of	ADP	O	O	2766
doxorubicin	VERB	O	Chemical	2766
and	CCONJ	O	O	2766
irradiation	NOUN	O	O	2766
on	ADP	O	O	2766
cardiac	ADJ	O	O	2766
muscle	NOUN	O	O	2766
.	PUNCT	O	O	2766
It	PRON	O	O	2767
is	AUX	O	O	2767
recommended	VERB	O	O	2767
that	SCONJ	O	O	2767
doxorubicin	VERB	O	Chemical	2767
dosage	NOUN	O	O	2767
be	AUX	O	O	2767
sharply	ADV	O	O	2767
restricted	VERB	O	O	2767
in	ADP	O	O	2767
children	NOUN	O	O	2767
with	ADP	O	O	2767
Wilms tumor	NOUN	O	Disease	2767
of	ADP	O	O	2767
the	PRON	O	O	2767
left	VERB	O	O	2767
kidney	NOUN	O	O	2767
who	PRON	O	O	2767
receive	VERB	O	O	2767
postoperative	ADJ	O	O	2767
irradiation	NOUN	O	O	2767
.	PUNCT	O	O	2767
Promotional	ADJ	O	O	2770
effects	NOUN	O	O	2770
of	ADP	O	O	2770
testosterone	PROPN	O	Chemical	2770
and	CCONJ	O	O	2770
dietary	ADJ	O	O	2770
fat	ADJ	O	Chemical	2770
on	ADP	O	O	2770
prostate	NOUN	O	O	2770
carcinogenesis	NOUN	O	Disease	2770
in	ADP	O	O	2770
genetically	ADV	O	O	2770
susceptible	ADJ	O	O	2770
rats	NOUN	O	O	2770
.	PUNCT	O	O	2770
Wistar	PROPN	O	O	2771
(	PUNCT	O	O	2771
LW	PROPN	O	O	2771
)	PUNCT	O	O	2771
rats	NOUN	O	O	2771
,	PUNCT	O	O	2771
fed	VERB	O	O	2771
vegetable	NOUN	O	O	2771
diet	PROPN	O	O	2771
L-485	NOUN	O	O	2771
,	PUNCT	O	O	2771
have	VERB	O	O	2771
developed	VERB	O	O	2771
prostate adenocarcinomas	VERB	O	Disease	2771
spontaneously	ADV	O	O	2771
(	PUNCT	O	O	2771
10%	NOUN	O	O	2771
incidence	NOUN	O	O	2771
)	PUNCT	O	O	2771
at	ADP	O	O	2771
average	ADJ	O	O	2771
age	NOUN	O	O	2771
34	NUM	O	O	2771
months	NOUN	O	O	2771
.	PUNCT	O	O	2771
Conventional	ADJ	O	O	2772
LW	PROPN	O	O	2772
rats	NOUN	O	O	2772
,	PUNCT	O	O	2772
implanted	VERB	O	O	2772
with	ADP	O	O	2772
testosterone	PROPN	O	Chemical	2772
at	ADP	O	O	2772
age	NOUN	O	O	2772
4	NUM	O	O	2772
months	NOUN	O	O	2772
,	PUNCT	O	O	2772
developed	VERB	O	O	2772
a	PRON	O	O	2772
higher	ADJ	O	O	2772
incidence	NOUN	O	O	2772
of	ADP	O	O	2772
prostate cancer	NOUN	O	Disease	2772
after	ADP	O	O	2772
an	PRON	O	O	2772
average	ADJ	O	O	2772
interval	NOUN	O	O	2772
of	ADP	O	O	2772
14	NUM	O	O	2772
months	NOUN	O	O	2772
:	PUNCT	O	O	2772
24%	NOUN	O	O	2772
had	VERB	O	O	2772
developed	VERB	O	O	2772
gross	ADJ	O	O	2772
tumors	NOUN	O	Disease	2772
,	PUNCT	O	O	2772
and	CCONJ	O	O	2772
40%	NOUN	O	O	2772
when	SCONJ	O	O	2772
it	PRON	O	O	2772
included	VERB	O	O	2772
microscopic	ADJ	O	O	2772
tumors	NOUN	O	Disease	2772
.	PUNCT	O	O	2772
Preliminary	PROPN	O	O	2773
results	VERB	O	O	2773
indicate	VERB	O	O	2773
that	SCONJ	O	O	2773
testosterone	PROPN	O	Chemical	2773
-	PUNCT	O	O	2773
treated	VERB	O	O	2773
LW	PROPN	O	O	2773
rats	NOUN	O	O	2773
that	SCONJ	O	O	2773
were	AUX	O	O	2773
fed	VERB	O	O	2773
the	PRON	O	O	2773
same	ADJ	O	O	2773
diet	PROPN	O	O	2773
,	PUNCT	O	O	2773
which	PRON	O	O	2773
was	AUX	O	O	2773
supplemented	VERB	O	O	2773
with	ADP	O	O	2773
corn	NOUN	O	O	2773
oil	NOUN	O	O	2773
up	ADP	O	O	2773
to	PART	O	O	2773
20%	NOUN	O	O	2773
fat	ADJ	O	Chemical	2773
,	PUNCT	O	O	2773
developed	VERB	O	O	2773
prostate cancer	NOUN	O	Disease	2773
after	ADP	O	O	2773
intervals	NOUN	O	O	2773
of	ADP	O	O	2773
6	NUM	O	O	2773
-	PUNCT	O	O	2773
12	NUM	O	O	2773
months	NOUN	O	O	2773
.	PUNCT	O	O	2773
rats	NOUN	O	O	2774
have	VERB	O	O	2774
not	PART	O	O	2774
developed	VERB	O	O	2774
prostate cancer	NOUN	O	Disease	2774
spontaneously	ADV	O	O	2774
.	PUNCT	O	O	2774
Conventional	ADJ	O	O	2775
SD	NOUN	O	O	2775
rats	NOUN	O	O	2775
fed	VERB	O	O	2775
diet	PROPN	O	O	2775
L-485	NOUN	O	O	2775
and	CCONJ	O	O	2775
treated	VERB	O	O	2775
with	ADP	O	O	2775
testosterone	PROPN	O	Chemical	2775
developed	VERB	O	O	2775
only	ADV	O	O	2775
prostatitis	NOUN	O	Disease	2775
.	PUNCT	O	O	2775
Experimental	ADJ	O	O	2776
designs	VERB	O	O	2776
should	AUX	O	O	2776
consider	VERB	O	O	2776
genetic	ADJ	O	O	2776
susceptibility	NOUN	O	O	2776
as	ADP	O	O	2776
a	PRON	O	O	2776
basic	ADJ	O	O	2776
prerequisite	NOUN	O	O	2776
for	ADP	O	O	2776
studies	NOUN	O	O	2776
on	ADP	O	O	2776
experimental	ADJ	O	O	2776
prostate cancer	NOUN	O	Disease	2776
.	PUNCT	O	O	2776
Mitomycin C	PROPN	O	Chemical	2779
associated	VERB	O	O	2779
hemolytic uremic syndrome	NOUN	O	Disease	2779
.	PUNCT	O	O	2779
Mitomycin C	PROPN	O	Chemical	2780
associated	VERB	O	O	2780
Hemolytic Uremic Syndrome	PROPN	O	Disease	2780
(	PUNCT	O	O	2780
HUS	PROPN	O	Disease	2780
)	PUNCT	O	O	2780
is	AUX	O	O	2780
a	PRON	O	O	2780
potentially	ADV	O	O	2780
fatal	ADJ	O	O	2780
but	CCONJ	O	O	2780
uncommon	ADJ	O	O	2780
condition	NOUN	O	O	2780
that	SCONJ	O	O	2780
is	AUX	O	O	2780
not	PART	O	O	2780
yet	ADV	O	O	2780
widely	ADV	O	O	2780
recognised	VERB	O	O	2780
.	PUNCT	O	O	2780
It	PRON	O	O	2781
consists	VERB	O	O	2781
of	ADP	O	O	2781
microangiopathic	ADV	O	O	2781
hemolytic anemia	NOUN	O	Disease	2781
,	PUNCT	O	O	2781
thrombocytopenia	PROPN	O	Disease	2781
and	CCONJ	O	O	2781
progressive renal failure	NOUN	O	Disease	2781
associated	VERB	O	O	2781
with	ADP	O	O	2781
mitomycin C	PROPN	O	Chemical	2781
treatment	NOUN	O	O	2781
and	CCONJ	O	O	2781
affects	VERB	O	O	2781
about	ADP	O	O	2781
10%	NOUN	O	O	2781
of	ADP	O	O	2781
patients	NOUN	O	O	2781
treated	VERB	O	O	2781
with	ADP	O	O	2781
this	PRON	O	O	2781
agent	NOUN	O	O	2781
.	PUNCT	O	O	2781
The	PRON	O	O	2782
renal failure	NOUN	O	Disease	2782
usually	ADV	O	O	2782
develops	VERB	O	O	2782
about	ADP	O	O	2782
8	NUM	O	O	2782
-	PUNCT	O	O	2782
10	NUM	O	O	2782
mth	PROPN	O	O	2782
after	ADP	O	O	2782
start	VERB	O	O	2782
of	ADP	O	O	2782
mitomycin C	PROPN	O	Chemical	2782
treatment	NOUN	O	O	2782
and	CCONJ	O	O	2782
the	PRON	O	O	2782
mortality	NOUN	O	O	2782
is	AUX	O	O	2782
approximately	ADV	O	O	2782
60%	NOUN	O	O	2782
from	ADP	O	O	2782
renal failure	NOUN	O	Disease	2782
or	CCONJ	O	O	2782
pulmonary edema	NOUN	O	Disease	2782
.	PUNCT	O	O	2782
Renal lesions	NOUN	O	Disease	2783
are	AUX	O	O	2783
similar	ADJ	O	O	2783
to	PART	O	O	2783
those	PRON	O	O	2783
seen	VERB	O	O	2783
in	ADP	O	O	2783
idiopathic	ADJ	O	O	2783
HUS	PROPN	O	Disease	2783
and	CCONJ	O	O	2783
include	VERB	O	O	2783
arteriolar	ADJ	O	O	2783
fibrin	PROPN	O	O	2783
thrombi	NOUN	O	Disease	2783
,	PUNCT	O	O	2783
expanded	VERB	O	O	2783
subendothelial	ADJ	O	O	2783
zones	NOUN	O	O	2783
in	ADP	O	O	2783
glomerular	ADJ	O	O	2783
capillary	NOUN	O	O	2783
walls	NOUN	O	O	2783
,	PUNCT	O	O	2783
ischemic	VERB	O	Disease	2783
wrinkling	VERB	O	O	2783
of	ADP	O	O	2783
glomerular	ADJ	O	O	2783
basement	NOUN	O	O	2783
membranes	NOUN	O	O	2783
and	CCONJ	O	O	2783
mesangiolysis	NOUN	O	O	2783
.	PUNCT	O	O	2783
The	PRON	O	O	2784
mechanism	NOUN	O	O	2784
of	ADP	O	O	2784
action	NOUN	O	O	2784
is	AUX	O	O	2784
postulated	VERB	O	O	2784
as	ADP	O	O	2784
mitomycin C	PROPN	O	Chemical	2784
-	PUNCT	O	O	2784
induced	VERB	O	O	2784
endothelial	NOUN	O	O	2784
cell	NOUN	O	O	2784
damage	NOUN	O	O	2784
.	PUNCT	O	O	2784
We	PRON	O	O	2785
describe	VERB	O	O	2785
the	PRON	O	O	2785
clinical	ADJ	O	O	2785
course	NOUN	O	O	2785
and	CCONJ	O	O	2785
pathological	ADJ	O	O	2785
findings	NOUN	O	O	2785
in	ADP	O	O	2785
a	PRON	O	O	2785
65	NUM	O	O	2785
yr	NOUN	O	O	2785
-	PUNCT	O	O	2785
old	ADJ	O	O	2785
man	NOUN	O	O	2785
with	ADP	O	O	2785
gastric adenocarcinoma	NOUN	O	Disease	2785
who	PRON	O	O	2785
developed	VERB	O	O	2785
renal failure	NOUN	O	Disease	2785
and	CCONJ	O	O	2785
thrombocytopenia	PROPN	O	Disease	2785
while	SCONJ	O	O	2785
on	ADP	O	O	2785
treatment	NOUN	O	O	2785
with	ADP	O	O	2785
mitomycin C	PROPN	O	Chemical	2785
and	CCONJ	O	O	2785
died	VERB	O	O	2785
in	ADP	O	O	2785
pulmonary edema	NOUN	O	Disease	2785
.	PUNCT	O	O	2785
Continuous	ADJ	O	O	2788
ambulatory	ADJ	O	O	2788
ECG	PROPN	O	O	2788
monitoring	NOUN	O	O	2788
during	ADP	O	O	2788
fluorouracil	NOUN	O	Chemical	2788
therapy	NOUN	O	O	2788
:	PUNCT	O	O	2788
a	PRON	O	O	2788
prospective	ADJ	O	O	2788
study	VERB	O	O	2788
.	PUNCT	O	O	2788
Although	SCONJ	O	O	2789
there	ADV	O	O	2789
have	VERB	O	O	2789
been	AUX	O	O	2789
anecdotal	ADJ	O	O	2789
reports	VERB	O	O	2789
of	ADP	O	O	2789
cardiac toxicity	NOUN	O	Disease	2789
associated	VERB	O	O	2789
with	ADP	O	O	2789
fluorouracil	NOUN	O	Chemical	2789
(	PUNCT	O	O	2789
5-FU	NOUN	O	Chemical	2789
)	PUNCT	O	O	2789
therapy	NOUN	O	O	2789
,	PUNCT	O	O	2789
this	PRON	O	O	2789
phenomenon	NOUN	O	O	2789
has	VERB	O	O	2789
not	PART	O	O	2789
been	AUX	O	O	2789
studied	VERB	O	O	2789
in	ADP	O	O	2789
a	PRON	O	O	2789
systematic	ADJ	O	O	2789
fashion	NOUN	O	O	2789
.	PUNCT	O	O	2789
We	PRON	O	O	2790
prospectively	ADV	O	O	2790
performed	VERB	O	O	2790
continuous	ADJ	O	O	2790
ambulatory	ADJ	O	O	2790
ECG	PROPN	O	O	2790
monitoring	NOUN	O	O	2790
on	ADP	O	O	2790
25	NUM	O	O	2790
patients	NOUN	O	O	2790
undergoing	VERB	O	O	2790
5-FU	NOUN	O	Chemical	2790
infusion	NOUN	O	O	2790
for	ADP	O	O	2790
treatment	NOUN	O	O	2790
of	ADP	O	O	2790
solid	ADJ	O	O	2790
tumors	NOUN	O	Disease	2790
in	ADP	O	O	2790
order	NOUN	O	O	2790
to	PART	O	O	2790
assess	VERB	O	O	2790
the	PRON	O	O	2790
incidence	NOUN	O	O	2790
of	ADP	O	O	2790
ischemic	VERB	O	Disease	2790
ST	PROPN	O	O	2790
changes	VERB	O	O	2790
.	PUNCT	O	O	2790
4	NUM	O	O	2791
hours	NOUN	O	O	2791
before	ADP	O	O	2791
5-FU	NOUN	O	Chemical	2791
infusion	NOUN	O	O	2791
,	PUNCT	O	O	2791
and	CCONJ	O	O	2791
98	NUM	O	O	2791
+	ADP	O	O	2791
/-	PUNCT	O	O	2791
9	NUM	O	O	2792
hours	NOUN	O	O	2792
during	ADP	O	O	2792
5-FU	NOUN	O	Chemical	2792
infusion	NOUN	O	O	2792
.	PUNCT	O	O	2792
Anginal	PROPN	O	Disease	2793
episodes	NOUN	O	O	2793
were	AUX	O	O	2793
rare	ADJ	O	O	2793
:	PUNCT	O	O	2793
only	ADV	O	O	2793
one	NUM	O	O	2793
patient	NOUN	O	O	2793
had	VERB	O	O	2793
angina	NOUN	O	Disease	2793
(	PUNCT	O	O	2793
during	ADP	O	O	2793
5-FU	NOUN	O	Chemical	2793
infusion	NOUN	O	O	2793
)	PUNCT	O	O	2793
.	PUNCT	O	O	2793
However	ADV	O	O	2794
,	PUNCT	O	O	2794
asymptomatic	ADJ	O	O	2794
ST	PROPN	O	O	2794
changes	VERB	O	O	2794
(	PUNCT	O	O	2794
greater	ADJ	O	O	2794
than	ADP	O	O	2794
or	CCONJ	O	O	2794
equal	ADJ	O	O	2794
to	PART	O	O	2794
1	X	O	O	2794
mm	INTJ	O	O	2794
ST	PROPN	O	O	2794
deviation	NOUN	O	O	2794
)	PUNCT	O	O	2794
were	AUX	O	O	2794
common	ADJ	O	O	2794
:	PUNCT	O	O	2794
six	NUM	O	O	2794
of	ADP	O	O	2794
25	NUM	O	O	2794
patients	NOUN	O	O	2794
(	PUNCT	O	O	2794
24%	NOUN	O	O	2794
)	PUNCT	O	O	2794
had	VERB	O	O	2794
ST	PROPN	O	O	2794
changes	VERB	O	O	2794
before	ADP	O	O	2794
5-FU	NOUN	O	Chemical	2794
infusion	NOUN	O	O	2794
v	NOUN	O	O	2794
17	NUM	O	O	2794
(	PUNCT	O	O	2794
68%	NOUN	O	O	2794
)	PUNCT	O	O	2794
during	ADP	O	O	2794
5-FU	NOUN	O	Chemical	2794
infusion	NOUN	O	O	2794
(	PUNCT	O	O	2794
P	NOUN	O	Chemical	2794
less	ADV	O	O	2794
than	ADP	O	O	2794
.002	NUM	O	O	2794
)	PUNCT	O	O	2794
.	PUNCT	O	O	2794
The	PRON	O	O	2795
incidence	NOUN	O	O	2795
of	ADP	O	O	2795
ischemic	VERB	O	Disease	2795
episodes	NOUN	O	O	2795
per	ADP	O	O	2795
patient	NOUN	O	O	2795
per	ADP	O	O	2795
hour	NOUN	O	O	2795
was	AUX	O	O	2795
0.05	NUM	O	O	2795
+	ADP	O	O	2795
/-	PUNCT	O	O	2795
0.02	NUM	O	O	2796
prior	ADV	O	O	2796
to	PART	O	O	2796
5-FU	NOUN	O	Chemical	2796
infusion	NOUN	O	O	2796
v	NOUN	O	O	2796
0.13	NUM	O	O	2796
+	ADP	O	O	2796
/-	PUNCT	O	O	2796
0.03	NUM	O	O	2797
during	ADP	O	O	2797
5-FU	NOUN	O	Chemical	2797
infusion	NOUN	O	O	2797
(	PUNCT	O	O	2797
P	NOUN	O	Chemical	2797
less	ADV	O	O	2797
than	ADP	O	O	2797
.001	NUM	O	O	2797
)	PUNCT	O	O	2797
;	PUNCT	O	O	2797
the	PRON	O	O	2797
duration	NOUN	O	O	2797
of	ADP	O	O	2797
ECG	PROPN	O	O	2797
changes	VERB	O	O	2797
was	AUX	O	O	2797
0.6	NUM	O	O	2797
+	ADP	O	O	2797
/-	PUNCT	O	O	2797
0.3	NUM	O	O	2798
minutes	NOUN	O	O	2798
per	ADP	O	O	2798
patient	NOUN	O	O	2798
per	ADP	O	O	2798
hour	NOUN	O	O	2798
before	ADP	O	O	2798
5-FU	NOUN	O	Chemical	2798
v	NOUN	O	O	2798
1.9	NUM	O	O	2798
+	ADP	O	O	2798
/-	PUNCT	O	O	2798
0.5	NUM	O	O	2799
minutes	NOUN	O	O	2799
per	ADP	O	O	2799
patient	NOUN	O	O	2799
per	ADP	O	O	2799
hour	NOUN	O	O	2799
during	ADP	O	O	2799
5-FU	NOUN	O	Chemical	2799
(	PUNCT	O	O	2799
P	NOUN	O	Chemical	2799
less	ADV	O	O	2799
than	ADP	O	O	2799
.01	NUM	O	O	2799
)	PUNCT	O	O	2799
.	PUNCT	O	O	2799
ECG	PROPN	O	O	2800
changes	VERB	O	O	2800
were	AUX	O	O	2800
more	ADJ	O	O	2800
common	ADJ	O	O	2800
among	ADP	O	O	2800
patients	NOUN	O	O	2800
with	ADP	O	O	2800
known	VERB	O	O	2800
coronary artery disease	NOUN	O	Disease	2800
.	PUNCT	O	O	2800
There	ADV	O	O	2801
were	AUX	O	O	2801
two	NUM	O	O	2801
cases	NOUN	O	O	2801
of	ADP	O	O	2801
sudden death	NOUN	O	Disease	2801
,	PUNCT	O	O	2801
both	PRON	O	O	2801
of	ADP	O	O	2801
which	PRON	O	O	2801
occurred	VERB	O	O	2801
at	ADP	O	O	2801
the	PRON	O	O	2801
end	VERB	O	O	2801
of	ADP	O	O	2801
the	PRON	O	O	2801
chemotherapy	NOUN	O	O	2801
course	NOUN	O	O	2801
.	PUNCT	O	O	2801
We	PRON	O	O	2802
conclude	VERB	O	O	2802
that	SCONJ	O	O	2802
5-FU	NOUN	O	Chemical	2802
infusion	NOUN	O	O	2802
is	AUX	O	O	2802
associated	VERB	O	O	2802
with	ADP	O	O	2802
a	PRON	O	O	2802
significant	ADJ	O	O	2802
increase	VERB	O	O	2802
in	ADP	O	O	2802
silent	ADJ	O	O	2802
ST	PROPN	O	O	2802
segment	NOUN	O	O	2802
deviation	NOUN	O	O	2802
suggestive	ADJ	O	O	2802
of	ADP	O	O	2802
ischemia	NOUN	O	Disease	2802
,	PUNCT	O	O	2802
particularly	ADV	O	O	2802
among	ADP	O	O	2802
patients	NOUN	O	O	2802
with	ADP	O	O	2802
coronary artery disease	NOUN	O	Disease	2802
.	PUNCT	O	O	2802
Lethal	ADJ	O	O	2805
anuria	VERB	O	Disease	2805
complicating	VERB	O	O	2805
high	ADJ	O	O	2805
dose	NOUN	O	O	2805
ifosfamide	ADP	O	Chemical	2805
chemotherapy	NOUN	O	O	2805
in	ADP	O	O	2805
a	PRON	O	O	2805
breast cancer	NOUN	O	Disease	2805
patient	NOUN	O	O	2805
with	ADP	O	O	2805
an	PRON	O	O	2805
impaired renal function	NOUN	O	Disease	2805
.	PUNCT	O	O	2805
A	PRON	O	O	2806
sixty	NUM	O	O	2806
-	PUNCT	O	O	2806
year	NOUN	O	O	2806
-	PUNCT	O	O	2806
old	ADJ	O	O	2806
woman	NOUN	O	O	2806
with	ADP	O	O	2806
advanced	ADJ	O	O	2806
breast cancer	NOUN	O	Disease	2806
,	PUNCT	O	O	2806
previously	ADV	O	O	2806
treated	VERB	O	O	2806
with	ADP	O	O	2806
cisplatin	NOUN	O	Chemical	2806
,	PUNCT	O	O	2806
developed	VERB	O	O	2806
an	PRON	O	O	2806
irreversible	ADJ	O	O	2806
lethal	ADJ	O	O	2806
renal failure	NOUN	O	Disease	2806
with	ADP	O	O	2806
anuria	VERB	O	Disease	2806
,	PUNCT	O	O	2806
the	PRON	O	O	2806
day	NOUN	O	O	2806
after	ADP	O	O	2806
5	NUM	O	O	2806
g	X	O	O	2806
/	PUNCT	O	O	2806
m2	PROPN	O	O	2806
bolus	NOUN	O	O	2806
ifosfamide	ADP	O	Chemical	2806
.	PUNCT	O	O	2806
Postrenal failure	NOUN	O	Disease	2807
was	AUX	O	O	2807
excluded	VERB	O	O	2807
by	ADP	O	O	2807
echography	NOUN	O	O	2807
.	PUNCT	O	O	2807
A	PRON	O	O	2808
prerenal	ADJ	O	O	2808
component	NOUN	O	O	2808
could	AUX	O	O	2808
have	VERB	O	O	2808
contributed	VERB	O	O	2808
to	PART	O	O	2808
renal failure	NOUN	O	Disease	2808
because	SCONJ	O	O	2808
of	ADP	O	O	2808
a	PRON	O	O	2808
transient	ADJ	O	O	2808
hypotension	NOUN	O	Disease	2808
,	PUNCT	O	O	2808
due	ADJ	O	O	2808
to	PART	O	O	2808
an	PRON	O	O	2808
increasing	VERB	O	O	2808
ascitis	NOUN	O	O	2808
,	PUNCT	O	O	2808
occurring	VERB	O	O	2808
just	ADV	O	O	2808
before	ADP	O	O	2808
anuria	VERB	O	Disease	2808
.	PUNCT	O	O	2808
Ifosfamide	PROPN	O	Chemical	2809
is	AUX	O	O	2809
a	PRON	O	O	2809
known	VERB	O	O	2809
nephrotoxic	NOUN	O	Disease	2809
drug	NOUN	O	O	2809
with	ADP	O	O	2809
demonstrated	VERB	O	O	2809
tubulopathies	NOUN	O	Disease	2809
.	PUNCT	O	O	2809
We	PRON	O	O	2810
strongly	ADV	O	O	2810
suspect	VERB	O	O	2810
that	SCONJ	O	O	2810
this	PRON	O	O	2810
lethal	ADJ	O	O	2810
anuria	VERB	O	Disease	2810
was	AUX	O	O	2810
mainly	ADV	O	O	2810
due	ADJ	O	O	2810
to	PART	O	O	2810
ifosfamide	ADP	O	Chemical	2810
,	PUNCT	O	O	2810
occurring	VERB	O	O	2810
in	ADP	O	O	2810
a	PRON	O	O	2810
patient	NOUN	O	O	2810
having	VERB	O	O	2810
received	VERB	O	O	2810
previous	ADJ	O	O	2810
cisplatin	NOUN	O	Chemical	2810
chemotherapy	NOUN	O	O	2810
and	CCONJ	O	O	2810
with	ADP	O	O	2810
poor	ADJ	O	O	2810
kidney	NOUN	O	O	2810
perfusion	NOUN	O	O	2810
due	ADJ	O	O	2810
to	PART	O	O	2810
transient	ADJ	O	O	2810
hypotension	NOUN	O	Disease	2810
.	PUNCT	O	O	2810
We	PRON	O	O	2811
recommend	VERB	O	O	2811
careful	ADJ	O	O	2811
use	VERB	O	O	2811
of	ADP	O	O	2811
ifosfamide	ADP	O	Chemical	2811
in	ADP	O	O	2811
patients	NOUN	O	O	2811
pretreated	VERB	O	O	2811
with	ADP	O	O	2811
nephrotoxic	NOUN	O	Disease	2811
chemotherapy	NOUN	O	O	2811
and	CCONJ	O	O	2811
inadequate	ADJ	O	O	2811
renal	ADJ	O	O	2811
perfusion	NOUN	O	O	2811
.	PUNCT	O	O	2811
Central	ADJ	O	O	2814
vein thrombosis	NOUN	O	Disease	2814
and	CCONJ	O	O	2814
topical	ADJ	O	O	2814
dipivalyl epinephrine	NOUN	O	Chemical	2814
.	PUNCT	O	O	2814
A	PRON	O	O	2815
report	VERB	O	O	2815
is	AUX	O	O	2815
given	VERB	O	O	2815
on	ADP	O	O	2815
an	PRON	O	O	2815
83-year	NOUN	O	O	2815
-	PUNCT	O	O	2815
old	ADJ	O	O	2815
female	ADJ	O	O	2815
who	PRON	O	O	2815
acquired	VERB	O	O	2815
central	ADJ	O	O	2815
vein thrombosis	NOUN	O	Disease	2815
in	ADP	O	O	2815
her	PRON	O	O	2815
seeing	VERB	O	O	2815
eye	NOUN	O	O	2815
one	NUM	O	O	2815
day	NOUN	O	O	2815
after	ADP	O	O	2815
having	VERB	O	O	2815
started	VERB	O	O	2815
topical	ADJ	O	O	2815
medication	NOUN	O	O	2815
with	ADP	O	O	2815
dipivalyl epinephrine	NOUN	O	Chemical	2815
for	ADP	O	O	2815
advanced	ADJ	O	O	2815
glaucoma	NOUN	O	Disease	2815
discovered	VERB	O	O	2815
in	ADP	O	O	2815
the	PRON	O	O	2815
other	ADJ	O	O	2815
eye	NOUN	O	O	2815
.	PUNCT	O	O	2815
Amelioration	NOUN	O	O	2818
of	ADP	O	O	2818
bendrofluazide	NOUN	O	Chemical	2818
-	PUNCT	O	O	2818
induced	VERB	O	O	2818
hypokalemia	PROPN	O	Disease	2818
by	ADP	O	O	2818
timolol	PROPN	O	Chemical	2818
.	PUNCT	O	O	2818
The	PRON	O	O	2819
beta	NOUN	O	O	2819
adrenergic	NOUN	O	O	2819
blocking	VERB	O	O	2819
drug	NOUN	O	O	2819
,	PUNCT	O	O	2819
timolol	PROPN	O	Chemical	2819
,	PUNCT	O	O	2819
tended	VERB	O	O	2819
to	PART	O	O	2819
correct	VERB	O	O	2819
the	PRON	O	O	2819
hypokalemia	PROPN	O	Disease	2819
of	ADP	O	O	2819
short	ADJ	O	O	2819
-	PUNCT	O	O	2819
term	NOUN	O	O	2819
bendrofluazide	NOUN	O	Chemical	2819
treatment	NOUN	O	O	2819
in	ADP	O	O	2819
6	NUM	O	O	2819
healthy	ADJ	O	O	2819
male	NOUN	O	O	2819
subjects	NOUN	O	O	2819
and	CCONJ	O	O	2819
although	SCONJ	O	O	2819
the	PRON	O	O	2819
effect	VERB	O	O	2819
was	AUX	O	O	2819
small	ADJ	O	O	2819
it	PRON	O	O	2819
was	AUX	O	O	2819
significant	ADJ	O	O	2819
.	PUNCT	O	O	2819
Timolol	PROPN	O	Chemical	2820
also	ADV	O	O	2820
reduced	VERB	O	O	2820
the	PRON	O	O	2820
rise	VERB	O	O	2820
in	ADP	O	O	2820
plasma	NOUN	O	O	2820
aldosterone	NOUN	O	Chemical	2820
and	CCONJ	O	O	2820
urine	NOUN	O	O	2820
potassium	NOUN	O	Chemical	2820
excretion	NOUN	O	O	2820
following	VERB	O	O	2820
bendrofluazide	NOUN	O	Chemical	2820
and	CCONJ	O	O	2820
increased	VERB	O	O	2820
the	PRON	O	O	2820
urine	NOUN	O	O	2820
sodium	NOUN	O	Chemical	2820
/	PUNCT	O	O	2820
potassium	NOUN	O	Chemical	2820
ratio	NOUN	O	O	2820
.	PUNCT	O	O	2820
There	ADV	O	O	2821
was	AUX	O	O	2821
no	PRON	O	O	2821
evidence	NOUN	O	O	2821
of	ADP	O	O	2821
a	PRON	O	O	2821
shift	NOUN	O	O	2821
of	ADP	O	O	2821
potassium	NOUN	O	Chemical	2821
from	ADP	O	O	2821
the	PRON	O	O	2821
intracellular	ADJ	O	O	2821
to	PART	O	O	2821
the	PRON	O	O	2821
extracellular	ADJ	O	O	2821
space	NOUN	O	O	2821
.	PUNCT	O	O	2821
A	PRON	O	O	2824
cross	VERB	O	O	2824
-	PUNCT	O	O	2824
sectional	ADJ	O	O	2824
evaluation	NOUN	O	O	2824
of	ADP	O	O	2824
the	PRON	O	O	2824
effect	VERB	O	O	2824
of	ADP	O	O	2824
risperidone	VERB	O	Chemical	2824
and	CCONJ	O	O	2824
selective	ADJ	O	O	2824
serotonin	PROPN	O	Chemical	2824
reuptake	PROPN	O	O	2824
inhibitors	NOUN	O	O	2824
on	ADP	O	O	2824
bone	NOUN	O	O	2824
mineral	NOUN	O	O	2824
density	NOUN	O	O	2824
in	ADP	O	O	2824
boys	NOUN	O	O	2824
.	PUNCT	O	O	2824
The	PRON	O	O	2825
aim	VERB	O	O	2825
of	ADP	O	O	2825
the	PRON	O	O	2825
present	NOUN	O	O	2825
study	VERB	O	O	2825
was	AUX	O	O	2825
to	PART	O	O	2825
investigate	VERB	O	O	2825
the	PRON	O	O	2825
effect	VERB	O	O	2825
of	ADP	O	O	2825
risperidone	VERB	O	Chemical	2825
-	PUNCT	O	O	2825
induced	VERB	O	O	2825
hyperprolactinemia	NOUN	O	Disease	2825
on	ADP	O	O	2825
trabecular	NOUN	O	O	2825
bone	NOUN	O	O	2825
mineral	NOUN	O	O	2825
density	NOUN	O	O	2825
(	PUNCT	O	O	2825
BMD	PROPN	O	O	2825
)	PUNCT	O	O	2825
in	ADP	O	O	2825
children	NOUN	O	O	2825
and	CCONJ	O	O	2825
adolescents	NOUN	O	O	2825
.	PUNCT	O	O	2825
Medically	ADV	O	O	2826
healthy	ADJ	O	O	2826
7-	X	O	O	2826
to	PART	O	O	2826
17-year	NOUN	O	O	2826
-	PUNCT	O	O	2826
old	ADJ	O	O	2826
males	NOUN	O	O	2826
chronically	ADV	O	O	2826
treated	VERB	O	O	2826
,	PUNCT	O	O	2826
in	ADP	O	O	2826
a	PRON	O	O	2826
naturalistic	ADJ	O	O	2826
setting	VERB	O	O	2826
,	PUNCT	O	O	2826
with	ADP	O	O	2826
risperidone	VERB	O	Chemical	2826
were	AUX	O	O	2826
recruited	VERB	O	O	2826
for	ADP	O	O	2826
this	PRON	O	O	2826
cross	VERB	O	O	2826
-	PUNCT	O	O	2826
sectional	ADJ	O	O	2826
study	VERB	O	O	2826
through	ADP	O	O	2826
child	NOUN	O	O	2826
psychiatry	NOUN	O	O	2826
outpatient	NOUN	O	O	2826
clinics	NOUN	O	O	2826
between	ADP	O	O	2826
November	PROPN	O	O	2826
2005	NUM	O	O	2826
and	CCONJ	O	O	2826
June	PROPN	O	O	2826
2007	NUM	O	O	2826
.	PUNCT	O	O	2826
Hyperprolactinemia	PROPN	O	Disease	2827
was	AUX	O	O	2827
present	NOUN	O	O	2827
in	ADP	O	O	2827
49%	NOUN	O	O	2827
of	ADP	O	O	2827
83	NUM	O	O	2827
boys	NOUN	O	O	2827
(	PUNCT	O	O	2827
n	CCONJ	O	O	2827
=	PUNCT	O	O	2827
41	NUM	O	O	2827
)	PUNCT	O	O	2827
treated	VERB	O	O	2827
with	ADP	O	O	2827
risperidone	VERB	O	Chemical	2827
for	ADP	O	O	2827
a	PRON	O	O	2827
mean	VERB	O	O	2827
of	ADP	O	O	2827
2.9	NUM	O	O	2827
years	NOUN	O	O	2827
.	PUNCT	O	O	2827
Serum	NOUN	O	O	2828
testosterone	PROPN	O	Chemical	2828
concentration	NOUN	O	O	2828
increased	VERB	O	O	2828
with	ADP	O	O	2828
pubertal	ADJ	O	O	2828
status	NOUN	O	O	2828
but	CCONJ	O	O	2828
was	AUX	O	O	2828
not	PART	O	O	2828
affected	VERB	O	O	2828
by	ADP	O	O	2828
hyperprolactinemia	NOUN	O	Disease	2828
.	PUNCT	O	O	2828
Controlling	VERB	O	O	2829
for	ADP	O	O	2829
relevant	ADJ	O	O	2829
covariates	NOUN	O	O	2829
,	PUNCT	O	O	2829
we	PRON	O	O	2829
also	ADV	O	O	2829
found	VERB	O	O	2829
treatment	NOUN	O	O	2829
with	ADP	O	O	2829
selective	ADJ	O	O	2829
serotonin	PROPN	O	Chemical	2829
reuptake	PROPN	O	O	2829
inhibitors	NOUN	O	O	2829
(	PUNCT	O	O	2829
SSRIs	NOUN	O	O	2829
)	PUNCT	O	O	2829
to	PART	O	O	2829
be	AUX	O	O	2829
associated	VERB	O	O	2829
with	ADP	O	O	2829
lower	ADJ	O	O	2829
trabecular	NOUN	O	O	2829
BMD	PROPN	O	O	2829
at	ADP	O	O	2829
the	PRON	O	O	2829
radius	PROPN	O	O	2829
(	PUNCT	O	O	2829
P	NOUN	O	Chemical	2829
=	PUNCT	O	O	2829
.03	NUM	O	O	2829
)	PUNCT	O	O	2829
and	CCONJ	O	O	2829
BMD	PROPN	O	O	2829
z	X	O	O	2829
score	VERB	O	O	2829
at	ADP	O	O	2829
the	PRON	O	O	2829
lumbar	NOUN	O	O	2829
spine	NOUN	O	O	2829
(	PUNCT	O	O	2829
P	NOUN	O	Chemical	2829
<	X	O	O	2829
.05	NUM	O	O	2829
)	PUNCT	O	O	2829
.	PUNCT	O	O	2829
Of	ADV	O	O	2830
13	NUM	O	O	2830
documented	VERB	O	O	2830
fractures	NOUN	O	Disease	2830
,	PUNCT	O	O	2830
3	X	O	O	2830
occurred	VERB	O	O	2830
after	ADP	O	O	2830
risperidone	VERB	O	Chemical	2830
and	CCONJ	O	O	2830
SSRIs	NOUN	O	O	2830
were	AUX	O	O	2830
started	VERB	O	O	2830
,	PUNCT	O	O	2830
and	CCONJ	O	O	2830
none	NOUN	O	O	2830
occurred	VERB	O	O	2830
in	ADP	O	O	2830
patients	NOUN	O	O	2830
with	ADP	O	O	2830
hyperprolactinemia	NOUN	O	Disease	2830
.	PUNCT	O	O	2830
This	PRON	O	O	2831
is	AUX	O	O	2831
the	PRON	O	O	2831
first	ADV	O	O	2831
study	VERB	O	O	2831
to	PART	O	O	2831
link	VERB	O	O	2831
risperidone	VERB	O	Chemical	2831
-	PUNCT	O	O	2831
induced	VERB	O	O	2831
hyperprolactinemia	NOUN	O	Disease	2831
and	CCONJ	O	O	2831
SSRI	NOUN	O	O	2831
treatment	NOUN	O	O	2831
to	PART	O	O	2831
lower	ADJ	O	O	2831
BMD	PROPN	O	O	2831
in	ADP	O	O	2831
children	NOUN	O	O	2831
and	CCONJ	O	O	2831
adolescents	NOUN	O	O	2831
.	PUNCT	O	O	2831
Seizures	NOUN	O	Disease	2834
associated	VERB	O	O	2834
with	ADP	O	O	2834
levofloxacin	PROPN	O	Chemical	2834
:	PUNCT	O	O	2834
case	NOUN	O	O	2834
presentation	NOUN	O	O	2834
and	CCONJ	O	O	2834
literature	NOUN	O	O	2834
review	VERB	O	O	2834
.	PUNCT	O	O	2834
PURPOSE	NOUN	O	O	2835
:	PUNCT	O	O	2835
We	PRON	O	O	2835
present	NOUN	O	O	2835
a	PRON	O	O	2835
case	NOUN	O	O	2835
of	ADP	O	O	2835
a	PRON	O	O	2835
patient	NOUN	O	O	2835
who	PRON	O	O	2835
developed	VERB	O	O	2835
seizures	NOUN	O	Disease	2835
shortly	ADV	O	O	2835
after	ADP	O	O	2835
initiating	VERB	O	O	2835
treatment	NOUN	O	O	2835
with	ADP	O	O	2835
levofloxacin	PROPN	O	Chemical	2835
and	CCONJ	O	O	2835
to	PART	O	O	2835
discuss	VERB	O	O	2835
the	PRON	O	O	2835
potential	ADJ	O	O	2835
drug	NOUN	O	O	2835
-	PUNCT	O	O	2835
drug	NOUN	O	O	2835
interactions	NOUN	O	O	2835
related	ADJ	O	O	2835
to	PART	O	O	2835
the	PRON	O	O	2835
inhibition	NOUN	O	O	2835
of	ADP	O	O	2835
cytochrome	ADP	O	O	2835
P450	VERB	O	O	2835
(	PUNCT	O	O	2835
CYP	PROPN	O	Chemical	2835
)	PUNCT	O	O	2835
1A2	NUM	O	O	2835
in	ADP	O	O	2835
this	PRON	O	O	2835
case	NOUN	O	O	2835
,	PUNCT	O	O	2835
as	ADP	O	O	2835
well	ADV	O	O	2835
as	ADP	O	O	2835
in	ADP	O	O	2835
other	ADJ	O	O	2835
cases	NOUN	O	O	2835
,	PUNCT	O	O	2835
of	ADP	O	O	2835
levofloxacin	PROPN	O	Chemical	2835
-	PUNCT	O	O	2835
induced	VERB	O	O	2835
seizures	NOUN	O	Disease	2835
.	PUNCT	O	O	2835
The	PRON	O	O	2836
main	ADJ	O	O	2836
search	NOUN	O	O	2836
terms	NOUN	O	O	2836
utilized	VERB	O	O	2836
were	AUX	O	O	2836
case	NOUN	O	O	2836
report	VERB	O	O	2836
and	CCONJ	O	O	2836
levofloxacin	PROPN	O	Chemical	2836
.	PUNCT	O	O	2836
Six	NUM	O	O	2837
cases	NOUN	O	O	2837
of	ADP	O	O	2837
levofloxacin	PROPN	O	Chemical	2837
-	PUNCT	O	O	2837
induced	VERB	O	O	2837
seizures	NOUN	O	Disease	2837
have	VERB	O	O	2837
been	AUX	O	O	2837
reported	VERB	O	O	2837
in	ADP	O	O	2837
the	PRON	O	O	2837
literature	NOUN	O	O	2837
.	PUNCT	O	O	2837
Drug	NOUN	O	O	2838
-	PUNCT	O	O	2838
drug	NOUN	O	O	2838
interactions	NOUN	O	O	2838
related	ADJ	O	O	2838
to	PART	O	O	2838
the	PRON	O	O	2838
inhibition	NOUN	O	O	2838
of	ADP	O	O	2838
CYP1A2	NOUN	O	O	2838
by	ADP	O	O	2838
levofloxacin	PROPN	O	Chemical	2838
are	AUX	O	O	2838
likely	ADV	O	O	2838
involved	VERB	O	O	2838
in	ADP	O	O	2838
the	PRON	O	O	2838
clinical	ADJ	O	O	2838
outcome	NOUN	O	O	2838
of	ADP	O	O	2838
these	PRON	O	O	2838
cases	NOUN	O	O	2838
.	PUNCT	O	O	2838
Clinicians	NOUN	O	O	2839
are	AUX	O	O	2839
exhorted	VERB	O	O	2839
to	PART	O	O	2839
pay	VERB	O	O	2839
close	ADV	O	O	2839
attention	NOUN	O	O	2839
when	SCONJ	O	O	2839
initiating	VERB	O	O	2839
levofloxacin	PROPN	O	Chemical	2839
therapy	NOUN	O	O	2839
in	ADP	O	O	2839
patients	NOUN	O	O	2839
taking	VERB	O	O	2839
medications	NOUN	O	O	2839
with	ADP	O	O	2839
epileptogenic	NOUN	O	O	2839
properties	NOUN	O	O	2839
that	SCONJ	O	O	2839
are	AUX	O	O	2839
CYP1A2	NOUN	O	O	2839
substrates	NOUN	O	O	2839
.	PUNCT	O	O	2839
Mice	NOUN	O	O	2842
lacking	VERB	O	O	2842
mPGES-1	NOUN	O	O	2842
are	AUX	O	O	2842
resistant	ADJ	O	O	2842
to	PART	O	O	2842
lithium	NOUN	O	Chemical	2842
-	PUNCT	O	O	2842
induced	VERB	O	O	2842
polyuria	PROPN	O	Disease	2842
.	PUNCT	O	O	2842
Cyclooxygenase-2	PROPN	O	O	2843
activity	NOUN	O	O	2843
is	AUX	O	O	2843
required	VERB	O	O	2843
for	ADP	O	O	2843
the	PRON	O	O	2843
development	NOUN	O	O	2843
of	ADP	O	O	2843
lithium	NOUN	O	Chemical	2843
-	PUNCT	O	O	2843
induced	VERB	O	O	2843
polyuria	PROPN	O	Disease	2843
.	PUNCT	O	O	2843
However	ADV	O	O	2844
,	PUNCT	O	O	2844
the	PRON	O	O	2844
involvement	NOUN	O	O	2844
of	ADP	O	O	2844
a	PRON	O	O	2844
specific	ADJ	O	O	2844
,	PUNCT	O	O	2844
terminal	PROPN	O	O	2844
prostaglandin	NOUN	O	Chemical	2844
(	PUNCT	O	O	2844
PG	PROPN	O	Chemical	2844
)	PUNCT	O	O	2844
isomerase	NOUN	O	O	2844
has	VERB	O	O	2844
not	PART	O	O	2844
been	AUX	O	O	2844
evaluated	VERB	O	O	2844
.	PUNCT	O	O	2844
The	PRON	O	O	2845
present	NOUN	O	O	2845
study	VERB	O	O	2845
was	AUX	O	O	2845
undertaken	VERB	O	O	2845
to	PART	O	O	2845
assess	VERB	O	O	2845
lithium	NOUN	O	Chemical	2845
-	PUNCT	O	O	2845
induced	VERB	O	O	2845
polyuria	PROPN	O	Disease	2845
in	ADP	O	O	2845
mice	NOUN	O	O	2845
deficient	ADJ	O	O	2845
in	ADP	O	O	2845
microsomal	PROPN	O	O	2845
prostaglandin E	NOUN	O	Chemical	2845
synthase-1	NUM	O	O	2845
(	PUNCT	O	O	2845
mPGES-1	NOUN	O	O	2845
)	PUNCT	O	O	2845
.	PUNCT	O	O	2845
A	PRON	O	O	2846
2-wk	NOUN	O	O	2846
administration	NOUN	O	O	2846
of	ADP	O	O	2846
LiCl	NOUN	O	Chemical	2846
(	PUNCT	O	O	2846
4	NUM	O	O	2846
mmol.kg(-1).day(-1	ADV	O	O	2846
)	PUNCT	O	O	2846
ip	X	O	O	2847
)	PUNCT	O	O	2847
in	ADP	O	O	2847
mPGES-1	NOUN	O	O	2847
+	ADP	O	O	2847
/+	PUNCT	O	O	2847
mice	NOUN	O	O	2847
led	VERB	O	O	2847
to	PART	O	O	2847
a	PRON	O	O	2847
marked	VERB	O	O	2847
polyuria	PROPN	O	Disease	2847
with	ADP	O	O	2847
hyposmotic	NOUN	O	O	2847
urine	NOUN	O	O	2847
.	PUNCT	O	O	2847
This	PRON	O	O	2848
was	AUX	O	O	2848
associated	VERB	O	O	2848
with	ADP	O	O	2848
elevated	ADJ	O	O	2848
renal	ADJ	O	O	2848
mPGES-1	NOUN	O	O	2848
protein	NOUN	O	O	2848
expression	NOUN	O	O	2848
and	CCONJ	O	O	2848
increased	VERB	O	O	2848
urine	NOUN	O	O	2848
PGE(2	NOUN	O	O	2848
)	PUNCT	O	O	2848
In	ADP	O	O	2849
contrast	NOUN	O	O	2849
,	PUNCT	O	O	2849
mPGES-1	NOUN	O	O	2849
-/-	PROPN	O	O	2849
mice	NOUN	O	O	2849
were	AUX	O	O	2849
largely	ADV	O	O	2849
resistant	ADJ	O	O	2849
to	PART	O	O	2849
lithium	NOUN	O	Chemical	2849
-	PUNCT	O	O	2849
induced	VERB	O	O	2849
polyuria	PROPN	O	Disease	2849
and	CCONJ	O	O	2849
a	PRON	O	O	2849
urine	NOUN	O	O	2849
concentrating	VERB	O	O	2849
defect	NOUN	O	O	2849
,	PUNCT	O	O	2849
accompanied	VERB	O	O	2849
by	ADP	O	O	2849
nearly	ADV	O	O	2849
complete	VERB	O	O	2849
blockade	VERB	O	O	2849
of	ADP	O	O	2849
high	ADJ	O	O	2849
urine	NOUN	O	O	2849
PGE(2	NOUN	O	O	2849
)	PUNCT	O	O	2849
and	CCONJ	O	O	2849
cAMP	NOUN	O	Chemical	2849
output	NOUN	O	O	2849
.	PUNCT	O	O	2849
RT	PROPN	O	O	2850
-	PUNCT	O	O	2850
PCR	PROPN	O	O	2850
consistently	ADV	O	O	2850
detected	VERB	O	O	2850
a	PRON	O	O	2850
significant	ADJ	O	O	2850
decrease	VERB	O	O	2850
in	ADP	O	O	2850
aquaporin-2	X	O	O	2850
(	PUNCT	O	O	2850
AQP2	PROPN	O	O	2850
)	PUNCT	O	O	2850
protein	NOUN	O	O	2850
expression	NOUN	O	O	2850
in	ADP	O	O	2850
both	PRON	O	O	2850
the	PRON	O	O	2850
renal	ADJ	O	O	2850
cortex	VERB	O	O	2850
and	CCONJ	O	O	2850
medulla	NOUN	O	O	2850
of	ADP	O	O	2850
lithium	NOUN	O	Chemical	2850
-	PUNCT	O	O	2850
treated	VERB	O	O	2850
+	ADP	O	O	2850
/+	PUNCT	O	O	2850
mice	NOUN	O	O	2850
.	PUNCT	O	O	2850
Similarly	ADV	O	O	2851
,	PUNCT	O	O	2851
the	PRON	O	O	2851
total	ADJ	O	O	2851
protein	NOUN	O	O	2851
abundance	NOUN	O	O	2851
of	ADP	O	O	2851
the	PRON	O	O	2851
Na	INTJ	O	Chemical	2851
-	PUNCT	O	O	2851
K-2Cl	NOUN	O	O	2851
cotransporter	NOUN	O	O	2851
(	PUNCT	O	O	2851
NKCC2	PROPN	O	O	2851
)	PUNCT	O	O	2851
in	ADP	O	O	2851
the	PRON	O	O	2851
medulla	NOUN	O	O	2851
but	CCONJ	O	O	2851
not	PART	O	O	2851
in	ADP	O	O	2851
the	PRON	O	O	2851
cortex	VERB	O	O	2851
of	ADP	O	O	2851
the	PRON	O	O	2851
+	ADP	O	O	2851
/+	PUNCT	O	O	2851
mice	NOUN	O	O	2851
was	AUX	O	O	2851
significantly	ADV	O	O	2851
reduced	VERB	O	O	2851
by	ADP	O	O	2851
lithium	NOUN	O	Chemical	2851
treatment	NOUN	O	O	2851
.	PUNCT	O	O	2851
We	PRON	O	O	2852
conclude	VERB	O	O	2852
that	SCONJ	O	O	2852
mPGES-1-derived	VERB	O	O	2852
PGE(2	NOUN	O	O	2852
)	PUNCT	O	O	2852
mediates	VERB	O	O	2852
lithium	NOUN	O	Chemical	2852
-	PUNCT	O	O	2852
induced	VERB	O	O	2852
polyuria	PROPN	O	Disease	2852
likely	ADV	O	O	2852
via	ADP	O	O	2852
inhibition	NOUN	O	O	2852
of	ADP	O	O	2852
AQP2	PROPN	O	O	2852
and	CCONJ	O	O	2852
NKCC2	PROPN	O	O	2852
expression	NOUN	O	O	2852
.	PUNCT	O	O	2852
Identification	NOUN	O	O	2855
of	ADP	O	O	2855
a	PRON	O	O	2855
simple	ADJ	O	O	2855
and	CCONJ	O	O	2855
sensitive	ADJ	O	O	2855
microplate	NOUN	O	O	2855
method	NOUN	O	O	2855
for	ADP	O	O	2855
the	PRON	O	O	2855
detection	NOUN	O	O	2855
of	ADP	O	O	2855
oversulfated	VERB	O	O	2855
chondroitin sulfate	NOUN	O	Chemical	2855
in	ADP	O	O	2855
heparin	NOUN	O	Chemical	2855
products	NOUN	O	O	2855
.	PUNCT	O	O	2855
Heparin	PROPN	O	Chemical	2856
is	AUX	O	O	2856
a	PRON	O	O	2856
commonly	ADV	O	O	2856
implemented	VERB	O	O	2856
anticoagulant	ADJ	O	O	2856
used	VERB	O	O	2856
to	PART	O	O	2856
treat	VERB	O	O	2856
critically	ADV	O	O	2856
ill	PROPN	O	O	2856
patients	NOUN	O	O	2856
.	PUNCT	O	O	2856
Recently	ADV	O	O	2857
,	PUNCT	O	O	2857
a	PRON	O	O	2857
number	NOUN	O	O	2857
of	ADP	O	O	2857
commercial	ADJ	O	O	2857
lots	NOUN	O	O	2857
of	ADP	O	O	2857
heparin	NOUN	O	Chemical	2857
products	NOUN	O	O	2857
were	AUX	O	O	2857
found	VERB	O	O	2857
to	PART	O	O	2857
be	AUX	O	O	2857
contaminated	VERB	O	O	2857
with	ADP	O	O	2857
an	PRON	O	O	2857
oversulfated	VERB	O	O	2857
chondroitin sulfate	NOUN	O	Chemical	2857
(	PUNCT	O	O	2857
OSCS	ADJ	O	O	2857
)	PUNCT	O	O	2857
derivative	ADJ	O	O	2857
that	SCONJ	O	O	2857
could	AUX	O	O	2857
elicit	VERB	O	O	2857
a	PRON	O	O	2857
hypotensive	ADJ	O	Disease	2857
response	NOUN	O	O	2857
in	ADP	O	O	2857
pigs	NOUN	O	O	2857
following	VERB	O	O	2857
a	PRON	O	O	2857
single	ADJ	O	O	2857
high	ADJ	O	O	2857
-	PUNCT	O	O	2857
dose	NOUN	O	O	2857
infusion	NOUN	O	O	2857
.	PUNCT	O	O	2857
Using	VERB	O	O	2858
both	PRON	O	O	2858
contaminated	VERB	O	O	2858
heparin	NOUN	O	Chemical	2858
products	NOUN	O	O	2858
and	CCONJ	O	O	2858
the	PRON	O	O	2858
synthetically	ADV	O	O	2858
produced	VERB	O	O	2858
derivative	ADJ	O	O	2858
,	PUNCT	O	O	2858
we	PRON	O	O	2858
showed	VERB	O	O	2858
that	SCONJ	O	O	2858
the	PRON	O	O	2858
OSCS	ADJ	O	O	2858
produces	VERB	O	O	2858
dose	NOUN	O	O	2858
-	PUNCT	O	O	2858
dependent	ADJ	O	O	2858
hypotension	NOUN	O	Disease	2858
in	ADP	O	O	2858
pigs	NOUN	O	O	2858
.	PUNCT	O	O	2858
We	PRON	O	O	2859
also	ADV	O	O	2859
demonstrated	VERB	O	O	2859
that	SCONJ	O	O	2859
OSCS	ADJ	O	O	2859
can	AUX	O	O	2859
be	AUX	O	O	2859
identified	VERB	O	O	2859
in	ADP	O	O	2859
heparin	NOUN	O	Chemical	2859
products	NOUN	O	O	2859
using	VERB	O	O	2859
a	PRON	O	O	2859
simple	ADJ	O	O	2859
,	PUNCT	O	O	2859
inexpensive	ADJ	O	O	2859
,	PUNCT	O	O	2859
commercially	ADV	O	O	2859
available	ADJ	O	O	2859
heparin	NOUN	O	Chemical	2859
enzyme	NOUN	O	O	2859
immunoassay	PROPN	O	O	2859
(	PUNCT	O	O	2859
EIA	PROPN	O	O	2859
)	PUNCT	O	O	2859
kit	NOUN	O	O	2859
that	SCONJ	O	O	2859
has	VERB	O	O	2859
a	PRON	O	O	2859
limit	NOUN	O	O	2859
of	ADP	O	O	2859
detection	NOUN	O	O	2859
of	ADP	O	O	2859
approximately	ADV	O	O	2859
0.1%	NOUN	O	O	2859
,	PUNCT	O	O	2859
well	ADV	O	O	2859
below	ADP	O	O	2859
the	PRON	O	O	2859
NOEL	PROPN	O	O	2859
.	PUNCT	O	O	2859
This	PRON	O	O	2860
kit	NOUN	O	O	2860
may	AUX	O	O	2860
provide	VERB	O	O	2860
a	PRON	O	O	2860
useful	ADJ	O	O	2860
method	NOUN	O	O	2860
to	PART	O	O	2860
test	NOUN	O	O	2860
heparin	NOUN	O	Chemical	2860
products	NOUN	O	O	2860
for	ADP	O	O	2860
contamination	NOUN	O	O	2860
with	ADP	O	O	2860
oversulfated	VERB	O	O	2860
GAG	NOUN	O	O	2860
derivatives	NOUN	O	O	2860
.	PUNCT	O	O	2860
Doxorubicin	PROPN	O	Chemical	2863
cardiomyopathy	ADJ	O	Disease	2863
-	PUNCT	O	O	2863
induced	VERB	O	O	2863
inflammation	NOUN	O	Disease	2863
and	CCONJ	O	O	2863
apoptosis	NOUN	O	O	2863
are	AUX	O	O	2863
attenuated	VERB	O	O	2863
by	ADP	O	O	2863
gene	NOUN	O	O	2863
deletion	NOUN	O	O	2863
of	ADP	O	O	2863
the	PRON	O	O	2863
kinin	PROPN	O	O	2863
B1	NOUN	O	O	2863
receptor	NOUN	O	O	2863
.	PUNCT	O	O	2863
Clinical	NOUN	O	O	2864
use	VERB	O	O	2864
of	ADP	O	O	2864
the	PRON	O	O	2864
anthracycline	NOUN	O	Chemical	2864
doxorubicin	VERB	O	Chemical	2864
(	PUNCT	O	O	2864
DOX	PROPN	O	Chemical	2864
)	PUNCT	O	O	2864
is	AUX	O	O	2864
limited	VERB	O	O	2864
by	ADP	O	O	2864
its	PRON	O	O	2864
cardiotoxic	ADJ	O	Disease	2864
effects	NOUN	O	O	2864
,	PUNCT	O	O	2864
which	PRON	O	O	2864
are	AUX	O	O	2864
attributed	VERB	O	O	2864
to	PART	O	O	2864
the	PRON	O	O	2864
induction	NOUN	O	O	2864
of	ADP	O	O	2864
apoptosis	NOUN	O	O	2864
.	PUNCT	O	O	2864
To	PART	O	O	2865
elucidate	VERB	O	O	2865
the	PRON	O	O	2865
possible	ADJ	O	O	2865
role	NOUN	O	O	2865
of	ADP	O	O	2865
the	PRON	O	O	2865
kinin	PROPN	O	O	2865
B1	NOUN	O	O	2865
receptor	NOUN	O	O	2865
(	PUNCT	O	O	2865
B1R	PROPN	O	O	2865
)	PUNCT	O	O	2865
during	ADP	O	O	2865
the	PRON	O	O	2865
development	NOUN	O	O	2865
of	ADP	O	O	2865
DOX	PROPN	O	Chemical	2865
cardiomyopathy	ADJ	O	Disease	2865
,	PUNCT	O	O	2865
we	PRON	O	O	2865
studied	VERB	O	O	2865
B1R	PROPN	O	O	2865
knockout	NOUN	O	O	2865
mice	NOUN	O	O	2865
(	PUNCT	O	O	2865
B1R(-/-	NOUN	O	O	2865
)	PUNCT	O	O	2865
)	PUNCT	O	O	2865
by	ADP	O	O	2865
investigating	VERB	O	O	2865
cardiac	ADJ	O	O	2865
inflammation	NOUN	O	Disease	2865
and	CCONJ	O	O	2865
apoptosis	NOUN	O	O	2865
after	ADP	O	O	2865
induction	NOUN	O	O	2865
of	ADP	O	O	2865
DOX	PROPN	O	Chemical	2865
-	PUNCT	O	O	2865
induced	VERB	O	O	2865
cardiomyopathy	ADJ	O	Disease	2865
.	PUNCT	O	O	2865
DOX	PROPN	O	Chemical	2866
control	VERB	O	O	2866
mice	NOUN	O	O	2866
showed	VERB	O	O	2866
cardiac dysfunction	NOUN	O	Disease	2866
measured	VERB	O	O	2866
by	ADP	O	O	2866
pressure	NOUN	O	O	2866
-	PUNCT	O	O	2866
volume	PROPN	O	O	2866
loops	NOUN	O	O	2866
in	ADP	O	O	2866
vivo	VERB	O	O	2866
.	PUNCT	O	O	2866
This	PRON	O	O	2867
was	AUX	O	O	2867
associated	VERB	O	O	2867
with	ADP	O	O	2867
a	PRON	O	O	2867
reduced	VERB	O	O	2867
activation	NOUN	O	O	2867
state	NOUN	O	O	2867
of	ADP	O	O	2867
AKT	PROPN	O	O	2867
,	PUNCT	O	O	2867
as	ADP	O	O	2867
well	ADV	O	O	2867
as	ADP	O	O	2867
an	PRON	O	O	2867
increased	VERB	O	O	2867
bax	VERB	O	O	2867
/	PUNCT	O	O	2867
bcl2	ADP	O	O	2867
ratio	NOUN	O	O	2867
in	ADP	O	O	2867
Western	ADJ	O	O	2867
blots	NOUN	O	O	2867
,	PUNCT	O	O	2867
indicating	VERB	O	O	2867
cardiac apoptosis	NOUN	O	Disease	2867
.	PUNCT	O	O	2867
In	ADP	O	O	2868
DOX	PROPN	O	Chemical	2868
B1R(-/-	NOUN	O	O	2868
)	PUNCT	O	O	2868
mice	NOUN	O	O	2868
,	PUNCT	O	O	2868
cardiac dysfunction	NOUN	O	Disease	2868
was	AUX	O	O	2868
improved	VERB	O	O	2868
compared	VERB	O	O	2868
to	PART	O	O	2868
DOX	PROPN	O	Chemical	2868
control	VERB	O	O	2868
mice	NOUN	O	O	2868
,	PUNCT	O	O	2868
which	PRON	O	O	2868
was	AUX	O	O	2868
associated	VERB	O	O	2868
with	ADP	O	O	2868
normalization	NOUN	O	O	2868
of	ADP	O	O	2868
the	PRON	O	O	2868
bax	VERB	O	O	2868
/	PUNCT	O	O	2868
bcl-2	PUNCT	O	O	2868
ratio	NOUN	O	O	2868
and	CCONJ	O	O	2868
interleukin	ADJ	O	O	2868
6	NUM	O	O	2868
,	PUNCT	O	O	2868
as	ADP	O	O	2868
well	ADV	O	O	2868
as	ADP	O	O	2868
AKT	PROPN	O	O	2868
activation	NOUN	O	O	2868
state	NOUN	O	O	2868
.	PUNCT	O	O	2868
These	PRON	O	O	2869
findings	NOUN	O	O	2869
suggest	VERB	O	O	2869
that	SCONJ	O	O	2869
B1R	PROPN	O	O	2869
is	AUX	O	O	2869
detrimental	ADJ	O	O	2869
in	ADP	O	O	2869
DOX	PROPN	O	Chemical	2869
cardiomyopathy	ADJ	O	Disease	2869
in	ADP	O	O	2869
that	SCONJ	O	O	2869
it	PRON	O	O	2869
mediates	VERB	O	O	2869
the	PRON	O	O	2869
inflammatory	ADJ	O	O	2869
response	NOUN	O	O	2869
and	CCONJ	O	O	2869
apoptosis	NOUN	O	O	2869
.	PUNCT	O	O	2869
These	PRON	O	O	2870
insights	NOUN	O	O	2870
might	AUX	O	O	2870
have	VERB	O	O	2870
useful	ADJ	O	O	2870
implications	NOUN	O	O	2870
for	ADP	O	O	2870
future	NOUN	O	O	2870
studies	NOUN	O	O	2870
utilizing	VERB	O	O	2870
B1R	PROPN	O	O	2870
antagonists	NOUN	O	O	2870
for	ADP	O	O	2870
treatment	NOUN	O	O	2870
of	ADP	O	O	2870
human	PROPN	O	O	2870
DOX	PROPN	O	Chemical	2870
cardiomyopathy	ADJ	O	Disease	2870
.	PUNCT	O	O	2870
Hepatotoxicity	NOUN	O	Disease	2873
associated	VERB	O	O	2873
with	ADP	O	O	2873
sulfasalazine	PROPN	O	Chemical	2873
in	ADP	O	O	2873
inflammatory	ADJ	O	O	2873
arthritis	NOUN	O	Disease	2873
:	PUNCT	O	O	2873
We	PRON	O	O	2874
report	VERB	O	O	2874
an	PRON	O	O	2874
investigation	NOUN	O	O	2874
from	ADP	O	O	2874
a	PRON	O	O	2874
local	ADJ	O	O	2874
surveillance	NOUN	O	O	2874
for	ADP	O	O	2874
serious	ADJ	O	O	2874
adverse	ADJ	O	O	2874
drug	NOUN	O	O	2874
reactions	NOUN	O	O	2874
associated	VERB	O	O	2874
with	ADP	O	O	2874
disease	PROPN	O	O	2874
modifying	VERB	O	O	2874
anti	ADJ	O	O	2874
-	PUNCT	O	O	2874
rheumatic	ADJ	O	O	2874
drugs	NOUN	O	O	2874
that	SCONJ	O	O	2874
was	AUX	O	O	2874
triggered	VERB	O	O	2874
by	ADP	O	O	2874
the	PRON	O	O	2874
occurrence	NOUN	O	O	2874
of	ADP	O	O	2874
liver failure	NOUN	O	Disease	2874
in	ADP	O	O	2874
two	NUM	O	O	2874
of	ADP	O	O	2874
our	PRON	O	O	2874
patients	NOUN	O	O	2874
.	PUNCT	O	O	2874
Patients	NOUN	O	O	2875
'	PUNCT	O	O	2875
,	PUNCT	O	O	2875
who	PRON	O	O	2875
had	VERB	O	O	2875
hepatotoxicity	NOUN	O	Disease	2875
on	ADP	O	O	2875
sulfasalazine	PROPN	O	Chemical	2875
and	CCONJ	O	O	2875
met	VERB	O	O	2875
a	PRON	O	O	2875
definition	NOUN	O	O	2875
of	ADP	O	O	2875
a	PRON	O	O	2875
serious	ADJ	O	O	2875
ADR	PROPN	O	Chemical	2875
,	PUNCT	O	O	2875
were	AUX	O	O	2875
identified	VERB	O	O	2875
.	PUNCT	O	O	2875
The	PRON	O	O	2876
likely	ADV	O	O	2876
frequency	NOUN	O	O	2876
of	ADP	O	O	2876
hepatotoxicity	NOUN	O	Disease	2876
with	ADP	O	O	2876
sulfasalazine	PROPN	O	Chemical	2876
was	AUX	O	O	2876
estimated	VERB	O	O	2876
by	ADP	O	O	2876
making	VERB	O	O	2876
a	PRON	O	O	2876
series	PROPN	O	O	2876
of	ADP	O	O	2876
conservative	ADJ	O	O	2876
assumptions	NOUN	O	O	2876
.	PUNCT	O	O	2876
Eight	NUM	O	O	2877
patients	NOUN	O	O	2877
were	AUX	O	O	2877
hospitalised	VERB	O	O	2877
,	PUNCT	O	O	2877
two	NUM	O	O	2877
in	ADP	O	O	2877
hepatic failure	NOUN	O	Disease	2877
-	PUNCT	O	O	2877
one	NUM	O	O	2877
died	VERB	O	O	2877
after	ADP	O	O	2877
a	PRON	O	O	2877
liver	NOUN	O	O	2877
transplant	NOUN	O	O	2877
.	PUNCT	O	O	2877
Seven	NUM	O	O	2878
patients	NOUN	O	O	2878
had	VERB	O	O	2878
a	PRON	O	O	2878
skin rash	ADJ	O	Disease	2878
,	PUNCT	O	O	2878
three	NUM	O	O	2878
eosinophilia	PROPN	O	Disease	2878
and	CCONJ	O	O	2878
one	NUM	O	O	2878
interstitial nephritis	NOUN	O	Disease	2878
.	PUNCT	O	O	2878
Drug	NOUN	O	O	2879
-	PUNCT	O	O	2879
related	ADJ	O	O	2879
hepatotoxicity	NOUN	O	Disease	2879
was	AUX	O	O	2879
judged	VERB	O	O	2879
probable	ADJ	O	O	2879
or	CCONJ	O	O	2879
highly	ADV	O	O	2879
probable	ADJ	O	O	2879
in	ADP	O	O	2879
8	NUM	O	O	2879
patients	NOUN	O	O	2879
.	PUNCT	O	O	2879
The	PRON	O	O	2880
likely	ADV	O	O	2880
frequency	NOUN	O	O	2880
of	ADP	O	O	2880
serious	ADJ	O	O	2880
hepatotoxicity	NOUN	O	Disease	2880
with	ADP	O	O	2880
sulfasalazine	PROPN	O	Chemical	2880
was	AUX	O	O	2880
estimated	VERB	O	O	2880
at	ADP	O	O	2880
0.4%	NOUN	O	O	2880
of	ADP	O	O	2880
treated	VERB	O	O	2880
patients	NOUN	O	O	2880
.	PUNCT	O	O	2880
CONCLUSION	PROPN	O	O	2881
:	PUNCT	O	O	2881
Serious	ADJ	O	O	2881
hepatotoxicity	NOUN	O	Disease	2881
associated	VERB	O	O	2881
with	ADP	O	O	2881
sulfasalazine	PROPN	O	Chemical	2881
appears	VERB	O	O	2881
to	PART	O	O	2881
be	AUX	O	O	2881
under	ADP	O	O	2881
-	PUNCT	O	O	2881
appreciated	VERB	O	O	2881
and	CCONJ	O	O	2881
intensive	ADJ	O	O	2881
monitoring	NOUN	O	O	2881
and	CCONJ	O	O	2881
vigilance	NOUN	O	O	2881
in	ADP	O	O	2881
the	PRON	O	O	2881
first	ADV	O	O	2881
6	NUM	O	O	2881
weeks	NOUN	O	O	2881
of	ADP	O	O	2881
treatment	NOUN	O	O	2881
is	AUX	O	O	2881
especially	ADV	O	O	2881
important	ADJ	O	O	2881
.	PUNCT	O	O	2881
An	PRON	O	O	2884
evaluation	NOUN	O	O	2884
of	ADP	O	O	2884
amikacin	VERB	O	Chemical	2884
nephrotoxicity	NOUN	O	Disease	2884
in	ADP	O	O	2884
the	PRON	O	O	2884
hematology	NOUN	O	O	2884
/	PUNCT	O	O	2884
oncology	NOUN	O	O	2884
population	NOUN	O	O	2884
.	PUNCT	O	O	2884
Amikacin	PROPN	O	Chemical	2885
is	AUX	O	O	2885
an	PRON	O	O	2885
aminoglycoside	ADV	O	Chemical	2885
commonly	ADV	O	O	2885
used	VERB	O	O	2885
to	PART	O	O	2885
provide	VERB	O	O	2885
empirical	ADJ	O	O	2885
double	ADJ	O	O	2885
gram	PROPN	O	O	2885
-	PUNCT	O	O	2885
negative	ADJ	O	O	2885
treatment	NOUN	O	O	2885
for	ADP	O	O	2885
febrile neutropenia	NOUN	O	Disease	2885
and	CCONJ	O	O	2885
other	ADJ	O	O	2885
suspected	VERB	O	O	2885
infections	NOUN	O	Disease	2885
.	PUNCT	O	O	2885
To	PART	O	O	2886
evaluate	VERB	O	O	2886
amikacin	VERB	O	Chemical	2886
-	PUNCT	O	O	2886
associated	VERB	O	O	2886
nephrotoxicity	NOUN	O	Disease	2886
in	ADP	O	O	2886
an	PRON	O	O	2886
adult	NOUN	O	O	2886
hematology	NOUN	O	O	2886
/	PUNCT	O	O	2886
oncology	NOUN	O	O	2886
population	NOUN	O	O	2886
,	PUNCT	O	O	2886
a	PRON	O	O	2886
prospective	ADJ	O	O	2886
,	PUNCT	O	O	2886
randomized	VERB	O	O	2886
,	PUNCT	O	O	2886
open	VERB	O	O	2886
-	PUNCT	O	O	2886
label	PROPN	O	O	2886
trial	NOUN	O	O	2886
was	AUX	O	O	2886
conducted	VERB	O	O	2886
at	ADP	O	O	2886
a	PRON	O	O	2886
university	NOUN	O	O	2886
-	PUNCT	O	O	2886
affiliated	VERB	O	O	2886
medical	ADJ	O	O	2886
center	PROPN	O	O	2886
.	PUNCT	O	O	2886
Forty	NUM	O	O	2887
patients	NOUN	O	O	2887
with	ADP	O	O	2887
a	PRON	O	O	2887
diagnosis	NOUN	O	O	2887
consistent	ADJ	O	O	2887
with	ADP	O	O	2887
a	PRON	O	O	2887
hematologic	ADJ	O	O	2887
/	PUNCT	O	O	2887
oncologic disorder	NOUN	O	Disease	2887
that	SCONJ	O	O	2887
required	VERB	O	O	2887
treatment	NOUN	O	O	2887
with	ADP	O	O	2887
an	PRON	O	O	2887
aminoglycoside	ADV	O	Chemical	2887
were	AUX	O	O	2887
randomized	VERB	O	O	2887
to	PART	O	O	2887
either	ADV	O	O	2887
conventional	ADJ	O	O	2887
or	CCONJ	O	O	2887
extended	VERB	O	O	2887
-	PUNCT	O	O	2887
interval	NOUN	O	O	2887
amikacin	VERB	O	Chemical	2887
.	PUNCT	O	O	2887
The	PRON	O	O	2888
occurrence	NOUN	O	O	2888
of	ADP	O	O	2888
nephrotoxicity	NOUN	O	Disease	2888
by	ADP	O	O	2888
means	VERB	O	O	2888
of	ADP	O	O	2888
an	PRON	O	O	2888
increase	VERB	O	O	2888
in	ADP	O	O	2888
serum	NOUN	O	O	2888
creatinine	PROPN	O	Chemical	2888
and	CCONJ	O	O	2888
evaluation	NOUN	O	O	2888
of	ADP	O	O	2888
efficacy	NOUN	O	O	2888
via	ADP	O	O	2888
amikacin	VERB	O	Chemical	2888
serum	NOUN	O	O	2888
concentrations	NOUN	O	O	2888
with	ADP	O	O	2888
respective	ADJ	O	O	2888
pathogens	NOUN	O	O	2888
were	AUX	O	O	2888
assessed	VERB	O	O	2888
.	PUNCT	O	O	2888
The	PRON	O	O	2889
occurrence	NOUN	O	O	2889
of	ADP	O	O	2889
nephrotoxicity	NOUN	O	Disease	2889
was	AUX	O	O	2889
similar	ADJ	O	O	2889
between	ADP	O	O	2889
the	PRON	O	O	2889
conventional	ADJ	O	O	2889
and	CCONJ	O	O	2889
extended	VERB	O	O	2889
-	PUNCT	O	O	2889
interval	NOUN	O	O	2889
groups	NOUN	O	O	2889
,	PUNCT	O	O	2889
at	ADP	O	O	2889
10%	NOUN	O	O	2889
and	CCONJ	O	O	2889
5%	NOUN	O	O	2889
,	PUNCT	O	O	2889
respectively	ADV	O	O	2889
(	PUNCT	O	O	2889
P	NOUN	O	Chemical	2889
=	PUNCT	O	O	2889
1.00	NUM	O	O	2889
)	PUNCT	O	O	2889
.	PUNCT	O	O	2889
The	PRON	O	O	2890
occurrence	NOUN	O	O	2890
of	ADP	O	O	2890
nephrotoxicity	NOUN	O	Disease	2890
was	AUX	O	O	2890
similar	ADJ	O	O	2890
between	ADP	O	O	2890
the	PRON	O	O	2890
two	NUM	O	O	2890
dosing	VERB	O	O	2890
regimens	NOUN	O	O	2890
,	PUNCT	O	O	2890
but	CCONJ	O	O	2890
the	PRON	O	O	2890
distribution	NOUN	O	O	2890
of	ADP	O	O	2890
risk	NOUN	O	O	2890
factors	NOUN	O	O	2890
was	AUX	O	O	2890
variable	NOUN	O	O	2890
between	ADP	O	O	2890
the	PRON	O	O	2890
two	NUM	O	O	2890
groups	NOUN	O	O	2890
.	PUNCT	O	O	2890
Memory	NOUN	O	O	2893
function	NOUN	O	O	2893
and	CCONJ	O	O	2893
serotonin	PROPN	O	Chemical	2893
transporter	NOUN	O	O	2893
promoter	NOUN	O	O	2893
gene	NOUN	O	O	2893
polymorphism	NOUN	O	O	2893
in	ADP	O	O	2893
ecstasy	NOUN	O	Chemical	2893
(	PUNCT	O	O	2893
MDMA	PROPN	O	Chemical	2893
)	PUNCT	O	O	2893
users	NOUN	O	O	2893
.	PUNCT	O	O	2893
Although	SCONJ	O	O	2894
3,4-methylenedioxymethamphetamine	NOUN	O	Chemical	2894
(	PUNCT	O	O	2894
MDMA	PROPN	O	Chemical	2894
or	CCONJ	O	O	2894
ecstasy	NOUN	O	Chemical	2894
)	PUNCT	O	O	2894
has	VERB	O	O	2894
been	AUX	O	O	2894
shown	VERB	O	O	2894
to	PART	O	O	2894
damage	NOUN	O	O	2894
brain	NOUN	O	O	2894
serotonin	PROPN	O	Chemical	2894
(	PUNCT	O	O	2894
5-HT	NOUN	O	Chemical	2894
)	PUNCT	O	O	2894
neurons	NOUN	O	O	2894
in	ADP	O	O	2894
animals	NOUN	O	O	2894
and	CCONJ	O	O	2894
possibly	ADV	O	O	2894
humans	NOUN	O	O	2894
,	PUNCT	O	O	2894
little	ADJ	O	O	2894
is	AUX	O	O	2894
known	VERB	O	O	2894
about	ADP	O	O	2894
the	PRON	O	O	2894
long	ADV	O	O	2894
-	PUNCT	O	O	2894
term	NOUN	O	O	2894
consequences	NOUN	O	O	2894
of	ADP	O	O	2894
MDMA	PROPN	O	Chemical	2894
-	PUNCT	O	O	2894
induced	VERB	O	O	2894
5-HT	NOUN	O	Chemical	2894
neurotoxic lesions	NOUN	O	Disease	2894
on	ADP	O	O	2894
functions	VERB	O	O	2894
in	ADP	O	O	2894
which	PRON	O	O	2894
5-HT	NOUN	O	Chemical	2894
is	AUX	O	O	2894
involved	VERB	O	O	2894
,	PUNCT	O	O	2894
such	ADJ	O	O	2894
as	ADP	O	O	2894
cognitive	ADJ	O	O	2894
function	NOUN	O	O	2894
.	PUNCT	O	O	2894
Because	SCONJ	O	O	2895
5-HT	NOUN	O	Chemical	2895
transporters	NOUN	O	O	2895
play	VERB	O	O	2895
a	PRON	O	O	2895
key	NOUN	O	O	2895
element	NOUN	O	O	2895
in	ADP	O	O	2895
the	PRON	O	O	2895
regulation	NOUN	O	O	2895
of	ADP	O	O	2895
synaptic	ADJ	O	O	2895
5-HT	NOUN	O	Chemical	2895
transmission	NOUN	O	O	2895
it	PRON	O	O	2895
may	AUX	O	O	2895
be	AUX	O	O	2895
important	ADJ	O	O	2895
to	PART	O	O	2895
control	VERB	O	O	2895
for	ADP	O	O	2895
the	PRON	O	O	2895
potential	ADJ	O	O	2895
covariance	NOUN	O	O	2895
effect	VERB	O	O	2895
of	ADP	O	O	2895
a	PRON	O	O	2895
polymorphism	NOUN	O	O	2895
in	ADP	O	O	2895
the	PRON	O	O	2895
5-HT	NOUN	O	Chemical	2895
transporter	NOUN	O	O	2895
promoter	NOUN	O	O	2895
gene	NOUN	O	O	2895
region	NOUN	O	O	2895
(	PUNCT	O	O	2895
5-HTTLPR	PROPN	O	O	2895
)	PUNCT	O	O	2895
when	SCONJ	O	O	2895
studying	VERB	O	O	2895
the	PRON	O	O	2895
effects	NOUN	O	O	2895
of	ADP	O	O	2895
MDMA	PROPN	O	Chemical	2895
as	ADP	O	O	2895
well	ADV	O	O	2895
as	ADP	O	O	2895
cognitive	ADJ	O	O	2895
functioning	VERB	O	O	2895
.	PUNCT	O	O	2895
The	PRON	O	O	2896
aim	VERB	O	O	2896
of	ADP	O	O	2896
the	PRON	O	O	2896
study	VERB	O	O	2896
was	AUX	O	O	2896
to	PART	O	O	2896
investigate	VERB	O	O	2896
the	PRON	O	O	2896
effects	NOUN	O	O	2896
of	ADP	O	O	2896
moderate	ADJ	O	O	2896
and	CCONJ	O	O	2896
heavy	ADJ	O	O	2896
MDMA	PROPN	O	Chemical	2896
use	VERB	O	O	2896
on	ADP	O	O	2896
cognitive	ADJ	O	O	2896
function	NOUN	O	O	2896
,	PUNCT	O	O	2896
as	ADP	O	O	2896
well	ADV	O	O	2896
as	ADP	O	O	2896
the	PRON	O	O	2896
effects	NOUN	O	O	2896
of	ADP	O	O	2896
long	ADV	O	O	2896
-	PUNCT	O	O	2896
term	NOUN	O	O	2896
abstention	NOUN	O	O	2896
from	ADP	O	O	2896
MDMA	PROPN	O	Chemical	2896
,	PUNCT	O	O	2896
in	ADP	O	O	2896
subjects	NOUN	O	O	2896
genotyped	VERB	O	O	2896
for	ADP	O	O	2896
5-HTTLPR	PROPN	O	O	2896
.	PUNCT	O	O	2896
Fifteen	NUM	O	O	2897
moderate	ADJ	O	O	2897
MDMA	PROPN	O	Chemical	2897
users	NOUN	O	O	2897
(	PUNCT	O	O	2897
<	X	O	O	2897
55	NUM	O	O	2897
lifetime	NOUN	O	O	2897
tablets	NOUN	O	O	2897
)	PUNCT	O	O	2897
,	PUNCT	O	O	2897
22	NUM	O	O	2897
heavy	ADJ	O	O	2897
MDMA+	NUM	O	O	2897
users	NOUN	O	O	2897
(	PUNCT	O	O	2897
>	PUNCT	O	O	2897
55	NUM	O	O	2897
lifetime	NOUN	O	O	2897
tablets	NOUN	O	O	2897
)	PUNCT	O	O	2897
,	PUNCT	O	O	2897
16	NUM	O	O	2897
ex	PRON	O	O	2897
-	PUNCT	O	O	2897
MDMA+	NUM	O	O	2897
users	NOUN	O	O	2897
(	PUNCT	O	O	2897
last	VERB	O	O	2897
tablet	PROPN	O	O	2897
>	PUNCT	O	O	2897
1	X	O	O	2897
year	NOUN	O	O	2897
ago	ADV	O	O	2897
)	PUNCT	O	O	2897
and	CCONJ	O	O	2897
13	NUM	O	O	2897
controls	VERB	O	O	2897
were	AUX	O	O	2897
compared	VERB	O	O	2897
on	ADP	O	O	2897
a	PRON	O	O	2897
battery	NOUN	O	O	2897
of	ADP	O	O	2897
neuropsychological	ADJ	O	O	2897
tests	VERB	O	O	2897
.	PUNCT	O	O	2897
Heavy	ADJ	O	O	2898
and	CCONJ	O	O	2898
ex	PRON	O	O	2898
-	PUNCT	O	O	2898
MDMA+	NUM	O	O	2898
users	NOUN	O	O	2898
performed	VERB	O	O	2898
significantly	ADV	O	O	2898
poorer	ADV	O	O	2898
on	ADP	O	O	2898
memory	NOUN	O	O	2898
tasks	NOUN	O	O	2898
than	ADP	O	O	2898
controls	VERB	O	O	2898
.	PUNCT	O	O	2898
In	ADP	O	O	2899
contrast	NOUN	O	O	2899
,	PUNCT	O	O	2899
no	PRON	O	O	2899
evidence	NOUN	O	O	2899
of	ADP	O	O	2899
memory impairment	NOUN	O	Disease	2899
was	AUX	O	O	2899
observed	VERB	O	O	2899
in	ADP	O	O	2899
moderate	ADJ	O	O	2899
MDMA	PROPN	O	Chemical	2899
users	NOUN	O	O	2899
.	PUNCT	O	O	2899
While	SCONJ	O	O	2900
the	PRON	O	O	2900
use	VERB	O	O	2900
of	ADP	O	O	2900
MDMA	PROPN	O	Chemical	2900
in	ADP	O	O	2900
quantities	NOUN	O	O	2900
that	SCONJ	O	O	2900
may	AUX	O	O	2900
be	AUX	O	O	2900
considered	VERB	O	O	2900
""""	PUNCT	O	O	2900
moderate	ADJ	O	O	2900
""""	PUNCT	O	O	2900
is	AUX	O	O	2900
not	PART	O	O	2900
associated	VERB	O	O	2900
with	ADP	O	O	2900
impaired memory	NOUN	O	Disease	2900
functioning	VERB	O	O	2900
,	PUNCT	O	O	2900
heavy	ADJ	O	O	2900
use	VERB	O	O	2900
of	ADP	O	O	2900
MDMA	PROPN	O	Chemical	2900
use	VERB	O	O	2900
may	AUX	O	O	2900
lead	VERB	O	Chemical	2900
to	PART	O	O	2900
long	ADV	O	O	2900
lasting	VERB	O	O	2900
memory impairments	NOUN	O	Disease	2900
.	PUNCT	O	O	2900
No	PRON	O	O	2901
effect	VERB	O	O	2901
of	ADP	O	O	2901
5-HTTLPR	PROPN	O	O	2901
or	CCONJ	O	O	2901
gender	NOUN	O	O	2901
on	ADP	O	O	2901
memory	NOUN	O	O	2901
function	NOUN	O	O	2901
or	CCONJ	O	O	2901
MDMA	PROPN	O	Chemical	2901
use	VERB	O	O	2901
was	AUX	O	O	2901
observed	VERB	O	O	2901
.	PUNCT	O	O	2901
Aging	VERB	O	O	2904
process	NOUN	O	O	2904
of	ADP	O	O	2904
epithelial	ADJ	O	O	2904
cells	NOUN	O	O	2904
of	ADP	O	O	2904
the	PRON	O	O	2904
rat	NOUN	O	O	2904
prostate	NOUN	O	O	2904
lateral	PROPN	O	O	2904
lobe	NOUN	O	O	2904
in	ADP	O	O	2904
experimental	ADJ	O	O	2904
hyperprolactinemia	NOUN	O	Disease	2904
induced	VERB	O	O	2904
by	ADP	O	O	2904
haloperidol	NOUN	O	Chemical	2904
.	PUNCT	O	O	2904
The	PRON	O	O	2905
aim	VERB	O	O	2905
of	ADP	O	O	2905
the	PRON	O	O	2905
study	VERB	O	O	2905
was	AUX	O	O	2905
to	PART	O	O	2905
examine	VERB	O	O	2905
the	PRON	O	O	2905
influence	NOUN	O	O	2905
of	ADP	O	O	2905
hyperprolactinemia	NOUN	O	Disease	2905
,	PUNCT	O	O	2905
induced	VERB	O	O	2905
by	ADP	O	O	2905
haloperidol	NOUN	O	Chemical	2905
(	PUNCT	O	O	2905
HAL	PROPN	O	Chemical	2905
)	PUNCT	O	O	2905
on	ADP	O	O	2905
age	NOUN	O	O	2905
related	ADJ	O	O	2905
morphology	NOUN	O	O	2905
and	CCONJ	O	O	2905
function	NOUN	O	O	2905
changes	VERB	O	O	2905
of	ADP	O	O	2905
epithelial	ADJ	O	O	2905
cells	NOUN	O	O	2905
in	ADP	O	O	2905
rat	NOUN	O	O	2905
prostate	NOUN	O	O	2905
lateral	PROPN	O	O	2905
lobe	NOUN	O	O	2905
.	PUNCT	O	O	2905
Serum	NOUN	O	O	2906
concentrations	NOUN	O	O	2906
of	ADP	O	O	2906
prolactin	PROPN	O	O	2906
(	PUNCT	O	O	2906
PRL	NOUN	O	Chemical	2906
)	PUNCT	O	O	2906
and	CCONJ	O	O	2906
testosterone	PROPN	O	Chemical	2906
(	PUNCT	O	O	2906
T	NOUN	O	Chemical	2906
)	PUNCT	O	O	2906
were	AUX	O	O	2906
measured	VERB	O	O	2906
.	PUNCT	O	O	2906
In	ADP	O	O	2907
rats	NOUN	O	O	2907
of	ADP	O	O	2907
the	PRON	O	O	2907
experimental	ADJ	O	O	2907
group	NOUN	O	O	2907
,	PUNCT	O	O	2907
the	PRON	O	O	2907
mean	VERB	O	O	2907
concentration	NOUN	O	O	2907
of	ADP	O	O	2907
:	PUNCT	O	O	2907
PRL	NOUN	O	Chemical	2907
was	AUX	O	O	2907
more	ADJ	O	O	2907
than	ADP	O	O	2907
twice	ADV	O	O	2907
higher	ADJ	O	O	2907
,	PUNCT	O	O	2907
whereas	SCONJ	O	O	2907
T	NOUN	O	Chemical	2907
concentration	NOUN	O	O	2907
was	AUX	O	O	2907
almost	ADV	O	O	2907
twice	ADV	O	O	2907
lower	ADJ	O	O	2907
than	ADP	O	O	2907
that	SCONJ	O	O	2907
in	ADP	O	O	2907
the	PRON	O	O	2907
control	VERB	O	O	2907
group	NOUN	O	O	2907
.	PUNCT	O	O	2907
Light	NOUN	O	O	2908
microscopy	NOUN	O	O	2908
visualized	VERB	O	O	2908
the	PRON	O	O	2908
following	VERB	O	O	2908
:	PUNCT	O	O	2908
hypertrophy	VERB	O	Disease	2908
and	CCONJ	O	O	2908
epithelium	NOUN	O	O	2908
hyperplasia	NOUN	O	Disease	2908
of	ADP	O	O	2908
the	PRON	O	O	2908
glandular	ADJ	O	O	2908
ducts	NOUN	O	O	2908
,	PUNCT	O	O	2908
associated	VERB	O	O	2908
with	ADP	O	O	2908
increased	VERB	O	O	2908
PCNA	PROPN	O	O	2908
expression	NOUN	O	O	2908
.	PUNCT	O	O	2908
Does	VERB	O	O	2911
supplemental	PROPN	O	O	2911
vitamin C	NOUN	O	Chemical	2911
increase	VERB	O	O	2911
cardiovascular disease	NOUN	O	Disease	2911
risk	NOUN	O	O	2911
in	ADP	O	O	2911
women	NOUN	O	O	2911
with	ADP	O	O	2911
diabetes	NOUN	O	Disease	2911
?	PUNCT	O	O	2911
Vitamin C	NOUN	O	Chemical	2912
acts	VERB	O	O	2912
as	ADP	O	O	2912
a	PRON	O	O	2912
potent	ADJ	O	O	2912
antioxidant	ADJ	O	O	2912
;	PUNCT	O	O	2912
however	ADV	O	O	2912
,	PUNCT	O	O	2912
it	PRON	O	O	2912
can	AUX	O	O	2912
also	ADV	O	O	2912
be	AUX	O	O	2912
a	PRON	O	O	2912
prooxidant	VERB	O	O	2912
and	CCONJ	O	O	2912
glycate	VERB	O	O	2912
protein	NOUN	O	O	2912
under	ADP	O	O	2912
certain	ADJ	O	O	2912
circumstances	NOUN	O	O	2912
in	ADP	O	O	2912
vitro	X	O	O	2912
.	PUNCT	O	O	2912
These	PRON	O	O	2913
observations	NOUN	O	O	2913
led	VERB	O	O	2913
us	PRON	O	O	2913
to	PART	O	O	2913
hypothesize	VERB	O	O	2913
that	SCONJ	O	O	2913
a	PRON	O	O	2913
high	ADJ	O	O	2913
intake	PROPN	O	O	2913
of	ADP	O	O	2913
vitamin C	NOUN	O	Chemical	2913
in	ADP	O	O	2913
diabetic	ADJ	O	Disease	2913
persons	NOUN	O	O	2913
might	AUX	O	O	2913
promote	VERB	O	O	2913
atherosclerosis	NOUN	O	Disease	2913
.	PUNCT	O	O	2913
The	PRON	O	O	2914
objective	VERB	O	O	2914
was	AUX	O	O	2914
to	PART	O	O	2914
examine	VERB	O	O	2914
the	PRON	O	O	2914
relation	NOUN	O	O	2914
between	ADP	O	O	2914
vitamin C	NOUN	O	Chemical	2914
intake	PROPN	O	O	2914
and	CCONJ	O	O	2914
mortality	NOUN	O	O	2914
from	ADP	O	O	2914
cardiovascular disease	NOUN	O	Disease	2914
.	PUNCT	O	O	2914
DESIGN	NOUN	O	O	2915
:	PUNCT	O	O	2915
We	PRON	O	O	2915
studied	VERB	O	O	2915
the	PRON	O	O	2915
relation	NOUN	O	O	2915
between	ADP	O	O	2915
vitamin C	NOUN	O	Chemical	2915
intake	PROPN	O	O	2915
and	CCONJ	O	O	2915
mortality	NOUN	O	O	2915
from	ADP	O	O	2915
total	ADJ	O	O	2915
cardiovascular disease	NOUN	O	Disease	2915
(	PUNCT	O	O	2915
n	CCONJ	O	O	2915
=	PUNCT	O	O	2915
281	NUM	O	O	2915
)	PUNCT	O	O	2915
,	PUNCT	O	O	2915
coronary artery disease	NOUN	O	Disease	2915
(	PUNCT	O	O	2915
n	CCONJ	O	O	2915
=	PUNCT	O	O	2915
175	NUM	O	O	2915
)	PUNCT	O	O	2915
,	PUNCT	O	O	2915
and	CCONJ	O	O	2915
stroke	VERB	O	Disease	2915
(	PUNCT	O	O	2915
n	CCONJ	O	O	2915
=	PUNCT	O	O	2915
57	NUM	O	O	2915
)	PUNCT	O	O	2915
in	ADP	O	O	2915
1923	NUM	O	O	2915
postmenopausal	NOUN	O	O	2915
women	NOUN	O	O	2915
who	PRON	O	O	2915
reported	VERB	O	O	2915
being	AUX	O	O	2915
diabetic	ADJ	O	Disease	2915
at	ADP	O	O	2915
baseline	VERB	O	O	2915
.	PUNCT	O	O	2915
Diet	NOUN	O	O	2916
was	AUX	O	O	2916
assessed	VERB	O	O	2916
with	ADP	O	O	2916
a	PRON	O	O	2916
food	NOUN	O	O	2916
-	PUNCT	O	O	2916
frequency	NOUN	O	O	2916
questionnaire	NOUN	O	O	2916
at	ADP	O	O	2916
baseline	VERB	O	O	2916
,	PUNCT	O	O	2916
and	CCONJ	O	O	2916
subjects	NOUN	O	O	2916
initially	ADV	O	O	2916
free	ADJ	O	O	2916
of	ADP	O	O	2916
coronary artery disease	NOUN	O	Disease	2916
were	AUX	O	O	2916
prospectively	ADV	O	O	2916
followed	VERB	O	O	2916
for	ADP	O	O	2916
15	NUM	O	O	2916
y.	PROPN	O	O	2916
RESULTS	VERB	O	O	2916
:	PUNCT	O	O	2916
After	ADP	O	O	2917
adjustment	NOUN	O	O	2917
for	ADP	O	O	2917
cardiovascular disease	NOUN	O	Disease	2917
risk	NOUN	O	O	2917
factors	NOUN	O	O	2917
,	PUNCT	O	O	2917
type	NOUN	O	O	2917
of	ADP	O	O	2917
diabetes	NOUN	O	Disease	2917
medication	NOUN	O	O	2917
used	VERB	O	O	2917
,	PUNCT	O	O	2917
duration	NOUN	O	O	2917
of	ADP	O	O	2917
diabetes	NOUN	O	Disease	2917
,	PUNCT	O	O	2917
and	CCONJ	O	O	2917
intakes	NOUN	O	O	2917
of	ADP	O	O	2917
folate	VERB	O	Chemical	2917
,	PUNCT	O	O	2917
vitamin E	NOUN	O	Chemical	2917
,	PUNCT	O	O	2917
and	CCONJ	O	O	2917
beta	NOUN	O	O	2917
-	PUNCT	O	O	2917
carotene	NOUN	O	O	2917
,	PUNCT	O	O	2917
the	PRON	O	O	2917
adjusted	VERB	O	O	2917
relative	ADJ	O	O	2917
risks	NOUN	O	O	2917
of	ADP	O	O	2917
total	ADJ	O	O	2917
cardiovascular disease	NOUN	O	Disease	2917
mortality	NOUN	O	O	2917
were	AUX	O	O	2917
1.0	NUM	O	O	2917
,	PUNCT	O	O	2917
0.97	NUM	O	O	2917
,	PUNCT	O	O	2917
1.11	NUM	O	O	2917
,	PUNCT	O	O	2917
1.47	NUM	O	O	2917
,	PUNCT	O	O	2917
and	CCONJ	O	O	2917
1.84	NUM	O	O	2917
(	PUNCT	O	O	2917
P	NOUN	O	Chemical	2917
for	ADP	O	O	2917
trend	NOUN	O	O	2917
<	X	O	O	2917
0.01	NUM	O	O	2917
)	PUNCT	O	O	2917
across	ADP	O	O	2917
quintiles	NOUN	O	O	2917
of	ADP	O	O	2917
total	ADJ	O	O	2917
vitamin C	NOUN	O	Chemical	2917
intake	PROPN	O	O	2917
from	ADP	O	O	2917
food	NOUN	O	O	2917
and	CCONJ	O	O	2917
supplements	NOUN	O	O	2917
.	PUNCT	O	O	2917
Adjusted	VERB	O	O	2918
relative	ADJ	O	O	2918
risks	NOUN	O	O	2918
of	ADP	O	O	2918
coronary artery disease	NOUN	O	Disease	2918
were	AUX	O	O	2918
1.0	NUM	O	O	2918
,	PUNCT	O	O	2918
0.81	NUM	O	O	2918
,	PUNCT	O	O	2918
0.99	NUM	O	O	2918
,	PUNCT	O	O	2918
1.26	NUM	O	O	2918
,	PUNCT	O	O	2918
and	CCONJ	O	O	2918
1.91	NUM	O	O	2918
(	PUNCT	O	O	2918
P	NOUN	O	Chemical	2918
for	ADP	O	O	2918
trend	NOUN	O	O	2918
=	PUNCT	O	O	2918
0.01	NUM	O	O	2918
)	PUNCT	O	O	2918
and	CCONJ	O	O	2918
of	ADP	O	O	2918
stroke	VERB	O	Disease	2918
were	AUX	O	O	2918
1.0	NUM	O	O	2918
,	PUNCT	O	O	2918
0.52	NUM	O	O	2918
,	PUNCT	O	O	2918
1.23	NUM	O	O	2918
,	PUNCT	O	O	2918
2.22	NUM	O	O	2918
,	PUNCT	O	O	2918
and	CCONJ	O	O	2918
2.57	NUM	O	O	2918
(	PUNCT	O	O	2918
P	NOUN	O	Chemical	2918
for	ADP	O	O	2918
trend	NOUN	O	O	2918
<	X	O	O	2918
0.01	NUM	O	O	2918
)	PUNCT	O	O	2918
.	PUNCT	O	O	2918
When	SCONJ	O	O	2919
dietary	ADJ	O	O	2919
and	CCONJ	O	O	2919
supplemental	PROPN	O	O	2919
vitamin C	NOUN	O	Chemical	2919
were	AUX	O	O	2919
analyzed	VERB	O	O	2919
separately	ADV	O	O	2919
,	PUNCT	O	O	2919
only	ADV	O	O	2919
supplemental	PROPN	O	O	2919
vitamin C	NOUN	O	Chemical	2919
showed	VERB	O	O	2919
a	PRON	O	O	2919
positive	ADJ	O	O	2919
association	PROPN	O	O	2919
with	ADP	O	O	2919
mortality	NOUN	O	O	2919
endpoints	NOUN	O	O	2919
.	PUNCT	O	O	2919
Vitamin C	NOUN	O	Chemical	2920
intake	PROPN	O	O	2920
was	AUX	O	O	2920
unrelated	ADJ	O	O	2920
to	PART	O	O	2920
mortality	NOUN	O	O	2920
from	ADP	O	O	2920
cardiovascular disease	NOUN	O	Disease	2920
in	ADP	O	O	2920
the	PRON	O	O	2920
nondiabetic	ADJ	O	O	2920
subjects	NOUN	O	O	2920
at	ADP	O	O	2920
baseline	VERB	O	O	2920
.	PUNCT	O	O	2920
CONCLUSION	PROPN	O	O	2921
:	PUNCT	O	O	2921
A	PRON	O	O	2921
high	ADJ	O	O	2921
vitamin C	NOUN	O	Chemical	2921
intake	PROPN	O	O	2921
from	ADP	O	O	2921
supplements	NOUN	O	O	2921
is	AUX	O	O	2921
associated	VERB	O	O	2921
with	ADP	O	O	2921
an	PRON	O	O	2921
increased	VERB	O	O	2921
risk	NOUN	O	O	2921
of	ADP	O	O	2921
cardiovascular disease	NOUN	O	Disease	2921
mortality	NOUN	O	O	2921
in	ADP	O	O	2921
postmenopausal	NOUN	O	O	2921
women	NOUN	O	O	2921
with	ADP	O	O	2921
diabetes	NOUN	O	Disease	2921
.	PUNCT	O	O	2921
Absolute	PROPN	O	O	2924
and	CCONJ	O	O	2924
attributable	ADJ	O	O	2924
risk	NOUN	O	O	2924
of	ADP	O	O	2924
venous thromboembolism	NOUN	O	Disease	2924
in	ADP	O	O	2924
women	NOUN	O	O	2924
on	ADP	O	O	2924
combined	VERB	O	O	2924
cyproterone acetate	NOUN	O	Chemical	2924
and	CCONJ	O	O	2924
ethinylestradiol	NOUN	O	Chemical	2924
.	PUNCT	O	O	2924
OBJECTIVE	VERB	O	O	2925
:	PUNCT	O	O	2925
To	PART	O	O	2925
achieve	VERB	O	O	2925
absolute	ADJ	O	O	2925
risk	NOUN	O	O	2925
estimates	VERB	O	O	2925
of	ADP	O	O	2925
venous thromboembolism	NOUN	O	Disease	2925
(	PUNCT	O	O	2925
VTE	PROPN	O	Disease	2925
)	PUNCT	O	O	2925
among	ADP	O	O	2925
women	NOUN	O	O	2925
on	ADP	O	O	2925
cyproterone acetate	NOUN	O	Chemical	2925
plus	CCONJ	O	O	2925
ethinylestradiol	NOUN	O	Chemical	2925
(	PUNCT	O	O	2925
CPA	NOUN	O	Chemical	2925
/	PUNCT	O	O	2925
EE	NOUN	O	Chemical	2925
)	PUNCT	O	O	2925
,	PUNCT	O	O	2925
and	CCONJ	O	O	2925
among	ADP	O	O	2925
women	NOUN	O	O	2925
on	ADP	O	O	2925
combined oral contraceptives	NOUN	O	Chemical	2925
(	PUNCT	O	O	2925
COCs	NOUN	O	Chemical	2925
)	PUNCT	O	O	2925
.	PUNCT	O	O	2925
From	ADP	O	O	2926
the	PRON	O	O	2926
Danish	ADJ	O	O	2926
National	ADJ	O	O	2926
Register	VERB	O	O	2926
of	ADP	O	O	2926
Patients	NOUN	O	O	2926
(	PUNCT	O	O	2926
NRP	PROPN	O	O	2926
)	PUNCT	O	O	2926
,	PUNCT	O	O	2926
1996	NUM	O	O	2926
to	PART	O	O	2926
1998	NUM	O	O	2926
,	PUNCT	O	O	2926
the	PRON	O	O	2926
records	NOUN	O	O	2926
of	ADP	O	O	2926
1.1	NUM	O	O	2926
million	NUM	O	O	2926
Danish	ADJ	O	O	2926
women	NOUN	O	O	2926
,	PUNCT	O	O	2926
ages	NOUN	O	O	2926
15	NUM	O	O	2926
to	PART	O	O	2926
44	NUM	O	O	2926
years	NOUN	O	O	2926
,	PUNCT	O	O	2926
were	AUX	O	O	2926
searched	VERB	O	O	2926
for	ADP	O	O	2926
evidence	NOUN	O	O	2926
of	ADP	O	O	2926
VTE	PROPN	O	Disease	2926
.	PUNCT	O	O	2926
COC	PROPN	O	Chemical	2927
use	VERB	O	O	2927
was	AUX	O	O	2927
ascertained	VERB	O	O	2927
through	ADP	O	O	2927
mailed	VERB	O	O	2927
questionnaires	NOUN	O	O	2927
.	PUNCT	O	O	2927
Sales	NOUN	O	O	2928
statistics	NOUN	O	O	2928
of	ADP	O	O	2928
COCs	NOUN	O	Chemical	2928
and	CCONJ	O	O	2928
CPA	NOUN	O	Chemical	2928
/	PUNCT	O	O	2928
EE	NOUN	O	Chemical	2928
were	AUX	O	O	2928
provided	VERB	O	O	2928
through	ADP	O	O	2928
Danish	ADJ	O	O	2928
Drug	NOUN	O	O	2928
Statistics	NOUN	O	O	2928
.	PUNCT	O	O	2928
During	ADP	O	O	2929
the	PRON	O	O	2929
time	NOUN	O	O	2929
frame	PROPN	O	O	2929
of	ADP	O	O	2929
the	PRON	O	O	2929
study	VERB	O	O	2929
,	PUNCT	O	O	2929
330	NUM	O	O	2929
women	NOUN	O	O	2929
were	AUX	O	O	2929
found	VERB	O	O	2929
to	PART	O	O	2929
have	VERB	O	O	2929
had	VERB	O	O	2929
VTE	PROPN	O	Disease	2929
while	SCONJ	O	O	2929
on	ADP	O	O	2929
COCs	NOUN	O	Chemical	2929
.	PUNCT	O	O	2929
Of	ADV	O	O	2930
these	PRON	O	O	2930
women	NOUN	O	O	2930
,	PUNCT	O	O	2930
67	NUM	O	O	2930
were	AUX	O	O	2930
on	ADP	O	O	2930
levonorgestrel	NOUN	O	Chemical	2930
-	PUNCT	O	O	2930
containing	VERB	O	O	2930
COCs	NOUN	O	Chemical	2930
.	PUNCT	O	O	2930
Eleven	NUM	O	O	2931
were	AUX	O	O	2931
on	ADP	O	O	2931
CPA	NOUN	O	Chemical	2931
/	PUNCT	O	O	2931
EE	NOUN	O	Chemical	2931
.	PUNCT	O	O	2931
The	PRON	O	O	2932
corresponding	VERB	O	O	2932
absolute	ADJ	O	O	2932
risk	NOUN	O	O	2932
of	ADP	O	O	2932
VTE	PROPN	O	Disease	2932
was	AUX	O	O	2932
3.4	NUM	O	O	2932
(	PUNCT	O	O	2932
range	VERB	O	O	2932
,	PUNCT	O	O	2932
3.1	NUM	O	O	2932
-	PUNCT	O	O	2932
3.8	NUM	O	O	2932
)	PUNCT	O	O	2932
per	ADP	O	O	2932
10	NUM	O	O	2932
000	NUM	O	O	2932
women	NOUN	O	O	2932
years	NOUN	O	O	2932
among	ADP	O	O	2932
the	PRON	O	O	2932
women	NOUN	O	O	2932
on	ADP	O	O	2932
COCs	NOUN	O	Chemical	2932
,	PUNCT	O	O	2932
4.2	NUM	O	O	2932
(	PUNCT	O	O	2932
range	VERB	O	O	2932
,	PUNCT	O	O	2932
3.2	NUM	O	O	2932
-	PUNCT	O	O	2932
5.2	NUM	O	O	2932
)	PUNCT	O	O	2932
per	ADP	O	O	2932
10	NUM	O	O	2932
000	NUM	O	O	2932
women	NOUN	O	O	2932
years	NOUN	O	O	2932
among	ADP	O	O	2932
women	NOUN	O	O	2932
on	ADP	O	O	2932
levonorgestrel	NOUN	O	Chemical	2932
-	PUNCT	O	O	2932
containing	VERB	O	O	2932
COCs	NOUN	O	Chemical	2932
,	PUNCT	O	O	2932
and	CCONJ	O	O	2932
3.1	NUM	O	O	2932
(	PUNCT	O	O	2932
range	VERB	O	O	2932
,	PUNCT	O	O	2932
1.3	NUM	O	O	2932
-	PUNCT	O	O	2932
4.9	NUM	O	O	2932
)	PUNCT	O	O	2932
per	ADP	O	O	2932
10	NUM	O	O	2932
000	NUM	O	O	2932
women	NOUN	O	O	2932
years	NOUN	O	O	2932
among	ADP	O	O	2932
the	PRON	O	O	2932
women	NOUN	O	O	2932
on	ADP	O	O	2932
CPA	NOUN	O	Chemical	2932
/	PUNCT	O	O	2932
EE	NOUN	O	Chemical	2932
.	PUNCT	O	O	2932
CONCLUSION	PROPN	O	O	2933
:	PUNCT	O	O	2933
Our	PRON	O	O	2933
results	VERB	O	O	2933
suggest	VERB	O	O	2933
the	PRON	O	O	2933
absolute	ADJ	O	O	2933
risk	NOUN	O	O	2933
of	ADP	O	O	2933
VTE	PROPN	O	Disease	2933
among	ADP	O	O	2933
Danish	ADJ	O	O	2933
women	NOUN	O	O	2933
on	ADP	O	O	2933
COCs	NOUN	O	Chemical	2933
is	AUX	O	O	2933
similar	ADJ	O	O	2933
to	PART	O	O	2933
that	SCONJ	O	O	2933
among	ADP	O	O	2933
women	NOUN	O	O	2933
taking	VERB	O	O	2933
CPA	NOUN	O	Chemical	2933
/	PUNCT	O	O	2933
EE	NOUN	O	Chemical	2933
.	PUNCT	O	O	2933
Effect	VERB	O	O	2936
of	ADP	O	O	2936
lindane	NOUN	O	Chemical	2936
on	ADP	O	O	2936
hepatic	ADJ	O	O	2936
and	CCONJ	O	O	2936
brain	NOUN	O	O	2936
cytochrome	ADP	O	O	2936
P450s	NUM	O	O	2936
and	CCONJ	O	O	2936
influence	NOUN	O	O	2936
of	ADP	O	O	2936
P450	VERB	O	O	2936
modulation	NOUN	O	O	2936
in	ADP	O	O	2936
lindane	NOUN	O	Chemical	2936
induced	VERB	O	O	2936
neurotoxicity	NOUN	O	Disease	2936
.	PUNCT	O	O	2936
Oral	NOUN	O	O	2937
administration	NOUN	O	O	2937
of	ADP	O	O	2937
lindane	NOUN	O	Chemical	2937
(	PUNCT	O	O	2937
2.5	NUM	O	O	2937
,	PUNCT	O	O	2937
5	NUM	O	O	2937
,	PUNCT	O	O	2937
10	NUM	O	O	2937
and	CCONJ	O	O	2937
15	NUM	O	O	2937
mg	VERB	O	O	2937
/	PUNCT	O	O	2937
kg	VERB	O	O	2937
,	PUNCT	O	O	2937
body	NOUN	O	O	2937
weight	NOUN	O	O	2937
)	PUNCT	O	O	2937
for	ADP	O	O	2937
5	NUM	O	O	2937
days	NOUN	O	O	2937
was	AUX	O	O	2937
found	VERB	O	O	2937
to	PART	O	O	2937
produce	VERB	O	O	2937
a	PRON	O	O	2937
dose	NOUN	O	O	2937
-	PUNCT	O	O	2937
dependent	ADJ	O	O	2937
increase	VERB	O	O	2937
in	ADP	O	O	2937
the	PRON	O	O	2937
activity	NOUN	O	O	2937
of	ADP	O	O	2937
P450	VERB	O	O	2937
dependent	ADJ	O	O	2937
7-ethoxyresorufin	NOUN	O	O	2937
-	PUNCT	O	O	2937
O	INTJ	O	O	2937
-	PUNCT	O	O	2937
deethylase	NOUN	O	O	2937
(	PUNCT	O	O	2937
EROD	PROPN	O	O	2937
)	PUNCT	O	O	2937
,	PUNCT	O	O	2937
7-pentoxyresorufin	NOUN	O	O	2937
-	PUNCT	O	O	2937
O	INTJ	O	O	2937
-	PUNCT	O	O	2937
dealkylase	PROPN	O	O	2937
(	PUNCT	O	O	2937
PROD	PROPN	O	O	2937
)	PUNCT	O	O	2937
and	CCONJ	O	O	2937
N	NUM	O	O	2937
-	PUNCT	O	O	2937
nitrosodimethylamine	NOUN	O	O	2937
demethylase	VERB	O	O	2937
(	PUNCT	O	O	2937
NDMA	PROPN	O	Chemical	2937
-	PUNCT	O	O	2937
d	X	O	O	2937
)	PUNCT	O	O	2937
in	ADP	O	O	2937
rat	NOUN	O	O	2937
brain	NOUN	O	O	2937
and	CCONJ	O	O	2937
liver	NOUN	O	O	2937
.	PUNCT	O	O	2937
brain	NOUN	O	O	2938
P450	VERB	O	O	2938
monooxygenases	NOUN	O	O	2938
was	AUX	O	O	2938
also	ADV	O	O	2938
observed	VERB	O	O	2938
when	SCONJ	O	O	2938
the	PRON	O	O	2938
duration	NOUN	O	O	2938
of	ADP	O	O	2938
exposure	NOUN	O	O	2938
of	ADP	O	O	2938
low	ADJ	O	O	2938
dose	NOUN	O	O	2938
(	PUNCT	O	O	2938
2.5	NUM	O	O	2938
mg	VERB	O	O	2938
/	PUNCT	O	O	2938
kg	VERB	O	O	2938
)	PUNCT	O	O	2938
of	ADP	O	O	2938
lindane	NOUN	O	Chemical	2938
was	AUX	O	O	2938
increased	VERB	O	O	2938
from	ADP	O	O	2938
5	NUM	O	O	2938
days	NOUN	O	O	2938
to	PART	O	O	2938
15	NUM	O	O	2938
or	CCONJ	O	O	2938
21	NUM	O	O	2938
days	NOUN	O	O	2938
.	PUNCT	O	O	2938
In	ADP	O	O	2939
vitro	X	O	O	2939
studies	NOUN	O	O	2939
using	VERB	O	O	2939
organic	ADJ	O	O	2939
inhibitors	NOUN	O	O	2939
specific	ADJ	O	O	2939
for	ADP	O	O	2939
individual	ADJ	O	O	2939
P450	VERB	O	O	2939
isoenzymes	NOUN	O	O	2939
and	CCONJ	O	O	2939
antibody	NOUN	O	O	2939
inhibition	NOUN	O	O	2939
experiments	NOUN	O	O	2939
have	VERB	O	O	2939
further	ADV	O	O	2939
demonstrated	VERB	O	O	2939
that	SCONJ	O	O	2939
the	PRON	O	O	2939
increase	VERB	O	O	2939
in	ADP	O	O	2939
the	PRON	O	O	2939
activity	NOUN	O	O	2939
of	ADP	O	O	2939
PROD	PROPN	O	O	2939
,	PUNCT	O	O	2939
EROD	PROPN	O	O	2939
and	CCONJ	O	O	2939
NDMA	PROPN	O	Chemical	2939
-	PUNCT	O	O	2939
d	X	O	O	2939
are	AUX	O	O	2939
due	ADJ	O	O	2939
to	PART	O	O	2939
the	PRON	O	O	2939
increase	VERB	O	O	2939
in	ADP	O	O	2939
the	PRON	O	O	2939
levels	NOUN	O	O	2939
of	ADP	O	O	2939
P450	VERB	O	O	2939
2B1/2B2	NUM	O	O	2939
,	PUNCT	O	O	2939
1A1/1A2	NUM	O	O	2939
and	CCONJ	O	O	2939
2E1	NUM	O	O	2939
isoenzymes	NOUN	O	O	2939
,	PUNCT	O	O	2939
respectively	ADV	O	O	2939
.	PUNCT	O	O	2939
Induction	NOUN	O	O	2940
studies	NOUN	O	O	2940
have	VERB	O	O	2940
further	ADV	O	O	2940
shown	VERB	O	O	2940
that	SCONJ	O	O	2940
while	SCONJ	O	O	2940
pretreatment	NOUN	O	O	2940
of	ADP	O	O	2940
3-methylcholanthrene	ADJ	O	Chemical	2940
(	PUNCT	O	O	2940
MC	PROPN	O	Chemical	2940
)	PUNCT	O	O	2940
,	PUNCT	O	O	2940
an	PRON	O	O	2940
inducer	NOUN	O	O	2940
of	ADP	O	O	2940
P4501A1/1A2	NOUN	O	O	2940
,	PUNCT	O	O	2940
did	VERB	O	O	2940
not	PART	O	O	2940
produce	VERB	O	O	2940
any	PRON	O	O	2940
significant	ADJ	O	O	2940
effect	VERB	O	O	2940
in	ADP	O	O	2940
the	PRON	O	O	2940
incidence	NOUN	O	O	2940
of	ADP	O	O	2940
lindane	NOUN	O	Chemical	2940
induced	VERB	O	O	2940
convulsions	NOUN	O	Disease	2940
,	PUNCT	O	O	2940
pretreatment	NOUN	O	O	2940
with	ADP	O	O	2940
phenobarbital	NOUN	O	Chemical	2940
(	PUNCT	O	O	2940
PB	PROPN	O	Chemical	2940
)	PUNCT	O	O	2940
,	PUNCT	O	O	2940
an	PRON	O	O	2940
inducer	NOUN	O	O	2940
of	ADP	O	O	2940
P450	VERB	O	O	2940
2B1/2B2	NUM	O	O	2940
or	CCONJ	O	O	2940
ethanol	NOUN	O	Chemical	2940
,	PUNCT	O	O	2940
an	PRON	O	O	2940
inducer	NOUN	O	O	2940
of	ADP	O	O	2940
P450	VERB	O	O	2940
2E1	NUM	O	O	2940
catalysed	VERB	O	O	2941
reactions	NOUN	O	O	2941
,	PUNCT	O	O	2941
significantly	ADV	O	O	2941
increased	VERB	O	O	2941
the	PRON	O	O	2941
incidence	NOUN	O	O	2941
of	ADP	O	O	2941
lindane	NOUN	O	Chemical	2941
induced	VERB	O	O	2941
convulsions	NOUN	O	Disease	2941
.	PUNCT	O	O	2941
Similarly	ADV	O	O	2942
,	PUNCT	O	O	2942
when	SCONJ	O	O	2942
the	PRON	O	O	2942
P450-mediated	VERB	O	O	2942
metabolism	NOUN	O	O	2942
of	ADP	O	O	2942
lindane	NOUN	O	Chemical	2942
was	AUX	O	O	2942
blocked	VERB	O	O	2942
by	ADP	O	O	2942
cobalt chloride	NOUN	O	Chemical	2942
incidence	NOUN	O	O	2942
of	ADP	O	O	2942
convulsions	NOUN	O	Disease	2942
was	AUX	O	O	2942
increased	VERB	O	O	2942
in	ADP	O	O	2942
animals	NOUN	O	O	2942
treated	VERB	O	O	2942
with	ADP	O	O	2942
lindane	NOUN	O	Chemical	2942
indicating	VERB	O	O	2942
that	SCONJ	O	O	2942
lindane	NOUN	O	Chemical	2942
per	ADP	O	O	2942
se	X	O	O	2942
or	CCONJ	O	O	2942
its	PRON	O	O	2942
metabolites	VERB	O	O	2942
formed	VERB	O	O	2942
by	ADP	O	O	2942
PB	PROPN	O	Chemical	2942
or	CCONJ	O	O	2942
ethanol	NOUN	O	Chemical	2942
inducible	VERB	O	O	2942
P450	VERB	O	O	2943
isoenzymes	NOUN	O	O	2943
are	AUX	O	O	2943
involved	VERB	O	O	2943
in	ADP	O	O	2943
its	PRON	O	O	2943
neurobehavioral	ADJ	O	O	2943
toxicity	NOUN	O	Disease	2943
.	PUNCT	O	O	2943
Seizure	NOUN	O	Disease	2946
associated	VERB	O	O	2946
with	ADP	O	O	2946
sleep deprivation	NOUN	O	Disease	2946
and	CCONJ	O	O	2946
sustained	VERB	O	O	2946
-	PUNCT	O	O	2946
release	NOUN	O	O	2946
bupropion	NOUN	O	Chemical	2946
.	PUNCT	O	O	2946
This	PRON	O	O	2947
case	NOUN	O	O	2947
report	VERB	O	O	2947
describes	VERB	O	O	2947
a	PRON	O	O	2947
generalized	VERB	O	O	2947
seizure	NOUN	O	Disease	2947
associated	VERB	O	O	2947
with	ADP	O	O	2947
sustained	VERB	O	O	2947
-	PUNCT	O	O	2947
release	NOUN	O	O	2947
bupropion	NOUN	O	Chemical	2947
use	VERB	O	O	2947
and	CCONJ	O	O	2947
sleep deprivation	NOUN	O	Disease	2947
.	PUNCT	O	O	2947
The	PRON	O	O	2948
subject	ADJ	O	O	2948
,	PUNCT	O	O	2948
a	PRON	O	O	2948
31-year	NOUN	O	O	2948
-	PUNCT	O	O	2948
old	ADJ	O	O	2948
female	ADJ	O	O	2948
smoker	NOUN	O	O	2948
,	PUNCT	O	O	2948
was	AUX	O	O	2948
participating	VERB	O	O	2948
in	ADP	O	O	2948
a	PRON	O	O	2948
clinical	ADJ	O	O	2948
trial	NOUN	O	O	2948
evaluating	VERB	O	O	2948
an	PRON	O	O	2948
investigational	ADJ	O	O	2948
medication	NOUN	O	O	2948
for	ADP	O	O	2948
smoking	VERB	O	O	2948
cessation	NOUN	O	O	2948
that	SCONJ	O	O	2948
used	VERB	O	O	2948
sustained	VERB	O	O	2948
-	PUNCT	O	O	2948
release	NOUN	O	O	2948
bupropion	NOUN	O	Chemical	2948
as	ADP	O	O	2948
an	PRON	O	O	2948
active	ADJ	O	O	2948
control	VERB	O	O	2948
.	PUNCT	O	O	2948
After	ADP	O	O	2949
5	NUM	O	O	2949
weeks	NOUN	O	O	2949
of	ADP	O	O	2949
bupropion	NOUN	O	Chemical	2949
use	VERB	O	O	2949
,	PUNCT	O	O	2949
the	PRON	O	O	2949
subject	ADJ	O	O	2949
experienced	ADJ	O	O	2949
a	PRON	O	O	2949
generalized	VERB	O	O	2949
tonic	PROPN	O	O	2949
clonic	ADJ	O	O	2949
seizure	NOUN	O	Disease	2949
after	ADP	O	O	2949
staying	VERB	O	O	2949
up	ADP	O	O	2949
nearly	ADV	O	O	2949
all	PRON	O	O	2949
night	NOUN	O	O	2949
packing	VERB	O	O	2949
and	CCONJ	O	O	2949
moving	VERB	O	O	2949
to	PART	O	O	2949
a	PRON	O	O	2949
new	ADJ	O	O	2949
residence	NOUN	O	O	2949
.	PUNCT	O	O	2949
The	PRON	O	O	2950
patient	NOUN	O	O	2950
had	VERB	O	O	2950
no	PRON	O	O	2950
other	ADJ	O	O	2950
risk	NOUN	O	O	2950
factors	NOUN	O	O	2950
for	ADP	O	O	2950
seizures	NOUN	O	Disease	2950
.	PUNCT	O	O	2950
We	PRON	O	O	2951
suggest	VERB	O	O	2951
that	SCONJ	O	O	2951
sleep deprivation	NOUN	O	Disease	2951
may	AUX	O	O	2951
add	VERB	O	O	2951
to	PART	O	O	2951
the	PRON	O	O	2951
risk	NOUN	O	O	2951
of	ADP	O	O	2951
bupropion	NOUN	O	Chemical	2951
-	PUNCT	O	O	2951
associated	VERB	O	O	2951
seizures	NOUN	O	Disease	2951
.	PUNCT	O	O	2951
Nephrotoxic	NOUN	O	Disease	2954
effects	NOUN	O	O	2954
in	ADP	O	O	2954
high	ADJ	O	O	2954
-	PUNCT	O	O	2954
risk	NOUN	O	O	2954
patients	NOUN	O	O	2954
undergoing	VERB	O	O	2954
angiography	NOUN	O	O	2954
.	PUNCT	O	O	2954
:	PUNCT	O	O	2955
The	PRON	O	O	2955
use	VERB	O	O	2955
of	ADP	O	O	2955
iodinated	VERB	O	O	2955
contrast	NOUN	O	O	2955
medium	ADJ	O	O	2955
can	AUX	O	O	2955
result	VERB	O	O	2955
in	ADP	O	O	2955
nephropathy	NOUN	O	Disease	2955
.	PUNCT	O	O	2955
Whether	SCONJ	O	O	2956
iso	VERB	O	O	2956
-	PUNCT	O	O	2956
osmolar	ADJ	O	O	2956
contrast	NOUN	O	O	2956
medium	ADJ	O	O	2956
is	AUX	O	O	2956
less	ADV	O	O	2956
nephrotoxic	NOUN	O	Disease	2956
than	ADP	O	O	2956
low	ADJ	O	O	2956
-	PUNCT	O	O	2956
osmolar	ADJ	O	O	2956
contrast	NOUN	O	O	2956
medium	ADJ	O	O	2956
in	ADP	O	O	2956
high	ADJ	O	O	2956
-	PUNCT	O	O	2956
risk	NOUN	O	O	2956
patients	NOUN	O	O	2956
is	AUX	O	O	2956
uncertain	ADJ	O	O	2956
.	PUNCT	O	O	2956
METHODS	NOUN	O	O	2957
:	PUNCT	O	O	2957
We	PRON	O	O	2957
conducted	VERB	O	O	2957
a	PRON	O	O	2957
randomized	VERB	O	O	2957
,	PUNCT	O	O	2957
double	ADJ	O	O	2957
-	PUNCT	O	O	2957
blind	ADJ	O	Disease	2957
,	PUNCT	O	O	2957
prospective	ADJ	O	O	2957
,	PUNCT	O	O	2957
multicenter	ADJ	O	O	2957
study	VERB	O	O	2957
comparing	VERB	O	O	2957
the	PRON	O	O	2957
nephrotoxic	NOUN	O	Disease	2957
effects	NOUN	O	O	2957
of	ADP	O	O	2957
an	PRON	O	O	2957
iso	VERB	O	O	2957
-	PUNCT	O	O	2957
osmolar	ADJ	O	O	2957
,	PUNCT	O	O	2957
dimeric	ADJ	O	O	2957
,	PUNCT	O	O	2957
nonionic	ADJ	O	O	2957
contrast	NOUN	O	O	2957
medium	ADJ	O	O	2957
,	PUNCT	O	O	2957
iodixanol	NOUN	O	Chemical	2957
,	PUNCT	O	O	2957
with	ADP	O	O	2957
those	PRON	O	O	2957
of	ADP	O	O	2957
a	PRON	O	O	2957
low	ADJ	O	O	2957
-	PUNCT	O	O	2957
osmolar	ADJ	O	O	2957
,	PUNCT	O	O	2957
nonionic	ADJ	O	O	2957
,	PUNCT	O	O	2957
monomeric	ADJ	O	O	2957
contrast	NOUN	O	O	2957
medium	ADJ	O	O	2957
,	PUNCT	O	O	2957
iohexol	NOUN	O	Chemical	2957
.	PUNCT	O	O	2957
The	PRON	O	O	2958
study	VERB	O	O	2958
involved	VERB	O	O	2958
129	NUM	O	O	2958
patients	NOUN	O	O	2958
with	ADP	O	O	2958
diabetes	NOUN	O	Disease	2958
with	ADP	O	O	2958
serum	NOUN	O	O	2958
creatinine	PROPN	O	Chemical	2958
concentrations	NOUN	O	O	2958
of	ADP	O	O	2958
1.5	NUM	O	O	2958
to	PART	O	O	2958
3.5	NUM	O	O	2958
mg	VERB	O	O	2958
per	ADP	O	O	2958
deciliter	NOUN	O	O	2958
who	PRON	O	O	2958
underwent	VERB	O	O	2958
coronary	ADJ	O	O	2958
or	CCONJ	O	O	2958
aortofemoral	ADJ	O	O	2958
angiography	NOUN	O	O	2958
.	PUNCT	O	O	2958
The	PRON	O	O	2959
primary	NOUN	O	O	2959
end	VERB	O	O	2959
point	VERB	O	O	2959
was	AUX	O	O	2959
the	PRON	O	O	2959
peak	PROPN	O	O	2959
increase	VERB	O	O	2959
from	ADP	O	O	2959
base	PROPN	O	O	2959
line	NOUN	O	O	2959
in	ADP	O	O	2959
the	PRON	O	O	2959
creatinine	PROPN	O	Chemical	2959
concentration	NOUN	O	O	2959
during	ADP	O	O	2959
the	PRON	O	O	2959
three	NUM	O	O	2959
days	NOUN	O	O	2959
after	ADP	O	O	2959
angiography	NOUN	O	O	2959
.	PUNCT	O	O	2959
Other	ADJ	O	O	2960
end	VERB	O	O	2960
points	VERB	O	O	2960
were	AUX	O	O	2960
an	PRON	O	O	2960
increase	VERB	O	O	2960
in	ADP	O	O	2960
the	PRON	O	O	2960
creatinine	PROPN	O	Chemical	2960
concentration	NOUN	O	O	2960
of	ADP	O	O	2960
0.5	NUM	O	O	2960
mg	VERB	O	O	2960
per	ADP	O	O	2960
deciliter	NOUN	O	O	2960
or	CCONJ	O	O	2960
more	ADJ	O	O	2960
,	PUNCT	O	O	2960
an	PRON	O	O	2960
increase	VERB	O	O	2960
of	ADP	O	O	2960
1.0	NUM	O	O	2960
mg	VERB	O	O	2960
per	ADP	O	O	2960
deciliter	NOUN	O	O	2960
or	CCONJ	O	O	2960
more	ADJ	O	O	2960
,	PUNCT	O	O	2960
and	CCONJ	O	O	2960
a	PRON	O	O	2960
change	VERB	O	O	2960
in	ADP	O	O	2960
the	PRON	O	O	2960
creatinine	PROPN	O	Chemical	2960
concentration	NOUN	O	O	2960
from	ADP	O	O	2960
day	NOUN	O	O	2960
0	NUM	O	O	2960
to	PART	O	O	2960
day	NOUN	O	O	2960
7	NUM	O	O	2960
.	PUNCT	O	O	2960
The	PRON	O	O	2961
creatinine	PROPN	O	Chemical	2961
concentration	NOUN	O	O	2961
increased	VERB	O	O	2961
significantly	ADV	O	O	2961
less	ADV	O	O	2961
in	ADP	O	O	2961
patients	NOUN	O	O	2961
who	PRON	O	O	2961
received	VERB	O	O	2961
iodixanol	NOUN	O	Chemical	2961
.	PUNCT	O	O	2961
From	ADP	O	O	2962
day	NOUN	O	O	2962
0	NUM	O	O	2962
to	PART	O	O	2962
day	NOUN	O	O	2962
3	X	O	O	2962
,	PUNCT	O	O	2962
the	PRON	O	O	2962
mean	VERB	O	O	2962
peak	PROPN	O	O	2962
increase	VERB	O	O	2962
in	ADP	O	O	2962
creatinine	PROPN	O	Chemical	2962
was	AUX	O	O	2962
0.13	NUM	O	O	2962
mg	VERB	O	O	2962
per	ADP	O	O	2962
deciliter	NOUN	O	O	2962
in	ADP	O	O	2962
the	PRON	O	O	2962
iodixanol	NOUN	O	Chemical	2962
group	NOUN	O	O	2962
and	CCONJ	O	O	2962
0.55	NUM	O	O	2962
mg	VERB	O	O	2962
per	ADP	O	O	2962
deciliter	NOUN	O	O	2962
in	ADP	O	O	2962
the	PRON	O	O	2962
iohexol	NOUN	O	Chemical	2962
group	NOUN	O	O	2962
(	PUNCT	O	O	2962
P=0.001	NUM	O	O	2962
;	PUNCT	O	O	2962
the	PRON	O	O	2962
increase	VERB	O	O	2962
with	ADP	O	O	2962
iodixanol	NOUN	O	Chemical	2962
minus	CCONJ	O	O	2962
the	PRON	O	O	2962
increase	VERB	O	O	2962
with	ADP	O	O	2962
iohexol	NOUN	O	Chemical	2962
,	PUNCT	O	O	2962
-0.42	NUM	O	O	2962
mg	VERB	O	O	2962
per	ADP	O	O	2962
deciliter	NOUN	O	O	2962
[	X	O	O	2962
95	NUM	O	O	2962
percent	NOUN	O	O	2962
confidence	NOUN	O	O	2962
interval	NOUN	O	O	2962
,	PUNCT	O	O	2962
-0.73	NUM	O	O	2962
to	PART	O	O	2962
-0.22	NUM	O	O	2962
]	PUNCT	O	O	2962
)	PUNCT	O	O	2962
.	PUNCT	O	O	2962
Two	NUM	O	O	2963
of	ADP	O	O	2963
the	PRON	O	O	2963
64	NUM	O	O	2963
patients	NOUN	O	O	2963
in	ADP	O	O	2963
the	PRON	O	O	2963
iodixanol	NOUN	O	Chemical	2963
group	NOUN	O	O	2963
(	PUNCT	O	O	2963
3	X	O	O	2963
percent	NOUN	O	O	2963
)	PUNCT	O	O	2963
had	VERB	O	O	2963
an	PRON	O	O	2963
increase	VERB	O	O	2963
in	ADP	O	O	2963
the	PRON	O	O	2963
creatinine	PROPN	O	Chemical	2963
concentration	NOUN	O	O	2963
of	ADP	O	O	2963
0.5	NUM	O	O	2963
mg	VERB	O	O	2963
per	ADP	O	O	2963
deciliter	NOUN	O	O	2963
or	CCONJ	O	O	2963
more	ADJ	O	O	2963
,	PUNCT	O	O	2963
as	ADP	O	O	2963
compared	VERB	O	O	2963
with	ADP	O	O	2963
17	NUM	O	O	2963
of	ADP	O	O	2963
the	PRON	O	O	2963
65	NUM	O	O	2963
patients	NOUN	O	O	2963
in	ADP	O	O	2963
the	PRON	O	O	2963
iohexol	NOUN	O	Chemical	2963
group	NOUN	O	O	2963
(	PUNCT	O	O	2963
26	NUM	O	O	2963
percent	NOUN	O	O	2963
)	PUNCT	O	O	2963
(	PUNCT	O	O	2963
P=0.002	PUNCT	O	O	2963
;	PUNCT	O	O	2963
odds	NOUN	O	O	2963
ratio	NOUN	O	O	2963
for	ADP	O	O	2963
such	ADJ	O	O	2963
an	PRON	O	O	2963
increase	VERB	O	O	2963
in	ADP	O	O	2963
the	PRON	O	O	2963
iodixanol	NOUN	O	Chemical	2963
group	NOUN	O	O	2963
,	PUNCT	O	O	2963
0.09	NUM	O	O	2963
[	X	O	O	2963
95	NUM	O	O	2963
percent	NOUN	O	O	2963
confidence	NOUN	O	O	2963
interval	NOUN	O	O	2963
,	PUNCT	O	O	2963
0.02	NUM	O	O	2963
to	PART	O	O	2963
0.41	NUM	O	O	2963
]	PUNCT	O	O	2963
)	PUNCT	O	O	2963
.	PUNCT	O	O	2963
No	PRON	O	O	2964
patient	NOUN	O	O	2964
receiving	VERB	O	O	2964
iodixanol	NOUN	O	Chemical	2964
had	VERB	O	O	2964
an	PRON	O	O	2964
increase	VERB	O	O	2964
of	ADP	O	O	2964
1.0	NUM	O	O	2964
mg	VERB	O	O	2964
per	ADP	O	O	2964
deciliter	NOUN	O	O	2964
or	CCONJ	O	O	2964
more	ADJ	O	O	2964
,	PUNCT	O	O	2964
but	CCONJ	O	O	2964
10	NUM	O	O	2964
patients	NOUN	O	O	2964
in	ADP	O	O	2964
the	PRON	O	O	2964
iohexol	NOUN	O	Chemical	2964
group	NOUN	O	O	2964
(	PUNCT	O	O	2964
15	NUM	O	O	2964
percent	NOUN	O	O	2964
)	PUNCT	O	O	2964
did	VERB	O	O	2964
.	PUNCT	O	O	2964
The	PRON	O	O	2965
mean	VERB	O	O	2965
change	VERB	O	O	2965
in	ADP	O	O	2965
the	PRON	O	O	2965
creatinine	PROPN	O	Chemical	2965
concentration	NOUN	O	O	2965
from	ADP	O	O	2965
day	NOUN	O	O	2965
0	NUM	O	O	2965
to	PART	O	O	2965
day	NOUN	O	O	2965
7	NUM	O	O	2965
was	AUX	O	O	2965
0.07	NUM	O	O	2965
mg	VERB	O	O	2965
per	ADP	O	O	2965
deciliter	NOUN	O	O	2965
in	ADP	O	O	2965
the	PRON	O	O	2965
iodixanol	NOUN	O	Chemical	2965
group	NOUN	O	O	2965
and	CCONJ	O	O	2965
0.24	NUM	O	O	2965
mg	VERB	O	O	2965
per	ADP	O	O	2965
deciliter	NOUN	O	O	2965
in	ADP	O	O	2965
the	PRON	O	O	2965
iohexol	NOUN	O	Chemical	2965
group	NOUN	O	O	2965
(	PUNCT	O	O	2965
P=0.003	NUM	O	O	2965
;	PUNCT	O	O	2965
value	NOUN	O	O	2965
in	ADP	O	O	2965
the	PRON	O	O	2965
iodixanol	NOUN	O	Chemical	2965
group	NOUN	O	O	2965
minus	CCONJ	O	O	2965
the	PRON	O	O	2965
value	NOUN	O	O	2965
in	ADP	O	O	2965
the	PRON	O	O	2965
iohexol	NOUN	O	Chemical	2965
group	NOUN	O	O	2965
,	PUNCT	O	O	2965
-0.17	NUM	O	O	2965
mg	VERB	O	O	2965
per	ADP	O	O	2965
deciliter	NOUN	O	O	2965
[	X	O	O	2965
95	NUM	O	O	2965
percent	NOUN	O	O	2965
confidence	NOUN	O	O	2965
interval	NOUN	O	O	2965
,	PUNCT	O	O	2965
-0.34	NUM	O	O	2965
to	PART	O	O	2965
-0.07	NUM	O	O	2965
]	PUNCT	O	O	2965
)	PUNCT	O	O	2965
.	PUNCT	O	O	2965
Nephropathy	PROPN	O	Disease	2966
induced	VERB	O	O	2966
by	ADP	O	O	2966
contrast	NOUN	O	O	2966
medium	ADJ	O	O	2966
may	AUX	O	O	2966
be	AUX	O	O	2966
less	ADV	O	O	2966
likely	ADV	O	O	2966
to	PART	O	O	2966
develop	VERB	O	O	2966
in	ADP	O	O	2966
high	ADJ	O	O	2966
-	PUNCT	O	O	2966
risk	NOUN	O	O	2966
patients	NOUN	O	O	2966
when	SCONJ	O	O	2966
iodixanol	NOUN	O	Chemical	2966
is	AUX	O	O	2966
used	VERB	O	O	2966
rather	ADV	O	O	2966
than	ADP	O	O	2966
a	PRON	O	O	2966
low	ADJ	O	O	2966
-	PUNCT	O	O	2966
osmolar	ADJ	O	O	2966
,	PUNCT	O	O	2966
nonionic	ADJ	O	O	2966
contrast	NOUN	O	O	2966
medium	ADJ	O	O	2966
.	PUNCT	O	O	2966
Experimental	ADJ	O	O	2969
cranial	ADJ	O	O	2969
pain	NOUN	O	Disease	2969
elicited	VERB	O	O	2969
by	ADP	O	O	2969
capsaicin	NOUN	O	Chemical	2969
:	PUNCT	O	O	2969
a	PRON	O	O	2969
PET	NOUN	O	O	2969
study	VERB	O	O	2969
.	PUNCT	O	O	2969
Using	VERB	O	O	2970
a	PRON	O	O	2970
positron	NOUN	O	O	2970
emission	NOUN	O	O	2970
tomography	NOUN	O	O	2970
(	PUNCT	O	O	2970
PET	NOUN	O	O	2970
)	PUNCT	O	O	2970
study	VERB	O	O	2970
it	PRON	O	O	2970
was	AUX	O	O	2970
shown	VERB	O	O	2970
recently	ADV	O	O	2970
that	SCONJ	O	O	2970
in	ADP	O	O	2970
migraine without aura	NOUN	O	Disease	2970
certain	ADJ	O	O	2970
areas	NOUN	O	O	2970
in	ADP	O	O	2970
the	PRON	O	O	2970
brain	NOUN	O	O	2970
stem	VERB	O	O	2970
were	AUX	O	O	2970
activated	VERB	O	O	2970
during	ADP	O	O	2970
the	PRON	O	O	2970
headache	PROPN	O	Disease	2970
state	NOUN	O	O	2970
,	PUNCT	O	O	2970
but	CCONJ	O	O	2970
not	PART	O	O	2970
in	ADP	O	O	2970
the	PRON	O	O	2970
headache	PROPN	O	Disease	2970
free	ADJ	O	O	2970
interval	NOUN	O	O	2970
.	PUNCT	O	O	2970
It	PRON	O	O	2971
was	AUX	O	O	2971
suggested	VERB	O	O	2971
that	SCONJ	O	O	2971
this	PRON	O	O	2971
brain	NOUN	O	O	2971
stem	VERB	O	O	2971
activation	NOUN	O	O	2971
is	AUX	O	O	2971
inherent	ADJ	O	O	2971
to	PART	O	O	2971
the	PRON	O	O	2971
migraine	NOUN	O	Disease	2971
attack	VERB	O	O	2971
itself	PRON	O	O	2971
and	CCONJ	O	O	2971
represents	VERB	O	O	2971
the	PRON	O	O	2971
so	ADV	O	O	2971
called	VERB	O	O	2971
'	PUNCT	O	O	2971
migraine	NOUN	O	Disease	2971
generator	NOUN	O	O	2971
'	PUNCT	O	O	2971
.	PUNCT	O	O	2971
To	PART	O	O	2972
test	NOUN	O	O	2972
this	PRON	O	O	2972
hypothesis	NOUN	O	O	2972
we	PRON	O	O	2972
performed	VERB	O	O	2972
an	PRON	O	O	2972
experimental	ADJ	O	O	2972
pain	NOUN	O	Disease	2972
study	VERB	O	O	2972
in	ADP	O	O	2972
seven	NUM	O	O	2972
healthy	ADJ	O	O	2972
volunteers	NOUN	O	O	2972
,	PUNCT	O	O	2972
using	VERB	O	O	2972
the	PRON	O	O	2972
same	ADJ	O	O	2972
positioning	NOUN	O	O	2972
in	ADP	O	O	2972
the	PRON	O	O	2972
PET	NOUN	O	O	2972
scanner	NOUN	O	O	2972
as	ADP	O	O	2972
in	ADP	O	O	2972
the	PRON	O	O	2972
migraine	NOUN	O	Disease	2972
patients	NOUN	O	O	2972
.	PUNCT	O	O	2972
A	PRON	O	O	2973
small	ADJ	O	O	2973
amount	NOUN	O	O	2973
of	ADP	O	O	2973
capsaicin	NOUN	O	Chemical	2973
was	AUX	O	O	2973
administered	VERB	O	O	2973
subcutaneously	ADV	O	O	2973
in	ADP	O	O	2973
the	PRON	O	O	2973
right	ADV	O	O	2973
forehead	NOUN	O	O	2973
to	PART	O	O	2973
evoke	VERB	O	O	2973
a	PRON	O	O	2973
burning	VERB	O	O	2973
painful	ADJ	O	Disease	2973
sensation	NOUN	O	O	2973
in	ADP	O	O	2973
the	PRON	O	O	2973
first	ADV	O	O	2973
division	NOUN	O	O	2973
of	ADP	O	O	2973
the	PRON	O	O	2973
trigeminal	ADJ	O	O	2973
nerve	NOUN	O	O	2973
.	PUNCT	O	O	2973
Using	VERB	O	O	2974
the	PRON	O	O	2974
same	ADJ	O	O	2974
stereotactic	NOUN	O	O	2974
space	NOUN	O	O	2974
limits	NOUN	O	O	2974
as	ADP	O	O	2974
in	ADP	O	O	2974
the	PRON	O	O	2974
above	ADP	O	O	2974
mentioned	VERB	O	O	2974
migraine	NOUN	O	Disease	2974
study	VERB	O	O	2974
no	PRON	O	O	2974
brain	NOUN	O	O	2974
stem	VERB	O	O	2974
activation	NOUN	O	O	2974
was	AUX	O	O	2974
found	VERB	O	O	2974
in	ADP	O	O	2974
the	PRON	O	O	2974
acute pain	NOUN	O	Disease	2974
state	NOUN	O	O	2974
compared	VERB	O	O	2974
to	PART	O	O	2974
the	PRON	O	O	2974
pain	NOUN	O	Disease	2974
free	ADJ	O	O	2974
state	NOUN	O	O	2974
.	PUNCT	O	O	2974
The	PRON	O	O	2975
increase	VERB	O	O	2975
of	ADP	O	O	2975
activation	NOUN	O	O	2975
in	ADP	O	O	2975
the	PRON	O	O	2975
region	NOUN	O	O	2975
of	ADP	O	O	2975
the	PRON	O	O	2975
cavernous	ADJ	O	O	2975
sinus	NOUN	O	O	2975
however	ADV	O	O	2975
,	PUNCT	O	O	2975
suggests	VERB	O	O	2975
that	SCONJ	O	O	2975
this	PRON	O	O	2975
structure	NOUN	O	O	2975
is	AUX	O	O	2975
more	ADJ	O	O	2975
likely	ADV	O	O	2975
to	PART	O	O	2975
be	AUX	O	O	2975
involved	VERB	O	O	2975
in	ADP	O	O	2975
trigeminal	ADJ	O	O	2975
transmitted	VERB	O	O	2975
pain	NOUN	O	Disease	2975
as	ADP	O	O	2975
such	ADJ	O	O	2975
,	PUNCT	O	O	2975
rather	ADV	O	O	2975
than	ADP	O	O	2975
in	ADP	O	O	2975
a	PRON	O	O	2975
specific	ADJ	O	O	2975
type	NOUN	O	O	2975
of	ADP	O	O	2975
headache	PROPN	O	Disease	2975
as	ADP	O	O	2975
was	AUX	O	O	2975
suggested	VERB	O	O	2975
for	ADP	O	O	2975
cluster headache	NOUN	O	Disease	2975
.	PUNCT	O	O	2975
Neuroleptic malignant syndrome	NOUN	O	Disease	2978
with	ADP	O	O	2978
risperidone	VERB	O	Chemical	2978
.	PUNCT	O	O	2978
Neuroleptic malignant syndrome	NOUN	O	Disease	2979
is	AUX	O	O	2979
thought	VERB	O	O	2979
to	PART	O	O	2979
be	AUX	O	O	2979
a	PRON	O	O	2979
result	VERB	O	O	2979
of	ADP	O	O	2979
dopamine	NOUN	O	Chemical	2979
D2	NOUN	O	O	2979
receptor	NOUN	O	O	2979
blockade	VERB	O	O	2979
in	ADP	O	O	2979
the	PRON	O	O	2979
striatum	NOUN	O	O	2979
of	ADP	O	O	2979
the	PRON	O	O	2979
basal	PROPN	O	O	2979
ganglia	NOUN	O	O	2979
.	PUNCT	O	O	2979
Risperidone	NOUN	O	Chemical	2980
,	PUNCT	O	O	2980
a	PRON	O	O	2980
benzisoxazole	PROPN	O	Chemical	2980
derivative	ADJ	O	O	2980
antipsychotic	ADJ	O	O	2980
,	PUNCT	O	O	2980
has	VERB	O	O	2980
high	ADJ	O	O	2980
serotonin	PROPN	O	Chemical	2980
5-HT2	PROPN	O	O	2980
receptor	NOUN	O	O	2980
blockade	VERB	O	O	2980
and	CCONJ	O	O	2980
dose	NOUN	O	O	2980
-	PUNCT	O	O	2980
related	ADJ	O	O	2980
D2	NOUN	O	O	2980
receptor	NOUN	O	O	2980
blockade	VERB	O	O	2980
.	PUNCT	O	O	2980
The	PRON	O	O	2981
high	ADJ	O	O	2981
ratio	NOUN	O	O	2981
is	AUX	O	O	2981
believed	VERB	O	O	2981
to	PART	O	O	2981
impart	VERB	O	O	2981
the	PRON	O	O	2981
low	ADJ	O	O	2981
frequency	NOUN	O	O	2981
of	ADP	O	O	2981
extrapyramidal symptoms	NOUN	O	Disease	2981
with	ADP	O	O	2981
risperidone	VERB	O	Chemical	2981
at	ADP	O	O	2981
low	ADJ	O	O	2981
dosages	NOUN	O	O	2981
.	PUNCT	O	O	2981
With	ADP	O	O	2982
this	PRON	O	O	2982
low	ADJ	O	O	2982
frequency	NOUN	O	O	2982
of	ADP	O	O	2982
extrapyramidal symptoms	NOUN	O	Disease	2982
,	PUNCT	O	O	2982
it	PRON	O	O	2982
was	AUX	O	O	2982
thought	VERB	O	O	2982
the	PRON	O	O	2982
frequency	NOUN	O	O	2982
of	ADP	O	O	2982
neuroleptic malignant syndrome	NOUN	O	Disease	2982
might	AUX	O	O	2982
also	ADV	O	O	2982
be	AUX	O	O	2982
lowered	VERB	O	O	2982
.	PUNCT	O	O	2982
A	PRON	O	O	2983
73-year	NOUN	O	O	2983
-	PUNCT	O	O	2983
old	ADJ	O	O	2983
woman	NOUN	O	O	2983
developed	VERB	O	O	2983
neuroleptic malignant syndrome	NOUN	O	Disease	2983
after	ADP	O	O	2983
monotherapy	X	O	O	2983
with	ADP	O	O	2983
risperidone	VERB	O	Chemical	2983
.	PUNCT	O	O	2983
The	PRON	O	O	2984
syndrome	NOUN	O	O	2984
reversed	VERB	O	O	2984
after	ADP	O	O	2984
discontinuing	VERB	O	O	2984
risperidone	VERB	O	Chemical	2984
and	CCONJ	O	O	2984
starting	VERB	O	O	2984
treatment	NOUN	O	O	2984
with	ADP	O	O	2984
dantrolene	PROPN	O	Chemical	2984
and	CCONJ	O	O	2984
bromocriptine	NOUN	O	Chemical	2984
.	PUNCT	O	O	2984
It	PRON	O	O	2985
appears	VERB	O	O	2985
that	SCONJ	O	O	2985
the	PRON	O	O	2985
protection	NOUN	O	O	2985
from	ADP	O	O	2985
extrapyramidal	ADJ	O	O	2985
side	NOUN	O	O	2985
effects	NOUN	O	O	2985
observed	VERB	O	O	2985
with	ADP	O	O	2985
risperidone	VERB	O	Chemical	2985
does	VERB	O	O	2985
not	PART	O	O	2985
ensure	VERB	O	O	2985
protection	NOUN	O	O	2985
from	ADP	O	O	2985
neuroleptic malignant syndrome	NOUN	O	Disease	2985
.	PUNCT	O	O	2985
Hepatic	ADJ	O	O	2988
and	CCONJ	O	O	2988
extrahepatic	ADJ	O	O	2988
angiotensinogen	PROPN	O	O	2988
gene	NOUN	O	O	2988
expression	NOUN	O	O	2988
in	ADP	O	O	2988
rats	NOUN	O	O	2988
with	ADP	O	O	2988
acute	ADJ	O	O	2988
nephrotic syndrome	NOUN	O	Disease	2988
.	PUNCT	O	O	2988
Plasma	NOUN	O	O	2989
concentration	NOUN	O	O	2989
and	CCONJ	O	O	2989
urine	NOUN	O	O	2989
excretion	NOUN	O	O	2989
of	ADP	O	O	2989
the	PRON	O	O	2989
renin	PROPN	O	O	2989
-	PUNCT	O	O	2989
angiotensin	NOUN	O	Chemical	2989
system	NOUN	O	O	2989
proteins	NOUN	O	O	2989
are	AUX	O	O	2989
altered	VERB	O	O	2989
in	ADP	O	O	2989
rats	NOUN	O	O	2989
with	ADP	O	O	2989
nephrotic syndrome	NOUN	O	Disease	2989
(	PUNCT	O	O	2989
NS	PROPN	O	Disease	2989
)	PUNCT	O	O	2989
.	PUNCT	O	O	2989
In	ADP	O	O	2990
this	PRON	O	O	2990
work	NOUN	O	O	2990
the	PRON	O	O	2990
messenger	NOUN	O	O	2990
ribonucleic	ADJ	O	O	2990
acid	PROPN	O	O	2990
(	PUNCT	O	O	2990
mRNA	PROPN	O	O	2990
)	PUNCT	O	O	2990
levels	NOUN	O	O	2990
of	ADP	O	O	2990
angiotensinogen	PROPN	O	O	2990
(	PUNCT	O	O	2990
Ao	PROPN	O	O	2990
)	PUNCT	O	O	2990
were	AUX	O	O	2990
analyzed	VERB	O	O	2990
with	ADP	O	O	2990
the	PRON	O	O	2990
slot	NOUN	O	O	2990
-	PUNCT	O	O	2990
blot	NOUN	O	O	2990
hybridization	NOUN	O	O	2990
technique	NOUN	O	O	2990
in	ADP	O	O	2990
liver	NOUN	O	O	2990
and	CCONJ	O	O	2990
other	ADJ	O	O	2990
extrahepatic	ADJ	O	O	2990
tissues	NOUN	O	O	2990
:	PUNCT	O	O	2990
kidney	NOUN	O	O	2990
,	PUNCT	O	O	2990
heart	NOUN	O	O	2990
,	PUNCT	O	O	2990
brain	NOUN	O	O	2990
,	PUNCT	O	O	2990
and	CCONJ	O	O	2990
adrenal	ADJ	O	O	2990
gland	NOUN	O	O	2990
from	ADP	O	O	2990
control	VERB	O	O	2990
,	PUNCT	O	O	2990
nephrotic	NOUN	O	Disease	2990
,	PUNCT	O	O	2990
and	CCONJ	O	O	2990
pair	ADJ	O	O	2990
-	PUNCT	O	O	2990
fed	VERB	O	O	2990
(	PUNCT	O	O	2990
PF	PROPN	O	O	2990
)	PUNCT	O	O	2990
rats	NOUN	O	O	2990
.	PUNCT	O	O	2990
NS	PROPN	O	Disease	2991
was	AUX	O	O	2991
induced	VERB	O	O	2991
by	ADP	O	O	2991
a	PRON	O	O	2991
single	ADJ	O	O	2991
injection	NOUN	O	O	2991
of	ADP	O	O	2991
puromycin	PROPN	O	O	2991
amino	NOUN	O	O	2991
-	PUNCT	O	O	2991
nucleoside	NOUN	O	O	2991
(	PUNCT	O	O	2991
PAN	PROPN	O	Chemical	2991
)	PUNCT	O	O	2991
.	PUNCT	O	O	2991
Although	SCONJ	O	O	2992
a	PRON	O	O	2992
great	ADJ	O	O	2992
urinary	ADJ	O	O	2992
excretion	NOUN	O	O	2992
and	CCONJ	O	O	2992
half	NOUN	O	O	2992
-	PUNCT	O	O	2992
normal	ADJ	O	O	2992
plasma	NOUN	O	O	2992
levels	NOUN	O	O	2992
of	ADP	O	O	2992
Ao	PROPN	O	O	2992
were	AUX	O	O	2992
observed	VERB	O	O	2992
on	ADP	O	O	2992
day	NOUN	O	O	2992
6	NUM	O	O	2992
after	ADP	O	O	2992
PAN	PROPN	O	Chemical	2992
injection	NOUN	O	O	2992
,	PUNCT	O	O	2992
when	SCONJ	O	O	2992
NS	PROPN	O	Disease	2992
was	AUX	O	O	2992
clearly	ADV	O	O	2992
established	VERB	O	O	2992
,	PUNCT	O	O	2992
hepatic	ADJ	O	O	2992
Ao	PROPN	O	O	2992
mRNA	PROPN	O	O	2992
levels	NOUN	O	O	2992
did	VERB	O	O	2992
not	PART	O	O	2992
change	VERB	O	O	2992
.	PUNCT	O	O	2992
Furthermore	ADV	O	O	2993
,	PUNCT	O	O	2993
the	PRON	O	O	2993
Ao	PROPN	O	O	2993
mRNA	PROPN	O	O	2993
levels	NOUN	O	O	2993
did	VERB	O	O	2993
not	PART	O	O	2993
change	VERB	O	O	2993
in	ADP	O	O	2993
any	PRON	O	O	2993
of	ADP	O	O	2993
the	PRON	O	O	2993
extrahepatic	ADJ	O	O	2993
tissues	NOUN	O	O	2993
studied	VERB	O	O	2993
on	ADP	O	O	2993
day	NOUN	O	O	2993
6	NUM	O	O	2993
,	PUNCT	O	O	2993
nor	CCONJ	O	O	2993
did	VERB	O	O	2993
its	PRON	O	O	2993
hepatic	ADJ	O	O	2993
levels	NOUN	O	O	2993
at	ADP	O	O	2993
days	NOUN	O	O	2993
1	X	O	O	2993
,	PUNCT	O	O	2993
3	X	O	O	2993
,	PUNCT	O	O	2993
5	NUM	O	O	2993
,	PUNCT	O	O	2993
or	CCONJ	O	O	2993
7	NUM	O	O	2993
after	ADP	O	O	2993
PAN	PROPN	O	Chemical	2993
injection	NOUN	O	O	2993
.	PUNCT	O	O	2993
These	PRON	O	O	2994
data	NOUN	O	O	2994
suggest	VERB	O	O	2994
that	SCONJ	O	O	2994
the	PRON	O	O	2994
hepatic	ADJ	O	O	2994
and	CCONJ	O	O	2994
extrahepatic	ADJ	O	O	2994
Ao	PROPN	O	O	2994
mRNA	PROPN	O	O	2994
levels	NOUN	O	O	2994
are	AUX	O	O	2994
unaltered	ADJ	O	O	2994
during	ADP	O	O	2994
the	PRON	O	O	2994
development	NOUN	O	O	2994
of	ADP	O	O	2994
the	PRON	O	O	2994
acute	ADJ	O	O	2994
NS	PROPN	O	Disease	2994
induced	VERB	O	O	2994
by	ADP	O	O	2994
PAN	PROPN	O	Chemical	2994
.	PUNCT	O	O	2994
Cyclophosphamide	PROPN	O	Chemical	2997
associated	VERB	O	O	2997
bladder cancer	NOUN	O	Disease	2997
--	PUNCT	O	O	2997
a	PRON	O	O	2997
highly	ADV	O	O	2997
aggressive	ADJ	O	O	2997
disease	PROPN	O	O	2997
:	PUNCT	O	O	2997
analysis	NOUN	O	O	2997
of	ADP	O	O	2997
12	NUM	O	O	2997
cases	NOUN	O	O	2997
.	PUNCT	O	O	2997
We	PRON	O	O	2998
gained	VERB	O	O	2998
knowledge	NOUN	O	O	2998
of	ADP	O	O	2998
the	PRON	O	O	2998
etiology	NOUN	O	O	2998
,	PUNCT	O	O	2998
treatment	NOUN	O	O	2998
and	CCONJ	O	O	2998
prevention	NOUN	O	O	2998
of	ADP	O	O	2998
cyclophosphamide	VERB	O	Chemical	2998
associated	VERB	O	O	2998
urothelial cancer	NOUN	O	Disease	2998
.	PUNCT	O	O	2998
The	PRON	O	O	2999
medical	ADJ	O	O	2999
records	NOUN	O	O	2999
of	ADP	O	O	2999
6	NUM	O	O	2999
men	NOUN	O	O	2999
and	CCONJ	O	O	2999
6	NUM	O	O	2999
women	NOUN	O	O	2999
(	PUNCT	O	O	2999
mean	VERB	O	O	2999
age	NOUN	O	O	2999
55	NUM	O	O	2999
years	NOUN	O	O	2999
)	PUNCT	O	O	2999
with	ADP	O	O	2999
cyclophosphamide	VERB	O	Chemical	2999
associated	VERB	O	O	2999
bladder cancer	NOUN	O	Disease	2999
were	AUX	O	O	2999
reviewed	VERB	O	O	2999
.	PUNCT	O	O	2999
RESULTS	VERB	O	O	3000
:	PUNCT	O	O	3000
All	PRON	O	O	3000
tumors	NOUN	O	Disease	3000
were	AUX	O	O	3000
grade	NOUN	O	O	3000
3	X	O	O	3000
or	CCONJ	O	O	3000
4	NUM	O	O	3000
transitional	ADJ	O	O	3000
cell	NOUN	O	O	3000
carcinoma	NOUN	O	Disease	3000
.	PUNCT	O	O	3000
The	PRON	O	O	3001
remaining	VERB	O	O	3001
patient	NOUN	O	O	3001
with	ADP	O	O	3001
extensive	ADJ	O	O	3001
cancer	NOUN	O	Disease	3001
underwent	VERB	O	O	3001
partial	ADJ	O	O	3001
cystectomy	NOUN	O	O	3001
for	ADP	O	O	3001
palliation	NOUN	O	O	3001
and	CCONJ	O	O	3001
died	VERB	O	O	3001
3	X	O	O	3001
months	NOUN	O	O	3001
later	ADV	O	O	3001
.	PUNCT	O	O	3001
Cyclophosphamide	PROPN	O	Chemical	3002
associated	VERB	O	O	3002
bladder tumor	NOUN	O	Disease	3002
is	AUX	O	O	3002
an	PRON	O	O	3002
aggressive	ADJ	O	O	3002
disease	PROPN	O	O	3002
.	PUNCT	O	O	3002
However	ADV	O	O	3003
,	PUNCT	O	O	3003
long	ADV	O	O	3003
-	PUNCT	O	O	3003
term	NOUN	O	O	3003
survival	NOUN	O	O	3003
is	AUX	O	O	3003
possible	ADJ	O	O	3003
when	SCONJ	O	O	3003
radical	ADJ	O	O	3003
cystectomy	NOUN	O	O	3003
is	AUX	O	O	3003
performed	VERB	O	O	3003
for	ADP	O	O	3003
bladder tumors	NOUN	O	Disease	3003
with	ADP	O	O	3003
any	PRON	O	O	3003
sign	VERB	O	O	3003
of	ADP	O	O	3003
invasion	NOUN	O	O	3003
and	CCONJ	O	O	3003
for	ADP	O	O	3003
recurrent	ADJ	O	O	3003
high	ADJ	O	O	3003
grade	NOUN	O	O	3003
disease	PROPN	O	O	3003
,	PUNCT	O	O	3003
even	ADV	O	O	3003
when	SCONJ	O	O	3003
noninvasive	ADJ	O	O	3003
.	PUNCT	O	O	3003
Leg and back pain	NOUN	O	Disease	3006
after	ADP	O	O	3006
spinal	NOUN	O	O	3006
anaesthesia	NOUN	O	O	3006
involving	VERB	O	O	3006
hyperbaric	PROPN	O	O	3006
5%	NOUN	O	O	3006
lignocaine	NOUN	O	Chemical	3006
.	PUNCT	O	O	3006
Fifty	NUM	O	O	3007
-	PUNCT	O	O	3007
four	NUM	O	O	3007
patients	NOUN	O	O	3007
,	PUNCT	O	O	3007
aged	ADJ	O	O	3007
27	NUM	O	O	3007
-	PUNCT	O	O	3007
90	NUM	O	O	3007
years	NOUN	O	O	3007
,	PUNCT	O	O	3007
who	PRON	O	O	3007
were	AUX	O	O	3007
given	VERB	O	O	3007
lignocaine	NOUN	O	Chemical	3007
5%	NOUN	O	O	3007
in	ADP	O	O	3007
6.8%	NOUN	O	O	3007
glucose	NOUN	O	Chemical	3007
solution	NOUN	O	O	3007
for	ADP	O	O	3007
spinal	NOUN	O	O	3007
anaesthesia	NOUN	O	O	3007
were	AUX	O	O	3007
studied	VERB	O	O	3007
.	PUNCT	O	O	3007
Thirteen	NUM	O	O	3008
of	ADP	O	O	3008
these	PRON	O	O	3008
patients	NOUN	O	O	3008
experienced	ADJ	O	O	3008
pain in the legs and/or back	ADV	O	Disease	3008
after	ADP	O	O	3008
recovery	NOUN	O	O	3008
from	ADP	O	O	3008
anaesthesia	NOUN	O	O	3008
.	PUNCT	O	O	3008
The	PRON	O	O	3009
patients	NOUN	O	O	3009
affected	VERB	O	O	3009
were	AUX	O	O	3009
younger	ADJ	O	O	3009
(	PUNCT	O	O	3009
p	NOUN	O	O	3009
<	X	O	O	3009
0.05	NUM	O	O	3009
)	PUNCT	O	O	3009
and	CCONJ	O	O	3009
the	PRON	O	O	3009
site	NOUN	O	O	3009
of	ADP	O	O	3009
the	PRON	O	O	3009
dural	NOUN	O	O	3009
puncture	VERB	O	O	3009
was	AUX	O	O	3009
higher	ADJ	O	O	3009
(	PUNCT	O	O	3009
p	NOUN	O	O	3009
<	X	O	O	3009
0.01	NUM	O	O	3009
)	PUNCT	O	O	3009
than	ADP	O	O	3009
those	PRON	O	O	3009
individuals	NOUN	O	O	3009
without	ADP	O	O	3009
pain	NOUN	O	Disease	3009
.	PUNCT	O	O	3009
Five	NUM	O	O	3010
of	ADP	O	O	3010
the	PRON	O	O	3010
13	NUM	O	O	3010
patients	NOUN	O	O	3010
(	PUNCT	O	O	3010
38%	NOUN	O	O	3010
)	PUNCT	O	O	3010
with	ADP	O	O	3010
pain	NOUN	O	Disease	3010
and	CCONJ	O	O	3010
seven	NUM	O	O	3010
of	ADP	O	O	3010
the	PRON	O	O	3010
41	NUM	O	O	3010
patients	NOUN	O	O	3010
(	PUNCT	O	O	3010
17%	NOUN	O	O	3010
)	PUNCT	O	O	3010
without	ADP	O	O	3010
pain	NOUN	O	Disease	3010
admitted	VERB	O	O	3010
to	PART	O	O	3010
a	PRON	O	O	3010
high	ADJ	O	O	3010
alcohol	NOUN	O	Chemical	3010
intake	PROPN	O	O	3010
,	PUNCT	O	O	3010
which	PRON	O	O	3010
might	AUX	O	O	3010
be	AUX	O	O	3010
a	PRON	O	O	3010
contributing	VERB	O	O	3010
factor	NOUN	O	O	3010
.	PUNCT	O	O	3010
Leg and/or back pain	NOUN	O	Disease	3011
is	AUX	O	O	3011
associated	VERB	O	O	3011
with	ADP	O	O	3011
the	PRON	O	O	3011
intrathecal	ADJ	O	O	3011
use	VERB	O	O	3011
of	ADP	O	O	3011
hyperbaric	PROPN	O	O	3011
5%	NOUN	O	O	3011
lignocaine	NOUN	O	Chemical	3011
.	PUNCT	O	O	3011
Acute	PROPN	O	O	3014
blood	NOUN	O	O	3014
pressure	NOUN	O	O	3014
elevations	NOUN	O	O	3014
with	ADP	O	O	3014
caffeine	NOUN	O	Chemical	3014
in	ADP	O	O	3014
men	NOUN	O	O	3014
with	ADP	O	O	3014
borderline	ADJ	O	O	3014
systemic	ADJ	O	O	3014
hypertension	NOUN	O	Disease	3014
.	PUNCT	O	O	3014
Whether	SCONJ	O	O	3015
the	PRON	O	O	3015
vasoconstrictive	ADJ	O	O	3015
actions	NOUN	O	O	3015
of	ADP	O	O	3015
caffeine	NOUN	O	Chemical	3015
are	AUX	O	O	3015
enhanced	VERB	O	O	3015
in	ADP	O	O	3015
hypertensive	ADJ	O	Disease	3015
persons	NOUN	O	O	3015
has	VERB	O	O	3015
not	PART	O	O	3015
been	AUX	O	O	3015
demonstrated	VERB	O	O	3015
.	PUNCT	O	O	3015
Thus	ADV	O	O	3016
,	PUNCT	O	O	3016
caffeine	NOUN	O	Chemical	3016
(	PUNCT	O	O	3016
3.3	NUM	O	O	3016
mg	VERB	O	O	3016
/	PUNCT	O	O	3016
kg	VERB	O	O	3016
)	PUNCT	O	O	3016
versus	ADP	O	O	3016
placebo	NOUN	O	O	3016
was	AUX	O	O	3016
tested	VERB	O	O	3016
in	ADP	O	O	3016
48	NUM	O	O	3016
healthy	ADJ	O	O	3016
men	NOUN	O	O	3016
(	PUNCT	O	O	3016
aged	ADJ	O	O	3016
20	NUM	O	O	3016
to	PART	O	O	3016
35	NUM	O	O	3016
years	NOUN	O	O	3016
)	PUNCT	O	O	3016
selected	VERB	O	O	3016
after	ADP	O	O	3016
screening	VERB	O	O	3016
on	ADP	O	O	3016
2	X	O	O	3016
separate	VERB	O	O	3016
occasions	NOUN	O	O	3016
.	PUNCT	O	O	3016
Borderline	NOUN	O	O	3017
hypertensive	ADJ	O	Disease	3017
men	NOUN	O	O	3017
(	PUNCT	O	O	3017
n	CCONJ	O	O	3017
=	PUNCT	O	O	3017
24	NUM	O	O	3017
)	PUNCT	O	O	3017
were	AUX	O	O	3017
selected	VERB	O	O	3017
with	ADP	O	O	3017
screening	VERB	O	O	3017
systolic	ADV	O	O	3017
blood	NOUN	O	O	3017
pressure	NOUN	O	O	3017
(	PUNCT	O	O	3017
BP	PROPN	O	O	3017
)	PUNCT	O	O	3017
of	ADP	O	O	3017
140	NUM	O	O	3017
to	PART	O	O	3017
160	NUM	O	O	3017
mm	INTJ	O	O	3017
Hg	PROPN	O	O	3017
and/or	CCONJ	O	O	3017
diastolic	ADV	O	O	3017
BP	PROPN	O	O	3017
90	NUM	O	O	3017
to	PART	O	O	3017
99	NUM	O	O	3017
mm	INTJ	O	O	3017
Hg	PROPN	O	O	3017
.	PUNCT	O	O	3017
Low	ADJ	O	O	3018
-	PUNCT	O	O	3018
risk	NOUN	O	O	3018
controls	VERB	O	O	3018
(	PUNCT	O	O	3018
n	CCONJ	O	O	3018
=	PUNCT	O	O	3018
24	NUM	O	O	3018
)	PUNCT	O	O	3018
reported	VERB	O	O	3018
no	PRON	O	O	3018
parental	ADJ	O	O	3018
history	NOUN	O	O	3018
of	ADP	O	O	3018
hypertension	NOUN	O	Disease	3018
and	CCONJ	O	O	3018
had	VERB	O	O	3018
screening	VERB	O	O	3018
BP	PROPN	O	O	3018
<	X	O	O	3018
130/85	NUM	O	O	3018
mm	INTJ	O	O	3018
Hg	PROPN	O	O	3018
.	PUNCT	O	O	3018
Participants	NOUN	O	O	3019
were	AUX	O	O	3019
then	ADV	O	O	3019
tested	VERB	O	O	3019
on	ADP	O	O	3019
2	X	O	O	3019
occasions	NOUN	O	O	3019
after	ADP	O	O	3019
12-hour	NOUN	O	O	3019
abstinence	NOUN	O	O	3019
from	ADP	O	O	3019
caffeine	NOUN	O	Chemical	3019
in	ADP	O	O	3019
each	PRON	O	O	3019
of	ADP	O	O	3019
2	X	O	O	3019
protocols	NOUN	O	O	3019
;	PUNCT	O	O	3019
this	PRON	O	O	3019
required	VERB	O	O	3019
a	PRON	O	O	3019
total	ADJ	O	O	3019
of	ADP	O	O	3019
4	NUM	O	O	3019
laboratory	NOUN	O	O	3019
visits	VERB	O	O	3019
.	PUNCT	O	O	3019
Caffeine	NOUN	O	Chemical	3020
-	PUNCT	O	O	3020
induced	VERB	O	O	3020
changes	VERB	O	O	3020
in	ADP	O	O	3020
diastolic	ADV	O	O	3020
BP	PROPN	O	O	3020
were	AUX	O	O	3020
2	X	O	O	3020
to	PART	O	O	3020
3	X	O	O	3020
times	NOUN	O	O	3020
larger	ADJ	O	O	3020
in	ADP	O	O	3020
borderline	ADJ	O	O	3020
subjects	NOUN	O	O	3020
than	ADP	O	O	3020
in	ADP	O	O	3020
controls	VERB	O	O	3020
(	PUNCT	O	O	3020
+	ADP	O	O	3020
8.4	NUM	O	O	3020
vs	ADP	O	O	3020
+	ADP	O	O	3020
3.8	NUM	O	O	3020
mm	INTJ	O	O	3020
Hg	PROPN	O	O	3020
,	PUNCT	O	O	3020
p	NOUN	O	O	3020
<	X	O	O	3020
0.0001	NUM	O	O	3020
)	PUNCT	O	O	3020
,	PUNCT	O	O	3020
and	CCONJ	O	O	3020
were	AUX	O	O	3020
attributable	ADJ	O	O	3020
to	PART	O	O	3020
larger	ADJ	O	O	3020
changes	VERB	O	O	3020
in	ADP	O	O	3020
impedance	NOUN	O	O	3020
-	PUNCT	O	O	3020
derived	VERB	O	O	3020
measures	NOUN	O	O	3020
of	ADP	O	O	3020
systemic	ADJ	O	O	3020
vascular	ADJ	O	O	3020
resistance	NOUN	O	O	3020
(	PUNCT	O	O	3020
+	ADP	O	O	3020
135	NUM	O	O	3020
vs	ADP	O	O	3020
+	ADP	O	O	3020
45	NUM	O	O	3020
dynes.s.cm-5	PROPN	O	O	3020
,	PUNCT	O	O	3020
p	NOUN	O	O	3020
Consequently	ADV	O	O	3021
,	PUNCT	O	O	3021
whereas	SCONJ	O	O	3021
all	PRON	O	O	3021
participants	NOUN	O	O	3021
exhibited	VERB	O	O	3021
normotensive	PROPN	O	O	3021
levels	NOUN	O	O	3021
during	ADP	O	O	3021
the	PRON	O	O	3021
resting	VERB	O	O	3021
predrug	ADJ	O	O	3021
baseline	VERB	O	O	3021
,	PUNCT	O	O	3021
33%	NOUN	O	O	3021
of	ADP	O	O	3021
borderline	ADJ	O	O	3021
subjects	NOUN	O	O	3021
achieved	VERB	O	O	3021
hypertensive	ADJ	O	Disease	3021
BP	PROPN	O	O	3021
levels	NOUN	O	O	3021
after	ADP	O	O	3021
caffeine	NOUN	O	Chemical	3021
ingestion	NOUN	O	O	3021
.	PUNCT	O	O	3021
Thus	ADV	O	O	3022
,	PUNCT	O	O	3022
in	ADP	O	O	3022
borderline	ADJ	O	O	3022
hypertensive	ADJ	O	Disease	3022
men	NOUN	O	O	3022
,	PUNCT	O	O	3022
exaggerated	ADJ	O	O	3022
responses	NOUN	O	O	3022
to	PART	O	O	3022
caffeine	NOUN	O	Chemical	3022
were	AUX	O	O	3022
:	PUNCT	O	O	3022
selective	ADJ	O	O	3022
for	ADP	O	O	3022
diastolic	ADV	O	O	3022
BP	PROPN	O	O	3022
,	PUNCT	O	O	3022
consistent	ADJ	O	O	3022
with	ADP	O	O	3022
greater	ADJ	O	O	3022
vasoconstriction	NOUN	O	O	3022
,	PUNCT	O	O	3022
replicated	VERB	O	O	3022
in	ADP	O	O	3022
2	X	O	O	3022
protocols	NOUN	O	O	3022
,	PUNCT	O	O	3022
and	CCONJ	O	O	3022
representative	NOUN	O	O	3022
of	ADP	O	O	3022
nearly	ADV	O	O	3022
all	PRON	O	O	3022
borderline	ADJ	O	O	3022
hypertensives	VERB	O	Disease	3022
.	PUNCT	O	O	3022
We	PRON	O	O	3023
suspect	VERB	O	O	3023
that	SCONJ	O	O	3023
the	PRON	O	O	3023
potential	ADJ	O	O	3023
for	ADP	O	O	3023
caffeine	NOUN	O	Chemical	3023
to	PART	O	O	3023
stabilize	VERB	O	O	3023
high	ADJ	O	O	3023
resistance	NOUN	O	O	3023
states	VERB	O	O	3023
in	ADP	O	O	3023
susceptible	ADJ	O	O	3023
persons	NOUN	O	O	3023
suggests	VERB	O	O	3023
that	SCONJ	O	O	3023
its	PRON	O	O	3023
use	VERB	O	O	3023
may	AUX	O	O	3023
facilitate	VERB	O	O	3023
their	PRON	O	O	3023
disease	PROPN	O	O	3023
progression	NOUN	O	O	3023
,	PUNCT	O	O	3023
as	ADP	O	O	3023
well	ADV	O	O	3023
as	ADP	O	O	3023
hinder	VERB	O	O	3023
accurate	ADJ	O	O	3023
diagnosis	NOUN	O	O	3023
and	CCONJ	O	O	3023
treatment	NOUN	O	O	3023
.	PUNCT	O	O	3023
Hallucinations	NOUN	O	Disease	3026
and	CCONJ	O	O	3026
ifosfamide	ADP	O	Chemical	3026
-	PUNCT	O	O	3026
induced	VERB	O	O	3026
neurotoxicity	NOUN	O	Disease	3026
.	PUNCT	O	O	3026
Hallucinations	NOUN	O	Disease	3027
as	ADP	O	O	3027
a	PRON	O	O	3027
symptom	NOUN	O	O	3027
of	ADP	O	O	3027
central	ADJ	O	O	3027
neurotoxicity	NOUN	O	Disease	3027
are	AUX	O	O	3027
a	PRON	O	O	3027
known	VERB	O	O	3027
but	CCONJ	O	O	3027
poorly	ADV	O	O	3027
described	VERB	O	O	3027
side	NOUN	O	O	3027
effect	VERB	O	O	3027
of	ADP	O	O	3027
ifosfamide	ADP	O	Chemical	3027
.	PUNCT	O	O	3027
Most	ADV	O	O	3028
cases	NOUN	O	O	3028
of	ADP	O	O	3028
ifosfamide	ADP	O	Chemical	3028
-	PUNCT	O	O	3028
induced	VERB	O	O	3028
hallucinations	NOUN	O	Disease	3028
have	VERB	O	O	3028
been	AUX	O	O	3028
reported	VERB	O	O	3028
with	ADP	O	O	3028
other	ADJ	O	O	3028
mental	ADJ	O	O	3028
status	NOUN	O	O	3028
changes	VERB	O	O	3028
.	PUNCT	O	O	3028
:	PUNCT	O	O	3029
The	PRON	O	O	3029
authors	NOUN	O	O	3029
interviewed	VERB	O	O	3029
six	NUM	O	O	3029
persons	NOUN	O	O	3029
with	ADP	O	O	3029
ifosfamide	ADP	O	Chemical	3029
-	PUNCT	O	O	3029
induced	VERB	O	O	3029
hallucinations	NOUN	O	Disease	3029
in	ADP	O	O	3029
the	PRON	O	O	3029
presence	NOUN	O	O	3029
of	ADP	O	O	3029
a	PRON	O	O	3029
clear	ADJ	O	O	3029
sensorium	NOUN	O	O	3029
.	PUNCT	O	O	3029
All	PRON	O	O	3030
patients	NOUN	O	O	3030
were	AUX	O	O	3030
receiving	VERB	O	O	3030
high	ADJ	O	O	3030
-	PUNCT	O	O	3030
dose	NOUN	O	O	3030
ifosfamide	ADP	O	Chemical	3030
as	ADP	O	O	3030
part	NOUN	O	O	3030
of	ADP	O	O	3030
their	PRON	O	O	3030
bone	NOUN	O	O	3030
marrow	PROPN	O	O	3030
transplant	NOUN	O	O	3030
procedure	NOUN	O	O	3030
.	PUNCT	O	O	3030
Hallucinations	NOUN	O	Disease	3031
occurred	VERB	O	O	3031
only	ADV	O	O	3031
when	SCONJ	O	O	3031
the	PRON	O	O	3031
patient	NOUN	O	O	3031
's	AUX	O	O	3031
eyes	NOUN	O	O	3031
were	AUX	O	O	3031
closed	VERB	O	O	3031
and	CCONJ	O	O	3031
,	PUNCT	O	O	3031
in	ADP	O	O	3031
all	PRON	O	O	3031
but	CCONJ	O	O	3031
one	NUM	O	O	3031
case	NOUN	O	O	3031
,	PUNCT	O	O	3031
were	AUX	O	O	3031
reported	VERB	O	O	3031
as	ADP	O	O	3031
disturbing	ADJ	O	O	3031
or	CCONJ	O	O	3031
frightening	ADJ	O	O	3031
.	PUNCT	O	O	3031
Underreporting	VERB	O	O	3032
of	ADP	O	O	3032
these	PRON	O	O	3032
hallucinations	NOUN	O	Disease	3032
by	ADP	O	O	3032
patients	NOUN	O	O	3032
is	AUX	O	O	3032
likely	ADV	O	O	3032
.	PUNCT	O	O	3032
Hallucinations	NOUN	O	Disease	3033
may	AUX	O	O	3033
be	AUX	O	O	3033
the	PRON	O	O	3033
sole	NOUN	O	O	3033
or	CCONJ	O	O	3033
first	ADV	O	O	3033
manifestation	NOUN	O	O	3033
of	ADP	O	O	3033
neurotoxicity	NOUN	O	Disease	3033
.	PUNCT	O	O	3033
The	PRON	O	O	3034
clinician	NOUN	O	O	3034
should	AUX	O	O	3034
be	AUX	O	O	3034
alerted	VERB	O	O	3034
for	ADP	O	O	3034
possible	ADJ	O	O	3034
ifosfamide	ADP	O	Chemical	3034
-	PUNCT	O	O	3034
induced	VERB	O	O	3034
hallucinations	NOUN	O	Disease	3034
,	PUNCT	O	O	3034
which	PRON	O	O	3034
may	AUX	O	O	3034
occur	VERB	O	O	3034
without	ADP	O	O	3034
other	ADJ	O	O	3034
signs	NOUN	O	O	3034
of	ADP	O	O	3034
neurotoxicity	NOUN	O	Disease	3034
.	PUNCT	O	O	3034
""""	PUNCT	O	O	3035
Eyes	NOUN	O	O	3035
-	PUNCT	O	O	3035
closed	VERB	O	O	3035
""""	PUNCT	O	O	3035
hallucinatory	ADJ	O	Disease	3035
experiences	NOUN	O	O	3035
appear	VERB	O	O	3035
to	PART	O	O	3035
be	AUX	O	O	3035
an	PRON	O	O	3035
unusual	ADJ	O	O	3035
feature	VERB	O	O	3035
of	ADP	O	O	3035
this	PRON	O	O	3035
presentation	NOUN	O	O	3035
.	PUNCT	O	O	3035
If	SCONJ	O	O	3036
agitation	NOUN	O	Disease	3036
becomes	VERB	O	O	3036
marked	VERB	O	O	3036
,	PUNCT	O	O	3036
high	ADJ	O	O	3036
-	PUNCT	O	O	3036
potency	NOUN	O	O	3036
neuroleptics	NOUN	O	O	3036
(	PUNCT	O	O	3036
i.e.	X	O	O	3036
,	PUNCT	O	O	3036
haloperidol	NOUN	O	Chemical	3036
)	PUNCT	O	O	3036
may	AUX	O	O	3036
be	AUX	O	O	3036
effective	ADJ	O	O	3036
.	PUNCT	O	O	3036
Chlorpropamide	PROPN	O	Chemical	3039
-	PUNCT	O	O	3039
induced	VERB	O	O	3039
optic neuropathy	NOUN	O	Disease	3039
.	PUNCT	O	O	3039
A	PRON	O	O	3040
65-year	NOUN	O	O	3040
-	PUNCT	O	O	3040
old	ADJ	O	O	3040
woman	NOUN	O	O	3040
with	ADP	O	O	3040
adult	NOUN	O	O	3040
-	PUNCT	O	O	3040
onset	VERB	O	O	3040
diabetes	NOUN	O	Disease	3040
treated	VERB	O	O	3040
with	ADP	O	O	3040
chlorpropamide	VERB	O	Chemical	3040
(	PUNCT	O	O	3040
Diabenese	PROPN	O	Chemical	3040
)	PUNCT	O	O	3040
had	VERB	O	O	3040
a	PRON	O	O	3040
toxic optic neuropathy	NOUN	O	Disease	3040
that	SCONJ	O	O	3040
resolved	VERB	O	O	3040
with	ADP	O	O	3040
discontinuation	NOUN	O	O	3040
of	ADP	O	O	3040
chlorpropamide	VERB	O	Chemical	3040
therapy	NOUN	O	O	3040
.	PUNCT	O	O	3040
Visual loss	NOUN	O	Disease	3041
occurs	VERB	O	O	3041
in	ADP	O	O	3041
diabetics	NOUN	O	Disease	3041
for	ADP	O	O	3041
a	PRON	O	O	3041
variety	NOUN	O	O	3041
of	ADP	O	O	3041
reasons	NOUN	O	O	3041
,	PUNCT	O	O	3041
and	CCONJ	O	O	3041
accurate	ADJ	O	O	3041
diagnosis	NOUN	O	O	3041
is	AUX	O	O	3041
necessary	ADJ	O	O	3041
to	PART	O	O	3041
institute	PROPN	O	O	3041
appropriate	ADJ	O	O	3041
therapy	NOUN	O	O	3041
.	PUNCT	O	O	3041
The	PRON	O	O	3042
possibility	NOUN	O	O	3042
of	ADP	O	O	3042
a	PRON	O	O	3042
drug	NOUN	O	O	3042
-	PUNCT	O	O	3042
induced	VERB	O	O	3042
optic neuropathy	NOUN	O	Disease	3042
should	AUX	O	O	3042
be	AUX	O	O	3042
considered	VERB	O	O	3042
in	ADP	O	O	3042
the	PRON	O	O	3042
differential	ADJ	O	O	3042
diagnosis	NOUN	O	O	3042
of	ADP	O	O	3042
visual loss	NOUN	O	Disease	3042
in	ADP	O	O	3042
diabetics	NOUN	O	Disease	3042
.	PUNCT	O	O	3042
Levodopa	NOUN	O	Chemical	3045
-	PUNCT	O	O	3045
induced	VERB	O	O	3045
dyskinesia	NOUN	O	Disease	3045
and	CCONJ	O	O	3045
thalamotomy	NOUN	O	O	3045
.	PUNCT	O	O	3045
Levodopa	NOUN	O	Chemical	3046
-	PUNCT	O	O	3046
induced	VERB	O	O	3046
dyskinesia	NOUN	O	Disease	3046
of	ADP	O	O	3046
the	PRON	O	O	3046
limbs	NOUN	O	O	3046
in	ADP	O	O	3046
thirteen	NUM	O	O	3046
cases	NOUN	O	O	3046
of	ADP	O	O	3046
Parkinsonism	NOUN	O	Disease	3046
,	PUNCT	O	O	3046
which	PRON	O	O	3046
was	AUX	O	O	3046
choreic	PROPN	O	O	3046
,	PUNCT	O	O	3046
ballistic	ADJ	O	O	3046
or	CCONJ	O	O	3046
dystonic	ADJ	O	Disease	3046
in	ADP	O	O	3046
type	NOUN	O	O	3046
,	PUNCT	O	O	3046
was	AUX	O	O	3046
alleviated	VERB	O	O	3046
almost	ADV	O	O	3046
completely	ADV	O	O	3046
by	ADP	O	O	3046
stereotaxic	ADJ	O	O	3046
surgery	NOUN	O	O	3046
using	VERB	O	O	3046
a	PRON	O	O	3046
microelectrode	PROPN	O	O	3046
technique	NOUN	O	O	3046
for	ADP	O	O	3046
the	PRON	O	O	3046
ventralis	PROPN	O	O	3046
oralis	VERB	O	O	3046
anterior	PROPN	O	O	3046
and	CCONJ	O	O	3046
posterior	ADJ	O	O	3046
nuclei	NOUN	O	O	3046
of	ADP	O	O	3046
the	PRON	O	O	3046
thalamus	NOUN	O	O	3046
,	PUNCT	O	O	3046
but	CCONJ	O	O	3046
much	ADJ	O	O	3046
less	ADV	O	O	3046
by	ADP	O	O	3046
the	PRON	O	O	3046
ventralis	PROPN	O	O	3046
intermedius	PROPN	O	O	3046
nucleus	PROPN	O	O	3046
.	PUNCT	O	O	3046
Control	NOUN	O	O	3047
of	ADP	O	O	3047
levodopa	NOUN	O	Chemical	3047
-	PUNCT	O	O	3047
induced	VERB	O	O	3047
dyskinesias	PROPN	O	Disease	3047
by	ADP	O	O	3047
thalamic lesions	NOUN	O	Disease	3047
in	ADP	O	O	3047
the	PRON	O	O	3047
course	NOUN	O	O	3047
of	ADP	O	O	3047
routine	ADJ	O	O	3047
treatment	NOUN	O	O	3047
of	ADP	O	O	3047
Parkinsonism	NOUN	O	Disease	3047
is	AUX	O	O	3047
discussed	VERB	O	O	3047
.	PUNCT	O	O	3047
Factors	NOUN	O	O	3050
associated	VERB	O	O	3050
with	ADP	O	O	3050
nephrotoxicity	NOUN	O	Disease	3050
and	CCONJ	O	O	3050
clinical	ADJ	O	O	3050
outcome	NOUN	O	O	3050
in	ADP	O	O	3050
patients	NOUN	O	O	3050
receiving	VERB	O	O	3050
amikacin	VERB	O	Chemical	3050
.	PUNCT	O	O	3050
Data	NOUN	O	O	3051
from	ADP	O	O	3051
60	NUM	O	O	3051
patients	NOUN	O	O	3051
treated	VERB	O	O	3051
with	ADP	O	O	3051
amikacin	VERB	O	Chemical	3051
were	AUX	O	O	3051
analyzed	VERB	O	O	3051
for	ADP	O	O	3051
factors	NOUN	O	O	3051
associated	VERB	O	O	3051
with	ADP	O	O	3051
nephrotoxicity	NOUN	O	Disease	3051
.	PUNCT	O	O	3051
Variables	NOUN	O	O	3052
evaluated	VERB	O	O	3052
included	VERB	O	O	3052
patient	NOUN	O	O	3052
weight	NOUN	O	O	3052
,	PUNCT	O	O	3052
age	NOUN	O	O	3052
,	PUNCT	O	O	3052
sex	NOUN	O	O	3052
,	PUNCT	O	O	3052
serum	NOUN	O	O	3052
creatinine	PROPN	O	Chemical	3052
level	VERB	O	O	3052
,	PUNCT	O	O	3052
creatinine	PROPN	O	Chemical	3052
clearance	NOUN	O	O	3052
,	PUNCT	O	O	3052
duration	NOUN	O	O	3052
of	ADP	O	O	3052
therapy	NOUN	O	O	3052
,	PUNCT	O	O	3052
total	ADJ	O	O	3052
dose	NOUN	O	O	3052
,	PUNCT	O	O	3052
mean	VERB	O	O	3052
daily	ADV	O	O	3052
dose	NOUN	O	O	3052
,	PUNCT	O	O	3052
organism	NOUN	O	O	3052
minimum	ADJ	O	O	3052
inhibitory	ADJ	O	O	3052
concentration	NOUN	O	O	3052
(	PUNCT	O	O	3052
MIC	PROPN	O	O	3052
)	PUNCT	O	O	3052
,	PUNCT	O	O	3052
mean	VERB	O	O	3052
peak	PROPN	O	O	3052
levels	NOUN	O	O	3052
,	PUNCT	O	O	3052
mean	VERB	O	O	3052
trough	NOUN	O	O	3052
levels	NOUN	O	O	3052
,	PUNCT	O	O	3052
When	SCONJ	O	O	3053
the	PRON	O	O	3053
parameters	NOUN	O	O	3053
were	AUX	O	O	3053
examined	VERB	O	O	3053
individually	ADV	O	O	3053
,	PUNCT	O	O	3053
duration	NOUN	O	O	3053
of	ADP	O	O	3053
therapy	NOUN	O	O	3053
and	CCONJ	O	O	3053
total	ADJ	O	O	3053
AUC	NOUN	O	O	3053
correlated	VERB	O	O	3053
significantly	ADV	O	O	3053
(	PUNCT	O	O	3053
P	NOUN	O	Chemical	3053
less	ADV	O	O	3053
than	ADP	O	O	3053
.05	NUM	O	O	3053
)	PUNCT	O	O	3053
with	ADP	O	O	3053
nephrotoxicity	NOUN	O	Disease	3053
.	PUNCT	O	O	3053
Based	VERB	O	O	3054
on	ADP	O	O	3054
this	PRON	O	O	3054
model	NOUN	O	O	3054
and	CCONJ	O	O	3054
on	ADP	O	O	3054
Bayes	PROPN	O	O	3054
'	PUNCT	O	O	3054
theorem	NOUN	O	O	3054
,	PUNCT	O	O	3054
the	PRON	O	O	3054
predictive	ADJ	O	O	3054
accuracy	NOUN	O	O	3054
of	ADP	O	O	3054
identifying	VERB	O	O	3054
""""	PUNCT	O	O	3054
nephrotoxic	NOUN	O	Disease	3054
""""	PUNCT	O	O	3054
patients	NOUN	O	O	3054
increased	VERB	O	O	3054
from	ADP	O	O	3054
0.17	NUM	O	O	3054
to	PART	O	O	3054
0.39	NUM	O	O	3054
.	PUNCT	O	O	3054
In	ADP	O	O	3057
group	NOUN	O	O	3057
I	PRON	O	O	3057
,	PUNCT	O	O	3057
cyclosporine	NOUN	O	Chemical	3057
was	AUX	O	O	3057
given	VERB	O	O	3057
before	ADP	O	O	3057
the	PRON	O	O	3057
procedure	NOUN	O	O	3057
at	ADP	O	O	3057
a	PRON	O	O	3057
loading	NOUN	O	O	3057
dose	NOUN	O	O	3057
of	ADP	O	O	3057
17.5	NUM	O	O	3057
mg	VERB	O	O	3057
/	PUNCT	O	O	3057
kg	VERB	O	O	3057
and	CCONJ	O	O	3057
then	ADV	O	O	3057
continued	VERB	O	O	3057
after	ADP	O	O	3057
the	PRON	O	O	3057
procedure	NOUN	O	O	3057
to	PART	O	O	3057
keep	VERB	O	O	3057
a	PRON	O	O	3057
whole	NOUN	O	O	3057
blood	NOUN	O	O	3057
level	VERB	O	O	3057
about	ADP	O	O	3057
1000	NUM	O	O	3057
ng	PROPN	O	O	3057
/	PUNCT	O	O	3057
ml	ADP	O	O	3057
.	PUNCT	O	O	3057
In	ADP	O	O	3058
group	NOUN	O	O	3058
II	NUM	O	O	3058
,	PUNCT	O	O	3058
cyclosporine	NOUN	O	Chemical	3058
was	AUX	O	O	3058
started	VERB	O	O	3058
only	ADV	O	O	3058
after	ADP	O	O	3058
the	PRON	O	O	3058
procedure	NOUN	O	O	3058
at	ADP	O	O	3058
a	PRON	O	O	3058
lower	ADJ	O	O	3058
dosage	NOUN	O	O	3058
and	CCONJ	O	O	3058
was	AUX	O	O	3058
complemented	VERB	O	O	3058
by	ADP	O	O	3058
azathioprine	ADV	O	Chemical	3058
,	PUNCT	O	O	3058
which	PRON	O	O	3058
was	AUX	O	O	3058
used	VERB	O	O	3058
for	ADP	O	O	3058
the	PRON	O	O	3058
first	ADV	O	O	3058
postoperative	ADJ	O	O	3058
week	NOUN	O	O	3058
.	PUNCT	O	O	3058
Group	PROPN	O	O	3059
II	NUM	O	O	3059
showed	VERB	O	O	3059
a	PRON	O	O	3059
better	ADV	O	O	3059
perioperative	ADJ	O	O	3059
renal	ADJ	O	O	3059
function	NOUN	O	O	3059
as	ADP	O	O	3059
determined	VERB	O	O	3059
by	ADP	O	O	3059
serum	NOUN	O	O	3059
blood	NOUN	O	O	3059
urea nitrogen	NOUN	O	Chemical	3059
and	CCONJ	O	O	3059
serum	NOUN	O	O	3059
creatinine	PROPN	O	Chemical	3059
levels	NOUN	O	O	3059
.	PUNCT	O	O	3059
Group	PROPN	O	O	3060
II	NUM	O	O	3060
also	ADV	O	O	3060
showed	VERB	O	O	3060
a	PRON	O	O	3060
significant	ADJ	O	O	3060
decrease	VERB	O	O	3060
of	ADP	O	O	3060
chronic	ADJ	O	O	3060
nephrotoxicity	NOUN	O	Disease	3060
secondary	ADJ	O	O	3060
to	PART	O	O	3060
long	ADV	O	O	3060
-	PUNCT	O	O	3060
term	NOUN	O	O	3060
therapy	NOUN	O	O	3060
with	ADP	O	O	3060
cyclosporine	NOUN	O	Chemical	3060
.	PUNCT	O	O	3060
Despite	SCONJ	O	O	3061
this	PRON	O	O	3061
improvement	NOUN	O	O	3061
in	ADP	O	O	3061
late	ADV	O	O	3061
renal	ADJ	O	O	3061
function	NOUN	O	O	3061
,	PUNCT	O	O	3061
group	NOUN	O	O	3061
II	NUM	O	O	3061
still	ADV	O	O	3061
shows	VERB	O	O	3061
a	PRON	O	O	3061
slow	VERB	O	O	3061
rise	VERB	O	O	3061
in	ADP	O	O	3061
serum	NOUN	O	O	3061
creatinine	PROPN	O	Chemical	3061
.	PUNCT	O	O	3061
We	PRON	O	O	3062
think	VERB	O	O	3062
that	SCONJ	O	O	3062
even	ADV	O	O	3062
these	PRON	O	O	3062
lower	ADJ	O	O	3062
dosages	NOUN	O	O	3062
of	ADP	O	O	3062
cyclosporine	NOUN	O	Chemical	3062
can	AUX	O	O	3062
cause	VERB	O	O	3062
chronic	ADJ	O	O	3062
nephrotoxicity	NOUN	O	Disease	3062
and	CCONJ	O	O	3062
that	SCONJ	O	O	3062
further	ADV	O	O	3062
modification	NOUN	O	O	3062
of	ADP	O	O	3062
the	PRON	O	O	3062
immunosuppressive	ADJ	O	O	3062
regimen	NOUN	O	O	3062
is	AUX	O	O	3062
required	VERB	O	O	3062
to	PART	O	O	3062
completely	ADV	O	O	3062
abolish	VERB	O	O	3062
this	PRON	O	O	3062
toxic	ADJ	O	O	3062
side	NOUN	O	O	3062
effect	VERB	O	O	3062
.	PUNCT	O	O	3062
Reversible	ADJ	O	O	3065
cholestasis	NOUN	O	Disease	3065
with	ADP	O	O	3065
bile duct injury	NOUN	O	Disease	3065
following	VERB	O	O	3065
azathioprine	ADV	O	Chemical	3065
therapy	NOUN	O	O	3065
.	PUNCT	O	O	3065
A	PRON	O	O	3066
67-year	NOUN	O	O	3066
-	PUNCT	O	O	3066
old	ADJ	O	O	3066
patient	NOUN	O	O	3066
,	PUNCT	O	O	3066
with	ADP	O	O	3066
primary	NOUN	O	O	3066
polymyositis	NOUN	O	Disease	3066
and	CCONJ	O	O	3066
without	ADP	O	O	3066
previous	ADJ	O	O	3066
evidence	NOUN	O	O	3066
of	ADP	O	O	3066
liver disease	NOUN	O	Disease	3066
,	PUNCT	O	O	3066
developed	VERB	O	O	3066
clinical	ADJ	O	O	3066
and	CCONJ	O	O	3066
biochemical	ADJ	O	O	3066
features	VERB	O	O	3066
of	ADP	O	O	3066
severe	ADJ	O	O	3066
cholestasis	NOUN	O	Disease	3066
3	X	O	O	3066
months	NOUN	O	O	3066
after	ADP	O	O	3066
initiation	NOUN	O	O	3066
of	ADP	O	O	3066
azathioprine	ADV	O	Chemical	3066
therapy	NOUN	O	O	3066
.	PUNCT	O	O	3066
Liver	NOUN	O	O	3067
biopsy	PROPN	O	O	3067
showed	VERB	O	O	3067
cholestasis	NOUN	O	Disease	3067
with	ADP	O	O	3067
both	PRON	O	O	3067
cytological	PROPN	O	O	3067
and	CCONJ	O	O	3067
architectural	ADJ	O	O	3067
alterations	NOUN	O	O	3067
of	ADP	O	O	3067
interlobular	ADJ	O	O	3067
bile	NOUN	O	O	3067
ducts	NOUN	O	O	3067
.	PUNCT	O	O	3067
Azathioprine	ADV	O	Chemical	3068
withdrawal	NOUN	O	O	3068
resulted	VERB	O	O	3068
after	ADP	O	O	3068
7	NUM	O	O	3068
weeks	NOUN	O	O	3068
in	ADP	O	O	3068
the	PRON	O	O	3068
resolution	NOUN	O	O	3068
of	ADP	O	O	3068
clinical	ADJ	O	O	3068
and	CCONJ	O	O	3068
biochemical	ADJ	O	O	3068
abnormalities	NOUN	O	O	3068
.	PUNCT	O	O	3068
It	PRON	O	O	3069
is	AUX	O	O	3069
believed	VERB	O	O	3069
that	SCONJ	O	O	3069
this	PRON	O	O	3069
is	AUX	O	O	3069
the	PRON	O	O	3069
first	ADV	O	O	3069
reported	VERB	O	O	3069
case	NOUN	O	O	3069
of	ADP	O	O	3069
reversible	ADJ	O	O	3069
azathioprine	ADV	O	Chemical	3069
-	PUNCT	O	O	3069
induced	VERB	O	O	3069
cholestasis	NOUN	O	Disease	3069
associated	VERB	O	O	3069
with	ADP	O	O	3069
histological	ADJ	O	O	3069
evidence	NOUN	O	O	3069
of	ADP	O	O	3069
bile duct injury	NOUN	O	Disease	3069
.	PUNCT	O	O	3069
Renal	NOUN	O	O	3072
function	NOUN	O	O	3072
and	CCONJ	O	O	3072
hemodynamics	NOUN	O	O	3072
during	ADP	O	O	3072
prolonged	VERB	O	O	3072
isoflurane	NOUN	O	Chemical	3072
-	PUNCT	O	O	3072
induced	VERB	O	O	3072
hypotension	NOUN	O	Disease	3072
in	ADP	O	O	3072
humans	NOUN	O	O	3072
.	PUNCT	O	O	3072
The	PRON	O	O	3073
effect	VERB	O	O	3073
of	ADP	O	O	3073
isoflurane	NOUN	O	Chemical	3073
-	PUNCT	O	O	3073
induced	VERB	O	O	3073
hypotension	NOUN	O	Disease	3073
on	ADP	O	O	3073
glomerular	ADJ	O	O	3073
function	NOUN	O	O	3073
and	CCONJ	O	O	3073
renal	ADJ	O	O	3073
blood	NOUN	O	O	3073
flow	NOUN	O	O	3073
was	AUX	O	O	3073
investigated	VERB	O	O	3073
in	ADP	O	O	3073
20	NUM	O	O	3073
human	PROPN	O	O	3073
subjects	NOUN	O	O	3073
.	PUNCT	O	O	3073
Glomerular	PROPN	O	O	3074
filtration	NOUN	O	O	3074
rate	NOUN	O	O	3074
(	PUNCT	O	O	3074
GFR	NOUN	O	O	3074
)	PUNCT	O	O	3074
and	CCONJ	O	O	3074
effective	ADJ	O	O	3074
renal	ADJ	O	O	3074
plasma	NOUN	O	O	3074
flow	NOUN	O	O	3074
(	PUNCT	O	O	3074
ERPF	PROPN	O	O	3074
)	PUNCT	O	O	3074
were	AUX	O	O	3074
measured	VERB	O	O	3074
by	ADP	O	O	3074
inulin	PROPN	O	O	3074
and	CCONJ	O	O	3074
para	PROPN	O	O	3074
-	PUNCT	O	O	3074
aminohippurate	VERB	O	O	3074
(	PUNCT	O	O	3074
PAH	PROPN	O	Chemical	3074
)	PUNCT	O	O	3074
clearance	NOUN	O	O	3074
,	PUNCT	O	O	3074
respectively	ADV	O	O	3074
.	PUNCT	O	O	3074
Anesthesia	NOUN	O	O	3075
was	AUX	O	O	3075
maintained	VERB	O	O	3075
with	ADP	O	O	3075
fentanyl	ADJ	O	Chemical	3075
,	PUNCT	O	O	3075
nitrous oxide	NOUN	O	Chemical	3075
,	PUNCT	O	O	3075
oxygen	NOUN	O	Chemical	3075
,	PUNCT	O	O	3075
and	CCONJ	O	O	3075
isoflurane	NOUN	O	Chemical	3075
.	PUNCT	O	O	3075
Hypotension	NOUN	O	Disease	3076
was	AUX	O	O	3076
induced	VERB	O	O	3076
for	ADP	O	O	3076
236.9	NUM	O	O	3076
+	ADP	O	O	3076
/-	PUNCT	O	O	3076
15.1	NUM	O	O	3077
min	NOUN	O	O	3077
by	ADP	O	O	3077
increasing	VERB	O	O	3077
the	PRON	O	O	3077
isoflurane	NOUN	O	Chemical	3077
inspired	VERB	O	O	3077
concentration	NOUN	O	O	3077
to	PART	O	O	3077
maintain	VERB	O	O	3077
a	PRON	O	O	3077
mean	VERB	O	O	3077
arterial	ADJ	O	O	3077
pressure	NOUN	O	O	3077
of	ADP	O	O	3077
59.8	NUM	O	O	3077
+	ADP	O	O	3077
/-	PUNCT	O	O	3077
GFR	NOUN	O	O	3078
and	CCONJ	O	O	3078
ERPF	PROPN	O	O	3078
decreased	VERB	O	O	3078
with	ADP	O	O	3078
the	PRON	O	O	3078
induction	NOUN	O	O	3078
of	ADP	O	O	3078
anesthesia	NOUN	O	O	3078
but	CCONJ	O	O	3078
not	PART	O	O	3078
significantly	ADV	O	O	3078
more	ADJ	O	O	3078
during	ADP	O	O	3078
hypotension	NOUN	O	Disease	3078
.	PUNCT	O	O	3078
Renal	NOUN	O	O	3079
vascular	ADJ	O	O	3079
resistance	NOUN	O	O	3079
increased	VERB	O	O	3079
during	ADP	O	O	3079
anesthesia	NOUN	O	O	3079
but	CCONJ	O	O	3079
decreased	VERB	O	O	3079
when	SCONJ	O	O	3079
hypotension	NOUN	O	Disease	3079
was	AUX	O	O	3079
induced	VERB	O	O	3079
,	PUNCT	O	O	3079
allowing	VERB	O	O	3079
the	PRON	O	O	3079
maintenance	NOUN	O	O	3079
of	ADP	O	O	3079
renal	ADJ	O	O	3079
blood	NOUN	O	O	3079
flow	NOUN	O	O	3079
.	PUNCT	O	O	3079
We	PRON	O	O	3080
conclude	VERB	O	O	3080
that	SCONJ	O	O	3080
renal	ADJ	O	O	3080
compensatory	ADJ	O	O	3080
mechanisms	NOUN	O	O	3080
are	AUX	O	O	3080
preserved	VERB	O	O	3080
during	ADP	O	O	3080
isoflurane	NOUN	O	Chemical	3080
-	PUNCT	O	O	3080
induced	VERB	O	O	3080
hypotension	NOUN	O	Disease	3080
and	CCONJ	O	O	3080
that	SCONJ	O	O	3080
renal	ADJ	O	O	3080
function	NOUN	O	O	3080
and	CCONJ	O	O	3080
hemodynamics	NOUN	O	O	3080
quickly	ADV	O	O	3080
return	VERB	O	O	3080
to	PART	O	O	3080
normal	ADJ	O	O	3080
when	SCONJ	O	O	3080
normotension	NOUN	O	O	3080
is	AUX	O	O	3080
resumed	VERB	O	O	3080
.	PUNCT	O	O	3080
Debrisoquine	NOUN	O	Chemical	3083
phenotype	NOUN	O	O	3083
and	CCONJ	O	O	3083
the	PRON	O	O	3083
pharmacokinetics	NOUN	O	O	3083
and	CCONJ	O	O	3083
beta-2	NUM	O	O	3083
receptor	NOUN	O	O	3083
pharmacodynamics	NOUN	O	O	3083
of	ADP	O	O	3083
metoprolol	NOUN	O	Chemical	3083
and	CCONJ	O	O	3083
its	PRON	O	O	3083
enantiomers	NOUN	O	O	3083
.	PUNCT	O	O	3083
The	PRON	O	O	3084
metabolism	NOUN	O	O	3084
of	ADP	O	O	3084
the	PRON	O	O	3084
cardioselective	PROPN	O	O	3084
beta	NOUN	O	O	3084
-	PUNCT	O	O	3084
blocker	NOUN	O	O	3084
metoprolol	NOUN	O	Chemical	3084
is	AUX	O	O	3084
under	ADP	O	O	3084
genetic	ADJ	O	O	3084
control	VERB	O	O	3084
of	ADP	O	O	3084
the	PRON	O	O	3084
debrisoquine	NOUN	O	Chemical	3084
/	PUNCT	O	O	3084
sparteine	NOUN	O	Chemical	3084
type	NOUN	O	O	3084
.	PUNCT	O	O	3084
The	PRON	O	O	3085
two	NUM	O	O	3085
metabolic	ADJ	O	O	3085
phenotypes	NOUN	O	O	3085
,	PUNCT	O	O	3085
extensive	ADJ	O	O	3085
(	PUNCT	O	O	3085
EM	INTJ	O	O	3085
)	PUNCT	O	O	3085
and	CCONJ	O	O	3085
poor	ADJ	O	O	3085
metabolizers	NOUN	O	O	3085
(	PUNCT	O	O	3085
PM	PROPN	O	O	3085
)	PUNCT	O	O	3085
,	PUNCT	O	O	3085
show	VERB	O	O	3085
different	ADJ	O	O	3085
stereoselective	NOUN	O	O	3085
metabolism	NOUN	O	O	3085
,	PUNCT	O	O	3085
resulting	VERB	O	O	3085
in	ADP	O	O	3085
apparently	ADV	O	O	3085
higher	ADJ	O	O	3085
beta-1	NUM	O	O	3085
adrenoceptor	NOUN	O	O	3085
antagonistic	ADJ	O	O	3085
potency	NOUN	O	O	3085
of	ADP	O	O	3085
racemic	ADJ	O	O	3085
metoprolol	NOUN	O	Chemical	3085
in	ADP	O	O	3085
EMs	NOUN	O	O	3085
.	PUNCT	O	O	3085
We	PRON	O	O	3086
investigated	VERB	O	O	3086
if	SCONJ	O	O	3086
the	PRON	O	O	3086
latter	ADJ	O	O	3086
also	ADV	O	O	3086
applies	VERB	O	O	3086
to	PART	O	O	3086
the	PRON	O	O	3086
beta-2	NUM	O	O	3086
adrenoceptor	NOUN	O	O	3086
antagonism	NOUN	O	O	3086
by	ADP	O	O	3086
metoprolol	NOUN	O	Chemical	3086
.	PUNCT	O	O	3086
The	PRON	O	O	3087
drug	NOUN	O	O	3087
effect	VERB	O	O	3087
studied	VERB	O	O	3087
was	AUX	O	O	3087
the	PRON	O	O	3087
antagonism	NOUN	O	O	3087
by	ADP	O	O	3087
metoprolol	NOUN	O	Chemical	3087
of	ADP	O	O	3087
terbutaline	NOUN	O	Chemical	3087
-	PUNCT	O	O	3087
induced	VERB	O	O	3087
hypokalemia	PROPN	O	Disease	3087
.	PUNCT	O	O	3087
By	ADP	O	O	3088
using	VERB	O	O	3088
pharmacokinetic	VERB	O	O	3088
pharmacodynamic	ADJ	O	O	3088
modeling	VERB	O	O	3088
the	PRON	O	O	3088
pharmacodynamics	NOUN	O	O	3088
of	ADP	O	O	3088
racemic	ADJ	O	O	3088
metoprolol	NOUN	O	Chemical	3088
and	CCONJ	O	O	3088
the	PRON	O	O	3088
active	ADJ	O	O	3088
S	NOUN	O	O	3088
-	PUNCT	O	O	3088
isomer	PROPN	O	O	3088
,	PUNCT	O	O	3089
were	AUX	O	O	3089
quantitated	VERB	O	O	3089
in	ADP	O	O	3089
EMs	NOUN	O	O	3089
and	CCONJ	O	O	3089
PMs	NOUN	O	O	3089
in	ADP	O	O	3089
terms	NOUN	O	O	3089
of	ADP	O	O	3089
IC50	NOUN	O	O	3089
values	NOUN	O	O	3089
,	PUNCT	O	O	3089
representing	VERB	O	O	3089
metoprolol	NOUN	O	Chemical	3089
plasma	NOUN	O	O	3089
concentrations	NOUN	O	O	3089
resulting	VERB	O	O	3089
in	ADP	O	O	3089
half	NOUN	O	O	3089
-	PUNCT	O	O	3089
maximum	ADV	O	O	3089
receptor	NOUN	O	O	3089
occupancy	NOUN	O	O	3089
.	PUNCT	O	O	3089
Six	NUM	O	O	3090
EMs	NOUN	O	O	3090
received	VERB	O	O	3090
0.5	NUM	O	O	3090
mg	VERB	O	O	3090
of	ADP	O	O	3090
terbutaline	NOUN	O	Chemical	3090
s.c	PROPN	O	O	3090
.	PUNCT	O	O	3090
on	ADP	O	O	3091
two	NUM	O	O	3091
different	ADJ	O	O	3091
occasions	NOUN	O	O	3091
:	PUNCT	O	O	3091
1	X	O	O	3091
)	PUNCT	O	O	3091
1	X	O	O	3091
hr	NOUN	O	O	3091
after	ADP	O	O	3091
administration	NOUN	O	O	3091
of	ADP	O	O	3091
a	PRON	O	O	3091
placebo	NOUN	O	O	3091
and	CCONJ	O	O	3091
2	X	O	O	3091
)	PUNCT	O	O	3091
1	X	O	O	3091
hr	NOUN	O	O	3091
after	ADP	O	O	3091
150	NUM	O	O	3091
mg	VERB	O	O	3091
of	ADP	O	O	3091
metoprolol	NOUN	O	Chemical	3091
p.o	PROPN	O	O	3091
.	PUNCT	O	O	3091
Five	NUM	O	O	3092
PMs	NOUN	O	O	3092
were	AUX	O	O	3092
studied	VERB	O	O	3092
according	VERB	O	O	3092
to	PART	O	O	3092
the	PRON	O	O	3092
same	ADJ	O	O	3092
protocol	PROPN	O	O	3092
,	PUNCT	O	O	3092
except	SCONJ	O	O	3092
for	ADP	O	O	3092
a	PRON	O	O	3092
higher	ADJ	O	O	3092
terbutaline	NOUN	O	Chemical	3092
dose	NOUN	O	O	3092
(	PUNCT	O	O	3092
0.75	NUM	O	O	3092
mg	VERB	O	O	3092
)	PUNCT	O	O	3092
on	ADP	O	O	3092
day	NOUN	O	O	3092
2	X	O	O	3092
.	PUNCT	O	O	3092
Blood	NOUN	O	O	3093
samples	NOUN	O	O	3093
for	ADP	O	O	3093
the	PRON	O	O	3093
analysis	NOUN	O	O	3093
of	ADP	O	O	3093
plasma	NOUN	O	O	3093
potassium	NOUN	O	Chemical	3093
,	PUNCT	O	O	3093
terbutaline	NOUN	O	Chemical	3093
,	PUNCT	O	O	3093
metoprolol	NOUN	O	Chemical	3093
(	PUNCT	O	O	3093
racemic	ADJ	O	O	3093
,	PUNCT	O	O	3093
R-	PROPN	O	O	3093
and	CCONJ	O	O	3093
S	NOUN	O	O	3093
-	PUNCT	O	O	3093
isomer	PROPN	O	O	3093
)	PUNCT	O	O	3093
,	PUNCT	O	O	3093
and	CCONJ	O	O	3093
alpha	PROPN	O	O	3094
-	PUNCT	O	O	3094
hydroxymetoprolol	VERB	O	O	3094
concentrations	NOUN	O	O	3094
were	AUX	O	O	3094
taken	VERB	O	O	3094
at	ADP	O	O	3094
regular	ADJ	O	O	3094
time	NOUN	O	O	3094
intervals	NOUN	O	O	3094
,	PUNCT	O	O	3094
during	ADP	O	O	3094
8	NUM	O	O	3094
hr	NOUN	O	O	3094
after	ADP	O	O	3094
metoprolol	NOUN	O	Chemical	3094
.	PUNCT	O	O	3094
In	ADP	O	O	3095
PMs	NOUN	O	O	3095
,	PUNCT	O	O	3095
metoprolol	NOUN	O	Chemical	3095
increased	VERB	O	O	3095
the	PRON	O	O	3095
terbutaline	NOUN	O	Chemical	3095
area	NOUN	O	O	3095
under	ADP	O	O	3095
the	PRON	O	O	3095
plasma	NOUN	O	O	3095
concentration	NOUN	O	O	3095
vs.	CCONJ	O	O	3095
time	NOUN	O	O	3095
curve	NOUN	O	O	3095
(	PUNCT	O	O	3095
+	ADP	O	O	3095
67%	NOUN	O	O	3095
)	PUNCT	O	O	3095
.	PUNCT	O	O	3095
Higher	ADV	O	O	3096
metoprolol	NOUN	O	Chemical	3096
/	PUNCT	O	O	3096
alpha	PROPN	O	O	3096
-	PUNCT	O	O	3096
hydroxymetoprolol	VERB	O	O	3096
ratios	VERB	O	O	3096
in	ADP	O	O	3096
PMs	NOUN	O	O	3096
were	AUX	O	O	3096
predictive	ADJ	O	O	3096
for	ADP	O	O	3096
higher	ADJ	O	O	3096
R-/S	NOUN	O	O	3096
-	PUNCT	O	O	3096
isomer	PROPN	O	O	3096
ratios	VERB	O	O	3096
of	ADP	O	O	3096
unchanged	ADJ	O	O	3096
drug	NOUN	O	O	3096
.	PUNCT	O	O	3096
There	ADV	O	O	3097
was	AUX	O	O	3097
a	PRON	O	O	3097
difference	NOUN	O	O	3097
in	ADP	O	O	3097
metoprolol	NOUN	O	Chemical	3097
potency	NOUN	O	O	3097
with	ADP	O	O	3097
higher	ADJ	O	O	3097
racemic	ADJ	O	O	3097
metoprolol	NOUN	O	Chemical	3097
IC50	NOUN	O	O	3097
values	NOUN	O	O	3097
in	ADP	O	O	3097
PMs	NOUN	O	O	3097
(	PUNCT	O	O	3097
72	NUM	O	O	3097
+	ADP	O	O	3097
/-	PUNCT	O	O	3097
Cefotetan	PROPN	O	Chemical	3100
-	PUNCT	O	O	3100
induced	VERB	O	O	3100
immune	NOUN	O	O	3100
hemolytic anemia	NOUN	O	Disease	3100
.	PUNCT	O	O	3100
Immune	PROPN	O	O	3101
hemolytic anemia	NOUN	O	Disease	3101
due	ADJ	O	O	3101
to	PART	O	O	3101
a	PRON	O	O	3101
drug	NOUN	O	O	3101
-	PUNCT	O	O	3101
adsorption	NOUN	O	O	3101
mechanism	NOUN	O	O	3101
has	VERB	O	O	3101
been	AUX	O	O	3101
described	VERB	O	O	3101
primarily	ADV	O	O	3101
in	ADP	O	O	3101
patients	NOUN	O	O	3101
receiving	VERB	O	O	3101
penicillins	NOUN	O	Chemical	3101
and	CCONJ	O	O	3101
first	ADV	O	O	3101
-	PUNCT	O	O	3101
generation	NOUN	O	O	3101
cephalosporins	VERB	O	Chemical	3101
.	PUNCT	O	O	3101
We	PRON	O	O	3102
describe	VERB	O	O	3102
a	PRON	O	O	3102
patient	NOUN	O	O	3102
who	PRON	O	O	3102
developed	VERB	O	O	3102
anemia	NOUN	O	Disease	3102
while	SCONJ	O	O	3102
receiving	VERB	O	O	3102
intravenous	ADJ	O	O	3102
cefotetan	PROPN	O	Chemical	3102
.	PUNCT	O	O	3102
Cefotetan	PROPN	O	Chemical	3103
-	PUNCT	O	O	3103
dependent	ADJ	O	O	3103
antibodies	NOUN	O	O	3103
were	AUX	O	O	3103
detected	VERB	O	O	3103
in	ADP	O	O	3103
the	PRON	O	O	3103
patient	NOUN	O	O	3103
's	AUX	O	O	3103
serum	NOUN	O	O	3103
and	CCONJ	O	O	3103
in	ADP	O	O	3103
an	PRON	O	O	3103
eluate	ADJ	O	O	3103
prepared	VERB	O	O	3103
from	ADP	O	O	3103
his	PRON	O	O	3103
red	ADJ	O	O	3103
blood	NOUN	O	O	3103
cells	NOUN	O	O	3103
.	PUNCT	O	O	3103
The	PRON	O	O	3104
eluate	ADJ	O	O	3104
also	ADV	O	O	3104
reacted	VERB	O	O	3104
weakly	ADV	O	O	3104
with	ADP	O	O	3104
red	ADJ	O	O	3104
blood	NOUN	O	O	3104
cells	NOUN	O	O	3104
in	ADP	O	O	3104
the	PRON	O	O	3104
absence	NOUN	O	O	3104
of	ADP	O	O	3104
cefotetan	PROPN	O	Chemical	3104
,	PUNCT	O	O	3104
suggesting	VERB	O	O	3104
the	PRON	O	O	3104
concomitant	ADJ	O	O	3104
formation	NOUN	O	O	3104
of	ADP	O	O	3104
warm	ADJ	O	O	3104
-	PUNCT	O	O	3104
reactive	ADJ	O	O	3104
autoantibodies	NOUN	O	O	3104
.	PUNCT	O	O	3104
These	PRON	O	O	3105
observations	NOUN	O	O	3105
,	PUNCT	O	O	3105
in	ADP	O	O	3105
conjunction	NOUN	O	O	3105
with	ADP	O	O	3105
clinical	ADJ	O	O	3105
and	CCONJ	O	O	3105
laboratory	NOUN	O	O	3105
evidence	NOUN	O	O	3105
of	ADP	O	O	3105
extravascular	VERB	O	O	3105
hemolysis	NOUN	O	Disease	3105
,	PUNCT	O	O	3105
are	AUX	O	O	3105
consistent	ADJ	O	O	3105
with	ADP	O	O	3105
drug	NOUN	O	O	3105
-	PUNCT	O	O	3105
induced	VERB	O	O	3105
hemolytic anemia	NOUN	O	Disease	3105
,	PUNCT	O	O	3105
possibly	ADV	O	O	3105
involving	VERB	O	O	3105
both	PRON	O	O	3105
drug	NOUN	O	O	3105
-	PUNCT	O	O	3105
adsorption	NOUN	O	O	3105
and	CCONJ	O	O	3105
autoantibody	ADV	O	O	3105
formation	NOUN	O	O	3105
mechanisms	NOUN	O	O	3105
.	PUNCT	O	O	3105
This	PRON	O	O	3106
case	NOUN	O	O	3106
emphasizes	VERB	O	O	3106
the	PRON	O	O	3106
need	VERB	O	O	3106
for	ADP	O	O	3106
increased	VERB	O	O	3106
awareness	NOUN	O	O	3106
of	ADP	O	O	3106
hemolytic	ADJ	O	O	3106
reactions	NOUN	O	O	3106
to	PART	O	O	3106
all	PRON	O	O	3106
cephalosporins	VERB	O	Chemical	3106
.	PUNCT	O	O	3106
Acute	PROPN	O	O	3109
renal failure	NOUN	O	Disease	3109
subsequent	ADJ	O	O	3109
to	PART	O	O	3109
the	PRON	O	O	3109
administration	NOUN	O	O	3109
of	ADP	O	O	3109
rifampicin	VERB	O	Chemical	3109
.	PUNCT	O	O	3109
A	PRON	O	O	3110
clinical	ADJ	O	O	3110
presentation	NOUN	O	O	3110
is	AUX	O	O	3110
made	VERB	O	O	3110
of	ADP	O	O	3110
a	PRON	O	O	3110
2	X	O	O	3110
-	PUNCT	O	O	3110
3	X	O	O	3110
year	NOUN	O	O	3110
follow	VERB	O	O	3110
-	PUNCT	O	O	3110
up	ADP	O	O	3110
of	ADP	O	O	3110
six	NUM	O	O	3110
cases	NOUN	O	O	3110
of	ADP	O	O	3110
acute	ADJ	O	O	3110
renal failure	NOUN	O	Disease	3110
that	SCONJ	O	O	3110
have	VERB	O	O	3110
been	AUX	O	O	3110
reported	VERB	O	O	3110
earlier	ADV	O	O	3110
.	PUNCT	O	O	3110
The	PRON	O	O	3111
patients	NOUN	O	O	3111
had	VERB	O	O	3111
developed	VERB	O	O	3111
transient	ADJ	O	O	3111
renal failure	NOUN	O	Disease	3111
after	ADP	O	O	3111
the	PRON	O	O	3111
intermittent	ADJ	O	O	3111
administration	NOUN	O	O	3111
of	ADP	O	O	3111
rifampicin	VERB	O	Chemical	3111
.	PUNCT	O	O	3111
The	PRON	O	O	3112
stage	NOUN	O	O	3112
of	ADP	O	O	3112
olig	PROPN	O	O	3112
-	PUNCT	O	O	3112
anuria	VERB	O	Disease	3112
lasted	VERB	O	O	3112
for	ADP	O	O	3112
1	X	O	O	3112
-	PUNCT	O	O	3112
3	X	O	O	3112
weeks	NOUN	O	O	3112
,	PUNCT	O	O	3112
and	CCONJ	O	O	3112
five	NUM	O	O	3112
of	ADP	O	O	3112
the	PRON	O	O	3112
patients	NOUN	O	O	3112
were	AUX	O	O	3112
treated	VERB	O	O	3112
by	ADP	O	O	3112
hemodialysis	NOUN	O	O	3112
.	PUNCT	O	O	3112
Although	SCONJ	O	O	3113
in	ADP	O	O	3113
the	PRON	O	O	3113
acute	ADJ	O	O	3113
stage	NOUN	O	O	3113
the	PRON	O	O	3113
renal lesions	NOUN	O	Disease	3113
histologically	ADV	O	O	3113
appeared	VERB	O	O	3113
toxic	ADJ	O	O	3113
,	PUNCT	O	O	3113
evidence	NOUN	O	O	3113
suggestive	ADJ	O	O	3113
of	ADP	O	O	3113
an	PRON	O	O	3113
immunological	ADJ	O	O	3113
mechanism	NOUN	O	O	3113
can	AUX	O	O	3113
not	PART	O	O	3113
be	AUX	O	O	3113
excluded	VERB	O	O	3113
.	PUNCT	O	O	3113
Type B hepatitis	NOUN	O	Disease	3116
after	ADP	O	O	3116
needle	NOUN	O	O	3116
-	PUNCT	O	O	3116
stick	VERB	O	O	3116
exposure	NOUN	O	O	3116
:	PUNCT	O	O	3116
prevention	NOUN	O	O	3117
with	ADP	O	O	3117
hepatitis B	PROPN	O	Disease	3117
immune	NOUN	O	O	3117
globulin	NOUN	O	O	3117
.	PUNCT	O	O	3117
Hepatitis B	PROPN	O	Disease	3118
immune	NOUN	O	O	3118
globulin	NOUN	O	O	3118
(	PUNCT	O	O	3118
HBIG	PROPN	O	O	3118
)	PUNCT	O	O	3118
and	CCONJ	O	O	3118
immune	NOUN	O	O	3118
serum	NOUN	O	O	3118
globulin	NOUN	O	O	3118
(	PUNCT	O	O	3118
ISG	PROPN	O	O	3118
)	PUNCT	O	O	3118
were	AUX	O	O	3118
examined	VERB	O	O	3118
in	ADP	O	O	3118
a	PRON	O	O	3118
randomized	VERB	O	O	3118
,	PUNCT	O	O	3118
double	ADJ	O	O	3118
-	PUNCT	O	O	3118
blind	ADJ	O	Disease	3118
trial	NOUN	O	O	3118
to	PART	O	O	3118
assess	VERB	O	O	3118
their	PRON	O	O	3118
relative	ADJ	O	O	3118
efficacies	NOUN	O	O	3118
in	ADP	O	O	3118
preventing	VERB	O	O	3118
type B hepatitis	NOUN	O	Disease	3118
after	ADP	O	O	3118
needle	NOUN	O	O	3118
-	PUNCT	O	O	3118
stick	VERB	O	O	3118
exposure	NOUN	O	O	3118
to	PART	O	O	3118
hepatitis B surface antigen	NOUN	O	Chemical	3118
(	PUNCT	O	O	3118
HBsAG)-positive	NUM	O	O	3118
donors	NOUN	O	O	3118
.	PUNCT	O	O	3118
Clinical	NOUN	O	O	3119
hepatitis	NOUN	O	Disease	3119
developed	VERB	O	O	3119
in	ADP	O	O	3119
1.4%	NOUN	O	O	3119
of	ADP	O	O	3119
HBIG	PROPN	O	O	3119
and	CCONJ	O	O	3119
in	ADP	O	O	3119
5.9%	NOUN	O	O	3119
of	ADP	O	O	3119
ISG	PROPN	O	O	3119
recipients	NOUN	O	O	3119
(	PUNCT	O	O	3119
Available	ADJ	O	O	3120
donor	NOUN	O	O	3120
sera	PROPN	O	O	3120
were	AUX	O	O	3120
examined	VERB	O	O	3120
for	ADP	O	O	3120
DNA	NOUN	O	O	3120
polymerase	NOUN	O	O	3120
(	PUNCT	O	O	3120
DNAP	PROPN	O	O	3120
)	PUNCT	O	O	3120
and	CCONJ	O	O	3120
e	X	O	O	3120
antigen	PROPN	O	O	3120
and	CCONJ	O	O	3120
antibody	NOUN	O	O	3120
(	PUNCT	O	O	3120
HBeAg	PROPN	O	Chemical	3120
;	PUNCT	O	O	3120
anti	ADJ	O	O	3120
-	PUNCT	O	O	3120
HBE	PROPN	O	O	3120
)	PUNCT	O	O	3120
.	PUNCT	O	O	3120
Both	PRON	O	O	3121
DNAP	PROPN	O	O	3121
and	CCONJ	O	O	3121
HBeAg	PROPN	O	Chemical	3121
showed	VERB	O	O	3121
a	PRON	O	O	3121
highly	ADV	O	O	3121
statistically	ADV	O	O	3121
significant	ADJ	O	O	3121
correlation	NOUN	O	O	3121
with	ADP	O	O	3121
the	PRON	O	O	3121
infectivity	NOUN	O	O	3121
of	ADP	O	O	3121
HBsAg	PROPN	O	Chemical	3121
-	PUNCT	O	O	3121
positive	ADJ	O	O	3121
donors	NOUN	O	O	3121
.	PUNCT	O	O	3121
Hepatitis B	PROPN	O	Disease	3122
immune	NOUN	O	O	3122
globulin	NOUN	O	O	3122
remained	VERB	O	O	3122
significantly	ADV	O	O	3122
superior	PROPN	O	O	3122
to	PART	O	O	3122
ISG	PROPN	O	O	3122
in	ADP	O	O	3122
preventing	VERB	O	O	3122
type B hepatitis	NOUN	O	Disease	3122
even	ADV	O	O	3122
when	SCONJ	O	O	3122
the	PRON	O	O	3122
analysis	NOUN	O	O	3122
was	AUX	O	O	3122
confined	VERB	O	O	3122
to	PART	O	O	3122
these	PRON	O	O	3122
two	NUM	O	O	3122
high	ADJ	O	O	3122
-	PUNCT	O	O	3122
risk	NOUN	O	O	3122
subgroups	NOUN	O	O	3122
.	PUNCT	O	O	3122
The	PRON	O	O	3123
efficacy	NOUN	O	O	3123
of	ADP	O	O	3123
ISG	PROPN	O	O	3123
in	ADP	O	O	3123
preventing	VERB	O	O	3123
type B hepatitis	NOUN	O	Disease	3123
can	AUX	O	O	3123
not	PART	O	O	3123
be	AUX	O	O	3123
ascertained	VERB	O	O	3123
because	SCONJ	O	O	3123
a	PRON	O	O	3123
true	ADJ	O	O	3123
placebo	NOUN	O	O	3123
group	NOUN	O	O	3123
was	AUX	O	O	3123
not	PART	O	O	3123
included	VERB	O	O	3123
.	PUNCT	O	O	3123
Serotonin syndrome	NOUN	O	Disease	3126
from	ADP	O	O	3126
venlafaxine	NOUN	O	Chemical	3126
-	PUNCT	O	O	3126
tranylcypromine	NOUN	O	Chemical	3126
interaction	NOUN	O	O	3126
.	PUNCT	O	O	3126
Excessive	ADJ	O	O	3127
stimulation	NOUN	O	O	3127
of	ADP	O	O	3127
serotonin	PROPN	O	Chemical	3127
5HT1A	NUM	O	O	3127
receptors	NOUN	O	O	3127
causes	VERB	O	O	3127
a	PRON	O	O	3127
syndrome	NOUN	O	O	3127
of	ADP	O	O	3127
serotonin	PROPN	O	Chemical	3127
excess	ADJ	O	O	3127
that	SCONJ	O	O	3127
consists	VERB	O	O	3127
of	ADP	O	O	3127
shivering	VERB	O	O	3127
,	PUNCT	O	O	3127
muscle rigidity	NOUN	O	Disease	3127
,	PUNCT	O	O	3127
salivation	NOUN	O	Disease	3127
,	PUNCT	O	O	3127
confusion	NOUN	O	Disease	3127
,	PUNCT	O	O	3127
agitation	NOUN	O	Disease	3127
and	CCONJ	O	O	3127
hyperthermia	NOUN	O	Disease	3127
.	PUNCT	O	O	3127
The	PRON	O	O	3128
most	ADV	O	O	3128
common	ADJ	O	O	3128
cause	VERB	O	O	3128
of	ADP	O	O	3128
this	PRON	O	O	3128
syndrome	NOUN	O	O	3128
is	AUX	O	O	3128
an	PRON	O	O	3128
interaction	NOUN	O	O	3128
between	ADP	O	O	3128
a	PRON	O	O	3128
monoamine	NOUN	O	O	3128
oxidase	NOUN	O	O	3128
inhibitor	NOUN	O	O	3128
(	PUNCT	O	O	3128
MAOI	NOUN	O	O	3128
)	PUNCT	O	O	3128
and	CCONJ	O	O	3128
a	PRON	O	O	3128
specific	ADJ	O	O	3128
serotonin	PROPN	O	Chemical	3128
reuptake	PROPN	O	O	3128
inhibitor	NOUN	O	O	3128
.	PUNCT	O	O	3128
Venlafaxine	NOUN	O	Chemical	3129
is	AUX	O	O	3129
a	PRON	O	O	3129
new	ADJ	O	O	3129
antidepressant	NOUN	O	O	3129
agent	NOUN	O	O	3129
that	SCONJ	O	O	3129
inhibits	VERB	O	O	3129
the	PRON	O	O	3129
reuptake	PROPN	O	O	3129
of	ADP	O	O	3129
serotonin	PROPN	O	Chemical	3129
and	CCONJ	O	O	3129
norepinephrine	NOUN	O	Chemical	3129
.	PUNCT	O	O	3129
We	PRON	O	O	3130
report	VERB	O	O	3130
a	PRON	O	O	3130
venlafaxine	NOUN	O	Chemical	3130
-	PUNCT	O	O	3130
MAOI	NOUN	O	O	3130
interaction	NOUN	O	O	3130
that	SCONJ	O	O	3130
resulted	VERB	O	O	3130
in	ADP	O	O	3130
the	PRON	O	O	3130
serotonin syndrome	NOUN	O	Disease	3130
in	ADP	O	O	3130
a	PRON	O	O	3130
23-y	NOUN	O	O	3130
-	PUNCT	O	O	3130
old	ADJ	O	O	3130
male	NOUN	O	O	3130
who	PRON	O	O	3130
was	AUX	O	O	3130
taking	VERB	O	O	3130
tranylcypromine	NOUN	O	Chemical	3130
for	ADP	O	O	3130
depression	PROPN	O	Disease	3130
.	PUNCT	O	O	3130
He	PRON	O	O	3131
had	VERB	O	O	3131
been	AUX	O	O	3131
well	ADV	O	O	3131
until	ADP	O	O	3131
the	PRON	O	O	3131
morning	NOUN	O	O	3131
of	ADP	O	O	3131
presentation	NOUN	O	O	3131
when	SCONJ	O	O	3131
he	PRON	O	O	3131
took	VERB	O	O	3131
1/2	NUM	O	O	3131
tab	VERB	O	O	3131
of	ADP	O	O	3131
venlafaxine	NOUN	O	Chemical	3131
.	PUNCT	O	O	3131
Within	ADP	O	O	3132
2	X	O	O	3132
h	X	O	O	3132
he	PRON	O	O	3132
became	VERB	O	O	3132
confused	ADJ	O	O	3132
with	ADP	O	O	3132
jerking	VERB	O	O	3132
movements	NOUN	O	O	3132
of	ADP	O	O	3132
his	PRON	O	O	3132
extremities	NOUN	O	O	3132
,	PUNCT	O	O	3132
tremors	NOUN	O	Disease	3132
and	CCONJ	O	O	3132
rigidity	NOUN	O	Disease	3132
.	PUNCT	O	O	3132
He	PRON	O	O	3133
was	AUX	O	O	3133
brought	VERB	O	O	3133
directly	ADV	O	O	3133
to	PART	O	O	3133
a	PRON	O	O	3133
hospital	PROPN	O	O	3133
where	SCONJ	O	O	3133
he	PRON	O	O	3133
was	AUX	O	O	3133
found	VERB	O	O	3133
to	PART	O	O	3133
be	AUX	O	O	3133
agitated	ADJ	O	O	3133
and	CCONJ	O	O	3133
confused	ADJ	O	O	3133
with	ADP	O	O	3133
shivering	VERB	O	O	3133
,	PUNCT	O	O	3133
myoclonic jerks	NOUN	O	Disease	3133
,	PUNCT	O	O	3133
rigidity	NOUN	O	Disease	3133
,	PUNCT	O	O	3133
salivation	NOUN	O	Disease	3133
and	CCONJ	O	O	3133
diaphoresis	NOUN	O	O	3133
.	PUNCT	O	O	3133
After	ADP	O	O	3134
180	NUM	O	O	3134
mg	VERB	O	O	3134
of	ADP	O	O	3134
diazepam	NOUN	O	Chemical	3134
i.v	NOUN	O	O	3134
.	PUNCT	O	O	3134
he	PRON	O	O	3135
remained	VERB	O	O	3135
tremulous	ADJ	O	O	3135
with	ADP	O	O	3135
muscle rigidity	NOUN	O	Disease	3135
and	CCONJ	O	O	3135
clenched	VERB	O	O	3135
jaws	NOUN	O	O	3135
.	PUNCT	O	O	3135
He	PRON	O	O	3136
was	AUX	O	O	3136
intubated	VERB	O	O	3136
for	ADP	O	O	3136
airway	NOUN	O	O	3136
protection	NOUN	O	O	3136
and	CCONJ	O	O	3136
because	SCONJ	O	O	3136
of	ADP	O	O	3136
hypoventilation	NOUN	O	Disease	3136
,	PUNCT	O	O	3136
and	CCONJ	O	O	3136
was	AUX	O	O	3136
paralyzed	ADJ	O	Disease	3136
to	PART	O	O	3136
control	VERB	O	O	3136
muscle rigidity	NOUN	O	Disease	3136
.	PUNCT	O	O	3136
His	PRON	O	O	3137
subsequent	ADJ	O	O	3137
course	NOUN	O	O	3137
was	AUX	O	O	3137
remarkable	ADJ	O	O	3137
for	ADP	O	O	3137
non	ADJ	O	O	3137
-	PUNCT	O	O	3137
immune	NOUN	O	O	3137
thrombocytopenia	PROPN	O	Disease	3137
which	PRON	O	O	3137
resolved	VERB	O	O	3137
.	PUNCT	O	O	3137
The	PRON	O	O	3138
patient	NOUN	O	O	3138
's	AUX	O	O	3138
maximal	ADJ	O	O	3138
temperature	NOUN	O	O	3138
was	AUX	O	O	3138
101.2	NUM	O	O	3138
F	NOUN	O	O	3138
and	CCONJ	O	O	3138
his	PRON	O	O	3138
CPK	PROPN	O	O	3138
remained	VERB	O	O	3138
<	X	O	O	3138
500	NUM	O	O	3138
units	NOUN	O	O	3138
/	PUNCT	O	O	3138
L	NOUN	O	O	3138
with	ADP	O	O	3138
no	PRON	O	O	3138
other	ADJ	O	O	3138
evidence	NOUN	O	O	3138
of	ADP	O	O	3138
rhabdomyolysis	NOUN	O	Disease	3138
.	PUNCT	O	O	3138
This	PRON	O	O	3139
patient	NOUN	O	O	3139
survived	VERB	O	O	3139
without	ADP	O	O	3139
sequelae	ADJ	O	O	3139
due	ADJ	O	O	3139
to	PART	O	O	3139
the	PRON	O	O	3139
aggressive	ADJ	O	O	3139
sedation	NOUN	O	O	3139
and	CCONJ	O	O	3139
neuromuscular	ADJ	O	O	3139
paralysis	NOUN	O	Disease	3139
.	PUNCT	O	O	3139
Effect	VERB	O	O	3142
of	ADP	O	O	3142
nondopaminergic	ADJ	O	O	3142
drugs	NOUN	O	O	3142
on	ADP	O	O	3142
L	NOUN	O	O	3142
-	PUNCT	O	O	3142
dopa	PROPN	O	O	3142
-	PUNCT	O	O	3142
induced	VERB	O	O	3142
dyskinesias	PROPN	O	Disease	3142
in	ADP	O	O	3142
MPTP	PROPN	O	Chemical	3142
-	PUNCT	O	O	3142
treated	VERB	O	O	3142
monkeys	NOUN	O	O	3142
.	PUNCT	O	O	3142
A	PRON	O	O	3143
group	NOUN	O	O	3143
of	ADP	O	O	3143
four	NUM	O	O	3143
monkeys	NOUN	O	O	3143
was	AUX	O	O	3143
rendered	VERB	O	O	3143
parkinsonian	PROPN	O	Disease	3143
with	ADP	O	O	3143
the	PRON	O	O	3143
toxin	NOUN	O	O	3143
MPTP	PROPN	O	Chemical	3143
.	PUNCT	O	O	3143
They	PRON	O	O	3144
were	AUX	O	O	3144
then	ADV	O	O	3144
treated	VERB	O	O	3144
chronically	ADV	O	O	3144
with	ADP	O	O	3144
L	NOUN	O	O	3144
-	PUNCT	O	O	3144
DOPA	PROPN	O	O	3144
/	PUNCT	O	O	3144
benserazide	VERB	O	Chemical	3144
50/12.5	NUM	O	O	3144
mg	VERB	O	O	3144
/	PUNCT	O	O	3144
kg	VERB	O	O	3144
given	VERB	O	O	3144
orally	ADV	O	O	3144
daily	ADV	O	O	3144
for	ADP	O	O	3144
2	X	O	O	3144
months	NOUN	O	O	3144
.	PUNCT	O	O	3144
This	PRON	O	O	3145
dose	NOUN	O	O	3145
produced	VERB	O	O	3145
a	PRON	O	O	3145
striking	VERB	O	O	3145
antiparkinsonian	ADJ	O	O	3145
effect	VERB	O	O	3145
,	PUNCT	O	O	3145
but	CCONJ	O	O	3145
all	PRON	O	O	3145
animals	NOUN	O	O	3145
manifested	VERB	O	O	3145
dyskinesia	NOUN	O	Disease	3145
.	PUNCT	O	O	3145
A	PRON	O	O	3146
series	PROPN	O	O	3146
of	ADP	O	O	3146
agents	NOUN	O	O	3146
acting	VERB	O	O	3146
primarily	ADV	O	O	3146
on	ADP	O	O	3146
neurotransmitters	NOUN	O	O	3146
other	ADJ	O	O	3146
than	ADP	O	O	3146
dopamine	NOUN	O	Chemical	3146
were	AUX	O	O	3146
then	ADV	O	O	3146
tested	VERB	O	O	3146
in	ADP	O	O	3146
combination	NOUN	O	O	3146
with	ADP	O	O	3146
L	NOUN	O	O	3146
-	PUNCT	O	O	3146
DOPA	PROPN	O	O	3146
to	PART	O	O	3146
see	VERB	O	O	3146
if	SCONJ	O	O	3146
the	PRON	O	O	3146
dyskinetic	VERB	O	Disease	3146
movements	NOUN	O	O	3146
would	AUX	O	O	3146
be	AUX	O	O	3146
modified	VERB	O	O	3146
.	PUNCT	O	O	3146
Several	ADJ	O	O	3147
drugs	NOUN	O	O	3147
,	PUNCT	O	O	3147
including	VERB	O	O	3147
clonidine	NOUN	O	Chemical	3147
,	PUNCT	O	O	3147
physostigmine	NOUN	O	Chemical	3147
,	PUNCT	O	O	3147
methysergide	NOUN	O	Chemical	3147
,	PUNCT	O	O	3147
5-MDOT	NOUN	O	Chemical	3147
,	PUNCT	O	O	3147
propranolol	NOUN	O	Chemical	3147
,	PUNCT	O	O	3147
and	CCONJ	O	O	3147
MK-801	PROPN	O	Chemical	3147
,	PUNCT	O	O	3147
markedly	ADV	O	O	3147
reduced	VERB	O	O	3147
the	PRON	O	O	3147
dyskinetic	VERB	O	Disease	3147
movements	NOUN	O	O	3147
but	CCONJ	O	O	3147
at	ADP	O	O	3147
the	PRON	O	O	3147
cost	NOUN	O	O	3147
of	ADP	O	O	3147
a	PRON	O	O	3147
return	VERB	O	O	3147
of	ADP	O	O	3147
parkinsonian	PROPN	O	Disease	3147
symptomatology	NOUN	O	O	3147
.	PUNCT	O	O	3147
However	ADV	O	O	3148
,	PUNCT	O	O	3148
yohimbine	NOUN	O	Chemical	3148
and	CCONJ	O	O	3148
meperidine	NOUN	O	Chemical	3148
reduced	VERB	O	O	3148
predominantly	ADV	O	O	3148
the	PRON	O	O	3148
dyskinetic	VERB	O	Disease	3148
movements	NOUN	O	O	3148
.	PUNCT	O	O	3148
Baclofen	NOUN	O	Chemical	3149
was	AUX	O	O	3149
also	ADV	O	O	3149
useful	ADJ	O	O	3149
in	ADP	O	O	3149
one	NUM	O	O	3149
monkey	NOUN	O	O	3149
against	ADP	O	O	3149
a	PRON	O	O	3149
more	ADJ	O	O	3149
dystonic	ADJ	O	Disease	3149
form	NOUN	O	O	3149
of	ADP	O	O	3149
dyskinesia	NOUN	O	Disease	3149
.	PUNCT	O	O	3149
Atropine	NOUN	O	Chemical	3150
converted	VERB	O	O	3150
the	PRON	O	O	3150
dystonic	ADJ	O	Disease	3150
movements	NOUN	O	O	3150
into	ADP	O	O	3150
chorea	PROPN	O	Disease	3150
.	PUNCT	O	O	3150
CCNU	NOUN	O	Chemical	3153
(	PUNCT	O	O	3153
lomustine	PROPN	O	Chemical	3153
)	PUNCT	O	O	3153
toxicity	NOUN	O	Disease	3153
in	ADP	O	O	3153
dogs	NOUN	O	O	3153
:	PUNCT	O	O	3153
a	PRON	O	O	3153
retrospective	ADJ	O	O	3153
study	VERB	O	O	3153
(	PUNCT	O	O	3153
2002	NUM	O	O	3153
-	PUNCT	O	O	3153
07	NUM	O	O	3153
)	PUNCT	O	O	3153
.	PUNCT	O	O	3153
OBJECTIVE	VERB	O	O	3154
:	PUNCT	O	O	3154
To	PART	O	O	3154
describe	VERB	O	O	3154
the	PRON	O	O	3154
incidence	NOUN	O	O	3154
of	ADP	O	O	3154
haematological	NOUN	O	O	3154
,	PUNCT	O	O	3154
renal	ADJ	O	O	3154
,	PUNCT	O	O	3154
hepatic	ADJ	O	O	3154
and	CCONJ	O	O	3154
gastrointestinal toxicities	NOUN	O	Disease	3154
in	ADP	O	O	3154
tumour	NOUN	O	O	3154
-	PUNCT	O	O	3154
bearing	VERB	O	O	3154
dogs	NOUN	O	O	3154
receiving	VERB	O	O	3154
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	ADJ	O	Chemical	3154
(	PUNCT	O	O	3154
CCNU	NOUN	O	Chemical	3154
)	PUNCT	O	O	3154
.	PUNCT	O	O	3154
The	PRON	O	O	3155
medical	ADJ	O	O	3155
records	NOUN	O	O	3155
of	ADP	O	O	3155
206	NUM	O	O	3155
dogs	NOUN	O	O	3155
that	SCONJ	O	O	3155
were	AUX	O	O	3155
treated	VERB	O	O	3155
with	ADP	O	O	3155
CCNU	NOUN	O	Chemical	3155
at	ADP	O	O	3155
the	PRON	O	O	3155
Melbourne	PROPN	O	O	3155
Veterinary	NOUN	O	O	3155
Specialist	NOUN	O	O	3155
Centre	NOUN	O	O	3155
between	ADP	O	O	3155
February	PROPN	O	O	3155
2002	NUM	O	O	3155
and	CCONJ	O	O	3155
December	PROPN	O	O	3155
2007	NUM	O	O	3155
were	AUX	O	O	3155
retrospectively	ADV	O	O	3155
evaluated	VERB	O	O	3155
.	PUNCT	O	O	3155
Of	ADV	O	O	3156
the	PRON	O	O	3156
206	NUM	O	O	3156
dogs	NOUN	O	O	3156
treated	VERB	O	O	3156
with	ADP	O	O	3156
CCNU	NOUN	O	Chemical	3156
,	PUNCT	O	O	3156
185	NUM	O	O	3156
met	VERB	O	O	3156
the	PRON	O	O	3156
inclusion	NOUN	O	O	3156
criteria	NOUN	O	O	3156
for	ADP	O	O	3156
at	ADP	O	O	3156
least	ADJ	O	O	3156
one	NUM	O	O	3156
class	NOUN	O	O	3156
of	ADP	O	O	3156
toxicity	NOUN	O	Disease	3156
.	PUNCT	O	O	3156
CCNU	NOUN	O	Chemical	3157
was	AUX	O	O	3157
used	VERB	O	O	3157
most	ADV	O	O	3157
commonly	ADV	O	O	3157
in	ADP	O	O	3157
the	PRON	O	O	3157
treatment	NOUN	O	O	3157
of	ADP	O	O	3157
lymphoma	PROPN	O	Disease	3157
,	PUNCT	O	O	3157
mast cell tumour	NOUN	O	Disease	3157
,	PUNCT	O	O	3157
brain tumour	NOUN	O	Disease	3157
,	PUNCT	O	O	3157
histiocytic tumours	NOUN	O	Disease	3157
and	CCONJ	O	O	3157
epitheliotropic lymphoma	NOUN	O	Disease	3157
.	PUNCT	O	O	3157
experienced	ADJ	O	O	3158
neutropenia	ADJ	O	Disease	3158
,	PUNCT	O	O	3158
34.2%	NOUN	O	O	3158
experienced	ADJ	O	O	3158
anaemia	NOUN	O	Disease	3158
and	CCONJ	O	O	3158
14.2%	NOUN	O	O	3158
experienced	ADJ	O	O	3158
thrombocytopenia	PROPN	O	Disease	3158
.	PUNCT	O	O	3158
Gastrointestinal toxicosis	NOUN	O	Disease	3159
was	AUX	O	O	3159
detected	VERB	O	O	3159
in	ADP	O	O	3159
37.8%	NOUN	O	O	3159
of	ADP	O	O	3159
dogs	NOUN	O	O	3159
,	PUNCT	O	O	3159
the	PRON	O	O	3159
most	ADV	O	O	3159
common	ADJ	O	O	3159
sign	VERB	O	O	3159
of	ADP	O	O	3159
which	PRON	O	O	3159
was	AUX	O	O	3159
vomiting	VERB	O	Disease	3159
(	PUNCT	O	O	3159
24.3%	NOUN	O	O	3159
)	PUNCT	O	O	3159
.	PUNCT	O	O	3159
Potential	ADJ	O	O	3160
renal toxicity	NOUN	O	Disease	3160
and	CCONJ	O	O	3160
elevated	ADJ	O	O	3160
alanine	NOUN	O	Chemical	3160
transaminase	X	O	O	3160
(	PUNCT	O	O	3160
ALT	PROPN	O	O	3160
)	PUNCT	O	O	3160
The	PRON	O	O	3161
incidence	NOUN	O	O	3161
of	ADP	O	O	3161
hepatic failure	NOUN	O	Disease	3161
was	AUX	O	O	3161
1.2%	NOUN	O	O	3161
.	PUNCT	O	O	3161
CONCLUSIONS	NOUN	O	O	3162
:	PUNCT	O	O	3162
CCNU	NOUN	O	Chemical	3162
-	PUNCT	O	O	3162
associated	VERB	O	O	3162
toxicity	NOUN	O	Disease	3162
in	ADP	O	O	3162
dogs	NOUN	O	O	3162
is	AUX	O	O	3162
common	ADJ	O	O	3162
,	PUNCT	O	O	3162
but	CCONJ	O	O	3162
is	AUX	O	O	3162
usually	ADV	O	O	3162
not	PART	O	O	3162
life	NOUN	O	O	3162
threatening	VERB	O	O	3162
.	PUNCT	O	O	3162
Neuroactive	NOUN	O	O	3165
steroids	NOUN	O	Chemical	3165
protect	VERB	O	O	3165
against	ADP	O	O	3165
pilocarpine-	NOUN	O	O	3165
and	CCONJ	O	O	3165
kainic acid	NOUN	O	Chemical	3165
-	PUNCT	O	O	3165
induced	VERB	O	O	3165
limbic	PROPN	O	O	3165
seizures	NOUN	O	Disease	3165
and	CCONJ	O	O	3165
status epilepticus	VERB	O	Disease	3165
in	ADP	O	O	3165
mice	NOUN	O	O	3165
.	PUNCT	O	O	3165
Several	ADJ	O	O	3166
structurally	ADV	O	O	3166
related	ADJ	O	O	3166
metabolites	VERB	O	O	3166
of	ADP	O	O	3166
progesterone	NOUN	O	Chemical	3166
(	PUNCT	O	O	3166
3	X	O	O	3166
alpha	PROPN	O	O	3166
-	PUNCT	O	O	3166
hydroxy	X	O	O	3166
pregnane-20-ones	NOUN	O	O	3166
)	PUNCT	O	O	3166
and	CCONJ	O	O	3166
deoxycorticosterone	VERB	O	Chemical	3166
(	PUNCT	O	O	3166
3	X	O	O	3166
alpha	PROPN	O	O	3166
-	PUNCT	O	O	3166
hydroxy	X	O	O	3166
pregnane-21-diol-20-ones	NOUN	O	O	3166
)	PUNCT	O	O	3166
and	CCONJ	O	O	3166
their	PRON	O	O	3166
3	X	O	O	3166
beta	NOUN	O	O	3166
-	PUNCT	O	O	3166
epimers	NOUN	O	O	3166
were	AUX	O	O	3166
evaluated	VERB	O	O	3166
for	ADP	O	O	3166
protective	ADJ	O	O	3166
activity	NOUN	O	O	3166
against	ADP	O	O	3166
pilocarpine-	NOUN	O	O	3166
,	PUNCT	O	O	3166
kainic acid-	NUM	O	O	3166
and	CCONJ	O	O	3166
N	NUM	O	O	3166
-	PUNCT	O	O	3166
methyl	NOUN	O	O	3166
-	PUNCT	O	O	3166
D	NOUN	O	O	3166
-	PUNCT	O	O	3166
aspartate	NOUN	O	Chemical	3166
(	PUNCT	O	O	3166
NMDA)-induced	NOUN	O	O	3166
seizures	NOUN	O	Disease	3166
in	ADP	O	O	3166
mice	NOUN	O	O	3166
.	PUNCT	O	O	3166
Steroids	NOUN	O	Chemical	3167
with	ADP	O	O	3167
the	PRON	O	O	3167
3-hydroxy	NOUN	O	O	3167
group	NOUN	O	O	3167
in	ADP	O	O	3167
the	PRON	O	O	3167
alpha	PROPN	O	O	3167
-	PUNCT	O	O	3167
position	NOUN	O	O	3167
and	CCONJ	O	O	3167
5-H	NOUN	O	O	3167
in	ADP	O	O	3167
the	PRON	O	O	3167
alpha-	X	O	O	3167
or	CCONJ	O	O	3167
beta	NOUN	O	O	3167
-	PUNCT	O	O	3167
configurations	NOUN	O	O	3167
were	AUX	O	O	3167
highly	ADV	O	O	3167
effective	ADJ	O	O	3167
in	ADP	O	O	3167
protecting	VERB	O	O	3167
against	ADP	O	O	3167
pilocarpine	NOUN	O	Chemical	3167
(	PUNCT	O	O	3167
416	NUM	O	O	3167
mg	VERB	O	O	3167
/	PUNCT	O	O	3167
kg	VERB	O	O	3167
,	PUNCT	O	O	3167
s.c.)-induced	VERB	O	O	3167
limbic	PROPN	O	O	3167
motor	NOUN	O	O	3167
seizures	NOUN	O	Disease	3167
and	CCONJ	O	O	3167
status epilepticus	VERB	O	Disease	3167
(	PUNCT	O	O	3167
ED50	PROPN	O	O	3167
values	NOUN	O	O	3167
,	PUNCT	O	O	3167
7.0	X	O	O	3167
-	PUNCT	O	O	3167
18.7	NUM	O	O	3167
mg	VERB	O	O	3167
/	PUNCT	O	O	3167
kg	VERB	O	O	3167
,	PUNCT	O	O	3167
i.p	NOUN	O	O	3167
.	PUNCT	O	O	3167
)	PUNCT	O	O	3167
.	PUNCT	O	O	3167
Although	SCONJ	O	O	3168
the	PRON	O	O	3168
neuroactive	PROPN	O	O	3168
steroids	NOUN	O	Chemical	3168
were	AUX	O	O	3168
considerably	ADV	O	O	3168
less	ADV	O	O	3168
potent	ADJ	O	O	3168
than	ADP	O	O	3168
the	PRON	O	O	3168
benzodiazepine	PROPN	O	Chemical	3168
clonazepam	NOUN	O	Chemical	3168
in	ADP	O	O	3168
protecting	VERB	O	O	3168
against	ADP	O	O	3168
pilocarpine	NOUN	O	Chemical	3168
seizures	NOUN	O	Disease	3168
,	PUNCT	O	O	3168
steroids	NOUN	O	Chemical	3168
with	ADP	O	O	3168
the	PRON	O	O	3168
5	NUM	O	O	3168
alpha,3	NOUN	O	O	3168
alpha	PROPN	O	O	3168
-	PUNCT	O	O	3168
configuration	NOUN	O	O	3168
had	VERB	O	O	3168
comparable	ADJ	O	O	3168
or	CCONJ	O	O	3168
higher	ADJ	O	O	3168
protective	ADJ	O	O	3168
index	NOUN	O	O	3168
values	NOUN	O	O	3168
(	PUNCT	O	O	3168
TD50	NOUN	O	O	3168
for	ADP	O	O	3168
motor	NOUN	O	O	3168
impairment	NOUN	O	O	3168
divided	VERB	O	O	3168
by	ADP	O	O	3168
ED50	PROPN	O	O	3168
for	ADP	O	O	3168
seizure	NOUN	O	Disease	3168
protection	NOUN	O	O	3168
)	PUNCT	O	O	3168
than	ADP	O	O	3168
clonazepam	NOUN	O	Chemical	3168
,	PUNCT	O	O	3168
indicating	VERB	O	O	3168
that	SCONJ	O	O	3168
some	PRON	O	O	3168
neuroactive	PROPN	O	O	3168
steroids	NOUN	O	Chemical	3168
may	AUX	O	O	3168
have	VERB	O	O	3168
lower	ADJ	O	O	3168
relative	ADJ	O	O	3168
toxicity	NOUN	O	Disease	3168
.	PUNCT	O	O	3168
Steroids	NOUN	O	Chemical	3169
with	ADP	O	O	3169
the	PRON	O	O	3169
5	NUM	O	O	3169
alpha,3	NOUN	O	O	3169
alpha-	X	O	O	3169
or	CCONJ	O	O	3169
5	NUM	O	O	3169
beta,3	NOUN	O	O	3169
alpha	PROPN	O	O	3169
-	PUNCT	O	O	3169
configurations	NOUN	O	O	3169
also	ADV	O	O	3169
produced	VERB	O	O	3169
a	PRON	O	O	3169
dose	NOUN	O	O	3169
-	PUNCT	O	O	3169
dependent	ADJ	O	O	3169
delay	NOUN	O	O	3169
in	ADP	O	O	3169
the	PRON	O	O	3169
onset	VERB	O	O	3169
of	ADP	O	O	3169
limbic	PROPN	O	O	3169
seizures	NOUN	O	Disease	3169
induced	VERB	O	O	3169
by	ADP	O	O	3169
kainic acid	NOUN	O	Chemical	3169
(	PUNCT	O	O	3169
32	NUM	O	O	3169
mg	VERB	O	O	3169
/	PUNCT	O	O	3169
kg	VERB	O	O	3169
,	PUNCT	O	O	3169
s.c	PROPN	O	O	3169
.	PUNCT	O	O	3169
)	PUNCT	O	O	3169
,	PUNCT	O	O	3169
but	CCONJ	O	O	3169
did	VERB	O	O	3169
not	PART	O	O	3169
completely	ADV	O	O	3169
protect	VERB	O	O	3169
against	ADP	O	O	3169
the	PRON	O	O	3169
seizures	NOUN	O	Disease	3169
.	PUNCT	O	O	3169
However	ADV	O	O	3170
,	PUNCT	O	O	3170
when	SCONJ	O	O	3170
a	PRON	O	O	3170
second	ADV	O	O	3170
dose	NOUN	O	O	3170
of	ADP	O	O	3170
the	PRON	O	O	3170
steroid	NOUN	O	Chemical	3170
was	AUX	O	O	3170
administered	VERB	O	O	3170
1	X	O	O	3170
hr	NOUN	O	O	3170
after	ADP	O	O	3170
the	PRON	O	O	3170
first	ADV	O	O	3170
dose	NOUN	O	O	3170
,	PUNCT	O	O	3170
complete	VERB	O	O	3170
protection	NOUN	O	O	3170
from	ADP	O	O	3170
the	PRON	O	O	3170
kainic acid	NOUN	O	Chemical	3170
-	PUNCT	O	O	3170
induced	VERB	O	O	3170
limbic	PROPN	O	O	3170
seizures	NOUN	O	Disease	3170
and	CCONJ	O	O	3170
status epilepticus	VERB	O	Disease	3170
was	AUX	O	O	3170
obtained	VERB	O	O	3170
.	PUNCT	O	O	3170
The	PRON	O	O	3171
steroids	NOUN	O	Chemical	3171
also	ADV	O	O	3171
caused	VERB	O	O	3171
a	PRON	O	O	3171
dose	NOUN	O	O	3171
-	PUNCT	O	O	3171
dependent	ADJ	O	O	3171
delay	NOUN	O	O	3171
in	ADP	O	O	3171
NMDA	PROPN	O	Chemical	3171
(	PUNCT	O	O	3171
257	NUM	O	O	3171
mg	VERB	O	O	3171
/	PUNCT	O	O	3171
kg	VERB	O	O	3171
,	PUNCT	O	O	3171
s.c.)-induced	VERB	O	O	3171
lethality	NOUN	O	O	3171
,	PUNCT	O	O	3171
but	CCONJ	O	O	3171
did	VERB	O	O	3171
not	PART	O	O	3171
completely	ADV	O	O	3171
protect	VERB	O	O	3171
against	ADP	O	O	3171
NMDA	PROPN	O	Chemical	3171
seizures	NOUN	O	Disease	3171
or	CCONJ	O	O	3171
lethality	NOUN	O	O	3171
.	PUNCT	O	O	3171
We	PRON	O	O	3172
conclude	VERB	O	O	3172
that	SCONJ	O	O	3172
neuroactive	PROPN	O	O	3172
steroids	NOUN	O	Chemical	3172
are	AUX	O	O	3172
highly	ADV	O	O	3172
effective	ADJ	O	O	3172
in	ADP	O	O	3172
protecting	VERB	O	O	3172
against	ADP	O	O	3172
pilocarpine-	NOUN	O	O	3172
and	CCONJ	O	O	3172
kainic acid	NOUN	O	Chemical	3172
-	PUNCT	O	O	3172
induced	VERB	O	O	3172
seizures	NOUN	O	Disease	3172
and	CCONJ	O	O	3172
status epilepticus	VERB	O	Disease	3172
in	ADP	O	O	3172
mice	NOUN	O	O	3172
,	PUNCT	O	O	3172
and	CCONJ	O	O	3172
may	AUX	O	O	3172
be	AUX	O	O	3172
of	ADP	O	O	3172
utility	NOUN	O	O	3172
in	ADP	O	O	3172
the	PRON	O	O	3172
treatment	NOUN	O	O	3172
of	ADP	O	O	3172
some	PRON	O	O	3172
forms	NOUN	O	O	3172
of	ADP	O	O	3172
status epilepticus	VERB	O	Disease	3172
in	ADP	O	O	3172
humans	NOUN	O	O	3172
.	PUNCT	O	O	3172
The	PRON	O	O	3175
safety	NOUN	O	O	3175
and	CCONJ	O	O	3175
efficacy	NOUN	O	O	3175
of	ADP	O	O	3175
combination	NOUN	O	O	3175
N	NUM	O	O	3175
-	PUNCT	O	O	3175
butyl	NOUN	O	O	3175
-	PUNCT	O	O	3175
deoxynojirimycin	VERB	O	O	3175
(	PUNCT	O	O	3175
SC-48334	ADP	O	Chemical	3175
)	PUNCT	O	O	3175
and	CCONJ	O	O	3175
zidovudine	NOUN	O	Chemical	3175
in	ADP	O	O	3175
patients	NOUN	O	O	3175
with	ADP	O	O	3175
HIV-1 infection	NOUN	O	Disease	3175
and	CCONJ	O	O	3175
200	NUM	O	O	3175
-	PUNCT	O	O	3175
500	NUM	O	O	3175
CD4	PROPN	O	O	3175
cells	NOUN	O	O	3175
/	PUNCT	O	O	3175
mm3	NUM	O	O	3175
.	PUNCT	O	O	3175
We	PRON	O	O	3176
conducted	VERB	O	O	3176
a	PRON	O	O	3176
double	ADJ	O	O	3176
-	PUNCT	O	O	3176
blind	ADJ	O	Disease	3176
,	PUNCT	O	O	3176
randomized	VERB	O	O	3176
phase	NOUN	O	O	3176
II	NUM	O	O	3176
study	VERB	O	O	3176
to	PART	O	O	3176
evaluate	VERB	O	O	3176
the	PRON	O	O	3176
safety	NOUN	O	O	3176
and	CCONJ	O	O	3176
activity	NOUN	O	O	3176
of	ADP	O	O	3176
combination	NOUN	O	O	3176
therapy	NOUN	O	O	3176
with	ADP	O	O	3176
N	NUM	O	O	3176
-	PUNCT	O	O	3176
butyl	NOUN	O	O	3176
-	PUNCT	O	O	3176
deoxynojirimycin	VERB	O	O	3176
(	PUNCT	O	O	3176
SC-48334	ADP	O	Chemical	3176
)	PUNCT	O	O	3176
(	PUNCT	O	O	3176
an	PRON	O	O	3176
alpha	PROPN	O	O	3176
-	PUNCT	O	O	3176
glucosidase	VERB	O	O	3176
I	PRON	O	O	3176
inhibitor	NOUN	O	O	3176
)	PUNCT	O	O	3176
and	CCONJ	O	O	3176
zidovudine	NOUN	O	Chemical	3176
versus	ADP	O	O	3176
zidovudine	NOUN	O	Chemical	3176
alone	ADV	O	O	3176
.	PUNCT	O	O	3176
mm3	NUM	O	O	3177
who	PRON	O	O	3177
tolerated	VERB	O	O	3177
<	X	O	O	3177
or	CCONJ	O	O	3177
=	PUNCT	O	O	3177
12	NUM	O	O	3177
weeks	NOUN	O	O	3177
of	ADP	O	O	3177
prior	ADV	O	O	3177
zidovudine	NOUN	O	Chemical	3177
therapy	NOUN	O	O	3177
received	VERB	O	O	3177
SC-48334	ADP	O	Chemical	3177
(	PUNCT	O	O	3177
1000	NUM	O	O	3177
mg	VERB	O	O	3177
every	PRON	O	O	3177
8	NUM	O	O	3177
h	X	O	O	3177
)	PUNCT	O	O	3177
and	CCONJ	O	O	3177
zidovudine	NOUN	O	Chemical	3177
(	PUNCT	O	O	3177
100	NUM	O	O	3177
mg	VERB	O	O	3177
every	PRON	O	O	3177
8	NUM	O	O	3177
h	X	O	O	3177
)	PUNCT	O	O	3177
or	CCONJ	O	O	3177
zidovudine	NOUN	O	Chemical	3177
and	CCONJ	O	O	3177
placebo	NOUN	O	O	3177
.	PUNCT	O	O	3177
Sixty	NUM	O	O	3178
patients	NOUN	O	O	3178
received	VERB	O	O	3178
combination	NOUN	O	O	3178
therapy	NOUN	O	O	3178
and	CCONJ	O	O	3178
58	NUM	O	O	3178
,	PUNCT	O	O	3178
zidovudine	NOUN	O	Chemical	3178
and	CCONJ	O	O	3178
placebo	NOUN	O	O	3178
.	PUNCT	O	O	3178
Twenty	NUM	O	O	3179
-	PUNCT	O	O	3179
three	NUM	O	O	3179
patients	NOUN	O	O	3179
(	PUNCT	O	O	3179
38%	NOUN	O	O	3179
)	PUNCT	O	O	3179
and	CCONJ	O	O	3179
15	NUM	O	O	3179
(	PUNCT	O	O	3179
26%	NOUN	O	O	3179
)	PUNCT	O	O	3179
,	PUNCT	O	O	3179
in	ADP	O	O	3179
the	PRON	O	O	3179
combination	NOUN	O	O	3179
and	CCONJ	O	O	3179
zidovudine	NOUN	O	Chemical	3179
groups	NOUN	O	O	3179
,	PUNCT	O	O	3179
respectively	ADV	O	O	3179
,	PUNCT	O	O	3179
discontinued	VERB	O	O	3179
therapy	NOUN	O	O	3179
(	PUNCT	O	O	3179
p	NOUN	O	O	3179
=	PUNCT	O	O	3179
0.15	NUM	O	O	3179
)	PUNCT	O	O	3179
.	PUNCT	O	O	3179
The	PRON	O	O	3180
mean	VERB	O	O	3180
SC-48334	ADP	O	Chemical	3180
steady	ADJ	O	O	3180
-	PUNCT	O	O	3180
state	NOUN	O	O	3180
trough	NOUN	O	O	3180
level	VERB	O	O	3180
(	PUNCT	O	O	3180
4.04	NUM	O	O	3180
+	ADP	O	O	3180
/-	PUNCT	O	O	3180
0.99	NUM	O	O	3181
micrograms	NOUN	O	O	3181
/	PUNCT	O	O	3181
ml	ADP	O	O	3181
)	PUNCT	O	O	3181
was	AUX	O	O	3181
below	ADP	O	O	3181
the	PRON	O	O	3181
in	ADP	O	O	3181
vitro	X	O	O	3181
inhibitory	ADJ	O	O	3181
concentration	NOUN	O	O	3181
for	ADP	O	O	3181
human	PROPN	O	O	3181
immunodeficiency	NOUN	O	Disease	3181
virus	NOUN	O	O	3181
(	PUNCT	O	O	3181
HIV	PROPN	O	O	3181
)	PUNCT	O	O	3181
.	PUNCT	O	O	3181
/	PUNCT	O	O	3182
mm3	NUM	O	O	3182
for	ADP	O	O	3182
the	PRON	O	O	3182
combination	NOUN	O	O	3182
and	CCONJ	O	O	3182
zidovudine	NOUN	O	Chemical	3182
groups	NOUN	O	O	3182
,	PUNCT	O	O	3182
respectively	ADV	O	O	3182
(	PUNCT	O	O	3182
p	NOUN	O	O	3182
>	PUNCT	O	O	3182
0.36	NUM	O	O	3182
)	PUNCT	O	O	3182
.	PUNCT	O	O	3182
For	ADP	O	O	3183
patients	NOUN	O	O	3183
with	ADP	O	O	3183
prior	ADV	O	O	3183
zidovudine	NOUN	O	Chemical	3183
therapy	NOUN	O	O	3183
,	PUNCT	O	O	3183
the	PRON	O	O	3183
mean	VERB	O	O	3183
change	VERB	O	O	3183
in	ADP	O	O	3183
CD4	PROPN	O	O	3183
cells	NOUN	O	O	3183
in	ADP	O	O	3183
the	PRON	O	O	3183
combination	NOUN	O	O	3183
and	CCONJ	O	O	3183
zidovudine	NOUN	O	Chemical	3183
groups	NOUN	O	O	3183
was	AUX	O	O	3183
63.7	NUM	O	O	3183
cells	NOUN	O	O	3183
/	PUNCT	O	O	3183
mm3	NUM	O	O	3183
and	CCONJ	O	O	3183
4.9	NUM	O	O	3183
cells	NOUN	O	O	3183
/	PUNCT	O	O	3183
mm3	NUM	O	O	3183
at	ADP	O	O	3183
week	NOUN	O	O	3183
8	NUM	O	O	3183
and	CCONJ	O	O	3183
6.8	NUM	O	O	3183
cells	NOUN	O	O	3183
/	PUNCT	O	O	3183
mm3	NUM	O	O	3183
and	CCONJ	O	O	3183
-45.1	PROPN	O	O	3183
cells	NOUN	O	O	3183
/	PUNCT	O	O	3183
mm3	NUM	O	O	3183
at	ADP	O	O	3183
week	NOUN	O	O	3183
16	NUM	O	O	3183
,	PUNCT	O	O	3183
respectively	ADV	O	O	3183
.	PUNCT	O	O	3183
The	PRON	O	O	3184
number	NOUN	O	O	3184
of	ADP	O	O	3184
patients	NOUN	O	O	3184
with	ADP	O	O	3184
suppression	NOUN	O	O	3184
of	ADP	O	O	3184
HIV	PROPN	O	O	3184
p24	VERB	O	O	3184
antigenemia	NOUN	O	O	3184
in	ADP	O	O	3184
the	PRON	O	O	3184
combination	NOUN	O	O	3184
and	CCONJ	O	O	3184
zidovudine	NOUN	O	Chemical	3184
groups	NOUN	O	O	3184
was	AUX	O	O	3184
six	NUM	O	O	3184
(	PUNCT	O	O	3184
40%	NOUN	O	O	3184
)	PUNCT	O	O	3184
and	CCONJ	O	O	3184
two	NUM	O	O	3184
(	PUNCT	O	O	3184
11%	NOUN	O	O	3184
)	PUNCT	O	O	3184
at	ADP	O	O	3184
week	NOUN	O	O	3184
4	NUM	O	O	3184
(	PUNCT	O	O	3184
p	NOUN	O	O	3184
=	PUNCT	O	O	3184
0.10	NUM	O	O	3184
)	PUNCT	O	O	3184
and	CCONJ	O	O	3184
five	NUM	O	O	3184
(	PUNCT	O	O	3184
45%	NOUN	O	O	3184
)	PUNCT	O	O	3184
and	CCONJ	O	O	3184
two	NUM	O	O	3184
(	PUNCT	O	O	3184
14%	NOUN	O	O	3184
)	PUNCT	O	O	3184
at	ADP	O	O	3184
week	NOUN	O	O	3184
24	NUM	O	O	3184
(	PUNCT	O	O	3184
p	NOUN	O	O	3184
=	PUNCT	O	O	3184
0.08	NUM	O	O	3184
)	PUNCT	O	O	3184
,	PUNCT	O	O	3184
respectively	ADV	O	O	3184
.	PUNCT	O	O	3184
Diarrhea	PROPN	O	Disease	3185
,	PUNCT	O	O	3185
flatulence	NOUN	O	Disease	3185
,	PUNCT	O	O	3185
abdominal pain	NOUN	O	Disease	3185
,	PUNCT	O	O	3185
and	CCONJ	O	O	3185
weight loss	NOUN	O	Disease	3185
were	AUX	O	O	3185
common	ADJ	O	O	3185
for	ADP	O	O	3185
combination	NOUN	O	O	3185
recipients.(ABSTRACT	X	O	O	3185
TRUNCATED	ADJ	O	O	3185
AT	ADP	O	O	3185
250	NUM	O	O	3185
WORDS	NOUN	O	O	3185
)	PUNCT	O	O	3185
Recent	ADJ	O	O	3188
preclinical	ADJ	O	O	3188
and	CCONJ	O	O	3188
clinical	ADJ	O	O	3188
studies	NOUN	O	O	3188
with	ADP	O	O	3188
the	PRON	O	O	3188
thymidylate	PROPN	O	O	3188
synthase	NOUN	O	O	3188
inhibitor	NOUN	O	O	3188
N10-propargyl-5,8-dideazafolic acid	NOUN	O	Chemical	3188
(	PUNCT	O	O	3188
CB 3717	NUM	O	Chemical	3188
)	PUNCT	O	O	3188
.	PUNCT	O	O	3188
CB 3717	NUM	O	Chemical	3189
,	PUNCT	O	O	3189
N10-propargyl-5,8-dideazafolic acid	NOUN	O	Chemical	3189
,	PUNCT	O	O	3189
is	AUX	O	O	3189
a	PRON	O	O	3189
tight	ADJ	O	O	3189
-	PUNCT	O	O	3189
binding	VERB	O	O	3189
inhibitor	NOUN	O	O	3189
of	ADP	O	O	3189
thymidylate	PROPN	O	O	3189
synthase	NOUN	O	O	3189
(	PUNCT	O	O	3189
TS	NOUN	O	O	3189
)	PUNCT	O	O	3189
whose	DET	O	O	3189
cytotoxicity	NOUN	O	Disease	3189
is	AUX	O	O	3189
mediated	VERB	O	O	3189
solely	ADV	O	O	3189
through	ADP	O	O	3189
the	PRON	O	O	3189
inhibition	NOUN	O	O	3189
of	ADP	O	O	3189
this	PRON	O	O	3189
enzyme	NOUN	O	O	3189
.	PUNCT	O	O	3189
Recent	ADJ	O	O	3190
preclinical	ADJ	O	O	3190
studies	NOUN	O	O	3190
have	VERB	O	O	3190
focused	VERB	O	O	3190
on	ADP	O	O	3190
the	PRON	O	O	3190
intracellular	ADJ	O	O	3190
formation	NOUN	O	O	3190
of	ADP	O	O	3190
CB 3717	NUM	O	Chemical	3190
polyglutamates	NOUN	O	O	3190
.	PUNCT	O	O	3190
Following	VERB	O	O	3191
a	PRON	O	O	3191
12-hour	NOUN	O	O	3191
exposure	NOUN	O	O	3191
of	ADP	O	O	3191
L1210	NOUN	O	O	3191
cells	NOUN	O	O	3191
to	PART	O	O	3191
50	NUM	O	O	3191
microM	ADJ	O	O	3191
[	X	O	O	3191
3H]CB 3717	NUM	O	O	3191
,	PUNCT	O	O	3191
30%	NOUN	O	O	3191
of	ADP	O	O	3191
the	PRON	O	O	3191
extractable	ADJ	O	O	3191
radioactivity	NOUN	O	O	3191
could	AUX	O	O	3191
be	AUX	O	O	3191
accounted	VERB	O	O	3191
for	ADP	O	O	3191
as	ADP	O	O	3191
CB 3717	NUM	O	Chemical	3191
tetra-	NOUN	O	O	3191
and	CCONJ	O	O	3191
pentaglutamate	NOUN	O	O	3191
,	PUNCT	O	O	3191
as	ADP	O	O	3191
determined	VERB	O	O	3191
by	ADP	O	O	3191
high	ADJ	O	O	3191
-	PUNCT	O	O	3191
pressure	NOUN	O	O	3191
liquid	ADJ	O	O	3191
chromatography	NOUN	O	O	3191
(	PUNCT	O	O	3191
HPLC	PROPN	O	O	3191
)	PUNCT	O	O	3191
analyses	NOUN	O	O	3191
.	PUNCT	O	O	3191
As	ADP	O	O	3192
inhibitors	NOUN	O	O	3192
of	ADP	O	O	3192
isolated	VERB	O	O	3192
L1210	NOUN	O	O	3192
TS	NOUN	O	O	3192
,	PUNCT	O	O	3192
CB 3717	NUM	O	Chemical	3192
di-	PROPN	O	O	3192
,	PUNCT	O	O	3192
tri-	X	O	O	3192
,	PUNCT	O	O	3192
tetra-	NOUN	O	O	3192
and	CCONJ	O	O	3192
pentaglutamate	NOUN	O	O	3192
are	AUX	O	O	3192
26-	X	O	O	3192
,	PUNCT	O	O	3192
87-	X	O	O	3192
,	PUNCT	O	O	3192
119-	NUM	O	O	3192
and	CCONJ	O	O	3192
114-fold	ADV	O	O	3192
more	ADJ	O	O	3192
potent	ADJ	O	O	3192
than	ADP	O	O	3192
CB 3717	NUM	O	Chemical	3192
,	PUNCT	O	O	3192
respectively	ADV	O	O	3192
,	PUNCT	O	O	3192
and	CCONJ	O	O	3192
their	PRON	O	O	3192
formation	NOUN	O	O	3192
may	AUX	O	O	3192
,	PUNCT	O	O	3192
therefore	ADV	O	O	3192
,	PUNCT	O	O	3192
be	AUX	O	O	3192
an	PRON	O	O	3192
important	ADJ	O	O	3192
determinant	NOUN	O	O	3192
of	ADP	O	O	3192
CB 3717	NUM	O	Chemical	3192
cytotoxicity	NOUN	O	Disease	3192
.	PUNCT	O	O	3192
In	ADP	O	O	3193
early	ADV	O	O	3193
clinical	ADJ	O	O	3193
studies	NOUN	O	O	3193
with	ADP	O	O	3193
CB 3717	NUM	O	Chemical	3193
,	PUNCT	O	O	3193
activity	NOUN	O	O	3193
has	VERB	O	O	3193
been	AUX	O	O	3193
seen	VERB	O	O	3193
in	ADP	O	O	3193
breast cancer	NOUN	O	Disease	3193
,	PUNCT	O	O	3193
ovarian cancer	NOUN	O	Disease	3193
,	PUNCT	O	O	3193
hepatoma	VERB	O	Disease	3193
,	PUNCT	O	O	3193
and	CCONJ	O	O	3193
mesothelioma	NOUN	O	Disease	3193
.	PUNCT	O	O	3193
Toxicities	NOUN	O	Disease	3194
included	VERB	O	O	3194
hepatotoxicity	NOUN	O	Disease	3194
,	PUNCT	O	O	3194
malaise	NOUN	O	Disease	3194
,	PUNCT	O	O	3194
and	CCONJ	O	O	3194
dose	NOUN	O	O	3194
-	PUNCT	O	O	3194
limiting	VERB	O	O	3194
nephrotoxicity	NOUN	O	Disease	3194
.	PUNCT	O	O	3194
This	PRON	O	O	3195
latter	ADJ	O	O	3195
effect	VERB	O	O	3195
is	AUX	O	O	3195
thought	VERB	O	O	3195
to	PART	O	O	3195
be	AUX	O	O	3195
due	ADJ	O	O	3195
to	PART	O	O	3195
drug	NOUN	O	O	3195
precipitation	NOUN	O	O	3195
within	ADP	O	O	3195
the	PRON	O	O	3195
renal	ADJ	O	O	3195
tubule	NOUN	O	O	3195
as	ADP	O	O	3195
a	PRON	O	O	3195
result	VERB	O	O	3195
of	ADP	O	O	3195
the	PRON	O	O	3195
poor	ADJ	O	O	3195
solubility	NOUN	O	O	3195
of	ADP	O	O	3195
CB 3717	NUM	O	Chemical	3195
under	ADP	O	O	3195
acidic	ADJ	O	O	3195
conditions	NOUN	O	O	3195
.	PUNCT	O	O	3195
In	ADP	O	O	3196
an	PRON	O	O	3196
attempt	VERB	O	O	3196
to	PART	O	O	3196
overcome	VERB	O	O	3196
this	PRON	O	O	3196
problem	NOUN	O	O	3196
,	PUNCT	O	O	3196
a	PRON	O	O	3196
clinical	ADJ	O	O	3196
trial	NOUN	O	O	3196
of	ADP	O	O	3196
CB 3717	NUM	O	Chemical	3196
administered	VERB	O	O	3196
with	ADP	O	O	3196
alkaline	NOUN	O	O	3196
diuresis	VERB	O	O	3196
is	AUX	O	O	3196
under	ADP	O	O	3196
way	NOUN	O	O	3196
.	PUNCT	O	O	3196
Preliminary	PROPN	O	O	3197
results	VERB	O	O	3197
at	ADP	O	O	3197
400	NUM	O	O	3197
and	CCONJ	O	O	3197
500	NUM	O	O	3197
mg	VERB	O	O	3197
/	PUNCT	O	O	3197
m2	PROPN	O	O	3197
suggest	VERB	O	O	3197
that	SCONJ	O	O	3197
a	PRON	O	O	3197
reduction	NOUN	O	O	3197
in	ADP	O	O	3197
nephrotoxicity	NOUN	O	Disease	3197
may	AUX	O	O	3197
have	VERB	O	O	3197
been	AUX	O	O	3197
achieved	VERB	O	O	3197
with	ADP	O	O	3197
only	ADV	O	O	3197
1	X	O	O	3197
instance	NOUN	O	O	3197
of	ADP	O	O	3197
renal toxicity	NOUN	O	Disease	3197
in	ADP	O	O	3197
10	NUM	O	O	3197
patients	NOUN	O	O	3197
.	PUNCT	O	O	3197
Hepatotoxicity	NOUN	O	Disease	3198
and	CCONJ	O	O	3198
malaise	NOUN	O	Disease	3198
are	AUX	O	O	3198
again	ADV	O	O	3198
the	PRON	O	O	3198
most	ADV	O	O	3198
frequent	ADJ	O	O	3198
side	NOUN	O	O	3198
effects	NOUN	O	O	3198
.	PUNCT	O	O	3198
Pharmacokinetic	NOUN	O	O	3199
investigations	NOUN	O	O	3199
have	VERB	O	O	3199
shown	VERB	O	O	3199
that	SCONJ	O	O	3199
alkaline	NOUN	O	O	3199
diuresis	VERB	O	O	3199
does	VERB	O	O	3199
not	PART	O	O	3199
alter	VERB	O	O	3199
CB 3717	NUM	O	Chemical	3199
plasma	NOUN	O	O	3199
levels	NOUN	O	O	3199
or	CCONJ	O	O	3199
urinary	ADJ	O	O	3199
excretion	NOUN	O	O	3199
and	CCONJ	O	O	3199
that	SCONJ	O	O	3199
satisfactory	ADJ	O	O	3199
urinary	ADJ	O	O	3199
alkalinization	ADJ	O	O	3199
can	AUX	O	O	3199
be	AUX	O	O	3199
readily	ADV	O	O	3199
achieved	VERB	O	O	3199
.	PUNCT	O	O	3199
Ethopropazine	NOUN	O	Chemical	3202
and	CCONJ	O	O	3202
benztropine	NOUN	O	Chemical	3202
in	ADP	O	O	3202
neuroleptic	NOUN	O	O	3202
-	PUNCT	O	O	3202
induced	VERB	O	O	3202
parkinsonism	NOUN	O	Disease	3202
.	PUNCT	O	O	3202
In	ADP	O	O	3203
a	PRON	O	O	3203
12-week	NOUN	O	O	3203
controlled	VERB	O	O	3203
study	VERB	O	O	3203
ethopropazine	NOUN	O	Chemical	3203
was	AUX	O	O	3203
compared	VERB	O	O	3203
to	PART	O	O	3203
benztropine	NOUN	O	Chemical	3203
in	ADP	O	O	3203
the	PRON	O	O	3203
treatment	NOUN	O	O	3203
of	ADP	O	O	3203
parkinsonism	NOUN	O	Disease	3203
induced	VERB	O	O	3203
by	ADP	O	O	3203
fluphenazine enanthate	PROPN	O	Chemical	3203
in	ADP	O	O	3203
60	NUM	O	O	3203
schizophrenic	ADJ	O	Disease	3203
outpatients	NOUN	O	O	3203
.	PUNCT	O	O	3203
Ethopropazine	NOUN	O	Chemical	3204
and	CCONJ	O	O	3204
benztropine	NOUN	O	Chemical	3204
were	AUX	O	O	3204
found	VERB	O	O	3204
to	PART	O	O	3204
be	AUX	O	O	3204
equally	ADV	O	O	3204
effective	ADJ	O	O	3204
in	ADP	O	O	3204
controlling	VERB	O	O	3204
parkinsonian symptoms	NOUN	O	Disease	3204
and	CCONJ	O	O	3204
were	AUX	O	O	3204
as	ADP	O	O	3204
efficacious	ADJ	O	O	3204
as	ADP	O	O	3204
procyclidine	NOUN	O	Chemical	3204
,	PUNCT	O	O	3204
their	PRON	O	O	3204
previous	ADJ	O	O	3204
antiparkinsonian	ADJ	O	O	3204
drug	NOUN	O	O	3204
.	PUNCT	O	O	3204
However	ADV	O	O	3205
,	PUNCT	O	O	3205
benztropine	NOUN	O	Chemical	3205
treated	VERB	O	O	3205
patients	NOUN	O	O	3205
had	VERB	O	O	3205
a	PRON	O	O	3205
significant	ADJ	O	O	3205
increase	VERB	O	O	3205
in	ADP	O	O	3205
tardive dyskinesia	NOUN	O	Disease	3205
compared	VERB	O	O	3205
to	PART	O	O	3205
their	PRON	O	O	3205
condition	NOUN	O	O	3205
during	ADP	O	O	3205
procyclindine	NOUN	O	Chemical	3205
treatment	NOUN	O	O	3205
,	PUNCT	O	O	3205
and	CCONJ	O	O	3205
significantly	ADV	O	O	3205
more	ADJ	O	O	3205
anxiety	NOUN	O	Disease	3205
and	CCONJ	O	O	3205
depression	PROPN	O	Disease	3205
than	ADP	O	O	3205
ethopropazine	NOUN	O	Chemical	3205
treated	VERB	O	O	3205
patients	NOUN	O	O	3205
.	PUNCT	O	O	3205
This	PRON	O	O	3206
suggests	VERB	O	O	3206
that	SCONJ	O	O	3206
benztropine	NOUN	O	Chemical	3206
is	AUX	O	O	3206
not	PART	O	O	3206
the	PRON	O	O	3206
anticholinergic	ADJ	O	O	3206
drug	NOUN	O	O	3206
of	ADP	O	O	3206
choice	NOUN	O	O	3206
in	ADP	O	O	3206
the	PRON	O	O	3206
treatment	NOUN	O	O	3206
of	ADP	O	O	3206
neuroleptic	NOUN	O	O	3206
-	PUNCT	O	O	3206
induced	VERB	O	O	3206
parkinsonian symptoms	NOUN	O	Disease	3206
,	PUNCT	O	O	3206
because	SCONJ	O	O	3206
of	ADP	O	O	3206
its	PRON	O	O	3206
more	ADJ	O	O	3206
toxic	ADJ	O	O	3206
central	ADJ	O	O	3206
and	CCONJ	O	O	3206
peripheral	ADJ	O	O	3206
atropinic	ADJ	O	O	3206
effect	VERB	O	O	3206
.	PUNCT	O	O	3206
Effect	VERB	O	O	3209
of	ADP	O	O	3209
alpha	PROPN	O	O	3209
-	PUNCT	O	O	3209
tocopherol	NOUN	O	O	3209
and	CCONJ	O	O	3209
deferoxamine	PROPN	O	Chemical	3209
on	ADP	O	O	3209
methamphetamine	NOUN	O	Chemical	3209
-	PUNCT	O	O	3209
induced	VERB	O	O	3209
neurotoxicity	NOUN	O	Disease	3209
.	PUNCT	O	O	3209
Methamphetamine	NOUN	O	Chemical	3210
(	PUNCT	O	O	3211
MA)-induced	VERB	O	O	3211
dopaminergic	ADJ	O	O	3211
neurotoxicity	NOUN	O	Disease	3211
is	AUX	O	O	3211
believed	VERB	O	O	3211
to	PART	O	O	3211
be	AUX	O	O	3211
associated	VERB	O	O	3211
with	ADP	O	O	3211
the	PRON	O	O	3211
increased	VERB	O	O	3211
formation	NOUN	O	O	3211
of	ADP	O	O	3211
free	ADJ	O	O	3211
radicals	NOUN	O	O	3211
.	PUNCT	O	O	3211
This	PRON	O	O	3212
study	VERB	O	O	3212
examined	VERB	O	O	3212
the	PRON	O	O	3212
effect	VERB	O	O	3212
of	ADP	O	O	3212
alpha	PROPN	O	O	3212
-	PUNCT	O	O	3212
tocopherol	NOUN	O	O	3212
(	PUNCT	O	O	3212
alpha	PROPN	O	O	3212
-	PUNCT	O	O	3212
TC	NOUN	O	O	3212
)	PUNCT	O	O	3212
,	PUNCT	O	O	3212
a	PRON	O	O	3212
scavenger	NOUN	O	O	3212
of	ADP	O	O	3212
reactive	ADJ	O	O	3212
oxygen	NOUN	O	Chemical	3212
species	NOUN	O	O	3212
,	PUNCT	O	O	3212
and	CCONJ	O	O	3212
deferoxamine	PROPN	O	Chemical	3212
(	PUNCT	O	O	3212
DFO	PROPN	O	Chemical	3212
)	PUNCT	O	O	3212
,	PUNCT	O	O	3212
an	PRON	O	O	3212
iron	NOUN	O	Chemical	3212
chelator	NOUN	O	O	3212
,	PUNCT	O	O	3212
on	ADP	O	O	3212
the	PRON	O	O	3212
MA	PROPN	O	Chemical	3212
-	PUNCT	O	O	3212
induced	VERB	O	O	3212
neurotoxicity	NOUN	O	Disease	3212
.	PUNCT	O	O	3212
Male	NOUN	O	O	3213
rats	NOUN	O	O	3213
were	AUX	O	O	3213
treated	VERB	O	O	3213
with	ADP	O	O	3213
MA	PROPN	O	Chemical	3213
(	PUNCT	O	O	3213
10	NUM	O	O	3213
mg	VERB	O	O	3213
/	PUNCT	O	O	3213
kg	VERB	O	O	3213
,	PUNCT	O	O	3213
every	PRON	O	O	3213
2	X	O	O	3213
h	X	O	O	3213
for	ADP	O	O	3213
four	NUM	O	O	3213
injections	NOUN	O	O	3213
)	PUNCT	O	O	3213
.	PUNCT	O	O	3213
The	PRON	O	O	3214
rat	NOUN	O	O	3214
received	VERB	O	O	3214
either	ADV	O	O	3214
alpha	PROPN	O	O	3214
-	PUNCT	O	O	3214
TC	NOUN	O	O	3214
(	PUNCT	O	O	3214
20	NUM	O	O	3214
mg	VERB	O	O	3214
/	PUNCT	O	O	3214
kg	VERB	O	O	3214
)	PUNCT	O	O	3214
intraperitoneally	ADV	O	O	3214
for	ADP	O	O	3214
3	X	O	O	3214
days	NOUN	O	O	3214
and	CCONJ	O	O	3214
30	NUM	O	O	3214
min	NOUN	O	O	3214
prior	ADV	O	O	3214
to	PART	O	O	3214
MA	PROPN	O	Chemical	3214
administration	NOUN	O	O	3214
or	CCONJ	O	O	3214
DFO	PROPN	O	Chemical	3214
(	PUNCT	O	O	3214
50	NUM	O	O	3214
mg	VERB	O	O	3214
/	PUNCT	O	O	3214
kg	VERB	O	O	3214
)	PUNCT	O	O	3214
min	NOUN	O	O	3215
before	ADP	O	O	3215
MA	PROPN	O	Chemical	3215
administration	NOUN	O	O	3215
.	PUNCT	O	O	3215
The	PRON	O	O	3216
concentrations	NOUN	O	O	3216
of	ADP	O	O	3216
dopamine	NOUN	O	Chemical	3216
(	PUNCT	O	O	3216
DA	NOUN	O	Chemical	3216
)	PUNCT	O	O	3216
,	PUNCT	O	O	3216
serotonin	PROPN	O	Chemical	3216
and	CCONJ	O	O	3216
their	PRON	O	O	3216
metabolites	VERB	O	O	3216
decreased	VERB	O	O	3216
significantly	ADV	O	O	3216
after	ADP	O	O	3216
MA	PROPN	O	Chemical	3216
administration	NOUN	O	O	3216
,	PUNCT	O	O	3216
which	PRON	O	O	3216
was	AUX	O	O	3216
inhibited	VERB	O	O	3216
by	ADP	O	O	3216
the	PRON	O	O	3216
alpha	PROPN	O	O	3216
-	PUNCT	O	O	3216
TC	NOUN	O	O	3216
and	CCONJ	O	O	3216
DFO	PROPN	O	Chemical	3216
pretreatment	NOUN	O	O	3216
.	PUNCT	O	O	3216
alpha	PROPN	O	O	3217
-	PUNCT	O	O	3217
TC	NOUN	O	O	3217
and	CCONJ	O	O	3217
DFO	PROPN	O	Chemical	3217
attenuated	VERB	O	O	3217
the	PRON	O	O	3217
MA	PROPN	O	Chemical	3217
-	PUNCT	O	O	3217
induced	VERB	O	O	3217
hyperthermia	NOUN	O	Disease	3217
as	ADP	O	O	3217
well	ADV	O	O	3217
as	ADP	O	O	3217
the	PRON	O	O	3217
alterations	NOUN	O	O	3217
in	ADP	O	O	3217
the	PRON	O	O	3217
locomotor	PROPN	O	O	3217
activity	NOUN	O	O	3217
.	PUNCT	O	O	3217
The	PRON	O	O	3218
level	VERB	O	O	3218
of	ADP	O	O	3218
lipid	NOUN	O	O	3218
peroxidation	NOUN	O	O	3218
was	AUX	O	O	3218
higher	ADJ	O	O	3218
and	CCONJ	O	O	3218
the	PRON	O	O	3218
reduced glutathione	NOUN	O	Chemical	3218
concentration	NOUN	O	O	3218
was	AUX	O	O	3218
lower	ADJ	O	O	3218
in	ADP	O	O	3218
the	PRON	O	O	3218
MA	PROPN	O	Chemical	3218
-	PUNCT	O	O	3218
treated	VERB	O	O	3218
rats	NOUN	O	O	3218
.	PUNCT	O	O	3218
These	PRON	O	O	3219
changes	VERB	O	O	3219
were	AUX	O	O	3219
significantly	ADV	O	O	3219
attenuated	VERB	O	O	3219
by	ADP	O	O	3219
alpha	PROPN	O	O	3219
-	PUNCT	O	O	3219
TC	NOUN	O	O	3219
and	CCONJ	O	O	3219
DFO	PROPN	O	Chemical	3219
.	PUNCT	O	O	3219
This	PRON	O	O	3220
suggests	VERB	O	O	3220
that	SCONJ	O	O	3220
alpha	PROPN	O	O	3220
-	PUNCT	O	O	3220
TC	NOUN	O	O	3220
and	CCONJ	O	O	3220
DFO	PROPN	O	Chemical	3220
ameliorate	VERB	O	O	3220
the	PRON	O	O	3220
MA	PROPN	O	Chemical	3220
-	PUNCT	O	O	3220
induced	VERB	O	O	3220
neuronal damage	NOUN	O	Disease	3220
by	ADP	O	O	3220
decreasing	VERB	O	O	3220
the	PRON	O	O	3220
level	VERB	O	O	3220
of	ADP	O	O	3220
oxidative	NOUN	O	O	3220
stress	NOUN	O	O	3220
.	PUNCT	O	O	3220
Use	VERB	O	O	3223
of	ADP	O	O	3223
dexamethasone	NOUN	O	Chemical	3223
with	ADP	O	O	3223
mesna	NOUN	O	Chemical	3223
for	ADP	O	O	3223
the	PRON	O	O	3223
prevention	NOUN	O	O	3223
of	ADP	O	O	3223
ifosfamide	ADP	O	Chemical	3223
-	PUNCT	O	O	3223
induced	VERB	O	O	3223
hemorrhagic cystitis	NOUN	O	Disease	3223
.	PUNCT	O	O	3223
AIM	VERB	O	O	3224
:	PUNCT	O	O	3224
Hemorrhagic cystitis	NOUN	O	Disease	3224
(	PUNCT	O	O	3224
HC	NOUN	O	Disease	3224
)	PUNCT	O	O	3224
is	AUX	O	O	3224
a	PRON	O	O	3224
limiting	VERB	O	O	3224
side	NOUN	O	O	3224
-	PUNCT	O	O	3224
effect	VERB	O	O	3224
of	ADP	O	O	3224
chemotherapy	NOUN	O	O	3224
with	ADP	O	O	3224
ifosfamide	ADP	O	Chemical	3224
(	PUNCT	O	O	3224
IFS	PROPN	O	Chemical	3224
)	PUNCT	O	O	3224
.	PUNCT	O	O	3224
In	ADP	O	O	3225
the	PRON	O	O	3225
study	VERB	O	O	3225
presented	VERB	O	O	3225
here	ADV	O	O	3225
,	PUNCT	O	O	3225
we	PRON	O	O	3225
investigated	VERB	O	O	3225
the	PRON	O	O	3225
use	VERB	O	O	3225
of	ADP	O	O	3225
dexamethasone	NOUN	O	Chemical	3225
in	ADP	O	O	3225
combination	NOUN	O	O	3225
with	ADP	O	O	3225
mesna	NOUN	O	Chemical	3225
for	ADP	O	O	3225
the	PRON	O	O	3225
prevention	NOUN	O	O	3225
of	ADP	O	O	3225
IFS	PROPN	O	Chemical	3225
-	PUNCT	O	O	3225
induced	VERB	O	O	3225
HC	NOUN	O	Disease	3225
.	PUNCT	O	O	3225
Male	NOUN	O	O	3226
Wistar	PROPN	O	O	3226
rats	NOUN	O	O	3226
(	PUNCT	O	O	3226
150	NUM	O	O	3226
-	PUNCT	O	O	3226
200	NUM	O	O	3226
g	X	O	O	3226
;	PUNCT	O	O	3226
6	NUM	O	O	3226
rats	NOUN	O	O	3226
per	ADP	O	O	3226
group	NOUN	O	O	3226
)	PUNCT	O	O	3226
were	AUX	O	O	3226
treated	VERB	O	O	3226
with	ADP	O	O	3226
saline	NOUN	O	O	3226
or	CCONJ	O	O	3226
mesna	NOUN	O	Chemical	3226
5	NUM	O	O	3226
min	NOUN	O	O	3226
(	PUNCT	O	O	3226
i.p	NOUN	O	O	3226
.	PUNCT	O	O	3226
)	PUNCT	O	O	3226
before	ADP	O	O	3226
and	CCONJ	O	O	3226
2	X	O	O	3226
and	CCONJ	O	O	3226
6	NUM	O	O	3226
h	X	O	O	3226
after	ADP	O	O	3226
(	PUNCT	O	O	3226
v.o	PROPN	O	O	3226
.	PUNCT	O	O	3226
)	PUNCT	O	O	3226
administration	NOUN	O	O	3227
of	ADP	O	O	3227
IFS	PROPN	O	Chemical	3227
.	PUNCT	O	O	3227
One	NUM	O	O	3228
,	PUNCT	O	O	3228
two	NUM	O	O	3228
or	CCONJ	O	O	3228
three	NUM	O	O	3228
doses	NOUN	O	O	3228
of	ADP	O	O	3228
mesna	NOUN	O	Chemical	3228
were	AUX	O	O	3228
replaced	VERB	O	O	3228
with	ADP	O	O	3228
dexamethasone	NOUN	O	Chemical	3228
alone	ADV	O	O	3228
or	CCONJ	O	O	3228
with	ADP	O	O	3228
dexamethasone	NOUN	O	Chemical	3228
plus	CCONJ	O	O	3228
mesna	NOUN	O	Chemical	3228
.	PUNCT	O	O	3228
Cystitis	NOUN	O	Disease	3229
was	AUX	O	O	3229
evaluated	VERB	O	O	3229
24	NUM	O	O	3229
h	X	O	O	3229
after	ADP	O	O	3229
its	PRON	O	O	3229
induction	NOUN	O	O	3229
by	ADP	O	O	3229
the	PRON	O	O	3229
changes	VERB	O	O	3229
in	ADP	O	O	3229
bladder	NOUN	O	O	3229
wet	ADJ	O	O	3229
weight	NOUN	O	O	3229
and	CCONJ	O	O	3229
by	ADP	O	O	3229
macroscopic	ADJ	O	O	3229
and	CCONJ	O	O	3229
microscopic	ADJ	O	O	3229
analysis	NOUN	O	O	3229
.	PUNCT	O	O	3229
The	PRON	O	O	3230
replacement	NOUN	O	O	3230
of	ADP	O	O	3230
the	PRON	O	O	3230
last	VERB	O	O	3230
dose	NOUN	O	O	3230
or	CCONJ	O	O	3230
the	PRON	O	O	3230
last	VERB	O	O	3230
two	NUM	O	O	3230
doses	NOUN	O	O	3230
of	ADP	O	O	3230
mesna	NOUN	O	Chemical	3230
with	ADP	O	O	3230
dexamethasone	NOUN	O	Chemical	3230
reduced	VERB	O	O	3230
the	PRON	O	O	3230
increase	VERB	O	O	3230
in	ADP	O	O	3230
bladder	NOUN	O	O	3230
wet	ADJ	O	O	3230
weight	NOUN	O	O	3230
induced	VERB	O	O	3230
by	ADP	O	O	3230
IFS	PROPN	O	Chemical	3230
by	ADP	O	O	3230
84.79%	NOUN	O	O	3230
and	CCONJ	O	O	3230
89.13%	NOUN	O	O	3230
,	PUNCT	O	O	3230
respectively	ADV	O	O	3230
.	PUNCT	O	O	3230
In	ADP	O	O	3231
addition	NOUN	O	O	3231
,	PUNCT	O	O	3231
it	PRON	O	O	3231
almost	ADV	O	O	3231
abolished	VERB	O	O	3231
the	PRON	O	O	3231
macroscopic	ADJ	O	O	3231
and	CCONJ	O	O	3231
microscopic	ADJ	O	O	3231
alterations	NOUN	O	O	3231
induced	VERB	O	O	3231
by	ADP	O	O	3231
IFS	PROPN	O	Chemical	3231
.	PUNCT	O	O	3231
Moreover	ADV	O	O	3232
,	PUNCT	O	O	3232
the	PRON	O	O	3232
addition	NOUN	O	O	3232
of	ADP	O	O	3232
dexamethasone	NOUN	O	Chemical	3232
to	PART	O	O	3232
the	PRON	O	O	3232
last	VERB	O	O	3232
two	NUM	O	O	3232
doses	NOUN	O	O	3232
of	ADP	O	O	3232
mesna	NOUN	O	Chemical	3232
was	AUX	O	O	3232
more	ADJ	O	O	3232
efficient	ADJ	O	O	3232
than	ADP	O	O	3232
three	NUM	O	O	3232
doses	NOUN	O	O	3232
of	ADP	O	O	3232
mesna	NOUN	O	Chemical	3232
alone	ADV	O	O	3232
when	SCONJ	O	O	3232
evaluated	VERB	O	O	3232
microscopically	ADV	O	O	3232
.	PUNCT	O	O	3232
CONCLUSION	PROPN	O	O	3233
:	PUNCT	O	O	3233
Dexamethasone	NOUN	O	Chemical	3233
in	ADP	O	O	3233
combination	NOUN	O	O	3233
with	ADP	O	O	3233
mesna	NOUN	O	Chemical	3233
was	AUX	O	O	3233
efficient	ADJ	O	O	3233
in	ADP	O	O	3233
blocking	VERB	O	O	3233
IFS	PROPN	O	Chemical	3233
-	PUNCT	O	O	3233
induced	VERB	O	O	3233
HC	NOUN	O	Disease	3233
.	PUNCT	O	O	3233
However	ADV	O	O	3234
,	PUNCT	O	O	3234
the	PRON	O	O	3234
replacement	NOUN	O	O	3234
of	ADP	O	O	3234
last	VERB	O	O	3234
two	NUM	O	O	3234
doses	NOUN	O	O	3234
of	ADP	O	O	3234
mesna	NOUN	O	Chemical	3234
with	ADP	O	O	3234
saline	NOUN	O	O	3234
or	CCONJ	O	O	3234
all	PRON	O	O	3234
of	ADP	O	O	3234
the	PRON	O	O	3234
mesna	NOUN	O	Chemical	3234
doses	NOUN	O	O	3234
with	ADP	O	O	3234
dexamethasone	NOUN	O	Chemical	3234
did	VERB	O	O	3234
not	PART	O	O	3234
prevent	VERB	O	O	3234
HC	NOUN	O	Disease	3234
.	PUNCT	O	O	3234
Behavioral	NOUN	O	O	3237
effects	NOUN	O	O	3237
of	ADP	O	O	3237
MK-801	PROPN	O	Chemical	3237
on	ADP	O	O	3237
reserpine	NOUN	O	Chemical	3237
-	PUNCT	O	O	3237
treated	VERB	O	O	3237
mice	NOUN	O	O	3237
.	PUNCT	O	O	3237
The	PRON	O	O	3238
effects	NOUN	O	O	3238
of	ADP	O	O	3238
dizocilpine	PROPN	O	Chemical	3238
(	PUNCT	O	O	3238
MK-801	PROPN	O	Chemical	3238
)	PUNCT	O	O	3238
,	PUNCT	O	O	3238
a	PRON	O	O	3238
noncompetitive	ADJ	O	O	3238
N	NUM	O	O	3238
-	PUNCT	O	O	3238
methyl	NOUN	O	O	3238
-	PUNCT	O	O	3238
D	NOUN	O	O	3238
-	PUNCT	O	O	3238
aspartate	NOUN	O	Chemical	3238
(	PUNCT	O	O	3238
NMDA	PROPN	O	Chemical	3238
)	PUNCT	O	O	3238
receptor	NOUN	O	O	3238
antagonist	NOUN	O	O	3238
,	PUNCT	O	O	3238
were	AUX	O	O	3238
studied	VERB	O	O	3238
on	ADP	O	O	3238
dopamine	NOUN	O	Chemical	3238
-	PUNCT	O	O	3238
related	ADJ	O	O	3238
behaviors	NOUN	O	O	3238
induced	VERB	O	O	3238
by	ADP	O	O	3238
reserpine	NOUN	O	Chemical	3238
treatments	NOUN	O	O	3238
.	PUNCT	O	O	3238
This	PRON	O	O	3239
study	VERB	O	O	3239
focuses	VERB	O	O	3239
on	ADP	O	O	3239
behavioral	ADJ	O	O	3239
syndromes	NOUN	O	O	3239
that	SCONJ	O	O	3239
may	AUX	O	O	3239
used	VERB	O	O	3239
as	ADP	O	O	3239
models	NOUN	O	O	3239
for	ADP	O	O	3239
Parkinson	NOUN	O	O	3239
's	AUX	O	O	3239
disease	PROPN	O	O	3239
,	PUNCT	O	O	3239
or	CCONJ	O	O	3239
tardive dyskinesia	NOUN	O	Disease	3239
,	PUNCT	O	O	3239
and	CCONJ	O	O	3239
its	PRON	O	O	3239
response	NOUN	O	O	3239
after	ADP	O	O	3239
glutamatergic	ADJ	O	O	3239
blockage	NOUN	O	O	3239
.	PUNCT	O	O	3239
Reserpine	NOUN	O	Chemical	3240
(	PUNCT	O	O	3240
1	X	O	O	3240
mg	VERB	O	O	3240
/	PUNCT	O	O	3240
kg	VERB	O	O	3240
)	PUNCT	O	O	3240
,	PUNCT	O	O	3240
administered	VERB	O	O	3240
once	ADV	O	O	3240
every	PRON	O	O	3240
other	ADJ	O	O	3240
day	NOUN	O	O	3240
for	ADP	O	O	3240
4	NUM	O	O	3240
days	NOUN	O	O	3240
,	PUNCT	O	O	3240
produced	VERB	O	O	3240
increases	VERB	O	O	3240
in	ADP	O	O	3240
orofacial dyskinesia	NOUN	O	Disease	3240
,	PUNCT	O	O	3240
tongue	NOUN	O	O	3240
protrusion	NOUN	O	O	3240
and	CCONJ	O	O	3240
vacuous	ADJ	O	O	3240
chewing	VERB	O	O	3240
in	ADP	O	O	3240
mice	NOUN	O	O	3240
,	PUNCT	O	O	3240
which	PRON	O	O	3240
are	AUX	O	O	3240
signs	NOUN	O	O	3240
indicative	ADJ	O	O	3240
of	ADP	O	O	3240
tardive dyskinesia	NOUN	O	Disease	3240
.	PUNCT	O	O	3240
Reserpine	NOUN	O	Chemical	3241
also	ADV	O	O	3241
produced	VERB	O	O	3241
tremor	NOUN	O	Disease	3241
and	CCONJ	O	O	3241
catalepsy	VERB	O	Disease	3241
,	PUNCT	O	O	3241
which	PRON	O	O	3241
are	AUX	O	O	3241
signs	NOUN	O	O	3241
suggestive	ADJ	O	O	3241
of	ADP	O	O	3241
Parkinson	NOUN	O	O	3241
's	AUX	O	O	3241
disease	PROPN	O	O	3241
.	PUNCT	O	O	3241
MK-801	PROPN	O	Chemical	3242
(	PUNCT	O	O	3242
0.1	NUM	O	O	3242
mg	VERB	O	O	3242
/	PUNCT	O	O	3242
kg	VERB	O	O	3242
)	PUNCT	O	O	3242
,	PUNCT	O	O	3242
administered	VERB	O	O	3242
30	NUM	O	O	3242
min	NOUN	O	O	3242
before	ADP	O	O	3242
the	PRON	O	O	3242
observation	NOUN	O	O	3242
test	NOUN	O	O	3242
,	PUNCT	O	O	3242
prevented	VERB	O	O	3242
the	PRON	O	O	3242
vacuous	ADJ	O	O	3242
chewing	VERB	O	O	3242
movements	NOUN	O	O	3242
,	PUNCT	O	O	3242
tongue	NOUN	O	O	3242
protrusions	NOUN	O	O	3242
and	CCONJ	O	O	3242
catalepsy	VERB	O	Disease	3242
induced	VERB	O	O	3242
by	ADP	O	O	3242
reserpine	NOUN	O	Chemical	3242
.	PUNCT	O	O	3242
However	ADV	O	O	3243
,	PUNCT	O	O	3243
MK-801	PROPN	O	Chemical	3243
injection	NOUN	O	O	3243
produced	VERB	O	O	3243
a	PRON	O	O	3243
significant	ADJ	O	O	3243
increase	VERB	O	O	3243
of	ADP	O	O	3243
tremor	NOUN	O	Disease	3243
in	ADP	O	O	3243
reserpine	NOUN	O	Chemical	3243
-	PUNCT	O	O	3243
treated	VERB	O	O	3243
mice	NOUN	O	O	3243
.	PUNCT	O	O	3243
Reserpine	NOUN	O	Chemical	3244
(	PUNCT	O	O	3244
1	X	O	O	3244
mg	VERB	O	O	3244
/	PUNCT	O	O	3244
kg	VERB	O	O	3244
)	PUNCT	O	O	3244
,	PUNCT	O	O	3244
administered	VERB	O	O	3244
90	NUM	O	O	3244
min	NOUN	O	O	3244
before	ADP	O	O	3244
the	PRON	O	O	3244
test	NOUN	O	O	3244
and	CCONJ	O	O	3244
followed	VERB	O	O	3244
by	ADP	O	O	3244
apomophine	NOUN	O	Chemical	3244
injection	NOUN	O	O	3244
(	PUNCT	O	O	3244
0.1	NUM	O	O	3244
mg	VERB	O	O	3244
/	PUNCT	O	O	3244
kg	VERB	O	O	3244
)	PUNCT	O	O	3244
5	NUM	O	O	3245
min	NOUN	O	O	3245
before	ADP	O	O	3245
the	PRON	O	O	3245
test	NOUN	O	O	3245
,	PUNCT	O	O	3245
did	VERB	O	O	3245
not	PART	O	O	3245
produce	VERB	O	O	3245
oral dyskinesia	NOUN	O	Disease	3245
in	ADP	O	O	3245
mice	NOUN	O	O	3245
.	PUNCT	O	O	3245
On	ADP	O	O	3246
the	PRON	O	O	3246
other	ADJ	O	O	3246
hand	NOUN	O	O	3246
,	PUNCT	O	O	3246
reserpine	NOUN	O	Chemical	3246
induced	VERB	O	O	3246
increases	VERB	O	O	3246
in	ADP	O	O	3246
tremor	NOUN	O	Disease	3246
and	CCONJ	O	O	3246
catalepsy	VERB	O	Disease	3246
compared	VERB	O	O	3246
to	PART	O	O	3246
control	VERB	O	O	3246
mice	NOUN	O	O	3246
.	PUNCT	O	O	3246
MK-801	PROPN	O	Chemical	3247
(	PUNCT	O	O	3247
0.1	NUM	O	O	3247
mg	VERB	O	O	3247
/	PUNCT	O	O	3247
kg	VERB	O	O	3247
)	PUNCT	O	O	3247
administration	NOUN	O	O	3247
attenuated	VERB	O	O	3247
the	PRON	O	O	3247
catalepsy	VERB	O	Disease	3247
and	CCONJ	O	O	3247
tremor	NOUN	O	Disease	3247
induced	VERB	O	O	3247
by	ADP	O	O	3247
reserpine	NOUN	O	Chemical	3247
.	PUNCT	O	O	3247
Pretreatment	NOUN	O	O	3248
with	ADP	O	O	3248
reserpine	NOUN	O	Chemical	3248
(	PUNCT	O	O	3248
1	X	O	O	3248
mg	VERB	O	O	3248
/	PUNCT	O	O	3248
kg	VERB	O	O	3248
)	PUNCT	O	O	3248
24	NUM	O	O	3248
h	X	O	O	3249
before	ADP	O	O	3249
the	PRON	O	O	3249
observation	NOUN	O	O	3249
test	NOUN	O	O	3249
produced	VERB	O	O	3249
increases	VERB	O	O	3249
in	ADP	O	O	3249
vacuous	ADJ	O	O	3249
chewing	VERB	O	O	3249
movements	NOUN	O	O	3249
and	CCONJ	O	O	3249
tongue	NOUN	O	O	3249
protrusion	NOUN	O	O	3249
,	PUNCT	O	O	3249
as	ADP	O	O	3249
well	ADV	O	O	3249
as	ADP	O	O	3249
increases	VERB	O	O	3249
in	ADP	O	O	3249
tremor	NOUN	O	Disease	3249
and	CCONJ	O	O	3249
catalepsy	VERB	O	Disease	3249
,	PUNCT	O	O	3249
whereas	SCONJ	O	O	3249
MK-801	PROPN	O	Chemical	3249
(	PUNCT	O	O	3249
0.1	NUM	O	O	3249
mg	VERB	O	O	3249
/	PUNCT	O	O	3249
kg	VERB	O	O	3249
)	PUNCT	O	O	3249
injection	NOUN	O	O	3249
90	NUM	O	O	3249
min	NOUN	O	O	3249
before	ADP	O	O	3249
the	PRON	O	O	3249
test	NOUN	O	O	3249
reversed	VERB	O	O	3249
the	PRON	O	O	3249
effects	NOUN	O	O	3249
of	ADP	O	O	3249
reserpine	NOUN	O	Chemical	3249
.	PUNCT	O	O	3249
These	PRON	O	O	3250
results	VERB	O	O	3250
show	VERB	O	O	3250
that	SCONJ	O	O	3250
reserpine	NOUN	O	Chemical	3250
produces	VERB	O	O	3250
different	ADJ	O	O	3250
and	CCONJ	O	O	3250
abnormal movements	NOUN	O	Disease	3250
,	PUNCT	O	O	3250
which	PRON	O	O	3250
are	AUX	O	O	3250
related	ADJ	O	O	3250
to	PART	O	O	3250
dose	NOUN	O	O	3250
and	CCONJ	O	O	3250
schedule	NOUN	O	O	3250
employed	VERB	O	O	3250
and	CCONJ	O	O	3250
can	AUX	O	O	3250
be	AUX	O	O	3250
considered	VERB	O	O	3250
as	ADP	O	O	3250
parkinsonian	PROPN	O	Disease	3250
-	PUNCT	O	O	3250
like	INTJ	O	O	3250
and	CCONJ	O	O	3250
tardive dsykinesia	NOUN	O	Disease	3250
signs	NOUN	O	O	3250
.	PUNCT	O	O	3250
The	PRON	O	O	3251
glutamatergic	ADJ	O	O	3251
blockage	NOUN	O	O	3251
produced	VERB	O	O	3251
by	ADP	O	O	3251
NMDA	PROPN	O	Chemical	3251
can	AUX	O	O	3251
restore	VERB	O	O	3251
these	PRON	O	O	3251
signs	NOUN	O	O	3251
,	PUNCT	O	O	3251
such	ADJ	O	O	3251
as	ADP	O	O	3251
vacuous	ADJ	O	O	3251
chewing	VERB	O	O	3251
movements	NOUN	O	O	3251
,	PUNCT	O	O	3251
tongue	NOUN	O	O	3251
protrusions	NOUN	O	O	3251
,	PUNCT	O	O	3251
catalepsy	VERB	O	Disease	3251
and	CCONJ	O	O	3251
tremor	NOUN	O	Disease	3251
according	VERB	O	O	3251
to	PART	O	O	3251
the	PRON	O	O	3251
employed	VERB	O	O	3251
model	NOUN	O	O	3251
.	PUNCT	O	O	3251
Effect	VERB	O	O	3254
of	ADP	O	O	3254
glyceryl trinitrate	PROPN	O	Chemical	3254
on	ADP	O	O	3254
the	PRON	O	O	3254
sphincter of Oddi spasm	NOUN	O	Disease	3254
evoked	VERB	O	O	3254
by	ADP	O	O	3254
prostigmine	PROPN	O	Chemical	3254
-	PUNCT	O	O	3254
morphine	NOUN	O	Chemical	3254
administration	NOUN	O	O	3254
.	PUNCT	O	O	3254
In	ADP	O	O	3255
this	PRON	O	O	3255
study	VERB	O	O	3255
the	PRON	O	O	3255
effect	VERB	O	O	3255
of	ADP	O	O	3255
glyceryl trinitrate	PROPN	O	Chemical	3255
on	ADP	O	O	3255
the	PRON	O	O	3255
prostigmine	PROPN	O	Chemical	3255
-	PUNCT	O	O	3255
morphine	NOUN	O	Chemical	3255
-	PUNCT	O	O	3255
induced	VERB	O	O	3255
sphincter of Oddi spasm	NOUN	O	Disease	3255
was	AUX	O	O	3255
evaluated	VERB	O	O	3255
in	ADP	O	O	3255
nine	NUM	O	O	3255
female	ADJ	O	O	3255
patients	NOUN	O	O	3255
with	ADP	O	O	3255
sphincter of Oddi dyskinesia	NOUN	O	Disease	3255
.	PUNCT	O	O	3255
METHOD	NOUN	O	O	3256
:	PUNCT	O	O	3256
Sphincter of Oddi spasm	NOUN	O	Disease	3256
was	AUX	O	O	3256
induced	VERB	O	O	3256
by	ADP	O	O	3256
prostigmine	PROPN	O	Chemical	3256
-	PUNCT	O	O	3256
morphine	NOUN	O	Chemical	3256
administration	NOUN	O	O	3256
(	PUNCT	O	O	3256
0.5	NUM	O	O	3256
mg	VERB	O	O	3256
prostigmine	PROPN	O	Chemical	3256
intramuscularly	ADV	O	O	3256
and	CCONJ	O	O	3256
10	NUM	O	O	3256
mg	VERB	O	O	3256
morphine	NOUN	O	Chemical	3256
subcutaneously	ADV	O	O	3256
)	PUNCT	O	O	3256
and	CCONJ	O	O	3256
visualized	VERB	O	O	3256
by	ADP	O	O	3256
quantitative	ADJ	O	O	3256
hepatobiliary	ADJ	O	O	3256
scintigraphy	VERB	O	O	3256
.	PUNCT	O	O	3256
The	PRON	O	O	3257
entire	ADJ	O	O	3257
procedure	NOUN	O	O	3257
was	AUX	O	O	3257
repeated	VERB	O	O	3257
during	ADP	O	O	3257
glyceryl trinitrate	PROPN	O	Chemical	3257
infusion	NOUN	O	O	3257
(	PUNCT	O	O	3257
Nitrolingual	PROPN	O	Chemical	3257
1	X	O	O	3257
RESULTS	VERB	O	O	3258
:	PUNCT	O	O	3258
Prostigmine	PROPN	O	Chemical	3258
-	PUNCT	O	O	3258
morphine	NOUN	O	Chemical	3258
provocation	NOUN	O	O	3258
caused	VERB	O	O	3258
significant	ADJ	O	O	3258
increases	VERB	O	O	3258
in	ADP	O	O	3258
the	PRON	O	O	3258
time	NOUN	O	O	3258
to	PART	O	O	3258
peak	PROPN	O	O	3258
activity	NOUN	O	O	3258
(	PUNCT	O	O	3258
Tmax	NOUN	O	O	3258
)	PUNCT	O	O	3258
over	ADP	O	O	3258
the	PRON	O	O	3258
hepatic	ADJ	O	O	3258
hilum	NOUN	O	O	3258
(	PUNCT	O	O	3258
HH	NOUN	O	O	3258
:	PUNCT	O	O	3258
34.33	NUM	O	O	3258
+	ADP	O	O	3258
/-	PUNCT	O	O	3258
6.24	NUM	O	O	3259
)	PUNCT	O	O	3259
,	PUNCT	O	O	3259
indicating	VERB	O	O	3259
a	PRON	O	O	3259
complete	VERB	O	O	3259
spasm	NOUN	O	Disease	3259
at	ADP	O	O	3259
the	PRON	O	O	3259
level	VERB	O	O	3259
of	ADP	O	O	3259
the	PRON	O	O	3259
sphincter	NOUN	O	O	3259
of	ADP	O	O	3259
Oddi	NOUN	O	O	3259
.	PUNCT	O	O	3259
Glyceryl trinitrate	NOUN	O	Chemical	3260
infusion	NOUN	O	O	3260
completely	ADV	O	O	3260
normalized	VERB	O	O	3260
the	PRON	O	O	3260
prostigmine	PROPN	O	Chemical	3260
-	PUNCT	O	O	3260
morphine	NOUN	O	Chemical	3260
-	PUNCT	O	O	3260
induced	VERB	O	O	3260
alterations	NOUN	O	O	3260
in	ADP	O	O	3260
these	PRON	O	O	3260
quantitative	ADJ	O	O	3260
parameters	NOUN	O	O	3260
(	PUNCT	O	O	3260
TmaX	NOUN	O	O	3260
over	ADP	O	O	3260
the	PRON	O	O	3260
LP	NOUN	O	O	3260
:	PUNCT	O	O	3260
11.33	NUM	O	O	3260
+	ADP	O	O	3260
/-	PUNCT	O	O	3260
6.33	NUM	O	O	3261
)	PUNCT	O	O	3261
,	PUNCT	O	O	3261
suggesting	VERB	O	O	3261
an	PRON	O	O	3261
effective	ADJ	O	O	3261
sphincter	NOUN	O	O	3261
-	PUNCT	O	O	3261
relaxing	VERB	O	O	3261
effect	VERB	O	O	3261
of	ADP	O	O	3261
glyceryl trinitrate	PROPN	O	Chemical	3261
.	PUNCT	O	O	3261
CONCLUSION	PROPN	O	O	3262
:	PUNCT	O	O	3262
These	PRON	O	O	3262
results	VERB	O	O	3262
provide	VERB	O	O	3262
the	PRON	O	O	3262
first	ADV	O	O	3262
evidence	NOUN	O	O	3262
of	ADP	O	O	3262
the	PRON	O	O	3262
effectiveness	NOUN	O	O	3262
of	ADP	O	O	3262
glyceryl trinitrate	PROPN	O	Chemical	3262
on	ADP	O	O	3262
the	PRON	O	O	3262
morphine	NOUN	O	Chemical	3262
-	PUNCT	O	O	3262
induced	VERB	O	O	3262
sphincter of Oddi spasm	NOUN	O	Disease	3262
in	ADP	O	O	3262
humans	NOUN	O	O	3262
.	PUNCT	O	O	3262
Since	SCONJ	O	O	3263
glyceryl trinitrate	PROPN	O	Chemical	3263
is	AUX	O	O	3263
able	ADJ	O	O	3263
to	PART	O	O	3263
overcome	VERB	O	O	3263
even	ADV	O	O	3263
the	PRON	O	O	3263
drastic	ADJ	O	O	3263
effect	VERB	O	O	3263
of	ADP	O	O	3263
morphine	NOUN	O	Chemical	3263
,	PUNCT	O	O	3263
it	PRON	O	O	3263
might	AUX	O	O	3263
be	AUX	O	O	3263
of	ADP	O	O	3263
relevance	NOUN	O	O	3263
in	ADP	O	O	3263
the	PRON	O	O	3263
treatment	NOUN	O	O	3263
of	ADP	O	O	3263
sphincter of Oddi dyskinesia	NOUN	O	Disease	3263
.	PUNCT	O	O	3263
Effects	NOUN	O	O	3266
of	ADP	O	O	3266
acute	ADJ	O	O	3266
steroid	NOUN	O	Chemical	3266
administration	NOUN	O	O	3266
on	ADP	O	O	3266
ventilatory	ADJ	O	O	3266
and	CCONJ	O	O	3266
peripheral	ADJ	O	O	3266
muscles	NOUN	O	O	3266
in	ADP	O	O	3266
rats	NOUN	O	O	3266
.	PUNCT	O	O	3266
Occasional	ADJ	O	O	3267
case	NOUN	O	O	3267
reports	VERB	O	O	3267
have	VERB	O	O	3267
shown	VERB	O	O	3267
that	SCONJ	O	O	3267
acute	ADJ	O	O	3267
myopathy	PROPN	O	Disease	3267
may	AUX	O	O	3267
occur	VERB	O	O	3267
in	ADP	O	O	3267
patients	NOUN	O	O	3267
treated	VERB	O	O	3267
with	ADP	O	O	3267
massive	ADJ	O	O	3267
doses	NOUN	O	O	3267
of	ADP	O	O	3267
corticosteroids	NOUN	O	Chemical	3267
.	PUNCT	O	O	3267
The	PRON	O	O	3268
mechanism	NOUN	O	O	3268
of	ADP	O	O	3268
this	PRON	O	O	3268
myopathy	PROPN	O	Disease	3268
is	AUX	O	O	3268
poorly	ADV	O	O	3268
understood	VERB	O	O	3268
.	PUNCT	O	O	3268
Therefore	ADV	O	O	3269
,	PUNCT	O	O	3269
60	NUM	O	O	3269
male	NOUN	O	O	3269
rats	NOUN	O	O	3269
were	AUX	O	O	3269
randomly	ADV	O	O	3269
assigned	VERB	O	O	3269
to	PART	O	O	3269
receive	VERB	O	O	3269
daily	ADV	O	O	3269
injection	NOUN	O	O	3269
of	ADP	O	O	3269
saline	NOUN	O	O	3269
(	PUNCT	O	O	3269
C	NOUN	O	O	3269
)	PUNCT	O	O	3269
,	PUNCT	O	O	3269
methylprednisolone	NOUN	O	Chemical	3269
(	PUNCT	O	O	3269
M	NOUN	O	Chemical	3269
)	PUNCT	O	O	3269
,	PUNCT	O	O	3269
or	CCONJ	O	O	3269
triamcinolone	NOUN	O	Chemical	3269
(	PUNCT	O	O	3269
T	NOUN	O	Chemical	3269
)	PUNCT	O	O	3269
80	NUM	O	O	3269
mg	VERB	O	O	3269
/	PUNCT	O	O	3269
kg	VERB	O	O	3269
/	PUNCT	O	O	3269
d	X	O	O	3269
for	ADP	O	O	3269
5	NUM	O	O	3269
d.	PROPN	O	O	3269
Nutritional	ADJ	O	O	3269
intake	PROPN	O	O	3269
,	PUNCT	O	O	3269
measured	VERB	O	O	3269
daily	ADV	O	O	3269
in	ADP	O	O	3269
15	NUM	O	O	3269
animals	NOUN	O	O	3269
,	PUNCT	O	O	3269
showed	VERB	O	O	3269
a	PRON	O	O	3269
significant	ADJ	O	O	3269
reduction of food intake	NOUN	O	Disease	3269
in	ADP	O	O	3269
the	PRON	O	O	3269
steroid	NOUN	O	Chemical	3269
-	PUNCT	O	O	3269
treated	VERB	O	O	3269
groups	NOUN	O	O	3269
(	PUNCT	O	O	3269
-50	NUM	O	O	3269
and	CCONJ	O	O	3269
-79%	NOUN	O	O	3269
in	ADP	O	O	3269
M	NOUN	O	Chemical	3269
and	CCONJ	O	O	3269
T	NOUN	O	Chemical	3269
,	PUNCT	O	O	3269
respectively	ADV	O	O	3269
)	PUNCT	O	O	3269
.	PUNCT	O	O	3269
This	PRON	O	O	3270
was	AUX	O	O	3270
associated	VERB	O	O	3270
with	ADP	O	O	3270
a	PRON	O	O	3270
similar	ADJ	O	O	3270
loss in body weight	NOUN	O	Disease	3270
.	PUNCT	O	O	3270
Weights	NOUN	O	O	3271
of	ADP	O	O	3271
respiratory	NOUN	O	O	3271
and	CCONJ	O	O	3271
peripheral	ADJ	O	O	3271
muscles	NOUN	O	O	3271
were	AUX	O	O	3271
similarly	ADV	O	O	3271
decreased	VERB	O	O	3271
after	ADP	O	O	3271
steroid	NOUN	O	Chemical	3271
treatment	NOUN	O	O	3271
.	PUNCT	O	O	3271
174	NUM	O	O	3272
g	X	O	O	3272
/	PUNCT	O	O	3272
cm(2	X	O	O	3272
)	PUNCT	O	O	3272
)	PUNCT	O	O	3272
than	ADP	O	O	3272
in	ADP	O	O	3272
the	PRON	O	O	3272
M	NOUN	O	Chemical	3272
group	NOUN	O	O	3272
(	PUNCT	O	O	3272
837	NUM	O	O	3272
+	ADP	O	O	3272
/-	PUNCT	O	O	3272
p	NOUN	O	O	3273
<	X	O	O	3273
0.05	NUM	O	O	3273
)	PUNCT	O	O	3273
and	CCONJ	O	O	3273
the	PRON	O	O	3273
T	NOUN	O	Chemical	3273
group	NOUN	O	O	3273
(	PUNCT	O	O	3273
765	NUM	O	O	3273
+	ADP	O	O	3273
/-	PUNCT	O	O	3273
Half	ADV	O	O	3274
-	PUNCT	O	O	3274
relaxation	NOUN	O	O	3274
time	NOUN	O	O	3274
was	AUX	O	O	3274
prolonged	VERB	O	O	3274
in	ADP	O	O	3274
both	PRON	O	O	3274
steroid	NOUN	O	Chemical	3274
groups	NOUN	O	O	3274
,	PUNCT	O	O	3274
and	CCONJ	O	O	3274
time	NOUN	O	O	3274
to	PART	O	O	3274
peak	PROPN	O	O	3274
tension	NOUN	O	O	3274
was	AUX	O	O	3274
longer	ADV	O	O	3274
with	ADP	O	O	3274
M	NOUN	O	Chemical	3274
,	PUNCT	O	O	3274
whereas	SCONJ	O	O	3274
tetanic	ADJ	O	Disease	3274
tensions	NOUN	O	O	3274
were	AUX	O	O	3274
similar	ADJ	O	O	3274
.	PUNCT	O	O	3274
Steroid	NOUN	O	Chemical	3275
treatment	NOUN	O	O	3275
also	ADV	O	O	3275
induced	VERB	O	O	3275
a	PRON	O	O	3275
leftward	ADV	O	O	3275
shift	NOUN	O	O	3275
of	ADP	O	O	3275
the	PRON	O	O	3275
force	NOUN	O	O	3275
-	PUNCT	O	O	3275
frequency	NOUN	O	O	3275
curve	NOUN	O	O	3275
at	ADP	O	O	3275
25	NUM	O	O	3275
and	CCONJ	O	O	3275
50	NUM	O	O	3275
Hz	NOUN	O	O	3275
when	SCONJ	O	O	3275
compared	VERB	O	O	3275
with	ADP	O	O	3275
saline	NOUN	O	O	3275
treatment	NOUN	O	O	3275
(	PUNCT	O	O	3275
p	NOUN	O	O	3275
<	X	O	O	3275
0.05	NUM	O	O	3275
)	PUNCT	O	O	3275
.	PUNCT	O	O	3275
ATPase	X	O	O	3276
staining	VERB	O	O	3276
of	ADP	O	O	3276
the	PRON	O	O	3276
diaphragm	NOUN	O	O	3276
,	PUNCT	O	O	3276
scalenus	ADP	O	O	3276
medius	NOUN	O	O	3276
,	PUNCT	O	O	3276
and	CCONJ	O	O	3276
gastrocnemius	NOUN	O	O	3276
showed	VERB	O	O	3276
type	NOUN	O	O	3276
IIb	PROPN	O	O	3276
fiber	PROPN	O	O	3276
atrophy	NOUN	O	Disease	3276
in	ADP	O	O	3276
the	PRON	O	O	3276
steroid	NOUN	O	Chemical	3276
groups	NOUN	O	O	3276
and	CCONJ	O	O	3276
also	ADV	O	O	3276
diaphragmatic	ADJ	O	O	3276
type	NOUN	O	O	3276
IIa	NOUN	O	O	3276
atrophy	NOUN	O	Disease	3276
with	ADP	O	O	3276
T	NOUN	O	Chemical	3276
,	PUNCT	O	O	3276
whereas	SCONJ	O	O	3276
histologic	ADJ	O	O	3276
examinations	NOUN	O	O	3276
revealed	VERB	O	O	3276
a	PRON	O	O	3276
normal	ADJ	O	O	3276
muscular	ADJ	O	O	3276
pattern	NOUN	O	O	3276
with	ADP	O	O	3276
absence	NOUN	O	O	3276
of	ADP	O	O	3276
necrosis	NOUN	O	Disease	3276
.	PUNCT	O	O	3276
Finally	ADV	O	O	3277
,	PUNCT	O	O	3277
a	PRON	O	O	3277
pair	ADJ	O	O	3277
-	PUNCT	O	O	3277
fed	VERB	O	O	3277
(	PUNCT	O	O	3277
PF	PROPN	O	O	3277
)	PUNCT	O	O	3277
study	VERB	O	O	3277
,	PUNCT	O	O	3277
performed	VERB	O	O	3277
in	ADP	O	O	3277
18	NUM	O	O	3277
rats	NOUN	O	O	3277
(	PUNCT	O	O	3277
C	NOUN	O	O	3277
,	PUNCT	O	O	3277
T	NOUN	O	Chemical	3277
,	PUNCT	O	O	3277
and	CCONJ	O	O	3277
PF	PROPN	O	O	3277
)	PUNCT	O	O	3277
,	PUNCT	O	O	3277
showed	VERB	O	O	3277
that	SCONJ	O	O	3277
muscle atrophy	NOUN	O	Disease	3277
was	AUX	O	O	3277
considerably	ADV	O	O	3277
less	ADV	O	O	3277
pronounced	VERB	O	O	3277
in	ADP	O	O	3277
PF	PROPN	O	O	3277
animals	NOUN	O	O	3277
than	ADP	O	O	3277
in	ADP	O	O	3277
T	NOUN	O	Chemical	3277
-	PUNCT	O	O	3277
treated	VERB	O	O	3277
animals	NOUN	O	O	3277
.	PUNCT	O	O	3277
We	PRON	O	O	3278
conclude	VERB	O	O	3278
that	SCONJ	O	O	3278
(	PUNCT	O	O	3278
1	X	O	O	3278
)	PUNCT	O	O	3278
short	ADJ	O	O	3278
-	PUNCT	O	O	3278
term	NOUN	O	O	3278
treatment	NOUN	O	O	3278
with	ADP	O	O	3278
massive	ADJ	O	O	3278
doses	NOUN	O	O	3278
of	ADP	O	O	3278
steroids	NOUN	O	Chemical	3278
induced	VERB	O	O	3278
severe	ADJ	O	O	3278
respiratory	NOUN	O	O	3278
and	CCONJ	O	O	3278
limb	NOUN	O	O	3278
muscle	NOUN	O	O	3278
wasting	VERB	O	O	3278
;	PUNCT	O	O	3278
(	PUNCT	O	O	3278
2	X	O	O	3278
)	PUNCT	O	O	3278
both	PRON	O	O	3278
types	NOUN	O	O	3278
of	ADP	O	O	3278
steroids	NOUN	O	Chemical	3278
induced	VERB	O	O	3278
predominantly	ADV	O	O	3278
type	NOUN	O	O	3278
IIb	PROPN	O	O	3278
atrophy	NOUN	O	Disease	3278
,	PUNCT	O	O	3278
resulting	VERB	O	O	3278
in	ADP	O	O	3278
the	PRON	O	O	3278
expected	VERB	O	O	3278
alterations	NOUN	O	O	3278
in	ADP	O	O	3278
diaphragm	NOUN	O	O	3278
contractile	ADJ	O	O	3278
properties	NOUN	O	O	3278
;	PUNCT	O	O	3278
(	PUNCT	O	O	3278
3	X	O	O	3278
)	PUNCT	O	O	3278
neither	ADV	O	O	3278
steroid	NOUN	O	Chemical	3278
caused	VERB	O	O	3278
muscle	NOUN	O	O	3278
necrosis	NOUN	O	Disease	3278
;	PUNCT	O	O	3278
(	PUNCT	O	O	3278
4	NUM	O	O	3278
)	PUNCT	O	O	3278
type	NOUN	O	O	3278
IIb	PROPN	O	O	3278
atrophy	NOUN	O	Disease	3278
was	AUX	O	O	3278
not	PART	O	O	3278
caused	VERB	O	O	3278
by	ADP	O	O	3278
acute	ADJ	O	O	3278
nutritional	ADJ	O	O	3278
deprivation	NOUN	O	O	3278
alone	ADV	O	O	3278
.	PUNCT	O	O	3278
Refractory	NOUN	O	O	3281
cardiogenic shock	NOUN	O	Disease	3281
and	CCONJ	O	O	3281
complete	VERB	O	O	3281
heart block	NOUN	O	Disease	3281
after	ADP	O	O	3281
verapamil	PROPN	O	Chemical	3281
SR	PROPN	O	O	3281
and	CCONJ	O	O	3281
metoprolol	NOUN	O	Chemical	3281
treatment	NOUN	O	O	3281
.	PUNCT	O	O	3281
A	PRON	O	O	3282
seventy	NUM	O	O	3282
-	PUNCT	O	O	3282
eight	NUM	O	O	3282
-	PUNCT	O	O	3282
year	NOUN	O	O	3282
-	PUNCT	O	O	3282
old	ADJ	O	O	3282
woman	NOUN	O	O	3282
presented	VERB	O	O	3282
with	ADP	O	O	3282
complete	VERB	O	O	3282
heart block	NOUN	O	Disease	3282
and	CCONJ	O	O	3282
refractory	ADJ	O	O	3282
hypotension	NOUN	O	Disease	3282
two	NUM	O	O	3282
days	NOUN	O	O	3282
after	ADP	O	O	3282
a	PRON	O	O	3282
therapeutic	ADJ	O	O	3282
dose	NOUN	O	O	3282
of	ADP	O	O	3282
sustained	VERB	O	O	3282
-	PUNCT	O	O	3282
release	NOUN	O	O	3282
verapamil	PROPN	O	Chemical	3282
with	ADP	O	O	3282
concomitant	ADJ	O	O	3282
use	VERB	O	O	3282
of	ADP	O	O	3282
metoprolol	NOUN	O	Chemical	3282
.	PUNCT	O	O	3282
The	PRON	O	O	3283
patient	NOUN	O	O	3283
continued	VERB	O	O	3283
to	PART	O	O	3283
remain	VERB	O	O	3283
hypotensive	ADJ	O	Disease	3283
with	ADP	O	O	3283
complete	VERB	O	O	3283
heart block	NOUN	O	Disease	3283
,	PUNCT	O	O	3283
even	ADV	O	O	3283
with	ADP	O	O	3283
multiple	ADJ	O	O	3283
uses	VERB	O	O	3283
of	ADP	O	O	3283
intravenous	ADJ	O	O	3283
atropine	NOUN	O	Chemical	3283
as	ADP	O	O	3283
well	ADV	O	O	3283
as	ADP	O	O	3283
high	ADJ	O	O	3283
doses	NOUN	O	O	3283
of	ADP	O	O	3283
pressor	ADJ	O	O	3283
agents	NOUN	O	O	3283
such	ADJ	O	O	3283
as	ADP	O	O	3283
dopamine	NOUN	O	Chemical	3283
and	CCONJ	O	O	3283
dobutamine	NOUN	O	Chemical	3283
.	PUNCT	O	O	3283
However	ADV	O	O	3284
,	PUNCT	O	O	3284
shortly	ADV	O	O	3284
after	ADP	O	O	3284
the	PRON	O	O	3284
use	VERB	O	O	3284
of	ADP	O	O	3284
intravenous	ADJ	O	O	3284
calcium chloride	NOUN	O	Chemical	3284
,	PUNCT	O	O	3284
the	PRON	O	O	3284
refractory	ADJ	O	O	3284
hypotension	NOUN	O	Disease	3284
and	CCONJ	O	O	3284
complete	VERB	O	O	3284
heart block	NOUN	O	Disease	3284
resolved	VERB	O	O	3284
.	PUNCT	O	O	3284
A	PRON	O	O	3287
phase	NOUN	O	O	3287
I	PRON	O	O	3287
clinical	ADJ	O	O	3287
study	VERB	O	O	3287
of	ADP	O	O	3287
the	PRON	O	O	3287
antipurine	ADJ	O	Chemical	3287
antifolate	PROPN	O	O	3287
lometrexol	VERB	O	Chemical	3287
(	PUNCT	O	O	3287
DDATHF	PROPN	O	Chemical	3287
)	PUNCT	O	O	3287
given	VERB	O	O	3287
with	ADP	O	O	3287
oral	ADJ	O	O	3287
folic acid	NOUN	O	Chemical	3287
.	PUNCT	O	O	3287
Lometrexol	NOUN	O	Chemical	3288
is	AUX	O	O	3288
an	PRON	O	O	3288
antifolate	PROPN	O	O	3288
which	PRON	O	O	3288
inhibits	VERB	O	O	3288
glycinamide ribonucleotide	NOUN	O	Chemical	3288
formyltransferase	NOUN	O	O	3288
(	PUNCT	O	O	3288
GARFT	PROPN	O	O	3288
)	PUNCT	O	O	3288
,	PUNCT	O	O	3288
an	PRON	O	O	3288
enzyme	NOUN	O	O	3288
essential	ADJ	O	O	3288
for	ADP	O	O	3288
de	VERB	O	O	3288
novo	PROPN	O	O	3288
purine	NOUN	O	Chemical	3288
synthesis	NOUN	O	O	3288
.	PUNCT	O	O	3288
Extensive	PROPN	O	O	3289
experimental	ADJ	O	O	3289
and	CCONJ	O	O	3289
limited	VERB	O	O	3289
clinical	ADJ	O	O	3289
data	NOUN	O	O	3289
have	VERB	O	O	3289
shown	VERB	O	O	3289
that	SCONJ	O	O	3289
lometrexol	VERB	O	Chemical	3289
has	VERB	O	O	3289
activity	NOUN	O	O	3289
against	ADP	O	O	3289
tumours	NOUN	O	Disease	3289
which	PRON	O	O	3289
are	AUX	O	O	3289
refractory	ADJ	O	O	3289
to	PART	O	O	3289
other	ADJ	O	O	3289
drugs	NOUN	O	O	3289
,	PUNCT	O	O	3289
notably	ADV	O	O	3289
methotrexate	CCONJ	O	Chemical	3289
.	PUNCT	O	O	3289
However	ADV	O	O	3290
,	PUNCT	O	O	3290
the	PRON	O	O	3290
initial	ADJ	O	O	3290
clinical	ADJ	O	O	3290
development	NOUN	O	O	3290
of	ADP	O	O	3290
lometrexol	VERB	O	Chemical	3290
was	AUX	O	O	3290
curtailed	VERB	O	O	3290
because	SCONJ	O	O	3290
of	ADP	O	O	3290
severe	ADJ	O	O	3290
and	CCONJ	O	O	3290
cumulative	ADJ	O	O	3290
antiproliferative	PROPN	O	O	3290
toxicities	NOUN	O	Disease	3290
.	PUNCT	O	O	3290
Preclinical	PROPN	O	O	3291
murine	ADJ	O	O	3291
studies	NOUN	O	O	3291
demonstrated	VERB	O	O	3291
that	SCONJ	O	O	3291
the	PRON	O	O	3291
toxicity	NOUN	O	Disease	3291
of	ADP	O	O	3291
lometrexol	VERB	O	Chemical	3291
can	AUX	O	O	3291
be	AUX	O	O	3291
prevented	VERB	O	O	3291
by	ADP	O	O	3291
low	ADJ	O	O	3291
dose	NOUN	O	O	3291
folic acid	NOUN	O	Chemical	3291
administration	NOUN	O	O	3291
,	PUNCT	O	O	3291
i.e.	X	O	O	3291
for	ADP	O	O	3291
7	NUM	O	O	3291
days	NOUN	O	O	3291
prior	ADV	O	O	3291
to	PART	O	O	3291
and	CCONJ	O	O	3291
7	NUM	O	O	3291
days	NOUN	O	O	3291
following	VERB	O	O	3291
a	PRON	O	O	3291
single	ADJ	O	O	3291
bolus	NOUN	O	O	3291
dose	NOUN	O	O	3291
.	PUNCT	O	O	3291
This	PRON	O	O	3292
observation	NOUN	O	O	3292
prompted	VERB	O	O	3292
a	PRON	O	O	3292
Phase	NOUN	O	O	3292
I	PRON	O	O	3292
clinical	ADJ	O	O	3292
study	VERB	O	O	3292
of	ADP	O	O	3292
lometrexol	VERB	O	Chemical	3292
given	VERB	O	O	3292
with	ADP	O	O	3292
folic acid	NOUN	O	Chemical	3292
supplementation	NOUN	O	O	3292
which	PRON	O	O	3292
has	VERB	O	O	3292
confirmed	VERB	O	O	3292
that	SCONJ	O	O	3292
the	PRON	O	O	3292
toxicity	NOUN	O	Disease	3292
of	ADP	O	O	3292
lometrexol	VERB	O	Chemical	3292
can	AUX	O	O	3292
be	AUX	O	O	3292
markedly	ADV	O	O	3292
reduced	VERB	O	O	3292
by	ADP	O	O	3292
folic acid	NOUN	O	Chemical	3292
supplementation	NOUN	O	O	3292
.	PUNCT	O	O	3292
Thrombocytopenia	PROPN	O	Disease	3293
and	CCONJ	O	O	3293
mucositis	NOUN	O	Disease	3293
were	AUX	O	O	3293
the	PRON	O	O	3293
major	ADJ	O	O	3293
toxicities	NOUN	O	Disease	3293
.	PUNCT	O	O	3293
There	ADV	O	O	3294
was	AUX	O	O	3294
no	PRON	O	O	3294
clear	ADJ	O	O	3294
relationship	NOUN	O	O	3294
between	ADP	O	O	3294
clinical	ADJ	O	O	3294
toxicity	NOUN	O	Disease	3294
and	CCONJ	O	O	3294
the	PRON	O	O	3294
extent	NOUN	O	O	3294
of	ADP	O	O	3294
plasma	NOUN	O	O	3294
folate	VERB	O	Chemical	3294
elevation	NOUN	O	O	3294
.	PUNCT	O	O	3294
Associated	NOUN	O	O	3295
studies	NOUN	O	O	3295
demonstrated	VERB	O	O	3295
that	SCONJ	O	O	3295
lometrexol	VERB	O	Chemical	3295
plasma	NOUN	O	O	3295
pharmacokinetics	NOUN	O	O	3295
were	AUX	O	O	3295
not	PART	O	O	3295
altered	VERB	O	O	3295
by	ADP	O	O	3295
folic acid	NOUN	O	Chemical	3295
administration	NOUN	O	O	3295
indicating	VERB	O	O	3295
that	SCONJ	O	O	3295
supplementation	NOUN	O	O	3295
is	AUX	O	O	3295
unlikely	ADJ	O	O	3295
to	PART	O	O	3295
reduce	VERB	O	O	3295
toxicity	NOUN	O	Disease	3295
by	ADP	O	O	3295
enhancing	VERB	O	O	3295
lometrexol	VERB	O	Chemical	3295
plasma	NOUN	O	O	3295
clearance	NOUN	O	O	3295
.	PUNCT	O	O	3295
This	PRON	O	O	3296
information	NOUN	O	O	3296
will	AUX	O	O	3296
facilitate	VERB	O	O	3296
the	PRON	O	O	3296
future	NOUN	O	O	3296
evaluation	NOUN	O	O	3296
of	ADP	O	O	3296
this	PRON	O	O	3296
class	NOUN	O	O	3296
of	ADP	O	O	3296
compounds	NOUN	O	O	3296
in	ADP	O	O	3296
cancer	NOUN	O	Disease	3296
therapy	NOUN	O	O	3296
.	PUNCT	O	O	3296
Involvement	NOUN	O	O	3299
of	ADP	O	O	3299
the	PRON	O	O	3299
mu	NOUN	O	O	3299
-	PUNCT	O	O	3299
opiate	NOUN	O	O	3299
receptor	NOUN	O	O	3299
in	ADP	O	O	3299
peripheral	ADJ	O	O	3299
analgesia	NOUN	O	Disease	3299
.	PUNCT	O	O	3299
The	PRON	O	O	3300
intradermal	ADJ	O	O	3300
injection	NOUN	O	O	3300
of	ADP	O	O	3300
mu	NOUN	O	O	3300
(	PUNCT	O	O	3300
morphine	NOUN	O	Chemical	3300
,	PUNCT	O	O	3300
Tyr	PROPN	O	O	3300
-	PUNCT	O	O	3300
D	NOUN	O	O	3300
-	PUNCT	O	O	3300
Ala	PROPN	O	O	3300
-	PUNCT	O	O	3300
Gly	PROPN	O	O	3300
-	PUNCT	O	O	3300
NMe	NOUN	O	O	3300
-	PUNCT	O	O	3300
Phe	PROPN	O	O	3300
-	PUNCT	O	O	3300
Gly	PROPN	O	O	3300
-	PUNCT	O	O	3300
ol	PROPN	O	O	3300
and	CCONJ	O	O	3300
morphiceptin	NOUN	O	Chemical	3300
)	PUNCT	O	O	3300
,	PUNCT	O	O	3300
kappa	PROPN	O	O	3300
(	PUNCT	O	O	3300
trans-3,4-dichloro	NOUN	O	O	3300
-	PUNCT	O	O	3300
N	NUM	O	O	3300
-	PUNCT	O	O	3300
methyl	NOUN	O	O	3300
-	PUNCT	O	O	3300
N[2-(1-pyrrolidinyl	NOUN	O	O	3300
)	PUNCT	O	O	3300
cyclohexyl]benzeneactemide	NUM	O	O	3300
)	PUNCT	O	O	3300
and	CCONJ	O	O	3300
delta	PROPN	O	O	3300
(	PUNCT	O	O	3300
[	X	O	O	3300
D	NOUN	O	O	3300
-	PUNCT	O	O	3300
Pen2.5]-enkephalin	PROPN	O	O	3300
and	CCONJ	O	O	3300
[	X	O	O	3300
D	NOUN	O	O	3300
-	PUNCT	O	O	3300
Ser2]-[Leu]enkephalin	PUNCT	O	O	3300
-	PUNCT	O	O	3300
Thr	PROPN	O	O	3300
)	PUNCT	O	O	3300
selective	ADJ	O	O	3300
opioid	NOUN	O	O	3300
-	PUNCT	O	O	3300
agonists	NOUN	O	O	3300
,	PUNCT	O	O	3300
by	ADP	O	O	3300
themselves	PRON	O	O	3300
,	PUNCT	O	O	3300
did	VERB	O	O	3300
not	PART	O	O	3300
significantly	ADV	O	O	3300
affect	VERB	O	O	3300
the	PRON	O	O	3300
mechanical	ADJ	O	O	3300
nociceptive	ADJ	O	O	3300
threshold	NOUN	O	O	3300
in	ADP	O	O	3300
the	PRON	O	O	3300
hindpaw	PROPN	O	O	3300
of	ADP	O	O	3300
the	PRON	O	O	3300
rat	NOUN	O	O	3300
.	PUNCT	O	O	3300
,	PUNCT	O	O	3301
however	ADV	O	O	3301
,	PUNCT	O	O	3301
produced	VERB	O	O	3301
dose	NOUN	O	O	3301
-	PUNCT	O	O	3301
dependent	ADJ	O	O	3301
inhibition	NOUN	O	O	3301
of	ADP	O	O	3301
prostaglandin E2-induced	VERB	O	O	3301
hyperalgesia	NOUN	O	Disease	3301
.	PUNCT	O	O	3301
The	PRON	O	O	3302
analgesic	PROPN	O	O	3302
effect	VERB	O	O	3302
of	ADP	O	O	3302
the	PRON	O	O	3302
mu	NOUN	O	O	3302
-	PUNCT	O	O	3302
agonist	NOUN	O	O	3302
morphine	NOUN	O	Chemical	3302
was	AUX	O	O	3302
dose	NOUN	O	O	3302
-	PUNCT	O	O	3302
dependently	ADV	O	O	3302
antagonized	VERB	O	O	3302
by	ADP	O	O	3302
naloxone	NOUN	O	Chemical	3302
and	CCONJ	O	O	3302
prevented	VERB	O	O	3302
by	ADP	O	O	3302
co	NOUN	O	O	3302
-	PUNCT	O	O	3302
injection	NOUN	O	O	3302
of	ADP	O	O	3302
pertussis	NOUN	O	O	3302
toxin	NOUN	O	O	3302
.	PUNCT	O	O	3302
Morphine	NOUN	O	Chemical	3303
did	VERB	O	O	3303
not	PART	O	O	3303
,	PUNCT	O	O	3303
however	ADV	O	O	3303
,	PUNCT	O	O	3303
alter	VERB	O	O	3303
the	PRON	O	O	3303
hyperalgesia	NOUN	O	Disease	3303
induced	VERB	O	O	3303
by	ADP	O	O	3303
8-bromo cyclic adenosine monophosphate	PROPN	O	Chemical	3303
.	PUNCT	O	O	3303
We	PRON	O	O	3304
conclude	VERB	O	O	3304
that	SCONJ	O	O	3304
the	PRON	O	O	3304
analgesic	PROPN	O	O	3304
action	NOUN	O	O	3304
of	ADP	O	O	3304
opioids	NOUN	O	O	3304
on	ADP	O	O	3304
the	PRON	O	O	3304
peripheral	ADJ	O	O	3304
terminals	NOUN	O	O	3304
of	ADP	O	O	3304
primary	NOUN	O	O	3304
afferents	NOUN	O	O	3304
is	AUX	O	O	3304
via	ADP	O	O	3304
a	PRON	O	O	3304
binding	VERB	O	O	3304
site	NOUN	O	O	3304
with	ADP	O	O	3304
characteristics	NOUN	O	O	3304
of	ADP	O	O	3304
the	PRON	O	O	3304
mu	NOUN	O	O	3304
-	PUNCT	O	O	3304
opioid	NOUN	O	O	3304
receptor	NOUN	O	O	3304
and	CCONJ	O	O	3304
that	SCONJ	O	O	3304
this	PRON	O	O	3304
action	NOUN	O	O	3304
is	AUX	O	O	3304
mediated	VERB	O	O	3304
by	ADP	O	O	3304
inhibition	NOUN	O	O	3304
of	ADP	O	O	3304
the	PRON	O	O	3304
cyclic adenosine monophosphate	NOUN	O	Chemical	3304
second	ADV	O	O	3304
messenger	NOUN	O	O	3304
system	NOUN	O	O	3304
.	PUNCT	O	O	3304
Adequate	PROPN	O	O	3307
timing	NOUN	O	O	3307
of	ADP	O	O	3307
ribavirin	NOUN	O	Chemical	3307
reduction	NOUN	O	O	3307
in	ADP	O	O	3307
patients	NOUN	O	O	3307
with	ADP	O	O	3307
hemolysis	NOUN	O	Disease	3307
during	ADP	O	O	3307
combination	NOUN	O	O	3307
therapy	NOUN	O	O	3307
of	ADP	O	O	3307
interferon	PROPN	O	Chemical	3307
and	CCONJ	O	O	3307
ribavirin	NOUN	O	Chemical	3307
for	ADP	O	O	3307
chronic hepatitis C.	PROPN	O	O	3307
BACKGROUND	NOUN	O	O	3307
:	PUNCT	O	O	3307
Hemolytic anemia	NOUN	O	Disease	3308
is	AUX	O	O	3308
one	NUM	O	O	3308
of	ADP	O	O	3308
the	PRON	O	O	3308
major	ADJ	O	O	3308
adverse	ADJ	O	O	3308
events	NOUN	O	O	3308
of	ADP	O	O	3308
the	PRON	O	O	3308
combination	NOUN	O	O	3308
therapy	NOUN	O	O	3308
of	ADP	O	O	3308
interferon	PROPN	O	Chemical	3308
and	CCONJ	O	O	3308
ribavirin	NOUN	O	Chemical	3308
.	PUNCT	O	O	3308
Because	SCONJ	O	O	3309
of	ADP	O	O	3309
ribavirin	NOUN	O	Chemical	3309
-	PUNCT	O	O	3309
related	ADJ	O	O	3309
hemolytic anemia	NOUN	O	Disease	3309
,	PUNCT	O	O	3309
dose	NOUN	O	O	3309
reduction	NOUN	O	O	3309
is	AUX	O	O	3309
a	PRON	O	O	3309
common	ADJ	O	O	3309
event	NOUN	O	O	3309
in	ADP	O	O	3309
this	PRON	O	O	3309
therapy	NOUN	O	O	3309
.	PUNCT	O	O	3309
In	ADP	O	O	3310
this	PRON	O	O	3310
clinical	ADJ	O	O	3310
retrospective	ADJ	O	O	3310
cohort	NOUN	O	O	3310
study	VERB	O	O	3310
we	PRON	O	O	3310
have	VERB	O	O	3310
examined	VERB	O	O	3310
the	PRON	O	O	3310
suitable	ADJ	O	O	3310
timing	NOUN	O	O	3310
of	ADP	O	O	3310
ribavirin	NOUN	O	Chemical	3310
reduction	NOUN	O	O	3310
in	ADP	O	O	3310
patients	NOUN	O	O	3310
with	ADP	O	O	3310
hemolysis	NOUN	O	Disease	3310
during	ADP	O	O	3310
combination	NOUN	O	O	3310
therapy	NOUN	O	O	3310
.	PUNCT	O	O	3310
METHODS	NOUN	O	O	3311
:	PUNCT	O	O	3311
Thirty	NUM	O	O	3311
-	PUNCT	O	O	3311
seven	NUM	O	O	3311
of	ADP	O	O	3311
160	NUM	O	O	3311
patients	NOUN	O	O	3311
who	PRON	O	O	3311
had	VERB	O	O	3311
HCV	PROPN	O	O	3311
-	PUNCT	O	O	3311
genotype	NOUN	O	O	3311
1b	NUM	O	O	3311
,	PUNCT	O	O	3311
had	VERB	O	O	3311
high	ADJ	O	O	3311
virus	NOUN	O	O	3311
load	NOUN	O	O	3311
,	PUNCT	O	O	3311
and	CCONJ	O	O	3311
received	VERB	O	O	3311
24-week	NOUN	O	O	3311
combination	NOUN	O	O	3311
therapy	NOUN	O	O	3311
developed	VERB	O	O	3311
anemia	NOUN	O	Disease	3311
with	ADP	O	O	3311
hemoglobin	NOUN	O	O	3311
level	VERB	O	O	3311
<	X	O	O	3311
10	NUM	O	O	3311
g	X	O	O	3311
/	PUNCT	O	O	3311
dl	X	O	O	3311
or	CCONJ	O	O	3311
anemia	NOUN	O	Disease	3311
-	PUNCT	O	O	3311
related	ADJ	O	O	3311
signs	NOUN	O	O	3311
during	ADP	O	O	3311
therapy	NOUN	O	O	3311
.	PUNCT	O	O	3311
After	ADP	O	O	3312
that	SCONJ	O	O	3312
,	PUNCT	O	O	3312
these	PRON	O	O	3312
37	NUM	O	O	3312
patients	NOUN	O	O	3312
were	AUX	O	O	3312
reduced	VERB	O	O	3312
one	NUM	O	O	3312
tablet	PROPN	O	O	3312
of	ADP	O	O	3312
ribavirin	NOUN	O	Chemical	3312
(	PUNCT	O	O	3312
200	NUM	O	O	3312
mg	VERB	O	O	3312
)	PUNCT	O	O	3312
per	ADP	O	O	3312
day	NOUN	O	O	3312
.	PUNCT	O	O	3312
After	ADP	O	O	3313
reduction	NOUN	O	O	3313
of	ADP	O	O	3313
ribavirin	NOUN	O	Chemical	3313
,	PUNCT	O	O	3313
27	NUM	O	O	3313
of	ADP	O	O	3313
37	NUM	O	O	3313
patients	NOUN	O	O	3313
could	AUX	O	O	3313
continue	VERB	O	O	3313
combination	NOUN	O	O	3313
therapy	NOUN	O	O	3313
for	ADP	O	O	3313
a	PRON	O	O	3313
total	ADJ	O	O	3313
of	ADP	O	O	3313
24	NUM	O	O	3313
weeks	NOUN	O	O	3313
(	PUNCT	O	O	3313
group	NOUN	O	O	3313
A	PRON	O	O	3313
)	PUNCT	O	O	3313
.	PUNCT	O	O	3313
However	ADV	O	O	3314
,	PUNCT	O	O	3314
10	NUM	O	O	3314
of	ADP	O	O	3314
37	NUM	O	O	3314
patients	NOUN	O	O	3314
with	ADP	O	O	3314
reduction	NOUN	O	O	3314
of	ADP	O	O	3314
ribavirin	NOUN	O	Chemical	3314
could	AUX	O	O	3314
not	PART	O	O	3314
continue	VERB	O	O	3314
combination	NOUN	O	O	3314
therapy	NOUN	O	O	3314
because	SCONJ	O	O	3314
their	PRON	O	O	3315
<	X	O	O	3315
8.5	NUM	O	O	3315
g	X	O	O	3315
/	PUNCT	O	O	3315
dl	X	O	O	3315
hemoglobin	NOUN	O	O	3315
values	NOUN	O	O	3315
decreased	VERB	O	O	3315
to	PART	O	O	3315
or	CCONJ	O	O	3315
anemia	NOUN	O	Disease	3315
-	PUNCT	O	O	3315
related	ADJ	O	O	3315
severe	ADJ	O	O	3315
side	NOUN	O	O	3315
effects	NOUN	O	O	3315
occurred	VERB	O	O	3315
(	PUNCT	O	O	3315
group	NOUN	O	O	3315
B	NOUN	O	O	3315
)	PUNCT	O	O	3315
.	PUNCT	O	O	3315
We	PRON	O	O	3316
assessed	VERB	O	O	3316
the	PRON	O	O	3316
final	ADJ	O	O	3316
efficacy	NOUN	O	O	3316
and	CCONJ	O	O	3316
safety	NOUN	O	O	3316
after	ADP	O	O	3316
reduction	NOUN	O	O	3316
of	ADP	O	O	3316
ribavirin	NOUN	O	Chemical	3316
in	ADP	O	O	3316
groups	NOUN	O	O	3316
A	PRON	O	O	3316
and	CCONJ	O	O	3316
B.	PROPN	O	O	3316
RESULTS	VERB	O	O	3316
:	PUNCT	O	O	3316
With	ADP	O	O	3317
respect	VERB	O	O	3317
to	PART	O	O	3317
hemoglobin	NOUN	O	O	3317
level	VERB	O	O	3317
at	ADP	O	O	3317
the	PRON	O	O	3317
time	NOUN	O	O	3317
of	ADP	O	O	3317
ribavirin	NOUN	O	Chemical	3317
reduction	NOUN	O	O	3317
,	PUNCT	O	O	3317
a	PRON	O	O	3317
rate	NOUN	O	O	3317
of	ADP	O	O	3317
continuation	NOUN	O	O	3317
of	ADP	O	O	3317
therapy	NOUN	O	O	3317
in	ADP	O	O	3317
patients	NOUN	O	O	3317
with	ADP	O	O	3317
>	PUNCT	O	O	3317
or	CCONJ	O	O	3317
=	PUNCT	O	O	3317
10	NUM	O	O	3317
g	X	O	O	3317
/	PUNCT	O	O	3317
dl	X	O	O	3317
hemoglobin	NOUN	O	O	3317
was	AUX	O	O	3317
higher	ADJ	O	O	3317
than	ADP	O	O	3317
that	SCONJ	O	O	3317
in	ADP	O	O	3317
patients	NOUN	O	O	3317
with	ADP	O	O	3317
<	X	O	O	3317
10	NUM	O	O	3317
g	X	O	O	3317
/	PUNCT	O	O	3317
dl	X	O	O	3317
(	PUNCT	O	O	3317
P	NOUN	O	Chemical	3317
=	PUNCT	O	O	3317
0.036	NUM	O	O	3317
)	PUNCT	O	O	3317
.	PUNCT	O	O	3317
Reduction	NOUN	O	O	3318
of	ADP	O	O	3318
ribavirin	NOUN	O	Chemical	3318
at	ADP	O	O	3318
hemoglobin	NOUN	O	O	3318
level	VERB	O	O	3318
>	PUNCT	O	O	3318
or	CCONJ	O	O	3318
=	PUNCT	O	O	3318
Increased	VERB	O	O	3321
expression	NOUN	O	O	3321
and	CCONJ	O	O	3321
apical	ADJ	O	O	3321
targeting	VERB	O	O	3321
of	ADP	O	O	3321
renal	ADJ	O	O	3321
ENaC	PROPN	O	O	3321
subunits	NOUN	O	O	3321
in	ADP	O	O	3321
puromycin aminonucleoside	NOUN	O	Chemical	3321
-	PUNCT	O	O	3321
induced	VERB	O	O	3321
nephrotic syndrome	NOUN	O	Disease	3321
in	ADP	O	O	3321
rats	NOUN	O	O	3321
.	PUNCT	O	O	3321
Nephrotic syndrome	NOUN	O	Disease	3322
is	AUX	O	O	3322
often	ADV	O	O	3322
accompanied	VERB	O	O	3322
by	ADP	O	O	3322
sodium	NOUN	O	Chemical	3322
retention	NOUN	O	O	3322
and	CCONJ	O	O	3322
generalized	VERB	O	O	3322
edema	NOUN	O	Disease	3322
.	PUNCT	O	O	3322
However	ADV	O	O	3323
,	PUNCT	O	O	3323
the	PRON	O	O	3323
molecular	ADJ	O	O	3323
basis	NOUN	O	O	3323
for	ADP	O	O	3323
the	PRON	O	O	3323
decreased	VERB	O	O	3323
renal	ADJ	O	O	3323
sodium	NOUN	O	Chemical	3323
excretion	NOUN	O	O	3323
remains	VERB	O	O	3323
undefined	ADJ	O	O	3323
.	PUNCT	O	O	3323
We	PRON	O	O	3324
hypothesized	VERB	O	O	3324
that	SCONJ	O	O	3324
epithelial	ADJ	O	O	3324
Na	INTJ	O	Chemical	3324
channel	PROPN	O	O	3324
(	PUNCT	O	O	3324
ENaC	PROPN	O	O	3324
)	PUNCT	O	O	3324
subunit	NOUN	O	O	3324
dysregulation	NOUN	O	O	3324
may	AUX	O	O	3324
be	AUX	O	O	3324
responsible	ADJ	O	O	3324
for	ADP	O	O	3324
the	PRON	O	O	3324
increased	VERB	O	O	3324
sodium	NOUN	O	Chemical	3324
retention	NOUN	O	O	3324
.	PUNCT	O	O	3324
An	PRON	O	O	3325
experimental	ADJ	O	O	3325
group	NOUN	O	O	3325
of	ADP	O	O	3325
rats	NOUN	O	O	3325
was	AUX	O	O	3325
treated	VERB	O	O	3325
with	ADP	O	O	3325
puromycin aminonucleoside	NOUN	O	Chemical	3325
(	PUNCT	O	O	3325
PAN	PROPN	O	Chemical	3325
;	PUNCT	O	O	3325
180	NUM	O	O	3325
mg	VERB	O	O	3325
/	PUNCT	O	O	3325
kg	VERB	O	O	3325
iv	X	O	O	3325
)	PUNCT	O	O	3325
,	PUNCT	O	O	3325
whereas	SCONJ	O	O	3325
the	PRON	O	O	3325
control	VERB	O	O	3325
group	NOUN	O	O	3325
received	VERB	O	O	3325
only	ADV	O	O	3325
vehicle	NOUN	O	O	3325
.	PUNCT	O	O	3325
After	ADP	O	O	3326
7	NUM	O	O	3326
days	NOUN	O	O	3326
,	PUNCT	O	O	3326
PAN	PROPN	O	Chemical	3326
treatment	NOUN	O	O	3326
induced	VERB	O	O	3326
significant	ADJ	O	O	3326
proteinuria	X	O	Disease	3326
,	PUNCT	O	O	3326
hypoalbuminemia	ADV	O	Disease	3326
,	PUNCT	O	O	3326
decreased	VERB	O	O	3326
urinary	ADJ	O	O	3326
sodium	NOUN	O	Chemical	3326
excretion	NOUN	O	O	3326
,	PUNCT	O	O	3326
and	CCONJ	O	O	3326
extensive	ADJ	O	O	3326
ascites	NOUN	O	Disease	3326
.	PUNCT	O	O	3326
Immunoelectron	NOUN	O	O	3327
microscopy	NOUN	O	O	3327
further	ADV	O	O	3327
revealed	VERB	O	O	3327
an	PRON	O	O	3327
increased	VERB	O	O	3327
labeling	NOUN	O	O	3327
of	ADP	O	O	3327
alpha	PROPN	O	O	3327
-	PUNCT	O	O	3327
ENaC	PROPN	O	O	3327
in	ADP	O	O	3327
the	PRON	O	O	3327
apical	ADJ	O	O	3327
plasma	NOUN	O	O	3327
membrane	NOUN	O	O	3327
of	ADP	O	O	3327
cortical	ADJ	O	O	3327
collecting	VERB	O	O	3327
duct	NOUN	O	O	3327
principal	NOUN	O	O	3327
cells	NOUN	O	O	3327
of	ADP	O	O	3327
PAN	PROPN	O	Chemical	3327
-	PUNCT	O	O	3327
treated	VERB	O	O	3327
rats	NOUN	O	O	3327
,	PUNCT	O	O	3327
indicating	VERB	O	O	3327
enhanced	VERB	O	O	3327
apical	ADJ	O	O	3327
targeting	VERB	O	O	3327
of	ADP	O	O	3327
alpha	PROPN	O	O	3327
-	PUNCT	O	O	3327
ENaC	PROPN	O	O	3327
subunits	NOUN	O	O	3327
.	PUNCT	O	O	3327
In	ADP	O	O	3328
contrast	NOUN	O	O	3328
,	PUNCT	O	O	3328
the	PRON	O	O	3328
protein	NOUN	O	O	3328
abundances	VERB	O	O	3328
of	ADP	O	O	3328
Na(+)/H(+	NOUN	O	O	3328
)	PUNCT	O	O	3328
exchanger	NOUN	O	O	3328
type	NOUN	O	O	3328
3	X	O	O	3328
(	PUNCT	O	O	3328
NHE3	PROPN	O	O	3328
)	PUNCT	O	O	3328
,	PUNCT	O	O	3328
Na(+)-K(+)-2Cl(-	X	O	O	3328
)	PUNCT	O	O	3328
cotransporter	NOUN	O	O	3329
(	PUNCT	O	O	3329
BSC-1	NUM	O	O	3329
)	PUNCT	O	O	3329
,	PUNCT	O	O	3329
and	CCONJ	O	O	3329
thiazide	ADJ	O	Chemical	3329
-	PUNCT	O	O	3329
sensitive	ADJ	O	O	3329
Na(+)-Cl(-	PROPN	O	O	3329
)	PUNCT	O	O	3329
Moreover	ADV	O	O	3330
,	PUNCT	O	O	3330
the	PRON	O	O	3330
abundance	NOUN	O	O	3330
of	ADP	O	O	3330
the	PRON	O	O	3330
alpha(1)-subunit	X	O	O	3330
of	ADP	O	O	3330
the	PRON	O	O	3330
Na	INTJ	O	Chemical	3330
-	PUNCT	O	O	3330
K	PROPN	O	Chemical	3330
-	PUNCT	O	O	3330
ATPase	X	O	O	3330
was	AUX	O	O	3330
decreased	VERB	O	O	3330
in	ADP	O	O	3330
the	PRON	O	O	3330
cortex	VERB	O	O	3330
and	CCONJ	O	O	3330
ISOM	NOUN	O	O	3330
,	PUNCT	O	O	3330
but	CCONJ	O	O	3330
it	PRON	O	O	3330
remained	VERB	O	O	3330
unchanged	ADJ	O	O	3330
in	ADP	O	O	3330
the	PRON	O	O	3330
IM	PROPN	O	O	3330
.	PUNCT	O	O	3330
In	ADP	O	O	3331
conclusion	NOUN	O	O	3331
,	PUNCT	O	O	3331
the	PRON	O	O	3331
increased	VERB	O	O	3331
or	CCONJ	O	O	3331
sustained	VERB	O	O	3331
expression	NOUN	O	O	3331
of	ADP	O	O	3331
ENaC	PROPN	O	O	3331
subunits	NOUN	O	O	3331
combined	VERB	O	O	3331
with	ADP	O	O	3331
increased	VERB	O	O	3331
apical	ADJ	O	O	3331
targeting	VERB	O	O	3331
in	ADP	O	O	3331
the	PRON	O	O	3331
DCT2	PROPN	O	O	3331
,	PUNCT	O	O	3331
connecting	VERB	O	O	3331
tubule	NOUN	O	O	3331
,	PUNCT	O	O	3331
and	CCONJ	O	O	3331
collecting	VERB	O	O	3331
duct	NOUN	O	O	3331
are	AUX	O	O	3331
likely	ADV	O	O	3331
to	PART	O	O	3331
play	VERB	O	O	3331
a	PRON	O	O	3331
role	NOUN	O	O	3331
in	ADP	O	O	3331
the	PRON	O	O	3331
sodium	NOUN	O	Chemical	3331
retention	NOUN	O	O	3331
associated	VERB	O	O	3331
with	ADP	O	O	3331
PAN	PROPN	O	Chemical	3331
-	PUNCT	O	O	3331
induced	VERB	O	O	3331
nephrotic syndrome	NOUN	O	Disease	3331
.	PUNCT	O	O	3331
The	PRON	O	O	3332
decreased	VERB	O	O	3332
abundance	NOUN	O	O	3332
of	ADP	O	O	3332
NHE3	PROPN	O	O	3332
,	PUNCT	O	O	3332
BSC-1	NUM	O	O	3332
,	PUNCT	O	O	3332
TSC	PROPN	O	O	3332
,	PUNCT	O	O	3332
and	CCONJ	O	O	3332
Na	INTJ	O	Chemical	3332
-	PUNCT	O	O	3332
K	PROPN	O	Chemical	3332
-	PUNCT	O	O	3332
ATPase	X	O	O	3332
may	AUX	O	O	3332
play	VERB	O	O	3332
a	PRON	O	O	3332
compensatory	ADJ	O	O	3332
role	NOUN	O	O	3332
to	PART	O	O	3332
promote	VERB	O	O	3332
sodium	NOUN	O	Chemical	3332
excretion	NOUN	O	O	3332
.	PUNCT	O	O	3332
Does	VERB	O	O	3335
hormone	NOUN	O	O	3335
therapy	NOUN	O	O	3335
for	ADP	O	O	3335
the	PRON	O	O	3335
treatment	NOUN	O	O	3335
of	ADP	O	O	3335
breast cancer	NOUN	O	Disease	3335
have	VERB	O	O	3335
a	PRON	O	O	3335
detrimental effect on memory	NOUN	O	Disease	3335
and	CCONJ	O	O	3335
cognition	NOUN	O	O	3335
?	PUNCT	O	O	3335
This	PRON	O	O	3336
pilot	NOUN	O	O	3336
study	VERB	O	O	3336
examines	VERB	O	O	3336
whether	SCONJ	O	O	3336
hormone	NOUN	O	O	3336
therapy	NOUN	O	O	3336
for	ADP	O	O	3336
breast cancer	NOUN	O	Disease	3336
affects	VERB	O	O	3336
cognition	NOUN	O	O	3336
.	PUNCT	O	O	3336
Patients	NOUN	O	O	3337
participating	VERB	O	O	3337
in	ADP	O	O	3337
a	PRON	O	O	3337
randomised	VERB	O	O	3337
trial	NOUN	O	O	3337
of	ADP	O	O	3337
anastrozole	NOUN	O	Chemical	3337
,	PUNCT	O	O	3337
tamoxifen	PROPN	O	Chemical	3337
alone	ADV	O	O	3337
or	CCONJ	O	O	3337
combined	VERB	O	O	3337
(	PUNCT	O	O	3337
ATAC	PROPN	O	O	3337
)	PUNCT	O	O	3337
(	PUNCT	O	O	3337
n=94	PROPN	O	O	3337
)	PUNCT	O	O	3337
and	CCONJ	O	O	3337
a	PRON	O	O	3337
group	NOUN	O	O	3337
of	ADP	O	O	3337
women	NOUN	O	O	3337
without	ADP	O	O	3337
breast cancer	NOUN	O	Disease	3337
(	PUNCT	O	O	3337
n=35	NOUN	O	O	3337
)	PUNCT	O	O	3337
completed	VERB	O	O	3337
a	PRON	O	O	3337
battery	NOUN	O	O	3337
of	ADP	O	O	3337
neuropsychological	ADJ	O	O	3337
measures	NOUN	O	O	3337
.	PUNCT	O	O	3337
The	PRON	O	O	3338
results	VERB	O	O	3338
showed	VERB	O	O	3338
specific	ADJ	O	O	3338
impairments	VERB	O	O	3338
in	ADP	O	O	3338
processing	NOUN	O	O	3338
speed	NOUN	O	O	3338
and	CCONJ	O	O	3338
verbal	ADJ	O	O	3338
memory	NOUN	O	O	3338
in	ADP	O	O	3338
women	NOUN	O	O	3338
receiving	VERB	O	O	3338
hormonal	ADJ	O	O	3338
therapy	NOUN	O	O	3338
for	ADP	O	O	3338
the	PRON	O	O	3338
treatment	NOUN	O	O	3338
of	ADP	O	O	3338
breast cancer	NOUN	O	Disease	3338
.	PUNCT	O	O	3338
Verbal	ADJ	O	O	3339
memory	NOUN	O	O	3339
may	AUX	O	O	3339
be	AUX	O	O	3339
especially	ADV	O	O	3339
sensitive	ADJ	O	O	3339
to	PART	O	O	3339
changes	VERB	O	O	3339
in	ADP	O	O	3339
oestrogen	PROPN	O	Chemical	3339
levels	NOUN	O	O	3339
,	PUNCT	O	O	3339
a	PRON	O	O	3339
finding	VERB	O	O	3339
commonly	ADV	O	O	3339
reported	VERB	O	O	3339
in	ADP	O	O	3339
studies	NOUN	O	O	3339
of	ADP	O	O	3339
hormone	NOUN	O	O	3339
replacement	NOUN	O	O	3339
therapy	NOUN	O	O	3339
in	ADP	O	O	3339
healthy	ADJ	O	O	3339
women	NOUN	O	O	3339
.	PUNCT	O	O	3339
Association	PROPN	O	O	3342
of	ADP	O	O	3342
nitric oxide	NOUN	O	Chemical	3342
production	NOUN	O	O	3342
and	CCONJ	O	O	3342
apoptosis	NOUN	O	O	3342
in	ADP	O	O	3342
a	PRON	O	O	3342
model	NOUN	O	O	3342
of	ADP	O	O	3342
experimental	ADJ	O	O	3342
nephropathy	NOUN	O	Disease	3342
.	PUNCT	O	O	3342
In	ADP	O	O	3343
recent	ADJ	O	O	3343
studies	NOUN	O	O	3343
increased	VERB	O	O	3343
amounts	VERB	O	O	3343
of	ADP	O	O	3343
nitric oxide	NOUN	O	Chemical	3343
(	PUNCT	O	O	3343
NO	PRON	O	Chemical	3343
)	PUNCT	O	O	3343
and	CCONJ	O	O	3343
apoptosis	NOUN	O	O	3343
have	VERB	O	O	3343
been	AUX	O	O	3343
implicated	VERB	O	O	3343
in	ADP	O	O	3343
various	ADJ	O	O	3343
pathological	ADJ	O	O	3343
conditions	NOUN	O	O	3343
in	ADP	O	O	3343
the	PRON	O	O	3343
kidney	NOUN	O	O	3343
.	PUNCT	O	O	3343
We	PRON	O	O	3344
have	VERB	O	O	3344
studied	VERB	O	O	3344
the	PRON	O	O	3344
role	NOUN	O	O	3344
of	ADP	O	O	3344
NO	PRON	O	Chemical	3344
and	CCONJ	O	O	3344
its	PRON	O	O	3344
association	PROPN	O	O	3344
with	ADP	O	O	3344
apoptosis	NOUN	O	O	3344
in	ADP	O	O	3344
an	PRON	O	O	3344
experimental	ADJ	O	O	3344
model	NOUN	O	O	3344
of	ADP	O	O	3344
nephrotic syndrome	NOUN	O	Disease	3344
induced	VERB	O	O	3344
by	ADP	O	O	3344
a	PRON	O	O	3344
single	ADJ	O	O	3344
injection	NOUN	O	O	3344
of	ADP	O	O	3344
adriamycin	PROPN	O	Chemical	3344
(	PUNCT	O	O	3344
ADR	PROPN	O	Chemical	3344
)	PUNCT	O	O	3344
.	PUNCT	O	O	3344
The	PRON	O	O	3345
alteration	NOUN	O	O	3345
in	ADP	O	O	3345
the	PRON	O	O	3345
NO	PRON	O	Chemical	3345
pathway	NOUN	O	O	3345
was	AUX	O	O	3345
assessed	VERB	O	O	3345
by	ADP	O	O	3345
measuring	VERB	O	O	3345
nitrite	PROPN	O	Chemical	3345
levels	NOUN	O	O	3345
in	ADP	O	O	3345
serum	NOUN	O	O	3345
/	PUNCT	O	O	3345
urine	NOUN	O	O	3345
and	CCONJ	O	O	3345
by	ADP	O	O	3345
evaluating	VERB	O	O	3345
the	PRON	O	O	3345
changes	VERB	O	O	3345
in	ADP	O	O	3345
vascular	ADJ	O	O	3345
reactivity	NOUN	O	O	3345
of	ADP	O	O	3345
the	PRON	O	O	3345
isolated	VERB	O	O	3345
perfused	VERB	O	O	3345
rat	NOUN	O	O	3345
kidney	NOUN	O	O	3345
(	PUNCT	O	O	3345
IPRK	PROPN	O	O	3345
)	PUNCT	O	O	3345
system	NOUN	O	O	3345
.	PUNCT	O	O	3345
Rats	NOUN	O	O	3346
were	AUX	O	O	3346
stratified	ADJ	O	O	3346
into	ADP	O	O	3346
control	VERB	O	O	3346
groups	NOUN	O	O	3346
and	CCONJ	O	O	3346
ADR	PROPN	O	Chemical	3346
-	PUNCT	O	O	3346
induced	VERB	O	O	3346
nephropathy	NOUN	O	Disease	3346
groups	NOUN	O	O	3346
.	PUNCT	O	O	3346
These	PRON	O	O	3347
two	NUM	O	O	3347
groups	NOUN	O	O	3347
were	AUX	O	O	3347
then	ADV	O	O	3347
divided	VERB	O	O	3347
into	ADP	O	O	3347
:	PUNCT	O	O	3347
group	NOUN	O	O	3347
1	X	O	O	3347
,	PUNCT	O	O	3347
animals	NOUN	O	O	3347
receiving	VERB	O	O	3347
saline	NOUN	O	O	3347
;	PUNCT	O	O	3347
and	CCONJ	O	O	3347
group	NOUN	O	O	3347
2	X	O	O	3347
,	PUNCT	O	O	3347
animals	NOUN	O	O	3347
receiving	VERB	O	O	3347
aminoguanidine	ADJ	O	Chemical	3347
(	PUNCT	O	O	3347
AG	PROPN	O	Chemical	3347
)	PUNCT	O	O	3347
which	PRON	O	O	3347
is	AUX	O	O	3347
a	PRON	O	O	3347
specific	ADJ	O	O	3347
inhibitor	NOUN	O	O	3347
of	ADP	O	O	3347
inducible	VERB	O	O	3347
-	PUNCT	O	O	3347
NO	PRON	O	Chemical	3347
synthase	NOUN	O	O	3347
.	PUNCT	O	O	3347
RESULTS	VERB	O	O	3348
:	PUNCT	O	O	3348
Histopathological	PROPN	O	O	3348
examination	NOUN	O	O	3348
of	ADP	O	O	3348
the	PRON	O	O	3348
kidneys	NOUN	O	O	3348
of	ADP	O	O	3348
rats	NOUN	O	O	3348
treated	VERB	O	O	3348
with	ADP	O	O	3348
ADR	PROPN	O	Chemical	3348
revealed	VERB	O	O	3348
focal	ADJ	O	O	3348
areas	NOUN	O	O	3348
of	ADP	O	O	3348
mesangial proliferation	NOUN	O	Disease	3348
and	CCONJ	O	O	3348
mild	ADJ	O	O	3348
tubulointerstitial inflammation	NOUN	O	Disease	3348
.	PUNCT	O	O	3348
They	PRON	O	O	3349
also	ADV	O	O	3349
had	VERB	O	O	3349
significantly	ADV	O	O	3349
higher	ADJ	O	O	3349
levels	NOUN	O	O	3349
of	ADP	O	O	3349
proteinuria	X	O	Disease	3349
compared	VERB	O	O	3349
with	ADP	O	O	3349
control	VERB	O	O	3349
and	CCONJ	O	O	3349
treatment	NOUN	O	O	3349
groups	NOUN	O	O	3349
(	PUNCT	O	O	3349
P	NOUN	O	Chemical	3349
<	X	O	O	3349
0.05	NUM	O	O	3349
)	PUNCT	O	O	3349
.	PUNCT	O	O	3349
Urine	NOUN	O	O	3350
nitrite	PROPN	O	Chemical	3350
levels	NOUN	O	O	3350
were	AUX	O	O	3350
significantly	ADV	O	O	3350
increased	VERB	O	O	3350
in	ADP	O	O	3350
the	PRON	O	O	3350
ADR	PROPN	O	Chemical	3350
-	PUNCT	O	O	3350
nephropathy	NOUN	O	Disease	3350
group	NOUN	O	O	3350
(	PUNCT	O	O	3350
P	NOUN	O	Chemical	3350
<	X	O	O	3350
0.05	NUM	O	O	3350
)	PUNCT	O	O	3350
.	PUNCT	O	O	3350
In	ADP	O	O	3351
the	PRON	O	O	3351
IPRK	PROPN	O	O	3351
phenylephrine	NOUN	O	Chemical	3351
and	CCONJ	O	O	3351
acetylcholine	NOUN	O	Chemical	3351
related	ADJ	O	O	3351
responses	NOUN	O	O	3351
were	AUX	O	O	3351
significantly	ADV	O	O	3351
impaired	VERB	O	O	3351
in	ADP	O	O	3351
the	PRON	O	O	3351
ADR	PROPN	O	Chemical	3351
-	PUNCT	O	O	3351
nephropathy	NOUN	O	Disease	3351
group	NOUN	O	O	3351
.	PUNCT	O	O	3351
However	ADV	O	O	3352
,	PUNCT	O	O	3352
in	ADP	O	O	3352
the	PRON	O	O	3352
ADR	PROPN	O	Chemical	3352
-	PUNCT	O	O	3352
nephropathy	NOUN	O	Disease	3352
group	NOUN	O	O	3352
,	PUNCT	O	O	3352
numerous	ADJ	O	O	3352
apoptotic	ADJ	O	O	3352
cells	NOUN	O	O	3352
were	AUX	O	O	3352
identified	VERB	O	O	3352
in	ADP	O	O	3352
the	PRON	O	O	3352
tubulointerstitial	ADJ	O	O	3352
areas	NOUN	O	O	3352
.	PUNCT	O	O	3352
Treatment	NOUN	O	O	3353
with	ADP	O	O	3353
AG	PROPN	O	Chemical	3353
prevented	VERB	O	O	3353
the	PRON	O	O	3353
impairment	NOUN	O	O	3353
of	ADP	O	O	3353
renal	ADJ	O	O	3353
vascular	ADJ	O	O	3353
bed	NOUN	O	O	3353
responses	NOUN	O	O	3353
and	CCONJ	O	O	3353
reduced	VERB	O	O	3353
both	PRON	O	O	3353
urine	NOUN	O	O	3353
nitrite	PROPN	O	Chemical	3353
levels	NOUN	O	O	3353
and	CCONJ	O	O	3353
apoptosis	NOUN	O	O	3353
to	PART	O	O	3353
control	VERB	O	O	3353
levels	NOUN	O	O	3353
.	PUNCT	O	O	3353
:	PUNCT	O	O	3354
We	PRON	O	O	3354
suggest	VERB	O	O	3354
that	SCONJ	O	O	3354
interactions	NOUN	O	O	3354
between	ADP	O	O	3354
NO	PRON	O	Chemical	3354
and	CCONJ	O	O	3354
apoptosis	NOUN	O	O	3354
are	AUX	O	O	3354
important	ADJ	O	O	3354
in	ADP	O	O	3354
the	PRON	O	O	3354
pathogenesis	NOUN	O	O	3354
of	ADP	O	O	3354
the	PRON	O	O	3354
ADR	PROPN	O	Chemical	3354
-	PUNCT	O	O	3354
induced	VERB	O	O	3354
nephrosis	NOUN	O	Disease	3354
.	PUNCT	O	O	3354
The	PRON	O	O	3357
attenuating	VERB	O	O	3357
effect	VERB	O	O	3357
of	ADP	O	O	3357
carteolol hydrochloride	NOUN	O	Chemical	3357
,	PUNCT	O	O	3357
a	PRON	O	O	3357
beta	NOUN	O	O	3357
-	PUNCT	O	O	3357
adrenoceptor	NOUN	O	O	3357
antagonist	NOUN	O	O	3357
,	PUNCT	O	O	3357
on	ADP	O	O	3357
neuroleptic	NOUN	O	O	3357
-	PUNCT	O	O	3357
induced	VERB	O	O	3357
catalepsy	VERB	O	Disease	3357
in	ADP	O	O	3357
rats	NOUN	O	O	3357
.	PUNCT	O	O	3357
It	PRON	O	O	3358
is	AUX	O	O	3358
known	VERB	O	O	3358
that	SCONJ	O	O	3358
beta	NOUN	O	O	3358
-	PUNCT	O	O	3358
adrenoceptor	NOUN	O	O	3358
antagonists	NOUN	O	O	3358
are	AUX	O	O	3358
effective	ADJ	O	O	3358
in	ADP	O	O	3358
the	PRON	O	O	3358
treatment	NOUN	O	O	3358
of	ADP	O	O	3358
akathisia	PROPN	O	Disease	3358
,	PUNCT	O	O	3358
one	NUM	O	O	3358
of	ADP	O	O	3358
the	PRON	O	O	3358
extrapyramidal	ADJ	O	O	3358
side	NOUN	O	O	3358
effects	NOUN	O	O	3358
that	SCONJ	O	O	3358
occur	VERB	O	O	3358
during	ADP	O	O	3358
neuroleptic	NOUN	O	O	3358
treatment	NOUN	O	O	3358
.	PUNCT	O	O	3358
Neuroleptic	NOUN	O	O	3359
-	PUNCT	O	O	3359
induced	VERB	O	O	3359
catalepsy	VERB	O	Disease	3359
,	PUNCT	O	O	3359
a	PRON	O	O	3359
model	NOUN	O	O	3359
of	ADP	O	O	3359
neuroleptic	NOUN	O	O	3359
-	PUNCT	O	O	3359
induced	VERB	O	O	3359
extrapyramidal	ADJ	O	O	3359
side	NOUN	O	O	3359
effects	NOUN	O	O	3359
,	PUNCT	O	O	3359
was	AUX	O	O	3359
considered	VERB	O	O	3359
suitable	ADJ	O	O	3359
as	ADP	O	O	3359
a	PRON	O	O	3359
model	NOUN	O	O	3359
for	ADP	O	O	3359
predicting	VERB	O	O	3359
neuroleptic	NOUN	O	O	3359
-	PUNCT	O	O	3359
induced	VERB	O	O	3359
akathisia	PROPN	O	Disease	3359
in	ADP	O	O	3359
humans	NOUN	O	O	3359
,	PUNCT	O	O	3359
although	SCONJ	O	O	3359
neuroleptic	NOUN	O	O	3359
-	PUNCT	O	O	3359
induced	VERB	O	O	3359
catalepsy	VERB	O	Disease	3359
was	AUX	O	O	3359
not	PART	O	O	3359
considered	VERB	O	O	3359
a	PRON	O	O	3359
specific	ADJ	O	O	3359
test	NOUN	O	O	3359
for	ADP	O	O	3359
neuroleptic	NOUN	O	O	3359
-	PUNCT	O	O	3359
induced	VERB	O	O	3359
akathisia	PROPN	O	Disease	3359
.	PUNCT	O	O	3359
Therefore	ADV	O	O	3360
,	PUNCT	O	O	3360
the	PRON	O	O	3360
effects	NOUN	O	O	3360
of	ADP	O	O	3360
carteolol	PROPN	O	Chemical	3360
,	PUNCT	O	O	3360
a	PRON	O	O	3360
beta	NOUN	O	O	3360
-	PUNCT	O	O	3360
adrenoceptor	NOUN	O	O	3360
antagonist	NOUN	O	O	3360
,	PUNCT	O	O	3360
on	ADP	O	O	3360
haloperidol	NOUN	O	Chemical	3360
-	PUNCT	O	O	3360
induced	VERB	O	O	3360
catalepsy	VERB	O	Disease	3360
in	ADP	O	O	3360
rats	NOUN	O	O	3360
were	AUX	O	O	3360
behaviorally	ADV	O	O	3360
studied	VERB	O	O	3360
and	CCONJ	O	O	3360
compared	VERB	O	O	3360
with	ADP	O	O	3360
those	PRON	O	O	3360
of	ADP	O	O	3360
propranolol	NOUN	O	Chemical	3360
and	CCONJ	O	O	3360
biperiden	VERB	O	Chemical	3360
,	PUNCT	O	O	3360
a	PRON	O	O	3360
muscarinic	PROPN	O	O	3360
receptor	NOUN	O	O	3360
antagonist	NOUN	O	O	3360
.	PUNCT	O	O	3360
Carteolol	PROPN	O	Chemical	3361
,	PUNCT	O	O	3361
as	ADP	O	O	3361
well	ADV	O	O	3361
as	ADP	O	O	3361
propranolol	NOUN	O	Chemical	3361
and	CCONJ	O	O	3361
biperiden	VERB	O	Chemical	3361
,	PUNCT	O	O	3361
inhibited	VERB	O	O	3361
the	PRON	O	O	3361
haloperidol	NOUN	O	Chemical	3361
-	PUNCT	O	O	3361
induced	VERB	O	O	3361
catalepsy	VERB	O	Disease	3361
.	PUNCT	O	O	3361
The	PRON	O	O	3362
inhibitory	ADJ	O	O	3362
effect	VERB	O	O	3362
of	ADP	O	O	3362
carteolol	PROPN	O	Chemical	3362
was	AUX	O	O	3362
almost	ADV	O	O	3362
comparable	ADJ	O	O	3362
to	PART	O	O	3362
that	SCONJ	O	O	3362
of	ADP	O	O	3362
propranolol	NOUN	O	Chemical	3362
,	PUNCT	O	O	3362
but	CCONJ	O	O	3362
was	AUX	O	O	3362
weaker	ADJ	O	O	3362
than	ADP	O	O	3362
that	SCONJ	O	O	3362
of	ADP	O	O	3362
biperiden	VERB	O	Chemical	3362
.	PUNCT	O	O	3362
Carteolol	PROPN	O	Chemical	3363
did	VERB	O	O	3363
not	PART	O	O	3363
evoke	VERB	O	O	3363
postsynaptic	ADJ	O	O	3363
dopamine	NOUN	O	Chemical	3364
receptor	NOUN	O	O	3364
-	PUNCT	O	O	3364
stimulating	VERB	O	O	3364
behavioral	ADJ	O	O	3364
signs	NOUN	O	O	3364
such	ADJ	O	O	3364
as	ADP	O	O	3364
stereotypy	PROPN	O	O	3364
and	CCONJ	O	O	3364
hyperlocomotion	NOUN	O	Disease	3364
in	ADP	O	O	3364
rats	NOUN	O	O	3364
.	PUNCT	O	O	3364
Carteolol	PROPN	O	Chemical	3365
did	VERB	O	O	3365
not	PART	O	O	3365
antagonize	VERB	O	O	3365
the	PRON	O	O	3365
inhibitory	ADJ	O	O	3365
effects	NOUN	O	O	3365
of	ADP	O	O	3365
haloperidol	NOUN	O	Chemical	3365
on	ADP	O	O	3365
apomorphine	PROPN	O	Chemical	3365
-	PUNCT	O	O	3365
induced	VERB	O	O	3365
stereotypy	PROPN	O	O	3365
and	CCONJ	O	O	3365
locomotor	PROPN	O	O	3365
activity	NOUN	O	O	3365
in	ADP	O	O	3365
rats	NOUN	O	O	3365
.	PUNCT	O	O	3365
In	ADP	O	O	3366
addition	NOUN	O	O	3366
,	PUNCT	O	O	3366
carteolol	PROPN	O	Chemical	3366
did	VERB	O	O	3366
not	PART	O	O	3366
evoke	VERB	O	O	3366
5-HT1A	NOUN	O	O	3366
receptor	NOUN	O	O	3366
-	PUNCT	O	O	3366
stimulating	VERB	O	O	3366
behavioral	ADJ	O	O	3366
signs	NOUN	O	O	3366
such	ADJ	O	O	3366
as	ADP	O	O	3366
flat	ADJ	O	O	3366
body	NOUN	O	O	3366
posture	NOUN	O	O	3366
and	CCONJ	O	O	3366
forepaw	ADJ	O	O	3366
treading	VERB	O	O	3366
and	CCONJ	O	O	3366
did	VERB	O	O	3366
not	PART	O	O	3366
inhibit	VERB	O	O	3366
5-hydroxytryptophan	NOUN	O	Chemical	3366
-	PUNCT	O	O	3366
induced	VERB	O	O	3366
head	NOUN	O	O	3366
twitch	VERB	O	O	3366
in	ADP	O	O	3366
rats	NOUN	O	O	3366
.	PUNCT	O	O	3366
Finally	ADV	O	O	3367
,	PUNCT	O	O	3367
carteolol	PROPN	O	Chemical	3367
did	VERB	O	O	3367
not	PART	O	O	3367
inhibit	VERB	O	O	3367
physostigmine	NOUN	O	Chemical	3367
-	PUNCT	O	O	3367
induced	VERB	O	O	3367
lethality	NOUN	O	O	3367
in	ADP	O	O	3367
rats	NOUN	O	O	3367
.	PUNCT	O	O	3367
These	PRON	O	O	3368
results	VERB	O	O	3368
strongly	ADV	O	O	3368
suggest	VERB	O	O	3368
that	SCONJ	O	O	3368
carteolol	PROPN	O	Chemical	3368
improves	VERB	O	O	3368
haloperidol	NOUN	O	Chemical	3368
-	PUNCT	O	O	3368
induced	VERB	O	O	3368
catalepsy	VERB	O	Disease	3368
via	ADP	O	O	3368
its	PRON	O	O	3368
beta	NOUN	O	O	3368
-	PUNCT	O	O	3368
adrenoceptor	NOUN	O	O	3368
antagonistic	ADJ	O	O	3368
activity	NOUN	O	O	3368
and	CCONJ	O	O	3368
is	AUX	O	O	3368
expected	VERB	O	O	3368
to	PART	O	O	3368
be	AUX	O	O	3368
effective	ADJ	O	O	3368
in	ADP	O	O	3368
the	PRON	O	O	3368
treatment	NOUN	O	O	3368
of	ADP	O	O	3368
akathisia	PROPN	O	Disease	3368
without	ADP	O	O	3368
attenuating	VERB	O	O	3368
neuroleptic	NOUN	O	O	3368
-	PUNCT	O	O	3368
induced	VERB	O	O	3368
antipsychotic	ADJ	O	O	3368
effects	NOUN	O	O	3368
due	ADJ	O	O	3368
to	PART	O	O	3368
its	PRON	O	O	3368
postsynaptic	ADJ	O	O	3368
dopamine	NOUN	O	Chemical	3368
receptor	NOUN	O	O	3368
antagonistic	ADJ	O	O	3368
activity	NOUN	O	O	3368
.	PUNCT	O	O	3368
Penicillamine	NOUN	O	Chemical	3371
-	PUNCT	O	O	3371
induced	VERB	O	O	3371
rapidly	ADV	O	O	3371
progressive	ADJ	O	O	3371
glomerulonephritis	NOUN	O	Disease	3371
in	ADP	O	O	3371
a	PRON	O	O	3371
patient	NOUN	O	O	3371
with	ADP	O	O	3371
rheumatoid arthritis	NOUN	O	Disease	3371
.	PUNCT	O	O	3371
A	PRON	O	O	3372
67-year	NOUN	O	O	3372
-	PUNCT	O	O	3372
old	ADJ	O	O	3372
woman	NOUN	O	O	3372
with	ADP	O	O	3372
rheumatoid arthritis	NOUN	O	Disease	3372
presented	VERB	O	O	3372
rapidly	ADV	O	O	3372
progressive	ADJ	O	O	3372
glomerulonephritis	NOUN	O	Disease	3372
(	PUNCT	O	O	3372
RPGN	PROPN	O	Disease	3372
)	PUNCT	O	O	3372
after	ADP	O	O	3372
5	NUM	O	O	3372
months	NOUN	O	O	3372
of	ADP	O	O	3372
D	NOUN	O	O	3372
-	PUNCT	O	O	3372
penicillamine	NOUN	O	Chemical	3372
(	PUNCT	O	O	3372
250	NUM	O	O	3372
mg	VERB	O	O	3372
/	PUNCT	O	O	3372
day	NOUN	O	O	3372
)	PUNCT	O	O	3372
treatment	NOUN	O	O	3372
.	PUNCT	O	O	3372
Light	NOUN	O	O	3373
microscopy	NOUN	O	O	3373
study	VERB	O	O	3373
showed	VERB	O	O	3373
severe	ADJ	O	O	3373
glomerulonephritis	NOUN	O	Disease	3373
with	ADP	O	O	3373
crescent	NOUN	O	O	3373
formation	NOUN	O	O	3373
in	ADP	O	O	3373
60%	NOUN	O	O	3373
of	ADP	O	O	3373
the	PRON	O	O	3373
glomeruli	VERB	O	O	3373
and	CCONJ	O	O	3373
infiltration	NOUN	O	O	3373
of	ADP	O	O	3373
inflammatory	ADJ	O	O	3373
cells	NOUN	O	O	3373
in	ADP	O	O	3373
the	PRON	O	O	3373
wall	PROPN	O	O	3373
of	ADP	O	O	3373
an	PRON	O	O	3373
arteriole	NOUN	O	O	3373
.	PUNCT	O	O	3373
The	PRON	O	O	3374
patient	NOUN	O	O	3374
was	AUX	O	O	3374
treated	VERB	O	O	3374
with	ADP	O	O	3374
steroid	NOUN	O	Chemical	3374
pulse	NOUN	O	O	3374
,	PUNCT	O	O	3374
plasmapheresis	NOUN	O	O	3374
,	PUNCT	O	O	3374
cyclophosphamide	VERB	O	Chemical	3374
and	CCONJ	O	O	3374
antiplatelet agents	NOUN	O	Chemical	3374
.	PUNCT	O	O	3374
This	PRON	O	O	3375
new	ADJ	O	O	3375
case	NOUN	O	O	3375
of	ADP	O	O	3375
RPGN	PROPN	O	Disease	3375
in	ADP	O	O	3375
the	PRON	O	O	3375
course	NOUN	O	O	3375
of	ADP	O	O	3375
D	NOUN	O	O	3375
-	PUNCT	O	O	3375
penicillamine	NOUN	O	Chemical	3375
treatment	NOUN	O	O	3375
emphasizes	VERB	O	O	3375
the	PRON	O	O	3375
need	VERB	O	O	3375
for	ADP	O	O	3375
frequent	ADJ	O	O	3375
monitoring	NOUN	O	O	3375
of	ADP	O	O	3375
renal	ADJ	O	O	3375
function	NOUN	O	O	3375
and	CCONJ	O	O	3375
evaluation	NOUN	O	O	3375
of	ADP	O	O	3375
urinary	ADJ	O	O	3375
sediment	NOUN	O	O	3375
and	CCONJ	O	O	3375
proteinuria	X	O	Disease	3375
in	ADP	O	O	3375
these	PRON	O	O	3375
patients	NOUN	O	O	3375
.	PUNCT	O	O	3375
The	PRON	O	O	3376
prompt	PROPN	O	O	3376
discontinuation	NOUN	O	O	3376
of	ADP	O	O	3376
D	NOUN	O	O	3376
-	PUNCT	O	O	3376
penicillamine	NOUN	O	Chemical	3376
and	CCONJ	O	O	3376
vigorous	ADJ	O	O	3376
treatment	NOUN	O	O	3376
measures	NOUN	O	O	3376
could	AUX	O	O	3376
allow	VERB	O	O	3376
for	ADP	O	O	3376
a	PRON	O	O	3376
good	ADJ	O	O	3376
prognosis	VERB	O	O	3376
as	ADP	O	O	3376
in	ADP	O	O	3376
this	PRON	O	O	3376
case	NOUN	O	O	3376
.	PUNCT	O	O	3376
Nature	NOUN	O	O	3379
,	PUNCT	O	O	3379
time	NOUN	O	O	3379
course	NOUN	O	O	3379
and	CCONJ	O	O	3379
dose	NOUN	O	O	3379
dependence	NOUN	O	O	3379
of	ADP	O	O	3379
zidovudine	NOUN	O	Chemical	3379
-	PUNCT	O	O	3379
related	ADJ	O	O	3379
side	NOUN	O	O	3379
effects	NOUN	O	O	3379
:	PUNCT	O	O	3379
results	VERB	O	O	3379
from	ADP	O	O	3379
the	PRON	O	O	3379
Multicenter	NOUN	O	O	3379
Canadian	ADJ	O	O	3379
Azidothymidine	NOUN	O	Chemical	3379
Trial	NOUN	O	O	3379
.	PUNCT	O	O	3379
To	PART	O	O	3380
characterize	VERB	O	O	3380
the	PRON	O	O	3380
nature	NOUN	O	O	3380
,	PUNCT	O	O	3380
time	NOUN	O	O	3380
course	NOUN	O	O	3380
and	CCONJ	O	O	3380
dose	NOUN	O	O	3380
dependency	NOUN	O	O	3380
of	ADP	O	O	3380
zidovudine	NOUN	O	Chemical	3380
-	PUNCT	O	O	3380
related	ADJ	O	O	3380
side	NOUN	O	O	3380
effects	NOUN	O	O	3380
,	PUNCT	O	O	3380
we	PRON	O	O	3380
undertook	VERB	O	O	3380
a	PRON	O	O	3380
multicenter	ADJ	O	O	3380
,	PUNCT	O	O	3380
prospective	ADJ	O	O	3380
,	PUNCT	O	O	3380
dose	NOUN	O	O	3380
-	PUNCT	O	O	3380
range	VERB	O	O	3380
finding	VERB	O	O	3380
study	VERB	O	O	3380
.	PUNCT	O	O	3380
Our	PRON	O	O	3381
study	VERB	O	O	3381
group	NOUN	O	O	3381
consisted	VERB	O	O	3381
of	ADP	O	O	3381
74	NUM	O	O	3381
HIV	PROPN	O	O	3381
-	PUNCT	O	O	3381
positive	ADJ	O	O	3381
homosexual	ADJ	O	O	3381
men	NOUN	O	O	3381
belonging	VERB	O	O	3381
to	PART	O	O	3381
groups	NOUN	O	O	3381
II	NUM	O	O	3381
B	NOUN	O	O	3381
,	PUNCT	O	O	3381
III	NUM	O	O	3381
and	CCONJ	O	O	3381
IV	NUM	O	O	3381
C2	PROPN	O	O	3381
from	ADP	O	O	3381
the	PRON	O	O	3381
Centers	NOUN	O	O	3381
for	ADP	O	O	3381
Disease	NOUN	O	O	3381
Control	NOUN	O	O	3381
(	PUNCT	O	O	3381
CDC	PROPN	O	O	3381
)	PUNCT	O	O	3381
classification	NOUN	O	O	3381
of	ADP	O	O	3381
HIV disease	NOUN	O	Disease	3381
.	PUNCT	O	O	3381
Following	VERB	O	O	3382
a	PRON	O	O	3382
3-week	NOUN	O	O	3382
observation	NOUN	O	O	3382
period	NOUN	O	O	3382
,	PUNCT	O	O	3382
volunteers	NOUN	O	O	3382
were	AUX	O	O	3382
treated	VERB	O	O	3382
with	ADP	O	O	3382
zidovudine	NOUN	O	Chemical	3382
600	NUM	O	O	3382
mg	VERB	O	O	3382
/	PUNCT	O	O	3382
day	NOUN	O	O	3382
for	ADP	O	O	3382
18	NUM	O	O	3382
weeks	NOUN	O	O	3382
,	PUNCT	O	O	3382
900	NUM	O	O	3382
mg	VERB	O	O	3382
/	PUNCT	O	O	3382
day	NOUN	O	O	3382
for	ADP	O	O	3382
9	NUM	O	O	3382
weeks	NOUN	O	O	3382
and	CCONJ	O	O	3382
1200	NUM	O	O	3382
mg	VERB	O	O	3382
Symptomatic	ADJ	O	O	3383
adverse	ADJ	O	O	3383
effects	NOUN	O	O	3383
were	AUX	O	O	3383
present	NOUN	O	O	3383
in	ADP	O	O	3383
96%	NOUN	O	O	3383
of	ADP	O	O	3383
subjects	NOUN	O	O	3383
,	PUNCT	O	O	3383
most	ADV	O	O	3383
commonly	ADV	O	O	3383
nausea	NOUN	O	Disease	3383
(	PUNCT	O	O	3383
64%	NOUN	O	O	3383
)	PUNCT	O	O	3383
,	PUNCT	O	O	3383
fatigue	NOUN	O	Disease	3383
(	PUNCT	O	O	3383
55%	NOUN	O	O	3383
)	PUNCT	O	O	3383
and	CCONJ	O	O	3383
headache	PROPN	O	Disease	3383
(	PUNCT	O	O	3383
49%	NOUN	O	O	3383
)	PUNCT	O	O	3383
.	PUNCT	O	O	3383
Bone	NOUN	O	O	3384
marrow	PROPN	O	O	3384
changes	VERB	O	O	3384
occurred	VERB	O	O	3384
rapidly	ADV	O	O	3384
as	ADP	O	O	3384
demonstrated	VERB	O	O	3384
by	ADP	O	O	3384
megaloblastosis	NOUN	O	Disease	3384
in	ADP	O	O	3384
95%	NOUN	O	O	3384
of	ADP	O	O	3384
65	NUM	O	O	3384
specimens	NOUN	O	O	3384
at	ADP	O	O	3384
week	NOUN	O	O	3384
18.(ABSTRACT	NUM	O	O	3384
TRUNCATED	ADJ	O	O	3384
AT	ADP	O	O	3384
250	NUM	O	O	3384
WORDS	NOUN	O	O	3384
)	PUNCT	O	O	3384
Bilateral	ADJ	O	O	3387
optic neuropathy	NOUN	O	Disease	3387
due	ADJ	O	O	3387
to	PART	O	O	3387
combined	VERB	O	O	3387
ethambutol	PROPN	O	Chemical	3387
and	CCONJ	O	O	3387
isoniazid	NOUN	O	Chemical	3387
treatment	NOUN	O	O	3387
.	PUNCT	O	O	3387
The	PRON	O	O	3388
case	NOUN	O	O	3388
of	ADP	O	O	3388
a	PRON	O	O	3388
40-year	NOUN	O	O	3388
-	PUNCT	O	O	3388
old	ADJ	O	O	3388
patient	NOUN	O	O	3388
who	PRON	O	O	3388
underwent	VERB	O	O	3388
an	PRON	O	O	3388
unsuccessful	ADJ	O	O	3388
cadaver	NOUN	O	O	3388
kidney	NOUN	O	O	3388
transplantation	NOUN	O	O	3388
and	CCONJ	O	O	3388
was	AUX	O	O	3388
treated	VERB	O	O	3388
with	ADP	O	O	3388
ethambutol	PROPN	O	Chemical	3388
and	CCONJ	O	O	3388
isoniazid	NOUN	O	Chemical	3388
is	AUX	O	O	3388
reported	VERB	O	O	3388
.	PUNCT	O	O	3388
A	PRON	O	O	3389
bilateral retrobulbar neuropathy	NOUN	O	Disease	3389
with	ADP	O	O	3389
an	PRON	O	O	3389
unusual	ADJ	O	O	3389
central	ADJ	O	O	3389
bitemporal	ADJ	O	O	3389
hemianopic	NOUN	O	O	3389
scotoma	PROPN	O	Disease	3389
was	AUX	O	O	3389
found	VERB	O	O	3389
.	PUNCT	O	O	3389
Ethambutol	PROPN	O	Chemical	3390
was	AUX	O	O	3390
stopped	VERB	O	O	3390
and	CCONJ	O	O	3390
only	ADV	O	O	3390
small	ADJ	O	O	3390
improvement	NOUN	O	O	3390
of	ADP	O	O	3390
the	PRON	O	O	3390
visual	ADJ	O	O	3390
acuity	NOUN	O	O	3390
followed	VERB	O	O	3390
.	PUNCT	O	O	3390
Isoniazid	PROPN	O	Chemical	3391
was	AUX	O	O	3391
discontinued	VERB	O	O	3391
later	ADV	O	O	3391
,	PUNCT	O	O	3391
followed	VERB	O	O	3391
by	ADP	O	O	3391
a	PRON	O	O	3391
dramatic	ADJ	O	O	3391
improvement	NOUN	O	O	3391
in	ADP	O	O	3391
the	PRON	O	O	3391
visual	ADJ	O	O	3391
acuity	NOUN	O	O	3391
.	PUNCT	O	O	3391
The	PRON	O	O	3392
hazards	NOUN	O	O	3392
of	ADP	O	O	3392
optic	NOUN	O	O	3392
nerve	NOUN	O	O	3392
toxicity	NOUN	O	Disease	3392
due	ADJ	O	O	3392
to	PART	O	O	3392
ethambutol	PROPN	O	Chemical	3392
are	AUX	O	O	3392
known	VERB	O	O	3392
.	PUNCT	O	O	3392
We	PRON	O	O	3393
emphasize	VERB	O	O	3393
the	PRON	O	O	3393
potential	ADJ	O	O	3393
danger	NOUN	O	O	3393
in	ADP	O	O	3393
the	PRON	O	O	3393
use	VERB	O	O	3393
of	ADP	O	O	3393
ethambutol	PROPN	O	Chemical	3393
and	CCONJ	O	O	3393
isoniazid	NOUN	O	Chemical	3393
.	PUNCT	O	O	3393
Progestational	PROPN	O	O	3396
agents	NOUN	O	O	3396
and	CCONJ	O	O	3396
blood coagulation	NOUN	O	Disease	3396
.	PUNCT	O	O	3396
Thromboembolic	PROPN	O	Disease	3397
and	CCONJ	O	O	3397
other	ADJ	O	O	3397
complications	NOUN	O	O	3397
of	ADP	O	O	3397
oral contraceptive	NOUN	O	Chemical	3397
therapy	NOUN	O	O	3397
in	ADP	O	O	3397
relationship	NOUN	O	O	3397
to	PART	O	O	3397
pretreatment	NOUN	O	O	3397
levels	NOUN	O	O	3397
of	ADP	O	O	3397
blood coagulation	NOUN	O	Disease	3397
factors	NOUN	O	O	3397
:	PUNCT	O	O	3397
summary	NOUN	O	O	3397
report	VERB	O	O	3397
of	ADP	O	O	3397
a	PRON	O	O	3397
ten	NUM	O	O	3397
-	PUNCT	O	O	3397
year	NOUN	O	O	3397
study	VERB	O	O	3397
.	PUNCT	O	O	3397
During	ADP	O	O	3398
a	PRON	O	O	3398
ten	NUM	O	O	3398
-	PUNCT	O	O	3398
year	NOUN	O	O	3398
period	NOUN	O	O	3398
,	PUNCT	O	O	3398
348	NUM	O	O	3398
women	NOUN	O	O	3398
were	AUX	O	O	3398
studied	VERB	O	O	3398
for	ADP	O	O	3398
a	PRON	O	O	3398
total	ADJ	O	O	3398
of	ADP	O	O	3398
5,877	NUM	O	O	3398
patient	NOUN	O	O	3398
months	NOUN	O	O	3398
in	ADP	O	O	3398
four	NUM	O	O	3398
separate	VERB	O	O	3398
studies	NOUN	O	O	3398
relating	VERB	O	O	3398
oral contraceptives	NOUN	O	Chemical	3398
to	PART	O	O	3398
changes	VERB	O	O	3398
in	ADP	O	O	3398
hematologic	ADJ	O	O	3398
parameters	NOUN	O	O	3398
.	PUNCT	O	O	3398
Significant	ADJ	O	O	3399
increases	VERB	O	O	3399
in	ADP	O	O	3399
certain	ADJ	O	O	3399
factors	NOUN	O	O	3399
of	ADP	O	O	3399
the	PRON	O	O	3399
blood coagulation	NOUN	O	Disease	3399
and	CCONJ	O	O	3399
fibrinolysin	PROPN	O	O	3399
systems	NOUN	O	O	3399
(	PUNCT	O	O	3399
factors	NOUN	O	O	3399
I	PRON	O	O	3399
,	PUNCT	O	O	3399
II	NUM	O	O	3399
,	PUNCT	O	O	3399
VII	PROPN	O	O	3399
,	PUNCT	O	O	3399
VIII	PROPN	O	O	3399
,	PUNCT	O	O	3399
IX	NOUN	O	O	3399
,	PUNCT	O	O	3399
and	CCONJ	O	O	3399
X	NOUN	O	O	3399
and	CCONJ	O	O	3399
plasminogen	NOUN	O	O	3399
)	PUNCT	O	O	3399
were	AUX	O	O	3399
observed	VERB	O	O	3399
in	ADP	O	O	3399
the	PRON	O	O	3399
treated	VERB	O	O	3399
groups	NOUN	O	O	3399
.	PUNCT	O	O	3399
All	PRON	O	O	3400
four	NUM	O	O	3400
had	VERB	O	O	3400
an	PRON	O	O	3400
abnormal	ADJ	O	O	3400
blood coagulation	NOUN	O	Disease	3400
profile	NOUN	O	O	3400
,	PUNCT	O	O	3400
suggesting	VERB	O	O	3400
""""	PUNCT	O	O	3400
hypercoagulability	NOUN	O	Disease	3400
""""	PUNCT	O	O	3400
before	ADP	O	O	3400
initiation	NOUN	O	O	3400
of	ADP	O	O	3400
therapy	NOUN	O	O	3400
.	PUNCT	O	O	3400
One	NUM	O	O	3401
of	ADP	O	O	3401
these	PRON	O	O	3401
patients	NOUN	O	O	3401
developed	VERB	O	O	3401
a	PRON	O	O	3401
myocardial infarction	NOUN	O	Disease	3401
before	ADP	O	O	3401
receiving	VERB	O	O	3401
any	PRON	O	O	3401
medication	NOUN	O	O	3401
,	PUNCT	O	O	3401
shortly	ADV	O	O	3401
after	ADP	O	O	3401
the	PRON	O	O	3401
base	PROPN	O	O	3401
-	PUNCT	O	O	3401
line	NOUN	O	O	3401
values	NOUN	O	O	3401
were	AUX	O	O	3401
obtained	VERB	O	O	3401
.	PUNCT	O	O	3401
One	NUM	O	O	3402
patient	NOUN	O	O	3402
developed	VERB	O	O	3402
retinopathy	ADJ	O	Disease	3402
19	NUM	O	O	3402
months	NOUN	O	O	3402
after	ADP	O	O	3402
she	PRON	O	O	3402
began	VERB	O	O	3402
therapy	NOUN	O	O	3402
,	PUNCT	O	O	3402
and	CCONJ	O	O	3402
another	PRON	O	O	3402
developed	VERB	O	O	3402
thrombophlebitis	NOUN	O	Disease	3402
after	ADP	O	O	3402
27	NUM	O	O	3402
months	NOUN	O	O	3402
of	ADP	O	O	3402
therapy	NOUN	O	O	3402
.	PUNCT	O	O	3402
The	PRON	O	O	3403
fourth	ADV	O	O	3403
patient	NOUN	O	O	3403
developed	VERB	O	O	3403
thrombophlebitis	NOUN	O	Disease	3403
14	NUM	O	O	3403
days	NOUN	O	O	3403
after	ADP	O	O	3403
initiation	NOUN	O	O	3403
of	ADP	O	O	3403
contraceptive	NOUN	O	O	3403
therapy	NOUN	O	O	3403
.	PUNCT	O	O	3403
Previous	ADJ	O	O	3404
studies	NOUN	O	O	3404
suggested	VERB	O	O	3404
the	PRON	O	O	3404
possiblility	NOUN	O	O	3404
of	ADP	O	O	3404
increased	VERB	O	O	3404
propensity	NOUN	O	O	3404
for	ADP	O	O	3404
thromboembolic episodes	NOUN	O	Disease	3404
in	ADP	O	O	3404
patients	NOUN	O	O	3404
possessing	VERB	O	O	3404
the	PRON	O	O	3404
A	PRON	O	O	3404
antigen	PROPN	O	O	3404
.	PUNCT	O	O	3404
It	PRON	O	O	3405
appears	VERB	O	O	3405
from	ADP	O	O	3405
these	PRON	O	O	3405
data	NOUN	O	O	3405
that	SCONJ	O	O	3405
hematologic	ADJ	O	O	3405
work	NOUN	O	O	3405
-	PUNCT	O	O	3405
ups	NOUN	O	O	3405
may	AUX	O	O	3405
be	AUX	O	O	3405
useful	ADJ	O	O	3405
in	ADP	O	O	3405
women	NOUN	O	O	3405
who	PRON	O	O	3405
are	AUX	O	O	3405
about	ADP	O	O	3405
to	PART	O	O	3405
start	VERB	O	O	3405
long	ADV	O	O	3405
-	PUNCT	O	O	3405
term	NOUN	O	O	3405
oral contraceptive	NOUN	O	Chemical	3405
therapy	NOUN	O	O	3405
.	PUNCT	O	O	3405
Cardiac arrest	NOUN	O	Disease	3408
in	ADP	O	O	3408
a	PRON	O	O	3408
child	NOUN	O	O	3408
with	ADP	O	O	3408
cerebral palsy	NOUN	O	Disease	3408
undergoing	VERB	O	O	3408
sevoflurane	VERB	O	Chemical	3408
induction	NOUN	O	O	3408
of	ADP	O	O	3408
anesthesia	NOUN	O	O	3408
after	ADP	O	O	3408
preoperative	ADJ	O	O	3408
clonidine	NOUN	O	Chemical	3408
.	PUNCT	O	O	3408
Clonidine	NOUN	O	Chemical	3409
is	AUX	O	O	3409
a	PRON	O	O	3409
frequently	ADV	O	O	3409
administered	VERB	O	O	3409
alpha2-adrenergic	NOUN	O	O	3409
agonist	NOUN	O	O	3409
which	PRON	O	O	3409
can	AUX	O	O	3409
decrease	VERB	O	O	3409
heart	NOUN	O	O	3409
rate	NOUN	O	O	3409
and	CCONJ	O	O	3409
blood	NOUN	O	O	3409
pressure	NOUN	O	O	3409
.	PUNCT	O	O	3409
We	PRON	O	O	3410
present	NOUN	O	O	3410
a	PRON	O	O	3410
case	NOUN	O	O	3410
of	ADP	O	O	3410
a	PRON	O	O	3410
5-year	NOUN	O	O	3410
-	PUNCT	O	O	3410
old	ADJ	O	O	3410
child	NOUN	O	O	3410
with	ADP	O	O	3410
cerebral palsy	NOUN	O	Disease	3410
and	CCONJ	O	O	3410
seizure disorder	NOUN	O	Disease	3410
,	PUNCT	O	O	3410
receiving	VERB	O	O	3410
clonidine	NOUN	O	Chemical	3410
for	ADP	O	O	3410
restlessness	NOUN	O	Disease	3410
,	PUNCT	O	O	3410
who	PRON	O	O	3410
presented	VERB	O	O	3410
for	ADP	O	O	3410
placement	NOUN	O	O	3410
of	ADP	O	O	3410
a	PRON	O	O	3410
baclofen	VERB	O	Chemical	3410
pump	VERB	O	O	3410
.	PUNCT	O	O	3410
Without	ADP	O	O	3411
the	PRON	O	O	3411
knowledge	NOUN	O	O	3411
of	ADP	O	O	3411
the	PRON	O	O	3411
medical	ADJ	O	O	3411
personnel	NOUN	O	O	3411
,	PUNCT	O	O	3411
the	PRON	O	O	3411
patient	NOUN	O	O	3411
's	AUX	O	O	3411
mother	NOUN	O	O	3411
administered	VERB	O	O	3411
three	NUM	O	O	3411
doses	NOUN	O	O	3411
of	ADP	O	O	3411
clonidine	NOUN	O	Chemical	3411
during	ADP	O	O	3411
the	PRON	O	O	3411
evening	NOUN	O	O	3411
before	ADP	O	O	3411
and	CCONJ	O	O	3411
morning	NOUN	O	O	3411
of	ADP	O	O	3411
surgery	NOUN	O	O	3411
to	PART	O	O	3411
reduce	VERB	O	O	3411
anxiety	NOUN	O	Disease	3411
.	PUNCT	O	O	3411
During	ADP	O	O	3412
induction	NOUN	O	O	3412
of	ADP	O	O	3412
anesthesia	NOUN	O	O	3412
,	PUNCT	O	O	3412
the	PRON	O	O	3412
patient	NOUN	O	O	3412
developed	VERB	O	O	3412
bradycardia	NOUN	O	Disease	3412
and	CCONJ	O	O	3412
hypotension	NOUN	O	Disease	3412
requiring	VERB	O	O	3412
cardiac	ADJ	O	O	3412
resuscitation	NOUN	O	O	3412
.	PUNCT	O	O	3412
There	ADV	O	O	3413
are	AUX	O	O	3413
no	PRON	O	O	3413
previous	ADJ	O	O	3413
reports	VERB	O	O	3413
of	ADP	O	O	3413
clonidine	NOUN	O	Chemical	3413
-	PUNCT	O	O	3413
associated	VERB	O	O	3413
cardiac arrest	NOUN	O	Disease	3413
in	ADP	O	O	3413
a	PRON	O	O	3413
child	NOUN	O	O	3413
undergoing	VERB	O	O	3413
induction	NOUN	O	O	3413
of	ADP	O	O	3413
anesthesia	NOUN	O	O	3413
.	PUNCT	O	O	3413
Effects	NOUN	O	O	3416
of	ADP	O	O	3416
UMB24	PROPN	O	Chemical	3416
and	CCONJ	O	O	3416
(	PUNCT	O	O	3416
+	ADP	O	O	3416
/-)-SM 21	NUM	O	O	3416
,	PUNCT	O	O	3416
putative	ADJ	O	O	3416
sigma2-preferring	NOUN	O	O	3416
antagonists	NOUN	O	O	3416
,	PUNCT	O	O	3416
on	ADP	O	O	3416
behavioral	ADJ	O	O	3416
toxic	ADJ	O	O	3416
and	CCONJ	O	O	3416
stimulant	NOUN	O	O	3416
effects	NOUN	O	O	3416
of	ADP	O	O	3416
cocaine	NOUN	O	Chemical	3416
in	ADP	O	O	3416
mice	NOUN	O	O	3416
.	PUNCT	O	O	3416
Earlier	ADV	O	O	3417
studies	NOUN	O	O	3417
have	VERB	O	O	3417
demonstrated	VERB	O	O	3417
that	SCONJ	O	O	3417
antagonism	NOUN	O	O	3417
of	ADP	O	O	3417
sigma1	ADJ	O	O	3417
receptors	NOUN	O	O	3417
attenuates	VERB	O	O	3417
the	PRON	O	O	3417
convulsive	ADJ	O	Disease	3417
,	PUNCT	O	O	3417
lethal	ADJ	O	O	3417
,	PUNCT	O	O	3417
locomotor	PROPN	O	O	3417
stimulatory	ADJ	O	O	3417
and	CCONJ	O	O	3417
rewarding	VERB	O	O	3417
actions	NOUN	O	O	3417
of	ADP	O	O	3417
cocaine	NOUN	O	Chemical	3417
in	ADP	O	O	3417
mice	NOUN	O	O	3417
.	PUNCT	O	O	3417
To	PART	O	O	3418
begin	VERB	O	O	3418
addressing	VERB	O	O	3418
this	PRON	O	O	3418
need	VERB	O	O	3418
,	PUNCT	O	O	3418
we	PRON	O	O	3418
characterized	VERB	O	O	3418
UMB24	PROPN	O	Chemical	3418
(	PUNCT	O	O	3418
1-(2-phenethyl)-4-(2-pyridyl)-piperazine	NOUN	O	Chemical	3418
)	PUNCT	O	O	3418
and	CCONJ	O	O	3418
(	PUNCT	O	O	3418
+	ADP	O	O	3418
/-)-SM 21	NUM	O	O	3418
(	PUNCT	O	O	3418
3alpha	NUM	O	O	3418
-	PUNCT	O	O	3418
tropanyl-2-(4-chorophenoxy)butyrate	NOUN	O	O	3418
)	PUNCT	O	O	3418
in	ADP	O	O	3418
receptor	NOUN	O	O	3418
binding	VERB	O	O	3418
and	CCONJ	O	O	3418
behavioral	ADJ	O	O	3418
studies	NOUN	O	O	3418
.	PUNCT	O	O	3418
Receptor	NOUN	O	O	3419
binding	VERB	O	O	3419
studies	NOUN	O	O	3419
confirmed	VERB	O	O	3419
that	SCONJ	O	O	3419
UMB24	PROPN	O	Chemical	3419
and	CCONJ	O	O	3419
(	PUNCT	O	O	3419
+	ADP	O	O	3419
/-)-SM 21	NUM	O	O	3419
display	NOUN	O	O	3419
preferential	ADJ	O	O	3419
affinity	NOUN	O	O	3419
for	ADP	O	O	3419
sigma2	NOUN	O	O	3419
over	ADP	O	O	3419
sigma1	ADJ	O	O	3419
receptors	NOUN	O	O	3419
.	PUNCT	O	O	3419
In	ADP	O	O	3420
behavioral	ADJ	O	O	3420
studies	NOUN	O	O	3420
,	PUNCT	O	O	3420
pretreatment	NOUN	O	O	3420
of	ADP	O	O	3420
Swiss	PROPN	O	O	3420
Webster	PROPN	O	O	3420
mice	NOUN	O	O	3420
with	ADP	O	O	3420
UMB24	PROPN	O	Chemical	3420
or	CCONJ	O	O	3420
(	PUNCT	O	O	3420
+	ADP	O	O	3420
/-)-SM 21	NUM	O	O	3420
significantly	ADV	O	O	3420
attenuated	VERB	O	O	3420
cocaine	NOUN	O	Chemical	3420
-	PUNCT	O	O	3420
induced	VERB	O	O	3420
convulsions	NOUN	O	Disease	3420
and	CCONJ	O	O	3420
locomotor	PROPN	O	O	3420
activity	NOUN	O	O	3420
,	PUNCT	O	O	3420
but	CCONJ	O	O	3420
not	PART	O	O	3420
lethality	NOUN	O	O	3420
.	PUNCT	O	O	3420
When	SCONJ	O	O	3421
administered	VERB	O	O	3421
alone	ADV	O	O	3421
,	PUNCT	O	O	3421
(	PUNCT	O	O	3421
+	ADP	O	O	3421
/-)-SM 21	NUM	O	O	3421
produced	VERB	O	O	3421
no	PRON	O	O	3421
significant	ADJ	O	O	3421
effects	NOUN	O	O	3421
compared	VERB	O	O	3421
to	PART	O	O	3421
control	VERB	O	O	3421
injections	NOUN	O	O	3421
of	ADP	O	O	3421
saline	NOUN	O	O	3421
,	PUNCT	O	O	3421
but	CCONJ	O	O	3421
UMB24	PROPN	O	Chemical	3421
had	VERB	O	O	3421
locomotor	PROPN	O	O	3421
depressant	NOUN	O	O	3421
actions	NOUN	O	O	3421
.	PUNCT	O	O	3421
Together	ADV	O	O	3422
,	PUNCT	O	O	3422
the	PRON	O	O	3422
data	NOUN	O	O	3422
suggest	VERB	O	O	3422
that	SCONJ	O	O	3422
sigma2	NOUN	O	O	3422
receptor	NOUN	O	O	3422
antagonists	NOUN	O	O	3422
have	VERB	O	O	3422
the	PRON	O	O	3422
potential	ADJ	O	O	3422
to	PART	O	O	3422
attenuate	VERB	O	O	3422
some	PRON	O	O	3422
of	ADP	O	O	3422
the	PRON	O	O	3422
behavioral	ADJ	O	O	3422
effects	NOUN	O	O	3422
of	ADP	O	O	3422
cocaine	NOUN	O	Chemical	3422
,	PUNCT	O	O	3422
and	CCONJ	O	O	3422
further	ADV	O	O	3422
development	NOUN	O	O	3422
of	ADP	O	O	3422
more	ADJ	O	O	3422
selective	ADJ	O	O	3422
,	PUNCT	O	O	3422
high	ADJ	O	O	3422
affinity	NOUN	O	O	3422
ligands	NOUN	O	O	3422
are	AUX	O	O	3422
warranted	VERB	O	O	3422
.	PUNCT	O	O	3422
Methimazole	NOUN	O	Chemical	3425
-	PUNCT	O	O	3425
induced	VERB	O	O	3425
cholestatic jaundice	NOUN	O	Disease	3425
.	PUNCT	O	O	3425
Methimazole	NOUN	O	Chemical	3426
is	AUX	O	O	3426
a	PRON	O	O	3426
widely	ADV	O	O	3426
used	VERB	O	O	3426
and	CCONJ	O	O	3426
generally	ADV	O	O	3426
well	ADV	O	O	3426
-	PUNCT	O	O	3426
tolerated	VERB	O	O	3426
antithyroid	ADJ	O	O	3426
agent	NOUN	O	O	3426
.	PUNCT	O	O	3426
A	PRON	O	O	3427
43-year	NOUN	O	O	3427
-	PUNCT	O	O	3427
old	ADJ	O	O	3427
woman	NOUN	O	O	3427
had	VERB	O	O	3427
severe	ADJ	O	O	3427
jaundice	NOUN	O	Disease	3427
and	CCONJ	O	O	3427
itching	VERB	O	Disease	3427
1	X	O	O	3427
month	NOUN	O	O	3427
after	ADP	O	O	3427
receiving	VERB	O	O	3427
methimazole	VERB	O	Chemical	3427
(	PUNCT	O	O	3427
10	NUM	O	O	3427
mg	VERB	O	O	3427
tid	PROPN	O	O	3427
)	PUNCT	O	O	3427
and	CCONJ	O	O	3427
propranolol	NOUN	O	Chemical	3427
(	PUNCT	O	O	3427
20	NUM	O	O	3427
mg	VERB	O	O	3427
tid	PROPN	O	O	3427
)	PUNCT	O	O	3427
for	ADP	O	O	3427
treatment	NOUN	O	O	3427
of	ADP	O	O	3427
hyperthyroidism	NOUN	O	Disease	3427
.	PUNCT	O	O	3427
The	PRON	O	O	3428
patient	NOUN	O	O	3428
continued	VERB	O	O	3428
treatment	NOUN	O	O	3428
for	ADP	O	O	3428
another	PRON	O	O	3428
4	NUM	O	O	3428
days	NOUN	O	O	3428
after	ADP	O	O	3428
the	PRON	O	O	3428
appearance	NOUN	O	O	3428
of	ADP	O	O	3428
jaundice	NOUN	O	Disease	3428
until	ADP	O	O	3428
she	PRON	O	O	3428
finished	VERB	O	O	3428
both	PRON	O	O	3428
medications	NOUN	O	O	3428
.	PUNCT	O	O	3428
When	SCONJ	O	O	3429
seen	VERB	O	O	3429
at	ADP	O	O	3429
the	PRON	O	O	3429
emergency	NOUN	O	O	3429
department	NOUN	O	O	3429
2	X	O	O	3429
weeks	NOUN	O	O	3429
later	ADV	O	O	3429
,	PUNCT	O	O	3429
she	PRON	O	O	3429
still	ADV	O	O	3429
had	VERB	O	O	3429
severe	ADJ	O	O	3429
icterus	PROPN	O	Disease	3429
,	PUNCT	O	O	3429
pruritus	PROPN	O	Disease	3429
,	PUNCT	O	O	3429
and	CCONJ	O	O	3429
hyperbilirubinemia	PROPN	O	Disease	3429
,	PUNCT	O	O	3429
formed	VERB	O	O	3429
mainly	ADV	O	O	3429
of	ADP	O	O	3429
the	PRON	O	O	3429
conjugated	VERB	O	O	3429
fraction	NOUN	O	O	3429
.	PUNCT	O	O	3429
Methimazole	NOUN	O	Chemical	3430
-	PUNCT	O	O	3430
induced	VERB	O	O	3430
cholestasis	NOUN	O	Disease	3430
was	AUX	O	O	3430
diagnosed	VERB	O	O	3430
,	PUNCT	O	O	3430
and	CCONJ	O	O	3430
propranolol	NOUN	O	Chemical	3430
therapy	NOUN	O	O	3430
was	AUX	O	O	3430
resumed	VERB	O	O	3430
.	PUNCT	O	O	3430
Over	ADP	O	O	3431
the	PRON	O	O	3431
following	VERB	O	O	3431
9	NUM	O	O	3431
days	NOUN	O	O	3431
,	PUNCT	O	O	3431
the	PRON	O	O	3431
symptoms	NOUN	O	O	3431
improved	VERB	O	O	3431
and	CCONJ	O	O	3431
plasma	NOUN	O	O	3431
bilirubin	ADJ	O	Chemical	3431
levels	NOUN	O	O	3431
were	AUX	O	O	3431
normal	ADJ	O	O	3431
after	ADP	O	O	3431
12	NUM	O	O	3431
weeks	NOUN	O	O	3431
without	ADP	O	O	3431
methimazole	VERB	O	Chemical	3431
.	PUNCT	O	O	3431
In	ADP	O	O	3432
rare	ADJ	O	O	3432
cases	NOUN	O	O	3432
within	ADP	O	O	3432
the	PRON	O	O	3432
first	ADV	O	O	3432
few	ADJ	O	O	3432
weeks	NOUN	O	O	3432
of	ADP	O	O	3432
therapy	NOUN	O	O	3432
,	PUNCT	O	O	3432
this	PRON	O	O	3432
drug	NOUN	O	O	3432
can	AUX	O	O	3432
cause	VERB	O	O	3432
severe	ADJ	O	O	3432
and	CCONJ	O	O	3432
reversible	ADJ	O	O	3432
cholestatic jaundice	NOUN	O	Disease	3432
.	PUNCT	O	O	3432
Physicians	NOUN	O	O	3433
and	CCONJ	O	O	3433
patients	NOUN	O	O	3433
should	AUX	O	O	3433
be	AUX	O	O	3433
aware	ADJ	O	O	3433
of	ADP	O	O	3433
this	PRON	O	O	3433
adverse	ADJ	O	O	3433
effect	VERB	O	O	3433
so	ADV	O	O	3433
that	SCONJ	O	O	3433
,	PUNCT	O	O	3433
upon	SCONJ	O	O	3433
occurrence	NOUN	O	O	3433
,	PUNCT	O	O	3433
they	PRON	O	O	3433
can	AUX	O	O	3433
discontinue	VERB	O	O	3433
methimazole	VERB	O	Chemical	3433
therapy	NOUN	O	O	3433
and	CCONJ	O	O	3433
avoid	VERB	O	O	3433
unnecessary	ADJ	O	O	3433
invasive	ADJ	O	O	3433
procedures	NOUN	O	O	3433
.	PUNCT	O	O	3433
Ciprofloxacin	PROPN	O	Chemical	3436
-	PUNCT	O	O	3436
induced	VERB	O	O	3436
acute	ADJ	O	O	3436
interstitial nephritis	NOUN	O	Disease	3436
and	CCONJ	O	O	3436
autoimmune	PROPN	O	O	3436
hemolytic anemia	NOUN	O	Disease	3436
.	PUNCT	O	O	3436
Ciprofloxacin	PROPN	O	Chemical	3437
has	VERB	O	O	3437
been	AUX	O	O	3437
associated	VERB	O	O	3437
with	ADP	O	O	3437
several	ADJ	O	O	3437
side	NOUN	O	O	3437
effects	NOUN	O	O	3437
including	VERB	O	O	3437
interstitial nephritis	NOUN	O	Disease	3437
and	CCONJ	O	O	3437
hemolytic anemia	NOUN	O	Disease	3437
.	PUNCT	O	O	3437
In	ADP	O	O	3438
this	PRON	O	O	3438
report	VERB	O	O	3438
,	PUNCT	O	O	3438
we	PRON	O	O	3438
describe	VERB	O	O	3438
a	PRON	O	O	3438
case	NOUN	O	O	3438
of	ADP	O	O	3438
ciprofloxacin	VERB	O	Chemical	3438
-	PUNCT	O	O	3438
induced	VERB	O	O	3438
interstitial nephritis	NOUN	O	Disease	3438
and	CCONJ	O	O	3438
autoimmune	PROPN	O	O	3438
hemolytic anemia	NOUN	O	Disease	3438
.	PUNCT	O	O	3438
Hemolytic anemia	NOUN	O	Disease	3439
improved	VERB	O	O	3439
after	ADP	O	O	3439
stopping	VERB	O	O	3439
the	PRON	O	O	3439
drug	NOUN	O	O	3439
and	CCONJ	O	O	3439
initiation	NOUN	O	O	3439
of	ADP	O	O	3439
steroid	NOUN	O	Chemical	3439
therapy	NOUN	O	O	3439
.	PUNCT	O	O	3439
Unfortunately	ADV	O	O	3440
,	PUNCT	O	O	3440
acute	ADJ	O	O	3440
interstitial nephritis	NOUN	O	Disease	3440
was	AUX	O	O	3440
irreversible	ADJ	O	O	3440
and	CCONJ	O	O	3440
the	PRON	O	O	3440
patient	NOUN	O	O	3440
developed	VERB	O	O	3440
end	VERB	O	O	3440
-	PUNCT	O	O	3440
stage	NOUN	O	O	3440
renal disease	NOUN	O	Disease	3440
.	PUNCT	O	O	3440
Contribution	NOUN	O	O	3443
of	ADP	O	O	3443
sodium valproate	VERB	O	Chemical	3443
to	PART	O	O	3443
the	PRON	O	O	3443
syndrome of inappropriate secretion of antidiuretic hormone	NOUN	O	Disease	3443
.	PUNCT	O	O	3443
We	PRON	O	O	3444
report	VERB	O	O	3444
the	PRON	O	O	3444
case	NOUN	O	O	3444
of	ADP	O	O	3444
a	PRON	O	O	3444
62-year	NOUN	O	O	3444
-	PUNCT	O	O	3444
old	ADJ	O	O	3444
man	NOUN	O	O	3444
who	PRON	O	O	3444
was	AUX	O	O	3444
administered	VERB	O	O	3444
sodium valproate	VERB	O	Chemical	3444
(	PUNCT	O	O	3444
VPA	PROPN	O	Chemical	3444
)	PUNCT	O	O	3444
and	CCONJ	O	O	3444
who	PRON	O	O	3444
subsequently	ADV	O	O	3444
developed	VERB	O	O	3444
the	PRON	O	O	3444
syndrome of inappropriate secretion of antidiuretic hormone	NOUN	O	Disease	3444
(	PUNCT	O	O	3444
SIADH	PROPN	O	Disease	3444
)	PUNCT	O	O	3444
.	PUNCT	O	O	3444
He	PRON	O	O	3445
had	VERB	O	O	3445
been	AUX	O	O	3445
taking	VERB	O	O	3445
VPA	PROPN	O	Chemical	3445
for	ADP	O	O	3445
treatment	NOUN	O	O	3445
of	ADP	O	O	3445
idiopathic	ADJ	O	O	3445
generalized	VERB	O	O	3445
tonic	PROPN	O	O	3445
-	PUNCT	O	O	3445
clonic	ADJ	O	O	3445
convulsions	NOUN	O	Disease	3445
since	SCONJ	O	O	3445
he	PRON	O	O	3445
was	AUX	O	O	3445
56	NUM	O	O	3445
years	NOUN	O	O	3445
old	ADJ	O	O	3445
.	PUNCT	O	O	3445
After	ADP	O	O	3446
substituting	VERB	O	O	3446
VPA	PROPN	O	Chemical	3446
with	ADP	O	O	3446
zonisamide	ADV	O	Chemical	3446
,	PUNCT	O	O	3446
the	PRON	O	O	3446
serum	NOUN	O	O	3446
sodium	NOUN	O	Chemical	3446
level	VERB	O	O	3446
returned	VERB	O	O	3446
to	PART	O	O	3446
normal	ADJ	O	O	3446
.	PUNCT	O	O	3446
We	PRON	O	O	3447
consider	VERB	O	O	3447
this	PRON	O	O	3447
episode	PROPN	O	O	3447
of	ADP	O	O	3447
SIADH	PROPN	O	Disease	3447
to	PART	O	O	3447
be	AUX	O	O	3447
the	PRON	O	O	3447
result	VERB	O	O	3447
of	ADP	O	O	3447
a	PRON	O	O	3447
combination	NOUN	O	O	3447
of	ADP	O	O	3447
factors	NOUN	O	O	3447
including	VERB	O	O	3447
a	PRON	O	O	3447
weakness of the central nervous system	NOUN	O	Disease	3447
and	CCONJ	O	O	3447
the	PRON	O	O	3447
long	ADV	O	O	3447
-	PUNCT	O	O	3447
term	NOUN	O	O	3447
administration	NOUN	O	O	3447
of	ADP	O	O	3447
VPA	PROPN	O	Chemical	3447
.	PUNCT	O	O	3447
Vasopressin	NOUN	O	Chemical	3450
in	ADP	O	O	3450
the	PRON	O	O	3450
treatment	NOUN	O	O	3450
of	ADP	O	O	3450
milrinone	NOUN	O	Chemical	3450
-	PUNCT	O	O	3450
induced	VERB	O	O	3450
hypotension	NOUN	O	Disease	3450
in	ADP	O	O	3450
severe	ADJ	O	O	3450
heart failure	NOUN	O	Disease	3450
.	PUNCT	O	O	3450
The	PRON	O	O	3451
use	VERB	O	O	3451
of	ADP	O	O	3451
phosphodiesterase	NOUN	O	O	3451
inhibitors	NOUN	O	O	3451
such	ADJ	O	O	3451
as	ADP	O	O	3451
milrinone	NOUN	O	Chemical	3451
in	ADP	O	O	3451
the	PRON	O	O	3451
treatment	NOUN	O	O	3451
of	ADP	O	O	3451
severe	ADJ	O	O	3451
heart failure	NOUN	O	Disease	3451
is	AUX	O	O	3451
frequently	ADV	O	O	3451
restricted	VERB	O	O	3451
because	SCONJ	O	O	3451
they	PRON	O	O	3451
cause	VERB	O	O	3451
vasodilation	NOUN	O	O	3451
and	CCONJ	O	O	3451
hypotension	NOUN	O	Disease	3451
.	PUNCT	O	O	3451
In	ADP	O	O	3452
patients	NOUN	O	O	3452
with	ADP	O	O	3452
decompensated	VERB	O	O	3452
heart failure	NOUN	O	Disease	3452
with	ADP	O	O	3452
hypotension	NOUN	O	Disease	3452
after	ADP	O	O	3452
treatment	NOUN	O	O	3452
with	ADP	O	O	3452
milrinone	NOUN	O	Chemical	3452
,	PUNCT	O	O	3452
low	ADJ	O	O	3452
doses	NOUN	O	O	3452
of	ADP	O	O	3452
vasopressin	NOUN	O	Chemical	3452
restored	VERB	O	O	3452
blood	NOUN	O	O	3452
pressure	NOUN	O	O	3452
without	ADP	O	O	3452
inhibiting	VERB	O	O	3452
the	PRON	O	O	3452
inotropic	NOUN	O	O	3452
effect	VERB	O	O	3452
of	ADP	O	O	3452
milrinone	NOUN	O	Chemical	3452
.	PUNCT	O	O	3452
Halogenated	VERB	O	O	3455
anesthetics	NOUN	O	O	3455
form	NOUN	O	O	3455
liver	NOUN	O	O	3455
adducts	VERB	O	O	3455
and	CCONJ	O	O	3455
antigens	NOUN	O	O	3455
that	SCONJ	O	O	3455
cross	VERB	O	O	3455
-	PUNCT	O	O	3455
react	VERB	O	O	3455
with	ADP	O	O	3455
halothane	VERB	O	Chemical	3455
-	PUNCT	O	O	3455
induced	VERB	O	O	3455
antibodies	NOUN	O	O	3455
.	PUNCT	O	O	3455
Two	NUM	O	O	3456
halogenated	VERB	O	O	3456
anesthetics	NOUN	O	O	3456
,	PUNCT	O	O	3456
enflurane	NOUN	O	Chemical	3456
and	CCONJ	O	O	3456
isoflurane	NOUN	O	Chemical	3456
,	PUNCT	O	O	3456
have	VERB	O	O	3456
been	AUX	O	O	3456
associated	VERB	O	O	3456
with	ADP	O	O	3456
an	PRON	O	O	3456
allergic	ADJ	O	O	3456
-	PUNCT	O	O	3456
type	NOUN	O	O	3456
hepatic injury	NOUN	O	Disease	3456
both	PRON	O	O	3456
alone	ADV	O	O	3456
and	CCONJ	O	O	3456
following	VERB	O	O	3456
previous	ADJ	O	O	3456
exposure	NOUN	O	O	3456
to	PART	O	O	3456
halothane	VERB	O	Chemical	3456
.	PUNCT	O	O	3456
Halothane	NOUN	O	Chemical	3457
hepatitis	NOUN	O	Disease	3457
appears	VERB	O	O	3457
to	PART	O	O	3457
involve	VERB	O	O	3457
an	PRON	O	O	3457
aberrant	ADJ	O	O	3457
immune	NOUN	O	O	3457
response	NOUN	O	O	3457
.	PUNCT	O	O	3457
An	PRON	O	O	3458
antibody	NOUN	O	O	3458
response	NOUN	O	O	3458
to	PART	O	O	3458
a	PRON	O	O	3458
protein	NOUN	O	O	3458
-	PUNCT	O	O	3458
bound	VERB	O	O	3458
biotransformation	NOUN	O	O	3458
product	NOUN	O	O	3458
(	PUNCT	O	O	3458
trifluoroacetyl	VERB	O	Chemical	3458
adduct	NOUN	O	O	3458
)	PUNCT	O	O	3458
has	VERB	O	O	3458
been	AUX	O	O	3458
detected	VERB	O	O	3458
on	ADP	O	O	3458
halothane hepatitis	NOUN	O	Disease	3458
patients	NOUN	O	O	3458
.	PUNCT	O	O	3458
This	PRON	O	O	3459
study	VERB	O	O	3459
was	AUX	O	O	3459
performed	VERB	O	O	3459
to	PART	O	O	3459
determine	VERB	O	O	3459
cross	VERB	O	O	3459
-	PUNCT	O	O	3459
reactivity	NOUN	O	O	3459
between	ADP	O	O	3459
enflurane	NOUN	O	Chemical	3459
and	CCONJ	O	O	3459
isoflurane	NOUN	O	Chemical	3459
with	ADP	O	O	3459
the	PRON	O	O	3459
hypersensitivity	NOUN	O	Disease	3459
induced	VERB	O	O	3459
by	ADP	O	O	3459
halothane	VERB	O	Chemical	3459
.	PUNCT	O	O	3459
The	PRON	O	O	3460
subcellular	ADJ	O	O	3460
and	CCONJ	O	O	3460
lobular	ADJ	O	O	3460
production	NOUN	O	O	3460
of	ADP	O	O	3460
hepatic	ADJ	O	O	3460
neoantigens	NOUN	O	O	3460
recognized	VERB	O	O	3460
by	ADP	O	O	3460
halothane	VERB	O	Chemical	3460
-	PUNCT	O	O	3460
induced	VERB	O	O	3460
antibodies	NOUN	O	O	3460
following	VERB	O	O	3460
enflurane	NOUN	O	Chemical	3460
and	CCONJ	O	O	3460
isoflurane	NOUN	O	Chemical	3460
,	PUNCT	O	O	3460
and	CCONJ	O	O	3460
the	PRON	O	O	3460
biochemical	ADJ	O	O	3460
nature	NOUN	O	O	3460
of	ADP	O	O	3460
these	PRON	O	O	3460
neoantigens	NOUN	O	O	3460
was	AUX	O	O	3460
investigated	VERB	O	O	3460
in	ADP	O	O	3460
two	NUM	O	O	3460
animal	NOUN	O	O	3460
models	NOUN	O	O	3460
.	PUNCT	O	O	3460
Enflurane	NOUN	O	Chemical	3461
administration	NOUN	O	O	3461
resulted	VERB	O	O	3461
in	ADP	O	O	3461
neoantigens	NOUN	O	O	3461
detected	VERB	O	O	3461
in	ADP	O	O	3461
both	PRON	O	O	3461
the	PRON	O	O	3461
microsomal	PROPN	O	O	3461
and	CCONJ	O	O	3461
cytosolic	ADJ	O	O	3461
fraction	NOUN	O	O	3461
of	ADP	O	O	3461
liver	NOUN	O	O	3461
homogenates	VERB	O	O	3461
and	CCONJ	O	O	3461
in	ADP	O	O	3461
the	PRON	O	O	3461
centrilobular	ADJ	O	O	3461
region	NOUN	O	O	3461
of	ADP	O	O	3461
the	PRON	O	O	3461
liver	NOUN	O	O	3461
.	PUNCT	O	O	3461
This	PRON	O	O	3462
supports	VERB	O	O	3462
and	CCONJ	O	O	3462
extends	VERB	O	O	3462
previous	ADJ	O	O	3462
evidence	NOUN	O	O	3462
for	ADP	O	O	3462
a	PRON	O	O	3462
mechanism	NOUN	O	O	3462
by	ADP	O	O	3462
which	PRON	O	O	3462
enflurane	NOUN	O	Chemical	3462
and/or	CCONJ	O	O	3462
isoflurane	NOUN	O	Chemical	3462
could	AUX	O	O	3462
produce	VERB	O	O	3462
a	PRON	O	O	3462
hypersensitivity	NOUN	O	Disease	3462
condition	NOUN	O	O	3462
similar	ADJ	O	O	3462
to	PART	O	O	3462
that	SCONJ	O	O	3462
of	ADP	O	O	3462
halothane hepatitis	NOUN	O	Disease	3462
either	ADV	O	O	3462
alone	ADV	O	O	3462
or	CCONJ	O	O	3462
subsequent	ADJ	O	O	3462
to	PART	O	O	3462
halothane	VERB	O	Chemical	3462
administration	NOUN	O	O	3462
.	PUNCT	O	O	3462
Induction	NOUN	O	O	3465
by	ADP	O	O	3465
paracetamol	PROPN	O	Chemical	3465
of	ADP	O	O	3465
bladder and liver tumours	NOUN	O	Disease	3465
in	ADP	O	O	3465
the	PRON	O	O	3465
rat	NOUN	O	O	3465
.	PUNCT	O	O	3465
Groups	NOUN	O	O	3466
of	ADP	O	O	3466
male	NOUN	O	O	3466
and	CCONJ	O	O	3466
female	ADJ	O	O	3466
inbred	ADJ	O	O	3466
Leeds	NOUN	O	O	3466
strain	VERB	O	O	3466
rats	NOUN	O	O	3466
were	AUX	O	O	3466
fed	VERB	O	O	3466
diets	NOUN	O	O	3466
containing	VERB	O	O	3466
either	ADV	O	O	3466
0.5%	NOUN	O	O	3466
or	CCONJ	O	O	3466
1.0%	NOUN	O	O	3466
paracetamol	PROPN	O	Chemical	3466
by	ADP	O	O	3466
weight	NOUN	O	O	3466
for	ADP	O	O	3466
up	ADP	O	O	3466
to	PART	O	O	3466
18	NUM	O	O	3466
months	NOUN	O	O	3466
.	PUNCT	O	O	3466
Papillomas	NOUN	O	Disease	3467
of	ADP	O	O	3467
the	PRON	O	O	3467
transitional	ADJ	O	O	3467
epithelium	NOUN	O	O	3467
of	ADP	O	O	3467
the	PRON	O	O	3467
bladder	NOUN	O	O	3467
developed	VERB	O	O	3467
in	ADP	O	O	3467
all	PRON	O	O	3467
paracetamol	PROPN	O	Chemical	3467
-	PUNCT	O	O	3467
treated	VERB	O	O	3467
groups	NOUN	O	O	3467
,	PUNCT	O	O	3467
and	CCONJ	O	O	3467
three	NUM	O	O	3467
rats	NOUN	O	O	3467
bore	VERB	O	O	3467
bladder carcinomas	NOUN	O	Disease	3467
.	PUNCT	O	O	3467
However	ADV	O	O	3468
,	PUNCT	O	O	3468
significant	ADJ	O	O	3468
yields	VERB	O	O	3468
of	ADP	O	O	3468
bladder tumours	NOUN	O	Disease	3468
were	AUX	O	O	3468
only	ADV	O	O	3468
obtained	VERB	O	O	3468
from	ADP	O	O	3468
low	ADJ	O	O	3468
dosage	NOUN	O	O	3468
females	NOUN	O	O	3468
and	CCONJ	O	O	3468
high	ADJ	O	O	3468
dosage	NOUN	O	O	3468
males	NOUN	O	O	3468
.	PUNCT	O	O	3468
Additionally	ADV	O	O	3469
,	PUNCT	O	O	3469
20	NUM	O	O	3469
to	PART	O	O	3469
25%	NOUN	O	O	3469
of	ADP	O	O	3469
paracetamol	PROPN	O	Chemical	3469
-	PUNCT	O	O	3469
treated	VERB	O	O	3469
rats	NOUN	O	O	3469
developed	VERB	O	O	3469
hyperplasia	NOUN	O	Disease	3469
of	ADP	O	O	3469
the	PRON	O	O	3469
bladder	NOUN	O	O	3469
epithelium	NOUN	O	O	3469
,	PUNCT	O	O	3469
which	PRON	O	O	3469
was	AUX	O	O	3469
not	PART	O	O	3469
coincident	VERB	O	O	3469
with	ADP	O	O	3469
the	PRON	O	O	3469
presence	NOUN	O	O	3469
of	ADP	O	O	3469
bladder calculi	NOUN	O	Disease	3469
.	PUNCT	O	O	3469
A	PRON	O	O	3470
low	ADJ	O	O	3470
yield	VERB	O	O	3470
of	ADP	O	O	3470
tumours	NOUN	O	Disease	3470
at	ADP	O	O	3470
various	ADJ	O	O	3470
other	ADJ	O	O	3470
sites	NOUN	O	O	3470
also	ADV	O	O	3470
arose	VERB	O	O	3470
following	VERB	O	O	3470
paracetamol	PROPN	O	Chemical	3470
feeding	VERB	O	O	3470
.	PUNCT	O	O	3470
An	PRON	O	O	3471
electron	NOUN	O	O	3471
microscope	NOUN	O	O	3471
study	VERB	O	O	3471
of	ADP	O	O	3471
the	PRON	O	O	3471
livers	NOUN	O	O	3471
of	ADP	O	O	3471
paracetamol	PROPN	O	Chemical	3471
-	PUNCT	O	O	3471
treated	VERB	O	O	3471
rats	NOUN	O	O	3471
revealed	VERB	O	O	3471
ultrastructural	ADJ	O	O	3471
changes	VERB	O	O	3471
in	ADP	O	O	3471
the	PRON	O	O	3471
hepatocytes	VERB	O	O	3471
that	SCONJ	O	O	3471
resemble	VERB	O	O	3471
those	PRON	O	O	3471
that	SCONJ	O	O	3471
result	VERB	O	O	3471
from	ADP	O	O	3471
exposure	NOUN	O	O	3471
to	PART	O	O	3471
a	PRON	O	O	3471
variety	NOUN	O	O	3471
of	ADP	O	O	3471
known	VERB	O	O	3471
hepatocarcinogens	NOUN	O	Disease	3471
.	PUNCT	O	O	3471
Local	ADJ	O	O	3474
anesthetics	NOUN	O	O	3474
that	SCONJ	O	O	3474
are	AUX	O	O	3474
commonly	ADV	O	O	3474
used	VERB	O	O	3474
in	ADP	O	O	3474
ophthalmic	ADJ	O	O	3474
surgery	NOUN	O	O	3474
(	PUNCT	O	O	3474
0.75%	NOUN	O	O	3474
bupivacaine hydrochloride	NOUN	O	Chemical	3474
,	PUNCT	O	O	3474
2.0%	NOUN	O	O	3474
mepivacaine hydrochloride	NOUN	O	Chemical	3474
,	PUNCT	O	O	3474
and	CCONJ	O	O	3474
2.0%	NOUN	O	O	3474
lidocaine hydrochloride	NOUN	O	Chemical	3474
plus	CCONJ	O	O	3474
1:100,000	NUM	O	O	3474
epinephrine	NOUN	O	Chemical	3474
)	PUNCT	O	O	3474
were	AUX	O	O	3474
injected	VERB	O	O	3474
into	ADP	O	O	3474
the	PRON	O	O	3474
retrobulbar	NOUN	O	O	3474
area	NOUN	O	O	3474
of	ADP	O	O	3474
rat	NOUN	O	O	3474
eyes	NOUN	O	O	3474
.	PUNCT	O	O	3474
Muscle degeneration	NOUN	O	Disease	3475
is	AUX	O	O	3475
followed	VERB	O	O	3475
by	ADP	O	O	3475
regeneration	NOUN	O	O	3475
of	ADP	O	O	3475
the	PRON	O	O	3475
damaged	VERB	O	O	3475
muscle	NOUN	O	O	3475
fibers	NOUN	O	O	3475
.	PUNCT	O	O	3475
In	ADP	O	O	3476
addition	NOUN	O	O	3476
to	PART	O	O	3476
muscle damage	NOUN	O	Disease	3476
,	PUNCT	O	O	3476
severe	ADJ	O	O	3476
damage	NOUN	O	O	3476
was	AUX	O	O	3476
also	ADV	O	O	3476
seen	VERB	O	O	3476
in	ADP	O	O	3476
harderian	ADJ	O	O	3476
glands	NOUN	O	O	3476
,	PUNCT	O	O	3476
especially	ADV	O	O	3476
after	ADP	O	O	3476
exposure	NOUN	O	O	3476
to	PART	O	O	3476
mepivacaine	NOUN	O	Chemical	3476
and	CCONJ	O	O	3476
lidocaine	NOUN	O	Chemical	3476
plus	CCONJ	O	O	3476
epinephrine	NOUN	O	Chemical	3476
.	PUNCT	O	O	3476
With	ADP	O	O	3477
these	PRON	O	O	3477
findings	NOUN	O	O	3477
in	ADP	O	O	3477
rats	NOUN	O	O	3477
,	PUNCT	O	O	3477
it	PRON	O	O	3477
is	AUX	O	O	3477
hypothesized	VERB	O	O	3477
that	SCONJ	O	O	3477
the	PRON	O	O	3477
temporary	ADJ	O	O	3477
diplopia	NOUN	O	Disease	3477
sometimes	ADV	O	O	3477
seen	VERB	O	O	3477
in	ADP	O	O	3477
patients	NOUN	O	O	3477
after	ADP	O	O	3477
ophthalmic	ADJ	O	O	3477
surgery	NOUN	O	O	3477
might	AUX	O	O	3477
be	AUX	O	O	3477
due	ADJ	O	O	3477
to	PART	O	O	3477
anesthetic	NOUN	O	O	3477
-	PUNCT	O	O	3477
induced	VERB	O	O	3477
damage	NOUN	O	O	3477
to	PART	O	O	3477
the	PRON	O	O	3477
extraocular	ADJ	O	O	3477
muscles	NOUN	O	O	3477
.	PUNCT	O	O	3477
Reversal	NOUN	O	O	3480
of	ADP	O	O	3480
neuroleptic	NOUN	O	O	3480
-	PUNCT	O	O	3480
induced	VERB	O	O	3480
catalepsy	VERB	O	Disease	3480
by	ADP	O	O	3480
novel	NOUN	O	O	3480
aryl	ADJ	O	O	3480
-	PUNCT	O	O	3480
piperazine	NOUN	O	O	3480
anxiolytic	ADJ	O	O	3480
drugs	NOUN	O	O	3480
.	PUNCT	O	O	3480
The	PRON	O	O	3481
novel	NOUN	O	O	3481
anxiolytic	ADJ	O	O	3481
drug	NOUN	O	O	3481
,	PUNCT	O	O	3481
buspirone	PROPN	O	Chemical	3481
,	PUNCT	O	O	3481
reverses	VERB	O	O	3481
catalepsy	VERB	O	Disease	3481
induced	VERB	O	O	3481
by	ADP	O	O	3481
haloperidol	NOUN	O	Chemical	3481
.	PUNCT	O	O	3481
A	PRON	O	O	3482
series	PROPN	O	O	3482
of	ADP	O	O	3482
aryl	ADJ	O	O	3482
-	PUNCT	O	O	3482
piperazine	NOUN	O	O	3482
analogues	NOUN	O	O	3482
of	ADP	O	O	3482
buspirone	PROPN	O	Chemical	3482
and	CCONJ	O	O	3482
other	ADJ	O	O	3482
5-hydroxytryptaminergic agonists	NOUN	O	Chemical	3482
were	AUX	O	O	3482
tested	VERB	O	O	3482
for	ADP	O	O	3482
their	PRON	O	O	3482
ability	NOUN	O	O	3482
to	PART	O	O	3482
reverse	VERB	O	O	3482
haloperidol	NOUN	O	Chemical	3482
induced	VERB	O	O	3482
catalepsy	VERB	O	Disease	3482
.	PUNCT	O	O	3482
Those	PRON	O	O	3483
drugs	NOUN	O	O	3483
with	ADP	O	O	3483
strong	ADJ	O	O	3483
affinity	NOUN	O	O	3483
for	ADP	O	O	3483
5-hydroxytryptamine1a	NOUN	O	O	3483
receptors	NOUN	O	O	3483
were	AUX	O	O	3483
able	ADJ	O	O	3483
to	PART	O	O	3483
reverse	VERB	O	O	3483
catalepsy	VERB	O	Disease	3483
.	PUNCT	O	O	3483
Drugs	NOUN	O	O	3484
with	ADP	O	O	3484
affinity	NOUN	O	O	3484
for	ADP	O	O	3484
other	ADJ	O	O	3484
5-HT	NOUN	O	Chemical	3484
receptors	NOUN	O	O	3484
or	CCONJ	O	O	3484
weak	ADJ	O	O	3484
affinity	NOUN	O	O	3484
were	AUX	O	O	3484
ineffective	ADJ	O	O	3484
.	PUNCT	O	O	3484
However	ADV	O	O	3485
,	PUNCT	O	O	3485
inhibition	NOUN	O	O	3485
of	ADP	O	O	3485
postsynaptic	ADJ	O	O	3485
5-HT	NOUN	O	Chemical	3485
receptors	NOUN	O	O	3485
neither	ADV	O	O	3485
inhibited	VERB	O	O	3485
nor	CCONJ	O	O	3485
potentiated	VERB	O	O	3485
reversal	NOUN	O	O	3485
of	ADP	O	O	3485
catalepsy	VERB	O	Disease	3485
and	CCONJ	O	O	3485
leaves	VERB	O	O	3485
open	VERB	O	O	3485
the	PRON	O	O	3485
question	NOUN	O	O	3485
as	ADP	O	O	3485
to	PART	O	O	3485
the	PRON	O	O	3485
site	NOUN	O	O	3485
or	CCONJ	O	O	3485
mechanism	NOUN	O	O	3485
for	ADP	O	O	3485
this	PRON	O	O	3485
effect	VERB	O	O	3485
.	PUNCT	O	O	3485
Diazepam	NOUN	O	Chemical	3488
facilitates	VERB	O	O	3488
reflex	NOUN	O	O	3488
bradycardia	NOUN	O	Disease	3488
in	ADP	O	O	3488
conscious	ADJ	O	O	3488
rats	NOUN	O	O	3488
.	PUNCT	O	O	3488
The	PRON	O	O	3489
effects	NOUN	O	O	3489
of	ADP	O	O	3489
diazepam	NOUN	O	Chemical	3489
on	ADP	O	O	3489
cardiovascular	ADJ	O	O	3489
function	NOUN	O	O	3489
were	AUX	O	O	3489
assessed	VERB	O	O	3489
in	ADP	O	O	3489
conscious	ADJ	O	O	3489
rats	NOUN	O	O	3489
.	PUNCT	O	O	3489
Intravenous	PROPN	O	O	3490
administration	NOUN	O	O	3490
of	ADP	O	O	3490
diazepam	NOUN	O	Chemical	3490
(	PUNCT	O	O	3490
1	X	O	O	3490
-	PUNCT	O	O	3490
30	NUM	O	O	3490
mg	VERB	O	O	3490
kg-1	VERB	O	O	3490
)	PUNCT	O	O	3490
produced	VERB	O	O	3490
a	PRON	O	O	3490
dose	NOUN	O	O	3490
-	PUNCT	O	O	3490
dependent	ADJ	O	O	3490
decrease	VERB	O	O	3490
in	ADP	O	O	3490
both	PRON	O	O	3490
the	PRON	O	O	3490
mean	VERB	O	O	3490
arterial	ADJ	O	O	3490
pressure	NOUN	O	O	3490
and	CCONJ	O	O	3490
the	PRON	O	O	3490
heart	NOUN	O	O	3490
rate	NOUN	O	O	3490
.	PUNCT	O	O	3490
Also	ADV	O	O	3491
,	PUNCT	O	O	3491
reflex	NOUN	O	O	3491
bradycardia	NOUN	O	Disease	3491
was	AUX	O	O	3491
produced	VERB	O	O	3491
in	ADP	O	O	3491
rats	NOUN	O	O	3491
by	ADP	O	O	3491
intravenous	ADJ	O	O	3491
infusion	NOUN	O	O	3491
of	ADP	O	O	3491
adrenaline	NOUN	O	Chemical	3491
(	PUNCT	O	O	3491
1.25	NUM	O	O	3491
-	PUNCT	O	O	3491
2.5	NUM	O	O	3491
micrograms	NOUN	O	O	3491
kg-1	VERB	O	O	3491
)	PUNCT	O	O	3491
.	PUNCT	O	O	3491
Intravenous	PROPN	O	O	3492
pretreatment	NOUN	O	O	3492
of	ADP	O	O	3492
the	PRON	O	O	3492
rats	NOUN	O	O	3492
with	ADP	O	O	3492
diazepam	NOUN	O	Chemical	3492
,	PUNCT	O	O	3492
although	SCONJ	O	O	3492
causing	VERB	O	O	3492
no	PRON	O	O	3492
change	VERB	O	O	3492
in	ADP	O	O	3492
the	PRON	O	O	3492
adrenaline	NOUN	O	Chemical	3492
-	PUNCT	O	O	3492
induced	VERB	O	O	3492
pressor	ADJ	O	O	3492
effect	VERB	O	O	3492
,	PUNCT	O	O	3492
did	VERB	O	O	3492
enhance	VERB	O	O	3492
the	PRON	O	O	3492
adrenaline	NOUN	O	Chemical	3492
-	PUNCT	O	O	3492
induced	VERB	O	O	3492
reflex	NOUN	O	O	3492
bradycardia	NOUN	O	Disease	3492
.	PUNCT	O	O	3492
However	ADV	O	O	3493
,	PUNCT	O	O	3493
the	PRON	O	O	3493
diazepam	NOUN	O	Chemical	3493
enhancement	NOUN	O	O	3493
of	ADP	O	O	3493
adrenaline	NOUN	O	Chemical	3493
-	PUNCT	O	O	3493
induced	VERB	O	O	3493
reflex	NOUN	O	O	3493
bradycardia	NOUN	O	Disease	3493
was	AUX	O	O	3493
antagonized	VERB	O	O	3493
by	ADP	O	O	3493
pretreatment	NOUN	O	O	3493
of	ADP	O	O	3493
rats	NOUN	O	O	3493
with	ADP	O	O	3493
an	PRON	O	O	3493
intravenous	ADJ	O	O	3493
dose	NOUN	O	O	3493
of	ADP	O	O	3493
picrotoxin	PROPN	O	Chemical	3493
(	PUNCT	O	O	3493
an	PRON	O	O	3493
agent	NOUN	O	O	3493
blocks	NOUN	O	O	3493
chloride	NOUN	O	Chemical	3493
channels	NOUN	O	O	3493
by	ADP	O	O	3493
binding	VERB	O	O	3493
to	PART	O	O	3493
sites	NOUN	O	O	3493
associated	VERB	O	O	3493
with	ADP	O	O	3493
the	PRON	O	O	3493
benzodiazepine	PROPN	O	Chemical	3493
-	PUNCT	O	O	3493
GABA	PROPN	O	Chemical	3493
-	PUNCT	O	O	3493
chloride	NOUN	O	Chemical	3493
channel	PROPN	O	O	3493
macromolecular	PROPN	O	O	3493
complex	ADJ	O	O	3493
)	PUNCT	O	O	3493
.	PUNCT	O	O	3493
The	PRON	O	O	3494
data	NOUN	O	O	3494
indicate	VERB	O	O	3494
that	SCONJ	O	O	3494
diazepam	NOUN	O	Chemical	3494
acts	VERB	O	O	3494
through	ADP	O	O	3494
the	PRON	O	O	3494
benzodiazepine	PROPN	O	Chemical	3494
-	PUNCT	O	O	3494
GABA	PROPN	O	Chemical	3494
-	PUNCT	O	O	3494
chloride	NOUN	O	Chemical	3494
channel	PROPN	O	O	3494
macromolecular	PROPN	O	O	3494
complex	ADJ	O	O	3494
within	ADP	O	O	3494
the	PRON	O	O	3494
central	ADJ	O	O	3494
nervous	ADJ	O	O	3494
system	NOUN	O	O	3494
to	PART	O	O	3494
facilitate	VERB	O	O	3494
reflex	NOUN	O	O	3494
bradycardia	NOUN	O	Disease	3494
mediated	VERB	O	O	3494
through	ADP	O	O	3494
baroreceptor	VERB	O	O	3494
reflexes	NOUN	O	O	3494
in	ADP	O	O	3494
response	NOUN	O	O	3494
to	PART	O	O	3494
an	PRON	O	O	3494
acute	ADJ	O	O	3494
increase	VERB	O	O	3494
in	ADP	O	O	3494
arterial	ADJ	O	O	3494
pressure	NOUN	O	O	3494
.	PUNCT	O	O	3494
Chronic	NOUN	O	O	3497
carbamazepine	NOUN	O	Chemical	3497
inhibits	VERB	O	O	3497
the	PRON	O	O	3497
development	NOUN	O	O	3497
of	ADP	O	O	3497
local	ADJ	O	O	3497
anesthetic	NOUN	O	O	3497
seizures	NOUN	O	Disease	3497
kindled	VERB	O	O	3497
by	ADP	O	O	3497
cocaine	NOUN	O	Chemical	3497
and	CCONJ	O	O	3497
lidocaine	NOUN	O	Chemical	3497
.	PUNCT	O	O	3497
The	PRON	O	O	3498
effects	NOUN	O	O	3498
of	ADP	O	O	3498
carbamazepine	NOUN	O	Chemical	3498
(	PUNCT	O	O	3498
CBZ	PROPN	O	Chemical	3498
)	PUNCT	O	O	3498
treatment	NOUN	O	O	3498
on	ADP	O	O	3498
local	ADJ	O	O	3498
anesthetic	NOUN	O	O	3498
-	PUNCT	O	O	3498
kindled	VERB	O	O	3498
seizures	NOUN	O	Disease	3498
and	CCONJ	O	O	3498
lethality	NOUN	O	O	3498
were	AUX	O	O	3498
evaluated	VERB	O	O	3498
in	ADP	O	O	3498
different	ADJ	O	O	3498
stages	NOUN	O	O	3498
of	ADP	O	O	3498
the	PRON	O	O	3498
kindling	VERB	O	O	3498
process	NOUN	O	O	3498
and	CCONJ	O	O	3498
under	ADP	O	O	3498
different	ADJ	O	O	3498
methods	NOUN	O	O	3498
of	ADP	O	O	3498
CBZ	PROPN	O	Chemical	3498
administration	NOUN	O	O	3498
.	PUNCT	O	O	3498
Chronic	NOUN	O	O	3499
oral	ADJ	O	O	3499
CBZ	PROPN	O	Chemical	3499
inhibited	VERB	O	O	3499
the	PRON	O	O	3499
development	NOUN	O	O	3499
of	ADP	O	O	3499
both	PRON	O	O	3499
lidocaine-	ADJ	O	O	3499
and	CCONJ	O	O	3499
cocaine	NOUN	O	Chemical	3499
-	PUNCT	O	O	3499
induced	VERB	O	O	3499
seizures	NOUN	O	Disease	3499
,	PUNCT	O	O	3499
but	CCONJ	O	O	3499
had	VERB	O	O	3499
little	ADJ	O	O	3499
effect	VERB	O	O	3499
on	ADP	O	O	3499
the	PRON	O	O	3499
fully	ADV	O	O	3499
developed	VERB	O	O	3499
local	ADJ	O	O	3499
anesthetic	NOUN	O	O	3499
seizures	NOUN	O	Disease	3499
.	PUNCT	O	O	3499
Chronic	NOUN	O	O	3500
CBZ	PROPN	O	Chemical	3500
also	ADV	O	O	3500
decreased	VERB	O	O	3500
the	PRON	O	O	3500
incidence	NOUN	O	O	3500
of	ADP	O	O	3500
seizure	NOUN	O	Disease	3500
-	PUNCT	O	O	3500
related	ADJ	O	O	3500
mortality	NOUN	O	O	3500
in	ADP	O	O	3500
the	PRON	O	O	3500
cocaine	NOUN	O	Chemical	3500
-	PUNCT	O	O	3500
injected	VERB	O	O	3500
rats	NOUN	O	O	3500
.	PUNCT	O	O	3500
Acute	PROPN	O	O	3501
CBZ	PROPN	O	Chemical	3501
over	ADP	O	O	3501
a	PRON	O	O	3501
range	VERB	O	O	3501
of	ADP	O	O	3501
doses	NOUN	O	O	3501
(	PUNCT	O	O	3501
15	NUM	O	O	3501
-	PUNCT	O	O	3501
50	NUM	O	O	3501
mg	VERB	O	O	3501
/	PUNCT	O	O	3501
kg	VERB	O	O	3501
)	PUNCT	O	O	3501
had	VERB	O	O	3501
no	PRON	O	O	3501
effect	VERB	O	O	3501
on	ADP	O	O	3501
completed	VERB	O	O	3501
lidocaine	NOUN	O	Chemical	3501
-	PUNCT	O	O	3501
kindled	VERB	O	O	3501
or	CCONJ	O	O	3501
acute	ADJ	O	O	3501
cocaine	NOUN	O	Chemical	3501
-	PUNCT	O	O	3501
induced	VERB	O	O	3501
seizures	NOUN	O	Disease	3501
.	PUNCT	O	O	3501
injection	NOUN	O	O	3502
of	ADP	O	O	3502
CBZ	PROPN	O	Chemical	3502
(	PUNCT	O	O	3502
15	NUM	O	O	3502
mg	VERB	O	O	3502
/	PUNCT	O	O	3502
kg	VERB	O	O	3502
)	PUNCT	O	O	3502
also	ADV	O	O	3502
was	AUX	O	O	3502
without	ADP	O	O	3502
effect	VERB	O	O	3502
on	ADP	O	O	3502
the	PRON	O	O	3502
development	NOUN	O	O	3502
of	ADP	O	O	3502
lidocaine-	ADJ	O	O	3502
or	CCONJ	O	O	3502
cocaine	NOUN	O	Chemical	3502
-	PUNCT	O	O	3502
kindled	VERB	O	O	3502
seizures	NOUN	O	Disease	3502
.	PUNCT	O	O	3502
The	PRON	O	O	3503
differential	ADJ	O	O	3503
effects	NOUN	O	O	3503
of	ADP	O	O	3503
CBZ	PROPN	O	Chemical	3503
depending	VERB	O	O	3503
upon	SCONJ	O	O	3503
stage	NOUN	O	O	3503
of	ADP	O	O	3503
seizure	NOUN	O	Disease	3503
development	NOUN	O	O	3503
suggest	VERB	O	O	3503
that	SCONJ	O	O	3503
distinct	ADJ	O	O	3503
mechanisms	NOUN	O	O	3503
underlie	VERB	O	O	3503
the	PRON	O	O	3503
development	NOUN	O	O	3503
versus	ADP	O	O	3503
maintenance	NOUN	O	O	3503
of	ADP	O	O	3503
local	ADJ	O	O	3503
anesthetic	NOUN	O	O	3503
-	PUNCT	O	O	3503
kindled	VERB	O	O	3503
seizures	NOUN	O	Disease	3503
.	PUNCT	O	O	3503
The	PRON	O	O	3504
effectiveness	NOUN	O	O	3504
of	ADP	O	O	3504
chronic	ADJ	O	O	3504
but	CCONJ	O	O	3504
not	PART	O	O	3504
repeated	VERB	O	O	3504
,	PUNCT	O	O	3504
intermittent	ADJ	O	O	3504
injections	NOUN	O	O	3504
of	ADP	O	O	3504
CBZ	PROPN	O	Chemical	3504
suggests	VERB	O	O	3504
that	SCONJ	O	O	3504
different	ADJ	O	O	3504
biochemical	ADJ	O	O	3504
consequences	NOUN	O	O	3504
result	VERB	O	O	3504
from	ADP	O	O	3504
the	PRON	O	O	3504
different	ADJ	O	O	3504
treatment	NOUN	O	O	3504
regimens	NOUN	O	O	3504
.	PUNCT	O	O	3504
The	PRON	O	O	3505
possible	ADJ	O	O	3505
utility	NOUN	O	O	3505
of	ADP	O	O	3505
chronic	ADJ	O	O	3505
CBZ	PROPN	O	Chemical	3505
in	ADP	O	O	3505
preventing	VERB	O	O	3505
the	PRON	O	O	3505
development	NOUN	O	O	3505
of	ADP	O	O	3505
toxic	ADJ	O	O	3505
side	NOUN	O	O	3505
effects	NOUN	O	O	3505
in	ADP	O	O	3505
human	PROPN	O	O	3505
cocaine	NOUN	O	Chemical	3505
users	NOUN	O	O	3505
is	AUX	O	O	3505
suggested	VERB	O	O	3505
by	ADP	O	O	3505
these	PRON	O	O	3505
data	NOUN	O	O	3505
,	PUNCT	O	O	3505
but	CCONJ	O	O	3505
remains	VERB	O	O	3505
to	PART	O	O	3505
be	AUX	O	O	3505
directly	ADV	O	O	3505
evaluated	VERB	O	O	3505
.	PUNCT	O	O	3505
D	NOUN	O	O	3508
-	PUNCT	O	O	3508
penicillamine	NOUN	O	Chemical	3508
in	ADP	O	O	3508
the	PRON	O	O	3508
treatment	NOUN	O	O	3508
of	ADP	O	O	3508
localized scleroderma	NOUN	O	Disease	3508
.	PUNCT	O	O	3508
Localized scleroderma	NOUN	O	Disease	3509
has	VERB	O	O	3509
no	PRON	O	O	3509
recognized	VERB	O	O	3509
internal	ADJ	O	O	3509
organ	NOUN	O	O	3509
involvement	NOUN	O	O	3509
but	CCONJ	O	O	3509
may	AUX	O	O	3509
be	AUX	O	O	3509
disfiguring	VERB	O	O	3509
and	CCONJ	O	O	3509
disabling	VERB	O	O	3509
when	SCONJ	O	O	3509
the	PRON	O	O	3509
cutaneous	ADJ	O	O	3509
lesions	NOUN	O	O	3509
are	AUX	O	O	3509
extensive	ADJ	O	O	3509
or	CCONJ	O	O	3509
affect	VERB	O	O	3509
children	NOUN	O	O	3509
.	PUNCT	O	O	3509
There	ADV	O	O	3510
is	AUX	O	O	3510
no	PRON	O	O	3510
accepted	VERB	O	O	3510
or	CCONJ	O	O	3510
proven	VERB	O	O	3510
treatment	NOUN	O	O	3510
for	ADP	O	O	3510
localized scleroderma	NOUN	O	Disease	3510
.	PUNCT	O	O	3510
Case	NOUN	O	O	3511
reports	VERB	O	O	3511
of	ADP	O	O	3511
11	NUM	O	O	3511
patients	NOUN	O	O	3511
with	ADP	O	O	3511
severe	ADJ	O	O	3511
,	PUNCT	O	O	3511
extensive	ADJ	O	O	3511
localized scleroderma	NOUN	O	Disease	3511
who	PRON	O	O	3511
were	AUX	O	O	3511
treated	VERB	O	O	3511
with	ADP	O	O	3511
D	NOUN	O	O	3511
-	PUNCT	O	O	3511
penicillamine	NOUN	O	Chemical	3511
are	AUX	O	O	3511
summarized	VERB	O	O	3511
in	ADP	O	O	3511
this	PRON	O	O	3511
article	NOUN	O	O	3511
.	PUNCT	O	O	3511
Joint	ADJ	O	O	3512
stiffness	VERB	O	O	3512
and	CCONJ	O	O	3512
contractures	VERB	O	Disease	3512
also	ADV	O	O	3512
improved	VERB	O	O	3512
.	PUNCT	O	O	3512
The	PRON	O	O	3513
dose	NOUN	O	O	3513
of	ADP	O	O	3513
D	NOUN	O	O	3513
-	PUNCT	O	O	3513
penicillamine	NOUN	O	Chemical	3513
associated	VERB	O	O	3513
with	ADP	O	O	3513
a	PRON	O	O	3513
favorable	ADJ	O	O	3513
response	NOUN	O	O	3513
was	AUX	O	O	3513
as	ADP	O	O	3513
low	ADJ	O	O	3513
as	ADP	O	O	3513
2	X	O	O	3513
to	PART	O	O	3513
5	NUM	O	O	3513
mg	VERB	O	O	3513
/	PUNCT	O	O	3513
kg	VERB	O	O	3513
per	ADP	O	O	3513
day	NOUN	O	O	3513
given	VERB	O	O	3513
over	ADP	O	O	3513
a	PRON	O	O	3513
period	NOUN	O	O	3513
ranging	VERB	O	O	3513
from	ADP	O	O	3513
15	NUM	O	O	3513
to	PART	O	O	3513
53	NUM	O	O	3513
months	NOUN	O	O	3513
.	PUNCT	O	O	3513
D	NOUN	O	O	3514
-	PUNCT	O	O	3514
Penicillamine	NOUN	O	Chemical	3514
caused	VERB	O	O	3514
nephrotic syndrome	NOUN	O	Disease	3514
in	ADP	O	O	3514
1	X	O	O	3514
patient	NOUN	O	O	3514
and	CCONJ	O	O	3514
milder	ADJ	O	O	3514
reversible	ADJ	O	O	3514
proteinuria	X	O	Disease	3514
in	ADP	O	O	3514
3	X	O	O	3514
other	ADJ	O	O	3514
patients	NOUN	O	O	3514
;	PUNCT	O	O	3514
none	NOUN	O	O	3514
developed	VERB	O	O	3514
renal insufficiency	NOUN	O	Disease	3514
.	PUNCT	O	O	3514
These	PRON	O	O	3515
data	NOUN	O	O	3515
suggest	VERB	O	O	3515
that	SCONJ	O	O	3515
D	NOUN	O	O	3515
-	PUNCT	O	O	3515
penicillamine	NOUN	O	Chemical	3515
may	AUX	O	O	3515
be	AUX	O	O	3515
effective	ADJ	O	O	3515
in	ADP	O	O	3515
severe	ADJ	O	O	3515
cases	NOUN	O	O	3515
of	ADP	O	O	3515
localized scleroderma	NOUN	O	Disease	3515
.	PUNCT	O	O	3515
Preservation	NOUN	O	O	3518
of	ADP	O	O	3518
renal	ADJ	O	O	3518
blood	NOUN	O	O	3518
flow	NOUN	O	O	3518
during	ADP	O	O	3518
hypotension	NOUN	O	Disease	3518
induced	VERB	O	O	3518
with	ADP	O	O	3518
fenoldopam	NOUN	O	Chemical	3518
in	ADP	O	O	3518
dogs	NOUN	O	O	3518
.	PUNCT	O	O	3518
The	PRON	O	O	3519
introduction	NOUN	O	O	3519
of	ADP	O	O	3519
drugs	NOUN	O	O	3519
that	SCONJ	O	O	3519
could	AUX	O	O	3519
induce	VERB	O	O	3519
hypotension	NOUN	O	Disease	3519
with	ADP	O	O	3519
different	ADJ	O	O	3519
pharmacological	ADJ	O	O	3519
actions	NOUN	O	O	3519
would	AUX	O	O	3519
be	AUX	O	O	3519
advantageous	ADJ	O	O	3519
because	SCONJ	O	O	3519
side	NOUN	O	O	3519
effects	NOUN	O	O	3519
unique	ADJ	O	O	3519
to	PART	O	O	3519
a	PRON	O	O	3519
specific	ADJ	O	O	3519
drug	NOUN	O	O	3519
could	AUX	O	O	3519
be	AUX	O	O	3519
minimized	VERB	O	O	3519
by	ADP	O	O	3519
selecting	VERB	O	O	3519
appropriate	ADJ	O	O	3519
therapy	NOUN	O	O	3519
.	PUNCT	O	O	3519
Specific	ADJ	O	O	3520
dopamine-1	PUNCT	O	O	3520
,	PUNCT	O	O	3520
(	PUNCT	O	O	3520
DA1	PROPN	O	O	3520
)	PUNCT	O	O	3520
and	CCONJ	O	O	3520
dopamine-2	X	O	O	3520
(	PUNCT	O	O	3520
DA2	PROPN	O	O	3520
)	PUNCT	O	O	3520
Fenoldopam mesylate	NOUN	O	Chemical	3521
is	AUX	O	O	3521
a	PRON	O	O	3521
specific	ADJ	O	O	3521
DA1	PROPN	O	O	3521
receptor	NOUN	O	O	3521
agonist	NOUN	O	O	3521
that	SCONJ	O	O	3521
lowers	VERB	O	O	3521
blood	NOUN	O	O	3521
pressure	NOUN	O	O	3521
by	ADP	O	O	3521
vasodilatation	NOUN	O	O	3521
.	PUNCT	O	O	3521
The	PRON	O	O	3522
hypothesis	NOUN	O	O	3522
that	SCONJ	O	O	3522
fenoldopam	NOUN	O	Chemical	3522
could	AUX	O	O	3522
be	AUX	O	O	3522
used	VERB	O	O	3522
to	PART	O	O	3522
induce	VERB	O	O	3522
hypotension	NOUN	O	Disease	3522
and	CCONJ	O	O	3522
preserve	VERB	O	O	3522
blood	NOUN	O	O	3522
flow	NOUN	O	O	3522
to	PART	O	O	3522
the	PRON	O	O	3522
kidney	NOUN	O	O	3522
was	AUX	O	O	3522
tested	VERB	O	O	3522
.	PUNCT	O	O	3522
Systemic	ADJ	O	O	3523
aortic	ADJ	O	O	3523
blood	NOUN	O	O	3523
pressure	NOUN	O	O	3523
and	CCONJ	O	O	3523
renal	ADJ	O	O	3523
blood	NOUN	O	O	3523
flow	NOUN	O	O	3523
were	AUX	O	O	3523
measured	VERB	O	O	3523
continuously	ADV	O	O	3523
with	ADP	O	O	3523
a	PRON	O	O	3523
carotid	NOUN	O	O	3523
arterial	ADJ	O	O	3523
catheter	VERB	O	O	3523
and	CCONJ	O	O	3523
an	PRON	O	O	3523
electromagnetic	ADJ	O	O	3523
flow	NOUN	O	O	3523
probe	NOUN	O	O	3523
respectively	ADV	O	O	3523
,	PUNCT	O	O	3523
in	ADP	O	O	3523
order	NOUN	O	O	3523
to	PART	O	O	3523
compare	VERB	O	O	3523
the	PRON	O	O	3523
cardiovascular	ADJ	O	O	3523
and	CCONJ	O	O	3523
renal	ADJ	O	O	3523
vascular	ADJ	O	O	3523
effects	NOUN	O	O	3523
of	ADP	O	O	3523
fenoldopam	NOUN	O	Chemical	3523
and	CCONJ	O	O	3523
sodium	NOUN	O	Chemical	3523
nitroprusside	ADV	O	Chemical	3523
in	ADP	O	O	3523
ten	NUM	O	O	3523
dogs	NOUN	O	O	3523
under	ADP	O	O	3523
halothane	VERB	O	Chemical	3523
general	ADJ	O	O	3523
anaesthesia	NOUN	O	O	3523
.	PUNCT	O	O	3523
8	NUM	O	O	3524
per	ADP	O	O	3524
cent	NOUN	O	O	3524
from	ADP	O	O	3524
control	VERB	O	O	3524
with	ADP	O	O	3524
infusion	NOUN	O	O	3524
of	ADP	O	O	3524
fenoldopam	NOUN	O	Chemical	3524
(	PUNCT	O	O	3524
3.4	NUM	O	O	3524
+	ADP	O	O	3524
/-	PUNCT	O	O	3524
4	NUM	O	O	3525
per	ADP	O	O	3525
cent	NOUN	O	O	3525
with	ADP	O	O	3525
infusion	NOUN	O	O	3525
of	ADP	O	O	3525
sodium	NOUN	O	Chemical	3525
nitroprusside	ADV	O	Chemical	3525
(	PUNCT	O	O	3525
5.9	NUM	O	O	3525
micrograms.kg-1.min-1	VERB	O	O	3525
)	PUNCT	O	O	3525
(	PUNCT	O	O	3525
NS	PROPN	O	Disease	3525
)	PUNCT	O	O	3525
.	PUNCT	O	O	3525
Renal	NOUN	O	O	3526
blood	NOUN	O	O	3526
flow	NOUN	O	O	3526
(	PUNCT	O	O	3526
RBF	PROPN	O	O	3526
)	PUNCT	O	O	3526
increased	VERB	O	O	3526
during	ADP	O	O	3526
fenoldopam	NOUN	O	Chemical	3526
-	PUNCT	O	O	3526
induced	VERB	O	O	3526
hypotension	NOUN	O	Disease	3526
11	NUM	O	O	3526
+	ADP	O	O	3526
/-	PUNCT	O	O	3526
8	NUM	O	O	3527
per	ADP	O	O	3527
cent	NOUN	O	O	3527
during	ADP	O	O	3527
sodium	NOUN	O	Chemical	3527
nitroprusside	ADV	O	Chemical	3527
-	PUNCT	O	O	3527
induced	VERB	O	O	3527
hypotension	NOUN	O	Disease	3527
(	PUNCT	O	O	3527
P	NOUN	O	Chemical	3527
less	ADV	O	O	3527
than	ADP	O	O	3527
0.01	NUM	O	O	3527
)	PUNCT	O	O	3527
.	PUNCT	O	O	3527
Sodium	NOUN	O	Chemical	3528
nitroprusside	ADV	O	Chemical	3528
is	AUX	O	O	3528
a	PRON	O	O	3528
non	ADJ	O	O	3528
-	PUNCT	O	O	3528
selective	ADJ	O	O	3528
arteriolar	ADJ	O	O	3528
and	CCONJ	O	O	3528
venous	ADJ	O	O	3528
vasodilator	NOUN	O	O	3528
that	SCONJ	O	O	3528
can	AUX	O	O	3528
produce	VERB	O	O	3528
redistribution	NOUN	O	O	3528
of	ADP	O	O	3528
blood	NOUN	O	O	3528
flow	NOUN	O	O	3528
away	ADV	O	O	3528
from	ADP	O	O	3528
the	PRON	O	O	3528
kidney	NOUN	O	O	3528
during	ADP	O	O	3528
induced	VERB	O	O	3528
hypotension	NOUN	O	Disease	3528
.	PUNCT	O	O	3528
Fenoldopam	NOUN	O	O	3529
is	AUX	O	O	3529
a	PRON	O	O	3529
selective	ADJ	O	O	3529
dopamine-1	PUNCT	O	O	3529
(	PUNCT	O	O	3529
DA1	PROPN	O	O	3529
)	PUNCT	O	O	3529
receptor	NOUN	O	O	3529
agonist	NOUN	O	O	3529
that	SCONJ	O	O	3529
causes	VERB	O	O	3529
vasodilatation	NOUN	O	O	3529
to	PART	O	O	3529
the	PRON	O	O	3529
kidney	NOUN	O	O	3529
and	CCONJ	O	O	3529
other	ADJ	O	O	3529
organs	NOUN	O	O	3529
with	ADP	O	O	3529
DA1	PROPN	O	O	3529
receptors	NOUN	O	O	3529
and	CCONJ	O	O	3529
preserves	VERB	O	O	3529
blood	NOUN	O	O	3529
flow	NOUN	O	O	3529
to	PART	O	O	3529
the	PRON	O	O	3529
kidney	NOUN	O	O	3529
during	ADP	O	O	3529
induced	VERB	O	O	3529
hypotension	NOUN	O	Disease	3529
.	PUNCT	O	O	3529
Antiarrhythmic	PROPN	O	O	3532
effects	NOUN	O	O	3532
of	ADP	O	O	3532
optical	PROPN	O	O	3532
isomers	NOUN	O	O	3532
of	ADP	O	O	3532
cibenzoline	VERB	O	Chemical	3532
on	ADP	O	O	3532
canine	NOUN	O	O	3532
ventricular arrhythmias	NOUN	O	Disease	3532
.	PUNCT	O	O	3532
Antiarrhythmic	PROPN	O	O	3533
effects	NOUN	O	O	3533
of	ADP	O	O	3533
(	PUNCT	O	O	3533
+	ADP	O	O	3533
)	PUNCT	O	O	3533
-cibenzoline	NOUN	O	O	3533
and	CCONJ	O	O	3533
(	PUNCT	O	O	3533
-)-cibenzoline	INTJ	O	O	3533
were	AUX	O	O	3533
examined	VERB	O	O	3533
using	VERB	O	O	3533
two	NUM	O	O	3533
canine	NOUN	O	O	3533
ventricular arrhythmia	NOUN	O	Disease	3533
models	NOUN	O	O	3533
.	PUNCT	O	O	3533
Digitalis	NOUN	O	Chemical	3534
arrhythmia	NOUN	O	Disease	3534
,	PUNCT	O	O	3534
which	PRON	O	O	3534
is	AUX	O	O	3534
suppressed	VERB	O	O	3534
by	ADP	O	O	3534
Na	INTJ	O	Chemical	3534
channel	PROPN	O	O	3534
blockers	NOUN	O	O	3534
,	PUNCT	O	O	3534
was	AUX	O	O	3534
induced	VERB	O	O	3534
by	ADP	O	O	3534
intermittent	ADJ	O	O	3534
intravenous	ADJ	O	O	3534
(	PUNCT	O	O	3534
i.v	NOUN	O	O	3534
.	PUNCT	O	O	3534
)	PUNCT	O	O	3534
injection	NOUN	O	O	3535
of	ADP	O	O	3535
ouabain	PROPN	O	Chemical	3535
in	ADP	O	O	3535
pentobarbital	NOUN	O	Chemical	3535
-	PUNCT	O	O	3535
anesthetized	VERB	O	O	3535
dogs	NOUN	O	O	3535
.	PUNCT	O	O	3535
Adrenaline arrhythmia	NOUN	O	Disease	3536
,	PUNCT	O	O	3536
which	PRON	O	O	3536
is	AUX	O	O	3536
suppressed	VERB	O	O	3536
by	ADP	O	O	3536
Ca	AUX	O	Chemical	3536
channel	PROPN	O	O	3536
blockers	NOUN	O	O	3536
,	PUNCT	O	O	3536
was	AUX	O	O	3536
induced	VERB	O	O	3536
by	ADP	O	O	3536
adrenaline	NOUN	O	Chemical	3536
infusion	NOUN	O	O	3536
in	ADP	O	O	3536
halothane	VERB	O	Chemical	3536
-	PUNCT	O	O	3536
anesthetized	VERB	O	O	3536
dogs	NOUN	O	O	3536
.	PUNCT	O	O	3536
(	PUNCT	O	O	3537
+	ADP	O	O	3537
)	PUNCT	O	O	3537
-cibenzoline	NOUN	O	O	3537
suppressed	VERB	O	O	3537
digitalis-	X	O	O	3537
and	CCONJ	O	O	3537
adrenaline	NOUN	O	Chemical	3537
-	PUNCT	O	O	3537
induced	VERB	O	O	3537
arrhythmias	VERB	O	Disease	3537
,	PUNCT	O	O	3537
respectively	ADV	O	O	3537
.	PUNCT	O	O	3537
The	PRON	O	O	3538
minimum	ADJ	O	O	3538
effective	ADJ	O	O	3538
plasma	NOUN	O	O	3538
concentrations	NOUN	O	O	3538
of	ADP	O	O	3538
(	PUNCT	O	O	3538
+	ADP	O	O	3538
)	PUNCT	O	O	3538
-cibenzoline	NOUN	O	O	3538
for	ADP	O	O	3538
digitalis-	X	O	O	3538
and	CCONJ	O	O	3538
adrenaline	NOUN	O	Chemical	3538
-	PUNCT	O	O	3538
induced	VERB	O	O	3538
arrhythmias	VERB	O	Disease	3538
were	AUX	O	O	3538
1.4	NUM	O	O	3538
+	ADP	O	O	3538
/-	PUNCT	O	O	3538
(	PUNCT	O	O	3539
-)-cibenzoline	INTJ	O	O	3539
suppressed	VERB	O	O	3539
the	PRON	O	O	3539
digitalis	NOUN	O	Chemical	3539
-	PUNCT	O	O	3539
induced	VERB	O	O	3539
arrhythmia	NOUN	O	Disease	3539
,	PUNCT	O	O	3539
whereas	SCONJ	O	O	3539
5	NUM	O	O	3539
mg	VERB	O	O	3539
/	PUNCT	O	O	3539
kg	VERB	O	O	3539
i.v	NOUN	O	O	3539
.	PUNCT	O	O	3539
was	AUX	O	O	3540
needed	VERB	O	O	3540
to	PART	O	O	3540
suppress	VERB	O	O	3540
adrenaline	NOUN	O	Chemical	3540
-	PUNCT	O	O	3540
induced	VERB	O	O	3540
arrhythmias	VERB	O	Disease	3540
.	PUNCT	O	O	3540
The	PRON	O	O	3541
minimum	ADJ	O	O	3541
effective	ADJ	O	O	3541
plasma	NOUN	O	O	3541
concentrations	NOUN	O	O	3541
of	ADP	O	O	3541
(	PUNCT	O	O	3541
-)-cibenzoline	INTJ	O	O	3541
for	ADP	O	O	3541
digitalis-	X	O	O	3541
and	CCONJ	O	O	3541
adrenaline	NOUN	O	Chemical	3541
-	PUNCT	O	O	3541
induced	VERB	O	O	3541
arrhythmia	NOUN	O	Disease	3541
were	AUX	O	O	3541
0.06	NUM	O	O	3541
+	ADP	O	O	3541
/-	PUNCT	O	O	3541
The	PRON	O	O	3542
stronger	ADJ	O	O	3542
antiarrhythmic	PROPN	O	O	3542
effect	VERB	O	O	3542
of	ADP	O	O	3542
(	PUNCT	O	O	3542
-)-cibenzoline	INTJ	O	O	3542
indicates	VERB	O	O	3542
that	SCONJ	O	O	3542
(	PUNCT	O	O	3542
-)-isomer	X	O	O	3542
may	AUX	O	O	3542
have	VERB	O	O	3542
an	PRON	O	O	3542
effect	VERB	O	O	3542
nearly	ADV	O	O	3542
5	NUM	O	O	3542
-	PUNCT	O	O	3542
20	NUM	O	O	3542
times	NOUN	O	O	3542
stronger	ADJ	O	O	3542
in	ADP	O	O	3542
suppressing	VERB	O	O	3542
Na	INTJ	O	Chemical	3542
channels	NOUN	O	O	3542
,	PUNCT	O	O	3542
but	CCONJ	O	O	3542
effects	NOUN	O	O	3542
of	ADP	O	O	3542
both	PRON	O	O	3542
drugs	NOUN	O	O	3542
on	ADP	O	O	3542
Ca	AUX	O	Chemical	3542
channels	NOUN	O	O	3542
may	AUX	O	O	3542
be	AUX	O	O	3542
almost	ADV	O	O	3542
equipotent	ADJ	O	O	3542
.	PUNCT	O	O	3542
Effect	VERB	O	O	3545
of	ADP	O	O	3545
Hibiscus rosa sinensis	NOUN	O	Chemical	3545
on	ADP	O	O	3545
reserpine	NOUN	O	Chemical	3545
-	PUNCT	O	O	3545
induced	VERB	O	O	3545
neurobehavioral	ADJ	O	O	3545
and	CCONJ	O	O	3545
biochemical	ADJ	O	O	3545
alterations	NOUN	O	O	3545
in	ADP	O	O	3545
rats	NOUN	O	O	3545
.	PUNCT	O	O	3545
Effect	VERB	O	O	3546
of	ADP	O	O	3546
methanolic	PROPN	O	O	3546
extract	VERB	O	O	3546
of	ADP	O	O	3546
Hibiscus rosa sinensis	NOUN	O	Chemical	3546
(	PUNCT	O	O	3546
100	NUM	O	O	3546
-	PUNCT	O	O	3546
300	NUM	O	O	3546
mg	VERB	O	O	3546
/	PUNCT	O	O	3546
kg	VERB	O	O	3546
)	PUNCT	O	O	3546
was	AUX	O	O	3546
studied	VERB	O	O	3546
on	ADP	O	O	3546
reserpine	NOUN	O	Chemical	3546
-	PUNCT	O	O	3546
induced	VERB	O	O	3546
orofacial dyskinesia	NOUN	O	Disease	3546
and	CCONJ	O	O	3546
neurochemical	ADJ	O	O	3546
alterations	NOUN	O	O	3546
.	PUNCT	O	O	3546
The	PRON	O	O	3547
rats	NOUN	O	O	3547
were	AUX	O	O	3547
treated	VERB	O	O	3547
with	ADP	O	O	3547
intraperitoneal	ADJ	O	O	3547
reserpine	NOUN	O	Chemical	3547
Reserpine	NOUN	O	Chemical	3548
treated	VERB	O	O	3548
rats	NOUN	O	O	3548
significantly	ADV	O	O	3548
developed	VERB	O	O	3548
vacuous	ADJ	O	O	3548
chewing	VERB	O	O	3548
movements	NOUN	O	O	3548
and	CCONJ	O	O	3548
tongue	NOUN	O	O	3548
protrusions	NOUN	O	O	3548
however	ADV	O	O	3548
,	PUNCT	O	O	3548
coadministration	NOUN	O	O	3548
of	ADP	O	O	3548
Hibiscus rosa sinensis	NOUN	O	Chemical	3548
roots	NOUN	O	O	3548
extract	VERB	O	O	3548
(	PUNCT	O	O	3548
100	NUM	O	O	3548
,	PUNCT	O	O	3548
200	NUM	O	O	3548
and	CCONJ	O	O	3548
300	NUM	O	O	3548
mg	VERB	O	O	3548
/	PUNCT	O	O	3548
kg	VERB	O	O	3548
,	PUNCT	O	O	3548
per	ADP	O	O	3548
orally	ADV	O	O	3548
)	PUNCT	O	O	3548
attenuated	VERB	O	O	3548
the	PRON	O	O	3548
effects	NOUN	O	O	3548
.	PUNCT	O	O	3548
Biochemical	ADJ	O	O	3549
analysis	NOUN	O	O	3549
of	ADP	O	O	3549
brain	NOUN	O	O	3549
revealed	VERB	O	O	3549
that	SCONJ	O	O	3549
the	PRON	O	O	3549
reserpine	NOUN	O	Chemical	3549
treatment	NOUN	O	O	3549
significantly	ADV	O	O	3549
increased	VERB	O	O	3549
lipid	NOUN	O	O	3549
peroxidation	NOUN	O	O	3549
and	CCONJ	O	O	3549
decreased	VERB	O	O	3549
levels	NOUN	O	O	3549
of	ADP	O	O	3549
superoxide	NOUN	O	Chemical	3549
dismutase	ADP	O	O	3549
(	PUNCT	O	O	3549
SOD	PROPN	O	O	3549
)	PUNCT	O	O	3549
,	PUNCT	O	O	3549
catalase	VERB	O	O	3549
(	PUNCT	O	O	3549
CAT	NOUN	O	O	3549
)	PUNCT	O	O	3549
and	CCONJ	O	O	3549
glutathione	NOUN	O	Chemical	3549
reductase	NOUN	O	O	3549
(	PUNCT	O	O	3549
GSH	PROPN	O	O	3549
)	PUNCT	O	O	3549
,	PUNCT	O	O	3549
an	PRON	O	O	3549
index	NOUN	O	O	3549
of	ADP	O	O	3549
oxidative	NOUN	O	O	3549
stress	NOUN	O	O	3549
process	NOUN	O	O	3549
.	PUNCT	O	O	3549
The	PRON	O	O	3550
results	VERB	O	O	3550
of	ADP	O	O	3550
the	PRON	O	O	3550
present	NOUN	O	O	3550
study	VERB	O	O	3550
suggested	VERB	O	O	3550
that	SCONJ	O	O	3550
Hibiscus rosa sinensis	NOUN	O	Chemical	3550
had	VERB	O	O	3550
a	PRON	O	O	3550
protective	ADJ	O	O	3550
role	NOUN	O	O	3550
against	ADP	O	O	3550
reserpine	NOUN	O	Chemical	3550
-	PUNCT	O	O	3550
induced	VERB	O	O	3550
orofacial dyskinesia	NOUN	O	Disease	3550
and	CCONJ	O	O	3550
oxidative	NOUN	O	O	3550
stress	NOUN	O	O	3550
.	PUNCT	O	O	3550
Comparison	NOUN	O	O	3553
of	ADP	O	O	3553
aqueous	ADJ	O	O	3553
and	CCONJ	O	O	3553
gellan	NOUN	O	O	3553
ophthalmic	ADJ	O	O	3553
timolol	PROPN	O	Chemical	3553
with	ADP	O	O	3553
placebo	NOUN	O	O	3553
on	ADP	O	O	3553
the	PRON	O	O	3553
24-hour	NOUN	O	O	3553
heart	NOUN	O	O	3553
rate	NOUN	O	O	3553
response	NOUN	O	O	3553
in	ADP	O	O	3553
patients	NOUN	O	O	3553
on	ADP	O	O	3553
treatment	NOUN	O	O	3553
for	ADP	O	O	3553
glaucoma	NOUN	O	Disease	3553
.	PUNCT	O	O	3553
Topical	PROPN	O	O	3554
beta	NOUN	O	O	3554
-	PUNCT	O	O	3554
blocker	NOUN	O	O	3554
treatment	NOUN	O	O	3554
is	AUX	O	O	3554
routine	ADJ	O	O	3554
therapy	NOUN	O	O	3554
in	ADP	O	O	3554
the	PRON	O	O	3554
management	NOUN	O	O	3554
of	ADP	O	O	3554
patients	NOUN	O	O	3554
with	ADP	O	O	3554
glaucoma	NOUN	O	Disease	3554
.	PUNCT	O	O	3554
This	PRON	O	O	3555
trial	NOUN	O	O	3555
evaluated	VERB	O	O	3555
the	PRON	O	O	3555
effect	VERB	O	O	3555
of	ADP	O	O	3555
placebo	NOUN	O	O	3555
,	PUNCT	O	O	3555
0.5%	NOUN	O	O	3555
aqueous	ADJ	O	O	3555
timolol	PROPN	O	Chemical	3555
(	PUNCT	O	O	3555
timolol	PROPN	O	Chemical	3555
solution	NOUN	O	O	3555
)	PUNCT	O	O	3555
and	CCONJ	O	O	3555
a	PRON	O	O	3555
0.5%	NOUN	O	O	3555
timolol	PROPN	O	Chemical	3555
suspension	NOUN	O	O	3555
that	SCONJ	O	O	3555
forms	NOUN	O	O	3555
a	PRON	O	O	3555
gel	PROPN	O	O	3555
on	ADP	O	O	3555
application	NOUN	O	O	3555
to	PART	O	O	3555
the	PRON	O	O	3555
conjunctiva	PROPN	O	O	3555
(	PUNCT	O	O	3555
timolol	PROPN	O	Chemical	3555
gellan	NOUN	O	O	3555
)	PUNCT	O	O	3555
on	ADP	O	O	3555
the	PRON	O	O	3555
24-hour	NOUN	O	O	3555
heart	NOUN	O	O	3555
rate	NOUN	O	O	3555
in	ADP	O	O	3555
patients	NOUN	O	O	3555
currently	ADV	O	O	3555
being	AUX	O	O	3555
treated	VERB	O	O	3555
for	ADP	O	O	3555
glaucoma	NOUN	O	Disease	3555
to	PART	O	O	3555
quantify	VERB	O	O	3555
the	PRON	O	O	3555
reduction	NOUN	O	O	3555
in	ADP	O	O	3555
mean	VERB	O	O	3555
heart	NOUN	O	O	3555
rate	NOUN	O	O	3555
.	PUNCT	O	O	3555
METHODS	NOUN	O	O	3556
:	PUNCT	O	O	3556
Forty	NUM	O	O	3556
-	PUNCT	O	O	3556
three	NUM	O	O	3556
Caucasian	ADJ	O	O	3556
patients	NOUN	O	O	3556
with	ADP	O	O	3556
primary	NOUN	O	O	3556
open	VERB	O	O	3556
-	PUNCT	O	O	3556
angle	NOUN	O	O	3556
glaucoma	NOUN	O	Disease	3556
or	CCONJ	O	O	3556
ocular hypertension	NOUN	O	Disease	3556
with	ADP	O	O	3556
a	PRON	O	O	3556
mean	VERB	O	O	3556
(	PUNCT	O	O	3556
+	ADP	O	O	3556
/-SD	PUNCT	O	O	3556
)	PUNCT	O	O	3556
age	NOUN	O	O	3556
of	ADP	O	O	3556
63	NUM	O	O	3556
(	PUNCT	O	O	3556
+	ADP	O	O	3556
/-8	PUNCT	O	O	3556
)	PUNCT	O	O	3556
years	NOUN	O	O	3556
were	AUX	O	O	3556
randomized	VERB	O	O	3556
and	CCONJ	O	O	3556
crossed	VERB	O	O	3556
over	ADP	O	O	3556
in	ADP	O	O	3556
a	PRON	O	O	3556
double	ADJ	O	O	3556
-	PUNCT	O	O	3556
masked	VERB	O	O	3556
manner	VERB	O	O	3556
to	PART	O	O	3556
14	NUM	O	O	3556
days	NOUN	O	O	3556
of	ADP	O	O	3556
treatment	NOUN	O	O	3556
with	ADP	O	O	3556
placebo	NOUN	O	O	3556
(	PUNCT	O	O	3556
morning	NOUN	O	O	3556
and	CCONJ	O	O	3556
evening	NOUN	O	O	3556
in	ADP	O	O	3556
both	PRON	O	O	3556
eyes	NOUN	O	O	3556
)	PUNCT	O	O	3556
,	PUNCT	O	O	3556
timolol	PROPN	O	Chemical	3556
solution	NOUN	O	O	3556
(	PUNCT	O	O	3556
morning	NOUN	O	O	3556
and	CCONJ	O	O	3556
evening	NOUN	O	O	3556
in	ADP	O	O	3556
both	PRON	O	O	3556
eyes	NOUN	O	O	3556
)	PUNCT	O	O	3556
,	PUNCT	O	O	3556
or	CCONJ	O	O	3556
timolol	PROPN	O	Chemical	3556
gellan	NOUN	O	O	3556
(	PUNCT	O	O	3556
morning	NOUN	O	O	3556
in	ADP	O	O	3556
both	PRON	O	O	3556
eyes	NOUN	O	O	3556
with	ADP	O	O	3556
placebo	NOUN	O	O	3556
in	ADP	O	O	3556
the	PRON	O	O	3556
evening	NOUN	O	O	3556
)	PUNCT	O	O	3556
.	PUNCT	O	O	3556
Both	PRON	O	O	3557
timolol	PROPN	O	Chemical	3557
solution	NOUN	O	O	3557
and	CCONJ	O	O	3557
timolol	PROPN	O	Chemical	3557
gellan	NOUN	O	O	3557
reduced	VERB	O	O	3557
the	PRON	O	O	3557
mean	VERB	O	O	3557
24-hour	NOUN	O	O	3557
heart	NOUN	O	O	3557
rate	NOUN	O	O	3557
compared	VERB	O	O	3557
with	ADP	O	O	3557
placebo	NOUN	O	O	3557
(	PUNCT	O	O	3557
P	NOUN	O	Chemical	3557
<	X	O	O	3557
or	CCONJ	O	O	3557
=	PUNCT	O	O	3557
.001	NUM	O	O	3557
)	PUNCT	O	O	3557
,	PUNCT	O	O	3557
and	CCONJ	O	O	3557
this	PRON	O	O	3557
reduction	NOUN	O	O	3557
was	AUX	O	O	3557
most	ADV	O	O	3557
pronounced	VERB	O	O	3557
during	ADP	O	O	3557
the	PRON	O	O	3557
daytime	ADV	O	O	3557
(	PUNCT	O	O	3557
-7.5%	NOUN	O	O	3557
change	VERB	O	O	3557
in	ADP	O	O	3557
mean	VERB	O	O	3557
heart	NOUN	O	O	3557
rate	NOUN	O	O	3557
Timolol	PROPN	O	Chemical	3558
gellan	NOUN	O	O	3558
showed	VERB	O	O	3558
a	PRON	O	O	3558
numerically	ADV	O	O	3558
but	CCONJ	O	O	3558
not	PART	O	O	3558
significantly	ADV	O	O	3558
smaller	ADJ	O	O	3558
reduction	NOUN	O	O	3558
in	ADP	O	O	3558
24-hour	NOUN	O	O	3558
heart	NOUN	O	O	3558
rate	NOUN	O	O	3558
,	PUNCT	O	O	3558
compared	VERB	O	O	3558
with	ADP	O	O	3558
timolol	PROPN	O	Chemical	3558
solution	NOUN	O	O	3558
.	PUNCT	O	O	3558
During	ADP	O	O	3559
the	PRON	O	O	3559
night	NOUN	O	O	3559
,	PUNCT	O	O	3559
the	PRON	O	O	3559
mean	VERB	O	O	3559
12-hour	NOUN	O	O	3559
heart	NOUN	O	O	3559
rate	NOUN	O	O	3559
on	ADP	O	O	3559
placebo	NOUN	O	O	3559
and	CCONJ	O	O	3559
timolol	PROPN	O	Chemical	3559
gellan	NOUN	O	O	3559
were	AUX	O	O	3559
both	PRON	O	O	3559
significantly	ADV	O	O	3559
less	ADV	O	O	3559
than	ADP	O	O	3559
on	ADP	O	O	3559
timolol	PROPN	O	Chemical	3559
solution	NOUN	O	O	3559
;	PUNCT	O	O	3559
the	PRON	O	O	3559
difference	NOUN	O	O	3559
between	ADP	O	O	3559
solution	NOUN	O	O	3559
and	CCONJ	O	O	3559
gellan	NOUN	O	O	3559
treatments	NOUN	O	O	3559
was	AUX	O	O	3559
statistically	ADV	O	O	3559
significant	ADJ	O	O	3559
(	PUNCT	O	O	3559
P	NOUN	O	Chemical	3559
=	PUNCT	O	O	3559
.01	NUM	O	O	3559
)	PUNCT	O	O	3559
.	PUNCT	O	O	3559
Both	PRON	O	O	3560
timolol	PROPN	O	Chemical	3560
solution	NOUN	O	O	3560
and	CCONJ	O	O	3560
timolol	PROPN	O	Chemical	3560
gellan	NOUN	O	O	3560
decrease	VERB	O	O	3560
the	PRON	O	O	3560
mean	VERB	O	O	3560
24-hour	NOUN	O	O	3560
heart	NOUN	O	O	3560
rate	NOUN	O	O	3560
compared	VERB	O	O	3560
with	ADP	O	O	3560
placebo	NOUN	O	O	3560
.	PUNCT	O	O	3560
These	PRON	O	O	3561
data	NOUN	O	O	3561
quantify	VERB	O	O	3561
the	PRON	O	O	3561
modest	ADJ	O	O	3561
bradycardia	NOUN	O	Disease	3561
associated	VERB	O	O	3561
with	ADP	O	O	3561
ophthalmic	ADJ	O	O	3561
beta	NOUN	O	O	3561
-	PUNCT	O	O	3561
blocker	NOUN	O	O	3561
therapy	NOUN	O	O	3561
in	ADP	O	O	3561
a	PRON	O	O	3561
typical	ADJ	O	O	3561
patient	NOUN	O	O	3561
population	NOUN	O	O	3561
on	ADP	O	O	3561
therapy	NOUN	O	O	3561
for	ADP	O	O	3561
glaucoma	NOUN	O	Disease	3561
.	PUNCT	O	O	3561
5 flourouracil	NOUN	O	Chemical	3564
-	PUNCT	O	O	3564
induced	VERB	O	O	3564
apical ballooning	NOUN	O	Disease	3564
syndrome	NOUN	O	O	3564
:	PUNCT	O	O	3564
a	PRON	O	O	3564
case	NOUN	O	O	3564
report	VERB	O	O	3564
.	PUNCT	O	O	3564
The	PRON	O	O	3565
apical ballooning	NOUN	O	Disease	3565
syndrome	NOUN	O	O	3565
(	PUNCT	O	O	3565
ABS	NOUN	O	Disease	3565
)	PUNCT	O	O	3565
is	AUX	O	O	3565
a	PRON	O	O	3565
recently	ADV	O	O	3565
described	VERB	O	O	3565
stress	NOUN	O	O	3565
-	PUNCT	O	O	3565
mediated	VERB	O	O	3565
acute cardiac syndrome	NOUN	O	Disease	3565
characterized	VERB	O	O	3565
by	ADP	O	O	3565
transient	ADJ	O	O	3565
wall	PROPN	O	O	3565
-	PUNCT	O	O	3565
motion	NOUN	O	O	3565
abnormalities	NOUN	O	O	3565
involving	VERB	O	O	3565
the	PRON	O	O	3565
apex	PROPN	O	O	3565
and	CCONJ	O	O	3565
midventricle	NOUN	O	O	3565
with	ADP	O	O	3565
hyperkinesis	NOUN	O	Disease	3565
of	ADP	O	O	3565
the	PRON	O	O	3565
basal	PROPN	O	O	3565
left	VERB	O	O	3565
ventricular	ADJ	O	O	3565
(	PUNCT	O	O	3565
LV	PROPN	O	Disease	3565
)	PUNCT	O	O	3565
segments	NOUN	O	O	3565
without	ADP	O	O	3565
obstructive	ADJ	O	O	3565
epicardial	ADJ	O	O	3565
coronary disease	NOUN	O	Disease	3565
.	PUNCT	O	O	3565
Cardiotoxicity	NOUN	O	Disease	3566
is	AUX	O	O	3566
not	PART	O	O	3566
an	PRON	O	O	3566
uncommon	ADJ	O	O	3566
adverse	ADJ	O	O	3566
effect	VERB	O	O	3566
of	ADP	O	O	3566
chemotherapeutic	NOUN	O	O	3566
agents	NOUN	O	O	3566
.	PUNCT	O	O	3566
However	ADV	O	O	3567
,	PUNCT	O	O	3567
there	ADV	O	O	3567
are	AUX	O	O	3567
no	PRON	O	O	3567
reports	VERB	O	O	3567
of	ADP	O	O	3567
ABS	NOUN	O	Disease	3567
secondary	ADJ	O	O	3567
to	PART	O	O	3567
chemotherapeutic	NOUN	O	O	3567
agents	NOUN	O	O	3567
.	PUNCT	O	O	3567
We	PRON	O	O	3568
describe	VERB	O	O	3568
the	PRON	O	O	3568
case	NOUN	O	O	3568
of	ADP	O	O	3568
a	PRON	O	O	3568
woman	NOUN	O	O	3568
who	PRON	O	O	3568
developed	VERB	O	O	3568
the	PRON	O	O	3568
syndrome	NOUN	O	O	3568
after	ADP	O	O	3568
chemotherapy	NOUN	O	O	3568
for	ADP	O	O	3568
metastatic	ADJ	O	O	3568
cancer	NOUN	O	Disease	3568
.	PUNCT	O	O	3568
A	PRON	O	O	3569
79-year	NOUN	O	O	3569
-	PUNCT	O	O	3569
old	ADJ	O	O	3569
woman	NOUN	O	O	3569
presented	VERB	O	O	3569
with	ADP	O	O	3569
typical	ADJ	O	O	3569
ischemic	VERB	O	Disease	3569
chest pain	NOUN	O	Disease	3569
,	PUNCT	O	O	3569
elevated	ADJ	O	O	3569
cardiac	ADJ	O	O	3569
enzymes	NOUN	O	O	3569
with	ADP	O	O	3569
significant	ADJ	O	O	3569
ST	PROPN	O	O	3569
-	PUNCT	O	O	3569
segment	NOUN	O	O	3569
abnormalities	NOUN	O	O	3569
on	ADP	O	O	3569
her	PRON	O	O	3569
electrocardiogram	PROPN	O	O	3569
.	PUNCT	O	O	3569
She	PRON	O	O	3570
underwent	VERB	O	O	3570
recent	ADJ	O	O	3570
chemotherapy	NOUN	O	O	3570
with	ADP	O	O	3570
fluorouracil	NOUN	O	Chemical	3570
for	ADP	O	O	3570
metastatic	ADJ	O	O	3570
colorectal cancer	NOUN	O	Disease	3570
.	PUNCT	O	O	3570
Echocardiography	NOUN	O	O	3571
revealed	VERB	O	O	3571
a	PRON	O	O	3571
wall	PROPN	O	O	3571
-	PUNCT	O	O	3571
motion	NOUN	O	O	3571
abnormality	NOUN	O	O	3571
involving	VERB	O	O	3571
the	PRON	O	O	3571
apical	ADJ	O	O	3571
and	CCONJ	O	O	3571
periapical	ADJ	O	O	3571
segments	NOUN	O	O	3571
which	PRON	O	O	3571
appeared	VERB	O	O	3571
akinetic	ADJ	O	Disease	3571
.	PUNCT	O	O	3571
Echocardiogram	PROPN	O	O	3572
revealed	VERB	O	O	3572
a	PRON	O	O	3572
normal	ADJ	O	O	3572
ejection	NOUN	O	O	3572
fraction	NOUN	O	O	3572
and	CCONJ	O	O	3572
a	PRON	O	O	3572
resolution	NOUN	O	O	3572
of	ADP	O	O	3572
the	PRON	O	O	3572
apical	ADJ	O	O	3572
akinesis	VERB	O	Disease	3572
.	PUNCT	O	O	3572
Pathogenetic	PROPN	O	O	3573
mechanisms	NOUN	O	O	3573
of	ADP	O	O	3573
cardiac complications	NOUN	O	Disease	3573
in	ADP	O	O	3573
cancer	NOUN	O	Disease	3573
patients	NOUN	O	O	3573
undergoing	VERB	O	O	3573
chemotherapy	NOUN	O	O	3573
include	VERB	O	O	3573
coronary vasospasm	NOUN	O	Disease	3573
,	PUNCT	O	O	3573
endothelial	NOUN	O	O	3573
damage	NOUN	O	O	3573
and	CCONJ	O	O	3573
consequent	NOUN	O	O	3573
thrombus	NOUN	O	Disease	3573
formation	NOUN	O	O	3573
.	PUNCT	O	O	3573
In	ADP	O	O	3574
our	PRON	O	O	3574
patient	NOUN	O	O	3574
,	PUNCT	O	O	3574
both	PRON	O	O	3574
supraphysiologic	ADJ	O	O	3574
levels	NOUN	O	O	3574
of	ADP	O	O	3574
plasma	NOUN	O	O	3574
catecholamines	NOUN	O	Chemical	3574
and	CCONJ	O	O	3574
stress	NOUN	O	O	3574
related	ADJ	O	O	3574
neuropeptides	NOUN	O	O	3574
caused	VERB	O	O	3574
by	ADP	O	O	3574
cancer	NOUN	O	Disease	3574
diagnosis	NOUN	O	O	3574
as	ADP	O	O	3574
well	ADV	O	O	3574
as	ADP	O	O	3574
chemotherapy	NOUN	O	O	3574
may	AUX	O	O	3574
have	VERB	O	O	3574
contributed	VERB	O	O	3574
the	PRON	O	O	3574
development	NOUN	O	O	3574
of	ADP	O	O	3574
ABS	NOUN	O	Disease	3574
.	PUNCT	O	O	3574
Reduction	NOUN	O	O	3577
of	ADP	O	O	3577
pain	NOUN	O	Disease	3577
during	ADP	O	O	3577
induction	NOUN	O	O	3577
with	ADP	O	O	3577
target	NOUN	O	O	3577
-	PUNCT	O	O	3577
controlled	VERB	O	O	3577
propofol	VERB	O	Chemical	3577
and	CCONJ	O	O	3577
remifentanil	NOUN	O	Chemical	3577
.	PUNCT	O	O	3577
Pain	NOUN	O	Disease	3578
on	ADP	O	O	3578
injection	NOUN	O	O	3578
of	ADP	O	O	3578
propofol	VERB	O	Chemical	3578
is	AUX	O	O	3578
unpleasant	ADJ	O	O	3578
.	PUNCT	O	O	3578
We	PRON	O	O	3579
hypothesized	VERB	O	O	3579
that	SCONJ	O	O	3579
propofol	VERB	O	Chemical	3579
infusion	NOUN	O	O	3579
pain	NOUN	O	Disease	3579
might	AUX	O	O	3579
be	AUX	O	O	3579
prevented	VERB	O	O	3579
by	ADP	O	O	3579
infusing	VERB	O	O	3579
remifentanil	NOUN	O	Chemical	3579
before	ADP	O	O	3579
starting	VERB	O	O	3579
the	PRON	O	O	3579
propofol	VERB	O	Chemical	3579
infusion	NOUN	O	O	3579
in	ADP	O	O	3579
a	PRON	O	O	3579
clinical	ADJ	O	O	3579
setting	VERB	O	O	3579
where	SCONJ	O	O	3579
target	NOUN	O	O	3579
-	PUNCT	O	O	3579
controlled	VERB	O	O	3579
infusions	NOUN	O	O	3579
(	PUNCT	O	O	3579
TCI	PROPN	O	O	3579
)	PUNCT	O	O	3579
of	ADP	O	O	3579
both	PRON	O	O	3579
drugs	NOUN	O	O	3579
were	AUX	O	O	3579
used	VERB	O	O	3579
.	PUNCT	O	O	3579
A	PRON	O	O	3580
prospective	ADJ	O	O	3580
,	PUNCT	O	O	3580
randomized	VERB	O	O	3580
,	PUNCT	O	O	3580
double	ADJ	O	O	3580
-	PUNCT	O	O	3580
blind	ADJ	O	Disease	3580
,	PUNCT	O	O	3580
placebo	NOUN	O	O	3580
-	PUNCT	O	O	3580
controlled	VERB	O	O	3580
trial	NOUN	O	O	3580
was	AUX	O	O	3580
performed	VERB	O	O	3580
to	PART	O	O	3580
determine	VERB	O	O	3580
the	PRON	O	O	3580
effect	VERB	O	O	3580
-	PUNCT	O	O	3580
site	NOUN	O	O	3580
concentration	NOUN	O	O	3580
(	PUNCT	O	O	3580
Ce	PROPN	O	O	3580
)	PUNCT	O	O	3580
of	ADP	O	O	3580
remifentanil	NOUN	O	Chemical	3580
to	PART	O	O	3580
prevent	VERB	O	O	3580
the	PRON	O	O	3580
pain	NOUN	O	Disease	3580
without	ADP	O	O	3580
producing	VERB	O	O	3580
complications	NOUN	O	O	3580
.	PUNCT	O	O	3580
A	PRON	O	O	3581
total	ADJ	O	O	3581
of	ADP	O	O	3581
128	NUM	O	O	3581
patients	NOUN	O	O	3581
undergoing	VERB	O	O	3581
general	ADJ	O	O	3581
surgery	NOUN	O	O	3581
were	AUX	O	O	3581
randomly	ADV	O	O	3581
allocated	VERB	O	O	3581
to	PART	O	O	3581
receive	VERB	O	O	3581
normal	ADJ	O	O	3581
saline	NOUN	O	O	3581
(	PUNCT	O	O	3581
control	VERB	O	O	3581
)	PUNCT	O	O	3581
or	CCONJ	O	O	3581
remifentanil	NOUN	O	Chemical	3581
to	PART	O	O	3581
a	PRON	O	O	3581
target	NOUN	O	O	3581
Ce	PROPN	O	O	3581
of	ADP	O	O	3581
2	X	O	O	3581
ng	PROPN	O	O	3581
ml(-1	VERB	O	O	3581
)	PUNCT	O	O	3581
(	PUNCT	O	O	3581
R2	NOUN	O	O	3581
)	PUNCT	O	O	3581
,	PUNCT	O	O	3581
4	NUM	O	O	3581
ng	PROPN	O	O	3581
ml(-1	VERB	O	O	3581
)	PUNCT	O	O	3581
(	PUNCT	O	O	3581
R4	VERB	O	O	3581
)	PUNCT	O	O	3581
,	PUNCT	O	O	3581
or	CCONJ	O	O	3581
6	NUM	O	O	3581
ng	PROPN	O	O	3581
ml(-1	VERB	O	O	3581
)	PUNCT	O	O	3581
(	PUNCT	O	O	3581
R6	NOUN	O	O	3581
)	PUNCT	O	O	3581
administered	VERB	O	O	3581
via	ADP	O	O	3581
TCI	PROPN	O	O	3581
.	PUNCT	O	O	3581
After	ADP	O	O	3582
the	PRON	O	O	3582
target	NOUN	O	O	3582
Ce	PROPN	O	O	3582
was	AUX	O	O	3582
achieved	VERB	O	O	3582
,	PUNCT	O	O	3582
the	PRON	O	O	3582
infusion	NOUN	O	O	3582
of	ADP	O	O	3582
propofol	VERB	O	Chemical	3582
was	AUX	O	O	3582
started	VERB	O	O	3582
.	PUNCT	O	O	3582
Remifentanil	NOUN	O	Chemical	3583
-	PUNCT	O	O	3583
related	ADJ	O	O	3583
complications	NOUN	O	O	3583
were	AUX	O	O	3583
assessed	VERB	O	O	3583
during	ADP	O	O	3583
the	PRON	O	O	3583
remifentanil	NOUN	O	Chemical	3583
infusion	NOUN	O	O	3583
,	PUNCT	O	O	3583
and	CCONJ	O	O	3583
pain	NOUN	O	Disease	3583
caused	VERB	O	O	3583
by	ADP	O	O	3583
propofol	VERB	O	Chemical	3583
was	AUX	O	O	3583
evaluated	VERB	O	O	3583
using	VERB	O	O	3583
a	PRON	O	O	3583
four	NUM	O	O	3583
-	PUNCT	O	O	3583
point	VERB	O	O	3583
scale	NOUN	O	O	3583
during	ADP	O	O	3583
the	PRON	O	O	3583
propofol	VERB	O	Chemical	3583
infusion	NOUN	O	O	3583
.	PUNCT	O	O	3583
The	PRON	O	O	3584
incidence	NOUN	O	O	3584
of	ADP	O	O	3584
pain	NOUN	O	Disease	3584
was	AUX	O	O	3584
significantly	ADV	O	O	3584
lower	ADJ	O	O	3584
in	ADP	O	O	3584
Groups	NOUN	O	O	3584
R4	VERB	O	O	3584
and	CCONJ	O	O	3584
R6	NOUN	O	O	3584
than	ADP	O	O	3584
in	ADP	O	O	3584
the	PRON	O	O	3584
control	VERB	O	O	3584
and	CCONJ	O	O	3584
R2	NOUN	O	O	3584
groups	NOUN	O	O	3584
(	PUNCT	O	O	3584
12/32	NUM	O	O	3584
and	CCONJ	O	O	3584
6/31	NUM	O	O	3584
vs	ADP	O	O	3584
26/31	NUM	O	O	3584
and	CCONJ	O	O	3584
25/32	NUM	O	O	3584
,	PUNCT	O	O	3584
respectively	ADV	O	O	3584
,	PUNCT	O	O	3584
P<0.001	ADJ	O	O	3584
)	PUNCT	O	O	3584
.	PUNCT	O	O	3584
Pain	NOUN	O	Disease	3585
was	AUX	O	O	3585
less	ADV	O	O	3585
severe	ADJ	O	O	3585
in	ADP	O	O	3585
Groups	NOUN	O	O	3585
R4	VERB	O	O	3585
and	CCONJ	O	O	3585
R6	NOUN	O	O	3585
than	ADP	O	O	3585
in	ADP	O	O	3585
the	PRON	O	O	3585
control	VERB	O	O	3585
and	CCONJ	O	O	3585
R2	NOUN	O	O	3585
groups	NOUN	O	O	3585
(	PUNCT	O	O	3585
P<0.001	ADJ	O	O	3585
)	PUNCT	O	O	3585
.	PUNCT	O	O	3585
However	ADV	O	O	3586
,	PUNCT	O	O	3586
both	PRON	O	O	3586
incidence	NOUN	O	O	3586
and	CCONJ	O	O	3586
severity	NOUN	O	O	3586
of	ADP	O	O	3586
pain	NOUN	O	Disease	3586
were	AUX	O	O	3586
not	PART	O	O	3586
different	ADJ	O	O	3586
between	ADP	O	O	3586
Groups	NOUN	O	O	3586
R4	VERB	O	O	3586
and	CCONJ	O	O	3586
R6	NOUN	O	O	3586
.	PUNCT	O	O	3586
During	ADP	O	O	3587
induction	NOUN	O	O	3587
of	ADP	O	O	3587
anaesthesia	NOUN	O	O	3587
with	ADP	O	O	3587
TCI	PROPN	O	O	3587
of	ADP	O	O	3587
propofol	VERB	O	Chemical	3587
and	CCONJ	O	O	3587
remifentanil	NOUN	O	Chemical	3587
,	PUNCT	O	O	3587
a	PRON	O	O	3587
significant	ADJ	O	O	3587
reduction	NOUN	O	O	3587
in	ADP	O	O	3587
propofol	VERB	O	Chemical	3587
infusion	NOUN	O	O	3587
pain	NOUN	O	Disease	3587
was	AUX	O	O	3587
achieved	VERB	O	O	3587
without	ADP	O	O	3587
significant	ADJ	O	O	3587
complications	NOUN	O	O	3587
by	ADP	O	O	3587
prior	ADV	O	O	3587
administration	NOUN	O	O	3587
of	ADP	O	O	3587
remifentanil	NOUN	O	Chemical	3587
at	ADP	O	O	3587
a	PRON	O	O	3587
target	NOUN	O	O	3587
Ce	PROPN	O	O	3587
of	ADP	O	O	3587
4	NUM	O	O	3587
ng	PROPN	O	O	3587
ml(-1	VERB	O	O	3587
)	PUNCT	O	O	3587
.	PUNCT	O	O	3587
Prenatal	NOUN	O	O	3590
exposure	NOUN	O	O	3590
to	PART	O	O	3590
fluoxetine	NOUN	O	Chemical	3590
induces	VERB	O	O	3590
fetal pulmonary hypertension	NOUN	O	Disease	3590
in	ADP	O	O	3590
the	PRON	O	O	3590
rat	NOUN	O	O	3590
.	PUNCT	O	O	3590
Fluoxetine	NOUN	O	Chemical	3591
is	AUX	O	O	3591
a	PRON	O	O	3591
selective	ADJ	O	O	3591
serotonin	PROPN	O	Chemical	3591
reuptake	PROPN	O	O	3591
inhibitor	NOUN	O	O	3591
antidepressant	NOUN	O	O	3591
widely	ADV	O	O	3591
used	VERB	O	O	3591
by	ADP	O	O	3591
pregnant	ADJ	O	O	3591
women	NOUN	O	O	3591
.	PUNCT	O	O	3591
Epidemiological	ADJ	O	O	3592
data	NOUN	O	O	3592
suggest	VERB	O	O	3592
that	SCONJ	O	O	3592
fluoxetine	NOUN	O	Chemical	3592
exposure	NOUN	O	O	3592
prenatally	ADV	O	O	3592
increases	VERB	O	O	3592
the	PRON	O	O	3592
prevalence	NOUN	O	O	3592
of	ADP	O	O	3592
persistent	ADJ	O	O	3592
pulmonary hypertension	NOUN	O	Disease	3592
syndrome	NOUN	O	O	3592
of	ADP	O	O	3592
the	PRON	O	O	3592
newborn	ADJ	O	O	3592
.	PUNCT	O	O	3592
The	PRON	O	O	3593
mechanism	NOUN	O	O	3593
responsible	ADJ	O	O	3593
for	ADP	O	O	3593
this	PRON	O	O	3593
effect	VERB	O	O	3593
is	AUX	O	O	3593
unclear	ADJ	O	O	3593
and	CCONJ	O	O	3593
paradoxical	ADJ	O	O	3593
,	PUNCT	O	O	3593
considering	VERB	O	O	3593
the	PRON	O	O	3593
current	ADJ	O	O	3593
evidence	NOUN	O	O	3593
of	ADP	O	O	3593
a	PRON	O	O	3593
pulmonary hypertension	NOUN	O	Disease	3593
protective	ADJ	O	O	3593
fluoxetine	NOUN	O	Chemical	3593
effect	VERB	O	O	3593
in	ADP	O	O	3593
adult	NOUN	O	O	3593
rodents	NOUN	O	O	3593
.	PUNCT	O	O	3593
To	PART	O	O	3594
evaluate	VERB	O	O	3594
the	PRON	O	O	3594
fluoxetine	NOUN	O	Chemical	3594
effect	VERB	O	O	3594
on	ADP	O	O	3594
fetal	ADJ	O	O	3594
rat	NOUN	O	O	3594
pulmonary	ADJ	O	O	3594
vascular	ADJ	O	O	3594
smooth	VERB	O	O	3594
muscle	NOUN	O	O	3594
mechanical	ADJ	O	O	3594
properties	NOUN	O	O	3594
and	CCONJ	O	O	3594
cell	NOUN	O	O	3594
proliferation	NOUN	O	O	3594
rate	NOUN	O	O	3594
.	PUNCT	O	O	3594
Pregnant	ADJ	O	O	3595
rats	NOUN	O	O	3595
were	AUX	O	O	3595
treated	VERB	O	O	3595
with	ADP	O	O	3595
fluoxetine	NOUN	O	Chemical	3595
(	PUNCT	O	O	3595
10	NUM	O	O	3595
mg	VERB	O	O	3595
/	PUNCT	O	O	3595
kg	VERB	O	O	3595
)	PUNCT	O	O	3595
from	ADP	O	O	3595
Day	NOUN	O	O	3595
11	NUM	O	O	3595
through	ADP	O	O	3595
Day	NOUN	O	O	3595
21	NUM	O	O	3595
of	ADP	O	O	3595
gestation	NOUN	O	O	3595
.	PUNCT	O	O	3595
As	ADP	O	O	3596
compared	VERB	O	O	3596
with	ADP	O	O	3596
controls	VERB	O	O	3596
,	PUNCT	O	O	3596
fluoxetine	NOUN	O	Chemical	3596
exposure	NOUN	O	O	3596
resulted	VERB	O	O	3596
in	ADP	O	O	3596
fetal pulmonary hypertension	NOUN	O	Disease	3596
as	ADP	O	O	3596
evidenced	VERB	O	O	3596
by	ADP	O	O	3596
an	PRON	O	O	3596
increase	VERB	O	O	3596
in	ADP	O	O	3596
the	PRON	O	O	3596
weight	NOUN	O	O	3596
ratio	NOUN	O	O	3596
of	ADP	O	O	3596
the	PRON	O	O	3596
right	ADV	O	O	3596
ventricle	NOUN	O	O	3596
to	PART	O	O	3596
the	PRON	O	O	3596
left	VERB	O	O	3596
ventricle	NOUN	O	O	3596
plus	CCONJ	O	O	3596
septum	NOUN	O	O	3596
(	PUNCT	O	O	3596
P	NOUN	O	Chemical	3596
=	PUNCT	O	O	3596
0.02	NUM	O	O	3596
)	PUNCT	O	O	3596
and	CCONJ	O	O	3596
by	ADP	O	O	3596
an	PRON	O	O	3596
increase	VERB	O	O	3596
in	ADP	O	O	3596
pulmonary	ADJ	O	O	3596
arterial	ADJ	O	O	3596
medial	ADJ	O	O	3596
thickness	NOUN	O	O	3596
(	PUNCT	O	O	3596
P	NOUN	O	Chemical	3596
<	X	O	O	3596
0.01	NUM	O	O	3596
)	PUNCT	O	O	3596
.	PUNCT	O	O	3596
Postnatal	NOUN	O	O	3597
mortality	NOUN	O	O	3597
was	AUX	O	O	3597
increased	VERB	O	O	3597
among	ADP	O	O	3597
experimental	ADJ	O	O	3597
animals	NOUN	O	O	3597
,	PUNCT	O	O	3597
and	CCONJ	O	O	3597
arterial	ADJ	O	O	3597
oxygen	NOUN	O	Chemical	3597
saturation	NOUN	O	O	3597
was	AUX	O	O	3597
96	NUM	O	O	3597
+	ADP	O	O	3597
/-	PUNCT	O	O	3597
1%	NOUN	O	O	3598
in	ADP	O	O	3598
1-day	NOUN	O	O	3598
-	PUNCT	O	O	3598
old	ADJ	O	O	3598
control	VERB	O	O	3598
animals	NOUN	O	O	3598
and	CCONJ	O	O	3598
significantly	ADV	O	O	3598
lower	ADJ	O	O	3598
(	PUNCT	O	O	3598
P	NOUN	O	Chemical	3598
<	X	O	O	3598
0.01	NUM	O	O	3598
)	PUNCT	O	O	3598
in	ADP	O	O	3598
fluoxetine	NOUN	O	Chemical	3598
-	PUNCT	O	O	3598
exposed	VERB	O	O	3598
pups	NOUN	O	O	3598
(	PUNCT	O	O	3598
79	NUM	O	O	3598
+	ADP	O	O	3598
/-	PUNCT	O	O	3598
In	ADP	O	O	3599
vitro	X	O	O	3599
,	PUNCT	O	O	3599
fluoxetine	NOUN	O	Chemical	3599
induced	VERB	O	O	3599
pulmonary	ADJ	O	O	3599
arterial	ADJ	O	O	3599
muscle	NOUN	O	O	3599
contraction	NOUN	O	O	3599
in	ADP	O	O	3599
fetal	ADJ	O	O	3599
,	PUNCT	O	O	3599
but	CCONJ	O	O	3599
not	PART	O	O	3599
adult	NOUN	O	O	3599
,	PUNCT	O	O	3599
animals	NOUN	O	O	3599
(	PUNCT	O	O	3599
P	NOUN	O	Chemical	3599
<	X	O	O	3599
0.01	NUM	O	O	3599
)	PUNCT	O	O	3599
and	CCONJ	O	O	3599
reduced	VERB	O	O	3599
serotonin	PROPN	O	Chemical	3599
-	PUNCT	O	O	3599
induced	VERB	O	O	3599
contraction	NOUN	O	O	3599
at	ADP	O	O	3599
both	PRON	O	O	3599
ages	NOUN	O	O	3599
(	PUNCT	O	O	3599
P	NOUN	O	Chemical	3599
<	X	O	O	3599
0.01	NUM	O	O	3599
)	PUNCT	O	O	3599
.	PUNCT	O	O	3599
After	ADP	O	O	3600
in	ADP	O	O	3600
utero	NOUN	O	O	3600
exposure	NOUN	O	O	3600
to	PART	O	O	3600
a	PRON	O	O	3600
low	ADJ	O	O	3600
fluoxetine	NOUN	O	Chemical	3600
concentration	NOUN	O	O	3600
the	PRON	O	O	3600
pulmonary	ADJ	O	O	3600
arterial	ADJ	O	O	3600
smooth	VERB	O	O	3600
muscle	NOUN	O	O	3600
cell	NOUN	O	O	3600
proliferation	NOUN	O	O	3600
rate	NOUN	O	O	3600
was	AUX	O	O	3600
significantly	ADV	O	O	3600
increased	VERB	O	O	3600
in	ADP	O	O	3600
fetal	ADJ	O	O	3600
,	PUNCT	O	O	3600
but	CCONJ	O	O	3600
not	PART	O	O	3600
adult	NOUN	O	O	3600
,	PUNCT	O	O	3600
cells	NOUN	O	O	3600
(	PUNCT	O	O	3600
P	NOUN	O	Chemical	3600
<	X	O	O	3600
0.01	NUM	O	O	3600
)	PUNCT	O	O	3600
.	PUNCT	O	O	3600
In	ADP	O	O	3601
contrast	NOUN	O	O	3601
to	PART	O	O	3601
the	PRON	O	O	3601
adult	NOUN	O	O	3601
,	PUNCT	O	O	3601
fluoxetine	NOUN	O	Chemical	3601
exposure	NOUN	O	O	3601
in	ADP	O	O	3601
utero	NOUN	O	O	3601
induces	VERB	O	O	3601
pulmonary hypertension	NOUN	O	Disease	3601
in	ADP	O	O	3601
the	PRON	O	O	3601
fetal	ADJ	O	O	3601
rat	NOUN	O	O	3601
as	ADP	O	O	3601
a	PRON	O	O	3601
result	VERB	O	O	3601
of	ADP	O	O	3601
a	PRON	O	O	3601
developmentally	ADV	O	O	3601
regulated	VERB	O	O	3601
increase	VERB	O	O	3601
in	ADP	O	O	3601
pulmonary	ADJ	O	O	3601
vascular	ADJ	O	O	3601
smooth	VERB	O	O	3601
muscle	NOUN	O	O	3601
proliferation	NOUN	O	O	3601
.	PUNCT	O	O	3601
Syncope	NOUN	O	Disease	3604
and	CCONJ	O	O	3604
QT prolongation	NOUN	O	Disease	3604
among	ADP	O	O	3604
patients	NOUN	O	O	3604
treated	VERB	O	O	3604
with	ADP	O	O	3604
methadone	NOUN	O	Chemical	3604
for	ADP	O	O	3604
heroin	NOUN	O	Chemical	3604
dependence	NOUN	O	O	3604
in	ADP	O	O	3604
the	PRON	O	O	3604
city	NOUN	O	O	3604
of	ADP	O	O	3604
Copenhagen	PROPN	O	O	3604
.	PUNCT	O	O	3604
Methadone	NOUN	O	Chemical	3605
is	AUX	O	O	3605
prescribed	VERB	O	O	3605
to	PART	O	O	3605
heroin	NOUN	O	Chemical	3605
addicts	NOUN	O	O	3605
to	PART	O	O	3605
decrease	VERB	O	O	3605
illicit	ADJ	O	O	3605
opioid	NOUN	O	O	3605
use	VERB	O	O	3605
.	PUNCT	O	O	3605
Prolongation of the QT interval	NOUN	O	Disease	3606
in	ADP	O	O	3606
the	PRON	O	O	3606
ECG	PROPN	O	O	3606
of	ADP	O	O	3606
patients	NOUN	O	O	3606
with	ADP	O	O	3606
torsade de pointes	NOUN	O	Disease	3606
(	PUNCT	O	O	3606
TdP	NOUN	O	Disease	3606
)	PUNCT	O	O	3606
has	VERB	O	O	3606
been	AUX	O	O	3606
reported	VERB	O	O	3606
in	ADP	O	O	3606
methadone	NOUN	O	Chemical	3606
users	NOUN	O	O	3606
.	PUNCT	O	O	3606
As	ADP	O	O	3607
heroin	NOUN	O	Chemical	3607
addicts	NOUN	O	O	3607
sometimes	ADV	O	O	3607
faint	ADJ	O	O	3607
while	SCONJ	O	O	3607
using	VERB	O	O	3607
illicit	ADJ	O	O	3607
drugs	NOUN	O	O	3607
,	PUNCT	O	O	3607
doctors	NOUN	O	O	3607
might	AUX	O	O	3607
attribute	NOUN	O	O	3607
too	ADV	O	O	3607
many	ADJ	O	O	3607
episodes	NOUN	O	O	3607
of	ADP	O	O	3607
syncope	VERB	O	Disease	3607
to	PART	O	O	3607
illicit	ADJ	O	O	3607
drug	NOUN	O	O	3607
use	VERB	O	O	3607
and	CCONJ	O	O	3607
thereby	ADV	O	O	3607
underestimate	VERB	O	O	3607
the	PRON	O	O	3607
incidence	NOUN	O	O	3607
of	ADP	O	O	3607
TdP	NOUN	O	Disease	3607
in	ADP	O	O	3607
this	PRON	O	O	3607
special	ADJ	O	O	3607
population	NOUN	O	O	3607
,	PUNCT	O	O	3607
and	CCONJ	O	O	3607
the	PRON	O	O	3607
high	ADJ	O	O	3607
mortality	NOUN	O	O	3607
in	ADP	O	O	3607
this	PRON	O	O	3607
population	NOUN	O	O	3607
may	AUX	O	O	3607
,	PUNCT	O	O	3607
in	ADP	O	O	3607
part	NOUN	O	O	3607
,	PUNCT	O	O	3607
be	AUX	O	O	3607
caused	VERB	O	O	3607
by	ADP	O	O	3607
the	PRON	O	O	3607
proarrhythmic	ADJ	O	O	3607
effect	VERB	O	O	3607
of	ADP	O	O	3607
methadone	NOUN	O	Chemical	3607
.	PUNCT	O	O	3607
In	ADP	O	O	3608
this	PRON	O	O	3608
cross	VERB	O	O	3608
-	PUNCT	O	O	3608
sectional	ADJ	O	O	3608
study	VERB	O	O	3608
interview	VERB	O	O	3608
,	PUNCT	O	O	3608
ECGs	X	O	O	3608
and	CCONJ	O	O	3608
blood	NOUN	O	O	3608
samples	NOUN	O	O	3608
were	AUX	O	O	3608
collected	VERB	O	O	3608
in	ADP	O	O	3608
a	PRON	O	O	3608
population	NOUN	O	O	3608
of	ADP	O	O	3608
adult	NOUN	O	O	3608
heroin	NOUN	O	Chemical	3608
addicts	NOUN	O	O	3608
treated	VERB	O	O	3608
with	ADP	O	O	3608
methadone	NOUN	O	Chemical	3608
or	CCONJ	O	O	3608
buprenorphine	NOUN	O	Chemical	3608
on	ADP	O	O	3608
a	PRON	O	O	3608
daily	ADV	O	O	3608
basis	NOUN	O	O	3608
.	PUNCT	O	O	3608
All	PRON	O	O	3609
participants	NOUN	O	O	3609
were	AUX	O	O	3609
interviewed	VERB	O	O	3609
about	ADP	O	O	3609
any	PRON	O	O	3609
experience	NOUN	O	O	3609
of	ADP	O	O	3609
syncope	VERB	O	Disease	3609
.	PUNCT	O	O	3609
The	PRON	O	O	3610
association	PROPN	O	O	3610
between	ADP	O	O	3610
opioid	NOUN	O	O	3610
dose	NOUN	O	O	3610
and	CCONJ	O	O	3610
QT	NOUN	O	O	3610
,	PUNCT	O	O	3610
and	CCONJ	O	O	3610
methadone	NOUN	O	Chemical	3610
dose	NOUN	O	O	3610
and	CCONJ	O	O	3610
reporting	VERB	O	O	3610
of	ADP	O	O	3610
syncope	VERB	O	Disease	3610
was	AUX	O	O	3610
assessed	VERB	O	O	3610
using	VERB	O	O	3610
multivariate	ADJ	O	O	3610
linear	ADJ	O	O	3610
regression	NOUN	O	O	3610
and	CCONJ	O	O	3610
logistic	ADJ	O	O	3610
regression	NOUN	O	O	3610
,	PUNCT	O	O	3610
respectively	ADV	O	O	3610
.	PUNCT	O	O	3610
Methadone	NOUN	O	Chemical	3611
dose	NOUN	O	O	3611
was	AUX	O	O	3611
associated	VERB	O	O	3611
with	ADP	O	O	3611
longer	ADV	O	O	3611
QT	NOUN	O	O	3611
interval	NOUN	O	O	3611
of	ADP	O	O	3611
0.140	NUM	O	O	3611
ms	PROPN	O	O	3611
/	PUNCT	O	O	3611
mg	VERB	O	O	3611
(	PUNCT	O	O	3611
p	NOUN	O	O	3611
=	PUNCT	O	O	3611
0.002	NUM	O	O	3611
)	PUNCT	O	O	3611
.	PUNCT	O	O	3611
No	PRON	O	O	3612
association	PROPN	O	O	3612
between	ADP	O	O	3612
buprenorphine	NOUN	O	Chemical	3612
and	CCONJ	O	O	3612
QTc	VERB	O	O	3612
was	AUX	O	O	3612
found	VERB	O	O	3612
.	PUNCT	O	O	3612
Among	ADP	O	O	3613
the	PRON	O	O	3613
subjects	NOUN	O	O	3613
treated	VERB	O	O	3613
with	ADP	O	O	3613
methadone	NOUN	O	Chemical	3613
,	PUNCT	O	O	3613
28%	NOUN	O	O	3613
men	NOUN	O	O	3613
and	CCONJ	O	O	3613
32%	NOUN	O	O	3613
women	NOUN	O	O	3613
had	VERB	O	O	3613
prolonged QTc interval	NOUN	O	Disease	3613
.	PUNCT	O	O	3613
None	NOUN	O	O	3614
of	ADP	O	O	3614
the	PRON	O	O	3614
subjects	NOUN	O	O	3614
treated	VERB	O	O	3614
with	ADP	O	O	3614
buprenorphine	NOUN	O	Chemical	3614
had	VERB	O	O	3614
QTc	VERB	O	O	3614
interval	NOUN	O	O	3614
>	PUNCT	O	O	3614
0.440	NUM	O	O	3614
s((1/2	VERB	O	O	3614
)	PUNCT	O	O	3614
)	PUNCT	O	O	3614
.	PUNCT	O	O	3614
A	PRON	O	O	3615
50	NUM	O	O	3615
mg	VERB	O	O	3615
higher	ADJ	O	O	3615
methadone	NOUN	O	Chemical	3615
dose	NOUN	O	O	3615
was	AUX	O	O	3615
associated	VERB	O	O	3615
with	ADP	O	O	3615
a	PRON	O	O	3615
1.2	NUM	O	O	3615
(	PUNCT	O	O	3615
95%	NOUN	O	O	3615
CI	NOUN	O	O	3615
1.1	NUM	O	O	3615
to	PART	O	O	3615
1.4	NUM	O	O	3615
)	PUNCT	O	O	3615
times	NOUN	O	O	3615
higher	ADJ	O	O	3615
odds	NOUN	O	O	3615
for	ADP	O	O	3615
syncope	VERB	O	Disease	3615
.	PUNCT	O	O	3615
Methadone	NOUN	O	Chemical	3616
is	AUX	O	O	3616
associated	VERB	O	O	3616
with	ADP	O	O	3616
QT prolongation	NOUN	O	Disease	3616
and	CCONJ	O	O	3616
higher	ADJ	O	O	3616
reporting	VERB	O	O	3616
of	ADP	O	O	3616
syncope	VERB	O	Disease	3616
in	ADP	O	O	3616
a	PRON	O	O	3616
population	NOUN	O	O	3616
of	ADP	O	O	3616
heroin	NOUN	O	Chemical	3616
addicts	NOUN	O	O	3616
.	PUNCT	O	O	3616
Peripheral neuropathy	NOUN	O	Disease	3619
caused	VERB	O	O	3619
by	ADP	O	O	3619
high	ADJ	O	O	3619
-	PUNCT	O	O	3619
dose	NOUN	O	O	3619
cytosine arabinoside	NOUN	O	Chemical	3619
treatment	NOUN	O	O	3619
in	ADP	O	O	3619
a	PRON	O	O	3619
patient	NOUN	O	O	3619
with	ADP	O	O	3619
acute myeloid leukemia	NOUN	O	Disease	3619
.	PUNCT	O	O	3619
The	PRON	O	O	3620
central nervous system toxicity	NOUN	O	Disease	3620
of	ADP	O	O	3620
high	ADJ	O	O	3620
-	PUNCT	O	O	3620
dose	NOUN	O	O	3620
cytosine arabinoside	NOUN	O	Chemical	3620
is	AUX	O	O	3620
well	ADV	O	O	3620
recognized	VERB	O	O	3620
,	PUNCT	O	O	3620
but	CCONJ	O	O	3620
the	PRON	O	O	3620
toxicity	NOUN	O	Disease	3620
of	ADP	O	O	3620
cytosine arabinoside	NOUN	O	Chemical	3620
in	ADP	O	O	3620
the	PRON	O	O	3620
peripheral	ADJ	O	O	3620
nervous	ADJ	O	O	3620
system	NOUN	O	O	3620
has	VERB	O	O	3620
been	AUX	O	O	3620
infrequently	ADV	O	O	3620
reported	VERB	O	O	3620
.	PUNCT	O	O	3620
A	PRON	O	O	3621
49-year	NOUN	O	O	3621
-	PUNCT	O	O	3621
old	ADJ	O	O	3621
Japanese	NOUN	O	O	3621
man	NOUN	O	O	3621
was	AUX	O	O	3621
diagnosed	VERB	O	O	3621
with	ADP	O	O	3621
acute myeloid leukemia	NOUN	O	Disease	3621
.	PUNCT	O	O	3621
After	ADP	O	O	3622
he	PRON	O	O	3622
achieved	VERB	O	O	3622
complete	VERB	O	O	3622
remission	NOUN	O	O	3622
,	PUNCT	O	O	3622
he	PRON	O	O	3622
received	VERB	O	O	3622
high	ADJ	O	O	3622
-	PUNCT	O	O	3622
dose	NOUN	O	O	3622
cytosine arabinoside	NOUN	O	Chemical	3622
treatment	NOUN	O	O	3622
(	PUNCT	O	O	3622
2	X	O	O	3622
g	X	O	O	3622
/	PUNCT	O	O	3622
m2	PROPN	O	O	3622
twice	ADV	O	O	3622
a	PRON	O	O	3622
day	NOUN	O	O	3622
for	ADP	O	O	3622
5	NUM	O	O	3622
days	NOUN	O	O	3622
;	PUNCT	O	O	3622
total	ADJ	O	O	3622
,	PUNCT	O	O	3622
20	NUM	O	O	3622
g	X	O	O	3622
/	PUNCT	O	O	3622
m2	PROPN	O	O	3622
)	PUNCT	O	O	3622
as	ADP	O	O	3622
consolidation	NOUN	O	O	3622
therapy	NOUN	O	O	3622
.	PUNCT	O	O	3622
The	PRON	O	O	3623
first	ADV	O	O	3623
course	NOUN	O	O	3623
of	ADP	O	O	3623
high	ADJ	O	O	3623
-	PUNCT	O	O	3623
dose	NOUN	O	O	3623
cytosine arabinoside	NOUN	O	Chemical	3623
resulted	VERB	O	O	3623
in	ADP	O	O	3623
no	PRON	O	O	3623
unusual	ADJ	O	O	3623
symptoms	NOUN	O	O	3623
,	PUNCT	O	O	3623
but	CCONJ	O	O	3623
on	ADP	O	O	3623
day	NOUN	O	O	3623
21	NUM	O	O	3623
of	ADP	O	O	3623
the	PRON	O	O	3623
second	ADV	O	O	3623
course	NOUN	O	O	3623
of	ADP	O	O	3623
treatment	NOUN	O	O	3623
,	PUNCT	O	O	3623
the	PRON	O	O	3623
patient	NOUN	O	O	3623
complained	VERB	O	O	3623
of	ADP	O	O	3623
numbness	NOUN	O	Disease	3623
in	ADP	O	O	3623
his	PRON	O	O	3623
right	ADV	O	O	3623
foot	NOUN	O	O	3623
.	PUNCT	O	O	3623
Electromyogram	PROPN	O	O	3624
and	CCONJ	O	O	3624
nerve	NOUN	O	O	3624
-	PUNCT	O	O	3624
conduction	NOUN	O	O	3624
studies	NOUN	O	O	3624
showed	VERB	O	O	3624
peripheral neuropathy	NOUN	O	Disease	3624
in	ADP	O	O	3624
both	PRON	O	O	3624
peroneal	ADJ	O	O	3624
nerves	NOUN	O	O	3624
.	PUNCT	O	O	3624
This	PRON	O	O	3625
neuropathy	NOUN	O	Disease	3625
was	AUX	O	O	3625
gradually	ADV	O	O	3625
resolving	VERB	O	O	3625
;	PUNCT	O	O	3625
however	ADV	O	O	3625
,	PUNCT	O	O	3625
after	ADP	O	O	3625
the	PRON	O	O	3625
patient	NOUN	O	O	3625
received	VERB	O	O	3625
allogeneic	ADJ	O	O	3625
bone	NOUN	O	O	3625
marrow	PROPN	O	O	3625
transplantation	NOUN	O	O	3625
,	PUNCT	O	O	3625
the	PRON	O	O	3625
symptoms	NOUN	O	O	3625
worsened	VERB	O	O	3625
,	PUNCT	O	O	3625
with	ADP	O	O	3625
the	PRON	O	O	3625
development	NOUN	O	O	3625
of	ADP	O	O	3625
graft	NOUN	O	O	3625
-	PUNCT	O	O	3625
versus	ADP	O	O	3625
-	PUNCT	O	O	3625
host	NOUN	O	O	3625
disease	PROPN	O	O	3625
,	PUNCT	O	O	3625
and	CCONJ	O	O	3625
the	PRON	O	O	3625
symptoms	NOUN	O	O	3625
subsequently	ADV	O	O	3625
responded	VERB	O	O	3625
to	PART	O	O	3625
methylprednisolone	NOUN	O	Chemical	3625
.	PUNCT	O	O	3625
Although	SCONJ	O	O	3626
the	PRON	O	O	3626
mechanisms	NOUN	O	O	3626
of	ADP	O	O	3626
peripheral neuropathy	NOUN	O	Disease	3626
are	AUX	O	O	3626
still	ADV	O	O	3626
unclear	ADJ	O	O	3626
,	PUNCT	O	O	3626
high	ADJ	O	O	3626
-	PUNCT	O	O	3626
dose	NOUN	O	O	3626
cytosine arabinoside	NOUN	O	Chemical	3626
is	AUX	O	O	3626
a	PRON	O	O	3626
therapy	NOUN	O	O	3626
that	SCONJ	O	O	3626
is	AUX	O	O	3626
potentially	ADV	O	O	3626
toxic	ADJ	O	O	3626
to	PART	O	O	3626
the	PRON	O	O	3626
peripheral	ADJ	O	O	3626
nervous	ADJ	O	O	3626
system	NOUN	O	O	3626
,	PUNCT	O	O	3626
and	CCONJ	O	O	3626
auto	NOUN	O	O	3626
/	PUNCT	O	O	3626
alloimmunity	NOUN	O	O	3626
may	AUX	O	O	3626
play	VERB	O	O	3626
an	PRON	O	O	3626
important	ADJ	O	O	3626
role	NOUN	O	O	3626
in	ADP	O	O	3626
these	PRON	O	O	3626
mechanisms	NOUN	O	O	3626
.	PUNCT	O	O	3626
Atorvastatin	PROPN	O	Chemical	3629
prevented	VERB	O	O	3629
and	CCONJ	O	O	3629
reversed	VERB	O	O	3629
dexamethasone	NOUN	O	Chemical	3629
-	PUNCT	O	O	3629
induced	VERB	O	O	3629
hypertension	NOUN	O	Disease	3629
in	ADP	O	O	3629
the	PRON	O	O	3629
rat	NOUN	O	O	3629
.	PUNCT	O	O	3629
To	PART	O	O	3630
assess	VERB	O	O	3630
the	PRON	O	O	3630
antioxidant	ADJ	O	O	3630
effects	NOUN	O	O	3630
of	ADP	O	O	3630
atorvastatin	PROPN	O	Chemical	3630
(	PUNCT	O	O	3630
atorva	PROPN	O	Chemical	3630
)	PUNCT	O	O	3630
on	ADP	O	O	3630
dexamethasone	NOUN	O	Chemical	3630
(	PUNCT	O	O	3630
dex)-induced	NOUN	O	O	3630
hypertension	NOUN	O	Disease	3630
,	PUNCT	O	O	3630
60	NUM	O	O	3630
male	NOUN	O	O	3630
Sprague	PROPN	O	O	3630
-	PUNCT	O	O	3630
Dawley	NOUN	O	O	3630
rats	NOUN	O	O	3630
were	AUX	O	O	3630
treated	VERB	O	O	3630
with	ADP	O	O	3630
atorva	PROPN	O	Chemical	3630
30	NUM	O	O	3630
mg	VERB	O	O	3630
/	PUNCT	O	O	3630
kg	VERB	O	O	3630
/	PUNCT	O	O	3630
day	NOUN	O	O	3630
or	CCONJ	O	O	3630
tap	NOUN	O	O	3630
water	PROPN	O	O	3630
for	ADP	O	O	3630
15	NUM	O	O	3630
days	NOUN	O	O	3630
.	PUNCT	O	O	3630
Dex	PROPN	O	Chemical	3631
increased	VERB	O	O	3631
systolic	ADV	O	O	3631
blood	NOUN	O	O	3631
pressure	NOUN	O	O	3631
(	PUNCT	O	O	3631
SBP	NOUN	O	O	3631
)	PUNCT	O	O	3631
from	ADP	O	O	3631
109	NUM	O	O	3631
+	ADP	O	O	3631
/-	PUNCT	O	O	3631
0.6	NUM	O	O	3632
mmHg	PROPN	O	O	3632
and	CCONJ	O	O	3632
plasma	NOUN	O	O	3632
superoxide	NOUN	O	Chemical	3632
(	PUNCT	O	O	3632
5711	NUM	O	O	3632
+	ADP	O	O	3632
/-	PUNCT	O	O	3632
392.8	NUM	O	O	3633
U	NOUN	O	O	3633
/	PUNCT	O	O	3633
ml	ADP	O	O	3633
dex	PROPN	O	Chemical	3633
,	PUNCT	O	O	3633
P	NOUN	O	Chemical	3633
<	X	O	O	3633
0.001	NUM	O	O	3633
)	PUNCT	O	O	3633
.	PUNCT	O	O	3633
In	ADP	O	O	3634
this	PRON	O	O	3634
prevention	NOUN	O	O	3634
study	VERB	O	O	3634
,	PUNCT	O	O	3634
SBP	NOUN	O	O	3634
in	ADP	O	O	3634
the	PRON	O	O	3634
atorva	PROPN	O	Chemical	3634
+	ADP	O	O	3634
dex	PROPN	O	Chemical	3634
group	NOUN	O	O	3634
was	AUX	O	O	3634
increased	VERB	O	O	3634
from	ADP	O	O	3634
115	NUM	O	O	3634
+	ADP	O	O	3634
/-	PUNCT	O	O	3634
1.5	NUM	O	O	3635
mmHg	PROPN	O	O	3635
,	PUNCT	O	O	3635
but	CCONJ	O	O	3635
this	PRON	O	O	3635
was	AUX	O	O	3635
significantly	ADV	O	O	3635
lower	ADJ	O	O	3635
than	ADP	O	O	3635
in	ADP	O	O	3635
the	PRON	O	O	3635
dex	PROPN	O	Chemical	3635
-	PUNCT	O	O	3635
only	ADV	O	O	3635
group	NOUN	O	O	3635
(	PUNCT	O	O	3635
Atorva	PROPN	O	Chemical	3636
reversed	VERB	O	O	3636
dex	PROPN	O	Chemical	3636
-	PUNCT	O	O	3636
induced	VERB	O	O	3636
hypertension	NOUN	O	Disease	3636
(	PUNCT	O	O	3636
129	NUM	O	O	3636
+	ADP	O	O	3636
/-	PUNCT	O	O	3636
0.6	NUM	O	O	3637
mmHg	PROPN	O	O	3637
P	NOUN	O	Chemical	3637
'	PUNCT	O	O	3637
<	X	O	O	3637
0.05	NUM	O	O	3637
)	PUNCT	O	O	3637
and	CCONJ	O	O	3637
decreased	VERB	O	O	3637
plasma	NOUN	O	O	3637
superoxide	NOUN	O	Chemical	3637
(	PUNCT	O	O	3637
7931	NUM	O	O	3637
+	ADP	O	O	3637
/-	PUNCT	O	O	3637
392.8	NUM	O	O	3638
dex	PROPN	O	Chemical	3638
,	PUNCT	O	O	3638
1187	NUM	O	O	3638
441.2	NUM	O	O	3639
atorva	PROPN	O	Chemical	3639
+	ADP	O	O	3639
dex	PROPN	O	Chemical	3639
,	PUNCT	O	O	3639
P	NOUN	O	Chemical	3639
<	X	O	O	3639
0.0001	NUM	O	O	3639
)	PUNCT	O	O	3639
.	PUNCT	O	O	3639
Plasma	NOUN	O	O	3640
nitrate	NOUN	O	Chemical	3640
/	PUNCT	O	O	3640
nitrite	PROPN	O	Chemical	3640
(	PUNCT	O	O	3640
NOx	PROPN	O	O	3640
)	PUNCT	O	O	3640
was	AUX	O	O	3640
decreased	VERB	O	O	3640
in	ADP	O	O	3640
dex	PROPN	O	Chemical	3640
-	PUNCT	O	O	3640
treated	VERB	O	O	3640
rats	NOUN	O	O	3640
compared	VERB	O	O	3640
to	PART	O	O	3640
saline	NOUN	O	O	3640
-	PUNCT	O	O	3640
treated	VERB	O	O	3640
rats	NOUN	O	O	3640
(	PUNCT	O	O	3640
11.2	NUM	O	O	3640
+	ADP	O	O	3640
/-	PUNCT	O	O	3640
Atorva	PROPN	O	Chemical	3641
affected	VERB	O	O	3641
neither	ADV	O	O	3641
plasma	NOUN	O	O	3641
NOx	PROPN	O	O	3641
nor	CCONJ	O	O	3641
thymus	NOUN	O	O	3641
weight	NOUN	O	O	3641
.	PUNCT	O	O	3641
Thus	ADV	O	O	3642
,	PUNCT	O	O	3642
atorvastatin	PROPN	O	Chemical	3642
prevented	VERB	O	O	3642
and	CCONJ	O	O	3642
reversed	VERB	O	O	3642
dexamethasone	NOUN	O	Chemical	3642
-	PUNCT	O	O	3642
induced	VERB	O	O	3642
hypertension	NOUN	O	Disease	3642
in	ADP	O	O	3642
the	PRON	O	O	3642
rat	NOUN	O	O	3642
.	PUNCT	O	O	3642
Two	NUM	O	O	3645
prodrugs	NOUN	O	O	3645
of	ADP	O	O	3645
potent	ADJ	O	O	3645
and	CCONJ	O	O	3645
selective	ADJ	O	O	3645
GluR5	NOUN	O	O	3645
kainate	VERB	O	Chemical	3645
receptor	NOUN	O	O	3645
antagonists	NOUN	O	O	3645
actives	NOUN	O	O	3645
in	ADP	O	O	3645
three	NUM	O	O	3645
animal	NOUN	O	O	3645
models	NOUN	O	O	3645
of	ADP	O	O	3645
pain	NOUN	O	Disease	3645
.	PUNCT	O	O	3645
Amino	ADJ	O	O	3646
acids	NOUN	O	O	3646
5	NUM	O	O	3646
and	CCONJ	O	O	3646
7	NUM	O	O	3646
,	PUNCT	O	O	3646
two	NUM	O	O	3646
potent	ADJ	O	O	3646
and	CCONJ	O	O	3646
selective	ADJ	O	O	3646
competitive	ADJ	O	O	3646
GluR5	NOUN	O	O	3646
KA	PROPN	O	Chemical	3646
receptor	NOUN	O	O	3646
antagonists	NOUN	O	O	3646
,	PUNCT	O	O	3646
exhibited	VERB	O	O	3646
high	ADJ	O	O	3646
GluR5	NOUN	O	O	3646
receptor	NOUN	O	O	3646
affinity	NOUN	O	O	3646
over	ADP	O	O	3646
other	ADJ	O	O	3646
glutamate	NOUN	O	Chemical	3646
receptors	NOUN	O	O	3646
.	PUNCT	O	O	3646
Their	PRON	O	O	3647
ester	PROPN	O	O	3647
prodrugs	NOUN	O	O	3647
6	NUM	O	O	3647
and	CCONJ	O	O	3647
8	NUM	O	O	3647
were	AUX	O	O	3647
orally	ADV	O	O	3647
active	ADJ	O	O	3647
in	ADP	O	O	3647
three	NUM	O	O	3647
models	NOUN	O	O	3647
of	ADP	O	O	3647
pain	NOUN	O	Disease	3647
:	PUNCT	O	O	3647
reversal	NOUN	O	O	3647
of	ADP	O	O	3647
formalin	NOUN	O	Chemical	3647
-	PUNCT	O	O	3647
induced	VERB	O	O	3647
paw	PROPN	O	O	3647
licking	VERB	O	O	3647
,	PUNCT	O	O	3647
carrageenan	NOUN	O	Chemical	3647
-	PUNCT	O	O	3647
induced	VERB	O	O	3647
thermal hyperalgesia	NOUN	O	Disease	3647
,	PUNCT	O	O	3647
and	CCONJ	O	O	3647
capsaicin	NOUN	O	Chemical	3647
-	PUNCT	O	O	3647
induced	VERB	O	O	3647
mechanical hyperalgesia	NOUN	O	Disease	3647
.	PUNCT	O	O	3647
Sirolimus	NOUN	O	Chemical	3650
and	CCONJ	O	O	3650
mycophenolate mofetil	PROPN	O	Chemical	3650
for	ADP	O	O	3650
calcineurin	NOUN	O	O	3650
-	PUNCT	O	O	3650
free	ADJ	O	O	3650
immunosuppression	NOUN	O	O	3650
in	ADP	O	O	3650
renal	ADJ	O	O	3650
transplant	NOUN	O	O	3650
recipients	NOUN	O	O	3650
.	PUNCT	O	O	3650
Calcineurin	NOUN	O	O	3651
inhibitors	NOUN	O	O	3651
,	PUNCT	O	O	3651
such	ADJ	O	O	3651
as	ADP	O	O	3651
cyclosporine	NOUN	O	Chemical	3651
and	CCONJ	O	O	3651
tacrolimus	NOUN	O	Chemical	3651
,	PUNCT	O	O	3651
have	VERB	O	O	3651
been	AUX	O	O	3651
available	ADJ	O	O	3651
for	ADP	O	O	3651
almost	ADV	O	O	3651
20	NUM	O	O	3651
years	NOUN	O	O	3651
.	PUNCT	O	O	3651
Although	SCONJ	O	O	3652
these	PRON	O	O	3652
drugs	NOUN	O	O	3652
are	AUX	O	O	3652
highly	ADV	O	O	3652
effective	ADJ	O	O	3652
and	CCONJ	O	O	3652
represent	VERB	O	O	3652
the	PRON	O	O	3652
mainstay	NOUN	O	O	3652
of	ADP	O	O	3652
transplant	NOUN	O	O	3652
immunosuppression	NOUN	O	O	3652
,	PUNCT	O	O	3652
they	PRON	O	O	3652
are	AUX	O	O	3652
associated	VERB	O	O	3652
with	ADP	O	O	3652
acute	ADJ	O	O	3652
and	CCONJ	O	O	3652
chronic	ADJ	O	O	3652
nephrotoxicity	NOUN	O	Disease	3652
.	PUNCT	O	O	3652
Acute	PROPN	O	O	3653
nephrotoxicity	NOUN	O	Disease	3653
,	PUNCT	O	O	3653
which	PRON	O	O	3653
occurs	VERB	O	O	3653
in	ADP	O	O	3653
the	PRON	O	O	3653
early	ADV	O	O	3653
period	NOUN	O	O	3653
after	ADP	O	O	3653
transplantation	NOUN	O	O	3653
,	PUNCT	O	O	3653
leads	VERB	O	O	3653
to	PART	O	O	3653
a	PRON	O	O	3653
higher	ADJ	O	O	3653
rate	NOUN	O	O	3653
of	ADP	O	O	3653
dialysis	NOUN	O	O	3653
,	PUNCT	O	O	3653
and	CCONJ	O	O	3653
chronic	ADJ	O	O	3653
nephrotoxicity	NOUN	O	Disease	3653
may	AUX	O	O	3653
eventually	ADV	O	O	3653
result	VERB	O	O	3653
in	ADP	O	O	3653
graft	NOUN	O	O	3653
loss	NOUN	O	O	3653
.	PUNCT	O	O	3653
Acute	PROPN	O	O	3654
and	CCONJ	O	O	3654
chronic	ADJ	O	O	3654
nephrotoxicity	NOUN	O	Disease	3654
is	AUX	O	O	3654
becoming	VERB	O	O	3654
more	ADJ	O	O	3654
common	ADJ	O	O	3654
as	ADP	O	O	3654
the	PRON	O	O	3654
use	VERB	O	O	3654
of	ADP	O	O	3654
marginal	ADJ	O	O	3654
kidneys	NOUN	O	O	3654
for	ADP	O	O	3654
transplantation	NOUN	O	O	3654
increases	VERB	O	O	3654
.	PUNCT	O	O	3654
Two	NUM	O	O	3655
recently	ADV	O	O	3655
available	ADJ	O	O	3655
immunosuppressive	ADJ	O	O	3655
agents	NOUN	O	O	3655
,	PUNCT	O	O	3655
mycophenolate mofetil	PROPN	O	Chemical	3655
and	CCONJ	O	O	3655
sirolimus	NOUN	O	Chemical	3655
(	PUNCT	O	O	3655
rapamycin	NOUN	O	Chemical	3655
)	PUNCT	O	O	3655
,	PUNCT	O	O	3655
have	VERB	O	O	3655
no	PRON	O	O	3655
nephrotoxicity	NOUN	O	Disease	3655
.	PUNCT	O	O	3655
Erythropoietin	NOUN	O	O	3658
restores	VERB	O	O	3658
the	PRON	O	O	3658
anemia	NOUN	O	Disease	3658
-	PUNCT	O	O	3658
induced	VERB	O	O	3658
reduction	NOUN	O	O	3658
in	ADP	O	O	3658
cyclophosphamide	VERB	O	Chemical	3658
cytotoxicity	NOUN	O	Disease	3658
in	ADP	O	O	3658
rat	NOUN	O	O	3658
tumors	NOUN	O	Disease	3658
.	PUNCT	O	O	3658
The	PRON	O	O	3659
aim	VERB	O	O	3659
of	ADP	O	O	3659
this	PRON	O	O	3659
study	VERB	O	O	3659
was	AUX	O	O	3659
to	PART	O	O	3659
examine	VERB	O	O	3659
the	PRON	O	O	3659
impact	NOUN	O	O	3659
of	ADP	O	O	3659
anemia	NOUN	O	Disease	3659
prevention	NOUN	O	O	3659
by	ADP	O	O	3659
recombinant	ADJ	O	O	3659
human	PROPN	O	O	3659
erythropoietin	NOUN	O	O	3659
(	PUNCT	O	O	3659
rHuEPO	ADJ	O	O	3659
)	PUNCT	O	O	3659
treatment	NOUN	O	O	3659
on	ADP	O	O	3659
the	PRON	O	O	3659
cytotoxicity	NOUN	O	Disease	3659
of	ADP	O	O	3659
cyclophosphamide	VERB	O	Chemical	3659
in	ADP	O	O	3659
solid	ADJ	O	O	3659
experimental	ADJ	O	O	3659
tumors	NOUN	O	Disease	3659
.	PUNCT	O	O	3659
Anemia	NOUN	O	Disease	3660
was	AUX	O	O	3660
induced	VERB	O	O	3660
using	VERB	O	O	3660
a	PRON	O	O	3660
single	ADJ	O	O	3660
dose	NOUN	O	O	3660
of	ADP	O	O	3660
carboplatin	PROPN	O	Chemical	3660
(	PUNCT	O	O	3660
50	NUM	O	O	3660
mg	VERB	O	O	3660
/	PUNCT	O	O	3660
kg	VERB	O	O	3660
i.v	NOUN	O	O	3660
.	PUNCT	O	O	3660
)	PUNCT	O	O	3660
In	ADP	O	O	3661
a	PRON	O	O	3661
second	ADV	O	O	3661
group	NOUN	O	O	3661
,	PUNCT	O	O	3661
the	PRON	O	O	3661
development	NOUN	O	O	3661
of	ADP	O	O	3661
anemia	NOUN	O	Disease	3661
was	AUX	O	O	3661
prevented	VERB	O	O	3661
by	ADP	O	O	3661
rHuEPO	ADJ	O	O	3661
(	PUNCT	O	O	3661
1000	NUM	O	O	3661
IU	PROPN	O	O	3661
/	PUNCT	O	O	3661
kg	VERB	O	O	3661
)	PUNCT	O	O	3661
administered	VERB	O	O	3661
s.c	PROPN	O	O	3661
.	PUNCT	O	O	3661
three	NUM	O	O	3662
times	NOUN	O	O	3662
/	PUNCT	O	O	3662
week	NOUN	O	O	3662
starting	VERB	O	O	3662
7	NUM	O	O	3662
days	NOUN	O	O	3662
before	ADP	O	O	3662
carboplatin	PROPN	O	Chemical	3662
application	NOUN	O	O	3662
.	PUNCT	O	O	3662
Four	NUM	O	O	3663
days	NOUN	O	O	3663
after	ADP	O	O	3663
carboplatin	PROPN	O	Chemical	3663
treatment	NOUN	O	O	3663
,	PUNCT	O	O	3663
tumors	NOUN	O	Disease	3663
(	PUNCT	O	O	3663
DS	PROPN	O	O	3663
-	PUNCT	O	O	3663
sarcoma	NOUN	O	Disease	3663
of	ADP	O	O	3663
the	PRON	O	O	3663
rat	NOUN	O	O	3663
)	PUNCT	O	O	3663
were	AUX	O	O	3663
implanted	VERB	O	O	3663
s.c	PROPN	O	O	3663
.	PUNCT	O	O	3663
Neither	PRON	O	O	3664
carboplatin	PROPN	O	Chemical	3664
nor	CCONJ	O	O	3664
rHuEPO	ADJ	O	O	3664
treatment	NOUN	O	O	3664
influenced	VERB	O	O	3664
tumor	NOUN	O	Disease	3664
growth	NOUN	O	O	3664
rate	NOUN	O	O	3664
per	ADP	O	O	3664
se	X	O	O	3664
.	PUNCT	O	O	3664
When	SCONJ	O	O	3665
tumors	NOUN	O	Disease	3665
were	AUX	O	O	3665
treated	VERB	O	O	3665
with	ADP	O	O	3665
a	PRON	O	O	3665
single	ADJ	O	O	3665
dose	NOUN	O	O	3665
of	ADP	O	O	3665
cyclophosphamide	VERB	O	Chemical	3665
(	PUNCT	O	O	3665
60	NUM	O	O	3665
mg	VERB	O	O	3665
/	PUNCT	O	O	3665
kg	VERB	O	O	3665
i.p	NOUN	O	O	3665
.	PUNCT	O	O	3665
)	PUNCT	O	O	3665
5	NUM	O	O	3665
days	NOUN	O	O	3665
after	ADP	O	O	3665
implantation	NOUN	O	O	3665
,	PUNCT	O	O	3665
a	PRON	O	O	3665
growth	NOUN	O	O	3665
delay	NOUN	O	O	3665
with	ADP	O	O	3665
a	PRON	O	O	3665
subsequent	ADJ	O	O	3665
regrowth	VERB	O	O	3665
of	ADP	O	O	3665
the	PRON	O	O	3665
tumors	NOUN	O	Disease	3665
was	AUX	O	O	3665
observed	VERB	O	O	3665
.	PUNCT	O	O	3665
In	ADP	O	O	3666
the	PRON	O	O	3666
anemia	NOUN	O	Disease	3666
group	NOUN	O	O	3666
,	PUNCT	O	O	3666
the	PRON	O	O	3666
growth	NOUN	O	O	3666
delay	NOUN	O	O	3666
was	AUX	O	O	3666
significantly	ADV	O	O	3666
shorter	ADJ	O	O	3666
compared	VERB	O	O	3666
with	ADP	O	O	3666
nonanemic	PROPN	O	O	3666
controls	VERB	O	O	3666
(	PUNCT	O	O	3666
13.3	NUM	O	O	3666
days	NOUN	O	O	3666
versus	ADP	O	O	3666
8.6	NUM	O	O	3666
days	NOUN	O	O	3666
)	PUNCT	O	O	3666
.	PUNCT	O	O	3666
In	ADP	O	O	3667
the	PRON	O	O	3667
group	NOUN	O	O	3667
where	SCONJ	O	O	3667
anemia	NOUN	O	Disease	3667
was	AUX	O	O	3667
prevented	VERB	O	O	3667
by	ADP	O	O	3667
rHuEPO	ADJ	O	O	3667
treatment	NOUN	O	O	3667
,	PUNCT	O	O	3667
growth	NOUN	O	O	3667
delay	NOUN	O	O	3667
was	AUX	O	O	3667
comparable	ADJ	O	O	3667
with	ADP	O	O	3667
that	SCONJ	O	O	3667
of	ADP	O	O	3667
nonanemic	PROPN	O	O	3667
controls	VERB	O	O	3667
(	PUNCT	O	O	3667
13.3	NUM	O	O	3667
days	NOUN	O	O	3667
)	PUNCT	O	O	3667
.	PUNCT	O	O	3667
These	PRON	O	O	3668
results	VERB	O	O	3668
suggest	VERB	O	O	3668
that	SCONJ	O	O	3668
chemotherapy	NOUN	O	O	3668
-	PUNCT	O	O	3668
induced	VERB	O	O	3668
anemia	NOUN	O	Disease	3668
reduces	VERB	O	O	3668
cytotoxicity	NOUN	O	Disease	3668
of	ADP	O	O	3668
cyclophosphamide	VERB	O	Chemical	3668
in	ADP	O	O	3668
tumors	NOUN	O	Disease	3668
,	PUNCT	O	O	3668
whereas	SCONJ	O	O	3668
correction	PROPN	O	O	3668
of	ADP	O	O	3668
anemia	NOUN	O	Disease	3668
by	ADP	O	O	3668
rHuEPO	ADJ	O	O	3668
treatment	NOUN	O	O	3668
(	PUNCT	O	O	3668
epoetin	NOUN	O	O	3668
alpha	PROPN	O	O	3668
)	PUNCT	O	O	3668
increases	VERB	O	O	3668
the	PRON	O	O	3668
sensitivity	NOUN	O	O	3668
,	PUNCT	O	O	3668
probably	ADV	O	O	3668
as	ADP	O	O	3668
a	PRON	O	O	3668
result	VERB	O	O	3668
of	ADP	O	O	3668
an	PRON	O	O	3668
improved	VERB	O	O	3668
oxygen	NOUN	O	Chemical	3668
supply	NOUN	O	O	3668
to	PART	O	O	3668
tumor	NOUN	O	Disease	3668
tissue	NOUN	O	O	3668
.	PUNCT	O	O	3668
The	PRON	O	O	3671
role	NOUN	O	O	3671
of	ADP	O	O	3671
nitrergic	PROPN	O	O	3671
system	NOUN	O	O	3671
in	ADP	O	O	3671
lidocaine	NOUN	O	Chemical	3671
-	PUNCT	O	O	3671
induced	VERB	O	O	3671
convulsion	NOUN	O	Disease	3671
in	ADP	O	O	3671
the	PRON	O	O	3671
mouse	PROPN	O	O	3671
.	PUNCT	O	O	3671
The	PRON	O	O	3672
effects	NOUN	O	O	3672
of	ADP	O	O	3672
N	NUM	O	O	3672
-	PUNCT	O	O	3672
nitro	NOUN	O	O	3672
-	PUNCT	O	O	3672
L	NOUN	O	O	3672
-	PUNCT	O	O	3672
arginine	PROPN	O	O	3672
-	PUNCT	O	O	3672
methyl	NOUN	O	O	3672
ester	PROPN	O	O	3672
(	PUNCT	O	O	3672
L	NOUN	O	O	3672
-	PUNCT	O	O	3672
NAME	NOUN	O	O	3672
)	PUNCT	O	O	3672
a	PRON	O	O	3672
nitric oxide	NOUN	O	Chemical	3672
(	PUNCT	O	O	3672
NO	PRON	O	Chemical	3672
)	PUNCT	O	O	3672
synthase	NOUN	O	O	3673
inhibitor	NOUN	O	O	3673
and	CCONJ	O	O	3673
L	NOUN	O	O	3673
-	PUNCT	O	O	3673
arginine	PROPN	O	O	3673
,	PUNCT	O	O	3673
a	PRON	O	O	3673
NO	PRON	O	Chemical	3673
precursor	NOUN	O	O	3673
,	PUNCT	O	O	3673
were	AUX	O	O	3673
investigated	VERB	O	O	3673
on	ADP	O	O	3673
lidocaine	NOUN	O	Chemical	3673
-	PUNCT	O	O	3673
induced	VERB	O	O	3673
convulsions	NOUN	O	Disease	3673
.	PUNCT	O	O	3673
In	ADP	O	O	3674
the	PRON	O	O	3674
first	ADV	O	O	3674
experiment	NOUN	O	O	3674
,	PUNCT	O	O	3674
four	NUM	O	O	3674
groups	NOUN	O	O	3674
of	ADP	O	O	3674
mice	NOUN	O	O	3674
received	VERB	O	O	3674
physiological	ADJ	O	O	3674
saline	NOUN	O	O	3674
(	PUNCT	O	O	3674
0.9%	NOUN	O	O	3674
)	PUNCT	O	O	3674
,	PUNCT	O	O	3674
L	NOUN	O	O	3674
-	PUNCT	O	O	3674
arginine	PROPN	O	O	3674
(	PUNCT	O	O	3674
300	NUM	O	O	3674
mg	VERB	O	O	3674
/	PUNCT	O	O	3674
kg	VERB	O	O	3674
,	PUNCT	O	O	3674
i.p	NOUN	O	O	3674
.	PUNCT	O	O	3674
)	PUNCT	O	O	3674
,	PUNCT	O	O	3674
L	NOUN	O	O	3675
-	PUNCT	O	O	3675
NAME	NOUN	O	O	3675
(	PUNCT	O	O	3675
100	NUM	O	O	3675
mg	VERB	O	O	3675
/	PUNCT	O	O	3675
kg	VERB	O	O	3675
,	PUNCT	O	O	3675
i.p	NOUN	O	O	3675
.	PUNCT	O	O	3675
)	PUNCT	O	O	3675
and	CCONJ	O	O	3675
diazepam	NOUN	O	Chemical	3676
(	PUNCT	O	O	3676
2	X	O	O	3676
mg	VERB	O	O	3676
/	PUNCT	O	O	3676
kg	VERB	O	O	3676
)	PUNCT	O	O	3676
,	PUNCT	O	O	3676
respectively	ADV	O	O	3676
.	PUNCT	O	O	3676
Thirty	NUM	O	O	3677
minutes	NOUN	O	O	3677
after	ADP	O	O	3677
these	PRON	O	O	3677
injections	NOUN	O	O	3677
,	PUNCT	O	O	3677
all	PRON	O	O	3677
mice	NOUN	O	O	3677
received	VERB	O	O	3677
lidocaine	NOUN	O	Chemical	3677
(	PUNCT	O	O	3677
50	NUM	O	O	3677
mg	VERB	O	O	3677
/	PUNCT	O	O	3677
kg	VERB	O	O	3677
,	PUNCT	O	O	3677
i.p	NOUN	O	O	3677
.	PUNCT	O	O	3677
)	PUNCT	O	O	3677
.	PUNCT	O	O	3677
In	ADP	O	O	3678
the	PRON	O	O	3678
second	ADV	O	O	3678
experiment	NOUN	O	O	3678
,	PUNCT	O	O	3678
four	NUM	O	O	3678
groups	NOUN	O	O	3678
of	ADP	O	O	3678
mice	NOUN	O	O	3678
received	VERB	O	O	3678
similar	ADJ	O	O	3678
treatment	NOUN	O	O	3678
in	ADP	O	O	3678
the	PRON	O	O	3678
first	ADV	O	O	3678
experiment	NOUN	O	O	3678
,	PUNCT	O	O	3678
and	CCONJ	O	O	3678
30	NUM	O	O	3678
min	NOUN	O	O	3678
after	ADP	O	O	3678
these	PRON	O	O	3678
injections	NOUN	O	O	3678
,	PUNCT	O	O	3678
all	PRON	O	O	3678
mice	NOUN	O	O	3678
received	VERB	O	O	3678
a	PRON	O	O	3678
higher	ADJ	O	O	3678
dose	NOUN	O	O	3678
of	ADP	O	O	3678
lidocaine	NOUN	O	Chemical	3678
(	PUNCT	O	O	3678
80	NUM	O	O	3678
mg	VERB	O	O	3678
/	PUNCT	O	O	3678
kg	VERB	O	O	3678
)	PUNCT	O	O	3678
.	PUNCT	O	O	3678
L	NOUN	O	O	3679
-	PUNCT	O	O	3679
NAME	NOUN	O	O	3679
(	PUNCT	O	O	3679
100	NUM	O	O	3679
mg	VERB	O	O	3679
/	PUNCT	O	O	3679
kg	VERB	O	O	3680
,	PUNCT	O	O	3680
i.p	NOUN	O	O	3680
.	PUNCT	O	O	3680
)	PUNCT	O	O	3680
and	CCONJ	O	O	3680
diazepam	NOUN	O	Chemical	3680
(	PUNCT	O	O	3680
2	X	O	O	3680
mg	VERB	O	O	3680
/	PUNCT	O	O	3680
kg	VERB	O	O	3680
)	PUNCT	O	O	3680
significantly	ADV	O	O	3680
decreased	VERB	O	O	3680
the	PRON	O	O	3680
incidence	NOUN	O	O	3680
of	ADP	O	O	3680
lidocaine	NOUN	O	Chemical	3680
(	PUNCT	O	O	3680
50	NUM	O	O	3680
mg	VERB	O	O	3680
/	PUNCT	O	O	3680
kg)-induced	VERB	O	O	3680
convulsions	NOUN	O	Disease	3680
.	PUNCT	O	O	3680
In	ADP	O	O	3681
contrast	NOUN	O	O	3681
,	PUNCT	O	O	3681
the	PRON	O	O	3681
L	NOUN	O	O	3681
-	PUNCT	O	O	3681
arginine	PROPN	O	O	3681
treatment	NOUN	O	O	3681
increased	VERB	O	O	3681
the	PRON	O	O	3681
incidence	NOUN	O	O	3681
of	ADP	O	O	3681
lidocaine	NOUN	O	Chemical	3681
(	PUNCT	O	O	3681
80	NUM	O	O	3681
mg	VERB	O	O	3681
/	PUNCT	O	O	3681
kg	VERB	O	O	3681
,	PUNCT	O	O	3681
i.p.)-induced	VERB	O	O	3681
convulsions	NOUN	O	Disease	3681
significantly	ADV	O	O	3681
.	PUNCT	O	O	3681
These	PRON	O	O	3682
results	VERB	O	O	3682
may	AUX	O	O	3682
suggest	VERB	O	O	3682
that	SCONJ	O	O	3682
NO	PRON	O	Chemical	3682
is	AUX	O	O	3682
a	PRON	O	O	3682
proconvulsant	ADJ	O	O	3682
mediator	NOUN	O	O	3682
in	ADP	O	O	3682
lidocaine	NOUN	O	Chemical	3682
-	PUNCT	O	O	3682
induced	VERB	O	O	3682
convulsions	NOUN	O	Disease	3682
.	PUNCT	O	O	3682
Effect	VERB	O	O	3685
of	ADP	O	O	3685
intravenous	ADJ	O	O	3685
metoprolol	NOUN	O	Chemical	3685
or	CCONJ	O	O	3685
intravenous	ADJ	O	O	3685
metoprolol	NOUN	O	Chemical	3685
plus	CCONJ	O	O	3685
glucagon	NOUN	O	O	3685
on	ADP	O	O	3685
dobutamine	NOUN	O	Chemical	3685
-	PUNCT	O	O	3685
induced	VERB	O	O	3685
myocardial ischemia	NOUN	O	Disease	3685
.	PUNCT	O	O	3685
STUDY	NOUN	O	O	3686
OBJECTIVE	VERB	O	O	3686
:	PUNCT	O	O	3686
To	PART	O	O	3686
determine	VERB	O	O	3686
the	PRON	O	O	3686
effect	VERB	O	O	3686
of	ADP	O	O	3686
metoprolol	NOUN	O	Chemical	3686
on	ADP	O	O	3686
dobutamine	NOUN	O	Chemical	3686
stress	NOUN	O	O	3686
testing	NOUN	O	O	3686
with	ADP	O	O	3686
technetium-99	X	O	O	3686
m	VERB	O	O	3686
sestamibi	NOUN	O	O	3686
single	ADJ	O	O	3686
-	PUNCT	O	O	3686
photon	NOUN	O	O	3686
emission	NOUN	O	O	3686
computed	VERB	O	O	3686
tomography	NOUN	O	O	3686
imaging	VERB	O	O	3686
and	CCONJ	O	O	3686
ST	PROPN	O	O	3686
-	PUNCT	O	O	3686
segment	NOUN	O	O	3686
monitoring	NOUN	O	O	3686
,	PUNCT	O	O	3686
and	CCONJ	O	O	3686
to	PART	O	O	3686
assess	VERB	O	O	3686
the	PRON	O	O	3686
impact	NOUN	O	O	3686
of	ADP	O	O	3686
intravenous	ADJ	O	O	3686
glucagon	NOUN	O	O	3686
on	ADP	O	O	3686
metoprolol	NOUN	O	Chemical	3686
's	AUX	O	O	3686
effects	NOUN	O	O	3686
.	PUNCT	O	O	3686
Patients	NOUN	O	O	3687
underwent	VERB	O	O	3687
dobutamine	NOUN	O	Chemical	3687
stress	NOUN	O	O	3687
tests	VERB	O	O	3687
per	ADP	O	O	3687
standard	PROPN	O	O	3687
protocol	PROPN	O	O	3687
.	PUNCT	O	O	3687
Before	ADP	O	O	3688
dobutamine	NOUN	O	Chemical	3688
was	AUX	O	O	3688
begun	VERB	O	O	3688
,	PUNCT	O	O	3688
no	PRON	O	O	3688
therapy	NOUN	O	O	3688
was	AUX	O	O	3688
given	VERB	O	O	3688
during	ADP	O	O	3688
the	PRON	O	O	3688
first	ADV	O	O	3688
visit	VERB	O	O	3688
,	PUNCT	O	O	3688
and	CCONJ	O	O	3688
patients	NOUN	O	O	3688
were	AUX	O	O	3688
randomized	VERB	O	O	3688
on	ADP	O	O	3688
subsequent	ADJ	O	O	3688
visits	VERB	O	O	3688
to	PART	O	O	3688
receive	VERB	O	O	3688
metoprolol	NOUN	O	Chemical	3688
or	CCONJ	O	O	3688
metoprolol	NOUN	O	Chemical	3688
plus	CCONJ	O	O	3688
glucagon	NOUN	O	O	3688
1	X	O	O	3688
mg	VERB	O	O	3688
.	PUNCT	O	O	3688
Metoprolol	NOUN	O	Chemical	3689
was	AUX	O	O	3689
dosed	VERB	O	O	3689
to	PART	O	O	3689
achieve	VERB	O	O	3689
a	PRON	O	O	3689
resting	VERB	O	O	3689
predobutamine	NOUN	O	Chemical	3689
heart	NOUN	O	O	3689
rate	NOUN	O	O	3689
below	ADP	O	O	3689
65	NUM	O	O	3689
beats	NOUN	O	O	3689
/	PUNCT	O	O	3689
minute	VERB	O	O	3689
or	CCONJ	O	O	3689
a	PRON	O	O	3689
total	ADJ	O	O	3689
intravenous	ADJ	O	O	3689
dose	NOUN	O	O	3689
of	ADP	O	O	3689
20	NUM	O	O	3689
mg	VERB	O	O	3689
.	PUNCT	O	O	3689
Metoprolol	NOUN	O	Chemical	3690
reduced	VERB	O	O	3690
maximum	ADV	O	O	3690
heart	NOUN	O	O	3690
rate	NOUN	O	O	3690
31%	NOUN	O	O	3690
,	PUNCT	O	O	3690
summed	VERB	O	O	3690
stress	NOUN	O	O	3690
scores	NOUN	O	O	3690
29%	NOUN	O	O	3690
,	PUNCT	O	O	3690
and	CCONJ	O	O	3690
summed	VERB	O	O	3690
difference	NOUN	O	O	3690
scores	NOUN	O	O	3690
43%	NOUN	O	O	3690
versus	ADP	O	O	3690
control	VERB	O	O	3690
.	PUNCT	O	O	3690
Metoprolol	NOUN	O	Chemical	3691
plus	CCONJ	O	O	3691
glucagon	NOUN	O	O	3691
also	ADV	O	O	3691
reduced	VERB	O	O	3691
the	PRON	O	O	3691
maximum	ADV	O	O	3691
heart	NOUN	O	O	3691
rate	NOUN	O	O	3691
29%	NOUN	O	O	3691
versus	ADP	O	O	3691
control	VERB	O	O	3691
.	PUNCT	O	O	3691
No	PRON	O	O	3692
significant	ADJ	O	O	3692
differences	NOUN	O	O	3692
were	AUX	O	O	3692
found	VERB	O	O	3692
in	ADP	O	O	3692
any	PRON	O	O	3692
parameter	NOUN	O	O	3692
between	ADP	O	O	3692
metoprolol	NOUN	O	Chemical	3692
and	CCONJ	O	O	3692
metoprolol	NOUN	O	Chemical	3692
-	PUNCT	O	O	3692
glucagon	NOUN	O	O	3692
.	PUNCT	O	O	3692
During	ADP	O	O	3693
dobutamine	NOUN	O	Chemical	3693
stress	NOUN	O	O	3693
testing	NOUN	O	O	3693
,	PUNCT	O	O	3693
metoprolol	NOUN	O	Chemical	3693
attenuates	VERB	O	O	3693
or	CCONJ	O	O	3693
eliminates	VERB	O	O	3693
evidence	NOUN	O	O	3693
of	ADP	O	O	3693
myocardial ischemia	NOUN	O	Disease	3693
.	PUNCT	O	O	3693
Prednisolone	NOUN	O	Chemical	3696
-	PUNCT	O	O	3696
induced	VERB	O	O	3696
muscle dysfunction	NOUN	O	Disease	3696
is	AUX	O	O	3696
caused	VERB	O	O	3696
more	ADJ	O	O	3696
by	ADP	O	O	3696
atrophy	NOUN	O	Disease	3696
than	ADP	O	O	3696
by	ADP	O	O	3696
altered	VERB	O	O	3696
acetylcholine	NOUN	O	Chemical	3696
receptor	NOUN	O	O	3696
expression	NOUN	O	O	3696
.	PUNCT	O	O	3696
We	PRON	O	O	3697
investigated	VERB	O	O	3697
the	PRON	O	O	3697
effects	NOUN	O	O	3697
of	ADP	O	O	3697
moderate	ADJ	O	O	3697
and	CCONJ	O	O	3697
large	ADJ	O	O	3697
doses	NOUN	O	O	3697
of	ADP	O	O	3697
prednisolone	NOUN	O	Chemical	3697
on	ADP	O	O	3697
muscle	NOUN	O	O	3697
function	NOUN	O	O	3697
and	CCONJ	O	O	3697
pharmacology	NOUN	O	O	3697
,	PUNCT	O	O	3697
and	CCONJ	O	O	3697
their	PRON	O	O	3697
relationship	NOUN	O	O	3697
to	PART	O	O	3697
changes	VERB	O	O	3697
in	ADP	O	O	3697
muscle	NOUN	O	O	3697
size	NOUN	O	O	3697
and	CCONJ	O	O	3697
acetylcholine	NOUN	O	Chemical	3697
receptor	NOUN	O	O	3697
(	PUNCT	O	O	3697
AChR	NUM	O	O	3697
)	PUNCT	O	O	3697
expression	NOUN	O	O	3697
.	PUNCT	O	O	3697
With	ADP	O	O	3698
institutional	ADJ	O	O	3698
approval	NOUN	O	O	3698
,	PUNCT	O	O	3698
35	NUM	O	O	3698
Sprague	PROPN	O	O	3698
-	PUNCT	O	O	3698
Dawley	NOUN	O	O	3698
rats	NOUN	O	O	3698
were	AUX	O	O	3698
randomly	ADV	O	O	3698
allocated	VERB	O	O	3698
to	PART	O	O	3698
receive	VERB	O	O	3698
daily	ADV	O	O	3698
subcutaneous	ADJ	O	O	3698
doses	NOUN	O	O	3698
of	ADP	O	O	3698
10	NUM	O	O	3698
mg	VERB	O	O	3698
/	PUNCT	O	O	3698
kg	VERB	O	O	3698
prednisolone	NOUN	O	Chemical	3698
(	PUNCT	O	O	3698
P10	NOUN	O	O	3698
group	NOUN	O	O	3698
)	PUNCT	O	O	3698
,	PUNCT	O	O	3698
100	NUM	O	O	3698
mg	VERB	O	O	3698
/	PUNCT	O	O	3698
kg	VERB	O	O	3698
prednisolone	NOUN	O	Chemical	3698
(	PUNCT	O	O	3698
P100	NOUN	O	O	3698
group	NOUN	O	O	3698
)	PUNCT	O	O	3698
,	PUNCT	O	O	3698
or	CCONJ	O	O	3698
an	PRON	O	O	3698
equal	ADJ	O	O	3698
volume	PROPN	O	O	3698
of	ADP	O	O	3698
saline	NOUN	O	O	3698
(	PUNCT	O	O	3698
S	NOUN	O	O	3698
group	NOUN	O	O	3698
)	PUNCT	O	O	3698
for	ADP	O	O	3698
7	NUM	O	O	3698
days	NOUN	O	O	3698
.	PUNCT	O	O	3698
On	ADP	O	O	3699
Day	NOUN	O	O	3699
8	NUM	O	O	3699
,	PUNCT	O	O	3699
the	PRON	O	O	3699
nerve	NOUN	O	O	3699
-	PUNCT	O	O	3699
evoked	VERB	O	O	3699
peak	PROPN	O	O	3699
twitch	VERB	O	O	3699
tensions	NOUN	O	O	3699
,	PUNCT	O	O	3699
tetanic	ADJ	O	Disease	3699
tensions	NOUN	O	O	3699
,	PUNCT	O	O	3699
and	CCONJ	O	O	3699
fatigability	NOUN	O	O	3699
,	PUNCT	O	O	3699
and	CCONJ	O	O	3699
the	PRON	O	O	3699
dose	NOUN	O	O	3699
-	PUNCT	O	O	3699
response	NOUN	O	O	3699
curves	NOUN	O	O	3699
of	ADP	O	O	3699
d	X	O	O	3699
-	PUNCT	O	O	3699
tubocurarine	NOUN	O	O	3699
in	ADP	O	O	3699
the	PRON	O	O	3699
tibialis	PROPN	O	O	3699
cranialis	VERB	O	O	3699
muscle	NOUN	O	O	3699
were	AUX	O	O	3699
measured	VERB	O	O	3699
in	ADP	O	O	3699
vivo	VERB	O	O	3699
and	CCONJ	O	O	3699
related	ADJ	O	O	3699
to	PART	O	O	3699
muscle	NOUN	O	O	3699
mass	PROPN	O	O	3699
or	CCONJ	O	O	3699
expression	NOUN	O	O	3699
of	ADP	O	O	3699
AChRs	PROPN	O	O	3699
.	PUNCT	O	O	3699
The	PRON	O	O	3700
evoked	VERB	O	O	3700
peak	PROPN	O	O	3700
twitch	VERB	O	O	3700
and	CCONJ	O	O	3700
tetanic	ADJ	O	Disease	3700
tensions	NOUN	O	O	3700
were	AUX	O	O	3700
less	ADV	O	O	3700
in	ADP	O	O	3700
the	PRON	O	O	3700
P100	NOUN	O	O	3700
group	NOUN	O	O	3700
than	ADP	O	O	3700
in	ADP	O	O	3700
the	PRON	O	O	3700
P10	NOUN	O	O	3700
or	CCONJ	O	O	3700
S	NOUN	O	O	3700
groups	NOUN	O	O	3700
,	PUNCT	O	O	3700
however	ADV	O	O	3700
,	PUNCT	O	O	3700
tension	NOUN	O	O	3700
per	ADP	O	O	3700
milligram	PROPN	O	O	3700
of	ADP	O	O	3700
muscle	NOUN	O	O	3700
mass	PROPN	O	O	3700
was	AUX	O	O	3700
greater	ADJ	O	O	3700
in	ADP	O	O	3700
the	PRON	O	O	3700
P100	NOUN	O	O	3700
group	NOUN	O	O	3700
than	ADP	O	O	3700
in	ADP	O	O	3700
the	PRON	O	O	3700
S	NOUN	O	O	3700
group	NOUN	O	O	3700
.	PUNCT	O	O	3700
The	PRON	O	O	3701
50%	NOUN	O	O	3701
effective	ADJ	O	O	3701
dose	NOUN	O	O	3701
of	ADP	O	O	3701
d	X	O	O	3701
-	PUNCT	O	O	3701
tubocurarine	NOUN	O	O	3701
(	PUNCT	O	O	3701
microg	PROPN	O	O	3701
/	PUNCT	O	O	3701
kg	VERB	O	O	3701
)	PUNCT	O	O	3701
in	ADP	O	O	3701
the	PRON	O	O	3701
tibialis	PROPN	O	O	3701
muscle	NOUN	O	O	3701
was	AUX	O	O	3701
smaller	ADJ	O	O	3701
in	ADP	O	O	3701
the	PRON	O	O	3701
P10	NOUN	O	O	3701
(	PUNCT	O	O	3701
33.6	NUM	O	O	3701
+	ADP	O	O	3701
/-	PUNCT	O	O	3701
The	PRON	O	O	3702
50%	NOUN	O	O	3702
effective	ADJ	O	O	3702
dose	NOUN	O	O	3702
of	ADP	O	O	3702
d	X	O	O	3702
-	PUNCT	O	O	3702
tubocurarine	NOUN	O	O	3702
did	VERB	O	O	3702
not	PART	O	O	3702
correlate	VERB	O	O	3702
with	ADP	O	O	3702
muscle	NOUN	O	O	3702
mass	PROPN	O	O	3702
or	CCONJ	O	O	3702
AChR	NUM	O	O	3702
expression	NOUN	O	O	3702
.	PUNCT	O	O	3702
Our	PRON	O	O	3703
results	VERB	O	O	3703
suggest	VERB	O	O	3703
that	SCONJ	O	O	3703
the	PRON	O	O	3703
neuromuscular dysfunction	NOUN	O	Disease	3703
after	ADP	O	O	3703
prednisolone	NOUN	O	Chemical	3703
is	AUX	O	O	3703
dose	NOUN	O	O	3703
-	PUNCT	O	O	3703
dependent	ADJ	O	O	3703
,	PUNCT	O	O	3703
and	CCONJ	O	O	3703
derives	VERB	O	O	3703
primarily	ADV	O	O	3703
from	ADP	O	O	3703
muscle atrophy	NOUN	O	Disease	3703
and	CCONJ	O	O	3703
derives	VERB	O	O	3703
less	ADV	O	O	3703
so	ADV	O	O	3703
from	ADP	O	O	3703
changes	VERB	O	O	3703
in	ADP	O	O	3703
AChR	NUM	O	O	3703
expression	NOUN	O	O	3703
.	PUNCT	O	O	3703
We	PRON	O	O	3704
suggest	VERB	O	O	3704
that	SCONJ	O	O	3704
the	PRON	O	O	3704
observed	VERB	O	O	3704
effects	NOUN	O	O	3704
are	AUX	O	O	3704
dose	NOUN	O	O	3704
-	PUNCT	O	O	3704
dependent	ADJ	O	O	3704
and	CCONJ	O	O	3704
derive	VERB	O	O	3704
primarily	ADV	O	O	3704
from	ADP	O	O	3704
muscle atrophy	NOUN	O	Disease	3704
and	CCONJ	O	O	3704
derive	VERB	O	O	3704
less	ADV	O	O	3704
from	ADP	O	O	3704
changes	VERB	O	O	3704
in	ADP	O	O	3704
acetylcholine	NOUN	O	Chemical	3704
receptor	NOUN	O	O	3704
expression	NOUN	O	O	3704
.	PUNCT	O	O	3704
Rapid	ADJ	O	O	3707
reversal	NOUN	O	O	3707
of	ADP	O	O	3707
life	NOUN	O	O	3707
-	PUNCT	O	O	3707
threatening	VERB	O	O	3707
diltiazem	VERB	O	Chemical	3707
-	PUNCT	O	O	3707
induced	VERB	O	O	3707
tetany	NOUN	O	Disease	3707
with	ADP	O	O	3707
calcium chloride	NOUN	O	Chemical	3707
.	PUNCT	O	O	3707
We	PRON	O	O	3708
describe	VERB	O	O	3708
a	PRON	O	O	3708
patient	NOUN	O	O	3708
who	PRON	O	O	3708
developed	VERB	O	O	3708
tetany	NOUN	O	Disease	3708
with	ADP	O	O	3708
sudden	ADJ	O	O	3708
respiratory arrest	NOUN	O	Disease	3708
after	ADP	O	O	3708
the	PRON	O	O	3708
infusion	NOUN	O	O	3708
of	ADP	O	O	3708
intravenous	ADJ	O	O	3708
diltiazem	VERB	O	Chemical	3708
.	PUNCT	O	O	3708
The	PRON	O	O	3709
administration	NOUN	O	O	3709
of	ADP	O	O	3709
calcium chloride	NOUN	O	Chemical	3709
rapidly	ADV	O	O	3709
resolved	VERB	O	O	3709
the	PRON	O	O	3709
patient	NOUN	O	O	3709
's	AUX	O	O	3709
tetany	NOUN	O	Disease	3709
with	ADP	O	O	3709
prompt	PROPN	O	O	3709
recovery	NOUN	O	O	3709
of	ADP	O	O	3709
respiratory	NOUN	O	O	3709
function	NOUN	O	O	3709
,	PUNCT	O	O	3709
averting	VERB	O	O	3709
the	PRON	O	O	3709
need	VERB	O	O	3709
for	ADP	O	O	3709
more	ADJ	O	O	3709
aggressive	ADJ	O	O	3709
airway	NOUN	O	O	3709
management	NOUN	O	O	3709
and	CCONJ	O	O	3709
ventilatory	ADJ	O	O	3709
support	NOUN	O	O	3709
.	PUNCT	O	O	3709
The	PRON	O	O	3710
emergency	NOUN	O	O	3710
physician	NOUN	O	O	3710
should	AUX	O	O	3710
be	AUX	O	O	3710
aware	ADJ	O	O	3710
that	SCONJ	O	O	3710
life	NOUN	O	O	3710
-	PUNCT	O	O	3710
threatening	VERB	O	O	3710
tetany	NOUN	O	Disease	3710
may	AUX	O	O	3710
accompany	VERB	O	O	3710
the	PRON	O	O	3710
administration	NOUN	O	O	3710
of	ADP	O	O	3710
intravenous	ADJ	O	O	3710
diltiazem	VERB	O	Chemical	3710
and	CCONJ	O	O	3710
that	SCONJ	O	O	3710
calcium chloride	NOUN	O	Chemical	3710
may	AUX	O	O	3710
be	AUX	O	O	3710
a	PRON	O	O	3710
rapid	ADJ	O	O	3710
and	CCONJ	O	O	3710
effective	ADJ	O	O	3710
remedy	NOUN	O	O	3710
.	PUNCT	O	O	3710
Effects	NOUN	O	O	3713
of	ADP	O	O	3713
nonsteroidal	ADJ	O	O	3713
anti	ADJ	O	O	3713
-	PUNCT	O	O	3713
inflammatory	ADJ	O	O	3713
drugs	NOUN	O	O	3713
on	ADP	O	O	3713
hemostasis	VERB	O	O	3713
in	ADP	O	O	3713
patients	NOUN	O	O	3713
with	ADP	O	O	3713
aneurysmal	VERB	O	Disease	3713
subarachnoid hemorrhage	NOUN	O	Disease	3713
.	PUNCT	O	O	3713
Patients	NOUN	O	O	3714
with	ADP	O	O	3714
aneurysmal	VERB	O	Disease	3714
subarachnoid hemorrhage	NOUN	O	Disease	3714
(	PUNCT	O	O	3714
SAH	PROPN	O	Disease	3714
)	PUNCT	O	O	3714
were	AUX	O	O	3714
randomized	VERB	O	O	3714
to	PART	O	O	3714
receive	VERB	O	O	3714
either	ADV	O	O	3714
ketoprofen	VERB	O	Chemical	3714
,	PUNCT	O	O	3714
100	NUM	O	O	3714
mg	VERB	O	O	3714
,	PUNCT	O	O	3714
three	NUM	O	O	3714
times	NOUN	O	O	3714
a	PRON	O	O	3714
day	NOUN	O	O	3714
(	PUNCT	O	O	3714
ketoprofen	VERB	O	Chemical	3714
group	NOUN	O	O	3714
,	PUNCT	O	O	3714
n	CCONJ	O	O	3715
=	PUNCT	O	O	3715
9	NUM	O	O	3715
)	PUNCT	O	O	3715
or	CCONJ	O	O	3715
a	PRON	O	O	3715
weak	ADJ	O	O	3715
NSAID	PROPN	O	Chemical	3715
,	PUNCT	O	O	3715
acetaminophen	PROPN	O	Chemical	3715
,	PUNCT	O	O	3715
1	X	O	O	3715
g	X	O	O	3715
,	PUNCT	O	O	3715
three	NUM	O	O	3715
times	NOUN	O	O	3715
a	PRON	O	O	3715
day	NOUN	O	O	3715
(	PUNCT	O	O	3715
acetaminophen	PROPN	O	Chemical	3715
group	NOUN	O	O	3715
,	PUNCT	O	O	3715
n	CCONJ	O	O	3716
=	PUNCT	O	O	3716
9	NUM	O	O	3716
)	PUNCT	O	O	3716
starting	VERB	O	O	3716
immediately	ADV	O	O	3716
after	ADP	O	O	3716
the	PRON	O	O	3716
diagnosis	NOUN	O	O	3716
of	ADP	O	O	3716
aneurysmal	VERB	O	Disease	3716
SAH	PROPN	O	Disease	3716
.	PUNCT	O	O	3716
Maximal	PROPN	O	O	3717
platelet aggregation	NOUN	O	Disease	3717
induced	VERB	O	O	3717
by	ADP	O	O	3717
6	NUM	O	O	3717
microM	ADJ	O	O	3717
of	ADP	O	O	3717
adenosine diphosphate	NOUN	O	Chemical	3717
decreased	VERB	O	O	3717
after	ADP	O	O	3717
administration	NOUN	O	O	3717
of	ADP	O	O	3717
ketoprofen	VERB	O	Chemical	3717
.	PUNCT	O	O	3717
Aggregation	NOUN	O	O	3718
was	AUX	O	O	3718
lower	ADJ	O	O	3718
(	PUNCT	O	O	3718
P	NOUN	O	Chemical	3718
<	X	O	O	3718
.05	NUM	O	O	3718
)	PUNCT	O	O	3718
in	ADP	O	O	3718
the	PRON	O	O	3718
ketoprofen	VERB	O	Chemical	3718
group	NOUN	O	O	3718
than	ADP	O	O	3718
in	ADP	O	O	3718
the	PRON	O	O	3718
acetaminophen	PROPN	O	Chemical	3718
group	NOUN	O	O	3718
just	ADV	O	O	3718
before	ADP	O	O	3718
surgery	NOUN	O	O	3718
and	CCONJ	O	O	3718
on	ADP	O	O	3718
the	PRON	O	O	3718
third	ADV	O	O	3718
postoperative	ADJ	O	O	3718
day	NOUN	O	O	3718
.	PUNCT	O	O	3718
In	ADP	O	O	3719
contrast	NOUN	O	O	3719
,	PUNCT	O	O	3719
maximal	ADJ	O	O	3719
platelet aggregation	NOUN	O	Disease	3719
increased	VERB	O	O	3719
in	ADP	O	O	3719
the	PRON	O	O	3719
acetaminophen	PROPN	O	Chemical	3719
group	NOUN	O	O	3719
on	ADP	O	O	3719
the	PRON	O	O	3719
third	ADV	O	O	3719
postoperative	ADJ	O	O	3719
day	NOUN	O	O	3719
as	ADP	O	O	3719
compared	VERB	O	O	3719
with	ADP	O	O	3719
the	PRON	O	O	3719
pretreatment	NOUN	O	O	3719
platelet aggregation	NOUN	O	Disease	3719
results	VERB	O	O	3719
(	PUNCT	O	O	3719
P	NOUN	O	Chemical	3719
<	X	O	O	3719
.05	NUM	O	O	3719
)	PUNCT	O	O	3719
.	PUNCT	O	O	3719
One	NUM	O	O	3720
patient	NOUN	O	O	3720
in	ADP	O	O	3720
the	PRON	O	O	3720
ketoprofen	VERB	O	Chemical	3720
group	NOUN	O	O	3720
developed	VERB	O	O	3720
a	PRON	O	O	3720
postoperative	ADJ	O	O	3720
intracranial	ADJ	O	O	3720
hematoma	NOUN	O	Disease	3720
.	PUNCT	O	O	3720
Ketoprofen	PROPN	O	Chemical	3721
but	CCONJ	O	O	3721
not	PART	O	O	3721
acetaminophen	PROPN	O	Chemical	3721
impaired	VERB	O	O	3721
platelet	NOUN	O	O	3721
function	NOUN	O	O	3721
in	ADP	O	O	3721
patients	NOUN	O	O	3721
with	ADP	O	O	3721
SAH	PROPN	O	Disease	3721
.	PUNCT	O	O	3721
If	SCONJ	O	O	3722
ketoprofen	VERB	O	Chemical	3722
is	AUX	O	O	3722
used	VERB	O	O	3722
before	ADP	O	O	3722
surgery	NOUN	O	O	3722
on	ADP	O	O	3722
cerebral	ADJ	O	O	3722
artery aneurysms	NOUN	O	Disease	3722
,	PUNCT	O	O	3722
it	PRON	O	O	3722
may	AUX	O	O	3722
pose	VERB	O	O	3722
an	PRON	O	O	3722
additional	ADJ	O	O	3722
risk	NOUN	O	O	3722
factor	NOUN	O	O	3722
for	ADP	O	O	3722
hemorrhage	NOUN	O	Disease	3722
.	PUNCT	O	O	3722
Value	NOUN	O	O	3725
of	ADP	O	O	3725
methylprednisolone	NOUN	O	Chemical	3725
in	ADP	O	O	3725
prevention	NOUN	O	O	3725
of	ADP	O	O	3725
the	PRON	O	O	3725
arthralgia	ADV	O	Disease	3725
-	PUNCT	O	O	3725
myalgia	NOUN	O	Disease	3725
syndrome	NOUN	O	O	3725
associated	VERB	O	O	3725
with	ADP	O	O	3725
the	PRON	O	O	3725
total	ADJ	O	O	3725
dose	NOUN	O	O	3725
infusion	NOUN	O	O	3725
of	ADP	O	O	3725
iron dextran	NOUN	O	Chemical	3725
:	PUNCT	O	O	3725
a	PRON	O	O	3725
double	ADJ	O	O	3725
blind	ADJ	O	Disease	3725
randomized	VERB	O	O	3725
trial	NOUN	O	O	3725
.	PUNCT	O	O	3725
The	PRON	O	O	3726
safety	NOUN	O	O	3726
and	CCONJ	O	O	3726
efficacy	NOUN	O	O	3726
of	ADP	O	O	3726
total	ADJ	O	O	3726
dose	NOUN	O	O	3726
infusion	NOUN	O	O	3726
(	PUNCT	O	O	3726
TDI	PROPN	O	O	3726
)	PUNCT	O	O	3726
of	ADP	O	O	3726
iron dextran	NOUN	O	Chemical	3726
has	VERB	O	O	3726
been	AUX	O	O	3726
well	ADV	O	O	3726
documented	VERB	O	O	3726
.	PUNCT	O	O	3726
In	ADP	O	O	3727
40%	NOUN	O	O	3727
of	ADP	O	O	3727
treated	VERB	O	O	3727
patients	NOUN	O	O	3727
,	PUNCT	O	O	3727
an	PRON	O	O	3727
arthralgia	ADV	O	Disease	3727
-	PUNCT	O	O	3727
myalgia	NOUN	O	Disease	3727
syndrome	NOUN	O	O	3727
develops	VERB	O	O	3727
.	PUNCT	O	O	3727
administration	NOUN	O	O	3728
of	ADP	O	O	3728
methylprednisolone	NOUN	O	Chemical	3728
(	PUNCT	O	O	3728
MP	PROPN	O	Chemical	3728
)	PUNCT	O	O	3728
prevents	VERB	O	O	3728
this	PRON	O	O	3728
complication	NOUN	O	O	3728
.	PUNCT	O	O	3728
MP	PROPN	O	Chemical	3729
before	ADP	O	O	3729
and	CCONJ	O	O	3729
saline	NOUN	O	O	3729
after	ADP	O	O	3729
TDI	PROPN	O	O	3729
(	PUNCT	O	O	3729
group	NOUN	O	O	3729
2	X	O	O	3729
)	PUNCT	O	O	3729
,	PUNCT	O	O	3729
or	CCONJ	O	O	3729
125	NUM	O	O	3729
mg	VERB	O	O	3729
i.v	NOUN	O	O	3729
.	PUNCT	O	O	3729
MP	PROPN	O	Chemical	3730
before	ADP	O	O	3730
and	CCONJ	O	O	3730
after	ADP	O	O	3730
TDI	PROPN	O	O	3730
(	PUNCT	O	O	3730
group	NOUN	O	O	3730
3	X	O	O	3730
)	PUNCT	O	O	3730
.	PUNCT	O	O	3730
These	PRON	O	O	3731
data	NOUN	O	O	3731
demonstrate	VERB	O	O	3731
that	SCONJ	O	O	3731
administration	NOUN	O	O	3731
of	ADP	O	O	3731
MP	PROPN	O	Chemical	3731
before	ADP	O	O	3731
and	CCONJ	O	O	3731
after	ADP	O	O	3731
TDI	PROPN	O	O	3731
reduces	VERB	O	O	3731
the	PRON	O	O	3731
frequency	NOUN	O	O	3731
and	CCONJ	O	O	3731
severity	NOUN	O	O	3731
of	ADP	O	O	3731
the	PRON	O	O	3731
arthralgia	ADV	O	Disease	3731
-	PUNCT	O	O	3731
myalgia	NOUN	O	Disease	3731
syndrome	NOUN	O	O	3731
.	PUNCT	O	O	3731
MP	PROPN	O	Chemical	3732
should	AUX	O	O	3732
be	AUX	O	O	3732
given	VERB	O	O	3732
routinely	ADV	O	O	3732
before	ADP	O	O	3732
and	CCONJ	O	O	3732
after	ADP	O	O	3732
TDI	PROPN	O	O	3732
of	ADP	O	O	3732
iron dextran	NOUN	O	Chemical	3732
.	PUNCT	O	O	3732
Long	ADV	O	O	3735
-	PUNCT	O	O	3735
term	NOUN	O	O	3735
effects	NOUN	O	O	3735
of	ADP	O	O	3735
vincristine	NOUN	O	Chemical	3735
on	ADP	O	O	3735
the	PRON	O	O	3735
peripheral	ADJ	O	O	3735
nervous	ADJ	O	O	3735
system	NOUN	O	O	3735
.	PUNCT	O	O	3735
Forty	NUM	O	O	3736
patients	NOUN	O	O	3736
with	ADP	O	O	3736
Non	NOUN	O	O	3736
-	PUNCT	O	O	3736
Hodgkin	PROPN	O	O	3736
's	AUX	O	O	3736
Lymphoma	PROPN	O	O	3736
treated	VERB	O	O	3736
with	ADP	O	O	3736
vincristine	NOUN	O	Chemical	3736
between	ADP	O	O	3736
1984	NUM	O	O	3736
and	CCONJ	O	O	3736
1990	NUM	O	O	3736
(	PUNCT	O	O	3736
cumulative	ADJ	O	O	3736
dose	NOUN	O	O	3736
12	NUM	O	O	3736
mg	VERB	O	O	3736
in	ADP	O	O	3736
18	NUM	O	O	3736
-	PUNCT	O	O	3736
24	NUM	O	O	3736
weeks	NOUN	O	O	3736
)	PUNCT	O	O	3736
were	AUX	O	O	3736
investigated	VERB	O	O	3736
in	ADP	O	O	3736
order	NOUN	O	O	3736
to	PART	O	O	3736
evaluate	VERB	O	O	3736
the	PRON	O	O	3736
long	ADV	O	O	3736
term	NOUN	O	O	3736
effects	NOUN	O	O	3736
of	ADP	O	O	3736
vincristine	NOUN	O	Chemical	3736
on	ADP	O	O	3736
the	PRON	O	O	3736
peripheral	ADJ	O	O	3736
nervous	ADJ	O	O	3736
system	NOUN	O	O	3736
.	PUNCT	O	O	3736
The	PRON	O	O	3737
patients	NOUN	O	O	3737
were	AUX	O	O	3737
interviewed	VERB	O	O	3737
with	ADP	O	O	3737
emphasis	NOUN	O	O	3737
on	ADP	O	O	3737
neuropathic symptoms	NOUN	O	Disease	3737
.	PUNCT	O	O	3737
Physical	NOUN	O	O	3738
and	CCONJ	O	O	3738
quantitative	ADJ	O	O	3738
sensory	ADJ	O	O	3738
examination	NOUN	O	O	3738
with	ADP	O	O	3738
determination	NOUN	O	O	3738
of	ADP	O	O	3738
vibratory	NOUN	O	O	3738
perception	NOUN	O	O	3738
and	CCONJ	O	O	3738
thermal	PROPN	O	O	3738
discrimination	NOUN	O	O	3738
thresholds	NOUN	O	O	3738
were	AUX	O	O	3738
performed	VERB	O	O	3738
,	PUNCT	O	O	3738
four	NUM	O	O	3738
to	PART	O	O	3738
77	NUM	O	O	3738
months	NOUN	O	O	3738
(	PUNCT	O	O	3738
median	ADJ	O	O	3738
34	NUM	O	O	3738
months	NOUN	O	O	3738
)	PUNCT	O	O	3738
after	ADP	O	O	3738
vincristine	NOUN	O	Chemical	3738
treatment	NOUN	O	O	3738
.	PUNCT	O	O	3738
Twenty	NUM	O	O	3739
-	PUNCT	O	O	3739
seven	NUM	O	O	3739
patients	NOUN	O	O	3739
reported	VERB	O	O	3739
neuropathic symptoms	NOUN	O	Disease	3739
.	PUNCT	O	O	3739
It	PRON	O	O	3740
is	AUX	O	O	3740
concluded	VERB	O	O	3740
that	SCONJ	O	O	3740
with	ADP	O	O	3740
the	PRON	O	O	3740
above	ADP	O	O	3740
mentioned	VERB	O	O	3740
vincristine	NOUN	O	Chemical	3740
dose	NOUN	O	O	3740
schedule	NOUN	O	O	3740
signs	NOUN	O	O	3740
and	CCONJ	O	O	3740
symptoms	NOUN	O	O	3740
of	ADP	O	O	3740
vincristine	NOUN	O	Chemical	3740
neuropathy	NOUN	O	Disease	3740
are	AUX	O	O	3740
reversible	ADJ	O	O	3740
for	ADP	O	O	3740
a	PRON	O	O	3740
great	ADJ	O	O	3740
deal	VERB	O	O	3740
and	CCONJ	O	O	3740
prognosis	VERB	O	O	3740
is	AUX	O	O	3740
fairly	ADV	O	O	3740
good	ADJ	O	O	3740
.	PUNCT	O	O	3740
A	PRON	O	O	3743
case	NOUN	O	O	3743
of	ADP	O	O	3743
polymyositis	NOUN	O	Disease	3743
in	ADP	O	O	3743
a	PRON	O	O	3743
patient	NOUN	O	O	3743
with	ADP	O	O	3743
primary biliary cirrhosis	NOUN	O	Disease	3743
treated	VERB	O	O	3743
with	ADP	O	O	3743
D	NOUN	O	O	3743
-	PUNCT	O	O	3743
penicillamine	NOUN	O	Chemical	3743
.	PUNCT	O	O	3743
Although	SCONJ	O	O	3744
D	NOUN	O	O	3744
-	PUNCT	O	O	3744
penicillamine	NOUN	O	Chemical	3744
has	VERB	O	O	3744
been	AUX	O	O	3744
used	VERB	O	O	3744
for	ADP	O	O	3744
many	ADJ	O	O	3744
rheumatologic diseases	NOUN	O	Disease	3744
,	PUNCT	O	O	3744
toxicity	NOUN	O	Disease	3744
limits	NOUN	O	O	3744
its	PRON	O	O	3744
usefulness	NOUN	O	O	3744
in	ADP	O	O	3744
many	ADJ	O	O	3744
patients	NOUN	O	O	3744
.	PUNCT	O	O	3744
Polymyositis	NOUN	O	Disease	3745
/	PUNCT	O	O	3745
dermatomyositis	NOUN	O	Disease	3745
can	AUX	O	O	3745
develop	VERB	O	O	3745
as	ADP	O	O	3745
one	NUM	O	O	3745
of	ADP	O	O	3745
the	PRON	O	O	3745
autoimmune	PROPN	O	O	3745
complications	NOUN	O	O	3745
of	ADP	O	O	3745
D	NOUN	O	O	3745
-	PUNCT	O	O	3745
penicillamine	NOUN	O	Chemical	3745
treatment	NOUN	O	O	3745
,	PUNCT	O	O	3745
but	CCONJ	O	O	3745
its	PRON	O	O	3745
exact	VERB	O	O	3745
pathogenesis	NOUN	O	O	3745
remains	VERB	O	O	3745
unclear	ADJ	O	O	3745
.	PUNCT	O	O	3745
We	PRON	O	O	3746
report	VERB	O	O	3746
a	PRON	O	O	3746
patient	NOUN	O	O	3746
with	ADP	O	O	3746
primary biliary cirrhosis	NOUN	O	Disease	3746
,	PUNCT	O	O	3746
who	PRON	O	O	3746
developed	VERB	O	O	3746
polymyositis	NOUN	O	Disease	3746
while	SCONJ	O	O	3746
receiving	VERB	O	O	3746
D	NOUN	O	O	3746
-	PUNCT	O	O	3746
penicillamine	NOUN	O	Chemical	3746
therapy	NOUN	O	O	3746
.	PUNCT	O	O	3746
Patients	NOUN	O	O	3747
receiving	VERB	O	O	3747
D	NOUN	O	O	3747
-	PUNCT	O	O	3747
penicillamine	NOUN	O	Chemical	3747
therapy	NOUN	O	O	3747
should	AUX	O	O	3747
be	AUX	O	O	3747
followed	VERB	O	O	3747
carefully	ADV	O	O	3747
for	ADP	O	O	3747
the	PRON	O	O	3747
development	NOUN	O	O	3747
of	ADP	O	O	3747
autoimmune	PROPN	O	O	3747
complications	NOUN	O	O	3747
like	INTJ	O	O	3747
polymyositis	NOUN	O	Disease	3747
/	PUNCT	O	O	3747
dermatomyositis	NOUN	O	Disease	3747
.	PUNCT	O	O	3747
Photodistributed	VERB	O	O	3750
nifedipine	PROPN	O	Chemical	3750
-	PUNCT	O	O	3750
induced	VERB	O	O	3750
facial	ADJ	O	O	3750
telangiectasia	NOUN	O	Disease	3750
.	PUNCT	O	O	3750
Five	NUM	O	O	3751
months	NOUN	O	O	3751
after	ADP	O	O	3751
starting	VERB	O	O	3751
nifedipine	PROPN	O	Chemical	3751
(	PUNCT	O	O	3751
Adalat	PROPN	O	Chemical	3751
)	PUNCT	O	O	3751
,	PUNCT	O	O	3751
two	NUM	O	O	3751
patients	NOUN	O	O	3751
developed	VERB	O	O	3751
photodistributed	VERB	O	O	3751
facial	ADJ	O	O	3751
telangiectasia	NOUN	O	Disease	3751
,	PUNCT	O	O	3751
which	PRON	O	O	3751
became	VERB	O	O	3751
more	ADJ	O	O	3751
noticeable	ADJ	O	O	3751
with	ADP	O	O	3751
time	NOUN	O	O	3751
.	PUNCT	O	O	3751
Neither	PRON	O	O	3752
patient	NOUN	O	O	3752
complained	VERB	O	O	3752
of	ADP	O	O	3752
photosensitivity	NOUN	O	O	3752
or	CCONJ	O	O	3752
flushing	VERB	O	Disease	3752
.	PUNCT	O	O	3752
One	NUM	O	O	3753
commenced	VERB	O	O	3753
the	PRON	O	O	3753
closely	ADV	O	O	3753
related	ADJ	O	O	3753
drug	NOUN	O	O	3753
amlodipine	NOUN	O	Chemical	3753
3	X	O	O	3753
years	NOUN	O	O	3753
later	ADV	O	O	3753
,	PUNCT	O	O	3753
with	ADP	O	O	3753
recurrence	NOUN	O	O	3753
of	ADP	O	O	3753
telangiectasia	NOUN	O	Disease	3753
.	PUNCT	O	O	3753
The	PRON	O	O	3754
photodistribution	NOUN	O	O	3754
of	ADP	O	O	3754
the	PRON	O	O	3754
telangiectasia	NOUN	O	Disease	3754
suggests	VERB	O	O	3754
a	PRON	O	O	3754
significant	ADJ	O	O	3754
drug	NOUN	O	O	3754
/	PUNCT	O	O	3754
light	ADJ	O	O	3754
interaction	NOUN	O	O	3754
.	PUNCT	O	O	3754
Nephrotoxicity	NOUN	O	Disease	3757
of	ADP	O	O	3757
cyclosporin A	PRON	O	Chemical	3757
and	CCONJ	O	O	3757
FK506	NOUN	O	Chemical	3757
:	PUNCT	O	O	3757
inhibition	NOUN	O	O	3757
of	ADP	O	O	3757
calcineurin	NOUN	O	O	3757
phosphatase	ADJ	O	O	3757
.	PUNCT	O	O	3757
Cyclosporin A	PROPN	O	Chemical	3758
(	PUNCT	O	O	3758
CsA	PROPN	O	Chemical	3758
;	PUNCT	O	O	3758
50	NUM	O	O	3758
mg	VERB	O	O	3758
/	PUNCT	O	O	3758
kg	VERB	O	O	3758
)	PUNCT	O	O	3758
and	CCONJ	O	O	3758
Fujimycine	NOUN	O	Chemical	3758
(	PUNCT	O	O	3758
FK506	NOUN	O	Chemical	3758
;	PUNCT	O	O	3758
5	NUM	O	O	3758
mg	VERB	O	O	3758
/	PUNCT	O	O	3758
kg	VERB	O	O	3758
)	PUNCT	O	O	3758
,	PUNCT	O	O	3758
but	CCONJ	O	O	3758
not	PART	O	O	3758
the	PRON	O	O	3758
related	ADJ	O	O	3758
macrolide	ADV	O	Chemical	3758
immunosuppressant	ADJ	O	O	3758
rapamycin	NOUN	O	Chemical	3758
(	PUNCT	O	O	3758
5	NUM	O	O	3758
mg	VERB	O	O	3758
/	PUNCT	O	O	3758
kg	VERB	O	O	3758
)	PUNCT	O	O	3758
,	PUNCT	O	O	3758
caused	VERB	O	O	3758
a	PRON	O	O	3758
reduction	NOUN	O	O	3758
of	ADP	O	O	3758
glomerular	ADJ	O	O	3758
filtration	NOUN	O	O	3758
rate	NOUN	O	O	3758
,	PUNCT	O	O	3758
degenerative	ADJ	O	O	3758
changes	VERB	O	O	3758
of	ADP	O	O	3758
proximal	ADJ	O	O	3758
tubular	ADJ	O	O	3758
epithelium	NOUN	O	O	3758
,	PUNCT	O	O	3758
and	CCONJ	O	O	3758
hypertrophy	VERB	O	Disease	3758
of	ADP	O	O	3758
the	PRON	O	O	3758
juxtaglomerular	NOUN	O	O	3758
apparatus	NOUN	O	O	3758
in	ADP	O	O	3758
male	NOUN	O	O	3758
Wistar	PROPN	O	O	3758
rats	NOUN	O	O	3758
when	SCONJ	O	O	3758
given	VERB	O	O	3758
for	ADP	O	O	3758
10	NUM	O	O	3758
days	NOUN	O	O	3758
.	PUNCT	O	O	3758
The	PRON	O	O	3759
molecular	ADJ	O	O	3759
mechanisms	NOUN	O	O	3759
of	ADP	O	O	3759
CsA	PROPN	O	Chemical	3759
and	CCONJ	O	O	3759
FK506	NOUN	O	Chemical	3759
toxicity	NOUN	O	Disease	3759
were	AUX	O	O	3759
investigated	VERB	O	O	3759
.	PUNCT	O	O	3759
Cyclophilin	PROPN	O	O	3760
A	PRON	O	O	3760
and	CCONJ	O	O	3760
FK506-binding	VERB	O	O	3760
protein	NOUN	O	O	3760
,	PUNCT	O	O	3760
the	PRON	O	O	3760
main	ADJ	O	O	3760
intracytoplasmic	PROPN	O	O	3760
receptors	NOUN	O	O	3760
for	ADP	O	O	3760
CsA	PROPN	O	Chemical	3760
and	CCONJ	O	O	3760
FK506	NOUN	O	Chemical	3760
,	PUNCT	O	O	3760
respectively	ADV	O	O	3760
,	PUNCT	O	O	3760
were	AUX	O	O	3760
each	PRON	O	O	3760
detected	VERB	O	O	3760
in	ADP	O	O	3760
renal	ADJ	O	O	3760
tissue	NOUN	O	O	3760
extract	VERB	O	O	3760
.	PUNCT	O	O	3760
In	ADP	O	O	3761
the	PRON	O	O	3761
kidney	NOUN	O	O	3761
,	PUNCT	O	O	3761
high	ADJ	O	O	3761
levels	NOUN	O	O	3761
of	ADP	O	O	3761
immunoreactive	ADP	O	O	3761
and	CCONJ	O	O	3761
enzymatically	ADV	O	O	3761
active	ADJ	O	O	3761
calcineurin	NOUN	O	O	3761
were	AUX	O	O	3761
found	VERB	O	O	3761
which	PRON	O	O	3761
were	AUX	O	O	3761
inhibited	VERB	O	O	3761
by	ADP	O	O	3761
the	PRON	O	O	3761
immunosuppressants	NOUN	O	O	3761
CsA	PROPN	O	Chemical	3761
and	CCONJ	O	O	3761
FK506	NOUN	O	Chemical	3761
,	PUNCT	O	O	3761
but	CCONJ	O	O	3761
not	PART	O	O	3761
by	ADP	O	O	3761
rapamycin	NOUN	O	Chemical	3761
.	PUNCT	O	O	3761
Finally	ADV	O	O	3762
,	PUNCT	O	O	3762
specific	ADJ	O	O	3762
immunophilin	PROPN	O	O	3762
-	PUNCT	O	O	3762
drug	NOUN	O	O	3762
-	PUNCT	O	O	3762
calcineurin	NOUN	O	O	3762
complexes	NOUN	O	O	3762
formed	VERB	O	O	3762
only	ADV	O	O	3762
in	ADP	O	O	3762
the	PRON	O	O	3762
presence	NOUN	O	O	3762
of	ADP	O	O	3762
CsA	PROPN	O	Chemical	3762
and	CCONJ	O	O	3762
FK506	NOUN	O	Chemical	3762
,	PUNCT	O	O	3762
but	CCONJ	O	O	3762
not	PART	O	O	3762
rapamycin	NOUN	O	Chemical	3762
.	PUNCT	O	O	3762
These	PRON	O	O	3763
results	VERB	O	O	3763
suggest	VERB	O	O	3763
that	SCONJ	O	O	3763
the	PRON	O	O	3763
nephrotoxic	NOUN	O	Disease	3763
effects	NOUN	O	O	3763
of	ADP	O	O	3763
CsA	PROPN	O	Chemical	3763
and	CCONJ	O	O	3763
FK506	NOUN	O	Chemical	3763
is	AUX	O	O	3763
likely	ADV	O	O	3763
mediated	VERB	O	O	3763
through	ADP	O	O	3763
binding	VERB	O	O	3763
to	PART	O	O	3763
renal	ADJ	O	O	3763
immunophilin	PROPN	O	O	3763
and	CCONJ	O	O	3763
inhibiting	VERB	O	O	3763
calcineurin	NOUN	O	O	3763
phosphatase	ADJ	O	O	3763
.	PUNCT	O	O	3763
Massive	ADJ	O	O	3766
cerebral edema	NOUN	O	Disease	3766
associated	VERB	O	O	3766
with	ADP	O	O	3766
fulminant	ADJ	O	O	3766
hepatic failure	NOUN	O	Disease	3766
in	ADP	O	O	3766
acetaminophen	PROPN	O	Chemical	3766
overdose	NOUN	O	Disease	3766
:	PUNCT	O	O	3766
possible	ADJ	O	O	3766
role	NOUN	O	O	3766
of	ADP	O	O	3766
cranial	ADJ	O	O	3766
decompression	NOUN	O	O	3766
.	PUNCT	O	O	3766
Cerebral edema	NOUN	O	Disease	3767
may	AUX	O	O	3767
complicate	VERB	O	O	3767
the	PRON	O	O	3767
course	NOUN	O	O	3767
of	ADP	O	O	3767
fulminant	ADJ	O	O	3767
hepatic failure	NOUN	O	Disease	3767
.	PUNCT	O	O	3767
We	PRON	O	O	3768
present	NOUN	O	O	3768
a	PRON	O	O	3768
patient	NOUN	O	O	3768
with	ADP	O	O	3768
fatal	ADJ	O	O	3768
acetaminophen	PROPN	O	Chemical	3768
-	PUNCT	O	O	3768
induced	VERB	O	O	3768
fulminant	ADJ	O	O	3768
hepatic failure	NOUN	O	Disease	3768
,	PUNCT	O	O	3768
with	ADP	O	O	3768
signs	NOUN	O	O	3768
and	CCONJ	O	O	3768
symptoms	NOUN	O	O	3768
of	ADP	O	O	3768
cerebral edema	NOUN	O	Disease	3768
,	PUNCT	O	O	3768
unresponsive	ADJ	O	O	3768
to	PART	O	O	3768
conventional	ADJ	O	O	3768
medical	ADJ	O	O	3768
therapy	NOUN	O	O	3768
.	PUNCT	O	O	3768
Gentamicin	PROPN	O	Chemical	3771
nephropathy	NOUN	O	Disease	3771
in	ADP	O	O	3771
a	PRON	O	O	3771
neonate	NOUN	O	O	3771
.	PUNCT	O	O	3771
The	PRON	O	O	3772
clinical	ADJ	O	O	3772
and	CCONJ	O	O	3772
autopsy	ADJ	O	O	3772
findings	NOUN	O	O	3772
in	ADP	O	O	3772
a	PRON	O	O	3772
premature	ADJ	O	O	3772
baby	NOUN	O	O	3772
who	PRON	O	O	3772
died	VERB	O	O	3772
of	ADP	O	O	3772
acute	ADJ	O	O	3772
renal failure	NOUN	O	Disease	3772
after	ADP	O	O	3772
therapy	NOUN	O	O	3772
with	ADP	O	O	3772
gentamicin	VERB	O	Chemical	3772
(	PUNCT	O	O	3772
5	NUM	O	O	3772
mg	VERB	O	O	3772
/	PUNCT	O	O	3772
kg	VERB	O	O	3772
/	PUNCT	O	O	3772
day	NOUN	O	O	3772
)	PUNCT	O	O	3772
and	CCONJ	O	O	3772
penicillin	NOUN	O	Chemical	3772
are	AUX	O	O	3772
presented	VERB	O	O	3772
.	PUNCT	O	O	3772
The	PRON	O	O	3773
serum	NOUN	O	O	3773
gentamicin	VERB	O	Chemical	3773
concentration	NOUN	O	O	3773
had	VERB	O	O	3773
reached	VERB	O	O	3773
toxic	ADJ	O	O	3773
levels	NOUN	O	O	3773
when	SCONJ	O	O	3773
anuria	VERB	O	Disease	3773
developed	VERB	O	O	3773
.	PUNCT	O	O	3773
Numerous	ADJ	O	O	3774
periodic acid	NOUN	O	Chemical	3774
Schiff	PROPN	O	O	3774
(	PUNCT	O	O	3774
PAS	PROPN	O	O	3774
)	PUNCT	O	O	3774
positive	ADJ	O	O	3774
,	PUNCT	O	O	3774
diastase	PROPN	O	O	3774
resistant	ADJ	O	O	3774
cytoplasmic	ADJ	O	O	3774
inclusion	NOUN	O	O	3774
bodies	NOUN	O	O	3774
which	PRON	O	O	3774
appeared	VERB	O	O	3774
as	ADP	O	O	3774
myelin	NOUN	O	O	3774
figures	VERB	O	O	3774
in	ADP	O	O	3774
cytosegresomes	NOUN	O	O	3774
under	ADP	O	O	3774
the	PRON	O	O	3774
electron	NOUN	O	O	3774
microscope	NOUN	O	O	3774
were	AUX	O	O	3774
identified	VERB	O	O	3774
in	ADP	O	O	3774
the	PRON	O	O	3774
proximal	ADJ	O	O	3774
convoluted	ADJ	O	O	3774
tubules	NOUN	O	O	3774
.	PUNCT	O	O	3774
The	PRON	O	O	3775
pathological	ADJ	O	O	3775
changes	VERB	O	O	3775
induced	VERB	O	O	3775
by	ADP	O	O	3775
gentamicin	VERB	O	Chemical	3775
in	ADP	O	O	3775
the	PRON	O	O	3775
human	PROPN	O	O	3775
neonatal	NOUN	O	O	3775
kidneys	NOUN	O	O	3775
have	VERB	O	O	3775
not	PART	O	O	3775
been	AUX	O	O	3775
previously	ADV	O	O	3775
reported	VERB	O	O	3775
.	PUNCT	O	O	3775
Anti	ADJ	O	O	3778
-	PUNCT	O	O	3778
carcinogenic	ADJ	O	Disease	3778
action	NOUN	O	O	3778
of	ADP	O	O	3778
phenobarbital	NOUN	O	Chemical	3778
given	VERB	O	O	3778
simultaneously	ADV	O	O	3778
with	ADP	O	O	3778
diethylnitrosamine	PROPN	O	Chemical	3778
in	ADP	O	O	3778
the	PRON	O	O	3778
rat	NOUN	O	O	3778
.	PUNCT	O	O	3778
The	PRON	O	O	3779
present	NOUN	O	O	3779
work	NOUN	O	O	3779
has	VERB	O	O	3779
been	AUX	O	O	3779
planned	VERB	O	O	3779
in	ADP	O	O	3779
order	NOUN	O	O	3779
to	PART	O	O	3779
elucidate	VERB	O	O	3779
the	PRON	O	O	3779
effect	VERB	O	O	3779
of	ADP	O	O	3779
phenobarbital	NOUN	O	Chemical	3779
(	PUNCT	O	O	3779
PB	PROPN	O	Chemical	3779
:	PUNCT	O	O	3779
15	NUM	O	O	3779
mg	VERB	O	O	3779
per	ADP	O	O	3779
rat	NOUN	O	O	3779
of	ADP	O	O	3779
ingested	VERB	O	O	3779
dose	NOUN	O	O	3779
)	PUNCT	O	O	3779
on	ADP	O	O	3779
carcinogenesis	NOUN	O	Disease	3779
when	SCONJ	O	O	3779
it	PRON	O	O	3779
is	AUX	O	O	3779
administered	VERB	O	O	3779
simultaneously	ADV	O	O	3779
with	ADP	O	O	3779
diethylnitrosamine	PROPN	O	Chemical	3779
(	PUNCT	O	O	3779
DEN	PROPN	O	Chemical	3779
:	PUNCT	O	O	3779
10	NUM	O	O	3779
mg	VERB	O	O	3779
/	PUNCT	O	O	3779
kg	VERB	O	O	3779
/	PUNCT	O	O	3779
day	NOUN	O	O	3779
)	PUNCT	O	O	3779
.	PUNCT	O	O	3779
Wistar	PROPN	O	O	3780
rats	NOUN	O	O	3780
(	PUNCT	O	O	3780
180	NUM	O	O	3780
g	X	O	O	3780
)	PUNCT	O	O	3780
were	AUX	O	O	3780
treated	VERB	O	O	3780
by	ADP	O	O	3780
DEN	PROPN	O	Chemical	3780
alone	ADV	O	O	3780
or	CCONJ	O	O	3780
by	ADP	O	O	3780
DEN	PROPN	O	Chemical	3780
+	ADP	O	O	3780
PB	PROPN	O	Chemical	3780
during	ADP	O	O	3780
2	X	O	O	3780
,	PUNCT	O	O	3780
4	NUM	O	O	3780
and	CCONJ	O	O	3780
6	NUM	O	O	3780
weeks	NOUN	O	O	3780
according	VERB	O	O	3780
to	PART	O	O	3780
our	PRON	O	O	3780
schedule	NOUN	O	O	3780
for	ADP	O	O	3780
hepatocarcinogenesis	NOUN	O	Disease	3780
.	PUNCT	O	O	3780
After	ADP	O	O	3781
the	PRON	O	O	3781
end	VERB	O	O	3781
of	ADP	O	O	3781
the	PRON	O	O	3781
treatment	NOUN	O	O	3781
,	PUNCT	O	O	3781
the	PRON	O	O	3781
number	NOUN	O	O	3781
and	CCONJ	O	O	3781
the	PRON	O	O	3781
size	NOUN	O	O	3781
of	ADP	O	O	3781
induced	VERB	O	O	3781
PAS	PROPN	O	O	3781
positive	ADJ	O	O	3781
preneoplastic foci	VERB	O	Disease	3781
was	AUX	O	O	3781
significantly	ADV	O	O	3781
reduced	VERB	O	O	3781
when	SCONJ	O	O	3781
PB	PROPN	O	Chemical	3781
was	AUX	O	O	3781
given	VERB	O	O	3781
simultaneously	ADV	O	O	3781
with	ADP	O	O	3781
DEN	PROPN	O	Chemical	3781
for	ADP	O	O	3781
4	NUM	O	O	3781
and	CCONJ	O	O	3781
6	NUM	O	O	3781
weeks	NOUN	O	O	3781
.	PUNCT	O	O	3781
The	PRON	O	O	3782
mitotic	ADJ	O	O	3782
inhibition	NOUN	O	O	3782
and	CCONJ	O	O	3782
the	PRON	O	O	3782
production	NOUN	O	O	3782
of	ADP	O	O	3782
micronuclei	NOUN	O	O	3782
normally	ADV	O	O	3782
observed	VERB	O	O	3782
after	ADP	O	O	3782
partial	ADJ	O	O	3782
hepatectomy	NOUN	O	O	3782
in	ADP	O	O	3782
DEN	PROPN	O	Chemical	3782
treated	VERB	O	O	3782
rats	NOUN	O	O	3782
were	AUX	O	O	3782
also	ADV	O	O	3782
significantly	ADV	O	O	3782
decreased	VERB	O	O	3782
in	ADP	O	O	3782
DEN	PROPN	O	Chemical	3782
+	ADP	O	O	3782
PB	PROPN	O	Chemical	3782
treated	VERB	O	O	3782
rats	NOUN	O	O	3782
.	PUNCT	O	O	3782
When	SCONJ	O	O	3783
the	PRON	O	O	3783
treatment	NOUN	O	O	3783
last	VERB	O	O	3783
only	ADV	O	O	3783
2	X	O	O	3783
weeks	NOUN	O	O	3783
,	PUNCT	O	O	3783
the	PRON	O	O	3783
presence	NOUN	O	O	3783
of	ADP	O	O	3783
PB	PROPN	O	Chemical	3783
did	VERB	O	O	3783
not	PART	O	O	3783
change	VERB	O	O	3783
significantly	ADV	O	O	3783
the	PRON	O	O	3783
last	VERB	O	O	3783
parameters	NOUN	O	O	3783
.	PUNCT	O	O	3783
In	ADP	O	O	3784
DEN	PROPN	O	Chemical	3784
+	ADP	O	O	3784
PB	PROPN	O	Chemical	3784
treated	VERB	O	O	3784
rats	NOUN	O	O	3784
,	PUNCT	O	O	3784
the	PRON	O	O	3784
survival	NOUN	O	O	3784
was	AUX	O	O	3784
prolonged	VERB	O	O	3784
and	CCONJ	O	O	3784
the	PRON	O	O	3784
tumor	NOUN	O	Disease	3784
incidence	NOUN	O	O	3784
decreased	VERB	O	O	3784
as	ADP	O	O	3784
compared	VERB	O	O	3784
with	ADP	O	O	3784
the	PRON	O	O	3784
results	VERB	O	O	3784
obtained	VERB	O	O	3784
by	ADP	O	O	3784
DEN	PROPN	O	Chemical	3784
alone	ADV	O	O	3784
.	PUNCT	O	O	3784
It	PRON	O	O	3785
is	AUX	O	O	3785
concluded	VERB	O	O	3785
that	SCONJ	O	O	3785
PB	PROPN	O	Chemical	3785
,	PUNCT	O	O	3785
which	PRON	O	O	3785
promotes	VERB	O	O	3785
carcinogenesis	NOUN	O	Disease	3785
when	SCONJ	O	O	3785
administered	VERB	O	O	3785
after	ADP	O	O	3785
the	PRON	O	O	3785
DEN	PROPN	O	Chemical	3785
treatment	NOUN	O	O	3785
,	PUNCT	O	O	3785
reduces	VERB	O	O	3785
the	PRON	O	O	3785
carcinogen	PROPN	O	O	3785
effect	VERB	O	O	3785
when	SCONJ	O	O	3785
given	VERB	O	O	3785
simultaneously	ADV	O	O	3785
with	ADP	O	O	3785
DEN	PROPN	O	Chemical	3785
.	PUNCT	O	O	3785
This	PRON	O	O	3786
'	PUNCT	O	O	3786
anti	ADJ	O	O	3786
-	PUNCT	O	O	3786
carcinogen	PROPN	O	O	3786
'	PUNCT	O	O	3786
effect	VERB	O	O	3786
acts	VERB	O	O	3786
on	ADP	O	O	3786
the	PRON	O	O	3786
initiation	NOUN	O	O	3786
as	ADP	O	O	3786
well	ADV	O	O	3786
as	ADP	O	O	3786
on	ADP	O	O	3786
the	PRON	O	O	3786
promotion	NOUN	O	O	3786
of	ADP	O	O	3786
the	PRON	O	O	3786
precancerous lesions	NOUN	O	Disease	3786
.	PUNCT	O	O	3786
Biochemical	ADJ	O	O	3787
investigations	NOUN	O	O	3787
are	AUX	O	O	3787
in	ADP	O	O	3787
progress	VERB	O	O	3787
to	PART	O	O	3787
obtain	VERB	O	O	3787
more	ADJ	O	O	3787
information	NOUN	O	O	3787
about	ADP	O	O	3787
this	PRON	O	O	3787
'	PUNCT	O	O	3787
paradoxical	ADJ	O	O	3787
'	PUNCT	O	O	3787
PB	PROPN	O	Chemical	3787
effect	VERB	O	O	3787
.	PUNCT	O	O	3787
Post	NOUN	O	O	3790
-	PUNCT	O	O	3790
operative	NOUN	O	O	3790
rigidity	NOUN	O	Disease	3790
after	ADP	O	O	3790
fentanyl	ADJ	O	Chemical	3790
administration	NOUN	O	O	3790
.	PUNCT	O	O	3790
A	PRON	O	O	3791
case	NOUN	O	O	3791
of	ADP	O	O	3791
thoraco	PROPN	O	O	3791
-	PUNCT	O	O	3791
abdominal	ADJ	O	O	3791
rigidity	NOUN	O	Disease	3791
leading	VERB	O	O	3791
to	PART	O	O	3791
respiratory failure	NOUN	O	Disease	3791
is	AUX	O	O	3791
described	VERB	O	O	3791
in	ADP	O	O	3791
the	PRON	O	O	3791
post	VERB	O	O	3791
-	PUNCT	O	O	3791
operative	NOUN	O	O	3791
period	NOUN	O	O	3791
in	ADP	O	O	3791
an	PRON	O	O	3791
elderly	ADJ	O	O	3791
patient	NOUN	O	O	3791
who	PRON	O	O	3791
received	VERB	O	O	3791
a	PRON	O	O	3791
moderate	ADJ	O	O	3791
dose	NOUN	O	O	3791
of	ADP	O	O	3791
fentanyl	ADJ	O	Chemical	3791
.	PUNCT	O	O	3791
This	PRON	O	O	3792
was	AUX	O	O	3792
successfully	ADV	O	O	3792
reversed	VERB	O	O	3792
by	ADP	O	O	3792
naloxone	NOUN	O	Chemical	3792
.	PUNCT	O	O	3792
Postpartum	NOUN	O	O	3795
psychosis	VERB	O	Disease	3795
induced	VERB	O	O	3795
by	ADP	O	O	3795
bromocriptine	NOUN	O	Chemical	3795
.	PUNCT	O	O	3795
Two	NUM	O	O	3796
multigravida	PROPN	O	O	3796
patients	NOUN	O	O	3796
with	ADP	O	O	3796
no	PRON	O	O	3796
prior	ADV	O	O	3796
psychiatric	ADJ	O	Disease	3796
history	NOUN	O	O	3796
were	AUX	O	O	3796
seen	VERB	O	O	3796
with	ADP	O	O	3796
postpartum	PROPN	O	O	3796
psychosis	VERB	O	Disease	3796
,	PUNCT	O	O	3796
having	VERB	O	O	3796
received	VERB	O	O	3796
bromocriptine	NOUN	O	Chemical	3796
for	ADP	O	O	3796
inhibition of lactation	NOUN	O	Disease	3796
.	PUNCT	O	O	3796
Bromocriptine	PROPN	O	Chemical	3797
given	VERB	O	O	3797
in	ADP	O	O	3797
high	ADJ	O	O	3797
doses	NOUN	O	O	3797
has	VERB	O	O	3797
been	AUX	O	O	3797
associated	VERB	O	O	3797
with	ADP	O	O	3797
psychosis	VERB	O	Disease	3797
in	ADP	O	O	3797
patients	NOUN	O	O	3797
receiving	VERB	O	O	3797
the	PRON	O	O	3797
drug	NOUN	O	O	3797
for	ADP	O	O	3797
Parkinson	NOUN	O	O	3797
's	AUX	O	O	3797
disease	PROPN	O	O	3797
.	PUNCT	O	O	3797
These	PRON	O	O	3798
cases	NOUN	O	O	3798
demonstrate	VERB	O	O	3798
that	SCONJ	O	O	3798
bromocriptine	NOUN	O	Chemical	3798
may	AUX	O	O	3798
cause	VERB	O	O	3798
psychosis	VERB	O	Disease	3798
even	ADV	O	O	3798
when	SCONJ	O	O	3798
given	VERB	O	O	3798
in	ADP	O	O	3798
low	ADJ	O	O	3798
doses	NOUN	O	O	3798
.	PUNCT	O	O	3798
A	PRON	O	O	3801
prospective	ADJ	O	O	3801
study	VERB	O	O	3801
on	ADP	O	O	3801
the	PRON	O	O	3801
dose	NOUN	O	O	3801
dependency	NOUN	O	O	3801
of	ADP	O	O	3801
cardiotoxicity	NOUN	O	Disease	3801
induced	VERB	O	O	3801
by	ADP	O	O	3801
mitomycin C.	PROPN	O	O	3801
Since	SCONJ	O	O	3802
1975	NUM	O	O	3802
mitomycin C	PROPN	O	Chemical	3802
(	PUNCT	O	O	3802
MMC	PROPN	O	Chemical	3802
)	PUNCT	O	O	3802
has	VERB	O	O	3802
been	AUX	O	O	3802
suggested	VERB	O	O	3802
to	PART	O	O	3802
be	AUX	O	O	3802
cardiotoxic	ADJ	O	Disease	3802
,	PUNCT	O	O	3802
especially	ADV	O	O	3802
when	SCONJ	O	O	3802
combined	VERB	O	O	3802
with	ADP	O	O	3802
or	CCONJ	O	O	3802
given	VERB	O	O	3802
following	VERB	O	O	3802
doxorubicin	VERB	O	Chemical	3802
.	PUNCT	O	O	3802
Forty	NUM	O	O	3803
-	PUNCT	O	O	3803
four	NUM	O	O	3803
MMC	PROPN	O	Chemical	3803
-	PUNCT	O	O	3803
treated	VERB	O	O	3803
patients	NOUN	O	O	3803
were	AUX	O	O	3803
studied	VERB	O	O	3803
,	PUNCT	O	O	3803
37	NUM	O	O	3803
of	ADP	O	O	3803
them	PRON	O	O	3803
could	AUX	O	O	3803
be	AUX	O	O	3803
evaluated	VERB	O	O	3803
.	PUNCT	O	O	3803
One	NUM	O	O	3804
of	ADP	O	O	3804
the	PRON	O	O	3804
patients	NOUN	O	O	3804
developed	VERB	O	O	3804
cardiac failure	NOUN	O	Disease	3804
after	ADP	O	O	3804
30	NUM	O	O	3804
mg	VERB	O	O	3804
m-2	NOUN	O	O	3804
MMC	PROPN	O	Chemical	3804
and	CCONJ	O	O	3804
only	ADV	O	O	3804
150	NUM	O	O	3804
mg	VERB	O	O	3804
m-2	NOUN	O	O	3804
doxorubicin	VERB	O	Chemical	3804
.	PUNCT	O	O	3804
The	PRON	O	O	3805
cardiac failure	NOUN	O	Disease	3805
was	AUX	O	O	3805
predicted	VERB	O	O	3805
by	ADP	O	O	3805
a	PRON	O	O	3805
drop	VERB	O	O	3805
in	ADP	O	O	3805
EF	PROPN	O	O	3805
determined	VERB	O	O	3805
during	ADP	O	O	3805
a	PRON	O	O	3805
cold	ADJ	O	O	3805
pressor	ADJ	O	O	3805
test	NOUN	O	O	3805
.	PUNCT	O	O	3805
None	NOUN	O	O	3806
of	ADP	O	O	3806
the	PRON	O	O	3806
other	ADJ	O	O	3806
patients	NOUN	O	O	3806
developed	VERB	O	O	3806
clinical	ADJ	O	O	3806
cardiotoxicity	NOUN	O	Disease	3806
,	PUNCT	O	O	3806
nor	CCONJ	O	O	3806
did	VERB	O	O	3806
the	PRON	O	O	3806
studied	VERB	O	O	3806
parameters	NOUN	O	O	3806
change	VERB	O	O	3806
.	PUNCT	O	O	3806
Based	VERB	O	O	3807
on	ADP	O	O	3807
the	PRON	O	O	3807
combined	VERB	O	O	3807
data	NOUN	O	O	3807
from	ADP	O	O	3807
the	PRON	O	O	3807
present	NOUN	O	O	3807
study	VERB	O	O	3807
and	CCONJ	O	O	3807
the	PRON	O	O	3807
literature	NOUN	O	O	3807
,	PUNCT	O	O	3807
we	PRON	O	O	3807
suggest	VERB	O	O	3807
that	SCONJ	O	O	3807
MMC	PROPN	O	Chemical	3807
-	PUNCT	O	O	3807
related	ADJ	O	O	3807
cardiotoxicity	NOUN	O	Disease	3807
is	AUX	O	O	3807
dose	NOUN	O	O	3807
dependent	ADJ	O	O	3807
,	PUNCT	O	O	3807
occurring	VERB	O	O	3807
at	ADP	O	O	3807
cumulative	ADJ	O	O	3807
dose	NOUN	O	O	3807
levels	NOUN	O	O	3807
of	ADP	O	O	3807
30	NUM	O	O	3807
mg	VERB	O	O	3807
m-2	NOUN	O	O	3807
or	CCONJ	O	O	3807
more	ADJ	O	O	3807
,	PUNCT	O	O	3807
mainly	ADV	O	O	3807
in	ADP	O	O	3807
patients	NOUN	O	O	3807
also	ADV	O	O	3807
(	PUNCT	O	O	3807
previously	ADV	O	O	3807
or	CCONJ	O	O	3807
simultaneously	ADV	O	O	3807
)	PUNCT	O	O	3807
treated	VERB	O	O	3807
with	ADP	O	O	3807
doxorubicin	VERB	O	Chemical	3807
.	PUNCT	O	O	3807
Phlorizin	NOUN	O	Chemical	3810
-	PUNCT	O	O	3810
induced	VERB	O	O	3810
glycosuria	VERB	O	Disease	3810
does	VERB	O	O	3810
not	PART	O	O	3810
prevent	VERB	O	O	3810
gentamicin	VERB	O	Chemical	3810
nephrotoxicity	NOUN	O	Disease	3810
in	ADP	O	O	3810
rats	NOUN	O	O	3810
.	PUNCT	O	O	3810
Because	SCONJ	O	O	3811
rats	NOUN	O	O	3811
with	ADP	O	O	3811
streptozotocin	PROPN	O	Chemical	3811
-	PUNCT	O	O	3811
induced	VERB	O	O	3811
diabetes mellitus	ADJ	O	Disease	3811
(	PUNCT	O	O	3811
DM	PROPN	O	Disease	3811
)	PUNCT	O	O	3811
have	VERB	O	O	3811
a	PRON	O	O	3811
high	ADJ	O	O	3811
solute	NOUN	O	O	3811
diuresis	VERB	O	O	3811
(	PUNCT	O	O	3811
glycosuria	VERB	O	Disease	3811
of	ADP	O	O	3811
10	NUM	O	O	3811
to	PART	O	O	3811
12	NUM	O	O	3811
g	X	O	O	3811
/	PUNCT	O	O	3811
day	NOUN	O	O	3811
)	PUNCT	O	O	3811
,	PUNCT	O	O	3811
we	PRON	O	O	3811
have	VERB	O	O	3811
suggested	VERB	O	O	3811
that	SCONJ	O	O	3811
this	PRON	O	O	3811
may	AUX	O	O	3811
in	ADP	O	O	3811
part	NOUN	O	O	3811
be	AUX	O	O	3811
responsible	ADJ	O	O	3811
for	ADP	O	O	3811
their	PRON	O	O	3811
resistance	NOUN	O	O	3811
to	PART	O	O	3811
gentamicin	VERB	O	Chemical	3811
-	PUNCT	O	O	3811
induced	VERB	O	O	3811
acute	ADJ	O	O	3811
renal failure	NOUN	O	Disease	3811
(	PUNCT	O	O	3811
ARF	PROPN	O	Disease	3811
)	PUNCT	O	O	3811
.	PUNCT	O	O	3811
The	PRON	O	O	3812
protection	NOUN	O	O	3812
from	ADP	O	O	3812
gentamicin	VERB	O	Chemical	3812
nephrotoxicity	NOUN	O	Disease	3812
was	AUX	O	O	3812
studied	VERB	O	O	3812
in	ADP	O	O	3812
non	ADJ	O	O	3812
-	PUNCT	O	O	3812
diabetic	ADJ	O	Disease	3812
rats	NOUN	O	O	3812
with	ADP	O	O	3812
chronic	ADJ	O	O	3812
solute	NOUN	O	O	3812
diuresis	VERB	O	O	3812
induced	VERB	O	O	3812
by	ADP	O	O	3812
blockage	NOUN	O	O	3812
of	ADP	O	O	3812
tubular	ADJ	O	O	3812
glucose	NOUN	O	Chemical	3812
reabsorption	NOUN	O	O	3812
with	ADP	O	O	3812
phlorizin	PROPN	O	Chemical	3812
(	PUNCT	O	O	3812
P	NOUN	O	Chemical	3812
)	PUNCT	O	O	3812
.	PUNCT	O	O	3812
DM	PROPN	O	Disease	3813
rats	NOUN	O	O	3813
with	ADP	O	O	3813
mild	ADJ	O	O	3813
glycosuria	VERB	O	Disease	3813
(	PUNCT	O	O	3813
similar	ADJ	O	O	3813
in	ADP	O	O	3813
degree	PROPN	O	O	3813
to	PART	O	O	3813
that	SCONJ	O	O	3813
of	ADP	O	O	3813
the	PRON	O	O	3813
P	NOUN	O	Chemical	3813
treated	VERB	O	O	3813
animals	NOUN	O	O	3813
)	PUNCT	O	O	3813
were	AUX	O	O	3813
also	ADV	O	O	3813
studied	VERB	O	O	3813
.	PUNCT	O	O	3813
Group	PROPN	O	O	3814
1	X	O	O	3814
(	PUNCT	O	O	3814
P	NOUN	O	Chemical	3814
alone	ADV	O	O	3814
)	PUNCT	O	O	3814
received	VERB	O	O	3814
P	NOUN	O	Chemical	3814
,	PUNCT	O	O	3814
360	NUM	O	O	3814
mg	VERB	O	O	3814
/	PUNCT	O	O	3814
day	NOUN	O	O	3814
,	PUNCT	O	O	3814
for	ADP	O	O	3814
15	NUM	O	O	3814
days	NOUN	O	O	3814
;	PUNCT	O	O	3814
Group	PROPN	O	O	3814
II	NUM	O	O	3814
(	PUNCT	O	O	3814
P	NOUN	O	Chemical	3814
+	ADP	O	O	3814
gentamicin	VERB	O	Chemical	3814
)	PUNCT	O	O	3814
;	PUNCT	O	O	3814
Group	PROPN	O	O	3814
III	NUM	O	O	3814
(	PUNCT	O	O	3814
gentamicin	VERB	O	Chemical	3814
alone	ADV	O	O	3814
)	PUNCT	O	O	3814
and	CCONJ	O	O	3814
Group	PROPN	O	O	3814
IV	NUM	O	O	3814
(	PUNCT	O	O	3814
mild	ADJ	O	O	3814
DM	PROPN	O	Disease	3814
+	ADP	O	O	3814
gentamicin	VERB	O	Chemical	3814
)	PUNCT	O	O	3814
.	PUNCT	O	O	3814
Nephrotoxic	NOUN	O	Disease	3815
doses	NOUN	O	O	3815
(	PUNCT	O	O	3815
40	NUM	O	O	3815
mg	VERB	O	O	3815
/	PUNCT	O	O	3815
kg	VERB	O	O	3815
body	NOUN	O	O	3815
wt	NOUN	O	O	3815
/	PUNCT	O	O	3815
day	NOUN	O	O	3815
)	PUNCT	O	O	3815
of	ADP	O	O	3815
gentamicin	VERB	O	Chemical	3815
were	AUX	O	O	3815
injected	VERB	O	O	3815
during	ADP	O	O	3815
the	PRON	O	O	3815
last	VERB	O	O	3815
nine	NUM	O	O	3815
days	NOUN	O	O	3815
of	ADP	O	O	3815
study	VERB	O	O	3815
to	PART	O	O	3815
the	PRON	O	O	3815
animals	NOUN	O	O	3815
of	ADP	O	O	3815
groups	NOUN	O	O	3815
II	NUM	O	O	3815
to	PART	O	O	3815
IV	NUM	O	O	3815
.	PUNCT	O	O	3815
In	ADP	O	O	3816
Group	PROPN	O	O	3816
I	PRON	O	O	3816
,	PUNCT	O	O	3816
P	NOUN	O	Chemical	3816
induced	VERB	O	O	3816
a	PRON	O	O	3816
moderate	ADJ	O	O	3816
and	CCONJ	O	O	3816
stable	ADJ	O	O	3816
glycosuria	VERB	O	Disease	3816
(	PUNCT	O	O	3816
3.9	NUM	O	O	3816
+	ADP	O	O	3816
/-	PUNCT	O	O	3816
0.1	NUM	O	O	3817
g	X	O	O	3817
/	PUNCT	O	O	3817
day	NOUN	O	O	3817
,	PUNCT	O	O	3817
SE	PROPN	O	O	3817
)	PUNCT	O	O	3817
,	PUNCT	O	O	3817
and	CCONJ	O	O	3817
no	PRON	O	O	3817
functional	ADJ	O	O	3817
or	CCONJ	O	O	3817
morphologic	ADJ	O	O	3817
evidence	NOUN	O	O	3817
of	ADP	O	O	3817
renal dysfunction	NOUN	O	Disease	3817
(	PUNCT	O	O	3817
baseline	VERB	O	O	3817
CCr	NOUN	O	O	3817
2.1	NUM	O	O	3817
+	ADP	O	O	3817
/-	PUNCT	O	O	3817
ml	ADP	O	O	3818
/	PUNCT	O	O	3818
min	NOUN	O	O	3818
,	PUNCT	O	O	3818
undetectable	ADJ	O	O	3818
lysozymuria	VERB	O	O	3818
)	PUNCT	O	O	3818
or	CCONJ	O	O	3818
damage	NOUN	O	O	3818
(	PUNCT	O	O	3818
tubular necrosis	NOUN	O	Disease	3818
score	VERB	O	O	3818
[	X	O	O	3818
maximum	ADV	O	O	3818
4	NUM	O	O	3818
]	PUNCT	O	O	3818
,	PUNCT	O	O	3818
zero	NUM	O	O	3818
)	PUNCT	O	O	3818
.	PUNCT	O	O	3818
In	ADP	O	O	3819
Group	PROPN	O	O	3819
II	NUM	O	O	3819
,	PUNCT	O	O	3819
P	NOUN	O	Chemical	3819
did	VERB	O	O	3819
not	PART	O	O	3819
prevent	VERB	O	O	3819
gentamicin	VERB	O	Chemical	3819
-	PUNCT	O	O	3819
ARF	PROPN	O	Disease	3819
(	PUNCT	O	O	3819
maximal	ADJ	O	O	3819
decrease	VERB	O	O	3819
in	ADP	O	O	3819
CCr	NOUN	O	O	3819
at	ADP	O	O	3819
day	NOUN	O	O	3819
9.89%	NOUN	O	O	3819
,	PUNCT	O	O	3819
P	NOUN	O	Chemical	3819
less	ADV	O	O	3819
than	ADP	O	O	3819
0.001	NUM	O	O	3819
;	PUNCT	O	O	3819
peak	PROPN	O	O	3819
lysozymuria	VERB	O	O	3819
,	PUNCT	O	O	3819
1863	NUM	O	O	3819
+	ADP	O	O	3819
/-	PUNCT	O	O	3819
321	NUM	O	O	3820
micrograms	NOUN	O	O	3820
/	PUNCT	O	O	3820
day	NOUN	O	O	3820
;	PUNCT	O	O	3820
and	CCONJ	O	O	3820
tubular necrosis	NOUN	O	Disease	3820
score	VERB	O	O	3820
,	PUNCT	O	O	3820
3.9	NUM	O	O	3820
+	ADP	O	O	3820
/-	PUNCT	O	O	3820
These	PRON	O	O	3821
values	NOUN	O	O	3821
were	AUX	O	O	3821
not	PART	O	O	3821
different	ADJ	O	O	3821
from	ADP	O	O	3821
those	PRON	O	O	3821
of	ADP	O	O	3821
Group	PROPN	O	O	3821
III	NUM	O	O	3821
:	PUNCT	O	O	3821
maximal	ADJ	O	O	3821
decrease	VERB	O	O	3821
in	ADP	O	O	3821
CCr	NOUN	O	O	3821
73%	NOUN	O	O	3821
(	PUNCT	O	O	3821
P	NOUN	O	Chemical	3821
less	ADV	O	O	3821
than	ADP	O	O	3821
0.001	NUM	O	O	3821
)	PUNCT	O	O	3821
;	PUNCT	O	O	3821
lysozymuria	VERB	O	O	3821
,	PUNCT	O	O	3821
2147	NUM	O	O	3821
+	ADP	O	O	3821
/-	PUNCT	O	O	3821
701	NUM	O	O	3822
micrograms	NOUN	O	O	3822
/	PUNCT	O	O	3822
day	NOUN	O	O	3822
;	PUNCT	O	O	3822
tubular necrosis	NOUN	O	Disease	3822
score	VERB	O	O	3822
,	PUNCT	O	O	3822
3.8	NUM	O	O	3822
+	ADP	O	O	3822
/-	PUNCT	O	O	3822
Tiapride	NOUN	O	Chemical	3825
in	ADP	O	O	3825
levodopa	NOUN	O	Chemical	3825
-	PUNCT	O	O	3825
induced	VERB	O	O	3825
involuntary movements	NOUN	O	Disease	3825
.	PUNCT	O	O	3825
Tiapride	NOUN	O	Chemical	3826
,	PUNCT	O	O	3826
a	PRON	O	O	3826
substituted	VERB	O	O	3826
benzamide	NOUN	O	Chemical	3826
derivative	ADJ	O	O	3826
closely	ADV	O	O	3826
related	ADJ	O	O	3826
to	PART	O	O	3826
metoclopramide	NOUN	O	Chemical	3826
,	PUNCT	O	O	3826
reduced	VERB	O	O	3826
levodopa	NOUN	O	Chemical	3826
-	PUNCT	O	O	3826
induced	VERB	O	O	3826
peak	PROPN	O	O	3826
dose	NOUN	O	O	3826
involuntary movements	NOUN	O	Disease	3826
in	ADP	O	O	3826
16	NUM	O	O	3826
patients	NOUN	O	O	3826
with	ADP	O	O	3826
idiopathic	ADJ	O	O	3826
Parkinson	NOUN	O	O	3826
's	AUX	O	O	3826
disease	PROPN	O	O	3826
.	PUNCT	O	O	3826
However	ADV	O	O	3827
,	PUNCT	O	O	3827
an	PRON	O	O	3827
unacceptable	ADJ	O	O	3827
increase	VERB	O	O	3827
in	ADP	O	O	3827
disability	NOUN	O	O	3827
from	ADP	O	O	3827
Parkinsonism	NOUN	O	Disease	3827
with	ADP	O	O	3827
aggravation	NOUN	O	O	3827
of	ADP	O	O	3827
end	VERB	O	O	3827
-	PUNCT	O	O	3827
of	ADP	O	O	3827
-	PUNCT	O	O	3827
dose	NOUN	O	O	3827
akinesia	NOUN	O	Disease	3827
led	VERB	O	O	3827
to	PART	O	O	3827
its	PRON	O	O	3827
cessation	NOUN	O	O	3827
in	ADP	O	O	3827
14	NUM	O	O	3827
patients	NOUN	O	O	3827
.	PUNCT	O	O	3827
Tiapride	NOUN	O	Chemical	3828
had	VERB	O	O	3828
no	PRON	O	O	3828
effect	VERB	O	O	3828
on	ADP	O	O	3828
levodopa	NOUN	O	Chemical	3828
-	PUNCT	O	O	3828
induced	VERB	O	O	3828
early	ADV	O	O	3828
morning	NOUN	O	O	3828
of	ADP	O	O	3828
""""	PUNCT	O	O	3828
off	ADP	O	O	3828
-	PUNCT	O	O	3828
period	NOUN	O	O	3828
""""	PUNCT	O	O	3828
segmental	ADJ	O	O	3828
dystonia	NOUN	O	Disease	3828
.	PUNCT	O	O	3828
These	PRON	O	O	3829
results	VERB	O	O	3829
fail	VERB	O	O	3829
to	PART	O	O	3829
support	NOUN	O	O	3829
the	PRON	O	O	3829
notion	NOUN	O	O	3829
that	SCONJ	O	O	3829
levodopa	NOUN	O	Chemical	3829
-	PUNCT	O	O	3829
induced	VERB	O	O	3829
dyskinesias	PROPN	O	Disease	3829
are	AUX	O	O	3829
caused	VERB	O	O	3829
by	ADP	O	O	3829
overstimulation	NOUN	O	O	3829
of	ADP	O	O	3829
a	PRON	O	O	3829
separate	VERB	O	O	3829
group	NOUN	O	O	3829
of	ADP	O	O	3829
dopamine	NOUN	O	Chemical	3829
receptors	NOUN	O	O	3829
.	PUNCT	O	O	3829
Effects	NOUN	O	O	3832
of	ADP	O	O	3832
the	PRON	O	O	3832
hippocampal	NOUN	O	O	3832
deep	ADJ	O	O	3832
brain	NOUN	O	O	3832
stimulation	NOUN	O	O	3832
on	ADP	O	O	3832
cortical	ADJ	O	O	3832
epileptic	ADJ	O	Disease	3832
discharges	VERB	O	O	3832
in	ADP	O	O	3832
penicillin	NOUN	O	Chemical	3832
-	PUNCT	O	O	3832
induced	VERB	O	O	3832
epilepsy	NOUN	O	Disease	3832
model	NOUN	O	O	3832
in	ADP	O	O	3832
rats	NOUN	O	O	3832
.	PUNCT	O	O	3832
AIM	VERB	O	O	3833
:	PUNCT	O	O	3833
Experimental	ADJ	O	O	3833
and	CCONJ	O	O	3833
clinical	ADJ	O	O	3833
studies	NOUN	O	O	3833
have	VERB	O	O	3833
revealed	VERB	O	O	3833
that	SCONJ	O	O	3833
hippocampal	NOUN	O	O	3833
DBS	PROPN	O	O	3833
can	AUX	O	O	3833
control	VERB	O	O	3833
epileptic	ADJ	O	Disease	3833
activity	NOUN	O	O	3833
,	PUNCT	O	O	3833
but	CCONJ	O	O	3833
the	PRON	O	O	3833
mechanism	NOUN	O	O	3833
of	ADP	O	O	3833
action	NOUN	O	O	3833
is	AUX	O	O	3833
obscure	ADJ	O	O	3833
and	CCONJ	O	O	3833
optimal	ADJ	O	O	3833
stimulation	NOUN	O	O	3833
parameters	NOUN	O	O	3833
are	AUX	O	O	3833
not	PART	O	O	3833
clearly	ADV	O	O	3833
defined	VERB	O	O	3833
.	PUNCT	O	O	3833
The	PRON	O	O	3834
aim	VERB	O	O	3834
was	AUX	O	O	3834
to	PART	O	O	3834
evaluate	VERB	O	O	3834
the	PRON	O	O	3834
effects	NOUN	O	O	3834
of	ADP	O	O	3834
high	ADJ	O	O	3834
frequency	NOUN	O	O	3834
hippocampal	NOUN	O	O	3834
stimulation	NOUN	O	O	3834
on	ADP	O	O	3834
cortical	ADJ	O	O	3834
epileptic	ADJ	O	Disease	3834
activity	NOUN	O	O	3834
in	ADP	O	O	3834
penicillin	NOUN	O	Chemical	3834
-	PUNCT	O	O	3834
induced	VERB	O	O	3834
epilepsy	NOUN	O	Disease	3834
model	NOUN	O	O	3834
.	PUNCT	O	O	3834
In	ADP	O	O	3835
group-1	ADJ	O	O	3835
(	PUNCT	O	O	3835
n=10	VERB	O	O	3835
)	PUNCT	O	O	3835
hippocampal	NOUN	O	O	3835
DBS	PROPN	O	O	3835
was	AUX	O	O	3835
off	ADP	O	O	3835
and	CCONJ	O	O	3835
in	ADP	O	O	3835
the	PRON	O	O	3835
group-2	NUM	O	O	3835
(	PUNCT	O	O	3835
n=10	VERB	O	O	3835
)	PUNCT	O	O	3835
hippocampal	NOUN	O	O	3835
DBS	PROPN	O	O	3835
was	AUX	O	O	3835
on	ADP	O	O	3835
(	PUNCT	O	O	3835
185	NUM	O	O	3835
Hz	NOUN	O	O	3835
,	PUNCT	O	O	3835
0.5V	NOUN	O	O	3835
,	PUNCT	O	O	3835
1V	ADJ	O	O	3835
,	PUNCT	O	O	3835
2V	VERB	O	O	3835
,	PUNCT	O	O	3835
and	CCONJ	O	O	3835
5V	X	O	O	3835
for	ADP	O	O	3835
60	NUM	O	O	3835
sec	PROPN	O	O	3835
)	PUNCT	O	O	3835
following	VERB	O	O	3835
penicillin G	NOUN	O	Chemical	3835
injection	NOUN	O	O	3835
intracortically	ADV	O	O	3835
.	PUNCT	O	O	3835
EEG	NOUN	O	O	3836
recordings	NOUN	O	O	3836
were	AUX	O	O	3836
obtained	VERB	O	O	3836
before	ADP	O	O	3836
and	CCONJ	O	O	3836
15	NUM	O	O	3836
minutes	NOUN	O	O	3836
following	VERB	O	O	3836
penicillin	NOUN	O	Chemical	3836
-	PUNCT	O	O	3836
G	NOUN	O	O	3836
injection	NOUN	O	O	3836
,	PUNCT	O	O	3836
and	CCONJ	O	O	3836
at	ADP	O	O	3836
10th	ADJ	O	O	3836
minutes	NOUN	O	O	3836
following	VERB	O	O	3836
each	PRON	O	O	3836
stimulus	NOUN	O	O	3836
for	ADP	O	O	3836
analysis	NOUN	O	O	3836
in	ADP	O	O	3836
terms	NOUN	O	O	3836
of	ADP	O	O	3836
frequency	NOUN	O	O	3836
,	PUNCT	O	O	3836
amplitude	VERB	O	O	3836
,	PUNCT	O	O	3836
and	CCONJ	O	O	3836
power	NOUN	O	O	3836
spectrum	NOUN	O	O	3836
.	PUNCT	O	O	3836
High	ADJ	O	O	3837
frequency	NOUN	O	O	3837
hippocampal	NOUN	O	O	3837
DBS	PROPN	O	O	3837
suppressed	VERB	O	O	3837
the	PRON	O	O	3837
acute	ADJ	O	O	3837
penicillin	NOUN	O	Chemical	3837
-	PUNCT	O	O	3837
induced	VERB	O	O	3837
cortical	ADJ	O	O	3837
epileptic	ADJ	O	Disease	3837
activity	NOUN	O	O	3837
independent	ADJ	O	O	3837
from	ADP	O	O	3837
stimulus	NOUN	O	O	3837
intensity	NOUN	O	O	3837
.	PUNCT	O	O	3837
CONCLUSION	PROPN	O	O	3838
:	PUNCT	O	O	3838
Our	PRON	O	O	3838
results	VERB	O	O	3838
revealed	VERB	O	O	3838
that	SCONJ	O	O	3838
continuous	ADJ	O	O	3838
high	ADJ	O	O	3838
frequency	NOUN	O	O	3838
stimulation	NOUN	O	O	3838
of	ADP	O	O	3838
the	PRON	O	O	3838
hippocampus	NOUN	O	O	3838
suppressed	VERB	O	O	3838
acute	ADJ	O	O	3838
cortical	ADJ	O	O	3838
epileptic	ADJ	O	Disease	3838
activity	NOUN	O	O	3838
effectively	ADV	O	O	3838
without	ADP	O	O	3838
causing	VERB	O	O	3838
secondary	ADJ	O	O	3838
epileptic	ADJ	O	Disease	3838
discharges	VERB	O	O	3838
.	PUNCT	O	O	3838
These	PRON	O	O	3839
results	VERB	O	O	3839
are	AUX	O	O	3839
important	ADJ	O	O	3839
in	ADP	O	O	3839
terms	NOUN	O	O	3839
of	ADP	O	O	3839
defining	VERB	O	O	3839
the	PRON	O	O	3839
optimal	ADJ	O	O	3839
parameters	NOUN	O	O	3839
of	ADP	O	O	3839
hippocampal	NOUN	O	O	3839
DBS	PROPN	O	O	3839
in	ADP	O	O	3839
patients	NOUN	O	O	3839
with	ADP	O	O	3839
epilepsy	NOUN	O	Disease	3839
.	PUNCT	O	O	3839
Neural	NOUN	O	O	3842
correlates	VERB	O	O	3842
of	ADP	O	O	3842
S	NOUN	O	O	3842
-	PUNCT	O	O	3842
ketamine	VERB	O	Chemical	3842
induced	VERB	O	O	3842
psychosis	VERB	O	Disease	3842
during	ADP	O	O	3842
overt	ADJ	O	O	3842
continuous	ADJ	O	O	3842
verbal	ADJ	O	O	3842
fluency	NOUN	O	O	3842
.	PUNCT	O	O	3842
N	NUM	O	O	3843
-	PUNCT	O	O	3843
methyl	NOUN	O	O	3843
-	PUNCT	O	O	3843
D	NOUN	O	O	3843
-	PUNCT	O	O	3843
aspartate	NOUN	O	Chemical	3843
(	PUNCT	O	O	3843
NMDA	PROPN	O	Chemical	3843
)	PUNCT	O	O	3843
receptor	NOUN	O	O	3844
has	VERB	O	O	3844
been	AUX	O	O	3844
implicated	VERB	O	O	3844
in	ADP	O	O	3844
the	PRON	O	O	3844
pathophysiology	NOUN	O	O	3844
of	ADP	O	O	3844
schizophrenia	PROPN	O	Disease	3844
.	PUNCT	O	O	3844
Administered	VERB	O	O	3845
to	PART	O	O	3845
healthy	ADJ	O	O	3845
volunteers	NOUN	O	O	3845
,	PUNCT	O	O	3845
a	PRON	O	O	3845
subanesthetic	NOUN	O	O	3845
dose	NOUN	O	O	3845
of	ADP	O	O	3845
the	PRON	O	O	3845
non	ADJ	O	O	3845
-	PUNCT	O	O	3845
competitive	ADJ	O	O	3845
NMDA	PROPN	O	Chemical	3845
receptor	NOUN	O	O	3845
antagonist	NOUN	O	O	3845
ketamine	VERB	O	Chemical	3845
leads	VERB	O	O	3845
to	PART	O	O	3845
psychopathological	ADJ	O	O	3845
symptoms	NOUN	O	O	3845
similar	ADJ	O	O	3845
to	PART	O	O	3845
those	PRON	O	O	3845
observed	VERB	O	O	3845
in	ADP	O	O	3845
schizophrenia	PROPN	O	Disease	3845
.	PUNCT	O	O	3845
In	ADP	O	O	3846
patients	NOUN	O	O	3846
with	ADP	O	O	3846
schizophrenia	PROPN	O	Disease	3846
,	PUNCT	O	O	3846
ketamine	VERB	O	Chemical	3846
exacerbates	VERB	O	O	3846
the	PRON	O	O	3846
core	NOUN	O	O	3846
symptoms	NOUN	O	O	3846
of	ADP	O	O	3846
illness	VERB	O	O	3846
,	PUNCT	O	O	3846
supporting	VERB	O	O	3846
the	PRON	O	O	3846
hypothesis	NOUN	O	O	3846
of	ADP	O	O	3846
a	PRON	O	O	3846
glutamatergic dysfunction	NOUN	O	Disease	3846
.	PUNCT	O	O	3846
In	ADP	O	O	3847
a	PRON	O	O	3847
counterbalanced	VERB	O	O	3847
,	PUNCT	O	O	3847
placebo	NOUN	O	O	3847
-	PUNCT	O	O	3847
controlled	VERB	O	O	3847
,	PUNCT	O	O	3847
double	ADJ	O	O	3847
-	PUNCT	O	O	3847
blind	ADJ	O	Disease	3847
study	VERB	O	O	3847
design	NOUN	O	O	3847
,	PUNCT	O	O	3847
healthy	ADJ	O	O	3847
subjects	NOUN	O	O	3847
were	AUX	O	O	3847
administered	VERB	O	O	3847
a	PRON	O	O	3847
continuous	ADJ	O	O	3847
subanesthetic	NOUN	O	O	3847
S	NOUN	O	O	3847
-	PUNCT	O	O	3847
ketamine	VERB	O	Chemical	3847
infusion	NOUN	O	O	3847
while	SCONJ	O	O	3847
differences	NOUN	O	O	3847
in	ADP	O	O	3847
BOLD	ADJ	O	O	3847
responses	NOUN	O	O	3847
measured	VERB	O	O	3847
with	ADP	O	O	3847
fMRI	PROPN	O	O	3847
were	AUX	O	O	3847
detected	VERB	O	O	3847
.	PUNCT	O	O	3847
Ketamine	PROPN	O	Chemical	3848
-	PUNCT	O	O	3848
induced	VERB	O	O	3848
psychopathological	ADJ	O	O	3848
symptoms	NOUN	O	O	3848
were	AUX	O	O	3848
assessed	VERB	O	O	3848
with	ADP	O	O	3848
the	PRON	O	O	3848
Positive	PROPN	O	O	3848
and	CCONJ	O	O	3848
Negative	ADJ	O	O	3848
Syndrome	NOUN	O	O	3848
Scale	NOUN	O	O	3848
(	PUNCT	O	O	3848
PANSS	PROPN	O	O	3848
)	PUNCT	O	O	3848
.	PUNCT	O	O	3848
Ketamine	PROPN	O	Chemical	3849
elicited	VERB	O	O	3849
psychosis	VERB	O	Disease	3849
like	INTJ	O	O	3849
psychopathology	NOUN	O	O	3849
.	PUNCT	O	O	3849
Post	NOUN	O	O	3850
-	PUNCT	O	O	3850
hoc	PROPN	O	O	3850
t	NOUN	O	O	3850
-	PUNCT	O	O	3850
tests	VERB	O	O	3850
revealed	VERB	O	O	3850
significant	ADJ	O	O	3850
differences	NOUN	O	O	3850
between	ADP	O	O	3850
placebo	NOUN	O	O	3850
and	CCONJ	O	O	3850
ketamine	VERB	O	Chemical	3850
for	ADP	O	O	3850
the	PRON	O	O	3850
amounts	VERB	O	O	3850
of	ADP	O	O	3850
words	VERB	O	O	3850
generated	VERB	O	O	3850
during	ADP	O	O	3850
lexical	ADJ	O	O	3850
and	CCONJ	O	O	3850
semantic	ADJ	O	O	3850
verbal	ADJ	O	O	3850
fluency	NOUN	O	O	3850
,	PUNCT	O	O	3850
while	SCONJ	O	O	3850
the	PRON	O	O	3850
phonological	ADJ	O	O	3850
domain	NOUN	O	O	3850
remained	VERB	O	O	3850
unaffected	ADJ	O	O	3850
.	PUNCT	O	O	3850
Ketamine	PROPN	O	Chemical	3851
led	VERB	O	O	3851
to	PART	O	O	3851
enhanced	VERB	O	O	3851
cortical	ADJ	O	O	3851
activations	VERB	O	O	3851
in	ADP	O	O	3851
supramarginal	PROPN	O	O	3851
and	CCONJ	O	O	3851
frontal	ADJ	O	O	3851
brain	NOUN	O	O	3851
regions	NOUN	O	O	3851
for	ADP	O	O	3851
phonological	ADJ	O	O	3851
and	CCONJ	O	O	3851
lexical	ADJ	O	O	3851
verbal	ADJ	O	O	3851
fluency	NOUN	O	O	3851
,	PUNCT	O	O	3851
but	CCONJ	O	O	3851
not	PART	O	O	3851
for	ADP	O	O	3851
semantic	ADJ	O	O	3851
verbal	ADJ	O	O	3851
fluency	NOUN	O	O	3851
.	PUNCT	O	O	3851
Ketamine	PROPN	O	Chemical	3852
induces	VERB	O	O	3852
activation	NOUN	O	O	3852
changes	VERB	O	O	3852
in	ADP	O	O	3852
healthy	ADJ	O	O	3852
subjects	NOUN	O	O	3852
similar	ADJ	O	O	3852
to	PART	O	O	3852
those	PRON	O	O	3852
observed	VERB	O	O	3852
in	ADP	O	O	3852
patients	NOUN	O	O	3852
with	ADP	O	O	3852
schizophrenia	PROPN	O	Disease	3852
,	PUNCT	O	O	3852
particularly	ADV	O	O	3852
in	ADP	O	O	3852
frontal	ADJ	O	O	3852
and	CCONJ	O	O	3852
temporal	ADJ	O	O	3852
brain	NOUN	O	O	3852
regions	NOUN	O	O	3852
.	PUNCT	O	O	3852
Our	PRON	O	O	3853
results	VERB	O	O	3853
provide	VERB	O	O	3853
further	ADV	O	O	3853
support	NOUN	O	O	3853
for	ADP	O	O	3853
the	PRON	O	O	3853
hypothesis	NOUN	O	O	3853
of	ADP	O	O	3853
an	PRON	O	O	3853
NMDA	PROPN	O	Chemical	3853
receptor	NOUN	O	O	3853
dysfunction	NOUN	O	O	3853
in	ADP	O	O	3853
the	PRON	O	O	3853
pathophysiology	NOUN	O	O	3853
of	ADP	O	O	3853
schizophrenia	PROPN	O	Disease	3853
.	PUNCT	O	O	3853
Dopamine	NOUN	O	Chemical	3856
is	AUX	O	O	3856
not	PART	O	O	3856
essential	ADJ	O	O	3856
for	ADP	O	O	3856
the	PRON	O	O	3856
development	NOUN	O	O	3856
of	ADP	O	O	3856
methamphetamine	NOUN	O	Chemical	3856
-	PUNCT	O	O	3856
induced	VERB	O	O	3856
neurotoxicity	NOUN	O	Disease	3856
.	PUNCT	O	O	3856
It	PRON	O	O	3857
is	AUX	O	O	3857
widely	ADV	O	O	3857
believed	VERB	O	O	3857
that	SCONJ	O	O	3857
dopamine	NOUN	O	Chemical	3857
(	PUNCT	O	O	3857
DA	NOUN	O	Chemical	3857
)	PUNCT	O	O	3857
mediates	VERB	O	O	3857
methamphetamine	NOUN	O	Chemical	3857
(	PUNCT	O	O	3857
METH)-induced	VERB	O	O	3857
toxicity	NOUN	O	Disease	3857
to	PART	O	O	3857
brain	NOUN	O	O	3857
dopaminergic	ADJ	O	O	3857
neurons	NOUN	O	O	3857
,	PUNCT	O	O	3857
because	SCONJ	O	O	3857
drugs	NOUN	O	O	3857
that	SCONJ	O	O	3857
interfere	VERB	O	O	3857
with	ADP	O	O	3857
DA	NOUN	O	Chemical	3857
neurotransmission	NOUN	O	O	3857
decrease	VERB	O	O	3857
toxicity	NOUN	O	Disease	3857
,	PUNCT	O	O	3857
whereas	SCONJ	O	O	3857
drugs	NOUN	O	O	3857
that	SCONJ	O	O	3857
increase	VERB	O	O	3857
DA	NOUN	O	Chemical	3857
neurotransmission	NOUN	O	O	3857
enhance	VERB	O	O	3857
toxicity	NOUN	O	Disease	3857
.	PUNCT	O	O	3857
However	ADV	O	O	3858
,	PUNCT	O	O	3858
temperature	NOUN	O	O	3858
effects	NOUN	O	O	3858
of	ADP	O	O	3858
drugs	NOUN	O	O	3858
that	SCONJ	O	O	3858
have	VERB	O	O	3858
been	AUX	O	O	3858
used	VERB	O	O	3858
to	PART	O	O	3858
manipulate	VERB	O	O	3858
brain	NOUN	O	O	3858
DA	NOUN	O	Chemical	3858
neurotransmission	NOUN	O	O	3858
confound	VERB	O	O	3858
interpretation	NOUN	O	O	3858
of	ADP	O	O	3858
the	PRON	O	O	3858
data	NOUN	O	O	3858
.	PUNCT	O	O	3858
Here	ADV	O	O	3859
we	PRON	O	O	3859
show	VERB	O	O	3859
that	SCONJ	O	O	3859
the	PRON	O	O	3859
recently	ADV	O	O	3859
reported	VERB	O	O	3859
ability	NOUN	O	O	3859
of	ADP	O	O	3859
L	NOUN	O	O	3859
-	PUNCT	O	O	3859
dihydroxyphenylalanine	PROPN	O	O	3859
to	PART	O	O	3859
reverse	VERB	O	O	3859
the	PRON	O	O	3859
protective	ADJ	O	O	3859
effect	VERB	O	O	3859
of	ADP	O	O	3859
alpha	PROPN	O	O	3859
-	PUNCT	O	O	3859
methyl	NOUN	O	O	3859
-	PUNCT	O	O	3859
para	PROPN	O	O	3859
-	PUNCT	O	O	3859
tyrosine	NOUN	O	Chemical	3859
on	ADP	O	O	3859
METH	NOUN	O	Chemical	3859
-	PUNCT	O	O	3859
induced	VERB	O	O	3859
DA	NOUN	O	Chemical	3859
neurotoxicity	NOUN	O	Disease	3859
is	AUX	O	O	3859
also	ADV	O	O	3859
confounded	VERB	O	O	3859
by	ADP	O	O	3859
drug	NOUN	O	O	3859
effects	NOUN	O	O	3859
on	ADP	O	O	3859
body	NOUN	O	O	3859
temperature	NOUN	O	O	3859
.	PUNCT	O	O	3859
Further	ADV	O	O	3860
,	PUNCT	O	O	3860
we	PRON	O	O	3860
show	VERB	O	O	3860
that	SCONJ	O	O	3860
mice	NOUN	O	O	3860
genetically	ADV	O	O	3860
engineered	VERB	O	O	3860
to	PART	O	O	3860
be	AUX	O	O	3860
deficient	ADJ	O	O	3860
in	ADP	O	O	3860
brain	NOUN	O	O	3860
DA	NOUN	O	Chemical	3860
develop	VERB	O	O	3860
METH	NOUN	O	Chemical	3860
neurotoxicity	NOUN	O	Disease	3860
,	PUNCT	O	O	3860
as	ADP	O	O	3860
long	ADV	O	O	3860
as	ADP	O	O	3860
the	PRON	O	O	3860
thermic	ADJ	O	O	3860
effects	NOUN	O	O	3860
of	ADP	O	O	3860
METH	NOUN	O	Chemical	3860
are	AUX	O	O	3860
preserved	VERB	O	O	3860
.	PUNCT	O	O	3860
In	ADP	O	O	3861
addition	NOUN	O	O	3861
,	PUNCT	O	O	3861
we	PRON	O	O	3861
demonstrate	VERB	O	O	3861
that	SCONJ	O	O	3861
mice	NOUN	O	O	3861
genetically	ADV	O	O	3861
engineered	VERB	O	O	3861
to	PART	O	O	3861
have	VERB	O	O	3861
unilateral	ADJ	O	O	3861
brain	NOUN	O	O	3861
DA	NOUN	O	Chemical	3861
deficits	NOUN	O	O	3861
develop	VERB	O	O	3861
METH	NOUN	O	Chemical	3861
-	PUNCT	O	O	3861
induced	VERB	O	O	3861
dopaminergic deficits	NOUN	O	Disease	3861
that	SCONJ	O	O	3861
are	AUX	O	O	3861
of	ADP	O	O	3861
comparable	ADJ	O	O	3861
magnitude	NOUN	O	O	3861
on	ADP	O	O	3861
both	PRON	O	O	3861
sides	NOUN	O	O	3861
of	ADP	O	O	3861
the	PRON	O	O	3861
brain	NOUN	O	O	3861
.	PUNCT	O	O	3861
Taken	VERB	O	O	3862
together	ADV	O	O	3862
,	PUNCT	O	O	3862
these	PRON	O	O	3862
findings	NOUN	O	O	3862
demonstrate	VERB	O	O	3862
that	SCONJ	O	O	3862
DA	NOUN	O	Chemical	3862
is	AUX	O	O	3862
not	PART	O	O	3862
essential	ADJ	O	O	3862
for	ADP	O	O	3862
the	PRON	O	O	3862
development	NOUN	O	O	3862
of	ADP	O	O	3862
METH	NOUN	O	Chemical	3862
-	PUNCT	O	O	3862
induced	VERB	O	O	3862
dopaminergic	ADJ	O	O	3862
neurotoxicity	NOUN	O	Disease	3862
and	CCONJ	O	O	3862
suggest	VERB	O	O	3862
that	SCONJ	O	O	3862
mechanisms	NOUN	O	O	3862
independent	ADJ	O	O	3862
of	ADP	O	O	3862
DA	NOUN	O	Chemical	3862
warrant	NOUN	O	O	3862
more	ADJ	O	O	3862
intense	ADJ	O	O	3862
investigation	NOUN	O	O	3862
.	PUNCT	O	O	3862
Brainstem dysgenesis	NOUN	O	Disease	3865
in	ADP	O	O	3865
an	PRON	O	O	3865
infant	NOUN	O	O	3865
prenatally	ADV	O	O	3865
exposed	VERB	O	O	3865
to	PART	O	O	3865
cocaine	NOUN	O	Chemical	3865
.	PUNCT	O	O	3865
Many	ADJ	O	O	3866
authors	NOUN	O	O	3866
described	VERB	O	O	3866
the	PRON	O	O	3866
effects	NOUN	O	O	3866
on	ADP	O	O	3866
the	PRON	O	O	3866
fetus	NOUN	O	O	3866
of	ADP	O	O	3866
maternal	ADJ	O	O	3866
cocaine abuse	NOUN	O	Disease	3866
during	ADP	O	O	3866
pregnancy	NOUN	O	O	3866
.	PUNCT	O	O	3866
Vasoconstriction	NOUN	O	O	3867
appears	VERB	O	O	3867
to	PART	O	O	3867
be	AUX	O	O	3867
the	PRON	O	O	3867
common	ADJ	O	O	3867
mechanism	NOUN	O	O	3867
of	ADP	O	O	3867
action	NOUN	O	O	3867
leading	VERB	O	O	3867
to	PART	O	O	3867
a	PRON	O	O	3867
wide	ADV	O	O	3867
range	VERB	O	O	3867
of	ADP	O	O	3867
fetal anomalies	NOUN	O	Disease	3867
.	PUNCT	O	O	3867
We	PRON	O	O	3868
report	VERB	O	O	3868
on	ADP	O	O	3868
an	PRON	O	O	3868
infant	NOUN	O	O	3868
with	ADP	O	O	3868
multiple	ADJ	O	O	3868
cranial	ADJ	O	O	3868
-	PUNCT	O	O	3868
nerve	NOUN	O	O	3868
involvement	NOUN	O	O	3868
attributable	ADJ	O	O	3868
to	PART	O	O	3868
brainstem dysgenesis	NOUN	O	Disease	3868
,	PUNCT	O	O	3868
born	VERB	O	O	3868
to	PART	O	O	3868
a	PRON	O	O	3868
cocaine	NOUN	O	Chemical	3868
-	PUNCT	O	O	3868
addicted	VERB	O	O	3868
mother	NOUN	O	O	3868
.	PUNCT	O	O	3868
The	PRON	O	O	3871
protective	ADJ	O	O	3871
role	NOUN	O	O	3871
of	ADP	O	O	3871
Nrf2	NUM	O	O	3871
in	ADP	O	O	3871
streptozotocin	PROPN	O	Chemical	3871
-	PUNCT	O	O	3871
induced	VERB	O	O	3871
diabetic nephropathy	NOUN	O	Disease	3871
.	PUNCT	O	O	3871
Diabetic nephropathy	NOUN	O	Disease	3872
is	AUX	O	O	3872
one	NUM	O	O	3872
of	ADP	O	O	3872
the	PRON	O	O	3872
major	ADJ	O	O	3872
causes	VERB	O	O	3872
of	ADP	O	O	3872
renal failure	NOUN	O	Disease	3872
,	PUNCT	O	O	3872
which	PRON	O	O	3872
is	AUX	O	O	3872
accompanied	VERB	O	O	3872
by	ADP	O	O	3872
the	PRON	O	O	3872
production	NOUN	O	O	3872
of	ADP	O	O	3872
reactive	ADJ	O	O	3872
oxygen	NOUN	O	Chemical	3872
species	NOUN	O	O	3872
(	PUNCT	O	O	3872
ROS	PROPN	O	O	3872
)	PUNCT	O	O	3872
.	PUNCT	O	O	3872
Here	ADV	O	O	3873
,	PUNCT	O	O	3873
we	PRON	O	O	3873
report	VERB	O	O	3873
our	PRON	O	O	3873
findings	NOUN	O	O	3873
demonstrating	VERB	O	O	3873
a	PRON	O	O	3873
protective	ADJ	O	O	3873
role	NOUN	O	O	3873
of	ADP	O	O	3873
Nrf2	NUM	O	O	3873
against	ADP	O	O	3873
diabetic nephropathy	NOUN	O	Disease	3873
.	PUNCT	O	O	3873
We	PRON	O	O	3874
explore	VERB	O	O	3874
the	PRON	O	O	3874
protective	ADJ	O	O	3874
role	NOUN	O	O	3874
of	ADP	O	O	3874
Nrf2	NUM	O	O	3874
against	ADP	O	O	3874
diabetic nephropathy	NOUN	O	Disease	3874
using	VERB	O	O	3874
human	PROPN	O	O	3874
kidney	NOUN	O	O	3874
biopsy	PROPN	O	O	3874
tissues	NOUN	O	O	3874
from	ADP	O	O	3874
diabetic nephropathy	NOUN	O	Disease	3874
patients	NOUN	O	O	3874
,	PUNCT	O	O	3874
a	PRON	O	O	3874
streptozotocin	PROPN	O	Chemical	3874
-	PUNCT	O	O	3874
induced	VERB	O	O	3874
diabetic nephropathy	NOUN	O	Disease	3874
model	NOUN	O	O	3874
in	ADP	O	O	3874
Nrf2(-/-	NUM	O	O	3874
)	PUNCT	O	O	3874
mice	NOUN	O	O	3874
,	PUNCT	O	O	3874
and	CCONJ	O	O	3874
cultured	ADJ	O	O	3874
human	PROPN	O	O	3874
mesangial	ADJ	O	O	3874
cells	NOUN	O	O	3874
.	PUNCT	O	O	3874
The	PRON	O	O	3875
glomeruli	VERB	O	O	3875
of	ADP	O	O	3875
human	PROPN	O	O	3875
diabetic nephropathy	NOUN	O	Disease	3875
patients	NOUN	O	O	3875
were	AUX	O	O	3875
under	ADP	O	O	3875
oxidative	NOUN	O	O	3875
stress	NOUN	O	O	3875
and	CCONJ	O	O	3875
had	VERB	O	O	3875
elevated	ADJ	O	O	3875
Nrf2	NUM	O	O	3875
levels	NOUN	O	O	3875
.	PUNCT	O	O	3875
In	ADP	O	O	3876
the	PRON	O	O	3876
animal	NOUN	O	O	3876
study	VERB	O	O	3876
,	PUNCT	O	O	3876
Nrf2	NUM	O	O	3876
was	AUX	O	O	3876
demonstrated	VERB	O	O	3876
to	PART	O	O	3876
be	AUX	O	O	3876
crucial	ADJ	O	O	3876
in	ADP	O	O	3876
ameliorating	VERB	O	O	3876
streptozotocin	PROPN	O	Chemical	3876
-	PUNCT	O	O	3876
induced	VERB	O	O	3876
renal damage	NOUN	O	Disease	3876
.	PUNCT	O	O	3876
This	PRON	O	O	3877
is	AUX	O	O	3877
evident	ADJ	O	O	3877
by	ADP	O	O	3877
Nrf2(-/-	NUM	O	O	3877
)	PUNCT	O	O	3877
mice	NOUN	O	O	3877
having	VERB	O	O	3877
higher	ADJ	O	O	3877
ROS	PROPN	O	O	3877
production	NOUN	O	O	3877
and	CCONJ	O	O	3877
suffering	VERB	O	O	3877
from	ADP	O	O	3877
greater	ADJ	O	O	3877
oxidative	NOUN	O	O	3877
DNA	NOUN	O	O	3877
damage	NOUN	O	O	3877
and	CCONJ	O	O	3877
renal injury	NOUN	O	Disease	3877
compared	VERB	O	O	3877
with	ADP	O	O	3877
Nrf2(+/+	NUM	O	O	3877
)	PUNCT	O	O	3877
mice	NOUN	O	O	3877
.	PUNCT	O	O	3877
Mechanistic	PROPN	O	O	3878
studies	NOUN	O	O	3878
in	ADP	O	O	3878
both	PRON	O	O	3878
in	ADP	O	O	3878
vivo	VERB	O	O	3878
and	CCONJ	O	O	3878
in	ADP	O	O	3878
vitro	X	O	O	3878
systems	NOUN	O	O	3878
showed	VERB	O	O	3878
that	SCONJ	O	O	3878
the	PRON	O	O	3878
Nrf2-mediated	VERB	O	O	3878
protection	NOUN	O	O	3878
against	ADP	O	O	3878
diabetic nephropathy	NOUN	O	Disease	3878
is	AUX	O	O	3878
,	PUNCT	O	O	3878
at	ADP	O	O	3878
least	ADJ	O	O	3878
,	PUNCT	O	O	3878
partially	ADV	O	O	3878
through	ADP	O	O	3878
inhibition	NOUN	O	O	3878
of	ADP	O	O	3878
transforming	VERB	O	O	3878
growth	NOUN	O	O	3878
factor	NOUN	O	O	3878
-	PUNCT	O	O	3878
beta1	NOUN	O	O	3878
(	PUNCT	O	O	3878
TGF	PROPN	O	O	3878
-	PUNCT	O	O	3878
beta1	NOUN	O	O	3878
)	PUNCT	O	O	3878
and	CCONJ	O	O	3878
reduction	NOUN	O	O	3878
of	ADP	O	O	3878
extracellular	ADJ	O	O	3878
matrix	NOUN	O	O	3878
production	NOUN	O	O	3878
.	PUNCT	O	O	3878
In	ADP	O	O	3879
human	PROPN	O	O	3879
renal	ADJ	O	O	3879
mesangial	ADJ	O	O	3879
cells	NOUN	O	O	3879
,	PUNCT	O	O	3879
high	ADJ	O	O	3879
glucose	NOUN	O	Chemical	3879
induced	VERB	O	O	3879
ROS	PROPN	O	O	3879
production	NOUN	O	O	3879
and	CCONJ	O	O	3879
activated	VERB	O	O	3879
expression	NOUN	O	O	3879
of	ADP	O	O	3879
Nrf2	NUM	O	O	3879
and	CCONJ	O	O	3879
its	PRON	O	O	3879
downstream	ADJ	O	O	3879
genes	NOUN	O	O	3879
.	PUNCT	O	O	3879
This	PRON	O	O	3880
work	NOUN	O	O	3880
clearly	ADV	O	O	3880
indicates	VERB	O	O	3880
a	PRON	O	O	3880
protective	ADJ	O	O	3880
role	NOUN	O	O	3880
of	ADP	O	O	3880
Nrf2	NUM	O	O	3880
in	ADP	O	O	3880
diabetic nephropathy	NOUN	O	Disease	3880
,	PUNCT	O	O	3880
suggesting	VERB	O	O	3880
that	SCONJ	O	O	3880
dietary	ADJ	O	O	3880
or	CCONJ	O	O	3880
therapeutic	ADJ	O	O	3880
activation	NOUN	O	O	3880
of	ADP	O	O	3880
Nrf2	NUM	O	O	3880
could	AUX	O	O	3880
be	AUX	O	O	3880
used	VERB	O	O	3880
as	ADP	O	O	3880
a	PRON	O	O	3880
strategy	NOUN	O	O	3880
to	PART	O	O	3880
prevent	VERB	O	O	3880
or	CCONJ	O	O	3880
slow	VERB	O	O	3880
down	ADP	O	O	3880
the	PRON	O	O	3880
progression	NOUN	O	O	3880
of	ADP	O	O	3880
diabetic nephropathy	NOUN	O	Disease	3880
.	PUNCT	O	O	3880
High	ADJ	O	O	3883
-	PUNCT	O	O	3883
dose	NOUN	O	O	3883
tranexamic Acid	PROPN	O	Chemical	3883
is	AUX	O	O	3883
associated	VERB	O	O	3883
with	ADP	O	O	3883
nonischemic	ADJ	O	O	3883
clinical	ADJ	O	O	3883
seizures	NOUN	O	Disease	3883
in	ADP	O	O	3883
cardiac	ADJ	O	O	3883
surgical	ADJ	O	O	3883
patients	NOUN	O	O	3883
.	PUNCT	O	O	3883
In	ADP	O	O	3884
2	X	O	O	3884
separate	VERB	O	O	3884
centers	NOUN	O	O	3884
,	PUNCT	O	O	3884
we	PRON	O	O	3884
observed	VERB	O	O	3884
a	PRON	O	O	3884
notable	ADJ	O	O	3884
increase	VERB	O	O	3884
in	ADP	O	O	3884
the	PRON	O	O	3884
incidence	NOUN	O	O	3884
of	ADP	O	O	3884
postoperative	ADJ	O	O	3884
convulsive	ADJ	O	Disease	3884
seizures	NOUN	O	Disease	3884
from	ADP	O	O	3884
1.3%	NOUN	O	O	3884
to	PART	O	O	3884
3.8%	NOUN	O	O	3884
in	ADP	O	O	3884
patients	NOUN	O	O	3884
having	VERB	O	O	3884
undergone	VERB	O	O	3884
major	ADJ	O	O	3884
cardiac	ADJ	O	O	3884
surgical	ADJ	O	O	3884
procedures	NOUN	O	O	3884
.	PUNCT	O	O	3884
These	PRON	O	O	3885
events	NOUN	O	O	3885
were	AUX	O	O	3885
temporally	ADV	O	O	3885
coincident	VERB	O	O	3885
with	ADP	O	O	3885
the	PRON	O	O	3885
initial	ADJ	O	O	3885
use	VERB	O	O	3885
of	ADP	O	O	3885
high	ADJ	O	O	3885
-	PUNCT	O	O	3885
dose	NOUN	O	O	3885
tranexamic acid	PROPN	O	Chemical	3885
(	PUNCT	O	O	3885
TXA	PROPN	O	Chemical	3885
)	PUNCT	O	O	3885
therapy	NOUN	O	O	3885
after	ADP	O	O	3885
withdrawal	NOUN	O	O	3885
of	ADP	O	O	3885
aprotinin	PROPN	O	O	3885
from	ADP	O	O	3885
general	ADJ	O	O	3885
clinical	ADJ	O	O	3885
usage	NOUN	O	O	3885
.	PUNCT	O	O	3885
The	PRON	O	O	3886
purpose	NOUN	O	O	3886
of	ADP	O	O	3886
this	PRON	O	O	3886
review	VERB	O	O	3886
was	AUX	O	O	3886
to	PART	O	O	3886
perform	VERB	O	O	3886
a	PRON	O	O	3886
retrospective	ADJ	O	O	3886
analysis	NOUN	O	O	3886
to	PART	O	O	3886
examine	VERB	O	O	3886
whether	SCONJ	O	O	3886
there	ADV	O	O	3886
was	AUX	O	O	3886
a	PRON	O	O	3886
relation	NOUN	O	O	3886
between	ADP	O	O	3886
TXA	PROPN	O	Chemical	3886
usage	NOUN	O	O	3886
and	CCONJ	O	O	3886
seizures	NOUN	O	Disease	3886
after	ADP	O	O	3886
cardiac	ADJ	O	O	3886
surgery	NOUN	O	O	3886
.	PUNCT	O	O	3886
An	PRON	O	O	3887
in	ADP	O	O	3887
-	PUNCT	O	O	3887
depth	NOUN	O	O	3887
chart	NOUN	O	O	3887
review	VERB	O	O	3887
was	AUX	O	O	3887
undertaken	VERB	O	O	3887
in	ADP	O	O	3887
all	PRON	O	O	3887
24	NUM	O	O	3887
patients	NOUN	O	O	3887
who	PRON	O	O	3887
developed	VERB	O	O	3887
perioperative	ADJ	O	O	3887
seizures	NOUN	O	Disease	3887
.	PUNCT	O	O	3887
Twenty	NUM	O	O	3888
-	PUNCT	O	O	3888
one	NUM	O	O	3888
of	ADP	O	O	3888
the	PRON	O	O	3888
24	NUM	O	O	3888
patients	NOUN	O	O	3888
did	VERB	O	O	3888
not	PART	O	O	3888
have	VERB	O	O	3888
evidence	NOUN	O	O	3888
of	ADP	O	O	3888
new	ADJ	O	O	3888
cerebral ischemic injury	NOUN	O	Disease	3888
,	PUNCT	O	O	3888
but	CCONJ	O	O	3888
seizures	NOUN	O	Disease	3888
were	AUX	O	O	3888
likely	ADV	O	O	3888
due	ADJ	O	O	3888
to	PART	O	O	3888
ischemic brain injury	NOUN	O	Disease	3888
in	ADP	O	O	3888
3	X	O	O	3888
patients	NOUN	O	O	3888
.	PUNCT	O	O	3888
All	PRON	O	O	3889
patients	NOUN	O	O	3889
with	ADP	O	O	3889
seizures	NOUN	O	Disease	3889
did	VERB	O	O	3889
not	PART	O	O	3889
have	VERB	O	O	3889
permanent	ADJ	O	O	3889
neurological abnormalities	NOUN	O	Disease	3889
.	PUNCT	O	O	3889
All	PRON	O	O	3890
24	NUM	O	O	3890
patients	NOUN	O	O	3890
with	ADP	O	O	3890
seizures	NOUN	O	Disease	3890
received	VERB	O	O	3890
high	ADJ	O	O	3890
doses	NOUN	O	O	3890
of	ADP	O	O	3890
TXA	PROPN	O	Chemical	3890
intraoperatively	ADV	O	O	3890
ranging	VERB	O	O	3890
from	ADP	O	O	3890
61	NUM	O	O	3890
to	PART	O	O	3890
259	NUM	O	O	3890
mg	VERB	O	O	3890
/	PUNCT	O	O	3890
kg	VERB	O	O	3890
,	PUNCT	O	O	3890
had	VERB	O	O	3890
a	PRON	O	O	3890
mean	VERB	O	O	3890
age	NOUN	O	O	3890
of	ADP	O	O	3890
69.9	NUM	O	O	3890
years	NOUN	O	O	3890
,	PUNCT	O	O	3890
and	CCONJ	O	O	3890
21	NUM	O	O	3890
of	ADP	O	O	3890
24	NUM	O	O	3890
had	VERB	O	O	3890
undergone	VERB	O	O	3890
open	VERB	O	O	3890
chamber	PROPN	O	O	3890
rather	ADV	O	O	3890
than	ADP	O	O	3890
coronary	ADJ	O	O	3890
bypass	NOUN	O	O	3890
procedures	NOUN	O	O	3890
.	PUNCT	O	O	3890
No	PRON	O	O	3891
evidence	NOUN	O	O	3891
of	ADP	O	O	3891
brain ischemic	VERB	O	Disease	3891
,	PUNCT	O	O	3891
metabolic	ADJ	O	O	3891
,	PUNCT	O	O	3891
or	CCONJ	O	O	3891
hyperthermia	NOUN	O	Disease	3891
-	PUNCT	O	O	3891
induced	VERB	O	O	3891
causes	VERB	O	O	3891
for	ADP	O	O	3891
their	PRON	O	O	3891
seizures	NOUN	O	Disease	3891
was	AUX	O	O	3891
apparent	ADJ	O	O	3891
.	PUNCT	O	O	3891
:	PUNCT	O	O	3892
Our	PRON	O	O	3892
results	VERB	O	O	3892
suggest	VERB	O	O	3892
that	SCONJ	O	O	3892
use	VERB	O	O	3892
of	ADP	O	O	3892
high	ADJ	O	O	3892
-	PUNCT	O	O	3892
dose	NOUN	O	O	3892
TXA	PROPN	O	Chemical	3892
in	ADP	O	O	3892
older	ADJ	O	O	3892
patients	NOUN	O	O	3892
in	ADP	O	O	3892
conjunction	NOUN	O	O	3892
with	ADP	O	O	3892
cardiopulmonary	VERB	O	O	3892
bypass	NOUN	O	O	3892
and	CCONJ	O	O	3892
open	VERB	O	O	3892
-	PUNCT	O	O	3892
chamber	PROPN	O	O	3892
cardiac	ADJ	O	O	3892
surgery	NOUN	O	O	3892
is	AUX	O	O	3892
associated	VERB	O	O	3892
with	ADP	O	O	3892
clinical	ADJ	O	O	3892
seizures	NOUN	O	Disease	3892
in	ADP	O	O	3892
susceptible	ADJ	O	O	3892
patients	NOUN	O	O	3892
.	PUNCT	O	O	3892
Recurrent	ADJ	O	O	3895
dysosmia	NOUN	O	Disease	3895
induced	VERB	O	O	3895
by	ADP	O	O	3895
pyrazinamide	NOUN	O	Chemical	3895
.	PUNCT	O	O	3895
Pyrazinamide	NOUN	O	Chemical	3896
can	AUX	O	O	3896
have	VERB	O	O	3896
adverse	ADJ	O	O	3896
effects	NOUN	O	O	3896
such	ADJ	O	O	3896
as	ADP	O	O	3896
hepatic toxicity	NOUN	O	Disease	3896
,	PUNCT	O	O	3896
hyperuricemia	NOUN	O	Disease	3896
or	CCONJ	O	O	3896
digestive	ADJ	O	O	3896
disorders	NOUN	O	O	3896
.	PUNCT	O	O	3896
In	ADP	O	O	3897
rare	ADJ	O	O	3897
cases	NOUN	O	O	3897
,	PUNCT	O	O	3897
alterations	NOUN	O	O	3897
in	ADP	O	O	3897
taste	NOUN	O	O	3897
and	CCONJ	O	O	3897
smell	VERB	O	O	3897
function	NOUN	O	O	3897
have	VERB	O	O	3897
been	AUX	O	O	3897
reported	VERB	O	O	3897
for	ADP	O	O	3897
pyrazinamide	NOUN	O	Chemical	3897
when	SCONJ	O	O	3897
combined	VERB	O	O	3897
with	ADP	O	O	3897
other	ADJ	O	O	3897
drugs	NOUN	O	O	3897
.	PUNCT	O	O	3897
We	PRON	O	O	3898
report	VERB	O	O	3898
a	PRON	O	O	3898
case	NOUN	O	O	3898
of	ADP	O	O	3898
reversible	ADJ	O	O	3898
olfactory disorder	NOUN	O	Disease	3898
related	ADJ	O	O	3898
to	PART	O	O	3898
pyrazinamide	NOUN	O	Chemical	3898
in	ADP	O	O	3898
a	PRON	O	O	3898
woman	NOUN	O	O	3898
,	PUNCT	O	O	3898
with	ADP	O	O	3898
a	PRON	O	O	3898
positive	ADJ	O	O	3898
rechallenge	VERB	O	O	3898
.	PUNCT	O	O	3898
Dysosmia	NOUN	O	Disease	3899
disappeared	VERB	O	O	3899
completely	ADV	O	O	3899
after	ADP	O	O	3899
pyrazinamide	NOUN	O	Chemical	3899
withdrawal	NOUN	O	O	3899
and	CCONJ	O	O	3899
recurred	VERB	O	O	3899
after	ADP	O	O	3899
its	PRON	O	O	3899
rechallenge	VERB	O	O	3899
.	PUNCT	O	O	3899
Longitudinal	PROPN	O	O	3902
assessment	NOUN	O	O	3902
of	ADP	O	O	3902
air	NOUN	O	O	3902
conduction	NOUN	O	O	3902
audiograms	NOUN	O	O	3902
in	ADP	O	O	3902
a	PRON	O	O	3902
phase	NOUN	O	O	3902
III	NUM	O	O	3902
clinical	ADJ	O	O	3902
trial	NOUN	O	O	3902
of	ADP	O	O	3902
difluoromethylornithine	ADJ	O	Chemical	3902
and	CCONJ	O	O	3902
sulindac	PROPN	O	Chemical	3902
for	ADP	O	O	3902
prevention	NOUN	O	O	3902
of	ADP	O	O	3902
sporadic	ADJ	O	O	3902
colorectal adenomas	NOUN	O	Disease	3902
.	PUNCT	O	O	3902
A	PRON	O	O	3903
phase	NOUN	O	O	3903
III	NUM	O	O	3903
clinical	ADJ	O	O	3903
trial	NOUN	O	O	3903
assessed	VERB	O	O	3903
the	PRON	O	O	3903
recurrence	NOUN	O	O	3903
of	ADP	O	O	3903
adenomatous polyps	NOUN	O	Disease	3903
after	ADP	O	O	3903
treatment	NOUN	O	O	3903
for	ADP	O	O	3903
36	NUM	O	O	3903
months	NOUN	O	O	3903
with	ADP	O	O	3903
difluoromethylornithine	ADJ	O	Chemical	3903
(	PUNCT	O	O	3903
DFMO	PROPN	O	Chemical	3903
)	PUNCT	O	O	3903
plus	CCONJ	O	O	3903
sulindac	PROPN	O	Chemical	3903
or	CCONJ	O	O	3903
matched	VERB	O	O	3903
placebos	NOUN	O	O	3903
.	PUNCT	O	O	3903
Temporary	ADJ	O	O	3904
hearing loss	NOUN	O	Disease	3904
is	AUX	O	O	3904
a	PRON	O	O	3904
known	VERB	O	O	3904
toxicity	NOUN	O	Disease	3904
of	ADP	O	O	3904
treatment	NOUN	O	O	3904
with	ADP	O	O	3904
DFMO	PROPN	O	Chemical	3904
,	PUNCT	O	O	3904
thus	ADV	O	O	3904
a	PRON	O	O	3904
comprehensive	ADJ	O	O	3904
approach	NOUN	O	O	3904
was	AUX	O	O	3904
developed	VERB	O	O	3904
to	PART	O	O	3904
analyze	VERB	O	O	3904
serial	ADJ	O	O	3904
air	NOUN	O	O	3904
conduction	NOUN	O	O	3904
audiograms	NOUN	O	O	3904
.	PUNCT	O	O	3904
Based	VERB	O	O	3905
on	ADP	O	O	3905
290	NUM	O	O	3905
subjects	NOUN	O	O	3905
,	PUNCT	O	O	3905
there	ADV	O	O	3905
was	AUX	O	O	3905
an	PRON	O	O	3905
average	ADJ	O	O	3905
difference	NOUN	O	O	3905
of	ADP	O	O	3905
0.50	NUM	O	O	3905
dB	NOUN	O	O	3905
between	ADP	O	O	3905
subjects	NOUN	O	O	3905
treated	VERB	O	O	3905
with	ADP	O	O	3905
DFMO	PROPN	O	Chemical	3905
plus	CCONJ	O	O	3905
sulindac	PROPN	O	Chemical	3905
compared	VERB	O	O	3905
with	ADP	O	O	3905
those	PRON	O	O	3905
treated	VERB	O	O	3905
with	ADP	O	O	3905
placebo	NOUN	O	O	3905
(	PUNCT	O	O	3905
95%	NOUN	O	O	3905
confidence	NOUN	O	O	3905
interval	NOUN	O	O	3905
,	PUNCT	O	O	3905
-0.64	NUM	O	O	3905
to	PART	O	O	3905
1.63	NUM	O	O	3905
dB	NOUN	O	O	3905
;	PUNCT	O	O	3905
P	NOUN	O	Chemical	3905
=	PUNCT	O	O	3905
0.39	NUM	O	O	3905
)	PUNCT	O	O	3905
,	PUNCT	O	O	3905
adjusted	VERB	O	O	3905
for	ADP	O	O	3905
baseline	VERB	O	O	3905
values	NOUN	O	O	3905
,	PUNCT	O	O	3905
age	NOUN	O	O	3905
,	PUNCT	O	O	3905
and	CCONJ	O	O	3905
frequencies	NOUN	O	O	3905
.	PUNCT	O	O	3905
There	ADV	O	O	3906
were	AUX	O	O	3906
14	NUM	O	O	3906
of	ADP	O	O	3906
151	NUM	O	O	3906
(	PUNCT	O	O	3906
9.3%	NOUN	O	O	3906
)	PUNCT	O	O	3906
in	ADP	O	O	3906
the	PRON	O	O	3906
DFMO	PROPN	O	Chemical	3906
plus	CCONJ	O	O	3906
sulindac	PROPN	O	Chemical	3906
group	NOUN	O	O	3906
and	CCONJ	O	O	3906
4	NUM	O	O	3906
of	ADP	O	O	3906
139	NUM	O	O	3906
(	PUNCT	O	O	3906
2.9%	NOUN	O	O	3906
)	PUNCT	O	O	3906
in	ADP	O	O	3906
the	PRON	O	O	3906
placebo	NOUN	O	O	3906
group	NOUN	O	O	3906
who	PRON	O	O	3906
experienced	ADJ	O	O	3906
at	ADP	O	O	3906
least	ADJ	O	O	3906
15	NUM	O	O	3906
dB	NOUN	O	O	3906
hearing	NOUN	O	O	3906
reduction	NOUN	O	O	3906
from	ADP	O	O	3906
baseline	VERB	O	O	3906
in	ADP	O	O	3906
2	X	O	O	3906
or	CCONJ	O	O	3906
more	ADJ	O	O	3906
consecutive	ADJ	O	O	3906
frequencies	NOUN	O	O	3906
across	ADP	O	O	3906
the	PRON	O	O	3906
entire	ADJ	O	O	3906
range	VERB	O	O	3906
tested	VERB	O	O	3906
(	PUNCT	O	O	3906
P	NOUN	O	Chemical	3906
=	PUNCT	O	O	3906
0.02	NUM	O	O	3906
)	PUNCT	O	O	3906
.	PUNCT	O	O	3906
There	ADV	O	O	3907
was	AUX	O	O	3907
no	PRON	O	O	3907
significant	ADJ	O	O	3907
difference	NOUN	O	O	3907
in	ADP	O	O	3907
the	PRON	O	O	3907
proportion	NOUN	O	O	3907
of	ADP	O	O	3907
subjects	NOUN	O	O	3907
in	ADP	O	O	3907
the	PRON	O	O	3907
DFMO	PROPN	O	Chemical	3907
plus	CCONJ	O	O	3907
sulindac	PROPN	O	Chemical	3907
group	NOUN	O	O	3907
who	PRON	O	O	3907
experienced	ADJ	O	O	3907
clinically	ADV	O	O	3907
significant	ADJ	O	O	3907
hearing loss	NOUN	O	Disease	3907
compared	VERB	O	O	3907
with	ADP	O	O	3907
the	PRON	O	O	3907
placebo	NOUN	O	O	3907
group	NOUN	O	O	3907
.	PUNCT	O	O	3907
The	PRON	O	O	3908
estimated	VERB	O	O	3908
attributable	ADJ	O	O	3908
risk	NOUN	O	O	3908
of	ADP	O	O	3908
ototoxicity	NOUN	O	Disease	3908
from	ADP	O	O	3908
exposure	NOUN	O	O	3908
to	PART	O	O	3908
the	PRON	O	O	3908
drug	NOUN	O	O	3908
is	AUX	O	O	3908
8.4%	NOUN	O	O	3908
(	PUNCT	O	O	3908
95%	NOUN	O	O	3908
confidence	NOUN	O	O	3908
interval	NOUN	O	O	3908
,	PUNCT	O	O	3908
-2.0%	NOUN	O	O	3908
to	PART	O	O	3908
18.8%	NOUN	O	O	3908
;	PUNCT	O	O	3908
P	NOUN	O	Chemical	3908
=	PUNCT	O	O	3908
0.12	NUM	O	O	3908
)	PUNCT	O	O	3908
.	PUNCT	O	O	3908
There	ADV	O	O	3909
is	AUX	O	O	3909
a	PRON	O	O	3909
<	X	O	O	3909
2	X	O	O	3909
dB	NOUN	O	O	3909
difference	NOUN	O	O	3909
in	ADP	O	O	3909
mean	VERB	O	O	3909
threshold	NOUN	O	O	3909
for	ADP	O	O	3909
patients	NOUN	O	O	3909
treated	VERB	O	O	3909
with	ADP	O	O	3909
DFMO	PROPN	O	Chemical	3909
plus	CCONJ	O	O	3909
sulindac	PROPN	O	Chemical	3909
compared	VERB	O	O	3909
with	ADP	O	O	3909
those	PRON	O	O	3909
treated	VERB	O	O	3909
with	ADP	O	O	3909
placebo	NOUN	O	O	3909
.	PUNCT	O	O	3909
Increased	VERB	O	O	3912
mental slowing	NOUN	O	Disease	3912
associated	VERB	O	O	3912
with	ADP	O	O	3912
the	PRON	O	O	3912
APOE	NOUN	O	O	3912
epsilon4	PROPN	O	O	3912
allele	PROPN	O	O	3912
after	ADP	O	O	3912
trihexyphenidyl	ADJ	O	Chemical	3912
oral	ADJ	O	O	3912
anticholinergic	ADJ	O	O	3912
challenge	NOUN	O	O	3912
in	ADP	O	O	3912
healthy	ADJ	O	O	3912
elderly	ADJ	O	O	3912
.	PUNCT	O	O	3912
The	PRON	O	O	3913
objectives	NOUN	O	O	3913
of	ADP	O	O	3913
this	PRON	O	O	3913
study	VERB	O	O	3913
were	AUX	O	O	3913
to	PART	O	O	3913
examine	VERB	O	O	3913
the	PRON	O	O	3913
relationship	NOUN	O	O	3913
between	ADP	O	O	3913
APOE	NOUN	O	O	3913
epsilon4	PROPN	O	O	3913
and	CCONJ	O	O	3913
subjective	ADJ	O	O	3913
effects	NOUN	O	O	3913
of	ADP	O	O	3913
trihexyphenidyl	ADJ	O	Chemical	3913
on	ADP	O	O	3913
measures	NOUN	O	O	3913
reflecting	VERB	O	O	3913
sedation	NOUN	O	O	3913
and	CCONJ	O	O	3913
confusion	NOUN	O	Disease	3913
and	CCONJ	O	O	3913
to	PART	O	O	3913
investigate	VERB	O	O	3913
the	PRON	O	O	3913
relationship	NOUN	O	O	3913
between	ADP	O	O	3913
trihexyphenidyl	ADJ	O	Chemical	3913
-	PUNCT	O	O	3913
induced	VERB	O	O	3913
subjective	ADJ	O	O	3913
effects	NOUN	O	O	3913
and	CCONJ	O	O	3913
objective	VERB	O	O	3913
memory	NOUN	O	O	3913
performance	NOUN	O	O	3913
.	PUNCT	O	O	3913
All	PRON	O	O	3914
participants	NOUN	O	O	3914
received	VERB	O	O	3914
1.0	NUM	O	O	3914
mg	VERB	O	O	3914
or	CCONJ	O	O	3914
2.0	NUM	O	O	3914
mg	VERB	O	O	3914
trihexyphenidyl	ADJ	O	Chemical	3914
or	CCONJ	O	O	3914
placebo	NOUN	O	O	3914
administered	VERB	O	O	3914
in	ADP	O	O	3914
counterbalanced	VERB	O	O	3914
sequences	NOUN	O	O	3914
over	ADP	O	O	3914
a	PRON	O	O	3914
period	NOUN	O	O	3914
of	ADP	O	O	3914
three	NUM	O	O	3914
consecutive	ADJ	O	O	3914
weeks	NOUN	O	O	3914
.	PUNCT	O	O	3914
A	PRON	O	O	3915
2.0-mg	NOUN	O	O	3915
oral	ADJ	O	O	3915
dose	NOUN	O	O	3915
of	ADP	O	O	3915
trihexyphenidyl	ADJ	O	Chemical	3915
resulted	VERB	O	O	3915
in	ADP	O	O	3915
increased	VERB	O	O	3915
subjective	ADJ	O	O	3915
ratings	NOUN	O	O	3915
of	ADP	O	O	3915
mental slowness	NOUN	O	Disease	3915
in	ADP	O	O	3915
carriers	NOUN	O	O	3915
of	ADP	O	O	3915
the	PRON	O	O	3915
APOE	NOUN	O	O	3915
epsilon4	PROPN	O	O	3915
allele	PROPN	O	O	3915
only	ADV	O	O	3915
.	PUNCT	O	O	3915
Drug	NOUN	O	O	3916
effects	NOUN	O	O	3916
as	ADP	O	O	3916
determined	VERB	O	O	3916
by	ADP	O	O	3916
difference	NOUN	O	O	3916
scores	NOUN	O	O	3916
between	ADP	O	O	3916
2.0	NUM	O	O	3916
mg	VERB	O	O	3916
trihexyphenidyl	ADJ	O	Chemical	3916
and	CCONJ	O	O	3916
placebo	NOUN	O	O	3916
on	ADP	O	O	3916
ratings	NOUN	O	O	3916
of	ADP	O	O	3916
mental slowness	NOUN	O	Disease	3916
significantly	ADV	O	O	3916
correlated	VERB	O	O	3916
with	ADP	O	O	3916
total	ADJ	O	O	3916
and	CCONJ	O	O	3916
delayed	VERB	O	O	3916
recall	VERB	O	O	3916
on	ADP	O	O	3916
the	PRON	O	O	3916
Buschke	NOUN	O	O	3916
Selective	PROPN	O	O	3916
Reminding	VERB	O	O	3916
Test	NOUN	O	O	3916
in	ADP	O	O	3916
carriers	NOUN	O	O	3916
of	ADP	O	O	3916
the	PRON	O	O	3916
APOE	NOUN	O	O	3916
epsilon4	PROPN	O	O	3916
allele	PROPN	O	O	3916
only	ADV	O	O	3916
.	PUNCT	O	O	3916
The	PRON	O	O	3917
epsilon4	PROPN	O	O	3917
allele	PROPN	O	O	3917
in	ADP	O	O	3917
healthy	ADJ	O	O	3917
elderly	ADJ	O	O	3917
was	AUX	O	O	3917
associated	VERB	O	O	3917
with	ADP	O	O	3917
increased	VERB	O	O	3917
subjective	ADJ	O	O	3917
mental slowing	NOUN	O	Disease	3917
after	ADP	O	O	3917
trihexyphenidyl	ADJ	O	Chemical	3917
anticholinergic	ADJ	O	O	3917
challenge	NOUN	O	O	3917
.	PUNCT	O	O	3917
Behavioral	NOUN	O	O	3920
effects	NOUN	O	O	3920
of	ADP	O	O	3920
pubertal	ADJ	O	O	3920
anabolic	ADJ	O	O	3920
androgenic	ADJ	O	O	3920
steroid	NOUN	O	Chemical	3920
exposure	NOUN	O	O	3920
in	ADP	O	O	3920
male	NOUN	O	O	3920
rats	NOUN	O	O	3920
with	ADP	O	O	3920
low	ADJ	O	O	3920
serotonin	PROPN	O	Chemical	3920
.	PUNCT	O	O	3920
The	PRON	O	O	3921
goal	NOUN	O	O	3921
of	ADP	O	O	3921
this	PRON	O	O	3921
study	VERB	O	O	3921
was	AUX	O	O	3921
to	PART	O	O	3921
assess	VERB	O	O	3921
the	PRON	O	O	3921
interactive	ADJ	O	O	3921
effects	NOUN	O	O	3921
of	ADP	O	O	3921
chronic	ADJ	O	O	3921
anabolic	ADJ	O	O	3921
androgenic	ADJ	O	O	3921
steroid	NOUN	O	Chemical	3921
(	PUNCT	O	O	3921
AAS	PROPN	O	O	3921
)	PUNCT	O	O	3921
exposure	NOUN	O	O	3921
and	CCONJ	O	O	3921
brain	NOUN	O	O	3921
serotonin	PROPN	O	Chemical	3921
(	PUNCT	O	O	3921
5-hydroxytryptamine	NOUN	O	Chemical	3921
,	PUNCT	O	O	3921
5-HT	NOUN	O	Chemical	3921
)	PUNCT	O	O	3921
depletion	NOUN	O	O	3921
on	ADP	O	O	3921
behavior	NOUN	O	O	3921
of	ADP	O	O	3921
pubertal	ADJ	O	O	3921
male	NOUN	O	O	3921
rats	NOUN	O	O	3921
.	PUNCT	O	O	3921
Serotonin	NOUN	O	Chemical	3922
was	AUX	O	O	3922
depleted	VERB	O	O	3922
beginning	VERB	O	O	3922
on	ADP	O	O	3922
postnatal	ADJ	O	O	3922
day	NOUN	O	O	3922
26	NUM	O	O	3922
with	ADP	O	O	3922
parachlorophenylalanine	VERB	O	Chemical	3922
(	PUNCT	O	O	3922
PCPA	PROPN	O	Chemical	3922
100	NUM	O	O	3922
mg	VERB	O	O	3922
/	PUNCT	O	O	3922
kg	VERB	O	O	3922
,	PUNCT	O	O	3922
every	PRON	O	O	3922
other	ADJ	O	O	3922
day	NOUN	O	O	3922
)	PUNCT	O	O	3922
;	PUNCT	O	O	3922
controls	VERB	O	O	3922
received	VERB	O	O	3922
saline	NOUN	O	O	3922
.	PUNCT	O	O	3922
At	ADP	O	O	3923
puberty	VERB	O	O	3923
(	PUNCT	O	O	3923
P40	PROPN	O	O	3923
)	PUNCT	O	O	3923
,	PUNCT	O	O	3923
half	NOUN	O	O	3923
the	PRON	O	O	3923
PCPA	PROPN	O	Chemical	3923
-	PUNCT	O	O	3923
treated	VERB	O	O	3923
rats	NOUN	O	O	3923
and	CCONJ	O	O	3923
half	NOUN	O	O	3923
the	PRON	O	O	3923
saline	NOUN	O	O	3923
-	PUNCT	O	O	3923
treated	VERB	O	O	3923
rats	NOUN	O	O	3923
began	VERB	O	O	3923
treatment	NOUN	O	O	3923
with	ADP	O	O	3923
testosterone	PROPN	O	Chemical	3923
(	PUNCT	O	O	3923
T	NOUN	O	Chemical	3923
,	PUNCT	O	O	3923
5	NUM	O	O	3923
mg	VERB	O	O	3923
/	PUNCT	O	O	3923
kg	VERB	O	O	3923
,	PUNCT	O	O	3923
5	NUM	O	O	3923
days	NOUN	O	O	3923
/	PUNCT	O	O	3923
week	NOUN	O	O	3923
)	PUNCT	O	O	3923
.	PUNCT	O	O	3923
Behavioral	NOUN	O	O	3924
measures	NOUN	O	O	3924
included	VERB	O	O	3924
locomotion	NOUN	O	O	3924
,	PUNCT	O	O	3924
irritability	NOUN	O	Disease	3924
,	PUNCT	O	O	3924
copulation	NOUN	O	O	3924
,	PUNCT	O	O	3924
partner	NOUN	O	O	3924
preference	NOUN	O	O	3924
,	PUNCT	O	O	3924
and	CCONJ	O	O	3924
aggression	NOUN	O	Disease	3924
.	PUNCT	O	O	3924
Animals	NOUN	O	O	3925
were	AUX	O	O	3925
tested	VERB	O	O	3925
for	ADP	O	O	3925
aggression	NOUN	O	Disease	3925
in	ADP	O	O	3925
their	PRON	O	O	3925
home	NOUN	O	O	3925
cage	NOUN	O	O	3925
,	PUNCT	O	O	3925
both	PRON	O	O	3925
with	ADP	O	O	3925
and	CCONJ	O	O	3925
without	ADP	O	O	3925
physical	ADJ	O	O	3925
provocation	NOUN	O	O	3925
(	PUNCT	O	O	3925
mild	ADJ	O	O	3925
tail	NOUN	O	O	3925
pinch	VERB	O	O	3925
)	PUNCT	O	O	3925
.	PUNCT	O	O	3925
Brain	NOUN	O	O	3926
levels	NOUN	O	O	3926
of	ADP	O	O	3926
5-HT	NOUN	O	Chemical	3926
and	CCONJ	O	O	3926
its	PRON	O	O	3926
metabolite	NOUN	O	O	3926
,	PUNCT	O	O	3926
5-hydroxyindoleacetic acid	NOUN	O	Chemical	3926
(	PUNCT	O	O	3926
5-HIAA	PROPN	O	Chemical	3926
)	PUNCT	O	O	3926
,	PUNCT	O	O	3926
were	AUX	O	O	3926
determined	VERB	O	O	3926
using	VERB	O	O	3926
HPLC	PROPN	O	O	3926
.	PUNCT	O	O	3926
PCPA	PROPN	O	Chemical	3927
significantly	ADV	O	O	3927
and	CCONJ	O	O	3927
substantially	ADV	O	O	3927
depleted	VERB	O	O	3927
5-HT	NOUN	O	Chemical	3927
and	CCONJ	O	O	3927
5-HIAA	PROPN	O	Chemical	3927
in	ADP	O	O	3927
all	PRON	O	O	3927
brain	NOUN	O	O	3927
regions	NOUN	O	O	3927
examined	VERB	O	O	3927
.	PUNCT	O	O	3927
Chronic	NOUN	O	O	3928
T	NOUN	O	Chemical	3928
treatment	NOUN	O	O	3928
significantly	ADV	O	O	3928
decreased	VERB	O	O	3928
5-HT	NOUN	O	Chemical	3928
and	CCONJ	O	O	3928
5-HIAA	PROPN	O	Chemical	3928
in	ADP	O	O	3928
certain	ADJ	O	O	3928
brain	NOUN	O	O	3928
areas	NOUN	O	O	3928
,	PUNCT	O	O	3928
but	CCONJ	O	O	3928
to	PART	O	O	3928
a	PRON	O	O	3928
much	ADJ	O	O	3928
lesser	ADJ	O	O	3928
extent	NOUN	O	O	3928
than	ADP	O	O	3928
PCPA	PROPN	O	Chemical	3928
.	PUNCT	O	O	3928
Chronic	NOUN	O	O	3929
exposure	NOUN	O	O	3929
to	PART	O	O	3929
PCPA	PROPN	O	Chemical	3929
alone	ADV	O	O	3929
significantly	ADV	O	O	3929
decreased	VERB	O	O	3929
locomotor	PROPN	O	O	3929
activity	NOUN	O	O	3929
and	CCONJ	O	O	3929
increased	VERB	O	O	3929
irritability	NOUN	O	Disease	3929
but	CCONJ	O	O	3929
had	VERB	O	O	3929
no	PRON	O	O	3929
effect	VERB	O	O	3929
on	ADP	O	O	3929
sexual	ADJ	O	O	3929
behavior	NOUN	O	O	3929
,	PUNCT	O	O	3929
partner	NOUN	O	O	3929
preference	NOUN	O	O	3929
,	PUNCT	O	O	3929
or	CCONJ	O	O	3929
aggression	NOUN	O	Disease	3929
.	PUNCT	O	O	3929
T	NOUN	O	Chemical	3930
alone	ADV	O	O	3930
had	VERB	O	O	3930
no	PRON	O	O	3930
effect	VERB	O	O	3930
on	ADP	O	O	3930
locomotion	NOUN	O	O	3930
,	PUNCT	O	O	3930
irritability	NOUN	O	Disease	3930
,	PUNCT	O	O	3930
or	CCONJ	O	O	3930
sexual	ADJ	O	O	3930
behavior	NOUN	O	O	3930
but	CCONJ	O	O	3930
increased	VERB	O	O	3930
partner	NOUN	O	O	3930
preference	NOUN	O	O	3930
and	CCONJ	O	O	3930
aggression	NOUN	O	Disease	3930
.	PUNCT	O	O	3930
The	PRON	O	O	3931
most	ADV	O	O	3931
striking	VERB	O	O	3931
effect	VERB	O	O	3931
of	ADP	O	O	3931
combining	VERB	O	O	3931
T+PCPA	NUM	O	O	3931
was	AUX	O	O	3931
a	PRON	O	O	3931
significant	ADJ	O	O	3931
increase	VERB	O	O	3931
in	ADP	O	O	3931
attack	VERB	O	O	3931
frequency	NOUN	O	O	3931
as	ADP	O	O	3931
well	ADV	O	O	3931
as	ADP	O	O	3931
a	PRON	O	O	3931
significant	ADJ	O	O	3931
decrease	VERB	O	O	3931
in	ADP	O	O	3931
the	PRON	O	O	3931
latency	VERB	O	O	3931
to	PART	O	O	3931
attack	VERB	O	O	3931
,	PUNCT	O	O	3931
particularly	ADV	O	O	3931
following	VERB	O	O	3931
physical	ADJ	O	O	3931
provocation	NOUN	O	O	3931
.	PUNCT	O	O	3931
Based	VERB	O	O	3932
on	ADP	O	O	3932
these	PRON	O	O	3932
data	NOUN	O	O	3932
,	PUNCT	O	O	3932
it	PRON	O	O	3932
can	AUX	O	O	3932
be	AUX	O	O	3932
speculated	VERB	O	O	3932
that	SCONJ	O	O	3932
pubertal	ADJ	O	O	3932
AAS	PROPN	O	O	3932
users	NOUN	O	O	3932
with	ADP	O	O	3932
low	ADJ	O	O	3932
central	ADJ	O	O	3932
5-HT	NOUN	O	Chemical	3932
may	AUX	O	O	3932
be	AUX	O	O	3932
especially	ADV	O	O	3932
prone	ADJ	O	O	3932
to	PART	O	O	3932
exhibit	VERB	O	O	3932
aggressive behavior	NOUN	O	Disease	3932
.	PUNCT	O	O	3932
Intracavitary	NOUN	O	O	3935
chemotherapy	NOUN	O	O	3935
(	PUNCT	O	O	3935
paclitaxel	NOUN	O	Chemical	3935
/	PUNCT	O	O	3935
carboplatin	PROPN	O	Chemical	3935
liquid	ADJ	O	O	3935
crystalline	ADJ	O	O	3935
cubic	ADJ	O	O	3935
phases	NOUN	O	O	3935
)	PUNCT	O	O	3935
for	ADP	O	O	3935
recurrent	ADJ	O	O	3935
glioblastoma	NOUN	O	Disease	3935
--	PUNCT	O	O	3935
clinical	ADJ	O	O	3935
observations	NOUN	O	O	3935
.	PUNCT	O	O	3935
Human	NOUN	O	O	3936
malignant	ADJ	O	O	3936
brain tumors	NOUN	O	Disease	3936
have	VERB	O	O	3936
a	PRON	O	O	3936
poor	ADJ	O	O	3936
prognosis	VERB	O	O	3936
in	ADP	O	O	3936
spite	NOUN	O	O	3936
of	ADP	O	O	3936
surgery	NOUN	O	O	3936
and	CCONJ	O	O	3936
radiation	NOUN	O	O	3936
therapy	NOUN	O	O	3936
.	PUNCT	O	O	3936
For	ADP	O	O	3937
human	PROPN	O	O	3937
glioblastoma	NOUN	O	Disease	3937
recurrences	NOUN	O	O	3937
,	PUNCT	O	O	3937
the	PRON	O	O	3937
feasibility	NOUN	O	O	3937
,	PUNCT	O	O	3937
safety	NOUN	O	O	3937
,	PUNCT	O	O	3937
and	CCONJ	O	O	3937
short	ADJ	O	O	3937
-	PUNCT	O	O	3937
term	NOUN	O	O	3937
effects	NOUN	O	O	3937
of	ADP	O	O	3937
a	PRON	O	O	3937
surgical	ADJ	O	O	3937
intracavitary	NOUN	O	O	3937
application	NOUN	O	O	3937
of	ADP	O	O	3937
paclitaxel	NOUN	O	Chemical	3937
and	CCONJ	O	O	3937
carboplatin	PROPN	O	Chemical	3937
encapsulated	VERB	O	O	3937
by	ADP	O	O	3937
liquid	ADJ	O	O	3937
crystalline	ADJ	O	O	3937
cubic	ADJ	O	O	3937
phases	NOUN	O	O	3937
are	AUX	O	O	3937
examined	VERB	O	O	3937
in	ADP	O	O	3937
a	PRON	O	O	3937
pilot	NOUN	O	O	3937
study	VERB	O	O	3937
.	PUNCT	O	O	3937
A	PRON	O	O	3938
total	ADJ	O	O	3938
of	ADP	O	O	3938
12	NUM	O	O	3938
patients	NOUN	O	O	3938
with	ADP	O	O	3938
a	PRON	O	O	3938
recurrence	NOUN	O	O	3938
of	ADP	O	O	3938
a	PRON	O	O	3938
glioblastoma	NOUN	O	Disease	3938
multiforme	NOUN	O	O	3938
underwent	VERB	O	O	3938
re	ADP	O	O	3938
-	PUNCT	O	O	3938
resection	NOUN	O	O	3938
and	CCONJ	O	O	3938
received	VERB	O	O	3938
an	PRON	O	O	3938
intracavitary	NOUN	O	O	3938
application	NOUN	O	O	3938
of	ADP	O	O	3938
paclitaxel	NOUN	O	Chemical	3938
and	CCONJ	O	O	3938
carboplatin	PROPN	O	Chemical	3938
cubic	ADJ	O	O	3938
phases	NOUN	O	O	3938
in	ADP	O	O	3938
different	ADJ	O	O	3938
dosages	NOUN	O	O	3938
.	PUNCT	O	O	3938
Six	NUM	O	O	3939
of	ADP	O	O	3939
the	PRON	O	O	3939
patients	NOUN	O	O	3939
received	VERB	O	O	3939
more	ADJ	O	O	3939
than	ADP	O	O	3939
15	NUM	O	O	3939
mg	VERB	O	O	3939
paclitaxel	NOUN	O	Chemical	3939
and	CCONJ	O	O	3939
suffered	VERB	O	O	3939
from	ADP	O	O	3939
moderate	ADJ	O	O	3939
to	PART	O	O	3939
severe	ADJ	O	O	3939
brain edema	NOUN	O	Disease	3939
,	PUNCT	O	O	3939
while	SCONJ	O	O	3939
the	PRON	O	O	3939
remaining	VERB	O	O	3939
patients	NOUN	O	O	3939
received	VERB	O	O	3939
only	ADV	O	O	3939
a	PRON	O	O	3939
total	ADJ	O	O	3939
of	ADP	O	O	3939
15	NUM	O	O	3939
mg	VERB	O	O	3939
paclitaxel	NOUN	O	Chemical	3939
.	PUNCT	O	O	3939
In	ADP	O	O	3940
the	PRON	O	O	3940
latter	ADJ	O	O	3940
group	NOUN	O	O	3940
,	PUNCT	O	O	3940
brain edema	NOUN	O	Disease	3940
was	AUX	O	O	3940
markedly	ADV	O	O	3940
reduced	VERB	O	O	3940
and	CCONJ	O	O	3940
dealt	VERB	O	O	3940
medically	ADV	O	O	3940
.	PUNCT	O	O	3940
Intracavitary	NOUN	O	O	3941
chemotherapy	NOUN	O	O	3941
in	ADP	O	O	3941
recurrent	ADJ	O	O	3941
glioblastoma	NOUN	O	Disease	3941
using	VERB	O	O	3941
cubic	ADJ	O	O	3941
phases	NOUN	O	O	3941
is	AUX	O	O	3941
feasible	ADJ	O	O	3941
and	CCONJ	O	O	3941
safe	ADJ	O	O	3941
,	PUNCT	O	O	3941
yet	ADV	O	O	3941
the	PRON	O	O	3941
clinical	ADJ	O	O	3941
benefit	VERB	O	O	3941
remains	VERB	O	O	3941
to	PART	O	O	3941
be	AUX	O	O	3941
examined	VERB	O	O	3941
in	ADP	O	O	3941
a	PRON	O	O	3941
clinical	ADJ	O	O	3941
phase	NOUN	O	O	3941
II	NUM	O	O	3941
study	VERB	O	O	3941
.	PUNCT	O	O	3941
Methylphenidate	VERB	O	Chemical	3944
-	PUNCT	O	O	3944
induced	VERB	O	O	3944
obsessive	ADJ	O	O	3944
-	PUNCT	O	O	3944
compulsive	ADJ	O	O	3944
symptoms	NOUN	O	O	3944
in	ADP	O	O	3944
an	PRON	O	O	3944
elderly	ADJ	O	O	3944
man	NOUN	O	O	3944
.	PUNCT	O	O	3944
An	PRON	O	O	3945
82-year	NOUN	O	O	3945
-	PUNCT	O	O	3945
old	ADJ	O	O	3945
man	NOUN	O	O	3945
with	ADP	O	O	3945
treatment	NOUN	O	O	3945
-	PUNCT	O	O	3945
resistant	ADJ	O	O	3945
depression	PROPN	O	Disease	3945
and	CCONJ	O	O	3945
early	ADV	O	O	3945
Alzheimer	NOUN	O	Disease	3945
's	AUX	O	O	3945
disease	PROPN	O	O	3945
was	AUX	O	O	3945
started	VERB	O	O	3945
on	ADP	O	O	3945
methylphenidate	VERB	O	Chemical	3945
.	PUNCT	O	O	3945
Significant	ADJ	O	O	3946
obsessive	ADJ	O	O	3946
-	PUNCT	O	O	3946
compulsive	ADJ	O	O	3946
behavior	NOUN	O	O	3946
ensued	VERB	O	O	3946
but	CCONJ	O	O	3946
diminished	VERB	O	O	3946
over	ADP	O	O	3946
several	ADJ	O	O	3946
weeks	NOUN	O	O	3946
when	SCONJ	O	O	3946
methylphenidate	VERB	O	Chemical	3946
was	AUX	O	O	3946
replaced	VERB	O	O	3946
by	ADP	O	O	3946
fluvoxamine	NOUN	O	Chemical	3946
.	PUNCT	O	O	3946
The	PRON	O	O	3947
patient	NOUN	O	O	3947
had	VERB	O	O	3947
no	PRON	O	O	3947
prior	ADV	O	O	3947
psychiatric	ADJ	O	Disease	3947
history	NOUN	O	O	3947
,	PUNCT	O	O	3947
but	CCONJ	O	O	3947
he	PRON	O	O	3947
had	VERB	O	O	3947
a	PRON	O	O	3947
sister	NOUN	O	O	3947
with	ADP	O	O	3947
obsessive	ADJ	O	O	3947
-	PUNCT	O	O	3947
compulsive	ADJ	O	O	3947
disorder	NOUN	O	O	3947
.	PUNCT	O	O	3947
It	PRON	O	O	3948
appears	VERB	O	O	3948
that	SCONJ	O	O	3948
methylphenidate	VERB	O	Chemical	3948
precipitated	VERB	O	O	3948
the	PRON	O	O	3948
patient	NOUN	O	O	3948
's	AUX	O	O	3948
pathological	ADJ	O	O	3948
behavior	NOUN	O	O	3948
.	PUNCT	O	O	3948
Cardiac arrest	NOUN	O	Disease	3951
after	ADP	O	O	3951
intravenous	ADJ	O	O	3951
metoclopramide	NOUN	O	Chemical	3951
-	PUNCT	O	O	3951
a	PRON	O	O	3951
case	NOUN	O	O	3951
of	ADP	O	O	3951
five	NUM	O	O	3951
repeated	VERB	O	O	3951
injections	NOUN	O	O	3951
of	ADP	O	O	3951
metoclopramide	NOUN	O	Chemical	3951
causing	VERB	O	O	3951
five	NUM	O	O	3951
episodes	NOUN	O	O	3951
of	ADP	O	O	3951
cardiac arrest	NOUN	O	Disease	3951
.	PUNCT	O	O	3951
We	PRON	O	O	3952
describe	VERB	O	O	3952
a	PRON	O	O	3952
patient	NOUN	O	O	3952
where	SCONJ	O	O	3952
intravenous	ADJ	O	O	3952
injection	NOUN	O	O	3952
of	ADP	O	O	3952
metoclopramide	NOUN	O	Chemical	3952
was	AUX	O	O	3952
immediately	ADV	O	O	3952
followed	VERB	O	O	3952
by	ADP	O	O	3952
asystole	NOUN	O	Disease	3952
repeatedly	ADV	O	O	3952
.	PUNCT	O	O	3952
The	PRON	O	O	3953
patient	NOUN	O	O	3953
received	VERB	O	O	3953
metoclopramide	NOUN	O	Chemical	3953
10	NUM	O	O	3953
mg	VERB	O	O	3953
i.v	NOUN	O	O	3953
.	PUNCT	O	O	3953
After	ADP	O	O	3954
interviewing	VERB	O	O	3954
the	PRON	O	O	3954
attending	VERB	O	O	3954
nurses	NOUN	O	O	3954
and	CCONJ	O	O	3954
reviewing	VERB	O	O	3954
the	PRON	O	O	3954
written	VERB	O	O	3954
documentation	NOUN	O	O	3954
,	PUNCT	O	O	3954
it	PRON	O	O	3954
is	AUX	O	O	3954
clear	ADJ	O	O	3954
that	SCONJ	O	O	3954
every	PRON	O	O	3954
administration	NOUN	O	O	3954
of	ADP	O	O	3954
metoclopramide	NOUN	O	Chemical	3954
was	AUX	O	O	3954
immediately	ADV	O	O	3954
(	PUNCT	O	O	3954
within	ADP	O	O	3954
s	X	O	O	3954
)	PUNCT	O	O	3954
followed	VERB	O	O	3954
by	ADP	O	O	3954
asystole	NOUN	O	Disease	3954
.	PUNCT	O	O	3954
The	PRON	O	O	3955
asystole	NOUN	O	Disease	3955
lasted	VERB	O	O	3955
15	NUM	O	O	3955
-	PUNCT	O	O	3955
30	NUM	O	O	3955
s	X	O	O	3955
on	ADP	O	O	3955
four	NUM	O	O	3955
occasions	NOUN	O	O	3955
,	PUNCT	O	O	3955
on	ADP	O	O	3955
one	NUM	O	O	3955
occasion	NOUN	O	O	3955
it	PRON	O	O	3955
lasted	VERB	O	O	3955
2	X	O	O	3955
min	NOUN	O	O	3955
.	PUNCT	O	O	3955
The	PRON	O	O	3956
patient	NOUN	O	O	3956
received	VERB	O	O	3956
atropine	NOUN	O	Chemical	3956
0.5	NUM	O	O	3956
-	PUNCT	O	O	3956
1	X	O	O	3956
mg	VERB	O	O	3956
and	CCONJ	O	O	3956
chest	NOUN	O	O	3956
compressions	NOUN	O	O	3956
,	PUNCT	O	O	3956
before	ADP	O	O	3956
sinus	NOUN	O	O	3956
rhythm	VERB	O	O	3956
again	ADV	O	O	3956
took	VERB	O	O	3956
over	ADP	O	O	3956
.	PUNCT	O	O	3956
We	PRON	O	O	3957
interpret	VERB	O	O	3957
this	PRON	O	O	3957
as	ADP	O	O	3957
episodes	NOUN	O	O	3957
of	ADP	O	O	3957
cardiac arrest	NOUN	O	Disease	3957
caused	VERB	O	O	3957
by	ADP	O	O	3957
metoclopramide	NOUN	O	Chemical	3957
.	PUNCT	O	O	3957
The	PRON	O	O	3958
rapid	ADJ	O	O	3958
injection	NOUN	O	O	3958
via	ADP	O	O	3958
the	PRON	O	O	3958
central	ADJ	O	O	3958
venous	ADJ	O	O	3958
route	VERB	O	O	3958
and	CCONJ	O	O	3958
the	PRON	O	O	3958
concomitant	ADJ	O	O	3958
tapering	VERB	O	O	3958
of	ADP	O	O	3958
dopamine	NOUN	O	Chemical	3958
infusion	NOUN	O	O	3958
might	AUX	O	O	3958
have	VERB	O	O	3958
contributed	VERB	O	O	3958
in	ADP	O	O	3958
precipitating	VERB	O	O	3958
the	PRON	O	O	3958
adverse	ADJ	O	O	3958
drug	NOUN	O	O	3958
reaction	NOUN	O	O	3958
.	PUNCT	O	O	3958
Severe	ADJ	O	O	3961
immune	NOUN	O	O	3961
hemolytic anemia	NOUN	O	Disease	3961
associated	VERB	O	O	3961
with	ADP	O	O	3961
prophylactic	ADJ	O	O	3961
use	VERB	O	O	3961
of	ADP	O	O	3961
cefotetan	PROPN	O	Chemical	3961
in	ADP	O	O	3961
obstetric	ADJ	O	O	3961
and	CCONJ	O	O	3961
gynecologic	ADJ	O	O	3961
procedures	NOUN	O	O	3961
.	PUNCT	O	O	3961
Second-	PROPN	O	O	3962
and	CCONJ	O	O	3962
third	ADV	O	O	3962
-	PUNCT	O	O	3962
generation	NOUN	O	O	3962
cephalosporins	VERB	O	Chemical	3962
,	PUNCT	O	O	3962
especially	ADV	O	O	3962
cefotetan	PROPN	O	Chemical	3962
,	PUNCT	O	O	3962
are	AUX	O	O	3962
increasingly	ADV	O	O	3962
associated	VERB	O	O	3962
with	ADP	O	O	3962
severe	ADJ	O	O	3962
,	PUNCT	O	O	3962
sometimes	ADV	O	O	3962
fatal	ADJ	O	O	3962
immune	NOUN	O	O	3962
hemolytic anemia	NOUN	O	Disease	3962
.	PUNCT	O	O	3962
We	PRON	O	O	3963
noticed	VERB	O	O	3963
that	SCONJ	O	O	3963
10	NUM	O	O	3963
of	ADP	O	O	3963
our	PRON	O	O	3963
35	NUM	O	O	3963
cases	NOUN	O	O	3963
of	ADP	O	O	3963
cefotetan	PROPN	O	Chemical	3963
-	PUNCT	O	O	3963
induced	VERB	O	O	3963
hemolytic anemias	NOUN	O	Disease	3963
were	AUX	O	O	3963
in	ADP	O	O	3963
patients	NOUN	O	O	3963
who	PRON	O	O	3963
had	VERB	O	O	3963
received	VERB	O	O	3963
cefotetan	PROPN	O	Chemical	3963
prophylactically	ADV	O	O	3963
for	ADP	O	O	3963
obstetric	ADJ	O	O	3963
and	CCONJ	O	O	3963
gynecologic	ADJ	O	O	3963
procedures	NOUN	O	O	3963
.	PUNCT	O	O	3963
Eight	NUM	O	O	3964
of	ADP	O	O	3964
these	PRON	O	O	3964
cases	NOUN	O	O	3964
of	ADP	O	O	3964
severe	ADJ	O	O	3964
immune	NOUN	O	O	3964
hemolytic anemia	NOUN	O	Disease	3964
are	AUX	O	O	3964
described	VERB	O	O	3964
.	PUNCT	O	O	3964
Cauda equina syndrome	NOUN	O	Disease	3967
after	ADP	O	O	3967
spinal	NOUN	O	O	3967
anaesthesia	NOUN	O	O	3967
with	ADP	O	O	3967
hyperbaric	PROPN	O	O	3967
5%	NOUN	O	O	3967
lignocaine	NOUN	O	Chemical	3968
:	PUNCT	O	O	3968
a	PRON	O	O	3968
review	VERB	O	O	3968
of	ADP	O	O	3968
six	NUM	O	O	3968
cases	NOUN	O	O	3968
of	ADP	O	O	3968
cauda equina syndrome	NOUN	O	Disease	3968
reported	VERB	O	O	3968
to	PART	O	O	3968
the	PRON	O	O	3968
Swedish	ADJ	O	O	3968
Pharmaceutical	NOUN	O	O	3968
Insurance	NOUN	O	O	3968
1993	NUM	O	O	3968
-	PUNCT	O	O	3968
1997	NUM	O	O	3968
.	PUNCT	O	O	3968
Six	NUM	O	O	3969
cases	NOUN	O	O	3969
of	ADP	O	O	3969
cauda equina syndrome	NOUN	O	Disease	3969
with	ADP	O	O	3969
varying	VERB	O	O	3969
severity	NOUN	O	O	3969
were	AUX	O	O	3969
reported	VERB	O	O	3969
to	PART	O	O	3969
the	PRON	O	O	3969
Swedish	ADJ	O	O	3969
Pharmaceutical	NOUN	O	O	3969
Insurance	NOUN	O	O	3969
during	ADP	O	O	3969
the	PRON	O	O	3969
period	NOUN	O	O	3969
1993	NUM	O	O	3969
-	PUNCT	O	O	3969
1997	NUM	O	O	3969
.	PUNCT	O	O	3969
All	PRON	O	O	3970
were	AUX	O	O	3970
associated	VERB	O	O	3970
with	ADP	O	O	3970
spinal	NOUN	O	O	3970
anaesthesia	NOUN	O	O	3970
using	VERB	O	O	3970
hyperbaric	PROPN	O	O	3970
5%	NOUN	O	O	3970
lignocaine	NOUN	O	Chemical	3970
.	PUNCT	O	O	3970
The	PRON	O	O	3971
dose	NOUN	O	O	3971
of	ADP	O	O	3971
hyperbaric	PROPN	O	O	3971
5%	NOUN	O	O	3971
lignocaine	NOUN	O	Chemical	3971
administered	VERB	O	O	3971
ranged	VERB	O	O	3971
from	ADP	O	O	3971
60	NUM	O	O	3971
to	PART	O	O	3971
120	NUM	O	O	3971
mg	VERB	O	O	3971
.	PUNCT	O	O	3971
Three	NUM	O	O	3972
of	ADP	O	O	3972
the	PRON	O	O	3972
cases	NOUN	O	O	3972
were	AUX	O	O	3972
most	ADV	O	O	3972
likely	ADV	O	O	3972
caused	VERB	O	O	3972
by	ADP	O	O	3972
direct	ADJ	O	O	3972
neurotoxicity	NOUN	O	Disease	3972
of	ADP	O	O	3972
hyperbaric	PROPN	O	O	3972
5%	NOUN	O	O	3972
lignocaine	NOUN	O	Chemical	3972
.	PUNCT	O	O	3972
In	ADP	O	O	3973
the	PRON	O	O	3973
other	ADJ	O	O	3973
3	X	O	O	3973
cases	NOUN	O	O	3973
,	PUNCT	O	O	3973
direct	ADJ	O	O	3973
neurotoxicity	NOUN	O	Disease	3973
was	AUX	O	O	3973
also	ADV	O	O	3973
probable	ADJ	O	O	3973
,	PUNCT	O	O	3973
but	CCONJ	O	O	3973
unfortunately	ADV	O	O	3973
radiological	ADJ	O	O	3973
investigations	NOUN	O	O	3973
were	AUX	O	O	3973
not	PART	O	O	3973
done	VERB	O	O	3973
to	PART	O	O	3973
definitely	ADV	O	O	3973
exclude	VERB	O	O	3973
a	PRON	O	O	3973
compressive	ADJ	O	O	3973
aetiology	NOUN	O	O	3973
.	PUNCT	O	O	3973
All	PRON	O	O	3974
cases	NOUN	O	O	3974
sustained	VERB	O	O	3974
permanent	ADJ	O	O	3974
neurological deficits	NOUN	O	Disease	3974
.	PUNCT	O	O	3974
We	PRON	O	O	3975
recommend	VERB	O	O	3975
that	SCONJ	O	O	3975
hyperbaric	PROPN	O	O	3975
lignocaine	NOUN	O	Chemical	3975
should	AUX	O	O	3975
be	AUX	O	O	3975
administered	VERB	O	O	3975
in	ADP	O	O	3975
concentrations	NOUN	O	O	3975
not	PART	O	O	3975
greater	ADJ	O	O	3975
than	ADP	O	O	3975
2%	NOUN	O	O	3975
and	CCONJ	O	O	3975
at	ADP	O	O	3975
a	PRON	O	O	3975
total	ADJ	O	O	3975
dose	NOUN	O	O	3975
preferably	ADV	O	O	3975
not	PART	O	O	3975
exceeding	VERB	O	O	3975
60	NUM	O	O	3975
mg	VERB	O	O	3975
.	PUNCT	O	O	3975
Cortical	ADJ	O	O	3978
motor	NOUN	O	O	3978
overactivation	NOUN	O	O	3978
in	ADP	O	O	3978
parkinsonian	PROPN	O	Disease	3978
patients	NOUN	O	O	3978
with	ADP	O	O	3978
L	NOUN	O	O	3978
-	PUNCT	O	O	3978
dopa	PROPN	O	O	3978
-	PUNCT	O	O	3978
induced	VERB	O	O	3978
peak	PROPN	O	O	3978
-	PUNCT	O	O	3978
dose	NOUN	O	O	3978
dyskinesia	NOUN	O	Disease	3978
.	PUNCT	O	O	3978
We	PRON	O	O	3979
have	VERB	O	O	3979
studied	VERB	O	O	3979
the	PRON	O	O	3979
regional	ADJ	O	O	3979
cerebral	ADJ	O	O	3979
blood	NOUN	O	O	3979
flow	NOUN	O	O	3979
(	PUNCT	O	O	3979
rCBF	X	O	O	3979
)	PUNCT	O	O	3979
changes	VERB	O	O	3979
induced	VERB	O	O	3979
by	ADP	O	O	3979
the	PRON	O	O	3979
execution	NOUN	O	O	3979
of	ADP	O	O	3979
a	PRON	O	O	3979
finger	NOUN	O	O	3979
-	PUNCT	O	O	3979
to	PART	O	O	3979
-	PUNCT	O	O	3979
thumb	NOUN	O	O	3979
opposition	NOUN	O	O	3979
motor	NOUN	O	O	3979
task	NOUN	O	O	3979
in	ADP	O	O	3979
the	PRON	O	O	3979
supplementary	ADJ	O	O	3979
and	CCONJ	O	O	3979
primary	NOUN	O	O	3979
motor	NOUN	O	O	3979
cortex	VERB	O	O	3979
of	ADP	O	O	3979
two	NUM	O	O	3979
groups	NOUN	O	O	3979
of	ADP	O	O	3979
parkinsonian	PROPN	O	Disease	3979
patients	NOUN	O	O	3979
on	ADP	O	O	3979
L	NOUN	O	O	3979
-	PUNCT	O	O	3979
dopa	PROPN	O	O	3979
medication	NOUN	O	O	3979
,	PUNCT	O	O	3979
the	PRON	O	O	3979
first	ADV	O	O	3979
one	NUM	O	O	3979
without	ADP	O	O	3979
L	NOUN	O	O	3979
-	PUNCT	O	O	3979
dopa	PROPN	O	O	3979
induced	VERB	O	O	3979
dyskinesia	NOUN	O	Disease	3979
(	PUNCT	O	O	3979
n	CCONJ	O	O	3979
=	PUNCT	O	O	3979
23	NUM	O	O	3979
)	PUNCT	O	O	3979
and	CCONJ	O	O	3979
the	PRON	O	O	3979
other	ADJ	O	O	3979
with	ADP	O	O	3979
moderate	ADJ	O	O	3979
peak	PROPN	O	O	3979
-	PUNCT	O	O	3979
dose	NOUN	O	O	3979
dyskinesia	NOUN	O	Disease	3979
(	PUNCT	O	O	3979
n	CCONJ	O	O	3979
=	PUNCT	O	O	3979
15	NUM	O	O	3979
)	PUNCT	O	O	3979
,	PUNCT	O	O	3979
and	CCONJ	O	O	3979
of	ADP	O	O	3979
a	PRON	O	O	3979
group	NOUN	O	O	3979
of	ADP	O	O	3979
14	NUM	O	O	3979
normal	ADJ	O	O	3979
subjects	NOUN	O	O	3979
.	PUNCT	O	O	3979
The	PRON	O	O	3980
dyskinetic	VERB	O	Disease	3980
parkinsonian	PROPN	O	Disease	3980
patients	NOUN	O	O	3980
exhibited	VERB	O	O	3980
a	PRON	O	O	3980
pattern	NOUN	O	O	3980
of	ADP	O	O	3980
response	NOUN	O	O	3980
which	PRON	O	O	3980
was	AUX	O	O	3980
markedly	ADV	O	O	3980
different	ADJ	O	O	3980
from	ADP	O	O	3980
those	PRON	O	O	3980
of	ADP	O	O	3980
the	PRON	O	O	3980
normal	ADJ	O	O	3980
subjects	NOUN	O	O	3980
and	CCONJ	O	O	3980
non	ADJ	O	O	3980
-	PUNCT	O	O	3980
dyskinetic	VERB	O	Disease	3980
parkinsonian	PROPN	O	Disease	3980
patients	NOUN	O	O	3980
,	PUNCT	O	O	3980
with	ADP	O	O	3980
a	PRON	O	O	3980
significant	ADJ	O	O	3980
overactivation	NOUN	O	O	3980
in	ADP	O	O	3980
the	PRON	O	O	3980
supplementary	ADJ	O	O	3980
motor	NOUN	O	O	3980
area	NOUN	O	O	3980
and	CCONJ	O	O	3980
the	PRON	O	O	3980
ipsi-	PROPN	O	O	3980
and	CCONJ	O	O	3980
contralateral	ADJ	O	O	3980
primary	NOUN	O	O	3980
motor	NOUN	O	O	3980
areas	NOUN	O	O	3980
.	PUNCT	O	O	3980
These	PRON	O	O	3981
results	VERB	O	O	3981
are	AUX	O	O	3981
compatible	ADJ	O	O	3981
with	ADP	O	O	3981
the	PRON	O	O	3981
hypothesis	NOUN	O	O	3981
that	SCONJ	O	O	3981
an	PRON	O	O	3981
hyperkinetic	ADJ	O	Disease	3981
abnormal involuntary movement	NOUN	O	Disease	3981
,	PUNCT	O	O	3981
like	INTJ	O	O	3981
L	NOUN	O	O	3981
-	PUNCT	O	O	3981
dopa	PROPN	O	O	3981
-	PUNCT	O	O	3981
induced	VERB	O	O	3981
peak	PROPN	O	O	3981
dose	NOUN	O	O	3981
dyskinesia	NOUN	O	Disease	3981
,	PUNCT	O	O	3981
is	AUX	O	O	3981
due	ADJ	O	O	3981
to	PART	O	O	3981
a	PRON	O	O	3981
disinhibition	NOUN	O	O	3981
of	ADP	O	O	3981
the	PRON	O	O	3981
primary	NOUN	O	O	3981
and	CCONJ	O	O	3981
associated	VERB	O	O	3981
motor	NOUN	O	O	3981
cortex	VERB	O	O	3981
secondary	ADJ	O	O	3981
to	PART	O	O	3981
an	PRON	O	O	3981
excessive	ADJ	O	O	3981
outflow	NOUN	O	O	3981
of	ADP	O	O	3981
the	PRON	O	O	3981
pallidothalamocortical	VERB	O	O	3981
motor	NOUN	O	O	3981
loop	NOUN	O	O	3981
.	PUNCT	O	O	3981
Dexamethasone	NOUN	O	Chemical	3984
-	PUNCT	O	O	3984
induced	VERB	O	O	3984
ocular hypertension	NOUN	O	Disease	3984
in	ADP	O	O	3984
perfusion	NOUN	O	O	3984
-	PUNCT	O	O	3984
cultured	ADJ	O	O	3984
human	PROPN	O	O	3984
eyes	NOUN	O	O	3984
.	PUNCT	O	O	3984
Glucocorticoid	PROPN	O	O	3985
administration	NOUN	O	O	3985
can	AUX	O	O	3985
lead	VERB	O	Chemical	3985
to	PART	O	O	3985
the	PRON	O	O	3985
development	NOUN	O	O	3985
of	ADP	O	O	3985
ocular hypertension	NOUN	O	Disease	3985
and	CCONJ	O	O	3985
corticosteroid glaucoma	NOUN	O	Disease	3985
in	ADP	O	O	3985
a	PRON	O	O	3985
subset	VERB	O	O	3985
of	ADP	O	O	3985
the	PRON	O	O	3985
population	NOUN	O	O	3985
through	ADP	O	O	3985
a	PRON	O	O	3985
decrease	VERB	O	O	3985
in	ADP	O	O	3985
the	PRON	O	O	3985
aqueous	ADJ	O	O	3985
humor	NOUN	O	O	3985
outflow	NOUN	O	O	3985
facility	NOUN	O	O	3985
.	PUNCT	O	O	3985
M	NOUN	O	Chemical	3986
dexamethasone	NOUN	O	Chemical	3986
for	ADP	O	O	3986
12	NUM	O	O	3986
days	NOUN	O	O	3986
.	PUNCT	O	O	3986
A	PRON	O	O	3987
significant	ADJ	O	O	3987
increase	VERB	O	O	3987
in	ADP	O	O	3987
intraocular	ADJ	O	O	3987
pressure	NOUN	O	O	3987
developed	VERB	O	O	3987
in	ADP	O	O	3987
13	NUM	O	O	3987
of	ADP	O	O	3987
the	PRON	O	O	3987
44	NUM	O	O	3987
pairs	NOUN	O	O	3987
of	ADP	O	O	3987
eyes	NOUN	O	O	3987
perfused	VERB	O	O	3987
with	ADP	O	O	3987
dexamethasone	NOUN	O	Chemical	3987
with	ADP	O	O	3987
an	PRON	O	O	3987
average	ADJ	O	O	3987
pressure	NOUN	O	O	3987
rise	VERB	O	O	3987
of	ADP	O	O	3987
17.5	NUM	O	O	3987
+	ADP	O	O	3987
/-	PUNCT	O	O	3987
3.8	NUM	O	O	3988
mm	INTJ	O	O	3988
Hg	PROPN	O	O	3988
after	ADP	O	O	3988
12	NUM	O	O	3988
days	NOUN	O	O	3988
of	ADP	O	O	3988
dexamethasone	NOUN	O	Chemical	3988
exposure	NOUN	O	O	3988
.	PUNCT	O	O	3988
The	PRON	O	O	3989
contralateral	ADJ	O	O	3989
control	VERB	O	O	3989
eyes	NOUN	O	O	3989
,	PUNCT	O	O	3989
which	PRON	O	O	3989
did	VERB	O	O	3989
not	PART	O	O	3989
receive	VERB	O	O	3989
dexamethasone	NOUN	O	Chemical	3989
,	PUNCT	O	O	3989
maintained	VERB	O	O	3989
a	PRON	O	O	3989
stable	ADJ	O	O	3989
intraocular	ADJ	O	O	3989
pressure	NOUN	O	O	3989
during	ADP	O	O	3989
the	PRON	O	O	3989
same	ADJ	O	O	3989
period	NOUN	O	O	3989
.	PUNCT	O	O	3989
In	ADP	O	O	3990
contrast	NOUN	O	O	3990
,	PUNCT	O	O	3990
the	PRON	O	O	3990
dexamethasone	NOUN	O	Chemical	3990
-	PUNCT	O	O	3990
treated	VERB	O	O	3990
hypertensive eyes	NOUN	O	Disease	3990
had	VERB	O	O	3990
thickened	VERB	O	O	3990
trabecular	NOUN	O	O	3990
beams	NOUN	O	O	3990
,	PUNCT	O	O	3990
decreased	VERB	O	O	3990
intertrabecular	ADJ	O	O	3990
spaces	NOUN	O	O	3990
,	PUNCT	O	O	3990
thickened	VERB	O	O	3990
juxtacanalicular	PROPN	O	O	3990
tissue	NOUN	O	O	3990
,	PUNCT	O	O	3990
activated	VERB	O	O	3990
trabecular	NOUN	O	O	3990
meshwork	NOUN	O	O	3990
cells	NOUN	O	O	3990
,	PUNCT	O	O	3990
and	CCONJ	O	O	3990
increased	VERB	O	O	3990
amounts	VERB	O	O	3990
of	ADP	O	O	3990
amorphogranular	ADJ	O	O	3990
extracellular	ADJ	O	O	3990
material	ADJ	O	O	3990
,	PUNCT	O	O	3990
especially	ADV	O	O	3990
in	ADP	O	O	3990
the	PRON	O	O	3990
juxtacanalicular	PROPN	O	O	3990
tissue	NOUN	O	O	3990
and	CCONJ	O	O	3990
beneath	ADP	O	O	3990
the	PRON	O	O	3990
endothelial	NOUN	O	O	3990
lining	VERB	O	O	3990
of	ADP	O	O	3990
the	PRON	O	O	3990
canal	PROPN	O	O	3990
of	ADP	O	O	3990
Schlemm	NOUN	O	O	3990
.	PUNCT	O	O	3990
The	PRON	O	O	3991
dexamethasone	NOUN	O	Chemical	3991
-	PUNCT	O	O	3991
treated	VERB	O	O	3991
nonresponder	NOUN	O	O	3991
eyes	NOUN	O	O	3991
appeared	VERB	O	O	3991
to	PART	O	O	3991
be	AUX	O	O	3991
morphologically	ADV	O	O	3991
similar	ADJ	O	O	3991
to	PART	O	O	3991
the	PRON	O	O	3991
untreated	ADJ	O	O	3991
eyes	NOUN	O	O	3991
,	PUNCT	O	O	3991
although	SCONJ	O	O	3991
several	ADJ	O	O	3991
subtle	ADJ	O	O	3991
dexamethasone	NOUN	O	Chemical	3991
-	PUNCT	O	O	3991
induced	VERB	O	O	3991
morphologic	ADJ	O	O	3991
changes	VERB	O	O	3991
were	AUX	O	O	3991
evident	ADJ	O	O	3991
.	PUNCT	O	O	3991
Dexamethasone	NOUN	O	Chemical	3992
treatment	NOUN	O	O	3992
of	ADP	O	O	3992
isolated	VERB	O	O	3992
,	PUNCT	O	O	3992
perfusion	NOUN	O	O	3992
-	PUNCT	O	O	3992
cultured	ADJ	O	O	3992
human	PROPN	O	O	3992
eyes	NOUN	O	O	3992
led	VERB	O	O	3992
to	PART	O	O	3992
the	PRON	O	O	3992
generation	NOUN	O	O	3992
of	ADP	O	O	3992
ocular hypertension	NOUN	O	Disease	3992
in	ADP	O	O	3992
approximately	ADV	O	O	3992
30%	NOUN	O	O	3992
of	ADP	O	O	3992
the	PRON	O	O	3992
dexamethasone	NOUN	O	Chemical	3992
-	PUNCT	O	O	3992
treated	VERB	O	O	3992
eyes	NOUN	O	O	3992
.	PUNCT	O	O	3992
Steroid	NOUN	O	Chemical	3993
treatment	NOUN	O	O	3993
resulted	VERB	O	O	3993
in	ADP	O	O	3993
morphologic	ADJ	O	O	3993
changes	VERB	O	O	3993
in	ADP	O	O	3993
the	PRON	O	O	3993
trabecular	NOUN	O	O	3993
meshwork	NOUN	O	O	3993
similar	ADJ	O	O	3993
to	PART	O	O	3993
those	PRON	O	O	3993
reported	VERB	O	O	3993
for	ADP	O	O	3993
corticosteroid glaucoma	NOUN	O	Disease	3993
and	CCONJ	O	O	3993
open angle glaucoma	NOUN	O	Disease	3993
.	PUNCT	O	O	3993
This	PRON	O	O	3994
system	NOUN	O	O	3994
may	AUX	O	O	3994
provide	VERB	O	O	3994
an	PRON	O	O	3994
acute	ADJ	O	O	3994
model	NOUN	O	O	3994
in	ADP	O	O	3994
which	PRON	O	O	3994
to	PART	O	O	3994
study	VERB	O	O	3994
the	PRON	O	O	3994
pathogenic	ADJ	O	O	3994
mechanisms	NOUN	O	O	3994
involved	VERB	O	O	3994
in	ADP	O	O	3994
steroid glaucoma	NOUN	O	Disease	3994
and	CCONJ	O	O	3994
primary open angle glaucoma	NOUN	O	Disease	3994
.	PUNCT	O	O	3994
Cognitive deterioration	NOUN	O	Disease	3997
from	ADP	O	O	3997
long	ADV	O	O	3997
-	PUNCT	O	O	3997
term	NOUN	O	O	3997
abuse	VERB	O	O	3997
of	ADP	O	O	3997
dextromethorphan	PROPN	O	Chemical	3997
:	PUNCT	O	O	3997
a	PRON	O	O	3997
case	NOUN	O	O	3997
report	VERB	O	O	3997
.	PUNCT	O	O	3997
Dextromethorphan	PROPN	O	Chemical	3998
(	PUNCT	O	O	3998
DM	PROPN	O	Disease	3998
)	PUNCT	O	O	3998
,	PUNCT	O	O	3998
the	PRON	O	O	3998
dextrorotatory	NOUN	O	O	3998
isomer	PROPN	O	O	3998
of	ADP	O	O	3998
3-hydroxy	NOUN	O	O	3998
-	PUNCT	O	O	3998
N	NUM	O	O	3998
-	PUNCT	O	O	3998
methylmorphinan	ADJ	O	O	3998
,	PUNCT	O	O	3998
is	AUX	O	O	3998
the	PRON	O	O	3998
main	ADJ	O	O	3998
ingredient	NOUN	O	O	3998
in	ADP	O	O	3998
a	PRON	O	O	3998
number	NOUN	O	O	3998
of	ADP	O	O	3998
widely	ADV	O	O	3998
available	ADJ	O	O	3998
,	PUNCT	O	O	3998
over	ADP	O	O	3998
-	PUNCT	O	O	3998
the	PRON	O	O	3998
-	PUNCT	O	O	3998
counter	VERB	O	O	3998
antitussives	VERB	O	O	3998
.	PUNCT	O	O	3998
The	PRON	O	O	3999
drug	NOUN	O	O	3999
is	AUX	O	O	3999
known	VERB	O	O	3999
to	PART	O	O	3999
cause	VERB	O	O	3999
a	PRON	O	O	3999
variety	NOUN	O	O	3999
of	ADP	O	O	3999
acute	ADJ	O	O	3999
toxic	ADJ	O	O	3999
effects	NOUN	O	O	3999
,	PUNCT	O	O	3999
ranging	VERB	O	O	3999
from	ADP	O	O	3999
nausea	NOUN	O	Disease	3999
,	PUNCT	O	O	3999
restlessness	NOUN	O	Disease	3999
,	PUNCT	O	O	3999
insomnia	NOUN	O	Disease	3999
,	PUNCT	O	O	3999
ataxia	NOUN	O	Disease	3999
,	PUNCT	O	O	3999
slurred	VERB	O	O	3999
speech	NOUN	O	O	3999
and	CCONJ	O	O	3999
nystagmus	VERB	O	Disease	3999
to	PART	O	O	3999
mood	NOUN	O	O	3999
changes	VERB	O	O	3999
,	PUNCT	O	O	3999
perceptual	ADJ	O	O	3999
alterations	NOUN	O	O	3999
,	PUNCT	O	O	3999
inattention	NOUN	O	O	3999
,	PUNCT	O	O	3999
disorientation	NOUN	O	O	3999
and	CCONJ	O	O	3999
aggressive behavior	NOUN	O	Disease	3999
(	PUNCT	O	O	3999
Rammer	NOUN	O	O	3999
et	PRON	O	O	3999
al	PROPN	O	O	3999
1988	NUM	O	O	3999
;	PUNCT	O	O	3999
Katona	PROPN	O	O	3999
and	CCONJ	O	O	3999
Watson	PROPN	O	O	3999
1986	NUM	O	O	3999
;	PUNCT	O	O	3999
Isbell	NOUN	O	O	3999
and	CCONJ	O	O	3999
Fraser	PROPN	O	O	3999
1953	NUM	O	O	3999
;	PUNCT	O	O	3999
There	ADV	O	O	4000
have	VERB	O	O	4000
also	ADV	O	O	4000
been	AUX	O	O	4000
two	NUM	O	O	4000
reported	VERB	O	O	4000
fatalities	NOUN	O	O	4000
from	ADP	O	O	4000
DM	PROPN	O	Disease	4000
overdoses	VERB	O	O	4000
(	PUNCT	O	O	4000
Fleming	NOUN	O	O	4000
1986	NUM	O	O	4000
)	PUNCT	O	O	4000
.	PUNCT	O	O	4000
This	PRON	O	O	4001
report	VERB	O	O	4001
describes	VERB	O	O	4001
a	PRON	O	O	4001
case	NOUN	O	O	4001
of	ADP	O	O	4001
cognitive deterioration	NOUN	O	Disease	4001
resulting	VERB	O	O	4001
from	ADP	O	O	4001
prolonged	VERB	O	O	4001
use	VERB	O	O	4001
of	ADP	O	O	4001
DM	PROPN	O	Disease	4001
.	PUNCT	O	O	4001
Long	ADV	O	O	4004
-	PUNCT	O	O	4004
term	NOUN	O	O	4004
lithium	NOUN	O	Chemical	4004
treatment	NOUN	O	O	4004
and	CCONJ	O	O	4004
the	PRON	O	O	4004
kidney	NOUN	O	O	4004
.	PUNCT	O	O	4004
This	PRON	O	O	4005
is	AUX	O	O	4005
a	PRON	O	O	4005
report	VERB	O	O	4005
on	ADP	O	O	4005
the	PRON	O	O	4005
first	ADV	O	O	4005
part	NOUN	O	O	4005
of	ADP	O	O	4005
our	PRON	O	O	4005
study	VERB	O	O	4005
of	ADP	O	O	4005
the	PRON	O	O	4005
effects	NOUN	O	O	4005
of	ADP	O	O	4005
long	ADV	O	O	4005
-	PUNCT	O	O	4005
term	NOUN	O	O	4005
lithium	NOUN	O	Chemical	4005
treatment	NOUN	O	O	4005
on	ADP	O	O	4005
the	PRON	O	O	4005
kidney	NOUN	O	O	4005
.	PUNCT	O	O	4005
Creatinine	NOUN	O	Chemical	4006
clearance	NOUN	O	O	4006
,	PUNCT	O	O	4006
maximum	ADV	O	O	4006
urinary	ADJ	O	O	4006
osmolality	NOUN	O	O	4006
and	CCONJ	O	O	4006
24	NUM	O	O	4006
hour	NOUN	O	O	4006
urine	NOUN	O	O	4006
volume	PROPN	O	O	4006
have	VERB	O	O	4006
been	AUX	O	O	4006
tested	VERB	O	O	4006
in	ADP	O	O	4006
50	NUM	O	O	4006
affectively	ADV	O	O	4006
ill	PROPN	O	O	4006
patients	NOUN	O	O	4006
who	PRON	O	O	4006
have	VERB	O	O	4006
been	AUX	O	O	4006
on	ADP	O	O	4006
long	ADV	O	O	4006
-	PUNCT	O	O	4006
term	NOUN	O	O	4006
lithium	NOUN	O	Chemical	4006
for	ADP	O	O	4006
more	ADJ	O	O	4006
than	ADP	O	O	4006
one	NUM	O	O	4006
year	NOUN	O	O	4006
.	PUNCT	O	O	4006
These	PRON	O	O	4007
findings	NOUN	O	O	4007
have	VERB	O	O	4007
been	AUX	O	O	4007
compared	VERB	O	O	4007
with	ADP	O	O	4007
norms	NOUN	O	O	4007
and	CCONJ	O	O	4007
with	ADP	O	O	4007
values	NOUN	O	O	4007
of	ADP	O	O	4007
the	PRON	O	O	4007
same	ADJ	O	O	4007
tests	VERB	O	O	4007
from	ADP	O	O	4007
screening	VERB	O	O	4007
prior	ADV	O	O	4007
to	PART	O	O	4007
lithium	NOUN	O	Chemical	4007
,	PUNCT	O	O	4007
available	ADJ	O	O	4007
for	ADP	O	O	4007
most	ADV	O	O	4007
of	ADP	O	O	4007
our	PRON	O	O	4007
patients	NOUN	O	O	4007
.	PUNCT	O	O	4007
No	PRON	O	O	4008
evidence	NOUN	O	O	4008
was	AUX	O	O	4008
found	VERB	O	O	4008
for	ADP	O	O	4008
any	PRON	O	O	4008
reduction	NOUN	O	O	4008
of	ADP	O	O	4008
glomerular	ADJ	O	O	4008
filtration	NOUN	O	O	4008
during	ADP	O	O	4008
lithium	NOUN	O	Chemical	4008
treatment	NOUN	O	O	4008
.	PUNCT	O	O	4008
Low	ADJ	O	O	4009
clearance	NOUN	O	O	4009
values	NOUN	O	O	4009
found	VERB	O	O	4009
in	ADP	O	O	4009
several	ADJ	O	O	4009
patients	NOUN	O	O	4009
could	AUX	O	O	4009
be	AUX	O	O	4009
accounted	VERB	O	O	4009
for	ADP	O	O	4009
by	ADP	O	O	4009
their	PRON	O	O	4009
age	NOUN	O	O	4009
and	CCONJ	O	O	4009
their	PRON	O	O	4009
pre	VERB	O	O	4009
-	PUNCT	O	O	4009
lithium	NOUN	O	Chemical	4009
values	NOUN	O	O	4009
.	PUNCT	O	O	4009
Polyuria	PROPN	O	Disease	4010
above	ADP	O	O	4010
3	X	O	O	4010
litres/24	NOUN	O	O	4010
hours	NOUN	O	O	4010
was	AUX	O	O	4010
found	VERB	O	O	4010
in	ADP	O	O	4010
10%	NOUN	O	O	4010
of	ADP	O	O	4010
patients	NOUN	O	O	4010
.	PUNCT	O	O	4010
Complete	ADJ	O	O	4013
heart block	NOUN	O	Disease	4013
following	VERB	O	O	4013
a	PRON	O	O	4013
single	ADJ	O	O	4013
dose	NOUN	O	O	4013
of	ADP	O	O	4013
trazodone	NOUN	O	Chemical	4013
.	PUNCT	O	O	4013
Forty	NUM	O	O	4014
minutes	NOUN	O	O	4014
after	ADP	O	O	4014
receiving	VERB	O	O	4014
a	PRON	O	O	4014
single	ADJ	O	O	4014
starting	VERB	O	O	4014
dose	NOUN	O	O	4014
of	ADP	O	O	4014
trazodone	NOUN	O	Chemical	4014
,	PUNCT	O	O	4014
a	PRON	O	O	4014
patient	NOUN	O	O	4014
developed	VERB	O	O	4014
complete	VERB	O	O	4014
heart block	NOUN	O	Disease	4014
.	PUNCT	O	O	4014
The	PRON	O	O	4015
case	NOUN	O	O	4015
illustrates	VERB	O	O	4015
that	SCONJ	O	O	4015
,	PUNCT	O	O	4015
despite	SCONJ	O	O	4015
the	PRON	O	O	4015
results	VERB	O	O	4015
of	ADP	O	O	4015
earlier	ADV	O	O	4015
studies	NOUN	O	O	4015
,	PUNCT	O	O	4015
trazodone	NOUN	O	Chemical	4015
's	AUX	O	O	4015
effect	VERB	O	O	4015
on	ADP	O	O	4015
cardiac	ADJ	O	O	4015
conduction	NOUN	O	O	4015
may	AUX	O	O	4015
be	AUX	O	O	4015
severe	ADJ	O	O	4015
in	ADP	O	O	4015
individuals	NOUN	O	O	4015
at	ADP	O	O	4015
risk	NOUN	O	O	4015
for	ADP	O	O	4015
conduction	NOUN	O	O	4015
delay	NOUN	O	O	4015
.	PUNCT	O	O	4015
Quinidine phenylethylbarbiturate	NOUN	O	Chemical	4018
-	PUNCT	O	O	4018
induced	VERB	O	O	4018
fulminant	ADJ	O	O	4018
hepatitis	NOUN	O	Disease	4018
in	ADP	O	O	4018
a	PRON	O	O	4018
pregnant	ADJ	O	O	4018
woman	NOUN	O	O	4018
.	PUNCT	O	O	4018
We	PRON	O	O	4019
report	VERB	O	O	4019
the	PRON	O	O	4019
case	NOUN	O	O	4019
of	ADP	O	O	4019
a	PRON	O	O	4019
19-year	NOUN	O	O	4019
-	PUNCT	O	O	4019
old	ADJ	O	O	4019
Laotian	ADJ	O	O	4019
patient	NOUN	O	O	4019
affected	VERB	O	O	4019
by	ADP	O	O	4019
fulminant	ADJ	O	O	4019
hepatitis	NOUN	O	Disease	4019
during	ADP	O	O	4019
the	PRON	O	O	4019
third	ADV	O	O	4019
trimester	VERB	O	O	4019
of	ADP	O	O	4019
her	PRON	O	O	4019
pregnancy	NOUN	O	O	4019
after	ADP	O	O	4019
a	PRON	O	O	4019
1-month	NOUN	O	O	4019
administration	NOUN	O	O	4019
of	ADP	O	O	4019
quinidine phenylethylbarbiturate	NOUN	O	Chemical	4019
.	PUNCT	O	O	4019
Quinidine	PROPN	O	Chemical	4020
itself	PRON	O	O	4020
or	CCONJ	O	O	4020
phenylethylbarbiturate	NOUN	O	Chemical	4020
may	AUX	O	O	4020
be	AUX	O	O	4020
responsible	ADJ	O	O	4020
for	ADP	O	O	4020
fulminant	ADJ	O	O	4020
hepatitis	NOUN	O	Disease	4020
in	ADP	O	O	4020
this	PRON	O	O	4020
patient	NOUN	O	O	4020
.	PUNCT	O	O	4020
The	PRON	O	O	4023
epidemiology	NOUN	O	O	4023
of	ADP	O	O	4023
the	PRON	O	O	4023
acute	ADJ	O	O	4023
flank pain	NOUN	O	Disease	4023
syndrome	NOUN	O	O	4023
from	ADP	O	O	4023
suprofen	NOUN	O	Chemical	4023
.	PUNCT	O	O	4023
Suprofen	NOUN	O	Chemical	4024
,	PUNCT	O	O	4024
a	PRON	O	O	4024
new	ADJ	O	O	4024
nonsteroidal	ADJ	O	O	4024
anti	ADJ	O	O	4024
-	PUNCT	O	O	4024
inflammatory	ADJ	O	O	4024
drug	NOUN	O	O	4024
,	PUNCT	O	O	4024
was	AUX	O	O	4024
marketed	VERB	O	O	4024
in	ADP	O	O	4024
early	ADV	O	O	4024
1986	NUM	O	O	4024
as	ADP	O	O	4024
an	PRON	O	O	4024
analgesic	PROPN	O	O	4024
agent	NOUN	O	O	4024
.	PUNCT	O	O	4024
Until	ADP	O	O	4025
physicians	NOUN	O	O	4025
began	VERB	O	O	4025
reporting	VERB	O	O	4025
an	PRON	O	O	4025
unusual	ADJ	O	O	4025
acute	ADJ	O	O	4025
flank pain	NOUN	O	Disease	4025
syndrome	NOUN	O	O	4025
to	PART	O	O	4025
the	PRON	O	O	4025
spontaneous	ADJ	O	O	4025
reporting	VERB	O	O	4025
system	NOUN	O	O	4025
,	PUNCT	O	O	4025
700,000	NUM	O	O	4025
persons	NOUN	O	O	4025
used	VERB	O	O	4025
the	PRON	O	O	4025
drug	NOUN	O	O	4025
in	ADP	O	O	4025
the	PRON	O	O	4025
United	PROPN	O	O	4025
States	NOUN	O	O	4025
.	PUNCT	O	O	4025
To	PART	O	O	4026
elucidate	VERB	O	O	4026
the	PRON	O	O	4026
epidemiology	NOUN	O	O	4026
of	ADP	O	O	4026
the	PRON	O	O	4026
syndrome	NOUN	O	O	4026
,	PUNCT	O	O	4026
a	PRON	O	O	4026
case	NOUN	O	O	4026
-	PUNCT	O	O	4026
control	VERB	O	O	4026
study	VERB	O	O	4026
was	AUX	O	O	4026
performed	VERB	O	O	4026
,	PUNCT	O	O	4026
comparing	VERB	O	O	4026
62	NUM	O	O	4026
of	ADP	O	O	4026
the	PRON	O	O	4026
case	NOUN	O	O	4026
patients	NOUN	O	O	4026
who	PRON	O	O	4026
had	VERB	O	O	4026
been	AUX	O	O	4026
reported	VERB	O	O	4026
to	PART	O	O	4026
the	PRON	O	O	4026
spontaneous	ADJ	O	O	4026
reporting	VERB	O	O	4026
system	NOUN	O	O	4026
to	PART	O	O	4026
185	NUM	O	O	4026
suprofen	NOUN	O	Chemical	4026
-	PUNCT	O	O	4026
exposed	VERB	O	O	4026
control	VERB	O	O	4026
subjects	NOUN	O	O	4026
who	PRON	O	O	4026
did	VERB	O	O	4026
not	PART	O	O	4026
have	VERB	O	O	4026
the	PRON	O	O	4026
syndrome	NOUN	O	O	4026
.	PUNCT	O	O	4026
Case	NOUN	O	O	4027
patients	NOUN	O	O	4027
were	AUX	O	O	4027
more	ADJ	O	O	4027
likely	ADV	O	O	4027
to	PART	O	O	4027
be	AUX	O	O	4027
men	NOUN	O	O	4027
(	PUNCT	O	O	4027
odds	NOUN	O	O	4027
ratio	NOUN	O	O	4027
,	PUNCT	O	O	4027
3.8	NUM	O	O	4027
;	PUNCT	O	O	4027
95%	NOUN	O	O	4027
confidence	NOUN	O	O	4027
interval	NOUN	O	O	4027
,	PUNCT	O	O	4027
1.2	NUM	O	O	4027
-	PUNCT	O	O	4027
12.1	NUM	O	O	4027
)	PUNCT	O	O	4027
,	PUNCT	O	O	4027
suffer	VERB	O	O	4027
from	ADP	O	O	4027
hay fever	NOUN	O	Disease	4027
and	CCONJ	O	O	4027
asthma	PROPN	O	Disease	4027
(	PUNCT	O	O	4027
odds	NOUN	O	O	4027
ratio	NOUN	O	O	4027
,	PUNCT	O	O	4027
3.4	NUM	O	O	4027
;	PUNCT	O	O	4027
95%	NOUN	O	O	4027
confidence	NOUN	O	O	4027
interval	NOUN	O	O	4027
,	PUNCT	O	O	4027
1.0	NUM	O	O	4027
-	PUNCT	O	O	4027
11.9	NUM	O	O	4027
)	PUNCT	O	O	4027
;	PUNCT	O	O	4027
to	PART	O	O	4027
participate	VERB	O	O	4027
in	ADP	O	O	4027
regular	ADJ	O	O	4027
exercise	VERB	O	O	4027
(	PUNCT	O	O	4027
odds	NOUN	O	O	4027
ratio	NOUN	O	O	4027
,	PUNCT	O	O	4027
5.9	NUM	O	O	4027
;	PUNCT	O	O	4027
95%	NOUN	O	O	4027
confidence	NOUN	O	O	4027
interval	NOUN	O	O	4027
,	PUNCT	O	O	4027
1.1	NUM	O	O	4027
-	PUNCT	O	O	4027
30.7	NUM	O	O	4027
)	PUNCT	O	O	4027
,	PUNCT	O	O	4027
especially	ADV	O	O	4027
in	ADP	O	O	4027
the	PRON	O	O	4027
use	VERB	O	O	4027
of	ADP	O	O	4027
Nautilus	NOUN	O	O	4027
equipment	NOUN	O	O	4027
(	PUNCT	O	O	4027
p	NOUN	O	O	4027
=	PUNCT	O	O	4027
0.02	NUM	O	O	4027
)	PUNCT	O	O	4027
;	PUNCT	O	O	4027
and	CCONJ	O	O	4027
to	PART	O	O	4027
use	VERB	O	O	4027
alcohol	NOUN	O	Chemical	4027
(	PUNCT	O	O	4027
odds	NOUN	O	O	4027
ratio	NOUN	O	O	4027
,	PUNCT	O	O	4027
4.4	NUM	O	O	4027
;	PUNCT	O	O	4027
95%	NOUN	O	O	4027
confidence	NOUN	O	O	4027
interval	NOUN	O	O	4027
,	PUNCT	O	O	4027
1.1	NUM	O	O	4027
-	PUNCT	O	O	4027
17.5	NUM	O	O	4027
)	PUNCT	O	O	4027
.	PUNCT	O	O	4027
Possible	ADJ	O	O	4028
risk	NOUN	O	O	4028
factors	NOUN	O	O	4028
included	VERB	O	O	4028
young	ADJ	O	O	4028
age	NOUN	O	O	4028
,	PUNCT	O	O	4028
concurrent	ADJ	O	O	4028
use	VERB	O	O	4028
of	ADP	O	O	4028
other	ADJ	O	O	4028
analgesic	PROPN	O	O	4028
agents	NOUN	O	O	4028
(	PUNCT	O	O	4028
especially	ADV	O	O	4028
ibuprofen	PROPN	O	Chemical	4028
)	PUNCT	O	O	4028
,	PUNCT	O	O	4028
preexisting	VERB	O	O	4028
renal disease	NOUN	O	Disease	4028
,	PUNCT	O	O	4028
a	PRON	O	O	4028
history	NOUN	O	O	4028
of	ADP	O	O	4028
kidney stones	NOUN	O	Disease	4028
,	PUNCT	O	O	4028
a	PRON	O	O	4028
history	NOUN	O	O	4028
of	ADP	O	O	4028
gout	NOUN	O	Disease	4028
,	PUNCT	O	O	4028
a	PRON	O	O	4028
recent	ADJ	O	O	4028
increase	VERB	O	O	4028
in	ADP	O	O	4028
activity	NOUN	O	O	4028
,	PUNCT	O	O	4028
a	PRON	O	O	4028
recent	ADJ	O	O	4028
increase	VERB	O	O	4028
in	ADP	O	O	4028
sun	PROPN	O	O	4028
exposure	NOUN	O	O	4028
,	PUNCT	O	O	4028
and	CCONJ	O	O	4028
residence	NOUN	O	O	4028
in	ADP	O	O	4028
the	PRON	O	O	4028
Sunbelt	PROPN	O	O	4028
.	PUNCT	O	O	4028
These	PRON	O	O	4029
findings	NOUN	O	O	4029
are	AUX	O	O	4029
consistent	ADJ	O	O	4029
with	ADP	O	O	4029
the	PRON	O	O	4029
postulated	VERB	O	O	4029
mechanism	NOUN	O	O	4029
for	ADP	O	O	4029
this	PRON	O	O	4029
unusual	ADJ	O	O	4029
syndrome	NOUN	O	O	4029
:	PUNCT	O	O	4029
acute	ADJ	O	O	4029
diffuse	VERB	O	O	4029
crystallization	NOUN	O	O	4029
of	ADP	O	O	4029
uric acid	NOUN	O	Chemical	4029
in	ADP	O	O	4029
renal	ADJ	O	O	4029
tubules	NOUN	O	O	4029
.	PUNCT	O	O	4029
Hemolytic	ADJ	O	O	4032
-	PUNCT	O	O	4032
uremic	ADJ	O	O	4032
syndrome	NOUN	O	O	4032
associated	VERB	O	O	4032
with	ADP	O	O	4032
ingestion	NOUN	O	O	4032
of	ADP	O	O	4032
quinine	NOUN	O	Chemical	4032
.	PUNCT	O	O	4032
Hemolytic	ADJ	O	O	4033
-	PUNCT	O	O	4033
uremic	ADJ	O	O	4033
syndrome	NOUN	O	O	4033
following	VERB	O	O	4033
quinine	NOUN	O	Chemical	4033
ingestion	NOUN	O	O	4033
is	AUX	O	O	4033
a	PRON	O	O	4033
newly	ADV	O	O	4033
described	VERB	O	O	4033
phenomenon	NOUN	O	O	4033
,	PUNCT	O	O	4033
with	ADP	O	O	4033
just	ADV	O	O	4033
two	NUM	O	O	4033
previous	ADJ	O	O	4033
descriptions	NOUN	O	O	4033
of	ADP	O	O	4033
4	NUM	O	O	4033
cases	NOUN	O	O	4033
in	ADP	O	O	4033
the	PRON	O	O	4033
literature	NOUN	O	O	4033
.	PUNCT	O	O	4033
The	PRON	O	O	4034
reaction	NOUN	O	O	4034
may	AUX	O	O	4034
be	AUX	O	O	4034
mediated	VERB	O	O	4034
by	ADP	O	O	4034
the	PRON	O	O	4034
presence	NOUN	O	O	4034
of	ADP	O	O	4034
antibodies	NOUN	O	O	4034
reactive	ADJ	O	O	4034
against	ADP	O	O	4034
platelets	VERB	O	O	4034
in	ADP	O	O	4034
the	PRON	O	O	4034
presence	NOUN	O	O	4034
of	ADP	O	O	4034
quinine	NOUN	O	Chemical	4034
.	PUNCT	O	O	4034
Treatment	NOUN	O	O	4035
has	VERB	O	O	4035
included	VERB	O	O	4035
use	VERB	O	O	4035
of	ADP	O	O	4035
plasma	NOUN	O	O	4035
exchange	VERB	O	O	4035
,	PUNCT	O	O	4035
prednisone	NOUN	O	Chemical	4035
,	PUNCT	O	O	4035
aspirin	NOUN	O	Chemical	4035
,	PUNCT	O	O	4035
and	CCONJ	O	O	4035
dipyridamole	NOUN	O	Chemical	4035
.	PUNCT	O	O	4035
Quinine	NOUN	O	Chemical	4036
-	PUNCT	O	O	4036
associated	VERB	O	O	4036
hemolytic	ADJ	O	O	4036
-	PUNCT	O	O	4036
uremic	ADJ	O	O	4036
syndrome	NOUN	O	O	4036
probably	ADV	O	O	4036
occurs	VERB	O	O	4036
more	ADJ	O	O	4036
often	ADV	O	O	4036
than	ADP	O	O	4036
is	AUX	O	O	4036
recognized	VERB	O	O	4036
.	PUNCT	O	O	4036
It	PRON	O	O	4037
is	AUX	O	O	4037
important	ADJ	O	O	4037
to	PART	O	O	4037
recognize	VERB	O	O	4037
this	PRON	O	O	4037
reaction	NOUN	O	O	4037
when	SCONJ	O	O	4037
it	PRON	O	O	4037
occurs	VERB	O	O	4037
and	CCONJ	O	O	4037
to	PART	O	O	4037
avoid	VERB	O	O	4037
further	ADV	O	O	4037
quinine	NOUN	O	Chemical	4037
exposure	NOUN	O	O	4037
,	PUNCT	O	O	4037
since	SCONJ	O	O	4037
the	PRON	O	O	4037
reaction	NOUN	O	O	4037
seems	VERB	O	O	4037
to	PART	O	O	4037
be	AUX	O	O	4037
recurrent	ADJ	O	O	4037
.	PUNCT	O	O	4037
The	PRON	O	O	4040
etiology	NOUN	O	O	4040
of	ADP	O	O	4040
pyeloureteritis cystica	NOUN	O	Disease	4040
has	VERB	O	O	4040
long	ADV	O	O	4040
been	AUX	O	O	4040
attributed	VERB	O	O	4040
to	PART	O	O	4040
chronic	ADJ	O	O	4040
infection	NOUN	O	Disease	4040
and	CCONJ	O	O	4040
inflammation	NOUN	O	Disease	4040
.	PUNCT	O	O	4040
There	ADV	O	O	4041
is	AUX	O	O	4041
no	PRON	O	O	4041
evidence	NOUN	O	O	4041
of	ADP	O	O	4041
antecedent	NOUN	O	O	4041
or	CCONJ	O	O	4041
concurrent	ADJ	O	O	4041
infection	NOUN	O	Disease	4041
in	ADP	O	O	4041
this	PRON	O	O	4041
patient	NOUN	O	O	4041
.	PUNCT	O	O	4041
The	PRON	O	O	4042
disease	PROPN	O	O	4042
occurred	VERB	O	O	4042
subsequent	ADJ	O	O	4042
to	PART	O	O	4042
the	PRON	O	O	4042
initiation	NOUN	O	O	4042
of	ADP	O	O	4042
heparin	NOUN	O	Chemical	4042
therapy	NOUN	O	O	4042
for	ADP	O	O	4042
suspected	VERB	O	O	4042
pelvic	VERB	O	O	4042
thrombophlebitis	NOUN	O	Disease	4042
and	CCONJ	O	O	4042
cleared	VERB	O	O	4042
rapidly	ADV	O	O	4042
subsequent	ADJ	O	O	4042
to	PART	O	O	4042
its	PRON	O	O	4042
discontinuation	NOUN	O	O	4042
.	PUNCT	O	O	4042
The	PRON	O	O	4043
rate	NOUN	O	O	4043
of	ADP	O	O	4043
resolution	NOUN	O	O	4043
of	ADP	O	O	4043
the	PRON	O	O	4043
radiographic	ADJ	O	O	4043
findings	NOUN	O	O	4043
may	AUX	O	O	4043
be	AUX	O	O	4043
helpful	ADJ	O	O	4043
in	ADP	O	O	4043
distinguishing	VERB	O	O	4043
between	ADP	O	O	4043
true	ADJ	O	O	4043
pyeloureteritis cystica	NOUN	O	Disease	4043
and	CCONJ	O	O	4043
submucosal hemorrhage	NOUN	O	Disease	4043
.	PUNCT	O	O	4043
Changes	NOUN	O	O	4046
in	ADP	O	O	4046
peroxisomes	VERB	O	O	4046
in	ADP	O	O	4046
preneoplastic	PROPN	O	O	4046
liver	NOUN	O	O	4046
and	CCONJ	O	O	4046
hepatoma	VERB	O	Disease	4046
of	ADP	O	O	4046
mice	NOUN	O	O	4046
induced	VERB	O	O	4046
by	ADP	O	O	4046
alpha	PROPN	O	O	4046
-	PUNCT	O	O	4046
benzene	PROPN	O	O	4046
hexachloride	NOUN	O	O	4046
.	PUNCT	O	O	4046
Peroxisomes	NOUN	O	O	4047
in	ADP	O	O	4047
hepatomas	VERB	O	Disease	4047
and	CCONJ	O	O	4047
hyperplastic	NOUN	O	O	4047
preneoplastic	PROPN	O	O	4047
liver lesions	NOUN	O	Disease	4047
induced	VERB	O	O	4047
in	ADP	O	O	4047
mice	NOUN	O	O	4047
by	ADP	O	O	4047
500	NUM	O	O	4047
ppm	ADP	O	O	4047
alpha	PROPN	O	O	4047
-	PUNCT	O	O	4047
benzene	PROPN	O	O	4047
hexachloride	NOUN	O	O	4047
were	AUX	O	O	4047
examined	VERB	O	O	4047
histochemically	NOUN	O	O	4047
and	CCONJ	O	O	4047
electron	NOUN	O	O	4047
microscopically	ADV	O	O	4047
.	PUNCT	O	O	4047
Although	SCONJ	O	O	4048
most	ADV	O	O	4048
of	ADP	O	O	4048
the	PRON	O	O	4048
hepatomas	VERB	O	Disease	4048
were	AUX	O	O	4048
well	ADV	O	O	4048
-	PUNCT	O	O	4048
differentiated	VERB	O	O	4048
tumors	NOUN	O	Disease	4048
and	CCONJ	O	O	4048
contained	VERB	O	O	4048
a	PRON	O	O	4048
considerable	ADJ	O	O	4048
number	NOUN	O	O	4048
of	ADP	O	O	4048
peroxisomes	VERB	O	O	4048
,	PUNCT	O	O	4048
the	PRON	O	O	4048
tumor	NOUN	O	Disease	4048
cells	NOUN	O	O	4048
did	VERB	O	O	4048
not	PART	O	O	4048
respond	VERB	O	O	4048
to	PART	O	O	4048
ethyl	PROPN	O	O	4048
-	PUNCT	O	O	4048
alpha	PROPN	O	O	4048
-	PUNCT	O	O	4048
p	NOUN	O	O	4048
-	PUNCT	O	O	4048
chlorophenoxyisobutyrate	NOUN	O	O	4048
with	ADP	O	O	4048
proliferation	NOUN	O	O	4048
of	ADP	O	O	4048
peroxisomes	VERB	O	O	4048
.	PUNCT	O	O	4048
These	PRON	O	O	4049
cells	NOUN	O	O	4049
proliferated	VERB	O	O	4049
further	ADV	O	O	4049
,	PUNCT	O	O	4049
replacing	VERB	O	O	4049
the	PRON	O	O	4049
most	ADV	O	O	4049
part	NOUN	O	O	4049
of	ADP	O	O	4049
the	PRON	O	O	4049
nodules	NOUN	O	O	4049
,	PUNCT	O	O	4049
and	CCONJ	O	O	4049
with	ADP	O	O	4049
this	PRON	O	O	4049
process	NOUN	O	O	4049
hepatomas	VERB	O	Disease	4049
appeared	VERB	O	O	4049
to	PART	O	O	4049
have	VERB	O	O	4049
been	AUX	O	O	4049
formed	VERB	O	O	4049
.	PUNCT	O	O	4049
No	PRON	O	O	4050
abnormal	ADJ	O	O	4050
matrical	ADJ	O	O	4050
inclusions	NOUN	O	O	4050
of	ADP	O	O	4050
peroxisomes	VERB	O	O	4050
were	AUX	O	O	4050
formed	VERB	O	O	4050
in	ADP	O	O	4050
the	PRON	O	O	4050
cells	NOUN	O	O	4050
of	ADP	O	O	4050
hyperplastic	NOUN	O	O	4050
nodules	NOUN	O	O	4050
by	ADP	O	O	4050
ethyl	PROPN	O	O	4050
-	PUNCT	O	O	4050
alpha	PROPN	O	O	4050
-	PUNCT	O	O	4050
p	NOUN	O	O	4050
-	PUNCT	O	O	4050
chlorophenoxyisobutyrate	NOUN	O	O	4050
unlike	ADP	O	O	4050
in	ADP	O	O	4050
the	PRON	O	O	4050
case	NOUN	O	O	4050
of	ADP	O	O	4050
rats	NOUN	O	O	4050
.	PUNCT	O	O	4050
Quinidine	PROPN	O	Chemical	4053
hepatitis	NOUN	O	Disease	4053
.	PUNCT	O	O	4053
Long	ADV	O	O	4054
-	PUNCT	O	O	4054
term	NOUN	O	O	4054
administration	NOUN	O	O	4054
of	ADP	O	O	4054
quinidine	PROPN	O	Chemical	4054
was	AUX	O	O	4054
associated	VERB	O	O	4054
with	ADP	O	O	4054
persistent	ADJ	O	O	4054
elevation	NOUN	O	O	4054
of	ADP	O	O	4054
serum	NOUN	O	O	4054
concentrations	NOUN	O	O	4054
of	ADP	O	O	4054
SGOT	NOUN	O	O	4054
,	PUNCT	O	O	4054
lactic acid	NOUN	O	Chemical	4054
dehydrogenase	NOUN	O	O	4054
,	PUNCT	O	O	4054
and	CCONJ	O	O	4054
alkaline	NOUN	O	O	4054
phosphatase	ADJ	O	O	4054
.	PUNCT	O	O	4054
Liver	NOUN	O	O	4055
biopsy	PROPN	O	O	4055
showed	VERB	O	O	4055
active	ADJ	O	O	4055
hepatitis	NOUN	O	Disease	4055
.	PUNCT	O	O	4055
Discontinuance	NOUN	O	O	4056
of	ADP	O	O	4056
quinidine	PROPN	O	Chemical	4056
therapy	NOUN	O	O	4056
led	VERB	O	O	4056
to	PART	O	O	4056
normalization	NOUN	O	O	4056
of	ADP	O	O	4056
liver	NOUN	O	O	4056
function	NOUN	O	O	4056
tests	VERB	O	O	4056
.	PUNCT	O	O	4056
A	PRON	O	O	4057
challenge	NOUN	O	O	4057
dose	NOUN	O	O	4057
of	ADP	O	O	4057
quinidine	PROPN	O	Chemical	4057
caused	VERB	O	O	4057
clinical	ADJ	O	O	4057
symptoms	NOUN	O	O	4057
and	CCONJ	O	O	4057
abrupt	ADJ	O	O	4057
elevation	NOUN	O	O	4057
of	ADP	O	O	4057
SGOT	NOUN	O	O	4057
,	PUNCT	O	O	4057
alkaline	NOUN	O	O	4057
phosphatase	ADJ	O	O	4057
,	PUNCT	O	O	4057
and	CCONJ	O	O	4057
lactic acid	NOUN	O	Chemical	4057
dehydrogenase	NOUN	O	O	4057
values	NOUN	O	O	4057
.	PUNCT	O	O	4057
We	PRON	O	O	4058
concluded	VERB	O	O	4058
that	SCONJ	O	O	4058
this	PRON	O	O	4058
patient	NOUN	O	O	4058
had	VERB	O	O	4058
quinidine	PROPN	O	Chemical	4058
hepatotoxicity	NOUN	O	Disease	4058
and	CCONJ	O	O	4058
believe	VERB	O	O	4058
that	SCONJ	O	O	4058
this	PRON	O	O	4058
is	AUX	O	O	4058
the	PRON	O	O	4058
first	ADV	O	O	4058
case	NOUN	O	O	4058
reported	VERB	O	O	4058
with	ADP	O	O	4058
liver	NOUN	O	O	4058
biopsy	PROPN	O	O	4058
documentation	NOUN	O	O	4058
.	PUNCT	O	O	4058
This	PRON	O	O	4059
report	VERB	O	O	4059
also	ADV	O	O	4059
suggests	VERB	O	O	4059
that	SCONJ	O	O	4059
,	PUNCT	O	O	4059
even	ADV	O	O	4059
after	ADP	O	O	4059
long	ADV	O	O	4059
-	PUNCT	O	O	4059
term	NOUN	O	O	4059
administration	NOUN	O	O	4059
,	PUNCT	O	O	4059
the	PRON	O	O	4059
hepatic toxicity	NOUN	O	Disease	4059
is	AUX	O	O	4059
reversible	ADJ	O	O	4059
.	PUNCT	O	O	4059
Cholesteryl hemisuccinate	NOUN	O	Chemical	4062
treatment	NOUN	O	O	4062
protects	VERB	O	O	4062
rodents	NOUN	O	O	4062
from	ADP	O	O	4062
the	PRON	O	O	4062
toxic	ADJ	O	O	4062
effects	NOUN	O	O	4062
of	ADP	O	O	4062
acetaminophen	PROPN	O	Chemical	4062
,	PUNCT	O	O	4062
adriamycin	PROPN	O	Chemical	4062
,	PUNCT	O	O	4062
carbon tetrachloride	NOUN	O	Chemical	4062
,	PUNCT	O	O	4062
chloroform	NOUN	O	Chemical	4062
and	CCONJ	O	O	4062
galactosamine	NOUN	O	Chemical	4062
.	PUNCT	O	O	4062
In	ADP	O	O	4063
addition	NOUN	O	O	4063
to	PART	O	O	4063
its	PRON	O	O	4063
use	VERB	O	O	4063
as	ADP	O	O	4063
a	PRON	O	O	4063
stabilizer	NOUN	O	O	4063
/	PUNCT	O	O	4063
rigidifier	ADJ	O	O	4063
of	ADP	O	O	4063
membranes	NOUN	O	O	4063
,	PUNCT	O	O	4063
cholesteryl hemisuccinate	PROPN	O	Chemical	4063
,	PUNCT	O	O	4063
tris salt	PROPN	O	Chemical	4063
(	PUNCT	O	O	4063
CS	NOUN	O	Chemical	4063
)	PUNCT	O	O	4063
administration	NOUN	O	O	4063
has	VERB	O	O	4063
also	ADV	O	O	4063
been	AUX	O	O	4063
shown	VERB	O	O	4063
to	PART	O	O	4063
protect	VERB	O	O	4063
rats	NOUN	O	O	4063
from	ADP	O	O	4063
the	PRON	O	O	4063
hepatotoxic	ADJ	O	Disease	4063
effects	NOUN	O	O	4063
of	ADP	O	O	4063
carbon tetrachloride	NOUN	O	Chemical	4063
(	PUNCT	O	O	4063
CCl4	PROPN	O	Chemical	4063
)	PUNCT	O	O	4063
.	PUNCT	O	O	4063
To	PART	O	O	4064
further	ADV	O	O	4064
our	PRON	O	O	4064
understanding	NOUN	O	O	4064
of	ADP	O	O	4064
the	PRON	O	O	4064
mechanism	NOUN	O	O	4064
of	ADP	O	O	4064
CS	NOUN	O	Chemical	4064
cytoprotection	NOUN	O	O	4064
,	PUNCT	O	O	4064
we	PRON	O	O	4064
examined	VERB	O	O	4064
in	ADP	O	O	4064
rats	NOUN	O	O	4064
and	CCONJ	O	O	4064
mice	NOUN	O	O	4064
the	PRON	O	O	4064
protective	ADJ	O	O	4064
abilities	NOUN	O	O	4064
of	ADP	O	O	4064
CS	NOUN	O	Chemical	4064
and	CCONJ	O	O	4064
the	PRON	O	O	4064
non	ADJ	O	O	4064
-	PUNCT	O	O	4064
hydrolyzable	ADJ	O	O	4064
ether	X	O	O	4064
form	NOUN	O	O	4064
of	ADP	O	O	4064
CS	NOUN	O	Chemical	4064
,	PUNCT	O	O	4064
gamma	PROPN	O	O	4064
-	PUNCT	O	O	4064
cholesteryloxybutyric	VERB	O	O	4064
acid	PROPN	O	O	4064
,	PUNCT	O	O	4064
tris salt	PROPN	O	Chemical	4064
(	PUNCT	O	O	4064
CSE	PROPN	O	Chemical	4064
)	PUNCT	O	O	4064
against	ADP	O	O	4064
acetaminophen-	PROPN	O	O	4064
,	PUNCT	O	O	4064
adriamycin-	ADV	O	O	4064
,	PUNCT	O	O	4064
carbon tetrachloride-	NOUN	O	O	4064
,	PUNCT	O	O	4064
chloroform-	PUNCT	O	O	4064
and	CCONJ	O	O	4064
galactosamine	NOUN	O	Chemical	4064
-	PUNCT	O	O	4064
induced	VERB	O	O	4064
toxicity	NOUN	O	Disease	4064
.	PUNCT	O	O	4064
The	PRON	O	O	4065
results	VERB	O	O	4065
of	ADP	O	O	4065
these	PRON	O	O	4065
studies	NOUN	O	O	4065
demonstrated	VERB	O	O	4065
that	SCONJ	O	O	4065
CS	NOUN	O	Chemical	4065
-	PUNCT	O	O	4065
mediated	VERB	O	O	4065
protection	NOUN	O	O	4065
is	AUX	O	O	4065
not	PART	O	O	4065
selective	ADJ	O	O	4065
for	ADP	O	O	4065
a	PRON	O	O	4065
particular	ADJ	O	O	4065
species	NOUN	O	O	4065
,	PUNCT	O	O	4065
organ	NOUN	O	O	4065
system	NOUN	O	O	4065
or	CCONJ	O	O	4065
toxic	ADJ	O	O	4065
chemical	PROPN	O	O	4065
.	PUNCT	O	O	4065
A	PRON	O	O	4066
24-h	NOUN	O	O	4066
pretreatment	NOUN	O	O	4066
of	ADP	O	O	4066
both	PRON	O	O	4066
rats	NOUN	O	O	4066
and	CCONJ	O	O	4066
mice	NOUN	O	O	4066
with	ADP	O	O	4066
a	PRON	O	O	4066
single	ADJ	O	O	4066
dose	NOUN	O	O	4066
of	ADP	O	O	4066
CS	NOUN	O	Chemical	4066
(	PUNCT	O	O	4066
100mg	ADV	O	O	4066
/	PUNCT	O	O	4066
kg	VERB	O	O	4066
,	PUNCT	O	O	4066
i.p	NOUN	O	O	4066
.	PUNCT	O	O	4066
)	PUNCT	O	O	4066
,	PUNCT	O	O	4066
resulted	VERB	O	O	4066
in	ADP	O	O	4066
significant	ADJ	O	O	4066
protection	NOUN	O	O	4066
against	ADP	O	O	4066
the	PRON	O	O	4066
hepatotoxic	ADJ	O	Disease	4066
effects	NOUN	O	O	4066
of	ADP	O	O	4066
CCl4	PROPN	O	Chemical	4066
,	PUNCT	O	O	4066
CHCl3	PROPN	O	Chemical	4066
,	PUNCT	O	O	4066
acetaminophen	PROPN	O	Chemical	4066
and	CCONJ	O	O	4066
galactosamine	NOUN	O	Chemical	4066
and	CCONJ	O	O	4066
against	ADP	O	O	4066
the	PRON	O	O	4066
lethal	ADJ	O	O	4066
(	PUNCT	O	O	4066
and	CCONJ	O	O	4066
presumably	ADV	O	O	4066
cardiotoxic	ADJ	O	Disease	4066
)	PUNCT	O	O	4066
effect	VERB	O	O	4066
of	ADP	O	O	4066
adriamycin	PROPN	O	Chemical	4066
administration	NOUN	O	O	4066
.	PUNCT	O	O	4066
Maximal	PROPN	O	O	4067
CS	NOUN	O	Chemical	4067
-	PUNCT	O	O	4067
mediated	VERB	O	O	4067
protection	NOUN	O	O	4067
was	AUX	O	O	4067
observed	VERB	O	O	4067
in	ADP	O	O	4067
experimental	ADJ	O	O	4067
animals	NOUN	O	O	4067
pretreated	VERB	O	O	4067
24	NUM	O	O	4067
h	X	O	O	4067
prior	ADV	O	O	4067
to	PART	O	O	4067
the	PRON	O	O	4067
toxic	ADJ	O	O	4067
insult	NOUN	O	O	4067
.	PUNCT	O	O	4067
These	PRON	O	O	4068
data	NOUN	O	O	4068
suggest	VERB	O	O	4068
that	SCONJ	O	O	4068
CS	NOUN	O	Chemical	4068
intervenes	VERB	O	O	4068
in	ADP	O	O	4068
a	PRON	O	O	4068
critical	ADJ	O	O	4068
cellular	NOUN	O	O	4068
event	NOUN	O	O	4068
that	SCONJ	O	O	4068
is	AUX	O	O	4068
an	PRON	O	O	4068
important	ADJ	O	O	4068
common	ADJ	O	O	4068
pathway	NOUN	O	O	4068
to	PART	O	O	4068
toxic	ADJ	O	O	4068
cell	NOUN	O	O	4068
death	NOUN	O	O	4068
.	PUNCT	O	O	4068
The	PRON	O	O	4069
mechanism	NOUN	O	O	4069
of	ADP	O	O	4069
CS	NOUN	O	Chemical	4069
protection	NOUN	O	O	4069
does	VERB	O	O	4069
not	PART	O	O	4069
appear	VERB	O	O	4069
to	PART	O	O	4069
be	AUX	O	O	4069
dependent	ADJ	O	O	4069
on	ADP	O	O	4069
the	PRON	O	O	4069
inhibition	NOUN	O	O	4069
of	ADP	O	O	4069
chemical	PROPN	O	O	4069
bioactivation	PROPN	O	O	4069
to	PART	O	O	4069
a	PRON	O	O	4069
toxic	ADJ	O	O	4069
reactive	ADJ	O	O	4069
intermediate	PROPN	O	O	4069
(	PUNCT	O	O	4069
in	ADP	O	O	4069
light	ADJ	O	O	4069
of	ADP	O	O	4069
the	PRON	O	O	4069
protection	NOUN	O	O	4069
observed	VERB	O	O	4069
against	ADP	O	O	4069
galactosamine	NOUN	O	Chemical	4069
hepatotoxicity	NOUN	O	Disease	4069
)	PUNCT	O	O	4069
.	PUNCT	O	O	4069
However	ADV	O	O	4070
,	PUNCT	O	O	4070
based	VERB	O	O	4070
on	ADP	O	O	4070
the	PRON	O	O	4070
data	NOUN	O	O	4070
presented	VERB	O	O	4070
,	PUNCT	O	O	4070
we	PRON	O	O	4070
can	AUX	O	O	4070
not	PART	O	O	4070
exclude	VERB	O	O	4070
the	PRON	O	O	4070
possibility	NOUN	O	O	4070
that	SCONJ	O	O	4070
CS	NOUN	O	Chemical	4070
administration	NOUN	O	O	4070
inhibits	VERB	O	O	4070
chemical	PROPN	O	O	4070
bioactivation	PROPN	O	O	4070
.	PUNCT	O	O	4070
Our	PRON	O	O	4071
findings	NOUN	O	O	4071
do	VERB	O	O	4071
suggest	VERB	O	O	4071
that	SCONJ	O	O	4071
CS	NOUN	O	Chemical	4071
-	PUNCT	O	O	4071
mediated	VERB	O	O	4071
protection	NOUN	O	O	4071
is	AUX	O	O	4071
dependent	ADJ	O	O	4071
on	ADP	O	O	4071
the	PRON	O	O	4071
action	NOUN	O	O	4071
of	ADP	O	O	4071
the	PRON	O	O	4071
intact	ADJ	O	O	4071
anionic	ADJ	O	O	4071
CS	NOUN	O	Chemical	4071
molecule	PROPN	O	O	4071
(	PUNCT	O	O	4071
non	ADJ	O	O	4071
-	PUNCT	O	O	4071
hydrolyzable	ADJ	O	O	4071
CSE	PROPN	O	Chemical	4071
was	AUX	O	O	4071
as	ADP	O	O	4071
protective	ADJ	O	O	4071
as	ADP	O	O	4071
CS	NOUN	O	Chemical	4071
)	PUNCT	O	O	4071
,	PUNCT	O	O	4071
whose	DET	O	O	4071
mechanism	NOUN	O	O	4071
has	VERB	O	O	4071
yet	ADV	O	O	4071
to	PART	O	O	4071
be	AUX	O	O	4071
defined	VERB	O	O	4071
.	PUNCT	O	O	4071
DSMM	PROPN	O	O	4074
XI	PROPN	O	O	4074
study	VERB	O	O	4074
:	PUNCT	O	O	4074
dose	NOUN	O	O	4074
definition	NOUN	O	O	4074
for	ADP	O	O	4074
intravenous	ADJ	O	O	4074
cyclophosphamide	VERB	O	Chemical	4074
in	ADP	O	O	4074
combination	NOUN	O	O	4074
with	ADP	O	O	4074
bortezomib	VERB	O	Chemical	4074
/	PUNCT	O	O	4074
dexamethasone	NOUN	O	Chemical	4074
for	ADP	O	O	4074
remission	NOUN	O	O	4074
induction	NOUN	O	O	4074
in	ADP	O	O	4074
patients	NOUN	O	O	4074
with	ADP	O	O	4074
newly	ADV	O	O	4074
diagnosed	VERB	O	O	4074
myeloma	NOUN	O	Disease	4074
.	PUNCT	O	O	4074
A	PRON	O	O	4075
clinical	ADJ	O	O	4075
trial	NOUN	O	O	4075
was	AUX	O	O	4075
initiated	VERB	O	O	4075
to	PART	O	O	4075
evaluate	VERB	O	O	4075
the	PRON	O	O	4075
recommended	VERB	O	O	4075
dose	NOUN	O	O	4075
of	ADP	O	O	4075
cyclophosphamide	VERB	O	Chemical	4075
in	ADP	O	O	4075
combination	NOUN	O	O	4075
with	ADP	O	O	4075
bortezomib	VERB	O	Chemical	4075
and	CCONJ	O	O	4075
dexamethasone	NOUN	O	Chemical	4075
as	ADP	O	O	4075
induction	NOUN	O	O	4075
treatment	NOUN	O	O	4075
before	ADP	O	O	4075
stem	VERB	O	O	4075
cell	NOUN	O	O	4075
transplantation	NOUN	O	O	4075
for	ADP	O	O	4075
younger	ADJ	O	O	4075
patients	NOUN	O	O	4075
with	ADP	O	O	4075
newly	ADV	O	O	4075
diagnosed	VERB	O	O	4075
multiple myeloma	NOUN	O	Disease	4075
(	PUNCT	O	O	4075
MM	PROPN	O	Disease	4075
)	PUNCT	O	O	4075
.	PUNCT	O	O	4075
Thirty	NUM	O	O	4076
patients	NOUN	O	O	4076
were	AUX	O	O	4076
treated	VERB	O	O	4076
with	ADP	O	O	4076
three	NUM	O	O	4076
21-day	NOUN	O	O	4076
cycles	NOUN	O	O	4076
of	ADP	O	O	4076
bortezomib	VERB	O	Chemical	4076
1.3	NUM	O	O	4076
mg	VERB	O	O	4076
/	PUNCT	O	O	4076
m(2	NUM	O	O	4076
)	PUNCT	O	O	4076
on	ADP	O	O	4076
days	NOUN	O	O	4076
1	X	O	O	4076
,	PUNCT	O	O	4076
4	NUM	O	O	4076
,	PUNCT	O	O	4076
8	NUM	O	O	4076
,	PUNCT	O	O	4076
and	CCONJ	O	O	4076
11	NUM	O	O	4076
plus	CCONJ	O	O	4076
dexamethasone	NOUN	O	Chemical	4076
40	NUM	O	O	4076
mg	VERB	O	O	4076
on	ADP	O	O	4076
the	PRON	O	O	4076
day	NOUN	O	O	4076
of	ADP	O	O	4076
bortezomib	VERB	O	Chemical	4076
injection	NOUN	O	O	4076
and	CCONJ	O	O	4076
the	PRON	O	O	4076
day	NOUN	O	O	4076
after	ADP	O	O	4076
plus	CCONJ	O	O	4076
cyclophosphamide	VERB	O	Chemical	4076
at	ADP	O	O	4076
900	NUM	O	O	4076
,	PUNCT	O	O	4076
1,200	NUM	O	O	4076
,	PUNCT	O	O	4076
or	CCONJ	O	O	4076
1,500	NUM	O	O	4076
mg	VERB	O	O	4076
/	PUNCT	O	O	4076
m(2	NUM	O	O	4076
)	PUNCT	O	O	4076
on	ADP	O	O	4076
day	NOUN	O	O	4076
1	X	O	O	4076
.	PUNCT	O	O	4076
The	PRON	O	O	4077
maximum	ADV	O	O	4077
tolerated	VERB	O	O	4077
dose	NOUN	O	O	4077
of	ADP	O	O	4077
cyclophosphamide	VERB	O	Chemical	4077
was	AUX	O	O	4077
defined	VERB	O	O	4077
as	ADP	O	O	4077
900	NUM	O	O	4077
mg	VERB	O	O	4077
/	PUNCT	O	O	4077
m(2	NUM	O	O	4077
)	PUNCT	O	O	4077
.	PUNCT	O	O	4077
The	PRON	O	O	4078
most	ADV	O	O	4078
frequent	ADJ	O	O	4078
adverse	ADJ	O	O	4078
events	NOUN	O	O	4078
were	AUX	O	O	4078
hematological	ADJ	O	O	4078
and	CCONJ	O	O	4078
gastrointestinal toxicities	NOUN	O	Disease	4078
as	ADP	O	O	4078
well	ADV	O	O	4078
as	ADP	O	O	4078
neuropathy	NOUN	O	Disease	4078
.	PUNCT	O	O	4078
The	PRON	O	O	4079
results	VERB	O	O	4079
suggest	VERB	O	O	4079
that	SCONJ	O	O	4079
bortezomib	VERB	O	Chemical	4079
in	ADP	O	O	4079
combination	NOUN	O	O	4079
with	ADP	O	O	4079
cyclophosphamide	VERB	O	Chemical	4079
at	ADP	O	O	4079
900	NUM	O	O	4079
mg	VERB	O	O	4079
/	PUNCT	O	O	4079
m(2	NUM	O	O	4079
)	PUNCT	O	O	4079
and	CCONJ	O	O	4079
dexamethasone	NOUN	O	Chemical	4079
is	AUX	O	O	4079
an	PRON	O	O	4079
effective	ADJ	O	O	4079
induction	NOUN	O	O	4079
treatment	NOUN	O	O	4079
for	ADP	O	O	4079
patients	NOUN	O	O	4079
with	ADP	O	O	4079
newly	ADV	O	O	4079
diagnosed	VERB	O	O	4079
MM	PROPN	O	Disease	4079
that	SCONJ	O	O	4079
warrants	NOUN	O	O	4079
further	ADV	O	O	4079
investigation	NOUN	O	O	4079
.	PUNCT	O	O	4079
Results	NOUN	O	O	4082
of	ADP	O	O	4082
a	PRON	O	O	4082
comparative	ADJ	O	O	4082
,	PUNCT	O	O	4082
phase	NOUN	O	O	4082
III	NUM	O	O	4082
,	PUNCT	O	O	4082
12-week	NOUN	O	O	4082
,	PUNCT	O	O	4082
multicenter	ADJ	O	O	4082
,	PUNCT	O	O	4082
prospective	ADJ	O	O	4082
,	PUNCT	O	O	4082
randomized	VERB	O	O	4082
,	PUNCT	O	O	4082
double	ADJ	O	O	4082
-	PUNCT	O	O	4082
blind	ADJ	O	Disease	4082
assessment	NOUN	O	O	4082
of	ADP	O	O	4082
the	PRON	O	O	4082
efficacy	NOUN	O	O	4082
and	CCONJ	O	O	4082
tolerability	NOUN	O	O	4082
of	ADP	O	O	4082
a	PRON	O	O	4082
fixed	VERB	O	O	4082
-	PUNCT	O	O	4082
dose	NOUN	O	O	4082
combination	NOUN	O	O	4082
of	ADP	O	O	4082
telmisartan	PROPN	O	Chemical	4082
and	CCONJ	O	O	4082
amlodipine	NOUN	O	Chemical	4082
versus	ADP	O	O	4082
amlodipine	NOUN	O	Chemical	4082
monotherapy	X	O	O	4082
in	ADP	O	O	4082
Indian	PROPN	O	O	4082
adults	NOUN	O	O	4082
with	ADP	O	O	4082
stage	NOUN	O	O	4082
II	NUM	O	O	4082
hypertension	NOUN	O	Disease	4082
.	PUNCT	O	O	4082
The	PRON	O	O	4083
aim	VERB	O	O	4083
of	ADP	O	O	4083
this	PRON	O	O	4083
study	VERB	O	O	4083
was	AUX	O	O	4083
to	PART	O	O	4083
evaluate	VERB	O	O	4083
the	PRON	O	O	4083
efficacy	NOUN	O	O	4083
and	CCONJ	O	O	4083
tolerability	NOUN	O	O	4083
of	ADP	O	O	4083
a	PRON	O	O	4083
new	ADJ	O	O	4083
fixed	VERB	O	O	4083
-	PUNCT	O	O	4083
dose	NOUN	O	O	4083
combination	NOUN	O	O	4083
(	PUNCT	O	O	4083
FDC	PROPN	O	O	4083
)	PUNCT	O	O	4083
of	ADP	O	O	4083
telmisartan	PROPN	O	Chemical	4083
40	NUM	O	O	4083
mg	VERB	O	O	4083
+	ADP	O	O	4083
amlodipine	NOUN	O	Chemical	4083
5	NUM	O	O	4083
mg	VERB	O	O	4083
(	PUNCT	O	O	4083
T+A	PROPN	O	O	4083
)	PUNCT	O	O	4083
compared	VERB	O	O	4083
with	ADP	O	O	4083
amlodipine	NOUN	O	Chemical	4083
5-mg	NOUN	O	O	4083
monotherapy	X	O	O	4083
(	PUNCT	O	O	4083
A	PRON	O	O	4083
)	PUNCT	O	O	4083
in	ADP	O	O	4083
adult	NOUN	O	O	4083
Indian	PROPN	O	O	4083
patients	NOUN	O	O	4083
with	ADP	O	O	4083
stage	NOUN	O	O	4083
II	NUM	O	O	4083
hypertension	NOUN	O	Disease	4083
.	PUNCT	O	O	4083
This	PRON	O	O	4084
comparative	ADJ	O	O	4084
,	PUNCT	O	O	4084
Phase	NOUN	O	O	4084
III	NUM	O	O	4084
,	PUNCT	O	O	4084
12-week	NOUN	O	O	4084
,	PUNCT	O	O	4084
multicenter	ADJ	O	O	4084
,	PUNCT	O	O	4084
prospective	ADJ	O	O	4084
,	PUNCT	O	O	4084
randomized	VERB	O	O	4084
,	PUNCT	O	O	4084
double	ADJ	O	O	4084
-	PUNCT	O	O	4084
blind	ADJ	O	Disease	4084
study	VERB	O	O	4084
was	AUX	O	O	4084
conducted	VERB	O	O	4084
in	ADP	O	O	4084
Indian	PROPN	O	O	4084
patients	NOUN	O	O	4084
aged	ADJ	O	O	4084
18	NUM	O	O	4084
to	PART	O	O	4084
65	NUM	O	O	4084
years	NOUN	O	O	4084
with	ADP	O	O	4084
established	VERB	O	O	4084
stage	NOUN	O	O	4084
II	NUM	O	O	4084
hypertension	NOUN	O	Disease	4084
.	PUNCT	O	O	4084
Peripheral	ADJ	O	O	4085
edema	NOUN	O	Disease	4085
was	AUX	O	O	4085
reported	VERB	O	O	4085
in	ADP	O	O	4085
8.5%	NOUN	O	O	4085
patients	NOUN	O	O	4085
(	PUNCT	O	O	4085
9/106	NUM	O	O	4085
)	PUNCT	O	O	4085
in	ADP	O	O	4085
the	PRON	O	O	4085
T+A	PROPN	O	O	4085
group	NOUN	O	O	4085
compared	VERB	O	O	4085
with	ADP	O	O	4085
13.5%	NOUN	O	O	4085
(	PUNCT	O	O	4085
14/104	X	O	O	4085
)	PUNCT	O	O	4085
in	ADP	O	O	4085
the	PRON	O	O	4085
A	PRON	O	O	4085
group	NOUN	O	O	4085
,	PUNCT	O	O	4085
and	CCONJ	O	O	4085
cough	VERB	O	Disease	4085
was	AUX	O	O	4085
reported	VERB	O	O	4085
in	ADP	O	O	4085
3.8%	NOUN	O	O	4085
patients	NOUN	O	O	4085
(	PUNCT	O	O	4085
4/106	NUM	O	O	4085
)	PUNCT	O	O	4085
in	ADP	O	O	4085
the	PRON	O	O	4085
T+A	PROPN	O	O	4085
group	NOUN	O	O	4085
and	CCONJ	O	O	4085
1.0%	NOUN	O	O	4085
(	PUNCT	O	O	4085
1/104	NUM	O	O	4085
)	PUNCT	O	O	4085
patients	NOUN	O	O	4085
in	ADP	O	O	4085
the	PRON	O	O	4085
A	PRON	O	O	4085
group	NOUN	O	O	4085
;	PUNCT	O	O	4085
these	PRON	O	O	4085
differences	NOUN	O	O	4085
did	VERB	O	O	4085
not	PART	O	O	4085
reach	VERB	O	O	4085
statistical	ADJ	O	O	4085
significance	NOUN	O	O	4085
.	PUNCT	O	O	4085
The	PRON	O	O	4086
incidences	NOUN	O	O	4086
of	ADP	O	O	4086
headache	PROPN	O	Disease	4086
,	PUNCT	O	O	4086
dizziness	NOUN	O	Disease	4086
,	PUNCT	O	O	4086
and	CCONJ	O	O	4086
diarrhea	PROPN	O	Disease	4086
were	AUX	O	O	4086
similar	ADJ	O	O	4086
between	ADP	O	O	4086
the	PRON	O	O	4086
2	X	O	O	4086
groups	NOUN	O	O	4086
.	PUNCT	O	O	4086
CONCLUSIONS	NOUN	O	O	4087
:	PUNCT	O	O	4087
Among	ADP	O	O	4087
these	PRON	O	O	4087
Indian	PROPN	O	O	4087
patients	NOUN	O	O	4087
with	ADP	O	O	4087
stage	NOUN	O	O	4087
II	NUM	O	O	4087
hypertension	NOUN	O	Disease	4087
,	PUNCT	O	O	4087
the	PRON	O	O	4087
FDC	PROPN	O	O	4087
of	ADP	O	O	4087
T+A	PROPN	O	O	4087
was	AUX	O	O	4087
found	VERB	O	O	4087
to	PART	O	O	4087
be	AUX	O	O	4087
significantly	ADV	O	O	4087
more	ADJ	O	O	4087
effective	ADJ	O	O	4087
,	PUNCT	O	O	4087
with	ADP	O	O	4087
regard	NOUN	O	O	4087
to	PART	O	O	4087
BP	PROPN	O	O	4087
reductions	NOUN	O	O	4087
,	PUNCT	O	O	4087
than	ADP	O	O	4087
A	PRON	O	O	4087
,	PUNCT	O	O	4087
and	CCONJ	O	O	4087
both	PRON	O	O	4087
treatments	NOUN	O	O	4087
were	AUX	O	O	4087
well	ADV	O	O	4087
tolerated	VERB	O	O	4087
.	PUNCT	O	O	4087
Cutaneous	ADJ	O	O	4090
leucocytoclastic vasculitis	NOUN	O	Disease	4090
associated	VERB	O	O	4090
with	ADP	O	O	4090
oxacillin	PROPN	O	Chemical	4090
.	PUNCT	O	O	4090
A	PRON	O	O	4091
67-year	NOUN	O	O	4091
-	PUNCT	O	O	4091
old	ADJ	O	O	4091
man	NOUN	O	O	4091
who	PRON	O	O	4091
was	AUX	O	O	4091
treated	VERB	O	O	4091
with	ADP	O	O	4091
oxacillin	PROPN	O	Chemical	4091
for	ADP	O	O	4091
one	NUM	O	O	4091
week	NOUN	O	O	4091
because	SCONJ	O	O	4091
of	ADP	O	O	4091
Staphylococcus aureus bacteremia	NOUN	O	Disease	4091
,	PUNCT	O	O	4091
developed	VERB	O	O	4091
renal failure	NOUN	O	Disease	4091
and	CCONJ	O	O	4091
diffuse	VERB	O	O	4091
,	PUNCT	O	O	4091
symmetric	PROPN	O	O	4091
,	PUNCT	O	O	4091
palpable	ADJ	O	O	4091
purpuric lesions	NOUN	O	Disease	4091
on	ADP	O	O	4091
his	PRON	O	O	4091
feet	NOUN	O	O	4091
.	PUNCT	O	O	4091
Necrotic blisters	NOUN	O	Disease	4092
were	AUX	O	O	4092
noted	VERB	O	O	4092
on	ADP	O	O	4092
his	PRON	O	O	4092
fingers	NOUN	O	O	4092
.	PUNCT	O	O	4092
Skin	NOUN	O	O	4093
biopsies	NOUN	O	O	4093
showed	VERB	O	O	4093
findings	NOUN	O	O	4093
diagnostic	ADJ	O	O	4093
of	ADP	O	O	4093
leucocytoclastic vasculitis	NOUN	O	Disease	4093
.	PUNCT	O	O	4093
Oxacillin	NOUN	O	Chemical	4094
was	AUX	O	O	4094
discontinued	VERB	O	O	4094
and	CCONJ	O	O	4094
patient	NOUN	O	O	4094
was	AUX	O	O	4094
treated	VERB	O	O	4094
with	ADP	O	O	4094
corticosteroids	NOUN	O	Chemical	4094
.	PUNCT	O	O	4094
The	PRON	O	O	4095
rash	ADJ	O	Disease	4095
disappeared	VERB	O	O	4095
after	ADP	O	O	4095
three	NUM	O	O	4095
weeks	NOUN	O	O	4095
and	CCONJ	O	O	4095
renal	ADJ	O	O	4095
function	NOUN	O	O	4095
returned	VERB	O	O	4095
to	PART	O	O	4095
normal	ADJ	O	O	4095
.	PUNCT	O	O	4095
Leucocytoclastic vasculitis	NOUN	O	Disease	4096
presents	VERB	O	O	4096
as	ADP	O	O	4096
palpable	ADJ	O	O	4096
purpura	NOUN	O	Disease	4096
of	ADP	O	O	4096
the	PRON	O	O	4096
lower	ADJ	O	O	4096
extremities	NOUN	O	O	4096
often	ADV	O	O	4096
accompanied	VERB	O	O	4096
by	ADP	O	O	4096
abdominal pain	NOUN	O	Disease	4096
,	PUNCT	O	O	4096
arthralgia	ADV	O	Disease	4096
,	PUNCT	O	O	4096
and	CCONJ	O	O	4096
renal involvement	NOUN	O	Disease	4096
.	PUNCT	O	O	4096
Etiologic	PROPN	O	O	4097
factors	NOUN	O	O	4097
or	CCONJ	O	O	4097
associated	VERB	O	O	4097
disorders	NOUN	O	O	4097
include	VERB	O	O	4097
infections	NOUN	O	Disease	4097
,	PUNCT	O	O	4097
medications	NOUN	O	O	4097
,	PUNCT	O	O	4097
collagen vascular disease	NOUN	O	Disease	4097
and	CCONJ	O	O	4097
neoplasia	NOUN	O	Disease	4097
.	PUNCT	O	O	4097
Usually	ADV	O	O	4098
it	PRON	O	O	4098
is	AUX	O	O	4098
a	PRON	O	O	4098
self	VERB	O	O	4098
-	PUNCT	O	O	4098
limited	VERB	O	O	4098
disorder	NOUN	O	O	4098
,	PUNCT	O	O	4098
but	CCONJ	O	O	4098
corticosteroid	NOUN	O	Chemical	4098
therapy	NOUN	O	O	4098
may	AUX	O	O	4098
be	AUX	O	O	4098
needed	VERB	O	O	4098
in	ADP	O	O	4098
life	NOUN	O	O	4098
-	PUNCT	O	O	4098
threatening	VERB	O	O	4098
cases	NOUN	O	O	4098
since	SCONJ	O	O	4098
early	ADV	O	O	4098
treatment	NOUN	O	O	4098
with	ADP	O	O	4098
corticosteroids	NOUN	O	Chemical	4098
in	ADP	O	O	4098
severe	ADJ	O	O	4098
cases	NOUN	O	O	4098
can	AUX	O	O	4098
prevent	VERB	O	O	4098
complications	NOUN	O	O	4098
.	PUNCT	O	O	4098
Oxacillin	NOUN	O	Chemical	4099
should	AUX	O	O	4099
be	AUX	O	O	4099
included	VERB	O	O	4099
among	ADP	O	O	4099
the	PRON	O	O	4099
drugs	NOUN	O	O	4099
that	SCONJ	O	O	4099
can	AUX	O	O	4099
cause	VERB	O	O	4099
leucocytoclastic vasculitis	NOUN	O	Disease	4099
.	PUNCT	O	O	4099
Naloxazone	NOUN	O	Chemical	4102
pretreatment	NOUN	O	O	4102
modifies	VERB	O	O	4102
cardiorespiratory	NOUN	O	O	4102
,	PUNCT	O	O	4102
temperature	NOUN	O	O	4102
,	PUNCT	O	O	4102
and	CCONJ	O	O	4102
behavioral	ADJ	O	O	4102
effects	NOUN	O	O	4102
of	ADP	O	O	4102
morphine	NOUN	O	Chemical	4102
.	PUNCT	O	O	4102
Behavioral	NOUN	O	O	4103
and	CCONJ	O	O	4103
cardiorespiratory	NOUN	O	O	4103
responses	NOUN	O	O	4103
to	PART	O	O	4103
a	PRON	O	O	4103
lethal	ADJ	O	O	4103
dose	NOUN	O	O	4103
of	ADP	O	O	4103
morphine	NOUN	O	Chemical	4103
were	AUX	O	O	4103
evaluated	VERB	O	O	4103
in	ADP	O	O	4103
rats	NOUN	O	O	4103
pretreated	VERB	O	O	4103
with	ADP	O	O	4103
saline	NOUN	O	O	4103
or	CCONJ	O	O	4103
naloxazone	VERB	O	Chemical	4103
,	PUNCT	O	O	4103
an	PRON	O	O	4103
antagonist	NOUN	O	O	4103
of	ADP	O	O	4103
high	ADJ	O	O	4103
-	PUNCT	O	O	4103
affinity	NOUN	O	O	4103
mu	NOUN	O	O	4103
1	X	O	O	4103
opioid	NOUN	O	O	4103
receptors	NOUN	O	O	4103
.	PUNCT	O	O	4103
Pretreatment	NOUN	O	O	4104
with	ADP	O	O	4104
naloxazone	VERB	O	Chemical	4104
significantly	ADV	O	O	4104
blocked	VERB	O	O	4104
morphine	NOUN	O	Chemical	4104
analgesia	NOUN	O	Disease	4104
,	PUNCT	O	O	4104
catalepsy	VERB	O	Disease	4104
and	CCONJ	O	O	4104
hypothermia	VERB	O	Disease	4104
at	ADP	O	O	4104
a	PRON	O	O	4104
dose	NOUN	O	O	4104
which	PRON	O	O	4104
completely	ADV	O	O	4104
eliminated	VERB	O	O	4104
high	ADJ	O	O	4104
-	PUNCT	O	O	4104
affinity	NOUN	O	O	4104
binding	VERB	O	O	4104
in	ADP	O	O	4104
brain	NOUN	O	O	4104
membranes	NOUN	O	O	4104
.	PUNCT	O	O	4104
Moreover	ADV	O	O	4105
,	PUNCT	O	O	4105
naloxazone	VERB	O	Chemical	4105
significantly	ADV	O	O	4105
attenuated	VERB	O	O	4105
the	PRON	O	O	4105
morphine	NOUN	O	Chemical	4105
-	PUNCT	O	O	4105
induced	VERB	O	O	4105
hypotension	NOUN	O	Disease	4105
and	CCONJ	O	O	4105
respiratory depression	NOUN	O	Disease	4105
,	PUNCT	O	O	4105
whereas	SCONJ	O	O	4105
morphine	NOUN	O	Chemical	4105
-	PUNCT	O	O	4105
induced	VERB	O	O	4105
bradycardia	NOUN	O	Disease	4105
was	AUX	O	O	4105
less	ADV	O	O	4105
affected	VERB	O	O	4105
.	PUNCT	O	O	4105
Results	NOUN	O	O	4106
indicate	VERB	O	O	4106
that	SCONJ	O	O	4106
subpopulations	NOUN	O	O	4106
of	ADP	O	O	4106
mu	NOUN	O	O	4106
receptors	NOUN	O	O	4106
may	AUX	O	O	4106
mediate	VERB	O	O	4106
selective	ADJ	O	O	4106
behavioral	ADJ	O	O	4106
and	CCONJ	O	O	4106
cardiorespiratory	NOUN	O	O	4106
responses	NOUN	O	O	4106
to	PART	O	O	4106
morphine	NOUN	O	Chemical	4106
.	PUNCT	O	O	4106
Dexrazoxane	PROPN	O	Chemical	4109
protects	VERB	O	O	4109
against	ADP	O	O	4109
myelosuppression	NOUN	O	Disease	4109
from	ADP	O	O	4109
the	PRON	O	O	4109
DNA	NOUN	O	O	4109
cleavage	NOUN	O	O	4109
-	PUNCT	O	O	4109
enhancing	VERB	O	O	4109
drugs	NOUN	O	O	4109
etoposide	ADV	O	Chemical	4109
and	CCONJ	O	O	4109
daunorubicin	VERB	O	Chemical	4109
but	CCONJ	O	O	4109
not	PART	O	O	4109
doxorubicin	VERB	O	Chemical	4109
.	PUNCT	O	O	4109
The	PRON	O	O	4110
anthracyclines	NOUN	O	Chemical	4110
daunorubicin	VERB	O	Chemical	4110
and	CCONJ	O	O	4110
doxorubicin	VERB	O	Chemical	4110
and	CCONJ	O	O	4110
the	PRON	O	O	4110
epipodophyllotoxin	NOUN	O	Chemical	4110
etoposide	ADV	O	Chemical	4110
are	AUX	O	O	4110
potent	ADJ	O	O	4110
DNA	NOUN	O	O	4110
cleavage	NOUN	O	O	4110
-	PUNCT	O	O	4110
enhancing	VERB	O	O	4110
drugs	NOUN	O	O	4110
that	SCONJ	O	O	4110
are	AUX	O	O	4110
widely	ADV	O	O	4110
used	VERB	O	O	4110
in	ADP	O	O	4110
clinical	ADJ	O	O	4110
oncology	NOUN	O	O	4110
;	PUNCT	O	O	4110
however	ADV	O	O	4110
,	PUNCT	O	O	4110
myelosuppression	NOUN	O	Disease	4110
and	CCONJ	O	O	4110
cardiac toxicity	NOUN	O	Disease	4110
limit	NOUN	O	O	4110
their	PRON	O	O	4110
use	VERB	O	O	4110
.	PUNCT	O	O	4110
Dexrazoxane	PROPN	O	Chemical	4111
(	PUNCT	O	O	4111
ICRF-187	PUNCT	O	Chemical	4111
)	PUNCT	O	O	4111
is	AUX	O	O	4111
recommended	VERB	O	O	4111
for	ADP	O	O	4111
protection	NOUN	O	O	4111
against	ADP	O	O	4111
anthracycline	NOUN	O	Chemical	4111
-	PUNCT	O	O	4111
induced	VERB	O	O	4111
cardiotoxicity	NOUN	O	Disease	4111
.	PUNCT	O	O	4111
Because	SCONJ	O	O	4112
of	ADP	O	O	4112
their	PRON	O	O	4112
widespread	ADJ	O	O	4112
use	VERB	O	O	4112
,	PUNCT	O	O	4112
the	PRON	O	O	4112
hematologic toxicity	NOUN	O	Disease	4112
following	VERB	O	O	4112
coadministration	NOUN	O	O	4112
of	ADP	O	O	4112
dexrazoxane	PROPN	O	Chemical	4112
and	CCONJ	O	O	4112
these	PRON	O	O	4112
three	NUM	O	O	4112
structurally	ADV	O	O	4112
different	ADJ	O	O	4112
DNA	NOUN	O	O	4112
cleavage	NOUN	O	O	4112
enhancers	NOUN	O	O	4112
was	AUX	O	O	4112
investigated	VERB	O	O	4112
:	PUNCT	O	O	4112
Sensitivity	NOUN	O	O	4113
of	ADP	O	O	4113
human	PROPN	O	O	4113
and	CCONJ	O	O	4113
murine	ADJ	O	O	4113
blood	NOUN	O	O	4113
progenitor	NOUN	O	O	4113
cells	NOUN	O	O	4113
to	PART	O	O	4113
etoposide	ADV	O	Chemical	4113
,	PUNCT	O	O	4113
daunorubicin	VERB	O	Chemical	4113
,	PUNCT	O	O	4113
and	CCONJ	O	O	4113
doxorubicin	VERB	O	Chemical	4113
+	ADP	O	O	4113
/-	PUNCT	O	O	4113
dexrazoxane	PROPN	O	Chemical	4114
was	AUX	O	O	4114
determined	VERB	O	O	4114
in	ADP	O	O	4114
granulocyte	NOUN	O	O	4114
-	PUNCT	O	O	4114
macrophage	NOUN	O	O	4114
colony	NOUN	O	O	4114
forming	VERB	O	O	4114
assays	NOUN	O	O	4114
.	PUNCT	O	O	4114
Likewise	ADV	O	O	4115
,	PUNCT	O	O	4115
in	ADP	O	O	4115
vivo	VERB	O	O	4115
,	PUNCT	O	O	4115
B6D2F1	ADJ	O	O	4115
mice	NOUN	O	O	4115
were	AUX	O	O	4115
treated	VERB	O	O	4115
with	ADP	O	O	4115
etoposide	ADV	O	Chemical	4115
,	PUNCT	O	O	4115
daunorubicin	VERB	O	Chemical	4115
,	PUNCT	O	O	4115
and	CCONJ	O	O	4115
doxorubicin	VERB	O	Chemical	4115
,	PUNCT	O	O	4115
with	ADP	O	O	4115
or	CCONJ	O	O	4115
without	ADP	O	O	4115
dexrazoxane	PROPN	O	Chemical	4115
over	ADP	O	O	4115
a	PRON	O	O	4115
wide	ADV	O	O	4115
range	VERB	O	O	4115
of	ADP	O	O	4115
doses	NOUN	O	O	4115
:	PUNCT	O	O	4115
posttreatment	NOUN	O	O	4115
,	PUNCT	O	O	4115
a	PRON	O	O	4115
full	ADJ	O	O	4115
hematologic	ADJ	O	O	4115
evaluation	NOUN	O	O	4115
was	AUX	O	O	4115
done	VERB	O	O	4115
.	PUNCT	O	O	4115
RESULTS	VERB	O	O	4116
:	PUNCT	O	O	4116
Nontoxic	ADJ	O	O	4116
doses	NOUN	O	O	4116
of	ADP	O	O	4116
dexrazoxane	PROPN	O	Chemical	4116
reduced	VERB	O	O	4116
myelosuppression	NOUN	O	Disease	4116
and	CCONJ	O	O	4116
weight loss	NOUN	O	Disease	4116
from	ADP	O	O	4116
daunorubicin	VERB	O	Chemical	4116
and	CCONJ	O	O	4116
etoposide	ADV	O	Chemical	4116
in	ADP	O	O	4116
mice	NOUN	O	O	4116
and	CCONJ	O	O	4116
antagonized	VERB	O	O	4116
their	PRON	O	O	4116
antiproliferative	PROPN	O	O	4116
effects	NOUN	O	O	4116
in	ADP	O	O	4116
the	PRON	O	O	4116
colony	NOUN	O	O	4116
assay	NOUN	O	O	4116
;	PUNCT	O	O	4116
however	ADV	O	O	4116
,	PUNCT	O	O	4116
dexrazoxane	PROPN	O	Chemical	4116
neither	ADV	O	O	4116
reduced	VERB	O	O	4116
myelosuppression	NOUN	O	Disease	4116
,	PUNCT	O	O	4116
weight loss	NOUN	O	Disease	4116
,	PUNCT	O	O	4116
nor	CCONJ	O	O	4116
the	PRON	O	O	4116
in	ADP	O	O	4116
vitro	X	O	O	4116
cytotoxicity	NOUN	O	Disease	4116
from	ADP	O	O	4116
doxorubicin	VERB	O	Chemical	4116
.	PUNCT	O	O	4116
CONCLUSION	PROPN	O	O	4117
:	PUNCT	O	O	4117
Although	SCONJ	O	O	4117
our	PRON	O	O	4117
findings	NOUN	O	O	4117
support	NOUN	O	O	4117
the	PRON	O	O	4117
observation	NOUN	O	O	4117
that	SCONJ	O	O	4117
dexrazoxane	PROPN	O	Chemical	4117
reduces	VERB	O	O	4117
neither	ADV	O	O	4117
hematologic	ADJ	O	O	4117
activity	NOUN	O	O	4117
nor	CCONJ	O	O	4117
antitumor	PROPN	O	O	4117
activity	NOUN	O	O	4117
from	ADP	O	O	4117
doxorubicin	VERB	O	Chemical	4117
clinically	ADV	O	O	4117
,	PUNCT	O	O	4117
the	PRON	O	O	4117
potent	ADJ	O	O	4117
antagonism	NOUN	O	O	4117
of	ADP	O	O	4117
daunorubicin	VERB	O	Chemical	4117
activity	NOUN	O	O	4117
raises	VERB	O	O	4117
concern	NOUN	O	O	4117
;	PUNCT	O	O	4117
a	PRON	O	O	4117
possible	ADJ	O	O	4117
interference	NOUN	O	O	4117
with	ADP	O	O	4117
anticancer	NOUN	O	O	4117
efficacy	NOUN	O	O	4117
certainly	ADV	O	O	4117
would	AUX	O	O	4117
call	VERB	O	O	4117
for	ADP	O	O	4117
renewed	VERB	O	O	4117
attention	NOUN	O	O	4117
.	PUNCT	O	O	4117
Our	PRON	O	O	4118
data	NOUN	O	O	4118
also	ADV	O	O	4118
suggest	VERB	O	O	4118
that	SCONJ	O	O	4118
significant	ADJ	O	O	4118
etoposide	ADV	O	Chemical	4118
dose	NOUN	O	O	4118
escalation	NOUN	O	O	4118
is	AUX	O	O	4118
perhaps	ADV	O	O	4118
possible	ADJ	O	O	4118
by	ADP	O	O	4118
the	PRON	O	O	4118
use	VERB	O	O	4118
of	ADP	O	O	4118
dexrazoxane	PROPN	O	Chemical	4118
.	PUNCT	O	O	4118
Clinical	NOUN	O	O	4119
trials	NOUN	O	O	4119
in	ADP	O	O	4119
patients	NOUN	O	O	4119
with	ADP	O	O	4119
brain	NOUN	O	O	4119
metastases	NOUN	O	Disease	4119
combining	VERB	O	O	4119
dexrazoxane	PROPN	O	Chemical	4119
and	CCONJ	O	O	4119
high	ADJ	O	O	4119
doses	NOUN	O	O	4119
of	ADP	O	O	4119
etoposide	ADV	O	Chemical	4119
is	AUX	O	O	4119
ongoing	ADJ	O	O	4119
with	ADP	O	O	4119
the	PRON	O	O	4119
aim	VERB	O	O	4119
of	ADP	O	O	4119
improving	VERB	O	O	4119
efficacy	NOUN	O	O	4119
without	ADP	O	O	4119
aggravating	ADJ	O	O	4119
hematologic toxicity	NOUN	O	Disease	4119
.	PUNCT	O	O	4119
Effects	NOUN	O	O	4122
of	ADP	O	O	4122
the	PRON	O	O	4122
novel	NOUN	O	O	4122
compound	NOUN	O	O	4122
aniracetam	PROPN	O	Chemical	4122
(	PUNCT	O	O	4122
Ro	INTJ	O	O	4122
13	NUM	O	O	4122
-	PUNCT	O	O	4122
5057	NUM	O	O	4122
)	PUNCT	O	O	4122
upon	SCONJ	O	O	4122
impaired learning and memory	NOUN	O	Disease	4122
in	ADP	O	O	4122
rodents	NOUN	O	O	4122
.	PUNCT	O	O	4122
The	PRON	O	O	4123
effect	VERB	O	O	4123
of	ADP	O	O	4123
aniracetam	PROPN	O	Chemical	4123
(	PUNCT	O	O	4123
Ro	INTJ	O	O	4123
13	NUM	O	O	4123
-	PUNCT	O	O	4123
5057	NUM	O	O	4123
,	PUNCT	O	O	4123
1-anisoyl-2-pyrrolidinone	NOUN	O	Chemical	4123
)	PUNCT	O	O	4123
was	AUX	O	O	4123
studied	VERB	O	O	4123
on	ADP	O	O	4123
various	ADJ	O	O	4123
forms	NOUN	O	O	4123
of	ADP	O	O	4123
experimentally	ADV	O	O	4123
impaired cognitive functions	NOUN	O	Disease	4123
(	PUNCT	O	O	4123
learning	VERB	O	O	4123
and	CCONJ	O	O	4123
memory	NOUN	O	O	4123
)	PUNCT	O	O	4123
in	ADP	O	O	4123
rodents	NOUN	O	O	4123
and	CCONJ	O	O	4123
produced	VERB	O	O	4123
the	PRON	O	O	4123
following	VERB	O	O	4123
effects	NOUN	O	O	4123
:	PUNCT	O	O	4123
(	PUNCT	O	O	4123
1	X	O	O	4123
)	PUNCT	O	O	4123
almost	ADV	O	O	4123
complete	VERB	O	O	4123
prevention	NOUN	O	O	4123
of	ADP	O	O	4123
the	PRON	O	O	4123
incapacity	NOUN	O	O	4123
to	PART	O	O	4123
learn	VERB	O	O	4123
a	PRON	O	O	4123
discrete	ADJ	O	O	4123
escape	VERB	O	O	4123
response	NOUN	O	O	4123
in	ADP	O	O	4123
rats	NOUN	O	O	4123
exposed	VERB	O	O	4123
to	PART	O	O	4123
sublethal	VERB	O	O	4123
hypercapnia	PROPN	O	Disease	4123
immediately	ADV	O	O	4123
before	ADP	O	O	4123
the	PRON	O	O	4123
acquisition	NOUN	O	O	4123
session	NOUN	O	O	4123
;	PUNCT	O	O	4123
(	PUNCT	O	O	4123
2	X	O	O	4123
)	PUNCT	O	O	4123
partial	ADJ	O	O	4123
(	PUNCT	O	O	4123
rats	NOUN	O	O	4123
)	PUNCT	O	O	4123
or	CCONJ	O	O	4123
complete	VERB	O	O	4123
(	PUNCT	O	O	4123
mice	NOUN	O	O	4123
)	PUNCT	O	O	4123
prevention	NOUN	O	O	4123
of	ADP	O	O	4123
the	PRON	O	O	4123
scopolamine	NOUN	O	Chemical	4123
-	PUNCT	O	O	4123
induced	VERB	O	O	4123
short	ADJ	O	O	4123
-	PUNCT	O	O	4123
term	NOUN	O	O	4123
amnesia	NOUN	O	Disease	4123
for	ADP	O	O	4123
a	PRON	O	O	4123
passive	ADJ	O	O	4123
avoidance	NOUN	O	O	4123
task	NOUN	O	O	4123
;	PUNCT	O	O	4123
(	PUNCT	O	O	4124
3	X	O	O	4124
)	PUNCT	O	O	4124
complete	VERB	O	O	4124
protection	NOUN	O	O	4124
against	ADP	O	O	4124
amnesia	NOUN	O	Disease	4124
for	ADP	O	O	4124
a	PRON	O	O	4124
passive	ADJ	O	O	4124
avoidance	NOUN	O	O	4124
task	NOUN	O	O	4124
in	ADP	O	O	4124
rats	NOUN	O	O	4124
submitted	VERB	O	O	4124
to	PART	O	O	4124
electroconvulsive	VERB	O	O	4124
shock	NOUN	O	O	4124
immediately	ADV	O	O	4124
after	ADP	O	O	4124
avoidance	NOUN	O	O	4124
acquisition	NOUN	O	O	4124
;	PUNCT	O	O	4124
(	PUNCT	O	O	4124
4	NUM	O	O	4124
)	PUNCT	O	O	4124
prevention	NOUN	O	O	4124
of	ADP	O	O	4124
the	PRON	O	O	4124
long	ADV	O	O	4124
-	PUNCT	O	O	4124
term	NOUN	O	O	4124
retention-	X	O	O	4124
or	CCONJ	O	O	4124
retrieval	PROPN	O	O	4124
-	PUNCT	O	O	4124
deficit	NOUN	O	O	4124
for	ADP	O	O	4124
a	PRON	O	O	4124
passive	ADJ	O	O	4124
avoidance	NOUN	O	O	4124
task	NOUN	O	O	4124
induced	VERB	O	O	4124
in	ADP	O	O	4124
rats	NOUN	O	O	4124
and	CCONJ	O	O	4124
mice	NOUN	O	O	4124
by	ADP	O	O	4124
chloramphenicol	PROPN	O	Chemical	4124
or	CCONJ	O	O	4124
cycloheximide	NOUN	O	Chemical	4124
administered	VERB	O	O	4124
immediately	ADV	O	O	4124
after	ADP	O	O	4124
acquisition	NOUN	O	O	4124
;	PUNCT	O	O	4124
(	PUNCT	O	O	4124
5	NUM	O	O	4124
)	PUNCT	O	O	4124
reversal	NOUN	O	O	4124
,	PUNCT	O	O	4124
when	SCONJ	O	O	4125
administered	VERB	O	O	4125
as	ADP	O	O	4125
late	ADV	O	O	4125
as	ADP	O	O	4125
1	X	O	O	4125
h	X	O	O	4125
before	ADP	O	O	4125
the	PRON	O	O	4125
retention	NOUN	O	O	4125
test	NOUN	O	O	4125
,	PUNCT	O	O	4125
of	ADP	O	O	4125
the	PRON	O	O	4125
deficit	NOUN	O	O	4125
in	ADP	O	O	4125
retention	NOUN	O	O	4125
or	CCONJ	O	O	4125
retrieval	PROPN	O	O	4125
of	ADP	O	O	4125
a	PRON	O	O	4125
passive	ADJ	O	O	4125
avoidance	NOUN	O	O	4125
task	NOUN	O	O	4125
induced	VERB	O	O	4125
by	ADP	O	O	4125
cycloheximide	NOUN	O	Chemical	4125
injected	VERB	O	O	4125
2	X	O	O	4125
days	NOUN	O	O	4125
previously	ADV	O	O	4125
;	PUNCT	O	O	4125
(	PUNCT	O	O	4125
6	NUM	O	O	4125
)	PUNCT	O	O	4125
prevention	NOUN	O	O	4125
of	ADP	O	O	4125
the	PRON	O	O	4125
deficit	NOUN	O	O	4125
in	ADP	O	O	4125
the	PRON	O	O	4125
retrieval	PROPN	O	O	4125
of	ADP	O	O	4125
an	PRON	O	O	4125
active	ADJ	O	O	4125
avoidance	NOUN	O	O	4125
task	NOUN	O	O	4125
induced	VERB	O	O	4125
in	ADP	O	O	4125
mice	NOUN	O	O	4125
by	ADP	O	O	4125
subconvulsant	NOUN	O	O	4125
electroshock	NOUN	O	O	4125
or	CCONJ	O	O	4125
hypercapnia	PROPN	O	Disease	4125
applied	VERB	O	O	4125
immediately	ADV	O	O	4125
before	ADP	O	O	4125
retrieval	PROPN	O	O	4125
testing	NOUN	O	O	4125
(	PUNCT	O	O	4125
24	NUM	O	O	4125
h	X	O	O	4125
after	ADP	O	O	4125
acquisition	NOUN	O	O	4125
)	PUNCT	O	O	4125
.	PUNCT	O	O	4125
These	PRON	O	O	4126
improvements	NOUN	O	O	4126
or	CCONJ	O	O	4126
normalizations	NOUN	O	O	4126
of	ADP	O	O	4126
impaired cognitive functions	NOUN	O	Disease	4126
were	AUX	O	O	4126
seen	VERB	O	O	4126
at	ADP	O	O	4126
oral	ADJ	O	O	4126
aniracetam	PROPN	O	Chemical	4126
doses	NOUN	O	O	4126
of	ADP	O	O	4126
10	NUM	O	O	4126
-	PUNCT	O	O	4126
100	NUM	O	O	4126
mg	VERB	O	O	4126
/	PUNCT	O	O	4126
kg	VERB	O	O	4126
.	PUNCT	O	O	4126
The	PRON	O	O	4127
mechanisms	NOUN	O	O	4127
underlying	VERB	O	O	4127
the	PRON	O	O	4127
activity	NOUN	O	O	4127
of	ADP	O	O	4127
aniracetam	PROPN	O	Chemical	4127
and	CCONJ	O	O	4127
its	PRON	O	O	4127
'	PUNCT	O	O	4127
therapeutic	ADJ	O	O	4127
window	NOUN	O	O	4127
'	PUNCT	O	O	4127
are	AUX	O	O	4127
unknown	ADJ	O	O	4127
.	PUNCT	O	O	4127
Piracetam	PROPN	O	Chemical	4128
,	PUNCT	O	O	4128
another	PRON	O	O	4128
pyrrolidinone	NOUN	O	Chemical	4128
derivative	ADJ	O	O	4128
was	AUX	O	O	4128
used	VERB	O	O	4128
for	ADP	O	O	4128
comparison	NOUN	O	O	4128
.	PUNCT	O	O	4128
It	PRON	O	O	4129
was	AUX	O	O	4129
active	ADJ	O	O	4129
only	ADV	O	O	4129
in	ADP	O	O	4129
six	NUM	O	O	4129
of	ADP	O	O	4129
nine	NUM	O	O	4129
tests	VERB	O	O	4129
and	CCONJ	O	O	4129
had	VERB	O	O	4129
about	ADP	O	O	4129
one	NUM	O	O	4129
-	PUNCT	O	O	4129
tenth	ADJ	O	O	4129
the	PRON	O	O	4129
potency	NOUN	O	O	4129
of	ADP	O	O	4129
aniracetam	PROPN	O	Chemical	4129
.	PUNCT	O	O	4129
The	PRON	O	O	4130
results	VERB	O	O	4130
indicate	VERB	O	O	4130
that	SCONJ	O	O	4130
aniracetam	PROPN	O	Chemical	4130
improves	VERB	O	O	4130
cognitive	ADJ	O	O	4130
functions	VERB	O	O	4130
which	PRON	O	O	4130
are	AUX	O	O	4130
impaired	VERB	O	O	4130
by	ADP	O	O	4130
different	ADJ	O	O	4130
procedure	NOUN	O	O	4130
and	CCONJ	O	O	4130
in	ADP	O	O	4130
different	ADJ	O	O	4130
phases	NOUN	O	O	4130
of	ADP	O	O	4130
the	PRON	O	O	4130
learning	VERB	O	O	4130
and	CCONJ	O	O	4130
memory	NOUN	O	O	4130
process	NOUN	O	O	4130
.	PUNCT	O	O	4130
Nicotine	NOUN	O	Chemical	4133
potentiation	NOUN	O	O	4133
of	ADP	O	O	4133
morphine	NOUN	O	Chemical	4133
-	PUNCT	O	O	4133
induced	VERB	O	O	4133
catalepsy	VERB	O	Disease	4133
in	ADP	O	O	4133
mice	NOUN	O	O	4133
.	PUNCT	O	O	4133
In	ADP	O	O	4134
the	PRON	O	O	4134
present	NOUN	O	O	4134
study	VERB	O	O	4134
,	PUNCT	O	O	4134
effects	NOUN	O	O	4134
of	ADP	O	O	4134
nicotine	NOUN	O	Chemical	4134
on	ADP	O	O	4134
catalepsy	VERB	O	Disease	4134
induced	VERB	O	O	4134
by	ADP	O	O	4134
morphine	NOUN	O	Chemical	4134
in	ADP	O	O	4134
mice	NOUN	O	O	4134
have	VERB	O	O	4134
been	AUX	O	O	4134
investigated	VERB	O	O	4134
.	PUNCT	O	O	4134
Morphine	NOUN	O	Chemical	4135
but	CCONJ	O	O	4135
not	PART	O	O	4135
nicotine	NOUN	O	Chemical	4135
induced	VERB	O	O	4135
a	PRON	O	O	4135
dose	NOUN	O	O	4135
-	PUNCT	O	O	4135
dependent	ADJ	O	O	4135
catalepsy	VERB	O	Disease	4135
.	PUNCT	O	O	4135
The	PRON	O	O	4136
response	NOUN	O	O	4136
of	ADP	O	O	4136
morphine	NOUN	O	Chemical	4136
was	AUX	O	O	4136
potentiated	VERB	O	O	4136
by	ADP	O	O	4136
nicotine	NOUN	O	Chemical	4136
.	PUNCT	O	O	4136
Intraperitoneal	NOUN	O	O	4137
administration	NOUN	O	O	4137
of	ADP	O	O	4137
atropine	NOUN	O	Chemical	4137
,	PUNCT	O	O	4137
naloxone	NOUN	O	Chemical	4137
,	PUNCT	O	O	4137
mecamylamine	PROPN	O	Chemical	4137
,	PUNCT	O	O	4137
and	CCONJ	O	O	4137
hexamethonium	ADJ	O	Chemical	4137
to	PART	O	O	4137
mice	NOUN	O	O	4137
reduced	VERB	O	O	4137
catalepsy	VERB	O	Disease	4138
induced	VERB	O	O	4138
by	ADP	O	O	4138
a	PRON	O	O	4138
combination	NOUN	O	O	4138
of	ADP	O	O	4138
morphine	NOUN	O	Chemical	4138
with	ADP	O	O	4138
nicotine	NOUN	O	Chemical	4138
.	PUNCT	O	O	4138
Intracerebroventricular	PROPN	O	O	4139
injection	NOUN	O	O	4139
of	ADP	O	O	4139
atropine	NOUN	O	Chemical	4139
,	PUNCT	O	O	4139
hexamethonium	ADJ	O	Chemical	4139
,	PUNCT	O	O	4139
and	CCONJ	O	O	4139
naloxone	NOUN	O	Chemical	4139
also	ADV	O	O	4139
decreased	VERB	O	O	4139
catalepsy	VERB	O	Disease	4139
induced	VERB	O	O	4139
by	ADP	O	O	4139
morphine	NOUN	O	Chemical	4139
plus	CCONJ	O	O	4139
nicotine	NOUN	O	Chemical	4139
.	PUNCT	O	O	4139
Intraperitoneal	NOUN	O	O	4140
administration	NOUN	O	O	4140
of	ADP	O	O	4140
atropine	NOUN	O	Chemical	4140
,	PUNCT	O	O	4140
but	CCONJ	O	O	4140
not	PART	O	O	4140
intraperitoneal	ADJ	O	O	4140
or	CCONJ	O	O	4140
intracerebroventricular	PROPN	O	O	4140
injection	NOUN	O	O	4140
of	ADP	O	O	4140
hexamethonium	ADJ	O	Chemical	4140
,	PUNCT	O	O	4140
decreased	VERB	O	O	4140
the	PRON	O	O	4140
effect	VERB	O	O	4140
of	ADP	O	O	4140
a	PRON	O	O	4140
single	ADJ	O	O	4140
dose	NOUN	O	O	4140
of	ADP	O	O	4140
morphine	NOUN	O	Chemical	4140
.	PUNCT	O	O	4140
It	PRON	O	O	4141
was	AUX	O	O	4141
concluded	VERB	O	O	4141
that	SCONJ	O	O	4141
morphine	NOUN	O	Chemical	4141
catalepsy	VERB	O	Disease	4141
can	AUX	O	O	4141
be	AUX	O	O	4141
elicited	VERB	O	O	4141
by	ADP	O	O	4141
opioid	NOUN	O	O	4141
and	CCONJ	O	O	4141
cholinergic	ADJ	O	O	4141
receptors	NOUN	O	O	4141
,	PUNCT	O	O	4141
and	CCONJ	O	O	4141
the	PRON	O	O	4141
potentiation	NOUN	O	O	4141
of	ADP	O	O	4141
morphine	NOUN	O	Chemical	4141
induced	VERB	O	O	4141
by	ADP	O	O	4141
nicotine	NOUN	O	Chemical	4141
may	AUX	O	O	4141
also	ADV	O	O	4141
be	AUX	O	O	4141
mediated	VERB	O	O	4141
through	ADP	O	O	4141
cholinergic	ADJ	O	O	4141
receptor	NOUN	O	O	4141
mechanisms	NOUN	O	O	4141
.	PUNCT	O	O	4141
Reduced	VERB	O	O	4144
cardiotoxicity	NOUN	O	Disease	4144
and	CCONJ	O	O	4144
preserved	VERB	O	O	4144
antitumor	PROPN	O	O	4144
efficacy	NOUN	O	O	4144
of	ADP	O	O	4144
liposome	NOUN	O	O	4144
-	PUNCT	O	O	4144
encapsulated	VERB	O	O	4144
doxorubicin	VERB	O	Chemical	4144
and	CCONJ	O	O	4144
cyclophosphamide	VERB	O	Chemical	4144
compared	VERB	O	O	4144
with	ADP	O	O	4144
conventional	ADJ	O	O	4144
doxorubicin	VERB	O	Chemical	4144
and	CCONJ	O	O	4144
cyclophosphamide	VERB	O	Chemical	4144
in	ADP	O	O	4144
a	PRON	O	O	4144
randomized	VERB	O	O	4144
,	PUNCT	O	O	4144
multicenter	ADJ	O	O	4144
trial	NOUN	O	O	4144
of	ADP	O	O	4144
metastatic	ADJ	O	O	4144
breast cancer	NOUN	O	Disease	4144
.	PUNCT	O	O	4144
To	PART	O	O	4145
determine	VERB	O	O	4145
whether	SCONJ	O	O	4145
Myocet	PROPN	O	Chemical	4145
(	PUNCT	O	O	4145
liposome	NOUN	O	O	4145
-	PUNCT	O	O	4145
encapsulated	VERB	O	O	4145
doxorubicin	VERB	O	Chemical	4145
;	PUNCT	O	O	4145
The	PRON	O	O	4145
Liposome	NOUN	O	O	4145
Company	NOUN	O	O	4145
,	PUNCT	O	O	4145
Elan	PROPN	O	O	4145
Corporation	NOUN	O	O	4145
,	PUNCT	O	O	4145
Princeton	PROPN	O	O	4145
,	PUNCT	O	O	4145
NJ	PROPN	O	O	4145
)	PUNCT	O	O	4145
in	ADP	O	O	4145
combination	NOUN	O	O	4145
with	ADP	O	O	4145
cyclophosphamide	VERB	O	Chemical	4145
significantly	ADV	O	O	4145
reduces	VERB	O	O	4145
doxorubicin	VERB	O	Chemical	4145
cardiotoxicity	NOUN	O	Disease	4145
while	SCONJ	O	O	4145
providing	VERB	O	O	4145
comparable	ADJ	O	O	4145
antitumor	PROPN	O	O	4145
efficacy	NOUN	O	O	4145
in	ADP	O	O	4145
first	ADV	O	O	4145
-	PUNCT	O	O	4145
line	NOUN	O	O	4145
treatment	NOUN	O	O	4145
of	ADP	O	O	4145
metastatic	ADJ	O	O	4145
breast cancer	NOUN	O	Disease	4145
(	PUNCT	O	O	4145
MBC	PROPN	O	Disease	4145
)	PUNCT	O	O	4145
.	PUNCT	O	O	4145
Two	NUM	O	O	4146
hundred	NUM	O	O	4146
ninety	NUM	O	O	4146
-	PUNCT	O	O	4146
seven	NUM	O	O	4146
patients	NOUN	O	O	4146
with	ADP	O	O	4146
MBC	PROPN	O	Disease	4146
and	CCONJ	O	O	4146
no	PRON	O	O	4146
prior	ADV	O	O	4146
chemotherapy	NOUN	O	O	4146
for	ADP	O	O	4146
metastatic	ADJ	O	O	4146
disease	PROPN	O	O	4146
were	AUX	O	O	4146
randomized	VERB	O	O	4146
to	PART	O	O	4146
receive	VERB	O	O	4146
either	ADV	O	O	4146
60	NUM	O	O	4146
mg	VERB	O	O	4146
/	PUNCT	O	O	4146
m(2	NUM	O	O	4146
)	PUNCT	O	O	4146
of	ADP	O	O	4146
Myocet	PROPN	O	Chemical	4146
(	PUNCT	O	O	4146
M	NOUN	O	Chemical	4146
)	PUNCT	O	O	4146
or	CCONJ	O	O	4146
conventional	ADJ	O	O	4146
doxorubicin	VERB	O	Chemical	4146
(	PUNCT	O	O	4146
A	PRON	O	O	4146
)	PUNCT	O	O	4146
,	PUNCT	O	O	4146
in	ADP	O	O	4146
combination	NOUN	O	O	4146
with	ADP	O	O	4146
600	NUM	O	O	4146
mg	VERB	O	O	4146
/	PUNCT	O	O	4146
m(2	NUM	O	O	4146
)	PUNCT	O	O	4146
of	ADP	O	O	4146
cyclophosphamide	VERB	O	Chemical	4146
(	PUNCT	O	O	4146
C	NOUN	O	O	4146
)	PUNCT	O	O	4146
,	PUNCT	O	O	4146
every	PRON	O	O	4146
3	X	O	O	4146
weeks	NOUN	O	O	4146
until	ADP	O	O	4146
disease	PROPN	O	O	4146
progression	NOUN	O	O	4146
or	CCONJ	O	O	4146
unacceptable	ADJ	O	O	4146
toxicity	NOUN	O	Disease	4146
.	PUNCT	O	O	4146
Cardiotoxicity	NOUN	O	Disease	4147
was	AUX	O	O	4147
defined	VERB	O	O	4147
by	ADP	O	O	4147
reductions	NOUN	O	O	4147
in	ADP	O	O	4147
left	VERB	O	O	4147
-	PUNCT	O	O	4147
ventricular	ADJ	O	O	4147
ejection	NOUN	O	O	4147
fraction	NOUN	O	O	4147
,	PUNCT	O	O	4147
assessed	VERB	O	O	4147
by	ADP	O	O	4147
serial	ADJ	O	O	4147
multigated	VERB	O	O	4147
radionuclide	NOUN	O	O	4147
angiography	NOUN	O	O	4147
scans	VERB	O	O	4147
,	PUNCT	O	O	4147
or	CCONJ	O	O	4147
congestive	ADJ	O	O	4147
heart failure	NOUN	O	Disease	4147
(	PUNCT	O	O	4147
CHF	PROPN	O	Disease	4147
)	PUNCT	O	O	4147
.	PUNCT	O	O	4147
Antitumor	PROPN	O	O	4148
efficacy	NOUN	O	O	4148
was	AUX	O	O	4148
assessed	VERB	O	O	4148
by	ADP	O	O	4148
objective	VERB	O	O	4148
tumor	NOUN	O	Disease	4148
response	NOUN	O	O	4148
rates	NOUN	O	O	4148
(	PUNCT	O	O	4148
World	NOUN	O	O	4148
Health	NOUN	O	O	4148
Organization	PROPN	O	O	4148
criteria	NOUN	O	O	4148
)	PUNCT	O	O	4148
,	PUNCT	O	O	4148
time	NOUN	O	O	4148
to	PART	O	O	4148
progression	NOUN	O	O	4148
,	PUNCT	O	O	4148
and	CCONJ	O	O	4148
survival	NOUN	O	O	4148
.	PUNCT	O	O	4148
Six	NUM	O	O	4149
percent	NOUN	O	O	4149
of	ADP	O	O	4149
MC	PROPN	O	Chemical	4149
patients	NOUN	O	O	4149
versus	ADP	O	O	4149
21%	NOUN	O	O	4149
(	PUNCT	O	O	4149
including	VERB	O	O	4149
five	NUM	O	O	4149
cases	NOUN	O	O	4149
of	ADP	O	O	4149
CHF	PROPN	O	Disease	4149
)	PUNCT	O	O	4149
of	ADP	O	O	4149
AC	PROPN	O	O	4149
patients	NOUN	O	O	4149
developed	VERB	O	O	4149
cardiotoxicity	NOUN	O	Disease	4149
(	PUNCT	O	O	4149
P	NOUN	O	Chemical	4149
=	PUNCT	O	O	4149
.0002	PUNCT	O	O	4149
)	PUNCT	O	O	4149
.	PUNCT	O	O	4149
Median	ADJ	O	O	4150
cumulative	ADJ	O	O	4150
doxorubicin	VERB	O	Chemical	4150
dose	NOUN	O	O	4150
at	ADP	O	O	4150
onset	VERB	O	O	4150
was	AUX	O	O	4150
more	ADJ	O	O	4150
than	ADP	O	O	4150
2,220	NUM	O	O	4150
mg	VERB	O	O	4150
/	PUNCT	O	O	4150
m(2	NUM	O	O	4150
)	PUNCT	O	O	4150
for	ADP	O	O	4150
MC	PROPN	O	Chemical	4150
versus	ADP	O	O	4150
480	NUM	O	O	4150
mg	VERB	O	O	4150
/	PUNCT	O	O	4150
m(2	NUM	O	O	4150
)	PUNCT	O	O	4150
for	ADP	O	O	4150
AC	PROPN	O	O	4150
(	PUNCT	O	O	4150
P	NOUN	O	Chemical	4150
=	PUNCT	O	O	4150
.0001	PUNCT	O	O	4150
,	PUNCT	O	O	4150
hazard	NOUN	O	O	4150
ratio	NOUN	O	O	4150
,	PUNCT	O	O	4150
5.04	NUM	O	O	4150
)	PUNCT	O	O	4150
.	PUNCT	O	O	4150
MC	PROPN	O	Chemical	4151
patients	NOUN	O	O	4151
also	ADV	O	O	4151
experienced	ADJ	O	O	4151
less	ADV	O	O	4151
grade	NOUN	O	O	4151
4	NUM	O	O	4151
neutropenia	ADJ	O	Disease	4151
.	PUNCT	O	O	4151
CONCLUSION	PROPN	O	O	4152
:	PUNCT	O	O	4152
Myocet	PROPN	O	Chemical	4152
improves	VERB	O	O	4152
the	PRON	O	O	4152
therapeutic	ADJ	O	O	4152
index	NOUN	O	O	4152
of	ADP	O	O	4152
doxorubicin	VERB	O	Chemical	4152
by	ADP	O	O	4152
significantly	ADV	O	O	4152
reducing	VERB	O	O	4152
cardiotoxicity	NOUN	O	Disease	4152
and	CCONJ	O	O	4152
grade	NOUN	O	O	4152
4	NUM	O	O	4152
neutropenia	ADJ	O	Disease	4152
and	CCONJ	O	O	4152
provides	VERB	O	O	4152
comparable	ADJ	O	O	4152
antitumor	PROPN	O	O	4152
efficacy	NOUN	O	O	4152
,	PUNCT	O	O	4152
when	SCONJ	O	O	4152
used	VERB	O	O	4152
in	ADP	O	O	4152
combination	NOUN	O	O	4152
with	ADP	O	O	4152
cyclophosphamide	VERB	O	Chemical	4152
as	ADP	O	O	4152
first	ADV	O	O	4152
-	PUNCT	O	O	4152
line	NOUN	O	O	4152
therapy	NOUN	O	O	4152
for	ADP	O	O	4152
MBC	PROPN	O	Disease	4152
.	PUNCT	O	O	4152
Protective	NOUN	O	O	4155
effect	VERB	O	O	4155
of	ADP	O	O	4155
a	PRON	O	O	4155
specific	ADJ	O	O	4155
platelet	NOUN	O	O	4155
-	PUNCT	O	O	4155
activating	VERB	O	O	4155
factor	NOUN	O	O	4155
antagonist	NOUN	O	O	4155
,	PUNCT	O	O	4155
BN 52021	NUM	O	Chemical	4155
,	PUNCT	O	O	4155
on	ADP	O	O	4155
bupivacaine	NOUN	O	Chemical	4155
-	PUNCT	O	O	4155
induced	VERB	O	O	4155
cardiovascular impairments	NOUN	O	Disease	4155
in	ADP	O	O	4155
rats	NOUN	O	O	4155
.	PUNCT	O	O	4155
Administration	NOUN	O	O	4156
of	ADP	O	O	4156
the	PRON	O	O	4156
local	ADJ	O	O	4156
anaesthetic	NOUN	O	O	4156
bupivacaine	NOUN	O	Chemical	4156
(	PUNCT	O	O	4156
1.5	NUM	O	O	4156
or	CCONJ	O	O	4156
2	X	O	O	4156
mg	VERB	O	O	4156
/	PUNCT	O	O	4156
kg	VERB	O	O	4156
,	PUNCT	O	O	4156
i.v	NOUN	O	O	4156
.	PUNCT	O	O	4156
)	PUNCT	O	O	4156
to	PART	O	O	4157
rats	NOUN	O	O	4157
elicited	VERB	O	O	4157
a	PRON	O	O	4157
marked	VERB	O	O	4157
decrease	VERB	O	O	4157
of	ADP	O	O	4157
mean	VERB	O	O	4157
arterial	ADJ	O	O	4157
blood	NOUN	O	O	4157
pressure	NOUN	O	O	4157
(	PUNCT	O	O	4157
MBP	PROPN	O	O	4157
)	PUNCT	O	O	4157
and	CCONJ	O	O	4157
heart	NOUN	O	O	4157
rate	NOUN	O	O	4157
(	PUNCT	O	O	4157
HR	NOUN	O	O	4157
)	PUNCT	O	O	4157
leading	VERB	O	O	4157
to	PART	O	O	4157
death	NOUN	O	O	4157
(	PUNCT	O	O	4157
in	ADP	O	O	4157
67%	NOUN	O	O	4157
or	CCONJ	O	O	4157
90%	NOUN	O	O	4157
of	ADP	O	O	4157
animals	NOUN	O	O	4157
respectively	ADV	O	O	4157
)	PUNCT	O	O	4157
.	PUNCT	O	O	4157
Intravenous	PROPN	O	O	4158
injection	NOUN	O	O	4158
of	ADP	O	O	4158
the	PRON	O	O	4158
specific	ADJ	O	O	4158
platelet	NOUN	O	O	4158
-	PUNCT	O	O	4158
activating	VERB	O	O	4158
factor	NOUN	O	O	4158
(	PUNCT	O	O	4158
PAF	PROPN	O	O	4158
)	PUNCT	O	O	4158
antagonist	NOUN	O	O	4158
BN 52021	NUM	O	Chemical	4158
(	PUNCT	O	O	4158
10	NUM	O	O	4158
mg	VERB	O	O	4158
/	PUNCT	O	O	4158
kg	VERB	O	O	4158
)	PUNCT	O	O	4158
,	PUNCT	O	O	4158
30	NUM	O	O	4158
min	NOUN	O	O	4158
before	ADP	O	O	4158
bupivacaine	NOUN	O	Chemical	4158
administration	NOUN	O	O	4158
(	PUNCT	O	O	4158
2	X	O	O	4158
mg	VERB	O	O	4158
/	PUNCT	O	O	4158
kg	VERB	O	O	4158
i.v	NOUN	O	O	4158
.	PUNCT	O	O	4158
)	PUNCT	O	O	4158
suppressed	VERB	O	O	4158
both	PRON	O	O	4158
the	PRON	O	O	4158
decrease of MBP	PROPN	O	Disease	4158
and	CCONJ	O	O	4158
HR	NOUN	O	O	4158
.	PUNCT	O	O	4158
In	ADP	O	O	4159
contrast	NOUN	O	O	4159
,	PUNCT	O	O	4159
doses	NOUN	O	O	4159
of	ADP	O	O	4159
1	X	O	O	4159
mg	VERB	O	O	4159
/	PUNCT	O	O	4159
kg	VERB	O	O	4159
BN 52021	NUM	O	Chemical	4159
given	VERB	O	O	4159
30	NUM	O	O	4159
min	NOUN	O	O	4159
before	ADP	O	O	4159
or	CCONJ	O	O	4159
10	NUM	O	O	4159
mg	VERB	O	O	4159
/	PUNCT	O	O	4159
kg	VERB	O	O	4159
administered	VERB	O	O	4159
5	NUM	O	O	4159
min	NOUN	O	O	4159
before	ADP	O	O	4159
i.v	NOUN	O	O	4159
.	PUNCT	O	O	4159
injection	NOUN	O	O	4160
of	ADP	O	O	4160
bupivacaine	NOUN	O	Chemical	4160
were	AUX	O	O	4160
ineffective	ADJ	O	O	4160
.	PUNCT	O	O	4160
When	SCONJ	O	O	4161
BN 52021	NUM	O	Chemical	4161
(	PUNCT	O	O	4161
20	NUM	O	O	4161
mg	VERB	O	O	4161
was	AUX	O	O	4162
injected	VERB	O	O	4162
immediately	ADV	O	O	4162
after	ADP	O	O	4162
bupivacaine	NOUN	O	Chemical	4162
(	PUNCT	O	O	4162
2	X	O	O	4162
mg	VERB	O	O	4162
/	PUNCT	O	O	4162
kg	VERB	O	O	4162
)	PUNCT	O	O	4162
,	PUNCT	O	O	4162
a	PRON	O	O	4162
partial	ADJ	O	O	4162
reversion	NOUN	O	O	4162
of	ADP	O	O	4162
the	PRON	O	O	4162
decrease of MBP	PROPN	O	Disease	4162
and	CCONJ	O	O	4162
HR	NOUN	O	O	4162
was	AUX	O	O	4162
observed	VERB	O	O	4162
,	PUNCT	O	O	4162
whereas	SCONJ	O	O	4162
the	PRON	O	O	4162
dose	NOUN	O	O	4162
of	ADP	O	O	4162
10	NUM	O	O	4162
mg	VERB	O	O	4162
/	PUNCT	O	O	4162
kg	VERB	O	O	4162
was	AUX	O	O	4162
ineffective	ADJ	O	O	4162
.	PUNCT	O	O	4162
A	PRON	O	O	4163
partial	ADJ	O	O	4163
recovery	NOUN	O	O	4163
of	ADP	O	O	4163
bupivacaine	NOUN	O	Chemical	4163
-	PUNCT	O	O	4163
induced	VERB	O	O	4163
ECG	PROPN	O	O	4163
alterations	NOUN	O	O	4163
was	AUX	O	O	4163
observed	VERB	O	O	4163
after	ADP	O	O	4163
pretreatment	NOUN	O	O	4163
of	ADP	O	O	4163
the	PRON	O	O	4163
rats	NOUN	O	O	4163
with	ADP	O	O	4163
BN 52021	NUM	O	Chemical	4163
.	PUNCT	O	O	4163
Since	SCONJ	O	O	4164
the	PRON	O	O	4164
administration	NOUN	O	O	4164
of	ADP	O	O	4164
BN 52021	NUM	O	Chemical	4164
,	PUNCT	O	O	4164
at	ADP	O	O	4164
all	PRON	O	O	4164
doses	NOUN	O	O	4164
studied	VERB	O	O	4164
,	PUNCT	O	O	4164
did	VERB	O	O	4164
not	PART	O	O	4164
alter	VERB	O	O	4164
MBP	PROPN	O	O	4164
and	CCONJ	O	O	4164
HR	NOUN	O	O	4164
at	ADP	O	O	4164
the	PRON	O	O	4164
doses	NOUN	O	O	4164
used	VERB	O	O	4164
,	PUNCT	O	O	4164
the	PRON	O	O	4164
bulk	NOUN	O	O	4164
of	ADP	O	O	4164
these	PRON	O	O	4164
results	VERB	O	O	4164
clearly	ADV	O	O	4164
demonstrate	VERB	O	O	4164
a	PRON	O	O	4164
protective	ADJ	O	O	4164
action	NOUN	O	O	4164
of	ADP	O	O	4164
BN 52021	NUM	O	Chemical	4164
,	PUNCT	O	O	4164
a	PRON	O	O	4164
specific	ADJ	O	O	4164
antagonist	NOUN	O	O	4164
of	ADP	O	O	4164
PAF	PROPN	O	O	4164
,	PUNCT	O	O	4164
against	ADP	O	O	4164
bupivacaine	NOUN	O	Chemical	4164
-	PUNCT	O	O	4164
induced	VERB	O	O	4164
cardiovascular toxicity	NOUN	O	Disease	4164
.	PUNCT	O	O	4164
Thus	ADV	O	O	4165
,	PUNCT	O	O	4165
consistent	ADJ	O	O	4165
with	ADP	O	O	4165
its	PRON	O	O	4165
direct	ADJ	O	O	4165
effect	VERB	O	O	4165
on	ADP	O	O	4165
heart	NOUN	O	O	4165
,	PUNCT	O	O	4165
PAF	PROPN	O	O	4165
appears	VERB	O	O	4165
to	PART	O	O	4165
be	AUX	O	O	4165
implicated	VERB	O	O	4165
in	ADP	O	O	4165
bupivacaine	NOUN	O	Chemical	4165
-	PUNCT	O	O	4165
induced	VERB	O	O	4165
cardiovascular alterations	NOUN	O	Disease	4165
.	PUNCT	O	O	4165
Benzylacyclouridine	NOUN	O	Chemical	4168
reverses	VERB	O	O	4168
azidothymidine	NOUN	O	Chemical	4168
-	PUNCT	O	O	4168
induced	VERB	O	O	4168
marrow suppression	NOUN	O	Disease	4168
without	ADP	O	O	4168
impairment	NOUN	O	O	4168
of	ADP	O	O	4168
anti	ADJ	O	O	4168
-	PUNCT	O	O	4168
human	PROPN	O	O	4168
immunodeficiency	NOUN	O	Disease	4168
virus	NOUN	O	O	4168
activity	NOUN	O	O	4168
.	PUNCT	O	O	4168
Increased	VERB	O	O	4169
extracellular	ADJ	O	O	4169
concentrations	NOUN	O	O	4169
of	ADP	O	O	4169
uridine	NOUN	O	Chemical	4169
(	PUNCT	O	O	4169
Urd	NOUN	O	Chemical	4169
)	PUNCT	O	O	4169
have	VERB	O	O	4169
been	AUX	O	O	4169
reported	VERB	O	O	4169
to	PART	O	O	4169
reduce	VERB	O	O	4169
,	PUNCT	O	O	4169
in	ADP	O	O	4169
vitro	X	O	O	4169
,	PUNCT	O	O	4169
azidothymidine	NOUN	O	Chemical	4169
(	PUNCT	O	O	4169
AZT)-induced	NOUN	O	O	4169
inhibition	NOUN	O	O	4169
of	ADP	O	O	4169
human	PROPN	O	O	4169
granulocyte	NOUN	O	O	4169
-	PUNCT	O	O	4169
macrophage	NOUN	O	O	4169
progenitor	NOUN	O	O	4169
cells	NOUN	O	O	4169
without	ADP	O	O	4169
impairment	NOUN	O	O	4169
of	ADP	O	O	4169
its	PRON	O	O	4169
antihuman	ADJ	O	O	4169
immunodeficiency	NOUN	O	Disease	4169
virus	NOUN	O	O	4169
(	PUNCT	O	O	4169
HIV	PROPN	O	O	4169
)	PUNCT	O	O	4169
activity	NOUN	O	O	4169
.	PUNCT	O	O	4169
Because	SCONJ	O	O	4170
of	ADP	O	O	4170
the	PRON	O	O	4170
clinical	ADJ	O	O	4170
toxicities	NOUN	O	Disease	4170
associated	VERB	O	O	4170
with	ADP	O	O	4170
chronic	ADJ	O	O	4170
Urd	NOUN	O	Chemical	4170
administration	NOUN	O	O	4170
,	PUNCT	O	O	4170
the	PRON	O	O	4170
ability	NOUN	O	O	4170
of	ADP	O	O	4170
benzylacyclouridine	NOUN	O	Chemical	4170
(	PUNCT	O	O	4170
BAU	PROPN	O	Chemical	4170
)	PUNCT	O	O	4170
to	PART	O	O	4170
effect	VERB	O	O	4170
,	PUNCT	O	O	4170
in	ADP	O	O	4170
vivo	VERB	O	O	4170
,	PUNCT	O	O	4170
AZT	PROPN	O	Chemical	4170
-	PUNCT	O	O	4170
induced	VERB	O	O	4170
anemia	NOUN	O	Disease	4170
and	CCONJ	O	O	4170
leukopenia	PROPN	O	Disease	4170
was	AUX	O	O	4170
assessed	VERB	O	O	4170
.	PUNCT	O	O	4170
This	PRON	O	O	4171
agent	NOUN	O	O	4171
inhibits	VERB	O	O	4171
Urd	NOUN	O	Chemical	4171
catabolism	NOUN	O	O	4171
and	CCONJ	O	O	4171
,	PUNCT	O	O	4171
in	ADP	O	O	4171
vivo	VERB	O	O	4171
,	PUNCT	O	O	4171
increases	VERB	O	O	4171
the	PRON	O	O	4171
plasma	NOUN	O	O	4171
concentration	NOUN	O	O	4171
of	ADP	O	O	4171
Urd	NOUN	O	Chemical	4171
in	ADP	O	O	4171
a	PRON	O	O	4171
dose	NOUN	O	O	4171
-	PUNCT	O	O	4171
dependent	ADJ	O	O	4171
manner	VERB	O	O	4171
,	PUNCT	O	O	4171
without	ADP	O	O	4171
Urd	NOUN	O	Chemical	4171
-	PUNCT	O	O	4171
related	ADJ	O	O	4171
toxicity	NOUN	O	Disease	4171
.	PUNCT	O	O	4171
In	ADP	O	O	4172
mice	NOUN	O	O	4172
rendered	VERB	O	O	4172
anemic	ADJ	O	Disease	4172
and	CCONJ	O	O	4172
leukopenic	NOUN	O	Disease	4172
by	ADP	O	O	4172
the	PRON	O	O	4172
administration	NOUN	O	O	4172
of	ADP	O	O	4172
AZT	PROPN	O	Chemical	4172
for	ADP	O	O	4172
28	NUM	O	O	4172
days	NOUN	O	O	4172
in	ADP	O	O	4172
drinking	VERB	O	O	4172
water	PROPN	O	O	4172
(	PUNCT	O	O	4172
1.5	NUM	O	O	4172
mg	VERB	O	O	4172
/	PUNCT	O	O	4172
mL	PROPN	O	O	4172
)	PUNCT	O	O	4172
,	PUNCT	O	O	4172
the	PRON	O	O	4172
continued	VERB	O	O	4172
administration	NOUN	O	O	4172
of	ADP	O	O	4172
AZT	PROPN	O	Chemical	4172
plus	CCONJ	O	O	4172
daily	ADV	O	O	4172
BAU	PROPN	O	Chemical	4172
(	PUNCT	O	O	4172
300	NUM	O	O	4172
mg	VERB	O	O	4172
/	PUNCT	O	O	4172
kg	VERB	O	O	4172
,	PUNCT	O	O	4172
orally	ADV	O	O	4172
)	PUNCT	O	O	4172
partially	ADV	O	O	4172
reversed	VERB	O	O	4172
AZT	PROPN	O	Chemical	4172
-	PUNCT	O	O	4172
induced	VERB	O	O	4172
anemia	NOUN	O	Disease	4172
and	CCONJ	O	O	4172
leukopenia	PROPN	O	Disease	4172
(	PUNCT	O	O	4172
P	NOUN	O	Chemical	4172
less	ADV	O	O	4172
than	ADP	O	O	4172
.05	NUM	O	O	4172
)	PUNCT	O	O	4172
,	PUNCT	O	O	4172
increased	VERB	O	O	4172
peripheral	ADJ	O	O	4172
reticulocytes	NOUN	O	O	4172
(	PUNCT	O	O	4172
to	PART	O	O	4172
4.9%	NOUN	O	O	4172
,	PUNCT	O	O	4172
P	NOUN	O	Chemical	4172
less	ADV	O	O	4172
than	ADP	O	O	4172
.01	NUM	O	O	4172
)	PUNCT	O	O	4172
,	PUNCT	O	O	4172
increased	VERB	O	O	4172
cellularity	NOUN	O	O	4172
in	ADP	O	O	4172
the	PRON	O	O	4172
marrow	PROPN	O	O	4172
,	PUNCT	O	O	4172
and	CCONJ	O	O	4172
improved	VERB	O	O	4172
megaloblastosis	NOUN	O	Disease	4172
.	PUNCT	O	O	4172
When	SCONJ	O	O	4173
coadministered	VERB	O	O	4173
with	ADP	O	O	4173
AZT	PROPN	O	Chemical	4173
from	ADP	O	O	4173
the	PRON	O	O	4173
onset	VERB	O	O	4173
of	ADP	O	O	4173
drug	NOUN	O	O	4173
administration	NOUN	O	O	4173
,	PUNCT	O	O	4173
BAU	PROPN	O	Chemical	4173
reduced	VERB	O	O	4173
AZT	PROPN	O	Chemical	4173
-	PUNCT	O	O	4173
induced	VERB	O	O	4173
marrow toxicity	NOUN	O	Disease	4173
.	PUNCT	O	O	4173
In	ADP	O	O	4174
vitro	X	O	O	4174
,	PUNCT	O	O	4174
at	ADP	O	O	4174
a	PRON	O	O	4174
concentration	NOUN	O	O	4174
of	ADP	O	O	4174
100	NUM	O	O	4174
mumol	PROPN	O	O	4174
/	PUNCT	O	O	4174
L	NOUN	O	O	4174
,	PUNCT	O	O	4174
BAU	PROPN	O	Chemical	4174
possesses	VERB	O	O	4174
minimal	ADJ	O	O	4174
anti	ADJ	O	O	4174
-	PUNCT	O	O	4174
HIV	PROPN	O	O	4174
activity	NOUN	O	O	4174
and	CCONJ	O	O	4174
has	VERB	O	O	4174
no	PRON	O	O	4174
effect	VERB	O	O	4174
on	ADP	O	O	4174
the	PRON	O	O	4174
ability	NOUN	O	O	4174
of	ADP	O	O	4174
AZT	PROPN	O	Chemical	4174
to	PART	O	O	4174
reverse	VERB	O	O	4174
the	PRON	O	O	4174
HIV	PROPN	O	O	4174
-	PUNCT	O	O	4174
induced	VERB	O	O	4174
cytopathic	ADJ	O	O	4174
effect	VERB	O	O	4174
in	ADP	O	O	4174
MT4	PROPN	O	O	4174
cells	NOUN	O	O	4174
.	PUNCT	O	O	4174
Cyclophosphamide	PROPN	O	Chemical	4177
-	PUNCT	O	O	4177
induced	VERB	O	O	4177
cystitis	NOUN	O	Disease	4177
in	ADP	O	O	4177
freely	ADV	O	O	4177
-	PUNCT	O	O	4177
moving	VERB	O	O	4177
conscious	ADJ	O	O	4177
rats	NOUN	O	O	4177
:	PUNCT	O	O	4177
behavioral	ADJ	O	O	4177
approach	NOUN	O	O	4177
to	PART	O	O	4177
a	PRON	O	O	4177
new	ADJ	O	O	4177
model	NOUN	O	O	4177
of	ADP	O	O	4177
visceral pain	NOUN	O	Disease	4177
.	PUNCT	O	O	4177
PURPOSE	NOUN	O	O	4178
:	PUNCT	O	O	4178
To	PART	O	O	4178
develop	VERB	O	O	4178
a	PRON	O	O	4178
model	NOUN	O	O	4178
of	ADP	O	O	4178
visceral pain	NOUN	O	Disease	4178
in	ADP	O	O	4178
rats	NOUN	O	O	4178
using	VERB	O	O	4178
a	PRON	O	O	4178
behavioral	ADJ	O	O	4178
approach	NOUN	O	O	4178
.	PUNCT	O	O	4178
Cyclophosphamide	PROPN	O	Chemical	4179
(	PUNCT	O	O	4179
CP	PROPN	O	Chemical	4179
)	PUNCT	O	O	4179
,	PUNCT	O	O	4179
an	PRON	O	O	4179
antitumoral	ADJ	O	O	4179
agent	NOUN	O	O	4179
known	VERB	O	O	4179
to	PART	O	O	4179
produce	VERB	O	O	4179
toxic	ADJ	O	O	4179
effects	NOUN	O	O	4179
on	ADP	O	O	4179
the	PRON	O	O	4179
bladder	NOUN	O	O	4179
wall	PROPN	O	O	4179
through	ADP	O	O	4179
its	PRON	O	O	4179
main	ADJ	O	O	4179
toxic	ADJ	O	O	4179
metabolite	NOUN	O	O	4179
acrolein	PROPN	O	Chemical	4179
,	PUNCT	O	O	4179
was	AUX	O	O	4179
used	VERB	O	O	4179
to	PART	O	O	4179
induce	VERB	O	O	4179
cystitis	NOUN	O	Disease	4179
.	PUNCT	O	O	4179
CP	PROPN	O	Chemical	4180
was	AUX	O	O	4180
administered	VERB	O	O	4180
at	ADP	O	O	4180
doses	NOUN	O	O	4180
of	ADP	O	O	4180
50	NUM	O	O	4180
,	PUNCT	O	O	4180
100	NUM	O	O	4180
and	CCONJ	O	O	4180
200	NUM	O	O	4180
mg./kg	NOUN	O	O	4180
.	PUNCT	O	O	4180
The	PRON	O	O	4181
effects	NOUN	O	O	4181
of	ADP	O	O	4181
morphine	NOUN	O	Chemical	4181
(	PUNCT	O	O	4181
0.5	NUM	O	O	4181
to	PART	O	O	4181
4	NUM	O	O	4181
mg./kg	NOUN	O	O	4181
.	PUNCT	O	O	4181
i.v	NOUN	O	O	4182
.	PUNCT	O	O	4182
)	PUNCT	O	O	4182
on	ADP	O	O	4182
CP	PROPN	O	Chemical	4182
-	PUNCT	O	O	4182
induced	VERB	O	O	4182
behavioral	ADJ	O	O	4182
modifications	NOUN	O	O	4182
were	AUX	O	O	4182
tested	VERB	O	O	4182
administered	VERB	O	O	4182
alone	ADV	O	O	4182
and	CCONJ	O	O	4182
after	ADP	O	O	4182
naloxone	NOUN	O	Chemical	4182
(	PUNCT	O	O	4182
1	X	O	O	4182
mg./kg	NOUN	O	O	4182
.	PUNCT	O	O	4182
In	ADP	O	O	4183
addition	NOUN	O	O	4183
,	PUNCT	O	O	4183
90	NUM	O	O	4183
minutes	NOUN	O	O	4183
after	ADP	O	O	4183
CP	PROPN	O	Chemical	4183
injection	NOUN	O	O	4183
,	PUNCT	O	O	4183
that	SCONJ	O	O	4183
is	AUX	O	O	4183
,	PUNCT	O	O	4183
at	ADP	O	O	4183
the	PRON	O	O	4183
time	NOUN	O	O	4183
of	ADP	O	O	4183
administration	NOUN	O	O	4183
of	ADP	O	O	4183
morphine	NOUN	O	Chemical	4183
,	PUNCT	O	O	4183
the	PRON	O	O	4183
bladder	NOUN	O	O	4183
was	AUX	O	O	4183
removed	VERB	O	O	4183
in	ADP	O	O	4183
some	PRON	O	O	4183
rats	NOUN	O	O	4183
for	ADP	O	O	4183
histological	ADJ	O	O	4183
examination	NOUN	O	O	4183
.	PUNCT	O	O	4183
Finally	ADV	O	O	4184
,	PUNCT	O	O	4184
to	PART	O	O	4184
show	VERB	O	O	4184
that	SCONJ	O	O	4184
the	PRON	O	O	4184
bladder	NOUN	O	O	4184
is	AUX	O	O	4184
essential	ADJ	O	O	4184
for	ADP	O	O	4184
the	PRON	O	O	4184
CP	PROPN	O	Chemical	4184
-	PUNCT	O	O	4184
induced	VERB	O	O	4184
behavioral	ADJ	O	O	4184
modifications	NOUN	O	O	4184
,	PUNCT	O	O	4184
female	ADJ	O	O	4184
rats	NOUN	O	O	4184
also	ADV	O	O	4184
received	VERB	O	O	4184
CP	PROPN	O	Chemical	4184
at	ADP	O	O	4184
doses	NOUN	O	O	4184
of	ADP	O	O	4184
200	NUM	O	O	4184
mg./kg	NOUN	O	O	4184
.	PUNCT	O	O	4184
by	ADP	O	O	4185
the	PRON	O	O	4185
intravesical	ADJ	O	O	4185
route	VERB	O	O	4185
,	PUNCT	O	O	4185
and	CCONJ	O	O	4185
acrolein	PROPN	O	Chemical	4185
at	ADP	O	O	4185
doses	NOUN	O	O	4185
of	ADP	O	O	4185
0.5	NUM	O	O	4185
mg	VERB	O	O	4185
.	PUNCT	O	O	4185
CP	PROPN	O	Chemical	4186
dose	NOUN	O	O	4186
-	PUNCT	O	O	4186
relatedly	ADV	O	O	4186
induced	VERB	O	O	4186
marked	VERB	O	O	4186
behavioral	ADJ	O	O	4186
modifications	NOUN	O	O	4186
in	ADP	O	O	4186
male	NOUN	O	O	4186
rats	NOUN	O	O	4186
:	PUNCT	O	O	4186
breathing	VERB	O	O	4186
rate	NOUN	O	O	4186
decrease	VERB	O	O	4186
,	PUNCT	O	O	4186
closing	VERB	O	O	4186
of	ADP	O	O	4186
the	PRON	O	O	4186
eyes	NOUN	O	O	4186
and	CCONJ	O	O	4186
occurrence	NOUN	O	O	4186
of	ADP	O	O	4186
specific	ADJ	O	O	4186
postures	NOUN	O	O	4186
.	PUNCT	O	O	4186
Morphine	NOUN	O	Chemical	4187
dose	NOUN	O	O	4187
-	PUNCT	O	O	4187
dependently	ADV	O	O	4187
reversed	VERB	O	O	4187
these	PRON	O	O	4187
behavioral disorders	NOUN	O	Disease	4187
.	PUNCT	O	O	4187
produced	VERB	O	O	4188
a	PRON	O	O	4188
reduction	NOUN	O	O	4188
of	ADP	O	O	4188
almost	ADV	O	O	4188
50%	NOUN	O	O	4188
of	ADP	O	O	4188
the	PRON	O	O	4188
behavioral	ADJ	O	O	4188
score	VERB	O	O	4188
induced	VERB	O	O	4188
by	ADP	O	O	4188
CP	PROPN	O	Chemical	4188
200	NUM	O	O	4188
mg./kg	NOUN	O	O	4188
.	PUNCT	O	O	4188
This	PRON	O	O	4189
effect	VERB	O	O	4189
was	AUX	O	O	4189
completely	ADV	O	O	4189
prevented	VERB	O	O	4189
by	ADP	O	O	4189
pretreatment	NOUN	O	O	4189
with	ADP	O	O	4189
naloxone	NOUN	O	Chemical	4189
.	PUNCT	O	O	4189
At	ADP	O	O	4190
the	PRON	O	O	4190
time	NOUN	O	O	4190
of	ADP	O	O	4190
administration	NOUN	O	O	4190
of	ADP	O	O	4190
morphine	NOUN	O	Chemical	4190
,	PUNCT	O	O	4190
histological	ADJ	O	O	4190
modifications	NOUN	O	O	4190
of	ADP	O	O	4190
the	PRON	O	O	4190
bladder	NOUN	O	O	4190
wall	PROPN	O	O	4190
,	PUNCT	O	O	4190
such	ADJ	O	O	4190
as	ADP	O	O	4190
chorionic	ADJ	O	O	4190
and	CCONJ	O	O	4190
muscle	NOUN	O	O	4190
layer	NOUN	O	O	4190
edema	NOUN	O	Disease	4190
,	PUNCT	O	O	4190
were	AUX	O	O	4190
observed	VERB	O	O	4190
.	PUNCT	O	O	4190
In	ADP	O	O	4191
female	ADJ	O	O	4191
rats	NOUN	O	O	4191
,	PUNCT	O	O	4191
CP	PROPN	O	Chemical	4191
200	NUM	O	O	4191
mg./kg	NOUN	O	O	4191
.	PUNCT	O	O	4191
intravesically	ADV	O	O	4192
,	PUNCT	O	O	4192
CP	PROPN	O	Chemical	4192
did	VERB	O	O	4192
not	PART	O	O	4192
produce	VERB	O	O	4192
any	PRON	O	O	4192
behavioral	ADJ	O	O	4192
effects	NOUN	O	O	4192
,	PUNCT	O	O	4192
whereas	SCONJ	O	O	4192
acrolein	PROPN	O	Chemical	4192
at	ADP	O	O	4192
0.5	NUM	O	O	4192
mg	VERB	O	O	4192
.	PUNCT	O	O	4192
intravesically	ADV	O	O	4193
induced	VERB	O	O	4193
behavioral	ADJ	O	O	4193
modifications	NOUN	O	O	4193
identical	ADJ	O	O	4193
to	PART	O	O	4193
those	PRON	O	O	4193
under	ADP	O	O	4193
CP	PROPN	O	Chemical	4193
200	NUM	O	O	4193
mg./kg	NOUN	O	O	4193
.	PUNCT	O	O	4193
Conversely	ADV	O	O	4194
,	PUNCT	O	O	4194
acrolein	PROPN	O	Chemical	4194
5	NUM	O	O	4194
mg./kg	NOUN	O	O	4194
.	PUNCT	O	O	4194
Overall	ADV	O	O	4195
,	PUNCT	O	O	4195
these	PRON	O	O	4195
results	VERB	O	O	4195
indicate	VERB	O	O	4195
that	SCONJ	O	O	4195
this	PRON	O	O	4195
experimental	ADJ	O	O	4195
model	NOUN	O	O	4195
of	ADP	O	O	4195
CP	PROPN	O	Chemical	4195
-	PUNCT	O	O	4195
induced	VERB	O	O	4195
cystitis	NOUN	O	Disease	4195
may	AUX	O	O	4195
be	AUX	O	O	4195
an	PRON	O	O	4195
interesting	ADJ	O	O	4195
new	ADJ	O	O	4195
behavioral	ADJ	O	O	4195
model	NOUN	O	O	4195
of	ADP	O	O	4195
inflammatory	ADJ	O	O	4195
visceral pain	NOUN	O	Disease	4195
,	PUNCT	O	O	4195
allowing	VERB	O	O	4195
a	PRON	O	O	4195
better	ADV	O	O	4195
understanding	NOUN	O	O	4195
of	ADP	O	O	4195
these	PRON	O	O	4195
painful syndromes	NOUN	O	Disease	4195
and	CCONJ	O	O	4195
thus	ADV	O	O	4195
a	PRON	O	O	4195
better	ADV	O	O	4195
therapeutic	ADJ	O	O	4195
approach	NOUN	O	O	4195
to	PART	O	O	4195
them	PRON	O	O	4195
.	PUNCT	O	O	4195
Hyperalgesia	NOUN	O	Disease	4198
and	CCONJ	O	O	4198
myoclonus	NOUN	O	Disease	4198
in	ADP	O	O	4198
terminal	PROPN	O	O	4198
cancer	NOUN	O	Disease	4198
patients	NOUN	O	O	4198
treated	VERB	O	O	4198
with	ADP	O	O	4198
continuous	ADJ	O	O	4198
intravenous	ADJ	O	O	4198
morphine	NOUN	O	Chemical	4198
.	PUNCT	O	O	4198
Eight	NUM	O	O	4199
cancer	NOUN	O	Disease	4199
patients	NOUN	O	O	4199
in	ADP	O	O	4199
the	PRON	O	O	4199
terminal	PROPN	O	O	4199
stages	NOUN	O	O	4199
of	ADP	O	O	4199
the	PRON	O	O	4199
disease	PROPN	O	O	4199
treated	VERB	O	O	4199
with	ADP	O	O	4199
high	ADJ	O	O	4199
doses	NOUN	O	O	4199
of	ADP	O	O	4199
intravenous	ADJ	O	O	4199
morphine	NOUN	O	Chemical	4199
developed	VERB	O	O	4199
hyperalgesia	NOUN	O	Disease	4199
.	PUNCT	O	O	4199
Five	NUM	O	O	4200
patients	NOUN	O	O	4200
developed	VERB	O	O	4200
universal	ADJ	O	O	4200
hyperalgesia	NOUN	O	Disease	4200
and	CCONJ	O	O	4200
hyperesthesia	ADV	O	Disease	4200
which	PRON	O	O	4200
in	ADP	O	O	4200
2	X	O	O	4200
cases	NOUN	O	O	4200
were	AUX	O	O	4200
accompanied	VERB	O	O	4200
by	ADP	O	O	4200
myoclonus	NOUN	O	Disease	4200
.	PUNCT	O	O	4200
In	ADP	O	O	4201
3	X	O	O	4201
patients	NOUN	O	O	4201
a	PRON	O	O	4201
pre	VERB	O	O	4201
-	PUNCT	O	O	4201
existing	VERB	O	O	4201
neuralgia	NOUN	O	Disease	4201
increased	VERB	O	O	4201
to	PART	O	O	4201
excruciating	ADJ	O	O	4201
intensity	NOUN	O	O	4201
and	CCONJ	O	O	4201
in	ADP	O	O	4201
2	X	O	O	4201
of	ADP	O	O	4201
these	PRON	O	O	4201
cases	NOUN	O	O	4201
myoclonus	NOUN	O	Disease	4201
occurred	VERB	O	O	4201
simultaneously	ADV	O	O	4201
.	PUNCT	O	O	4201
Although	SCONJ	O	O	4202
only	ADV	O	O	4202
few	ADJ	O	O	4202
clinical	ADJ	O	O	4202
descriptions	NOUN	O	O	4202
of	ADP	O	O	4202
the	PRON	O	O	4202
relationship	NOUN	O	O	4202
between	ADP	O	O	4202
hyperalgesia	NOUN	O	Disease	4202
/	PUNCT	O	O	4202
myoclonus	NOUN	O	Disease	4202
and	CCONJ	O	O	4202
high	ADJ	O	O	4202
doses	NOUN	O	O	4202
of	ADP	O	O	4202
morphine	NOUN	O	Chemical	4202
are	AUX	O	O	4202
available	ADJ	O	O	4202
,	PUNCT	O	O	4202
experimental	ADJ	O	O	4202
support	NOUN	O	O	4202
from	ADP	O	O	4202
animal	NOUN	O	O	4202
studies	NOUN	O	O	4202
indicates	VERB	O	O	4202
that	SCONJ	O	O	4202
morphine	NOUN	O	Chemical	4202
,	PUNCT	O	O	4202
or	CCONJ	O	O	4202
its	PRON	O	O	4202
metabolites	VERB	O	O	4202
,	PUNCT	O	O	4202
plays	VERB	O	O	4202
a	PRON	O	O	4202
causative	ADJ	O	O	4202
role	NOUN	O	O	4202
for	ADP	O	O	4202
the	PRON	O	O	4202
observed	VERB	O	O	4202
behavioural	ADJ	O	O	4202
syndrome	NOUN	O	O	4202
.	PUNCT	O	O	4202
A	PRON	O	O	4205
prospective	ADJ	O	O	4205
study	VERB	O	O	4205
of	ADP	O	O	4205
adverse	ADJ	O	O	4205
reactions	NOUN	O	O	4205
associated	VERB	O	O	4205
with	ADP	O	O	4205
vancomycin	VERB	O	Chemical	4205
therapy	NOUN	O	O	4205
.	PUNCT	O	O	4205
A	PRON	O	O	4206
prospective	ADJ	O	O	4206
evaluation	NOUN	O	O	4206
of	ADP	O	O	4206
the	PRON	O	O	4206
efficacy	NOUN	O	O	4206
and	CCONJ	O	O	4206
safety	NOUN	O	O	4206
of	ADP	O	O	4206
vancomycin	VERB	O	Chemical	4206
was	AUX	O	O	4206
conducted	VERB	O	O	4206
in	ADP	O	O	4206
54	NUM	O	O	4206
consecutive	ADJ	O	O	4206
patients	NOUN	O	O	4206
over	ADP	O	O	4206
a	PRON	O	O	4206
16-month	NOUN	O	O	4206
period	NOUN	O	O	4206
.	PUNCT	O	O	4206
Vancomycin	PROPN	O	Chemical	4207
was	AUX	O	O	4207
curative	ADJ	O	O	4207
in	ADP	O	O	4207
95%	NOUN	O	O	4207
of	ADP	O	O	4207
43	NUM	O	O	4207
patients	NOUN	O	O	4207
with	ADP	O	O	4207
proven	VERB	O	O	4207
infection	NOUN	O	Disease	4207
.	PUNCT	O	O	4207
Drugs	NOUN	O	O	4208
were	AUX	O	O	4208
ceased	VERB	O	O	4208
in	ADP	O	O	4208
six	NUM	O	O	4208
patients	NOUN	O	O	4208
because	SCONJ	O	O	4208
of	ADP	O	O	4208
adverse	ADJ	O	O	4208
reactions	NOUN	O	O	4208
;	PUNCT	O	O	4208
in	ADP	O	O	4208
three	NUM	O	O	4208
of	ADP	O	O	4208
these	PRON	O	O	4208
vancomycin	VERB	O	Chemical	4208
was	AUX	O	O	4208
considered	VERB	O	O	4208
the	PRON	O	O	4208
likely	ADV	O	O	4208
cause	VERB	O	O	4208
.	PUNCT	O	O	4208
Reactions	NOUN	O	O	4209
included	VERB	O	O	4209
thrombophlebitis	NOUN	O	Disease	4209
(	PUNCT	O	O	4209
20	NUM	O	O	4209
of	ADP	O	O	4209
54	NUM	O	O	4209
patients	NOUN	O	O	4209
)	PUNCT	O	O	4209
,	PUNCT	O	O	4209
rash	ADJ	O	Disease	4209
(	PUNCT	O	O	4209
4	NUM	O	O	4209
of	ADP	O	O	4209
54	NUM	O	O	4209
)	PUNCT	O	O	4209
,	PUNCT	O	O	4209
nephrotoxicity	NOUN	O	Disease	4209
(	PUNCT	O	O	4209
4	NUM	O	O	4209
of	ADP	O	O	4209
50	NUM	O	O	4209
)	PUNCT	O	O	4209
,	PUNCT	O	O	4209
proteinuria	X	O	Disease	4209
(	PUNCT	O	O	4209
1	X	O	O	4209
of	ADP	O	O	4209
50	NUM	O	O	4209
)	PUNCT	O	O	4209
and	CCONJ	O	O	4209
ototoxicity	NOUN	O	Disease	4209
(	PUNCT	O	O	4209
1	X	O	O	4209
of	ADP	O	O	4209
11	NUM	O	O	4209
patients	NOUN	O	O	4209
tested	VERB	O	O	4209
by	ADP	O	O	4209
audiometry	NOUN	O	O	4209
)	PUNCT	O	O	4209
.	PUNCT	O	O	4209
Thrombophlebitis	NOUN	O	Disease	4210
occurred	VERB	O	O	4210
only	ADV	O	O	4210
with	ADP	O	O	4210
infusion	NOUN	O	O	4210
through	ADP	O	O	4210
peripheral	ADJ	O	O	4210
cannulae	NOUN	O	O	4210
;	PUNCT	O	O	4210
nephrotoxicity	NOUN	O	Disease	4210
and	CCONJ	O	O	4210
ototoxicity	NOUN	O	Disease	4210
were	AUX	O	O	4210
confined	VERB	O	O	4210
to	PART	O	O	4210
patients	NOUN	O	O	4210
receiving	VERB	O	O	4210
an	PRON	O	O	4210
aminoglycoside	ADV	O	Chemical	4210
plus	CCONJ	O	O	4210
vancomycin	VERB	O	Chemical	4210
.	PUNCT	O	O	4210
We	PRON	O	O	4211
conclude	VERB	O	O	4211
that	SCONJ	O	O	4211
vancomycin	VERB	O	Chemical	4211
,	PUNCT	O	O	4211
administered	VERB	O	O	4211
appropriately	ADV	O	O	4211
,	PUNCT	O	O	4211
constitutes	VERB	O	O	4211
safe	ADJ	O	O	4211
,	PUNCT	O	O	4211
effective	ADJ	O	O	4211
therapy	NOUN	O	O	4211
for	ADP	O	O	4211
infections	NOUN	O	Disease	4211
caused	VERB	O	O	4211
by	ADP	O	O	4211
susceptible	ADJ	O	O	4211
bacteria	NOUN	O	O	4211
.	PUNCT	O	O	4211
Blockade	NOUN	O	O	4214
of	ADP	O	O	4214
both	PRON	O	O	4214
D-1	NOUN	O	O	4214
and	CCONJ	O	O	4214
D-2	NOUN	O	O	4214
dopamine	NOUN	O	Chemical	4214
receptors	NOUN	O	O	4214
may	AUX	O	O	4214
induce	VERB	O	O	4214
catalepsy	VERB	O	Disease	4214
in	ADP	O	O	4214
mice	NOUN	O	O	4214
.	PUNCT	O	O	4214
The	PRON	O	O	4215
catalepsy	VERB	O	Disease	4215
induced	VERB	O	O	4215
by	ADP	O	O	4215
dopamine	NOUN	O	Chemical	4215
antagonists	NOUN	O	O	4215
has	VERB	O	O	4215
been	AUX	O	O	4215
tested	VERB	O	O	4215
and	CCONJ	O	O	4215
the	PRON	O	O	4215
possible	ADJ	O	O	4215
dopamine	NOUN	O	Chemical	4215
subtypes	NOUN	O	O	4215
involved	VERB	O	O	4215
in	ADP	O	O	4215
catalepsy	VERB	O	Disease	4215
was	AUX	O	O	4215
determined	VERB	O	O	4215
.	PUNCT	O	O	4215
Dopamine	NOUN	O	Chemical	4216
antagonist	NOUN	O	O	4216
fluphenazine	NOUN	O	Chemical	4216
,	PUNCT	O	O	4216
D-1	NOUN	O	O	4216
antagonist	NOUN	O	O	4216
SCH 23390	NUM	O	Chemical	4216
or	CCONJ	O	O	4216
D-2	NOUN	O	O	4217
antagonist	NOUN	O	O	4217
sulpiride	NOUN	O	Chemical	4217
induced	VERB	O	O	4217
catalepsy	VERB	O	Disease	4217
.	PUNCT	O	O	4217
The	PRON	O	O	4218
effect	VERB	O	O	4218
of	ADP	O	O	4218
fluphenazine	NOUN	O	Chemical	4218
and	CCONJ	O	O	4218
sulpiride	NOUN	O	Chemical	4218
was	AUX	O	O	4218
dose	NOUN	O	O	4218
-	PUNCT	O	O	4218
dependent	ADJ	O	O	4218
.	PUNCT	O	O	4218
Combination	NOUN	O	O	4219
of	ADP	O	O	4219
SCH 23390	NUM	O	Chemical	4219
with	ADP	O	O	4219
sulpiride	NOUN	O	Chemical	4219
did	VERB	O	O	4219
not	PART	O	O	4219
induce	VERB	O	O	4219
catalepsy	VERB	O	Disease	4219
potentiation	NOUN	O	O	4219
.	PUNCT	O	O	4219
SKF 38393	NUM	O	Chemical	4220
or	CCONJ	O	O	4220
D-2	NOUN	O	O	4220
agonist	NOUN	O	O	4220
quinpirole	NOUN	O	Chemical	4220
decreased	VERB	O	O	4220
the	PRON	O	O	4220
catalepsy	VERB	O	Disease	4220
induced	VERB	O	O	4220
by	ADP	O	O	4220
fluphenazine	NOUN	O	Chemical	4220
,	PUNCT	O	O	4220
SCH 23390	NUM	O	Chemical	4220
or	CCONJ	O	O	4220
sulpiride	NOUN	O	Chemical	4220
.	PUNCT	O	O	4220
4	NUM	O	O	4221
.	PUNCT	O	O	4221
Combination	NOUN	O	O	4221
of	ADP	O	O	4221
SKF 38393	NUM	O	Chemical	4221
with	ADP	O	O	4221
quinpirole	NOUN	O	Chemical	4221
did	VERB	O	O	4221
not	PART	O	O	4221
cause	VERB	O	O	4221
potentiated	VERB	O	O	4221
inhibitory	ADJ	O	O	4221
effect	VERB	O	O	4221
on	ADP	O	O	4221
catalepsy	VERB	O	Disease	4221
induced	VERB	O	O	4221
by	ADP	O	O	4221
dopamine	NOUN	O	Chemical	4221
antagonists	NOUN	O	O	4221
.	PUNCT	O	O	4221
The	PRON	O	O	4222
data	NOUN	O	O	4222
may	AUX	O	O	4222
indicate	VERB	O	O	4222
that	SCONJ	O	O	4222
although	SCONJ	O	O	4222
D-2	NOUN	O	O	4222
receptor	NOUN	O	O	4222
blockade	VERB	O	O	4222
is	AUX	O	O	4222
involved	VERB	O	O	4222
in	ADP	O	O	4222
catalepsy	VERB	O	Disease	4222
,	PUNCT	O	O	4222
the	PRON	O	O	4222
D-1	NOUN	O	O	4222
receptor	NOUN	O	O	4222
may	AUX	O	O	4222
plan	NOUN	O	O	4222
a	PRON	O	O	4222
role	NOUN	O	O	4222
.	PUNCT	O	O	4222
Dextran	NOUN	O	Chemical	4225
-	PUNCT	O	O	4225
etodolac	PROPN	O	Chemical	4225
conjugates	NOUN	O	O	4225
:	PUNCT	O	O	4225
synthesis	NOUN	O	O	4225
,	PUNCT	O	O	4225
in	ADP	O	O	4225
vitro	X	O	O	4225
and	CCONJ	O	O	4225
in	ADP	O	O	4225
vivo	VERB	O	O	4225
evaluation	NOUN	O	O	4225
.	PUNCT	O	O	4225
Etodolac	PROPN	O	Chemical	4226
(	PUNCT	O	O	4226
E	NOUN	O	Chemical	4226
)	PUNCT	O	O	4226
,	PUNCT	O	O	4226
is	AUX	O	O	4226
a	PRON	O	O	4226
non	ADJ	O	O	4226
-	PUNCT	O	O	4226
narcotic	ADJ	O	O	4226
analgesic	PROPN	O	O	4226
and	CCONJ	O	O	4226
antiinflammatory	ADJ	O	O	4226
drug	NOUN	O	O	4226
.	PUNCT	O	O	4226
A	PRON	O	O	4227
biodegradable	ADJ	O	O	4227
polymer	NOUN	O	O	4227
dextran	NOUN	O	Chemical	4227
has	VERB	O	O	4227
been	AUX	O	O	4227
utilized	VERB	O	O	4227
as	ADP	O	O	4227
a	PRON	O	O	4227
carrier	NOUN	O	O	4227
for	ADP	O	O	4227
synthesis	NOUN	O	O	4227
of	ADP	O	O	4227
etodolac	PROPN	O	Chemical	4227
-	PUNCT	O	O	4227
dextran	NOUN	O	Chemical	4227
conjugates	NOUN	O	O	4227
(	PUNCT	O	O	4227
ED	PROPN	O	O	4227
)	PUNCT	O	O	4227
to	PART	O	O	4227
improve	VERB	O	O	4227
its	PRON	O	O	4227
aqueous	ADJ	O	O	4227
solubility	NOUN	O	O	4227
and	CCONJ	O	O	4227
reduce	VERB	O	O	4227
gastrointestinal	ADJ	O	O	4227
side	NOUN	O	O	4227
effects	NOUN	O	O	4227
.	PUNCT	O	O	4227
An	PRON	O	O	4228
activated	VERB	O	O	4228
moiety	NOUN	O	O	4228
,	PUNCT	O	O	4228
i.e.	X	O	O	4228
N	NUM	O	O	4228
-	PUNCT	O	O	4228
acylimidazole	PUNCT	O	O	4228
derivative	ADJ	O	O	4228
of	ADP	O	O	4228
etodolac	PROPN	O	Chemical	4228
(	PUNCT	O	O	4228
EAI	PROPN	O	Chemical	4228
)	PUNCT	O	O	4228
,	PUNCT	O	O	4228
was	AUX	O	O	4228
condensed	VERB	O	O	4228
with	ADP	O	O	4228
the	PRON	O	O	4228
polysaccharide	NOUN	O	O	4228
polymer	NOUN	O	O	4228
dextran	NOUN	O	Chemical	4228
of	ADP	O	O	4228
different	ADJ	O	O	4228
molecular	ADJ	O	O	4228
weights	NOUN	O	O	4228
(	PUNCT	O	O	4228
40000	NUM	O	O	4228
,	PUNCT	O	O	4228
60000	NUM	O	O	4228
,	PUNCT	O	O	4228
110000	NUM	O	O	4228
and	CCONJ	O	O	4228
200000	NUM	O	O	4228
)	PUNCT	O	O	4228
.	PUNCT	O	O	4228
Etodolac	PROPN	O	Chemical	4229
contents	NOUN	O	O	4229
were	AUX	O	O	4229
evaluated	VERB	O	O	4229
by	ADP	O	O	4229
UV	NOUN	O	O	4229
-	PUNCT	O	O	4229
spectrophotometric	ADJ	O	O	4229
analysis	NOUN	O	O	4229
.	PUNCT	O	O	4229
At	ADP	O	O	4230
pH	NOUN	O	O	4230
9	NUM	O	O	4230
,	PUNCT	O	O	4230
a	PRON	O	O	4230
higher	ADJ	O	O	4230
rate	NOUN	O	O	4230
of	ADP	O	O	4230
etodolac	PROPN	O	Chemical	4230
release	NOUN	O	O	4230
from	ADP	O	O	4230
ED	PROPN	O	O	4230
was	AUX	O	O	4230
observed	VERB	O	O	4230
as	ADP	O	O	4230
compared	VERB	O	O	4230
to	PART	O	O	4230
aqueous	ADJ	O	O	4230
buffer	NOUN	O	O	4230
of	ADP	O	O	4230
pH	NOUN	O	O	4230
7.4	NUM	O	O	4230
and	CCONJ	O	O	4230
80%	NOUN	O	O	4230
human	PROPN	O	O	4230
plasma	NOUN	O	O	4230
(	PUNCT	O	O	4230
pH	NOUN	O	O	4230
7.4	NUM	O	O	4230
)	PUNCT	O	O	4230
,	PUNCT	O	O	4230
following	VERB	O	O	4230
first	ADV	O	O	4230
-	PUNCT	O	O	4230
order	NOUN	O	O	4230
kinetics	NOUN	O	O	4230
.	PUNCT	O	O	4230
Acute	PROPN	O	O	4231
analgesic	PROPN	O	O	4231
and	CCONJ	O	O	4231
antiinflammatory	ADJ	O	O	4231
activities	NOUN	O	O	4231
were	AUX	O	O	4231
ascertained	VERB	O	O	4231
using	VERB	O	O	4231
acetic acid	NOUN	O	Chemical	4231
induced	VERB	O	O	4231
writhing	VERB	O	Disease	4231
model	NOUN	O	O	4231
(	PUNCT	O	O	4231
mice	NOUN	O	O	4231
)	PUNCT	O	O	4231
and	CCONJ	O	O	4231
carrageenan	NOUN	O	Chemical	4231
-	PUNCT	O	O	4231
induced	VERB	O	O	4231
rat	NOUN	O	O	4231
paw	PROPN	O	O	4231
edema	NOUN	O	Disease	4231
model	NOUN	O	O	4231
,	PUNCT	O	O	4231
respectively	ADV	O	O	4231
.	PUNCT	O	O	4231
In	ADP	O	O	4232
comparison	NOUN	O	O	4232
to	PART	O	O	4232
control	VERB	O	O	4232
,	PUNCT	O	O	4232
E	NOUN	O	Chemical	4232
and	CCONJ	O	O	4232
ED1-ED4	PROPN	O	O	4232
showed	VERB	O	O	4232
highly	ADV	O	O	4232
significant	ADJ	O	O	4232
analgesic	PROPN	O	O	4232
and	CCONJ	O	O	4232
antiinflammatory	ADJ	O	O	4232
activities	NOUN	O	O	4232
(	PUNCT	O	O	4232
p	NOUN	O	O	4232
<	X	O	O	4232
0.001	NUM	O	O	4232
)	PUNCT	O	O	4232
.	PUNCT	O	O	4232
Biological	ADJ	O	O	4233
evaluation	NOUN	O	O	4233
suggested	VERB	O	O	4233
that	SCONJ	O	O	4233
conjugates	NOUN	O	O	4233
(	PUNCT	O	O	4233
ED1-ED4	PROPN	O	O	4233
)	PUNCT	O	O	4233
retained	VERB	O	O	4233
comparable	ADJ	O	O	4233
analgesic	PROPN	O	O	4233
and	CCONJ	O	O	4233
antiinflammatory	ADJ	O	O	4233
activities	NOUN	O	O	4233
with	ADP	O	O	4233
remarkably	ADV	O	O	4233
reduced	VERB	O	O	4233
ulcerogenicity	NOUN	O	O	4233
as	ADP	O	O	4233
compared	VERB	O	O	4233
to	PART	O	O	4233
their	PRON	O	O	4233
parent	NOUN	O	O	4233
drug	NOUN	O	O	4233
--	PUNCT	O	O	4233
etodolac	PROPN	O	Chemical	4233
.	PUNCT	O	O	4233
Hypersensitivity	NOUN	O	Disease	4236
myocarditis	ADV	O	Disease	4236
complicating	VERB	O	O	4236
hypertrophic cardiomyopathy	NOUN	O	Disease	4236
heart	NOUN	O	O	4236
.	PUNCT	O	O	4236
The	PRON	O	O	4237
present	NOUN	O	O	4237
report	VERB	O	O	4237
describes	VERB	O	O	4237
a	PRON	O	O	4237
case	NOUN	O	O	4237
of	ADP	O	O	4237
eosinophilic myocarditis	ADV	O	Disease	4237
complicating	VERB	O	O	4237
hypertrophic cardiomyopathy	NOUN	O	Disease	4237
.	PUNCT	O	O	4237
The	PRON	O	O	4238
47-year	NOUN	O	O	4238
-	PUNCT	O	O	4238
old	ADJ	O	O	4238
female	ADJ	O	O	4238
patient	NOUN	O	O	4238
,	PUNCT	O	O	4238
known	VERB	O	O	4238
to	PART	O	O	4238
have	VERB	O	O	4238
hypertrophic cardiomyopathy	NOUN	O	Disease	4238
,	PUNCT	O	O	4238
was	AUX	O	O	4238
admitted	VERB	O	O	4238
with	ADP	O	O	4238
biventricular failure	NOUN	O	Disease	4238
and	CCONJ	O	O	4238
managed	VERB	O	O	4238
aggressively	ADV	O	O	4238
with	ADP	O	O	4238
dobutamine	NOUN	O	Chemical	4238
infusion	NOUN	O	O	4238
and	CCONJ	O	O	4238
other	ADJ	O	O	4238
drugs	NOUN	O	O	4238
while	SCONJ	O	O	4238
being	AUX	O	O	4238
assessed	VERB	O	O	4238
for	ADP	O	O	4238
heart	NOUN	O	O	4238
transplantation	NOUN	O	O	4238
.	PUNCT	O	O	4238
On	ADP	O	O	4239
transthoracic	PROPN	O	O	4239
echocardiogram	PROPN	O	O	4239
,	PUNCT	O	O	4239
she	PRON	O	O	4239
had	VERB	O	O	4239
moderate	ADJ	O	O	4239
left ventricular dysfunction	NOUN	O	Disease	4239
with	ADP	O	O	4239
regional	ADJ	O	O	4239
variability	NOUN	O	O	4239
and	CCONJ	O	O	4239
moderate	ADJ	O	O	4239
mitral regurgitation	NOUN	O	Disease	4239
.	PUNCT	O	O	4239
The	PRON	O	O	4240
recipient	NOUN	O	O	4240
's	AUX	O	O	4240
heart	NOUN	O	O	4240
showed	VERB	O	O	4240
the	PRON	O	O	4240
features	VERB	O	O	4240
of	ADP	O	O	4240
apical	ADJ	O	O	4240
hypertrophic cardiomyopathy	NOUN	O	Disease	4240
and	CCONJ	O	O	4240
myocarditis	ADV	O	Disease	4240
with	ADP	O	O	4240
abundant	ADJ	O	O	4240
eosinophils	VERB	O	O	4240
.	PUNCT	O	O	4240
Myocarditis	PROPN	O	Disease	4241
is	AUX	O	O	4241
rare	ADJ	O	O	4241
and	CCONJ	O	O	4241
eosinophilic myocarditis	ADV	O	Disease	4241
is	AUX	O	O	4241
rarer	ADJ	O	O	4241
.	PUNCT	O	O	4241
It	PRON	O	O	4242
is	AUX	O	O	4242
likely	ADV	O	O	4242
that	SCONJ	O	O	4242
the	PRON	O	O	4242
hypersensitivity	NOUN	O	Disease	4242
(	PUNCT	O	O	4242
eosinophilic	ADJ	O	Disease	4242
)	PUNCT	O	O	4242
myocarditis	ADV	O	Disease	4243
was	AUX	O	O	4243
related	ADJ	O	O	4243
to	PART	O	O	4243
dobutamine	NOUN	O	Chemical	4243
infusion	NOUN	O	O	4243
therapy	NOUN	O	O	4243
.	PUNCT	O	O	4243
Eosinophilic myocarditis	ADV	O	Disease	4244
has	VERB	O	O	4244
been	AUX	O	O	4244
reported	VERB	O	O	4244
with	ADP	O	O	4244
an	PRON	O	O	4244
incidence	NOUN	O	O	4244
of	ADP	O	O	4244
2.4%	NOUN	O	O	4244
to	PART	O	O	4244
7.2%	NOUN	O	O	4244
in	ADP	O	O	4244
explanted	VERB	O	O	4244
hearts	NOUN	O	O	4244
and	CCONJ	O	O	4244
may	AUX	O	O	4244
be	AUX	O	O	4244
related	ADJ	O	O	4244
to	PART	O	O	4244
multidrug	NOUN	O	O	4244
therapy	NOUN	O	O	4244
.	PUNCT	O	O	4244
All-	PROPN	O	O	4247
trans	PROPN	O	O	4247
-	PUNCT	O	O	4247
retinoic	NOUN	O	O	4247
acid	PROPN	O	O	4247
-	PUNCT	O	O	4247
induced	VERB	O	O	4247
erythema nodosum	NOUN	O	Disease	4247
in	ADP	O	O	4247
patients	NOUN	O	O	4247
with	ADP	O	O	4247
acute promyelocytic leukemia	NOUN	O	Disease	4247
.	PUNCT	O	O	4247
Erythema nodosum	NOUN	O	Disease	4248
associated	VERB	O	O	4248
with	ADP	O	O	4248
all-	PUNCT	O	O	4248
trans	PROPN	O	O	4248
-	PUNCT	O	O	4248
retinoic	NOUN	O	O	4248
acid	PROPN	O	O	4248
(	PUNCT	O	O	4248
ATRA	NOUN	O	Chemical	4248
)	PUNCT	O	O	4248
for	ADP	O	O	4248
acute promyelocytic leukemia	NOUN	O	Disease	4248
(	PUNCT	O	O	4248
APL	PROPN	O	Disease	4248
)	PUNCT	O	O	4248
is	AUX	O	O	4248
very	ADV	O	O	4248
rare	ADJ	O	O	4248
.	PUNCT	O	O	4248
We	PRON	O	O	4249
describe	VERB	O	O	4249
four	NUM	O	O	4249
patients	NOUN	O	O	4249
with	ADP	O	O	4249
classic	ADJ	O	O	4249
APL	PROPN	O	Disease	4249
who	PRON	O	O	4249
developed	VERB	O	O	4249
erythema nodosum	NOUN	O	Disease	4249
during	ADP	O	O	4249
ATRA	NOUN	O	Chemical	4249
therapy	NOUN	O	O	4249
.	PUNCT	O	O	4249
Fever	NOUN	O	Disease	4250
and	CCONJ	O	O	4250
subsequent	ADJ	O	O	4250
multiple	ADJ	O	O	4250
painful	ADJ	O	Disease	4250
erythematous nodules	NOUN	O	Disease	4250
over	ADP	O	O	4250
extremities	NOUN	O	O	4250
developed	VERB	O	O	4250
on	ADP	O	O	4250
D11	PROPN	O	O	4250
,	PUNCT	O	O	4250
D16	PROPN	O	O	4250
,	PUNCT	O	O	4250
D17	NOUN	O	O	4250
,	PUNCT	O	O	4250
and	CCONJ	O	O	4250
D19	PROPN	O	O	4250
,	PUNCT	O	O	4250
respectively	ADV	O	O	4250
,	PUNCT	O	O	4250
after	ADP	O	O	4250
ATRA	NOUN	O	Chemical	4250
therapy	NOUN	O	O	4250
.	PUNCT	O	O	4250
The	PRON	O	O	4251
skin	NOUN	O	O	4251
biopsy	PROPN	O	O	4251
taken	VERB	O	O	4251
from	ADP	O	O	4251
each	PRON	O	O	4251
patient	NOUN	O	O	4251
was	AUX	O	O	4251
consistent	ADJ	O	O	4251
with	ADP	O	O	4251
erythema nodosum	NOUN	O	Disease	4251
.	PUNCT	O	O	4251
All	PRON	O	O	4252
patients	NOUN	O	O	4252
received	VERB	O	O	4252
short	ADJ	O	O	4252
course	NOUN	O	O	4252
of	ADP	O	O	4252
steroids	NOUN	O	Chemical	4252
.	PUNCT	O	O	4252
Fever	NOUN	O	Disease	4253
subsided	VERB	O	O	4253
rapidly	ADV	O	O	4253
and	CCONJ	O	O	4253
the	PRON	O	O	4253
skin lesions	NOUN	O	O	4253
regressed	VERB	O	O	4253
completely	ADV	O	O	4253
.	PUNCT	O	O	4253
All	PRON	O	O	4254
patients	NOUN	O	O	4254
achieved	VERB	O	O	4254
complete	VERB	O	O	4254
remission	NOUN	O	O	4254
without	ADP	O	O	4254
withdrawal	NOUN	O	O	4254
of	ADP	O	O	4254
ATRA	NOUN	O	Chemical	4254
.	PUNCT	O	O	4254
ATRA	NOUN	O	Chemical	4255
seemed	VERB	O	O	4255
to	PART	O	O	4255
be	AUX	O	O	4255
the	PRON	O	O	4255
most	ADV	O	O	4255
possible	ADJ	O	O	4255
etiology	NOUN	O	O	4255
of	ADP	O	O	4255
erythema nodosum	NOUN	O	Disease	4255
in	ADP	O	O	4255
our	PRON	O	O	4255
patients	NOUN	O	O	4255
.	PUNCT	O	O	4255
Short	ADJ	O	O	4256
-	PUNCT	O	O	4256
term	NOUN	O	O	4256
use	VERB	O	O	4256
of	ADP	O	O	4256
steroid	NOUN	O	Chemical	4256
is	AUX	O	O	4256
very	ADV	O	O	4256
effective	ADJ	O	O	4256
in	ADP	O	O	4256
ATRA	NOUN	O	Chemical	4256
-	PUNCT	O	O	4256
induced	VERB	O	O	4256
erythema nodosum	NOUN	O	Disease	4256
.	PUNCT	O	O	4256
Delayed	VERB	O	O	4259
-	PUNCT	O	O	4259
onset	VERB	O	O	4259
heparin	NOUN	O	Chemical	4259
-	PUNCT	O	O	4259
induced	VERB	O	O	4259
thrombocytopenia	PROPN	O	Disease	4259
.	PUNCT	O	O	4259
Heparin	PROPN	O	Chemical	4260
-	PUNCT	O	O	4260
induced	VERB	O	O	4260
thrombocytopenia	PROPN	O	Disease	4260
presents	VERB	O	O	4260
5	NUM	O	O	4260
to	PART	O	O	4260
12	NUM	O	O	4260
days	NOUN	O	O	4260
after	ADP	O	O	4260
heparin	NOUN	O	Chemical	4260
exposure	NOUN	O	O	4260
,	PUNCT	O	O	4260
with	ADP	O	O	4260
or	CCONJ	O	O	4260
without	ADP	O	O	4260
arterial or venous thromboemboli	NOUN	O	Disease	4260
.	PUNCT	O	O	4260
Delayed	VERB	O	O	4261
recognition	NOUN	O	O	4261
and	CCONJ	O	O	4261
treatment	NOUN	O	O	4261
of	ADP	O	O	4261
heparin	NOUN	O	Chemical	4261
-	PUNCT	O	O	4261
induced	VERB	O	O	4261
thrombocytopenia	PROPN	O	Disease	4261
contribute	VERB	O	O	4261
to	PART	O	O	4261
poor	ADJ	O	O	4261
patient	NOUN	O	O	4261
outcomes	NOUN	O	O	4261
.	PUNCT	O	O	4261
OBJECTIVE	VERB	O	O	4262
:	PUNCT	O	O	4262
To	PART	O	O	4262
describe	VERB	O	O	4262
and	CCONJ	O	O	4262
increase	VERB	O	O	4262
awareness	NOUN	O	O	4262
of	ADP	O	O	4262
a	PRON	O	O	4262
clinical	ADJ	O	O	4262
scenario	NOUN	O	O	4262
in	ADP	O	O	4262
which	PRON	O	O	4262
the	PRON	O	O	4262
onset	VERB	O	O	4262
or	CCONJ	O	O	4262
manifestations	NOUN	O	O	4262
of	ADP	O	O	4262
heparin	NOUN	O	Chemical	4262
-	PUNCT	O	O	4262
induced	VERB	O	O	4262
thrombocytopenia	PROPN	O	Disease	4262
are	AUX	O	O	4262
delayed	VERB	O	O	4262
.	PUNCT	O	O	4262
PATIENTS	NOUN	O	O	4263
:	PUNCT	O	O	4263
14	NUM	O	O	4263
patients	NOUN	O	O	4263
seen	VERB	O	O	4263
over	ADP	O	O	4263
a	PRON	O	O	4263
3-year	NOUN	O	O	4263
period	NOUN	O	O	4263
in	ADP	O	O	4263
whom	PRON	O	O	4263
heparin	NOUN	O	Chemical	4263
-	PUNCT	O	O	4263
induced	VERB	O	O	4263
thrombocytopenia	PROPN	O	Disease	4263
became	VERB	O	O	4263
apparent	ADJ	O	O	4263
on	ADP	O	O	4263
delayed	VERB	O	O	4263
presentation	NOUN	O	O	4263
with	ADP	O	O	4263
thromboembolic complications	NOUN	O	Disease	4263
.	PUNCT	O	O	4263
MEASUREMENTS	NOUN	O	O	4264
:	PUNCT	O	O	4264
Platelet	NOUN	O	O	4264
counts	VERB	O	O	4264
,	PUNCT	O	O	4264
onset	VERB	O	O	4264
of	ADP	O	O	4264
objectively	ADV	O	O	4264
determined	VERB	O	O	4264
thromboembolism	NOUN	O	Disease	4264
,	PUNCT	O	O	4264
results	VERB	O	O	4264
of	ADP	O	O	4264
heparin	NOUN	O	Chemical	4264
-	PUNCT	O	O	4264
induced	VERB	O	O	4264
platelet	NOUN	O	O	4264
factor	NOUN	O	O	4264
4	NUM	O	O	4264
antibody	NOUN	O	O	4264
tests	VERB	O	O	4264
,	PUNCT	O	O	4264
and	CCONJ	O	O	4264
outcomes	NOUN	O	O	4264
.	PUNCT	O	O	4264
Patients	NOUN	O	O	4265
went	VERB	O	O	4265
home	NOUN	O	O	4265
after	ADP	O	O	4265
hospitalizations	NOUN	O	O	4265
that	SCONJ	O	O	4265
had	VERB	O	O	4265
included	VERB	O	O	4265
heparin	NOUN	O	Chemical	4265
exposure	NOUN	O	O	4265
--	PUNCT	O	O	4265
in	ADP	O	O	4265
most	ADV	O	O	4265
cases	NOUN	O	O	4265
,	PUNCT	O	O	4265
with	ADP	O	O	4265
no	PRON	O	O	4265
thrombocytopenia	PROPN	O	Disease	4265
recognized	VERB	O	O	4265
--	PUNCT	O	O	4265
only	ADV	O	O	4265
to	PART	O	O	4265
return	VERB	O	O	4265
to	PART	O	O	4265
the	PRON	O	O	4265
hospital	PROPN	O	O	4265
(	PUNCT	O	O	4265
median	ADJ	O	O	4265
,	PUNCT	O	O	4265
day	NOUN	O	O	4265
14	NUM	O	O	4265
)	PUNCT	O	O	4265
with	ADP	O	O	4265
thromboembolic complications	NOUN	O	Disease	4265
.	PUNCT	O	O	4265
Thromboemboli	PROPN	O	Disease	4266
were	AUX	O	O	4266
venous	ADJ	O	O	4266
(	PUNCT	O	O	4266
12	NUM	O	O	4266
patients	NOUN	O	O	4266
,	PUNCT	O	O	4266
7	NUM	O	O	4266
with	ADP	O	O	4266
pulmonary emboli	NOUN	O	Disease	4266
)	PUNCT	O	O	4266
or	CCONJ	O	O	4266
arterial	ADJ	O	O	4266
(	PUNCT	O	O	4266
4	NUM	O	O	4266
patients	NOUN	O	O	4266
)	PUNCT	O	O	4266
or	CCONJ	O	O	4266
both	PRON	O	O	4266
.	PUNCT	O	O	4266
On	ADP	O	O	4267
readmission	NOUN	O	O	4267
,	PUNCT	O	O	4267
11	NUM	O	O	4267
patients	NOUN	O	O	4267
received	VERB	O	O	4267
therapeutic	ADJ	O	O	4267
heparin	NOUN	O	Chemical	4267
,	PUNCT	O	O	4267
which	PRON	O	O	4267
worsened	VERB	O	O	4267
the	PRON	O	O	4267
patients	NOUN	O	O	4267
'	PUNCT	O	O	4267
clinical	ADJ	O	O	4267
condition	NOUN	O	O	4267
and	CCONJ	O	O	4267
,	PUNCT	O	O	4267
in	ADP	O	O	4267
all	PRON	O	O	4267
11	NUM	O	O	4267
cases	NOUN	O	O	4267
,	PUNCT	O	O	4267
decreased	VERB	O	O	4267
the	PRON	O	O	4267
platelet	NOUN	O	O	4267
count	VERB	O	O	4267
(	PUNCT	O	O	4267
mean	VERB	O	O	4267
at	ADP	O	O	4267
readmission	NOUN	O	O	4267
,	PUNCT	O	O	4267
143	NUM	O	O	4267
x	X	O	O	4267
10(9	NUM	O	O	4267
)	PUNCT	O	O	4267
cells	NOUN	O	O	4267
/	PUNCT	O	O	4267
L	NOUN	O	O	4267
;	PUNCT	O	O	4267
mean	VERB	O	O	4267
nadir	PROPN	O	O	4267
after	ADP	O	O	4267
heparin	NOUN	O	Chemical	4267
re	ADP	O	O	4267
-	PUNCT	O	O	4267
exposure	NOUN	O	O	4267
,	PUNCT	O	O	4267
39	NUM	O	O	4267
x	X	O	O	4267
10(9	NUM	O	O	4267
)	PUNCT	O	O	4267
cells	NOUN	O	O	4267
/	PUNCT	O	O	4267
L	NOUN	O	O	4267
)	PUNCT	O	O	4267
.	PUNCT	O	O	4267
Results	NOUN	O	O	4268
of	ADP	O	O	4268
serologic	NOUN	O	O	4268
tests	VERB	O	O	4268
for	ADP	O	O	4268
heparin	NOUN	O	Chemical	4268
-	PUNCT	O	O	4268
induced	VERB	O	O	4268
antibodies	NOUN	O	O	4268
were	AUX	O	O	4268
positive	ADJ	O	O	4268
in	ADP	O	O	4268
all	PRON	O	O	4268
patients	NOUN	O	O	4268
.	PUNCT	O	O	4268
Subsequent	PROPN	O	O	4269
treatments	NOUN	O	O	4269
included	VERB	O	O	4269
alternative	ADV	O	O	4269
anticoagulants	NOUN	O	O	4269
(	PUNCT	O	O	4269
11	NUM	O	O	4269
patients	NOUN	O	O	4269
)	PUNCT	O	O	4269
,	PUNCT	O	O	4269
thrombolytic	ADJ	O	O	4269
drugs	NOUN	O	O	4269
(	PUNCT	O	O	4269
3	X	O	O	4269
patients	NOUN	O	O	4269
)	PUNCT	O	O	4269
,	PUNCT	O	O	4269
inferior	ADJ	O	O	4269
vena	PROPN	O	O	4269
cava	NOUN	O	O	4269
filters	NOUN	O	O	4269
(	PUNCT	O	O	4269
3	X	O	O	4269
patients	NOUN	O	O	4269
)	PUNCT	O	O	4269
and	CCONJ	O	O	4269
,	PUNCT	O	O	4269
eventually	ADV	O	O	4269
,	PUNCT	O	O	4269
warfarin	VERB	O	Chemical	4269
(	PUNCT	O	O	4269
11	NUM	O	O	4269
patients	NOUN	O	O	4269
)	PUNCT	O	O	4269
.	PUNCT	O	O	4269
heparin	NOUN	O	Chemical	4270
-	PUNCT	O	O	4270
induced	VERB	O	O	4270
thrombocytopenia	PROPN	O	Disease	4270
is	AUX	O	O	4270
increasingly	ADV	O	O	4270
being	AUX	O	O	4270
recognized	VERB	O	O	4270
.	PUNCT	O	O	4270
To	PART	O	O	4271
avoid	VERB	O	O	4271
disastrous	ADJ	O	O	4271
outcomes	NOUN	O	O	4271
,	PUNCT	O	O	4271
physicians	NOUN	O	O	4271
must	AUX	O	O	4271
consider	VERB	O	O	4271
heparin	NOUN	O	Chemical	4271
-	PUNCT	O	O	4271
induced	VERB	O	O	4271
thrombocytopenia	PROPN	O	Disease	4271
whenever	SCONJ	O	O	4271
a	PRON	O	O	4271
recently	ADV	O	O	4271
hospitalized	VERB	O	O	4271
patient	NOUN	O	O	4271
returns	VERB	O	O	4271
with	ADP	O	O	4271
thromboembolism	NOUN	O	Disease	4271
;	PUNCT	O	O	4271
therapy	NOUN	O	O	4271
with	ADP	O	O	4271
alternative	ADV	O	O	4271
anticoagulants	NOUN	O	O	4271
,	PUNCT	O	O	4271
not	PART	O	O	4271
heparin	NOUN	O	Chemical	4271
,	PUNCT	O	O	4271
should	AUX	O	O	4271
be	AUX	O	O	4271
initiated	VERB	O	O	4271
.	PUNCT	O	O	4271
Valsartan	PROPN	O	Chemical	4274
,	PUNCT	O	O	4274
a	PRON	O	O	4274
new	ADJ	O	O	4274
angiotensin II	PROPN	O	Chemical	4274
antagonist	NOUN	O	O	4274
for	ADP	O	O	4274
the	PRON	O	O	4274
treatment	NOUN	O	O	4274
of	ADP	O	O	4274
essential	ADJ	O	O	4274
hypertension	NOUN	O	Disease	4274
:	PUNCT	O	O	4274
a	PRON	O	O	4274
comparative	ADJ	O	O	4274
study	VERB	O	O	4274
of	ADP	O	O	4274
the	PRON	O	O	4274
efficacy	NOUN	O	O	4274
and	CCONJ	O	O	4274
safety	NOUN	O	O	4274
against	ADP	O	O	4274
amlodipine	NOUN	O	Chemical	4274
.	PUNCT	O	O	4274
OBJECTIVE	VERB	O	O	4275
:	PUNCT	O	O	4275
To	PART	O	O	4275
compare	VERB	O	O	4275
the	PRON	O	O	4275
antihypertensive	ADV	O	O	4275
efficacy	NOUN	O	O	4275
of	ADP	O	O	4275
a	PRON	O	O	4275
new	ADJ	O	O	4275
angiotensin II	PROPN	O	Chemical	4275
antagonist	NOUN	O	O	4275
,	PUNCT	O	O	4275
valsartan	PROPN	O	Chemical	4275
,	PUNCT	O	O	4275
with	ADP	O	O	4275
a	PRON	O	O	4275
reference	NOUN	O	O	4275
therapy	NOUN	O	O	4275
,	PUNCT	O	O	4275
amlodipine	NOUN	O	Chemical	4275
.	PUNCT	O	O	4275
One	NUM	O	O	4276
hundred	NUM	O	O	4276
sixty	NUM	O	O	4276
-	PUNCT	O	O	4276
eight	NUM	O	O	4276
adult	NOUN	O	O	4276
outpatients	NOUN	O	O	4276
with	ADP	O	O	4276
mild	ADJ	O	O	4276
to	PART	O	O	4276
moderate	ADJ	O	O	4276
hypertension	NOUN	O	Disease	4276
were	AUX	O	O	4276
randomly	ADV	O	O	4276
allocated	VERB	O	O	4276
in	ADP	O	O	4276
double	ADJ	O	O	4276
-	PUNCT	O	O	4276
blind	ADJ	O	Disease	4276
fashion	NOUN	O	O	4276
and	CCONJ	O	O	4276
equal	ADJ	O	O	4276
number	NOUN	O	O	4276
to	PART	O	O	4276
receive	VERB	O	O	4276
80	NUM	O	O	4276
mg	VERB	O	O	4276
valsartan	PROPN	O	Chemical	4276
or	CCONJ	O	O	4276
5	NUM	O	O	4276
mg	VERB	O	O	4276
amlodipine	NOUN	O	Chemical	4276
for	ADP	O	O	4276
12	NUM	O	O	4276
weeks	NOUN	O	O	4276
.	PUNCT	O	O	4276
After	ADP	O	O	4277
8	NUM	O	O	4277
weeks	NOUN	O	O	4277
of	ADP	O	O	4277
therapy	NOUN	O	O	4277
,	PUNCT	O	O	4277
in	ADP	O	O	4277
patients	NOUN	O	O	4277
whose	DET	O	O	4277
blood	NOUN	O	O	4277
pressure	NOUN	O	O	4277
remained	VERB	O	O	4277
uncontrolled	ADJ	O	O	4277
,	PUNCT	O	O	4277
5	NUM	O	O	4277
mg	VERB	O	O	4277
amlodipine	NOUN	O	Chemical	4277
was	AUX	O	O	4277
added	VERB	O	O	4277
to	PART	O	O	4277
the	PRON	O	O	4277
initial	ADJ	O	O	4277
therapy	NOUN	O	O	4277
.	PUNCT	O	O	4277
Both	PRON	O	O	4278
valsartan	PROPN	O	Chemical	4278
and	CCONJ	O	O	4278
amlodipine	NOUN	O	Chemical	4278
were	AUX	O	O	4278
effective	ADJ	O	O	4278
at	ADP	O	O	4278
lowering	VERB	O	O	4278
blood	NOUN	O	O	4278
pressure	NOUN	O	O	4278
at	ADP	O	O	4278
4	NUM	O	O	4278
,	PUNCT	O	O	4278
8	NUM	O	O	4278
,	PUNCT	O	O	4278
and	CCONJ	O	O	4278
12	NUM	O	O	4278
weeks	NOUN	O	O	4278
.	PUNCT	O	O	4278
For	ADP	O	O	4279
the	PRON	O	O	4279
primary	NOUN	O	O	4279
variable	NOUN	O	O	4279
the	PRON	O	O	4279
difference	NOUN	O	O	4279
was	AUX	O	O	4279
0.5	NUM	O	O	4279
mm	INTJ	O	O	4279
Hg	PROPN	O	O	4279
in	ADP	O	O	4279
favor	NOUN	O	O	4279
of	ADP	O	O	4279
valsartan	PROPN	O	Chemical	4279
(	PUNCT	O	O	4279
p	NOUN	O	O	4279
=	PUNCT	O	O	4279
0.68	NUM	O	O	4279
;	PUNCT	O	O	4279
95%	NOUN	O	O	4279
confidence	NOUN	O	O	4279
interval	NOUN	O	O	4279
,	PUNCT	O	O	4279
-2.7	NOUN	O	O	4279
to	PART	O	O	4279
1.7	NUM	O	O	4279
)	PUNCT	O	O	4279
.	PUNCT	O	O	4279
Responder	NOUN	O	O	4280
rates	NOUN	O	O	4280
at	ADP	O	O	4280
8	NUM	O	O	4280
weeks	NOUN	O	O	4280
were	AUX	O	O	4280
66.7%	NOUN	O	O	4280
for	ADP	O	O	4280
valsartan	PROPN	O	Chemical	4280
and	CCONJ	O	O	4280
60.2%	NOUN	O	O	4280
for	ADP	O	O	4280
amlodipine	NOUN	O	Chemical	4280
The	PRON	O	O	4281
incidence	NOUN	O	O	4281
of	ADP	O	O	4281
drug	NOUN	O	O	4281
-	PUNCT	O	O	4281
related	ADJ	O	O	4281
dependent	ADJ	O	O	4281
edema	NOUN	O	Disease	4281
was	AUX	O	O	4281
somewhat	ADV	O	O	4281
higher	ADJ	O	O	4281
in	ADP	O	O	4281
the	PRON	O	O	4281
amlodipine	NOUN	O	Chemical	4281
group	NOUN	O	O	4281
,	PUNCT	O	O	4281
particularly	ADV	O	O	4281
at	ADP	O	O	4281
a	PRON	O	O	4281
dose	NOUN	O	O	4281
of	ADP	O	O	4281
10	NUM	O	O	4281
mg	VERB	O	O	4281
per	ADP	O	O	4281
day	NOUN	O	O	4281
(	PUNCT	O	O	4281
2.4%	NOUN	O	O	4281
for	ADP	O	O	4281
80	NUM	O	O	4281
mg	VERB	O	O	4281
valsartan	PROPN	O	Chemical	4281
;	PUNCT	O	O	4281
3.6%	NOUN	O	O	4281
for	ADP	O	O	4281
5	NUM	O	O	4281
mg	VERB	O	O	4281
amlodipine	NOUN	O	Chemical	4281
;	PUNCT	O	O	4281
0%	NOUN	O	O	4281
for	ADP	O	O	4281
valsartan	PROPN	O	Chemical	4281
plus	CCONJ	O	O	4281
5	NUM	O	O	4281
mg	VERB	O	O	4281
amlodipine	NOUN	O	Chemical	4281
;	PUNCT	O	O	4281
14.3%	NOUN	O	O	4281
for	ADP	O	O	4281
10	NUM	O	O	4281
mg	VERB	O	O	4281
amlodipine	NOUN	O	Chemical	4281
)	PUNCT	O	O	4281
.	PUNCT	O	O	4281
CONCLUSIONS	NOUN	O	O	4282
:	PUNCT	O	O	4282
The	PRON	O	O	4282
data	NOUN	O	O	4282
show	VERB	O	O	4282
that	SCONJ	O	O	4282
valsartan	PROPN	O	Chemical	4282
is	AUX	O	O	4282
at	ADP	O	O	4282
least	ADJ	O	O	4282
as	ADP	O	O	4282
effective	ADJ	O	O	4282
as	ADP	O	O	4282
amlodipine	NOUN	O	Chemical	4282
in	ADP	O	O	4282
the	PRON	O	O	4282
treatment	NOUN	O	O	4282
of	ADP	O	O	4282
mild	ADJ	O	O	4282
to	PART	O	O	4282
moderate	ADJ	O	O	4282
hypertension	NOUN	O	Disease	4282
.	PUNCT	O	O	4282
The	PRON	O	O	4283
results	VERB	O	O	4283
also	ADV	O	O	4283
show	VERB	O	O	4283
valsartan	PROPN	O	Chemical	4283
to	PART	O	O	4283
be	AUX	O	O	4283
well	ADV	O	O	4283
tolerated	VERB	O	O	4283
and	CCONJ	O	O	4283
suggest	VERB	O	O	4283
that	SCONJ	O	O	4283
it	PRON	O	O	4283
is	AUX	O	O	4283
not	PART	O	O	4283
associated	VERB	O	O	4283
with	ADP	O	O	4283
side	NOUN	O	O	4283
effects	NOUN	O	O	4283
characteristic	ADJ	O	O	4283
of	ADP	O	O	4283
this	PRON	O	O	4283
comparator	NOUN	O	O	4283
class	NOUN	O	O	4283
,	PUNCT	O	O	4283
dihydropyridine	NOUN	O	Chemical	4283
calcium	NOUN	O	Chemical	4283
antagonists	NOUN	O	O	4283
.	PUNCT	O	O	4283
KF17837	NOUN	O	Chemical	4286
:	PUNCT	O	O	4286
a	PRON	O	O	4286
novel	NOUN	O	O	4286
selective	ADJ	O	O	4286
adenosine	PROPN	O	Chemical	4286
A2A	PROPN	O	O	4286
receptor	NOUN	O	O	4286
antagonist	NOUN	O	O	4286
with	ADP	O	O	4286
anticataleptic	NOUN	O	O	4286
activity	NOUN	O	O	4286
.	PUNCT	O	O	4286
KF17837	NOUN	O	Chemical	4287
is	AUX	O	O	4287
a	PRON	O	O	4287
novel	NOUN	O	O	4287
selective	ADJ	O	O	4287
adenosine	PROPN	O	Chemical	4287
A2A	PROPN	O	O	4287
receptor	NOUN	O	O	4287
antagonist	NOUN	O	O	4287
.	PUNCT	O	O	4287
Oral	NOUN	O	O	4288
administration	NOUN	O	O	4288
of	ADP	O	O	4288
KF17837	NOUN	O	Chemical	4288
(	PUNCT	O	O	4288
2.5	NUM	O	O	4288
,	PUNCT	O	O	4288
10.0	NUM	O	O	4288
and	CCONJ	O	O	4288
30.0	NUM	O	O	4288
mg	VERB	O	O	4288
/	PUNCT	O	O	4288
kg	VERB	O	O	4288
)	PUNCT	O	O	4288
significantly	ADV	O	O	4288
ameliorated	VERB	O	O	4288
the	PRON	O	O	4288
cataleptic	NOUN	O	Disease	4288
responses	NOUN	O	O	4288
induced	VERB	O	O	4288
by	ADP	O	O	4288
intracerebroventricular	PROPN	O	O	4288
administration	NOUN	O	O	4288
of	ADP	O	O	4288
an	PRON	O	O	4288
adenosine	PROPN	O	Chemical	4288
A2A	PROPN	O	O	4288
receptor	NOUN	O	O	4288
agonist	NOUN	O	O	4288
,	PUNCT	O	O	4288
CGS 21680	NUM	O	Chemical	4288
(	PUNCT	O	O	4288
10	NUM	O	O	4288
micrograms	NOUN	O	O	4288
)	PUNCT	O	O	4288
,	PUNCT	O	O	4288
in	ADP	O	O	4288
a	PRON	O	O	4288
dose	NOUN	O	O	4288
-	PUNCT	O	O	4288
dependent	ADJ	O	O	4288
manner	VERB	O	O	4288
.	PUNCT	O	O	4288
KF17837	NOUN	O	Chemical	4289
also	ADV	O	O	4289
reduced	VERB	O	O	4289
the	PRON	O	O	4289
catalepsy	VERB	O	Disease	4289
induced	VERB	O	O	4289
by	ADP	O	O	4289
haloperidol	NOUN	O	Chemical	4289
(	PUNCT	O	O	4289
1	X	O	O	4289
mg	VERB	O	O	4289
/	PUNCT	O	O	4289
kg	VERB	O	O	4289
i.p	NOUN	O	O	4289
.	PUNCT	O	O	4289
)	PUNCT	O	O	4289
and	CCONJ	O	O	4289
by	ADP	O	O	4289
reserpine	NOUN	O	Chemical	4289
(	PUNCT	O	O	4289
5	NUM	O	O	4289
mg	VERB	O	O	4289
/	PUNCT	O	O	4289
kg	VERB	O	O	4289
i.p	NOUN	O	O	4289
.	PUNCT	O	O	4289
)	PUNCT	O	O	4289
.	PUNCT	O	O	4289
Moreover	ADV	O	O	4290
,	PUNCT	O	O	4290
KF17837	NOUN	O	Chemical	4290
(	PUNCT	O	O	4290
0.625	NUM	O	O	4290
mg	VERB	O	O	4290
/	PUNCT	O	O	4290
kg	VERB	O	O	4290
p.o	PROPN	O	O	4290
.	PUNCT	O	O	4290
)	PUNCT	O	O	4290
potentiated	VERB	O	O	4291
the	PRON	O	O	4291
anticataleptic	NOUN	O	O	4291
effects	NOUN	O	O	4291
of	ADP	O	O	4291
a	PRON	O	O	4291
subthreshold	VERB	O	O	4291
dose	NOUN	O	O	4291
of	ADP	O	O	4291
L-3,4-dihydroxyphenylalanine	NOUN	O	Chemical	4291
(	PUNCT	O	O	4291
L	NOUN	O	O	4291
-	PUNCT	O	O	4291
DOPA	PROPN	O	O	4291
;	PUNCT	O	O	4291
25	NUM	O	O	4291
mg	VERB	O	O	4291
/	PUNCT	O	O	4291
kg	VERB	O	O	4291
i.p	NOUN	O	O	4291
.	PUNCT	O	O	4291
)	PUNCT	O	O	4291
plus	CCONJ	O	O	4292
benserazide	VERB	O	Chemical	4292
(	PUNCT	O	O	4292
6.25	NUM	O	O	4292
mg	VERB	O	O	4292
/	PUNCT	O	O	4292
kg	VERB	O	O	4292
i.p	NOUN	O	O	4292
.	PUNCT	O	O	4292
)	PUNCT	O	O	4292
.	PUNCT	O	O	4292
These	PRON	O	O	4293
results	VERB	O	O	4293
suggested	VERB	O	O	4293
that	SCONJ	O	O	4293
KF17837	NOUN	O	Chemical	4293
is	AUX	O	O	4293
a	PRON	O	O	4293
centrally	ADV	O	O	4293
active	ADJ	O	O	4293
adenosine	PROPN	O	Chemical	4293
A2A	PROPN	O	O	4293
receptor	NOUN	O	O	4293
antagonist	NOUN	O	O	4293
and	CCONJ	O	O	4293
that	SCONJ	O	O	4293
the	PRON	O	O	4293
dopaminergic	ADJ	O	O	4293
function	NOUN	O	O	4293
of	ADP	O	O	4293
the	PRON	O	O	4293
nigrostriatal	NOUN	O	O	4293
pathway	NOUN	O	O	4293
is	AUX	O	O	4293
potentiated	VERB	O	O	4293
by	ADP	O	O	4293
adenosine	PROPN	O	Chemical	4293
A2A	PROPN	O	O	4293
receptor	NOUN	O	O	4293
antagonists	NOUN	O	O	4293
.	PUNCT	O	O	4293
Furthermore	ADV	O	O	4294
,	PUNCT	O	O	4294
KF17837	NOUN	O	Chemical	4294
may	AUX	O	O	4294
be	AUX	O	O	4294
a	PRON	O	O	4294
useful	ADJ	O	O	4294
drug	NOUN	O	O	4294
in	ADP	O	O	4294
the	PRON	O	O	4294
treatment	NOUN	O	O	4294
of	ADP	O	O	4294
parkinsonism	NOUN	O	Disease	4294
.	PUNCT	O	O	4294
Some	PRON	O	O	4297
central	ADJ	O	O	4297
effects	NOUN	O	O	4297
of	ADP	O	O	4297
repeated	VERB	O	O	4297
treatment	NOUN	O	O	4297
with	ADP	O	O	4297
fluvoxamine	NOUN	O	Chemical	4297
.	PUNCT	O	O	4297
We	PRON	O	O	4298
investigated	VERB	O	O	4298
the	PRON	O	O	4298
effect	VERB	O	O	4298
of	ADP	O	O	4298
repeated	VERB	O	O	4298
treatment	NOUN	O	O	4298
with	ADP	O	O	4298
fluvoxamine	NOUN	O	Chemical	4298
,	PUNCT	O	O	4298
a	PRON	O	O	4298
selective	ADJ	O	O	4298
serotonin	PROPN	O	Chemical	4298
uptake	NOUN	O	O	4298
inhibitor	NOUN	O	O	4298
,	PUNCT	O	O	4298
on	ADP	O	O	4298
behavioral	ADJ	O	O	4298
effects	NOUN	O	O	4298
of	ADP	O	O	4298
dopaminomimetics	NOUN	O	O	4298
and	CCONJ	O	O	4298
methoxamine	NOUN	O	Chemical	4298
and	CCONJ	O	O	4298
on	ADP	O	O	4298
the	PRON	O	O	4298
animal	NOUN	O	O	4298
behavior	NOUN	O	O	4298
in	ADP	O	O	4298
the	PRON	O	O	4298
""""	PUNCT	O	O	4298
behavioral	ADJ	O	O	4298
despair	NOUN	O	O	4298
""""	PUNCT	O	O	4298
test	NOUN	O	O	4298
.	PUNCT	O	O	4298
A	PRON	O	O	4299
repeated	VERB	O	O	4299
treatment	NOUN	O	O	4299
with	ADP	O	O	4299
fluvoxamine	NOUN	O	Chemical	4299
(	PUNCT	O	O	4299
twice	ADV	O	O	4299
daily	ADV	O	O	4299
for	ADP	O	O	4299
14	NUM	O	O	4299
days	NOUN	O	O	4299
)	PUNCT	O	O	4299
potentiated	VERB	O	O	4299
in	ADP	O	O	4299
mice	NOUN	O	O	4299
and	CCONJ	O	O	4299
in	ADP	O	O	4299
rats	NOUN	O	O	4299
(	PUNCT	O	O	4299
weaker	ADJ	O	O	4299
)	PUNCT	O	O	4299
the	PRON	O	O	4299
amphetamine	NOUN	O	Chemical	4299
-	PUNCT	O	O	4299
induced	VERB	O	O	4299
hyperactivity	NOUN	O	Disease	4299
.	PUNCT	O	O	4299
The	PRON	O	O	4300
hyperactivity	NOUN	O	Disease	4300
induced	VERB	O	O	4300
by	ADP	O	O	4300
nomifensine	ADJ	O	Chemical	4300
in	ADP	O	O	4300
mice	NOUN	O	O	4300
remained	VERB	O	O	4300
unaffected	ADJ	O	O	4300
by	ADP	O	O	4300
fluvoxamine	NOUN	O	Chemical	4300
.	PUNCT	O	O	4300
The	PRON	O	O	4301
stimulation	NOUN	O	O	4301
of	ADP	O	O	4301
locomotor	PROPN	O	O	4301
activity	NOUN	O	O	4301
by	ADP	O	O	4301
intracerebroventricularly	ADV	O	O	4301
administered	VERB	O	O	4301
methoxamine	NOUN	O	Chemical	4301
was	AUX	O	O	4301
not	PART	O	O	4301
affected	VERB	O	O	4301
by	ADP	O	O	4301
repeated	VERB	O	O	4301
treatment	NOUN	O	O	4301
with	ADP	O	O	4301
fluvoxamine	NOUN	O	Chemical	4301
.	PUNCT	O	O	4301
Given	VERB	O	O	4302
three	NUM	O	O	4302
times	NOUN	O	O	4302
fluvoxamine	NOUN	O	Chemical	4302
had	VERB	O	O	4302
no	PRON	O	O	4302
effect	VERB	O	O	4302
on	ADP	O	O	4302
the	PRON	O	O	4302
immobilization	NOUN	O	O	4302
time	NOUN	O	O	4302
in	ADP	O	O	4302
the	PRON	O	O	4302
""""	PUNCT	O	O	4302
behavioral	ADJ	O	O	4302
despair	NOUN	O	O	4302
""""	PUNCT	O	O	4302
test	NOUN	O	O	4302
in	ADP	O	O	4302
rats	NOUN	O	O	4302
.	PUNCT	O	O	4302
The	PRON	O	O	4303
results	VERB	O	O	4303
indicate	VERB	O	O	4303
that	SCONJ	O	O	4303
fluvoxamine	NOUN	O	Chemical	4303
given	VERB	O	O	4303
repeatedly	ADV	O	O	4303
acts	VERB	O	O	4303
differently	ADV	O	O	4303
than	ADP	O	O	4303
citalopram	PROPN	O	Chemical	4303
,	PUNCT	O	O	4303
another	PRON	O	O	4303
selective	ADJ	O	O	4303
serotonin	PROPN	O	Chemical	4303
uptake	NOUN	O	O	4303
inhibitor	NOUN	O	O	4303
,	PUNCT	O	O	4303
and	CCONJ	O	O	4303
differs	VERB	O	O	4303
also	ADV	O	O	4303
from	ADP	O	O	4303
other	ADJ	O	O	4303
antidepressant	NOUN	O	O	4303
drugs	NOUN	O	O	4303
.	PUNCT	O	O	4303
Severe	ADJ	O	O	4306
congestive	ADJ	O	O	4306
heart failure	NOUN	O	Disease	4306
patient	NOUN	O	O	4306
on	ADP	O	O	4306
amiodarone	NOUN	O	Chemical	4306
presenting	VERB	O	O	4306
with	ADP	O	O	4306
myxedemic coma	NOUN	O	Disease	4306
:	PUNCT	O	O	4306
a	PRON	O	O	4306
case	NOUN	O	O	4306
report	VERB	O	O	4306
.	PUNCT	O	O	4306
This	PRON	O	O	4307
is	AUX	O	O	4307
a	PRON	O	O	4307
case	NOUN	O	O	4307
report	VERB	O	O	4307
of	ADP	O	O	4307
myxedema coma	NOUN	O	Disease	4307
secondary	ADJ	O	O	4307
to	PART	O	O	4307
amiodarone	NOUN	O	Chemical	4307
-	PUNCT	O	O	4307
induced	VERB	O	O	4307
hypothyroidism	PROPN	O	Disease	4307
in	ADP	O	O	4307
a	PRON	O	O	4307
patient	NOUN	O	O	4307
with	ADP	O	O	4307
severe	ADJ	O	O	4307
congestive	ADJ	O	O	4307
heart failure	NOUN	O	Disease	4307
(	PUNCT	O	O	4307
CHF	PROPN	O	Disease	4307
)	PUNCT	O	O	4307
.	PUNCT	O	O	4307
To	PART	O	O	4308
our	PRON	O	O	4308
knowledge	NOUN	O	O	4308
and	CCONJ	O	O	4308
after	ADP	O	O	4308
reviewing	VERB	O	O	4308
the	PRON	O	O	4308
literature	NOUN	O	O	4308
there	ADV	O	O	4308
is	AUX	O	O	4308
one	NUM	O	O	4308
case	NOUN	O	O	4308
report	VERB	O	O	4308
of	ADP	O	O	4308
myxedema coma	NOUN	O	Disease	4308
during	ADP	O	O	4308
long	ADV	O	O	4308
term	NOUN	O	O	4308
amiodarone	NOUN	O	Chemical	4308
therapy	NOUN	O	O	4308
.	PUNCT	O	O	4308
Myxedema coma	NOUN	O	Disease	4309
is	AUX	O	O	4309
a	PRON	O	O	4309
life	NOUN	O	O	4309
threatening	VERB	O	O	4309
condition	NOUN	O	O	4309
that	SCONJ	O	O	4309
carries	VERB	O	O	4309
a	PRON	O	O	4309
mortality	NOUN	O	O	4309
reaching	VERB	O	O	4309
as	ADP	O	O	4309
high	ADJ	O	O	4309
as	ADP	O	O	4309
20%	NOUN	O	O	4309
with	ADP	O	O	4309
treatment	NOUN	O	O	4309
.	PUNCT	O	O	4309
The	PRON	O	O	4310
condition	NOUN	O	O	4310
is	AUX	O	O	4310
treated	VERB	O	O	4310
with	ADP	O	O	4310
intravenous	ADJ	O	O	4310
thyroxine	NOUN	O	Chemical	4310
(	PUNCT	O	O	4310
T4	PROPN	O	Chemical	4310
)	PUNCT	O	O	4310
or	CCONJ	O	O	4310
intravenous	ADJ	O	O	4310
tri	PROPN	O	O	4310
-	PUNCT	O	O	4310
iodo	PROPN	O	O	4310
-	PUNCT	O	O	4310
thyronine	PROPN	O	O	4310
(	PUNCT	O	O	4310
T3	PROPN	O	Chemical	4310
)	PUNCT	O	O	4310
.	PUNCT	O	O	4310
Patients	NOUN	O	O	4311
with	ADP	O	O	4311
CHF	PROPN	O	Disease	4311
on	ADP	O	O	4311
amiodarone	NOUN	O	Chemical	4311
may	AUX	O	O	4311
suffer	VERB	O	O	4311
serious	ADJ	O	O	4311
morbidity	NOUN	O	O	4311
and	CCONJ	O	O	4311
mortality	NOUN	O	O	4311
from	ADP	O	O	4311
hypothyroidism	PROPN	O	Disease	4311
,	PUNCT	O	O	4311
and	CCONJ	O	O	4311
thus	ADV	O	O	4311
may	AUX	O	O	4311
deserve	VERB	O	O	4311
closer	ADV	O	O	4311
follow	VERB	O	O	4311
up	ADP	O	O	4311
for	ADP	O	O	4311
thyroid	NOUN	O	O	4311
stimulating	VERB	O	O	4311
hormone	NOUN	O	O	4311
(	PUNCT	O	O	4311
TSH	PROPN	O	O	4311
)	PUNCT	O	O	4311
levels	NOUN	O	O	4311
.	PUNCT	O	O	4311
This	PRON	O	O	4312
case	NOUN	O	O	4312
report	VERB	O	O	4312
carries	VERB	O	O	4312
an	PRON	O	O	4312
important	ADJ	O	O	4312
clinical	ADJ	O	O	4312
application	NOUN	O	O	4312
given	VERB	O	O	4312
the	PRON	O	O	4312
frequent	ADJ	O	O	4312
usage	NOUN	O	O	4312
of	ADP	O	O	4312
amiodarone	NOUN	O	Chemical	4312
among	ADP	O	O	4312
CHF	PROPN	O	Disease	4312
patients	NOUN	O	O	4312
.	PUNCT	O	O	4312
The	PRON	O	O	4313
myriad	ADV	O	O	4313
clinical	ADJ	O	O	4313
presentation	NOUN	O	O	4313
of	ADP	O	O	4313
myxedema coma	NOUN	O	Disease	4313
and	CCONJ	O	O	4313
its	PRON	O	O	4313
serious	ADJ	O	O	4313
morbidity	NOUN	O	O	4313
and	CCONJ	O	O	4313
mortality	NOUN	O	O	4313
stresses	VERB	O	O	4313
the	PRON	O	O	4313
need	VERB	O	O	4313
to	PART	O	O	4313
suspect	VERB	O	O	4313
this	PRON	O	O	4313
clinical	ADJ	O	O	4313
syndrome	NOUN	O	O	4313
among	ADP	O	O	4313
CHF	PROPN	O	Disease	4313
patients	NOUN	O	O	4313
presenting	VERB	O	O	4313
with	ADP	O	O	4313
hypotension	NOUN	O	Disease	4313
,	PUNCT	O	O	4313
weakness	NOUN	O	Disease	4313
or	CCONJ	O	O	4313
other	ADJ	O	O	4313
unexplained	ADJ	O	O	4313
symptoms	NOUN	O	O	4313
.	PUNCT	O	O	4313
Fear	NOUN	O	O	4316
-	PUNCT	O	O	4316
potentiated	VERB	O	O	4316
startle	VERB	O	Disease	4316
,	PUNCT	O	O	4316
but	CCONJ	O	O	4316
not	PART	O	O	4316
light	ADJ	O	O	4316
-	PUNCT	O	O	4316
enhanced	VERB	O	O	4316
startle	VERB	O	Disease	4316
,	PUNCT	O	O	4316
is	AUX	O	O	4316
enhanced	VERB	O	O	4316
by	ADP	O	O	4316
anxiogenic	ADJ	O	O	4316
drugs	NOUN	O	O	4316
.	PUNCT	O	O	4316
The	PRON	O	O	4317
light	ADJ	O	O	4317
-	PUNCT	O	O	4317
enhanced	VERB	O	O	4317
startle	VERB	O	Disease	4317
paradigm	NOUN	O	O	4317
(	PUNCT	O	O	4317
LES	PROPN	O	O	4317
)	PUNCT	O	O	4317
is	AUX	O	O	4317
suggested	VERB	O	O	4317
to	PART	O	O	4317
model	NOUN	O	O	4317
anxiety	NOUN	O	Disease	4317
,	PUNCT	O	O	4317
because	SCONJ	O	O	4317
of	ADP	O	O	4317
the	PRON	O	O	4317
non	ADJ	O	O	4317
-	PUNCT	O	O	4317
specific	ADJ	O	O	4317
cue	VERB	O	O	4317
and	CCONJ	O	O	4317
the	PRON	O	O	4317
long	ADV	O	O	4317
-	PUNCT	O	O	4317
term	NOUN	O	O	4317
effect	VERB	O	O	4317
.	PUNCT	O	O	4317
In	ADP	O	O	4318
contrast	NOUN	O	O	4318
,	PUNCT	O	O	4318
the	PRON	O	O	4318
fear	VERB	O	O	4318
-	PUNCT	O	O	4318
potentiated	VERB	O	O	4318
startle	VERB	O	Disease	4318
(	PUNCT	O	O	4318
FPS	NOUN	O	O	4318
)	PUNCT	O	O	4318
is	AUX	O	O	4318
suggested	VERB	O	O	4318
to	PART	O	O	4318
model	NOUN	O	O	4318
conditioned	VERB	O	O	4318
fear	VERB	O	O	4318
.	PUNCT	O	O	4318
Male	NOUN	O	O	4319
Wistar	PROPN	O	O	4319
rats	NOUN	O	O	4319
received	VERB	O	O	4319
each	PRON	O	O	4319
dose	NOUN	O	O	4319
of	ADP	O	O	4319
the	PRON	O	O	4319
alpha(2)-adrenoceptor	NUM	O	O	4319
antagonist	NOUN	O	O	4319
yohimbine	NOUN	O	Chemical	4319
(	PUNCT	O	O	4319
0.25	NUM	O	O	4319
-	PUNCT	O	O	4319
1.0mg	NOUN	O	O	4319
/	PUNCT	O	O	4319
kg	VERB	O	O	4319
)	PUNCT	O	O	4319
,	PUNCT	O	O	4319
the	PRON	O	O	4319
5-HT(2C	NOUN	O	O	4319
)	PUNCT	O	O	4319
receptor	NOUN	O	O	4319
agonist	NOUN	O	O	4319
m	VERB	O	O	4319
-	PUNCT	O	O	4319
chlorophenylpiperazine	NOUN	O	O	4319
(	PUNCT	O	O	4319
mCPP	X	O	Chemical	4319
,	PUNCT	O	O	4319
0.5	NUM	O	O	4319
-	PUNCT	O	O	4319
2.0mg	VERB	O	O	4319
/	PUNCT	O	O	4320
kg	VERB	O	O	4320
)	PUNCT	O	O	4320
or	CCONJ	O	O	4320
the	PRON	O	O	4320
GABA(A	X	O	O	4320
)	PUNCT	O	O	4320
inverse	VERB	O	O	4320
receptor	NOUN	O	O	4320
agonist	NOUN	O	O	4320
pentylenetetrazole	NOUN	O	Chemical	4320
(	PUNCT	O	O	4320
PTZ	PROPN	O	Chemical	4320
,	PUNCT	O	O	4320
3	X	O	O	4320
-	PUNCT	O	O	4320
30mg	NOUN	O	O	4320
/	PUNCT	O	O	4320
kg	VERB	O	O	4320
)	PUNCT	O	O	4320
and	CCONJ	O	O	4320
were	AUX	O	O	4320
subsequently	ADV	O	O	4320
tested	VERB	O	O	4320
in	ADP	O	O	4320
either	ADV	O	O	4320
LES	PROPN	O	O	4320
or	CCONJ	O	O	4320
FPS	NOUN	O	O	4320
.	PUNCT	O	O	4320
None	NOUN	O	O	4321
of	ADP	O	O	4321
the	PRON	O	O	4321
drugs	NOUN	O	O	4321
enhanced	VERB	O	O	4321
LES	PROPN	O	O	4321
,	PUNCT	O	O	4321
whereas	SCONJ	O	O	4321
mCPP	X	O	Chemical	4321
increased	VERB	O	O	4321
percentage	NOUN	O	O	4321
FPS	NOUN	O	O	4321
and	CCONJ	O	O	4321
yohimbine	NOUN	O	Chemical	4321
increased	VERB	O	O	4321
absolute	ADJ	O	O	4321
FPS	NOUN	O	O	4321
values	NOUN	O	O	4321
.	PUNCT	O	O	4321
Furthermore	ADV	O	O	4322
,	PUNCT	O	O	4322
yohimbine	NOUN	O	Chemical	4322
increased	VERB	O	O	4322
baseline	VERB	O	O	4322
startle	VERB	O	Disease	4322
amplitude	VERB	O	O	4322
in	ADP	O	O	4322
the	PRON	O	O	4322
LES	PROPN	O	O	4322
,	PUNCT	O	O	4322
while	SCONJ	O	O	4322
mCPP	X	O	Chemical	4322
suppressed	VERB	O	O	4322
baseline	VERB	O	O	4322
startle	VERB	O	Disease	4322
in	ADP	O	O	4322
both	PRON	O	O	4322
the	PRON	O	O	4322
LES	PROPN	O	O	4322
and	CCONJ	O	O	4322
FPS	NOUN	O	O	4322
and	CCONJ	O	O	4322
PTZ	PROPN	O	Chemical	4322
suppressed	VERB	O	O	4322
baseline	VERB	O	O	4322
startle	VERB	O	Disease	4322
in	ADP	O	O	4322
the	PRON	O	O	4322
FPS	NOUN	O	O	4322
.	PUNCT	O	O	4322
Proteinase	NOUN	O	O	4325
3-antineutrophil	NOUN	O	O	4325
cytoplasmic	ADJ	O	O	4325
antibody-(PR3-ANCA	NOUN	O	O	4325
)	PUNCT	O	O	4325
positive	ADJ	O	O	4325
necrotizing	VERB	O	Disease	4325
glomerulonephritis	NOUN	O	Disease	4325
after	ADP	O	O	4325
restarting	VERB	O	O	4325
sulphasalazine	VERB	O	Chemical	4325
treatment	NOUN	O	O	4325
.	PUNCT	O	O	4325
A	PRON	O	O	4326
59-year	NOUN	O	O	4326
-	PUNCT	O	O	4326
old	ADJ	O	O	4326
woman	NOUN	O	O	4326
with	ADP	O	O	4326
ulcerative colitis	NOUN	O	Disease	4326
developed	VERB	O	O	4326
red eyes	NOUN	O	Disease	4326
,	PUNCT	O	O	4326
pleural effusion	NOUN	O	Disease	4326
,	PUNCT	O	O	4326
eosinophilia	PROPN	O	Disease	4326
and	CCONJ	O	O	4326
urinary abnormalities	NOUN	O	Disease	4326
after	ADP	O	O	4326
restarting	VERB	O	O	4326
of	ADP	O	O	4326
sulphasalazine	VERB	O	Chemical	4326
treatment	NOUN	O	O	4326
.	PUNCT	O	O	4326
Light	NOUN	O	O	4327
microscopy	NOUN	O	O	4327
of	ADP	O	O	4327
a	PRON	O	O	4327
kidney	NOUN	O	O	4327
biopsy	PROPN	O	O	4327
revealed	VERB	O	O	4327
segmental necrotizing glomerulonephritis	NOUN	O	Disease	4327
without	ADP	O	O	4327
deposition	NOUN	O	O	4327
of	ADP	O	O	4327
immunoglobulin	NOUN	O	O	4327
or	CCONJ	O	O	4327
complement	VERB	O	O	4327
.	PUNCT	O	O	4327
PR3-ANCA	PROPN	O	O	4328
titer	NOUN	O	O	4328
was	AUX	O	O	4328
250	NUM	O	O	4328
and	CCONJ	O	O	4328
1,070	NUM	O	O	4328
EU	PROPN	O	O	4328
in	ADP	O	O	4328
pleural effusions	NOUN	O	Disease	4328
on	ADP	O	O	4328
right	ADV	O	O	4328
and	CCONJ	O	O	4328
left	VERB	O	O	4328
side	NOUN	O	O	4328
,	PUNCT	O	O	4328
respectively	ADV	O	O	4328
.	PUNCT	O	O	4328
Although	SCONJ	O	O	4329
cessation	NOUN	O	O	4329
of	ADP	O	O	4329
sulphasalazine	VERB	O	Chemical	4329
treatment	NOUN	O	O	4329
resulted	VERB	O	O	4329
in	ADP	O	O	4329
improvements	NOUN	O	O	4329
in	ADP	O	O	4329
fever	NOUN	O	Disease	4329
,	PUNCT	O	O	4329
red eyes	NOUN	O	Disease	4329
,	PUNCT	O	O	4329
chest pain	NOUN	O	Disease	4329
,	PUNCT	O	O	4329
titer	NOUN	O	O	4329
of	ADP	O	O	4329
C	NOUN	O	O	4329
-	PUNCT	O	O	4329
reactive	ADJ	O	O	4329
protein	NOUN	O	O	4329
and	CCONJ	O	O	4329
volume	PROPN	O	O	4329
of	ADP	O	O	4329
the	PRON	O	O	4329
pleural effusions	NOUN	O	Disease	4329
,	PUNCT	O	O	4329
we	PRON	O	O	4329
initiated	VERB	O	O	4329
steroid	NOUN	O	Chemical	4329
therapy	NOUN	O	O	4329
,	PUNCT	O	O	4329
because	SCONJ	O	O	4329
PR3-ANCA	PROPN	O	O	4329
titer	NOUN	O	O	4329
rose	VERB	O	O	4329
to	PART	O	O	4329
320	NUM	O	O	4329
EU	PROPN	O	O	4329
,	PUNCT	O	O	4329
eosinophil	NOUN	O	O	4329
count	VERB	O	O	4329
increased	VERB	O	O	4329
to	PART	O	O	4329
1,100	NUM	O	O	4329
cells	NOUN	O	O	4329
/	PUNCT	O	O	4329
microl	NOUN	O	O	4329
,	PUNCT	O	O	4329
and	CCONJ	O	O	4329
the	PRON	O	O	4329
pleural effusion	NOUN	O	Disease	4329
remained	VERB	O	O	4329
.	PUNCT	O	O	4329
One	NUM	O	O	4330
month	NOUN	O	O	4330
after	ADP	O	O	4330
steroid	NOUN	O	Chemical	4330
therapy	NOUN	O	O	4330
,	PUNCT	O	O	4330
the	PRON	O	O	4330
pleural effusion	NOUN	O	Disease	4330
disappeared	VERB	O	O	4330
,	PUNCT	O	O	4330
and	CCONJ	O	O	4330
PR3-ANCA	PROPN	O	O	4330
titer	NOUN	O	O	4330
normalized	VERB	O	O	4330
3	X	O	O	4330
months	NOUN	O	O	4330
later	ADV	O	O	4330
.	PUNCT	O	O	4330
This	PRON	O	O	4331
case	NOUN	O	O	4331
suggests	VERB	O	O	4331
that	SCONJ	O	O	4331
sulphasalazine	VERB	O	Chemical	4331
can	AUX	O	O	4331
induce	VERB	O	O	4331
PR3-ANCA	PROPN	O	O	4331
-	PUNCT	O	O	4331
positive	ADJ	O	O	4331
necrotizing	VERB	O	Disease	4331
glomerulonephritis	NOUN	O	Disease	4331
.	PUNCT	O	O	4331
Is	AUX	O	O	4334
phenytoin	NOUN	O	Chemical	4334
administration	NOUN	O	O	4334
safe	ADJ	O	O	4334
in	ADP	O	O	4334
a	PRON	O	O	4334
hypothermic	ADJ	O	Disease	4334
child	NOUN	O	O	4334
?	PUNCT	O	O	4334
A	PRON	O	O	4335
male	NOUN	O	O	4335
neonate	NOUN	O	O	4335
with	ADP	O	O	4335
a	PRON	O	O	4335
Chiari malformation	NOUN	O	Disease	4335
and	CCONJ	O	O	4335
a	PRON	O	O	4335
leaking	VERB	O	O	4335
myelomeningocoele	PROPN	O	O	4335
underwent	VERB	O	O	4335
ventriculoperitoneal	PROPN	O	O	4335
shunt	VERB	O	O	4335
insertion	NOUN	O	O	4335
followed	VERB	O	O	4335
by	ADP	O	O	4335
repair	PROPN	O	O	4335
of	ADP	O	O	4335
myelomeningocoele	PROPN	O	O	4335
.	PUNCT	O	O	4335
During	ADP	O	O	4336
anaesthesia	NOUN	O	O	4336
and	CCONJ	O	O	4336
surgery	NOUN	O	O	4336
,	PUNCT	O	O	4336
he	PRON	O	O	4336
inadvertently	ADV	O	O	4336
became	VERB	O	O	4336
moderately	ADV	O	O	4336
hypothermic	ADJ	O	Disease	4336
.	PUNCT	O	O	4336
Intravenous	PROPN	O	O	4337
phenytoin	NOUN	O	Chemical	4337
was	AUX	O	O	4337
administered	VERB	O	O	4337
during	ADP	O	O	4337
the	PRON	O	O	4337
later	ADV	O	O	4337
part	NOUN	O	O	4337
of	ADP	O	O	4337
the	PRON	O	O	4337
surgery	NOUN	O	O	4337
for	ADP	O	O	4337
seizure	NOUN	O	Disease	4337
prophylaxis	NOUN	O	O	4337
.	PUNCT	O	O	4337
Following	VERB	O	O	4338
phenytoin	NOUN	O	Chemical	4338
administration	NOUN	O	O	4338
,	PUNCT	O	O	4338
the	PRON	O	O	4338
patient	NOUN	O	O	4338
developed	VERB	O	O	4338
acute	ADJ	O	O	4338
severe	ADJ	O	O	4338
bradycardia	NOUN	O	Disease	4338
,	PUNCT	O	O	4338
refractory	ADJ	O	O	4338
to	PART	O	O	4338
atropine	NOUN	O	Chemical	4338
and	CCONJ	O	O	4338
adrenaline	NOUN	O	Chemical	4338
.	PUNCT	O	O	4338
The	PRON	O	O	4339
cardiac	ADJ	O	O	4339
depressant	NOUN	O	O	4339
actions	NOUN	O	O	4339
of	ADP	O	O	4339
phenytoin	NOUN	O	Chemical	4339
and	CCONJ	O	O	4339
hypothermia	VERB	O	Disease	4339
can	AUX	O	O	4339
be	AUX	O	O	4339
additive	NOUN	O	O	4339
.	PUNCT	O	O	4339
Administration	NOUN	O	O	4340
of	ADP	O	O	4340
phenytoin	NOUN	O	Chemical	4340
in	ADP	O	O	4340
the	PRON	O	O	4340
presence	NOUN	O	O	4340
of	ADP	O	O	4340
hypothermia	VERB	O	Disease	4340
may	AUX	O	O	4340
lead	VERB	O	Chemical	4340
to	PART	O	O	4340
an	PRON	O	O	4340
adverse	ADJ	O	O	4340
cardiac	ADJ	O	O	4340
event	NOUN	O	O	4340
in	ADP	O	O	4340
children	NOUN	O	O	4340
.	PUNCT	O	O	4340
As	ADP	O	O	4341
phenytoin	NOUN	O	Chemical	4341
is	AUX	O	O	4341
a	PRON	O	O	4341
commonly	ADV	O	O	4341
used	VERB	O	O	4341
drug	NOUN	O	O	4341
,	PUNCT	O	O	4341
clinicians	NOUN	O	O	4341
need	VERB	O	O	4341
to	PART	O	O	4341
be	AUX	O	O	4341
aware	ADJ	O	O	4341
of	ADP	O	O	4341
this	PRON	O	O	4341
interaction	NOUN	O	O	4341
.	PUNCT	O	O	4341
Amisulpride	ADV	O	Chemical	4344
related	ADJ	O	O	4344
tic	ADJ	O	O	4344
-	PUNCT	O	O	4344
like	INTJ	O	O	4344
symptoms	NOUN	O	O	4344
in	ADP	O	O	4344
an	PRON	O	O	4344
adolescent	ADJ	O	O	4344
schizophrenic	ADJ	O	Disease	4344
.	PUNCT	O	O	4344
Tic disorders	NOUN	O	Disease	4345
can	AUX	O	O	4345
be	AUX	O	O	4345
effectively	ADV	O	O	4345
treated	VERB	O	O	4345
by	ADP	O	O	4345
atypical	ADJ	O	O	4345
antipsychotics	NOUN	O	O	4345
such	ADJ	O	O	4345
as	ADP	O	O	4345
risperidone	VERB	O	Chemical	4345
,	PUNCT	O	O	4345
olanzapine	NOUN	O	Chemical	4345
and	CCONJ	O	O	4345
ziprasidone	NOUN	O	Chemical	4345
.	PUNCT	O	O	4345
However	ADV	O	O	4346
,	PUNCT	O	O	4346
there	ADV	O	O	4346
are	AUX	O	O	4346
two	NUM	O	O	4346
case	NOUN	O	O	4346
reports	VERB	O	O	4346
that	SCONJ	O	O	4346
show	VERB	O	O	4346
tic	ADJ	O	O	4346
-	PUNCT	O	O	4346
like	INTJ	O	O	4346
symptoms	NOUN	O	O	4346
,	PUNCT	O	O	4346
including	VERB	O	O	4346
motor	NOUN	O	O	4346
and	CCONJ	O	O	4346
phonic	PROPN	O	O	4346
variants	NOUN	O	O	4346
,	PUNCT	O	O	4346
occurring	VERB	O	O	4346
during	ADP	O	O	4346
treatment	NOUN	O	O	4346
with	ADP	O	O	4346
quetiapine	ADV	O	Chemical	4346
or	CCONJ	O	O	4346
clozapine	PROPN	O	Chemical	4346
.	PUNCT	O	O	4346
We	PRON	O	O	4347
present	NOUN	O	O	4347
a	PRON	O	O	4347
15-year	NOUN	O	O	4347
-	PUNCT	O	O	4347
old	ADJ	O	O	4347
girl	NOUN	O	O	4347
schizophrenic	ADJ	O	Disease	4347
who	PRON	O	O	4347
developed	VERB	O	O	4347
frequent	ADJ	O	O	4347
involuntary	ADJ	O	O	4347
eye	NOUN	O	O	4347
-	PUNCT	O	O	4347
blinking	VERB	O	O	4347
movements	NOUN	O	O	4347
after	ADP	O	O	4347
5	NUM	O	O	4347
months	NOUN	O	O	4347
of	ADP	O	O	4347
amisulpride	ADV	O	Chemical	4347
treatment	NOUN	O	O	4347
(	PUNCT	O	O	4347
1000	NUM	O	O	4347
mg	VERB	O	O	4347
per	ADP	O	O	4347
day	NOUN	O	O	4347
)	PUNCT	O	O	4347
.	PUNCT	O	O	4347
The	PRON	O	O	4348
tic	ADJ	O	O	4348
-	PUNCT	O	O	4348
like	INTJ	O	O	4348
symptoms	NOUN	O	O	4348
resolved	VERB	O	O	4348
completely	ADV	O	O	4348
after	ADP	O	O	4348
we	PRON	O	O	4348
reduced	VERB	O	O	4348
the	PRON	O	O	4348
dose	NOUN	O	O	4348
of	ADP	O	O	4348
amisulpride	ADV	O	Chemical	4348
down	ADP	O	O	4348
to	PART	O	O	4348
800	NUM	O	O	4348
mg	VERB	O	O	4348
per	ADP	O	O	4348
day	NOUN	O	O	4348
.	PUNCT	O	O	4348
However	ADV	O	O	4349
,	PUNCT	O	O	4349
her	PRON	O	O	4349
psychosis	VERB	O	Disease	4349
recurred	VERB	O	O	4349
after	ADP	O	O	4349
the	PRON	O	O	4349
dose	NOUN	O	O	4349
reduction	NOUN	O	O	4349
.	PUNCT	O	O	4349
We	PRON	O	O	4350
then	ADV	O	O	4350
placed	VERB	O	O	4350
her	PRON	O	O	4350
on	ADP	O	O	4350
an	PRON	O	O	4350
additional	ADJ	O	O	4350
100	NUM	O	O	4350
mg	VERB	O	O	4350
per	ADP	O	O	4350
day	NOUN	O	O	4350
of	ADP	O	O	4350
quetiapine	ADV	O	Chemical	4350
.	PUNCT	O	O	4350
No	PRON	O	O	4351
more	ADJ	O	O	4351
tic	ADJ	O	O	4351
-	PUNCT	O	O	4351
like	INTJ	O	O	4351
symptoms	NOUN	O	O	4351
or	CCONJ	O	O	4351
other	ADJ	O	O	4351
side	NOUN	O	O	4351
effects	NOUN	O	O	4351
have	VERB	O	O	4351
been	AUX	O	O	4351
reported	VERB	O	O	4351
.	PUNCT	O	O	4351
Together	ADV	O	O	4352
with	ADP	O	O	4352
previously	ADV	O	O	4352
reported	VERB	O	O	4352
cases	NOUN	O	O	4352
,	PUNCT	O	O	4352
our	PRON	O	O	4352
patient	NOUN	O	O	4352
suggests	VERB	O	O	4352
that	SCONJ	O	O	4352
tic	ADJ	O	O	4352
-	PUNCT	O	O	4352
like	INTJ	O	O	4352
symptoms	NOUN	O	O	4352
might	AUX	O	O	4352
occur	VERB	O	O	4352
in	ADP	O	O	4352
certain	ADJ	O	O	4352
vulnerable	ADJ	O	O	4352
individuals	NOUN	O	O	4352
during	ADP	O	O	4352
treatment	NOUN	O	O	4352
with	ADP	O	O	4352
atypical	ADJ	O	O	4352
antipsychotics	NOUN	O	O	4352
such	ADJ	O	O	4352
as	ADP	O	O	4352
quetiapine	ADV	O	Chemical	4352
,	PUNCT	O	O	4352
clozapine	PROPN	O	Chemical	4352
,	PUNCT	O	O	4352
or	CCONJ	O	O	4352
amisulpride	ADV	O	Chemical	4352
.	PUNCT	O	O	4352
Comparison	NOUN	O	O	4355
of	ADP	O	O	4355
developmental	ADJ	O	O	4355
toxicology	NOUN	O	O	4355
of	ADP	O	O	4355
aspirin	NOUN	O	Chemical	4355
(	PUNCT	O	O	4355
acetylsalicylic acid	NOUN	O	Chemical	4355
)	PUNCT	O	O	4355
in	ADP	O	O	4355
rats	NOUN	O	O	4355
using	VERB	O	O	4355
selected	VERB	O	O	4355
dosing	VERB	O	O	4355
paradigms	NOUN	O	O	4355
.	PUNCT	O	O	4355
Analysis	NOUN	O	O	4356
of	ADP	O	O	4356
the	PRON	O	O	4356
literature	NOUN	O	O	4356
for	ADP	O	O	4356
nonsteroidal	ADJ	O	O	4356
anti	ADJ	O	O	4356
-	PUNCT	O	O	4356
inflammatory	ADJ	O	O	4356
drugs	NOUN	O	O	4356
(	PUNCT	O	O	4356
NSAIDs	NOUN	O	Chemical	4356
)	PUNCT	O	O	4356
suggests	VERB	O	O	4356
that	SCONJ	O	O	4356
a	PRON	O	O	4356
low	ADJ	O	O	4356
incidence	NOUN	O	O	4356
of	ADP	O	O	4356
developmental anomalies	NOUN	O	Disease	4356
occurs	VERB	O	O	4356
in	ADP	O	O	4356
rats	NOUN	O	O	4356
given	VERB	O	O	4356
NSAIDs	NOUN	O	Chemical	4356
on	ADP	O	O	4356
specific	ADJ	O	O	4356
days	NOUN	O	O	4356
during	ADP	O	O	4356
organogenesis	NOUN	O	O	4356
.	PUNCT	O	O	4356
Aspirin	NOUN	O	Chemical	4357
(	PUNCT	O	O	4357
acetylsalicylic acid	NOUN	O	Chemical	4357
[	X	O	O	4357
ASA	PROPN	O	Chemical	4357
]	PUNCT	O	O	4357
)	PUNCT	O	O	4357
,	PUNCT	O	O	4357
an	PRON	O	O	4357
irreversible	ADJ	O	O	4357
cyclooxygenase	PROPN	O	O	4357
1	X	O	O	4357
and	CCONJ	O	O	4357
2	X	O	O	4357
inhibitor	NOUN	O	O	4357
,	PUNCT	O	O	4357
induces	VERB	O	O	4357
developmental anomalies	NOUN	O	Disease	4357
when	SCONJ	O	O	4357
administered	VERB	O	O	4357
to	PART	O	O	4357
Wistar	PROPN	O	O	4357
rats	NOUN	O	O	4357
on	ADP	O	O	4357
gestational	ADJ	O	O	4357
day	NOUN	O	O	4357
(	PUNCT	O	O	4357
GD	PROPN	O	O	4357
)	PUNCT	O	O	4357
9	NUM	O	O	4357
,	PUNCT	O	O	4357
10	NUM	O	O	4357
,	PUNCT	O	O	4357
or	CCONJ	O	O	4357
11	NUM	O	O	4357
There	ADV	O	O	4358
are	AUX	O	O	4358
no	PRON	O	O	4358
published	VERB	O	O	4358
ASA	PROPN	O	Chemical	4358
studies	NOUN	O	O	4358
using	VERB	O	O	4358
the	PRON	O	O	4358
multiple	ADJ	O	O	4358
dosing	VERB	O	O	4358
paradigm	NOUN	O	O	4358
of	ADP	O	O	4358
GDs	NOUN	O	O	4358
6	NUM	O	O	4358
to	PART	O	O	4358
17	NUM	O	O	4358
.	PUNCT	O	O	4358
Objectives	NOUN	O	O	4359
of	ADP	O	O	4359
the	PRON	O	O	4359
current	ADJ	O	O	4359
study	VERB	O	O	4359
were	AUX	O	O	4359
to	PART	O	O	4359
compare	VERB	O	O	4359
results	VERB	O	O	4359
between	ADP	O	O	4359
Sprague	PROPN	O	O	4359
-	PUNCT	O	O	4359
Dawley	NOUN	O	O	4359
(	PUNCT	O	O	4359
SD	NOUN	O	O	4359
)	PUNCT	O	O	4359
and	CCONJ	O	O	4359
Wistar	PROPN	O	O	4359
strains	VERB	O	O	4359
when	SCONJ	O	O	4359
ASA	PROPN	O	Chemical	4359
is	AUX	O	O	4359
administered	VERB	O	O	4359
on	ADP	O	O	4359
GD	PROPN	O	O	4359
9	NUM	O	O	4359
,	PUNCT	O	O	4359
10	NUM	O	O	4359
,	PUNCT	O	O	4359
or	CCONJ	O	O	4359
11	NUM	O	O	4359
;	PUNCT	O	O	4359
to	PART	O	O	4359
compare	VERB	O	O	4359
the	PRON	O	O	4359
malformation	NOUN	O	O	4359
patterns	NOUN	O	O	4359
following	VERB	O	O	4359
single	ADJ	O	O	4359
and	CCONJ	O	O	4359
multiple	ADJ	O	O	4359
dosings	NOUN	O	O	4359
during	ADP	O	O	4359
organogenesis	NOUN	O	O	4359
in	ADP	O	O	4359
SD	NOUN	O	O	4359
rats	NOUN	O	O	4359
;	PUNCT	O	O	4359
and	CCONJ	O	O	4359
to	PART	O	O	4359
test	NOUN	O	O	4359
the	PRON	O	O	4359
hypothesis	NOUN	O	O	4359
that	SCONJ	O	O	4359
maternal	ADJ	O	O	4359
gastrointestinal toxicity	NOUN	O	Disease	4359
confounds	VERB	O	O	4359
the	PRON	O	O	4359
detection	NOUN	O	O	4359
of	ADP	O	O	4359
low	ADJ	O	O	4359
incidence	NOUN	O	O	4359
malformations	NOUN	O	Disease	4359
with	ADP	O	O	4359
ASA	PROPN	O	Chemical	4359
when	SCONJ	O	O	4359
a	PRON	O	O	4359
multiple	ADJ	O	O	4359
dosing	VERB	O	O	4359
paradigm	NOUN	O	O	4359
is	AUX	O	O	4359
used	VERB	O	O	4359
.	PUNCT	O	O	4359
ASA	PROPN	O	Chemical	4360
was	AUX	O	O	4360
administered	VERB	O	O	4360
as	ADP	O	O	4360
a	PRON	O	O	4360
single	ADJ	O	O	4360
dose	NOUN	O	O	4360
on	ADP	O	O	4360
GD	PROPN	O	O	4360
9	NUM	O	O	4360
(	PUNCT	O	O	4360
0	NUM	O	O	4360
,	PUNCT	O	O	4360
250	NUM	O	O	4360
,	PUNCT	O	O	4360
500	NUM	O	O	4360
,	PUNCT	O	O	4360
or	CCONJ	O	O	4360
625	NUM	O	O	4360
mg	VERB	O	O	4360
/	PUNCT	O	O	4360
kg	VERB	O	O	4360
)	PUNCT	O	O	4360
,	PUNCT	O	O	4360
10	NUM	O	O	4360
(	PUNCT	O	O	4360
0	NUM	O	O	4360
,	PUNCT	O	O	4360
500	NUM	O	O	4360
,	PUNCT	O	O	4360
625	NUM	O	O	4360
,	PUNCT	O	O	4360
or	CCONJ	O	O	4360
750	NUM	O	O	4360
mg	VERB	O	O	4360
/	PUNCT	O	O	4360
kg	VERB	O	O	4360
)	PUNCT	O	O	4360
,	PUNCT	O	O	4360
or	CCONJ	O	O	4360
11	NUM	O	O	4360
(	PUNCT	O	O	4360
0	NUM	O	O	4360
,	PUNCT	O	O	4360
500	NUM	O	O	4360
,	PUNCT	O	O	4360
750	NUM	O	O	4360
,	PUNCT	O	O	4360
or	CCONJ	O	O	4360
1000	NUM	O	O	4360
mg	VERB	O	O	4360
/	PUNCT	O	O	4360
kg	VERB	O	O	4360
)	PUNCT	O	O	4360
and	CCONJ	O	O	4360
from	ADP	O	O	4360
GD	PROPN	O	O	4360
6	NUM	O	O	4360
to	PART	O	O	4360
GD	PROPN	O	O	4360
17	NUM	O	O	4360
(	PUNCT	O	O	4360
0	NUM	O	O	4360
,	PUNCT	O	O	4360
50	NUM	O	O	4360
,	PUNCT	O	O	4360
125	NUM	O	O	4360
,	PUNCT	O	O	4360
or	CCONJ	O	O	4360
250	NUM	O	O	4360
mg	VERB	O	O	4360
/	PUNCT	O	O	4360
kg	VERB	O	O	4360
a	PRON	O	O	4360
day	NOUN	O	O	4360
)	PUNCT	O	O	4360
in	ADP	O	O	4360
the	PRON	O	O	4360
multiple	ADJ	O	O	4360
dose	NOUN	O	O	4360
study	VERB	O	O	4360
to	PART	O	O	4360
SD	NOUN	O	O	4360
rats	NOUN	O	O	4360
.	PUNCT	O	O	4360
The	PRON	O	O	4361
literature	NOUN	O	O	4361
evaluation	NOUN	O	O	4361
suggested	VERB	O	O	4361
that	SCONJ	O	O	4361
NSAIDs	NOUN	O	Chemical	4361
induce	VERB	O	O	4361
ventricular septal defects	NOUN	O	Disease	4361
(	PUNCT	O	O	4361
VSDs	NOUN	O	Disease	4361
)	PUNCT	O	O	4361
and	CCONJ	O	O	4361
midline defects	NOUN	O	Disease	4361
(	PUNCT	O	O	4361
MDs	NOUN	O	Disease	4361
)	PUNCT	O	O	4361
in	ADP	O	O	4361
rats	NOUN	O	O	4361
and	CCONJ	O	O	4361
diaphragmatic hernia	NOUN	O	Disease	4361
(	PUNCT	O	O	4361
DH	NOUN	O	Disease	4361
)	PUNCT	O	O	4361
,	PUNCT	O	O	4361
MDs	NOUN	O	Disease	4361
,	PUNCT	O	O	4361
and	CCONJ	O	O	4361
VSDs	NOUN	O	Disease	4361
in	ADP	O	O	4361
rabbits	NOUN	O	O	4361
;	PUNCT	O	O	4362
hence	ADV	O	O	4362
,	PUNCT	O	O	4362
the	PRON	O	O	4362
present	NOUN	O	O	4362
study	VERB	O	O	4362
focused	VERB	O	O	4362
on	ADP	O	O	4362
these	PRON	O	O	4362
malformations	NOUN	O	Disease	4362
,	PUNCT	O	O	4362
even	ADV	O	O	4362
though	SCONJ	O	O	4362
ASA	PROPN	O	Chemical	4362
induces	VERB	O	O	4362
several	ADJ	O	O	4362
other	ADJ	O	O	4362
low	ADJ	O	O	4362
-	PUNCT	O	O	4362
incidence	NOUN	O	O	4362
malformations	NOUN	O	Disease	4362
.	PUNCT	O	O	4362
In	ADP	O	O	4363
single	ADJ	O	O	4363
dose	NOUN	O	O	4363
studies	NOUN	O	O	4363
,	PUNCT	O	O	4363
DH	NOUN	O	Disease	4363
,	PUNCT	O	O	4363
MD	PROPN	O	Disease	4363
,	PUNCT	O	O	4363
and	CCONJ	O	O	4363
VSD	PROPN	O	Disease	4363
were	AUX	O	O	4363
induced	VERB	O	O	4363
on	ADP	O	O	4363
GDs	NOUN	O	O	4363
9	NUM	O	O	4363
and	CCONJ	O	O	4363
10	NUM	O	O	4363
.	PUNCT	O	O	4363
VSD	PROPN	O	Disease	4364
also	ADV	O	O	4364
was	AUX	O	O	4364
noted	VERB	O	O	4364
following	VERB	O	O	4364
treatment	NOUN	O	O	4364
on	ADP	O	O	4364
GD	PROPN	O	O	4364
11	NUM	O	O	4364
.	PUNCT	O	O	4364
In	ADP	O	O	4365
contrast	NOUN	O	O	4365
,	PUNCT	O	O	4365
DH	NOUN	O	Disease	4365
and	CCONJ	O	O	4365
MD	PROPN	O	Disease	4365
were	AUX	O	O	4365
noted	VERB	O	O	4365
in	ADP	O	O	4365
the	PRON	O	O	4365
multiple	ADJ	O	O	4365
dose	NOUN	O	O	4365
study	VERB	O	O	4365
design	NOUN	O	O	4365
only	ADV	O	O	4365
in	ADP	O	O	4365
the	PRON	O	O	4365
high	ADJ	O	O	4365
-	PUNCT	O	O	4365
dose	NOUN	O	O	4365
group	NOUN	O	O	4365
,	PUNCT	O	O	4365
and	CCONJ	O	O	4365
VSD	PROPN	O	Disease	4365
was	AUX	O	O	4365
noted	VERB	O	O	4365
across	ADP	O	O	4365
all	PRON	O	O	4365
dose	NOUN	O	O	4365
groups	NOUN	O	O	4365
.	PUNCT	O	O	4365
CONCLUSIONS	NOUN	O	O	4366
:	PUNCT	O	O	4366
High	ADJ	O	O	4366
concordance	NOUN	O	O	4366
in	ADP	O	O	4366
major	ADJ	O	O	4366
developmental anomalies	NOUN	O	Disease	4366
between	ADP	O	O	4366
Wistar	PROPN	O	O	4366
and	CCONJ	O	O	4366
SD	NOUN	O	O	4366
rats	NOUN	O	O	4366
were	AUX	O	O	4366
noted	VERB	O	O	4366
with	ADP	O	O	4366
the	PRON	O	O	4366
exception	NOUN	O	O	4366
of	ADP	O	O	4366
VSD	PROPN	O	Disease	4366
in	ADP	O	O	4366
the	PRON	O	O	4366
SD	NOUN	O	O	4366
rats	NOUN	O	O	4366
and	CCONJ	O	O	4366
hydrocephalus	NOUN	O	Disease	4366
in	ADP	O	O	4366
the	PRON	O	O	4366
Wistar	PROPN	O	O	4366
rats	NOUN	O	O	4366
.	PUNCT	O	O	4366
Variations	NOUN	O	O	4367
and	CCONJ	O	O	4367
malformations	NOUN	O	Disease	4367
were	AUX	O	O	4367
similar	ADJ	O	O	4367
when	SCONJ	O	O	4367
ASA	PROPN	O	Chemical	4367
was	AUX	O	O	4367
administered	VERB	O	O	4367
as	ADP	O	O	4367
a	PRON	O	O	4367
single	ADJ	O	O	4367
dose	NOUN	O	O	4367
or	CCONJ	O	O	4367
during	ADP	O	O	4367
the	PRON	O	O	4367
period	NOUN	O	O	4367
of	ADP	O	O	4367
organogenesis	NOUN	O	O	4367
(	PUNCT	O	O	4367
GDs	NOUN	O	O	4367
6	NUM	O	O	4367
to	PART	O	O	4367
17	NUM	O	O	4367
)	PUNCT	O	O	4367
.	PUNCT	O	O	4367
It	PRON	O	O	4368
was	AUX	O	O	4368
also	ADV	O	O	4368
evident	ADJ	O	O	4368
that	SCONJ	O	O	4368
,	PUNCT	O	O	4368
by	ADP	O	O	4368
titrating	VERB	O	O	4368
the	PRON	O	O	4368
dose	NOUN	O	O	4368
to	PART	O	O	4368
achieve	VERB	O	O	4368
a	PRON	O	O	4368
maximum	ADV	O	O	4368
tolerated	VERB	O	O	4368
dose	NOUN	O	O	4368
,	PUNCT	O	O	4368
malformations	NOUN	O	Disease	4368
that	SCONJ	O	O	4368
normally	ADV	O	O	4368
occur	VERB	O	O	4368
at	ADP	O	O	4368
low	ADJ	O	O	4368
incidence	NOUN	O	O	4368
,	PUNCT	O	O	4368
as	ADP	O	O	4368
reported	VERB	O	O	4368
from	ADP	O	O	4368
previous	ADJ	O	O	4368
single	ADJ	O	O	4368
dose	NOUN	O	O	4368
studies	NOUN	O	O	4368
,	PUNCT	O	O	4368
could	AUX	O	O	4368
also	ADV	O	O	4368
be	AUX	O	O	4368
induced	VERB	O	O	4368
with	ADP	O	O	4368
ASA	PROPN	O	Chemical	4368
given	VERB	O	O	4368
at	ADP	O	O	4368
multiple	ADJ	O	O	4368
doses	NOUN	O	O	4368
.	PUNCT	O	O	4368
Torsade de pointes	VERB	O	Disease	4371
induced	VERB	O	O	4371
by	ADP	O	O	4371
metoclopramide	NOUN	O	Chemical	4371
in	ADP	O	O	4371
an	PRON	O	O	4371
elderly	ADJ	O	O	4371
woman	NOUN	O	O	4371
with	ADP	O	O	4371
preexisting	VERB	O	O	4371
complete	VERB	O	O	4371
left bundle branch block	NOUN	O	Disease	4371
.	PUNCT	O	O	4371
There	ADV	O	O	4372
is	AUX	O	O	4372
a	PRON	O	O	4372
growing	VERB	O	O	4372
list	NOUN	O	O	4372
of	ADP	O	O	4372
drugs	NOUN	O	O	4372
implicated	VERB	O	O	4372
in	ADP	O	O	4372
acquired	VERB	O	O	4372
long QT syndrome	NOUN	O	Disease	4372
and	CCONJ	O	O	4372
torsade de pointes	NOUN	O	Disease	4372
.	PUNCT	O	O	4372
However	ADV	O	O	4373
,	PUNCT	O	O	4373
the	PRON	O	O	4373
torsadogenic	PROPN	O	O	4373
potential	ADJ	O	O	4373
of	ADP	O	O	4373
metoclopramide	NOUN	O	Chemical	4373
,	PUNCT	O	O	4373
a	PRON	O	O	4373
commonly	ADV	O	O	4373
used	VERB	O	O	4373
antiemetic	ADJ	O	O	4373
and	CCONJ	O	O	4373
prokinetic	ADJ	O	O	4373
drug	NOUN	O	O	4373
,	PUNCT	O	O	4373
has	VERB	O	O	4373
not	PART	O	O	4373
been	AUX	O	O	4373
reported	VERB	O	O	4373
in	ADP	O	O	4373
the	PRON	O	O	4373
literature	NOUN	O	O	4373
,	PUNCT	O	O	4373
despite	SCONJ	O	O	4373
its	PRON	O	O	4373
chemical	PROPN	O	O	4373
similarity	NOUN	O	O	4373
to	PART	O	O	4373
procainamide	PROPN	O	Chemical	4373
.	PUNCT	O	O	4373
We	PRON	O	O	4374
report	VERB	O	O	4374
on	ADP	O	O	4374
a	PRON	O	O	4374
92-year	NOUN	O	O	4374
-	PUNCT	O	O	4374
old	ADJ	O	O	4374
woman	NOUN	O	O	4374
with	ADP	O	O	4374
preexisting	VERB	O	O	4374
complete	VERB	O	O	4374
left bundle branch block	NOUN	O	Disease	4374
who	PRON	O	O	4374
developed	VERB	O	O	4374
torsade de pointes	NOUN	O	Disease	4374
after	ADP	O	O	4374
intravenous	ADJ	O	O	4374
and	CCONJ	O	O	4374
oral	ADJ	O	O	4374
administration	NOUN	O	O	4374
of	ADP	O	O	4374
metoclopramide	NOUN	O	Chemical	4374
.	PUNCT	O	O	4374
This	PRON	O	O	4375
patient	NOUN	O	O	4375
also	ADV	O	O	4375
developed	VERB	O	O	4375
torsade de pointes	NOUN	O	Disease	4375
when	SCONJ	O	O	4375
cisapride	ADV	O	Chemical	4375
and	CCONJ	O	O	4375
erythromycin	PROPN	O	Chemical	4375
were	AUX	O	O	4375
given	VERB	O	O	4375
simultaneously	ADV	O	O	4375
.	PUNCT	O	O	4375
This	PRON	O	O	4376
is	AUX	O	O	4376
the	PRON	O	O	4376
first	ADV	O	O	4376
documentation	NOUN	O	O	4376
that	SCONJ	O	O	4376
metoclopramide	NOUN	O	Chemical	4376
provokes	VERB	O	O	4376
torsade de pointes	NOUN	O	Disease	4376
clinically	ADV	O	O	4376
.	PUNCT	O	O	4376
Metoclopramide	PROPN	O	Chemical	4377
should	AUX	O	O	4377
be	AUX	O	O	4377
used	VERB	O	O	4377
cautiously	ADV	O	O	4377
in	ADP	O	O	4377
patients	NOUN	O	O	4377
with	ADP	O	O	4377
a	PRON	O	O	4377
risk	NOUN	O	O	4377
of	ADP	O	O	4377
torsade de pointes	NOUN	O	Disease	4377
.	PUNCT	O	O	4377
Apomorphine	PROPN	O	Chemical	4380
:	PUNCT	O	O	4380
an	PRON	O	O	4380
underutilized	VERB	O	O	4380
therapy	NOUN	O	O	4380
for	ADP	O	O	4380
Parkinson	NOUN	O	O	4380
's	AUX	O	O	4380
disease	PROPN	O	O	4380
.	PUNCT	O	O	4380
Apomorphine	PROPN	O	Chemical	4381
was	AUX	O	O	4381
the	PRON	O	O	4381
first	ADV	O	O	4381
dopaminergic	ADJ	O	O	4381
drug	NOUN	O	O	4381
ever	ADV	O	O	4381
used	VERB	O	O	4381
to	PART	O	O	4381
treat	VERB	O	O	4381
symptoms	NOUN	O	O	4381
of	ADP	O	O	4381
Parkinson	NOUN	O	O	4381
's	AUX	O	O	4381
disease	PROPN	O	O	4381
.	PUNCT	O	O	4381
While	SCONJ	O	O	4382
powerful	ADJ	O	O	4382
antiparkinsonian	ADJ	O	O	4382
effects	NOUN	O	O	4382
had	VERB	O	O	4382
been	AUX	O	O	4382
observed	VERB	O	O	4382
as	ADP	O	O	4382
early	ADV	O	O	4382
as	ADP	O	O	4382
1951	NUM	O	O	4382
,	PUNCT	O	O	4382
the	PRON	O	O	4382
potential	ADJ	O	O	4382
of	ADP	O	O	4382
treating	VERB	O	O	4382
fluctuating	VERB	O	O	4382
Parkinson	NOUN	O	O	4382
's	AUX	O	O	4382
disease	PROPN	O	O	4382
by	ADP	O	O	4382
subcutaneous	ADJ	O	O	4382
administration	NOUN	O	O	4382
of	ADP	O	O	4382
apomorphine	PROPN	O	Chemical	4382
has	VERB	O	O	4382
only	ADV	O	O	4382
recently	ADV	O	O	4382
become	VERB	O	O	4382
the	PRON	O	O	4382
subject	ADJ	O	O	4382
of	ADP	O	O	4382
systematic	ADJ	O	O	4382
study	VERB	O	O	4382
.	PUNCT	O	O	4382
A	PRON	O	O	4383
number	NOUN	O	O	4383
of	ADP	O	O	4383
small	ADJ	O	O	4383
scale	NOUN	O	O	4383
clinical	ADJ	O	O	4383
trials	NOUN	O	O	4383
have	VERB	O	O	4383
unequivocally	ADV	O	O	4383
shown	VERB	O	O	4383
that	SCONJ	O	O	4383
intermittent	ADJ	O	O	4383
subcutaneous	ADJ	O	O	4383
apomorphine	PROPN	O	Chemical	4383
injections	NOUN	O	O	4383
produce	VERB	O	O	4383
antiparkinsonian	ADJ	O	O	4383
benefit	VERB	O	O	4383
close	ADV	O	O	4383
if	SCONJ	O	O	4383
not	PART	O	O	4383
identical	ADJ	O	O	4383
to	PART	O	O	4383
that	SCONJ	O	O	4383
seen	VERB	O	O	4383
with	ADP	O	O	4383
levodopa	NOUN	O	Chemical	4383
and	CCONJ	O	O	4383
that	SCONJ	O	O	4383
apomorphine	PROPN	O	Chemical	4383
rescue	NOUN	O	O	4383
injections	NOUN	O	O	4383
can	AUX	O	O	4383
reliably	ADV	O	O	4383
revert	VERB	O	O	4383
off	ADP	O	O	4383
-	PUNCT	O	O	4383
periods	NOUN	O	O	4383
even	ADV	O	O	4383
in	ADP	O	O	4383
patients	NOUN	O	O	4383
with	ADP	O	O	4383
complex	ADJ	O	O	4383
on	ADP	O	O	4383
-	PUNCT	O	O	4383
off	ADP	O	O	4383
motor	NOUN	O	O	4383
swings	VERB	O	O	4383
.	PUNCT	O	O	4383
Continuous	ADJ	O	O	4384
subcutaneous	ADJ	O	O	4384
apomorphine	PROPN	O	Chemical	4384
infusions	NOUN	O	O	4384
can	AUX	O	O	4384
reduce	VERB	O	O	4384
daily	ADV	O	O	4384
off	ADP	O	O	4384
-	PUNCT	O	O	4384
time	NOUN	O	O	4384
by	ADP	O	O	4384
more	ADJ	O	O	4384
than	ADP	O	O	4384
50%	NOUN	O	O	4384
in	ADP	O	O	4384
this	PRON	O	O	4384
group	NOUN	O	O	4384
of	ADP	O	O	4384
patients	NOUN	O	O	4384
,	PUNCT	O	O	4384
which	PRON	O	O	4384
appears	VERB	O	O	4384
to	PART	O	O	4384
be	AUX	O	O	4384
a	PRON	O	O	4384
stronger	ADJ	O	O	4384
effect	VERB	O	O	4384
than	ADP	O	O	4384
that	SCONJ	O	O	4384
generally	ADV	O	O	4384
seen	VERB	O	O	4384
with	ADP	O	O	4384
add	VERB	O	O	4384
-	PUNCT	O	O	4384
on	ADP	O	O	4384
therapy	NOUN	O	O	4384
with	ADP	O	O	4384
oral	ADJ	O	O	4384
dopamine	NOUN	O	Chemical	4384
agonists	NOUN	O	O	4384
or	CCONJ	O	O	4384
COMT	PROPN	O	O	4384
inhibitors	NOUN	O	O	4384
.	PUNCT	O	O	4384
Extended	VERB	O	O	4385
follow	VERB	O	O	4385
-	PUNCT	O	O	4385
up	ADP	O	O	4385
studies	NOUN	O	O	4385
of	ADP	O	O	4385
up	ADP	O	O	4385
to	PART	O	O	4385
8	NUM	O	O	4385
years	NOUN	O	O	4385
have	VERB	O	O	4385
demonstrated	VERB	O	O	4385
long	ADV	O	O	4385
-	PUNCT	O	O	4385
term	NOUN	O	O	4385
persistence	NOUN	O	O	4385
of	ADP	O	O	4385
apomorphine	PROPN	O	Chemical	4385
efficacy	NOUN	O	O	4385
.	PUNCT	O	O	4385
In	ADP	O	O	4386
addition	NOUN	O	O	4386
,	PUNCT	O	O	4386
there	ADV	O	O	4386
is	AUX	O	O	4386
convincing	ADJ	O	O	4386
clinical	ADJ	O	O	4386
evidence	NOUN	O	O	4386
that	SCONJ	O	O	4386
monotherapy	X	O	O	4386
with	ADP	O	O	4386
continuous	ADJ	O	O	4386
subcutaneous	ADJ	O	O	4386
apomorphine	PROPN	O	Chemical	4386
infusions	NOUN	O	O	4386
is	AUX	O	O	4386
associated	VERB	O	O	4386
with	ADP	O	O	4386
marked	VERB	O	O	4386
reductions	NOUN	O	O	4386
of	ADP	O	O	4386
preexisting	VERB	O	O	4386
levodopa	NOUN	O	Chemical	4386
-	PUNCT	O	O	4386
induced	VERB	O	O	4386
dyskinesias	PROPN	O	Disease	4386
.	PUNCT	O	O	4386
The	PRON	O	O	4387
main	ADJ	O	O	4387
side	NOUN	O	O	4387
effects	NOUN	O	O	4387
of	ADP	O	O	4387
subcutaneous	ADJ	O	O	4387
apomorphine	PROPN	O	Chemical	4387
treatment	NOUN	O	O	4387
are	AUX	O	O	4387
related	ADJ	O	O	4387
to	PART	O	O	4387
cutaneous	ADJ	O	O	4387
tolerability	NOUN	O	O	4387
problems	NOUN	O	O	4387
,	PUNCT	O	O	4387
whereas	SCONJ	O	O	4387
sedation	NOUN	O	O	4387
and	CCONJ	O	O	4387
psychiatric	ADJ	O	Disease	4387
complications	NOUN	O	O	4387
play	VERB	O	O	4387
a	PRON	O	O	4387
lesser	ADJ	O	O	4387
role	NOUN	O	O	4387
.	PUNCT	O	O	4387
Given	VERB	O	O	4388
the	PRON	O	O	4388
marked	VERB	O	O	4388
degree	PROPN	O	O	4388
of	ADP	O	O	4388
efficacy	NOUN	O	O	4388
of	ADP	O	O	4388
subcutaneous	ADJ	O	O	4388
apomorphine	PROPN	O	Chemical	4388
treatment	NOUN	O	O	4388
in	ADP	O	O	4388
fluctuating	VERB	O	O	4388
Parkinson	NOUN	O	O	4388
's	AUX	O	O	4388
disease	PROPN	O	O	4388
,	PUNCT	O	O	4388
this	PRON	O	O	4388
approach	NOUN	O	O	4388
seems	VERB	O	O	4388
to	PART	O	O	4388
deserve	VERB	O	O	4388
more	ADJ	O	O	4388
widespread	ADJ	O	O	4388
clinical	ADJ	O	O	4388
use	VERB	O	O	4388
.	PUNCT	O	O	4388
Fatal	ADJ	O	O	4391
excited	ADJ	O	O	4391
delirium	NOUN	O	Disease	4391
following	VERB	O	O	4391
cocaine	NOUN	O	Chemical	4391
use	VERB	O	O	4391
:	PUNCT	O	O	4391
epidemiologic	ADJ	O	O	4391
findings	NOUN	O	O	4391
provide	VERB	O	O	4391
new	ADJ	O	O	4391
evidence	NOUN	O	O	4391
for	ADP	O	O	4391
mechanisms	NOUN	O	O	4391
of	ADP	O	O	4391
cocaine	NOUN	O	Chemical	4391
toxicity	NOUN	O	Disease	4391
.	PUNCT	O	O	4391
We	PRON	O	O	4392
describe	VERB	O	O	4392
an	PRON	O	O	4392
outbreak	NOUN	O	O	4392
of	ADP	O	O	4392
deaths	NOUN	O	O	4392
from	ADP	O	O	4392
cocaine	NOUN	O	Chemical	4392
-	PUNCT	O	O	4392
induced	VERB	O	O	4392
excited	ADJ	O	O	4392
delirium	NOUN	O	Disease	4392
(	PUNCT	O	O	4392
EDDs	NOUN	O	Disease	4392
)	PUNCT	O	O	4392
in	ADP	O	O	4392
Dade	NOUN	O	O	4392
County	NOUN	O	O	4392
,	PUNCT	O	O	4392
Florida	PROPN	O	O	4392
between	ADP	O	O	4392
1979	NUM	O	O	4392
and	CCONJ	O	O	4392
1990	NUM	O	O	4392
.	PUNCT	O	O	4392
From	ADP	O	O	4393
a	PRON	O	O	4393
registry	NOUN	O	O	4393
of	ADP	O	O	4393
all	PRON	O	O	4393
cocaine	NOUN	O	Chemical	4393
-	PUNCT	O	O	4393
related	ADJ	O	O	4393
deaths	NOUN	O	O	4393
in	ADP	O	O	4393
Dade	NOUN	O	O	4393
County	NOUN	O	O	4393
,	PUNCT	O	O	4393
Florida	PROPN	O	O	4393
,	PUNCT	O	O	4393
from	ADP	O	O	4393
1969	NUM	O	O	4393
-	PUNCT	O	O	4393
1990	NUM	O	O	4393
,	PUNCT	O	O	4393
58	NUM	O	O	4393
EDDs	NOUN	O	Disease	4393
were	AUX	O	O	4393
compared	VERB	O	O	4393
with	ADP	O	O	4393
125	NUM	O	O	4393
victims	NOUN	O	O	4393
of	ADP	O	O	4393
accidental	ADJ	O	O	4393
cocaine	NOUN	O	Chemical	4393
overdose	NOUN	O	Disease	4393
without	ADP	O	O	4393
excited	ADJ	O	O	4393
delirium	NOUN	O	Disease	4393
.	PUNCT	O	O	4393
Compared	VERB	O	O	4394
with	ADP	O	O	4394
controls	VERB	O	O	4394
,	PUNCT	O	O	4394
EDDs	NOUN	O	Disease	4394
were	AUX	O	O	4394
more	ADJ	O	O	4394
frequently	ADV	O	O	4394
black	ADJ	O	O	4394
,	PUNCT	O	O	4394
male	NOUN	O	O	4394
,	PUNCT	O	O	4394
and	CCONJ	O	O	4394
younger	ADJ	O	O	4394
.	PUNCT	O	O	4394
They	PRON	O	O	4395
were	AUX	O	O	4395
less	ADV	O	O	4395
likely	ADV	O	O	4395
to	PART	O	O	4395
have	VERB	O	O	4395
a	PRON	O	O	4395
low	ADJ	O	O	4395
body	NOUN	O	O	4395
mass	PROPN	O	O	4395
index	NOUN	O	O	4395
,	PUNCT	O	O	4395
and	CCONJ	O	O	4395
more	ADJ	O	O	4395
likely	ADV	O	O	4395
to	PART	O	O	4395
have	VERB	O	O	4395
died	VERB	O	O	4395
in	ADP	O	O	4395
police	NOUN	O	O	4395
custody	NOUN	O	O	4395
,	PUNCT	O	O	4395
to	PART	O	O	4395
have	VERB	O	O	4395
received	VERB	O	O	4395
medical	ADJ	O	O	4395
treatment	NOUN	O	O	4395
immediately	ADV	O	O	4395
before	ADP	O	O	4395
death	NOUN	O	O	4395
,	PUNCT	O	O	4395
to	PART	O	O	4395
have	VERB	O	O	4395
survived	VERB	O	O	4395
for	ADP	O	O	4395
a	PRON	O	O	4395
longer	ADV	O	O	4395
period	NOUN	O	O	4395
,	PUNCT	O	O	4395
to	PART	O	O	4395
have	VERB	O	O	4395
developed	VERB	O	O	4395
hyperthermia	NOUN	O	Disease	4395
,	PUNCT	O	O	4395
and	CCONJ	O	O	4395
to	PART	O	O	4395
have	VERB	O	O	4395
died	VERB	O	O	4395
in	ADP	O	O	4395
summer	NOUN	O	O	4395
months	NOUN	O	O	4395
.	PUNCT	O	O	4395
EDDs	NOUN	O	Disease	4396
had	VERB	O	O	4396
concentrations	NOUN	O	O	4396
of	ADP	O	O	4396
cocaine	NOUN	O	Chemical	4396
and	CCONJ	O	O	4396
benzoylecgonine	ADJ	O	Chemical	4396
in	ADP	O	O	4396
autopsy	ADJ	O	O	4396
blood	NOUN	O	O	4396
that	SCONJ	O	O	4396
were	AUX	O	O	4396
similar	ADJ	O	O	4396
to	PART	O	O	4396
those	PRON	O	O	4396
for	ADP	O	O	4396
controls	VERB	O	O	4396
.	PUNCT	O	O	4396
The	PRON	O	O	4397
epidemiologic	ADJ	O	O	4397
findings	NOUN	O	O	4397
are	AUX	O	O	4397
most	ADV	O	O	4397
consistent	ADJ	O	O	4397
with	ADP	O	O	4397
the	PRON	O	O	4397
hypothesis	NOUN	O	O	4397
that	SCONJ	O	O	4397
chronic	ADJ	O	O	4397
cocaine	NOUN	O	Chemical	4397
use	VERB	O	O	4397
disrupts	VERB	O	O	4397
dopaminergic	ADJ	O	O	4397
function	NOUN	O	O	4397
and	CCONJ	O	O	4397
,	PUNCT	O	O	4397
when	SCONJ	O	O	4397
coupled	VERB	O	O	4397
with	ADP	O	O	4397
recent	ADJ	O	O	4397
cocaine	NOUN	O	Chemical	4397
use	VERB	O	O	4397
,	PUNCT	O	O	4397
may	AUX	O	O	4397
precipitate	VERB	O	O	4397
agitation	NOUN	O	Disease	4397
,	PUNCT	O	O	4397
delirium	NOUN	O	Disease	4397
,	PUNCT	O	O	4397
aberrant	ADJ	O	O	4397
thermoregulation	NOUN	O	O	4397
,	PUNCT	O	O	4397
rhabdomyolysis	NOUN	O	Disease	4397
,	PUNCT	O	O	4397
and	CCONJ	O	O	4397
sudden death	NOUN	O	Disease	4397
.	PUNCT	O	O	4397
Heparin	PROPN	O	Chemical	4400
-	PUNCT	O	O	4400
induced	VERB	O	O	4400
thrombocytopenia	PROPN	O	Disease	4400
,	PUNCT	O	O	4400
thrombosis	NOUN	O	Disease	4400
,	PUNCT	O	O	4400
and	CCONJ	O	O	4400
hemorrhage	NOUN	O	Disease	4400
.	PUNCT	O	O	4400
Sixty	NUM	O	O	4401
-	PUNCT	O	O	4401
two	NUM	O	O	4401
patients	NOUN	O	O	4401
with	ADP	O	O	4401
a	PRON	O	O	4401
heparin	NOUN	O	Chemical	4401
-	PUNCT	O	O	4401
induced	VERB	O	O	4401
thrombocytopenia	PROPN	O	Disease	4401
are	AUX	O	O	4401
reported	VERB	O	O	4401
.	PUNCT	O	O	4401
Clinical	NOUN	O	O	4402
manifestations	NOUN	O	O	4402
of	ADP	O	O	4402
this	PRON	O	O	4402
disorder	NOUN	O	O	4402
include	VERB	O	O	4402
hemorrhage	NOUN	O	Disease	4402
or	CCONJ	O	O	4402
,	PUNCT	O	O	4402
more	ADJ	O	O	4402
frequently	ADV	O	O	4402
,	PUNCT	O	O	4402
thromboembolic	PROPN	O	Disease	4402
events	NOUN	O	O	4402
in	ADP	O	O	4402
patients	NOUN	O	O	4402
receiving	VERB	O	O	4402
heparin	NOUN	O	Chemical	4402
.	PUNCT	O	O	4402
Laboratory	NOUN	O	O	4403
testing	NOUN	O	O	4403
has	VERB	O	O	4403
revealed	VERB	O	O	4403
a falling platelet count	NOUN	O	Disease	4403
,	PUNCT	O	O	4403
increased	VERB	O	O	4403
resistance	NOUN	O	O	4403
to	PART	O	O	4403
heparin	NOUN	O	Chemical	4403
,	PUNCT	O	O	4403
and	CCONJ	O	O	4403
aggregation	NOUN	O	O	4403
of	ADP	O	O	4403
platelets	VERB	O	O	4403
by	ADP	O	O	4403
the	PRON	O	O	4403
patient	NOUN	O	O	4403
's	AUX	O	O	4403
plasma	NOUN	O	O	4403
when	SCONJ	O	O	4403
heparin	NOUN	O	Chemical	4403
is	AUX	O	O	4403
added	VERB	O	O	4403
.	PUNCT	O	O	4403
Immunologic	PROPN	O	O	4404
testing	NOUN	O	O	4404
has	VERB	O	O	4404
demonstrated	VERB	O	O	4404
the	PRON	O	O	4404
presence	NOUN	O	O	4404
of	ADP	O	O	4404
a	PRON	O	O	4404
heparin	NOUN	O	Chemical	4404
-	PUNCT	O	O	4404
dependent	ADJ	O	O	4404
platelet	NOUN	O	O	4404
membrane	NOUN	O	O	4404
antibody	NOUN	O	O	4404
.	PUNCT	O	O	4404
The	PRON	O	O	4405
20	NUM	O	O	4405
deaths	NOUN	O	O	4405
,	PUNCT	O	O	4405
52	NUM	O	O	4405
hemorrhagic	ADJ	O	Disease	4405
and	CCONJ	O	O	4405
thromboembolic complications	NOUN	O	Disease	4405
,	PUNCT	O	O	4405
and	CCONJ	O	O	4405
21	NUM	O	O	4405
surgical	ADJ	O	O	4405
procedures	NOUN	O	O	4405
to	PART	O	O	4405
manage	VERB	O	O	4405
the	PRON	O	O	4405
complications	NOUN	O	O	4405
confirm	VERB	O	O	4405
the	PRON	O	O	4405
seriousness	VERB	O	O	4405
of	ADP	O	O	4405
the	PRON	O	O	4405
disorder	NOUN	O	O	4405
.	PUNCT	O	O	4405
Specific	ADJ	O	O	4406
risk	NOUN	O	O	4406
factors	NOUN	O	O	4406
have	VERB	O	O	4406
not	PART	O	O	4406
been	AUX	O	O	4406
identified	VERB	O	O	4406
;	PUNCT	O	O	4406
therefore	ADV	O	O	4406
,	PUNCT	O	O	4406
all	PRON	O	O	4406
patients	NOUN	O	O	4406
receiving	VERB	O	O	4406
heparin	NOUN	O	Chemical	4406
should	AUX	O	O	4406
be	AUX	O	O	4406
monitored	VERB	O	O	4406
.	PUNCT	O	O	4406
If	SCONJ	O	O	4407
the	PRON	O	O	4407
platelet	NOUN	O	O	4407
count	VERB	O	O	4407
falls	VERB	O	O	4407
to	PART	O	O	4407
less	ADV	O	O	4407
than	ADP	O	O	4407
100,000/mm3	NOUN	O	O	4407
,	PUNCT	O	O	4407
while	SCONJ	O	O	4407
the	PRON	O	O	4407
patient	NOUN	O	O	4407
is	AUX	O	O	4407
receiving	VERB	O	O	4407
heparin	NOUN	O	Chemical	4407
,	PUNCT	O	O	4407
platelet aggregation	NOUN	O	Disease	4407
testing	NOUN	O	O	4407
,	PUNCT	O	O	4407
using	VERB	O	O	4407
the	PRON	O	O	4407
patient	NOUN	O	O	4407
's	AUX	O	O	4407
plasma	NOUN	O	O	4407
,	PUNCT	O	O	4407
is	AUX	O	O	4407
indicated	VERB	O	O	4407
.	PUNCT	O	O	4407
Management	NOUN	O	O	4408
consists	VERB	O	O	4408
of	ADP	O	O	4408
cessation	NOUN	O	O	4408
of	ADP	O	O	4408
heparin	NOUN	O	Chemical	4408
,	PUNCT	O	O	4408
platelet	NOUN	O	O	4408
anti	ADJ	O	O	4408
-	PUNCT	O	O	4408
aggregating	VERB	O	O	4408
agents	NOUN	O	O	4408
,	PUNCT	O	O	4408
and	CCONJ	O	O	4408
alternate	ADJ	O	O	4408
forms	NOUN	O	O	4408
of	ADP	O	O	4408
anticoagulation	NOUN	O	O	4408
when	SCONJ	O	O	4408
indicated	VERB	O	O	4408
.	PUNCT	O	O	4408
Cardiac toxicity	NOUN	O	Disease	4411
of	ADP	O	O	4411
5-fluorouracil	NOUN	O	Chemical	4411
.	PUNCT	O	O	4411
Report	NOUN	O	O	4412
of	ADP	O	O	4412
a	PRON	O	O	4412
case	NOUN	O	O	4412
of	ADP	O	O	4412
spontaneous	ADJ	O	O	4412
angina	NOUN	O	Disease	4412
.	PUNCT	O	O	4412
We	PRON	O	O	4413
report	VERB	O	O	4413
a	PRON	O	O	4413
case	NOUN	O	O	4413
of	ADP	O	O	4413
a	PRON	O	O	4413
patient	NOUN	O	O	4413
with	ADP	O	O	4413
colon carcinoma	NOUN	O	Disease	4413
and	CCONJ	O	O	4413
liver	NOUN	O	O	4413
metastasis	NOUN	O	Disease	4413
who	PRON	O	O	4413
presented	VERB	O	O	4413
chest pain	NOUN	O	Disease	4413
after	ADP	O	O	4413
5-fluorouracil	NOUN	O	Chemical	4413
(	PUNCT	O	O	4413
5-FU	NOUN	O	Chemical	4413
)	PUNCT	O	O	4413
administration	NOUN	O	O	4413
.	PUNCT	O	O	4413
Clinical	NOUN	O	O	4414
electrocardiographic	NOUN	O	O	4414
evolution	NOUN	O	O	4414
was	AUX	O	O	4414
similar	ADJ	O	O	4414
to	PART	O	O	4414
that	SCONJ	O	O	4414
observed	VERB	O	O	4414
in	ADP	O	O	4414
Prinzmetal	PROPN	O	O	4414
's	AUX	O	O	4414
angina	NOUN	O	Disease	4414
,	PUNCT	O	O	4414
and	CCONJ	O	O	4414
chest pain	NOUN	O	Disease	4414
promptly	ADV	O	O	4414
resolved	VERB	O	O	4414
with	ADP	O	O	4414
nifedipine	PROPN	O	Chemical	4414
.	PUNCT	O	O	4414
These	PRON	O	O	4415
data	NOUN	O	O	4415
suggest	VERB	O	O	4415
that	SCONJ	O	O	4415
coronary spasm	NOUN	O	Disease	4415
may	AUX	O	O	4415
be	AUX	O	O	4415
the	PRON	O	O	4415
cause	VERB	O	O	4415
of	ADP	O	O	4415
cardiotoxicity	NOUN	O	Disease	4415
due	ADJ	O	O	4415
to	PART	O	O	4415
5-FU	NOUN	O	Chemical	4415
,	PUNCT	O	O	4415
and	CCONJ	O	O	4415
that	SCONJ	O	O	4415
calcium	NOUN	O	Chemical	4415
antagonists	NOUN	O	O	4415
may	AUX	O	O	4415
probably	ADV	O	O	4415
be	AUX	O	O	4415
used	VERB	O	O	4415
in	ADP	O	O	4415
the	PRON	O	O	4415
prevention	NOUN	O	O	4415
or	CCONJ	O	O	4415
treatment	NOUN	O	O	4415
of	ADP	O	O	4415
5-FU	NOUN	O	Chemical	4415
cardiotoxicity	NOUN	O	Disease	4415
.	PUNCT	O	O	4415
Toxicity	NOUN	O	Disease	4418
due	ADJ	O	O	4418
to	PART	O	O	4418
remission	NOUN	O	O	4418
inducing	VERB	O	O	4418
drugs	NOUN	O	O	4418
in	ADP	O	O	4418
rheumatoid arthritis	NOUN	O	Disease	4418
.	PUNCT	O	O	4418
Twenty	NUM	O	O	4419
-	PUNCT	O	O	4419
five	NUM	O	O	4419
patients	NOUN	O	O	4419
with	ADP	O	O	4419
rheumatoid arthritis	NOUN	O	Disease	4419
(	PUNCT	O	O	4419
RA	PROPN	O	Disease	4419
)	PUNCT	O	O	4419
who	PRON	O	O	4419
developed	VERB	O	O	4419
toxicity	NOUN	O	Disease	4419
while	SCONJ	O	O	4419
taking	VERB	O	O	4419
remission	NOUN	O	O	4419
inducing	VERB	O	O	4419
drugs	NOUN	O	O	4419
and	CCONJ	O	O	4419
30	NUM	O	O	4419
without	ADP	O	O	4419
toxicity	NOUN	O	Disease	4419
were	AUX	O	O	4419
studied	VERB	O	O	4419
for	ADP	O	O	4419
possible	ADJ	O	O	4419
associations	NOUN	O	O	4419
with	ADP	O	O	4419
class	NOUN	O	O	4419
I	PRON	O	O	4419
and	CCONJ	O	O	4419
II	NUM	O	O	4419
HLA	PROPN	O	O	4419
antigens	NOUN	O	O	4419
.	PUNCT	O	O	4419
A	PRON	O	O	4420
strong	ADJ	O	O	4420
association	PROPN	O	O	4420
has	VERB	O	O	4420
been	AUX	O	O	4420
found	VERB	O	O	4420
between	ADP	O	O	4420
nephritis	NOUN	O	Disease	4420
and	CCONJ	O	O	4420
dermatitis	NOUN	O	Disease	4420
due	ADJ	O	O	4420
to	PART	O	O	4420
Tiopronin	PROPN	O	Chemical	4420
(	PUNCT	O	O	4420
a	PRON	O	O	4420
D	NOUN	O	O	4420
-	PUNCT	O	O	4420
Penicillamine	NOUN	O	Chemical	4420
like	INTJ	O	O	4420
compound	NOUN	O	O	4420
)	PUNCT	O	O	4420
and	CCONJ	O	O	4420
class	NOUN	O	O	4420
I	PRON	O	O	4420
antigens	NOUN	O	O	4420
B35-Cw4	NOUN	O	O	4420
,	PUNCT	O	O	4420
and	CCONJ	O	O	4420
between	ADP	O	O	4420
dermatitis	NOUN	O	Disease	4420
due	ADJ	O	O	4420
to	PART	O	O	4420
gold	NOUN	O	Chemical	4420
thiosulphate	NOUN	O	Chemical	4420
and	CCONJ	O	O	4420
B35	PROPN	O	O	4420
.	PUNCT	O	O	4420
Compared	VERB	O	O	4421
to	PART	O	O	4421
healthy	ADJ	O	O	4421
controls	VERB	O	O	4421
a	PRON	O	O	4421
lower	ADJ	O	O	4421
DR5	NOUN	O	O	4421
frequency	NOUN	O	O	4421
was	AUX	O	O	4421
observed	VERB	O	O	4421
in	ADP	O	O	4421
patients	NOUN	O	O	4421
with	ADP	O	O	4421
RA	PROPN	O	Disease	4421
except	SCONJ	O	O	4421
for	ADP	O	O	4421
the	PRON	O	O	4421
Tiopronin	PROPN	O	Chemical	4421
related	ADJ	O	O	4421
nephritis	NOUN	O	Disease	4421
group	NOUN	O	O	4421
.	PUNCT	O	O	4421
Transient	ADJ	O	O	4424
hemiparesis	PROPN	O	Disease	4424
:	PUNCT	O	O	4424
a	PRON	O	O	4424
rare	ADJ	O	O	4424
manifestation	NOUN	O	O	4424
of	ADP	O	O	4424
diphenylhydantoin	ADJ	O	Chemical	4424
toxicity	NOUN	O	Disease	4424
.	PUNCT	O	O	4424
Among	ADP	O	O	4425
the	PRON	O	O	4425
common	ADJ	O	O	4425
side	NOUN	O	O	4425
effects	NOUN	O	O	4425
of	ADP	O	O	4425
diphenylhydantoin	ADJ	O	Chemical	4425
(	PUNCT	O	O	4425
DPH	PROPN	O	Chemical	4425
)	PUNCT	O	O	4425
overdose	NOUN	O	Disease	4425
,	PUNCT	O	O	4425
the	PRON	O	O	4425
most	ADV	O	O	4425
frequently	ADV	O	O	4425
encountered	VERB	O	O	4425
neurological	ADJ	O	O	4425
signs	NOUN	O	O	4425
are	AUX	O	O	4425
those	PRON	O	O	4425
of	ADP	O	O	4425
cerebellar dysfunction	NOUN	O	Disease	4425
.	PUNCT	O	O	4425
Two	NUM	O	O	4426
patients	NOUN	O	O	4426
are	AUX	O	O	4426
presented	VERB	O	O	4426
who	PRON	O	O	4426
suffered	VERB	O	O	4426
progressive	ADJ	O	O	4426
hemiparesis	PROPN	O	Disease	4426
due	ADJ	O	O	4426
to	PART	O	O	4426
DPH	PROPN	O	Chemical	4426
overdose	NOUN	O	Disease	4426
.	PUNCT	O	O	4426
Both	PRON	O	O	4427
had	VERB	O	O	4427
brain	NOUN	O	O	4427
surgery	NOUN	O	O	4427
before	ADP	O	O	4427
DPH	PROPN	O	Chemical	4427
treatment	NOUN	O	O	4427
.	PUNCT	O	O	4427
It	PRON	O	O	4428
is	AUX	O	O	4428
assumed	VERB	O	O	4428
that	SCONJ	O	O	4428
patients	NOUN	O	O	4428
with	ADP	O	O	4428
some	PRON	O	O	4428
cerebral damage	NOUN	O	Disease	4428
are	AUX	O	O	4428
liable	ADJ	O	O	4428
to	PART	O	O	4428
manifest	VERB	O	O	4428
DPH	PROPN	O	Chemical	4428
toxicity	NOUN	O	Disease	4428
as	ADP	O	O	4428
focal	ADJ	O	O	4428
neurological	ADJ	O	O	4428
signs	NOUN	O	O	4428
.	PUNCT	O	O	4428
Nerve	NOUN	O	O	4431
growth	NOUN	O	O	4431
factor	NOUN	O	O	4431
and	CCONJ	O	O	4431
prostaglandins	NOUN	O	Chemical	4431
in	ADP	O	O	4431
the	PRON	O	O	4431
urine	NOUN	O	O	4431
of	ADP	O	O	4431
female	ADJ	O	O	4431
patients	NOUN	O	O	4431
with	ADP	O	O	4431
overactive bladder	NOUN	O	Disease	4431
.	PUNCT	O	O	4431
NGF	PROPN	O	O	4432
and	CCONJ	O	O	4432
PGs	NOUN	O	Chemical	4432
in	ADP	O	O	4432
the	PRON	O	O	4432
bladder	NOUN	O	O	4432
can	AUX	O	O	4432
be	AUX	O	O	4432
affected	VERB	O	O	4432
by	ADP	O	O	4432
pathological	ADJ	O	O	4432
changes	VERB	O	O	4432
in	ADP	O	O	4432
the	PRON	O	O	4432
bladder	NOUN	O	O	4432
and	CCONJ	O	O	4432
these	PRON	O	O	4432
changes	VERB	O	O	4432
can	AUX	O	O	4432
be	AUX	O	O	4432
detected	VERB	O	O	4432
in	ADP	O	O	4432
urine	NOUN	O	O	4432
.	PUNCT	O	O	4432
We	PRON	O	O	4433
investigated	VERB	O	O	4433
changes	VERB	O	O	4433
in	ADP	O	O	4433
urinary	ADJ	O	O	4433
NGF	PROPN	O	O	4433
and	CCONJ	O	O	4433
PGs	NOUN	O	Chemical	4433
in	ADP	O	O	4433
women	NOUN	O	O	4433
with	ADP	O	O	4433
OAB	PROPN	O	Disease	4433
.	PUNCT	O	O	4433
The	PRON	O	O	4434
study	VERB	O	O	4434
groups	NOUN	O	O	4434
included	VERB	O	O	4434
65	NUM	O	O	4434
women	NOUN	O	O	4434
with	ADP	O	O	4434
OAB	PROPN	O	Disease	4434
and	CCONJ	O	O	4434
20	NUM	O	O	4434
without	ADP	O	O	4434
bladder	NOUN	O	O	4434
symptoms	NOUN	O	O	4434
who	PRON	O	O	4434
served	VERB	O	O	4434
as	ADP	O	O	4434
controls	VERB	O	O	4434
.	PUNCT	O	O	4434
NGF	PROPN	O	O	4435
,	PUNCT	O	O	4435
PGE2	NOUN	O	Chemical	4435
,	PUNCT	O	O	4435
PGF2alpha	PROPN	O	Chemical	4435
and	CCONJ	O	O	4435
PGI2	PROPN	O	Chemical	4435
were	AUX	O	O	4435
measured	VERB	O	O	4435
using	VERB	O	O	4435
enzyme	NOUN	O	O	4435
-	PUNCT	O	O	4435
linked	VERB	O	O	4435
immunosorbent	NOUN	O	O	4435
assay	NOUN	O	O	4435
and	CCONJ	O	O	4435
compared	VERB	O	O	4435
between	ADP	O	O	4435
the	PRON	O	O	4435
groups	NOUN	O	O	4435
.	PUNCT	O	O	4435
In	ADP	O	O	4436
addition	NOUN	O	O	4436
,	PUNCT	O	O	4436
correlations	NOUN	O	O	4436
between	ADP	O	O	4436
urinary	ADJ	O	O	4436
NGF	PROPN	O	O	4436
and	CCONJ	O	O	4436
PG	PROPN	O	Chemical	4436
,	PUNCT	O	O	4436
and	CCONJ	O	O	4436
urodynamic	ADJ	O	O	4436
parameters	NOUN	O	O	4436
in	ADP	O	O	4436
patients	NOUN	O	O	4436
with	ADP	O	O	4436
OAB	PROPN	O	Disease	4436
were	AUX	O	O	4436
examined	VERB	O	O	4436
.	PUNCT	O	O	4436
Urinary	NOUN	O	O	4437
NGF	PROPN	O	O	4437
,	PUNCT	O	O	4437
PGE2	NOUN	O	Chemical	4437
and	CCONJ	O	O	4437
PGF2alpha	PROPN	O	Chemical	4437
were	AUX	O	O	4437
significantly	ADV	O	O	4437
increased	VERB	O	O	4437
in	ADP	O	O	4437
patients	NOUN	O	O	4437
with	ADP	O	O	4437
OAB	PROPN	O	Disease	4437
compared	VERB	O	O	4437
with	ADP	O	O	4437
controls	VERB	O	O	4437
(	PUNCT	O	O	4437
p	NOUN	O	O	4437
<	X	O	O	4437
0.05	NUM	O	O	4437
)	PUNCT	O	O	4437
.	PUNCT	O	O	4437
However	ADV	O	O	4438
,	PUNCT	O	O	4438
urinary	ADJ	O	O	4438
PGI2	PROPN	O	Chemical	4438
was	AUX	O	O	4438
not	PART	O	O	4438
different	ADJ	O	O	4438
between	ADP	O	O	4438
controls	VERB	O	O	4438
and	CCONJ	O	O	4438
patients	NOUN	O	O	4438
with	ADP	O	O	4438
OAB	PROPN	O	Disease	4438
.	PUNCT	O	O	4438
In	ADP	O	O	4439
patients	NOUN	O	O	4439
with	ADP	O	O	4439
OAB	PROPN	O	Disease	4439
urinary	ADJ	O	O	4439
PGE2	NOUN	O	Chemical	4439
positively	ADV	O	O	4439
correlated	VERB	O	O	4439
with	ADP	O	O	4439
volume	PROPN	O	O	4439
at	ADP	O	O	4439
first	ADV	O	O	4439
desire	VERB	O	O	4439
to	PART	O	O	4439
void	VERB	O	O	4439
and	CCONJ	O	O	4439
maximum	ADV	O	O	4439
cystometric	PROPN	O	O	4439
capacity	NOUN	O	O	4439
(	PUNCT	O	O	4439
p	NOUN	O	O	4439
<	X	O	O	4439
0.05	NUM	O	O	4439
)	PUNCT	O	O	4439
.	PUNCT	O	O	4439
Urinary	NOUN	O	O	4440
NGF	PROPN	O	O	4440
,	PUNCT	O	O	4440
PGF2alpha	PROPN	O	Chemical	4440
and	CCONJ	O	O	4440
PGI2	PROPN	O	Chemical	4440
did	VERB	O	O	4440
not	PART	O	O	4440
correlate	VERB	O	O	4440
with	ADP	O	O	4440
urodynamic	ADJ	O	O	4440
parameters	NOUN	O	O	4440
in	ADP	O	O	4440
patients	NOUN	O	O	4440
with	ADP	O	O	4440
OAB	PROPN	O	Disease	4440
.	PUNCT	O	O	4440
NGF	PROPN	O	O	4441
and	CCONJ	O	O	4441
PGs	NOUN	O	Chemical	4441
have	VERB	O	O	4441
important	ADJ	O	O	4441
roles	NOUN	O	O	4441
in	ADP	O	O	4441
the	PRON	O	O	4441
development	NOUN	O	O	4441
of	ADP	O	O	4441
OAB	PROPN	O	Disease	4441
symptoms	NOUN	O	O	4441
in	ADP	O	O	4441
female	ADJ	O	O	4441
patients	NOUN	O	O	4441
.	PUNCT	O	O	4441
Urinary	NOUN	O	O	4442
levels	NOUN	O	O	4442
of	ADP	O	O	4442
these	PRON	O	O	4442
factors	NOUN	O	O	4442
may	AUX	O	O	4442
be	AUX	O	O	4442
used	VERB	O	O	4442
as	ADP	O	O	4442
markers	NOUN	O	O	4442
to	PART	O	O	4442
evaluate	VERB	O	O	4442
OAB	PROPN	O	Disease	4442
symptoms	NOUN	O	O	4442
.	PUNCT	O	O	4442
Acute	PROPN	O	O	4445
low back pain	NOUN	O	Disease	4445
during	ADP	O	O	4445
intravenous	ADJ	O	O	4445
administration	NOUN	O	O	4445
of	ADP	O	O	4445
amiodarone	NOUN	O	Chemical	4445
:	PUNCT	O	O	4445
a	PRON	O	O	4445
report	VERB	O	O	4445
of	ADP	O	O	4445
two	NUM	O	O	4445
cases	NOUN	O	O	4445
.	PUNCT	O	O	4445
Amiodarone	NOUN	O	Chemical	4446
represents	VERB	O	O	4446
an	PRON	O	O	4446
effective	ADJ	O	O	4446
antiarrhythmic	PROPN	O	O	4446
drug	NOUN	O	O	4446
for	ADP	O	O	4446
cardioversion	NOUN	O	O	4446
of	ADP	O	O	4446
recent	ADJ	O	O	4446
-	PUNCT	O	O	4446
onset	VERB	O	O	4446
atrial fibrillation	NOUN	O	Disease	4446
(	PUNCT	O	O	4446
AF	PROPN	O	Disease	4446
)	PUNCT	O	O	4446
and	CCONJ	O	O	4446
maintenance	NOUN	O	O	4446
of	ADP	O	O	4446
sinus	NOUN	O	O	4446
rhythm	VERB	O	O	4446
.	PUNCT	O	O	4446
We	PRON	O	O	4447
briefly	ADV	O	O	4447
describe	VERB	O	O	4447
two	NUM	O	O	4447
patients	NOUN	O	O	4447
suffering	VERB	O	O	4447
from	ADP	O	O	4447
recent	ADJ	O	O	4447
-	PUNCT	O	O	4447
onset	VERB	O	O	4447
atrial fibrillation	NOUN	O	Disease	4447
,	PUNCT	O	O	4447
who	PRON	O	O	4447
experienced	ADJ	O	O	4447
an	PRON	O	O	4447
acute	ADJ	O	O	4447
devastating	ADJ	O	O	4447
low back pain	NOUN	O	Disease	4447
a	PRON	O	O	4447
few	ADJ	O	O	4447
minutes	NOUN	O	O	4447
after	ADP	O	O	4447
initiation	NOUN	O	O	4447
of	ADP	O	O	4447
intravenous	ADJ	O	O	4447
amiodarone	NOUN	O	Chemical	4447
loading	NOUN	O	O	4447
.	PUNCT	O	O	4447
Postoperative myalgia	NOUN	O	Disease	4450
after	ADP	O	O	4450
succinylcholine	NOUN	O	Chemical	4450
:	PUNCT	O	O	4450
no	PRON	O	O	4450
evidence	NOUN	O	O	4450
for	ADP	O	O	4450
an	PRON	O	O	4450
inflammatory	ADJ	O	O	4450
origin	NOUN	O	O	4450
.	PUNCT	O	O	4450
A	PRON	O	O	4451
common	ADJ	O	O	4451
side	NOUN	O	O	4451
effect	VERB	O	O	4451
associated	VERB	O	O	4451
with	ADP	O	O	4451
succinylcholine	NOUN	O	Chemical	4451
is	AUX	O	O	4451
postoperative myalgia	NOUN	O	Disease	4451
.	PUNCT	O	O	4451
The	PRON	O	O	4452
pathogenesis	NOUN	O	O	4452
of	ADP	O	O	4452
this	PRON	O	O	4452
myalgia	NOUN	O	Disease	4452
is	AUX	O	O	4452
still	ADV	O	O	4452
unclear	ADJ	O	O	4452
;	PUNCT	O	O	4452
inflammation	NOUN	O	Disease	4452
has	VERB	O	O	4452
been	AUX	O	O	4452
suggested	VERB	O	O	4452
but	CCONJ	O	O	4452
without	ADP	O	O	4452
convincing	ADJ	O	O	4452
evidence	NOUN	O	O	4452
.	PUNCT	O	O	4452
We	PRON	O	O	4453
designed	VERB	O	O	4453
the	PRON	O	O	4453
present	NOUN	O	O	4453
study	VERB	O	O	4453
to	PART	O	O	4453
investigate	VERB	O	O	4453
whether	SCONJ	O	O	4453
an	PRON	O	O	4453
inflammatory	ADJ	O	O	4453
reaction	NOUN	O	O	4453
contributes	VERB	O	O	4453
to	PART	O	O	4453
this	PRON	O	O	4453
myalgia	NOUN	O	Disease	4453
.	PUNCT	O	O	4453
The	PRON	O	O	4454
incidence	NOUN	O	O	4454
and	CCONJ	O	O	4454
severity	NOUN	O	O	4454
of	ADP	O	O	4454
succinylcholine	NOUN	O	Chemical	4454
-	PUNCT	O	O	4454
associated	VERB	O	O	4454
myalgia	NOUN	O	Disease	4454
was	AUX	O	O	4454
determined	VERB	O	O	4454
in	ADP	O	O	4454
64	NUM	O	O	4454
patients	NOUN	O	O	4454
pretreated	VERB	O	O	4454
with	ADP	O	O	4454
saline	NOUN	O	O	4454
or	CCONJ	O	O	4454
dexamethasone	NOUN	O	Chemical	4454
before	ADP	O	O	4454
succinylcholine	NOUN	O	Chemical	4454
(	PUNCT	O	O	4454
n	CCONJ	O	O	4454
=	PUNCT	O	O	4454
32	NUM	O	O	4454
for	ADP	O	O	4454
each	PRON	O	O	4454
)	PUNCT	O	O	4454
.	PUNCT	O	O	4454
Incidence	NOUN	O	O	4455
and	CCONJ	O	O	4455
severity	NOUN	O	O	4455
of	ADP	O	O	4455
myalgia	NOUN	O	Disease	4455
did	VERB	O	O	4455
not	PART	O	O	4455
differ	VERB	O	O	4455
significantly	ADV	O	O	4455
between	ADP	O	O	4455
the	PRON	O	O	4455
two	NUM	O	O	4455
groups	NOUN	O	O	4455
:	PUNCT	O	O	4455
15	NUM	O	O	4455
patients	NOUN	O	O	4455
in	ADP	O	O	4455
the	PRON	O	O	4455
dexamethasone	NOUN	O	Chemical	4455
group	NOUN	O	O	4455
complained	VERB	O	O	4455
of	ADP	O	O	4455
myalgia	NOUN	O	Disease	4455
compared	VERB	O	O	4455
with	ADP	O	O	4455
18	NUM	O	O	4455
patients	NOUN	O	O	4455
in	ADP	O	O	4455
the	PRON	O	O	4455
saline	NOUN	O	O	4455
group	NOUN	O	O	4455
,	PUNCT	O	O	4455
and	CCONJ	O	O	4455
severe	ADJ	O	O	4455
myalgia	NOUN	O	Disease	4455
was	AUX	O	O	4455
reported	VERB	O	O	4455
by	ADP	O	O	4455
five	NUM	O	O	4455
patients	NOUN	O	O	4455
and	CCONJ	O	O	4455
three	NUM	O	O	4455
patients	NOUN	O	O	4455
,	PUNCT	O	O	4455
respectively	ADV	O	O	4455
(	PUNCT	O	O	4455
not	PART	O	O	4455
significant	ADJ	O	O	4455
)	PUNCT	O	O	4455
.	PUNCT	O	O	4455
At	ADP	O	O	4456
48	NUM	O	O	4456
h	X	O	O	4456
after	ADP	O	O	4456
surgery	NOUN	O	O	4456
,	PUNCT	O	O	4456
12	NUM	O	O	4456
patients	NOUN	O	O	4456
in	ADP	O	O	4456
both	PRON	O	O	4456
groups	NOUN	O	O	4456
still	ADV	O	O	4456
suffered	VERB	O	O	4456
from	ADP	O	O	4456
myalgia	NOUN	O	Disease	4456
(	PUNCT	O	O	4456
not	PART	O	O	4456
significant	ADJ	O	O	4456
)	PUNCT	O	O	4456
.	PUNCT	O	O	4456
In	ADP	O	O	4457
addition	NOUN	O	O	4457
,	PUNCT	O	O	4457
interleukin-6	NUM	O	O	4457
(	PUNCT	O	O	4457
IL-6	NUM	O	O	4457
)	PUNCT	O	O	4457
as	ADP	O	O	4457
an	PRON	O	O	4457
early	ADV	O	O	4457
marker	NOUN	O	O	4457
of	ADP	O	O	4457
inflammation	NOUN	O	Disease	4457
was	AUX	O	O	4457
assessed	VERB	O	O	4457
in	ADP	O	O	4457
a	PRON	O	O	4457
subgroup	PROPN	O	O	4457
of	ADP	O	O	4457
10	NUM	O	O	4457
patients	NOUN	O	O	4457
pretreated	VERB	O	O	4457
with	ADP	O	O	4457
saline	NOUN	O	O	4457
.	PUNCT	O	O	4457
We	PRON	O	O	4458
found	VERB	O	O	4458
an	PRON	O	O	4458
increase	VERB	O	O	4458
of	ADP	O	O	4458
IL-6	NUM	O	O	4458
for	ADP	O	O	4458
only	ADV	O	O	4458
three	NUM	O	O	4458
patients	NOUN	O	O	4458
,	PUNCT	O	O	4458
but	CCONJ	O	O	4458
only	ADV	O	O	4458
one	NUM	O	O	4458
patient	NOUN	O	O	4458
reported	VERB	O	O	4458
myalgia	NOUN	O	Disease	4458
;	PUNCT	O	O	4458
no	PRON	O	O	4458
relationship	NOUN	O	O	4458
between	ADP	O	O	4458
myalgia	NOUN	O	Disease	4458
and	CCONJ	O	O	4458
the	PRON	O	O	4458
increase	VERB	O	O	4458
of	ADP	O	O	4458
IL-6	NUM	O	O	4458
was	AUX	O	O	4458
found	VERB	O	O	4458
.	PUNCT	O	O	4458
In	ADP	O	O	4459
conclusion	NOUN	O	O	4459
,	PUNCT	O	O	4459
there	ADV	O	O	4459
is	AUX	O	O	4459
no	PRON	O	O	4459
evidence	NOUN	O	O	4459
for	ADP	O	O	4459
an	PRON	O	O	4459
inflammatory	ADJ	O	O	4459
origin	NOUN	O	O	4459
of	ADP	O	O	4459
succinylcholine	NOUN	O	Chemical	4459
-	PUNCT	O	O	4459
associated	VERB	O	O	4459
myalgia	NOUN	O	Disease	4459
.	PUNCT	O	O	4459
Administration	NOUN	O	O	4460
of	ADP	O	O	4460
dexamethasone	NOUN	O	Chemical	4460
before	ADP	O	O	4460
succinylcholine	NOUN	O	Chemical	4460
was	AUX	O	O	4460
not	PART	O	O	4460
effective	ADJ	O	O	4460
in	ADP	O	O	4460
decreasing	VERB	O	O	4460
the	PRON	O	O	4460
incidence	NOUN	O	O	4460
or	CCONJ	O	O	4460
the	PRON	O	O	4460
severity	NOUN	O	O	4460
of	ADP	O	O	4460
succinylcholine	NOUN	O	Chemical	4460
-	PUNCT	O	O	4460
induced	VERB	O	O	4460
postoperative myalgia	NOUN	O	Disease	4460
.	PUNCT	O	O	4460
Furthermore	ADV	O	O	4461
,	PUNCT	O	O	4461
there	ADV	O	O	4461
was	AUX	O	O	4461
no	PRON	O	O	4461
significant	ADJ	O	O	4461
relationship	NOUN	O	O	4461
between	ADP	O	O	4461
postoperative myalgia	NOUN	O	Disease	4461
and	CCONJ	O	O	4461
time	NOUN	O	O	4461
course	NOUN	O	O	4461
of	ADP	O	O	4461
interleukin-6	NUM	O	O	4461
concentrations	NOUN	O	O	4461
,	PUNCT	O	O	4461
a	PRON	O	O	4461
marker	NOUN	O	O	4461
of	ADP	O	O	4461
inflammation	NOUN	O	Disease	4461
.	PUNCT	O	O	4461
Pretreatment	NOUN	O	O	4462
with	ADP	O	O	4462
dexamethasone	NOUN	O	Chemical	4462
is	AUX	O	O	4462
not	PART	O	O	4462
justified	VERB	O	O	4462
to	PART	O	O	4462
prevent	VERB	O	O	4462
postoperative myalgia	NOUN	O	Disease	4462
after	ADP	O	O	4462
succinylcholine	NOUN	O	Chemical	4462
.	PUNCT	O	O	4462
Levodopa	NOUN	O	Chemical	4465
-	PUNCT	O	O	4465
induced	VERB	O	O	4465
oromandibular	NOUN	O	O	4465
dystonia	NOUN	O	Disease	4465
in	ADP	O	O	4465
progressive supranuclear palsy	PROPN	O	Disease	4465
.	PUNCT	O	O	4465
Levodopa	NOUN	O	Chemical	4466
-	PUNCT	O	O	4466
induced	VERB	O	O	4466
dyskinesias	PROPN	O	Disease	4466
have	VERB	O	O	4466
been	AUX	O	O	4466
reported	VERB	O	O	4466
in	ADP	O	O	4466
Parkinson	NOUN	O	O	4466
's	AUX	O	O	4466
disease	PROPN	O	O	4466
and	CCONJ	O	O	4466
multiple system atrophy	NOUN	O	Disease	4466
.	PUNCT	O	O	4466
Cranial	ADJ	O	O	4467
dystonias	PROPN	O	Disease	4467
are	AUX	O	O	4467
rare	ADJ	O	O	4467
in	ADP	O	O	4467
patients	NOUN	O	O	4467
with	ADP	O	O	4467
progressive supranuclear palsy	PROPN	O	Disease	4467
(	PUNCT	O	O	4467
PSP	PROPN	O	Disease	4467
)	PUNCT	O	O	4467
.	PUNCT	O	O	4467
In	ADP	O	O	4468
this	PRON	O	O	4468
report	VERB	O	O	4468
we	PRON	O	O	4468
describe	VERB	O	O	4468
an	PRON	O	O	4468
unusual	ADJ	O	O	4468
case	NOUN	O	O	4468
of	ADP	O	O	4468
reversible	ADJ	O	O	4468
levodopa	NOUN	O	Chemical	4468
-	PUNCT	O	O	4468
induced	VERB	O	O	4468
Oromandibular dystonia	NOUN	O	Disease	4468
(	PUNCT	O	O	4468
OMD	PROPN	O	Disease	4468
)	PUNCT	O	O	4468
in	ADP	O	O	4468
a	PRON	O	O	4468
PSP	PROPN	O	Disease	4468
patient	NOUN	O	O	4468
to	PART	O	O	4468
highlight	VERB	O	O	4468
the	PRON	O	O	4468
importance	NOUN	O	O	4468
of	ADP	O	O	4468
recognizing	VERB	O	O	4468
this	PRON	O	O	4468
drug	NOUN	O	O	4468
related	ADJ	O	O	4468
complication	NOUN	O	O	4468
in	ADP	O	O	4468
the	PRON	O	O	4468
management	NOUN	O	O	4468
of	ADP	O	O	4468
PSP	PROPN	O	Disease	4468
,	PUNCT	O	O	4468
and	CCONJ	O	O	4468
discuss	VERB	O	O	4468
the	PRON	O	O	4468
possible	ADJ	O	O	4468
underlying	VERB	O	O	4468
pathophysiology	NOUN	O	O	4468
.	PUNCT	O	O	4468
Protective	NOUN	O	O	4471
effect	VERB	O	O	4471
of	ADP	O	O	4471
edaravone	NOUN	O	Chemical	4471
against	ADP	O	O	4471
streptomycin	PROPN	O	Chemical	4471
-	PUNCT	O	O	4471
induced	VERB	O	O	4471
vestibulotoxicity	NOUN	O	Disease	4471
in	ADP	O	O	4471
the	PRON	O	O	4471
guinea	NOUN	O	O	4471
pig	NOUN	O	O	4471
.	PUNCT	O	O	4471
This	PRON	O	O	4472
study	VERB	O	O	4472
investigated	VERB	O	O	4472
alleviation	NOUN	O	O	4472
of	ADP	O	O	4472
streptomycin	PROPN	O	Chemical	4472
-	PUNCT	O	O	4472
induced	VERB	O	O	4472
vestibulotoxicity	NOUN	O	Disease	4472
by	ADP	O	O	4472
edaravone	NOUN	O	Chemical	4472
in	ADP	O	O	4472
guinea	NOUN	O	O	4472
pigs	NOUN	O	O	4472
.	PUNCT	O	O	4472
Edaravone	NOUN	O	Chemical	4473
,	PUNCT	O	O	4473
a	PRON	O	O	4473
free	ADJ	O	O	4473
radical	ADJ	O	O	4473
scavenger	NOUN	O	O	4473
,	PUNCT	O	O	4473
has	VERB	O	O	4473
potent	ADJ	O	O	4473
free	ADJ	O	O	4473
radical	ADJ	O	O	4473
quenching	VERB	O	O	4473
action	NOUN	O	O	4473
and	CCONJ	O	O	4473
is	AUX	O	O	4473
used	VERB	O	O	4473
in	ADP	O	O	4473
clinical	ADJ	O	O	4473
practice	VERB	O	O	4473
to	PART	O	O	4473
treat	VERB	O	O	4473
cerebral infarction	NOUN	O	Disease	4473
.	PUNCT	O	O	4473
Streptomycin	PROPN	O	Chemical	4474
was	AUX	O	O	4474
administered	VERB	O	O	4474
to	PART	O	O	4474
the	PRON	O	O	4474
inner	ADJ	O	O	4474
ear	NOUN	O	O	4474
by	ADP	O	O	4474
osmotic	NOUN	O	O	4474
pump	VERB	O	O	4474
for	ADP	O	O	4474
24	NUM	O	O	4474
h	X	O	O	4474
,	PUNCT	O	O	4474
and	CCONJ	O	O	4474
edaravone	NOUN	O	Chemical	4474
(	PUNCT	O	O	4474
n=8	PROPN	O	O	4474
)	PUNCT	O	O	4474
or	CCONJ	O	O	4474
saline	NOUN	O	O	4474
(	PUNCT	O	O	4474
n=6	NOUN	O	O	4474
)	PUNCT	O	O	4474
was	AUX	O	O	4474
intraperitoneally	ADV	O	O	4474
injected	VERB	O	O	4474
once	ADV	O	O	4474
a	PRON	O	O	4474
day	NOUN	O	O	4474
for	ADP	O	O	4474
7	NUM	O	O	4474
days	NOUN	O	O	4474
.	PUNCT	O	O	4474
Animals	NOUN	O	O	4475
injected	VERB	O	O	4475
with	ADP	O	O	4475
saline	NOUN	O	O	4475
showed	VERB	O	O	4475
statistically	ADV	O	O	4475
smaller	ADJ	O	O	4475
gains	VERB	O	O	4475
than	ADP	O	O	4475
those	PRON	O	O	4475
injected	VERB	O	O	4475
with	ADP	O	O	4475
edaravone	NOUN	O	Chemical	4475
.	PUNCT	O	O	4475
These	PRON	O	O	4476
results	VERB	O	O	4476
suggest	VERB	O	O	4476
that	SCONJ	O	O	4476
edaravone	NOUN	O	Chemical	4476
suppresses	VERB	O	O	4476
streptomycin	PROPN	O	Chemical	4476
-	PUNCT	O	O	4476
induced	VERB	O	O	4476
vestibulotoxicity	NOUN	O	Disease	4476
.	PUNCT	O	O	4476
Ketamine	PROPN	O	Chemical	4479
in	ADP	O	O	4479
war	NOUN	O	O	4479
/	PUNCT	O	O	4479
tropical	ADJ	O	O	4479
surgery	NOUN	O	O	4479
(	PUNCT	O	O	4479
a	PRON	O	O	4479
final	ADJ	O	O	4479
tribute	NOUN	O	O	4479
to	PART	O	O	4479
the	PRON	O	O	4479
racemic	ADJ	O	O	4479
mixture	NOUN	O	O	4479
)	PUNCT	O	O	4479
.	PUNCT	O	O	4479
A	PRON	O	O	4480
technique	NOUN	O	O	4480
of	ADP	O	O	4480
continuous	ADJ	O	O	4480
intravenous	ADJ	O	O	4480
anaesthesia	NOUN	O	O	4480
with	ADP	O	O	4480
ketamine	VERB	O	Chemical	4480
was	AUX	O	O	4480
used	VERB	O	O	4480
successfully	ADV	O	O	4480
during	ADP	O	O	4480
the	PRON	O	O	4480
Somalia	PROPN	O	O	4480
civil	ADJ	O	O	4480
war	NOUN	O	O	4480
in	ADP	O	O	4480
1994	NUM	O	O	4480
and	CCONJ	O	O	4480
in	ADP	O	O	4480
north	NOUN	O	O	4480
Uganda	PROPN	O	O	4480
in	ADP	O	O	4480
1999	NUM	O	O	4480
for	ADP	O	O	4480
64	NUM	O	O	4480
operations	NOUN	O	O	4480
in	ADP	O	O	4480
62	NUM	O	O	4480
patients	NOUN	O	O	4480
,	PUNCT	O	O	4480
aged	ADJ	O	O	4480
from	ADP	O	O	4480
6	NUM	O	O	4480
weeks	NOUN	O	O	4480
to	PART	O	O	4480
70	NUM	O	O	4480
years	NOUN	O	O	4480
,	PUNCT	O	O	4480
undergoing	VERB	O	O	4480
limb	NOUN	O	O	4480
and	CCONJ	O	O	4480
abdominal	ADJ	O	O	4480
surgery	NOUN	O	O	4480
including	VERB	O	O	4480
caesarian	ADJ	O	O	4480
sections	NOUN	O	O	4480
and	CCONJ	O	O	4480
interventions	NOUN	O	O	4480
in	ADP	O	O	4480
neonates	NOUN	O	O	4480
.	PUNCT	O	O	4480
Operations	NOUN	O	O	4481
lasting	VERB	O	O	4481
up	ADP	O	O	4481
to	PART	O	O	4481
2h	NUM	O	O	4481
could	AUX	O	O	4481
be	AUX	O	O	4481
performed	VERB	O	O	4481
in	ADP	O	O	4481
the	PRON	O	O	4481
absence	NOUN	O	O	4481
of	ADP	O	O	4481
sophisticated	ADJ	O	O	4481
equipment	NOUN	O	O	4481
such	ADJ	O	O	4481
as	ADP	O	O	4481
pulse	NOUN	O	O	4481
oximeters	NOUN	O	O	4481
or	CCONJ	O	O	4481
ventilators	NOUN	O	O	4481
in	ADP	O	O	4481
patients	NOUN	O	O	4481
on	ADP	O	O	4481
spontaneous	ADJ	O	O	4481
ventilation	NOUN	O	O	4481
breathing	VERB	O	O	4481
air	NOUN	O	O	4481
/	PUNCT	O	O	4481
oxygen	NOUN	O	Chemical	4481
only	ADV	O	O	4481
.	PUNCT	O	O	4481
After	ADP	O	O	4482
premedication	NOUN	O	O	4482
with	ADP	O	O	4482
diazepam	NOUN	O	Chemical	4482
,	PUNCT	O	O	4482
glycopyrrolate	VERB	O	Chemical	4482
and	CCONJ	O	O	4482
local	ADJ	O	O	4482
anaesthesia	NOUN	O	O	4482
,	PUNCT	O	O	4482
and	CCONJ	O	O	4482
induction	NOUN	O	O	4482
with	ADP	O	O	4482
standard	PROPN	O	O	4482
doses	NOUN	O	O	4482
of	ADP	O	O	4482
ketamine	VERB	O	Chemical	4482
,	PUNCT	O	O	4482
a	PRON	O	O	4482
maintenance	NOUN	O	O	4482
dose	NOUN	O	O	4482
of	ADP	O	O	4482
10	NUM	O	O	4482
-	PUNCT	O	O	4482
20	NUM	O	O	4482
microg	PROPN	O	O	4482
/	PUNCT	O	O	4482
kg	VERB	O	O	4482
/	PUNCT	O	O	4483
min	NOUN	O	O	4483
of	ADP	O	O	4483
ketamine	VERB	O	Chemical	4483
proved	VERB	O	O	4483
safe	ADJ	O	O	4483
and	CCONJ	O	O	4483
effective	ADJ	O	O	4483
.	PUNCT	O	O	4483
Diazepam	NOUN	O	Chemical	4484
,	PUNCT	O	O	4484
unless	SCONJ	O	O	4484
contraindicated	VERB	O	O	4484
or	CCONJ	O	O	4484
risky	ADJ	O	O	4484
,	PUNCT	O	O	4484
remains	VERB	O	O	4484
the	PRON	O	O	4484
only	ADV	O	O	4484
necessary	ADJ	O	O	4484
complementary	ADJ	O	O	4484
drug	NOUN	O	O	4484
to	PART	O	O	4484
ketamine	VERB	O	Chemical	4484
as	ADP	O	O	4484
it	PRON	O	O	4484
buffers	NOUN	O	O	4484
its	PRON	O	O	4484
cardiovascular	ADJ	O	O	4484
response	NOUN	O	O	4484
and	CCONJ	O	O	4484
decreases	VERB	O	O	4484
the	PRON	O	O	4484
duration	NOUN	O	O	4484
and	CCONJ	O	O	4484
intensity	NOUN	O	O	4484
of	ADP	O	O	4484
operative	NOUN	O	O	4484
and	CCONJ	O	O	4484
postoperative	ADJ	O	O	4484
hallucinations	NOUN	O	Disease	4484
.	PUNCT	O	O	4484
Local	ADJ	O	O	4485
anaesthetic	NOUN	O	O	4485
blocks	NOUN	O	O	4485
were	AUX	O	O	4485
useful	ADJ	O	O	4485
in	ADP	O	O	4485
decreasing	VERB	O	O	4485
the	PRON	O	O	4485
requirement	NOUN	O	O	4485
for	ADP	O	O	4485
postoperative	ADJ	O	O	4485
analgesia	NOUN	O	Disease	4485
.	PUNCT	O	O	4485
An	PRON	O	O	4486
antisialogue	PROPN	O	O	4486
was	AUX	O	O	4486
usually	ADV	O	O	4486
unnecessary	ADJ	O	O	4486
in	ADP	O	O	4486
operations	NOUN	O	O	4486
lasting	VERB	O	O	4486
up	ADP	O	O	4486
to	PART	O	O	4486
2	X	O	O	4486
h	X	O	O	4486
,	PUNCT	O	O	4486
glycopyrrolate	VERB	O	Chemical	4486
being	AUX	O	O	4486
the	PRON	O	O	4486
best	ADV	O	O	4486
choice	NOUN	O	O	4486
for	ADP	O	O	4486
its	PRON	O	O	4486
lowest	ADJ	O	O	4486
psychotropic	NOUN	O	O	4486
and	CCONJ	O	O	4486
chronotropic	NOUN	O	O	4486
effects	NOUN	O	O	4486
,	PUNCT	O	O	4486
especially	ADV	O	O	4486
in	ADP	O	O	4486
a	PRON	O	O	4486
hot	ADJ	O	O	4486
climate	NOUN	O	O	4486
.	PUNCT	O	O	4486
Steroid	NOUN	O	Chemical	4489
structure	NOUN	O	O	4489
and	CCONJ	O	O	4489
pharmacological	ADJ	O	O	4489
properties	NOUN	O	O	4489
determine	VERB	O	O	4489
the	PRON	O	O	4489
anti	ADJ	O	O	4489
-	PUNCT	O	O	4489
amnesic	ADJ	O	Disease	4489
effects	NOUN	O	O	4489
of	ADP	O	O	4489
pregnenolone sulphate	NOUN	O	Chemical	4489
in	ADP	O	O	4489
the	PRON	O	O	4489
passive	ADJ	O	O	4489
avoidance	NOUN	O	O	4489
task	NOUN	O	O	4489
in	ADP	O	O	4489
rats	NOUN	O	O	4489
.	PUNCT	O	O	4489
Pregnenolone sulphate	NOUN	O	Chemical	4490
(	PUNCT	O	O	4490
PREGS	NOUN	O	Chemical	4490
)	PUNCT	O	O	4490
has	VERB	O	O	4490
generated	VERB	O	O	4490
interest	NOUN	O	O	4490
as	ADP	O	O	4490
one	NUM	O	O	4490
of	ADP	O	O	4490
the	PRON	O	O	4490
most	ADV	O	O	4490
potent	ADJ	O	O	4490
memory	NOUN	O	O	4490
-	PUNCT	O	O	4490
enhancing	VERB	O	O	4490
neurosteroids	PROPN	O	O	4490
to	PART	O	O	4490
be	AUX	O	O	4490
examined	VERB	O	O	4490
in	ADP	O	O	4490
rodent	NOUN	O	O	4490
learning	VERB	O	O	4490
studies	NOUN	O	O	4490
,	PUNCT	O	O	4490
with	ADP	O	O	4490
particular	ADJ	O	O	4490
importance	NOUN	O	O	4490
in	ADP	O	O	4490
the	PRON	O	O	4490
ageing	VERB	O	O	4490
process	NOUN	O	O	4490
.	PUNCT	O	O	4490
The	PRON	O	O	4491
mechanism	NOUN	O	O	4491
by	ADP	O	O	4491
which	PRON	O	O	4491
this	PRON	O	O	4491
endogenous	ADJ	O	O	4491
steroid	NOUN	O	Chemical	4491
enhances	VERB	O	O	4491
memory	NOUN	O	O	4491
formation	NOUN	O	O	4491
is	AUX	O	O	4491
hypothesized	VERB	O	O	4491
to	PART	O	O	4491
involve	VERB	O	O	4491
actions	NOUN	O	O	4491
on	ADP	O	O	4491
glutamatergic	ADJ	O	O	4491
and	CCONJ	O	O	4491
GABAergic	PROPN	O	O	4491
systems	NOUN	O	O	4491
.	PUNCT	O	O	4491
This	PRON	O	O	4492
hypothesis	NOUN	O	O	4492
stems	VERB	O	O	4492
from	ADP	O	O	4492
findings	NOUN	O	O	4492
that	SCONJ	O	O	4492
PREGS	NOUN	O	Chemical	4492
is	AUX	O	O	4492
a	PRON	O	O	4492
potent	ADJ	O	O	4492
positive	ADJ	O	O	4492
modulator	PROPN	O	O	4492
of	ADP	O	O	4492
N	NUM	O	O	4492
-	PUNCT	O	O	4492
methyl	NOUN	O	O	4492
-	PUNCT	O	O	4492
d	X	O	O	4492
-	PUNCT	O	O	4492
aspartate	NOUN	O	Chemical	4492
receptors	NOUN	O	O	4492
(	PUNCT	O	O	4492
NMDARs	NOUN	O	O	4492
)	PUNCT	O	O	4492
and	CCONJ	O	O	4492
a	PRON	O	O	4492
negative	ADJ	O	O	4492
modulator	PROPN	O	O	4492
of	ADP	O	O	4492
gamma	PROPN	O	O	4492
-	PUNCT	O	O	4492
aminobutyric	PROPN	O	O	4492
acid(A	NOUN	O	O	4492
)	PUNCT	O	O	4492
receptors	NOUN	O	O	4492
(	PUNCT	O	O	4492
GABA(A)Rs	INTJ	O	O	4492
)	PUNCT	O	O	4492
.	PUNCT	O	O	4492
Moreover	ADV	O	O	4493
,	PUNCT	O	O	4493
PREGS	NOUN	O	Chemical	4493
is	AUX	O	O	4493
able	ADJ	O	O	4493
to	PART	O	O	4493
reverse	VERB	O	O	4493
the	PRON	O	O	4493
amnesic	ADJ	O	Disease	4493
-	PUNCT	O	O	4493
like	INTJ	O	O	4493
effects	NOUN	O	O	4493
of	ADP	O	O	4493
NMDAR	PROPN	O	O	4493
and	CCONJ	O	O	4493
GABA(A)R	NOUN	O	O	4493
ligands	NOUN	O	O	4493
.	PUNCT	O	O	4493
To	PART	O	O	4494
investigate	VERB	O	O	4494
this	PRON	O	O	4494
hypothesis	NOUN	O	O	4494
,	PUNCT	O	O	4494
the	PRON	O	O	4494
present	NOUN	O	O	4494
study	VERB	O	O	4494
in	ADP	O	O	4494
rats	NOUN	O	O	4494
examined	VERB	O	O	4494
the	PRON	O	O	4494
memory	NOUN	O	O	4494
-	PUNCT	O	O	4494
altering	VERB	O	O	4494
abilities	NOUN	O	O	4494
of	ADP	O	O	4494
structural	ADJ	O	O	4494
analogs	NOUN	O	O	4494
of	ADP	O	O	4494
PREGS	NOUN	O	Chemical	4494
,	PUNCT	O	O	4494
which	PRON	O	O	4494
differ	VERB	O	O	4494
in	ADP	O	O	4494
their	PRON	O	O	4494
modulation	NOUN	O	O	4494
of	ADP	O	O	4494
NMDAR	PROPN	O	O	4494
and/or	CCONJ	O	O	4494
GABA(A)R	NOUN	O	O	4494
function	NOUN	O	O	4494
.	PUNCT	O	O	4494
The	PRON	O	O	4495
analogs	NOUN	O	O	4495
tested	VERB	O	O	4495
were	AUX	O	O	4495
:	PUNCT	O	O	4495
11-ketopregnenolone sulphate	NOUN	O	Chemical	4495
(	PUNCT	O	O	4495
an	PRON	O	O	4495
agent	NOUN	O	O	4495
that	SCONJ	O	O	4495
is	AUX	O	O	4495
inactive	ADJ	O	O	4495
at	ADP	O	O	4495
GABA(A)Rs	INTJ	O	O	4495
and	CCONJ	O	O	4495
NMDARs	NOUN	O	O	4495
)	PUNCT	O	O	4495
,	PUNCT	O	O	4495
epipregnanolone	NOUN	O	O	4495
(	PUNCT	O	O	4495
[	X	O	O	4495
3beta	NUM	O	O	4495
-	PUNCT	O	O	4495
hydroxy-5beta	NOUN	O	O	4495
-	PUNCT	O	O	4495
pregnan-20-one	NUM	O	O	4495
]	PUNCT	O	O	4495
sulphate	NOUN	O	O	4495
,	PUNCT	O	O	4495
an	PRON	O	O	4495
inhibitor	NOUN	O	O	4495
of	ADP	O	O	4495
both	PRON	O	O	4495
GABA(A)Rs	INTJ	O	O	4495
and	CCONJ	O	O	4495
NMDARs	NOUN	O	O	4495
)	PUNCT	O	O	4495
,	PUNCT	O	O	4495
and	CCONJ	O	O	4495
a	PRON	O	O	4495
newly	ADV	O	O	4495
synthesized	VERB	O	O	4495
(	PUNCT	O	O	4495
-	PUNCT	O	O	4495
)	PUNCT	O	O	4495
PREGS	NOUN	O	Chemical	4496
enantiomer	NOUN	O	O	4496
(	PUNCT	O	O	4496
which	PRON	O	O	4496
is	AUX	O	O	4496
identical	ADJ	O	O	4496
to	PART	O	O	4496
PREGS	NOUN	O	Chemical	4496
in	ADP	O	O	4496
effects	NOUN	O	O	4496
on	ADP	O	O	4496
GABA(A)Rs	INTJ	O	O	4496
and	CCONJ	O	O	4496
NMDARs	NOUN	O	O	4496
)	PUNCT	O	O	4496
.	PUNCT	O	O	4496
The	PRON	O	O	4497
memory	NOUN	O	O	4497
-	PUNCT	O	O	4497
enhancing	VERB	O	O	4497
effects	NOUN	O	O	4497
of	ADP	O	O	4497
PREGS	NOUN	O	Chemical	4497
and	CCONJ	O	O	4497
its	PRON	O	O	4497
analogs	NOUN	O	O	4497
were	AUX	O	O	4497
tested	VERB	O	O	4497
in	ADP	O	O	4497
the	PRON	O	O	4497
passive	ADJ	O	O	4497
avoidance	NOUN	O	O	4497
task	NOUN	O	O	4497
using	VERB	O	O	4497
the	PRON	O	O	4497
model	NOUN	O	O	4497
of	ADP	O	O	4497
scopolamine	NOUN	O	Chemical	4497
-	PUNCT	O	O	4497
induced	VERB	O	O	4497
amnesia	NOUN	O	Disease	4497
.	PUNCT	O	O	4497
Both	PRON	O	O	4498
PREGS	NOUN	O	Chemical	4498
and	CCONJ	O	O	4498
its	PRON	O	O	4498
(	PUNCT	O	O	4498
-	PUNCT	O	O	4498
)	PUNCT	O	O	4498
enantiomer	NOUN	O	O	4498
blocked	VERB	O	O	4498
the	PRON	O	O	4498
effects	NOUN	O	O	4498
of	ADP	O	O	4498
scopolamine	NOUN	O	Chemical	4498
.	PUNCT	O	O	4498
The	PRON	O	O	4499
results	VERB	O	O	4499
show	VERB	O	O	4499
that	SCONJ	O	O	4499
,	PUNCT	O	O	4499
unlike	ADP	O	O	4499
PREGS	NOUN	O	Chemical	4499
,	PUNCT	O	O	4499
11-ketopregnenolone sulphate	NOUN	O	Chemical	4499
and	CCONJ	O	O	4499
epipregnanolone sulphate	NOUN	O	Chemical	4499
failed	VERB	O	O	4499
to	PART	O	O	4499
block	NOUN	O	O	4499
the	PRON	O	O	4499
effect	VERB	O	O	4499
of	ADP	O	O	4499
scopolamine	NOUN	O	Chemical	4499
,	PUNCT	O	O	4499
suggesting	VERB	O	O	4499
that	SCONJ	O	O	4499
altering	VERB	O	O	4499
the	PRON	O	O	4499
modulation	NOUN	O	O	4499
of	ADP	O	O	4499
NMDA	PROPN	O	Chemical	4499
receptors	NOUN	O	O	4499
diminishes	VERB	O	O	4499
the	PRON	O	O	4499
memory	NOUN	O	O	4499
-	PUNCT	O	O	4499
enhancing	VERB	O	O	4499
effects	NOUN	O	O	4499
of	ADP	O	O	4499
PREGS	NOUN	O	Chemical	4499
.	PUNCT	O	O	4499
Moreover	ADV	O	O	4500
,	PUNCT	O	O	4500
enantioselectivity	NOUN	O	O	4500
was	AUX	O	O	4500
demonstrated	VERB	O	O	4500
by	ADP	O	O	4500
the	PRON	O	O	4500
ability	NOUN	O	O	4500
of	ADP	O	O	4500
natural	ADJ	O	O	4500
PREGS	NOUN	O	Chemical	4500
to	PART	O	O	4500
be	AUX	O	O	4500
an	PRON	O	O	4500
order	NOUN	O	O	4500
of	ADP	O	O	4500
magnitude	NOUN	O	O	4500
more	ADJ	O	O	4500
effective	ADJ	O	O	4500
than	ADP	O	O	4500
its	PRON	O	O	4500
synthetic	NOUN	O	O	4500
enantiomer	NOUN	O	O	4500
in	ADP	O	O	4500
reversing	VERB	O	O	4500
scopolamine	NOUN	O	Chemical	4500
-	PUNCT	O	O	4500
induced	VERB	O	O	4500
amnesia	NOUN	O	Disease	4500
.	PUNCT	O	O	4500
These	PRON	O	O	4501
results	VERB	O	O	4501
identify	VERB	O	O	4501
a	PRON	O	O	4501
novel	NOUN	O	O	4501
neuropharmacological	ADJ	O	O	4501
site	NOUN	O	O	4501
for	ADP	O	O	4501
the	PRON	O	O	4501
modulation	NOUN	O	O	4501
of	ADP	O	O	4501
memory	NOUN	O	O	4501
processes	NOUN	O	O	4501
by	ADP	O	O	4501
neuroactive	PROPN	O	O	4501
steroids	NOUN	O	Chemical	4501
.	PUNCT	O	O	4501
Preliminary	PROPN	O	O	4504
efficacy	NOUN	O	O	4504
assessment	NOUN	O	O	4504
of	ADP	O	O	4504
intrathecal	ADJ	O	O	4504
injection	NOUN	O	O	4504
of	ADP	O	O	4504
an	PRON	O	O	4504
American	ADJ	O	O	4504
formulation	NOUN	O	O	4504
of	ADP	O	O	4504
adenosine	PROPN	O	Chemical	4504
in	ADP	O	O	4504
humans	NOUN	O	O	4504
.	PUNCT	O	O	4504
Preclinical	PROPN	O	O	4505
studies	NOUN	O	O	4505
of	ADP	O	O	4505
intrathecal	ADJ	O	O	4505
adenosine	PROPN	O	Chemical	4505
suggest	VERB	O	O	4505
it	PRON	O	O	4505
may	AUX	O	O	4505
be	AUX	O	O	4505
effective	ADJ	O	O	4505
in	ADP	O	O	4505
the	PRON	O	O	4505
treatment	NOUN	O	O	4505
of	ADP	O	O	4505
acute	ADJ	O	O	4505
and	CCONJ	O	O	4505
chronic pain	NOUN	O	Disease	4505
in	ADP	O	O	4505
humans	NOUN	O	O	4505
,	PUNCT	O	O	4505
and	CCONJ	O	O	4505
preliminary	ADJ	O	O	4505
studies	NOUN	O	O	4505
in	ADP	O	O	4505
volunteers	NOUN	O	O	4505
and	CCONJ	O	O	4505
patients	NOUN	O	O	4505
with	ADP	O	O	4505
a	PRON	O	O	4505
Swedish	ADJ	O	O	4505
formulation	NOUN	O	O	4505
of	ADP	O	O	4505
adenosine	PROPN	O	Chemical	4505
suggests	VERB	O	O	4505
it	PRON	O	O	4505
may	AUX	O	O	4505
be	AUX	O	O	4505
effective	ADJ	O	O	4505
in	ADP	O	O	4505
hypersensitivity	NOUN	O	Disease	4505
states	VERB	O	O	4505
but	CCONJ	O	O	4505
not	PART	O	O	4505
with	ADP	O	O	4505
acute	ADJ	O	O	4505
noxious	ADJ	O	O	4505
stimulation	NOUN	O	O	4505
.	PUNCT	O	O	4505
The	PRON	O	O	4506
purpose	NOUN	O	O	4506
of	ADP	O	O	4506
this	PRON	O	O	4506
study	VERB	O	O	4506
was	AUX	O	O	4506
to	PART	O	O	4506
screen	NOUN	O	O	4506
for	ADP	O	O	4506
efficacy	NOUN	O	O	4506
of	ADP	O	O	4506
a	PRON	O	O	4506
different	ADJ	O	O	4506
formulation	NOUN	O	O	4506
of	ADP	O	O	4506
adenosine	PROPN	O	Chemical	4506
marketed	VERB	O	O	4506
in	ADP	O	O	4506
the	PRON	O	O	4506
US	PROPN	O	O	4506
,	PUNCT	O	O	4506
using	VERB	O	O	4506
both	PRON	O	O	4506
acute	ADJ	O	O	4506
noxious	ADJ	O	O	4506
stimulation	NOUN	O	O	4506
and	CCONJ	O	O	4506
capsaicin	NOUN	O	Chemical	4506
-	PUNCT	O	O	4506
evoked	VERB	O	O	4506
mechanical	ADJ	O	O	4506
hypersensitivity	NOUN	O	Disease	4506
.	PUNCT	O	O	4506
Following	VERB	O	O	4507
Food	NOUN	O	O	4507
and	CCONJ	O	O	4507
Drug	NOUN	O	O	4507
Administration	NOUN	O	O	4507
and	CCONJ	O	O	4507
institutional	ADJ	O	O	4507
review	VERB	O	O	4507
board	PROPN	O	O	4507
approval	NOUN	O	O	4507
and	CCONJ	O	O	4507
written	VERB	O	O	4507
informed	VERB	O	O	4507
consent	NOUN	O	O	4507
,	PUNCT	O	O	4507
65	NUM	O	O	4507
volunteers	NOUN	O	O	4507
were	AUX	O	O	4507
studied	VERB	O	O	4507
in	ADP	O	O	4507
two	NUM	O	O	4507
trials	NOUN	O	O	4507
:	PUNCT	O	O	4507
an	PRON	O	O	4507
open	VERB	O	O	4507
-	PUNCT	O	O	4507
label	PROPN	O	O	4507
,	PUNCT	O	O	4507
dose	NOUN	O	O	4507
-	PUNCT	O	O	4507
escalating	VERB	O	O	4507
trial	NOUN	O	O	4507
with	ADP	O	O	4507
intrathecal	ADJ	O	O	4507
adenosine	PROPN	O	Chemical	4507
doses	NOUN	O	O	4507
of	ADP	O	O	4507
0.25	NUM	O	O	4507
-	PUNCT	O	O	4507
2.0	NUM	O	O	4507
mg	VERB	O	O	4507
and	CCONJ	O	O	4507
a	PRON	O	O	4507
double	ADJ	O	O	4507
-	PUNCT	O	O	4507
blind	ADJ	O	Disease	4507
,	PUNCT	O	O	4507
placebo	NOUN	O	O	4507
-	PUNCT	O	O	4507
controlled	VERB	O	O	4507
trial	NOUN	O	O	4507
of	ADP	O	O	4507
adenosine	PROPN	O	Chemical	4507
,	PUNCT	O	O	4507
2	X	O	O	4507
mg	VERB	O	O	4507
.	PUNCT	O	O	4507
Cerebrospinal	NOUN	O	O	4508
fluid	NOUN	O	O	4508
was	AUX	O	O	4508
obtained	VERB	O	O	4508
for	ADP	O	O	4508
pharmacokinetic	VERB	O	O	4508
analysis	NOUN	O	O	4508
,	PUNCT	O	O	4508
and	CCONJ	O	O	4508
pain	NOUN	O	Disease	4508
ratings	NOUN	O	O	4508
in	ADP	O	O	4508
response	NOUN	O	O	4508
to	PART	O	O	4508
acute	ADJ	O	O	4508
heat	NOUN	O	O	4508
stimuli	NOUN	O	O	4508
and	CCONJ	O	O	4508
areas	NOUN	O	O	4508
of	ADP	O	O	4508
mechanical hyperalgesia	NOUN	O	Disease	4508
and	CCONJ	O	O	4508
allodynia	NOUN	O	Disease	4508
after	ADP	O	O	4508
intradermal	ADJ	O	O	4508
capsaicin	NOUN	O	Chemical	4508
injection	NOUN	O	O	4508
were	AUX	O	O	4508
determined	VERB	O	O	4508
.	PUNCT	O	O	4508
Adenosine	NOUN	O	Chemical	4509
produced	VERB	O	O	4509
no	PRON	O	O	4509
effect	VERB	O	O	4509
on	ADP	O	O	4509
pain	NOUN	O	Disease	4509
report	VERB	O	O	4509
to	PART	O	O	4509
acute	ADJ	O	O	4509
noxious	ADJ	O	O	4509
thermal	PROPN	O	O	4509
or	CCONJ	O	O	4509
chemical	PROPN	O	O	4509
stimulation	NOUN	O	O	4509
but	CCONJ	O	O	4509
reduced	VERB	O	O	4509
mechanical hyperalgesia	NOUN	O	Disease	4509
and	CCONJ	O	O	4509
allodynia	NOUN	O	Disease	4509
from	ADP	O	O	4509
intradermal	ADJ	O	O	4509
capsaicin	NOUN	O	Chemical	4509
injection	NOUN	O	O	4509
for	ADP	O	O	4509
at	ADP	O	O	4509
least	ADJ	O	O	4509
24	NUM	O	O	4509
h.	PROPN	O	O	4509
In	ADP	O	O	4510
contrast	NOUN	O	O	4510
,	PUNCT	O	O	4510
residence	NOUN	O	O	4510
time	NOUN	O	O	4510
of	ADP	O	O	4510
adenosine	PROPN	O	Chemical	4510
in	ADP	O	O	4510
cerebrospinal	ADJ	O	O	4510
fluid	NOUN	O	O	4510
was	AUX	O	O	4510
short	ADJ	O	O	4510
(	PUNCT	O	O	4510
<	X	O	O	4510
4	NUM	O	O	4510
h	X	O	O	4510
)	PUNCT	O	O	4510
.	PUNCT	O	O	4510
These	PRON	O	O	4511
results	VERB	O	O	4511
show	VERB	O	O	4511
selective	ADJ	O	O	4511
inhibition	NOUN	O	O	4511
by	ADP	O	O	4511
intrathecal	ADJ	O	O	4511
adenosine	PROPN	O	Chemical	4511
of	ADP	O	O	4511
hypersensitivity	NOUN	O	Disease	4511
,	PUNCT	O	O	4511
presumed	VERB	O	O	4511
to	PART	O	O	4511
reflect	VERB	O	O	4511
central	ADJ	O	O	4511
sensitization	NOUN	O	O	4511
in	ADP	O	O	4511
humans	NOUN	O	O	4511
after	ADP	O	O	4511
peripheral	ADJ	O	O	4511
capsaicin	NOUN	O	Chemical	4511
injection	NOUN	O	O	4511
.	PUNCT	O	O	4511
The	PRON	O	O	4512
long	ADV	O	O	4512
-	PUNCT	O	O	4512
lasting	VERB	O	O	4512
effect	VERB	O	O	4512
is	AUX	O	O	4512
consistent	ADJ	O	O	4512
with	ADP	O	O	4512
that	SCONJ	O	O	4512
observed	VERB	O	O	4512
in	ADP	O	O	4512
preliminary	ADJ	O	O	4512
reports	VERB	O	O	4512
of	ADP	O	O	4512
patients	NOUN	O	O	4512
with	ADP	O	O	4512
chronic	ADJ	O	O	4512
neuropathic pain	NOUN	O	Disease	4512
and	CCONJ	O	O	4512
is	AUX	O	O	4512
not	PART	O	O	4512
due	ADJ	O	O	4512
to	PART	O	O	4512
prolonged	VERB	O	O	4512
residence	NOUN	O	O	4512
of	ADP	O	O	4512
adenosine	PROPN	O	Chemical	4512
in	ADP	O	O	4512
cerebrospinal	ADJ	O	O	4512
fluid	NOUN	O	O	4512
.	PUNCT	O	O	4512
Effect	VERB	O	O	4515
of	ADP	O	O	4515
lithium	NOUN	O	Chemical	4515
maintenance	NOUN	O	O	4515
therapy	NOUN	O	O	4515
on	ADP	O	O	4515
thyroid	NOUN	O	O	4515
and	CCONJ	O	O	4515
parathyroid	ADJ	O	O	4515
function	NOUN	O	O	4515
.	PUNCT	O	O	4515
To	PART	O	O	4516
assess	VERB	O	O	4516
changes	VERB	O	O	4516
induced	VERB	O	O	4516
by	ADP	O	O	4516
lithium	NOUN	O	Chemical	4516
maintenance	NOUN	O	O	4516
therapy	NOUN	O	O	4516
on	ADP	O	O	4516
the	PRON	O	O	4516
incidence	NOUN	O	O	4516
of	ADP	O	O	4516
thyroid	NOUN	O	O	4516
,	PUNCT	O	O	4516
parathyroid	ADJ	O	O	4516
and	CCONJ	O	O	4516
ion	PROPN	O	O	4516
alterations	NOUN	O	O	4516
.	PUNCT	O	O	4516
These	PRON	O	O	4517
were	AUX	O	O	4517
evaluated	VERB	O	O	4517
with	ADP	O	O	4517
respect	VERB	O	O	4517
to	PART	O	O	4517
the	PRON	O	O	4517
duration	NOUN	O	O	4517
of	ADP	O	O	4517
lithium	NOUN	O	Chemical	4517
therapy	NOUN	O	O	4517
,	PUNCT	O	O	4517
age	NOUN	O	O	4517
,	PUNCT	O	O	4517
sex	NOUN	O	O	4517
,	PUNCT	O	O	4517
and	CCONJ	O	O	4517
family	NOUN	O	O	4517
history	NOUN	O	O	4517
(	PUNCT	O	O	4517
whether	SCONJ	O	O	4517
or	CCONJ	O	O	4517
not	PART	O	O	4517
the	PRON	O	O	4517
patient	NOUN	O	O	4517
had	VERB	O	O	4517
a	PRON	O	O	4517
first	ADV	O	O	4517
-	PUNCT	O	O	4517
degree	PROPN	O	O	4517
relative	ADJ	O	O	4517
with	ADP	O	O	4517
thyroid disease	NOUN	O	Disease	4517
)	PUNCT	O	O	4517
.	PUNCT	O	O	4517
One	NUM	O	O	4518
hundred	NUM	O	O	4518
and	CCONJ	O	O	4518
one	NUM	O	O	4518
patients	NOUN	O	O	4518
(	PUNCT	O	O	4518
28	NUM	O	O	4518
men	NOUN	O	O	4518
and	CCONJ	O	O	4518
73	NUM	O	O	4518
women	NOUN	O	O	4518
)	PUNCT	O	O	4518
with	ADP	O	O	4518
bipolar disorder	NOUN	O	Disease	4518
receiving	VERB	O	O	4518
lithium	NOUN	O	Chemical	4518
maintenance	NOUN	O	O	4518
therapy	NOUN	O	O	4518
ranging	VERB	O	O	4518
from	ADP	O	O	4518
1	X	O	O	4518
year	NOUN	O	O	4518
's	AUX	O	O	4518
to	PART	O	O	4518
32	NUM	O	O	4518
years	NOUN	O	O	4518
'	PUNCT	O	O	4518
duration	NOUN	O	O	4518
.	PUNCT	O	O	4518
The	PRON	O	O	4519
control	VERB	O	O	4519
group	NOUN	O	O	4519
consisted	VERB	O	O	4519
of	ADP	O	O	4519
82	NUM	O	O	4519
patients	NOUN	O	O	4519
with	ADP	O	O	4519
no	PRON	O	O	4519
psychiatric	ADJ	O	Disease	4519
or	CCONJ	O	O	4519
endocrinological	ADJ	O	O	4519
diagnoses	NOUN	O	O	4519
from	ADP	O	O	4519
the	PRON	O	O	4519
hospital	PROPN	O	O	4519
's	AUX	O	O	4519
out	ADP	O	O	4519
-	PUNCT	O	O	4519
patient	NOUN	O	O	4519
clinics	NOUN	O	O	4519
.	PUNCT	O	O	4519
Laboratory	NOUN	O	O	4520
analyses	NOUN	O	O	4520
of	ADP	O	O	4520
calcium	NOUN	O	Chemical	4520
,	PUNCT	O	O	4520
magnesium	NOUN	O	Chemical	4520
and	CCONJ	O	O	4520
thyroid	NOUN	O	O	4520
-	PUNCT	O	O	4520
stimulating	VERB	O	O	4520
hormone	NOUN	O	O	4520
levels	NOUN	O	O	4520
performed	VERB	O	O	4520
before	ADP	O	O	4520
beginning	VERB	O	O	4520
lithium	NOUN	O	Chemical	4520
therapy	NOUN	O	O	4520
and	CCONJ	O	O	4520
at	ADP	O	O	4520
biannual	ADJ	O	O	4520
follow	VERB	O	O	4520
-	PUNCT	O	O	4520
up	ADP	O	O	4520
.	PUNCT	O	O	4520
Hypothyroidism	NOUN	O	Disease	4521
developed	VERB	O	O	4521
in	ADP	O	O	4521
40	NUM	O	O	4521
patients	NOUN	O	O	4521
,	PUNCT	O	O	4521
excluding	VERB	O	O	4521
8	NUM	O	O	4521
patients	NOUN	O	O	4521
who	PRON	O	O	4521
were	AUX	O	O	4521
hypothyroid	PROPN	O	Disease	4521
at	ADP	O	O	4521
baseline	VERB	O	O	4521
.	PUNCT	O	O	4521
All	PRON	O	O	4522
patients	NOUN	O	O	4522
having	VERB	O	O	4522
first	ADV	O	O	4522
-	PUNCT	O	O	4522
degree	PROPN	O	O	4522
relatives	NOUN	O	O	4522
affected	VERB	O	O	4522
by	ADP	O	O	4522
thyroid illness	NOUN	O	Disease	4522
had	VERB	O	O	4522
accelerated	VERB	O	O	4522
onset	VERB	O	O	4522
of	ADP	O	O	4522
hypothyroidism	PROPN	O	Disease	4522
(	PUNCT	O	O	4522
3.7	NUM	O	O	4522
years	NOUN	O	O	4522
after	ADP	O	O	4522
onset	VERB	O	O	4522
of	ADP	O	O	4522
lithium	NOUN	O	Chemical	4522
therapy	NOUN	O	O	4522
)	PUNCT	O	O	4522
compared	VERB	O	O	4522
with	ADP	O	O	4522
patients	NOUN	O	O	4522
without	ADP	O	O	4522
a	PRON	O	O	4522
family	NOUN	O	O	4522
history	NOUN	O	O	4522
(	PUNCT	O	O	4522
8.6	NUM	O	O	4522
years	NOUN	O	O	4522
after	ADP	O	O	4522
onset	VERB	O	O	4522
of	ADP	O	O	4522
lithium	NOUN	O	Chemical	4522
therapy	NOUN	O	O	4522
)	PUNCT	O	O	4522
.	PUNCT	O	O	4522
Women	NOUN	O	O	4523
over	ADP	O	O	4523
60	NUM	O	O	4523
years	NOUN	O	O	4523
of	ADP	O	O	4523
age	NOUN	O	O	4523
were	AUX	O	O	4523
more	ADJ	O	O	4523
often	ADV	O	O	4523
affected	VERB	O	O	4523
by	ADP	O	O	4523
hypothyroidism	PROPN	O	Disease	4523
than	ADP	O	O	4523
women	NOUN	O	O	4523
under	ADP	O	O	4523
60	NUM	O	O	4523
years	NOUN	O	O	4523
of	ADP	O	O	4523
age	NOUN	O	O	4523
(	PUNCT	O	O	4523
34.6%	NOUN	O	O	4523
versus	ADP	O	O	4523
31.9%	NOUN	O	O	4523
)	PUNCT	O	O	4523
.	PUNCT	O	O	4523
Magnesium	NOUN	O	Chemical	4524
levels	NOUN	O	O	4524
in	ADP	O	O	4524
patients	NOUN	O	O	4524
on	ADP	O	O	4524
lithium	NOUN	O	Chemical	4524
treatment	NOUN	O	O	4524
were	AUX	O	O	4524
unchanged	ADJ	O	O	4524
from	ADP	O	O	4524
baseline	VERB	O	O	4524
levels	NOUN	O	O	4524
.	PUNCT	O	O	4524
After	ADP	O	O	4525
lithium	NOUN	O	Chemical	4525
treatment	NOUN	O	O	4525
,	PUNCT	O	O	4525
calcium	NOUN	O	Chemical	4525
levels	NOUN	O	O	4525
were	AUX	O	O	4525
higher	ADJ	O	O	4525
than	ADP	O	O	4525
either	ADV	O	O	4525
baseline	VERB	O	O	4525
levels	NOUN	O	O	4525
or	CCONJ	O	O	4525
control	VERB	O	O	4525
levels	NOUN	O	O	4525
.	PUNCT	O	O	4525
Thus	ADV	O	O	4526
,	PUNCT	O	O	4526
lithium	NOUN	O	Chemical	4526
treatment	NOUN	O	O	4526
counteracted	VERB	O	O	4526
the	PRON	O	O	4526
decrease	VERB	O	O	4526
in	ADP	O	O	4526
plasma	NOUN	O	O	4526
calcium	NOUN	O	Chemical	4526
levels	NOUN	O	O	4526
associated	VERB	O	O	4526
with	ADP	O	O	4526
aging	VERB	O	O	4526
.	PUNCT	O	O	4526
CONCLUSIONS	NOUN	O	O	4527
:	PUNCT	O	O	4527
Familial	ADJ	O	O	4527
thyroid illness	NOUN	O	Disease	4527
is	AUX	O	O	4527
a	PRON	O	O	4527
risk	NOUN	O	O	4527
factor	NOUN	O	O	4527
for	ADP	O	O	4527
hypothyroidism	PROPN	O	Disease	4527
and	CCONJ	O	O	4527
hypercalcemia	NOUN	O	Disease	4527
during	ADP	O	O	4527
lithium	NOUN	O	Chemical	4527
therapy	NOUN	O	O	4527
.	PUNCT	O	O	4527
Systemic	ADJ	O	O	4530
toxicity	NOUN	O	Disease	4530
following	VERB	O	O	4530
administration	NOUN	O	O	4530
of	ADP	O	O	4530
sirolimus	NOUN	O	Chemical	4530
(	PUNCT	O	O	4530
formerly	ADV	O	O	4530
rapamycin	NOUN	O	Chemical	4530
)	PUNCT	O	O	4530
for	ADP	O	O	4530
psoriasis	NOUN	O	Disease	4530
:	PUNCT	O	O	4530
association	PROPN	O	O	4530
of	ADP	O	O	4530
capillary leak syndrome	NOUN	O	Disease	4530
with	ADP	O	O	4530
apoptosis	NOUN	O	O	4530
of	ADP	O	O	4530
lesional	NOUN	O	O	4530
lymphocytes	VERB	O	O	4530
.	PUNCT	O	O	4530
BACKGROUND	NOUN	O	O	4531
:	PUNCT	O	O	4531
Sirolimus	NOUN	O	Chemical	4531
(	PUNCT	O	O	4531
formerly	ADV	O	O	4531
rapamycin	NOUN	O	Chemical	4531
)	PUNCT	O	O	4531
is	AUX	O	O	4531
an	PRON	O	O	4531
immunosuppressive	ADJ	O	O	4531
agent	NOUN	O	O	4531
that	SCONJ	O	O	4531
interferes	VERB	O	O	4531
with	ADP	O	O	4531
T	NOUN	O	Chemical	4531
-	PUNCT	O	O	4531
cell	NOUN	O	O	4531
activation	NOUN	O	O	4531
.	PUNCT	O	O	4531
After	ADP	O	O	4532
2	X	O	O	4532
individuals	NOUN	O	O	4532
with	ADP	O	O	4532
psoriasis	NOUN	O	Disease	4532
developed	VERB	O	O	4532
a	PRON	O	O	4532
capillary leak syndrome	NOUN	O	Disease	4532
following	VERB	O	O	4532
treatment	NOUN	O	O	4532
with	ADP	O	O	4532
oral	ADJ	O	O	4532
sirolimus	NOUN	O	Chemical	4532
lesional	NOUN	O	O	4532
skin	NOUN	O	O	4532
cells	NOUN	O	O	4532
and	CCONJ	O	O	4532
activated	VERB	O	O	4532
peripheral	ADJ	O	O	4532
blood	NOUN	O	O	4532
cells	NOUN	O	O	4532
were	AUX	O	O	4532
analyzed	VERB	O	O	4532
for	ADP	O	O	4532
induction	NOUN	O	O	4532
of	ADP	O	O	4532
apoptosis	NOUN	O	O	4532
.	PUNCT	O	O	4532
A	PRON	O	O	4533
keratome	VERB	O	O	4533
skin	NOUN	O	O	4533
specimen	NOUN	O	O	4533
from	ADP	O	O	4533
1	X	O	O	4533
patient	NOUN	O	O	4533
with	ADP	O	O	4533
sirolimus	NOUN	O	Chemical	4533
-	PUNCT	O	O	4533
induced	VERB	O	O	4533
capillary leak syndrome	NOUN	O	Disease	4533
had	VERB	O	O	4533
a	PRON	O	O	4533
2.3-fold	ADV	O	O	4533
increase	VERB	O	O	4533
in	ADP	O	O	4533
percentage	NOUN	O	O	4533
of	ADP	O	O	4533
apoptotic	ADJ	O	O	4533
cells	NOUN	O	O	4533
(	PUNCT	O	O	4533
to	PART	O	O	4533
48%	NOUN	O	O	4533
)	PUNCT	O	O	4533
compared	VERB	O	O	4533
with	ADP	O	O	4533
an	PRON	O	O	4533
unaffected	ADJ	O	O	4533
sirolimus	NOUN	O	Chemical	4533
-	PUNCT	O	O	4533
treated	VERB	O	O	4533
patient	NOUN	O	O	4533
with	ADP	O	O	4533
psoriasis	NOUN	O	Disease	4533
(	PUNCT	O	O	4533
21%	NOUN	O	O	4533
)	PUNCT	O	O	4533
.	PUNCT	O	O	4533
Activated	VERB	O	O	4534
peripheral	ADJ	O	O	4534
blood	NOUN	O	O	4534
T	NOUN	O	Chemical	4534
cells	NOUN	O	O	4534
from	ADP	O	O	4534
patients	NOUN	O	O	4534
with	ADP	O	O	4534
psoriasis	NOUN	O	Disease	4534
tended	VERB	O	O	4534
to	PART	O	O	4534
exhibit	VERB	O	O	4534
greater	ADJ	O	O	4534
spontaneous	ADJ	O	O	4534
or	CCONJ	O	O	4534
dexamethasone	NOUN	O	Chemical	4534
-	PUNCT	O	O	4534
induced	VERB	O	O	4534
apoptosis	NOUN	O	O	4534
than	ADP	O	O	4534
did	VERB	O	O	4534
normal	ADJ	O	O	4534
T	NOUN	O	Chemical	4534
cells	NOUN	O	O	4534
,	PUNCT	O	O	4534
particularly	ADV	O	O	4534
in	ADP	O	O	4534
the	PRON	O	O	4534
presence	NOUN	O	O	4534
of	ADP	O	O	4534
sirolimus	NOUN	O	Chemical	4534
.	PUNCT	O	O	4534
Severe	ADJ	O	O	4535
adverse	ADJ	O	O	4535
effects	NOUN	O	O	4535
of	ADP	O	O	4535
sirolimus	NOUN	O	Chemical	4535
include	VERB	O	O	4535
fever	NOUN	O	Disease	4535
,	PUNCT	O	O	4535
anemia	NOUN	O	Disease	4535
,	PUNCT	O	O	4535
and	CCONJ	O	O	4535
capillary leak syndrome	NOUN	O	Disease	4535
.	PUNCT	O	O	4535
Because	SCONJ	O	O	4536
patients	NOUN	O	O	4536
with	ADP	O	O	4536
severe	ADJ	O	O	4536
psoriasis	NOUN	O	Disease	4536
may	AUX	O	O	4536
develop	VERB	O	O	4536
capillary leak	NOUN	O	Disease	4536
from	ADP	O	O	4536
various	ADJ	O	O	4536
systemic	ADJ	O	O	4536
therapies	NOUN	O	O	4536
,	PUNCT	O	O	4536
clinical	ADJ	O	O	4536
monitoring	NOUN	O	O	4536
is	AUX	O	O	4536
advisable	ADJ	O	O	4536
for	ADP	O	O	4536
patients	NOUN	O	O	4536
with	ADP	O	O	4536
inflammatory diseases	NOUN	O	Disease	4536
who	PRON	O	O	4536
are	AUX	O	O	4536
treated	VERB	O	O	4536
with	ADP	O	O	4536
immune	NOUN	O	O	4536
modulators	NOUN	O	O	4536
.	PUNCT	O	O	4536
Contribution	NOUN	O	O	4539
of	ADP	O	O	4539
the	PRON	O	O	4539
glycine	NOUN	O	Chemical	4539
site	NOUN	O	O	4539
of	ADP	O	O	4539
NMDA	PROPN	O	Chemical	4539
receptors	NOUN	O	O	4539
in	ADP	O	O	4539
rostral	ADJ	O	O	4539
and	CCONJ	O	O	4539
intermediate	PROPN	O	O	4539
-	PUNCT	O	O	4539
caudal	ADJ	O	O	4539
parts	NOUN	O	O	4539
of	ADP	O	O	4539
the	PRON	O	O	4539
striatum	NOUN	O	O	4539
to	PART	O	O	4539
the	PRON	O	O	4539
regulation	NOUN	O	O	4539
of	ADP	O	O	4539
muscle	NOUN	O	O	4539
tone	NOUN	O	O	4539
in	ADP	O	O	4539
rats	NOUN	O	O	4539
.	PUNCT	O	O	4539
The	PRON	O	O	4540
aim	VERB	O	O	4540
of	ADP	O	O	4540
the	PRON	O	O	4540
present	NOUN	O	O	4540
study	VERB	O	O	4540
was	AUX	O	O	4540
to	PART	O	O	4540
assess	VERB	O	O	4540
the	PRON	O	O	4540
contribution	NOUN	O	O	4540
of	ADP	O	O	4540
the	PRON	O	O	4540
glycine	NOUN	O	Chemical	4540
site	NOUN	O	O	4540
of	ADP	O	O	4540
NMDA	PROPN	O	Chemical	4540
receptors	NOUN	O	O	4540
in	ADP	O	O	4540
the	PRON	O	O	4540
striatum	NOUN	O	O	4540
to	PART	O	O	4540
the	PRON	O	O	4540
regulation	NOUN	O	O	4540
of	ADP	O	O	4540
muscle	NOUN	O	O	4540
tone	NOUN	O	O	4540
.	PUNCT	O	O	4540
Muscle rigidity	NOUN	O	Disease	4541
was	AUX	O	O	4541
induced	VERB	O	O	4541
by	ADP	O	O	4541
haloperidol	NOUN	O	Chemical	4541
(	PUNCT	O	O	4541
2.5	NUM	O	O	4541
mg	VERB	O	O	4541
/	PUNCT	O	O	4541
kg	VERB	O	O	4541
i.p	NOUN	O	O	4541
.	PUNCT	O	O	4541
)	PUNCT	O	O	4541
.	PUNCT	O	O	4541
5,7-dichlorokynurenic acid	NOUN	O	Chemical	4542
(	PUNCT	O	O	4542
5,7-DCKA	NOUN	O	Chemical	4542
)	PUNCT	O	O	4542
,	PUNCT	O	O	4542
a	PRON	O	O	4542
selective	ADJ	O	O	4542
glycine	NOUN	O	Chemical	4542
site	NOUN	O	O	4542
antagonist	NOUN	O	O	4542
,	PUNCT	O	O	4542
injected	VERB	O	O	4542
in	ADP	O	O	4542
doses	NOUN	O	O	4542
of	ADP	O	O	4542
2.5	NUM	O	O	4542
and	CCONJ	O	O	4542
4.5	NUM	O	O	4542
microg/0.5	NUM	O	O	4542
microl	NOUN	O	O	4542
bilaterally	ADV	O	O	4542
,	PUNCT	O	O	4542
into	ADP	O	O	4542
the	PRON	O	O	4542
rostral	ADJ	O	O	4542
region	NOUN	O	O	4542
of	ADP	O	O	4542
the	PRON	O	O	4542
striatum	NOUN	O	O	4542
,	PUNCT	O	O	4542
decreased	VERB	O	O	4542
both	PRON	O	O	4542
the	PRON	O	O	4542
haloperidol	NOUN	O	Chemical	4542
-	PUNCT	O	O	4542
induced	VERB	O	O	4542
muscle rigidity	NOUN	O	Disease	4542
(	PUNCT	O	O	4542
MMG	X	O	O	4542
)	PUNCT	O	O	4542
and	CCONJ	O	O	4542
the	PRON	O	O	4542
enhanced	VERB	O	O	4542
electromyographic	ADJ	O	O	4542
activity	NOUN	O	O	4542
(	PUNCT	O	O	4542
EMG	PROPN	O	O	4542
)	PUNCT	O	O	4542
.	PUNCT	O	O	4542
5,7-DCKA	NOUN	O	Chemical	4543
injected	VERB	O	O	4543
bilaterally	ADV	O	O	4543
in	ADP	O	O	4543
a	PRON	O	O	4543
dose	NOUN	O	O	4543
of	ADP	O	O	4543
4.5	NUM	O	O	4543
microg/0.5	NUM	O	O	4543
microl	NOUN	O	O	4543
into	ADP	O	O	4543
the	PRON	O	O	4543
intermediate	PROPN	O	O	4543
-	PUNCT	O	O	4543
caudal	ADJ	O	O	4543
region	NOUN	O	O	4543
of	ADP	O	O	4543
the	PRON	O	O	4543
striatum	NOUN	O	O	4543
of	ADP	O	O	4543
rats	NOUN	O	O	4543
not	PART	O	O	4543
pretreated	VERB	O	O	4543
with	ADP	O	O	4543
haloperidol	NOUN	O	Chemical	4543
had	VERB	O	O	4543
no	PRON	O	O	4543
effect	VERB	O	O	4543
on	ADP	O	O	4543
the	PRON	O	O	4543
muscle	NOUN	O	O	4543
tone	NOUN	O	O	4543
.	PUNCT	O	O	4543
The	PRON	O	O	4544
present	NOUN	O	O	4544
results	VERB	O	O	4544
suggest	VERB	O	O	4544
that	SCONJ	O	O	4544
blockade	VERB	O	O	4544
of	ADP	O	O	4544
the	PRON	O	O	4544
glycine	NOUN	O	Chemical	4544
site	NOUN	O	O	4544
of	ADP	O	O	4544
NMDA	PROPN	O	Chemical	4544
receptors	NOUN	O	O	4544
in	ADP	O	O	4544
the	PRON	O	O	4544
rostral	ADJ	O	O	4544
part	NOUN	O	O	4544
of	ADP	O	O	4544
the	PRON	O	O	4544
striatum	NOUN	O	O	4544
may	AUX	O	O	4544
be	AUX	O	O	4544
mainly	ADV	O	O	4544
responsible	ADJ	O	O	4544
for	ADP	O	O	4544
the	PRON	O	O	4544
antiparkinsonian	ADJ	O	O	4544
action	NOUN	O	O	4544
of	ADP	O	O	4544
this	PRON	O	O	4544
drug	NOUN	O	O	4544
.	PUNCT	O	O	4544
Efficacy	NOUN	O	O	4547
and	CCONJ	O	O	4547
tolerability	NOUN	O	O	4547
of	ADP	O	O	4547
lovastatin	NOUN	O	Chemical	4547
in	ADP	O	O	4547
3390	NUM	O	O	4547
women	NOUN	O	O	4547
with	ADP	O	O	4547
moderate	ADJ	O	O	4547
hypercholesterolemia	NOUN	O	Disease	4547
.	PUNCT	O	O	4547
OBJECTIVE	VERB	O	O	4548
:	PUNCT	O	O	4548
To	PART	O	O	4548
evaluate	VERB	O	O	4548
the	PRON	O	O	4548
efficacy	NOUN	O	O	4548
and	CCONJ	O	O	4548
safety	NOUN	O	O	4548
of	ADP	O	O	4548
lovastatin	NOUN	O	Chemical	4548
in	ADP	O	O	4548
women	NOUN	O	O	4548
with	ADP	O	O	4548
moderate	ADJ	O	O	4548
hypercholesterolemia	NOUN	O	Disease	4548
.	PUNCT	O	O	4548
The	PRON	O	O	4549
Expanded	VERB	O	O	4549
Clinical	NOUN	O	O	4549
Evaluation	NOUN	O	O	4549
of	ADP	O	O	4549
Lovastatin	PROPN	O	Chemical	4549
(	PUNCT	O	O	4549
EXCEL	NOUN	O	O	4549
)	PUNCT	O	O	4549
Study	NOUN	O	O	4549
,	PUNCT	O	O	4549
a	PRON	O	O	4549
multicenter	ADJ	O	O	4549
,	PUNCT	O	O	4549
double	ADJ	O	O	4549
-	PUNCT	O	O	4549
blind	ADJ	O	Disease	4549
,	PUNCT	O	O	4549
diet-	PROPN	O	O	4549
and	CCONJ	O	O	4549
placebo	NOUN	O	O	4549
-	PUNCT	O	O	4549
controlled	VERB	O	O	4549
trial	NOUN	O	O	4549
,	PUNCT	O	O	4549
in	ADP	O	O	4549
which	PRON	O	O	4549
participants	NOUN	O	O	4549
were	AUX	O	O	4549
randomly	ADV	O	O	4549
assigned	VERB	O	O	4549
to	PART	O	O	4549
receive	VERB	O	O	4549
placebo	NOUN	O	O	4549
or	CCONJ	O	O	4549
lovastatin	NOUN	O	Chemical	4549
at	ADP	O	O	4549
doses	NOUN	O	O	4549
of	ADP	O	O	4549
20	NUM	O	O	4549
or	CCONJ	O	O	4549
40	NUM	O	O	4549
mg	VERB	O	O	4549
once	ADV	O	O	4549
daily	ADV	O	O	4549
,	PUNCT	O	O	4549
or	CCONJ	O	O	4549
20	NUM	O	O	4549
or	CCONJ	O	O	4549
40	NUM	O	O	4549
mg	VERB	O	O	4549
twice	ADV	O	O	4549
daily	ADV	O	O	4549
for	ADP	O	O	4549
48	NUM	O	O	4549
weeks	NOUN	O	O	4549
.	PUNCT	O	O	4549
MEASUREMENTS	NOUN	O	O	4550
:	PUNCT	O	O	4550
Plasma	NOUN	O	O	4550
total	ADJ	O	O	4550
,	PUNCT	O	O	4550
low	ADJ	O	O	4550
-	PUNCT	O	O	4550
density	NOUN	O	O	4550
lipoprotein	NOUN	O	O	4550
(	PUNCT	O	O	4550
LDL	NOUN	O	O	4550
)	PUNCT	O	O	4550
,	PUNCT	O	O	4550
and	CCONJ	O	O	4550
high	ADJ	O	O	4550
-	PUNCT	O	O	4550
density	NOUN	O	O	4550
lipoprotein	NOUN	O	O	4550
(	PUNCT	O	O	4550
HDL	PROPN	O	O	4550
)	PUNCT	O	O	4550
cholesterol	NOUN	O	Chemical	4550
,	PUNCT	O	O	4550
and	CCONJ	O	O	4550
triglycerides	NOUN	O	Chemical	4550
;	PUNCT	O	O	4550
and	CCONJ	O	O	4550
laboratory	NOUN	O	O	4550
and	CCONJ	O	O	4550
clinical	ADJ	O	O	4550
evidence	NOUN	O	O	4550
of	ADP	O	O	4550
adverse	ADJ	O	O	4550
events	NOUN	O	O	4550
monitored	VERB	O	O	4550
periodically	ADV	O	O	4550
throughout	ADP	O	O	4550
the	PRON	O	O	4550
study	VERB	O	O	4550
.	PUNCT	O	O	4550
Among	ADP	O	O	4551
women	NOUN	O	O	4551
,	PUNCT	O	O	4551
lovastatin	NOUN	O	Chemical	4551
(	PUNCT	O	O	4551
20	NUM	O	O	4551
to	PART	O	O	4551
80	NUM	O	O	4551
mg	VERB	O	O	4551
/	PUNCT	O	O	4551
d	X	O	O	4551
)	PUNCT	O	O	4551
produced	VERB	O	O	4551
sustained	VERB	O	O	4551
(	PUNCT	O	O	4551
12-	NUM	O	O	4551
to	PART	O	O	4551
48-week	NOUN	O	O	4551
)	PUNCT	O	O	4551
,	PUNCT	O	O	4551
dose	NOUN	O	O	4551
-	PUNCT	O	O	4551
related	ADJ	O	O	4551
changes	VERB	O	O	4551
(	PUNCT	O	O	4551
P	NOUN	O	Chemical	4551
<	X	O	O	4551
0.001	NUM	O	O	4551
)	PUNCT	O	O	4551
:	PUNCT	O	O	4551
decreases	VERB	O	O	4551
in	ADP	O	O	4551
LDL	NOUN	O	O	4551
cholesterol	NOUN	O	Chemical	4551
(	PUNCT	O	O	4551
24%	NOUN	O	O	4551
to	PART	O	O	4551
40%	NOUN	O	O	4551
)	PUNCT	O	O	4551
and	CCONJ	O	O	4551
triglycerides	NOUN	O	Chemical	4551
(	PUNCT	O	O	4551
9%	NOUN	O	O	4551
to	PART	O	O	4551
18%	NOUN	O	O	4551
)	PUNCT	O	O	4551
,	PUNCT	O	O	4551
and	CCONJ	O	O	4551
increases	VERB	O	O	4551
in	ADP	O	O	4551
HDL	PROPN	O	O	4551
cholesterol	NOUN	O	Chemical	4551
(	PUNCT	O	O	4551
6.7%	NOUN	O	O	4551
to	PART	O	O	4551
8.6%	NOUN	O	O	4551
)	PUNCT	O	O	4551
.	PUNCT	O	O	4551
Depending	VERB	O	O	4552
on	ADP	O	O	4552
the	PRON	O	O	4552
dose	NOUN	O	O	4552
,	PUNCT	O	O	4552
from	ADP	O	O	4552
82%	NOUN	O	O	4552
to	PART	O	O	4552
95%	NOUN	O	O	4552
of	ADP	O	O	4552
lovastatin	NOUN	O	Chemical	4552
-	PUNCT	O	O	4552
treated	VERB	O	O	4552
women	NOUN	O	O	4552
achieved	VERB	O	O	4552
the	PRON	O	O	4552
National	ADJ	O	O	4552
Cholesterol	NOUN	O	Chemical	4552
Education	NOUN	O	O	4552
Program	PROPN	O	O	4552
goal	NOUN	O	O	4552
of	ADP	O	O	4552
LDL	NOUN	O	O	4552
cholesterol	NOUN	O	Chemical	4552
levels	NOUN	O	O	4552
less	ADV	O	O	4552
than	ADP	O	O	4552
4.14	NUM	O	O	4552
mmol	NOUN	O	O	4552
/	PUNCT	O	O	4552
L	NOUN	O	O	4552
(	PUNCT	O	O	4552
160	NUM	O	O	4552
mg	VERB	O	O	4552
/	PUNCT	O	O	4552
dL	VERB	O	O	4552
)	PUNCT	O	O	4552
,	PUNCT	O	O	4552
and	CCONJ	O	O	4552
40%	NOUN	O	O	4552
to	PART	O	O	4552
87%	NOUN	O	O	4552
achieved	VERB	O	O	4552
the	PRON	O	O	4552
goal	NOUN	O	O	4552
of	ADP	O	O	4552
3.36	NUM	O	O	4552
mmol	NOUN	O	O	4552
/	PUNCT	O	O	4552
L	NOUN	O	O	4552
(	PUNCT	O	O	4552
130	NUM	O	O	4552
mg	VERB	O	O	4552
/	PUNCT	O	O	4552
dL	VERB	O	O	4552
)	PUNCT	O	O	4552
.	PUNCT	O	O	4552
Myopathy	PROPN	O	Disease	4553
,	PUNCT	O	O	4553
defined	VERB	O	O	4553
as	ADP	O	O	4553
muscle	NOUN	O	O	4553
symptoms	NOUN	O	O	4553
with	ADP	O	O	4553
creatine	PROPN	O	Chemical	4553
kinase	VERB	O	O	4553
elevations	NOUN	O	O	4553
greater	ADJ	O	O	4553
than	ADP	O	O	4553
10	NUM	O	O	4553
times	NOUN	O	O	4553
the	PRON	O	O	4553
upper	ADJ	O	O	4553
limit	NOUN	O	O	4553
of	ADP	O	O	4553
normal	ADJ	O	O	4553
,	PUNCT	O	O	4553
was	AUX	O	O	4553
rare	ADJ	O	O	4553
and	CCONJ	O	O	4553
associated	VERB	O	O	4553
with	ADP	O	O	4553
the	PRON	O	O	4553
highest	ADJ	O	O	4553
recommended	VERB	O	O	4553
daily	ADV	O	O	4553
dose	NOUN	O	O	4553
of	ADP	O	O	4553
lovastatin	NOUN	O	Chemical	4553
(	PUNCT	O	O	4553
80	NUM	O	O	4553
mg	VERB	O	O	4553
)	PUNCT	O	O	4553
.	PUNCT	O	O	4553
Estrogen	NOUN	O	O	4554
-	PUNCT	O	O	4554
replacement	NOUN	O	O	4554
therapy	NOUN	O	O	4554
appeared	VERB	O	O	4554
to	PART	O	O	4554
have	VERB	O	O	4554
no	PRON	O	O	4554
effect	VERB	O	O	4554
on	ADP	O	O	4554
either	ADV	O	O	4554
the	PRON	O	O	4554
efficacy	NOUN	O	O	4554
or	CCONJ	O	O	4554
safety	NOUN	O	O	4554
profile	NOUN	O	O	4554
of	ADP	O	O	4554
lovastatin	NOUN	O	Chemical	4554
.	PUNCT	O	O	4554
CONCLUSION	PROPN	O	O	4555
:	PUNCT	O	O	4555
Lovastatin	PROPN	O	Chemical	4555
is	AUX	O	O	4555
highly	ADV	O	O	4555
effective	ADJ	O	O	4555
and	CCONJ	O	O	4555
generally	ADV	O	O	4555
well	ADV	O	O	4555
tolerated	VERB	O	O	4555
as	ADP	O	O	4555
therapy	NOUN	O	O	4555
for	ADP	O	O	4555
primary	NOUN	O	O	4555
hypercholesterolemia	NOUN	O	Disease	4555
in	ADP	O	O	4555
women	NOUN	O	O	4555
.	PUNCT	O	O	4555
REM sleep deprivation	NOUN	O	Disease	4558
changes	VERB	O	O	4558
behavioral	ADJ	O	O	4558
response	NOUN	O	O	4558
to	PART	O	O	4558
catecholaminergic	PROPN	O	O	4558
and	CCONJ	O	O	4558
serotonergic	ADJ	O	O	4558
receptor	NOUN	O	O	4558
activation	NOUN	O	O	4558
in	ADP	O	O	4558
rats	NOUN	O	O	4558
.	PUNCT	O	O	4558
The	PRON	O	O	4559
effects	NOUN	O	O	4559
of	ADP	O	O	4559
REM sleep deprivation	NOUN	O	Disease	4559
(	PUNCT	O	O	4559
REMD	NOUN	O	Disease	4559
)	PUNCT	O	O	4559
on	ADP	O	O	4559
apomorphine	PROPN	O	Chemical	4559
-	PUNCT	O	O	4559
induced	VERB	O	O	4559
aggressiveness	NOUN	O	Disease	4559
and	CCONJ	O	O	4559
quipazine	NOUN	O	Chemical	4559
-	PUNCT	O	O	4559
induced	VERB	O	O	4559
head twitches	VERB	O	Disease	4559
in	ADP	O	O	4559
rats	NOUN	O	O	4559
were	AUX	O	O	4559
determined	VERB	O	O	4559
.	PUNCT	O	O	4559
hr	NOUN	O	O	4560
of	ADP	O	O	4560
REMD	NOUN	O	Disease	4560
increased	VERB	O	O	4560
apomorphine	PROPN	O	Chemical	4560
-	PUNCT	O	O	4560
induced	VERB	O	O	4560
aggressiveness	NOUN	O	Disease	4560
,	PUNCT	O	O	4560
and	CCONJ	O	O	4560
reduced	VERB	O	O	4560
(	PUNCT	O	O	4560
immediately	ADV	O	O	4560
after	ADP	O	O	4560
completing	VERB	O	O	4560
of	ADP	O	O	4560
REMD	NOUN	O	Disease	4560
)	PUNCT	O	O	4560
or	CCONJ	O	O	4560
increased	VERB	O	O	4560
(	PUNCT	O	O	4560
96	NUM	O	O	4560
hr	NOUN	O	O	4560
after	ADP	O	O	4560
completing	VERB	O	O	4560
of	ADP	O	O	4560
REMD	NOUN	O	Disease	4560
)	PUNCT	O	O	4560
quipazine	NOUN	O	Chemical	4561
-	PUNCT	O	O	4561
induced	VERB	O	O	4561
head twitches	VERB	O	Disease	4561
.	PUNCT	O	O	4561
Extrapyramidal	NOUN	O	O	4564
side	NOUN	O	O	4564
effects	NOUN	O	O	4564
and	CCONJ	O	O	4564
oral	ADJ	O	O	4564
haloperidol	NOUN	O	Chemical	4564
:	PUNCT	O	O	4564
an	PRON	O	O	4564
analysis	NOUN	O	O	4564
of	ADP	O	O	4564
explanatory	ADJ	O	O	4564
patient	NOUN	O	O	4564
and	CCONJ	O	O	4564
treatment	NOUN	O	O	4564
characteristics	NOUN	O	O	4564
.	PUNCT	O	O	4564
The	PRON	O	O	4565
incidence	NOUN	O	O	4565
of	ADP	O	O	4565
extrapyramidal	ADJ	O	O	4565
side	NOUN	O	O	4565
effects	NOUN	O	O	4565
(	PUNCT	O	O	4565
EPS	PROPN	O	Disease	4565
)	PUNCT	O	O	4565
was	AUX	O	O	4565
evaluated	VERB	O	O	4565
in	ADP	O	O	4565
98	NUM	O	O	4565
patients	NOUN	O	O	4565
treated	VERB	O	O	4565
with	ADP	O	O	4565
haloperidol	NOUN	O	Chemical	4565
.	PUNCT	O	O	4565
The	PRON	O	O	4566
incidence	NOUN	O	O	4566
of	ADP	O	O	4566
parkinsonism	NOUN	O	Disease	4566
was	AUX	O	O	4566
higher	ADJ	O	O	4566
at	ADP	O	O	4566
higher	ADJ	O	O	4566
doses	NOUN	O	O	4566
of	ADP	O	O	4566
haloperidol	NOUN	O	Chemical	4566
and	CCONJ	O	O	4566
in	ADP	O	O	4566
younger	ADJ	O	O	4566
patients	NOUN	O	O	4566
.	PUNCT	O	O	4566
However	ADV	O	O	4567
,	PUNCT	O	O	4567
these	PRON	O	O	4567
medications	NOUN	O	O	4567
were	AUX	O	O	4567
more	ADJ	O	O	4567
effective	ADJ	O	O	4567
in	ADP	O	O	4567
both	PRON	O	O	4567
young	ADJ	O	O	4567
and	CCONJ	O	O	4567
old	ADJ	O	O	4567
patients	NOUN	O	O	4567
when	SCONJ	O	O	4567
given	VERB	O	O	4567
after	ADP	O	O	4567
parkinsonism	NOUN	O	Disease	4567
developed	VERB	O	O	4567
.	PUNCT	O	O	4567
Akathisia	PROPN	O	Disease	4568
was	AUX	O	O	4568
controlled	VERB	O	O	4568
by	ADP	O	O	4568
the	PRON	O	O	4568
benzodiazepine	PROPN	O	Chemical	4568
lorazepam	PROPN	O	Chemical	4568
in	ADP	O	O	4568
14	NUM	O	O	4568
out	ADP	O	O	4568
of	ADP	O	O	4568
16	NUM	O	O	4568
patients	NOUN	O	O	4568
,	PUNCT	O	O	4568
while	SCONJ	O	O	4568
prophylactic	ADJ	O	O	4568
antiparkinsonians	NOUN	O	O	4568
were	AUX	O	O	4568
ineffective	ADJ	O	O	4568
.	PUNCT	O	O	4568
The	PRON	O	O	4569
present	NOUN	O	O	4569
study	VERB	O	O	4569
points	VERB	O	O	4569
to	PART	O	O	4569
patient	NOUN	O	O	4569
characteristics	NOUN	O	O	4569
that	SCONJ	O	O	4569
may	AUX	O	O	4569
be	AUX	O	O	4569
of	ADP	O	O	4569
significance	NOUN	O	O	4569
in	ADP	O	O	4569
the	PRON	O	O	4569
development	NOUN	O	O	4569
of	ADP	O	O	4569
EPS	PROPN	O	Disease	4569
due	ADJ	O	O	4569
to	PART	O	O	4569
haloperidol	NOUN	O	Chemical	4569
.	PUNCT	O	O	4569
Hepatic	ADJ	O	O	4572
veno	VERB	O	O	4572
-	PUNCT	O	O	4572
occlusive	ADJ	O	O	4572
disease	PROPN	O	O	4572
caused	VERB	O	O	4572
by	ADP	O	O	4572
6-thioguanine	NOUN	O	Chemical	4572
.	PUNCT	O	O	4572
Clinically	ADV	O	O	4573
reversible	ADJ	O	O	4573
veno	VERB	O	O	4573
-	PUNCT	O	O	4573
occlusive	ADJ	O	O	4573
disease	PROPN	O	O	4573
of	ADP	O	O	4573
the	PRON	O	O	4573
liver	NOUN	O	O	4573
developed	VERB	O	O	4573
in	ADP	O	O	4573
a	PRON	O	O	4573
23-year	NOUN	O	O	4573
-	PUNCT	O	O	4573
old	ADJ	O	O	4573
man	NOUN	O	O	4573
with	ADP	O	O	4573
acute lymphocytic leukemia	NOUN	O	Disease	4573
after	ADP	O	O	4573
10	NUM	O	O	4573
months	NOUN	O	O	4573
of	ADP	O	O	4573
maintenance	NOUN	O	O	4573
therapy	NOUN	O	O	4573
with	ADP	O	O	4573
6-thioguanine	NOUN	O	Chemical	4573
.	PUNCT	O	O	4573
Although	SCONJ	O	O	4574
this	PRON	O	O	4574
disease	PROPN	O	O	4574
was	AUX	O	O	4574
clinically	ADV	O	O	4574
reversible	ADJ	O	O	4574
,	PUNCT	O	O	4574
some	PRON	O	O	4574
subintimal	ADJ	O	O	4574
fibrosis	NOUN	O	Disease	4574
about	ADP	O	O	4574
the	PRON	O	O	4574
terminal	PROPN	O	O	4574
hepatic	ADJ	O	O	4574
veins	NOUN	O	O	4574
persisted	VERB	O	O	4574
.	PUNCT	O	O	4574
This	PRON	O	O	4575
case	NOUN	O	O	4575
presented	VERB	O	O	4575
a	PRON	O	O	4575
unique	ADJ	O	O	4575
opportunity	NOUN	O	O	4575
to	PART	O	O	4575
observe	VERB	O	O	4575
the	PRON	O	O	4575
histologic	ADJ	O	O	4575
features	VERB	O	O	4575
of	ADP	O	O	4575
clinically	ADV	O	O	4575
reversible	ADJ	O	O	4575
hepatic	ADJ	O	O	4575
veno	VERB	O	O	4575
-	PUNCT	O	O	4575
occlusive	ADJ	O	O	4575
disease	PROPN	O	O	4575
over	ADP	O	O	4575
time	NOUN	O	O	4575
,	PUNCT	O	O	4575
and	CCONJ	O	O	4575
may	AUX	O	O	4575
be	AUX	O	O	4575
the	PRON	O	O	4575
first	ADV	O	O	4575
case	NOUN	O	O	4575
of	ADP	O	O	4575
veno	VERB	O	O	4575
-	PUNCT	O	O	4575
occlusive	ADJ	O	O	4575
related	ADJ	O	O	4575
solely	ADV	O	O	4575
to	PART	O	O	4575
6-thioguanine	NOUN	O	Chemical	4575
.	PUNCT	O	O	4575
Treatment	NOUN	O	O	4578
of	ADP	O	O	4578
ifosfamide	ADP	O	Chemical	4578
-	PUNCT	O	O	4578
induced	VERB	O	O	4578
urothelial toxicity	NOUN	O	Disease	4578
by	ADP	O	O	4578
oral	ADJ	O	O	4578
administration	NOUN	O	O	4578
of	ADP	O	O	4578
sodium 2-mercaptoethane sulphonate	NOUN	O	Chemical	4578
(	PUNCT	O	O	4578
MESNA	PROPN	O	Chemical	4578
)	PUNCT	O	O	4578
to	PART	O	O	4578
patients	NOUN	O	O	4578
with	ADP	O	O	4578
inoperable	ADJ	O	O	4578
lung cancer	NOUN	O	Disease	4578
.	PUNCT	O	O	4578
The	PRON	O	O	4579
protective	ADJ	O	O	4579
effect	VERB	O	O	4579
of	ADP	O	O	4579
oral	ADJ	O	O	4579
administration	NOUN	O	O	4579
of	ADP	O	O	4579
the	PRON	O	O	4579
thiol	NOUN	O	Chemical	4579
compound	NOUN	O	O	4579
sodium 2-mercaptoethane sulphonate	NOUN	O	Chemical	4579
(	PUNCT	O	O	4579
MESNA	PROPN	O	Chemical	4579
)	PUNCT	O	O	4579
against	ADP	O	O	4579
urothelial toxicity	NOUN	O	Disease	4579
induced	VERB	O	O	4579
by	ADP	O	O	4579
ifosfamide	ADP	O	Chemical	4579
(	PUNCT	O	O	4579
IF	SCONJ	O	Chemical	4579
)	PUNCT	O	O	4579
was	AUX	O	O	4579
tested	VERB	O	O	4579
in	ADP	O	O	4579
a	PRON	O	O	4579
group	NOUN	O	O	4579
of	ADP	O	O	4579
45	NUM	O	O	4579
patients	NOUN	O	O	4579
with	ADP	O	O	4579
inoperable	ADJ	O	O	4579
lung cancer	NOUN	O	Disease	4579
under	ADP	O	O	4579
treatment	NOUN	O	O	4579
with	ADP	O	O	4579
IF	SCONJ	O	Chemical	4579
(	PUNCT	O	O	4579
2250	NUM	O	O	4579
mg	VERB	O	O	4579
/	PUNCT	O	O	4579
m2	PROPN	O	O	4579
on	ADP	O	O	4579
days	NOUN	O	O	4579
2	X	O	O	4579
-	PUNCT	O	O	4579
5	NUM	O	O	4579
)	PUNCT	O	O	4579
as	ADP	O	O	4579
part	NOUN	O	O	4579
of	ADP	O	O	4579
a	PRON	O	O	4579
polychemotherapy	NOUN	O	O	4579
regimen	NOUN	O	O	4579
repeated	VERB	O	O	4579
in	ADP	O	O	4579
a	PRON	O	O	4579
4-week	NOUN	O	O	4579
cycle	PROPN	O	O	4579
.	PUNCT	O	O	4579
MESNA	PROPN	O	Chemical	4580
was	AUX	O	O	4580
given	VERB	O	O	4580
orally	ADV	O	O	4580
on	ADP	O	O	4580
the	PRON	O	O	4580
days	NOUN	O	O	4580
of	ADP	O	O	4580
treatment	NOUN	O	O	4580
with	ADP	O	O	4580
IF	SCONJ	O	Chemical	4580
in	ADP	O	O	4580
3	X	O	O	4580
doses	NOUN	O	O	4580
of	ADP	O	O	4580
840	NUM	O	O	4580
mg	VERB	O	O	4580
/	PUNCT	O	O	4580
m2	PROPN	O	O	4580
,	PUNCT	O	O	4580
each	PRON	O	O	4580
administered	VERB	O	O	4580
at	ADP	O	O	4580
0	NUM	O	O	4580
hr	NOUN	O	O	4580
(=	NOUN	O	O	4580
injection	NOUN	O	O	4580
of	ADP	O	O	4580
IF	SCONJ	O	Chemical	4580
)	PUNCT	O	O	4580
,	PUNCT	O	O	4580
4	NUM	O	O	4580
hr	NOUN	O	O	4580
and	CCONJ	O	O	4580
8	NUM	O	O	4580
hr	NOUN	O	O	4580
p.i	PROPN	O	O	4580
.	PUNCT	O	O	4580
Out	ADP	O	O	4581
of	ADP	O	O	4581
a	PRON	O	O	4581
total	ADJ	O	O	4581
of	ADP	O	O	4581
88	NUM	O	O	4581
courses	NOUN	O	O	4581
of	ADP	O	O	4581
this	PRON	O	O	4581
treatment	NOUN	O	O	4581
we	PRON	O	O	4581
observed	VERB	O	O	4581
10	NUM	O	O	4581
episodes	NOUN	O	O	4581
of	ADP	O	O	4581
asymptomatic	ADJ	O	O	4581
microscopic	ADJ	O	O	4581
haematuria	PROPN	O	Disease	4581
and	CCONJ	O	O	4581
no	PRON	O	O	4581
episodes	NOUN	O	O	4581
of	ADP	O	O	4581
gross	ADJ	O	O	4581
haematuria	PROPN	O	Disease	4581
.	PUNCT	O	O	4581
In	ADP	O	O	4582
this	PRON	O	O	4582
group	NOUN	O	O	4582
of	ADP	O	O	4582
45	NUM	O	O	4582
patients	NOUN	O	O	4582
under	ADP	O	O	4582
protection	NOUN	O	O	4582
with	ADP	O	O	4582
MESNA	PROPN	O	Chemical	4582
there	ADV	O	O	4582
were	AUX	O	O	4582
5	NUM	O	O	4582
complete	VERB	O	O	4582
remissions	NOUN	O	O	4582
and	CCONJ	O	O	4582
9	NUM	O	O	4582
partial	ADJ	O	O	4582
remissions	NOUN	O	O	4582
(	PUNCT	O	O	4582
total	ADJ	O	O	4582
31%	NOUN	O	O	4582
)	PUNCT	O	O	4582
.	PUNCT	O	O	4582
A	PRON	O	O	4583
further	ADV	O	O	4583
group	NOUN	O	O	4583
of	ADP	O	O	4583
25	NUM	O	O	4583
patients	NOUN	O	O	4583
under	ADP	O	O	4583
polychemotherapy	NOUN	O	O	4583
with	ADP	O	O	4583
IF	SCONJ	O	Chemical	4583
were	AUX	O	O	4583
treated	VERB	O	O	4583
by	ADP	O	O	4583
conventional	ADJ	O	O	4583
prophylactic	ADJ	O	O	4583
measures	NOUN	O	O	4583
(	PUNCT	O	O	4583
raised	VERB	O	O	4583
fluid	NOUN	O	O	4583
intake	PROPN	O	O	4583
and	CCONJ	O	O	4583
forced	VERB	O	O	4583
diuresis	VERB	O	O	4583
)	PUNCT	O	O	4583
.	PUNCT	O	O	4583
In	ADP	O	O	4584
this	PRON	O	O	4584
group	NOUN	O	O	4584
there	ADV	O	O	4584
were	AUX	O	O	4584
1	X	O	O	4584
complete	VERB	O	O	4584
and	CCONJ	O	O	4584
5	NUM	O	O	4584
partial	ADJ	O	O	4584
remissions	NOUN	O	O	4584
(	PUNCT	O	O	4584
total	ADJ	O	O	4584
24%	NOUN	O	O	4584
)	PUNCT	O	O	4584
,	PUNCT	O	O	4584
but	CCONJ	O	O	4584
nearly	ADV	O	O	4584
all	PRON	O	O	4584
patients	NOUN	O	O	4584
developed	VERB	O	O	4584
either	ADV	O	O	4584
gross	ADJ	O	O	4584
haematuria	PROPN	O	Disease	4584
and/or	CCONJ	O	O	4584
symptoms	NOUN	O	O	4584
of	ADP	O	O	4584
bladder irritation	NOUN	O	Disease	4584
(	PUNCT	O	O	4584
cystitis	NOUN	O	Disease	4584
and	CCONJ	O	O	4584
pollakisuria	PROPN	O	Disease	4584
)	PUNCT	O	O	4584
.	PUNCT	O	O	4584
There	ADV	O	O	4585
were	AUX	O	O	4585
no	PRON	O	O	4585
appreciable	ADJ	O	O	4585
differences	NOUN	O	O	4585
between	ADP	O	O	4585
the	PRON	O	O	4585
MESNA	PROPN	O	Chemical	4585
series	PROPN	O	O	4585
and	CCONJ	O	O	4585
the	PRON	O	O	4585
conventional	ADJ	O	O	4585
prophylaxis	NOUN	O	O	4585
series	PROPN	O	O	4585
with	ADP	O	O	4585
respect	VERB	O	O	4585
to	PART	O	O	4585
either	ADV	O	O	4585
haematological	NOUN	O	O	4585
or	CCONJ	O	O	4585
systemic	ADJ	O	O	4585
toxicity	NOUN	O	Disease	4585
of	ADP	O	O	4585
the	PRON	O	O	4585
cytostatic	ADJ	O	O	4585
treatment	NOUN	O	O	4585
.	PUNCT	O	O	4585
Our	PRON	O	O	4586
results	VERB	O	O	4586
support	NOUN	O	O	4586
the	PRON	O	O	4586
view	VERB	O	O	4586
that	SCONJ	O	O	4586
MESNA	PROPN	O	Chemical	4586
,	PUNCT	O	O	4586
given	VERB	O	O	4586
orally	ADV	O	O	4586
in	ADP	O	O	4586
conjunction	NOUN	O	O	4586
with	ADP	O	O	4586
combined	VERB	O	O	4586
cytostatic	ADJ	O	O	4586
regimens	NOUN	O	O	4586
which	PRON	O	O	4586
include	VERB	O	O	4586
IF	SCONJ	O	Chemical	4586
,	PUNCT	O	O	4586
simplifies	VERB	O	O	4586
the	PRON	O	O	4586
treatment	NOUN	O	O	4586
and	CCONJ	O	O	4586
provides	VERB	O	O	4586
optimum	ADJ	O	O	4586
protection	NOUN	O	O	4586
for	ADP	O	O	4586
the	PRON	O	O	4586
urinary	ADJ	O	O	4586
epithelium	NOUN	O	O	4586
.	PUNCT	O	O	4586
Protection	NOUN	O	O	4587
with	ADP	O	O	4587
oral	ADJ	O	O	4587
MESNA	PROPN	O	Chemical	4587
is	AUX	O	O	4587
particularly	ADV	O	O	4587
suitable	ADJ	O	O	4587
for	ADP	O	O	4587
outpatients	NOUN	O	O	4587
.	PUNCT	O	O	4587
Time	NOUN	O	O	4590
course	NOUN	O	O	4590
alterations	NOUN	O	O	4590
of	ADP	O	O	4590
QTC	PROPN	O	O	4590
interval	NOUN	O	O	4590
due	ADJ	O	O	4590
to	PART	O	O	4590
hypaque 76	NUM	O	Chemical	4590
.	PUNCT	O	O	4590
Sequential	ADJ	O	O	4591
measurement	NOUN	O	O	4591
of	ADP	O	O	4591
QT	NOUN	O	O	4591
interval	NOUN	O	O	4591
during	ADP	O	O	4591
left	VERB	O	O	4591
ventricular	ADJ	O	O	4591
angiography	NOUN	O	O	4591
was	AUX	O	O	4591
made	VERB	O	O	4591
30	NUM	O	O	4591
seconds	NOUN	O	O	4591
and	CCONJ	O	O	4591
one	NUM	O	O	4591
,	PUNCT	O	O	4591
three	NUM	O	O	4591
,	PUNCT	O	O	4591
five	NUM	O	O	4591
and	CCONJ	O	O	4591
ten	NUM	O	O	4591
minutes	NOUN	O	O	4591
after	ADP	O	O	4591
injection	NOUN	O	O	4591
of	ADP	O	O	4591
hypaque 76	NUM	O	Chemical	4591
.	PUNCT	O	O	4591
Significant	ADJ	O	O	4592
QTC prolongation	NOUN	O	Disease	4592
occurred	VERB	O	O	4592
in	ADP	O	O	4592
30	NUM	O	O	4592
seconds	NOUN	O	O	4592
to	PART	O	O	4592
one	NUM	O	O	4592
minute	VERB	O	O	4592
in	ADP	O	O	4592
association	PROPN	O	O	4592
with	ADP	O	O	4592
marked	VERB	O	O	4592
hypotension	NOUN	O	Disease	4592
and	CCONJ	O	O	4592
elevation	NOUN	O	O	4592
of	ADP	O	O	4592
cardiac	ADJ	O	O	4592
output	NOUN	O	O	4592
.	PUNCT	O	O	4592
Production	NOUN	O	O	4595
of	ADP	O	O	4595
autochthonous	ADJ	O	O	4595
prostate cancer	NOUN	O	Disease	4595
in	ADP	O	O	4595
Lobund	NOUN	O	O	4595
-	PUNCT	O	O	4595
Wistar	PROPN	O	O	4595
rats	NOUN	O	O	4595
by	ADP	O	O	4595
treatments	NOUN	O	O	4595
with	ADP	O	O	4595
N	NUM	O	O	4595
-	PUNCT	O	O	4595
nitroso	NOUN	O	O	4595
-	PUNCT	O	O	4595
N	NUM	O	O	4595
-	PUNCT	O	O	4595
methylurea	PROPN	O	O	4595
and	CCONJ	O	O	4595
testosterone	PROPN	O	Chemical	4595
.	PUNCT	O	O	4595
strain	VERB	O	O	4596
rats	NOUN	O	O	4596
developed	VERB	O	O	4596
large	ADJ	O	O	4596
,	PUNCT	O	O	4596
palpable	ADJ	O	O	4596
prostate adenocarcinomas	VERB	O	Disease	4596
(	PUNCT	O	O	4596
PAs	NOUN	O	Disease	4596
)	PUNCT	O	O	4596
following	VERB	O	O	4596
treatments	NOUN	O	O	4596
with	ADP	O	O	4596
N	NUM	O	O	4596
-	PUNCT	O	O	4596
nitroso	NOUN	O	O	4596
-	PUNCT	O	O	4596
N	NUM	O	O	4596
-	PUNCT	O	O	4596
methylurea	PROPN	O	O	4596
(	PUNCT	O	O	4597
CAS	NOUN	O	O	4597
:	PUNCT	O	O	4597
684	NUM	O	O	4597
-	PUNCT	O	O	4597
93	NUM	O	O	4597
-	PUNCT	O	O	4597
5	NUM	O	O	4597
)	PUNCT	O	O	4597
and	CCONJ	O	O	4597
testosterone propionate	NOUN	O	Chemical	4597
[	X	O	O	4597
(	PUNCT	O	O	4597
TP	VERB	O	Chemical	4597
)	PUNCT	O	O	4597
CAS	NOUN	O	O	4597
:	PUNCT	O	O	4597
57	NUM	O	O	4597
-	PUNCT	O	O	4597
85	NUM	O	O	4597
-	PUNCT	O	O	4597
2	X	O	O	4597
]	PUNCT	O	O	4597
,	PUNCT	O	O	4597
and	CCONJ	O	O	4597
most	ADV	O	O	4597
of	ADP	O	O	4597
the	PRON	O	O	4597
tumor	NOUN	O	Disease	4597
-	PUNCT	O	O	4597
bearing	VERB	O	O	4597
rats	NOUN	O	O	4597
manifested	VERB	O	O	4597
metastatic	ADJ	O	O	4597
lesions	NOUN	O	O	4597
.	PUNCT	O	O	4597
Within	ADP	O	O	4598
the	PRON	O	O	4598
same	ADJ	O	O	4598
timeframe	NOUN	O	O	4598
,	PUNCT	O	O	4598
no	PRON	O	O	4598
L	NOUN	O	O	4598
-	PUNCT	O	O	4598
W	NOUN	O	O	4598
rat	NOUN	O	O	4598
developed	VERB	O	O	4598
a	PRON	O	O	4598
similar	ADJ	O	O	4598
palpable	ADJ	O	O	4598
PA	PROPN	O	Disease	4598
when	SCONJ	O	O	4598
treated	VERB	O	O	4598
only	ADV	O	O	4598
with	ADP	O	O	4598
TP	VERB	O	Chemical	4598
.	PUNCT	O	O	4598
In	ADP	O	O	4599
L	NOUN	O	O	4599
-	PUNCT	O	O	4599
W	NOUN	O	O	4599
rats	NOUN	O	O	4599
,	PUNCT	O	O	4599
TP	VERB	O	Chemical	4599
acted	VERB	O	O	4599
as	ADP	O	O	4599
a	PRON	O	O	4599
tumor	NOUN	O	Disease	4599
enhancement	NOUN	O	O	4599
agent	NOUN	O	O	4599
,	PUNCT	O	O	4599
with	ADP	O	O	4599
primary	NOUN	O	O	4599
emphasis	NOUN	O	O	4599
on	ADP	O	O	4599
the	PRON	O	O	4599
development	NOUN	O	O	4599
of	ADP	O	O	4599
prostate cancer	NOUN	O	Disease	4599
.	PUNCT	O	O	4599
A	PRON	O	O	4602
dystonia	NOUN	O	Disease	4602
-	PUNCT	O	O	4602
like	INTJ	O	O	4602
syndrome	NOUN	O	O	4602
after	ADP	O	O	4602
neuropeptide	NOUN	O	O	4602
(	PUNCT	O	O	4602
MSH	PROPN	O	Chemical	4602
/	PUNCT	O	O	4602
ACTH	PROPN	O	Chemical	4602
)	PUNCT	O	O	4602
stimulation	NOUN	O	O	4602
of	ADP	O	O	4602
the	PRON	O	O	4602
rat	NOUN	O	O	4602
locus	NOUN	O	O	4602
ceruleus	PROPN	O	O	4602
.	PUNCT	O	O	4602
The	PRON	O	O	4603
movement disorder	NOUN	O	Disease	4603
investigated	VERB	O	O	4603
in	ADP	O	O	4603
these	PRON	O	O	4603
studies	NOUN	O	O	4603
has	VERB	O	O	4603
some	PRON	O	O	4603
features	VERB	O	O	4603
in	ADP	O	O	4603
common	ADJ	O	O	4603
with	ADP	O	O	4603
human	PROPN	O	O	4603
idiopathic	ADJ	O	O	4603
dystonia	NOUN	O	Disease	4603
,	PUNCT	O	O	4603
and	CCONJ	O	O	4603
information	NOUN	O	O	4603
obtained	VERB	O	O	4603
in	ADP	O	O	4603
these	PRON	O	O	4603
studies	NOUN	O	O	4603
may	AUX	O	O	4603
be	AUX	O	O	4603
of	ADP	O	O	4603
potential	ADJ	O	O	4603
clinical	ADJ	O	O	4603
benefit	VERB	O	O	4603
.	PUNCT	O	O	4603
However	ADV	O	O	4604
,	PUNCT	O	O	4604
it	PRON	O	O	4604
is	AUX	O	O	4604
not	PART	O	O	4604
certain	ADJ	O	O	4604
as	ADP	O	O	4604
to	PART	O	O	4604
the	PRON	O	O	4604
following	VERB	O	O	4604
:	PUNCT	O	O	4604
(	PUNCT	O	O	4604
a	PRON	O	O	4604
)	PUNCT	O	O	4604
what	PRON	O	O	4604
receptors	NOUN	O	O	4604
were	AUX	O	O	4604
stimulated	VERB	O	O	4604
by	ADP	O	O	4604
the	PRON	O	O	4604
ACTH	PROPN	O	Chemical	4604
N	NUM	O	O	4604
-	PUNCT	O	O	4604
terminal	PROPN	O	O	4604
fragments	NOUN	O	O	4604
at	ADP	O	O	4604
the	PRON	O	O	4604
LC	PROPN	O	O	4604
that	SCONJ	O	O	4604
resulted	VERB	O	O	4604
in	ADP	O	O	4604
this	PRON	O	O	4604
disorder	NOUN	O	O	4604
;	PUNCT	O	O	4604
(	PUNCT	O	O	4604
b	X	O	O	4604
)	PUNCT	O	O	4604
whether	SCONJ	O	O	4604
NE	PROPN	O	Chemical	4604
,	PUNCT	O	O	4604
released	VERB	O	O	4604
onto	ADP	O	O	4604
Purkinje	PROPN	O	O	4604
cell	NOUN	O	O	4604
synapses	NOUN	O	O	4604
located	VERB	O	O	4604
at	ADP	O	O	4604
terminals	NOUN	O	O	4604
of	ADP	O	O	4604
the	PRON	O	O	4604
ceruleo	VERB	O	O	4604
-	PUNCT	O	O	4604
cerebellar	ADJ	O	O	4604
pathway	NOUN	O	O	4604
,	PUNCT	O	O	4604
did	VERB	O	O	4604
indeed	ADV	O	O	4604
cause	VERB	O	O	4604
the	PRON	O	O	4604
long	ADV	O	O	4604
-	PUNCT	O	O	4604
term	NOUN	O	O	4604
depression	PROPN	O	Disease	4604
at	ADP	O	O	4604
Purkinje	PROPN	O	O	4604
cell	NOUN	O	O	4604
synapses	NOUN	O	O	4604
(	PUNCT	O	O	4604
previously	ADV	O	O	4604
described	VERB	O	O	4604
by	ADP	O	O	4604
others	NOUN	O	O	4604
)	PUNCT	O	O	4604
that	SCONJ	O	O	4604
resulted	VERB	O	O	4604
in	ADP	O	O	4604
the	PRON	O	O	4604
long	ADV	O	O	4604
duration	NOUN	O	O	4604
of	ADP	O	O	4604
the	PRON	O	O	4604
movement disorder	NOUN	O	Disease	4604
;	PUNCT	O	O	4604
(	PUNCT	O	O	4604
c	X	O	O	4604
)	PUNCT	O	O	4604
whether	SCONJ	O	O	4604
the	PRON	O	O	4604
inhibition	NOUN	O	O	4604
of	ADP	O	O	4604
inhibitory	ADJ	O	O	4604
Purkinje	PROPN	O	O	4604
cells	NOUN	O	O	4604
resulted	VERB	O	O	4604
in	ADP	O	O	4604
disinhibition	NOUN	O	O	4604
or	CCONJ	O	O	4604
increased	VERB	O	O	4604
excitability	NOUN	O	O	4604
of	ADP	O	O	4604
the	PRON	O	O	4604
unilateral	ADJ	O	O	4604
cerebellar	ADJ	O	O	4604
Dexmedetomidine	PROPN	O	Chemical	4607
,	PUNCT	O	O	4607
acting	VERB	O	O	4607
through	ADP	O	O	4607
central	ADJ	O	O	4607
alpha-2	NUM	O	O	4607
adrenoceptors	VERB	O	O	4607
,	PUNCT	O	O	4607
prevents	VERB	O	O	4607
opiate	NOUN	O	O	4607
-	PUNCT	O	O	4607
induced	VERB	O	O	4607
muscle rigidity	NOUN	O	Disease	4607
in	ADP	O	O	4607
the	PRON	O	O	4607
rat	NOUN	O	O	4607
.	PUNCT	O	O	4607
The	PRON	O	O	4608
highly	ADV	O	O	4608
-	PUNCT	O	O	4608
selective	ADJ	O	O	4608
alpha-2	NUM	O	O	4608
adrenergic	NOUN	O	O	4608
agonist	NOUN	O	O	4608
dexmedetomidine	PROPN	O	Chemical	4608
(	PUNCT	O	O	4608
D	NOUN	O	O	4608
-	PUNCT	O	O	4608
MED	NOUN	O	O	4608
)	PUNCT	O	O	4608
is	AUX	O	O	4608
capable	ADJ	O	O	4608
of	ADP	O	O	4608
inducing	VERB	O	O	4608
muscle flaccidity	NOUN	O	Disease	4608
and	CCONJ	O	O	4608
anesthesia	NOUN	O	O	4608
in	ADP	O	O	4608
rats	NOUN	O	O	4608
and	CCONJ	O	O	4608
dogs	NOUN	O	O	4608
.	PUNCT	O	O	4608
Intense	ADJ	O	O	4609
generalized	VERB	O	O	4609
muscle rigidity	NOUN	O	Disease	4609
is	AUX	O	O	4609
an	PRON	O	O	4609
undesirable	ADJ	O	O	4609
side	NOUN	O	O	4609
effect	VERB	O	O	4609
of	ADP	O	O	4609
potent	ADJ	O	O	4609
opiate	NOUN	O	O	4609
agonists	NOUN	O	O	4609
.	PUNCT	O	O	4609
Although	SCONJ	O	O	4610
the	PRON	O	O	4610
neurochemistry	NOUN	O	O	4610
of	ADP	O	O	4610
opiate	NOUN	O	O	4610
-	PUNCT	O	O	4610
induced	VERB	O	O	4610
rigidity	NOUN	O	Disease	4610
has	VERB	O	O	4610
yet	ADV	O	O	4610
to	PART	O	O	4610
be	AUX	O	O	4610
fully	ADV	O	O	4610
elucidated	VERB	O	O	4610
,	PUNCT	O	O	4610
recent	ADJ	O	O	4610
work	NOUN	O	O	4610
suggests	VERB	O	O	4610
a	PRON	O	O	4610
role	NOUN	O	O	4610
for	ADP	O	O	4610
a	PRON	O	O	4610
central	ADJ	O	O	4610
adrenergic	NOUN	O	O	4610
mechanism	NOUN	O	O	4610
.	PUNCT	O	O	4610
In	ADP	O	O	4611
the	PRON	O	O	4611
present	NOUN	O	O	4611
study	VERB	O	O	4611
,	PUNCT	O	O	4611
the	PRON	O	O	4611
authors	NOUN	O	O	4611
determined	VERB	O	O	4611
if	SCONJ	O	O	4611
treatment	NOUN	O	O	4611
with	ADP	O	O	4611
D	NOUN	O	O	4611
-	PUNCT	O	O	4611
MED	NOUN	O	O	4611
prevents	VERB	O	O	4611
the	PRON	O	O	4611
muscle rigidity	NOUN	O	Disease	4611
caused	VERB	O	O	4611
by	ADP	O	O	4611
high	ADJ	O	O	4611
-	PUNCT	O	O	4611
dose	NOUN	O	O	4611
alfentanil	NOUN	O	Chemical	4611
anesthesia	NOUN	O	O	4611
in	ADP	O	O	4611
the	PRON	O	O	4611
rat	NOUN	O	O	4611
.	PUNCT	O	O	4611
Animals	NOUN	O	O	4612
(	PUNCT	O	O	4612
n	CCONJ	O	O	4612
=	PUNCT	O	O	4612
42	NUM	O	O	4612
)	PUNCT	O	O	4612
were	AUX	O	O	4612
treated	VERB	O	O	4612
intraperitoneally	ADV	O	O	4612
with	ADP	O	O	4612
one	NUM	O	O	4612
of	ADP	O	O	4612
the	PRON	O	O	4612
following	VERB	O	O	4612
six	NUM	O	O	4612
regimens	NOUN	O	O	4612
:	PUNCT	O	O	4612
1	X	O	O	4612
)	PUNCT	O	O	4612
L	NOUN	O	O	4612
-	PUNCT	O	O	4612
MED	NOUN	O	O	4612
(	PUNCT	O	O	4612
the	PRON	O	O	4612
inactive	ADJ	O	O	4612
L	NOUN	O	O	4612
-	PUNCT	O	O	4612
isomer	PROPN	O	O	4612
of	ADP	O	O	4612
medetomidine	PROPN	O	Chemical	4612
)	PUNCT	O	O	4612
,	PUNCT	O	O	4612
30	NUM	O	O	4612
micrograms	NOUN	O	O	4612
/	PUNCT	O	O	4612
kg	VERB	O	O	4612
;	PUNCT	O	O	4612
2	X	O	O	4612
)	PUNCT	O	O	4612
D	NOUN	O	O	4612
-	PUNCT	O	O	4612
MED	NOUN	O	O	4612
,	PUNCT	O	O	4612
10	NUM	O	O	4612
micrograms	NOUN	O	O	4612
/	PUNCT	O	O	4612
kg	VERB	O	O	4612
;	PUNCT	O	O	4612
3	X	O	O	4613
)	PUNCT	O	O	4613
D	NOUN	O	O	4613
-	PUNCT	O	O	4613
MED	NOUN	O	O	4613
,	PUNCT	O	O	4613
30	NUM	O	O	4613
micrograms	NOUN	O	O	4613
/	PUNCT	O	O	4613
kg	VERB	O	O	4613
;	PUNCT	O	O	4613
4	NUM	O	O	4613
)	PUNCT	O	O	4613
D	NOUN	O	O	4613
-	PUNCT	O	O	4613
MED	NOUN	O	O	4613
[	X	O	O	4613
30	NUM	O	O	4613
micrograms	NOUN	O	O	4613
/	PUNCT	O	O	4613
kg	VERB	O	O	4613
]	PUNCT	O	O	4613
and	CCONJ	O	O	4613
the	PRON	O	O	4613
central	ADJ	O	O	4613
-	PUNCT	O	O	4613
acting	VERB	O	O	4613
alpha-2	NUM	O	O	4613
antagonist	NOUN	O	O	4613
,	PUNCT	O	O	4613
idazoxan	NOUN	O	Chemical	4613
[	X	O	O	4613
10	NUM	O	O	4613
mg	VERB	O	O	4613
/	PUNCT	O	O	4613
kg	VERB	O	O	4613
]	PUNCT	O	O	4613
;	PUNCT	O	O	4613
5	NUM	O	O	4613
)	PUNCT	O	O	4613
D	NOUN	O	O	4613
-	PUNCT	O	O	4613
MED	NOUN	O	O	4613
[	X	O	O	4613
30	NUM	O	O	4613
micrograms	NOUN	O	O	4613
/	PUNCT	O	O	4613
kg	VERB	O	O	4613
]	PUNCT	O	O	4613
and	CCONJ	O	O	4613
the	PRON	O	O	4613
peripheral	ADJ	O	O	4613
-	PUNCT	O	O	4613
acting	VERB	O	O	4613
alpha-2	NUM	O	O	4613
antagonist	NOUN	O	O	4613
DG-5128	NOUN	O	Chemical	4613
[	X	O	O	4613
10	NUM	O	O	4613
mg	VERB	O	O	4613
/	PUNCT	O	O	4613
kg	VERB	O	O	4613
]	PUNCT	O	O	4613
,	PUNCT	O	O	4613
or	CCONJ	O	O	4613
;	PUNCT	O	O	4613
6	NUM	O	O	4613
)	PUNCT	O	O	4613
Each	PRON	O	O	4614
rat	NOUN	O	O	4614
was	AUX	O	O	4614
then	ADV	O	O	4614
injected	VERB	O	O	4614
with	ADP	O	O	4614
alfentanil	NOUN	O	Chemical	4614
(	PUNCT	O	O	4614
ALF	PROPN	O	Disease	4614
,	PUNCT	O	O	4614
0.5	NUM	O	O	4614
mg	VERB	O	O	4614
/	PUNCT	O	O	4614
kg	VERB	O	O	4614
sc	PROPN	O	O	4614
)	PUNCT	O	O	4614
.	PUNCT	O	O	4614
ALF	PROPN	O	Disease	4615
injection	NOUN	O	O	4615
resulted	VERB	O	O	4615
in	ADP	O	O	4615
a	PRON	O	O	4615
marked	VERB	O	O	4615
increase	VERB	O	O	4615
in	ADP	O	O	4615
hindlimb	NOUN	O	O	4615
EMG	PROPN	O	O	4615
activity	NOUN	O	O	4615
in	ADP	O	O	4615
the	PRON	O	O	4615
L	NOUN	O	O	4615
-	PUNCT	O	O	4615
MED	NOUN	O	O	4615
treatment	NOUN	O	O	4615
group	NOUN	O	O	4615
which	PRON	O	O	4615
was	AUX	O	O	4615
indistinguishable	ADJ	O	O	4615
from	ADP	O	O	4615
that	SCONJ	O	O	4615
seen	VERB	O	O	4615
in	ADP	O	O	4615
animals	NOUN	O	O	4615
treated	VERB	O	O	4615
with	ADP	O	O	4615
saline	NOUN	O	O	4615
.	PUNCT	O	O	4615
In	ADP	O	O	4616
contrast	NOUN	O	O	4616
,	PUNCT	O	O	4616
D	NOUN	O	O	4616
-	PUNCT	O	O	4616
MED	NOUN	O	O	4616
prevented	VERB	O	O	4616
alfentanil	NOUN	O	Chemical	4616
-	PUNCT	O	O	4616
induced	VERB	O	O	4616
muscle rigidity	NOUN	O	Disease	4616
in	ADP	O	O	4616
a	PRON	O	O	4616
dose	NOUN	O	O	4616
-	PUNCT	O	O	4616
dependent	ADJ	O	O	4616
fashion	NOUN	O	O	4616
.	PUNCT	O	O	4616
The	PRON	O	O	4617
small	ADJ	O	O	4617
EMG	PROPN	O	O	4617
values	NOUN	O	O	4617
obtained	VERB	O	O	4617
in	ADP	O	O	4617
the	PRON	O	O	4617
high	ADJ	O	O	4617
-	PUNCT	O	O	4617
dose	NOUN	O	O	4617
D	NOUN	O	O	4617
-	PUNCT	O	O	4617
MED	NOUN	O	O	4617
group	NOUN	O	O	4617
were	AUX	O	O	4617
comparable	ADJ	O	O	4617
with	ADP	O	O	4617
those	PRON	O	O	4617
recorded	VERB	O	O	4617
in	ADP	O	O	4617
earlier	ADV	O	O	4617
studies	NOUN	O	O	4617
from	ADP	O	O	4617
control	VERB	O	O	4617
animals	NOUN	O	O	4617
not	PART	O	O	4617
given	VERB	O	O	4617
any	PRON	O	O	4617
opiate	NOUN	O	O	4617
.	PUNCT	O	O	4617
The	PRON	O	O	4618
high	ADJ	O	O	4618
-	PUNCT	O	O	4618
dose	NOUN	O	O	4618
D	NOUN	O	O	4618
-	PUNCT	O	O	4618
MED	NOUN	O	O	4618
animals	NOUN	O	O	4618
were	AUX	O	O	4618
flaccid	ADJ	O	O	4618
,	PUNCT	O	O	4618
akinetic	ADJ	O	Disease	4618
,	PUNCT	O	O	4618
and	CCONJ	O	O	4618
lacked	VERB	O	O	4618
a	PRON	O	O	4618
startle	VERB	O	Disease	4618
response	NOUN	O	O	4618
during	ADP	O	O	4618
the	PRON	O	O	4618
entire	ADJ	O	O	4618
experimental	ADJ	O	O	4618
period.(ABSTRACT	NOUN	O	O	4618
TRUNCATED	ADJ	O	O	4618
AT	ADP	O	O	4618
250	NUM	O	O	4618
WORDS	NOUN	O	O	4618
)	PUNCT	O	O	4618
Seizure	NOUN	O	Disease	4621
activity	NOUN	O	O	4621
with	ADP	O	O	4621
imipenem	PROPN	O	Chemical	4621
therapy	NOUN	O	O	4621
:	PUNCT	O	O	4621
incidence	NOUN	O	O	4621
and	CCONJ	O	O	4621
risk	NOUN	O	O	4621
factors	NOUN	O	O	4621
.	PUNCT	O	O	4621
Two	NUM	O	O	4622
elderly	ADJ	O	O	4622
patients	NOUN	O	O	4622
with	ADP	O	O	4622
a	PRON	O	O	4622
history	NOUN	O	O	4622
of	ADP	O	O	4622
either	ADV	O	O	4622
cerebral vascular accident	NOUN	O	Disease	4622
(	PUNCT	O	O	4622
CVA	PROPN	O	Disease	4622
)	PUNCT	O	O	4622
or	CCONJ	O	O	4622
head trauma	NOUN	O	Disease	4622
and	CCONJ	O	O	4622
no	PRON	O	O	4622
evidence	NOUN	O	O	4622
of	ADP	O	O	4622
renal disease	NOUN	O	Disease	4622
developed	VERB	O	O	4622
seizures	NOUN	O	Disease	4622
while	SCONJ	O	O	4622
receiving	VERB	O	O	4622
maximum	ADV	O	O	4622
doses	NOUN	O	O	4622
of	ADP	O	O	4622
imipenem	PROPN	O	Chemical	4622
/	PUNCT	O	O	4622
cilastatin	PROPN	O	O	4622
.	PUNCT	O	O	4622
Neither	PRON	O	O	4623
patient	NOUN	O	O	4623
had	VERB	O	O	4623
reported	VERB	O	O	4623
previous	ADJ	O	O	4623
seizures	NOUN	O	Disease	4623
or	CCONJ	O	O	4623
seizure	NOUN	O	Disease	4623
-	PUNCT	O	O	4623
like	INTJ	O	O	4623
activity	NOUN	O	O	4623
nor	CCONJ	O	O	4623
was	AUX	O	O	4623
receiving	VERB	O	O	4623
anticonvulsant	ADJ	O	O	4623
agents	NOUN	O	O	4623
.	PUNCT	O	O	4623
All	PRON	O	O	4624
seizures	NOUN	O	Disease	4624
were	AUX	O	O	4624
controlled	VERB	O	O	4624
with	ADP	O	O	4624
therapeutic	ADJ	O	O	4624
doses	NOUN	O	O	4624
of	ADP	O	O	4624
phenytoin	NOUN	O	Chemical	4624
.	PUNCT	O	O	4624
Both	PRON	O	O	4625
patients	NOUN	O	O	4625
had	VERB	O	O	4625
received	VERB	O	O	4625
maximum	ADV	O	O	4625
doses	NOUN	O	O	4625
of	ADP	O	O	4625
other	ADJ	O	O	4625
beta	NOUN	O	O	4625
-	PUNCT	O	O	4625
lactam	NOUN	O	O	4625
antibiotics	VERB	O	O	4625
without	ADP	O	O	4625
evidence	NOUN	O	O	4625
of	ADP	O	O	4625
seizure	NOUN	O	Disease	4625
activity	NOUN	O	O	4625
.	PUNCT	O	O	4625
The	PRON	O	O	4628
ability	NOUN	O	O	4628
of	ADP	O	O	4628
insulin	NOUN	O	O	4628
treatment	NOUN	O	O	4628
to	PART	O	O	4628
reverse	VERB	O	O	4628
or	CCONJ	O	O	4628
prevent	VERB	O	O	4628
the	PRON	O	O	4628
changes	VERB	O	O	4628
in	ADP	O	O	4628
urinary	ADJ	O	O	4628
bladder	NOUN	O	O	4628
function	NOUN	O	O	4628
caused	VERB	O	O	4628
by	ADP	O	O	4628
streptozotocin	PROPN	O	Chemical	4628
-	PUNCT	O	O	4628
induced	VERB	O	O	4628
diabetes mellitus	ADJ	O	Disease	4628
.	PUNCT	O	O	4628
1	X	O	O	4628
.	PUNCT	O	O	4628
The	PRON	O	O	4629
effects	NOUN	O	O	4629
of	ADP	O	O	4629
insulin	NOUN	O	O	4629
treatment	NOUN	O	O	4629
on	ADP	O	O	4629
in	ADP	O	O	4629
vivo	VERB	O	O	4629
and	CCONJ	O	O	4629
in	ADP	O	O	4629
vitro	X	O	O	4629
urinary	ADJ	O	O	4629
bladder	NOUN	O	O	4629
function	NOUN	O	O	4629
in	ADP	O	O	4629
streptozotocin	PROPN	O	Chemical	4629
-	PUNCT	O	O	4629
diabetic	ADJ	O	Disease	4629
rats	NOUN	O	O	4629
were	AUX	O	O	4629
investigated	VERB	O	O	4629
.	PUNCT	O	O	4629
Diabetes	NOUN	O	Disease	4630
of	ADP	O	O	4630
2	X	O	O	4630
months	NOUN	O	O	4630
duration	NOUN	O	O	4630
resulted	VERB	O	O	4630
in	ADP	O	O	4630
decreases	VERB	O	O	4630
in	ADP	O	O	4630
body	NOUN	O	O	4630
weight	NOUN	O	O	4630
and	CCONJ	O	O	4630
increases	VERB	O	O	4630
in	ADP	O	O	4630
fluid	NOUN	O	O	4630
consumption	NOUN	O	O	4630
,	PUNCT	O	O	4630
urine	NOUN	O	O	4630
volume	PROPN	O	O	4630
,	PUNCT	O	O	4630
frequency	NOUN	O	O	4630
of	ADP	O	O	4630
micturition	NOUN	O	O	4630
,	PUNCT	O	O	4630
and	CCONJ	O	O	4630
average	ADJ	O	O	4630
volume	PROPN	O	O	4630
per	ADP	O	O	4630
micturition	NOUN	O	O	4630
;	PUNCT	O	O	4630
effects	NOUN	O	O	4630
which	PRON	O	O	4630
were	AUX	O	O	4630
prevented	VERB	O	O	4630
by	ADP	O	O	4630
insulin	NOUN	O	O	4630
treatment	NOUN	O	O	4630
.	PUNCT	O	O	4630
3	X	O	O	4631
.	PUNCT	O	O	4631
Insulin	NOUN	O	O	4631
treatment	NOUN	O	O	4631
also	ADV	O	O	4631
prevented	VERB	O	O	4631
the	PRON	O	O	4631
increases	VERB	O	O	4631
in	ADP	O	O	4631
contractile	ADJ	O	O	4631
responses	NOUN	O	O	4631
of	ADP	O	O	4631
bladder	NOUN	O	O	4631
body	NOUN	O	O	4631
strips	NOUN	O	O	4631
from	ADP	O	O	4631
diabetic	ADJ	O	Disease	4631
rats	NOUN	O	O	4631
to	PART	O	O	4631
nerve	NOUN	O	O	4631
stimulation	NOUN	O	O	4631
,	PUNCT	O	O	4631
ATP	PROPN	O	Chemical	4631
,	PUNCT	O	O	4631
and	CCONJ	O	O	4631
bethanechol	NOUN	O	Chemical	4631
.	PUNCT	O	O	4631
Diabetes	NOUN	O	Disease	4632
of	ADP	O	O	4632
4	NUM	O	O	4632
months	NOUN	O	O	4632
duration	NOUN	O	O	4632
also	ADV	O	O	4632
resulted	VERB	O	O	4632
in	ADP	O	O	4632
decreases	VERB	O	O	4632
in	ADP	O	O	4632
body	NOUN	O	O	4632
weight	NOUN	O	O	4632
,	PUNCT	O	O	4632
and	CCONJ	O	O	4632
increases	VERB	O	O	4632
in	ADP	O	O	4632
fluid	NOUN	O	O	4632
consumption	NOUN	O	O	4632
,	PUNCT	O	O	4632
urine	NOUN	O	O	4632
volume	PROPN	O	O	4632
,	PUNCT	O	O	4632
frequency	NOUN	O	O	4632
of	ADP	O	O	4632
micturition	NOUN	O	O	4632
,	PUNCT	O	O	4632
and	CCONJ	O	O	4632
average	ADJ	O	O	4632
volume	PROPN	O	O	4632
per	ADP	O	O	4632
micturition	NOUN	O	O	4632
,	PUNCT	O	O	4632
effects	NOUN	O	O	4632
which	PRON	O	O	4632
were	AUX	O	O	4632
reversed	VERB	O	O	4632
by	ADP	O	O	4632
insulin	NOUN	O	O	4632
treatment	NOUN	O	O	4632
for	ADP	O	O	4632
the	PRON	O	O	4632
final	ADJ	O	O	4632
2	X	O	O	4632
months	NOUN	O	O	4632
of	ADP	O	O	4632
the	PRON	O	O	4632
study	VERB	O	O	4632
.	PUNCT	O	O	4632
Insulin	NOUN	O	O	4633
treatment	NOUN	O	O	4633
reversed	VERB	O	O	4633
the	PRON	O	O	4633
increases	VERB	O	O	4633
in	ADP	O	O	4633
contractile	ADJ	O	O	4633
responses	NOUN	O	O	4633
of	ADP	O	O	4633
bladder	NOUN	O	O	4633
body	NOUN	O	O	4633
strips	NOUN	O	O	4633
from	ADP	O	O	4633
diabetic	ADJ	O	Disease	4633
rats	NOUN	O	O	4633
to	PART	O	O	4633
nerve	NOUN	O	O	4633
stimulation	NOUN	O	O	4633
,	PUNCT	O	O	4633
ATP	PROPN	O	Chemical	4633
,	PUNCT	O	O	4633
and	CCONJ	O	O	4633
bethanechol	NOUN	O	Chemical	4633
.	PUNCT	O	O	4633
The	PRON	O	O	4634
data	NOUN	O	O	4634
indicate	VERB	O	O	4634
that	SCONJ	O	O	4634
the	PRON	O	O	4634
effects	NOUN	O	O	4634
of	ADP	O	O	4634
streptozotocin	PROPN	O	Chemical	4634
-	PUNCT	O	O	4634
induced	VERB	O	O	4634
diabetes	NOUN	O	Disease	4634
on	ADP	O	O	4634
urinary	ADJ	O	O	4634
bladder	NOUN	O	O	4634
function	NOUN	O	O	4634
are	AUX	O	O	4634
both	PRON	O	O	4634
prevented	VERB	O	O	4634
and	CCONJ	O	O	4634
reversed	VERB	O	O	4634
by	ADP	O	O	4634
insulin	NOUN	O	O	4634
treatment	NOUN	O	O	4634
.	PUNCT	O	O	4634
Delayed	VERB	O	O	4637
institution	NOUN	O	O	4637
of	ADP	O	O	4637
hypertension	NOUN	O	Disease	4637
during	ADP	O	O	4637
focal	ADJ	O	O	4637
cerebral ischemia	NOUN	O	Disease	4637
:	PUNCT	O	O	4637
effect	VERB	O	O	4637
on	ADP	O	O	4637
brain edema	NOUN	O	Disease	4637
.	PUNCT	O	O	4637
The	PRON	O	O	4638
effect	VERB	O	O	4638
of	ADP	O	O	4638
induced	VERB	O	O	4638
hypertension	NOUN	O	Disease	4638
instituted	VERB	O	O	4638
after	ADP	O	O	4638
a	PRON	O	O	4638
2-h	NOUN	O	O	4638
delay	NOUN	O	O	4638
following	VERB	O	O	4638
middle	ADJ	O	O	4638
cerebral artery occlusion	NOUN	O	Disease	4638
(	PUNCT	O	O	4638
MCAO	NOUN	O	Disease	4638
)	PUNCT	O	O	4638
on	ADP	O	O	4638
brain edema	NOUN	O	Disease	4638
formation	NOUN	O	O	4638
and	CCONJ	O	O	4638
histochemical	ADJ	O	O	4638
injury	NOUN	O	O	4638
was	AUX	O	O	4638
studied	VERB	O	O	4638
.	PUNCT	O	O	4638
Under	ADP	O	O	4639
isoflurane	NOUN	O	Chemical	4639
anesthesia	NOUN	O	O	4639
,	PUNCT	O	O	4639
the	PRON	O	O	4639
MCA	PROPN	O	O	4639
of	ADP	O	O	4639
14	NUM	O	O	4639
spontaneously	ADV	O	O	4639
hypertensive	ADJ	O	Disease	4639
rats	NOUN	O	O	4639
was	AUX	O	O	4639
occluded	VERB	O	O	4639
.	PUNCT	O	O	4639
In	ADP	O	O	4640
the	PRON	O	O	4640
hypertensive	ADJ	O	Disease	4640
group	NOUN	O	O	4640
(	PUNCT	O	O	4640
n	CCONJ	O	O	4640
=	PUNCT	O	O	4640
7	NUM	O	O	4640
)	PUNCT	O	O	4640
,	PUNCT	O	O	4640
the	PRON	O	O	4640
MAP	PROPN	O	O	4640
was	AUX	O	O	4640
elevated	ADJ	O	O	4640
by	ADP	O	O	4640
25	NUM	O	O	4640
-	PUNCT	O	O	4640
30	NUM	O	O	4640
mm	INTJ	O	O	4640
Hg	PROPN	O	O	4640
beginning	VERB	O	O	4640
2	X	O	O	4640
h	X	O	O	4640
after	ADP	O	O	4640
MCAO	NOUN	O	Disease	4640
.	PUNCT	O	O	4640
Four	NUM	O	O	4641
hours	NOUN	O	O	4641
after	ADP	O	O	4641
MCAO	NOUN	O	Disease	4641
,	PUNCT	O	O	4641
the	PRON	O	O	4641
rats	NOUN	O	O	4641
were	AUX	O	O	4641
killed	VERB	O	O	4641
and	CCONJ	O	O	4641
the	PRON	O	O	4641
brains	NOUN	O	O	4641
harvested	VERB	O	O	4641
.	PUNCT	O	O	4641
The	PRON	O	O	4642
brains	NOUN	O	O	4642
were	AUX	O	O	4642
sectioned	VERB	O	O	4642
along	ADV	O	O	4642
coronal	ADJ	O	O	4642
planes	NOUN	O	O	4642
spanning	VERB	O	O	4642
the	PRON	O	O	4642
distribution	NOUN	O	O	4642
of	ADP	O	O	4642
ischemia	NOUN	O	Disease	4642
produced	VERB	O	O	4642
by	ADP	O	O	4642
MCAO	NOUN	O	Disease	4642
.	PUNCT	O	O	4642
Specific	ADJ	O	O	4643
gravity	NOUN	O	O	4643
(	PUNCT	O	O	4643
SG	PROPN	O	O	4643
)	PUNCT	O	O	4643
was	AUX	O	O	4643
determined	VERB	O	O	4643
in	ADP	O	O	4643
the	PRON	O	O	4643
subcortex	NOUN	O	O	4643
and	CCONJ	O	O	4643
in	ADP	O	O	4643
two	NUM	O	O	4643
sites	NOUN	O	O	4643
in	ADP	O	O	4643
the	PRON	O	O	4643
cortex	VERB	O	O	4643
(	PUNCT	O	O	4643
core	NOUN	O	O	4643
and	CCONJ	O	O	4643
periphery	NOUN	O	O	4643
of	ADP	O	O	4643
the	PRON	O	O	4643
ischemic	VERB	O	Disease	4643
territory	NOUN	O	O	4643
)	PUNCT	O	O	4643
.	PUNCT	O	O	4643
The	PRON	O	O	4644
extent	NOUN	O	O	4644
of	ADP	O	O	4644
neuronal injury	NOUN	O	Disease	4644
was	AUX	O	O	4644
determined	VERB	O	O	4644
by	ADP	O	O	4644
2,3,5-triphenyltetrazolium	NOUN	O	Chemical	4644
staining	VERB	O	O	4644
.	PUNCT	O	O	4644
In	ADP	O	O	4645
the	PRON	O	O	4645
ischemic	VERB	O	Disease	4645
core	NOUN	O	O	4645
,	PUNCT	O	O	4645
there	ADV	O	O	4645
was	AUX	O	O	4645
no	PRON	O	O	4645
difference	NOUN	O	O	4645
in	ADP	O	O	4645
SG	PROPN	O	O	4645
in	ADP	O	O	4645
the	PRON	O	O	4645
subcortex	NOUN	O	O	4645
and	CCONJ	O	O	4645
cortex	VERB	O	O	4645
in	ADP	O	O	4645
the	PRON	O	O	4645
two	NUM	O	O	4645
groups	NOUN	O	O	4645
.	PUNCT	O	O	4645
In	ADP	O	O	4646
the	PRON	O	O	4646
periphery	NOUN	O	O	4646
of	ADP	O	O	4646
the	PRON	O	O	4646
ischemic	VERB	O	Disease	4646
territory	NOUN	O	O	4646
,	PUNCT	O	O	4646
SG	PROPN	O	O	4646
in	ADP	O	O	4646
the	PRON	O	O	4646
cortex	VERB	O	O	4646
was	AUX	O	O	4646
greater	ADJ	O	O	4646
(	PUNCT	O	O	4646
less	ADV	O	O	4646
edema	NOUN	O	Disease	4646
accumulation	NOUN	O	O	4646
)	PUNCT	O	O	4646
in	ADP	O	O	4646
the	PRON	O	O	4646
hypertensive	ADJ	O	Disease	4646
group	NOUN	O	O	4646
(	PUNCT	O	O	4646
1.041	NUM	O	O	4646
+	ADP	O	O	4646
/-	PUNCT	O	O	4646
The	PRON	O	O	4647
area	NOUN	O	O	4647
of	ADP	O	O	4647
histochemical	ADJ	O	O	4647
injury	NOUN	O	O	4647
(	PUNCT	O	O	4647
as	ADP	O	O	4647
a	PRON	O	O	4647
percent	NOUN	O	O	4647
of	ADP	O	O	4647
the	PRON	O	O	4647
cross	VERB	O	O	4647
-	PUNCT	O	O	4647
sectional	ADJ	O	O	4647
area	NOUN	O	O	4647
of	ADP	O	O	4647
the	PRON	O	O	4647
hemisphere	ADV	O	O	4647
)	PUNCT	O	O	4647
was	AUX	O	O	4647
less	ADV	O	O	4647
in	ADP	O	O	4647
the	PRON	O	O	4647
hypertensive	ADJ	O	Disease	4647
group	NOUN	O	O	4647
(	PUNCT	O	O	4647
33	NUM	O	O	4647
+	ADP	O	O	4647
/-	PUNCT	O	O	4647
The	PRON	O	O	4648
data	NOUN	O	O	4648
indicate	VERB	O	O	4648
that	SCONJ	O	O	4648
phenylephrine	NOUN	O	Chemical	4648
-	PUNCT	O	O	4648
induced	VERB	O	O	4648
hypertension	NOUN	O	Disease	4648
instituted	VERB	O	O	4648
2	X	O	O	4648
h	X	O	O	4648
after	ADP	O	O	4648
MCAO	NOUN	O	Disease	4648
does	VERB	O	O	4648
not	PART	O	O	4648
aggravate	VERB	O	O	4648
edema	NOUN	O	Disease	4648
in	ADP	O	O	4648
the	PRON	O	O	4648
ischemic	VERB	O	Disease	4648
core	NOUN	O	O	4648
,	PUNCT	O	O	4648
that	SCONJ	O	O	4648
it	PRON	O	O	4648
improves	VERB	O	O	4648
edema	NOUN	O	Disease	4648
in	ADP	O	O	4648
the	PRON	O	O	4648
periphery	NOUN	O	O	4648
of	ADP	O	O	4648
the	PRON	O	O	4648
ischemic	VERB	O	Disease	4648
territory	NOUN	O	O	4648
,	PUNCT	O	O	4648
and	CCONJ	O	O	4648
that	SCONJ	O	O	4648
it	PRON	O	O	4648
reduces	VERB	O	O	4648
the	PRON	O	O	4648
area	NOUN	O	O	4648
of	ADP	O	O	4648
histochemical	ADJ	O	O	4648
neuronal dysfunction	NOUN	O	Disease	4648
.	PUNCT	O	O	4648
Amiodarone	NOUN	O	Chemical	4651
pulmonary toxicity	NOUN	O	Disease	4651
.	PUNCT	O	O	4651
Amiodarone	NOUN	O	Chemical	4652
is	AUX	O	O	4652
an	PRON	O	O	4652
effective	ADJ	O	O	4652
antiarrhythmic	PROPN	O	O	4652
agent	NOUN	O	O	4652
whose	DET	O	O	4652
utility	NOUN	O	O	4652
is	AUX	O	O	4652
limited	VERB	O	O	4652
by	ADP	O	O	4652
many	ADJ	O	O	4652
side	NOUN	O	O	4652
-	PUNCT	O	O	4652
effects	NOUN	O	O	4652
,	PUNCT	O	O	4652
the	PRON	O	O	4652
most	ADV	O	O	4652
problematic	ADJ	O	O	4652
being	AUX	O	O	4652
pneumonitis	NOUN	O	Disease	4652
.	PUNCT	O	O	4652
The	PRON	O	O	4653
pulmonary toxicity	NOUN	O	Disease	4653
of	ADP	O	O	4653
amiodarone	NOUN	O	Chemical	4653
is	AUX	O	O	4653
thought	VERB	O	O	4653
to	PART	O	O	4653
result	VERB	O	O	4653
from	ADP	O	O	4653
direct	ADJ	O	O	4653
injury	NOUN	O	O	4653
related	ADJ	O	O	4653
to	PART	O	O	4653
the	PRON	O	O	4653
intracellular	ADJ	O	O	4653
accumulation	NOUN	O	O	4653
of	ADP	O	O	4653
phospholipid	NOUN	O	O	4653
and	CCONJ	O	O	4653
T	NOUN	O	Chemical	4653
cell	NOUN	O	O	4653
-	PUNCT	O	O	4653
mediated	VERB	O	O	4653
hypersensitivity pneumonitis	NOUN	O	Disease	4653
.	PUNCT	O	O	4653
The	PRON	O	O	4654
clinical	ADJ	O	O	4654
and	CCONJ	O	O	4654
radiographic	ADJ	O	O	4654
features	VERB	O	O	4654
of	ADP	O	O	4654
amiodarone	NOUN	O	Chemical	4654
-	PUNCT	O	O	4654
induced	VERB	O	O	4654
pulmonary toxicity	NOUN	O	Disease	4654
are	AUX	O	O	4654
characteristic	ADJ	O	O	4654
but	CCONJ	O	O	4654
nonspecific	ADJ	O	O	4654
.	PUNCT	O	O	4654
The	PRON	O	O	4655
diagnosis	NOUN	O	O	4655
depends	VERB	O	O	4655
on	ADP	O	O	4655
exclusion	NOUN	O	O	4655
of	ADP	O	O	4655
other	ADJ	O	O	4655
entities	NOUN	O	O	4655
,	PUNCT	O	O	4655
such	ADJ	O	O	4655
as	ADP	O	O	4655
heart failure	NOUN	O	Disease	4655
,	PUNCT	O	O	4655
infection	NOUN	O	Disease	4655
,	PUNCT	O	O	4655
and	CCONJ	O	O	4655
malignancy	NOUN	O	Disease	4655
.	PUNCT	O	O	4655
While	SCONJ	O	O	4656
withdrawal	NOUN	O	O	4656
of	ADP	O	O	4656
amiodarone	NOUN	O	Chemical	4656
leads	VERB	O	O	4656
to	PART	O	O	4656
clinical	ADJ	O	O	4656
improvement	NOUN	O	O	4656
in	ADP	O	O	4656
majority	NOUN	O	O	4656
of	ADP	O	O	4656
cases	NOUN	O	O	4656
,	PUNCT	O	O	4656
this	PRON	O	O	4656
is	AUX	O	O	4656
not	PART	O	O	4656
always	ADV	O	O	4656
possible	ADJ	O	O	4656
or	CCONJ	O	O	4656
advisable	ADJ	O	O	4656
.	PUNCT	O	O	4656
Dose	NOUN	O	O	4657
reduction	NOUN	O	O	4657
or	CCONJ	O	O	4657
concomitant	ADJ	O	O	4657
steroid	NOUN	O	Chemical	4657
therapy	NOUN	O	O	4657
may	AUX	O	O	4657
have	VERB	O	O	4657
a	PRON	O	O	4657
role	NOUN	O	O	4657
in	ADP	O	O	4657
selected	VERB	O	O	4657
patients	NOUN	O	O	4657
.	PUNCT	O	O	4657
Light	NOUN	O	O	4660
chain	NOUN	O	O	4660
proteinuria	X	O	Disease	4660
and	CCONJ	O	O	4660
cellular	NOUN	O	O	4660
mediated	VERB	O	O	4660
immunity	NOUN	O	O	4660
in	ADP	O	O	4660
rifampin	ADV	O	Chemical	4660
treated	VERB	O	O	4660
patients	NOUN	O	O	4660
with	ADP	O	O	4660
tuberculosis	NOUN	O	Disease	4660
.	PUNCT	O	O	4660
Light	NOUN	O	O	4661
chain	NOUN	O	O	4661
proteinuria	X	O	Disease	4661
was	AUX	O	O	4661
found	VERB	O	O	4661
in	ADP	O	O	4661
9	NUM	O	O	4661
of	ADP	O	O	4661
17	NUM	O	O	4661
tuberculosis	NOUN	O	Disease	4661
patients	NOUN	O	O	4661
treated	VERB	O	O	4661
with	ADP	O	O	4661
rifampin	ADV	O	Chemical	4661
.	PUNCT	O	O	4661
Response	NOUN	O	O	4662
to	PART	O	O	4662
Varidase	PROPN	O	O	4662
skin	NOUN	O	O	4662
test	NOUN	O	O	4662
antigen	PROPN	O	O	4662
was	AUX	O	O	4662
negative	ADJ	O	O	4662
for	ADP	O	O	4662
all	PRON	O	O	4662
eight	NUM	O	O	4662
tuberculosis	NOUN	O	Disease	4662
patients	NOUN	O	O	4662
tested	VERB	O	O	4662
,	PUNCT	O	O	4662
but	CCONJ	O	O	4662
there	ADV	O	O	4662
occurred	VERB	O	O	4662
a	PRON	O	O	4662
hyper	ADJ	O	O	4662
-	PUNCT	O	O	4662
responsiveness	NOUN	O	O	4662
of	ADP	O	O	4662
the	PRON	O	O	4662
lymphocytes	VERB	O	O	4662
of	ADP	O	O	4662
these	PRON	O	O	4662
eight	NUM	O	O	4662
patients	NOUN	O	O	4662
to	PART	O	O	4662
phytomitogen	PROPN	O	O	4662
(	PUNCT	O	O	4662
PHA	NOUN	O	O	4662
-	PUNCT	O	O	4662
P	NOUN	O	Chemical	4662
)	PUNCT	O	O	4662
.	PUNCT	O	O	4662
as	ADP	O	O	4663
well	ADV	O	O	4663
as	ADP	O	O	4663
of	ADP	O	O	4663
those	PRON	O	O	4663
of	ADP	O	O	4663
seven	NUM	O	O	4663
other	ADJ	O	O	4663
tuberculous	ADJ	O	Disease	4663
patients	NOUN	O	O	4663
.	PUNCT	O	O	4663
This	PRON	O	O	4664
last	VERB	O	O	4664
finding	VERB	O	O	4664
may	AUX	O	O	4664
be	AUX	O	O	4664
related	ADJ	O	O	4664
to	PART	O	O	4664
time	NOUN	O	O	4664
of	ADP	O	O	4664
testing	NOUN	O	O	4664
and/or	CCONJ	O	O	4664
endogenous	ADJ	O	O	4664
serum	NOUN	O	O	4664
binding	VERB	O	O	4664
of	ADP	O	O	4664
rifampin	ADV	O	Chemical	4664
which	PRON	O	O	4664
could	AUX	O	O	4664
have	VERB	O	O	4664
inhibited	VERB	O	O	4664
mitogen	NOUN	O	O	4664
activity	NOUN	O	O	4664
for	ADP	O	O	4664
the	PRON	O	O	4664
lymphocyte	NOUN	O	O	4664
.	PUNCT	O	O	4664
Initial	ADJ	O	O	4667
potassium	NOUN	O	Chemical	4667
loss	NOUN	O	O	4667
and	CCONJ	O	O	4667
hypokalaemia	NOUN	O	Disease	4667
during	ADP	O	O	4667
chlorthalidone	PROPN	O	Chemical	4667
administration	NOUN	O	O	4667
in	ADP	O	O	4667
patients	NOUN	O	O	4667
with	ADP	O	O	4667
essential	ADJ	O	O	4667
hypertension	NOUN	O	Disease	4667
:	PUNCT	O	O	4667
the	PRON	O	O	4667
influence	NOUN	O	O	4667
of	ADP	O	O	4667
dietary	ADJ	O	O	4667
sodium	NOUN	O	Chemical	4667
restriction	NOUN	O	O	4667
.	PUNCT	O	O	4667
To	PART	O	O	4668
investigate	VERB	O	O	4668
the	PRON	O	O	4668
initial	ADJ	O	O	4668
potassium	NOUN	O	Chemical	4668
loss	NOUN	O	O	4668
and	CCONJ	O	O	4668
development	NOUN	O	O	4668
of	ADP	O	O	4668
hypokalaemia	NOUN	O	Disease	4668
during	ADP	O	O	4668
the	PRON	O	O	4668
administration	NOUN	O	O	4668
of	ADP	O	O	4668
an	PRON	O	O	4668
oral	ADJ	O	O	4668
diuretic	ADJ	O	Chemical	4668
,	PUNCT	O	O	4668
metabolic	ADJ	O	O	4668
balance	NOUN	O	O	4668
studies	NOUN	O	O	4668
were	AUX	O	O	4668
performed	VERB	O	O	4668
in	ADP	O	O	4668
ten	NUM	O	O	4668
patients	NOUN	O	O	4668
with	ADP	O	O	4668
essential	ADJ	O	O	4668
hypertension	NOUN	O	Disease	4668
who	PRON	O	O	4668
had	VERB	O	O	4668
shown	VERB	O	O	4668
hypokalaemia	NOUN	O	Disease	4668
under	ADP	O	O	4668
prior	ADV	O	O	4668
oral	ADJ	O	O	4668
diuretic	ADJ	O	Chemical	4668
treatment	NOUN	O	O	4668
.	PUNCT	O	O	4668
Chlorthalidone	NOUN	O	Chemical	4669
(	PUNCT	O	O	4669
50	NUM	O	O	4669
mg	VERB	O	O	4669
daily	ADV	O	O	4669
)	PUNCT	O	O	4669
was	AUX	O	O	4669
given	VERB	O	O	4669
for	ADP	O	O	4669
14	NUM	O	O	4669
days	NOUN	O	O	4669
.	PUNCT	O	O	4669
Six	NUM	O	O	4670
patients	NOUN	O	O	4670
received	VERB	O	O	4670
a	PRON	O	O	4670
normal	ADJ	O	O	4670
-	PUNCT	O	O	4670
sodium	NOUN	O	Chemical	4670
diet	PROPN	O	O	4670
and	CCONJ	O	O	4670
four	NUM	O	O	4670
a	PRON	O	O	4670
low	ADJ	O	O	4670
-	PUNCT	O	O	4670
sodium	NOUN	O	Chemical	4670
(	PUNCT	O	O	4670
17	NUM	O	O	4670
mmol	NOUN	O	O	4670
/	PUNCT	O	O	4670
day	NOUN	O	O	4670
)	PUNCT	O	O	4670
diet	PROPN	O	O	4670
.	PUNCT	O	O	4670
All	PRON	O	O	4671
patients	NOUN	O	O	4671
had	VERB	O	O	4671
a	PRON	O	O	4671
normal	ADJ	O	O	4671
initial	ADJ	O	O	4671
total	ADJ	O	O	4671
body	NOUN	O	O	4671
potassium	NOUN	O	Chemical	4671
(	PUNCT	O	O	4671
40	NUM	O	O	4671
K	PROPN	O	Chemical	4671
)	PUNCT	O	O	4671
.	PUNCT	O	O	4671
The	PRON	O	O	4672
electrolyte	NOUN	O	O	4672
balances	NOUN	O	O	4672
,	PUNCT	O	O	4672
weight	NOUN	O	O	4672
,	PUNCT	O	O	4672
bromide	NOUN	O	O	4672
space	NOUN	O	O	4672
,	PUNCT	O	O	4672
plasma	NOUN	O	O	4672
renin	PROPN	O	O	4672
activity	NOUN	O	O	4672
,	PUNCT	O	O	4672
and	CCONJ	O	O	4672
aldosterone	NOUN	O	Chemical	4672
secretion	NOUN	O	O	4672
rate	NOUN	O	O	4672
were	AUX	O	O	4672
measured	VERB	O	O	4672
.	PUNCT	O	O	4672
In	ADP	O	O	4673
both	PRON	O	O	4673
groups	NOUN	O	O	4673
a	PRON	O	O	4673
potassium	NOUN	O	Chemical	4673
deficit	NOUN	O	O	4673
developed	VERB	O	O	4673
,	PUNCT	O	O	4673
with	ADP	O	O	4673
proportionally	ADV	O	O	4673
larger	ADJ	O	O	4673
losses	NOUN	O	O	4673
from	ADP	O	O	4673
the	PRON	O	O	4673
extracellular	ADJ	O	O	4673
than	ADP	O	O	4673
from	ADP	O	O	4673
the	PRON	O	O	4673
intracellular	ADJ	O	O	4673
compartment	NOUN	O	O	4673
.	PUNCT	O	O	4673
In	ADP	O	O	4674
the	PRON	O	O	4674
normal	ADJ	O	O	4674
-	PUNCT	O	O	4674
sodium	NOUN	O	Chemical	4674
group	NOUN	O	O	4674
the	PRON	O	O	4674
highest	ADJ	O	O	4674
mean	VERB	O	O	4674
potassium	NOUN	O	Chemical	4674
deficit	NOUN	O	O	4674
was	AUX	O	O	4674
176	NUM	O	O	4674
mmol	NOUN	O	O	4674
on	ADP	O	O	4674
day	NOUN	O	O	4674
9	NUM	O	O	4674
,	PUNCT	O	O	4674
after	ADP	O	O	4674
which	PRON	O	O	4674
some	PRON	O	O	4674
potassium	NOUN	O	Chemical	4674
was	AUX	O	O	4674
regained	VERB	O	O	4674
;	PUNCT	O	O	4674
in	ADP	O	O	4674
the	PRON	O	O	4674
low	ADJ	O	O	4674
-	PUNCT	O	O	4674
sodium	NOUN	O	Chemical	4674
group	NOUN	O	O	4674
the	PRON	O	O	4674
highest	ADJ	O	O	4674
deficit	NOUN	O	O	4674
was	AUX	O	O	4674
276	NUM	O	O	4674
mmol	NOUN	O	O	4674
on	ADP	O	O	4674
day	NOUN	O	O	4674
13	NUM	O	O	4674
.	PUNCT	O	O	4674
The	PRON	O	O	4675
normal	ADJ	O	O	4675
-	PUNCT	O	O	4675
sodium	NOUN	O	Chemical	4675
group	NOUN	O	O	4675
showed	VERB	O	O	4675
an	PRON	O	O	4675
immediate	ADJ	O	O	4675
but	CCONJ	O	O	4675
temporary	ADJ	O	O	4675
rise	VERB	O	O	4675
of	ADP	O	O	4675
the	PRON	O	O	4675
renin	PROPN	O	O	4675
and	CCONJ	O	O	4675
aldosterone	NOUN	O	Chemical	4675
levels	NOUN	O	O	4675
;	PUNCT	O	O	4675
in	ADP	O	O	4675
the	PRON	O	O	4675
low	ADJ	O	O	4675
-	PUNCT	O	O	4675
sodium	NOUN	O	Chemical	4675
group	NOUN	O	O	4675
renin	PROPN	O	O	4675
and	CCONJ	O	O	4675
aldosterone	NOUN	O	Chemical	4675
increased	VERB	O	O	4675
more	ADJ	O	O	4675
slowly	ADV	O	O	4675
but	CCONJ	O	O	4675
remained	VERB	O	O	4675
elevated	ADJ	O	O	4675
.	PUNCT	O	O	4675
It	PRON	O	O	4676
is	AUX	O	O	4676
concluded	VERB	O	O	4676
that	SCONJ	O	O	4676
dietary	ADJ	O	O	4676
sodium	NOUN	O	Chemical	4676
restriction	NOUN	O	O	4676
increases	VERB	O	O	4676
diuretic	ADJ	O	Chemical	4676
-	PUNCT	O	O	4676
induced	VERB	O	O	4676
potassium	NOUN	O	Chemical	4676
loss	NOUN	O	O	4676
,	PUNCT	O	O	4676
presumably	ADV	O	O	4676
by	ADP	O	O	4676
an	PRON	O	O	4676
increased	VERB	O	O	4676
activity	NOUN	O	O	4676
of	ADP	O	O	4676
the	PRON	O	O	4676
renin	PROPN	O	O	4676
-	PUNCT	O	O	4676
angiotensin	NOUN	O	Chemical	4676
-	PUNCT	O	O	4676
aldosterone	NOUN	O	Chemical	4676
system	NOUN	O	O	4676
,	PUNCT	O	O	4676
while	SCONJ	O	O	4676
sodium	NOUN	O	Chemical	4676
delivery	NOUN	O	O	4676
to	PART	O	O	4676
the	PRON	O	O	4676
distal	NOUN	O	O	4676
renal	ADJ	O	O	4676
tubules	NOUN	O	O	4676
remains	VERB	O	O	4676
sufficiently	ADV	O	O	4676
high	ADJ	O	O	4676
to	PART	O	O	4676
allow	VERB	O	O	4676
increased	VERB	O	O	4676
potassium	NOUN	O	Chemical	4676
secretion	NOUN	O	O	4676
.	PUNCT	O	O	4676
Dynamic	ADJ	O	O	4679
response	NOUN	O	O	4679
of	ADP	O	O	4679
blood	NOUN	O	O	4679
vessel	NOUN	O	O	4679
in	ADP	O	O	4679
acute	ADJ	O	O	4679
renal failure	NOUN	O	Disease	4679
.	PUNCT	O	O	4679
In	ADP	O	O	4680
this	PRON	O	O	4680
study	VERB	O	O	4680
we	PRON	O	O	4680
postulated	VERB	O	O	4680
that	SCONJ	O	O	4680
during	ADP	O	O	4680
acute	ADJ	O	O	4680
renal failure	NOUN	O	Disease	4680
induced	VERB	O	O	4680
by	ADP	O	O	4680
gentamicin	VERB	O	Chemical	4680
the	PRON	O	O	4680
transient	ADJ	O	O	4680
or	CCONJ	O	O	4680
dynamic	ADJ	O	O	4680
response	NOUN	O	O	4680
of	ADP	O	O	4680
blood	NOUN	O	O	4680
vessels	NOUN	O	O	4680
could	AUX	O	O	4680
be	AUX	O	O	4680
affected	VERB	O	O	4680
,	PUNCT	O	O	4680
and	CCONJ	O	O	4680
that	SCONJ	O	O	4680
antioxidants	NOUN	O	O	4680
can	AUX	O	O	4680
prevent	VERB	O	O	4680
the	PRON	O	O	4680
changes	VERB	O	O	4680
in	ADP	O	O	4680
dynamic	ADJ	O	O	4680
responses	NOUN	O	O	4680
of	ADP	O	O	4680
blood	NOUN	O	O	4680
vessels	NOUN	O	O	4680
.	PUNCT	O	O	4680
Our	PRON	O	O	4681
results	VERB	O	O	4681
confirm	VERB	O	O	4681
the	PRON	O	O	4681
alteration	NOUN	O	O	4681
in	ADP	O	O	4681
dynamic	ADJ	O	O	4681
response	NOUN	O	O	4681
of	ADP	O	O	4681
blood	NOUN	O	O	4681
vessels	NOUN	O	O	4681
during	ADP	O	O	4681
the	PRON	O	O	4681
change	VERB	O	O	4681
of	ADP	O	O	4681
pressure	NOUN	O	O	4681
in	ADP	O	O	4681
gentamicin	VERB	O	Chemical	4681
-	PUNCT	O	O	4681
treated	VERB	O	O	4681
animals	NOUN	O	O	4681
.	PUNCT	O	O	4681
The	PRON	O	O	4682
beneficial	ADJ	O	O	4682
effects	NOUN	O	O	4682
of	ADP	O	O	4682
vitamin C	NOUN	O	Chemical	4682
administration	NOUN	O	O	4682
to	PART	O	O	4682
gentamicin	VERB	O	Chemical	4682
-	PUNCT	O	O	4682
treated	VERB	O	O	4682
animals	NOUN	O	O	4682
are	AUX	O	O	4682
also	ADV	O	O	4682
confirmed	VERB	O	O	4682
through	ADP	O	O	4682
:	PUNCT	O	O	4682
lower	ADJ	O	O	4682
level	VERB	O	O	4682
of	ADP	O	O	4682
blood	NOUN	O	O	4682
urea	PROPN	O	Chemical	4682
and	CCONJ	O	O	4682
creatinine	PROPN	O	Chemical	4682
and	CCONJ	O	O	4682
higher	ADJ	O	O	4682
level	VERB	O	O	4682
of	ADP	O	O	4682
potassium	NOUN	O	Chemical	4682
.	PUNCT	O	O	4682
The	PRON	O	O	4683
pressure	NOUN	O	O	4683
dynamic	ADJ	O	O	4683
responses	NOUN	O	O	4683
of	ADP	O	O	4683
isolated	VERB	O	O	4683
blood	NOUN	O	O	4683
vessels	NOUN	O	O	4683
show	VERB	O	O	4683
a	PRON	O	O	4683
faster	ADV	O	O	4683
pressure	NOUN	O	O	4683
change	VERB	O	O	4683
in	ADP	O	O	4683
gentamicin	VERB	O	Chemical	4683
-	PUNCT	O	O	4683
treated	VERB	O	O	4683
animals	NOUN	O	O	4683
(	PUNCT	O	O	4683
8.07	NUM	O	O	4683
+	ADP	O	O	4683
/-	PUNCT	O	O	4683
Vitamin C	NOUN	O	Chemical	4684
administration	NOUN	O	O	4684
induced	VERB	O	O	4684
slowdown	PROPN	O	O	4684
of	ADP	O	O	4684
pressure	NOUN	O	O	4684
change	VERB	O	O	4684
back	ADV	O	O	4684
to	PART	O	O	4684
the	PRON	O	O	4684
control	VERB	O	O	4684
values	NOUN	O	O	4684
.	PUNCT	O	O	4684
The	PRON	O	O	4685
pressure	NOUN	O	O	4685
dynamic	ADJ	O	O	4685
properties	NOUN	O	O	4685
,	PUNCT	O	O	4685
quantitatively	ADV	O	O	4685
defined	VERB	O	O	4685
by	ADP	O	O	4685
comparative	ADJ	O	O	4685
pressure	NOUN	O	O	4685
dynamic	ADJ	O	O	4685
and	CCONJ	O	O	4685
total	ADJ	O	O	4685
pressure	NOUN	O	O	4685
dynamic	ADJ	O	O	4685
,	PUNCT	O	O	4685
confirm	VERB	O	O	4685
the	PRON	O	O	4685
alteration	NOUN	O	O	4685
in	ADP	O	O	4685
dynamic	ADJ	O	O	4685
response	NOUN	O	O	4685
of	ADP	O	O	4685
blood	NOUN	O	O	4685
vessels	NOUN	O	O	4685
during	ADP	O	O	4685
the	PRON	O	O	4685
change	VERB	O	O	4685
of	ADP	O	O	4685
pressure	NOUN	O	O	4685
in	ADP	O	O	4685
gentamicin	VERB	O	Chemical	4685
-	PUNCT	O	O	4685
treated	VERB	O	O	4685
animals	NOUN	O	O	4685
and	CCONJ	O	O	4685
beneficial	ADJ	O	O	4685
effects	NOUN	O	O	4685
of	ADP	O	O	4685
vitamin C	NOUN	O	Chemical	4685
administration	NOUN	O	O	4685
.	PUNCT	O	O	4685
The	PRON	O	O	4688
hemodynamics	NOUN	O	O	4688
of	ADP	O	O	4688
oxytocin	PROPN	O	Chemical	4688
and	CCONJ	O	O	4688
other	ADJ	O	O	4688
vasoactive	ADJ	O	O	4688
agents	NOUN	O	O	4688
during	ADP	O	O	4688
neuraxial	ADJ	O	O	4688
anesthesia	NOUN	O	O	4688
for	ADP	O	O	4688
cesarean	PROPN	O	O	4688
delivery	NOUN	O	O	4688
:	PUNCT	O	O	4688
findings	NOUN	O	O	4688
in	ADP	O	O	4688
six	NUM	O	O	4688
cases	NOUN	O	O	4688
.	PUNCT	O	O	4688
Oxytocin	PROPN	O	Chemical	4689
is	AUX	O	O	4689
a	PRON	O	O	4689
commonly	ADV	O	O	4689
used	VERB	O	O	4689
uterotonic	ADJ	O	O	4689
that	SCONJ	O	O	4689
can	AUX	O	O	4689
cause	VERB	O	O	4689
significant	ADJ	O	O	4689
and	CCONJ	O	O	4689
even	ADV	O	O	4689
fatal	ADJ	O	O	4689
hypotension	NOUN	O	Disease	4689
,	PUNCT	O	O	4689
particularly	ADV	O	O	4689
when	SCONJ	O	O	4689
given	VERB	O	O	4689
as	ADP	O	O	4689
a	PRON	O	O	4689
bolus	NOUN	O	O	4689
.	PUNCT	O	O	4689
The	PRON	O	O	4690
resulting	VERB	O	O	4690
hypotension	NOUN	O	Disease	4690
can	AUX	O	O	4690
be	AUX	O	O	4690
produced	VERB	O	O	4690
by	ADP	O	O	4690
a	PRON	O	O	4690
decrease	VERB	O	O	4690
in	ADP	O	O	4690
systemic	ADJ	O	O	4690
vascular	ADJ	O	O	4690
resistance	NOUN	O	O	4690
or	CCONJ	O	O	4690
cardiac	ADJ	O	O	4690
output	NOUN	O	O	4690
through	ADP	O	O	4690
a	PRON	O	O	4690
decrease	VERB	O	O	4690
in	ADP	O	O	4690
venous	ADJ	O	O	4690
return	VERB	O	O	4690
.	PUNCT	O	O	4690
Parturients	NOUN	O	O	4691
with	ADP	O	O	4691
normal	ADJ	O	O	4691
volume	PROPN	O	O	4691
status	NOUN	O	O	4691
,	PUNCT	O	O	4691
heart	NOUN	O	O	4691
valves	NOUN	O	O	4691
and	CCONJ	O	O	4691
pulmonary	ADJ	O	O	4691
vasculature	NOUN	O	O	4691
most	ADV	O	O	4691
often	ADV	O	O	4691
respond	VERB	O	O	4691
to	PART	O	O	4691
this	PRON	O	O	4691
hypotension	NOUN	O	Disease	4691
with	ADP	O	O	4691
a	PRON	O	O	4691
compensatory	ADJ	O	O	4691
increase	VERB	O	O	4691
in	ADP	O	O	4691
heart	NOUN	O	O	4691
rate	NOUN	O	O	4691
and	CCONJ	O	O	4691
stroke	VERB	O	Disease	4691
volume	PROPN	O	O	4691
.	PUNCT	O	O	4691
Oxytocin	PROPN	O	Chemical	4692
-	PUNCT	O	O	4692
induced	VERB	O	O	4692
hypotension	NOUN	O	Disease	4692
at	ADP	O	O	4692
cesarean	PROPN	O	O	4692
delivery	NOUN	O	O	4692
may	AUX	O	O	4692
be	AUX	O	O	4692
incorrectly	ADV	O	O	4692
attributed	VERB	O	O	4692
to	PART	O	O	4692
blood loss	NOUN	O	Disease	4692
.	PUNCT	O	O	4692
Hypotension	NOUN	O	Disease	4693
in	ADP	O	O	4693
response	NOUN	O	O	4693
to	PART	O	O	4693
oxytocin	PROPN	O	Chemical	4693
was	AUX	O	O	4693
associated	VERB	O	O	4693
with	ADP	O	O	4693
a	PRON	O	O	4693
decrease	VERB	O	O	4693
in	ADP	O	O	4693
systemic	ADJ	O	O	4693
vascular	ADJ	O	O	4693
resistance	NOUN	O	O	4693
and	CCONJ	O	O	4693
a	PRON	O	O	4693
compensatory	ADJ	O	O	4693
increase	VERB	O	O	4693
in	ADP	O	O	4693
stroke	VERB	O	Disease	4693
volume	PROPN	O	O	4693
,	PUNCT	O	O	4693
heart	NOUN	O	O	4693
rate	NOUN	O	O	4693
and	CCONJ	O	O	4693
cardiac	ADJ	O	O	4693
output	NOUN	O	O	4693
.	PUNCT	O	O	4693
Pulse	NOUN	O	O	4694
power	NOUN	O	O	4694
analysis	NOUN	O	O	4694
may	AUX	O	O	4694
be	AUX	O	O	4694
helpful	ADJ	O	O	4694
in	ADP	O	O	4694
determining	VERB	O	O	4694
the	PRON	O	O	4694
etiology	NOUN	O	O	4694
of	ADP	O	O	4694
and	CCONJ	O	O	4694
treating	VERB	O	O	4694
hypotension	NOUN	O	Disease	4694
during	ADP	O	O	4694
cesarean	PROPN	O	O	4694
delivery	NOUN	O	O	4694
under	ADP	O	O	4694
neuraxial	ADJ	O	O	4694
anesthesia	NOUN	O	O	4694
.	PUNCT	O	O	4694
Exaggerated	VERB	O	O	4697
expression	NOUN	O	O	4697
of	ADP	O	O	4697
inflammatory	ADJ	O	O	4697
mediators	NOUN	O	O	4697
in	ADP	O	O	4697
vasoactive	ADJ	O	O	4697
intestinal	ADJ	O	Disease	4697
polypeptide	ADP	O	O	4697
knockout	NOUN	O	O	4697
(	PUNCT	O	O	4697
VIP-/-	NOUN	O	O	4697
)	PUNCT	O	O	4697
mice	NOUN	O	O	4697
with	ADP	O	O	4697
cyclophosphamide	VERB	O	Chemical	4697
(	PUNCT	O	O	4697
CYP)-induced	VERB	O	O	4697
cystitis	NOUN	O	Disease	4697
.	PUNCT	O	O	4697
VIP(-/-	NOUN	O	O	4698
)	PUNCT	O	O	4698
mice	NOUN	O	O	4698
exhibit	VERB	O	O	4698
altered	VERB	O	O	4698
bladder	NOUN	O	O	4698
function	NOUN	O	O	4698
and	CCONJ	O	O	4698
neurochemical	ADJ	O	O	4698
properties	NOUN	O	O	4698
in	ADP	O	O	4698
micturition	NOUN	O	O	4698
pathways	NOUN	O	O	4698
after	ADP	O	O	4698
cyclophosphamide	VERB	O	Chemical	4698
(	PUNCT	O	O	4698
CYP)-induced	VERB	O	O	4698
cystitis	NOUN	O	Disease	4698
.	PUNCT	O	O	4698
Given	VERB	O	O	4699
VIP	VERB	O	O	4699
's	AUX	O	O	4699
role	NOUN	O	O	4699
as	ADP	O	O	4699
an	PRON	O	O	4699
anti	ADJ	O	O	4699
-	PUNCT	O	O	4699
inflammatory	ADJ	O	O	4699
mediator	NOUN	O	O	4699
,	PUNCT	O	O	4699
we	PRON	O	O	4699
hypothesized	VERB	O	O	4699
that	SCONJ	O	O	4699
VIP(-/-	NOUN	O	O	4699
)	PUNCT	O	O	4699
mice	NOUN	O	O	4699
would	AUX	O	O	4699
exhibit	VERB	O	O	4699
enhanced	VERB	O	O	4699
inflammatory	ADJ	O	O	4699
mediator	NOUN	O	O	4699
expression	NOUN	O	O	4699
after	ADP	O	O	4699
cystitis	NOUN	O	Disease	4699
.	PUNCT	O	O	4699
A	PRON	O	O	4700
mouse	PROPN	O	O	4700
inflammatory	ADJ	O	O	4700
cytokine	NOUN	O	O	4700
and	CCONJ	O	O	4700
receptor	NOUN	O	O	4700
RT2	PROPN	O	O	4700
profiler	NOUN	O	O	4700
array	NOUN	O	O	4700
was	AUX	O	O	4700
used	VERB	O	O	4700
to	PART	O	O	4700
determine	VERB	O	O	4700
regulated	VERB	O	O	4700
transcripts	NOUN	O	O	4700
in	ADP	O	O	4700
the	PRON	O	O	4700
urinary	ADJ	O	O	4700
bladder	NOUN	O	O	4700
of	ADP	O	O	4700
wild	ADJ	O	O	4700
type	NOUN	O	O	4700
(	PUNCT	O	O	4700
WT	NOUN	O	O	4700
)	PUNCT	O	O	4700
and	CCONJ	O	O	4700
VIP(-/-	NOUN	O	O	4700
)	PUNCT	O	O	4700
mice	NOUN	O	O	4700
with	ADP	O	O	4700
or	CCONJ	O	O	4700
without	ADP	O	O	4700
CYP	PROPN	O	Chemical	4700
-	PUNCT	O	O	4700
induced	VERB	O	O	4700
cystitis	NOUN	O	Disease	4700
(	PUNCT	O	O	4700
150	NUM	O	O	4700
mg	VERB	O	O	4700
/	PUNCT	O	O	4700
kg	VERB	O	O	4700
;	PUNCT	O	O	4700
i.p	NOUN	O	O	4700
.	PUNCT	O	O	4700
;	PUNCT	O	O	4700
48	NUM	O	O	4700
h	X	O	O	4700
)	PUNCT	O	O	4700
.	PUNCT	O	O	4700
Four	NUM	O	O	4701
binary	ADJ	O	O	4701
comparisons	NOUN	O	O	4701
were	AUX	O	O	4701
made	VERB	O	O	4701
:	PUNCT	O	O	4701
WT	NOUN	O	O	4701
control	VERB	O	O	4701
versus	ADP	O	O	4701
CYP	PROPN	O	Chemical	4701
treatment	NOUN	O	O	4701
(	PUNCT	O	O	4701
48	NUM	O	O	4701
h	X	O	O	4701
)	PUNCT	O	O	4701
,	PUNCT	O	O	4701
VIP(-/-	NOUN	O	O	4701
)	PUNCT	O	O	4701
control	VERB	O	O	4702
versus	ADP	O	O	4702
CYP	PROPN	O	Chemical	4702
treatment	NOUN	O	O	4702
(	PUNCT	O	O	4702
48	NUM	O	O	4702
h	X	O	O	4702
)	PUNCT	O	O	4702
,	PUNCT	O	O	4702
WT	NOUN	O	O	4702
control	VERB	O	O	4702
versus	ADP	O	O	4702
VIP(-/-	NOUN	O	O	4702
)	PUNCT	O	O	4702
control	VERB	O	O	4702
,	PUNCT	O	O	4702
and	CCONJ	O	O	4702
WT	NOUN	O	O	4702
with	ADP	O	O	4702
CYP	PROPN	O	Chemical	4702
treatment	NOUN	O	O	4702
(	PUNCT	O	O	4702
48	NUM	O	O	4702
h	X	O	O	4702
)	PUNCT	O	O	4702
versus	ADP	O	O	4702
VIP(-/-	NOUN	O	O	4702
)	PUNCT	O	O	4702
with	ADP	O	O	4702
CYP	PROPN	O	Chemical	4702
treatment	NOUN	O	O	4702
(	PUNCT	O	O	4702
48	NUM	O	O	4702
h	X	O	O	4702
)	PUNCT	O	O	4702
.	PUNCT	O	O	4702
CYP	PROPN	O	Chemical	4703
treatment	NOUN	O	O	4703
significantly	ADV	O	O	4703
(	PUNCT	O	O	4703
p	NOUN	O	O	4703
<	X	O	O	4703
or	CCONJ	O	O	4703
=	PUNCT	O	O	4703
0.001	NUM	O	O	4703
)	PUNCT	O	O	4703
increased	VERB	O	O	4703
expression	NOUN	O	O	4703
of	ADP	O	O	4703
CXCL1	PROPN	O	O	4703
and	CCONJ	O	O	4703
IL-1beta	VERB	O	O	4703
in	ADP	O	O	4703
the	PRON	O	O	4703
urinary	ADJ	O	O	4703
bladder	NOUN	O	O	4703
of	ADP	O	O	4703
WT	NOUN	O	O	4703
and	CCONJ	O	O	4703
VIP(-/-	NOUN	O	O	4703
)	PUNCT	O	O	4703
mice	NOUN	O	O	4703
,	PUNCT	O	O	4703
but	CCONJ	O	O	4703
expression	NOUN	O	O	4703
in	ADP	O	O	4703
VIP(-/-	NOUN	O	O	4703
)	PUNCT	O	O	4703
mice	NOUN	O	O	4703
with	ADP	O	O	4703
CYP	PROPN	O	Chemical	4703
treatment	NOUN	O	O	4703
was	AUX	O	O	4703
significantly	ADV	O	O	4703
(	PUNCT	O	O	4703
p	NOUN	O	O	4703
<	X	O	O	4703
or	CCONJ	O	O	4703
=	PUNCT	O	O	4703
0.001	NUM	O	O	4703
)	PUNCT	O	O	4703
greater	ADJ	O	O	4703
(	PUNCT	O	O	4703
4.2-	NUM	O	O	4703
to	PART	O	O	4703
13-fold	ADV	O	O	4703
increase	VERB	O	O	4703
)	PUNCT	O	O	4703
than	ADP	O	O	4703
that	SCONJ	O	O	4703
observed	VERB	O	O	4703
in	ADP	O	O	4703
WT	NOUN	O	O	4703
urinary	ADJ	O	O	4703
bladder	NOUN	O	O	4703
(	PUNCT	O	O	4703
3.6-	NUM	O	O	4703
to	PART	O	O	4703
5-fold	ADV	O	O	4703
increase	VERB	O	O	4703
)	PUNCT	O	O	4703
.	PUNCT	O	O	4703
The	PRON	O	O	4704
data	NOUN	O	O	4704
suggest	VERB	O	O	4704
that	SCONJ	O	O	4704
in	ADP	O	O	4704
VIP(-/-	NOUN	O	O	4704
)	PUNCT	O	O	4704
mice	NOUN	O	O	4704
with	ADP	O	O	4704
bladder inflammation	NOUN	O	Disease	4704
,	PUNCT	O	O	4704
inflammatory	ADJ	O	O	4704
mediators	NOUN	O	O	4704
are	AUX	O	O	4704
increased	VERB	O	O	4704
above	ADP	O	O	4704
that	SCONJ	O	O	4704
observed	VERB	O	O	4704
in	ADP	O	O	4704
WT	NOUN	O	O	4704
with	ADP	O	O	4704
CYP	PROPN	O	Chemical	4704
.	PUNCT	O	O	4704
This	PRON	O	O	4705
shift	NOUN	O	O	4705
in	ADP	O	O	4705
balance	NOUN	O	O	4705
may	AUX	O	O	4705
contribute	VERB	O	O	4705
to	PART	O	O	4705
increased	VERB	O	O	4705
bladder dysfunction	NOUN	O	Disease	4705
in	ADP	O	O	4705
VIP(-/-	NOUN	O	O	4705
)	PUNCT	O	O	4705
mice	NOUN	O	O	4705
with	ADP	O	O	4705
bladder inflammation	NOUN	O	Disease	4705
and	CCONJ	O	O	4705
altered	VERB	O	O	4705
neurochemical	ADJ	O	O	4705
expression	NOUN	O	O	4705
in	ADP	O	O	4705
micturition	NOUN	O	O	4705
pathways	NOUN	O	O	4705
.	PUNCT	O	O	4705
Intraocular	NOUN	O	O	4708
pressure	NOUN	O	O	4708
in	ADP	O	O	4708
patients	NOUN	O	O	4708
with	ADP	O	O	4708
uveitis	PROPN	O	Disease	4708
treated	VERB	O	O	4708
with	ADP	O	O	4708
fluocinolone acetonide	NOUN	O	Chemical	4708
implants	NOUN	O	O	4708
.	PUNCT	O	O	4708
OBJECTIVE	VERB	O	O	4709
:	PUNCT	O	O	4709
To	PART	O	O	4709
report	VERB	O	O	4709
the	PRON	O	O	4709
incidence	NOUN	O	O	4709
and	CCONJ	O	O	4709
management	NOUN	O	O	4709
of	ADP	O	O	4709
elevated intraocular pressure	NOUN	O	Disease	4709
(	PUNCT	O	O	4709
IOP	PROPN	O	O	4709
)	PUNCT	O	O	4709
in	ADP	O	O	4709
patients	NOUN	O	O	4709
with	ADP	O	O	4709
uveitis	PROPN	O	Disease	4709
treated	VERB	O	O	4709
with	ADP	O	O	4709
the	PRON	O	O	4709
fluocinolone acetonide	NOUN	O	Chemical	4709
(	PUNCT	O	O	4709
FA	NOUN	O	Chemical	4709
)	PUNCT	O	O	4709
DESIGN	NOUN	O	O	4710
:	PUNCT	O	O	4710
Pooled	VERB	O	O	4710
data	NOUN	O	O	4710
from	ADP	O	O	4710
3	X	O	O	4710
multicenter	ADJ	O	O	4710
,	PUNCT	O	O	4710
double	ADJ	O	O	4710
-	PUNCT	O	O	4710
masked	VERB	O	O	4710
,	PUNCT	O	O	4710
randomized	VERB	O	O	4710
,	PUNCT	O	O	4710
controlled	VERB	O	O	4710
,	PUNCT	O	O	4710
phase	NOUN	O	O	4710
2b/3	NUM	O	O	4710
clinical	ADJ	O	O	4710
trials	NOUN	O	O	4710
evaluating	VERB	O	O	4710
the	PRON	O	O	4710
safety	NOUN	O	O	4710
and	CCONJ	O	O	4710
efficacy	NOUN	O	O	4710
of	ADP	O	O	4710
the	PRON	O	O	4710
0.59-mg	NOUN	O	O	4710
or	CCONJ	O	O	4710
2.1-mg	NOUN	O	O	4710
FA	NOUN	O	Chemical	4710
intravitreal	NOUN	O	O	4710
implant	NOUN	O	O	4710
or	CCONJ	O	O	4710
standard	PROPN	O	O	4710
therapy	NOUN	O	O	4710
were	AUX	O	O	4710
analyzed	VERB	O	O	4710
.	PUNCT	O	O	4710
The	PRON	O	O	4711
rate	NOUN	O	O	4711
of	ADP	O	O	4711
hypotony	VERB	O	Disease	4711
(	PUNCT	O	O	4711
IOP	PROPN	O	O	4711
<	X	O	O	4711
/=	PUNCT	O	O	4711
5	NUM	O	O	4711
mm	INTJ	O	O	4711
Hg	PROPN	O	O	4711
)	PUNCT	O	O	4711
following	VERB	O	O	4711
IOP	PROPN	O	O	4711
-	PUNCT	O	O	4711
lowering	VERB	O	O	4711
surgery	NOUN	O	O	4711
(	PUNCT	O	O	4711
42.5%	NOUN	O	O	4711
)	PUNCT	O	O	4711
was	AUX	O	O	4711
not	PART	O	O	4711
different	ADJ	O	O	4711
from	ADP	O	O	4711
that	SCONJ	O	O	4711
of	ADP	O	O	4711
implanted	VERB	O	O	4711
eyes	NOUN	O	O	4711
not	PART	O	O	4711
subjected	VERB	O	O	4711
to	PART	O	O	4711
surgery	NOUN	O	O	4711
(	PUNCT	O	O	4711
35.4%	NOUN	O	O	4711
)	PUNCT	O	O	4711
A	PRON	O	O	4714
resurgence	NOUN	O	O	4714
of	ADP	O	O	4714
interest	NOUN	O	O	4714
in	ADP	O	O	4714
the	PRON	O	O	4714
surgical	ADJ	O	O	4714
treatment	NOUN	O	O	4714
of	ADP	O	O	4714
Parkinson	NOUN	O	O	4714
's	AUX	O	O	4714
disease	PROPN	O	O	4714
(	PUNCT	O	O	4714
PD	PROPN	O	Disease	4714
)	PUNCT	O	O	4714
came	VERB	O	O	4714
with	ADP	O	O	4714
the	PRON	O	O	4714
rediscovery	NOUN	O	O	4714
of	ADP	O	O	4714
posteroventral	ADJ	O	O	4714
pallidotomy	NOUN	O	O	4714
by	ADP	O	O	4714
Laitinen	PROPN	O	O	4714
in	ADP	O	O	4714
1985	NUM	O	O	4714
.	PUNCT	O	O	4714
Laitinen	PROPN	O	O	4715
's	AUX	O	O	4715
procedure	NOUN	O	O	4715
improved	VERB	O	O	4715
most	ADV	O	O	4715
symptoms	NOUN	O	O	4715
in	ADP	O	O	4715
drug	NOUN	O	O	4715
-	PUNCT	O	O	4715
resistant	ADJ	O	O	4715
PD	PROPN	O	Disease	4715
,	PUNCT	O	O	4715
which	PRON	O	O	4715
engendered	VERB	O	O	4715
wide	ADV	O	O	4715
interest	NOUN	O	O	4715
in	ADP	O	O	4715
the	PRON	O	O	4715
neurosurgical	ADJ	O	O	4715
community	NOUN	O	O	4715
.	PUNCT	O	O	4715
According	VERB	O	O	4716
to	PART	O	O	4716
the	PRON	O	O	4716
literature	NOUN	O	O	4716
pallidotomy	NOUN	O	O	4716
improves	VERB	O	O	4716
the	PRON	O	O	4716
""""	PUNCT	O	O	4716
on	ADP	O	O	4716
""""	PUNCT	O	O	4716
symptoms	NOUN	O	O	4716
of	ADP	O	O	4716
PD	PROPN	O	Disease	4716
,	PUNCT	O	O	4716
such	ADJ	O	O	4716
as	ADP	O	O	4716
dyskinesias	PROPN	O	Disease	4716
,	PUNCT	O	O	4716
as	ADP	O	O	4716
well	ADV	O	O	4716
as	ADP	O	O	4716
the	PRON	O	O	4716
""""	PUNCT	O	O	4716
off	ADP	O	O	4716
""""	PUNCT	O	O	4716
symptoms	NOUN	O	O	4716
,	PUNCT	O	O	4716
such	ADJ	O	O	4716
as	ADP	O	O	4716
rigidity	NOUN	O	Disease	4716
,	PUNCT	O	O	4716
bradykinesia	NOUN	O	Disease	4716
,	PUNCT	O	O	4716
and	CCONJ	O	O	4716
on	ADP	O	O	4716
-	PUNCT	O	O	4716
off	ADP	O	O	4716
fluctuations	NOUN	O	O	4716
.	PUNCT	O	O	4716
Pallidal	ADJ	O	O	4717
stimulation	NOUN	O	O	4717
improves	VERB	O	O	4717
bradykinesia	NOUN	O	Disease	4717
and	CCONJ	O	O	4717
rigidity	NOUN	O	Disease	4717
to	PART	O	O	4717
a	PRON	O	O	4717
minor	ADJ	O	O	4717
extent	NOUN	O	O	4717
;	PUNCT	O	O	4717
however	ADV	O	O	4717
,	PUNCT	O	O	4717
its	PRON	O	O	4717
strength	NOUN	O	O	4717
seems	VERB	O	O	4717
to	PART	O	O	4717
be	AUX	O	O	4717
in	ADP	O	O	4717
improving	VERB	O	O	4717
levodopa	NOUN	O	Chemical	4717
-	PUNCT	O	O	4717
induced	VERB	O	O	4717
dyskinesias	PROPN	O	Disease	4717
.	PUNCT	O	O	4717
Stimulation	NOUN	O	O	4718
often	ADV	O	O	4718
produces	VERB	O	O	4718
an	PRON	O	O	4718
improvement	NOUN	O	O	4718
in	ADP	O	O	4718
the	PRON	O	O	4718
hyper- or dyskinetic	ADJ	O	Disease	4718
upper	ADJ	O	O	4718
limbs	NOUN	O	O	4718
,	PUNCT	O	O	4718
but	CCONJ	O	O	4718
increases	VERB	O	O	4718
the	PRON	O	O	4718
""""	PUNCT	O	O	4718
freezing	VERB	O	O	4718
""""	PUNCT	O	O	4718
phenomenon	NOUN	O	O	4718
in	ADP	O	O	4718
the	PRON	O	O	4718
lower	ADJ	O	O	4718
limbs	NOUN	O	O	4718
at	ADP	O	O	4718
the	PRON	O	O	4718
same	ADJ	O	O	4718
time	NOUN	O	O	4718
.	PUNCT	O	O	4718
Case	NOUN	O	O	4721
report	VERB	O	O	4721
:	PUNCT	O	O	4721
Dexatrim	PROPN	O	Chemical	4721
(	PUNCT	O	O	4721
Phenylpropanolamine	NOUN	O	Chemical	4721
)	PUNCT	O	O	4721
as	ADP	O	O	4721
a	PRON	O	O	4721
cause	VERB	O	O	4721
of	ADP	O	O	4721
myocardial infarction	NOUN	O	Disease	4721
.	PUNCT	O	O	4721
Phenylpropanolamine	NOUN	O	Chemical	4722
(	PUNCT	O	O	4722
PPA	PROPN	O	Chemical	4722
)	PUNCT	O	O	4722
is	AUX	O	O	4722
a	PRON	O	O	4722
sympathetic	ADJ	O	O	4722
amine	NOUN	O	Chemical	4722
used	VERB	O	O	4722
in	ADP	O	O	4722
over	ADP	O	O	4722
-	PUNCT	O	O	4722
the	PRON	O	O	4722
-	PUNCT	O	O	4722
counter	VERB	O	O	4722
cold	ADJ	O	O	4722
remedies	NOUN	O	O	4722
and	CCONJ	O	O	4722
weight	NOUN	O	O	4722
-	PUNCT	O	O	4722
control	VERB	O	O	4722
preparations	NOUN	O	O	4722
worldwide	ADV	O	O	4722
.	PUNCT	O	O	4722
Its	PRON	O	O	4723
use	VERB	O	O	4723
has	VERB	O	O	4723
been	AUX	O	O	4723
associated	VERB	O	O	4723
with	ADP	O	O	4723
hypertensive	ADJ	O	Disease	4723
episodes	NOUN	O	O	4723
and	CCONJ	O	O	4723
hemorrhagic strokes	NOUN	O	Disease	4723
in	ADP	O	O	4723
younger	ADJ	O	O	4723
women	NOUN	O	O	4723
.	PUNCT	O	O	4723
Several	ADJ	O	O	4724
reports	VERB	O	O	4724
have	VERB	O	O	4724
linked	VERB	O	O	4724
the	PRON	O	O	4724
abuse	VERB	O	O	4724
of	ADP	O	O	4724
PPA	PROPN	O	Chemical	4724
with	ADP	O	O	4724
myocardial injury	NOUN	O	Disease	4724
,	PUNCT	O	O	4724
especially	ADV	O	O	4724
when	SCONJ	O	O	4724
overdose	NOUN	O	Disease	4724
is	AUX	O	O	4724
involved	VERB	O	O	4724
.	PUNCT	O	O	4724
We	PRON	O	O	4725
report	VERB	O	O	4725
here	ADV	O	O	4725
the	PRON	O	O	4725
first	ADV	O	O	4725
case	NOUN	O	O	4725
of	ADP	O	O	4725
Dexatrim	PROPN	O	Chemical	4725
(	PUNCT	O	O	4725
PPA)-induced	VERB	O	O	4725
myocardial injury	NOUN	O	Disease	4725
in	ADP	O	O	4725
a	PRON	O	O	4725
young	ADJ	O	O	4725
woman	NOUN	O	O	4725
who	PRON	O	O	4725
was	AUX	O	O	4725
using	VERB	O	O	4725
it	PRON	O	O	4725
at	ADP	O	O	4725
recommended	VERB	O	O	4725
doses	NOUN	O	O	4725
for	ADP	O	O	4725
weight	NOUN	O	O	4725
control	VERB	O	O	4725
.	PUNCT	O	O	4725
In	ADP	O	O	4726
addition	NOUN	O	O	4726
,	PUNCT	O	O	4726
we	PRON	O	O	4726
review	VERB	O	O	4726
the	PRON	O	O	4726
7	NUM	O	O	4726
other	ADJ	O	O	4726
cases	NOUN	O	O	4726
of	ADP	O	O	4726
PPA	PROPN	O	Chemical	4726
related	ADJ	O	O	4726
myocardial injury	NOUN	O	Disease	4726
that	SCONJ	O	O	4726
have	VERB	O	O	4726
been	AUX	O	O	4726
reported	VERB	O	O	4726
so	ADV	O	O	4726
far	ADV	O	O	4726
.	PUNCT	O	O	4726
Physicians	NOUN	O	O	4727
and	CCONJ	O	O	4727
patients	NOUN	O	O	4727
should	AUX	O	O	4727
be	AUX	O	O	4727
alert	ADJ	O	O	4727
to	PART	O	O	4727
the	PRON	O	O	4727
potential	ADJ	O	O	4727
cardiac	ADJ	O	O	4727
risk	NOUN	O	O	4727
associated	VERB	O	O	4727
with	ADP	O	O	4727
the	PRON	O	O	4727
use	VERB	O	O	4727
of	ADP	O	O	4727
PPA	PROPN	O	Chemical	4727
,	PUNCT	O	O	4727
even	ADV	O	O	4727
at	ADP	O	O	4727
doses	NOUN	O	O	4727
generally	ADV	O	O	4727
considered	VERB	O	O	4727
to	PART	O	O	4727
be	AUX	O	O	4727
safe	ADJ	O	O	4727
.	PUNCT	O	O	4727
Risperidone	NOUN	O	Chemical	4730
-	PUNCT	O	O	4730
associated	VERB	O	O	4730
,	PUNCT	O	O	4730
benign	ADJ	O	O	4730
transient	ADJ	O	O	4730
visual disturbances	NOUN	O	Disease	4730
in	ADP	O	O	4730
schizophrenic	ADJ	O	Disease	4730
patients	NOUN	O	O	4730
with	ADP	O	O	4730
a	PRON	O	O	4730
past	ADP	O	O	4730
history	NOUN	O	O	4730
of	ADP	O	O	4730
LSD	PROPN	O	Chemical	4730
abuse	VERB	O	O	4730
.	PUNCT	O	O	4730
Two	NUM	O	O	4731
schizophrenic	ADJ	O	Disease	4731
patients	NOUN	O	O	4731
,	PUNCT	O	O	4731
who	PRON	O	O	4731
had	VERB	O	O	4731
a	PRON	O	O	4731
prior	ADV	O	O	4731
history	NOUN	O	O	4731
of	ADP	O	O	4731
LSD	PROPN	O	Chemical	4731
abuse	VERB	O	O	4731
and	CCONJ	O	O	4731
who	PRON	O	O	4731
had	VERB	O	O	4731
previously	ADV	O	O	4731
developed	VERB	O	O	4731
EPS	PROPN	O	Disease	4731
with	ADP	O	O	4731
classic	ADJ	O	O	4731
antipsychotics	NOUN	O	O	4731
,	PUNCT	O	O	4731
were	AUX	O	O	4731
successfully	ADV	O	O	4731
treated	VERB	O	O	4731
with	ADP	O	O	4731
risperidone	VERB	O	Chemical	4731
.	PUNCT	O	O	4731
They	PRON	O	O	4732
both	PRON	O	O	4732
reported	VERB	O	O	4732
short	ADJ	O	O	4732
episodes	NOUN	O	O	4732
of	ADP	O	O	4732
transient	ADJ	O	O	4732
visual disturbances	NOUN	O	Disease	4732
,	PUNCT	O	O	4732
which	PRON	O	O	4732
appeared	VERB	O	O	4732
immediately	ADV	O	O	4732
after	ADP	O	O	4732
starting	VERB	O	O	4732
treatment	NOUN	O	O	4732
with	ADP	O	O	4732
risperidone	VERB	O	Chemical	4732
.	PUNCT	O	O	4732
This	PRON	O	O	4733
imagery	NOUN	O	O	4733
resembled	VERB	O	O	4733
visual disturbances	NOUN	O	Disease	4733
previously	ADV	O	O	4733
experienced	ADJ	O	O	4733
as	ADP	O	O	4733
""""	PUNCT	O	O	4733
flashbacks	NOUN	O	O	4733
""""	PUNCT	O	O	4733
related	ADJ	O	O	4733
to	PART	O	O	4733
prior	ADV	O	O	4733
LSD	PROPN	O	Chemical	4733
consumption	NOUN	O	O	4733
.	PUNCT	O	O	4733
Risperidone	NOUN	O	Chemical	4734
administration	NOUN	O	O	4734
was	AUX	O	O	4734
continued	VERB	O	O	4734
and	CCONJ	O	O	4734
the	PRON	O	O	4734
visual disturbances	NOUN	O	Disease	4734
gradually	ADV	O	O	4734
wore	VERB	O	O	4734
off	ADP	O	O	4734
.	PUNCT	O	O	4734
During	ADP	O	O	4735
a	PRON	O	O	4735
six	NUM	O	O	4735
-	PUNCT	O	O	4735
month	NOUN	O	O	4735
follow	VERB	O	O	4735
-	PUNCT	O	O	4735
up	ADP	O	O	4735
period	NOUN	O	O	4735
,	PUNCT	O	O	4735
there	ADV	O	O	4735
was	AUX	O	O	4735
no	PRON	O	O	4735
recurrence	NOUN	O	O	4735
of	ADP	O	O	4735
visual disturbances	NOUN	O	Disease	4735
.	PUNCT	O	O	4735
This	PRON	O	O	4736
phenomenon	NOUN	O	O	4736
may	AUX	O	O	4736
be	AUX	O	O	4736
interpreted	VERB	O	O	4736
as	ADP	O	O	4736
a	PRON	O	O	4736
benign	ADJ	O	O	4736
,	PUNCT	O	O	4736
short	ADJ	O	O	4736
-	PUNCT	O	O	4736
term	NOUN	O	O	4736
and	CCONJ	O	O	4736
self	VERB	O	O	4736
-	PUNCT	O	O	4736
limiting	VERB	O	O	4736
side	NOUN	O	O	4736
effect	VERB	O	O	4736
which	PRON	O	O	4736
does	VERB	O	O	4736
not	PART	O	O	4736
contraindicate	VERB	O	O	4736
the	PRON	O	O	4736
use	VERB	O	O	4736
of	ADP	O	O	4736
risperidone	VERB	O	Chemical	4736
or	CCONJ	O	O	4736
interfere	VERB	O	O	4736
with	ADP	O	O	4736
treatment	NOUN	O	O	4736
.	PUNCT	O	O	4736
Activation	NOUN	O	O	4739
of	ADP	O	O	4739
poly(ADP	ADV	O	O	4739
-	PUNCT	O	O	4739
ribose	NOUN	O	O	4739
)	PUNCT	O	O	4739
polymerase	NOUN	O	O	4739
contributes	VERB	O	O	4739
to	PART	O	O	4739
development	NOUN	O	O	4739
of	ADP	O	O	4739
doxorubicin	VERB	O	Chemical	4739
-	PUNCT	O	O	4739
induced	VERB	O	O	4739
heart failure	NOUN	O	Disease	4739
.	PUNCT	O	O	4739
Activation	NOUN	O	O	4740
of	ADP	O	O	4740
the	PRON	O	O	4740
nuclear	ADJ	O	O	4740
enzyme	NOUN	O	O	4740
poly(ADP	ADV	O	O	4740
-	PUNCT	O	O	4740
ribose	NOUN	O	O	4740
)	PUNCT	O	O	4740
polymerase	NOUN	O	O	4740
(	PUNCT	O	O	4740
PARP	PROPN	O	O	4740
)	PUNCT	O	O	4740
by	ADP	O	O	4740
oxidant	ADJ	O	O	4740
-	PUNCT	O	O	4740
mediated	VERB	O	O	4740
DNA	NOUN	O	O	4740
damage	NOUN	O	O	4740
is	AUX	O	O	4740
an	PRON	O	O	4740
important	ADJ	O	O	4740
pathway	NOUN	O	O	4740
of	ADP	O	O	4740
cell	NOUN	O	O	4740
dysfunction	NOUN	O	O	4740
and	CCONJ	O	O	4740
tissue	NOUN	O	O	4740
injury	NOUN	O	O	4740
in	ADP	O	O	4740
conditions	NOUN	O	O	4740
associated	VERB	O	O	4740
with	ADP	O	O	4740
oxidative	NOUN	O	O	4740
stress	NOUN	O	O	4740
.	PUNCT	O	O	4740
Increased	VERB	O	O	4741
oxidative	NOUN	O	O	4741
stress	NOUN	O	O	4741
is	AUX	O	O	4741
a	PRON	O	O	4741
major	ADJ	O	O	4741
factor	NOUN	O	O	4741
implicated	VERB	O	O	4741
in	ADP	O	O	4741
the	PRON	O	O	4741
cardiotoxicity	NOUN	O	Disease	4741
of	ADP	O	O	4741
doxorubicin	VERB	O	Chemical	4741
(	PUNCT	O	O	4741
DOX	PROPN	O	Chemical	4741
)	PUNCT	O	O	4741
,	PUNCT	O	O	4741
a	PRON	O	O	4741
widely	ADV	O	O	4741
used	VERB	O	O	4741
antitumor	PROPN	O	O	4741
anthracycline	NOUN	O	Chemical	4741
antibiotic	ADJ	O	O	4741
.	PUNCT	O	O	4741
Thus	ADV	O	O	4742
,	PUNCT	O	O	4742
we	PRON	O	O	4742
hypothesized	VERB	O	O	4742
that	SCONJ	O	O	4742
the	PRON	O	O	4742
activation	NOUN	O	O	4742
of	ADP	O	O	4742
PARP	PROPN	O	O	4742
may	AUX	O	O	4742
contribute	VERB	O	O	4742
to	PART	O	O	4742
the	PRON	O	O	4742
DOX	PROPN	O	Chemical	4742
-	PUNCT	O	O	4742
induced	VERB	O	O	4742
cardiotoxicity	NOUN	O	Disease	4742
.	PUNCT	O	O	4742
Using	VERB	O	O	4743
a	PRON	O	O	4743
dual	ADJ	O	O	4743
approach	NOUN	O	O	4743
of	ADP	O	O	4743
PARP-1	PROPN	O	O	4743
suppression	NOUN	O	O	4743
,	PUNCT	O	O	4743
by	ADP	O	O	4743
genetic	ADJ	O	O	4743
deletion	NOUN	O	O	4743
or	CCONJ	O	O	4743
pharmacological	ADJ	O	O	4743
inhibition	NOUN	O	O	4743
with	ADP	O	O	4743
the	PRON	O	O	4743
phenanthridinone	NOUN	O	O	4743
PARP	PROPN	O	O	4743
inhibitor	NOUN	O	O	4743
PJ34	PROPN	O	Chemical	4743
,	PUNCT	O	O	4743
we	PRON	O	O	4743
now	ADV	O	O	4743
demonstrate	VERB	O	O	4743
the	PRON	O	O	4743
role	NOUN	O	O	4743
of	ADP	O	O	4743
PARP	PROPN	O	O	4743
in	ADP	O	O	4743
the	PRON	O	O	4743
development	NOUN	O	O	4743
of	ADP	O	O	4743
cardiac dysfunction	NOUN	O	Disease	4743
induced	VERB	O	O	4743
by	ADP	O	O	4743
DOX	PROPN	O	Chemical	4743
.	PUNCT	O	O	4743
PARP-1+/+	PROPN	O	O	4744
and	CCONJ	O	O	4744
PARP-1-/-	NUM	O	O	4744
mice	NOUN	O	O	4744
received	VERB	O	O	4744
a	PRON	O	O	4744
single	ADJ	O	O	4744
injection	NOUN	O	O	4744
of	ADP	O	O	4744
DOX	PROPN	O	Chemical	4744
(	PUNCT	O	O	4744
25	NUM	O	O	4744
mg	VERB	O	O	4744
/	PUNCT	O	O	4744
kg	VERB	O	O	4744
i.p	NOUN	O	O	4744
)	PUNCT	O	O	4744
.	PUNCT	O	O	4744
Five	NUM	O	O	4745
days	NOUN	O	O	4745
after	ADP	O	O	4745
DOX	PROPN	O	Chemical	4745
administration	NOUN	O	O	4745
,	PUNCT	O	O	4745
left	VERB	O	O	4745
ventricular	ADJ	O	O	4745
performance	NOUN	O	O	4745
was	AUX	O	O	4745
significantly	ADV	O	O	4745
depressed	ADJ	O	O	4745
in	ADP	O	O	4745
PARP-1+/+	PROPN	O	O	4745
mice	NOUN	O	O	4745
,	PUNCT	O	O	4745
but	CCONJ	O	O	4745
only	ADV	O	O	4745
to	PART	O	O	4745
a	PRON	O	O	4745
smaller	ADJ	O	O	4745
extent	NOUN	O	O	4745
in	ADP	O	O	4745
PARP-1-/-	NUM	O	O	4745
ones	NOUN	O	O	4745
.	PUNCT	O	O	4745
Similar	ADJ	O	O	4746
experiments	NOUN	O	O	4746
were	AUX	O	O	4746
conducted	VERB	O	O	4746
in	ADP	O	O	4746
BALB	PROPN	O	O	4746
/	PUNCT	O	O	4746
c	X	O	O	4746
mice	NOUN	O	O	4746
treated	VERB	O	O	4746
with	ADP	O	O	4746
PJ34	PROPN	O	Chemical	4746
or	CCONJ	O	O	4746
vehicle	NOUN	O	O	4746
.	PUNCT	O	O	4746
Treatment	NOUN	O	O	4747
with	ADP	O	O	4747
a	PRON	O	O	4747
PJ34	PROPN	O	Chemical	4747
significantly	ADV	O	O	4747
improved	VERB	O	O	4747
cardiac dysfunction	NOUN	O	Disease	4747
and	CCONJ	O	O	4747
increased	VERB	O	O	4747
the	PRON	O	O	4747
survival	NOUN	O	O	4747
of	ADP	O	O	4747
the	PRON	O	O	4747
animals	NOUN	O	O	4747
.	PUNCT	O	O	4747
In	ADP	O	O	4748
addition	NOUN	O	O	4748
PJ34	PROPN	O	Chemical	4748
significantly	ADV	O	O	4748
reduced	VERB	O	O	4748
the	PRON	O	O	4748
DOX	PROPN	O	Chemical	4748
-	PUNCT	O	O	4748
induced	VERB	O	O	4748
increase	VERB	O	O	4748
in	ADP	O	O	4748
the	PRON	O	O	4748
serum	NOUN	O	O	4748
lactate	NOUN	O	Chemical	4748
dehydrogenase	NOUN	O	O	4748
and	CCONJ	O	O	4748
creatine	PROPN	O	Chemical	4748
kinase	VERB	O	O	4748
activities	NOUN	O	O	4748
but	CCONJ	O	O	4748
not	PART	O	O	4748
metalloproteinase	NOUN	O	O	4748
activation	NOUN	O	O	4748
in	ADP	O	O	4748
the	PRON	O	O	4748
heart	NOUN	O	O	4748
.	PUNCT	O	O	4748
Thus	ADV	O	O	4749
,	PUNCT	O	O	4749
PARP	PROPN	O	O	4749
activation	NOUN	O	O	4749
contributes	VERB	O	O	4749
to	PART	O	O	4749
the	PRON	O	O	4749
cardiotoxicity	NOUN	O	Disease	4749
of	ADP	O	O	4749
DOX	PROPN	O	Chemical	4749
.	PUNCT	O	O	4749
PARP	PROPN	O	O	4750
inhibitors	NOUN	O	O	4750
may	AUX	O	O	4750
exert	VERB	O	O	4750
protective	ADJ	O	O	4750
effects	NOUN	O	O	4750
against	ADP	O	O	4750
the	PRON	O	O	4750
development	NOUN	O	O	4750
of	ADP	O	O	4750
severe	ADJ	O	O	4750
cardiac complications	NOUN	O	Disease	4750
associated	VERB	O	O	4750
with	ADP	O	O	4750
the	PRON	O	O	4750
DOX	PROPN	O	Chemical	4750
treatment	NOUN	O	O	4750
.	PUNCT	O	O	4750
Fluconazole	PROPN	O	Chemical	4753
-	PUNCT	O	O	4753
induced	VERB	O	O	4753
torsade de pointes	NOUN	O	Disease	4753
.	PUNCT	O	O	4753
OBJECTIVE	VERB	O	O	4754
:	PUNCT	O	O	4754
To	PART	O	O	4754
present	NOUN	O	O	4754
a	PRON	O	O	4754
case	NOUN	O	O	4754
of	ADP	O	O	4754
fluconazole	CCONJ	O	Chemical	4754
-	PUNCT	O	O	4754
associated	VERB	O	O	4754
torsade de pointes	NOUN	O	Disease	4754
(	PUNCT	O	O	4754
TDP	PROPN	O	Disease	4754
)	PUNCT	O	O	4754
and	CCONJ	O	O	4754
discuss	VERB	O	O	4754
fluconazole	CCONJ	O	Chemical	4754
's	AUX	O	O	4754
role	NOUN	O	O	4754
in	ADP	O	O	4754
causing	VERB	O	O	4754
TDP	PROPN	O	Disease	4754
.	PUNCT	O	O	4754
A	PRON	O	O	4755
68-year	NOUN	O	O	4755
-	PUNCT	O	O	4755
old	ADJ	O	O	4755
white	ADJ	O	O	4755
woman	NOUN	O	O	4755
with	ADP	O	O	4755
Candida	PROPN	O	O	4755
glabrata	NOUN	O	O	4755
isolated	VERB	O	O	4755
from	ADP	O	O	4755
a	PRON	O	O	4755
presacral	ADJ	O	O	4755
abscess	NOUN	O	O	4755
developed	VERB	O	O	4755
TDP	PROPN	O	Disease	4755
eight	NUM	O	O	4755
days	NOUN	O	O	4755
after	ADP	O	O	4755
commencing	VERB	O	O	4755
oral	ADJ	O	O	4755
fluconazole	CCONJ	O	Chemical	4755
The	PRON	O	O	4756
patient	NOUN	O	O	4756
had	VERB	O	O	4756
no	PRON	O	O	4756
other	ADJ	O	O	4756
risk	NOUN	O	O	4756
factors	NOUN	O	O	4756
for	ADP	O	O	4756
TDP	PROPN	O	Disease	4756
,	PUNCT	O	O	4756
including	VERB	O	O	4756
coronary artery disease	NOUN	O	Disease	4756
,	PUNCT	O	O	4756
cardiomyopathy	ADJ	O	Disease	4756
,	PUNCT	O	O	4756
congestive	ADJ	O	O	4756
heart failure	NOUN	O	Disease	4756
,	PUNCT	O	O	4756
and	CCONJ	O	O	4756
electrolyte	NOUN	O	O	4756
abnormalities	NOUN	O	O	4756
There	ADV	O	O	4756
was	AUX	O	O	4756
a	PRON	O	O	4756
temporal	ADJ	O	O	4756
association	PROPN	O	O	4756
between	ADP	O	O	4756
the	PRON	O	O	4756
initiation	NOUN	O	O	4756
of	ADP	O	O	4756
fluconazole	CCONJ	O	Chemical	4756
and	CCONJ	O	O	4756
TDP	PROPN	O	Disease	4756
.	PUNCT	O	O	4756
The	PRON	O	O	4757
TDP	PROPN	O	Disease	4757
resolved	VERB	O	O	4757
when	SCONJ	O	O	4757
fluconazole	CCONJ	O	Chemical	4757
was	AUX	O	O	4757
discontinued	VERB	O	O	4757
;	PUNCT	O	O	4757
however	ADV	O	O	4757
,	PUNCT	O	O	4757
the	PRON	O	O	4757
patient	NOUN	O	O	4757
continued	VERB	O	O	4757
to	PART	O	O	4757
have	VERB	O	O	4757
premature ventricular contractions	NOUN	O	Disease	4757
and	CCONJ	O	O	4757
nonsustained	VERB	O	O	4757
ventricular tachycardia	NOUN	O	Disease	4757
(	PUNCT	O	O	4757
NSVT	PROPN	O	Disease	4757
)	PUNCT	O	O	4757
until	ADP	O	O	4757
six	NUM	O	O	4757
days	NOUN	O	O	4757
after	ADP	O	O	4757
drug	NOUN	O	O	4757
cessation	NOUN	O	O	4757
DISCUSSION	NOUN	O	O	4757
:	PUNCT	O	O	4757
Use	VERB	O	O	4758
of	ADP	O	O	4758
the	PRON	O	O	4758
Naranjo	PROPN	O	O	4758
probability	NOUN	O	O	4758
scale	NOUN	O	O	4758
indicates	VERB	O	O	4758
a	PRON	O	O	4758
probable	ADJ	O	O	4758
relationship	NOUN	O	O	4758
between	ADP	O	O	4758
the	PRON	O	O	4758
use	VERB	O	O	4758
of	ADP	O	O	4758
fluconazole	CCONJ	O	Chemical	4758
and	CCONJ	O	O	4758
the	PRON	O	O	4758
development	NOUN	O	O	4758
of	ADP	O	O	4758
TDP	PROPN	O	Disease	4758
.	PUNCT	O	O	4758
The	PRON	O	O	4759
possible	ADJ	O	O	4759
mechanism	NOUN	O	O	4759
is	AUX	O	O	4759
depression	PROPN	O	Disease	4759
of	ADP	O	O	4759
rapidly	ADV	O	O	4759
activating	VERB	O	O	4759
delayed	VERB	O	O	4759
rectifier	PROPN	O	O	4759
potassium	NOUN	O	Chemical	4759
currents	NOUN	O	O	4759
.	PUNCT	O	O	4759
In	ADP	O	O	4760
our	PRON	O	O	4760
patient	NOUN	O	O	4760
,	PUNCT	O	O	4760
there	ADV	O	O	4760
was	AUX	O	O	4760
no	PRON	O	O	4760
other	ADJ	O	O	4760
etiology	NOUN	O	O	4760
identified	VERB	O	O	4760
that	SCONJ	O	O	4760
could	AUX	O	O	4760
explain	VERB	O	O	4760
QT prolongation	NOUN	O	Disease	4760
or	CCONJ	O	O	4760
TDP	PROPN	O	Disease	4760
The	PRON	O	O	4761
complete	VERB	O	O	4761
disappearance	NOUN	O	O	4761
of	ADP	O	O	4761
NSVT	PROPN	O	Disease	4761
and	CCONJ	O	O	4761
premature ventricular contractions	NOUN	O	Disease	4761
followed	VERB	O	O	4761
by	ADP	O	O	4761
normalization	NOUN	O	O	4761
of	ADP	O	O	4761
QT	NOUN	O	O	4761
interval	NOUN	O	O	4761
after	ADP	O	O	4761
the	PRON	O	O	4761
drug	NOUN	O	O	4761
was	AUX	O	O	4761
stopped	VERB	O	O	4761
strongly	ADV	O	O	4761
suggests	VERB	O	O	4761
fluconazole	CCONJ	O	Chemical	4761
as	ADP	O	O	4761
the	PRON	O	O	4761
etiology	NOUN	O	O	4761
.	PUNCT	O	O	4761
Clinicians	NOUN	O	O	4762
should	AUX	O	O	4762
be	AUX	O	O	4762
aware	ADJ	O	O	4762
that	SCONJ	O	O	4762
fluconazole	CCONJ	O	Chemical	4762
,	PUNCT	O	O	4762
even	ADV	O	O	4762
at	ADP	O	O	4762
low	ADJ	O	O	4762
doses	NOUN	O	O	4762
,	PUNCT	O	O	4762
may	AUX	O	O	4762
cause	VERB	O	O	4762
prolongation of the QT interval	NOUN	O	Disease	4762
,	PUNCT	O	O	4762
leading	VERB	O	O	4762
to	PART	O	O	4762
TDP	PROPN	O	Disease	4762
.	PUNCT	O	O	4762
Serial	ADJ	O	O	4763
electrocardiographic	NOUN	O	O	4763
monitoring	NOUN	O	O	4763
may	AUX	O	O	4763
be	AUX	O	O	4763
considered	VERB	O	O	4763
when	SCONJ	O	O	4763
fluconazole	CCONJ	O	Chemical	4763
is	AUX	O	O	4763
administered	VERB	O	O	4763
in	ADP	O	O	4763
patients	NOUN	O	O	4763
who	PRON	O	O	4763
are	AUX	O	O	4763
at	ADP	O	O	4763
risk	NOUN	O	O	4763
for	ADP	O	O	4763
ventricular arrhythmias	NOUN	O	Disease	4763
.	PUNCT	O	O	4763
High	ADJ	O	O	4766
-	PUNCT	O	O	4766
dose	NOUN	O	O	4766
methylprednisolone	NOUN	O	Chemical	4766
may	AUX	O	O	4766
do	VERB	O	O	4766
more	ADJ	O	O	4766
harm	NOUN	O	O	4766
for	ADP	O	O	4766
spinal cord injury	NOUN	O	Disease	4766
.	PUNCT	O	O	4766
Because	SCONJ	O	O	4767
of	ADP	O	O	4767
the	PRON	O	O	4767
National	ADJ	O	O	4767
Acute	PROPN	O	O	4767
Spinal Cord Injury	NOUN	O	Disease	4767
Studies	NOUN	O	O	4767
(	PUNCT	O	O	4767
NASCIS	NOUN	O	O	4767
)	PUNCT	O	O	4767
,	PUNCT	O	O	4767
high	ADJ	O	O	4767
-	PUNCT	O	O	4767
dose	NOUN	O	O	4767
methylprednisolone	NOUN	O	Chemical	4767
became	VERB	O	O	4767
the	PRON	O	O	4767
standard	PROPN	O	O	4767
of	ADP	O	O	4767
care	VERB	O	O	4767
for	ADP	O	O	4767
the	PRON	O	O	4767
acute	ADJ	O	O	4767
spinal cord injury	NOUN	O	Disease	4767
.	PUNCT	O	O	4767
In	ADP	O	O	4768
the	PRON	O	O	4768
NASCIS	NOUN	O	O	4768
,	PUNCT	O	O	4768
there	ADV	O	O	4768
was	AUX	O	O	4768
no	PRON	O	O	4768
mention	VERB	O	O	4768
regarding	VERB	O	O	4768
the	PRON	O	O	4768
possibility	NOUN	O	O	4768
of	ADP	O	O	4768
acute	ADJ	O	O	4768
corticosteroid	NOUN	O	Chemical	4768
myopathy	PROPN	O	Disease	4768
that	SCONJ	O	O	4768
high	ADJ	O	O	4768
-	PUNCT	O	O	4768
dose	NOUN	O	O	4768
methylprednisolone	NOUN	O	Chemical	4768
may	AUX	O	O	4768
cause	VERB	O	O	4768
.	PUNCT	O	O	4768
The	PRON	O	O	4769
dosage	NOUN	O	O	4769
of	ADP	O	O	4769
methylprednisolone	NOUN	O	Chemical	4769
recommended	VERB	O	O	4769
by	ADP	O	O	4769
the	PRON	O	O	4769
NASCIS	NOUN	O	O	4769
3	X	O	O	4769
is	AUX	O	O	4769
the	PRON	O	O	4769
highest	ADJ	O	O	4769
dose	NOUN	O	O	4769
of	ADP	O	O	4769
steroids	NOUN	O	Chemical	4769
ever	ADV	O	O	4769
being	AUX	O	O	4769
used	VERB	O	O	4769
during	ADP	O	O	4769
a	PRON	O	O	4769
2-day	NOUN	O	O	4769
period	NOUN	O	O	4769
for	ADP	O	O	4769
any	PRON	O	O	4769
clinical	ADJ	O	O	4769
condition	NOUN	O	O	4769
.	PUNCT	O	O	4769
We	PRON	O	O	4770
hypothesize	VERB	O	O	4770
that	SCONJ	O	O	4770
it	PRON	O	O	4770
may	AUX	O	O	4770
cause	VERB	O	O	4770
some	PRON	O	O	4770
damage to the muscle	NOUN	O	Disease	4770
of	ADP	O	O	4770
spinal cord injury	NOUN	O	Disease	4770
patients	NOUN	O	O	4770
.	PUNCT	O	O	4770
Further	ADV	O	O	4771
,	PUNCT	O	O	4771
steroid	NOUN	O	Chemical	4771
myopathy	PROPN	O	Disease	4771
recovers	VERB	O	O	4771
naturally	ADV	O	O	4771
and	CCONJ	O	O	4771
the	PRON	O	O	4771
neurological	ADJ	O	O	4771
improvement	NOUN	O	O	4771
shown	VERB	O	O	4771
in	ADP	O	O	4771
the	PRON	O	O	4771
NASCIS	NOUN	O	O	4771
may	AUX	O	O	4771
be	AUX	O	O	4771
just	ADV	O	O	4771
a	PRON	O	O	4771
recording	NOUN	O	O	4771
of	ADP	O	O	4771
this	PRON	O	O	4771
natural	ADJ	O	O	4771
motor	NOUN	O	O	4771
recovery	NOUN	O	O	4771
from	ADP	O	O	4771
the	PRON	O	O	4771
steroid	NOUN	O	Chemical	4771
myopathy	PROPN	O	Disease	4771
,	PUNCT	O	O	4771
instead	ADV	O	O	4771
of	ADP	O	O	4771
any	PRON	O	O	4771
protection	NOUN	O	O	4771
that	SCONJ	O	O	4771
methylprednisolone	NOUN	O	Chemical	4771
offers	VERB	O	O	4771
to	PART	O	O	4771
the	PRON	O	O	4771
spinal cord injury	NOUN	O	Disease	4771
.	PUNCT	O	O	4771
To	PART	O	O	4772
our	PRON	O	O	4772
knowledge	NOUN	O	O	4772
,	PUNCT	O	O	4772
this	PRON	O	O	4772
is	AUX	O	O	4772
the	PRON	O	O	4772
first	ADV	O	O	4772
discussion	NOUN	O	O	4772
considering	VERB	O	O	4772
the	PRON	O	O	4772
possibility	NOUN	O	O	4772
that	SCONJ	O	O	4772
the	PRON	O	O	4772
methylprednisolone	NOUN	O	Chemical	4772
recommended	VERB	O	O	4772
by	ADP	O	O	4772
NASCIS	NOUN	O	O	4772
may	AUX	O	O	4772
cause	VERB	O	O	4772
acute	ADJ	O	O	4772
corticosteroid	NOUN	O	Chemical	4772
myopathy	PROPN	O	Disease	4772
.	PUNCT	O	O	4772
The	PRON	O	O	4775
pharmacological	ADJ	O	O	4775
response	NOUN	O	O	4775
to	PART	O	O	4775
drugs	NOUN	O	O	4775
that	SCONJ	O	O	4775
act	VERB	O	O	4775
on	ADP	O	O	4775
the	PRON	O	O	4775
cholinergic	ADJ	O	O	4775
system	NOUN	O	O	4775
of	ADP	O	O	4775
the	PRON	O	O	4775
iris	PROPN	O	O	4775
has	VERB	O	O	4775
been	AUX	O	O	4775
used	VERB	O	O	4775
to	PART	O	O	4775
predict	VERB	O	O	4775
deficits	NOUN	O	O	4775
in	ADP	O	O	4775
central	ADJ	O	O	4775
cholinergic	ADJ	O	O	4775
functioning	VERB	O	O	4775
due	ADJ	O	O	4775
to	PART	O	O	4775
diseases	NOUN	O	O	4775
such	ADJ	O	O	4775
as	ADP	O	O	4775
Alzheimer	NOUN	O	Disease	4775
's	AUX	O	O	4775
disease	PROPN	O	O	4775
,	PUNCT	O	O	4775
yet	ADV	O	O	4775
correlations	NOUN	O	O	4775
between	ADP	O	O	4775
central	ADJ	O	O	4775
and	CCONJ	O	O	4775
peripheral	ADJ	O	O	4775
responses	NOUN	O	O	4775
have	VERB	O	O	4775
not	PART	O	O	4775
been	AUX	O	O	4775
properly	ADV	O	O	4775
studied	VERB	O	O	4775
.	PUNCT	O	O	4775
This	PRON	O	O	4776
study	VERB	O	O	4776
assessed	VERB	O	O	4776
the	PRON	O	O	4776
effect	VERB	O	O	4776
of	ADP	O	O	4776
normal	ADJ	O	O	4776
aging	VERB	O	O	4776
on	ADP	O	O	4776
(	PUNCT	O	O	4776
1	X	O	O	4776
)	PUNCT	O	O	4776
the	PRON	O	O	4776
tropicamide	NOUN	O	Chemical	4776
-	PUNCT	O	O	4776
induced	VERB	O	O	4776
increase	VERB	O	O	4776
in	ADP	O	O	4776
pupil	NOUN	O	O	4776
diameter	NOUN	O	O	4776
,	PUNCT	O	O	4776
and	CCONJ	O	O	4776
(	PUNCT	O	O	4776
2	X	O	O	4776
)	PUNCT	O	O	4776
the	PRON	O	O	4776
reversal	NOUN	O	O	4776
of	ADP	O	O	4776
this	PRON	O	O	4776
effect	VERB	O	O	4776
with	ADP	O	O	4776
pilocarpine	NOUN	O	Chemical	4776
.	PUNCT	O	O	4776
Scopolamine	NOUN	O	Chemical	4777
was	AUX	O	O	4777
used	VERB	O	O	4777
as	ADP	O	O	4777
a	PRON	O	O	4777
positive	ADJ	O	O	4777
control	VERB	O	O	4777
to	PART	O	O	4777
detect	VERB	O	O	4777
age	NOUN	O	O	4777
-	PUNCT	O	O	4777
dependent	ADJ	O	O	4777
changes	VERB	O	O	4777
in	ADP	O	O	4777
central	ADJ	O	O	4777
cholinergic	ADJ	O	O	4777
functioning	VERB	O	O	4777
in	ADP	O	O	4777
the	PRON	O	O	4777
elderly	ADJ	O	O	4777
.	PUNCT	O	O	4777
In	ADP	O	O	4778
1	X	O	O	4778
session	NOUN	O	O	4778
,	PUNCT	O	O	4778
tropicamide	NOUN	O	Chemical	4778
(	PUNCT	O	O	4778
20	NUM	O	O	4778
microL	CCONJ	O	O	4778
,	PUNCT	O	O	4778
0.01%	NOUN	O	O	4778
)	PUNCT	O	O	4778
was	AUX	O	O	4778
administered	VERB	O	O	4778
to	PART	O	O	4778
one	NUM	O	O	4778
eye	NOUN	O	O	4778
and	CCONJ	O	O	4778
placebo	NOUN	O	O	4778
to	PART	O	O	4778
the	PRON	O	O	4778
other	ADJ	O	O	4778
.	PUNCT	O	O	4778
In	ADP	O	O	4779
another	PRON	O	O	4779
session	NOUN	O	O	4779
,	PUNCT	O	O	4779
tropicamide	NOUN	O	Chemical	4779
(	PUNCT	O	O	4779
20	NUM	O	O	4779
microL	CCONJ	O	O	4779
,	PUNCT	O	O	4779
0.01%	NOUN	O	O	4779
)	PUNCT	O	O	4779
was	AUX	O	O	4779
administered	VERB	O	O	4779
to	PART	O	O	4779
both	PRON	O	O	4779
eyes	NOUN	O	O	4779
,	PUNCT	O	O	4779
followed	VERB	O	O	4779
23	NUM	O	O	4779
minutes	NOUN	O	O	4779
later	ADV	O	O	4779
by	ADP	O	O	4779
the	PRON	O	O	4779
application	NOUN	O	O	4779
of	ADP	O	O	4779
pilocarpine	NOUN	O	Chemical	4779
(	PUNCT	O	O	4779
20	NUM	O	O	4779
microL	CCONJ	O	O	4779
,	PUNCT	O	O	4779
0.1%	NOUN	O	O	4779
)	PUNCT	O	O	4779
to	PART	O	O	4779
one	NUM	O	O	4779
eye	NOUN	O	O	4779
and	CCONJ	O	O	4779
placebo	NOUN	O	O	4779
to	PART	O	O	4779
the	PRON	O	O	4779
other	ADJ	O	O	4779
.	PUNCT	O	O	4779
In	ADP	O	O	4780
2	X	O	O	4780
separate	VERB	O	O	4780
sessions	NOUN	O	O	4780
,	PUNCT	O	O	4780
a	PRON	O	O	4780
single	ADJ	O	O	4780
dose	NOUN	O	O	4780
of	ADP	O	O	4780
scopolamine	NOUN	O	Chemical	4780
(	PUNCT	O	O	4780
0.5	NUM	O	O	4780
mg	VERB	O	O	4780
,	PUNCT	O	O	4780
intravenously	ADV	O	O	4780
)	PUNCT	O	O	4780
or	CCONJ	O	O	4780
placebo	NOUN	O	O	4780
was	AUX	O	O	4780
administered	VERB	O	O	4780
,	PUNCT	O	O	4780
and	CCONJ	O	O	4780
the	PRON	O	O	4780
effects	NOUN	O	O	4780
on	ADP	O	O	4780
word	NOUN	O	O	4780
recall	VERB	O	O	4780
were	AUX	O	O	4780
measured	VERB	O	O	4780
using	VERB	O	O	4780
the	PRON	O	O	4780
Buschke	NOUN	O	O	4780
Selective	PROPN	O	O	4780
Reminding	VERB	O	O	4780
Test	NOUN	O	O	4780
over	ADP	O	O	4780
2	X	O	O	4780
hours	NOUN	O	O	4780
.	PUNCT	O	O	4780
Pupil	NOUN	O	O	4781
size	NOUN	O	O	4781
at	ADP	O	O	4781
time	NOUN	O	O	4781
points	VERB	O	O	4781
after	ADP	O	O	4781
administration	NOUN	O	O	4781
of	ADP	O	O	4781
tropicamide	NOUN	O	Chemical	4781
and	CCONJ	O	O	4781
pilocarpine	NOUN	O	Chemical	4781
;	PUNCT	O	O	4781
scopolamine	NOUN	O	Chemical	4781
-	PUNCT	O	O	4781
induced	VERB	O	O	4781
impairment in word recall	NOUN	O	Disease	4781
.	PUNCT	O	O	4781
There	ADV	O	O	4782
was	AUX	O	O	4782
no	PRON	O	O	4782
significant	ADJ	O	O	4782
difference	NOUN	O	O	4782
between	ADP	O	O	4782
elderly	ADJ	O	O	4782
and	CCONJ	O	O	4782
young	ADJ	O	O	4782
volunteers	NOUN	O	O	4782
in	ADP	O	O	4782
pupillary	ADJ	O	O	4782
response	NOUN	O	O	4782
to	PART	O	O	4782
tropicamide	NOUN	O	Chemical	4782
at	ADP	O	O	4782
any	PRON	O	O	4782
time	NOUN	O	O	4782
point	VERB	O	O	4782
(	PUNCT	O	O	4782
p	NOUN	O	O	4782
>	PUNCT	O	O	4782
0.05	NUM	O	O	4782
)	PUNCT	O	O	4782
.	PUNCT	O	O	4782
The	PRON	O	O	4783
elderly	ADJ	O	O	4783
group	NOUN	O	O	4783
had	VERB	O	O	4783
a	PRON	O	O	4783
significantly	ADV	O	O	4783
greater	ADJ	O	O	4783
pilocarpine	NOUN	O	Chemical	4783
-	PUNCT	O	O	4783
induced	VERB	O	O	4783
net	PROPN	O	O	4783
decrease	VERB	O	O	4783
in	ADP	O	O	4783
pupil	NOUN	O	O	4783
size	NOUN	O	O	4783
85	NUM	O	O	4783
,	PUNCT	O	O	4783
125	NUM	O	O	4783
,	PUNCT	O	O	4783
165	NUM	O	O	4783
and	CCONJ	O	O	4783
215	NUM	O	O	4783
minutes	NOUN	O	O	4783
after	ADP	O	O	4783
administration	NOUN	O	O	4783
,	PUNCT	O	O	4783
compared	VERB	O	O	4783
with	ADP	O	O	4783
the	PRON	O	O	4783
young	ADJ	O	O	4783
group	NOUN	O	O	4783
(	PUNCT	O	O	4783
p	NOUN	O	O	4783
<	X	O	O	4783
0.05	NUM	O	O	4783
)	PUNCT	O	O	4783
.	PUNCT	O	O	4783
Compared	VERB	O	O	4784
with	ADP	O	O	4784
the	PRON	O	O	4784
young	ADJ	O	O	4784
group	NOUN	O	O	4784
,	PUNCT	O	O	4784
the	PRON	O	O	4784
elderly	ADJ	O	O	4784
group	NOUN	O	O	4784
had	VERB	O	O	4784
greater	ADJ	O	O	4784
scopolamine	NOUN	O	Chemical	4784
-	PUNCT	O	O	4784
induced	VERB	O	O	4784
impairment in word recall	NOUN	O	Disease	4784
60	NUM	O	O	4784
,	PUNCT	O	O	4784
90	NUM	O	O	4784
and	CCONJ	O	O	4784
120	NUM	O	O	4784
minutes	NOUN	O	O	4784
after	ADP	O	O	4784
administration	NOUN	O	O	4784
(	PUNCT	O	O	4784
CONCLUSION	PROPN	O	O	4785
:	PUNCT	O	O	4785
There	ADV	O	O	4785
is	AUX	O	O	4785
an	PRON	O	O	4785
age	NOUN	O	O	4785
-	PUNCT	O	O	4785
related	ADJ	O	O	4785
pupillary	ADJ	O	O	4785
response	NOUN	O	O	4785
to	PART	O	O	4785
pilocarpine	NOUN	O	Chemical	4785
that	SCONJ	O	O	4785
is	AUX	O	O	4785
not	PART	O	O	4785
found	VERB	O	O	4785
with	ADP	O	O	4785
tropicamide	NOUN	O	Chemical	4785
.	PUNCT	O	O	4785
Thus	ADV	O	O	4786
,	PUNCT	O	O	4786
pilocarpine	NOUN	O	Chemical	4786
may	AUX	O	O	4786
be	AUX	O	O	4786
useful	ADJ	O	O	4786
to	PART	O	O	4786
assess	VERB	O	O	4786
variations	NOUN	O	O	4786
in	ADP	O	O	4786
central	ADJ	O	O	4786
cholinergic	ADJ	O	O	4786
function	NOUN	O	O	4786
in	ADP	O	O	4786
elderly	ADJ	O	O	4786
patients	NOUN	O	O	4786
.	PUNCT	O	O	4786
Acetazolamide	NOUN	O	Chemical	4789
-	PUNCT	O	O	4789
induced	VERB	O	O	4789
Gerstmann syndrome	NOUN	O	Disease	4789
.	PUNCT	O	O	4789
Acute	PROPN	O	O	4790
confusion	NOUN	O	Disease	4790
induced	VERB	O	O	4790
by	ADP	O	O	4790
acetazolamide	PROPN	O	Chemical	4790
is	AUX	O	O	4790
a	PRON	O	O	4790
well	ADV	O	O	4790
known	VERB	O	O	4790
adverse	ADJ	O	O	4790
drug	NOUN	O	O	4790
reaction	NOUN	O	O	4790
in	ADP	O	O	4790
patients	NOUN	O	O	4790
with	ADP	O	O	4790
renal impairment	NOUN	O	Disease	4790
.	PUNCT	O	O	4790
We	PRON	O	O	4791
report	VERB	O	O	4791
a	PRON	O	O	4791
case	NOUN	O	O	4791
of	ADP	O	O	4791
acetazolamide	PROPN	O	Chemical	4791
-	PUNCT	O	O	4791
induced	VERB	O	O	4791
Gerstmann syndrome	NOUN	O	Disease	4791
in	ADP	O	O	4791
a	PRON	O	O	4791
patient	NOUN	O	O	4791
with	ADP	O	O	4791
normal	ADJ	O	O	4791
renal	ADJ	O	O	4791
function	NOUN	O	O	4791
,	PUNCT	O	O	4791
to	PART	O	O	4791
highlight	VERB	O	O	4791
predisposing	VERB	O	O	4791
factors	NOUN	O	O	4791
that	SCONJ	O	O	4791
are	AUX	O	O	4791
frequently	ADV	O	O	4791
overlooked	VERB	O	O	4791
.	PUNCT	O	O	4791
Hypomania	NOUN	O	Disease	4794
-	PUNCT	O	O	4794
like	INTJ	O	O	4794
syndrome	NOUN	O	O	4794
induced	VERB	O	O	4794
by	ADP	O	O	4794
olanzapine	NOUN	O	Chemical	4794
.	PUNCT	O	O	4794
We	PRON	O	O	4795
report	VERB	O	O	4795
a	PRON	O	O	4795
female	ADJ	O	O	4795
patient	NOUN	O	O	4795
with	ADP	O	O	4795
a	PRON	O	O	4795
diagnosis	NOUN	O	O	4795
of	ADP	O	O	4795
a	PRON	O	O	4795
not	PART	O	O	4795
otherwise	ADV	O	O	4795
specified	VERB	O	O	4795
psychotic disorder	NOUN	O	Disease	4795
(	PUNCT	O	O	4795
DSM	PROPN	O	O	4795
-	PUNCT	O	O	4795
IV	NUM	O	O	4795
)	PUNCT	O	O	4795
who	PRON	O	O	4795
developed	VERB	O	O	4795
hypomania	PROPN	O	Disease	4795
shortly	ADV	O	O	4795
after	ADP	O	O	4795
the	PRON	O	O	4795
introduction	NOUN	O	O	4795
of	ADP	O	O	4795
olanzapine	NOUN	O	Chemical	4795
treatment	NOUN	O	O	4795
.	PUNCT	O	O	4795
Neutrophil	PROPN	O	O	4798
superoxide	NOUN	O	Chemical	4798
and	CCONJ	O	O	4798
hydrogen peroxide	NOUN	O	Chemical	4798
production	NOUN	O	O	4798
in	ADP	O	O	4798
patients	NOUN	O	O	4798
with	ADP	O	O	4798
acute liver failure	NOUN	O	Disease	4798
.	PUNCT	O	O	4798
Defects	NOUN	O	O	4799
in	ADP	O	O	4799
superoxide	NOUN	O	Chemical	4799
and	CCONJ	O	O	4799
hydrogen peroxide	NOUN	O	Chemical	4799
production	NOUN	O	O	4799
may	AUX	O	O	4799
be	AUX	O	O	4799
implicated	VERB	O	O	4799
in	ADP	O	O	4799
the	PRON	O	O	4799
high	ADJ	O	O	4799
incidence	NOUN	O	O	4799
of	ADP	O	O	4799
bacterial infections	NOUN	O	Disease	4799
in	ADP	O	O	4799
patients	NOUN	O	O	4799
with	ADP	O	O	4799
acute liver failure	NOUN	O	Disease	4799
(	PUNCT	O	O	4799
ALF	PROPN	O	Disease	4799
)	PUNCT	O	O	4799
.	PUNCT	O	O	4799
In	ADP	O	O	4800
the	PRON	O	O	4800
present	NOUN	O	O	4800
study	VERB	O	O	4800
,	PUNCT	O	O	4800
oxygen	NOUN	O	Chemical	4800
radical	ADJ	O	O	4800
production	NOUN	O	O	4800
in	ADP	O	O	4800
patients	NOUN	O	O	4800
with	ADP	O	O	4800
ALF	PROPN	O	Disease	4800
due	ADJ	O	O	4800
to	PART	O	O	4800
paracetamol	PROPN	O	Chemical	4800
overdose	NOUN	O	Disease	4800
was	AUX	O	O	4800
compared	VERB	O	O	4800
with	ADP	O	O	4800
that	SCONJ	O	O	4800
of	ADP	O	O	4800
healthy	ADJ	O	O	4800
volunteers	NOUN	O	O	4800
.	PUNCT	O	O	4800
Neutrophils	NOUN	O	O	4801
from	ADP	O	O	4801
14	NUM	O	O	4801
ALF	PROPN	O	Disease	4801
patients	NOUN	O	O	4801
were	AUX	O	O	4801
stimulated	VERB	O	O	4801
via	ADP	O	O	4801
the	PRON	O	O	4801
complement	VERB	O	O	4801
receptors	NOUN	O	O	4801
using	VERB	O	O	4801
zymosan	PROPN	O	O	4801
opsonized	VERB	O	O	4801
with	ADP	O	O	4801
ALF	PROPN	O	Disease	4801
or	CCONJ	O	O	4801
control	VERB	O	O	4801
serum	NOUN	O	O	4801
.	PUNCT	O	O	4801
Superoxide	NOUN	O	Chemical	4802
and	CCONJ	O	O	4802
hydrogen peroxide	NOUN	O	Chemical	4802
production	NOUN	O	O	4802
by	ADP	O	O	4802
ALF	PROPN	O	Disease	4802
neutrophils	VERB	O	O	4802
stimulated	VERB	O	O	4802
with	ADP	O	O	4802
zymosan	PROPN	O	O	4802
opsonized	VERB	O	O	4802
with	ADP	O	O	4802
ALF	PROPN	O	Disease	4802
serum	NOUN	O	O	4802
was	AUX	O	O	4802
significantly	ADV	O	O	4802
reduced	VERB	O	O	4802
compared	VERB	O	O	4802
with	ADP	O	O	4802
the	PRON	O	O	4802
control	VERB	O	O	4802
subjects	NOUN	O	O	4802
(	PUNCT	O	O	4802
P	NOUN	O	Chemical	4802
<	X	O	O	4802
0.01	NUM	O	O	4802
)	PUNCT	O	O	4802
.	PUNCT	O	O	4802
Superoxide	NOUN	O	Chemical	4803
and	CCONJ	O	O	4803
hydrogen peroxide	NOUN	O	Chemical	4803
production	NOUN	O	O	4803
in	ADP	O	O	4803
neutrophils	VERB	O	O	4803
stimulated	VERB	O	O	4803
with	ADP	O	O	4803
formyl	NOUN	O	O	4803
-	PUNCT	O	O	4803
methionyl	NOUN	O	O	4803
-	PUNCT	O	O	4803
leucyl	NOUN	O	O	4803
-	PUNCT	O	O	4803
phenylalanine	NOUN	O	O	4803
(	PUNCT	O	O	4803
fMLP	PROPN	O	Chemical	4803
)	PUNCT	O	O	4803
from	ADP	O	O	4803
a	PRON	O	O	4803
further	ADV	O	O	4803
18	NUM	O	O	4803
ALF	PROPN	O	Disease	4803
patients	NOUN	O	O	4803
was	AUX	O	O	4803
unaffected	ADJ	O	O	4803
compared	VERB	O	O	4803
with	ADP	O	O	4803
control	VERB	O	O	4803
neutrophils	VERB	O	O	4803
.	PUNCT	O	O	4803
Serum	NOUN	O	O	4804
C3	NOUN	O	O	4804
complement	VERB	O	O	4804
levels	NOUN	O	O	4804
were	AUX	O	O	4804
significantly	ADV	O	O	4804
reduced	VERB	O	O	4804
in	ADP	O	O	4804
ALF	PROPN	O	Disease	4804
patients	NOUN	O	O	4804
compared	VERB	O	O	4804
with	ADP	O	O	4804
control	VERB	O	O	4804
subjects	NOUN	O	O	4804
(	PUNCT	O	O	4804
P	NOUN	O	Chemical	4804
<	X	O	O	4804
0.0005	NUM	O	O	4804
)	PUNCT	O	O	4804
.	PUNCT	O	O	4804
These	PRON	O	O	4805
results	VERB	O	O	4805
demonstrate	VERB	O	O	4805
a	PRON	O	O	4805
neutrophil	ADJ	O	O	4805
defect	NOUN	O	O	4805
in	ADP	O	O	4805
ALF	PROPN	O	Disease	4805
due	ADJ	O	O	4805
to	PART	O	O	4805
paracetamol	PROPN	O	Chemical	4805
overdose	NOUN	O	Disease	4805
,	PUNCT	O	O	4805
that	SCONJ	O	O	4805
is	AUX	O	O	4805
complement	VERB	O	O	4805
dependent	ADJ	O	O	4805
but	CCONJ	O	O	4805
independent	ADJ	O	O	4805
of	ADP	O	O	4805
serum	NOUN	O	O	4805
complement	VERB	O	O	4805
,	PUNCT	O	O	4805
possibly	ADV	O	O	4805
connected	VERB	O	O	4805
to	PART	O	O	4805
the	PRON	O	O	4805
complement	VERB	O	O	4805
receptor	NOUN	O	O	4805
.	PUNCT	O	O	4805
Absence	NOUN	O	O	4808
of	ADP	O	O	4808
effect	VERB	O	O	4808
of	ADP	O	O	4808
sertraline	PROPN	O	Chemical	4808
on	ADP	O	O	4808
time	NOUN	O	O	4808
-	PUNCT	O	O	4808
based	VERB	O	O	4808
sensitization	NOUN	O	O	4808
of	ADP	O	O	4808
cognitive impairment	NOUN	O	Disease	4808
with	ADP	O	O	4808
haloperidol	NOUN	O	Chemical	4808
.	PUNCT	O	O	4808
This	PRON	O	O	4809
double	ADJ	O	O	4809
-	PUNCT	O	O	4809
blind	ADJ	O	Disease	4809
,	PUNCT	O	O	4809
randomized	VERB	O	O	4809
,	PUNCT	O	O	4809
placebo	NOUN	O	O	4809
-	PUNCT	O	O	4809
controlled	VERB	O	O	4809
study	VERB	O	O	4809
evaluated	VERB	O	O	4809
the	PRON	O	O	4809
effects	NOUN	O	O	4809
of	ADP	O	O	4809
haloperidol	NOUN	O	Chemical	4809
alone	ADV	O	O	4809
and	CCONJ	O	O	4809
haloperidol	NOUN	O	Chemical	4809
plus	CCONJ	O	O	4809
sertraline	PROPN	O	Chemical	4809
on	ADP	O	O	4809
cognitive	ADJ	O	O	4809
and	CCONJ	O	O	4809
psychomotor	NOUN	O	O	4809
function	NOUN	O	O	4809
in	ADP	O	O	4809
24	NUM	O	O	4809
healthy	ADJ	O	O	4809
male	NOUN	O	O	4809
subjects	NOUN	O	O	4809
.	PUNCT	O	O	4809
All	PRON	O	O	4810
subjects	NOUN	O	O	4810
received	VERB	O	O	4810
placebo	NOUN	O	O	4810
on	ADP	O	O	4810
Day	NOUN	O	O	4810
1	X	O	O	4810
and	CCONJ	O	O	4810
haloperidol	NOUN	O	Chemical	4810
2	X	O	O	4810
mg	VERB	O	O	4810
on	ADP	O	O	4810
Days	NOUN	O	O	4810
2	X	O	O	4810
and	CCONJ	O	O	4810
25	NUM	O	O	4810
.	PUNCT	O	O	4810
From	ADP	O	O	4811
Days	NOUN	O	O	4811
9	NUM	O	O	4811
to	PART	O	O	4811
25	NUM	O	O	4811
,	PUNCT	O	O	4811
subjects	NOUN	O	O	4811
were	AUX	O	O	4811
randomly	ADV	O	O	4811
assigned	VERB	O	O	4811
to	PART	O	O	4811
either	ADV	O	O	4811
sertraline	PROPN	O	Chemical	4811
(	PUNCT	O	O	4811
12	NUM	O	O	4811
subjects	NOUN	O	O	4811
)	PUNCT	O	O	4811
or	CCONJ	O	O	4811
placebo	NOUN	O	O	4811
(	PUNCT	O	O	4811
12	NUM	O	O	4811
subjects	NOUN	O	O	4811
)	PUNCT	O	O	4811
;	PUNCT	O	O	4811
the	PRON	O	O	4811
sertraline	PROPN	O	Chemical	4811
dose	NOUN	O	O	4811
was	AUX	O	O	4811
titrated	VERB	O	O	4811
from	ADP	O	O	4811
50	NUM	O	O	4811
to	PART	O	O	4811
200	NUM	O	O	4811
mg	VERB	O	O	4811
/	PUNCT	O	O	4811
day	NOUN	O	O	4811
from	ADP	O	O	4811
Days	NOUN	O	O	4811
9	NUM	O	O	4811
to	PART	O	O	4811
16	NUM	O	O	4811
,	PUNCT	O	O	4811
and	CCONJ	O	O	4811
remained	VERB	O	O	4811
at	ADP	O	O	4811
200	NUM	O	O	4811
mg	VERB	O	O	4811
/	PUNCT	O	O	4811
day	NOUN	O	O	4811
for	ADP	O	O	4811
the	PRON	O	O	4811
final	ADJ	O	O	4811
10	NUM	O	O	4811
days	NOUN	O	O	4811
of	ADP	O	O	4811
the	PRON	O	O	4811
drug	NOUN	O	O	4811
administration	NOUN	O	O	4811
period	NOUN	O	O	4811
.	PUNCT	O	O	4811
RESULTS	VERB	O	O	4812
:	PUNCT	O	O	4812
Impairment of cognitive function	NOUN	O	Disease	4812
was	AUX	O	O	4812
observed	VERB	O	O	4812
6	NUM	O	O	4812
to	PART	O	O	4812
8	NUM	O	O	4812
hours	NOUN	O	O	4812
after	ADP	O	O	4812
administration	NOUN	O	O	4812
of	ADP	O	O	4812
haloperidol	NOUN	O	Chemical	4812
on	ADP	O	O	4812
Day	NOUN	O	O	4812
2	X	O	O	4812
but	CCONJ	O	O	4812
was	AUX	O	O	4812
not	PART	O	O	4812
evident	ADJ	O	O	4812
23	NUM	O	O	4812
hours	NOUN	O	O	4812
after	ADP	O	O	4812
dosing	VERB	O	O	4812
.	PUNCT	O	O	4812
When	SCONJ	O	O	4813
single	ADJ	O	O	4813
-	PUNCT	O	O	4813
dose	NOUN	O	O	4813
haloperidol	NOUN	O	Chemical	4813
was	AUX	O	O	4813
given	VERB	O	O	4813
again	ADV	O	O	4813
25	NUM	O	O	4813
days	NOUN	O	O	4813
later	ADV	O	O	4813
,	PUNCT	O	O	4813
greater	ADJ	O	O	4813
impairment	NOUN	O	O	4813
with	ADP	O	O	4813
earlier	ADV	O	O	4813
onset	VERB	O	O	4813
was	AUX	O	O	4813
noted	VERB	O	O	4813
in	ADP	O	O	4813
several	ADJ	O	O	4813
tests	VERB	O	O	4813
in	ADP	O	O	4813
both	PRON	O	O	4813
treatment	NOUN	O	O	4813
groups	NOUN	O	O	4813
,	PUNCT	O	O	4813
suggesting	VERB	O	O	4813
enhancement	NOUN	O	O	4813
of	ADP	O	O	4813
this	PRON	O	O	4813
effect	VERB	O	O	4813
.	PUNCT	O	O	4813
There	ADV	O	O	4814
was	AUX	O	O	4814
no	PRON	O	O	4814
indication	NOUN	O	O	4814
that	SCONJ	O	O	4814
sertraline	PROPN	O	Chemical	4814
exacerbated	VERB	O	O	4814
the	PRON	O	O	4814
impairment	NOUN	O	O	4814
produced	VERB	O	O	4814
by	ADP	O	O	4814
haloperidol	NOUN	O	Chemical	4814
since	SCONJ	O	O	4814
an	PRON	O	O	4814
equivalent	ADJ	O	O	4814
effect	VERB	O	O	4814
also	ADV	O	O	4814
occurred	VERB	O	O	4814
in	ADP	O	O	4814
the	PRON	O	O	4814
placebo	NOUN	O	O	4814
group	NOUN	O	O	4814
.	PUNCT	O	O	4814
Three	NUM	O	O	4815
subjects	NOUN	O	O	4815
(	PUNCT	O	O	4815
2	X	O	O	4815
on	ADP	O	O	4815
sertraline	PROPN	O	Chemical	4815
and	CCONJ	O	O	4815
1	X	O	O	4815
on	ADP	O	O	4815
placebo	NOUN	O	O	4815
)	PUNCT	O	O	4815
withdrew	VERB	O	O	4815
from	ADP	O	O	4815
the	PRON	O	O	4815
study	VERB	O	O	4815
because	SCONJ	O	O	4815
of	ADP	O	O	4815
side	NOUN	O	O	4815
effects	NOUN	O	O	4815
.	PUNCT	O	O	4815
The	PRON	O	O	4816
side	NOUN	O	O	4816
effect	VERB	O	O	4816
profiles	NOUN	O	O	4816
of	ADP	O	O	4816
sertraline	PROPN	O	Chemical	4816
and	CCONJ	O	O	4816
of	ADP	O	O	4816
placebo	NOUN	O	O	4816
were	AUX	O	O	4816
similar	ADJ	O	O	4816
.	PUNCT	O	O	4816
Haloperidol	NOUN	O	Chemical	4817
produced	VERB	O	O	4817
a	PRON	O	O	4817
clear	ADJ	O	O	4817
profile	NOUN	O	O	4817
of	ADP	O	O	4817
cognitive impairment	NOUN	O	Disease	4817
that	SCONJ	O	O	4817
was	AUX	O	O	4817
not	PART	O	O	4817
worsened	VERB	O	O	4817
by	ADP	O	O	4817
concomitant	ADJ	O	O	4817
sertraline	PROPN	O	Chemical	4817
administration	NOUN	O	O	4817
.	PUNCT	O	O	4817
Ciprofloxacin	PROPN	O	Chemical	4820
-	PUNCT	O	O	4820
induced	VERB	O	O	4820
nephrotoxicity	NOUN	O	Disease	4820
in	ADP	O	O	4820
patients	NOUN	O	O	4820
with	ADP	O	O	4820
cancer	NOUN	O	Disease	4820
.	PUNCT	O	O	4820
Nephrotoxicity	NOUN	O	Disease	4821
associated	VERB	O	O	4821
with	ADP	O	O	4821
ciprofloxacin	VERB	O	Chemical	4821
is	AUX	O	O	4821
uncommon	ADJ	O	O	4821
.	PUNCT	O	O	4821
Five	NUM	O	O	4822
patients	NOUN	O	O	4822
with	ADP	O	O	4822
cancer	NOUN	O	Disease	4822
who	PRON	O	O	4822
developed	VERB	O	O	4822
acute	ADJ	O	O	4822
renal failure	NOUN	O	Disease	4822
that	SCONJ	O	O	4822
followed	VERB	O	O	4822
treatment	NOUN	O	O	4822
with	ADP	O	O	4822
ciprofloxacin	VERB	O	Chemical	4822
are	AUX	O	O	4822
described	VERB	O	O	4822
and	CCONJ	O	O	4822
an	PRON	O	O	4822
additional	ADJ	O	O	4822
15	NUM	O	O	4822
cases	NOUN	O	O	4822
reported	VERB	O	O	4822
in	ADP	O	O	4822
the	PRON	O	O	4822
literature	NOUN	O	O	4822
are	AUX	O	O	4822
reviewed	VERB	O	O	4822
.	PUNCT	O	O	4822
Other	ADJ	O	O	4823
than	ADP	O	O	4823
elevation	NOUN	O	O	4823
of	ADP	O	O	4823
serum	NOUN	O	O	4823
creatinine	PROPN	O	Chemical	4823
levels	NOUN	O	O	4823
,	PUNCT	O	O	4823
characteristic	ADJ	O	O	4823
clinical	ADJ	O	O	4823
manifestations	NOUN	O	O	4823
and	CCONJ	O	O	4823
abnormal	ADJ	O	O	4823
laboratory	NOUN	O	O	4823
findings	NOUN	O	O	4823
are	AUX	O	O	4823
not	PART	O	O	4823
frequently	ADV	O	O	4823
present	NOUN	O	O	4823
.	PUNCT	O	O	4823
Allergic	ADJ	O	O	4824
interstitial nephritis	NOUN	O	Disease	4824
is	AUX	O	O	4824
believed	VERB	O	O	4824
to	PART	O	O	4824
be	AUX	O	O	4824
the	PRON	O	O	4824
underlying	VERB	O	O	4824
pathological	ADJ	O	O	4824
-	PUNCT	O	O	4824
process	NOUN	O	O	4824
.	PUNCT	O	O	4824
An	PRON	O	O	4825
improvement	NOUN	O	O	4825
in	ADP	O	O	4825
renal	ADJ	O	O	4825
function	NOUN	O	O	4825
that	SCONJ	O	O	4825
followed	VERB	O	O	4825
the	PRON	O	O	4825
discontinuation	NOUN	O	O	4825
of	ADP	O	O	4825
the	PRON	O	O	4825
offending	VERB	O	O	4825
antibiotic	ADJ	O	O	4825
supports	VERB	O	O	4825
the	PRON	O	O	4825
presumptive	ADJ	O	O	4825
diagnosis	NOUN	O	O	4825
of	ADP	O	O	4825
ciprofloxacin	VERB	O	Chemical	4825
-	PUNCT	O	O	4825
induced	VERB	O	O	4825
acute	ADJ	O	O	4825
renal failure	NOUN	O	Disease	4825
.	PUNCT	O	O	4825
Case	NOUN	O	O	4828
report	VERB	O	O	4828
:	PUNCT	O	O	4828
pentamidine	VERB	O	Chemical	4828
and	CCONJ	O	O	4828
polymorphic	ADJ	O	O	4828
ventricular tachycardia	NOUN	O	Disease	4828
revisited	VERB	O	O	4828
.	PUNCT	O	O	4828
Pentamidine isethionate	NOUN	O	Chemical	4829
has	VERB	O	O	4829
been	AUX	O	O	4829
associated	VERB	O	O	4829
with	ADP	O	O	4829
ventricular tachyarrhythmias	NOUN	O	Disease	4829
,	PUNCT	O	O	4829
including	VERB	O	O	4829
torsade de pointes	NOUN	O	Disease	4829
.	PUNCT	O	O	4829
Pentamidine	NOUN	O	Chemical	4830
-	PUNCT	O	O	4830
induced	VERB	O	O	4830
torsade de pointes	NOUN	O	Disease	4830
may	AUX	O	O	4830
be	AUX	O	O	4830
related	ADJ	O	O	4830
to	PART	O	O	4830
serum	NOUN	O	O	4830
magnesium	NOUN	O	Chemical	4830
levels	NOUN	O	O	4830
and	CCONJ	O	O	4830
hypomagnesemia	ADV	O	Disease	4830
may	AUX	O	O	4830
synergistically	ADV	O	O	4830
induce	VERB	O	O	4830
torsade	NOUN	O	O	4830
.	PUNCT	O	O	4830
Torsade de pointes	VERB	O	Disease	4831
occurred	VERB	O	O	4831
after	ADP	O	O	4831
an	PRON	O	O	4831
average	ADJ	O	O	4831
of	ADP	O	O	4831
10	NUM	O	O	4831
days	NOUN	O	O	4831
of	ADP	O	O	4831
treatment	NOUN	O	O	4831
with	ADP	O	O	4831
pentamidine	VERB	O	Chemical	4831
.	PUNCT	O	O	4831
In	ADP	O	O	4832
these	PRON	O	O	4832
patients	NOUN	O	O	4832
,	PUNCT	O	O	4832
no	PRON	O	O	4832
other	ADJ	O	O	4832
acute	ADJ	O	O	4832
side	NOUN	O	O	4832
effects	NOUN	O	O	4832
of	ADP	O	O	4832
pentamidine	VERB	O	Chemical	4832
were	AUX	O	O	4832
observed	VERB	O	O	4832
.	PUNCT	O	O	4832
Torsade de pointes	VERB	O	Disease	4833
can	AUX	O	O	4833
be	AUX	O	O	4833
treated	VERB	O	O	4833
when	SCONJ	O	O	4833
recognized	VERB	O	O	4833
early	ADV	O	O	4833
,	PUNCT	O	O	4833
possibly	ADV	O	O	4833
without	ADP	O	O	4833
discontinuation	NOUN	O	O	4833
of	ADP	O	O	4833
pentamidine	VERB	O	Chemical	4833
.	PUNCT	O	O	4833
When	SCONJ	O	O	4834
QTc interval prolongation	NOUN	O	Disease	4834
is	AUX	O	O	4834
observed	VERB	O	O	4834
,	PUNCT	O	O	4834
early	ADV	O	O	4834
magnesium	NOUN	O	Chemical	4834
supplementation	NOUN	O	O	4834
is	AUX	O	O	4834
advocated	VERB	O	O	4834
.	PUNCT	O	O	4834
Time	NOUN	O	O	4837
dependence	NOUN	O	O	4837
of	ADP	O	O	4837
plasma	NOUN	O	O	4837
malondialdehyde	PROPN	O	Chemical	4837
,	PUNCT	O	O	4837
oxypurines	NOUN	O	Chemical	4837
,	PUNCT	O	O	4837
and	CCONJ	O	O	4837
nucleosides	VERB	O	Chemical	4837
during	ADP	O	O	4837
incomplete	ADJ	O	O	4837
cerebral ischemia	NOUN	O	Disease	4837
in	ADP	O	O	4837
the	PRON	O	O	4837
rat	NOUN	O	O	4837
.	PUNCT	O	O	4837
Incomplete	ADJ	O	O	4838
cerebral ischemia	NOUN	O	Disease	4838
(	PUNCT	O	O	4838
30	NUM	O	O	4838
min	NOUN	O	O	4838
)	PUNCT	O	O	4838
was	AUX	O	O	4838
induced	VERB	O	O	4838
in	ADP	O	O	4838
the	PRON	O	O	4838
rat	NOUN	O	O	4838
by	ADP	O	O	4838
bilaterally	ADV	O	O	4838
clamping	VERB	O	O	4838
the	PRON	O	O	4838
common	ADJ	O	O	4838
carotid	NOUN	O	O	4838
arteries	NOUN	O	O	4838
.	PUNCT	O	O	4838
Peripheral	ADJ	O	O	4839
venous	ADJ	O	O	4839
blood	NOUN	O	O	4839
samples	NOUN	O	O	4839
were	AUX	O	O	4839
withdrawn	VERB	O	O	4839
from	ADP	O	O	4839
the	PRON	O	O	4839
femoral	ADJ	O	O	4839
vein	NOUN	O	O	4839
four	NUM	O	O	4839
times	NOUN	O	O	4839
(	PUNCT	O	O	4839
once	ADV	O	O	4839
every	PRON	O	O	4839
5	NUM	O	O	4839
min	NOUN	O	O	4839
)	PUNCT	O	O	4839
before	ADP	O	O	4839
ischemia	NOUN	O	Disease	4839
(	PUNCT	O	O	4839
0	NUM	O	O	4839
time	NOUN	O	O	4839
)	PUNCT	O	O	4839
and	CCONJ	O	O	4839
5	NUM	O	O	4839
,	PUNCT	O	O	4839
15	NUM	O	O	4839
,	PUNCT	O	O	4839
and	CCONJ	O	O	4839
30	NUM	O	O	4839
min	NOUN	O	O	4839
after	ADP	O	O	4839
ischemia	NOUN	O	Disease	4839
.	PUNCT	O	O	4839
Plasma	NOUN	O	O	4840
extracts	VERB	O	O	4840
were	AUX	O	O	4840
analyzed	VERB	O	O	4840
by	ADP	O	O	4840
a	PRON	O	O	4840
highly	ADV	O	O	4840
sensitive	ADJ	O	O	4840
high	ADJ	O	O	4840
-	PUNCT	O	O	4840
performance	NOUN	O	O	4840
liquid	ADJ	O	O	4840
chromatographic	PROPN	O	O	4840
method	NOUN	O	O	4840
for	ADP	O	O	4840
the	PRON	O	O	4840
direct	ADJ	O	O	4840
determination	NOUN	O	O	4840
of	ADP	O	O	4840
malondialdehyde	PROPN	O	Chemical	4840
,	PUNCT	O	O	4840
oxypurines	NOUN	O	Chemical	4840
,	PUNCT	O	O	4840
and	CCONJ	O	O	4840
nucleosides	VERB	O	Chemical	4840
.	PUNCT	O	O	4840
During	ADP	O	O	4841
ischemia	NOUN	O	Disease	4841
,	PUNCT	O	O	4841
a	PRON	O	O	4841
time	NOUN	O	O	4841
-	PUNCT	O	O	4841
dependent	ADJ	O	O	4841
increase	VERB	O	O	4841
of	ADP	O	O	4841
plasma	NOUN	O	O	4841
oxypurines	NOUN	O	Chemical	4841
and	CCONJ	O	O	4841
nucleosides	VERB	O	Chemical	4841
was	AUX	O	O	4841
observed	VERB	O	O	4841
.	PUNCT	O	O	4841
Plasma	NOUN	O	O	4842
malondialdehyde	PROPN	O	Chemical	4842
,	PUNCT	O	O	4842
which	PRON	O	O	4842
was	AUX	O	O	4842
present	NOUN	O	O	4842
in	ADP	O	O	4842
minimal	ADJ	O	O	4842
amount	NOUN	O	O	4842
at	ADP	O	O	4842
zero	NUM	O	O	4842
time	NOUN	O	O	4842
(	PUNCT	O	O	4842
0.058	NUM	O	O	4842
mumol	PROPN	O	O	4842
/	PUNCT	O	O	4842
liter	NOUN	O	O	4842
plasma	NOUN	O	O	4842
;	PUNCT	O	O	4842
SD	NOUN	O	O	4843
0.015	NUM	O	O	4843
)	PUNCT	O	O	4843
,	PUNCT	O	O	4843
increased	VERB	O	O	4843
after	ADP	O	O	4843
5	NUM	O	O	4843
min	NOUN	O	O	4843
of	ADP	O	O	4843
ischemia	NOUN	O	Disease	4843
,	PUNCT	O	O	4843
resulting	VERB	O	O	4843
in	ADP	O	O	4843
a	PRON	O	O	4843
fivefold	ADV	O	O	4843
increase	VERB	O	O	4843
after	ADP	O	O	4843
30	NUM	O	O	4843
min	NOUN	O	O	4843
of	ADP	O	O	4843
carotid	NOUN	O	O	4843
occlusion	NOUN	O	O	4843
(	PUNCT	O	O	4843
0.298	NUM	O	O	4843
mumol	PROPN	O	O	4843
/	PUNCT	O	O	4843
liter	NOUN	O	O	4843
plasma	NOUN	O	O	4843
;	PUNCT	O	O	4843
SD	NOUN	O	O	4843
0.078	NUM	O	O	4843
)	PUNCT	O	O	4843
.	PUNCT	O	O	4843
Increased	VERB	O	O	4844
plasma	NOUN	O	O	4844
malondialdehyde	PROPN	O	Chemical	4844
was	AUX	O	O	4844
also	ADV	O	O	4844
recorded	VERB	O	O	4844
in	ADP	O	O	4844
two	NUM	O	O	4844
other	ADJ	O	O	4844
groups	NOUN	O	O	4844
of	ADP	O	O	4844
animals	NOUN	O	O	4844
subjected	VERB	O	O	4844
to	PART	O	O	4844
the	PRON	O	O	4844
same	ADJ	O	O	4844
experimental	ADJ	O	O	4844
model	NOUN	O	O	4844
,	PUNCT	O	O	4844
one	NUM	O	O	4844
receiving	VERB	O	O	4844
20	NUM	O	O	4844
mg	VERB	O	O	4844
/	PUNCT	O	O	4844
kg	VERB	O	O	4844
b.w	PROPN	O	O	4844
.	PUNCT	O	O	4844
of	ADP	O	O	4844
the	PRON	O	O	4844
cyclooxygenase	PROPN	O	O	4844
inhibitor	NOUN	O	O	4845
acetylsalicylate	NOUN	O	Chemical	4845
intravenously	ADV	O	O	4845
immediately	ADV	O	O	4845
before	ADP	O	O	4845
ischemia	NOUN	O	Disease	4845
,	PUNCT	O	O	4845
the	PRON	O	O	4845
other	ADJ	O	O	4845
receiving	VERB	O	O	4845
650	NUM	O	O	4845
micrograms	NOUN	O	O	4845
/	PUNCT	O	O	4845
kg	VERB	O	O	4845
b.w	PROPN	O	O	4845
.	PUNCT	O	O	4845
of	ADP	O	O	4846
the	PRON	O	O	4846
hypotensive	ADJ	O	Disease	4846
drug	NOUN	O	O	4846
nitroprusside	ADV	O	Chemical	4846
at	ADP	O	O	4846
a	PRON	O	O	4846
flow	NOUN	O	O	4846
rate	NOUN	O	O	4846
of	ADP	O	O	4846
103	NUM	O	O	4846
microliters	NOUN	O	O	4846
/	PUNCT	O	O	4846
min	NOUN	O	O	4847
intravenously	ADV	O	O	4847
during	ADP	O	O	4847
ischemia	NOUN	O	Disease	4847
,	PUNCT	O	O	4847
although	SCONJ	O	O	4847
in	ADP	O	O	4847
this	PRON	O	O	4847
latter	ADJ	O	O	4847
group	NOUN	O	O	4847
malondialdehyde	PROPN	O	Chemical	4847
was	AUX	O	O	4847
significantly	ADV	O	O	4847
higher	ADJ	O	O	4847
.	PUNCT	O	O	4847
The	PRON	O	O	4848
present	NOUN	O	O	4848
data	NOUN	O	O	4848
indicate	VERB	O	O	4848
that	SCONJ	O	O	4848
the	PRON	O	O	4848
determination	NOUN	O	O	4848
of	ADP	O	O	4848
malondialdehyde	PROPN	O	Chemical	4848
,	PUNCT	O	O	4848
oxypurines	NOUN	O	Chemical	4848
,	PUNCT	O	O	4848
and	CCONJ	O	O	4848
nucleosides	VERB	O	Chemical	4848
in	ADP	O	O	4848
peripheral	ADJ	O	O	4848
blood	NOUN	O	O	4848
,	PUNCT	O	O	4848
may	AUX	O	O	4848
be	AUX	O	O	4848
used	VERB	O	O	4848
to	PART	O	O	4848
monitor	VERB	O	O	4848
the	PRON	O	O	4848
metabolic	ADJ	O	O	4848
alterations	NOUN	O	O	4848
of	ADP	O	O	4848
tissues	NOUN	O	O	4848
occurring	VERB	O	O	4848
during	ADP	O	O	4848
ischemic	VERB	O	Disease	4848
phenomena.(ABSTRACT	X	O	O	4848
TRUNCATED	ADJ	O	O	4848
AT	ADP	O	O	4848
250	NUM	O	O	4848
WORDS	NOUN	O	O	4848
)	PUNCT	O	O	4848
Cholinergic	ADJ	O	O	4851
toxicity	NOUN	O	Disease	4851
resulting	VERB	O	O	4851
from	ADP	O	O	4851
ocular	ADJ	O	O	4851
instillation	NOUN	O	O	4851
of	ADP	O	O	4851
echothiophate iodide	NOUN	O	Chemical	4851
eye	NOUN	O	O	4851
drops	VERB	O	O	4851
.	PUNCT	O	O	4851
A	PRON	O	O	4852
patient	NOUN	O	O	4852
developed	VERB	O	O	4852
a	PRON	O	O	4852
severe	ADJ	O	O	4852
cholinergic	ADJ	O	O	4852
syndrome	NOUN	O	O	4852
from	ADP	O	O	4852
the	PRON	O	O	4852
use	VERB	O	O	4852
of	ADP	O	O	4852
echothiophate iodide	NOUN	O	Chemical	4852
ophthalmic	ADJ	O	O	4852
drops	VERB	O	O	4852
,	PUNCT	O	O	4852
presented	VERB	O	O	4852
with	ADP	O	O	4852
profound	ADJ	O	O	4852
muscle weakness	NOUN	O	Disease	4852
and	CCONJ	O	O	4852
was	AUX	O	O	4852
initially	ADV	O	O	4852
given	VERB	O	O	4852
the	PRON	O	O	4852
diagnosis	NOUN	O	O	4852
of	ADP	O	O	4852
myasthenia gravis	PROPN	O	Disease	4852
.	PUNCT	O	O	4852
Acute	PROPN	O	O	4855
renal failure	NOUN	O	Disease	4855
in	ADP	O	O	4855
high	ADJ	O	O	4855
dose	NOUN	O	O	4855
carboplatin	PROPN	O	Chemical	4855
chemotherapy	NOUN	O	O	4855
.	PUNCT	O	O	4855
Carboplatin	NOUN	O	Chemical	4856
has	VERB	O	O	4856
been	AUX	O	O	4856
reported	VERB	O	O	4856
to	PART	O	O	4856
cause	VERB	O	O	4856
acute	ADJ	O	O	4856
renal failure	NOUN	O	Disease	4856
when	SCONJ	O	O	4856
administered	VERB	O	O	4856
in	ADP	O	O	4856
high	ADJ	O	O	4856
doses	NOUN	O	O	4856
to	PART	O	O	4856
adult	NOUN	O	O	4856
patients	NOUN	O	O	4856
.	PUNCT	O	O	4856
We	PRON	O	O	4857
report	VERB	O	O	4857
a	PRON	O	O	4857
4	NUM	O	O	4857
1/2-year	NOUN	O	O	4857
-	PUNCT	O	O	4857
old	ADJ	O	O	4857
girl	NOUN	O	O	4857
who	PRON	O	O	4857
was	AUX	O	O	4857
treated	VERB	O	O	4857
with	ADP	O	O	4857
high	ADJ	O	O	4857
-	PUNCT	O	O	4857
dose	NOUN	O	O	4857
carboplatin	PROPN	O	Chemical	4857
for	ADP	O	O	4857
metastatic	ADJ	O	O	4857
parameningeal	NOUN	O	O	4857
embryonal rhabdomyosarcoma	PROPN	O	Disease	4857
.	PUNCT	O	O	4857
Acute	PROPN	O	O	4858
renal failure	NOUN	O	Disease	4858
developed	VERB	O	O	4858
followed	VERB	O	O	4858
by	ADP	O	O	4858
a	PRON	O	O	4858
slow	VERB	O	O	4858
partial	ADJ	O	O	4858
recovery	NOUN	O	O	4858
of	ADP	O	O	4858
renal	ADJ	O	O	4858
function	NOUN	O	O	4858
.	PUNCT	O	O	4858
Endometrial carcinoma	NOUN	O	Disease	4861
after	ADP	O	O	4861
Hodgkin disease	NOUN	O	Disease	4861
in	ADP	O	O	4861
childhood	NOUN	O	O	4861
.	PUNCT	O	O	4861
A	PRON	O	O	4862
34-year	NOUN	O	O	4862
-	PUNCT	O	O	4862
old	ADJ	O	O	4862
patient	NOUN	O	O	4862
developed	VERB	O	O	4862
metastic	NOUN	O	O	4862
endometrial carcinoma	NOUN	O	Disease	4862
after	ADP	O	O	4862
Hodgkin disease	NOUN	O	Disease	4862
in	ADP	O	O	4862
childhood	NOUN	O	O	4862
.	PUNCT	O	O	4862
She	PRON	O	O	4863
had	VERB	O	O	4863
ovarian failure	NOUN	O	Disease	4863
after	ADP	O	O	4863
abdominal	ADJ	O	O	4863
irradiation	NOUN	O	O	4863
and	CCONJ	O	O	4863
chemotherapy	NOUN	O	O	4863
for	ADP	O	O	4863
Hodgkin disease	NOUN	O	Disease	4863
,	PUNCT	O	O	4863
and	CCONJ	O	O	4863
received	VERB	O	O	4863
exogenous	ADJ	O	O	4863
estrogens	NOUN	O	Chemical	4863
,	PUNCT	O	O	4863
a	PRON	O	O	4863
treatment	NOUN	O	O	4863
implicated	VERB	O	O	4863
in	ADP	O	O	4863
the	PRON	O	O	4863
development	NOUN	O	O	4863
of	ADP	O	O	4863
endometrial cancer	NOUN	O	Disease	4863
in	ADP	O	O	4863
menopausal	PROPN	O	O	4863
women	NOUN	O	O	4863
.	PUNCT	O	O	4863
Young	ADJ	O	O	4864
women	NOUN	O	O	4864
on	ADP	O	O	4864
replacement	NOUN	O	O	4864
estrogens	NOUN	O	Chemical	4864
for	ADP	O	O	4864
ovarian failure	NOUN	O	Disease	4864
after	ADP	O	O	4864
cancer	NOUN	O	Disease	4864
therapy	NOUN	O	O	4864
may	AUX	O	O	4864
also	ADV	O	O	4864
have	VERB	O	O	4864
increased	VERB	O	O	4864
risk	NOUN	O	O	4864
of	ADP	O	O	4864
endometrial carcinoma	NOUN	O	Disease	4864
and	CCONJ	O	O	4864
should	AUX	O	O	4864
be	AUX	O	O	4864
examined	VERB	O	O	4864
periodically	ADV	O	O	4864
.	PUNCT	O	O	4864
Induction	NOUN	O	O	4867
of	ADP	O	O	4867
the	PRON	O	O	4867
obstructive sleep apnea syndrome	NOUN	O	Disease	4867
in	ADP	O	O	4867
a	PRON	O	O	4867
woman	NOUN	O	O	4867
by	ADP	O	O	4867
exogenous	ADJ	O	O	4867
androgen	PROPN	O	Chemical	4867
administration	NOUN	O	O	4867
.	PUNCT	O	O	4867
We	PRON	O	O	4868
documented	VERB	O	O	4868
airway	NOUN	O	O	4868
occlusion	NOUN	O	O	4868
during	ADP	O	O	4868
sleep	VERB	O	O	4868
and	CCONJ	O	O	4868
an	PRON	O	O	4868
abnormally	ADV	O	O	4868
high	ADJ	O	O	4868
supraglottic	ADJ	O	O	4868
resistance	NOUN	O	O	4868
while	SCONJ	O	O	4868
awake	ADJ	O	O	4868
in	ADP	O	O	4868
a	PRON	O	O	4868
54-yr	NOUN	O	O	4868
-	PUNCT	O	O	4868
old	ADJ	O	O	4868
woman	NOUN	O	O	4868
who	PRON	O	O	4868
had	VERB	O	O	4868
developed	VERB	O	O	4868
physical	ADJ	O	O	4868
changes	VERB	O	O	4868
and	CCONJ	O	O	4868
the	PRON	O	O	4868
syndrome of obstructive sleep apnea	NOUN	O	Disease	4868
while	SCONJ	O	O	4868
being	AUX	O	O	4868
administered	VERB	O	O	4868
exogenous	ADJ	O	O	4868
androgens	VERB	O	Chemical	4868
.	PUNCT	O	O	4868
When	SCONJ	O	O	4869
the	PRON	O	O	4869
androgens	VERB	O	Chemical	4869
were	AUX	O	O	4869
withdrawn	VERB	O	O	4869
,	PUNCT	O	O	4869
the	PRON	O	O	4869
patient	NOUN	O	O	4869
's	AUX	O	O	4869
physical	ADJ	O	O	4869
changes	VERB	O	O	4869
,	PUNCT	O	O	4869
symptoms	NOUN	O	O	4869
,	PUNCT	O	O	4869
sleep	VERB	O	O	4869
study	VERB	O	O	4869
,	PUNCT	O	O	4869
and	CCONJ	O	O	4869
supraglottic	ADJ	O	O	4869
resistance	NOUN	O	O	4869
all	PRON	O	O	4869
returned	VERB	O	O	4869
to	PART	O	O	4869
normal	ADJ	O	O	4869
.	PUNCT	O	O	4869
A	PRON	O	O	4870
rechallenge	VERB	O	O	4870
with	ADP	O	O	4870
androgen	PROPN	O	Chemical	4870
produced	VERB	O	O	4870
symptoms	NOUN	O	O	4870
of	ADP	O	O	4870
obstructive sleep apnea	NOUN	O	Disease	4870
that	SCONJ	O	O	4870
abated	VERB	O	O	4870
upon	SCONJ	O	O	4870
withdrawal	NOUN	O	O	4870
of	ADP	O	O	4870
the	PRON	O	O	4870
hormone	NOUN	O	O	4870
.	PUNCT	O	O	4870
Previous	ADJ	O	O	4871
reports	VERB	O	O	4871
have	VERB	O	O	4871
favored	VERB	O	O	4871
a	PRON	O	O	4871
role	NOUN	O	O	4871
of	ADP	O	O	4871
androgens	VERB	O	Chemical	4871
in	ADP	O	O	4871
the	PRON	O	O	4871
pathogenesis	NOUN	O	O	4871
of	ADP	O	O	4871
sleep apnea	NOUN	O	Disease	4871
.	PUNCT	O	O	4871
Structural	ADJ	O	O	4872
and	CCONJ	O	O	4872
functional	ADJ	O	O	4872
measurements	NOUN	O	O	4872
indicate	VERB	O	O	4872
that	SCONJ	O	O	4872
androgens	VERB	O	Chemical	4872
exert	VERB	O	O	4872
a	PRON	O	O	4872
permissive	ADJ	O	O	4872
or	CCONJ	O	O	4872
necessary	ADJ	O	O	4872
action	NOUN	O	O	4872
on	ADP	O	O	4872
the	PRON	O	O	4872
structural	ADJ	O	O	4872
configuration	NOUN	O	O	4872
of	ADP	O	O	4872
the	PRON	O	O	4872
oropharynx	NOUN	O	O	4872
that	SCONJ	O	O	4872
predisposes	VERB	O	O	4872
to	PART	O	O	4872
obstruction	NOUN	O	O	4872
during	ADP	O	O	4872
sleep	VERB	O	O	4872
.	PUNCT	O	O	4872
Development	NOUN	O	O	4873
of	ADP	O	O	4873
the	PRON	O	O	4873
obstructive sleep apnea syndrome	NOUN	O	Disease	4873
must	AUX	O	O	4873
be	AUX	O	O	4873
considered	VERB	O	O	4873
a	PRON	O	O	4873
possible	ADJ	O	O	4873
side	NOUN	O	O	4873
effect	VERB	O	O	4873
of	ADP	O	O	4873
androgen	PROPN	O	Chemical	4873
therapy	NOUN	O	O	4873
.	PUNCT	O	O	4873
Effect	VERB	O	O	4876
of	ADP	O	O	4876
captopril	PROPN	O	Chemical	4876
on	ADP	O	O	4876
pre	VERB	O	O	4876
-	PUNCT	O	O	4876
existing	VERB	O	O	4876
and	CCONJ	O	O	4876
aminonucleoside	NOUN	O	Chemical	4876
-	PUNCT	O	O	4876
induced	VERB	O	O	4876
proteinuria	X	O	Disease	4876
in	ADP	O	O	4876
spontaneously	ADV	O	O	4876
hypertensive	ADJ	O	Disease	4876
rats	NOUN	O	O	4876
.	PUNCT	O	O	4876
Proteinuria	PROPN	O	Disease	4877
is	AUX	O	O	4877
a	PRON	O	O	4877
side	NOUN	O	O	4877
effect	VERB	O	O	4877
of	ADP	O	O	4877
captopril	PROPN	O	Chemical	4877
treatment	NOUN	O	O	4877
in	ADP	O	O	4877
hypertensive	ADJ	O	Disease	4877
patients	NOUN	O	O	4877
.	PUNCT	O	O	4877
The	PRON	O	O	4878
possibility	NOUN	O	O	4878
of	ADP	O	O	4878
reproducing	VERB	O	O	4878
the	PRON	O	O	4878
same	ADJ	O	O	4878
renal abnormality	NOUN	O	Disease	4878
with	ADP	O	O	4878
captopril	PROPN	O	Chemical	4878
was	AUX	O	O	4878
examined	VERB	O	O	4878
in	ADP	O	O	4878
SHR	PROPN	O	O	4878
.	PUNCT	O	O	4878
Oral	NOUN	O	O	4879
administration	NOUN	O	O	4879
of	ADP	O	O	4879
captopril	PROPN	O	Chemical	4879
at	ADP	O	O	4879
100	NUM	O	O	4879
mg	VERB	O	O	4879
/	PUNCT	O	O	4879
kg	VERB	O	O	4879
for	ADP	O	O	4879
14	NUM	O	O	4879
days	NOUN	O	O	4879
failed	VERB	O	O	4879
to	PART	O	O	4879
aggravate	VERB	O	O	4879
proteinuria	X	O	Disease	4879
pre	VERB	O	O	4879
-	PUNCT	O	O	4879
existing	VERB	O	O	4879
in	ADP	O	O	4879
SHR	PROPN	O	O	4879
.	PUNCT	O	O	4879
Also	ADV	O	O	4880
,	PUNCT	O	O	4880
captopril	PROPN	O	Chemical	4880
treatment	NOUN	O	O	4880
failed	VERB	O	O	4880
to	PART	O	O	4880
potentiate	VERB	O	O	4880
or	CCONJ	O	O	4880
facilitate	VERB	O	O	4880
development	NOUN	O	O	4880
of	ADP	O	O	4880
massive	ADJ	O	O	4880
proteinuria	X	O	Disease	4880
invoked	VERB	O	O	4880
by	ADP	O	O	4880
puromycin aminonucleoside	NOUN	O	Chemical	4880
in	ADP	O	O	4880
SHR	PROPN	O	O	4880
.	PUNCT	O	O	4880
Captopril	PROPN	O	Chemical	4881
had	VERB	O	O	4881
little	ADJ	O	O	4881
or	CCONJ	O	O	4881
no	PRON	O	O	4881
demonstrable	ADJ	O	O	4881
effects	NOUN	O	O	4881
on	ADP	O	O	4881
serum	NOUN	O	O	4881
electrolyte	NOUN	O	O	4881
concentrations	NOUN	O	O	4881
,	PUNCT	O	O	4881
excretion	NOUN	O	O	4881
of	ADP	O	O	4881
urine	NOUN	O	O	4881
,	PUNCT	O	O	4881
sodium	NOUN	O	Chemical	4881
and	CCONJ	O	O	4881
potassium	NOUN	O	Chemical	4881
,	PUNCT	O	O	4881
endogenous	ADJ	O	O	4881
creatinine	PROPN	O	Chemical	4881
clearance	NOUN	O	O	4881
,	PUNCT	O	O	4881
body	NOUN	O	O	4881
weight	NOUN	O	O	4881
,	PUNCT	O	O	4881
and	CCONJ	O	O	4881
food	NOUN	O	O	4881
and	CCONJ	O	O	4881
water	PROPN	O	O	4881
consumption	NOUN	O	O	4881
.	PUNCT	O	O	4881
However	ADV	O	O	4882
,	PUNCT	O	O	4882
ketone	NOUN	O	Chemical	4882
bodies	NOUN	O	O	4882
were	AUX	O	O	4882
consistently	ADV	O	O	4882
present	NOUN	O	O	4882
in	ADP	O	O	4882
urine	NOUN	O	O	4882
and	CCONJ	O	O	4882
several	ADJ	O	O	4882
lethalities	NOUN	O	O	4882
occurred	VERB	O	O	4882
during	ADP	O	O	4882
multiple	ADJ	O	O	4882
dosing	VERB	O	O	4882
of	ADP	O	O	4882
captopril	PROPN	O	Chemical	4882
in	ADP	O	O	4882
SHR	PROPN	O	O	4882
.	PUNCT	O	O	4882
Epileptogenic	NOUN	O	O	4885
properties	NOUN	O	O	4885
of	ADP	O	O	4885
enflurane	NOUN	O	Chemical	4885
and	CCONJ	O	O	4885
their	PRON	O	O	4885
clinical	ADJ	O	O	4885
interpretation	NOUN	O	O	4885
.	PUNCT	O	O	4885
Three	NUM	O	O	4886
cases	NOUN	O	O	4886
of	ADP	O	O	4886
EEG	NOUN	O	O	4886
changes	VERB	O	O	4886
induced	VERB	O	O	4886
by	ADP	O	O	4886
single	ADJ	O	O	4886
exposure	NOUN	O	O	4886
to	PART	O	O	4886
enflurane	NOUN	O	Chemical	4886
anesthesia	NOUN	O	O	4886
are	AUX	O	O	4886
reported	VERB	O	O	4886
.	PUNCT	O	O	4886
In	ADP	O	O	4887
one	NUM	O	O	4887
patient	NOUN	O	O	4887
,	PUNCT	O	O	4887
enflurane	NOUN	O	Chemical	4887
administered	VERB	O	O	4887
during	ADP	O	O	4887
a	PRON	O	O	4887
donor	NOUN	O	O	4887
nephrectomy	NOUN	O	O	4887
resulted	VERB	O	O	4887
in	ADP	O	O	4887
unexpected	ADJ	O	O	4887
partial	ADJ	O	O	4887
motor	NOUN	O	O	4887
seizures	NOUN	O	Disease	4887
.	PUNCT	O	O	4887
Until	ADP	O	O	4888
the	PRON	O	O	4888
cause	VERB	O	O	4888
of	ADP	O	O	4888
the	PRON	O	O	4888
seizures	NOUN	O	Disease	4888
was	AUX	O	O	4888
correctly	ADV	O	O	4888
identified	VERB	O	O	4888
,	PUNCT	O	O	4888
the	PRON	O	O	4888
patient	NOUN	O	O	4888
was	AUX	O	O	4888
inappropriately	ADV	O	O	4888
treated	VERB	O	O	4888
with	ADP	O	O	4888
anticonvulsants	NOUN	O	O	4888
.	PUNCT	O	O	4888
Two	NUM	O	O	4889
other	ADJ	O	O	4889
patients	NOUN	O	O	4889
suffered	VERB	O	O	4889
from	ADP	O	O	4889
partial	ADJ	O	O	4889
,	PUNCT	O	O	4889
complex	ADJ	O	O	4889
and	CCONJ	O	O	4889
generalized	VERB	O	O	4889
seizures	NOUN	O	Disease	4889
uncontrolled	ADJ	O	O	4889
by	ADP	O	O	4889
medication	NOUN	O	O	4889
.	PUNCT	O	O	4889
Epileptic	ADJ	O	Disease	4890
foci	VERB	O	O	4890
delineated	VERB	O	O	4890
and	CCONJ	O	O	4890
activated	VERB	O	O	4890
by	ADP	O	O	4890
enflurane	NOUN	O	Chemical	4890
were	AUX	O	O	4890
surgically	ADV	O	O	4890
ablated	VERB	O	O	4890
and	CCONJ	O	O	4890
the	PRON	O	O	4890
patients	NOUN	O	O	4890
are	AUX	O	O	4890
now	ADV	O	O	4890
seizure	NOUN	O	Disease	4890
-	PUNCT	O	O	4890
free	ADJ	O	O	4890
.	PUNCT	O	O	4890
Previous	ADJ	O	O	4891
exposures	NOUN	O	O	4891
to	PART	O	O	4891
enflurane	NOUN	O	Chemical	4891
have	VERB	O	O	4891
to	PART	O	O	4891
be	AUX	O	O	4891
disclosed	VERB	O	O	4891
to	PART	O	O	4891
avoid	VERB	O	O	4891
mistakes	NOUN	O	O	4891
in	ADP	O	O	4891
clinical	ADJ	O	O	4891
interpretation	NOUN	O	O	4891
of	ADP	O	O	4891
the	PRON	O	O	4891
EEG	NOUN	O	O	4891
.	PUNCT	O	O	4891
On	ADP	O	O	4892
the	PRON	O	O	4892
other	ADJ	O	O	4892
hand	NOUN	O	O	4892
,	PUNCT	O	O	4892
enflurane	NOUN	O	Chemical	4892
may	AUX	O	O	4892
prove	VERB	O	O	4892
to	PART	O	O	4892
be	AUX	O	O	4892
a	PRON	O	O	4892
safe	ADJ	O	O	4892
fast	ADV	O	O	4892
acting	VERB	O	O	4892
activator	NOUN	O	O	4892
of	ADP	O	O	4892
epileptic	ADJ	O	Disease	4892
foci	VERB	O	O	4892
during	ADP	O	O	4892
corticography	NOUN	O	O	4892
or	CCONJ	O	O	4892
depth	NOUN	O	O	4892
electrode	ADV	O	O	4892
intraoperative	ADJ	O	O	4892
recordings	NOUN	O	O	4892
.	PUNCT	O	O	4892
Reversible	ADJ	O	O	4895
cerebral lesions	NOUN	O	Disease	4895
associated	VERB	O	O	4895
with	ADP	O	O	4895
tiazofurin	NOUN	O	Chemical	4895
usage	NOUN	O	O	4895
:	PUNCT	O	O	4895
MR	PROPN	O	O	4895
demonstration	NOUN	O	O	4895
.	PUNCT	O	O	4895
Tiazofurin	PROPN	O	Chemical	4896
is	AUX	O	O	4896
an	PRON	O	O	4896
experimental	ADJ	O	O	4896
chemotherapeutic	NOUN	O	O	4896
agent	NOUN	O	O	4896
currently	ADV	O	O	4896
undergoing	VERB	O	O	4896
clinical	ADJ	O	O	4896
evaluation	NOUN	O	O	4896
.	PUNCT	O	O	4896
We	PRON	O	O	4897
report	VERB	O	O	4897
our	PRON	O	O	4897
results	VERB	O	O	4897
with	ADP	O	O	4897
magnetic	ADJ	O	O	4897
resonance	NOUN	O	O	4897
(	PUNCT	O	O	4897
MR	PROPN	O	O	4897
)	PUNCT	O	O	4897
in	ADP	O	O	4897
demonstrating	VERB	O	O	4897
reversible	ADJ	O	O	4897
cerebral abnormalities	NOUN	O	Disease	4897
concurrent	ADJ	O	O	4897
with	ADP	O	O	4897
the	PRON	O	O	4897
use	VERB	O	O	4897
of	ADP	O	O	4897
this	PRON	O	O	4897
drug	NOUN	O	O	4897
.	PUNCT	O	O	4897
Antagonism	NOUN	O	O	4900
of	ADP	O	O	4900
diazepam	NOUN	O	Chemical	4900
-	PUNCT	O	O	4900
induced	VERB	O	O	4900
sedative	NOUN	O	O	4900
effects	NOUN	O	O	4900
by	ADP	O	O	4900
Ro15	NOUN	O	O	4900
-	PUNCT	O	O	4900
1788	NUM	O	O	4900
in	ADP	O	O	4900
patients	NOUN	O	O	4900
after	ADP	O	O	4900
surgery	NOUN	O	O	4900
under	ADP	O	O	4900
lumbar	NOUN	O	O	4900
epidural	ADV	O	O	4900
block	NOUN	O	O	4900
.	PUNCT	O	O	4900
The	PRON	O	O	4901
aim	VERB	O	O	4901
of	ADP	O	O	4901
this	PRON	O	O	4901
study	VERB	O	O	4901
was	AUX	O	O	4901
to	PART	O	O	4901
assess	VERB	O	O	4901
the	PRON	O	O	4901
efficacy	NOUN	O	O	4901
of	ADP	O	O	4901
Ro15	NOUN	O	O	4901
-	PUNCT	O	O	4901
1788	NUM	O	O	4901
and	CCONJ	O	O	4901
a	PRON	O	O	4901
placebo	NOUN	O	O	4901
in	ADP	O	O	4901
reversing	VERB	O	O	4901
diazepam	NOUN	O	Chemical	4901
-	PUNCT	O	O	4901
induced	VERB	O	O	4901
effects	NOUN	O	O	4901
after	ADP	O	O	4901
surgery	NOUN	O	O	4901
under	ADP	O	O	4901
epidural	ADV	O	O	4901
block	NOUN	O	O	4901
,	PUNCT	O	O	4901
and	CCONJ	O	O	4901
to	PART	O	O	4901
evaluate	VERB	O	O	4901
the	PRON	O	O	4901
local	ADJ	O	O	4901
tolerance	NOUN	O	O	4901
and	CCONJ	O	O	4901
general	ADJ	O	O	4901
safety	NOUN	O	O	4901
of	ADP	O	O	4901
Ro15	NOUN	O	O	4901
-	PUNCT	O	O	4901
1788	NUM	O	O	4901
.	PUNCT	O	O	4901
Fifty	NUM	O	O	4902
-	PUNCT	O	O	4902
seven	NUM	O	O	4902
patients	NOUN	O	O	4902
were	AUX	O	O	4902
sedated	VERB	O	O	4902
with	ADP	O	O	4902
diazepam	NOUN	O	Chemical	4902
for	ADP	O	O	4902
surgery	NOUN	O	O	4902
under	ADP	O	O	4902
epidural	ADV	O	O	4902
anaesthesia	NOUN	O	O	4902
.	PUNCT	O	O	4902
Antagonism	NOUN	O	O	4903
of	ADP	O	O	4903
diazepam	NOUN	O	Chemical	4903
-	PUNCT	O	O	4903
induced	VERB	O	O	4903
effects	NOUN	O	O	4903
by	ADP	O	O	4903
Ro15	NOUN	O	O	4903
-	PUNCT	O	O	4903
1788	NUM	O	O	4903
was	AUX	O	O	4903
investigated	VERB	O	O	4903
postoperatively	PROPN	O	O	4903
in	ADP	O	O	4903
a	PRON	O	O	4903
double	ADJ	O	O	4903
-	PUNCT	O	O	4903
blind	ADJ	O	Disease	4903
placebo	NOUN	O	O	4903
-	PUNCT	O	O	4903
controlled	VERB	O	O	4903
trial	NOUN	O	O	4903
.	PUNCT	O	O	4903
The	PRON	O	O	4904
patient	NOUN	O	O	4904
's	AUX	O	O	4904
subjective	ADJ	O	O	4904
assessment	NOUN	O	O	4904
of	ADP	O	O	4904
mood	NOUN	O	O	4904
rating	NOUN	O	O	4904
,	PUNCT	O	O	4904
an	PRON	O	O	4904
objective	VERB	O	O	4904
test	NOUN	O	O	4904
of	ADP	O	O	4904
performance	NOUN	O	O	4904
,	PUNCT	O	O	4904
a	PRON	O	O	4904
test	NOUN	O	O	4904
for	ADP	O	O	4904
amnesia	NOUN	O	Disease	4904
,	PUNCT	O	O	4904
and	CCONJ	O	O	4904
vital	ADJ	O	O	4904
signs	NOUN	O	O	4904
were	AUX	O	O	4904
recorded	VERB	O	O	4904
for	ADP	O	O	4904
up	ADP	O	O	4904
to	PART	O	O	4904
300	NUM	O	O	4904
min	NOUN	O	O	4904
after	ADP	O	O	4904
administration	NOUN	O	O	4904
of	ADP	O	O	4904
the	PRON	O	O	4904
trial	NOUN	O	O	4904
drug	NOUN	O	O	4904
.	PUNCT	O	O	4904
No	PRON	O	O	4905
significant	ADJ	O	O	4905
differences	NOUN	O	O	4905
between	ADP	O	O	4905
the	PRON	O	O	4905
two	NUM	O	O	4905
groups	NOUN	O	O	4905
were	AUX	O	O	4905
observed	VERB	O	O	4905
for	ADP	O	O	4905
mood	NOUN	O	O	4905
rating	NOUN	O	O	4905
,	PUNCT	O	O	4905
amnesia	NOUN	O	Disease	4905
,	PUNCT	O	O	4905
or	CCONJ	O	O	4905
vital	ADJ	O	O	4905
signs	NOUN	O	O	4905
.	PUNCT	O	O	4905
The	PRON	O	O	4906
Ro15	NOUN	O	O	4906
-	PUNCT	O	O	4906
1788	NUM	O	O	4906
group	NOUN	O	O	4906
showed	VERB	O	O	4906
a	PRON	O	O	4906
significant	ADJ	O	O	4906
improvement	NOUN	O	O	4906
in	ADP	O	O	4906
the	PRON	O	O	4906
performance	NOUN	O	O	4906
test	NOUN	O	O	4906
up	ADP	O	O	4906
to	PART	O	O	4906
120	NUM	O	O	4906
min	NOUN	O	O	4906
after	ADP	O	O	4906
administration	NOUN	O	O	4906
of	ADP	O	O	4906
the	PRON	O	O	4906
drug	NOUN	O	O	4906
.	PUNCT	O	O	4906
Enhanced	VERB	O	O	4909
stimulus	NOUN	O	O	4909
-	PUNCT	O	O	4909
induced	VERB	O	O	4909
neurotransmitter	NOUN	O	O	4909
overflow	NOUN	O	O	4909
in	ADP	O	O	4909
epinephrine	NOUN	O	Chemical	4909
-	PUNCT	O	O	4909
induced	VERB	O	O	4909
hypertensive	ADJ	O	Disease	4909
rats	NOUN	O	O	4909
is	AUX	O	O	4909
not	PART	O	O	4909
mediated	VERB	O	O	4909
by	ADP	O	O	4909
prejunctional	ADJ	O	O	4909
beta	NOUN	O	O	4909
-	PUNCT	O	O	4909
adrenoceptor	NOUN	O	O	4909
activation	NOUN	O	O	4909
.	PUNCT	O	O	4909
The	PRON	O	O	4910
present	NOUN	O	O	4910
study	VERB	O	O	4910
examines	VERB	O	O	4910
the	PRON	O	O	4910
effect	VERB	O	O	4910
of	ADP	O	O	4910
6-day	NOUN	O	O	4910
epinephrine	NOUN	O	Chemical	4910
treatment	NOUN	O	O	4910
(	PUNCT	O	O	4910
100	NUM	O	O	4910
micrograms	NOUN	O	O	4910
/	PUNCT	O	O	4910
kg	VERB	O	O	4910
per	ADP	O	O	4910
h	X	O	O	4910
,	PUNCT	O	O	4910
s.c	PROPN	O	O	4910
.	PUNCT	O	O	4910
)	PUNCT	O	O	4910
endogenous	ADJ	O	O	4911
neurotransmitter	NOUN	O	O	4911
overflow	NOUN	O	O	4911
from	ADP	O	O	4911
the	PRON	O	O	4911
isolated	VERB	O	O	4911
perfused	VERB	O	O	4911
kidney	NOUN	O	O	4911
of	ADP	O	O	4911
vehicle-	ADJ	O	O	4911
and	CCONJ	O	O	4911
epinephrine	NOUN	O	Chemical	4911
-	PUNCT	O	O	4911
treated	VERB	O	O	4911
rats	NOUN	O	O	4911
.	PUNCT	O	O	4911
Renal	NOUN	O	O	4912
catecholamine	ADJ	O	Chemical	4912
stores	NOUN	O	O	4912
and	CCONJ	O	O	4912
stimulus	NOUN	O	O	4912
-	PUNCT	O	O	4912
induced	VERB	O	O	4912
overflow	NOUN	O	O	4912
in	ADP	O	O	4912
the	PRON	O	O	4912
vehicle	NOUN	O	O	4912
-	PUNCT	O	O	4912
treated	VERB	O	O	4912
group	NOUN	O	O	4912
consisted	VERB	O	O	4912
of	ADP	O	O	4912
norepinephrine	NOUN	O	Chemical	4912
only	ADV	O	O	4912
.	PUNCT	O	O	4912
However	ADV	O	O	4913
,	PUNCT	O	O	4913
epinephrine	NOUN	O	Chemical	4913
treatment	NOUN	O	O	4913
resulted	VERB	O	O	4913
in	ADP	O	O	4913
the	PRON	O	O	4913
incorporation	NOUN	O	O	4913
of	ADP	O	O	4913
epinephrine	NOUN	O	Chemical	4913
into	ADP	O	O	4913
renal	ADJ	O	O	4913
catecholamine	ADJ	O	Chemical	4913
stores	NOUN	O	O	4913
such	ADJ	O	O	4913
that	SCONJ	O	O	4913
approximately	ADV	O	O	4913
40%	NOUN	O	O	4913
of	ADP	O	O	4913
the	PRON	O	O	4913
catecholamine	ADJ	O	Chemical	4913
present	NOUN	O	O	4913
was	AUX	O	O	4913
epinephrine	NOUN	O	Chemical	4913
while	SCONJ	O	O	4913
the	PRON	O	O	4913
norepinephrine	NOUN	O	Chemical	4913
content	NOUN	O	O	4913
was	AUX	O	O	4913
reduced	VERB	O	O	4913
by	ADP	O	O	4913
a	PRON	O	O	4913
similar	ADJ	O	O	4913
degree	PROPN	O	O	4913
.	PUNCT	O	O	4913
Total	ADJ	O	O	4914
tissue	NOUN	O	O	4914
catecholamine	ADJ	O	Chemical	4914
content	NOUN	O	O	4914
of	ADP	O	O	4914
the	PRON	O	O	4914
kidney	NOUN	O	O	4914
on	ADP	O	O	4914
a	PRON	O	O	4914
molar	ADJ	O	O	4914
basis	NOUN	O	O	4914
was	AUX	O	O	4914
unchanged	ADJ	O	O	4914
.	PUNCT	O	O	4914
Stimulus	NOUN	O	O	4915
-	PUNCT	O	O	4915
induced	VERB	O	O	4915
fractional	ADJ	O	O	4915
overflow	NOUN	O	O	4915
of	ADP	O	O	4915
neurotransmitter	NOUN	O	O	4915
from	ADP	O	O	4915
the	PRON	O	O	4915
epinephrine	NOUN	O	Chemical	4915
-	PUNCT	O	O	4915
treated	VERB	O	O	4915
kidneys	NOUN	O	O	4915
was	AUX	O	O	4915
approximately	ADV	O	O	4915
twice	ADV	O	O	4915
normal	ADJ	O	O	4915
and	CCONJ	O	O	4915
consisted	VERB	O	O	4915
of	ADP	O	O	4915
both	PRON	O	O	4915
norepinephrine	NOUN	O	Chemical	4915
and	CCONJ	O	O	4915
epinephrine	NOUN	O	Chemical	4915
in	ADP	O	O	4915
proportions	NOUN	O	O	4915
similar	ADJ	O	O	4915
to	PART	O	O	4915
those	PRON	O	O	4915
found	VERB	O	O	4915
in	ADP	O	O	4915
the	PRON	O	O	4915
kidney	NOUN	O	O	4915
.	PUNCT	O	O	4915
Propranolol	NOUN	O	Chemical	4916
had	VERB	O	O	4916
no	PRON	O	O	4916
effect	VERB	O	O	4916
on	ADP	O	O	4916
stimulus	NOUN	O	O	4916
-	PUNCT	O	O	4916
induced	VERB	O	O	4916
overflow	NOUN	O	O	4916
in	ADP	O	O	4916
either	ADV	O	O	4916
group	NOUN	O	O	4916
.	PUNCT	O	O	4916
Phentolamine	PROPN	O	Chemical	4917
increased	VERB	O	O	4917
stimulus	NOUN	O	O	4917
-	PUNCT	O	O	4917
induced	VERB	O	O	4917
overflow	NOUN	O	O	4917
in	ADP	O	O	4917
both	PRON	O	O	4917
groups	NOUN	O	O	4917
although	SCONJ	O	O	4917
the	PRON	O	O	4917
increment	NOUN	O	O	4917
in	ADP	O	O	4917
overflow	NOUN	O	O	4917
was	AUX	O	O	4917
greater	ADJ	O	O	4917
in	ADP	O	O	4917
the	PRON	O	O	4917
epinephrine	NOUN	O	Chemical	4917
-	PUNCT	O	O	4917
treated	VERB	O	O	4917
group	NOUN	O	O	4917
.	PUNCT	O	O	4917
In	ADP	O	O	4918
conclusion	NOUN	O	O	4918
,	PUNCT	O	O	4918
chronic	ADJ	O	O	4918
epinephrine	NOUN	O	Chemical	4918
treatment	NOUN	O	O	4918
results	VERB	O	O	4918
in	ADP	O	O	4918
enhanced	VERB	O	O	4918
fractional	ADJ	O	O	4918
neurotransmitter	NOUN	O	O	4918
overflow	NOUN	O	O	4918
.	PUNCT	O	O	4918
Furthermore	ADV	O	O	4919
,	PUNCT	O	O	4919
data	NOUN	O	O	4919
obtained	VERB	O	O	4919
with	ADP	O	O	4919
phentolamine	ADV	O	Chemical	4919
alone	ADV	O	O	4919
do	VERB	O	O	4919
not	PART	O	O	4919
suggest	VERB	O	O	4919
alpha	PROPN	O	O	4919
-	PUNCT	O	O	4919
adrenoceptor	NOUN	O	O	4919
desensitization	NOUN	O	O	4919
as	ADP	O	O	4919
the	PRON	O	O	4919
cause	VERB	O	O	4919
of	ADP	O	O	4919
the	PRON	O	O	4919
enhanced	VERB	O	O	4919
neurotransmitter	NOUN	O	O	4919
overflow	NOUN	O	O	4919
after	ADP	O	O	4919
epinephrine	NOUN	O	Chemical	4919
treatment	NOUN	O	O	4919
.	PUNCT	O	O	4919
Ocular	ADJ	O	O	4922
manifestations	NOUN	O	O	4922
of	ADP	O	O	4922
juvenile	NOUN	O	O	4922
rheumatoid arthritis	NOUN	O	Disease	4922
.	PUNCT	O	O	4922
We	PRON	O	O	4923
followed	VERB	O	O	4923
210	NUM	O	O	4923
cases	NOUN	O	O	4923
of	ADP	O	O	4923
juvenile	NOUN	O	O	4923
rheumatoid arthritis	NOUN	O	Disease	4923
closely	ADV	O	O	4923
for	ADP	O	O	4923
eleven	NUM	O	O	4923
years	NOUN	O	O	4923
.	PUNCT	O	O	4923
Thirty	NUM	O	O	4924
-	PUNCT	O	O	4924
six	NUM	O	O	4924
of	ADP	O	O	4924
the	PRON	O	O	4924
210	NUM	O	O	4924
patients	NOUN	O	O	4924
(	PUNCT	O	O	4924
17.2%	NOUN	O	O	4924
)	PUNCT	O	O	4924
developed	VERB	O	O	4924
iridocyclitis	NOUN	O	Disease	4924
.	PUNCT	O	O	4924
Iridocyclitis	NOUN	O	Disease	4925
was	AUX	O	O	4925
seen	VERB	O	O	4925
most	ADV	O	O	4925
frequently	ADV	O	O	4925
in	ADP	O	O	4925
young	ADJ	O	O	4925
female	ADJ	O	O	4925
patients	NOUN	O	O	4925
(	PUNCT	O	O	4925
0	NUM	O	O	4925
to	PART	O	O	4925
4	NUM	O	O	4925
years	NOUN	O	O	4925
)	PUNCT	O	O	4925
with	ADP	O	O	4925
the	PRON	O	O	4925
monoarticular	NOUN	O	O	4925
or	CCONJ	O	O	4925
pauciatricular	PROPN	O	O	4925
form	NOUN	O	O	4925
of	ADP	O	O	4925
the	PRON	O	O	4925
arthritis	NOUN	O	Disease	4925
.	PUNCT	O	O	4925
However	ADV	O	O	4926
,	PUNCT	O	O	4926
30%	NOUN	O	O	4926
of	ADP	O	O	4926
the	PRON	O	O	4926
patients	NOUN	O	O	4926
developed	VERB	O	O	4926
uveitis	PROPN	O	Disease	4926
after	ADP	O	O	4926
16	NUM	O	O	4926
years	NOUN	O	O	4926
of	ADP	O	O	4926
age	NOUN	O	O	4926
.	PUNCT	O	O	4926
Although	SCONJ	O	O	4927
61%	NOUN	O	O	4927
of	ADP	O	O	4927
patients	NOUN	O	O	4927
had	VERB	O	O	4927
a	PRON	O	O	4927
noncontributory	NOUN	O	O	4927
ocular	ADJ	O	O	4927
history	NOUN	O	O	4927
on	ADP	O	O	4927
entry	NOUN	O	O	4927
,	PUNCT	O	O	4927
42%	NOUN	O	O	4927
had	VERB	O	O	4927
active	ADJ	O	O	4927
uveitis	PROPN	O	Disease	4927
on	ADP	O	O	4927
entry	NOUN	O	O	4927
.	PUNCT	O	O	4927
Our	PRON	O	O	4928
approach	NOUN	O	O	4928
was	AUX	O	O	4928
effective	ADJ	O	O	4928
in	ADP	O	O	4928
detecting	VERB	O	O	4928
uveitis	PROPN	O	Disease	4928
in	ADP	O	O	4928
new	ADJ	O	O	4928
cases	NOUN	O	O	4928
and	CCONJ	O	O	4928
exacerbations	NOUN	O	O	4928
of	ADP	O	O	4928
uveitis	PROPN	O	Disease	4928
in	ADP	O	O	4928
established	VERB	O	O	4928
cases	NOUN	O	O	4928
.	PUNCT	O	O	4928
Forty	NUM	O	O	4929
-	PUNCT	O	O	4929
four	NUM	O	O	4929
percent	NOUN	O	O	4929
of	ADP	O	O	4929
patients	NOUN	O	O	4929
with	ADP	O	O	4929
uveitis	PROPN	O	Disease	4929
had	VERB	O	O	4929
one	NUM	O	O	4929
or	CCONJ	O	O	4929
more	ADJ	O	O	4929
identifiable	ADJ	O	O	4929
signs	NOUN	O	O	4929
or	CCONJ	O	O	4929
symptoms	NOUN	O	O	4929
,	PUNCT	O	O	4929
such	ADJ	O	O	4929
as	ADP	O	O	4929
red	ADJ	O	O	4929
eye	NOUN	O	O	4929
,	PUNCT	O	O	4929
ocular pain	NOUN	O	Disease	4929
,	PUNCT	O	O	4929
decreased visual acuity	NOUN	O	Disease	4929
,	PUNCT	O	O	4929
or	CCONJ	O	O	4929
photophobia	NOUN	O	Disease	4929
,	PUNCT	O	O	4929
in	ADP	O	O	4929
order	NOUN	O	O	4929
of	ADP	O	O	4929
decreasing	VERB	O	O	4929
frequency	NOUN	O	O	4929
.	PUNCT	O	O	4929
Even	ADV	O	O	4930
after	ADP	O	O	4930
early	ADV	O	O	4930
detection	NOUN	O	O	4930
and	CCONJ	O	O	4930
prompt	PROPN	O	O	4930
treatment	NOUN	O	O	4930
,	PUNCT	O	O	4930
41%	NOUN	O	O	4930
of	ADP	O	O	4930
cases	NOUN	O	O	4930
of	ADP	O	O	4930
uveitis	PROPN	O	Disease	4930
did	VERB	O	O	4930
not	PART	O	O	4930
respond	VERB	O	O	4930
to	PART	O	O	4930
more	ADJ	O	O	4930
than	ADP	O	O	4930
six	NUM	O	O	4930
months	NOUN	O	O	4930
of	ADP	O	O	4930
intensive	ADJ	O	O	4930
topical	ADJ	O	O	4930
treatment	NOUN	O	O	4930
with	ADP	O	O	4930
corticosteroids	NOUN	O	Chemical	4930
and	CCONJ	O	O	4930
mydriatics	NOUN	O	O	4930
.	PUNCT	O	O	4930
Despite	SCONJ	O	O	4931
this	PRON	O	O	4931
,	PUNCT	O	O	4931
there	ADV	O	O	4931
was	AUX	O	O	4931
a	PRON	O	O	4931
dramatic	ADJ	O	O	4931
decrease	VERB	O	O	4931
in	ADP	O	O	4931
the	PRON	O	O	4931
50%	NOUN	O	O	4931
incidence	NOUN	O	O	4931
of	ADP	O	O	4931
blinding	VERB	O	O	4931
complications	NOUN	O	O	4931
of	ADP	O	O	4931
uveitis	PROPN	O	Disease	4931
cited	VERB	O	O	4931
in	ADP	O	O	4931
earlier	ADV	O	O	4931
studies	NOUN	O	O	4931
.	PUNCT	O	O	4931
Cataract	NOUN	O	Disease	4932
and	CCONJ	O	O	4932
band keratopathy	VERB	O	Disease	4932
occurred	VERB	O	O	4932
in	ADP	O	O	4932
only	ADV	O	O	4932
22	NUM	O	O	4932
and	CCONJ	O	O	4932
13%	NOUN	O	O	4932
of	ADP	O	O	4932
our	PRON	O	O	4932
group	NOUN	O	O	4932
,	PUNCT	O	O	4932
respectively	ADV	O	O	4932
.	PUNCT	O	O	4932
We	PRON	O	O	4933
used	VERB	O	O	4933
chloroquine	ADJ	O	Chemical	4933
or	CCONJ	O	O	4933
hydroxychloroquine	NOUN	O	Chemical	4933
in	ADP	O	O	4933
173	NUM	O	O	4933
of	ADP	O	O	4933
210	NUM	O	O	4933
cases	NOUN	O	O	4933
and	CCONJ	O	O	4933
found	VERB	O	O	4933
only	ADV	O	O	4933
one	NUM	O	O	4933
case	NOUN	O	O	4933
of	ADP	O	O	4933
chorioretinopathy	ADJ	O	Disease	4933
attributable	ADJ	O	O	4933
to	PART	O	O	4933
these	PRON	O	O	4933
drugs	NOUN	O	O	4933
.	PUNCT	O	O	4933
Systemically	ADV	O	O	4934
administered	VERB	O	O	4934
corticosteroids	NOUN	O	Chemical	4934
were	AUX	O	O	4934
used	VERB	O	O	4934
in	ADP	O	O	4934
75	NUM	O	O	4934
of	ADP	O	O	4934
210	NUM	O	O	4934
cases	NOUN	O	O	4934
;	PUNCT	O	O	4934
a	PRON	O	O	4934
significant	ADJ	O	O	4934
number	NOUN	O	O	4934
of	ADP	O	O	4934
posterior	ADJ	O	O	4934
subcapsular	PROPN	O	O	4934
cataracts	NOUN	O	Disease	4934
was	AUX	O	O	4934
found	VERB	O	O	4934
.	PUNCT	O	O	4934
Typical	ADJ	O	O	4935
keratoconjunctivitis	NOUN	O	Disease	4935
sicca	NOUN	O	O	4935
developed	VERB	O	O	4935
in	ADP	O	O	4935
three	NUM	O	O	4935
of	ADP	O	O	4935
the	PRON	O	O	4935
uveitis	PROPN	O	Disease	4935
cases	NOUN	O	O	4935
.	PUNCT	O	O	4935
This	PRON	O	O	4936
association	PROPN	O	O	4936
with	ADP	O	O	4936
uveitis	PROPN	O	Disease	4936
and	CCONJ	O	O	4936
JRA	PROPN	O	O	4936
was	AUX	O	O	4936
not	PART	O	O	4936
noted	VERB	O	O	4936
previously	ADV	O	O	4936
.	PUNCT	O	O	4936
Surgical	ADJ	O	O	4937
treatment	NOUN	O	O	4937
of	ADP	O	O	4937
cataracts	NOUN	O	Disease	4937
,	PUNCT	O	O	4937
band keratopathy	VERB	O	Disease	4937
,	PUNCT	O	O	4937
and	CCONJ	O	O	4937
glaucoma	NOUN	O	Disease	4937
achieved	VERB	O	O	4937
uniformly	ADV	O	O	4937
discouraging	VERB	O	O	4937
results	VERB	O	O	4937
.	PUNCT	O	O	4937
Water intoxication	NOUN	O	Disease	4940
associated	VERB	O	O	4940
with	ADP	O	O	4940
oxytocin	PROPN	O	Chemical	4940
administration	NOUN	O	O	4940
during	ADP	O	O	4940
saline	NOUN	O	O	4940
-	PUNCT	O	O	4940
induced	VERB	O	O	4940
abortion	NOUN	O	Disease	4940
.	PUNCT	O	O	4940
Four	NUM	O	O	4941
cases	NOUN	O	O	4941
of	ADP	O	O	4941
water intoxication	NOUN	O	Disease	4941
in	ADP	O	O	4941
connection	NOUN	O	O	4941
with	ADP	O	O	4941
oxytocin	PROPN	O	Chemical	4941
administration	NOUN	O	O	4941
during	ADP	O	O	4941
saline	NOUN	O	O	4941
-	PUNCT	O	O	4941
induced	VERB	O	O	4941
abortions	NOUN	O	Disease	4941
are	AUX	O	O	4941
described	VERB	O	O	4941
.	PUNCT	O	O	4941
The	PRON	O	O	4942
mechanism	NOUN	O	O	4942
of	ADP	O	O	4942
water intoxication	NOUN	O	Disease	4942
is	AUX	O	O	4942
discussed	VERB	O	O	4942
in	ADP	O	O	4942
regard	NOUN	O	O	4942
to	PART	O	O	4942
these	PRON	O	O	4942
cases	NOUN	O	O	4942
.	PUNCT	O	O	4942
Oxytocin	PROPN	O	Chemical	4943
administration	NOUN	O	O	4943
during	ADP	O	O	4943
midtrimester	VERB	O	O	4943
-	PUNCT	O	O	4943
induced	VERB	O	O	4943
abortions	NOUN	O	Disease	4943
is	AUX	O	O	4943
advocated	VERB	O	O	4943
only	ADV	O	O	4943
if	SCONJ	O	O	4943
it	PRON	O	O	4943
can	AUX	O	O	4943
be	AUX	O	O	4943
carried	VERB	O	O	4943
out	ADP	O	O	4943
under	ADP	O	O	4943
careful	ADJ	O	O	4943
observations	NOUN	O	O	4943
of	ADP	O	O	4943
an	PRON	O	O	4943
alert	ADJ	O	O	4943
nursing	NOUN	O	O	4943
staff	NOUN	O	O	4943
,	PUNCT	O	O	4943
aware	ADJ	O	O	4943
of	ADP	O	O	4943
the	PRON	O	O	4943
symptoms	NOUN	O	O	4943
of	ADP	O	O	4943
water intoxication	NOUN	O	Disease	4943
and	CCONJ	O	O	4943
instructed	VERB	O	O	4943
to	PART	O	O	4943
watch	VERB	O	O	4943
the	PRON	O	O	4943
diuresis	VERB	O	O	4943
and	CCONJ	O	O	4943
report	VERB	O	O	4943
such	ADJ	O	O	4943
early	ADV	O	O	4943
signs	NOUN	O	O	4943
of	ADP	O	O	4943
the	PRON	O	O	4943
syndrome	NOUN	O	O	4943
as	ADP	O	O	4943
asthenia	NOUN	O	Disease	4943
,	PUNCT	O	O	4943
muscular	ADJ	O	O	4943
irritability	NOUN	O	Disease	4943
,	PUNCT	O	O	4943
or	CCONJ	O	O	4943
headaches	NOUN	O	Disease	4943
.	PUNCT	O	O	4943
The	PRON	O	O	4944
oxytocin	PROPN	O	Chemical	4944
should	AUX	O	O	4944
be	AUX	O	O	4944
given	VERB	O	O	4944
only	ADV	O	O	4944
in	ADP	O	O	4944
Ringers	NOUN	O	O	4944
lactate	NOUN	O	Chemical	4944
or	CCONJ	O	O	4944
,	PUNCT	O	O	4944
alternately	ADV	O	O	4944
,	PUNCT	O	O	4944
in	ADP	O	O	4944
Ringers	NOUN	O	O	4944
lactate	NOUN	O	Chemical	4944
and	CCONJ	O	O	4944
a	PRON	O	O	4944
5	NUM	O	O	4944
per	ADP	O	O	4944
cent	NOUN	O	O	4944
dextrose	ADJ	O	Chemical	4944
and	CCONJ	O	O	4944
water	PROPN	O	O	4944
solutions	NOUN	O	O	4944
.	PUNCT	O	O	4944
The	PRON	O	O	4945
urinary	ADJ	O	O	4945
output	NOUN	O	O	4945
should	AUX	O	O	4945
be	AUX	O	O	4945
monitored	VERB	O	O	4945
and	CCONJ	O	O	4945
the	PRON	O	O	4945
oxytocin	PROPN	O	Chemical	4945
administration	NOUN	O	O	4945
discontinued	VERB	O	O	4945
and	CCONJ	O	O	4945
the	PRON	O	O	4945
serum	NOUN	O	O	4945
electrolytes	NOUN	O	O	4945
checked	VERB	O	O	4945
if	SCONJ	O	O	4945
the	PRON	O	O	4945
urinary	ADJ	O	O	4945
output	NOUN	O	O	4945
decreases	VERB	O	O	4945
.	PUNCT	O	O	4945
The	PRON	O	O	4946
oxytocin	PROPN	O	Chemical	4946
should	AUX	O	O	4946
not	PART	O	O	4946
be	AUX	O	O	4946
administered	VERB	O	O	4946
in	ADP	O	O	4946
excess	ADJ	O	O	4946
of	ADP	O	O	4946
36	NUM	O	O	4946
hours	NOUN	O	O	4946
.	PUNCT	O	O	4946
If	SCONJ	O	O	4947
the	PRON	O	O	4947
patient	NOUN	O	O	4947
has	VERB	O	O	4947
not	PART	O	O	4947
aborted	VERB	O	O	4947
by	ADP	O	O	4947
then	ADV	O	O	4947
the	PRON	O	O	4947
oxytocin	PROPN	O	Chemical	4947
should	AUX	O	O	4947
be	AUX	O	O	4947
discontinued	VERB	O	O	4947
for	ADP	O	O	4947
10	NUM	O	O	4947
to	PART	O	O	4947
12	NUM	O	O	4947
hours	NOUN	O	O	4947
in	ADP	O	O	4947
order	NOUN	O	O	4947
to	PART	O	O	4947
perform	VERB	O	O	4947
electrolyte	NOUN	O	O	4947
determinations	NOUN	O	O	4947
and	CCONJ	O	O	4947
correct	VERB	O	O	4947
any	PRON	O	O	4947
electrolyte	NOUN	O	O	4947
imbalance	NOUN	O	O	4947
.	PUNCT	O	O	4947
